PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	WE	SC	GA	UT	PM	OA	HC	HP	DA	WOS
J	Wood, RL; Yurdakul, LK				Wood, RL; Yurdakul, LK			Change in relationship status following traumatic brain injury	BRAIN INJURY			English	Article							SEVERE HEAD-INJURY; SOCIAL-ADJUSTMENT; RELATIVES; REHABILITATION	Previous studies have highlighted the burden placed on family members and close partners of individuals who have sustained traumatic brain injury. This burden of stress has been attributed to the neurobehavioural sequelae of such injuries. However, the extent to which brain injury affects marriages and close relationships has never been statistically evaluated. This study looked at 131 adults with traumatic brain injury in order to determine the incidence of divorce/separation; 49 per cent of our sample reported chat they had divorced or separated from their partners during a 5-8-year period following brain injury. Factors which may predict the outcome of relationships include severity of injury (as determined by length of post-traumatic amnesia), length of relationship, and time since injury. The influence of these factors in determining the risk of relationship breakdown is discussed.			Wood, RL (corresponding author), BRAIN INJURY REHABIL TRUST, ACORN HOUSE, 397A MIDSUMMER BLVD, MILTON KEYNES MK9 2HP, BUCKS, ENGLAND.						BLAZYK S, 1983, SOC WORK HEALTH CARE, V8, P55, DOI 10.1300/J010v08n04_05; BOND MR, 1984, CLOSED HEAD INJURY P, P148; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; BROOKS N, 1984, CLOSED HEAD INJURY P, P123; JACOBS HE, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P37; JACOBS HE, 1989, TRAUMATIC BRAIN INJU; Liss M, 1990, Int J Rehabil Res, V13, P309, DOI 10.1097/00004356-199012000-00004; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; NAJENSON T, 1974, SCAND J REHABIL MED, V6, P5; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; *OFF POP CENS SURV, 1993, SER OFF POP CENS SUR; Panting A, 1972, REHABILITATION, V38, P33; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; RUSSELL WR, 1971, TRAUMATIC ANNESIAS; STRATTON MC, 1994, BRAIN INJURY, V8, P631, DOI 10.3109/02699059409151016; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; Thomsen I V, 1989, Brain Inj, V3, P157, DOI 10.3109/02699058909004547; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019	22	111	112	0	6	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	1997	11	7					491	501		10.1080/713802183			11	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	XF661	WOS:A1997XF66100003	9210986				2022-02-06	
J	Dixon, CE; Ma, XC; Marion, DW				Dixon, CE; Ma, XC; Marion, DW			Effects of CDP-choline treatment on neurobehavioral deficits after TBI and on hippocampal and neocortical acetylcholine release	JOURNAL OF NEUROTRAUMA			English	Article						acetylcholine; behavior; microdialysis; rats; traumatic brain injury; water maze	TRAUMATIC BRAIN INJURY; FLUID-PERCUSSION INJURY; COGNITIVE IMPAIRMENT; HEAD-INJURY; RATS; RECEPTOR; MOTOR; HYPOTHERMIA; EXPERIENCE; IMPACT	The exogenous administration of cytidine-5'-diphosphate (CDP)-choline has been used extensively as a brain activator in different neurological disorders that are associated with memory deficits. A total of 50 rats were utilized to (a) determine whether exogenously administered CDP-choline could attenuate posttraumatic motor and spatial memory performance deficits and (b) determine whether intraperitoneal (i.p.) administration of CDP-choline increases acetylcholine (ACh) release in the dorsal hippocampus and neocortex. In the behavioral study, traumatic brain injury (TBI) was produced by lateral controlled cortical impact (2-mm deformation/6 m/sec) and administered CDP-choline (100 mg/kg) or saline daily for 18 days beginning 1 day postinjury. At 1 day postinjury, rats treated with CDP-choline 15 min prior to assessment performed significantly better than saline-treated rats. Between 14-18 days postinjury, CDP-choline-treated rats had significantly less cognitive (Morris water maze performance) deficits that injured saline-treated rats. CDP-choline treatment also attenuated the TBI-induced increased sensitivity to the memory-disrupting effects of scopolamine, a muscarinic antagonist. The microdialysis studies demonstrated for the first time that a single i.p. administration of CDP-choline can significantly increase extracellular levels of ACh in dorsal hippocampus and neocortex in normal, awake, freely moving rats. This article provides additional evidence that spatial memory performance deficits are, at least partially, associated with deficits in central cholinergic neurotransmission and that treatments that enhance ACh release in the chronic phase after TBI may attenuate cholinergic-dependent neurobehavioral deficits.			Dixon, CE (corresponding author), UNIV PITTSBURGH,DEPT NEUROL SURG,201 HILL BLDG,3434 5TH AVE,PITTSBURGH,PA 15260, USA.		Marion, Donald/AAR-5749-2021	Marion, Donald/0000-0003-4627-7702	NIDCR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [CDE-CCR30347] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS33150] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [NIH-30318] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS033150] Funding Source: NIH RePORTER		AGUT J, 1993, ANN NY ACAD SCI, V695, P318, DOI 10.1111/j.1749-6632.1993.tb23075.x; ALTHAUS JS, 1993, MOL CHEM NEUROPATHOL, V20, P147, DOI 10.1007/BF02815368; CACABELOS R, 1994, ANN NY ACAD SCI, V16, P211; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Cooper JR, 1996, BIOCH BASIS NEUROPHA; Dietrich WD, 1996, J NEUROTRAUM, V13, P309, DOI 10.1089/neu.1996.13.309; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; Dixon CE, 1996, PHARMACOL BIOCHEM BE, V53, P679, DOI 10.1016/0091-3057(95)02069-1; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DIXON CE, 1995, P SOC NEUR ANN M SOC, V21, P762; DIXON CE, 1996, IN PRESS BRAIN RES; DORLANDO KJ, 1995, NEUROL RES, V17, P281, DOI 10.1080/01616412.1995.11740327; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Gorman LK, 1996, J NEUROTRAUM, V13, P457, DOI 10.1089/neu.1996.13.457; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; Jackson Darrell A., 1995, Life Sciences, V56, P45; KAKIHANA M, 1988, STROKE, V19, P217, DOI 10.1161/01.STR.19.2.217; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LEVIN HS, 1991, J NEUROL SCI, V103, pS39; Long DA, 1996, BRAIN RES, V717, P109, DOI 10.1016/0006-8993(95)01500-0; LOPEZCOVIELLA I, 1995, J NEUROCHEM, V65, P889; LYETH BG, 1988, BRAIN RES, V448, P88, DOI 10.1016/0006-8993(88)91104-3; Marion DW, 1996, J NEUROTRAUM, V13, P139, DOI 10.1089/neu.1996.13.139; MARSHALL DL, 1993, BRAIN RES, V269, P269; MCINTOSH TK, 1992, J NEUROTRAUM, V9, P33, DOI 10.1089/neu.1992.9.33; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; ODELL DM, 1995, J NEUROSURG, V83, P878, DOI 10.3171/jns.1995.83.5.0878; PETKOV VD, 1993, ARZNEIMITTELFORSCH, V43-2, P822; PIKE BR, 1995, BRAIN RES, V686, P37, DOI 10.1016/0006-8993(95)00448-Y; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496; SINSON G, 1995, J NEUROCHEM, V65, P2209; SMITH DH, 1993, J NEUROSCI, V13, P5383, DOI 10.1523/JNEUROSCI.13-12-05383.1993; VILLA RF, 1993, INT J DEV NEUROSCI, V11, P83, DOI 10.1016/0736-5748(93)90037-E; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	41	111	112	0	4	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	1997	14	3					161	169		10.1089/neu.1997.14.161			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	WT814	WOS:A1997WT81400004	9104933				2022-02-06	
J	SHARPLES, PM; STUART, AG; MATTHEWS, DSF; AYNSLEYGREEN, A; EYRE, JA				SHARPLES, PM; STUART, AG; MATTHEWS, DSF; AYNSLEYGREEN, A; EYRE, JA			CEREBRAL BLOOD-FLOW AND METABOLISM IN CHILDREN WITH SEVERE HEAD-INJURY .1. RELATION TO AGE, GLASGOW COMA SCORE, OUTCOME, INTRACRANIAL-PRESSURE, AND TIME AFTER INJURY	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						HEAD INJURY; CEREBRAL BLOOD FLOW; INTRACRANIAL PRESSURE	TRAUMATIC BRAIN INJURY; MITOCHONDRIAL RESPIRATION; ANOXIA ISCHEMIA; DYNAMIC CHANGES; ACUTE PHASE; OXYGEN; RATS; DETERIORATION; CONSCIOUSNESS; REPERFUSION	Understanding the pathophysiology of paediatric head trauma is essential for rational acute management. It has been proposed that the response to severe head injury in children differs from that in adults, with increased cerebral blood flow (cerebral hyperaemia) representing the most common cause of raised intracranial pressure, but this has recently been disputed. The relation between the pathophysiological response and time after injury has not been defined in children. This paper describes 151 serial measurements of cerebral blood flow, arteriojugular venous oxygen difference (AJVDo(2)), and cerebral metabolic rate for oxygen (CMRo(2)) that were performed in 21 children with severe head injury, mean age 8 (range 2-16) years, Glasgow coma score less than or equal to 8. Absolute cerebral hyperaemia was uncommon, only 10 (7%) of the 151 cerebral blood flow values being at or above the upper Limit of the range published in normal children. There was an inverse correlation between cerebral blood flow and intracranial pressure. (r= -0.24, p = 0.009). Contrary to the widespread assumption that cerebral metabolic rate in patients with head injury is always low, CMRo(2) was initially within the normal range in 17/21 (81%) children. Both CMRo(2) and AJVDo(2) fell significantly between the first and third days after injury. There was a non-significant rise in cerebral blood how over time. These data represent the first evidence that the temporal change in cerebral metabolic rate reported in experimental models of traumatic brain injury also occurs in patients with head injury. The in the pathophysiological over time suggest that the management may need to be modified accordingly. If cerebral metabolic rate and cerebral oxygen extraction are maximal shortly after injury in children with severe head injury then the children are most likely to sustain secondary damage during this period.	UNIV NEWCASTLE UPON TYNE, DEPT CHILD HLTH, PAEDIAT NEUROL RES UNIT, NEWCASTLE UPON TYNE NE2 4HH, TYNE & WEAR, ENGLAND					Stuart, Alan Graham/0000-0003-2789-2216	Wellcome TrustWellcome TrustEuropean Commission Funding Source: Medline		Benumof J.L., 1986, ANESTHESIA, V2, P1115; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; BRUCE DA, 1984, BRIT MED J, V289, P715, DOI 10.1136/bmj.289.6447.715; BRUCE DA, 1979, CHILD BRAIN, V5, P174; BRUCE DA, 1973, J NEUROSURG, V38, P131, DOI 10.3171/jns.1973.38.2.0131; BRUCE DA, 1985, BRAIN INSULTS INFANT, P83; BURKE AM, 1981, J NEUROSURG, V55, P550, DOI 10.3171/jns.1981.55.4.0550; CHAMBERS IR, 1990, NEUROSURGERY, V26, P421, DOI 10.1227/00006123-199003000-00007; CHRISTENSEN MS, 1974, BRIT J ANAESTH, V46, P348, DOI 10.1093/bja/46.5.348; COLD GE, 1980, ACTA ANAESTH SCAND, V24, P245, DOI 10.1111/j.1399-6576.1980.tb01544.x; CRAFT AW, 1972, HDB CLIN NEUROLOGY, V23, P445; DUCKROW RB, 1981, J NEUROSURG, V54, P607, DOI 10.3171/jns.1981.54.5.0607; ENEVOLDSEN EM, 1976, J NEUROSURG, V44, P191, DOI 10.3171/jns.1976.44.2.0191; EYRE JA, 1983, ARCH DIS CHILD, V58, P785, DOI 10.1136/adc.58.10.785; FERRARI R, 1989, MOL CELL BIOCHEM, V88, P161; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; HAYWARD R, 1987, ARCH DIS CHILD, V62, P1283, DOI 10.1136/adc.62.12.1283; James HE, 1985, BRAIN INSULTS INFANT, P179; KETY SS, 1948, J CLIN INVEST, V27, P476, DOI 10.1172/JCI101994; KURODA Y, 1992, J NEUROSURG, V76, P471, DOI 10.3171/jns.1992.76.3.0471; KURUP CKR, 1990, J BIOENERG BIOMEMBR, V22, P61; LANGFITT TW, 1977, ANN SURG, V186, P411, DOI 10.1097/00000658-197710000-00002; LEVASSEUR JE, 1979, J APPL PHYSIOL, V46, P89, DOI 10.1152/jappl.1979.46.1.89; LINN F, 1987, EXP NEUROL, V96, P321, DOI 10.1016/0014-4886(87)90050-1; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MCDOWALL DG, 1968, SCAND J CLIN LAB INV, VS 22, pE8; MESSETER K, 1986, J NEUROSURG, V64, P231, DOI 10.3171/jns.1986.64.2.0231; MICHENFELDER JD, 1988, ANESTHESIA BRAIN, P113; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; MUIZELAAR JP, 1988, J NEUROSURG, V69, P923, DOI 10.3171/jns.1988.69.6.0923; Nelson S, 1966, HEAD INJURY, P444; NILSSON B, 1977, J NEUROSURG, V47, P252, DOI 10.3171/jns.1977.47.2.0252; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; PASCUCCI RC, 1988, INTENS CARE MED, V14, P185, DOI 10.1007/BF00717985; Raichle ME, 1972, STROKE, V3, P566, DOI 10.1161/01.STR.3.5.566; REHNCRONA S, 1979, STROKE, V10, P437, DOI 10.1161/01.STR.10.4.437; REHNCRONA S, 1981, J CEREBR BLOOD F MET, V1, P297, DOI 10.1038/jcbfm.1981.34; ROBERTSON CS, 1989, J NEUROSURG, V70, P222, DOI 10.3171/jns.1989.70.2.0222; ROBERTSON CS, 1987, J NEUROSURG, V67, P361, DOI 10.3171/jns.1987.67.3.0361; SETTERGREN G, 1980, ACTA PAEDIATR SCAND, V69, P457, DOI 10.1111/j.1651-2227.1980.tb07114.x; SEVERINGHAUS JW, 1966, CIRC RES, V19, P274, DOI 10.1161/01.RES.19.2.274; SHARPLES PM, 1990, BRIT MED J, V300, P87, DOI 10.1136/bmj.300.6717.87; SHARPLES PM, 1991, ARCH DIS CHILD, V66, P1326, DOI 10.1136/adc.66.11.1326; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; SWEDLOW D, 1984, BRAIN EDEMA, P365; TAKEO S, 1989, J PHARMACOL EXP THER, V248, P1207; TASKER RC, 1988, ARCH DIS CHILD, V63, P888, DOI 10.1136/adc.63.8.888; TEASDALE G, 1974, LANCET, V2, P81; VINK R, 1988, MAGNET RESON MED, V6, P37, DOI 10.1002/mrm.1910060105; WAGNER KR, 1990, J CEREBR BLOOD F MET, V10, P417, DOI 10.1038/jcbfm.1990.72; WAGNER KR, 1990, J NEUROL SCI, V100, P142, DOI 10.1016/0022-510X(90)90025-I; YANG MS, 1985, J NEUROSURG, V1, P297; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	57	111	111	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	FEB	1995	58	2					145	152		10.1136/jnnp.58.2.145			8	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	QG825	WOS:A1995QG82500003	7876842	Green Published, Bronze			2022-02-06	
J	OMALLEY, DE; MAZUR, JM; CUMMINGS, RJ				OMALLEY, DE; MAZUR, JM; CUMMINGS, RJ			FEMORAL-HEAD AVASCULAR NECROSIS ASSOCIATED WITH INTRAMEDULLARY NAILING IN AN ADOLESCENT	JOURNAL OF PEDIATRIC ORTHOPAEDICS			English	Article						FEMORAL HEAD NECROSIS; FEMUR FRACTURE; INTRAMEDULLARY NAILING		An adolescent developed avascular necrosis of the femoral head after intramedullary nailing for a femoral diaphyseal fracture. This complication is most likely secondary to injury to the posterior superior ascending branch of the medial circumflex artery at the time of rod insertion. This artery is situated close to the proximal insertion hole just posterior to the trochanteric notch and piriformis fossa. Other methods of fracture treatment, either operative or nonoperative, should be considered in skeletally immature patients.	NATL NAVAL MED CTR, DEPT ORTHOPAED, BETHESDA, MD USA				yudong, LI/AAR-5902-2021					0	111	113	0	3	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0271-6798			J PEDIATR ORTHOPED	J. Pediatr. Orthop.	JAN-FEB	1995	15	1					21	23		10.1097/01241398-199501000-00005			3	Orthopedics; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Pediatrics	PZ115	WOS:A1995PZ11500005	7883920				2022-02-06	
J	NILSSON, P; RONNEENGSTROM, E; FLINK, R; UNGERSTEDT, U; CARLSON, H; HILLERED, L				NILSSON, P; RONNEENGSTROM, E; FLINK, R; UNGERSTEDT, U; CARLSON, H; HILLERED, L			EPILEPTIC SEIZURE ACTIVITY IN THE ACUTE-PHASE FOLLOWING CORTICAL IMPACT TRAUMA IN RAT	BRAIN RESEARCH			English	Article						ELECTROENCEPHALOGRAPHY; EXCITATORY AMINO ACID; GLUTAMATE; ASPARTATE; RAT; SECONDARY ISCHEMIA; SEIZURE ACTIVITY; TRAUMATIC BRAIN INJURY	CONCUSSIVE BRAIN INJURY; CEREBRAL BLOOD-FLOW; EXTRACELLULAR AMINO-ACIDS; EXPERIMENTAL HEAD-INJURY; INTRACEREBRAL MICRODIALYSIS; METABOLITES; POTASSIUM; RELEASE	The aim of this investigation was to determine the incidence of seizure activity in the acute phase following traumatic brain injury. Compression contusion trauma was produced in the right parietal cortex in 19 artificially ventilated rats. Electroencephalographic recordings were carried out in 17 of the animals for 2 h following the impact. The extracellular levels of neuroactive amino acids were simultaneously monitored in 9 of the experiments using microdialysis. In 14 of the 17 animals a generalized seizure activity with an average duration of 59s (range 30-101s) was recorded. The mean time lag between trauma and seizure onset was 67s (range 26-90 s). The seizure activity was consistently followed by post-ictal depression. The trauma was accompanied by a transient increase of aspartate, taurine, glutamate and glycine, in decreasing rank order. The seizure activity occurred when the levels of these neuroactive amino acids were elevated. It is concluded that the high incidence of seizure activity observed may be an important factor contributing to secondary ischemia after traumatic brain injury. Aspartate and glutamate, potentiated by glycine, may play a role in post-traumatic seizure activity.	UNIV HOSP UPPSALA,DEPT CLIN CHEM,S-75285 UPPSALA,SWEDEN; UNIV HOSP UPPSALA,DEPT NEUROSURG,S-75285 UPPSALA,SWEDEN; UNIV HOSP UPPSALA,DEPT CLIN NEUROPHYSIOL,S-75185 UPPSALA,SWEDEN; KAROLINSKA INST,DEPT PHARMACOL,S-10401 STOCKHOLM,SWEDEN								ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; BECKER DP, 1990, NEUROLOGICAL SURG, P2017; BRAZIER MAB, 1974, NEUROLOGY, V24, P903, DOI 10.1212/WNL.24.10.903; CARLSON H, 1992, NEUROSCI LETT, V140, P30, DOI 10.1016/0304-3940(92)90674-V; CARLSON H, 1992, J NEUROTRAUM, V9, P57; CHAPMAN AG, 1993, BIOCHEM SOC T, V21, P106, DOI 10.1042/bst0210106; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Delgado-Escueta A V, 1986, Adv Neurol, V44, P3; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Gade GF, 1990, NEUROLOGICAL SURG, P1965; GOVONS SR, 1972, EXP NEUROL, V34, P121, DOI 10.1016/0014-4886(72)90193-8; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HILLERED L, 1989, J CEREBR BLOOD F MET, V9, P607, DOI 10.1038/jcbfm.1989.87; HILLERED L, 1992, J NEUROTRAUM, V9, P62; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; LINDROTH P, 1979, ANAL CHEM, V51, P1667, DOI 10.1021/ac50047a019; Lux H D, 1986, Adv Neurol, V44, P619; MELDRUM B, 1984, EPILEPSIA, V25, P140; MEYER JS, 1970, J NEUROSURG, V32, P304, DOI 10.3171/jns.1970.32.3.0304; MILLAN MH, 1993, EPILEPSY RES, V14, P139, DOI 10.1016/0920-1211(93)90018-3; NILSSON B, 1977, J NEUROSURG, V47, P262, DOI 10.3171/jns.1977.47.2.0262; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; REID MS, 1990, ACTA PHYSIOL SCAND, V140, P527, DOI 10.1111/j.1748-1716.1990.tb09030.x; RONNEENGSTROM E, 1992, J CEREBR BLOOD F MET, V12, P873, DOI 10.1038/jcbfm.1992.119; RONNEENGSTROM E, 1992, J NEUROTRAUM, V9, P68; SIESJO BK, 1976, CRIT CARE MED, V4, P283, DOI 10.1097/00003246-197611000-00001; TAKAHASHI H, 1981, J NEUROSURG, V55, P708, DOI 10.3171/jns.1981.55.5.0708; TOSSMAN U, 1986, ACTA PHYSIOL SCAND, V128, P9, DOI 10.1111/j.1748-1716.1986.tb07943.x; WEST M, 1982, ELECTROEN CLIN NEURO, V53, P192, DOI 10.1016/0013-4694(82)90023-2; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16	35	111	112	0	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	FEB 21	1994	637	1-2					227	232		10.1016/0006-8993(94)91237-8			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	MY436	WOS:A1994MY43600028	8180800				2022-02-06	
J	LEROUX, PD; HAGLUND, MM; NEWELL, DW; GRADY, MS; WINN, HR; TEASDALE, G				LEROUX, PD; HAGLUND, MM; NEWELL, DW; GRADY, MS; WINN, HR; TEASDALE, G			INTRAVENTRICULAR HEMORRHAGE IN BLUNT HEAD TRAUMA - AN ANALYSIS OF 43 CASES	NEUROSURGERY			English	Article						COMPUTED TOMOGRAPHY; HEAD INJURY; INTRAVENTRICULAR HEMORRHAGE; VENTRICLE	DIFFUSE AXONAL INJURY; CEREBRAL BLOOD-FLOW; COMPUTED-TOMOGRAPHY; BASAL GANGLIA; BRAIN; CONSCIOUSNESS; INSULTS; COMA	BEFORE THE ADVENT of computed tomography, intraventricular hemorrhage (IVH) from any source was thought rare and invariably fatal. Although intraventricular blood is readily identifiable with computed tomography,there has been little systematic study of its significance in blunt head trauma. Forty-three patients with traumatic IVH were prospectively identified in 1 year at Harborview Medical Center (University of Washington). Most were victims of motor vehicle accidents and suffered severe head injuries. IVH occurred alone in two patients; superficial contusions and subarachnoid hemorrhage were the most common associated finding. Blood was present in only one or both lateral ventricles in 25 patients; only the 3rd or 4th ventricles in 4 and all ventricles in 14 instances. There were 3 intracerebral hematomas and 14 basal ganglion hemorrhages. All of the former and half of the latter communicated with the adjacent lateral ventricle. Extra-axial hematomas appeared more common when only the lateral ventricles were involved, whereas corpus callosum or brain-stem hemorrhage appeared more likely when all the ventricles were involved. Acute hydrocephalus was rare, and ventricular drainage was needed in only four cases. Intracranial pressure (ICP) was elevated (> 15 mm Hg) in 46% of patients. The amount of IVH was related inversely with the Glasgow Coma Scale, but not with increased ICP. The presence of IVH indicated a poor outcome, with only half of the patients being independent at a 6-month follow-up. Poor outcome was associated with increasing age, low admission Glasgow Coma Scale, the presence of space occupying lesions if only the lateral ventricles were involved, and hemorrhage in all four ventricles. IVH after blunt head trauma is uncommon and reflects the severity of the head injury. The pattern of associated lesions suggests that the extent of IVH may be related to the direction of force applied to the head.	UNIV WASHINGTON, HARBORVIEW MED CTR, DEPT NEUROL SURG, SEATTLE, WA 98104 USA		LEROUX, PD (corresponding author), UNIV WASHINGTON, DEPT NEUROSURG, 325 9TH AVE ZA-86, SEATTLE, WA 98104 USA.						ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1990, HDB CLIN NEUROLOGY H, V13; Chan K H, 1988, Br J Neurosurg, V2, P465, DOI 10.3109/02688698809029600; Christie M, 1988, Br J Neurosurg, V2, P343, DOI 10.3109/02688698809001005; CORDOBES F, 1983, J NEUROSURG, V58, P217, DOI 10.3171/jns.1983.58.2.0217; DEWEERD AW, 1979, J NEUROL, V222, P45; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; FRENCH BN, 1977, SURG NEUROL, V7, P171; FUJITSU K, 1988, NEUROSURGERY, V23, P423, DOI 10.1227/00006123-198810000-00003; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GRAEB DA, 1982, RADIOLOGY, V143, P91, DOI 10.1148/radiology.143.1.6977795; GREVIC N, 1983, ACTA NEUROCHIR SUPP, V32, P79; GROSS A, 1989, Z RECHTSMED, V102, P409; Hayashi M, 1988, Br J Neurosurg, V2, P23, DOI 10.3109/02688698808999655; HOWARD MA, 1989, J NEUROSURG, V71, P858, DOI 10.3171/jns.1989.71.6.0858; JENNETT B, 1975, LANCET, V1, P480; KATZ DI, 1989, NEUROLOGY, V39, P897, DOI 10.1212/WNL.39.7.897; KIM CH, 1981, SURG NEUROL, V16, P415, DOI 10.1016/0090-3019(81)90233-0; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; LITTLE JR, 1977, SURG NEUROL, V8, P143; MACPHERSON P, 1986, J NEUROL NEUROSUR PS, V49, P29, DOI 10.1136/jnnp.49.1.29; MARSHALL LF, 1985, NEUROSURGERY, P1605; MCCALLUM JE, 1978, NEUROSURGERY, V3, P22, DOI 10.1227/00006123-197807000-00004; MENT LR, 1986, J NEUROSURG, V65, P847, DOI 10.3171/jns.1986.65.6.0847; MILLER JD, 1985, ARCH NEUROL-CHICAGO, V42, P1191, DOI 10.1001/archneur.1985.04060110073018; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; MOHR G, 1983, J NEUROSURG, V58, P482, DOI 10.3171/jns.1983.58.4.0482; MULLER H, 1987, SURG NEUROL, V27, P398, DOI 10.1016/0090-3019(87)90021-8; OLIFF M, 1978, J COMPUT ASSIST TOMO, V2, P625, DOI 10.1097/00004728-197811000-00020; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PIA HW, 1973, ACTA NEUROCHIR, V27, P149; PIEK J, 1986, ACTA NEUROCHIR, V83, P105, DOI 10.1007/BF01402386; STRICH SJ, 1961, LANCET, V2, P443; TEASDALE G, 1974, LANCET, V2, P81; UNTERHANRSCHEIDT F, 1963, MONOGRAPHIEN GESANTG; VILLASANTE JM, 1976, AM J ROENTGENOL, V126, P765; VOLPE JJ, 1989, ANN NEUROL, V25, P3, DOI 10.1002/ana.410250103; WILBERGER JE, 1990, NEUROSURGERY, V27, P208, DOI 10.1227/00006123-199008000-00006; ZIMMERMAN RA, 1978, RADIOLOGY, V127, P393, DOI 10.1148/127.2.393; ZUCCARELLO M, 1981, ACTA NEUROCHIR, V55, P283, DOI 10.1007/BF01808444	40	111	113	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	OCT	1992	31	4					678	685		10.1227/00006123-199210000-00010			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	JR981	WOS:A1992JR98100010	1407453				2022-02-06	
J	Hiploylee, C; Dufort, PA; Davis, HS; Wennberg, RA; Tartaglia, MC; Mikulis, D; Hazrati, LN; Tator, CH				Hiploylee, Carmen; Dufort, Paul A.; Davis, Hannah S.; Wennberg, Richard A.; Tartaglia, Maria Carmela; Mikulis, David; Hazrati, Lili-Naz; Tator, Charles H.			Longitudinal Study of Postconcussion Syndrome: Not Everyone Recovers	JOURNAL OF NEUROTRAUMA			English	Article						definitions; eligibility; and exclusions; number of symptoms; postconcussion syndrome; recovery	POST-CONCUSSION SYMPTOMS; TRAUMATIC BRAIN-INJURY; HEAD-INJURY; GENE-EXPRESSION; MILD; PREDICTORS; QUESTIONNAIRE; VALIDATION; MANAGEMENT; AGE	We examined recovery from postconcussion syndrome (PCS) in a series of 285 patients diagnosed with concussion based on international sport concussion criteria who received a questionnaire regarding recovery. Of 141 respondents, those with postconcussion symptoms lasting less than 3 months, a positive computed tomography (CT) and/or magnetic resonance imaging (MRI), litigants, and known Test of Memory Malingering (TOMM)-positive cases were excluded, leaving 110 eligible respondents. We found that only 27% of our population eventually recovered and 67% of those who recovered did so within the first year. Notably, no eligible respondent recovered from PCS lasting 3 years or longer. Those who did not recover (n = 80) were more likely to be non-compliant with a do-not-return-to-play recommendation (p = 0.006) but did not differ from the recovered group (n = 30) in other demographic variables, including age and sex (p >= 0.05). Clustergram analysis revealed that symptoms tended to appear in a predictable order, such that symptoms later in the order were more likely to be present if those earlier in the order were already present. Cox proportional hazards model analysis showed that the more symptoms reported, the longer the time to recovery (p = 7.4 x 10(-6)), with each additional symptom reducing the recovery rate by approximately 20%. This is the first longitudinal PCS study to focus on PCS defined specifically as a minimum of 3 months of symptoms, negative CT and/or MRI, negative TOMM test, and no litigation. PCS may be permanent if recovery has not occurred by 3 years. Symptoms appear in a predictable order, and each additional PCS symptom reduces recovery rate by 20%. More long-term follow-up studies are needed to examine recovery from PCS.	[Hiploylee, Carmen; Davis, Hannah S.; Tator, Charles H.] Univ Toronto, Div Neurosurg, Toronto, ON, Canada; [Wennberg, Richard A.; Tartaglia, Maria Carmela] Univ Toronto, Div Neurol, Toronto, ON, Canada; [Mikulis, David] Univ Toronto, Div Neuroradiol, Toronto, ON, Canada; [Hiploylee, Carmen] Toronto Western Hosp, 399 Bathurst St,Room 4W-422, Toronto, ON M5T 2S8, Canada; [Hiploylee, Carmen; Dufort, Paul A.; Davis, Hannah S.; Wennberg, Richard A.; Tartaglia, Maria Carmela; Mikulis, David; Hazrati, Lili-Naz; Tator, Charles H.] Toronto Western Hosp, Canadian Concuss Ctr, Toronto, ON, Canada; [Hazrati, Lili-Naz] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada		Hiploylee, C (corresponding author), Toronto Western Hosp, 399 Bathurst St,Room 4W-422, Toronto, ON M5T 2S8, Canada.	charles.tator@uhn.ca	Mikulis, David J/H-5167-2019; hazrati, lili-naz/AAE-7785-2020	hazrati, lili-naz/0000-0003-2715-1485; Mikulis, David/0000-0003-3956-0892	Ontario Brain Institute; Toronto General and Western Hospital Foundation; SmartCentres Limited; Marion and Gerald Soloway Concussion Chair Fund	The authors thank Dr. Adrian Crawley for his helpful comments on the statistical analyses and manuscript. This study was funded by grants from the Ontario Brain Institute and the Toronto General and Western Hospital Foundation, including grants from SmartCentres Limited and the Marion and Gerald Soloway Concussion Chair Fund.	Bar-Joseph Z, 2001, BIOINFORMATICS, V17, pS22, DOI 10.1093/bioinformatics/17.suppl_1.S22; Baruch Y, 1999, HUM RELAT, V52, P421, DOI 10.1177/001872679905200401; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Calinski TT., 1974, COMMUN STAT, V3, P1, DOI 10.1080/03610927408827101; Carroll Linda J., 2004, Journal of Rehabilitation Medicine Supplement, P113; Cox DR, 1984, ANAL SURVIVAL DATA; DAVIES DL, 1979, IEEE T PATTERN ANAL, V1, P224, DOI 10.1109/TPAMI.1979.4766909; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Hazrati LN, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00222; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2010, J HEAD TRAUMA REHAB, V25, P23, DOI 10.1097/HTR.0b013e3181b4b6ab; Jolliffe I.T., 2002, PRINCIPAL COMPONENT; Jotwani V, 2010, CURR SPORT MED REP, V9, P21, DOI 10.1249/JSR.0b013e3181ccb55e; King N, 2014, NEUROREHABILITATION, V34, P741, DOI 10.3233/NRE-141072; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Koller D., 2009, PROBABILISTIC GRAPHI; Lingsma HF, 2015, J NEUROTRAUM, V32, P83, DOI 10.1089/neu.2014.3384; Makdissi M, 2013, BRIT J SPORT MED, V47, P308, DOI 10.1136/bjsports-2013-092255; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Paniak C, 2000, J MUSCULOSKELET PAIN, V8, P193, DOI 10.1300/J094v08n01_16; Pearl J., 2009, CAUSALITY MODELS REA; Rousseeuw, 2009, FINDING GROUPS DATA; ROUSSEEUW PJ, 1987, J COMPUT APPL MATH, V20, P53, DOI 10.1016/0377-0427(87)90125-7; Silverberg ND, 2015, J NEUROTRAUM, V32, P517, DOI 10.1089/neu.2014.3600; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Spirtes P., 2001, CAUSATION PREDICTION, V2nd; Tator CH, 2016, J NEUROSURG, V125, P1206, DOI 10.3171/2015.6.JNS15664; Tator CH, 2013, CAN MED ASSOC J, V185, P975, DOI 10.1503/cmaj.120039; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Waljas M, 2015, J NEUROTRAUM, V32, P534, DOI 10.1089/neu.2014.3339; Wall PLH, 2012, J AM PSYCHIAT NURSES, V18, P278, DOI 10.1177/1078390312460578; Zemek RL, 2013, JAMA PEDIATR, V167, P259, DOI 10.1001/2013.jamapediatrics.216; Zhang HH, 2007, BIOMETRIKA, V94, P691, DOI 10.1093/biomet/asm037	38	110	110	0	19	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2017	34	8					1511	1523		10.1089/neu.2016.4677			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	ES1ZM	WOS:000399325500002	27784191	Bronze, Green Published			2022-02-06	
J	Xu, JG; Wang, HD; Ding, K; Zhang, L; Wang, CX; Li, T; Wei, WT; Lu, XY				Xu, Jianguo; Wang, Handong; Ding, Ke; Zhang, Li; Wang, Chunxi; Li, Tao; Wei, Wuting; Lu, Xinyu			Luteolin provides neuroprotection in models of traumatic brain injury via the Nrf2-ARE pathway	FREE RADICAL BIOLOGY AND MEDICINE			English	Article						Luteolin; Neuroprotection; Traumatic brain injury; Nrf2	TRANSCRIPTION FACTOR NRF2; OXIDATIVE STRESS; ANTIOXIDANT THERAPIES; SELECTIVE AUTOPHAGY; IN-VITRO; EXPRESSION; PROTECTS; CELLS; P62/SQSTM1; MODULATION	Luteolin has recently been proven to exert neuroprotection in a variety of neurological diseases; however, its roles and the underlying mechanisms in traumatic brain injury are not fully understood. The present study was aimed to investigate the neuroprotective effects of luteolin in models of traumatic brain injury (TBI) and the possible role of the Nrf2-ARE pathway in the putative neuroprotection. A modified Marmarou's weight-drop model in mice and the scratch model in mice primary cultured neurons were used to induce TBI. We determined that luteolin significantly ameliorated secondary brain injury induced by TBI, including neurological deficits, brain water content, and neuronal apoptosis. Furthermore, the level of malondialdehyde (MDA) and the activity of glutathione peroxidase (GPx) were restored in the group with luteolin treatment. in vitro studies showed that luteolin administration lowered the intracellular reactive oxygen species (ROS) level and increased the neuron survival. Moreover, luteolin enhanced the translocation of Nrf2 to the nucleus both in vivo and in vitro, which was proved by the results of Western blot, immunohistochemistry, and electrophoretic mobility shift assay (EMSA). Subsequently upregulation of the expression of the downstream factors such as heme oxygenase 1 (HO1) and NAD(P)H:quinone oxidoreductase 1 (NQO1) was also examined. However, luteolin treatment failed to provide neuroprotection after TBI in Nrf2(-/-) mice. Taken together, these in vivo and in vitro data demonstrated that luteolin provided neuroprotective effects in the models of TBI, possibly through the activation of the Nrf2-ARE pathway. (C) 2014 Elsevier Inc. All rights reserved.	[Xu, Jianguo; Wang, Handong; Ding, Ke; Zhang, Li; Wang, Chunxi; Li, Tao; Lu, Xinyu] Nanjing Univ, Jinling Hosp, Sch Med, Dept Neurosurg, Nanjing 210008, Jiangsu, Peoples R China; [Wei, Wuting] Southern Med Univ Guangzhou, Jinling Hosp, Sch Med, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China		Wang, HD (corresponding author), Nanjing Univ, Jinling Hosp, Sch Med, Dept Neurosurg, Nanjing 210008, Jiangsu, Peoples R China.	njhdwang@hotmail.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81371357]	The authors thank Dr. Jin He and Dr. Bo Yu for their technical assistance on histochemistry. This work was supported by grants from the National Natural Science Foundation of China (No. 81371357).	Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Bermpohl D, 2006, J CEREBR BLOOD F MET, V26, P625, DOI 10.1038/sj.jcbfm.9600258; Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002; Brooks JC, 2013, ARCH PHYS MED REHAB, V94, P2203, DOI 10.1016/j.apmr.2013.07.005; Bryan HK, 2013, BIOCHEM PHARMACOL, V85, P705, DOI 10.1016/j.bcp.2012.11.016; Chen G, 2011, J NEUROSCI RES, V89, P515, DOI 10.1002/jnr.22577; Coleta M, 2008, BEHAV BRAIN RES, V189, P75, DOI 10.1016/j.bbr.2007.12.010; Copple IM, 2010, J BIOL CHEM, V285, P16782, DOI 10.1074/jbc.M109.096545; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Dajas Federico, 2013, Central Nervous System Agents in Medicinal Chemistry, V13, P30; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Siraichi JTG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072733; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Hang CH, 2007, J SURG RES, V137, P53, DOI 10.1016/j.jss.2006.06.026; Hatic H, 2012, J NEUROTRAUM, V29, P1188, DOI 10.1089/neu.2011.1806; Hendricks JJA, 2004, J EXP MED, V200, P1667, DOI 10.1084/jem.20040819; Hou ZG, 2012, BRAIN RES BULL, V88, P560, DOI 10.1016/j.brainresbull.2012.06.006; Huang CS, 2013, ARCH TOXICOL, V87, P167, DOI 10.1007/s00204-012-0913-4; Hyeon S, 2013, FREE RADICAL BIO MED, V65, P789, DOI 10.1016/j.freeradbiomed.2013.08.005; Ichimura Y, 2013, MOL CELL, V51, P618, DOI 10.1016/j.molcel.2013.08.003; Jain A, 2010, J BIOL CHEM, V285, P22576, DOI 10.1074/jbc.M110.118976; Jang S, 2008, P NATL ACAD SCI USA, V105, P7534, DOI 10.1073/pnas.0802865105; Jin W, 2011, INJURY, V42, P714, DOI 10.1016/j.injury.2011.03.009; Komatsu M, 2010, NAT CELL BIOL, V12, P213, DOI 10.1038/ncb2021; Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200; Park CM, 2013, NUTR RES PRACT, V7, P423, DOI 10.4162/nrp.2013.7.6.423; Park SH, 2013, FOOD CHEM TOXICOL, V56, P100, DOI 10.1016/j.fct.2013.02.022; Povlishock J T, 1992, Hum Cell, V5, P345; Qiao HM, 2012, NEUROCHEM RES, V37, P2014, DOI 10.1007/s11064-012-0822-1; Qiao HM, 2012, BRAIN RES, V1448, P71, DOI 10.1016/j.brainres.2012.02.003; Rodriguez-Rodriguez A., 2013, CURR MED CHEM; Sauzeau V, 2003, J BIOL CHEM, V278, P9472, DOI 10.1074/jbc.M212776200; Sawmiller D, 2014, INT J MOL SCI, V15, P895, DOI 10.3390/ijms15010895; Saykally JN, 2012, NEUROSCIENCE, V223, P305, DOI 10.1016/j.neuroscience.2012.07.070; Sharma V, 2007, BRAIN RES BULL, V73, P55, DOI 10.1016/j.brainresbull.2007.01.016; Smith JA, 2013, NEUROCHEM INT, V62, P764, DOI 10.1016/j.neuint.2013.02.013; Sun M., 2013, J NEUROTRAUMA; Tang XW, 2011, FREE RADICAL BIO MED, V50, P1599, DOI 10.1016/j.freeradbiomed.2011.03.008; Villeneuve NF, 2010, ANTIOXID REDOX SIGN, V13, P1699, DOI 10.1089/ars.2010.3211; Wang B, 2012, FREE RADICAL BIO MED, V52, P928, DOI 10.1016/j.freeradbiomed.2011.12.006; Wang JA, 2007, FREE RADICAL BIO MED, V43, P408, DOI 10.1016/j.freeradbiomed.2007.04.020; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wruck CJ, 2007, J NEURAL TRANSM-SUPP, P57; Xu JG, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/187873; Yan W, 2008, NEUROSCI LETT, V431, P150, DOI 10.1016/j.neulet.2007.11.060; Yan W, 2009, J TRAUMA, V66, P1431, DOI 10.1097/TA.0b013e318180f5c7; Zhang MJ, 2013, PROG NEUROBIOL, V100, P30, DOI 10.1016/j.pneurobio.2012.09.003; Zhang YC, 2013, FOOD CHEM TOXICOL, V59, P272, DOI 10.1016/j.fct.2013.05.058; Zhao G, 2011, J NUTR BIOCHEM, V22, P929, DOI 10.1016/j.jnutbio.2010.07.014; Zhao YB, 2012, EXP NEUROL, V237, P489, DOI 10.1016/j.expneurol.2012.07.004	51	110	113	2	56	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0891-5849	1873-4596		FREE RADICAL BIO MED	Free Radic. Biol. Med.	JUN	2014	71						186	195		10.1016/j.freeradbiomed.2014.03.009			10	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Endocrinology & Metabolism	AI5FP	WOS:000336891100017	24642087				2022-02-06	
J	Burlew, CC; Biffl, WL; Moore, EE; Barnett, CC; Johnson, JL; Bensard, DD				Burlew, Clay Cothren; Biffl, Walter L.; Moore, Ernest E.; Barnett, Carlton C.; Johnson, Jeffrey L.; Bensard, Denis D.			Blunt cerebrovascular injuries: Redefining screening criteria in the era of noninvasive diagnosis	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	70th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma (AAST) / Clinical Congress of Acute Care Surgery	SEP 14-17, 2011	Chicago, IL	Amer Assoc Surg Trauma		Cerebrovascular injury; carotid artery injury; vertebral artery injury; trauma; antithrombotics; screening criteria; guidelines	COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CAROTID ARTERIAL INJURIES; VASCULAR NECK INJURIES; TRAUMA; OUTCOMES; ASSOCIATION; ACCURACY; IMPROVES	BACKGROUND: Screening for blunt cerebrovascular injuries (BCVIs) and early treatment has virtually eliminated injury-related strokes. Screening protocols developed in the 1990s captured similar to 80% of ultimately identified BCVI. With the availability of noninvasive diagnosis with computed tomographic angiography, broader indications for screening seem warranted. The purpose of this study was to identify injury patterns of patients with BCVI that are not currently recommended screening criteria. METHODS: Our prospective BCVI database, initiated in 1997, was queried through December 2010. Indications for screening, injury mechanism, and outcomes were analyzed. Patients younger than 18 years were excluded. RESULTS: During the 14-year study period, 585 BCVIs were identified in 418 patients (66% men; age, 40 years +/- 0.7 years). Eighty-three (20%) patients with BCVI did not have standard screening criteria; 66% were asymptomatic at diagnosis. Injury patterns in these patients included mandible fracture (27 patients), complex skull fractures (21 patients), traumatic brain injury with thoracic trauma (6 patients), scalp degloving (6 patients), and great vessel or cardiac injuries (4 patients). Other injuries (11 patients) and no injuries (8 patients) were identified in the remainder. Of the 307 asymptomatic patients who received antithrombotic treatment, one patient suffered stroke (0.3%) and one patient a transient ischemic attack (0.3%). CONCLUSIONS: A significant number of patients suffering BCVI are not captured by current screening guidelines. Screening for BCVI should be considered in patients with mandible fractures, complex skull fractures, traumatic brain injury with thoracic injuries, scalp degloving, and thoracic vascular injuries. (J Trauma. 2012; 72: 330-337. Copyright (C) 2012 by Lippincott Williams & Wilkins)	[Burlew, Clay Cothren] Denver Hlth Med Ctr, Dept Surg, Denver, CO 80204 USA; Univ Colorado, Sch Med, Denver, CO USA		Burlew, CC (corresponding author), Denver Hlth Med Ctr, Dept Surg, 777 Bannock St,MC 0206, Denver, CO 80204 USA.	clay.cothren@dhha.org					Berne JD, 2006, J TRAUMA, V60, P1204, DOI 10.1097/01.ta.0000220435.55791.ce; Berne JD, 2010, J VASC SURG, V51, P57, DOI 10.1016/j.jvs.2009.08.071; Biffl WL, 2009, J TRAUMA, V67, P1150, DOI 10.1097/TA.0b013e3181c1c1d6; Biffl WL, 2006, J TRAUMA, V60, P745, DOI 10.1097/01.ta.0000204034.94034.c4; Biffl WL, 2002, ANN SURG, V235, P699, DOI 10.1097/00000658-200205000-00012; Biffl WL, 1998, ANN SURG, V228, P462, DOI 10.1097/00000658-199810000-00003; Biffl WL, 1999, J TRAUMA, V47, P845, DOI 10.1097/00005373-199911000-00004; Biffl WL, 1999, AM J SURG, V178, P517, DOI 10.1016/S0002-9610(99)00245-7; Bromberg WJ, 2010, J TRAUMA, V68, P471, DOI 10.1097/TA.0b013e3181cb43da; COGBILL TH, 1994, J TRAUMA, V37, P473, DOI 10.1097/00005373-199409000-00024; Cook A, 2011, J TRAUMA, V71, P114, DOI 10.1097/TA.0b013e31821c350f; Cothren CC, 2007, SURGERY, V141, P76, DOI 10.1016/j.surg.2006.04.005; Cothren CC, 2009, ARCH SURG-CHICAGO, V144, P685, DOI 10.1001/archsurg.2009.111; Cothren CC, 2005, AM J SURG, V190, P845, DOI 10.1016/j.amsurg.2005.08.007; Cothren CC, 2004, ARCH SURG-CHICAGO, V139, P540, DOI 10.1001/archsurg.139.5.540; CRISSEY MM, 1974, SURGERY, V75, P543; DAVIS JW, 1990, J TRAUMA, V30, P1514, DOI 10.1097/00005373-199012000-00013; DiCocco JM, 2011, J AM COLL SURGEONS, V212, P549, DOI 10.1016/j.jamcollsurg.2010.12.035; DiCocco JM, 2011, ANN SURG, V253, P444, DOI 10.1097/SLA.0b013e31820d946b; Eastman AL, 2006, J TRAUMA, V60, P925, DOI 10.1097/01.ta.0000197479.28714.62; Eastman AL, 2009, J TRAUMA, V67, P551, DOI 10.1097/TA.0b013e3181b84408; Emmett KP, 2011, J TRAUMA, V70, P1058, DOI 10.1097/TA.0b013e318213f849; Fabian TC, 2002, ANN SURG, V235, P706; Fabian TC, 1996, ANN SURG, V223, P513, DOI 10.1097/00000658-199605000-00007; FABIAN TC, 1990, J TRAUMA, V30, P953, DOI 10.1097/00005373-199008000-00003; Fleck SK, 2011, NEUROSURGERY, V69, P615, DOI 10.1227/NEU.0b013e31821a8701; Flint L, 2011, J AM COLL SURGEONS, V212, P557; Hipp A, 2008, EUR J EMERG MED, V15, P134, DOI 10.1097/MEJ.0b013e328270367d; Jones TS, 2011, AM J SURG; KRAJEWSKI LP, 1980, ANN SURG, V191, P341, DOI 10.1097/00000658-198003000-00014; Mayberry JC, 2004, ARCH SURG-CHICAGO, V139, P609, DOI 10.1001/archsurg.139.6.609; McKevitt EC, 2002, J TRAUMA, V53, P472, DOI 10.1097/00005373-200209000-00013; Miller PR, 2002, ANN SURG, V236, P386, DOI 10.1097/00000658-200209000-00015; MOKRI B, 1988, J NEUROSURG, V68, P189, DOI 10.3171/jns.1988.68.2.0189; Parikh AA, 1997, J AM COLL SURGEONS, V185, P80, DOI 10.1016/S1072-7515(97)00002-1; Schneidereit NP, 2006, J TRAUMA, V60, P209, DOI 10.1097/01.ta.0000195651.60080.2c; Sliker CW, 2008, AM J ROENTGENOL, V190, P790, DOI 10.2214/AJR.07.2378; Stein DM, 2009, J TRAUMA, V66, P132, DOI 10.1097/TA.0b013e318142d146; Utter GH, 2006, J AM COLL SURGEONS, V203, P838, DOI 10.1016/j.jamcollsurg.2006.08.003	39	110	111	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	FEB	2012	72	2					330	337		10.1097/TA.0b013e31823de8a0			8	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	898ZN	WOS:000300781000021	22327974				2022-02-06	
J	Kimpara, H; Iwamoto, M				Kimpara, Hideyuki; Iwamoto, Masami			Mild Traumatic Brain Injury Predictors Based on Angular Accelerations During Impacts	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Concussion; Traumatic brain injury; Acceleration; Rotation; Injury; Injury criterion; Finite Element model; Head; Brain	AXONAL INJURY; HEAD IMPACTS; TOLERANCE; FOOTBALL; CONCUSSION; STRAIN	Although Head Injury Criterion (HIC) is an effective criterion for head injuries caused by linear acceleration such as skull fractures, no criteria for head injuries caused by rotational kinematics has been accepted as effective so far. This study proposed two criteria based on angular accelerations for Traumatic Brain Injury (TBI), which we call Rotational Injury Criterion (RIC) and Power Rotational Head Injury Criterion (PRHIC). Concussive and non-concussive head acceleration data obtained from football head impacts were utilized to develop new injury criteria. A well-validated human brain Finite Element (FE) model was employed to find out effective injury criteria for TBI. Correlation analyses were performed between the proposed criteria and FE-based brain injury predictors such as Cumulative Strain Damage Measure (CSDM), which is defined as the percent volume of the brain that exceeds a specified first principal strain threshold, proposed to predict Diffuse Axonal Injury (DAI) which is one of TBI. The RIC was significantly correlated with the CSDMs with the strain thresholds of less than 15% (R > 0.89), which might predict mild TBI. In addition, PRHIC was also strongly correlated with the CSDMs with the strain thresholds equal to or greater than 20% (R > 0.90), which might predict more severe TBI.	[Kimpara, Hideyuki; Iwamoto, Masami] Toyota Cent Res & Dev Labs Inc, Vehicle Safety & Biomech Lab, Nagakute, Aichi 4801192, Japan		Kimpara, H (corresponding author), Toyota Cent Res & Dev Labs Inc, Vehicle Safety & Biomech Lab, 41-1 Yokomichi, Nagakute, Aichi 4801192, Japan.	h-kimpara@mosk.tytlabs.co.jp	Kimpara, Hideyuki/W-9542-2019	Kimpara, Hideyuki/0000-0001-6441-6062	THUMS(TM)	The THUMS (TM) has been developed by Toyota Central R&D Labs., Inc. (TCRDL) and Toyota Motor Corporation (TMC) in conjunctions with the Wayne State University (WSU). The authors work for TCRDL which has a financial interest in the THUMS (TM). However, there is no financial interest in the basic ideas of this study regarding RIC and PRHIC.	Beusenberg MC., 2000, P INT RES C BIOM IMP; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Dokko Y., 2003, P 18 INT TECHN C ENH; Donnelly B. R., 1983, P 27 STAPP CAR CRASH; Ellen Hertz, 1993, 37 ANN P ASS ADV AUT, V37, P303; Ewing C. L., 1975, P 19 STAPP CAR CRASH; Feist F., 2009, P 21 INT TECHN C ENH, P15; Gadd C. W., 1966, P 10 STAPP CAR CRASH; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Hardy, 2003, P INT RES C BIOM IMP; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Kimpara, 2011, INT J AUTOMOT ENG, V2, P13, DOI [10.20485/jsaeijae.2.2_13, DOI 10.20485/JSAEIJAE.2.2_13]; Kimpara Hideyuki, 2006, Stapp Car Crash J, V50, P509; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; LOWENHIELM P, 1974, Z RECHTSMED, V75, P131, DOI 10.1007/BF02114709; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Nahum AM, 1977, P 21 STAPP CAR CRASH; NAKAHIRA Y, 2000, P IRCOBI C, P147; Newman J A, 2000, Stapp Car Crash J, V44, P215; Ommaya A. K., 1967, P 11 STAPP CAR CRASH; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; Patrick L. M., 1963, P 7 STAPP CAR CRASH, P483; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; PRASAD P, 1985, 851246 SAE; Rowson S, 2011, J APPL BIOMECH, V27, P8, DOI 10.1123/jab.27.1.8; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Takhounts E.G., 2011, 22 INT TECHN C ENH S; Takhounts Erik G, 2003, Stapp Car Crash J, V47, P107; Takhounts EG, 2008, STAPP CAR C, V52, P1; Tamura A, 2007, STAPP CAR CRASH JO, V51, P139; Thibault L. E., 1985, 10 INT TECHN C EXP S; Trosseille X., 1992, P 36 STAPP CAR CRASH; Versace, 1971, P 15 STAPP CAR CRASH, DOI DOI 10.4271/710881; VIANO DC, 1999, CRASH PREV INJ CONTR, V1, P35; Willinger R, 2003, INT J CRASHWORTHINES, V8, P605, DOI 10.1533/ijcr.2003.0264	37	110	112	2	33	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	JAN	2012	40	1			SI		114	126		10.1007/s10439-011-0414-2			13	Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Engineering	895HJ	WOS:000300486700011	21994065				2022-02-06	
J	Wang, X; Sirianni, A; Pei, ZJ; Cormier, K; Smith, K; Jiang, JY; Zhou, SH; Wang, H; Zhao, R; Yano, H; Kim, JE; Li, W; Kristal, BS; Ferrante, RJ; Friedlander, RM				Wang, Xin; Sirianni, Ana; Pei, Zhijuan; Cormier, Kerry; Smith, Karen; Jiang, Jiying; Zhou, Shuanhu; Wang, Hui; Zhao, Rong; Yano, Hiroko; Kim, Jeong Eun; Li, Wei; Kristal, Bruce S.; Ferrante, Robert J.; Friedlander, Robert M.			The Melatonin MT1 Receptor Axis Modulates Mutant Huntingtin-Mediated Toxicity	JOURNAL OF NEUROSCIENCE			English	Article							MITOCHONDRIAL PERMEABILITY TRANSITION; CYTOCHROME-C RELEASE; TRANSGENIC MOUSE MODEL; TRAUMATIC BRAIN-INJURY; OXIDATIVE DAMAGE; DOUBLE-BLIND; NEURONAL DYSFUNCTION; COENZYME Q(10); DISEASE; INHIBITION	Melatonin mediates neuroprotection in several experimental models of neurodegeneration. It is not yet known, however, whether melatonin provides neuroprotection in genetic models of Huntington's disease (HD). We report that melatonin delays disease onset and mortality in a transgenic mouse model of HD. Moreover, mutant huntingtin (htt)-mediated toxicity in cells, mice, and humans is associated with loss of the type 1 melatonin receptor (MT1). We observe high levels of MT1 receptor in mitochondria from the brains of wild-type mice but much less in brains from HD mice. Moreover, we demonstrate that melatonin inhibits mutant htt-induced caspase activation and preserves MT1 receptor expression. This observation is critical, because melatonin-mediated protection is dependent on the presence and activation of the MT1 receptor. In summary, we delineate a pathologic process whereby mutant htt-induced loss of the mitochondrial MT1 receptor enhances neuronal vulnerability and potentially accelerates the neurodegenerative process.	[Yano, Hiroko; Friedlander, Robert M.] Univ Pittsburgh, Dept Neurol Surg, Sch Med, Neuroapoptosis Lab, Pittsburgh, PA 15213 USA; [Wang, Xin; Sirianni, Ana; Pei, Zhijuan; Jiang, Jiying; Wang, Hui; Zhao, Rong; Yano, Hiroko; Kim, Jeong Eun; Li, Wei] Harvard Univ, Sch Med, Brigham & Womens Hosp, Neuroapoptosis Lab, Boston, MA 02115 USA; [Wang, Xin; Sirianni, Ana; Pei, Zhijuan; Jiang, Jiying; Wang, Hui; Zhao, Rong; Yano, Hiroko; Kim, Jeong Eun; Li, Wei; Kristal, Bruce S.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02115 USA; [Zhou, Shuanhu] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Orthoped Surg, Boston, MA 02115 USA; [Cormier, Kerry; Smith, Karen; Ferrante, Robert J.] Bedford Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bedford, MA 01730 USA; [Cormier, Kerry; Smith, Karen; Ferrante, Robert J.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Cormier, Kerry; Smith, Karen; Ferrante, Robert J.] Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA; [Cormier, Kerry; Smith, Karen; Ferrante, Robert J.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA		Friedlander, RM (corresponding author), Univ Pittsburgh, Med Ctr, Presbyterian Hosp, Dept Neurol Surg,Sch Med, Suite 449,200 Lothrop St, Pittsburgh, PA 15213 USA.	xwang@rics.bwh.harvard.edu; friedlanderr@upmc.edu	Kim, Jeong Eun/J-5434-2012; Zhou, Shuanhu/AAW-4405-2021; Friedlander, Robert M/A-2845-2016; Zhou, Shuanhu/Q-7137-2019	Friedlander, Robert M/0000-0003-4423-9219; Zhou, Shuanhu/0000-0003-4745-5347	National Institutes of Health/National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); Muscular Dystrophy AssociationMuscular Dystrophy Association; Huntington's Disease Society of America; Veterans AdministrationUS Department of Veterans Affairs; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [P30DK040561] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS051756, R01NS039324] Funding Source: NIH RePORTER	This work was supported by grants from the National Institutes of Health/National Institute of Neurological Disorders and Stroke (R. M. F., X. W., R.J.F.), the Muscular Dystrophy Association (X. W.), the Huntington's Disease Society of America (R. M. F.,) and the Veterans Administration (R.J.F.). We thank Dr. Ethan M. Shimony and Dr. Diane Carlisle for editorial assistance, Dr. Irina Stavrovskaya, Jennifer Moody, and Diane Sheldon for experimental assistance, and Dr. Ahmad Aziz for insightful discussion.	Adamczyk A, 2005, J Physiol Pharmacol, V56 Suppl 2, P5; Andrabi SA, 2004, FASEB J, V18, P869, DOI 10.1096/fj.03-1031fje; Aziz NA, 2009, J NEUROL, V256, P1961, DOI 10.1007/s00415-009-5196-1; Bennett EJ, 2007, NATURE, V448, P704, DOI 10.1038/nature06022; Blazejova K, 2000, Sb Lek, V101, P347; Brydon L, 2001, ENDOCRINOLOGY, V142, P4264, DOI 10.1210/en.142.10.4264; Caballero B, 2008, J PINEAL RES, V45, P302, DOI 10.1111/j.1600-079X.2008.00591.x; Carranza-Lira S, 2000, Med Sci Monit, V6, P1209; Cazevieille C, 1997, BRAIN RES, V768, P120, DOI 10.1016/S0006-8993(97)00611-2; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; Chopra V, 2007, P NATL ACAD SCI USA, V104, P16685, DOI 10.1073/pnas.0707842104; COGBURN LA, 1987, GEN COMP ENDOCR, V68, P343, DOI 10.1016/0016-6480(87)90073-6; Das A, 2008, J PINEAL RES, V45, P117, DOI 10.1111/j.1600-079X.2008.00582.x; Dominguez-Rodriguez A, 2007, CONTEMP CLIN TRIALS, V28, P532, DOI 10.1016/j.cct.2006.10.007; Drew JE, 2001, J NEUROENDOCRINOL, V13, P453, DOI 10.1046/j.1365-2826.2001.00651.x; Engidawork E, 2001, BIOCHEM BIOPH RES CO, V281, P84, DOI 10.1006/bbrc.2001.4306; Ferrante RJ, 2002, J NEUROSCI, V22, P1592, DOI 10.1523/JNEUROSCI.22-05-01592.2002; Franklin K.B., 2000, MOUSE BRAIN STEREOTA; Friedlander RM, 2003, NEW ENGL J MED, V348, P1365, DOI 10.1056/NEJMra022366; Graham RK, 2006, CELL, V125, P1179, DOI 10.1016/j.cell.2006.04.026; Gupta M, 2004, EPILEPSY BEHAV, V5, P316, DOI 10.1016/j.yebeh.2004.01.012; Heiser V, 2000, P NATL ACAD SCI USA, V97, P6739, DOI 10.1073/pnas.110138997; Kasahara T, 2010, P NATL ACAD SCI USA, V107, P6412, DOI 10.1073/pnas.0914399107; Kiechle T, 2002, NEUROMOL MED, V1, P183; Kilic E, 2004, J PINEAL RES, V36, P171, DOI 10.1046/j.1600-079X.2003.00115.x; Kobayashi H, 2005, FASEB J, V19, P1710, DOI 10.1096/fj.04-2293fje; Krasnikov BF, 2005, BBA-BIOENERGETICS, V1708, P375, DOI 10.1016/j.bbabio.2005.05.009; Lena PJ, 2003, POL J PHARMACOL, V55, P1031; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li XJ, 1999, MOL NEUROBIOL, V20, P111, DOI 10.1007/BF02742437; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Martin M, 2000, FASEB J, V14, P1677; Masuda N, 2008, NEUROBIOL DIS, V30, P293, DOI 10.1016/j.nbd.2008.01.014; Medeiros CAM, 2007, J NEUROL, V254, P459, DOI 10.1007/s00415-006-0390-x; MOCCHEGIANI E, 1994, J NEUROIMMUNOL, V53, P189, DOI 10.1016/0165-5728(94)90029-9; Niles LP, 2004, BMC NEUROSCI, V5, DOI 10.1186/1471-2202-5-41; Niles LP, 1999, MOL CELL ENDOCRINOL, V156, P107, DOI 10.1016/S0303-7207(99)00135-5; Ona VO, 1999, NATURE, V399, P263, DOI 10.1038/20446; Ozcankaya R, 2002, CROAT MED J, V43, P28; Ozdemir D, 2005, PHYSIOL RES, V54, P631; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; Ravindra T, 2006, Indian J Med Sci, V60, P523; Reiter RJ, 2002, J PINEAL RES, V33, P61, DOI 10.1034/j.1600-079X.2002.2e001.x; Rigamonti D, 2001, J BIOL CHEM, V276, P14545, DOI 10.1074/jbc.C100044200; Sanchez-Hidalgo M, 2009, J PINEAL RES, V46, P29, DOI 10.1111/j.1600-079X.2008.00604.x; Savaskan E, 2002, J HISTOCHEM CYTOCHEM, V50, P519, DOI 10.1177/002215540205000408; Savaskan E, 2007, CURR ALZHEIMER RES, V4, P47, DOI 10.2174/156720507779939823; Savina TA, 2006, B EXP BIOL MED+, V142, P601, DOI 10.1007/s10517-006-0429-0; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Southgate G, 1999, METAB BRAIN DIS, V14, P165, DOI 10.1023/A:1020610708637; Srinivasan V, 2006, Behav Brain Funct, V2, P15, DOI 10.1186/1744-9081-2-15; Stack EC, 2006, BBA-MOL BASIS DIS, V1762, P373, DOI 10.1016/j.bbadis.2005.11.002; Stavrovskaya IG, 2005, FREE RADICAL BIO MED, V38, P687, DOI 10.1016/j.freeradbiomed.2004.11.032; Tan Dun-Xian, 2002, Current Topics in Medicinal Chemistry, V2, P181, DOI 10.2174/1568026023394443; Thome M, 1998, CURR BIOL, V8, P885, DOI 10.1016/S0960-9822(07)00352-1; Tunez I, 2004, J PINEAL RES, V37, P252, DOI 10.1111/j.1600-079X.2004.00163.x; Turmaine M, 2000, P NATL ACAD SCI USA, V97, P8093, DOI 10.1073/pnas.110078997; WALDHAUSER F, 1984, NEUROENDOCRINOLOGY, V39, P307, DOI 10.1159/000123997; Wang X, 2005, J NEUROSCI, V25, P11645, DOI 10.1523/JNEUROSCI.4181-05.2005; Wang X, 2003, P NATL ACAD SCI USA, V100, P10483, DOI 10.1073/pnas.1832501100; Wang X, 2008, J NEUROSCI, V28, P9473, DOI 10.1523/JNEUROSCI.1867-08.2008; Wang X, 2009, STROKE, V40, P1877, DOI 10.1161/STROKEAHA.108.540765; Weishaupt JH, 2006, J PINEAL RES, V41, P313, DOI 10.1111/j.1600-079X.2006.00377.x; Willis GL, 1999, PHYSIOL BEHAV, V66, P785, DOI 10.1016/S0031-9384(99)00023-2; Zhang WH, 2003, P NATL ACAD SCI USA, V100, P16012, DOI 10.1073/pnas.2534856100; Zhang Y, 2003, J NEUROCHEM, V87, P1184, DOI 10.1046/j.1471-4159.2003.02105.x; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a	68	110	113	0	8	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	OCT 12	2011	31	41					14496	14507		10.1523/JNEUROSCI.3059-11.2011			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	835FB	WOS:000296019600007	21994366	Green Accepted, Green Published, Bronze			2022-02-06	
J	Greer, JE; McGinn, MJ; Povlishock, JT				Greer, John E.; McGinn, Melissa J.; Povlishock, John T.			Diffuse Traumatic Axonal Injury in the Mouse Induces Atrophy, c-Jun Activation, and Axonal Outgrowth in the Axotomized Neuronal Population	JOURNAL OF NEUROSCIENCE			English	Article							RAT CORTICOSPINAL NEURONS; EXPERIMENTAL BRAIN-INJURY; ADULT-RAT; TRANSCRIPTION FACTOR; PROTEIN EXPRESSION; WHITE-MATTER; RED NUCLEUS; CELL-DEATH; REGENERATION; RECOVERY	Traumatic axonal injury (TAI) is a consistent component of traumatic brain injury (TBI) and is associated with much of its morbidity. Little is known regarding the long-term retrograde neuronal consequences of TAI and/or the potential that TAI could lead to anterograde axonal reorganization and repair. To investigate the repertoire of anterograde and retrograde responses triggered by TIA, Thy1-YFP-H mice were subjected to mild central fluid percussion injury and killed at various times between 15 min and 28 d post-injury. Based upon confocal assessment of the endogenous neuronal fluorescence, such injury was found to result in diffuse TAI throughout layer V of the neocortex within yellow fluorescent protein (YFP)-positive axons. When these fluorescent approaches were coupled with various quantitative and immunohistochemical approaches, we found that this TAI did not result in neuronal death over the 28 d period assessed. Rather, it elicited neuronal atrophy. Within these same axotomized neuronal populations, TAI was also found to induce an early and sustained activation of the transcription factors c-Jun and ATF-3 (activating transcription factor 3), known regulators of axon regeneration. Parallel ultrastructural studies confirmed that these reactive changes are consistent with atrophy in the absence of neuronal death. Concurrent with those events ongoing in the neuronal cell bodies, their downstream axonal segments revealed, as early as 1 d post-injury, morphological changes consistent with reactive sprouting that was accompanied by significant axonal elongation over time. Collectively, these TAI-linked events are consistent with sustained neuronal recovery, an activation of a regenerative genetic program, and subsequent axonal reorganization suggestive of some form of regenerative response.	[Greer, John E.; McGinn, Melissa J.; Povlishock, John T.] Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA 23298 USA		Greer, JE (corresponding author), Virginia Commonwealth Univ, Dept Anat & Neurobiol, POB 980709, Richmond, VA 23298 USA.	jtpovlis@vcu.edu	Greer, John/K-1008-2012		National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD055813, NS047463, NS007288]; NIH-NINDS CenterUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5P30NS047463-02]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD055813] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045824, T32NS007288, P30NS047463] Funding Source: NIH RePORTER	This research was supported by National Institutes of Health (NIH) Grants HD055813, NS047463, and NS007288. Microscopy was performed at the VCU Department of Anatomy and Neurobiology Microscopy Facility, supported, in part, with funding from NIH-NINDS Center core grant (5P30NS047463-02). We thank Scott Henderson, PhD, Robert J Hamm, PhD, Thomas Reeves, PhD, Susan A Walker, Carol Lynn Davis, and Audrey Lafrenaye, PhD, for their technical assistance and guidance in various aspects of this study.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; BARRON KD, 1988, J NEUROPATH EXP NEUR, V47, P62, DOI 10.1097/00005072-198801000-00008; BARRON KD, 1979, J NEUROPATH EXP NEUR, V38, P128, DOI 10.1097/00005072-197903000-00005; Barron KD, 2004, J NEUROL SCI, V220, P119, DOI 10.1016/j.jns.2004.03.009; BARRON KD, 1975, J NEUROPATH EXP NEUR, V34, P222, DOI 10.1097/00005072-197505000-00002; Bonatz H, 2000, J NEUROSCI METH, V100, P105, DOI 10.1016/S0165-0270(00)00238-7; BRECHT S, 1995, EXP NEUROL, V134, P112, DOI 10.1006/exnr.1995.1042; Broude E, 1997, EXP NEUROL, V148, P367, DOI 10.1006/exnr.1997.6665; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Campbell G, 2005, EXP NEUROL, V192, P340, DOI 10.1016/j.expneurol.2004.11.026; Carter LM, 2008, J NEUROSCI, V28, P14107, DOI 10.1523/JNEUROSCI.2217-08.2008; Casafont I, 2007, J STRUCT BIOL, V159, P451, DOI 10.1016/j.jsb.2007.05.004; CORDOBES F, 1986, ACTA NEUROCHIR, V81, P27, DOI 10.1007/BF01456261; Csuka E, 2000, NEUROREPORT, V11, P2587, DOI 10.1097/00001756-200008030-00047; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dray C, 2009, P NATL ACAD SCI USA, V106, P9459, DOI 10.1073/pnas.0900222106; Emery DL, 2000, J COMP NEUROL, V424, P521; ERB DE, 1991, EXP BRAIN RES, V83, P253; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; Gervasi NM, 2008, REGEN MED, V3, P907, DOI 10.2217/17460751.3.6.907; Giehl KM, 1997, EUR J NEUROSCI, V9, P2479, DOI 10.1111/j.1460-9568.1997.tb01665.x; Giehl KM, 1996, EUR J NEUROSCI, V8, P1167, DOI 10.1111/j.1460-9568.1996.tb01284.x; Ham J, 2000, BIOCHEM PHARMACOL, V60, P1015, DOI 10.1016/S0006-2952(00)00372-5; Harris NG, 2009, J NEUROSCI RES, V87, P2937, DOI 10.1002/jnr.22115; Harris NG, 2010, J NEUROPATH EXP NEUR, V69, P139, DOI 10.1097/NEN.0b013e3181cb5bee; Herdegen T, 1997, TRENDS NEUROSCI, V20, P227, DOI 10.1016/S0166-2236(96)01000-4; Herdegen T, 1998, J NEUROSCI, V18, P5124, DOI 10.1523/JNEUROSCI.18-14-05124.1998; Huber AB, 2002, J NEUROSCI, V22, P3553; Hughes PE, 1999, PROG NEUROBIOL, V57, P421, DOI 10.1016/S0301-0082(98)00057-4; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Iseda T, 2003, J COMP NEUROL, V464, P343, DOI 10.1002/cne.10786; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kenney AM, 1998, J NEUROSCI, V18, P1318; Kreutzberg Georg W., 1995, P355; Li P, 2008, J NEUROSCI, V28, P11970, DOI 10.1523/JNEUROSCI.3724-08.2008; Li Y, 1998, J NEUROSCI, V18, P10514; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Mandolesi G, 2004, FASEB J, V18, P1934, DOI 10.1096/fj.04-1805fje; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MCBRIDE RL, 1989, J NEUROPATH EXP NEUR, V48, P568, DOI 10.1097/00005072-198909000-00007; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MERLINE M, 1990, J COMP NEUROL, V296, P506, DOI 10.1002/cne.902960313; Nakagomi S, 2003, J NEUROSCI, V23, P5187; Pan YA, 2003, J NEUROSCI, V23, P11479; Paxinos G., 2003, MOUSE BRAIN STEREOTA, V2; Peters A., 1991, FINE STRUCTURE NERVO, V3rd ed.; Pettigrew DB, 1999, J NEUROSCI, V19, P8358; PETTIGREW DB, 2001, BMC NEUROSCI, V2, pNIL14; Phillips LL, 2001, RESTOR NEUROL NEUROS, V19, P213; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Raisman G, 2004, NAT REV NEUROSCI, V5, P157, DOI 10.1038/nrn1328; Raivich G, 2004, NEURON, V43, P57, DOI 10.1016/j.neuron.2004.06.005; Raivich G, 2008, J NEUROCHEM, V107, P898, DOI 10.1111/j.1471-4159.2008.05684.x; Raivich G, 2007, BRAIN RES REV, V53, P287, DOI 10.1016/j.brainresrev.2006.09.005; Raivich G, 2006, PROG NEUROBIOL, V78, P347, DOI 10.1016/j.pneurobio.2006.03.006; Reid AJ, 2010, BRAIN RES, V1310, P1, DOI 10.1016/j.brainres.2009.11.011; Richardson PM, 2009, NEUROSURGERY, V65, pA74, DOI 10.1227/01.NEU.0000352378.26755.C3; Seijffers R, 2007, J NEUROSCI, V27, P7911, DOI 10.1523/JNEUROSCI.5313-06.2007; Seijffers R, 2006, MOL CELL NEUROSCI, V32, P143, DOI 10.1016/j.mcn.2006.03.005; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; Sugino K, 2006, NAT NEUROSCI, V9, P99, DOI 10.1038/nn1618; Tang XQ, 2004, NEUROREPORT, V15, P425, DOI 10.1097/00001756-200403010-00009; Weber JT, 2004, CURR NEUROVASC RES, V1, P151, DOI 10.2174/1567202043480134; Yamamoto T, 1988, J NEUROTRAUM, V5, P69, DOI 10.1089/neu.1988.5.69	73	110	111	0	12	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474	1529-2401		J NEUROSCI	J. Neurosci.	MAR 30	2011	31	13					5089	5105		10.1523/JNEUROSCI.5103-10.2011			17	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	742JM	WOS:000288938200034	21451046	Green Published, Bronze, Green Accepted			2022-02-06	
J	Mihalik, JP; Blackburn, JT; Greenwald, RM; Cantu, RC; Marshall, SW; Guskiewicz, KM				Mihalik, Jason P.; Blackburn, J. Troy; Greenwald, Richard M.; Cantu, Robert C.; Marshall, Stephen W.; Guskiewicz, Kevin M.			Collision Type and Player Anticipation Affect Head Impact Severity Among Youth Ice Hockey Players	PEDIATRICS			English	Article						child; concussion; injury; physical activity; sports; trauma	SEGMENT DYNAMIC STABILIZATION; TRAUMATIC UNCONSCIOUSNESS; CEREBRAL CONCUSSION; FOOTBALL PLAYERS; INJURIES; ACCELERATION; CHIMPANZEE; MILD	OBJECTIVE: The objective was to determine how body collision type and player anticipation affected the severity of head impacts sustained by young athletes. For anticipated collisions, we sought to evaluate different body position descriptors during delivery and receipt of body collisions and their effects on head impact severity. We hypothesized that head impact biomechanical features would be more severe in unanticipated collisions and open-ice collisions, compared with anticipated collisions and collisions along the playing boards, respectively. METHODS: Sixteen ice hockey players (age: 14.0 +/- 0.5 years) wore instrumented helmets from which biomechanical measures (ie, linear acceleration, rotational acceleration, and severity profile) associated with head impacts were computed. Body collisions observed in video footage captured over a 54-game season were evaluated for collision type (open ice versus along the playing boards), level of anticipation (anticipated versus unanticipated), and relative body positioning by using a new tool developed for this purpose. RESULTS: Open-ice collisions resulted in greater head linear (P = .036) and rotational (P = .003) accelerations, compared with collisions along the playing boards. Anticipated collisions tended to result in less-severe head impacts than unanticipated collisions, especially for medium-intensity impacts (50th to 75th percentiles of severity scores). CONCLUSION: Our data underscore the need to provide players with the necessary technical skills to heighten their awareness of imminent collisions and to mitigate the severity of head impacts in this sport. Pediatrics 2010; 125: e1394-e1401	[Mihalik, Jason P.] Univ N Carolina, Dept Exercise & Sport Sci, Sports Med Res Lab, Chapel Hill, NC 27599 USA; [Blackburn, J. Troy] Univ N Carolina, Dept Exercise & Sport Sci, Neuromuscular Res Lab, Chapel Hill, NC 27599 USA; [Mihalik, Jason P.; Blackburn, J. Troy; Guskiewicz, Kevin M.] Univ N Carolina, Curriculum Human Movement Sci, Sch Med, Chapel Hill, NC 27599 USA; [Marshall, Stephen W.] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27599 USA; [Marshall, Stephen W.; Guskiewicz, Kevin M.] Univ N Carolina, Injury Prevent Res Ctr, Chapel Hill, NC 27599 USA; [Greenwald, Richard M.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA; [Cantu, Robert C.] Emerson Hosp, Dept Neurosurg, Concord, MA USA; [Cantu, Robert C.] Emerson Hosp, Dept Sport Med, Concord, MA USA		Mihalik, JP (corresponding author), Univ N Carolina, Dept Exercise & Sport Sci, Sports Med Res Lab, 209 Fetzer Gymnasium,South Rd, Chapel Hill, NC 27599 USA.	jmihalik@email.unc.edu	Mihalik, Jason P/E-7059-2010	Mihalik, Jason/0000-0001-6085-8322; Guskiewicz, Kevin/0000-0002-8682-2130; Marshall, Stephen/0000-0002-2664-9233	HIT System technology; Ontario Neurotrauma Foundation; National Operating Committee on Standards for Athletic Equipment; USA Hockey Foundation	FINANCIAL DISCLOSURE: Dr Greenwald has a financial interest in the HIT System technology used to collect data in this study.; Funding for this research was obtained from the Ontario Neurotrauma Foundation, the National Operating Committee on Standards for Athletic Equipment, and the USA Hockey Foundation.	Bailes JE, 2001, J ATHL TRAINING, V36, P236; BRUST JD, 1992, AM J DIS CHILD, V146, P741, DOI 10.1001/archpedi.1992.02160180101026; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Demidenko E., 2004, MIXED MODELS THEORY; Finkelstein E., 2006, INCIDENCE EC BURDEN; GERBERICH SG, 1987, CHILD NERV SYST, V3, P59, DOI 10.1007/BF00271123; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Holbourn AHS, 1943, LANCET, V2, P438; HOLBOURN AHS, 1945, BRIT MED BULL, V3, P147, DOI 10.1093/oxfordjournals.bmb.a071895; Langlois JA., 2004, TRAUMATIC BRAIN INJU; LETCHER FS, 1973, J NEUROSURG, V39, P167, DOI 10.3171/jns.1973.39.2.0167; Mansell J, 2005, J ATHL TRAINING, V40, P310; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; Mihalik JP, 2008, P I MECH ENG P-J SPO, V222, P45, DOI 10.1243/17543371JSET4; OMMAYA AK, 1964, J NEUROSURG, V21, P249, DOI 10.3171/jns.1964.21.4.0249; OMMAYA AK, 1973, J NEUROSURG, V39, P152, DOI 10.3171/jns.1973.39.2.0152; OMMAYA AK, 1966, SCIENCE, V153, P211, DOI 10.1126/science.153.3732.211; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Roberts WO, 1999, MED SCI SPORT EXER, V31, P46, DOI 10.1097/00005768-199901000-00009; Tierney RT, 2005, MED SCI SPORT EXER, V37, P272, DOI 10.1249/01.MSS.0000152734.47516.AA; *US HOCK, 2009, HEADS HOCK PROGR GUI	25	110	111	1	21	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	JUN	2010	125	6					E1394	E1401		10.1542/peds.2009-2849			8	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	604GX	WOS:000278268600044	20478933				2022-02-06	
J	Alcala-Barraza, SR; Lee, MS; Hanson, LR; McDonald, AA; Frey, WH; McLoon, LK				Alcala-Barraza, Sandra R.; Lee, Michael S.; Hanson, Leah R.; McDonald, Abby A.; Frey, William H., II; McLoon, Linda K.			Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO, and NT-4 to the CNS	JOURNAL OF DRUG TARGETING			English	Article						Nasal drug delivery; protein delivery; central nervous system (CNS); blood-brain barrier; distribution; neurotrophic factor; ciliary neurotrophic factor; brain-derived neurotrophic factor; insulin growth factor-1; erythropoietin; neurotrophin-4/5; intranasal delivery; brain injury; Akt	NERVE GROWTH-FACTOR; BLOOD-BRAIN-BARRIER; IN-VIVO; DRUG-DELIVERY; INDUCED NEUROTOXICITY; AXONAL REGENERATION; CHOLINERGIC NEURONS; SPINAL-CORD; RAT RETINA; INSULIN	Injury to the central nervous system (CNS) generally results in significant neuronal death and functional loss. In vitro experiments have demonstrated that neurotrophic factors such as brain-derived neurotrophic factor ( BDNF), ciliary neurotrophic factor ( CNTF), and neurotrophin-4/5 (NT-4/5) can promote neuronal survival. However, delivery to the injured CNS is difficult as these large protein molecules do not efficiently cross the blood-brain barrier. Intranasal delivery of 70 mu g [I-125]-radiolabeled BDNF, CNTF, NT-4, or erythropoietin (EPO) resulted in 0.1-1.0 nM neurotrophin concentrations within 25 min in brain parenchyma. In addition, not only did these neurotrophic factors reach the CNS, they were present in sufficient concentrations to activate the prosurvival PI3Kinase/Akt pathway, even where lower levels of neurotrophic factors were measured. Currently traumatic, ischemic and compressive injuries to the CNS have no effective treatment. There is potential clinical relevancy of this method for rescuing injured CNS tissues in order to maintain CNS function in affected patients. The intranasal delivery method has great clinical potential due to ( 1) simplicity of administration, ( 2) noninvasive drug administration, ( 3) relatively rapid CNS delivery, ( 4) ability to repeat dosing easily, ( 5) no requirement for drug modification, and ( 6) minimal systemic exposure.	[Alcala-Barraza, Sandra R.; Lee, Michael S.; McDonald, Abby A.; McLoon, Linda K.] Univ Minnesota, Dept Ophthalmol, Minneapolis, MN 55455 USA; [McLoon, Linda K.] Univ Minnesota, Dept Neurosci, Minneapolis, MN 55455 USA; [Hanson, Leah R.; Frey, William H., II; McLoon, Linda K.] Reg Hosp, Alzheimers Res Ctr, HealthPartners Res Fdn, St Paul, MN USA		McLoon, LK (corresponding author), Univ Minnesota, Dept Ophthalmol, 2001 6th St SE, Minneapolis, MN 55455 USA.	mcloo001@umn.edu		Frey II, William/0000-0002-6373-0794	National Eye Institute, Prevent Blindness AmericaUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI); Glaucoma Foundation; Minnesota Lions and Lionesses; Wasserman Mid-Career Merit Award from Research to Prevent Blindness (RPB)Research to Prevent Blindness (RPB); RPB Inc; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [P30EY011374, P30EY001730] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008471] Funding Source: NIH RePORTER	This work was supported by EY11374 from the National Eye Institute, Prevent Blindness America, the Glaucoma Foundation, the Minnesota Lions and Lionesses, the Lew Wasserman Mid-Career Merit Award from Research to Prevent Blindness (RPB), and an unrestricted grant to the Department of Ophthalmology from RPB Inc.	Agnello D, 2002, BRAIN RES, V952, P128, DOI 10.1016/S0006-8993(02)03239-0; Anderson KD, 1996, P NATL ACAD SCI USA, V93, P7346, DOI 10.1073/pnas.93.14.7346; Arancibia S, 2008, NEUROBIOL DIS, V31, P316, DOI 10.1016/j.nbd.2008.05.012; Azadi S, 2007, BRAIN RES, V1129, P116, DOI 10.1016/j.brainres.2006.10.031; Azoulay D, 2008, J NEUROIMMUNOL, V195, P186, DOI 10.1016/j.jneuroim.2008.01.010; Benedict C, 2004, PSYCHONEUROENDOCRINO, V29, P1326, DOI 10.1016/j.psyneuen.2004.04.003; Benedict C, 2008, J CLIN ENDOCR METAB, V93, P1339, DOI 10.1210/jc.2007-2606; Benedict C, 2007, NEUROENDOCRINOLOGY, V86, P136, DOI 10.1159/000106378; Blitts B, 2003, NEUROSCIENCE, V118, P271, DOI 10.1016/S0306-4522(02)00970-3; Born J, 2002, NAT NEUROSCI, V5, P514, DOI 10.1038/nn849; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Canals JM, 2004, J NEUROSCI, V24, P7727, DOI 10.1523/JNEUROSCI.1197-04.2004; Capsoni S, 2002, P NATL ACAD SCI USA, V99, P12432, DOI 10.1073/pnas.192442999; Chen Xue-Qing, 1998, J Alzheimers Dis, V1, P35; Chu K, 2008, EPILEPSIA, V49, P1723, DOI 10.1111/j.1528-1167.2008.01644.x; CLATTERBUCK RE, 1993, P NATL ACAD SCI USA, V90, P2222, DOI 10.1073/pnas.90.6.2222; Danielyan L, 2005, EUR J CELL BIOL, V84, P907, DOI 10.1016/j.ejcb.2005.07.001; De Rosa R, 2005, P NATL ACAD SCI USA, V102, P3811, DOI 10.1073/pnas.0500195102; DECKNER ML, 1993, NEUROREPORT, V5, P301, DOI 10.1097/00001756-199312000-00030; Diem R, 2005, BRAIN, V128, P375, DOI 10.1093/brain/awh365; Digicaylioglu M, 2004, P NATL ACAD SCI USA, V101, P9855, DOI 10.1073/pnas.0403172101; Emerich DF, 1997, CELL TRANSPLANT, V6, P249, DOI 10.1016/S0963-6897(97)00035-3; Endres M, 2003, J CEREBR BLOOD F MET, V23, P150, DOI 10.1097/01.WCB.0000043949.67811.C6; Ferrer I, 2003, J NEUROPATH EXP NEUR, V62, P329, DOI 10.1093/jnen/62.4.329; Fischer AJ, 2004, MOL CELL NEUROSCI, V27, P531, DOI 10.1016/j.mcn.2004.08.007; Francis G, 2009, DIABETES, V58, P934, DOI 10.2337/db08-1287; Francis GJ, 2008, BRAIN, V131, P3311, DOI 10.1093/brain/awn288; Frey WH, 1997, DRUG DELIV, V4, P87, DOI 10.3109/10717549709051878; Grasso G, 2007, BRAIN RES, V1182, P99, DOI 10.1016/j.brainres.2007.08.078; Hallschmid M, 2008, INT J OBESITY, V32, P275, DOI 10.1038/sj.ijo.0803722; Hallschmid M, 2004, PHYSIOL BEHAV, V83, P55, DOI 10.1016/j.physbeh.2004.07.023; HYMAN C, 1991, NATURE, V350, P230, DOI 10.1038/350230a0; Ikeda K, 2004, CURR EYE RES, V29, P349, DOI 10.1080/02713680490516279; Illum L, 2004, J PHARM PHARMACOL, V56, P3, DOI 10.1211/0022357022539; KOKAIA Z, 1993, P NATL ACAD SCI USA, V90, P6711, DOI 10.1073/pnas.90.14.6711; LEE MY, 1997, NEUROSCIENCE, V68, P979; LEFEBVRE PP, 1994, NEUROREPORT, V5, P865, DOI 10.1097/00001756-199404000-00003; LINDHOLM D, 1993, EUR J NEUROSCI, V5, P1455, DOI 10.1111/j.1460-9568.1993.tb00213.x; Liu XF, 2001, NEUROSCI LETT, V308, P91, DOI 10.1016/S0304-3940(01)01982-6; Liu Xin-Feng, 2004, J Stroke Cerebrovasc Dis, V13, P16, DOI 10.1016/j.jstrokecerebrovasdis.2004.01.005; MAGAL E, 1993, NEUROREPORT, V4, P779, DOI 10.1097/00001756-199306000-00046; Mandel RJ, 1999, EXP NEUROL, V155, P59, DOI 10.1006/exnr.1998.6961; Merkus Frans W H M, 2007, Drugs R D, V8, P133, DOI 10.2165/00126839-200708030-00001; Merkus P, 2003, NEUROLOGY, V60, P1669, DOI 10.1212/01.WNL.0000067993.60735.77; Misra A, 2003, J PHARM PHARM SCI, V6, P252; Nowis D, 2007, INT J ONCOL, V31, P1547; Park K, 2004, J NEUROSCI, V24, P10806, DOI 10.1523/JNEUROSCI.3532-04.2004; Pietrowsky R, 1996, BIOL PSYCHIAT, V39, P332, DOI 10.1016/0006-3223(95)00180-8; Poduslo JF, 1996, MOL BRAIN RES, V36, P280, DOI 10.1016/0169-328X(95)00250-V; Qu HY, 2008, EUR J PHARMACOL, V594, P93, DOI 10.1016/j.ejphar.2008.06.109; Rabacchi SA, 1999, J NEUROBIOL, V40, P254, DOI 10.1002/(SICI)1097-4695(199908)40:2<254::AID-NEU11>3.0.CO;2-4; Rami A, 2008, PROG NEUROBIOL, V85, P273, DOI 10.1016/j.pneurobio.2008.04.003; Reger MA, 2008, NEUROLOGY, V70, P440, DOI 10.1212/01.WNL.0000265401.62434.36; Reger MA, 2006, NEUROBIOL AGING, V27, P451, DOI 10.1016/j.neurobiolaging.2005.03.016; Royo NC, 2006, EUR J NEUROSCI, V23, P1089, DOI 10.1111/j.1460-9568.2006.04642.x; Sadick MD, 1997, EXP CELL RES, V234, P354, DOI 10.1006/excr.1997.3614; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Samelson LE, 2001, CURR PROTOC IMMUNOL; Siren AL, 2001, ACTA NEUROPATHOL, V101, P271, DOI 10.1007/s004010000297; SKAPER SD, 1992, J NEUROSCI RES, V33, P330, DOI 10.1002/jnr.490330217; Sun XM, 2008, INT J DEV NEUROSCI, V26, P363, DOI 10.1016/j.ijdevneu.2007.11.005; Tapia-Arancibia L, 2008, BRAIN RES REV, V59, P201, DOI 10.1016/j.brainresrev.2008.07.007; Thoenen H, 2002, NAT NEUROSCI, V5, P1046, DOI 10.1038/nn938; Thorne RG, 2008, NEUROSCIENCE, V152, P785, DOI 10.1016/j.neuroscience.2008.01.013; Thorne RG, 2004, NEUROSCIENCE, V127, P481, DOI 10.1016/j.neuroscience.2004.05.029; THORNE RG, 1995, BRAIN RES, V692, P278, DOI 10.1016/0006-8993(95)00637-6; Thorne RG, 2001, CLIN PHARMACOKINET, V40, P907, DOI 10.2165/00003088-200140120-00003; TSUKAHARA T, 1994, NEUROSURGERY, V34, P323, DOI 10.1227/00006123-199402000-00016; van Wijngaarden P, 2007, MOL VIS, V13, P1508; WAJCHENBERG BL, 1978, J NUCL MED, V19, P900; Weise J, 2000, NEUROBIOL DIS, V7, P212, DOI 10.1006/nbdi.2000.0285; WIDMER HR, 1993, NEUROREPORT, V4, P363, DOI 10.1097/00001756-199304000-00005; WILLIAMS LR, 1986, P NATL ACAD SCI USA, V83, P9231, DOI 10.1073/pnas.83.23.9231; Yamada K, 2007, J DRUG TARGET, V15, P59, DOI 10.1080/10611860601029496; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0; Yu YP, 2005, NEUROSCI LETT, V387, P5, DOI 10.1016/j.neulet.2005.07.008; Zhang QZ, 2006, J DRUG TARGET, V14, P281, DOI 10.1080/10611860600721051; Zuccato C, 2007, PROG NEUROBIOL, V81, P294, DOI 10.1016/j.pneurobio.2007.01.003	78	110	121	0	14	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1061-186X	1029-2330		J DRUG TARGET	J. Drug Target.	APR	2010	18	3					179	190		10.3109/10611860903318134			12	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	577ZN	WOS:000276262800003	19807216	Green Accepted			2022-02-06	
J	Schwarzmaier, SM; Kim, SW; Trabold, R; Plesnila, N				Schwarzmaier, Susanne M.; Kim, Seong-Woong; Trabold, Raimund; Plesnila, Nikolaus			Temporal Profile of Thrombogenesis in the Cerebral Microcirculation after Traumatic Brain Injury in Mice	JOURNAL OF NEUROTRAUMA			English	Article						cerebral blood flow; leukocytes; mice; microcirculation; microthrombi; platelets; traumatic brain injury	CONTROLLED CORTICAL IMPACT; LEUKOCYTE-ENDOTHELIUM INTERACTIONS; BLOOD-FLOW; INTRAVASCULAR COAGULATION; HEMODYNAMIC DEPRESSION; SECONDARY EXPANSION; THROMBUS FORMATION; RATS; ISCHEMIA; CONTUSION	Traumatic brain injury (TBI) is associated with an almost immediate reduction in cerebral blood flow (CBF). Because cerebral perfusion pressure is often normal under these circumstances it was hypothesized that the reduction of post-traumatic CBF has to occur at the level of the microcirculation. The aim of the current study was to investigate whether cerebral microvessels are involved in the development of blood flow disturbances following experimental TBI. C57/BL6 mice (n = 12) were intubated and ventilated under control of end-tidal PCO2 (ETPCO2). After preparation of a cranial window and baseline recordings, the animals were subjected to experimental TBI by controlled cortical impact (CCI; 6m/sec, 0.5 mm). Vessel lumina and intravascular cells were visualized by in vivo fluorescence microscopy (IVM) using the fluorescent dyes FITC-dextran and rhodamine 6G, respectively. Vessel diameter, cell-endothelial interactions, and thrombus formation were quantified within the traumatic penumbra by IVM up to 2 h after CCI. Arteriolar diameters increased after CCI by 26.2 +/- 2.5% (mean +/- SEM, p<0.01 versus baseline), and remained at this level until the end of the observation period. Rolling of leukocytes on the cerebrovascular endothelium was observed both in arterioles and venules, while leukocyte-platelet aggregates were found only in venules. Microthrombi occluded up to 70% of venules and 33% of arterioles. The current data suggest that the immediate post-traumatic decrease in peri-contusional blood flow is not caused by arteriolar vasoconstriction, but by platelet activation and the subsequent formation of thrombi in the cerebral microcirculation.	[Schwarzmaier, Susanne M.; Kim, Seong-Woong; Plesnila, Nikolaus] Royal Coll Surgeons Ireland, Dublin 2, Ireland; [Schwarzmaier, Susanne M.; Kim, Seong-Woong; Trabold, Raimund; Plesnila, Nikolaus] Univ Munich, Inst Surg Res, Walter Brendel Ctr Expt Med, D-8000 Munich, Germany; [Schwarzmaier, Susanne M.; Kim, Seong-Woong; Trabold, Raimund; Plesnila, Nikolaus] Univ Munich, Dept Neurosurg, Univ Munich Med Ctr Grosshadern, Munich, Germany		Plesnila, N (corresponding author), Royal Coll Surgeons Ireland, 123 St Stephens Green, Dublin 2, Ireland.	nikolausplesnila@rcsi.ie	Plesnila, Nikolaus/T-7522-2019				ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIETRICH WD, 1980, AM J PHYSIOL, V238, pH172, DOI 10.1152/ajpheart.1980.238.2.H172; Engel DC, 2008, J NEUROTRAUM, V25, P739, DOI 10.1089/neu.2007.0480; Hartl R, 1997, J CEREBR BLOOD F MET, V17, P1210; HEKMATPANAH J, 1985, J NEUROSURG, V62, P888, DOI 10.3171/jns.1985.62.6.0888; Ishikawa M, 2009, NEUROSURGERY, V64, P546, DOI 10.1227/01.NEU.0000337579.05110.F4; Kataoka H, 2004, J CEREBR BLOOD F MET, V24, P668, DOI 10.1097/01.WCB.0000117812.35136.5B; KAWAMURA S, 1990, INT J MICROCIRC, V9, P369; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kontos H A, 1981, Trans Am Clin Climatol Assoc, V92, P111; Lafuente JV, 1999, J NEUROTRAUM, V16, P425, DOI 10.1089/neu.1999.16.425; LEHR HA, 1994, LAB INVEST, V71, P380; Lu DY, 2004, J NEUROTRAUM, V21, P1756, DOI 10.1089/neu.2004.21.1756; MA YP, 1974, MICROVASC RES, V8, P1, DOI 10.1016/0026-2862(74)90059-4; Maeda T, 1997, ACT NEUR S, V70, P102; Plesnila N, 2003, NEUROSCI LETT, V345, P85, DOI 10.1016/S0304-3940(03)00396-3; Rivera J, 2009, HAEMATOL-HEMATOL J, V94, P700, DOI 10.3324/haematol.2008.003178; ROSENBLUM WI, 1963, ARCH NEUROL-CHICAGO, V9, P414, DOI 10.1001/archneur.1963.00460100102012; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; SEGAWA H, 1981, ARCH NEUROL-CHICAGO, V38, P265, DOI 10.1001/archneur.1981.00510050031002; Stein SC, 2004, NEUROSURGERY, V54, P687, DOI 10.1227/01.NEU.0000108641.98845.88; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; Stein SC, 2009, J NEUROTRAUM, V26, P1585, DOI [10.1089/neu.2008.0720, 10.1089/neu.2008-0720]; Thal SC, 2007, J NEUROSCI METH, V159, P261, DOI 10.1016/j.jneumeth.2006.07.016; Thomale UW, 2002, J NEUROTRAUM, V19, P403, DOI 10.1089/08977150252932361; Uhl E, 2000, J CEREBR BLOOD F MET, V20, P979, DOI 10.1097/00004647-200006000-00010; Vaage J, 1980, Acta Chir Scand Suppl, V499, P141; VANDERSANDE JJ, 1981, J NEUROSURG, V54, P21, DOI 10.3171/jns.1981.54.1.0021; von Oettingen G, 2002, NEUROSURGERY, V50, P781, DOI 10.1097/00006123-200204000-00019; Wei EP, 2009, J NEUROTRAUM, V26, P527, DOI 10.1089/neu.2008.0797; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; White H, 2008, ANESTH ANALG, V107, P979, DOI 10.1213/ane.0b013e31817e7b1a; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	40	110	118	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2010	27	1					121	130		10.1089/neu.2009.1114			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	548RF	WOS:000273983200010	19803784				2022-02-06	
J	Wu, TC; Wilde, EA; Bigler, ED; Li, XQ; Merkley, TL; Yallampalli, R; McCauley, SR; Schnelle, KP; Vasquez, AC; Chu, ZL; Hanten, G; Hunter, JV; Levin, HS				Wu, Trevor C.; Wilde, Elisabeth A.; Bigler, Erin D.; Li, Xiaoqi; Merkley, Tricia L.; Yallampalli, Ragini; McCauley, Stephen R.; Schnelle, Kathleen P.; Vasquez, Ana C.; Chu, Zili; Hanten, Gerri; Hunter, Jill V.; Levin, Harvey S.			Longitudinal Changes in the Corpus Callosum following Pediatric Traumatic Brain Injury	DEVELOPMENTAL NEUROSCIENCE			English	Article						Cognitive development; Developmental changes; Morphometry; Neurodevelopment; Traumatic brain injury; White matter; Diffusion tensor imaging	DIFFUSE AXONAL INJURY; WHITE-MATTER INJURY; CLOSED-HEAD-INJURY; TENSOR IMAGING METRICS; INTERHEMISPHERIC-TRANSFER; NEUROIMAGING TECHNIQUES; ALZHEIMERS-DISEASE; PROCESSING SPEED; SERIAL CHANGES; MILD	Background: Atrophy of the corpus callosum (CC) is a documented consequence of moderate-to-severe traumatic brain injury (TBI), which has been expressed as volume loss using quantitative magnetic resonance imaging (MRI). Other advanced imaging modalities such as diffusion tensor imaging (DTI) have also detected white matter microstructural alteration following TBI in the CC. The manner and degree to which macrostructural changes such as volume and microstructural changes develop over time following pediatric TBI, and their relation to a measure of processing speed is the focus of this longitudinal investigation. As such, DTI and volumetric changes in the CC in participants with TBI and a comparison group at approximately 3 and 18 months after injury as well as their relation to processing speed were determined. Methods: Forty-eight children and adolescents aged 7-17 years who sustained either complicated mild or moderate-to-severe TBI (n = 23) or orthopedic injury (OI; n = 25) were studied. The participants underwent brain MRI and were administered the Eriksen flanker task at both time points. Results: At 3 months after injury, there were significant group differences in DTI metrics in the total CC and its subregions (genu/anterior, body/central and splenium/posterior), with the TBI group demonstrating significantly lower fractional anisotropy (FA) and a higher apparent diffusion coefficient (ADC) in comparison to the OI group. These group differences were also present at 18 months after injury in all CC subregions, with lower FA and a higher ADC in the TBI group. In terms of longitudinal changes in DTI, despite the group difference in mean FA, both groups generally demonstrated a modest increase in FA over time though this increase was only significant in the splenium/posterior subregion. Interestingly, the TBI group also generally demonstrated ADC increases from 3 to 18 months though the OI group demonstrated ADC decreases over time. Volumetrically, the group differences at 3 months were marginal for the midanterior and body/central subregions and total CC. However, by 18 months, the TBI group demonstrated a significantly decreased volume in all subregions except the splenium/posterior area relative to the OI group. Unlike the OI group, which showed a significant volume increase in subregions of the CC over time, the TBI group demonstrated a significant and consistent volume decrease. Performance on a measure of processing speed did not differentiate the groups at either visit, and only the OI group showed significantly improved performance over time. Processing speed was related to FA in the splenium/posterior and total CC only in the TBI group on both occasions, with a stronger relation at 18 months. Conclusion: In response to TBI, macrostructural volume loss in the CC occurred over time; yet, at the microstructural level, DTI demonstrated both indicators of continued maturation and development even in the damaged CC, as well as evidence of potential degenerative change. Unlike volumetrics, which likely reflects the degree of overall neuronal loss and axonal damage, DTI may reflect some aspects of postinjury maturation and adaptation in white matter following TBI. Multimodality imaging studies may be important to further understand the long-term consequences of pediatric TBI. Copyright (C) 2010 S. Karger AG, Basel	[Wilde, Elisabeth A.] Univ Texas Houston, Sch Med, Baylor Coll Med, Cognit Neurosci Lab,Dept Radiol & Neurol, Houston, TX 77030 USA; [Wu, Trevor C.; Bigler, Erin D.; Merkley, Tricia L.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.] Brigham Young Univ, Ctr Neurosci, Provo, UT 84602 USA; [Bigler, Erin D.] Univ Utah, Dept Psychiat, Salt Lake City, UT USA; [Bigler, Erin D.] Univ Utah, Utah Brain Inst, Salt Lake City, UT USA; [McCauley, Stephen R.] Univ Texas Houston, Sch Med, Baylor Coll Med, Dept Neurol & Pediat, Houston, TX 77030 USA; [Chu, Zili; Hunter, Jill V.] Univ Texas Houston, Sch Med, Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Levin, Harvey S.] Univ Texas Houston, Sch Med, Baylor Coll Med, Dept Neurol Neurosurg & Pediat, Houston, TX 77030 USA; [Chu, Zili; Hunter, Jill V.] Texas Childrens Hosp, EB Singleton Dept Diagnost Imaging, Houston, TX 77030 USA		Wilde, EA (corresponding author), Univ Texas Houston, Sch Med, Baylor Coll Med, Cognit Neurosci Lab,Dept Radiol & Neurol, 1709 Dryden Rd Ste 1200, Houston, TX 77030 USA.	ewilde@bcm.edu	Merkley, Tricia L./AAN-2989-2020	Merkley, Tricia/0000-0002-0897-8391	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS-21889]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER	This research was supported by grant NS-21889 awarded to H.S.L. by the National Institutes of Health. We would also like to acknowledge the generous support by Mission Connect of the TIRR Foundation. We acknowledge the contribution of Stacey K. Martin by assisting in manuscript preparation, and the technical assistance of Tracy J. Abildskov. We also wish to thank Ms. Lori Cook and Drs. Sandra B. Chapman and Gillian Hotz. We would also like to thank the patients and their families for involvement in this study. This research paper is also the work of a doctoral dissertation.	Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; ANDERSON CV, 1994, BRAIN INJURY, V8, P565, DOI 10.3109/02699059409151008; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ashwal S, 2006, DEV NEUROSCI-BASEL, V28, P309, DOI 10.1159/000094157; Assaf Y, 1997, MAGN RESON IMAGING, V15, P77, DOI 10.1016/S0730-725X(96)00246-9; Aukema EJ, 2009, INT J RADIAT ONCOL, V74, P837, DOI 10.1016/j.ijrobp.2008.08.060; Babikian T, 2010, J NEUROTRAUM, V27, P473, DOI 10.1089/neu.2009.1058; Battistone M, 2008, APPL NEUROPSYCHOL, V15, P69, DOI 10.1080/09084280801917863; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Beauchamp MH, 2009, J NEUROTRAUM, V26, P1645, DOI [10.1089/neu.2009.0916, 10.1089/neu.2009-0916]; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Benavidez DA, 1999, CORTEX, V35, P315, DOI 10.1016/S0010-9452(08)70803-7; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; BIEGON A, 1994, NEUROBIOL AGING, V15, P393, DOI 10.1016/0197-4580(94)90070-1; Bigler ED, 2010, NEUROIMAGE, V50, P1017, DOI 10.1016/j.neuroimage.2010.01.003; Bloom JS, 2005, NEUROPSYCHOL REV, V15, P59, DOI 10.1007/s11065-005-6252-y; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Bunge SA, 2002, NEURON, V33, P301, DOI 10.1016/S0896-6273(01)00583-9; Canu E, 2010, J ALZHEIMERS DIS, V19, P963, DOI 10.3233/JAD-2010-1295; Chepuri NB, 2002, AM J NEURORADIOL, V23, P803; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Di Paola M, 2010, NEUROIMAGE, V49, P141, DOI 10.1016/j.neuroimage.2009.07.050; Ducreux D, 2005, NEURORADIOLOGY, V47, P604, DOI 10.1007/s00234-005-1389-1; ERIKSEN BA, 1974, PERCEPT PSYCHOPHYS, V16, P143, DOI 10.3758/BF03203267; Ewing-Cobbs L, 2006, AM J NEURORADIOL, V27, P879; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Fischl B, 2004, NEUROIMAGE, V23, pS69, DOI 10.1016/j.neuroimage.2004.07.016; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Gorrie C, 2001, J NEUROTRAUM, V18, P849, DOI 10.1089/089771501750451776; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Johansson B, 2009, BRAIN INJURY, V23, P1027, DOI 10.3109/02699050903421099; Jokinen H, 2007, J NEUROL NEUROSUR PS, V78, P491, DOI 10.1136/jnnp.2006.096792; Kim J, 2008, NEUROIMAGE, V39, P1014, DOI 10.1016/j.neuroimage.2007.10.005; KOCHUNOV P, 2010, NEUROBIOL AGING; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2010, J HEAD TRAUMA REHAB, V25, P31, DOI 10.1097/HTR.0b013e3181bff331; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; Lobel U, 2009, NEURORADIOLOGY, V51, P253, DOI 10.1007/s00234-008-0488-1; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; Markham JA, 2009, BRAIN RES, V1288, P9, DOI 10.1016/j.brainres.2009.06.087; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Merkley TL, 2008, J NEUROTRAUM, V25, P1343, DOI 10.1089/neu.2008.0615; MOREY RA, 2010, HUM BRAIN MAPP; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Mori S, 2006, NEURON, V51, P527, DOI 10.1016/j.neuron.2006.08.012; Mukherjee P, 2008, AM J NEURORADIOL, V29, P632, DOI 10.3174/ajnr.A1051; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; NETSCH T, 2001, INT C COMP VIS VANC, V1, P718; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Pannek K, 2010, NEUROIMAGE, V50, P1044, DOI 10.1016/j.neuroimage.2010.01.020; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; PATEL MD, 2010, MAGMA; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Ptak T, 2003, AM J ROENTGENOL, V181, P1401, DOI 10.2214/ajr.181.5.1811401; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Sled JG, 1998, IEEE T MED IMAGING, V17, P87, DOI 10.1109/42.668698; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Tanriverdi T, 2009, J NEUROSURG, V110, P332, DOI 10.3171/2008.3.17570; Taylor HG, 2004, DEV NEUROPSYCHOL, V25, P199, DOI 10.1207/s15326942dn2501&2_11; TEASDALE G, 1974, LANCET, V2, P81; Thurman DJ, 2007, BRAIN INJURY MED PRI, P45; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Turken AU, 2008, NEUROIMAGE, V42, P1032, DOI 10.1016/j.neuroimage.2008.03.057; van der Zijden JP, 2008, EXP NEUROL, V212, P207, DOI 10.1016/j.expneurol.2008.03.027; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; Wang SL, 2009, CANCER RES, V69, P1190, DOI 10.1158/0008-5472.CAN-08-2661; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wu TC, 2010, J NEUROTRAUM, V27, P303, DOI 10.1089/neu.2009.1110; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; Yamada K, 2009, MAGN RESON MED SCI, V8, P165, DOI 10.2463/mrms.8.165; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yuan W, 2007, AM J NEURORADIOL, V28, P1919, DOI 10.3174/ajnr.A0698; Zhang LJ, 2005, AM J NEURORADIOL, V26, P45	89	110	112	0	10	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866	1421-9859		DEV NEUROSCI-BASEL	Dev. Neurosci.		2010	32	5-6					361	373		10.1159/000317058			13	Developmental Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Developmental Biology; Neurosciences & Neurology	725RO	WOS:000287663900004	20948181	Green Published, Bronze			2022-02-06	
J	Pietrzak, RH; Johnson, DC; Goldstein, MB; Malley, JC; Southwick, SM				Pietrzak, Robert H.; Johnson, Douglas C.; Goldstein, Marc B.; Malley, James C.; Southwick, Steven M.			Posttraumatic Stress Disorder Mediates the Relationship Between Mild Traumatic Brain Injury and Health and Psychosocial Functioning in Veterans of Operations Enduring Freedom and Iraqi Freedom	JOURNAL OF NERVOUS AND MENTAL DISEASE			English	Article						Veterans; combat; soldiers; posttraumatic stress disorder; mild traumatic brain injury; psychosocial; functioning; barriers to care	POSTCONCUSSIVE SYMPTOMS; AFGHANISTAN; DEPLOYMENT; BARRIERS; WAR	This study evaluated whether posttraumatic stress disorder (PTSD) mediated the relationship between mild traumatic brain injury (MTBI) and general health ratings, psychosocial functioning, and perceived barriers to receiving mental healthcare 2 years following return from deployment in veterans of Operations Enduring Freedom and Iraqi Freedom (OEF/OIF). A total of 277 OEF/OIF veterans completed the Connecticut OEF/OIF Veterans Needs Assessment Survey; 18.8% of the sample screened positive for MTBI. Compared with respondents who screened negative for MTBI, respondents who screened positive for MTBI were younger, more likely to have PTSD, more likely to report fair/poor overall health and unmet medical and psychological needs, and scored higher on measures of psychosocial difficulties and perceived barriers to mental healthcare. Injuries involving loss of consciousness were associated with greater work-related difficulties and unmet psychological needs. PTSD mediated the relationship between MTBI and all of these outcomes. These results underscore the importance of assessing PTSD in OEF/OIF veterans who screen positive for MTBI.	[Pietrzak, Robert H.] Yale Univ, Sch Med, Natl Ctr PTSD, VA Connecticut Healthcare Syst, West Haven, CT 06516 USA; [Pietrzak, Robert H.; Southwick, Steven M.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA; [Johnson, Douglas C.] Univ Calif San Diego, Dept Psychiat, Sch Med, San Diego, CA 92103 USA; [Johnson, Douglas C.] VA San Diego Healthcare Syst, San Diego, CA USA; [Goldstein, Marc B.] Cent Connecticut State Univ, Dept Psychol, New Britain, CT 06050 USA; [Malley, James C.] Cent Connecticut State Univ, Dept Counseling & Family Therapy, New Britain, CT 06050 USA		Pietrzak, RH (corresponding author), Yale Univ, Sch Med, Natl Ctr PTSD, VA Connecticut Healthcare Syst, 950 Campbell Ave 151E, West Haven, CT 06516 USA.	robert.pietrzak@yale.com			State of Connecticut; National Center for PTSD; private donation	Supported by the State of Connecticut. the National Center for PTSD, and a private donation.	BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Britt TW, 2008, J SOC CLIN PSYCHOL, V27, P317, DOI 10.1521/jscp.2008.27.4.317; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Bryant RA, 2001, J CLIN EXP NEUROPSYC, V23, P718, DOI 10.1076/jcen.23.6.718.1024; Cohen J., 2013, STAT POWER ANAL BEHA; Fear NT, 2009, PSYCHOL MED, V39, P1379, DOI 10.1017/S0033291708004595; *GOV ACC OFF, 2008, GAO08276; Hill JJ, 2009, AM J PHYS MED REHAB, V88, P605, DOI 10.1097/PHM.0b013e3181ae0f83; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; Peloso PM, 2004, J REHABIL MED, V36, P106, DOI 10.1080/16501960410023868; Pickelsimer EE, 2007, J HEAD TRAUMA REHAB, V22, P1, DOI 10.1097/00001199-200701000-00001; Rees PM, 2003, ARCH PHYS MED REHAB, V84, P1885, DOI 10.1016/j.apmr.2003.03.001; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Stalnacke BM, 2007, BRAIN INJURY, V21, P933, DOI 10.1080/02699050701553189; Tate AR, 2007, BMC MED RES METHODOL, V7, DOI 10.1186/1471-2288-7-51; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Weathers F.W., 1991, PTSD CHECKLIST MILIT; Wessely S, 2003, BRIT J PSYCHIAT, V183, P314, DOI 10.1192/bjp.183.4.314	20	110	111	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-3018	1539-736X		J NERV MENT DIS	J. Nerv. Ment. Dis.	OCT	2009	197	10					748	753		10.1097/NMD.0b013e3181b97a75			6	Clinical Neurology; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry	507CZ	WOS:000270829900006	19829203				2022-02-06	
J	Homsi, S; Federico, F; Croci, N; Palmier, B; Plotkine, M; Marchand-Leroux, C; Jafarian-Tehrani, M				Homsi, Shadi; Federico, Fabiola; Croci, Nicole; Palmier, Bruno; Plotkine, Michel; Marchand-Leroux, Catherine; Jafarian-Tehrani, Mehrnaz			Minocycline effects on cerebral edema: Relations with inflammatory and oxidative stress markers following traumatic brain injury in mice	BRAIN RESEARCH			English	Article						Traumatic brain injury; Mice; Minocycline; Cerebral edema; Interleukin-1 beta; Matrix metalloproteinase-9; Glutathione	MATRIX METALLOPROTEINASES; IN-VIVO; INTRACEREBRAL HEMORRHAGE; MICROGLIAL ACTIVATION; VASOGENIC EDEMA; MOUSE-BRAIN; ISCHEMIA; NEUROPROTECTION; MATRIX-METALLOPROTEINASE-9; INTERLEUKIN-1	One of the severe complications following traumatic brain injury (TBI) is cerebral edema and its effective treatment is of great interest to prevent further brain damage. This study investigated the effects of minocycline, known for its anti-inflammatory properties, on cerebral edema and its respective inflammatory markers by comparing different dose regimens, on oxidative stress and on neurological dysfunction following TBI. The weight drop model was used to induce TBI in mice. The brain water content was measured to evaluate cerebral edema. Inflammatory markers were detected by ELISA (IL-1 beta), zymography and Western blot (MMP-9). The oxidative stress marker (glutathione levels) and neurological function were measured by Griffith technique and string test, respectively. Minocycline was administered i.p. once (5 min), twice (5 min and 3 h) or triple (5 min, 3 h and 9 h) following TBI. The first dose of minocycline only varied (45 or 90 mg/kg), whereas the following doses were all at 45 mg/kg. The single and double administrations of minocycline reduced the increase of inflammatory markers at 6 h post-TBI. Minocycline also reduced cerebral edema at this time point, only after double administration and at the high dose regimen, although with no effect on the TBI-induced oxidized glutathione increase. The anti-edematous effect of minocycline persisted up to 24 h, upon a triple administration, and accompanied by a neurological recovery. In conclusion, we reported an anti-edematous effect of minocycline after TBI in mice according to a specific treatment regimen. These findings emphasize that the beneficial effects of minocycline depend on the treatment regimen following a brain injury. (C) 2009 Elsevier B.V. All rights reserved.	[Homsi, Shadi; Federico, Fabiola; Croci, Nicole; Palmier, Bruno; Plotkine, Michel; Marchand-Leroux, Catherine; Jafarian-Tehrani, Mehrnaz] Univ Paris 05, Lab Pharmacol Circulat Cerebrale, EA 2510, Fac Sci Pharmaceut & Biol, F-75006 Paris, France		Jafarian-Tehrani, M (corresponding author), Univ Paris 05, Lab Pharmacol Circulat Cerebrale, EA 2510, Fac Sci Pharmaceut & Biol, 4 Ave Observ, F-75006 Paris, France.	mehrnaz.jafarian@parisdescartes.fr	MARCHAND-LEROUX, Catherine/L-7453-2017	MARCHAND-LEROUX, Catherine/0000-0003-0113-5348; Jafarian-Tehrani, Mehrnaz/0000-0001-6895-5856			Andes D, 2002, INT J ANTIMICROB AG, V19, P261, DOI 10.1016/S0924-8579(02)00022-5; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Basu A, 2004, J NEUROSCI RES, V78, P151, DOI 10.1002/jnr.20266; Blum D, 2004, NEUROBIOL DIS, V17, P359, DOI 10.1016/j.nbd.2004.07.012; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Cardozo-Pelaez F, 1999, MOVEMENT DISORD, V14, P972, DOI 10.1002/1531-8257(199911)14:6<972::AID-MDS1010>3.0.CO;2-0; Chen XR, 2007, J NEUROTRAUM, V24, P1119, DOI 10.1089/neu.2006.0216; Colovic M, 2003, J CHROMATOGR B, V791, P337, DOI 10.1016/S1570-0232(03)00247-2; Ding JY, 2009, BRAIN RES, V1268, P125, DOI 10.1016/j.brainres.2009.02.060; Domercq M, 2004, TRENDS PHARMACOL SCI, V25, P609, DOI 10.1016/j.tips.2004.10.001; Elewa HF, 2006, PHARMACOTHERAPY, V26, P515, DOI 10.1592/phco.26.4.515; Fagan SC, 2004, EXP NEUROL, V186, P248, DOI 10.1016/j.expneurol.2003.12.006; Fujimura M, 1999, BRAIN RES, V842, P92, DOI 10.1016/S0006-8993(99)01843-0; Golding EM, 2002, BRAIN RES REV, V38, P377, DOI 10.1016/S0165-0173(02)00141-8; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; Hall E D, 1985, Cent Nerv Syst Trauma, V2, P75; Haorah J, 2007, J NEUROCHEM, V101, P566, DOI 10.1111/j.1471-4159.2006.04393.x; Hellal F, 2004, NEUROSCI LETT, V357, P21, DOI 10.1016/j.neulet.2003.12.036; Hellal F, 2003, J NEUROTRAUM, V20, P841, DOI 10.1089/089771503322385773; Heo JH, 2005, FREE RADICAL BIO MED, V39, P51, DOI 10.1016/j.freeradbiomed.2005.03.035; Heo JH, 1999, J CEREBR BLOOD F MET, V19, P624, DOI 10.1097/00004647-199906000-00005; Holmin S, 2000, J NEUROSURG, V92, P108, DOI 10.3171/jns.2000.92.1.0108; Jafarian-Tehrani M, 2005, NITRIC OXIDE-BIOL CH, V12, P61, DOI 10.1016/j.niox.2004.12.001; Kawakita Kenya, 2006, J Stroke Cerebrovasc Dis, V15, P88, DOI 10.1016/j.jstrokecerebrovasdis.2006.01.002; Kraus RL, 2005, J NEUROCHEM, V94, P819, DOI 10.1111/j.1471-4159.2005.03219.x; Lazovic J, 2005, STROKE, V36, P2226, DOI 10.1161/01.STR.0000182255.08162.6a; Lee CZ, 2006, J CEREBR BLOOD F MET, V26, P1157, DOI 10.1038/sj.jcbfm.9600268; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Louin G, 2006, NEUROPHARMACOLOGY, V50, P182, DOI 10.1016/j.neuropharm.2005.08.020; Machado LS, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-56; Mejia ROS, 2001, NEUROSURGERY, V48, P1393, DOI 10.1097/00006123-200106000-00051; Morimoto N, 2005, BRAIN RES, V1044, P8, DOI 10.1016/j.brainres.2005.02.062; Nagel S, 2008, BRAIN RES, V1188, P198, DOI 10.1016/j.brainres.2007.10.052; Romanic AM, 1998, STROKE, V29, P1020, DOI 10.1161/01.STR.29.5.1020; Rosenberg GA, 1996, J CEREBR BLOOD F MET, V16, P360, DOI 10.1097/00004647-199605000-00002; Rosenberg Gary A, 2007, Neurosurg Focus, V22, pE4; Rothwell N, 2003, BRAIN BEHAV IMMUN, V17, P152, DOI 10.1016/S0889-1591(02)00098-3; SAIVIN S, 1988, CLIN PHARMACOKINET, V15, P355, DOI 10.2165/00003088-198815060-00001; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Schulz JB, 2000, EUR J BIOCHEM, V267, P4904, DOI 10.1046/j.1432-1327.2000.01595.x; Shigemori Y, 2006, ACTA NEUROCHIR SUPPL, V96, P130; Simi A, 2007, BIOCHEM SOC T, V35, P1122, DOI 10.1042/BST0351122; Stirling DP, 2005, NEUROSCIENTIST, V11, P308, DOI 10.1177/1073858405275175; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vecil GG, 2000, J NEUROSCI RES, V61, P212, DOI 10.1002/1097-4547(20000715)61:2<212::AID-JNR12>3.0.CO;2-9; Wang J, 2005, BRAIN, V128, P1622, DOI 10.1093/brain/awh489; Wang KKW, 2006, CURR OPIN NEUROL, V19, P514, DOI 10.1097/WCO.0b013e3280102b10; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Wasserman JK, 2007, EXP NEUROL, V207, P227, DOI 10.1016/j.expneurol.2007.06.025; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Yamaguchi M, 2007, NEUROSURGERY, V61, P1067, DOI 10.1227/01.neu.0000303203.07866.18; YAMASAKI Y, 1994, ACTA NEUROCHIR, P300; Yong VW, 2004, LANCET NEUROL, V3, P744, DOI 10.1016/S1474-4422(04)00937-8; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769	55	110	112	0	19	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	SEP 21	2009	1291						122	132		10.1016/j.brainres.2009.07.031			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	497GF	WOS:000270045200013	19631631				2022-02-06	
J	McCrory, P; Meeuwisse, W; Johnston, K; Dvorak, J; Aubry, M; Molloy, M; Cantu, R				McCrory, Paul; Meeuwisse, Willem; Johnston, Karen; Dvorak, Jiri; Aubry, Mark; Molloy, Mick; Cantu, Robert			Consensus Statement on Concussion in Sport - The Third International Conference on Concussion in Sport Held in Zurich, November 2008	PHYSICIAN AND SPORTSMEDICINE			English	Article							CHRONIC TRAUMATIC ENCEPHALOPATHY; COLLEGIATE FOOTBALL PLAYERS; HIGH-SCHOOL; PROFESSIONAL FOOTBALL; POSTURAL CONTROL; HEAD-INJURIES; POSTCONCUSSION SYNDROME; COGNITIVE IMPAIRMENT; RECURRENT CONCUSSION; AUSTRALIAN RULES		[McCrory, Paul] Univ Melbourne, Ctr Hlth Exercise & Sports Med, Parkville, Vic 3010, Australia; [Meeuwisse, Willem] Univ Calgary, Calgary, AB, Canada; [Johnston, Karen] Toronto Rehabil Inst, Toronto, ON, Canada; [Dvorak, Jiri] FIFA Med Assessment & Res Ctr F MARC, Zurich, Switzerland; [Dvorak, Jiri] Schulthess Clin, Zurich, Switzerland; [Aubry, Mark] Ottawa Sport Med Ctr, Ottawa, ON, Canada; [Molloy, Mick] Int Rugby Board, Dublin, Ireland; [Cantu, Robert] Emerson Hosp, Concord, MA USA		McCrory, P (corresponding author), Univ Melbourne, Ctr Hlth Exercise & Sports Med, Parkville, Vic 3010, Australia.	paulmccr@bigpond.net.au	McCrory, Paul/Q-8688-2019	McCrory, Paul/0000-0003-4850-0568			Andersen TE, 2004, BRIT J SPORT MED, V38, P690, DOI 10.1136/bjsm.2003.009357; [Anonymous], 2006, MED SCI SPORT EXER, V38, P395, DOI 10.1249/01.mss.0000202025.48774.31; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bazarian JJ, 2001, CLIN PEDIATR, V40, P207, DOI 10.1177/000992280104000405; Begaz T, 2006, J NEUROTRAUM, V23, P1201, DOI 10.1089/neu.2006.23.1201; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Bleiberg Joseph, 2005, Neurosurgery, V56, pE1166; Bloom GA, 2004, BRIT J SPORT MED, V38, P519, DOI 10.1136/bjsm.2004.011999; Boutin D, 2008, NEUROCASE, V14, P239, DOI 10.1080/13554790802247543; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Broshek DK, 2005, CLIN SPORT MED, V24, P663, DOI 10.1016/j.csm.2005.04.005; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Cavanaugh JT, 2006, J ATHL TRAINING, V41, P305; Cavanaugh JT, 2005, SPORTS MED, V35, P935, DOI 10.2165/00007256-200535110-00002; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Chen JK, 2004, CLIN J SPORT MED, V14, P379; Chen JK, 2004, BRIT J SPORT MED, V38, P659; Collie A, 2003, BRIT J SPORT MED, V37, P556, DOI 10.1136/bjsm.37.6.556; Collie A, 2003, BRIT J SPORT MED, V37, P2, DOI 10.1136/bjsm.37.1.2; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Curnow WJ, 2008, HEALTH PROMOT J AUST, V19, P10, DOI 10.1071/HE08010; Davidhizar R, 2002, Accid Emerg Nurs, V10, P149, DOI 10.1054/aaen.2002.0365; Davidson JA, 2005, EUR J EMERG MED, V12, P24, DOI 10.1097/00063110-200502000-00007; Lima DPD, 2008, INJURY, V39, P604, DOI 10.1016/j.injury.2007.11.008; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; de Boussard CN, 2005, J REHABIL MED, V37, P53, DOI 10.1080/16501970410015587; Delaney JS, 2008, BRIT J SPORT MED, V42, P110, DOI 10.1136/bjsm.2007.037689; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Denke NJ, 2008, J EMERG NURS, V34, P363, DOI 10.1016/j.jen.2008.04.013; Dvorak J, 2007, BRIT J SPORT MED, V41, pI44, DOI 10.1136/bjsm.2007.037960; Dvorak J, 2007, BRIT J SPORT MED, V41, DOI 10.1136/bjsm.2007.039362; Finch C, 2005, INJURY PREV, V11, P242, DOI 10.1136/ip.2004.006882; Finch C, 1993, 51 MON U ACC RES CTR; Finch CF, 2003, J SCI MED SPORT, V6, P505, DOI 10.1016/S1440-2440(03)80275-X; Finch CF, 2001, BRIT J SPORT MED, V35, P89, DOI 10.1136/bjsm.35.2.89; Fleminger S, 2008, EUR J ANAESTH, V25, P123, DOI 10.1017/S0265021507003250; Fox ZG, 2008, J ATHL TRAINING, V43, P456, DOI 10.4085/1062-6050-43.5.456; FUKUHARA T, 1994, BRAIN RES, V657, P333, DOI 10.1016/0006-8993(94)90987-3; Gabbe B, 2003, J SCI MED SPORT, V6, P231, DOI 10.1016/S1440-2440(03)80259-1; Gaetz M, 2000, BRAIN INJURY, V14, P815; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gianotti S, 2007, NEUROREHABILITATION, V22, P181; Gioia G, 2004, BRIT J SPORT MED, V38, P657; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Guilmette TJ, 2007, BRAIN INJURY, V21, P1039, DOI 10.1080/02699050701633080; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Hagel B, 2004, CLIN J SPORT MED, V14, P193, DOI 10.1097/00042752-200407000-00001; Hagel BE, 2005, BRIT MED J, V330, P281, DOI 10.1136/bmj.38314.480035.7C; Hang CH, 2006, BRAIN RES, V1109, P14, DOI 10.1016/j.brainres.2006.06.045; Hansen Kari Schroder, 2003, Traffic Inj Prev, V4, P285, DOI 10.1080/714040486; Hayden MG, 2007, CHILD NERV SYST, V23, P431, DOI 10.1007/s00381-006-0277-2; Hewson Paul J, 2005, Traffic Inj Prev, V6, P127, DOI 10.1080/15389580590931590; Hinkle DA, 1997, J NEUROTRAUM, V14, P729, DOI 10.1089/neu.1997.14.729; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; JENNETT B, 1975, LANCET, V1, P480; Johnston Karen M, 2004, Curr Sports Med Rep, V3, P316; Johnston KM, 2001, J AM COLL SURGEONS, V192, P515, DOI 10.1016/S1072-7515(01)00797-9; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; Kashluba S, 2004, ARCH CLIN NEUROPSYCH, V19, P805, DOI 10.1016/j.acn.2003.09.005; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Kelly JP, 1998, J HEAD TRAUMA REHAB, V13, P53, DOI 10.1097/00001199-199804000-00008; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Kristman VL, 2008, CLIN J SPORT MED, V18, P322, DOI 10.1097/JSM.0b013e31817e6f3e; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; Lee LK, 2007, PEDIATR EMERG CARE, V23, P580, DOI 10.1097/PEC.0b013e31813444ea; Lee Michael A, 2006, Conn Med, V70, P377; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; Lovell Mark R, 2002, Curr Sports Med Rep, V1, P7; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Ma M, 2008, AM J EMERG MED, V26, P763, DOI 10.1016/j.ajem.2007.10.029; MADDOCKS D, 1989, SPORT HLTH S, V7, P6; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; McCrea M., 2000, STANDARDIZED ASSESSM; McCrory P, 2004, CLIN J SPORT MED, V14, P139, DOI 10.1097/00042752-200405000-00006; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P, 2002, BRIT J SPORT MED, V36, P316, DOI 10.1136/bjsm.36.5.316; McCrory P, 2002, BRIT J SPORT MED, V36, P314, DOI 10.1136/bjsm.36.5.314; McCrory P, 2002, BRIT J SPORT MED, V36, P3, DOI 10.1136/bjsm.36.1.3; McCrory PR, 2000, NEUROLOGY, V54, P1488, DOI 10.1212/WNL.54.7.1488; McCrory PR, 1997, BRIT MED J, V314, P171, DOI 10.1136/bmj.314.7075.171; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; McIntosh A, 2005, RUGBY HEADGEAR STUDY; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; McIntosh AS, 2000, BRIT J SPORT MED, V34, P337, DOI 10.1136/bjsm.34.5.337; McIntosh AS, 2001, BRIT J SPORT MED, V35, P167, DOI 10.1136/bjsm.35.3.167; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140, DOI 10.1097/JSM.0b013e31803212ae; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Mueller BA, 2008, EPIDEMIOLOGY, V19, P270, DOI 10.1097/EDE.0b013e318163567c; Nandoe RDS, 2002, J ALZHEIMERS DIS, V4, P303, DOI 10.3233/JAD-2002-4405; Nordqvist ACS, 1996, MOL BRAIN RES, V38, P285; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Pellman EJ, 2005, NEUROSURGERY, V56, P79, DOI 10.1227/01.NEU.0000150180.16552.8D; Pellman EJ, 2003, NEUROSURGERY, V53, P797, DOI 10.1093/neurosurgery/53.3.797; PENG RY, 2003, WEI ZHONG BING JI JI, V15, P213; Ptito A, 2007, NEUROREHABILITATION, V22, P217; Purcell L, 2008, CLIN PEDIATR, V47, P106, DOI 10.1177/0009922807306053; Reece RM, 2000, ARCH PEDIAT ADOL MED, V154, P11; Rousseff R T, 2006, Electromyogr Clin Neurophysiol, V46, P275; Schnadower D, 2007, CURR OPIN PEDIATR, V19, P258, DOI 10.1097/MOP.0b013e3281084e85; Shaw NH, 2004, CAN MED ASSOC J, V170, P15; Stalnacke BM, 2004, BRAIN INJURY, V18, P899, DOI 10.1080/02699050410001671865; Stalnacke BM, 2003, CLIN J SPORT MED, V13, P292; STERN MB, 1991, MOVEMENT DISORD, V6, P95, DOI 10.1002/mds.870060202; Sulheim S, 2006, JAMA-J AM MED ASSOC, V295, P919, DOI 10.1001/jama.295.8.919; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; Terrell TR, 2008, CLIN J SPORT MED, V18, P10, DOI 10.1097/JSM.0b013e31815c1d4c; Theye Fred, 2004, Clin Med Res, V2, P165; Townend W, 2006, INJURY, V37, P1098, DOI 10.1016/j.injury.2006.07.014; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Viano DC, 2006, NEUROSURGERY, V59, P591, DOI 10.1227/01.NEU.0000231851.97287.C2; WIESS MR, 2005, RES Q EXERCISE SPORT, V76, pS71; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; YARNELL PR, 1973, NEUROLOGY, V23, P196, DOI 10.1212/WNL.23.2.196; YARNELL PR, 1970, LANCET, V1, P863; Yunoki M, 1998, ACT NEUR S, V71, P142	146	110	111	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0091-3847	2326-3660		PHYSICIAN SPORTSMED	Physician Sportsmed.	JUN	2009	37	2					141	159		10.3810/psm.2009.06.1721			19	Primary Health Care; Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Orthopedics; Sport Sciences	V17IM	WOS:000207930900030	20048521				2022-02-06	
J	McDonald, S; Tate, R; Togher, L; Bornhofen, C; Long, E; Gertler, P; Bowen, R				McDonald, Skye; Tate, Robyn; Togher, Leanne; Bornhofen, Cristina; Long, Esther; Gertler, Paul; Bowen, Rebecca			Social skills treatment for people with severe, chronic acquired brain injuries: A multicenter trial	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						behavior therapy; cognition; higher nervous activity; psychology; clinical; psychotherapy; multiple; rehabilitation	EMOTION PERCEPTION DEFICITS; PERFORMANCE SURVEY SCHEDULE; KATZ ADJUSTMENT SCALE; COMMUNICATION-SKILLS; BEHAVIOR; INDIVIDUALS; VALIDITY; DEPRESSION; THERAPY; RECOGNITION	Objective: To determine whether social skills deficits including unskilled, inappropriate behavior, problems reading social cues (social perception), and mood disturbances (such as depression and anxiety.) could be remediated after severe traumatic brain injuries. Design: Randomized controlled trial comparing a social skills program with social activity alone or with waitlist control. Several participants were reassigned after randomization. Setting: Hospital Outpatient and community facilities. Participants: Fifty-one outpatients from 3 brain injury units in Sydney, Australia, with severe, chronic acquired brain injuries were recruited. A total of 39 people (13 in skills training, 13 in social activity, 13 in waitlist) completed all phases of the Study. Intervention: Twelve-week social skills treatment program encompassing weekly 3-hour group sessions focused on shaping social behavior and remediating social perception and 1-hour individual sessions to address psychologic issues with mood, self-esteem, etc. Main Outcome Measures: Primary Outcomes were: (1) social behavior during encounters with a confederate as rated on the Behaviorally Referenced Rating System of Intermediary Social Skills-Revised (BRISS-R), (2) social perception as measured by The Awareness of Social Inference Test, and (3) depression and anxiety as measured by the Depression, Anxiety and Stress Scale. Secondary outcomes were: relative report off social behavior and participation using: the Katz Adjustment Scale-R1: the Social Performance Survey Schedule; the La Trobe Communication Questionnaire. and the Sydney Psychosocial Reintegration Scale (both relative and self-report). Results: Repeated-measures analysis of variance indicated that social activity alone did not lead to improved performance relative to waitlist (placebo effect) on any outcome variable. On the other hand, the skills training group improved differentially on the Partner Directed Behavior Scale of the BRISS-R, specifically the self-centered behavior and partner involvement behavior sub-scales. No treatment effects were found for the remaining primary outcomes (social perception, emotional adjustment) or for secondary Outcome variables (relative and self-report measures of social function). Conclusions: This study Suggested that treatment effects after social skills training in people with severe, chronic brain injuries are modest and are limited to direct measures of social behavior.	[McDonald, Skye; Bornhofen, Cristina; Long, Esther; Gertler, Paul] Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia; [Tate, Robyn] Univ Sydney, Fac Med, Rehabil Studies Unit, Sydney, NSW 2006, Australia; [Togher, Leanne] Univ Sydney, Fac Hlth Sci, Sydney, NSW 2006, Australia; [Bowen, Rebecca] Liverpool Brain Injury Unit, Sydney, NSW, Australia		McDonald, S (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.	s.mcdonald@unsw.edu.au	McDonald, Skye/G-4118-2014; Togher, Leanne/AAC-7083-2019	McDonald, Skye/0000-0003-0723-6094; Togher, Leanne/0000-0002-4518-6748	Australian National Health and Medical Research CouncilNational Health and Medical Research Council of Australia [222754]	Supported by the Australian National Health and Medical Research Council (project grant no. 222754).	Anson K, 2006, BRAIN INJURY, V20, P167, DOI 10.1080/02699050500442956; Bellack A.S., 2004, SOCIAL SKILLS TRAINI; Benton AL, 1994, MULTILINGUAL APHASIA; BENTON MK, 1990, J CONSULT CLIN PSYCH, V58, P741, DOI 10.1037/0022-006X.58.6.741; BIRD K, 2001, PSY PROGRAM CONTRAST; Bolte S, 2006, BEHAV NEUROSCI, V120, P211, DOI 10.1037/0735-7044.120.1.211; Bornhofen C, 2008, J HEAD TRAUMA REHAB, V23, P103, DOI 10.1097/01.HTR.0000314529.22777.43; Bornhofen C, 2008, NEUROPSYCHOL REHABIL, V18, P22, DOI 10.1080/09602010601061213; BRAMSTON P, 1985, BEHAV RES THER, V23, P239, DOI 10.1016/0005-7967(85)90001-4; Butler AC, 2006, CLIN PSYCHOL REV, V26, P17, DOI 10.1016/j.cpr.2005.07.003; Cicchetti D.V., 1994, PSYCHOL ASSESS, V6, P284, DOI [10.1037/1040-3590.6.4.284, DOI 10.1037/1040-3590.6.4.284]; Combs DR, 2006, SCHIZOPHR RES, V87, P340, DOI 10.1016/j.schres.2006.05.003; Dahlberg C, 2006, BRAIN INJURY, V20, P425, DOI 10.1080/02699050600664574; Dahlberg CA, 2007, ARCH PHYS MED REHAB, V88, P1561, DOI 10.1016/j.apmr.2007.07.033; Deb S, 1999, AM J PSYCHIAT, V156, P374; DELIS DC, 2001, DELISKAPLAN EXECUTIV; Demakis GJ, 2007, ARCH CLIN NEUROPSYCH, V22, P123, DOI 10.1016/j.acn.2006.09.004; Doctor JN, 2005, J INT NEUROPSYCH SOC, V11, P747, DOI 10.1017/S1355617705050836; Douglas JM, 2000, APHASIOLOGY, V14, P251, DOI 10.1080/026870300401469; Ekman Paul, 2003, EMOTIONS REVEALED RE; FABIANO RJ, 1992, REHABIL PSYCHOL, V37, P75, DOI 10.1037/h0079096; FARRELL AD, 1985, BEHAV ASSESS, V7, P155; FLANAGAN S, 1995, BRAIN INJURY, V9, P321, DOI 10.3109/02699059509005773; Furukawa TA, 2006, BRIT J PSYCHIAT, V188, P305, DOI 10.1192/bjp.188.4.305; GIANNINI AJ, 1995, PERCEPT MOTOR SKILL, V81, P555, DOI 10.1177/003151259508100239; Glang A, 1997, J HEAD TRAUMA REHAB, V12, P32, DOI 10.1097/00001199-199704000-00005; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; GORAN DA, 1993, BRAIN INJURY, V7, P219, DOI 10.3109/02699059309029674; GOTLIB IH, 1989, J ABNORM PSYCHOL, V98, P23, DOI 10.1037/0021-843X.98.1.23; Hale WW, 1998, J AFFECT DISORDERS, V47, P63, DOI 10.1016/S0165-0327(97)00112-2; Hale WW, 2005, BRAIN IMPAIR, V6, P169; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P991, DOI 10.1016/S0003-9993(99)90049-7; HARTLEY L L, 1992, Brain Injury, V6, P271, DOI 10.3109/02699059209029669; Heaton PDRK., 1993, WISCONSIN CARD SORTI; HELFFENSTEIN DA, 1982, INT J CLIN NEUROPSYC, V4, P139; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; JACKSON H F, 1992, Brain Injury, V6, P109, DOI 10.3109/02699059209029650; JOHNSON DA, 1987, BRIT J CLIN PSYCHOL, V26, P289, DOI 10.1111/j.2044-8260.1987.tb01362.x; Johnson K, 1998, BEHAV MODIF, V22, P502, DOI 10.1177/01454455980224004; KATZ MM, 1963, PSYCHOL REP, V13, P503, DOI 10.2466/pr0.1963.13.2.503; Kavale KA, 1996, J LEARN DISABIL, V29, P226, DOI 10.1177/002221949602900301; Khan-Bourne N, 2003, NEUROPSYCHOL REHABIL, V13, P89, DOI 10.1080/09602010244000318; Lanham RA, 2000, J HEAD TRAUMA REHAB, V15, P1123, DOI 10.1097/00001199-200010000-00006; LIBET JM, 1973, J CONSULT CLIN PSYCH, V40, P304, DOI 10.1037/h0034530; LOVIBOND PF, 1995, BEHAV RES THER, V33, P335, DOI 10.1016/0005-7967(94)00075-U; LOWE MR, 1978, BEHAV THER, V9, P535, DOI 10.1016/S0005-7894(78)80126-9; LOWE MR, 1982, PSYCHOL REP, V50, P83, DOI 10.2466/pr0.1982.50.1.83; LOWE MR, 1985, J PSYCHOPATHOL BEHAV, V7, P13, DOI 10.1007/BF00961843; MARSH NV, 1991, J CLIN EXP NEUROPSYC, V13, P729, DOI 10.1080/01688639108401086; McDonald S, 2005, J INT NEUROPSYCH SOC, V11, P392, DOI 10.1017/S1355617705050447; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; McDonald S, 2004, NEUROPSYCHOL REHABIL, V14, P285, DOI 10.1080/09602010343000237; McDonald S, 2006, DISABIL REHABIL, V28, P1529, DOI 10.1080/09638280600646185; MCFALL RM, 1982, BEHAV ASSESS, V4, P1; McKenzie K., 2000, BRIT J LEARN DISABIL, V28, P143; Medd J, 2000, NEUROPSYCHOL REHABIL, V10, P185, DOI 10.1080/096020100389246; MEDONALD S, 2003, BRAIN IMPAIR, V4, P36; Meghji C, 2002, J COGN REHABIL, V20, P12; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; MILLER LS, 1984, BEHAV ASSESS, V6, P33; OZONOFF S, 1995, J AUTISM DEV DISORD, V25, P415, DOI 10.1007/BF02179376; PONSFORD J, 1995, TRAUMATIC BRAIN INJU; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Sohlberg M., 2001, COGNITIVE REHABILITA; Spence S. H., 1995, SOCIAL SKILLS TRAINI; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; TATE RL, 1987, SCAND J REHABIL MED, V19, P13; Togher L., 2000, BRAIN DAM B, P1; TROWER P, 1980, J CONSULT CLIN PSYCH, V48, P327, DOI 10.1037/0022-006X.48.3.327; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; WALLANDER JL, 1985, BEHAV ASSESS, V7, P137; Wechsler D., 1997, WECHSLER MEMORY SCAL; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; WechslerD, 2001, WECHSLER TEST ADULT	75	110	112	0	43	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	2008	89	9					1648	1659		10.1016/j.apmr.2008.02.029			12	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	346GR	WOS:000259057300003	18760150				2022-02-06	
J	Clark, RSB; Bayir, H; Chu, CT; Alber, SM; Kochanek, PM; Watkins, SC				Clark, Robert S. B.; Bayir, Hulya; Chu, Charleen T.; Alber, Sean M.; Kochanek, Patrick M.; Watkins, Simon C.			Autophagy is increased in mice after traumatic brain injury and is detectable in human brain after trauma and critical illness	AUTOPHAGY			English	Article						autophagosome; controlled cortical impact; antioxidant; head injury; LC3; mitophagy	HEAD-INJURY; DISEASE; PROTEOLYSIS; LYSOSOMES	Autophagy is a homeostatic process for recycling of proteins and organelles, that increases during times of nutrient deprivation and is regulated by reactive oxygen species. We reported that autophagy can also be induced after traumatic brain injury (TBI) in mice.1 Specifically, autophagosomes and multilamellar bodies were frequently observed in cell processes and axons in injured brain regions by electron microscopy, and lipidated microtubule-associated protein light chain 3 (LC3-II), was increased after TBI vs. controls. To determine if antioxidants could reduce autophagy, separate mice were treated with the antioxidant gamma-glutamylcysteinyl ethyl ester (GCEE). Treatment with GCEE preserved total antioxidant reserves, reduced LC3-II in injured brains, and improved both behavioral and histological outcome after TBI. Here we report that LC3-II and autophagosomes were detectable in brain tissue from humans after TBI. Taken together, we show that autophagy occurs after both experimental and clinical TBI, and that oxidative stress contributes to overall neuropathology after TBI in mice, at least in part by initiating or influencing autophagy. Addendum to: Lai Y, Hickey RW, Chen Y, Bayir H, Sullivan M, Chu CT, Kochanek PM, Dixon CE, Jenkins LW, Graham SH, Watkins SC, Clark RSB. Autophagy is increased after traumatic brain injury in mice and is partially inhibited by the antioxidant gamma-glutamylcysteinyl ethyl ester. J Cereb Blood Flow Metab 2007; In press.	[Clark, Robert S. B.; Bayir, Hulya; Kochanek, Patrick M.] Safar Ctr Resuscitat Res, Dept Crit Care Med, Pittsburgh, PA 15260 USA; [Clark, Robert S. B.; Kochanek, Patrick M.] Safar Ctr Resuscitat Res, Dept Pediat, Pittsburgh, PA 15260 USA; [Bayir, Hulya] Safar Ctr Resuscitat Res, Dept Environm & Occupat Hlth, Pittsburgh, PA 15260 USA; [Chu, Charleen T.] Safar Ctr Resuscitat Res, Dept Pathol, Pittsburgh, PA 15260 USA; [Alber, Sean M.; Watkins, Simon C.] Safar Ctr Resuscitat Res, Dept Cell Biol & Physiol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA		Clark, RSB (corresponding author), Safar Ctr Resuscitat Res, 3434 Fifth Ave, Pittsburgh, PA 15260 USA.	clarkrs@ccm.upmc.edu	Kochanek, Patrick M/D-2371-2015; Watkins, Simon/ABG-2590-2021; Chu, Charleen T/B-1601-2008	Kochanek, Patrick M/0000-0002-2627-913X; Watkins, Simon/0000-0003-4092-1552; Chu, Charleen T/0000-0002-5052-8271	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50 NS30318, R01 NS38620] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [AHA 0535365N] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038620, P50NS030318] Funding Source: NIH RePORTER		Clark RSB, 1999, FASEB J, V13, P813, DOI 10.1096/fasebj.13.8.813; Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724; Koike M, 2005, AM J PATHOL, V167, P1713, DOI 10.1016/S0002-9440(10)61253-9; Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723; LAI Y, 2007, J CEREB BLOOD F EPUB; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Mizushima N, 2006, AUTOPHAGY, V2, P302, DOI 10.4161/auto.2945; NEELY N, 1974, BIOCHEM BIOPH RES CO, V59, P680, DOI 10.1016/S0006-291X(74)80033-1; Nixon RA, 2005, J NEUROPATH EXP NEUR, V64, P113, DOI 10.1093/jnen/64.2.113; Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; Wang QJ, 2006, J NEUROSCI, V26, P8057, DOI 10.1523/JNEUROSCI.2261-06.2006; Yu WH, 2005, J CELL BIOL, V171, P87, DOI 10.1083/jcb.200505082; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100; Zhang XP, 2003, FASEB J, V17, P1367, DOI 10.1096/fj.02-1067fje; Zhu JH, 2007, AM J PATHOL, V170, P75, DOI 10.2353/ajpath.2007.060524	16	110	120	0	3	LANDES BIOSCIENCE	AUSTIN	1002 WEST AVENUE, 2ND FLOOR, AUSTIN, TX 78701 USA	1554-8627			AUTOPHAGY	Autophagy	JAN 1	2008	4	1					88	90		10.4161/auto.5173			3	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	249FB	WOS:000252211800033	17957135	Bronze			2022-02-06	
J	Alexander, DM; Williams, LM; Gatt, JM; Dobson-Stone, C; Kuan, SA; Todd, EG; Schofield, PR; Cooper, NJ; Gordon, E				Alexander, D. M.; Williams, L. M.; Gatt, J. M.; Dobson-Stone, C.; Kuan, S. A.; Todd, E. G.; Schofield, P. R.; Cooper, N. J.; Gordon, E.			The contribution of apolipoprotein E alleles on cognitive performance and dynamic neural activity over six decades	BIOLOGICAL PSYCHOLOGY			English	Article						apolipoprotein E; development; electro-encephalogram; spatio-temporal waves; cognition; verbal fluency	TRAUMATIC BRAIN-INJURY; E EPSILON-4 ALLELE; ALZHEIMERS-DISEASE; E POLYMORPHISM; E GENOTYPE; APOE GENOTYPE; LIPOPROTEIN RECEPTORS; MEMORY PERFORMANCE; YOUNG-ADULTS; OLDER ADULTS	Neuroimaging shows brain-functional differences due to apolipoprotein E (APOE) polymorphisms may exist decades before the increased risk period for Alzheimer's disease, but little is known about their effect on cognition and brain function in children and young adults. This study assessed 415 healthy epsilon 2 and epsilon 4 carriers and matched epsilon 3/epsilon 3 controls, spanning ages 6-65, on a range of cognitive tests. Subjects were also compared on a new dynamical measure of EEG activity during a visual working memory task using alphabetical stimuli. epsilon 4 subjects had better verbal fluency compared to epsilon 3, an effect that was strongest in 51-65 year-olds. No epsilon 4 deficits in cognition were found. In 6-15 year-olds, there were differences in total spatio-temporal wave activity between epsilon 3 and epsilon 4 subjects in the theta band, approximately 200 ms post-stimulus. Differences in brain function in younger epsilon 4 subjects and superior verbal fluency across the entire age range suggest that the APOE epsilon 4 allele is an example of antagonistic pleiotropy. (c) 2007 Elsevier B.V. All rights reserved.	RIKEN BSI, Lab Perceptual Dynam, Wako, Saitama 3510198, Japan; Brain Resource Co, Broadway, NSW 2007, Australia; Brain Resource Int Database, Broadway, NSW 2007, Australia; Univ Technol Sydney, Fac Informat Technol, Broadway, NSW 2007, Australia; Westmead Millennium Inst, Brain Dynam Ctr, Westmead, NSW 2145, Australia; Univ Sydney, Westmead Hosp, Western Clin Sch, Sydney, NSW 2145, Australia; Univ Sydney, Westmead Hosp, Western Clin Sch, Westmead, NSW 2145, Australia; Garvan Inst Med Res, Darlinghurst, NSW 2010, Australia; Prince Wales Med Res Inst, Randwick, NSW 2031, Australia; Univ New S Wales, Kensington, NSW 2052, Australia		Alexander, DM (corresponding author), RIKEN BSI, Lab Perceptual Dynam, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	dalex@brain.riken.jp	Cooper, Nicholas J/C-6467-2013; Williams, Leanne M/B-4095-2012; Gatt, Justine M/C-4624-2008; Alexander, David M/J-5829-2017; Schofield, Peter/C-9669-2011	Gatt, Justine M/0000-0002-9276-6358; Dobson-Stone, Carol/0000-0002-2211-0257; Alexander, David/0000-0003-4583-8950; Cooper, Nicholas/0000-0003-0049-2204; Schofield, Peter/0000-0003-2967-9662			Alexander D, 2006, Acta Neuropsychiatr, V18, P240, DOI 10.1111/j.1601-5215.2006.00158.x; Alexander DM, 2006, J NEUROSCI METH, V156, P111, DOI 10.1016/j.jneumeth.2006.02.016; Alexander David M., 2006, Journal of Integrative Neuroscience, V5, P49, DOI 10.1142/S0219635206001021; ALEXANDER DM, 2006, CLIN EEG NEUROSCI, V37, P144; Beffert U, 1998, BRAIN RES REV, V27, P119, DOI 10.1016/S0165-0173(98)00008-3; Beffert U, 2004, J LIPID RES, V45, P403, DOI 10.1194/jlr.R300017-JLR200; Bothwell M, 2000, CELL, V102, P271, DOI 10.1016/S0092-8674(00)00032-5; Buzsaki G, 1994, TEMPORAL CODING BRAI, P145, DOI [10.1007/978-3-642-85148-3_9, DOI 10.1007/978-3-642-85148-3_9]; Clark CR, 2006, ARCH CLIN NEUROPSYCH, V21, P449, DOI 10.1016/j.acn.2006.06.005; Cohen RM, 2001, NEUROLOGY, V57, P2223, DOI 10.1212/WNL.57.12.2223; Cooper JA, 1999, CELL, V97, P671, DOI 10.1016/S0092-8674(00)80778-3; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Deary IJ, 2002, NATURE, V418, P932, DOI 10.1038/418932a; den Heijer T, 2002, NEUROLOGY, V59, P746, DOI 10.1212/WNL.59.5.746; Dietschy JM, 2001, CURR OPIN LIPIDOL, V12, P105, DOI 10.1097/00041433-200104000-00003; Fillenbaum GG, 2001, J AM GERIATR SOC, V49, P1148, DOI 10.1046/j.1532-5415.2001.49230.x; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Gordon E, 2005, CLIN EEG NEUROSCI, V36, P64, DOI 10.1177/155005940503600205; Gordon E, 2003, NEUROPSYCHOPHARMACOL, V28, pS2, DOI 10.1038/sj.npp.1300136; GRATTON G, 1983, ELECTROEN CLIN NEURO, V55, P468, DOI 10.1016/0013-4694(83)90135-9; Green J, 1999, ARCH NEUROL-CHICAGO, V56, P1398, DOI 10.1001/archneur.56.11.1398; HELKALA EL, 1995, NEUROSCI LETT, V191, P141, DOI 10.1016/0304-3940(95)11575-H; Helkala EL, 2001, DIABETIC MED, V18, P991, DOI 10.1046/j.0742-3071.2001.00588.x; HERRMANN W, 1994, PEDIATRICS, V93, P296; Herz J, 2000, NAT REV NEUROSCI, V1, P51, DOI 10.1038/35036221; Hofer SM, 2002, PSYCHOL AGING, V17, P194, DOI 10.1037//0882-7974.17.2.194; Hubacek JA, 2001, NEUROPSYCHOBIOLOGY, V43, P200, DOI 10.1159/000054890; Ito J, 2005, BIOL CYBERN, V92, P54, DOI 10.1007/s00422-004-0533-z; Jelic V, 1997, J NEUROL NEUROSUR PS, V63, P59, DOI 10.1136/jnnp.63.1.59; Jordan J, 1998, J NEUROSCI, V18, P195; Kim KW, 2002, INT J GERIATR PSYCH, V17, P635, DOI 10.1002/gps.664; Klages J, 2002, BRAIN COGNITION, V49, P201, DOI 10.1006/brcg.2001.1465; Klimesch W, 2004, COGNITIVE BRAIN RES, V19, P302, DOI 10.1016/j.cogbrainres.2003.11.016; Klimesch W, 1999, BRAIN RES REV, V29, P169, DOI 10.1016/S0165-0173(98)00056-3; Kutner KC, 2000, NEUROSURGERY, V47, P651, DOI 10.1097/00006123-200009000-00026; KUUSISTO J, 1994, BRIT MED J, V309, P636, DOI 10.1136/bmj.309.6955.636; Lehtovirta M, 1996, NEUROBIOL AGING, V17, P523; Lehtovirta M, 2000, DEMENT GERIATR COGN, V11, P29, DOI 10.1159/000017210; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Marquis S, 2002, ARCH NEUROL-CHICAGO, V59, P601, DOI 10.1001/archneur.59.4.601; Massimini M, 2004, J NEUROSCI, V24, P6862, DOI 10.1523/JNEUROSCI.1318-04.2004; Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; NELSON CA, 1995, DEV PSYCHOL, V31, P723, DOI 10.1037/0012-1649.31.5.723; Ohkubo N, 2001, J BIOL CHEM, V276, P3046, DOI 10.1074/jbc.M005070200; Oria RB, 2005, PEDIATR RES, V57, P310, DOI 10.1203/01.PDR.0000148719.82468.CA; Paul RH, 2005, INT J NEUROSCI, V115, P1549, DOI 10.1080/00207450590957890; Paul RH, 2007, INT J NEUROSCI, V117, P549, DOI 10.1080/00207450600773665; Pendleton N, 2002, NEUROSCI LETT, V324, P74, DOI 10.1016/S0304-3940(02)00135-0; Pitas RE, 1998, BIOCHEM SOC T, V26, P257, DOI 10.1042/bst0260257; Poirier J, 1998, J NEURAL TRANSM-SUPP, P199; PRITCHARD WS, 1986, INT J NEUROSCI, V29, P199, DOI 10.3109/00207458608986151; Puttonen S, 2003, NEUROPSYCHOBIOLOGY, V48, P35, DOI 10.1159/000071827; REBECK GW, 1994, NEUROLOGY, V44, P1513, DOI 10.1212/WNL.44.8.1513; Reiman EM, 2005, P NATL ACAD SCI USA, V102, P8299, DOI 10.1073/pnas.0500579102; Reiman EM, 2004, P NATL ACAD SCI USA, V101, P284, DOI 10.1073/pnas.2635903100; Reinvang I, 2005, NEUROSCI LETT, V382, P346, DOI 10.1016/j.neulet.2005.03.024; RIBARY U, 1991, P NATL ACAD SCI USA, V88, P11037, DOI 10.1073/pnas.88.24.11037; Sager MA, 2005, J GERIATR PSYCH NEUR, V18, P245, DOI 10.1177/0891988705281882; Sauseng P, 2002, NEUROSCI LETT, V324, P121, DOI 10.1016/S0304-3940(02)00225-2; Scarmeas N, 2005, J NEUROL NEUROSUR PS, V76, P1440, DOI 10.1136/jnnp.2004.053645; Small BJ, 2000, NEUROLOGY, V54, P2082, DOI 10.1212/WNL.54.11.2082; Smith CD, 1999, NEUROLOGY, V53, P1391, DOI 10.1212/WNL.53.7.1391; Smith CD, 2002, NEUROLOGY, V58, P1197, DOI 10.1212/WNL.58.8.1197; Smith GE, 1998, NEUROLOGY, V50, P355, DOI 10.1212/WNL.50.2.355; SNYDER E, 1976, BEHAV BIOL, V16, P319, DOI 10.1016/S0091-6773(76)91447-4; STRITTMATTER WJ, 1994, EXP NEUROL, V125, P163, DOI 10.1006/exnr.1994.1019; Tammi A, 2000, ATHEROSCLEROSIS, V152, P135, DOI 10.1016/S0021-9150(99)00436-0; Teter B, 1999, J NEUROCHEM, V73, P2613, DOI 10.1046/j.1471-4159.1999.0732613.x; Tolar M, 1999, J NEUROSCI, V19, P7100, DOI 10.1523/JNEUROSCI.19-16-07100.1999; Turic D, 2001, NEUROSCI LETT, V299, P97, DOI 10.1016/S0304-3940(00)01789-4; WEISGRABER KH, 1982, J BIOL CHEM, V257, P2518; Wetter S, 2001, NEUROBIOL AGING, V22, P439, DOI 10.1016/S0197-4580(01)00215-9; Williams LM, 2005, INT J NEUROSCI, V115, P1605, DOI 10.1080/00207450590958475; Wilson RS, 2002, J NEUROL NEUROSUR PS, V73, P672, DOI 10.1136/jnnp.73.6.672; Winnock M, 2002, J NEUROL NEUROSUR PS, V72, P794, DOI 10.1136/jnnp.72.6.794; Wright RO, 2003, PEDIATR RES, V54, P819, DOI 10.1203/01.PDR.0000090927.53818.DE; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4; Yu VWY, 2000, NEUROSCI LETT, V294, P179, DOI 10.1016/S0304-3940(00)01569-X; Zetterberg H, 2002, NEUROSCI LETT, V324, P189, DOI 10.1016/S0304-3940(02)00198-2	81	110	112	0	10	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0301-0511	1873-6246		BIOL PSYCHOL	Biol. Psychol.	JUL	2007	75	3					229	238		10.1016/j.biopsycho.2007.03.001			10	Psychology, Biological; Behavioral Sciences; Psychology; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Behavioral Sciences	191EQ	WOS:000248113400002	17433528				2022-02-06	
J	Ono, K; Wada, K; Takahara, T; Shirotani, T				Ono, Kenichiro; Wada, Kojiro; Takahara, Takashi; Shirotani, Toshiki			Indications for computed tomography in patients with mild head injury	NEUROLOGIA MEDICO-CHIRURGICA			English	Article						mild head injury; intracranial lesion; indications for computed tomography; Japan Coma Scale; Glasgow Coma Scale; risk factor	TRAUMATIC BRAIN INJURY; GLASGOW COMA SCALE; INITIAL MANAGEMENT; RISK; DIAGNOSIS; RECOMMENDATIONS; RELIABILITY; VALIDATION; PREDICTORS; HEMORRHAGE	The factors affecting outcome were analyzed in 1,064 patients, 621 males and 443 females aged 10 to 104 years (mean 46 23 years), with mild head injury (Glasgow Coma Scale [GCS] score +/- 14) but no neurological signs presenting within 6 hours after injury. Intracranial lesion was found in 4.7% (50/1,064), and 0.66% (7/1,064) required surgical treatment. The Japan Coma Scale (JCS) and GCS assessments were well correlated (r = 0.797). Multivariate analysis revealed significant correlations between computed tomography (CT) abnormality and age >= 60 years, male sex, JCS score >= 1, alcohol consumption, headache, nausea/vomiting, and transient loss of consciousness (LOC)/amnesia. Univariate analysis revealed that pedestrian in a motor vehicle accident, falling from height, and mechanisms of injuries except blows were correlated to intracranial injury. No significant correlations were found between craniofacial soft tissue injury and intracranial injury. Patients with occipital impact, nonfrontal impact, or skull fracture were more likely have intracranial lesions. Bleeding tendency was not correlated with CT abnormality. The following indications were proposed for CT: JCS score > 0, presence of accessory symptoms (headache, nausea/vomiting, LOC/amnesia), and age >= 60 years. These criteria would reduce the frequency of CT by 29% (309/1,064). Applying these indications to subsequent patients with GCS scores 14-15, 114 of 168 patients required CT, and intracranial lesions were found in 13. Two refused CT. Fifty-four of the 168 patients did not need CT according to the indications, but 38 of the 54 patients actually underwent CT because of social reasons (n = 21) or patient request (n = 17). These indications for CT including JCS may be useful in the management of patients with mild head injury.	Japan Self Def Forces Cent Hosp, Dept Neurosurg, Tokyo, Japan		Ono, K (corresponding author), Ground Self Def Force 7th Div Headquarters, Camp Higashichitose 1016 Shukubai, Chitose, Hokkaido 0668577, Japan.						Bartlett J, 1998, BRIT J NEUROSURG, V12, P349, DOI 10.1080/02688699844871; BORCZUK P, 1995, ANN EMERG MED, V25, P731, DOI 10.1016/S0196-0644(95)70199-0; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; Dunham CM, 1996, J TRAUMA, V41, P679, DOI 10.1097/00005373-199610000-00014; Fabbri A, 2004, J NEUROL NEUROSUR PS, V75, P410, DOI 10.1136/jnnp.2003.016113; GOTOH O, NO TO SHINKEI, V47, P49; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Hofman PAM, 2000, J NEUROL NEUROSUR PS, V68, P416, DOI 10.1136/jnnp.68.4.416; Ibanez J, 2004, J NEUROSURG, V100, P825, DOI 10.3171/jns.2004.100.5.0825; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Iverson GL, 2000, BRAIN INJURY, V14, P1057; Jagoda AS, 2002, ANN EMERG MED, V40, P231, DOI [10.1067/mem.2002.125782, 10.1016/j.jen.2008.12.010]; *JAP SOC NEUR, 2006, SHINKEL GAISHI S1, V29, P1; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; Katada Kazuhiro, 2006, Nihon Hoshasen Gijutsu Gakkai Zasshi, V62, P649; LEE ST, 1995, ACTA NEUROCHIR, V135, P136, DOI 10.1007/BF02187757; MASTERS SJ, 1987, NEW ENGL J MED, V316, P84, DOI 10.1056/NEJM198701083160205; MENEGAZZI JJ, 1993, J TRAUMA, V34, P46, DOI 10.1097/00005373-199301000-00008; Miller Erik C., 1997, Journal of Emergency Medicine, V15, P453, DOI 10.1016/S0736-4679(97)00071-1; Nagy KK, 1999, J TRAUMA, V46, P268, DOI 10.1097/00005373-199902000-00012; Norwood SH, 2002, J TRAUMA, V53, P503, DOI 10.1097/00005373-200209000-00018; Ohta T., 1985, SOGO RINSHO, V34, P477; *SCOTT INT GUID NE, 2000, EARL MAN PAT HEAD IN, P7; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Shiomi N, 2004, NEUROL SURG TOKYO, V32, P465; Spektor S, 2003, J NEUROSURG, V99, P661, DOI 10.3171/jns.2003.99.4.0661; STEIN SC, 1990, NEUROSURGERY, V26, P638, DOI 10.1227/00006123-199004000-00012; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Takagi K, 1998, NEUROL SURG TOKYO, V26, P509; TEASDALE GM, 1990, BRIT MED J, V300, P363, DOI 10.1136/bmj.300.6721.363; TOMEI G, 1996, J NEUROSURG SCI, V40, P11; Volans AP, 1998, J ACCID EMERG MED, V15, P159; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x	34	110	113	0	3	JAPAN NEUROSURGICAL SOC	TOKYO	C/O AKAMON-MAE IWATA BLDG, 5-27-8 HONGO, BUNKYO-KU, TOKYO, 113-0033, JAPAN	0470-8105			NEUROL MED-CHIR	Neurol. Med.-Chir.	JUL	2007	47	7					291	297		10.2176/nmc.47.291			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	191LH	WOS:000248132200001	17652914	Bronze			2022-02-06	
J	Vespa, PM; O'Phelan, K; McArthur, D; Miller, C; Eliseo, M; Hirt, D; Glenn, T; Hovda, DA				Vespa, Paul M.; O'Phelan, Kristine; McArthur, David; Miller, Chad; Eliseo, Matthew; Hirt, Daniel; Glenn, Thomas; Hovda, David A.			Pericontusional brain tissue exhibits persistent elevation of lactate/pyruvate ratio independent of cerebral perfusion pressure	CRITICAL CARE MEDICINE			English	Article						brain injury; microdialysis; cerebral perfusion pressure; coma; lactate/pyruvate ratio; intracranial pressure	INTRACEREBRAL MICRODIALYSIS; INJURY; GLUCOSE; LACTATE; ISCHEMIA; INCREASE	Objective. To determine whether pericontusional tissue exhibits neurochemical responsiveness to changes in cerebral perfusion pressure as measured by microdialysis lactate/pyruvate ratio. Design: Prospective monitoring with retrospective data analysis. Setting, Single-center academic neurologic intensive care unit. Patients: Twenty-one patients with severe traumatic brain injury (Glasgow Coma Scale score 3-8). Interventions, None. Measurements and Main Results., Cerebral microdialysis was performed for the initial 7 days after traumatic brain injury. Thirteen patients had microdialysis probes in normal tissue and eight had two probes, one of which was located in pericontusional tissue. Retrospective analysis was performed to determine if microdialysis levels in pericontusional tissue demonstrates higher levels of lactate/pyruvate ratio than normal tissue and if lactate/ pyruvate ratio increased with reductions in cerebral perfusion pressure. Univariate analysis revealed higher values for glutamate and lactate/pyruvate ratio in pericontusional tissue compared with normal tissue. However, based on the mixed-effects model analysis, the percent time of elevated lactate/pyruvate ratio was significantly higher in pericontusional tissue (40 +/- 59% vs. 17 +/- 37%, p <.05), and the mean lactate/pyruvate ratio values showed only a trend relationship (62 +/- 134 vs. 34 +/- 78, p <.06). When examined by cerebral perfusion pressure threshold, cerebral perfusion pressure < 60 mm Hg was not associated with higher lactate/pyruvate ratio values in normal or pericontusional tissue. In addition, no single cerebral perfusion pressure threshold was associated with a significant reduction in lactate/pyruvate ratio in either pericontusional or normal tissue (p <.08). Conclusions. Sustained increases in lactate/pyruvate ratio occurred more frequently in pericontusional tissue compared with normal brain tissue. The lactate/pyruvate ratio was not related to cerebral perfusion pressure, nor was the percent time-burden of elevated lactate/pyruvate ratio related to any particular sustained cerebral perfusion pressure threshold. Lactate/pyruvate ratio values appear to be elevated despite cerebral perfusion pressure values customarily considered to be adequate.	Univ Calif Los Angeles, Div Neurosurg, Los Angeles, CA 90024 USA; Univ Hawaii, Honolulu, HI 96822 USA		Vespa, PM (corresponding author), Univ Calif Los Angeles, Div Neurosurg, Los Angeles, CA 90024 USA.	PVespa@mednet.ucla.edu		Glenn, Thomas/0000-0003-4273-3408			Alessandri B, 2000, ACTA NEUROCHIR SUPPL, V76, P425; Alessandri B, 1999, ACT NEUR S, V75, P25; Bell MJ, 2001, CRIT CARE MED, V29, P399, DOI 10.1097/00003246-200102000-00033; Clausen T, 2001, BRAIN RES, V908, P35, DOI 10.1016/S0006-8993(01)02566-5; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P191, DOI 10.1097/01.WCB.0000100045.07481.DE; Diringer MN, 2002, J NEUROSURG, V96, P103, DOI 10.3171/jns.2002.96.1.0103; Enblad P, 1996, J CEREBR BLOOD F MET, V16, P637, DOI 10.1097/00004647-199607000-00014; Enblad P, 2001, STROKE, V32, P1574, DOI 10.1161/01.STR.32.7.1574; Engstrom M, 2005, J NEUROSURG, V102, P460, DOI 10.3171/jns.2005.102.3.0460; Faraway J., 2006, MIXED EFFECTS NONPAR; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Johnston AJ, 2005, CRIT CARE MED, V33, P189, DOI 10.1097/01.CCM.0000149837.09225.BD; Nordstrom CH, 2003, ANESTHESIOLOGY, V98, P809, DOI 10.1097/00000542-200304000-00004; Parkin MC, 2005, J CEREBR BLOOD F MET, V25, P402, DOI 10.1038/sj.jcbfm.9600051; Pinheiro J. C., 2000, MIXED EFFECTS MODELS; Reinert M, 2000, ACTA NEUROCHIR SUPPL, V76, P439; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Wu HM, 2004, NEUROSURGERY, V55, P1306, DOI 10.1227/01.NEU.0000143028.08719.42	23	110	112	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	APR	2007	35	4					1153	1160		10.1097/01.CCM.0000259466.66310.4F			8	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151PJ	WOS:000245302400021	17334254				2022-02-06	
J	Stiefel, MF; Udoetuk, JD; Spiotta, AM; Gracias, VH; Goldberg, A; Maloney-Wilensky, E; Bloom, S; Le Roux, PD				Stiefel, Michael F.; Udoetuk, Joshua D.; Spiotta, Alejandro M.; Gracias, Vicente H.; Goldberg, Aaron; Maloney-Wilensky, Eileen; Bloom, Stephanie; Le Roux, Peter D.			Conventional neurocritical care and cerebral oxygenation after traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; conventional care; brain oxygen; intracranial pressure	SEVERE HEAD-INJURY; PERFUSION-PRESSURE; TISSUE OXYGEN; BLOOD-FLOW; END-POINTS; INTRACRANIAL HYPERTENSION; LACTATE CLEARANCE; RANDOMIZED-TRIAL; INTENSIVE-CARE; CARBON-DIOXIDE	Object. Control of intracranial pressure (ICP) and cerebral perfusion pressure (CPP) is the foundation of traumatic brain injury (TBI) management. In this study, the authors examined whether conventional ICP- and CPP-guided neurocritical care ensures adequate brain tissue O-2 in the first 6 hours after resuscitation. Methods. Resuscitated patients with severe TBI (Glasgow Coma Scale score <= 8 and Injury Severity Scale score >= 16) who were admitted to a Level I trauma center and who underwent brain tissue O-2 monitoring within 6 hours of injury were evaluated as part of a prospective observational database. Therapy was directed to maintain an ICP of 25 mm Hg or less and a CPP of 60 mm Hg or higher. Data from a group of 25 patients that included 19 men and six women (mean age 39 +/- 20 years) were examined. After resuscitation, ICP was 25 mm Hg or less in 84% and CPP was 60 mm Hg or greater in 88% of the patients. Brain O-2 probes were allowed to stabilize; the initial brain tissue O-2 level was 25 mm Hg or less in 68% of the patients, 20 mm Hg or less in 56%, and 10 mm Hg or less in 36%. Nearly one third (29%) of patients with ICP readings of 25 mm Hg or less and 27% with CPP levels of 60 mm Hg or greater had severe cerebral hypoxia (brain tissue O-2 <= 10 mm Hg). Nineteen patients had both optimal ICP (< 25 mm Hg) and CPP (> 60 mm Hg); brain tissue O-2 was 20 mm Hg or less in 47% and 10 mm Hg or less in 21% of these patients. The mortality rate was higher in patients with reduced brain tissue O-2. Conclusions. Brain resuscitation based on current neurocritical care standards (that is, control of ICP and CPP) does not prevent cerebral hypoxia in some patients. This finding may help explain why secondary neuronal injury occurs in some patients with adequate CPP and suggests that the definition of adequate brain resuscitation after TBI may need to be reconsidered.	Univ Penn, Dept Neurosurg, Sch Med, Philadelphia, PA 19107 USA; Univ Penn, Div Trauma Surg & Surg Crit Care, Sch Med, Philadelphia, PA 19107 USA		Le Roux, PD (corresponding author), Univ Penn, Dept Neurosurg, Sch Med, 330 S 9th St, Philadelphia, PA 19107 USA.	lerouxp@uphs.upenn.edu					ABOUKHALIL B, 1994, CRIT CARE MED, V22, P633, DOI 10.1097/00003246-199404000-00020; ABRAMSON D, 1993, J TRAUMA, V35, P584, DOI 10.1097/00005373-199310000-00014; American College of Surgeons Committee on Trauma, 1997, ADV TRAUM LIF SUPP C; Bardt TF, 1998, ACT NEUR S, V71, P153; BISHOP MH, 1995, J TRAUMA, V38, P780, DOI 10.1097/00005373-199505000-00018; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; *BRAIN TRAUM FDN A, 2000, MAN PROGN SEV TRAUM; Bruzzone P, 1998, ACT NEUR S, V71, P111; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Clay H D, 2000, J Neurosci Nurs, V32, P194; Clifton GL, 2002, CRIT CARE MED, V30, P739, DOI 10.1097/00003246-200204000-00003; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; CRUZ J, 1995, CRIT CARE MED, V23, P1412, DOI 10.1097/00003246-199508000-00016; Cruz J, 1998, CRIT CARE MED, V26, P344, DOI 10.1097/00003246-199802000-00039; Dearden NM, 1998, CLIN NEUROPATHOL, V17, P221; Dings J, 1998, NEUROL RES, V20, pS71; FIDDIANGREEN RG, 1993, CRIT CARE MED, V21, pS25, DOI 10.1097/00003246-199302001-00006; Gopinath SP, 1999, CRIT CARE MED, V27, P2337, DOI 10.1097/00003246-199911000-00003; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; Gracias VH, 2004, J TRAUMA, V56, P469, DOI 10.1097/01.TA.0000114274.95423.C0; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; Gupta AK, 1999, ANESTH ANALG, V88, P549, DOI 10.1097/00000539-199903000-00016; Hemphill JC, 2001, NEUROSURGERY, V48, P377, DOI 10.1097/00006123-200102000-00028; Hoffman WE, 1999, SURG NEUROL, V51, P654, DOI 10.1016/S0090-3019(99)00011-7; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kelly DF, 1997, J NEUROSURG, V86, P633, DOI 10.3171/jns.1997.86.4.0633; Kern JW, 2002, CRIT CARE MED, V30, P1686, DOI 10.1097/00003246-200208000-00002; Kiening KL, 1997, NEUROL RES, V19, P233, DOI 10.1080/01616412.1997.11740805; Kroppenstedt SN, 2003, CRIT CARE MED, V31, P2211, DOI 10.1097/01.CCM.0000080482.06856.62; LeRoux PD, 1997, J NEUROSURG, V87, P1, DOI 10.3171/jns.1997.87.1.0001; MAAS AIR, 1993, ACTA NEUROCHIR, P50; Mapstone J, 2003, J TRAUMA, V55, P571, DOI 10.1097/01.TA.0000062968.69867.6F; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; McIntyre L, 2004, J TRAUMA, V57, P563, DOI 10.1097/01.TA.0000136158.93864.54; McNelis J, 2001, AM J SURG, V182, P481, DOI 10.1016/S0002-9610(01)00755-3; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Miller PR, 1998, J TRAUMA, V45, P868, DOI 10.1097/00005373-199811000-00004; MOORE FA, 1992, J TRAUMA, V33, P58, DOI 10.1097/00005373-199207000-00012; MURR R, 1995, NEUROL RES, V17, P329, DOI 10.1080/01616412.1995.11740338; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; ROBERTSON C, 1996, YOUMANS NEUROLOGICAL, P5103; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Sarrafzadeh AS, 2003, BRIT J NEUROSURG, V17, P340, DOI 10.1080/02688690310001601234; SCALEA TM, 1994, CRIT CARE MED, V22, P1610; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; SHOEMAKER WC, 1983, AM J SURG, V146, P43, DOI 10.1016/0002-9610(83)90257-X; SHOEMAKER WC, 1973, ARCH SURG-CHICAGO, V106, P630; Soehle M, 2003, NEUROL RES, V25, P411, DOI 10.1179/016164103101201580; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Stocchetti N, 1998, ACT NEUR S, V71, P162; Suazo JAC, 2000, CRIT CARE MED, V28, P3268, DOI 10.1097/00003246-200009000-00024; Tisherman SA, 2004, J TRAUMA, V57, P898, DOI 10.1097/01.TA.0000133577.25793.E5; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; van Santbrink H, 2003, ACTA NEUROCHIR, V145, P429, DOI 10.1007/s00701-003-0032-3; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; Velmahos GC, 2000, ANN SURG, V232, P409, DOI 10.1097/00000658-200009000-00013; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; Wilensky Eileen Maloney, 2005, J Neurosci Nurs, V37, P278; 2000, J NEUROTRAUMA, V17, P549	65	110	116	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	OCT	2006	105	4					568	575		10.3171/jns.2006.105.4.568			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	092AZ	WOS:000241070700014	17044560				2022-02-06	
J	Brandt, C; Gastens, AM; Sun, MZ; Hausknecht, M; Loscher, W				Brandt, Claudia; Gastens, Alexandra M.; Sun, Mei zhen; Hausknecht, Maria; Loescher, Wolfgang			Treatment with valproate after status epilepticus: Effect on neuronal damage, epileptogenesis, and behavioral alterations in rats	NEUROPHARMACOLOGY			English	Article						epilepsy; antiepileptic drugs; neuroprotection; Morris water maze; dentate hilus	LITHIUM-PILOCARPINE MODEL; ELECTRICAL-STIMULATION; ANTIEPILEPTIC DRUGS; BRAIN-DAMAGE; ANIMAL-MODELS; EPILEPSY; SEIZURES; ANXIETY; PREVENTION; DIAZEPAM	Epileptogenesis, i.e. the process leading to epilepsy with spontaneous recurrent seizures, can be initiated by a number of brain damaging insults, including traumatic brain injury, status epilepticus (SE), and stroke. Such acquired epilepsy is often associated with memory impairment and behavioral problems. There has been a growing interest in the use of antiepileptic drugs (AEDs) for neuroprotection and prevention or modification of epileptogenesis induced by such brain insults. One promising candidate in this respect is valproic acid (VPA), a widely used AED that has been reported to exert neuroprotective activity in a number of in vitro and in vivo models. The present study investigated whether VPA reduces brain damage and improves functional outcome in a rat model of post-SE epilepsy. A self-sustaining SE was induced by prolonged electrical stimulation of the basal amygdala via a depth electrode. SE was terminated after 4 h by diazepam, immediately followed by onset of treatment with VPA. VPA was injected i.p. at a bolus dose of 400 mg/kg, followed by three times daily administration of 200 mg/kg for 4 weeks. A control group received vehicle instead of VPA after SE. Spontaneous seizures were recorded in all rats of both groups following termination of treatment, without significant inter-group difference in seizure frequency or severity. However, treatment with VPA after SE prevented the hyperexcitability and locomotor hyperactivity observed in vehicle-treated epileptic rats. Furthermore, VPA completely counteracted the neuronal damage in the hippocampal formation, including the dentate hilus. The data demonstrate that, although VPA does not prevent the occurrence of spontaneous seizures after SE, it exerts powerful neuroprotective effects and prevents part of the behavioral alterations, demonstrating that administration of VPA immediately after SE exerts a favorable effect on long-term functional outcome. (c) 2006 Elsevier Ltd. All rights reserved.	Univ Vet Med, Dept Pharmacol Toxicol & Pharm, D-30559 Hannover, Germany		Loscher, W (corresponding author), Univ Vet Med, Dept Pharmacol Toxicol & Pharm, Bunteweg 17, D-30559 Hannover, Germany.	wolfgang.loescher@tiho-hannover.de					Aerden LAM, 2004, NEUROSCI LETT, V367, P76, DOI 10.1016/j.neulet.2004.05.083; Andre V, 2001, EPILEPSY RES, V47, P99, DOI 10.1016/S0920-1211(01)00299-6; Bachmann RF, 2005, MOL NEUROBIOL, V32, P173, DOI 10.1385/MN:32:2:173; Barch DM, 2003, J ABNORM PSYCHOL, V112, P132, DOI 10.1037/0021-843X.112.1.132; Benardo LS, 2003, EPILEPSIA, V44, P27, DOI 10.1046/j.1528-1157.44.s10.2.x; Bolanos AR, 1998, NEUROLOGY, V51, P41, DOI 10.1212/WNL.51.1.41; Brandt C, 2003, EPILEPSY RES, V55, P83, DOI 10.1016/S0920-1211(03)00114-1; Brandt C, 2003, NEUROSCIENCE, V118, P727, DOI 10.1016/S0306-4522(03)00027-7; Cilio MR, 2001, NEUROPHARMACOLOGY, V40, P139, DOI 10.1016/S0028-3908(00)00103-9; De Sarno P, 2002, NEUROPHARMACOLOGY, V43, P1158, DOI 10.1016/S0028-3908(02)00215-0; DeLorenzo RJ, 2005, PHARMACOL THERAPEUT, V105, P229, DOI 10.1016/j.pharmthera.2004.10.004; Detour J, 2005, EPILEPSIA, V46, P499, DOI 10.1111/j.0013-9580.2005.38704.x; Devinsky O, 2004, EPILEPSIA, V45, P34, DOI 10.1111/j.0013-9580.2004.452003.x; dos Santos JG, 2005, BRAIN RES, V1066, P37, DOI 10.1016/j.brainres.2005.09.037; DUNHAM NW, 1957, J AM PHARM ASSOC, V46, P208, DOI 10.1002/jps.3030460322; FILE SE, 1993, BEHAV BRAIN RES, V58, P199, DOI 10.1016/0166-4328(93)90103-W; Fujikawa DG, 2000, TRENDS NEUROSCI, V23, P410, DOI 10.1016/S0166-2236(00)01601-5; Fujikawa DG, 2005, EPILEPSY BEHAV, V7, pS3, DOI 10.1016/j.yebeh.2005.08.003; Fujikawa TG, 2000, EPILEPSIA, V41, P981, DOI 10.1111/j.1528-1157.2000.tb00283.x; Gaitatzis A, 2004, ACTA NEUROL SCAND, V110, P207, DOI 10.1111/j.1600-0404.2004.00324.x; GOODMAN JH, 1998, NEUROPHARMACOLOGY ME, P95; Halonen T, 2001, NEUROPHARMACOLOGY, V40, P536, DOI 10.1016/S0028-3908(00)00183-0; Kalviainen R, 2005, CNS DRUGS, V19, P759; Kanner AM, 2004, EPILEPSIA, V45, P22, DOI 10.1111/j.0013-9580.2004.452004.x; LANDOLT H, 1953, ELECTROEN CLIN NEURO, V5, P121; Loscher W, 2004, EPILEPSY RES, V60, P77, DOI 10.1016/j.eplepsyres.2004.06.004; Loscher W, 2002, EPILEPSY RES, V50, P105, DOI 10.1016/S0920-1211(02)00073-6; Loscher W, 2002, CNS DRUGS, V16, P669; MILGRAM NW, 1988, NEUROTOXICOLOGY, V9, P611; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MOSER VC, 1988, FUND APPL TOXICOL, V11, P189, DOI 10.1016/0272-0590(88)90144-3; Nissinen J, 2000, EPILEPSY RES, V38, P177, DOI 10.1016/S0920-1211(99)00088-1; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Pitkanen A, 2004, IDRUGS, V7, P471; Pitkanen A, 2004, EXPERT OPIN PHARMACO, V5, P777, DOI 10.1517/eoph.5.4.777.30162; Pitkanen A, 2002, NEUROLOGY, V59, pS27, DOI 10.1212/WNL.59.9_suppl_5.S27; Pitkanen A, 2002, EPILEPSY RES, V50, P141, DOI 10.1016/S0920-1211(02)00076-1; Pitkanen A, 2002, PROG BRAIN RES, V135, P67; PORSOLT RD, 1979, EUR J PHARMACOL, V57, P201, DOI 10.1016/0014-2999(79)90366-2; Potschka H, 2001, EPILEPSIA, V42, P1231, DOI 10.1046/j.1528-1157.2001.01901.x; Prut L, 2003, EUR J PHARMACOL, V463, P3, DOI 10.1016/S0014-2999(03)01272-X; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Ren M, 2004, J NEUROCHEM, V89, P1358, DOI 10.1111/j.1471-4159.2004.02406.x; Rice AC, 1998, EPILEPSIA, V39, P1148, DOI 10.1111/j.1528-1157.1998.tb01305.x; Rigoulot MA, 2004, J PHARMACOL EXP THER, V308, P787, DOI 10.1124/jpet.103.057091; Rosenow F, 2002, EPILEPTIC DISORD, V4, pS41; SCHWARTZ RD, 1995, J NEUROSCI, V15, P529; Sloviter RS, 2002, TRENDS PHARMACOL SCI, V23, P19, DOI 10.1016/S0165-6147(00)01867-8; Stafstrom CE, 2006, MODELS OF SEIZURES AND EPILEPSY, P613, DOI 10.1016/B978-012088554-1/50051-7; STAFSTROM CE, 1993, EPILEPSIA, V34, P420, DOI 10.1111/j.1528-1157.1993.tb02582.x; Szot P, 2005, MOL BRAIN RES, V135, P285, DOI 10.1016/j.molbrainres.2004.11.011; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; Temkin NR, 2001, DRUGS, V61, P1045, DOI 10.2165/00003495-200161080-00002; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; van den Buuse M, 2005, AUST NZ J PSYCHIAT, V39, P550, DOI 10.1111/j.1440-1614.2005.01626.x; Volk HA, 2006, NEUROBIOL DIS, V21, P633, DOI 10.1016/j.nbd.2005.09.006; VOLL CL, 1991, NEUROLOGY, V41, P423, DOI 10.1212/WNL.41.3.423	57	110	116	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	SEP	2006	51	4					789	804		10.1016/j.neuropharm.2006.05.021			16	Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	088LB	WOS:000240812100012	16806297				2022-02-06	
J	Lew, HL; Poole, JH; Lee, EH; Jaffe, DL; Huang, HC; Brodd, E				Lew, HL; Poole, JH; Lee, EH; Jaffe, DL; Huang, HC; Brodd, E			Predictive validity of driving-simulator assessments following traumatic brain injury: a preliminary study	BRAIN INJURY			English	Article						closed head injuries; cognition; computer simulation; driving behavior; ecological validity; predictive value of tests; risk assessment; safety standards; virtual reality systems	DIVIDED ATTENTION; ON-ROAD; PERFORMANCE; DAMAGE; DRIVERS; FITNESS; VISION; SAFETY; TESTS; CAR	Objective: To evaluate whether driving simulator and road test evaluations can predict long- term driving performance, we conducted a prospective study on 11 patients with moderate to severe traumatic brain injury. Sixteen healthy subjects were also tested to provide normative values on the simulator at baseline. Method: At their initial evaluation ( time- 1), subjects' driving skills were measured during a 30- minute simulator trial using an automated 12- measure Simulator Performance Index ( SPI), while a trained observer also rated their performance using a Driving Performance Inventory ( DPI). In addition, patients were evaluated on the road by a certified driving evaluator. Ten months later ( time- 2), family members observed patients driving for at least 3 hours over 4 weeks and rated their driving performance using the DPI. Results: At time- 1, patients were significantly impaired on automated SPI measures of driving skill, including: speed and steering control, accidents, and vigilance to a divided- attention task. These simulator indices significantly predicted the following aspects of observed driving performance at time- 2: handling of automobile controls, regulation of vehicle speed and direction, higher- order judgment and self- control, as well as a trend- level association with car accidents. Automated measures of simulator skill ( SPI) were more sensitive and accurate than observational measures of simulator skill ( DPI) in predicting actual driving performance. To our surprise, the road test results at time- 1 showed no significant relation to driving performance at time- 2. Conclusion: Simulator- based assessment of patients with brain injuries can provide ecologically valid measures that, in some cases, may be more sensitive than a traditional road test as predictors of long- term driving performance in the community.	VA Palo Alto Hlth Care Syst, Phys Med & Rehabil Serv, Palo Alto, CA 94304 USA; Def & Vet Brain Injury Ctr, Palo Alto, CA USA; Stanford Univ, Sch Med, Div Phys Med & Rehabil, Stanford, CA 94305 USA; VA Palo Alto Hlth Care Syst, Rehabil Res & Dev Ctr, Palo Alto, CA USA		Poole, JH (corresponding author), VA Palo Alto Hlth Care Syst, Phys Med & Rehabil Serv, 140-117,3801 Miranda Ave, Palo Alto, CA 94304 USA.	john.poole@med.va.gov					BLAAUW GJ, 1982, HUM FACTORS, V24, P473, DOI 10.1177/001872088202400408; Blana E, 2002, HUM FACTORS, V44, P303, DOI 10.1518/0018720024497899; Brouwer WH, 2002, J HEAD TRAUMA REHAB, V17, P1, DOI 10.1097/00001199-200202000-00003; BROUWER WH, 1991, HUM FACTORS, V33, P573, DOI 10.1177/001872089103300508; Bylsma FW, 1997, ALZ DIS ASSOC DIS, V11, P17, DOI 10.1097/00002093-199706001-00005; EDWARDS DS, 1977, J APPL PSYCHOL, V62, P559, DOI 10.1037/0021-9010.62.5.559; Fisk GD, 1998, BRAIN INJURY, V12, P683; Freund B, 2002, J AM GERIATR SOC, V50, P1309, DOI 10.1046/j.1532-5415.2002.50325.x; GALSKI T, 1993, AM J OCCUP THER, V47, P391, DOI 10.5014/ajot.47.5.391; GALSKI T, 1992, AM J OCCUP THER, V46, P324, DOI 10.5014/ajot.46.4.324; GIANUTSOS R, 1994, BEHAV RES METH INSTR, V26, P183, DOI 10.3758/BF03204615; HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.2307/2336325; Huchler S., 2001, EURA MEDICOPHYS, V37, P283; KATZ RT, 1990, ARCH PHYS MED REHAB, V71, P133; Keller M, 2003, NEUROREHAB NEURAL RE, V17, P168, DOI 10.1177/0888439003256048; Korteling JE, 1996, ARCH PHYS MED REHAB, V77, P138, DOI 10.1016/S0003-9993(96)90158-6; Lam LT, 2002, J SAFETY RES, V33, P411, DOI 10.1016/S0022-4375(02)00034-8; Lansdown T, 2004, ERGONOMICS, V47, P91, DOI 10.1080/00140130310001629775; Lee H. C., 2002, AUST, V49, P138, DOI DOI 10.1046/J.1440-1630.2002.00314.X; Lengenfelder J, 2002, J HEAD TRAUMA REHAB, V17, P26, DOI 10.1097/00001199-200202000-00005; Liu L, 1999, Cyberpsychol Behav, V2, P53, DOI 10.1089/cpb.1999.2.53; Lundqvist A, 2000, APPL COGNITIVE PSYCH, V14, P135, DOI 10.1002/(SICI)1099-0720(200003/04)14:2<135::AID-ACP628>3.0.CO;2-S; NETZ J, 2001, EUROPA MEDICOPHYSICA, V37, P275; NOURI FM, 1988, CLIN REHABIL, V2, P99; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; PRIDDY D A, 1990, Brain Injury, V4, P267, DOI 10.3109/02699059009026176; Reed MP, 1999, ERGONOMICS, V42, P1015, DOI 10.1080/001401399185117; Roge J, 2003, VISION RES, V43, P1465, DOI 10.1016/S0042-6989(03)00143-3; Stutts J C, 2001, Annu Proc Assoc Adv Automot Med, V45, P287; SZLYK JP, 1995, HUM FACTORS, V37, P430, DOI 10.1518/001872095779064645; Szlyk JP, 2002, J REHABIL RES DEV, V39, P467; Szlyk JP, 2002, J REHABIL RES DEV, V39, P483; Tornros J, 1998, ACCIDENT ANAL PREV, V30, P497, DOI 10.1016/S0001-4575(97)00099-7; VOLKERTS ER, 1992, HUM PSYCHOPHARM CLIN, V7, P297, DOI 10.1002/hup.470070502; Zesiewicz TA, 2002, NEUROLOGY, V59, P1787, DOI 10.1212/01.WNL.0000035636.83680.C6	35	110	112	1	22	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	2005	19	3					177	188		10.1080/02699050400017171			12	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	906WJ	WOS:000227675000004	15832892				2022-02-06	
J	Tavazzi, B; Signoretti, S; Lazzarino, G; Delfini, R; Cimatti, M; Marmarou, A; Vagnozzi, R				Tavazzi, B; Signoretti, S; Lazzarino, G; Delfini, R; Cimatti, M; Marmarou, A; Vagnozzi, R			Cerebral oxidative stress and depression of energy metabolism correlate with severity of diffuse brain injury in rats	NEUROSURGERY			English	Article						energy metabolism; N-acetylaspartate; nicotinic coenzymes; oxidative stress; secondary insult; traumatic brain injury	POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE; LIQUID-CHROMATOGRAPHIC METHOD; ACETYL-L-ASPARTATE; N-ACETYLASPARTATE; LIPID-PEROXIDATION; SECONDARY INSULTS; CELL-DEATH; MITOCHONDRIAL DYSFUNCTION; VERTEBRATE BRAIN; CORTICAL IMPACT	OBJECTIVE: The combined effect of traumatic brain injury (TBI) and secondary insult on biochemical changes of cerebral tissue is not well known. For this purpose, we studied the time-course changes of parameters reflecting ROS-mediated oxidative stress and modifications of cell energy metabolism determined in rats subjected to cerebral insult of increasing severity. METHODS: Rats were divided into four groups: 1) sham-operated, 2) subjected to 10 minutes of hypoxia and hypotension (HH), 3) subjected to severe diffuse TBI, and 4) subjected to severe diffuse TBI + HH. Rats were killed at different times after injury, and analyses of malonclialclehyde, ascorbate, high-energy phosphates, nicotinic co-enzymes, oxypurines, nucleosides, and 4-acetylaspartate (NAA) were made by high-performance liquid chromatography on whole-brain tissue extracts. RESULTS: Data indicated a close relationship between degree of oxidative stress and severity of brain insult, as evidenced by the highest malondialdehyde values and lowest ascorbate levels in rats subjected to TBI + HH. Similarly, modifications of parameters related to cell energy metabolism were modulated by increasing severity of brain injury, as demonstrated by the lowest values of energy charge potential, nicotinic coenzymes, and NAA and the highest levels of oxypurines and nucleosides recorded in TBI + HH rats. Both the intensity of oxidative stress-mediated cerebral damage and perturbation of energy metabolism were minimally affected in rats subjected to HH only. CONCLUSION: These results showed that the severity of brain insult can be graded by measuring biochemical modifications, specifically, reactive oxygen species-mediated damage, energy metabolism depression, and NAA, thereby validating the rodent model of closed-head diffuse TBI coupled with HH and proposing NAA as a marker with diagnostic relevance to monitor the metabolic state of post-injured brain.	Univ Catania, Dept Chem Sci, Biochem Lab, I-95125 Catania, Italy; Univ Cattolica Sacro Cuore, Inst Biochem & Clin Biochem, Rome, Italy; Virginia Commonwealth Univ, Div Neurosurg, Med Coll Virginia, Richmond, VA USA; Univ Roma La Sapienza, Dept Neurol Sci Neurosurg, Rome, Italy; Univ Roma Tor Vergata, Dept Neurosci, Brain Trauma Res Ctr, Rome, Italy		Lazzarino, G (corresponding author), Univ Catania, Dept Chem Sci, Biochem Lab, Viale A Doria 6, I-95125 Catania, Italy.	lazzarig@mbox.unict.it	Signoretti, stefano/AAL-5631-2020; TAVAZZI, BARBARA/AAB-9830-2019; lazzarino, giuseppe/K-2277-2015	Signoretti, stefano/0000-0002-8086-1622; TAVAZZI, BARBARA/0000-0001-8743-0895; AMORINI, Angela Maria/0000-0003-3525-9955; lazzarino, giuseppe/0000-0002-5917-7279	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019235, P50NS012587] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [2R01-NS-19235, P50-NS-12587] Funding Source: Medline		Ang BT, 2003, J NEUROSURG, V99, P125, DOI 10.3171/jns.2003.99.1.0125; Baslow MH, 2003, NEUROCHEM RES, V28, P941, DOI 10.1023/A:1023250721185; Baslow MH, 2000, J NEUROCHEM, V75, P453, DOI 10.1046/j.1471-4159.2000.0750453.x; Baslow MH, 2002, NEUROCHEM INT, V40, P295, DOI 10.1016/S0197-0186(01)00095-X; Bramlett HM, 1999, J NEUROTRAUM, V16, P1035, DOI 10.1089/neu.1999.16.1035; Bramlett HM, 1999, J NEUROSURG, V91, P653, DOI 10.3171/jns.1999.91.4.0653; Cernak I, 2000, J NEUROTRAUM, V17, P53, DOI 10.1089/neu.2000.17.53; Chakraborty G, 2001, J NEUROCHEM, V78, P736, DOI 10.1046/j.1471-4159.2001.00456.x; Cherian L, 1996, J NEUROTRAUM, V13, P371, DOI 10.1089/neu.1996.13.371; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Cristofori L, 2001, J INVEST MED, V49, P450, DOI 10.2310/6650.2001.33790; Davie CA, 1997, J NEUROL NEUROSUR PS, V63, P736, DOI 10.1136/jnnp.63.6.736; DIGIACOMO JE, 1992, BIOL NEONATE, V61, P25, DOI 10.1159/000243527; DIPIERRO D, 1995, ANAL BIOCHEM, V231, P407, DOI 10.1006/abio.1995.0071; Du LN, 2003, J BIOL CHEM, V278, P18426, DOI 10.1074/jbc.M301295200; EBISU T, 1994, J CEREBR BLOOD F MET, V14, P373, DOI 10.1038/jcbfm.1994.48; Fatouros PP, 2000, ACT NEUR S, V76, P35; Harms L, 1997, J NEUROL NEUROSUR PS, V62, P27, DOI 10.1136/jnnp.62.1.27; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; KEHRER JP, 1994, FREE RADICAL BIO MED, V17, P65, DOI 10.1016/0891-5849(94)90008-6; KIRSCH I, 1992, CONT HYPNOSIS, V9, P1; Laurer HL., 2000, EUR J TRAUMA, V26, P95, DOI [10.1007/s000680050007, DOI 10.1007/S000680050007]; LAUTIER D, 1994, BBA-MOL CELL RES, V1221, P215, DOI 10.1016/0167-4889(94)90243-7; LAZZARINO G, 1991, ANAL BIOCHEM, V197, P191, DOI 10.1016/0003-2697(91)90378-7; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Matsushita Y, 2000, J NEUROTRAUM, V17, P143, DOI 10.1089/neu.2000.17.143; MEHTA V, 1995, MOL BRAIN RES, V31, P151, DOI 10.1016/0169-328X(95)00044-S; Nanavaty UB, 2002, EXP LUNG RES, V28, P591, DOI 10.1080/01902140260426715; Pacher P, 2002, J AM COLL CARDIOL, V40, P1006, DOI 10.1016/S0735-1097(02)02062-4; Sager TN, 1999, J CEREBR BLOOD F MET, V19, P164, DOI 10.1097/00004647-199902000-00008; Sawauchi S, 2002, ACT NEUR S, V81, P241; Shadid M, 1998, PEDIATR RES, V44, P119, DOI 10.1203/00006450-199807000-00019; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P26, DOI 10.1136/jnnp.66.1.26; Slatter DA, 1999, J BIOL CHEM, V274, P19661, DOI 10.1074/jbc.274.28.19661; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Srinivasan KN, 1998, CLIN CHIM ACTA, V275, P197, DOI 10.1016/S0009-8981(98)00071-0; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; Tavazzi B, 1998, FREE RADICAL RES, V28, P25, DOI 10.3109/10715769809097873; Tavazzi B, 2000, ANAL BIOCHEM, V277, P104, DOI 10.1006/abio.1999.4386; Tavazzi B, 2000, FREE RADICAL RES, V33, P1, DOI 10.1080/10715760000300561; Vagnozzi R, 1997, EXP BRAIN RES, V117, P411, DOI 10.1007/s002210050235; Vagnozzi R, 1999, J NEUROTRAUM, V16, P903, DOI 10.1089/neu.1999.16.903; VINK R, 1988, MAGNET RESON MED, V6, P37, DOI 10.1002/mrm.1910060105; Vink R, 1988, J NEUROTRAUM, V5, P315, DOI 10.1089/neu.1988.5.315; Yamamoto M, 1999, J NEUROTRAUM, V16, P487, DOI 10.1089/neu.1999.16.487; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Zhou F, 2001, J CLIN NEUROSCI, V8, P561, DOI 10.1054/jocn.2001.0980	50	110	111	0	6	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	MAR	2005	56	3					582	588		10.1227/01.NEU.0000156715.04900.E6			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	905IP	WOS:000227562100047	15730584				2022-02-06	
J	Conte, V; Uryu, K; Fujimoto, S; Yao, Y; Rokach, J; Longhi, L; Trojanowski, JQ; Lee, VMY; McIntosh, TK; Pratico, D				Conte, V; Uryu, K; Fujimoto, S; Yao, Y; Rokach, J; Longhi, L; Trojanowski, JQ; Lee, VMY; McIntosh, TK; Pratico, D			Vitamin E reduces amyloidosis and improves cognitive function in Tg2576 mice following repetitive concussive brain injury	JOURNAL OF NEUROCHEMISTRY			English	Article						Alzheimer's disease; amyloidosis; head trauma; oxidative stress; vitamin E	CONTROLLED CORTICAL IMPACT; TRANSGENIC MOUSE MODEL; A-BETA DEPOSITION; ALZHEIMERS-DISEASE; HEAD-INJURY; APOLIPOPROTEIN-E; LIPID-PEROXIDATION; OXIDATIVE STRESS; CEREBROSPINAL-FLUID; PRECURSOR PROTEIN	Traumatic brain injury is a well-recognized environmental risk factor for developing Alzheimer's disease. Repetitive concussive brain injury (RCBI) exacerbates brain lipid peroxidation, accelerates amyloid (Abeta) formation and deposition, as well as cognitive impairments in Tg2576 mice. This study evaluated the effects of vitamin E on these four parameters in Tg2576 mice following RCBI. Eleven-month-old mice were randomized to receive either regular chow or chow-supplemented with vitamin E for 4 weeks, and subjected to RCBI (two injuries, 24 h apart) using a modified controlled cortical impact model of closed head injury. The same dietary regimens were maintained up to 8 weeks post-injury, when the animals were killed for biochemical and immunohistochemical analyses after behavioral evaluation. Vitamin E-treated animals showed a significant increase in brain vitamin E levels and a significant decrease in brain lipid peroxidation levels. After RBCI, compared with the group on regular chow, animals receiving vitamin E did not show the increase in Abeta peptides, and had a significant attenuation of learning deficits. This study suggests that the exacerbation of brain oxidative stress following RCBI plays a mechanistic role in accelerating Abeta accumulation and behavioral impairments in the Tg2576 mice.	Univ Penn, Ctr Expt Therapeut, Dept Pharmacol, Philadelphia, PA 19104 USA; Florida Inst Technol, Dept Chem, Claude Pepper Inst, Melbourne, FL 32901 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Inst Aging, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA; Osped Maggiore, Policlin IRCCS, Dept Anesthesia & Crit Care Med, Neurosurg Intens Care Unit, Milan, Italy; Vet Adm Med Ctr, Philadelphia, PA 19104 USA; Univ Penn, Head Injury Ctr, Philadelphia, PA 19104 USA		Pratico, D (corresponding author), Univ Penn, Ctr Expt Therapeut, Dept Pharmacol, BRB 2-3,Room 812,421 Curie Blvd, Philadelphia, PA 19104 USA.	domenico@spirit.gcrc.upenn.edu	Pratico, Domenico/ABA-9590-2020	Rokach, Joshu/0000-0003-1814-7505	NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL69835] Funding Source: Medline; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG11542] Funding Source: Medline; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM 34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS08803, NS40978] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL069835] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, P01NS008803, R01NS040978] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG011542] Funding Source: NIH RePORTER		Callahan MJ, 2001, AM J PATHOL, V158, P1173, DOI 10.1016/S0002-9440(10)64064-3; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DeMattos RB, 2002, J NEUROCHEM, V81, P229, DOI 10.1046/j.1471-4159.2002.00889.x; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Franklin K.B., 1997, MOUSE BRAIN STEREOTA; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; Hartman RE, 2002, J NEUROSCI, V22, P10083; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Jellinger KA, 2001, EUR J NEUROL, V8, P707, DOI 10.1046/j.1468-1331.2001.00322.x; Kawarabayashi T, 2001, J NEUROSCI, V21, P372, DOI 10.1523/JNEUROSCI.21-02-00372.2001; Kay AD, 2003, J NEUROTRAUM, V20, P943, DOI 10.1089/089771503770195795; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Lee EB, 2003, J BIOL CHEM, V278, P4458, DOI 10.1074/jbc.M210105200; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Marklund N, 2001, J NEUROTRAUM, V18, P1217, DOI 10.1089/089771501317095250; Misonou H, 2000, BIOCHEMISTRY-US, V39, P6951, DOI 10.1021/bi000169p; Montine TJ, 1999, NEUROLOGY, V52, P562, DOI 10.1212/WNL.52.3.562; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; Nakagawa Y, 1999, J COMP NEUROL, V411, P390; Nakagawa Y, 2000, EXP NEUROL, V163, P244, DOI 10.1006/exnr.2000.7375; Nandoe RDS, 2002, J ALZHEIMERS DIS, V4, P303, DOI 10.3233/JAD-2002-4405; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Nunomura A, 2001, J NEUROPATH EXP NEUR, V60, P759, DOI 10.1093/jnen/60.8.759; Parks E, 2000, ANTIOXID REDOX SIGN, V2, P405, DOI 10.1089/15230860050192189; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Pratico D, 2001, Ital Heart J, V2, P878; Pratico D, 2001, TRENDS ENDOCRIN MET, V12, P243, DOI 10.1016/S1043-2760(01)00411-8; Pratico D, 1998, FASEB J, V12, P1777, DOI 10.1096/fasebj.12.15.1777; Pratico D, 2001, J NEUROSCI, V21, P4183, DOI 10.1523/JNEUROSCI.21-12-04183.2001; Pratico D, 2002, BIOCHEM PHARMACOL, V63, P563, DOI 10.1016/S0006-2952(01)00919-4; Pratico D, 1998, NAT MED, V4, P1189, DOI 10.1038/2685; Pratico D, 2002, J NEUROCHEM, V80, P894, DOI 10.1046/j.0022-3042.2002.00777.x; Pratico D, 2000, ANN NEUROL, V48, P809, DOI 10.1002/1531-8249(200011)48:5<809::AID-ANA19>3.0.CO;2-9; Raby CA, 1998, J NEUROCHEM, V71, P2505; Ritchie K, 2002, LANCET, V360, P1759, DOI 10.1016/S0140-6736(02)11667-9; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Smith MA, 2000, BBA-MOL BASIS DIS, V1502, P139, DOI 10.1016/S0925-4439(00)00040-5; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Sung S, 2003, FASEB J, V17, P323, DOI 10.1096/fj.03-0961fje; Tamagno E, 2002, NEUROBIOL DIS, V10, P279, DOI 10.1006/nbdi.2002.0515; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Veinbergs I, 2000, EUR J NEUROSCI, V12, P4541, DOI 10.1046/j.1460-9568.2000.01308.x; Wang J, 1999, EXP NEUROL, V158, P328, DOI 10.1006/exnr.1999.7085	53	110	114	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	AUG	2004	90	3					758	764		10.1111/j.1471-4159.2004.02560.x			7	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	838NQ	WOS:000222720500027	15255955	Green Submitted, Bronze			2022-02-06	
J	Hansson, MJ; Mattiasson, G; Mansson, R; Karlsson, J; Keep, MF; Waldmeier, P; Ruegg, UT; Dumont, JM; Besseghir, K; Elmer, E				Hansson, MJ; Mattiasson, G; Mansson, R; Karlsson, J; Keep, MF; Waldmeier, P; Ruegg, UT; Dumont, JM; Besseghir, K; Elmer, E			The nonimmunosuppressive cyclosporin analogs NIM811 and UNIL025 display nanomolar potencies on permeability transition in brain-derived mitochondria	JOURNAL OF BIOENERGETICS AND BIOMEMBRANES			English	Article; Proceedings Paper	Mitochondria and Neuroprotection Symposium	APR 16-19, 2004	Ft Lauderdale, FL			cell death; apoptosis; neuron; ischemia; neurodegeneration; traumatic brain injury; amyotrophic lateral sclerosis; cyclophilin; mitochondrial permeability transition; flow cytometry	DOSE-RESPONSE; CELL-DEATH; INJURY; PORE; RAT; CYCLOPHILIN; INHIBITION; ACTIVATION; APOPTOSIS; ISCHEMIA	CyclosporinA(CsA) is highly neuroprotective in several animal models of acute neurological damage and neurodegenerative disease with inhibition of the mitochondrial permeability transition (mPT) having emerged as a possible mechanism for the observed neuroprotection. In the present study, we have evaluated two new nonimmunosuppressive cyclosporin analogs NIM811 (Novartis) and UNIL025 (Debiopharm) for their ability to inhibit mPT in rat brain-derived mitochondria. Both NIM811 and UNIL025 were found to be powerful inhibitors of calcium-induced mitochondrial swelling under energized and deenergized conditions, and the maximal effects were identical to those of native CsA. The potencies of mPT inhibition by NIM811 and UNIL025 were stronger, with almost one order of magnitude higher potency for UNIL025 compared to CsA, correlating to their respective inhibitory action of cyclophilin activity. These compounds will be instrumental in the evaluation of mPT as a central target for neuroprotection in vivo.	Lund Univ, Wallenberg Neurosci Ctr, Expt Brain Res Lab, SE-22184 Lund, Sweden; Ryhov Hosp, Dept Internal Med, Jonkoping, Sweden; Malmo Univ Hosp, Dept Neurol, Malmo, Sweden; Univ New Mexico, Dept Internal Med, Community Environm Hlth Program, Albuquerque, NM 87131 USA; Univ New Mexico, Div Neurosurg, Albuquerque, NM 87131 USA; Novartis Inst Biomed Res, Dept Neurosci, Basel, Switzerland; Univ Lausanne, Sch Pharm, Pharmacol Grp, CH-1015 Lausanne, Switzerland; Debiopharm SA, Lausanne, Switzerland		Elmer, E (corresponding author), Lund Univ, Wallenberg Neurosci Ctr, Expt Brain Res Lab, BMC A13, SE-22184 Lund, Sweden.		Elmer, Eskil/F-9341-2014; Hansson, Magnus/G-4486-2014	Elmer, Eskil/0000-0001-7901-1826; Hansson, Magnus/0000-0002-0201-0638; RUEGG, Urs/0000-0001-6078-8280			Alves O, 2003, J NEUROTRAUM, V20, P1125; Bambrick L, 2004, NEUROCHEM RES, V29, P601, DOI 10.1023/B:NERE.0000014830.06376.e6; BEGLEY DJ, 1990, J NEUROCHEM, V55, P1222, DOI 10.1111/j.1471-4159.1990.tb03128.x; BILLICH A, 1995, J VIROL, V69, P2451, DOI 10.1128/JVI.69.4.2451-2461.1995; Borel J F, 1996, Adv Pharmacol, V35, P115, DOI 10.1016/S1054-3589(08)60276-8; Brophy GM, 2003, J NEUROTRAUM, V20, P1125; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Friberg H, 1999, J NEUROCHEM, V72, P2488, DOI 10.1046/j.1471-4159.1999.0722488.x; Friberg H, 2002, BIOCHIMIE, V84, P241, DOI 10.1016/S0300-9084(02)01381-0; Halestrap AP, 2002, BIOCHIMIE, V84, P153, DOI 10.1016/S0300-9084(02)01375-5; Hansson MJ, 2004, J NEUROCHEM, V89, P715, DOI 10.1111/j.1471-4159.2004.02400.x; Hansson MJ, 2003, BRAIN RES, V960, P99, DOI 10.1016/S0006-8993(02)03798-8; Keep M, 2001, BRAIN RES, V894, P327, DOI 10.1016/S0006-8993(01)02012-1; Keep Marcus F., 2003, P3; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Mattiasson G, 2003, J NEUROCHEM, V87, P532, DOI 10.1046/j.1471-4159.2003.02026.x; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; Okonkwo DO, 2003, NEUROREPORT, V14, P463, DOI 10.1097/01.wnr.0000058958.85541.d3; PETRONILLI V, 1994, BBA-BIOENERGETICS, V1187, P255, DOI 10.1016/0005-2728(94)90122-8; ROSENWIRTH B, 1994, ANTIMICROB AGENTS CH, V38, P1763, DOI 10.1128/AAC.38.8.1763; SIMS NR, 1990, J NEUROCHEM, V55, P698, DOI 10.1111/j.1471-4159.1990.tb04189.x; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; TSUJI A, 1993, BIOCHEM PHARMACOL, V46, P1096, DOI 10.1016/0006-2952(93)90677-O; Uchino H, 1995, ACTA PHYSIOL SCAND, V155, P469, DOI 10.1111/j.1748-1716.1995.tb09999.x; Waldmeier PC, 2002, MOL PHARMACOL, V62, P22, DOI 10.1124/mol.62.1.22; Waldmeier PC, 2003, CURR MED CHEM, V10, P1485, DOI 10.2174/0929867033457160; Yoshimoto T, 1999, BRAIN RES, V839, P283, DOI 10.1016/S0006-8993(99)01733-3; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073	28	110	112	0	8	KLUWER ACADEMIC/PLENUM PUBL	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0145-479X			J BIOENERG BIOMEMBR	J. Bioenerg. Biomembr.	AUG	2004	36	4					407	413		10.1023/B:JOBB.0000041776.31885.45			7	Biophysics; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Cell Biology	854PR	WOS:000223916300025	15377880				2022-02-06	
J	Stiefel, MF; Heuer, GG; Smith, MJ; Bloom, S; Maloney-Wilensky, E; Gracias, VH; Grady, MS; LeRoux, PD				Stiefel, MF; Heuer, GG; Smith, MJ; Bloom, S; Maloney-Wilensky, E; Gracias, VH; Grady, MS; LeRoux, PD			Cerebral oxygenation following decompressive hemicraniectomy for the treatment of refractory intracranial hypertension	JOURNAL OF NEUROSURGERY			English	Article						intracranial pressure; cerebral oxygenation; hemicraniectomy; decompression surgery	TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; BLOOD-FLOW; COMATOSE PATIENTS; TISSUE OXYGEN; SUBARACHNOID HEMORRHAGE; SUBSTRATE DELIVERY; PERFUSION-PRESSURE; CARBON-DIOXIDE; CRANIECTOMY	Object. Medically intractable intracranial hypertension is a major cause of morbidity and mortality after severe brain injury. One potential treatment for intracranial hypertension is decompressive hemicraniectomy (DCH). Whether and when to use DCH, however, remain unclear. The authors therefore studied the effects of DCH on cerebral 0, to develop a better understanding of the effects of this treatment on the recovery from injury and disease. Methods. The study focused on seven patients (mean age 30.6 +/- 9.7 years) admitted to the hospital after traumatic brain injury (five patients) or subarachnoid hemorrhage (two patients) as part of a prospective observational database at a Level I trauma center. At admission the Glasgow Coma Scale (GCS) score was 6 or less in all patients. Patients received continuous monitoring of intracranial pressure (ICP), cerebral perfusion pressure (CPP), blood pressure, and arterial 0, saturation. Cerebral oxygenation was measured using the commercially available Licox Brain Tissue Oxygen Monitoring System manufactured by Integra NeuroSciences. A DCH was performed when the patient's ICP remained elevated despite maximal medical management. Conclusions. All patients tolerated DCH without complications. Before the operation, the mean ICP was elevated in all patients (26 +/- 4 rum Hg), despite maximal medical management. After surgery, there was an immediate and sustained decrease in ICP (19 +/- 11 turn Hg) and an increase in CPP (81 +/- 17 mm Hg). Following DCH, cerebral oxygenation improved from a mean of 21.2 +/- 13.8 turn Hg to 45.5 +/- 25.4 rum Hg, a 114.8% increase. The change in brain tissue 0, and the change in ICP after DCH demonstrated only a modest relationship (r(2) = 0.3). These results indicate that the use of DCH in the treatment of severe brain injury is associated with a significant improvement in brain O-2.	Univ Penn, Dept Neurosurg, Sch Med, Philadelphia, PA 19107 USA; Univ Penn, Div Trauma Surg & Crit Care, Sch Med, Philadelphia, PA 19107 USA		LeRoux, PD (corresponding author), Univ Penn, Dept Neurosurg, Sch Med, 330 S 9th St, Philadelphia, PA 19107 USA.	lerouxp@uphs.upenn.edu					Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Bullock R, 1995, GUIDELINES MANAGEMEN; BURNETT M, 2004, MANAGEMENT CEREBRAL, P127; Chesnut RM, 1997, CRIT CARE MED, V25, P1275, DOI 10.1097/00003246-199708000-00011; CHESTNUT RM, 2000, HEAD INJURY, P229; Clay H D, 2000, J Neurosci Nurs, V32, P194; Coles JP, 2002, CRIT CARE MED, V30, P1950, DOI 10.1097/00003246-200209000-00002; Coplin WM, 2001, J TRAUMA, V50, P1050, DOI 10.1097/00005373-200106000-00013; Cruz J, 1996, J NEUROSURG, V85, P758, DOI 10.3171/jns.1996.85.5.0758; Cruz J, 1998, CRIT CARE MED, V26, P344, DOI 10.1097/00003246-199802000-00039; Dearden NM, 1998, CLIN NEUROPATHOL, V17, P221; Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123-199811000-00045; Filippi R, 2000, NEUROSURG REV, V23, P94; FORSTING M, 1995, STROKE, V26, P259, DOI 10.1161/01.STR.26.2.259; FRANK JI, 1995, NEUROLOGY, V45, P1286, DOI 10.1212/WNL.45.7.1286; Gopinath SP, 1999, CRIT CARE MED, V27, P2337, DOI 10.1097/00003246-199911000-00003; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; Gracias VH, 2004, J TRAUMA, V56, P469, DOI 10.1097/01.TA.0000114274.95423.C0; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Gupta AK, 1999, ANESTH ANALG, V88, P549, DOI 10.1097/00000539-199903000-00016; Hoffman WE, 1999, SURG NEUROL, V51, P654, DOI 10.1016/S0090-3019(99)00011-7; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; KAUFMANN AM, 1992, J NEUROSURG, V77, P584, DOI 10.3171/jns.1992.77.4.0584; Kelly DF, 1996, J NEUROSURG, V85, P762, DOI 10.3171/jns.1996.85.5.0762; Kett-White R, 2002, NEUROSURGERY, V50, P1213, DOI 10.1097/00006123-200206000-00008; Kiening KL, 1997, NEUROL RES, V19, P233, DOI 10.1080/01616412.1997.11740805; KONDZIOLKA D, 1988, NEUROSURGERY, V23, P143, DOI 10.1227/00006123-198808000-00002; Lee JH, 2001, J NEUROSURG, V95, P222, DOI 10.3171/jns.2001.95.2.0222; Lee JH, 1997, J NEUROSURG, V87, P221, DOI 10.3171/jns.1997.87.2.0221; MAAS AIR, 1993, ACTA NEUROCHIR, P50; MARSHALL LF, 1978, J NEUROSURG, V48, P169, DOI 10.3171/jns.1978.48.2.0169; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; McKhann GM, 2004, MANAGEMENT CEREBRAL, P431; Meixensberger J, 2003, NEUROL RES, V25, P445, DOI 10.1179/016164103101201823; MENDELOW AD, 1985, J NEUROSURG, V63, P43, DOI 10.3171/jns.1985.63.1.0043; Menzel M, 1999, J NEUROSURG ANESTH, V11, P240, DOI 10.1097/00008506-199910000-00003; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Munch E, 2000, NEUROSURGERY, V47, P315, DOI 10.1097/00006123-200008000-00009; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Piek Jurgen, 2002, Curr Opin Crit Care, V8, P134, DOI 10.1097/00075198-200204000-00008; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Procaccio F, 2000, J Neurosurg Sci, V44, P11; RENGACHARY SS, 1981, NEUROSURGERY, V8, P321, DOI 10.1227/00006123-198103000-00004; RIEKE K, 1993, CEREBROVASC DIS, V3, P45, DOI 10.1159/000108670; ROBERTSON C, 2004, YOUMANS NEUROLOGICAL, P5103; ROBERTSON CS, 1989, J NEUROSURG, V70, P222, DOI 10.3171/jns.1989.70.2.0222; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Sarrafzadeh AS, 2003, BRIT J NEUROSURG, V17, P340, DOI 10.1080/02688690310001601234; Sarrafzadeh AS, 2002, ACTA NEUROCHIR SUPPL, V81, P319; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; Schwab S, 1997, NEUROLOGY, V48, P1608, DOI 10.1212/WNL.48.6.1608; Schwab S, 1998, STROKE, V29, P1888, DOI 10.1161/01.STR.29.9.1888; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; Smith ER, 2002, NEUROSURGERY, V51, P117, DOI 10.1097/00006123-200207000-00018; STOCCHETTI N, 1994, NEUROSURGERY, V34, P38; Suazo JAC, 2000, CRIT CARE MED, V28, P3268, DOI 10.1097/00003246-200009000-00024; TEASDALE G, 1974, LANCET, V2, P81; UMEZAWA H, 1990, ACT NEUR S, V51, P351; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; van Santbrink H, 2003, ACTA NEUROCHIR, V145, P429, DOI 10.1007/s00701-003-0032-3; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; Yundt KD, 1998, J CEREBR BLOOD F MET, V18, P419, DOI 10.1097/00004647-199804000-00010; ZAUNER A, 1995, NEUROSURGERY, V37, P1168, DOI 10.1227/00006123-199512000-00017; Zauner A, 1997, NEUROL RES, V19, P265, DOI 10.1080/01616412.1997.11740812; Zauner A, 2002, NEUROSURGERY, V51, P289, DOI 10.1097/00006123-200208000-00003; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011; Ziai WC, 2003, J NEUROSURG ANESTH, V15, P25, DOI 10.1097/00008506-200301000-00005	72	110	118	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	AUG	2004	101	2					241	247		10.3171/jns.2004.101.2.0241			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	842JQ	WOS:000223000600011	15309914				2022-02-06	
J	Zurita, M; Vaquero, J				Zurita, M; Vaquero, J			Functional recovery in chronic paraplegia after bone marrow stromal cells transplantation	NEUROREPORT			English	Article						bone marrow stromal cells; paraplegia; nervous system regeneration; spinal cord injury; transplantation	SPINAL-CORD-INJURY; INTRACEREBRAL TRANSPLANTATION; INTERMEDIATE FILAMENT; RATS; EXPRESSION; MIGRATION; NESTIN; BRAIN	Previous reports showed the therapeutic effect of transplants of bone marrow stromal cells (BMSC) after incomplete traumatic spinal cord lesions. We studied the effect of this form of therapy in chronically paraplegic Wistar rats due to severe spinal cord injury (SCI). Rats were subjected to weight-drop impact causing paraplegia, and BMSC or phosphate buffered saline (PBS) was injected into spinal cord 3 months after injury. Functional outcome was measured using the Basso-Beattie-Bresnehan score until sacrifice of the animals, 4 weeks after transplantation. At this time, samples of spinal cord tissue were studied histologically. The results showed a clear and progressive functional recovery of the animals treated with BMSC transplantation, compared to controls. Grafted BMSC survived into spinal cord tissue, forming cell bridges within the traumatic centromedullary cavity. In this tissue, cells expressing neuronal and astroglial markers can be seen, together with a marked ependymal proliferation, showing nestin-positivity. These findings suggest the utility of BMSC transplantation in chronically established paraplegia.	Autonomous Univ Madrid, Dept Surg, Puerta Hierro Hosp, Neurosurg Serv,Mapfre Med Fdn,Neurosci Res Unit, E-28049 Madrid, Spain		Vaquero, J (corresponding author), Autonomous Univ Madrid, Dept Surg, Puerta Hierro Hosp, Neurosurg Serv,Mapfre Med Fdn,Neurosci Res Unit, E-28049 Madrid, Spain.	jvaqueroc@telefonica.net					Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; BARONVANEVERCOOREN A, 1991, NEUROSCI LETT, V131, P241, DOI 10.1016/0304-3940(91)90623-2; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; Hofstetter CP, 2002, P NATL ACAD SCI USA, V99, P2199, DOI 10.1073/pnas.042678299; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; Lee JB, 2003, NEUROPATHOLOGY, V23, P169, DOI 10.1046/j.1440-1789.2003.00496.x; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; Namiki J, 1999, J NEUROPATH EXP NEUR, V58, P489, DOI 10.1097/00005072-199905000-00008; Shibuya S, 2002, NEUROSCIENCE, V114, P905, DOI 10.1016/S0306-4522(02)00323-8; Zurita M, 2000, SURG NEUROL, V54, P117, DOI 10.1016/S0090-3019(00)00287-1; Zurita M, 2001, SURG NEUROL, V55, P249, DOI 10.1016/S0090-3019(01)00442-6; ZURITA M, 1994, POLYTRAUMATIZED, P343	17	110	124	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0959-4965	1473-558X		NEUROREPORT	Neuroreport	MAY 19	2004	15	7					1105	1108		10.1097/00001756-200405190-00004			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	871NM	WOS:000225140400004	15129154				2022-02-06	
J	Ng, I; Lim, J; Wong, HB				Ng, I; Lim, J; Wong, HB			Effects of head posture on cerebral hemodynamics: Its influences on intracranial pressure, cerebral perfusion pressure, and cerebral oxygenation	NEUROSURGERY			English	Article						cerebral perfusion pressure; cerebral tissue oxygenation; head posture; severe head injury	INTRA-CRANICAL PRESSURE; BLOOD-FLOW; COMATOSE PATIENTS; BODY POSITION; SATURATION; ELEVATION; VENTILATION; MANAGEMENT; METABOLISM; INJURY	OBJECTIVE: Severely head-injured patients have traditionally been maintained in the head-up position to ameliorate the effects of increased intracranial pressure (ICP). However, it has been reported that the supine position may improve cerebral perfusion pressure (CPP) and outcome. We sought to determine the impact of supine and 30 degrees semirecumbent postures on cerebrovascular dynamics and global as well as regional cerebral oxygenation within 24 hours of trauma. METHODS: Patients with a closed head injury and a Glasgow Coma Scale score of 8 or less were included in the study. On admission to the neurocritical care unit, a standardized protocol aimed at minimizing secondary insults was instituted, and the influences of head posture were evaluated after all acute necessary interventions had been performed. ICP, CPP, mean arterial pressure, global cerebral oxygenation, and regional cerebral oxygenation were noted at 0 and 30 degrees of head elevation. RESULTS: We studied 38 patients with severe closed head injury. The median Glasgow Coma Scale score was 7.0, and the mean age was 34.05 +/- 16.02 years. ICP was significantly lower at 30 degrees than at 0 degrees of head elevation (P = 0.0005). Mean arterial pressure remained relatively unchanged. CPP was slightly but not significantly higher at 30 degrees than at 0 degrees (P = 0.412). However, global venous cerebral oxygenation and regional cerebral oxygenation were not affected significantly by head elevation. All global venous cerebral oxygenation values were above the critical threshold for ischemia at 0 and 30 degrees. CONCLUSION: Routine nursing of patients with severe head injury at 30 degrees of head elevation within 24 hours after trauma leads to a consistent reduction of ICP (statistically significant) and an improvement in CPP (although not statistically significant) without concomitant deleterious changes in cerebral oxygenation.	Natl Inst Neurosci, Dept Neurosurg, Neurocrit Care Unit, Singapore 308433, Singapore; Natl Univ Singapore, Fac Med, Singapore, Singapore; Clin Trials & Epidemiol Res Unit, Singapore, Singapore		Ng, I (corresponding author), Natl Inst Neurosci, Dept Neurosurg, Neurocrit Care Unit, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.	ivan_ng@ttsh.com.sg					ABBUSHI W, 1980, ANAESTHESIST, V29, P521; ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bullock Ross, 1996, Journal of Neurotrauma, V13, P639; Cruz J, 1998, CRIT CARE MED, V26, P344, DOI 10.1097/00003246-199802000-00039; DEARDEN NM, 1991, CURR OPIN ANESTHESIO, V4, P279; deDeyne C, 1996, ACTA NEUROCHIR, V138, P1409, DOI 10.1007/BF01411119; DeWitt D S, 1995, New Horiz, V3, P376; DURWARD QJ, 1983, J NEUROSURG, V59, P938, DOI 10.3171/jns.1983.59.6.0938; EMERY JR, 1983, J PEDIATR-US, V103, P950, DOI 10.1016/S0022-3476(83)80728-8; FELDMAN Z, 1992, J NEUROSURG, V76, P207, DOI 10.3171/jns.1992.76.2.0207; Gupta AK, 1999, ANESTH ANALG, V88, P549, DOI 10.1097/00000539-199903000-00016; Hulme A, 1976, INTRACRANIAL PRESSUR, VIII, P259; KENNING JA, 1981, SURG NEUROL, V15, P148, DOI 10.1016/0090-3019(81)90037-9; MAGNAES B, 1976, J NEUROSURG, V44, P687, DOI 10.3171/jns.1976.44.6.0687; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; Meixensberger J, 1997, NEUROL RES, V19, P249, DOI 10.1080/01616412.1997.11740808; Moraine JJ, 2000, J NEUROSURG, V92, P606, DOI 10.3171/jns.2000.92.4.0606; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; PINSKY MR, 1991, CARDIOPULMONARY CRIT, P87; ROBERTSON C, 1993, ACTA NEUROCHIR, P98; ROPPER AH, 1982, NEUROLOGY, V32, P1288, DOI 10.1212/WNL.32.11.1288; ROSNER MJ, 1986, J NEUROSURG, V65, P636, DOI 10.3171/jns.1986.65.5.0636; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; ROTHE CF, 1983, PHYSIOL REV, V63, P1281, DOI 10.1152/physrev.1983.63.4.1281; SALVANT JB, 1993, NEUROSURGERY, V33, P387; SCHNEIDER GH, 1993, ACTA NEUROCHIR, P107; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; Smielewski P, 1996, STROKE, V27, P2197, DOI 10.1161/01.STR.27.12.2197; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; TORRES A, 1992, ANN INTERN MED, V116, P540, DOI 10.7326/0003-4819-116-7-540; WINKELMAN C, 2000, AM J CRIT CARE, V6, P373	32	110	113	0	7	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	MAR	2004	54	3					593	598		10.1227/01.NEU.0000108639.16783.39			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	802FN	WOS:000220149500021	15028132				2022-02-06	
J	Zhao, XR; Ahram, A; Berman, RF; Muizelaar, JP; Lyeth, BG				Zhao, XR; Ahram, A; Berman, RF; Muizelaar, JP; Lyeth, BG			Early loss of astrocytes after experimental traumatic brain injury	GLIA			English	Article						fluid percussion; traumatic brain injury; immunohistochemistry; glial fibrillary acidic protein; hippocampus	FIBRILLARY ACIDIC PROTEIN; EXTRACELLULAR ION SHIFTS; FLUID-PERCUSSION MODEL; EXCITATORY AMINO-ACIDS; SYNAPTIC TRANSMISSION; ARBITRARY PARTICLES; TRANSIENT HYPOXIA; NEURONAL INJURY; RAT ASTROCYTES; GLIAL-CELLS	Neuronal-glial interactions are important for normal brain function and contribute to the maintenance of the brain's extracellular environment. Damage to glial cells following traumatic brain injury (TBI) could therefore be an important contributing factor to brain dysfunction and neuronal injury. We examined the early fate of astrocytes and neurons after TBI in rats. A total of 27 rats were euthanized at 0.5, 1, 2, 4, or 24 h after moderate lateral fluid percussion TBI or after sham TBI. Ipsilateral and contralateral hippocampi were examined in coronal sections from -2.12 to -4.80 mm relative to bregma. Adjacent sections were processed with markers for either astrocytes or degenerating neurons. Astrocytes were visualized using glial fibrillary acidic protein (GFAP) or glutamine I synthetase immunohistochemistry. Neuronal degeneration was visualized using Fluoro-Jade (FJ) histofluorescence. At 30 min, there was a significant loss of GFAP immunoreactivity in ipsilateral hippocampal CA3 with some loss of normal astrocyte morphology in the remaining cells. The number of normal staining astrocytes decreased progressively over time with extensive astrocyte loss at 24 h. At 4 h, lightly stained FJ-positive neurons were scattered in the ipsilateral CA3. The intensity and number of FJ-positive neurons progressively increased over time with moderate numbers of degenerating neurons in the ipsilateral hippocampal CA3 evident at 24 h. We conclude that astrocyte loss occurs in the hippocampus early after TBI. The data suggest that loss of supporting glial cell may contribute to subsequent neuronal degeneration. (C) 2003 Wiley-Liss, Inc.	Univ Calif Davis, Dept Neurol Surg, Ctr Neurosci, Davis, CA 95616 USA		Lyeth, BG (corresponding author), Univ Calif Davis, Dept Neurol Surg, Ctr Neurosci, 1515 Newton Court,1 Shields Ave, Davis, CA 95616 USA.			Lyeth, Bruce/0000-0003-4811-1474	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS45136] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045136] Funding Source: NIH RePORTER		AMADUCCI L, 1981, NEUROSCI LETT, V21, P27, DOI 10.1016/0304-3940(81)90052-5; BAKAY L, 1977, J NEUROSURG, V47, P525, DOI 10.3171/jns.1977.47.4.0525; Baldwin SA, 1996, GLIA, V16, P266; Bignami A, 1991, DISCUSSIONS NEUROSCI, V8, P1; Bondarenko A, 2001, GLIA, V34, P134, DOI 10.1002/glia.1048; Bondarenko A, 2001, GLIA, V34, P143, DOI 10.1002/glia.1049; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; Castejon OJ, 1998, BRAIN INJURY, V12, P409, DOI 10.1080/026990598122539; CHARLES AC, 1994, DEV NEUROSCI-BASEL, V16, P196, DOI 10.1159/000112107; CHARLES AC, 1992, J CELL BIOL, V118, P195, DOI 10.1083/jcb.118.1.195; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Cui W, 2001, GLIA, V34, P272, DOI 10.1002/glia.1061; D'Ambrosio R, 1999, J NEUROSCI, V19, P8152; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; DANBOLT NC, 1994, PROG NEUROBIOL, V44, P377, DOI 10.1016/0301-0082(94)90033-7; Dietrich WD, 1999, J NEUROTRAUM, V16, P567, DOI 10.1089/neu.1999.16.567; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fitch MT, 1999, J NEUROSCI, V19, P8182; GLAUM SR, 1990, P NATL ACAD SCI USA, V87, P3454, DOI 10.1073/pnas.87.9.3454; GUNDERSEN HJG, 1986, J MICROSC-OXFORD, V143, P3, DOI 10.1111/j.1365-2818.1986.tb02764.x; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; HOLZWARTH JA, 1994, J NEUROSCI, V14, P1879; JENKINS LW, 1982, RECENT PROGR STUDY T, P523; Jiang ZW, 2000, BRAIN RES, V852, P37, DOI 10.1016/S0006-8993(99)02230-1; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KELLEHER JA, 1993, STROKE, V24, P855, DOI 10.1161/01.STR.24.6.855; KIM WT, 1994, GLIA, V11, P173, DOI 10.1002/glia.440110211; KIMELBERG HK, 1992, J NEUROTRAUM, V9, pS71; KIMELBERG HK, 1992, ASTROCYTES PHARM FUN; KONDOU H, 1994, NEUROSCI LETT, V180, P131, DOI 10.1016/0304-3940(94)90504-5; Labourdette G., 1995, P441; Largo C, 1996, NEUROL RES, V18, P445; Liu D, 1999, MOL BRAIN RES, V68, P29, DOI 10.1016/S0169-328X(99)00063-7; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MULLER HW, 1995, PHARMACOL THERAPEUT, V65, P1, DOI 10.1016/0163-7258(94)00047-7; NEDERGAARD M, 1994, SCIENCE, V263, P1768, DOI 10.1126/science.8134839; NELSON LR, 1982, HEAD INJURY BASIC CL, P117; OLNEY JW, 1970, NATURE, V227, P609, DOI 10.1038/227609b0; Parri HR, 2001, NAT NEUROSCI, V4, P803, DOI 10.1038/90507; PEAKMAN MC, 1995, BRIT J PHARMACOL, V115, P801, DOI 10.1111/j.1476-5381.1995.tb15004.x; PLUM F, 1983, NEUROLOGY, V33, P222, DOI 10.1212/WNL.33.2.222; RANSOM BR, 1992, J CLIN NEUROPHYSIOL, V9, P224, DOI 10.1097/00004691-199204010-00005; Reier P., 1983, SPINAL CORD RECONSTR, P163; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; SHAO Y, 1995, CELL CALCIUM, V17, P187, DOI 10.1016/0143-4160(95)90033-0; SOCHOCKA E, 1994, BRAIN RES, V638, P21, DOI 10.1016/0006-8993(94)90628-9; STERIO DC, 1984, J MICROSC-OXFORD, V134, P127, DOI 10.1111/j.1365-2818.1984.tb02501.x; Swanson L.W., 1998, BRAIN MAPS STRUCTURE, V2; Swanson RA, 1997, GLIA, V21, P142, DOI 10.1002/(SICI)1098-1136(199709)21:1<142::AID-GLIA16>3.0.CO;2-S; TIFFANYCASTIGLI.E, 1986, ASTROCYTES CELL BIOL, P401; Ullian EM, 2001, SCIENCE, V291, P657, DOI 10.1126/science.291.5504.657; Verkhratsky A, 1998, PHYSIOL REV, V78, P99, DOI 10.1152/physrev.1998.78.1.99; Vernadakis A, 1996, PROG NEUROBIOL, V49, P185, DOI 10.1016/S0301-0082(96)00012-3; Vesce S, 1999, CELL MOL LIFE SCI, V56, P991, DOI 10.1007/s000180050488; Vesce S, 2001, NEWS PHYSIOL SCI, V16, P178; Vesce Sabino, 1999, Science Progress, V82, P251; VIBULSRETH S, 1987, BRAIN RES, V422, P303, DOI 10.1016/0006-8993(87)90937-1; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; YU ACH, 1989, J CEREBR BLOOD F MET, V9, P20, DOI 10.1038/jcbfm.1989.3	68	110	114	0	9	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0894-1491			GLIA	Glia	NOV	2003	44	2					140	152		10.1002/glia.10283			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	733BQ	WOS:000185980400006	14515330				2022-02-06	
J	Levi, O; Jongen-Relo, AL; Feldon, J; Roses, AD; Michaelson, DM				Levi, O; Jongen-Relo, AL; Feldon, J; Roses, AD; Michaelson, DM			ApoE4 impairs hippocampal plasticity isoform-specifically and blocks the environmental stimulation of synaptogenesis and memory	NEUROBIOLOGY OF DISEASE			English	Article						Alzheimer's disease; apolipoprotein E; enriched environment; learning; synaptogenesis; synaptophysin; transgenic mice; working memory	CLOSED-HEAD INJURY; APOLIPOPROTEIN-E; ALZHEIMERS-DISEASE; TRANSGENIC MICE; ENRICHED ENVIRONMENT; DEFICIENT MICE; E4; ALLELE; E3; EDUCATION	Alzheimer's disease (AD) is associated with genetic risk factors, of which the allele E4 of apolipoprotein E (apoE4) is the most prevalent, and is affected by environmental factors that include education early in life and socioeconomic background. The extent to which environmental factors affect the phenotypic expression of the AD genetic risk factors is not known. Here we show that the neuronal and cognitive stimulations, which are elicited by environmental enrichment at a young age, are markedly affected by the apoE genotype. Accordingly, exposure to an enriched environment of young mice transgenic for human apoE3, which is the benign AD apoE allele, resulted in improved learning and memory, whereas mice transgenic for human apoE4 were unaffected by the enriched environment and their learning and memory were similar to those of the nonenriched apoE3 transgenic mice. These cognitive effects were associated with higher hippocampal levels of the presynaptic protein synaptophysin and of NGF in apoE3 but not apoE4 transgenic mice. In contrast, cortical synaptophysin and NGF levels of the apoE3 and apoE4 transgenic mice were similarly elevated by environmental enrichment. These findings show that apoE4 impairs hippocampal plasticity and isoform-specifically blocks the environmental stimulation of synaptogenesis and memory. This provides a novel mechanism by which environmental factors can modulate the function and phenotypic expression of the apoE genotype. (C) 2003 Elsevier Science (USA). All rights reserved.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Ramat Aviv, Israel; Swiss Fed Inst Technol, Dept Biol, Lab Behav Neurobiol, Zurich, Switzerland; Duke Univ, Dept Neurol, Durham, NC USA		Michaelson, DM (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Ramat Aviv, Israel.						ANGER WK, 1991, NEUROTOXICOLOGY, V12, P403; Arendt T, 1997, J NEUROSCI, V17, P516; Buttini M, 2000, NEUROSCIENCE, V97, P207, DOI 10.1016/S0306-4522(00)00069-5; Chapman J, 2001, NEUROLOGY, V57, P1482, DOI 10.1212/WNL.57.8.1482; Chapman J, 1996, NEUROLOGY, V46, P1484, DOI 10.1212/WNL.46.5.1484-a; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DIAMOND MC, 1966, J COMP NEUROL, V128, P117, DOI 10.1002/cne.901280110; Fagan AM, 2000, MICROSC RES TECHNIQ, V50, P297, DOI 10.1002/1097-0029(20000815)50:4<297::AID-JEMT9>3.0.CO;2-C; Gould E, 1999, NAT NEUROSCI, V2, P260, DOI 10.1038/6365; Hartman RE, 2001, EXP NEUROL, V170, P326, DOI 10.1006/exnr.2001.7715; Herz J, 2000, NAT REV NEUROSCI, V1, P51, DOI 10.1038/35036221; Herz J, 2001, TRENDS NEUROSCI, V24, P193, DOI 10.1016/S0166-2236(00)01768-9; JONES BJ, 1968, N-S ARCH PHARMAKOL, V259, P211, DOI 10.1007/BF00537801; Kalmijn S, 1997, BRIT MED J, V314, P34, DOI 10.1136/bmj.314.7073.34; KATZMAN R, 1993, NEUROLOGY, V43, P13, DOI 10.1212/WNL.43.1_Part_1.13; KAWAS CH, 1999, ALZHEIMERS DIS; Li S, 2002, NEUROSCIENCE, V115, P1221, DOI 10.1016/S0306-4522(02)00485-2; Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507; Masliah E, 1997, BRAIN RES, V751, P307, DOI 10.1016/S0006-8993(96)01420-5; Moceri VM, 2000, NEUROLOGY, V54, P415, DOI 10.1212/WNL.54.2.415; Moceri VM, 2001, EPIDEMIOLOGY, V12, P383, DOI 10.1097/00001648-200107000-00007; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; OPHIR S, 2003, IN PRESS NEUROBIOL D; Pham TM, 1999, NEUROSCIENCE, V94, P279, DOI 10.1016/S0306-4522(99)00316-4; Pitas RE, 1998, BIOCHEM SOC T, V26, P257, DOI 10.1042/bst0260257; Price DL, 1998, ANNU REV GENET, V32, P461, DOI 10.1146/annurev.genet.32.1.461; Ramirez-Amaya V, 2001, J NEUROSCI, V21, P7340; ROSENZWE.MR, 1966, AM PSYCHOL, V21, P321, DOI 10.1037/h0023555; Rosenzweig MR, 1996, BEHAV BRAIN RES, V78, P57, DOI 10.1016/0166-4328(95)00216-2; Roses AD, 1998, AM J MED GENET, V81, P49, DOI 10.1002/(SICI)1096-8628(19980207)81:1<49::AID-AJMG10>3.0.CO;2-W; ROSES AD, 1996, A REV MED, V47, P378; Sabo T, 2000, NEUROSCIENCE, V101, P879, DOI 10.1016/S0306-4522(00)00438-3; SAITO S, 1994, J NEUROSCI RES, V39, P57, DOI 10.1002/jnr.490390108; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SELKOE DJ, 2001, PHYSIOL REV, V81, P751; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Veinbergs I, 1999, NEUROSCIENCE, V91, P401, DOI 10.1016/S0306-4522(98)00602-2; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K; White F, 2001, NEUROBIOL DIS, V8, P611, DOI 10.1006/nbdi.2001.0401; Xu PT, 1996, NEUROBIOL DIS, V3, P229, DOI 10.1006/nbdi.1996.0023; ZHANG MY, 1990, ANN NEUROL, V27, P428, DOI 10.1002/ana.410270412	43	110	113	0	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961			NEUROBIOL DIS	Neurobiol. Dis.	AUG	2003	13	3					273	282		10.1016/S0969-9961(03)00045-7			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	708GT	WOS:000184559400011	12901842				2022-02-06	
J	Magnoni, S; Ghisoni, L; Locatelli, M; Caimi, M; Colombo, A; Valeriani, V; Stocchetti, N				Magnoni, S; Ghisoni, L; Locatelli, M; Caimi, M; Colombo, A; Valeriani, V; Stocchetti, N			Lack of improvement in cerebral metabolism after hyperoxia in severe head injury: a microdialysis study	JOURNAL OF NEUROSURGERY			English	Article						brain metabolism; head injury; hyperoxia; lactate; microdialysis	BRAIN INJURY; BLOOD-FLOW; INTRACEREBRAL MICRODIALYSIS; PHYSIOLOGICAL STIMULATION; INTRACRANIAL-PRESSURE; CEREBROSPINAL-FLUID; ARTERIAL HYPEROXIA; ENERGY-METABOLISM; LACTIC-ACIDOSIS; OXYGEN	Object. The authors investigated the effects of hyperoxia on brain tissue PO2 and on glucose metabolism in cerebral and adipose tissue after traumatic brain injury (TBI). Methods. After 3 hours of ventilation with pure O-2, 18 tests were performed on different days in eight comatose patients with TBI. Lactate, pyruvate, glucose, glutamate, and brain tissue PO2 were measured in the cerebral extracellular fluid (ECF) by using microdialysis. Analytes were also measured in the ECF of abdominal adipose tissue. After 3 hours of increase in the fraction of inspired O-2, brain tissue PO2 rose from the baseline value of 32.7 +/- 18 to 122.6 +/- 45.2 mm Hg (p < 0.0001), whereas brain lactate dropped from its baseline (3.21 +/- 2.77 mmol/L), reaching its lowest value (2.90 +/- 2.58 mmol/L) after 3 hours of hyperoxia (p < 0.01). Pyruvate dropped as well, from 153 +/- 56 to 141 +/- 56 mumol/L (p < 0.05), so the lactate/pyruvate ratio did not change. No significant changes were observed in glucose and glutamate. The arteriovenous difference in O-2 content dropped, although not significantly, from a baseline of 4.52 +/- 1.22 to 4.15 +/- 0.76 ml/100 ml. The mean concentration of lactate in adipose tissue fell significantly as well (p < 0.01), but the lactate/pyruvate ratio did not change. Conclusions. Hyperoxia slightly reduced lactate levels in brain tissue after TBI. The estimated redox status of the cells, however, did not change and cerebral O-2 extraction seemed to be reduced. These data indicate that oxidation of glucose was not improved by hyperoxia in cerebral and adipose tissue, and might even be impaired.	Univ Milan, Dept Anesthesia, I-20122 Milan, Italy; Univ Milan, Dept Intens Care, I-20122 Milan, Italy; Osped Maggiore, Div Neurosurg, IRCCS, Milan, Italy		Stocchetti, N (corresponding author), Osped Policlin IRCCS, Terapia Intens Neurosci, Via F Sforza 35,Padiglione Beretta Neuro, I-20122 Milan, Italy.		Magnoni, Sandra/AAC-7479-2022; Locatelli, Marco/AAC-5745-2022; Stocchetti, Nino/O-7444-2017	Magnoni, Sandra/0000-0002-1723-0844; Locatelli, Marco/0000-0003-0778-3653; Stocchetti, Nino/0000-0003-3250-6834			ALBERTI KGM, 1974, LANCET, V2, P1519; ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; BENVENISTE H, 1990, PROG NEUROBIOL, V35, P195, DOI 10.1016/0301-0082(90)90027-E; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BISSONNETTE B, 1991, CAN J ANAESTH, V38, P654, DOI 10.1007/BF03008204; Boveris A, 2000, ANN NY ACAD SCI, V899, P121; Cady L D Jr, 1973, Crit Care Med, V1, P75, DOI 10.1097/00003246-197303000-00003; DESALLES AAF, 1986, J NEUROSURG, V65, P615, DOI 10.3171/jns.1986.65.5.0615; DESALLES AAF, 1987, NEUROSURGERY, V21, P45, DOI 10.1227/00006123-198707000-00009; DICKENS F, 1946, BIOCHEM J, V40, P145, DOI 10.1042/bj0400145; Edwards J. D., 1993, OXYGEN TRANSPORT PRI; FELLOWS LK, 1993, J NEUROCHEM, V60, P1258, DOI 10.1111/j.1471-4159.1993.tb03285.x; Gnaiger E, 1995, J BIOENERG BIOMEMBR, V27, P583, DOI 10.1007/BF02111656; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; HOLBACH KH, 1977, J NEUROL, V217, P17, DOI 10.1007/BF00316313; HOWSE DC, 1975, J NEUROCHEM, V24, P935, DOI 10.1111/j.1471-4159.1975.tb03658.x; INAO S, 1988, J NEUROSURG, V69, P736, DOI 10.3171/jns.1988.69.5.0736; JACKSON RM, 1990, CLIN CHEST MED, V11, P73; JACOBSON I, 1964, SURG GYNECOL OBSTET, V119, P737; KETY SS, 1948, J CLIN INVEST, V27, P484, DOI 10.1172/JCI101995; LAMBERTSEN CJ, 1953, J APPL PHYSIOL, V5, P471, DOI 10.1152/jappl.1953.5.9.471; Love S, 1999, BRAIN PATHOL, V9, P119; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Menzel M, 1999, J NEUROSURG ANESTH, V11, P240, DOI 10.1097/00008506-199910000-00003; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; Moberg E, 1997, DIABETOLOGIA, V40, P1320, DOI 10.1007/s001250050827; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; PERETZ DI, 1965, ANN NY ACAD SCI, V119, P1133, DOI 10.1111/j.1749-6632.1965.tb47467.x; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; Persson L, 1996, J NEUROSURG, V84, P606, DOI 10.3171/jns.1996.84.4.0606; PRICHARD J, 1991, P NATL ACAD SCI USA, V88, P5829, DOI 10.1073/pnas.88.13.5829; ROBERTSON CS, 1987, J NEUROSURG, V67, P361, DOI 10.3171/jns.1987.67.3.0361; Ronning OM, 1999, STROKE, V30, P2033, DOI 10.1161/01.STR.30.10.2033; Rosdahl H, 1998, AM J PHYSIOL-ENDOC M, V274, pE936, DOI 10.1152/ajpendo.1998.274.5.E936; Rossi S, 2001, J NEUROTRAUM, V18, P163, DOI 10.1089/08977150150502596; Siesj? BK., 1978, BRAIN ENERGY METABOL; Singhal AB, 2002, J CEREBR BLOOD F MET, V22, P861, DOI 10.1097/00004647-200207000-00011; Sjoberg F, 1999, ACTA PHYSIOL SCAND, V165, P33; STOGNER SW, 1992, ANN PHARMACOTHER, V26, P1554, DOI 10.1177/106002809202601214; TEASDALE G, 1974, LANCET, V2, P81; UNTERBERG AW, 1988, J NEUROSURG, V68, P594, DOI 10.3171/jns.1988.68.4.0594; WEIL MH, 1970, CIRCULATION, V41, P989, DOI 10.1161/01.CIR.41.6.989; WILLIAMS CD, 1970, J NEUROCHEM, V17, P709, DOI 10.1111/j.1471-4159.1970.tb03341.x; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011; ZUPPING R, 1970, J NEUROSURG, V33, P498, DOI 10.3171/jns.1970.33.5.0498	47	110	112	0	7	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	MAY	2003	98	5					952	958		10.3171/jns.2003.98.5.0952			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	674CJ	WOS:000182619000009	12744353				2022-02-06	
J	Simpson, G; Tate, R				Simpson, G; Tate, R			Suicidality after traumatic brain injury: demographic, injury and clinical correlates	PSYCHOLOGICAL MEDICINE			English	Article							HEAD-INJURY; IDEATION; HOPELESSNESS; BEHAVIOR; MODEL	Background. In spite of the high frequency of emotional distress after traumatic brain injury (TBI), few investigations have examined the extreme of such distress, namely, suicidality, and no large scale surveys have been conducted. The current study examined both the prevalence and demographic, injury, and clinical correlates of hopelessness, suicidal ideation and suicide attempts after TBI. Methods. Out-patients (N = 172) with TBI were screened for suicidal ideation and hopelessness using the Beek Scale for Suicide Ideation and the Beck Hopelessness Scale. Data were also collected on demographic, injury, pre-morbid and post-injury psychosocial variables and included known risk factors for suicide. Results. A substantial proportion of participants had clinically significant levels of hopelessness (35%) and suicide ideation (23%), and 18% had made a suicide attempt post-injury, There was a high degree of co-morbidity between suicide attempts and emotional/psychiatric disturbance. Results from regression analyses indicated that a high level of hopelessness was the most significant association of suicide ideation and a high level of suicide ideation, along with occurrence of post-injury emotional/psychiatric disturbance, were the most significant associations of post-injury suicide attempts. Neither injury severity nor the presence of pre-morbid suicide risk factors contributed to elevated levels of suicidality post-injury. Conclusions. Suicidality is a common psychological reaction to TBI among out-patient populations. Management should involve careful history taking of previous post-injury suicidal behaviour, assessment of post-injury adjustment to TBI with particular focus on the degree of emotional/psychiatric disturbance, and close monitoring of those individuals with high levels of hopelessness and suicide ideation.	Liverpool Hosp, Brain Injury Rehabil Unit, Liverpool BC, NSW 1871, Australia; Univ Sydney, Dept Med, Rehabil Studies Unit, Sydney, NSW 2006, Australia; Royal Rehabil Ctr, Sydney, NSW, Australia		Simpson, G (corresponding author), Liverpool Hosp, Brain Injury Rehabil Unit, Locked Bag 7103, Liverpool BC, NSW 1871, Australia.		Simpson, Grahame K/W-1074-2019	Simpson, Grahame K/0000-0001-8156-9060			BECK AT, 1979, J CONSULT CLIN PSYCH, V47, P343, DOI 10.1037/0022-006X.47.2.343; BECK AT, 1985, AM J PSYCHIAT, V142, P559; BECK AT, 1974, J CONSULT CLIN PSYCH, V42, P861, DOI 10.1037/h0037562; BERNARD, 2000, HEADING NEWSLETTER S, P2; Bongar B., 1989, J INTEGRATIVE ECLECT, V8, P53; BONGAT B, 1991, SUICIDAL PATIENT CLI; BONNER RL, 1987, SUICIDE LIFE-THREAT, V17, P50; Bowman ML, 1996, CLIN NEUROPSYCHOL, V10, P382, DOI 10.1080/13854049608406699; Deb S, 1999, AM J PSYCHIAT, V156, P374; DICKSTRA RF, 1995, SUICIDE PREVENTION Y, P36; Graham A, 2000, AUST PSYCHOL, V35, P1, DOI 10.1080/00050060008257463; HIRSCHFIELD R, 1988, AM PSYCHIAT PRESS VI, P307; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; Kendall E, 1996, NEUROPSYCHOL REHABIL, V6, P101, DOI 10.1080/713755502; KIENHORST CWM, 1990, SUICIDE LIFE-THREAT, V20, P101; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; KLONOFF PS, 1995, J HEAD TRAUMA REHAB, V10, P16, DOI 10.1097/00001199-199512000-00005; KREUTZER J S, 1991, Brain Injury, V5, P177, DOI 10.3109/02699059109008088; Leon-Carrion J, 1997, NEUROPSYCHOL REHABIL, P415; Maris R., 1981, PATHWAYS SUICIDE SUR; Moore A D, 1989, Brain Inj, V3, P171, DOI 10.3109/02699058909004549; MOTTO JA, 1977, SUICIDE LIFE-THREAT, V7, P236; Parmelee D X, 1989, Brain Inj, V3, P295, DOI 10.3109/02699058909029642; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Robins E., 1986, SUICIDE, P123; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; SCHOTTE DE, 1982, J CONSULT CLIN PSYCH, V50, P690, DOI 10.1037/0022-006X.50.5.690; SCHWEITZER R, 1995, AUST NZ J PSYCHIAT, V29, P473, DOI 10.3109/00048679509064956; SHAFFER D, 1988, J AM ACAD CHILD PSY, V27, P675, DOI 10.1097/00004583-198811000-00001; Tate R, 1997, J HEAD TRAUMA REHAB, V12, P16, DOI 10.1097/00001199-199712000-00003; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; [No title captured]	34	110	112	0	7	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	0033-2917	1469-8978		PSYCHOL MED	Psychol. Med.	MAY	2002	32	4					687	697		10.1017/S0033291702005561			11	Psychology, Clinical; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Psychiatry	552VD	WOS:000175640000013	12102383				2022-02-06	
J	Dennis, M; Purvis, K; Barnes, MA; Wilkinson, M; Winner, E				Dennis, M; Purvis, K; Barnes, MA; Wilkinson, M; Winner, E			Understanding of literal truth, ironic criticism, and deceptive praise following childhood head injury	BRAIN AND LANGUAGE			English	Article						closed head injury; irony; deception; nonliteral language; intentionality	VERBAL IRONY; PRETENSE THEORY; BRAIN INJURY; CHILDREN; DISCOURSE; ADOLESCENTS; COMPREHENSION; NARRATIVES; KNOWLEDGE; SARCASM	Children with closed head injury (CHI) have semantic-pragmatic language problems that include difficulty in understanding and producing both literal and nonliteral statements. For example, they are relatively insensitive to some of the social messages in nonstandard communication as well as to words that code distinctions among mental states. This suggests that they may have difficulty with comprehension tasks involving first- and second-order intentionality, such as those involved in understanding irony and deception. We studied how 6- to 15-year-old children, typically developing or with CHI, interpret scenarios involving literal truth, ironic criticism, and deceptive praise. Children with severe CHI had overall poorer mastery of the task. Even mild CHI impaired the ability to understand the intentionality underlying deceptive praise. CHI, especially biologically significant CI-II, appears to place children at risk for failure to understand language as externalized thought. (C) 2001 Academic Press.	Hosp Sick Children, Dept Psychol Res, Toronto, ON M5G 1X8, Canada; Boston Coll, Dept Psychol, Chestnut Hill, MA 02167 USA; Univ Toronto, Dept Pediat, Toronto, ON, Canada; Univ Toronto, Dept Surg, Toronto, ON, Canada		Dennis, M (corresponding author), Hosp Sick Children, Dept Psychol Res, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [2R01NS 21889-16] Funding Source: Medline		AIRENTI G, 1993, J PRAGMATICS, V20, P303, DOI 10.1016/0378-2166(93)90055-T; ANDREWS J, 1986, COMMUN COGNITION, V19, P281; ASTINGTON J, 1995, CHILDS DISCOVERY MIN; Bara BG, 1997, BRAIN LANG, V59, P7, DOI 10.1006/brln.1997.1812; BARA BG, 1998, COGNITION CONTEX; Bara Bruno G., 1995, COGNITIVE SCI DEV AP; Barnes MA, 2001, BRAIN LANG, V76, P253, DOI 10.1006/brln.2000.2385; Barnes MA, 1996, J EXP CHILD PSYCHOL, V61, P216, DOI 10.1006/jecp.1996.0015; BARNES MA, 1992, J PEDIATR PSYCHOL, V17, P445, DOI 10.1093/jpepsy/17.4.445; BARONCOHEN S, 1994, BRIT J PSYCHIAT, V165, P640, DOI 10.1192/bjp.165.5.640; BJORKLUND DF, 1986, J EXP CHILD PSYCHOL, V41, P367, DOI 10.1016/0022-0965(86)90045-7; BOCK JK, 1982, PSYCHOL REV, V89, P1, DOI 10.1037/0033-295X.89.1.1; CAMPBELL TF, 1990, J SPEECH HEAR DISORD, V55, P567, DOI 10.1044/jshd.5503.567; CAPELLI CA, 1990, CHILD DEV, V61, P1824, DOI 10.1111/j.1467-8624.1990.tb03568.x; Carlson SM, 1998, CHILD DEV, V69, P672, DOI 10.2307/1132197; Chapman SB, 1998, BRAIN LANG, V61, P420, DOI 10.1006/brln.1997.1885; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; CHAPMAN SB, 1999, COMMUNICATION DISORD; CLARK HH, 1984, J EXP PSYCHOL GEN, V113, P121, DOI 10.1037/0096-3445.113.1.121; DEMOREST A, 1984, CHILD DEV, V55, P1527, DOI 10.2307/1130022; Dennis M, 1998, BRAIN LANG, V61, P450, DOI 10.1006/brln.1997.1886; Dennis M, 1996, DEV NEUROPSYCHOL, V12, P77, DOI 10.1080/87565649609540641; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; Dennis M, 2000, APHASIOLOGY, V14, P391, DOI 10.1080/026870300401423; Dews S, 1996, CHILD DEV, V67, P3071, DOI 10.2307/1131767; Dews S, 1999, J PRAGMATICS, V31, P1579, DOI 10.1016/S0378-2166(99)00005-3; Dews Shelly, 1995, AM PSYCH ASS NEW YOR; Docking K, 2000, BRAIN INJURY, V14, P89, DOI 10.1080/026990500120952; Ewing-Cobbs L, 1998, BRAIN LANG, V61, P395, DOI 10.1006/brln.1997.1884; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; EWINGCOBBS L, 1985, SPEECH LANGUAGE EVAL; FELDMAN RS, 1991, CHILDRENS INTERPERSO; GAIDOLFI E, 1980, ITAL J NEUROL SCI, V1, P65; Gazdar G., 1981, ELEMENTS DISCOURSE U; Gibbs R.W., 1989, METAPHOR SYMBOLIC AC, V3, P145; GIBBS RW, 1995, DISCOURSE PROCESS, V20, P187, DOI 10.1080/01638539509544937; GIBBS RW, 1986, J EXP PSYCHOL GEN, V115, P3, DOI 10.1037/0096-3445.115.1.3; GIBBS RW, 1984, COGNITIVE SCI, V8, P275, DOI 10.1207/s15516709cog0803_4; GIORA R, 1997, COGN LINGUIST, V7, P182; GOEL V, 1995, NEUROREPORT, V6, P1741, DOI 10.1097/00001756-199509000-00009; HALL WS, 1987, J PSYCHOLINGUIST RES, V16, P289, DOI 10.1007/BF01069284; HAVERKATE H, 1990, J PRAGMATICS, V14, P77, DOI 10.1016/0378-2166(90)90065-L; JASZCZOLT K, 1999, DISCOURSE BELIEFS IN; Jordan F M, 1988, Brain Inj, V2, P179, DOI 10.3109/02699058809150943; JORGENSEN J, 1984, J EXP PSYCHOL GEN, V113, P112, DOI 10.1037/0096-3445.113.1.112; KAUFER DS, 1981, J PRAGMATICS, V5, P494; KREUZ RJ, 1991, METAPHOR SYMB ACT, V6, P149, DOI 10.1207/s15327868ms0603_1; KREUZ RJ, 1989, J EXP PSYCHOL GEN, V118, P374, DOI 10.1037/0096-3445.118.4.374; KREUZ RJ, 1993, METAPHOR SYMB ACT, V8, P97, DOI 10.1207/s15327868ms0802_2; KUMONNAKAMURA S, 1995, J EXP PSYCHOL GEN, V124, P3, DOI 10.1037/0096-3445.124.1.3; Leggitt JS, 2000, DISCOURSE PROCESS, V29, P1, DOI 10.1207/S15326950dp2901_1; Levin H., 1979, J PEDIATR PSYCHOL, V4, P389, DOI DOI 10.1093/JPEPSY/4.4.389; Levin H S, 1997, J Int Neuropsychol Soc, V3, P598; Levinson Stephen., 1983, PRAGMATICS; LONG DL, 1988, DISCOURSE PROCESS, V11, P35, DOI 10.1080/01638538809544690; McDonald S, 1998, BRAIN LANG, V61, P88, DOI 10.1006/brln.1997.1846; MCDONALD S, 1992, APPL PSYCHOLINGUIST, V13, P295, DOI 10.1017/S0142716400005658; McDonald S, 1996, BRAIN LANG, V53, P81, DOI 10.1006/brln.1996.0038; MCDONALD S, 1995, BRAIN INJURY, V9, P255, DOI 10.3109/02699059509008197; McDonald S., 2000, ADV UNDERSTANDING CO; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; MORROW DG, 1990, INFERENCES TEXT COMP; Muecke Douglas C., 1969, COMPASS IRONY; Peskin J, 1996, CHILD DEV, V67, P1735, DOI 10.2307/1131728; PESKIN J, 1989, CONCEALING ONES INTE; PETERSON CC, 1991, CHILDRENS INTERPERSO; Pexman PM, 2000, DISCOURSE PROCESS, V29, P201, DOI 10.1207/S15326950dp2903_2; SCHOLNICK EK, 1991, PERSPECTIVES LANGUAG; Schwoebel John, 2000, METAPHOR SYMBOL, V15, P47, DOI [10.1080/10926488.2000.9678864, DOI 10.1080/10926488.2000.9678864]; SODIAN B, 1994, CHILDRENS EARLY UNDE; Sperber D., 1981, RADICAL PRAGMATICS; Stone VE, 1998, J COGNITIVE NEUROSCI, V10, P640, DOI 10.1162/089892998562942; SULLIVAN K, 1995, BRIT J DEV PSYCHOL, V13, P191, DOI 10.1111/j.2044-835X.1995.tb00673.x; Wechsler D., 1974, WECHSLER INTELLIGENC; Wechsler D, 1991, WECHSLER INTELLIGENC, VTHIRD; Wilson D., 1986, RELEVANCE COMMUNICAT; WINNER E, 1991, BRIT J DEV PSYCHOL, V9, P257, DOI 10.1111/j.2044-835X.1991.tb00875.x; Winner E., 1988, POINT WORDS CHILDREN; Winner E., 1997, PROBLEM MEANING BEHA; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218; WOODCOCK RW, 1990, WOOCKCOCKJOHNSON PSY	81	110	112	0	14	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0093-934X			BRAIN LANG	Brain Lang.	JUL	2001	78	1					1	16		10.1006/brln.2000.2431			16	Audiology & Speech-Language Pathology; Linguistics; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Psychology	445WF	WOS:000169481000001	11412012				2022-02-06	
J	Erlanger, D; Saliba, E; Barth, J; Almquist, J; Webright, W; Freeman, J				Erlanger, D; Saliba, E; Barth, J; Almquist, J; Webright, W; Freeman, J			Monitoring resolution of postconcussion symptoms in athletes: Preliminary results of a web-based neuropsychological test protocol	JOURNAL OF ATHLETIC TRAINING			English	Article						brain injury; return-to-play guidelines; computerized testing; Internet testing	TEST-PERFORMANCE; HEAD-INJURY; SPORTS; CONCUSSION	Objective: A new Web-based neuropsychological test was field tested to determine usefulness in detecting and monitoring resolution of symptoms after sport-related concussions and in providing objective information for return-to-play decisions. Design and Setting: We obtained neuropsychological baseline data on all subjects, After concussion, subjects; were administered alternate, equivalent follow-up tests until symptoms resolved. Follow-up testing typically occurred at 1- to 2-day intervals after the concussion. Subjects: Baseline testing was obtained for 834 athletes as part of ongoing field trials. Subsequently, 26 athletes sustained concussions and were studied. Measurements: We administered The Concussion Resolution Index (CRI) at baseline and alternate forms posttrauma. Follow-up tests included a self-report inventory of neurophysiologic symptoms. Results: A total of 88% of patients were identified as symptomatic on initial postconcussion testing. The CRI appeared relatively resistant to retest effects, and multiple administrations tracked resolution of symptoms over short and extended time periods. Conclusions: Although the CRI is still in field trials, preliminary data indicate that the CRI may be a useful method for athletic trainers and other professionals to expeditiously track resolution of symptoms after sport-related concussion.	HeadMinder Inc, New York, NY 10038 USA; Columbia Univ, New York, NY USA; Univ Virginia, Charlottesville, VA USA; Fairfax Cty Sch, Vienna, VA USA		Erlanger, D (corresponding author), HeadMinder Inc, 15 Maiden Lane,Suite 205, New York, NY 10038 USA.	david@headminder.com					Barth JT, 1989, MILD HEAD INJURY, P257; Bleiberg J, 1998, J HEAD TRAUMA REHAB, V13, P36, DOI 10.1097/00001199-199804000-00006; Bleiberg J, 2000, CLIN NEUROPSYCHOL, V14, P287, DOI 10.1076/1385-4046(200008)14:3;1-P;FT287; Cantu RC, 1996, BRIT J SPORT MED, V30, P289, DOI 10.1136/bjsm.30.4.289; CANTU RC, 1991, ADOLESCENT MED STATE, P17; Cohen J., 2013, STAT POWER ANAL BEHA; Echemendia R. J., 1999, 107 ANN M AM PSYCH A; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Erlanger DM, 2000, ARCH CLIN NEUROPSYCH, V15, P675; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; Erlanger DM, 1999, CONCUSSION RESOLUTIO; Heaton RK, 2001, ARCH CLIN NEUROPSYCH, V16, P75, DOI 10.1016/S0887-6177(99)00062-1; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; KUTNER KC, 1998, NATL ACAD NEUROPSYCH, V14, P19; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Temkin NR, 1999, J INT NEUROPSYCH SOC, V5, P357, DOI 10.1017/S1355617799544068; Zemper Eric D., 1994, Journal of Athletic Training, V29, P44	22	110	111	0	4	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	JUL-SEP	2001	36	3					280	287					8	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Sport Sciences	557NC	WOS:000175913800011	12937497				2022-02-06	
J	Bleiberg, J; Kane, RL; Reeves, DL; Garmoe, WS; Halpern, E				Bleiberg, J; Kane, RL; Reeves, DL; Garmoe, WS; Halpern, E			Factor analysis of computerized and traditional tests used in mild brain injury research	CLINICAL NEUROPSYCHOLOGIST			English	Article							HEAD-INJURY; NEUROPSYCHOLOGICAL ASSESSMENT; PERFORMANCE; CONCUSSION; CONSISTENCY; DEFICITS; PLAYERS	The present study examines the relation between a set of computerized neuropsychological measures, Automated Neuropsychological Assessment Metrics (ANAM), acid a set of traditional clinical neuropsychological tests. Both sets of tests have been employed in recent studies of mild brain injury. Factor analysis and stepwise regression indicate that both sets of tests measure similar underlying constructs of cognitive processing speed, resistance to interference, and working memory. The present findings indicate strong concordance between computerized and traditional neuropsychological measures and support the construct validity of ANAM and similar procedures.	Natl Rehabil Hosp, Washington, DC 20010 USA; Univ Maryland, College Pk, MD 20742 USA		Bleiberg, J (corresponding author), Natl Rehabil Hosp, 102 Irving St NW, Washington, DC 20010 USA.			Bleiberg, Joseph/0000-0003-0867-5494			Benton A., 1978, MULTILINGUAL APHASIA; Bleiberg J, 1998, J HEAD TRAUMA REHAB, V13, P36, DOI 10.1097/00001199-199804000-00006; Bleiberg J, 1997, NEUROPSY NEUROPSY BE, V10, P247; BLEIBERG J, 1993, NEUROPSY NEUROPSY BE, V6, P245; BOHNEN NI, 1995, BRAIN INJURY, V9, P27, DOI 10.3109/02699059509004568; Brandt J, 1991, CLIN NEUROPSYCHOL, V5, P125, DOI [10.1080/13854049108403297, DOI 10.1080/13854049108403297]; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Daniel JC, 1999, NEUROPSY NEUROPSY BE, V12, P167; DELIS C, 1987, CALIFORNIA VERBAL LE; Golden CJ, 1978, STROOP COLOR WORD TE; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; KANE RL, 1992, NEUROPSYCHOL REV, V3, P1, DOI 10.1007/BF01108787; KANE RL, 1997, NEUROPSYCHOLOGY HDB, V2; Kay GG, 1997, ARCH INTERN MED, V157, P2350, DOI 10.1001/archinte.157.20.2350; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; McDiarmid MA, 2000, ENVIRON RES, V82, P168, DOI 10.1006/enrs.1999.4012; Milner B, 1972, Clin Neurosurg, V19, P421; Reitan R, 1985, HALSTEAD REITAN NEUR; STARBUCK VN, 1995, NEUROPSY NEUROPSY BE, V8, P189; Stuss DT, 1989, CLIN NEUROPSYCHOL, V3, P145, DOI [DOI 10.1080/13854048908403287, 10.1080/ 13854048908403287]; Wechsler, 1997, WECHSLER ADULT INTEL	26	110	113	0	9	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	0920-1637			CLIN NEUROPSYCHOL	Clin. Neuropsychol.	AUG	2000	14	3					287	294		10.1076/1385-4046(200008)14:3;1-P;FT287			8	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	392FV	WOS:000166401600004	11262703				2022-02-06	
J	Bryant, RA; Marosszeky, JE; Crooks, H; Gurka, JA				Bryant, RA; Marosszeky, JE; Crooks, H; Gurka, JA			Posttraumatic stress disorder after severe traumatic brain injury	AMERICAN JOURNAL OF PSYCHIATRY			English	Article							PSEUDOMEMORIES; SCALE	Objective: This study indexed the profile of posttraumatic stress disorder (PTSD) after severe traumatic injury to the brain. Method: Patients who sustained a severe traumatic brain injury (N=96) were assessed for PTSD 6 months after the injury with the PTSD Interview, a structured clinical interview based on DSM-III-R criteria. Results: PTSD was diagnosed in 26 (27.1%) of the patients. While only 19.2% (N=5) of the patients with PTSD reported intrusive memories of the trauma, 96.2% (N=25) reported emotional reactivity. Intrusive memories, nightmares, and emotional reactivity had very strong positive predictive values for the presence of PTSD. Conclusions: These findings indicate that PTSD can develop after severe traumatic brain injury, The predominance of emotional reactivity and the relative absence of traumatic memories in patients with PTSD who suffered impaired consciousness during trauma suggest that traumatic experiences can mediate PTSD at an implicit level.	Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia; Westmead Hosp, Dept Rehabil Med, Sydney, NSW, Australia		Bryant, RA (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.		Bryant, Richard/AAA-6479-2019	Bryant, Richard/0000-0002-9607-819X			BLANCHARD EB, 1994, BEHAV RES THER, V32, P283, DOI 10.1016/0005-7967(94)90123-6; Bryant RA, 1996, J TRAUMA STRESS, V9, P621; Bryant RA, 1998, APPL COGNITIVE PSYCH, V12, P81, DOI 10.1002/(SICI)1099-0720(199802)12:1<81::AID-ACP507>3.0.CO;2-8; Fleiss J.L., 1981, STAT METHODS RATES P; FOA EB, 1995, AM J PSYCHIAT, V152, P116; LOGHREY GC, 1993, INT HDB TRAUMATIC ST, P377; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; TEASDALE G, 1974, LANCET, V2, P81; Van Der Kolk Bessel A., 1996, P214; WATSON CG, 1991, J CLIN PSYCHOL, V47, P179, DOI 10.1002/1097-4679(199103)47:2<179::AID-JCLP2270470202>3.0.CO;2-P	11	110	110	1	4	AMER PSYCHIATRIC PRESS, INC	WASHINGTON	1400 K ST, N W, STE 1101, WASHINGTON, DC 20005 USA	0002-953X			AM J PSYCHIAT	Am. J. Psychiat.	APR	2000	157	4					629	631		10.1176/appi.ajp.157.4.629			3	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	300BE	WOS:000086232300022	10739426				2022-02-06	
J	Delaney, JS; Lacroix, VJ; Leclerc, S; Johnston, KM				Delaney, JS; Lacroix, VJ; Leclerc, S; Johnston, KM			Concussions during the 1997 Canadian Football League season	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; professional football; risk factors; symptom duration	ATHLETIC HEAD-INJURIES; CEREBRAL CONCUSSION; AMERICAN FOOTBALL; SOCCER INJURIES; CONTACT SPORTS; CERVICAL-SPINE; PLAYERS; GUIDELINES; PREVENTION; BRAIN	Objective: To examine the incidence and characteristics of concussions for one season in the Canadian Football League (CFL). Design: Retrospective survey. Participants: 289 players reporting to CFL training camp. Of these, 154 players had played in the CFL during the 1997 season. Main Outcome Measures: Based on self-reported symptoms, calculations were made to determine the number of concussions experienced during the previous season, the duration of symptoms, the time for return to play after concussion, and any associated risk factors for concussions. Results: Of all the athletes who played during the 1997 season, 44.8% experienced symptoms of a concussion. Only 18.8% of these concussed players recognized they had suffered a concussion. 69.6% of all concussed players experienced more than one episode. Symptoms lasted at least 1 day in 25.8% of cases. The odds of experiencing a concussion increased 13% with each game played. A past history of a loss of consciousness while playing football and a recognized concussion while playing football were both associated with increased odds of experiencing a concussion during the 1997 season. Conclusion: Many players experienced a concussion during the 1997 CFL season, but the majority of these players may not have recognized that fact. Players need to be better informed about the symptoms and effects of concussions.	McGill Sport Med Clin, Montreal, PQ H2W 1S4, Canada; McGill Univ, Ctr Hlth, Dept Emergency Med, Montreal, PQ, Canada; McGill Univ, Ctr Hlth, Dept Neurosurg, Montreal, PQ, Canada		Delaney, JS (corresponding author), McGill Sport Med Clin, 475 Pine Ave W, Montreal, PQ H2W 1S4, Canada.						Autti T, 1997, LANCET, V349, P1144, DOI 10.1016/S0140-6736(05)63019-X; Baum KA, 1996, NEURORADIOLOGY, V38, P755, DOI 10.1007/s002340050342; BUCKLEY WE, 1988, AM J SPORT MED, V16, P51, DOI 10.1177/036354658801600109; Cantu RC, 1996, BRIT J SPORT MED, V30, P289, DOI 10.1136/bjsm.30.4.289; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; Cantu RC, 1997, CLIN SPORT MED, V16, P531, DOI 10.1016/S0278-5919(05)70038-7; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; CANTU RC, 1988, SPORTS MED DIGEST, V10, P1; *COL MED SOC, 1991, REP SPORTS MED COMM; Committee on Head Injury Nomenclature of Congress of Neurological Surgeons, 1966, CLIN NEUROSURG, V12, P386; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GRONWALL D, 1975, LANCET, V2, P995; GRONWALL D, 1974, LANCET, V2, P606; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; KASS RE, 1995, J AM STAT ASSOC, V90, P773, DOI 10.1080/01621459.1995.10476572; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; LINDSAY KW, 1980, BRIT MED J, V281, P789, DOI 10.1136/bmj.281.6243.789; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; MARSH NV, 1995, BRAIN INJURY, V9, P553, DOI 10.3109/02699059509008214; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; McCrory PR, 1997, MED SCI SPORT EXER, V29, pS207; MUELLER FO, 1987, CLIN SPORT MED, V6, P185; Nelson W. E., 1984, PHYSICIAN SPORTSMED, V12, P103; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; ROBERTS WO, 1992, PHYSICIAN SPORTSMED, V20, P66, DOI 10.1080/00913847.1992.11710295; SAAL JA, 1991, SPORTS MED, V12, P132, DOI 10.2165/00007256-199112020-00005; Schneider RC., 1973, HEAD NECK INJURIES F; TORG JS, 1985, MED SCI SPORT EXER, V17, P295; TORG JS, 1985, JAMA-J AM MED ASSOC, V254, P3439, DOI 10.1001/jama.254.24.3439; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; TYSVAER AT, 1989, AM J SPORT MED, V17, P573, DOI 10.1177/036354658901700421; Warren WL, 1998, CLIN SPORT MED, V17, P13, DOI 10.1016/S0278-5919(05)70057-0; WILBERGER JE, 1989, CLIN SPORT MED, V8, P1; WILBERGER JE, 1993, SPORTS MED, V15, P338, DOI 10.2165/00007256-199315050-00005; YARNELL PR, 1973, NEUROLOGY, V23, P196, DOI 10.1212/WNL.23.2.196; Zemper Eric D., 1994, Journal of Athletic Training, V29, P44	39	110	111	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1050-642X			CLIN J SPORT MED	Clin. J. Sport Med.	JAN	2000	10	1					9	14		10.1097/00042752-200001000-00003			6	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Physiology; Sport Sciences	284VU	WOS:000085354200003	10695844				2022-02-06	
J	Tate, R; Hodgkinson, A; Veerabangsa, A; Maggiotto, S				Tate, R; Hodgkinson, A; Veerabangsa, A; Maggiotto, S			Measuring psychosocial recovery after traumatic brain injury: Psychometric properties of a new scale	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							COMMUNITY INTEGRATION QUESTIONNAIRE; BLUNT HEAD-INJURY; RATING-SCALE; DISABILITY; RELATIVES; OUTCOMES	Objectives: To determine the psychometric properties of the Sydney Psychosocial Reintegration Scale (SPRS), an instrument developed to quantify disability and handicap in persons with traumatic brain injury (TBI). Design: Descriptive correlational study. Setting: Brain Injury Rehabilitation Unit and Brain Injury Outpatient Clinic. Participants: Two samples, a "subacute" group (n = 20) and a "long-term" group (n = 40), were studied to examine responsiveness (subacute group), reliability, and validity (long-term group) of the SPRS. Main Outcome Measure: The SPRS is a 12-item questionnaire measuring three domains of everyday Living commonly disrupted after severe TBI: occupational activities, interpersonal relationships, and independent living skills. Procedure: Patients in the subacute group were rated with the SPRS by a clinician at admission to the rehabilitation unit and again three months later or at discharge from the unit (whichever occurred first). For individuals from the long-term group attending the outpatient clinic, a close relative was interviewed with the SPRS and other validating measures. The SPRS was readministered one month later Results: Internal consistency of the SPRS was high (alpha coefficient = .90), as was agreement between raters and stability over a one-month period (r(i) = .95 and .90, respectively). Reliability and stability coefficients for the three domains of the scale were also high, ranging from .86 to .94 for reliability and .77 to .93 for stability Preliminary evidence for construct validity was established with a number of standard instruments, with evidence of both convergent and discriminant construct validity from the Sickness Impact Profile (SIP). The SPRS was sensitive to group differences on the Glasgow Outcome Scale (GOS) and to changes occurring during the period of active recovery Conclusions: The results suggest that the SPRS has sound psychometric properties, being a reliable, stable, sensitive, and valid instrument. It is potentially useful in both clinical and research settings.	Univ Sydney, Royal Rehabil Ctr, Dept Med, Rehabil Studies Unit, Ryde, NSW 1680, Australia; Liverpool Hosp, Brain Injury Rehabil Unit, Liverpool, NSW, Australia; Univ Sydney, Dept Psychol, Sydney, NSW 2006, Australia		Tate, R (corresponding author), Univ Sydney, Royal Rehabil Ctr, Dept Med, Rehabil Studies Unit, POB 6, Ryde, NSW 1680, Australia.						BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BROE GA, 1982, BRAIN IMPAIRMENT; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; BRUININKS RH, 1985, DEV STANDARDIZATIION; Cicchetti D.V., 1994, PSYCHOL ASSESS, V6, P284, DOI [10.1037/1040-3590.6.4.284, DOI 10.1037/1040-3590.6.4.284]; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; Dijkers M, 1997, J HEAD TRAUMA REHAB, V12, P74, DOI 10.1097/00001199-199712000-00007; DODWELL D, 1988, J NEUROL NEUROSUR PS, V51, P833, DOI 10.1136/jnnp.51.6.833; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; Harwood R H, 1994, Qual Health Care, V3, P11, DOI 10.1136/qshc.3.1.11; Hobart JC, 1996, J NEUROL NEUROSUR PS, V60, P127, DOI 10.1136/jnnp.60.2.127; Howell DC., 1997, STAT METHODS PSYCHOL, V4th ed; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KATZ MM, 1963, PSYCHOL REP, V13, P503, DOI 10.2466/pr0.1963.13.2.503; KLONOFF PS, 1986, NEUROSURGERY, V19, P735, DOI 10.1227/00006123-198611000-00004; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Livingston M G, 1985, Int Rehabil Med, V7, P145; MCDOWELL I, 1987, MEASURING HLTH GUIDE; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; MOORE A D, 1990, Brain Injury, V4, P379, DOI 10.3109/02699059009026191; Murphy KR, 1994, PSYCHOL TESTING PRIN; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Smith H.E., 1992, CLIN REHABIL, V6, P31; TABACHNIK BG, 1996, USING MULTIVARIATE; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; TEMKIN N, 1988, J CLIN EPIDEMIOL, V41, P47, DOI 10.1016/0895-4356(88)90008-X; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009; World Health Organization, 1980, INT CLASS IMP DIS HA; World Health Organization, 1997, ICIDH 2 INT CLASS IM	33	110	111	0	5	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	DEC	1999	14	6					543	557		10.1097/00001199-199912000-00003			15	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	269AV	WOS:000084454300002	10671700				2022-02-06	
J	Raghupathi, R; Fernandez, SC; Murai, H; Trusko, SP; Scott, RW; Nishioka, WK; McIntosh, TK				Raghupathi, R; Fernandez, SC; Murai, H; Trusko, SP; Scott, RW; Nishioka, WK; McIntosh, TK			BCL-2 overexpression attenuates cortical cell loss after traumatic brain injury in transgenic mice	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						traumatic brain injury; cell death; BCL-2; transgenic mice; neuroprotection; behavior	HUMAN HEAD-INJURY; SYNAPSIN-I GENE; SYMPATHETIC NEURONS; MEMORY DEFICITS; IMPACT INJURY; DEATH; RAT; EXPRESSION; APOPTOSIS; DAMAGE	The proto-oncogene, BCL-2, has been suggested to participate in cell survival during development of, and after injury to, the CNS. Transgenic (TG) mice overexpressing human Bcl-2 (n = 21) and their wild-type (WT) littermates (n = 18) were subjected to lateral controlled cortical impact brain injury. Lateral controlled cortical impact brain injury resulted in the formation of a contusion in the injured cortex at 2 days, which developed into a well-defined cavity by 7 days in both WT and TG mice. At 7 days after injury, brain-injured TG mice had a significantly reduced cortical lesion (volume = 1.99 mm(3)) compared with that of the injured WT mice (volume = 5.1 mm(3), P < 0.01). In contrast, overexpression of BCL-2 did not affect the extent of hippocampal cell death after lateral controlled cortical impact brain injury. Analysis of motor function revealed that both brain-injured WT and TG mice exhibited significant right-sided deficits at 2 and 7 days after injury (P < 0.05 compared with the uninjured controls). Although composite neuroscores (sum of scores from forelimb and hind limb flexion, lateral pulsion, and inclined plane tests) were not different between WT and TG brain-injured mice, TC mice had a slightly but significantly reduced deficit in the inclined plane test (P < 0.05 compared to the WT mice). These data suggest that the cell death regulatory gene, BCL-2, may play a protective role in the pathophysiology of traumatic brain injury.	Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Cephalon Inc, W Chester, PA USA; VICAL, La Jolla, CA USA		Raghupathi, R (corresponding author), Univ Penn, Dept Neurosurg, 102B Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS008803, R01NS026818] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS08803, R01-NS26818] Funding Source: Medline		ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; ALLSOPP TE, 1995, EUR J NEUROSCI, V7, P1266, DOI 10.1111/j.1460-9568.1995.tb01116.x; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Bredesen DE, 1995, ANN NEUROL, V38, P839, DOI 10.1002/ana.410380604; CHAN PH, 1995, J NEUROTRAUM, V12, P815, DOI 10.1089/neu.1995.12.815; CHEN J, 1995, NEUROREPORT, V6, P394, DOI 10.1097/00001756-199501000-00040; Clark RSB, 1997, J NEUROSCI, V17, P9172; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Conti AC, 1998, J NEUROSCI, V18, P5663; DAVIES AM, 1995, TRENDS NEUROSCI, V18, P355, DOI 10.1016/0166-2236(95)93928-Q; DeBilbao F, 1996, NEUROSCIENCE, V71, P1111, DOI 10.1016/0306-4522(95)00505-6; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FARLIE PG, 1995, P NATL ACAD SCI USA, V92, P4397, DOI 10.1073/pnas.92.10.4397; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Franklin K.P.G., 1996, MOUSE BRAIN STEREOTA; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; Gennarelli TA, 1997, NEUROSCIENTIST, V3, P73, DOI 10.1177/107385849700300117; Gillardon F, 1996, MOL BRAIN RES, V40, P254, DOI 10.1016/0169-328X(96)00059-9; GREENLUND LJS, 1995, NEURON, V15, P649, DOI 10.1016/0896-6273(95)90153-1; GROSCHE J, 1995, NEUROSCI LETT, V185, P119, DOI 10.1016/0304-3940(94)11239-F; GRUBBS FE, 1972, TECHNOMETRICS, V14, P847, DOI 10.2307/1267134; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOESCHE C, 1993, J BIOL CHEM, V268, P26494; HOGAN B, 1982, MANIPULATING MOUSE E; HOWLAND DS, 1995, NEUROBIOL AGING, V16, P685, DOI 10.1016/0197-4580(95)00078-S; HOWLAND DS, 1991, MOL BRAIN RES, V11, P345, DOI 10.1016/0169-328X(91)90044-X; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; Jia WWG, 1996, MOL BRAIN RES, V42, P350, DOI 10.1016/S0169-328X(96)00223-9; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KANE DJ, 1995, J NEUROSCI RES, V40, P269, DOI 10.1002/jnr.490400216; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; KURTH SM, 1994, BRAIN INJURY, V8, P489, DOI 10.3109/02699059409151001; Lawrence MS, 1997, J CEREBR BLOOD F MET, V17, P740; Lawrence MS, 1996, J NEUROSCI, V16, P486; Li GL, 1996, J NEUROPATH EXP NEUR, V55, P280, DOI 10.1097/00005072-199603000-00003; LINNIK MD, 1995, STROKE, V26, P1670, DOI 10.1161/01.STR.26.9.1670; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Mikawa S, 1996, J NEUROSURG, V85, P885, DOI 10.3171/jns.1996.85.5.0885; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; RAGHUPATHI R, 1995, J NEUROTRAUM, V12, P966; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; RINK A, 1995, AM J PATHOL, V147, P1575; ROSS DT, 1993, J NEUROTRAUM, V10, P151, DOI 10.1089/neu.1993.10.151; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Soblosky JS, 1996, BEHAV BRAIN RES, V79, P79, DOI 10.1016/0166-4328(95)00264-2; STRAUSS KI, 1996, J NEUROTRAUM, V13, P620; Su JH, 1996, NEUROREPORT, V7, P437, DOI 10.1097/00001756-199601310-00015; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Troost D, 1995, NEUROPATH APPL NEURO, V21, P498, DOI 10.1111/j.1365-2990.1995.tb01096.x; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YOUNG W, 1992, J NEUROTRAUMA S1, V9, P9; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533	64	110	116	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	NOV	1998	18	11					1259	1269		10.1097/00004647-199811000-00013			11	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	134VP	WOS:000076764600013	9809516	Bronze			2022-02-06	
J	Koizumi, H; Povlishock, JT				Koizumi, H; Povlishock, JT			Posttraumatic hypothermia in the treatment of axonal damage in an animal model of traumatic axonal injury	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; axonal injury; beta-amyloid precursor protein immunohistochemistry; rat	AMYLOID PRECURSOR PROTEIN; CONTROLLED CORTICAL IMPACT; DIFFUSE BRAIN INJURY; MODERATE HYPOTHERMIA; HEAD-INJURY; THERAPEUTIC HYPOTHERMIA; GLUTAMATE RELEASE; MILD HYPOTHERMIA; RATS; PROTECTION	Object. Many investigators have demonstrated the protective effects of hypothermia following traumatic brain injury (TBI) in both animals and humans. Typically,:his protection has been evaluated in relation to the preservation of neurons and/or the blunting of behavioral abnormalities. However, little consideration has been given to any potential protection afforded in regard to TBI-induced axonal injury, a feature of human TBI. In this study, the authors evaluated the protective effects of hypothermia on axonal injury after TBT in rats. Methods. Male Sprague-Dawley rats weighing 380 to 400 g were subjected to experimental TBI induced by an impact-acceleration device. These rats were subjected to hypothermia either before or after injury, with their temporalis muscle and rectal temperatures maintained at 32 degrees C for 1 hour. After this I-hour period of hypothermia, rewarming to normothermic levels was accomplished over a 90-minute period. Twenty-four hours later, the animals were killed and semiserial sagittal sections of the brain were reacted for visualization of the amyloid precursor protein (APP), a marker of axonal injury. The density of APP-marked damaged axons within the corticospinal tract at the pontomedullary junction was calculated for each animal. In all hypothermic animals, a significant reduction in APP-marked damaged axonal density was found. In animals treated with preinjury, immediate postinjury, and delayed hypothermia, the density of damaged axons was dramatically reduced in comparison with the untreated controls (p < 0.05). Conclusions. The authors infer from these findings that early as well as delayed posttraumatic hypothermia results in substantial protection in TBI, at least in terms of the injured axons.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA; Yamaguchi Univ, Sch Med, Dept Neurosurg, Yamaguchi, Japan		Povlishock, JT (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, POB 980709, Richmond, VA 23298 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 20193] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020193] Funding Source: NIH RePORTER		BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Farooque M, 1997, J NEUROTRAUM, V14, P63, DOI 10.1089/neu.1997.14.63; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; KATSURA K, 1992, BRAIN RES, V590, P6, DOI 10.1016/0006-8993(92)91075-P; KOIZUMI H, 1997, JBRAIN RES, V747, P304; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; Mansfield RT, 1996, J CEREBR BLOOD F MET, V16, P244, DOI 10.1097/00004647-199603000-00009; Marion DW, 1996, J NEUROTRAUM, V13, P139, DOI 10.1089/neu.1996.13.139; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Novack TA, 1996, J CLIN EXP NEUROPSYC, V18, P685, DOI 10.1080/01688639608408292; PADILLA S, 1986, J NEUROCHEM, V46, P1227, DOI 10.1111/j.1471-4159.1986.tb00642.x; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; PATEL PM, 1994, BRAIN RES, V650, P205, DOI 10.1016/0006-8993(94)91783-3; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Povlishock JT, 1996, ACT NEUR S, V66, P81; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; POVLISHOCK JT, 1992, J NEUROTRAUMA, V9, P189; RESNICK DK, 1994, NEUROSURGERY, V34, P252, DOI 10.1227/00006123-199402000-00007; Rosomoff HL, 1996, CRIT CARE MED, V24, pS48; SAKAMOTO K, 1995, J NEUROTRAUM, V14, P349; SHERRIFF FE, 1994, NEUROREPORT, V5, P1085, DOI 10.1097/00001756-199405000-00016; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; SIMONS M, 1995, J NEUROSCI RES, V41, P121, DOI 10.1002/jnr.490410114; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; Stone J., 1997, Society for Neuroscience Abstracts, V23, P2194; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; TOMLINSON DR, 1984, MED BIOL, V62, P34; WHITELEY SJ, 1985, DIABETOLOGIA, V28, P847, DOI 10.1007/BF00291076	47	110	112	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	AUG	1998	89	2					303	309		10.3171/jns.1998.89.2.0303			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	104CM	WOS:000074994900018	9688127				2022-02-06	
J	Albrecht, RF; Wass, CT; Lanier, WL				Albrecht, RF; Wass, CT; Lanier, WL			Occurrence of potentially detrimental temperature alterations in hospitalized patients at risk for brain injury	MAYO CLINIC PROCEEDINGS			English	Article							COMPLETE CEREBRAL-ISCHEMIA; ACUTE STROKE; HYPOTHERMIA; THERMOREGULATION; MANAGEMENT; NIMODIPINE; PROGNOSIS; DAMAGE; HUMANS; ARREST	Objective: To ascertain the incidence and timing of fever in patients at risk for temperature modulation of brain injury resulting from ischemia or trauma. Design: We retrospectively reviewed the medical records of patients admitted between January 1991 and December 1994, Material and Methods: We investigated three groups of hospitalized patients considered at risk fdr ongoing brain injury resulting from a prior cerebral insult: successful resuscitation from out-of-hospital cardiac arrest (CA), subarachnoid hemorrhage (SAH), or traumatic closed-head injury (CHI), Forty patients per condition were randomly selected from those who survived for more than 24 hours after hospital admission. Results: During the initial 72 hours of hospitalization, temperature increases to 38 degrees C or more (that is, temperatures previously reported to worsen neurologic outcome after brain injury) were noted in 83% of patients with CA, 70% of those with SAH, and 68% of those with CHI. Within the cohort of febrile patients, 18 to 44% of all temperature measurements were 38 degrees C or higher, and the febrile episodes occurred randomly throughout the study interval. Fewer than one-eighth of the febrile patients received drugs possessing antipyretic properties (such as aspirin or acetaminophen) in a dose appropriate to treat fever, No other method of temperature control (for example, physical means) was used in any patient. The fractions of patients who mere dismissed; from the hospital with permanent neurologic injury were as follows: CA, 20%; SAH, 45%; and CHI, 43%. Conclusion: In these hospitalized patients at risk for ongoing brain injury, the incidence of temperature increases within the range reported to worsen neurologic outcome (elevations of 1.0 degrees C or more) was very high. The characterization of these potentially injurious, randomly occurring, and traditionally undertreated temperature increases may have implications for thf design of future protocols aimed at providing cerebral protection.	Mayo Clin & Mayo Fdn, Dept Anesthesiol, Rochester, MN 55905 USA		Lanier, WL (corresponding author), Mayo Clin & Mayo Fdn, Dept Anesthesiol, 200 1St St SW, Rochester, MN 55905 USA.				NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM 08288] Funding Source: Medline		AZZIMONDI G, 1995, STROKE, V26, P2040, DOI 10.1161/01.STR.26.11.2040; BAENA RC, 1997, J CEREB BLOOD FLO S1, V17, pS34; BECKSTEAD JE, 1978, STROKE, V9, P569, DOI 10.1161/01.STR.9.6.569; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; Crowder CM, 1996, J NEUROSURG, V85, P98, DOI 10.3171/jns.1996.85.1.0098; DIEM K, 1971, SCI TALBES, P85; DRUMMOND JC, 1994, ANESTHESIA, V1, P689; HINDFELT B, 1976, ACTA NEUROL SCAND, V53, P72, DOI 10.1111/j.1600-0404.1976.tb04326.x; KAKUDA W, 1997, J CEREB BLOOD FLO S1, V17, pS43; KASSELL NF, 1990, J NEUROSURG, V73, P18, DOI 10.3171/jns.1990.73.1.0018; LANIER WL, 1992, RESUSCITATION, V23, P121, DOI 10.1016/0300-9572(92)90197-K; LANLER WL, 1995, J NEUROSURG ANESTHES, V7, P216; LIBERTHSON RR, 1974, NEW ENGL J MED, V291, P317, DOI 10.1056/NEJM197408152910701; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MEMEZAWA H, 1995, BRAIN RES, V670, P48, DOI 10.1016/0006-8993(94)01251-C; MILDE LN, 1994, ANESTHESIA NEUROSURG, P59; MILDE LN, 1990, CLIN NEUROANESTHESIA, P171; MILLS SA, 1993, ANN THORAC SURG, V56, pS86, DOI 10.1016/0003-4975(93)91142-A; Nurse S, 1996, J CEREBR BLOOD F MET, V16, P474, DOI 10.1097/00004647-199605000-00014; PETITO CK, 1987, NEUROLOGY, V37, P1281, DOI 10.1212/WNL.37.8.1281; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; ROOT RK, 1991, HARRISONS PRINCIPLES, P125; ROUSSEAUX P, 1993, NEUROCHIRURGIE, V39, P157; ROWLAND JP, 1995, MERRITTS TXB NEUROLO, P417; SESSLER DI, 1993, FASEB J, V7, P638, DOI 10.1096/fasebj.7.8.8500688; SEWESTER CS, 1996, DRUG FACTS COMP, pA247; SMITHSON WA, 1983, CANCER TREAT REP, V67, P318; STEEN PA, 1985, ANESTHESIOLOGY, V62, P406, DOI 10.1097/00000542-198504000-00007; WARNER DS, 1993, ANESTHESIOLOGY, V79, P985, DOI 10.1097/00000542-199311000-00017; Wass CT, 1996, INT ANESTHESIOL CLIN, V34, P95, DOI 10.1097/00004311-199603440-00008; WASS CT, 1995, ANESTHESIOLOGY, V83, P325, DOI 10.1097/00000542-199508000-00013; WASS CT, 1995, ANESTHESIOL CLIN N A, V13, P869	33	110	111	0	1	MAYO CLINIC PROCEEDINGS	ROCHESTER	660 SIEBENS BLDG MAYO CLINIC, ROCHESTER, MN 55905 USA	0025-6196			MAYO CLIN PROC	Mayo Clin. Proc.	JUL	1998	73	7					629	635					7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY221	WOS:000074598400003	9663190				2022-02-06	
J	Alderson, P; Roberts, I				Alderson, P; Roberts, I			Corticosteroids in acute traumatic brain injury: Systematic review of randomised controlled trials	BRITISH MEDICAL JOURNAL			English	Article							SEVERE HEAD-INJURY; CLINICAL-TRIAL; DEXAMETHASONE THERAPY; MANAGEMENT; STEROIDS	Objective: To quantify the effectiveness and safety of corticosteroids in the treatment of acute traumatic brain injury. Design: Systematic review of randomised controlled trials of corticosteroids in acute traumatic brain injury. Summary odds ratios were estimated as an inverse variance weighted average of the odds ratios for each study. Setting: Randomised trials available by March 1996. Subjects: The included trials with outcome data comprised 2073 randomised participants. Results: The effect of corticosteroids on the risk of death was reported in 13 included trials. The pooled odds ratio for the 13 trials was 0.91 (95% confidence interval 0.74 to 1.12). Pooled absolute risk reduction was 1.8% (-2.5% to 5.7%). For the 10 trials that reported death or disability the pooled odds ratio was 0.90 (0.72 to 1.11). For infections of any type the pooled odds ratio was 0.92 (0.69 to 1.23) and for the seven trials reporting gastrointestinal bleeding it was 1.05 (0.44 to 2.52). With only those trials with the best quality of concealment of allocation, the pooled odds ratio estimates for death and death or disability became closer to unity. Conclusions: This systematic review of randomised controlled trials of corticosteroids in acute traumatic brain injury shows that there remains considerable uncertainty over their effects. Neither moderate benefits nor moderate harmful effects can be excluded. The widely practicable nature of the drugs and the importance of the health problem suggest that large simple trials are feasible and worth while to establish whether there are any benefits from use of corticosteroids in this setting.	UNIV LONDON,INST CHILD HLTH,LONDON WC1N 1EH,ENGLAND		Alderson, P (corresponding author), UK COCHRANE CTR,NHS RES & DEV PROGRAMME,OXFORD OX2 7LG,ENGLAND.						ALEXANDER E, 1972, CLIN NEUROSURG, V19, P210; BRAAKMAN R, 1983, J NEUROSURG, V58, P326, DOI 10.3171/jns.1983.58.3.0326; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BRAUN SR, 1986, CRIT CARE MED, V14, P198, DOI 10.1097/00003246-198603000-00006; *CDCP, 1996, EP INF  VERS 6 03; *COCHR COLL, 1996, COCHR LIB DAT DISK C; COOPER PR, 1979, J NEUROSURG, V51, P307, DOI 10.3171/jns.1979.51.3.0307; DEARDEN NM, 1986, J NEUROSURG, V64, P81, DOI 10.3171/jns.1986.64.1.0081; DICKERSIN K, 1994, BMJ-BRIT MED J, V309, P1286, DOI 10.1136/bmj.309.6964.1286; FANCONI S, 1988, INTENS CARE MED, V14, P163; Faupel G, 1976, DYNAMICS BRAIN EDEMA, P337; Gaab M R, 1994, Zentralbl Neurochir, V55, P135; GALICICH JH, 1961, AM PRACT DIG TREAT, V12, P169; GIANNOTTA SL, 1984, NEUROSURGERY, V15, P497, DOI 10.1227/00006123-198410000-00004; GRUMME T, 1995, RES EXP MED, V195, P217, DOI 10.1007/BF02576791; Hernesniemi J, 1979, Acta Neurochir Suppl (Wien), V28, P499; HOYT HJ, 1972, PHARMACOL THERAPEUT, V13, P141; Jeevaratnam DR, 1996, BRIT MED J, V312, P944; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; JENNETT B, 1975, LANCET, V1, P480; KLOTI J, 1987, CHILD NERV SYST, V3, P103, DOI 10.1007/BF00271134; Kraus JF, 1993, HEAD INJURY, P1; MILLER JD, 1992, BRIT J SURG, V79, P60, DOI 10.1002/bjs.1800790122; Murray CJL, 1994, GLOBAL COMP ASSESSME; PICKARD JD, 1993, J NEUROL NEUROSUR PS, V56, P845, DOI 10.1136/jnnp.56.8.845; PITTS LH, 1980, INTRACRANIAL PRESSUR, V4, P638; Ransohoff J, 1972, STEROIDS BRAIN EDEMA, P211; ROBERTS I, 1995, BRIT MED J, V310, P1311, DOI 10.1136/bmj.310.6990.1311; SAUL TG, 1981, J NEUROSURG, V54, P596, DOI 10.3171/jns.1981.54.5.0596; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; TAHARA I, 1972, NEUROL MED CHIR TOKY, V12, P111; *TASK FORC AM ASS, 1995, GUID MAN SEV HEAD IN; *UPD SOFTW, 1996, REVM VERS 3 0 WIND; YUSUF S, 1984, STAT MED, V3, P409, DOI 10.1002/sim.4780030421; Zagara G, 1987, J Neurosurg Sci, V31, P207	35	110	116	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 28	1997	314	7098					1855	1859		10.1136/bmj.314.7098.1855			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH738	WOS:A1997XH73800018	9224126	Green Published			2022-02-06	
J	WOOLF, PD				WOOLF, PD			HORMONAL RESPONSES TO TRAUMA	CRITICAL CARE MEDICINE			English	Article						ADRENOCORTICOTROPIN HORMONE; GROWTH HORMONE; PROLACTIN; GLASGOW COMA SCORE; TRAUMA; PITUITARY GLAND; THYROID HORMONES; HYPOPITUITARISM; SEVERITY OF ILLNESS INDEX; GONADOTROPIN	TRANSIENT HYPOGONADOTROPIC HYPOGONADISM; RECENTLY INJURED PATIENTS; LOW-THYROXINE STATE; CLOSED HEAD TRAUMA; THYROID-HORMONE; BRAIN INJURY; THERMAL-INJURY; NONTHYROIDAL ILLNESSES; PLASMA-CORTISOL; CRITICALLY ILL	Objectives: To review the hormonal changes that have been reported after trauma, to define their etiologies, and to describe their consequences. Data Sources: Literature review using MEDLINE and original data. Data Synthesis: Hormonal responses to trauma are bidirectional. Functional derangements include increases in adrenocorticotropin hormone and cortisol, growth hormone, and prolactin levels. In contrast, gonadotropin and gonadal steroid, and thyroid hormone concentrations decrease. The response is immediate but not necessarily sustained for those hormones that respond with increased secretion, whereas the effect may not become apparent for several hours, may be maximal after 1 to 4 days, and may persist for the duration of illness for those hormones that decrease. The reduction in hormone concentrations generally reflect diminished secretion, with the exception of the thyroid hormones where altered metabolic pathways and enhanced metabolic clearance play a major role. Conclusions: The changes in circulating levels do not appear to be injury specific, but tend to reflect the severity of the traumatic insult, and there are some data for cortisol and thyroxine that show their concentrations may be of predictive value. In head-injured patients, structural as well as functional pituitary changes may be present. Patients may show varying degrees of pituitary insufficiency. However, the presence of hyperprolactinemia strongly suggests involvement of the hypothalamus. With the exception of bonafide hypopituitarism, the relevance of the hormonal changes after trauma awaits clarification.	UNIV ROCHESTER, SCH MED & DENT, DEPT MED, ENDOCRINE METAB UNIT, ROCHESTER, NY 14642 USA						NIAAA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [AA7066] Funding Source: Medline		AGRIMONTI F, 1981, J ENDOCRINOL INVEST, V4, P49, DOI 10.1007/BF03349414; AUN F, 1983, J TRAUMA, V23, P1048, DOI 10.1097/00005373-198312000-00005; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BARTALENA L, 1990, J CLIN ENDOCR METAB, V70, P293, DOI 10.1210/jcem-70-1-293; BARTON RN, 1981, CLIN SCI, V61, P399, DOI 10.1042/cs0610399; BARTON RN, 1987, J TRAUMA, V27, P384, DOI 10.1097/00005373-198704000-00007; BECKER RA, 1980, ARCH SURG-CHICAGO, V115, P439; BECKER RA, 1980, J TRAUMA, V20, P713, DOI 10.1097/00005373-198009000-00001; BECKER RA, 1982, CRIT CARE MED, V10, P870, DOI 10.1097/00003246-198212000-00014; BLACK JA, 1977, BURNS, V3, P218, DOI 10.1016/0305-4179(77)90044-4; BRENT GA, 1986, J CLIN ENDOCR METAB, V63, P1; BRIZIOMOLTENI L, 1984, J TRAUMA, V24, P1, DOI 10.1097/00005373-198401000-00001; CAREY LC, 1971, ANN SURG, V174, P451, DOI 10.1097/00000658-197109000-00014; Ceballos R, 1966, Ala J Med Sci, V3, P185; CHERNOW B, 1987, ARCH INTERN MED, V147, P1273, DOI 10.1001/archinte.147.7.1273; CHIOLERO R, 1988, J TRAUMA, V28, P1368, DOI 10.1097/00005373-198809000-00011; CHIOLERO RL, 1988, ACTA ENDOCRINOL-COP, V117, P80, DOI 10.1530/acta.0.1170080; CHOPRA IJ, 1980, J CLIN ENDOCR METAB, V51, P135, DOI 10.1210/jcem-51-1-135; CLARK JDA, 1988, CLIN ENDOCRINOL, V29, P153, DOI 10.1111/j.1365-2265.1988.tb00257.x; COPE O, 1953, ANN SURG, V137, P165, DOI 10.1097/00000658-195302000-00003; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; CYRAU E, 1918, BERL KLIN WCHNSCHR, V55, P1059; CYTOWIC RE, 1986, NEW ENGL J MED, V314, P715; DANIEL PM, 1959, LANCET, V2, P927; DESAI D, 1989, J TRAUMA, V29, P719, DOI 10.1097/00005373-198906000-00003; DOLECEK R, 1983, ENDOCRINOL EXP, V17, P33; DOLECEK R, 1979, SCAND J PLAST RECONS, V13, P9, DOI 10.3109/02844317909013013; EDWARDS OM, 1986, MEDICINE, V65, P281; ESTEP HL, 1966, J CLIN ENDOCR METAB, V26, P513, DOI 10.1210/jcem-26-5-513; FAGLIA G, 1979, J CLIN ENDOCR METAB, V48, P989, DOI 10.1210/jcem-48-6-989; FEIBEL J, 1983, J CLIN ENDOCR METAB, V57, P1245, DOI 10.1210/jcem-57-6-1245; FLEISCHER AS, 1978, J NEUROSURG, V49, P650, DOI 10.3171/jns.1978.49.5.0650; FOK ACK, 1989, AUST NZ J MED, V19, P354, DOI 10.1111/j.1445-5994.1989.tb00279.x; FRAYN KN, 1984, CLIN ENDOCRINOL, V20, P179, DOI 10.1111/j.1365-2265.1984.tb00073.x; FRAYN KN, 1983, AGE AGEING, V12, P70, DOI 10.1093/ageing/12.1.70; GANN DS, 1979, NEPHRON, V23, P119, DOI 10.1159/000181620; HARRISON TS, 1967, ANN SURG, V165, P169, DOI 10.1097/00000658-196702000-00002; HOLNESS RO, 1983, J NEUROSURG, V59, P677, DOI 10.3171/jns.1983.59.4.0677; HUME DM, 1959, ANN SURG, V150, P697, DOI 10.1097/00000658-195910000-00013; JACKSON RD, 1989, AM J PHYS MED REHAB, V68, P18, DOI 10.1097/00002060-198902000-00006; JENNETT B, 1975, LANCET, V1, P480; KAPTEIN EM, 1982, CLIN ENDOCRINOL, V16, P565, DOI 10.1111/j.1365-2265.1982.tb03173.x; KAPTEIN EM, 1982, J CLIN INVEST, V69, P526, DOI 10.1172/JCI110478; KENNEY PR, 1983, J TRAUMA, V23, P712, DOI 10.1097/00005373-198308000-00006; KIKUCHI K, 1988, J CLIN ENDOCR METAB, V67, P817, DOI 10.1210/jcem-67-4-817; KING LR, 1981, NEUROSURGERY, V9, P229, DOI 10.1227/00006123-198109000-00002; KING LR, 1970, ANN SURG, V172, P975, DOI 10.1097/00000658-197012000-00008; KORNBLUM RN, 1969, ARCH PATHOL, V88, P242; LEE LA, 1986, CLIN CHEM, V32, P797; LEEBAW WF, 1978, J CLIN ENDOCR METAB, V47, P480, DOI 10.1210/jcem-47-3-480; LEPHART ED, 1987, J CLIN ENDOCR METAB, V64, P842, DOI 10.1210/jcem-64-4-842; MADSEN M, 1986, ACTA CHIR SCAND, V152, P91; MADSEN M, 1986, ACTA CHIR SCAND, V152, P413; MASTERS JN, 1989, ENDOCRINOLOGY, V124, P3083, DOI 10.1210/endo-124-6-3083; MATSUURA H, 1985, NEUROSURGERY, V16, P791, DOI 10.1227/00006123-198506000-00009; MILLER WL, 1980, NEW ENGL J MED, V302, P724, DOI 10.1056/NEJM198003273021305; MOLTENI A, 1979, ANN CLIN LAB SCI, V9, P518; MOUSSALLI C, 1986, MIL MED, V151, P120, DOI 10.1093/milmed/151.2.120; PARKER CR, 1985, J TRAUMA, V25, P508, DOI 10.1097/00005373-198506000-00006; PARKER LN, 1985, J CLIN ENDOCR METAB, V60, P947, DOI 10.1210/jcem-60-5-947; PENTELENYI T, 1984, INJURY, V15, P397, DOI 10.1016/0020-1383(84)90205-5; PHILLIPS RH, 1984, J TRAUMA, V24, P116, DOI 10.1097/00005373-198402000-00004; PLYMATE SR, 1987, HORM RES, V27, P152, DOI 10.1159/000180803; POPP MB, 1977, SURG GYNECOL OBSTET, V145, P517; ROMIJN JA, 1990, J CLIN ENDOCR METAB, V70, P35, DOI 10.1210/jcem-70-1-35; RUDMAN D, 1977, J CLIN ENDOCR METAB, V45, P747, DOI 10.1210/jcem-45-4-747; SAPOLSKY RM, 1987, TRENDS NEUROSCI, V10, P346, DOI 10.1016/0166-2236(87)90065-8; SEMPLE CG, 1987, BRIT MED J, V295, P403, DOI 10.1136/bmj.295.6595.403; SHAUL PW, 1985, AM J DIS CHILD, V139, P467, DOI 10.1001/archpedi.1985.02140070041029; SMITH PJ, 1984, ENDOCR REV, V5, P514, DOI 10.1210/edrv-5-4-514; SOCKALOSKY JJ, 1987, J PEDIATR-US, V110, P373, DOI 10.1016/S0022-3476(87)80497-3; STEINBOK P, 1979, NEUROSURGERY, V5, P559, DOI 10.1227/00006123-197911000-00003; STONER HB, 1979, CLIN SCI, V56, P563, DOI 10.1042/cs0560563; TAMASAWA N, 1988, J ENDOCRINOL INVEST, V11, P429, DOI 10.1007/BF03349076; THOMASSON B, 1959, Scand J Clin Lab Invest, V11 Suppl 42, P1; UDELSMAN R, 1987, J CLIN ENDOCR METAB, V64, P986, DOI 10.1210/jcem-64-5-986; VAUGHAN GM, 1982, J TRAUMA, V22, P263, DOI 10.1097/00005373-198204000-00001; VELDHUIS JD, 1988, CLIN RES, V36, P11; VOGEL AV, 1985, J CLIN ENDOCR METAB, V60, P658, DOI 10.1210/jcem-60-4-658; WADE CE, 1988, J CLIN ENDOCR METAB, V67, P223, DOI 10.1210/jcem-67-2-223; WARTOFSKY L, 1982, ENDOCR REV, V3, P164, DOI 10.1210/edrv-3-2-164; WEHMANN RE, 1985, NEW ENGL J MED, V312, P546, DOI 10.1056/NEJM198502283120904; WILMORE DW, 1975, J TRAUMA, V15, P697, DOI 10.1097/00005373-197508000-00012; WILMORE DW, 1974, ANN SURG, V180, P653, DOI 10.1097/00000658-197410000-00031; WISE L, 1972, ARCH SURG-CHICAGO, V105, P213; WOOLF PD, 1990, ALCOHOL CLIN EXP RES, V14, P917, DOI 10.1111/j.1530-0277.1990.tb01838.x; WOOLF PD, 1986, CLIN ENDOCRINOL, V25, P265, DOI 10.1111/j.1365-2265.1986.tb01691.x; WOOLF PD, 1985, J CLIN ENDOCR METAB, V60, P444, DOI 10.1210/jcem-60-3-444; WOOLF PD, 1988, AM J MED, V84, P201, DOI 10.1016/0002-9343(88)90414-7; WOOLF PD, 1974, J CLIN ENDOCR METAB, V38, P71, DOI 10.1210/jcem-38-1-71; ZALOGA GP, 1985, ANN SURG, V201, P456, DOI 10.1097/00000658-198504000-00010; ZIEGLER MG, 1990, CRIT CARE MED, V18, P253, DOI 10.1097/00003246-199003000-00001; [No title captured]	93	110	112	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	FEB	1992	20	2					216	226		10.1097/00003246-199202000-00011			11	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC983	WOS:A1992HC98300011	1737456				2022-02-06	
J	JENNETT, WB; LEWIN, W				JENNETT, WB; LEWIN, W			TRAUMATIC EPILEPSY AFTER CLOSED HEAD INJURIES	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article																	ASCROFT PB, 1941, BRIT MED J, V1, P739; FEINBERG P, 1934, EPILEPSIE TRAUMA; GARLAND HG, 1942, P ROY SOC MED, V35, P773; GURDJIAN ES, 1958, HEAD INJURIES; LEWIN W, 1953, BMJ-BRIT MED J, V1, P1239, DOI 10.1136/bmj.1.4822.1239; Penfield W, 1954, EPILEPSY FUNCTIONAL; PENFIELD W, 1945, RES PUBL ASSOC RES N, V24, P620; PHILLIPS G, 1954, J NEUROL NEUROSUR PS, V17, P1, DOI 10.1136/jnnp.17.1.1; Rowbotham GF, 1942, ACUTE INJURIES HEAD; RUSSELL WR, 1952, J NEUROL NEUROSUR PS, V15, P93, DOI 10.1136/jnnp.15.2.93; RUSSELL WR, 1932, P ROY SOC MED, V25, P751; SYMONDS CP, 1935, LANCET, V2, P1217; Wagstaffe WW, 1928, LANCET, V2, P861; Walton JN, 1956, SUBARACHNOID HAEMORR	14	110	110	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry		1960	23	4					295	301		10.1136/jnnp.23.4.295			7	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	XG402	WOS:A1960XG40200004	13789853	Bronze, Green Published			2022-02-06	
J	Shively, SB; Horkayne-Szakaly, I; Jones, RV; Kelly, JP; Armstrong, RC; Perl, DP				Shively, Sharon Baughman; Horkayne-Szakaly, Iren; Jones, Robert V.; Kelly, James P.; Armstrong, Regina C.; Perl, Daniel P.			Characterisation of interface astroglial scarring in the human brain after blast exposure: a post-mortem case series	LANCET NEUROLOGY			English	Article							CHRONIC TRAUMATIC ENCEPHALOPATHY; POSTTRAUMATIC-STRESS-DISORDER; U.S. MILITARY PERSONNEL; HEAD-INJURY; EXPLOSIVE BLAST; MODEL; PATHOLOGY; IRAQ	Background No evidence-based guidelines are available for the definitive diagnosis or directed treatment of most blast-associated traumatic brain injuries, partly because the underlying pathology is unknown. Moreover, few neuropathological studies have addressed whether blast exposure produces unique lesions in the human brain, and if those lesions are comparable with impact-induced traumatic brain injury. We aimed to test the hypothesis that blast exposure produces unique patterns of damage, differing from that associated with impact-induced, non-blast traumatic brain injuries. Methods In this post-mortem case series, we investigated several features of traumatic brain injuries, using clinical histopathology techniques and markers, in brain specimens from male military service members with chronic blast exposures and from those who had died shortly after severe blast exposures. We then compared these results with those from brain specimens from male civilian (ie, non-military) cases with no history of blast exposure, including cases with and without chronic impact traumatic brain injuries and cases with chronic exposure to opiates, and analysed the limited associated clinical histories of all cases. Brain specimens had been archived in tissue banks in the USA. Findings We analysed brain specimens from five cases with chronic blast exposure, three cases with acute blast exposure, five cases with chronic impact traumatic brain injury, five cases with exposure to opiates, and three control cases with no known neurological disorders. All five cases with chronic blast exposure showed prominent astroglial scarring that involved the subpial glial plate, penetrating cortical blood vessels, grey white matter junctions, and structures lining the ventricles; all cases of acute blast exposure showed early astroglial scarring in the same brain regions. All cases of chronic blast exposure had an antemortem diagnosis of post traumatic stress disorder. The civilian cases, with or without history of impact traumatic brain injury or a history of opiate use, did not have any astroglial scarring in the brain regions analysed. Interpretation The blast exposure cases showed a distinct and previously undescribed pattern of interface astroglial scarring at boundaries between brain parenchyma and fluids, and at junctions between grey and white matter. This distinctive pattern of scarring may indicate specific areas of damage from blast exposure consistent with the general principles of blast biophysics, and further, could account for aspects of the neuropsychiatric clinical sequelae reported. The generalisability of these findings needs to be explored in future studies, as the number of cases, clinical data, and tissue availability were limited.	[Shively, Sharon Baughman; Perl, Daniel P.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Pathol, Bethesda, MD 20814 USA; [Armstrong, Regina C.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; [Shively, Sharon Baughman; Armstrong, Regina C.; Perl, Daniel P.] Ctr Neurosci & Regenerat Med, Bethesda, MD USA; [Horkayne-Szakaly, Iren; Jones, Robert V.] Def Hlth Agcy, Joint Pathol Ctr, Silver Spring, MD USA; [Kelly, James P.] Univ Colorado, Sch Med, Dept Neurosurg, Aurora, CO USA; [Shively, Sharon Baughman] Henry M Jackson Fdn Adv Mil Med, Bethesda, MD USA		Perl, DP (corresponding author), Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Ctr Neurosci & Regenerat Med, Dept Pathol, Bethesda, MD 20814 USA.	daniel.perl@usuhs.edu			Defense Health Program of the United States Department of Defense	This study was funded by the Defense Health Program of the United States Department of Defense. This study utilized neuropathology core facilities of the Center for Neuroscience and Regenerative Medicine (CNRM), Uniformed Services University of the Health Sciences (USUHS), and The Joint Pathology Center (JPC), within the US Department of Defense. We thank Charles Rice, Thomas Baker, Arthur Kellermann, and Steven Kaminsky for their continuous encouragement and support; and Patricia Lee for histotechnology support and Leslie Sawyers for administrative support. Human tissue for most civilian cases was obtained from University of Maryland Brain and Tissue Bank (UMB BTB), which is a Brain and Tissue Repository of the NIH NeuroBioBank. The opinions expressed herein are those of the authors and are not necessarily representative of those of the Uniformed Services University of the Health Sciences (USUHS), the Department of Defense (DOD); or, the United States Army, Navy, or Air Force.	Bass CR, 2012, ANN BIOMED ENG, V40, P185, DOI 10.1007/s10439-011-0424-0; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI [10.1089/neu.2008.0898, 10.1089/neu.2009-0898]; Benzinger T., 1950, GERMAN AVIATION MED, V2, P1225; Cameron KL, 2012, J NEUROTRAUM, V29, P1313, DOI 10.1089/neu.2011.2168; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chase RP, 2015, J HEAD TRAUMA REHAB, V30, pE57, DOI 10.1097/HTR.0000000000000061; COHEN H, 1946, ARCH PATHOL, V42, P12; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; CRAMER F, 1949, ARCH NEURO PSYCHIATR, V61, P1; de Lanerolle NC, 2011, J NEUROPATH EXP NEUR, V70, P1046, DOI 10.1097/NEN.0b013e318235bef2; Elder GA, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00269; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Gupta RK, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00059; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iliff JJ, 2014, J NEUROSCI, V34, P16180, DOI 10.1523/JNEUROSCI.3020-14.2014; Kocsis JD, 2009, J REHABIL RES DEV, V46, P667, DOI 10.1682/JRRD.2008.08.0100; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Mac Donald CL, 2015, BRAIN, V138, P1314, DOI 10.1093/brain/awv038; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2014, ALZHEIMERS DEMENT, V10, pS242, DOI 10.1016/j.jalz.2014.04.003; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mott F W, 1917, Br Med J, V2, P612; Mott F. W., 1919, WAR NEUROSES SHELL S; Mott FW, 1916, LANCET, V1, P441; Mott FW, 1916, LANCET, V1, P331; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Petrie EC, 2014, J NEUROTRAUM, V31, P425, DOI [10.1089/NEU.2013.2952, 10.1089/neu.2013.2952]; Pitman RK, 2012, NAT REV NEUROSCI, V13, P769, DOI 10.1038/nrn3339; Ritenour AE, 2010, ANN SURG, V251, P1140, DOI 10.1097/SLA.0b013e3181e01270; Rosenfeld JV, 2013, LANCET NEUROL, V12, P882, DOI 10.1016/S1474-4422(13)70161-3; Ruff RL, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000312; Ryu J, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0153-3; Simard JM, 2014, J NEUROTRAUM, V31, P1292, DOI 10.1089/neu.2013.3016; Stahl S., 2013, STAHLS ESSENTIAL PSY; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; The Management of Concussion/mTBI Working Group, 2009, VA DOD CLIN PRACT GU; Xie LL, 2013, SCIENCE, V342, P373, DOI 10.1126/science.1241224	41	109	110	0	18	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2016	15	9					944	953		10.1016/S1474-4422(16)30057-6			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DT1YY	WOS:000381279200014	27291520	Bronze			2022-02-06	
J	Jacka, FN; Cherbuin, N; Anstey, KJ; Sachdev, P; Butterworth, P				Jacka, Felice N.; Cherbuin, Nicolas; Anstey, Kaarin J.; Sachdev, Perminder; Butterworth, Peter			Western diet is associated with a smaller hippocampus: a longitudinal investigation	BMC MEDICINE			English	Article						Brain derived neurotrophic factor; Hippocampus; Diet; Magnetic resonance imaging; Neurogenesis; Nutrition	TRAUMATIC BRAIN-INJURY; SATURATED-FAT DIET; NEUROTROPHIC FACTOR; MEDITERRANEAN DIET; COGNITIVE IMPAIRMENT; AMYGDALA VOLUMES; OXIDATIVE STRESS; DEPRESSION; NEUROGENESIS; DISEASE	Background: Recent meta-analyses confirm a relationship between diet quality and both depression and cognitive health in adults. While the biological pathways that underpin these relationships are likely multitudinous, extensive evidence from animal studies points to the involvement of the hippocampus. The aim of this study was to examine the association between dietary patterns and hippocampal volume in humans, and to assess whether diet was associated with differential rates of hippocampal atrophy over time. Methods: Data were drawn from the Personality and Total Health Through Life Study and focused on a subsample of the cohort (n = 255) who were aged 60-64 years at baseline in 2001, completed a food frequency questionnaire, and underwent two magnetic resonance imaging scans approximately 4 years apart. Longitudinal generalized estimating equation linear regression models were used to assess the association between dietary factors and left and right hippocampal volumes over time. Results: Every one standard deviation increase in healthy "prudent" dietary pattern was associated with a 45.7 mm(3) (standard error 22.9 mm(3)) larger left hippocampal volume, while higher consumption of an unhealthy " Western" dietary pattern was (independently) associated with a 52.6 mm(3) (SE 26.6 mm(3)) smaller left hippocampal volume. These relationships were independent of covariates including age, gender, education, labour-force status, depressive symptoms and medication, physical activity, smoking, hypertension and diabetes. While hippocampal volume declined over time, there was no evidence that dietary patterns influenced this decline. No relationships were observed between dietary patterns and right hippocampal volume. Conclusions: Lower intakes of nutrient-dense foods and higher intakes of unhealthy foods are each independently associated with smaller left hippocampal volume. To our knowledge, this is the first human study to demonstrate associations between diet and hippocampal volume concordant with data previously observed in animal models.	[Jacka, Felice N.] Deakin Univ, IMPACT Strateg Res Ctr, Div Nutr Psychiat Res, Geelong, Vic 3217, Australia; [Jacka, Felice N.] Univ Melbourne, Dept Psychiat, Melbourne, Vic, Australia; [Jacka, Felice N.] Murdoch Childrens Res Inst, Ctr Adolescent Hlth, Melbourne, Vic, Australia; [Jacka, Felice N.] Black Dog Inst, Sydney, NSW, Australia; [Cherbuin, Nicolas; Anstey, Kaarin J.; Butterworth, Peter] Australian Natl Univ, Ctr Res Ageing Hlth & Wellbeing, Res Sch Populat Hlth, Canberra, ACT, Australia; [Sachdev, Perminder] Univ New S Wales, Fac Med, Sch Psychiat, CHeBA, Sydney, NSW, Australia		Jacka, FN (corresponding author), Deakin Univ, IMPACT Strateg Res Ctr, Div Nutr Psychiat Res, Geelong, Vic 3217, Australia.	f.jacka@deakin.edu.au	Jacka, Felice N/D-9424-2012; Cherbuin, Nicolas/A-8515-2008; Anstey, Kaarin/A-3852-2008; Sachdev, Perminder/ABC-1137-2020	Jacka, Felice N/0000-0002-9825-0328; Cherbuin, Nicolas/0000-0001-6481-0748; Anstey, Kaarin/0000-0002-9706-9316; Sachdev, Perminder/0000-0002-9595-3220; Butterworth, Peter/0000-0002-1531-3881	Deakin University; Brain and Behaviour Research Institute; National Health and Medical Research Council (NHMRC)National Health and Medical Research Council of Australia; Australian Rotary Health; Geelong Medical Research Foundation; Ian Potter Foundation; Eli LillyEli Lilly; Meat and Livestock Board; University of MelbourneUniversity of Melbourne; NHMRC Research FellowshipNational Health and Medical Research Council of Australia [1002560]; ARC Future FellowshipAustralian Research Council [120100227, FT130101444]; NHMRCNational Health and Medical Research Council of Australia [973302, 179805, 350833, 157125, 1063907]	FNJ is funded by Deakin University and has received Grant/Research support from the Brain and Behaviour Research Institute, the National Health and Medical Research Council (NHMRC), Australian Rotary Health, the Geelong Medical Research Foundation, the Ian Potter Foundation, Eli Lilly, the Meat and Livestock Board and The University of Melbourne and has received speakers' honoraria from Sanofi-Synthelabo, Janssen Cilag, Servier, Pfizer, Health Ed, Network Nutrition, Angelini Farmaceutica, and Eli Lilly. KJA is funded by NHMRC Research Fellowship No. 1002560. NC is funded by an ARC Future Fellowship No. 120100227. PB is funded by an ARC Future Fellowship # FT130101444. The PATH study was supported by NHMRC Grants No. 973302, Program Grants No. 179805 and 350833, and NHMRC project grant No. 157125 and 1063907. The authors are grateful to Anthony Jorm, Bryan Rodgers, Helen Christensen, Simon Easteal, Patricia Jacomb, Karen Maxwell, and the PATH interviewers and participants. PB had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.	Adair LS, 2005, OBES RES, V13, P1281, DOI 10.1038/oby.2005.153; ALBANES D, 1995, AM J CLIN NUTR, V62, P1427, DOI 10.1093/ajcn/62.6.1427S; An L, 2008, PROG NEURO-PSYCHOPH, V32, P1484, DOI 10.1016/j.pnpbp.2008.05.005; Anstey KJ, 2012, INT J EPIDEMIOL, V41, P951, DOI 10.1093/ije/dyr025; Anstey KJ, 2004, NEUROREPORT, V15, P2825; Beilharz JE, 2014, BRAIN BEHAV IMMUN, V37, P134, DOI 10.1016/j.bbi.2013.11.016; Berk M, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-200; Cherbuin N, 2012, NEUROLOGY, V79, P1019, DOI 10.1212/WNL.0b013e31826846de; Cherbuin N, 2012, AM J GERIAT PSYCHIAT, V20, P635, DOI 10.1097/JGP.0b013e31823032a9; Das S, 2008, J NEUROSCI RES, V86, P1199, DOI 10.1002/jnr.21585; Dash S, 2015, CURR OPIN PSYCHIATR, V28, P1, DOI 10.1097/YCO.0000000000000117; Dias GP, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/541971; Edwards LM, 2011, FASEB J, V25, P1088, DOI 10.1096/fj.10-171983; Fotuhi M, 2009, NAT CLIN PRACT NEURO, V5, P140, DOI 10.1038/ncpneuro1044; Fraser MA, 2015, NEUROIMAGE, V112, P364, DOI 10.1016/j.neuroimage.2015.03.035; Frodl T, 2008, J PSYCHIATR NEUROSCI, V33, P423; Gardener S, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.91; Giannakopoulos P, 2009, STROKE, V40, P983, DOI 10.1161/STROKEAHA.108.530337; GOLDBERG D, 1988, BRIT MED J, V297, P897, DOI 10.1136/bmj.297.6653.897; Granzotto A, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00095; Guimaraes LR, 2008, PROG NEURO-PSYCHOPH, V32, P1595, DOI 10.1016/j.pnpbp.2008.06.004; Heyward FD, 2012, NEUROBIOL LEARN MEM, V98, P25, DOI 10.1016/j.nlm.2012.04.005; Jacka FN, 2014, BMC PSYCHIATRY, V14, DOI 10.1186/1471-244X-14-132; Jacka FN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087657; Jacka FN, 2011, PSYCHOSOM MED, V73, P483, DOI 10.1097/PSY.0b013e318222831a; Jacka FN, 2010, AM J PSYCHIAT, V167, P305, DOI 10.1176/appi.ajp.2009.09060881; Kawakita E, 2006, NEUROSCIENCE, V139, P991, DOI 10.1016/j.neuroscience.2006.01.021; Lai JS, 2014, AM J CLIN NUTR, V99, P181, DOI 10.3945/ajcn.113.069880; Lassale C, 2009, J HUM NUTR DIET, V22, P559, DOI 10.1111/j.1365-277X.2009.00990.x; Lee S, 2010, NEUROCHEM RES, V35, P1725, DOI 10.1007/s11064-010-0235-y; Malberg JE, 2000, J NEUROSCI, V20, P9104, DOI 10.1523/jneurosci.20-24-09104.2000; Maller JJ, 2007, PSYCHIAT RES-NEUROIM, V156, P185, DOI 10.1016/j.pscychresns.2007.06.005; Maller JJ, 2006, HIPPOCAMPUS, V16, P80, DOI 10.1002/hipo.20133; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; Martire SI, 2014, BEHAV BRAIN RES, V265, P132, DOI 10.1016/j.bbr.2014.02.027; Molteni R, 2002, NEUROSCIENCE, V112, P803, DOI 10.1016/S0306-4522(02)00123-9; Morrison CD, 2010, J NEUROCHEM, V114, P1581, DOI 10.1111/j.1471-4159.2010.06865.x; Moylan S, 2014, NEUROSCI BIOBEHAV R, V45, P46, DOI 10.1016/j.neubiorev.2014.05.007; O'Neil A, 2014, AM J PUBLIC HEALTH, V104, pE31, DOI 10.2105/AJPH.2014.302110; Psaltopoulou T, 2013, ANN NEUROL, V74, P580, DOI 10.1002/ana.23944; Ross AP, 2009, NEUROBIOL LEARN MEM, V92, P410, DOI 10.1016/j.nlm.2009.05.007; Samieri C, 2013, J NUTR, V143, P493, DOI 10.3945/jn.112.169896; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; Sapolsky RM, 2000, ARCH GEN PSYCHIAT, V57, P925, DOI 10.1001/archpsyc.57.10.925; Sarris J, 2015, LANCET PSYCHIAT, V2, P271, DOI 10.1016/S2215-0366(14)00051-0; Scarmeas N, 2006, ANN NEUROL, V59, P912, DOI 10.1002/ana.20854; Sen S, 2008, BIOL PSYCHIAT, V64, P527, DOI 10.1016/j.biopsych.2008.05.005; Shi F, 2009, HIPPOCAMPUS, V19, P1055, DOI 10.1002/hipo.20573; Swinburn BA, 2011, LANCET, V378, P804, DOI 10.1016/S0140-6736(11)60813-1; Thompson PM, 2007, ANN NY ACAD SCI, V1097, P183, DOI 10.1196/annals.1379.017; Valente T, 2009, J ALZHEIMERS DIS, V18, P849, DOI 10.3233/JAD-2009-1188; Videbech P, 2004, AM J PSYCHIAT, V161, P1957, DOI 10.1176/appi.ajp.161.11.1957; WATSON C, 1992, NEUROLOGY, V42, P1743, DOI 10.1212/WNL.42.9.1743; Williams CM, 2008, FREE RADICAL BIO MED, V45, P295, DOI 10.1016/j.freeradbiomed.2008.04.008; World Health Organization, 2010, GLOBAL STATUS REPORT; Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457; Wu A, 2003, NEUROSCIENCE, V119, P365, DOI 10.1016/S0306-4522(03)00154-4; Wu AG, 2004, EUR J NEUROSCI, V19, P1699, DOI 10.1111/j.1460-9568.2004.03246.x; Zainuddin MSA, 2012, BRIT MED BULL, V103, P89, DOI 10.1093/bmb/lds021	59	109	111	4	42	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1741-7015			BMC MED	BMC Med.	SEP 8	2015	13								215	10.1186/s12916-015-0461-x			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CQ7SU	WOS:000360805300001	26349802	Green Published, gold			2022-02-06	
J	Ransom, DM; Vaughan, CG; Pratson, L; Sady, MD; McGill, CA; Gioia, GA				Ransom, Danielle M.; Vaughan, Christopher G.; Pratson, Lincoln; Sady, Maegan D.; McGill, Catherine A.; Gioia, Gerard A.			Academic Effects of Concussion in Children and Adolescents	PEDIATRICS			English	Article							SPORT	OBJECTIVE: The aim of this work is to study the nature and extent of the adverse academic effects faced by students recovering from concussion. METHOD: A sample of 349 students ages 5 to 18 who sustained a concussion and their parents reported academic concerns and problems (eg, symptoms interfering, diminished academic skills) on a structured school questionnaire within 4 weeks of injury. Postconcussion symptoms were measured as a marker of injury severity. Results were examined based on recovery status (recovered or actively symptomatic) and level of schooling (elementary, middle, and high school). RESULTS: Actively symptomatic students and their parents reported higher levels of concern for the impact of concussion on school performance (P < .05) and more school-related problems (P < .001) than recovered peers and their parents. High school students who had not yet recovered reported significantly more adverse academic effects than their younger counterparts (P < .05). Greater severity of postconcussion symptoms was associated with more school-related problems and worse academic effects, regardless of time since injury (P < .001). CONCLUSIONS: This study provides initial evidence for a concussion's impact on academic learning and performance, with more adverse effects reported by students who had not yet recovered from the injury. School-based management with targeted recommendations informed by postinjury symptoms may mitigate adverse academic effects, reduce parent and student concerns for the impact of the injury on learning and scholastic performance, and lower the risk of prolonged recovery for students with active postconcussion symptoms.	[Ransom, Danielle M.; Vaughan, Christopher G.; Sady, Maegan D.; McGill, Catherine A.; Gioia, Gerard A.] Childrens Natl Hlth Syst, Washington, DC USA; [Ransom, Danielle M.; Vaughan, Christopher G.; Sady, Maegan D.; McGill, Catherine A.; Gioia, Gerard A.] George Washington Univ, Sch Med, Washington, DC USA; [Pratson, Lincoln] E Carolina Univ, Brody Sch Med, Greenville, NC USA		Gioia, GA (corresponding author), Childrens Natl Hlth Syst, Div Neuropsychol, 15425 Shady Grove Rd,Suite 350, Rockville, MD 20850 USA.	ggioia@childrensnational.org					Gioia GA, 2016, J CHILD NEUROL, V31, P93, DOI 10.1177/0883073814555604; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Halstead ME, 2013, PEDIATRICS, V132, P948, DOI 10.1542/peds.2013-2867; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; McAvoy K, 2009, REAP BENEFITS GOOD C; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Sady MD, 2014, ARCH CLIN NEUROPSYCH, V29, P348, DOI 10.1093/arclin/acu014; Sady MD, 2011, PHYS MED REH CLIN N, V22, P701, DOI 10.1016/j.pmr.2011.08.008	10	109	110	0	19	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	JUN	2015	135	6					1043	1050		10.1542/peds.2014-3434			8	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	CJ5UR	WOS:000355557400042	25963014				2022-02-06	
J	Bryant, RA; Nickerson, A; Creamer, M; O'Donnell, M; Forbes, D; Galatzer-Levy, I; McFarlane, AC; Silove, D				Bryant, Richard A.; Nickerson, Angela; Creamer, Mark; O'Donnell, Meaghan; Forbes, David; Galatzer-Levy, Isaac; McFarlane, Alexander C.; Silove, Derrick			Trajectory of post-traumatic stress following traumatic injury: 6-year follow-up	BRITISH JOURNAL OF PSYCHIATRY			English	Article							BRAIN-INJURY; RISK-FACTORS; WHOQOL-BREF; DISORDER; RESILIENCE; PTSD; EXTINCTION; DEPRESSION; GROWTH; US	Background Traumatic injuries affect millions of patients each year, and resulting post-traumatic stress disorder (PTSD) significantly contributes to subsequent impairment. Aims To map the distinctive long-term trajectories of PTSD responses over 6 years by using latent growth mixture modelling. Method Randomly selected injury patients (n = 1084) admitted to four hospitals around Australia were assessed in hospital, and at 3, 12, 24 and 72 months. Lifetime psychiatric history and current PTSD severity and functioning were assessed. Results Five trajectories of PTSD response were noted across the 6 years: (a) chronic (4%), (b) recovery (6%), (c) worsening/recovery (8%), (d) worsening (10%) and (e) resilient (73%). A poorer trajectory was predicted by female gender, recent life stressors, presence of mild traumatic brain injury and admission to intensive care unit. Conclusions These findings demonstrate the long-term PTSD effects that can occur following traumatic injury. The different trajectories highlight that monitoring a subset of patients over time is probably a more accurate means of identifying PTSD rather than relying on factors that can be assessed during hospital admission. (C) The Royal College of Psychiatrists 2015.	[Bryant, Richard A.; Nickerson, Angela] Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia; [Bryant, Richard A.] Univ Sydney, Brain Dynam Ctr, Sydney, NSW 2006, Australia; [Bryant, Richard A.] Westmead Millennium Inst, Sydney, NSW, Australia; [Creamer, Mark; O'Donnell, Meaghan; Forbes, David] Univ Melbourne, Australian Ctr Posttraumat Mental Hlth, Dept Psychiat, Melbourne, Vic 3010, Australia; [Galatzer-Levy, Isaac] NYU, Dept Psychiat, New York, NY 10016 USA; [McFarlane, Alexander C.] Univ Adelaide, Ctr Mil & Veteran Hlth, Adelaide, SA, Australia; [Silove, Derrick] Univ New S Wales, Sch Psychiat, Sydney, NSW 2052, Australia		Bryant, RA (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.	r.bryant@unsw.edu.au	Bryant, Richard/AAA-6479-2019	Bryant, Richard/0000-0002-9607-819X; Nickerson, Angela/0000-0001-9171-4209; Forbes, David/0000-0001-9145-1605; Galatzer-Levy, Isaac/0000-0003-1864-064X; O'Donnell, Meaghan/0000-0003-4349-0022			American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Aziz Mohamed A, 2004, J Psychiatr Pract, V10, P307, DOI 10.1097/00131746-200409000-00004; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Blake DD, 1998, CLIN ADM PTSD SCALE; Bonanno GA, 2012, REHABIL PSYCHOL, V57, P236, DOI 10.1037/a0029256; Bonanno GA, 2012, BRIT J PSYCHIAT, V200, P317, DOI 10.1192/bjp.bp.111.096552; BRESLAU N, 1995, AM J PSYCHIAT, V152, P529; Brewin CR, 2000, J CONSULT CLIN PSYCH, V68, P748, DOI 10.1037/0022-006X.68.5.748; BRUGHA T, 1985, PSYCHOL MED, V15, P189, DOI 10.1017/S003329170002105X; Bryant RA, 2003, BIOL PSYCHIAT, V53, P789, DOI 10.1016/S0006-3223(02)01895-4; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; DeRoon-Cassini TA, 2010, REHABIL PSYCHOL, V55, P1, DOI 10.1037/a0018601; Harper A, 1998, PSYCHOL MED, V28, P551, DOI 10.1017/S0033291798006667; Hawthorne G, 2006, SOC INDIC RES, V77, P37, DOI 10.1007/s11205-005-5552-1; Hobfoll SE, 2006, J TRAUMA STRESS, V19, P867, DOI 10.1002/jts.20166; Kaplan D., 2004, SAGE HDB QUANTITATIV, P345, DOI DOI 10.4135/9781412986311.N19; McFarlane AC, 2010, WORLD PSYCHIATRY, V9, P3; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Muthen L.K., 2012, MPLUS USERS GUIDE, V7; Norrholm SD, 2006, LEARN MEMORY, V13, P681, DOI 10.1101/lm.393906; Norris FH, 2009, SOC SCI MED, V68, P2190, DOI 10.1016/j.socscimed.2009.03.043; Pietrzak RH, 2013, J PSYCHIATR RES, V47, P520, DOI 10.1016/j.jpsychires.2012.12.005; Post Robert M., 1995, P203; Rauch SL, 2006, BIOL PSYCHIAT, V60, P376, DOI 10.1016/j.biopsych.2006.06.004; Shalev AY, 2000, AM J PSYCHIAT, V157, P255, DOI 10.1176/appi.ajp.157.2.255; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Smid GE, 2012, PSYCHOL MED, V42, P1675, DOI 10.1017/S0033291711002765; Stein MB, 1997, AM J PSYCHIAT, V154, P1114; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; World Health Organization, 1992, ICD 10 CLASSIFICATIO; Zatzick DF, 2007, PSYCHOL MED, V37, P1469, DOI 10.1017/S0033291707000943; Zlotnick C, 2002, COMPR PSYCHIAT, V43, P413, DOI 10.1053/comp.2002.35900	34	109	111	0	25	CAMBRIDGE UNIV PRESS	CAMBRIDGE	EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND	0007-1250	1472-1465		BRIT J PSYCHIAT	Br. J. Psychiatry	MAY	2015	206	5					417	423		10.1192/bjp.bp.114.145516			7	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	CH6PA	WOS:000354157300010	25657356	Bronze			2022-02-06	
J	Maegele, M; Schochl, H; Cohen, MJ				Maegele, Marc; Schoechl, Herbert; Cohen, Mitchell J.			AN UPDATE ON THE COAGULOPATHY OF TRAUMA	SHOCK			English	Article						Trauma; hemorrhage; coagulopathy; mechanisms	ENDOTHELIAL GLYCOCALYX DEGRADATION; PROTEIN-C; PLATELET DYSFUNCTION; GLOBAL BURDEN; FACTOR VIIA; INJURY; TEMPERATURE; HYPOTHERMIA; DEATH; HYPERFIBRINOLYSIS	Trauma remains the leading cause of death with bleeding as the primary cause of preventable mortality during the first 24 h following trauma. When death occurs, it happens quickly, typically within the first 6 h after injury. One of four patients to arrive in the emergency department after trauma is already in the state of acute traumatic coagulopathy and shock. The principal drivers of acute traumatic coagulopathy have been characterized by tissue hypoperfusion, inflammation, and the acute activation of the neurohumoral system. Hypoperfusion leads to an activation of protein C with cleavage of activated factors V and VIII and the inhibition of plasminogen activator inhibitor 1 with subsequent hyperfibrinolysis. Endothelial damage and activation result in Weibel-Palade body degradation and glycocalyx shedding associated with autoheparinization. In contrast, there is an iatrogenic coagulopathy that occurs secondary to uncritical volume therapy leading to acidosis, hypothermia, and hemodilution. This coagulopathy then may be an integral part of the "vicious cycle" when combined with acidosis and hypothermia. The present article summarizes an update on the principal mechanisms and triggers of the coagulopathy of trauma including traumatic brain injury.	[Maegele, Marc] Univ Witten Herdecke, Cologne Merheim Med Ctr, Dept Traumatol Orthoped Surg & Sportsmed, D-51109 Cologne, Germany; [Maegele, Marc] Univ Witten Herdecke, Inst Res Operat Med, D-51109 Cologne, Germany; [Schoechl, Herbert] Ludwig Boltzmann Inst Expt & Clin Traumatol, Vienna, Austria; [Schoechl, Herbert] AUVA Trauma Hosp, Dept Anaesthesiol & Intens Care, Salzburg, Austria; [Cohen, Mitchell J.] Univ Calif San Francisco, Dept Surg, San Francisco, CA USA		Maegele, M (corresponding author), Univ Witten Herdecke, Cologne Merheim Med Ctr, Dept Traumatol Orthoped Surg & Sportsmed, Ostmerheimerstr 200, D-51109 Cologne, Germany.	Marc.Maegele@t-online.de					BELLAMY RF, 1984, MIL MED, V149, P55; Brohi K, 2003, J TRAUMA, V54, P1127, DOI 10.1097/01.TA.0000069184.82147.06; Brohi K, 2007, ANN SURG, V245, P812, DOI 10.1097/01.sla.0000256862.79374.31; Chesebro BB, 2009, SHOCK, V32, P659, DOI 10.1097/SHK.0b013e3181a5a632; Cohen MJ, 2013, J TRAUMA ACUTE CARE, V75, pS40, DOI 10.1097/TA.0b013e31828fa43d; Cosgriff N, 1997, J TRAUMA, V42, P857, DOI 10.1097/00005373-199705000-00016; ESMON CT, 1989, J BIOL CHEM, V264, P4743; ESPOSITO TJ, 1995, J TRAUMA, V39, P955, DOI 10.1097/00005373-199511000-00022; Floccard B, 2012, INJURY, V43, P26, DOI 10.1016/j.injury.2010.11.003; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; Gonzalez E, 2006, SHOCK, V25, P88, DOI 10.1097/00024382-200606001-00264; Greuters S, 2011, CRIT CARE, V15, DOI 10.1186/cc9399; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Hess JR, 2008, J TRAUMA, V65, P748, DOI 10.1097/TA.0b013e3181877a9c; Hess JR, 2006, J TRAUMA, V60, pS12, DOI 10.1097/01.ta.0000199545.06536.22; Holcomb JB, 2007, ANN SURG, V245, P986, DOI 10.1097/01.sla.0000259433.03754.98; Hoyt DB, 2004, SEMIN HEMATOL, V41, P40, DOI 10.1053/j.seminhematol.2003.11.009; Ives C, 2012, J AM COLL SURGEONS, V215, P496, DOI 10.1016/j.jamcollsurg.2012.06.005; Johansson PI, 2011, ANN SURG, V254, P194, DOI 10.1097/SLA.0b013e318226113d; JURKOVICH GJ, 1987, J TRAUMA, V27, P1019, DOI 10.1097/00005373-198709000-00011; Kashuk JL, 2010, ANN SURG, V252, P434, DOI 10.1097/SLA.0b013e3181f09191; Kermode JC, 1999, BLOOD, V94, P199, DOI 10.1182/blood.V94.1.199.413k14_199_207; Krug EG, 2000, AM J PUBLIC HEALTH, V90, P523, DOI 10.2105/AJPH.90.4.523; Kutcher ME, 2012, J TRAUMA ACUTE CARE, V73, P1389, DOI 10.1097/TA.0b013e318270d595; Kutcher ME, 2012, J TRAUMA ACUTE CARE, V73, P87, DOI 10.1097/TA.0b013e3182598c70; Kutcher ME, 2012, J TRAUMA ACUTE CARE, V73, P13, DOI 10.1097/TA.0b013e318256deab; Lowenstein CJ, 2005, TRENDS CARDIOVAS MED, V15, P302, DOI 10.1016/j.tcm.2005.09.005; MacLeod JBA, 2003, J TRAUMA, V55, P39, DOI 10.1097/01.TA.0000075338.21177.EF; Maegele M, 2006, SHOCK, V25, P56, DOI 10.1097/00024382-200606001-00170; Maegele M, 2007, INJURY, V38, P298, DOI 10.1016/j.injury.2006.10.003; Maegele M, 2013, TRANSFUSION, V53, p28S, DOI 10.1111/trf.12033; Maegele M, 2012, SHOCK, V38, P450, DOI 10.1097/SHK.0b013e31826dbd23; Martini WZ, 2009, J TRAUMA, V67, P202, DOI 10.1097/TA.0b013e3181a602a7; Meng ZH, 2003, J TRAUMA, V55, P886, DOI 10.1097/01.TA.0000066184.20808.A5; Monroe DM, 2008, THROMB RES, V122, pS7, DOI 10.1016/S0049-3848(08)70010-0; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; Nieuwdorp M, 2005, CURR OPIN LIPIDOL, V16, P507, DOI 10.1097/01.mol.0000181325.08926.9c; Noel P, 2013, SEMIN HEMATOL, V50, P259, DOI 10.1053/j.seminhematol.2013.06.009; Ostrowski SR, 2012, J TRAUMA ACUTE CARE, V73, P60, DOI 10.1097/TA.0b013e31825b5c10; Raza I, 2013, J THROMB HAEMOST, V11, P307, DOI 10.1111/jth.12078; Rehm M, 2007, CIRCULATION, V116, P1896, DOI 10.1161/CIRCULATIONAHA.106.684852; Rezaie AR, 2010, CURR MED CHEM, V17, P2059, DOI 10.2174/092986710791233706; Rourke C, 2012, J THROMB HAEMOST, V10, P1342, DOI 10.1111/j.1538-7836.2012.04752.x; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; Schochl H, 2009, J TRAUMA, V67, P125, DOI 10.1097/TA.0b013e31818b2483; Wafaisade A, 2010, EMERG MED J, V27, P934, DOI 10.1136/emj.2009.088484; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1; Wohlauer MV, 2012, J AM COLL SURGEONS, V214, P739, DOI 10.1016/j.jamcollsurg.2012.01.050; Wolberg AS, 2004, J TRAUMA, V56, P1221, DOI 10.1097/01.TA.0000064328.97941.FC; Xu J, 2009, NAT MED, V15, P1318, DOI 10.1038/nm.2053	50	109	121	0	18	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1073-2322	1540-0514		SHOCK	Shock	MAY	2014	41			1			21	25		10.1097/SHK.0000000000000088			5	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	AI6EX	WOS:000336965100004	24192549				2022-02-06	
J	Naviaux, RK				Naviaux, Robert K.			Metabolic features of the cell danger response	MITOCHONDRION			English	Article						Oxidative stress; Oxidative shielding; Innate immunity; Inflammation; Purinergic signaling; Mitochondria	CYSTINE/GLUTAMATE ANTIPORTER; MOLECULAR-MECHANISMS; IMPROVES RECOVERY; STRESS-RESPONSE; ATP RELEASE; KAPPA-B; RECEPTOR; SURAMIN; MITOCHONDRIA; DISEASE	The cell danger response (CDR) is the evolutionarily conserved metabolic response that protects cells and hosts from harm. It is triggered by encounters with chemical, physical, or biological threats that exceed the cellular capacity for homeostasis. The resulting metabolic mismatch between available resources and functional capacity produces a cascade of changes in cellular electron flow, oxygen consumption, redox, membrane fluidity, lipid dynamics, bioenergetics, carbon and sulfur resource allocation, protein folding and aggregation, vitamin availability, metal homeostasis, indole, pterin, 1-carbon and polyamine metabolism, and polymer formation. The first wave of danger signals consists of the release of metabolic intermediates like ATP and ADP, Krebs cycle intermediates, oxygen, and reactive oxygen species (ROS), and is sustained by purinergic signaling. After the danger has been eliminated or neutralized, a choreographed sequence of anti-inflammatoty and regenerative pathways is activated to reverse the CDR and to heal. When the CDR persists abnormally, whole body metabolism and the gut microbiome are disturbed, the collective performance of multiple organ systems is impaired, behavior is changed, and chronic disease results. Metabolic memory of past stress encounters is stored in the form of altered mitochondrial and cellular macromolecule content, resulting in an increase in functional reserve capacity through a process known as mitocellular hormesis. The systemic form of the CDR, and its magnified form, the purinergic life-threat response (PLTR), are under direct control by ancient pathways in the brain that are ultimately coordinated by centers in the brainstem. Chemosensory integration of whole body metabolism occurs in the brainstem and is a prerequisite for normal brain, motor, vestibular, sensory, social, and speech development. An understanding of the CDR permits us to reframe old concepts of pathogenesis for a broad array of chronic, developmental, autoimmune, and degenerative disorders. These disorders include autism spectrum disorders (ASD), attention deficit hyperactivity disorder (ADHD), asthma, atopy, gluten and many other food and chemical sensitivity syndromes, emphysema, Tourette's syndrome, bipolar disorder, schizophrenia, post-traumatic stress disorder (PTSD), chronic traumatic encephalopathy (CTE), traumatic brain injury (TB!), epilepsy, suicidal ideation, organ transplant biology, diabetes, kidney, liver, and heart disease, cancer, Alzheimer and Parkinson disease, and autoimmune disorders like lupus, rheumatoid arthritis, multiple sclerosis, and primary sclerosing cholangitis. (C) 2013 The Author. Published by Elsevier B.V. and Mitochondria Research Society. All rights reserved.	[Naviaux, Robert K.] Univ Calif San Diego, Sch Med, Mitochondrial & Metab Dis Ctr, Dept Med, San Diego, CA 92103 USA; [Naviaux, Robert K.] Univ Calif San Diego, Sch Med, Mitochondrial & Metab Dis Ctr, Dept Pediat, San Diego, CA 92103 USA; [Naviaux, Robert K.] Univ Calif San Diego, Sch Med, Mitochondrial & Metab Dis Ctr, Dept Pathol, San Diego, CA 92103 USA; [Naviaux, Robert K.] Vet Affairs Ctr Excellence Stress & Mental Hlth C, La Jolla, CA USA		Naviaux, RK (corresponding author), Univ Calif San Diego, Sch Med, Mitochondrial & Metab Dis Ctr, 214 Dickinson St,Bldg CTF,Rm C102, San Diego, CA 92103 USA.	Naviaux@ucsd.edu			UCSD Christini Fund; Jane Botsford Johnson Foundation; Wright Foundation; Lennox Foundation; Takes Guts Foundation; UCSD Mitochondrial Disease Research Foundation; Hailey's Wish Foundation	RKN thanks Jane Naviaux, Will Alaynick, Jim Adams, Steve Edelson, Kate Crowley, and Vicki Kobliner for helpful comments on the manuscript. This work was made possible by support from the UCSD Christini Fund, the Jane Botsford Johnson Foundation, the Wright Foundation, the Lennox Foundation, the It Takes Guts Foundation, the UCSD Mitochondrial Disease Research Foundation, and the Hailey's Wish Foundation.	Ajioka RS, 2006, BBA-MOL CELL RES, V1763, P723, DOI 10.1016/j.bbamcr.2006.05.005; Angata T, 2012, ANN NY ACAD SCI, V1253, P159, DOI 10.1111/j.1749-6632.2012.06469.x; Arispe N, 2002, FASEB J, V16, P1526, DOI 10.1096/fj.02-0829com; Arnoult D, 2011, EMBO REP, V12, P901, DOI 10.1038/embor.2011.157; Bachrach U, 2007, AMINO ACIDS, V33, P267, DOI 10.1007/s00726-007-0535-y; Ballok DA, 2008, BRAIN BEHAV IMMUN, V22, P1208, DOI 10.1016/j.bbi.2008.06.002; Bernstein HG, 2012, NEUROPHARMACOLOGY, V62, P237, DOI 10.1016/j.neuropharm.2011.07.012; Bezvenyuk Z, 2000, NEUROSCI LETT, V292, P111, DOI 10.1016/S0304-3940(00)01453-1; Blumberg Stephen J, 2013, Natl Health Stat Report, P1; Bours Martijn Jan Leo, 2011, Front Biosci (Schol Ed), V3, P1443; Bridges RJ, 2012, BRIT J PHARMACOL, V165, P20, DOI 10.1111/j.1476-5381.2011.01480.x; BURNSTOCK G, 1972, BRIT J PHARMACOL, V44, P451, DOI 10.1111/j.1476-5381.1972.tb07283.x; Burnstock G, 2012, CURR OPIN PHARMACOL, V12, P80, DOI 10.1016/j.coph.2011.10.008; Burnstock G, 2010, ACTA PHYSIOL, V199, P93, DOI 10.1111/j.1748-1716.2010.02114.x; Burnstock G, 2009, ACTA PHYSIOL, V195, P415, DOI 10.1111/j.1748-1716.2009.01957.x; Burnstock G, 2011, PROG NEUROBIOL, V95, P229, DOI 10.1016/j.pneurobio.2011.08.006; Caccamo D, 2012, AMINO ACIDS, V42, P1037, DOI 10.1007/s00726-011-1018-8; Cantin LD, 2012, BIOORG MED CHEM LETT, V22, P2565, DOI 10.1016/j.bmcl.2012.01.124; Cervelli M, 2012, AMINO ACIDS, V42, P441, DOI 10.1007/s00726-011-1014-z; Choo AM, 2013, BRAIN, V136, P65, DOI 10.1093/brain/aws286; Cicko S, 2010, J IMMUNOL, V185, P688, DOI 10.4049/jimmunol.0904042; Corcoran JA, 2009, J VIROL, V83, P2601, DOI 10.1128/JVI.02087-08; Darwin C.R., 1839, C DARWIN AUSTR, P30; De Clercq E, 2009, MED RES REV, V29, P611, DOI 10.1002/med.20153; de Oliveira Moreira D., 2013, MUSCLE NERVE; Degtyar E, 2009, CELL MICROBIOL, V11, P1219, DOI 10.1111/j.1462-5822.2009.01328.x; DiNatale BC, 2010, TOXICOL SCI, V115, P89, DOI 10.1093/toxsci/kfq024; Dreifus Claudia, 1998, NY TIMES; Edmonds JL, 2002, ARCH OTOLARYNGOL, V128, P355, DOI 10.1001/archotol.128.4.355; Ehlert U., 2013, PSYCHONEUROENDOCRINO; Eisner V, 2010, CELL CALCIUM, V48, P358, DOI 10.1016/j.ceca.2010.11.001; Engel T, 2012, FASEB J, V26, P1616, DOI 10.1096/fj.11-196089; Forstermann U, 2012, EUR HEART J, V33, P829, DOI 10.1093/eurheartj/ehr304; Fontecave M, 2004, TRENDS BIOCHEM SCI, V29, P243, DOI 10.1016/j.tibs.2004.03.007; Fuchs E J, 1996, Semin Immunol, V8, P271, DOI 10.1006/smim.1996.0035; Fulkerson PC, 2013, NAT REV DRUG DISCOV, V12, P117, DOI 10.1038/nrd3838; Garrod AE, 1902, LANCET, V2, P1616; Gray TJ, 1999, J CARDIOVASC PHARM, V33, P960, DOI 10.1097/00005344-199906000-00018; Gunderson LH, 2000, ANNU REV ECOL SYST, V31, P425, DOI 10.1146/annurev.ecolsys.31.1.425; Halassa MM, 2011, SEMIN CELL DEV BIOL, V22, P245, DOI 10.1016/j.semcdb.2011.02.008; Haynes CM, 2013, TRENDS CELL BIOL, V23, P311, DOI 10.1016/j.tcb.2013.02.002; He SQ, 2013, J PHARMACOL EXP THER, V344, P417, DOI 10.1124/jpet.112.199919; HeberKatz E, 2013, CURR TOP MICROBIOL, V367, P1, DOI 10.1007/978-3-642-35810-4; Hecker L, 2009, NAT MED, V15, P1077, DOI 10.1038/nm.2005; HSU HC, 1994, AUTOIMMUNITY, V19, P253, DOI 10.3109/08916939409071351; Hultqvist M, 2009, TRENDS IMMUNOL, V30, P201, DOI 10.1016/j.it.2009.03.004; Ibrahim D, 2006, CLIN LAB MED, V26, P67, DOI 10.1016/j.cll.2006.02.003; Jacobs SA, 2007, MED HYPOTHESES, V68, P308, DOI 10.1016/j.mehy.2006.07.023; Jiang XM, 2012, IMMUNITY, V36, P959, DOI 10.1016/j.immuni.2012.03.022; Jin S, 2009, CURR ATHEROSCLER REP, V11, P220, DOI 10.1007/s11883-009-0034-6; Junger WG, 2011, NAT REV IMMUNOL, V11, P201, DOI 10.1038/nri2938; Kannan KB, 2007, J IMMUNOL, V178, P5253, DOI 10.4049/jimmunol.178.8.5253; KAWAMURA M, 1991, JPN J PHARMACOL, V56, P543, DOI 10.1254/jjp.56.543; Kharlamov A, 2002, EXP BRAIN RES, V147, P353, DOI 10.1007/s00221-002-1251-1; Kim HP, 2006, EXPERT OPIN THER TAR, V10, P759, DOI 10.1517/14728222.10.5.759; Kim HJ, 2012, BBA-MOL CELL RES, V1823, P1604, DOI 10.1016/j.bbamcr.2012.04.008; Kivity S, 2011, CELL MOL IMMUNOL, V8, P243, DOI 10.1038/cmi.2010.73; Knight JC, 2013, TRENDS GENET, V29, P74, DOI 10.1016/j.tig.2012.10.006; Kobayashi S, 2012, FREE RADICAL BIO MED, V53, P2197, DOI 10.1016/j.freeradbiomed.2012.09.040; Korrapati MC, 2012, J PHARMACOL EXP THER, V343, P34, DOI 10.1124/jpet.112.196964; Kruidenier L, 2012, NATURE, V488, P404, DOI 10.1038/nature11262; Kuijpers T, 2012, CELL MOL LIFE SCI, V69, P7, DOI 10.1007/s00018-011-0834-z; Landrigan PJ, 2012, ENVIRON HEALTH PERSP, V120, pA258, DOI 10.1289/ehp.1104285; Lee AH, 2009, CELL MOL LIFE SCI, V66, P2835, DOI 10.1007/s00018-009-0049-8; LESCH M, 1964, AM J MED, V36, P561, DOI 10.1016/0002-9343(64)90104-4; Lewerenz J, 2013, ANTIOXID REDOX SIGN, V18, P522, DOI 10.1089/ars.2011.4391; Liu C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052703; Liu GG, 2008, BIOCHEM BIOPH RES CO, V370, P651, DOI 10.1016/j.bbrc.2008.04.031; Liu GW, 2010, NAT IMMUNOL, V11, P1047, DOI 10.1038/ni.1939; Lluis JM, 2007, CANCER RES, V67, P7368, DOI 10.1158/0008-5472.CAN-07-0515; Lucki NC, 2012, ANNU REV PHYSIOL, V74, P131, DOI 10.1146/annurev-physiol-020911-153321; Lushchak VI, 2011, COMP BIOCHEM PHYS C, V153, P175, DOI 10.1016/j.cbpc.2010.10.004; MacLennan AJ, 2006, HEARING RES, V220, P38, DOI 10.1016/j.heares.2006.06.016; Mahankali M, 2011, P NATL ACAD SCI USA, V108, P19617, DOI 10.1073/pnas.1114692108; Mandi Y, 2012, J NEURAL TRANSM, V119, P197, DOI 10.1007/s00702-011-0681-y; Marina N, 2013, BASIC RES CARDIOL, V108, DOI 10.1007/s00395-012-0317-x; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; Matzinger P, 2011, NAT REV IMMUNOL, V11, P221, DOI 10.1038/nri2940; McLain AL, 2013, FREE RADICAL BIO MED, V61, P161, DOI 10.1016/j.freeradbiomed.2013.03.020; Micheli V, 2011, CURR TOP MED CHEM, V11, P923, DOI 10.2174/156802611795347645; Nathanson N, 2010, AM J EPIDEMIOL, V172, P1213, DOI 10.1093/aje/kwq320; Naviaux RK, 2008, CANCER BIOL THER, V7, P1191, DOI 10.4161/cbt.7.8.6741; Naviaux RK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057380; Naviaux RK, 2012, J PHARMACOL EXP THER, V342, P608, DOI 10.1124/jpet.112.192120; Nie XW, 2013, INT J BIOCHEM CELL B, V45, P964, DOI 10.1016/j.biocel.2013.01.017; Nielsen MJ, 2012, NAT REV GASTRO HEPAT, V9, P345, DOI 10.1038/nrgastro.2012.76; NovalesLi P, 1996, IMMUNOPHARMACOLOGY, V35, P155, DOI 10.1016/S0162-3109(96)00141-5; Novgorodov Sergei A, 2011, Int J Biochem Mol Biol, V2, P347; Nyhan WL, 2005, MOL GENET METAB, V86, P25, DOI 10.1016/j.ymgme.2005.07.027; NYHAN WL, 1969, J PEDIATR, V74, P20, DOI 10.1016/S0022-3476(69)80004-1; Oguma T, 2007, CLIN EXP ALLERGY, V37, P893, DOI 10.1111/j.1365-2222.2007.02719.x; Ohta A, 2011, MITOCHONDRION, V11, P1, DOI 10.1016/j.mito.2010.08.006; Ong WY, 2010, CURR MED CHEM, V17, P2746, DOI 10.2174/092986710791859289; Panossian A, 2009, CURR CLIN PHARMACOL, V4, P198, DOI 10.2174/157488409789375311; Pastural E, 2009, PROSTAG LEUKOTR ESS, V81, P253, DOI 10.1016/j.plefa.2009.06.003; Paul L, 2013, NUTR REV, V71, P239, DOI 10.1111/nure.12014; Peng WG, 2009, P NATL ACAD SCI USA, V106, P12489, DOI 10.1073/pnas.0902531106; Peng X, 2012, ACTA PHYSIOL, V204, P219, DOI 10.1111/j.1748-1716.2011.02298.x; Pimentel VC, 2013, NEUROCHEM RES, V38, P886, DOI 10.1007/s11064-013-0994-3; Rabiet MJ, 2005, EUR J IMMUNOL, V35, P2486, DOI 10.1002/eji.200526338; Riegl B, 2009, ANN NY ACAD SCI, V1162, P136, DOI 10.1111/j.1749-6632.2009.04493.x; Riteau N, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.144; Romero P, 2005, GENOME BIOL, V6; Sahu D, 2012, INT IMMUNOPHARMACOL, V12, P288, DOI 10.1016/j.intimp.2011.12.003; Salminen A, 2012, AGEING RES REV, V11, P230, DOI 10.1016/j.arr.2011.12.005; Scott I, 2010, MITOCHONDRION, V10, P316, DOI 10.1016/j.mito.2010.02.005; Sentelle RD, 2012, NAT CHEM BIOL, V8, P831, DOI 10.1038/NCHEMBIO.1059; Seong SY, 2004, NAT REV IMMUNOL, V4, P469, DOI 10.1038/nri1372; Seth RB, 2005, CELL, V122, P669, DOI 10.1016/j.cell.2005.08.012; Shanmugasundaram R, 2012, POULTRY SCI, V91, P1819, DOI 10.3382/ps.2011-02129; Silva JM, 2009, NEUROBIOL DIS, V34, P357, DOI 10.1016/j.nbd.2009.02.005; Smriga M, 2003, P NATL ACAD SCI USA, V100, P15370, DOI 10.1073/pnas.2436556100; Stipanuk MH, 2011, J INHERIT METAB DIS, V34, P17, DOI 10.1007/s10545-009-9006-9; SUTTON RAL, 1993, MINER ELECTROL METAB, V19, P232; Takabe K, 2008, PHARMACOL REV, V60, P181, DOI 10.1124/pr.107.07113; Thompson CR, 2005, J IMMUNOL, V174, P3551, DOI 10.4049/jimmunol.174.6.3551; West AP, 2011, NAT REV IMMUNOL, V11, P389, DOI 10.1038/nri2975; Williams BL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024585; Wood JH, 2010, CURR OPIN PEDIATR, V22, P315, DOI 10.1097/MOP.0b013e328338da48; Xia JS, 2012, J PHYSIOL-LONDON, V590, P2285, DOI 10.1113/jphysiol.2012.227983; Yang Z, 2012, OBES REV, V13, P58, DOI 10.1111/j.1467-789X.2012.01038.x; Yousefi S, 2008, NAT MED, V14, P949, DOI 10.1038/nm.1855; Zamek-Gliszczynski MJ, 2006, EUR J PHARM SCI, V27, P447, DOI 10.1016/j.ejps.2005.12.007; Zhang XY, 2011, AM J PHYSIOL-CELL PH, V301, pC451, DOI 10.1152/ajpcell.00458.2010; Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663	125	109	113	1	90	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1567-7249	1872-8278		MITOCHONDRION	Mitochondrion	MAY	2014	16				SI		7	17		10.1016/j.mito.2013.08.006			11	Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Genetics & Heredity	AH9OP	WOS:000336472000003	23981537	hybrid			2022-02-06	
J	Boussi-Gross, R; Golan, H; Fishlev, G; Bechor, Y; Volkov, O; Bergan, J; Friedman, M; Hoofien, D; Shlamkovitch, N; Ben-Jacob, E; Efrati, S				Boussi-Gross, Rahav; Golan, Haim; Fishlev, Gregori; Bechor, Yair; Volkov, Olga; Bergan, Jacob; Friedman, Mony; Hoofien, Dan; Shlamkovitch, Nathan; Ben-Jacob, Eshel; Efrati, Shai			Hyperbaric Oxygen Therapy Can Improve Post Concussion Syndrome Years after Mild Traumatic Brain Injury - Randomized Prospective Trial	PLOS ONE			English	Article							EMISSION COMPUTED-TOMOGRAPHY; CYSTIC-FIBROSIS PATIENTS; FLUID-PERCUSSION INJURY; ACUTE ISCHEMIC-STROKE; MINOR HEAD-INJURY; DEAD-SEA; LOW-ALTITUDE; NEUROPSYCHOLOGICAL DEFICITS; MITOCHONDRIAL-FUNCTION; CEREBRAL OXYGENATION	Traumatic brain injury (TBI) is the leading cause of death and disability in the US. Approximately 70-90% of the TBI cases are classified as mild, and up to 25% of them will not recover and suffer chronic neurocognitive impairments. The main pathology in these cases involves diffuse brain injuries, which are hard to detect by anatomical imaging yet noticeable in metabolic imaging. The current study tested the effectiveness of Hyperbaric Oxygen Therapy (HBOT) in improving brain function and quality of life in mTBI patients suffering chronic neurocognitive impairments.	[Boussi-Gross, Rahav; Fishlev, Gregori; Bechor, Yair; Bergan, Jacob; Friedman, Mony; Efrati, Shai] Assaf Harofeh Med Ctr, Inst Hyperbar Med, IL-70300 Zerifin, Israel; [Ben-Jacob, Eshel; Efrati, Shai] Assaf Harofeh Med Ctr, Res & Dev Unit, IL-70300 Zerifin, Israel; [Golan, Haim; Volkov, Olga; Efrati, Shai] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel; [Golan, Haim; Volkov, Olga] Assaf Harofeh Med Ctr, Inst Nucl Med, IL-70300 Zerifin, Israel; [Ben-Jacob, Eshel] Tel Aviv Univ, Raymond & Beverly Sackler Fac Exact Sci, Sch Phys & Astron, IL-69978 Tel Aviv, Israel; [Hoofien, Dan] Hebrew Univ Jerusalem, Dept Psychol, IL-91905 Jerusalem, Israel; [Hoofien, Dan] Natl Inst Rehabil Brain Injured, Tel Aviv, Israel; [Shlamkovitch, Nathan] Assaf Harofeh Med Ctr, IL-70300 Zerifin, Israel; [Ben-Jacob, Eshel] Rice Univ, Ctr Theoret Biol Phys, Houston, TX USA; [Ben-Jacob, Eshel; Efrati, Shai] Tel Aviv Univ, Sagol Sch Neurosci, IL-69978 Tel Aviv, Israel		Ben-Jacob, E (corresponding author), Assaf Harofeh Med Ctr, Res & Dev Unit, IL-70300 Zerifin, Israel.	eshel@rice.edu; efratishai@013.net	Golan, Haim/K-2831-2019		Assaf-Harofeh medical center; Tauber Family Foundation; Maguy-Glass Chair in Physics of Complex Systems at Tel Aviv University	The study was supported by the research fund of Assaf-Harofeh medical center, by the Tauber Family Foundation and by the Maguy-Glass Chair in Physics of Complex Systems at Tel Aviv University. None of the supporting bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abinader EG, 1999, AM J CARDIOL, V83, P250, DOI 10.1016/S0002-9149(98)00829-7; Vilela DSA, 2008, ACTA OTO-LARYNGOL, V128, P1048, DOI 10.1080/00016480701827525; ANDERSON DC, 1991, STROKE, V22, P1137, DOI 10.1161/01.STR.22.9.1137; Austin D, 1998, LANCET, V351, P1815, DOI 10.1016/S0140-6736(05)78781-X; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; BOHNEN N, 1992, NEUROSURGERY, V30, P692, DOI 10.1097/00006123-199205000-00007; Calvert JW, 2007, NEUROL RES, V29, P132, DOI 10.1179/016164107X174156; Cao H, 2013, EXP THER MED, V5, P1609, DOI 10.3892/etm.2013.1043; Catafau AM, 1998, PSYCHIAT RES-NEUROIM, V83, P67, DOI 10.1016/S0925-4927(98)00031-6; Chang CC, 2009, J NEUROTRAUM, V26, P1263, DOI [10.1089/neu.2008.0619, 10.1089/neu.2008-0619]; Chen ZQ, 2008, NEURAL REGEN RES, V3, P117; Cifu DX, 2013, J HEAD TRAUMA REHABI; Cohen J., 2013, STAT POWER ANAL BEHA; Collet JP, 2001, LANCET, V357, P582, DOI 10.1016/S0140-6736(00)04054-X; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Daugherty WP, 2004, J NEUROSURG, V101, P499, DOI 10.3171/jns.2004.101.3.0499; de Frias CM, 2003, J GERONTOL B-PSYCHOL, V58, pP12, DOI 10.1093/geronb/58.1.P12; Doniger GM, 2007, MINDSTREAMS VALIDITY; Doniger GM, 2007, MINDSTREAMS COMPUTER; Doniger GM, 2007, CONSTRUCT VALIDITY M; Doniger GM, 2012, GUIDE MINDSTREAMS NO; Efrati S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053716; Falk B, 2006, PEDIATR PULM, V41, P234, DOI 10.1002/ppul.20342; Faul M, 2010, TRAUMATIC BRAIN INJU; Gabizon I, 2011, ISR MED ASSOC J, V13, P402; Glisky EL, 2004, SCI PRACT NEUROPSYCH, P100; Goldbart AD, 2007, ISR MED ASSOC J, V9, P806; Golden Z, 2006, DISABIL REHABIL, V28, P1379, DOI 10.1080/09638280600638364; Golden ZL, 2002, INT J NEUROSCI, V112, P119, DOI 10.1080/00207450212027; GOLDING F C, 1960, Br J Ind Med, V17, P167; Gunther A, 2005, EUR J NEUROSCI, V21, P3189, DOI 10.1111/j.1460-9568.2005.04151.x; Harch PG, 2007, BRAIN RES, V1174, P120, DOI 10.1016/j.brainres.2007.06.105; Harch PG, 2012, J NEUROTRAUM, V29, P168, DOI 10.1089/neu.2011.1895; Hattori N, 2009, J NUCL MED, V50, P1054, DOI 10.2967/jnumed.108.060368; Imai K, 2006, NEUROL MED-CHIR, V46, P373, DOI 10.2176/nmc.46.373; Insel Thomas R, 2010, Sci Am, V302, P44; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; James PB, 2001, LANCET, V357, P2052, DOI 10.1016/S0140-6736(00)05137-0; JASZCZAK RJ, 1979, PHYS MED BIOL, V24, P1123, DOI 10.1088/0031-9155/24/6/003; Kan EM, 2012, BRAIN RES BULL, V87, P359, DOI 10.1016/j.brainresbull.2012.01.007; Kashluba S, 2004, ARCH CLIN NEUROPSYCH, V19, P805, DOI 10.1016/j.acn.2003.09.005; Kochanek PM, 2007, BRAIN INJURY MED PRI, P81; Kramer MR, 1998, CHEST, V113, P571, DOI 10.1378/chest.113.3.571; Kuffler DP, 2011, P R HEALTH SCI J, V30, P35; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lin AP, 2012, BRAIN IMAGING BEHAV, V6, P208, DOI 10.1007/s11682-012-9181-4; Lin JW, 2008, ACTA NEUROCHIR SUPPL, V101, P145; Lo CP, 2007, EUR J NEUROL, V14, P777, DOI 10.1111/j.1468-1331.2007.01854.x; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; McCauley SR, 2005, J NERV MENT DIS, V193, P540, DOI 10.1097/01.nmd.0000172592.05801.71; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Mychaskiw G, 2013, J NEUROTRAUMA; Mychaskiw Ii G, 2012, J NEUROTRAUMA; Neubauer RA, 1998, NEUROL RES, V20, pS33; Neubauer RA, 2000, HYPERBARIC OXYGEN TH; NIGHOGHOSSIAN N, 1995, STROKE, V26, P1369, DOI 10.1161/01.STR.26.8.1369; Niklas A, 2004, J NEUROL SCI, V219, P77, DOI 10.1016/j.jns.2003.12.013; Palzur E, 2004, J NEUROTRAUM, V21, P41, DOI 10.1089/089771504772695931; Palzur E, 2008, BRAIN RES, V1221, P126, DOI 10.1016/j.brainres.2008.04.078; Posner MI, 2007, COGN AFFECT BEHAV NE, V7, P391, DOI 10.3758/CABN.7.4.391; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; Rabin R, 2001, ANN MED, V33, P337, DOI 10.3109/07853890109002087; Reinert M, 2003, ACTA NEUROCHIR, V145, P341, DOI 10.1007/s00701-003-0027-0; ROCKSWOLD GL, 1992, J NEUROSURG, V76, P929, DOI 10.3171/jns.1992.76.6.0929; Rockswold SB, 2007, NEUROL RES, V29, P162, DOI 10.1179/016164107X181798; Rockswold SB, 2010, J NEUROSURG, V112, P1080, DOI 10.3171/2009.7.JNS09363; Rusyniak DE, 2003, STROKE, V34, P571, DOI 10.1161/01.STR.0000050644.48393.D0; SCOVILLE WB, 1973, ACTA NEUROCHIR, V28, P251, DOI 10.1007/BF01405644; Sohlberg M., 2001, COGNITIVE REHABILITA; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; Squire LR, 2004, NEUROBIOL LEARN MEM, V82, P171, DOI 10.1016/j.nlm.2004.06.005; Stuss DT, 2011, J INT NEUROPSYCH SOC, V17, P759, DOI 10.1017/S1355617711000695; Stuss DT, 2000, PSYCHOL RES-PSYCH FO, V63, P289, DOI 10.1007/s004269900007; Vila JF, 2005, UNDERSEA HYPERBAR M, V32, P341; Vlodavsky E, 2006, NEUROPATH APPL NEURO, V32, P40, DOI 10.1111/j.1365-2990.2005.00698.x; Wolf G, 2012, J NEUROTRAUM, V29, P2606, DOI 10.1089/neu.2012.2549; Yang YJ, 2008, UNDERSEA HYPERBAR M, V35, P113; Zhang John H, 2005, Pathophysiology, V12, P63, DOI 10.1016/j.pathophys.2005.01.003; Zhou ZW, 2007, J NEUROSURG, V106, P687, DOI 10.3171/jns.2007.106.4.687	83	109	116	0	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 15	2013	8	11							e79995	10.1371/journal.pone.0079995			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255RX	WOS:000327258600052	24260334	Green Submitted, gold, Green Published			2022-02-06	
J	Tapia, NM; Chang, A; Norman, M; Welsh, F; Scott, B; Wall, MJ; Mattox, KL; Suliburk, J				Tapia, Nicole M.; Chang, Alex; Norman, Michael; Welsh, Francis; Scott, Bradford; Wall, Matthew J., Jr.; Mattox, Kenneth L.; Suliburk, James			TEG-guided resuscitation is superior to standardized MTP resuscitation in massively transfused penetrating trauma patients	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Thromboelastogram; massive transfusion protocol; penetrating trauma	FRESH-FROZEN PLASMA; BLOOD-PRODUCT RATIOS; IMPROVED SURVIVAL; CELL RATIOS; THROMBELASTOGRAPHY; THROMBOELASTOGRAPHY; COAGULOPATHY; PLATELET; OUTCOMES; IMPACT	BACKGROUND: For nearly a decade, our center performed thromboelastograms (TEGs) to analyze coagulation profiles, allowing rapid data-driven blood component therapy. After consensus recommendations for massive transfusion protocols (MTPs), we implemented an MTP in October 2009 with 1:1:1 ratio of blood (red blood cells [RBC]), plasma (fresh-frozen plasma [FFP]), and platelets. We hypothesized that TEG-directed resuscitation is equivalent to MTP resuscitation. METHODS: All patients receiving 6 units (U) or more of RBC in the first 24 hours for 21 months before and after MTP initiation in an urban Level I trauma center were examined. Demographics, mechanism of injury (MOI), Injury Severity Score (ISS), 24-hour volume of RBC, FFP, platelets, crystalloid, and 30-day mortality were compared, excluding patients with traumatic brain injuries. Variables were analyzed using Student's t-test and chi(2) or Fisher's exact test. RESULTS: For the preMTP group, there were 165 patients. In the MTP group, there were 124 patients. There were no significant differences in ISS, age, or sex. PreMTP patients with 6U or more RBC had significantly more penetrating MOI (p = 0.017), whereas preMTP patients with 10U or more RBC had similar MOIs. All patients received less crystalloid after MTP adoption (p G 0.001). There was no difference in volume of blood products or mortality in patients receiving 6U or more RBC. Blunt trauma MTP patients who received 10U or more RBC received more FFP (p = 0.02), with no change in mortality. Penetrating trauma patients who received 10U or more RBC received a similar volume of FFP; however, mortality increased from 54.1% for MTP versus 33.3% preMTP (p = 0.04). CONCLUSION: TEG-directed resuscitation is equivalent to standardizedMTP for patients receiving 6U or more RBC and for bluntMOI patients receiving 10UormoreRBC. MTP therapyworsenedmortality in penetratingMOI patients receiving 10UormoreRBC, indicating a continued need for TEG-directed therapy. A 1:1:1 strategy may not be adequate in all patients. (J Trauma Acute Care Surg. 2013;74: 378-386. Copyright (C) 2013 by Lippincott Williams & Wilkins)	[Tapia, Nicole M.; Chang, Alex; Norman, Michael; Welsh, Francis; Scott, Bradford; Wall, Matthew J., Jr.; Mattox, Kenneth L.; Suliburk, James] Baylor Coll Med, Houston, TX 77030 USA		Tapia, NM (corresponding author), 1 Baylor Plaza,Suite 404D, Houston, TX 77030 USA.	nmtapia@bcm.edu		Suliburk, James/0000-0002-6421-269X			Alam HB, 2009, J TRAUMA, V67, P856, DOI 10.1097/TA.0b013e3181b5ae75; BEAL RW, 1976, AUST NZ J SURG, V46, P309; Brohi K, 2003, J TRAUMA, V54, P1127, DOI 10.1097/01.TA.0000069184.82147.06; Carroll RC, 2009, TRANSL RES, V154, P34, DOI 10.1016/j.trsl.2009.04.001; Cinat ME, 1999, ARCH SURG-CHICAGO, V134, P964, DOI 10.1001/archsurg.134.9.964; Cothren CC, 2007, WORLD J SURG, V31, P1507, DOI 10.1007/s00268-007-9087-2; Cotton BA, 2008, J TRAUMA, V64, P1177, DOI 10.1097/TA.0b013e31816c5c80; Davenport R, 2011, J TRAUMA, V70, P90, DOI 10.1097/TA.0b013e318202e486; DAVIS CL, 1995, J AM SOC NEPHROL, V6, P1250; Duchesne JC, 2008, J TRAUMA, V65, P272, DOI 10.1097/TA.0b013e31817e5166; Floccard B, 2012, INJURY, V43, P26, DOI 10.1016/j.injury.2010.11.003; Frith D, 2012, CURR OPIN ANESTHESIO, V25, P229, DOI 10.1097/ACO.0b013e3283509675; Gunter OL, 2008, J TRAUMA, V65, P527, DOI 10.1097/TA.0b013e3181826ddf; Hansen Mads Koch, 2006, Ugeskr Laeger, V168, P3535; Hess JR, 2003, TRANSFUSION, V43, P1622, DOI 10.1046/j.1537-2995.2003.00576.x; Hodgetts T J, 2007, J R Army Med Corps, V153, P299; Holcomb JB, 2008, ANN SURG, V248, P447, DOI 10.1097/SLA.0b013e318185a9ad; Holcomb JB, 2011, J TRAUMA, V71, pS318, DOI 10.1097/TA.0b013e318227edbb; Inaba K, 2012, TEG TRAUM CRIT CAR A; Inaba K, 2010, J AM COLL SURGEONS, V211, P573, DOI 10.1016/j.jamcollsurg.2010.06.392; Jeger V, 2011, EMERG MED INT, V2011, DOI 10.1155/2011/895674; Kashuk JL, 2008, J TRAUMA, V65, P261, DOI 10.1097/TA.0b013e31817de3e1; Kashuk JL, 2012, TRANSFUSION, V52, P23, DOI 10.1111/j.1537-2995.2011.03264.x; Kaufmann CR, 1997, J TRAUMA, V42, P716, DOI 10.1097/00005373-199704000-00023; Lucas CE, 2012, J TRAUMA ACUTE CARE, V72, P821, DOI 10.1097/TA.0b013e3182484111; Malone DL, 2006, J TRAUMA, V60, pS91, DOI 10.1097/01.ta.0000199549.80731.e6; Martini WZ, 2008, J TRAUMA, V65, P535, DOI 10.1097/TA.0b013e31818379a6; Miller BE, 1997, ANESTH ANALG, V85, P1196, DOI 10.1097/00000539-199712000-00003; OWEN CA, 1987, MAYO CLIN PROC, V62, P761, DOI 10.1016/S0025-6196(12)62328-3; Park MS, 2009, J TRAUMA, V67, P266, DOI 10.1097/TA.0b013e3181ae6f1c; Plotkin AJ, 2008, J TRAUMA, V64, pS64, DOI 10.1097/TA.0b013e318160772d; Repine TB, 2006, J TRAUMA, V60, pS59, DOI 10.1097/01.ta.0000219013.64168.b2; Riskin DJ, 2009, J AM COLL SURGEONS, V209, P198, DOI 10.1016/j.jamcollsurg.2009.04.016; Shore-Lesserson L, 1999, ANESTH ANALG, V88, P312, DOI 10.1097/00000539-199902000-00016; Sisak K, 2012, ANZ J SURG, V82, P161, DOI 10.1111/j.1445-2197.2011.05967.x; Spoerke N, 2011, J TRAUMA, V71, pS380, DOI 10.1097/TA.0b013e318227f1c5; Tieu BH, 2007, WORLD J SURG, V31, P1055, DOI 10.1007/s00268-006-0653-9; Watson GA, 2009, J TRAUMA, V67, P221, DOI 10.1097/TA.0b013e3181ad5957; WILSON RF, 1971, J TRAUM, V11, P275, DOI 10.1097/00005373-197104000-00001; Zink KA, 2009, AM J SURG, V197, P565, DOI 10.1016/j.amjsurg.2008.12.014	40	109	112	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	FEB	2013	74	2					378	385		10.1097/TA.0b013e31827e20e0			8	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	108UH	WOS:000316321200009	23354228				2022-02-06	
J	Bolkvadze, T; Pitkanen, A				Bolkvadze, Tamuna; Pitkanen, Asla			Development of Post-Traumatic Epilepsy after Controlled Cortical Impact and Lateral Fluid-Percussion-Induced Brain Injury in the Mouse	JOURNAL OF NEUROTRAUMA			English	Article						electroencephalogram; epilepsy; post-traumatic seizure; traumatic brain injury	LONG-TERM HYPEREXCITABILITY; SEIZURE SUSCEPTIBILITY; HEAD-INJURY; ELECTRICAL-STIMULATION; DENTATE GYRUS; CELL LOSS; MODEL; HIPPOCAMPUS; PENTYLENETETRAZOL; EPILEPTOGENESIS	The present study investigated the development of hyperexcitability and epilepsy in mice with traumatic brain injury (TBI) induced by controlled cortical impact (CCI) or lateral fluid-percussion injury (FPI), which are the two most commonly used experimental models of human TBI in rodents. TBI was induced with CCI to 50 (14 controls) and with lateral FPI to 45 (15 controls) C57BL/6S adult male mice. The animals were followed-up for 9 months, including three 2-week periods of continuous video-electroencephalographic (EEG) monitoring, and a seizure susceptibility test with pentylenetetrazol (PTZ). In the end, the animals were perfusion-fixed for histology. The experiment included two independent cohorts of animals. Late post-traumatic spontaneous electrographic seizures were detected in 9% of mice after CCI and 3% after lateral FPI. Eighty-two percent of mice after CCI and 71% after lateral FPI had spontaneous epileptiform spiking on EEG. In addition, 58% of mice with lateral FPI showed spontaneous epileptiform discharges. A PTZ test demonstrated increased seizure susceptibility in the majority of mice in both models, compared to control mice. There was no further progression in the occurrence of epilepsy or epileptiform spiking when follow-up was extended from 6 to 9 months. The severity of cortical or hippocampal damage did not differentiate mice with or without epileptiform activity in either model. Finally, two independent series of experiments in both injury models provided comparable data demonstrating reproducibility of the modeling. These data show that different types of impact can trigger epileptogenesis in mice. Even though the frequency of spontaneous seizures in C57BL/6S mice is low, a large majority of animals develop hyperexcitability.	[Bolkvadze, Tamuna; Pitkanen, Asla] Univ Eastern Finland, AI Virtanen Inst Mol Sci, Dept Neurobiol, FIN-70211 Kuopio, Finland; [Pitkanen, Asla] Kuopio Univ Hosp, Dept Neurol, SF-70210 Kuopio, Finland		Pitkanen, A (corresponding author), Univ Eastern Finland, AI Virtanen Inst Mol Sci, Dept Neurobiol, POB 1627, FIN-70211 Kuopio, Finland.	asla.pitkanen@uef.fi	Ritter, Stefanie L/D-9312-2012		Academy of FinlandAcademy of FinlandEuropean Commission; Sigrid Juselius FoundationSigrid Juselius Foundation; CURE; Finnish Epilepsy Foundation	This study was supported by the Academy of Finland (AP), The Sigrid Juselius Foundation (AP), CURE (AP), and The Finnish Epilepsy Foundation (TB). We thank Drs. M. S. Grady and D.J. Watson, Department of Neurosurgery, University of Pennsylvania, Philadelphia, for their help in setting up the lateral fluid-percussionmodel in mice. We also thank Marja-Leena Hannila, M.Sc., statistician of the Faculty of Health of the University of Eastern Finland, for her help in statistical analysis.	Akasu T, 2002, NEUROSCI LETT, V329, P305, DOI 10.1016/S0304-3940(02)00707-3; Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; Anderson GD, 2009, EPILEPSY BEHAV, V16, P501, DOI 10.1016/j.yebeh.2009.08.025; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Atkins CM, 2010, EUR J NEUROSCI, V32, P1912, DOI 10.1111/j.1460-9568.2010.07467.x; Bao YH, 2011, J NEUROTRAUM, V28, P35, DOI 10.1089/neu.2010.1383; Blanco MM, 2009, EPILEPSIA, V50, P824, DOI 10.1111/j.1528-1167.2008.01797.x; Bortel A, 2010, NEUROBIOL DIS, V40, P478, DOI 10.1016/j.nbd.2010.07.015; Calcagni ML, 2002, EUR J NUCL MED MOL I, V29, P1298, DOI 10.1007/s00259-002-0879-1; Carbonell WS, 1998, J NEUROTRAUM, V15, P217, DOI 10.1089/neu.1998.15.217; CAVAZOS JE, 1991, J NEUROSCI, V11, P2795; Centers for Disease Control and Prevention, 2001, TRAUM BRAIN INJ US R; Chrzaszcz M, 2010, J NEUROTRAUM, V27, P1283, DOI 10.1089/neu.2009.1227; Coulter DA, 1996, EPILEPSY RES, V26, P81, DOI 10.1016/S0920-1211(96)00044-7; D'Ambrosio R, 2005, BRAIN, V128, P174, DOI 10.1093/brain/awh337; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; Dardiotis E., 2010, NEUROSURG FOCUS, V28, P9; DASILVA AM, 1990, ACT NEUR S, V50, P48; Diaz-Arrastia R, 2003, ARCH NEUROL-CHICAGO, V60, P818, DOI 10.1001/archneur.60.6.818; Diaz-Arrastia R, 2000, ARCH NEUROL-CHICAGO, V57, P1611, DOI 10.1001/archneur.57.11.1611; Dudek FE, 2009, NEUROTHERAPEUTICS, V6, P319, DOI 10.1016/j.nurt.2009.01.020; Echegoyen J, 2009, EPILEPSY RES, V85, P123, DOI 10.1016/j.eplepsyres.2009.02.019; Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0; Fisher RS, 2005, EPILEPSIA, V46, P470, DOI 10.1111/j.0013-9580.2005.66104.x; Fox GB, 1999, J NEUROTRAUM, V16, P377, DOI 10.1089/neu.1999.16.377; Golarai G, 2001, J NEUROSCI, V21, P8523, DOI 10.1523/JNEUROSCI.21-21-08523.2001; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; Guo D., 2010, AM EP SOC ANN M; Gurkoff GG, 2009, NEUROSCIENCE, V164, P862, DOI 10.1016/j.neuroscience.2009.08.021; Haltiner AM, 1997, ARCH PHYS MED REHAB, V78, P835, DOI 10.1016/S0003-9993(97)90196-9; HAMM RJ, 1995, EXP NEUROL, V136, P143, DOI 10.1006/exnr.1995.1091; Hanell A, 2010, J NEUROTRAUM, V27, P1297, DOI 10.1089/neu.2009.1255; Herman ST, 2002, NEUROLOGY, V59, pS21, DOI 10.1212/WNL.59.9_suppl_5.S21; Hudak AM, 2004, J HEAD TRAUMA REHAB, V19, P290, DOI 10.1097/00001199-200407000-00003; Hunt RF, 2010, J NEUROPHYSIOL, V103, P1490, DOI 10.1152/jn.00957.2009; Hunt RF, 2009, EXP NEUROL, V215, P243, DOI 10.1016/j.expneurol.2008.10.005; Kazemi M, 2004, MAGN RESON IMAGING, V22, P653, DOI 10.1016/j.mri.2004.01.043; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharatishvili I, 2007, BRAIN, V130, P3155, DOI 10.1093/brain/awm268; Kharatishvili I, 2010, EPILEPSY RES, V90, P47, DOI 10.1016/j.eplepsyres.2010.03.007; Kraus J., 2006, ACTA NEUROCHIR, V148, P255; LOSCHER W, 1991, EPILEPSY RES, V9, P1, DOI 10.1016/0920-1211(91)90041-D; Lowenstein DH, 2009, EPILEPSIA, V50, P4, DOI 10.1111/j.1528-1167.2008.02004.x; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Marklund N, 2001, ACTA NEUROCHIR, V143, P73, DOI 10.1007/s007010170141; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; MATHERN GW, 1995, J NEUROSURG, V82, P220, DOI 10.3171/jns.1995.82.2.0220; Mora GN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005759; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; NG T, 1989, ACTA NEUROPATHOL, V78, P438, DOI 10.1007/BF00688181; Nissinen J, 2000, EPILEPSY RES, V38, P177, DOI 10.1016/S0920-1211(99)00088-1; Nissinen J, 2001, HIPPOCAMPUS, V11, P299, DOI 10.1002/hipo.1044; Pitkanen A, 2006, J NEUROTRAUM, V23, P241, DOI 10.1089/neu.2006.23.241; Pitkanen A., 2011, NEUROSCI LETT   0321; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Rattka M, 2011, NEUROPHARMACOLOGY, V60, P505, DOI 10.1016/j.neuropharm.2010.11.005; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Santhakumar V, 2000, J PHYSIOL-LONDON, V524, P117, DOI 10.1111/j.1469-7793.2000.00117.x; Schauwecker PE, 1997, P NATL ACAD SCI USA, V94, P4103, DOI 10.1073/pnas.94.8.4103; Schauwecker PE, 2002, PROG BRAIN RES, V135, P139; Scheid R, 2010, DTSCH ARZTEBL INT, V107, P199, DOI 10.3238/arztebl.2010.0199; Schwartzkroin PA, 2010, EPILEPSY RES, V92, P74, DOI 10.1016/j.eplepsyres.2010.08.009; SLOVITER RS, 1982, BRAIN RES BULL, V8, P771, DOI 10.1016/0361-9230(82)90104-6; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Specht CG, 2004, GENOMICS, V83, P1176, DOI 10.1016/j.ygeno.2003.12.014; Specht CG, 2001, BMC NEUROSCI, V2, DOI 10.1186/1471-2202-2-11; Statler KD, 2009, EPILEPSY RES, V86, P221, DOI 10.1016/j.eplepsyres.2009.05.006; Statler KD, 2008, EPILEPSY RES, V80, P163, DOI 10.1016/j.eplepsyres.2008.04.001; Swartz BE, 2006, EPILEPSIA, V47, P1373, DOI 10.1111/j.1528-1167.2006.00602.x; Toth Z, 1997, J NEUROSCI, V17, P8106; Tran LD, 2006, J NEUROTRAUM, V23, P1330, DOI 10.1089/neu.2006.23.1330; Vaishnavi S, 2009, PSYCHOSOMATICS, V50, P198, DOI 10.1176/appi.psy.50.3.198; Vezzani A, 1995, EUR J NEUROSCI, V7, P2513, DOI 10.1111/j.1460-9568.1995.tb01050.x; WIESER HG, 1979, EPILEPSIA, V20, P47, DOI 10.1111/j.1528-1157.1979.tb04775.x; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Wotjak CT, 2003, TRENDS GENET, V19, P183, DOI 10.1016/S0168-9525(02)00049-5; Yang L, 2010, J NEUROTRAUM, V27, P1541, DOI 10.1089/neu.2009.1244; YONEKAWA WD, 1980, J PHARMACOL EXP THER, V214, P589	81	109	109	0	18	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2012	29	5					789	812		10.1089/neu.2011.1954			24	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	907TZ	WOS:000301442900009	22023672				2022-02-06	
J	Bass, CR; Panzer, MB; Rafaels, KA; Wood, G; Shridharani, J; Capehart, B				Bass, Cameron R.; Panzer, Matthew B.; Rafaels, Karen A.; Wood, Garrett; Shridharani, Jay; Capehart, Bruce			Brain Injuries from Blast	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Traumatic brain injury; Post-traumatic stress disorder; Shock tube; Animal models; Injury mechanisms; Pathophysiology; Military; Civilian	POSTTRAUMATIC-STRESS-DISORDER; OPERATION-IRAQI-FREEDOM; NAVY-MARINE-CORPS; CLOSED-HEAD INJURY; SMOKE-INHALATION; RISK-ASSESSMENT; WHITE-MATTER; AFGHANISTAN; CARE; EXPLOSIONS	Traumatic brain injury (TBI) from blast produces a number of conundrums. This review focuses on five fundamental questions including: (1) What are the physical correlates for blast TBI in humans? (2) Why is there limited evidence of traditional pulmonary injury from blast in current military field epidemiology? (3) What are the primary blast brain injury mechanisms in humans? (4) If TBI can present with clinical symptoms similar to those of Post-Traumatic Stress Disorder (PTSD), how do we clinically differentiate blast TBI from PTSD and other psychiatric conditions? (5) How do we scale experimental animal models to human response? The preponderance of the evidence from a combination of clinical practice and experimental models suggests that blast TBI from direct blast exposure occurs on the modern battlefield. Progress has been made in establishing injury risk functions in terms of blast overpressure time histories, and there is strong experimental evidence in animal models that mild brain injuries occur at blast intensities that are similar to the pulmonary injury threshold. Enhanced thoracic protection from ballistic protective body armor likely plays a role in the occurrence of blast TBI by preventing lung injuries at blast intensities that could cause TBI. Principal areas of uncertainty include the need for a more comprehensive injury assessment for mild blast injuries in humans, an improved understanding of blast TBI pathophysiology of blast TBI in animal models and humans, the relationship between clinical manifestations of PTSD and mild TBI from blunt or blast trauma including possible synergistic effects, and scaling between animals models and human exposure to blasts in wartime and terrorist attacks. Experimental methodologies, including location of the animal model relative to the shock or blast source, should be carefully designed to provide a realistic blast experiment with conditions comparable to blasts on humans. If traditional blast scaling is appropriate between species, many reported rodent blast TBI experiments using air shock tubes have blast overpressure conditions that are similar to human long-duration nuclear blasts, not high explosive blasts.	[Bass, Cameron R.; Panzer, Matthew B.; Wood, Garrett; Shridharani, Jay] Duke Univ, Dept Biomed Engn, Durham, NC 27708 USA; [Rafaels, Karen A.] Univ Virginia, Charlottesville, VA USA; [Capehart, Bruce] Duke Univ, Durham VA Med Ctr, Durham, NC USA		Bass, CR (corresponding author), Duke Univ, Dept Biomed Engn, 136 Hudson Hall, Durham, NC 27708 USA.	dale.bass@duke.edu		Wood, Garrett/0000-0002-5619-5527	Duke University Pratt School of Engineering; Department of Biomedical Engineering	The authors gratefully acknowledge support from Duke University Pratt School of Engineering and the Department of Biomedical Engineering.	American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; [Anonymous], SIAD INDEPENDENT PAN; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Aschkenasy-Steuer G, 2005, CRIT CARE, V9, P490, DOI 10.1186/cc3762; Baker F.W., 2008, SENSORS MAY LEAD FAS; Baker W.E., 1973, EXPLOSIONS AIR; Bass CR, 2008, J TRAUMA, V65, P604, DOI 10.1097/TA.0b013e3181454ab4; Bass Cameron R Dale, 2005, Int J Occup Saf Ergon, V11, P347; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI [10.1089/neu.2008.0898, 10.1089/neu.2009-0898]; Bell Monte K, 2008, Mil Med, V173, pv; Bochicchio GV, 2008, AM SURGEON, V74, P267; Bogo V., 1971, 2659 DASA LOV FDN ME; Bombardier CH, 2006, J NEUROPSYCH CLIN N, V18, P501, DOI 10.1176/appi.neuropsych.18.4.501; Bowen I.G., 1968, DASA2113 LOV FDN MED; Bowen I.G., 1965, DASA1675 LOV FDN MED; Breeze J., 2010, BR J ORAL MAXILLOFAC; Brethauer SA, 2008, ARCH SURG-CHICAGO, V143, P564, DOI 10.1001/archsurg.143.6.564; Brolen P, 2007, PREHOSP DISASTER MED, V22, P246, DOI 10.1017/S1049023X00004763; Brown W. T., 2005, SHOCK COMPR COND MAT; Burns JC, 2008, J PEDIATR-US, V153, P833, DOI 10.1016/j.jpeds.2008.06.011; Capehart B., 2011, DEP VET AFF OFF MENT; CELANDER H, 1955, ACTA PHYSIOL SCAND, V33, P6, DOI 10.1111/j.1748-1716.1955.tb01188.x; Cernak I, 1999, J TRAUMA, V47, P96, DOI 10.1097/00005373-199907000-00021; Cernak I, 1996, J TRAUMA, V40, pS100, DOI 10.1097/00005373-199603001-00023; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Chalton LD, 2009, BRAIN INJURY, V23, P77, DOI 10.1080/02699050802635273; Champion HR, 2009, J TRAUMA, V66, P1468, DOI 10.1097/TA.0b013e3181a27e7f; CHAN PH, 1995, J NEUROTRAUM, V12, P815, DOI 10.1089/neu.1995.12.815; Chatelin S, 2010, BIORHEOLOGY, V47, P255, DOI 10.3233/BIR-2010-0576; Ciraulo DL, 2006, J AM COLL SURGEONS, V203, P942, DOI 10.1016/j.jamcollsurg.2006.07.028; CLEMEDSON CJ, 1953, AM J PHYSIOL, V174, P316, DOI 10.1152/ajplegacy.1953.174.2.316; CLEMEDSON CJ, 1956, AM J PHYSIOL, V184, P119, DOI 10.1152/ajplegacy.1955.184.1.119; CLEMEDSON CJ, 1956, ACTA PHYSIOL SCAND, V37, P202; Cripps NPJ, 1996, J TRAUMA, V40, pS206, DOI 10.1097/00005373-199603001-00045; Denes A, 2010, BRAIN BEHAV IMMUN, V24, P708, DOI 10.1016/j.bbi.2009.09.010; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; DeWitt DS, 2009, J NEUROTRAUM, V26, P877, DOI 10.1089/neu.2007.0439; Eppinger R. H., 1984, SAE GOV IND M EXPL M; First M. B., 1995, HDB DIFFERENTIAL DIA; Galarneau MR, 2008, J NEUROSURG, V108, P950, DOI 10.3171/JNS/2008/108/5/0950; Gawande A, 2004, NEW ENGL J MED, V351, P2471, DOI 10.1056/NEJMp048317; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; Gomez AM, 2007, EUR J EMERG MED, V14, P247; Goroshin S, 2006, PROPELL EXPLOS PYROT, V31, P169, DOI 10.1002/prep.200600024; Guy RJ, 2004, J ROY SOC MED, V97, P255, DOI 10.1258/jrsm.97.5.255-a; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Heitger MH, 2005, BRAIN INJURY, V19, P109, DOI 10.1080/02699050410001720095; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hooker DR, 1924, AM J PHYSIOL, V67, P219; Hyde DW, 2004, CONWEP 2 1 0 8 CONVE; IREMONGER MJ, 1997, SCI FDN TRAUMA, P189; KAUR C, 1995, NEUROPATH APPL NEURO, V21, P369, DOI 10.1111/j.1365-2990.1995.tb01073.x; Kauvar DS, 2006, BURNS, V32, P853, DOI 10.1016/j.burns.2006.03.008; Kennedy MRT, 2009, J INT NEUROPSYCH SOC, V15, P130, DOI 10.1017/S1355617708090024; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Kincaid J., 1830, ADVENTURES RIFLE BRI; KOLSKY H, 1954, NATURE, V173, P77, DOI 10.1038/173077a0; Kraus MF, 2007, COGN BEHAV NEUROL, V20, P170, DOI 10.1097/WNN.0b013e318142badb; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Krohn PL, 1941, 249 RC MIN HOM SEC C; Larray D. J., 1812, MEMOIRES CHIRURG CAM, P440; Lee KYK, 2011, NEUROIMAGE, V54, pS30, DOI 10.1016/j.neuroimage.2010.05.042; Leung Lai Yee, 2008, Molecular & Cellular Biomechanics, V5, P155; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Lockey DJ, 2005, RESUSCITATION, V66, pIX, DOI 10.1016/j.resuscitation.2005.07.005; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mairet A., 1917, PRESSE MED, V25, P478; Mekel Michal, 2009, Am J Disaster Med, V4, P233; Montanarelli N., 1975, LIGHTWEIGHT BODY ARM; Mott F. W., 1919, AM J MED SCI, V159, P136; Mott FW, 1916, LANCET, V1, P331; Nelson TJ, 2008, J TRAUMA, V65, P212, DOI 10.1097/01.ta.0000196010.50246.9a; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Palm E. J., 2010, PERS ARM SYST S QUEB; Panzer M. B., 2011, J TRAUMA IN PRESS; Panzer MB, 2010, PERS ARM SYST S QUEB; Pare A., 1985, OUEVRES A PARE CONSE, P1585; Perry VH, 2010, ACTA NEUROPATHOL, V120, P277, DOI 10.1007/s00401-010-0722-x; PHILLIPS YY, 1988, J TRAUMA, V28, pS149, DOI 10.1097/00005373-198801001-00030; Rafaels K. A., 2011, J NEUROTRAU IN PRESS; Rafaels K. A., 2011, THESIS U VIRGINIA; Rafaels K. A., 2011, J NEUROTRAUMA UNPUB; Rafaels KA, 2010, PERS ARM SYST S QUEB; Rafaels KA, 2010, J TRAUMA, V69, P368, DOI 10.1097/TA.0b013e3181e88122; Raftenberg MN, 2004, ARLTR3343; Reper P, 2002, BURNS, V28, P503, DOI 10.1016/S0305-4179(02)00051-7; Richmond D. R., 1959, TID6056 US AT EN COM; Richmond D. R., 1966, 1854 DASA; Richmond D. R., 1985, 9 INT S MABS OXF ENG; Ritenour AE, 2008, CRIT CARE MED, V36, pS311, DOI 10.1097/CCM.0b013e31817e2a8c; Rodoplu Ulkumen, 2004, Prehosp Disaster Med, V19, P133; Rosenfeld JV, 2010, INJURY, V41, P437, DOI 10.1016/j.injury.2009.11.018; Ruff RL, 2008, J REHABIL RES DEV, V45, P941, DOI 10.1682/JRRD.2008.02.0028; Rusca F, 1915, Z CHIR, V132, P315; Rutland-Brown W, 2007, PREHOSP DISASTER MED, V22, P157, DOI 10.1017/S1049023X00004593; Saljo A, 2002, J NEUROTRAUM, V19, P379, DOI 10.1089/089771502753594945; Saljo A, 2008, J NEUROTRAUM, V25, P1397, DOI 10.1089/neu.2008.0602; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Seal KH, 2011, DRUG ALCOHOL DEPEN, V116, P93, DOI 10.1016/j.drugalcdep.2010.11.027; Sharma SP, 1996, J THERMOPHYS HEAT TR, V10, P169, DOI 10.2514/3.768; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smith JE, 2011, PHILOS T R SOC B, V366, P291, DOI 10.1098/rstb.2010.0251; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Sterner James B., 2009, Inflammation & Allergy Drug Targets, V8, P63; Sumpter RE, 2005, BRIT J PSYCHIAT, V186, P423, DOI 10.1192/bjp.186.5.423; Svetlov S, 2009, J NEUROTRAUM, V26, pA75; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Vaishnavi S, 2009, PSYCHOSOMATICS, V50, P198, DOI 10.1176/appi.psy.50.3.198; Wade AL, 2007, J TRAUMA, V63, P836, DOI 10.1097/01.ta.0000251453.54663.66; Wang Y, 2006, NAT NEUROSCI, V9, P534, DOI 10.1038/nn1670; Wang Y., 2011, J NEUROTRAUMA; Warden DL, 2009, NEUROIMAGE, V47, pT152, DOI 10.1016/j.neuroimage.2009.01.060; Warden DL, 2005, J NEUROTRAUM, V22, P1178; White C. S., 1971, DNA2738T NUCL DEF AG; Wojcik BE, 2010, AM J PREV MED, V38, pS108, DOI 10.1016/j.amepre.2009.10.006; Wood GW, 2010, PERS ARM SYST S QUEB; Yoganandan N, 2011, CLIN ANAT, V24, P282, DOI 10.1002/ca.21106; Zatzick DF, 2010, ARCH GEN PSYCHIAT, V67, P1291, DOI 10.1001/archgenpsychiatry.2010.158; ZOROYA G, 2005, KEY IRAQ WOUND BRAIN; Zouris JM, 2006, MIL MED, V171, P246, DOI 10.7205/MILMED.171.3.246	125	109	111	3	46	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	JAN	2012	40	1			SI		185	202		10.1007/s10439-011-0424-0			18	Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Engineering	895HJ	WOS:000300486700017	22012085				2022-02-06	
J	Whiteneck, GG; Dijkers, MP; Heinemann, AW; Bogner, JA; Bushnik, T; Cicerone, KD; Corrigan, JD; Hart, T; Malec, JF; Millis, SR				Whiteneck, Gale G.; Dijkers, Marcel P.; Heinemann, Allen W.; Bogner, Jennifer A.; Bushnik, Tamara; Cicerone, Keith D.; Corrigan, John D.; Hart, Tessa; Malec, James F.; Millis, Scott R.			Development of the Participation Assessment With Recombined Tools-Objective for Use After Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injury, chronic; Interpersonal relations; Outcome assessment, health care; Psychometrics; Questionnaires; Rehabilitation; Reproducibility of results; Role; Social adjustment	DISABILITY RATING-SCALE; COMMUNITY INTEGRATION QUESTIONNAIRE; PORTLAND ADAPTABILITY INVENTORY; GALVESTON ORIENTATION; HEAD-INJURY; AMNESIA TEST; OUTCOMES; REHABILITATION; VALIDITY; SATISFACTION	Whiteneck GG, Dijkers MP, Heinemann AW, Bogner JA, Bushnik T, Cicerone KD, Corrigan JD, Hart T, Malec JF, Millis SR. Development of the Participation Assessment With Recombined Tools Objective for use after traumatic brain injury. Arch Phys Med Rehabil 2011;92:542-51. Objective: To develop a new measure, the Participation Assessment With Recombined Tools Objective (PART-O), based on items from 3 participation instruments. Design: Instrument development based on survey research. Setting: Community. Participants: Adults (N=400) with traumatic brain injury (TBI) 1 to 15 years postinjury, recruited from 8 TBI Model Systems (TBIMS). Interventions: None. Main Outcome Measure: Community Integration Questionnaire version 2; Participation Objective, Participation Subjective; Craig Handicap Assessment and Reporting Technique; PART-O. Results: Using Rasch rating scale analysis to evaluate the psychometric properties of participation items drawn from 3 instruments, a set of 24 items was developed that covered a broad range of participation content and formed a measure with person separation of 2.47, person reliability of .86, item spread of 4.25 logits, item separation of 11.36, and item reliability of .99. Items were well targeted on the sample with only 1 item misfitting. The PART-O showed expected relationships with measures of impairment, activity limitations, and subjective well-being. Conclusions: The 24-item PART-O is an acceptable measure of objective participation for persons with moderate and severe TBI. It has been adopted as the measure of participation in the TBIMS.	[Whiteneck, Gale G.] Craig Hosp, Englewood, CO 80113 USA; [Dijkers, Marcel P.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA; [Heinemann, Allen W.] Northwestern Univ, Dept Phys Med & Rehabil, Feinberg Sch Med, Chicago, IL 60611 USA; [Heinemann, Allen W.] Rehabil Inst Chicago, Chicago, IL 60611 USA; [Bogner, Jennifer A.; Corrigan, John D.] Ohio State Univ, Columbus, OH 43210 USA; [Bushnik, Tamara] NYU, Rusk Inst Rehabil Med, Langone Med Ctr, New York, NY USA; [Cicerone, Keith D.] JFK Johnson Rehabil Inst, Edison, NJ USA; [Hart, Tessa] Moss Rehabil Res Inst, Elkins Pk, PA USA; [Malec, James F.] Rehabil Hosp Indiana, Indianapolis, IN USA; [Millis, Scott R.] Wayne State Univ, Sch Med, Detroit, MI USA		Whiteneck, GG (corresponding author), Craig Hosp, 3425 S Clarkson St, Englewood, CO 80113 USA.	gale@craig-hospital.org	Heinemann, Allen W./AAI-2790-2021; Heinemann, Allen W/K-6283-2012; Corrigan, John D./E-2921-2011	Heinemann, Allen W./0000-0003-2782-7326; Heinemann, Allen W/0000-0003-2782-7326; Dijkers, Marcel/0000-0002-8362-5596; Bushnik, Tamara/0000-0003-3328-257X	National Institute on Disability and Rehabilitation Research [H133A020510, H133A070022]; New York TBIMS [H1331020501, H133A070033]; Ohio Regional TBIMS [H133A020503, H133A070029]; Northern California TBIMS [H133A020524, H133A070038]; JFK Johnson Rehabilitation Institute TBIMS [H133A020518, H133A070030]; Moss TBIMS [H133A020505, H133A070040]; Rehabilitation Research and Training Center on the Community Integration of Individuals With Traumatic Brain Injury [H133B30038]; Rehabilitation Research and Training Center on Measuring Rehabilitation Outcomes and Effectiveness [H133B040032]	Supported by the National Institute on Disability and Rehabilitation Research through Traumatic Brain Injury Model System (TBIMS) awards to the Rocky Mountain Regional Brain Injury System (grant nos. H133A020510, H133A070022); New York TBIMS (grant nos. H1331020501, H133A070033); Ohio Regional TBIMS (grant nos. H133A020503, H133A070029); Northern California TBIMS (grant nos. H133A020524, H133A070038); JFK Johnson Rehabilitation Institute TBIMS (grant nos. H133A020518, H133A070030); The Moss TBIMS (grant nos. H133A020505, H133A070040); Rehabilitation Research and Training Center on the Community Integration of Individuals With Traumatic Brain Injury (grant no. H133B30038); and Rehabilitation Research and Training Center on Measuring Rehabilitation Outcomes and Effectiveness (grant no. H133B040032).	Boake C, 1996, ARCH PHYS MED REHAB, V77, P765, DOI 10.1016/S0003-9993(96)90254-3; BOAKE C, SUPERVISION RATING S; Bode RK, 2000, J HEAD TRAUMA REHAB, V15, P637, DOI 10.1097/00001199-200002000-00004; Bond T, 2001, APPL RASCH MODEL FUN; Brown M, 2004, J HEAD TRAUMA REHAB, V19, P459, DOI 10.1097/00001199-200411000-00004; Bushnik T, 2003, ARCH PHYS MED REHAB, V84, P151, DOI 10.1053/apmr.2003.50123; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P828, DOI 10.1016/S0003-9993(97)90195-7; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P445, DOI 10.1097/00001199-200411000-00003; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Cusick CP, 2001, ARCH PHYS MED REHAB, V82, P1018, DOI 10.1053/apmr.2001.25098; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dijkers M, 1997, J HEAD TRAUMA REHAB, V12, P74, DOI 10.1097/00001199-199712000-00007; Dijkers M, 2009, ARCH PHYS MED REHAB, V90, pe39, DOI DOI 10.1016/j.apmr.2009.08.123; Dijkers MP, 2010, ARCH PHYS MED REHAB, V91, pS5, DOI 10.1016/j.apmr.2009.10.036; Dijkers MPJM, 2000, ARCH PHYS MED REHAB, V81, pS63, DOI 10.1053/apmr.2000.20627; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; Evans CC, 2005, J HEAD TRAUMA REHAB, V20, P488, DOI 10.1097/00001199-200511000-00002; Frey KL, 2007, BRAIN INJURY, V21, P513, DOI 10.1080/02699050701311026; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; Granger C. V., 1986, TOP GERIATR REHABIL, V1, P59, DOI DOI 10.1097/00013614-198604000-00007; GRANGER CV, 1993, AM J PHYS MED REHAB, V72, P84, DOI 10.1097/00002060-199304000-00005; Green J, 2001, DISABIL REHABIL, V23, P670, DOI 10.1080/09638280110045382; Hall K. M., 1993, J HEAD TRAUMA REHAB, V8, P60, DOI DOI 10.1097/00001199-199308020-00008; Hammel J, 2008, DISABIL REHABIL, V30, P1445, DOI 10.1080/09638280701625534; Hanks RA, 2008, ARCH PHYS MED REHAB, V89, P950, DOI 10.1016/j.apmr.2008.01.011; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P158, DOI 10.1097/00001199-200503000-00004; Hart T, 2010, J HEAD TRAUMA REHAB, V25, P339, DOI 10.1097/HTR.0b013e3181c7e60b; Heinemann AW, 2011, ARCH PHYS MED REHAB, V92, P564, DOI 10.1016/j.apmr.2010.07.220; Heinemann AW, 1997, ARCH PHYS MED REHAB, V78, P143, DOI 10.1016/S0003-9993(97)90255-0; Jackson WT, 1998, ARCH PHYS MED REHAB, V79, P718, DOI 10.1016/S0003-9993(98)90051-X; Jacobsson LJ, 2010, BRAIN INJURY, V24, P1075, DOI 10.3109/02699052.2010.494590; Johnston MV, 2005, ARCH PHYS MED REHAB, V86, P735, DOI 10.1016/j.apmr.2004.10.031; Kreutzer J., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI [10.1097/00001199-199308020-00009, DOI 10.1097/00001199-199308020-00009]; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Linacre J, USERS GUIDE WINSTEPS; Linacre J M, 1999, J Outcome Meas, V3, P103; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; Magasi S, 2009, J REHABIL MED, V41, P936, DOI 10.2340/16501977-0450; Malec JF, 2004, ARCH PHYS MED REHAB, V85, P1989, DOI 10.1016/j.apmr.2004.01.032; Malec JF, 2004, BRAIN INJURY, V18, P563, DOI 10.1080/02699050310001646134; Malec JF, 2003, J HEAD TRAUMA REHAB, V18, P479, DOI 10.1097/00001199-200311000-00002; MELLICK D, 1999, J REHABIL OUTCOMES, V3, P12; Mushkudiani NA, 2008, J CLIN EPIDEMIOL, V61, P331, DOI 10.1016/j.jclinepi.2007.06.011; *NAT DAT STAT CTR, SYLL; Nouri F. M., 1987, CLIN REHABIL, V1, P301, DOI [DOI 10.1177/026921558700100409, 10.1177/026921558700100409]; Novack TA, 2000, J HEAD TRAUMA REHAB, V15, P957, DOI 10.1097/00001199-200006000-00008; NOVACK TA, 1991, J HEAD TRAUMA REHAB, V6, P69, DOI DOI 10.1097/00001199-199112000-00014; Pavot W., 1993, PSYCHOL ASSESSMENT, V52, P164, DOI DOI 10.1037/1040-3590.5.2.164; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Resnik L, 2009, ARCH PHYS MED REHAB, V90, P856, DOI 10.1016/j.apmr.2008.11.010; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, pR5, DOI 10.1097/00001199-199602000-00001; Sherer M, 2003, J HEAD TRAUMA REHAB, V18, P408, DOI 10.1097/00001199-200309000-00003; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Wade D T, 1985, Int Rehabil Med, V7, P176; Whiteneck G, 1999, ARCH PHYS MED REHAB, V80, P1485, DOI 10.1016/S0003-9993(99)90262-9; Whiteneck G, 2009, ARCH PHYS MED REHAB, V90, pS22, DOI 10.1016/j.apmr.2009.06.009; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; Wiersma D, 1996, SOC PSYCH PSYCH EPID, V31, P101, DOI 10.1007/BF00785755; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204; World Health Organization, 1980, INT CLASS IMP DIS HA; World Health Organization, 2007, INT CLASS FUNCT DIS; Wright BD, 1996, RASCH MEASUREMENT T, V10, P509; Wright BD., 1982, RATING SCALE ANAL; Wright J, 2000, DISABILITY RATING SC; Zhang L, 2002, J HEAD TRAUMA REHAB, V17, P497, DOI 10.1097/00001199-200212000-00002	69	109	109	0	16	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	2011	92	4					542	551		10.1016/j.apmr.2010.08.002			10	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	743VT	WOS:000289047500004	21367393				2022-02-06	
J	De Bonis, P; Pompucci, A; Mangiola, A; Rigante, L; Anile, C				De Bonis, Pasquale; Pompucci, Angelo; Mangiola, Annunziato; Rigante, Luigi; Anile, Carmelo			Post-Traumatic Hydrocephalus after Decompressive Craniectomy: An Underestimated Risk Factor	JOURNAL OF NEUROTRAUMA			English	Article						decompressive craniectomy; post-traumatic hydrocephalus; risk factor; traumatic brain injury	TRAUMATIC BRAIN-INJURY; INTRACRANIAL HYPERTENSION; MANAGEMENT	The incidence of post-traumatic hydrocephalus (PTH) has been reported to be 0.7-51.4%, and we have frequently observed the development of PTH in patients undergoing decompressive craniectomy (DC). For this reason we performed a retrospective review of a consecutive series of patients undergoing DC after traumatic brain injury (TBI). From January 2006 to December 2009, 41 patients underwent DC after closed head injury. Study outcomes focused specifically on the development of hydrocephalus after DC. Variables described by other authors to be associated with PTH were studied, including advanced age, the timing of cranioplasty, higher score on the Fisher grading system, low post-resuscitation Glasgow Coma Scale (GCS) score, and cerebrospinal fluid (CSF) infection. We also analyzed the influence of the area of craniotomy and the distance of craniotomy from the midline. Logistic regression was used with hydrocephalus as the primary outcome measure. Of the nine patients who developed hydrocephalus, eight patients (89%) had undergone craniotomy with the superior limit <25mm from the midline. This association was statistically significant (p=0.01 - Fisher's exact test). Logistic regression analysis showed that the only factor independently associated with the development of hydrocephalus was the distance from the midline. Patients with craniotomy whose superior limit was <25mm from the midline had a markedly increased risk of developing hydrocephalus (OR 17). Craniectomy with a superior limit too close to the midline can predispose patients undergoing DC to the development of hydrocephalus. We therefore suggest performing wide DCs with the superior limit >25mm from the midline.	[De Bonis, Pasquale; Pompucci, Angelo; Mangiola, Annunziato; Rigante, Luigi; Anile, Carmelo] Catholic Univ, Sch Med, Inst Neurosurg, I-00168 Rome, Italy		De Bonis, P (corresponding author), Catholic Univ, Sch Med, Inst Neurosurg, Lgo F Vito 1, I-00168 Rome, Italy.	debonisvox@gmail.com	de bonis, pasquale/K-8200-2016; Rigante, Luigi/K-7260-2016	de bonis, pasquale/0000-0002-9879-8940; Rigante, Luigi/0000-0003-0539-526X			Anile C, 2009, CHILD NERV SYST, V25, P325, DOI 10.1007/s00381-008-0749-7; ANILE C, 1999, EUR CONTR C ECC 99 3; Choi I, 2008, J KOREAN NEUROSURG S, V43, P227, DOI 10.3340/jkns.2008.43.5.227; Cooper DJ, 2008, J CRIT CARE, V23, P387, DOI 10.1016/j.jcrc.2007.05.002; Guyot LL, 2000, NEUROL RES, V22, P25; HOCHWALD G M, 1972, Developmental Medicine and Child Neurology, V27, P65; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Jiao Qing-fang, 2007, Chin J Traumatol, V10, P159; Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337; Kaufman H H, 1978, Neurosurgery, V2, P136; Mazzini L, 2003, ARCH PHYS MED REHAB, V84, P1637, DOI 10.1053/S0003-9993(03)00314-9; Munch E, 2000, NEUROSURGERY, V47, P315, DOI 10.1097/00006123-200008000-00009; Olivecrona M, 2007, J NEUROTRAUM, V24, P927, DOI 10.1089/neu.2005.356E; Phuenpathom Nakornchai, 1999, Journal of the Medical Association of Thailand, V82, P46; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Pompucci A, 2007, J NEUROTRAUM, V24, P1182, DOI 10.1089/neu.2006.0244; Tian HL, 2008, SURG NEUROL, V69, P241, DOI 10.1016/j.surneu.2007.02.032; Waziri A, 2007, NEUROSURGERY, V61, P489, DOI 10.1227/01.NEU.0000290894.85072.37; WEIFORD EC, 1949, J NEUROSURG, V6, P13, DOI 10.3171/jns.1949.6.1.0013; Whitfield PC, 2001, BRIT J NEUROSURG, V15, P500, DOI 10.1080/02688690120105110; Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9	21	109	111	0	12	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	NOV	2010	27	11					1965	1970		10.1089/neu.2010.1425			6	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	682BZ	WOS:000284375500004	20812777				2022-02-06	
J	Ferguson, PL; Smith, GM; Wannamaker, BB; Thurman, DJ; Pickelsimer, EE; Selassie, AW				Ferguson, Pamela L.; Smith, Gigi M.; Wannamaker, Braxton B.; Thurman, David J.; Pickelsimer, E. Elisabeth; Selassie, Anbesaw W.			A population-based study of risk of epilepsy after hospitalization for traumatic brain injury	EPILEPSIA			English	Article						Posttraumatic epilepsy; Traumatic brain injuries; Incidence cohort studies; Population surveillance; Depressive disorder	LATE POSTTRAUMATIC SEIZURES; UNPROVOKED SEIZURES; MAJOR DEPRESSION; SOUTH-CAROLINA; HEAD-INJURY; HIPPOCAMPAL VOLUME; ADULTS; PREVALENCE; COMMUNITY; EPIDEMIOLOGY	P>Purpose: This study was undertaken to determine the risk of developing posttraumatic epilepsy (PTE) within 3 years after discharge among a population-based sample of older adolescents and adults hospitalized with traumatic brain injury (TBI) in South Carolina. It also identifies characteristics related to development of PTE within this population. Methods: A stratified random sample of persons aged 15 and older with TBI was selected from the South Carolina nonfederal hospital discharge dataset for four consecutive years. Medical records of recruits were reviewed, and they participated in up to three yearly follow-up telephone interviews. Results: The cumulative incidence of PTE in the first 3 years after discharge, after adjusting for loss to follow-up, was 4.4 per 100 persons over 3 years for hospitalized mild TBI, 7.6 for moderate, and 13.6 for severe. Those with severe TBI, posttraumatic seizures prior to discharge, and a history of depression were most at risk for PTE. This higher risk group also included persons with three or more chronic medical conditions at discharge. Discussion: These results raise the possibility that although some of the characteristics related to development of PTE are nonmodifiable, other factors, such as depression, might be altered with intervention. Further research into factors associated with developing PTE could lead to risk-reducing treatments.	[Ferguson, Pamela L.; Pickelsimer, E. Elisabeth; Selassie, Anbesaw W.] Med Univ S Carolina, Div Biostat & Epidemiol, Dept Med, Charleston, SC 29425 USA; [Smith, Gigi M.; Wannamaker, Braxton B.] Med Univ S Carolina, Dept Neurol, Charleston, SC 29425 USA; [Smith, Gigi M.] Med Univ S Carolina, Coll Nursing, Charleston, SC 29425 USA; [Thurman, David J.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA		Ferguson, PL (corresponding author), Med Univ S Carolina, Div Biostat & Epidemiol, Dept Med, 135 Cannon St,Suite 303,MSC 835, Charleston, SC 29425 USA.	ferguspl@musc.edu	Cusco, Xavier Garcia/S-7576-2019	Cusco, Xavier Garcia/0000-0001-7199-6931; Thurman, David/0000-0002-0533-7062; Smith, Gigi/0000-0002-0921-7498	Division of Injury Response, National Center for Injury Prevention and Control (NCIPC) [U17/CCU421926]; National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP); Centers for Disease Control and Prevention (CDC)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA	This study was supported by cooperative agreement U17/CCU421926 (PI: Anbesaw W. Selassie) from the Division of Injury Response, National Center for Injury Prevention and Control (NCIPC), National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP), Centers for Disease Control and Prevention (CDC). The study was performed pursuant to a jointly financed cooperative arrangement between the NCPIC, the NCCDPHP, CDC, and the Social Security Administration (SSA), Office of Disability Income and Support Programs. The opinions and conclusions expressed are solely the authors' and should not be construed as representing the opinions or policy of CDC, SSA, or any agency of the federal government.We would like to thank the individuals at the SC Office of Research and Statistics and the SC Department of Health and Environmental Control who were invaluable in collecting data for this study, and Monica Gardner, who read and answered questions on a cited article published in German.We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.Disclosure: None of the authors has any conflict of interest to disclose.	Angeleri F, 1999, EPILEPSIA, V40, P1222, DOI 10.1111/j.1528-1157.1999.tb00850.x; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Annegers JF, 2000, SEIZURE-EUR J EPILEP, V9, P453, DOI 10.1053/seiz.2000.0458; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Annegers JF, 1999, EPILEPSIA, V40, P502, DOI 10.1111/j.1528-1157.1999.tb00748.x; Armitage P, 2002, STAT METHODS MED RES, P568; ARMSTRONG KK, 1990, ARCH PHYS MED REHAB, V71, P156; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; Berg AT, 1996, NEUROL CLIN, V14, P383, DOI 10.1016/S0733-8619(05)70263-2; Christensen J, 2009, LANCET, V373, P1105, DOI 10.1016/S0140-6736(09)60214-2; Corrigan J., 2003, TECHN REP PROBL SUBS; De Santis A, 1992, Acta Neurochir Suppl (Wien), V55, P64; DESAI BT, 1983, ANN EMERG MED, V12, P543, DOI 10.1016/S0196-0644(83)80294-7; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; Ettinger A, 2004, NEUROLOGY, V63, P1008, DOI 10.1212/01.WNL.0000138430.11829.61; Expert Group on Injury Severity Measurement in Administrative Datasets, 2004, DISC DOC INJ SEV MEA; Ferguson PL, 2008, EPILEPSY BEHAV, V13, P529, DOI 10.1016/j.yebeh.2008.05.005; Foreman BP, 2007, J TRAUMA, V62, P946, DOI 10.1097/01.ta.0000229796.14717.3a; Forsgren L, 1996, EPILEPSIA, V37, P224, DOI 10.1111/j.1528-1157.1996.tb00017.x; FORSGREN L, 1990, EPILEPSY RES, V6, P66, DOI 10.1016/0920-1211(90)90010-S; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Gaitatzis A, 2002, EPILEPSY RES, V50, P233, DOI 10.1016/S0920-1211(02)00031-1; HAERER AF, 1986, EPILEPSIA, V27, P66, DOI 10.1111/j.1528-1157.1986.tb03503.x; Haltiner AM, 1997, ARCH PHYS MED REHAB, V78, P835, DOI 10.1016/S0003-9993(97)90196-9; HAUSER WA, 1984, NEUROLOGY, V34, P746, DOI 10.1212/WNL.34.6.746; HAUSER WA, 1991, EPILEPSIA, V32, P429, DOI 10.1111/j.1528-1157.1991.tb04675.x; HAUSER WA, 1993, EPILEPSIA, V34, P453, DOI 10.1111/j.1528-1157.1993.tb02586.x; Heaney DC, 2002, BMJ-BRIT MED J, V325, P1013, DOI 10.1136/bmj.325.7371.1013; Hermann BP, 2000, EPILEPSIA, V41, pS31, DOI 10.1111/j.1528-1157.2000.tb01522.x; Hesdorffer DC, 2006, ANN NEUROL, V59, P35, DOI 10.1002/ana.20685; Hesdorffer DC, 2000, ANN NEUROL, V47, P246, DOI 10.1002/1531-8249(200002)47:2<246::AID-ANA17>3.3.CO;2-5; Hillbom E., 1959, ACTA PSYCHIAT NEUROL, V34, P7; Hirtz D, 2007, NEUROLOGY, V68, P326, DOI 10.1212/01.wnl.0000252807.38124.a3; *J HOPK U TRIAN IN, 1998, ICDMAP 90 US GUID; Jorge RE, 2007, BIOL PSYCHIAT, V62, P332, DOI 10.1016/j.biopsych.2006.07.024; Kotsopoulos I, 2005, SEIZURE-EUR J EPILEP, V14, P175, DOI 10.1016/j.seizure.2005.01.005; MACKENZIE EJ, 1984, AM J EMERG MED, V2, P537, DOI 10.1016/0735-6757(84)90081-0; Malberg JE, 2003, NEUROPSYCHOPHARMACOL, V28, P1562, DOI 10.1038/sj.npp.1300234; Mensah SA, 2006, EPILEPSY BEHAV, V8, P213, DOI 10.1016/j.yebeh.2005.09.014; Pickelsimer EE, 2006, J HEAD TRAUMA REHAB, V21, P491, DOI 10.1097/00001199-200611000-00004; *SAS I INC, 2002, SAS HELP DOC COCHR A; Schmitz EB, 1999, EPILEPSY RES, V35, P59, DOI 10.1016/S0920-1211(98)00129-6; Schutze M, 1999, ZBL NEUROCHIR, V60, P163; Selassie AW, 2005, J HEAD TRAUMA REHAB, V20, P257, DOI 10.1097/00001199-200505000-00008; Selassie AW, 2004, AM J EMERG MED, V22, P465, DOI 10.1016/j.ajem.2004.07.024; Sheline YI, 1999, J NEUROSCI, V19, P5034; Singer R B, 2001, J Insur Med, V33, P42; STOKES ME, 2000, CATEGORICAL DATA ANA, P349; Swartz BE, 2006, EPILEPSIA, V47, P1373, DOI 10.1111/j.1528-1167.2006.00602.x; SZKLO M, 2000, EPIDEMIOLOGY BASICS, P55; Thurman DJ., 1995, GUIDELINES SURVEILLA; Timmons S, 2002, Ir Med J, V95, P47; *US CENS BUR, 2007, INC 2007 MED HOUS IN; Wallace H, 1998, LANCET, V352, P1970, DOI 10.1016/S0140-6736(98)04512-7; Wang HC, 2008, J TRAUMA, V64, P883, DOI 10.1097/TA.0b013e31804a7fa4; WEISS GH, 1983, ARCH NEUROL-CHICAGO, V40, P7, DOI 10.1001/archneur.1983.04050010027006; Wiebe S, 1999, CAN J NEUROL SCI, V26, P263, DOI 10.1017/S0317167100000354; Yablon SA, 1998, ARCH PHYS MED REHAB, V79, P594	59	109	113	0	12	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0013-9580			EPILEPSIA	Epilepsia	MAY	2010	51	5					891	898		10.1111/j.1528-1167.2009.02384.x			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	587OA	WOS:000277000900023	19845734	Bronze			2022-02-06	
J	Chen, G; Zhang, SM; Shi, JX; Ai, JL; Qi, M; Hang, CH				Chen, Gang; Zhang, Shiming; Shi, Jixin; Ai, Jinglu; Qi, Meng; Hang, Chunhua			Simvastatin reduces secondary brain injury caused by cortical contusion in rats: Possible involvement of TLR4/NF-kappa B pathway	EXPERIMENTAL NEUROLOGY			English	Article						Simvastatin; Traumatic brain injury; Cerebral inflammation; Toll-like receptor 4; Nuclear factor-kappa B	TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; ENDOTHELIAL NITRIC-OXIDE; COA REDUCTASE INHIBITOR; DELAYED NEURONAL DEATH; TOLL-LIKE RECEPTORS; INFLAMMATORY RESPONSE; BARRIER PERMEABILITY; ADHESION MOLECULES; CEREBRAL-ISCHEMIA	Simvastatin, a cholesterol-lowering agent, has demonstrated neuroprotective effects against brain injury, but the underlying mechanisms remain unclear. This study was undertaken to evaluate the effect of simvastatin on the Toll-like receptor 4 (TLR4) and nuclear factor-kappa B (NF-kappa B) related signaling pathway and secondary brain injury in rats after traumatic brain injury (TBI). Adult male Wistar rats were divided into four groups: (1) Sham group (n=25); (2) Sham+vehicle group (n=25): (3) TBI+vehicle group (n=30): and (4) TBI+simvastatin group (n=30). Right parietal cortical contusion was made by using a weight-dropping method. In TBI+simvastatin group, simvastatin was administered orally at a dose of 37.5 mg/kg at 1 and 6 h after TBI. Brain samples were extracted at 24 h after trauma. As a result, we found that treatment with simvastatin markedly inhibited the mRNA and protein expressions of TLR4, NF-kappa B and the downstream inflammatory agents, such as interleukin-1 beta (IL-beta), tumor necrosis factor-alpha (TNF-alpha), interleukin-6(IL-6),and intercellular adhesion molecule-1 (ICAM-1). Administration of simvastatin following TBI significantly ameliorated the secondary brain damage, such as cortical apoptosis, brain edema, blood-brain barrier (BBB) impairment, and motor deficits. In conclusion, post-TBI simvastatin administration may attenuate TLR4/NF-kappa B-mediated inflammatory response in the injured rat brain, and this may be one mechanism by which simvastatin improves outcome following TBI. (c) 2009 Elsevier Inc. All rights reserved.	[Chen, Gang; Zhang, Shiming] Soochow Univ, Affiliated Hosp 1, Dept Neurosurg, Suzhou 215006, Peoples R China; [Shi, Jixin; Qi, Meng; Hang, Chunhua] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Peoples R China; [Ai, Jinglu] Univ Toronto, Sch Med, St Michaels Hosp, Div Neurosurg, Toronto, ON M5B 1W8, Canada		Chen, G (corresponding author), Soochow Univ, Affiliated Hosp 1, Dept Neurosurg, Suzhou 215006, Peoples R China.	Dr.Chen@utoronto.ca; nju_neurosurgery@163.com	QI, Meng/F-2802-2012	AI, JINGLU/0000-0001-7414-0207; Chen, Gang/0000-0002-0758-1907	Natural Science Foundation of Jiangsu ProvinceNatural Science Foundation of Jiangsu Province [2007153]; Natural Science Foundation of Nanjing Military AreaNational Natural Science Foundation of China (NSFC) [07M080]	We thank Dr. Bo Wu and Dr. Geng-bao Feng for their technical assistance. This work was supported by a grant from the Natural Science Foundation of Jiangsu Province (No. BI(2007153) and a grant from the Natural Science Foundation of Nanjing Military Area (No. 07M080).	Ahn KS, 2008, BIOCHEM PHARMACOL, V75, P907, DOI 10.1016/j.bcp.2007.10.010; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Balabanov R, 2001, NEUROL RES, V23, P175, DOI 10.1179/016164101101198514; Balduini W, 2003, STROKE, V34, P2007, DOI 10.1161/01.STR.0000080677.24419.88; Beauparlant Pierre, 1996, Cytokine and Growth Factor Reviews, V7, P175, DOI 10.1016/1359-6101(96)00020-2; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Chen XR, 2008, J PHARMACOL EXP THER, V326, P966, DOI 10.1124/jpet.108.140368; Daimon M, 2004, NEUROSCI LETT, V362, P122, DOI 10.1016/j.neulet.2004.03.012; Endres M, 1998, P NATL ACAD SCI USA, V95, P8880, DOI 10.1073/pnas.95.15.8880; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hang CH, 2004, BRAIN RES, V1026, P23, DOI 10.1016/j.brainres.2004.07.090; Holmin S, 2000, J NEUROSURG, V92, P108, DOI 10.3171/jns.2000.92.1.0108; Johnson GB, 2003, CRIT REV IMMUNOL, V23, P15, DOI 10.1615/CritRevImmunol.v23.i12.20; JONES BJ, 1968, J PHARM PHARMACOL, V20, P302, DOI 10.1111/j.2042-7158.1968.tb09743.x; Kariko K, 2004, J CEREBR BLOOD F MET, V24, P1288, DOI 10.1097/01.WCB.0000145666.68576.71; KIM KS, 1992, LYMPHOKINE CYTOK RES, V11, P293; Knoblach SM, 2002, J NEUROTRAUM, V19, P1039, DOI 10.1089/089771502760341956; Laflamme N, 2001, FASEB J, V15, P155, DOI 10.1096/fj.00-0339com; Lai YC, 2006, DEV NEUROSCI-BASEL, V28, P336, DOI 10.1159/000094159; Lazzerini PE, 2007, CLIN EXP RHEUMATOL, V25, P696; Lee Sung Joong, 2002, Current Drug Targets - Inflammation and Allergy, V1, P181; Lehnardt S, 2003, P NATL ACAD SCI USA, V100, P8514, DOI 10.1073/pnas.1432609100; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; McKee JA, 2005, NEUROCRIT CARE, V2, P342, DOI 10.1385/NCC:2:3:342; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; MEGYERI P, 1992, NEUROSCI LETT, V148, P137, DOI 10.1016/0304-3940(92)90823-P; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; Niessner A, 2006, ATHEROSCLEROSIS, V189, P408, DOI 10.1016/j.atherosclerosis.2005.12.022; Niwa S, 1996, INT J IMMUNOPHARMACO, V18, P669, DOI 10.1016/S0192-0561(96)00068-9; Omi H, 2003, MICROVASC RES, V65, P118, DOI 10.1016/S0026-2862(02)00033-X; Pahan K, 1997, J CLIN INVEST, V100, P2671, DOI 10.1172/JCI119812; Pleines UE, 1998, J NEUROTRAUM, V15, P399, DOI 10.1089/neu.1998.15.399; RAMILO O, 1990, J EXP MED, V172, P497, DOI 10.1084/jem.172.2.497; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; Shao HT, 2007, ANN THORAC SURG, V84, P2011, DOI 10.1016/j.athoracsur.2007.07.022; Sironi L, 2006, NEUROBIOL DIS, V22, P445, DOI 10.1016/j.nbd.2005.12.004; Stanislaus R, 1999, NEUROSCI LETT, V269, P71, DOI 10.1016/S0304-3940(99)00414-0; Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003; Touzani O, 1999, J NEUROIMMUNOL, V100, P203, DOI 10.1016/S0165-5728(99)00202-7; Truettner J, 1999, J NEUROTRAUM, V16, P471, DOI 10.1089/neu.1999.16.471; Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031; Weitz-Schmidt G, 2001, NAT MED, V7, P687, DOI 10.1038/89058; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158	46	109	120	0	17	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	APR	2009	216	2					398	406		10.1016/j.expneurol.2008.12.019			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	424ZK	WOS:000264606600020	19166837				2022-02-06	
J	Sun, D; Bullock, MR; McGinn, MJ; Zhou, Z; Altememi, N; Hagood, S; Hamm, R; Colello, RJ				Sun, Dong; Bullock, M. Ross; McGinn, Melissa J.; Zhou, Zhengwen; Altememi, Nabil; Hagood, Sarah; Hamm, Robert; Colello, Raymond J.			Basic fibroblast growth factor-enhanced neurogenesis contributes to cognitive recovery in rats following traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						Neurogenesis; bFGF; Traumatic brain injury; Hippocampus; SVZ; Morris water maze	NEURAL STEM-CELLS; DENTATE GYRUS; HIPPOCAMPAL-NEURONS; SUBVENTRICULAR ZONE; GRANULE CELLS; ADULT RATS; IN-VITRO; PROLIFERATION; FGF-2; DIFFERENTIATION	Stem/progenitor cells reside throughout the adult CNS and are actively dividing in the subventricular zone (SVZ) and the dentate gyrus (DG) of the hippocampus. This neurogenic capacity of the SVZ and DG is enhanced following traumatic brain injury (TBI) suggesting that the adult brain has the inherent potential to restore populations lost to injury. This raises the possibility of developing strategies aimed at harnessing the neurogenic capacity of these regions to repair the damaged brain. One strategy is to enhance neurogenesis with mitogenic factors. As basic fibroblast growth factor (bFGF) is a potent stem cell mitogen, we set out to determine if an intraventricular administration of bFGF following TBI could affect the levels of injury-induced neurogenesis in the SVZ and DG, and the degree to which this is associated with cognitive recovery. Specifically, adult rats received a bFGF intraventricular infusion for 7 days immediately following TBI. BrdU was administered to animals daily at 2-7 days post-injury to label cell proliferation. At 1 or 4 weeks post-injury, brain sections were immunostained for BrdU and neuronal or astrocytic markers. We found that injured animals infused with bFGF exhibited significantly enhanced cell proliferation in the SVZ and the DG at 1 week post-TBI as compared to vehicle-infused animals. Moreover, following bFGF infusion, a greater number of the newly generated cells survived to 4 weeks post-injury, with the majority being neurons. Additionally, animals infused with bFGF showed significant cognitive improvement. Collectively, the current findings suggest that bFGF-enhanced neurogenesis contributes to cognitive recovery following TBI. (C) 2008 Elsevier Inc. All rights reserved.	[Sun, Dong; Bullock, M. Ross; Zhou, Zhengwen; Altememi, Nabil; Hagood, Sarah] Virginia Commonwealth Univ, Med Coll Virginia Campus, Dept Neurosurg, Richmond, VA 23298 USA; [McGinn, Melissa J.; Colello, Raymond J.] Virginia Commonwealth Univ, Med Coll Virginia Campus, Dept Anat & Neurobiol, Richmond, VA 23298 USA; [Hamm, Robert] Virginia Commonwealth Univ, Med Coll Virginia Campus, Dept Psychol, Richmond, VA 23298 USA		Sun, D (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia Campus, Dept Neurosurg, Richmond, VA 23298 USA.	dsun@vcu.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1. NS055086]; NIH-NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5P30NS047463]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS047463, R01NS055086] Funding Source: NIH RePORTER	This study was funded by the National Institutes of Health Grant RO1. NS055086 (D. Sun). Microscopy work was performed at the VCU - Department of Anatomy and Neurobiology Microscopy Facility, supported, in part, with funding from NIH-NINDS center core grant 5P30NS047463.	AKANEYA Y, 1993, J CEREBR BLOOD F MET, V13, P1029, DOI 10.1038/jcbfm.1993.130; ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; AOYAGI A, 1994, BRAIN RES, V661, P117, DOI 10.1016/0006-8993(94)91188-6; BOGLER O, 1990, P NATL ACAD SCI USA, V87, P6368, DOI 10.1073/pnas.87.16.6368; CADAY CG, 1990, DEV BRAIN RES, V52, P241, DOI 10.1016/0165-3806(90)90240-Y; Calof Anne L., 1995, Current Opinion in Neurobiology, V5, P19, DOI 10.1016/0959-4388(95)80082-4; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; CASPER D, 1995, J NEUROCHEM, V65, P1016; CHENG B, 1991, NEURON, V7, P1031, DOI 10.1016/0896-6273(91)90347-3; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Coggeshall RE, 1996, J COMP NEUROL, V364, P6, DOI 10.1002/(SICI)1096-9861(19960101)364:1<6::AID-CNE2>3.0.CO;2-9; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Dayer AG, 2003, J COMP NEUROL, V460, P563, DOI 10.1002/cne.10675; Dietrich WD, 1996, J NEUROTRAUM, V13, P309, DOI 10.1089/neu.1996.13.309; Fitzsimonds RM, 1998, PHYSIOL REV, V78, P143, DOI 10.1152/physrev.1998.78.1.143; FREESE A, 1992, BRAIN RES, V575, P351, DOI 10.1016/0006-8993(92)90104-H; FRESSINAUD C, 1993, DEV BIOL, V158, P317, DOI 10.1006/dbio.1993.1191; GONZALEZ AM, 1995, BRAIN RES, V701, P201, DOI 10.1016/0006-8993(95)01002-X; Gould E, 1996, DEV NEUROSCI-BASEL, V18, P22, DOI 10.1159/000111392; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Gritti A, 1996, J NEUROSCI, V16, P1091; Hagood SK, 2006, J NEUROTRAUM, V23, P205, DOI 10.1089/neu.2006.23.205; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; Jin KL, 2003, AGING CELL, V2, P175, DOI 10.1046/j.1474-9728.2003.00046.x; Kempermann G, 1998, J NEUROSCI, V18, P3206; Kempermann G, 2003, DEVELOPMENT, V130, P391, DOI 10.1242/dev.00203; Keuker JIH, 2001, BRAIN RES PROTOC, V7, P211, DOI 10.1016/S1385-299X(01)00064-2; Kuhn HG, 1997, J NEUROSCI, V17, P5820; KUMON Y, 1993, BRAIN RES, V605, P169, DOI 10.1016/0006-8993(93)91369-4; Li AJ, 2002, EUR J NEUROSCI, V16, P1313, DOI 10.1046/j.1460-9568.2002.02193.x; LOGAN A, 1992, J NEUROSCI, V12, P3828; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; Maric D, 2007, J NEUROSCI, V27, P1836, DOI 10.1523/JNEUROSCI.5141-06.2007; McDermott KL, 1997, J NEUROTRAUM, V14, P191, DOI 10.1089/neu.1997.14.191; Monfils MH, 2008, EXP BRAIN RES, V185, P453, DOI 10.1007/s00221-007-1172-0; MOREHEAD M, 1994, J NEUROTRAUM, V11, P657, DOI 10.1089/neu.1994.11.657; NAKATA N, 1993, BRAIN RES, V605, P354, DOI 10.1016/0006-8993(93)91766-L; Palmer TD, 1999, J NEUROSCI, V19, P8487; PATEL MN, 1995, NEUROSCIENCE, V69, P763, DOI 10.1016/0306-4522(95)00281-M; Qian XM, 1997, NEURON, V18, P81, DOI 10.1016/S0896-6273(01)80048-9; Raballo R, 2000, J NEUROSCI, V20, P5012; Rai KS, 2007, EUR J NEUROSCI, V26, P1765, DOI 10.1111/j.1460-9568.2007.05820.x; Ramirez JJ, 1999, NEUROREPORT, V10, P1201, DOI 10.1097/00001756-199904260-00008; RAY J, 1993, P NATL ACAD SCI USA, V90, P3602, DOI 10.1073/pnas.90.8.3602; Schuman EM, 1999, CURR OPIN NEUROBIOL, V9, P105, DOI 10.1016/S0959-4388(99)80013-0; Shetty AK, 2005, GLIA, V51, P173, DOI 10.1002/glia.20187; Sun D, 2005, J NEUROTRAUM, V22, P95, DOI 10.1089/neu.2005.22.95; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Tao Y, 1997, J NEUROBIOL, V33, P289, DOI 10.1002/(SICI)1097-4695(199709)33:3<289::AID-NEU7>3.0.CO;2-Y; Tran LD, 2006, J NEUROTRAUM, V23, P1330, DOI 10.1089/neu.2006.23.1330; Tureyen K, 2005, NEUROSURGERY, V57, P1254, DOI 10.1227/01.NEU.0000186040.96929.8A; Vicario-Abejon Carlos, 2004, Curr Protoc Neurosci, VChapter 3, DOI 10.1002/0471142301.ns0302s26; Wagner JP, 1999, J NEUROSCI, V19, P6006, DOI 10.1523/JNEUROSCI.19-14-06006.1999; Weickert CS, 2005, NEUROSCIENCE, V131, P219, DOI 10.1016/j.neuroscience.2004.09.070; Yan HQ, 2000, BRAIN RES, V887, P134, DOI 10.1016/S0006-8993(00)03002-X; Yoshimura S, 2003, J CLIN INVEST, V112, P1202, DOI 10.1172/JCI200316618; Yoshimura S, 2001, P NATL ACAD SCI USA, V98, P5874, DOI 10.1073/pnas.101034998	57	109	125	0	9	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	MAR	2009	216	1					56	65		10.1016/j.expneurol.2008.11.011			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	413UK	WOS:000263817800008	19100261	Green Accepted			2022-02-06	
J	Lannsjo, M; Af Geijerstam, JL; Johansson, U; Bring, J; Borg, J				Lannsjo, Marianne; Af Geijerstam, Jean-Luc; Johansson, Ulla; Bring, Johan; Borg, Jorgen			Prevalence and structure of symptoms at 3 months after mild traumatic brain injury in a national cohort	BRAIN INJURY			English	Article						Mild Traumatic Brain Injury; Post-concussion Symptoms; Rivermead Post-concussion Symptoms Questionnaire	POST-CONCUSSION SYNDROME; MINOR HEAD-INJURY; POSTCONCUSSION SYNDROME; DIAGNOSTIC-CRITERIA; SOCIAL SUPPORT; CHRONIC PAIN; QUESTIONNAIRE; MODERATE; EXPECTATION; RELIABILITY	Objectives: To describe symptom prevalence and structure after mild traumatic brain injury (MTBI) in a population-based cohort. Methods: Symptoms data were collected at 3 months post-MTBI by use of the Rivermead Post-concussion Symptoms Questionnaire (RPQ) at follow-up of 2602 patients attending 39 Swedish hospitals. Spearmans rank correlation analysis was used to explore correlations between symptoms and structural equation modelling (SEM) was performed by use of several fit indices to explore if data were compatible with one or more factors. Results: Questionnaires were received from 2523 (97%) patients with a mean age of 31 years (median 22, range 6-96). A majority of the respondents (56%) reported no remaining injury related symptoms, 24% reported three or more symptoms and 10% reported seven or more symptoms. All symptoms exhibited strong positive inter-relations and SEM provided strong support for a single or two factor solution. Fit indices were only slightly weaker for three and four factor solutions. Conclusions: A significant minority of patients reported multiple symptoms to persist at 3 months after MTBI. The observed structure of symptoms according to RPQ demonstrates a common factor for all symptoms, but also sub-groups of symptoms as previously suggested.	[Lannsjo, Marianne; Borg, Jorgen] Uppsala Univ, Dept Neurosci, Uppsala, Sweden; [Lannsjo, Marianne; Johansson, Ulla] Uppsala Univ, Cty Council Gavleborg, Ctr Res & Dev, Uppsala, Sweden; [Af Geijerstam, Jean-Luc] Karolinska Univ Hosp, Dept Med, Clin Epidemiol Unit, Stockholm, Sweden; [Bring, Johan] Univ Gavle, Dept Math Nat & Comp Sci, Gavle, Sweden		Lannsjo, M (corresponding author), Univ Uppsala Hosp, S-75185 Uppsala, Sweden.	marianne.lannsjo@lg.se		Borg, Jorgen/0000-0002-2372-7478; Lannsjo, Marianne/0000-0001-8792-3796	Swedish insurance company AFA; Centre for Research and Development Uppsala University/ County Council of Gavleborg	This study was supported by grants from the Swedish insurance company AFA and Centre for Research and Development Uppsala University/ County Council of Gavleborg.	af Geijerstam JL, 2006, BMJ-BRIT MED J, V333, P465, DOI 10.1136/bmj.38918.669317.4F; Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Boake C, 2005, NEUROSURGERY, V56, P994, DOI 10.1227/01.NEU.0000158319.38230.C3; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Ferrari R, 2001, CLIN NEUROL NEUROSUR, V103, P254, DOI 10.1016/S0303-8467(01)00161-5; Gasquoine P G, 2000, Appl Neuropsychol, V7, P83, DOI 10.1207/S15324826AN0702_3; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Haldorsen T, 2003, APPL NEUROPSYCHOL, V10, P170, DOI 10.1207/S15324826AN1003_06; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 2003, BRIT J PSYCHIAT, V183, P276, DOI 10.1192/bjp.183.4.276; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; McCauley SR, 2005, J NERV MENT DIS, V193, P540, DOI 10.1097/01.nmd.0000172592.05801.71; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; Mickeviciene D, 2002, EUR J NEUROL, V9, P581, DOI 10.1046/j.1468-1331.2002.00497.x; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Nolin P, 2006, J HEAD TRAUMA REHAB, V21, P514, DOI 10.1097/00001199-200611000-00006; Norlund A, 2006, BMJ-BRIT MED J, V333, P469, DOI 10.1136/bmj.38918.659120.4F; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Stalnacke BM, 2007, BRAIN INJURY, V21, P933, DOI 10.1080/02699050701553189; STALNACKE BM, 2004, THESIS UMEA U SWEDEN; TEASDALE GM, 1995, J NEUROL NEUROSUR PS, V58, P526, DOI 10.1136/jnnp.58.5.526; World Health Organization, 1993, ICD 10 CLASS MENT BE; World Health Organization, 1992, ICD 10 CLASSIFICATIO	41	109	109	0	11	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	3					213	219	PII 908613182	10.1080/02699050902748356			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	406AJ	WOS:000263267100004	19205957				2022-02-06	
J	Leventhal, JM; Martin, KD; Asnes, AG				Leventhal, John M.; Martin, Kimberly D.; Asnes, Andrea G.			Incidence of fractures attributable to abuse in young hospitalized children: Results from analysis of a United States database	PEDIATRICS			English	Article						fracture; incidence; abuse	TRAUMATIC BRAIN-INJURY; INFANTS	OBJECTIVE. The goal was to assess the proportion of children with fractures attributable to abuse and the incidence of fractures caused by abuse among children <36 months of age who were hospitalized in the United States. METHODS. We used the Kids' Inpatient Database, which has discharge data on 80% of acute pediatric hospitalizations in the United States, for 3 time periods (1997, 2000, and 2003). Fractures attributable to abuse in children <36 months of age were identified by both an International Classification of Diseases, Ninth Revision, Clinical Modification code for fracture and a diagnosis external-cause-of-injury code for abuse. Weighted estimates of the incidence were calculated. RESULTS. Among children <36 months of age who were hospitalized with fractures, the proportions of cases attributable to abuse were 11.9% in 1997, 11.9% in 2000, and 12.1% in 2003. The proportions of cases attributable to abuse decreased with increasing age; for example, in 2003, the proportions attributable to abuse were 24.9% for children <12 months of age, 7.2% for children 12 to 23 months of age, and 2.9% for children 24 to 35 months of age. In 2003, the incidence of fractures caused by abuse was 15.3 cases per 100 000 children <36 months of age. The incidence was 36.1 cases per 100 000 among children <12 months of age; this decreased to 4.8 cases per 100 000 among 12-to 23-month-old children and 4.8 cases per 100 000 among 24-to 35-month-old children. CONCLUSIONS. The Kids' Inpatient Database can be used to provide reasonable estimates of the incidence of hospitalization with fractures attributable to child abuse. For children <12 months of age, the incidence was 36.1 cases per 100 000, a rate similar to that of inflicted traumatic brain injury (25-32 cases per 100 000).	[Leventhal, John M.; Asnes, Andrea G.] Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06520 USA; [Martin, Kimberly D.] Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA		Leventhal, JM (corresponding author), Yale Univ, Sch Med, Dept Pediat, POB 208064,333 Cedar St, New Haven, CT 06520 USA.	john.leventhal@yale.edu					Agency for Healthcare Research and Quality Healthcare Cost and Utilization Project, OV KIDS INP DAT KID; Barlow KM, 2000, LANCET, V356, P1571, DOI 10.1016/S0140-6736(00)03130-5; Barnes PM, 2005, LANCET, V366, P234, DOI 10.1016/S0140-6736(05)66913-9; Brown D, 2004, AM J PUBLIC HEALTH, V94, P558, DOI 10.2105/AJPH.94.4.558; Ellingson KD, 2008, AM J PREV MED, V34, pS157, DOI 10.1016/j.amepre.2007.12.021; Jayawant S, 1998, BMJ-BRIT MED J, V317, P1558, DOI 10.1136/bmj.317.7172.1558; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; Leventhal JM, 2005, CHILD ABUSE NEGLECT, V29, P209, DOI 10.1016/j.chiabu.2005.02.008; LEVENTHAL JM, 1993, AM J DIS CHILD, V147, P87, DOI 10.1001/archpedi.1993.02160250089028; Leventhal JM, 2007, CHILD ABUSE NEGLECT, V31, P311, DOI 10.1016/j.chiabu.2006.07.004; National Center for Health Statistics Centers for Medicare and Medicaid Services, 1999, INT CLASS DIS 9 REV; REWERS A, 2005, PEDIATRICS, V115; Sibert JR, 2002, CHILD ABUSE NEGLECT, V26, P267, DOI 10.1016/S0145-2134(01)00324-6; Trokel M, 2006, PEDIATRICS, V117, P722, DOI 10.1542/peds.2004-2731; WINN DG, 1995, PUBLIC HEALTH REP, V110, P277	15	109	109	0	3	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	SEP	2008	122	3					599	604		10.1542/peds.2007-1959			6	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	342ZR	WOS:000258822600017	18762531				2022-02-06	
J	Davis, LM; Pauly, JR; Readnower, RD; Rho, JM; Sullivan, PG				Davis, Laurie M.; Pauly, James R.; Readnower, Ryan D.; Rho, Jong M.; Sullivan, Patrick G.			Fasting is neuroprotective following traumatic brain injury	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						acute caloric reduction; fasting; ketone bodies; mitochondria; reactive oxygen species; trauma	PENTOSE-PHOSPHATE PATHWAY; BETA-HYDROXYBUTYRATE; UNITED-STATES; KETONE-BODIES; MITOCHONDRIAL; METABOLISM; PROTECTS; GLUCOSE; DAMAGE; ACETOACETATE	To determine the neuroprotective effect of fasting after traumatic brain injury (TBI) and to elucidate the potential underlying mechanisms, we used a controlled cortical impact (CCI) injury model to induce either a moderate or a severe injury to adult male Sprague Dawley rats. Tissue-sparing assessments were used to determine the level of neuroprotection of fasting, hypoglycemia (insulin 10 U), or ketone (1.66 mmoles/kg/day or 0.83 mmoles/kg/day; D-beta-hydroxtbutyrate) administration. Mitochondrial isolation and respiratory studies were utilized to determine the functionality of mitochondria at the site of injury. We also investigated biomarkers of oxidative stress, such as lipid/protein oxidation, reactive oxygen species (ROS) production, and intramitochondrial calcium load, as a secondary measure of mitochondrial homeostasis. We found that fasting animals for 24 hr, but not 48 hr, after a moderate (1.5 mm), but not severe (2.0 mm), CCI resulted in a significant increase in tissue sparing. This 24-hr fast also decreased biomarkers of oxidative stress and calcium loading and increased mitochondrial oxidative phosphorylation in mitochondria isolated from the site of injury. Insulin administration, designed to mimic the hypoglycemic effect seen during fasting did not result in significant tissue sparing after moderate CCI injury and in fact induced increased mortality at some injection time points. However, the administration of ketones resulted in increased tissue sparing after moderate injury. Fasting for 24 hr confers neuroprotection, maintains cognitive function, and improves mitochondrial function after moderate (1.5 mm) TBI. The underlying mechanism appears to involve ketosis rather than hypoglycemia. (c) 2008 Wiley-Liss, Inc.	[Davis, Laurie M.; Readnower, Ryan D.; Sullivan, Patrick G.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; [Davis, Laurie M.; Readnower, Ryan D.; Sullivan, Patrick G.] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; [Pauly, James R.] Univ Kentucky, Coll Pharm, Lexington, KY 40536 USA; [Rho, Jong M.] Barrow Neurol Inst, Phoenix, AZ 85013 USA; [Rho, Jong M.] St Joseph Hosp, Phoenix, AZ 85013 USA; [Rho, Jong M.] Med Ctr, Phoenix, AZ 85013 USA		Sullivan, PG (corresponding author), 741 S Limestone,375 BBSRB, Lexington, KY 40536 USA.	patsullivan@uky.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS044846, NS48191, NS42196] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K02NS044846, R01NS042196, R01NS048191] Funding Source: NIH RePORTER		Alquier T, 2001, NEUROSCI LETT, V308, P75, DOI 10.1016/S0304-3940(01)01936-X; Bartnik BL, 2005, J NEUROTRAUM, V22, P1052, DOI 10.1089/neu.2005.22.1052; Bartnik BL, 2007, J NEUROTRAUM, V24, P181, DOI 10.1089/neu.2006.0038; Bough KJ, 2003, EPILEPSIA, V44, P752, DOI 10.1046/j.1528-1157.2003.55502.x; Bough KJ, 2007, EPILEPSIA, V48, P43, DOI 10.1111/j.1528-1167.2007.00915.x; Bough KJ, 2006, ANN NEUROL, V60, P223, DOI 10.1002/ana.20899; Brookes PS, 2004, AM J PHYSIOL-CELL PH, V287, pC817, DOI 10.1152/ajpcell.00139.2004; Brown MR, 2004, J NEUROSCI METH, V137, P299, DOI 10.1016/j.jneumeth.2004.02.028; BURGE MR, 1993, J CLIN ENDOCR METAB, V76, P1192, DOI 10.1210/jc.76.5.1192; Caron M J, 1991, Neurosurg Clin N Am, V2, P483; Cherian L, 1998, J NEUROTRAUM, V15, P1059, DOI 10.1089/neu.1998.15.1059; Dardzinski BJ, 2000, PEDIATR RES, V48, P248, DOI 10.1203/00006450-200008000-00021; Dusick JR, 2007, J CEREBR BLOOD F MET, V27, P1593, DOI 10.1038/sj.jcbfm.9600458; El Messari S, 1998, J COMP NEUROL, V399, P492, DOI 10.1002/(SICI)1096-9861(19981005)399:4<492::AID-CNE4>3.0.CO;2-X; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fromenty B, 2004, DIABETES METAB, V30, P121, DOI 10.1016/S1262-3636(07)70098-8; Greene AE, 2003, J NEUROCHEM, V86, P529, DOI 10.1046/j.1471-4159.2003.01862.x; Gunter TE, 2004, FEBS LETT, V567, P96, DOI 10.1016/j.febslet.2004.03.071; Hatton J, 2001, CNS DRUGS, V15, P553, DOI 10.2165/00023210-200115070-00005; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; Kashiwaya Y, 2000, P NATL ACAD SCI USA, V97, P5440, DOI 10.1073/pnas.97.10.5440; Kim DY, 2007, J NEUROCHEM, V101, P1316, DOI 10.1111/j.1471-4159.2007.04483.x; Krakau K, 2006, BRAIN INJURY, V20, P345, DOI 10.1080/02699050500487571; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Maalouf M, 2007, NEUROSCIENCE, V145, P256, DOI 10.1016/j.neuroscience.2006.11.065; Massieu L, 2003, NEUROSCIENCE, V120, P365, DOI 10.1016/S0306-4522(03)00266-5; McKee T., 2003, BIOCH MOL BASIS LIFE; MICHEL RP, 1988, J MICROSC-OXFORD, V150, P117, DOI 10.1111/j.1365-2818.1988.tb04603.x; Morris AAM, 2005, J INHERIT METAB DIS, V28, P109, DOI 10.1007/s10545-005-5518-0; Nehlig A, 2004, PROSTAG LEUKOTR ESS, V70, P265, DOI 10.1016/j.plefa.2003.07.006; Nicholls DG, 2000, PHYSIOL REV, V80, P315, DOI 10.1152/physrev.2000.80.1.315; Nicholls DG, 2003, CELL CALCIUM, V34, P407, DOI 10.1016/S0143-4160(03)00144-1; Nicholls DG, 2002, BIOENERGETICS; Noh HS, 2006, J NEUROSCI RES, V83, P702, DOI 10.1002/jnr.20736; Nukala VN, 2006, J NEUROSCI METH, V152, P48, DOI 10.1016/j.jneumeth.2005.08.017; Pan JW, 2000, J CEREBR BLOOD F MET, V20, P1502, DOI 10.1097/00004647-200010000-00012; Pandya JD, 2007, J NEUROTRAUM, V24, P798, DOI 10.1089/neu.2006.3673; Pepe JL, 1999, J HEAD TRAUMA REHAB, V14, P462, DOI 10.1097/00001199-199910000-00007; Perel P, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001530.pub2; Prins ML, 2006, DEV NEUROSCI-BASEL, V28, P447, DOI 10.1159/000094170; Prins ML, 2004, J NEUROCHEM, V90, P666, DOI 10.1111/j.1471-4159.2004.02542.x; Rho JM, 2002, EPILEPSIA, V43, P358, DOI 10.1046/j.1528-1157.2002.47901.x; ROBERTSON CS, 1991, J NEUROSURG, V74, P43, DOI 10.3171/jns.1991.74.1.0043; Scheff SW, 2004, NEUROCHEM RES, V29, P469, DOI 10.1023/B:NERE.0000013753.22615.59; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Sensi SL, 2003, P NATL ACAD SCI USA, V100, P6157, DOI 10.1073/pnas.1031598100; Smith SL, 2005, CNS DRUG REV, V11, P113; Sullivan PG, 2004, ANN NEUROL, V55, P576, DOI 10.1002/ana.20062; Sullivan PG, 2004, J BIOENERG BIOMEMBR, V36, P353, DOI 10.1023/B:JOBB.0000041767.30992.19; Sullivan PG, 2000, ANN NEUROL, V48, P723, DOI 10.1002/1531-8249(200011)48:5&lt;723::AID-ANA5&gt;3.0.CO;2-W; Sullivan PG, 2005, EPILEPSY BEHAV, V7, pS12, DOI 10.1016/j.yebeh.2005.08.004; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 2003, ANN NEUROL, V53, P711, DOI 10.1002/ana.10543; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tieu K, 2003, J CLIN INVEST, V112, P892, DOI 10.1172/JCI200318797; Totland GK, 2000, BIOL CELL, V92, P317, DOI 10.1016/S0248-4900(00)01077-7; Verbois SL, 2003, NEUROSCIENCE, V119, P1199, DOI 10.1016/S0306-4522(03)00206-9; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; YAGER JY, 1992, PEDIATR RES, V31, P138, DOI 10.1203/00006450-199202000-00009; Yamada KA, 2005, NEUROSCI LETT, V385, P210, DOI 10.1016/j.neulet.2005.05.038	68	109	112	0	22	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	JUN	2008	86	8					1812	1822		10.1002/jnr.21628			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	312CJ	WOS:000256646400014	18241053				2022-02-06	
J	DeKosky, ST; Abrahamson, EE; Ciallella, JR; Paljug, WR; Wisniewski, SR; Clark, RSB; Ikonomovic, MD				DeKosky, Steven T.; Abrahamson, Eric E.; Ciallella, John R.; Paljug, William R.; Wisniewski, Stephen R.; Clark, Robert S. B.; Ikonomovic, Milos D.			Association of increased cortical soluble A beta(42) levels with diffuse plaques after severe brain injury in humans	ARCHIVES OF NEUROLOGY			English	Article							AMYLOID-BETA-PROTEIN; HEAD-INJURY; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; APOLIPOPROTEIN-E; NEURONS; EXPRESSION; DEPOSITION; A-BETA-40; CORTEX	Background: Traumatic brain injury (TBI) is an environmental risk factor for developing Alzheimer disease. This may be due, in part, to changes associated with beta-amyloid (A beta) plaque formation, which can occur within hours after injury, regardless of the patient's age. In addition to being precursors of toxic fibrils that deposit into plaques, soluble (nonfibrillar) A beta peptides are posited to disrupt synaptic function and are associated with cognitive decline in Alzheimer disease. Changes in soluble A beta levels and their relationship to A beta plaque formation following TBI are unknown. Objective: To quantify brain tissue levels of soluble A beta peptides and their precursor protein in relation to A beta plaque formation after TBI in humans. Design: Surgically resected temporal cortex tissue from patients with severe TBI was processed for biochemical assays of soluble A beta peptides with COOH-termini ending in amino acid 40 (A beta(40)) or 42 (A beta(42)) and A beta precursor protein to compare patients with cortical A beta plaques and those without. Patients: Nineteen subjects admitted to the University of Pittsburgh Medical Center for treatment of severe closed head injury. Results: Patients with severe TBI and cortical plaques had higher levels of soluble A beta(1-42) but not A beta(1-40); half of them were apolipoprotein E (APOE) epsilon 4 allele carriers. The lowest A beta levels were in 1 patient without plaques who was the only subject with an APOE epsilon 2 allele. beta-Amyloid precursor protein levels were comparable in the 2 TBI groups. Conclusions: Selective increases in soluble A beta(1-42) after TBI may predispose individuals with a brain injury to Alzheimer disease pathology. This may be influenced by the APOE genotype, and it may confer increased risk for developing Alzheimer disease later in life.	Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Grad Sch Publ Hlth, Epidemiol Data Ctr, Pittsburgh, PA 15213 USA		DeKosky, ST (corresponding author), Univ Pittsburgh, Sch Med, Dept Neurol, 3471 5th Ave,Suite 811, Pittsburgh, PA 15213 USA.	dekoskyst@upmc.edu		DeKosky, Steven/0000-0003-3743-2758; Wisniewski, Stephen/0000-0002-3877-9860	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG05133] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30318] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, P01NS030318, P50NS030318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005133] Funding Source: NIH RePORTER		Braak H, 1997, NEUROBIOL AGING, V18, P351, DOI 10.1016/S0197-4580(97)00056-0; Ciallella JR, 2002, J NEUROTRAUM, V19, P1555, DOI 10.1089/089771502762300229; Cleary JP, 2005, NAT NEUROSCI, V8, P79, DOI 10.1038/nn1372; Deshpande A, 2006, J NEUROSCI, V26, P6011, DOI 10.1523/JNEUROSCI.1189-06.2006; DICKSON DW, 1992, NEUROBIOL AGING, V13, P179, DOI 10.1016/0197-4580(92)90027-U; Fagan AM, 2006, ANN NEUROL, V59, P512, DOI 10.1002/ana.20730; Gentleman SM, 1997, NEUROREPORT, V8, P1519, DOI 10.1097/00001756-199704140-00039; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Horsburgh K, 2000, NEUROPATH APPL NEURO, V26, P124, DOI 10.1046/j.1365-2990.2000.026002124.x; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; Kay AD, 2003, J NEUROTRAUM, V20, P943, DOI 10.1089/089771503770195795; Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533; Maier M, 2006, J NEUROSCI, V26, P4717, DOI 10.1523/JNEUROSCI.0381-06.2006; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MCKENZIE JE, 1994, NEUROREPORT, V6, P161, DOI 10.1097/00001756-199412300-00041; Murakami N, 1998, J NEUROTRAUM, V15, P993, DOI 10.1089/neu.1998.15.993; Naslund J, 2000, JAMA-J AM MED ASSOC, V283, P1571, DOI 10.1001/jama.283.12.1571; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; Rockenstein E, 2006, J NEUROSCI RES, V83, P1252, DOI 10.1002/jnr.20818; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; Walsh DM, 2004, NEURON, V44, P181, DOI 10.1016/j.neuron.2004.09.010; Wang J, 1999, EXP NEUROL, V158, P328, DOI 10.1006/exnr.1999.7085	26	109	110	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0003-9942			ARCH NEUROL-CHICAGO	Arch. Neurol.	APR	2007	64	4					541	544		10.1001/archneur.64.4.541			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	155AG	WOS:000245549300011	17420316	Bronze			2022-02-06	
J	Marx, CE; Trost, WT; Shampine, LJ; Stevens, RD; Hulette, CM; Steffens, DC; Ervin, JF; Butterfield, MI; Blazer, DG; Massing, MW; Lieberman, JA				Marx, Christine E.; Trost, William T.; Shampine, Lawrence J.; Stevens, Robert D.; Hulette, Christine M.; Steffens, David C.; Ervin, John F.; Butterfield, Marian I.; Blazer, Daniel G.; Massing, Mark W.; Lieberman, Jeffrey A.			The neurosteroid allopregnanolone is reduced in prefrontal cortex in Alzheimer's disease	BIOLOGICAL PSYCHIATRY			English	Article						allopregnanolone; Alzheimer's disease; dehydroepiandrosterone; neurosteroid; postmortem; prefrontal cortex	TRAUMATIC BRAIN-INJURY; STEROID-HORMONE METABOLITES; OXIDATIVE STRESS; NEUROACTIVE STEROIDS; DEHYDROEPIANDROSTERONE DHEA; PREGNENOLONE SULFATE; HIPPOCAMPAL-NEURONS; GABA-RECEPTOR; CELL-DEATH; RAT-BRAIN	Background: Few data are currently available investigating neurosteroids (NS) in Alzheimer's disease (AD). The NS allopregnanolone may be decreased in serum and plasma in patients with AD, but it is unclear if allopregnanolone is also reduced in brain. Because a number of NS exhibit neuroprotective effects and impact cognitive performance in rodent models, these molecules may be relevant to the pathophysiology of neurodegenerative disorders. We therefore investigated prefrontal cortex (PFC) NS levels in AD. Methods: Neurosteroid levels (allopregnanolone, pregnenolone, dehydroepiandrosterone [DHEA]) were determined in postmortem PFC in 14 male subjects with AD and 15 cognitively intact male control subjects by gas chromatography mass spectrometry preceded by high-performance liquid chromatography purification. Results: Subjects with AD exhibit significant reductions in allopregnanolone compared with cognitively intact control subjects (median levels = 2.50 ng/g vs, 5.59 ng/g, respectively; p = .02). Allopregnanolone levels are inversely correlated with neuropathological disease stage (Braak), r = -.49, p = .007. Median DHEA levels are elevated in subjects with AD (p = .01). Conclusions: Subjects with AD demonstrate significant reductions in PFC allopregnanolone levels, a finding that may be relevant to neuropathological disease stage severity. Neurosteroids may have utility as candidate biomarkers in AD.	Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Mental Hlth Serv Line 116A, Durham, NC 27705 USA; Duke Univ, Med Ctr, Sarah W Stedman Nutr & Metab Ctr, Durham, NC 27705 USA; Duke Univ, Med Ctr, Joseph & Kathleen Bryan Alzheimers Dis Res Ctr, Durham, NC 27705 USA; Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27705 USA; Durham Vet Affairs Med Ctr, Durham, NC 27705 USA; Columbia Univ Coll Phys & Surg, New York, NY 10032 USA		Marx, CE (corresponding author), Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Mental Hlth Serv Line 116A, 508 Fulton St, Durham, NC 27705 USA.	marx0001@mc.duke.edu	Lieberman, Jeffrey/AAY-8239-2020		NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50 AG05128] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23 MH65080, T32 MH70448] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32MH070448, K23MH065080] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005128] Funding Source: NIH RePORTER		Ahmad I, 2005, J NEUROSCI RES, V82, P811, DOI 10.1002/jnr.20685; Akwa Y, 2001, P NATL ACAD SCI USA, V98, P14033, DOI 10.1073/pnas.241503698; ALHAJ HA, 2005, PSYCHOPHARMACOLOGY B, P1; Alomary AA, 2001, INT REV NEUROBIOL, V46, P97; Azcoitia I, 2003, NEUROBIOL AGING, V24, P853, DOI 10.1016/S0197-4580(02)00234-8; Barbaccia ML, 2001, NEUROPSYCHOPHARMACOL, V25, P489, DOI 10.1016/S0893-133X(01)00254-8; Bartzokis G, 2004, NEUROBIOL AGING, V25, P5, DOI 10.1016/j.neurobiolaging.2003.03.001; Bastianetto S, 1999, MOL BRAIN RES, V66, P35, DOI 10.1016/S0169-328X(99)00002-9; Belelli D, 2005, NAT REV NEUROSCI, V6, P565, DOI 10.1038/nrn1703; Benes FM, 2004, NEUROBIOL AGING, V25, P41, DOI 10.1016/j.neurobiolaging.2003.06.003; Bergeron R, 1996, J NEUROSCI, V16, P1193; Bernardi F, 2000, EUR J ENDOCRINOL, V142, P466, DOI 10.1530/eje.0.1420466; Bixo M, 1997, BRAIN RES, V764, P173, DOI 10.1016/S0006-8993(97)00455-1; Boccuzzi G, 1997, FREE RADICAL BIO MED, V22, P1289, DOI 10.1016/S0891-5849(96)00543-6; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Brown RC, 2000, J NEUROCHEM, V74, P847, DOI 10.1046/j.1471-4159.2000.740847.x; Brown RC, 2003, NEUROBIOL AGING, V24, P57, DOI 10.1016/S0197-4580(02)00048-9; Cardounel A, 1999, P SOC EXP BIOL MED, V222, P145, DOI 10.1046/j.1525-1373.1999.d01-124.x; Ciriza I, 2004, J NEUROENDOCRINOL, V16, P58, DOI 10.1111/j.1365-2826.2004.01121.x; Compagnone NA, 1998, P NATL ACAD SCI USA, V95, P4678, DOI 10.1073/pnas.95.8.4678; CORPECHOT C, 1981, P NATL ACAD SCI-BIOL, V78, P4704, DOI 10.1073/pnas.78.8.4704; Counterman AE, 2006, P NATL ACAD SCI USA, V103, P5262, DOI 10.1073/pnas.0504134103; Cutler RG, 2004, P NATL ACAD SCI USA, V101, P2070, DOI 10.1073/pnas.0305799101; Debonnel G, 1996, NEUROSCIENCE, V71, P977, DOI 10.1016/0306-4522(96)80001-7; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Dong E, 2001, P NATL ACAD SCI USA, V98, P2849, DOI 10.1073/pnas.051628598; Ebner MJ, 2006, ENDOCRINOLOGY, V147, P179, DOI 10.1210/en.2005-1065; FLOOD JF, 1995, P NATL ACAD SCI USA, V92, P10806, DOI 10.1073/pnas.92.23.10806; FLOOD JF, 1992, P NATL ACAD SCI USA, V89, P1567, DOI 10.1073/pnas.89.5.1567; Francis PT, 2005, CNS SPECTRUMS, V10, P6, DOI 10.1017/S1092852900014164; Genazzani AR, 1998, J CLIN ENDOCR METAB, V83, P2099, DOI 10.1210/jc.83.6.2099; Ghoumari AM, 2003, J NEUROCHEM, V86, P848, DOI 10.1046/j.1471-4159.2003.01881.x; Girdler SS, 2001, BIOL PSYCHIAT, V49, P788, DOI 10.1016/S0006-3223(00)01044-1; Glantz LA, 2000, ARCH GEN PSYCHIAT, V57, P65, DOI 10.1001/archpsyc.57.1.65; Griffin LD, 2001, ENDOCRINOLOGY, V142, P4617, DOI 10.1210/en.142.11.4617; Griffin LD, 1999, P NATL ACAD SCI USA, V96, P13512, DOI 10.1073/pnas.96.23.13512; Griffin LD, 2004, NAT MED, V10, P704, DOI 10.1038/nm1073; He J, 2004, RESTOR NEUROL NEUROS, V22, P19; Higashi T, 2003, J PHARMACEUT BIOMED, V30, P1907, DOI 10.1016/S0731-7085(02)00534-4; Hulette CM, 1997, ARCH PATHOL LAB MED, V121, P615; Hynd MR, 2004, NEUROCHEM INT, V45, P583, DOI 10.1016/j.neuint.2004.03.007; Jellinger KA, 2004, CURR OPIN NEUROL, V17, P719, DOI 10.1097/00019052-200412000-00012; Jin LW, 2004, AM J PATHOL, V164, P975, DOI 10.1016/S0002-9440(10)63185-9; Karishma KK, 2002, EUR J NEUROSCI, V16, P445, DOI 10.1046/j.1460-9568.2002.02099.x; Kim SB, 2003, J CLIN ENDOCR METAB, V88, P5199, DOI 10.1210/jc.2003-030646; Kimonides VG, 1999, NEUROSCIENCE, V89, P429, DOI 10.1016/S0306-4522(98)00347-9; Kimonides VG, 1998, P NATL ACAD SCI USA, V95, P1852, DOI 10.1073/pnas.95.4.1852; Korolainen MA, 2006, NEUROBIOL AGING, V27, P42, DOI 10.1016/j.neurobiolaging.2004.11.010; Liere P, 2004, J LIPID RES, V45, P2287, DOI 10.1194/jlr.M400244-JLR200; Lipton Stuart A., 2005, Current Alzheimer Research, V2, P155, DOI 10.2174/1567205053585846; Liu SY, 2003, ANAL CHEM, V75, P5835, DOI 10.1021/ac0346297; Lockhart EM, 2002, NEUROSCI LETT, V328, P33, DOI 10.1016/S0304-3940(02)00448-2; MAJEWSKA MD, 1986, SCIENCE, V232, P1004, DOI 10.1126/science.2422758; Mariani E, 2005, J CHROMATOGR B, V827, P65, DOI 10.1016/j.jchromb.2005.04.023; Marx CE, 2000, BIOL PSYCHIAT, V47, P1000, DOI 10.1016/S0006-3223(99)00305-4; Marx CE, 2003, NEUROPSYCHOPHARMACOL, V28, P1, DOI 10.1038/sj.npp.1300015; MARX CE, IN PRESS PHARM BIOCH; Marx CE, 2006, NEUROPSYCHOPHARMACOL, V31, P1249, DOI 10.1038/sj.npp.1300952; Maurice T, 1998, NEUROSCIENCE, V83, P413, DOI 10.1016/S0306-4522(97)00405-3; Mellon SH, 2002, ENDOCR RES, V28, P463, DOI 10.1081/ERC-120016823; Meunier J, 2004, NEUROTOXICOL TERATOL, V26, P783, DOI 10.1016/j.ntt.2004.07.003; MORROW AL, 1990, MOL PHARMACOL, V37, P263; MORROW AL, 1987, EUR J PHARMACOL, V142, P483, DOI 10.1016/0014-2999(87)90094-X; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Papassotiropoulos A, 2005, J CLIN PSYCHIAT, V66, P940, DOI 10.4088/JCP.v66n0720; PAUL SM, 1992, FASEB J, V6, P2311, DOI 10.1096/fasebj.6.6.1347506; Pinna G, 2003, P NATL ACAD SCI USA, V100, P2035, DOI 10.1073/pnas.0337642100; Prabakaran S, 2004, MOL PSYCHIATR, V9, P684, DOI 10.1038/sj.mp.4001511; Puglielli L, 2003, NAT NEUROSCI, V6, P345, DOI 10.1038/nn0403-345; PURDY R, 2006, HDB NEUROCHEMISTRY M, V18, P1; PURDY RH, 1990, J MED CHEM, V33, P1572, DOI 10.1021/jm00168a008; Ramassamy C, 1999, FREE RADICAL BIO MED, V27, P544, DOI 10.1016/S0891-5849(99)00102-1; ROBERTS E, 1987, BRAIN RES, V406, P357, DOI 10.1016/0006-8993(87)90807-9; Rupprecht R, 1999, TRENDS NEUROSCI, V22, P410, DOI 10.1016/S0166-2236(99)01399-5; Shobab LA, 2005, LANCET NEUROL, V4, P841, DOI 10.1016/S1474-4422(05)70248-9; Shu HJ, 2004, J NEUROSCI, V24, P6667, DOI 10.1523/JNEUROSCI.1399-04.2004; Smith AB, 2003, ORG LETT, V5, P1, DOI 10.1021/ol0202520; Suzuki M, 2004, P NATL ACAD SCI USA, V101, P3202, DOI 10.1073/pnas.0307325101; Torrey EF, 2005, BIOL PSYCHIAT, V57, P252, DOI 10.1016/j.biopsych.2004.10.019; Treiber-Held S, 2003, J PATHOL, V200, P95, DOI 10.1002/path.1345; Tunez I, 2005, PHARMACOLOGY, V74, P113, DOI 10.1159/000084169; Uzunov DP, 1996, P NATL ACAD SCI USA, V93, P12599, DOI 10.1073/pnas.93.22.12599; Uzunova V, 1998, P NATL ACAD SCI USA, V95, P3239, DOI 10.1073/pnas.95.6.3239; Vallee M, 2003, J STEROID BIOCHEM, V85, P329, DOI 10.1016/S0960-0760(03)00227-9; Vallee M, 1997, P NATL ACAD SCI USA, V94, P14865, DOI 10.1073/pnas.94.26.14865; Vance JE, 2005, SEMIN CELL DEV BIOL, V16, P193, DOI 10.1016/j.semcdb.2005.01.005; Wang JM, 2005, J NEUROSCI, V25, P4706, DOI 10.1523/JNEUROSCI.4520-04.2005; Weill-Engerer S, 2002, J CLIN ENDOCR METAB, V87, P5138, DOI 10.1210/jc.2002-020878; Wenk GL, 2006, J CLIN PSYCHIAT, V67, P3; Wolf OT, 1999, BRAIN RES REV, V30, P264, DOI 10.1016/S0165-0173(99)00021-1; Wolkowitz OM, 2003, NEUROLOGY, V60, P1071, DOI 10.1212/01.WNL.0000052994.54660.58; Wolozin B, 2004, NEURON, V41, P7, DOI 10.1016/S0896-6273(03)00840-7; Yu WX, 2005, J BIOL CHEM, V280, P27296, DOI 10.1074/jbc.M503922200	94	109	115	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0006-3223	1873-2402		BIOL PSYCHIAT	Biol. Psychiatry	DEC 15	2006	60	12					1287	1294		10.1016/j.biopsych.2006.06.017			8	Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry	115LL	WOS:000242735700001	16997284				2022-02-06	
J	Stulemeijer, M; van der Werf, S; Bleijenberg, G; Biert, J; Brauer, J; Vos, PE				Stulemeijer, Maja; van der Werf, Sieberen; Bleijenberg, Gijs; Biert, Jan; Brauer, Jolanda; Vos, Pieter E.			Recovery from mild traumatic brain injury - A focus on fatigue	JOURNAL OF NEUROLOGY			English	Article						mild traumatic brain injury; fatigue; outcome studies	MINOR HEAD-INJURY; PATIENT COMPLAINTS; SYMPTOMS; STROKE; REHABILITATION; RELIABILITY; DEPRESSION; EXPERIENCE; SEQUELAE	Background. Fatigue is one of the most frequently reported symptoms after Mild Traumatic Brain Injury (MTBI). To date, systematic and comparative studies on fatigue after MTBI are scarce, and knowledge on causal mechanisms is lacking. Objectives To determine the severity of fatigue six months after MTBI and its relation to outcome. Furthermore, to test whether injury indices, such as Glasgow Coma Scale scores, are related to higher levels of fatigue. Methods Postal questionnaires were sent to a consecutive group of patients with an MTBI and a minor-injury control group, aged 18-60, six months after injury. Fatigue severity was measured with the Checklist Individual Strength. Postconcussional symptoms and limitations in daily functioning were assessed using the Rivermead Post Concussion Questionnaire and the SF-36. Results A total of 299 out of 618 eligible (response rate 52%) MTBI patients and 287 out of 482 eligible (response rate 60%) minor-injury patients returned the questionnaire. Ninety-five MTBI patients (32%) and 35 control patients (12%) were severely fatigued. Severe fatigue was highly associated with the experience of other symptoms, limitations in physical and social functioning, and fatigue related problems like reduced activity. Of various trauma severity indices, nausea and headache experienced on the ED were significantly related to higher levels of fatigue at six months. Conclusions In conclusion, one third of a large sample of MTBI patients experiences severe fatigue six months after injury, and this experience is associated with limitations in daily functioning. Our finding that acute symptoms and mechanism of injury rather than injury severity indices appear to be related to higher levels of fatigue warrants further investigation.	Radboud Univ Nijmegen, Med Ctr, Dept Med Psychol, NL-6500 HB Nijmegen, Netherlands; Radboud Univ Nijmegen, Expert Ctr Chron Fatigue, Med Ctr, Nijmegen, Netherlands; Radboud Univ Nijmegen, Med Ctr, Dept Surg, Nijmegen, Netherlands; Radboud Univ Nijmegen, Med Ctr, Dept Neurol, Nijmegen, Netherlands		Stulemeijer, M (corresponding author), Radboud Univ Nijmegen, Med Ctr, Dept Med Psychol, POB 9101, NL-6500 HB Nijmegen, Netherlands.	M.Stulemeijer@neuro.umcn.nl	Vos, Pieter/A-6043-2012; Bleijenberg, Gijs/E-6984-2010; Biert, J./L-4200-2015				Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chaudhuri A, 2004, LANCET, V363, P978, DOI 10.1016/S0140-6736(04)15794-2; Cicerone KD, 1997, BRAIN INJURY, V11, P643, DOI 10.1080/026990597123197; de Groot MH, 2003, ARCH PHYS MED REHAB, V84, P1714, DOI 10.1053/S0003-9993(03)00346-0; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; Haboubi NHJ, 2001, DISABIL REHABIL, V23, P635; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Ingles JL, 1999, ARCH PHYS MED REHAB, V80, P173, DOI 10.1016/S0003-9993(99)90116-8; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Kalkman J, 2002, NEUROMUSCULAR DISORD, V12, P779; Kashluba S, 2004, ARCH CLIN NEUROPSYCH, V19, P805, DOI 10.1016/j.acn.2003.09.005; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; McCullagh S, 2001, BRAIN INJURY, V15, P489, DOI 10.1080/02699050010007353; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; Paniak C, 2002, ARCH CLIN NEUROPSYCH, V17, P319, DOI 10.1016/S0887-6177(01)00115-9; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Rutherford W. H., 1989, MILD HEAD INJURY, P217; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; STALNACKE B, 2004, THESIS U UMEA, P35; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; van der Werf SP, 2001, EUR NEUROL, V45, P28, DOI 10.1159/000052085; Vercoulen J. H, 1999, GEDRAGSTHERAPIE, V32, P31; VERCOULEN JHMM, 1994, J PSYCHOSOM RES, V38, P383, DOI 10.1016/0022-3999(94)90099-X; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; World Health Organization, 1978, ICD 9 CLASS MENT BEH	30	109	109	0	14	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0340-5354	1432-1459		J NEUROL	J. Neurol.	AUG	2006	253	8					1041	1047		10.1007/s00415-006-0156-5			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	086FR	WOS:000240659700010	16708266				2022-02-06	
J	Farkas, O; Lifshitz, J; Povlishock, JT				Farkas, O; Lifshitz, J; Povlishock, JT			Mechanoporation induced by diffuse traumatic brain injury: An irreversible or reversible response to injury?	JOURNAL OF NEUROSCIENCE			English	Article						diffuse traumatic brain injury; neuron; dextrans; membrane disruption; membrane resealing; calpain	PLASMA-MEMBRANE DISRUPTIONS; SPECTRIN BREAKDOWN PRODUCTS; CORTICAL IMPACT INJURY; SEVERE HEAD-INJURY; SPINAL-CORD AXONS; IN-VITRO MODEL; CALPAIN ACTIVATION; NEURONAL DEATH; CELL-DEATH; CEREBROSPINAL-FLUID	Diffuse traumatic brain injury (DTBI) is associated with neuronal plasmalemmal disruption, leading to either necrosis or reactive change without cell death. This study examined whether enduring membrane perturbation consistently occurs, leading to cell death, or if there is the potential for transient perturbation followed by resealing/recovery. We also examined the relationship of these events to calpain-mediated spectrin proteolysis (CMSP). To assess plasmalemmal disruption, rats ( n = 21) received intracerebroventricular infusion 2 h before DTBI of a normally excluded 10 kDa fluorophore-labeled dextran. To reveal plasmalemmal resealing or enduring disruption, rats were infused with another labeled dextran 2 h ( n = 10) or 6 h ( n = 11) after injury. Immunohistochemistry for the 150 kDa spectrin breakdown product evaluated the concomitant role of CMSP. Neocortical neurons were followed with confocal and electron microscopy. After DTBI at 4 and 8 h, 55% of all tracer-flooded neurons contained both dextrans, demonstrating enduring plasmalemmal leakage, with many demonstrating necrosis. At 4 h, 12.0% and at 8 h, 15.7% of the dual tracer-flooded neurons showed CMSP, yet, these demonstrated less advanced cellular change. At 4 h, 39.0% and at 8 h, 24.4% of all tracer-flooded neurons revealed only preinjury dextran uptake, consistent with membrane resealing, whereas 7.6 and 11.1%, respectively, showed CMSP. At 4 h, 35% and at 8 h, 33% of neurons demonstrated CMSP without dextran flooding. At 4 h, 5.5% and at 8 h, 20.9% of tracer-flooded neurons revealed only postinjury dextran uptake, consistent with delayed membrane perturbation, with 55.0 and 35.4%, respectively, showing CMSP. These studies illustrate that DTBI evokes evolving plasmalemmal changes that highlight mechanical and potential secondary events in membrane poration.	Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA 23298 USA; Univ Pecs, Fac Med, Dept Neurosurg, H-7623 Pecs, Hungary		Povlishock, JT (corresponding author), Virginia Commonwealth Univ, Dept Anat & Neurobiol, Med Coll Virginia Campus,POB 980709, Richmond, VA 23298 USA.	jtpovlis@vcu.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [F32HD049343] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS047463] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [F32 HD049343, F32 HD-49343] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-47463, R01 NS-045834] Funding Source: Medline		Amorini AM, 2003, ACT NEUR S, V86, P261; ANDREWS NW, 2005, SCI STKE, pE19; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Brana C, 1999, EUR J NEUROSCI, V11, P2375, DOI 10.1046/j.1460-9568.1999.00653.x; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Chan PH, 1996, STROKE, V27, P1124, DOI 10.1161/01.STR.27.6.1124; CLARKE MSF, 1995, CIRC RES, V76, P927, DOI 10.1161/01.RES.76.6.927; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Czogalla A, 2005, CELL MOL LIFE SCI, V62, P1913, DOI 10.1007/s00018-005-5097-0; DERESKI MO, 1993, ACTA NEUROPATHOL, V85, P327; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1987, J CEREBR BLOOD F MET, V7, P300, DOI 10.1038/jcbfm.1987.67; Dietrich WD, 1998, INT REV NEUROBIOL, V42, P55, DOI 10.1016/S0074-7742(08)60608-X; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Farkas O, 2005, ACTA NEUROCHIR, V147, P855, DOI 10.1007/s00701-005-0559-6; FISHMAN HM, 1990, BIOCHIM BIOPHYS ACTA, V1023, P421, DOI 10.1016/0005-2736(90)90135-B; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; Geddes DM, 2001, J BIOMECH ENG-T ASME, V123, P247, DOI 10.1115/1.1374201; Godell CM, 1997, P NATL ACAD SCI USA, V94, P4751, DOI 10.1073/pnas.94.9.4751; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Howard MJ, 1999, NEUROSCIENCE, V93, P807, DOI 10.1016/S0306-4522(99)00195-5; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kampfl A, 1996, J NEUROCHEM, V67, P1575; Kupina NC, 2002, J CEREBR BLOOD F MET, V22, P1212, DOI 10.1097/01.wbc.0000037994.34930.bc; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; Liu XL, 2003, J PHARMACOL EXP THER, V304, P63, DOI 10.1124/jpet.102.043406; Liu XL, 2004, ANNU REV PHARMACOL, V44, P349, DOI 10.1146/annurev.pharmtox.44.101802.121804; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; McCracken E, 1999, J NEUROTRAUM, V16, P749, DOI 10.1089/neu.1999.16.749; MCNEIL PL, 1990, J CELL SCI, V96, P549; McNeil PL, 2000, J CELL SCI, V113, P1891; MCNEIL PL, 1989, GASTROENTEROLOGY, V96, P1238, DOI 10.1016/S0016-5085(89)80010-1; MCNEIL PL, 1992, AM J PATHOL, V140, P1097; Mennel HD, 2000, EXP TOXICOL PATHOL, V52, P395, DOI 10.1016/S0940-2993(00)80070-6; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; Neumar RW, 2001, EXP NEUROL, V170, P27, DOI 10.1006/exnr.2001.7708; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Pike BR, 2000, J NEUROTRAUM, V17, P283, DOI 10.1089/neu.2000.17.283; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Prado GR, 2004, J NEUROTRAUM, V21, P1331; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; SAIDO TC, 1993, J BIOL CHEM, V268, P25239; Shi R, 2001, J NEUROCYTOL, V30, P829, DOI 10.1023/A:1019645505848; Shi R, 2000, NEUROSCIENCE, V98, P157, DOI 10.1016/S0306-4522(00)00096-8; Shi RY, 2000, J NEUROPHYSIOL, V84, P1763, DOI 10.1152/jn.2000.84.4.1763; SIMAN R, 1989, J NEUROSCI, V9, P1579; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; STEINHARDT RA, 1994, SCIENCE, V263, P390, DOI 10.1126/science.7904084; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; Terasaki M, 1997, J CELL BIOL, V139, P63, DOI 10.1083/jcb.139.1.63; The Brain Trauma Foundation; The American Association of Neurological Surgeons, 2000, J NEUROTRAUM, V17, P479; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; WHITE BC, 1993, ACTA NEUROPATHOL, V86, P1, DOI 10.1007/BF00454891; XIE XY, 1991, J NEUROSCI, V11, P3257; Yamashima T, 2004, CELL CALCIUM, V36, P285, DOI 10.1016/j.ceca.2004.03.001; Yamashima T, 1998, EUR J NEUROSCI, V10, P1723, DOI 10.1046/j.1460-9568.1998.00184.x; YAWO H, 1983, SCIENCE, V222, P1351, DOI 10.1126/science.6658457; YAWO H, 1985, J NEUROSCI, V5, P1626; YOKOTA M, 1995, STROKE, V26, P1901, DOI 10.1161/01.STR.26.10.1901; YU QC, 1992, AM J PATHOL, V141, P1349	71	109	112	1	11	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	MAR 22	2006	26	12					3130	3140		10.1523/JNEUROSCI.5119-05.2006			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	024NM	WOS:000236202200006	16554464	Green Published, Bronze			2022-02-06	
J	Anson, K; Ponsford, J				Anson, K; Ponsford, J			Evaluation of a coping skills group following traumatic brain injury	BRAIN INJURY			English	Article						coping; psychological outcome; cognitive behaviour therapy	SICKNESS IMPACT PROFILE; CLOSED-HEAD-INJURY; SELF-AWARENESS; DEPRESSION SCALE; HOSPITAL ANXIETY; ADULTS; DEFICITS; REHABILITATION; AGGRESSION; VALIDATION	Primary objective: To examine the impact of a cognitive behaviour therapy (CBT) based intervention programme, termed the Coping Skills Group (CSG), on coping strategy use and emotional adjustment. Research design: Thirty-one individuals with TBI participated and a wait-list control design was used. Methods and procedures: The CSG ran twice a week, for 5 weeks and focused on developing adaptive coping skills for the management of emotional and adjustment issues. Main outcomes and results: Following the CSG, the majority of participants subjectively reported that they had a better understanding of emotional issues and an improved ability to implement strategies to manage these issues. Adaptive coping, as measured on the Coping Scale for Adults, increased significantly immediately following intervention. However, no significant changes in anxiety, depression, self-esteem and psychosocial function were observed on the measures used. Conclusions: The results suggest that it may be possible to modify coping strategy use following brain injury, through CBT.	Monash Univ, Sch Psychol Psychiat & Psychol Med, Clayton, Vic 3168, Australia; Epworth Med Fdn, Melbourne, Vic, Australia		Anson, K (corresponding author), 36 Auburn Parade, Hawthorn, Vic 3123, Australia.	katie.anson@gmail.com					ADAMS N, 1996, AUSTR NZ J FAMILY TH, V17, P75; Alderman N, 2003, NEUROPSYCHOL REHABIL, V13, P211, DOI 10.1080/09602010244000327; ANSON K, IN PRESS BRAIN INJUR; Bajo A, 2002, BRAIN INJURY, V16, P385, DOI 10.1080/02699050110119826; Beck J.S., 1995, COGNITIVE THERAPY BA; BenYishay Y, 1996, NEUROPSYCHOL REHABIL, V6, P327, DOI 10.1080/713755514; BENYISHAY Y, 1980, DEV CORE CURRICULUM, P175; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Blascovich J., 1993, MEASURES PERSONALITY, P115, DOI DOI 10.1016/B978-0-12-590241-0.50008-3; Bowen A, 1998, BRAIN INJURY, V12, P177, DOI 10.1080/026990598122656; Bryant RA, 2000, BRAIN INJURY, V14, P175, DOI 10.1080/026990500120826; Burgess P, 1996, BEHAV ASSESSMENT DYS; Christensen A., 2000, INT HDB NEUROPSYCHOL, P183; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; Deb S, 1999, AM J PSYCHIAT, V156, P374; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; DOUGLAS J, 2003, 25 ANN C AUSTR SOC S; Finset A, 2000, BRAIN INJURY, V14, P887; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Fleming JM, 1996, BRAIN INJURY, V10, P1; Fleminger S, 2003, NEUROPSYCHOL REHABIL, V13, P65, DOI 10.1080/09602010244000354; Frydenberg E., 1996, COPING SCALE ADULTS; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; GrayLittle B, 1997, PERS SOC PSYCHOL B, V23, P443, DOI 10.1177/0146167297235001; Herrmann C, 1997, J PSYCHOSOM RES, V42, P17, DOI 10.1016/S0022-3999(96)00216-4; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hiott DW, 2002, NEUROREHABILITATION, V17, P345; Johnston M, 2000, J PSYCHOSOM RES, V48, P579, DOI 10.1016/S0022-3999(00)00102-1; Kendall E, 2001, BRAIN IMPAIR, V2, P81; Khan-Bourne N, 2003, NEUROPSYCHOL REHABIL, V13, P89, DOI 10.1080/09602010244000318; Kim E, 2002, NEUROREHABILITATION, V17, P297; Kortte KB, 2003, REHABIL PSYCHOL, V48, P131, DOI 10.1037/0090-5550.48.3.131; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; Medd J, 2000, NEUROPSYCHOL REHABIL, V10, P185, DOI 10.1080/096020100389246; MONTGOMERY GK, 1995, BRAIN INJURY, V9, P453, DOI 10.3109/02699059509008205; Nelson H.E., 1991, NATL ADULT READING T, V2nd ed.; Norris G, 2000, NEUROPSYCHOL REHABIL, V10, P33, DOI 10.1080/096020100389282; O'Leary CA, 2000, BEHAV INTERVENT, V15, P205, DOI 10.1002/1099-078X(200007/09)15:3<205::AID-BIN56>3.3.CO;2-B; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; OWNSWORTH T, 2001, ASSBI 24 BRAIN IMP C; Ownsworth TL, 2000, NEUROPSYCHOL REHABIL, V10, P465, DOI 10.1080/09602010050143559; PONSFORD JL, 2003, INT NEUR SOC ANN C H; Powell J, 2002, J NEUROL NEUROSUR PS, V72, P193, DOI 10.1136/jnnp.72.2.193; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; Prigatano GP., 1999, PRINCIPLES NEUROPSYC, P244; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P1; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; Rosenberg M., 1965, SOC ADOLESCENT SELF; Rosenberg M., 1986, CONCEIVING SELF; Scheutzow MH, 1999, BRAIN INJURY, V13, P705; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Simmond M, 2003, BRAIN INJURY, V17, P325, DOI 10.1080/0269905021000013219; SIMPSON GK, 2001, SUICIDE PREVENTION T; Snaith R., 1994, HOSP ANXIETY DEPRESS; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); TEMKIN N, 1988, J CLIN EPIDEMIOL, V41, P47, DOI 10.1016/0895-4356(88)90008-X; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; Wallace CA, 2000, BRAIN INJURY, V14, P549; Wiseman-Hakes C, 1998, J HEAD TRAUMA REHAB, V13, P23, DOI 10.1097/00001199-199812000-00005; Ylvisaker M., 2000, BRAIN IMPAIR, V1, P12, DOI [DOI 10.1375/BRIM.1.1.12, 10.1375/brim.1.1.12]	64	109	111	0	16	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	FEB	2006	20	2					167	178		10.1080/02699050500442956			12	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	003KX	WOS:000234681700007	16421066				2022-02-06	
J	Anderson, V; Catroppa, C				Anderson, V; Catroppa, C			Recovery of executive skills following paediatric traumatic brain injury (TBI): A 2 year follow-up	BRAIN INJURY			English	Article						TBI; children; recovery	CLOSED HEAD-INJURY; ATTENTIONAL DEFICITS; CHILDREN; CHILDHOOD; METACOGNITION; ADOLESCENCE; ABILITY; MEMORY	Primary objective: Disruptions to executive function (EF) may occur as a result of traumatic brain injury (TBI), in the context of direct damage to frontal regions or in association with disruption of connections between these areas and other brain regions. Little investigation of EF has occurred following TBI during childhood and there is little evidence of possible recovery trajectories in the years post-injury. The present study aimed to (i) examine whether a dose-response relationship exists between injury severity and EF; (ii) document recovery of EF in the 2 years post-injury and (iii) determine any additional predictors of outcome in the domain of EF. Research design: The study employed a prospective, longitudinal design, with participants recruited at time of injury and followed over a 2-year period. Methods and procedures: The study examined EF in a group of 69 children who had sustained a mild, moderate or severe TBI. Four components of EF were assessed: (i) attentional control; (ii) planning, goal setting and problem solving; (iii) cognitive flexibility; and (iv) abstract reasoning. Outcomes and results: Results showed that, while children with severe TBI performed most poorly during the acute stage post-injury, they exhibited greatest recovery of EF over a 24-month period. Regardless, functional deficits remained most severe for this group 2 years post-injury. Results demonstrated the multi-dimensional nature of EF and the differential recovery of skills, following childhood TBI. Pre-injury ability and age at injury were identified as significant predictors of EF and functional skills. Conclusions: Children sustaining severe TBI at a young age are particularly vulnerable to impairments in EF. While these difficulties do show some recovery with time since injury, long-term deficits remain and may impact on ongoing development.	Univ Melbourne, Royal Childrens Hosp, Melbourne, Vic, Australia; Murdoch Childrens Res Inst, Melbourne, Vic, Australia		Anderson, V (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.	v.anderson@psych.unimelb.edu.au	Catroppa, Cathy/AAX-9458-2021	Catroppa, Cathy/0000-0002-9750-0436			Anderson P, 2001, CLIN NEUROPSYCHOL, V15, P81, DOI 10.1076/clin.15.1.81.1905; Anderson PJ., 2000, CLIN NEUROPSYCHOL AS, V1, P247; Anderson V, 1998, NEUROPSYCHOL REHABIL, V8, P283; ANDERSON V, 2001, PEDIAT NEUROPSYCHOLO; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Anderson VA, 2001, DEV NEUROPSYCHOL, V20, P385, DOI 10.1207/S15326942DN2001_5; Benson D.F., 1986, FRONTAL LOBES; BROUWER WH, 1989, CORTEX, V25, P219, DOI 10.1016/S0010-9452(89)80038-3; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879, DOI 10.1016/S0733-8619(18)30185-3; Casey BJ, 2000, BIOL PSYCHOL, V54, P241, DOI 10.1016/S0301-0511(00)00058-2; Catroppa C, 1999, J INT NEUROPSYCH SOC, V5, P48, DOI 10.1017/S1355617799511077; Ciccetti D., 1984, VINELAND ADAPTIVE BE; Daniel A., 1983, POWER PRIVILEGE PRES; Dennis M, 1996, DEV NEUROPSYCHOL, V12, P77, DOI 10.1080/87565649609540641; Dennis M, 1989, CLIN NEUROPSYCHOLOGY, P89; FENNELL EB, 1992, ADV CHILD NEUROPSYCH, V1; GADDES WH, 1973, RES MONOGRAPH U VICT, V25; GOLDENBERG G, 1992, J NEUROL NEUROSUR PS, V55, P362, DOI 10.1136/jnnp.55.5.362; Goldstein FC, 1992, COGNITIVE DISORDERS; Hanten G, 2000, DEV NEUROPSYCHOL, V18, P383, DOI 10.1207/S1532694206Hanten; Hanten G, 1999, DEV NEUROPSYCHOL, V16, P393, DOI 10.1207/S15326942DN1603_23; HYND GW, 1988, INTERCRANIAL INJURIE; Klingberg T, 1999, NEUROREPORT, V10, P2817, DOI 10.1097/00001756-199909090-00022; Levin H S, 1997, J Int Neuropsychol Soc, V3, P598; LEVIN HS, 1991, DEV NEUROPSYCHOL, V7, P377, DOI 10.1080/87565649109540499; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; MILLER JD, 1991, NEUROPSYCHOLOGY, V5, P235; MURRAY R, 1992, BRAIN COGNITION, V18, P99, DOI 10.1016/0278-2626(92)90072-T; Pentland L, 1998, NEUROPSYCHOL REHABIL, V8, P301, DOI 10.1080/713755572; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Reitan R.M., 1974, CLIN NEUROPSYCHOLOGY; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; ROWE JK, 1995, ROWE BEHAV RATING IN; Stablum F, 1996, CORTEX, V32, P261, DOI 10.1016/S0010-9452(96)80050-5; STUSS DT, 1992, BRAIN COGNITION, V20, P8, DOI 10.1016/0278-2626(92)90059-U; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; TEASDALE G, 1974, LANCET, V2, P81; Todd JA, 1996, NEUROPSYCHOL REHABIL, V6, P81, DOI 10.1080/713755500; Walsh K. W., 1978, NEUROPSYCHOLOGY CLIN; Wechsler D., 1992, MANUAL WECHSLER INTE; WELSH MC, 1988, DEV NEUROPSYCHOL, V4, P199, DOI 10.1080/87565648809540405; WEYANDT LL, 1994, DEV NEUROPSYCHOL, V10, P27, DOI 10.1080/87565649409540564; [No title captured]; [No title captured]	44	109	110	0	13	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUN	2005	19	6					459	470		10.1080/02699050400004823			12	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	932JI	WOS:000229549600007	16101268				2022-02-06	
J	Shiozaki, T; Hayakata, T; Tasaki, O; Hosotubo, H; Fuijita, K; Mouri, T; Tajima, G; Kajino, K; Nakae, H; Tanaka, H; Shimazu, T; Sugimoto, H				Shiozaki, T; Hayakata, T; Tasaki, O; Hosotubo, H; Fuijita, K; Mouri, T; Tajima, G; Kajino, K; Nakae, H; Tanaka, H; Shimazu, T; Sugimoto, H			Cerebrospinal fluid concentrations of anti-inflammatory mediators in early-phase severe traumatic brain injury	SHOCK			English	Article						IL-1ra; sTNFr-I; IL-10; cerebrospinal fluid; head injury	INTERLEUKIN-1 RECEPTOR ANTAGONIST; NECROSIS-FACTOR RECEPTORS; MULTIPLE INJURIES; PRACTICAL SCALE; RELEASE; SERUM; BARRIER; PATTERN; ALPHA; SCORE	In our previous study of patients with early-phase severe traumatic brain injury (TBI), the anti-inflammatory interleukin (IL)-10 concentration was lower in cerebrospinal fluid (CSF) than in serum, whereas proinflammatory IL-1&beta; and tumor necrosis factor (TNF)-&alpha; concentrations were higher in CSF than in serum. To clarify the influence of additional injury on this disproportion between proinflammatory and anti-inflammatory mediators, we compared their CSF and serum concentrations in patients with severe TBI with and without additional injury. All 35 study patients (18 with and 17 without additional injury) had a Glasgow Coma Scale score of 8 or less upon admission. With the exception of additional injury, clinical characteristics did not differ significantly between groups. CSF and serum concentrations of two proinflammatory mediators (IL-1&beta; and TNF-&alpha;,) and three anti-inflammatory mediators (IL-1 receptor antagonist [IL-1ra], soluble TNF receptor-I [sTNFr-1], and IL-10) were measured and compared at 6 h after injury. CSF concentrations of proinflammatory mediators were much higher than the corresponding serum concentrations in both patient groups (P &LT; 0.001). In contrast, serum concentrations of anti-inflammatory mediators were much higher than the paired CSF concentrations in patients with additional injury (P&LT; 0.001), but serum concentrations were lower than or equal to the corresponding CSF concentrations in patients without additional injury. CSF concentrations of IL-10, IL-1ra, sTNFr-1, and IL-10 were significantly higher (P&LT; 0.01 for all) in patients with high intracranial pressure (ICP; n = 11) than in patients with low ICP (n = 24), and were also significantly higher (P &LT; 0.05 for all) in patients with an unfavorable outcome (n = 14) than in patients with a favorable outcome (n = 21). These findings indicate that increased serum concentrations of anti-inflammatory mediators after severe TBI are mainly due to additional extracranial injury. We conclude that anti-inflammatory mediators in CSF may be useful indicators of the severity of brain damage in terms of ICP as well as overall prognosis of patients with severe TBI.	Osaka Univ, Grad Sch Med, Dept Traumatol, Suita, Osaka 5650871, Japan		Shiozaki, T (corresponding author), Osaka Univ, Grad Sch Med, Dept Traumatol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	shiozaki@hp-emerg.med.osaka-u.ac.jp					AREND WP, 1991, J IMMUNOL, V147, P1530; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; CHRISTIAN S, 2005, SHOCK, V23, P30; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; ERTEL W, 1995, J TRAUMA, V39, P879, DOI 10.1097/00005373-199511000-00011; Gruber A, 2000, J NEUROSURG ANESTH, V12, P297, DOI 10.1097/00008506-200010000-00001; GUTIERREZ EG, 1994, J NEUROIMMUNOL, V55, P153, DOI 10.1016/0165-5728(94)90005-1; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Hensler T, 2002, J TRAUMA, V52, P962, DOI 10.1097/00005373-200205000-00023; JENNETT B, 1975, LANCET, V1, P480; Lanzrein AS, 1998, ALZ DIS ASSOC DIS, V12, P215, DOI 10.1097/00002093-199809000-00016; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Partrick DA, 1999, AM J SURG, V178, P564, DOI 10.1016/S0002-9610(99)00240-8; POUTSIAKA DD, 1991, BLOOD, V78, P1275; Shimonkevitz R, 1999, SHOCK, V12, P10, DOI 10.1097/00024382-199907000-00002; Shiozaki T, 1999, J NEUROSURG, V91, P185, DOI 10.3171/jns.1999.91.2.0185; Tarkowski E, 2003, BRAIN RES BULL, V61, P255, DOI 10.1016/S0361-9230(03)00088-1; TEASDALE G, 1974, LANCET, V2, P81	20	109	112	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1073-2322			SHOCK	Shock	MAY	2005	23	5					406	410		10.1097/01.shk.0000161385.62758.24			5	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	923MH	WOS:000228913500003	15834305				2022-02-06	
J	Baskin, YK; Dietrich, WD; Green, EJ				Baskin, YK; Dietrich, WD; Green, EJ			Two effective behavioral tasks for evaluating sensorimotor dysfunction following traumatic brain injury in mice	JOURNAL OF NEUROSCIENCE METHODS			English	Article						controlled cortical impact (CCI); gridwalk; insult location; spontaneous forelimb use; forebrain injury; mouse; hindlimb; forelimb	RECOVERY; FORELIMB; PLASTICITY; DEFICITS; MOUSE	Variants of two sensorimotor tasks, the gridwalk and spontaneous forelimb use (SFL) tasks, were assessed for their ability to reveal behavioral dysfunction following traumatic brain injury (TBI) in mice. These tests have previously been used almost exclusively in evaluating models of spinal injury, ischemia and other forebrain lesions in rats. Male C57BL/6 mice were anesthetized and given unilateral parasagittal controlled cortical impact injury or sham (n = 9) procedures, targeting right anterior (17 = 9), middle (n = 9), or posterior (n = 10) locations relative to bregma. Significant forelimb and hindlimb deficits contralateral to the injured hemisphere were observed for at least I month and 3 weeks, respectively, on the gridwalk task depending upon insult location. The SFL task revealed a significant asymmetry in forelimb use for at least 5 months following injury. These results demonstrate the effectiveness of the SFL and gridwalk tests in evaluating sensorimotor deficits in mouse injury models involving unilateral forebrain damage. (C) 2003 Elsevier B.V. All rights reserved.	Univ Miami, Dept Psychol, Coral Gables, FL 33124 USA; Univ Miami, Dept Neurol Surg, Coral Gables, FL 33124 USA		Green, EJ (corresponding author), Univ Miami, Dept Psychol, POB 248185, Coral Gables, FL 33124 USA.	cgreen@miami.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30291] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291] Funding Source: NIH RePORTER		Bland ST, 2000, STROKE, V31, P1144, DOI 10.1161/01.STR.31.5.1144; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; CONROY C, 1988, NEUROEPIDEMIOLOGY, V7, P13, DOI 10.1159/000110131; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Fox GB, 1998, J NEUROTRAUM, V15, P1037, DOI 10.1089/neu.1998.15.1037; Fox S, 1998, INFECT MED, V15, P8; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; HERNANDEZ TD, 1988, EXP NEUROL, V102, P318, DOI 10.1016/0014-4886(88)90226-9; Kolb B, 1997, NEUROSCIENCE, V76, P1139, DOI 10.1016/S0306-4522(96)00448-4; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; KUNKELBAGDEN E, 1993, EXP NEUROL, V119, P153, DOI 10.1006/exnr.1993.1017; Longhi L, 2001, J CEREBR BLOOD F MET, V21, P1241, DOI 10.1097/00004647-200111000-00001; Metz GA, 2002, J NEUROSCI METH, V115, P169, DOI 10.1016/S0165-0270(02)00012-2; Muir GD, 1999, BEHAV BRAIN RES, V103, P45, DOI 10.1016/S0166-4328(99)00018-2; PAXINOS G, 2001, MOUSE BRAN STEREOTAX; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; Schallert T., 2002, PHARM CEREB ISCHEMIA, V2002, P201; SCHALLERT T, 2000, INNOVATIVE MODELS CN; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Soblosky JS, 1997, J NEUROSCI METH, V78, P75, DOI 10.1016/S0165-0270(97)00131-3; STROEMER RP, 1995, STROKE, V26, P2135, DOI 10.1161/01.STR.26.11.2135; Yakovlev AG, 2001, MOL MED, V7, P205, DOI 10.1007/BF03401955; Z'Graggen WJ, 1998, J NEUROSCI, V18, P4744; Zhang L, 2002, J NEUROSCI METH, V117, P207, DOI 10.1016/S0165-0270(02)00114-0	24	109	112	0	14	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	OCT 15	2003	129	1					87	93		10.1016/S0165-0270(03)00212-7			7	Biochemical Research Methods; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	721GF	WOS:000185308100010	12951236				2022-02-06	
J	Stein, SC; Chen, XH; Sinson, GP; Smith, DH				Stein, SC; Chen, XH; Sinson, GP; Smith, DH			Intravascular coagulation: a major secondary insult in nonfatal traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; thrombosis; disseminated intravascular coagulation; secondary insult; rat; pig	SEVERE HEAD-INJURY; BLOOD; COAGULOPATHY; CONTUSION; DAMAGE; RAT; DISTURBANCES; HYPEREMIA; VASOSPASM; ISCHEMIA	Object. The goal of this study was to determine the frequency with which cerebral intravascular coagulation (IC) complicates traumatic brain injury (TBI). The authors also investigated the incidence of IC in relation to varying mechanisms, time courses, and severities of TBI and in different species. Methods. Tissue was sampled from surgical specimens of human cerebral contusions, from rats with lateral fluid-percussion injuries, and from pigs with head rotational acceleration injuries. Immunohistochemical fluorescent staining for antithrombin III was performed to detect cerebral intravascular microthrombi. Abundant IC was found in all specimens, and microthrombi had formed in arterioles and venules of all sizes, ranging from 10 to 600 mum. Although it was more pronounced in focal lesions and more severe injuries, considerable IC was also observed in mild and diffuse injuries. The authors found a strong association between the severity of coagulopathy and the density of IC. Conclusions. These results strongly support the contention that IC is a universal response to TBI and an important secondary cerebral insult.	Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA		Smith, DH (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, 105 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.	smithdou@mail.med.upenn.edu	smith, douglas/A-1321-2007				ATTAR S, 1969, J TRAUM, V9, P939, DOI 10.1097/00005373-196911000-00004; AUER L, 1978, ACTA NEUROCHIR, V43, P51, DOI 10.1007/BF01809225; Bostrom K, 1986, Acta Neurochir Suppl (Wien), V36, P51; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BREDBACKA S, 1992, J NEUROSURG ANESTH, V4, P128, DOI 10.1097/00008506-199204000-00008; Cortiana M, 1986, J Neurosurg Sci, V30, P133; CUNNINGHAM DD, 1993, THROMB HAEMOSTASIS, V70, P168; Daneyemez M, 1999, NEUROSCIENCE, V92, P783, DOI 10.1016/S0306-4522(99)00035-4; Gando S, 1999, J TRAUMA, V46, P1070, DOI 10.1097/00005373-199906000-00018; GOODNIGHT SH, 1974, NEW ENGL J MED, V290, P1043, DOI 10.1056/NEJM197405092901903; GRAHAM DI, 1971, LANCET, V1, P265; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; HOOTS K, 1983, BLOOD S, V62, pA275; HOOTS WK, 1996, NEUROTRAUMA, P673; JING ZA, 1992, J TRAUMA, V33, P83, DOI 10.1097/00005373-199207000-00016; KAUFMAN HH, 1984, NEUROSURGERY, V15, P34, DOI 10.1227/00006123-198407000-00008; KAUFMAN HH, 1985, CENTRAL NERVOUS SYST, P187; Kaufmann CR, 1997, J TRAUMA, V42, P716, DOI 10.1097/00005373-199704000-00023; KEIMOWITZ RM, 1973, J NEUROSURG, V39, P178, DOI 10.3171/jns.1973.39.2.0178; Lafuente JV, 1999, J NEUROTRAUM, V16, P425, DOI 10.1089/neu.1999.16.425; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; Mathew P, 1996, J NEUROSURG, V85, P860, DOI 10.3171/jns.1996.85.5.0860; May AK, 1997, AM SURGEON, V63, P233; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MINER ME, 1982, J PEDIATR-US, V100, P687, DOI 10.1016/S0022-3476(82)80565-9; Nilsson P, 1996, J NEUROTRAUM, V13, P201, DOI 10.1089/neu.1996.13.201; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; Romner B, 1996, J NEUROSURG, V85, P90, DOI 10.3171/jns.1996.85.1.0090; Schroder ML, 1998, NEUROSURGERY, V42, P1276, DOI 10.1097/00006123-199806000-00042; Selladurai BM, 1997, BRIT J NEUROSURG, V11, P398; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; Stein SC, 1995, PEDIATR NEUROSURG, V23, P299, DOI 10.1159/000120975; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; SUZUKI M, 1994, THROMB HAEMOSTASIS, V71, P155; Takahashi H, 1997, J NEUROSURG, V86, P768, DOI 10.3171/jns.1997.86.5.0768; Tikk A, 1979, Acta Neurochir Suppl (Wien), V28, P96; VANDERSANDE JJ, 1981, J NEUROSURG, V54, P21, DOI 10.3171/jns.1981.54.1.0021; von Oettingen G, 2002, NEUROSURGERY, V50, P781, DOI 10.1097/00006123-200204000-00019; Wahl F, 2000, J NEUROTRAUM, V17, P1055, DOI 10.1089/neu.2000.17.1055; 1989, LANCET, V2, P957	42	109	116	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	DEC	2002	97	6					1373	1377		10.3171/jns.2002.97.6.1373			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	626YG	WOS:000179901000018	12507136				2022-02-06	
J	Noshita, N; Lewen, A; Sugawara, T; Chan, PH				Noshita, N; Lewen, A; Sugawara, T; Chan, PH			Akt phosphorylation and neuronal survival after traumatic brain injury in mice	NEUROBIOLOGY OF DISEASE			English	Article							PROTEIN-KINASE-B; GLYCOGEN-SYNTHASE KINASE-3; MITOCHONDRIAL CYTOCHROME-C; CONTROLLED CORTICAL IMPACT; TRANSIENT FOCAL ISCHEMIA; DNA FRAGMENTATION; CELL-DEATH; PHOSPHATIDYLINOSITOL 3-KINASE; APOPTOSIS; ACTIVATION	The serine-threonine kinase, Akt, is involved in the survival signaling pathways in many cell systems. The present study examined phosphorylation of Akt at serine-473 and DNA fragmentation after traumatic brain injury (TBI) in mice. Immunohistochemistry showed phospho-Akt was decreased in the injured cortex 1 h after TBI, whereas it was temporally increased at 4 h in the perifocal damaged cortex. In the CA1 region of the hippocampus, phospho-Akt was increased after TBI. Western blot analysis showed that Akt was significantly decreased as early as 1 h after trauma; however, the phosphorylation was accelerated at 4 h. Double staining with phospho-Akt and phospho-BAD or phospho-GSK-3beta revealed the colocalization of phospho-Akt and downstream elements. Double staining with phospho-Akt and terminal deoxynucleotidyl transferase-mediated uridine 5'-triphosphate-biotin nick end-labeling showed different cellular distributions after TBI. The present study implicates Akt phosphorylation in the signaling pathways that are involved in cell survival after TBI. (C) 2002 Elsevier Science (USA).	Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Program Neurosci, Stanford, CA 94305 USA		Noshita, N (corresponding author), Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA.		Lewen, Anders/A-5156-2013	Lewen, Anders/0000-0003-4925-1348	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 38653, NS 36147, NS 25372, NS 14534] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038653, R01NS025372, R01NS036147] Funding Source: NIH RePORTER		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chalecka-Franaszek E, 1999, P NATL ACAD SCI USA, V96, P8745, DOI 10.1073/pnas.96.15.8745; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1997, J NEUROSCI, V17, P9172; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Crowder RJ, 1998, J NEUROSCI, V18, P2933; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; FRANK J, 1997, RETINOIDS, V13, P88; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Fujimura M, 1999, J CEREBR BLOOD F MET, V19, P495, DOI 10.1097/00004647-199905000-00003; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Janelidze S, 2001, NEUROBIOL DIS, V8, P147, DOI 10.1006/nbdi.2000.0325; KERR LE, 2001, J CEREB BLOOD FLOW S, V21, pS44; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuida K, 2000, INT J BIOCHEM CELL B, V32, P121, DOI 10.1016/S1357-2725(99)00024-2; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P914, DOI 10.1097/00004647-200108000-00003; Lewen A, 2001, NEUROBIOL DIS, V8, P380, DOI 10.1006/nbdi.2001.0396; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P344, DOI 10.1097/00004647-200104000-00003; Lu J, 2000, NEUROSCI LETT, V290, P89, DOI 10.1016/S0304-3940(00)01307-0; Morita-Fujimura Y, 1999, NEUROSCI LETT, V267, P201, DOI 10.1016/S0304-3940(99)00327-4; Namikawa K, 2000, J NEUROSCI, V20, P2875; Namura S, 2000, J CEREBR BLOOD F MET, V20, P1301, DOI 10.1097/00004647-200009000-00004; Noshita N, 2001, J CEREBR BLOOD F MET, V21, P1442, DOI 10.1097/00004647-200112000-00009; Ouyang YB, 1999, J CEREBR BLOOD F MET, V19, P1126, DOI 10.1097/00004647-199910000-00009; RINK A, 1995, AM J PATHOL, V147, P1575; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Springer JE, 2000, J NEUROSCI, V20, P7246; Srivastava AK, 1998, MOL CELL BIOCHEM, V182, P135, DOI 10.1023/A:1006857527588; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yano S, 2001, J CEREBR BLOOD F MET, V21, P351, DOI 10.1097/00004647-200104000-00004; Yoshimoto T, 2001, BRAIN RES, V899, P148, DOI 10.1016/S0006-8993(01)02220-X; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhou HL, 2000, J CELL BIOL, V151, P483, DOI 10.1083/jcb.151.3.483; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	51	109	112	0	6	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961			NEUROBIOL DIS	Neurobiol. Dis.	APR	2002	9	3					294	304		10.1006/nbdi.2002.0482			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	545AF	WOS:000175193500003	11950275				2022-02-06	
J	Joshi, M; Fehlings, MG				Joshi, M; Fehlings, MG			Development and characterization of a novel, graded model of clip compressive spinal cord injury in the mouse: Part 2. Quantitative neuroanatomical assessment and analysis of the relationships between axonal tracts, residual tissue, and locomotor recovery	JOURNAL OF NEUROTRAUMA			English	Article						in vivo model; knockout mouse; locomotion assessment; motor tract axons; neurotrauma; pathophysiology	RUBROSPINAL NEURONS; OVERGROUND LOCOMOTION; NEUROLOGICAL FUNCTION; LESIONS; RATS; CATS; CONTUSION	A detailed examination of the histopathological features of the clip compression injury in mice was performed to understand the relationships between neurological function and existing pathology of the spinal cord. Adult, female CD1 mice underwent three grades of extradural clip compression injury (3-g, 8-g, and 24-g FEJOTA(TM) Mouse clips), transection, and sham injury at T3-4. Quantitative behavioural assessments were performed for 4 weeks following SCI. After 4 weeks, Fluoro-Gold was introduced caudal to the SCI site, at T9, and was retrogradely transported for 5 days to the origin of spared axons through the injury site. Counts of retrogradely labeled neurons in the brain-stem, midbrain, and sensory-motor cortex indicated that the number of intact descending axons that traversed the lesion decreased with increasing injury severity (F > 28; df = 4; p < 0.0001; one-way ANOVA). Independent linear correlation analyses were performed between indices of neurological recovery (BBB and IP test), counts of retrogradely labeled neurons and morphometric assessments of normal residual tissue at the injury epicenter. The BBB test correlated strongly with the amount of residual tissue at the injury epicenter (R = 0.945, df = 28, p < 0.0001). Counts of neurons retrogradely labeled with Fluoro-Gold were also strongly correlated with the BBB scores. The extrapyramidal (raphespinal, reticulospinal, vestibulospinal, and rubrospinal) tracts had Pearson correlation coefficients (R) of 0.814, 0.812, 0.813, and 0.747, respectively (df = 28, p < 0.0001). The pyramidal (corticospinal) tract had a correlation of R = 0.747, df = 28, p < 0.0001 with the BBB scores. The IP scores also correlated strongly with the persistence of extrapyramidal (raphespinal, reticulospinal, vestibulospinal and rubrospinal) tracts with correlation coefficients of 0.801, 0.782, 0.790, and 0.836, respectively (df = 28, p < 0.0001). These data indicate that the counts of retrogradely labeled neurons at the origin of distinct descending motor pathways are predictors of the variance of the functional recovery measured by the BBB and IP tests following spinal cord injury. In addition, we provide a detailed neuroanatomical study of clip compression injury in mice that can be used to study the molecular mechanisms of SCI in knockout and transgenic mice.	Univ Toronto, Toronto Western Hosp, Dept Surg, Div Neurosurg, Toronto, ON M5T 2S8, Canada		Fehlings, MG (corresponding author), Univ Toronto, Univ Hlth Network, Dept Surg, 399 Bathurst St,Suite 2-417, Toronto, ON M5T 2S8, Canada.			Fehlings, Michael/0000-0002-5722-6364			Agrawal SK, 1997, J NEUROTRAUM, V14, P81, DOI 10.1089/neu.1997.14.81; ARMSTRONG DM, 1988, J PHYSIOL-LONDON, V405, P1, DOI 10.1113/jphysiol.1988.sp017319; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; BEHRMANN DL, 1992, J NEUROTRAUM, V9, P197, DOI 10.1089/neu.1992.9.197; BLIGHT AR, 1991, J NEUROSURG SCI, V35, P131; BRESNAHAN JC, 1987, EXP NEUROL, V96, P82; EIDELBERG E, 1981, EXP BRAIN RES, V42, P81; Eidelberg E, 1976, Surg Neurol, V6, P35; EIDELBERG E, 1981, EXP BRAIN RES, V43, P101; Farooque M, 2000, ACTA NEUROPATHOL, V100, P13, DOI 10.1007/s004010051187; FEHLINGS MG, 1995, EXP NEUROL, V132, P220, DOI 10.1016/0014-4886(95)90027-6; Franklin K.B., 1997, MOUSE BRAIN STEREOTA; Gruner JA, 1996, BRAIN RES, V729, P90, DOI 10.1016/S0006-8993(96)00366-6; Huang DW, 1999, NEURON, V24, P639, DOI 10.1016/S0896-6273(00)81118-6; JENKINS R, 1993, EUR J NEUROSCI, V5, P203, DOI 10.1111/j.1460-9568.1993.tb00486.x; Kuhn PL, 1998, J NEUROTRAUM, V15, P125, DOI 10.1089/neu.1998.15.125; LITTLE JW, 1988, NEUROSCI LETT, V87, P189, DOI 10.1016/0304-3940(88)90168-1; Ma MH, 2001, EXP NEUROL, V169, P239, DOI 10.1006/exnr.2001.7679; MIDHA R, 1987, BRAIN RES, V410, P299, DOI 10.1016/0006-8993(87)90328-3; Muir GD, 1999, BEHAV BRAIN RES, V103, P45, DOI 10.1016/S0166-4328(99)00018-2; Muir GD, 2000, EUR J NEUROSCI, V12, P1113, DOI 10.1046/j.1460-9568.2000.00987.x; NASO WB, 1993, NEUROSCI LETT, V155, P125, DOI 10.1016/0304-3940(93)90688-H; NOBLE LJ, 1985, EXP NEUROL, V88, P135, DOI 10.1016/0014-4886(85)90119-0; Norman G.R., 1998, BIOSTATISTICS BARE E; Paxinos G, 1995, RAT NERVOUS SYSTEM; Pikov V, 2001, J NEUROSCI, V21, P559, DOI 10.1523/JNEUROSCI.21-02-00559.2001; Schumacher PA, 2000, J NEUROCHEM, V74, P1646, DOI 10.1046/j.1471-4159.2000.0741646.x; Schwartz G, 2001, J NEUROSURG, V94, P245, DOI 10.3171/spi.2001.94.2.0245; WRATHALL JR, 1994, J NEUROSCI, V14, P6598; YU J, 1981, BRAIN RES, V220, P179, DOI 10.1016/0006-8993(81)90222-5	31	109	114	0	5	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	FEB	2002	19	2					191	203		10.1089/08977150252806956			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	526ER	WOS:000174117100002	11893022				2022-02-06	
J	Thatcher, RW; North, DM; Curtin, RT; Walker, RA; Biver, CJ; Gomez, JF; Salazar, AM				Thatcher, RW; North, DM; Curtin, RT; Walker, RA; Biver, CJ; Gomez, JF; Salazar, AM			An EEG severity index of traumatic brain injury	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							HEAD-INJURY; COMA; SCALE	EEG spectral analyses were conducted from 19 scalp locations for patients with mild (n = 40), moderate (n = 25), and severe (n = 43) traumatic brain injury (TBI), 15 days to 4 years after injury. Severity of TBI was judged by emergency hospital admission records (Glasgow Coma Score and duration of coma and amnesia). Highest-loading EEG variables on each factor that differed significantly between severe and mild TBI by univariate t-test were entered into a multivariate discriminant analysis, yielding 16 variables. Discriminant analysis between mild and severe TBI groups showed classification accuracy of 96.39%, sensitivity 95.45%, and specificity 97.44%. The EEG discriminant score also measured intermediate severity in moderate TBI patients. Results were cross-validated in 503 VA patients. Significant correlations between EEG discriminant scores, emergency admission measures, and post-trauma neuropsychological test scores validated the discriminant function as an index of severity of injury and a classifier of the extremes of severity.	Vet Affairs Med Ctr, Res & Dev Serv 151, Bay Pines, FL 33744 USA; Def & Vet Head Injury Program, Washington, DC USA		Thatcher, RW (corresponding author), Vet Affairs Med Ctr, Res & Dev Serv 151, Bay Pines, FL 33744 USA.						BARTH J, 1983, NEUROSURGERY, V13, P520; CAVENESS W, 1977, TRAUMA, V18, P61; COHEN WC, 1971, MULTIVARIATE DATA AN; Gentry L.R., 1990, MAGNETIC RESONANCE I, P439; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1994, RADIOLOGY, V191, P1; Hoffman D. A., 1995, J NEUROTHERAPY, V1, P14, DOI [10.1300/ J184v01n01_03, DOI 10.1300/J184V01N01_03]; Hughes JR, 1999, J NEUROPSYCH CLIN N, V11, P190, DOI 10.1176/jnp.11.2.190; JENNETT B, 1986, DIS NERV SYST, P1282; JOHN ER, 1988, SCIENCE, V239, P162, DOI 10.1126/science.3336779; JOHN ER, 1977, SCIENCE, V196, P1393, DOI 10.1126/science.867036; KWENTUS JA, 1985, PSYCHOSOMATICS, V26, P8, DOI 10.1016/S0033-3182(85)72900-3; Levin HS., 1982, NEUROBEHAVIORAL CONS; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; Norusis M.J., 1994, SPSS ADV STAT 6 1; OMMAYA AK, 1994, INT J IMPACT ENG, V15, P535, DOI 10.1016/0734-743X(94)80033-6; Ommaya AK, 1968, J BIOMECH; Otnes RK, 1972, DIGITAL TIME SERIES; PAL J, 1989, J TRAUMA, V29, P746, DOI 10.1097/00005373-198906000-00008; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROSS BL, 1994, AM J PHYS MED REHAB, V73, P341, DOI 10.1097/00002060-199409000-00007; RUSSELL WR, 1946, BRAIN, V69, P183; TEASDALE G, 1974, LANCET, V2, P81; Thatcher R W, 1991, Ann N Y Acad Sci, V620, P82, DOI 10.1111/j.1749-6632.1991.tb51576.x; Thatcher R. W., 1989, ELECTROENCEPHALOGR C, V73, DOI [10.1016/0013-4694(89)90188-0, DOI 10.1016/0013-4694(89)90188-0, https://doi.org/10.1016/0013-4694(89)90188-0]; THATCHER RW, 1986, ELECTROEN CLIN NEURO, V64, P123, DOI 10.1016/0013-4694(86)90107-0; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; VELLEMAN PF, 1997, DATADESK VERSION 6 0; WILDER CS, 1976, HLTH INTERVIEW SURVE	29	109	111	0	12	AMER PSYCHIATRIC PRESS, INC	WASHINGTON	1400 K ST, N W, STE 1101, WASHINGTON, DC 20005 USA	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	WIN	2001	13	1					77	87		10.1176/appi.neuropsych.13.1.77			11	Clinical Neurology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry	401TR	WOS:000166944800010	11207333				2022-02-06	
J	Downard, C; Hulka, F; Mullins, RJ; Piatt, J; Chesnut, R; Quint, P; Mann, NC				Downard, C; Hulka, F; Mullins, RJ; Piatt, J; Chesnut, R; Quint, P; Mann, NC			Relationship of cerebral perfusion pressure and survival in pediatric brain-injured patients	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	59th Annual Meeting of the American-Association-of-Trauma	SEP 16-18, 1999	BOSTON, MA	Amer Assoc Trauma			SEVERE HEAD-INJURY; BLOOD-FLOW; MANAGEMENT; HYPOTENSION; METABOLISM; CHILDREN; RESISTANCE	Background: Adult brain injury studies recommend maintaining cerebral perfusion pressure (CPP) above 70 mm Hg, We evaluated CPP and outcome in brain-injured children. Methods: We retrospectively reviewed the hospital courses of children at two Level I trauma centers who required insertion of intracranial pressure (ICP) monitors for management of traumatic brain injury. ICP, CPP, and mean arterial pressure were evaluated hourly, and means were calculated for the first 48 hours after injury. Results: Of 188 brain-injured children, 118 had ICP monitors placed within 24 hours of injury. They suffered severe brain injury, with average admitting Glasgow Coma Scale scores of 6 +/- 3, Overall mortality rate was 28%, No patient with mean CPP less than 40 mm Hg survived. among patients with mean CPP in deciles of 40 to 49, 50 to 59, 60 to 69, or 70 mm Bg, no significant difference in Glasgow Outcome Scale distribution existed. Conclusion: Low mean CPP was lethal. In children with survivable brain injury (mean CPP > 40 mm Hg), CPP did not stratify patients for risk of adverse outcome.	Oregon Hlth & Sci Univ, Div Gen Surg, Dept Surg, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Neurosurg, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Emergency Med, Portland, OR 97201 USA; Emanuel Hosp & Hlth Ctr, Dept Pediat, Portland, OR USA		Mullins, RJ (corresponding author), Oregon Hlth & Sci Univ, Div Gen Surg, Dept Surg, L223A,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.			Chesnut, Randall/0000-0001-6377-3666; Piatt, Joseph/0000-0002-9332-8376			*AM COLL SURG COMM, 1997, ADV TRAUM LIF SUPP S, P181; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chesnut RM, 1997, J TRAUMA, V42, pS4, DOI 10.1097/00005373-199705001-00002; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; CRUZ J, 1995, CRIT CARE MED, V23, P1412, DOI 10.1097/00003246-199508000-00016; Cruz J, 1998, CRIT CARE MED, V26, P344, DOI 10.1097/00003246-199802000-00039; JENNETT B, 1975, LANCET, V1, P480; KRAUS JF, 1987, PEDIATRICS, V79, P501; Marion DW, 2000, CRIT CARE MED, V28, P16, DOI 10.1097/00003246-200001000-00003; McGraw CP, 1989, INTRACRANIAL PRESSUR, P839; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER B, 1993, J PEDIATR-US, V123, P871, DOI 10.1016/S0022-3476(05)80382-8; Rosner Michael J., 1993, P57; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P153, DOI 10.1136/jnnp.58.2.153; TEPAS JJ, 1990, J PEDIATR SURG, V25, P92, DOI 10.1016/S0022-3468(05)80170-8; Winchell RJ, 1996, ARCH SURG-CHICAGO, V131, P533	21	109	114	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	OCT	2000	49	4					654	658		10.1097/00005373-200010000-00012			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	362VF	WOS:000089798400016	11038082				2022-02-06	
J	Benson, BW; Mohtadi, NGH; Rose, MS; Meeuwisse, WH				Benson, BW; Mohtadi, NGH; Rose, MS; Meeuwisse, WH			Head and neck injuries among ice hockey players wearing full face shields vs half face shields	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SPINAL-INJURIES	Context Speculation exists that use of a full face shield by ice hockey players may increase their risk of concussions and neck injuries, offsetting the benefits of protection from dental, facial, and ocular injuries, but, to our knowledge, no data exist regarding this possibility. Objective To determine the risk of sustaining a head or neck injury among intercollegiate ice hockey players wearing full face shields compared with those wearing half shields. Design, Setting, and Participants Prospective cohort study conducted during the 1997-1998 Canadian Inter-University Athletics Union hockey season of 642 male hockey players (mean age, 22 years) from 22 teams. Athletes from 11 teams wore full face shields and athletes from 11 teams wore half face shields during play. Main Outcome Measure Reportable injury, defined as any event requiring assessment or treatment by a team therapist or physician or any mild traumatic brain injury or brachial plexus stretch, categorized by time lost from subsequent participation and compared by type of face shield. Results Of 379 athletes who wore full face shields, 195 (61.6%) had at least 1 injury during the study season, whereas of 323 who wore half lace shields, 204 (63.2%) were injured. The risk of sustaining a facial laceration and dental injury was 2.31 (95% confidence interval [CI], 1.53-3.48; P < .001) and 9.90 (95% CI, 1.88-52.1; P = .007) times greater, respectively, for players wearing half vs full face shields. No statistically significant risk differences were found for neck injuries, concussion, or other injuries, although time lost from participation because of concussion was significantly greater in the half shield group (P < .001), than in the group wearing full shields. Conclusions These data provide evidence that the use of full face shields is associated with significantly reduced risk of sustaining facial and dental injuries without an increase in the risk of neck injuries, concussions, or other injuries.	Univ Calgary, Ctr Sports Med, Fac Kinesiol, Calgary, AB T2N 1N4, Canada; Univ Calgary, Fac Med, Calgary, AB T2N 1N4, Canada		Meeuwisse, WH (corresponding author), Univ Calgary, Ctr Sports Med, Fac Kinesiol, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.	meeuwiss@ucalgary.ca					Bishop P J, 1983, Can J Appl Sport Sci, V8, P19; BJORKENHEIM JM, 1993, ACTA ORTHOP SCAND, V64, P459; Brukner P, 1996, Aust Fam Physician, V25, P1445; CANTU RC, 1992, SPORTS MED, V14, P64, DOI 10.2165/00007256-199214010-00005; Deady B, 1996, J Emerg Med, V14, P645, DOI 10.1016/S0736-4679(96)00134-5; GOODWINGERBERIC.S, 1987, CHILD NERV SYST, V3, P59; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR; LAPRADE RF, 1995, AM J SPORT MED, V23, P773, DOI 10.1177/036354659502300624; Meeuwisse WH, 1998, CLIN J SPORT MED, V8, P164, DOI 10.1097/00042752-199807000-00003; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; MONTELPARE WJ, 1996, EPIDEMIOLOGY SPORTS, P247; PASHBY T, 1987, CAN J OPHTHALMOL, V22, P293; PASHBY T, 1985, CAN J OPHTHALMOL, V20, P2; PASHBY T, 1993, SAFETY ICE HOCKEY, P159; PATTERSSON M, 1993, BRIT J SPORT MED, V27, P251, DOI 10.1136/bjsm.27.4.251; PELLETIER RL, 1993, AM J SPORT MED, V21, P78, DOI 10.1177/036354659302100114; Rampton J, 1997, CLIN J SPORT MED, V7, P162, DOI 10.1097/00042752-199707000-00002; REILLY M, 1982, ATHL TRAIN, V17, P88; SIM FH, 1987, AM J SPORT MED, V15, P30, DOI 10.1177/036354658701500105; Smith A W, 1985, Can J Appl Sport Sci, V10, P68; Tator CH, 1997, CLIN J SPORT MED, V7, P17, DOI 10.1097/00042752-199701000-00004; TATOR CH, 1984, CAN J NEUROL SCI, V11, P34, DOI 10.1017/S0317167100045297; TATOR CH, 1991, CAN J SURG, V34, P63; TATOR CH, 1982, CAN MED ASSOC J, V127, P1077; Voaklander DC, 1996, CLIN J SPORT MED, V6, P15, DOI 10.1097/00042752-199601000-00005; WALSH S, 1989, SAFETY ICE HOCKEY, P55; Watson RC, 1996, CLIN J SPORT MED, V6, P108, DOI 10.1097/00042752-199604000-00008	27	109	109	0	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 22	1999	282	24					2328	2332		10.1001/jama.282.24.2328			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	265TK	WOS:000084261700026	10612320	Bronze			2022-02-06	
J	Dahiya, R; Keller, JD; Litofsky, NS; Bankey, PE; Bonassar, LJ; Megerian, CA				Dahiya, R; Keller, JD; Litofsky, NS; Bankey, PE; Bonassar, LJ; Megerian, CA			Temporal bone fractures: Otic capsule sparing versus otic capsule violating clinical and radiographic considerations	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						temporal bone fractures; otic capsule sparing fractures; otic capsule violating fractures; intracranial complications; otologic complications	TRAUMA	Objective: To assess the practicality and utility of the traditional classification system for temporal bone fracture (transverse vs, longitudinal) in the modern Level I trauma setting and to determine whether a newer system of designation (otic capsule sparing vs. otic capsule violating fracture) is practical from a clinical and radiographic standpoint, Methods: The University of Massachusetts Medical Center Trauma Registry was reviewed for the years 1995 to 1997. Patients identified as sustaining closed head injury were reviewed for basilar skull fracture and temporal bone fracture. Clinical and radiographic records were evaluated by using the two classification schemes. Results: A total of 2,977 patients were treated at the trauma center during this time, Ninety (3%) patients sustained a temporal bone fracture. The classic characterization of transverse versus longitudinal fracture (20% vs. 80%, respectively) was unable to be determined in this group; therefore, clinical correlation to complications using that paradigm was not possible. By using the otic capsule violating versus sparing designation, an important difference in clinical sequelae and intracranial complications became apparent, Compared with otic capsule sparing fractures, patients with otic capsule violating fractures were approximately two times more likely to develop facial paralysis, four times more likely to develop CSF leak, and seven times more likely to experience profound hearing loss, as well as more likely to sustain intracranial complications including epidural hematoma and subarachnoid hemorrhage, Conclusion: The use of a classification system for temporal bone fractures that emphasizes violation or lack of violation of the otic capsule seems to offer the advantage of radiographic utility and stratification of clinical severity, including severity of Glasgow Coma Scale scores and intracranial complications such as subarachnoid hemorrhage and epidural hematoma.	Univ Massachusetts, Sch Med, Dept Otolaryngol HNS, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Dept Radiol, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Dept Surg, Div Neurosurg, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Div Trauma Surg, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Dept Anesthesiol, Worcester, MA 01655 USA		Megerian, CA (corresponding author), Univ Massachusetts, Sch Med, Dept Otolaryngol HNS, 55 Lake Ave N, Worcester, MA 01655 USA.		Bonassar, Lawrence J/C-2103-2016	Bonassar, Lawrence J/0000-0003-1094-6433			BARRS DM, 1991, LARYNGOSCOPE, V101, P835; Brodie HA, 1997, AM J OTOL, V18, P188; GHORAYEB BY, 1992, LARYNGOSCOPE, V102, P129; GURDJIAN ES, 1946, SURG GYNECOL OBSTET, V83, P219; LIEBETRAU R, 1993, J OTOLARYNGOL, V22, P249; LYOS AT, 1995, ARCH OTOLARYNGOL, V121, P795; MCKENNAN KX, 1992, AM J OTOL, V13, P1167; NAGERIS B, 1995, AM J EMERG MED, V13, P211, DOI 10.1016/0735-6757(95)90096-9; Nosan DK, 1997, OTOLARYNG HEAD NECK, V117, P67, DOI 10.1016/S0194-5998(97)70209-2; SOFFERMAN RA, 1993, SURG EAR TEMPORAL BO, P333; TRAVIS LV, 1997, J TRAUMA, V17, P761; WENNMO C, 1993, AM J OTOLARYNG, V14, P38, DOI 10.1016/0196-0709(93)90008-U; Yanagihara N, 1997, Ear Nose Throat J, V76, P79	13	109	113	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	1999	47	6					1079	1083		10.1097/00005373-199912000-00014			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	266JD	WOS:000084296100019	10608536				2022-02-06	
J	Saatman, KE; Graham, DI; McIntosh, TK				Saatman, KE; Graham, DI; McIntosh, TK			The neuronal cytoskeleton is at risk after mild and moderate brain injury	JOURNAL OF NEUROTRAUMA			English	Article						axonal injury; calpain; cytoskeleton; microtubule-associated protein-2; neurofilament; proteolysis; traumatic brain injury	DIFFUSE AXONAL INJURY; MICROTUBULE-ASSOCIATED PROTEIN-2; AMYLOID PRECURSOR PROTEIN; CORTICAL IMPACT INJURY; MINOR HEAD-INJURY; INTERMEDIATE FILAMENTS; NEUROFILAMENT SUBUNITS; LEVELS DECREASE; RAT; HUMANS	Recent studies have described alterations in cytoskeletal proteins such as microtubule-associated protein 2 (MAP-2) and neurofilament (NF) resulting from moderate and severe experimental brain injury; however, few have investigated the consequences of mild injury, which is associated clinically and experimentally with cognitive dysfunction and neuronal damage, To contrast cytoskeletal changes within 7 days following mild injury with those following moderate injury, we subjected anesthetized, adult rats to mild (1.1-1.3 atm) or moderate (2.3-2.5 atm) lateral fluid percussion brain injury or sham injury, Rats were sacrificed at 6 h (n = 4 mild; n = 4 moderate; n = 2 sham), 24 h (n = 4 mild; n = 4 moderate; n = 1 sham), or 7 days (n = 5 mild; n = 4 moderate; rt = 1 sham) following injury, and immunohistochemistry was performed for MAP-2 and NF, Both mild and moderate injury produced notable cytoskeletal changes in multiple brain regions; however, mild injury generally resulted in a lesser degree of MAP-2 and NF loss over a smaller spatial extent, When compared to moderately injured animals, animals subjected to mild injury showed substantially delayed MAP-2 and NF alterations within the cortex and hippocampal dentate gyrus and no evidence of MAP-2 loss in the hippocampal CA3 region, While mild and moderate injury resulted for the most part in similar patterns of axonal injury, tissue tears in the fimbria and loss of NF immunoreactivity in regions containing injured axons were only observed following moderate injury. Elucidating the effects of modulating injury severity may yield insight into the mechanisms involved in traumatic damage to the cytoskeleton and guide future treatment strategies.	Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Glasgow, So Gen Hosp, Dept Neuropathol, Inst Neurol Sci, Glasgow, Lanark, Scotland		Saatman, KE (corresponding author), Univ Penn, Dept Neurosurg, 105C Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.				NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS08803, R01-NS26818] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026818, P01NS008803] Funding Source: NIH RePORTER		ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; BILLGER M, 1988, CELL CALCIUM, V9, P33, DOI 10.1016/0143-4160(88)90036-X; Blostein PA, 1997, J NEUROTRAUM, V14, P171, DOI 10.1089/neu.1997.14.171; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Borczuk Pierre, 1997, Emergency Medicine Clinics of North America, V15, P563, DOI 10.1016/S0733-8627(05)70318-7; CHAPIN SJ, 1992, CELL MOTIL CYTOSKEL, V23, P236, DOI 10.1002/cm.970230403; CHEN J, 1992, NATURE, V360, P674, DOI 10.1038/360674a0; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Folkerts MM, 1998, J NEUROTRAUM, V15, P349, DOI 10.1089/neu.1998.15.349; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GOLDMAN R, 1985, ANN NY ACAD SCI, V455, P1, DOI 10.1111/j.1749-6632.1985.tb50400.x; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; GRAHAM DI, 1989, MILD MODERATE HEAD I, P63; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hicks RR, 1997, MOL CHEM NEUROPATHOL, V32, P1, DOI 10.1007/BF02815164; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HOFFMAN PN, 1984, J CELL BIOL, V99, P705, DOI 10.1083/jcb.99.2.705; Jafari SS, 1997, J NEUROCYTOL, V26, P207, DOI 10.1023/A:1018588114648; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; Kampfl A, 1996, J NEUROCHEM, V67, P1575; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KITAGAWA K, 1989, NEUROSCIENCE, V31, P401, DOI 10.1016/0306-4522(89)90383-7; Kraus Jess F., 1994, P3; LAZARIDES E, 1980, NATURE, V283, P249, DOI 10.1038/283249a0; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MATESIC DF, 1994, J NEUROCHEM, V63, P1012; MATUS A, 1988, ANNU REV NEUROSCI, V11, P29, DOI 10.1146/annurev.ne.11.030188.000333; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MEANEY DF, 1994, J NEUROTRAUM, V11, P599, DOI 10.1089/neu.1994.11.599; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Perri BR, 1997, J NEUROTRAUM, V14, P15, DOI 10.1089/neu.1997.14.15; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Pierce JES, 1996, J NEUROSCI, V16, P1083; Pilz P, 1983, Acta Neurochir Suppl (Wien), V32, P119; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; Posmantur RM, 1996, J NEUROTRAUM, V13, P125, DOI 10.1089/neu.1996.13.125; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; POVLISHOCK JT, 1979, ACTA NEUROPATHOL, V47, P1, DOI 10.1007/BF00698266; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Raghupathi R, 1996, MOL BRAIN RES, V37, P134, DOI 10.1016/0169-328X(95)00289-5; RICH KM, 1992, J NEUROTRAUM, V9, pS61; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; SCHLAEPFER WW, 1987, J NEUROPATH EXP NEUR, V46, P117, DOI 10.1097/00005072-198703000-00001; SCHLAEPFER WW, 1990, INTRACELLULAR CALCIU, P241; SKALLI O, 1991, CELL MOTIL CYTOSKEL, V19, P67, DOI 10.1002/cm.970190202; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; STRICH SJ, 1961, LANCET, V2, P443; SUN FY, 1994, BRAIN RES, V661, P63, DOI 10.1016/0006-8993(94)91181-9; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; Zhao XR, 1998, J CEREBR BLOOD F MET, V18, P161, DOI 10.1097/00004647-199802000-00006	67	109	111	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	1998	15	12					1047	1058		10.1089/neu.1998.15.1047			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	148FW	WOS:000077495200005	9872461				2022-02-06	
J	Shannon, P; Smith, CR; Deck, J; Ang, LC; Ho, M; Becker, L				Shannon, P; Smith, CR; Deck, J; Ang, LC; Ho, M; Becker, L			Axonal injury and the neuropathology of shaken baby syndrome	ACTA NEUROPATHOLOGICA			English	Article						shaken baby syndrome; shaken infant; axonal injury; beta-amyloid precursor protein	AMYLOID PRECURSOR PROTEIN; PERMANENT BRAIN-DAMAGE; MENTAL-RETARDATION; INFANT SYNDROME; CHILD-ABUSE; SHAKING; TRAUMA	We examined an autopsy series of 14 children with shaken baby syndrome (SBS) who lacked skull fracture. Evidence of axonal injury was sought using immunohistochemical stains for neurofilament, 68-kDa neurofilament and beta-amyloid precursor protein (beta APP). beta APP-positive axons were present in the cerebral white matter of all cases of SBS but were also present in 6 of 7 children dying of non-traumatic hypoxic ischemic encephalopathy (HIE). Swollen axons were present in 11 of 14 cases of SBS and in 6 of 7 cases of HIE. beta APP-positive axons were present in both groups in the midbrain and medulla. The cervical spinal cord in SBS contained beta APP-positive axons in 7 of 11 cases; 5 of 7 contained swollen axons within the white matter tracts; in 2 immunoreactivity was localized to spinal nerve roots; in all 7 there was a predilection for staining at the glial head of the nerve root. Among cases of HIE, none showed abnormal axons or beta APP-positive reactivity in the cervical cord white matter. We con elude that cerebral axonal injury is common in SBS, and may be due in part to hypoxic/ischemic injury. Cervical cord injury is also common, and cannot be attributed to HIE. These findings corroborate suggestions that flexion extension injury about the cervical spinal column may be important in the pathogenesis of SBS.	Hosp Sick Children, Dept Pediat Lab Med, Div Pathol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Toronto, ON M5G 1X8, Canada; Off Chief Coroner, Div Forens Pathol, Toronto, ON, Canada; Sunnybrook Hlth Sci Ctr, Dept Lab Med, Div Pathol, Toronto, ON M4N 3M5, Canada		Becker, L (corresponding author), Hosp Sick Children, Dept Pediat Lab Med, Div Pathol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.						ALEXANDER R, 1990, AM J DIS CHILD, V144, P724, DOI 10.1001/archpedi.1990.02150300124032; CAFFEY J, 1974, PEDIATRICS, V54, P396; CAFFEY J, 1972, AM J DIS CHILD, V124, P161, DOI 10.1001/archpedi.1972.02110140011001; CALDER IM, 1984, J CLIN PATHOL, V37, P1095, DOI 10.1136/jcp.37.10.1095; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Gilliland MGF, 1996, J FORENSIC SCI, V41, P114; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; GUTHKELCH AN, 1971, BMJ-BRIT MED J, V2, P430, DOI 10.1136/bmj.2.5759.430; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; JACOBI G, 1986, MONATSSCHR KINDERH, V134, P307; LINDENBERG R, 1969, ARCH PATHOL, V87, P298; LUDWIG S, 1984, ANN EMERG MED, V13, P104, DOI 10.1016/S0196-0644(84)80571-5; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; MUNGER CE, 1993, AM J FOREN MED PATH, V14, P193, DOI 10.1097/00000433-199309000-00004; OHGAMI T, 1992, NEUROSCI LETT, V136, P75, DOI 10.1016/0304-3940(92)90651-M; PIATT JH, 1995, PEDIATRICS, V96, P780; RUGE JR, 1988, J NEUROSURG, V68, P25, DOI 10.3171/jns.1988.68.1.0025; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; VOWLES GH, 1987, J CLIN PATHOL, V40, P185, DOI 10.1136/jcp.40.2.185	20	109	109	0	9	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0001-6322			ACTA NEUROPATHOL	Acta Neuropathol.	JUN	1998	95	6					625	631		10.1007/s004010050849			7	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	ZR230	WOS:000073953300011	9650755				2022-02-06	
J	Gennarelli, TA; Thibault, LE; Graham, DI				Gennarelli, TA; Thibault, LE; Graham, DI			Diffuse axonal injury: An important form of traumatic brain damage	NEUROSCIENTIST			English	Article						axonal injury; brain trauma; head injury	AMYLOID PRECURSOR PROTEIN; NONMISSILE HEAD-INJURY; OPTIC-NERVE; BETA-APP; PATHOGENESIS; AXOPLASM; HUMANS; DEGENERATION; SHEARING; STRETCH	Diffuse axonal injury (DAI) is a frequent form of traumatic brain injury in which a clinical spectrum of increasing injury severity is paralleled by progressively increasing amounts of axonal damage in the brain. When less severe, DAI is associated with concussive syndromes; when most severe, it causes prolonged traumatic coma that is not related to mass lesions, increased intracranial pressure, or ischemia. Pathological investigations of DAI demonstrate widespread but heterogeneous microscopic damage to axons throughout the white matter of the cerebral and cerebellar hemispheres and brainstem, There is a propensity for injury to occur in the central third of the brain, and the corpus callosum and brain stem are especially prone to injury. In these locations, traumatic axonal damage can occur in several degrees of severity, ranging from transient disturbances of ionic homeostasis to swelling, impairment of axoplasmic transport with secondary (delayed) axotomy and primary axotomy (tearing). A more detailed understanding of the processes involved in axonal damage is crucial to the development of effective treatment for the clinical syndromes of DAI.	Allegheny Univ Hlth Sci, Dept Neurosurg, Philadelphia, PA 19102 USA; Allegheny Univ Hlth Sci, Ctr Neurosci, Philadelphia, PA 19102 USA; Univ Glasgow, Dept Neuropathol, Glasgow G12 8QQ, Lanark, Scotland			gennarelli@auhs.edu					AbouHamden A, 1997, J NEUROTRAUM, V14, P699, DOI 10.1089/neu.1997.14.699; ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1986, ARCH PATHOL LAB MED, V110, P485; ADAMS JH, 1985, MED SCI LAW, V25, P265, DOI 10.1177/002580248502500407; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1986, J NEUROL NEUROSUR PS, V49, P1039, DOI 10.1136/jnnp.49.9.1039; ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; Adams JH, 1992, GREENFIELDS NEUROPAT, P106; BALENTINE JD, 1988, J NEUROPATH EXP NEUR, V47, P77, DOI 10.1097/00005072-198803000-00001; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; CAJAL SR, 1928, DENERVATION REGENERA, P631; Cargill RS, 1996, J NEUROTRAUM, V13, P395, DOI 10.1089/neu.1996.13.395; CLARK JM, 1974, J NEUROL NEUROSUR PS, V37, P463, DOI 10.1136/jnnp.37.4.463; CROOKS DA, 1991, J PATHOL, V165, P5, DOI 10.1002/path.1711650103; DUCHEN LW, 1992, GREENFIELDS NEUROPAT, P811; FERN R, 1995, NEUROSCIENTIST, V1, P253; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; GALLANT PE, 1992, J NEUROPATH EXP NEUR, V51, P220, DOI 10.1097/00005072-199203000-00011; GANOT G, 1981, BIOCHIM BIOPHYS ACTA, V649, P487, DOI 10.1016/0005-2736(81)90440-5; Gennarelli T A, 1983, Acta Neurochir Suppl (Wien), V32, P1; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; Gennarelli TA, 1996, NEUROPATH APPL NEURO, V22, P509, DOI 10.1111/j.1365-2990.1996.tb01126.x; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli TA, 1997, NEUROSCIENTIST, V3, P73, DOI 10.1177/107385849700300117; Gennarelli TA, 1997, SHOCK, SEPSIS AND ORGAN FAILURE, P185; GENNARELLI TA, 1987, 31ST P STAPP CAR CRA, P49; Gennarelli TA, 1993, HEAD INJURY, P137; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GRADY MS, 1993, J NEUROPATHOL EXP NE, V31, P299; GRAHAM DI, 1992, J CLIN PATHOL, V45, P840, DOI 10.1136/jcp.45.9.840; Graham DI, 1997, GREENFIELDS NEUROPAT, P197; GRAHAM DI, 1981, MILD MODERATE HEAD I, P63; GRCEVIC N, 1977, APALLIC SYNDROME, P109; GULTEKIN SH, 1994, ARCH PATHOL LAB MED, V118, P168; HASHIN Z, 1969, INT J ENG SCI, V7, P11, DOI 10.1016/0020-7225(69)90020-2; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; IMAJO T, 1987, AM J FOREN MED PATH, V8, P217, DOI 10.1097/00000433-198708030-00004; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; JELLINGER K, 1970, J NEUROL SCI, V10, P51, DOI 10.1016/0022-510X(70)90091-2; Kreutzberg GW, 1997, GREENFIELDS NEUROPAT, P85; LaPlaca MC, 1997, ANN BIOMED ENG, V25, P665, DOI 10.1007/BF02684844; LAPLACA MC, 1996, J NEUROTRAUM, V13, P608; LAPLACA MC, 1994, J NEUROTRAUM, V11, P116; LAPLACA MC, 1995, J NEUROTRAUM, V12, P128; LAPLACA MC, 1995, J NEUROTRAUM, V12, P969; MATA M, 1986, J NEUROBIOL, V17, P449, DOI 10.1002/neu.480170508; Maxwell WL, 1995, J NEUROCYTOL, V24, P925, DOI 10.1007/BF01215643; MAXWELL WL, 1991, J NEUROCYTOL, V20, P157, DOI 10.1007/BF01186989; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; NG HK, 1994, CLIN NEUROL NEUROSUR, V96, P24, DOI 10.1016/0303-8467(94)90025-6; OHGAMI T, 1992, NEUROSCI LETT, V136, P75, DOI 10.1016/0304-3940(92)90651-M; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Pilz P, 1983, Acta Neurochir Suppl (Wien), V32, P119; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; Povlishock J T, 1985, Cent Nerv Syst Trauma, V2, P285; POVLISHOCK JT, 1985, LAB INVEST, V52, P540; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; POVLISHOCK JT, 1986, ACTA NEUROPATHOL, V70, P53, DOI 10.1007/BF00689514; SAATMAN K, 1991, INT RES COUNC BIOM I, V13, P115; SAATMAN KE, 1994, J NEUROTRAUMA, V11, P125; SAHUQUILLOBARRIS J, 1988, J NEUROSURG, V68, P894, DOI 10.3171/jns.1988.68.6.0894; SCHLAEPFER WW, 1978, J CELL BIOL, V78, P369, DOI 10.1083/jcb.78.2.369; SCHLAEPFER WW, 1974, BRAIN RES, V69, P203, DOI 10.1016/0006-8993(74)90002-X; Seitelberger F., 1971, ACTA NEUROPATH BER S, V5, P17; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; STRICH SJ, 1968, J NEUROL NEUROSUR PS, V31, P110, DOI 10.1136/jnnp.31.2.110; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1961, LANCET, V2, P443; STRICH SJ, 1970, J CLIN PATHOL S4, V23, P166; TERAKAWA S, 1982, PFLUG ARCH EUR J PHY, V395, P59, DOI 10.1007/BF00584969; THIBAULT LE, 1992, INT RES COUNCIL BIOM, V14, P3; TOMEI G, 1990, ACTA NEUROPATHOL, V80, P506, DOI 10.1007/BF00294611; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; YAWO H, 1983, SCIENCE, V222, P1351, DOI 10.1126/science.6658457; ZIMMERMAN RA, 1978, RADIOLOGY, V127, P393, DOI 10.1148/127.2.393; [No title captured]; [No title captured]; [No title captured]	90	109	112	1	10	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-8584	1089-4098		NEUROSCIENTIST	Neuroscientist	MAY	1998	4	3					202	215		10.1177/107385849800400316			14	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	ZR036	WOS:000073929300015					2022-02-06	
J	Kreuter, M; Sullivan, M; Dahllof, AG; Siosteen, A				Kreuter, M; Sullivan, M; Dahllof, AG; Siosteen, A			Partner relationships, functioning, mood and global quality of life in persons with spinal cord injury and traumatic brain injury	SPINAL CORD			English	Article						spinal cord injuries; traumatic brain injuries; sexuality; partner relationship; divorce; functioning	GLASGOW OUTCOME SCALE; CLOSED HEAD-INJURY; SOCIAL SUPPORT; FOLLOW-UP; OF-LIFE; ADJUSTMENT; COMMUNITY; SATISFACTION; RELIABILITY; IMPAIRMENT	The aim of this study was to assess and compare spinal cord injured (SCI) and traumatic brain injured (TBI) persons and people from the general population concerning partner relationships, functioning, mood and global quality of life. One hundred and sixty seven SCI persons, 92 TBI persons and 264 controls participated in the study. The median age was: SCI persons 33 years (range 19 to 79 years), TBI persons 40 years (range 20 to 70 years), and controls 31 years (range 19 to 79 years). Age at injury ranged among SCI persons from 14 to 76 years (Md 28 years), and among TBI persons from 16 to 56 years (Md 32 years). Half of the SCI group (51%), 58% of the TBI group and 59% of the controls had a stable partner relationship at the time of the investigation. Many of these SCI and TBI relationships (38% and 55% respectively) were established after injury, Both SCI and TBI persons showed significantly more depressive feelings compared with the controls. Perceived quality of life (global QL rating) was significantly lower in the SCI group compared with the controls, whereas the ratings of TBI persons and controls did not differ significantly, SCI and TBI persons did not differ significantly in level of education, perceived duality of life or distress. In all three groups, global quality-of-life ratings were significantly lower among single persons compared to those with a partner relationship. It was concluded that both SCI and TBI appear to affect overall quality of life and mental well-being negatively. The number of partner relationships contracted after-injury among both SCI and TBI persons indicates, however, that the injury is not a major barrier to establishing close partner relationships. Being in good spirits, that is, lack of depressive feelings has a profound impact on the perception of a high quality of life in all three groups. For the SCI and TBI persons, a high level of physical and social independence were further positive determinants of a perceived high quality of life.	Sahlgrens Univ Hosp, Spinal Injuries Unit, Dept 12, S-41345 Gothenburg, Sweden; Sahlgrens Univ Hosp, Hlth Care Res Unit, S-41345 Gothenburg, Sweden		Kreuter, M (corresponding author), Sahlgrens Univ Hosp, Spinal Injuries Unit, Dept 12, S-41345 Gothenburg, Sweden.						Anderson Shirley I., 1993, Brain Injury, V7, P309, DOI 10.3109/02699059309034957; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BERKMAN AH, 1978, ARCH PHYS MED REHAB, V59, P29; CALMAN KC, 1984, J MED ETHICS, V10, P124, DOI 10.1136/jme.10.3.124; CARLSSON AM, 1983, PAIN, V16, P87, DOI 10.1016/0304-3959(83)90088-X; CARPENTER C, 1994, PHYS THER, V74, P614, DOI 10.1093/ptj/74.7.614; COMARR AE, 1978, AM J PHYS MED REHAB, V57, P215; Crewe N M, 1992, J Am Paraplegia Soc, V15, P14; CREWE NM, 1988, ARCH PHYS MED REHAB, V69, P435; CUSHMAN LA, 1992, PARAPLEGIA, V30, P690, DOI 10.1038/sc.1992.135; DEVIVO MJ, 1985, ARCH PHYS MED REHAB, V66, P501; DEVIVO MJ, 1995, ARCH PHYS MED REHAB, V76, P130, DOI 10.1016/S0003-9993(95)80022-0; EISENBERG MG, 1991, PARAPLEGIA, V29, P514, DOI 10.1038/sc.1991.74; ELGHATIT AZ, 1975, J CHRON DIS, V28, P383, DOI 10.1016/0021-9681(75)90034-X; ELLIOTT TR, 1992, REHABIL PSYCHOL, V37, P37, DOI 10.1037/h0079091; Florian V, 1989, Brain Inj, V3, P219, DOI 10.3109/02699058909029637; FUHRER MJ, 1992, ARCH PHYS MED REHAB, V73, P552; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JUDD FK, 1991, PARAPLEGIA, V29, P173, DOI 10.1038/sc.1991.25; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; Krause JS, 1996, REHABIL COUNS BULL, V39, P244; Kreuter M, 1996, ARCH PHYS MED REHAB, V77, P541, DOI 10.1016/S0003-9993(96)90292-0; Liss M, 1990, Int J Rehabil Res, V13, P309, DOI 10.1097/00004356-199012000-00004; LUNDQVIST C, 1991, SPINE, V16, P78, DOI 10.1097/00007632-199101000-00014; Lundqvist C, 1997, SPINAL CORD, V35, P17, DOI 10.1038/sj.sc.3100347; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MCCOLL MA, 1994, PARAPLEGIA, V32, P261, DOI 10.1038/sc.1994.46; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MOORE A D, 1992, Brain Injury, V6, P89, DOI 10.3109/02699059209008129; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; Panting A, 1972, REHABILITATION, V38, P33; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; RINTALA DH, 1992, REHABIL PSYCHOL, V37, P155, DOI 10.1037/0090-5550.37.3.155; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; SIOSTEEN A, 1990, PARAPLEGIA, V28, P285; SIOSTEEN A, 1990, PARAPLEGIA, V28, P476, DOI 10.1038/sc.1990.64; TENNANT A, 1995, BRAIN INJURY, V9, P595, DOI 10.3109/02699059509008218; Thomsen I V, 1989, Brain Inj, V3, P157, DOI 10.3109/02699058909004547; Thomsen I V, 1987, Brain Inj, V1, P131, DOI 10.3109/02699058709034452; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Walker A E, 1972, Scand J Rehabil Med, V4, P5; WHITENECK GG, 1992, PARAPLEGIA, V30, P617, DOI 10.1038/sc.1992.124; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; [No title captured]; [No title captured]	46	109	109	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	1362-4393			SPINAL CORD	Spinal Cord	APR	1998	36	4					252	261		10.1038/sj.sc.3100592			10	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	ZG571	WOS:000073017000006	9589525				2022-02-06	
J	McLaughlin, MR; Marion, DW				McLaughlin, MR; Marion, DW			Cerebral blood flow and vasoresponsivity within and around cerebral contusions	JOURNAL OF NEUROSURGERY			English	Article						contusion; carbon dioxide reactivity; head injury; hyperventilation; regional cerebral blood flow; xenon-enhanced computerized tomography	SEVERE HEAD-INJURY; ISCHEMIC BRAIN-DAMAGE; STABLE-XENON-CT; INTRAVENTRICULAR PRESSURE; SUBDURAL-HEMATOMA; COMATOSE PATIENTS; HYPERVENTILATION; METABOLISM; CIRCULATION; TOMOGRAPHY	There is increasing evidence that regional ischemia plays a major role in secondary brain injury. Although the cortex underlying subdural hematomas seems particularly vulnerable to ischemia, little is known about the adequacy of cerebral blood flow (CBF) or the vasoresponsivity within the vascular bed of contusions. The authors used the xenon-enhanced computerized tomography (CT) CBF technique to define the CBF and vasoresponsivity of contusions, pericontusional parenchyma, and the remainder of the brain 24 to 48 hours after severe closed head injury in 10 patients: six patients with one contusion and four with two contusions, defined as mixed or high-density lesions on CT scanning. The CBF within the contusions (29.3 +/- 16.4 ml/100 g/minute, mean +/- standard deviation) was significantly lower than both that found in the adjacent I-cm perimeter of normal-appearing tissue (42.5 +/- 15.8 ml/100 g/minute) and the mean global CBF (52.5 +/- 17.5 ml/100 g/minute) (p < 0.004, repeated-measures analysis of variance). A subset of seven patients (10 contusions) also underwent a second Xe-CT CBF study during mild hyperventilation (a PaCO2 of 24-32 mm Hg). In only two of these: 10 contusions was vasoresponsivity less than 1% (range 0%-7.6%); in the rim of normal-appearing pericontusional tissue, it was 0.4% to 9.1%. The authors conclude that CBF within intracerebral contusions is highly variable and is often above 18 ml/100 g/minute, the reported threshold for irreversible ischemia. Intracontusional CBF is significantly reduced relative to surrounding brain parenchyma, and CO2 vasoresponsivity is usually present. In the contusion and the surrounding parenchyma, vasoresponsivity may be nearly three times normal, suggesting hypersensitivity to hyperventilation therapy. Given this possible hypersensitivity and relative hypoperfusion within and around cerebral contusions, these lesions are particularly vulnerable to secondary injury such as that which may be caused by hypotension or aggressive hyperventilation.			McLaughlin, MR (corresponding author), PRESBYTERIAN UNIV HOSP, DEPT NEUROL SURG, MED CTR, SUITE B-400, 200 LOTHROP ST, PITTSBURGH, PA 15213 USA.		Marion, Donald/AAR-5749-2021		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 30318] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318, P20NS030318, P01NS030318] Funding Source: NIH RePORTER		ADAMS H, 1972, SCI F NEUROLOGY, P478; BARCLAY L, 1985, BIOL PSYCHIAT, V20, P146, DOI 10.1016/0006-3223(85)90074-5; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Bullock R, 1992, Acta Neurochir Suppl (Wien), V55, P14; COLD GE, 1989, ACTA NEUROCHIR, V96, P100, DOI 10.1007/BF01456166; COOPER PR, 1985, CENTRAL NERVOUS SYST, P217; CRUZ J, 1995, J NEUROSURG, V82, P379, DOI 10.3171/jns.1995.82.3.0379; DARBY JM, 1988, NEUROSURGERY, V23, P84, DOI 10.1227/00006123-198807000-00014; DARBY JM, 1989, INTRACRANIAL PRESSUR, V7, P643; ENEVOLDSEN EM, 1976, J NEUROSURG, V44, P191, DOI 10.3171/jns.1976.44.2.0191; FIESCHI C, 1974, J NEUROL NEUROSUR PS, V37, P1378, DOI 10.1136/jnnp.37.12.1378; GOOD WF, 1987, MED PHYS, V14, P557, DOI 10.1118/1.596067; GRAHAM DI, 1988, J CLIN PATHOL, V41, P34, DOI 10.1136/jcp.41.1.34; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; GUR D, 1982, SCIENCE, V215, P1267, DOI 10.1126/science.7058347; HARRINGTON T., 1986, INTRACRANIAL PRESSUR, VVI, P680; HOLL K, 1987, ACTA NEUROCHIR, V87, P129, DOI 10.1007/BF01476063; Jenkins LW, 1988, J NEUROTRAUM, V5, P275, DOI 10.1089/neu.1988.5.275; LASSEN NA, 1966, LANCET, V2, P1113, DOI 10.1016/S0140-6736(66)92199-4; LATCHAW RE, 1987, RADIOLOGY, V163, P251, DOI 10.1148/radiology.163.1.3823444; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARION DW, 1991, J CEREBR BLOOD F MET, V11, P347, DOI 10.1038/jcbfm.1991.69; MARION DW, 1991, NEUROSURGERY, V29, P869, DOI 10.1227/00006123-199112000-00011; MILLER JD, 1990, NEUROSURGERY, V27, P433, DOI 10.1227/00006123-199009000-00016; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; MUIZELAAR JP, 1983, ADV NEUROTRAUMATOLOG, P92; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; OVERGAARD J, 1981, J NEUROSURG, V55, P63, DOI 10.3171/jns.1981.55.1.0063; PAUL RL, 1972, J NEUROSURG, V36, P714, DOI 10.3171/jns.1972.36.6.0714; Pistolese GR, 1972, STROKE, V3, P456, DOI 10.1161/01.STR.3.4.456; ROSS DT, 1993, J NEUROTRAUM, V10, P151, DOI 10.1089/neu.1993.10.151; ROSSANDA M, 1972, EUR NEUROL, V8, P169, DOI 10.1159/000114573; SALVANT JB, 1993, NEUROSURGERY, V33, P387; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966	39	109	110	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	NOV	1996	85	5					871	876		10.3171/jns.1996.85.5.0871			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	VP489	WOS:A1996VP48900018	8893726				2022-02-06	
J	Cifu, DX; Kreutzer, JS; Marwitz, JH; Rosenthal, M; Englander, J; High, W				Cifu, DX; Kreutzer, JS; Marwitz, JH; Rosenthal, M; Englander, J; High, W			Functional outcomes of older adults with traumatic brain injury: A prospective, multicenter analysis	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							HEAD-INJURY; STROKE REHABILITATION; EARLY INTERVENTION; PREDICTORS; ALCOHOL; PATIENT	Objective: To investigate improvement rates and medical services costs in older brain injured adults relative to younger patients. Design: Descriptive statistics were computed in a prospective comparative study of 50 patients 55 years and older and 50 patients 18 to 54 years old matched for gender and injury severity (number of days in coma, admission Glasgow Coma Score, intracranial pressure). Independent t tests were performed to examine differences between the two samples on specific variables. Setting: Five medical centers in the federally sponsored Traumatic Brain Injury Model Systems Project that provide emergency medical services, intensive and acute medical care, inpatient rehabilitation, and a spectrum of community rehabilitation services. Participants: Patients were selected from a national database of 531 rehabilitation inpatients admitted to acute care within 8 hours of traumatic brain injury between 1989 and 1994. Main Outcome Measures: Disability Rating Scale, Functional Independence Measure, Rancho Los Amigos Levels of Cognitive Functioning Scale, length of stay, acute care and rehabilitation charges, and discharge disposition. Results: Older persons averaged a significantly longer rehabilitation length of stay, higher total rehabilitation charges, and a lower rate of change on functional measures. No significant differences between groups were found for acute care length of stay, daily rehabilitation charges, acute care charges (daily or total), or discharge disposition. Conclusions: Although older persons demonstrated functional changes, the cost of change was substantially higher than for younger patients, coincident with longer lengths of stay. These higher overall charges and slower rates of change may effect changes in referral and management patterns. (C) 1996 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation	VIRGINIA COMMONWEALTH UNIV MED COLL VIRGINIA,DEPT PHYS MED & REHABIL,RICHMOND,VA 23298; WAYNE STATE UNIV,DEPT PHYS MED & REHABIL,DETROIT,MI 48202; SANTA CLARA VALLEY MED CTR,DEPT REHABIL,SANTA CLARA,CA; BAYLOR COLL MED,DEPT PHYS MED & REHABIL,HOUSTON,TX 77030					Cifu, David/0000-0003-1600-9387			AMACHER AL, 1979, NEUROSURGERY, V20, P954; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; CARLSSON CA, 1968, J NEUROSURG, V29, P242, DOI 10.3171/jns.1968.29.3.0242; Cifu D X, 1993, Clin Geriatr Med, V9, P473; Cifu D X, 1993, Arch Phys Med Rehabil, V74, pS406; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; FEIGENSON JS, 1977, STROKE, V8, P657, DOI 10.1161/01.STR.8.6.657; FORER S, 1982, J ORGAN REHABIL EVAL, V2, P29; GALBRAITH S, 1976, BRIT J SURG, V63, P128, DOI 10.1002/bjs.1800630210; GALBRAITH S, 1987, BRIT MED J, V294, P294; Gershkoff A M, 1993, Arch Phys Med Rehabil, V74, pS402; GOODMAN H, 1992, PHYS MED REH CLIN N, V3, P441; Gordon W, 1993, J HEAD TRAUMA REHAB, V8, P26; GRANGER CV, 1992, STROKE, V23, P978, DOI 10.1161/01.STR.23.7.978; GRANGER CV, 1994, TOP GERIATR REHABIL, V9, P72; Granger CV, 1986, TOPICS GERIATRIC REH; HAGEN C, 1982, COGNITIVE REHABILITA, P131; HALL KM, 1994, ARCH PHYS MED REHAB, V75, pSC10; HAYES SH, 1986, ARCH PHYS MED REHAB, V67, P319; HEISKANEN O, 1970, ACTA NEUROL SCAND, V46, P343, DOI 10.1111/j.1600-0404.1970.tb05798.x; HERNESNIEMI J, 1979, ACTA NEUROCHIR, V49, P67, DOI 10.1007/BF01809175; JENNET B, 1981, MANAGEMENT HEAD INJU, P1; JENNETT B, 1976, LANCET, V1, P1031; JONGBLOED L, 1986, STROKE, V17, P765, DOI 10.1161/01.STR.17.4.765; KALRA L, 1993, POSTGRAD MED J, V69, P33, DOI 10.1136/pgmj.69.807.33; KATZ DI, 1990, NEUROLOGY S, V40, pS276; KEITH RA, 1995, ARCH PHYS MED REHAB, V76, P495, DOI 10.1016/S0003-9993(95)80501-X; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; Levin HS., 1982, NEUROBEHAVIORAL CONS; MALKMUS D, 1979, REHABILITATION HEAD; MORRISON RG, 1986, JAMA-J AM MED ASSOC, V255, P2475, DOI 10.1001/jama.255.18.2475; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Reeder KP, 1996, J HEAD TRAUMA REHAB, V11, P22, DOI 10.1097/00001199-199606000-00006; SAYWELL RM, 1989, J AM GERIATR SOC, V37, P625, DOI 10.1111/j.1532-5415.1989.tb01253.x; SCHWARTZ RH, 1986, PEDIATRICS, V78, P1169; SHAH S, 1989, STROKE, V21, P766; SOSIN DN, 1989, JAMA-J AM MED ASSOC, V282, P2251; STEWART DG, 1994, J BACK MUSCULOSKELET, V4, P135, DOI 10.3233/BMR-1994-4211	40	109	110	0	6	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	1996	77	9					883	888		10.1016/S0003-9993(96)90274-9			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	VG419	WOS:A1996VG41900007	8822678				2022-02-06	
J	HOLMES, B; HARBAUGH, RE				HOLMES, B; HARBAUGH, RE			TRAUMATIC INTRACRANIAL ANEURYSMS - A CONTEMPORARY REVIEW	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article							INTERNAL CAROTID-ARTERY; PERIPHERAL CEREBRAL-ARTERIES; BALLOON EMBOLIZATION; WOUNDS; COMPLICATIONS; BRAIN; ANGIOGRAPHY; MANAGEMENT; CHILDHOOD; PATIENT	Intracranial aneurysms are rare complications of head injury. Clinical and pathologic features as well as the surgical treatment of patients harboring traumatic intracranial aneurysms are presented. The latest neuroradiologic procedures as they relate to traumatic aneurysms are discussed. An illustrative case report is followed by a review of the literature.	DARTMOUTH HITCHCOCK MED CTR,DEPT SURG,NEUROSURG SECT,LEBANON,NH					Harbaugh, Robert/0000-0003-3607-7926			AARABI B, 1988, NEUROSURGERY, V22, P1056, DOI 10.1227/00006123-198806010-00014; ACOSTA C, 1972, J NEUROSURG, V36, P531, DOI 10.3171/jns.1972.36.5.0531; ALMEIDA GM, 1977, CHILD BRAIN, V3, P193; ASARI S, 1977, J NEUROSURG, V46, P795, DOI 10.3171/jns.1977.46.6.0795; BENOIT BG, 1973, J NEUROL NEUROSUR PS, V36, P127, DOI 10.1136/jnnp.36.1.127; BERGSTROM K, 1973, ACTA RADIOL DIAGN, V14, P657, DOI 10.1177/028418517301400604; BUCKINGHAM MJ, 1988, NEUROSURGERY, V22, P398, DOI 10.1227/00006123-198802000-00022; BURTON C, 1968, J NEUROSURG, V28, P468, DOI 10.3171/jns.1968.28.5.0468; COCKRILL HH, 1977, J NEUROSURG, V46, P377, DOI 10.3171/jns.1977.46.3.0377; CRESSMAN MR, 1966, J NEUROSURG, V24, P102, DOI 10.3171/jns.1966.24.1.0102; DEGOS JD, 1987, BRAIN, V110, P1155, DOI 10.1093/brain/110.5.1155; DIAL DL, 1937, AM J SURG, V35, P2; EDELMAN RR, 1990, AM J ROENTGENOL, V154, P937, DOI 10.2214/ajr.154.5.2108568; ELGINDI S, 1979, ACTA NEUROCHIR, V48, P237, DOI 10.1007/BF02056972; Endo S, 1974, No Shinkei Geka, V2, P329; FEIN JM, 1979, NEUROSURGERY, V5, P254, DOI 10.1227/00006123-197908000-00010; FERRY DJ, 1972, J NEUROSURG, V36, P503, DOI 10.3171/jns.1972.36.4.0503; FLEISCHER A S, 1975, Surgical Neurology, V4, P233; FOX JL, 1983, INTRACRANIAL ANEURYS, V3, P1453; Funahashi K, 1977, No Shinkei Geka, V5, P619; GIANNOTTA SL, 1982, CLIN NEUR, V29, P288; HAMMON WM, 1971, J NEUROSURG, V34, P127, DOI 10.3171/jns.1971.34.2part1.0127; Handa J, 1976, Surg Neurol, V5, P241; HARBAUGH RE, 1992, J NEUROSURG, V76, P408, DOI 10.3171/jns.1992.76.3.0408; HIGASHIDA RT, 1990, J NEUROSURG, V72, P857, DOI 10.3171/jns.1990.72.6.0857; HIRSCH JF, 1962, NEURO-CHIR, V8, P189; HODES JE, 1990, J NEUROSURG, V72, P567, DOI 10.3171/jns.1990.72.4.0567; KASSELL NF, 1990, J NEUROSURG, V73, P18, DOI 10.3171/jns.1990.73.1.0018; KIECK CF, 1984, J NEUROSURG, V60, P42, DOI 10.3171/jns.1984.60.1.0042; KUHN RA, 1964, J NEUROSURG, V21, P92, DOI 10.3171/jns.1964.21.2.0092; LASSMAN LP, 1974, VASCULAR SURG, V8, P1; LEE JP, 1990, J TRAUMA, V30, P619, DOI 10.1097/00005373-199005000-00017; MANI RL, 1978, AM J ROENTGENOL, V131, P871, DOI 10.2214/ajr.131.5.871; MASANA Y, 1992, J NEUROSURG, V76, P524, DOI 10.3171/jns.1992.76.3.0524; MAURER JJ, 1961, J NEUROSURG, V18, P837, DOI 10.3171/jns.1961.18.6.0837; MORARD M, 1991, NEUROSURGERY, V29, P438, DOI 10.1227/00006123-199109000-00018; NOV AA, 1984, J NEURORADIOLOGY, V11, P3; OVERTON MC, 1966, J NEUROSURG, V24, P672, DOI 10.3171/jns.1966.24.3.0672; PARKINSON D, 1980, J NEUROSURG, V52, P11, DOI 10.3171/jns.1980.52.1.0011; PATEL AN, 1971, J NEUROSURG, V35, P571, DOI 10.3171/jns.1971.35.5.0571; PAUL GA, 1980, J NEUROSURG, V53, P101, DOI 10.3171/jns.1980.53.1.0101; RUMBAUGH CL, 1970, RADIOLOGY, V96, P49, DOI 10.1148/96.1.49; SEKHAR LN, 1986, NEUROSURGERY, V19, P967, DOI 10.1227/00006123-198612000-00012; SENEGOR M, 1991, J NEUROSURG, V75, P475, DOI 10.3171/jns.1991.75.3.0475; SHALLAT RF, 1981, NEUROSURGERY, V8, P569, DOI 10.1227/00006123-198105000-00010; SMITH DR, 1970, J NEUROSURG, V32, P357, DOI 10.3171/jns.1970.32.3.0357; SMITH KR, 1968, J NEUROSURG, V29, P551, DOI 10.3171/jns.1968.29.5.0551; STEHBENS WE, 1972, PATHOLOGY CEREBRAL B, P452; TEAL JS, 1973, J NEUROSURG, V38, P568, DOI 10.3171/jns.1973.38.5.0568; THOMPSON JR, 1973, AM J ROENTGENOL, V118, P163, DOI 10.2214/ajr.118.1.163; WANG AN, 1986, SURG NEUROL, V25, P77, DOI 10.1016/0090-3019(86)90120-5	51	109	114	0	2	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	1993	35	6					855	860		10.1097/00005373-199312000-00009			6	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	MP518	WOS:A1993MP51800009	8263982				2022-02-06	
J	PANDA, S; JONAS, JB				PANDA, S; JONAS, JB			DECREASED PHOTORECEPTOR COUNT IN HUMAN EYES WITH SECONDARY ANGLE-CLOSURE GLAUCOMA	INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE			English	Article						GLAUCOMA; GLAUCOMATOUS OPTIC NERVE DAMAGE; RETINAL PHOTORECEPTORS; RETINAL PIGMENT EPITHELIUM; CYANDYSCHROMATOPSIA	NERVE-FIBER LAYER; INCLUDING FLOW DETERMINATIONS; BLOOD-FLOW; INTRAOCULAR PRESSURES; ATROPHY; TISSUES; DAMAGE; UVEAL; BRAIN	Glaucoma has been known to be associated with a loss of retinal ganglion cells and their axons throughout the fundus and a decreased count of photoreceptors and retinal pigment epithelial (RPE) cells in the parapapillary region. This study investigated whether glaucomatous changes of the deep retinal layer occur outside the parapapillary region. The nuclei of the retinal photoreceptors and RPE cells were counted in histologic slides of 23 eyes with painful secondary angle-closure glaucoma resulting from perforating corneal injuries. Fourteen eyes with malignant choroidal melanoma not involving the ciliary body or trabecular meshwork served as the control group. No surgical procedure, including laser treatment, had been performed posterior to the ora serrata. There were no hints of retinal vessel occlusion and localized traumatic retinopathy, historically, ophthalmoscopically, or histologically. Pbotoreceptor count was significantly lower (P < 0.05) in the glaucoma eyes than in the control group. Count of RPE cells did not differ between the two groups. This may indicate that glaucoma can be associated with a loss of photoreceptors. This could be important for psychophysical testing and may point to a more widespread involvement of ocular tissues in glaucoma than believed.	UNIV ERLANGEN NURNBERG,HOSP EYE,SCHWABACHANLAGE 6,W-8520 ERLANGEN,GERMANY; UNIV ERLANGEN NURNBERG,DEPT OPHTHALMOL,W-8520 ERLANGEN,GERMANY								AIRAKSINEN PJ, 1985, AM J OPHTHALMOL, V99, P1; ALM A, 1970, ACTA PHYSIOL SCAND, V80, P19, DOI 10.1111/j.1748-1716.1970.tb04765.x; ALM A, 1973, EXP EYE RES, V15, P15, DOI 10.1016/0014-4835(73)90185-1; ALM A, 1972, ACTA PHYSIOL SCAND, V84, P306, DOI 10.1111/j.1748-1716.1972.tb05182.x; Anderson DR., 1983, DOC OPHTHALMOL P SER, V35, P1; BETZ P, 1982, GRAEF ARCH CLIN EXP, V218, P70, DOI 10.1007/BF02153714; BRETON ME, 1989, GLAUCOMAS, P179; DECARVALHO CA, 1962, ARCH OPHTHALMOL-CHIC, V67, P483; DRANCE SM, 1981, ARCH OPHTHALMOL-CHIC, V99, P829, DOI 10.1001/archopht.1981.03930010829007; Drance SM, 1989, GLAUCOMAS, P393; FLOCKS M, 1959, AM J OPHTHALMOL, V48, P11, DOI 10.1016/0002-9394(59)90236-3; GREEN WR, 1985, OPHTHALMIC PATHOLOGY, V1, P792; HAMASAKI DI, 1965, ARCH OPHTHALMOL-CHIC, V73, P843; HOYT WF, 1973, INVEST OPHTH VISUAL, V12, P814; JONAS JB, 1989, INVEST OPHTH VIS SCI, V30, P908; JONAS JB, 1991, AM J OPHTHALMOL, V111, P559, DOI 10.1016/S0002-9394(14)73698-0; JONAS JB, 1992, GRAEF ARCH CLIN EXP, V230, P134, DOI 10.1007/BF00164651; KALVIN NH, 1966, ARCH OPHTHALMOL-CHIC, V76, P82, DOI 10.1001/archopht.1966.03850010084017; LAMPERT PW, 1968, INVEST OPHTH VISUAL, V7, P199; MAUMENEE AE, 1960, TRANS AMER ACAD OPHT, V64, P33; NAUMANN GOH, 1980, PATHOLOGIE AUGES, P783; Primrose J, 1971, T OPHTHAL SOC UK, V89, P585; QUIGLEY HA, 1980, ARCH OPHTHALMOL-CHIC, V98, P1564; QUIGLEY HA, 1982, ARCH OPHTHALMOL-CHIC, V100, P135, DOI 10.1001/archopht.1982.01030030137016; Ritch R, 1989, GLAUCOMAS; SAMPLE PA, 1988, AM J OPHTHALMOL, V106, P686, DOI 10.1016/0002-9394(88)90701-5; SHIELDS MB, 1987, TXB GLAUCOMA; SOMMER A, 1977, ARCH OPHTHALMOL-CHIC, V95, P2149; SPENCER WH, 1985, OPHTHALMIC PATHOLOGY, V1, P537; UENO M, 1989, GRAEF ARCH CLIN EXP, V227, P380, DOI 10.1007/BF02169417; WILENSKY JT, 1976, AM J OPHTHALMOL, V81, P341, DOI 10.1016/0002-9394(76)90251-8; ZIMMERMAN LORENZ E., 1967, INVEST OPHTHALMOL, V6, P109	32	109	116	0	4	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0146-0404			INVEST OPHTH VIS SCI	Invest. Ophthalmol. Vis. Sci.	JUL	1992	33	8					2532	2536					5	Ophthalmology	Science Citation Index Expanded (SCI-EXPANDED)	Ophthalmology	JE509	WOS:A1992JE50900024	1634350				2022-02-06	
J	BULLOCK, R; FUJISAWA, H				BULLOCK, R; FUJISAWA, H			THE ROLE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CNS INJURY	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	9TH ANNUAL MEETING OF THE NEUROTRAUMA SOC	NOV 09-10, 1991	NEW ORLEANS, LA	NEUROTRAUMA SOC			TRAUMATIC BRAIN INJURY; FOCAL CEREBRAL-ISCHEMIA; ACUTE SUBDURAL-HEMATOMA; CEREBROCORTICAL NEURONS; RECEPTOR ANTAGONIST; GLUCOSE-UTILIZATION; BLOOD-FLOW; RAT-BRAIN; MK-801; DAMAGE	Ischemic damage, chiefly of the focal type, and axonal disruption (diffuse axonal injury) are the major factors causing brain damage after human head injury. About one third of this damage may be delayed hours or days after the injury. Evidence from four animal models, each relevant to different aspects of human head injury, has shown that excitatory amino acid-induced changes are responsible for a proportion of the posttraumatic sequelae and that these effects can be blocked by EAA antagonists. This evidence is reviewed, and the implications for the conduct of human trials with EAA antagonists are discussed.			BULLOCK, R (corresponding author), UNIV GLASGOW,SO GEN HOSP,INST NEUROL SCI,DEPT NEUROSURG,GLASGOW G51 4TF,SCOTLAND.						Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; ALLEN HL, 1990, SCIENCE, V247, P221, DOI 10.1126/science.2403696; BIELENBERG GW, 1989, J CEREB BLOOD FLOW M, V9, pS298; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; BNECKER DP, 1989, J CBF METABOL S1, V9, pS302; BUCHAN AM, 1990, STROKE, V21, P163; BULLOCK R, 1991, J NEUROSURG, V74, P794, DOI 10.3171/jns.1991.74.5.0794; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; BULLOCK R, 1990, STROKE, V21, P32; BULLOCK R, 1991, J CEREB BLOOD FLO S2, V11, pS109; BULLOCK R, 1990, VINKEN BRUYNS HDB CL, V24, P249; BUTCHER SP, 1990, STROKE, V21, P1727, DOI 10.1161/01.STR.21.12.1727; CHAPMAN A, 1990, EXCITATORY AMINO ACI, P265; CHEN MH, 1991, J NEUROSURG, V74, P944, DOI 10.3171/jns.1991.74.6.0944; COYLE P, 1989, CEREBRAL ISCHAEMIA C, P69; DIETRICH WD, 1992, J NEUROTRAUM, V9, pS475; DIRNAGL U, 1990, BRAIN RES, V527, P62, DOI 10.1016/0006-8993(90)91060-T; ERB DE, 1988, ACTA NEUROPATHOL, V76, P347, DOI 10.1007/BF00686971; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FRANCE CP, 1990, BRAIN RES, V526, P355, DOI 10.1016/0006-8993(90)91247-E; GENTLEMAN D, 1981, LANCET, V2, P853; GERMANO IM, 1987, ANN NEUROL, V22, P730, DOI 10.1002/ana.410220609; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; GOTI B, 1988, J PHARM EXPT THERAPE, V247, P1211; GRAHAM DI, 1988, J CLIN PATHOL, V41, P34, DOI 10.1136/jcp.41.1.34; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; HAYES R, 1991, IN PRESS CNS TRAUMA; INGLIS FM, 1991, J CEREB BLOOD FLO S2, V11, pS307; INGLIS FM, 1991, J CEREB BLOOD FLO S2, V11, pS225; INGLIS FM, 1990, 8TH P INT S BRAIN OE, P277; JAMIESON KG, 1972, J NEUROSURG, V37, P137, DOI 10.3171/jns.1972.37.2.0137; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JENNETT B, 1981, MANAGEMENT HEAD INJU, P287; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, IN PRESS J CBF METAB; KIRINO T, 1984, ACTA NEUROPATHOL, V64, P139, DOI 10.1007/BF00695577; KOTAPKA M, 1992, IN PRESS J NEUROL NE; KURODA Y, 1991, J CBF METABOL S2, V11, pS74; KURODA Y, 1991, IN PRESS 8TH P INT S, V3; KURODA Y, 1992, IN PRESS J NEUROSURG; KURUMAJI A, 1989, J CEREBR BLOOD F MET, V9, P786, DOI 10.1038/jcbfm.1989.112; LYTHGOE D, 1989, British Journal of Pharmacology, V98, p903P; MCCULLOCH J, 1991, EXCITATORY AMINO ACI, P287; MELDRUM B, 1990, CEREBROVAS BRAIN MET, V2, P27; MELDRUM B, 1991, IN PRESS P KEY W SAT; MILLER JD, 1990, NEUROSURGERY, V27, P433, DOI 10.1227/00006123-199009000-00016; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; NEHLS DG, 1990, BRAIN RES, V511, P271, DOI 10.1016/0006-8993(90)90172-8; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; OZYURT E, 1988, J CEREBR BLOOD F MET, V8, P138, DOI 10.1038/jcbfm.1988.18; PANETTA JA, 1989, J CEREB BLOOD FLO S1, V9, pS635; PARK CK, 1988, ANN NEUROL, V24, P543, DOI 10.1002/ana.410240411; PINARD E, 1992, IN PRESS P KEY W S; ROMAN R, 1989, NEUROSCI LETT, V104, P19, DOI 10.1016/0304-3940(89)90322-4; ROUSSEL S, 1989, NEUROTRANSMISSION CE, P453; SCHELLER MS, 1989, NEUROPHARMACOLOGY, V28, P677, DOI 10.1016/0028-3908(89)90150-0; SHIRAISHI K, 1989, J CEREBR BLOOD F MET, V9, P765, DOI 10.1038/jcbfm.1989.110; STEINBERG GK, 1988, STROKE, V19, P1112, DOI 10.1161/01.STR.19.9.1112; STEINBERG GK, 1989, J CEREB BLOOD FLOW M, V9, pS283; STONE JL, 1983, SURG NEUROL, V19, P216, DOI 10.1016/S0090-3019(83)80005-6; TAKIZAWA S, 1991, J CEREBR BLOOD F MET, V11, P786, DOI 10.1038/jcbfm.1991.136; TAMURA A, 1988, J CLIN EXP MED, V146, P131; TEASDALE GM, 1992, IN PRESS 1ST P NEUR; UEMATSU D, 1991, NEUROLOGY, V41, P88, DOI 10.1212/WNL.41.1.88; UEMATSU D, 1990, STROKE S1, V21, P132; WALLACE MC, 1992, J NEUROSURG, V76, P127, DOI 10.3171/jns.1992.76.1.0127; WYPER DJ, 1991, J CEREB BLOOD FLOW M, V11, pS831; YOSHINO A, 1992, IN PRESS BRAIN RES	69	109	109	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	1992	9			2			S443	S462					20	Critical Care Medicine; Clinical Neurology; Neurosciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	HU819	WOS:A1992HU81900003	1613806				2022-02-06	
J	Meehan, WP; Mannix, R; Monuteaux, MC; Stein, CJ; Bachur, RG				Meehan, William P., III; Mannix, Rebekah; Monuteaux, Michael C.; Stein, Cynthia J.; Bachur, Richard G.			Early symptom burden predicts recovery after sport-related concussion	NEUROLOGY			English	Article							COLLEGIATE FOOTBALL PLAYERS; TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL; PROTRACTED RECOVERY; PROLONGED RECOVERY; SEVERITY; AGE	Objective:To identify independent predictors of and use recursive partitioning to develop a multivariate regression tree predicting symptom duration greater than 28 days after a sport-related concussion.Methods:We conducted a prospective cohort study of patients in a sports concussion clinic. Participants completed questionnaires that included the Post-Concussion Symptom Scale (PCSS). Participants were asked to record the date on which they last experienced symptoms. Potential predictor variables included age, sex, score on symptom inventories, history of prior concussions, performance on computerized neurocognitive assessments, loss of consciousness and amnesia at the time of injury, history of prior medical treatment for headaches, history of migraines, and family history of concussion. We used recursive partitioning analysis to develop a multivariate prediction model for identifying athletes at risk for a prolonged recovery from concussion.Results:A total of 531 patients ranged in age from 7 to 26 years (mean 14.6 2.9 years). The mean PCSS score at the initial visit was 26 +/- 26; mean time to presentation was 12 +/- 5 days. Only total score on symptom inventory was independently associated with symptoms lasting longer than 28 days (adjusted odds ratio 1.044; 95% confidence interval [CI] 1.034, 1.054 for PCSS). No other potential predictor variables were independently associated with symptom duration or useful in developing the optimal regression decision tree. Most participants (86%; 95% CI 80%, 90%) with an initial PCSS score of <13 had resolution of their symptoms within 28 days of injury.Conclusions:The only independent predictor of prolonged symptoms after sport-related concussion is overall symptom burden.	[Meehan, William P., III] Micheli Ctr Sports Injury Prevent, Waltham, MA 02453 USA; [Meehan, William P., III; Stein, Cynthia J.] Boston Childrens Hosp, Div Sports Med, Sports Concuss Clin, Boston, MA USA; [Meehan, William P., III; Mannix, Rebekah; Monuteaux, Michael C.; Bachur, Richard G.] Boston Childrens Hosp, Div Emergency Med, Boston, MA USA; [Meehan, William P., III; Mannix, Rebekah] Boston Childrens Hosp, Brain Injury Ctr, Boston, MA USA		Meehan, WP (corresponding author), Micheli Ctr Sports Injury Prevent, Waltham, MA 02453 USA.	William.meehan@childrens.harvard.edu	Mannix, Rebekah/AAD-8702-2020; Monuteaux, Michael C/O-5032-2018	Bachur, Richard/0000-0001-8831-014X	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 HD040128-06A]; NFL Players Association; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040128] Funding Source: NIH RePORTER	Funded by the NIH T32 HD040128-06A (Dr. Meehan) and the NFL Players Association (Dr. Meehan).	Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Chrisman SP, 2013, BRAIN INJURY, V27, P1, DOI 10.3109/02699052.2012.722251; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Dawson B, 2004, STAT METHODS MULTIPL; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Faux S, 2011, BRAIN INJURY, V25, P14, DOI 10.3109/02699052.2010.531686; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gordon KE, 2006, BRIT J SPORT MED, V40, P184, DOI 10.1136/bjsm.2005.022251; GRONWALL D, 1975, LANCET, V2, P995; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Lau BC, 2012, NEUROSURGERY, V70, P371, DOI 10.1227/NEU.0b013e31823150f0; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Meehan WP, 2011, AM J SPORT MED, V39, P2304, DOI 10.1177/0363546511423503; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Sperandei S, 2013, BIOCHEM MEDICA, V24, P12; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Zemek RL, 2013, JAMA PEDIATR, V167, P259, DOI 10.1001/2013.jamapediatrics.216	30	108	108	0	34	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	DEC 9	2014	83	24					2204	2210		10.1212/WNL.0000000000001073			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AW1SK	WOS:000346070000008	25381296	Green Published			2022-02-06	
J	Bass, C; Halligan, P				Bass, Christopher; Halligan, Peter			Factitious disorders and malingering: challenges for clinical assessment and management	LANCET			English	Article							MEDICALLY UNEXPLAINED SYMPTOMS; CHRONIC REGIONAL PAIN; MINOR HEAD-INJURY; MUNCHAUSENS-SYNDROME; COMPENSATION NEUROSIS; PERFORMANCE VALIDITY; ETHICAL IMPLICATIONS; RISK-FACTORS; ILLNESS; LITIGATION	Compared with other psychiatric disorders, diagnosis of factitious disorders is rare, with identification largely dependent on the systematic collection of relevant information, including a detailed chronology and scrutiny of the patient's medical record. Management of such disorders ideally requires a team-based approach and close involvement of the primary care doctor. As deception is a key defining component of factitious disorders, diagnosis has important implications for young children, particularly when identified in women and health-care workers. Malingering is considered to be rare in clinical practice, whereas simulation of symptoms, motivated by financial rewards, is regarded as more common in medicolegal settings. Although psychometric investigations (eg, symptom validity testing) can inform the detection of illness deception, such tests need support from converging evidence sources, including detailed interview assessments, medical notes, and relevant non-medical investigations. A key challenge in any discussion of abnormal health-care-seeking behaviour is the extent to which a person's reported symptoms are considered to be a product of choice, or psychopathology beyond volitional control, or perhaps both. Clinical skills alone are not typically sufficient for diagnosis or to detect malingering. Medical education needs to provide doctors with the conceptual, developmental, and management frameworks to understand and deal with patients whose symptoms appear to be simulated. Central to the understanding of factitious disorders and malingering are the explanatory models and beliefs used to provide meaning for both patients and doctors. Future progress in management will benefit from an increased appreciation of the contribution of non-medical factors and a greater awareness of the conceptual and clinical findings from social neuroscience, occupational health, and clinical psychology.	[Bass, Christopher] John Radcliffe Hosp, Dept Psychol Med, Oxford OX3 9DU, England; [Halligan, Peter] Cardiff Univ, Sch Psychol, Cardiff CF10 3AX, S Glam, Wales		Bass, C (corresponding author), John Radcliffe Hosp, Dept Psychol Med, Oxford OX3 9DU, England.	christopher.bass@oxfordhealth.nhs.uk	Halligan, Peter W/A-1669-2010	Halligan, Peter W/0000-0003-2784-6690			American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5th; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Angell M, 2011, NEW YORK REV BOOKS, V58, P14; Aronoff Gerald M, 2007, Pain Pract, V7, P178, DOI 10.1111/j.1533-2500.2007.00126.x; ASHER R, 1951, LANCET, V260, P339; BARSKY AJ, 1983, AM J PSYCHIAT, V140, P273; BASS C, 1995, J PSYCHOSOM RES, V39, P403, DOI 10.1016/0022-3999(94)00157-Z; Bass C, 2014, LANCET; Bass C, 2009, NEW OXFORD TXB PSYCH, P1049; Bass C, 2007, J ROY SOC MED, V100, P81, DOI 10.1258/jrsm.100.2.81; Bass C, 2013, PERSONAL MENT HEALTH, V7, P80, DOI 10.1002/pmh.1223; Bass C, 2011, BRIT J PSYCHIAT, V199, P113, DOI 10.1192/bjp.bp.109.074088; Berry DTR, 2010, PSYCHOL INJ LAW, V3, P295, DOI 10.1007/s12207-010-9087-7; Binder LM, 2012, CLIN NEUROPSYCHOL, V26, P116, DOI 10.1080/13854046.2011.633563; British Psychological Society (BPS), 2009, ASS EFF CLIN TEST CO; Burke FD, 2008, J HAND SURG-EUR VOL, V33E, P103, DOI 10.1177/1753193408087230; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Carone DA., 2013, MILD TRAUMATIC BRAIN, P101; Cassidy JD, 2011, INJURY, V42, P428, DOI 10.1016/j.injury.2010.11.027; Chafetz M, 2013, ARCH CLIN NEUROPSYCH, V28, P633, DOI 10.1093/arclin/act038; Creed F, 2011, MED UNEXPLAINED SYMP, P1, DOI DOI 10.1017/CBO9780511977862; Crittenden P.M., 2011, ASSESSING ADULT ATTA; Croft P., 2010, CHRONIC PAIN EPIDEMI, P3; Cunningham JM, 2011, PSYCHOSOMATICS, V52, P185, DOI 10.1016/j.psym.2010.11.005; de Asla R, 2011, J BONE JOINT SURG AM, V93, p[e116, 1], DOI DOI 10.2106/JBJS.K; DeWitt DE, 2010, MED J AUSTRALIA, V192, P55, DOI 10.5694/j.1326-5377.2010.tb03411.x; DeWitt DE, 2009, MED J AUSTRALIA, V191, P213, DOI 10.5694/j.1326-5377.2009.tb02755.x; Drob SL, 2009, J AM ACAD PSYCHIATRY, V37, P98; Dyer C, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e3226; Eastwood S, 2008, PSYCHOTHER PSYCHOSOM, V77, P209, DOI 10.1159/000126072; Ehrlich S, 2008, PSYCHOSOMATICS, V49, P392, DOI 10.1176/appi.psy.49.5.392; Eisendrath S, 1996, SPECTRUM FACTITIOUS, P65; Eisendrath SJ, 2004, PSYCHOSOMATICS, V45, P350, DOI 10.1176/appi.psy.45.4.350; Eisendrath SJ, 2002, J AM ACAD PSYCHIATRY, V30, P391; Eisendrath SJ, 1996, SPECTRUM FACTITIOUS, P195; Eisendrath SJ, 2008, ANN PLAS SURG, V60, P64, DOI 10.1097/SAP.0b013e318049cc41; Farnfield Steve, 2010, Clin Child Psychol Psychiatry, V15, P313, DOI 10.1177/1359104510364315; Fehnel CR, 2006, AM J PSYCHIAT, V163, P547, DOI 10.1176/appi.ajp.163.3.547-a; Feldman MD, 2006, INT J CLIN PRACT, V60, P1675, DOI 10.1111/j.1742-1241.2006.00975.x; Ferrari R, 2011, J NEUROL NEUROSUR PS, V82, P826, DOI 10.1136/jnnp.2010.213520; Ferrari R, 2012, J RHEUMATOL, V39, P655, DOI 10.3899/jrheum.110970; FINK P, 1992, J PSYCHOSOM RES, V36, P125, DOI 10.1016/0022-3999(92)90021-S; Fliege H, 2007, PSYCHOSOMATICS, V48, P60, DOI 10.1176/appi.psy.48.1.60; Ganis G, 2009, SOC NEUROSCI, V4, P465, DOI 10.1080/17470910802507660; Gervais RO, 2001, J RHEUMATOL, V28, P1892; Gieler U, 2004, DERMATOL PSYCHOSOM, V5, P93; Goebel RA, 2012, COMPLEX REGIONAL PAI; Goldstein AB, 1998, INT J PSYCHIAT MED, V28, P221, DOI 10.2190/8LRP-5YTD-3VP2-3HC6; Granacher R, 2008, CLIN ASSESSMENT MALI, P145; Green P, 2013, MILD TRAUMATIC BRAIN, P73; Green P., 2005, GREENS WORD MEMORY T, Vrev. ed.; Greiffenstein M, 2005, LEG CRIMINOL PSYCHOL, V10, P1; Greiffenstein M, 2013, CLIN NEUROPSYCHOL, V27, P138, DOI 10.1080/13854046.2012.722686; Greve K. W., 2012, COPING PSYCHIAT PSYC, P587, DOI DOI 10.1093/MED:PSYCH/9780195174113.003.0026; Greve KW, 2013, CLIN NEUROPSYCHOL, V27, P108, DOI 10.1080/13854046.2012.739646; Greve KW, 2009, ARCH PHYS MED REHAB, V90, P1117, DOI 10.1016/j.apmr.2009.01.018; Guidotti L. M., 2013, MILD TRAUMATIC BRAIN, P145; Hadeed V, 1998, ANN INTERN MED, V129, P73, DOI 10.7326/0003-4819-129-1-199807010-00027; Hall RCW, 2007, J FORENSIC SCI, V52, P717, DOI 10.1111/j.1556-4029.2007.00434.x; Hall RCW, 2006, GEN HOSP PSYCHIAT, V28, P525, DOI 10.1016/j.genhosppsych.2006.08.011; Hall RCW, 2012, J AM ACAD PSYCHIATRY, V40, P390; Hallett M, 2010, J CLIN NEUROSCI, V17, P959, DOI 10.1016/j.jocn.2009.11.021; Halligan P., 2003, MALINGERING ILLNESS, P3; Halligan P., 2011, PSYCHOGENIC MOVEMENT, P120; Hamilton JC, 2013, PSYCHOSOMATICS, V54, P142, DOI 10.1016/j.psym.2012.08.013; Hamilton JM, 2009, JOURNALISM'S ROVING EYE: A HISTORY OF AMERICAN FOREIGN REPORTING, UPDATED EDITION, P27; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Hoertel N, 2012, PSYCHIAT RES, V200, P1077, DOI 10.1016/j.psychres.2012.05.004; Holm LW, 2008, PLOS MED, V5, P760, DOI 10.1371/journal.pmed.0050105; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; Iverson GL, 2006, APPL NEUROPSYCHOL, V13, P77, DOI 10.1207/s15324826an1302_3; Iverson Grant L, 2007, Pain Pract, V7, P94, DOI 10.1111/j.1533-2500.2007.00116.x; Johnson-Greene D, 2013, CLIN NEUROPSYCHOL, V27, P148, DOI 10.1080/13854046.2012.733732; Jung B, 2007, PAIN MED, V8, P433, DOI 10.1111/j.1526-4637.2007.00315.x; Kanaan RAA, 2010, HIST HUM SCI, V23, P68, DOI 10.1177/0952695109357128; Kanaan RAA, 2010, PSYCHOSOMATICS, V51, P47, DOI 10.1176/appi.psy.51.1.47; Kapfhammer HP, 1998, NERVENARZT, V69, P401, DOI 10.1007/s001150050289; Kendell R, 2003, AM J PSYCHIAT, V160, P4, DOI 10.1176/appi.ajp.160.1.4; Kozlowska Kasia, 2007, Clin Child Psychol Psychiatry, V12, P487, DOI 10.1177/1359104507080977; Krahn LE, 2003, AM J PSYCHIAT, V160, P1163, DOI 10.1176/appi.ajp.160.6.1163; Krahn LE, 2008, PSYCHOSOMATICS, V49, P277, DOI 10.1176/appi.psy.49.4.277; Lamberty G. J., 2008, UNDERSTANDING SOMATI; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2004, DIFFERENTIAL DIAGNOSIS IN ADULT NEUROPSYCHOLOGICAL ASSESSMENT, P243; Larrabee GJ, 2012, J INT NEUROPSYCH SOC, V18, P625, DOI 10.1017/S1355617712000240; LIBOW JA, 1995, CHILD ABUSE NEGLECT, V19, P1131, DOI 10.1016/0145-2134(95)00073-H; LUCIRE Y, 2003, CONSTRUCTING RSI BEL; Mailis-Gagnon A, 2008, CLIN J PAIN, V24, P176, DOI 10.1097/AJP.0b013e31815ca278; Main CJ, 1998, SPINE, V23, P2367, DOI 10.1097/00007632-199811010-00025; McCullumsmith CB, 2011, PSYCHIAT CLIN N AM, V34, P621, DOI 10.1016/j.psc.2011.05.013; MECHANIC D, 1961, AM SOCIOL REV, V26, P51, DOI 10.2307/2090512; MENDELSON G, 1995, J PSYCHOSOM RES, V39, P695, DOI 10.1016/0022-3999(94)00154-W; Merckelbach H, 2012, CLIN NEUROPSYCHOL, V26, P1217, DOI 10.1080/13854046.2012.710252; Merten T, 2013, PSYCHOL INJ LAW, V6, P122, DOI 10.1007/s12207-013-9155-x; Merten T, 2009, PSYCHOL INJ LAW, V2, P284, DOI 10.1007/s12207-009-9057-0; MILLER H, 1972, LANCET, V1, P580; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Mohandas P, 2013, BRIT J DERMATOL, V169, P600, DOI 10.1111/bjd.12416; Morel K. R., 2010, DIFFERENTIAL DIAGNOS; Nicholas MK, 2011, PHYS THER, V91, P737, DOI 10.2522/ptj.20100224; Nimnuan C, 2000, QJM-INT J MED, V93, P21, DOI 10.1093/qjmed/93.1.21; O'Connor EA, 2013, J HAND SURG-AM, V38A, P1590, DOI 10.1016/j.jhsa.2013.04.047; Ochoa JL, 2010, J NEUROPSYCH CLIN N, V22, P278, DOI 10.1176/appi.neuropsych.22.3.278; Pankratz L, 1998, PATIENTS WHO DECEIVE; Pearce JMS, 2005, SPINAL CORD, V43, P263, DOI 10.1038/sj.sc.3101709; Pearce S, 2010, J MED ETHICS, V36, P831, DOI 10.1136/jme.2010.035865; Peebles R, 2005, CLIN PEDIATR, V44, P237, DOI 10.1177/000992280504400307; Petrie KJ, 2012, CURR DIR PSYCHOL SCI, V21, P60, DOI 10.1177/0963721411429456; Poole CJM, 2010, OCCUP MED-OXFORD, V60, P127, DOI 10.1093/occmed/kqp170; Raab S, 2005, MAFIA LEADER WHO FEI; REICH P, 1983, ANN INTERN MED, V99, P240, DOI 10.7326/0003-4819-99-2-240; Resnick P, 2008, CLIN ASSESSMENT MALI, P109; Rief W, 2004, J PSYCHOSOM RES, V57, P367, DOI 10.1016/S0022-3999(04)00047-9; Rief W, 2003, J PSYCHOSOM RES, V54, P405, DOI 10.1016/S0022-3999(02)00401-4; Robertson MD, 2009, MED J AUSTRALIA, V191, P217, DOI 10.5694/j.1326-5377.2009.tb02756.x; Rogers R, 1990, Bull Am Acad Psychiatry Law, V18, P323; Rogers R, 2009, LAW HUMAN BEHAV, V33, P213, DOI 10.1007/s10979-008-9145-9; Ronson G, 2009, LEADING FRONT; Rosen GM, 2007, J ANXIETY DISORD, V21, P201, DOI 10.1016/j.janxdis.2006.09.011; Salmon P, 2007, PATIENT EDUC COUNS, V67, P246, DOI 10.1016/j.pec.2007.03.008; Singh HP, 2006, J HAND SURG-BRIT EUR, V31B, P611, DOI 10.1016/j.jhsb.2006.08.009; Spence SA, 2004, PHILOS T R SOC B, V359, P1755, DOI 10.1098/rstb.2004.1555; Stone J, 2012, J NEUROL NEUROSUR PS, V83, P67, DOI 10.1136/jnnp-2011-300125; Suchy Y, 2012, CLIN NEUROPSYCHOL, V26, P1296, DOI 10.1080/13854046.2012.722230; Sullivan K., 2007, J FORENSIC NEUROPSYC, V4, P49, DOI DOI 10.1300/J151V04N04_04; Sullivan MJL, 2012, CLIN J PAIN, V28, P484, DOI 10.1097/AJP.0b013e3182527d13; Sweet JJ, 2013, J EXP PSYCHOPATHOL, V4, P6, DOI 10.5127/jep.022311; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Torres L, 2012, PSYCHOL INJ LAW, V5, P1, DOI 10.1007/s12207-012-9118-7; TRIVERS R, 2011, DECEIT SELF DECEPTIO; Tyrer P, 1999, J PSYCHOSOM RES, V46, P177, DOI 10.1016/S0022-3999(98)00072-5; Van Dinter TG, 2009, AM J MED, V122, pE4, DOI 10.1016/j.amjmed.2009.03.035; Vranceanu AM, 2011, J HAND THER, V24, P118, DOI 10.1016/j.jht.2010.12.002; Vranceanu AM, 2009, J BONE JOINT SURG AM, V91A, P2014, DOI 10.2106/JBJS.H.01512; Vrij A., 2008, DETECTING LIES DECEI, V2nd; Wade DT, 2007, CLIN REHABIL, V21, P291, DOI 10.1177/0269215507077799; Wade DT, 2004, BMJ-BRIT MED J, V329, P1398, DOI 10.1136/bmj.329.7479.1398; Wade DT, 2003, CLIN REHABIL, V17, P349, DOI 10.1191/0269215503cr619ed; Walters GD, 2009, J CLIN EXP NEUROPSYC, V31, P584, DOI 10.1080/13803390802363728; Whitley, 1998, STOLEN VALOR VIETNAM; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105; World Health Organization, 1992, ICD 10 CLASSIFICATIO	142	108	111	3	52	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 19	2014	383	9926					1422	1432		10.1016/S0140-6736(13)62186-8			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AG3LI	WOS:000335318400028	24612861				2022-02-06	
J	Jin, X; Zhu, F; Mao, HJ; Shen, M; Yang, KH				Jin, Xin; Zhu, Feng; Mao, Haojie; Shen, Ming; Yang, King H.			A comprehensive experimental study on material properties of human brain tissue	JOURNAL OF BIOMECHANICS			English	Article						Human brain tissue; Material properties; Tension; Compression; Shear	VISCOELASTIC PROPERTIES; MECHANICAL-PROPERTIES; AGE; BEHAVIOR; RAT	A comprehensive study on the biomechanical response of human brain tissue is necessary to investigate traumatic brain injury mechanisms. Published brain material property studies have been mostly performed under a specific type of loading, which is insufficient to develop accurate brain tissue constitutive equations. In addition, inconsistent or contradictory data in the literature made it impossible for computational model developers to create a single brain material model that can fit most, if not all, experimental results. In the current study, a total of 240 brain tissue specimens were tested under tension (n=72), compression (n=72), and shear (n=96) loading modes at varying strain rates. Gray-white matter difference, regional difference, and directional difference within white matter were also investigated. Stress-strain relationships of human brain tissue were obtained up to 50% of engineering strain. Strain rate dependency was observed under all three loading modes. White matter was stiffer than gray matter in compression and shear. Corona radiata was found to be stiffer than cortex, thalamus, and corpus callosum in tension and compression. Directional dependency of white matter was observed under shear loading. (C) 2013 Elsevier Ltd. All rights reserved.	[Jin, Xin; Zhu, Feng; Mao, Haojie; Shen, Ming; Yang, King H.] Wayne State Univ, Dept Biomed Engn, Detroit, MI 48201 USA		Jin, X (corresponding author), Wayne State Univ, Bioengn Ctr, 818 W Hancock, Detroit, MI 48201 USA.	mail.jinxin@gmail.com	Shen, Ming/AAN-9002-2020; Jin, Xin/J-6476-2015; Mao, Haojie/Q-7514-2018	Shen, Ming/0000-0002-9388-3513; Mao, Haojie/0000-0002-7563-9234	Global Human Body Model Consortium	This study was supported by the Global Human Body Model Consortium. The authors would like to express their appreciation to Abrar Wazir for his assistance with grammar correcting on the manuscript.	Arbogast K.B., 1995, P 39 STAPP CAR CRASH; Arbogast KB, 1998, J BIOMECH, V31, P801, DOI 10.1016/S0021-9290(98)00068-2; ARBOGAST KB, 1997, P 41 STAPP CAR CRASH, P293; Bilston LE, 1997, BIORHEOLOGY, V34, P377, DOI 10.1016/S0006-355X(98)00022-5; Center for Disease Control and Prevention (CDC), TRAUMATIC BRAIN INJU; Cheng S., 2007, J BIOMECHANICS; Donnelly B.R., 1997, ASME J BIOMECHANICAL; ESTES MS, 1970, 70BHF13 ASME; FALLENSTEIN GT, 1969, J BIOMECH, V2, P217, DOI 10.1016/0021-9290(69)90079-7; Finan JD, 2012, ANN BIOMED ENG, V40, P70, DOI 10.1007/s10439-011-0394-2; Galford J.E., 1970, J BIOMECHANICS; Garo A., 2007, BIORHEOLOGY; Gefen A, 2003, J NEUROTRAUM, V20, P1163, DOI 10.1089/089771503770802853; Hrapko M, 2006, BIORHEOLOGY, V43, P623; Manduca A, 2001, MED IMAGE ANAL, V5, P237, DOI 10.1016/S1361-8415(00)00039-6; Miller K, 2002, J BIOMECH, V35, P483, DOI 10.1016/S0021-9290(01)00234-2; Nicolle Stephane, 2004, Stapp Car Crash J, V48, P239; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; PRANGE MT, 2000, P 44 STAPP CAR CRASH; Takhounts E.G., 2003, STAPP CAR CRASH J; Thibault KL, 1998, J BIOMECH, V31, P1119, DOI 10.1016/S0021-9290(98)00122-5; Velardi F, 2006, BIOMECH MODEL MECHAN, V5, P53, DOI 10.1007/s10237-005-0007-9	22	108	111	4	33	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290	1873-2380		J BIOMECH	J. Biomech.	NOV 15	2013	46	16					2795	2801		10.1016/j.jbiomech.2013.09.001			7	Biophysics; Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Engineering	267JH	WOS:000328093200006	24112782				2022-02-06	
J	Elbin, RJ; Kontos, AP; Kegel, N; Johnson, E; Burkhart, S; Schatz, P				Elbin, R. J.; Kontos, Anthony P.; Kegel, Nate; Johnson, Eric; Burkhart, Scott; Schatz, Philip			Individual and Combined Effects of LD and ADHD on Computerized Neurocognitive Concussion Test Performance: Evidence for Separate Norms	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						ADHD; LD; Computerized neurocognitive testing; ImPACT	ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DEFICIT-HYPERACTIVITY DISORDER; SPORTS-RELATED CONCUSSION; TEST-RETEST RELIABILITY; TRAUMATIC BRAIN-INJURY; LEARNING-DISABILITIES; HIGH-SCHOOL; NEUROPSYCHOLOGICAL PERFORMANCE; EXECUTIVE FUNCTIONS; POSITION STATEMENT	Decreased neurocognitive performance in individuals with self-reported attention deficit hyperactivity disorder(ADHD) and learning disability (LD) is well documented in the neuropsychological research literature. Previous studies employing paper-and-pencil neurocognitive assessments report lower performance in individuals with ADHD and LD. The purpose of the current study was to examine the influence of a self-reported diagnosis of LD, ADHD, and combined LD/ADHD on baseline computerized neurocognitive testing (CNT) used for the concussion assessment. Results revealed athletes with a self-reported diagnosis of LD, ADHD, and/or combined LD/ADHD demonstrated lower performance on baseline CNT and reported larger numbers of symptoms than did control athletes without these diagnoses. These findings provide evidence for the development of separate normative data for athletes with LD, ADHD, and LD/ADHD diagnoses on CNT batteries commonly used for concussion management.	[Elbin, R. J.; Kontos, Anthony P.; Kegel, Nate; Johnson, Eric; Burkhart, Scott] Univ Pittsburgh, Dept Orthopaed Surg, UPMC Sports Med Concuss Program, Pittsburgh, PA 15260 USA; [Schatz, Philip] St Josephs Univ, Dept Psychol, Philadelphia, PA 19131 USA		Elbin, RJ (corresponding author), UPMC Ctr Sport Med, UPMC Sports Med Concuss Program, 3200 South Water St, Pittsburgh, PA 15203 USA.	rje13@pitt.edu		Kontos, Anthony/0000-0002-3749-4310			American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Barkley R. A., 2003, ATTENTION DEFICIT HY; Barkley RA, 2003, BRAIN DEV-JPN, V25, P77, DOI 10.1016/S0387-7604(02)00152-3; Barkley RA, 1997, PSYCHOL BULL, V121, P65, DOI 10.1037/0033-2909.121.1.65; Bauermeister JJ, 2007, J CHILD PSYCHOL PSYC, V48, P831, DOI 10.1111/j.1469-7610.2007.01750.x; Biederman J, 2006, PSYCHOL MED, V36, P167, DOI 10.1017/S0033291705006410; Biederman J, 2008, J CLIN PSYCHIAT, V69, P1150, DOI 10.4088/JCP.v69n0715; Birchwood J, 2012, J ADOLESCENCE, V35, P225, DOI 10.1016/j.adolescence.2010.08.011; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; DENCKLA MB, 1991, J CHILD NEUROL, V6, pS44, DOI 10.1177/0883073891006001S06; DuPaul GJ, 2001, J LEARN DISABIL-US, V34, P370, DOI 10.1177/002221940103400412; Echemendia RJ, 2012, CLIN NEUROPSYCHOL, V26, P1077, DOI 10.1080/13854046.2012.721006; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Glass K, 2011, ADHD-ATTEND DEFICIT, V3, P29, DOI 10.1007/s12402-010-0042-y; Gross-Tsur V, 2006, DEV MED CHILD NEUROL, V48, P901, DOI 10.1017/S0012162206001976; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Hoffman JB, 2000, CHILD ADOL PSYCH CL, V9, P647; IBM Corp. Released, 2012, IBM SPSS STAT WIND V; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Jakobson A, 2007, J LEARN DISABIL-US, V40, P194, DOI 10.1177/00222194070400030101; Johnson DE, 2001, ARCH CLIN NEUROPSYCH, V16, P587; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Lau BC, 2012, NEUROSURGERY, V70, P371, DOI 10.1227/NEU.0b013e31823150f0; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; Mayes SD, 2000, J LEARN DISABIL-US, V33, P417, DOI 10.1177/002221940003300502; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI [10.4085/1062-6050-44.4.434, 10.1016/j.jocn.2009.02.002]; MCGEE R, 1991, J AM ACAD CHILD PSY, V30, P224, DOI 10.1097/00004583-199103000-00010; Meehan WP, 2010, J PEDIATR-US, V157, P889, DOI 10.1016/j.jpeds.2010.06.040; Merikangas KR, 2010, PEDIATRICS, V125, P75, DOI 10.1542/peds.2008-2598; Pennington BF, 1996, J CHILD PSYCHOL PSYC, V37, P51, DOI 10.1111/j.1469-7610.1996.tb01380.x; Penttila Jani, 2011, Duodecim, V127, P1433; Purvis KL, 1997, J ABNORM CHILD PSYCH, V25, P133, DOI 10.1023/A:1025731529006; Putukian M, 2011, CLIN J SPORT MED, V21, P392, DOI 10.1097/JSM.0b013e3182262eb1; Randolph C, 2005, J ATHL TRAINING, V40, P139; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2012, J ATHL TRAINING, V47, P289, DOI 10.4085/1062-6050-47.3.14; Schatz P, 2012, J CLIN EXP NEUROPSYC, V34, P428, DOI 10.1080/13803395.2012.667789; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Seidman LJ, 2006, CLIN PSYCHOL REV, V26, P466, DOI 10.1016/j.cpr.2006.01.004; Seidman LJ, 1995, J CHILD PSYCHOL PSYC, V36, P1459, DOI 10.1111/j.1469-7610.1995.tb01675.x; Seidman LJ, 1997, J CONSULT CLIN PSYCH, V65, P150, DOI 10.1037/0022-006X.65.1.150; Seidman LJ, 2001, NEUROPSYCHOLOGY, V15, P544, DOI 10.1037/0894-4105.15.4.544; Seidman LJ, 2006, NEUROPSYCHOLOGY, V20, P166, DOI 10.1037/0894-4105.20.2.166; Seidman LJ, 2005, DEV NEUROPSYCHOL, V27, P79, DOI 10.1207/s15326942dn2701_4; Silver CH, 2008, ARCH CLIN NEUROPSYCH, V23, P217, DOI 10.1016/j.acn.2007.09.006; Skirrow C, 2009, EXPERT REV NEUROTHER, V9, P489, DOI 10.1586/ERN.09.2; Solomon GS, 2008, ARCH CLIN NEUROPSYCH, V23, P563, DOI 10.1016/j.acn.2008.05.008; Tsushima William T, 2008, Hawaii Med J, V67, P93; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Willcutt EG, 2001, J ABNORM PSYCHOL, V110, P157, DOI 10.1037//0021-843X.1001.1.157; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64	55	108	108	1	27	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	AUG	2013	28	5					476	484		10.1093/arclin/act024			9	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	186CN	WOS:000322019600009	23608188	Bronze, Green Published			2022-02-06	
J	Tzeng, YC; Ainslie, PN; Cooke, WH; Peebles, KC; Willie, CK; MacRae, BA; Smirl, JD; Horsman, HM; Rickards, CA				Tzeng, Y. C.; Ainslie, P. N.; Cooke, W. H.; Peebles, K. C.; Willie, C. K.; MacRae, B. A.; Smirl, J. D.; Horsman, H. M.; Rickards, C. A.			Assessment of cerebral autoregulation: the quandary of quantification	AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY			English	Article						cerebral blood flow; autoregulation; blood vessel; circulation	TRAUMATIC BRAIN-INJURY; BLOOD-FLOW; BAROREFLEX SENSITIVITY; ARTERIAL-PRESSURE; ACUTE HYPOTENSION; HEART-RATE; TRANSCRANIAL DOPPLER; CENTRAL HYPOVOLEMIA; HUMANS; VARIABILITY	Tzeng YC, Ainslie PN, Cooke WH, Peebles KC, Willie CK, MacRae BA, Smirl JD, Horsman HM, Rickards CA. Assessment of cerebral autoregulation: the quandary of quantification. Am J Physiol Heart Circ Physiol 303: H658-H671, 2012. First published July 20, 2012; doi:10.1152/ajpheart.00328.2012.-We assessed the convergent validity of commonly applied metrics of cerebral autoregulation (CA) to determine the extent to which the metrics can be used interchangeably. To examine between-subject relationships among low-frequency (LF; 0.07-0.2 Hz) and very-low-frequency (VLF; 0.02-0.07 Hz) transfer function coherence, phase, gain, and normalized gain, we performed retrospective transfer function analysis on spontaneous blood pressure and middle cerebral artery blood velocity recordings from 105 individuals. We characterized the relationships (n = 29) among spontaneous transfer function metrics and the rate of regulation index and autoregulatory index derived from bilateral thigh-cuff deflation tests. In addition, we analyzed data from subjects (n = 29) who underwent a repeated squat-to-stand protocol to determine the relationships between transfer function metrics during forced blood pressure fluctuations. Finally, data from subjects (n = 16) who underwent step changes in end-tidal PCO2 (PETCO2) were analyzed to determine whether transfer function metrics could reliably track the modulation of CA within individuals. CA metrics were generally unrelated or showed only weak to moderate correlations. Changes in PETCO2 were positively related to coherence [LF: beta = 0.0065 arbitrary units (AU)/mmHg and VLF: beta = 0.011 AU/mmHg, both P < 0.01] and inversely related to phase (LF: beta = -0.026 rad/mmHg and VLF: beta = -0.018 rad/mmHg, both P < 0.01) and normalized gain (LF: beta = -0.042%/mmHg(2) and VLF: beta = -0.013%/ mmHg(2), both P < 0.01). However, PETCO2 was positively associated with gain (LF: beta = 0.0070 cm.s(-1.)mmHg(-2), P < 0.05; and VLF: beta = 0.014 cm.s(-1).mmHg(-2), P < 0.01). Thus, during changes in PETCO2, LF phase was inversely related to LF gain (beta = -0.29 cm.s(-1).mmHg(-1).rad(-1), P < 0.01) but positively related to LF normalized gain (beta = 1.3% mmHg(-1)/rad, P < 0.01). These findings collectively suggest that only select CA metrics can be used interchangeably and that interpretation of these measures should be done cautiously.	[Tzeng, Y. C.; Peebles, K. C.; MacRae, B. A.; Horsman, H. M.] Univ Otago, Cardiovasc Syst Lab, Wellington, New Zealand; [Ainslie, P. N.; Willie, C. K.; Smirl, J. D.] Univ British Columbia, Sch Hlth & Exercise Sci, Kelowna, BC, Canada; [Cooke, W. H.; Rickards, C. A.] Univ Texas San Antonio, Dept Hlth & Kinesiol, San Antonio, TX USA		Tzeng, YC (corresponding author), Univ Otago, Cardiovasc Syst Lab, 23A Mein St,POB 7343, Wellington, New Zealand.	shieak.tzeng@otago.ac.nz		Smirl, Jonathan/0000-0003-1054-0038; MacRae, Braid/0000-0003-2077-3978; Rickards, Caroline/0000-0002-5759-6912; Peebles, Karen/0000-0002-9694-9127	New Zealand National Heart Foundation Grant [1284]; Health Research Council Grant [09/186]; United States Department of Defense Medical Research and Material Command Grant [W81XWH-11-2-0137]; Canada Research Chair and Natural Sciences and Engineering Council	The work was supported by New Zealand National Heart Foundation Grant 1284 and Health Research Council Grant 09/186, the United States Department of Defense Medical Research and Material Command Grant W81XWH-11-2-0137, and the Canada Research Chair and Natural Sciences and Engineering Council.	AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; Ainslie PN, 2008, BRAIN RES, V1230, P115, DOI 10.1016/j.brainres.2008.07.048; Ainslie PN, 2009, AM J PHYSIOL-REG I, V296, pR1473, DOI 10.1152/ajpregu.91008.2008; Aries MJH, 2010, STROKE, V41, P2697, DOI 10.1161/STROKEAHA.110.594168; Blockley NP, 2011, MAGN RESON MED, V65, P1278, DOI 10.1002/mrm.22719; Chacon M, 2008, PHYSIOL MEAS, V29, P1179, DOI 10.1088/0967-3334/29/10/003; Chan GSH, 2011, J APPL PHYSIOL, V110, P917, DOI 10.1152/japplphysiol.01407.2010; Claassen JAHR, 2009, J APPL PHYSIOL, V106, P153, DOI 10.1152/japplphysiol.90822.2008; Dawson SL, 2000, CEREBROVASC DIS, V10, P126, DOI 10.1159/000016041; Deegan BM, 2011, STROKE, V42, P1988, DOI 10.1161/STROKEAHA.110.605618; Edwards MR, 2002, AM J PHYSIOL-REG I, V283, pR653, DOI 10.1152/ajpregu.00452.2001; Elstad M, 2011, J HYPERTENS, V29, P1327, DOI 10.1097/HJH.0b013e328347a17a; Golding EM, 2002, BRAIN RES REV, V38, P377, DOI 10.1016/S0165-0173(02)00141-8; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; Gommer ED, 2008, PHYSIOL MEAS, V29, P1293, DOI 10.1088/0967-3334/29/11/005; Gommer ED, 2010, MED BIOL ENG COMPUT, V48, P1243, DOI 10.1007/s11517-010-0706-y; Hamner JW, 2010, STROKE, V41, P102, DOI 10.1161/STROKEAHA.109.557132; Hamner JW, 2004, J PHYSIOL-LONDON, V559, P965, DOI 10.1113/jphysiol.2004.066969; HOLM S, 1979, SCAND J STAT, V6, P65; KONTOS HA, 1978, AM J PHYSIOL, V234, pH371, DOI 10.1152/ajpheart.1978.234.4.H371; Kugler J, 1997, INT J CLIN MONIT COM, V14, P251, DOI 10.1023/A:1016927206619; La Rovere MT, 2001, CIRCULATION, V103, P2072; Lazic SE, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-5; Lewis Philip M, 1800, Acta Neurochir Suppl, V114, P141, DOI 10.1007/978-3-7091-0956-4_26; Lucas SJE, 2010, HYPERTENSION, V55, P698, DOI 10.1161/HYPERTENSIONAHA.109.146290; Mahony PJ, 2000, STROKE, V31, P476, DOI 10.1161/01.STR.31.2.476; Monson KL, 2008, ANN BIOMED ENG, V36, P2028, DOI 10.1007/s10439-008-9578-9; Nishimura N, 2010, J APPL PHYSIOL, V108, P1154, DOI 10.1152/japplphysiol.00656.2009; Ogoh S, 2008, STROKE, V39, P1979, DOI 10.1161/STROKEAHA.107.510008; Ogoh S, 2010, J PHYSIOL-LONDON, V588, P365, DOI 10.1113/jphysiol.2009.180844; Ogoh S, 2009, EXERC SPORT SCI REV, V37, P123, DOI 10.1097/JES.0b013e3181aa64d7; Panerai RB, 2010, J APPL PHYSIOL, V109, P1860, DOI 10.1152/japplphysiol.00857.2010; Panerai RB, 1999, PHYSIOL MEAS, V20, P265, DOI 10.1088/0967-3334/20/3/304; Panerai RB, 2008, CARDIOVASC ENG, V8, P42, DOI 10.1007/s10558-007-9044-6; Panerai RB, 2009, CLIN AUTON RES, V19, P197, DOI 10.1007/s10286-009-0011-8; Panerai RB, 2009, PHILOS T R SOC A, V367, P1319, DOI 10.1098/rsta.2008.0264; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; Pinna GD, 2002, CLIN SCI, V103, P81; Pinna GD, 2001, MED BIOL ENG COMPUT, V39, P338, DOI 10.1007/BF02345289; Reinhard M, 2003, PHYSIOL MEAS, V24, P27, DOI 10.1088/0967-3334/24/1/303; Romero SA, 2011, J APPL PHYSIOL, V110, P492, DOI 10.1152/japplphysiol.01060.2010; Rothwell PM, 2010, LANCET, V375, P938, DOI 10.1016/S0140-6736(10)60309-1; Ryan KL, 2011, J PHYSIOL-LONDON, V589, P5311, DOI 10.1113/jphysiol.2011.213074; Ryan KL, 2010, SHOCK, V33, P583, DOI 10.1097/SHK.0b013e3181cd8cbe; Serrador JM, 2000, STROKE, V31, P1672, DOI 10.1161/01.STR.31.7.1672; Slessarev M, 2007, J PHYSIOL-LONDON, V581, P1207, DOI 10.1113/jphysiol.2007.129395; Sorond FA, 2009, ULTRASOUND MED BIOL, V35, P21, DOI 10.1016/j.ultrasmedbio.2008.08.001; TIECKS FP, 1995, STROKE, V26, P1014, DOI 10.1161/01.STR.26.6.1014; TRIEDMAN JK, 1993, HYPERTENSION, V21, P236, DOI 10.1161/01.HYP.21.2.236; Tu YK, 2007, STAT MED, V26, P443, DOI 10.1002/sim.2538; Tzeng YC, 2011, J PHYSIOL-LONDON, V589, P3263, DOI 10.1113/jphysiol.2011.206953; Tzeng YC, 2010, J APPL PHYSIOL, V108, P1162, DOI 10.1152/japplphysiol.01390.2009; van Beek AHEA, 2010, ULTRASOUND MED BIOL, V36, P192, DOI 10.1016/j.ultrasmedbio.2009.10.011; Wilson TE, 2006, AM J PHYSIOL-REG I, V291, pR1443, DOI 10.1152/ajpregu.00712.2005; Zhang R, 1998, AM J PHYSIOL-HEART C, V274, pH233, DOI 10.1152/ajpheart.1998.274.1.H233; Zhang R, 2009, J PHYSIOL-LONDON, V587, P2567, DOI 10.1113/jphysiol.2008.168302	56	108	108	0	12	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0363-6135			AM J PHYSIOL-HEART C	Am. J. Physiol.-Heart Circul. Physiol.	SEP	2012	303	6					H658	H671		10.1152/ajpheart.00328.2012			14	Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology; Physiology	009AY	WOS:000308998900003	22821992				2022-02-06	
J	Dewan, Y; Komolafe, EO; Mejia-Mantilla, JH; Perel, P; Roberts, I; Shakur, H				Dewan, Yashbir; Komolafe, Edward O.; Mejia-Mantilla, Jorge H.; Perel, Pablo; Roberts, Ian; Shakur, Haleema		CRASH-3 Collaborators	CRASH-3-tranexamic acid for the treatment of significant traumatic brain injury: study protocol for an international randomized, double-blind, placebo-controlled trial	TRIALS			English	Article						Antifibrinolytic; Clinical trial; Emergency care; Intracranial bleeding; Tranexamic acid; Traumatic brain injury	CLINICAL-TRIALS; EDEMA FORMATION; HEMORRHAGE; EQUIPOISE	Background: Worldwide, over 10 million people are killed or hospitalized because of traumatic brain injury each year. About 90% of deaths occur in low- and middle-income countries. The condition mostly affects young adults, and many experience long lasting or permanent disability. The social and economic burden is considerable. Tranexamic acid (TXA) is commonly given to surgical patients to reduce bleeding and the need for blood transfusion. It has been shown to reduce the number of patients receiving a blood transfusion by about a third, reduces the volume of blood transfused by about one unit, and halves the need for further surgery to control bleeding in elective surgical patients. Methods/design: The CRASH-3 trial is an international, multicenter, pragmatic, randomized, double-blind, placebo-controlled trial to quantify the effects of the early administration of TXA on death and disability in patients with traumatic brain injury. Ten thousand adult patients who fulfil the eligibility criteria will be randomized to receive TXA or placebo. Adults with traumatic brain injury, who are within 8 h of injury and have any intracranial bleeding on computerized tomography (CT scan) or Glasgow Coma Score (GCS) of 12 or less can be included if the responsible doctor is substantially uncertain as to whether or not to use TXA in this patient. Patients with significant extracranial bleeding will be excluded since there is evidence that TXA improves outcome in these patients. Treatment will entail a 1 g loading dose followed by a 1 g maintenance dose over 8 h. The main analyses will be on an 'intention-to-treat' basis, irrespective of whether the allocated treatment was received. Results will be presented as appropriate effect estimates with a measure of precision (95% confidence intervals). Subgroup analyses for the primary outcome will be based on time from injury to randomization, the severity of the injury, location of the bleeding, and baseline risk. Interaction tests will be used to test whether the effect of treatment differs across these subgroups. A study with 10,000 patients will have approximately 90% power to detect a 15% relative reduction from 20% to 17% in all-cause mortality.	[Perel, Pablo; Roberts, Ian; Shakur, Haleema] Univ London London Sch Hyg & Trop Med, Clin Trials Unit, London WC1E 7HT, England; [Dewan, Yashbir] FLT Lt Rajan Dhall Fortis Hosp, Dept Neurosci, Delhi 110070, Ncr New Delhi, India; [Komolafe, Edward O.] Obafemi Awolowo Univ, Dept Surg, Ife 20022, Osun State, Nigeria; [Mejia-Mantilla, Jorge H.] Dept Anaesthesia & Resuscitat Fdn Valle del Lili, Cali, Colombia		Shakur, H (corresponding author), Univ London London Sch Hyg & Trop Med, Clin Trials Unit, Keppel St, London WC1E 7HT, England.	Haleema.Shakur@Lshtm.ac.uk	Dewan, Yashbir/C-6503-2013	Dewan, Yashbir/0000-0002-7154-1301; komolafe, edward/0000-0003-1261-3501; Shakur-Still, Haleema/0000-0002-6511-109X; /0000-0002-2342-301X			[Anonymous], 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d3795; Bayir A, 2006, NEUROL INDIA, V54, P363, DOI 10.4103/0028-3886.28106; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Edwards P, 2005, LANCET, V365, P1957; Figueroa BE, 1998, STROKE, V29, P1202, DOI 10.1161/01.STR.29.6.1202; FREEDMAN B, 1987, NEW ENGL J MED, V317, P141, DOI 10.1056/NEJM198707163170304; Gebel JM, 2002, STROKE, V33, P2636, DOI 10.1161/01.STR.0000035283.34109.EA; Guerriero C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018987; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; HAYBITTLE JL, 1971, BRIT J RADIOL, V44, P793, DOI 10.1259/0007-1285-44-526-793; Henry DA, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001886.pub4; HORROW JC, 1995, ANESTHESIOLOGY, V82, P383, DOI 10.1097/00000542-199502000-00009; Murray CJL., 1996, GLOBAL BURDEN DIS CO; Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Peden M., 2004, WORLD REPORT ROAD TR; Perel P, 2009, BMC EMERG MED, V9, DOI 10.1186/1471-227X-9-15; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; Peto R, 1998, BMJ-BRIT MED J, V317, P1170, DOI 10.1136/bmj.317.7167.1170; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Roberts I, 2011, LANCET, V377, P1096, DOI 10.1016/S0140-6736(11)60278-X; Roberts I, 2011, LANCET, V377, P1071, DOI 10.1016/S0140-6736(11)60317-6; Rubin DB, 2006, STAT SCI, V21, P299, DOI 10.1214/088342306000000114; Shakur H, 2010, LANCET, V376, P1051; Shakur H, 2010, LANCET, V376, P23, DOI 10.1016/S0140-6736(10)60835-5; Thiex R, 2004, EXP NEUROL, V189, P25, DOI 10.1016/j.expneurol.2004.05.021; Thiex R, 2003, NEUROL RES, V25, P254, DOI 10.1179/016164103101201463; Weijer C, 2000, BMJ-BRIT MED J, V321, P756, DOI 10.1136/bmj.321.7263.756; Yutthakasemsunt S, 2010, NAT NEUR S	29	108	112	0	11	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1745-6215		TRIALS	Trials	JUN 21	2012	13								87	10.1186/1745-6215-13-87			14	Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine	028VP	WOS:000310452600001	22721545	Green Published, gold			2022-02-06	
J	Byrnes, KR; Loane, DJ; Stoica, BA; Zhang, JY; Faden, AI				Byrnes, Kimberly R.; Loane, David J.; Stoica, Bogdan A.; Zhang, Jiangyang; Faden, Alan I.			Delayed mGluR5 activation limits neuroinflammation and neurodegeneration after traumatic brain injury	JOURNAL OF NEUROINFLAMMATION			English	Article						Traumatic brain injury; microglia; metabotropic glutamate receptor 5; delayed treatment; neuroprotection	METABOTROPIC GLUTAMATE RECEPTORS; AUTOMATED IMAGE REGISTRATION; CONTROLLED CORTICAL IMPACT; DIFFUSION-TENSOR; LONGITUDINAL CHANGES; PROGRESSIVE ATROPHY; NEURONAL APOPTOSIS; MICROGLIA; NEUROTOXICITY; INFLAMMATION	Background: Traumatic brain injury initiates biochemical processes that lead to secondary neurodegeneration. Imaging studies suggest that tissue loss may continue for months or years after traumatic brain injury in association with chronic microglial activation. Recently we found that metabotropic glutamate receptor 5 (mGluR5) activation by (RS)-2-chloro-5-hydroxyphenylglycine (CHPG) decreases microglial activation and release of associated pro-inflammatory factors in vitro, which is mediated in part through inhibition of reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase. Here we examined whether delayed CHPG administration reduces chronic neuroinflammation and associated neurodegeneration after experimental traumatic brain injury in mice. Methods: One month after controlled cortical impact traumatic brain injury, C57Bl/6 mice were randomly assigned to treatment with single dose intracerebroventricular CHPG, vehicle or CHPG plus a selective mGluR5 antagonist, 3(( 2-Methyl-4-thiazolyl)ethynyl) pyridine. Lesion volume, white matter tract integrity and neurological recovery were assessed over the following three months. Results: Traumatic brain injury resulted in mGluR5 expression in reactive microglia of the cortex and hippocampus at one month post-injury. Delayed CHPG treatment reduced expression of reactive microglia expressing NADPH oxidase subunits; decreased hippocampal neuronal loss; limited lesion progression, as measured by repeated T2-weighted magnetic resonance imaging (at one, two and three months) and white matter loss, as measured by high field ex vivo diffusion tensor imaging at four months; and significantly improved motor and cognitive recovery in comparison to the other treatment groups. Conclusion: Markedly delayed, single dose treatment with CHPG significantly improves functional recovery and limits lesion progression after experimental traumatic brain injury, likely in part through actions at mGluR5 receptors that modulate neuroinflammation.	[Byrnes, Kimberly R.; Loane, David J.; Stoica, Bogdan A.; Faden, Alan I.] Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20007 USA; [Byrnes, Kimberly R.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; [Loane, David J.; Stoica, Bogdan A.; Faden, Alan I.] Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; [Loane, David J.; Stoica, Bogdan A.; Faden, Alan I.] Univ Maryland, Sch Med, Ctr Shock Trauma & Anesthesiol Res STAR, Natl Study Ctr Trauma, Baltimore, MD 21201 USA; [Loane, David J.; Stoica, Bogdan A.; Faden, Alan I.] Univ Maryland, Sch Med, EMS, Baltimore, MD 21201 USA; [Zhang, Jiangyang] Johns Hopkins Univ, Dept Radiol, Baltimore, MD USA		Faden, AI (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20007 USA.	afaden@anes.umm.edu	Loane, David/ABD-5177-2021; STOICA, BOGDAN/H-9782-2013	Loane, David/0000-0003-0393-3503; STOICA, BOGDAN/0000-0002-2501-6434; Zhang, Jiangyang/0000-0003-0740-2662; Byrnes, Kimberly/0000-0002-7501-7734; Zhang, Jiangyang/0000-0003-4146-8163	NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5R01NS037313, NS NS059529]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037313, R21NS059529, R01NS052568] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG028747] Funding Source: NIH RePORTER	We would like to thank Nicole Hockenbury, Rainier Cabatbat, Kelly Wilson and Stephanie Custer for expert technical assistance. We thank Dr. Chunshu Piao for help with MRI analysis and Dr. Shruti Kabadi for helpful discussion. This work was supported by grants from the NIH/NINDS to AIF (5R01NS037313) and to JZ (NS NS059529).	Aggarwal M, 2009, NEUROSCIENCE, V162, P1339, DOI 10.1016/j.neuroscience.2009.05.070; Aggarwal M, 2010, MAGN RESON MED, V64, P249, DOI 10.1002/mrm.22426; Allen JW, 2000, CELL DEATH DIFFER, V7, P470, DOI 10.1038/sj.cdd.4400678; Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Bao WL, 2001, BRAIN RES, V922, P173, DOI 10.1016/S0006-8993(01)03062-1; Basser PJ, 1998, MAGNET RESON MED, V39, P928, DOI 10.1002/mrm.1910390610; BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Brody DL, 2006, EXP NEUROL, V197, P330, DOI 10.1016/j.expneurol.2005.10.020; Byrnes KR, 2009, ANN NEUROL, V66, P63, DOI 10.1002/ana.21673; Byrnes KR, 2009, NEUROTHERAPEUTICS, V6, P94, DOI 10.1016/j.nurt.2008.10.038; Byrnes KR, 2009, GLIA, V57, P550, DOI 10.1002/glia.20783; Byrnes KR, 2006, GLIA, V53, P420, DOI 10.1002/glia.20295; Chen H, 2011, NEUROBIOL DIS, V42, P341, DOI 10.1016/j.nbd.2011.01.027; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; DAVIS EJ, 1994, BRAIN RES BULL, V34, P73, DOI 10.1016/0361-9230(94)90189-9; Deng WB, 2004, P NATL ACAD SCI USA, V101, P7751, DOI 10.1073/pnas.0307850101; Drouin-Ouellet J, 2011, GLIA, V59, P188, DOI 10.1002/glia.21086; Eikelenboom P, 2002, GLIA, V40, P232, DOI 10.1002/glia.10146; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Frick KM, 2000, NEUROREPORT, V11, P3461, DOI 10.1097/00001756-200011090-00013; Gao HM, 2008, TRENDS IMMUNOL, V29, P357, DOI 10.1016/j.it.2008.05.002; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Jiang HY, 2006, COMPUT METH PROG BIO, V81, P106, DOI 10.1016/j.cmpb.2005.08.004; Kabadi SV, 2012, J CEREBR BLOOD F MET, V32, P137, DOI 10.1038/jcbfm.2011.117; Kabadi SV, 2012, J NEUROTRAUMA; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Loane DJ, 2009, J BIOL CHEM, V284, P15629, DOI 10.1074/jbc.M806139200; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Lynch MA, 2009, MOL NEUROBIOL, V40, P139, DOI 10.1007/s12035-009-8077-9; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Maxwell WL, 2006, J NEUROPATH EXP NEUR, V65, P478, DOI 10.1097/01.jnen.0000229241.28619.75; Menon DK, 2009, CRIT CARE MED, V37, pS129, DOI 10.1097/CCM.0b013e3181921225; Nagamoto-Combs K, 2007, J NEUROTRAUM, V24, P1719, DOI 10.1089/neu.2007.0377; Nicoletti E, 2011, NEUROPHARMACOLOGY, V60, P1017, DOI 10.1016/j.neuropharm.2010.10.022; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Qin LY, 2004, J BIOL CHEM, V279, P1415, DOI 10.1074/jbc.M307657200; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rodriguez-Paez AC, 2005, ACTA NEUROPATHOL, V109, P603, DOI 10.1007/s00401-005-1010-z; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Soltys Z, 2001, J NEUROSCI RES, V63, P90, DOI 10.1002/1097-4547(20010101)63:1<90::AID-JNR11>3.0.CO;2-9; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Trivedi MA, 2007, J NEUROTRAUM, V24, P766, DOI 10.1089/neu.2006.0205; Vilhardt F, 2005, INT J BIOCHEM CELL B, V37, P17, DOI 10.1016/j.biocel.2004.06.010; Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031; Wilson S, 2004, J NEUROTRAUM, V21, P239, DOI 10.1089/089771504322972031; Woods RP, 1998, J COMPUT ASSIST TOMO, V22, P139, DOI 10.1097/00004728-199801000-00027; Zhan XH, 2008, BRAIN RES, V1234, P183, DOI 10.1016/j.brainres.2008.07.094	60	108	108	1	11	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	FEB 28	2012	9								43	10.1186/1742-2094-9-43			15	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	917IT	WOS:000302168100001	22373400	Green Published, gold			2022-02-06	
J	Brady, KM; Mytar, JO; Lee, JK; Cameron, DE; Vricella, LA; Thompson, WR; Hogue, CW; Easley, RB				Brady, Ken M.; Mytar, Jennifer O.; Lee, Jennifer K.; Cameron, Duke E.; Vricella, Luca A.; Thompson, W. Reid; Hogue, Charles W.; Easley, R. Blaine			Monitoring Cerebral Blood Flow Pressure Autoregulation in Pediatric Patients During Cardiac Surgery	STROKE			English	Article						cerebrovascular pressure autoregulation; congenital heart disease; near-infrared spectroscopy; pediatrics	NEAR-INFRARED SPECTROSCOPY; CONGENITAL HEART-DISEASE; TRAUMATIC BRAIN INJURY; CARDIOPULMONARY BYPASS; PERFUSION-PRESSURE; REACTIVITY; OUTCOMES; CHILDREN	Background and Purpose-The limits of cerebral blood flow-pressure autoregulation have not been adequately defined for pediatric patients. Mean arterial blood pressure below these limits might contribute to brain injury during cardiac surgery. The purpose of this pilot study was to assess a novel method of determining the lower limits of pressure autoregulation in pediatric patients supported with cardiopulmonary bypass. Methods-A prospective, observational pilot study was conducted in children (n=54) undergoing cardiac surgery with cardiopulmonary bypass for correction of congenital heart defects. Cerebral oximetry index (COx) was calculated as a moving, linear correlation coefficient between slow waves of arterial blood pressure and cerebral oximetry measured with near-infrared spectroscopy. An autoregulation curve was constructed for each patient with averaged COx values sorted by arterial blood pressure. Results-Hypotension was associated with increased values of COx (P<0.0001). For 77% of patients, an individual estimate of lower limits of pressure autoregulation could be determined using a threshold COx value of 0.4. The mean lower limits of pressure autoregulation for the cohort using this method was 42 +/- 7 mm Hg. Conclusions-This pilot study of COx monitoring in pediatric patients demonstrates an association between hypotension during cardiopulmonary bypass and impairment of autoregulation. The COx may be useful to identify arterial blood pressure-dependent limits of cerebral autoregulation during cardiopulmonary bypass. Larger trials with neurological outcomes are indicated. (Stroke. 2010; 41:1957-1962.)	[Brady, Ken M.; Mytar, Jennifer O.; Lee, Jennifer K.; Hogue, Charles W.; Easley, R. Blaine] Johns Hopkins Univ Hosp, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21287 USA; [Cameron, Duke E.; Vricella, Luca A.] Johns Hopkins Univ Hosp, Div Cardiac Surg, Baltimore, MD 21287 USA; [Thompson, W. Reid] Johns Hopkins Univ Hosp, Div Pediat Cardiol, Baltimore, MD 21287 USA		Brady, KM (corresponding author), 600 N Wolfe St,Blalock 941, Baltimore, MD 21287 USA.	Kbrady5@jhmi.edu			Hartwell Foundation; Foundation for Anesthesia Education and Research; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL092259] Funding Source: NIH RePORTER	Supported by the Hartwell Foundation and the Foundation for Anesthesia Education and Research.	Bassan H, 2005, PEDIATR RES, V57, P35, DOI 10.1203/01.PDR.0000147576.84092.F9; Brady KM, 2008, STROKE, V39, P2531, DOI 10.1161/STROKEAHA.108.514877; Brady KM, 2007, STROKE, V38, P2818, DOI 10.1161/STROKEAHA.107.485706; Brady K, 2010, STROKE, V41, P1951, DOI 10.1161/STROKEAHA.109.575159; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka M, 1997, NEUROSURGERY, V41, P17; Czosnyka M, 2009, NEUROCRIT CARE, V10, P373, DOI 10.1007/s12028-008-9175-7; Galli KK, 2004, J THORAC CARDIOV SUR, V127, P692, DOI 10.1016/j.jtcvs.2003.09.053; Lee JK, 2009, STROKE, V40, P1820, DOI 10.1161/STROKEAHA.108.536094; Lemaire JJ, 2002, ACTA NEUROCHIR, V144, P243, DOI 10.1007/s007010200032; Lemeshow S, 2000, APPL LOGISTIC REGRES; LUNDBERG N, 1965, J NEUROSURG, V22, P581, DOI 10.3171/jns.1965.22.6.0581; Mahle WT, 2002, CIRCULATION, V106, pI109, DOI 10.1161/01.cir.0000032908.33237.b1; McKenzie ED, 2005, AM J SURG, V190, P289, DOI 10.1016/j.amjsurg.2005.05.029; Newburger JW, 2006, CIRCULATION, V113, P183, DOI 10.1161/CIRCULATIONAHA.105.594804; Pua HL, 1998, CAN J ANAESTH, V45, P960, DOI 10.1007/BF03012304; Schmoker JD, 2009, J THORAC CARDIOV SUR, V137, P459, DOI 10.1016/j.jtcvs.2008.08.022; Shillingford AJ, 2008, PEDIATRICS, V121, pE759, DOI 10.1542/peds.2007-1066; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Steiner LA, 2009, NEUROCRIT CARE, V10, P122, DOI 10.1007/s12028-008-9140-5; TAYLOR RH, 1992, ANESTH ANALG, V74, P636; Wernovsky G, 2005, CURR OPIN CARDIOL, V20, P94, DOI 10.1097/01.hco.0000153451.68212.68; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	24	108	109	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0039-2499			STROKE	Stroke	SEP	2010	41	9					1957	1962		10.1161/STROKEAHA.109.575167			6	Clinical Neurology; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Cardiovascular System & Cardiology	645YV	WOS:000281503000019	20651273	Bronze, Green Accepted			2022-02-06	
J	Fay, TB; Yeates, KO; Wade, SL; Drotar, D; Stancin, T; Taylor, HG				Fay, Taryn B.; Yeates, Keith Owen; Wade, Shari L.; Drotar, Dennis; Stancin, Terry; Taylor, H. Gerry			Predicting Longitudinal Patterns of Functional Deficits in Children With Traumatic Brain Injury	NEUROPSYCHOLOGY			English	Article						traumatic brain injury; children; functional deficits; outcomes	NEUROBEHAVIORAL SYMPTOMS; CLINICAL-SIGNIFICANCE; HEAD-INJURIES; SHORT-TERM; FAMILY; ADOLESCENTS; OUTCOMES; ACHIEVEMENT; PREVALENCE; SEVERITY	Longitudinal patterns of functional deficits were investigated in 37 children with severe traumatic brain injury (TBI), 40 children with moderate TBI, and 44 children with orthopedic injuries. They were from 6 to 12 years of age when injured. Their neuropsychological, behavioral, adaptive, and academic functioning were assessed at 6 months, 12 months, and 3-5 years postinjury. Functional deficits (<10th percentile for age) were identified within each outcome domain at each occasion. Children were classified into 4 a priori longitudinal patterns of outcomes within domains (i.e., no deficits, improvement, deterioration, persistent deficits). In multinomial logistic regression analyses, severe TBI predicted an increased likelihood of persistent deficits in all outcome domains, as well as deterioration in behavioral functioning and improvement in neuropsychological, adaptive, and academic functioning. Severe TBI also predicted a greater total number of functional deficits across domains at each occasion. However, many children with severe TBI showed no deficits from 6 months to 4 years postinjury in I or more outcome domains. The findings help clarify the course of recovery for individual children following TBI.	[Yeates, Keith Owen] Nationwide Childrens Hosp, Dept Psychol, Res Inst, Columbus, OH 43205 USA; [Fay, Taryn B.] Ohio State Univ, Dept Psychol, Columbus, OH 43210 USA; [Fay, Taryn B.; Yeates, Keith Owen] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Wade, Shari L.] Univ Cincinnati, Coll Med, Cincinnati, OH USA; [Wade, Shari L.] Cincinnati Childrens Hosp, Med Ctr, Dept Psychiat Med & Rehabil, Cincinnati, OH USA; [Drotar, Dennis; Stancin, Terry; Taylor, H. Gerry] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; [Drotar, Dennis; Taylor, H. Gerry] Rainbow Babies & Childrens Hosp, Dept Pediat, Cleveland, OH 44106 USA; [Stancin, Terry] Metrohlth Med Ctr, Dept Pediat, Cleveland, OH USA		Yeates, KO (corresponding author), Nationwide Childrens Hosp, Dept Psychol, Res Inst, 700 Childrens Dr, Columbus, OH 43205 USA.	keith.yeates@nationwidechildrens.org	Yeates, Keith/AAJ-4223-2020; Stancin, Terry/L-7993-2019	Yeates, Keith/0000-0001-7680-2892; Fay-McClymont, Taryn/0000-0002-2706-6179	National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS36335]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [MC-J-390611]; Maternal and Child Health Bureau (Tide V, Social Security Act, Health Resources and Services Administration, Department of Health and Human Services)United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA); NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000080] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS036335] Funding Source: NIH RePORTER	This work was supported by National Institute of Neurological Disorders and Stroke Grant NS36335, National Institutes of Health, and by Grant MC-J-390611, Maternal and Child Health Bureau (Tide V, Social Security Act, Health Resources and Services Administration, Department of Health and Human Services). We wish to acknowledge the contributions of Elizabeth Shaver, Barbara Shapero, Madeline Polonia, Marla Kemmerer, Matt Diamond, and Nichole Wood in data collection and coding. We also wish to acknowledge the participation of the Children's Hospital Medical Center of Akron and the collaboration of George Thompson, G. Dean Timmons, and Dennis Weiner. Assistance with recruitment was provided by the Rainbow Pediatric Trauma Center, Rainbow Babies & Children's Hospital, Columbus Children's Hospital Trauma Program, and MetroHealth Center Trauma Registry.	Achenbach TM, 1991, MANUAL CHILD BEHAV C; Anderson PJ., 2000, CLIN NEUROPSYCHOL AS, V1, P247; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Anderson VA, 2005, J NEUROL NEUROSUR PS, V76, P401, DOI 10.1136/jnnp.2003.019174; Barry CT, 1996, CHILD NEUROPSYCHOL, V2, P213, DOI 10.1080/09297049608402254; Bergman LR, 2006, MERRILL PALMER QUART, V52, P601, DOI 10.1353/mpq.2006.0023; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; Ciccetti D., 1984, VINELAND ADAPTIVE BE; Connell AM, 2006, MERRILL PALMER QUART, V52, P421, DOI 10.1353/mpq.2006.0025; Ewing-Cobbs L, 1998, J CLIN EXP NEUROPSYC, V20, P769, DOI 10.1076/jcen.20.6.769.1109; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Francis DJ, 2005, J LEARN DISABIL-US, V38, P98, DOI 10.1177/00222194050380020101; Golden CJ, 1991, LURIA NEBRASKA NEURO; HANNAY HJ, 2004, NEUROPSYCHOLOGICAL A, P133; Heaton RK, 1991, COMPREHENSIVE NORMS; Ingraham LJ, 1996, NEUROPSYCHOLOGY, V10, P120, DOI 10.1037/0894-4105.10.1.120; Jacobson NS, 1999, J CONSULT CLIN PSYCH, V67, P300, DOI 10.1037/0022-006X.67.3.300; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; KINSELLA G, 1995, J PEDIATR PSYCHOL, V20, P753, DOI 10.1093/jpepsy/20.6.753; Laursen B, 2006, MERRILL PALMER QUART, V52, P377, DOI 10.1353/mpq.2006.0029; LINDGREN S, 1984, PEDIAT ASSESSMENT CO; Magnusson D, 2003, NEW DIR CHILD ADOLES, V101, P3, DOI 10.1002/cd.79; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P125, DOI 10.1016/S0003-9993(96)90156-2; Masten AS, 2001, AM PSYCHOL, V56, P227, DOI 10.1037/0003-066X.56.3.227; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; MAYER T, 1980, J PEDIATR SURG, V15, P719, DOI 10.1016/S0022-3468(80)80271-5; MCDONALD CM, 1994, ARCH PHYS MED REHAB, V75, P328, DOI 10.1016/0003-9993(94)90038-8; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Moos RH, 1994, LIFE STRESSORS SOCIA; Muthen B, 2000, ALCOHOL CLIN EXP RES, V24, P882, DOI 10.1111/j.1530-0277.2000.tb02070.x; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; ROURKE BP, 1977, J ABNORM CHILD PSYCH, V5, P9, DOI 10.1007/BF00915756; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; SEMEL E, 1987, CELF R CLIN EVALUATI; Slick DJ, 2006, COMPENDIUM NEUROPSYC, P3; Spreen O, 1991, COMPENDIUM NEUROPSYC; Stancin T, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e34; STEVENS G, 1981, SOC SCI RES, V10, P364, DOI 10.1016/0049-089X(81)90011-9; STEVENSONHINDE J, 1995, FAM PROCESS, V34, P337, DOI 10.1111/j.1545-5300.1995.00337.x; Taylor HG, 1998, CHILD NEUROPSYCHOL, V4, P21, DOI 10.1076/chin.4.1.21.3188; Taylor HG, 2004, DEV NEUROPSYCHOL, V25, P199, DOI 10.1207/s15326942dn2501&2_11; Taylor HG, 2003, REHABIL PSYCHOL, V48, P227, DOI 10.1037/0090-5550.48.4.227; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TEASDALE G, 1974, LANCET, V2, P81; von Eye A, 2006, MERRILL PALMER QUART, V52, P390, DOI 10.1353/mpq.2006.0032; WECHSLER D, 1991, WISC 03 WECHSLER INT; YEATES KO, 1994, CLIN NEUROPSYCHOL, V8, P91, DOI 10.1080/13854049408401546; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514; Yeates KO, 1997, J CLIN EXP NEUROPSYC, V19, P825, DOI 10.1080/01688639708403763; Yeates KO, 2001, J PEDIATR PSYCHOL, V26, P79, DOI 10.1093/jpepsy/26.2.79; Yeates KO., 2006, EXCEPTIONALITY, V14, P141, DOI DOI 10.1207/S15327035EX1403_; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]	62	108	108	0	20	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	MAY	2009	23	3					271	282		10.1037/a0014936			12	Psychology, Clinical; Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	439XW	WOS:000265662000001	19413442	Green Accepted			2022-02-06	
J	Gosselin, N; Lassonde, M; Petit, D; Leclerc, S; Mongrain, V; Collie, A; Montplaisir, J				Gosselin, Nadia; Lassonde, Maryse; Petit, Dominique; Leclerc, Suzanne; Mongrain, Valerie; Collie, Alex; Montplaisir, Jacques			Sleep following sport-related concussions	SLEEP MEDICINE			English	Article						Concussion; Traumatic brain injury; Quantitative EEG; Sleep; Sport; Athletes; Delta activity; Spectral analysis	TRAUMATIC BRAIN-INJURY; MINOR HEAD-INJURY; SCHOOL FOOTBALL PLAYERS; POSTCONCUSSION SYNDROME; PATIENT COMPLAINTS; SECONDARY INSOMNIA; SPECTRAL-ANALYSIS; RISK-FACTORS; TIME-COURSE; EEG	Objectives: Sleep and vigilance disorders Lire among the most commonly reported symptoms following a concussion. The aim of the Study was thus to investigate the effects of sport-related concussions oil subjective and objective sleep quality. Methods: Ten concussed athletes and 11 non-concussed athletes were included. Concussed athletes had a history of 4.6 +/- 2.1 concussions with at least one concussion during the last year. They were recorded for two consecutive nights in the laboratory and during a 10-min period of wakefulness. They completed questionnaires related to sleep quality and symptoms as well as neuropsychological tests anti the CogSport computer battery. Results: Concussed athletes reported more symptoms and worse sleep quality than control athletes, but no between-group differences were found oil polysomnographic variables or on REM and NREM sleep quantitative EEG variables. However, concussed athletes showed significantly more delta activity and less alpha activity during wakefulness than did control athletes. Conclusion: In spite of the subjective complaints in sleep quality of concussed athletes, no change was observed in objective sleep characteristics. However, concussions were associated with,in increase in delta and a reduction in alpha power in the waking EEG. Sport-related concussions are thus associated with wakefulness problems rather than sleep disturbances. (C) 2007 Elsevier B.V. All rights reserved.	[Gosselin, Nadia; Petit, Dominique; Mongrain, Valerie; Montplaisir, Jacques] Hop Sacre Coeur, Res Ctr Sleep & Biol Rhythms, Montreal, PQ H4J 1C5, Canada; [Gosselin, Nadia; Lassonde, Maryse] Univ Montreal, Res Ctr Neuropsychol & Cognit, Montreal, PQ, Canada; [Leclerc, Suzanne; Mongrain, Valerie; Montplaisir, Jacques] Univ Montreal, Fac Med, Montreal, PQ H3C 3J7, Canada; [Collie, Alex] Univ Melbourne, Ctr Neurosci, Melbourne, Vic, Australia; [Collie, Alex] CogState Ltd, Melbourne, Vic, Australia		Montplaisir, J (corresponding author), Hop Sacre Coeur, Res Ctr Sleep & Biol Rhythms, 5400 Boul, Montreal, PQ H4J 1C5, Canada.	jy.montplaisir@umontreal.ca	Mongrain, Valerie/A-3931-2012	Collie, Alex/0000-0003-2617-9339	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Fonds pour la Recherche en Sante du QuebecFonds de la Recherche en Sante du Quebec; Natural Sciences and Engineering Research Council of CanadaNatural Sciences and Engineering Research Council of Canada (NSERC)CGIAR	This research was supported by the Canadian Institutes of Health Research (J.M. and N.G.), by the Fonds pour la Recherche en Sante du Quebec (M.L. and N.G.) and by the Natural Sciences and Engineering Research Council of Canada (V.M.). J.M. holds a Canada Research Chair in Sleep Disorders and M.L., a Canada Research Chair in Developmental Neuropsychology. The authors are grateful to Emmanuelle Baron, MD, Jimmy Gosselin, B.Sc., and Sylvie Rompre for their assistance.	Achermann P, 1995, ARCH ITAL BIOL, V134, P109; AESCHBACH D, 1993, J SLEEP RES, V2, P70, DOI 10.1111/j.1365-2869.1993.tb00065.x; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Beck AT., 1987, DEPRESSION INVENTORY; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; Besset A, 1998, ELECTROEN CLIN NEURO, V107, P122, DOI 10.1016/S0013-4694(98)00048-0; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; Collie A, 2006, BRIT J SPORT MED, V40, P550, DOI 10.1136/bjsm.2005.019802; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; De Gennaro L, 2004, PSYCHIAT RES, V128, P253, DOI 10.1016/j.psychres.2004.05.023; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Ferrara M, 2006, BEHAV BRAIN RES, V167, P237, DOI 10.1016/j.bbr.2005.09.012; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Guilleminault C, 2000, NEUROLOGY, V54, P653, DOI 10.1212/WNL.54.3.653; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; JENNETT B, 1975, LANCET, V1, P480; Jewett ME, 1999, J SLEEP RES, V8, P1, DOI 10.1111/j.1365-2869.1999.00128.x; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Kashluba S, 2004, ARCH CLIN NEUROPSYCH, V19, P805, DOI 10.1016/j.acn.2003.09.005; Kaufman Y, 2001, PEDIATR NEUROL, V24, P129, DOI 10.1016/S0887-8994(00)00254-X; Korn A, 2005, J CLIN NEUROPHYSIOL, V22, P1, DOI 10.1097/01.WNP.0000150973.24324.A7; Langburt W, 2001, J CHILD NEUROL, V16, P83, DOI 10.1177/088307380101600203; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Mongrain V, 2006, EUR J NEUROSCI, V23, P497, DOI 10.1111/j.1460-9568.2005.04561.x; Motulsky H.J., 2003, FITTING MODELS BIOLO; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Paniak C, 2002, ARCH CLIN NEUROPSYCH, V17, P319, DOI 10.1016/S0887-6177(01)00115-9; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; PARSONS LC, 1982, NURS RES, V31, P260; Parsons LC, 1997, J NEUROTRAUM, V14, P549, DOI 10.1089/neu.1997.14.549; Pellman E, 2004, NEUROSURGERY, V55, P860, DOI 10.1227/01.NEU.0000137657.00146.7D; Perlis ML, 2001, J SLEEP RES, V10, P93, DOI 10.1046/j.1365-2869.2001.00247.x; Perlis ML, 1997, PERCEPT MOTOR SKILL, V84, P595, DOI 10.2466/pms.1997.84.2.595; Perlis ML, 2001, SLEEP, V24, P110, DOI 10.1093/sleep/24.1.110; Rechtschaffen A., 1968, MANUAL STANDARDIZED; Schreiber S, 2008, SLEEP MED, V9, P481, DOI 10.1016/j.sleep.2007.04.014; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; TEBANO MT, 1988, ELECTROEN CLIN NEURO, V70, P185, DOI 10.1016/0013-4694(88)90118-6	48	108	111	3	35	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1389-9457	1878-5506		SLEEP MED	Sleep Med.	JAN	2009	10	1					35	46		10.1016/j.sleep.2007.11.023			12	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	407XN	WOS:000263397700008	18226956				2022-02-06	
J	Green, REA; Melo, B; Christensen, B; Ngo, LA; Monette, G; Bradbury, C				Green, Robin E. A.; Melo, Brenda; Christensen, Bruce; Ngo, Le-Anh; Monette, Georges; Bradbury, Cheryl			Measuring premorbid IQ in traumatic brain injury: An examination of the validity of the Wechsler Test of Adult Reading (WTAR)	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							WAIS-III; INTELLIGENCE; PERFORMANCE; INDEX; NART; DEMENTIA; SUBTEST	Estimation of premorbid IQ in traumatic brain injury (TBI) is clinically and scientifically valuable because it permits the quantification of the cognitive impact of injury. This is achieved by comparing performances on tests of current ability to estimates of premorbid IQ, thereby enabling current capacity to be interpreted in light of preinjury ability. However, the validity of premorbid IQ tests that are commonly used for TBI has been questioned. In the present study, we examined the psychometric properties of a recently developed test, the Wechsler Test of Adult Reading (WTAR), which has yet to be examined for TBI. The cognitive performance of a group of 24 patients recovering from TBI (with a mean Glasgow Coma Scale score in the severely impaired range) was measured at 2 and 5 months postinjury. On both occasions, patients were administered three tests that have been used to measure premorbid IQ (the WTAR and the Vocabulary and Matrix Reasoning subtests of the Wechsler Adult Intelligence Scale 3rd Edition, WAIS-III) and three tests of current ability (Symbol Digit Modalities Test-Oral and Similarities and Block Design subtests of the WAIS-III). We found that performance significantly improved on tests of current cognitive ability, confirming recovery. In contrast, stable performance was observed on the WTAR from Assessment 1 (M = 34.25/50) to Assessment 2 (M = 34.21/50; r = .970, p < .001). Mean improvement across assessments was negligible (t = -0.086, p = .47; Cohen's d = -0.005), and minimal individual participant change was observed (modal scaled score change = 0). WTAR scores were also highly similar to scores on a demographic estimate of premorbid IQ. Thus, converging evidence-high stability during recovery from TBI and similar IQ estimates to those of a demographic equation-suggests that the WTAR is a valid measure of premorbid IQ for TBI. Where word pronunciation tests are indicated (i.e., in patients for whom English is spoken and read fluently), these results endorse the use of the WTAR for patients with TBI.	[Green, Robin E. A.; Melo, Brenda; Ngo, Le-Anh; Bradbury, Cheryl] Univ Ctr, Toronto Rehabil Inst, Toronto, ON M5G 2A2, Canada; [Green, Robin E. A.] Univ Toronto, Dept Rehabil Sci, Toronto, ON, Canada; [Christensen, Bruce] McMaster Univ, Michael G DeGroote Sch Med, Dept Psychiat & Behav Neurosci, Hamilton, ON, Canada; [Monette, Georges] York Univ, Dept Math & Stat, Toronto, ON, Canada		Green, REA (corresponding author), Univ Ctr, Toronto Rehabil Inst, 550 Univ Ave, Toronto, ON M5G 2A2, Canada.	Green.Robin@Torontorehab.on.ca		Green, Robin/0000-0001-9451-3963			Baddeley A., 1992, SPEED CAPACITY LANGU; BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; Beck A., 1996, BECK DEPRESSION INVE, V78, P490; Bright P, 2002, J INT NEUROPSYCH SOC, V8, P847, DOI 10.1017/S1355617702860131; CIPOLOTTI L, 1995, J NEUROL NEUROSUR PS, V58, P655, DOI 10.1136/jnnp.58.6.655; Crawford JR, 1997, CLIN NEUROPSYCHOL, V11, P192, DOI 10.1080/13854049708407050; Crawford JR, 2001, PSYCHOL MED, V31, P451, DOI 10.1017/S0033291701003634; CRAWFORD JR, 1988, BRIT J PSYCHIAT, V153, P178, DOI 10.1192/bjp.153.2.178; Donders J, 2001, J INT NEUROPSYCH SOC, V7, P892, DOI 10.1017/S1355617701777132; Efron B., 1993, INTRO BOOTSTRAP; EPPINGER MG, 1987, J CONSULT CLIN PSYCH, V55, P86, DOI 10.1037/0022-006X.55.1.86; Freeman J, 2001, BRIT J CLIN PSYCHOL, V40, P221, DOI 10.1348/014466501163562; Gardner Howard, 1993, FRAMES MIND THEORY M; Hollingshead AB., 1975, 4 FACTOR INDEX SOCIA; Langeluddecke PM, 2004, CLIN NEUROPSYCHOL, V18, P423, DOI 10.1080/1385404049052422; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; McGurn B, 2004, NEUROLOGY, V62, P1184, DOI 10.1212/01.WNL.0000103169.80910.8B; Morris PG, 2005, BRIT J CLIN PSYCHOL, V44, P209, DOI 10.1348/014466505X34174; MOSS AR, 1991, BRIT J CLIN PSYCHOL, V30, P179, DOI 10.1111/j.2044-8260.1991.tb00934.x; NELSON HE, 1978, CORTEX, V14, P234, DOI 10.1016/S0010-9452(78)80049-5; Newson RS, 2005, J GERONTOL B-PSYCHOL, V60, pP113, DOI 10.1093/geronb/60.3.P113; REVEN JC, 1992, MANUAL REVENS PROGRE; Riley GA, 2003, BRIT J CLIN PSYCHOL, V42, P319, DOI 10.1348/01446650360703410; RUSSELL EW, 1980, PERCEPT MOTOR SKILL, V51, P121, DOI 10.2466/pms.1980.51.1.121; Ryan JJ, 2005, INT J NEUROSCI, V115, P129, DOI 10.1080/00207450490512704; Smith A, 1992, SYMBOL DIGIT MODALIT; SPEARMAN C, 2004, AM J PSYCHOL, V13, P671; Spreen O., 1989, CLIN NEUROPSYCHOL, V3, P129, DOI [10.1080/13854048908403285, DOI 10.1080/13854048908403285]; STERNBERG RJ, 1983, COGNITION, V15, P1, DOI 10.1016/0010-0277(83)90032-X; SWEET JJ, 1990, PSYCHOL ASSESSMENT J, V2, P41; TEASDALE G, 1974, LANCET, V2, P81; Tombaugh T.N., 1996, TEST MEMORY MALINGER; VANDERPLOEG RD, 1994, CLIN GUIDE NEUROPSYC; Watt KJ, 1999, J NEUROL NEUROSUR PS, V66, P474, DOI 10.1136/jnnp.66.4.474; Wechsler D., 2011, WECHSLER ABBREVIATED; Wechsler D., 1974, WECHSLER INTELLIGENC; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; WechslerD, 2001, WECHSLER TEST ADULT; Yuspeh RL, 1998, APPL NEUROPSYCHOL, V5, P149, DOI 10.1207/s15324826an0503_6	40	108	109	0	17	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	FEB	2008	30	2					163	172		10.1080/13803390701300524			10	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	264UY	WOS:000253317100005	18213530				2022-02-06	
J	Hesdorffer, DC; Ghajar, J				Hesdorffer, Dale C.; Ghajar, Jamshid			Marked improvement in adherence to traumatic brain injury guidelines in United States trauma centers	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						TBI; guidelines; US trauma centers	SEVERE HEAD-INJURY; CENTER DESIGNATION; CLINICAL PATHWAY; CENTER VOLUME; MANAGEMENT; CARE; MORTALITY; OUTCOMES; IMPACT; TRIAL	Background: Prior surveys of acute medical management of severe traumatic brain injury (TBI) indicate that care is fragmented and inconsistent, although Guidelines for the management of severe traumatic brain injury (guidelines) were distributed and endorsed by the American Association of Neurologic Surgeons. We conducted a survey of US trauma centers to evaluate guideline adherence, to examine predictors of adherence, and to compare our results with similar surveys conducted in 1991 and 2000. Methods: A Web-based survey was conducted in 413 designated trauma centers admitting patients with severe TBI. Good adherence was defined as adherence to the median number of guidelines (median = 6, interquartile range 5-7). Results: In adjusted analysis, good adherence was predicted by Level I trauma center designation and presence of treatment protocols. Compared with trauma centers without these predictive factors, the likelihood of good guideline adherence increased 2.4-fold with each additional predictor (95% confidence interval = 1.8-3.3). Routine intracranial pressure monitor use increased from 32.4% in 1991 and 50.8% in 2000 to 77.4% in the current survey (p < 0.0001). Avoidance of steroids in TBI rose from 47.8% in 1991 and 52.4% in 2000 to 86.0% in 2006 (p < 0.0001). Lack of guideline adherence decreased significantly from 67% in 2006 to 34.5%. Conclusions: Adherence to evidence-based guidelines for severe TBI has improved dramatically since 1991. Trauma center level and treatment protocols were associated with good adherence, suggesting that directing patients with severe TBI to Level I and Level II trauma centers with treatment protocols will improve outcome for these patients.	Columbia Univ, Gertrude H Sergievsky Ctr, New York, NY 10027 USA; Brain Trauma Foundat, New York, NY USA; Presbyterian Hosp, WeillCornell Med Ctr, Dept Neurosurg, New York, NY USA		Hesdorffer, DC (corresponding author), Columbia Univ, Sergievsky Ctr, 630 W 168th St,P&S Unit 16, New York, NY 10032 USA.	dch5@columbia.edu					*AMA, 1990, AMA OFF QUAL INS HLT; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Cabana MD, 1999, JAMA-J AM MED ASSOC, V282, P1458, DOI 10.1001/jama.282.15.1458; *CDC, 1997, MMWR-MORBID MORTAL W, V46, P8; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; COULDWELL WT, 2006, AM ASS NEUROLOGICAL, V15, P7; Demetriades D, 2006, J AM COLL SURGEONS, V202, P212, DOI 10.1016/j.jamcollsurg.2005.09.027; Demetriades D, 2005, ANN SURG, V242, P512, DOI 10.1097/01.sla.0000184169.73614.09; Demetriades D, 2006, J AM COLL SURGEONS, V202; Enblad P, 2004, INTENS CARE MED, V30, P1058, DOI 10.1007/s00134-004-2206-8; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; Glance LG, 2004, J TRAUMA, V56, P682, DOI 10.1097/01.TA.0000053469.92142.40; Hartl R, 2006, J TRAUMA, V60, P1250, DOI 10.1097/01.ta.0000203717.57821.8d; Hesdorffer DC, 2002, J TRAUMA, V52, P1202, DOI 10.1097/00005373-200206000-00031; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; London JA, 2003, J TRAUMA, V54, P16, DOI 10.1097/00005373-200301000-00003; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; MacKenzie EJ, 2003, JAMA-J AM MED ASSOC, V289, P1515, DOI 10.1001/jama.289.12.1515; Marion DW, 2000, CRIT CARE MED, V28, P16, DOI 10.1097/00003246-200001000-00003; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; Mcilvoy L, 2001, J Neurosci Nurs, V33, P72; Mcilvoy L, 2001, J NEUROSCI NURS, V32, P72, DOI DOI 10.1097/01376517-200104000-00002; McKinely BA, 1999, J TRAUMA, V46, P271, DOI 10.1097/00005373-199902000-00013; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; Nathens AB, 2001, JAMA-J AM MED ASSOC, V285, P1164, DOI 10.1001/jama.285.9.1164; *NIH, 1994, REP TASK FORC TRAUM; Palmer S, 2001, J TRAUMA, V50, P657, DOI 10.1097/00005373-200104000-00010; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Rosomoff HL, 1996, CRIT CARE MED, V24, pS48; Shackford SR, 1998, J TRAUMA, V44, P50, DOI 10.1097/00005373-199801000-00004; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Spain DA, 1998, J TRAUMA, V45, P101, DOI 10.1097/00005373-199807000-00022; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Valadka AB, 2001, NEUROSURGERY, V48, P17, DOI 10.1097/00006123-200101000-00004; Varelas PN, 2006, J NEUROSURG, V104, P713, DOI 10.3171/jns.2006.104.5.713; Vitaz TW, 2001, J TRAUMA, V51, P369, DOI 10.1097/00005373-200108000-00025	38	108	110	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	OCT	2007	63	4					841	847		10.1097/TA.0b013e318123fc21			7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	219XL	WOS:000250121400020	18090015				2022-02-06	
J	Haider, AH; Efron, DT; Haut, ER; DiRusso, SM; Sullivan, T; Cornwell, EE				Haider, Adil H.; Efron, David T.; Haut, Elliott R.; DiRusso, Stephen M.; Sullivan, Thomas; Cornwell, Edward E., III			Black children experience worse clinical and functional outcomes after traumatic brain injury: An analysis of the national pediatric trauma registry	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	65th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 28-30, 2006	New Orleans, LA	Amer Assoc Surg Trauma		racial disparities; pediatric traumatic brain injury; functional outcomes	RACIAL DISPARITIES; SEVERITY SCORE; MORTALITY; INDEPENDENCE	Background. Recent studies suggest racial disparities in the treatment and outcomes of children with traumatic brain injury (TBI). This study aims to identify race-based clinical and functional outcome differences among pediatric TBI patients in a national database. Methods: A total of 41,122 patients (ages 2-16 years) who were included in the National Pediatric Trauma Registry (from 1996-2001) were studied. TBI was categorized by Relative Head Injury Severity Score (RHISS) and patients with moderate to severe TBI were included. Individual race groups were compared with white as the majority group. Differences between races in functional outcomes at discharge in three domains-speech, locomotion, and feeding-were determined using multiple logistic regression. Cases were adjusted for age, sex, severity of head injury (using RHISS), severity of injury (using New Injury Severity Score and Pediatric Trauma Score), premorbidities, mechanism, and injury intent. Results: A total of 7,778 children had moderate or severe TBI with or without associated injuries. All races had similar demographics. Hispanics (n = 1,041) had outcomes comparable to whites (n = 4,762). Black children (n = 1,238) had significantly increased premorbidities, penetrating trauma, and violent intent. They also had higher unadjusted mortality and longer mean intensive care unit and floor stays. After adjustment, there was no difference in the odds of death between black and white children. However, black patients were more likely to be discharged to an inpatient rehabilitation facility and had increased odds of possessing a functional deficit at discharge for all three domains studied. Conclusion: Black children with traumatic brain injury have worse clinical and functional outcomes at discharge when compared with equivalently injured white children.	Johns Hopkins Sch Med, Dept Surg, Div Trauma, Baltimore, MD 21287 USA; New York Med Coll, Dept Surg, Valhalla, NY 10595 USA; St Barnabas Hosp, Dept Surg, Bronx, NY USA		Haider, AH (corresponding author), Johns Hopkins Sch Med, Dept Surg, Div Trauma, 600 N Wolfe St,Blalock 688, Baltimore, MD 21287 USA.	ahaider1@jhmi.edu	Haut, Elliott R./J-3948-2019	Haut, Elliott/0000-0001-7075-771X			Bazarian JJ, 2003, ACAD EMERG MED, V10, P1209, DOI 10.1197/S1069-6563(03)00491-3; DREXLER M, DISPARITIES BODY POL; Holbrook TL, 1999, J TRAUMA, V46, P765, DOI 10.1097/00005373-199905000-00003; *I MED NAT AC, 2002, UN TREATM CONFR RAC; Krause JS, 2006, J SPINAL CORD MED, V29, P17, DOI 10.1080/10790268.2006.11753852; McCarthy ML, 2002, ACAD EMERG MED, V9, P684; MSALL ME, 1994, CLIN PEDIATR, V33, P431, DOI 10.1177/000992289403300709; Msall ME., 1993, PHYS MED REH CLIN N, V4, P517; Osler T, 1997, J TRAUMA, V43, P922, DOI 10.1097/00005373-199712000-00009; Slover J, 2005, J PEDIATR ORTHOPED, V25, P717, DOI 10.1097/01.bpo.0000184835.79345.0e; Sperle PA, 1997, AM J OCCUP THER, V51, P35, DOI 10.5014/ajot.51.1.35; Sullivan T, 2003, J TRAUMA, V55, P1083, DOI 10.1097/01.TA.0000102175.58306.2A; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; TAN CP, 2004, N Z MED J, P117; TEPAS JJ, 1987, J PEDIATR SURG, V22, P14, DOI 10.1016/S0022-3468(87)80006-4; Wong MD, 2002, NEW ENGL J MED, V347, P1585, DOI 10.1056/NEJMsa012979	16	108	109	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAY	2007	62	5					1259	1262		10.1097/TA.0b013e31803c760e			4	Critical Care Medicine; Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	168OF	WOS:000246533200037	17495733				2022-02-06	
J	Wade, SL; Gerry Taylor, H; Yeates, KO; Drotar, D; Stancin, T; Minich, NM; Schluchter, M				Wade, Shari L.; Gerry Taylor, H.; Yeates, Keith Owen; Drotar, Dennis; Stancin, Terry; Minich, Nori M.; Schluchter, Mark			Long-term parental and family adaptation following pediatric brain injury	JOURNAL OF PEDIATRIC PSYCHOLOGY			English	Article						brain injury; family adaptation; stressors; support	CLOSED-HEAD-INJURY; ASSESSMENT DEVICE; TRAUMATIC INJURY; INITIAL YEAR; CHILDREN; PREDICTORS; RELIABILITY; VALIDITY; STRESSORS; CAREGIVER	Objective. To determine whether parents of children with traumatic brain injuries (TBI) report increased injury-related burden, distress, and family dysfunction and to examine the effects of attrition on the results. Methods. Children with severe TBI, moderate TBI, and orthopedic injuries were followed at six time points from baseline to 6 years after injury. Parents completed measures of injury-related burden, psychological distress, and family functioning at each assessment. Mixed model analysis was used to examine long-term changes. Results. Attrition was higher among families in the severe TBI group with lower burden thereby amplifying group differences. The severe TBI group reported higher injury-related burden over time after injury than the other groups. Family functioning was moderated by social resources. Families of children with severe TBI and low resources reporting deteriorating functioning over the follow-up interval. Conclusions. Although environmental advantages moderate long-term effects on family functioning, families of children with severe TBI experience long-standing injury-related burden.	Univ Cincinnati, Med Ctr, Cincinnati Childrens Hosp, Coll Med,Dept Pediat, Cincinnati, OH 45229 USA; Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, Dept Pediat, Sch Med, Cleveland, OH 44106 USA; Ohio State Univ, Columbus Childrens Hosp, Dept Pediat, Columbus, OH 43210 USA; Case Western Reserve Univ, Sch Med, Dept Pediat, MetroHlth Med Ctr, Cleveland, OH 44106 USA		Wade, SL (corresponding author), Univ Cincinnati, Med Ctr, Cincinnati Childrens Hosp, Coll Med,Dept Pediat, 333 Burnet Ave, Cincinnati, OH 45229 USA.	shari.wade@cchmc.org	Yeates, Keith/AAJ-4223-2020; Stancin, Terry/L-7993-2019	Yeates, Keith/0000-0001-7680-2892	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS036335] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS36335] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [MCJ-390611] Funding Source: Medline		BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Burgess ES, 1999, J HEAD TRAUMA REHAB, V14, P394, DOI 10.1097/00001199-199908000-00008; BYLES J, 1988, FAM PROCESS, V27, P97, DOI 10.1111/j.1545-5300.1988.00097.x; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; Derogatis LR., 1982, BRIEF SYMPTOM INVENT; Diggle PJ, 1994, ANAL LONGITUDINAL DA; Duncan GJ, 2000, CHILD DEV, V71, P188, DOI 10.1111/1467-8624.00133; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Folkman S., 1984, STRESS; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Hedeker D, 1997, PSYCHOL METHODS, V2, P64, DOI 10.1037/1082-989X.2.1.64; JENNETT B, 1975, LANCET, V1, P480; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Littell R.C., 1996, SAS SYSTEM MIXED MOD; Max JE, 1998, J AM ACAD CHILD PSY, V37, P83, DOI 10.1097/00004583-199801000-00021; MAYER T, 1980, J PEDIATR SURG, V15, P719, DOI 10.1016/S0022-3468(80)80271-5; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Miller W.R., 2002, MOTIVATIONAL INTERVI; Moos RH, 1994, LIFE STRESSORS SOCIA; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; Sander AM, 1997, BRAIN INJURY, V11, P235, DOI 10.1080/026990597123548; *SAS I I, 1990, STAT AN SYST VERS 6; Schafer JL, 1997, ANAL INCOMPLETE MULT; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Silverberg S. B., 1996, PARENTAL EXPERIENCE, P215; Singer JD, 1998, J EDUC BEHAV STAT, V23, P323; STEVENS G, 1981, SOC SCI RES, V10, P364, DOI 10.1016/0049-089X(81)90011-9; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Wade SL, 2005, J PEDIATR PSYCHOL, V30, P437, DOI 10.1093/jpepsy/jsi067; Wade SL, 2004, J CONSULT CLIN PSYCH, V72, P776, DOI 10.1037/0022-006X.72.5.776; Wade SL, 2002, J HEAD TRAUMA REHAB, V17, P96, DOI 10.1097/00001199-200204000-00003; Wade SL, 2001, J CONSULT CLIN PSYCH, V69, P406, DOI 10.1037//0022-006X.69.3.406; Wade SL, 1996, J LEARN DISABIL, V29, P652, DOI 10.1177/002221949602900609; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; Wallander JL, 1998, J CHILD PSYCHOL PSYC, V39, P29, DOI 10.1017/S0021963097001741; [No title captured]	40	108	108	0	8	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-8693			J PEDIATR PSYCHOL	J. Pediatr. Psychol.	NOV-DEC	2006	31	10					1072	1083		10.1093/jpepsy/jsj077			12	Psychology, Developmental	Social Science Citation Index (SSCI)	Psychology	104JU	WOS:000241955500007	16150875	Green Published, Bronze			2022-02-06	
J	Wade, SL; Carey, J; Wolfe, CR				Wade, Shari L.; Carey, JoAnne; Wolfe, Christopher R.			The efficacy of an online cognitive-behavioral family intervention in improving child behavior and social competence following pediatric brain injury	REHABILITATION PSYCHOLOGY			English	Article; Proceedings Paper	66th Annual Assembly of the American-Academy-for-Physical-Medicine-and-Rehabilitation	OCT 27-30, 2005	Philadelphia, PA	Amer Acad Phys Med & Rehabil		brain injury; telehealth; family; adaptation; problem solving	PROBLEM-SOLVING INTERVENTION; LONG-TERM OUTCOMES; ADOLESCENTS; RELIABILITY; MODERATOR; PIECES	Objective: To examine whether an online cognitive-behavioral intervention could improve child adjustment following traumatic brain injury (TBI). Participants: Thirty-nine families of children with moderate to severe TBI. Intervention: Families were randomly assigned to the online family problem-solving (FPS) group or to the Internet resources comparison (IRC) group. Main Outcome Measures: Outcomes included child behavior problems, social competence, and self-management/compliance. Results: The FPS group reported better child self-management/compliance at follow-up than did the IRC group. The child's age and socioeconomic status (SES) moderated treatment effects, with older children and those of lower SES who received FPS showing greater improvements in self-management and behavior problems, respectively. Conclusions: Findings suggest that an online cognitive-behavioral approach can improve child adjustment after TBI, particularly in older children and children of lower SES.	Childrens Hosp, Med Ctr, Div Phys Med & Rehabil, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Cincinnati, OH 45221 USA; Miami Univ, Sch Interdisciplinary Studies, Oxford, OH 45056 USA		Wade, SL (corresponding author), Childrens Hosp, Med Ctr, Div Phys Med & Rehabil, 3333 Burnet Ave,MLC 4009, Cincinnati, OH 45229 USA.	shari.wade@cchmc.org					Achenbach T. M., 2001, MANUAL ASEBA SCH AGE; Burgess ES, 1999, J HEAD TRAUMA REHAB, V14, P394, DOI 10.1097/00001199-199908000-00008; Cohen J., 2013, STAT POWER ANAL BEHA; EWINGCOBBS L, 1998, TRAUMATIC BRAIN INJU, P11; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FEENEY TJ, 1995, J HEAD TRAUMA REHAB, V10, P67; Feeney TJ, 2003, J HEAD TRAUMA REHAB, V18, P33, DOI 10.1097/00001199-200301000-00006; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Gurdin LS, 2005, BEHAV INTERVENT, V20, P3, DOI 10.1002/bin.172; Hauser RM, 1997, SOCIOL METHODOL, V27, P177, DOI 10.1111/1467-9531.271028; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; MCCLELLAND GH, 1993, PSYCHOL BULL, V114, P376, DOI 10.1037/0033-2909.114.2.376; Merrell KW, 2001, PSYCHOL SCHOOLS, V38, P313, DOI 10.1002/pits.1021; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Nezu AM, 1998, HELPING CANC PATIENT; OBRIEN RG, 1985, PSYCHOL BULL, V97, P316, DOI 10.1037/0033-2909.97.2.316; Ritterband LM, 2003, J CONSULT CLIN PSYCH, V71, P910, DOI 10.1037/0022-006X.71.5.910; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; Robin AL, 1989, NEGOTIATING PARENT A; Rotondi AJ, 2005, J HEAD TRAUMA REHAB, V20, P173, DOI 10.1097/00001199-200503000-00005; Selznick L, 2000, BEHAV INTERVENT, V15, P243, DOI 10.1002/1099-078X(200007/09)15:3<243::AID-BIN59>3.3.CO;2-T; Sohlberg MM, 1998, APHASIOLOGY, V12, P1047, DOI 10.1080/02687039808249469; Suzman KB, 1997, J BEHAV THER EXP PSY, V28, P203, DOI 10.1016/S0005-7916(97)00023-2; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; Wade SL, 2006, J HEAD TRAUMA REHAB, V21, P57, DOI 10.1097/00001199-200601000-00006; Wade SL, 2005, J PEDIATR PSYCHOL, V30, P437, DOI 10.1093/jpepsy/jsi067; Wade SL, 2005, REHABIL PSYCHOL, V50, P337, DOI 10.1037/0090-5550.50.4.337; Wade SL, 2004, BEHAV RES METH INS C, V36, P261, DOI 10.3758/BF03195572; Wade SL, 2002, J HEAD TRAUMA REHAB, V17, P96, DOI 10.1097/00001199-200204000-00003; WADE SL, IN PRESS J CONSULTIN; WADE SL, 2006, TREATING NEURODEVELO, P170; Yeates KO, 2002, J PEDIATR PSYCHOL, V27, P393, DOI 10.1093/jpepsy/27.4.393; Ylvisaker M., 1998, COLLABORATIVE BRAIN	37	108	108	1	22	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	AUG	2006	51	3					179	189		10.1037/0090-5550.51.3.179			11	Psychology, Clinical; Rehabilitation	Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH)	Psychology; Rehabilitation	072OK	WOS:000239682500001					2022-02-06	
J	Witting, A; Chen, LF; Cudaback, E; Straiker, A; Walter, L; Rickman, B; Moller, T; Brosnan, C; Stella, N				Witting, A; Chen, LF; Cudaback, E; Straiker, A; Walter, L; Rickman, B; Moller, T; Brosnan, C; Stella, N			Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotection	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						cannabinoid; microglia; purinergic; multiple sclerosis	MULTIPLE-SCLEROSIS MODEL; FOCAL CEREBRAL-ISCHEMIA; CANNABINOID RECEPTORS; CONTROL SPASTICITY; EXTRACELLULAR ATP; GLIAL-CELLS; VIRAL MODEL; SPINAL-CORD; SYSTEM; P2X(7)	Focal cerebral ischemia and traumatic brain injury induce an escalating amount of cell death because of harmful mediators diffusing from the original lesion site. Evidence suggests that healthy cells surrounding these lesions attempt to protect themselves by producing endocannabinoids (eCBs) and activating cannabinoid receptors, the molecular target for marijuana-derived compounds. Indeed, activation of cannabinoid receptors reduces the production and diffusion of harmful mediators. Here, we provide evidence that an exception to this pattern is found in experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis. We show that cell damage induced by EAE does not lead to increase in eCBs, even though cannabinoid receptors are functional because synthetic cannabinoid agonists are known to confine EAE-induced lesions. This lack of eCB increase is likely due to IFN-gamma, which is released by primed T cells invading the CNS. We show that IFN-gamma disrupts the functionality of purinergic P2X(7) receptors, a key step controlling eCB production by microglia, the main source of eCBs in brain. Accordingly, induction of EAE in P2X(7)(-/-) mice results in even lower eCB levels and more pronounced cell damage than in wild-type mice. Our data suggest that the high level of CNS IFN-gamma associated with EAE disrupts eCB-mediated neuroprotection while maintaining functional cannabinoid receptors, thus providing additional support for the use of cannabinoid-based medicine to treat multiple sclerosis.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA; Univ Washington, Dept Comparat Med, Seattle, WA 98195 USA; Univ Washington, Dept Neurol, Seattle, WA 98195 USA; Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; Univ Washington, Inst Stem Cell & Regenerat med, Seattle, WA 98195 USA; Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA		Stella, N (corresponding author), Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA.	nstella@u.washington.edu	Chen, Lanfen/B-7975-2016	Chen, Lanfen/0000-0002-9413-1284; Walter, Lisa/0000-0003-3421-2362			Arevalo-Martin A, 2003, J NEUROSCI, V23, P2511; Baker D, 2001, FASEB J, V15, P300, DOI 10.1096/fj.00-0399fje; Baker D, 2000, NATURE, V404, P84, DOI 10.1038/35003583; Bianco F, 2005, BRAIN RES REV, V48, P144, DOI 10.1016/j.brainresrev.2004.12.004; Bisogno T, 2003, J CELL BIOL, V163, P463, DOI 10.1083/jcb.200305129; Cabranes A, 2005, NEUROBIOL DIS, V20, P207, DOI 10.1016/j.nbd.2005.03.002; Croxford JL, 2003, J CLIN INVEST, V111, P1231, DOI 10.1172/JCI200317652; Ferrer B, 2003, EUR J NEUROSCI, V18, P1607, DOI 10.1046/j.1460-9568.2003.02896.x; Franklin A, 2003, J NEUROSCI, V23, P7767; Freund TF, 2003, PHYSIOL REV, V83, P1017, DOI 10.1152/physrev.00004.2003; Juedes AE, 2000, J IMMUNOL, V164, P419, DOI 10.4049/jimmunol.164.1.419; Klegeris A, 2003, BRIT J PHARMACOL, V139, P775, DOI 10.1038/sj.bjp.0705304; Labasi JM, 2002, J IMMUNOL, V168, P6436, DOI 10.4049/jimmunol.168.12.6436; Le Feuvre R, 2002, EUR J PHARMACOL, V447, P261, DOI 10.1016/S0014-2999(02)01848-4; Marsicano G, 2003, SCIENCE, V302, P84, DOI 10.1126/science.1088208; Mestre L, 2005, J NEUROCHEM, V92, P1327, DOI 10.1111/j.1471-4159.2004.02979.x; Nagayama T, 1999, J NEUROSCI, V19, P2987; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Parmentier-Batteur S, 2002, J NEUROSCI, V22, P9771, DOI 10.1523/jneurosci.22-22-09771.2002; Pertwee RG, 2002, PHARMACOL THERAPEUT, V95, P165, DOI 10.1016/S0163-7258(02)00255-3; Pryce G, 2005, TRENDS NEUROSCI, V28, P272, DOI 10.1016/j.tins.2005.03.006; Stella N, 2004, GLIA, V48, P267, DOI 10.1002/glia.20084; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Wallace MJ, 2003, J PHARMACOL EXP THER, V307, P129, DOI 10.1124/jpet.103.051920; Walter L, 2003, J NEUROSCI, V23, P1398, DOI 10.1523/JNEUROSCI.23-04-01398.2003; Wang XH, 2004, NAT MED, V10, P821, DOI 10.1038/nm1082; Witting A, 2004, J NEUROCHEM, V89, P1555, DOI 10.1111/j.1471-4159.2004.02544.x; Witting A, 2004, P NATL ACAD SCI USA, V101, P3214, DOI 10.1073/pnas.0306707101	28	108	112	0	4	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	APR 18	2006	103	16					6362	6367		10.1073/pnas.0510418103			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	035KF	WOS:000236999000055	16571660	Bronze, Green Published			2022-02-06	
J	Park, JH; Gimbel, DA; GrandPre, T; Lee, JK; Kim, JE; Li, WW; Lee, DHS; Strittmatter, SM				Park, JH; Gimbel, DA; GrandPre, T; Lee, JK; Kim, JE; Li, WW; Lee, DHS; Strittmatter, SM			Alzheimer precursor protein interaction with the Nogo-66 receptor reduces amyloid-beta plaque deposition	JOURNAL OF NEUROSCIENCE			English	Article						Alzheimer's disease; beta-amyloid plaque; Nogo; transgenic mice; Nogo-66 receptor; gene targeting; amyloid precursor protein; APP	NICOTINIC ACETYLCHOLINE-RECEPTOR; AXON REGENERATION; NEURITE OUTGROWTH; RECOVERY; DISEASE; MYELIN; INHIBITION; OLIGOMERS; BINDS; BETA-AMYLOID(1-42)	Pathophysiologic hypotheses for Alzheimer's disease (AD) are centered on the role of the amyloid plaque A beta peptide and the mechanism of its derivation from the amyloid precursor protein (APP). As part of the disease process, an aberrant axonal sprouting response is known to occur near A beta deposits. A Nogo to Nogo-66 receptor (NgR) pathway contributes to determining the ability of adult CNS axons to extend after traumatic injuries. Here, we consider the potential role of NgR mechanisms in AD. Both Nogo and NgR are mislocalized in AD brain samples. APP physically associates with the NgR. Overexpression of NgR decreases A beta production in neuroblastoma culture, and targeted disruption of NgR expression increases transgenic mouse brain A beta levels, A beta plaque deposition, and dystrophic neurites. Infusion of a soluble NgR fragment reduces A beta levels, amyloid plaque deposits, and dystrophic neurites in a mouse transgenic AD model. Changes in NgR level produce parallel changes in secreted APP alpha and A beta, implicating NgR as a blocker of secretase processing of APP. The NgR provides a novel site for modifying the course of AD and highlights the role of axonal dysfunction in the disease.	Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA; Biogen Idec Inc, Cambridge, MA 02140 USA		Strittmatter, SM (corresponding author), Yale Univ, Sch Med, Dept Neurol, POB 208018, New Haven, CT 06510 USA.	stephen.strittmatter@yale.edu	Strittmatter, Stephen/F-5739-2011; Kim, Jean Jieun/G-5774-2018	Strittmatter, Stephen/0000-0001-8188-3092; Kim, Jean Jieun/0000-0003-4709-262X; Park, James/0000-0002-1377-1707	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS056485, R01 NS056485-04, R01 NS042304-08, R01 NS039962, R37 NS033020-17, R37 NS033020, R01 NS042304, R01 NS039962-10] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R37NS033020, R01NS039962, R01NS042304, R01NS056485] Funding Source: NIH RePORTER		Borchelt DR, 1997, NEURON, V19, P939, DOI 10.1016/S0896-6273(00)80974-5; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; Dineley KT, 2001, J NEUROSCI, V21, P4125, DOI 10.1523/JNEUROSCI.21-12-04125.2001; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; Fournier AE, 2002, J NEUROSCI, V22, P8876; Fournier AE, 2001, NATURE, V409, P341, DOI 10.1038/35053072; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; GrandPre T, 2002, NATURE, V417, P547, DOI 10.1038/417547a; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; He WX, 2004, NAT MED, V10, P959, DOI 10.1038/nm1088; Jankowsky JL, 2003, J NEUROPATH EXP NEUR, V62, P1220, DOI 10.1093/jnen/62.12.1220; Kamal A, 2001, NATURE, V414, P643, DOI 10.1038/414643a; Kamenetz F, 2003, NEURON, V37, P925, DOI 10.1016/S0896-6273(03)00124-7; Kim JE, 2003, NEURON, V38, P187, DOI 10.1016/S0896-6273(03)00147-8; Kim JE, 2004, NEURON, V44, P439, DOI 10.1016/j.neuron.2004.10.015; Klein WL, 2002, NEUROCHEM INT, V41, P345, DOI 10.1016/S0197-0186(02)00050-5; Kuner P, 1998, J NEUROSCI RES, V54, P798, DOI 10.1002/(SICI)1097-4547(19981215)54:6<798::AID-JNR7>3.3.CO;2-K; Lazarov O, 2002, J NEUROSCI, V22, P9785; Lee JK, 2004, J NEUROSCI, V24, P6209, DOI 10.1523/JNEUROSCI.1643-04.2004; Li SX, 2003, J NEUROSCI, V23, P4219; Li SX, 2004, J NEUROSCI, V24, P10511, DOI 10.1523/JNEUROSCI.2828-04.2004; Lombardo JA, 2003, J NEUROSCI, V23, P10879, DOI 10.1523/jneurosci.23-34-10879.2003; McGee AW, 2003, TRENDS NEUROSCI, V26, P193, DOI 10.1016/S0166-2236(03)00062-6; Nagele RG, 2002, NEUROSCIENCE, V110, P199, DOI 10.1016/S0306-4522(01)00460-2; OTSUKA N, 1991, BRAIN RES, V568, P335, DOI 10.1016/0006-8993(91)91422-W; Prinjha R, 2000, NATURE, V403, P383, DOI 10.1038/35000287; SCOTT JN, 1991, MOL BRAIN RES, V10, P315, DOI 10.1016/0169-328X(91)90090-K; Selkoe DJ, 2003, ANNU REV PHARMACOL, V43, P545, DOI 10.1146/annurev.pharmtox.43.100901.140248; Sheng JG, 2002, J NEUROSCI, V22, P9794; Thinakaran G, 1996, J BIOL CHEM, V271, P9390, DOI 10.1074/jbc.271.16.9390; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Walsh DM, 2002, BIOCHEM SOC T, V30, P552, DOI 10.1042/BST0300552; Wang HY, 2000, J BIOL CHEM, V275, P5626, DOI 10.1074/jbc.275.8.5626; Wang XX, 2002, J NEUROSCI, V22, P5505; Yang XJ, 1996, P NATL ACAD SCI USA, V93, P475, DOI 10.1073/pnas.93.1.475	36	108	114	0	4	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474	1529-2401		J NEUROSCI	J. Neurosci.	FEB 1	2006	26	5					1386	1395		10.1523/JNEUROSCI.3291-05.2006			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	008MC	WOS:000235043800007	16452662	Green Accepted, Green Published, Bronze			2022-02-06	
J	Delaney, A; Bagshaw, SM; Ferland, A; Manns, B; Laupland, KB; Doig, CJ				Delaney, A; Bagshaw, SM; Ferland, A; Manns, B; Laupland, KB; Doig, CJ			A systematic evaluation of the quality of meta-analyses in the critical care literature	CRITICAL CARE			English	Article							RANDOMIZED CONTROLLED-TRIALS; EVIDENCE-BASED MEDICINE; TRAUMATIC BRAIN-INJURY; CRITICAL-APPRAISAL; ILL PATIENTS; REVIEWS; HYPOTHERMIA; STATEMENT; ARTICLES; ALBUMIN	Introduction Meta-analyses have been suggested to be the highest form of evidence available to clinicians to guide clinical practice in critical care. The purpose of this study was to systematically evaluate the quality of meta-analyses that address topics pertinent to critical care. Methods To identify potentially eligible meta-analyses for inclusion, a systematic search of Medline, EMBASE and the Cochrane Database of Systematic Reviews was undertaken, using broad search terms relevant to intensive care, including: intensive care, critical care, shock, resuscitation, inotropes and mechanical ventilation. Predetermined inclusion criteria were applied to each identified meta-analysis independently by two authors. To assess report quality, the included meta-analyses were assessed using the component and overall scores from the Overview Quality Assessment Questionnaire (OQAQ). The quality of reports published before and after the publication of the QUOROM statement was compared. Results A total of 139 reports of meta-analyses were included ( kappa = 0.93). The overall quality of reports of meta-analyses was found to be poor, with an estimated mean overall OQAQ score of 3.3 (95% CI; 3.0 - 3.6). Only 43 (30.9%) were scored as having minimal or minor flaws (> 5). We noted problems with the reporting of key characteristics of meta-analyses, such as performing a thorough literature search, avoidance of bias in the inclusion of studies and appropriately referring to the validity of the included studies. After the release of the QUOROM statement, however, an improvement in the overall quality of published meta-analyses was noted. Conclusion The overall quality of the reports of meta-analyses available to critical care physicians is poor. Physicians should critically evaluate these studies prior to considering applying the results of these studies in their clinical practice.	Royal N Shore Hosp, Dept Intens Care Med, Sydney, NSW, Australia; Univ Calgary, Dept Crit Care Med, Calgary, AB, Canada; Univ Calgary, Dept Med, Calgary, AB, Canada; Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada		Delaney, A (corresponding author), Royal N Shore Hosp, Dept Intens Care Med, Sydney, NSW, Australia.	adelaney@med.usyd.edu.au	Manns, Braden J/I-8942-2012; Doig, Christopher/AAC-7949-2020; Laupland, Kevin/AAG-3656-2020; Delaney, Anthony/AAE-3365-2019; Laupland, kevin/AAJ-6339-2020	Doig, Christopher/0000-0002-8576-9139; Laupland, kevin/0000-0002-1205-5354			ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; Cappelleri JC, 1996, JAMA-J AM MED ASSOC, V276, P1332, DOI 10.1001/jama.276.16.1332; Celermajer DS, 2001, MED J AUSTRALIA, V174, P293, DOI 10.5694/j.1326-5377.2001.tb143274.x; Choi PTL, 2001, ANESTH ANALG, V92, P700; Cook D, 1998, NEW ENGL J MED, V338, P791, DOI 10.1056/NEJM199803193381203; Cook DJ, 1996, CRIT CARE MED, V24, P1757, DOI 10.1097/00003246-199610000-00026; Cook DJ, 1996, JAMA-J AM MED ASSOC, V275, P308, DOI 10.1001/jama.275.4.308; Dixon E, 2005, ANN SURG, V241, P450, DOI 10.1097/01.sla.0000154258.30305.df; Egger M, 1997, BMJ-BRIT MED J, V315, P1371, DOI 10.1136/bmj.315.7119.1371; Finfer S, 2004, NEW ENGL J MED, V350, P2247; Flather MD, 1997, CONTROL CLIN TRIALS, V18, P568, DOI 10.1016/S0197-2456(97)00024-X; Guyatt GH, 2000, JAMA-J AM MED ASSOC, V284, P1290, DOI 10.1001/jama.284.10.1290; Henderson WR, 2003, INTENS CARE MED, V29, P1637, DOI 10.1007/s00134-003-1848-2; Hunt DL, 1997, ANN INTERN MED, V126, P532, DOI 10.7326/0003-4819-126-7-199704010-00006; Jadad AR, 1997, CAN MED ASSOC J, V156, P1411; Kelly KD, 2001, ANN EMERG MED, V38, P518, DOI 10.1067/mem.2001.115881; LeLorier J, 1997, NEW ENGL J MED, V337, P536, DOI 10.1056/NEJM199708213370806; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1992, DOI 10.1001/jama.285.15.1992; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; MULROW CD, 1987, ANN INTERN MED, V106, P485, DOI 10.7326/0003-4819-106-3-485; OXMAN AD, 1991, J CLIN EPIDEMIOL, V44, P1271, DOI 10.1016/0895-4356(91)90160-B; OXMAN AD, 1991, J CLIN EPIDEMIOL, V44, P91, DOI 10.1016/0895-4356(91)90205-N; Roberts I, 1998, BMJ-BRIT MED J, V317, P235; Shojania K G, 2001, Eff Clin Pract, V4, P157; VILLAR J, 1995, LANCET, V345, P772, DOI 10.1016/S0140-6736(95)90646-0	26	108	114	0	6	BIOMED CENTRAL LTD	LONDON	MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND	1466-609X			CRIT CARE	Crit. Care	OCT	2005	9	5					R575	R582		10.1186/cc3803			8	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	976JE	WOS:000232728800036	16277721	Green Published, gold			2022-02-06	
J	Mihalik, JP; Stump, JE; Collins, MW; Lovell, MR; Field, M; Maroon, JC				Mihalik, JP; Stump, JE; Collins, MW; Lovell, MR; Field, M; Maroon, JC			Posttraumatic migraine characteristics in athletes following sports-related concussion	JOURNAL OF NEUROSURGERY			English	Article						concussion; headache; ImPACT; neuropsychological testing; mild traumatic brain injury; high-school athlete	COLLEGIATE FOOTBALL PLAYERS; HIGH-SCHOOL; HEAD-INJURY; UNITED-STATES; MILD; EPIDEMIOLOGY; RECOVERY; PATHOGENESIS; PERFORMANCE; SEVERITY	Object. The object of this study was to compare symptom status and neurocognitive functioning in athletes with no headache (non-HA group), athletes complaining of headache (HA group), and athletes with characteristics of posttraumatic migraine (PTM group). Methods. Neurocognitive tests were undertaken by 261 high-school and collegiate athletes with a mean age of 16.36 +/- 2.6 years. Athletes were separated into three groups: the PTM group (74 athletes with a mean age of 16.39 +/- 3.06 years), the HA group (124 athletes with a mean age of 16.44 +/- 2.51 years), and the non-HA group (63 patients with a mean age of 16.14 +/- 2.18 years). Neurocognitive summary scores (outcome measures) for verbal and visual memory, visual motor speed, reaction time, and total symptom scores were collected using ImPACT, a computer software program designed to assess sports-related concussion. Significant differences existed among the three groups for all outcome measures. The PTM group demonstrated significantly greater neurocognitive deficits when compared with the HA and non-HA groups. The PTM group also exhibited the greatest amount of departure from baseline scores. Conclusions. The differences among these groups can be used as a basis to argue that PTM characteristics triggered by sports-related concussion are related to increased neurocognitive dysfunction following mild traumatic brain injury. Thus, athletes suffering a concussion accompanied by PTM should be examined in a setting that includes symptom status and neurocognitive testing to address their recovery more fully. Given the increased impairments observed in the PTM group, in this population clinicians should exercise increased caution in decisions about treatment and when the athlete should be allowed to return to play.	Univ Pittsburgh, Sch Hlth & Rehabil Sci, Ctr Med, Dept Sports Med & Nutr,Dept Orthopaed Surg, Pittsburgh, PA USA; Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA USA; Univ N Carolina, Sch Med, Dept Allied Hlth Sci, Chapel Hill, NC USA; Florida Hosp, Inst Neurosci, Dept Neurosurg, Orlando, FL USA; Ctr Sports Related Craniospinal Injuries, Orlando, FL USA		Lovell, MR (corresponding author), Univ Pittsburgh, Ctr Med, Sports Med Concuss Program, 3200 S Water St, Pittsburgh, PA 15203 USA.	lovellmr@upmc.edu	Mihalik, Jason P/E-7059-2010	Mihalik, Jason/0000-0001-6085-8322			Amer Assoc Study Headache, 1998, HEADACHE, V38, P736; BROWN SJ, 1994, J NEUROPSYCH CLIN N, V6, P15; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; DENNYBRO.D, 1973, BRAIN, V96, P783, DOI 10.1093/brain/96.4.783; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Gilkey SJ, 1997, HEADACHE, V37, P583, DOI 10.1046/j.1526-4610.1997.3709583.x; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Haas David C., 1993, P629; Haas DC, 1996, CEPHALALGIA, V16, P486, DOI 10.1046/j.1468-2982.1996.1607486.x; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Johnston KM, 2001, CLIN J SPORT MED, V11, P166, DOI 10.1097/00042752-200107000-00007; KATZ RT, 1992, AM FAM PHYSICIAN, V46, P1491; LARSSON LI, 1976, BRAIN RES, V113, P400, DOI 10.1016/0006-8993(76)90951-3; LAURITZEN M, 1994, BRAIN, V117, P199, DOI 10.1093/brain/117.1.199; Leclerc S, 2001, SPORTS MED, V31, P629, DOI 10.2165/00007256-200131080-00007; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; MANDEL S, 1989, POSTGRAD MED, V85, P213; Margulies S, 2000, J CLIN NEUROSCI, V7, P495, DOI 10.1054/jocn.1999.0773; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; Packard RC, 1999, J HEAD TRAUMA REHAB, V14, P9, DOI 10.1097/00001199-199902000-00004; Packard RC, 1997, HEADACHE, V37, P142, DOI 10.1046/j.1526-4610.1997.3703142.x; PERNOW B, 1983, PHARMACOL REV, V35, P85; Soloman S, 1998, HEADACHE, V38, P772, DOI 10.1046/j.1526-4610.1998.3810772.x; Sosin DM, 1996, BRAIN INJURY, V10, P47; SPEED WG, 1986, PRACTICING PHYSICIAN, P113; TAYLOR AR, 1966, LANCET, V2, P178; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Triplett G, 1996, PERCEPT MOTOR SKILL, V83, P1344, DOI 10.2466/pms.1996.83.3f.1344; WEISS HD, 1991, HEADACHE, V31, P451, DOI 10.1111/j.1526-4610.1991.hed3107451.x; YAMAGUCHI M, 1992, HEADACHE, V32, P427, DOI 10.1111/j.1526-4610.1992.hed3209427.x	44	108	108	1	12	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAY	2005	102	5					850	855		10.3171/jns.2005.102.5.0850			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Surgery	954KO	WOS:000231154200008	15926709				2022-02-06	
J	Yang, LQ; Jones, NR; Blumbergs, PC; Van Den Heuvel, C; Moore, EJ; Manavis, J; Sarvestani, GT; Ghabriel, MN				Yang, LQ; Jones, NR; Blumbergs, PC; Van Den Heuvel, C; Moore, EJ; Manavis, J; Sarvestani, GT; Ghabriel, MN			Severity-dependent expression of pro-inflammatory cytokines in traumatic spinal cord injury in the rat	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						interleukin-1b; interleukin-6; tumour necrosis factor-a; traumatic spinal cord injury; microglia; inflammatory response	TUMOR-NECROSIS-FACTOR; CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL BRAIN-INJURY; FACTOR-ALPHA; MESSENGER-RNA; GROWTH-FACTOR; CELLULAR-LOCALIZATION; CEREBROSPINAL-FLUID; MICROGLIA; INTERLEUKIN-6	The post-traumatic inflammatory response in acute spinal cord contusion injury was studied in the rat. Mild and severe spinal cord injury (SCI) was produced by dropping a 10 g weight from 3 and 12 cm at the T12 vertebral level. Increased immunoreactivity of TNF-a in mild and severe SCI was detected in neurons at 1 h post-injury, and in neurons and microglia. at 6 h post-injury, with a less significant increase in mild SCL Expression was short-lived and declined sharply by 1 d post-injury. RT-PCR showed an early significant up-regulation of IL-1b, IL-6 and TNF-a mRNAs, maximal at 6 h post-injury with return to control levels by 24 h post-injury, the changes being less statistically significantly in mild SCI. Western blot showed early transient increases of IL-1b, IL-6 and TNF-a proteins in severe SCI but not mild SCI. Immunocytochemical, western blotting and RT-PCR analyses suggest that endogenous cells (neurons and microglia) in the spinal cord, not blood-borne leucocytes, contribute to IL-1b, IL-6 and TNF-a production in the post-traumatic inflammatory response and that their up-regulation is greater in severe than mild SCI. (c) 2005 Elsevier Ltd. All rights reserved.	Univ Adelaide, Dept Surg Neurosurg, Adelaide, SA 5005, Australia; Univ Adelaide, Dept Pathol, Adelaide, SA 5005, Australia; Univ Adelaide, Dept Anat Sci, Adelaide, SA 5005, Australia; Inst Med & Vet Sci, Neuropathol Lab, Adelaide, SA 5000, Australia; Inst Med & Vet Sci, Div Haematol, Adelaide, SA 5000, Australia		Yang, LQ (corresponding author), Royal Adelaide Hosp, Dept Neurosurg, Level 5 McEwin Bldg, Adelaide, SA 5000, Australia.	Yangliqun98@hotmail.com		, Corinna/0000-0003-0664-8935			ALOISI F, 1992, J IMMUNOL, V149, P2358; Bartholdi D, 1997, EUR J NEUROSCI, V9, P1422, DOI 10.1111/j.1460-9568.1997.tb01497.x; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; BERRY M, 1997, GREENFIELDS NEUROPAT, P78; BLIGHT AR, 1992, J NEUROTRAUM, V9, pS83; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; DICKSON DW, 1997, TXB NEUROPATHOLOGY, P165; Dinarello Charles A., 1998, P35; DSOUZA S, 1995, J NEUROSCI, V15, P7293; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; Geddes JF, 1997, NEUROPATH APPL NEURO, V23, P339, DOI 10.1046/j.1365-2990.1997.4498044.x; GIULIAN D, 1989, J NEUROSCI, V9, P4416; Graeber M.B., 2002, GREENFIELDS NEUROPAT, P158; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; Gruol DL, 1997, MOL NEUROBIOL, V15, P307, DOI 10.1007/BF02740665; Hans VHJ, 1999, J CEREBR BLOOD F MET, V19, P184, DOI 10.1097/00004647-199902000-00010; Hayashi M, 2000, J NEUROTRAUM, V17, P203, DOI 10.1089/neu.2000.17.203; Hirano Toshio, 1998, P197; Ito T, 1997, ACTA NEUROPATHOL, V93, P13; Kingston R, 1990, CURRENT PROTOCOLS MO; Klusman I, 1997, BRAIN RES, V762, P173, DOI 10.1016/S0006-8993(97)00381-8; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; LEES GJ, 1993, J NEUROL SCI, V114, P119, DOI 10.1016/0022-510X(93)90285-7; MCLAURIN J, 1995, INT J DEV NEUROSCI, V13, P369, DOI 10.1016/0736-5748(95)00012-6; MEANS ED, 1983, J NEUROPATH EXP NEUR, V42, P707, DOI 10.1097/00005072-198311000-00009; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; MOCCHETTI I, 1995, J NEUROTRAUM, V12, P853, DOI 10.1089/neu.1995.12.853; Moore S, 1996, PROG NEUROBIOL, V48, P441, DOI 10.1016/0301-0082(95)00051-8; Oehmichen M, 1999, ACTA NEUROPATHOL, V97, P491, DOI 10.1007/s004010051018; POVLISHOCK JT, 1985, LAB INVEST, V52, P540; Prewitt CMF, 1997, EXP NEUROL, V148, P433, DOI 10.1006/exnr.1997.6694; Probert L, 1997, J NEUROIMMUNOL, V72, P137, DOI 10.1016/S0165-5728(96)00184-1; PSHENICHKIN SP, 1994, J NEUROCHEM, V63, P419; RAGHUPATHI R, 1995, BRAIN PATHOL, V5, P437, DOI 10.1111/j.1750-3639.1995.tb00622.x; REDFORD EJ, 1995, BRAIN, V118, P869, DOI 10.1093/brain/118.4.869; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; Sanderson KL, 1999, J CEREBR BLOOD F MET, V19, P1118, DOI 10.1097/00004647-199910000-00008; SAWADA M, 1992, BRAIN RES, V583, P296, DOI 10.1016/S0006-8993(10)80037-X; Schnell L, 1999, J NEUROPATH EXP NEUR, V58, P245, DOI 10.1097/00005072-199903000-00004; SCHWARTZ M, 1991, BRAIN RES, V545, P334, DOI 10.1016/0006-8993(91)91309-O; SempleRowland SL, 1995, J NEUROTRAUM, V12, P1003, DOI 10.1089/neu.1995.12.1003; Streit WJ, 1998, EXP NEUROL, V152, P74, DOI 10.1006/exnr.1998.6835; SUTHERLAND JC, 1987, ANAL BIOCHEM, V163, P446, DOI 10.1016/0003-2697(87)90247-8; TALLEY AK, 1995, MOL CELL BIOL, V15, P2359; Taoka Y, 1998, PROG NEUROBIOL, V56, P341, DOI 10.1016/S0301-0082(98)00049-5; Taoka Y, 2000, J NEUROTRAUM, V17, P219, DOI 10.1089/neu.2000.17.219; Taoka Y, 1997, CRIT CARE MED, V25, P874, DOI 10.1097/00003246-199705000-00026; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Tuna M, 2001, J NEUROSURG, V95, P64, DOI 10.3171/spi.2001.95.1.0064; Tzeng SF, 1999, GLIA, V26, P139, DOI 10.1002/(SICI)1098-1136(199904)26:2<139::AID-GLIA5>3.0.CO;2-1; Vallieres L, 1997, J NEUROCHEM, V69, P1668, DOI 10.1046/j.1471-4159.1997.69041668.x; Wagner JA, 1996, J EXP MED, V183, P2417, DOI 10.1084/jem.183.6.2417; Wang CX, 1996, J NEUROIMMUNOL, V69, P151; Watanabe D, 1996, EUR J NEUROSCI, V8, P1630, DOI 10.1111/j.1460-9568.1996.tb01307.x; WOOD PL, 1995, NEUROL RES, V17, P242, DOI 10.1080/01616412.1995.11740321; Xu J, 1998, MOL BRAIN RES, V59, P135, DOI 10.1016/S0169-328X(98)00142-9; Xu J, 2001, J NEUROSCI, V21, P92, DOI 10.1523/JNEUROSCI.21-01-00092.2001; Yan P, 2001, J NEUROTRAUM, V18, P563, DOI 10.1089/089771501300227369; Yang LQ, 2004, SPINE, V29, P966, DOI 10.1097/00007632-200405010-00004; YOSHIDA K, 1992, BRAIN RES, V569, P14, DOI 10.1016/0006-8993(92)90364-F; Young Wise, 1993, Journal of Emergency Medicine, V11, P13; Zhang Minghuang, 1998, P517	64	108	113	0	11	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0967-5868	1532-2653		J CLIN NEUROSCI	J. Clin. Neurosci.	APR	2005	12	3					276	284		10.1016/j.jocn.2004.06.011			9	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	929YU	WOS:000229383400015	15851082				2022-02-06	
J	Scott, GS; Cuzzocrea, S; Genovese, T; Koprowski, H; Hooper, DC				Scott, GS; Cuzzocrea, S; Genovese, T; Koprowski, H; Hooper, DC			Uric acid protects against secondary damage after spinal cord injury	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						blood-brain barrier; neutrophils; peroxynitrite; spinal cord neurons; cytotoxicity	EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; CENTRAL-NERVOUS-SYSTEM; INFLAMMATORY CELL INVASION; TRAUMATIC BRAIN-INJURY; MULTIPLE-SCLEROSIS; POLY(ADP-RIBOSE) POLYMERASE; PEROXYNITRITE SCAVENGER; PARKINSONS-DISEASE; PERMEABILITY CHANGES; ALZHEIMERS-DISEASE	Peroxynitrite contributes to the pathogenesis of various neurodegenerative disorders through multiple mechanisms and is thought to mediate secondary neuronal cell death after spinal cord injury (SCI). Here we establish that physiologically relevant levels of uric acid (UA), a selective inhibitor of certain peroxynitrite-mediated reactions, block the toxic effects of peroxynitrite on primary spinal cord neurons in vitro. Furthermore, administration of UA at the onset of SCI in a mouse model inhibits several pathological changes in the spinal cord including general tissue damage, nitrotyrosine formation, lipid peroxidation, activation of poly(ADP-ribose) polymerase, and neutrophil invasion. More importantly, UA treatment improves functional recovery from the injury. Taken together, our findings support the concept that peroxynitrite contributes to the pathophysiology of secondary damage after SCI. They also raise the possibility that elevating UA levels may provide a therapeutic approach for the treatment of SCI as well as other neurological diseases with a peroxynitrite-mediated pathological component.	Thomas Jefferson Univ, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA; Univ Messina, Policlin Univ, Sch Med, Dept Clin & Expt Med & Pharmacol, I-98100 Messina, Italy		Hooper, DC (corresponding author), Thomas Jefferson Univ, Dept Microbiol & Immunol, 1020 Locust St, Philadelphia, PA 19107 USA.	douglas.hooper@jefferson.edu		GENOVESE, Tiziana/0000-0002-3335-7327; Hooper, Douglas/0000-0002-8578-5104			Amar AP, 1999, NEUROSURGERY, V44, P1027, DOI 10.1097/00006123-199905000-00052; ANDERSON DK, 1993, ANN EMERG MED, V22, P987, DOI 10.1016/S0196-0644(05)82739-8; Bao F, 2004, J NEUROCHEM, V88, P1335, DOI 10.1046/j.1471-4159.2003.02240.x; Bao F, 2002, NEUROSCIENCE, V115, P839, DOI 10.1016/S0306-4522(02)00506-7; BOLANOS JP, 1995, J NEUROCHEM, V64, P1965; BRAUGHLER JM, 1992, J NEUROTRAUMA, V9, P1; Burkle A, 2001, BIOESSAYS, V23, P795, DOI 10.1002/bies.1115; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; CHURCH WH, 1994, BRAIN RES BULL, V33, P419, DOI 10.1016/0361-9230(94)90285-2; Cookson MR, 1998, J NEUROCHEM, V70, P501; Cuzzocrea S, 2004, EUR J PHARMACOL, V483, P79, DOI 10.1016/j.ejphar.2003.10.056; Davis JW, 1996, AM J EPIDEMIOL, V144, P480, DOI 10.1093/oxfordjournals.aje.a008954; Diaz-Ruiz A, 1999, NEUROSCI LETT, V266, P61, DOI 10.1016/S0304-3940(99)00255-4; Drulovic J, 2001, J NEUROL, V248, P121, DOI 10.1007/s004150170246; HOLTZ A, 1992, Neurological Research, V14, P49; Hooper DC, 1998, P NATL ACAD SCI USA, V95, P675, DOI 10.1073/pnas.95.2.675; Hooper DC, 2000, FASEB J, V14, P691, DOI 10.1096/fasebj.14.5.691; Hooper DC, 1997, P NATL ACAD SCI USA, V94, P2528, DOI 10.1073/pnas.94.6.2528; Hooper DC, 2001, J IMMUNOL, V167, P3470, DOI 10.4049/jimmunol.167.6.3470; Joosten EAJ, 2004, NEUROREPORT, V15, P1163, DOI 10.1097/00001756-200405190-00016; Joshi M, 2002, J NEUROTRAUM, V19, P175, DOI 10.1089/08977150252806947; Kastenbauer S, 2001, EUR J PHARMACOL, V425, P149, DOI 10.1016/S0014-2999(01)01137-2; Kean RB, 2000, J IMMUNOL, V165, P6511, DOI 10.4049/jimmunol.165.11.6511; Koprowski H, 2001, ANN NEUROL, V49, P139, DOI 10.1002/1531-8249(200101)49:1<139::AID-ANA28>3.0.CO;2-A; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; Liu DX, 2000, J NEUROCHEM, V75, P2144, DOI 10.1046/j.1471-4159.2000.0752144.x; MAESAKA JK, 1993, J AM GERIATR SOC, V41, P501, DOI 10.1111/j.1532-5415.1993.tb01885.x; MULLANE KM, 1985, J PHARMACOL METHOD, V14, P157, DOI 10.1016/0160-5402(85)90029-4; Muraoka S, 2003, PHARMACOL TOXICOL, V93, P284, DOI 10.1111/j.1600-0773.2003.pto930606.x; Nakazawa H, 2000, FREE RADICAL RES, V33, P771, DOI 10.1080/10715760000301291; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; Pearse DD, 2003, J NEUROPATH EXP NEUR, V62, P1096, DOI 10.1093/jnen/62.11.1096; Popovich PG, 1996, EXP NEUROL, V142, P258, DOI 10.1006/exnr.1996.0196; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Rinaldi P, 2003, NEUROBIOL AGING, V24, P915, DOI 10.1016/S0197-4580(03)00031-9; Santos CXC, 1999, ARCH BIOCHEM BIOPHYS, V372, P285, DOI 10.1006/abbi.1999.1491; Scott GS, 2002, P NATL ACAD SCI USA, V99, P16303, DOI 10.1073/pnas.212645999; Scott GS, 2004, J NEUROTRAUM, V21, P1255, DOI 10.1089/neu.2004.21.1255; Scott GS, 1999, ANN NEUROL, V45, P120, DOI 10.1002/1531-8249(199901)45:1<120::AID-ART18>3.0.CO;2-I; Scott GS, 2004, J NEUROIMMUNOL, V155, P32, DOI 10.1016/j.jneuroim.2004.05.011; Scott GS, 2003, GLIA, V41, P105, DOI 10.1002/glia.10137; Skaper SD, 2003, ANN NY ACAD SCI, V993, P217, DOI 10.1111/j.1749-6632.2003.tb07532.x; Spitsin S, 2001, MULT SCLER, V7, P165, DOI 10.1191/135245801678438384; Spitsin SV, 2000, NEUROSCI LETT, V292, P137, DOI 10.1016/S0304-3940(00)01446-4; Spitsin SV, 2002, FREE RADICAL BIO MED, V33, P1363, DOI 10.1016/S0891-5849(02)01048-1; Squadrito GL, 2000, ARCH BIOCHEM BIOPHYS, V376, P333, DOI 10.1006/abbi.2000.1721; Szabo C, 2003, TOXICOL LETT, V140, P105, DOI 10.1016/S0378-4274(02)00507-6; Taoka Y, 1997, NEUROSCIENCE, V79, P1177, DOI 10.1016/S0306-4522(97)00011-0; Terwel D, 2000, EUR J PHARMACOL, V400, P19, DOI 10.1016/S0014-2999(00)00379-4; Toborek M, 1999, J NEUROCHEM, V73, P684, DOI 10.1046/j.1471-4159.1999.0730684.x; TOHGI H, 1993, J NEURAL TRANSM-PARK, V6, P119, DOI 10.1007/BF02261005; TONEV G, 2002, EUR J NEUROL, V9, P221; Whalen MJ, 2000, ACT NEUR S, V76, P61; Whetstone WD, 2003, J NEUROSCI RES, V74, P227, DOI 10.1002/jnr.10759; Whiteman M, 2002, ANN NY ACAD SCI, V962, P242, DOI 10.1111/j.1749-6632.2002.tb04072.x; WU XW, 1992, J MOL EVOL, V34, P78, DOI 10.1007/BF00163854; Xu J, 2001, J NEUROTRAUM, V18, P523, DOI 10.1089/089771501300227323; YELDANDI AV, 1991, GENE, V109, P281, DOI 10.1016/0378-1119(91)90622-I; Yu ZF, 1998, J NEUROSCI RES, V53, P613, DOI 10.1002/(SICI)1097-4547(19980901)53:5<613::AID-JNR11>3.0.CO;2-1	59	108	117	0	5	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	MAR 1	2005	102	9					3483	3488		10.1073/pnas.0500307102			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	903KC	WOS:000227423700057	15728348	Green Published, Bronze			2022-02-06	
J	Andreasen, JO; Andreasen, FM; Mejare, I; Cvek, M				Andreasen, JO; Andreasen, FM; Mejare, I; Cvek, M			Healing of 400 intra-alveolar root fractures. 1. Effect of pre-injury and injury factors such as sex, age, stage of root development, fracture type, location of fracture and severity of dislocation	DENTAL TRAUMATOLOGY			English	Article						root fractures; pulp healing; periodontal healing; sex; age; stage of root development; fracture type; location of fracture; severity of dislocation	PERMANENT ANTERIOR TEETH; DENTAL INJURIES; PROGNOSIS; INCISORS; CHILDREN	This retrospective study consisted of 400 root-fractured, splinted or non-splinted incisors in young individuals aged 7-17 years (mean = 11.5 +/- 2.7 SD) who were treated in the period 1959-1995 at the Department of Pediatric Dentistry, Eastman Dental Institute, Stockholm. Four hundred of these root fractures were diagnosed at the time of injury; and 344 teeth were splinted with either cap-splints, orthodontic appliances, bonded metal wires, proximal bonding with composite resin or bonding with a Kevlar(R) or glass fiber splint. In 56 teeth, no splinting was carried out for various reasons. In the present study, only pre-injury and injury factors were analyzed. In a second study, treatment variables will be analyzed. The average observation period was 3.1 years +/- 2.6 SD. The clinical and radiographic findings showed that 120 teeth out of 400 teeth (30%) had healed by hard tissue fusion of the fragments. Interposition of periodontal ligament (PDL) and bone between fragments was found in 22 teeth (5%), whereas interposition of PDL alone was found in 170 teeth (43%). Finally, non-healing, with pulp necrosis and inflammatory changes between fragments, was seen in 88 teeth (22%). In a univariate and multivariate stratified analysis, a series of clinical factors were analyzed for their relation to the healing outcome with respect to pulp healing vs. pulp necrosis and type of healing (hard tissue vs. interposition of bone and/or PDL or pulp necrosis). Young age, immature root formation and positive pulp sensibility at the time of injury were found to be significantly and positively related to both pulpal healing and hard tissue repair of the fracture. The same applied to concussion or subluxation (i.e. no displacement) of the coronal fragment compared to extrusion or lateral luxation (i.e. displacement). Furthermore, no mobility vs. mobility of the coronal fragment. Healing was progressively worsened with increased millimeter diastasis between fragments. Sex was a significant factor, as girls showed more frequent hard tissue healing than boys. This relationship could possibly be explained by the fact that girls experienced trauma at an earlier age (i.e. with more immature root formation) and their traumas were of a less severe nature. Thus, the pre-injury or injury factors which had the greatest influence upon healing (i.e. whether hard tissue fusion or pulp necrosis) were age, stage of root development (i.e. the size of the pulpal lumen at the fracture site) and mobility of the coronal fragment, dislocation of the coronal fragment and diastasis between fragments (i.e. rupture or stretching of the pulp at the fracture site).	Univ Hosp, Rigshosp, Dept Oral & Maxillofacial Surg, DK-2200 Copenhagen N, Denmark; Eastman Dent Inst, Dept Pedodont, Stockholm, Sweden		Andreasen, JO (corresponding author), Univ Hosp, Rigshosp, Dept Oral & Maxillofacial Surg, 9 Blegdamsvej, DK-2200 Copenhagen N, Denmark.	rh11323@rh.dk					ANDREASEN F M, 1985, Endodontics and Dental Traumatology, V1, P207; ANDREASEN F M, 1986, Endodontics and Dental Traumatology, V2, P90; ANDREASEN FM, 1988, ENDOD DENT TRAUMATOL, V4, P202; ANDREASEN FM, 1989, ENDOD DENT TRAUMATOL, V5, P11; ANDREASEN FM, 1994, TXB COLOR ATLAS TRAU, P279; ANDREASEN JO, 1967, J ORAL SURG, V25, P414; Andreasen JO, 2004, DENT TRAUMATOL, V20, P203, DOI 10.1111/j.1600-9657.2004.00278.x; Andreasen JO, 2001, OPER DENT, V26, P328; BIRCH R, 1986, BRIT DENT J, V160, P119, DOI 10.1038/sj.bdj.4805786; Cvek M, 2002, DENT TRAUMATOL, V18, P57, DOI 10.1034/j.1600-9657.2002.180202.x; Cvek M, 2001, DENT TRAUMATOL, V17, P53, DOI 10.1034/j.1600-9657.2001.017002053.x; DE S, 1987, J ORAL MAXILLOFAC SU, V45, P111; DEAN AG, 2000, EPI INFO 2000; Feely L, 2003, DENT TRAUMATOL, V19, P52, DOI 10.1034/j.1600-9657.2003.00119.x; Glendor U, 1996, SWED DENT J, V20, P15; GROVE GL, 1982, ARCH DERMATOL RES, V272, P381, DOI 10.1007/BF00509069; Hedegard B, 1973, Sven Tandlak Tidskr, V66, P431; HOLM-PEDERSEN P, 1971, Scandinavian Journal of Dental Research, V79, P40; JACOBSEN I, 1975, SCAND J DENT RES, V83, P355; LENTNER C., 1981, GEIGY SCI TABLES, V1; MANTEL N, 1959, J NATL CANCER I, V22, P719; MOORREES COENRAAD F.A., 1963, JOUR DENT RES, V42, P1490, DOI 10.1177/00220345630420062701; RAVN JJ, 1974, COMMUNITY DENT ORAL, V2, P231, DOI 10.1111/j.1600-0528.1974.tb01658.x; ROBINS J, 1986, AM J EPIDEMIOL, V124, P719, DOI 10.1093/oxfordjournals.aje.a114447; Welbury R, 2002, Pediatr Dent, V24, P98; ZACHRISSON BU, 1975, SCAND J DENT RES, V83, P345	26	108	111	0	24	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1600-4469	1600-9657		DENT TRAUMATOL	Dent. Traumatol.	AUG	2004	20	4					192	202		10.1111/j.1600-9657.2004.00279.x			11	Dentistry, Oral Surgery & Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Dentistry, Oral Surgery & Medicine	841MU	WOS:000222935300002	15245518				2022-02-06	
J	Angelakis, E; Lubar, JF; Stathopoulou, S; Kounios, J				Angelakis, E; Lubar, JF; Stathopoulou, S; Kounios, J			Peak alpha frequency: an electroencephalographic measure of cognitive preparedness	CLINICAL NEUROPHYSIOLOGY			English	Article						electroencephalographic; peak alpha frequency; cognitive preparedness; traumatic brain injury; working memory; trait; state; resting baseline	CEREBRAL BLOOD-FLOW; QUANTITATIVE EEG; DOUBLE-BLIND; INDOMETHACIN; CAFFEINE; HYPOXIA; MEMORY	Objective: Electroencephalographic (EEG) peak alpha frequency (PAF) (measured in Hz) has been correlated to cognitive performance between healthy and clinical individuals, and among healthy individuals. PAF also varies within individuals across developmental stages, among different cognitive tasks, and among physiological states induced by administration of various substances. The present study suggests that, among other things, PAF reflects a trait or state of cognitive preparedness. Methods: Experiment 1 involved 19-channel EEG recordings from 10 individuals with traumatic brain injury (TBI) and 12 healthy matched controls, before, during, and after tasks of visual and auditory attention. Experiment 2 involved EEG recordings from 19 healthy young adults before and after a working memory task (WAIS-R Digit Span), repeated on 2 different days to measure within-individual differences. Results: Experiment 1 showed significantly lower PAF in individuals with TBI, mostly during post-task rest. Experiment 2 showed PAF during pre-task baseline to be significantly correlated with Digit Span performance of the same day but not with Digit Span performance of another day. Moreover, PAF was significantly increased after Digit Span for those participants whose PAF was lower than the sample median before the task, but not for those who had it higher. Finally, both PAF and Digit Span performance were increased during the second day. Conclusions: PAF was shown to detect both trait and state differences in cognitive preparedness, as well as to be affected by cognitive tasks. Traits are better reflected during post-task rest, whereas states are better reflected during initial resting baseline recordings. (C) 2004 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All fights reserved.	Drexel Univ, Dept Psychol, Philadelphia, PA 19102 USA; Univ Tennessee, Dept Psychol, Knoxville, TN 37996 USA		Angelakis, E (corresponding author), Drexel Univ, Dept Psychol, MS 626,245 N 15th St, Philadelphia, PA 19102 USA.	efthymis@mailcity.com			NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R01DC004818] Funding Source: NIH RePORTER; NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [DC04818] Funding Source: Medline		Angelakis E., 2002, Journal of Neurotherapy, V6, P5, DOI 10.1300/J184v06n02_03; Anokhin A, 1996, INTELLIGENCE, V23, P1, DOI 10.1016/S0160-2896(96)80002-X; BILLIOT K. M., 1997, J NEUROTHERAPY, V2, P20, DOI DOI 10.1300/J184V02N02_; Brunia CHM, 2001, INT J PSYCHOPHYSIOL, V43, P59, DOI 10.1016/S0167-8760(01)00179-9; Canive JM, 1998, PSYCHOPHARMACOL BULL, V34, P101; Congedo M., 2002, Journal of Neurotherapy, V6, P73, DOI 10.1300/J184v06n04_08; CONNERS CK, 1999, PRACTITIONERS GUIDE, P413; Doppelmayr MM, 1998, BRAIN TOPOGR, V11, P133, DOI 10.1023/A:1022206622348; FELDMAN RS, 1997, PRINCIPLES NEUROPSYC, P902; HEMLER RJB, 1990, METHOD FIND EXP CLIN, V12, P641; HOLM S, 1979, SCAND J STAT, V6, P65; Juhasz C, 1997, ACTA NEUROL SCAND, V96, P397; KINOSHITA T, 1990, Psychiatria et Neurologia Japonica, V92, P255; Klimesch W, 1997, INT J PSYCHOPHYSIOL, V26, P319, DOI 10.1016/S0167-8760(97)00773-3; Klimesch W., 1993, Brain Topography, V5, P241, DOI 10.1007/BF01128991; Klimesch W., 1990, J PSYCHOPHYSIOL, V4, P381; KNOTT VJ, 1988, NEUROPSYCHOBIOLOGY, V19, P54, DOI 10.1159/000118434; KOSTANDOV E, 1995, ZH VYSSH NERV DEYAT+, V45, P3; Kostyunina MB, 1998, ZH VYSSH NERV DEYAT+, V48, P213; KRAAIER V, 1992, ELECTROEN CLIN NEURO, V82, P208, DOI 10.1016/0013-4694(92)90169-I; Lindgren M, 1999, PSYCHOPHARMACOLOGY, V145, P342, DOI 10.1007/s002130051067; Lubar J. F., 1999, INTRO QUANTITATIVE E, P103; MECHANIC D, 1975, MED CARE, V13, P189, DOI 10.1097/00005650-197503000-00001; NEWMAN F, 1992, PSYCHIAT RES-NEUROIM, V45, P105, DOI 10.1016/0925-4927(92)90004-N; Osaka M, 1999, COGNITIVE BRAIN RES, V8, P365, DOI 10.1016/S0926-6410(99)00022-1; OSAKA M, 1984, PSYCHOPHYSIOLOGY, V21, P101, DOI 10.1111/j.1469-8986.1984.tb02325.x; PASSERO S, 1995, DEMENTIA, V6, P148, DOI 10.1159/000106938; PFURTSCHELLER G, 1989, Brain Topography, V2, P3, DOI 10.1007/BF01128838; PIERLOVISI-LAVAIVRE M, 1991, Neurophysiologie Clinique, V21, P411, DOI 10.1016/S0987-7053(05)80332-6; Posthuma D, 2001, BEHAV GENET, V31, P567, DOI 10.1023/A:1013345411774; PSATTA D M, 1991, Revue Roumaine de Neurologie et Psychiatrie, V29, P9; RICE WR, 1989, EVOLUTION, V43, P223, DOI 10.1111/j.1558-5646.1989.tb04220.x; SALETU B, 1984, INT J CLIN PHARM RES, V4, P95; SALETU B, 1995, INT J CLIN PHARM TH, V33, P249; Sterman MB, 2000, CLIN ELECTROENCEPHAL, V31, P45, DOI 10.1177/155005940003100111; Suldo S. M., 2001, Journal of Neurotherapy, V5, P39; Thatcher RW, 1999, INTRO QUANTITATIVE E, P29; TIFFIN P, 1995, PSYCHOPHARMACOLOGY, V121, P494, DOI 10.1007/BF02246500; VANDERWORP HB, 1991, ELECTROEN CLIN NEURO, V79, P335, DOI 10.1016/0013-4694(91)90197-C; WILSHER CR, 1994, CURRENT DIRECTIONS D; 李德明, 1996, [心理学报, Acta Psychologica Sinica], V28, P76	41	108	115	0	13	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457	1872-8952		CLIN NEUROPHYSIOL	Clin. Neurophysiol.	APR	2004	115	4					887	897		10.1016/j.clinph.2003.11.034			11	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	806DO	WOS:000220414800021	15003770				2022-02-06	
J	Borg, J; Holm, L; Peloso, PM; Cassidy, JD; Carroll, LJ; von Holst, H; Paniak, C; Yates, D				Borg, J; Holm, L; Peloso, PM; Cassidy, JD; Carroll, LJ; von Holst, H; Paniak, C; Yates, D			Non-surgical intervention and cost for mild traumatic brain injury: Results of the WHO Collaborating Centre Task Force on Mild Traumatic Brain Injury	JOURNAL OF REHABILITATION MEDICINE			English	Article						mild traumatic brain injury; treatment; economic cost	ROUTINE FOLLOW-UP; HEAD TRAUMA; RANDOMIZED-TRIAL; HOME	We examined the evidence for non-surgical interventions and for economic costs for mild traumatic brain injury patients by a systematic search of the literature and a best-evidence synthesis. After screening 38,806 abstracts, we critically reviewed 45 articles on intervention and accepted 16 (36%). We reviewed 16 articles on economic costs and accepted 7 (44%). We found some evidence that early educational information can reduce long-term complaints and that this early intervention need not be intensive. Most cost studies were performed more than a decade ago. Indirect costs are probably higher than direct costs. Studies comparing costs for routine hospitalized observation vs the use of computerized tomography scan examination for selective hospital admission indicate that the latter policy reduces costs, but comparable clinical outcome of these policies has not been demonstrated. The sparse scientific literature in these areas reflects both conceptual confusion and limited knowledge of the natural history of mild traumatic brain injury.	Univ Uppsala Hosp, Dept Neurosci, SE-78185 Uppsala, Sweden; Karolinska Inst, Dept Clin Neurosci, Sect Personal Injury Prevent, Stockholm, Sweden; Univ Iowa, Ctr Hlth, Dept Internal Med, Iowa City, IA USA; Univ Alberta, Dept Publ Hlth Sci, Alberta Ctr Injury Control & Res, Edmonton, AB, Canada; Univ Alberta, Dept Med, Edmonton, AB, Canada; Karolinska Inst, Dept Neurosurg, Stockholm, Sweden; Glenrose Rehabil Hosp, Edmonton, AB, Canada; Univ Alberta, Edmonton, AB T6G 2M7, Canada; Univ Manchester, Hope Hosp, Dept Emergency, Manchester M13 9PL, Lancs, England		Borg, J (corresponding author), Univ Uppsala Hosp, Dept Neurosci, SE-78185 Uppsala, Sweden.	jorgen.borg@rehab.uu.se		Borg, Jorgen/0000-0002-2372-7478; Carroll, Linda/0000-0003-0876-2336			Bergman DA, 1999, PEDIATRICS, V104, P1407; BOHNEN NI, 1993, NEUROLOGY, V43, P103, DOI 10.1212/WNL.43.1_Part_1.103; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; BRITTON M, 2000, 153 SBU SWED COUNC T; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Carroll LJ, 2004, J REHABIL MED, V36, P11, DOI 10.1080/16501960410023660; CASEY R, 1987, PEDIATRICS, V80, P159; Chapman EH, 1999, J HEAD TRAUMA REHAB, V14, P521, DOI 10.1097/00001199-199912000-00002; CLINE DM, 1988, ANN EMERG MED, V17, P127, DOI 10.1016/S0196-0644(88)80297-X; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; GRABOW JD, 1984, AM J PUBLIC HEALTH, V74, P710, DOI 10.2105/AJPH.74.7.710; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; King NS, 1997, CLIN REHABIL, V11, P13, DOI 10.1177/026921559701100104; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Kyle J M, 1988, W V Med J, V84, P283; LOWDON IMR, 1989, INJURY, V20, P193, DOI 10.1016/0020-1383(89)90109-5; MENDELOW AD, 1982, BRIT MED J, V285, P1530, DOI 10.1136/bmj.285.6354.1530; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Ommaya AK, 1996, J TRAUMA, V40, P211, DOI 10.1097/00005373-199602000-00007; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Paniak C, 2000, BRAIN INJURY, V14, P219; RELANDER M, 1972, BMJ-BRIT MED J, V4, P777, DOI 10.1136/bmj.4.5843.777; ROBERTS CJ, 1981, LANCET, V2, P791; SAUNDERS CE, 1986, ANN EMERG MED, V15, P160, DOI 10.1016/S0196-0644(86)80012-9; Wade DT, 1997, J NEUROL NEUROSUR PS, V62, P478, DOI 10.1136/jnnp.62.5.478; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177	27	108	108	0	4	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	FEB	2004	36			43			76	83		10.1080/16501960410023840			8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	800QR	WOS:000220043300009	15083872	gold			2022-02-06	
J	Green, REA; Turner, GR; Thompson, WF				Green, REA; Turner, GR; Thompson, WF			Deficits in facial emotion perception in adults with recent traumatic brain injury	NEUROPSYCHOLOGIA			English	Article						affect; neuropsychology; diffuse axonal injury; TBI; right hemisphere	RIGHT-HEMISPHERE; HUMAN AMYGDALA; RECOGNITION; DAMAGE; EXPRESSIONS; FACE; COMMUNICATION; CORTICES; SYSTEMS; STIMULI	We examined whether facial emotion perception was compromised in adults with recent traumatic brain injury (TBI). Few studies have examined emotion perception in TBI; those that have, examined chronic patients only. Recent and chronic TBI populations differ according to degree of functional reorganization of the brain, use of compensatory strategies, and severity of cognitive impairments-any of which might differentially affect presentation of emotion perception deficits. A secondary aim of the study was to utilize the TBI population-in whom diffuse axonal injury (DAI) is a cardinal neurological feature-to examine the suggestion of Adolphs et al. [Journal of Neuroscience 20(7) (2000) 2683] that damage to white matter tracts should give rise to emotion perception deficits. Methods: Thirty TBI participants and 30 age-matched controls were tested. A 2 x 3 mixed design was employed. The dependent variable was accuracy on neutral and emotional face perception tests. Results: (1) The TBI group performed significantly less accurately than the matched controls on the facial emotion perception tasks, whereas the groups performed equivalently on a non-emotional face perception control task. (2) A sub-group. of TBI participants without evidence of focal injury to areas of the brain most commonly implicated in facial emotion perception was as impaired on the emotion perception tasks as a second sub-group who had sustained focal lesions to these areas. This suggests an alternative neurological mechanism for deficits in the first sub-group, such as DAI Conclusions: Patients with recently acquired TBI are impaired in their ability to perceive emotions in faces. DAI alone may cause facial emotion perception deficits. (C) 2003 Elsevier Ltd. All rights reserved.	Toronto Rehabiol Inst, Toronto, ON M5G 2A2, Canada; Univ Toronto, Toronto, ON, Canada		Green, REA (corresponding author), Toronto Rehabiol Inst, 550 Univ Ave,Room 1004, Toronto, ON M5G 2A2, Canada.	green.robin@torontorehab.on.ca		Green, Robin/0000-0001-9451-3963; Thompson, William/0000-0002-4256-1338			Adolphs R, 2000, J NEUROSCI, V20, P2683; Adolphs R, 2002, CURR OPIN NEUROBIOL, V12, P169, DOI 10.1016/S0959-4388(02)00301-X; Adolphs R, 1996, J NEUROSCI, V16, P7678; ADOLPHS R, 1994, NATURE, V372, P669, DOI 10.1038/372669a0; BECK AT, 1984, J CLIN PSYCHOL, V40, P1365, DOI 10.1002/1097-4679(198411)40:6<1365::AID-JCLP2270400615>3.0.CO;2-D; BLONDER LX, 1991, BRAIN, V114, P1115, DOI 10.1093/brain/114.3.1115; Borod J, 1996, BLACKWELL DICT NEURO, P312; BOROD JC, 1990, J COMMUN DISORD, V23, P247, DOI 10.1016/0021-9924(90)90003-H; Borod JC, 1998, NEUROPSYCHOLOGY, V12, P446, DOI 10.1037/0894-4105.12.3.446; BOWERS D, 1991, BRAIN, V114, P2593, DOI 10.1093/brain/114.6.2593; Bowers D., 1993, NEUROPSYCHOLOGY, V7, P433, DOI [10.1037/0894-4105.7.4.433, DOI 10.1037/0894-4105.7.4.433]; Bowers D., 1989, FLORIDA AFFECT BATTE; BOWERS D, 1998, UNPUB FLORIDA AFFECT; Calder AJ, 1996, COGNITIVE NEUROPSYCH, V13, P699, DOI 10.1080/026432996381890; CANCELLIERE AEB, 1990, BRAIN COGNITION, V13, P133, DOI 10.1016/0278-2626(90)90046-Q; Hart AJ, 2000, NEUROREPORT, V11, P2351, DOI 10.1097/00001756-200008030-00004; Heilman KM, 1998, J CLIN NEUROPHYSIOL, V15, P409, DOI 10.1097/00004691-199809000-00005; Heilman KM, 1999, FLORIDA AFFECT BATTE; Hornak J, 2003, BRAIN, V126, P1691, DOI 10.1093/brain/awg168; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; Kawasaki H, 2001, NAT NEUROSCI, V4, P15, DOI 10.1038/82850; Keane J, 2002, NEUROPSYCHOLOGIA, V40, P655, DOI 10.1016/S0028-3932(01)00156-7; Leppanen JM, 2001, SCAND J PSYCHOL, V42, P429, DOI 10.1111/1467-9450.00255; Luria A.R., 1975, HDB CLIN NEUROLOGY, P368; Luria AR, 1963, RESTORATION FUNCTION; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; PRIGATANO GP, 1982, J PERCEPTUAL MOTOR S, V54, P859; RAO SM, 1992, J CONSULT CLIN PSYCH, V60, P369, DOI 10.1037/0022-006X.60.3.369; RASKIN S A, 1990, Neuropsychology Review, V1, P185, DOI 10.1007/BF01112571; Robertson IH, 1999, PSYCHOL BULL, V125, P544, DOI 10.1037/0033-2909.125.5.544; Rolls E. T., 2002, PRINCIPLES FRONTAL L; Spell LA, 2000, J NONVERBAL BEHAV, V24, P285, DOI 10.1023/A:1006675230193; STARKSTEIN SE, 1988, CEREBRAL HEMISPHERE, P25; STRAUSS E, 1981, BRAIN LANG, V13, P308, DOI 10.1016/0093-934X(81)90098-5; Szaflarski JP, 2002, NEUROLOGY, V59, P238, DOI 10.1212/WNL.59.2.238; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 1998, NEUROSURGERY, V43, P723, DOI 10.1097/00006123-199810000-00001; [No title captured]	40	108	114	0	18	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia		2004	42	2					133	141		10.1016/j.neuropsychologia.2003.07.005			9	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	753FC	WOS:000187220600001	14644100				2022-02-06	
J	Rao, VLR; Dhodda, VK; Song, GQ; Bowen, KK; Dempsey, RJ				Rao, VLR; Dhodda, VK; Song, GQ; Bowen, KK; Dempsey, RJ			Traumatic brain injury-induced acute gene expression changes in rat cerebral cortex identified by GeneChip analysis	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						cerebral cortex; controlled cortical impact; microarray; real-time PCR; GeneChip	MESSENGER-RNA EXPRESSION; HEAT-SHOCK-PROTEIN; GLUTAMATE TRANSPORTER GLT-1; CONTROLLED CORTICAL IMPACT; FIBRILLARY ACIDIC PROTEIN; SPINAL MUSCULAR-ATROPHY; NERVE GROWTH-FACTOR; DIFFERENTIAL EXPRESSION; REGIONAL EXPRESSION; UP-REGULATION	Proper CNS function depends on concerted expression of thousands of genes in a controlled and timely manner. Traumatic brain injury (TBI) in mammals results in neuronal death and neurological dysfunction, which might be mediated by altered expression of several genes. By employing a CNS-specific GeneChip and real-time polymerase chain reaction (PCR), the present study analyzed the gene expression changes in adult rat cerebral cortex in the first 24 hr after a controlled cortical impact injury. Many functional families of genes not previously implicated in TBI-induced brain damage are altered in the injured cortex. These include up-regulated transcription factors (SOCS-3, JAK-2, STAT-3, CREM, IRF-1, SMN, silencer factor-B, ANIA-3, ANIA-4, and HES-1) and signal transduction pathways (cpg21, Narp, and CRBP) and down-regulated transmitter release mechanisms (CITRON, synaptojanin 11, ras-related rab3, neurexin-1beta, and SNAP25A and -B), kinases (IP-3-kinase, Pak1, Ca2+/CaM-dependent protein kinases), and ion channels (K+ channels TWIK, RK5, X62839, and Na+ channel 1). In addition, several genes previously shown to play a role in TBI pathophysiology, including proinflammatory genes, proapoptotic genes, heat shock proteins, immediate early genes, neuropeptides, and glutamate receptor subunits, were also observed to be altered in the injured cortex. Real-time PCR analysis confirmed the GeneChip data for many of these transcripts. The novel physiologically relevant gene expression changes observed here might explain some of the molecular mechanisms of TBI-induced neuronal damage. (C) 2002 Wiley-Liss, Inc.	Univ Wisconsin, Dept Neurol Surg, Madison, WI 53792 USA		Rao, VLR (corresponding author), Univ Wisconsin, Dept Neurol Surg, 600 Highland Ave, Madison, WI 53792 USA.	vemugant@neurosurg.wisc.edu					Beer R, 2001, J NEUROCHEM, V78, P862, DOI 10.1046/j.1471-4159.2001.00460.x; Borden LA, 1996, NEUROCHEM INT, V29, P335, DOI 10.1016/0197-0186(95)00158-1; Chen MZ, 1998, J NEUROTRAUM, V15, P171, DOI 10.1089/neu.1998.15.171; Chen YA, 2001, NEURON, V30, P161, DOI 10.1016/S0896-6273(01)00270-7; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Dhillon HS, 2001, EXP NEUROL, V170, P140, DOI 10.1006/exnr.2001.7685; Dietrich WD, 1999, J NEUROTRAUM, V16, P567, DOI 10.1089/neu.1999.16.567; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Dong GX, 2001, BRAIN RES, V903, P45, DOI 10.1016/S0006-8993(01)02379-4; FAN L, 1995, MOL BRAIN RES, V30, P125; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Franz G, 1999, J NEUROCHEM, V73, P1615, DOI 10.1046/j.1471-4159.1999.0731615.x; Fukuda K, 1996, BRAIN RES, V736, P68, DOI 10.1016/0006-8993(96)00680-4; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; Giralt M, 2002, EXP NEUROL, V173, P114, DOI 10.1006/exnr.2001.7772; Giza CC, 2002, J NEUROTRAUM, V19, P387, DOI 10.1089/08977150252932352; Gong QZ, 1999, J NEUROTRAUM, V16, P893, DOI 10.1089/neu.1999.16.893; Grabs D, 1996, EUR J NEUROSCI, V8, P162, DOI 10.1111/j.1460-9568.1996.tb01177.x; Harris LK, 2001, J NEUROTRAUM, V18, P993, DOI 10.1089/08977150152693692; Hevroni D, 1998, J MOL NEUROSCI, V10, P75, DOI 10.1007/BF02737120; Hicks RR, 1999, EXP NEUROL, V160, P469, DOI 10.1006/exnr.1999.7216; Iadecola C, 1999, J EXP MED, V189, P719, DOI 10.1084/jem.189.4.719; Imagawa M, 1996, NEUROCHEM INT, V29, P565, DOI 10.1016/S0197-0186(96)00058-7; Iwahashi H, 1997, NATURE, V390, P413, DOI 10.1038/37144; IWAMOTO Y, 1994, LIFE SCI, V55, P1651, DOI 10.1016/0024-3205(94)00332-7; Kaya SS, 1999, BRAIN RES, V840, P153, DOI 10.1016/S0006-8993(99)01757-6; Keyvani K, 2001, ACTA NEUROPATHOL, V101, P79; Kile BT, 2001, CELL MOL LIFE SCI, V58, P1627, DOI 10.1007/PL00000801; Kusuhara H, 1999, J BIOL CHEM, V274, P13675, DOI 10.1074/jbc.274.19.13675; Lejeune D, 2001, BIOCHEM J, V353, P109, DOI 10.1042/bj3530109; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; LIU SL, 1994, J NEUROTRAUM, V11, P73, DOI 10.1089/neu.1994.11.73; Lowenstein D, 2001, ANN NEUROL, V50, P696, DOI 10.1002/ana.10090; LOWENSTEIN DH, 1994, MOL BRAIN RES, V22, P299, DOI 10.1016/0169-328X(94)90058-2; Magrangeas F, 2001, BIOCHEM J, V353, P223, DOI 10.1042/0264-6021:3530223; Masumura M, 2000, J NEUROTRAUM, V17, P123, DOI 10.1089/neu.2000.17.123; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; Mazzucchelli C, 1999, MOL CELL ENDOCRINOL, V155, P101, DOI 10.1016/S0303-7207(99)00103-3; MCINTOSH TK, 1992, J CEREBR BLOOD F MET, V12, P697, DOI 10.1038/jcbfm.1992.95; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Morrison B, 2000, NEUROSCIENCE, V96, P131, DOI 10.1016/S0306-4522(99)00537-0; Napieralski JA, 1999, MOL BRAIN RES, V71, P78, DOI 10.1016/S0169-328X(99)00155-2; NGUYEN H, 1997, CYTOINE GROWTH FACTO, V8, P2934; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Papavassiliou E, 1997, J NEUROSCI RES, V49, P451, DOI 10.1002/(SICI)1097-4547(19970815)49:4<451::AID-JNR6>3.0.CO;2-7; Pekny M, 1999, J CELL BIOL, V145, P503, DOI 10.1083/jcb.145.3.503; Raghupathi R, 1996, MOL BRAIN RES, V37, P134, DOI 10.1016/0169-328X(95)00289-5; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Rao VLR, 1999, J NEUROTRAUM, V16, P865, DOI 10.1089/neu.1999.16.865; Rao VLR, 2001, BRAIN RES, V911, P96; Rao VLR, 2000, EXP NEUROL, V161, P102, DOI 10.1006/exnr.1999.7269; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Rao VLR, 2001, EUR J NEUROSCI, V13, P119, DOI 10.1046/j.1460-9568.2001.01367.x; RAO VLR, 2002, IN PRESS J NEUROCHEM; Roe SY, 1998, EUR J NEUROSCI, V10, P553, DOI 10.1046/j.1460-9568.1998.00064.x; SANDERS JE, 1996, IEEE T REHABIL ENG, V4, P285; Sassone-Corsi P, 2000, MOL REPROD DEV, V56, P228, DOI 10.1002/(SICI)1098-2795(200006)56:2+<228::AID-MRD2>3.0.CO;2-B; Sendtner M, 2001, CURR OPIN NEUROL, V14, P629, DOI 10.1097/00019052-200110000-00012; Shao LF, 1999, J NEUROTRAUM, V16, P555, DOI 10.1089/neu.1999.16.555; Shouda T, 2001, J CLIN INVEST, V108, P1781, DOI 10.1172/JCI200113568; Solecki DJ, 2001, NEURON, V31, P557, DOI 10.1016/S0896-6273(01)00395-6; Song GQ, 2002, J NEUROSCI RES, V68, P730, DOI 10.1002/jnr.10268; Song GQ, 2001, J NEUROCHEM, V79, P804, DOI 10.1046/j.1471-4159.2001.00626.x; Stoffel M, 2001, J NEUROTRAUM, V18, P425, DOI 10.1089/089771501750171010; Strauss KI, 2000, J NEUROTRAUM, V17, P695, DOI 10.1089/089771500415436; Tolentino PJ, 2002, J NEUROCHEM, V80, P579, DOI 10.1046/j.0022-3042.2001.00726.x; Truettner J, 1999, J NEUROTRAUM, V16, P471, DOI 10.1089/neu.1999.16.471; Tsui CC, 1996, J NEUROSCI, V16, P2463; Turski L, 1998, P NATL ACAD SCI USA, V95, P10960, DOI 10.1073/pnas.95.18.10960; Wang JH, 2000, CHINESE CHEM LETT, V11, P1; Yakovlev AG, 2001, J NEUROSCI, V21, P7439, DOI 10.1523/JNEUROSCI.21-19-07439.2001; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YANG K, 1995, J NEUROSCI RES, V42, P571, DOI 10.1002/jnr.490420415; Zhang WD, 1999, J NEUROSCI, V19, P96, DOI 10.1523/JNEUROSCI.19-01-00096.1999; Zou LL, 1998, J NEUROCHEM, V71, P887	77	108	109	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	JAN 15	2003	71	2					208	219		10.1002/jnr.10486			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	631YU	WOS:000180196500005	12503083				2022-02-06	
J	Hawley, CA; Ward, AB; Magnay, AR; Long, J				Hawley, CA; Ward, AB; Magnay, AR; Long, J			Parental stress and burden following traumatic brain injury amongst children and adolescents	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; FAMILY; ADAPTATION; DISTRESS; CARERS; NEEDS	Primary objectives: To assess parental stress following paediatric traumatic brain injury (TBI), and examine the relationship between self-reported problems, parental stress and general health. Research design: Parents of 97 children admitted with a TBI (49 mild, 19 moderate, 29 severe) to North Staffordshire National Health Service Trust, and parents of 31 uninjured children were interviewed and assessed. Methods and procedures: Structured interviews were carried out with families, and parents assessed on the Parenting Stress Index (PSI/SF) and General Health Questionnaire (GHQ-12) at recruitment, and repeated 12 months later. Main outcomes and results: Forty parents (41.2%) of children with TBI exhibited clinically significant stress. Regardless of injury severity, parents of injured children suffered greater stress than control parents as measured by the PSI/SF (p=0.001). There was a highly significant relationship between number of problems reported and level of parental stress (p=0.001). Financial burden was related to severity of TBI. At follow-up, one third of parents of children with severe TBI scored 18 on the GHQ-12, signifying poor psychological health. Conclusions: The parents of a child with serious TBI should be screened for abnormal levels of stress. Parental stress and family burden may be alleviated by improved information, follow-up and support.	Univ Warwick, Ctr Hlth Serv Studies, Coventry CV4 7AL, W Midlands, England; N Staffordshire Rehabil Ctr, Stoke On Trent, Staffs, England; City Gen Hosp, Paediat Intens Care Unit, Stoke On Trent ST4 6QG, Staffs, England			c.a.hawley@warwick.ac.uk	Hawley, Carol/AAG-3830-2019				Abidin, 1995, PARENTING STRESS IND; Bowen A, 2001, BRAIN INJURY, V15, P29, DOI 10.1080/02699050150209101; *BRIT SOC REH MED, 1998, REH TRAUM BRAIN INJ; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; DEPOMPEI R, 1989, TOP LANG DISORD, V9, P78, DOI 10.1097/00011363-198903000-00008; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Gillen R, 1998, J HEAD TRAUMA REHAB, V13, P31, DOI 10.1097/00001199-199806000-00004; Goldberg D. P., 1991, USERS GUIDE GEN HLTH; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; McMordie W R, 1988, Brain Inj, V2, P357, DOI 10.3109/02699058809150908; McPherson KM, 2000, INT J REHABIL RES, V23, P295, DOI 10.1097/00004356-200023040-00005; *N STAFF HLTH AUTH, 1994, HLTH N STAFF ANN REP; ODDY M, 1993, NEUROPSYCHOL REHABIL, V3, P301, DOI 10.1080/09602019308401444; Parmelee D X, 1989, Psychiatr Med, V7, P11; Perlesz A, 2000, J HEAD TRAUMA REHAB, V15, P909, DOI 10.1097/00001199-200006000-00005; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; RIVARA JB, 1993, ARCH PHYSICAL MED RE, V74, P1947; ROMANO MD, 1974, SCAND J REHABIL MED, V6, P1; Sokol DK, 1996, BRAIN INJURY, V10, P439, DOI 10.1080/026990596124296; Stilwell P, 1999, NEUROPSYCHOL REHABIL, V9, P277, DOI 10.1080/096020199389374; TAYLOR GH, 1995, TRAUMATIC HEAD INJUR, P188; TEASDALE G, 1974, LANCET, V2, P81; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; Townsend P, 1986, INEQUALITIES HLTH NO; WAALAND PK, 1993, BRAIN INJURY, V7, P135, DOI 10.3109/02699059309008167; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; World Health Organization, 1980, INT CLASS IMP DIS HA	33	108	110	0	5	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2003	17	1					1	23		10.1080/0269905021000010096			23	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	633LK	WOS:000180284600001	12519644	Green Submitted			2022-02-06	
J	Gupta, RC; Milatovic, D; Dettbarn, WD				Gupta, RC; Milatovic, D; Dettbarn, WD			Depletion of energy metabolites following acetylcholinesterase inhibitor-induced status epilepticus: Protection by antioxidants	NEUROTOXICOLOGY			English	Article; Proceedings Paper	39th Annual Meeting of the Society-of-Toxicology	MAR 19-23, 2000	PHILADELPHIA, PA	Soc Toxicol		DFP; carbofuran; spin trap PEN; vitamin E; high-energy phosphates; nitric oxide (NO); NO synthesis; citrulline; antioxidants; seizures	NITRIC-OXIDE; ALPHA-TOCOPHEROL; RAT-BRAIN; VITAMIN-E; LIPID-PEROXIDATION; LITHIUM-CHLORIDE; DIAPHRAGM MUSCLE; OXIDATIVE STRESS; SKELETAL-MUSCLE; CELL INJURY	Status epilepticus (SE)-induced neuronal injury may involve excitotoxicity, energy impairment and increased generation of reactive oxygen species (ROS). Potential treatment therefore should consider agents that protect mitochondrial function and ROS scavengers. In the present study we examined whether the spin trapping agent N-tert-butyl-alpha -phenylnitrone (PBN) and the antioxidant vitamin E (DL-alpha -tocopherol) protect levels of high-energy phosphates during SE. In rats, SE was induced by either of two inhibitors of acetylcholinesterase (AChE), the organophosphate diisopropylphosphorofluoridate (DFP, 1.25 mg/kg, sc)- or the carbamate carbofuran (1.25 mg/kg, sc). Rats were sacrificed 1 h or 3 days after onset of seizures by head-focused microwave (power, 10 kW; duration 1.7 s) and levels of the energy-rich phosphates adenosine triphosphate (ATP) and phosphocreatine (PCr) and their metabolites adenosine diphosphate (ADP) and adenosine monophosphate (AMP), and creatine (Cr), respectively, were determined in the cortex, amygdala and hippocampus. Within 1 h of seizure activity, marked declines were seen in ATP (34-60%) and PCr (25-52%). Total adenine nucleotides (TAN = ATPS + ADP + AMP) and total creatine compounds (TCC = PCr + Cr) were also reduced (TAN 38-60% and TCC 25-47%). No changes in ATP/AMP ratio were seen. Three days after the onset of seizures, recovery of ATP and PCr was significant in the amygdala and hippocampus, but not in the cortex. Pretreatment of rats with PEN (200 mg/kg, ip, in a single dose), 30 min before DFP or carbofuran administration, prevented induced seizures and partially prevented depletion of high-energy phosphates. Pretreatment with the natural antioxidant vitamin E (100 mg/kg, ip.day for 3 days), partially prevented loss of high energy phosphates without affecting seizures. In controls, citrulline, a product of nitric oxide synthesis, was found so be highest in the amygdala, followed by hippocampus, and lowest in the cortex. DFP- or carbofuran-induced seizures caused elevation of citrulline levels seven- to eight-fold in the cortex and three- to four-fold in the amygdala and hippocampus. These results suggest a close relationship between SE, excitotoxicity and energy metabolism. The involvement of oxidative stress is supported by the findings that DFP and carbofuran trigger an excessive nitric oxide (NO) production in the seizure relevant regions of the brain. (C) 2001 Elsevier Science Inc. All rights reserved.	Murray State Univ, Breathitt Vet Ctr, Dept Toxicol, Hopkinsville, KY 42240 USA; Vanderbilt Univ, Med Ctr S, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr S, Dept Neurol, Nashville, TN 37232 USA		Gupta, RC (corresponding author), Murray State Univ, Breathitt Vet Ctr, Dept Toxicol, Hopkinsville, KY 42240 USA.	ramesh.gupta@murraystate.edu			NIEHS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [ES04597] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [R01ES004597] Funding Source: NIH RePORTER		ANDERSON DE, 1993, BIOCHEM BIOPH RES CO, V193, P878, DOI 10.1006/bbrc.1993.1707; ANDREOLI SP, 1993, J LAB CLIN MED, V122, P232; BAGETTA G, 1993, EUR J PHARMACOL, V237, P61, DOI 10.1016/0014-2999(93)90093-W; Bagetta G, 1995, EUR J PHARMACOL, V294, P341, DOI 10.1016/0014-2999(95)00689-3; Barclay LRC, 2000, FREE RADICAL BIO MED, V28, P1079, DOI 10.1016/S0891-5849(00)00197-0; BAST A, 1991, AM J MED, V91, pS2, DOI 10.1016/0002-9343(91)90278-6; BJORNEBOE A, 1991, J NUTR, V121, P1208, DOI 10.1093/jn/121.8.1208; BONDY SC, 1993, BRAIN RES, V610, P229, DOI 10.1016/0006-8993(93)91405-H; BOSE R, 1992, TOXICOL LETT, V60, P211, DOI 10.1016/0378-4274(92)90276-P; Boyer PD, 1998, BIOSCIENCE REP, V18, P97, DOI 10.1023/A:1020188311092; Brorson JR, 1999, J NEUROSCI, V19, P147, DOI 10.1523/JNEUROSCI.19-01-00147.1999; CASTANO A, 1994, B ENVIRON CONTAM TOX, V53, P309; CHOW CK, 1991, FREE RADICAL BIO MED, V11, P215; Chow CK, 1999, FREE RADICAL BIO MED, V27, P580, DOI 10.1016/S0891-5849(99)00121-5; DAWSON TM, 1992, ANN NEUROL, V32, P297, DOI 10.1002/ana.410320302; Delanty N, 1998, ACTA NEUROL SCAND, V98, P145, DOI 10.1111/j.1600-0404.1998.tb07285.x; Dettbarn W-D., 2001, INT C ANT, P183; ERECINSKA M, 1995, J NEUROCHEM, V65, P2699; FARBER E, 1973, FED PROC, V32, P1534; Floyd RA, 1999, P SOC EXP BIOL MED, V222, P236, DOI 10.1046/j.1525-1373.1999.d01-140.x; FOLBERGROVA J, 1995, P NATL ACAD SCI USA, V92, P5057, DOI 10.1073/pnas.92.11.5057; Fukushima T, 1997, EXP TOXICOL PATHOL, V49, P381, DOI 10.1016/S0940-2993(97)80123-6; GOLLNICK PD, 1990, PFLUG ARCH EUR J PHY, V415, P407, DOI 10.1007/BF00373617; Gupta R. C., 1998, TOXICOL SCI, V42, P156; Gupta R.C., 1999, TOXICOL SCI, V48, P188; GUPTA RC, 1989, J TOXICOL ENV HEALTH, V28, P111, DOI 10.1080/15287398909531332; GUPTA RC, 1985, FUND APPL TOXICOL, V5, pS17, DOI 10.1016/0272-0590(85)90111-3; Gupta RC, 2000, PFLUG ARCH EUR J PHY, V440, pR160, DOI 10.1007/s004240000047; Gupta RC, 2000, HUM EXP TOXICOL, V19, P297, DOI 10.1191/096032700678815927; GUPTA RC, 1991, ARCH TOXICOL, V65, P304, DOI 10.1007/BF01968964; GUPTA RC, 1994, J TOXICOL ENV HEALTH, V43, P291, DOI 10.1080/15287399409531922; GUPTA RC, 1994, NEUROTOXICOLOGY, V15, P321; GUPTA RC, 1991, ARCH ENVIRON CON TOX, V21, P263, DOI 10.1007/BF01055345; Gupta RC, 2000, ARCH TOXICOL, V74, P13, DOI 10.1007/s002040050646; GUPTA RC, 2000, IN PRESS TOXICOL SCI; KEMP RB, 1986, FOOD CHEM TOXICOL, V24, P465, DOI 10.1016/0278-6915(86)90093-1; Kim YB, 1997, ENVIRON TOXICOL PHAR, V3, P53, DOI 10.1016/S1382-6689(96)00139-1; KOTEGAWA M, 1993, J MOL CELL CARDIOL, V25, P1067, DOI 10.1006/jmcc.1993.1119; Leist M, 1999, EXP CELL RES, V249, P396, DOI 10.1006/excr.1999.4514; LUFT R, 1995, BBA-MOL BASIS DIS, V1271, P1, DOI 10.1016/0925-4439(95)00002-L; MARUBAYASHI S, 1986, SURGERY, V99, P184; MCDONOUGH JH, 1993, NEUROSCI BIOBEHAV R, V17, P203, DOI 10.1016/S0149-7634(05)80151-4; Milatovic D, 2000, NEUROSCI LETT, V278, P25, DOI 10.1016/S0304-3940(99)00904-0; Milatovic D, 2000, FREE RADICAL BIO MED, V28, P597, DOI 10.1016/S0891-5849(99)00270-1; MILATOVIC D, 2000, IN PRESS BRAIN RES; MISULIS KE, 1987, TOXICOL APPL PHARM, V89, P391, DOI 10.1016/0041-008X(87)90158-X; MORRISETT RA, 1987, EXP NEUROL, V98, P594, DOI 10.1016/0014-4886(87)90268-8; Murphy AN, 1999, J CEREBR BLOOD F MET, V19, P231, DOI 10.1097/00004647-199903000-00001; Nicotera P, 1998, TOXICOL LETT, V103, P139; Olney J W, 1986, Adv Neurol, V44, P857; Pazos AJ, 1999, BRAIN RES, V846, P186, DOI 10.1016/S0006-8993(99)02010-7; Pedersen PL, 1999, J BIOENERG BIOMEMBR, V31, P291, DOI 10.1023/A:1005453700533; PLANAS AM, 1995, EUR J NEUROSCI, V7, P293, DOI 10.1111/j.1460-9568.1995.tb01065.x; Punz A, 1998, CLIN NUTR, V17, P85, DOI 10.1016/S0261-5614(98)80311-7; RADI R, 1994, ARCH BIOCHEM BIOPHYS, V308, P89, DOI 10.1006/abbi.1994.1013; Raveh L, 1999, NEUROTOXICOLOGY, V20, P551; SAVOLAINEN KM, 1988, TOXICOL APPL PHARM, V96, P305, DOI 10.1016/0041-008X(88)90089-0; SCHLIEBS R, 1989, J NEUROCHEM, V53, P212, DOI 10.1111/j.1471-4159.1989.tb07316.x; Solberg Y, 1997, TRENDS PHARMACOL SCI, V18, P183, DOI 10.1016/S0165-6147(97)89540-5; SPERK G, 1985, BRAIN RES, V338, P289, DOI 10.1016/0006-8993(85)90159-3; Sperlagh B, 1996, SEMIN NEUROSCI, V8, P175, DOI 10.1006/smns.1996.0023; Tavazzi B, 2000, EUR J BIOCHEM, V267, P684, DOI 10.1046/j.1432-1327.2000.01042.x; Taylor DL, 1999, BRAIN PATHOL, V9, P93; TAYYABA K, 1985, ACTA PHARMACOL TOX, V57, P190, DOI 10.1111/bcpt.1985.57.3.190; Tsujimoto Y, 1997, CELL DEATH DIFFER, V4, P429, DOI 10.1038/sj.cdd.4400262; VANACKER SABE, 1993, FREE RADICAL BIO MED, V15, P311, DOI 10.1016/0891-5849(93)90078-9; VEDIA LM, 1992, J BIOL CHEM, V267, P24929; WASTERLAIN CG, 1994, BRAIN DEV-JPN, V16, P279, DOI 10.1016/0387-7604(94)90025-6; WECKER L, 1978, J PHARMACOL EXP THER, V206, P97; Yang PY, 2000, J TOXICOL-CLIN TOXIC, V38, P43, DOI 10.1081/CLT-100100914; Yang ZP, 1998, J PHYSIOLOGY-PARIS, V92, P157, DOI 10.1016/S0928-4257(98)80002-8; Zivin M, 1999, BRAIN RES, V850, P63, DOI 10.1016/S0006-8993(99)02101-0; Zivin M, 1999, FASEB J, V13, pA1102	73	108	115	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0161-813X	1872-9711		NEUROTOXICOLOGY	Neurotoxicology	APR	2001	22	2					271	282		10.1016/S0161-813X(01)00013-4			12	Neurosciences; Pharmacology & Pharmacy; Toxicology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology; Pharmacology & Pharmacy; Toxicology	439NE	WOS:000169122400010	11405258				2022-02-06	
S	Blass, JP		Khachaturian, ZS; Mesulam, MM		Blass, JP			The mitochondrial spiral - An adequate cause of dementia in the Alzheimer's syndrome	ALZHEIMERS DISEASE: A COMPENDIUM OF CURRENT THEORIES	Annals of the New York Academy of Sciences		English	Article; Proceedings Paper	Conference on Towards a Comprehensive Theory for Alzheimers Disease	APR 30-MAY 02, 1999	ORLANDO, FL	Bayer, EISAI, Hoechst Marion Roussel, Pfizer, Roche		mitochondria; energy; KGDHC; reactive oxygen species; calcium	AMYLOID-BETA-PEPTIDE; KETOGLUTARATE DEHYDROGENASE COMPLEX; APOLIPOPROTEIN-E GENOTYPE; TRAUMATIC BRAIN INJURY; OXIDATIVE STRESS; REACTIVE OXYGEN; PRECURSOR PROTEIN; IN-VIVO; COGNITIVE IMPAIRMENT; GLUCOSE-METABOLISM	A variety of chronic, relatively low-grade injuries to the brain occur in Alzheimer's disease (AD). The extent to which each of these contributes to the clinical syndrome is unclear. Several of the abnormalities that occur in AD brain can cause dementia by themselves, even in people who do not have the neuropathological hallmarks of AD. Prominent among these abnormalities is a deleterious "mitochondrial spiral," which consists of reduced brain metabolism, oxidative stress, and calcium dysregulation. The hypothesis presented in this paper is that the mitochondrial spiral contributes to dementia in AD and presents a reasonable target for the development of new approaches to the treatment of this syndrome.	Weill Cornell Med Coll, Burke Med Res Inst, White Plains, NY 10605 USA		Blass, JP (corresponding author), Weill Cornell Med Coll, Burke Med Res Inst, 785 Mamaroneck Ave, White Plains, NY 10605 USA.	jpblass@mail.med.cornell.edu					Albers DS, 2000, J NEUROCHEM, V74, P878, DOI 10.1046/j.1471-4159.2000.740878.x; Ashok BT, 1999, EXP GERONTOL, V34, P293, DOI 10.1016/S0531-5565(99)00005-4; BICK K, 1987, EARLY STORY ALZHEIME; BLASS JP, 1990, ARCH NEUROL-CHICAGO, V47, P864, DOI 10.1001/archneur.1990.00530080046009; Blass JP, 1999, NEW ENGL J MED, V341, P1694, DOI 10.1056/NEJM199911253412213; Blass JP, 1999, DEMENT GERIATR COGN, V10, P335, DOI 10.1159/000017165; Blass JP, 2000, ANN NY ACAD SCI, V903, P204, DOI 10.1111/j.1749-6632.2000.tb06370.x; BLASS JP, 1999, ANN NY ACAD SCI, V893; BLASS JP, 1999, ANN NY ACAD SCI, V893, P11; BLASS JP, 1997, ALZHEIMERS DIS CAUSE, P187; BLASS JP, 1997, ADV CELL AGING GERON, V2, P109; BOBINSKI M, 1995, DEMENTIA, V6, P205, DOI 10.1159/000106948; Butterfield DA, 1999, ANN NY ACAD SCI, V893, P265, DOI 10.1111/j.1749-6632.1999.tb07833.x; Cadroy Y, 2000, J IMMUNOL, V164, P3822, DOI 10.4049/jimmunol.164.7.3822; Chan SL, 2000, J BIOL CHEM, V275, P18195, DOI 10.1074/jbc.M000040200; Chandrasekaran K, 1998, BRAIN RES, V796, P13, DOI 10.1016/S0006-8993(98)00248-0; Coon AL, 1999, NEUROBIOL AGING, V20, P597, DOI 10.1016/S0197-4580(99)00068-8; CoreyBloom J, 1997, NEUROLOGY, V48, P154, DOI 10.1212/WNL.48.1.154; Craft S, 2000, ANN NY ACAD SCI, V903, P222, DOI 10.1111/j.1749-6632.2000.tb06371.x; Davis DG, 1999, J NEUROPATH EXP NEUR, V58, P376, DOI 10.1097/00005072-199904000-00008; Drachman DA, 1997, NEW ENGL J MED, V336, P1245, DOI 10.1056/NEJM199704243361710; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.278.16.1349; FISCHER P, 1991, WIEN MED WOCHENSCHR, V141, P455; Floyd RA, 1999, FREE RADICAL BIO MED, V26, P1346, DOI 10.1016/S0891-5849(98)00293-7; Fridovich I, 1999, ANN NY ACAD SCI, V893, P13, DOI 10.1111/j.1749-6632.1999.tb07814.x; Gibson GE, 1999, ANN NY ACAD SCI, V893, P79, DOI 10.1111/j.1749-6632.1999.tb07819.x; Gibson GE, 1997, NEUROBIOL AGING, V18, P573, DOI 10.1016/S0197-4580(97)00149-8; GIBSON GE, 1981, AM J MED, V70, P1247, DOI 10.1016/0002-9343(81)90834-2; GIBSON GE, 2000, IN PRESS ANN NEUROL; Hachinski V, 2000, ANN NY ACAD SCI, V903, P1, DOI 10.1111/j.1749-6632.2000.tb06343.x; Harding AJ, 2000, ACTA NEUROPATHOL, V99, P199, DOI 10.1007/PL00007425; HEVNER RF, 1993, J NEUROSCI, V13, P1805; Ishii K, 1996, J NUCL MED, V37, P1159; Ito S, 1999, P NATL ACAD SCI USA, V96, P2099, DOI 10.1073/pnas.96.5.2099; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; KALARIA RN, 2000, ANN NY ACAD SCI, V903; Kehoe P, 1999, HUM MOL GENET, V8, P237, DOI 10.1093/hmg/8.2.237; Keller JN, 1997, J NEUROSCI RES, V50, P522, DOI 10.1002/(SICI)1097-4547(19971115)50:4<522::AID-JNR3>3.0.CO;2-G; Klann E, 1998, J NEUROPHYSIOL, V80, P452, DOI 10.1152/jn.1998.80.1.452; KO L, 1990, ACTA NEUROPATHOL, V81, P30, DOI 10.1007/BF00662635; Kobayashi T, 1998, ANN NEUROL, V43, P120, DOI 10.1002/ana.410430121; Kokmen E, 1996, MAYO CLIN PROC, V71, P275, DOI 10.4065/71.3.275; Leissring MA, 2000, J CELL BIOL, V149, P793, DOI 10.1083/jcb.149.4.793; Lewen A, 1998, J NEUROTRAUM, V15, P521, DOI 10.1089/neu.1998.15.521; Markesbery WR, 1999, ARCH NEUROL-CHICAGO, V56, P1449, DOI 10.1001/archneur.56.12.1449; Markesbery WR, 1999, BRAIN PATHOL, V9, P133; Mastrogiacomo F, 1996, ANN NEUROL, V39, P592, DOI 10.1002/ana.410390508; Mattson MP, 1997, NEUROREPORT, V8, P2275, DOI 10.1097/00001756-199707070-00036; Mattson MP, 2000, J NEUROSCI, V20, P1358; Mattson MP, 1999, ANN NY ACAD SCI, V893, P154, DOI 10.1111/j.1749-6632.1999.tb07824.x; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; Mattson MP, 2000, TRENDS NEUROSCI, V23, P222, DOI 10.1016/S0166-2236(00)01548-4; McGeer EG, 1999, CURR PHARM DESIGN, V5, P821; Melov S, 1999, MUTAT RES-DNA REPAIR, V434, P233, DOI 10.1016/S0921-8777(99)00031-2; Morris JC, 1999, J CLIN INVEST, V104, P1171, DOI 10.1172/JCI8560; Neve RL, 1998, TRENDS NEUROSCI, V21, P15, DOI 10.1016/S0166-2236(97)01168-5; Nolan KA, 1998, J AM GERIATR SOC, V46, P597, DOI 10.1111/j.1532-5415.1998.tb01076.x; Pedersen WA, 2000, J NEUROCHEM, V74, P1426, DOI 10.1046/j.1471-4159.2000.0741426.x; Perry G, 2000, FREE RADICAL BIO MED, V28, P831, DOI 10.1016/S0891-5849(00)00158-1; POIRIER J, 1999, CLIN DIAGNOSIS MANAG, P17; Rego AC, 1999, FREE RADICAL BIO MED, V26, P1405, DOI 10.1016/S0891-5849(98)00337-2; Reiman EM, 1996, NEW ENGL J MED, V334, P752, DOI 10.1056/NEJM199603213341202; Rhodin J, 2000, ANN NY ACAD SCI, V903, P345, DOI 10.1111/j.1749-6632.2000.tb06385.x; Sano M, 1997, NEW ENGL J MED, V336, P1216, DOI 10.1056/NEJM199704243361704; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Sheu KFR, 1999, ANN NY ACAD SCI, V893, P61; Small DH, 1999, J NEUROCHEM, V73, P443, DOI 10.1046/j.1471-4159.1999.0730443.x; SMALL GW, 1995, JAMA-J AM MED ASSOC, V273, P942, DOI 10.1001/jama.273.12.942; Smith CD, 1999, J NEUROIMAGING, V9, P2, DOI 10.1111/jon1999912; Spillantini MG, 2000, BRAIN, V123, P857, DOI 10.1093/brain/123.5.857; St George-Hyslop PH, 2000, BIOL PSYCHIAT, V47, P183, DOI 10.1016/S0006-3223(99)00301-7; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; Sulger J, 1999, BIOL PSYCHIAT, V45, P737, DOI 10.1016/S0006-3223(98)00218-2; Vendite D, 1998, NEUROCHEM RES, V23, P211, DOI 10.1023/A:1022437110269; VOLPE BT, 1986, NEUROLOGY, V36, P408, DOI 10.1212/WNL.36.3.408; VOLPE BT, 1992, BEHAV NEUROSCI, V106, P457, DOI 10.1037/0735-7044.106.3.457; VOLPE BT, 1985, NEUROLOGY, V35, P1793, DOI 10.1212/WNL.35.12.1793; Yatin SM, 1999, NEUROBIOL AGING, V20, P325; Zsurka G, 1998, BIOL PSYCHIAT, V44, P371, DOI 10.1016/S0006-3223(97)00461-7	79	108	109	0	3	NEW YORK ACAD SCIENCES	NEW YORK	2 EAST 63RD ST, NEW YORK, NY 10021 USA	0077-8923		1-57331-297-5	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2000	924						170	183					14	Multidisciplinary Sciences; Clinical Neurology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics; Neurosciences & Neurology	BT10Q	WOS:000171966500025	11193795				2022-02-06	
J	Kant, R; SmithSeemiller, L; Isaac, G; Duffy, J				Kant, R; SmithSeemiller, L; Isaac, G; Duffy, J			Tc-HMPAO SPECT in persistent postconcussion syndrome after mild head injury: Comparison with MRI/CT	BRAIN INJURY			English	Article							TRAUMATIC BRAIN INJURY; HM-PAO-SPECT; TECHNETIUM-99M-HMPAO SPECT; COMPUTED-TOMOGRAPHY; CEREBRAL PERFUSION; CT; HISTORY; SCALE	The purposes of this study were: (1) to determine the prevalence of abnormal (99)mTc-HMPAO SPECT scans in patients suffering persistent post-concussive syndrome (PPCS) after mild closed head injury (CHI); (2) to compare SPECT with structural neuroimaging (MRI and CT) in patients with mild CHI; and (3) to investigate correlations between SPECT and clinical data obtained from the patient sample (neuropsychological testing, demographics, psychiatric diagnoses). Forty-three patients were included. SPECT was read as abnormal in 53% of patients and showed a total of 37 lesions while MRI was read as abnormal in 9% and CT scan in only 4.6% of patients after mild CHI. SPECT appears to be more sensitive in detecting cerebral abnormalities after mild CHI, especially in patients with PPCS symptoms, than either CT or MRI. No statistically significant relationship was found between SPECT scan abnormalities and age, past psychiatric history, history of substance abuse, or history of multiple CHI. Education level did differ between patients with normal and abnormal SPECT. Current neuropsychiatric symptoms did not seem to have any impact on the results oi SPECT scan.	ALLEGHENY GEN HOSP,PITTSBURGH,PA 15212; UNIV CONNECTICUT,FARMINGTON,CT		Kant, R (corresponding author), ST FRANCIS MED CTR,HEAD INJURY CLIN,4608 PENN AVE,PITTSBURGH,PA 15224, USA.						ABDELDAYEM HM, 1987, RADIOLOGY, V165, P221, DOI 10.1148/radiology.165.1.3498184; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; CHOKSEY MS, 1991, J NEUROL NEUROSUR PS, V54, P6, DOI 10.1136/jnnp.54.1.6; GRAY BG, 1992, J NUCL MED, V33, P52; Heaton PDRK., 1993, WISCONSIN CARD SORTI; JACOBS A, 1994, J NUCL MED, V35, P942; Kraus Jess F., 1994, P3; MARIN RS, 1991, PSYCHIAT RES, V38, P143, DOI 10.1016/0165-1781(91)90040-V; NEDD K, 1993, BRAIN INJURY, V7, P469, DOI 10.3109/02699059309008174; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; ODER W, 1991, INTENS CARE MED, V17, P149, DOI 10.1007/BF01704718; REID RH, 1990, CLIN NUCL MED, V15, P383, DOI 10.1097/00003072-199006000-00003; Reitan R, 1985, HALSTEAD REITAN NEUR; ROPER SN, 1991, J NUCL MED, V32, P1684; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; STERN Y, 1991, Society for Neuroscience Abstracts, V17, P1258; TEASDALE G, 1974, LANCET, V2, P81; TIKOFSKY RS, 1994, J NUCL MED, V35, P947; VARNEY NR, 1995, J HEAD TRAUMA REHAB, V10, P18; Wechsler D, 1987, MEMORY SCALE REVISED; Zimmerman RA, 1989, NEUROPSYCHOLOGY, V3, P191, DOI 10.1037/h0091791; 1996, NEUROLOGY, V46, P278	26	108	108	0	2	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	FEB	1997	11	2					115	124		10.1080/026990597123700			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	WD430	WOS:A1997WD43000003	9012944				2022-02-06	
J	Greenspan, AI; Wrigley, JM; Kresnow, M; BrancheDorsey, CM; Fine, PR				Greenspan, AI; Wrigley, JM; Kresnow, M; BrancheDorsey, CM; Fine, PR			Factors influencing failure to return to work due to traumatic brain injury	BRAIN INJURY			English	Article							SEVERE HEAD-INJURY; FOLLOW-UP; SOCIAL RECOVERY; REHABILITATION; IMPAIRMENT; DISABILITY	About 63% of all traumatic brain injuries (TBI) occur in teenagers and adults aged 15-64 years, the primary working population. Since reports of failure to return to work (FTRTW) vary, understanding the factors that influence FTRTW is key to improving work outcomes for this primarily working-age population Our study sample consists of 343 previously employed persons who were hospitalized following TBI and had either returned to work at 1 year or had failed to return to work because of their injury (injury-related FTRTW). Medical records were reviewed and participants were interviewed by telephone at 1 year post-discharge. Individuals with injury-related FTRTW were far more likely to report dependence or modified independence on the Functional Independence Measure (FIM) than those who were employed at 1 year. The joint distribution of motor and cognitive items suggests that, for a given level of cognitive function, the addition of a motor limitation will result in greater injury-related FTRTW. In addition as motor function declines, FTRTW is further increased. Injury-related FTRTW is also associated with being unmarried and not completing high school. While the importance of behavioural, economic, and psychosocial factors should not be minimized, services aimed at improving function can be expected to have an impact on RTW after TBI.	UNIV ALABAMA,INJURY CONTROL RES CTR,BIRMINGHAM,AL		Greenspan, AI (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INJURY PREVENT & CONTROL,4770 BUFORD HIGHWAY NE,MAILSTOP K-41,ATLANTA,GA 30341, USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR403641] Funding Source: Medline		AGRESTI A, 1990, CATEGORICAL DATA ANA, P43; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; BULL JP, 1985, ACCIDENT ANAL PREV, V17, P355; *COMM INJ SCAL, 1985, ABBR INJ SCAL 1985 R; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; FRASER R, 1988, REHABIL COUNS BULL, V31, P276; GRANGER CV, 1993, AM J PHYS MED REHAB, V72, P33, DOI 10.1097/00002060-199302000-00008; Hall K. M., 1993, J HEAD TRAUMA REHAB, V8, P60, DOI DOI 10.1097/00001199-199308020-00008; Hamilton BB, 1987, REHABILITATION OUTCO; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; HUMPHREY M, 1980, INJURY, V12, P107, DOI 10.1016/0020-1383(80)90133-3; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; Kaplan S. P., 1988, J APPLIED REHABILITA, V19, P3; Keith R A, 1987, Adv Clin Rehabil, V1, P6; KRAUS J, 1985, HEAD INJURY, P1; LEZAK MD, 1988, J LEARN DISABIL, V21, P456, DOI 10.1177/002221948802100802; MACKENZIE EJ, 1989, MED CARE, V27, P412, DOI 10.1097/00005650-198904000-00008; MACKENZIE EJ, 1987, AM J PUBLIC HEALTH, V77, P329, DOI 10.2105/AJPH.77.3.329; MACKENZIE EJ, 1986, MED CARE, V24, P377, DOI 10.1097/00005650-198605000-00001; MACKENZIE EJ, 1989, J TRAUMA, V29, P757, DOI 10.1097/00005373-198906000-00011; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; MORRIS JA, 1990, JAMA-J AM MED ASSOC, V263, P1942, DOI 10.1001/jama.263.14.1942; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; RAO N, 1990, Brain Injury, V4, P49, DOI 10.3109/02699059009026148; RHODES M, 1988, J TRAUMA, V28, P931, DOI 10.1097/00005373-198807000-00005; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Thomsen I V, 1989, Brain Inj, V3, P157, DOI 10.3109/02699058909004547; TYERMAN A, 1985, INT J REHABILITATION, V7, P21; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; WEHMAN PH, 1990, ARCH PHYS MED REHAB, V71, P1047; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3	36	108	109	0	6	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	MAR	1996	10	3					207	218		10.1080/026990596124520			12	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	UC765	WOS:A1996UC76500004	8777392				2022-02-06	
J	KIRBY, RL; ACKROYDSTOLARZ, SA; BROWN, MG; KIRKLAND, SA; MACLEOD, DA				KIRBY, RL; ACKROYDSTOLARZ, SA; BROWN, MG; KIRKLAND, SA; MACLEOD, DA			WHEELCHAIR-RELATED ACCIDENTS CAUSED BY TIPS AND FALLS AMONG NONINSTITUTIONALIZED USERS OF MANUALLY PROPELLED WHEELCHAIRS IN NOVA-SCOTIA	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						WHEELCHAIRS; EPIDEMIOLOGY; SAFETY; REHABILITATION	PREVENTION; INJURIES	The purpose of this study was to document what proportion of noninstitutionalized users of manually propelled wheelchairs are affected by wheelchair-related accidents caused by tips and falls, determine the nature and severity of the resulting injuries, and, by comparison with an unaffected group, identify factors associated with the risk of such accidents. We administered a postal questionnaire to as many as possible of the estimated 2055 members of the target population in the province of Nova Scotia. Among the 577 appropriate respondents, 57.4% reported they had completely tipped over or fallen from their wheelchairs at least once, and 66.0% reported having partially tipped. Of the falls and tips that were reported, 46.3% were forward in direction, 29.5% backward and 24.2% sideways. Many of the accidents occurred outdoors or on ramps. A total of 292 injuries were reported by 272 (47.1%) respondents. Most of the injuries (84.3%) were minor (e.g., abrasions, contusions, lacerations and sprains). Of the 15.8% of injuries that were serious, the most common were fractures (10.6%) and concussions (2.7%). Factors that appear to be associated with an increased risk of accidents and injuries included younger age, male gender, paraplegia or spina bifida as the reason for wheelchair use, having had a wheelchair prescribed, some wheelchair features (lightweight, camber, adjustable rear-axle positions, a knapsack), daily use of a wheelchair, propelling the chair with both hands, use of the wheelchair for recreation, use of a sideways transfer (without a transfer board) and doing repairs themselves or having them done by the dealer. Factors associated with a decreased risk include multiple sclerosis, stroke or arthritis as the reason for wheelchair use, attendant propulsion and the use of a one-person assist for transfers. The results of this study, that wheelchair-related accidents caused by tips and falls are very common, that serious injuries are not unusual and that there is a pattern of risk factors, should be useful to wheelchair users, clinicians, manufacturers and regulatory bodies.	DALHOUSIE UNIV,NOVA SCOTIA REHABIL CTR,DEPT EPIDEMIOL & COMMUNITY HLTH,HALIFAX,NS,CANADA		KIRBY, RL (corresponding author), DALHOUSIE UNIV,NOVA SCOTIA REHABIL CTR,DEPT MED,DIV PHYS MED & REHABIL,1341 SUMMER ST,HALIFAX B3H 4K4,NS,CANADA.			Kirkland, Susan/0000-0002-8182-2369			BATAVIA A I, 1990, Journal of Rehabilitation Research and Development, V27, P425, DOI 10.1682/JRRD.1990.10.0425; BECKER D G, 1991, Journal of Emergency Medicine, V9, P115, DOI 10.1016/0736-4679(91)90314-6; Bennett L, 1987, J Rehabil Res Dev, V24, P81; BLOOMQUIST LE, 1986, PHYSICIAN SPORTSMED, V14, P97; BREED AL, 1986, DEV MED CHILD NEUROL, V24, P366; CALDER CJ, 1990, AM J PHYS MED REHAB, V69, P184, DOI 10.1097/00002060-199008000-00003; CURTIS KA, 1985, PARAPLEGIA, V23, P170, DOI 10.1038/sc.1985.29; Dillman DA, 1978, MAIL TELEPHONE SURVE, V19; DUDLEY NJ, 1992, CLIN REHABIL, V7, P9; Fenwick D., 1977, WHEELCHAIRS THEIR US; GRAY B, 1992, DEV MED CHILD NEUROL, V34, P589; HAYS RM, 1985, ARCH PHYS MED REHAB, V66, P709; Hunter J, 1987, Int J Rehabil Res, V10, P77; KAUZLARICH JJ, 1981, WHEELCHAIR MOBILITY, P55; KETTLE M, 1992, CLIN REHABIL, V6, P67, DOI DOI 10.1177/026921559200600109; KIRBY RL, 1992, 7TH P WORLD C ISPO, P257; KIRBY RL, 1990, ASSISTIVE TECHNOLOGY, V2, P59; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LOANE TD, 1985, ARCH PHYS MED REHAB, V66, P174; MARWICK DP, 1975, SAMPLE SURVEY THEORY; Mion L C, 1989, Rehabil Nurs, V14, P17; NILSEN R, 1985, PARAPLEGIA, V23, P152, DOI 10.1038/sc.1985.26; NOTTAGE WM, 1981, CLIN ORTHOPAEDICS, V155, P65; PAULSON SM, 1983, ARCH PHYS MED REHAB, V64, P180; PLATTS EA, 1974, P ROY SOC MED, V67, P414, DOI 10.1177/003591577406700532; REED RL, 1993, ARCH PHYS MED REHAB, V74, P101; UMMAT S, 1994, AM J PHYS MED REHAB, V73, P163, DOI 10.1097/00002060-199406000-00004; WOODWARD CA, 1983, GUIDE QUESTIONNAIRE; 1982, STATISTICAL ABSTRACT, P115; 1991, NOVA SCOTIA FACT BOO; 1988, HLTH ACTIVITY LIMITA; 1992, PEOPLE DISABILITIES	32	108	109	0	7	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	SEP-OCT	1994	73	5					319	330		10.1097/00002060-199409000-00004			12	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	PL292	WOS:A1994PL29200003	7917161				2022-02-06	
J	GENTRY, LR; GODERSKY, JC; THOMPSON, BH				GENTRY, LR; GODERSKY, JC; THOMPSON, BH			TRAUMATIC BRAIN-STEM INJURY - MR IMAGING	RADIOLOGY			English	Article									UNIV IOWA HOSP & CLIN, DEPT SURG, DIV NEUROSURG, IOWA CITY, IA 52242 USA; UNIV IOWA HOSP & CLIN, DEPT RADIOL, IOWA CITY, IA 52242 USA		GENTRY, LR (corresponding author), UNIV WISCONSIN, HOSP & CLIN, DEPT RADIOL, NEURORADIOL SECT, 600 HIGHLAND AVE, MADISON, WI 53792 USA.						ADAMS JH, 1976, NEUROPATH APPL NEURO, V2, P323, DOI 10.1111/j.1365-2990.1976.tb00506.x; ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ADAMS JH, 1985, CENTRAL NERVOUS SYST, P65; ADAMS JH, 1984, GREENFIELDS NEUROPAT, P85; BRITT RH, 1980, NEUROSURGERY, V6, P623, DOI 10.1227/00006123-198006000-00002; CAPLAN LR, 1977, ANN NEUROL, V1, P587, DOI 10.1002/ana.410010613; CLARK JM, 1974, J NEUROL NEUROSUR PS, V37, P463, DOI 10.1136/jnnp.37.4.463; CLIFTON GL, 1981, NEUROSURGERY, V8, P309, DOI 10.1227/00006123-198103000-00002; COOPER PR, 1979, NEUROSURGERY, V5, P566, DOI 10.1227/00006123-197911000-00004; COOPER PR, 1979, NEUROSURGERY, V4, P115, DOI 10.1227/00006123-197902000-00002; CROMPTON MR, 1971, LANCET, V1, P669; DELAPAZ RL, 1984, J COMPUT ASSIST TOMO, V8, P599, DOI 10.1097/00004728-198408000-00004; DOOMS GC, 1986, NEURORADIOLOGY, V28, P132, DOI 10.1007/BF00327885; FRENCH BN, 1977, SURG NEUROL, V7, P171; FRIEDE RL, 1966, NEUROLOGY, V16, P1210, DOI 10.1212/WNL.16.12.1210; GENNARELLI TA, 1985, TRAUMA CENTRAL NERVO, P169; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1988, AM J NEURORADIOL, V9, P91; GENTRY LR, IN PRESS AJNR; GEORGE B, 1981, ACTA NEUROCHIR, V59, P35, DOI 10.1007/BF01411189; GIBSON PH, 1983, NEUROPATH APPL NEURO, V9, P135, DOI 10.1111/j.1365-2990.1983.tb00331.x; GOMORI JM, 1985, RADIOLOGY, V157, P87, DOI 10.1148/radiology.157.1.4034983; GROSWASSER Z, 1987, SURG NEUROL, V27, P331, DOI 10.1016/0090-3019(87)90007-3; Gruszkiewicz J, 1973, Surg Neurol, V1, P197; GURDJIAN ES, 1955, SURG GYNECOL OBSTET, V101, P680; GYORI E, 1985, CLIN NEUROPATHOL, V4, P121; Hardman J M, 1979, Adv Neurol, V22, P15; Holbourn AHS, 1943, LANCET, V2, P438; JELLINGER K, 1970, J NEUROL SCI, V10, P51, DOI 10.1016/0022-510X(70)90091-2; JENKINS A, 1986, LANCET, V2, P445; JOHNSON RT, 1956, ACTA RADIOL, V46, P250, DOI 10.3109/00016925609170834; LIPPER MH, 1985, AM J ROENTGENOL, V144, P483, DOI 10.2214/ajr.144.3.483; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; MATSUOKA K., 1967, MED J OSAKA UNIV, V17, P257; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; Pilz P, 1983, Acta Neurochir Suppl (Wien), V32, P119; Pilz P, 1983, Acta Neurochir Suppl (Wien), V32, P75; ROPPER AH, 1985, ANN NEUROL, V18, P80, DOI 10.1002/ana.410180114; ROSENBLUM WI, 1981, NEUROSURGERY, V9, P613, DOI 10.1227/00006123-198112000-00001; SAEKI N, 1985, Neurologia Medico-Chirurgica, V25, P939, DOI 10.2176/nmc.25.939; SEELIG JM, 1981, J NEUROSURG, V55, P516, DOI 10.3171/jns.1981.55.4.0516; SNOEK J, 1979, J NEUROL NEUROSUR PS, V42, P215, DOI 10.1136/jnnp.42.3.215; SNOW RB, 1986, NEUROSURGERY, V18, P45, DOI 10.1227/00006123-198601000-00008; STOVRING J, 1977, NEURORADIOLOGY, V14, P101, DOI 10.1007/BF00333050; STRICH SJ, 1961, LANCET, V2, P443; SUNDERLAND S, 1958, BRIT J SURG, V45, P422, DOI 10.1002/bjs.18004519306; TANDON PN, 1964, ACTA NEUROL SCAND, V40, P375; Tomlinson B E, 1970, J Clin Pathol Suppl (R Coll Pathol), V4, P154; TSAI FY, 1980, J COMPUT ASSIST TOMO, V4, P291, DOI 10.1097/00004728-198006000-00002; TSAI FY, 1980, AM J ROENTGENOL, V134, P717, DOI 10.2214/ajr.134.4.717; TSAI FY, 1978, J COMPUT ASSIST TOMO, V2, P323, DOI 10.1097/00004728-197807000-00018; Turazzi S, 1975, J Neurosurg Sci, V19, P215; WILBERGER JE, 1987, NEUROSURGERY, V20, P571, DOI 10.1227/00006123-198704000-00011; ZIMMERMAN RA, 1978, RADIOLOGY, V127, P393, DOI 10.1148/127.2.393; ZIMMERMAN RA, 1986, AM J ROENTGENOL, V147, P1215, DOI 10.2214/ajr.147.6.1215; ZUCCARELLO M, 1983, ACTA NEUROCHIR, V67, P103, DOI 10.1007/BF01401670; [No title captured]; [No title captured]	61	108	111	1	2	RADIOLOGICAL SOC NORTH AMERICA	OAK BROOK	820 JORIE BLVD, OAK BROOK, IL 60523 USA	0033-8419			RADIOLOGY	Radiology	APR	1989	171	1					177	187		10.1148/radiology.171.1.2928523			11	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	T8006	WOS:A1989T800600035	2928523				2022-02-06	
J	Joy, MT; Ben Assayag, E; Shabashov-Stone, D; Liraz-Zaltsman, S; Mazzitelli, J; Arenas, M; Abduljawad, N; Kliper, E; Korczyn, AD; Thareja, NS; Kesner, EL; Zhou, M; Huang, S; Silva, TK; Katz, N; Bornstein, NM; Silva, AJ; Shohami, E; Carmichael, ST				Joy, Mary T.; Ben Assayag, Einor; Shabashov-Stone, Dalia; Liraz-Zaltsman, Sigal; Mazzitelli, Jose; Arenas, Marcela; Abduljawad, Nora; Kliper, Efrat; Korczyn, Amos D.; Thareja, Nikita S.; Kesner, Efrat L.; Zhou, Miou; Huang, Shan; Silva, Tawnie K.; Katz, Noomi; Bornstein, Natan M.; Silva, Alcino J.; Shohami, Esther; Carmichael, S. Thomas			CCR5 Is a Therapeutic Target for Recovery after Stroke and Traumatic Brain Injury	CELL			English	Article							CLOSED-HEAD INJURY; FUNCTIONAL RECOVERY; DENDRITIC SPINES; PREMOTOR CORTEX; PLASTICITY; REHABILITATION; MEMORY; AGE; REGENERATION; HEMIPARESIS	We tested a newly described molecular memory system, CCR5 signaling, for its role in recovery after stroke and traumatic brain injury (TBI). CCR5 is uniquely expressed in cortical neurons after stroke. Post-stroke neuronal knockdown of CCR5 in pre-motor cortex leads to early recovery of motor control. Recovery is associated with preservation of dendritic spines, new patterns of cortical projections to contralateral pre-motor cortex, and upregulation of CREB and DLK signaling. Administration of a clinically utilized FDA-approved CCR5 antagonist, devised for HIV treatment, produces similar effects on motor recovery post stroke and cognitive decline post TBI. Finally, in a large clinical cohort of stroke patients, carriers for a naturally occurring loss-of-function mutation in CCR5 (CCR5-Delta 32) exhibited greater recovery of neurological impairments and cognitive function. In summary, CCR5 is a translational target for neural repair in stroke and TBI and the first reported gene associated with enhanced recovery in human stroke.	[Joy, Mary T.; Mazzitelli, Jose; Arenas, Marcela; Abduljawad, Nora; Thareja, Nikita S.; Carmichael, S. Thomas] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA; [Zhou, Miou; Huang, Shan; Silva, Tawnie K.; Silva, Alcino J.] Univ Calif Los Angeles, Dept Neurobiol, Integrat Ctr Learning & Memory, Los Angeles, CA 90095 USA; [Zhou, Miou; Huang, Shan; Silva, Tawnie K.; Silva, Alcino J.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Integrat Ctr Learning & Memory, Los Angeles, CA 90095 USA; [Zhou, Miou; Huang, Shan; Silva, Tawnie K.; Silva, Alcino J.] Univ Calif Los Angeles, Dept Psychol, Integrat Ctr Learning & Memory, Los Angeles, CA 90095 USA; [Zhou, Miou; Huang, Shan; Silva, Tawnie K.; Silva, Alcino J.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90095 USA; [Ben Assayag, Einor; Kliper, Efrat; Bornstein, Natan M.] Tel Aviv Sourasky Med Ctr, Dept Neurol, Tel Aviv, Israel; [Shabashov-Stone, Dalia; Liraz-Zaltsman, Sigal; Kesner, Efrat L.; Shohami, Esther] Hebrew Univ Jerusalem, Inst Drug Res, Dept Pharmacol, Jerusalem, Israel; [Ben Assayag, Einor; Korczyn, Amos D.; Bornstein, Natan M.] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel; [Liraz-Zaltsman, Sigal] Sheba Med Ctr, Joseph Sagol Neurosci Ctr, Tel Hashomer, Israel; [Liraz-Zaltsman, Sigal; Katz, Noomi] Ono Acad Coll, Inst Hlth & Med Profess, Kiryat Ono, Israel		Carmichael, ST (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA.	scarmichael@mednet.ucla.edu	Silva, Alcino/ABD-7684-2021; Joy, Mary Teena/S-9605-2018; Zhou, Miou/AAK-1515-2021	Silva, Alcino/0000-0002-1587-4558; Joy, Mary Teena/0000-0002-3120-2022; Joy, Mary Teena/0000-0003-4615-4067; Mazzitelli Perez, Jose/0000-0002-3896-3553; Zhou, Miou/0000-0001-8188-7392	Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; American Heart FoundationAmerican Heart Association [16POST27710039]; United States-Israel Binational Science FoundationUS-Israel Binational Science Foundation [2011344]; Alzheimer's AssociationAlzheimer's Association [16-442861]; American Federation for Aging Research [RAG11482]	These studies were funded by Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (S.T.C., E.S., and A.J.S.), American Heart Foundation (16POST27710039, M.T.J.), United States-Israel Binational Science Foundation (2011344, E.B.A.), Alzheimer's Association (16-442861, EBA), and the American Federation for Aging Research (RAG11482, E.B.A.). We thank Rex Lee for dedicated technical assistance. We thank Dr. Greg Khitrov for technical assistance at UCLA MIC; Felicia Codrea, Jessica Scholes, and Jeff Calimlim at the UCLA FACS core (BSCRC); and Dr. Joanna Liliental at TASC core at Stanford University. We thank Sali Usher for her dedicated help in genetic analyses and Tal Adamit for comprehensive data collection from stroke patients at 3 months post stroke.	Adelson JD, 2012, NEURON, V73, P1100, DOI 10.1016/j.neuron.2012.01.020; Artzi M, 2013, EUR J RADIOL, V82, P1512, DOI 10.1016/j.ejrad.2013.05.029; Balkaya M, 2019, NEUROBIOL DIS, V126, P36, DOI 10.1016/j.nbd.2018.08.009; Barreto GE, 2012, EXP NEUROL, V238, P284, DOI 10.1016/j.expneurol.2012.08.015; Ben Assayag E, 2012, INT J STROKE, V7, P341, DOI 10.1111/j.1747-4949.2011.00652.x; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Bigler ED, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00395; Brown CE, 2008, STROKE, V39, P1286, DOI 10.1161/STROKEAHA.107.498238; Brown CE, 2007, J NEUROSCI, V27, P4101, DOI 10.1523/JNEUROSCI.4295-06.2007; Caracciolo L, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04445-9; Chollet F, 2011, LANCET NEUROL, V10, P123, DOI 10.1016/S1474-4422(10)70314-8; Clarkson AN, 2011, J NEUROSCI, V31, P3766, DOI 10.1523/JNEUROSCI.5780-10.2011; Clarkson AN, 2010, NATURE, V468, P305, DOI 10.1038/nature09511; Cramer SC, 2012, EUR J NEUROL, V19, P718, DOI 10.1111/j.1468-1331.2011.03615.x; Di Lazzaro V, 2010, CEREB CORTEX, V20, P1523, DOI 10.1093/cercor/bhp216; Doniger Glen M, 2006, Am J Alzheimers Dis Other Demen, V21, P28; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; Fisher M, 2009, AM J PSYCHIAT, V166, P805, DOI 10.1176/appi.ajp.2009.08050757; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Fu M, 2012, NATURE, V483, P92, DOI 10.1038/nature10844; Ginhoux F, 2014, NAT REV IMMUNOL, V14, P392, DOI 10.1038/nri3671; Grafman Jordan, 2015, Handb Clin Neurol, V128, P795, DOI 10.1016/B978-0-444-63521-1.00049-2; Hammond MD, 2014, J NEUROSCI, V34, P3901, DOI 10.1523/JNEUROSCI.4070-13.2014; Horn KP, 2008, J NEUROSCI, V28, P9330, DOI 10.1523/JNEUROSCI.2488-08.2008; Huebner EA, 2009, RESULTS PROBL CELL D, V48, P339, DOI 10.1007/400_2009_19; Jorm AF, 2000, PSYCHOL MED, V30, P981, DOI 10.1017/S0033291799002299; Kantak SS, 2012, NEUROREHAB NEURAL RE, V26, P282, DOI 10.1177/1545968311420845; Lee S, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0544-4; Li N, 2016, NATURE, V532, P459, DOI 10.1038/nature17643; Li S, 2015, NAT NEUROSCI, V18, P1737, DOI 10.1038/nn.4146; Li SL, 2010, NAT NEUROSCI, V13, P1496, DOI 10.1038/nn.2674; Lucotte G, 1997, BIOMED PHARMACOTHER, V51, P469, DOI 10.1016/S0753-3322(97)82328-1; Ma VY, 2014, ARCH PHYS MED REHAB, V95, P986, DOI 10.1016/j.apmr.2013.10.032; Maayan S, 2000, GENES IMMUN, V1, P358, DOI 10.1038/sj.gene.6363690; Martin-Blondel G, 2016, NAT REV NEUROL, V12, P95, DOI 10.1038/nrneurol.2015.248; Middei S, 2012, LEARN MEMORY, V19, P330, DOI 10.1101/lm.025817.112; Moore DL, 2011, DEV NEUROBIOL, V71, P1186, DOI 10.1002/dneu.20934; Mostany R, 2010, J NEUROSCI, V30, P14116, DOI 10.1523/JNEUROSCI.3908-10.2010; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Overman JJ, 2012, P NATL ACAD SCI USA, V109, pE2230, DOI 10.1073/pnas.1204386109; Page SJ, 2012, ARCH PHYS MED REHAB, V93, P2373, DOI 10.1016/j.apmr.2012.06.017; Paterno R, 2017, CURR NEUROL NEUROSCI, V17, DOI 10.1007/s11910-017-0762-x; Posel C, 2016, JOVE-J VIS EXP, DOI 10.3791/53658; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Schaechter JD, 2004, PROG NEUROBIOL, V73, P61, DOI 10.1016/j.pneurobio.2004.04.001; Shin JE, 2012, NEURON, V74, P1015, DOI 10.1016/j.neuron.2012.04.028; Sullivan KJ, 2011, STROKE, V42, P427, DOI 10.1161/STROKEAHA.110.592766; Tarasenko M, 2016, SCHIZOPHR RES, V172, P123, DOI 10.1016/j.schres.2016.01.019; Tennant Alan, 2013, Handb Clin Neurol, V110, P77, DOI 10.1016/B978-0-444-52901-5.00007-1; Vilkki J, 2008, NEUROSURGERY, V63, P198, DOI 10.1227/01.NEU.0000320382.21577.8E; Wagner JM, 2008, PHYS THER, V88, P652, DOI 10.2522/ptj.20070255; Wahlund LO, 2001, STROKE, V32, P1318, DOI 10.1161/01.STR.32.6.1318; Wang L, 2016, P NATL ACAD SCI USA, V113, P2750, DOI 10.1073/pnas.1514682113; Watkins TA, 2013, P NATL ACAD SCI USA, V110, P4039, DOI 10.1073/pnas.1211074110; Xing SH, 2016, BRAIN, V139, P227, DOI 10.1093/brain/awv323; Yaka R, 2007, FASEB J, V21, P2033, DOI 10.1096/fj.06-7856com; Zhou M, 2016, ELIFE, V5, DOI 10.7554/eLife.20985	57	107	113	9	89	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 21	2019	176	5					1143	+		10.1016/j.cell.2019.01.044			28	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology	HM2AK	WOS:000459257500016	30794775	Bronze, Green Accepted			2022-02-06	
J	Mokalled, MH; Patra, C; Dickson, AL; Endo, T; Stainier, DYR; Poss, KD				Mokalled, Mayssa H.; Patra, Chinmoy; Dickson, Amy L.; Endo, Toyokazu; Stainier, Didier Y. R.; Poss, Kenneth D.			Injury-induced ctgfa directs glial bridging and spinal cord regeneration in zebrafish	SCIENCE			English	Article							TISSUE GROWTH-FACTOR; TRAUMATIC BRAIN-INJURY; ADULT ZEBRAFISH; ASTROCYTES; CELLS; SCAR; RAT	Unlike mammals, zebrafish efficiently regenerate functional nervous system tissue after major spinal cord injury. Whereas glial scarring presents a roadblock for mammalian spinal cord repair, glial cells in zebrafish form a bridge across severed spinal cord tissue and facilitate regeneration. We performed a genome-wide profiling screen for secreted factors that are up-regulated during zebrafish spinal cord regeneration. We found that connective tissue growth factor a (ctgfa) is induced in and around glial cells that participate in initial bridging events. Mutations in ctgfa disrupted spinal cord repair, and transgenic ctgfa overexpression or local delivery of human CTGF recombinant protein accelerated bridging and functional regeneration. Our study reveals that CTGF is necessary and sufficient to stimulate glial bridging and natural spinal cord regeneration.	[Mokalled, Mayssa H.; Dickson, Amy L.; Endo, Toyokazu; Poss, Kenneth D.] Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; [Patra, Chinmoy; Stainier, Didier Y. R.] Max Planck Inst Heart & Lung Res, Dept Dev Genet, D-61231 Bad Nauheim, Germany; [Patra, Chinmoy] Agharkar Res Inst, Pune, Maharashtra, India		Poss, KD (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA.	kenneth.poss@duke.edu		Stainier, Didier/0000-0002-0382-0026	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32HL007101, R01 HL081674]; Max Planck SocietyMax Planck Society; Duke University School of Medicine; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL081674, T32HL007101] Funding Source: NIH RePORTER	We thank A. Johnson, C. Eroglu, and M. Bagnat for discussions; N. Lee and K. Jones for technical and bioinformatics help; and the Duke University School of Medicine Zebrafish Shared Resource for animal care. Supported by NIH training grant T32HL007101 (M.H.M.), NIH grant R01 HL081674 (K.D.P.), the Max Planck Society (C.P. and D.Y.R.S.), and Duke University School of Medicine (K.D.P.). RNA sequencing data are archived at GEO (accession number GSE77025). The supplementary materials contain additional data. M.H.M. and K.D.P. are inventors on patent applications (62/159,413 and 62/398,781) submitted by Duke University that cover the use of Ctgf for spinal cord regeneration.	Anderson MA, 2016, NATURE, V532, P195, DOI 10.1038/nature17623; Becker T, 1997, J COMP NEUROL, V377, P577, DOI 10.1002/(SICI)1096-9861(19970127)377:4<577::AID-CNE8>3.0.CO;2-#; Conrad S, 2005, J NEUROSURG-SPINE, V2, P319, DOI 10.3171/spi.2005.2.3.0319; Goldshmit Y, 2012, J NEUROSCI, V32, P7477, DOI 10.1523/JNEUROSCI.0758-12.2012; Grotendorst GR, 2005, FASEB J, V19, P729, DOI 10.1096/fj.04-3217com; Hertel M, 2000, EUR J NEUROSCI, V12, P376, DOI 10.1046/j.1460-9568.2000.00930.x; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; Hui SP, 2010, DEV DYNAM, V239, P2962, DOI 10.1002/dvdy.22438; Lin CY, 2012, J NEUROTRAUM, V29, P589, DOI 10.1089/neu.2011.2059; Liu YQ, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-141; Meletis K, 2008, PLOS BIOL, V6, P1494, DOI 10.1371/journal.pbio.0060182; Raposo C, 2014, GLIA, V62, P1895, DOI 10.1002/glia.22676; Reimer MM, 2008, J NEUROSCI, V28, P8510, DOI 10.1523/JNEUROSCI.1189-08.2008; Robinson PM, 2012, INVEST OPHTH VIS SCI, V53, P8093, DOI 10.1167/iovs.12-10419; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Tom VJ, 2004, J NEUROSCI, V24, P9282, DOI 10.1523/JNEUROSCI.2120-04.2004; Wang JH, 2011, DEVELOPMENT, V138, P3421, DOI 10.1242/dev.068601; Waselle L, 2009, MOL CELL NEUROSCI, V42, P315, DOI 10.1016/j.mcn.2009.08.004; White BD, 2010, STEM CELLS, V28, P297, DOI 10.1002/stem.268	19	107	110	1	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 4	2016	354	6312					630	634		10.1126/science.aaf2679			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EA8FD	WOS:000386869800052	27811277	Green Accepted			2022-02-06	
J	Brooks, MA; Peterson, K; Biese, K; Sanfilippo, J; Heiderscheit, BC; Bell, DR				Brooks, M. Alison; Peterson, Kaitlin; Biese, Kevin; Sanfilippo, Jennifer; Heiderscheit, Bryan C.; Bell, David R.			Concussion Increases Odds of Sustaining a Lower Extremity Musculoskeletal Injury After Return to Play Among Collegiate Athletes	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						sports-related concussion; mild traumatic brain injury	TRAUMATIC BRAIN-INJURY; SPORT-RELATED CONCUSSION; RECURRENT CONCUSSION; RISK	Background: Previous studies have identified abnormalities in brain and motor functioning after concussion that persist well beyond observed clinical recovery. Recent work suggests subtle deficits in neurocognition may impair neuromuscular control and thus potentially increase risk of lower extremity musculoskeletal injury after concussion. Purpose: To determine the odds of sustaining an acute lower extremity musculoskeletal injury during the 90-day period after return to play from concussion in a cohort of National Collegiate Athletic Association (NCAA) Division I collegiate athletes. Study Design: Cohort study; Level of evidence, 3. Methods: Included in this study were 87 cases of concussion among 75 athletes (58 men; 17 women) participating in NCAA Division I football, soccer, hockey, softball, basketball, wrestling, or volleyball at a single institution from 2011 to 2014. The 90-day period after return to play for each case of concussion was reviewed for acute noncontact lower extremity musculoskeletal injury. Each 90-day period after return to play was matched to the same 90-day period in up to 3 controls. Control athletes without a history of concussion in the previous year were matched to concussed athletes by sport team/sex, games played, and position. A total of 182 control (136 men; 46 women) 90-day periods were reviewed for acute injury. Conditional logistic regression was used to assess the association between concussion and subsequent risk of acute lower extremity musculoskeletal injury. Results: The incidence of acute lower extremity musculoskeletal injury was higher among recently concussed athletes (15/87; 17%) compared with matched controls (17/182; 9%). The odds of sustaining an acute lower extremity musculoskeletal injury during the 90-day period after return to play were 2.48 times higher in concussed athletes than controls during the same 90-day period (odds ratio, 2.48; 95% CI, 1.04-5.91; P = .04). Conclusion: Concussed athletes have increased odds of sustaining an acute lower extremity musculoskeletal injury after return to play than their nonconcussed teammates. The study results suggest further investigation of neurocognitive and motor control deficits may be warranted beyond the acute injury phase to decrease risk for subsequent injury.	[Brooks, M. Alison; Peterson, Kaitlin; Biese, Kevin; Sanfilippo, Jennifer; Heiderscheit, Bryan C.; Bell, David R.] Univ Wisconsin, Madison, WI 53705 USA; [Brooks, M. Alison; Heiderscheit, Bryan C.; Bell, David R.] Univ Wisconsin, Dept Orthoped & Rehabil, 1685 Highland Ave, Madison, WI 53705 USA; [Brooks, M. Alison; Sanfilippo, Jennifer; Heiderscheit, Bryan C.; Bell, David R.] Univ Wisconsin, Badger Athlet Performance, 1685 Highland Ave, Madison, WI 53705 USA; [Biese, Kevin] Univ Wisconsin, Sch Med & Publ Hlth, 1685 Highland Ave, Madison, WI 53705 USA; [Biese, Kevin; Bell, David R.] Univ Wisconsin, Dept Kinesiol, 1685 Highland Ave, Madison, WI 53705 USA; [Sanfilippo, Jennifer] Univ Wisconsin, Div Intercollegiate Athlet, 1685 Highland Ave, Madison, WI 53705 USA		Brooks, MA (corresponding author), Univ Wisconsin, Dept Orthoped & Rehabil, 1685 Highland Ave, Madison, WI 53705 USA.	brooks@ortho.wisc.edu					Broglio SP, 2011, INT J PSYCHOPHYSIOL, V82, P16, DOI 10.1016/j.ijpsycho.2011.02.010; Buckley TA, 2013, GAIT POSTURE, V38, P549, DOI 10.1016/j.gaitpost.2013.02.008; Cantu RC, 2003, CLIN SPORT MED, V22, P593, DOI 10.1016/S0278-5919(02)00095-9; Ellemberg D, 2007, CLIN J SPORT MED, V17, P369, DOI 10.1097/JSM.0b013e31814c3e3e; Ellemberg D, 2009, J NEUROTRAUM, V26, P2365, DOI 10.1089/neu.2009.0906; Gaetz M, 2000, BRAIN INJURY, V14, P815; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN SPORTS MED, V30, P89; Herman D., 2013, CLIN J SPORT MED, V23, P124; Kelly JP, 1997, NEUROLOGY, V48, P581; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; Martini DN, 2011, ARCH PHYS MED REHAB, V92, P585, DOI 10.1016/j.apmr.2010.11.029; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Nordstrom A, 2014, BRIT J SPORT MED, V48, P1447, DOI 10.1136/bjsports-2013-093406; Polich J, 2007, CLIN NEUROPHYSIOL, V118, P2128, DOI 10.1016/j.clinph.2007.04.019; Prichep LS, 2013, J HEAD TRAUMA REHAB, V28, P266, DOI 10.1097/HTR.0b013e318247b54e; Sarris CE, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.7.FOCUS12224; Schneider KJ, 2014, BRIT J SPORT MED, V48, P1294, DOI 10.1136/bjsports-2013-093267; Sosnoff JJ, 2011, J ATHL TRAINING, V46, P85, DOI 10.4085/1062-6050-46.1.85; Swanik CB, 2007, AM J SPORT MED, V35, P943, DOI 10.1177/0363546507299532; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200	26	107	107	1	28	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	MAR	2016	44	3					742	747		10.1177/0363546515622387			6	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	DF9CQ	WOS:000371658300029	26786903				2022-02-06	
J	Mesia, R; Henke, M; Fortin, A; Minn, H; Ancona, ACY; Cmelak, A; Markowitz, AB; Hotte, SJ; Singh, S; Chan, ATC; Merlano, MC; Skladowski, K; Zhang, A; Oliner, KS; VanderWalde, A; Giralt, J				Mesia, Ricard; Henke, Michael; Fortin, Andre; Minn, Heikki; Yunes Ancona, Alejandro Cesar; Cmelak, Anthony; Markowitz, Avi B.; Hotte, Sebastien J.; Singh, Simron; Chan, Anthony T. C.; Merlano, Marco C.; Skladowski, Krzysztof; Zhang, Alicia; Oliner, Kelly S.; VanderWalde, Ari; Giralt, Jordi			Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial	LANCET ONCOLOGY			English	Article							OROPHARYNGEAL CANCER; HUMAN-PAPILLOMAVIRUS; RADIATION; RADIOTHERAPY; CISPLATIN; CETUXIMAB; RECURRENT	Background Panitumumab is a fully human monoclonal antibody that targets EGFR. We aimed to compare chemoradiotherapy plus panitumumab with chemoradiotherapy alone in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck. Methods In this international, open-label, randomised, controlled, phase 2 trial, we recruited patients with locally advanced squamous-cell carcinoma of the head and neck from 41 sites in nine countries worldwide. Patients aged 18 years and older with stage III, IVa, or IVb, previously untreated, measurable (>= 10 mm for at least one dimension), locally advanced squamous-cell carcinoma of the head and neck (non-nasopharygeal) and an Eastern Cooperative Oncology Group performance status of 0-1 were randomly assigned (2:3) by an independent vendor to open-label chemoradiotherapy (three cycles of cisplatin 100 mg/m(2)) or panitumumab plus chemoradiotherapy (three cycles of intravenous panitumumab 9.0 mg/kg every 3 weeks plus cisplatin 75 mg/m(2)) using stratified randomisation with a block size of five. All patients received 70 Gy to gross tumour and 50 Gy to areas at risk for subclinical disease with standard fractionation. The primary endpoint was local-regional control at 2 years, analysed in all randomised patients who received at least one dose of their assigned protocol-specific treatment (chemotherapy, radiation, or panitumumab). The trial is closed and this is the final analysis. This trial is registered with ClinicalTrials.gov, number NCT00500760. Findings Between Oct 26, 2007, and March 26, 2009, 153 patients were enrolled and 150 received treatment (63 in the chemoradiotherapy group and 87 in the panitumumab plus chemoradiotherapy group). Local-regional control at 2 years was 68% (95% CI 54-78) in the chemoradiotherapy group and 61% (50-71) in the panitumumab plus chemoradiotherapy group. The most frequent grade 3-4 adverse events were dysphagia (17 [27%] of 63 patients in the chemoradiotherapy group vs 35 [40%] of 87 in the panitumumab plus chemoradiotherapy group), mucosal inflammation (15 [24%] vs 48 [55%]), and radiation skin injury (eight [13%] vs 27 [31%]). Serious adverse events were reported in 20 (32%) of 63 patients in the chemoradiotherapy group and in 37 (43%) of 87 patients in the panitumumab plus chemo radio therapy group. Interpretation In patients with locally advanced squamous-cell carcinoma of the head and neck, the addition of panitumumab to standard fractionation radiotherapy and cisplatin did not confer any benefit, and the role of EGFR inhibition in these patients needs to be reassessed.	[Mesia, Ricard] Inst Catala Oncol ICO Hosp, Barcelona, Spain; [Henke, Michael] Univ Freiburg Klinikum, Freiburg, Germany; [Fortin, Andre] Ctr Hosp Univ Quebec, Hotel Dieu Quebec, Quebec City, PQ, Canada; [Minn, Heikki] Turku Univ Hosp, Dept Radiotherapy & Oncol, FIN-20520 Turku, Finland; [Yunes Ancona, Alejandro Cesar] Unidad Oncol Serv Salud Estado Puebla, Puebla, Mexico; [Cmelak, Anthony] Vanderbilt Univ, Med Ctr, Nashville, TN USA; [Markowitz, Avi B.] Univ Texas Med Branch, Galveston, TX 77555 USA; [Hotte, Sebastien J.] Juravinski Canc Ctr, Hamilton, ON, Canada; [Singh, Simron] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Toronto, ON M4N 3M5, Canada; [Chan, Anthony T. C.] Chinese Univ Hong Kong, Sir YK Pao Ctr Canc, State Key Lab Oncol South China, Hong Kong, Hong Kong, Peoples R China; [Merlano, Marco C.] Oncol Med ASOS Croce E Carle, Cuneo, Italy; [Skladowski, Krzysztof] Inst M Sklodowskiej Curie, Ctr Onkol, Gliwice, Poland; [Zhang, Alicia; Oliner, Kelly S.; VanderWalde, Ari] Amgen Inc, Thousand Oaks, CA USA; [Giralt, Jordi] Hosp Valle De Hebron, Barcelona, Spain; [Giralt, Jordi] Univ Autonoma Barcelona, Bellaterra, Spain		Mesia, R (corresponding author), Inst Catala Oncol, Dept Med Oncol, Head & Neck Oncol Clin Res Program, Granvia Hosp 199-203, Lhospitalet Llobregat 08908, Spain.	rmesia@iconcologia.net	de Sagredo, Jordi Giralt Lopez/J-1873-2018; Chan, Anthony Tak Cheung/R-3940-2018	de Sagredo, Jordi Giralt Lopez/0000-0002-1840-5159; Chan, Anthony Tak Cheung/0000-0002-6912-8091; Minn, Heikki/0000-0002-5878-4333; Skladowski, Krzysztof/0000-0002-0554-6171	AmgenAmgen	This study was funded by Amgen. We thank the study staff, and the patients and their families, for their contributions to this study. We also acknowledge Jennifer Gansert (Amgen) for her contributions to the study design and protocol development, and James Ziobro for assistance with the writing of this manuscript (funded by Amgen).	Adelstein DJ, 2003, J CLIN ONCOL, V21, P92, DOI 10.1200/JCO.2003.01.008; Ang K, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.5507; Ang KK, 2010, NEW ENGL J MED, V363, P24, DOI 10.1056/NEJMoa0912217; Ang KK, 2011, P AM SOC CLIN ONCO S, V29, P5500; [Anonymous], 2012, NATL COMPREHENSIVE C; Bonner JA, 2006, NEW ENGL J MED, V354, P567, DOI 10.1056/NEJMoa053422; BRITTAIN E, 1982, BIOMETRICS, V38, P1003, DOI 10.2307/2529880; Gillison ML, 2012, VACCINE, V30, pF34, DOI 10.1016/j.vaccine.2012.05.070; Gillison ML, 2012, J CLIN ONCOL, V30, P2102, DOI 10.1200/JCO.2011.38.4099; Giralt J, 2015, LANCET ONCOL; Gregoire Vincent, 2003, Rays, V28, P217; Kruser TJ, 2008, INT J RADIAT ONCOL, V72, P534, DOI 10.1016/j.ijrobp.2008.06.1490; Melkane AE, 2014, HEAD NECK-J SCI SPEC, V36, P257, DOI 10.1002/hed.23302; Pignon JP, 2000, LANCET, V355, P949, DOI 10.1016/S0140-6736(00)90011-4; Rischin D, 2010, J CLIN ONCOL, V28, P2989, DOI 10.1200/JCO.2009.27.4449; Rivera F, 2009, EXPERT REV ANTICANC, V9, P1421, DOI [10.1586/era.09.113, 10.1586/ERA.09.113]; Robinson M, 2010, ORAL ONCOL, V46, P492, DOI 10.1016/j.oraloncology.2010.02.013; Vermorken JB, 2013, LANCET ONCOL, V14, P697, DOI 10.1016/S1470-2045(13)70181-5; Wirth LJ, 2010, ANN ONCOL, V21, P342, DOI 10.1093/annonc/mdp477	19	107	109	0	13	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1470-2045	1474-5488		LANCET ONCOL	Lancet Oncol.	FEB	2015	16	2					208	220		10.1016/S1470-2045(14)71198-2			13	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	CA3YR	WOS:000348841700037	25596660				2022-02-06	
J	Simpson, SG; Reid, CL				Simpson, Susan G.; Reid, Corinne L.			Therapeutic alliance in videoconferencing psychotherapy: A review	AUSTRALIAN JOURNAL OF RURAL HEALTH			English	Article						rural mental health; telepsychology; videoconferencing; video therapy	FACE-TO-FACE; POSTTRAUMATIC-STRESS-DISORDER; COGNITIVE-BEHAVIORAL THERAPY; OBSESSIVE-COMPULSIVE DISORDER; TRAUMATIC BRAIN-INJURY; NONINFERIORITY TRIAL; WORKING ALLIANCE; PANIC DISORDER; HEALTH; TELEHEALTH	Psychotherapy services are limited in remote and rural areas in Australia and across the globe. Videoconferencing has become well established as a feasible and acceptable mode of psychological treatment delivery. Therapeutic alliance (TA) is an essential factor underlying successful therapy across therapeutic models. In order to determine the state of knowledge regarding TA in psychotherapy via videoconferencing, a literature review was conducted on research studies that formally measured TA as primary, secondary or tertiary outcome measures over the past 23 years. The databases searched were Medline, PsycArticles, PsycINFO, PsycEXTRA and EMBASE. Searching identified 9915 articles that measured satisfaction, acceptability or therapeutic rapport, of which 23 met criteria for the review. Three studies were carried out in Australia, 11 in USA, 4 in Canada, 3 in Scotland and 2 in England. Studies overwhelmingly supported the notion that TA can be developed in psychotherapy by videoconference, with clients rating bond and presence at least equally as strongly as in-person settings across a range of diagnostic groups. Therapists also rated high levels of TA, but often not quite as high as that of their clients early in treatment. The evidence was examined in the context of important aspects of TA, including bond, presence, therapist attitudes and abilities, and client attitudes and beliefs. Barriers and facilitators of alliance were identified. Future studies should include observational measures of bond and presence to supplement self-report.	[Simpson, Susan G.] Univ S Australia, Psychol Clin, Adelaide, SA 5001, Australia; [Reid, Corinne L.] Murdoch Univ, Sch Psychol & Exercise Sci, Perth, WA, Australia		Simpson, SG (corresponding author), Univ S Australia, Psychol Clin, Magill Campus,GPO Box 2471, Adelaide, SA 5001, Australia.	susan.simpson@unisa.edu.au	Simpson, Susan G/F-3261-2013	Simpson, Susan G/0000-0002-9625-0797			Ackerman SJ, 2001, PSYCHOTHERAPY, V38, P171, DOI 10.1037/0033-3204.38.2.171; Ackerman SJ, 2003, CLIN PSYCHOL REV, V23, P1, DOI 10.1016/S0272-7358(02)00146-0; Agnew-Davies R, 1998, BRIT J CLIN PSYCHOL, V37, P155, DOI 10.1111/j.2044-8260.1998.tb01291.x; Alexander LB., 1986, PSYCHOTHERAPEUTIC PR, P325; Austen S, 2006, J TELEMED TELECARE, V12, P146, DOI 10.1258/135763306776738594; Bachelor A, 1999, HEART AND SOUL OF CHANGE, P133, DOI 10.1037/11132-004; Backhaus A, 2012, PSYCHOL SERV, V9, P111, DOI 10.1037/a0027924; BARRETTLENNARD GT, 1981, J COUNS PSYCHOL, V28, P91, DOI 10.1037/0022-0167.28.2.91; Bischoff RJ, 2004, CONTEMP FAM THER, V26, P179, DOI 10.1023/B:COFT.0000031242.83259.fa; Bordin ES, 1979, PSYCHOTHER THEORY RE, V16, P252, DOI DOI 10.1037/H0085885; Bose U, 2001, J TELEMED TELECARE, V7, pS8, DOI 10.1258/1357633011936804; Bouchard S, 2004, TELEMED J E-HEALTH, V10, P13, DOI 10.1089/153056204773644535; Bouchard S, 2000, CYBERPSYCHOL BEHAV, V3, P999, DOI 10.1089/109493100452264; Bouchard S, 2007, P 10 INT WORKSH PRES; Bouchard S, 2000, TELEPRESENCE VIDEOCO; Bouchard S, 2004, 7 ANN M CAN SOC TEL; Cluver JS, 2005, J TELEMED TELECARE, V11, P157, DOI 10.1258/1357633053688741; Constantino M.J., 2002, COUNSELING BASED PRO, P81; Cowain T, 2001, AUST NZ J PSYCHIAT, V35, P62, DOI 10.1046/j.1440-1614.2001.00853.x; Day SX, 2002, J COUNS PSYCHOL, V49, P499, DOI 10.1037/0022-0167.49.4.499; Dunstan DA, 2012, RURAL REMOTE HEALTH, V12; Dunstan DA, 2012, AUST J RURAL HEALTH, V20, P88, DOI 10.1111/j.1440-1584.2012.01260.x; Elliot R, 1999, QUALITATIVE INTERVIE; Elliott R, 2011, PSYCHOTHERAPY, V48, P43, DOI 10.1037/a0022187; Ertelt TW, 2011, INT J EAT DISORDER, V44, P687, DOI 10.1002/eat.20874; Farber B. A., 2002, PSYCHOTHERAPY RELATI, P175; Frueh BC, 2007, J TELEMED TELECARE, V13, P142, DOI 10.1258/135763307780677604; Frueh BC, 2005, J TELEMED TELECARE, V11, P372, DOI 10.1258/135763305774472060; Garcia-Lizana Francisca, 2010, Prim Care Companion J Clin Psychiatry, V12, DOI 10.4088/PCC.09m00831whi; GASTON L, 1990, PSYCHOTHER, V27, P143, DOI 10.1037/0033-3204.27.2.143; Germain V, 2010, CYBERPSYCH BEH SOC N, V13, P29, DOI 10.1089/cyber.2009.0139; Ghosh G J, 1997, J Telemed Telecare, V3 Suppl 1, P33, DOI 10.1258/1357633971930283; Glueckauf RL, 2002, REHABIL PSYCHOL, V47, P49, DOI 10.1037/0090-5550.47.1.49; Goetter EM, 2013, J OBSESS-COMPULS REL, V2, P137, DOI 10.1016/j.jocrd.2013.01.003; Greenberg LS, 2001, PSYCHOTHERAPY, V38, P380, DOI 10.1037/0033-3204.38.4.380; Greene CJ, 2010, J CONSULT CLIN PSYCH, V78, P746, DOI 10.1037/a0020158; Griffiths L, 2006, J TELEMED TELECARE, V12, P136, DOI 10.1258/135763306776738567; GUBA EG, 1981, ECTJ-EDUC COMMUN TEC, V29, P75; Harvey-Berino J, 1998, BEHAV THER, V29, P505, DOI 10.1016/S0005-7894(98)80046-4; HATCHER RL, 1995, J CONSULT CLIN PSYCH, V63, P636, DOI 10.1037/0022-006X.63.4.636; Himle JA, 2006, BEHAV RES THER, V44, P1821, DOI 10.1016/j.brat.2005.12.010; Hollon SD, 2002, BIOL PSYCHIAT, V52, P610, DOI 10.1016/S0006-3223(02)01384-7; HORVATH A, 2010, EVIDENCE BASED THERA, V121, P5; Horvath A, 1982, INSTRUCTIONAL PSYCHO, P82; Horvath A.O., 1994, WORKING ALLIANCE THE; Horvath A. O., 1981, THESIS U BRIT COLUMB; Horvath AO, 2011, PSYCHOTHERAPY, V48, P9, DOI 10.1037/a0022186; HORVATH AO, 1993, J CONSULT CLIN PSYCH, V61, P561, DOI 10.1037/0022-006X.61.4.561; HORVATH AO, 1991, J COUNS PSYCHOL, V38, P139, DOI 10.1037/0022-0167.38.2.139; Jerome LW, 2000, PROF PSYCHOL-RES PR, V31, P478, DOI 10.1037//0735-7028.31.5.478; Kolden GG, 2011, PSYCHOTHERAPY, V48, P65, DOI 10.1037/a0022064; Krumm-Heller Roe I, 2006, THESIS FIELDING GRAD; Larsen R.J., 1992, REV PERSONALITY SOCI, P25; Lincoln Y.S., 1985, NATURALIS; Maheu MM, 2003, PSYCHOTHERAPY, V40, P20, DOI 10.1037/0033-3204.40.1-2.20; Mair F, 2000, BMJ-BRIT MED J, V320, P1517, DOI 10.1136/bmj.320.7248.1517; Manchanda M, 1998, J TELEMED TELECARE, V4, P53, DOI 10.1258/1357633981931452; Martin DJ, 2000, J CONSULT CLIN PSYCH, V68, P438, DOI 10.1037//0022-006X.68.3.438; Millar H, 2009, TELEMENTAL HLTH SCOT; Mohr DC, 2010, ANN BEHAV MED, V40, P89, DOI 10.1007/s12160-010-9203-7; Morgan RD, 2008, J CONSULT CLIN PSYCH, V76, P158, DOI 10.1037/0022-006X.76.1.158; Morland LA, 2010, J CLIN PSYCHIAT, V71, P855, DOI 10.4088/JCP.09m05604blu; Myers KM, 2007, PSYCHIAT SERV, V58, P1493, DOI 10.1176/appi.ps.58.11.1493; Norcross, 2002, PSYCHOTHERAPY RELATI; Norcross JC, 2011, PSYCHOTHERAPY, V48, P4, DOI 10.1037/a0022180; Nutting PA, 2002, J GEN INTERN MED, V17, P103, DOI 10.1046/j.1525-1497.2002.10128.x; OMALLEY SS, 1983, J CONSULT CLIN PSYCH, V51, P581, DOI 10.1037/0022-006X.51.4.581; PINSOF WM, 1986, J MARITAL FAM THER, V12, P137, DOI 10.1111/j.1752-0606.1986.tb01631.x; Porcari CE, 2009, J TELEMED TELECARE, V15, P89, DOI 10.1258/jtt.2008.080612; Rees CS, 2005, PROF PSYCHOL-RES PR, V36, P649, DOI 10.1037/0735-7028.36.6.649; Rees CS, 2004, AUST PSYCHOL, V39, P212, DOI 10.1080/00050060412331295108; Reid C, 2013, EUROPEAN J PERSON CT, V1, P336; REISENZEIN R, 1994, J PERS SOC PSYCHOL, V67, P525, DOI 10.1037/0022-3514.67.3.525; Richardson L, 2011, CAN YOU SEE WHAT I A; Richardson LK, 2009, CLIN PSYCHOL-SCI PR, V16, P323, DOI 10.1111/j.1468-2850.2009.01170.x; Rogers CR, 1951, CLIENT CTR THERAPY I; Ruskin PE, 2004, AM J PSYCHIAT, V161, P1471, DOI 10.1176/appi.ajp.161.8.1471; Sadowski W, 2002, HUM FAC ER, P791; Safran J. D., 1991, PSYCHOL ASSESSMENT J, V3, P188, DOI DOI 10.1037/1040-3590.3.2.188; Samstag LW, CORE PROCESSES BRIEF, P187; Schneider PL, 1999, 107 ANN CONV AM PSYC; Schopp L, 2000, PROF PSYCHOL-RES PR, V31, P179, DOI 10.1037/0735-7028.31.2.179; Shore JH, 2007, AM J PSYCHIAT, V164, P115, DOI 10.1176/appi.ajp.164.1.115; Simpson S, 2005, CLIN PSYCHOL PSYCHOT, V12, P156, DOI 10.1002/cpp.436; Simpson S, 2001, CLIN PSYCHOL PSYCHOT, V8, P130, DOI 10.1002/cpp.279; Simpson S, 2003, J TELEMED TELECARE, V9, pS37, DOI 10.1258/135763303322196286; Simpson S., 2005, EATING DISORDERS NEW, P99; Simpson SG, 2010, USE TECHNOLOGY MENTA, P94; Simpson S, 2006, EUR EAT DISORD REV, V14, P226, DOI 10.1002/erv.686; Simpson S, 2009, BRIT J GUID COUNS, V37, P271, DOI 10.1080/03069880902957007; Simpson Susan G, 2011, Clin Pract Epidemiol Ment Health, V7, P38, DOI 10.2174/1745017901107010038; Simpson SG, 2014, AUST PSYCHOL, V49, P193, DOI 10.1111/ap.12049; Sirey JA, 2001, PSYCHIAT SERV, V52, P1615, DOI 10.1176/appi.ps.52.12.1615; STILES WB, 1984, BRIT J CLIN PSYCHOL, V23, P59, DOI 10.1111/j.2044-8260.1984.tb00627.x; STILES WB, 1994, J COUNS PSYCHOL, V41, P175, DOI 10.1037/0022-0167.41.2.175; Stubbings DR, 2012, THESIS CURTIN U AUST; Tashakkori A., 1998, MIXED METHODOLOGY CO; TICHENOR V, 1989, PSYCHOTHER, V26, P195, DOI 10.1037/h0085419; Tracey T.J., 1989, J CONSULT CLIN PSYCH, V1, P207, DOI [10.1037/1040-3590.1.3.207, DOI 10.1037/1040-3590.1.3.207, 10.1037/1040-3590.1.3.207.]; Tuerk PW, 2010, J TRAUMA STRESS, V23, P116, DOI 10.1002/jts.20494; Wade SL, 2005, J PEDIATR PSYCHOL, V30, P437, DOI 10.1093/jpepsy/jsi067; Wade SL, 2004, BEHAV RES METH INS C, V36, P261, DOI 10.3758/BF03195572; Wampold, 2001, GREAT PSYCHOTHERAPY; Wray B, 2003, 11 AUSTR ASS COGN BE; Wray BT, 2003, THESIS CURTIN U TECH; Yin R. K., 1994, CASE STUDY RES DESIG, V2nd; Yuen EK, 2013, J ANXIETY DISORD, V27, P389, DOI 10.1016/j.janxdis.2013.03.002	107	107	109	0	43	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1038-5282	1440-1584		AUST J RURAL HEALTH	Aust. J. Rural Health	DEC	2014	22	6			SI		280	299		10.1111/ajr.12149			20	Public, Environmental & Occupational Health; Nursing	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health; Nursing	AW4GN	WOS:000346239400003	25495622				2022-02-06	
J	Turtzo, LC; Lescher, J; Janes, L; Dean, DD; Budde, MD; Frank, JA				Turtzo, L. Christine; Lescher, Jacob; Janes, Lindsay; Dean, Dana D.; Budde, Matthew D.; Frank, Joseph A.			Macrophagic and microglial responses after focal traumatic brain injury in the female rat	JOURNAL OF NEUROINFLAMMATION			English	Article						Controlled cortical impact; Inflammation; Macrophage; Microglia; MRI; Rat; Traumatic brain injury	TUMOR-ASSOCIATED MACROPHAGES; SPINAL-CORD-INJURY; CYTOKINE EXPRESSION; NERVOUS-SYSTEM; ESTROUS-CYCLE; PROGESTERONE; ACTIVATION; RECOVERY; NEUROINFLAMMATION; POLARIZATION	Background: After central nervous system injury, inflammatory macrophages (M1) predominate over anti-inflammatory macrophages (M2). The temporal profile of M1/M2 phenotypes in macrophages and microglia after traumatic brain injury (TBI) in rats is unknown. We subjected female rats to severe controlled cortical impact (CCI) and examined the postinjury M1/M2 time course in their brains. Methods: The motor cortex (2.5 mm left laterally and 1.0 mm anteriorly from the bregma) of anesthetized female Wistar rats (ages 8 to 10 weeks; N = 72) underwent histologically moderate to severe CCI with a 5-mm impactor tip. Separate cohorts of rats had their brains dissociated into cells for flow cytometry, perfusion-fixed for immunohistochemistry (IHC) and ex vivo magnetic resonance imaging or flash-frozen for RNA and protein analysis. For each analytical method used, separate postinjury times were included for 24 hours; 3 or 5 days; or 1, 2, 4 or 8 weeks. Results: By IHC, we found that the macrophagic and microglial responses peaked at 5 to 7 days post-TBI with characteristics of mixed populations of M1 and M2 phenotypes. Upon flow cytometry examination of immunological cells isolated from brain tissue, we observed that peak M2-associated staining occurred at 5 days post-TBI. Chemokine analysis by multiplex assay showed statistically significant increases in macrophage inflammatory protein 1 alpha and keratinocyte chemoattractant/growth-related oncogene on the ipsilateral side within the first 24 hours after injury relative to controls and to the contralateral side. Quantitative RT-PCR analysis demonstrated expression of both M1- and M2-associated markers, which peaked at 5 days post-TBI. Conclusions: The responses of macrophagic and microglial cells to histologically severe CCI in the female rat are maximal between days 3 and 7 postinjury. The response to injury is a mixture of M1 and M2 phenotypes.	[Turtzo, L. Christine; Lescher, Jacob; Janes, Lindsay; Frank, Joseph A.] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Turtzo, L. Christine; Lescher, Jacob; Janes, Lindsay; Dean, Dana D.; Budde, Matthew D.; Frank, Joseph A.] NIH, Frank Lab, Bethesda, MD 20814 USA; [Frank, Joseph A.] Natl Inst Biomed Imaging & Bioengn, NIH, Bethesda, MD 20814 USA; [Dean, Dana D.] Baylor Univ, Dept Environm Sci, Waco, TX 76798 USA; [Budde, Matthew D.] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA		Turtzo, LC (corresponding author), Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	turtzolc@mail.nih.gov	Frank, Joseph/W-2021-2019		US Department of Defense Center for Neuroscience and Regenerative Medicine under Henry M. Jackson Foundation for the Advancement of Military Medicine award [300604-13.01-60855]; National Institutes of Health Intramural Research ProgramUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; CLINICAL CENTER [ZIACL090020] Funding Source: NIH RePORTER	These studies were supported by the US Department of Defense Center for Neuroscience and Regenerative Medicine under Henry M. Jackson Foundation for the Advancement of Military Medicine award 300604-13.01-60855 and by the National Institutes of Health Intramural Research Program. We would also like to thank Aneeka Chaudhry, Tiziana Coppola and Eric Gold for their invaluable technical assistance with these studies.	Al Nimer F, 2013, BRAIN BEHAV IMMUN, V27, P109, DOI 10.1016/j.bbi.2012.10.002; ATTELLA MJ, 1987, BEHAV NEURAL BIOL, V48, P352, DOI 10.1016/S0163-1047(87)90918-6; Beck KD, 2010, BRAIN, V133, P433, DOI 10.1093/brain/awp322; Bedi SS, 2013, J NEUROSCI METH, V219, P176, DOI 10.1016/j.jneumeth.2013.07.017; Bell RS, 2009, J TRAUMA, V66, pS104, DOI 10.1097/TA.0b013e31819d88c8; Bonecchi R, 2000, J IMMUNOL, V164, P3862, DOI 10.4049/jimmunol.164.7.3862; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Brown CM, 2010, ENDOCRINOLOGY, V151, P4916, DOI 10.1210/en.2010-0371; BUTCHER RL, 1974, ENDOCRINOLOGY, V94, P1704, DOI 10.1210/endo-94-6-1704; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; CHUNG IY, 1990, J IMMUNOL, V144, P2999; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; Colton CA, 2009, J NEUROIMMUNE PHARM, V4, P399, DOI 10.1007/s11481-009-9164-4; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; Dalgard CL, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00006; DEGREEF WJ, 1974, ENDOCRINOLOGY, V95, P565, DOI 10.1210/endo-95-2-565; DING AH, 1988, J IMMUNOL, V141, P2407; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; Faul M, 2010, TRAUMATIC BRAIN INJU; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Hsieh CL, 2013, EUR J IMMUNOL, V43, P2010, DOI 10.1002/eji.201243084; Jacobowitz DM, 2012, BRAIN RES, V1465, P80, DOI 10.1016/j.brainres.2012.05.008; Jordan BD, 2007, NEUROCHEM RES, V32, P905, DOI 10.1007/s11064-006-9251-3; Khaksari M, 2013, CAN J PHYSIOL PHARM, V91, P700, DOI 10.1139/cjpp-2012-0359; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Komohara Y, 2008, J PATHOL, V216, P15, DOI 10.1002/path.2370; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Lagraoui Mouna, 2012, Front Neurol, V3, P155, DOI 10.3389/fneur.2012.00155; Liu L, 2014, NEUROBIOL AGING, V35, P309, DOI 10.1016/j.neurobiolaging.2013.08.016; LIU T, 1994, STROKE, V25, P1481, DOI 10.1161/01.STR.25.7.1481; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; McKimmie CS, 2010, BIOCHEM BIOPH RES CO, V394, P1006, DOI 10.1016/j.bbrc.2010.03.111; Popovich PG, 2008, NAT REV NEUROSCI, V9, P481, DOI 10.1038/nrn2398; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; Robertson CL, 2006, EXP NEUROL, V197, P235, DOI 10.1016/j.expneurol.2005.09.014; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Shahrokhi N, 2010, CAN J PHYSIOL PHARM, V88, P414, DOI [10.1139/Y09-126, 10.1139/y09-126]; Sica A, 2006, EUR J CANCER, V42, P717, DOI 10.1016/j.ejca.2006.01.003; STEIN M, 1992, J EXP MED, V176, P287, DOI 10.1084/jem.176.1.287; Stout RD, 2005, J IMMUNOL, V175, P342, DOI 10.4049/jimmunol.175.1.342; Stout RD, 2004, J LEUKOCYTE BIOL, V76, P509, DOI 10.1189/jlb.0504272; Turtzo LC, 2013, NMR BIOMED, V26, P468, DOI 10.1002/nbm.2886; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Wagner AK, 2012, BRAIN INJURY, V26, P1226, DOI 10.3109/02699052.2012.667594; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wei HH, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-19; Williams AJ, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-17; Ydens E, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-176; Zhang ZR, 2012, BRAIN RES, V1461, P102, DOI 10.1016/j.brainres.2012.04.038	57	107	110	2	29	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	APR 24	2014	11								82	10.1186/1742-2094-11-82			14	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	AG6IW	WOS:000335523300001	24761998	gold, Green Published			2022-02-06	
J	Beckwith, JG; Greenwald, RM; Chu, JJ; Crisco, JJ; Rowson, S; Duma, SM; Broglio, SP; Mcallister, TW; Guskiewicz, KM; Mihalik, JP; Anderson, S; Schnebel, B; Brolinson, PG; Collins, MW				Beckwith, Jonathan G.; Greenwald, Richard M.; Chu, Jeffrey J.; Crisco, Joseph J.; Rowson, Steven; Duma, Stefan M.; Broglio, Steven P.; Mcallister, Thomas W.; Guskiewicz, Kevin M.; Mihalik, Jason P.; Anderson, Scott; Schnebel, Brock; Brolinson, P. Gunnar; Collins, Michael W.			Head Impact Exposure Sustained by Football Players on Days of Diagnosed Concussion	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						HIT SYSTEM; SPORT; IMPACT BIOMECHANICS; mTBI; TBI; INJURY THRESHOLD	HIGH-SCHOOL FOOTBALL; DIFFUSE AXONAL INJURY; PROFESSIONAL FOOTBALL; RECURRENT CONCUSSION; COLLEGIATE; RISK; ACCELERATION; ASSOCIATION; EPIDEMIOLOGY; KINEMATICS	BECKWITH, J. G., R. M. GREENWALD, J. J. CHU, J. J. CRISCO, S. ROWSON, S. M. DUMA, S. P. BROGLIO, T. W. MCALLISTER, K. M. GUSKIEWICZ, J. P. MIHALIK, S. ANDERSON, B. SCHNEBEL, P. G. BROLINSON, and M. W. COLLINS. Head Impact Exposure Sustained by Football Players on Days of Diagnosed Concussion. Med. Sci. Sports Exerc., Vol. 45, No. 4, pp. 737-746, 2013. Purpose: This study compares the frequency and severity of head impacts sustained by football players on days with and without diagnosed concussion and to identify the sensitivity and specificity of single-impact severity measures to diagnosed injury. Methods: One thousand two hundred eight players from eight collegiate football teams and six high school football teams wore instrumented helmets to measure head impacts during all team sessions, of which 95 players were diagnosed with concussion. Eight players sustained two injuries and one sustained three, providing 105 injury cases. Measures of head kinematics (peak linear and rotational acceleration, Gadd severity index, head injury criteria (HIC15), and change in head velocity (Delta v)) and the number of head impacts sustained by individual players were compared between days with and without diagnosed concussion. Receiver operating characteristic curves were generated to evaluate the sensitivity and specificity of each kinematic measure to diagnosed concussion using only those impacts that directly preceded diagnosis. Results: Players sustained a higher frequency of impacts and impacts with more severe kinematic properties on days of diagnosed concussion than on days without diagnosed concussion. Forty-five injury cases were immediately diagnosed after head impact. For these cases, peak linear acceleration and HIC15 were most sensitive to immediately diagnosed concussion (area under the curve = 0.983). Peak rotational acceleration was less sensitive to diagnosed injury than all other kinematic measures (P = 0.01), which are derived from linear acceleration (peak linear, HIC15, Gadd severity index, and Delta v). Conclusions: Players sustained more impacts and impacts of higher severity on days of diagnosed concussion than on days without diagnosed concussion. In addition, of historical measures of impact severity, those associated with peak linear acceleration are the best predictors of immediately diagnosed concussion.	[Beckwith, Jonathan G.; Greenwald, Richard M.; Chu, Jeffrey J.] Simbex, Lebanon, NH 03766 USA; [Greenwald, Richard M.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA; [Crisco, Joseph J.] Brown Univ, Alpert Med Sch, Providence, RI 02912 USA; [Crisco, Joseph J.] Rhode Isl Hosp, Providence, RI USA; [Rowson, Steven; Duma, Stefan M.] Virginia Tech Wake Forest, Ctr Injury Biomech, Blacksburg, VA USA; [Broglio, Steven P.] Univ Michigan, Sch Kinesiol, Ann Arbor, MI USA; [Broglio, Steven P.] Michigan NeuroSport, Ann Arbor, MI USA; [Mcallister, Thomas W.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Psychiat, Hanover, NH 03756 USA; [Guskiewicz, Kevin M.; Mihalik, Jason P.] Univ N Carolina, Matthew Gfeller Sport Related Traumat Brain Injur, Chapel Hill, NC USA; [Anderson, Scott] Univ Oklahoma, Dept Intercollegiate Athlet, Norman, OK 73019 USA; [Schnebel, Brock] Univ Oklahoma, Dept Orthoped, Norman, OK 73019 USA; [Schnebel, Brock] Univ Oklahoma, Dept Athlet, Norman, OK 73019 USA; [Brolinson, P. Gunnar] Edward Via Coll Osteopath Med, Blacksburg, VA USA; [Collins, Michael W.] Univ Pittsburgh, Med Ctr, Dept Orthopaed Surg, Pittsburgh, PA USA; [Collins, Michael W.] Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Pittsburgh, PA USA		Beckwith, JG (corresponding author), Simbex, 10 Water St,Suite 410, Lebanon, NH 03766 USA.	jbeckwith@simbex.com	Duma, Stefan/A-8368-2012; Lang, Steven/AAE-8102-2021; Rowson, Steven/B-1270-2012	Lang, Steven/0000-0003-1669-9146; Rowson, Steven/0000-0002-3227-0596; Guskiewicz, Kevin/0000-0002-8682-2130; Mihalik, Jason/0000-0001-6085-8322; Crisco, Joseph/0000-0002-8786-0905	National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01HD048638, R01NS055020]; Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R01CE001254, 5R49CE000196]; NOCSAE [07-04, 14-19)]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048638] Funding Source: NIH RePORTER; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE000196, R01CE001254] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM104937] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055020] Funding Source: NIH RePORTER	This work was supported in part by award R01HD048638 and R01NS055020 from the National Institute of Health, R01CE001254 and 5R49CE000196 from the Centers for Disease Control and Prevention, and NOCSAE (07-04, 14-19). HIT System technology was developed in part under NIH R44HD40473 and research and development support from Riddell, Inc. (Chicago, IL).	Beckwith JG, 2010, 8 WORLD C BRAIN INJ, P446; Beckwith JG, 2012, ANN BIOMED ENG, V40, P237, DOI 10.1007/s10439-011-0422-2; Brainard LL, 2012, MED SCI SPORT EXER, V44, P297, DOI 10.1249/MSS.0b013e31822b0ab4; Broglio SP, 2012, ANN BIOMED ENG, V40, P37, DOI 10.1007/s10439-011-0396-0; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA, P1; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Crisco JJ, 2012, J APPL BIOMECH, V28, P174, DOI 10.1123/jab.28.2.174; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Dick R, 2007, J ATHL TRAINING, V42, P221; Duhaime AC, 2012, J NEUROSURG, V117, P1092, DOI 10.3171/2012.8.JNS112298; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Funk JR, 2012, ANN BIOMED ENG, V40, P79, DOI 10.1007/s10439-011-0400-8; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; GURDJIAN ES, 1966, J TRAUM, V6, P600, DOI 10.1097/00005373-196609000-00005; GURDJIAN ES, 1955, SURG GYNECOL OBSTET, V101, P680; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hodgson VR, 1970, 700901 SAE, DOI [10.4271/700901, DOI 10.4271/700901]; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; McAllister TW, 2012, NEUROLOGY, V78, P1777, DOI 10.1212/WNL.0b013e3182582fe7; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2009, J SCI MED SPORT, V12, P340, DOI 10.1016/j.jsams.2009.02.004; Mihalik JP, 2008, P I MECH ENG P-J SPO, V222, P45, DOI 10.1243/17543371JSET4; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Moon D W, 1971, Med Sci Sports, V3, P44; Ng TP, 2006, BIOMED SCI INSTRUM, V42, P25; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Rowson S, 2011, ANN BIOMED ENG, V39, P2130, DOI 10.1007/s10439-011-0322-5; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Talavage TM, 2010, J NEUROTRAUMA; Versace J, 1971, SAE TECHNICAL PAPER, DOI [10.4271/710881, DOI 10.4271/710881]; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	44	107	107	2	44	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	APR	2013	45	4					737	746		10.1249/MSS.0b013e3182792ed7			10	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	109ZK	WOS:000316410600017	23135363	Green Published, Green Accepted			2022-02-06	
J	Ojo, JO; Mouzon, B; Greenberg, MB; Bachmeier, C; Mullan, M; Crawford, F				Ojo, Joseph-Olubunmi; Mouzon, Benoit; Greenberg, M. Banks; Bachmeier, Corbin; Mullan, Mike; Crawford, Fiona			Repetitive Mild Traumatic Brain Injury Augments Tau Pathology and Glial Activation in Aged hTau Mice	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Aging; Chronic traumatic encephalopathy; Glia; Human tau; Mild traumatic brain injury; Phospho-tau	FOOTBALL-LEAGUE PLAYER; MOUSE MODEL; ALZHEIMERS-DISEASE; TRANSGENIC MICE; NEUROFIBRILLARY TANGLES; CEREBRAL-CORTEX; PHOSPHATASE-ACTIVITY; PHYSICAL DEVELOPMENT; REACTIVE ASTROCYTES; HIV-1 ENCEPHALITIS	Extensive tau-immunoreactive neurons and glial cells associated with chronic traumatic encephalopathy (CTE) have been documented in the brains of some professional athletes and others with a history of repetitive mild traumatic brain injury (r-mTBI). The neuropathology and tau involvement in mTBI have not been extensively studied in animal models, particularly in aged animals. We investigated the effects of single mTBI (s-mTBI) and r-mTBI in 18-month-old hTau mice, which express wild-type human tau isoforms on a null murine tau background (n = 3-5 per group). At this age, hTau mice already demonstrate tau pathology, but there was a significant increase in phospho-tau immunoreactivity in response to r-mTBI, but not to s-mTBI, as determined using multiple phospho-tau-specific antibodies. Repetitive mTBI also resulted in a marked increase in astrocyte/microglia activation notably in the superficial layer of the motor/somatosensory cortex and the corpus callosum. We did not observe the perivascular tau pathology, neuritic threads, or astrocytic tangles that are commonly found in human CTE. The increase in phosphotau in the r-mTBI mice suggests that this may be a useful model for investigating further the link between mTBI, particularly r-mTBI, and tau pathobiology in CTE and in understanding responses of the aged brain to mTBI.	[Ojo, Joseph-Olubunmi; Mouzon, Benoit; Greenberg, M. Banks; Bachmeier, Corbin; Mullan, Mike; Crawford, Fiona] Roskamp Inst, Sarasota, FL 34243 USA		Ojo, JO (corresponding author), Roskamp Inst, 2040 Whitfield Ave, Sarasota, FL 34243 USA.	bojo@roskampinstitute.net		Mullan, Michael/0000-0002-1473-7527	Department of DefenseUnited States Department of Defense [W81XWH-10-1-0759]; Roskamp Foundation	This work was supported by Department of Defense award W81XWH-10-1-0759 (to Fiona Crawford) and by the Roskamp Foundation.	Alldred MJ, 2012, NEUROBIOL DIS, V45, P751, DOI 10.1016/j.nbd.2011.10.022; Amenta F, 1998, MICROSC RES TECHNIQ, V43, P29, DOI 10.1002/(SICI)1097-0029(19981001)43:1<29::AID-JEMT5>3.0.CO;2-H; Andorfer C, 2005, J NEUROSCI, V25, P5446, DOI 10.1523/JNEUROSCI.4637-04.2005; Andorfer C, 2003, J NEUROCHEM, V86, P582, DOI 10.1046/j.1471-4159.2003.01879.x; Augustinack JC, 2002, ACTA NEUROPATHOL, V103, P26, DOI 10.1007/s004010100423; Bennett RE, 2012, NEUROSCI LETT, V513, P160, DOI 10.1016/j.neulet.2012.02.024; Blau CW, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.09.035; Blaylock Russell L, 2011, Surg Neurol Int, V2, P107, DOI 10.4103/2152-7806.83391; Chen LJ, 2010, J NEUROTRAUM, V27, P1657, DOI 10.1089/neu.2010.1308; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Cosenza MA, 2002, BRAIN PATHOL, V12, P442, DOI 10.1111/j.1750-3639.2002.tb00461.x; Cosenza-Nashat MA, 2006, BRAIN PATHOL, V16, P256, DOI 10.1111/j.1750-3639.2006.00027.x; CRITCHLEY M, 1957, BMJ-BRIT MED J, V1, P357, DOI 10.1136/bmj.1.5015.357; Dilger RN, 2008, J LEUKOCYTE BIOL, V84, P932, DOI 10.1189/jlb.0208108; Duff K, 2000, NEUROBIOL DIS, V7, P87, DOI 10.1006/nbdi.1999.0279; Eckenhoff RG, 2012, ANESTHESIOLOGY, V116, P751, DOI 10.1097/ALN.0b013e31824be8e1; GALLYAS F, 1971, ACTA MORPHOL HUNG, V19, P57; GALLYAS F, 1971, ACTA MORPHOL HUNG, V19, P1; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Geddes JF, 1996, NEUROPATH APPL NEURO, V22, P12, DOI 10.1046/j.1365-2990.1996.2598025.x; GEINISMAN Y, 1978, AM J ANAT, V153, P537, DOI 10.1002/aja.1001530405; GRAHMANN H, 1957, Psychiatr Neurol (Basel), V134, P261; Hall RCW, 2005, PSYCHOSOMATICS, V46, P195, DOI 10.1176/appi.psy.46.3.195; Harris FM, 2004, J BIOL CHEM, V279, P44795, DOI 10.1074/jbc.M408127200; Henry CJ, 2009, BRAIN BEHAV IMMUN, V23, P309, DOI 10.1016/j.bbi.2008.09.002; HOF PR, 1992, ACTA NEUROPATHOL, V85, P23, DOI 10.1007/BF00304630; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Iwakiri M, 2009, NEUROPATHOLOGY, V29, P263, DOI 10.1111/j.1440-1789.2008.00978.x; Johnson VE, 2011, ACTA NEUROPATHOL, V122, P715, DOI 10.1007/s00401-011-0909-9; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Kimura T, 1996, DEMENTIA, V7, P177, DOI 10.1159/000106875; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Liu L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031302; Majetschak M, 2005, CRIT CARE MED, V33, P1589, DOI 10.1097/01.CCM.0000169883.41245.23; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; Mavrogiorgou P, 2011, PSYCHIAT DANUB, V23, P334; Mazanetz MP, 2007, NAT REV DRUG DISCOV, V6, P464, DOI 10.1038/nrd2111; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Millspaugh JA, 1937, US NAVAL MED B, V35, P297; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Nowinski C, 2006, HEAD GAMES FOOTBALLS; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; Ojo B, 2011, EXP NEUROL, V232, P318, DOI 10.1016/j.expneurol.2011.09.025; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; OTVOS L, 1994, J NEUROSCI RES, V39, P669, DOI 10.1002/jnr.490390607; Papon MA, 2011, FRONT NEUROSCI-SWITZ, V4, DOI 10.3389/fnins.2010.00272; Paxinos GFK., 2001, MOUSE BRAIN STEREOTA, V2nd ed.; Planel E, 2007, J NEUROSCI, V27, P3090, DOI 10.1523/JNEUROSCI.4854-06.2007; Polydoro M, 2009, J NEUROSCI, V29, P10741, DOI 10.1523/JNEUROSCI.1065-09.2009; Roberts AH, 1969, BRAIN DAMAGE BOXERS; Shively S, 2012, ARCH NEUROL-CHICAGO, V69, P1245, DOI 10.1001/archneurol.2011.3747; Smith C, 2003, NEUROPATH APPL NEURO, V29, P496, DOI 10.1046/j.1365-2990.2003.00488.x; Sofroniew MV, 2005, NEUROSCIENTIST, V11, P400, DOI 10.1177/1073858405278321; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P280, DOI 10.1007/BF00308813; Tran HT, 2012, J NEUROPATH EXP NEUR, V71, P116, DOI 10.1097/NEN.0b013e3182456aed; Tran HT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025475; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; von Bernhardi R, 2010, J NEUROCHEM, V112, P1099, DOI 10.1111/j.1471-4159.2009.06537.x; Webbe FM, 2003, CLIN SPORT MED, V22, P577, DOI 10.1016/S0278-5919(02)00103-5; Yao XL, 2008, J NEUROCHEM, V104, P353, DOI 10.1111/j.1471-4159.2007.04970.x; Yoshiyama Y, 2005, J NEUROTRAUM, V22, P1134, DOI 10.1089/neu.2005.22.1134; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277; Zhukareva V, 2001, ACTA NEUROPATHOL, V101, P518	69	107	107	0	42	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	FEB	2013	72	2					137	151		10.1097/NEN.0b013e3182814cdf			15	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	079HE	WOS:000314160400006	23334597	Bronze			2022-02-06	
J	Mayes, SD; Gorman, AA; Hillwig-Garcia, J; Syed, E				Mayes, Susan Dickerson; Gorman, Angela A.; Hillwig-Garcia, Jolene; Syed, Ehsan			Suicide ideation and attempts in children with autism	RESEARCH IN AUTISM SPECTRUM DISORDERS			English	Article						Autism; Suicide ideation; Suicide attempts	DEFIANT DISORDER DIFFERENCES; TRAUMATIC BRAIN-INJURY; PSYCHIATRIC-DISORDERS; ASPERGER-SYNDROME; PROCESSING SPEED; GENDER-DIFFERENCES; SPECTRUM DISORDER; ADHD SUBTYPES; RISK-FACTORS; WISC-III	Frequency of suicide ideation and attempts in 791 children with autism (1-16 years), 35 nonautistic depressed children, and 186 typical children and risk factors in autism were determined. Percent of children with autism for whom suicide ideation or attempts was rated as sometimes to very often a problem by mothers (14%) was 28 times greater than that for typical children (0.5%) but less than for depressed children (43%). For children with autism, four demographic variables (age 10 or older, Black or Hispanic, lower SES, and male) were significant risk factors of suicide ideation or attempts. The majority of children (71%) who had all four demographic risk factors had ideation or attempts. Comorbid psychological problems most highly predictive of ideation or attempts were depression, behavior problems, and teased. Almost half of children with these problems had suicide ideation or attempts. All children with autism should be screened for suicide ideation or attempts because ideation and attempts in autism are significantly higher than the norm and are present across the spectrum. This is especially important for children who have the demographic and comorbid risk factors, many of which can be targeted for intervention to reduce and prevent suicide ideation and attempts. (C) 2012 Elsevier Ltd. All rights reserved.	[Mayes, Susan Dickerson; Gorman, Angela A.; Hillwig-Garcia, Jolene; Syed, Ehsan] Penn State Coll Med, Dept Psychiat, Hershey, PA USA		Mayes, SD (corresponding author), Hershey Med Ctr, Dept Psychiat H073, 500 Univ Dr, Hershey, PA 17033 USA.	smayes@psu.edu					American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Bae Sejong, 2005, Arch Suicide Res, V9, P193, DOI 10.1080/13811110590904034; Bellini S., 2004, FOCUS AUTISM DEV DIS, V19, P78, DOI DOI 10.1177/10883576040190020201; Bixler EO, 2009, SLEEP, V32, P731, DOI 10.1093/sleep/32.6.731; Bodfish JW, 2000, J AUTISM DEV DISORD, V30, P237, DOI 10.1023/A:1005596502855; Brereton AV, 2006, J AUTISM DEV DISORD, V36, P863, DOI 10.1007/s10803-006-0125-y; Calhoun SL, 2005, PSYCHOL SCHOOLS, V42, P333, DOI 10.1002/pits.20067; Centers for Disease Control, 2012, SUIC PREV; Cui S, 2011, CHILD CARE HLTH DEV, V37, P692, DOI 10.1111/j.1365-2214.2010.01181.x; Eisenmajer R, 1996, J AM ACAD CHILD PSY, V35, P1523, DOI 10.1097/00004583-199611000-00022; Epstein JA, 2010, ARCH SUICIDE RES, V14, P193, DOI 10.1080/13811118.2010.494130; Fleming TM, 2007, AUST NZ J PSYCHIAT, V41, P213, DOI 10.1080/00048670601050481; Gadow KD, 2005, AUTISM, V9, P392, DOI 10.1177/1362361305056079; Gadow KD, 2008, J AUTISM DEV DISORD, V38, P1710, DOI 10.1007/s10803-008-0556-8; Gadow KD, 2012, J AUTISM DEV DISORD, V42, P1353, DOI 10.1007/s10803-011-1367-x; Gould MS, 1998, J AM ACAD CHILD PSY, V37, P915, DOI 10.1097/00004583-199809000-00011; Green J, 2000, J AUTISM DEV DISORD, V30, P279, DOI 10.1023/A:1005523232106; Greening L, 2010, J YOUTH ADOLESCENCE, V39, P357, DOI 10.1007/s10964-009-9459-z; Gutierrez Peter M, 2005, Arch Suicide Res, V9, P177, DOI 10.1080/13811110590904025; Guttmann-Steinmetz S, 2009, J AUTISM DEV DISORD, V39, P976, DOI 10.1007/s10803-009-0706-7; Gvion Y, 2011, ARCH SUICIDE RES, V15, P93, DOI 10.1080/13811118.2011.565265; Hetrick SE, 2012, CRISIS, V33, P13, DOI 10.1027/0227-5910/a000095; Howlin P, 2003, J AUTISM DEV DISORD, V33, P3, DOI 10.1023/A:1022270118899; Hurtig T, 2009, AUTISM, V13, P583, DOI 10.1177/1362361309335719; Kanne SM, 2011, J AUTISM DEV DISORD, V41, P926, DOI 10.1007/s10803-010-1118-4; Karch Debra L., 2009, Morbidity and Mortality Weekly Report, V58, P1; Kim JA., 2000, AUTISM, V4, P117, DOI [DOI 10.1177/1362361300004002002, 10.1177/1362361300004002002]; Kim Young Shin, 2008, Int J Adolesc Med Health, V20, P133; Kim YS, 2009, ARCH SUICIDE RES, V13, P15, DOI 10.1080/13811110802572098; Kim YS, 2005, PEDIATRICS, V115, P357, DOI 10.1542/peds.2004-0902; Kirchner T, 2011, ACTAS ESP PSIQUIATRI, V39, P226; Klomek AB, 2007, J AM ACAD CHILD PSY, V46, P40, DOI 10.1097/01.chi.0000242237.84925.18; Leyfer OT, 2006, J AUTISM DEV DISORD, V36, P849, DOI 10.1007/s10803-006-0123-0; MANJIVIONA J, 1995, J AUTISM DEV DISORD, V25, P23, DOI 10.1007/BF02178165; Mann J John, 2007, Arch Suicide Res, V11, P3, DOI 10.1080/13811110600993124; Matson JL, 2007, RES DEV DISABIL, V28, P341, DOI 10.1016/j.ridd.2005.12.004; Mattison RE, 2012, J ATTEN DISORD, V16, P138, DOI 10.1177/1087054710380188; Max JE, 1998, J AM ACAD CHILD PSY, V37, P841, DOI 10.1097/00004583-199808000-00014; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 1998, J NEUROPSYCH CLIN N, V10, P290, DOI 10.1176/jnp.10.3.290; Mayes S., 2012, CHECKLIST AUTISM SPE; Mayes SD, 2004, CLIN NEUROPSYCHOL, V18, P559, DOI 10.1080/13854040490888530; Mayes SD, 2004, J DEV PHYS DISABIL, V16, P257, DOI 10.1023/B:JODD.0000032301.07550.0e; Mayes SD, 2001, J ABNORM CHILD PSYCH, V29, P263, DOI 10.1023/A:1010337916636; Mayes SD, 1999, INFANT YOUNG CHILD, V12, P90, DOI 10.1097/00001163-199910000-00011; Mayes SD, 2003, J AUTISM DEV DISORD, V33, P329, DOI 10.1023/A:1024462719081; Mayes SD, 2008, J AUTISM DEV DISORD, V38, P428, DOI 10.1007/s10803-007-0410-4; Mayes SD, 2007, CHILD NEUROPSYCHOL, V13, P469, DOI 10.1080/09297040601112773; Mayes SD, 2006, LEARN INDIVID DIFFER, V16, P145, DOI 10.1016/j.lindif.2005.07.004; Mayes SD, 2012, RES AUTISM SPECT DIS, V6, P277, DOI 10.1016/j.rasd.2011.05.009; Mayes SD, 2012, RES AUTISM SPECT DIS, V6, P1, DOI 10.1016/j.rasd.2011.08.001; Mayes SD, 2011, J DEV PHYS DISABIL, V23, P325, DOI 10.1007/s10882-011-9231-7; Mayes SD, 2011, RES AUTISM SPECT DIS, V5, P749, DOI 10.1016/j.rasd.2010.09.002; Mayes SD, 2011, RES AUTISM SPECT DIS, V5, P474, DOI 10.1016/j.rasd.2010.06.012; Mayes SD, 2009, J ATTEN DISORD, V12, P540, DOI 10.1177/1087054708320402; Mayes SD, 2009, J AUTISM DEV DISORD, V39, P1682, DOI 10.1007/s10803-009-0812-6; Mayes SD, 2009, SLEEP MED CLIN, V4, P19, DOI 10.1016/j.jsmc.2008.12.004; Mayes SD, 2009, RES AUTISM SPECT DIS, V3, P931, DOI 10.1016/j.rasd.2009.04.002; Mayes SD, 2009, J PEDIATR PSYCHOL, V34, P328, DOI 10.1093/jpepsy/jsn083; McKeown RE, 1998, J AM ACAD CHILD PSY, V37, P612, DOI 10.1097/00004583-199806000-00011; Mikami K, 2009, GEN HOSP PSYCHIAT, V31, P163, DOI 10.1016/j.genhosppsych.2008.12.003; Miller JN, 2000, J ABNORM PSYCHOL, V109, P227, DOI 10.1037/0021-843X.109.2.227; Miller JN, 1997, J CHILD PSYCHOL PSYC, V38, P247; Miller JN., 2000, AUTISM, V4, P29, DOI DOI 10.1177/1362361300041003; Murphy O, 2009, RES AUTISM SPECT DIS, V3, P474, DOI 10.1016/j.rasd.2008.09.008; Murray MJ, 2011, J AUTISM DEV DISORD, V41, P1586, DOI 10.1007/s10803-011-1178-0; Nichols S, 2000, J PEDIATR PSYCHOL, V25, P545, DOI 10.1093/jpepsy/25.8.545; Prinz R., 1987, ADV BEHAV ASSESSMENT, P57; ROTHERAMBORUS MJ, 1990, J CONSULT CLIN PSYCH, V58, P554, DOI 10.1037/0022-006X.58.5.554; Russell E, 2005, AUST NZ J PSYCHIAT, V39, P633, DOI 10.1111/j.1440-1614.2005.01637.x; Simonoff E, 2008, J AM ACAD CHILD PSY, V47, P921, DOI 10.1097/CHI.0b013e318179964f; SZATMARI P, 1995, J AM ACAD CHILD PSY, V34, P1662, DOI 10.1097/00004583-199512000-00017; Tryon P. A., 2006, FOCUS AUTISM OTHER D, V21, P2, DOI [10.1177/10883576060210010101, DOI 10.1177/10883576060210010101]; Wannan G, 1998, J ADOLESCENCE, V21, P371, DOI 10.1006/jado.1998.0162; Wichstrom L, 2000, J AM ACAD CHILD PSY, V39, P603, DOI 10.1097/00004583-200005000-00014; WING L, 1981, PSYCHOL MED, V11, P115, DOI 10.1017/S0033291700053332; WOLRAICH ML, 1994, NEW ENGL J MED, V330, P301, DOI 10.1056/NEJM199402033300501	77	107	108	0	57	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1750-9467	1878-0237		RES AUTISM SPECT DIS	Res. Autism Spectr. Disord.	JAN-MAR	2013	7	1					109	119		10.1016/j.rasd.2012.07.009			11	Education, Special; Psychology, Developmental; Psychiatry; Rehabilitation	Social Science Citation Index (SSCI)	Education & Educational Research; Psychology; Psychiatry; Rehabilitation	044WN	WOS:000311656000013					2022-02-06	
J	Topjian, AA; Gutierrez-Colina, AM; Sanchez, SM; Berg, RA; Friess, SH; Dlugos, DJ; Abend, NS				Topjian, Alexis A.; Gutierrez-Colina, Ana M.; Sanchez, Sarah M.; Berg, Robert A.; Friess, Stuart H.; Dlugos, Dennis J.; Abend, Nicholas S.			Electrographic Status Epilepticus Is Associated With Modality and Worse Short-Term Outcome in Critically Ill Children	CRITICAL CARE MEDICINE			English	Article						electroencephalographic monitoring; nonconvulsive seizure; outcome; pediatric; seizure; status epilepticus	NONCONVULSIVE STATUS EPILEPTICUS; INTENSIVE-CARE-UNIT; HYPOXIC-ISCHEMIC ENCEPHALOPATHY; TRAUMATIC BRAIN-INJURY; THERAPEUTIC HYPOTHERMIA; NEONATAL SEIZURES; EEG PATTERNS; PREDICTION; ELECTROENCEPHALOGRAPHY; ARREST	Objectives: Electrographic seizures and electrographic status epilepticus are common in critically ill children. We aimed to determine whether electrographic seizures and electrographic status epilepticus are associated with higher mortality or worse short-term neurologic outcome. Design: Prospective observational study. Setting: PICU of a tertiary children's hospital. Patients: Non-neonatal children admitted to a PICU with acute encephalopathy underwent continuous electroencephalographic monitoring. Electroencephalographs were scored as 1) no seizures, 2) electrographic seizures, or 3) electrographic status epilepticus. Covariates included age, acute neurologic disorder category, prior neurodevelopmental status, sex, and electroencephalographic background category. Outcomes were mortality and worsening of pediatric cerebral performance category from preadmission to PICU discharge. Chi-square analysis, Fisher's exact test, and multivariable logistic regression were used to evaluate the associations between electrographic seizures or electrographic status epilepticus and mortality or short-term neurologic outcome, using odds ratios and 95% confidence intervals. Interventions: None. Main Results: Two hundred children underwent continuous electroencephalographic monitoring. Eighty-four (42%) had seizures, which were categorized as electrographic seizures in 41 (20.5%) and electrographic status epilepticus in 43 (21.5%). Thirty-six subjects (18%) died, and 88 subjects (44%) had pediatric cerebral performance category worsening. In multivariable analysis, electrographic status epilepticus was associated with an increased risk of mortality (odds ratio 5.1; 95% confidence interval 1.4, 18; p = 0.01) and pediatric cerebral performance category worsening (odds ratio 17.3; 95% confidence interval 3.7, 80; p < 0.001), whereas electrographic seizures were not associated with an increased risk of mortality (odds ratio 1.3; 95% confidence interval 0.3, 5.1; p = 0.74) or pediatric cerebral performance category worsening (odds ratio 1.2; 95% confidence interval 0.4, 3.9; p = 0.77). Conclusions: Electrographic status epilepticus, but not electrographic seizures, is associated with mortality and worse short-term neurologic outcome in critically ill children with acute encephalopathy. (Crit Care Med 2013; 41:215-223)	[Topjian, Alexis A.; Berg, Robert A.; Friess, Stuart H.] Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA; [Gutierrez-Colina, Ana M.; Sanchez, Sarah M.; Dlugos, Dennis J.; Abend, Nicholas S.] Childrens Hosp Philadelphia, Div Neurol, Philadelphia, PA 19104 USA; [Dlugos, Dennis J.; Abend, Nicholas S.] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Dlugos, Dennis J.; Abend, Nicholas S.] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA		Abend, NS (corresponding author), Childrens Hosp Philadelphia, Div Neurol, Philadelphia, PA 19104 USA.	abend@email.chop.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5K12HD047349, U01HL094345, 5K08NS064051, K23NS076550]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD047349] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [U01HL094345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS076550, K08NS064051, K23NS075363] Funding Source: NIH RePORTER	Dr. Topjian received grant support from NIH 5K12HD047349 and U01HL094345. Dr. Friess received grant support from NIH 5K08NS064051. Dr. Abend received grant support from NIH K23NS076550.	Abend NS, 2011, NEUROLOGY, V76, P1071, DOI 10.1212/WNL.0b013e318211c19e; Abend NS, 2009, NEUROLOGY, V72, P1931, DOI 10.1212/WNL.0b013e3181a82687; Abend NS, 2007, PEDIATR NEUROL, V37, P165, DOI 10.1016/j.pediatrneurol.2007.05.012; Abend NS, 2010, NEUROCRIT CARE, V12, P382, DOI 10.1007/s12028-010-9337-2; Alehan FK, 2001, J CHILD NEUROL, V16, P484, DOI 10.2310/7010.2001.17060; Carrera E, 2008, ARCH NEUROL-CHICAGO, V65, P1612, DOI 10.1001/archneur.65.12.1612; CHELIOUT-HERAUT F, 1991, Neurophysiologie Clinique, V21, P121, DOI 10.1016/S0987-7053(05)80066-8; Chong DJ, 2005, J CLIN NEUROPHYSIOL, V22, P79, DOI 10.1097/01.WNP.0000158699.78529.AF; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; CLANCY RR, 1988, EPILEPSIA, V29, P256, DOI 10.1111/j.1528-1157.1988.tb03715.x; EVANS BM, 1995, J NEUROL NEUROSUR PS, V59, P17, DOI 10.1136/jnnp.59.1.17; Fiser DH, 2000, CRIT CARE MED, V28, P2616, DOI 10.1097/00003246-200007000-00072; Greiner HM, 2012, PEDIATRICS, V129, pE748, DOI 10.1542/peds.2011-2067; Hauf M, 2009, AM J NEURORADIOL, V30, P693, DOI 10.3174/ajnr.A1456; Hosain SA, 2005, PEDIATR NEUROL, V32, P162, DOI 10.1016/j.pediatrneurol.2004.09.008; Hyllienmark L, 2007, EUR J PAEDIATR NEURO, V11, P70, DOI 10.1016/j.ejpn.2006.11.005; Jette N, 2006, ARCH NEUROL-CHICAGO, V63, P1750, DOI 10.1001/archneur.63.12.1750; Jirsch J, 2007, CLIN NEUROPHYSIOL, V118, P1660, DOI 10.1016/j.clinph.2006.11.312; Kessler SK, 2011, NEUROCRIT CARE, V14, P37, DOI 10.1007/s12028-010-9450-2; Mandel R, 2002, J PEDIATR-US, V141, P45, DOI 10.1067/mpd.2002.125005; McBride MC, 2000, NEUROLOGY, V55, P506, DOI 10.1212/WNL.55.4.506; McCoy B, 2011, EPILEPSIA, V52, P1973, DOI 10.1111/j.1528-1167.2011.03291.x; Nash KB, 2011, NEUROLOGY, V76, P556, DOI 10.1212/WNL.0b013e31820af91a; Nishisaki A, 2007, PEDIATR CRIT CARE ME, V8, P10, DOI 10.1097/01.pcc.0000256621.63135.4b; Oddo M, 2009, CRIT CARE MED, V37, P2051, DOI 10.1097/CCM.0b013e3181a00604; PAMPIGLI.G, 1968, LANCET, V1, P1261; Pampiglione G, 1978, Ann N Y Acad Sci, V315, P281, DOI 10.1111/j.1749-6632.1978.tb50346.x; Pisani F, 2007, NEUROLOGY, V69, P2177, DOI 10.1212/01.wnl.0000295674.34193.9e; Pollack MM, 1996, CRIT CARE MED, V24, P743, DOI 10.1097/00003246-199605000-00004; RamachandranNair R, 2005, PEDIATR NEUROL, V33, P345, DOI 10.1016/j.pediatrneurol.2005.05.007; Saengpattrachai M, 2006, EPILEPSIA, V47, P1510, DOI 10.1111/j.1528-1167.2006.00624.x; Scher MS, 2003, PEDIATR NEUROL, V28, P277, DOI 10.1016/S0887-8994(02)00621-5; Shahwan A, 2010, EPILEPSIA, V51, P1198, DOI 10.1111/j.1528-1167.2009.02517.x; TASKER RC, 1988, ARCH DIS CHILD, V63, P895, DOI 10.1136/adc.63.8.895; Tay SKH, 2006, EPILEPSIA, V47, P1504, DOI 10.1111/j.1528-1167.2006.00623.x; Vespa PM, 2010, NEUROLOGY, V75, P792, DOI 10.1212/WNL.0b013e3181f07334; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 2003, NEUROLOGY, V60, P1441, DOI 10.1212/01.WNL.0000063316.47591.B4; Williams K, 2011, EPILEPSIA, V52, P1130, DOI 10.1111/j.1528-1167.2011.03070.x; Wusthoff CJ, 2011, J CHILD NEUROL, V26, P724, DOI 10.1177/0883073810390036; Young GB, 1996, NEUROLOGY, V47, P83	41	107	109	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JAN	2013	41	1					215	223		10.1097/CCM.0b013e3182668035			9	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	065LR	WOS:000313150300024	23164815	Green Accepted			2022-02-06	
J	Wang, HK; Lin, SH; Sung, PS; Wu, MH; Hung, KW; Wang, LC; Huang, CY; Lu, K; Chen, HJ; Tsai, KJ				Wang, Hao-Kuang; Lin, Sheng-Hsiang; Sung, Pi-Shan; Wu, Ming-Hsiu; Hung, Kuo-Wei; Wang, Liang-Chao; Huang, Chih-Yuan; Lu, Kang; Chen, Han-Jung; Tsai, Kuen-Jer			Population based study on patients with traumatic brain injury suggests increased risk of dementia	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							AMYLOID-BETA DYNAMICS; ALZHEIMERS-DISEASE; HEAD-INJURY; PARKINSONS-DISEASE; PREVALENCE; ONSET; TAIWAN; AGE	Objective The relationship between traumatic brain injury (TBI) and the risk of dementia remains controversial. This population based study was designed to estimate and compare the risk of dementia in TBI and non-TBI individuals during the 5 year period after TBI. Methods This study was a retrospective cohort study. Data were obtained from the Longitudinal Health Insurance Database 2000. We included 44 925 patients receiving ambulatory or hospital care and 224 625 non-TBI patients; patients were matched for sex, age and year of index use of healthcare. Patients < 15 years of age and those admitted to the intensive care unit were excluded. Each individual was studied for 5 years to identify the subsequent development of dementia. Data were analysed by Cox proportional hazard regression. Results During the 5 year follow-up period, 1196 TBI (2.66%) and 224 625 non-TBI patients (1.53%) patients developed dementia. During the 5 year follow-up period, TBI was independently associated with a 1.68 (range 1.57-1.80) times greater risk of dementia after adjusting for sociodemographic characteristics and selected comorbidities. Conclusions The findings of this study suggest an increased risk of dementia among individuals with TBI. We suggest the need for more intensive medical monitoring and health education in individuals with TBI.	[Wang, Hao-Kuang; Lin, Sheng-Hsiang; Sung, Pi-Shan; Wu, Ming-Hsiu; Hung, Kuo-Wei; Wang, Liang-Chao; Huang, Chih-Yuan; Tsai, Kuen-Jer] Natl Cheng Kung Univ, Inst Clin Med, Tainan 704, Taiwan; [Wang, Hao-Kuang; Lu, Kang; Chen, Han-Jung] I Shou Univ, E Da Hosp, Dept Neurosurg, Kaohsiung, Taiwan; [Sung, Pi-Shan] Natl Cheng Kung Univ, Dept Neurol, Tainan 704, Taiwan; [Wu, Ming-Hsiu] Chi Mei Med Ctr, Dept Neurol, Tainan, Taiwan; [Hung, Kuo-Wei] Yuans Gen Hosp, Dept Neurol, Kaohsiung, Taiwan; [Wang, Liang-Chao; Huang, Chih-Yuan] Natl Cheng Kung Univ Hosp, Dept Surg, Neurosurg Serv, Tainan 70428, Taiwan		Tsai, KJ (corresponding author), Natl Cheng Kung Univ, Inst Clin Med, Tainan 704, Taiwan.	kjtsai@mail.ncku.edu.tw	Tsai, Kuen-Jer/AAZ-2714-2021; Tsai, Kuen-Jer/B-9393-2009	Tsai, Kuen-Jer/0000-0002-2170-9735; Tsai, Kuen-Jer/0000-0002-2170-9735; Wang, Hao-Kuang/0000-0002-1928-7502			Almeida OP, 2012, EUR HEART J, V33, P1769, DOI 10.1093/eurheartj/ehr467; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Barnes DE, 2011, LANCET NEUROL, V10, P819, DOI 10.1016/S1474-4422(11)70072-2; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Brody DL, 2008, SCIENCE, V321, P1221, DOI 10.1126/science.1161591; Chen YH, 2011, STROKE, V42, P2733, DOI 10.1161/STROKEAHA.111.620112; Chiang CJ, 2007, AM J GERIAT PSYCHIAT, V15, P762, DOI 10.1097/JGP.0b013e318050c98f; Chien IC, 2004, PSYCHIAT SERV, V55, P691, DOI 10.1176/appi.ps.55.6.691; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; FRATIGLIONI L, 1993, ANN NEUROL, V33, P258, DOI 10.1002/ana.410330306; Hesdorffer DC, 2009, J HEAD TRAUMA REHAB, V24, P452, DOI 10.1097/HTR.0b013e3181c133fd; Hung C C, 1991, J Formos Med Assoc, V90, P1227; Jellinger KA, 2004, CURR OPIN NEUROL, V17, P719, DOI 10.1097/00019052-200412000-00012; Kung WM, 2011, INJURY, V42, P940, DOI 10.1016/j.injury.2010.09.019; Launer LJ, 1999, NEUROLOGY, V52, P78, DOI 10.1212/WNL.52.1.78; Levy G, 2002, MOVEMENT DISORD, V17, P250, DOI 10.1002/mds.10086; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Magnoni S, 2010, ARCH NEUROL-CHICAGO, V67, P1068, DOI 10.1001/archneurol.2010.214; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Mizrahi EH, 2011, AM J ALZHEIMERS DIS, V26, P623, DOI 10.1177/1533317511432733; Mura E, 2010, CURR PHARM DESIGN, V16, P672, DOI 10.2174/138161210790883723; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Roberson ED, 2007, SCIENCE, V316, P750, DOI 10.1126/science.1141736; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; Rossor MN, 2010, LANCET NEUROL, V9, P793, DOI 10.1016/S1474-4422(10)70159-9; Rugbjerg K, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a2494; Savva GM, 2009, NEW ENGL J MED, V360, P2302, DOI 10.1056/NEJMoa0806142; Schmidt S, 2010, J NEUROL SCI, V291, P22, DOI 10.1016/j.jns.2010.01.011; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; SWAAB DF, 1994, J NEUROENDOCRINOL, V6, P681, DOI 10.1111/j.1365-2826.1994.tb00635.x; Temkin NR, 2009, J HEAD TRAUMA REHAB, V24, P460, DOI 10.1097/HTR.0b013e3181c13413; Turner MR, 2010, J NEUROL SCI, V288, P45, DOI 10.1016/j.jns.2009.10.010; Urban RJ, 2005, BRAIN INJURY, V19, P349, DOI 10.1080/02699050400004807; Wancata J, 2007, AM J GERIAT PSYCHIAT, V15, P1034, DOI 10.1097/JGP.0b013e31813c6b6c; WILLIAMS DB, 1991, NEUROLOGY, V41, P1554, DOI 10.1212/WNL.41.10.1554; Yaffe K, 2003, NEUROLOGY, V61, P76, DOI 10.1212/01.WNL.0000073620.42047.D7; Yaffe K, 2010, ARCH GEN PSYCHIAT, V67, P608, DOI 10.1001/archgenpsychiatry.2010.61	41	107	107	0	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	NOV	2012	83	11					1080	1085		10.1136/jnnp-2012-302633			6	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Surgery	020MG	WOS:000309813600010	22842203				2022-02-06	
J	Xu, F; Liu, PY; Pascual, JM; Xiao, GH; Lu, HZ				Xu, Feng; Liu, Peiying; Pascual, Juan M.; Xiao, Guanghua; Lu, Hanzhang			Effect of hypoxia and hyperoxia on cerebral blood flow, blood oxygenation, and oxidative metabolism	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						cerebral metabolic rate of oxygen; cerebral venous oxygenation; hyperoxia; hypoxia	CARBON-DIOXIDE; GLUCOSE-METABOLISM; PERFUSION MRI; BOLD; HYPERCAPNIA; CALIBRATION; SATURATION; VELOCITY; NEURONS; CORTEX	Characterizing the effect of oxygen (O-2) modulation on the brain may provide a better understanding of several clinically relevant problems, including acute mountain sickness and hyperoxic therapy in patients with traumatic brain injury or ischemia. Quantifying the O-2 effects on brain metabolism is also critical when using this physiologic maneuver to calibrate functional magnetic resonance imaging (fMRI) signals. Although intuitively crucial, the question of whether the brain's metabolic rate depends on the amount of O-2 available has not been addressed in detail previously. This can be largely attributed to the scarcity and complexity of measurement techniques. Recently, we have developed an MR method that provides a noninvasive (devoid of exogenous agents), rapid (<5 minutes), and reliable (coefficient of variant, Coy <3%) measurement of the global cerebral metabolic rate of O-2 (CMRO2). In the present study, we evaluated metabolic and vascular responses to manipulation of the fraction of inspired O-2 (FiO(2)). Hypoxia with 14% FiO(2) was found to increase both CMRO2 (5.0 +/- 2.0%, N=16, P=0.02) and cerebral blood flow (CBF) (9.8 +/- 2.3%, P<0.001). However, hyperoxia decreased CMRO2 by 10.3 +/- 1.5% (P<0.001) and 16.9 +/- 2.7% (P<0.001) for FiO(2) of 50% and 98%, respectively. The CBF showed minimal changes with hyperoxia. Our results suggest that modulation of inspired O-2 alters brain metabolism in a dose-dependent manner. Journal of Cerebral Blood Flow & Metabolism (2012) 32, 1909-1918; doi:10.1038/jcbfm.2012.93; published online 27 June 2012	[Xu, Feng; Liu, Peiying; Lu, Hanzhang] Univ Texas SW Med Ctr Dallas, Adv Imaging Res Ctr, Dallas, TX 75390 USA; [Xiao, Guanghua] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA; [Pascual, Juan M.] Univ Texas SW Med Ctr Dallas, Dept Neurol & Neurotherapeut, Dallas, TX 75390 USA; [Pascual, Juan M.] Univ Texas SW Med Ctr Dallas, Dept Physiol, Dallas, TX 75390 USA; [Pascual, Juan M.] Univ Texas SW Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA		Lu, HZ (corresponding author), Univ Texas SW Med Ctr Dallas, Adv Imaging Res Ctr, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	hanzhang.lu@utsouthwestern.edu	Liu, Peiying/D-7512-2017; Xu, Feng/K-7760-2015	Liu, Peiying/0000-0003-0830-5960; Xu, Feng/0000-0001-7958-3787; Pascual, Juan/0000-0002-0843-8221	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 MH084021, R01 NS067015, R01 AG033106]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH084021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS078656, R01NS067015] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG033106, R21AG034318, R01AG042753] Funding Source: NIH RePORTER	This work was supported, in part, by the National Institutes of Health (R01 MH084021, R01 NS067015, and R01 AG033106).	AYRES SM, 1964, J APPL PHYSIOL, V19, P43, DOI 10.1152/jappl.1964.19.1.43; Baddeley H, 2000, BRIT J RADIOL, V73, P1100, DOI 10.1259/bjr.73.874.11271904; Bakker CJG, 1999, JMRI-J MAGN RESON IM, V9, P119, DOI 10.1002/(SICI)1522-2586(199901)9:1<119::AID-JMRI16>3.3.CO;2-6; BOGAERT YE, 1994, FREE RADICAL BIO MED, V16, P811, DOI 10.1016/0891-5849(94)90197-X; Braun AR, 1997, BRAIN, V120, P1173, DOI 10.1093/brain/120.7.1173; Brutus NA, 2009, NEUROCHEM RES, V34, P1219, DOI 10.1007/s11064-008-9898-z; Bulte DP, 2007, J CEREBR BLOOD F MET, V27, P69, DOI 10.1038/sj.jcbfm.9600319; Chen Y, 2009, NEUROCHEM RES, V34, P1047, DOI 10.1007/s11064-008-9873-8; Chiarelli PA, 2007, NEUROIMAGE, V37, P808, DOI 10.1016/j.neuroimage.2007.05.033; Cohen ER, 2002, J CEREBR BLOOD F MET, V22, P1042, DOI 10.1097/00004647-200209000-00002; Dean JB, 2004, J APPL PHYSIOL, V96, P784, DOI 10.1152/japplphysiol.00892.2003; Diringer MN, 2007, J NEUROSURG, V106, P526, DOI 10.3171/jns.2007.106.4.526; Dubowitz, 2011, P INT SOC MAGN RES M; EVANS AJ, 1993, INVEST RADIOL, V28, P109, DOI 10.1097/00004424-199302000-00004; Floyd TF, 2003, J APPL PHYSIOL, V95, P2453, DOI 10.1152/japplphysiol.00303.2003; Guyton A. C., 2005, TXB MED PHYSL; HAMBERGER A, 1963, J CELL BIOL, V16, P521, DOI 10.1083/jcb.16.3.521; HARIK SI, 1995, J APPL PHYSIOL, V79, P136, DOI 10.1152/jappl.1995.79.1.136; Imray C, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4943; JAMIESON D, 1986, ANNU REV PHYSIOL, V48, P703, DOI 10.1146/annurev.ph.48.030186.003415; KETY SS, 1948, J CLIN INVEST, V27, P484, DOI 10.1172/JCI101995; Kolbitsch C, 2002, MAGN RESON IMAGING, V20, P535, DOI 10.1016/S0730-725X(02)00534-9; Liu PY, 2013, MAGN RESON MED, V69, P675, DOI 10.1002/mrm.24295; LOEPPKY JA, 1983, RESP PHYSIOL, V51, P167; Lu HZ, 2008, MAGN RESON MED, V60, P357, DOI 10.1002/mrm.21627; Lu HZ, 2012, MAGN RESON MED, V67, P42, DOI 10.1002/mrm.22970; Maandag NJG, 2007, P NATL ACAD SCI USA, V104, P20546, DOI 10.1073/pnas.0709515104; Magistretti PJ, 1999, PHILOS T R SOC B, V354, P1155, DOI 10.1098/rstb.1999.0471; Magnoni S, 2003, J NEUROSURG, V98, P952, DOI 10.3171/jns.2003.98.5.0952; MINTUN MA, 1984, J NUCL MED, V25, P177; Moller K, 2002, J CEREBR BLOOD F MET, V22, P118, DOI 10.1097/00004647-200201000-00014; Mudduluru M, 2010, NEUROCHEM RES, V35, P1003, DOI 10.1007/s11064-010-0147-x; Nishimura N, 2007, AVIAT SPACE ENVIR MD, V78, P1121, DOI 10.3357/ASEM.2177.2007; Noth U, 2008, NMR BIOMED, V21, P464, DOI 10.1002/nbm.1210; Nofzinger EA, 2002, BRAIN, V125, P1105, DOI 10.1093/brain/awf103; Richards EM, 2007, STROKE, V38, P1578, DOI 10.1161/STROKEAHA.106.473967; Rockswold SB, 2010, J NEUROSURG, V112, P1080, DOI 10.3171/2009.7.JNS09363; Sicard KM, 2005, NEUROIMAGE, V25, P850, DOI 10.1016/j.neuroimage.2004.12.010; Silvennoinen MJ, 2003, MAGNET RESON MED, V49, P568, DOI 10.1002/mrm.10370; STEIN PD, 1995, CHEST, V107, P139, DOI 10.1378/chest.107.1.139; Tatarkova Z, 2011, NEUROCHEM RES, V36, P1475, DOI 10.1007/s11064-011-0473-7; Thom SR, 2009, J APPL PHYSIOL, V106, P988, DOI 10.1152/japplphysiol.91004.2008; Tuunanen PI, 2006, NEUROIMAGE, V30, P102, DOI 10.1016/j.neuroimage.2005.09.021; Wise RG, 2007, J CEREBR BLOOD F MET, V27, P1521, DOI 10.1038/sj.jcbfm.9600465; Xu F, 2011, J CEREBR BLOOD F MET, V31, P58, DOI 10.1038/jcbfm.2010.153; Xu F, 2009, MAGN RESON MED, V62, P141, DOI 10.1002/mrm.21994; Yezhuvath US, 2009, NMR BIOMED, V22, P779, DOI 10.1002/nbm.1392; ZANANIRI FV, 1991, J MED ENG TECHNOL, V15, P170, DOI 10.3109/03091909109023704	48	107	109	0	22	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	OCT	2012	32	10					1909	1918		10.1038/jcbfm.2012.93			10	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	014KY	WOS:000309375800009	22739621	Bronze, Green Published			2022-02-06	
J	Kimbler, DE; Shields, J; Yanasak, N; Vender, JR; Dhandapani, KM				Kimbler, Donald E.; Shields, Jessica; Yanasak, Nathan; Vender, John R.; Dhandapani, Krishnan M.			Activation of P2X7 Promotes Cerebral Edema and Neurological Injury after Traumatic Brain Injury in Mice	PLOS ONE			English	Article							INTERLEUKIN-1 RECEPTOR ANTAGONIST; SEVERE HEAD-INJURY; CONTROLLED CORTICAL IMPACT; FIBRILLARY ACIDIC PROTEIN; ATP-INDUCED RELEASE; SPINAL-CORD-INJURY; CEREBROSPINAL-FLUID; INTRACRANIAL HYPERTENSION; COGNITIVE DYSFUNCTION; AQUAPORIN-4	Traumatic brain injury (TBI) is a leading cause of death and disability worldwide. Cerebral edema, the abnormal accumulation of fluid within the brain parenchyma, contributes to elevated intracranial pressure (ICP) and is a common life-threatening neurological complication following TBI. Unfortunately, neurosurgical approaches to alleviate increased ICP remain controversial and medical therapies are lacking due in part to the absence of viable drug targets. In the present study, genetic inhibition (P2X7-/- mice) of the purinergic P2x7 receptor attenuated the expression of the pro-inflammatory cytokine, interleukin-1 beta (IL-1 beta) and reduced cerebral edema following controlled cortical impact, as compared to wild-type mice. Similarly, brilliant blue G (BBG), a clinically non-toxic P2X7 inhibitor, inhibited IL-1 beta expression, limited edemic development, and improved neurobehavioral outcomes after TBI. The beneficial effects of BBG followed either prophylactic administration via the drinking water for one week prior to injury or via an intravenous bolus administration up to four hours after TBI, suggesting a clinically-implementable therapeutic window. Notably, P2X7 localized within astrocytic end feet and administration of BBG decreased the expression of glial fibrillary acidic protein (GFAP), a reactive astrocyte marker, and attenuated the expression of aquaporin-4 (AQP4), an astrocytic water channel that promotes cellular edema. Together, these data implicate P2X7 as a novel therapeutic target to prevent secondary neurological injury after TBI, a finding that warrants further investigation.	[Kimbler, Donald E.; Shields, Jessica; Vender, John R.; Dhandapani, Krishnan M.] Georgia Hlth Sci Univ, Dept Neurosurg, Augusta, GA USA; [Yanasak, Nathan] Georgia Hlth Sci Univ, Dept Radiol, Augusta, GA USA		Kimbler, DE (corresponding author), Georgia Hlth Sci Univ, Dept Neurosurg, Augusta, GA USA.	kdhandapani@georgiahealth.edu		Dhandapani, Krishnan/0000-0001-7044-1117	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS065172]; TriServices Nursing Research Program [HU0001-10-1-TS11]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065172] Funding Source: NIH RePORTER	Financial support for this study was provided by grants from the National Institutes of Health (NS065172) and from the TriServices Nursing Research Program (HU0001-10-1-TS11). The content and views expressed herein do not necessarily represent the views of the Department of Defense, the TriServices Nursing Research Program, Uniformed Services University of the Health Sciences, or the United States Government. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], FED REG; Badaut J, 2011, J CEREBR BLOOD F MET, V31, P819, DOI 10.1038/jcbfm.2010.163; Basso AM, 2009, BEHAV BRAIN RES, V198, P83, DOI 10.1016/j.bbr.2008.10.018; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Calogero S, 1999, NAT GENET, V22, P276, DOI 10.1038/10338; Catala-Temprano A, 2007, J NEUROSURG, V106, P463, DOI 10.3171/ped.2007.106.6.463; Chiaretti A, 2005, CHILD NERV SYST, V21, P185, DOI 10.1007/s00381-004-1032-1; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Cristofori L, 2005, CLIN BIOCHEM, V38, P97, DOI 10.1016/j.clinbiochem.2004.09.013; Dhandapani KM, 2005, ENDOCRINOLOGY, V146, P2749, DOI 10.1210/en.2005-0014; Dhandapani KM, 2003, J BIOL CHEM, V278, P43329, DOI 10.1074/jbc.M305835200; Dhandapani KM, 2003, ENDOCRINE, V21, P59, DOI 10.1385/ENDO:21:1:59; Dietrich WD, 1999, J NEUROTRAUM, V16, P567, DOI 10.1089/neu.1999.16.567; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Farina C, 2007, TRENDS IMMUNOL, V28, P138, DOI 10.1016/j.it.2007.01.005; Fink KB, 1999, NEUROSCIENCE, V94, P1213, DOI 10.1016/S0306-4522(99)00345-0; Folkersma H, 2008, ACTA NEUROCHIR, V150, P1277, DOI 10.1007/s00701-008-0151-y; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Herx LM, 2000, J IMMUNOL, V165, P2232, DOI 10.4049/jimmunol.165.4.2232; Hinkle DA, 1997, J NEUROTRAUM, V14, P729, DOI 10.1089/neu.1997.14.729; Holmin S, 2004, NEUROSCI LETT, V369, P108, DOI 10.1016/j.neulet.2004.07.044; Ito H, 2006, J NEUROCHEM, V99, P107, DOI 10.1111/j.1471-4159.2006.04036.x; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; Jiang LH, 2000, MOL PHARMACOL, V58, P82, DOI 10.1124/mol.58.1.82; Jones NC, 2005, EUR J NEUROSCI, V22, P72, DOI 10.1111/j.1460-9568.2005.04221.x; Kamm K, 2006, J TRAUMA, V60, P152, DOI 10.1097/01.ta.0000196345.81169.a1; Katayama Y, 2003, ACTA NEUROCHIR SUPPL, V86, P323; Kawamata T, 2006, ACTA NEUROCHIR SUPPL, V96, P3; Kawamata T, 2007, PROG BRAIN RES, V161, P235, DOI 10.1016/S0079-6123(06)61016-9; Khakh BS, 2006, NATURE, V442, P527, DOI 10.1038/nature04886; Kiening KL, 2002, NEUROSCI LETT, V324, P105, DOI 10.1016/S0304-3940(02)00180-5; Kinoshita K, 2002, NEUROSURGERY, V51, P195, DOI 10.1097/00006123-200207000-00027; Kleinschmidt JJ, 2000, NEUROLOGY, V54, P319, DOI 10.1212/WNL.54.2.319; Koo JW, 2008, P NATL ACAD SCI USA, V105, P751, DOI 10.1073/pnas.0708092105; Koo JW, 2009, CURR OPIN INVEST DR, V10, P664; Koo JW, 2009, NEUROSCI LETT, V456, P39, DOI 10.1016/j.neulet.2009.03.068; Laird MD, 2008, FREE RADICAL BIO MED, V45, P1103, DOI 10.1016/j.freeradbiomed.2008.07.003; Laird MD, 2010, J NEUROCHEM, V113, P637, DOI 10.1111/j.1471-4159.2010.06630.x; Laliberte RE, 1999, J BIOL CHEM, V274, P36944, DOI 10.1074/jbc.274.52.36944; Latini S, 1996, NEUROCHEM INT, V28, P113, DOI 10.1016/0197-0186(95)00062-D; LEVIN HS, 1991, NEUROSURGERY, V28, P196, DOI 10.1227/00006123-199102000-00004; Lin HW, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-15; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Narotam PK, 2009, J NEUROSURG, V111, P672, DOI 10.3171/2009.4.JNS081150; NEARY JT, 1994, ACTA NEUROPATHOL, V87, P8; Norman GJ, 2010, MOL PSYCHIATR, V15, P404, DOI 10.1038/mp.2009.91; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; Oprica M, 2005, BRAIN BEHAV IMMUN, V19, P223, DOI 10.1016/j.bbi.2004.07.006; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Peng WG, 2009, P NATL ACAD SCI USA, V106, P12489, DOI 10.1073/pnas.0902531106; Perregaux DG, 1998, J IMMUNOL, V160, P2469; Pillai A, 2007, NEUROPSYCHOPHARMACOL; Ralevic V, 1998, PHARMACOL REV, V50, P413; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; Saadoun S, 2005, J CELL SCI, V118, P5691, DOI 10.1242/jcs.02680; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; Sanderson KL, 1999, J CEREBR BLOOD F MET, V19, P1118, DOI 10.1097/00004647-199910000-00008; Satchell MA, 2005, J CEREBR BLOOD F MET, V25, P919, DOI 10.1038/sj.jcbfm.9600088; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; Shiozaki T, 2005, SHOCK, V23, P406, DOI 10.1097/01.shk.0000161385.62758.24; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Takenouchi T, 2009, CRIT REV IMMUNOL, V29, P335, DOI 10.1615/CritRevImmunol.v29.i4.40; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P507; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; Wakade C, 2009, ANTIOXID REDOX SIGN, V11, P35, DOI 10.1089/ars.2008.2056; Wakade C, 2010, J NEUROSURG, V113, P1195, DOI 10.3171/2010.3.JNS091212; Wheaton P., 2011, J PSYCHOPHARMACOL; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	76	107	111	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 17	2012	7	7							e41229	10.1371/journal.pone.0041229			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975JG	WOS:000306507000083	22815977	gold, Green Published, Green Submitted			2022-02-06	
J	Fjalestad, T; Hole, MO; Hovden, IAH; Blucher, J				Fjalestad, Tore; Hole, Margrethe O.; Hovden, Inger Anette Hynas; Blucher, Judith			Surgical Treatment With an Angular Stable Plate for Complex Displaced Proximal Humeral Fractures in Elderly Patients: A Randomized Controlled Trial	JOURNAL OF ORTHOPAEDIC TRAUMA			English	Article						proximal humeral fracture; displaced; surgical treatment; conservative treatment; randomized controlled trial; functional outcome; axillary nerve injury	LOCKING COMPRESSION PLATE; 4-PART FRACTURES; INTERNAL-FIXATION; OPEN REDUCTION; CLASSIFICATIONS; RELIABILITY; 3-PART; HEAD	Objective: The objective of the study was to evaluate functional outcome, patient self-assessment, and radiographic outcome at 1 year in displaced three-and four-part proximal humeral fractures (OTA group 11-B2 and 11-C2). Design: Randomized controlled trial. Setting: Academic medical center. Patients/Participants: Fifty patients aged 60 years or older with displaced three-or four-part proximal humeral fractures and no previous shoulder injuries were randomized either to surgical treatment or to conservative closed treatment. Twenty-five patients were included in each group. Forty-eight patients completed 12-month follow-up. Two surgical patients died within 3 months. Intervention: The surgically treated group had a standardized surgical treatment with open reduction and internal fixation using an angular stable plate and cerclages. Instructed physical therapy started the third postoperative day. The conservative treatment group had a standardized nonoperative treatment that included closed reduction if displacement between the head and metaphyseal shaft fragment exceeded 50% of the diaphyseal diameter. Physical therapy started on the fifteenth postoperative day. Main Outcome Measurements: The main outcome was the mean difference in Constant score between the injured and noninjured shoulder at 12 months. The secondary outcomes were patient self-assessment (American Shoulder and Elbow Surgeons score) and radiographic ratings at 12 months. Results: At 12 months, mean Constant scores favored conservative treatment by 2.4 points (nonsignificant; P = 0.62). There was no significant difference in mean patient self-assessment. However, radiographic outcomes were significantly better for surgically treated patients. Conclusion: There is no evidence of a difference in functional outcome at 1-year follow-up between surgical treatment and conservative treatment of displaced proximal humeral fractures in elderly patients.	[Fjalestad, Tore; Blucher, Judith] Univ Oslo, Hosp Ulleval HF, Dept Orthoped, N-0514 Oslo, Norway; [Hole, Margrethe O.] Univ Oslo, Hosp Ulleval HF, Dept Physiotherapy, Div Med, N-0514 Oslo, Norway; [Hovden, Inger Anette Hynas] Univ Oslo, Hosp Ulleval HF, Neurophysiol Lab, N-0514 Oslo, Norway; [Blucher, Judith] Univ Oslo, Hosp Aker HF, Dept Radiol, N-0514 Oslo, Norway		Fjalestad, T (corresponding author), Univ Oslo, Hosp Aker HF, Dept Orthopaed, Trondheimsveien 235, N-0514 Oslo, Norway.	torfja@online.no		Hovden, Inger Anette Hynas/0000-0001-6347-3700	Helse Sor-Ost (Regional Hospital and Health Services in Norway)	Funding for this work was provided by Helse Sor-Ost (Regional Hospital and Health Services in Norway): payment of wage in a 50% occupation for a physiotherapist during the study period.	Audige L, 2004, ACTA ORTHOP SCAND, V75, P184, DOI 10.1080/00016470412331294445; Bigliani LU, 1997, TECH ORTHOP, V12, P42; Bjorkenheim JM, 2004, ACTA ORTHOP SCAND, V75, P741, DOI 10.1080/00016470410004120; Bogner R, 2008, J BONE JOINT SURG BR, V90B, P1602, DOI 10.1302/0301-620X.90B12.20269; Brunner A, 2009, J BONE JOINT SURG BR, V91B, P766, DOI 10.1302/0301-620X.91B6.22109; Conboy VB, 1996, J BONE JOINT SURG BR, V78B, P229, DOI 10.1302/0301-620X.78B2.0780229; Constant CR, 2008, J SHOULDER ELB SURG, V17, P355, DOI 10.1016/j.jse.2007.06.022; CONSTANT CR, 1987, CLIN ORTHOP RELAT R, P160; Fjalestad T, 2009, EUR J ORTHOP SURG TR, V19, P461, DOI 10.1007/s00590-009-0453-7; Frangen TM, 2007, ACTA ORTHOP BELG, V73, P571; Gaebler C, 2003, ACTA ORTHOP SCAND, V74, P580, DOI 10.1080/00016470310017992; Handoll HHG, 2008, COCHRANE DB SYST REV, V4; Hertel R, 2004, J SHOULDER ELB SURG, V13, P427, DOI 10.1016/j.jse.2004.01.034; Hertel R, 2005, OSTEOPOROSIS INT, V16, pS65, DOI 10.1007/s00198-004-1714-2; Hodgson SA, 2007, J SHOULDER ELB SURG, V16, P143, DOI 10.1016/j.jse.2006.06.003; King GJ, 1994, J SHOULDER ELB SURG, V3, P347; Kralinger F, 2004, J BONE JOINT SURG BR, V86B, P217, DOI 10.1302/0301-620X.86B2.14553; Lanting B, 2008, J SHOULDER ELB SURG, V17, P42, DOI 10.1016/j.jse.2007.03.016; Marsh JL, 2007, J ORTHOP TRAUMA, V21, pS1, DOI 10.1097/00005131-200711101-00001; Miranda MA, 2007, INJURY, V38, P35, DOI 10.1016/j.injury.2007.08.009; Moonot P, 2007, J BONE JOINT SURG BR, V89B, P1206, DOI 10.1302/0301-620X.89B9.18528; Nho SJ, 2007, J BONE JOINT SURG AM, V89A, P44, DOI 10.2106/JBJS.G.00648; Olsson C, 2005, ACTA ORTHOP, V76, P397, DOI 10.1080/17453670510041295; Owsley KC, 2008, J BONE JOINT SURG AM, V90A, P233, DOI 10.2106/JBJS.F.01351; Perren S M, 2005, Acta Chir Orthop Traumatol Cech, V72, P89; Resch H, 1997, J BONE JOINT SURG BR, V79B, P295, DOI 10.1302/0301-620X.79B2.6958; Ring D, 2007, INJURY, V38, P59, DOI 10.1016/j.injury.2007.08.013; Solberg BD, 2009, J BONE JOINT SURG AM, V91A, P1689, DOI 10.2106/JBJS.H.00133; Sommer C, 2003, INJURY, V34, P43, DOI 10.1016/j.injury.2003.09.024; Visser CPJ, 1999, CLIN NEUROL NEUROSUR, V101, P86, DOI 10.1016/S0303-8467(99)00011-6; Wall B, 2007, HAND CLIN, V23, P425, DOI 10.1016/j.hcl.2007.08.002; Wijgman AJ, 2002, J BONE JOINT SURG AM, V84A, P1919, DOI 10.2106/00004623-200211000-00002; Zyto K, 1998, INJURY, V29, P349, DOI 10.1016/S0020-1383(97)00211-8	33	107	112	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0890-5339	1531-2291		J ORTHOP TRAUMA	J. Orthop. Trauma	FEB	2012	26	2					98	106		10.1097/BOT.0b013e31821c2e15			9	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	877RQ	WOS:000299200000012	21804410				2022-02-06	
J	Pan, H; Wang, HD; Wang, XL; Zhu, L; Mao, L				Pan, Hao; Wang, Handong; Wang, Xiaoliang; Zhu, Lin; Mao, Lei			The Absence of Nrf2 Enhances NF-kappa B-Dependent Inflammation following Scratch Injury in Mouse Primary Cultured Astrocytes	MEDIATORS OF INFLAMMATION			English	Article							TRAUMATIC BRAIN-INJURY; NF-E2-RELATED FACTOR-2; TNF-ALPHA; ACTIVATION; EXPRESSION; CYTOKINES; PATHWAY; SULFORAPHANE; BARRIER	It has been proved that Nrf2 depletion enhances inflammatory process through activation of NF-kappa B in the brain after TBI, but little is known about the relationship between Nrf2 and NF-kappa B in astrocytes after TBI. Hence, we used primary cultured astrocytes from either Nrf2 wildtype or knockout mice to study the influence of Nrf2 on the activation of NF-kappa B and expression of proinflammatory cytokines in a model of TBI in vitro. Primary cultured astrocytes were scratched to mimic the traumatic injury in vitro. Then the DNA-binding activity of NF-kappa B was evaluated by EMSA. The mRNA and protein levels of TNF-alpha, IL-1 beta, IL-6, and MMP9 were also evaluated. Gelatin zymography was performed to detect the activity of MMP9. The activity of NF-kappa B and expression of proinflammatory cytokines mentioned above were upregulated at 24 h after scratch. The expression and activity of MMP9 were also elevated. And such tendency was much more prominent in Nrf2 KO astrocytes than that in WT astrocytes. These results suggest that the absence of Nrf2 may induce more aggressive inflammation through activation of NF-kappa B and downstream proinflammatory cytokines in astrocytes.	[Pan, Hao; Wang, Handong; Wang, Xiaoliang; Zhu, Lin; Mao, Lei] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China		Wang, HD (corresponding author), Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China.	hdwang_nj@yahoo.com.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81070974]; Jiangsu Provincial Key Subject [X4200722]; Jinling Hospital of Nanjing, China [2010Q017]	The authors would like to thank Dr. Geng-bao Feng for technical assistance. This work was supported by Grants from The National Natural Science Foundation of China (no. 81070974), the Jiangsu Provincial Key Subject (no. X4200722), and Jinling Hospital of Nanjing, China (no. 2010Q017). The authors alone are responsible for the content and writing of the paper.	Bethea JR, 1998, J NEUROSCI, V18, P3251; Dash PK, 2009, NEUROSCI LETT, V460, P103, DOI 10.1016/j.neulet.2009.04.028; Gottschall PE, 1996, NEUROIMMUNOMODULAT, V3, P69, DOI 10.1159/000097229; Hang CH, 2005, NEUROL INDIA, V53, P312, DOI 10.4103/0028-3886.16930; Hang CH, 2005, J SURG RES, V123, P188, DOI 10.1016/j.jss.2004.08.002; Hong YA, 2010, ACTA PHARMACOL SIN, V31, P1421, DOI 10.1038/aps.2010.101; Hsu CP, 2011, EUR J CLIN INVEST, V41, P277, DOI 10.1111/j.1365-2362.2010.02405.x; Hu R, 2010, ANTIOXID REDOX SIGN, V13, P1679, DOI 10.1089/ars.2010.3276; Jeong WS, 2004, PHARM RES-DORDR, V21, P661, DOI 10.1023/B:PHAM.0000022413.43212.cf; Jin W, 2008, ANN CLIN LAB SCI, V38, P221; Jin W, 2009, J SURG RES, V157, P251, DOI 10.1016/j.jss.2008.08.003; Jin W, 2009, J NEUROTRAUM, V26, P131, DOI 10.1089/neu.2008.0655; Jin W, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/725174; Kemler I, 1999, GLIA, V26, P212, DOI 10.1002/(SICI)1098-1136(199905)26:3<212::AID-GLIA3>3.0.CO;2-F; Li B, 2009, NEUROSURGERY, V65, P179, DOI 10.1227/01.NEU.0000346272.76537.DC; Liu GH, 2008, BBA-MOL CELL RES, V1783, P713, DOI 10.1016/j.bbamcr.2008.01.002; Pan H, 2011, NEUROCHEM RES, V36, P2434, DOI 10.1007/s11064-011-0571-6; Rosenberg GA, 1995, BRAIN RES, V703, P151, DOI 10.1016/0006-8993(95)01089-0; SAWADA M, 1995, INT J DEV NEUROSCI, V13, P253, DOI 10.1016/0736-5748(94)00076-F; Sohn Y, 2009, AM J CHINESE MED, V37, P273, DOI 10.1142/S0192415X09006849; Srinivasan D, 2004, J NEUROSCI, V24, P6482, DOI 10.1523/JNEUROSCI.5712-03.2004; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Thimmulappa RK, 2006, J CLIN INVEST, V116, P984, DOI 10.1172/JCI25790; Thompson WL, 2009, BRAIN RES, V1287, P47, DOI 10.1016/j.brainres.2009.06.081; Venetsanou K, 2007, EUR CYTOKINE NETW, V18, P206, DOI 10.1684/ecn.2007.0112; Xu CJ, 2005, ONCOGENE, V24, P4486, DOI 10.1038/sj.onc.1208656; Yan W, 2008, NEUROSCI LETT, V431, P150, DOI 10.1016/j.neulet.2007.11.060; Yan W, 2009, J TRAUMA, V66, P1431, DOI 10.1097/TA.0b013e318180f5c7; YU ACH, 1993, J NEUROSCI RES, V34, P295, DOI 10.1002/jnr.490340306	29	107	112	0	16	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	0962-9351	1466-1861		MEDIAT INFLAMM	Mediat. Inflamm.		2012	2012								217580	10.1155/2012/217580			9	Cell Biology; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Immunology	907JU	WOS:000301414400001	22529521	Green Published, Green Submitted, gold			2022-02-06	
J	Wright, RM; Ramesh, KT				Wright, Rika M.; Ramesh, K. T.			An axonal strain injury criterion for traumatic brain injury	BIOMECHANICS AND MODELING IN MECHANOBIOLOGY			English	Article						Diffuse axonal injury; Traumatic brain injury; Injury criteria; Finite element model; Diffusion tensor imaging; Anisotropic model; TBI; DAI	FINITE-ELEMENT-ANALYSIS; DYNAMIC STRETCH INJURY; MECHANICAL-PROPERTIES; WHITE-MATTER; HEAD-INJURY; CONSTITUTIVE-EQUATIONS; MODEL; TISSUE; SHEAR; TOLERANCE	Computational models are often used as tools to study traumatic brain injury. The fidelity of such models depends on the incorporation of an appropriate level of structural detail, the accurate representation of the material behavior, and the use of an appropriate measure of injury. In this study, an axonal strain injury criterion is used to estimate the probability of diffuse axonal injury (DAI), which accounts for a large percentage of deaths due to brain trauma and is characterized by damage to neural axons in the deep white matter regions of the brain. We present an analytical and computational model that treats the white matter as an anisotropic, hyperelastic material. Diffusion tensor imaging is used to incorporate the structural orientation of the neural axons into the model. It is shown that the degree of injury that is predicted in a computational model of DAI is highly dependent on the incorporation of the axonal orientation information and the inclusion of anisotropy into the constitutive model for white matter.	[Wright, Rika M.; Ramesh, K. T.] Johns Hopkins Univ, Dept Mech Engn, Baltimore, MD 21218 USA		Ramesh, KT (corresponding author), Johns Hopkins Univ, Dept Mech Engn, 3400 N Charles St, Baltimore, MD 21218 USA.	rika@jhu.edu; ramesh@jhu.edu	Ramesh, KT/D-5451-2009	Ramesh, KT/0000-0003-2659-4698	National Science FoundationNational Science Foundation (NSF); Center for Advanced Metallic and Ceramic Systems; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P41RR15241, R01AG020012]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41RR015241] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG020012] Funding Source: NIH RePORTER	We gratefully acknowledge Dr. Susumu Mori at the Johns Hopkins University School of Medicine for providing access to the diffusion tensor imaging data used in this study. This work is supported by a National Science Foundation Graduate Research Fellowship, the Center for Advanced Metallic and Ceramic Systems, and NIH grants P41RR15241 and R01AG020012.	Anderson RWG, 2003, J NEUROTRAUM, V20, P961, DOI 10.1089/089771503770195812; Arbogast KB, 1998, J BIOMECH, V31, P801, DOI 10.1016/S0021-9290(98)00068-2; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bandak F, 1994, 38 STAPP CAR CRASH C; Billiar KL, 2000, J BIOMECH ENG-T ASME, V122, P327, DOI 10.1115/1.1287158; Bilston LE, 2001, BIORHEOLOGY, V38, P335; Bovendeerd PHM, 2002, STAPP CAR CRASH J, V46, P1; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Deck C, 2008, INT J CRASHWORTHINES, V13, P667, DOI 10.1080/13588260802411523; El Sayed T, 2008, COMPUT METHOD APPL M, V197, P4692, DOI 10.1016/j.cma.2008.06.006; Elkin BS, 2007, STAPP CAR CRASH JO, V51, P127; ESTES MS, 1970, P 4 ASME BIOM C; FALLENSTEIN GT, 1969, J BIOMECH, V2, P217, DOI 10.1016/0021-9290(69)90079-7; Feist F, 2009, 21 INT C ENH SAF VEH, P1; Franceschini G, 2006, J MECH PHYS SOLIDS, V54, P2592, DOI 10.1016/j.jmps.2006.05.004; Freed AD, 2005, BIOMECH MODEL MECHAN, V4, P100, DOI 10.1007/s10237-005-0069-8; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; GALFORD JE, 1970, J BIOMECH, V3, P211, DOI 10.1016/0021-9290(70)90007-2; Gasser TC, 2006, J R SOC INTERFACE, V3, P15, DOI 10.1098/rsif.2005.0073; Geddes DM, 2001, J BIOMECH ENG-T ASME, V123, P247, DOI 10.1115/1.1374201; Holzapfel GA., 2000, NONLINEAR SOLID MECH; Hrapko M, 2008, J BIOMECH ENG-T ASME, V130, DOI 10.1115/1.2907746; Hurschler C, 1997, J BIOMECH ENG-T ASME, V119, P392, DOI 10.1115/1.2798284; Kimpara Hideyuki, 2006, Stapp Car Crash J, V50, P509; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; KUIJPERS AHWM, 1995, J NEUROTRAUM, V12, P715, DOI 10.1089/neu.1995.12.715; LANIR Y, 1983, J BIOMECH, V16, P1, DOI 10.1016/0021-9290(83)90041-6; LaPlaca MC, 2005, J BIOMECH, V38, P1093, DOI 10.1016/j.jbiomech.2004.05.032; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; LISSNER HR, 1960, SURG GYNECOL OBSTET, V111, P329; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; Meaney DF, 2003, BIOMECH MODEL MECHAN, V1, P279, DOI 10.1007/s10237-002-0020-1; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Mendis K., 1992, FINITE ELEMENT MODEL; Miller K, 1997, J BIOMECH, V30, P1115, DOI 10.1016/S0021-9290(97)00092-4; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; Morrison Barclay 3rd, 2003, Stapp Car Crash J, V47, P93; Ning XG, 2006, J BIOMECH ENG-T ASME, V128, P925, DOI 10.1115/1.2354208; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Ommaya A, 1967, 11 P STAPP CAR CRASH, P47; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; Raul JS, 2008, INT J LEGAL MED, V122, P359, DOI 10.1007/s00414-008-0248-0; Saraf H, 2007, J BIOMECH, V40, P1960, DOI 10.1016/j.jbiomech.2006.09.021; Shen F, 2006, J BIOMECH ENG-T ASME, V128, P797, DOI 10.1115/1.2264393; SHUCK LZ, 1972, J BASIC ENG-T ASME, V94, P905, DOI 10.1115/1.3425588; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Smith DH, 1999, J NEUROSCI, V19, P4263; Spencer A, 1972, DEFORMATIONS FIBRE R; Takhounts Erik G, 2003, Stapp Car Crash J, V47, P107; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; UENO K, 1995, J NEUROTRAUM, V12, P695, DOI 10.1089/neu.1995.12.695; van Dommelen JAW, 2010, J MECH BEHAV BIOMED, V3, P158, DOI 10.1016/j.jmbbm.2009.09.001; Velardi F, 2006, BIOMECH MODEL MECHAN, V5, P53, DOI 10.1007/s10237-005-0007-9; Versace J., 1971, REV SEVERITY INDEX; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Wang HC, 2010, J NEUROTRAUM, V27, P707, DOI 10.1089/neu.2009.1071; Watanabe D, 2009, J COMPUT SCI TECHNOL, V3, P252, DOI 10.1299/jcst.3.252; Willinger R, 1999, ANN BIOMED ENG, V27, P403, DOI 10.1114/1.165; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Yao JF, 2008, SAFETY SCI, V46, P1103, DOI 10.1016/j.ssci.2007.06.021; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749; Zhou C, 1994, 38 STAPP CAR CRASH C, P1697; Zou H, 2008, INT J CRASHWORTHINES, V13, P337, DOI 10.1080/13588260801943047	66	107	110	0	23	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1617-7959	1617-7940		BIOMECH MODEL MECHAN	Biomech. Model. Mechanobiol.	JAN	2012	11	1-2					245	260		10.1007/s10237-011-0307-1			16	Biophysics; Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Engineering	891QB	WOS:000300230600019	21476072				2022-02-06	
J	Bohmer, AE; Oses, JP; Schmidt, AP; Peron, CS; Krebs, CL; Oppitz, PP; D'Avila, TT; Souza, DO; Portela, LV; Stefani, MA				Boehmer, Ana Elisa; Oses, Jean Pierre; Schmidt, Andre Prato; Peron, Cleiton Schweister; Krebs, Claudio Liss; Oppitz, Paulo Petry; D'Avila, Thiago Torres; Souza, Diogo Onofre; Portela, Luis Valmor; Stefani, Marco Antonio			Neuron-Specific Enolase, S100B, and Glial Fibrillary Acidic Protein Levels as Outcome Predictors in Patients With Severe Traumatic Brain Injury	NEUROSURGERY			English	Article						Glial fibrillary acidic protein; Neuron-specific enolase; Outcome; S100B	SERUM S-100B PROTEIN; SEVERE HEAD-INJURY; BIOCHEMICAL MARKERS; DAMAGE; S-100-BETA; DIAGNOSIS; RELEASE; CSF	BACKGROUND: The availability of markers able to provide an early insight related to prognostic and functional outcome of patients with traumatic brain injury (TBI) are limited. OBJECTIVE: The relationship of clinical outcome with CSF neuron-specific enolase (NSE), S100B and glial fibrillary acidic protein (GFAP) levels in patients with severe TBI was investigated. METHODS: Twenty patients with severe TBI (7 days at unit care) and controls were studied. Patients were grouped according to the outcome: (1) nonsurvival (n = 5): patients who died; (2) survival A (n = 15): CSF sampled between 1st and 3rd day from patients who survived after hospital admission; and (3) survival B (n = 7): CSF sampled between 4th and 7th day from patients who survived after hospital admission and were maintained with intraventricular catheter up to 7 days. RESULTS: Up to 3 days, S100B and NSE levels (ng/mL) were significantly elevated in the nonsurvival compared with survival A group (S100: 12.45 +/- 5.46 vs 5.64 +/- 3.36; NSE: 313.20 +/- 45.51 vs 107.80 +/- 112.10). GFAP levels did not differ between groups. In the survival B group S100B, GFAP, and NSE levels were still elevated compared with control (4.59 +/- 2.19, 2.48 +/- 2.55, and 89.80 +/- 131.10, respectively). To compare S100B and NSE for the prediction of nonsurvival and survival patients we performed receiver operating characteristic curves. At admission, CSF NSE level predicts brain death more accurately than S100B. CONCLUSION: Early elevations (up to 3 days) of S100B and NSE secondary to severe TBI predict deterioration to brain death. However, this feature was more prominently associated with NSE than S100B.	[Boehmer, Ana Elisa; Schmidt, Andre Prato; Souza, Diogo Onofre; Portela, Luis Valmor] Univ Fed Rio Grande do Sul, Dept Biochem, ICBS, Alegre, RS, Brazil; [Oses, Jean Pierre] Univ Catolica Pelotas, Dept Psychol, Pelotas, RS, Brazil; [Peron, Cleiton Schweister; Krebs, Claudio Liss; Oppitz, Paulo Petry] Hosp Cristo Redentor, Porto Alegre, RS, Brazil; [D'Avila, Thiago Torres; Stefani, Marco Antonio] Hosp Clnicas Porto Alegre, Porto Alegre, RS, Brazil		Portela, LV (corresponding author), Ave Ramiro Barcelos,2600 Anexo, BR-90035003 Porto Alegre, RS, Brazil.	roskaportela@gmail.com	STEFANI, MARCO ANTONIO/C-3993-2013; Oses, Jean Pierre/E-2534-2013; Souza, Diogo O/J-8894-2014; Portela, Luis V/I-3410-2014; Schmidt, Andre P/E-4652-2012	STEFANI, MARCO ANTONIO/0000-0002-4728-8764; Souza, Diogo O/0000-0002-4322-0404; Portela, Luis Valmor/0000-0001-6113-8466; Oses, Jean Pierre/0000-0002-2012-273X	FAPERGSFundacao de Amparo a Ciencia e Tecnologia do Estado do Rio Grande do Sul (FAPERGS); PPSUS; CAPESCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); CNPQConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ); IBNET; INCTen	This research was supported by FAPERGS, PPSUS, CAPES, CNPQ, IBNET and INCTen. The authors have no personal financial or institutional interest in any of the drugs, materials, or devices described in this article.	Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Baker AJ, 2009, J NEUROTRAUM, V26, P1227, DOI 10.1089/neu.2008.0868; Begaz T, 2006, J NEUROTRAUM, V23, P1201, DOI 10.1089/neu.2006.23.1201; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Busnello JV, 2006, LIFE SCI, V78, P3013, DOI 10.1016/j.lfs.2005.11.028; Dimopoulou I, 2003, NEUROLOGY, V60, P947, DOI 10.1212/01.WNL.0000049931.77887.7F; Donato R, 2009, BBA-MOL CELL RES, V1793, P1008, DOI 10.1016/j.bbamcr.2008.11.009; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Herrmann M, 2003, RESTOR NEUROL NEUROS, V21, P177; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Jackson RGM, 2000, CLIN CHEM LAB MED, V38, P1165, DOI 10.1515/CCLM.2000.179; Kleindienst A, 2007, PROG BRAIN RES, V161, P317, DOI 10.1016/S0079-6123(06)61022-4; Kleindienst A, 2006, J NEUROTRAUM, V23, P1185, DOI 10.1089/neu.2006.23.1185; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Mazzini GS, 2009, RESUSCITATION, V80, P144, DOI 10.1016/j.resuscitation.2008.08.024; Oses JP, 2004, BRAIN RES BULL, V64, P237, DOI 10.1016/j.brainresbull.2004.07.006; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Petzold A, 2003, BRAIN RES BULL, V61, P281, DOI 10.1016/S0361-9230(03)00091-1; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Puvanachandra P, 2008, SALUD PUBLICA MEXICO, V50, pS3; Raabe A, 1999, J NEUROSURG, V91, P875, DOI 10.3171/jns.1999.91.5.0875; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Rainey T, 2009, RESUSCITATION, V80, P341, DOI 10.1016/j.resuscitation.2008.11.021; Tramontina F, 2007, J NEUROSCI METH, V162, P282, DOI 10.1016/j.jneumeth.2007.01.001; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977	27	107	123	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JUN	2011	68	6					1624	1630		10.1227/NEU.0b013e318214a81f			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	760CK	WOS:000290299700065	21368691				2022-02-06	
J	Korkmaz, B				Korkmaz, Bars			Theory of Mind and Neurodevelopmental Disorders of Childhood	PEDIATRIC RESEARCH			English	Article							SOCIAL COGNITIVE NEUROSCIENCE; EXECUTIVE FUNCTION; EMPATHIC ACCURACY; MENTAL STATES; FUNCTIONAL CONNECTIVITY; INDIVIDUAL-DIFFERENCES; ASPERGER-SYNDROME; CHILDREN; AUTISM; LANGUAGE	To a large extent, the human infant is socialized through the acquisition of a specific cognitive mechanism known as theory of mind (ToM), a term which is currently used to explain a related set of intellectual abilities that enable us to understand that others have beliefs, desires, plans, hopes, information, and intentions that may differ from our own. Various neurodevelopmental disorders, such as autism spectrum disorders, attention deficit hyperactivity disorder, developmental language disorders, and schizophrenia, as well as acquired disorders of the right brain (and traumatic brain injury) impair ToM. ToM is a composite function, which involves memory, joint attention, complex perceptual recognition (such as face and gaze processing), language, executive functions (such as tracking of intentions and goals and moral reasoning), emotion processing-recognition, empathy, and imitation. Hence, ToM development is dependent on the maturation of several brain systems and is shaped by parenting, social relations, training, and education; thus, it is an example of the dense interaction that occurs between brain development and (social) environment. (Pediatr Res 69: 101R-108R, 2011)	Istanbul Univ, Cerrahpasa Med Fac, Dept Neurol, Div Child Neurol, TR-34301 Istanbul, Turkey		Korkmaz, B (corresponding author), Istanbul Univ, Cerrahpasa Med Fac, Dept Neurol, Div Child Neurol, TR-34301 Istanbul, Turkey.	bkorkmaz@istanbul.edu.tr	Korkmaz, Baris/AAE-4742-2021				Akhutina T.V., 2003, J RUSSIAN E EUROPEAN, V41, P159, DOI [10.2753/RPO1061-0405370213, DOI 10.2753/RPO1061-0405370213, DOI 10.2753/RP01061-0405410304159]; Allman JM, 2005, TRENDS COGN SCI, V9, P367, DOI 10.1016/j.tics.2005.06.008; Ang GK, 2009, AUSTRALAS PSYCHIATRY, V17, P117, DOI 10.1080/10398560802375982; Apperly IA, 2008, COGNITION, V107, P266, DOI 10.1016/j.cognition.2007.07.019; Apperly IA, 2006, SOC NEUROSCI-UK, V1, P334, DOI 10.1080/17470910601038693; Apperly IA, 2009, PSYCHOL REV, V116, P953, DOI 10.1037/a0016923; Apperly IA, 2009, DEV PSYCHOL, V45, P190, DOI 10.1037/a0014098; Assaf M, 2010, NEUROIMAGE, V53, P247, DOI 10.1016/j.neuroimage.2010.05.067; Astington JW, 1999, DEV PSYCHOL, V35, P1311, DOI 10.1037/0012-1649.35.5.1311; Back E, 2010, COGNITION, V115, P54, DOI 10.1016/j.cognition.2009.11.008; Baron-Cohen S, 2001, J CHILD PSYCHOL PSYC, V42, P241, DOI 10.1017/S0021963001006643; Baron-Cohen S, 1999, J AUTISM DEV DISORD, V29, P407, DOI 10.1023/A:1023035012436; Baron-Cohen S., 1992, MIND LANG, V7, P172; BARONCOHEN S, 1986, BRIT J DEV PSYCHOL, V4, P113, DOI 10.1111/j.2044-835X.1986.tb01003.x; BaronCohen S, 1995, MINDBLINDNESS ESSAY, P1; Bedny M, 2009, P NATL ACAD SCI USA, V106, P11312, DOI 10.1073/pnas.0900010106; Begeer S, 2003, J AUTISM DEV DISORD, V33, P479, DOI 10.1023/A:1025875311062; Begeer S, 2010, EUR J DEV PSYCHOL, V7, P104, DOI 10.1080/17405620903024263; Blair RJR, 2008, Q J EXP PSYCHOL, V61, P157, DOI 10.1080/17470210701508855; Blakemore SJ, 2004, TRENDS COGN SCI, V8, P216, DOI 10.1016/j.tics.2004.03.012; Bora E, 2005, ACTA PSYCHIAT SCAND, V112, P110, DOI 10.1111/j.1600-0447.2005.00570.x; BROTHERS L, 1990, CONCEPTS NEUROSCIENC, V1, P27, DOI DOI 10.1093/SCHBUL/SBQ012; Brune M, 2006, NEUROSCI BIOBEHAV R, V30, P437, DOI 10.1016/j.neubiorev.2005.08.001; Brune M, 2005, SCHIZOPHRENIA BULL, V31, P21, DOI 10.1093/schbul/sbi002; Burnett S, 2009, EUR J NEUROSCI, V29, P1294, DOI 10.1111/j.1460-9568.2009.06674.x; Call J, 2008, TRENDS COGN SCI, V12, P187, DOI 10.1016/j.tics.2008.02.010; Camaioni L, 2004, INFANCY, V5, P291, DOI 10.1207/s15327078in0503_3; CAPPS L, 1993, AUTISM, V2, P325; Carlson SM, 2004, DEV PSYCHOL, V40, P1105, DOI 10.1037/0012-1649.40.6.1105; Carrington SJ, 2009, HUM BRAIN MAPP, V30, P2313, DOI 10.1002/hbm.20671; Chakrabarti S, 2005, AM J PSYCHIAT, V162, P1133, DOI 10.1176/appi.ajp.162.6.1133; CONNOLLY JA, 1984, DEV PSYCHOL, V20, P797, DOI 10.1037/0012-1649.20.5.797; Cutting AL, 1999, CHILD DEV, V70, P853, DOI 10.1111/1467-8624.00061; Dahlgren SO, 1996, J CHILD PSYCHOL PSYC, V37, P759, DOI 10.1111/j.1469-7610.1996.tb01469.x; Dale N, 2008, BRIT J VISUAL IMPA, V26, P135, DOI 10.1177/0264619607088282; De Villiers PA, 2005, WHY LANGUAGE MATTERS, P266, DOI [10.1093/acprof:oso/9780195159912.003.0013, DOI 10.1093/ACPROF:OSO/9780195159912.003.0013]; Decety J, 2006, BRAIN RES, V1079, P4, DOI 10.1016/j.brainres.2005.12.115; DODGE KA, 1993, ANNU REV PSYCHOL, V44, P559, DOI 10.1146/annurev.ps.44.020193.003015; Doherty MJ, 1999, COGNITIVE DEV, V14, P549, DOI 10.1016/S0885-2014(99)00019-2; DOHERTY MJ, 2008, THEORY MIND CHILDREN, P1; Dolan M, 2004, PSYCHOL MED, V34, P1093, DOI 10.1017/S0033291704002028; Dumontheil I, 2010, NEUROIMAGE, V52, P1574, DOI 10.1016/j.neuroimage.2010.05.056; Egeth M, 2009, CONSCIOUS COGN, V18, P244, DOI 10.1016/j.concog.2008.07.005; Farrar M. J., 2002, FIRST LANG, V22, P197, DOI [DOI 10.1177/014272370202206504, 10.1177/014272370202206504]; Farrar MJ, 2009, J COMMUN DISORD, V42, P428, DOI 10.1016/j.jcomdis.2009.07.001; Farroni T, 2002, P NATL ACAD SCI USA, V99, P9602, DOI 10.1073/pnas.152159999; Fine C, 2001, BRAIN, V124, P287, DOI 10.1093/brain/124.2.287; Fonagy P., 1989, B ANNA FREUD CTR, V12, P91; Martin-Rodriguez JF, 2010, NEUROPSYCHOLOGIA, V48, P1181, DOI 10.1016/j.neuropsychologia.2010.02.009; FRITH CD, 1992, COGNITIVE NEUROPSYCH, P124; Frith U, 2003, PHILOS T R SOC B, V358, P459, DOI 10.1098/rstb.2002.1218; FURNISS F., 2004, CHILD LANG TEACH THE, V20, P1, DOI DOI 10.1191/0265659004CT260OA; Gallagher HL, 2000, NEUROPSYCHOLOGIA, V38, P11, DOI 10.1016/S0028-3932(99)00053-6; Hamilton AFD, 2009, J CHILD PSYCHOL PSYC, V50, P881, DOI 10.1111/j.1469-7610.2009.02098.x; Happe F, 1996, BRAIN, V119, P1377, DOI 10.1093/brain/119.4.1377; HAPPE FGE, 1994, J AUTISM DEV DISORD, V24, P129, DOI 10.1007/BF02172093; Hobson RP, 1999, J AUTISM DEV DISORD, V29, P45; Hobson RP, 2003, PHILOS T R SOC B, V358, P335, DOI 10.1098/rstb.2002.1201; Hughes C, 2005, CHILD DEV, V76, P356, DOI 10.1111/j.1467-8624.2005.00850_a.x; Hughes C, 2007, DEV PSYCHOL, V43, P1447, DOI 10.1037/0012-1649.43.6.1447; Jenkins JM, 2003, CHILD DEV, V74, P905, DOI 10.1111/1467-8624.00575; Jenkins JM, 1996, DEV PSYCHOL, V32, P70, DOI 10.1037/0012-1649.32.1.70; Keysar B, 2003, COGNITION, V89, P25, DOI 10.1016/S0010-0277(03)00064-7; Klein KJK, 2001, PERS SOC PSYCHOL B, V27, P720, DOI 10.1177/0146167201276007; KNUPPEL A, 2007, LANG ACQ WORKSH SCL, V34, P110; Kushalnagar P, 2010, J CLIN ETHIC, V21, P143; Leslie AM, 2004, TRENDS COGN SCI, V8, P528, DOI 10.1016/j.tics.2004.10.001; Lewis C, 1996, CHILD DEV, V67, P2930, DOI 10.1111/j.1467-8624.1996.tb01896.x; LEWIS V, 1988, BRIT J DEV PSYCHOL, V6, P325, DOI 10.1111/j.2044-835X.1988.tb01105.x; Liddle B., 2006, J CULTURAL EVOLUTION, V4, P231, DOI [10.1556/jcep.4.2006.3-4.3, DOI 10.1556/JCEP.4.2006.3-4.3]; Lieberman M.D., 2010, HDB SOCIAL PSYCHOL, DOI DOI 10.1002/9780470561119.SOCPSY001005; Lin SH, 2010, J EXP SOC PSYCHOL, V46, P551, DOI 10.1016/j.jesp.2009.12.019; Liu D, 2008, DEV PSYCHOL, V44, P523, DOI 10.1037/0012-1649.44.2.523; Lu HJ, 2008, DEV PSYCHOL, V44, P1726, DOI 10.1037/a0013074; Malle BF, 2008, HANDBOOK OF MOTIVATION AND COGNITION ACROSS CULTURES, P267, DOI 10.1016/B978-0-12-373694-9.00012-X; McAlister A, 2007, COGNITIVE DEV, V22, P258, DOI 10.1111/cdev.12043; Meins E, 2002, CHILD DEV, V73, P1715, DOI 10.1111/1467-8624.00501; Mitchell P, 2009, BRIT J DEV PSYCHOL, V27, P513, DOI 10.1348/026151008X334737; Modinos G, 2009, J NEUROPSYCH CLIN N, V21, P100, DOI 10.1176/appi.neuropsych.21.1.100; Nelson KD, 2004, PSYCHOL REV, V111, P486, DOI 10.1037/0033-295X.111.2.486; Nielsen M, 2004, INFANT BEHAV DEV, V27, P342, DOI 10.1016/j.infbeh.2003.12.006; Onishi KH, 2005, SCIENCE, V308, P255, DOI 10.1126/science.1107621; Ontai LL, 2008, SOC DEV, V17, P47, DOI 10.1111/j.1467-9507.2007.00414.x; Paynter J, 2010, RES AUTISM SPECT DIS, V4, P377, DOI 10.1016/j.rasd.2009.10.005; Pears KC, 2005, DEV PSYCHOPATHOL, V17, P47, DOI 10.1017/S0954579405050030; Pellicano E, 2010, CHILD DEV, V81, P1400, DOI 10.1111/j.1467-8624.2010.01481.x; PEREZPEREIRA M, 1994, J CHILD LANG, V21, P317, DOI 10.1017/S0305000900009296; Perkins T, 2010, J CLIN NEUROSCI, V17, P1239, DOI 10.1016/j.jocn.2010.01.026; Perner J, 2002, INFANT CHILD DEV, V11, P141, DOI 10.1002/icd.302; Peterson CC, 2000, MIND LANG, V15, P123, DOI 10.1111/1468-0017.00126; Ponnet K, 2005, J AUTISM DEV DISORD, V35, P585, DOI 10.1007/s10803-005-0003-z; PREMACK D, 1978, BEHAV BRAIN SCI, V1, P515, DOI 10.1017/S0140525X00076512; Press C, 2010, NEUROPSYCHOLOGIA, V48, P3291, DOI 10.1016/j.neuropsychologia.2010.07.012; Qureshi AW, 2010, COGNITION, V117, P230, DOI 10.1016/j.cognition.2010.08.003; Redmond SM, 1998, J SPEECH LANG HEAR R, V41, P688, DOI 10.1044/jslhr.4103.688; Richell RA, 2003, NEUROPSYCHOLOGIA, V41, P523, DOI 10.1016/S0028-3932(02)00175-6; Rieffe C, 2000, J CHILD PSYCHOL PSYC, V41, P601, DOI 10.1017/S0021963099005843; Rieffe C, 2005, INFANT CHILD DEV, V14, P259, DOI 10.1002/icd.391; Rizzolatti G, 2008, CURR OPIN NEUROBIOL, V18, P179, DOI 10.1016/j.conb.2008.08.001; Roeyers H, 2001, J CHILD PSYCHOL PSYC, V42, P271, DOI 10.1111/1469-7610.00718; Rosenbaum RS, 2007, SCIENCE, V318, P1257, DOI 10.1126/science.1148763; Samson D, 2007, NEUROPSYCHOLOGIA, V45, P2561, DOI 10.1016/j.neuropsychologia.2007.03.013; SCAIFE M, 1975, NATURE, V253, P265, DOI 10.1038/253265a0; Schick B, 2007, CHILD DEV, V78, P376, DOI 10.1111/j.1467-8624.2007.01004.x; Spence SA, 2004, PHILOS T R SOC B, V359, P1755, DOI 10.1098/rstb.2004.1555; Surian L, 2007, PSYCHOL SCI, V18, P580, DOI 10.1111/j.1467-9280.2007.01943.x; Tager-Flusberg H, 1999, INT REV PSYCHIATR, V11, P325, DOI 10.1080/09540269974203; Teufel C, 2010, TRENDS COGN SCI, V14, P376, DOI 10.1016/j.tics.2010.05.005; Uddin LQ, 2007, TRENDS COGN SCI, V11, P153, DOI 10.1016/j.tics.2007.01.001; Uekermann J, 2010, NEUROSCI BIOBEHAV R, V34, P734, DOI 10.1016/j.neubiorev.2009.10.009; Varga S, 2011, PSYCHOPATHOLOGY, V44, P46, DOI 10.1159/000317777; Vecera S. P., 1995, Visual Cognition, V2, P59, DOI 10.1080/13506289508401722; Verbeke E, 2005, BEHAV BRAIN SCI, V28, P718, DOI 10.1017/S0140525X05510124; Vygotski LS, 1929, PEDAGOG SEMIN J GEN, V36, P415; VYGOTSKY LS, 1965, NEUROPSYCHOLOGIA, V3, P381, DOI 10.1016/0028-3932(65)90011-4; Watson AC, 1999, DEV PSYCHOL, V35, P386, DOI 10.1037/0012-1649.35.2.386; Wellman HM, 2008, HUM DEV, V51, P105, DOI 10.1159/000115958; WELLMAN HM, 1995, COGNITION EMOTION, V9, P117, DOI 10.1080/02699939508409005; WIMMER H, 1983, COGNITION, V13, P103, DOI 10.1016/0010-0277(83)90004-5; Woolfe Tyron, 2003, J Deaf Stud Deaf Educ, V8, P340, DOI 10.1093/deafed/eng023; Yagmurlu B, 2005, J APPL DEV PSYCHOL, V26, P521, DOI 10.1016/j.appdev.2005.06.004; ZAITCHIK D, 1990, COGNITION, V35, P41, DOI 10.1016/0010-0277(90)90036-J; Zaitchik D, 2010, NEUROPSYCHOLOGIA, V48, P2528, DOI 10.1016/j.neuropsychologia.2010.04.031	123	107	109	2	100	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0031-3998	1530-0447		PEDIATR RES	Pediatr. Res.	MAY	2011	69	5	2				101R	108R		10.1203/PDR.0b013e318212c177			8	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Pediatrics	753WO	WOS:000289811100015	21289541	Bronze			2022-02-06	
J	Sauerbeck, A; Gao, JX; Readnower, R; Liu, M; Pauly, JR; Bing, GY; Sullivan, PG				Sauerbeck, Andrew; Gao, Jianxin; Readnower, Ryan; Liu, Mei; Pauly, James R.; Bing, Guoying; Sullivan, Patrick G.			Pioglitazone attenuates mitochondrial dysfunction, cognitive impairment, cortical tissue loss, and inflammation following traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						Traumatic brain injury; Pioglitazone; Mitochondria; Inflammation; Microglia; Cortical lesion; Cortical impact; Contusion; PPAR; Peroxisome proliferator-activated receptor	ACTIVATED-RECEPTOR-GAMMA; NITRIC-OXIDE SYNTHASE; SPINAL-CORD-INJURY; AMYOTROPHIC-LATERAL-SCLEROSIS; PPAR-ALPHA AGONIST; NF-KAPPA-B; CELL-DEATH; OXIDATIVE STRESS; MOUSE MODEL; DOPAMINERGIC NEURODEGENERATION	Following traumatic brain injury (TBI) there is significant neuropathology which includes mitochondrial dysfunction, loss of cortical gray matter, microglial activation, and cognitive impairment. Previous evidence has shown that activation of the peroxisome proliferator-activated receptors (PPARs) provide neuroprotection following traumatic brain and spinal injuries. In the current study we hypothesized that treatment with the PPAR ligand Pioglitazone would promote neuroprotection following a rat controlled cortical impact model of TBI. Animals received a unilateral 1.5 mm controlled cortical impact followed by administration of Pioglitazone at 10 mg/kg beginning 15 min after the injury and subsequently every 24h for 5 days. Beginning 1 day after the injury there was significant impairment in mitochondrial bioenergetic function which was attenuated by treatments with Pioglitazone at 15 min and 24 h ( p< 0.05). In an additional set of animals, cognitive function was assessed using the Morris Water Maze (MWM) and it was observed that over the course of 4 days of testing the injury produced a significant increase in both latency ( p< 0.05) and distance ( p< 0.05) to the platform. Animals treated with Pioglitazone performed similarly to sham animals and did not exhibit any impairment in MWM performance. Sixteen days after the injury tissue sections through the lesion site were quantified to determine the size of the cortical lesion. Vehicle-treated animals had an average lesion size of 5.09 +/- 0.73 mm(3) and treatment with Pioglitazone significantly reduced the lesion size by 55% to 2.27 +/- 0.27 mm(3) ( p< 0.01). Co-administration of the antagonist T0070907 with Pioglitazone blocked the protective effect seen with administration of Pioglitazone by itself. Following the injury there was a significant increase in the number of activated microglia in the area of the cortex adjacent to the site of the lesion ( p< 0.05). Treatment with Pioglitazone prevented the increase in the number of activated microglia and no difference was observed between sham and Pioglitazone-treated animals. From these studies we conclude that following TBI Pioglitazone is capable ameliorating multiple aspects of neuropathology. These studies provide further support for the use of PPAR ligands, specifically Pioglitazone, for neuroprotection. (C) 2010 Elsevier Inc. All rights reserved.	[Sauerbeck, Andrew; Readnower, Ryan; Liu, Mei; Bing, Guoying; Sullivan, Patrick G.] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; [Sauerbeck, Andrew; Readnower, Ryan; Pauly, James R.; Sullivan, Patrick G.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; [Pauly, James R.] Univ Kentucky, Dept Pharmaceut Sci, Coll Pharm, Lexington, KY 40536 USA; [Gao, Jianxin] Shandong Univ, Sch Med, Dept Physiol, Jinan 250012, Shandong, Peoples R China		Sullivan, PG (corresponding author), BBSRB, 741 S Limestone St,Room 475, Lexington, KY 40536 USA.	Adsaue2@uky.edu; gaojx@sdu.edu.cn; rdread2@uky.edu; mei.liu@uky.edu; jim.pauly@uky.edu; guoying.bing@uky.edu; patsull@uky.edu		Bing, Guoying/0000-0003-0609-8152	National Institutes of Health, U.S. Public Health ServiceUnited States Department of Health & Human ServicesUnited States Public Health ServiceNational Institutes of Health (NIH) - USA [R01 NS48191, R01 NS062993, P30 NS051220, 5 T32 AG000242]; Kentucky Spinal Cord and Head Injury Research Trust; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS062993, P30NS051220, R01NS048191] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T32AG000242] Funding Source: NIH RePORTER	This research was supported by grants from the National Institutes of Health, U.S. Public Health Service grants R01 NS48191, R01 NS062993 (P.G.S.), P30 NS051220, 5 T32 AG000242, and funding from the Kentucky Spinal Cord and Head Injury Research Trust. The authors would like to thank Andrea Sebastian and Deann Hopkins for technical assistance.	Allahtavakoli M, 2009, BRAIN RES, V1271, P121, DOI 10.1016/j.brainres.2009.03.040; Arimoto T, 2003, NEUROBIOL DIS, V12, P35, DOI 10.1016/S0969-9961(02)00017-7; Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018; Bernardo A, 2000, EUR J NEUROSCI, V12, P2215, DOI 10.1046/j.1460-9568.2000.00110.x; Bernardo A, 2006, CURR PHARM DESIGN, V12, P93, DOI 10.2174/138161206780574579; Besson VC, 2005, NEUROSCI LETT, V388, P7, DOI 10.1016/j.neulet.2005.06.019; BRAISSANT, 1996, ENDOCRINOLOGY, V137, P354; Breidert T, 2002, J NEUROCHEM, V82, P615, DOI 10.1046/j.1471-4159.2002.00990.x; Chen XR, 2008, J PHARMACOL EXP THER, V326, P966, DOI 10.1124/jpet.108.140368; Chen XR, 2007, J NEUROTRAUM, V24, P1119, DOI 10.1089/neu.2006.0216; Clark RB, 2002, J LEUKOCYTE BIOL, V71, P388; Collino M, 2006, FREE RADICAL BIO MED, V41, P579, DOI 10.1016/j.freeradbiomed.2006.04.030; Cristiano L, 2001, J NEUROCYTOL, V30, P671, DOI 10.1023/A:1016525716209; CULLINGFORD IE, 1998, DISTRIBUTION, V70, P1366; Daynes RA, 2002, NAT REV IMMUNOL, V2, P748, DOI 10.1038/nri912; Dehmer T, 2004, J NEUROCHEM, V88, P494, DOI 10.1046/j.1471-4159.2003.02210.x; Delerive P, 2001, J ENDOCRINOL, V169, P453, DOI 10.1677/joe.0.1690453; Drew PD, 2006, NEUROCHEM INT, V49, P183, DOI 10.1016/j.neuint.2006.04.003; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; Feng D, 2008, J INT MED RES, V36, P783, DOI 10.1177/147323000803600421; GILMER LK, 2009, J NEUROTRAUMA; Guan YF, 2002, DRUG NEWS PERSPECT, V15, P147, DOI 10.1358/dnp.2002.15.3.840011; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Heneka MT, 2000, J NEUROSCI, V20, P6862, DOI 10.1523/JNEUROSCI.20-18-06862.2000; Heneka MT, 1999, J NEUROIMMUNOL, V100, P156, DOI 10.1016/S0165-5728(99)00192-7; Hunter RL, 2008, NEUROSCI LETT, V432, P198, DOI 10.1016/j.neulet.2007.12.019; Hunter RL, 2007, J NEUROCHEM, V100, P1375, DOI 10.1111/j.1471-4159.2006.04327.x; HUNTER RL, 2007, CURR NEUROPHARMACOL; Hyong A, 2008, BRAIN RES, V1215, P218, DOI 10.1016/j.brainres.2008.04.025; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Kapadia R, 2008, FRONT BIOSCI-LANDMRK, V13, P1813, DOI 10.2741/2802; Kiaei M, 2005, EXP NEUROL, V191, P331, DOI 10.1016/j.expneurol.2004.10.007; Kiaei M, 2008, PPAR RES, V2008, DOI 10.1155/2008/418765; Kitamura Y, 1999, NEUROSCI LETT, V262, P129, DOI 10.1016/S0304-3940(99)00055-5; Liberatore GT, 1999, NAT MED, V5, P1403; Marklund N, 2001, J NEUROTRAUM, V18, P821, DOI 10.1089/089771501316919184; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; McTigue DM, 2007, EXP NEUROL, V205, P396, DOI 10.1016/j.expneurol.2007.02.009; Michalik L, 1999, CURR OPIN BIOTECH, V10, P564, DOI 10.1016/S0958-1669(99)00030-0; Miglio G, 2009, NEUROCHEM INT, V55, P496, DOI 10.1016/j.neuint.2009.05.001; Minghetti L, 1998, PROG NEUROBIOL, V54, P99, DOI 10.1016/S0301-0082(97)00052-X; Moreno S, 2004, NEUROSCIENCE, V123, P131, DOI 10.1016/j.neuroscience.2003.08.064; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Ou ZS, 2006, BRAIN RES, V1096, P196, DOI 10.1016/j.brainres.2006.04.062; Paddock ML, 2007, P NATL ACAD SCI USA, V104, P14342, DOI 10.1073/pnas.0707189104; Pandya JD, 2007, J NEUROTRAUM, V24, P798, DOI 10.1089/neu.2006.3673; Pandya JD, 2009, EXP NEUROL, V218, P381, DOI 10.1016/j.expneurol.2009.05.023; Park EJ, 2003, J BIOL CHEM, V278, P14747, DOI 10.1074/jbc.M210819200; Park SW, 2007, J PHARMACOL EXP THER, V320, P1002, DOI 10.1124/jpet.106.113472; Pershadsingh HA, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-3; Przedborski S, 1996, P NATL ACAD SCI USA, V93, P4565, DOI 10.1073/pnas.93.10.4565; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Risner ME, 2006, PHARMACOGENOMICS J, V6, P246, DOI 10.1038/sj.tpj.6500369; Robertson CL, 2004, J BIOENERG BIOMEMBR, V36, P363, DOI 10.1023/B:JOBB.0000041769.06954.e4; Robertson CL, 2006, DEV NEUROSCI-BASEL, V28, P432, DOI 10.1159/000094169; Rose ME, 2002, BRAIN RES, V935, P40, DOI 10.1016/S0006-8993(02)02445-9; Sakamoto J, 2000, BIOCHEM BIOPH RES CO, V278, P704, DOI 10.1006/bbrc.2000.3868; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Schouten JW, 2007, CURR OPIN CRIT CARE, V13, P134, DOI 10.1097/MCC.0b013e3280895d5c; Schutz B, 2005, J NEUROSCI, V25, P7805, DOI 10.1523/JNEUROSCI.2038-05.2005; SOOD V, 2000, TECHNOL THER, V2, P429; Sullivan PG, 2000, ANN NEUROL, V48, P723, DOI 10.1002/1531-8249(200011)48:5&lt;723::AID-ANA5&gt;3.0.CO;2-W; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Sullivan PG, 2003, ANN NEUROL, V53, P711, DOI 10.1002/ana.10543; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Sun H, 2008, INT J DEV NEUROSCI, V26, P505, DOI 10.1016/j.ijdevneu.2008.01.009; Sundararajan S, 2006, NEUROCHEM INT, V49, P136, DOI 10.1016/j.neuint.2006.03.020; Tavazzi B, 2005, NEUROSURGERY, V56, P582, DOI 10.1227/01.NEU.0000156715.04900.E6; Torra IP, 2001, CURR OPIN LIPIDOL, V12, P245, DOI 10.1097/00041433-200106000-00002; Victor NA, 2006, EUR J NEUROSCI, V24, P1653, DOI 10.1111/j.1460-9568.2006.05037.x; Vijitruth R, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-6; Vlodavsky E, 2006, NEUROPATH APPL NEURO, V32, P40, DOI 10.1111/j.1365-2990.2005.00698.x; Wiley SE, 2007, P NATL ACAD SCI USA, V104, P5318, DOI 10.1073/pnas.0701078104; Xing B, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-4; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yamamoto T, 1999, ACT NEUR S, V75, P17; Yi JH, 2008, BRAIN RES, V1244, P164, DOI 10.1016/j.brainres.2008.09.074; Young PW, 1998, J PHARMACOL EXP THER, V284, P751	84	107	109	0	10	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	JAN	2011	227	1					128	135		10.1016/j.expneurol.2010.10.003			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	708NF	WOS:000286367800018	20965168	Green Accepted			2022-02-06	
J	Sosnoff, JJ; Broglio, SP; Shin, S; Ferrara, MS				Sosnoff, Jacob J.; Broglio, Steven P.; Shin, Sunghoon; Ferrara, Michael S.			Previous Mild Traumatic Brain Injury and Postural-Control Dynamics	JOURNAL OF ATHLETIC TRAINING			English	Article						concussions; balance; complexity analysis; long-term effects; nonlinear dynamics	PROFESSIONAL FOOTBALL PLAYERS; CEREBRAL CONCUSSION; RECURRENT CONCUSSION; APPROXIMATE ENTROPY; LEAGUE PLAYER; STABILITY; COMPLEXITY; ENCEPHALOPATHY; RECOVERY; SPORTS	Context: Postural control and cognitive function are adversely affected by acute mild traumatic brain injury (mTBI). Whether postural-control deficits persist beyond the acute stage in individuals with a history of mTBI is unclear. Objective: To determine if postural-control deficits persist in individuals with a history of mTBI. Design: Retrospective cross-sectional study. Setting: University research laboratory. Patients or Other Participants: As part of an ongoing investigation examining cognitive and motor deficits associated with mTBI, 224 individuals participated in the study. Of these, 62 participants self-reported at least 1 previous physician-diagnosed mTBI. Intervention(s): Postural control was assessed using the NeuroCom Sensory Organization Test (SOT) postural-assessment battery. Main Outcome Measure(s): The SOT postural assessment yields 4 indices of postural control: a composite balance score, a visual ratio score, a somatosensory score, and a vestibular score. Postural dynamics were also examined by calculating approximate entropy of center-of-pressure excursions in the anteroposterior and mediolateral axis for each test condition. Results: Minimal differences in the SOT indices were noted among individuals with and without a history of previous mTBI (P > .05). In the group with a history of mTBI, anteroposterior postural irregularity decreased as postural difficulty increased. In contrast, the group without a history of mTBI displayed increased postural irregularity in the mediolateral direction. Conclusions: Individuals with a history of mTBI exhibited altered postural dynamics compared with individuals without a history of mTBI. These findings support the notion that changes in cerebral functioning that affect postural control may persist long after acute injury resolution.	[Sosnoff, Jacob J.; Broglio, Steven P.; Shin, Sunghoon] Univ Illinois, Dept Kinesiol & Community Hlth, Urbana, IL 61801 USA; [Ferrara, Michael S.] Univ Georgia, Dept Exercise Sci, Athens, GA 30602 USA		Sosnoff, JJ (corresponding author), Univ Illinois, Dept Kinesiol & Community Hlth, 906 S Goodwin Ave, Urbana, IL 61801 USA.	jsosnoff@illinois.edu	Sosnoff, Jacob/P-3397-2019; Shin, Sunghoon/O-4478-2014	Sosnoff, Jacob/0000-0002-0286-9207; Shin, Sunghoon/0000-0001-5355-2157			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Broglio SP, 2009, J NEUROTRAUM, V26, P1463, DOI [10.1089/neu.2008.0766, 10.1089/neu.2008-0766]; Cavanaugh JT, 2006, J ATHL TRAINING, V41, P305; Cavanaugh JT, 2005, SPORTS MED, V35, P935, DOI 10.2165/00007256-200535110-00002; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; Finkelstein E., 2006, INCIDENCE EC BURDEN; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Keselman HJ, 1998, PSYCHOPHYSIOLOGY, V35, P470, DOI 10.1017/S0048577298000237; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LIPSITZ LA, 1992, JAMA-J AM MED ASSOC, V267, P1806, DOI 10.1001/jama.267.13.1806; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Nashner L.M., 1997, HDB BALANCE FUNCTION, P280; NeuroCom International Inc, 2001, NEUROCOM SYST OP MAN; Newell KarlM., 2006, HDB PSYCHOL AGING, P163, DOI [10.1016/B978-012101264-9/50011-2, DOI 10.1016/B978-012101264-9/50011-2]; Newell KM, 1998, APPLICATIONS OF NONLINEAR DYNAMICS TO DEVELOPMENTAL PROCESS MODELING, P63; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Piirtola M, 2006, GERONTOLOGY, V52, P1, DOI 10.1159/000089820; PINCUS SM, 1991, P NATL ACAD SCI USA, V88, P2297, DOI 10.1073/pnas.88.6.2297; Pontifex MB, 2009, NEUROPSYCHOLOGIA, V47, P3210, DOI 10.1016/j.neuropsychologia.2009.07.021; Sosnoff JJ, 2008, EXP BRAIN RES, V187, P563, DOI 10.1007/s00221-008-1324-x; Vaillancourt DE, 2002, NEUROBIOL AGING, V23, P1, DOI 10.1016/S0197-4580(01)00247-0; Winter D.A., 1990, BIOMECHANICS MOTOR C, VVol. 1	34	107	107	0	21	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	JAN-FEB	2011	46	1					85	91		10.4085/1062-6050-46.1.85			7	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	704SZ	WOS:000286074000011	21214355	Bronze, Green Published			2022-02-06	
J	McCrea, M; Prichep, L; Powell, MR; Chabot, R; Barr, WB				McCrea, Michael; Prichep, Leslie; Powell, Matthew R.; Chabot, Robert; Barr, William B.			Acute Effects and Recovery After Sport-Related Concussion: A Neurocognitive and Quantitative Brain Electrical Activity Study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; concussion; electroencephalography; neuropsychological tests	FOOTBALL PLAYERS; INJURY; EEG; COLLEGIATE; PERFORMANCE; SYMPTOMS; DEFICITS; INDEX; QEEG	Objective: To investigate the clinical utility and sensitivity of a portable, automatic, frontal quantitative electroencephalographic (QEEG) acquisition device currently in development in detecting abnormal brain electrical activity after sport-related concussion. Design: This was a prospective, non-randomized study of 396 high school and college football players, including cohorts of 28 athletes with concussion and 28 matched controls. All subjects underwent preseason baseline testing on measures of postconcussive symptoms, postural stability, and cognitive functioning, as well as QEEG. Clinical testing and QEEG were repeated on day of injury and days 8 and 45 postinjury for the concussion and control groups. Main Outcomes and Results: The injured group reported more significant postconcussive symptoms during the first 3 days postinjury, which resolved by days 5 and 8. Injured subjects also performed poorer than controls on neurocognitive testing on the day of injury, but no differences were evident on day 8 or day 45. QEEG studies revealed significant abnormalities in electrical brain activity in the injured group on day of injury and day 8 postinjury, but not on day 45. Conclusions: Results from the current study on clinical recovery after sport-related concussion are consistent with early reports indicating a typical course of full recovery in symptoms and cognitive dysfunction within the first week of injury. QEEG results, however, suggest that the duration of physiological recovery after concussion may extend longer than observed clinical recovery. Further study is required to replicate and extend these findings in a larger clinical sample, and further demonstrate the utility of QEEG as a marker of recovery after sport-related concussion.	[McCrea, Michael; Powell, Matthew R.] Waukesha Mem Hosp, Ctr Neurosci, Waukesha, WI 53188 USA; [Prichep, Leslie] NYU, Sch Med, Dept Psychiat, Brain Res Labs, New York, NY USA; [Barr, William B.] NYU, Sch Med, Dept Neurol, New York, NY USA; [Prichep, Leslie; Chabot, Robert] Nathan S Kline Inst Psychiat Res, New York State Dept Mental Hlth, Orangeburg, NY 10962 USA; [McCrea, Michael] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA		McCrea, M (corresponding author), Waukesha Mem Hosp, Ctr Neurosci, 721 Amer Ave,Ste 406, Waukesha, WI 53188 USA.	michael.mccrea@phci.org		Barr, William/0000-0001-7711-7758	BrainScope, Inc	This research was supported by a clinical research grant from BrainScope, Inc, as an investigator-initiated study, with Drs McCrea and Barr as principal investigators. The investigators thank the certified athletic trainers and student athletes from those high schools and colleges that participated. We also acknowledge the insights of E. Roy John, PhD, in the concept and design of this study. Drs McCrea and Barr had full access to all of the clinical data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis; Dr Prichep holds the same responsibility for the integrity and accuracy of the electrophysiological data. Drs Barr, Prichep, and Chabot serve as consultants to BrainScope, Inc, and Dr Prichep holds financial interest in BrainScope, Inc, through patented technology. None of the other authors has any conflict of interest to declare with respect to this study or article. The authors have no other personal financial or institutional interest in any of the drugs, materials, or devices described in the article. Aside from the author-investigators, representatives from BrainScope, Inc, did not play a role in the design or execution of the study beyond funding, and had no involvement in the preparation of this article.	ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Bleiberg J, 1997, NEUROPSY NEUROPSY BE, V10, P247; Bleiberg Joseph, 2005, Neurosurgery, V56, pE1166; Chen Xi-Ping, 2006, Neurosci Bull, V22, P165; Duff J, 2004, CLIN EEG NEUROSCI, V35, P198, DOI 10.1177/155005940403500410; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Giza CC, 2001, J ATHL TRAINING, V36, P228; Gurdjian ES, 1975, IMPACT HEAD INJURY; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Iverson G.L, 2007, BRAIN INJURY MED PRI, P373; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; JOHN ER, 1988, SCIENCE, V239, P162, DOI 10.1126/science.3336779; Kabat MH, 2001, CLIN NEUROPSYCHOL, V15, P498, DOI 10.1076/clin.15.4.498.1882; Kane RL, 2007, ARCH CLIN NEUROPSYCH, V22, pS115, DOI 10.1016/j.acn.2006.10.006; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; Kondacs A, 1999, CLIN NEUROPHYSIOL, V110, P1708, DOI 10.1016/S1388-2457(99)00122-4; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Leddy JJ, 2007, NEUROREHABILITATION, V22, P199; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Malloy, 1998, Semin Clin Neuropsychiatry, V3, P186; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M., 2000, STANDARDIZED ASSESSM; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McGowan JC, 2000, AM J NEURORADIOL, V21, P875; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Prichep LS, 2005, CLIN EEG NEUROSCI, V36, P82, DOI 10.1177/155005940503600207; Ptito A, 2007, NEUROREHABILITATION, V22, P217; Randolph C, 2009, ARCH CLIN NEUROPSYCH, V24, P219, DOI 10.1093/arclin/acp025; Slobounov S, 2009, CLIN NEUROPHYSIOL, V120, P862, DOI 10.1016/j.clinph.2009.03.009; TEBANO MT, 1988, ELECTROEN CLIN NEURO, V70, P185, DOI 10.1016/0013-4694(88)90118-6; Thatcher RW, 2001, J NEUROPSYCH CLIN N, V13, P77, DOI 10.1176/appi.neuropsych.13.1.77; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; Thompson J, 2005, NEUROSCI LETT, V377, P158, DOI 10.1016/j.neulet.2004.11.090; Thorne DR, 2006, BEHAV RES METHODS, V38, P569; Thornton KE, 1999, BRAIN INJURY, V13, P477, DOI 10.1080/026990599121395; WATSON MR, 1995, BRIT J PSYCHIAT, V167, P514, DOI 10.1192/bjp.167.4.514; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004	51	107	109	0	29	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2010	25	4					283	292		10.1097/HTR.0b013e3181e67923			10	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	622FO	WOS:000279646900006	20611046				2022-02-06	
J	Schnakers, C; Chatelle, C; Vanhaudenhuyse, A; Majerus, S; Ledoux, D; Boly, M; Bruno, MA; Boveroux, P; Demertzi, A; Moonen, G; Laureys, S				Schnakers, Caroline; Chatelle, Camille; Vanhaudenhuyse, Audrey; Majerus, Steve; Ledoux, Didier; Boly, Melanie; Bruno, Marie-Aurulie; Boveroux, Pierre; Demertzi, Athena; Moonen, Gustave; Laureys, Steven			The Nociception Coma scale: A new tool to assess nociception in disorders of consciousness	PAIN			English	Article						Nociception; Behavioral assessment; Brain injury; Consciousness; Vegetative state; Minimally conscious state	PAIN ASSESSMENT; STIMULI; STATE	Assessing behavioral responses to nociception is difficult in severely brain-injured patients recovering from coma. We here propose a new scale developed for assessing nociception in vegetative (VS) and minimally conscious (MCS) coma survivors, the Nociception Coma Scale (NCS), and explore its concurrent validity, inter-rater agreement and sensitivity. Concurrent validity was assessed by analyzing behavioral responses of 48 post-comatose patients to a noxious stimulation (pressure applied to the fingernail) (28 VS and 20 MCS; age range 20-82 years; 17 of traumatic etiology). Patients' were assessed using the NCS and four other scales employed in non-communicative patients: the 'Neonatal Infant Pain Scale' (NIPS) and the 'Faces, Legs, Activity, Cry, Consolability' (FLACC) used in newborns; and the 'Pain Assessment In Advanced Dementia Scale' (PAINAD) and the 'Checklist of Non-verbal Pain Indicators' (CNPI) used in dementia. For the establishment of inter-rater agreement, fifteen patients were concurrently assessed by two examiners. Concurrent validity, assessed by Spearman rank order correlations between the NCS and the four other validated scales, was good. Cohen's kappa analyses revealed a good to excellent inter-rater agreement for the NCS total and subscore measures, indicating that the scale yields reproducible findings across examiners. Finally, a significant difference between NCS total scores was observed as a function of diagnosis (i.e., VS or MCS). The NCS constitutes a sensitive clinical tool for assessing nociception in severely brain-injured patients. This scale constitutes the first step to a better management of patients recovering from coma. (C) 2009 International Association for the Study of Pain. Published by Elsevier B. V. All rights reserved.	[Schnakers, Caroline; Chatelle, Camille; Vanhaudenhuyse, Audrey; Boly, Melanie; Bruno, Marie-Aurulie; Boveroux, Pierre; Demertzi, Athena; Laureys, Steven] Univ Liege, Coma Sci Grp, Cyclotron Res Ctr, B-4000 Liege, Belgium; [Majerus, Steve] Univ Liege, Dept Cognit Sci, B-4000 Liege, Belgium; [Ledoux, Didier] CHU Sart Tilman, Dept Intens Care, B-4000 Liege, Belgium; [Boly, Melanie; Moonen, Gustave; Laureys, Steven] CHU Sart Tilman, Dept Neurol, B-4000 Liege, Belgium; [Boveroux, Pierre] Univ Liege, CHU Sart Tilman Hosp, Dept Anesthesia, B-4000 Liege, Belgium		Schnakers, C (corresponding author), Univ Liege, Coma Sci Grp, Cyclotron Res Ctr, Sart Tilman B30, B-4000 Liege, Belgium.	C.Schnakers@ulg.ac.be; steven.laureys@ulg.ac.be	Laureys, Steven/AAN-2097-2021; Ledoux, Didier/ABA-8401-2021; Majerus, Steve/D-4678-2009; Laureys, Steven/A-3349-2011; Vanhaudenhuyse, Audrey/AAP-2455-2020; Demertzi, Athena/I-1251-2019	Laureys, Steven/0000-0002-3096-3807; Ledoux, Didier/0000-0002-9314-6564; Demertzi, Athena/0000-0001-8021-3759; Majerus, Steve/0000-0002-8206-8097; Chatelle, Camille/0000-0002-7526-2107; Boly, Melanie/0000-0001-9584-0907	Belgian Fund for Scientific Research (FNRS)Fonds de la Recherche Scientifique - FNRS; European CommissionEuropean CommissionEuropean Commission Joint Research Centre; James McDonnell Foundation; Mind Science Foundation; French Speaking Community Concerted Research Action [ARC-06/11-340]; Fondation Medicale Reine Elisabeth, University of LiegeUniversity of Liege; CNRS/FNRS-CGRI collaboration fundsCentre National de la Recherche Scientifique (CNRS)Fonds de la Recherche Scientifique - FNRS	This research was funded by the Belgian Fund for Scientific Research (FNRS), European Commission, James McDonnell Foundation, Mind Science Foundation, French Speaking Community Concerted Research Action (ARC-06/11-340), Fondation Medicale Reine Elisabeth, University of Liege and the CNRS/FNRS-CGRI collaboration funds.	ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Boly M, 2005, NEUROPSYCHOL REHABIL, V15, P283, DOI 10.1080/09602010443000371; Boly M, 2008, LANCET NEUROL, V7, P1013, DOI 10.1016/S1474-4422(08)70219-9; Buttner W, 2000, PAEDIATR ANAESTH, V10, P303, DOI 10.1046/j.1460-9592.2000.00530.x; Chatelle C, 2008, Rev Med Liege, V63, P429; Feldt K S, 2000, Pain Manag Nurs, V1, P13, DOI 10.1053/jpmn.2000.5831; Ferrell B, 2002, J AM GERIATR SOC, V50, pS205, DOI 10.1046/j.1532-5415.50.6s.1.x; Giacino JT, 2006, ARCH PHYS MED REHAB, V87, pS67, DOI 10.1016/j.apmr.2006.07.272; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Halliburton J R, 1998, CRNA, V9, P39; Herr K, 2006, PAIN MANAG NURS, V7, P44, DOI 10.1016/j.pmn.2006.02.003; Hummel P, 2006, SEMIN FETAL NEONAT M, V11, P237, DOI 10.1016/j.siny.2006.02.004; *IASP, 1994, CLASS CHRON PAIN D S, V3; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Laureys S, 2002, NEUROIMAGE, V17, P732, DOI 10.1006/nimg.2002.1236; Laureys S, 2007, CURR OPIN NEUROL, V20, P609, DOI 10.1097/WCO.0b013e3282f1d6dd; Lawrence J, 1993, Neonatal Netw, V12, P59; Loeser JD, 2008, PAIN, V137, P473, DOI 10.1016/j.pain.2008.04.025; Majerus S, 2005, PROG BRAIN RES, V150, P397, DOI 10.1016/S0079-6123(05)50028-1; Merkel S I, 1997, Pediatr Nurs, V23, P293; SCHNAKERS C, 2009, ENCY CONSCIOUSNESS, V1, P243; Schnakers C, 2007, CURR OPIN NEUROL, V20, P620, DOI 10.1097/WCO.0b013e3282f169d9; Stevens RD, 2006, CRIT CARE CLIN, V22, P787, DOI 10.1016/j.ccc.2006.11.006; TEASDALE G, 1974, LANCET, V2, P81; Treede RD, 1999, PAIN, V79, P105, DOI 10.1016/S0304-3959(98)00184-5; Warden Victoria, 2003, J Am Med Dir Assoc, V4, P9, DOI 10.1016/S1525-8610(04)70258-3	27	107	114	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0304-3959	1872-6623		PAIN	Pain	FEB	2010	148	2					215	219		10.1016/j.pain.2009.09.028			5	Anesthesiology; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology; Neurosciences & Neurology	547MV	WOS:000273894600009	19854576				2022-02-06	
J	Pietrzak, RH; Olver, J; Norman, T; Piskulic, D; Maruff, P; Snyder, PJ				Pietrzak, Robert H.; Olver, James; Norman, Trevor; Piskulic, Danijela; Maruff, Paul; Snyder, Peter J.			A comparison of the CogState Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery in assessing cognitive impairment in chronic schizophrenia	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Schizophrenia; Computerized; Executive function; Psychopharmacology; Cognition	PHASE CLINICAL-TRIALS; TEST-RETEST INTERVALS; OLDER-ADULTS; NEUROCOGNITIVE DEFICITS; STATISTICAL APPROACH; FUNCTIONAL-CAPACITY; WORKING-MEMORY; PERFORMANCE; STANDARDIZATION; CONCUSSION	This study examined the criterion and construct validity of a brief computerized cognitive test battery (CogState Schizophrenia Battery) compared to a conventional cognitive test battery recommended by the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) consensus. The CogState and MATRICS batteries yielded comparable effect sizes in comparing patients with schizophrenia to healthy controls (Cohen's ds = -1.50 for both batteries). Moderate to large correlations were observed between CogState and MATRICS measures of processing speed, attention/vigilance, working memory, verbal and visual learning, reasoning/problem solving, and social cognition (rs = .56-.79). CogState and MATRICS composite scores also correlated strongly with scores on the University of California at San Diego (UCSD) Performance-Based Skills Assessment (UPSA; rs = .76 and .79, respectively) in patients with schizophrenia. Results of this study suggest that the CogState Schizophrenia Battery provides valid measurement of the cognitive domains nominated by the MATRICS consensus group as being important to consider in the context of pharmacological treatments for cognitive impairment in schizophrenia.	[Pietrzak, Robert H.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA; [Olver, James; Norman, Trevor; Piskulic, Danijela] Univ Melbourne, Sch Med, Dept Psychiat, Melbourne, Vic, Australia; [Maruff, Paul] Univ Melbourne, Ctr Neurosci, Melbourne, Vic, Australia; [Maruff, Paul] CogState Ltd, Melbourne, Vic, Australia; [Snyder, Peter J.] Brown Univ, Warren Alpert Med Sch, Dept Clin Neurosci, Providence, RI 02912 USA; [Snyder, Peter J.] Yale Univ, Sch Med, Ctr Child Study, New Haven, CT 06510 USA		Snyder, PJ (corresponding author), Rhode Isl Hosp, Off Res Adm, Aldrich Bldg,1st Floor, Providence, RI 02903 USA.	psnyder@lifespan.org	Maruff, Paul/AAD-2454-2021; Maruff, Paul/ABA-1673-2020; Snyder, Peter J./W-2609-2019; Piskulic, Danijela/O-9092-2017	Maruff, Paul/0000-0002-6947-9537; Snyder, Peter/0000-0003-0555-4654	Pfizer Global Research and DevelopmentPfizer	This research was supported in part by Pfizer Global Research and Development through the Australian P3 grants program and by CogState Ltd. Conflict of Interest Statement: Paul Maruff is employed by the company (CogState Ltd., Melbourne, Australia) that distributes the computer-based cognitive battery that was used in this study. Peter Snyder serves as a consultant to that company.	American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Bowie CR, 2008, BIOL PSYCHIAT, V63, P505, DOI 10.1016/j.biopsych.2007.05.022; Buchanan RW, 2007, SCHIZOPHRENIA BULL, V33, P1120, DOI 10.1093/schbul/sbm083; CAIRNEY S, 2006, INFORM TECHNOLOGY IN; Cargin JW, 2007, J CLIN EXP NEUROPSYC, V29, P706, DOI 10.1080/13825580600954256; CARGIN JW, 2007, J CLIN EXP NEUROPSYC, V21, P1; Carter CS, 2007, SCHIZOPHRENIA BULL, V33, P1131, DOI 10.1093/schbul/sbm081; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Cohen J., 2013, STAT POWER ANAL BEHA; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Collie A, 2003, BRIT J SPORT MED, V37, P370, DOI 10.1136/bjsm.37.4.370-a; Collie A, 2003, J INT NEUROPSYCH SOC, V9, P419, DOI 10.1017/S1355617703930074; Collie A, 2002, ANN THORAC SURG, V73, P2005, DOI 10.1016/S0003-4975(01)03375-6; Collie A, 2007, CONTEMP CLIN TRIALS, V28, P391, DOI 10.1016/j.cct.2006.10.010; Collie A, 2006, HUM PSYCHOPHARM CLIN, V21, P481, DOI 10.1002/hup.799; Coulston CM, 2007, SCHIZOPHR RES, V96, P169, DOI 10.1016/j.schres.2007.08.006; Crawford JR, 2007, NEUROPSYCHOLOGY, V21, P611, DOI 10.1037/0894-4105.21.5.611; Duff K, 2004, J INT NEUROPSYCH SOC, V10, P828, DOI 10.1017/S1355617704106048; Duff K, 2007, J CLIN EXP NEUROPSYC, V29, P854, DOI 10.1080/13803390601147629; Falleti MG, 2006, J CLIN EXP NEUROPSYC, V28, P1095, DOI 10.1080/13803390500205718; Fioravanti M, 2005, NEUROPSYCHOL REV, V15, P73, DOI 10.1007/s11065-005-6254-9; First M., 1995, STRUCTURED CLIN INTE, V9, P92; Freedman R, 2008, AM J PSYCHIAT, V165, P1040, DOI 10.1176/appi.ajp.2008.07071135; Goldberg TE, 2007, ARCH GEN PSYCHIAT, V64, P1115, DOI 10.1001/archpsyc.64.10.1115; Green MF, 2004, SCHIZOPHR RES, V72, P41, DOI 10.1016/j.schres.2004.09.009; Green MF, 1996, AM J PSYCHIAT, V153, P321; Green MF, 2008, AM J PSYCHIAT, V165, P221, DOI 10.1176/appi.ajp.2007.07010089; Harvey PD, 2008, AM J PSYCHIAT, V165, P163, DOI 10.1176/appi.ajp.2007.07111810; Heinrichs RW, 1998, NEUROPSYCHOLOGY, V12, P426, DOI 10.1037/0894-4105.12.3.426; Hill SK, 2008, J INT NEUROPSYCH SOC, V14, P209, DOI 10.1017/S1355617708080570; Keefe RSE, 2006, NEUROPSYCHOPHARMACOL, V31, P2033, DOI 10.1038/sj.npp.1301072; Keefe RSE, 2006, J CLIN EXP NEUROPSYC, V28, P260, DOI 10.1080/13803390500360539; Kern RS, 2008, AM J PSYCHIAT, V165, P214, DOI 10.1176/appi.ajp.2007.07010043; Krabbendam L, 2005, SCHIZOPHR RES, V80, P137, DOI 10.1016/j.schres.2005.08.004; Lewis MS, 2007, ARCH CLIN NEUROPSYCH, V22, P247, DOI 10.1016/j.acn.2007.01.002; Lewis MS, 2006, ANN THORAC SURG, V81, P2097, DOI 10.1016/j.athoracsur.2006.01.044; Maruff P, 2006, PSYCHOPHARMACOLOGY, V186, P7, DOI 10.1007/s00213-006-0331-5; MARUFF P, ARCH CLIN N IN PRESS; Mathewson KJ, 2008, PSYCHOPHYSIOLOGY, V45, P936, DOI 10.1111/j.1469-8986.2008.00699.x; Matza LS, 2006, SCHIZOPHRENIA BULL, V32, P666, DOI 10.1093/schbul/sbl004; Mollica CM, 2004, HUM PSYCHOPHARM CLIN, V19, P445, DOI 10.1002/hup.624; Nelson H.E., 1982, NATL ADULT READING T; Nuechterlein KH, 2008, AM J PSYCHIAT, V165, P203, DOI 10.1176/appi.ajp.2007.07010042; Pantelis C, 2002, J PSYCHOSOM RES, V53, P655, DOI 10.1016/S0022-3999(02)00434-8; Patterson TL, 2001, SCHIZOPHRENIA BULL, V27, P235, DOI 10.1093/oxfordjournals.schbul.a006870; PIETRZAK RH, HUMAN PSYCH IN PRESS; Prouteau A, 2005, SCHIZOPHR RES, V77, P343, DOI 10.1016/j.schres.2005.03.001; Reichenberg A, 2007, PSYCHOL BULL, V133, P833, DOI 10.1037/0033-2909.133.5.833; Snyder AM, 2008, CHILD NEUROPSYCHOL, V14, P211, DOI 10.1080/09297040701220005; Snyder PJ, 2008, PSYCHIAT RES, V160, P316, DOI 10.1016/j.psychres.2007.07.011; SNYDER PJ, 2006, HUMAN PSYCHOPHARMACO, V20, P263; Surguladze SA, 2007, J CLIN PSYCHOPHARM, V27, P560, DOI 10.1097/jcp.0b013e31815a256c; Thomas E, 2008, NEUROPSYCHOLOGIA, V46, P2476, DOI 10.1016/j.neuropsychologia.2008.04.010	53	107	109	0	11	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	OCT	2009	31	7					848	859		10.1080/13803390802592458			12	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	500AS	WOS:000270270000007	19142774				2022-02-06	
J	Hanson, B; Neidenbach, P; de Boer, P; Stengel, D				Hanson, Beate; Neidenbach, Philipp; de Boer, Piet; Stengel, Dirk			Functional outcomes after nonoperative management of fractures of the proximal humerus	JOURNAL OF SHOULDER AND ELBOW SURGERY			English	Article						Proximal humeral fracture; functional treatment; Constant score; Disabilities of the Arm; Shoulder and Hand	FIXATION; EPIDEMIOLOGY; HEAD	Background: Prospective follow-up data after nonoperative treatment for fractures of the proximal humerus are scarce. We studied functional outcomes and rates of complication and failure after conservative management of these common injuries. Materials and methods: Consecutive patients aged older than 18 years presenting to the emergency department of a large district hospital with an isolated, closed proximal humeral fracture considered suitable for functional treatment by the surgeon oil charge were enrolled in a prospective, externally monitored observational study. Surgeons were free to reduce the fracture and to prescribe any type of sling or brace. Active follow-up after 12 weeks, 6, and 12 months included plain radiographs, Constant score, and Disabilities of Arm, Shoulder and Hand (DASH) score. Results: We enrolled 160 patients (118 women; mean age. 63.3 +/- 14.8 years), and 124 completed I-year follow-up. There were 85, 71, and 4 AO 11 A B, and C fractures, and 75 one-part, 60 two-part. 23 three-part, and 2 four-part and head-splitting fractures. After I year, the mean difference in Constant scores between the injured and contralateral shoulder was 8.2 (95% confidence interval [Cl] 6.0-10.4). The mean difference in 1-year DASH scores to baseline assessment was 10.2 points (95% Cl 7.3-13.1 points). The risk of delayed and nonunion was 7.0% (95% CI, 3.6%-12.3%). Four patients subsequently underwent surgical fixation, and 5 had arthroscopic subacromial decompression. Conclusion: This study may provide reference values for future investigations and stresses ceiling effects that will make it difficult to demonstrate a significant advantage of surgical over nonoperative treatment in patients with proximal humeral fractures. Level of evidence: Level 4, Prospective case series without a control group. (C) 2009 Journal of Shoulder and Elbow Surgery Board of Trustees.	[Stengel, Dirk] Unfallkrankenhaus Berlin, Dept Orthoped & Trauma Surg, Clin Res Ctr, D-12683 Berlin, Germany; [Hanson, Beate; Neidenbach, Philipp; de Boer, Piet; Stengel, Dirk] AO Clin Invest & Documentat, Dubendorf, Switzerland; [de Boer, Piet] York Dist Gen Hosp, Dept Traumatol, York, N Yorkshire, England; [Stengel, Dirk] Univ Hosp Greifswald, Berlin, Germany		Stengel, D (corresponding author), Unfallkrankenhaus Berlin, Dept Orthoped & Trauma Surg, Clin Res Ctr, Warener Str 7, D-12683 Berlin, Germany.	stengeldirk@aol.com	Stengel, Dirk/AAF-6470-2019				Barrett JA, 1999, J CLIN EPIDEMIOL, V52, P243, DOI 10.1016/S0895-4356(98)00167-X; Calvo E, 2007, J SHOULDER ELB SURG, V16, P774, DOI 10.1016/j.jse.2007.03.019; CONSTANT CR, 1987, CLIN ORTHOP RELAT R, P160; Court-Brown CM, 2006, INJURY, V37, P691, DOI 10.1016/j.injury.2006.04.130; Court-Brown CM, 2001, J BONE JOINT SURG BR, V83B, P799, DOI 10.1302/0301-620X.83B6.11401; Court-Brown CM, 2002, J BONE JOINT SURG BR, V84B, P504, DOI 10.1302/0301-620X.84B4.12488; Court-Brown CM, 2004, ACTA ORTHOP SCAND, V75, P736, DOI 10.1080/00016470410004111; Fjalestad T, 2005, ARCH ORTHOP TRAUM SU, V125, P310, DOI 10.1007/s00402-005-0803-9; Frangen TM, 2007, ZBL CHIR, V132, P60, DOI 10.1055/s-2006-958639; Gradl G, 2007, ARCH ORTHOP TRAUM SU, V127, P937, DOI 10.1007/s00402-007-0425-5; Hagino H, 1999, BONE, V24, P265, DOI 10.1016/S8756-3282(98)00175-6; Handschin AE, 2008, INJURY, V39, P306, DOI 10.1016/j.injury.2007.10.011; Hudak PL, 1996, AM J IND MED, V29, P602, DOI 10.1002/(SICI)1097-0274(199606)29:6<602::AID-AJIM4>3.0.CO;2-L; Keener JD, 2007, J SHOULDER ELB SURG, V16, P330, DOI 10.1016/j.jse.2006.09.006; Kollig E, 2003, ZBL CHIR, V128, P111, DOI 10.1055/s-2003-37764; Lefevre-Colau MM, 2007, J BONE JOINT SURG AM, V89A, P2582, DOI 10.2106/JBJS.F.01419; Lill H, 2001, ZBL CHIR, V126, P205, DOI 10.1055/s-2001-12495; Linhart W, 2007, J ORTHOP TRAUMA, V21, P285, DOI 10.1097/BOT.0b013e318059b5a1; NEER CS, 1970, J BONE JOINT SURG AM, VA 52, P1077, DOI 10.2106/00004623-197052060-00001; Stiller J, 2005, ATHLET THER TODAY, V10, P34; van den Broek CM, 2007, ARCH ORTHOP TRAUM SU, V127, P459, DOI 10.1007/s00402-006-0250-2; Voigt C, 2007, CHIRURG, V78, P40, DOI 10.1007/s00104-006-1241-0; Zyto K, 1997, J BONE JOINT SURG BR, V79B, P412, DOI 10.1302/0301-620X.79B3.7419; Zyto K, 1998, INJURY, V29, P349, DOI 10.1016/S0020-1383(97)00211-8	24	107	119	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	1058-2746			J SHOULDER ELB SURG	J. Shoulder Elbow Surg.	JUL-AUG	2009	18	4			SI		612	621		10.1016/j.jse.2009.03.024			10	Orthopedics; Sport Sciences; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences; Surgery	468JB	WOS:000267812400019	19559373				2022-02-06	
J	Crowe, L; Babl, F; Anderson, V; Catroppa, C				Crowe, Louise; Babl, Franz; Anderson, Vicki; Catroppa, Cathy			The epidemiology of paediatric head injuries: Data from a referral centre in Victoria, Australia	JOURNAL OF PAEDIATRICS AND CHILD HEALTH			English	Article						closed head injury	TRAUMATIC BRAIN-INJURY; CHILDREN; ADOLESCENTS	Aim: Currently, there are no population-based or hospital-based studies on the full spectrum of paediatric head injuries (HIs) in Australia. We set out to provide detailed information on the incidence rates, causes and clinical management of all severities of HI in children and adolescents at an Australian tertiary referral centre using emergency department (ED) and admission data as a basis for further investigations and prevention efforts. Methods: A retrospective chart review of all children aged 0-16 years who attended the Royal Childrens Hospital (RCH), Melbourne, following a HI in 2004 was used. The cases were identified using the International Classification of Diseases 10th revision codes, and all medical records were reviewed based on a piloted data form. Information was collected on demographics, injury factors and clinical management of HIs in the hospital setting. Results: Over the 12-month period, there were 1115 children with an HI who attended the RCH ED, or were admitted. Ninety per cent were classified as mild, 8% as moderate and 3% as severe. Males and children under 3 years had the higher attendance rates. Falls, sports and motor vehicle accidents were the main HI causes. The main sport played (30%) when sustaining an HI was Australian rules football. Thirty-two per cent of children were admitted, 67% of these with mild HI. Twenty-one per cent had a radiology imaging study, most (67%) with a normal result. Conclusions: Many HI causes appear preventable, in particular, falls from heights in infants and sports safety. High rates of admission and radiology imaging of mild HI warrant further investigation.	[Crowe, Louise; Babl, Franz; Anderson, Vicki; Catroppa, Cathy] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Crowe, Louise; Babl, Franz; Anderson, Vicki; Catroppa, Cathy] Univ Melbourne, Melbourne, Vic, Australia; [Babl, Franz] Royal Childrens Hosp, Emergency Dept, Melbourne, Vic, Australia		Crowe, L (corresponding author), Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia.	louise.crowe@mcri.edu.au	Catroppa, Cathy/AAX-9458-2021	Catroppa, Cathy/0000-0002-9750-0436; Crowe, Louise/0000-0003-4619-9708			Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2001, J CLIN EXP NEUROPSYC, V23, P705, DOI 10.1076/jcen.23.6.705.1015; Atabaki SM, 2008, ARCH PEDIAT ADOL MED, V162, P439, DOI 10.1001/archpedi.162.5.439; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Browne GJ, 2006, BRIT J SPORT MED, V40, P163, DOI 10.1136/bjsm.2005.021220; Cameron PA, 2004, ANZ J SURG, V74, P424, DOI 10.1111/j.1445-1433.2004.03029.x; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Gilbert EH, 1996, ANN EMERG MED, V27, P305, DOI 10.1016/S0196-0644(96)70264-0; Gronwall D, 1997, J Int Neuropsychol Soc, V3, P592; HENDRIE D, 1998, AUST J PUBLIC HEALTH, V18, P380; Holsti M, 2005, PEDIATR EMERG CARE, V21, P639, DOI 10.1097/01.pec.0000181426.25342.a9; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; MCMAHON KA, 1993, MED J AUSTRALIA, V159, P301, DOI 10.5694/j.1326-5377.1993.tb137864.x; Mitra B, 2007, J PAEDIATR CHILD H, V43, P154, DOI 10.1111/j.1440-1754.2007.01035.x; Mower WR, 2005, J TRAUMA, V59, P954, DOI 10.1097/01.ta.0000187813.79047.42; NOLAN T, 1992, J PAEDIATR CHILD H, V28, P27, DOI 10.1111/j.1440-1754.1992.tb02613.x; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; World Health Organization, 1992, INT CLASS DIS; WRIGHTSON P, 1995, J NEUROL NEUROSUR PS, V59, P375, DOI 10.1136/jnnp.59.4.375	21	107	108	0	13	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1034-4810			J PAEDIATR CHILD H	J. Paediatr. Child Health	JUN	2009	45	6					346	350		10.1111/j.1440-1754.2009.01499.x			5	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	464WJ	WOS:000267539900006	19490410				2022-02-06	
J	Kumar, R; Gupta, RK; Husain, M; Chaudhry, C; Srivastava, A; Saksena, S; Rathore, RKS				Kumar, Raj; Gupta, Rakesh K.; Husain, Mazhar; Chaudhry, Chaynika; Srivastava, Arti; Saksena, Sona; Rathore, Ram K. S.			Comparative evaluation of corpus callosum DTI metrics in acute mild and moderate traumatic brain injury: Its correlation with neuropsychometric tests	BRAIN INJURY			English	Article						Mild and moderate TBI; diffuse axonal injury; corpus callosum; radial and axial diffusivity; neuropsychological test	DIFFUSE AXONAL INJURY; CLOSED-HEAD-INJURY; TENSOR IMAGING DETECTS; WHITE-MATTER INJURY; WALLERIAN DEGENERATION; HEPATIC-ENCEPHALOPATHY; ISCHEMIC-STROKE; SPINAL-CORD; MRI; CHILDREN	Primary objective: To look for differences in vulnerability of corpus callosum (CC) in patients of mild and moderate traumatic brain injury (TBI) in the acute stage using quantitative diffusion tensor imaging (DTI) and to correlate these with neuropsychometric tests (NPT) done at 6 months post-injury. Research design, methods and procedures: Conventional MRI, DTI and NPT were performed on 83 patients (moderate TBI, n = 57; mild TBI, n = 26) within 5-14 days after TBI. Thirty-three age- and sex-matched healthy controls were also included for comparison. Results: Significantly decreased fractional anisotropy (FA) in genu and splenium; significantly increased radial diffusivity (RD) values in genu, midbody and splenium with significant increase in mean diffusivity (MD) and a decrease in axial diffusivity (AD) only in genu, respectively, in patients with moderate TBI compared to healthy controls were observed. However, in moderate TBI, significantly decreased FA was found only in genu compared to mild TBI. Moderate TBI showed poor NPT scores compared to mild TBI, but this did not reach statistical significance. Conclusions: It is concluded that DTI abnormalities in the regions of CC were more in patients with moderate TBI compared to mild TBI and this was associated with relatively poor neuropsychological outcome 6 months post-injury.	[Gupta, Rakesh K.] Sanjay Gandhi Postgrad Inst Med Sci, Dept Radiodiag, MR Sect, Lucknow 226014, Uttar Pradesh, India; [Kumar, Raj; Husain, Mazhar] Chhatrapati Shahuji Maharaj Med Univ, Dept Neurosurg, Lucknow, Uttar Pradesh, India; [Rathore, Ram K. S.] Indian Inst Technol, Dept Math & Stat, Kanpur 208016, Uttar Pradesh, India		Gupta, RK (corresponding author), Sanjay Gandhi Postgrad Inst Med Sci, Dept Radiodiag, MR Sect, Lucknow 226014, Uttar Pradesh, India.	rgupta@sgpgi.ac.in			Indian Council of Medical ResearchIndian Council of Medical Research (ICMR) [5/4-5/13/Neuro/2004-NCD-1]; Indian Council of Medical Research, New Delhi, IndiaIndian Council of Medical Research (ICMR)	Part of the study was supported by Indian Council of Medical Research (Grant No. 5/4-5/13/Neuro/2004-NCD-1). Raj Kumar and Sona Saksena acknowledge the financial assistance from the Indian Council of Medical Research, New Delhi, India.	ADAMS JH, 1985, MED SCI LAW, V25, P265, DOI 10.1177/002580248502500407; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Alex BV, 1996, NEUROTRAUMA, P119; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ashikaga R, 1997, NEURORADIOLOGY, V39, P239, DOI 10.1007/s002340050401; Assaf Y, 1999, J NEUROTRAUM, V16, P1165, DOI 10.1089/neu.1999.16.1165; Barkovich AJ, 2005, J INHERIT METAB DIS, V28, P311, DOI 10.1007/s10545-005-5952-z; BASSER PJ, 1994, BIOPHYS J, V66, P259, DOI 10.1016/S0006-3495(94)80775-1; Basser PJ, 1995, NMR BIOMED, V8, P333, DOI 10.1002/nbm.1940080707; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Batchelor PG, 2003, MAGN RESON MED, V49, P1143, DOI 10.1002/mrm.10491; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; BROOKE MM, 1992, ARCH PHYS MED REHAB, V73, P320, DOI 10.1016/0003-9993(92)90003-F; Bruce JM, 2003, NEUROPSYCHOLOGY, V17, P622, DOI 10.1037/0894-4105.17.4.622; Bublak P, 2000, J CLIN EXP NEUROPSYC, V22, P176, DOI 10.1076/1380-3395(200004)22:2;1-1;FT176; Conturo TE, 1995, NMR BIOMED, V8, P307, DOI 10.1002/nbm.1940080706; COOPER PR, 2000, NEUROBEHAVIORAL SEQU, P525; Das A, 2001, J GASTROEN HEPATOL, V16, P531, DOI 10.1046/j.1440-1746.2001.02487.x; DELANEY KA, 2000, HEAD INJURY, P41; Deo AA, 2006, J NEUROSCI RES, V83, P801, DOI 10.1002/jnr.20783; DHIMAN RK, 1995, J GASTROEN HEPATOL, V10, P14, DOI 10.1111/j.1440-1746.1995.tb01041.x; EISENBERG HM, 1987, NEUROBEHAVIORAL RECO, P13; Eluvathingal TJ, 2007, CEREB CORTEX, V17, P2760, DOI 10.1093/cercor/bhm003; Etherton JL, 2006, J CLIN EXP NEUROPSYC, V28, P1218, DOI 10.1080/13803390500346595; Ferenci P, 2002, HEPATOLOGY, V35, P716, DOI 10.1053/jhep.2002.31250; Fogel Barry S., 1994, P413; GALSKI T, 1994, ARCH PHYS MED REHAB, V75, P380, DOI 10.1016/0003-9993(94)90158-9; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; Gorrie C, 2001, J NEUROTRAUM, V18, P849, DOI 10.1089/089771501750451776; Graham DI, 1996, NEUROPATH APPL NEURO, V22, P505, DOI 10.1111/j.1365-2990.1996.tb01125.x; Hasan KM, 2001, J MAGN RESON IMAGING, V13, P769, DOI 10.1002/jmri.1107; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; IIZUKA H, 1989, STROKE, V20, P1396, DOI 10.1161/01.STR.20.10.1396; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; LAMPERT PW, 1966, AM J PATHOL, V49, P1139; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Le Bihan D, 2003, NAT REV NEUROSCI, V4, P469, DOI 10.1038/nrn1119; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; LEXA FJ, 1994, AM J NEURORADIOL, V15, P201; Lieberman JD, 2003, J TRAUMA, V55, P437, DOI 10.1097/01.TA.0000081882.79587.17; Liston C, 2006, CEREB CORTEX, V16, P553, DOI 10.1093/cercor/bhj003; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Mac Donald CL, 2006, 24 ANN NAT NEUR SOC; Mateer CA, 1996, J LEARN DISABIL, V29, P618, DOI 10.1177/002221949602900606; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MCLELLAN DR, 1990, COMA EMERGING PATIEN, P389; MENDELSOHN DB, 1992, NEURORADIOLOGY, V34, P384, DOI 10.1007/BF00596495; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; PAL J, 1989, J TRAUMA, V29, P746, DOI 10.1097/00005373-198906000-00008; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; Plylar P A, 1989, J Neurosci Nurs, V21, P353; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Ptak T, 2003, AM J ROENTGENOL, V181, P1401, DOI 10.2214/ajr.181.5.1811401; PURWAR A, P ISMRM 2006, P325; Ramalingaswamy P., 1974, MANUAL INDIAN ADAPTA, P2; Reese TG, 2003, MAGN RESON MED, V49, P177, DOI 10.1002/mrm.10308; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Schiff ND, 2006, J HEAD TRAUMA REHAB, V21, P388, DOI 10.1097/00001199-200609000-00003; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; TEASDALE G, 1974, LANCET, V2, P81; The Brain Trauma Foundation. The American Association of Neurological Surgeons, 2000, J NEUROTRAUM, V17, P563, DOI 10.1089/neu.2000.17.563; Thomalla G, 2005, J NEUROL NEUROSUR PS, V76, P266, DOI 10.1136/jnnp.2004.046375; Thomalla G, 2004, NEUROIMAGE, V22, P1767, DOI 10.1016/j.neuroimage.2004.03.041; Wallesch CW, 2001, BRAIN INJURY, V15, P401, DOI 10.1080/02699050010005959; WITELSON SF, 1989, BRAIN, V112, P799, DOI 10.1093/brain/112.3.799; WOODS RP, 1993, J COMPUT ASSIST TOMO, V17, P536, DOI 10.1097/00004728-199307000-00004; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	75	107	108	0	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	7-8					675	685	PII 912685693	10.1080/02699050903014915			11	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	462QL	WOS:000267370600012	19557571				2022-02-06	
J	Pitkanen, A; Immonen, RJ; Grohn, OHJ; Kharatishvili, I				Pitkanen, Asla; Immonen, Riikka J.; Grohn, Olli H. J.; Kharatishvili, Irina			From traumatic brain injury to posttraumatic epilepsy: What animal models tell us about the process and treatment options	EPILEPSIA			English	Article						Antiepileptic drug; Epileptogenesis; Fluid-percussion injury; Recovery; Surrogate marker	FLUID PERCUSSION INJURY; TEMPORAL-LOBE EPILEPSY; DENTATE GYRUS; HIPPOCAMPAL CA1; CELL-DEATH; RAT; HYPEREXCITABILITY; EPILEPTOGENESIS; VULNERABILITY; EPIDEMIOLOGY	A large number of animal models of traumatic brain injury (TBI) are already available for studies on mechanisms and experimental treatments of TBI. Immediate and early seizures have been described in many of these models with focal or mixed type (both gray and white matter damage) injury. Recent long-term video-electroencephalography (EEG) monitoring studies have demonstrated that TBI produced by lateral fluid-percussion injury in rats results in the development of late seizures, that is, epilepsy. These animals develop hippocampal alterations that are well described in status epilepticus-induced spontaneous seizure models and human posttraumatic epilepsy (PTE). In addition, these rats have damage ipsilaterally in the cortical injury site and thalamus. Although studies in the trauma field provide a large amount of information about the molecular and cellular alterations corresponding to the immediate and early phases of PTE, chronic studies relevant to the epileptogenesis phase are sparse. Moreover, despite the multiple preclinical pharmacologic and cell therapy trials, there is no information available describing whether these therapeutic approaches aimed at improving posttraumatic recovery would also affect the development of lowered seizure threshold and epilepsy. To make progress, there is an obvious need for information exchange between the trauma and epilepsy fields. In addition, the inclusion of epilepsy as an outcome measure in preclinical trials aiming at improving somatomotor and cognitive recovery after TBI would provide valuable information about possible new avenues for antiepileptogenic interventions and disease modification after TBI.	[Pitkanen, Asla; Kharatishvili, Irina] Univ Kuopio, AI Virtanen Inst Mol Sci, Epilepsy Res Grp, Dept Neurobiol, FIN-70211 Kuopio, Finland; [Pitkanen, Asla] Kuopio Univ Hosp, Dept Neurol, SF-70210 Kuopio, Finland; [Immonen, Riikka J.; Grohn, Olli H. J.] Univ Kuopio, Biomed NMR Res Grp, Biomed Imaging Unit, Dept Neurobiol,AI Virtanen Inst Mol Sci, FIN-70211 Kuopio, Finland		Pitkanen, A (corresponding author), Univ Kuopio, AI Virtanen Inst Mol Sci, Epilepsy Res Grp, Dept Neurobiol, POB 1627, FIN-70211 Kuopio, Finland.	asla.pitkanen@uku.fi			Academy of FinlandAcademy of FinlandEuropean Commission; Sigrid Juselius FoundationSigrid Juselius Foundation; CURE; Finnish Technological Fund	This study was supported by the Academy of Finland, the Sigrid Juselius Foundation, CURE, and the Finnish Technological Fund. We thank Nick Hayward, M.Sc., for checking the English language.	Akasu T, 2002, NEUROSCI LETT, V329, P305, DOI 10.1016/S0304-3940(02)00707-3; Baker AJ, 2002, J NEUROTRAUM, V19, P587, DOI 10.1089/089771502753754064; Belayev L, 2001, J NEUROTRAUM, V18, P1031, DOI 10.1089/08977150152693728; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Coulter DA, 1996, EPILEPSY RES, V26, P81, DOI 10.1016/S0920-1211(96)00044-7; D'Ambrosio R, 2005, BRAIN, V128, P174, DOI 10.1093/brain/awh337; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Gennarelli T A, 1981, Acta Neuropathol Suppl, V7, P23; Golarai G, 2001, J NEUROSCI, V21, P8523, DOI 10.1523/JNEUROSCI.21-21-08523.2001; Griesemer D, 2007, J NEUROTRAUM, V24, P1823, DOI 10.1089/neu.2006.0237; HAMM RJ, 1995, EXP NEUROL, V136, P143, DOI 10.1006/exnr.1995.1091; Hoover RC, 2004, J NEUROTRAUM, V21, P501, DOI 10.1089/089771504774129847; Keck CA, 2007, RESTOR NEUROL NEUROS, V25, P77; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharatishvili I, 2007, BRAIN, V130, P3155, DOI 10.1093/brain/awm268; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; Nissinen J, 2000, EPILEPSY RES, V38, P177, DOI 10.1016/S0920-1211(99)00088-1; Nissinen J., 2006, P 7 EUR C EP, P87; Pitkanen A, 2006, J NEUROTRAUM, V23, P241, DOI 10.1089/neu.2006.23.241; Pitkanen A, 2006, DRUG DISCOV TODAY, V2, P409; Prince DA, 2009, EPILEPSIA, V50, P30, DOI 10.1111/j.1528-1167.2008.02008.x; Reeves TM, 2000, J NEUROSCI RES, V60, P370, DOI 10.1002/(SICI)1097-4547(20000501)60:3<370::AID-JNR12>3.0.CO;2-B; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; Reilly PL, 2001, J CLIN NEUROSCI, V8, P398, DOI 10.1054/jocn.2001.0916; Ross ST, 2000, J NEUROPHYSIOL, V83, P2916, DOI 10.1152/jn.2000.83.5.2916; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Santhakumar V, 2000, J PHYSIOL-LONDON, V524, P117, DOI 10.1111/j.1469-7793.2000.00117.x; Smith DH, 1997, NEUROSCI LETT, V231, P135, DOI 10.1016/S0304-3940(97)00551-X; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; Statler KD, 2008, EPILEPSY RES, V80, P163, DOI 10.1016/j.eplepsyres.2008.04.001; Statler KD, 2006, DEV NEUROSCI-BASEL, V28, P354, DOI 10.1159/000094162; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Toth Z, 1997, J NEUROSCI, V17, P8106; Tran LD, 2006, J NEUROTRAUM, V23, P1330, DOI 10.1089/neu.2006.23.1330; Williams AJ, 2005, J NEUROTRAUM, V22, P313, DOI 10.1089/neu.2005.22.313; Williams AJ, 2006, J NEUROTRAUM, V23, P1828, DOI 10.1089/neu.2006.23.1828; WILLMORE LJ, 1978, SCIENCE, V200, P501; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Yudofsky S.C., 2005, TXB TRAUMATIC BRAIN, P27; Zanier ER, 2003, J NEUROTRAUM, V20, P409, DOI 10.1089/089771503765355496	44	107	110	0	15	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0013-9580			EPILEPSIA	Epilepsia		2009	50						21	29		10.1111/j.1528-1167.2008.02007.x			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	399VN	WOS:000262827500005	19187291	Green Submitted, Bronze			2022-02-06	
J	Nutt, JG; Gunzler, SA; Kirchhoff, T; Hogarth, P; Weaver, JL; Krams, M; Jamerson, B; Menniti, FS; Landen, JW				Nutt, John G.; Gunzler, Steven A.; Kirchhoff, Trish; Hogarth, Penelope; Weaver, Jerry L.; Krams, Michael; Jamerson, Brenda; Menniti, Frank S.; Landen, Jaren W.			Effects of a NR2B Selective NMDA Glutamate Antagonist, CP-101,606, on Dyskinesia and Parkinsonism	MOVEMENT DISORDERS			English	Article						Parkinson's disease; levodopa; dysminesia; NR2B subunit selective glutamate antagonist; CP-101.606; amnesia; dissociation	LESIONED MARMOSET MODEL; TRAUMATIC BRAIN-INJURY; ANTIPARKINSONIAN ACTIONS; RECEPTOR ANTAGONIST; DOUBLE-BLIND; L-DOPA; DISEASE; SUBUNITS; MILD; RATS	Glutamate antagonists decrease dyskinesia and augment the antiparkinsonian effects of levodopa in animal models of Parkinson's disease (PD). In a randomized, double-blind, placebo-controlled clinical trial, we investigated the acute effects of placebo and two doses of a NR2B subunit selective NMDA glutamate antagonist, CP-101.606 on the response to 2-hour levodopa infusions in 12 PD subjects with motor fluctuations and dyskinesia. Both doses of CP-101.606 reduced the maximum severity of levodopa-induced dyskinesia similar to 30% but neither dose improved Parkinsonism. CP-101.606 was associated with a dose-related dissociation and amnesia. These results support the hypothesis that glutamate antagonists may be useful antidyskinetic agents. However, future studies will have to determine if the benefits of dyskinesia suppression can be achieved without adverse cognitive effects. (C) 2008 Movement Disorder Society.	[Nutt, John G.; Gunzler, Steven A.; Kirchhoff, Trish; Hogarth, Penelope] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA; [Weaver, Jerry L.; Krams, Michael; Menniti, Frank S.; Landen, Jaren W.] Pfizer Global Res & Dev, Groton, CT USA; [Jamerson, Brenda] Campbell Univ, Sch Pharm, VA Med Ctr, Ctr Geriatr Res Educ & Clin, Morrisville, NC USA; [Jamerson, Brenda] Campbell Univ, Sch Pharm, Dept Clin Res, Morrisville, NC USA		Nutt, JG (corresponding author), Oregon Hlth & Sci Univ, Dept Neurol, OP 32,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	nuttj@ohsu.edu		Menniti, Frank/0000-0003-2612-9534; Gunzler, Steven/0000-0003-2635-9022	Pfizer Global Research and DevelopmentPfizer; Oregon Clinical and Translational Research Institute [UL1-RR024140]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024140] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021062] Funding Source: NIH RePORTER	We thank the subjects for their voluntary participation in a demanding protocol. This project was funded by a grant from Pfizer Global Research and Development and support from the Oregon Clinical and Translational Research Institute, grant UL1-RR024140.	Blanchet PJ, 1999, J PHARMACOL EXP THER, V290, P1034; Bullock MR, 1999, ANN NY ACAD SCI, V890, P51, DOI 10.1111/j.1749-6632.1999.tb07980.x; Calon F, 2003, NEUROBIOL DIS, V14, P404, DOI 10.1016/j.nbd.2003.07.003; Chase TN, 2003, NEUROTOX RES, V5, P139, DOI 10.1007/BF03033378; Chazot P L, 2000, Curr Opin Investig Drugs, V1, P370; CHENARD BL, 1995, J MED CHEM, V38, P3138, DOI 10.1021/jm00016a017; Dunah AW, 2000, MOL PHARMACOL, V57, P342; Gelb DJ, 1999, ARCH NEUROL-CHICAGO, V56, P33, DOI 10.1001/archneur.56.1.33; GIBB WRG, 1988, J NEUROL NEUROSUR PS, V51, P745, DOI 10.1136/jnnp.51.6.745; GREENAMYRE JT, 1994, ANN NEUROL, V35, P655, DOI 10.1002/ana.410350605; HADJ TA, 2004, NEUROBIOL DIS, V15, P171; Hallett PJ, 2005, NEUROPHARMACOLOGY, V48, P503, DOI 10.1016/j.neuropharm.2004.11.008; Hurley MJ, 2005, EUR J NEUROSCI, V21, P3240, DOI 10.1111/j.1460-9568.2005.04169.x; KLOCKGETHER T, 1990, ANN NEUROL, V28, P539, DOI 10.1002/ana.410280411; Loftis JM, 2003, PHARMACOL THERAPEUT, V97, P55, DOI 10.1016/S0163-7258(02)00302-9; Loschmann PA, 2004, EXP NEUROL, V187, P86, DOI 10.1016/j.expneurol.2004.01.018; Meldrum BS, 2000, J NUTR, V130, p1007S, DOI 10.1093/jn/130.4.1007S; Merchant RE, 1999, ANN NY ACAD SCI, V890, P42, DOI 10.1111/j.1749-6632.1999.tb07979.x; Metman LV, 1998, NEUROLOGY, V50, P1323, DOI 10.1212/WNL.50.5.1323; Metman LV, 1997, NEUROLOGY, V49, P711, DOI 10.1212/WNL.49.3.711; Nash JE, 1999, EXP NEUROL, V155, P42, DOI 10.1006/exnr.1998.6963; Nash JE, 2004, EXP NEUROL, V188, P471, DOI 10.1016/j.expneurol.2004.05.004; Nash JE, 2000, EXP NEUROL, V165, P136, DOI 10.1006/exnr.2000.7444; Newcomer JW, 2001, HIPPOCAMPUS, V11, P529, DOI 10.1002/hipo.1069.abs; NUTT JG, 1984, NEW ENGL J MED, V311, P193; NUTT JG, 1984, NEW ENGL J MED, V310, P483, DOI 10.1056/NEJM198402233100802; *PFIZ GLOB RES DEV, 2004, INV BROCH CP 101 606; Steece-Collier K, 2000, EXP NEUROL, V163, P239, DOI 10.1006/exnr.2000.7374; vanHilten JJ, 1997, CLIN NEUROPHARMACOL, V20, P402, DOI 10.1097/00002826-199710000-00004; VANLAAR T, 1993, CLIN NEUROL NEUROSUR, V95, P231, DOI 10.1016/0303-8467(93)90128-4; Wessell RH, 2004, NEUROPHARMACOLOGY, V47, P184, DOI 10.1016/j.neuropharm.2004.03.011; Yurkewicz L, 2005, J NEUROTRAUM, V22, P1428, DOI 10.1089/neu.2005.22.1428	32	107	108	1	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0885-3185	1531-8257		MOVEMENT DISORD	Mov. Disord.	OCT 15	2008	23	13					1860	1866		10.1002/mds.22169			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	368DL	WOS:000260601400010	18759356	Green Accepted			2022-02-06	
J	Garay, L; Deniselle, MCG; Lima, A; Roig, P; De Nicola, AR				Garay, Laura; Gonzalez Deniselle, Maria Claudia; Lima, Analia; Roig, Paulina; De Nicola, Alejandro R.			Effects of progesterone in the spinal cord of a mouse model of multiple sclerosis	JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY			English	Article						EAE; multiple sclerosis; progesterone; myelination; neuroprotection	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MESSENGER-RNA EXPRESSION; TRAUMATIC BRAIN-INJURY; STEROID-HORMONES; DOWN-REGULATION; NITRIC-OXIDE; RAT-BRAIN; PROTEIN; DISEASE	The spinal cord is a target of progesterone (PROG), as demonstrated by the expression of intracellular and membrane PROG receptors and by its myelinating and neuroprotective effects in trauma and neurodegeneration. Here we studied PROG effects in mice with experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis characterized by demyelination and immune cell infiltration in the spinal cord. Female C57BL/6 mice were immunized with a myelin oligodendrocyte glycoprotein peptide (MOG(40-54)). One week before EAE induction, mice received single pellets of PROG weighing either 20 or 100 mg or remained free of steroid treatment. On average, mice developed clinical signs of EAE 9-10 days following MOG administration. The spinal cord white matter of EAE mice showed inflammatory cell infiltration and circumscribed demyelinating areas, demonstrated by reductions of luxol fast blue (LFB) staining, myelin basic protein (MBP) and proteolipid protein (PLP) immunoreactivity (IR) and PLP mRNA expression. In motoneurons, EAE reduced the expression of the alpha 3 subunit of Na,K-ATPase mRNA. In contrast, EAE mice receiving PROG showed less inflammatory cell infiltration, recovery of myelin proteins and normal grain density of neuronal Na,K-ATPase mRNA. Clinically, PROG produced a moderate delay of disease onset and reduced the clinical scores. Thus, PROG attenuated disease severity, and reduced the inflammatory response and the occurrence of demyelination in the spinal cord during the acute phase of EAE. (c) 2007 Elsevier Ltd. All rights reserved.	Inst & Biol Med Exp, Biochem Neuroendocrinol Lab, Buenos Aires, DF, Argentina; Univ Buenos Aires, Fac Med, Dept Human Biochem, Buenos Aires, DF, Argentina; Inst Univ Ciencias & Salud, Fundac Barcelo, Buenos Aires, DF, Argentina		De Nicola, AR (corresponding author), Inst & Biol Med Exp, Obligado 2490, RA-1428 Buenos Aires, DF, Argentina.	denicola@dna.uba.ar					Ayers MM, 2004, NEUROCHEM INT, V45, P409, DOI 10.1016/j.neuint.2003.08.018; Bebo BF, 2001, J IMMUNOL, V166, P2080, DOI 10.4049/jimmunol.166.3.2080; Cowden WB, 1998, J NEUROIMMUNOL, V88, P1, DOI 10.1016/S0165-5728(98)00040-X; Deniselle MCG, 2005, EXP NEUROL, V195, P518, DOI 10.1016/j.expneurol.2005.06.015; Deniselle MCG, 2002, J STEROID BIOCHEM, V83, P199, DOI 10.1016/S0960-0760(02)00262-5; Desarnaud F, 1998, J NEUROCHEM, V71, P1765; Druckmann R, 2005, J STEROID BIOCHEM, V97, P389, DOI 10.1016/j.jsbmb.2005.08.010; El-Etr M, 2005, J NEUROL SCI, V233, P49, DOI 10.1016/j.jns.2005.03.004; ELLIOTT GA, 1973, ACTA NEUROPATHOL, V23, P95, DOI 10.1007/BF00685763; Elloso MM, 2005, J ENDOCRINOL, V185, P243, DOI 10.1677/joe.1.06063; FERRINI M, 1995, LIFE SCI, V57, P2403, DOI 10.1016/0024-3205(95)02236-3; Gago N, 2001, GLIA, V36, P295, DOI 10.1002/glia.1117; GARAY L, 2005, MULT SCLER, V11, P43; Ghoumari AM, 2005, NEUROSCIENCE, V135, P47, DOI 10.1016/j.neuroscience.2005.05.023; Giardino L, 2004, NEUROPATH APPL NEURO, V30, P522, DOI 10.1111/j.1365-2990.2004.00559.x; Gibson CL, 2005, EXP NEUROL, V193, P522, DOI 10.1016/j.expneurol.2005.01.009; Gonzalez S, 1996, NEUROREPORT, V7, P1041, DOI 10.1097/00001756-199604100-00017; Gonzalez-Rey E, 2006, AM J PATHOL, V168, P1179, DOI 10.2353/ajpath.2006.051081; GRILLO C, 1994, BRAIN RES, V657, P83, DOI 10.1016/0006-8993(94)90956-3; Hoffman GE, 2001, EXP NEUROL, V171, P272, DOI 10.1006/exnr.2001.7783; Hughes MD, 2004, NEUROL CLIN, V22, P757, DOI 10.1016/j.ncl.2004.06.004; Ibanez C, 2003, PROG NEUROBIOL, V71, P49, DOI 10.1016/j.pneurobio.2003.09.002; Jones KJ, 1997, NEUROCHEM RES, V22, P1367, DOI 10.1023/A:1022071123255; JUNGTESTAS I, 1992, J STEROID BIOCHEM, V41, P621, DOI 10.1016/0960-0760(92)90394-X; Kim JH, 2006, NEUROBIOL DIS, V21, P626, DOI 10.1016/j.nbd.2005.09.009; Kim S, 1999, NEUROLOGY, V52, P1230, DOI 10.1212/WNL.52.6.1230; Kornek B, 2000, AM J PATHOL, V157, P267, DOI 10.1016/S0002-9440(10)64537-3; Labombarda F, 2006, J NEUROTRAUM, V23, P181, DOI 10.1089/neu.2006.23.181; Labombarda F, 2003, J NEUROCHEM, V87, P902, DOI 10.1046/j.1471-4159.2003.02055.x; Labombarda F, 2002, J NEUROTRAUM, V19, P343, DOI 10.1089/089771502753594918; LEES GJ, 1994, BRAIN RES, V649, P225, DOI 10.1016/0006-8993(94)91068-5; Levine JM, 2001, TRENDS NEUROSCI, V24, P39, DOI 10.1016/S0166-2236(00)01691-X; Li XB, 2006, ARCH IMMUNOL THER EX, V54, P51, DOI 10.1007/s00005-006-0005-3; Liu YR, 2006, FREE RADICAL BIO MED, V40, P960, DOI 10.1016/j.freeradbiomed.2005.07.021; Mason C.M., 1999, VENTURE CAPITAL, V1, DOI [https://doi.org/10.1080/136910699295974, DOI 10.1080/136910699295974]; Mathisen PM, 2001, J NEUROSCI RES, V64, P542, DOI 10.1002/jnr.1106; Melcangi RC, 2000, PROG NEUROBIOL, V60, P291, DOI 10.1016/S0301-0082(99)00028-3; Merrill JE, 1999, NEUROPATH APPL NEURO, V25, P435; Morales LBJ, 2006, J NEUROSCI, V26, P6823, DOI 10.1523/JNEUROSCI.0453-06.2006; Nicot A, 2003, BRAIN, V126, P398, DOI 10.1093/brain/awg041; Offner H, 2000, J CLIN INVEST, V105, P1465, DOI 10.1172/JCI9213; OGATA T, 1993, NEUROSCIENCE, V55, P445, DOI 10.1016/0306-4522(93)90513-F; Onuki I, 2001, MICROSC RES TECHNIQ, V52, P731; Palaszynski KM, 2004, J NEUROIMMUNOL, V149, P84, DOI 10.1016/j.jneuroim.2003.12.015; Palladino MJ, 2003, J NEUROSCI, V23, P1276, DOI 10.1523/JNEUROSCI.23-04-01276.2003; Papadopoulos D, 2006, EXP NEUROL, V197, P373, DOI 10.1016/j.expneurol.2005.10.033; PAXINOS G, 1983, RAT BRAIN STEREOTAXI; Penkowa M, 2003, J NEUROSCI RES, V72, P574, DOI 10.1002/jnr.10615; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; PICCINNI MP, 1995, J IMMUNOL, V155, P128; PRINEAS JW, 1993, ANN NEUROL, V33, P137, DOI 10.1002/ana.410330203; PRUDHOMME GJ, 1993, CLIN IMMUNOL IMMUNOP, V66, P185, DOI 10.1006/clin.1993.1024; RAINE CS, 1993, J NEUROPATH EXP NEUR, V52, P199, DOI 10.1097/00005072-199305000-00003; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Schilling S, 2006, CLIN EXP IMMUNOL, V145, P101, DOI 10.1111/j.1365-2249.2006.03094.x; Schumacher M, 2004, GROWTH HORM IGF RES, V14, pS18, DOI 10.1016/j.ghir.2004.03.007; Sim FJ, 2000, NEUROSCIENCE, V100, P131, DOI 10.1016/S0306-4522(00)00252-9; STAHL WL, 1984, ANN NEUROL, V16, pS121, DOI 10.1002/ana.410160718; Stein DG, 1998, NEUROSCIENTIST, V4, P435, DOI 10.1177/107385849800400615; Sun DM, 2003, INT IMMUNOL, V15, P261, DOI 10.1093/intimm/dxg023; Svensson L, 2002, EUR J IMMUNOL, V32, P1939, DOI 10.1002/1521-4141(200207)32:7<1939::AID-IMMU1939>3.0.CO;2-S; SzekeresBartho J, 1996, J REPROD IMMUNOL, V31, P81, DOI 10.1016/0165-0378(96)00964-3; Thomas AJ, 1999, SPINE, V24, P2134, DOI 10.1097/00007632-199910150-00013; Vizioli N M, 1999, J Capill Electrophor Microchip Technol, V6, P109; Wujek JR, 2002, J NEUROPATH EXP NEUR, V61, P23, DOI 10.1093/jnen/61.1.23	65	107	110	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0960-0760			J STEROID BIOCHEM	J. Steroid Biochem. Mol. Biol.	NOV-DEC	2007	107	3-5					228	237		10.1016/j.jsbmb.2007.03.040			10	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Endocrinology & Metabolism	220UU	WOS:000250183600012	17692515				2022-02-06	
J	Tavazzi, B; Vagnozzi, R; Signoretti, S; Amorini, AM; Belli, A; Cimatti, M; Delfini, R; Di Pietro, V; Finocchiaro, A; Lazzarino, G				Tavazzi, Barbara; Vagnozzi, Roberto; Signoretti, Stefano; Amorini, Angela M.; Belli, Antonio; Cimatti, Marco; Delfini, Roberto; Di Pietro, Valentina; Finocchiaro, Antonino; Lazzarino, Giuseppe			Temporal window of metabolic brain vulnerability to concussions: Oxidative and nitrosative stresses - Part II	NEUROSURGERY			English	Article						brain vulnerability; concussion; multiple concussions; nitrosative stress; oxidative stress; repeat concussions; repeat mild traumatic brain injury	NITRIC-OXIDE SYNTHASE; LIPID-PEROXIDATION; ASCORBIC-ACID; HEAD-INJURY; MITOCHONDRIAL DYSFUNCTION; PROFESSIONAL FOOTBALL; CEREBROSPINAL-FLUID; ENERGY-METABOLISM; MOUSE MODEL; PEROXYNITRITE	OBJECTIVE: In the present study, we investigated the occurrence of oxidative and nitrosative stresses in rats undergoing repeat mild traumatic brain injury (mTBI) delivered with increasing time intervals. METHODS: Rats were subjected to two diffuse mTBIs (450 g/1 m height), with the second mTBI delivered after 1 (n = 6), 2 (n = 6), 3 (n = 6), 4 (n = 6), or 5 days (n = 6). The rats were sacrificed 48 hours after the last mTBI. Sham-operated animals were used as controls (n = 6). Concentrations of biochemical indices of oxidative stress (malondialdehyde, ascorbic acid, reduced and oxidized glutathione) and nitrosative stress (nitrite, nitrate) were synchronously measured by high-performance liquid chromatography in deproteinized tissue extracts (three right + three left hemispheres for each group of animals). RESULTS: Increase of malondialdehyde, reduced/oxidized glutathione ratio, nitrite, nitrate, and decrease of ascorbic acid and glutathione were dependent on the interval between impacts with maximal changes recorded when mTBIs were spaced by 3 days. Biochemical markers of oxidative and nitrosative stresses were near control levels only in animals receiving mTBIs 5 days apart. CONCLUSION: This Study shows the remarkable negative contribution of reactive oxygen species overproduction and activation of inducible nitric oxide synthase in repeat mTBI. Because these effects were maximal when mTBIs were spaced by 3 days, it can be inferred that occurrence of a second mTBI within the temporal window of brain vulnerability not only causes profound derangement of mitochondrial functions, but also induces sustained oxidative and nitrosative stresses. Both phenomena certainly play a major role in the overall brain tissue damage occurring under these pathological conditions.	Univ Catania, Biochem Lab, Dept Chem Sci, I-95125 Catania, Italy; Univ Cattolica Sacro Cuore, Inst Biochem & Clin Biochem, Rome, Italy; Univ Roma Tor Vergata, Dept Neurosci, I-00173 Rome, Italy; San Camillo Hosp, Div Neurosurg, Rome, Italy; Univ Southampton, Div Clin Neurosci, Southampton SO9 5NH, Hants, England; Univ Roma La Sapienza, Dept Neurol Sci Neurosurg, Rome, Italy		Lazzarino, G (corresponding author), Univ Catania, Biochem Lab, Dept Chem Sci, Viale A Doria 6, I-95125 Catania, Italy.	lazzarig@mbox.unict.it	Belli, Antonio/I-3799-2015; TAVAZZI, BARBARA/AAB-9830-2019; Signoretti, stefano/AAL-5631-2020; lazzarino, giuseppe/K-2277-2015	Belli, Antonio/0000-0002-3211-9933; TAVAZZI, BARBARA/0000-0001-8743-0895; Signoretti, stefano/0000-0002-8086-1622; lazzarino, giuseppe/0000-0002-5917-7279; AMORINI, Angela Maria/0000-0003-3525-9955; Di Pietro, Valentina/0000-0001-9430-4723			Angelow S, 2003, BRAIN RES, V988, P105, DOI 10.1016/S0006-8993(03)03350-X; Asplund CA, 2004, CLIN J SPORT MED, V14, P339, DOI 10.1097/00042752-200411000-00003; BARTLETT D, 1995, FREE RADICAL BIO MED, V18, P85, DOI 10.1016/0891-5849(94)E0133-4; Cantu RC, 2003, CLIN SPORT MED, V22, P593, DOI 10.1016/S0278-5919(02)00095-9; Chan TS, 2005, FREE RADICAL BIO MED, V38, P867, DOI 10.1016/j.freeradbiomed.2004.12.006; Cherian L, 2004, BRAIN PATHOL, V14, P195, DOI 10.1111/j.1750-3639.2004.tb00053.x; Cristofori L, 2005, CLIN BIOCHEM, V38, P97, DOI 10.1016/j.clinbiochem.2004.09.013; Cristofori L, 2001, J INVEST MED, V49, P450, DOI 10.2310/6650.2001.33790; Donzelli S, 2006, FREE RADICAL BIO MED, V40, P1056, DOI 10.1016/j.freeradbiomed.2005.10.058; Donzelli S, 2006, ANTIOXID REDOX SIGN, V8, P1363, DOI 10.1089/ars.2006.8.1363; Giza CC, 2001, J ATHL TRAINING, V36, P228; Gordon KE, 2006, PEDIATR NEUROL, V34, P376, DOI 10.1016/j.pediatrneurol.2005.09.007; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hovda DA, 1999, SPORTS-RELATED CONCUSSION, P12; HOVDA DA, 1983, INTRACRANIAL PRESSUR, V8, P469; Kaminski KA, 2002, INT J CARDIOL, V86, P41, DOI 10.1016/S0167-5273(02)00189-4; Kikugawa K, 2004, BIOL PHARM BULL, V27, P17, DOI 10.1248/bpb.27.17; Kirsch M, 2000, J BIOL CHEM, V275, P16702, DOI 10.1074/jbc.M909228199; Kissick J, 2005, CLIN J SPORT MED, V15, P426, DOI 10.1097/01.jsm.0000186683.59158.8b; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Lazzarino G, 2003, ANAL BIOCHEM, V322, P51, DOI 10.1016/j.ab.2003.07.013; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Mendez DR, 2004, J TRAUMA, V56, P1235, DOI 10.1097/01.TA.0000130759.62286.0E; Mun GH, 2006, J NEUROSCI RES, V83, P919, DOI 10.1002/jnr.20751; Nojiri H, 2006, J BIOL CHEM, V281, P33789, DOI 10.1074/jbc.M602118200; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Pratico D, 2002, J NEUROCHEM, V80, P894, DOI 10.1046/j.0022-3042.2002.00777.x; Putukian Margot, 2006, Curr Sports Med Rep, V5, P15; Robertson CL, 2006, DEV NEUROSCI-BASEL, V28, P432, DOI 10.1159/000094169; Sawa T, 2006, NITRIC OXIDE-BIOL CH, V14, P91, DOI 10.1016/j.niox.2005.06.005; Schrammel A, 2003, FREE RADICAL BIO MED, V34, P1078, DOI 10.1016/S0891-5849(03)00038-8; Sharma HS, 2006, ACTA NEUROCHIR SUPPL, V96, P288; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Solaroglu I, 2005, J CLIN NEUROSCI, V12, P273, DOI 10.1016/j.jocn.2004.12.002; Sotiriou S, 2002, NAT MED, V8, P514, DOI 10.1038/nm0502-514; Sullivan PG, 2004, J BIOENERG BIOMEMBR, V36, P353, DOI 10.1023/B:JOBB.0000041767.30992.19; Tavazzi B, 2005, CLIN BIOCHEM, V38, P997, DOI 10.1016/j.clinbiochem.2005.08.002; Tavazzi B, 2005, NEUROSURGERY, V56, P582, DOI 10.1227/01.NEU.0000156715.04900.E6; Vagnozzi R, 2005, NEUROSURGERY, V57, P164, DOI 10.1227/01.NEU.0000163413.90259.85; Vagnozzi R, 1999, J NEUROTRAUM, V16, P903, DOI 10.1089/neu.1999.16.903; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Wilson JX, 2002, J NEUROSURG ANESTH, V14, P66, DOI 10.1097/00008506-200201000-00014; Ziylan YZ, 2006, INT J NEUROSCI, V116, P25, DOI 10.1080/00207450690962262	45	107	107	0	17	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	AUG	2007	61	2					390	395		10.1227/01.NEU.0000255525.34956.3F			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	197AN	WOS:000248525400038	17806141				2022-02-06	
J	Loy, DN; Kim, JH; Xie, M; Schmidt, RE; Trinkaus, K; Song, SK				Loy, David N.; Kim, Joong Hee; Xie, Mingqiang; Schmidt, Robert E.; Trinkaus, Kathryn; Song, Sheng-Kwei			Diffusion tensor Imaging predicts hyperacute spinal cord injury severity	JOURNAL OF NEUROTRAUMA			English	Article						anisotropy; axial diffusion; diffusion tensor imaging; hyperacute; ischemia; magnetic resonance; mouse; radial diffusion; spinal cord injury	WHITE-MATTER TRACTS; IN-VIVO; CONTUSION INJURY; MOUSE; MRI; ISCHEMIA; RECOVERY; BRAIN; AXON; DTI	Experimental strategies that focus on ventral white matter (VWM) preservation during the hyperacute phase hold great potential for our improved understanding of functional recovery following traumatic spinal cord injury (SCI). Critical comparisons of human SCI to rapidly accumulating data derived from rodent models are limited by a basic lack of in vivo measures of subclinical pathophysiologic changes and white matter damage in the spinal cord. Spinal cord edema and intra-parenchymal hemorrhage demonstrated with routine MR sequences have limited value for predicting functional outcomes in SCI animal models and in human patients. We recently demonstrated that in vivo derived diffusion tensor imaging (DTI) parameters are sensitive and specific biomarkers for spinal cord white matter damage. In this study, non-invasive in vivo DTI was utilized to evaluate the white matter of C57BL/6 mice 3 h after mild (0.3 mm), moderate (0.6 mm), or severe (0.9 mm) contusive SCI. In the hyperacute phase, relative anisotropy maps provided excellent gray-white matter contrast in all degrees of injury. In vivo DTI-derived measurements of axial diffusion differentiated between mild, moderate, and severe contusive SCI with good histological correlation. Cross-sectional regional measurements of white matter injury severity between dorsal columns and VWM varied with increasing cord displacement in a pattern consistent with spinal cord viscoelastic properties.	Washington Univ, Dept Radiol, St Louis, MO USA; Washington Univ, Dept Pathol, St Louis, MO USA; Washington Univ, Dept Biostat, St Louis, MO USA		Song, SK (corresponding author), Washington Univ, Sch Med, Biomed Mr Lab, Campus Box 8227,Rm 2313,4525 Scott Ave, St Louis, MO 63110 USA.	ssong@wustl.edu			NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R24-CA83060] Funding Source: Medline; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01-AG10299] Funding Source: Medline; NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01-DK19645] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS047592] Funding Source: Medline; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R24CA083060] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK019645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS047592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG010299] Funding Source: NIH RePORTER		Banik NL, 1997, BRAIN RES, V752, P301, DOI 10.1016/S0006-8993(96)01488-6; Basser PJ, 2002, NMR BIOMED, V15, P456, DOI 10.1002/nbm.783; Bilgen M, 2005, MAGN RESON MED, V54, P1226, DOI 10.1002/mrm.20672; Bilgen M, 2000, MAGN RESON MED, V43, P594; Blight A, 1988, J Am Paraplegia Soc, V11, P26; BLIGHT AR, 1986, NEUROSCIENCE, V19, P321, DOI 10.1016/0306-4522(86)90025-4; Boldin C, 2006, SPINE, V31, P554, DOI 10.1097/01.brs.0000201274.59427.a4; Bonny JM, 2004, NEUROBIOL DIS, V15, P474, DOI 10.1016/j.nbd.2003.11.026; Deo AA, 2006, J NEUROSCI RES, V83, P801, DOI 10.1002/jnr.20783; EDELSTEIN WA, 1984, MED PHYS, V11, P180, DOI 10.1118/1.595484; Gallyas F, 2002, ACTA NEUROPATHOL, V103, P36, DOI 10.1007/s004010100424; Garbow JR, 2004, CONCEPT MAGN RESON B, V21B, P40, DOI 10.1002/cmr.b.20010; Gullapalli J, 2006, J MAGN RESON IMAGING, V24, P231, DOI 10.1002/jmri.20622; Hasan KM, 2006, MAGN RESON MED, V56, P130, DOI 10.1002/mrm.20935; Kim JH, 2006, NEUROBIOL DIS, V21, P626, DOI 10.1016/j.nbd.2005.09.009; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; Ma MH, 2001, EXP NEUROL, V169, P239, DOI 10.1006/exnr.2001.7679; Madi S, 2005, MAGN RESON MED, V53, P118, DOI 10.1002/mrm.20304; Maxwell WL, 1996, MICROSC RES TECHNIQ, V34, P522, DOI 10.1002/(SICI)1097-0029(19960815)34:6<522::AID-JEMT4>3.0.CO;2-L; Schwartz ED, 2003, EXP NEUROL, V184, P570, DOI 10.1016/S0014-4886(03)00295-4; Shepard MJ, 1999, SPINAL CORD, V37, P833, DOI 10.1038/sj.sc.3100927; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Sotak CH, 2002, NMR BIOMED, V15, P561, DOI 10.1002/nbm.786; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; Sun SW, 2003, MAGNET RESON MED, V49, P271, DOI 10.1002/mrm.10362; Sundgren PC, 2004, NEURORADIOLOGY, V46, P339, DOI 10.1007/s00234-003-1114-x; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Thurnher MM, 2006, NEURORADIOLOGY, V48, P795, DOI 10.1007/s00234-006-0130-z; Zhang SX, 2000, J NEUROPATH EXP NEUR, V59, P287, DOI 10.1093/jnen/59.4.287	29	107	114	0	10	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUN	2007	24	6					979	990		10.1089/neu.2006.0253			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	184EA	WOS:000247622700006	17600514	Green Submitted			2022-02-06	
B	Sharma, HS; Ali, SF		Ali, SF; Fornai, F		Sharma, Hari Shanker; Ali, Syed F.			Alterations in blood-brain barrier function by morphine and methamphetamine	CELLULAR AND MOLECULAR MECHANISMS OF DRUGS OF ABUSE AND NEUROTOXICITY: COCAINE, GHB, AND SUBSTITUTED AMPHETAMINES	Annals of the New York Academy of Sciences-Series		English	Article; Proceedings Paper	Satellite Meeting on Cellular and Molecular Mechanisms of Drugs of Abuse and Neurotoxicity - Cocaine, GHB and Substituted Amphetamines	AUG 16-19, 2005	Venice Int Univ, Venice, ITALY	Int Soc Neurochem, Neuromed Pozzilli, FDA, Natl Ctr Toxicol Res	Venice Int Univ	morphine; methamphetamine; rats; mice; stress; blood-brain barrier; brain dysfunction; heat shock protein; glial cells; nerve cells; Evans blue; radioiodine	SEROTONIN SYNTHESIS INHIBITOR; PITUITARY-ADRENAL RESPONSES; SHOCK-PROTEIN RESPONSE; SPINAL-CORD-INJURY; NITRIC-OXIDE; HEAT-STRESS; INDUCED PATHOPHYSIOLOGY; P-CHLOROPHENYLALANINE; TRAUMATIC INJURY; 5-HT LEVEL	The possibility that stress associated with morphine and amphetamine administration or withdrawal will influence the blood-brain barrier (BBB) and brain dysfunction was examined in a rodent model. Repeated daily administration of morphine (10 mg/kg, i.p.) resulted in drug dependence in rats on the sixth-day and onwards. Measurement of the BBB permeability to large molecule tracers normally bound to proteins, e.g., Evans blue albumin and radioiodine (([131])Iodine) did not show any leakage on the 12th day of drug dependence. On the other hand, spontaneous withdrawal of morphine on day 1 resulted in profound stress symptoms. These symptoms were much more intense on the second day of morphine withdrawal. Alterations in the BBB to protein tracers were seen in several regions of the brain. This increase in BBB to protein tracers was most pronounced on the second day of morphine withdrawal. These rats also exhibited abnormal neuronal, glial and stress protein, the heat-shock protein 72 kD (HSP-72 kD) response. On the other hand, acute administration of methamphetamine (40 mg/kg, i.p.) in mice resulted in marked extravasation of endogenous serum protein as seen with increased expression of albumin immunohistochemistry. These observations suggest that psychostimulants and associated stress are capable to influence the brain function, probably through modifying the BBB function, not reported earlier.	Uppsala Univ, Univ Hosp, Dept Surg Sci Anesthesiol & Intens Care Med, Lab Cerebrovasc Res, SE-75185 Uppsala, Sweden; US FDA, Natl Ctr Toxicol Res, Div Neurotoxicol, Neurochem Lab, Jefferson, AR 72079 USA		Sharma, HS (corresponding author), Frodingsgatan 12-28, SE-75421 Uppsala, Sweden.	Sharma@surgsci.uu.se					Ali S F, 1995, Ann N Y Acad Sci, V765, P338, DOI 10.1111/j.1749-6632.1995.tb16610.x; ANDERSSON K, 1993, EUR J PHARM-ENVIRON, V228, P305, DOI 10.1016/0926-6917(93)90065-X; BHARGAVA HN, 1994, PHARMACOL REV, V46, P293; BHATNAGAR S, 1995, PHYSIOL BEHAV, V57, P633, DOI 10.1016/0031-9384(94)00161-8; Bhatnagar S, 1998, NEUROSCIENCE, V84, P1025, DOI 10.1016/S0306-4522(97)00577-0; BUCKINGHAM JC, 1984, NEUROENDOCRINOLOGY, V38, P411, DOI 10.1159/000123927; CHILDRESS AR, 1994, J SUBST ABUSE TREAT, V11, P17, DOI 10.1016/0740-5472(94)90060-4; DALLMAN MJ, 1991, J EXP MED, V173, P79, DOI 10.1084/jem.173.1.79; GIANUTSOS G, 1975, PSYCHOPHARMACOLOGIA, V43, P43, DOI 10.1007/BF00437613; GIANUTSOS G, 1975, METHODS NARCOTIC RES, P293; Himmelsbach CK, 1943, FED P, V2, P201; Houshyar H, 2001, J NEUROENDOCRINOL, V13, P862, DOI 10.1046/j.1365-2826.2001.00713.x; Houshyar H, 2001, J NEUROENDOCRINOL, V13, P875, DOI 10.1046/j.1365-2826.2001.00714.x; Itzhak Y, 2002, ANN NY ACAD SCI, V965, P127; KOSTEN TR, 1986, BIOL PSYCHIAT, V21, P217, DOI 10.1016/0006-3223(86)90150-2; Kristian T, 1998, STROKE, V29, P705, DOI 10.1161/01.STR.29.3.705; MARTI O, 1994, NEUROENDOCRINOLOGY, V60, P1, DOI 10.1159/000126713; Mitchell JM, 2000, NAT NEUROSCI, V3, P47, DOI 10.1038/71120; Nag Sukriti, 2003, Methods Mol Med, V89, P133; ODOHERTY F, 1991, DRUG ALCOHOL DEPEN, V29, P97, DOI 10.1016/0376-8716(91)90026-U; Olsson Y, 1995, PROG BRAIN RES, V104, P381; OLSSON Y, 1990, ACTA NEUROPATHOL, V79, P595, DOI 10.1007/BF00294236; OLSSON Y, 1992, PROG BRAIN RES, V91, P197; Rapoport S. I., 1976, BLOOD BRAIN BARRIER; RAY AK, 1980, ARCH INT PHARMACOD T, V246, P108; SHARMA H S, 1984, Indian Journal of Physiology and Pharmacology, V28, P259; SHARMA H S, 1981, Indian Journal of Physiology and Pharmacology, V25, P111; Sharma H. S., 2004, BLOOD SPINAL CORD BR, P299; Sharma H. S., 2004, BLOOD SPINAL CORD BR, P437; Sharma H. S., 2004, BLOOD SPINAL CORD BR, P231; SHARMA HS, 1995, NEUROSCI RES, V21, P241, DOI 10.1016/0168-0102(94)00855-A; Sharma HS, 2005, ANN NY ACAD SCI, V1053, P422, DOI 10.1196/annals.1344.037; SHARMA HS, 1991, NEUROSCI RES, V10, P211; Sharma HS, 1998, PROG BRAIN RES, V115, P351; Sharma HS, 2005, CURR PHARM DESIGN, V11, P1353, DOI 10.2174/1381612053507837; SHARMA HS, 1986, NEUROPHARMACOLOGY, V25, P161, DOI 10.1016/0028-3908(86)90037-7; Sharma HS, 2003, INT J HYPERTHER, V19, P325, DOI 10.1080/0265673021000054621; Sharma HS, 1998, PROG BRAIN RES, V115, P297; SHARMA HS, 1993, ACTA NEUROPATHOL, V86, P422; SHARMA HS, 1990, NEUROSCIENCE, V36, P725, DOI 10.1016/0306-4522(90)90014-U; Sharma HS, 1996, NEUROSCI RES, V24, P373, DOI 10.1016/0168-0102(95)01015-7; Sharma HS, 1998, NEW FRONTIERS IN STRESS RESEARCH: MODULATION OF BRAIN FUNCTION, P259; SHARMA HS, 1990, ACT NEUR S, V51, P383; SHARMA HS, 1994, ACT NEUR S, V60, P65; SHARMA HS, 1986, J NEUROL SCI, V72, P61, DOI 10.1016/0022-510X(86)90036-5; SHARMA HS, 1992, NEUROSCIENCE, V48, P889, DOI 10.1016/0306-4522(92)90277-9; SHARMA HS, 1987, BRAIN RES, V424, P153, DOI 10.1016/0006-8993(87)91205-4; Sharma HS, 1997, ACT NEUR S, V70, P269; Sharma HS, 1996, BEHAV BRAIN RES, V72, P189; SHARMA HS, 1987, MATH NATURWISSENSCHA, V36, P104; Sharma HS, 1999, ACTA U UPSAL, V830, P1; Sharma HS, 1982, THESIS BANARAS HINDU, P1; SHARMA HS, 2002, ENDOTHELIUM, V8, P302; Song P, 2001, NEUROSCI RES, V39, P281, DOI 10.1016/S0168-0102(00)00226-1; Westman J, 1998, PROG BRAIN RES, V115, P207; Williams JT, 2001, PHYSIOL REV, V81, P299, DOI 10.1152/physrev.2001.81.1.299; YOUNG E, 1985, NEUROPEPTIDES, V5, P545, DOI 10.1016/0143-4179(85)90075-7; Zea-Aragon Z, 2004, J NEUROSCI METH, V138, P89, DOI 10.1016/j.jneumeth.2004.03.018	58	107	107	0	9	WILEY-BLACKWELL	HOBOKEN	111 RIVER STREET, HOBOKEN, NJ, UNITED STATES			1-57331-629-6	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2006	1074						198	224		10.1196/annals.1369.020			27	Cell Biology; Substance Abuse; Multidisciplinary Sciences; Clinical Neurology; Pharmacology & Pharmacy	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Substance Abuse; Science & Technology - Other Topics; Neurosciences & Neurology; Pharmacology & Pharmacy	BFJ04	WOS:000242168100020	17105918				2022-02-06	
J	Statler, KD; Alexander, H; Vagni, V; Dixon, CE; Clark, RSB; Jenkins, L; Kochanek, PM				Statler, KD; Alexander, H; Vagni, V; Dixon, CE; Clark, RSB; Jenkins, L; Kochanek, PM			Comparison of seven anesthetic agents on outcome after experimental traumatic brain injury in adult, male rats	JOURNAL OF NEUROTRAUMA			English	Article						analgesia; benzodiazepine; controlled cortical impact; isoflurane; ketamine; narcotic; propofol; sedation	CEREBRAL-BLOOD-FLOW; PROPOFOL INFUSION; ENDOGENOUS OPIOIDS; NITROUS-OXIDE; ISOFLURANE ANESTHESIA; FOREBRAIN ISCHEMIA; GLOBAL-ISCHEMIA; KETAMINE; FENTANYL; NEUROPROTECTION	Isoflurane is commonly used in experimental traumatic brain injury (TBI), both before and early after injury, yet it is rarely used clinically. Narcotics and benzodiazepines are frequently used after injury in clinical TBI. We compared seven anesthetic/sedative agents applied after injury in the controlled cortical impact model: diazepam, fentanyl, isoflurane, ketamine, morphine, pentobarbital, and propofol. Our objective was to provide insight into the relative degrees of neuroprotection provided by these agents in a standard model of TBI. We hypothesized that the choice of anesthetic/sedative early after experimental TBI critically impacts outcome and that the agents most commonly used clinically may be less neuroprotective than isoflurane. Rats treated with isoflurane had the best cognitive recovery (p < 0.05) and hippocampal neuronal survival (p < 0.05). Conversely, rats treated with ketamine had the most hippocampal neuronal death (p < 0.05). Morphine or propofol, two agents commonly used clinically, were associated with the poorest motor function on post-trauma day 1-5 (p < 0.05). Our data support beneficial effects of isoflurane early after experimental TBI. Our data suggest that the early post-TBI use of isoflurane, despite practical logistical issues, could potentially provide clinical benefits in TBI-versus other commonly used sedatives or analgesics. Furthermore, the choice of post-injury sedation and analgesia could have important implications on attempts to translate novel therapies from bench to field or bedside.	Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA USA; Univ Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA USA; Safar Ctr Resuscitat Res, Pittsburgh, PA USA		Statler, KD (corresponding author), Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15260 USA.	kim.statler@hsc.utah.edu	Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, P01NS030318, P50NS030318] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32-HD40686] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30318] Funding Source: Medline		Bayona NA, 2004, ANESTHESIOLOGY, V100, P1151, DOI 10.1097/00000542-200405000-00017; BICKLER PE, 1994, ANESTHESIOLOGY, V81, P1461, DOI 10.1097/00000542-199412000-00022; Bickler PE, 2003, ANESTH ANALG, V97, P564, DOI 10.1213/01.ANE.0000068880.82739.7B; Brain Trauma Foundation The American Association of Neurological Surgeons, 2000, J NEUROTRAUM, V17, P527; BRAY RJ, 1995, ANAESTHESIA, V50, P94, DOI 10.1111/j.1365-2044.1995.tb04544.x; Cannon ML, 2001, J NEUROSURG, V95, P1053, DOI 10.3171/jns.2001.95.6.1053; CARLSSON C, 1981, ANESTHESIOLOGY, V54, P488, DOI 10.1097/00000542-198106000-00008; Carney Nancy A, 2003, Pediatr Crit Care Med, V4, pS1; CAVAZZUTI M, 1987, J CEREBR BLOOD F MET, V7, P806, DOI 10.1038/jcbfm.1987.138; CORRIGALL WA, 1980, BRAIN RES, V192, P227, DOI 10.1016/0006-8993(80)91022-7; Cremer OL, 2001, LANCET, V357, P117, DOI 10.1016/S0140-6736(00)03547-9; Elsersy H, 2004, ANESTHESIOLOGY, V100, P1160, DOI 10.1097/00000542-200405000-00018; Engelhard K, 2004, ANESTHESIOLOGY, V101, P912, DOI 10.1097/00000542-200410000-00016; Engelhard K, 2003, ANESTH ANALG, V96, P524, DOI 10.1097/00000539-200302000-00041; Ergun R, 2002, NEUROSURG REV, V25, P95, DOI 10.1007/s101430100171; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; FISHBACK AS, 1995, NEUROSURGERY, V37, P969, DOI 10.1227/00006123-199511000-00017; FRENK H, 1983, BRAIN RES REV, V6, P197, DOI 10.1016/0165-0173(83)90039-5; Gelb AW, 2002, ANESTHESIOLOGY, V96, P1183, DOI 10.1097/00000542-200205000-00023; Gilron I, 1999, ANESTH ANALG, V89, P128, DOI 10.1097/00000539-199907000-00022; Grasshoff C, 2002, ANESTH ANALG, V95, P920, DOI 10.1213/01.ANE.0000025705.93185.09; HANSEN TD, 1989, BRIT J ANAESTH, V63, P290, DOI 10.1093/bja/63.3.290; HAYES RL, 1990, J NEUROSURG, V72, P252, DOI 10.3171/jns.1990.72.2.0252; Hendrich KS, 2001, MAGNET RESON MED, V46, P202, DOI 10.1002/mrm.1178; HERNANDEZ MJ, 1978, STROKE, V9, P150, DOI 10.1161/01.STR.9.2.150; Hill GE, 1998, ANESTH ANALG, V87, P1015, DOI 10.1097/00000539-199811000-00006; HOFFMAN WE, 1991, ANESTH ANALG, V73, P753; Jacobi J, 2002, CRIT CARE MED, V30, P119, DOI 10.1097/00003246-200201000-00020; Kang TM, 2002, ANN PHARMACOTHER, V36, P1453; Kawaguchi M, 2004, ANESTH ANALG, V98, P798; Kawaguchi M, 2000, ANESTHESIOLOGY, V92, P1335, DOI 10.1097/00000542-200005000-00023; KISSIN I, 1987, CAN J ANAESTH, V34, P146, DOI 10.1007/BF03015332; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kofke WA, 1996, ANESTH ANALG, V83, P141, DOI 10.1097/00000539-199607000-00025; LARSSON JE, 1994, BRIT J ANAESTH, V73, P692, DOI 10.1093/bja/73.5.692; Lenz C, 1998, ANESTHESIOLOGY, V89, P1480, DOI 10.1097/00000542-199812000-00026; Lingamaneni R, 2003, BRIT J ANAESTH, V90, P199, DOI 10.1093/bja/aeg040; LYETH BG, 1993, BRAIN RES, V617, P69, DOI 10.1016/0006-8993(93)90614-S; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565, DOI 10.1152/ajpendo.1987.253.5.E565; McNamara RK, 1997, PHARMACOL BIOCHEM BE, V56, P383, DOI 10.1016/S0091-3057(96)00237-7; Miura Y, 1999, ANESTH ANALG, V88, P787, DOI 10.1097/00000539-199904000-00020; Miura Y, 1998, ANESTHESIOLOGY, V89, P391, DOI 10.1097/00000542-199808000-00016; MURR R, 1993, ANESTH ANALG, V77, P898; Nagase K, 2003, J NEUROSURG ANESTH, V15, P98, DOI 10.1097/00008506-200304000-00006; Neff SPW, 1997, ANAESTH INTENS CARE, V25, P581; Nemoto E M, 1983, Am J Emerg Med, V1, P175, DOI 10.1016/0735-6757(83)90086-4; Nikolaishvili L S, 2004, Neurosci Behav Physiol, V34, P467, DOI 10.1023/B:NEAB.0000022631.46176.6b; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PATEL PM, 1993, J CEREB BLOOD FLOW M, pS685; Proescholdt M, 2001, BRAIN RES, V904, P245, DOI 10.1016/S0006-8993(01)02465-9; Rudolph U, 2004, NAT REV NEUROSCI, V5, P709, DOI 10.1038/nrn1496; SAFO Y, 1985, ACTA ANAESTH SCAND, V29, P594, DOI 10.1111/j.1399-6576.1985.tb02261.x; SHAPIRA Y, 1993, J CEREBR BLOOD F MET, V13, P962, DOI 10.1038/jcbfm.1993.120; SHAPIRA Y, 1994, STROKE, V25, P1637, DOI 10.1161/01.STR.25.8.1637; SHIU GK, 1983, CRIT CARE MED, V11, P452, DOI 10.1097/00003246-198306000-00013; SHIU GK, 1981, J NEUROCHEM, V37, P1448, DOI 10.1111/j.1471-4159.1981.tb06314.x; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; Soonthon-Brant V, 1999, ANESTH ANALG, V88, P49, DOI 10.1097/00000539-199901000-00010; Statler KD, 2003, BRAIN RES, V994, P37, DOI 10.1016/j.brainres.2003.09.042; Statler KD, 2000, J NEUROTRAUM, V17, P1179, DOI 10.1089/neu.2000.17.1179; Tecoult E, 2000, J NEUROSURG ANESTH, V12, P255, DOI 10.1097/00008506-200007000-00010; TEMPELHOFF R, 1992, J NEUROSURG, V77, P201, DOI 10.3171/jns.1992.77.2.0201; Warner DS, 1996, ANESTHESIOLOGY, V84, P1475, DOI 10.1097/00000542-199606000-00024; WERNER C, 1993, ANESTH ANALG, V76, P971; Yang CCH, 1996, AM J PHYSIOL-HEART C, V270, pH575, DOI 10.1152/ajpheart.1996.270.2.H575	65	107	110	1	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2006	23	1					97	108		10.1089/neu.2006.23.97			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	009GP	WOS:000235100100008	16430376				2022-02-06	
J	Ware, ML; Nemani, VM; Meeker, M; Lee, C; Morabito, DJ; Manley, GT				Ware, ML; Nemani, VM; Meeker, M; Lee, C; Morabito, DJ; Manley, GT			Effects of 23.4% sodium chloride solution in reducing intracranial pressure in patients with traumatic brain injury: A preliminary study	NEUROSURGERY			English	Article						hypertonic saline; intracranial hypertension; traumatic brain injury	HYPERTONIC SALINE RESUSCITATION; SEVERE HEAD-INJURY; HEMORRHAGIC-SHOCK; CEREBRAL EDEMA; BLOOD-FLOW; HYPERTENSION; MANAGEMENT; HYPOTENSION; MANNITOL; DEXTRAN	OBJECTIVE: Mannitol is the standard of care for patients with increased intracranial pressure (ICP), but multiple administrations of mannitol risk renal toxicity and fluid accumulation in the brain parenchyma with consequent worsening of cerebral edema. This preliminary study assessed the safety and efficacy of small-volume injections of 23.4% sodium chloride solution for the treatment of intracranial hypertension in patients with traumatic brain injury who became tolerant to mannitol. METHODS: We retrospectively reviewed the charts of 13 adult patients with traumatic brain injury who received mannitol and 23.49% sodium chloride independently for the treatment of intracranial hypertension at San Francisco General Hospital between January and October 2003. Charts were reviewed to determine ICP, cerebral perfusion pressure, mean arterial pressure, serum sodium values, and serum osmolarity before and after treatment with 23.4% sodium chloride and mannitol. Complications were noted. RESULTS: The mean reductions in ICP after treatment were significant for both mannitol (P < 0.001) and hypertonic saline (P < 0.001); there were no significant differences between reductions in ICP when comparing the two agents (P = 0.174). The ICP reduction observed for hypertonic saline was durable, and its mean duration of effect (96 min) was significantly longer than that of mannitol treatment (59 min) (P = 0.016). No complications were associated with treatment with hypertonic saline. CONCLUSION: This study suggests that 23.4% hypertonic saline is a safe and effective treatment for elevated ICP in patients after traumatic brain injury. These results warrant a rigorous evaluation of its efficacy as compared to mannitol in a prospective randomized controlled trial.	Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94110 USA; Univ Calif San Francisco, Sch Med, San Francisco, CA 94110 USA; Univ Illinois, Sch Med, Chicago, IL USA		Manley, GT (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, 1001 Potrero Ave,Box 0899, San Francisco, CA 94110 USA.	manley@itsa.ucsf.edu	Ware, Marcus/E-4981-2011	Nemani, Venu/0000-0001-8895-7090	ODCDC CDC HHS [R49 CCR903697] Funding Source: Medline		BATTISTELLA FD, 1991, J TRAUMA, V31, P182, DOI 10.1097/00005373-199131020-00005; BERGER S, 1995, NEUROSURGERY, V37, P98, DOI 10.1227/00006123-199507000-00015; BITTERMAN H, 1987, CIRC SHOCK, V21, P271; Caroli M, 2001, SURG NEUROL, V56, P82, DOI 10.1016/S0090-3019(01)00540-7; Chesnut RM, 1998, J TRAUMA, V44, P958, DOI 10.1097/00005373-199806000-00003; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; DEFELIPPE J, 1980, LANCET, V2, P1002; Doyle JA, 2001, J TRAUMA, V50, P367, DOI 10.1097/00005373-200102000-00030; Hartl R, 1997, ACT NEUR S, V70, P126; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; Junger WG, 1997, SHOCK, V8, P235, DOI 10.1097/00024382-199710000-00001; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; KAUFMANN AM, 1992, J NEUROSURG, V77, P584, DOI 10.3171/jns.1992.77.4.0584; Khanna S, 2000, CRIT CARE MED, V28, P1144, DOI 10.1097/00003246-200004000-00038; KREIMEIER U, 1990, CIRC SHOCK, V32, P83; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; MANINGAS PA, 1987, CRIT CARE MED, V15, P1121, DOI 10.1097/00003246-198712000-00009; MAZZONI MC, 1988, AM J PHYSIOL, V255, pH629, DOI 10.1152/ajpheart.1988.255.3.H629; MESSMER K, 1989, RESUSCITATION, V18, pS51, DOI 10.1016/0300-9572(89)90053-1; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; NAKAYAMA S, 1984, CIRC SHOCK, V13, P149; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Peterson B, 2000, CRIT CARE MED, V28, P1136, DOI 10.1097/00003246-200004000-00037; Qureshi AI, 1998, CRIT CARE MED, V26, P440, DOI 10.1097/00003246-199803000-00011; ROBERTSON C, 2004, YOUMANS NEUROLOGICAL, P5103; Schell RM, 1996, J NEUROSURG ANESTH, V8, P178, DOI 10.1097/00008506-199604000-00022; Shackford SR, 1996, CRIT CARE MED, V24, P1933, DOI 10.1097/00003246-199611000-00031; Shackford SR, 1998, J TRAUMA, V44, P50, DOI 10.1097/00005373-199801000-00004; SHACKFORD SR, 1992, CRIT CARE MED, V20, P160; Simma B, 1998, CRIT CARE MED, V26, P1265, DOI 10.1097/00003246-199807000-00032; Soupart A, 1996, CLIN NEPHROL, V46, P149; Suarez JI, 1998, CRIT CARE MED, V26, P1118, DOI 10.1097/00003246-199806000-00038; Taylor G, 1996, J PEDIATR SURG, V31, P65, DOI 10.1016/S0022-3468(96)90321-8; VELASCO IT, 1980, AM J PHYSIOL, V239, pH664, DOI 10.1152/ajpheart.1980.239.5.H664; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; WALD SL, 1993, J TRAUMA, V34, P377, DOI 10.1097/00005373-199303000-00012; WISNER DH, 1990, J TRAUMA, V30, P75, DOI 10.1097/00005373-199001000-00011; WORTHLEY LIG, 1988, J NEUROSURG, V68, P478, DOI 10.3171/jns.1988.68.3.0478; ZORNOW MH, 1990, ACT NEUR S, V51, P324	40	107	110	0	8	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	OCT	2005	57	4					727	735		10.1227/01.NEU.0000175726.08903.OA			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	031CK	WOS:000236681500034	16239885				2022-02-06	
J	Ingebrigtsen, T; Romner, B				Ingebrigtsen, T; Romner, B			Biochemical serum markers for brain damage: A short review with emphasis on clinical utility in mild head injury	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article; Proceedings Paper	International Symposium on Molecular Markers of Brain Damage - Current State and Future Perspectives	JUN 13-15, 2002	BREMEN, GERMANY			head injury; biochemical markers; creatine kinase; neuron specific enolase; S-100B protein; glial fibrillary acidic protein	NEURON-SPECIFIC ENOLASE; S-100 PROTEIN MEASUREMENTS; CREATINE-KINASE-BB; CEREBROSPINAL-FLUID; TRAUMA PATIENTS; OUTCOME PREDICTION; PROGNOSTIC VALUE; S100B LEVELS; ELIMINATION; MANAGEMENT	Purpose. To provide an overview of clinical research on the use of biochemical serum markers for traumatic brain injury (TRI) in the evaluation of patients with mild head injuries (MHI). Methods. The MEDLINE database was searched for publications on biochemical serum markers of TBI until August 2002. Clinical studies addressing their use in MHI were reviewed. Results. Desirable characteristics for biochemical serum markers of TBI were identified. Creatine kinase isoenzyme 1313 (CK-BB), neuron specific enolase (NSE) and S-100B protein have been most extensively studied. The sensitivity and specificity of CK-BB is inadequate for use as an indicator of traumatic brain injury. Serum levels of NSE do not correspond to the amount of TBI, probably because of its long (20 h) half-life. S-100B serum levels are correlated to both clinical measures of injury severity, neuroradiological findings and outcomes in several studies from different authors. Conclusion. Currently, S-100B protein is the most promising marker for evaluation of TBI in patients with MHI.	Univ Hosp N Norway, Dept Neurosurg, N-9038 Tromso, Norway; Univ Lund Hosp, Dept Neurosurg, S-22185 Lund, Sweden		Ingebrigtsen, T (corresponding author), Univ Hosp N Norway, Dept Neurosurg, N-9038 Tromso, Norway.			Ingebrigtsen, Tor/0000-0001-5966-9786			Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; BAKAY RAE, 1986, NEUROSURGERY, V18, P376, DOI 10.1227/00006123-198603000-00026; BAKAY RAE, 1983, J NEUROSURG, V58, P27, DOI 10.3171/jns.1983.58.1.0027; Biberthaler P, 2000, ACT NEUR S, V76, P177; Biberthaler P, 2001, WORLD J SURG, V25, P93, DOI 10.1007/s002680020370; Biberthaler P, 2001, SHOCK, V16, P97, DOI 10.1097/00024382-200116020-00002; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; Ergun R, 1998, NEUROL RES, V20, P418; FRIDRIKSSON T, 2001, ACAD EMERG MED, V7, P404; GRAEBER GM, 1990, CHEST, V97, P521, DOI 10.1378/chest.97.3.521; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Herrmann M, 2001, NEUROSURGERY, V49, P1272, DOI 10.1097/00006123-200111000-00058; Herrmann M, 1999, RESTOR NEUROL NEUROS, V14, P109; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Ingebrigtsen T, 1996, ACTA NEUROL SCAND, V93, P207; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Ingebrigtsen T, 1996, J NEUROSURG, V85, P945, DOI 10.3171/jns.1996.85.5.0945; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; Ingebrigtsen T, 1997, J CLIN NEUROSCI, V4, P29, DOI 10.1016/S0967-5868(97)90007-2; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; Jackson RGM, 2000, CLIN CHEM LAB MED, V38, P1165, DOI 10.1515/CCLM.2000.179; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Johnsson P, 2000, ANN THORAC SURG, V69, P750, DOI 10.1016/S0003-4975(99)01393-4; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; Missler U, 1999, CLIN CHEM, V45, P138; Mussack T, 2000, ACT NEUR S, V76, P393; Nygaard O, 1997, CLIN CHEM, V43, P541; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Raabe A, 2001, NEUROSURGERY, V49, P1491, DOI 10.1097/00006123-200112000-00055; ROGULJIC A, 1989, TUMORI J, V75, P537, DOI 10.1177/030089168907500604; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Romner B, 2001, NEUROSURGERY, V49, P1490, DOI 10.1097/00006123-200112000-00053; Ross SA, 1996, BRIT J NEUROSURG, V10, P471, DOI 10.1080/02688699647104; SKOGSEID IM, 1992, ACTA NEUROCHIR, V115, P106, DOI 10.1007/BF01406367; Townend WJ, 2002, J NEUROL NEUROSUR PS, V73, P542, DOI 10.1136/jnnp.73.5.542; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; Wiesmann M, 1998, CLIN CHEM, V44, P1056; WONG SS, 1987, CLIN CHEM, V33, P809; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6; Ytrebo LM, 2001, SCAND J CLIN LAB INV, V61, P217	43	107	122	0	5	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028			RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2003	21	3-4					171	176					6	Neurosciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	745LV	WOS:000186690900009	14530579				2022-02-06	
J	Deniselle, MCG; Lopez-Costa, JJ; Saavedra, JP; Pietranera, L; Gonzalez, SL; Garay, L; Guennoun, R; Schumacher, M; De Nicola, AF				Deniselle, MCG; Lopez-Costa, JJ; Saavedra, JP; Pietranera, L; Gonzalez, SL; Garay, L; Guennoun, R; Schumacher, M; De Nicola, AF			Progesterone neuroprotection in the Wobbler mouse, a genetic model of spinal cord motor neuron disease	NEUROBIOLOGY OF DISEASE			English	Article						neuroprotection; progesterone; spinal cord; neurodegeneration; Wobbler mice; amyotrophic lateral sclerosis	TRAUMATIC BRAIN-INJURY; MURINE MUTANT WOBBLER; NITRIC-OXIDE SYNTHASE; NERVOUS-SYSTEM; DEGENERATING MOTONEURONS; SUPEROXIDE-DISMUTASE; NADPH-DIAPHORASE; TRANSGENIC MODEL; MESSENGER-RNA; CELL-DEATH	Motor neuron degeneration characterizes the spinal cord of patients with amyotrophic lateral sclerosis and the Wobbler mouse mutant. Considering that progesterone (PROG) provides neuroprotection in experimental ischemia and injury, its potential role in neurodegeneration was studied in the murine model. Two-month-old symptomatic Wobbler mice were left untreated or received sc a 20-mg PROG implant for 15 days. Both light and electron microscopy of Wobbler mice spinal cord showed severely affected motor neurons with profuse cytoplasmic vacuolation of the endoplasmic reticulum and/or Golgi apparatus and ruptured mitochondria with damaged cristae, a profile indicative of a type II cytoplasmic form of cell death. In contrast to untreated mice, neuropathology was less severe in Wobbler mice receiving PROG; including a reduction of vacuolation and of the number of vacuolated cells and better conservation of the mitochondrial ultrastructure. In biochemical studies, we determined the mRNA for the alpha3 subunit of Na,K-ATPase, a neuronal enzyme controlling ion fluxes, neurotransmission, membrane potential, and nutrient uptake. In untreated Wobbler mice, mRNA levels in motor neurons were reduced by half compared to controls, whereas PROG treatment of Wobbler mice restored the expression of a3 subunit Na,K-ATPase mRNA. Therefore, PROG was able to rescue motor neurons from degeneration, based on recovery of histopathological abnormalities and of mRNA levels of the sodium pump. However, because the gene mutation in Wobbler mice is still unknown, further studies are needed to unveil the action of PROG and the mechanism of neuronal death in this genetic model of neurodegeneration. (C) 2003 Elsevier Science (USA).	Inst Biol & Med Expt, RA-1428 Buenos Aires, DF, Argentina; Univ Buenos Aires, Fac Med, Dept Bioquim Humana, RA-1428 Buenos Aires, DF, Argentina; Univ Buenos Aires, Fac Med, Inst Biol Celular & Neurociencias Prof E De Rober, RA-1121 Buenos Aires, DF, Argentina; INSERM, U488, Le Kremlin Bicetre, France		De Nicola, AF (corresponding author), Inst Biol & Med Expt, Obligado 2490, RA-1428 Buenos Aires, DF, Argentina.	denicola@dna.uba.ar	Schumacher, Michael/G-3581-2013; Guennoun, Rachida/F-2420-2011	Schumacher, Michael/0000-0001-6117-5371; Guennoun, Rachida/0000-0002-9219-7300			Abe K, 1997, J NEUROSCI RES, V48, P63; Azcoitia I, 1999, J NEUROCYTOL, V28, P699, DOI 10.1023/A:1007025219044; BAULAC M, 1983, NEUROSCI LETT, V37, P99, DOI 10.1016/0304-3940(83)90511-6; Blondet B, 2001, NEUROSCI LETT, V305, P202, DOI 10.1016/S0304-3940(01)01741-4; Boillee S, 2001, GLIA, V33, P277, DOI 10.1002/1098-1136(20010315)33:4<277::AID-GLIA1026>3.3.CO;2-P; Boillee S, 2002, NEUROSCIENCE, V113, P825, DOI 10.1016/S0306-4522(02)00235-X; Brinton RD, 2001, LEARN MEMORY, V8, P121, DOI 10.1101/lm.39601; Chen JL, 1999, J NEUROL SCI, V171, P24, DOI 10.1016/S0022-510X(99)00247-6; CHUWANG IW, 1978, J COMP NEUROL, V177, P33, DOI 10.1002/cne.901770105; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; Clowry GJ, 1996, NEUROSCI LETT, V215, P177, DOI 10.1016/S0304-3940(96)12971-2; Coulpier M, 1996, J NEUROSCI, V16, P5897; CUDKOWICZ ME, 1998, PRINCIPLES MOL MED, P907; DENICOLA AF, 1993, ADV NEUROL, V59, P199; Deniselle MCG, 1999, BRAIN RES, V841, P78, DOI 10.1016/S0006-8993(99)01783-7; Deniselle MCG, 2001, CELL MOL NEUROBIOL, V21, P237, DOI 10.1023/A:1010943104315; Deniselle MCG, 1999, NEUROCHEM RES, V24, P1, DOI 10.1023/A:1020918310281; Desarnaud F, 1998, J NEUROCHEM, V71, P1765; DESPORTES V, 1994, NEUROREPORT, V5, P1861, DOI 10.1097/00001756-199410000-00005; Dikranian K, 2001, NEUROBIOL DIS, V8, P359, DOI 10.1006/nbdi.2001.0411; Dockery P, 1997, J ANAT, V191, P89, DOI 10.1046/j.1469-7580.1997.19110089.x; DUCHEN LW, 1968, J NEUROL NEUROSUR PS, V31, P535, DOI 10.1136/jnnp.31.6.535; FONNUM F, 1975, J NEUROCHEM, V24, P407, DOI 10.1111/j.1471-4159.1975.tb11895.x; Gonzalez S, 1996, NEUROREPORT, V7, P1041, DOI 10.1097/00001756-199604100-00017; GUANGPING X, 2001, NEUROSCI LETT, V300, P141; Gurney ME, 1996, ANN NEUROL, V39, P147, DOI 10.1002/ana.410390203; Gurney ME, 2000, BIOESSAYS, V22, P297, DOI 10.1002/(SICI)1521-1878(200003)22:3<297::AID-BIES12>3.0.CO;2-I; Hall ED, 1998, J NEUROSCI RES, V53, P66, DOI 10.1002/(SICI)1097-4547(19980701)53:1<66::AID-JNR7>3.0.CO;2-H; HALL ED, 1982, J NEUROSURG, V49, P563; Henderson JT, 1996, J NEUROSCI, V16, P7574; Henderson VW, 1997, NEUROLOGY, V48, pS27, DOI 10.1212/WNL.48.5_Suppl_7.27S; Ikeda K, 1998, J NEUROL SCI, V160, P9, DOI 10.1016/S0022-510X(98)00224-X; Ikeda K, 2000, BRAIN RES, V858, P84, DOI 10.1016/S0006-8993(99)02427-0; IKEDA K, 1995, J NEUROSCI RES, V48, P63; JUNIER MP, 1994, J NEUROSCI, V14, P4206; Junier MP, 1998, MOL CELL NEUROSCI, V12, P168, DOI 10.1006/mcne.1998.0708; KAUPMANN K, 1992, GENOMICS, V13, P39, DOI 10.1016/0888-7543(92)90199-3; KOENIG HL, 1995, SCIENCE, V268, P1500, DOI 10.1126/science.7770777; Kong JM, 1998, J NEUROSCI, V18, P3241; KRIEGER C, 1992, CAN J NEUROL SCI, V19, P462, DOI 10.1017/S0317167100041652; Labombarda F, 2002, J NEUROTRAUM, V19, P343, DOI 10.1089/089771502753594918; Labombarda F, 2000, NEUROSCI LETT, V288, P29, DOI 10.1016/S0304-3940(00)01191-5; Labombarda F, 2000, J STEROID BIOCHEM, V73, P159, DOI 10.1016/S0960-0760(00)00064-9; LEES GJ, 1991, BRAIN RES REV, V16, P283, DOI 10.1016/0165-0173(91)90011-V; Li MW, 2000, SCIENCE, V288, P335, DOI 10.1126/science.288.5464.335; Liere P, 2000, J CHROMATOGR B, V739, P301, DOI 10.1016/S0378-4347(99)00563-0; Mattson MP, 1998, TRENDS NEUROSCI, V21, P53, DOI 10.1016/S0166-2236(97)01188-0; McEwen BS, 1999, J CLIN ENDOCR METAB, V84, P1790, DOI 10.1210/jc.84.6.1790; MEIRI H, 1986, BRAIN RES, V385, P193, DOI 10.1016/0006-8993(86)91566-0; Migheli A, 1999, NAT MED, V5, P966, DOI 10.1038/12381; MITSUMOTO H, 1982, BRAIN, V105, P811, DOI 10.1093/brain/105.4.811; Morrison BM, 1998, J COMP NEUROL, V391, P64, DOI 10.1002/(SICI)1096-9861(19980202)391:1<64::AID-CNE6>3.0.CO;2-P; Mourelatos Z, 1996, P NATL ACAD SCI USA, V93, P5472, DOI 10.1073/pnas.93.11.5472; Murphy SJ, 2000, STROKE, V31, P1173, DOI 10.1161/01.STR.31.5.1173; OGATA T, 1993, NEUROSCIENCE, V55, P445, DOI 10.1016/0306-4522(93)90513-F; Pernas-Alonso R, 2001, NEUROBIOL DIS, V8, P581, DOI 10.1006/nbdi.2001.0403; POLLIN MM, 1990, J NEUROCYTOL, V19, P29, DOI 10.1007/BF01188437; Popper P, 1997, EXP NEUROL, V143, P246, DOI 10.1006/exnr.1996.6364; Price D L, 1994, Neurobiol Dis, V1, P3, DOI 10.1006/nbdi.1994.0002; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; RUPPRECHT R, 1993, NEURON, V11, P523, DOI 10.1016/0896-6273(93)90156-L; Schumacher M, 2000, J NEUROCYTOL, V29, P307, DOI 10.1023/A:1007152904926; Spooren WPJM, 2000, CELL MOL BIOL, V46, P63; STAHL WL, 1986, NEUROCHEM INT, V8, P449, DOI 10.1016/0197-0186(86)90179-8; Stein DG, 1998, NEUROSCIENTIST, V4, P435, DOI 10.1177/107385849800400615; Thomas AJ, 1999, SPINE, V24, P2134, DOI 10.1097/00007632-199910150-00013; Toran-Allerand C D, 2000, Novartis Found Symp, V230, P56, DOI 10.1002/0470870818.ch6; Tsuzaka K, 2001, MUSCLE NERVE, V24, P474, DOI 10.1002/mus.1029; Vongher JM, 1999, PHARMACOL BIOCHEM BE, V64, P777, DOI 10.1016/S0091-3057(99)00140-9; WONG PC, 1995, SCIENCE, V271, P515; YU WHA, 1989, BRAIN RES, V491, P379, DOI 10.1016/0006-8993(89)90075-9; YUNG KKL, 1992, NEUROSCIENCE, V50, P209, DOI 10.1016/0306-4522(92)90393-G	74	107	108	0	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	DEC	2002	11	3					457	468		10.1006/nbdi.2002.0564			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	643NC	WOS:000180866500009	12586554				2022-02-06	
J	Sullivan, PG; Keller, JN; Bussen, WL; Scheff, SW				Sullivan, PG; Keller, JN; Bussen, WL; Scheff, SW			Cytochrome c release and caspase activation after traumatic brain injury	BRAIN RESEARCH			English	Article						apoptosis; brain injury; cortical impact; mitochondria; neurotrauma; oncosis	CORTICAL IMPACT INJURY; SPINAL-CORD INJURY; FOCAL CEREBRAL-ISCHEMIA; EXCITATORY AMINO-ACIDS; PROGRAMMED CELL-DEATH; MITOCHONDRIAL DYSFUNCTION; CYCLOSPORINE-A; NEURONAL APOPTOSIS; DNA FRAGMENTATION; NERVOUS-SYSTEM	Experimental traumatic brain injury (TBI) results in a rapid and significant necrosis of cortical tissue at the site of injury. In the ensuing hours and days, secondary injury exacerbates the primary damage resulting in significant neurological dysfunction. The identification of cell death pathways that mediate this secondary traumatic injury have not been elucidated, however recent studies have implicated a role for apoptosis in the neuropathology of traumatic brain injury. The present study utilized a controlled cortical impact model of brain injury to assess the involvement of apoptotic pathways: release of cytochrome c from mitochondria and the activation of caspase-1- and caspase-3-like proteases in the injured cortex at 6, 12 and 24 h post-injury. Collectively, these results demonstrate cytochrome c release from mitochondria and its redistribution into the cytosol occurs in a time-dependent manner following TBI. The release of cytochrome c is accompanied by a time-dependent increase in caspase-3-like protease activity with no apparent increase in caspase-l-like activity. However, pretreatment with a general caspase inhibitor had no significant effect on the amount of cortical damage observed at 7 days post-injury. Our data suggest that several pro-apoptotic events occur following TBI, however the translocation of cytochrome c itself and/or other events upstream of caspase activation/inhibition may be sufficient to induce neuronal cell death. (C) 2002 Published by Elsevier Science B.V.	Univ Kentucky, Sanders Brown Ctr Aging 229, Lexington, KY 40536 USA; Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA		Scheff, SW (corresponding author), Univ Kentucky, Sanders Brown Ctr Aging 229, Lexington, KY 40536 USA.	sscheff@pop.uky.edu	Keller, Jeffrey N/N-1975-2017	keller, jeffrey/0000-0002-9892-7423	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039828] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS39828] Funding Source: Medline		ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Baldwin SA, 1996, GLIA, V16, P266; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Bernardi P, 1996, BBA-BIOENERGETICS, V1275, P5, DOI 10.1016/0005-2728(96)00041-2; BRAUGHLER JM, 1992, J NEUROTRAUM, V9, pS1; Brent K. J., 1998, FRAC MONOGRAPH, V2, P1; Buki A, 2000, J NEUROSCI, V20, P2825; CADOUXHUDSON TAD, 1990, ACTA NEUROCHIR, V104, P1, DOI 10.1007/BF01842884; Cheng Y, 1998, J CLIN INVEST, V101, P1992, DOI 10.1172/JCI2169; Choi D W, 1990, Adv Exp Med Biol, V268, P501; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1997, J NEUROSCI, V17, P9172; Clark RSB, 1999, FASEB J, V13, P813, DOI 10.1096/fasebj.13.8.813; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Conti AC, 1998, J NEUROSCI, V18, P5663; COOPER PR, 1985, CENTRAL NERVOUS SYST, P217; Dong GX, 2001, BRAIN RES, V903, P45, DOI 10.1016/S0006-8993(01)02379-4; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Emery E, 1998, J NEUROSURG, V89, P911, DOI 10.3171/jns.1998.89.6.0911; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fan L, 1999, J NEUROTRAUM, V16, P357, DOI 10.1089/neu.1999.16.357; Fujimura M, 1998, J CEREBR BLOOD F MET, V18, P1239, DOI 10.1097/00004647-199811000-00010; Fujimura M, 1999, J NEUROSCI, V19, P3414; HALL ED, 1993, RES P ARNMD, V71, P81; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; Keller JN, 1998, J NEUROSCI, V18, P687; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Krajewski S, 1999, P NATL ACAD SCI USA, V96, P5752, DOI 10.1073/pnas.96.10.5752; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; LaPlaca MC, 1999, J NEUROCHEM, V73, P205, DOI 10.1046/j.1471-4159.1999.0730205.x; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P914, DOI 10.1097/00004647-200108000-00003; LI Y, 1995, J CEREBR BLOOD F MET, V15, P389, DOI 10.1038/jcbfm.1995.49; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luetjens CM, 2000, J NEUROSCI, V20, P5715; Mattson MP, 1998, EXP NEUROL, V153, P35, DOI 10.1006/exnr.1998.6863; McNair ND, 1999, NURS CLIN N AM, V34, P637; MICHEL RP, 1988, J MICROSC-OXFORD, V150, P117, DOI 10.1111/j.1365-2818.1988.tb04603.x; Morita-Fujimura Y, 1999, NEUROSCI LETT, V267, P201, DOI 10.1016/S0304-3940(99)00327-4; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Nicholls DG, 1998, BBA-BIOENERGETICS, V1366, P97, DOI 10.1016/S0005-2728(98)00123-6; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.neuro.14.1.453; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; Pravdenkova SV, 1996, BRAIN RES, V729, P151, DOI 10.1016/S0006-8993(96)00222-3; PROCTOR HJ, 1988, J TRAUMA, V28, P347, DOI 10.1097/00005373-198803000-00010; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Richter C, 1997, BIOSCIENCE REP, V17, P53, DOI 10.1023/A:1027387301845; RINK A, 1995, AM J PATHOL, V147, P1575; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; Springer JE, 2000, J NEUROSCI, V20, P7246; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Sullivan PG, 2000, ANN NEUROL, V48, P723, DOI 10.1002/1531-8249(200011)48:5&lt;723::AID-ANA5&gt;3.0.CO;2-W; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Tibbs RE, 1998, ANAT REC, V253, P167; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Ye X, 2001, BIOCHEM BIOPH RES CO, V286, P401, DOI 10.1006/bbrc.2001.5396; Zamzami N, 1997, J BIOENERG BIOMEMBR, V29, P185, DOI 10.1023/A:1022694131572	76	107	108	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	SEP 13	2002	949	1-2					88	96	PII S0006-8993(02)02968-2	10.1016/S0006-8993(02)02968-2			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	599CQ	WOS:000178316900010	12213303				2022-02-06	
J	Kinoshita, K; Chatzipanteli, K; Vitarbo, E; Truettner, JS; Alonso, OF; Dietrich, WD				Kinoshita, K; Chatzipanteli, K; Vitarbo, E; Truettner, JS; Alonso, OF; Dietrich, WD			Interleukin-1 beta messenger ribonucleic acid and protein levels after fluid-percussion brain injury in rats: Importance of injury severity and brain temperature	NEUROSURGERY			English	Article						hyperthermia; hypothermia; inflammation and secondary injury; interleukin-1 beta; traumatic brain injury	TUMOR-NECROSIS-FACTOR; RECEPTOR ANTAGONIST; ADHESION MOLECULES; FACTOR-ALPHA; POLYMORPHONUCLEAR LEUKOCYTES; SUBARACHNOID HEMORRHAGE; MODERATE HYPOTHERMIA; PERMEABILITY CHANGES; CEREBROSPINAL-FLUID; TNF-ALPHA	OBJECTIVE: Posttraumatic temperature. manipulations have been reported to significantly influence the inflammatory traumatic brain injury (TBI). The purpose of this study was to determine the temporal and regional profiles of messenger ribonucleic acid (mRNA) expression-and protein levels for the proinflammatory cytokine interleukin-1beta (IL-1beta), after moderate or severe TBI. The effects of posttraumatic hypothermia (33degreesC) or hyperthermia (39.5degreesC) on these consequences of TBI were then determined. METHODS: Male Sprague-Dawley rat underwent fluid-percussion brain injury. In the first,phase of the study, rats were killed 15 minutes or 1, 3, or 24 hours after moderate TBI (1.8-2.2 atmospheres), for reverse transcription-polymerase chain reaction analysis. other groups of rats were killed 1, 3, 24, or 72 hours after moderate, or severe TB,l (2.4-27 atmospheres), for protein analysis. In the second phase, rats underwent moderate fluid-percussion brain injury, followed immediately by 3 hours of posttraumatic normothermia (37degreesC), hyperthermia (39.5degreesC), or hypothermia (33degreesC), and were then killed, for analyses of protein levels and mRNA expression. Brain samples, including cerebral cortex,, hippocampus, thalamus, and cerebellum, were dissected. and stored at -80degreesC until analyzed. RESULTS: The findings indicated that mRNA levels were increased (P<0.05) as early as 1 hour after TBI and remained elevated up to 3 hours after moderate TBI. Although I both, moderate and severe TBI induced increased levels of IL-1 beta (P < 0.05), increased protein levels were also noted in remote brain structures after severe TBI. Posttraumatic hypothermia attenuated IL-1beta protein levels, compared with hormothermia (P< 0.05), although the levels remained elevated in comparison with sham values. In contrast, hyperthermia had no significant effect on, IL-1 beta levels, compared with normothermic values. Posttraumatic temperature manipulations had no significant effect on IL-1 beta mRNA levels. CONCLUSION: Injury severity determines the degree of IL-1 beta protein level elevation after TBI. The effects of posttraumatic hypothermia on IL-1 beta protein levels (an important mediator of neurodegeneration after TBI) may partly explain the established effects of posttraumatic temperature manipulations on inflammatory processes after TBI.	Univ Miami, Sch Med, Lois Pope LIFE Ctr,Dept Neurol Surg, Miami Project Cure Paralysis R48,Neurotrauma Res, Miami, FL 33136 USA		Dietrich, WD (corresponding author), Univ Miami, Sch Med, Lois Pope LIFE Ctr,Dept Neurol Surg, Miami Project Cure Paralysis R48,Neurotrauma Res, 2nd Floor,1095 NW 14 Terrace, Miami, FL 33136 USA.	ddietrich@miami.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32-NS07459-01, NS42133-01, 5P50-NS30291-11] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042133, P50NS030291, T32NS007459] Funding Source: NIH RePORTER		ALBELDA SM, 1994, FASEB J, V8, P504, DOI 10.1096/fasebj.8.8.8181668; BANDTLOW CE, 1990, J CELL BIOL, V111, P1701, DOI 10.1083/jcb.111.4.1701; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.immunol.11.1.767; BEVILACQUA MP, 1985, J CLIN INVEST, V76, P2003, DOI 10.1172/JCI112200; Blasi F, 1999, BIOL CHEM, V380, P259, DOI 10.1515/BC.1999.034; Boutin H, 2001, J NEUROSCI, V21, P5528, DOI 10.1523/JNEUROSCI.21-15-05528.2001; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; CHAN PH, 1984, NEUROLOGY, V34, P315, DOI 10.1212/WNL.34.3.315; Chao CC, 1998, BIOCHEM PHARMACOL, V56, P397, DOI 10.1016/S0006-2952(98)00161-0; Chatzipanteli K, 1999, J NEUROCHEM, V72, P2047, DOI 10.1046/j.1471-4159.1999.0722047.x; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; DeKosky ST, 1996, ANN NEUROL, V39, P123, DOI 10.1002/ana.410390118; DESIMONI MG, 1993, AM J PHYSIOL, V265, pR739, DOI 10.1152/ajpregu.1993.265.4.R739; DESIMONI MG, 1990, J EXP MED, V171, P1773, DOI 10.1084/jem.171.5.1773; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DOCZI T, 1986, NEUROSURGERY, V18, P733, DOI 10.1227/00006123-198606000-00010; FAN L, 1995, MOL BRAIN RES, V30, P125; Fassbender K, 2000, NEUROSCI LETT, V284, P135, DOI 10.1016/S0304-3940(00)00977-0; Friedlander RM, 1996, J EXP MED, V184, P717, DOI 10.1084/jem.184.2.717; GERMANO A, 1992, NEUROSURGERY, V30, P882, DOI 10.1227/00006123-199206000-00011; GIULIAN D, 1988, J NEUROSCI, V8, P2485; GORDON CR, 1990, ACT NEUR S, V51, P268; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; Hays SJ, 1998, CURR PHARM DESIGN, V4, P335; Hirschberg DL, 1998, J NEUROIMMUNOL, V89, P88, DOI 10.1016/S0165-5728(98)00118-0; Holmin S, 2000, J NEUROSURG, V92, P108, DOI 10.3171/jns.2000.92.1.0108; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; JOHANSEN KS, 1983, ACTA PATH MICRO IM C, V91, P355; Kataoka K, 1998, NEUROSCI RES, V32, P103, DOI 10.1016/S0168-0102(98)00076-5; Keeling KL, 2000, J NEUROIMMUNOL, V105, P20, DOI 10.1016/S0165-5728(00)00183-1; Knoblach SM, 2000, NEUROSCI LETT, V289, P5, DOI 10.1016/S0304-3940(00)01263-5; LECHAN RM, 1990, BRAIN RES, V514, P135, DOI 10.1016/0006-8993(90)90445-H; LIU LX, 1993, INFECT MED, V10, P24; MAIMONE D, 1993, J NEUROIMMUNOL, V47, P73, DOI 10.1016/0165-5728(93)90286-8; Mantovani A, 1997, IMMUNOL TODAY, V18, P231, DOI 10.1016/S0167-5699(97)81662-3; Mautes AEM, 1996, NEUROSCI LETT, V214, P95, DOI 10.1016/0304-3940(96)12916-5; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; McIntosh TK, 1996, LAB INVEST, V74, P315; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; NORRIS JG, 1994, J IMMUNOL, V152, P841; Pearson VL, 1999, GLIA, V25, P311, DOI 10.1002/(SICI)1098-1136(19990215)25:4<311::AID-GLIA1>3.3.CO;2-5; QUAGLIARELLO VJ, 1991, J CLIN INVEST, V87, P1360, DOI 10.1172/JCI115140; Romero LI, 1996, AM J PHYSIOL-REG I, V270, pR518, DOI 10.1152/ajpregu.1996.270.3.R518; Rothwell NJ, 2000, TRENDS NEUROSCI, V23, P618, DOI 10.1016/S0166-2236(00)01661-1; Rothwell NJ, 1999, J PHYSIOL-LONDON, V514, P3, DOI 10.1111/j.1469-7793.1999.003af.x; Royo NC, 1999, NEUROREPORT, V10, P1363, DOI 10.1097/00001756-199904260-00038; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Si QS, 1997, NEUROSCIENCE, V81, P223, DOI 10.1016/S0306-4522(97)00172-3; Soares HD, 1995, J NEUROSCI, V15, P8223; Sutcliffe IT, 2001, J CEREBR BLOOD F MET, V21, P1310, DOI 10.1097/00004647-200111000-00007; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TONNESEN MG, 1988, MOL CELLULAR BIOL WO, P149; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; UTOH J, 1992, ARTIF ORGANS, V16, P377; Vitkovic L, 2000, MOL PSYCHIATR, V5, P604, DOI 10.1038/sj.mp.4000813; Wang CX, 1997, BRAIN RES, V759, P190, DOI 10.1016/S0006-8993(97)00254-0; Whalen MJ, 1997, ACT NEUR S, V70, P260; Whalen MJ, 1999, J NEUROTRAUM, V16, P583, DOI 10.1089/neu.1999.16.583; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YAMASAKI Y, 1995, STROKE, V26, P676, DOI 10.1161/01.STR.26.4.676; YAMASAKI Y, 1994, ACTA NEUROCHIR, P300; YAN HQ, 1992, EUR J IMMUNOL, V22, P2963, DOI 10.1002/eji.1830221131; Yang GY, 1997, BRAIN RES, V751, P181, DOI 10.1016/S0006-8993(96)01277-2; ZILLES KJL, 1985, CORTEX BRAIN STEREOT	77	107	111	0	5	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JUL	2002	51	1					195	203		10.1097/00006123-200207000-00027			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	569PU	WOS:000176611700041	12182417				2022-02-06	
J	McIntosh, AS; McCrory, P; Comerford, J				McIntosh, AS; McCrory, P; Comerford, J			The dynamics of concussive head impacts in rugby and Australian rules football	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						biomechanics; head injury		A study was commenced in 1998 at the University of New South Wales (UNSW) to investigate the dynamics of head impacts in football which resulted in concussion. Sixty-eight cases of medically verified concussion from Australian Rules Football and 32 from Rugby Union and Rugby League were analyzed. Video of each injury event was analyzed to obtain descriptive data regarding the head impact site and striking object. The video was analyzed quantitatively to obtain estimates of the closing speeds. A secondary analysis was undertaken using the conservation of momentum and energy relationships to estimate the change in velocity of the head during the impact, the change in momentum of the head, and the energy imparted to the head. Ninety-seven cases involved direct head contact, whereas three cases involved impulsive loading via the trunk. The majority of impacts were to the tempero-parietal region, and the striking body segment was commonly the ann or shoulder/thorax. The mean change in velocity of the head and head impact energy for all 97 cases of direct head impact were 4 m.s(-1) and 56 J, respectively. Head impact energy can be used as a performance criteria for testing and developing headgear for rugby and Australian rules football.	Univ New S Wales, Sch Safety Sci, Sydney, NSW 2052, Australia; Univ Melbourne, Dept Neurol, Austin & Repatriat Med Ctr, Heidelberg, Vic 3084, Australia		McIntosh, AS (corresponding author), Univ New S Wales, Sch Safety Sci, Sydney, NSW 2052, Australia.		McCrory, Paul/Q-8688-2019				*AUSTR NAT HLTH ME, 1994, FOOTB INJ HEAD NECK, P78; ENOUEN S, 1986, P 37 STAPP CAR CRASH, P199; McCrory P, 1998, SPORTS NEUROLOGY, P441; McIntosh A. S., 1992, P 1992 INT C BIOM IM, P51; MCINTOSH AS, 1993, P 37 STAPP CAR CRASH, P43; SEWARD H, 1993, MED J AUSTRALIA, V159, P298, DOI 10.5694/j.1326-5377.1993.tb137863.x; SEWARD H, 1986, 3 YEAR SURVEY VICTOR, P11; WINTER DA, 1990, BIOMECHANICS MOTOR C, P56	8	107	108	0	19	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0195-9131			MED SCI SPORT EXER	Med. Sci. Sports Exerc.	DEC	2000	32	12					1980	1984		10.1097/00005768-200012000-00002			5	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	380BG	WOS:000165678000002	11128839				2022-02-06	
J	Stone, JR; Singleton, RH; Povlishock, JT				Stone, JR; Singleton, RH; Povlishock, JT			Antibodies to the C-terminus of the beta-amyloid precursor protein (APP): a site specific marker for the detection of traumatic axonal injury	BRAIN RESEARCH			English	Article						traumatic axonal injury; traumatic brain injury; amyloid precursor protein C-terminus; axoplasmic transport; ultrastructure; rat	CLOSED-HEAD INJURY; MICROWAVE ANTIGEN RETRIEVAL; EXCITATORY AMINO-ACIDS; HEPARIN-BINDING DOMAIN; DIFFUSE BRAIN INJURY; ALZHEIMERS-DISEASE; TISSUE-SECTIONS; CYCLOSPORINE-A; RAT-BRAIN; POSTTRAUMATIC HYPOTHERMIA	Antibodies to the amyloid precursor protein (APP) are commonly used to detect traumatic axonal injury (TBI). Carried by fast anterograde axoplasmic transport, APP will pool at regions of impaired transport associated with TAI. Based primarily upon commercial antibody availability, previous studies have targeted the N-terminus of APP, which, with respect to antigen detection, is suboptimally located within anterogradely transported vesicles. Recently, antibodies to the APP C-terminus, located on the external surface of anterogradely transported vesicles, have become available, allowing for the exploration of their utility in detecting TAI. To this end, rats were subjected to an impact acceleration injury, surviving 30 min to 24 h post-injury. They were then perfused, their brains sectioned and prepared for dual label immunofluorescent microscopy, single label bright field microscopy, and electron microscopy (EM). antibodies to the APP C-terminus yielded the ready detection of intensely labeled TAI with significantly reduced diffuse background staining in comparison to antibodies to the APP N-terminus in both dual label immunofluorescent and single label bright-field approaches. EM examination of antibodies to the APP C-terminus in TAI revealed intense labeling of pooled intra-axonal vesicular profiles, confirming the anterogradely transported vesicular source of the APP seen in TAI. Interestingly, in addition to providing a technically superior approach and new detailed information on the subcellular localization of APP, antibodies to the APP C-terminus also proved more cost effective. Immunofluorescent studies of APP C-terminus immunoreactivity involved 1/3 the cost of targeting the N-terminus, while bright field APP C-terminus studies were performed for 1/20 the cost. (C) 2000 Elsevier Science B.V. All rights reserved.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, Richmond, VA 23298 USA		Stone, JR (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, Richmond, VA 23298 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 20193] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020193] Funding Source: NIH RePORTER		AbouHamden A, 1997, J NEUROTRAUM, V14, P699, DOI 10.1089/neu.1997.14.699; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Ahlgren S, 1996, ACTA NEUROPATHOL, V92, P49, DOI 10.1007/s004010050488; Aplin AE, 1996, J NEUROCHEM, V67, P699; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; BARGER SW, 1995, J NEUROCHEM, V64, P2087; BARGER SW, 1995, BIOCHEM J, V311, P45, DOI 10.1042/bj3110045; BENDOTTI C, 1988, P NATL ACAD SCI USA, V85, P3628, DOI 10.1073/pnas.85.10.3628; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Buki A, 1999, EXP NEUROL, V159, P319, DOI 10.1006/exnr.1999.7139; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; BUXBAUM JD, 1993, BIOCHEM BIOPH RES CO, V197, P639, DOI 10.1006/bbrc.1993.2527; Christman CW, 1997, ACTA NEUROPATHOL, V94, P329, DOI 10.1007/s004010050715; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; DYRKS T, 1988, EMBO J, V7, P949, DOI 10.1002/j.1460-2075.1988.tb02900.x; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; FORLONI G, 1992, MOL BRAIN RES, V16, P128, DOI 10.1016/0169-328X(92)90202-M; Furukawa K, 1996, J NEUROCHEM, V67, P1882, DOI 10.1046/j.1471-4159.1996.67051882.x; Furukawa K, 1998, NEUROSCIENCE, V83, P429, DOI 10.1016/S0306-4522(97)00398-9; Furukawa K, 1996, NATURE, V379, P74, DOI 10.1038/379074a0; Geddes JF, 1997, NEUROPATH APPL NEURO, V23, P339, DOI 10.1046/j.1365-2990.1997.4498044.x; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; Gleckman AM, 1999, ARCH PATHOL LAB MED, V123, P146; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; IGARASHI H, 1994, APMIS, V102, P295, DOI 10.1111/j.1699-0463.1994.tb04879.x; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Katoh H, 1997, BRAIN RES, V758, P153, DOI 10.1016/S0006-8993(97)00213-8; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; LEE RKK, 1995, P NATL ACAD SCI USA, V92, P8083, DOI 10.1073/pnas.92.17.8083; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; Lewis SB, 1996, J NEUROTRAUM, V13, P505, DOI 10.1089/neu.1996.13.505; LI GL, 1995, J NEUROTRAUM, V12, P269, DOI 10.1089/neu.1995.12.269; LIEBERMAN DN, 1994, NATURE, V369, P235, DOI 10.1038/369235a0; Maeda T, 1998, J NEUROTRAUM, V15, P655, DOI 10.1089/neu.1998.15.655; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; MULTHAUP G, 1994, FEBS LETT, V355, P151, DOI 10.1016/0014-5793(94)01176-1; NEVE RL, 1988, NEURON, V1, P669, DOI 10.1016/0896-6273(88)90166-3; NEVIN NC, 1967, J NEUROPATH EXP NEUR, V26, P77, DOI 10.1097/00005072-196701000-00006; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; NITSCH RM, 1993, P NATL ACAD SCI USA, V90, P5191, DOI 10.1073/pnas.90.11.5191; Oehmichen M, 1999, INT J LEGAL MED, V112, P261, DOI 10.1007/s004140050246; Oehmichen M, 1999, ACTA NEUROPATHOL, V97, P491, DOI 10.1007/s004010051018; Okonkwo DO, 1998, BRAIN RES, V784, P1, DOI 10.1016/S0006-8993(97)01075-5; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Pierce JES, 1996, J NEUROSCI, V16, P1083; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Povlishock JT, 1996, ACT NEUR S, V66, P81; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; POVLISHOCK JT, 1992, J NEUROTRAUMA, V9, P189; Rao VLR, 1999, J NEUROTRAUM, V16, P865, DOI 10.1089/neu.1999.16.865; ROBAKIS NK, 1987, P NATL ACAD SCI USA, V84, P4190, DOI 10.1073/pnas.84.12.4190; SCHUBERT D, 1993, BRAIN RES, V629, P275, DOI 10.1016/0006-8993(93)91331-L; SHERRIFF FE, 1994, NEUROREPORT, V5, P1085, DOI 10.1097/00001756-199405000-00016; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; SHI SR, 1991, J HISTOCHEM CYTOCHEM, V39, P741, DOI 10.1177/39.6.1709656; SMALL DH, 1994, J NEUROSCI, V14, P2117; SMITH RS, 1980, J NEUROCYTOL, V9, P39, DOI 10.1007/BF01205226; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; TSUKITA S, 1980, J CELL BIOL, V84, P513, DOI 10.1083/jcb.84.3.513; VANEZIS P, 1987, FORENSIC SCI INT, V35, P1, DOI 10.1016/0379-0738(87)90018-1; VONWASIELEWSKI R, 1994, HISTOCHEMISTRY, V102, P165, DOI 10.1007/BF00268892; WANG LY, 1994, NATURE, V369, P230, DOI 10.1038/369230a0; Westergren H, 1999, SPINAL CORD, V37, P696, DOI 10.1038/sj.sc.3100920; WHITE RE, 1993, NATURE, V361, P263, DOI 10.1038/361263a0; WOLOZIN B, 1992, J NEUROSCI RES, V33, P163, DOI 10.1002/jnr.490330121; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; YAMAZAKI T, 1993, VIRCHOWS ARCH B, V63, P173, DOI 10.1007/BF02899258	86	107	109	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	JUL 21	2000	871	2					288	302		10.1016/S0006-8993(00)02485-9			15	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	337TG	WOS:000088377300013	10899295				2022-02-06	
J	Cantu, RC				Cantu, RC			Return to play guidelines after a head injury	CLINICS IN SPORTS MEDICINE			English	Article							FOOTBALL; CONCUSSION; SPORTS; SPINE	Presently there are no universally accepted definitions of the grades of concussion or criteria for when to allow the athlete to return to competition after a head injury. What is agreed upon is that in order to avoid cumulative brain damage and the second impact syndrome, no athlete still suffering post-concussion symptoms should return to competition. This article is meant to serve only as a guideline as the final decision in every instance is a clinical judgement.	Emerson Hosp, Serv Sports Med, Concord, MA 01742 USA; Emerson Hosp, Neurosurg Serv, Concord, MA 01742 USA		Cantu, RC (corresponding author), Emerson Hosp, Serv Sports Med, Concord, MA 01742 USA.						ADAMS H, 1972, SCI F NEUROLOGY, P478; ALBRIGHT JP, 1985, AM J SPORT MED, V13, P147, DOI 10.1177/036354658501300301; BARBER HM, 1973, BRIT MED J, V3, P532, DOI 10.1136/bmj.3.5879.532; BARCLAY WR, 1978, JAMA-J AM MED ASSOC, V240, P1892, DOI 10.1001/jama.1978.03290170074037; Bodnar L M, 1977, Curr Pract Orthop Surg, V7, P116; CANTU RC, 1990, J SPINAL DISORD, V3, P227; CLARKE K, 1979, MED SCI SPORTS EXERC, V10, P94; Committee on Head Injury Nomenclature of Congress of Neurological Surgeons, 1966, CLIN NEUROSURG, V12, P386; Gennarelli T, 1982, HEAD INJURY BASIC CL, V1982, P129; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL D, 1975, LANCET, V2, P995; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; GRONWALL D, 1974, LANCET, V2, P605; GRONWALL D, 1977, PERCEPT MOTOR SKILL, V4, P367; GUTHKELCH AN, 1980, EUR NEUROL, V19, P91, DOI 10.1159/000115133; HOLTZ HH, 1982, CAN MED ASSOC J, V127, P827; JENNET B, 1971, SCI FDN NEUROLOGY, P441; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; KREL FW, 1965, JAMA-J AM MED ASSOC, V194, P264; LINDSAY KW, 1980, BRIT MED J, V281, P789, DOI 10.1136/bmj.281.6243.789; Maroon J C, 1980, Clin Neurosurg, V27, P414; MCCOY GF, 1984, J BONE JOINT SURG BR, V66, P500, DOI 10.1302/0301-620X.66B4.6746681; MCLATCHIE GR, 1980, J TRAUMA, V20, P956, DOI 10.1097/00005373-198011000-00009; Meggyesy Dave, 1970, OUT THEIR LEAGUE, P125; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; PETRAS AF, 1983, AM J SPORT MED, V11, P325, DOI 10.1177/036354658301100508; PUTNAM P, 1983, SPORTS ILLUSTRA 0606, P23; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; SCHNEIDE.RC, 1970, J NEUROSURG, V33, P363, DOI 10.3171/jns.1970.33.4.0363; SCHNEIDER RC, 1954, J NEUROSURG, V11, P546, DOI 10.3171/jns.1954.11.6.0546; Schneider RC., 1973, HEAD NECK INJURIES F; SCHNEIDER RC, 1961, JAMA-J AM MED ASSOC, V177, P106; SCHNEIDER RC, 1985, SPORTS INJURIES; STRICH SJ, 1961, LANCET, V2, P443; SYMONDS C, 1962, LANCET, V1, P1; YARNELL PR, 1973, NEUROLOGY, V23, P196, DOI 10.1212/WNL.23.2.196	37	107	107	1	10	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0278-5919			CLIN SPORT MED	Clin. Sports Med.	JAN	1998	17	1					45	+		10.1016/S0278-5919(05)70060-0			17	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	YU153	WOS:000071687600006	9475970				2022-02-06	
J	Borssen, E; Holm, AK				Borssen, E; Holm, AK			Traumatic dental injuries in a cohort of 16-year-olds in northern Sweden	ENDODONTICS & DENTAL TRAUMATOLOGY			English	Article						concussion; crown fractures; dental trauma; tooth luxation	CHILDREN	The prevalence and yearly incidence of traumatic tooth injury between 1 and 16 years of age were studied in a cohort of 16-year-olds, born in 1975, and residing in the County of Vasterbotten, northern Sweden. The study comprised 3007 dental records from the public dental health service. The general distribution was 50.3% girls and 49.7% boys. The records showed that 35% of the children on one or more occasions had sustained injury to their primary or permanent dentition. The frequency was nearly twice as high for boys (64%) as for girls (36%). Twenty-five percent of the 16-year-olds had met with tooth injury more than once and this group consisted predominantly of boys. The incidence of injury episodes to primary and permanent teeth was 28 per 1000 per year. The boys had sustained trauma to their teeth most frequently when they were 4 years of age and between the ages of 8 and 11. This was also true for girls at 4 and at 9 years of age, although less evidently so. In the primary dentition, the majority of dental injuries had affected the supporting tissue of the maxillary incisors. In the permanent dentition, 75% of the traumatised teeth were upper incisors. Fractures of varying severity constituted 60% of all registered diagnoses in this dentition, followed by subluxation (19%) and concussion (11%).			Borssen, E (corresponding author), UMEA UNIV,DEPT PEDODONT,S-90187 UMEA,SWEDEN.						Andreasen J O, 1972, Int J Oral Surg, V1, P235, DOI 10.1016/S0300-9785(72)80042-5; FORSBERG CM, 1990, SWED DENT J, V14, P115; Glendor U, 1996, SWED DENT J, V20, P15; Hedegard B, 1973, Sven Tandlak Tidskr, V66, P431; Holland T, 1988, J Paediatr Dent, V4, P13; HOLM AK, 1975, COMMUNITY DENT ORAL, V3, P25, DOI 10.1111/j.1600-0528.1975.tb00275.x; JARVINEN S, 1979, ACTA ODONTOL SCAND, V37, P47, DOI 10.3109/00016357909004684; Magnusson B, 1969, Sven Tandlak Tidskr, V62, P61; OIKARINEN K, 1987, ENDOD DENT TRAUMATOL, V3, P172; RAVN JJ, 1974, COMMUNITY DENT ORAL, V2, P231, DOI 10.1111/j.1600-0528.1974.tb01658.x; Stecksen-Blicks C, 1995, Int J Paediatr Dent, V5, P143; STOCKWELL AJ, 1988, COMMUNITY DENT ORAL, V16, P294, DOI 10.1111/j.1600-0528.1988.tb01779.x	12	107	114	0	5	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0109-2502			ENDOD DENT TRAUMATOL	Endod. Dent. Traumatol.	DEC	1997	13	6					276	280					5	Dentistry, Oral Surgery & Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Dentistry, Oral Surgery & Medicine	YK454	WOS:A1997YK45400005	9558509				2022-02-06	
J	Kreutzer, JS; Marwitz, JH; Seel, R; Serio, CD				Kreutzer, JS; Marwitz, JH; Seel, R; Serio, CD			Validation of a neurobehavioral functioning inventory for adults with traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							BLUNT HEAD-INJURY; RATING-SCALE; RELATIVES; PERFORMANCE; RECOVERY; PATIENT; TESTS	Objective: To examine the validity of a neurobehavioral inventory for adults with traumatic brain injury. Design: Construct validity was examined by applying principal components and confirmatory factor analytic procedures. internal consistency of factors was examined using Cronbach's alpha. Criterion-related validity was examined by comparing inventory scale scores with neuropsychological and personality test variables. Setting: Medical center outpatient clinic. Participants: 520 consecutive adult patients with traumatic brain injury were administered psychological and neuropsychological tests; 520 informants, primarily family members, completed the neurobehavioral inventory. Main Outcome Measure: Neurobehavioral inventory with items describing symptoms and daily living problems; scale scores were compared with a set of neuropsychological measures and Minnesota Multiphasic Personality Inventory scores. Results: Principal components and confirmatory factor analytic procedures identified six scales with a total of 70 items. The primary scale inclusion criterion required a minimum factor loading of .40. Chronbach's alpha analysis revealed acceptably high internal reliability for all scales ranging from .86 to .95. Scale scores were statistically compared with patients' scores on neuropsychological and personality tests. Poor neuropsychological test performance and greater levels of psychopathology were associated with greater frequency of perceived neurobehavioral problems. Conclusions: Findings suggest that the neurobehavioral inventory is a promising means of investigating informants' perceptions of outpatients' everyday problems. Such information can serve as a complement to historical information, test results, and information from standardized interviews to develop a holistic perspective of patients. Differential weighting of items, association of scales with other measures, and validation with other neurological patient populations are recommended avenues for future research. (C) 1996 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation .			Kreutzer, JS (corresponding author), VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT PHYS MED & REHABIL, MCV BOX 980542, RICHMOND, VA 23298 USA.						Anastasi A., 1988, PSYCHOL TESTING; ARCIA E, 1993, BRAIN INJURY, V7, P481, DOI 10.3109/02699059309008175; BECKER ME, 1993, BRAIN INJURY, V7, P515, DOI 10.3109/02699059309008179; Bentler P.M., 1992, EQS STRUCTURAL EQUAT; BLACK FW, 1975, PERCEPT MOTOR SKILL, V40, P87, DOI 10.2466/pms.1975.40.1.87; Bollen K.A., 1993, TESTING STRUCTURAL E, V154; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; BURKE J M, 1990, Brain Injury, V4, P223, DOI 10.3109/02699059009026171; Byrne B.M., 1994, STRUCTURAL EQUATION; CAMPBELL DT, 1959, PSYCHOL BULL, V56, P81, DOI 10.1037/h0046016; CHARTRAND JM, 1990, J COUNS PSYCHOL, V37, P491, DOI 10.1037/0022-0167.37.4.491; COLE DA, 1987, J CONSULT CLIN PSYCH, V55, P584, DOI 10.1037/0022-006X.55.4.584; COMREY AL, 1957, EDUC PSYCHOL MEAS, V17, P586, DOI 10.1177/001316445701700413; Dahlstrom W. G., 1972, MMPI HDB, V1; EAMES P, 1988, J HEAD TRAUMA REHAB, V3, P1; FASSINGER RE, 1987, J COUNS PSYCHOL, V34, P425, DOI 10.1037/0022-0167.34.4.425; Gilewski M.J., 1986, CLIN MEMORY ASSESSME, P93, DOI [10.1037/10057-008, DOI 10.1037/10057-008]; Graham J. R., 1987, MMPI PRACTICAL GUIDE; GREENE RL, 1991, MMPI2MMPI INTERPRETI; Hall K, 1992, NEUROREHABILITATION, V2, P98, DOI DOI 10.3233/NRE-1992-2410; HART T, 1986, CLIN NEUROPSYCHOLOGY, P21; HARTLAGE LC, 1987, ESSENTIALS NEUROPSYC; HEATON RK, 1981, J CONSULT CLIN PSYCH, V49, P807, DOI 10.1037/0022-006X.49.6.807; HOYLE RH, 1991, J CONSULT CLIN PSYCH, V59, P67, DOI 10.1037/0022-006X.59.1.67; KASZNIAK AW, 1986, CLIN MEMORY ASSESSME, P271; KAY T, 1988, J HEAD TRAUMA REHAB, V3, P65; KAY T, 1988, ADMINISTRATION MANUA; KEPPEL G, 1991, DESIGN ANAL RESEARCH; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; Kreutzer J., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI [10.1097/00001199-199308020-00009, DOI 10.1097/00001199-199308020-00009]; KREUTZER JS, 1987, GENERAL HLTH HIST QU; KREUTZER JS, 1993, J HEAD TRAUMA REHAB, V8, P47; LARZELERE RE, 1977, PSYCHOL BULL, V84, P557, DOI 10.1037/0033-2909.84.3.557; LEININGER B E, 1991, Brain Injury, V5, P199, DOI 10.3109/02699059109008090; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Levin HS., 1982, NEUROBEHAVIORAL CONS; Lezak M, 1994, NEUROPSYCHOLOGICAL A; Lezak M.D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI DOI 10.1097/00001199-198703000-00009; Lezak MD., 1993, J HEAD TRAUMA REHAB, V8, P24, DOI DOI 10.1097/00001199-199303000-00004; LISHMAN WA, 1968, BRIT J PSYCHIAT, V114, P373, DOI 10.1192/bjp.114.509.373; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; Lynch W. J., 1990, REHABILITATION ADULT, P310; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; NROUSIS MJ, 1993, SPSS WINDOWS BASE SY; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; OVERALL JE, 1962, PSYCHOL REP, V10, P799; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; Prigatano G. P., 1991, AWARENESS DEFICIT BR; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; REISBERG B, 1986, HDB CLIN MEMORY ASSE, P108; Reitan R, 1985, HALSTEAD REITAN NEUR; Ryan J.J., 1992, PSYCHOL ASSESSMENT, V4, P63, DOI [https://doi.org/10.1037/1040-3590.4.1.63, DOI 10.1037/1040-3590.4.1.63]; SILVER JM, 1994, J HEAD TRAUMA REHAB, V9, P61, DOI 10.1097/00001199-199409000-00006; Spreen O, 1991, COMPENDIUM NEUROPSYC; Tabachnick B. G., 1989, USING MULTIVARIATE S; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; TUEL S M, 1992, Brain Injury, V6, P363, DOI 10.3109/02699059209034951; Wechsler, 1997, WECHSLER ADULT INTEL; WILLER BS, 1991, ARCH PHYS MED REHAB, V72, P460; WILSON B, 1989, J CLIN EXP NEUROPSYC, V11, P855, DOI 10.1080/01688638908400940; WOOTEN AJ, 1983, J CLIN PSYCHOL, V39, P392, DOI 10.1002/1097-4679(198305)39:3<392::AID-JCLP2270390313>3.0.CO;2-H; [No title captured]; 1985, STANDARDS ED PSYCHOL; [No title captured]; [No title captured]	67	107	110	0	19	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	1996	77	2					116	124		10.1016/S0003-9993(96)90155-0			9	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	TU541	WOS:A1996TU54100002	8607734				2022-02-06	
J	COPE, DN				COPE, DN			THE EFFECTIVENESS OF TRAUMATIC BRAIN INJURY REHABILITATION - A REVIEW	BRAIN INJURY			English	Article							DISABILITY RATING-SCALE; CLOSED HEAD-INJURY; EARLY INTERVENTION; FOLLOW-UP; RECOVERY; PROGRAM	The rehabilitation of traumatic brain injury (TBI) has undergone tremendous development over the past 20 years. A much more aggressive, extended and comprehensive approach is now common and clinically accepted. Multiple new forms and sites of treatment are utilized such as cognitive, behavioural, sub-acute and post-acute rehabilitation programmes. While there has been widespread clinical acceptance of these treatments the appearance of well-designed experimental or quasi-experimental studies actually evaluating the results of such treatment have been, until recently, generally lacking. This review article selects, analyses, and critiques the most salient of recent studies published regarding the overall clinical benefit, and to some extent the cost benefit, of TBI treatment programmes in their multiple forms. A conclusion which is reached following this survey is that while truly randomized controlled studies still have not been achieved, an impressive variety of studies of quasi-experimental design have been completed. The overall conclusion from these studies is that the efficacy (and cost-effectiveness) of TBI rehabilitation is strongly supported.			COPE, DN (corresponding author), PARADIGM HLTH CORP,1001 GALAXY WAY,SUITE 400,CONCORD,CA 94520, USA.						ARONOW HU, 1987, J HEAD INJURY REHABI, V2, P24; ASHLEY MJ, 1990, J INSURANCE MED, V22, P156; BACHYRITA P, 1990, CAN J PSYCHOL, V44, P148, DOI 10.1037/h0084247; BARLOW DH, 1984, SINGLE CASE EXPT DES; BBUTLER RH, J NEUROLOGICAL REHAB, V2, P97; Ben-Yishay Y., 1987, J HEAD TRAUMA REHAB, V2, P35, DOI [10.1097/00001199-198703000-00007, DOI 10.1097/00001199-198703000-00007]; BERROL SM, 1982, SEVERE HEAD TRAUMA C, V1; BLACKERBY W F, 1990, Brain Injury, V4, P167, DOI 10.3109/02699059009026162; BLACKERBY WF, 1992, NOV AM C AC REH MED; Brooks N, 1989, Brain Inj, V3, P325, DOI 10.3109/02699058909004556; BROOKS N, 1991, Brain Injury, V5, P103, DOI 10.3109/02699059109008082; BURKE W H, 1990, Brain Injury, V4, P371, DOI 10.3109/02699059009026190; Burke W H, 1988, Brain Inj, V2, P313, DOI 10.3109/02699058809150902; BURKE W H, 1991, Brain Injury, V5, P241, DOI 10.3109/02699059109008095; COPE D N, 1991, Brain Injury, V5, P111, DOI 10.3109/02699059109008083; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; COPE DN, 1985, SEMIN NEUROL, V5, P212, DOI 10.1055/s-2008-1041518; COPE DN, 1993, IN PRESS PERSPECTIVE; DIKMEN S, 1983, ARCH NEUROL-CHICAGO, V40, P333, DOI 10.1001/archneur.1983.04050060033004; DILLER L, 1987, NEUROBEHAVIORAL RECO, P146; EAMES P, 1985, J NEUROL NEUROSUR PS, V48, P613, DOI 10.1136/jnnp.48.7.613; Eames P, 1985, Int Rehabil Med, V7, P130; Evans RW, 1992, J HEAD TRAUMA REHAB, V7, P24; FINGER S, 1988, BRAIN INJURY RECOVER; FREY WD, 1984, FUNCTIONAL ASSESSMEN, P11; FRYER LJ, 1987, J HEAD TRAUMA REHAB, V2, P51, DOI DOI 10.1097/00001199-198709000-00007; GIANUTSOS R, 1991, Brain Injury, V5, P353, DOI 10.3109/02699059109008108; Gray J M, 1989, Brain Inj, V3, P163, DOI 10.3109/02699058909004548; HAFFEY WJ, 1991, J HEAD TRAUMA REHAB, V6, P24; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; HALL K, UNPUB TRAUMATIC BRAI; Heinemann AW, 1990, J NEUROL REHABIL, V4, P27; JOHNSTON M V, 1991, Brain Injury, V5, P155, DOI 10.3109/02699059109008086; JOHNSTON M V, 1991, Brain Injury, V5, P141, DOI 10.3109/02699059109008085; JOHNSTON MV, 1992, ARCH PHYSICAL MED RE, V73; JOHNSTON MV, 1992, COMMUNICATION    MAY; KAPLAN MS, 1988, ARCH PHYS MED REHAB, V69, P984; MACKAY LE, 1992, ARCH PHYS MED REHAB, V73, P635; Malec James F., 1993, Brain Injury, V7, P15, DOI 10.3109/02699059309008153; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; MILLS V M, 1992, Brain Injury, V6, P219, DOI 10.3109/02699059209029663; MORGAN AS, 1988, 1ST E ASS SURG TRAUM; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; RAO N, 1990, Brain Injury, V4, P49, DOI 10.3109/02699059009026148; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; RUFF R M, 1990, Brain Injury, V4, P339, DOI 10.3109/02699059009026187; RUSK H A, 1969, Medical Clinics of North America, V53, P677; RUSK HA, 1966, CLIN NEUROSURG, V12, P312; SCHERZER BP, 1986, ARCH PHYS MED REHAB, V67, P366; SPIVACK G, 1992, Brain Injury, V6, P419, DOI 10.3109/02699059209008138; SUNDANCE PL, 1992, NOV AAPM R ANN M SAN; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; VOLPE BT, 1990, ARCH NEUROL-CHICAGO, V47, P220, DOI 10.1001/archneur.1990.00530020128026; WEHMAN PH, 1990, ARCH PHYS MED REHAB, V71, P1047; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WHITLOCK J A JR, 1992, Brain Injury, V6, P447, DOI 10.3109/02699059209008140	56	107	107	0	5	TAYLOR & FRANCIS LTD LONDON	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	OCT	1995	9	7					649	670		10.3109/02699059509008224			22	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	RZ814	WOS:A1995RZ81400001	8680395				2022-02-06	
J	WHYTE, J; POLANSKY, M; FLEMING, M; COSLETT, HB; CAVALLUCCI, C				WHYTE, J; POLANSKY, M; FLEMING, M; COSLETT, HB; CAVALLUCCI, C			SUSTAINED AROUSAL AND ATTENTION AFTER TRAUMATIC BRAIN INJURY	NEUROPSYCHOLOGIA			English	Article						BRAIN INJURY; ATTENTION; VIGILANCE; REACTION TIME; AROUSAL	CLOSED-HEAD-INJURY; VARIABILITY; SCALE; COMA	Clinicians report that patients with traumatic brain injury (TBI) often have difficulty with tasks requiring sustained attention, and there are neuroanatomical and neurophysiological reasons to expect such deficits. Nevertheless, laboratory measures of sustained attention or vigilance in TBI have produced conflicting results. These inconsistencies may be due to patient heterogeneity as well as the fact that vigilance performance is dependent on highly specific features of the task design. We developed a visual vigilance task in which the influence of non-attentional factors was minimized and task difficulty for patients and controls made comparable. Performance was characterized with respect to vigilance level as well as vigilance decrement, using measures of perceptual discrimination, response bias, reaction time and reaction time variability. Twenty-six patients with recent TBI and 18 control subjects were tested on this task. A MANOVA of ranked scores revealed significantly different patient and control performance overall. Initial level of performance (vigilance level) was slower and more variable for patients than controls, and patients showed more conservative response biases. Deterioration over time (vigilence decrement) was also steeper for patients than controls for reaction time, reaction time variability, and response bias. Deterioration in accuracy (D') did not differ significantly between patients and controls. Performance was not related to available measures of injury severity. Hypotheses relating arousal mechanisms to vigilance performance are discussed.	TEMPLE UNIV, SCH MED, DEPT PHYS MED & REHABIL, PHILADELPHIA, PA 19122 USA; HAHNEMANN UNIV, PHILADELPHIA, PA 19102 USA; TEMPLE UNIV, SCH MED, DEPT NEUROL, PHILADELPHIA, PA 19122 USA		WHYTE, J (corresponding author), MOSS REHABIL RES INST, 1200 W TABOR RD, PHILADELPHIA, PA 19141 USA.			Whyte, John/0000-0002-4381-1474	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R29NS027715] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R29 NS27715] Funding Source: Medline		AUERBACH SH, 1986, J HEAD TRAUMA REHAB, V1, P1, DOI DOI 10.1097/00001199-198609000-00004; BROUWER WH, 1985, CORTEX, V21, P111, DOI 10.1016/S0010-9452(85)80019-8; BRUHN P, 1977, CORTEX, V13, P373, DOI 10.1016/S0010-9452(77)80018-X; BUCHTEL HA, 1987, NEUROBEHAVIORAL RECO; COSLETT HB, 1987, NEUROLOGY, V37, P957, DOI 10.1212/WNL.37.6.957; DENCKER SJ, 1958, ACTA PSYCHIAT NEUROL, V33, P122; EWING R, 1980, Journal of Clinical Neuropsychology, V2, P147, DOI 10.1080/01688638008403789; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; JUTAI JW, 1984, INT J PSYCHOPHYSIOL, V1, P219, DOI 10.1016/0167-8760(84)90042-4; Kleinbaum D, 1988, APPLIED REGRESSION A; LEVIN HS, 1989, TRAUMATIC BRAIN INJU, V2, P53; LISPER H, 1972, J EXP PSYCHOL, V96, P287, DOI 10.1037/h0033615; Macmillan NA., 1991, DETECTION THEORY USE; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MELAMED S, 1985, SCAND J REHABIL MED, P16; Parasuraman R, 1984, VARIETIES ATTENTION, P243; PARDO JV, 1991, NATURE, V349, P61, DOI 10.1038/349061a0; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; POSNER MI, 1986, ENERGETICS HUMAN INF; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; ROBBINS TW, 1986, ENERGETICS HUMAN INF; Stuss DT, 1994, NEUROPSYCHOLOGY, V8, P316, DOI DOI 10.1037/0894-4105.8.3.316; TEASDALE G, 1974, LANCET, V2, P81; TROMP E, 1991, J CLIN EXP NEUROPSYC, V13, P821, DOI 10.1080/01688639108405100; van Zomeren AH, 1984, CLOSED HEAD INJURY P, P74; VANWOERKOM TCAM, 1977, LANCET, V1, P812; VANZOMEREN AH, 1981, REACTION TIME ATTENT, P9; VANZOMEREN AH, 1987, NEUROBEHAVIORAL RECO; VECHT CJ, 1975, ARCH NEUROL-CHICAGO, V32, P792, DOI 10.1001/archneur.1975.00490540036004; WHYTE J, 1993, REHABILITATION MED P; Wickens C. D., 1993, WORKLOAD TRANSITION, P139; WILKINS AJ, 1987, NEUROPSYCHOLOGIA, V25, P359, DOI 10.1016/0028-3932(87)90024-8	32	107	108	0	13	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia	JUL	1995	33	7					797	813		10.1016/0028-3932(95)00029-3			17	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	RJ268	WOS:A1995RJ26800001	7477808				2022-02-06	
J	YAKOVLEV, AG; FADEN, AI				YAKOVLEV, AG; FADEN, AI			SEQUENTIAL EXPRESSION OF C-FOS PROTOONCOGENE, TNF-ALPHA, AND DYNORPHIN GENES IN SPINAL-CORD FOLLOWING EXPERIMENTAL TRAUMATIC INJURY	MOLECULAR AND CHEMICAL NEUROPATHOLOGY			English	Article						C-FOS; DYNORPHIN; MESSENGER-RNA; PCR; SPINAL CORD INJURY; TUMOR NECROSIS FACTOR	BRAIN INJURY; MESSENGER-RNA; AMINO-ACIDS; RAT-BRAIN; TISSUE; INFLAMMATION; METABOLISM; MECHANISM; PROTEIN; NEURONS	Reverse transcription-polymerase chain reaction (RT-PCR) was used to estimate dynamic changes in levels of c-fos protooncogene, tumor necrosis factor alpha (TNF-alpha), and preprodynorphin messenger ribonucleic acid (mRNA) isolated from individual segments (T1 to T12) of rat spinal cord following graded impact trauma (50 or 100 g/cm) to the T9 segment of pentobarbital-anesthetized rats. Trauma caused elevation of c-fos mRNA at the trauma site by 30 min after injury that was related to injury severity. At this time, increased levels of TNF-alpha (but not of preprodynorphin) mRNA were also found. By 24 h, c-fos and TNF-alpha mRNA had returned to normal levels at trauma site, but were now increased at more distal segments (T5 and T12). At 4 h after trauma, induction of preprodynorphin mRNA was detected at the trauma site; levels continued to be elevated at 24 h when they were also detected at T5 and T12. Increases for each mRNA were greater for severe as compared to moderate trauma. The injury dose- and time-dependent changes in c-fos, TNF-alpha, and preprodynorphin gene expression suggest that their respective proteins are synthesized in response to trauma, and may play a part in the secondary injury response. Later accumulation of message distant from the trauma site may reflect a progression of delayed damage along the spinal cord.	GEORGETOWN UNIV,MED CTR,DEPT NEUROL,WASHINGTON,DC 20007; GEORGETOWN UNIV,MED CTR,DEPT PHARMACOL,WASHINGTON,DC 20007						PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR306634] Funding Source: Medline		BAKSHI R, 1992, BRAIN RES, V580, P255, DOI 10.1016/0006-8993(92)90952-6; BAKSHI R, 1990, J NEUROSCI, V10, P3793, DOI 10.1523/JNEUROSCI.10-12-03793.1990; BENVENISTE EN, 1992, AM J PHYSIOL, V263, pC1, DOI 10.1152/ajpcell.1992.263.1.C1; BLUMENFELD KS, 1992, J CEREBR BLOOD F MET, V12, P987, DOI 10.1038/jcbfm.1992.136; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DRAGUNOW M, 1990, EXP NEUROL, V107, P236, DOI 10.1016/0014-4886(90)90141-E; DUBNER R, 1992, TRENDS NEUROSCI, V15, P96, DOI 10.1016/0166-2236(92)90019-5; Faden A I, 1987, Cent Nerv Syst Trauma, V4, P227; FADEN AI, 1990, ANN NEUROL, V27, P67, DOI 10.1002/ana.410270111; FADEN AI, 1987, J NEUROCHEM, V48, P1809, DOI 10.1111/j.1471-4159.1987.tb05740.x; FADEN AI, 1988, BRAIN RES, V448, P287, DOI 10.1016/0006-8993(88)91265-6; FADEN AI, 1985, ANN NEUROL, V17, P386, DOI 10.1002/ana.410170414; FADEN AI, 1993, CRITICAL REV NEUROBI, P175; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; GIULIAN D, 1994, NEUROBIOLOGY CNS TRA, P155; Hall E D, 1986, Cent Nerv Syst Trauma, V3, P281; HERMAN BH, 1985, J PHARMACOL EXP THER, V232, P27; HSU CY, 1985, NEUROLOGY, V35, P1003, DOI 10.1212/WNL.35.7.1003; HSU CY, 1994, NEUROBIOLOGY CENTRAL, P145; HYLDEN JLK, 1992, J NEUROSCI, V12, P1716; Lemke M, 1990, J NEUROTRAUM, V7, P41, DOI 10.1089/neu.1990.7.41; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565, DOI 10.1152/ajpendo.1987.253.5.E565; NOBLE LJ, 1989, BRAIN RES, V482, P57, DOI 10.1016/0006-8993(89)90542-8; NOBLE LJ, 1989, EXP NEUROL, V103, P34, DOI 10.1016/0014-4886(89)90182-9; Panter S. S., 1992, PRINCIPLES PRACTICE, P32; PANTER SS, 1990, ANN NEUROL, V27, P96, DOI 10.1002/ana.410270115; PHILIPP E, 1990, INT J EAT DISORDER, V9, P323, DOI 10.1002/1098-108X(199005)9:3&lt;323::AID-EAT2260090310&gt;3.0.CO;2-K; PRZEWLOCKI R, 1983, NEUROPEPTIDES, V3, P233, DOI 10.1016/0143-4179(83)90019-7; RAWE SE, 1981, NEUROSURGERY, V9, P40, DOI 10.1227/00006123-198107000-00007; SANDLER AN, 1967, J NEUROSURG, V5, P638; SAUNDERS RD, 1987, J NEUROCHEM, V49, P24, DOI 10.1111/j.1471-4159.1987.tb03388.x; SHARMA HS, 1992, NEUROSCI RES, V14, P195; STEWART P, 1989, LIFE SCI, V44, P1505, DOI 10.1016/0024-3205(89)90330-5; VINK R, 1991, AM J PHYSIOL, V261, pR1527, DOI 10.1152/ajpregu.1991.261.6.R1527; VINK R, 1989, ANN NEUROL, V25, P26, DOI 10.1002/ana.410250105; WAHLESTEDT C, 1993, NATURE, V363, P260, DOI 10.1038/363260a0; YOUNG W, 1982, J NEUROSURG, V57, P667, DOI 10.3171/jns.1982.57.5.0667; ZIVIN JA, 1976, NEUROLOGY, V26, P99, DOI 10.1212/WNL.26.2.99	38	107	115	0	1	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07012	1044-7393			MOL CHEM NEUROPATHOL	Mol. Chem. Neuropathol.	OCT-DEC	1994	23	2-3					179	190		10.1007/BF02815410			12	Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	PY906	WOS:A1994PY90600009	7702707				2022-02-06	
J	JAFFE, KM; FAY, GC; POLISSAR, NL; MARTIN, KM; SHURTLEFF, HA; RIVARA, JB; WINN, HR				JAFFE, KM; FAY, GC; POLISSAR, NL; MARTIN, KM; SHURTLEFF, HA; RIVARA, JB; WINN, HR			SEVERITY OF PEDIATRIC TRAUMATIC BRAIN INJURY AND NEUROBEHAVIORAL RECOVERY AT ONE-YEAR - A COHORT STUDY	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						CHILDREN; CLOSED-HEAD INJURY; OUTCOME; TRAUMATIC BRAIN INJURY	CLOSED-HEAD-INJURY; CHILDREN; ADOLESCENTS		UNIV WASHINGTON,CHILDRENS HOSP & MED CTR,DEPT REHABIL MED,SEATTLE,WA 98195; UNIV WASHINGTON,CHILDRENS HOSP & MED CTR,DEPT PEDIAT,SEATTLE,WA 98195; UNIV WASHINGTON,CHILDRENS HOSP & MED CTR,DEPT PSYCHIAT & BEHAV SCI,SEATTLE,WA 98195; UNIV WASHINGTON,CHILDRENS HOSP & MED CTR,DEPT NEUROL SURG,SEATTLE,WA 98195		JAFFE, KM (corresponding author), UNIV WASHINGTON,CHILDRENS HOSP & MED CTR,SCH SOCIAL WORK,POB 5371,4800 SAND POINT WAY NE,SEATTLE,WA 98105, USA.			Shurtleff, Hillary/0000-0003-0959-2842	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR 002299] Funding Source: Medline		ACHENBACH TM, 1983, MANUAL CHILD BEHAVIO; Bruininks R. H., 1984, SCALES INDEPENDENT B; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; DELIS DC, 1989, CALIFORNIA VERBAL LE; DIKMEN S, 1983, ARCH NEUROL-CHICAGO, V40, P333, DOI 10.1001/archneur.1983.04050060033004; DIKMEN SS, 1991, JAMA-J AM MED ASSOC, V265, P1271, DOI 10.1001/jama.265.10.1271; Edelbrock C., 1986, MANUAL TEACHERS REPO; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; Goldstein FC, 1985, DEV NEUROPSYCHOL, V1, P195, DOI 10.1080/87565648509540310; GOTTFRIED AW, 1985, MERRILL PALMER QUART, V31, P85; Hollingshead AB., 1975, 4 FACTOR INDEX SOCIA; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; OBRIEN PC, 1984, BIOMETRICS, V40, P1079, DOI 10.2307/2531158; RATTAN G, 1987, COGNITIVE REHABILITA; Reitan R.M., 1974, CLIN NEUROPSYCHOLOGY; Shurtleff H. A., 1988, J PSYCHOEDUCATIONAL, V6, P298, DOI 10.1177/073428298800600313; SNEDECOR GW, 1967, STAT METHODS; Wechsler D., 1974, WECHSLER INTELLIGENC; Wilkinson, 1984, WIDE RANGE ACHIEVEME; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218	23	107	107	0	5	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUN	1993	74	6					587	595		10.1016/0003-9993(93)90156-5			9	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	LG423	WOS:A1993LG42300005	8503748				2022-02-06	
J	SHOHAMI, E; NOVIKOV, M; MECHOULAM, R				SHOHAMI, E; NOVIKOV, M; MECHOULAM, R			A NONPSYCHOTROPIC CANNABINOID, HU-211, HAS CEREBROPROTECTIVE EFFECTS AFTER CLOSED-HEAD INJURY IN THE RAT	JOURNAL OF NEUROTRAUMA			English	Article							TRANSIENT ISCHEMIA; BRAIN INJURY; ANTAGONISTS; RECEPTORS; GERBIL	HU-211 is a synthetic, nonpsychotropic cannabinoid, which has been shown to act as a noncompetitive N-methyl-D-asparate (NMDA) receptor antagonist. The cerebroprotective effects of this compound were assessed in a model of closed head injury in rats. Head trauma (HT) was induced in ether-anesthetized rats by a weight-drop device; recovery was followed up to 48 h. The clinical status of the rats was evaluated at 1, 24, and 48 h after injury, and the extent of edema formation was determined by specific gravity (SG) and water content measurements at 24 or 48 h. The integrity of the blood-brain barrier (BBB) was investigated using Evans-Blue extravasation at 4 h after HT. HU-211 at a dose of 25 mg/kg in middle-chain triglycerides (MCT) oil was given intraperitoneally immediately and 1, 2, or 3 h after impact, and its effect on the various parameters was studied. The drug was found to be very effective in improving motor function recovery. When the drug was given 1 h after HT, the percent of rats able to perform beam walking task on 8.5- and 5-cm wide beams was increased from 30% and 0% to 79% (p = 0.0172) and 57% (p = 0.0029), respectively. The percent of rats able to balance on a 1.5-cm beam for 20 and 40 sec was also significantly increased, from 9% and 0% to 72% (p = 0.0037) and 50% (p = 0.078), respectively. The drug was also effective in reducing the BBB breakdown by more than four fold, as compared with control (548 +/- 94 versus 128 +/- 19 ng Evans blue/g tissue; p < 0.05) and attenuating cerebral edema. SG was 1.0367 +/- 0.0007 versus 1.0399 +/- 0.0005, and percent water content was 83.06 +/- 0.57 versus 80.78 +/- 0.36 (p < 0.05) in control and HU-211 treated rats, respectively. Similar significant protection was found when the drug was injected 2 h after the injury; however, at 3 h the effect was somewhat less pronounced. We suggest that this novel drug is a potential cerebroprotector in head trauma with a therapeutic window of at least 2 to 3 h.	HEBREW UNIV JERUSALEM,FAC MED,DEPT PHARMACOL,JERUSALEM,ISRAEL; HEBREW UNIV JERUSALEM,FAC MED,DEPT NAT PROD,JERUSALEM,ISRAEL		SHOHAMI, E (corresponding author), HEBREW UNIV JERUSALEM,SCH PHARM,DEPT PHARMACOL,JERUSALEM,ISRAEL.						BENVENISTE H, 1984, J NEUROCHEM, V43, P169; CHAN P, 1992, J NEUROTRAUM, V9, P417; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; Domino EF, 1990, STATUS KETAMINE ANES; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FEIGENBAUM JJ, 1989, P NATL ACAD SCI USA, V86, P9584, DOI 10.1073/pnas.86.23.9584; FISCHER JB, 1992, J NERUOTRAUMA S2, V9, P531; GLOBUS MYT, 1988, J NEUROCHEM, V51, P1455, DOI 10.1111/j.1471-4159.1988.tb01111.x; HALL ED, 1992, J NEUROTRAUMA, V9, P425; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; Jenkins LW, 1988, J NEUROTRAUM, V5, P275, DOI 10.1089/neu.1988.5.275; KATAYAMA Y, 1988, Society for Neuroscience Abstracts, V14, P1154; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; KOENIG H, 1991, SOC NEUR ABSTR, V17, P12; KOENIG H, 1992, SOC NEUR ABS, V18, P11; LYETH BG, 1988, BRAIN RES, V448, P88, DOI 10.1016/0006-8993(88)91104-3; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; MARMAROU A, 1978, J NEUROSURG, V49, P536; MCINTOSH TK, 1988, 7TH INT S INTR PRESS, P199; MECHOULAM R, 1990, TETRAHEDRON-ASYMMETR, V1, P315, DOI 10.1016/S0957-4166(00)86322-3; MECHOULAM R, 1988, EXPERIENTIA, V44, P762, DOI 10.1007/BF01959156; ROD MR, 1989, CAN J NEUROL SCI, V16, P340, DOI 10.1017/S031716710002919X; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; SHAPIRA Y, 1992, J NEUROSURG ANESTH, V4, P231, DOI 10.1097/00008506-199210000-00001; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHAPIRA Y, 1993, IN PRESS ANESTH ANAL; SHOHAMI E, 1987, J CEREBR BLOOD F MET, V7, P58, DOI 10.1038/jcbfm.1987.8; SHOHAMI E, 1992, EXP NEUROL, V117, P189, DOI 10.1016/0014-4886(92)90126-B; SHOHAMI E, 1992, 4TH INT S PHARM CER; SWAN JH, 1990, J CEREBR BLOOD F MET, V10, P343, DOI 10.1038/jcbfm.1990.63; UYAMA O, 1988, J CEREBR BLOOD F MET, V8, P282, DOI 10.1038/jcbfm.1988.59; WARNER MA, 1991, J CEREBR BLOOD F MET, V11, P600, DOI 10.1038/jcbfm.1991.110; WROBLEWSKI JT, 1987, P NATL ACAD SCI USA, V84, P5068, DOI 10.1073/pnas.84.14.5068	34	107	109	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	SUM	1993	10	2					109	119		10.1089/neu.1993.10.109			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	LM056	WOS:A1993LM05600003	8411215				2022-02-06	
J	EWINGCOBBS, L; LEVIN, HS; EISENBERG, HM; FLETCHER, JM				EWINGCOBBS, L; LEVIN, HS; EISENBERG, HM; FLETCHER, JM			LANGUAGE FUNCTIONS FOLLOWING CLOSED-HEAD INJURY IN CHILDREN AND ADOLESCENTS	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article									UNIV TEXAS,MED BRANCH,GALVESTON,TX 77550; UNIV HOUSTON,HOUSTON,TX 77004		EWINGCOBBS, L (corresponding author), UNIV TEXAS,SCH MED,DEPT PSYCHIAT & BEHAV SCI,POB 20708,HOUSTON,TX 77225, USA.		fletcher, jack/Q-5975-2019		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 21889-02] Funding Source: Medline		ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ALAJOUANINE T, 1965, BRAIN, V88, P653, DOI 10.1093/brain/88.4.653; ARAM DM, 1983, ARCH NEUROL-CHICAGO, V40, P614, DOI 10.1001/archneur.1983.04050090050007; BAWDEN HN, 1985, J CLIN EXP NEUROPSYC, V7, P39, DOI 10.1080/01688638508401241; Benton A., 1978, MULTILINGUAL APHASIA; BENTON ARTHUR L., 1962, PSYCHIAT ET NEUROL, V144, P321; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; BRUCE DA, 1979, CHILD BRAIN, V5, P174; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; DENNIS M, 1985, J CLIN EXP NEUROPSYC, V7, P526, DOI 10.1080/01688638508401283; DENNIS M, 1980, LANGUAGE DEV APHASIA, P45; DERENZI E, 1962, BRAIN, V85, P665, DOI 10.1093/brain/85.4.665; EWINGCOBBS L, 1985, CLOSED HEAD INJURY R, P71; EWINGCOBBS L, 1985, SPEECH LANGUAGE EVAL, P71; FLETCHER JM, IN PRESS HDB PEDIATR; GADDES WH, 1975, BRAIN LANG, V2, P257, DOI 10.1016/S0093-934X(75)80070-8; GAIDOLFI E, 1980, ITAL J NEUROL SCI, V1, P65; Gibson E. J., 1975, PSYCHOL READING; Guttmann E, 1942, BRAIN, V65, P205, DOI 10.1093/brain/65.2.205; HALSTEAD WC, 1959, J SPEECH HEAR DISORD, V14, P9; HEBB DO, 1942, P AM PHILOS SOC, V1, P265; HECAEN H, 1976, BRAIN LANG, V3, P114, DOI 10.1016/0093-934X(76)90009-2; HECAEN H, 1984, EARLY BRAIN DAMAGE, V1, P277; HEILMAN KM, 1971, J NEUROL NEUROSUR PS, V34, P265, DOI 10.1136/jnnp.34.3.265; JENNETT B, 1972, DEV MED CHILD NEUROL, V14, P137; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; Levin H., 1979, J PEDIATR PSYCHOL, V4, P389, DOI DOI 10.1093/JPEPSY/4.4.389; LEVIN HS, 1985, SEMIN NEUROL, V5, P221, DOI 10.1055/s-2008-1041519; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1979, CHILD BRAIN, V5, P281; LEVIN HS, 1976, J NEUROL NEUROSUR PS, V39, P1062, DOI 10.1136/jnnp.39.11.1062; Levin HS., 1982, NEUROBEHAVIORAL CONS; RUTTER M, 1982, Journal of Clinical Neuropsychology, V4, P91, DOI 10.1080/01688638208401121; SARNO MT, 1980, J NERV MENT DIS, V168, P685, DOI 10.1097/00005053-198011000-00008; SARNO MT, 1984, J NERV MENT DIS, V172, P475, DOI 10.1097/00005053-198408000-00006; SATZ P, 1981, ACQUIRED APHASIA, P399; SHAFFER D, 1980, J AM ACAD CHILD PSY, V19, P592, DOI 10.1016/S0002-7138(09)60964-X; Spreen O., 1969, NEUROSENSORY CTR COM; TEASDALE G, 1974, LANCET, V2, P81; VANDONGEN HR, 1977, CORTEX, V13, P131, DOI 10.1016/S0010-9452(77)80004-X; VERMEULEN J, 1982, CORTEX, V18, P287; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218	44	107	107	1	7	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	OCT	1987	9	5					575	592		10.1080/01688638708410770			18	Psychology, Clinical; Clinical Neurology; Psychology	Social Science Citation Index (SSCI); Science Citation Index Expanded (SCI-EXPANDED)	Psychology; Neurosciences & Neurology	K0801	WOS:A1987K080100007	2444619				2022-02-06	
J	Lin, C; Chao, HL; Li, Z; Xu, XP; Liu, YL; Hou, LJ; Liu, N; Ji, J				Lin, Chao; Chao, Honglu; Li, Zheng; Xu, Xiupeng; Liu, Yinlong; Hou, Lijun; Liu, Ning; Ji, Jing			Melatonin attenuates traumatic brain injury-induced inflammation: a possible role for mitophagy	JOURNAL OF PINEAL RESEARCH			English	Article						inflammation; melatonin; mitophagy; traumatic brain injury	SUBARACHNOID HEMORRHAGE; PARKINSONS-DISEASE; NLRP3 INFLAMMASOME; INTRACEREBRAL HEMORRHAGE; POSSIBLE INVOLVEMENT; ALZHEIMERS-DISEASE; CELL-DEATH; AUTOPHAGY; ACTIVATION; PATHWAY	Melatonin functions as a crucial mediator of sterile neuroinflammation; however, the underlying mechanisms remain poorly understood. Dysfunctional mitochondria, a main source of reactive oxygen species, are impacted in inflammation activation. This study aimed to examine the effect of melatonin on inflammation via elimination of damaged mitochondria after controlled cortical impact, an invivo model of traumatic brain injury (TBI). Here, we demonstrated that inhibition of mitophagy, the selective degradation of damaged mitochondria by autophagy, markedly enhanced inflammation induced by TBI. Melatonin treatment activated mitophagy through the mTOR pathway, then to attenuate TBI-induced inflammation. Furthermore, treatment with melatonin significantly ameliorated neuronal death and behavioral deficits after TBI, while 3-methyladenine reversed this effect by inhibiting mitophagy. Taken together, these results highlight a role for melatonin in protecting against TBI-triggered immunopathology, which is accomplished by negatively regulating inflammation activation and IL-1 secretion via the autophagy of damaged mitochondria.	[Lin, Chao; Chao, Honglu; Li, Zheng; Xu, Xiupeng; Liu, Yinlong; Liu, Ning; Ji, Jing] Nanjing Med Univ, Dept Neurosurg, Affiliated Hosp 1, 300 Guangzhou Rd, Nanjing, Jiangsu, Peoples R China; [Hou, Lijun] Second Mil Med Univ, Dept Neurosurg, Changzheng Hosp, Shanghai, Peoples R China		Ji, J (corresponding author), Nanjing Med Univ, Dept Neurosurg, Affiliated Hosp 1, 300 Guangzhou Rd, Nanjing, Jiangsu, Peoples R China.	jijing@njmu.edu.cn			Jiangsu Innovation Project, China Scholarship Council [201508320270]; Jiangsu Province's Key Discipline of Medicine [XK201117]; Jiangsu Provincial Initiative Program for Excellency Disciplines, Jiangsu Province; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81471269, 81300998]	This study was supported by Jiangsu Innovation Project, China Scholarship Council (201508320270);Jiangsu Province's Key Discipline of Medicine (XK201117); the Jiangsu Provincial Initiative Program for Excellency Disciplines, Jiangsu Province and the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); National Natural Science Foundation of China (81471269 and 81300998).	Barth S, 2010, J PATHOL, V221, P117, DOI 10.1002/path.2694; Carloni S, 2014, J PINEAL RES, V57, P192, DOI 10.1111/jpi.12156; Chen JY, 2014, J PINEAL RES, V57, P340, DOI 10.1111/jpi.12173; Chen JY, 2014, J PINEAL RES, V56, P12, DOI 10.1111/jpi.12086; Cheung RTF, 2006, J PINEAL RES, V41, P337, DOI 10.1111/j.1600-079X.2006.00372.x; Cheung RTF, 2003, J PINEAL RES, V34, P153, DOI 10.1034/j.1600-079X.2003.00034.x; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Choi SI, 2013, J PINEAL RES, V54, P361, DOI 10.1111/jpi.12039; Dagda RK, 2009, J BIOL CHEM, V284, P13843, DOI 10.1074/jbc.M808515200; Ding K, 2015, NEUROCHEM INT, V91, P46, DOI 10.1016/j.neuint.2015.10.008; Ding K, 2014, NEUROCHEM INT, V76, P23, DOI 10.1016/j.neuint.2014.06.015; Dragicevic N, 2011, J PINEAL RES, V51, P75, DOI 10.1111/j.1600-079X.2011.00864.x; Esposito E, 2010, CURR NEUROPHARMACOL, V8, P228, DOI 10.2174/157015910792246155; Fluiter K, 2014, J IMMUNOL, V192, P2339, DOI 10.4049/jimmunol.1302793; Geisler S, 2010, NAT CELL BIOL, V12, P119, DOI 10.1038/ncb2012; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Guo WJ, 2014, AUTOPHAGY, V10, P972, DOI 10.4161/auto.28374; Hernandez-Ontiveros DG, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00030; Jabir MS, 2015, AUTOPHAGY, V11, P166, DOI 10.4161/15548627.2014.981915; Ji J, 2012, NAT NEUROSCI, V15, P1407, DOI 10.1038/nn.3195; Kaur C, 2013, J PINEAL RES, V54, P190, DOI 10.1111/jpi.12016; Kondo A, 2015, NATURE, V523, P431, DOI 10.1038/nature14658; Li Q, 2014, BIOCHEM BIOPH RES CO, V444, P182, DOI 10.1016/j.bbrc.2014.01.032; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Lupfer C, 2013, NAT IMMUNOL, V14, P480, DOI 10.1038/ni.2563; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Manchester LC, 2015, J PINEAL RES, V59, P403, DOI 10.1111/jpi.12267; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Naseem Mehar, 2014, ScientificWorldJournal, V2014, P586270, DOI 10.1155/2014/586270; Netea-Maier RT, 2016, AUTOPHAGY, V12, P245, DOI 10.1080/15548627.2015.1071759; Niyonkuru C, 2013, J NEUROTRAUM, V30, P938, DOI 10.1089/neu.2012.2578; Patki G, 2011, PHARMACOL BIOCHEM BE, V99, P704, DOI 10.1016/j.pbb.2011.06.026; Pattingre S, 2008, BIOCHIMIE, V90, P313, DOI 10.1016/j.biochi.2007.08.014; Pi HF, 2015, AUTOPHAGY, V11, P1037, DOI 10.1080/15548627.2015.1052208; Rosales-Corral SA, 2012, J PINEAL RES, V52, P167, DOI 10.1111/j.1600-079X.2011.00937.x; Rudnitskaya EA, 2015, BIOGERONTOLOGY, V16, P303, DOI 10.1007/s10522-014-9547-7; Sekiguchi A, 2012, J NEUROTRAUM, V29, P946, DOI 10.1089/neu.2011.1919; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Su LY, 2015, AUTOPHAGY, V11, P1745, DOI 10.1080/15548627.2015.1082020; Tajiri N, 2014, J NEUROSCI, V34, P313, DOI 10.1523/JNEUROSCI.2425-13.2014; Tapias V, 2010, J NEUROSCI RES, V88, P420, DOI 10.1002/jnr.22201; Twig G, 2008, EMBO J, V27, P433, DOI 10.1038/sj.emboj.7601963; Viscomi MT, 2012, AUTOPHAGY, V8, P222, DOI 10.4161/auto.8.2.18599; Wang XQ, 2014, NAT IMMUNOL, V15, P1126, DOI 10.1038/ni.3015; Wang Z, 2013, J PINEAL RES, V55, P399, DOI 10.1111/jpi.12087; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Xi G, 2002, ACT NEUR S, V81, P253; Yildirim FB, 2014, NEUROCHEM INT, V79, P1, DOI 10.1016/j.neuint.2014.09.005; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067; Yuan BQ, 2015, J NEUROIMMUNOL, V287, P71, DOI 10.1016/j.jneuroim.2015.08.002; Zhang HM, 2014, J PINEAL RES, V57, P131, DOI 10.1111/jpi.12162; Zhang ZR, 2013, J IMMUNOL, V190, P3517, DOI 10.4049/jimmunol.1202628; Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663	54	106	110	4	29	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0742-3098	1600-079X		J PINEAL RES	J. Pineal Res.	SEP	2016	61	2					177	186		10.1111/jpi.12337			10	Endocrinology & Metabolism; Neurosciences; Physiology	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Neurosciences & Neurology; Physiology	DS6OK	WOS:000380901300005	27117839				2022-02-06	
J	Fantini, S; Sassaroli, A; Tgavalekos, KT; Kornbluth, J				Fantini, Sergio; Sassaroli, Angelo; Tgavalekos, Kristen T.; Kornbluth, Joshua			Cerebral blood flow and autoregulation: current measurement techniques and prospects for noninvasive optical methods	NEUROPHOTONICS			English	Article						Cerebral perfusion; autoregulation; computed tomography perfusion; perfusion magnetic resonance imaging; transcranial Doppler; laser Doppler flowmetry; near-infrared spectroscopy; diffuse correlation spectroscopy; coherent hemodynamics spectroscopy	NEAR-INFRARED SPECTROSCOPY; TRANSCRANIAL DOPPLER ULTRASOUND; COHERENT HEMODYNAMICS SPECTROSCOPY; TRAUMATIC BRAIN-INJURY; DIFFUSE CORRELATION SPECTROSCOPY; INTRACRANIAL-PRESSURE; ARTERIAL-PRESSURE; SUBARACHNOID HEMORRHAGE; CEREBROVASCULAR REACTIVITY; MATHEMATICAL-MODEL	Cerebral blood flow (CBF) and cerebral autoregulation (CA) are critically important to maintain proper brain perfusion and supply the brain with the necessary oxygen and energy substrates. Adequate brain perfusion is required to support normal brain function, to achieve successful aging, and to navigate acute and chronic medical conditions. We review the general principles of CBF measurements and the current techniques to measure CBF based on direct intravascular measurements, nuclear medicine, X-ray imaging, magnetic resonance imaging, ultrasound techniques, thermal diffusion, and optical methods. We also review techniques for arterial blood pressure measurements as well as theoretical and experimental methods for the assessment of CA, including recent approaches based on optical techniques. The assessment of cerebral perfusion in the clinical practice is also presented. The comprehensive description of principles, methods, and clinical requirements of CBF and CA measurements highlights the potentially important role that noninvasive optical methods can play in the assessment of neurovascular health. In fact, optical techniques have the ability to provide a noninvasive, quantitative, and continuous monitor of CBF and autoregulation. (C) 2016 Society of Photo-Optical Instrumentation Engineers (SPIE)	[Fantini, Sergio; Sassaroli, Angelo; Tgavalekos, Kristen T.] Tufts Univ, Dept Biomed Engn, 4 Colby St, Medford, MA 02155 USA; [Kornbluth, Joshua] Tufts Univ, Div Neurocrit Care, Dept Neurol, Sch Med, 800 Washington St,Box 314, Boston, MA 02111 USA		Fantini, S (corresponding author), Tufts Univ, Dept Biomed Engn, 4 Colby St, Medford, MA 02155 USA.	sergio.fantini@tufts.edu	INECIKLI, MEHMET FATIH/AAK-5124-2020; Kornbluth, Joshua/U-7807-2019	INECIKLI, MEHMET FATIH/0000-0002-9796-8223; 	NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA154774] Funding Source: NIH RePORTER; NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01 CA154774] Funding Source: Medline		AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; Aaslid R, 2007, STROKE, V38, P1465, DOI 10.1161/STROKEAHA.106.473462; Agarwal N, 2008, J AFFECT DISORDERS, V110, P106, DOI 10.1016/j.jad.2008.01.013; Al-Rawi PG, 2006, STROKE, V37, P2720, DOI 10.1161/01.STR.0000244807.99073.ae; Andrews PJD, 2008, INTENS CARE MED, V34, P1362, DOI 10.1007/s00134-008-1103-y; Araki T, 2014, INT J GERIATR PSYCH, V29, P881, DOI 10.1002/gps.4074; Asenbaum S, 1998, J NUCL MED, V39, P613; Banaji M, 2005, MATH BIOSCI, V194, P125, DOI 10.1016/j.mbs.2004.10.005; Banaji M, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000212; BARBER TW, 1970, ACTA NEUROL SCAND, V46, P85, DOI 10.1111/j.1600-0404.1970.tb05606.x; Bassan H, 2005, PEDIATR RES, V57, P35, DOI 10.1203/01.PDR.0000147576.84092.F9; Beevers G, 2001, BMJ-BRIT MED J, V322, P1043, DOI 10.1136/bmj.322.7293.1043; Belanger M, 2011, CELL METAB, V14, P724, DOI 10.1016/j.cmet.2011.08.016; Bell RD, 2009, ACTA NEUROPATHOL, V118, P103, DOI 10.1007/s00401-009-0522-3; Berg RMG, 2016, SCAND J CLIN LAB INV, V76, P88, DOI 10.3109/00365513.2015.1091495; Bhatia A, 2007, INTENS CARE MED, V33, P1263, DOI 10.1007/s00134-007-0678-z; BIRCH AA, 1995, STROKE, V26, P834, DOI 10.1161/01.STR.26.5.834; Blokland JAK, 2002, EUR J RADIOL, V44, P70, DOI 10.1016/S0720-048X(02)00003-7; Boas DA, 1997, J OPT SOC AM A, V14, P192, DOI 10.1364/JOSAA.14.000192; BOGDAHN U, 1990, STROKE, V21, P1680, DOI 10.1161/01.STR.21.12.1680; Bor-Seng-Shu E, 2012, ARQ NEURO-PSIQUIAT, V70, P357, DOI 10.1590/S0004-282X2012000500010; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; Brady KM, 2007, STROKE, V38, P2818, DOI 10.1161/STROKEAHA.107.485706; Brickman AM, 2015, NEUROSCI LETT, V592, P54, DOI 10.1016/j.neulet.2015.03.005; Brown DW, 2002, PEDIATR RES, V51, P564, DOI 10.1203/00006450-200205000-00004; Buckley EM, 2014, NEUROPHOTONICS, V1, DOI 10.1117/1.NPh.1.1.011009; Budohoski KP, 2013, J CEREBR BLOOD F MET, V33, P449, DOI 10.1038/jcbfm.2012.189; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Burton VJ, 2015, BMC NEUROL, V15, DOI 10.1186/s12883-015-0464-4; Calamante F, 1999, J CEREBR BLOOD F MET, V19, P701, DOI 10.1097/00004647-199907000-00001; Caldwell M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126695; Calviere L, 2015, NEUROCRIT CARE, V23, P253, DOI 10.1007/s12028-015-0125-x; CARLSEN O, 1987, PHYS MED BIOL, V32, P1457, DOI 10.1088/0031-9155/32/11/007; Carlson AP, 2011, AM J NEURORADIOL, V32, P1315, DOI 10.3174/ajnr.A2522; Casati A, 2005, ANESTH ANALG, V101, P740, DOI 10.1213/01.ane.0000166974.96219.cd; Cebeci H, 2014, EUR J RADIOL, V83, P1914, DOI 10.1016/j.ejrad.2014.07.002; Charbel FT, 1999, J NEUROSURG, V91, P1050, DOI 10.3171/jns.1999.91.6.1050; CHEN RYZ, 1980, J APPL PHYSIOL, V49, P178, DOI 10.1152/jappl.1980.49.2.178; Chen XY, 2006, J NEUROPSYCH CLIN N, V18, P178, DOI 10.1176/appi.neuropsych.18.2.178; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Cooper JA, 2011, J APPL PHYSIOL, V110, P1691, DOI 10.1152/japplphysiol.01458.2010; Czosnyka M, 1997, J NEUROL NEUROSUR PS, V63, P721, DOI 10.1136/jnnp.63.6.721; da Costa Leodante, 2015, Acta Neurochir Suppl, V120, P105, DOI 10.1007/978-3-319-04981-6_18; de Boorder MJ, 2004, STROKE, V35, P1350, DOI 10.1161/01.STR.0000128530.75424.63; DETRE JA, 1992, MAGNET RESON MED, V23, P37, DOI 10.1002/mrm.1910230106; Detre JA, 1999, EUR J RADIOL, V30, P115, DOI 10.1016/S0720-048X(99)00050-9; DIEHL RR, 1995, STROKE, V26, P1801, DOI 10.1161/01.STR.26.10.1801; Dieterle T., 2012, SWISS MED WKLY, V142, P1; Dineen NE, 2010, J APPL PHYSIOL, V108, P604, DOI 10.1152/japplphysiol.01157.2009; DIRNAGL U, 1989, J CEREBR BLOOD F MET, V9, P589, DOI 10.1038/jcbfm.1989.84; Durduran T, 2004, THESIS; Durduran T, 2014, NEUROIMAGE, V85, P51, DOI 10.1016/j.neuroimage.2013.06.017; EDELMAN RR, 1994, RADIOLOGY, V192, P513, DOI 10.1148/radiology.192.2.8029425; EDWARDS AD, 1988, LANCET, V2, P770; ELWELL CE, 1994, J APPL PHYSIOL, V77, P2753, DOI 10.1152/jappl.1994.77.6.2753; Essig M, 2013, AM J ROENTGENOL, V200, P24, DOI 10.2214/AJR.12.9543; Fabbri F, 2003, BRAIN RES, V992, P193, DOI 10.1016/j.brainres.2003.08.034; Fantini S, 2016, PROC SPIE, V9690, DOI 10.1117/12.2213139; Fantini S, 2014, PHYSIOL MEAS, V35, pN1, DOI 10.1088/0967-3334/35/1/N1; Fantini S, 2014, NEUROIMAGE, V85, P202, DOI 10.1016/j.neuroimage.2013.03.065; Ferrari M, 2012, NEUROIMAGE, V63, P921, DOI 10.1016/j.neuroimage.2012.03.049; Fog M, 1939, ARCH NEURO PSYCHIATR, V41, P260, DOI 10.1001/archneurpsyc.1939.02270140046003; Fredriksson I, 2007, LASER DOPPLER FLOWME; GARDNER RM, 1981, ANESTHESIOLOGY, V54, P227, DOI 10.1097/00000542-198103000-00010; GILLER CA, 1990, NEUROSURGERY, V27, P362, DOI 10.1227/00006123-199009000-00004; Girouard H, 2006, J APPL PHYSIOL, V100, P328, DOI 10.1152/japplphysiol.00966.2005; Golay Xavier, 2004, Top Magn Reson Imaging, V15, P10, DOI 10.1097/00002142-200402000-00003; Granata G, 2015, AUTOIMMUN REV, V14, P830, DOI 10.1016/j.autrev.2015.05.006; Hahn GH, 2011, PEDIATR RES, V70, P166, DOI 10.1203/PDR.0b013e3182231d9e; Han SJ, 2015, J CLIN NEUROSCI, V22, P1771, DOI 10.1016/j.jocn.2015.05.026; HANSON EJ, 1975, CIRC RES, V36, P18, DOI 10.1161/01.RES.36.1.18; Hecht N, 2013, J CEREBR BLOOD F MET, V33, P1000, DOI 10.1038/jcbfm.2013.42; Hecht N, 2009, NEUROSURG FOCUS, V27, DOI 10.3171/2009.8.FOCUS09148; HERSCOVITCH P, 1985, J CEREBR BLOOD F MET, V5, P65, DOI 10.1038/jcbfm.1985.9; HERSCOVITCH P, 1983, J NUCL MED, V24, P782; HOEDTRASMUSSEN K, 1966, CIRC RES, V18, P237; Hoeffner EG, 2004, RADIOLOGY, V231, P632, DOI 10.1148/radiol.2313021488; HOLMAN BL, 1972, J NUCL MED, V13, P916; Hori D, 2015, ANESTH ANALG, V121, P1187, DOI 10.1213/ANE.0000000000000930; Horsfield MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062588; Hosoda K, 2001, STROKE, V32, P1567, DOI 10.1161/01.STR.32.7.1567; Iadecola C, 2004, NAT REV NEUROSCI, V5, P347, DOI 10.1038/nrn1387; Imamura K, 2012, ACTA NEUROL SCAND, V126, P210, DOI 10.1111/j.1600-0404.2012.01652.x; Imholz BPM, 1998, CARDIOVASC RES, V38, P605, DOI 10.1016/S0008-6363(98)00067-4; Indelicato E, 2015, PARKINSONISM RELAT D, V21, P1393, DOI 10.1016/j.parkreldis.2015.10.018; INGVAR DH, 1961, LANCET, V2, P806, DOI 10.1016/S0140-6736(61)91092-3; Ishizu K, 1996, J NUCL MED, V37, P1600; JOBES DR, 1975, ANESTHESIOLOGY, V42, P30, DOI 10.1097/00000542-197501000-00006; JOHNSON DW, 1991, AM J NEURORADIOL, V12, P201; Johnson U, 2014, NEUROCRIT CARE, V21, P259, DOI 10.1007/s12028-014-9954-2; Kainerstorfer JM, 2015, J CEREBR BLOOD F MET, V35, P959, DOI 10.1038/jcbfm.2015.5; Kainerstorfer JM, 2014, BIOMED OPT EXPRESS, V5, P3403, DOI 10.1364/BOE.5.003403; Kainerstorfer JM, 2014, ACAD RADIOL, V21, P185, DOI 10.1016/j.acra.2013.10.012; KETY SS, 1945, AM J PHYSIOL, V143, P53, DOI 10.1152/ajplegacy.1945.143.1.53; KETY SS, 1948, AM J PSYCHIAT, V104, P765, DOI 10.1176/ajp.104.12.765; KETY SS, 1951, PHARMACOL REV, V3, P1; KETY SS, 1948, J CLIN INVEST, V27, P476, DOI 10.1172/JCI101994; Kim MN, 2014, NEUROCRIT CARE, V20, P443, DOI 10.1007/s12028-013-9849-7; Kim S.- G., 1995, MAGN RESON MED, V37, P425; Kirkham SK, 2001, PHYSIOL MEAS, V22, P461, DOI 10.1088/0967-3334/22/3/305; KIRKPATRICK PJ, 1994, J NEUROL NEUROSUR PS, V57, P1382, DOI 10.1136/jnnp.57.11.1382; Knot HJ, 1998, J PHYSIOL-LONDON, V508, P199, DOI 10.1111/j.1469-7793.1998.199br.x; Koehler RC, 2009, TRENDS NEUROSCI, V32, P160, DOI 10.1016/j.tins.2008.11.005; Kolodjaschna J, 2005, INVEST OPHTH VIS SCI, V46, P636, DOI 10.1167/iovs.04-0717; Komoribayashi N, 2006, J CEREBR BLOOD F MET, V26, P878, DOI 10.1038/sj.jcbfm.9600244; KONTOS HA, 1981, ANNU REV PHYSIOL, V43, P397, DOI 10.1146/annurev.ph.43.030181.002145; Korfiatis P, 2014, APPL RADIOL, V43, P22; Kumar G, 2016, J NEUROSURG, V124, P1257, DOI 10.3171/2015.4.JNS15428; Kuo JR, 2013, J NEUROSCI METH, V214, P204, DOI 10.1016/j.jneumeth.2013.01.025; Lam JMK, 1997, J NEUROSURG, V86, P438, DOI 10.3171/jns.1997.86.3.0438; Lamy C, 2014, Handb Clin Neurol, V121, P1687, DOI 10.1016/B978-0-7020-4088-7.00109-7; LASSEN NA, 1988, J CEREBR BLOOD F MET, V8, pS13, DOI 10.1038/jcbfm.1988.28; LASSEN NA, 1985, J CEREBR BLOOD F MET, V5, P347, DOI 10.1038/jcbfm.1985.48; LASSEN NA, 1963, NEUROLOGY, V13, P719, DOI 10.1212/WNL.13.9.719; LASSEN NA, 1959, PHYSIOL REV, V39, P183, DOI 10.1152/physrev.1959.39.2.183; LASSEN NA, 1965, ACTA NEUROL SCAND, VS 41, P24; Latchaw RE, 2003, STROKE, V34, P1084, DOI 10.1161/01.STR.0000064840.99271.9E; Latka M, 2005, AM J PHYSIOL-HEART C, V289, pH2272, DOI 10.1152/ajpheart.01307.2004; Le Roux P., 2013, TXB NEUROINTENSIVE C, P127; Leal-Noval SR, 2010, INTENS CARE MED, V36, P1309, DOI 10.1007/s00134-010-1920-7; Lee JK, 2009, STROKE, V40, P1820, DOI 10.1161/STROKEAHA.108.536094; Lee SC, 2005, J CLIN NEUROSCI, V12, P520, DOI 10.1016/j.jocn.2004.07.016; Leung TS, 2007, APPL OPTICS, V46, P1604, DOI 10.1364/AO.46.001604; LEVEILLE J, 1989, J NUCL MED, V30, P1902; Li TQ, 2000, MAGN RESON IMAGING, V18, P503, DOI 10.1016/S0730-725X(00)00137-5; Lin BS, 2015, BMC NEUROL, V15, DOI 10.1186/s12883-015-0465-3; Lu J, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00199; Malinova V., 2015, J NEUROSURG, P1; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; Martin GT, 2000, MED BIOL ENG COMPUT, V38, P319, DOI 10.1007/BF02347053; MATSUDA H, 1992, CLIN NUCL MED, V17, P581, DOI 10.1097/00003072-199207000-00011; MCCORMICK PW, 1991, CRIT CARE MED, V19, P89, DOI 10.1097/00003246-199101000-00020; McDonnell MN, 2013, PEERJ, V1, DOI 10.7717/peerj.65; MEIER P, 1954, J APPL PHYSIOL, V6, P731, DOI 10.1152/jappl.1954.6.12.731; Melot C, 1996, J CEREBR BLOOD F MET, V16, P1263, DOI 10.1097/00004647-199611000-00022; Mesquita RC, 2013, BIOMED OPT EXPRESS, V4, P978, DOI 10.1364/BOE.4.000978; Miller C, 2014, NEUROCRIT CARE, V21, P121, DOI 10.1007/s12028-014-0021-9; Minciotti P, 1997, ITAL J NEUROL SCI, V18, P21, DOI 10.1007/BF02106226; Mitsis GD, 2004, IEEE T BIO-MED ENG, V51, P1932, DOI 10.1109/TBME.2004.834272; Monden Y, 2012, CLIN NEUROPHYSIOL, V123, P1147, DOI 10.1016/j.clinph.2011.10.006; Moxham IM, 2003, S AFRICAN J ANAESTH, V9, P33, DOI [10.1080/22201173.2003.10872990, DOI 10.1080/22201173.2003.10872990]; Nelson MR, 2010, MAYO CLIN PROC, V85, P460, DOI 10.4065/mcp.2009.0336; Nissen P, 2009, NEUROCRIT CARE, V11, P235, DOI 10.1007/s12028-009-9226-8; Novak V, 2004, BIOMED ENG ONLINE, V3, DOI 10.1186/1475-925X-3-39; Numan T, 2014, MED ENG PHYS, V36, P1487, DOI 10.1016/j.medengphy.2014.08.001; Ogedegbe G, 2010, CARDIOL CLIN, V28, P571, DOI 10.1016/j.ccl.2010.07.006; Olesen J, 1971, STROKE, V2, P519, DOI 10.1161/01.STR.2.6.519; Olufsen MS, 2002, AM J PHYSIOL-REG I, V282, pR611, DOI 10.1152/ajpregu.00285.2001; Orrison WW, 2011, CLIN RADIOL, V66, P566, DOI 10.1016/j.crad.2010.12.014; Ostergaard L, 2005, J MAGN RESON IMAGING, V22, P710, DOI 10.1002/jmri.20460; Ostergaard L, 1996, MAGN RESON MED, V36, P715, DOI 10.1002/mrm.1910360510; Ouriel K, 1999, J VASC SURG, V29, P82, DOI 10.1016/S0741-5214(99)70362-9; Panerai R. B., 1993, Proceedings. Computers in Cardiology 1993 (Cat. No.93CH3384-5), P779, DOI 10.1109/CIC.1993.378369; PANERAI RB, 1995, STROKE, V26, P74, DOI 10.1161/01.STR.26.1.74; Panerai RB, 1996, IEEE T BIO-MED ENG, V43, P779, DOI 10.1109/10.508541; Panerai RB, 1998, PHYSIOL MEAS, V19, P305, DOI 10.1088/0967-3334/19/3/001; Panerai RB, 1999, AM J PHYSIOL-HEART C, V277, pH1089, DOI 10.1152/ajpheart.1999.277.3.H1089; PARATI G, 1989, HYPERTENSION, V13, P647, DOI 10.1161/01.HYP.13.6.647; Payne SJ, 2006, MATH BIOSCI, V204, P260, DOI 10.1016/j.mbs.2006.08.006; Payne SJ, 2006, ANN BIOMED ENG, V34, P847, DOI 10.1007/s10439-006-9114-8; Payne SJ, 2011, BIOMED OPT EXPRESS, V2, P966, DOI 10.1364/BOE.2.000979; Peter L, 2014, IRBM, V35, P271, DOI 10.1016/j.irbm.2014.07.002; Pierro ML, 2014, J BIOMED OPT, V19, DOI 10.1117/1.JBO.19.2.026005; Pierro ML, 2014, NEUROIMAGE, V85, P222, DOI 10.1016/j.neuroimage.2013.03.037; Pinkham A, 2011, PSYCHIAT RES-NEUROIM, V194, P64, DOI 10.1016/j.pscychresns.2011.06.013; Pollard V, 1997, CRIT CARE MED, V25, P1700, DOI 10.1097/00003246-199710000-00020; POWERS WJ, 1985, J CEREBR BLOOD F MET, V5, P600, DOI 10.1038/jcbfm.1985.89; Proust F, 1999, STROKE, V30, P1091, DOI 10.1161/01.STR.30.5.1091; RAICHLE ME, 1983, J NUCL MED, V24, P790; RAICHLE ME, 1979, BRAIN RES REV, V1, P47, DOI 10.1016/0165-0173(79)90016-X; Reinhard M, 2014, J BIOMED OPT, V19, DOI 10.1117/1.JBO.19.9.097005; ROBERTS HC, 2001, SEM CEREBROVASC DIS, V1, P303; ROBERTS I, 1993, LANCET, V342, P1425, DOI 10.1016/0140-6736(93)92786-S; Rosenthal G, 2011, J NEUROSURG, V114, P62, DOI 10.3171/2010.6.JNS091360; Rostami E, 2014, FRONT NEUROL, V5, P1; Rostami E, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00089; Sabri O, 1997, LANCET, V349, P1735, DOI 10.1016/S0140-6736(96)08380-8; Sahani D. V., 2010, INT SOC MAGNETIC RES, V18; Salibi PN, 2014, AM J ROENTGENOL, V202, P397, DOI 10.2214/AJR.12.10294; Sanderson ML, 2002, FLOW MEAS INSTRUM, V13, P125, DOI 10.1016/S0955-5986(02)00043-2; Sassaroli A, 2016, J THEOR BIOL, V389, P132, DOI 10.1016/j.jtbi.2015.11.001; SATO T, 1993, HYPERTENSION, V21, P866, DOI 10.1161/01.HYP.21.6.866; Schmidt B, 2009, J NEUROTRAUM, V26, P651, DOI 10.1089/neu.2008.0784; SCHMIDT JF, 1990, J CARDIOVASC PHARM, V15, P983, DOI 10.1097/00005344-199006000-00017; Scholkmann F, 2014, NEUROIMAGE, V85, P6, DOI 10.1016/j.neuroimage.2013.05.004; Seubert C.N., 2013, TXB NEUROINTENSIVE C, P109, DOI [10.1007/978-1-4471-5226-2_7, DOI 10.1007/978-1-4471-5226-2_7]; Shin JH, 2002, AM J ROENTGENOL, V179, DOI 10.2214/ajr.179.3.1790783; Sidtis JJ, 2012, J CEREBR BLOOD F MET, V32, P41, DOI 10.1038/jcbfm.2011.135; Smith M, 2011, PHILOS T R SOC A, V369, P4452, DOI 10.1098/rsta.2011.0242; Smith NB, 2011, INTRO MED IMAGING PH; Soul JS, 2007, PEDIATR RES, V61, P467, DOI 10.1203/pdr.0b013e31803237f6; Soul JS, 2000, PEDIATR RES, V48, P445, DOI 10.1203/00006450-200010000-00005; Steiner LA, 2003, STROKE, V34, P2404, DOI 10.1161/01.STR.0000089014.59668.04; Steiner LA, 2009, NEUROCRIT CARE, V10, P122, DOI 10.1007/s12028-008-9140-5; STERN MD, 1975, NATURE, V254, P56, DOI 10.1038/254056a0; Sutherland BA, 2014, METHODS MOL BIOL, V1135, P237, DOI 10.1007/978-1-4939-0320-7_20; Tan CO, 2014, EXP PHYSIOL, V99, P3, DOI 10.1113/expphysiol.2013.072355; Tan CO, 2012, J APPL PHYSIOL, V113, P1194, DOI 10.1152/japplphysiol.00783.2012; Taussky P, 2012, NEUROSURG FOCUS, V32, DOI 10.3171/2011.12.FOCUS11280; TIECKS FP, 1995, STROKE, V26, P1014, DOI 10.1161/01.STR.26.6.1014; Tisdall MM, 2008, J NEUROSURG, V109, P424, DOI 10.3171/JNS/2008/109/9/0424; Togao O., 2016, NEUROONCOL, V18, P132; Torricelli A, 2014, NEUROIMAGE, V85, P28, DOI 10.1016/j.neuroimage.2013.05.106; Traystman RJ, 2004, J APPL PHYSIOL, V97, P1601, DOI 10.1152/classicessays.00023.2004; Tsalach A, 2015, BIOMED OPT EXPRESS, V6, P4871, DOI 10.1364/BOE.6.004871; Tsuji M, 2000, PEDIATRICS, V106, P625, DOI 10.1542/peds.106.4.625; Tsuji M, 1998, PEDIATR RES, V44, P591, DOI 10.1203/00006450-199810000-00020; Turowski B, 2015, CLIN NEURORADIOL, V25, P205, DOI 10.1007/s00062-015-0444-5; Tzeng YC, 2014, EUR J APPL PHYSIOL, V114, P545, DOI 10.1007/s00421-013-2667-y; Tzeng YC, 2011, J PHYSIOL-LONDON, V589, P3263, DOI 10.1113/jphysiol.2011.206953; Ursino M, 1998, AM J PHYSIOL-HEART C, V274, pH1715, DOI 10.1152/ajpheart.1998.274.5.H1715; Ursino M, 2000, AM J PHYSIOL-HEART C, V279, pH2439, DOI 10.1152/ajpheart.2000.279.5.H2439; URSINO M, 1991, ANN BIOMED ENG, V19, P15, DOI 10.1007/BF02368459; URSINO M, 1995, IEEE T BIO-MED ENG, V42, P529, DOI 10.1109/10.387192; URSINO M, 1988, ANN BIOMED ENG, V16, P379, DOI 10.1007/BF02364625; Ursino M, 1997, J APPL PHYSIOL, V82, P1256, DOI 10.1152/jappl.1997.82.4.1256; Vajkoczy P, 2000, J NEUROSURG, V93, P265, DOI 10.3171/jns.2000.93.2.0265; Valotassiou V, 2015, J ALZHEIMERS DIS, V47, P773, DOI 10.3233/JAD-150068; VALVANO JW, 1984, J BIOMECH ENG-T ASME, V106, P192, DOI 10.1115/1.3138482; Vasic N, 2015, J PSYCHIATR NEUROSCI, V40, P412, DOI 10.1503/jpn.140246; Vavilala Monica S, 2002, Anesthesiol Clin North Am, V20, P247, DOI 10.1016/S0889-8537(01)00012-8; Verdecchia K, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.2.027007; VILLRINGER A, 1988, MAGNET RESON MED, V6, P164, DOI 10.1002/mrm.1910060205; Wagner BP, 2011, PEDIATR RES, V69, P436, DOI 10.1203/PDR.0b013e3182110177; Wagner BP, 2002, CRIT CARE MED, V30, P2014, DOI 10.1097/00003246-200209000-00010; WALOVITCH RC, 1989, J NUCL MED, V30, P1892; WESSELING KH, 1995, HOMEOSTASIS HLTH DIS, V36, P67; Wierenga CE, 2014, J ALZHEIMERS DIS, V42, pS411, DOI 10.3233/JAD-141467; WILLIAMS DS, 1992, P NATL ACAD SCI USA, V89, P212, DOI 10.1073/pnas.89.1.212; Willie CK, 2012, J PHYSIOL-LONDON, V590, P3261, DOI 10.1113/jphysiol.2012.228551; Wilson EM, 1970, STROKE, V1, P348, DOI 10.1161/01.STR.1.5.348; Wintermark M, 2006, AM J NEURORADIOL, V27, P26; WOLFF J, 1994, ANESTHESIOLOGY, V81, P623, DOI 10.1097/00000542-199409000-00015; Wong EC, 1997, NMR BIOMED, V10, P237, DOI 10.1002/(SICI)1099-1492(199706/08)10:4/5<237::AID-NBM475>3.0.CO;2-X; Wong EC, 1998, MAGNET RESON MED, V39, P702, DOI 10.1002/mrm.1910390506; Wong FY, 2008, PEDIATRICS, V121, pE604, DOI 10.1542/peds.2007-1487; Yousem DM, 2014, NEUROIMAG CLIN N AM, V24, P717, DOI 10.1016/j.nic.2014.07.007; Zazulia AR, 2010, J CEREBR BLOOD F MET, V30, P1883, DOI 10.1038/jcbfm.2010.135; Zhang R, 1998, AM J PHYSIOL-HEART C, V274, pH233, DOI 10.1152/ajpheart.1998.274.1.H233; ZIERLER KL, 1965, CIRC RES, V16, P309, DOI 10.1161/01.RES.16.4.309; ZIERLER KL, 1962, CIRC RES, V10, P393, DOI 10.1161/01.RES.10.3.393; Zweifel C, 2010, STROKE, V41, P1963, DOI 10.1161/STROKEAHA.109.577320; ZYGMUNT SC, 1995, ACTA NEUROCHIR, V135, P179, DOI 10.1007/BF02187765	245	106	108	4	23	SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS	BELLINGHAM	1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA	2329-423X	2329-4248		NEUROPHOTONICS	Neurophotonics	JUL-SEP	2016	3	3							031411	10.1117/1.NPh.3.3.031411			31	Neurosciences; Optics	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Optics	EF8MG	WOS:000390582600011	27403447	Bronze, Green Published			2022-02-06	
J	Theadom, A; Parag, V; Dowell, T; McPherson, K; Starkey, N; Barker-Collo, S; Jones, K; Ameratunga, S; Feigin, VL				Theadom, Alice; Parag, Varsha; Dowell, Tony; McPherson, Kathryn; Starkey, Nicola; Barker-Collo, Suzanne; Jones, Kelly; Ameratunga, Shanthi; Feigin, Valery L.		BIONIC Res Grp	Persistent problems 1 year after mild traumatic brain injury: a longitudinal population study in New Zealand	BRITISH JOURNAL OF GENERAL PRACTICE			English	Article						epidemiology; head injury; mild traumatic brain injury; outcome; prediction	POST-CONCUSSION SYMPTOMS; HEAD-INJURY; RELIABILITY; QUESTIONNAIRE; GUIDELINES; VALIDITY; ADULTS; SCALE	Background Mild traumatic brain injury (mTBI) is a common problem in general practice settings, yet previous research does not take into account those who do not attend hospital after injury. This is important as there is evidence that effects may be far from mild. Aim To determine whether people sustain any persistent effects 1 year after mTBI, and to identify the predictors of health outcomes. Design and setting A community-based, longitudinal population study of an mTBI incidence cohort (n = 341) from a mixed urban and rural region (Hamilton and Waikato Districts) of the North Island of New Zealand (NZ). Method Adults (>16 years) completed assessments of cognitive functioning, global functioning, post-concussion symptoms, mood, and quality of life over the year after injury. Results Nearly half of participants (47.9%) reported experiencing four or more post-concussion symptoms 1 year post-injury. Additionally, 10.9% of participants revealed very low cognitive functioning. Levels of anxiety, depression, or reduced quality of life were comparable with the general population. Having at least one comorbidity, history of brain injury, living alone, non-white ethnic group, alcohol and medication use, and being female were significant predictors of poorer outcomes at 12 months. Conclusion Although some people make a spontaneous recovery after mTBI, nearly half continue to experience persistent symptoms linked to their injury. Monitoring of recovery from mTBI may be needed and interventions provided for those experiencing persistent difficulties. Demographic factors and medical history should be taken into account in treatment planning.	[Theadom, Alice; Jones, Kelly] Natl Inst Stroke & Appl Neurosci, Auckland, New Zealand; [Feigin, Valery L.] Natl Inst Stroke & Appl Neurosci, Neurol & Epidemiol, Auckland, New Zealand; [McPherson, Kathryn] Auckland Univ Technol, Hlth & Rehabil Inst, Person Centred Res Ctr, Rehabil, Auckland, New Zealand; [Parag, Varsha] Natl Inst Hlth Innovat, Auckland, New Zealand; [Barker-Collo, Suzanne] Univ Auckland, Sch Psychol, Psychol, Auckland 1, New Zealand; [Ameratunga, Shanthi] Univ Auckland, Sch Populat Hlth, Epidemiol, Auckland 1, New Zealand; [Dowell, Tony] Univ Otago, Primary Hlth Care & Gen Practice, Primary Hlth Care, Wellington, New Zealand; [Starkey, Nicola] Univ Waikato, Sch Psychol, Psychol, Hamilton, New Zealand		Theadom, A (corresponding author), Auckland Univ Technol, Natl Inst Stroke & Appl Neurosci, 90 Akoranga Dr, Auckland 1142, New Zealand.	alice.theadom@aut.ac.nz	Feigin, Valery/AAF-2313-2019; Jones, Kelly/I-5199-2019; Starkey, Nicola/AAJ-3795-2020	Starkey, Nicola/0000-0002-4370-8186; Ameratunga, Shanthi/0000-0001-8042-2251; McPherson, Kath/0000-0003-0487-8497; Feigin, Valery L./0000-0002-6372-1740; McPherson, Kathryn/0000-0003-1240-8882	Health Research Council of New ZealandHealth Research Council of New Zealand [09/063A, 11/192]; ABI Management Rehabilitation	This work was funded by the Health Research Council of New Zealand (09/063A, 11/192), although the research was conducted independently from the sponsor. Alice Theadom was co-funded by ABI Management Rehabilitation and Kathryn McPherson holds the Laura Fergusson Trust Chair.	Ahman S, 2013, J REHABIL MED, V45, P758, DOI 10.2340/16501977-1182; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Barker-Collo S, 2013, BRAIN INJURY, V27, P1124, DOI 10.3109/02699052.2013.801513; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Crawford JR, 2001, BRIT J CLIN PSYCHOL, V40, P429, DOI 10.1348/014466501163904; Cunningham J, 2011, J EMERG MED, V40, P262, DOI 10.1016/j.jemermed.2008.08.017; Dischinger P, 2003, Annu Proc Assoc Adv Automot Med, V47, P577; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Gualtieri CT, 2006, ARCH CLIN NEUROPSYCH, V21, P623, DOI 10.1016/j.acn.2006.05.007; Gualtieri C Thomas, 2008, Medscape J Med, V10, P90; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; IVERSON GL, 2012, REHABIL RES PRACT, V2012, DOI DOI 10.1155/2012/316575; JENNETT B, 1975, LANCET, V1, P480; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; MaGPIe Research Group, 2003, NZ MED J, V116, pU379; Marshall S, 2012, CAN FAM PHYSICIAN, V58, P257; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; O'Keeffe FM, 2004, COGNITIVE BRAIN RES, V22, P101, DOI 10.1016/j.cogbrainres.2004.07.012; Ontario Neurotrauma Foundation, 2013, GUID CONC MILD TRAUM; Petrie KJ, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005374; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; Ponsford J, 2005, CURR OPIN NEUROL, V18, P692, DOI 10.1097/01.wco.0000186840.61431.44; SANCHEZCRAIG M, 1995, AM J PUBLIC HEALTH, V85, P823, DOI 10.2105/AJPH.85.6.823; Silverberg ND, 2015, J NEUROTRAUM, V32, P517, DOI 10.1089/neu.2014.3600; Theadom A, 2012, NEUROEPIDEMIOLOGY, V38, P18, DOI 10.1159/000334746; Waljas M, 2015, J NEUROTRAUM, V32, P534, DOI 10.1089/neu.2014.3339; Ware J.E., 1994, SF 36 PHYS MENTAL SU; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	35	106	106	0	9	ROYAL COLL GENERAL PRACTITIONERS	LONDON	14 PRINCES GATE, HYDE PARK, LONDON SW7 1PU, ENGLAND	0960-1643	1478-5242		BRIT J GEN PRACT	Br. J. Gen. Pract.	JAN	2016	66	642					E16	E23		10.3399/bjgp16X683161			8	Primary Health Care; Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DC3UW	WOS:000369145400003	26719482	Bronze, Green Published			2022-02-06	
J	Lynall, RC; Mauntel, TC; Padua, DA; Mihalik, JP				Lynall, Robert C.; Mauntel, Timothy C.; Padua, Darin A.; Mihalik, Jason P.			Acute Lower Extremity Injury Rates Increase after Concussion in College Athletes	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						MUSCULOSKELETAL INJURY RISK; POSTCONCUSSION DEFICITS; CONCUSSION; INJURY; COLLEGE ATHLETICS	STABILITY FOLLOWING CONCUSSION; SPORT-RELATED CONCUSSION; BALANCE CONTROL; POSTURAL STABILITY; FOOTBALL PLAYERS; HIGH-SCHOOL; GAIT; RECOVERY; ATTENTION; RISK	Dynamic postural control deficits and disrupted cortical pathways have been reported to persist beyond an athlete's return to activity after concussion, potentially increasing the risk of acute lower extremity musculoskeletal injury. Purpose This study aimed to investigate acute lower extremity musculoskeletal injury rates before and after concussion in athletes with concussion and their matched control. Methods College athletes with concussion (n = 44; age, 20.0 1.2 yr) were physician-diagnosed. Nonconcussed college athletes (n = 58; age, 20.5 1.3 yr) were matched to individuals with concussion. Acute lower extremity musculoskeletal injury data were collected for 2 yr (+/- 1 yr of the diagnosed concussion) using electronic medical records. Control participants' 2-yr window for exposure and musculoskeletal injury data were anchored to their match's concussion injury date. Pre- and postconcussion musculoskeletal injury rates were calculated for 90-, 180-, and 365-d periods for both study cohorts. Risk ratios were calculated to determine differences within and between groups for all periods. Results Within 1 yr after concussion, the group with concussion was 1.97 (95% confidence interval (CI), 1.19-3.28; P = 0.01) times more likely to have experienced an acute lower extremity musculoskeletal injury after concussion than before concussion and 1.64 times (95% CI, 1.07-2.51; P = 0.02) more likely to have experienced an acute lower extremity musculoskeletal injury after concussion than their matched nonconcussed cohort over the same period. Up to 180 d after concussion, the group with concussion was 2.02 (95% CI, 1.08-3.78; P = 0.02) times more likely to have experienced an acute lower extremity musculoskeletal injury after concussion than before concussion. Conclusions Previous literature has identified dynamic postural control deficits along with increased motor evoked potential latency and decreased amplitude after concussion, suggesting that the brain may be unable to effectively coordinate movement. Our findings underscore the need to explore functional movement and dynamic postural control assessments in postconcussion injury assessment protocols.	[Lynall, Robert C.; Mihalik, Jason P.] Univ N Carolina, Dept Exercise & Sport Sci, Matthew Gfeller Sport Related Traumat Brain Injur, Chapel Hill, NC 27599 USA; [Lynall, Robert C.; Mauntel, Timothy C.; Padua, Darin A.; Mihalik, Jason P.] Univ N Carolina, Dept Allied Hlth Sci, Sch Med, Curriculum Human Movement Sci, Chapel Hill, NC 27599 USA; [Mauntel, Timothy C.; Padua, Darin A.] Univ N Carolina, Dept Exercise & Sport Sci, Sports Med Res Lab, Chapel Hill, NC 27599 USA; [Mihalik, Jason P.] Univ N Carolina, Injury Prevent Res Ctr, Chapel Hill, NC 27599 USA		Lynall, RC (corresponding author), Univ N Carolina, 2207 Stallings Evans Sports Med Ctr,Campus Box 87, Chapel Hill, NC 27599 USA.	rlynall@live.unc.edu	Lynall, Robert/M-2888-2014	Lynall, Robert/0000-0002-0785-6640; Padua, Darin/0000-0002-9383-4236			Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Catena RD, 2007, EXP BRAIN RES, V176, P23, DOI 10.1007/s00221-006-0596-2; Catena RD, 2007, GAIT POSTURE, V25, P406, DOI 10.1016/j.gaitpost.2006.05.006; Catena RD, 2011, J NEUROENG REHABIL, V8, DOI 10.1186/1743-0003-8-8; Catena RD, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-25; De Beaumont L, 2011, J ATHL TRAINING, V46, P234; Finch C F, 1999, J Sci Med Sport, V2, P42, DOI 10.1016/S1440-2440(99)80183-2; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Howell DR, 2015, MED SCI SPORT EXER, V47, P673, DOI 10.1249/MSS.0000000000000462; Kristenson K, 2013, AM J SPORT MED, V41, P1419, DOI 10.1177/0363546513485358; LINDENFELD TN, 1994, AM J SPORT MED, V22, P364, DOI 10.1177/036354659402200312; Livingston SC, 2012, J CLIN NEUROPHYSIOL, V29, P23, DOI 10.1097/WNP.0b013e318246ae46; Livingston SC, 2010, BRAIN INJURY, V24, P904, DOI 10.3109/02699051003789245; Martini DN, 2011, ARCH PHYS MED REHAB, V92, P585, DOI 10.1016/j.apmr.2010.11.029; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Nordstrom A, 2014, BRIT J SPORT MED, V48, P1447, DOI 10.1136/bjsports-2013-093406; Parker TM, 2005, CLIN BIOMECH, V20, P389, DOI 10.1016/j.clinbiomech.2004.12.004; Parker TM, 2007, BRIT J SPORT MED, V41, P868, DOI 10.1136/bjsm.2006.033761; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Pietrosimone B, 2015, MED SCI SPORT EXER, V47, P2366, DOI 10.1249/MSS.0000000000000684; Pietrosimone BG, 2012, J ATHL TRAINING, V47, P621, DOI 10.4085/1062-6050-47.6.11; Plisky PJ, 2006, J ORTHOP SPORT PHYS, V36, P911, DOI 10.2519/jospt.2006.2244; Powers KC, 2014, BRAIN INJURY, V28, P465, DOI 10.3109/02699052.2014.888759; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Zazulak BT, 2007, AM J SPORT MED, V35, P1123, DOI 10.1177/0363546507301585	30	106	106	0	44	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	DEC	2015	47	12					2487	2492		10.1249/MSS.0000000000000716			6	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	CV8TX	WOS:000364561800001	26057941				2022-02-06	
J	Hsieh, CL; Niemi, EC; Wang, SH; Lee, CC; Bingham, D; Zhang, JS; Cozen, ML; Charo, I; Huang, EJ; Liu, JL; Nakamura, MC				Hsieh, Christine L.; Niemi, Erene C.; Wang, Sarah H.; Lee, Chih Cheng; Bingham, Deborah; Zhang, Jiasheng; Cozen, Myrna L.; Charo, Israel; Huang, Eric J.; Liu, Jialing; Nakamura, Mary C.			CCR2 Deficiency Impairs Macrophage Infiltration and Improves Cognitive Function after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; CCR2; chemotaxis; inflammation; macrophage	CHEMOKINE RECEPTOR CCR2; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FOCAL CEREBRAL-ISCHEMIA; CENTRAL-NERVOUS-SYSTEM; SPINAL-CORD-INJURY; NEUROPATHIC PAIN; MOUSE MODEL; HIPPOCAMPAL NEUROGENESIS; MONOCYTE RECRUITMENT; CRANIAL IRRADIATION	Traumatic brain injury (TBI) provokes inflammatory responses, including a dramatic rise in brain macrophages in the area of injury. The pathway(s) responsible for macrophage infiltration of the traumatically injured brain and the effects of macrophages on functional outcomes are not well understood. C-C-chemokine receptor 2 (CCR2) is known for directing monocytes to inflamed tissues. To assess the role of macrophages and CCR2 in TBI, we determined outcomes in CCR2-deficient (Ccr2(-/-)) mice in a controlled cortical impact model. We quantified brain myeloid cell numbers post-TBI by flow cytometry and found that Ccr2(-/-) mice had greatly reduced macrophage numbers (similar to 80-90% reduction) early post-TBI, compared with wild-type mice. Motor, locomotor, and cognitive outcomes were assessed. Lack of Ccr2 improved locomotor activity with less hyperactivity in open field testing, but did not affect anxiety levels or motor coordination on the rotarod three weeks after TBI. Importantly, Ccr2(-/-) mice demonstrated greater spatial learning and memory, compared with wildtype mice eight weeks after TBI. Although there was no difference in the volume of tissue loss, Ccr2(-/-) mice had significantly increased neuronal density in the CA1-CA3 regions of the hippocampus after TBI, compared with wild-type mice. These data demonstrate that Ccr2 directs the majority of macrophage homing to the brain early after TBI and indicates that Ccr2 may facilitate harmful responses. Lack of Ccr2 improves functional recovery and neuronal survival. These results suggest that therapeutic blockade of CCR2-dependent responses may improve outcomes following TBI.	[Hsieh, Christine L.; Niemi, Erene C.; Wang, Sarah H.; Nakamura, Mary C.] San Francisco VA Med Ctr, Immunol Sect, San Francisco, CA 94121 USA; [Lee, Chih Cheng; Bingham, Deborah; Liu, Jialing] San Francisco VA Med Ctr, Dept Neurol Surg, San Francisco, CA 94121 USA; [Zhang, Jiasheng; Huang, Eric J.] San Francisco VA Med Ctr, Pathol Serv, San Francisco, CA 94121 USA; [Cozen, Myrna L.] San Francisco VA Med Ctr, Ctr Liver, San Francisco, CA 94121 USA; [Hsieh, Christine L.; Niemi, Erene C.; Wang, Sarah H.; Cozen, Myrna L.; Charo, Israel; Nakamura, Mary C.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Lee, Chih Cheng; Bingham, Deborah; Liu, Jialing] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA; [Zhang, Jiasheng; Huang, Eric J.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA; [Charo, Israel] Gladstone Inst Cardiovasc Dis, San Francisco, CA USA		Hsieh, CL (corresponding author), San Francisco VA Med Ctr, Immunol Sect, 4150 Clement St,111-R Bldg 2,Room 500, San Francisco, CA 94121 USA.	Christine.Hsieh@ucsf.edu	Huang, Eric J./AAH-7997-2019; Nakamura, Mary/ABI-2887-2020; Liu, Jialing/A-8627-2012	Huang, Eric J./0000-0002-5381-3801; Liu, Jialing/0000-0003-4420-4382; Nakamura, Mary C./0000-0001-8127-9426	Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development Career Development Award-2US Department of Veterans Affairs; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and DevelopmentUS Department of Veterans Affairs; Russell/Engelman Center for Arthritis Research; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL102475] Funding Source: NIH RePORTER	The authors thank Ruby Gribi of the San Francisco VA Flow Cytometry core, Ivy Hsieh and Sherry Kamiya of the San Francisco VA Cell Imaging core for their dedication and contributions to this project. This material is based upon work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development Career Development Award-2 to CLH. MCN is supported in part by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development Merit Award and by the Russell/Engelman Center for Arthritis Research. With tremendous gratitude, we acknowledge Dr. William E. Seaman for helpful discussions and an insightful review of this manuscript.	Abbadie C, 2003, P NATL ACAD SCI USA, V100, P7947, DOI 10.1073/pnas.1331358100; Ajami B, 2007, NAT NEUROSCI, V10, P1538, DOI 10.1038/nn2014; Ajami B, 2011, NAT NEUROSCI, V14, P1142, DOI 10.1038/nn.2887; Aoyama K, 2006, NAT NEUROSCI, V9, P119, DOI 10.1038/nn1609; Belarbi K, 2013, CANCER RES, V73, P1201, DOI 10.1158/0008-5472.CAN-12-2989; Bonecchi R, 2009, FRONT BIOSCI-LANDMRK, V14, P540, DOI 10.2741/3261; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; Bose S, 2013, ARCH PHARM RES, V36, P1039, DOI 10.1007/s12272-013-0161-z; Chawla A, 2010, CIRC RES, V106, P1559, DOI 10.1161/CIRCRESAHA.110.216523; Chen Y, 2006, J CLIN INVEST, V116, P1317, DOI 10.1172/JCI25308; Clausen F, 2011, EUR J NEUROSCI, V34, P110, DOI 10.1111/j.1460-9568.2011.07723.x; Colton CA, 2009, J NEUROIMMUNE PHARM, V4, P399, DOI 10.1007/s11481-009-9164-4; Daley JM, 2010, J LEUKOCYTE BIOL, V87, P59, DOI 10.1189/jlb.0409236; Derecki NC, 2011, BRAIN BEHAV IMMUN, V25, P379, DOI 10.1016/j.bbi.2010.11.009; Dimitrijevic OB, 2007, STROKE, V38, P1345, DOI 10.1161/01.STR.0000259709.16654.8f; Donnelly DJ, 2011, J NEUROSCI, V31, P9910, DOI 10.1523/JNEUROSCI.2114-11.2011; Dulawa SC, 1999, J NEUROSCI, V19, P9550; El Khoury J, 2007, NAT MED, V13, P432, DOI 10.1038/nm1555; Fan Y, 2007, EUR J NEUROSCI, V25, P38, DOI 10.1111/j.1460-9568.2006.05269.x; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Geissmann F, 2010, NAT REV IMMUNOL, V10, P453, DOI 10.1038/nri2784; Gomez CR, 2005, CURR OPIN IMMUNOL, V17, P457, DOI 10.1016/j.coi.2005.07.013; Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733; Greter M, 2013, GLIA, V61, P121, DOI 10.1002/glia.22408; Hammond MD, 2014, J NEUROSCI, V34, P3901, DOI 10.1523/JNEUROSCI.4070-13.2014; Hong SM, 2007, EXP NEUROL, V206, P24, DOI 10.1016/j.expneurol.2007.03.028; Hsieh CL, 2013, EUR J IMMUNOL, V43, P2010, DOI 10.1002/eji.201243084; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Izikson L, 2000, J EXP MED, V192, P1075, DOI 10.1084/jem.192.7.1075; Jain KK, 2008, DRUG DISCOV TODAY, V13, P1082, DOI 10.1016/j.drudis.2008.09.006; Jenkins SJ, 2011, SCIENCE, V332, P1284, DOI 10.1126/science.1204351; Jin XM, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0041892, 10.1371/journal.pone.0040637]; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Lam TI, 2013, NEUROREHAB NEURAL RE, V27, P889, DOI 10.1177/1545968313491003; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Leuschner F, 2011, NAT BIOTECHNOL, V29, P1005, DOI 10.1038/nbt.1989; Liu ZY, 2007, STROKE, V38, P146, DOI 10.1161/01.STR.0000251791.64910.cd; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Mahad DJ, 2003, SEMIN IMMUNOL, V15, P23, DOI 10.1016/S1044-5323(02)00125-2; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Manville J, 2007, J MOL NEUROSCI, V31, P95, DOI 10.1385/JMN/31:02:95; Matsumori Y, 2006, NEUROBIOL DIS, V22, P187, DOI 10.1016/j.nbd.2005.10.015; Melik-Parsadaniantz S, 2008, J NEUROIMMUNOL, V198, P62, DOI 10.1016/j.jneuroim.2008.04.022; Mizutani M, 2012, J IMMUNOL, V188, P29, DOI 10.4049/jimmunol.1100421; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Naert G, 2011, J NEUROSCI, V31, P6208, DOI 10.1523/JNEUROSCI.0299-11.2011; Niemi JP, 2013, J NEUROSCI, V33, P16236, DOI 10.1523/JNEUROSCI.3319-12.2013; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; Potts Mathew B, 2006, NeuroRx, V3, P143; Prut L, 2003, EUR J PHARMACOL, V463, P3, DOI 10.1016/S0014-2999(03)01272-X; Quinones MP, 2005, J MOL MED, V83, P672, DOI 10.1007/s00109-005-0637-5; Raber J, 2004, ANN NEUROL, V55, P381, DOI 10.1002/ana.10853; Saederup N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013693; Schall TJ, 2011, NAT REV IMMUNOL, V11, P355, DOI 10.1038/nri2972; SEDGWICK JD, 1991, P NATL ACAD SCI USA, V88, P7438, DOI 10.1073/pnas.88.16.7438; Semple BD, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-67; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Shechter R, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000113; Shi C, 2011, NAT REV IMMUNOL, V11, P762, DOI 10.1038/nri3070; Sinopoli KJ, 2012, INT J DEV NEUROSCI, V30, P207, DOI 10.1016/j.ijdevneu.2011.08.006; Smith C, 2013, NEUROPATH APPL NEURO, V39, P35, DOI 10.1111/nan.12006; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Sonoda KH, 2011, ACTA OPHTHALMOL, V89, pE180, DOI 10.1111/j.1755-3768.2010.01953.x; Suh SW, 2005, DIABETES, V54, P1452, DOI 10.2337/diabetes.54.5.1452; Suh SW, 2003, J NEUROSCI, V23, P10681; Tran PB, 2007, J COMP NEUROL, V500, P1007, DOI 10.1002/cne.21229; Weber MS, 2007, NAT MED, V13, P935, DOI 10.1038/nm1620; White FA, 2009, MOL INTERV, V9, P188, DOI 10.1124/mi.9.4.7; Willenborg S, 2012, BLOOD, V120, P613, DOI 10.1182/blood-2012-01-403386; Xing ZQ, 2010, DIS MODEL MECH, V3, P451, DOI 10.1242/dmm.003186; Zhang J, 2007, J NEUROSCI, V27, P12396, DOI 10.1523/JNEUROSCI.3016-07.2007; Zhang Z, 2006, NEUROSCIENCE, V141, P637, DOI 10.1016/j.neuroscience.2006.04.027; Ziebell JM, 2011, BRAIN RES, V1414, P94, DOI 10.1016/j.brainres.2011.07.056; Zweemer AJM, 2013, MOL PHARMACOL, V84, P551, DOI 10.1124/mol.113.086850	80	106	107	0	16	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 15	2014	31	20					1677	1688		10.1089/neu.2013.3252			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AP8BF	WOS:000342302200001	24806994	Green Published			2022-02-06	
J	Mishra, AM; Bai, XX; Sanganahalli, BG; Waxman, SG; Shatillo, O; Grohn, O; Hyder, F; Pitkanen, A; Blumenfeld, H				Mishra, Asht Mangal; Bai, Xiaoxiao; Sanganahalli, Basavaraju G.; Waxman, Stephen G.; Shatillo, Olena; Grohn, Olli; Hyder, Fahmeed; Pitkanen, Asla; Blumenfeld, Hal			Decreased Resting Functional Connectivity after Traumatic Brain Injury in the Rat	PLOS ONE			English	Article							CHILDHOOD ABSENCE EPILEPSY; TONIC-CLONIC SEIZURES; POSTTRAUMATIC EPILEPSY; WAG/RIJ RATS; FMRI; EPILEPTOGENESIS; MODEL; MRI; FLUCTUATIONS; NETWORKS	Traumatic brain injury (TBI) contributes to about 10% of acquired epilepsy. Even though the mechanisms of post-traumatic epileptogenesis are poorly known, a disruption of neuronal networks predisposing to altered neuronal synchrony remains a viable candidate mechanism. We tested a hypothesis that resting state BOLD-fMRI functional connectivity can reveal network abnormalities in brain regions that are connected to the lesioned cortex, and that these changes associate with functional impairment, particularly epileptogenesis. TBI was induced using lateral fluid-percussion injury in seven adult male Sprague-Dawley rats followed by functional imaging at 9.4T 4 months later. As controls we used six sham-operated animals that underwent all surgical operations but were not injured. Electroencephalogram (EEG)-functional magnetic resonance imaging (fMRI) was performed to measure resting functional connectivity. A week after functional imaging, rats were implanted with bipolar skull electrodes. After recovery, rats underwent pentyleneterazol (PTZ) seizure-susceptibility test under EEG. For image analysis, four pairs of regions of interests were analyzed in each hemisphere: ipsilateral and contralateral frontal and parietal cortex, hippocampus, and thalamus. High-pass and low-pass filters were applied to functional imaging data. Group statistics comparing injured and sham-operated rats and correlations over time between each region were calculated. In the end, rats were perfused for histology. None of the rats had epileptiform discharges during functional imaging. PTZ-test, however revealed increased seizure susceptibility in injured rats as compared to controls. Group statistics revealed decreased connectivity between the ipsilateral and contralateral parietal cortex and between the parietal cortex and hippocampus on the side of injury as compared to sham-operated animals. Injured animals also had abnormal negative connectivity between the ipsilateral and contralateral parietal cortex and other regions. Our data provide the first evidence on abnormal functional connectivity after experimental TBI assessed with resting state BOLD-fMRI.	[Mishra, Asht Mangal; Bai, Xiaoxiao; Waxman, Stephen G.; Blumenfeld, Hal] Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT 06520 USA; [Blumenfeld, Hal] Yale Univ, Sch Med, Dept Neurosurg, New Haven, CT USA; [Sanganahalli, Basavaraju G.; Hyder, Fahmeed] Yale Univ, Sch Med, Dept Diagnost Radiol, New Haven, CT 06510 USA; [Hyder, Fahmeed] Yale Univ, Sch Med, Dept Biomed Engn, New Haven, CT USA; [Mishra, Asht Mangal; Sanganahalli, Basavaraju G.; Hyder, Fahmeed; Blumenfeld, Hal] Yale Univ, Core Ctr Quantitat Neurosci Magnet Resonance, New Haven, CT USA; [Waxman, Stephen G.] Ctr Neurosci & Regenerat Res, West Haven, CT USA; [Grohn, Olli] Univ Eastern Finland, Biomed NMR Res Grp, Biomed Imaging Unit, Kuopio, Finland; [Shatillo, Olena; Pitkanen, Asla] Univ Eastern Finland, AI Virtanen Inst Mol Sci, Dept Neurobiol, Kuopio, Finland; [Pitkanen, Asla] Kuopio Univ Hosp, Dept Neurol, SF-70210 Kuopio, Finland		Blumenfeld, H (corresponding author), Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT 06520 USA.	hal.blumenfeld@yale.edu	khan, yusuf/AAQ-9470-2021; Hyder, Fahmeed/A-2644-2015; Sanganahalli, Basavaraju G/C-3296-2008; MISHRA, AWDHESH/U-1920-2019; khan, yusuf/E-6726-2015; Muthamilarasan, Mehanathan/H-9340-2017; Waxman, Stephen/Z-2507-2019; Prasad, Manoj/AAE-8540-2019	Hyder, Fahmeed/0000-0001-7822-4002; Sanganahalli, Basavaraju G/0000-0002-0851-6621; khan, yusuf/0000-0001-6986-4657; Muthamilarasan, Mehanathan/0000-0001-7589-6372; Waxman, Stephen/0000-0001-5718-7177; Prasad, Manoj/0000-0003-0691-0163; /0000-0002-3312-3264	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS049307]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS066974]; Epilepsy Foundation Postdoctoral Research and Training Award [123505]; Yale QNMR Pilot study; Betsy and Jonathan Blattmachr family; Academy of FinlandAcademy of FinlandEuropean Commission; Sigrid Juselius FoundationSigrid Juselius Foundation;  [P30 NS052519]	This work was supported by National Institutes of Health (NIH) R01 NS049307 (HB), NIH R01 NS066974 (HB), Epilepsy Foundation Postdoctoral Research and Training Award ID: 123505 (AMM), Yale QNMR Pilot study (AMM), P30 NS052519 (FH), the Betsy and Jonathan Blattmachr family (HB), the Academy of Finland (AP, OG), and by the Sigrid Juselius Foundation (AP). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bai X, 2011, NEUROLOGY, V76, P1960, DOI 10.1212/WNL.0b013e31821e54de; Bassett DS, 2009, CURR OPIN NEUROL, V22, P340, DOI 10.1097/WCO.0b013e32832d93dd; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Biswal BB, 2010, P NATL ACAD SCI USA, V107, P4734, DOI 10.1073/pnas.0911855107; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Coggan JS, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/6/065002; Cymerblit-Sabba A, 2010, J NEUROSCI, V30, P1619, DOI 10.1523/JNEUROSCI.5078-09.2010; D'Esposito M, 2003, NAT REV NEUROSCI, V4, P863, DOI 10.1038/nrn1246; DeSalvo MN, 2010, NEUROIMAGE, V50, P902, DOI 10.1016/j.neuroimage.2010.01.006; El-Hassar L, 2007, EPILEPSIA, V48, P131, DOI 10.1111/j.1528-1167.2007.01301.x; Englot DJ, 2008, J NEUROSCI, V28, P9066, DOI 10.1523/JNEUROSCI.2014-08.2008; Fox MD, 2007, NAT REV NEUROSCI, V8, P700, DOI 10.1038/nrn2201; Franken ND, 2008, VET ANAESTH ANALG, V35, P424, DOI 10.1111/j.1467-2995.2008.00404.x; Hayward NMEA, 2010, J NEUROTRAUM, V27, P2203, DOI 10.1089/neu.2010.1448; Hayward NMEA, 2011, J CEREBR BLOOD F MET, V31, P166, DOI 10.1038/jcbfm.2010.67; Hettinger PC, 2011, J NEUROSCI METH, V200, P106, DOI 10.1016/j.jneumeth.2011.06.018; Immonen R, 2013, J NEUROTRAUM, P1; Jenkins G.M., 1968, SPECTRAL ANAL ITS AP; Karhunen H, 2007, NEUROSCIENCE, V148, P314, DOI 10.1016/j.neuroscience.2007.05.047; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharatishvili I, 2007, BRAIN, V130, P3155, DOI 10.1093/brain/awm268; Khubchandani M, 2003, MAGNET RESON MED, V49, P962, DOI 10.1002/mrm.10441; Killory BD, 2011, NEUROIMAGE, V56, P2209, DOI 10.1016/j.neuroimage.2011.03.036; Kumar R, 2010, J HEAD TRAUMA REHAB, V25, P31, DOI 10.1097/HTR.0b013e3181bff331; Kumar S, 2009, J NEUROTRAUM, V26, P665, DOI [10.1089/neu.2008.0644, 10.1089/neu.2008-0644]; Lemieux L, 2011, FRONT SYST NEUROSCI, V5, DOI 10.3389/fnsys.2011.00012; Lowe MJ, 1998, NEUROIMAGE, V7, P119, DOI 10.1006/nimg.1997.0315; Makinen S, 2008, J CEREBR BLOOD F MET, V28, P263, DOI 10.1038/sj.jcbfm.9600529; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Mishra AM, 2009, EPILEPSIA, V50, P362; Mishra AM, 2011, J NEUROSCI, V31, P15053, DOI 10.1523/JNEUROSCI.0101-11.2011; Nersesyan H, 2004, J CEREBR BLOOD F MET, V24, P589, DOI 10.1097/01.WCB.0000117688.98763.23; Niskanen JP, 2013, J NEUROTRAUM, V30, P546, DOI 10.1089/neu.2012.2416; Pitkanen A, 2011, NEUROSCI LETT, V497, P163, DOI 10.1016/j.neulet.2011.02.033; Pitkanen A, 2009, EPILEPSIA, V50, P21, DOI 10.1111/j.1528-1167.2008.02007.x; Raz E, 2011, AM J NEURORADIOL, V32, P1851, DOI 10.3174/ajnr.A2637; Sachdev RNS, 2003, NEUROIMAGE, V19, P742, DOI 10.1016/S1053-8119(03)00093-4; Volman V, 2013, NEURAL COMPUT, V25, P2646, DOI 10.1162/NECO_a_00491; Waites AB, 2006, ANN NEUROL, V59, P335, DOI 10.1002/ana.20733; Weber R, 2006, NEUROIMAGE, V29, P1303, DOI 10.1016/j.neuroimage.2005.08.028; Zhao FQ, 2008, NEUROIMAGE, V39, P248, DOI 10.1016/j.neuroimage.2007.07.063	41	106	111	0	32	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 18	2014	9	4							e95280	10.1371/journal.pone.0095280			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AG2DP	WOS:000335226500074	24466268	gold, Green Published, Green Submitted			2022-02-06	
J	Tajiri, N; Acosta, SA; Shahaduzzaman, M; Ishikawa, H; Shinozuka, K; Pabon, M; Hernandez-Ontiveros, D; Kim, DW; Metcalf, C; Staples, M; Dailey, T; Vasconcellos, J; Franyuti, G; Gould, L; Patel, N; Cooper, D; Kaneko, Y; Borlongan, CV; Bickford, PC				Tajiri, Naoki; Acosta, Sandra A.; Shahaduzzaman, Md; Ishikawa, Hiroto; Shinozuka, Kazutaka; Pabon, Mibel; Hernandez-Ontiveros, Diana; Kim, Dae Won; Metcalf, Christopher; Staples, Meaghan; Dailey, Travis; Vasconcellos, Julie; Franyuti, Giorgio; Gould, Lisa; Patel, Niketa; Cooper, Denise; Kaneko, Yuji; Borlongan, Cesar V.; Bickford, Paula C.			Intravenous Transplants of Human Adipose-Derived Stem Cell Protect the Brain from Traumatic Brain Injury-Induced Neurodegeneration and Motor and Cognitive Impairments: Cell Graft Biodistribution and Soluble Factors in Young and Aged Rats	JOURNAL OF NEUROSCIENCE			English	Article						aging; brain injury; stem cell	LONG NONCODING RNAS; CONTROLLED CORTICAL IMPACT; NEURAL STEM; CONDITIONED MEDIUM; PARKINSONS-DISEASE; TISSUE INHIBITOR; PROGENITOR CELLS; THERAPY; ADULT; DIFFERENTIATION	Traumatic brain injury (TBI) survivors exhibit motor and cognitive symptoms from the primary injury that can become aggravated over time because of secondary cell death. In the present in vivo study, we examined the beneficial effects of human adipose-derived stem cells (hADSCs) in a controlled cortical impact model of mild TBI using young (6 months) and aged (20 months) F344 rats. Animals were transplanted intravenously with 4 X 10(6) hADSCs (Tx), conditioned media (CM), or vehicle (unconditioned media) at 3 h after TBI. Significant amelioration of motor and cognitive functions was revealed in young, but not aged, Tx and CM groups. Fluorescent imaging in vivo and ex vivo revealed 1,1' dioactadecyl-3-3-3',3'-tetramethylindotricarbocyanine iodide-labeled hADSCs in peripheral organs and brain after TBI. Spatiotemporal deposition of hADSCs differed between young and aged rats, most notably reduced migration to the aged spleen. Significant reduction in cortical damage and hippocampal cell loss was observed in both Tx and CM groups in young rats, whereas less neuroprotection was detected in the aged rats and mainly in the Tx group but not the CM group. CM harvested from hADSCs with silencing of either NEAT1 (nuclear enriched abundant transcript 1) or MALAT1 (metastasis associated lung adenocarcinoma transcript 1), long noncoding RNAs (lncRNAs) known to play a role in gene expression, lost the efficacy in our model. Altogether, hADSCs are promising therapeutic cells for TBI, and lncRNAs in the secretome is an important mechanism of cell therapy. Furthermore, hADSCs showed reduced efficacy in aged rats, which may in part result from decreased homing of the cells to the spleen.	[Tajiri, Naoki; Acosta, Sandra A.; Shahaduzzaman, Md; Ishikawa, Hiroto; Shinozuka, Kazutaka; Pabon, Mibel; Hernandez-Ontiveros, Diana; Kim, Dae Won; Metcalf, Christopher; Staples, Meaghan; Dailey, Travis; Vasconcellos, Julie; Franyuti, Giorgio; Kaneko, Yuji; Borlongan, Cesar V.; Bickford, Paula C.] Univ S Florida, Morsani Coll Med, Dept Neurosurg & Brain Repair, Ctr Excellence Aging & Brain Repair, Tampa, FL 33612 USA; [Tajiri, Naoki] Univ S Florida, Morsani Coll Med, Sch Phys Therapy & Rehabil Sci, Tampa, FL 33612 USA; [Shahaduzzaman, Md; Gould, Lisa; Patel, Niketa; Cooper, Denise; Bickford, Paula C.] James A Haley Vet Affairs Hosp, Res Serv, Tampa, FL 33612 USA; [Hernandez-Ontiveros, Diana; Gould, Lisa; Borlongan, Cesar V.; Bickford, Paula C.] Univ S Florida, Morsani Coll Med, Dept Mol Pharmacol & Physiol, Tampa, FL 33612 USA; [Patel, Niketa; Cooper, Denise] Univ S Florida, Morsani Coll Med, Dept Mol Med, Tampa, FL 33612 USA		Borlongan, CV (corresponding author), Univ S Florida, Dept Neurosurg & Brain Repair, 12901 Bruce B Downs Blvd, Tampa, FL 33612 USA.	Denise.cooper@va.gov; ykaneko@health.usf.edu; cborlong@health.usf.edu; pbickfor@health.usf.edu	Borlongan, Cesar/I-5696-2012; Bickford, Paula C/J-5970-2012	Borlongan, Cesar/0000-0002-2966-9782; Bickford, Paula C/0000-0001-9657-7725; Patel, Niketa A./0000-0003-4811-8596; Franyuti Kelly, Giorgio Alberto/0000-0002-7173-7339; Shinozuka, Kazutaka/0000-0002-6435-4460; Ishikawa, Hiroto/0000-0003-0760-7203	National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke Grant [1R01NS071956-01]; Department of Defense GrantUnited States Department of Defense [W81XWH1110634]; James and Esther King Foundation for Biomedical Research Program Grant [1KG01-33966]; SanBio; Celgene Cellular TherapeuticsBristol-Myers SquibbCelgene Corporation; KM Pharmaceutical Consulting LLC; NeuralStem; Veterans Affairs Medical Research ServiceUS Department of Veterans Affairs; NIH/National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [1PO1AG-04418-27, 1R01 AG044919]; Michael J. Fox Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS071956] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG004418, R01AG044919] Funding Source: NIH RePORTER	C.V.B. is supported by National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke Grant 1R01NS071956-01, Department of Defense Grant W81XWH1110634, James and Esther King Foundation for Biomedical Research Program Grant 1KG01-33966, SanBio, Celgene Cellular Therapeutics, KM Pharmaceutical Consulting LLC and NeuralStem. P.C.B. is supported by Veterans Affairs Medical Research Service, NIH/National Institute on Aging Grants 1PO1AG-04418-27 and 1R01 AG044919, and the Michael J. Fox Foundation.	Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Ajmo CT, 2008, J NEUROSCI RES, V86, P2227, DOI 10.1002/jnr.21661; Arslan F, 2013, STEM CELL RES, V10, P301, DOI 10.1016/j.scr.2013.01.002; Baek SJ, 2011, EXP MOL MED, V43, P596, DOI 10.3858/emm.2011.43.10.069; Bernard D, 2010, EMBO J, V29, P3082, DOI 10.1038/emboj.2010.199; Bjorklund LM, 2002, P NATL ACAD SCI USA, V99, P2344, DOI 10.1073/pnas.022438099; Bjugstad KB, 2008, EXP NEUROL, V211, P362, DOI 10.1016/j.expneurol.2008.01.025; Blaber SP, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-172; Boddington Sophie, 2008, J Vis Exp, DOI 10.3791/686; Bond CS, 2009, J CELL BIOL, V186, P637, DOI 10.1083/jcb.200906113; BORLONGAN CV, 1995, J NEUROSCI, V15, P5372; Borlongan CV, 1998, NEUROREPORT, V9, P3615, DOI 10.1097/00001756-199811160-00012; Carlson ME, 2007, AGING CELL, V6, P371, DOI 10.1111/j.1474-9726.2007.00286.x; Cho YJ, 2012, J NEUROSCI RES, V90, P1794, DOI 10.1002/jnr.23063; Clarkson ED, 2001, DRUG AGING, V18, P773, DOI 10.2165/00002512-200118100-00006; Clemson CM, 2009, MOL CELL, V33, P717, DOI 10.1016/j.molcel.2009.01.026; Conboy IM, 2005, NATURE, V433, P760, DOI 10.1038/nature03260; Darkazalli A, 2012, HISTOL HISTOPATHOL, V27, P1255, DOI 10.14670/HH-27.1255; Derrien T, 2012, GENOME RES, V22, P1775, DOI 10.1101/gr.132159.111; Detante O, 2009, CELL TRANSPLANT, V18, P1369, DOI 10.3727/096368909X474230; Egashira Y, 2012, BRAIN RES, V1461, P87, DOI 10.1016/j.brainres.2012.04.033; Faul M, 2010, TRAUMATIC BRAIN INJU; Fox AH, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000687; Fraser JK, 2006, TRENDS BIOTECHNOL, V24, P150, DOI 10.1016/j.tibtech.2006.01.010; Galindo LT, 2011, NEUROL RES INT, V2011, DOI 10.1155/2011/564089; Glover LE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033646; Harting MT, 2009, J SURG RES, V153, P188, DOI 10.1016/j.jss.2008.03.037; Hawkins BE, 2013, BRAIN RES, V1496, P28, DOI 10.1016/j.brainres.2012.12.027; Hayashi T, 2009, BRAIN RES, V1280, P172, DOI 10.1016/j.brainres.2009.05.040; Ibrahim AG, 2009, EXP NEUROL, V215, P142, DOI 10.1016/j.expneurol.2008.09.023; Ikegame Y, 2011, CYTOTHERAPY, V13, P675, DOI 10.3109/14653249.2010.549122; Isacson O, 2001, PARKINSONISM RELAT D, V7, P205, DOI 10.1016/S1353-8020(00)00059-6; Jang YY, 2011, MOL IMAGING, V10, P111, DOI 10.2310/7290.2010.00046; Katsuda T, 2013, SCI REP-UK, V3, DOI 10.1038/srep01197; Kim WS, 2007, J DERMATOL SCI, V48, P15, DOI 10.1016/j.jdermsci.2007.05.018; Lee P, 2012, EXP NEUROL, V234, P50, DOI 10.1016/j.expneurol.2011.12.016; Lefebvre JS, 2012, AGING CELL, V11, P732, DOI 10.1111/j.1474-9726.2012.00836.x; Lendeckel S, 2004, J CRANIO MAXILL SURG, V32, P370, DOI 10.1016/j.jcms.2004.06.002; Li M, 2011, J TRAUMA, V71, P141, DOI [10.1097/TA.0b013e3181f30fc9, 10.1088/1742-5468/2011/12/P12001]; LINDVALL O, 1990, SCIENCE, V247, P574, DOI 10.1126/science.2105529; Liu YP, 2009, ACTA NEUROPATHOL, V117, P469, DOI 10.1007/s00401-009-0516-1; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; McDonald KG, 2011, IMMUN AGEING, V8, DOI 10.1186/1742-4933-8-1; Mercer TR, 2013, NAT STRUCT MOL BIOL, V20, P300, DOI 10.1038/nsmb.2480; Michalet X, 2005, SCIENCE, V307, P538, DOI 10.1126/science.1104274; Mizuno H, 2012, STEM CELLS, V30, P804, DOI 10.1002/stem.1076; Muraoka K, 2008, J NEUROSURG, V108, P149, DOI 10.3171/JNS/2008/108/01/0149; Naganuma T, 2013, RNA BIOL, V10, P456, DOI 10.4161/rna.23547; Nakagawa S, 2012, CELL MOL LIFE SCI, V69, P3027, DOI 10.1007/s00018-012-0973-x; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6; Qi JH, 2003, NAT MED, V9, P407, DOI 10.1038/nm846; Ribeiro CA, 2012, STEM CELL RES THER, V3, DOI 10.1186/scrt109; Sasaki YTF, 2009, P NATL ACAD SCI USA, V106, P2525, DOI 10.1073/pnas.0807899106; Singer NG, 2011, ANNU REV PATHOL-MECH, V6, P457, DOI 10.1146/annurev-pathol-011110-130230; SOLANTO MV, 1984, PSYCHOL BULL, V95, P387; Spadaro Paola A., 2012, Frontiers in Genetics, V3, P132, DOI 10.3389/fgene.2012.00132; Sugiyama T, 2011, NEUROSURGERY, V68, P1036, DOI 10.1227/NEU.0b013e318208f891; Sun J, 2012, CELLS TISSUES ORGANS, V196, P510, DOI 10.1159/000339245; Ushiki T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011114; Vendrame M, 2006, EXP NEUROL, V199, P191, DOI 10.1016/j.expneurol.2006.03.017; Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116; Walker PA, 2010, EXP NEUROL, V225, P341, DOI 10.1016/j.expneurol.2010.07.005; Walker PA, 2009, DIS MODEL MECH, V2, P23, DOI 10.1242/dmm.001198; Wapinski O, 2011, TRENDS CELL BIOL, V21, P354, DOI 10.1016/j.tcb.2011.04.001; Xue S, 2010, NEUROSCI LETT, V473, P186, DOI 10.1016/j.neulet.2010.02.035; Yang M, 2003, CELL MOL NEUROBIOL, V23, P851, DOI 10.1023/A:1025017423102; Yao J, 2012, REJUV RES, V15, P495, DOI 10.1089/rej.2012.1325; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067; Zhang B, 2012, CELL REP, V2, P111, DOI 10.1016/j.celrep.2012.06.003	69	106	111	0	24	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474	1529-2401		J NEUROSCI	J. Neurosci.	JAN 1	2014	34	1					313	326		10.1523/JNEUROSCI.2425-13.2014			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	282NE	WOS:000329177800030	24381292	Green Published, Bronze			2022-02-06	
J	Talving, P; Karamanos, E; Teixeira, PG; Skiada, D; Lam, L; Belzberg, H; Inaba, K; Demetriades, D				Talving, Peep; Karamanos, Efstathios; Teixeira, Pedro G.; Skiada, Dimitra; Lam, Lydia; Belzberg, Howard; Inaba, Kenji; Demetriades, Demetrios			Intracranial pressure monitoring in severe head injury: compliance with Brain Trauma Foundation guidelines and effect on outcomes: a prospective study Clinical article	JOURNAL OF NEUROSURGERY			English	Article						intracranial pressure monitoring; mortality; brain herniation; Brain Trauma Foundation guidelines; traumatic brain injury	INTENSIVE-CARE; UNITED-STATES; MANAGEMENT	Object. The Brain Trauma Foundation (BTF) has established guidelines for intracranial pressure (ICP) monitoring in severe traumatic brain injury (TBI). This study assessed compliance with these guidelines and the effect on outcomes. Methods. This is a prospective, observational study including patients with severe blunt TBI (Glasgow Coma Scale score <= 8, head Abbreviated Injury Scale score a 3) between January 2010 and December 2011. Demographics, clinical characteristics, laboratory profile, head CT scans, injury severity indices, and interventions were collected. The study population was stratified into 2 study groups: ICP monitoring and no ICP monitoring. Primary outcomes included compliance with BTF guidelines, overall in-hospital mortality, and mortality due to brain herniation. Secondary outcomes were ICU and hospital lengths of stay. Multiple regression analyses were deployed to determine the effect of ICP monitoring on outcomes. Results. A total of 216 patients met the BTF guideline criteria for ICP monitoring. Compliance with BTF guidelines was 46.8% (101 patients). Patients with subarachnoid hemorrhage and those who underwent craniectomy/craniotomy were significantly more likely to undergo ICP monitoring. Hypotension, coagulopathy, and increasing age were negatively associated with the placement of ICP monitoring devices. The overall in-hospital mortality was significantly higher in patients who did not undergo ICP monitoring (53.9% vs 32.7%, adjusted p = 0.019). Similarly, mortality due to brain herniation was significantly higher for the group not undergoing ICP monitoring (21.7% vs 12.9%, adjusted p = 0.046). The ICU and hospital lengths of stay were significantly longer in patients subjected to ICP monitoring. Conclusions. Compliance with BTF ICP monitoring guidelines in our study sample was 46.8%. Patients managed according to the BTF ICP guidelines experienced significantly improved survival.	[Talving, Peep; Karamanos, Efstathios; Teixeira, Pedro G.; Skiada, Dimitra; Lam, Lydia; Belzberg, Howard; Inaba, Kenji; Demetriades, Demetrios] Los Angeles Cty Univ Southern Calif Med Ctr, Keck Sch Med, Div Acute Care Surg Trauma Emergency Surg & Surg, Dept Surg, Los Angeles, CA USA		Talving, P (corresponding author), LAC USC Med Ctr, Keck Sch Med, Dept Surg, Div Acute Care Surg, 2051 Marengo St,Rm IPT C5L100, Los Angeles, CA 90033 USA.	peep.talving@surgery.usc.edu	INABA, KENJI/AAC-8532-2020; Talving, Peep/E-6015-2013; Teixeira, Pedro/H-2239-2011; Karamanos, Efstathios/AAU-8082-2020; Talving, Peep/G-8621-2015	Teixeira, Pedro/0000-0002-7258-7977; Karamanos, Efstathios/0000-0002-5118-4642; Talving, Peep/0000-0002-9741-2073			Bratton SL, 2008, J NEUROTRAUM, V25, P276; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Hesdorffer DC, 2002, J TRAUMA, V52, P1202, DOI 10.1097/00005373-200206000-00031; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Idris Z, 2007, ASIAN J SURG, V30, P200, DOI 10.1016/S1015-9584(08)60023-8; Jeevaratnam DR, 1996, BRIT MED J, V312, P944; Lane PL, 2000, CAN J SURG, V43, P442; Lee TT, 1998, ACTA NEUROCHIR, V140, P41, DOI 10.1007/s007010050055; LOBATO RD, 1986, J NEUROSURG, V65, P784, DOI 10.3171/jns.1986.65.6.0784; Miller MT, 2004, J TRAUMA, V56, P967, DOI 10.1097/01.TA.0000123699.16465.8B; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; Palmer S, 2001, J TRAUMA, V50, P657, DOI 10.1097/00005373-200104000-00010; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Poca MA, 1998, ACT NEUR S, V71, P27; Sahjpaul R, 2000, CAN J NEUROL SCI, V27, P143; Shafi S, 2008, J TRAUMA, V64, P335, DOI 10.1097/TA.0b013e31815dd017; Stocchetti N, 2001, INTENS CARE MED, V27, P400, DOI 10.1007/s001340000825; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Wilkins IA, 2001, ANAESTHESIA, V56, P350, DOI 10.1046/j.1365-2044.2001.01708.x	23	106	113	0	17	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	NOV	2013	119	5					1248	1254		10.3171/2013.7.JNS122255			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	238OB	WOS:000325956200031	23971954				2022-02-06	
J	Mannix, R; Meehan, WP; Mandeville, J; Grant, PE; Gray, T; Berglass, J; Zhang, J; Bryant, J; Rezaie, S; Chung, JY; Peters, NV; Lee, C; Tien, LW; Kaplan, DL; Feany, M; Whalen, M				Mannix, Rebekah; Meehan, William P.; Mandeville, Joseph; Grant, Patricia E.; Gray, Tory; Berglass, Jacqueline; Zhang, Jimmy; Bryant, John; Rezaie, Shervin; Chung, Joon Yong; Peters, Nicholas V.; Lee, Christopher; Tien, Lee W.; Kaplan, David L.; Feany, Mel; Whalen, Michael			Clinical Correlates in an Experimental Model of Repetitive Mild Brain Injury	ANNALS OF NEUROLOGY			English	Article							APOLIPOPROTEIN-E; MOUSE MODEL; ALZHEIMERS-DISEASE; HEAD-INJURY; A-BETA; COGNITIVE PERFORMANCE; TRANSGENIC MICE; DEFICITS; E4; SUSCEPTIBILITY	ObjectiveAlthough there is growing awareness of the long-term cognitive effects of repetitive mild traumatic brain injury (rmTBI; eg, sports concussions), whether repeated concussions cause long-term cognitive deficits remains controversial. Moreover, whether cognitive deficits depend on increased amyloid deposition and tau phosphorylation or are worsened by the apolipoprotein E4 allele remains unknown. Here, we use an experimental model of rmTBI to address these clinical controversies. MethodsA weight drop rmTBI model was used that results in cognitive deficits without loss of consciousness, seizures, or gross or microscopic evidence of brain damage. Cognitive function was assessed using a Morris water maze (MWM) paradigm. Immunostaining and enzyme-linked immunosorbent assay (ELISA) were used to assess amyloid deposition and tau hyperphosphorylation. Brain volume and white matter integrity were assessed by magnetic resonance imaging (MRI). ResultsMice subjected to rmTBI daily or weekly but not biweekly or monthly had persistent cognitive deficits as long as 1 year after injuries. Long-term cognitive deficits were associated with increased astrocytosis but not tau phosphorylation or amyloid (by ELISA); plaques or tangles (by immunohistochemistry); or brain volume loss or changes in white matter integrity (by MRI). APOE4 was not associated with worse MWM performance after rmTBI. InterpretationWithin the vulnerable time period between injuries, rmTBI produces long-term cognitive deficits independent of increased amyloid or tau phosphorylation. In this model, cognitive outcome is not influenced by APOE4 status. The data have implications for the long-term mental health of athletes who suffer multiple concussions. Ann Neurol 2013;74:65-75	[Mannix, Rebekah; Meehan, William P.; Berglass, Jacqueline; Zhang, Jimmy] Boston Childrens Hosp, Div Emergency Med, Boston, MA USA; [Mannix, Rebekah; Meehan, William P.; Mandeville, Joseph; Grant, Patricia E.; Feany, Mel; Whalen, Michael] Harvard Univ, Sch Med, Boston, MA USA; [Meehan, William P.] Sports Concuss Clin, Div Sports Med, Boston, MA USA; [Meehan, William P.] Micheli Ctr Sports Injury Prevent, Boston, MA USA; [Mandeville, Joseph; Grant, Patricia E.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; [Grant, Patricia E.] Childrens Hosp Boston, Dept Radiol, Boston, MA 02115 USA; [Gray, Tory; Bryant, John; Rezaie, Shervin; Chung, Joon Yong; Peters, Nicholas V.; Lee, Christopher; Whalen, Michael] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA; [Gray, Tory; Bryant, John; Rezaie, Shervin; Chung, Joon Yong; Peters, Nicholas V.; Lee, Christopher; Whalen, Michael] Massachusetts Gen Hosp, Neurosci Ctr, Charlestown, MA 02129 USA; [Tien, Lee W.; Kaplan, David L.] Tufts Univ, Dept Biomed Engn, Boston, MA 02111 USA; [Feany, Mel] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA		Mannix, R (corresponding author), Childrens Hosp Boston, 300 Longwood Ave, Boston, MA 02115 USA.	Rebekah.Mannix@childrens.harvard.edu; MWhalen@Partners.org	Mannix, Rebekah/AAD-8702-2020	Feany, Mel/0000-0003-0315-7970; Chung, Joon Yong/0000-0002-3980-2065	NFL; NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040128-06]; Charles Hood Foundation; NIH National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS075226]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS075226] Funding Source: NIH RePORTER	This study was supported by the NFL Charities Medical Grant (R. M., W. P. M., M. W.), NICHD T32HD040128-06 (W. P. M.), Charles Hood Foundation (R. M.), and NIH National Institute of Neurological Disorders and Stroke R21NS075226 (M. W.).	Barreto GE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027881; Bower JH, 2003, NEUROLOGY, V60, P1610, DOI 10.1212/01.WNL.0000068008.78394.2C; Cai YM, 2012, ANESTHESIOLOGY, V116, P84, DOI 10.1097/ALN.0b013e31823da7a2; Callaway JK, 2012, EUR J ANAESTH, V29, P239, DOI 10.1097/EJA.0b013e32835103c1; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Chappell MH, 2006, J MAGN RESON IMAGING, V24, P537, DOI 10.1002/jmri.20656; Collie A, 2004, NEUROLOGY, V63, P2460, DOI 10.1212/WNL.63.12.2460; Creeley CE, 2004, ACAD EMERG MED, V11, P809, DOI 10.1197/j.aem.2004.03.006; CRITCHLEY M, 1957, BMJ-BRIT MED J, V1, P357, DOI 10.1136/bmj.1.5015.357; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; GRAHMANN H, 1957, Psychiatr Neurol (Basel), V134, P261; Hartman RE, 2001, EXP NEUROL, V170, P326, DOI 10.1006/exnr.2001.7715; Hinkle DA, 1997, J NEUROTRAUM, V14, P729, DOI 10.1089/neu.1997.14.729; Holtzman DM, 2000, P NATL ACAD SCI USA, V97, P2892, DOI 10.1073/pnas.050004797; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Jordan BD, 1998, PHYSICIAN SPORTSMED, V26, P25, DOI 10.3810/psm.1998.02.928; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Khuman J MWI, 2009, 2 JOINT S INT NAT NE, VSanta Barbara, CA; Kida K, 2012, RESUSCITATION, V83, P1292, DOI 10.1016/j.resuscitation.2012.02.020; Kutner KC, 2000, NEUROSURGERY, V47, P651, DOI 10.1097/00006123-200009000-00026; Lein ES, 2007, NATURE, V445, P168, DOI 10.1038/nature05453; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Mannix RC, 2011, J CEREBR BLOOD F MET, V31, P351, DOI 10.1038/jcbfm.2010.99; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; McCrory PR, 2000, NEUROLOGY, V54, P1488, DOI 10.1212/WNL.54.7.1488; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Moran LM, 2009, J NEUROTRAUM, V26, P1489, DOI 10.1089/neu.2008.0767; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Oddo S, 2006, J BIOL CHEM, V281, P39413, DOI 10.1074/jbc.M608485200; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Raber J, 1998, P NATL ACAD SCI USA, V95, P10914, DOI 10.1073/pnas.95.18.10914; Raber J, 2000, NATURE, V404, P352, DOI 10.1038/35006165; Shankar GM, 2008, NAT MED, V14, P837, DOI 10.1038/nm1782; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Wang J, 1999, EXP NEUROL, V158, P328, DOI 10.1006/exnr.1999.7085; Yoshiyama Y, 2005, J NEUROTRAUM, V22, P1134, DOI 10.1089/neu.2005.22.1134	45	106	106	1	25	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	JUL	2013	74	1					65	75		10.1002/ana.23858			11	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	282UH	WOS:000329198600009	23922306	Green Accepted			2022-02-06	
J	Register-Mihalik, JK; Linnan, LA; Marshall, SW; McLeod, TCV; Mueller, FO; Guskiewicz, KM				Register-Mihalik, Johna K.; Linnan, Laura A.; Marshall, Stephen W.; McLeod, Tamara C. Valovich; Mueller, Frederick O.; Guskiewicz, Kevin M.			Using theory to understand high school aged athletes' intentions to report sport-related concussion: Implications for concussion education initiatives	BRAIN INJURY			English	Article						Brain injury; care seeking; sports	FOOTBALL PLAYERS; ACHIEVEMENT GOALS; HEALTH; KNOWLEDGE; ATTITUDES; SOCCER; INJURY; COACH; PERCEPTIONS; PERFORMANCE	Objective: To assess the influence of psychosocial determinants from the Theory of Reasoned Action and Planned Behaviour (TRA/TPB) on concussion-reporting intentions. Methods: The present study employed the TRA/TPB to develop a cross-sectional survey to examine contributors to intention to report concussion symptoms. High school athletes (n = 167, age = 15.7 +/- 1.4) completed this survey. The TRA/TPB constructs of attitude (perceptions about concussion reporting), subjective norm (perception of important social referents beliefs about concussion reporting), perceived behavioural control (perceived control over concussion reporting) and intention to report concussion symptoms served as the independent variables. Linear regression models were used to predict intention to report concussion symptoms. Binomial regression models were used to predict concussion-reporting behaviours from intention. Results: Direct attitude, subjective norm and direct perceived behavioural control were all associated with intention to report concussion. Intention was associated with decreased prevalence of participating in practices and games while symptomatic from concussion. Conclusions: Favourable attitudes toward reporting and social referents' beliefs have the greatest impact on intention to report concussion symptoms. Reporting intention may not always be an indicator of concussion-reporting behaviours. Concussion education initiatives should focus on improving attitudes and beliefs among athletes, coaches and parents to promote better care-seeking behaviours among young athletes.	[Register-Mihalik, Johna K.] WakeMed Hlth & Hosp, Emergency Serv Inst, Clin Res Unit, Raleigh, NC 27610 USA; [Register-Mihalik, Johna K.; Mueller, Frederick O.; Guskiewicz, Kevin M.] Univ N Carolina, Dept Exercise & Sport Sci, Matthew Gfeller Sport Related Traumat Brain Injur, Chapel Hill, NC USA; [Linnan, Laura A.] Univ N Carolina, Sch Publ Hlth, Dept Hlth Behav & Hlth Educ, Chapel Hill, NC USA; [Marshall, Stephen W.] Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC USA; [McLeod, Tamara C. Valovich] AT Still Univ, Athlet Training Program, Mesa, AZ USA		Register-Mihalik, JK (corresponding author), WakeMed Hlth & Hosp, Emergency Serv Inst, Clin Res Unit, 3024 New Bern Ave,Suite G01, Raleigh, NC 27610 USA.	jmihalik@wakemed.org	Valovich McLeod, Tamara/AAU-9435-2020	Valovich McLeod, Tamara/0000-0001-9082-8722; Marshall, Stephen/0000-0002-2664-9233; Guskiewicz, Kevin/0000-0002-8682-2130; Register-Mihalik, Johna/0000-0002-4229-4743	National Football League Charities Medical Research Grant	This study was funded by a National Football League Charities Medical Research Grant.	Armitage CJ, 2001, BRIT J SOC PSYCHOL, V40, P471, DOI 10.1348/014466601164939; Bayer JK, 1997, AUST NZ J PSYCHIAT, V31, P504, DOI 10.3109/00048679709065072; Buzzini SRR, 2006, CURR OPIN PEDIATR, V18, P376, DOI 10.1097/01.mop.0000236385.26284.ec; Castile L, 2012, BRIT J SPORT MED, V46, P603, DOI 10.1136/bjsports-2011-090115; Fishbein M., 1975, BELIEF ATTITUDE INTE; Francis J., 2004, CONSTRUCTING QUESTIO; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2011, PM&R, V3, P353, DOI 10.1016/j.pmrj.2010.12.006; Hall-Lande JA, 2007, ADOLESCENCE, V42, P265; Jowett S, 2006, BRIT J SOC PSYCHOL, V45, P617, DOI 10.1348/014466605X58609; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Malinauskas R, 2008, J SPORT MED PHYS FIT, V48, P107; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Mckinlay A, 2011, BRAIN INJURY, V25, P761, DOI 10.3109/02699052.2011.579935; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140, DOI 10.1097/JSM.0b013e31803212ae; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Murnaghan DA, 2013, PSYCHOL HEALTH, V25, P925; Nattiv A, 1997, CLIN J SPORT MED, V7, P262, DOI 10.1097/00042752-199710000-00004; Ommundsen Y, 2005, J SPORT SCI, V23, P977, DOI 10.1080/02640410500127975; Ommundsen Y, 2006, CLIN J SPORT MED, V16, P522, DOI 10.1097/01.jsm.0000248845.39498.56; PENDER NJ, 1986, NURS RES, V35, P15; Raudsepp L, 2010, PERCEPT MOTOR SKILL, V110, P3, DOI 10.2466/PMS.110.1.3-18; Register-Mihalik J, 2013, J ATHLETIC IN PRESS, P48; Rosenbaum AM, 2010, J CLIN EXP NEUROPSYC, V32, P44, DOI 10.1080/13803390902806535; Silsupadol P, 2009, ARCH PHYS MED REHAB, V90, P381, DOI 10.1016/j.apmr.2008.09.559; McLeod TCV, 2008, CLIN J SPORT MED, V18, P235, DOI 10.1097/JSM.0b013e3181705756; Valovich McLeod TC, 2010, ATHL TRAIN SPORTS HL, V2, P219; Van Voorhees BW, 2006, SOC PSYCH PSYCH EPID, V41, P746, DOI 10.1007/s00127-006-0091-x; Van-Yperen NW, 1999, SCAND J MED SCI SPOR, V9, P358, DOI 10.1111/j.1600-0838.1999.tb00257.x; White SA, 2004, SCAND J MED SCI SPOR, V14, P57, DOI 10.1111/j.1600-0838.2003.00314.x; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	33	106	106	0	54	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	2013	27	7-8					878	886		10.3109/02699052.2013.775508			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	169UO	WOS:000320806200015	23789865				2022-02-06	
J	Isquith, PK; Roth, RM; Gioia, G				Isquith, Peter K.; Roth, Robert M.; Gioia, Gerard			Contribution of Rating Scales to the Assessment of Executive Functions	APPLIED NEUROPSYCHOLOGY-CHILD			English	Article						ecological validity; executive function; measurement; psychometric; rating scales	TRAUMATIC BRAIN-INJURY; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DEFICIT HYPERACTIVITY DISORDER; PERFORMANCE-BASED MEASURES; AUTISM SPECTRUM DISORDERS; WORKING-MEMORY; NEUROPSYCHOLOGICAL ASSESSMENT; FUNCTION IMPAIRMENTS; ECOLOGICAL VALIDITY; CORTICAL THICKNESS	Executive functions play a vital role in the everyday functioning of healthy individuals across the lifespan and have been implicated in a wide variety of clinical conditions. Historically, the assessment of executive functions in clinical and research settings relied on performance-based measures. A number of authors have argued, however, that such measures have limited ecological validity. In response to this limitation of performance-based measures, several rating scales have been developed that seek to gauge a person's or their knowledgeable informant's (e. g., parent or teacher) subjective view of executive functioning in everyday life. In this article we review evidence supporting the use of rating scales of executive function including profiles in clinical populations, biological correlates, relationships to relevant outcome measures such as academic performance, and correlations with performance-based measures. We conclude that performance-based and rating scale measures provide complementary information with respect to a child's executive functions, offering a more comprehension view than either approach alone.	[Isquith, Peter K.; Roth, Robert M.] Geisel Sch Med Dartmouth, Dept Psychiat, Neuropsychol Program, Lebanon, NH 03756 USA; [Gioia, Gerard] Childrens Natl Med Ctr, Div Neuropsychol, Washington, DC 20010 USA		Isquith, PK (corresponding author), Geisel Sch Med Dartmouth, Dept Psychiat, Neuropsychol Program, One Med Ctr Dr, Lebanon, NH 03756 USA.	peter@qpsych.com	Isquith, Peter/AAY-4851-2020				Anderson V, 2005, J INT NEUROPSYCH SOC, V11, P817, DOI 10.1017/S1355617705051052; Anderson V., 2008, EXECUTIVE FUNCTIONS, P123; Anderson VA, 2002, CHILD NEUROPSYCHOL, V8, P231, DOI 10.1076/chin.8.4.231.13509; Antshel KM, 2005, PSYCHIAT RES-NEUROIM, V138, P235, DOI 10.1016/j.pscychresns.2005.02.003; Benson D.F., 1986, FRONTAL LOBES; Bernstein J.H., 2007, EXECUTIVE FUNCTION E, V1st ed., P39; Bodnar LE, 2007, CHILD NEUROPSYCHOL, V13, P345, DOI 10.1080/09297040600899867; Brown TM, 2008, CHILD NEUROPSYCHOL, V14, P118, DOI 10.1080/09297040601147605; Burgess P, 1996, BEHAV ASSESSMENT DYS; Burgess P., 1997, METHODOLOGY FRONTAL, P81; Chapman LA, 2010, REHABIL PSYCHOL, V55, P48, DOI 10.1037/a0018418; Christ SE, 2010, NEUROPSYCHOLOGY, V24, P590, DOI 10.1037/a0019176; Clark CAC, 2010, DEV PSYCHOL, V46, P1176, DOI 10.1037/a0019672; Conklin HM, 2008, BRAIN INJURY, V22, P847, DOI 10.1080/02699050802403565; Culberton W. C., 2000, TOWER LONDON DX; Delis DC., 2001, DELIS KAPLAN EXECUTI; Diamond A, 1988, THOUGHT LANGUAGE, P337; Donders J, 2010, J NEUROPSYCHOL, V4, P197, DOI 10.1348/174866409X478970; Ferrier D., 1886, FUNCTIONS BRAIN, V2nd; Franzen M.D., 1996, ECOLOGICAL VALIDITY, P91; Garlinghouse MA, 2010, SCHIZOPHR RES, V120, P71, DOI 10.1016/j.schres.2010.02.1067; Ghassabian A, 2013, J CHILD PSYCHOL PSYC, V54, P96, DOI 10.1111/j.1469-7610.2012.02590.x; Gioia G.A., 2000, BRIEF BEHAV RATING I; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P121, DOI 10.1076/chin.8.2.121.8727; Gioia GA, 2010, J HEAD TRAUMA REHAB, V25, P433, DOI 10.1097/HTR.0b013e3181fbc272; Goldberg E, 2000, J CLIN EXP NEUROPSYC, V22, P56, DOI 10.1076/1380-3395(200002)22:1;1-8;FT056; Holmes-Bernstein J, 1990, NEUROPSYCHOLOGY, P311; Isquith PK, 2004, DEV NEUROPSYCHOL, V26, P403, DOI 10.1207/s15326942dn2601_3; Jarratt KP, 2005, APPL NEUROPSYCHOL, V12, P83, DOI 10.1207/s15324826an1202_4; KAPLAN E, 1988, CLIN NEUROPSYCHOLOGY, P00129, DOI DOI 10.1037/10063-000; Kenworthy L, 2009, CHILD NEUROPSYCHOL, V15, P425, DOI 10.1080/09297040802646983; Kenworthy L, 2008, NEUROPSYCHOL REV, V18, P320, DOI 10.1007/s11065-008-9077-7; Kenworthy LE, 2005, DEV NEUROPSYCHOL, V28, P809, DOI 10.1207/s15326942dn2803_4; Kesler SR, 2011, ARCH NEUROL-CHICAGO, V68, P1447, DOI 10.1001/archneurol.2011.245; Locascio G, 2010, J LEARN DISABIL-US, V43, P441, DOI 10.1177/0022219409355476; Long, 1996, ECOLOGICAL VALIDITY, P15; MacAllister WS, 2012, CHILD NEUROPSYCHOL, V18, P404, DOI 10.1080/09297049.2011.613812; Mahone EM, 2007, CLIN NEUROPSYCHOL, V21, P569, DOI 10.1080/13854040600762724; Mahone EM, 2009, J INT NEUROPSYCH SOC, V15, P31, DOI 10.1017/S1355617708090164; Mahone EM, 2002, ARCH CLIN NEUROPSYCH, V17, P643, DOI 10.1016/S0887-6177(01)00168-8; Maillard-Wermelinger A, 2009, DEV NEUROREHABIL, V12, P330, DOI 10.3109/17518420903087251; Malloy PF., 2002, FRONTAL SYSTEMS BEHA; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; Mares D, 2007, CAN J PSYCHIAT, V52, P527, DOI 10.1177/070674370705200811; McAuley T, 2010, J INT NEUROPSYCH SOC, V16, P495, DOI 10.1017/S1355617710000093; McCandless Stephen, 2007, J Atten Disord, V10, P381, DOI 10.1177/1087054706292115; McCauley JL, 2010, J CHILD PSYCHOL PSYC, V51, P84, DOI 10.1111/j.1469-7610.2009.02134.x; McDonald B. C., BRAIN BEHAV IN PRESS; Merkley TL, 2008, J NEUROTRAUM, V25, P1343, DOI 10.1089/neu.2008.0615; Nadebaum C, 2007, DEV NEUROPSYCHOL, V32, P703, DOI 10.1080/87565640701376086; Parrish J, 2007, DEV MED CHILD NEUROL, V49, P412, DOI 10.1111/j.1469-8749.2007.00412.x; Pennington BF, 1996, J CHILD PSYCHOL PSYC, V37, P51, DOI 10.1111/j.1469-7610.1996.tb01380.x; Reddy LA, 2011, SCHOOL PSYCHOL QUART, V26, P45, DOI 10.1037/a0022585; Reynolds CR., 1992, BEHAV ASSESSMENT SYS; Rotenberg-Shpigelman S., 2008, ISRAELI J OCCUPATION, V17, P77; Silver CH, 2000, J HEAD TRAUMA REHAB, V15, P973, DOI 10.1097/00001199-200008000-00002; Slick DJ, 2006, CHILD NEUROPSYCHOL, V12, P181, DOI 10.1080/09297040600611320; STUSS DT, 1984, PSYCHOL BULL, V95, P3, DOI 10.1037/0033-2909.95.1.3; Sullivan Jeremy R, 2007, J Atten Disord, V11, P398, DOI 10.1177/1087054707299399; Toplak ME, 2009, CHILD NEUROPSYCHOL, V15, P53, DOI 10.1080/09297040802070929; Turkstra Lyn S., 2005, Seminars in Speech and Language, V26, P215, DOI 10.1055/s-2005-922101; Vriezen ER, 2002, CHILD NEUROPSYCHOL, V8, P296, DOI 10.1076/chin.8.4.296.13505; Waber DP, 2006, DEV NEUROPSYCHOL, V29, P459, DOI 10.1207/s15326942dn2903_5; WELSH MC, 1988, DEV NEUROPSYCHOL, V4, P199, DOI 10.1080/87565648809540405; WELSH MC, 1991, DEV NEUROPSYCHOL, V7, P131, DOI 10.1080/87565649109540483; Wilde EA, 2012, INT J DEV NEUROSCI, V30, P267, DOI 10.1016/j.ijdevneu.2012.01.003; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Yerys BE, 2009, AUTISM RES, V2, P322, DOI 10.1002/aur.103	69	106	108	3	37	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND	2162-2965	2162-2973		APPL NEUROPSYCH-CHIL	Appl. Neuropsychol.-Child		2013	2	2			SI		125	132		10.1080/21622965.2013.748389			8	Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	AD0TF	WOS:000332946300007	23442015				2022-02-06	
J	Meehan, WP; Zhang, J; Mannix, R; Whalen, MJ				Meehan, William P., III; Zhang, Jimmy; Mannix, Rebekah; Whalen, Michael J.			Increasing Recovery Time Between Injuries Improves Cognitive Outcome After Repetitive Mild Concussive Brain Injuries in Mice	NEUROSURGERY			English	Article						Cell death; Concussion; Mice; Mild traumatic brain injury; Morris water maze; Repeated traumatic brain injury; Sport-related concussion	FLUID-PERCUSSION INJURY; CEREBRAL CONCUSSION; UNITED-STATES; HEAD-INJURIES; BLOOD-FLOW; SPORTS; PERFORMANCE; FOOTBALL; IMPACT; RATS	BACKGROUND: Although previous evidence suggests that the cognitive effects of concussions are cumulative, the effect of time interval between repeat concussions is largely unknown. OBJECTIVE: To determine the effect of time interval between repeat concussions on the cognitive function of mice. METHODS: We used a weight-drop model of concussion to subject anesthetized mice to 1, 3, 5, or 10 concussions, each a day apart. Additional mice were subjected to 5 concussions at varying time intervals: daily, weekly, and monthly. Morris water maze performance was measured 24 hours, 1 month, and 1 year after final injury. RESULTS: After 1 concussion, injured and sham-injured mice performed similarly in the Morris water maze. As the number of concussions increased, injured mice performed worse than sham-injured mice. Mice sustaining 5 concussions either 1 day or 1 week apart performed worse than sham-injured mice. When 5 concussions were delivered at 1-month time intervals, no difference in Morris water maze performance was observed between injured and sham-injured mice. After a 1-month recovery period, mice that sustained 5 concussions at daily and weekly time intervals continued to perform worse than sham-injured mice. One year after the final injury, mice sustaining 5 concussions at a daily time interval still performed worse than sham-injured mice. CONCLUSION: When delivered within a period of vulnerability, the cognitive effects of multiple concussions are cumulative, persistent, and may be permanent. Increasing the time interval between concussions attenuates the effects on cognition. When multiple concussions are sustained by mice daily, the effects on cognition are long term.	[Meehan, William P., III] Harvard Univ, Sch Med, Childrens Hosp Boston, Sports Concuss Clin,Div Sports Med,Dept Orthoped, Boston, MA 02115 USA; [Meehan, William P., III; Mannix, Rebekah] Harvard Univ, Sch Med, Childrens Hosp Boston, Div Emergency Med,Dept Med, Boston, MA 02115 USA; [Meehan, William P., III; Mannix, Rebekah] Harvard Univ, Sch Med, Childrens Hosp Boston, Brain Injury Ctr, Boston, MA 02115 USA; [Meehan, William P., III; Zhang, Jimmy; Mannix, Rebekah; Whalen, Michael J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Neurosci, Boston, MA 02114 USA; [Whalen, Michael J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA; [Meehan, William P., III] Micheli Ctr Sports Injury Prevent, Boston, MA USA		Meehan, WP (corresponding author), Harvard Univ, Sch Med, Childrens Hosp Boston, Sports Concuss Clin,Div Sports Med,Dept Orthoped, 319 Longwood Ave, Boston, MA 02115 USA.	concussion.sportsmed@childrens.harvard.edu; mwhalen@partners.org	Mannix, Rebekah/AAD-8702-2020		NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32 HD040128-06]; National Football League Charities; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5RO1NS047447, 1R21NS075226]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS075226, R01NS047447] Funding Source: NIH RePORTER	This work was supported by grants from the NICHD T32 HD040128-06 (Dr Meehan), National Football League Charities (Drs Meehan, Mannix, and Whalen), and NINDS 5RO1NS047447 (Dr Whalen) and 1R21NS075226 (Dr Whalen). The authors have no personal financial or institutional interest in any of the drugs, materials, or devices described in this article.	CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; Denny-Brown D, 1940, J PHYSIOL-LONDON, V99, P153, DOI 10.1113/jphysiol.1940.sp003887; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Fineman I, 2000, J NEUROTRAUM, V17, P739, DOI 10.1089/neu.2000.17.739; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859, DOI 10.1152/ajpheart.1997.272.6.H2859; Giza CC, 2001, J ATHL TRAINING, V36, P228; GRONWALL D, 1975, LANCET, V2, P995; Holbourn AHS, 1943, LANCET, V2, P438; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Khuman J, 2011, J CEREBR BLOOD F MET, V31, P778, DOI 10.1038/jcbfm.2010.172; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Mayers L, 2008, ARCH NEUROL-CHICAGO, V65, P1158, DOI 10.1001/archneur.65.9.1158; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P., 2009, J ATHL TRAINING, V44, P434, DOI [10.4085/1062-6050-44.4.434, DOI 10.4085/1062-6050-44.4.434]; McIntosh AS, 2000, BRIT J SPORT MED, V34, P337, DOI 10.1136/bjsm.34.5.337; Meehan WP, 2011, AM J SPORT MED, V39, P2304, DOI 10.1177/0363546511423503; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/S0165-3806(96)00098-3; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; SUNAMI K, 1989, Neurosurgical Review, V12, P400, DOI 10.1007/BF01790682; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Weber JT, 2007, PROG BRAIN RES, V161, P253, DOI 10.1016/S0079-6123(06)61018-2; Wetjen NM, 2010, J AM COLL SURGEONS, V211, P553, DOI 10.1016/j.jamcollsurg.2010.05.020; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Yu W, 1997, PHOTOCHEM PHOTOBIOL, V66, P866, DOI 10.1111/j.1751-1097.1997.tb03239.x	43	106	106	0	27	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	OCT	2012	71	4					885	891		10.1227/NEU.0b013e318265a439			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	010TO	WOS:000309117200045	22743360	Green Published, Bronze			2022-02-06	
J	Wu, AG; Ying, Z; Gomez-Pinilla, F				Wu, Aiguo; Ying, Zhe; Gomez-Pinilla, Fernando			The Salutary Effects of DHA Dietary Supplementation on Cognition, Neuroplasticity, and Membrane Homeostasis after Brain Trauma	JOURNAL OF NEUROTRAUMA			English	Article						brain-derived neurotrophic factor; plasticity; Sir2; superoxide dismutase; traumatic brain injury	LONG-TERM POTENTIATION; PROTEIN-KINASE-II; DOCOSAHEXAENOIC ACID; NEUROTROPHIC FACTOR; MOUSE MODEL; PHOSPHOLIPID DEGRADATION; SYNAPTIC PLASTICITY; ALZHEIMERS-DISEASE; LIPID-PEROXIDATION; NEURITE OUTGROWTH	The pathology of traumatic brain injury (TBI) is characterized by the decreased capacity of neurons to metabolize energy and sustain synaptic function, likely resulting in cognitive and emotional disorders. Based on the broad nature of the pathology, we have assessed the potential of the omega-3 fatty acid docosahexaenoic acid (DHA) to counteract the effects of concussive injury on important aspects of neuronal function and cognition. Fluid percussion injury (FPI) or sham injury was performed, and rats were then maintained on a diet high in DHA (1.2% DHA) for 12 days. We found that DHA supplementation, which elevates brain DHA content, normalized levels of brain-derived neurotrophic factor (BDNF), synapsin I (Syn-1), cAMP-responsive element-binding protein (CREB), and calcium/calmodulin-dependent kinase II (CaMKII), and improved learning ability in FPI rats. It is known that BDNF facilitates synaptic transmission and learning ability by modulating Syn-I, CREB, and CaMKII signaling. The DHA diet also counteracted the FPI-reduced manganese superoxide dismutase (SOD) and Sir2 (a NAD+-dependent deacetylase). Given the involvement of SOD and Sir2 in promoting metabolic homeostasis, DHA may help the injured brain by providing resistance to oxidative stress. Furthermore, DHA normalized levels of calcium-independent phospholipase A2 (iPLA2) and syntaxin-3, which may help preserve membrane homeostasis and function after FPI. The overall results emphasize the potential of dietary DHA to counteract broad and fundamental aspects of TBI pathology that may translate into preserved cognitive capacity.	[Wu, Aiguo; Ying, Zhe; Gomez-Pinilla, Fernando] Univ Calif Los Angeles, Dept Integrat Biol & Physiol, Los Angeles, CA 90095 USA; [Gomez-Pinilla, Fernando] Univ Calif Los Angeles, Brain Injury Res Ctr, Div Neurosurg, Los Angeles, CA 90095 USA		Gomez-Pinilla, F (corresponding author), Univ Calif Los Angeles, Dept Integrat Biol & Physiol, 621 Charles E Young Dr, Los Angeles, CA 90095 USA.	fgomezpi@ucla.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS50465]	This study was supported by NIH award NS50465.	Adasme T, 2011, P NATL ACAD SCI USA, V108, P3029, DOI 10.1073/pnas.1013580108; Bailes JE, 2010, J NEUROTRAUM, V27, P1617, DOI 10.1089/neu.2009.1239; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Calon F, 2005, EUR J NEUROSCI, V22, P617, DOI 10.1111/j.1460-9568.2005.04253.x; Cansev M, 2007, NEUROSCIENCE, V148, P421, DOI 10.1016/j.neuroscience.2007.06.016; Cesca F, 2010, PROG NEUROBIOL, V91, P313, DOI 10.1016/j.pneurobio.2010.04.006; Chytrova G, 2010, BRAIN RES, V1341, P32, DOI 10.1016/j.brainres.2009.05.018; Darios F, 2006, NATURE, V440, P813, DOI 10.1038/nature04598; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; Elgersma Y, 2004, J NEUROSCI, V24, P8410, DOI 10.1523/JNEUROSCI.3622-04.2004; Farooqui AA, 2004, NEUROCHEM RES, V29, P1961, DOI 10.1007/s11064-004-6871-3; FAROOQUI AA, 1994, INT REV NEUROBIOL, V36, P267, DOI 10.1016/S0074-7742(08)60306-2; Finkbeiner S, 2000, NEURON, V25, P11, DOI 10.1016/S0896-6273(00)80866-1; Fornasiero EF, 2010, CELL MOL LIFE SCI, V67, P1383, DOI 10.1007/s00018-009-0227-8; Gao J, 2010, NATURE, V466, P1105, DOI 10.1038/nature09271; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hashimoto M, 2002, J NEUROCHEM, V81, P1084, DOI 10.1046/j.1471-4159.2002.00905.x; HASHIMOTO M, 2011, J PHARM SCI IN PRESS; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Homayoun P, 1997, J NEUROCHEM, V69, P199; Jovanovic JN, 2000, NAT NEUROSCI, V3, P323, DOI 10.1038/73888; Jovanovic JN, 1996, P NATL ACAD SCI USA, V93, P3679, DOI 10.1073/pnas.93.8.3679; Kang HJ, 1997, NEURON, V19, P653, DOI 10.1016/S0896-6273(00)80378-5; Kenney JW, 2008, MOL NEUROBIOL, V38, P101, DOI 10.1007/s12035-008-8037-9; Lim GP, 2005, J NEUROSCI, V25, P3032, DOI 10.1523/JNEUROSCI.4225-04.2005; Marklund N, 1997, NEUROREPORT, V8, P1457, DOI 10.1097/00001756-199704140-00026; Martel MA, 2006, EUR J NEUROSCI, V23, P505, DOI 10.1111/j.1460-9568.2005.04565.x; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Neely MD, 1999, J NEUROCHEM, V72, P2323, DOI 10.1046/j.1471-4159.1999.0722323.x; Pillay NS, 2005, ANN NY ACAD SCI, V1056, P450, DOI 10.1196/annals.1352.021; Riedel G, 1999, NAT NEUROSCI, V2, P898, DOI 10.1038/13202; Sajikumar S, 2011, P NATL ACAD SCI USA, V108, P2551, DOI 10.1073/pnas.1016849108; Sato T, 2007, EUR J PHARMACOL, V560, P36, DOI 10.1016/j.ejphar.2007.01.011; Sharma S, 2010, EXP NEUROL, V226, P191, DOI 10.1016/j.expneurol.2010.08.027; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Tanaka JI, 2008, SCIENCE, V319, P1683, DOI 10.1126/science.1152864; Vaynman S, 2007, NEUROSCIENCE, V144, P825, DOI 10.1016/j.neuroscience.2006.10.005; Wang SW, 2011, J NEUROSCI, V31, P7275, DOI 10.1523/JNEUROSCI.6476-10.2011; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; Wolf MJ, 1995, FEBS LETT, V377, P358, DOI 10.1016/0014-5793(95)01371-7; Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457; Wu A, 2003, NEUROSCIENCE, V119, P365, DOI 10.1016/S0306-4522(03)00154-4; Ying SW, 2002, J NEUROSCI, V22, P1532, DOI 10.1523/JNEUROSCI.22-05-01532.2002	44	106	107	0	12	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	2011	28	10					2113	2122		10.1089/neu.2011.1872			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	839OX	WOS:000296378500012	21851229	Green Published			2022-02-06	
J	Hart, T; Brenner, L; Clark, AN; Bogner, JA; Novack, TA; Chervoneva, I; Nakase-Richardson, R; Arango-Lasprilla, JC				Hart, Tessa; Brenner, Lisa; Clark, Allison N.; Bogner, Jennifer A.; Novack, Thomas A.; Chervoneva, Inna; Nakase-Richardson, Risa; Arango-Lasprilla, Juan Carlos			Major and Minor Depression After Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Depression; Rehabilitation	GLASGOW OUTCOME SCALE; NATIONAL COMORBIDITY SURVEY; HEAD-INJURY; PARTICIPATION ASSESSMENT; SERVICE UTILIZATION; SYSTEMATIC BIAS; 1ST YEAR; MILD; COMMUNITY; SYMPTOMS	Hart T, Brenner L, Clark AN, Bogner JA, Novack TA, Chervoneva I, Nakase-Richardson R, Arango-Lasprilla JC. Major and minor depression after traumatic brain injury. Arch Phys Med Rehabil 2011;92:1211-9. Objective: To examine minor as well as major depression at 1 year posttraumatic brain injury (TB!), with particular attention to the contribution of depression severity to levels of societal participation. Design: Observational prospective study with a 2-wave longitudinal component. Setting: Inpatient rehabilitation centers, with 1-year follow up conducted primarily by telephone. Participants: Persons with TBI (N=1570) enrolled in the TBI Model System database and followed up at I-year postinjury. Interventions: Not applicable. Main Outcome Measures: FIM, Patient Health Questionnaire-9, Participation Assessment with Recombined Tools-Objective, Glasgow Outcome Scale-Extended, and the Satisfaction With Life Scale. Results: Twenty-two percent of the sample reported minor depression, and 26% reported major depression at 1-year post-TBI. Both levels of depression were associated with sex (women), age (younger), preinjury mental health treatment and substance abuse, and cause of injury (intentional). There was a monotonic dose-response relationship between severity of depression and all 1-year outcomes studied, including level of cognitive and physical disability, global outcome, and satisfaction with life. With other predictors controlled, depression severity remained significantly associated with the level of societal participation at 1-year post-TBI. Conclusions: Minor depression may be as common as major depression after TBI and should be taken seriously for its association to negative outcomes related to participation and quality of life. Findings suggest that, as in other populations, minor and major depression are not separate entities, but exist on a continuum. Further research should determine whether people with TBI traverse between the 2 diagnoses as in other patient groups.	[Hart, Tessa] Moss Rehabil Res Inst, Elkins Pk, PA 19027 USA; [Brenner, Lisa] Univ Colorado, Sch Med, VISN Mental Illness 19, Denver, CO USA; [Brenner, Lisa] Craig Hosp, Denver, CO USA; [Clark, Allison N.] Baylor Coll Med, Houston, TX 77030 USA; [Clark, Allison N.] TIRR Mem Hermann, Houston, TX USA; [Bogner, Jennifer A.] Ohio State Univ, Columbus, OH 43210 USA; [Novack, Thomas A.] Univ Alabama, Birmingham, AL USA; [Chervoneva, Inna] Thomas Jefferson Univ, Philadelphia, PA 19107 USA; [Nakase-Richardson, Risa] James A Haley Vet Hosp, Tampa, FL 33612 USA; [Nakase-Richardson, Risa] Univ S Florida, Tampa, FL USA; [Arango-Lasprilla, Juan Carlos] Virginia Commonwealth Univ, Richmond, VA USA		Hart, T (corresponding author), Moss Rehabil Res Inst, 50 Township Line Rd, Elkins Pk, PA 19027 USA.	thart@einstein.edu	Brenner, Lisa A./AAG-2442-2019		National Institute on Disability and Rehabilitation Research [H133A070040, H133A070039, H133A070022, H133A070029, H133A070036, H133A070043]	Supported by the National Institute on Disability and Rehabilitation Research (grant nos. H133A070040, H133A070039, HI33A070022, H133A070029, H133A070036, and H133A070043).	American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; BLAZER DG, 1994, AM J PSYCHIAT, V151, P979; Bogner JA, 2011, ARCH PHYS MED REHAB, V92, P552, DOI 10.1016/j.apmr.2010.11.014; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bombardier CH, 2009, J HEAD TRAUMA REHAB, V24, P230, DOI 10.1097/HTR.0b013e3181ad65f0; BOURDON KH, 1992, PUBLIC HEALTH REP, V107, P663; Bowen A, 1998, BRAIN INJURY, V12, P177, DOI 10.1080/026990598122656; Brown M, 2004, J HEAD TRAUMA REHAB, V19, P459, DOI 10.1097/00001199-200411000-00004; Centers for Disease Control and Prevention, 1998, BEH RISK FACT SURV S; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Cuijpers P, 2004, J AFFECT DISORDERS, V79, P71, DOI 10.1016/S0165-0327(02)00348-8; Cuijpers P, 2007, CLIN PSYCHOL REV, V27, P318, DOI 10.1016/j.cpr.2006.11.001; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; Fann JR, 2003, PSYCHOSOMATICS, V44, P161; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Pagulayan KF, 2007, J INT NEUROPSYCH SOC, V13, P561, DOI 10.1017/S1355617707070713; Gordon W, 1993, J HEAD TRAUMA REHAB, V8, P26; Hamilton BB, 1987, REHABILITATION OUTCO, P137; Hammond FM, 2001, J HEAD TRAUMA REHAB, V16, P318, DOI 10.1097/00001199-200108000-00003; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Howland RH, 2008, PSYCHOTHER PSYCHOSOM, V77, P384, DOI 10.1159/000151519; Jackson WT, 1998, ARCH PHYS MED REHAB, V79, P718, DOI 10.1016/S0003-9993(98)90051-X; JOHNSON J, 1992, JAMA-J AM MED ASSOC, V267, P1478, DOI 10.1001/jama.267.11.1478; Johnston MV, 2005, ARCH PHYS MED REHAB, V86, P735, DOI 10.1016/j.apmr.2004.10.031; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Judd LL, 1997, J AFFECT DISORDERS, V45, P5, DOI 10.1016/S0165-0327(97)00055-4; Kennedy RE, 2005, J HEAD TRAUMA REHAB, V20, P512, DOI 10.1097/00001199-200511000-00004; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; Kessler RC, 1997, J AFFECT DISORDERS, V45, P19, DOI 10.1016/S0165-0327(97)00056-6; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; Malec JF, 2010, ARCH PHYS MED REHAB, V91, P1087, DOI 10.1016/j.apmr.2010.04.002; Novack TA, 2009, J NEUROTRAUM, V26, P1921, DOI 10.1089/neu.2009.0895; Pagulayan KF, 2008, ARCH PHYS MED REHAB, V89, P1887, DOI 10.1016/j.apmr.2008.03.019; Rapaport MH, 2002, AM J PSYCHIAT, V159, P637, DOI 10.1176/appi.ajp.159.4.637; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Rapoport MJ, 2003, AM J GERIAT PSYCHIAT, V11, P365, DOI 10.1176/appi.ajgp.11.3.365; REIMHERR FW, 1990, J CLIN PSYCHIAT, V51, P18; RUTHERFORD WH, 1977, LANCET, V1, P1; SCHOENHUBER R, 1988, J NEUROL NEUROSUR PS, V51, P722, DOI 10.1136/jnnp.51.5.722; Seel RT, 2010, J HEAD TRAUMA REHAB, V25, P99, DOI 10.1097/HTR.0b013e3181ce3966; SKODOL AE, 1994, ARCH GEN PSYCHIAT, V51, P542; U.S. Department of Health and Human Services, 1998, NAT HOUS SURV DRUG A; Underhill AT, 2003, BRAIN INJURY, V17, P973, DOI 10.1080/0269905031000110418; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Wagner HR, 2000, PSYCHOL MED, V30, P1377, DOI 10.1017/S0033291799002998; Whelan-Goodinson R, 2010, J HEAD TRAUMA REHAB, V25, P320, DOI 10.1097/HTR.0b013e3181c8f8e7; Whelan-Goodinson R, 2008, J REHABIL MED, V40, P850, DOI 10.2340/16501977-0271; Whiteneck GG, 2011, ARCH PHYS MED REHAB, V92, P542, DOI 10.1016/j.apmr.2010.08.002; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; Whyte J, 2001, ARCH PHYS MED REHAB, V82, P1355, DOI 10.1053/apmr.2001.26091; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204; [No title captured]	59	106	107	0	32	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2011	92	8					1211	1219		10.1016/j.apmr.2011.03.005			9	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	803WL	WOS:000293612800004	21807140				2022-02-06	
J	Emmanouilidou, E; Elenis, D; Papasilekas, T; Stranjalis, G; Gerozissis, K; Ioannou, PC; Vekrellis, K				Emmanouilidou, Evangelia; Elenis, Dimitris; Papasilekas, Themis; Stranjalis, Georgios; Gerozissis, Kyriaki; Ioannou, Penelopi C.; Vekrellis, Kostas			Assessment of alpha-Synuclein Secretion in Mouse and Human Brain Parenchyma	PLOS ONE			English	Article							AMYLOID-BETA DYNAMICS; FLUORO-JADE-C; PARKINSONS-DISEASE; CEREBROSPINAL-FLUID; INTRACEREBRAL MICRODIALYSIS; HUMAN PLASMA; LEWY BODIES; IN-VIVO; NEURONS; MICE	Genetic, biochemical, and animal model studies strongly suggest a central role for alpha-synuclein in the pathogenesis of Parkinson's disease. alpha-synuclein lacks a signal peptide sequence and has thus been considered a cytosolic protein. Recent data has suggested that the protein may be released from cells via a non-classical secretory pathway and may therefore exert paracrine effects in the extracellular environment. However, proof that alpha-synuclein is actually secreted into the brain extracellular space in vivo has not been obtained. We developed a novel highly sensitive ELISA in conjugation with an in vivo microdialysis technique to measure alpha-synuclein in brain interstitial fluid. We show for the first time that alpha-synuclein is readily detected in the interstitial fluid of both alpha-synuclein transgenic mice and human patients with traumatic brain injury. Our data suggest that alpha-synuclein is physiologically secreted by neurons in vivo. This interstitial fluid pool of the protein may have a role in the propagation of synuclein pathology and progression of Parkinson's disease.	[Emmanouilidou, Evangelia; Vekrellis, Kostas] Acad Athens, Biomed Res Fdn, Div Basic Neurosci, Athens, Greece; [Elenis, Dimitris; Ioannou, Penelopi C.] Univ Athens, Dept Chem, GR-10680 Athens, Greece; [Papasilekas, Themis; Stranjalis, Georgios] Univ Athens, Evaggelismos Gen Hosp, Dept Neurosurg, Athens, Greece; [Gerozissis, Kyriaki] CNRS, Ctr Neurosci, UMR 8195, F-91405 Orsay, France; [Gerozissis, Kyriaki] Univ Paris 11, UMR 8195, Orsay, France; [Gerozissis, Kyriaki] Univ Paris 11, INSERM, F-91405 Orsay, France		Emmanouilidou, E (corresponding author), Acad Athens, Biomed Res Fdn, Div Basic Neurosci, Athens, Greece.	vekrellis@bioacademy.gr		Ioannou, Penelope/0000-0002-2595-1385	Michael J. Fox Foundation; MEFOPA FP7	This work was supported by a Rapid Innovation Response Award from the Michael J. Fox Foundation to EE and KV. Partial support was obtained from MEFOPA FP7. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barbour R, 2008, NEURODEGENER DIS, V5, P55, DOI 10.1159/000112832; Bian GL, 2007, BRAIN RES, V1150, P55, DOI 10.1016/j.brainres.2007.02.078; Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; Brody DL, 2008, SCIENCE, V321, P1221, DOI 10.1126/science.1161591; Chaurasia CS, 2007, PHARM RES, V24, P1014, DOI 10.1007/s11095-006-9206-z; Cirrito JR, 2003, J NEUROSCI, V23, P8844; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Danzer KM, 2011, FASEB J, V25, P326, DOI 10.1096/fj.10-164624; Desplats P, 2009, P NATL ACAD SCI USA, V106, P13010, DOI 10.1073/pnas.0903691106; DYKSTRA KH, 1992, J NEUROCHEM, V58, P931, DOI 10.1111/j.1471-4159.1992.tb09346.x; El-Agnaf OMA, 2003, FASEB J, V17, P1945, DOI 10.1096/fj.03-0098fje; El-Agnaf OMA, 2006, FASEB J, V20, P419, DOI 10.1096/fj.03-1449com; EMMANOUILIDOU E, J NEUROSCI, V30, P6838; Engstrom ER, 2001, EPILEPSY RES, V43, P135, DOI 10.1016/S0920-1211(00)00191-1; GEROZISSIS K, 1993, BRAIN RES, V611, P258, DOI 10.1016/0006-8993(93)90511-K; Giasson BI, 2002, NEURON, V34, P521, DOI 10.1016/S0896-6273(02)00682-7; HANSEN C, 2011, J CLIN INVEST; Hillman J, 2006, ACTA NEUROCHIR, V148, P319, DOI 10.1007/s00701-005-0670-8; Hutchinson PJ, 2000, J NEUROSURG, V93, P37, DOI 10.3171/jns.2000.93.1.0037; Kang JE, 2009, SCIENCE, V326, P1005, DOI 10.1126/science.1180962; Kim TD, 2000, PROTEIN SCI, V9, P2489, DOI 10.1110/ps.9.12.2489; Kordower JH, 2008, MOVEMENT DISORD, V23, P2303, DOI 10.1002/mds.22369; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lee HJ, 2005, J NEUROSCI, V25, P6016, DOI 10.1523/JNEUROSCI.0692-05.2005; Li JY, 2008, NAT MED, V14, P501, DOI 10.1038/nm1746; Lindberger M, 2001, EPILEPSIA, V42, P256, DOI 10.1046/j.1528-1157.2001.26600.x; Marklund N, 2009, J NEUROSURG, V110, P1227, DOI 10.3171/2008.9.JNS08584; Mollenhauer B, 2008, EXP NEUROL, V213, P315, DOI 10.1016/j.expneurol.2008.06.004; Moussa CEH, 2004, NEUROSCI LETT, V371, P239, DOI 10.1016/j.neulet.2004.09.004; Ohrfelt A, 2009, NEUROSCI LETT, V450, P332, DOI 10.1016/j.neulet.2008.11.015; Olanow CW, 2004, LANCET NEUROL, V3, P496, DOI 10.1016/S1474-4422(04)00827-0; Perrin RJ, 2003, NEUROSCI LETT, V349, P133, DOI 10.1016/S0304-3940(03)00781-X; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Reiber H, 2003, RESTOR NEUROL NEUROS, V21, P79; Roodveldt C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013481; Schmued LC, 2005, BRAIN RES, V1035, P24, DOI 10.1016/j.brainres.2004.11.054; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; SOTIRIOU E, NEUROBIOL AGING, V31, P2103; Specht CG, 2001, BMC NEUROSCI, V2, DOI 10.1186/1471-2202-2-11; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Su XM, 2008, NEUROBIOL AGING, V29, P1690, DOI 10.1016/j.neurobiolaging.2007.04.006; Sung JY, 2005, J BIOL CHEM, V280, P25216, DOI 10.1074/jbc.M503341200; TOKUDA T, NEUROLOGY, V75, P1766; Tokuda T, 2006, BIOCHEM BIOPH RES CO, V349, P162, DOI 10.1016/j.bbrc.2006.08.024; Vekrellis K, 2004, MOL NEUROBIOL, V30, P1, DOI 10.1385/MN:30:1:001; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; Winter CD, 2002, J NEUROSCI METH, V119, P45, DOI 10.1016/S0165-0270(02)00153-X; WOODS SC, 1977, AM J PHYSIOL, V233, pE331, DOI 10.1152/ajpendo.1977.233.4.E331	48	106	107	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUL 14	2011	6	7							e22225	10.1371/journal.pone.0022225			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	793HP	WOS:000292811300049	21779395	gold, Green Submitted, Green Published			2022-02-06	
J	Wolff, EF; Gao, XB; Yao, KV; Andrews, ZB; Du, HL; Elsworth, JD; Taylor, HS				Wolff, Erin F.; Gao, Xiao-Bing; Yao, Katherine V.; Andrews, Zane B.; Du, Hongling; Elsworth, John D.; Taylor, Hugh S.			Endometrial stem cell transplantation restores dopamine production in a Parkinson's disease model	JOURNAL OF CELLULAR AND MOLECULAR MEDICINE			English	Article						stem cells; adult stem cells; MSC; endometrium; Parkinson's disease; transplantation	MARROW STROMAL CELLS; TRAUMATIC BRAIN-INJURY; STEM/PROGENITOR CELLS; FUNCTIONAL RECOVERY; MOUSE MODEL; RATS; MICE; MICROCHIMERISM; IDENTIFICATION; MIGRATE	Parkinson's disease (PD) is a neurodegenerative disorder caused by the loss of dopaminergic neurons. Adult human endometrial derived stem cells (HEDSC), a readily obtainable type of mesenchymal stem-like cell, were used to generate dopaminergic cells and for transplantation. Cells expressing CD90, platelet derived growth factor (PDGF)-R beta and CD146 but not CD45 or CD31 were differentiated in vitro into dopaminergic neurons that exhibited axon projections, pyramidal cell bodies and dendritic projections that recapitulate synapse formation; these cells also expressed the neural marker nestin and tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis. Whole cell patch clamp recording identified G-protein coupled inwardly rectifying potassium current 2 channels characteristic of central neurons. A 1-methyl 4-phenyl 1,2,3,6-tetrahydro pyridine induced animal model of PD was used to demonstrate the ability of labelled HEDSC to engraft, migrate to the site of lesion, differentiate in vivo and significantly increase striatal dopamine and dopamine metabolite concentrations. HEDSC are a highly inducible source of allogenic stem cells that rescue dopamine concentrations in an immunocompetent PD mouse model.	[Wolff, Erin F.; Gao, Xiao-Bing; Yao, Katherine V.; Andrews, Zane B.; Du, Hongling; Taylor, Hugh S.] Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, New Haven, CT 06520 USA; [Elsworth, John D.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06520 USA; [Taylor, Hugh S.] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA		Taylor, HS (corresponding author), Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, 333 Cedar St,POB 208063, New Haven, CT 06520 USA.	hugh.taylor@yale.edu	Gao, Xiao-Bing/C-3121-2011	Gao, Xiao-Bing/0000-0002-2035-4936; Andrews, Zane B./0000-0002-9097-7944	Reproductive Scientist Development Program [NIH K12HD00849]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD000849] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U54HD052668] Funding Source: NIH RePORTER	This study was supported by the Reproductive Scientist Development Program (Berlex Foundation and NIH K12HD00849) and Specialized Cooperative Centers Program in Reproduction and Infertility Research (NIH U54 HD052668).	BERNSTEIN DC, 1988, ANN NY ACAD SCI, V532, P207, DOI 10.1111/j.1749-6632.1988.tb36339.x; Blondheim NR, 2006, STEM CELLS DEV, V15, P141, DOI 10.1089/scd.2006.15.141; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Cipriani S, 2007, CELL BIOL INT, V31, P845, DOI 10.1016/j.cellbi.2007.01.037; Dimitrov R, 2008, REPRODUCTION, V135, P551, DOI 10.1530/REP-07-0428; Elsworth JD, 1996, CELL TRANSPLANT, V5, P315, DOI 10.1016/0963-6897(95)02034-9; Freed CR, 2001, NEW ENGL J MED, V344, P710, DOI 10.1056/NEJM200103083441002; Gargett B E, 2006, Minerva Ginecol, V58, P511; Gargett CE, 2008, MOL CELL ENDOCRINOL, V288, P22, DOI 10.1016/j.mce.2008.02.026; Gargett CE, 2007, REPROD SCI, V14, P405, DOI 10.1177/1933719107306231; Gargett CE, 2009, BIOL REPROD, V80, P1136, DOI 10.1095/biolreprod.108.075226; Gargett CE, 2006, AUST NZ J OBSTET GYN, V46, P250, DOI 10.1111/j.1479-828X.2006.00582.x; Hellmann MA, 2006, NEUROSCI LETT, V395, P124, DOI 10.1016/j.neulet.2005.10.097; Korbling M, 2003, NEW ENGL J MED, V349, P570, DOI 10.1056/NEJMra022361; Lapaire O, 2007, J MATERN-FETAL NEO M, V20, P1, DOI 10.1080/14767050601144834; Li Y, 2001, NEUROSCI LETT, V316, P67, DOI 10.1016/S0304-3940(01)02384-9; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Li Y, 2000, J CEREBR BLOOD F MET, V20, P1311, DOI 10.1097/00004647-200009000-00006; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2002, CELL TRANSPLANT, V11, P275; Lu LL, 2005, BRAIN RES PROTOC, V15, P46, DOI 10.1016/j.brainresprot.2005.03.002; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mansilla E, 2005, TRANSPL P, V37, P292, DOI 10.1016/j.transproceed.2005.01.070; Mouiseddine M, 2007, BRIT J RADIOL, V80, pS49, DOI 10.1259/bjr/25927054; Olanow CW, 2003, ANN NEUROL, V54, P403, DOI 10.1002/ana.10720; Qu CS, 2008, BRAIN RES, V1208, P234, DOI 10.1016/j.brainres.2008.02.042; Rakic P, 2002, NAT REV NEUROSCI, V3, P65, DOI 10.1038/nrn700; Sasson IE, 2008, ANN NY ACAD SCI, V1127, P106, DOI 10.1196/annals.1434.014; Schwab KE, 2008, HUM REPROD, V23, P934, DOI 10.1093/humrep/den051; Schwab KE, 2007, HUM REPROD, V22, P2903, DOI 10.1093/humrep/dem265; Waldorf KMA, 2008, IMMUNOL INVEST, V37, P631, DOI 10.1080/08820130802205886; Wolff EF, 2007, REPROD SCI, V14, P524, DOI 10.1177/1933719107306896; Xu GW, 2007, CELL RES, V17, P240, DOI 10.1038/cr.2007.4; Ye M, 2007, BRAIN RES, V1142, P206, DOI 10.1016/j.brainres.2006.12.061; Zinkernagel R M, 1979, Adv Immunol, V27, P51, DOI 10.1016/S0065-2776(08)60262-X	37	106	117	0	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA		1582-4934		J CELL MOL MED	J. Cell. Mol. Med.	APR	2011	15	4					747	755		10.1111/j.1582-4934.2010.01068.x			9	Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Research & Experimental Medicine	760GL	WOS:000290312700004	20406327	Green Accepted, Green Published			2022-02-06	
J	McGrath, N				McGrath, Neal			Supporting the Student-Athlete's Return to the Classroom After a Sport-Related Concussion	JOURNAL OF ATHLETIC TRAINING			English	Article						athletic injuries; mild traumatic brain injuries; academic accommodations; school concussion programs	SCHOOL FOOTBALL PLAYERS; NEUROCOGNITIVE PERFORMANCE; INTERNATIONAL-CONFERENCE; COLLEGIATE; STATEMENT; RECOVERY; INJURY; RISK	Objective: This article provides a framework for school athletic trainers to use in advising colleagues about the health and academic needs of student-athletes presenting with concussions. Background: Management of sport-related concussions has been an area of growing concern for school athletic programs. Recent work in this area has highlighted significant risks for student-athletes presenting with these mild traumatic brain injuries. Description: Topics covered include general teaching points for the athletic trainer to use with school colleagues. Anintegrated model for school management of sport concussion injuries is presented that includes involvement of the student's athletic trainer, school nurse, guidance counselor, teachers, social worker, psychologist, physicians, and parents. Clinical Advantages: Academic accommodations for specific postconcussion symptoms are proposed that may help the student-athlete strike an optimum balance between rest and continued academic progress during recovery.	Sports Concuss New England, Brookline, MA 02446 USA		McGrath, N (corresponding author), Sports Concuss New England, 1368 Beacon St,Suite 116, Brookline, MA 02446 USA.	dr.neal@sportsconcussion.net					Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bleiberg J., 2006, SPORTS NEUROPSYCHOLO, P263; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cantu RC, 2003, CLIN SPORT MED, V22, P593, DOI 10.1016/S0278-5919(02)00095-9; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Cantu Robert C, 2006, Neurosurg Focus, V21, pE3; Collie A., 2006, SPORTS NEUROPSYCHOLO, P240; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Ellemberg D, 2007, CLIN J SPORT MED, V17, P369, DOI 10.1097/JSM.0b013e31814c3e3e; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Kaushik T., 2006, SPORTS NEUROPSYCHOLO, P216; Lovell M. R., 2006, SPORTS NEUROPSYCHOLO, P193; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Mayers L, 2008, ARCH NEUROL-CHICAGO, V65, P1158, DOI 10.1001/archneur.65.9.1158; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI [10.4085/1062-6050-44.4.434, 10.1016/j.jocn.2009.02.002]; Reddy CC, 2008, PHYS MED REH CLIN N, V19, P247, DOI 10.1016/j.pmr.2007.12.002; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; WEBBE FM, 2006, SPORTS NEUROPSYCHOLO, P45; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	31	106	107	0	38	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	SEP-OCT	2010	45	5					492	498		10.4085/1062-6050-45.5.492			7	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	654GZ	WOS:000282157800011	20831397	Green Published			2022-02-06	
J	Smilek, D; Carriere, JSA; Cheyne, JA				Smilek, Daniel; Carriere, Jonathan S. A.; Cheyne, J. Allan			Failures of sustained attention in life, lab, and brain: Ecological validity of the SART	NEUROPSYCHOLOGIA			English	Article						Sustained attention; SART; Cognitive failures; Cognitive Failures Questionnaire (CFQ); Attention failures; Traumatic brain injury; Attention-Related Cognitive Errors Scale (ARCES)	DEFICIT-HYPERACTIVITY-DISORDER; RESPONSE VARIABILITY; EVERYDAY ATTENTION; ADHD; ERROR; MIND; TASK; PERFORMANCE; AWARENESS; CHILDREN	The Sustained Attention to Response Task (SART) is a widely used tool in cognitive neuroscience increasingly employed to identify brain regions associated with failures of sustained attention. An important claim of the SART is that it is significantly related to real-world problems of sustained attention such as those experienced by TB! and ADHD patients. This claim is largely based on its association with the Cognitive Failures Questionnaire (CFQ), but recently concerns have been expressed about the reliability of the SART-CFQ association. Based on a review of the literature, meta-analysis of prior research, and analysis of original data, we conclude that, across studies sampling diverse populations and contexts, the SART is reliably associated with the CFQ. The CFQ-SART relation also holds for patients with TBI. We note, however, conceptual limitations of using the CFQ which was designed as a measure of general cognitive failures, to validate the SART, which was specifically designed to assess sustained attention. To remedy this limitation, we report on associations between the SART and a specific Attention-Related Cognitive Errors Scale (ARCES) and a Mindful Awareness of Attention Scale-Lapses Only (MAAS-LO). (C) 2010 Elsevier Ltd. All rights reserved.	[Smilek, Daniel] Univ Waterloo, Dept Psychol, Waterloo, ON N2L 3G1, Canada		Smilek, D (corresponding author), Univ Waterloo, Dept Psychol, Waterloo, ON N2L 3G1, Canada.	dsmilek@uwaterloo.ca			Natural Sciences and Engineering Research Council (NSERC) of CanadaNatural Sciences and Engineering Research Council of Canada (NSERC); NSERCNatural Sciences and Engineering Research Council of Canada (NSERC)	This work was supported by a research grant from the Natural Sciences and Engineering Research Council (NSERC) of Canada awarded to DS and a graduate scholarship from NSERC awarded to JSAC. All authors contributed equally to this work.	Bellgrove MA, 2005, NEUROPSYCHOLOGIA, V43, P1847, DOI 10.1016/j.neuropsychologia.2005.03.011; Bellgrove MA, 2004, NEUROPSYCHOLOGIA, V42, P1910, DOI 10.1016/j.neuropsychologia.2004.05.007; Bellgrove MA, 2006, CORTEX, V42, P838, DOI 10.1016/S0010-9452(08)70426-X; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Brown KW, 2003, J PERS SOC PSYCHOL, V84, P822, DOI 10.1037/0022-3514.84.4.822; Carriere JSA, 2008, CONSCIOUS COGN, V17, P835, DOI 10.1016/j.concog.2007.04.008; Cheyne D. O., 2009, NCM ANN M WAIK HAW A; Cheyne JA, 2009, COGNITION, V111, P98, DOI 10.1016/j.cognition.2008.12.009; Cheyne JA, 2006, CONSCIOUS COGN, V15, P578, DOI 10.1016/j.concog.2005.11.009; Christoff K, 2009, P NATL ACAD SCI USA, V106, P8719, DOI 10.1073/pnas.0900234106; Dockree PM, 2007, EUR J NEUROSCI, V25, P900, DOI 10.1111/j.1460-9568.2007.05324.x; Dockree PM, 2005, NEUROIMAGE, V27, P587, DOI 10.1016/j.neuroimage.2005.05.044; Dockree PM, 2004, COGNITIVE BRAIN RES, V20, P403, DOI 10.1016/j.cogbrainres.2004.03.019; Farrin L, 2003, J NEUROPSYCH CLIN N, V15, P98, DOI 10.1176/appi.neuropsych.15.1.98; Fassbender C, 2006, J PSYCHOPHYSIOL, V20, P286, DOI 10.1027/0269-8803.20.4.286; Field AP, 2001, PSYCHOL METHODS, V6, P161, DOI 10.1037//1082-989X.6.2.161; Hester R, 2005, NEUROIMAGE, V27, P602, DOI 10.1016/j.neuroimage.2005.04.035; Hester R, 2004, CEREB CORTEX, V14, P986, DOI 10.1093/cercor/bhh059; Hunter J.E., 2004, METHODS META ANAL CO, V2nd ed.; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Johnson KA, 2007, NEUROPSYCHOLOGIA, V45, P2234, DOI 10.1016/j.neuropsychologia.2007.02.019; Johnson KA, 2007, NEUROPSYCHOLOGIA, V45, P630, DOI 10.1016/j.neuropsychologia.2006.03.034; Kingstone A, 2003, CURR DIR PSYCHOL SCI, V12, P176, DOI 10.1111/1467-8721.01255; Kingstone A, 2008, BRIT J PSYCHOL, V99, P317, DOI 10.1348/000712607X251243; LOVIBOND PF, 1995, BEHAV RES THER, V33, P335, DOI 10.1016/0005-7967(94)00075-U; Manly T, 1999, NEUROPSYCHOLOGIA, V37, P661, DOI 10.1016/S0028-3932(98)00127-4; Manly T, 2001, J CHILD PSYCHOL PSYC, V42, P1065, DOI 10.1111/1469-7610.00806; Manly T, 2004, NEUROPSYCHOL REHABIL, V14, P89, DOI 10.1080/09602010343000110; Mullins C, 2005, J AM ACAD CHILD PSY, V44, P169, DOI 10.1097/00004583-200502000-00009; O'Connell RG, 2007, EUR J NEUROSCI, V25, P2571, DOI 10.1111/j.1460-9568.2007.05477.x; O'Connell RG, 2009, J COGNITIVE NEUROSCI, V21, P93, DOI 10.1162/jocn.2009.21008; O'Keeffe FM, 2004, COGNITIVE BRAIN RES, V22, P101, DOI 10.1016/j.cogbrainres.2004.07.012; REASON J, 1979, ASPECTS CONSCIOUSNES, P67; Reason J.T., 1977, ADULT LEARNING; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Smallwood J, 2008, J COGNITIVE NEUROSCI, V20, P458, DOI 10.1162/jocn.2008.20037; Smallwood J, 2007, COGNITION EMOTION, V21, P816, DOI 10.1080/02699930600911531; Van der Linden D, 2005, WORK STRESS, V19, P23, DOI 10.1080/02678370500065275; Wallace JC, 2002, J GEN PSYCHOL, V129, P238, DOI 10.1080/00221300209602098; Whyte J, 2006, NEUROPSYCHOLOGIA, V44, P2007, DOI 10.1016/j.neuropsychologia.2006.02.012; Zordan L, 2008, BRAIN COGNITION, V66, P57, DOI 10.1016/j.bandc.2007.05.005	41	106	106	0	24	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia	JUL	2010	48	9					2564	2570		10.1016/j.neuropsychologia.2010.05.002			7	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	634ID	WOS:000280573300016	20452366				2022-02-06	
J	Wu, AG; Ying, Z; Gomez-Pinilla, F				Wu, Aiguo; Ying, Zhe; Gomez-Pinilla, Fernando			Vitamin E Protects Against Oxidative Damage and Learning Disability After Mild Traumatic Brain Injury in Rats	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						traumatic brain injury; hippocampus; learning; BDNF; vitamin E	LONG-TERM POTENTIATION; NEUROTROPHIC FACTOR; SYNAPTIC-TRANSMISSION; SYNAPSIN-I; COGNITIVE FUNCTION; SPATIAL MEMORY; DENTATE GYRUS; FAT DIET; PLASTICITY; MICE	Background. Reactive oxygen species induce neuronal damage, and their role in reducing synaptic plasticity and function is beginning to be understood. Vitamin E is a potent reactive oxygen species scavenger, which has the potential to reduce oxidative damage encountered after traumatic brain injury (TBI). Brain-derived neurotrophic factor (BDNF) can facilitate synaptic function and support learning by modulating the CaMKII system, synapsin I, and cAMP-response element-binding protein (CREB). The elevation of superoxide dismutase (SOD) and Sir2 (silent information regulator 2) play an important role in resistance to oxidative stress. Objective. We examined the possibility that vitamin E supplemented in the diet may help counteract the effects of TBI on the molecular substrates underlying synaptic plasticity and cognitive function in the hippocampus. Methods. Rats were fed a regular diet with or without 500 IU/kg of vitamin E for 4 weeks (n = 6-8 per group) before a mild fluid percussion injury (FPI) was performed. Results. FPI increased protein oxidation as evidenced by elevated levels of protein carbonyls and reduced levels of SOD and Sir2. In addition, FPI resulted in poor performance in the Morris water maze, which was accompanied by reduced levels of BDNF and its downstream effectors on synaptic plasticity, synapsin I, CREB, and CaMKII. Supplementation of vitamin E in the diet counteracted all the observed effects of FPI. Conclusions. These results suggest that vitamin E dietary supplementation can protect the brain against the effects of mild TBI on synaptic plasticity and cognition, using molecular systems associated with the maintenance of long-term plasticity, such as BDNF and Sir2.	[Gomez-Pinilla, Fernando] Univ Calif Los Angeles, Brain Injury Res Ctr, Los Angeles, CA USA		Gomez-Pinilla, F (corresponding author), Dept Physiol Sci, 621 Charles E Young Dr, Los Angeles, CA 90095 USA.	fgomezpi@ucla.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS 50465]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS050465] Funding Source: NIH RePORTER	This study was supported by NIH award NS 50465.	BEHL C, 1992, BIOCHEM BIOPH RES CO, V186, P944, DOI 10.1016/0006-291X(92)90837-B; Bolton MM, 2000, PROG BRAIN RES, V128, P203; BROCK TO, 1987, J NEUROSCI, V7, P931; Cao L, 2009, NEUROSCIENCE, V161, P73, DOI 10.1016/j.neuroscience.2009.02.059; Conte V, 2004, J NEUROCHEM, V90, P758, DOI 10.1111/j.1471-4159.2004.02560.x; Daitoku H, 2004, P NATL ACAD SCI USA, V101, P10042, DOI 10.1073/pnas.0400593101; Drapeau E, 2003, P NATL ACAD SCI USA, V100, P14385, DOI 10.1073/pnas.2334169100; Erol FS, 2004, NEUROSURG REV, V27, P65, DOI 10.1007/s10143-003-0291-8; Ferri P, 2003, J NEUROCYTOL, V32, P1155, DOI 10.1023/B:NEUR.0000021909.84327.e8; Finkbeiner S, 2000, NEURON, V25, P11, DOI 10.1016/S0896-6273(00)80866-1; Fukui K, 2002, ANN NY ACAD SCI, V959, P275, DOI 10.1111/j.1749-6632.2002.tb02099.x; Gomez-Pinilla F, 2001, BRAIN RES, V904, P13, DOI 10.1016/S0006-8993(01)02394-0; Gomez-Pinilla F, 2008, NAT REV NEUROSCI, V9, P568, DOI 10.1038/nrn2421; Gonzalez-Polo RA, 2003, J NEUROCHEM, V84, P305, DOI 10.1046/j.1471-4159.2003.01520.x; HARA H, 1990, BRAIN RES, V510, P335, DOI 10.1016/0006-8993(90)91386-U; Joseph JA, 1998, J NEUROSCI, V18, P8047; Jovanovic JN, 1996, P NATL ACAD SCI USA, V93, P3679, DOI 10.1073/pnas.93.8.3679; Kafitz KW, 1999, NATURE, V401, P918, DOI 10.1038/44847; Kang HJ, 1996, SCIENCE, V273, P1402, DOI 10.1126/science.273.5280.1402; Kelly A, 2003, J NEUROSCI, V23, P5354; KORTE M, 1995, P NATL ACAD SCI USA, V92, P8856, DOI 10.1073/pnas.92.19.8856; Levine ES, 1998, P NATL ACAD SCI USA, V95, P10235, DOI 10.1073/pnas.95.17.10235; Linnarsson S, 1997, EUR J NEUROSCI, V9, P2581, DOI 10.1111/j.1460-9568.1997.tb01687.x; Mishima K, 2003, NEUROSCI LETT, V337, P56, DOI 10.1016/S0304-3940(02)01293-4; Molteni R, 2004, NEUROSCIENCE, V123, P429, DOI 10.1016/j.neuroscience.2003.09.020; Molteni R, 2002, NEUROSCIENCE, V112, P803, DOI 10.1016/S0306-4522(02)00123-9; Mu JS, 1999, BRAIN RES, V835, P259, DOI 10.1016/S0006-8993(99)01592-9; Murray CA, 1998, J BIOL CHEM, V273, P12161, DOI 10.1074/jbc.273.20.12161; Patterson SL, 1996, NEURON, V16, P1137, DOI 10.1016/S0896-6273(00)80140-3; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Sherwood NT, 1999, J NEUROSCI, V19, P7025, DOI 10.1523/JNEUROSCI.19-16-07025.1999; Steffenach HA, 2002, P NATL ACAD SCI USA, V99, P3194, DOI 10.1073/pnas.042700999; Sugaya K, 1996, J NEUROSCI, V16, P3427; Sung S, 2003, FASEB J, V17, P323, DOI 10.1096/fj.03-0961fje; Tyler WJ, 2001, J NEUROSCI, V21, P4249, DOI 10.1523/JNEUROSCI.21-12-04249.2001; Vaynman S, 2007, NEUROSCIENCE, V144, P825, DOI 10.1016/j.neuroscience.2006.10.005; Vaynman S, 2006, NEUROSCIENCE, V139, P1221, DOI 10.1016/j.neuroscience.2006.01.062; Veinbergs I, 2000, EUR J NEUROSCI, V12, P4541, DOI 10.1046/j.1460-9568.2000.01308.x; WANG T, 1995, J NEUROSCI, V15, P4796; Wilson IA, 2004, J NEUROSCI, V24, P3870, DOI 10.1523/JNEUROSCI.5205-03.2004; Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Wu AG, 2004, EUR J NEUROSCI, V19, P1699, DOI 10.1111/j.1460-9568.2004.03246.x; Wu AG, 2007, J NEUROTRAUM, V24, P1587, DOI 10.1089/neu.2007.0313; Ying SW, 2002, J NEUROSCI, V22, P1532, DOI 10.1523/JNEUROSCI.22-05-01532.2002	45	106	109	0	10	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683	1552-6844		NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	MAR	2010	24	3					290	298		10.1177/1545968309348318			9	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	556JI	WOS:000274586500009	19841436	Green Accepted			2022-02-06	
J	Reiber, GE; McFarland, LV; Hubbard, S; Maynard, C; Blough, DK; Gambel, JM; Smith, DG				Reiber, Gayle E.; McFarland, Lynne V.; Hubbard, Sharon; Maynard, Charles; Blough, David K.; Gambel, Jeffrey M.; Smith, Douglas G.			Servicemembers and veterans with major traumatic limb loss from Vietnam war and OIF/OEF conflicts: Survey methods, participants, and summary findings	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						benefits; combat; limb loss; OIF/OEF; prosthetic devices; traumatic amputation; veterans; Vietnam war; wounded servicemembers; wounded warriors	POSTTRAUMATIC-STRESS-DISORDER; OPERATIONS ENDURING FREEDOM; LOWER-EXTREMITY AMPUTATION; HEALTH-CARE UTILIZATION; PROSTHETIC-DEVICE USE; QUALITY-OF-LIFE; SKIN PROBLEMS; PSYCHOSOCIAL ADJUSTMENT; PHANTOM PAIN; AMPUTEES	Care of veterans and servicemembers with major traumatic limb loss from combat theaters is one of the highest priorities of the Department of Veteran Affairs. We achieved a 62% response rate in our Survey for Prosthetic Use from 298 Vietnam war veterans and 283 servicemembers/veterans from Operation Iraqi Freedom/Operation Enduring Freedom (OIF/OEF) who sustained major traumatic limb loss. Participants reported their combat injuries; health status; quality of life; and prosthetic device use, function, rejection, and satisfaction. Despite the serious injuries experienced, health status was rated excellent, very good, or good by 70.7% of Vietnam war and 85.5% of OIF/OEF survey participants. However, many health issues persist for Vietnam war and OIF/OEF survey participants (respectively): phantom limb pain (72.2%/76.0%), chronic back pain (36.2%/42.1%), residual-limb pain (48.3%/62.9%), prosthesis-related skin problems (51.0%/58.0%), hearing loss (47.0%/47.0%), traumatic brain injury (3.4%/33.9%), depression (24.5%/24.0%), and posttraumatic stress disorder (37.6%/58.7%). Prosthetic devices are currently used by 78.2% of Vietnam war and 90.5% of OIF/OEF survey participants to improve function and mobility. On average, the annual rate for prosthetic device receipt is 10.7-fold higher for OIF/OEF than for Vietnam war survey participants. Findings from this cross-conflict survey identify many strengths in prosthetic rehabilitation for those with limb loss and several areas for future attention.	[Reiber, Gayle E.; McFarland, Lynne V.; Maynard, Charles] Hlth Serv Res & Dev, Dept Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98101 USA; [Reiber, Gayle E.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA; [Reiber, Gayle E.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; [McFarland, Lynne V.] Univ Washington, Dept Med Chem, Seattle, WA 98195 USA; [Hubbard, Sharon] Prosthet Res Study, Seattle, WA USA; [Blough, David K.] Univ Washington, Dept Pharm, Seattle, WA 98195 USA; [Gambel, Jeffrey M.] Walter Reed Army Med Ctr, Armed Forces Amputee Patient Care Program, Washington, DC 20307 USA; [Smith, Douglas G.] Univ Washington, Harborview Med Ctr, Seattle, WA 98104 USA; [Smith, Douglas G.] Univ Washington, Dept Orthoped, Seattle, WA 98195 USA		Reiber, GE (corresponding author), Hlth Serv Res & Dev, Dept Vet Affairs Puget Sound Hlth Care Syst, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA.	Gayle.Reiber@va.gov	Maynard, Charles/N-3906-2015	Maynard, Charles/0000-0002-1644-7814	VA Health Services Research and DevelopmentUS Department of Veterans Affairs [IIR 05-244]; Senior Career Scientist Award [RCS 98-353]	This material is based on work supported by VA Health Services Research and Development (grant IIR 05-244) and a Senior Career Scientist Award to Dr. Reiber (grant RCS 98-353).	American Association for Public Opinion Research, 2008, STAND DEF FIN DISP C; Andersson GBJ, 1991, OCCUPATIONAL LOW BAC, P95; Behel JM, 2002, REHABIL PSYCHOL, V47, P92, DOI 10.1037/0090-5550.47.1.92; Bellamy RF, 2007, MIL MED, V172, p[i, 1023]; BERKE GM, 2010, CURRENT, V47, P361; Blough DK, 2010, J REHABIL RES DEV, V47, P387, DOI 10.1682/JRRD.2009.04.0037; BRADWAY JK, 1984, ORTHOTICS PROSTHET, V38, P46; Bui KM, 2009, J REHABIL RES DEV, V46, P1085, DOI 10.1682/JRRD.2009.04.0052; Burger H, 2007, DISABIL REHABIL, V29, P1323, DOI 10.1080/09638280701320797; Carlson K, 2009, ASSESSMENT TREATMENT; Chan D, 2009, PSYCHIAT SERV, V60, P1612, DOI 10.1176/ps.2009.60.12.1612; Clark ME, 2007, J REHABIL RES DEV, V44, P179, DOI 10.1682/JRRD.2006.05.0057; Collins Diane M., 2006, Critical Reviews in Biomedical Engineering, V34, P379; CUMMING JC, 2006, COCHRANE DB SYST REV, V11; Davidson JRT, 2004, J NEUROPSYCH CLIN N, V16, P135, DOI 10.1176/appi.neuropsych.16.2.135; DeSalvo KB, 2005, HEALTH SERV RES, V40, P1234, DOI 10.1111/j.1475-6773.2005.00404.x; DESTEFANO F, 1988, JAMA-J AM MED ASSOC, V259, P2701; Devlin M, 2004, ARCH PHYS MED REHAB, V85, P1339, DOI 10.1016/j.apmr.2003.09.025; DILLINGHAM TR, 1994, MIL MED, V159, P635, DOI 10.1093/milmed/159.10.635; Dillingham TR, 2001, AM J PHYS MED REHAB, V80, P563, DOI 10.1097/00002060-200108000-00003; Dillman D, 1999, MAIL INTERNET SURVEY, V2nd; Dougherty PJ, 2010, J REHABIL RES DEV, V47, P333, DOI 10.1682/JRRD.2009.04.0043; Dougherty PJ, 2003, J TRAUMA, V54, P718, DOI 10.1097/01.TA.0000046260.16866.A9; Dougherty PJ, 2001, J BONE JOINT SURG AM, V83A, P383, DOI 10.2106/00004623-200103000-00010; Dunn DS, 1996, REHABIL PSYCHOL, V41, P285, DOI 10.1037/0090-5550.41.4.285; Ebrahimzadeh Mohammad H, 2007, J Foot Ankle Surg, V46, P429, DOI 10.1053/j.jfas.2007.08.011; Edwards P, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.MR000008.pub3; Ehde DM, 2000, ARCH PHYS MED REHAB, V81, P1039, DOI 10.1053/apmr.2000.7583; Ephraim PL, 2005, ARCH PHYS MED REHAB, V86, P1910, DOI 10.1016/j.apmr.2005.03.031; Epstein RA, 2010, J REHABIL RES DEV, V47, P373, DOI 10.1682/JRRD.2009.03.0023; Esquenazi A, 2004, DISABIL REHABIL, V26, P831, DOI 10.1080/09638280410001708850; Fowler, 2013, SURV RES METHODS-GER; Gailey R, 2010, J REHABIL RES DEV, V47, P317, DOI 10.1682/JRRD.2009.04.0039; Gallagher P, 1999, BEHAV MED, V25, P117, DOI 10.1080/08964289909596741; Gauthier-Gagnon C, 1999, ARCH PHYS MED REHAB, V80, P706, DOI 10.1016/S0003-9993(99)90177-6; Gawande A, 2004, NEW ENGL J MED, V351, P2471, DOI 10.1056/NEJMp048317; Gironda RJ, 2006, PAIN MED, V7, P339, DOI 10.1111/j.1526-4637.2006.00146.x; Gondusky JS, 2005, MIL MED, V170, P546, DOI 10.7205/MILMED.170.6.546; Hagberg K, 2004, J REHABIL RES DEV, V41, P695, DOI 10.1682/JRRD.2003.11.0167; Heikkinen M, 2007, PROSTHET ORTHOT INT, V31, P277, DOI 10.1080/03093640601040244; Heinemann AW, 2003, PROSTHET ORTHOT INT, V27, P191, DOI 10.1080/03093640308726682; Highsmith James T, 2007, JAAPA, V20, P33; Hofmann SG, 2003, J ANXIETY DISORD, V17, P573, DOI 10.1016/S0887-6185(02)00227-X; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Horgan O, 2004, DISABIL REHABIL, V26, P837, DOI 10.1080/09638280410001708869; Jensen MP, 2002, PAIN, V95, P133, DOI 10.1016/S0304-3959(01)00390-6; Kerkovich DM, 2004, J REHABIL RES DEV, V41, pXI; KESSLER LG, 1987, AM J PUBLIC HEALTH, V77, P18, DOI 10.2105/AJPH.77.1.18; Ketz AK, 2008, ARCH PHYS MED REHAB, V89, P1127, DOI 10.1016/j.apmr.2007.11.037; KISHBAUGH D, 1995, MIL MED, V160, P82, DOI 10.1093/milmed/160.2.82; Kulkarni J, 1998, CLIN REHABIL, V12, P348, DOI 10.1191/026921598672367610; Laferrier JZ, 2010, J REHABIL RES DEV, V47, P349, DOI 10.1682/JRRD.2009.03.0022; Legro MW, 1998, ARCH PHYS MED REHAB, V79, P931, DOI 10.1016/S0003-9993(98)90090-9; Legro MW, 1999, J REHABIL RES DEV, V36, P155; LIVEH H, 1999, INT J REHABIL RES, V22, P21; Maconochie N, 2003, BMC PUBLIC HEALTH, V3, DOI 10.1186/1471-2458-3-4; Marshall RP, 2000, AUST NZ J PSYCHIAT, V34, P954, DOI 10.1080/000486700269; Maynard C, 2010, J REHABIL RES DEV, V47, P403, DOI 10.1682/JRRD.2009.02.0016; McFarland LV, 2010, J REHABIL RES DEV, V47, P299, DOI 10.1682/JRRD.2009.03.0027; Meatherall BL, 2005, ARCH PHYS MED REHAB, V86, P1594, DOI 10.1016/j.apmr.2004.11.026; Meulenbelt HEJ, 2007, J EUR ACAD DERMATOL, V21, P147, DOI 10.1111/j.1468-3083.2006.01936.x; Meulenbelt HEJ, 2006, DISABIL REHABIL, V28, P603, DOI 10.1080/09638280500277032; MULROW CD, QUALITY LIFE CHANGES; Murray CD, 2007, DISABIL REHABIL, V29, P1465, DOI 10.1080/09638280601107385; Nehler MR, 2003, J VASC SURG, V38, P7, DOI 10.1016/S0741-5214(03)00092-2; Norvell DC, 2005, ARCH PHYS MED REHAB, V86, P487, DOI 10.1016/j.apmr.2004.04.034; Ostojic L, 2001, CROAT MED J, V42, P535; Pasquina PF, 2008, J REHABIL RES DEV, V45, P953, DOI 10.1682/JRRD.2007.10.0163; Pasquina PF, 2006, ARCH PHYS MED REHAB, V87, pS34, DOI 10.1016/j.apmr.2005.11.026; Pasquina PF, 2004, J REHABIL RES DEV, V41, pVII; Peake JB, 2005, NEW ENGL J MED, V352, P219, DOI 10.1056/NEJMp048312; *PORTL DEP VET AFF, 2008, PAIN PAT POL SYST RE; Potter BK, 2007, J BONE JOINT SURG AM, V89A, P476, DOI 10.2106/JBJS.F.00412; Reed AB, 2008, ANN VASC SURG, V22, P335, DOI 10.1016/j.avsg.2007.07.039; Reiber GE, 2010, J REHABIL RES DEV, V47, pXXIX, DOI 10.1682/JRRD.2010.03.0031; RYBARCZYK B, 1995, REHABIL PSYCHOL, V40, P95; Sigford BJ, 2010, J REHABIL RES DEV, V47, pXV, DOI 10.1682/JRRD.2009.02.0020; Singh R, 2007, CLIN REHABIL, V21, P754, DOI 10.1177/0269215507077361; Spiro A, 2006, J AMBUL CARE MANAG, V29, P71, DOI 10.1097/00004479-200601000-00008; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Van der Linde H, 2007, DISABIL REHABIL, V29, P1049, DOI 10.1080/09638280600948375; VANDER L, 2003, J REHABIL RES DEV, V41, P555; *VET BEN ADM, 2008, ANN BENEFITS REPORT; VONKORFF M, 1992, PAIN, V50, P133, DOI 10.1016/0304-3959(92)90154-4; WARE JE, 1993, NEW ENGLAND MEDICAL; Webster Lynn R, 2008, Am J Manag Care, V14, pS116; WEED R, 1997, J REHABILITATION OUT, V1, P35; Williams RM, 2006, ARCH PHYS MED REHAB, V87, P989, DOI 10.1016/j.apmr.2006.03.006; WILLIAMSON GM, 1994, J SOC BEHAV PERS, V9, P249; 2010, J REHABIL RES DEV, V47, P409; 2007, MAJOR LIMB AMPUTEE S	91	106	110	2	24	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2010	47	4					275	297		10.1682/JRRD.2010.01.0009			23	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	623ZK	WOS:000279785700006	20803399	Bronze			2022-02-06	
J	Bansal, V; Costantini, T; Kroll, L; Peterson, C; Loomis, W; Eliceiri, B; Baird, A; Wolf, P; Coimbra, R				Bansal, Vishal; Costantini, Todd; Kroll, Lauren; Peterson, Carrie; Loomis, William; Eliceiri, Brian; Baird, Andrew; Wolf, Paul; Coimbra, Raul			Traumatic Brain Injury and Intestinal Dysfunction: Uncovering the Neuro-Enteric Axis	JOURNAL OF NEUROTRAUMA			English	Article						intestinal permeability; tight junctions; traumatic brain injury	FACTOR-KAPPA-B; INFLAMMATORY RESPONSE; BARRIER DYSFUNCTION; TIGHT JUNCTIONS; TNF-ALPHA; MICE; BLOOD; PERMEABILITY; EXPRESSION; APOPTOSIS	Traumatic brain injury (TBI) can lead to several physiologic complications including gastrointestinal dysfunction. Specifically, TBI can induce an increase in intestinal permeability, which may lead to bacterial translocation, sepsis, and eventually multi-system organ failure. However, the exact mechanism of increased intestinal permeability following TBI is unknown. We hypothesized that expression of tight junction protein ZO-1 and occludin, responsible for intestinal architectural and functional integrity, will decrease following TBI and increase intestinal permeability. BALB/c mice underwent a weight drop TBI model following anesthesia. Brain injury was confirmed by a neurologic assessment and gross brain pathology. Six hours following injury, FITC-dextran (25 mg 4.4 kDa FITC-dextran) was injected into the intact lumen of the isolated ileum. Intestinal permeability was measured in plasma 30 min following injection, by using spectrophotometry to determine plasma FITC-dextran concentrations. Whole ileum extracts were used to measure expression of tight junction proteins ZO-1 and occludin by Western blot. TBI caused a significant increase in intestinal permeability (110.0 mu g/mL +/- 22.2) compared to sham animals (29.4 mu g/mL +/- 9.7) 6 h after injury (p = 0.016). Expression of ZO-1 was decreased by 49% relative to sham animals (p < 0.02), whereas expression of occludin was decreased by 73% relative to sham animals (p < 0.001). An increase in intestinal permeability corresponds with decreased expression of tight junction proteins ZO-1 and occludin following TBI. Expression of intestinal tight junction proteins may be an important factor in gastrointestinal dysfunction following brain injury.	[Bansal, Vishal; Costantini, Todd; Kroll, Lauren; Peterson, Carrie; Loomis, William; Eliceiri, Brian; Baird, Andrew; Coimbra, Raul] Univ Calif San Diego, Dept Surg, Div Trauma Surg Crit Care & Burns, San Diego, CA 92103 USA; [Wolf, Paul] Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA		Coimbra, R (corresponding author), Univ Calif San Diego, Dept Surg, Div Trauma Surg Crit Care & Burns, 200 W Arbor Dr 8896, San Diego, CA 92103 USA.	rcoimbra@ucsd.edu	tao, li/G-7956-2011; Peterson, Carrie/AAF-8586-2021; Coimbra, Raul/AAP-3019-2020	Peterson, Carrie/0000-0002-8448-4633; Coimbra, Raul/0000-0002-3759-6851; Baird, Andrew/0000-0003-0027-9905; Eliceiri, Brian/0000-0003-1811-1916	NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL073396] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM078421] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01 HL073396-08, R01 HL073396] Funding Source: Medline; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20 GM078421-05, P20 GM078421] Funding Source: Medline		ANDERSON JM, 1995, AM J PHYSIOL-GASTR L, V269, pG467, DOI 10.1152/ajpgi.1995.269.4.G467; Baguley IJ, 2008, NEUROCRIT CARE, V8, P293, DOI 10.1007/s12028-007-9021-3; Bush TG, 1998, CELL, V93, P189, DOI 10.1016/S0092-8674(00)81571-8; Chen G, 2008, INFLAMM RES, V57, P57, DOI 10.1007/s00011-007-7101-7; Chen G, 2008, ANN CLIN LAB SCI, V38, P65; Costantini TW, 2009, SHOCK, V31, P416, DOI 10.1097/SHK.0b013e3181863080; Cuzzocrea S, 2002, SHOCK, V18, P169, DOI 10.1097/00024382-200208000-00014; Feighery L, 2008, J TRAUMA, V64, P131, DOI 10.1097/TA.0b013e3181568d9f; Fuentes JM, 2006, CLIN VACCINE IMMUNOL, V13, P281, DOI 10.1128/CVI.13.2.281-288.2006; GARCIA JH, 1995, STROKE, V26, P627, DOI 10.1161/01.STR.26.4.627; GARCIA JH, 1995, STROKE, V26, P636, DOI 10.1161/01.STR.26.4.636; Habgood MD, 2007, EUR J NEUROSCI, V25, P231, DOI 10.1111/j.1460-9568.2006.05275.x; Han XN, 2004, AM J PHYSIOL-GASTR L, V286, pG126, DOI 10.1152/ajpgi.00231.2003; Hang CH, 2005, J SURG RES, V123, P188, DOI 10.1016/j.jss.2004.08.002; Hang CH, 2003, WORLD J GASTROENTERO, V9, P2776; Hang CH, 2007, J SURG RES, V137, P53, DOI 10.1016/j.jss.2006.06.026; Hang CH, 2005, WORLD J GASTROENTERO, V11, P1149, DOI 10.3748/wjg.v11.i8.1149; Jin W, 2008, CYTOKINE, V44, P135, DOI 10.1016/j.cyto.2008.07.005; Kao CH, 1998, AM J GASTROENTEROL, V93, P1108; Kemp CD, 2008, AM SURGEON, V74, P866; Ma B, 2007, ANAT HISTOL EMBRYOL, V36, P62, DOI 10.1111/j.1439-0264.2006.00741.x; Mazzon E, 2006, SHOCK, V25, P515, DOI 10.1097/01.shk.0000209556.31457.e7; Mazzon E, 2008, AM J PHYSIOL-GASTR L, V294, pG1268, DOI 10.1152/ajpgi.00014.2008; McGarry LJ, 2002, J TRAUMA, V53, P1152, DOI 10.1097/00005373-200212000-00020; Osborn TM, 2004, CRIT CARE MED, V32, P2234, DOI 10.1097/01.CCM.0000145586.23276.0F; Schneeberger EE, 2004, AM J PHYSIOL-CELL PH, V286, pC1213, DOI 10.1152/ajpcell.00558.2003; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Wu Z, 2008, NEUROBIOL DIS, V32, P543, DOI 10.1016/j.nbd.2008.09.002; Zeissig S, 2007, GUT, V56, P61, DOI 10.1136/gut.2006.094375; Zeissig S, 2004, GUT, V53, P1295, DOI 10.1136/gut.2003.036632	30	106	116	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2009	26	8					1353	1359		10.1089/neu.2008.0858			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	479AF	WOS:000268629900018	19344293	Green Published			2022-02-06	
J	Preiss-Farzanegan, SJ; Chapman, B; Wong, TM; Wu, J; Bazarian, JJ				Preiss-Farzanegan, Sarah J.; Chapman, Benjamin; Wong, Tony M.; Wu, Joanne; Bazarian, Jeffrey J.			The Relationship Between Gender and Postconcussion Symptoms After Sport-Related Mild Traumatic Brain Injury	PM&R			English	Article							POST-CONCUSSION SYMPTOMS; COLLEGIATE FOOTBALL PLAYERS; HEAD-INJURY; SEX-DIFFERENCES; IMPACT; QUESTIONNAIRE; IMPAIRMENT; PREDICTION; RECOVERY; LONG	Objective: The authors sought to define the relationship between gender and post-concussion symptoms (PCSx) at 3 months after sport-related mild traumatic brain injury (mTBI) and, further, to examine whether age (minors vs. adults), source of PCSx reporting (self-reported vs. proxy), previous head injury or loss of consciousness, or the sport type in which the mTBI was incurred explain any observed gender differences in PCSx. Design: Prospective nested cohort study. Setting: Regional trauma center emergency department. Patients: A total of 260 patients who presented with sport-related mTBI, as defined by American Congress of Rehabilitation Medicine criteria, began the study. The participants who lacked litigation concerning the mTBI and had participated in the follow-up assessment completed the study (n = 215). Assessment of Risk Factors: Self, proxy, and interviewer report of age, gender, previous head injury or loss of consciousness, and sport in which injury was sustained. Main Outcome Measurements: Rivermead Post Concussion Symptoms Questionnaire (RPQ). Results: Adult females are at greater risk for elevated RPQ scores (odds ratio [OR] = 2.89, 95% confidence interval [95% CI] = 1.25-6.71; P = .013) but not female minors (OR = 0.87, 95% CI = 0.45-1.71]; P = .695), as compared with male subjects. Adjustment for empirically identified confounders in each age group revealed persisting elevated risk for adult females (OR = 2.57, 95% CI = 1.09-6.08; P = .031), but not minor females (OR = 1.07, 95% CI = 0.52-2.19, P = .852). The risk associated with female gender in adults could not be explained by characteristics of the sports, such as helmeted versus not, or contact versus no contact, in which women incurred mTBIs. No sport characteristics were associated with increased risk of PCSx after mTBI. Conclusions: Adult females, but not female minors, are at increased risk for PCSx after sport-related mTBI as compared with male patients. This increased risk cannot be explained by self-report, rather than proxy report, of symptoms, previous head injury or loss of consciousness, age, or sport characteristics. Further research is needed to elucidate the processes of age-differential recovery from mild brain injury in women and on how to most effectively incorporate appropriate follow-up after emergency department evaluation.	[Preiss-Farzanegan, Sarah J.; Wu, Joanne] Univ Rochester, Med Ctr, Dept Phys Med & Rehabil, Rochester, NY 14642 USA; [Chapman, Benjamin] Univ Rochester, Sch Med & Dent, Dept Psychiat, Rochester, NY 14642 USA; [Wong, Tony M.] Univ Rochester, Med Ctr, Dept Neuropsychol, Dept Phys Med & Rehabil,Unity Hlth Syst, Rochester, NY 14642 USA; [Bazarian, Jeffrey J.] Univ Rochester, Med Ctr, Dept Emergency Med, Rochester, NY 14642 USA; [Bazarian, Jeffrey J.] Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA; [Bazarian, Jeffrey J.] Univ Rochester, Med Ctr, Dept Neurosurg, Rochester, NY 14642 USA		Preiss-Farzanegan, SJ (corresponding author), Stanford Sports Med Ctr, 341 Galvez St, Stanford, CA 94305 USA.	Preiss18@yahoo.com		Chapman, Benjamin/0000-0002-5170-3131	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23 NS041952] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS041952] Funding Source: NIH RePORTER		Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Ananth CV, 1997, INT J EPIDEMIOL, V26, P1323, DOI 10.1093/ije/26.6.1323; Badie H, 1992, J NEUROTRAUM, V9, P56; Bazarian JJ, 2006, RESTOR NEUROL NEUROS, V24, P163; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bazarian JJ, 2001, ACAD EMERG MED, V8, P788, DOI 10.1111/j.1553-2712.2001.tb00208.x; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P15, DOI 10.1080/16501960410023688; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Covassin T, 2003, J ATHL TRAINING, V38, P238; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; FEE CRA, 1988, ARCH EMERG MED, V5, P12; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; Gaetz M, 2000, BRAIN INJURY, V14, P1077; GRONWALL D, 1975, LANCET, V2, P995; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Ives JC, 2007, J ATHL TRAINING, V42, P431; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kelly JP, 1997, NEUROLOGY, V48, P581; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; McCauley SR, 2005, J NERV MENT DIS, V193, P540, DOI 10.1097/01.nmd.0000172592.05801.71; McNamee R, 2005, OCCUP ENVIRON MED, V62, P500, DOI 10.1136/oem.2002.001115; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Miller LJ, 2001, BRAIN INJURY, V15, P297, DOI 10.1080/026990501750111238; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; National Center for Injury Prevention and Control, 2003, C MILD TRAUM BRAIN I; National Institute of Health, 2001, NIH PUBL, V01-3670; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Necajauskaite Olga, 2005, Medicina (Kaunas), V41, P457; Newman SC, 2004, J CLIN EPIDEMIOL, V57, P325, DOI 10.1016/j.jclinepi.2003.07.014; *NIH, 1982, NIH PUBL; Paniak C, 2000, J MUSCULOSKELET PAIN, V8, P193, DOI 10.1300/J094v08n01_16; Paniak C, 2002, J CLIN EXP NEUROPSYC, V24, P187, DOI 10.1076/jcen.24.2.187.999; Pavalko EK, 2000, J HEALTH SOC BEHAV, V41, P91, DOI 10.2307/2676362; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUTHERFORD WH, 1977, LANCET, V1, P1; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Setnik L, 2007, BRAIN INJURY, V21, P1, DOI 10.1080/02699050601111419; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004	56	106	107	0	20	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1934-1482	1934-1563		PM&R	PM&R	MAR	2009	1	3					245	253		10.1016/j.pmrj.2009.01.011			9	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	V24LF	WOS:000208411200008	19627902	Green Accepted			2022-02-06	
J	Roe, C; Sveen, U; Alvsaker, K; Bautz-Holter, E				Roe, Cecilie; Sveen, Unni; Alvsaker, Kristin; Bautz-Holter, Erik			Post-concussion symptoms after mild traumatic brain injury: influence of demographic factors and injury severity in a 1-year cohort study	DISABILITY AND REHABILITATION			English	Article						Mild traumatic brain injury; post concussion symptoms; injury severity; drop-out	MINOR HEAD-INJURY; NEUROPSYCHOLOGICAL DEFICITS; POSTCONCUSSION-SYNDROME; FOLLOW-UP; BASE-RATE; QUESTIONNAIRE; EPIDEMIOLOGY; SENSITIVITY; POPULATION; PREDICTORS	Purpose. To assess the prevalence and variation of post-concussion symptoms within the first year after mild traumatic brain injury (TBI), and explore the association between injury severity, demographic factors and symptoms. Methods. Prospective study of patients with mild TBI followed up at 3, 6 and 12 months (N = 96 included, n = 52 attending all follow-ups). Sociodemographic factors, injury mechanisms and impact of injury (Glasgow Coma Scale score, Abbreviated Injury Severity Score (AIS), Injury Severity Score) were recorded at inclusion. Symptoms were reported in the Rivermead Post-Concussion Symptoms Questionnaire (RPQ) at the follow-ups. The sumscore of all symptoms in RPQ was calculated for each subject. Scores were also calculated separately for the cognitive, physical and behavioural symptoms. Results. Twenty-nine subjects met the post-concussion syndrome criteria at 3 months, and 22 patients at 6 and 12 months. The cognitive symptoms were more prominent than the physical and behavioural symptoms. The cognitive and physical symptoms were associated with AIS for the head injury at 3 months, but not at 12 months. Considerable individual variability in the symptom pattern was found, and the subjects who attended only the 3-months follow-up reported a lower level of symptoms than those attending all follow-ups. Conclusions. Persistence of symptoms was a considerable problem even I year after the injury, with cognitive symptoms dominating. More severe AIS scores were associated with a higher level of cognitive and physical symptoms at 3 months, but not at later follow-ups. Strategies to prevent and treat these symptoms should be focussed in clinical practice.	[Roe, Cecilie; Sveen, Unni; Alvsaker, Kristin; Bautz-Holter, Erik] Ullevaal Univ Hosp, Dept Phys Med & Rehabil, N-0407 Oslo, Norway; [Roe, Cecilie; Bautz-Holter, Erik] Univ Oslo, Fac Med, N-0316 Oslo, Norway		Roe, C (corresponding author), Ullevaal Univ Hosp, Dept Phys Med & Rehabil, N-0407 Oslo, Norway.	cecilie.roe@ulleval.no					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; ARCIA E, 1993, BRAIN INJURY, V7, P481, DOI 10.3109/02699059309008175; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bazarian JJ, 2006, ACAD EMERG MED, V13, P199, DOI 10.1197/j.aem.2005.07.031; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; BOHNEN N, 1992, NEUROSURGERY, V30, P692, DOI 10.1097/00006123-199205000-00007; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Centers for Disease Control and Prevention, 1999, TRAUM BRAIN INJ US R; Chan RCK, 2005, BRAIN INJURY, V19, P1117, DOI 10.1080/026990500150088; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Edna T H, 1987, J Oslo City Hosp, V37, P101; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Fenton GW, 1996, CLIN ELECTROENCEPHAL, V27, P174; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; Gordon WA, 2000, BRAIN INJURY, V14, P21, DOI 10.1080/026990500120907; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; Gunstad J, 2004, ARCH CLIN NEUROPSYCH, V19, P391, DOI 10.1016/S0887-6177(03)00073-8; Haldorsen T, 2003, APPL NEUROPSYCHOL, V10, P170, DOI 10.1207/S15324826AN1003_06; Hasvold Toralf, 1993, Scandinavian Journal of Primary Health Care, V11, P219, DOI 10.3109/02813439308994834; Ingebrigtsen T, 1998, NEUROEPIDEMIOLOGY, V17, P139, DOI 10.1159/000026165; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Paniak C, 2000, BRAIN INJURY, V14, P219; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; Rating the severity of tissue damage. I, 1971, JAMA-J AM MED ASSOC, V215, P277; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Steingrimsdottir OA, 2004, PAIN, V110, P130, DOI 10.1016/j.pain.2004.03.016; TEASDALE G, 1974, LANCET, V2, P81; Wade DT, 1997, J NEUROL NEUROSUR PS, V62, P478, DOI 10.1136/jnnp.62.5.478; *WHO, 1981, ICD 10 CLASS; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3	51	106	106	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.		2009	31	15					1235	1243		10.1080/09638280802532720			9	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	473MX	WOS:000268212200003	19116810				2022-02-06	
J	Marcoux, J; McArthur, DA; Miller, C; Glenn, TC; Villablanca, P; Martin, NA; Hovda, DA; Alger, JR; Vespa, PM				Marcoux, Judith; McArthur, David A.; Miller, Chad; Glenn, Thomas C.; Villablanca, Pablo; Martin, Neil A.; Hovda, David A.; Alger, Jeffry R.; Vespa, Paul M.			Persistent metabolic crisis as measured by elevated cerebral microdialysis lactate-pyruvate ratio predicts chronic frontal lobe brain atrophy after traumatic brain injury	CRITICAL CARE MEDICINE			English	Article						brain trauma; microdialysis; lactate; pyruvate; MRI; atrophy; outcome; biomarker	POSITRON-EMISSION-TOMOGRAPHY; CLOSED-HEAD-INJURY; PERFUSION-PRESSURE; INTRACEREBRAL MICRODIALYSIS; SUBARACHNOID HEMORRHAGE; EXTRACELLULAR GLUTAMATE; LACTATE/PYRUVATE RATIO; QUANTITATIVE-ANALYSIS; ENERGY-METABOLISM; GLUCOSE	Objective: To determine whether persistent metabolic dysfunction in normal-appearing frontal lobe tissue is correlated with long-term tissue atrophy. Design: Prospective monitoring with retrospective data analysis. Setting: Single-center academic neurointensive care unit. Patients: Fifteen patients with moderate to severe traumatic brain injury (Glasgow Coma Scale score 3-12). Interventions: None. Measurements and Main Results: Hourly cerebral microdialysis was performed for the initial 96 hrs after trauma to determine extracellular levels of glucose, glutamate, glycerol, lactate, and pyruvate in normal appearing frontal lobes. Six months after injury, the anatomical outcome was assessed by measures of global and regional cerebral atrophy using volumetric brain magnetic resonance imaging. The lactate/pyruvate ratio was elevated >40 after traumatic brain injury in most patients, with a mean percent time of 32 +/- 29% of hours monitored. At 6 months after traumatic brain injury, there was a mean frontal lobe atrophy of 12 +/- 11% and global brain atrophy of 8.5 +/- 4.5%. The percentage of time of elevated lactate/pyruvate ratio correlated with the extent of frontal lobe brain atrophy (r = -.56, p < 0.01), but not global brain atrophy (r = -.31, p = 0.20). The predictive effect of lactate/pyruvate ratio was independent of patient age, Glasgow Coma Scale score, and volume of frontal lobe contusion. Conclusion: Persistent metabolic crisis, as reflected by an elevated lactate/pyruvate ratio, in normal appearing posttraumatic frontal lobe, is predictive of the degree of tissue atrophy at 6 months.	[Marcoux, Judith] McGill Univ, Montreal Neurol Inst, Dept Neurosurg, Montreal, PQ, Canada; [McArthur, David A.; Miller, Chad; Glenn, Thomas C.; Martin, Neil A.; Hovda, David A.; Vespa, Paul M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg Neurosurg, Los Angeles, CA 90095 USA; [Alger, Jeffry R.; Vespa, Paul M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA; [Villablanca, Pablo] Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiol, Los Angeles, CA 90095 USA		Marcoux, J (corresponding author), McGill Univ, Montreal Neurol Inst, Dept Neurosurg, Montreal, PQ, Canada.	PVespa@mednet.ucla.edu		Martin, Neil/0000-0002-6565-4131; Glenn, Thomas/0000-0003-4273-3408	 [NS049471];  [NS02089]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049471, K08NS002089] Funding Source: NIH RePORTER	Supported in part by grants NS049471 and NS02089.	Bartnik BL, 2007, J NEUROTRAUM, V24, P1079, DOI 10.1089/neu.2006.0210; Bigler E D, 1999, Appl Neuropsychol, V6, P217, DOI 10.1207/s15324826an0604_4; BLATTER DD, 1995, AM J NEURORADIOL, V16, P241; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; CULLUM CM, 1986, J CLIN EXP NEUROPSYC, V8, P437, DOI 10.1080/01688638608401333; Dusick JR, 2007, J CEREBR BLOOD F MET, V27, P1593, DOI 10.1038/sj.jcbfm.9600458; Enblad P, 1996, J CEREBR BLOOD F MET, V16, P637, DOI 10.1097/00004647-199607000-00014; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; Gopinath SP, 2000, ACT NEUR S, V76, P437; Henry-Feugeas MC, 2000, BRAIN INJURY, V14, P597; Hillered L, 2006, CURR OPIN CRIT CARE, V12, P112, DOI 10.1097/01.ccx.0000216576.11439.df; Hutchinson PJA, 2000, ACT NEUR S, V76, P431; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Nordstrom CH, 2003, ANESTHESIOLOGY, V98, P809, DOI 10.1097/00000542-200304000-00004; Samuelsson C, 2007, J CEREBR BLOOD F MET, V27, P1309, DOI 10.1038/sj.jcbfm.9600433; Sarrafzadeh AS, 2002, ACTA NEUROCHIR SUPPL, V81, P319; Shiozaki T, 2001, J NEUROTRAUM, V18, P665, DOI 10.1089/089771501750357618; Stahl N, 2001, ACTA ANAESTH SCAND, V45, P977, DOI 10.1034/j.1399-6576.2001.450810.x; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Verger K, 2001, BRAIN INJURY, V15, P211; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Wilde EA, 2004, J NEUROTRAUM, V21, P137, DOI 10.1089/089771504322778604; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yount R, 2002, J NEUROPSYCH CLIN N, V14, P416, DOI 10.1176/appi.neuropsych.14.4.416	29	106	108	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	OCT	2008	36	10					2871	2877		10.1097/CCM.0b013e318186a4a0			7	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	356GF	WOS:000259766000022	18766106				2022-02-06	
J	Yard, EE; Schroeder, MJ; Fields, SK; Collins, CL; Comstock, RD				Yard, Ellen E.; Schroeder, Matthew J.; Fields, Sarah K.; Collins, Christy L.; Comstock, R. Dawn			The epidemiology of United States high school soccer injuries, 2005-2007	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						high school; soccer; injury; gender; epidemiology; surveillance	CRUCIATE LIGAMENT INJURIES; FOOTBALL INJURIES; DESCRIPTIVE EPIDEMIOLOGY; EMERGENCY-DEPARTMENTS; SURVEILLANCE SYSTEM; SPORTS; CONCUSSIONS; POPULATION; MECHANISMS; PATTERNS	Background: United States high school soccer participation increased 5 fold over the last 30 years. With increased participation comes increased injury incidence. Hypothesis: High school soccer injury patterns will vary by gender and type of exposure. Study Design: Descriptive epidemiologic study. Methods: Soccer-related injury data were collected over the 2005-2006 and 2006-2007 school years from 100 nationally representative United States high schools via Reporting Information Online (RIO, an Internet-based sports-related injury surveillance system). Results: Participating certified athletic trainers reported 1524 soccer injuries during 637 446 athlete exposures (AEs), for an injury rate of 2.39 per 1000 AEs, corresponding to a nationally estimated 807 492 soccer-related injuries during the 2005-2006 and 2006-2007 seasons. The injury rate per 1000 AEs was greater during competition (4.77) than practice (1.37) (rate ratio [RR] = 3.49; 95% confidence interval [CI], 3.15-3.87). Overall, the most frequent diagnoses were incomplete ligament sprains (26.8%), incomplete muscle strains (17.9%), contusions (13.8%), and concussions (10.8%). The most commonly injured body sites were the ankle (23.4%), knee (18.7%), head/face (13.7%), and thigh/upper leg (13.1%). Similar proportions of boys (57.9%) and girls (53.9%) returned to activity in <1 week. During competition, girls sustained complete knee ligament sprains requiring surgery at a rate of 26.4 per 100 000 AEs, higher than the rate among boys during competition (1.98 per 100 000 AEs) (RR = 13.3; 95% CI, 3.15-56.35) and among girls during practice (2.34 per 100 000 AEs) (RR = 11.3; 95% CI, 4.31-29.58). Player-to-player contact was more common among competition injuries (injury proportion ratio [IPR] = 2.42; 95% CI, 2.01-2.92), while noncontact mechanisms were more common among practice injuries (IPR = 2.39; 95% CI, 1.90-3.01). Conclusions: High school soccer injury patterns vary by gender and type of exposure. Identifying such differences in injury patterns is the important first step in the development of evidence-based, targeted injury prevention efforts.	[Yard, Ellen E.; Collins, Christy L.; Comstock, R. Dawn] Nationwide Childrens Hosp, Res Inst, Ctr Injury Res & Policy, Columbus, OH 43205 USA; [Schroeder, Matthew J.; Comstock, R. Dawn] Ohio State Univ, Coll Publ Hlth, Div Epidemiol, Columbus, OH 43210 USA; [Fields, Sarah K.] Ohio State Univ, Sch Phys Activ & Educ Serv, Columbus, OH 43210 USA; [Comstock, R. Dawn] Ohio State Univ, Coll Med, Dept Pediat, Columbus, OH 43210 USA		Yard, EE (corresponding author), Nationwide Childrens Hosp, Res Inst, Ctr Injury Res & Policy, 700 Childrens Dr, Columbus, OH 43205 USA.	Ellen.Yard@NationwideChildrens.org			Centers for Disease Control and Prevention (CDC)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49/CE000674-01]; National Athletic Trainers' Association (NATA) Research; Education Foundation [905GGP008]	This research was in part funded by the Centers for Disease Control and Prevention (CDC), grant #R49/CE000674-01, and the National Athletic Trainers' Association (NATA) Research and Education Foundation, grant #905GGP008. The content of this report is solely the responsibility of the authors and does not necessarily represent the official view of the CDC or the NATA.	Agel J, 2005, AM J SPORT MED, V33, P524, DOI 10.1177/0363546504269937; Agel J, 2007, J ATHL TRAINING, V42, P270; Anderson SJ, 2000, PEDIATRICS, V105, P659, DOI 10.1542/peds.105.3.640; [Anonymous], 1997, MMWR Recomm Rep, V46, P1; Boden BP, 2000, ORTHOPEDICS, V23, P573, DOI 10.3928/0147-7447-20000601-15; Bonsell S, 2000, Proc (Bayl Univ Med Cent), V13, P327; Burt CW, 2001, ANN EMERG MED, V37, P301, DOI 10.1067/mem.2001.111707; Caraffa A, 1996, Knee Surg Sports Traumatol Arthrosc, V4, P19, DOI 10.1007/BF01565992; Comstock R. D., 2006, Morbidity and Mortality Weekly Report, V55, P1037; Conn JM, 2003, INJURY PREV, V9, P117, DOI 10.1136/ip.9.2.117; Covassin T, 2003, J ATHL TRAINING, V38, P238; Delaney JS, 2005, BRIT J SPORT MED, V39, DOI 10.1136/bjsm.2004.015735; Dick R, 2007, J ATHL TRAINING, V42, P278; Dvorak J, 2000, AM J SPORT MED, V28, pS3; Elias SR, 2001, MED SCI SPORT EXER, V33, P359, DOI 10.1097/00005768-200103000-00004; Emery CA, 2005, AM J SPORT MED, V33, P1882, DOI 10.1177/0363546505279576; *FED INT FOOTB ASS, FOOTB WORLDW 2000 OF; Fernandez WG, 2007, ACAD EMERG MED, V14, P641, DOI [10.1197/j.aem.2007.03.1354, 10.1111/j.1553-2712.2007.tb01851.x]; FULLER CW, 2005, BR J SPORTS MED S1, V39, P3; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Giza E, 2005, BRIT J SPORT MED, V39, P212, DOI 10.1136/bjsm.2004.011973; Giza Eric, 2005, Med Sport Sci, V49, P140, DOI 10.1159/000085395; Hewett TE, 2006, AM J SPORT MED, V34, P490, DOI 10.1177/0363546505282619; Hewett TE, 2006, AM J SPORT MED, V34, P299, DOI 10.1177/0363546505284183; HUTCHINSON MR, 1995, SPORTS MED, V19, P288, DOI 10.2165/00007256-199519040-00006; Kakavelakis KN, 2003, SCAND J MED SCI SPOR, V13, P175, DOI 10.1034/j.1600-0838.2003.00294.x; Knowles SB, 2006, AM J EPIDEMIOL, V164, P1209, DOI 10.1093/aje/kwj337; Leininger RE, 2007, AM J SPORT MED, V35, P288, DOI 10.1177/0363546506294060; Mandelbaum BR, 2005, AM J SPORT MED, V33, P1003, DOI 10.1177/0363546504272261; Marchi AG, 1999, ARCH DIS CHILD, V81, P324, DOI 10.1136/adc.81.4.324; McCrory PR, 2003, BRIT MED J, V327, P351, DOI 10.1136/bmj.327.7411.351; Metzl JD, 1999, PEDIATR EMERG CARE, V15, P130, DOI 10.1097/00006565-199904000-00013; *NAT FED STAT HIGH, 2006 07 HIGH SCH ATH; Nelson AJ, 2007, J ATHL TRAINING, V42, P381; Peterson L, 2000, AM J SPORT MED, V28, pS51; Pickett W, 2005, BRIT J SPORT MED, V39, P226, DOI 10.1136/bjsm.2004.013169; Powell JW, 1999, J ATHL TRAINING, V34, P277; Powell JW, 2000, AM J SPORT MED, V28, P385, DOI 10.1177/03635465000280031801; Rahnama N, 2002, BRIT J SPORT MED, V36, P354, DOI 10.1136/bjsm.36.5.354; Shankar PR, 2007, AM J SPORT MED, V35, P1295, DOI 10.1177/0363546507299745; Simon TD, 2004, ACAD EMERG MED, V11, P1042, DOI 10.1197/j.aem.2004.04.013; United States Census Bureau, CENS REG DIV US; Walden M, 2005, BRIT J SPORT MED, V39, P542, DOI 10.1136/bjsm.2004.014571; Wong P, 2005, BRIT J SPORT MED, V39, P473, DOI 10.1136/bjsm.2004.015511; Yardt EE, 2008, AM J SPORT MED, V36, P57, DOI 10.1177/0363546507307507	45	106	111	0	13	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	OCT	2008	36	10					1930	1937		10.1177/0363546508318047			8	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	354MA	WOS:000259642500009	18628486				2022-02-06	
J	Laupland, KB; Shahpori, R; Kirkpatrick, AW; Ross, T; Gregson, DB; Stelfox, HT				Laupland, Kevin B.; Shahpori, Reza; Kirkpatrick, Andrew W.; Ross, Terry; Gregson, Daniel B.; Stelfox, H. Thomas			Occurrence and outcome of fever in critically ill adults	CRITICAL CARE MEDICINE			English	Article; Proceedings Paper	37th Critical Care Congress of the Society-of-Critical-Care-Medicine	FEB 02-08, 2008	Honolulu, HI	Soc Crit Care Med		fever; mortality; intensive care unit; outcome; adult	INTENSIVE-CARE-UNIT; TRAUMATIC BRAIN-INJURY; RISK-FACTORS; INFECTION; SYSTEM; MORTALITY; SINUSITIS; PROGRESS; SEPSIS	Objective., Although fever is common in the critically ill, only a small number of studies have specifically investigated its epidemiology in the intensive care unit (ICU). The objective of this study was to describe the occurrence of fever in the critically ill and assess its effect on ICU outcome. Design: Retrospective cohort. Fever was defined by temperature >= 38.3 degrees C and high fever by >= 39.5 degrees C. Setting. Calgary Health Region during 2000-2006. Patients. All adults ( >= 18 yrs) admitted to ICUs. Interventions: None. Measurements and Main Results: A total of 24,204 ICU admission episodes occurred among 20,466 patients; 35% were classified as medical, 33% as cardiac surgical, 16% as other surgical, and 15% as trauma/neurologic. The cumulative incidence of fever and high fever was 44% and 8% and the incidence density was 24.3 and 2.7 per 100 days of ICU admission, respectively. The incidence density of fever was higher in trauma/neuro patients, males, younger patients, and was lower in those with admission Acute Physiology and Chronic Health Evaluation 11 scores >= 25. Seventeen percent and 31% of patients with fever and high fever had associated positive cultures. Resolution of fever and high fever occurred in 27% and 53% of patients before ICU discharge and prolonged fever and high fever lasting for 5 or more days in the ICU occurred in 18% and 11% of febrile patients, respectively. Although the presence of fever was not associated with increased ICU mortality (13% vs. 12%; p =.08), high fever was associated with significantly increased risk for death (20.3% vs. 12%, p <.0001). After controlling for confounding factors using multivariable logistic regression models, the influence of fever on the ICU mortality varied significantly according to its timing of onset, degree, and main admission category. Conclusions. Fever is common in patients admitted to the ICU and its occurrence and impact on outcome varies among defined patient populations.	[Laupland, Kevin B.; Gregson, Daniel B.] Univ Calgary, Dept Med, Calgary, AB, Canada; [Laupland, Kevin B.] Univ Calgary, Dept Pathol & Lab Med, Calgary, AB, Canada; [Laupland, Kevin B.; Shahpori, Reza; Kirkpatrick, Andrew W.; Gregson, Daniel B.; Stelfox, H. Thomas] Univ Calgary, Dept Crit Care Med, Calgary, AB, Canada; [Kirkpatrick, Andrew W.] Univ Calgary, Dept Surg, Calgary, AB, Canada; [Laupland, Kevin B.; Ross, Terry] Univ Calgary, Ctr Antimicrobial Resistance, Calgary, AB, Canada; Calgary Lab Serv, Calgary, AB, Canada		Laupland, KB (corresponding author), Univ Calgary, Dept Med, Calgary, AB, Canada.	kevin.laupland@calgaryhealthregion.ca	Laupland, Kevin/AAG-3656-2020; Viani, Rafael/V-1196-2018; Laupland, kevin/AAJ-6339-2020	Laupland, kevin/0000-0002-1205-5354; Stelfox, Henry/0000-0003-1231-1490			Andrews Peter J D, 2004, Curr Opin Crit Care, V10, P110, DOI 10.1097/00075198-200404000-00006; Barie Philip S, 2004, Surg Infect (Larchmt), V5, P145, DOI 10.1089/1096296041839534; BORMAN KR, 1992, AM J SURG, V164, P412, DOI 10.1016/S0002-9610(05)81171-7; Bota DP, 2004, INTENS CARE MED, V30, P811, DOI 10.1007/s00134-004-2166-z; Bouchama A, 2002, NEW ENGL J MED, V346, P1978, DOI 10.1056/NEJMra011089; CHIN R, 1991, CRIT CARE CLIN, V7, P23, DOI 10.1016/S0749-0704(18)30321-X; Circiumaru B, 1999, INTENS CARE MED, V25, P668, DOI 10.1007/s001340050928; CLARKE DE, 1991, CHEST, V100, P213, DOI 10.1378/chest.100.1.213; Commichau C, 2003, NEUROLOGY, V60, P837, DOI 10.1212/01.WNL.0000047344.28843.EB; Cullen D J, 1974, Crit Care Med, V2, P57, DOI 10.1097/00003246-197403000-00001; Cunha BA, 1999, INTENS CARE MED, V25, P648, DOI 10.1007/s001340050925; Cunha BA, 1996, INFECT DIS CLIN N AM, V10, P185, DOI 10.1016/S0891-5520(05)70294-4; Cunningham JA, 2005, ANAESTH INTENS CARE, V33, P534, DOI 10.1177/0310057X0503300421; Diringer MN, 2004, CRIT CARE MED, V32, P1489, DOI 10.1097/01.CCM.0000129484.61912.84; Gozzoli V, 2001, ARCH INTERN MED, V161, P121, DOI 10.1001/archinte.161.1.121; Hebbar Kiran, 2005, Pediatr Crit Care Med, V6, P557, DOI 10.1097/01.PCC.0000163671.69197.16; Hebert PC, 2003, JAMA-J AM MED ASSOC, V289, P1941, DOI 10.1001/jama.289.15.1941; Jaber S, 2005, CHEST, V127, P233, DOI 10.1378/chest.127.1.233; Kilpatrick MM, 2000, NEUROSURGERY, V47, P850, DOI 10.1097/00006123-200010000-00011; Kluger MJ, 1996, INFECT DIS CLIN N AM, V10, P1, DOI 10.1016/S0891-5520(05)70282-8; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Laupland KB, 2006, CHEST, V129, P954, DOI 10.1378/chest.129.4.954; Laupland KB, 2005, CRIT CARE, V9, pR60, DOI 10.1186/cc3023; Laupland KB, 2004, CRIT CARE, V8, pR431, DOI 10.1186/cc2947; Laupland KB, 2004, CRIT CARE MED, V32, P992, DOI 10.1097/01.CCM.0000119424.31648.1E; Laupland KB, 2002, J CRIT CARE, V17, P50, DOI 10.1053/jcrc.2002.33029; Laupland KB, 2005, INTENS CARE MED, V31, P213, DOI 10.1007/s00134-004-2544-6; Leon C, 2005, J CRIT CARE, V20, P106, DOI 10.1016/j.jcrc.2004.08.011; O'Grady NP, 1998, CLIN INFECT DIS, V26, P1042, DOI 10.1086/520308; Oliveira J, 2001, NEUROLOGY, V56, P1299, DOI 10.1212/WNL.56.10.1299; Rizoli SB, 2002, LANCET INFECT DIS, V2, P137, DOI 10.1016/S1473-3099(02)00220-7; Ryan M, 2003, CRIT CARE, V7, P221, DOI 10.1186/cc1879; Schulman Carl I, 2005, Surg Infect (Larchmt), V6, P369; Singh N, 1999, CLIN TRANSPLANT, V13, P504, DOI 10.1034/j.1399-0012.1999.130611.x; SMEGO RA, 1982, ARCH INTERN MED, V142, P1183, DOI 10.1001/archinte.142.6.1183; Thong WY, 2002, ANESTH ANALG, V95, P1489, DOI 10.1097/00000539-200212000-00006; Toltzis P, 2001, INFECT CONT HOSP EP, V22, P499, DOI 10.1086/501940; van Zanten ARH, 2005, CRIT CARE, V9, pR583, DOI 10.1186/cc3805; Zygun DA, 2003, CAN J NEUROL SCI, V30, P307, DOI 10.1017/S0317167100003000; Zygun D, 2006, CRIT CARE, V10, DOI 10.1186/cc5007	40	106	109	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	MAY	2008	36	5					1531	1535		10.1097/CCM.0b013e318170efd3			5	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	297NJ	WOS:000255623100021	18434882				2022-02-06	
J	Lu, DY; Mahmood, A; Qu, CS; Hong, X; Kaplan, D; Chopp, M				Lu, Dunyue; Mahmood, Asirn; Qu, Changsheng; Hong, Xin; Kaplan, David; Chopp, Michael			Collagen scaffolds populated with human marrow stromal cells reduce lesion volume and improve functional outcome after traumatic brain injury	NEUROSURGERY			English	Article						human marrow stromal cells; Lesion volume; Scaffold; traumatic brain injury	STEM-CELLS; RAT MODEL; TRANSPLANTATION; GROWTH	OBJECTIVE: Traumatic brain injury (TBI) causes extensive loss of cerebral parenchyma; however, no strategy for reconstruction has been clinically effective. Our group and others have used human marrow stromal cells (hMSCs) to treat rats subjected to TBI and found no significant changes in the lesion volume, although functional outcome was improved significantly. To identify new ways of delivering hMSCs into the injured brain and to maximize the therapeutic benefits of hMSC treatment, we investigated the use of Collagen scaffolds implanted with hMSCs as a cell delivery system for treatment of TBI. METHODS: Collagen scaffolds populated with 3 X 106 hMSCs were transplanted into the lesion cavity of the injured cortex 4 days after TBI, and the rats were euthanized 35 days after TBI. We measured sensorimotor function and spatial learning using an array of function tests, and the brain tissue was processed for histopathology analysis. CONCLUSION: The data show that scaffolds populated by hMSCs improve spatial learning and sensorimotor function, reduce the lesion volume, and foster the migration of hMSCs into the lesion boundary zone after TBI in rats. hMSC-populated scaffolds may be a new way to reconstruct the injured brain and improve neurological function after TBI.	Henry Ford Hosp, Dept Neurol, Detroit, MI 48202 USA; Oakland Univ, Dept Phys, Rochester, MI 48063 USA; Tufts Univ, Dept Biomed Engn, Medford, MA 02155 USA; Henry Ford Hosp, Dept Neurosurg, Detroit, MI 48202 USA		Chopp, M (corresponding author), Henry Ford Hosp, Dept Neurol, 2799 W Grand Blvd, Detroit, MI 48202 USA.	chopp@neuro.hfh.edu			NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB002520] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS042345, R01NS052280] Funding Source: NIH RePORTER; NIBIB NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41 EB002520] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS052280-01A1, R01 NS40225, P01 NS042345, P01 NS42345] Funding Source: Medline		Altman GH, 2002, BIOMATERIALS, V23, P4131, DOI 10.1016/S0142-9612(02)00156-4; Bakshi A, 2004, J NEUROSURG-SPINE, V1, P322, DOI 10.3171/spi.2004.1.3.0322; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Kempermann G, 2000, Prog Brain Res, V127, P35; Kim HJ, 2005, BIOMATERIALS, V26, P4442, DOI 10.1016/j.biomaterials.2004.11.013; Kim UJ, 2005, BIOMATERIALS, V26, P2775, DOI 10.1016/j.biomaterials.2004.07.044; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2003, J HEAD TRAUMA REHAB, V18, P357, DOI 10.1097/00001199-200307000-00006; Lu DY, 2002, J NEUROSURG, V97, P935, DOI 10.3171/jns.2002.97.4.0935; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Lu DY, 2004, J NEUROSURG, V101, P813, DOI 10.3171/jns.2004.101.5.0813; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Meinel L, 2005, BONE, V37, P688, DOI 10.1016/j.bone.2005.06.010; Meinel L, 2004, BIOTECHNOL BIOENG, V88, P379, DOI 10.1002/bit.20252; Meinel L, 2004, J BIOMED MATER RES A, V71A, P25, DOI 10.1002/jbm.a.30117; Park KI, 2002, NAT BIOTECHNOL, V20, P1111, DOI 10.1038/nbt751; REIER PJ, 1992, J NEUROTRAUM, V9, pS223; Wang YZ, 2005, BIOMATERIALS, V26, P7082, DOI 10.1016/j.biomaterials.2005.05.022; Witte OW, 1998, CURR OPIN NEUROL, V11, P655, DOI 10.1097/00019052-199812000-00008	23	106	112	0	14	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	SEP	2007	61	3					596	602		10.1227/01.NEU.0000290908.38438.B2			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	214FE	WOS:000249720600050	17881974	Green Accepted			2022-02-06	
J	Griffith, RW; Humphrey, DR				Griffith, Ronald W.; Humphrey, Donald R.			Long-term gliosis around chronically implanted platinum electrodes in the Rhesus macaque motor cortex	NEUROSCIENCE LETTERS			English	Article						microelectrode; glial scar; astrocyte; microglia; primate	DEEP BRAIN-STIMULATION; ASTROCYTES; ATTACHMENT; EXPRESSION; OUTGROWTH; SURFACES; INJURY; CELLS; CNS	Chronically implanted microelectrodes have been an important tool used by neuroscientists for many years and are critical for the development of neural prostheses designed to restore function after traumatic central nervous system (CNS) injury. It is well established that a variety of mammals, including non-human primates (NHP), tolerate noble metal electrodes in the cortex for extended periods of time, but little is known about the long-term effects of electrode implantation at the cellular level. While data from rodents have clearly shown gliosis around such implants, there have been difficulties in demonstrating these reactions in NHP. Glial reactions are to be expected in NHP, since any trauma to the mammalian CNS is believed to result in the formation of a glial scar consisting of reactive astrocytes and microglia around the injury site. Because a glial scar can potentially affect the quality of recordings or stimulations from implanted electrodes, it is important to determine the extent of gliosis around implants in NHP. We studied the response of cortical glial cells to chronic electrode implantation in the motor cortices of Rhestis macaques (Macaca mulatta) after 3 months and 3 years duration. Antibodies specific for astrocytes and microglia were used to detect the presence of glial reactions around electrode implant sites. Reactive glia were found within the cortical neuropil surrounding the chronically implanted noble metal electrodes. Reactive gliosis persisted over the time periods studied and demonstrates the importance of developing strategies to minimize this event, even around noble metal implants. (c) 2006 Elsevier Ireland Ltd. All rights reserved.	Emory Univ, Sch Med, Dept Physiol, Whitehead Biomed Res Ctr, Atlanta, GA 30322 USA		Griffith, RW (corresponding author), Emory Univ, Sch Med, Dept Physiol, Whitehead Biomed Res Ctr, Suite 605S,615 Michael St, Atlanta, GA 30322 USA.	ronald.griffith@emory.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS40437] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040437] Funding Source: NIH RePORTER		AGNEW WF, 1993, NEUROSCIENCE, V52, P45, DOI 10.1016/0306-4522(93)90180-N; Benabid AL, 2003, CURR OPIN NEUROBIOL, V13, P696, DOI 10.1016/j.conb.2003.11.001; Donoghue JP, 2002, NAT NEUROSCI, V5, P1085, DOI 10.1038/nn947; DONOGHUE JP, 2004, CLIN NEUROPHYSIOL, V57, P593; DUSART I, 1991, NEUROSCIENCE, V45, P541, DOI 10.1016/0306-4522(91)90269-T; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; GARRISON CJ, 1994, EXP NEUROL, V129, P237, DOI 10.1006/exnr.1994.1165; GILMORE SA, 1990, GLIA, V3, P342, DOI 10.1002/glia.440030505; GRAEBER MB, 1988, NEUROSCI LETT, V85, P317, DOI 10.1016/0304-3940(88)90585-X; Griffith R, 1996, J COMP NEUROL, V371, P362; Griffith R, 2000, EXP NEUROL, V161, P297, DOI 10.1006/exnr.1999.7257; Haberler C, 2000, ANN NEUROL, V48, P372, DOI 10.1002/1531-8249(200009)48:3<372::AID-ANA12>3.3.CO;2-S; HERRERA DG, 1992, BRAIN RES, P293; Humphrey D. R., 1997, Society for Neuroscience Abstracts, V23, P1556; Kam L, 2002, BIOMATERIALS, V23, P511, DOI 10.1016/S0142-9612(01)00133-8; Kam L, 1999, BIOMATERIALS, V20, P2343, DOI 10.1016/S0142-9612(99)00163-5; Kam L, 2001, BIOMATERIALS, V22, P1049, DOI 10.1016/S0142-9612(00)00352-5; Kennedy PR, 2004, IEEE T NEUR SYS REH, V12, P339, DOI 10.1109/TNSRE.2004.834629; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; Oka J, 2000, NEUROSCI RES, V36, P93, DOI 10.1016/S0168-0102(99)00106-6; Otto SR, 2002, J NEUROSURG, V96, P1063, DOI 10.3171/jns.2002.96.6.1063; Park MC, 2004, J NEUROPHYSIOL, V92, P2968, DOI 10.1152/jn.00649.2003; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; PUDENZ RH, 1977, BRAIN BEHAV EVOLUT, V14, P103, DOI 10.1159/000125578; Rauschecker JP, 2002, SCIENCE, V295, P1025, DOI 10.1126/science.1067796; STENSAAS SS, 1978, ACTA NEUROPATHOL, V41, P145, DOI 10.1007/BF00689766; StJohn PM, 1997, J NEUROSCI METH, V75, P171, DOI 10.1016/S0165-0270(97)00069-1; Suner S, 2005, IEEE T NEUR SYS REH, V13, P524, DOI 10.1109/TNSRE.2005.857687; Szarowski DH, 2003, BRAIN RES, V983, P23, DOI 10.1016/S0006-8993(03)03023-3; TOPP KS, 1989, GLIA, V2, P201, DOI 10.1002/glia.440020309; Trendelenburg G, 2005, GLIA, V50, P307, DOI 10.1002/glia.20204; Turner AMP, 2000, J BIOMED MATER RES, V51, P430, DOI 10.1002/1097-4636(20000905)51:3<430::AID-JBM18>3.0.CO;2-C; Turner JL, 2000, J NEUROCHEM, V74, pS82; Turner JN, 1999, EXP NEUROL, V156, P33, DOI 10.1006/exnr.1998.6983; Vitek JL, 2004, MOVEMENT DISORD, V19, P907, DOI 10.1002/mds.20137; YUEN TGH, 1995, BIOMATERIALS, V16, P951, DOI 10.1016/0142-9612(95)93121-S	36	106	106	0	16	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	OCT 2	2006	406	1-2					81	86		10.1016/j.neulet.2006.07.018			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	087XH	WOS:000240775600016	16905255				2022-02-06	
J	Ciriza, I; Carrero, P; Frye, CA; Garcia-Segura, LM				Ciriza, Iratxe; Carrero, Paloma; Frye, Cheryl A.; Garcia-Segura, Luis M.			Reduced metabolites mediate neuroprotective effects of progesterone in the adult rat hippocampus. The synthetic progestin medroxyprogesterone acetate (Provera) is not neuroprotective	JOURNAL OF NEUROBIOLOGY			English	Article						dihydroprogesterone; finasteride; indomethacin; kainic acid; tetrahydroprogesterone	TRAUMATIC BRAIN-INJURY; CEREBRAL-ARTERY OCCLUSION; 4-DAY ESTROUS-CYCLE; SPINAL-CORD TRAUMA; GABA-A RECEPTOR; CELL-DEATH; NEUROACTIVE STEROIDS; FEMALE RATS; KAINIC ACID; PREFRONTAL CORTEX	The ovarian hormone progesterone is neuroprotective in different experimental models of neuro-degeneration. In the nervous system, progesterone is metabolized to 5 alpha-dihydroprogesterone (DHP) by the enzyme 5 alpha-reductase. DHP is subsequently reduced to 3 alpha,5 alpha-tetrahydroprogesterone (THP) by a reversible reaction catalyzed by the enzyme 3 alpha-hydroxysteroid dehydrogenase. In this study we have analyzed whether progesterone metabolism is involved in the neuroprotective effect of the hormone in the hilus of the hippocampus of ovariectomized rats injected with kainic acid, an experimental model of excitotoxic cell death. Progesterone increased the levels of DHP and THP in plasma and hippocampus and prevented kainic-acid-induced neuronal loss. In contrast to progesterone, the synthetic progestin medroxyprogesterone acetate (NIPA, Provera) did not increase DHP and THP levels and did not prevent kainic-acid-induced neuronal loss. The administration of the 5m-reductase inhibitor finasteride prevented the increase in the levels of DHP and THP in plasma and hippocampus as a result of progesterone administration and abolished the neuroprotective effect of progesterone. Both DHP and THP were neuroprotective against kainic acid. However, the administration of indomethacin, a 3 alpha-hydroxysteroid dehydrogenase inhibitor, blocked the neuroprotective effect of both DHP and THP, suggesting that both metabolites are necessary for the neuroprotective effect of progesterone. In conclusion, our findings indicate that progesterone is neuroprotective against kainic acid excitotoxicity in vivo while the synthetic progestin MPA is not and suggest that progesterone metabolism to its reduced derivatives DHP and THP is necessary for the neuroprotective effect of the hormone. (c) 2006 Wiley Periodicals, Inc.	CSIC, Inst Cajal, E-28002 Madrid, Spain; SUNY Albany, Univ Albany, Dept Psychol, Dept Biol, Albany, NY 12222 USA; SUNY Albany, Univ Albany, Ctr Res Neurosci, Albany, NY 12222 USA		Garcia-Segura, LM (corresponding author), CSIC, Inst Cajal, Ave Doctor Arce 37, E-28002 Madrid, Spain.	lmgs@cajal.csic.es	Garcia-Segura, Luis M/U-3711-2017	Garcia-Segura, Luis M/0000-0002-2450-2916			Asbury ET, 1998, BEHAV BRAIN RES, V97, P99, DOI 10.1016/S0166-4328(98)00031-X; Baulieu EE, 2000, STEROIDS, V65, P605, DOI 10.1016/S0039-128X(00)00173-2; BELANGER A, 1981, BIOL REPROD, V24, P591, DOI 10.1095/biolreprod24.3.591; Belelli D, 2005, NAT REV NEUROSCI, V6, P565, DOI 10.1038/nrn1703; Belelli D, 2003, J NEUROSCI, V23, P10013; Bentel JM, 1999, MOL CELL ENDOCRINOL, V154, P11, DOI 10.1016/S0303-7207(99)00109-4; Beyer C, 1999, HORM BEHAV, V35, P1, DOI 10.1006/hbeh.1998.1457; Buckmaster PS, 1997, J COMP NEUROL, V385, P385; BUTCHER RL, 1974, ENDOCRINOLOGY, V94, P1704, DOI 10.1210/endo-94-6-1704; Callier S, 2001, SYNAPSE, V41, P131, DOI 10.1002/syn.1067; CELOTTI F, 1992, FRONT NEUROENDOCRIN, V13, P163; Cervantes M, 2002, ARCH MED RES, V33, P6, DOI 10.1016/S0188-4409(01)00347-2; Chen JL, 1999, J NEUROL SCI, V171, P24, DOI 10.1016/S0022-510X(99)00247-6; Ciriza I, 2004, J NEUROENDOCRINOL, V16, P58, DOI 10.1111/j.1365-2826.2004.01121.x; Deniselle MCG, 2002, NEUROBIOL DIS, V11, P457, DOI 10.1006/nbdi.2002.0564; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Follesa P, 2001, BRAIN RES REV, V37, P81, DOI 10.1016/S0165-0173(01)00125-4; Frank C, 2000, PROG NEURO-PSYCHOPH, V24, P1117, DOI 10.1016/S0278-5846(00)00124-X; Frye CA, 2000, PSYCHONEUROENDOCRINO, V25, P407, DOI 10.1016/S0306-4530(99)00068-2; Frye CA, 1999, J NEUROENDOCRINOL, V11, P839; Frye CA, 2000, PHARMACOL BIOCHEM BE, V67, P587, DOI 10.1016/S0091-3057(00)00392-0; FRYE CA, 1995, BRAIN RES, V696, P113, DOI 10.1016/0006-8993(95)00793-P; Frye CA, 1998, BRAIN RES, V808, P72, DOI 10.1016/S0006-8993(98)00764-1; Garcia-Estrada J, 1999, INT J DEV NEUROSCI, V17, P145, DOI 10.1016/S0736-5748(98)00065-3; GARCIAESTRADA J, 1993, BRAIN RES, V628, P271, DOI 10.1016/0006-8993(93)90964-O; Ghoumari AM, 2003, J NEUROCHEM, V86, P848, DOI 10.1046/j.1471-4159.2003.01881.x; Gibson CL, 2004, J CEREBR BLOOD F MET, V24, P805, DOI 10.1097/01.WCB.0000125365.83980.00; Gonzalez SL, 2005, J STEROID BIOCHEM, V94, P143, DOI 10.1016/j.jsbmb.2005.01.016; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Grossman KJ, 2004, BRAIN RES, V1008, P29, DOI 10.1016/j.brainres.2004.02.022; Guerra-Araiza C, 2003, J NEUROENDOCRINOL, V15, P984, DOI 10.1046/j.1365-2826.2003.01088.x; GUO Q, 2006, IN PRESS EXP NEUROL; Hapgood JP, 2004, TRENDS PHARMACOL SCI, V25, P554, DOI 10.1016/j.tips.2004.09.005; Hatton WJ, 1999, J COMP NEUROL, V409, P169; He J, 2004, RESTOR NEUROL NEUROS, V22, P19; Hoffman GE, 2003, EXP NEUROL, V182, P124, DOI 10.1016/S0014-4886(03)00104-3; HORIKOSHI H, 1974, ENDOCRINOL JAPON, V21, P69; Howard C.V., 1998, UNBIASED STEREOLOGY, V1; Kokate TG, 1999, J PHARMACOL EXP THER, V288, P679; Kumon Y, 2000, J NEUROSURG, V92, P848, DOI 10.3171/jns.2000.92.5.0848; Labombarda F, 2002, J NEUROTRAUM, V19, P343, DOI 10.1089/089771502753594918; Labombarda F, 2000, NEUROSCI LETT, V288, P29, DOI 10.1016/S0304-3940(00)01191-5; Lambert JJ, 2003, PROG NEUROBIOL, V71, P67, DOI 10.1016/j.pneurobio.2003.09.001; Littleton-Kearney MT, 2005, J CEREBR BLOOD F MET, V25, P421, DOI 10.1038/sj.jcbfm.9600052; Lockhart EM, 2002, NEUROSCI LETT, V328, P33, DOI 10.1016/S0304-3940(02)00448-2; MAJEWSKA MD, 1992, PROG NEUROBIOL, V38, P379, DOI 10.1016/0301-0082(92)90025-A; Maki PM, 2005, ANN NY ACAD SCI, V1052, P182, DOI 10.1196/annals.1347.012; Matsumoto K, 2005, STRESS, V8, P85, DOI 10.1080/10253890500159022; Meffre D, 2005, J NEUROCHEM, V93, P1314, DOI 10.1111/j.1471-4159.2005.03127.x; Melcangi RC, 1999, J NEUROBIOL, V40, P471, DOI 10.1002/(SICI)1097-4695(19990915)40:4<471::AID-NEU5>3.3.CO;2-G; Melcangi RC, 2005, BRAIN RES REV, V48, P328, DOI 10.1016/j.brainresrev.2004.12.021; Melcangi RC, 2003, PROG NEUROBIOL, V71, P57, DOI 10.1016/j.pneurobio.2003.09.003; Melcangi RC, 2001, INT REV NEUROBIOL, V46, P145; Mellon SH, 2001, BRAIN RES REV, V37, P3, DOI 10.1016/S0165-0173(01)00109-6; Morali G, 2005, NEUROSCI LETT, V382, P286, DOI 10.1016/j.neulet.2005.03.066; Murphy SJ, 2002, J CEREBR BLOOD F MET, V22, P1181, DOI 10.1097/01.WCB.0000037990.07114.07; Nilsen J, 2003, P NATL ACAD SCI USA, V100, P10506, DOI 10.1073/pnas.1334098100; Nilsen J, 2002, NEUROREPORT, V13, P825, DOI 10.1097/00001756-200205070-00018; Nilsen J, 2002, ENDOCRINOLOGY, V143, P205, DOI 10.1210/en.143.1.205; OGATA T, 1993, NEUROSCIENCE, V55, P445, DOI 10.1016/0306-4522(93)90513-F; Palumbo MA, 1995, J ENDOCRINOL INVEST, V18, P853, DOI 10.1007/BF03349832; Patte-Mensah C, 2005, P NATL ACAD SCI USA, V102, P9044, DOI 10.1073/pnas.0502968102; Paxinos G, 1986, RAT BRAIN STEROTAXIC; Petralia SM, 2005, J NEUROENDOCRINOL, V17, P545, DOI 10.1111/j.1365-2826.2005.01342.x; PUIA G, 1990, NEURON, V4, P759, DOI 10.1016/0896-6273(90)90202-Q; PURDY RH, 1990, STEROIDS, V55, P290, DOI 10.1016/0039-128X(90)90031-6; Rhodes ME, 2004, EPILEPSIA, V45, P1531, DOI 10.1111/j.0013-9580.2004.16504.x; Rhodes ME, 2004, PHARMACOL BIOCHEM BE, V78, P505, DOI 10.1016/j.pbb.2004.04.021; Robertson CL, 2006, EXP NEUROL, V197, P235, DOI 10.1016/j.expneurol.2005.09.014; RODBARD D, 1974, CLIN CHEM, V20, P1255; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; RUPPRECHT R, 1993, NEURON, V11, P523, DOI 10.1016/0896-6273(93)90156-L; Schumacher M, 2004, GROWTH HORM IGF RES, V14, pS18, DOI 10.1016/j.ghir.2004.03.007; SHAIKH AA, 1975, ENDOCRINOLOGY, V96, P37, DOI 10.1210/endo-96-1-37; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Singh M, 2005, ANN NY ACAD SCI, V1052, P145, DOI 10.1196/annals.1347.010; Singh M, 2001, ENDOCRINE, V14, P407, DOI 10.1385/ENDO:14:3:407; Stein DG, 2005, ANN NY ACAD SCI, V1052, P152, DOI 10.1196/annals.1347.011; Stoffel-Wagner B, 1998, J CLIN ENDOCR METAB, V83, P3636, DOI 10.1210/jc.83.10.3636; Thomas AJ, 1999, SPINE, V24, P2134, DOI 10.1097/00007632-199910150-00013; Vongher JM, 1999, PHARMACOL BIOCHEM BE, V64, P777, DOI 10.1016/S0091-3057(99)00140-9; WALF AA, 2006, IN PRESS PSYCHOPHARM; Wiegratz I, 2004, TRENDS ENDOCRIN MET, V15, P277, DOI 10.1016/j.tem.2004.06.006; Yao XL, 2005, J NEUROTRAUM, V22, P656, DOI 10.1089/neu.2005.22.656; YU WHA, 1989, BRAIN RES, V491, P379, DOI 10.1016/0006-8993(89)90075-9; Zhu Y, 2003, P NATL ACAD SCI USA, V100, P2231, DOI 10.1073/pnas.0336132100	89	106	107	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN, NJ 07030 USA	0022-3034			J NEUROBIOL	J. Neurobiol.	AUG	2006	66	9					916	928		10.1002/neu.20293			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	070SS	WOS:000239544900002	16758493				2022-02-06	
J	Halterman, CI; Langan, J; Drew, A; Rodriguez, E; Osternig, LR; Chou, LS; van Donkelaar, P				Halterman, CI; Langan, J; Drew, A; Rodriguez, E; Osternig, LR; Chou, LS; van Donkelaar, P			Tracking the recovery of visuospatial attention deficits in mild traumatic brain injury	BRAIN			English	Article						attention; mTBI; executive function; recovery	POSITRON-EMISSION-TOMOGRAPHY; CLOSED-HEAD INJURY; REACTION-TIME; CONCUSSION; CONFLICT; CORTEX; SYMPTOMS; NETWORK; SYSTEM; SPECT	The goal of the current investigation was to probe the deficits in the alerting, orienting and executive components of visuospatial attention in individuals who have recently suffered a mild traumatic brain injury (mTBI) and to assess the rate and degree of recovery for each of these components over a month post-injury. A group design was employed to assess and compare the performance of participants (12 males, 8 females; mean age: 21 +/- 1.74 years) identified with mTBI relative to control subjects matched for gender, age, height, weight and activity level. Participants performed the attentional network test, designed to isolate the constituents of attention into alerting, orienting and executive components. Reaction times (RTs) and response accuracy were the main dependent variables. The results showed that the orienting and executive components were significantly affected by mTBI immediately after the injury, whereas the alerting component was not. Furthermore, participants with mTBI recovered from the deficits in the orienting component of attention within a week of their injury, whereas the deficits in the executive component remained throughout the month post-injury. In addition, the RT cost to generate accurate compared with inaccurate responses was significantly larger in participants with mTBI than in controls, and this difference was maintained throughout the 1 month testing period. These findings indicate that the regions of the brain associated with the orienting and executive components of visuospatial attention may be most susceptible to neural damage resulting from mTBI. Moreover, the lack of recovery in the executive component indicates that the degree and time course for recovery may be regionally specific.	Univ Oregon, Dept Human Physiol, Eugene, OR 97403 USA; Univ Oregon, Inst Neurosci, Eugene, OR 97403 USA		van Donkelaar, P (corresponding author), Univ Oregon, Dept Human Physiol, Eugene, OR 97403 USA.	paulvd@darkwing.uoregon.edu	Rodriguez-Torres, Erika Elizabeth/A-3843-2019	Rodriguez-Torres, Erika Elizabeth/0000-0002-7738-1863; Langan, Jeanne/0000-0003-1417-2180			Casey BJ, 2000, P NATL ACAD SCI USA, V97, P8728, DOI 10.1073/pnas.97.15.8728; Chan RCK, 2003, BRAIN INJURY, V17, P131, DOI 10.1080/0269905021000010168; Chan RCK, 2002, J CLIN EXP NEUROPSYC, V24, P1081, DOI 10.1076/jcen.24.8.1081.8371; Chen SHA, 2003, J NEUROL NEUROSUR PS, V74, P326, DOI 10.1136/jnnp.74.3.326; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; Daffner KR, 2000, BRAIN, V123, P927, DOI 10.1093/brain/123.5.927; Fan J, 2002, J COGNITIVE NEUROSCI, V14, P340, DOI 10.1162/089892902317361886; Fan J, 2003, NEUROIMAGE, V18, P42, DOI 10.1006/nimg.2002.1319; Felmingham KL, 2004, NEUROPSYCHOLOGY, V18, P564, DOI 10.1037/0894-4105.18.3.564; Giza CC, 2001, J ATHL TRAINING, V36, P228; Hofman PAM, 2002, J NEUROPSYCH CLIN N, V14, P176, DOI 10.1176/appi.neuropsych.14.2.176; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; Kelly JP, 1997, NEUROLOGY, V48, P581; Kim YH, 1999, NEUROIMAGE, V9, P269, DOI 10.1006/nimg.1999.0408; Lorberboym M, 2002, AM J EMERG MED, V20, P310, DOI 10.1053/ajem.2002.34201; Nobre AC, 2004, J COGNITIVE NEUROSCI, V16, P363, DOI 10.1162/089892904322926700; Nobre AC, 1997, BRAIN, V120, P515, DOI 10.1093/brain/120.3.515; Parker TM, 2005, CLIN BIOMECH, V20, P389, DOI 10.1016/j.clinbiomech.2004.12.004; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; POSNER MI, 1980, Q J EXP PSYCHOL, V32, P3, DOI 10.1080/00335558008248231; POSNER MI, 1984, J NEUROSCI, V4, P1863; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; POSNER MI, 1987, NEUROPSYCHOLOGIA, V25, P135, DOI 10.1016/0028-3932(87)90049-2; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Sturm W, 1999, NEUROPSYCHOLOGIA, V37, P797, DOI 10.1016/S0028-3932(98)00141-9; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; STUSS DT, 1989, CAN J NEUROL SCI, V16, P161, DOI 10.1017/S0317167100028833; van Donkelaar P, 2005, BRAIN INJURY, V19, P1031, DOI 10.1080/02699050500110363; Vandenberghe R, 2001, NEUROIMAGE, V14, P661, DOI 10.1006/nimg.2001.0860; Weissman DH, 2003, NEUROIMAGE, V19, P1361, DOI 10.1016/S1053-8119(03)00167-8; Yantis S, 2002, NAT NEUROSCI, V5, P995, DOI 10.1038/nn921	32	106	108	0	19	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	MAR	2006	129		3				747	753		10.1093/brain/awh705			7	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	013TY	WOS:000235433800019	16330498	Green Published, Bronze			2022-02-06	
J	Mahmood, A; Lu, DY; Qu, CS; Goussev, A; Chopp, M				Mahmood, A; Lu, DY; Qu, CS; Goussev, A; Chopp, M			Long-term recovery after bone marrow stromal cell treatment of traumatic brain injury in rats	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; bone marrow stromal cell; growth factor; rat	RANDOMIZED CONTROLLED-TRIAL; SPINAL-CORD-INJURY; ADULT RATS; FUNCTIONAL RECOVERY; NEUROTROPHIC FACTOR; TIRILAZAD MESYLATE; GENE-EXPRESSION; TRANSPLANTATION; HIPPOCAMPUS; DEFICITS	Object. This study was designed to follow the effects of bone marrow stromal cell (BMSC) administration in rats after traumatic brain injury (TBI) for a 3-month period. Methods. Forty adult female Wistar rats were injured by a controlled cortical impact and, I week later, were injected intravenously with one of three different doses of BMSCs (2 X 10(6), 4 X 10(6), or 8 X 10(6) cells per animal) obtained in male rats. Control rats received phosphate-buffered saline (PBS). Neurological function in these rats was studied using a neurological severity scale (NSS). The rats were killed 3 months after injury, and immunohistochemical stains were applied to brain samples to study the distribution of the BMSCs. Additional brain samples were analyzed by quantitative enzyme-linked immunosorbent assays to measure the expression of the growth factors brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF). Three months after injury, BMSCs were present in the injured brain and their number was significantly greater in animals that received 4 X 10(6) or 8 X 10(6) BMSCs than in animals that received 2 X 106 BMSCs, The cells were primarily distributed around the lesion boundary zone. Functional outcome was significantly better in rats that received 4 X 10(6) or 8 X 10(6) BMSCs, compared with control animals, although no improvement was seen in animals that received 2 X 10(6) BMSCs. All doses of BMSCs significantly increased the expression of BDNF but not that of NGF; however, this increase was significantly larger in animals that received 4 X 10(6) or 8 X 10(6) BMSCs than in controls or animals that received 2 X 10(6) BMSCs. Conclusions. In summary, when injected in rats after TBI, BMSCs are present in the brain 3 months later and significantly improve functional outcome.	Henry Ford Hlth Sci Ctr, Dept Neurol, Detroit, MI USA; Henry Ford Hlth Sci Ctr, Dept Neurosurg, Detroit, MI USA		Mahmood, A (corresponding author), Henry Ford Hosp, Dept Neurosurg, 2799 W Grand Blvd, Detroit, MI 48202 USA.	nsaam@neuro.hfh.edu					Bracken MB, 1998, J NEUROSURG, V89, P699, DOI 10.3171/jns.1998.89.5.0699; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; Causing CG, 1997, NEURON, V18, P257, DOI 10.1016/S0896-6273(00)80266-4; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Hicks RR, 1998, RESTOR NEUROL NEUROS, V12, P41; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; Hicks RR, 1998, MOL BRAIN RES, V59, P264, DOI 10.1016/S0169-328X(98)00158-2; Hicks RR, 2002, NEUROSCIENCE, V112, P631, DOI 10.1016/S0306-4522(02)00104-5; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Lee J, 2002, J NEUROCHEM, V82, P1367, DOI 10.1046/j.1471-4159.2002.01085.x; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; LIAU LM, 1996, NEUROLOGICAL SURG, P1549; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2003, J HEAD TRAUMA REHAB, V18, P357, DOI 10.1097/00001199-200307000-00006; Lu DY, 2002, J NEUROSURG, V97, P935, DOI 10.3171/jns.2002.97.4.0935; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; MEMBERG SP, 1995, MOL CELL NEUROSCI, V6, P323, DOI 10.1006/mcne.1995.1025; Newman MP, 2000, NEUROSCIENCE, V99, P343, DOI 10.1016/S0306-4522(00)00194-9; Pencea V, 2001, J NEUROSCI, V21, P6706, DOI 10.1523/JNEUROSCI.21-17-06706.2001; Poo MM, 2001, NAT REV NEUROSCI, V2, P24, DOI 10.1038/35049004; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Rao VLR, 2003, J NEUROSCI RES, V71, P208, DOI 10.1002/jnr.10486; Rutherford LC, 1998, NEURON, V21, P521, DOI 10.1016/S0896-6273(00)80563-2; Seil FJ, 2000, J NEUROSCI, V20, P5367, DOI 10.1523/JNEUROSCI.20-14-05367.2000; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Snider WD, 1996, MOL CELL NEUROSCI, V7, P433, DOI 10.1006/mcne.1996.0031; Vicario-Abejon C, 1998, J NEUROSCI, V18, P7256; Zhao LR, 2002, EXP NEUROL, V174, P11, DOI 10.1006/exnr.2001.7853	35	106	130	0	6	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	FEB	2006	104	2					272	277		10.3171/jns.2006.104.2.272			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	009CY	WOS:000235090000015	16509501				2022-02-06	
J	Max, JE; Schachar, RJ; Levin, HS; Ewing-Cobbs, L; Chapman, SB; Dennis, M; Saunders, A; Landis, J				Max, JE; Schachar, RJ; Levin, HS; Ewing-Cobbs, L; Chapman, SB; Dennis, M; Saunders, A; Landis, J			Predictors of secondary attention-deficit/hyperactivity disorder in children and adolescents 6 to 24 months after traumatic brain injury	JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY			English	Article						traumatic brain injury; children and adolescents; secondary attention-deficit/hyperactivity disorder; adaptive function	CLOSED-HEAD INJURY; DEFICIT HYPERACTIVITY DISORDER; RELIABILITY; VALIDITY; SCHEDULE; ADHD	Objective: To assess the phenomenology and predictive factors of attention-deficit/hyperactivity disorder (ADHD) after traumatic brain injury (TBI), also called secondary ADHD (SADHD). Method: Children without preinjury ADHD 5-14 years old with TBI from consecutive admissions (n = 143) to five trauma centers were observed prospectively from 6 to 12 months (12-month assessment) and from 12 to 24 months (24-month assessment) postinjury with semistructured psychiatric interviews. Injury and preinjury psychosocial variables were assessed. Results: SADHD occurred in 15 of 103 (15%) of participants between 6 and 12 months after injury and 17 of 82 (21%) in the second year after injury. SADHD was significantly (p < .05) comorbid with personality change due to TBI and new-onset disruptive behavior disorders. Preinjury adaptive function was a consistent predictor of SADHD. Regression analyses revealed that preinjury psychosocial adversity was an independent predictor of SADHD in the second year after injury. Neither severity of injury nor lesion location predicted SADHD from 6 to 24 months postinjury. Conclusions: Determination of preinjury psychosocial adversity and the child's preinjury functioning during the index hospitalization would improve identification of children at highest risk of development of SADHD.	Childrens Hosp & Hlth Ctr, San Diego, CA 92123 USA; Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; Hosp Sick Children, Dept Psychiat, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Dept Psychol, Brain & Behav Program, Res Inst, Toronto, ON M5G 1X8, Canada; Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Dept Pediat, Houston, TX USA; Univ Texas, Hlth Sci Ctr, Dept Psychiat, Houston, TX USA; Univ Texas, Ctr Brain Hlth, Dallas, TX 75230 USA; Univ Houston, Dept Educ Psychol, Houston, TX 77004 USA		Max, JE (corresponding author), Childrens Hosp & Hlth Ctr, 3020 Childrens Way,MC 5033, San Diego, CA 92123 USA.	jmax@ucsd.edu		Schachar, Russell/0000-0002-2015-4395	NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K-08 MH01800] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K08MH001800] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; ANDREASEN NC, 1977, ARCH GEN PSYCHIAT, V34, P1229; Biederman J, 1997, J AFFECT DISORDERS, V44, P177, DOI 10.1016/S0165-0327(97)00043-8; Boyle MH, 1996, J AM ACAD CHILD PSY, V35, P1440, DOI 10.1097/00004583-199611000-00012; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Castellanos FX, 2001, ARCH GEN PSYCHIAT, V58, P289, DOI 10.1001/archpsyc.58.3.289; Ciccetti D., 1984, VINELAND ADAPTIVE BE; Gerring J, 2000, BRAIN INJURY, V14, P205; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; Herskovits EH, 1999, RADIOLOGY, V213, P389, DOI 10.1148/radiology.213.2.r99nv45389; Hollingshead AB., 1975, 4 FACTOR INDEX SOCIA; Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021; LECKMAN JF, 1982, ARCH GEN PSYCHIAT, V39, P879; LEHMKUHL G, 1990, BRAIN BEHAV CHILD PS, P267; Max JE, 1998, J AM ACAD CHILD PSY, V37, P841, DOI 10.1097/00004583-199808000-00014; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; Max JE, 1998, J AM ACAD CHILD PSY, V37, P297, DOI 10.1097/00004583-199803000-00015; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; MAX JE, IN PRESS J AM ACAD C; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; TEASDALE G, 1974, LANCET, V2, P81; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954	23	106	107	1	30	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA	0890-8567			J AM ACAD CHILD PSY	J. Am. Acad. Child Adolesc. Psychiatr.	OCT	2005	44	10					1041	1049		10.1097/01.chi.0000173292.05817.f8			9	Psychology, Developmental; Pediatrics; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Pediatrics; Psychiatry	967GD	WOS:000232078600015	16175109				2022-02-06	
J	Sewell, DL; Nacewicz, B; Liu, F; Macvilay, S; Erdei, A; Lambris, JD; Sandor, M; Fabry, Z				Sewell, DL; Nacewicz, B; Liu, F; Macvilay, S; Erdei, A; Lambris, JD; Sandor, M; Fabry, Z			Complement C3 and C5 play critical roles in traumatic brain cryoinjury: blocking effects on neutrophil extravasation by C5a receptor antagonist	JOURNAL OF NEUROIMMUNOLOGY			English	Article						inflammation; neutrophil; cryoinjury; trauma; CNS; cytokines; chemokines	CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; ALZHEIMERS-DISEASE BRAINS; MEMBRANE ATTACK COMPLEX; MULTIPLE-SCLEROSIS; LIVER-REGENERATION; CEREBRAL-ISCHEMIA; ANAPHYLATOXIN C5A; HUMAN ASTROCYTES; MESSENGER-RNA	The role of complement components in traumatic brain injury is poorly understood. Here we show that secondary damage after acute cryoinjury is significantly reduced in C3(-/-) or C5(-/-) mice or in mice treated with C5a receptor antagonist peptides. Injury sizes and neutrophil extravasation were compared. While neutrophil density increased following traumatic brain injury in wild type (C57BL/6) mice, C3-deficient mice demonstrated lower neutrophil extravasation and injury sizes in the brain. RNase protection assay indicated that C3 contributes to the induction of brain inflammatory mediators, MIF, RANTES (CCL5) and MCP-1 (CCL2). Intracranial C3 injection induced neutrophil extravasation in injured brains of C3(-/-) mice suggesting locally produced C3 is important in brain inflammation. We show that neutrophil extravasation is significantly reduced in both C5(-/-) mice and C5a receptor antagonist treated cryoinjured mice suggesting that one of the possible mechanisms of C3 effect on neutrophil extravasation is mediated via downstream complement activation products such as C5a. Our data indicates that complement inhibitors may ameliorate traumatic brain injury. (C) 2004 Elsevier B.V. All rights reserved.	Univ Wisconsin, Dept Pathol, Madison, WI 53706 USA; Eotvos Lorand Univ, Dept Immunol, Budapest, Hungary; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA		Fabry, Z (corresponding author), Univ Wisconsin, Dept Pathol, 1300 Univ Ave, Madison, WI 53706 USA.	zfabry@facstaff.wisc.edu	Erdei, Anna/AAN-5988-2020; Lambris, John D./O-8507-2019	Lambris, John D./0000-0002-9370-5776; Erdei, Anna/0000-0002-3622-6680	NIAID NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01 AI030040] Funding Source: Medline; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01 GM062135, GM-62135] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS037570, R01-NS 37570-01A2] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01AI030040] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM062135] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037570] Funding Source: NIH RePORTER		BARNUM SR, 1995, CRIT REV ORAL BIOL M, V6, P132, DOI 10.1177/10454411950060020301; Bergamaschini L, 1999, CLIN EXP IMMUNOL, V115, P526; Bradt BM, 1998, J EXP MED, V188, P431, DOI 10.1084/jem.188.3.431; Cancilla P A, 1980, Adv Exp Med Biol, V131, P257; CANCILLA PA, 1972, LAB INVEST, V26, P376; CANCILLA PA, 1979, LAB INVEST, V40, P74; CANCILLA PA, 1992, J NEUROPATH EXP NEUR, V51, P560, DOI 10.1097/00005072-199209000-00011; Cooper NR, 2000, IMMUNOL RES, V21, P159, DOI 10.1385/IR:21:2-3:159; Fee D, 2000, CYTOKINE, V12, P655, DOI 10.1006/cyto.1999.0599; Fee D, 2003, J NEUROIMMUNOL, V136, P54, DOI 10.1016/S0165-5728(03)00008-0; Finch AM, 1999, J MED CHEM, V42, P1965, DOI 10.1021/jm9806594; FISCHER B, 1995, J MOL MED, V73, P465; Gasque P, 1998, J IMMUNOL, V160, P3543; GASQUE P, 1995, J IMMUNOL, V155, P4882; Girardi G, 2003, J CLIN INVEST, V112, P1644, DOI 10.1172/JCI200318817; Glass WG, 2004, J IMMUNOL, V172, P4018, DOI 10.4049/jimmunol.172.7.4018; Glass WG, 2001, VIROLOGY, V288, P8, DOI 10.1006/viro.2001.1050; Hofstetter HH, 2003, J NEUROIMMUNOL, V134, P25, DOI 10.1016/S0165-5728(02)00358-2; Huber-Lang MS, 2002, FASEB J, V16, P1567, DOI 10.1096/fj.02-0209com; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; Kossmann T, 1997, J NEUROIMMUNOL, V73, P63, DOI 10.1016/S0165-5728(96)00164-6; Lane TE, 2000, J VIROL, V74, P1415, DOI 10.1128/JVI.74.3.1415-1424.2000; Lew SM, 1999, BRAIN RES BULL, V48, P325, DOI 10.1016/S0361-9230(99)00004-0; Ling CY, 2003, J NEUROIMMUNOL, V141, P90, DOI 10.1016/S0165-5728(03)00249-2; Mastellos D, 2001, J IMMUNOL, V166, P2479, DOI 10.4049/jimmunol.166.4.2479; Mukherjee P, 2000, J NEUROIMMUNOL, V105, P124, DOI 10.1016/S0165-5728(99)00261-1; Nadeau S, 2001, FASEB J, V15, P1410, DOI 10.1096/fj.00-0709fje; Niculescu T, 2004, J IMMUNOL, V172, P5702, DOI 10.4049/jimmunol.172.9.5702; Osaka H, 1999, J CELL BIOCHEM, V73, P303, DOI 10.1002/(SICI)1097-4644(19990601)73:3<303::AID-JCB2>3.3.CO;2-U; Rancan M, 2003, J CEREBR BLOOD F MET, V23, P1070, DOI 10.1097/01.WCB.0000084250.20114.2C; Schafer MKH, 2000, J IMMUNOL, V164, P5446, DOI 10.4049/jimmunol.164.10.5446; Shen Y, 1998, BRAIN RES, V796, P187, DOI 10.1016/S0006-8993(98)00346-1; Speth C, 2001, J VIROL, V75, P2604, DOI 10.1128/JVI.75.6.2604-2516.2001; Stahel PF, 2001, J NEUROTRAUM, V18, P773, DOI 10.1089/089771501316919139; Strey CW, 2003, J EXP MED, V198, P913, DOI 10.1084/jem.20030374; Swartz KR, 2001, BRAIN RES, V896, P86, DOI 10.1016/S0006-8993(01)02013-3; Van Beek J, 2000, EXP NEUROL, V161, P373, DOI 10.1006/exnr.1999.7273; VANDENBERG CW, 1989, J IMMUNOL METHODS, V122, P73, DOI 10.1016/0022-1759(89)90336-0; Veerhuis R, 1996, ACTA NEUROPATHOL, V91, P53; VEERHUIS R, 1995, VIRCHOWS ARCH, V426, P603, DOI 10.1007/BF00192116; WALKER DG, 1992, MOL BRAIN RES, V14, P109, DOI 10.1016/0169-328X(92)90017-6; Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506; Weerth SH, 2003, AM J PATHOL, V163, P1069, DOI 10.1016/S0002-9440(10)63466-9; Wyss-Coray T, 2002, P NATL ACAD SCI USA, V99, P10837, DOI 10.1073/pnas.162350199; Yasojima K, 1999, AM J PATHOL, V154, P927, DOI 10.1016/S0002-9440(10)65340-0	45	106	111	0	9	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-5728			J NEUROIMMUNOL	J. Neuroimmunol.	OCT	2004	155	1-2					55	63		10.1016/j.jneuroim.2004.06.003			9	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	855VV	WOS:000224003900006	15342196	Green Accepted			2022-02-06	
J	Engberg, AW; Teasdale, TW				Engberg, AW; Teasdale, TW			Psychosocial outcome following traumatic brain injury in adults: a long-term population-based follow-up	BRAIN INJURY			English	Article							HEAD-INJURY; EPIDEMIOLOGY; IMPAIRMENT; DISABILITY	Primary objective: On a national basis to conduct a 5, 10 and 15 year follow-up study of representative samples of survivors after traumatic brain injury (TBI) and to identify factors of importance for long-term survival and life satisfaction after TBI occurring in 1982, 1987 or 1992. Research design: Epidemiological, register-based questionnaire survey. Main outcomes, result and conclusions: Out of 389 survivors randomly chosen from a national complete hospital register, 173 had suffered a cranial fracture, 186 a cerebral lesion (brain contusion or traumatic haemorrhage) and 30 patients a chronic subdural haematoma. Out of 337 survivors found eligible for a questionnaire, 76% responded. Among the data registered according to the above mentioned areas, the main findings were that 23-31% of the cerebral lesion responders were unable to maintain earlier work/education at pre-injury level, against up to 14% of cranial fracture patients. Significantly more cerebral lesion patients than cranial fracture patients found emotional control more difficult, as well as increased difficulties with memory and concentration, maintenance of leisure time interests and general life satisfaction. In the long run, an important factor influencing survival among cerebral lesion patients seemed to be whether relations with family and friends could be maintained at the pre-injury level.	Copenhagen Univ Hosp, Hvidovre Hosp, Div Neurol Rehabil, DK-2650 Hvidovre, Denmark; Univ Copenhagen, Dept Psychol, DK-1168 Copenhagen, Denmark		Engberg, AW (corresponding author), Copenhagen Univ Hosp, Hvidovre Hosp, Div Neurol Rehabil, DK-2650 Hvidovre, Denmark.	aase.engberg@hh.hosp.dk					Andersen TF, 1999, DAN MED BULL, V46, P263; BROOKS N, 1984, CLOSED HEAD INJURY P; Enevoldsen B, 1980, Ugeskr Laeger, V142, P544; Engberg A, 1995, Acta Neurol Scand Suppl, V164, P1; Engberg AW, 2001, EUR J EPIDEMIOL, V17, P437, DOI 10.1023/A:1013733107520; Frank L, 2000, SCIENCE, V287, P2398, DOI 10.1126/science.287.5462.2398; Haase J, 1992, Acta Neurochir Suppl (Wien), V55, P75; Hillier SL, 1997, BRAIN INJURY, V11, P661; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; Linn Shai, 1995, Annals of Epidemiology, V5, P440, DOI 10.1016/1047-2797(95)00059-3; LUNDHOLM J, 1975, SCAND J REHABIL MED, V7, P97; Masson F, 1997, J CLIN EPIDEMIOL, V50, P595, DOI 10.1016/S0895-4356(97)00012-7; ODDY M, 1984, CLOSED HEAD INJURY P, P108; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; Teasdale TW, 1997, BRAIN INJURY, V11, P543, DOI 10.1080/026990597123250; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; 1994, NYT DANMARKS STAT, P179	22	106	106	1	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUN	2004	18	6					533	545		10.1080/02699050310001645829			13	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	811DX	WOS:000220753700002	15204335				2022-02-06	
J	Servadei, F; Begliomini, C; Gardini, E; Giustini, M; Taggi, F; Kraus, J				Servadei, F; Begliomini, C; Gardini, E; Giustini, M; Taggi, F; Kraus, J			Effect of Italy's motorcycle helmet law on traumatic brain injuries	INJURY PREVENTION			English	Article							HEAD-INJURY; FATALITIES; CRASHES; CALIFORNIA; ACCIDENTS; PATTERNS; DRIVERS; RIDERS; DEATHS	Objectives: To evaluate the impact of a revised Italian motorcycle-moped-scooter helmet law on crash brain injuries. Design: A pre-post law evaluation of helmet use and traumatic brain injury (TBI) occurrence from 1999 to 2001. Setting: Romagna region, northeastern Italy, with a 2000 resident population of 983 534 persons. Participants: Motorcycle-moped rider survey for helmet use compliance and all residents in the region admitted to the Division of Neurosurgery of the Maurizio Bufalini Hospital in Cesena, Italy for TBI. Outcome measures: Helmet use compliance and change in TBI admissions and type(s) of brain lesions. Results: Helmet use increased from an average of less than 20% to over 96%. A comparison of TBI incidence in the Romagna region shows that there was no significant variation before and after introduction of the revised helmet law, except for TBI admissions for motorcycle-moped crashes where a 66% decrease was observed. In the same area TBI admissions by age group showed that motorcycle mopeds riders aged 14-60 years sustained significantly fewer TBIs. The rate of TBI admissions to neurosurgery decreased by over 31% and epidural hematomas almost completely disappeared in crash injured moped riders. Conclusions: The revised Italian mandatory helmet law, with police enforcement, is an effective measure for TBI prevention at all ages.	Osped Gen Provinciale M Bufalini, WHO, Neurotrauma Collaborating Ctr, I-47023 Cesena, Italy; Osped Gen Provinciale M Bufalini, Div Neurosurg, I-47023 Cesena, Italy; Italian Natl Hlth Inst, Rome, Italy; Univ Calif Los Angeles, WHO, Collaborating Ctr Neurotrauma, So Calif Injury Prevent Res Ctr, Los Angeles, CA 90024 USA		Servadei, F (corresponding author), Osped Gen Provinciale M Bufalini, WHO, Neurotrauma Collaborating Ctr, I-47023 Cesena, Italy.		BEGLIOMINI, CHIARA/D-1516-2014; Giustini, Marco/Q-3166-2017	BEGLIOMINI, CHIARA/0000-0001-7433-0414; Giustini, Marco/0000-0003-2691-1956; Servadei, Franco/0000-0002-3595-3464			BEGG DJ, 1994, ACCIDENT ANAL PREV, V26, P157, DOI 10.1016/0001-4575(94)90085-X; BJORNSTIG UL, 1985, ACTA CHIR SCAND, V151, P577; BRICOLO AP, 1984, NEUROSURGERY, V14, P8, DOI 10.1227/00006123-198401000-00003; Chiu WT, 2000, AM J PUBLIC HEALTH, V90, P793, DOI 10.2105/AJPH.90.5.793; CLARKE JA, 1995, DISABIL REHABIL, V17, P377, DOI 10.3109/09638289509166725; DALL G, 1983, S AFR MED J, V64, P16; EVANS L, 1988, ACCIDENT ANAL PREV, V20, P447, DOI 10.1016/0001-4575(88)90043-7; Falope I A, 1991, West Afr J Med, V10, P187; Ferrando J, 2000, Inj Prev, V6, P184, DOI 10.1136/ip.6.3.184; HOLUBOWYCZ OT, 1995, J STUD ALCOHOL, V56, P513, DOI 10.15288/jsa.1995.56.513; KRAUS JF, 1988, B NEW YORK ACAD MED, V64, P788; KRAUS JF, 1991, AM J PUBLIC HEALTH, V81, P172, DOI 10.2105/AJPH.81.2.172; KRAUS JF, 1994, JAMA-J AM MED ASSOC, V272, P1506, DOI 10.1001/jama.272.19.1506; LaTorre G, 2002, EUR J PUBLIC HEALTH, V12, P99, DOI 10.1093/eurpub/12.2.99; PLASENCIA A, 1995, ACCIDENT ANAL PREV, V27, P591, DOI 10.1016/0001-4575(95)00007-M; Romano P, 1991, J HEAD TRAUMA REHAB, V6, P21; RUTLEDGE R, 1993, ACCIDENT ANAL PREV, V25, P347, DOI 10.1016/0001-4575(93)90028-U; Servadei F, 2002, BRIT J NEUROSURG, V16, P36, DOI 10.1080/02688690120114255; SHANKAR BS, 1992, ACCIDENT ANAL PREV, V24, P385, DOI 10.1016/0001-4575(92)90051-J; SOOD S, 1988, J TRAUMA, V28, P530, DOI 10.1097/00005373-198804000-00021; SOSIN DM, 1990, JAMA-J AM MED ASSOC, V264, P2395, DOI 10.1001/jama.264.18.2395; Taggi, 2001, P 57 C TRAFF INJ RIV, P152; TAGGI F, 1988, LANCET, V1, P182; WANG YC, 1995, CHINESE MED J, V55, P50; WATSON G, 1980, AM J PUBLIC HEALTH, V71, P297	25	106	110	1	8	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1353-8047			INJURY PREV	Inj. Prev.	SEP	2003	9	3					257	260		10.1136/ip.9.3.257			4	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	719QK	WOS:000185214900013	12966016	Bronze, Green Published			2022-02-06	
J	Yune, TY; Chang, MJ; Kim, SJ; Lee, YB; Shin, SW; Rhim, HW; Kim, YC; Shin, ML; Oh, YJ; Han, CT; Markelonis, GJ; Oh, TH				Yune, TY; Chang, MJ; Kim, SJ; Lee, YB; Shin, SW; Rhim, HW; Kim, YC; Shin, ML; Oh, YJ; Han, CT; Markelonis, GJ; Oh, TH			Increased production of tumor necrosis factor-alpha induces apoptosis after traumatic spinal cord injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						apoptosis; iNOS; NO; NOS inhibitors; spinal cord injury; TNF-alpha; TUNEL	NITRIC-OXIDE SYNTHASE; CENTRAL-NERVOUS-SYSTEM; CELL-DEATH; TNF-ALPHA; BRAIN-INJURY; FUNCTIONAL RECOVERY; NEURONAL APOPTOSIS; GLIAL APOPTOSIS; GENE-EXPRESSION; TRANSGENIC MICE	We showed previously that, after spinal cord injury (SCI), tumor necrosis factor-alpha (TNF-alpha) may serve as an external signal, initiating apoptosis in neurons and oligodendrocytes. To further characterize the apoptotic cascade initiated by TNF-alpha after SCI, we examined the expression of TNF-alpha, inducible nitric oxide (NO) synthase (iNOS), and the level of NO after SCI. Western blots and reverse transcription polymerase chain reactions showed an early upregulation of TNF-a after injury. A peak TNF-alpha expression was observed within 1 h of injury. By 4 h after injury, the expression of MOS and the level of NO were markedly increased in the injured spinal cord. Terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-biotin nick end labeling (TUNEL)positive cells were also first observed in the lesioned area 4 h after SCI. The largest number of TUNEL-positive cells was observed between 24-48 h after SCI. Injecting a neutralizing antibody against TNF-alpha into the lesion site after injury significantly reduced the expression of MOS, the level of NO and the number of TUNEL-positive cells in the injured spinal cord. Injecting the NOS inhibitors, N-G-monomethyl-L-arginine monoacetate and S-methylisothiourea sulfate, or an NO scavenger, carboxy-PTIO, into the lesion site also significantly reduced the level of NO and the degree of DNA laddering in the injured spinal cord. These data suggest that after SCI, apoptosis induced by TNF-alpha may be mediated in part by NO via upregulation of MOS, induced in response to TNF-alpha.	Univ Maryland, Sch Med, Dept Anat & Neurobiol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; KIST, Ctr Biomed Res, Seoul, South Korea; Yonsei Univ, Dept Biol, Seoul 120749, South Korea; Sogang Univ, Dept Life Sci, Seoul, South Korea		Oh, TH (corresponding author), Univ Maryland, Sch Med, Dept Anat & Neurobiol, 685 W Baltimore St, Baltimore, MD 21201 USA.	toh@umaryland.edu					Akassoglou K, 1998, AM J PATHOL, V153, P801, DOI 10.1016/S0002-9440(10)65622-2; Ankarcrona M, 1998, PROG BRAIN RES, V116, P265, DOI 10.1016/S0079-6123(08)60442-2; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BALENTINE JD, 1978, LAB INVEST, V39, P236; BARGER SW, 1995, P NATL ACAD SCI USA, V92, P9328, DOI 10.1073/pnas.92.20.9328; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BENVENISTE EN, 1992, AM J PHYSIOL, V263, pC1, DOI 10.1152/ajpcell.1992.263.1.C1; Bethea JR, 1999, J NEUROTRAUM, V16, P851, DOI 10.1089/neu.1999.16.851; Bethea JR, 1998, J NEUROSCI, V18, P3251; Bhat NR, 1999, J NEUROCHEM, V72, P472, DOI 10.1046/j.1471-4159.1999.0720472.x; BROSNAN JP, 1998, BIOCHEM SOC T, V25, P679; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Chiang LW, 2001, P NATL ACAD SCI USA, V98, P2814, DOI 10.1073/pnas.051630598; Cohen TI, 1996, J NEUROTRAUM, V13, P361, DOI 10.1089/neu.1996.13.361; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Coyle PK, 1996, ADV NEUROIMMUNOL, V6, P143, DOI 10.1016/0960-5428(96)00013-7; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; DAWSON VL, 1995, CLIN EXP PHARMACOL P, V22, P305, DOI 10.1111/j.1440-1681.1995.tb02005.x; DSOUZA S, 1995, J NEUROSCI, V15, P7293; Du S, 1999, EXP NEUROL, V157, P96, DOI 10.1006/exnr.1999.7041; Emery E, 1998, J NEUROSURG, V89, P911, DOI 10.3171/jns.1998.89.6.0911; ENG LF, 1992, PROG BRAIN RES, V94, P353; ESTLER HC, 1992, BIOL CHEM H-S, V373, P271, DOI 10.1515/bchm3.1992.373.1.271; Farooque M, 2001, J NEUROTRAUM, V18, P105, DOI 10.1089/089771501750055811; GADIENT RA, 1990, NEUROSCI LETT, V117, P335, DOI 10.1016/0304-3940(90)90687-5; GALEA E, 1994, J NEUROSCI RES, V37, P406, DOI 10.1002/jnr.490370313; Hayashi M, 2000, J NEUROTRAUM, V17, P203, DOI 10.1089/neu.2000.17.203; Kim GM, 2001, J NEUROSCI, V21, P6617, DOI 10.1523/JNEUROSCI.21-17-06617.2001; KIM HK, 1995, J IMMUNOL, V154, P4741; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Lee YB, 2000, EXP NEUROL, V166, P190, DOI 10.1006/exnr.2000.7494; Li GL, 1996, J NEUROPATH EXP NEUR, V55, P280, DOI 10.1097/00005072-199603000-00003; LIEBERMAN AP, 1989, P NATL ACAD SCI USA, V86, P6348, DOI 10.1073/pnas.86.16.6348; LIPTON SA, 1994, PROG BRAIN RES, V103, P359; Liu XZ, 1997, J NEUROSCI, V17, P5395; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; MATTSON MP, 1995, J NEUROSCI RES, V42, P357, DOI 10.1002/jnr.490420310; MincGolomb D, 1996, J NEUROCHEM, V66, P1504; MORIOKA T, 1991, J CEREBR BLOOD F MET, V11, P966, DOI 10.1038/jcbfm.1991.162; Nakajima W, 2000, J NEUROSCI, V20, P7994; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; Parkinson JF, 1997, J MOL MED, V75, P174, DOI 10.1007/s001090050102; RUDDLE NH, 1990, J EXP MED, V172, P1193, DOI 10.1084/jem.172.4.1193; Sasaki S, 2002, ACTA NEUROPATHOL, V103, P421, DOI 10.1007/s00401-001-0484-6; Satake K, 2000, MOL BRAIN RES, V85, P114, DOI 10.1016/S0169-328X(00)00253-9; Sato I, 1996, NEUROSCI LETT, V205, P45, DOI 10.1016/0304-3940(96)12377-6; SCHWARTZ M, 1991, BRAIN RES, V545, P334, DOI 10.1016/0006-8993(91)91309-O; SELINA CC, 1989, BRAIN RES, V482, P271; SELMAJ K, 1991, ANN NEUROL, V30, P694, DOI 10.1002/ana.410300510; SHARIEF MK, 1991, NEW ENGL J MED, V325, P467, DOI 10.1056/NEJM199108153250704; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.0.CO;2-Y; Sipe KJ, 1996, MOL BRAIN RES, V38, P222, DOI 10.1016/0169-328X(95)00310-O; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; Streit WJ, 1998, EXP NEUROL, V152, P74, DOI 10.1006/exnr.1998.6835; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TCHELINGERIAN JL, 1994, NEUROREPORT, V5, P585, DOI 10.1097/00001756-199401000-00013; Wang CX, 2002, NEUROREPORT, V13, P1391, DOI 10.1097/00001756-200208070-00008; Wang CX, 1996, J NEUROIMMUNOL, V69, P151; WU WT, 1993, EXP NEUROL, V120, P153, DOI 10.1006/exnr.1993.1050; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yan P, 2001, J NEUROTRAUM, V18, P563, DOI 10.1089/089771501300227369; Yong C, 1998, J NEUROTRAUM, V15, P459, DOI 10.1089/neu.1998.15.459; Zhao XR, 2001, J NEUROSCI RES, V64, P121, DOI 10.1002/jnr.1059; Zipfel GJ, 2000, J NEUROTRAUM, V17, P857, DOI 10.1089/neu.2000.17.857	65	106	120	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2003	20	2					207	219		10.1089/08977150360547116			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	652XV	WOS:000181406900007	12675973				2022-02-06	
J	Mathias, CW; Greve, KW; Bianchini, KJ; Houston, RJ; Crouch, JA				Mathias, CW; Greve, KW; Bianchini, KJ; Houston, RJ; Crouch, JA			Detecting malingered neurocognitive dysfunction using the reliable digit span in traumatic brain injury	ASSESSMENT			English	Article						response bias; malingering; forensic; neuropsychology; assessment; Wechsler Adult Intelligence Scale	NEUROPSYCHOLOGICAL ASSESSMENT; INCOMPLETE EFFORT; SCALES	This study assessed the effectiveness of Greiffenstein's Reliable Digit Span (RDS) score for the detection of malingered neurocognitive dysfunction. Participants were 54 traumatic brain injury patients referred for neuropsychological evaluation. Twenty-four met the Slick, Sherman, and Iverson criteria for at least probable malingered neurocognitive dysfunction. The control group was composed of 30 patients without external incentive and who thus did not meet the Slick criteria. All patients completed the digit span test as part of either the WAIS-R or WAIS-III. The RDS scores were calculated, and sensitivity, specificity, and predictive power were examined for several cutoffs. Classification accuracy for the RDS was excellent. Issues related to the clinical application of this technique are discussed.	Univ New Orleans, Dept Psychol, New Orleans, LA 70148 USA; Inst Living, Hartford, CT 06106 USA		Greve, KW (corresponding author), Univ New Orleans, Dept Psychol, New Orleans, LA 70148 USA.	kgreve@uno.edu		Mathias, Charles/0000-0003-1902-673X			Axelrod B. N., 1999, J FORENSIC NEUROPSYC, V1, P15; BEETAR JT, 1995, ARCH CLIN NEUROPSYCH, V10, P57, DOI 10.1016/0887-6177(94)E0005-A; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; BINDER LM, 1996, ASSESSMENT, V3, P403, DOI DOI 10.1177/107319119600300405; BINDER LM, 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI DOI 10.1037/1040-3590.3.2.175; DUNCAN SA, IN PRESS ASSESSMENT; Franzen M.D., 1994, ASSESSMENT, V1, P323, DOI [DOI 10.1177/1073191, https://doi.org/10.1177/107319119400100401]; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; GREVE KW, IN PRESS ARCH CLIN N; Hartlage LC, 1998, CRIT ISS NE, P239; HENNEKENS CH, 1987, EPIDEMIOLOGY MED; Heubrock D, 1998, EUR J PSYCHOL ASSESS, V14, P211, DOI 10.1027/1015-5759.14.3.211; Iverson GL, 1996, J CLIN EXP NEUROPSYC, V18, P38, DOI 10.1080/01688639608408260; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Meyers JE, 1998, ASSESSMENT, V5, P303, DOI 10.1177/107319119800500309; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; Millis SR, 1998, J CLIN EXP NEUROPSYC, V20, P167, DOI 10.1076/jcen.20.2.167.1171; MITTENBERG W, 1995, PROF PSYCHOL-RES PR, V26, P491, DOI 10.1037/0735-7028.26.5.491; NIES KJ, 1994, ARCH CLIN NEUROPSYCH, V9, P501, DOI 10.1016/0887-6177(94)90041-8; OWENS RG, 1995, AM J FORENSIC PSYCH, V13, P61; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Strauss E, 1999, CLIN NEUROPSYCHOL, V13, P420, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT420; TEASDALE G, 1974, LANCET, V2, P81; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D, 1987, MEMORY SCALE REVISED; Wechsler D., 1997, WECHSLER ADULT INTEL, VIII; Wechsler D., 1997, WECHSLER MEMORY SCAL, VIII; Youngjohn, 1995, ASSESSMENT, V2, DOI [https://doi.org/10.1177/1073191195002003007, DOI 10.1177/1073191195002003007]	32	106	107	0	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-1911	1552-3489		ASSESSMENT	Assessment	SEP	2002	9	3					301	308		10.1177/1073191102009003009			8	Psychology, Clinical	Social Science Citation Index (SSCI)	Psychology	588YL	WOS:000177729800009	12216787				2022-02-06	
J	Yogev-Falach, M; Amit, T; Bar-Am, O; Weinstock, M; Youdim, MBH				Yogev-Falach, M; Amit, T; Bar-Am, O; Weinstock, M; Youdim, MBH			The involvement of mitogen-activated protein (MAP) kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline	FASEB JOURNAL			English	Article						alpha-secretase; acetylcholinesterase inhibitors; signal transduction; Alzheimer's disease	ALPHA-SECRETASE CLEAVAGE; OXIDASE-B INHIBITOR; ANTI-PARKINSON DRUG; CLOSED-HEAD INJURY; ALZHEIMERS-DISEASE; BETA-PROTEIN; CONVERTING-ENZYME; BRAIN; PHOSPHORYLATION; RIVASTIGMINE	Two novel neuroprotective cholinesterase (ChE) inhibitors, TV3326, (N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate, and TV3279, (N-propargyl-(3S) aminoindan-5-yl)ethyl methyl carbamate, were derived from rasagiline for the treatment of Alzheimer's disease (AD). TV3326 also inhibits monoamine oxidase (MAO)-A and -B, whereas its S-isomer, TV3279, lacks MAO inhibitory activity. The action of these drugs in the regulation of amyloid precursor protein (APP) processing, using rat PC12 and human SH-SY5Y neuroblastoma cells, was examined. Both isomers stimulated the release of the non-amyloidogenic alpha-secretase form of soluble APP (sAPP) from these cell lines. The increases in sAPP induced by TV3326 and TV3279, were dose-dependent (0.1-100 muM) and blocked by the hydroxamic acid-based metalloprotease inhibitor, Ro31-9790, suggesting mediation via alpha-secretase activity. Using several signal transduction inhibitors, we identified the involvement of protein kinase C (PKC), mitogen-activated protein (MAP) kinase, and tyrosine kinase-dependent pathways in the enhancement of sAPP release by TV3326 and TV3279. In addition, both drugs directly induced the phosphorylation of p44 and p42 MAP kinase, which was abolished by the specific inhibitors of MAP kinase activation, PD98059 and U0126. These data suggest a novel pharmacological mechanism whereby these ChE inhibitors regulate the secretory processes of APP via activation of the MAP kinase pathway.	Technion Israel Inst Technol, Fac Med, Dept Pharmacol, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Fac Med, Eve Topf Ctr Neurodegenerat Dis, Haifa, Israel; Technion Israel Inst Technol, Fac Med, NPF Ctr Neurodegenerat Dis, Haifa, Israel; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Pharmacol, IL-91010 Jerusalem, Israel		Youdim, MBH (corresponding author), Technion Israel Inst Technol, Fac Med, Dept Pharmacol, POB 9697, IL-31096 Haifa, Israel.	Youdim@tx.technion.ac.il					Abu-Raya S, 1999, J NEUROSCI RES, V58, P456, DOI 10.1002/(SICI)1097-4547(19991101)58:3<456::AID-JNR12>3.0.CO;2-S; ANDERSON JP, 1991, NEUROSCI LETT, V128, P126, DOI 10.1016/0304-3940(91)90775-O; ARAKI W, 1991, BIOCHEM BIOPH RES CO, V181, P265, DOI 10.1016/S0006-291X(05)81412-3; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Bejar C, 1999, EUR J PHARMACOL, V383, P231, DOI 10.1016/S0014-2999(99)00643-3; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; BUXBAUM JD, 1993, P NATL ACAD SCI USA, V90, P9195, DOI 10.1073/pnas.90.19.9195; BUXBAUM JD, 1992, P NATL ACAD SCI USA, V89, P10075, DOI 10.1073/pnas.89.21.10075; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; CHECLER F, 1995, J NEUROCHEM, V65, P1431; Chen Y, 1998, J NEUROTRAUM, V15, P231, DOI 10.1089/neu.1998.15.231; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; DAVIES B, 1993, CANCER RES, V53, P2087; DAVISSALINAS J, 1994, J BIOL CHEM, V269, P22623; Desai A, 2001, Expert Opin Pharmacother, V2, P653, DOI 10.1517/14656566.2.4.653; Desdouits-Magnen J, 1998, J NEUROCHEM, V70, P524; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Finberg J P, 1999, Adv Neurol, V80, P495; Finberg JPM, 1998, NEUROREPORT, V9, P703; Furukawa K, 1996, NATURE, V379, P74, DOI 10.1038/379074a0; GABUZDA D, 1993, J NEUROCHEM, V61, P2326, DOI 10.1111/j.1471-4159.1993.tb07479.x; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; Giacobini E, 1998, NEUROCHEM INT, V32, P413, DOI 10.1016/S0197-0186(97)00124-1; Giacobini E, 1996, ANN NY ACAD SCI, V777, P393, DOI 10.1111/j.1749-6632.1996.tb34451.x; Gouras GK, 2000, P NATL ACAD SCI USA, V97, P1202, DOI 10.1073/pnas.97.3.1202; Guo Q, 1998, J BIOL CHEM, V273, P12341, DOI 10.1074/jbc.273.20.12341; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Huang W, 1999, EUR J PHARMACOL, V366, P127, DOI 10.1016/S0014-2999(98)00929-7; HUNG AY, 1993, J BIOL CHEM, V268, P22959; HUNG AY, 1994, EMBO J, V13, P534, DOI 10.1002/j.1460-2075.1994.tb06291.x; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Krall WJ, 1999, ANN PHARMACOTHER, V33, P441, DOI 10.1345/aph.18211; Lamb HM, 2001, PHARMACOECONOMICS, V19, P303, DOI 10.2165/00019053-200119030-00008; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; LeBlanc AC, 1998, J NEUROSCI, V18, P2907; LEE RKK, 1995, P NATL ACAD SCI USA, V92, P8083, DOI 10.1073/pnas.92.17.8083; Maruyama W, 2001, ANN NY ACAD SCI, V939, P320; Maruyama W, 2001, J NEUROCHEM, V78, P727, DOI 10.1046/j.1471-4159.2001.00448.x; MARUYAMA W, 2002, IN PRESS NEUROSCI LE; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; Meziane H, 1998, P NATL ACAD SCI USA, V95, P12683, DOI 10.1073/pnas.95.21.12683; Mills J, 1999, J NEUROCHEM, V72, P443, DOI 10.1046/j.1471-4159.1999.0720443.x; Mills J, 1997, J NEUROSCI, V17, P9415; MORI F, 1995, NEUROREPORT, V6, P633, DOI 10.1097/00001756-199503000-00012; Morimoto T, 1998, J NEUROSCI RES, V51, P185, DOI 10.1002/(SICI)1097-4547(19980115)51:2<185::AID-JNR7>3.0.CO;2-9; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; Nitsch RM, 1996, J BIOL CHEM, V271, P4188; NITSCH RM, 1993, ANN NY ACAD SCI, V695, P122, DOI 10.1111/j.1749-6632.1993.tb23039.x; Nunan J, 2000, FEBS LETT, V483, P6, DOI 10.1016/S0014-5793(00)02076-7; Pakaski M, 2001, NEUROCHEM INT, V38, P219, DOI 10.1016/S0197-0186(00)00091-7; Parvathy S, 1998, BIOCHEMISTRY-US, V37, P1680, DOI 10.1021/bi972034y; Racchi M, 1999, J NEUROCHEM, V72, P2464, DOI 10.1046/j.1471-4159.1999.0722464.x; Racchi M, 2001, MOL PSYCHIATR, V6, P520, DOI 10.1038/sj.mp.4000878; Rossner S, 2000, EUR J NEUROSCI, V12, P3191, DOI 10.1046/j.1460-9568.2000.00211.x; Savage MJ, 1998, J NEUROSCI, V18, P1743; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SILVA OABDE, 1993, NEUROSCIENCE, V57, P873, DOI 10.1016/0306-4522(93)90031-A; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SMALL DH, 1994, J NEUROSCI, V14, P2117; Solano DC, 2000, FASEB J, V14, P1015, DOI 10.1096/fasebj.14.7.1015; Sweatt JD, 2001, J NEUROCHEM, V76, P1, DOI 10.1046/j.1471-4159.2001.00054.x; Vincent B, 2001, J BIOL CHEM, V276, P37743; Weinstock M, 1999, CNS DRUGS, V12, P307, DOI 10.2165/00023210-199912040-00005; Weinstock M, 2000, DRUG DEVELOP RES, V50, P216, DOI 10.1002/1098-2299(200007/08)50:3/4<216::AID-DDR4>3.3.CO;2-Q; Weinstock M, 2001, ANN NY ACAD SCI, V939, P148; WEINSTOCK M, 2000, J NEURAL TRANSM-SUPP, V60, pS157; WOLF BA, 1995, J BIOL CHEM, V270, P4916, DOI 10.1074/jbc.270.9.4916; XU HX, 1995, J BIOL CHEM, V270, P23243, DOI 10.1074/jbc.270.40.23243; Youdim MBH, 2001, CELL MOL NEUROBIOL, V21, P555, DOI 10.1023/A:1015131516649; Youdim MBH, 2001, BRIT J PHARMACOL, V132, P500, DOI 10.1038/sj.bjp.0703826; Youdim MBH, 2001, ANN NY ACAD SCI, V939, P450; YOUDIM MBH, 1999, NEUROSCI LETT, V54, pS45	80	106	107	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2002	16	10					1674	+		10.1096/fj.02-0198fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	WOS:000177814000010	12206996				2022-02-06	
J	Norwood, SH; McAuley, CE; Berne, JD; Vallina, VL; Kerns, DB; Grahm, TW; Short, K; McLarty, MW				Norwood, SH; McAuley, CE; Berne, JD; Vallina, VL; Kerns, DB; Grahm, TW; Short, K; McLarty, MW			Prospective evaluation of the safety of enoxaparin prophylaxis for venous thromboembolism in patients with intracranial hemorrhagic injuries	ARCHIVES OF SURGERY			English	Article; Proceedings Paper	109th Scientific Session of the Western-Surgical-Association	NOV 12-14, 2001	SAN ANTONIO, TEXAS	Western Surg Assoc			MOLECULAR-WEIGHT HEPARIN; LOW-DOSE HEPARIN; TRAUMA PATIENTS; MAJOR TRAUMA; COMPRESSION STOCKINGS; PREVENTION; NEUROSURGERY; THROMBOSIS	Background: Patients with traumatic intracranial hemorrhagic injuries (lHIs) are at high risk for venous thromboembolism (VTE). The safety of early anticoagulation for IHI has not been established. Hypothesis: Enoxaparin can be safely administered to most patients with IHI for VTE prophylaxis. Setting: Level I trauma center. Design: Prospective, single-cohort, observational study Patients and Methods: One hundred fifty (85%) of 177 patients with blunt IHI received enoxaparin beginning approximately 24 hours after hospital admission until discharge. Brain computed tomographic (CT) scans were performed at admission, 24 hours after admission, and at variable intervals thereafter based on clinical course. Patients were excluded for coagulopathy, heparin allergy, expected brain death or discharge within 48 hours, and age younger than 14 years. Complications of enoxaparin prophylaxis were defined as Marshall CT grade progression of IHI expansion of an existing IHI, or development of a new hemorrhagic lesion on follow-up CT after beginning enoxaparin use. Results: Thirty-four patients (23%) had CT progression of IHI. Twenty-eight CT scans (19%) worsened before enoxaparin therapy and 6 (4%) worsened after beginning enoxaparin use. No differences between operative patient (2/24, 8%) and nonoperative patient (4/126, 3%) complications were identified (P=.23). Study group mortality was 7% (10/150). All 6 patients who developed progression of IHI after initiation of enoxaparin therapy survived hospitalization. A deep vein thrombosis was identified in 2 (2%) of 106 patients. Conclusion: Enoxaparin can be safely used for VTE prophylaxis in trauma patients with IHI when started 24 hours after hospital admission or after craniotomy.	E Texas Med Ctr, Dept Surg, Tyler, TX 75701 USA; E Texas Med Ctr, Dept Neurosurg, Tyler, TX 75701 USA; E Texas Med Ctr, Dept Radiol, Tyler, TX 75701 USA; Univ Texas Hlth Ctr, Dept Epidemiol Biomath, Tyler, TX USA		Norwood, SH (corresponding author), E Texas Med Ctr, Dept Surg, 1020 E Idel St, Tyler, TX 75701 USA.						Agnelli G, 1998, NEW ENGL J MED, V339, P80, DOI 10.1056/NEJM199807093390204; Brasel KJ, 1997, J TRAUMA, V42, P456, DOI 10.1097/00005373-199703000-00013; CERRATO D, 1978, J NEUROSURG, V49, P378, DOI 10.3171/jns.1978.49.3.0378; Devlin JW, 1998, PHARMACOTHERAPY, V18, P1335; Dickinson LD, 1998, NEUROSURGERY, V43, P1074, DOI 10.1097/00006123-199811000-00039; GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401; Geerts WH, 1996, NEW ENGL J MED, V335, P701, DOI 10.1056/NEJM199609053351003; Geerts WH, 2001, CHEST, V119, p132S, DOI 10.1378/chest.119.1_suppl.132S; Greenfield LJ, 2000, J VASC SURG, V32, P490, DOI 10.1067/mva.2000.108636; HAMILTON MG, 1994, NEUROSURGERY, V34, P280, DOI 10.1227/00006123-199402000-00012; JENNETT B, 1975, LANCET, V1, P480; Knudson MM, 1996, J TRAUMA, V41, P446, DOI 10.1097/00005373-199609000-00010; KNUDSON MM, 1994, J TRAUMA, V37, P480, DOI 10.1097/00005373-199409000-00025; KNUDSON MM, 1992, J TRAUMA, V32, P2, DOI 10.1097/00005373-199201000-00002; MARSHALL LF, 1992, J NEUROTRAUMA, V9, P287; Norwood SH, 2001, J AM COLL SURGEONS, V192, P161, DOI 10.1016/S1072-7515(00)00802-4; Nurmohamed MT, 1996, THROMB HAEMOSTASIS, V75, P233; Patel NY, 2000, J TRAUMA, V48, P367, DOI 10.1097/00005373-200003000-00001; Wojcik R, 2000, J TRAUMA, V49, P839, DOI 10.1097/00005373-200011000-00008	19	106	113	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0004-0010			ARCH SURG-CHICAGO	Arch. Surg.	JUN	2002	137	6					696	701		10.1001/archsurg.137.6.696			6	Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Surgery	559VF	WOS:000176045500018	12049541	Bronze			2022-02-06	
J	Fichtenberg, NL; Zafonte, RD; Putnam, S; Mann, NR; Millard, AE				Fichtenberg, NL; Zafonte, RD; Putnam, S; Mann, NR; Millard, AE			Insomnia in a post-acute brain injury sample	BRAIN INJURY			English	Article							MINOR HEAD-INJURIES; SLEEP DISTURBANCES; MULTIPLE-SCLEROSIS; PARKINSONS-DISEASE; DISORDERS; COMPLAINTS; PREVALENCE; CONCUSSION; SYMPTOMS; QUALITY	Objective: The purpose was to establish the frequency of insomnia within the post-acute TBI population and compare it with insomnia rates among other rehabilitation outpatients. Design: A prospective study was undertaken of 50 consecutive post-acute TBI admissions and a comparison group of 50 rehabilitation outpatients evenly divided between spinal cord injury (SCI) and musculoskeletal (MSK) cases. Setting: Subjects were recruited at various outpatient clinics of a major rehabilitation hospital. Patients: Among the TBI subjects, the predominant cause of injury was motor vehicle accident; both mild and severe injuries were well represented in the sample; and, on average, patients were almost 4 months post-injury. The comparison and TBI groups did not differ significantly with respect to education or marital status. However, the MSK group was older and a higher proportion of the SCI group was female. Measures: The Pittsburgh Sleep Quality Index (PSQI), Beck Depression Inventory (BDI), and sleep diaries were administered to the TBI group. Only the PSQI and BDI were completed by the comparison group. Results: Thirty per cent of the patients were found to suffer from insomnia. Sleep initiation was a problem almost twice as often as sleep duration. An additional 12% did not meet the DSM-IV criteria for insomnia but, nevertheless, experienced a degradation of sleep quality, as measured by the PSQI. Conversely, only slightly more than half (58%) of the TBI sample reported sleep to be relatively normal and satisfactory. Insomnia was also commonly reported by the patients in the rehabilitation comparison groups. They generated significantly higher mean PSQI Global Scores relative to the TBI group and the frequency of poor sleep quality was elevated significantly above the TBI rate. Relative to the TBI cases, twice as many comparison group patients were classified by the PSQI as insomniacs. Conclusion: Poor sleep quality and insomnia were definitely problems for the TBI group, although the magnitude of these problems was much greater for the rehabilitation comparison group. Degraded and disordered sleep may represent widespread challenges within the rehabilitation population in general.	Rehabil Inst Michigan, Novi Ctr, Novi, MI 48337 USA; Wayne State Univ, Sch Med, Detroit, MI 48202 USA; Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA; Univ Michigan Hosp & Hlth Care Ctrs, Ann Arbor, MI USA		Fichtenberg, NL (corresponding author), Rehabil Inst Michigan, Novi Ctr, 42005 W 12 Mile Rd, Novi, MI 48337 USA.						American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; CLARK CM, 1992, ARCH NEUROL-CHICAGO, V49, P641, DOI 10.1001/archneur.1992.00530300077013; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; COHEN M, 1992, J NEUROL NEUROSUR PS, V55, P313, DOI 10.1136/jnnp.55.4.313; FACTOR SA, 1990, MOVEMENT DISORD, V5, P280, DOI 10.1002/mds.870050404; FERINISTRAMBI L, 1994, J NEUROL SCI, V125, P194, DOI 10.1016/0022-510X(94)90035-3; Fichtenberg NL, 2000, BRAIN INJURY, V14, P659; Fichtenberg NL, 2001, AM J PHYS MED REHAB, V80, P339, DOI 10.1097/00002060-200105000-00003; FORD DE, 1989, JAMA-J AM MED ASSOC, V262, P1479, DOI 10.1001/jama.262.11.1479; GISLASON T, 1987, ACTA MED SCAND, V221, P475; Hagen C, 1979, REHABILITATION HEAD, P87; HOLLEY JL, 1992, AM J KIDNEY DIS, V19, P156, DOI 10.1016/S0272-6386(12)70125-7; HYPPA MT, 1989, J CLIN EPIDEMIOL, V42, P633; JANSON C, 1995, SLEEP, V18, P589; JANSON C, 1990, RESP MED, V84, P37, DOI 10.1016/S0954-6111(08)80092-3; JENNUM P, 1993, J RHEUMATOL, V20, P1756; KALES A, 1971, CLIN PHARMACOL THER, V12, P397; KESHAVAN MS, 1981, BRIT J PSYCHIAT, V138, P157, DOI 10.1192/bjp.138.2.157; KRUPP LB, 1993, J PSYCHOSOM RES, V37, P325, DOI 10.1016/0022-3999(93)90134-2; LAVERDIERE M, 1984, SLEEP RES, V13, P177; LEES AJ, 1988, CLIN NEUROPHARMACOL, V11, P512, DOI 10.1097/00002826-198812000-00004; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; MCLEAN A, 1984, NEUROSURGERY, V14, P393, DOI 10.1227/00006123-198404000-00001; RUTHERFORD WH, 1977, LANCET, V1, P1; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; SCHIAVI RC, 1993, BIOL PSYCHIAT, V34, P171, DOI 10.1016/0006-3223(93)90388-T; SHAPIRO CM, 1993, BRIT MED J, V306, P1532, DOI 10.1136/bmj.306.6891.1532; SRIDHAR GR, 1994, DIABETES RES CLIN PR, V23, P183, DOI 10.1016/0168-8227(94)90103-1; TACHIBANA N, 1994, EUR NEUROL, V34, P320, DOI 10.1159/000117070; VANKEIMPEMA ARJ, 1995, J ASTHMA, V32, P69, DOI 10.3109/02770909509089502; VERMA NP, 1991, J EPILEPSY, V4, P217, DOI 10.1016/0896-6974(91)90079-X; WITTIG RM, 1982, J NERV MENT DIS, V170, P429, DOI 10.1097/00005053-198207000-00011; Zafonte RD, 1996, NEUROREHABILITATION, V7, P189, DOI 10.3233/NRE-1996-7304	36	106	109	0	4	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK,, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	MAR	2002	16	3					197	206		10.1080/02699050110103940			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	526HP	WOS:000174124800002	11874613				2022-02-06	
J	Bryant, RA				Bryant, RA			Posttraumatic stress disorder and traumatic brain injury: Can they co-exist?	CLINICAL PSYCHOLOGY REVIEW			English	Article						posttraumatic stress disorder; brain injury; memory	MOTOR-VEHICLE ACCIDENTS; CLOSED-HEAD-INJURY; ROAD TRAFFIC ACCIDENTS; 2-YEAR PROSPECTIVE EVALUATION; PSYCHOLOGICAL CONSEQUENCES; NONSEXUAL ASSAULT; PTSD; SYMPTOMS; VICTIMS; MEMORY	The possibility that posttraumatic stress disorder (PTSD) can develop following traumatic brain injury (TBI) has been the subject of considerable debate. The traditional view has held that impaired consciousness that occurs with TBI precludes encoding of the traumatic experience, and this prevents subsequent reexperiencing symptoms. This paper critically reviews available empirical studies on PTSD in TBI populations and suggests that these two conditions can co-exist. The various mechanisms that may mediate PTSD following TBI are discussed, and special attention is given to issues that recognize the distinctive features of PTSD following TBI. These processes include implicit processing,, biologically mediated fear conditioning, and,reconstruction of trauma memories. Finally, implications for assessment, treatment, and forensic investigation of PTSD in TBI populations are addressed. This review concludes that TBI populations provide a useful means by which the role of traumatic memories (and impaired memories) in posttraumatic adjustment can be studied. (C) 2001 Elsevier Science Ltd. All rights reserved.	Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia		Bryant, RA (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.	r.bryant@unsw.edu.au	Bryant, Richard/AAA-6479-2019	Bryant, Richard/0000-0002-9607-819X			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Psychiatric Association, 1987, DIAGN STAT MAN MENT; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; ARTIOLAIFORTUNY L, 1980, J NEUROL NEUROSUR PS, V43, P377, DOI 10.1136/jnnp.43.5.377; Bell P., 1993, INT HDB TRAUMATIC ST, P377; Blanchard EB, 1996, BEHAV RES THER, V34, P1, DOI 10.1016/0005-7967(95)00058-6; BLANCHARD EB, 1994, BEHAV RES THER, V32, P283, DOI 10.1016/0005-7967(94)90123-6; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; BONTKE CF, 1996, J HEAD TRAUMA REHAB, V11, P95, DOI DOI 10.1097/00001199-199602000-00011; BREMNER JD, 1993, AM J PSYCHIAT, V150, P1015; Brewin CR, 1996, PSYCHOL REV, V103, P670, DOI 10.1037/0033-295X.103.4.670; Bryant RA, 2000, J ABNORM PSYCHOL, V109, P341, DOI 10.1037/0021-843X.109.2.341; BRYANT RA, 1995, AUST J PUBLIC HEALTH, V19, P185; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; Bryant RA, 2000, BRAIN INJURY, V14, P175, DOI 10.1080/026990500120826; Bryant RA, 1997, CLIN PSYCHOL REV, V17, P757, DOI 10.1016/S0272-7358(97)00052-4; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Bryant RA, 1996, J TRAUMA STRESS, V9, P621; Bryant RA, 1998, APPL COGNITIVE PSYCH, V12, P81, DOI 10.1002/(SICI)1099-0720(199802)12:1<81::AID-ACP507>3.0.CO;2-8; Bryant RA, 2001, J NERV MENT DIS, V189, P109, DOI 10.1097/00005053-200102000-00006; BRYANT RA, 1995, PSYCHOL MED, V25, P869, DOI 10.1017/S0033291700035121; Bryant RA, 1999, BRAIN INJURY, V13, P15, DOI 10.1080/026990599121836; Bryant RA, 1999, J HEAD TRAUMA REHAB, V14, P588, DOI 10.1097/00001199-199912000-00007; DALTON JE, 1989, INT J CLIN NEUROPSYC, V11, P121; Deb S, 1999, AM J PSYCHIAT, V156, P374; DEITZ J, 1992, J AM ACAD PSYCHOAN, V20, P277, DOI 10.1521/jaap.1.1992.20.2.277; DiGallo A, 1997, BRIT J PSYCHIAT, V170, P358, DOI 10.1192/bjp.170.4.358; DiGallo A, 1997, BRIT J PSYCHIAT, V171, P393; EVERLY GS, 1989, PERCEPT MOTOR SKILL, V68, P807, DOI 10.2466/pms.1989.68.3.807; Fearnley D, 1997, BRIT J PSYCHIAT, V171, P393, DOI 10.1192/bjp.171.4.393b; FLEMINGER S, 1993, BIOL PSYCHIAT, V33, P22, DOI 10.1016/0006-3223(93)90274-H; Foa EB, 1997, ANNU REV PSYCHOL, V48, P449, DOI 10.1146/annurev.psych.48.1.449; FOA EB, 1995, AM J PSYCHIAT, V152, P116; GRIGSBY J, 1993, BRAIN INJURY, V7, P507, DOI 10.3109/02699059309008178; GRIGSBY JP, 1986, INT J CLIN NEUROPSYC, V8, P65; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; Harvey AG, 1996, COGNITIVE THER RES, V20, P613, DOI 10.1007/BF02227964; Harvey AG, 1998, J CONSULT CLIN PSYCH, V66, P500, DOI 10.1037/0022-006X.66.3.500; Harvey AG, 1999, J NERV MENT DIS, V187, P443, DOI 10.1097/00005053-199907000-00009; Harvey AG, 1999, J CONSULT CLIN PSYCH, V67, P985, DOI 10.1037/0022-006X.67.6.985; Harvey AG, 1998, J CONSULT CLIN PSYCH, V66, P507, DOI 10.1037/0022-006X.66.3.507; Harvey AG, 1998, J NERV MENT DIS, V186, P333, DOI 10.1097/00005053-199806000-00002; Harvey AG, 2000, AM J PSYCHIAT, V157, P626, DOI 10.1176/appi.ajp.157.4.626; Harvey AG, 1998, BRAIN INJURY, V12, P147, DOI 10.1080/026990598122773; HARVEY AG, IN PRESS J TRAUMATIC; Hickling EJ, 1998, BRAIN INJURY, V12, P265, DOI 10.1080/026990598122566; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; HORTON AM, 1993, PERCEPT MOTOR SKILL, V76, P243, DOI 10.2466/pms.1993.76.1.243; Jennett B, 1981, MANAGEMENT HEAD INJU; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; King SM, 1996, VISUAL NEUROSCI, V13, P1, DOI 10.1017/S0952523800007082; KOCH WJ, 1995, COGN BEHAV PRACT, V2, P327, DOI 10.1016/S1077-7229(95)80016-6; KOLB LC, 1987, AM J PSYCHIAT, V144, P989; KOOPMAN C, 1995, J TRAUMA STRESS, V8, P29, DOI 10.1007/BF02105405; KOPELMAN MD, 1987, BRIT J PSYCHIAT, V150, P428, DOI 10.1192/bjp.150.4.428; Kraus Jess F., 1994, P3; KRYSTAL JH, 1989, BEHAV THER, V20, P177, DOI 10.1016/S0005-7894(89)80068-1; KWENTUS JA, 1985, PSYCHOSOMATICS, V26, P8, DOI 10.1016/S0033-3182(85)72900-3; Lahz S, 1996, ARCH PHYS MED REHAB, V77, P889, DOI 10.1016/S0003-9993(96)90275-0; LAYTON BS, 1995, CLIN NEUROPSYCHOL, V9, P2, DOI 10.1080/13854049508402050; Ledoux J E, 1989, J Cogn Neurosci, V1, P238, DOI 10.1162/jocn.1989.1.3.238; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Levi RB, 1999, J CLIN CHILD PSYCHOL, V28, P232, DOI 10.1207/s15374424jccp2802_10; Levin H. S., 1987, NEUROBEHAVIORAL RECO, P262; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; LONG C, 1983, PSYCHIAT MED, V1, P33; Max JE, 1998, J NERV MENT DIS, V186, P589, DOI 10.1097/00005053-199810000-00001; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1595, DOI 10.1016/S0890-8567(09)66570-9; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; McMillan TM, 1996, BRAIN INJURY, V10, P749, DOI 10.1080/026990596124016; MCMILLAN TM, 1991, BRIT J PSYCHIAT, V159, P431, DOI 10.1192/bjp.159.3.431; Middelboe T., 1992, European Psychiatry, V7, P183; MILLER L, 1993, J COGNITIVE REHABILI, V11, P18; Ohry A, 1996, BRAIN INJURY, V10, P687, DOI 10.1080/026990596124106; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Orr Scott P., 1997, P69; Peters L, 1996, INT J METHOD PSYCH, V6, P167, DOI 10.1002/(SICI)1234-988X(199610)6:3<167::AID-MPR159>3.3.CO;2-Z; Price K. P., 1994, DEF LAW J, V43, P113; PRIGATANO GP, 1990, CLIN NEUROPSYCHOL, V4, P163, DOI DOI 10.1080/13854049008401509; RIGGS DS, 1995, J INTERPERS VIOLENCE, V10, P201, DOI 10.1177/0886260595010002005; ROTHBAUM BO, 1992, J TRAUMA STRESS, V5, P455, DOI 10.1007/BF00977239; RUTHERFORD WH, 1989, NEUROBEHAVIORAL RECO, P217; SALMON K, IN PRESS CLIN PSYCHO; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; SBORDONE RJ, 1992, NEUROLAW LETT, V3; SCHACTER DL, 1993, ANNU REV NEUROSCI, V16, P159, DOI 10.1146/annurev.ne.16.030193.001111; SCHACTER DL, 1977, CORTEX, V13, P150, DOI 10.1016/S0010-9452(77)80006-3; Shalev AY, 1998, ARCH GEN PSYCHIAT, V55, P553, DOI 10.1001/archpsyc.55.6.553; SIVEC HJ, 1995, CLIN PSYCHOL REV, V15, P297, DOI 10.1016/0272-7358(95)00012-E; SOLOMON SD, 1990, COMPR PSYCHIAT, V31, P227, DOI 10.1016/0010-440X(90)90006-E; Tarrier N, 1999, J CONSULT CLIN PSYCH, V67, P13, DOI 10.1037/0022-006X.67.1.13; Taylor S, 1995, CLIN PSYCHOL REV, V15, P721, DOI 10.1016/0272-7358(95)00043-7; Valentiner DP, 1996, J ABNORM PSYCHOL, V105, P455, DOI 10.1037/0021-843X.105.3.455; Van Der Kolk Bessel A., 1996, P214; Warda G, 1998, BEHAV RES THER, V36, P1171, DOI 10.1016/S0005-7967(98)00082-5; Warden DL, 1997, J NEUROPSYCH CLIN N, V9, P18; WATSON CG, 1991, J CLIN PSYCHOL, V47, P179, DOI 10.1002/1097-4679(199103)47:2<179::AID-JCLP2270470202>3.0.CO;2-P	98	106	110	0	14	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0272-7358	1873-7811		CLIN PSYCHOL REV	Clin. Psychol. Rev.	AUG	2001	21	6					931	948					18	Psychology, Clinical	Social Science Citation Index (SSCI)	Psychology	458AC	WOS:000170170300005	11497213				2022-02-06	
J	Dash, PK; Mach, SA; Moore, AN				Dash, PK; Mach, SA; Moore, AN			Regional expression and role of cyclooxygenase-2 following experimental traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						celecoxib; cyclooxygenase; hippocampus; inflammation; rat; trauma	ENDOPEROXIDE SYNTHASE-2 GENE; CONTROLLED CORTICAL IMPACT; CLOSED-HEAD-INJURY; MESSENGER-RNA; RAT-BRAIN; PROSTAGLANDIN SYNTHASE; GRANULOSA-CELLS; AXONAL INJURY; PROMOTER; DAMAGE	Prostaglandins, potent mediators of inflammation, are generated from arachidonic acid (AA) via the action of cyclooxygenase-1 and -2 (COX-1 and COX-2), In this study, we report that lateral cortical impact injury in rats significantly increases COX-2 protein levels both in the cortex surrounding the injury site and the ipsilateral hippocampus. COX-2 protein level was elevated as early as 3 h postinjury and persisted for up to 3 days. Increases in immunoreactivity were detected not only in the adjacent cortex and hippocampus, but were also observed in the contralateral cortex and hippocampus, the ipsilateral piriform cortex and the ipsilateral amygdaloid complex. COX-2 immunoreactive cells appear morphologically normal and do not present any of the characteristic features of apoptosis. Double immunostaining experiments using either a neuron-specific or an astroglial-specific marker show that the expression of COX-2 is localized almost exclusively in neuronal cells. Administration of the COX-2 inhibitor 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-H-1-pyrazol-1-yl]benzenesulfonamide (celecoxib, marketed as Celebrex) worsens motor, but not cognitive, performance, suggesting that COX-2 induction following traumatic brain injury may play a protective role.	Univ Texas, Sch Med, Dept Neurobiol & Anat, WM Keck Ctr Neurobiol Learning & Memory, Houston, TX 77225 USA		Dash, PK (corresponding author), Univ Texas, Sch Med, Dept Neurobiol & Anat, WM Keck Ctr Neurobiol Learning & Memory, POB 20708, Houston, TX 77225 USA.	pdash@nba19.med.uth.tmc.edu			NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH049662] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS023327] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH49662] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS3545, P50NS23327] Funding Source: Medline		ARIASNEGRETE S, 1995, BIOCHEM BIOPH RES CO, V208, P582, DOI 10.1006/bbrc.1995.1378; Aronowski J, 1996, J CEREBR BLOOD F MET, V16, P705, DOI 10.1097/00004647-199607000-00022; Bauer MKA, 1997, EUR J BIOCHEM, V243, P726, DOI 10.1111/j.1432-1033.1997.00726.x; BAZAN NG, 1995, J NEUROTRAUM, V12, P791, DOI 10.1089/neu.1995.12.791; DASH PK, 1995, J NEUROSCI, V15, P2030, DOI 10.1523/JNEUROSCI.15-03-02030.1995; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; DeWitt DS, 1988, J NEUROTRAUM, V5, P303, DOI 10.1089/neu.1988.5.303; DHILLON HS, 1994, J NEUROTRAUM, V11, P405, DOI 10.1089/neu.1994.11.405; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; FADEN AI, 1996, PHARMACOL TOXICOL, V78, P21; Feuerstein GZ, 1997, ANN NY ACAD SCI, V825, P179, DOI 10.1111/j.1749-6632.1997.tb48428.x; Gierse JK, 1999, BIOCHEM J, V339, P607, DOI 10.1042/0264-6021:3390607; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; Guan ZH, 1998, J BIOL CHEM, V273, P28670, DOI 10.1074/jbc.273.44.28670; Hall ED, 1995, J NEUROL SCI, V134, P79, DOI 10.1016/0022-510X(95)00211-J; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hayaishi O, 1997, ADV EXP MED BIOL, V433, P347; Hayaishi O, 1996, ADV EXP MED BIOL, V398, P3; Homayoun P, 1997, J NEUROCHEM, V69, P199; KIM JJ, 1992, SCIENCE, V256, P675, DOI 10.1126/science.1585183; KLEIN J, 1995, J NEUROCHEM, V65, P1445; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KONTOS HA, 1980, SCIENCE, V209, P1242, DOI 10.1126/science.7403881; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; Long DA, 1996, BRAIN RES, V717, P109, DOI 10.1016/0006-8993(95)01500-0; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; MEANEY DF, 1994, J NEUROTRAUM, V11, P599, DOI 10.1089/neu.1994.11.599; Miller C, 1998, J CELL BIOCHEM, V69, P392, DOI 10.1002/(SICI)1097-4644(19980615)69:4<392::AID-JCB2>3.0.CO;2-I; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; Nogawa S, 1997, J NEUROSCI, V17, P2746; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; REGIER MK, 1993, ARCH BIOCHEM BIOPHYS, V301, P439, DOI 10.1006/abbi.1993.1168; Resnick DK, 1998, J NEUROTRAUM, V15, P1005, DOI 10.1089/neu.1998.15.1005; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; SHOHAMI E, 1989, J NEUROCHEM, V53, P1541, DOI 10.1111/j.1471-4159.1989.tb08550.x; SIROIS J, 1993, J BIOL CHEM, V268, P21931; SIROIS J, 1993, J BIOL CHEM, V268, P12199; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Subbaramaiah K, 1998, J BIOL CHEM, V273, P32943, DOI 10.1074/jbc.273.49.32943; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; WEI EP, 1982, J NEUROSURG, V56, P695, DOI 10.3171/jns.1982.56.5.0695; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T; YAN HQ, 1992, EUR J IMMUNOL, V22, P2963, DOI 10.1002/eji.1830221131	48	106	113	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2000	17	1					69	81		10.1089/neu.2000.17.69			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	278WR	WOS:000085012400006	10674759				2022-02-06	
J	Hinton-Bayre, AD; Geffen, GM; Geffen, LB; McFarland, KA; Friis, P				Hinton-Bayre, AD; Geffen, GM; Geffen, LB; McFarland, KA; Friis, P			Concussion in contact sports: Reliable change indices of impairment and recovery	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							MINOR HEAD-INJURY; CLINICAL-SIGNIFICANCE; NEUROPSYCHOLOGICAL DEFICITS; AUSTRALIAN RULES; MEANINGFUL CHANGE; FOOTBALL PLAYERS; MILD CONCUSSION; GUIDELINES; PSYCHOTHERAPY; THERAPY	This paper reports a follow-up study to an article on the sensitivity of three tests of speed of information processing to impairment after concussion (Hinton-Bayre, Geffen, BL McFarland, 1997). Group analyses showed that practice effects can obscure the effects of concussion on information processing, thereby making the assessment of functional impairment and recovery after injury unreliable. A Reliable Change Index (RCI) was used to assess individual variations following concussion. It was found that 16 of the 20 concussed professional rugby league players were impaired 1-3 days following injury. It was also demonstrated that 7 players still displayed cognitive deficits at 1-2 weeks, before returning to preseason levels at 3-5 weeks. The RCI permits comparisons between different tests, players, and repeated assessments, thereby providing a quantitative basis for decisions regarding return to play.	Univ Queensland, Sch Psychol, Dept Psychiat, Brisbane, Qld, Australia; Queensland Hlth, Brisbane, Qld, Australia; Holy Spirit Hosp, Sports Med Clin, Brisbane, Qld, Australia		Hinton-Bayre, AD (corresponding author), Univ Queensland, Cognit Psychophysiol Lab, Edith Cavell Bldg, Herston, Qld 4006, Australia.						ANKUTA GY, 1993, PROF PSYCHOL-RES PR, V24, P70, DOI 10.1037/0735-7028.24.1.70; BADDELEY A, 1992, SPEEC CAPACITY LANGU; BEIDEL DC, 1993, BEHAV RES THER, V31, P331, DOI 10.1016/0005-7967(93)90033-Q; Bleiberg J, 1998, J HEAD TRAUMA REHAB, V13, P36, DOI 10.1097/00001199-199804000-00006; BOHNEN N, 1992, NEUROSURGERY, V30, P692, DOI 10.1097/00006123-199205000-00007; Broadbent D.E., 1958, PERCEPTION COMMUNICA, DOI [10.1037/10037-000, DOI 10.1037/10037-000]; Brukner P, 1996, Aust Fam Physician, V25, P1445; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P10; Chelune G.J., 1993, NEUROPSYCHOLOGY, V7, P41, DOI [10.1037/0894-4105.7.1.41, DOI 10.1037/0894-4105.7.1.41]; Chomsky Noam, 1957, SYNTACTIC STRUCTURES; *COL MED SOC SPORT, 1991, GUID MAN CONC SPORTS; Committee on Head Injury Nomenclature of Congress of Neurological Surgeons, 1966, CLIN NEUROSURG, V12, P386; Crawford J.R., 1992, HDB NEUROPSYCHOLOGIC, P21; CREMONAMETEYARD SL, 1994, NEUROPSYCHOLOGIA, V32, P649, DOI 10.1016/0028-3932(94)90026-4; DEBEURS E, 1994, BEHAV THER, V25, P147, DOI 10.1016/S0005-7894(05)80150-9; Dicker G, 1993, Aust Fam Physician, V22, P750; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DORMAAR M, 1988, PSYCHOTHER PSYCHOSOM, V50, P95, DOI 10.1159/000288106; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GRONWALL D, 1975, LANCET, V2, P995; GRONWALL D, 1974, LANCET, V2, P605; GRONWALL D, 1992, NZ J SPORTS MED, V20, P19; HAWLEY DR, 1995, FAM RELAT, V44, P278, DOI 10.2307/585526; Hermann BP, 1996, EPILEPSIA, V37, P942, DOI 10.1111/j.1528-1157.1996.tb00531.x; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; HINTONBAYRE AD, IN PRESS P 21 ANN BR; HOY G, 1987, SPORT HLTH, V5, P26; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; JACOBSON NS, 1984, BEHAV THER, V15, P336, DOI 10.1016/S0005-7894(84)80002-7; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; LACKS P, 1992, J CONSULT CLIN PSYCH, V60, P586, DOI 10.1037/0022-006X.60.4.586; LEBLANC KE, 1994, AM FAM PHYSICIAN, V50, P801; Lee AJ, 1996, BRIT J SPORT MED, V30, P213, DOI 10.1136/bjsm.30.3.213; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; MACCIOCCHI SN, 1990, J CLIN PSYCHOL, V46, P628, DOI 10.1002/1097-4679(199009)46:5<628::AID-JCLP2270460514>3.0.CO;2-V; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; MADDOCKS D, 1989, SPORT HLTH S, V7, P6; MADDOCKS DL, 1995, AUST PSYCHOL, V30, P125, DOI 10.1080/00050069508258916; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; MCCRORY P, 1994, HEAD BRAIN INJURY SP; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; McCrory PR, 1997, BRIT MED J, V314, P171, DOI 10.1136/bmj.314.7075.171; McKay D, 1996, J ANXIETY DISORD, V10, P47, DOI 10.1016/0887-6185(95)00034-8; MILLER RE, 1984, HYPERTENSION, V6, P202, DOI 10.1161/01.HYP.6.2_Pt_1.202; National Health and Medical Research Council, 1994, FOOTB INJ HEAD NECK; NEWCOMBE F, 1994, J NEUROL NEUROSUR PS, V57, P709, DOI 10.1136/jnnp.57.6.709; OSHAUGHNESSY EJ, 1984, J FAM PRACTICE, V18, P391; Powell TJ, 1996, DISABIL REHABIL, V18, P231, DOI 10.3109/09638289609166306; Roos R, 1996, PHYSICIAN SPORTSMED, V24, P67, DOI 10.3810/psm.1996.10.1327; Sacks T. L., 1991, CLIN NEUROPSYCHOL, V5, P220, DOI [10.1080/13854049108404093, DOI 10.1080/13854049108404093]; Sawrie S M, 1996, J Int Neuropsychol Soc, V2, P556; SCOTT MJ, 1990, BEHAV PSYCHOTHER, V18, P1, DOI 10.1017/S014134730001795X; SEWARD H, 1993, MED J AUSTRALIA, V159, P298, DOI 10.5694/j.1326-5377.1993.tb137863.x; Smith A., 1982, SYMBOL DIGIT MODALIT; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Wechsler, 1997, WECHSLER ADULT INTEL; WHISMAN MA, 1989, ADV BEHAV RES THER, V11, P175, DOI 10.1016/0146-6402(89)90021-0; WRIGHTSON P, 1992, NZ J SPORTS MED, V20, P18; YOUNGJOHN JR, 1992, CLIN NEUROPSYCHOL, V6, P276, DOI DOI 10.1080/13854049208404129	70	106	107	0	23	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	FEB	1999	21	1					70	86		10.1076/jcen.21.1.70.945			17	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	214VN	WOS:000081348400008	10421003				2022-02-06	
J	McKeating, EG; Andrews, PJD; Signorini, DF; Mascia, L				McKeating, EG; Andrews, PJD; Signorini, DF; Mascia, L			Transcranial cytokine gradients in patients requiring intensive care after acute brain injury	BRITISH JOURNAL OF ANAESTHESIA			English	Article						brain, injury; polypeptides, cytokines; intensive care	HEAD-INJURY; RAT-BRAIN; IL-6; INTERLEUKIN-6; ELEVATION; SEPSIS; PLASMA	After acute brain injury there may be increased intracranial production of cytokines, with activation of inflammatory cascades. We have sought to determine if a transcranial cytokine gradient was demonstrable in paired sera of 32 patients requiring intensive care after acute brain injury. The difference between concentrations of IL-1 beta, IL-6, IL-8 and TNF alpha in jugular venous and arterial serum was measured on admission, and at 24, 48 and 96 h after the primary injury. There were no differences in IL-1 beta, IL-8 or TNF alpha, but median gradients of 6.7 and 11.5 pg ml(-1) for IL-6 were demonstrated in the traumatic brain injury (n=22) and subarachnoid haemorrhage (n=10) groups, respectively (normal values in serum <4.7 pg ml(-1); P<0.001 both groups). This suggests that there is significant production of IL-6 by intracranial cells after acute brain injury. Therapy directed towards combatting the negative effects of IL-6 may potentially benefit patients who have sustained an acute brain injury.	UNIV EDINBURGH,WESTERN GEN HOSP,DEPT ANAESTHET,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; UNIV BARI,DEPT INTENS CARE,BARI,ITALY		McKeating, EG (corresponding author), UNIV EDINBURGH,WESTERN GEN HOSP,DEPT CLIN NEUROSCI,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.		mascia, Luciana/L-3039-2018				ANDREWS PJD, 1991, BRIT J ANAESTH, V67, P553, DOI 10.1093/bja/67.5.553; BELLANTI JA, 1994, PEDIATR CLIN N AM, V41, P597; DAMAS P, 1992, ANN SURG, V215, P356, DOI 10.1097/00000658-199204000-00009; DONNELLY SC, 1993, LANCET, V341, P643, DOI 10.1016/0140-6736(93)90416-E; FOEX BA, 1993, INJURY, V24, P373, DOI 10.1016/0020-1383(93)90098-Q; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; HARIRI RJ, 1994, BRAIN RES, V636, P139, DOI 10.1016/0006-8993(94)90188-0; HAYES MA, 1994, NEW ENGL J MED, V330, P1717, DOI 10.1056/NEJM199406163302404; HOFMAN F M, 1990, Regional Immunology, V3, P268; Lam JMK, 1996, BRIT J NEUROSURG, V10, P357; MARUO N, 1992, ENDOCRINOLOGY, V131, P710, DOI 10.1210/en.131.2.710; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; MEDURI GU, 1995, CHEST, V107, P1062, DOI 10.1378/chest.107.4.1062; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; PARAMORE CG, 1994, ACTA NEUROCHIR, V127, P79, DOI 10.1007/BF01808552; PATEL RT, 1994, BRIT J SURG, V81, P1306, DOI 10.1002/bjs.1800810914; PINSKY MR, 1993, CHEST, V103, P565, DOI 10.1378/chest.103.2.565; Ronco JJ, 1996, CRIT CARE CLIN, V12, P645, DOI 10.1016/S0749-0704(05)70268-2; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Souter MJ, 1996, BRIT J ANAESTH, V76, P744, DOI 10.1093/bja/76.5.744; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; YAMASAKI Y, 1992, NEUROSCI LETT, V142, P45, DOI 10.1016/0304-3940(92)90616-F	25	106	108	0	0	PROF SCI PUBL	LONDON	TAVISTOCK HOUSE EAST, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0007-0912			BRIT J ANAESTH	Br. J. Anaesth.	MAY	1997	78	5					520	523		10.1093/bja/78.5.520			4	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	WZ848	WOS:A1997WZ84800007	9175965	Bronze			2022-02-06	
J	Mukhin, A; Fan, L; Faden, AI				Mukhin, A; Fan, L; Faden, AI			Activation of metabotropic glutamate receptor subtype mGluR1 contributes to post-traumatic neuronal injury	JOURNAL OF NEUROSCIENCE			English	Article						antisense oligodeoxynucleotides; brain trauma; metabotropic glutamate receptors; neuronal injury; neuroprotection; phosphoinositide hydrolysis	EXPERIMENTAL BRAIN INJURY; SODIUM-CHANNEL BLOCKER; SPINAL-CORD INJURY; PHENYLGLYCINE DERIVATIVES; CORTICAL CULTURES; RAT HIPPOCAMPUS; AGONIST; ACID; ANTAGONISTS; NMDA	The role of phospholipase C-coupled (group I) metabotropic glutamate receptors (mGluR1 and mGluR5) in post-traumatic neuronal injury was examined using rat in vivo and in vitro models. Traumatic injury to mixed neuronal/glial cultures induced phosphoinositide hydrolysis and caused neuronal death. Pharmacological blockade of group I receptors significantly reduced these effects in vitro and decreased neurological deficits as well as neuronal loss produced by traumatic brain injury in vivo. In contrast, activation of group I receptors by a specific agonist in vitro exacerbated post-traumatic neuronal death in a dose-dependent manner. Antisense oligodeoxynucleotide directed to mGluR1, but not to mGluR5, was neuroprotective in vitro, although each oligodeoxynucleotide reduced the respective receptor-stimulated accumulation of inositol phosphates to a similar degree. Together, these findings suggest that activation of mGluR1 contributes to post-traumatic neuronal injury and that mGluR1 antagonists may have therapeutic potential in brain injury.	GEORGETOWN UNIV,MED CTR,DEPT NEUROL,WASHINGTON,DC 20007; GEORGETOWN UNIV,MED CTR,DEPT PHARMACOL,WASHINGTON,DC 20007; GEORGETOWN UNIV,MED CTR,INST COGNIT & COMPUTAT SCI,WASHINGTON,DC 20007						NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS27849] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [CCR306634] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027849] Funding Source: NIH RePORTER		ABE T, 1992, J BIOL CHEM, V267, P13361; AMADOR E, 1963, CLIN CHEM, V9, P391; BERRIDGE MJ, 1982, BIOCHEM J, V206, P587, DOI 10.1042/bj2060587; BIRRELL GJ, 1993, NEUROPHARMACOLOGY, V32, P1351, DOI 10.1016/0028-3908(93)90030-7; BRABET I, 1995, NEUROPHARMACOLOGY, V34, P895, DOI 10.1016/0028-3908(95)00079-L; BRUNO V, 1994, EUR J PHARMACOL, V256, P109, DOI 10.1016/0014-2999(94)90624-6; Buisson A, 1996, EUR J NEUROSCI, V8, P138, DOI 10.1111/j.1460-9568.1996.tb01174.x; BUISSON A, 1995, NEUROPHARMACOLOGY, V34, P1081, DOI 10.1016/0028-3908(95)00073-F; CHIAMULERA C, 1992, EUR J PHARMACOL, V216, P335, DOI 10.1016/0014-2999(92)90382-E; DELAHUNTY TM, 1992, BRAIN RES, V594, P307, DOI 10.1016/0006-8993(92)91140-A; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; FADEN AI, 1989, SCIENCE, V244, P98; Fitzjohn SM, 1996, NEUROSCI LETT, V203, P211, DOI 10.1016/0304-3940(96)12301-6; GONG QZ, 1995, BRAIN RES, V700, P299, DOI 10.1016/0006-8993(95)01081-6; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KINGSTON AE, 1995, NEUROPHARMACOLOGY, V34, P887, DOI 10.1016/0028-3908(95)00069-I; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; KOH JY, 1991, P NATL ACAD SCI USA, V88, P9431, DOI 10.1073/pnas.88.21.9431; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MCDONALD JW, 1992, EUR J PHARMACOL, V215, P353, DOI 10.1016/0014-2999(92)90058-C; MCDONALD JW, 1993, J NEUROSCI, V13, P4445; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MCINTOSH TK, 1993, RECENT ADV EXCITATOR, P653; Mukhin A. G., 1995, Society for Neuroscience Abstracts, V21, P764; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; OPITZ T, 1994, NEUROPHARMACOLOGY, V33, P715, DOI 10.1016/0028-3908(94)90178-3; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PANTER SS, 1994, PRINCIPLES PRACTICE, P32; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; PIN JP, 1993, CURR DRUGS NEURODEGE, V12, P111; PRASAD MR, 1994, J NEUROCHEM, V63, P773; REGAN RF, 1994, BRAIN RES, V633, P236, DOI 10.1016/0006-8993(94)91544-X; REID SNM, 1995, J COMP NEUROL, V355, P470, DOI 10.1002/cne.903550311; ROMANO C, 1995, J COMP NEUROL, V355, P455, DOI 10.1002/cne.903550310; SACAAN AI, 1992, NEUROSCI LETT, V139, P77, DOI 10.1016/0304-3940(92)90862-2; SAUGSTAD JA, 1995, EUR J PHARM-MOLEC PH, V289, P395, DOI 10.1016/0922-4106(95)90120-5; SAUGSTAD JA, 1994, MOL PHARMACOL, V45, P367; SCHOEPP DD, 1993, TRENDS PHARMACOL SCI, V14, P13, DOI 10.1016/0165-6147(93)90107-U; SCHOEPP DD, 1994, J NEUROCHEM, V63, P769; SHARPIRA Y, 1990, J NEUROTRAUM, V1, P131; SILIPRANDI R, 1992, EUR J PHARMACOL, V219, P173, DOI 10.1016/0014-2999(92)90598-X; SLADECZEK F, 1985, NATURE, V317, P717, DOI 10.1038/317717a0; SMITH DH, 1993, J NEUROSCI, V13, P5383, DOI 10.1523/JNEUROSCI.13-12-05383.1993; SUN FY, 1995, BRAIN RES, V673, P133, DOI 10.1016/0006-8993(94)01413-C; SUN FY, 1995, BRAIN RES, V693, P163, DOI 10.1016/0006-8993(95)00731-5; TECOMA ES, 1989, NEURON, V2, P1541, DOI 10.1016/0896-6273(89)90042-1; TOULMOND S, 1993, BRAIN RES, V620, P32, DOI 10.1016/0006-8993(93)90267-Q; WATKINS J, 1994, TRENDS PHARMACOL SCI, V15, P333, DOI 10.1016/0165-6147(94)90028-0; WRATHALL JR, 1992, BRAIN RES, V586, P140, DOI 10.1016/0006-8993(92)91384-Q	56	106	107	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513	0270-6474			J NEUROSCI	J. Neurosci.	OCT 1	1996	16	19					6012	6020					9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	VH858	WOS:A1996VH85800013	8815884				2022-02-06	
J	Allen, K; Blascovich, J				Allen, K; Blascovich, J			The value of service dogs for people with severe ambulatory disabilities - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SOCIAL ACKNOWLEDGMENTS; DEPRESSION; STRESS; CHILDREN; SUPPORT	Objective.-To assess the value of service dogs for people with ambulatory disabilities. Design.-Randomized, controlled clinical trial. Setting.-Environments of study participants. Participants.-Forty-eight individuals with severe and chronic ambulatory disabilities requiring use of wheelchairs who were recruited from advocacy and support groups for persons with muscular dystrophy, multiple sclerosis, traumatic brain injury, and spinal cord injury. Participants were matched on age, sex, marital status, race, and the nature and severity of the disability in order to create 24 pairs. Within each pair, participants were randomly assigned to either the experimental group or a wait-list control group. Intervention.-Experimental group members received trained-service dogs 1 month after the study began, and subjects in the wait-list control group received dogs in month 13 of the study. Main Outcome Measures.-Dependent variables evaluated were self-reported assessments of psychological well-being, internal locus of control, community integration, school attendance, part-time work status, self-esteem, marital status, living arrangements, and number of biweekly paid and unpaid assistance hours. Data collection occurred every 6 months over a 2-year period, resulting in five data collection points for all subjects. Results.-Significant positive changes in all but two dependent measures were associated with the presence of a service dog both between and within groups (P<.001). Psychologically, all participants showed substantial improvements in self-esteem, internal locus of control, and psychological well-being within 6 months after receiving their service dog. Socially, all participants showed similar improvements in community integration. Demographically, all participants showed increases in school attendance and/or part-time employment. Economically, all participants showed dramatic decreases in the number of both paid and unpaid assistance hours. Conclusions.-Trained service dogs can be highly beneficial and potentially cost-effective components of independent living for people with physical disabilities.	SUNY BUFFALO,DEPT MED,BUFFALO,NY; UNIV CALIF SANTA BARBARA,DEPT PSYCHOL,SANTA BARBARA,CA 93106								ALLEN K, 1994, REHABIL PSYCHOL, V39, P29, DOI 10.1037/0090-5550.39.1.29; ALLEN KM, 1991, J PERS SOC PSYCHOL, V61, P582, DOI 10.1037/0022-3514.61.4.582; BATAVIA AI, 1991, J HEALTH POLIT POLIC, V16, P523, DOI 10.1215/03616878-16-3-523; Bradburn NM, 1969, STRUCTURE PSYCHOL WE; *CAN COMP IND, 1994, CAN COMP IND PROGR I; COVINSKY KE, 1994, JAMA-J AM MED ASSOC, V272, P1839, DOI 10.1001/jama.272.23.1839; EATON L, 1994, NY TIMES        0911, P1; EDDY J, 1988, J PSYCHOL, V122, P39, DOI 10.1080/00223980.1988.10542941; EISENBERG MG, 1982, DISABLED PEOPLE 2 CL; FITZPATRICK R, 1991, SOC SCI MED, V33, P605, DOI 10.1016/0277-9536(91)90218-2; FRIEDLAND J, 1992, SOC SCI MED, V34, P395, DOI 10.1016/0277-9536(92)90299-6; HARTMANN C, 1988, Biofactors, V1, P41; KEENAN MP, 1989, CHANGING NEEDS LONG; KINNEY WB, 1992, ARCH PHYS MED REHAB, V73, P863; Kirk R. E, 1982, EXPT DESIGN PROCEDUR; LAPLANTE MP, 1989, 1 U CAL I HLTH AG; LITVAK S, 1987, ATTENDING AM PERSONA; MADER B, 1989, CHILD DEV, V60, P1529, DOI 10.1111/j.1467-8624.1989.tb04023.x; MARINELLI RP, 1977, PSYCHOL SOCIAL IMPAC; PAULHUS D, 1983, J PERS SOC PSYCHOL, V44, P1253, DOI 10.1037/0022-3514.44.6.1253; Rosenberg M., 1965, SOC ADOLESCENT SELF; TURNER RJ, 1990, J NERV MENT DIS, V178, P343, DOI 10.1097/00005053-199006000-00001; VALENTINE DP, 1993, SOC WORK HEALTH CARE, V19, P109, DOI 10.1300/J010v19n01_07; VARNI JW, 1991, ARCH PHYS MED REHAB, V72, P1053; West J, 1991, AM DISABILITIES ACT; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; *WORLD I DIS, 1988, REP NAT COUNC HAND M	27	106	107	2	52	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1996	275	13					1001	1006		10.1001/jama.275.13.1001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UC123	WOS:A1996UC12300027	8596231				2022-02-06	
J	REEVES, TM; LYETH, BG; POVLISHOCK, JT				REEVES, TM; LYETH, BG; POVLISHOCK, JT			LONG-TERM POTENTIATION DEFICITS AND EXCITABILITY CHANGES FOLLOWING TRAUMATIC BRAIN INJURY	EXPERIMENTAL BRAIN RESEARCH			English	Article						LONG-TERM POTENTIATION; TRAUMATIC BRAIN INJURY; EXCITABILITY; HIPPOCAMPUS; RAT	EXCITATORY AMINO-ACIDS; RAT HIPPOCAMPUS; MECHANISMS; RELEASE; RECEPTORS; NEURONS; MEMORY; MODEL	The effects of traumatic brain injury (TBI) on hippocampal long-term potentiation (LTP) and cellular excitability were assessed at postinjury days 2, 7, and 15. TBI was induced using a well-characterized central fluid-percussion model. LTP of the Schaffer collateral/commissural system was assessed in vivo in urethane-anesthetized rats. Significant LTP of the population excitatory postsynaptic potential (EPSP) slope was found only in controls, and no recovery to control levels was observed for any postinjury time point. Four measurement parameters reflecting pyramidal cell discharges (population spike) indicated that TBI significantly increased cellular excitability, at postinjury day 2: (1) pretetanus baseline recording showed that TBI reduced population spike threshold and latency; (2) tetanic stimulation (400 Hz) increased population spike amplitudes to a greater degree in injured animals than in control animals; (3) tetanus-induced population spike latency shifts were greater in injured cases; and (4) tetanic stimulation elevated EPSP to spike ratios (E-S potentiation) to a greater degree in injured animals. These parameters returned to control levels, as measured on postinjury days 7 and 15. These results suggest that TBI induced excitability changes persist at least through 2 days postinjury and involve a differential impairment of mechanisms subserving LTP of synaptic efficacy and mechanisms related to action potential generation	VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DIV NEUROSURG, RICHMOND, VA 23298 USA		REEVES, TM (corresponding author), VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT ANAT, BOX 709, RICHMOND, VA 23298 USA.			Lyeth, Bruce/0000-0003-4811-1474	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS029995, P50NS012587, P01NS012587, K17NS001750] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 01750, NS 29995, NS 12587] Funding Source: Medline		ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Burke R.E., 1977, HDB PHYSL          1, P877; CHAVEZNORIEGA LE, 1989, NEUROSCI LETT, V104, P58, DOI 10.1016/0304-3940(89)90329-7; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; DELAHUNTY TM, 1992, BRAIN RES, V594, P307, DOI 10.1016/0006-8993(92)91140-A; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; HARRIS EW, 1984, BRAIN RES, V323, P132, DOI 10.1016/0006-8993(84)90275-0; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; ILLES P, 1986, NEUROSCIENCE, V17, P909, DOI 10.1016/0306-4522(86)90071-0; JEFFERY KJ, 1993, HIPPOCAMPUS, V3, P133, DOI 10.1002/hipo.450030205; Jenkins LW, 1988, J NEUROTRAUM, V5, P275, DOI 10.1089/neu.1988.5.275; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; LIU SL, 1994, J NEUROTRAUM, V11, P73, DOI 10.1089/neu.1994.11.73; LYETH BG, 1993, BRAIN RES, V617, P69, DOI 10.1016/0006-8993(93)90614-S; LYETH BG, 1994, BRAIN RES, V640, P240, DOI 10.1016/0006-8993(94)91879-1; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; LYNCH G, 1991, Brain Research Reviews, V16, P204; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; Reeves T. M., 1994, Society for Neuroscience Abstracts, V20, P425; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; TAUBE JS, 1988, J NEUROSCI, V8, P1632; WILSON R C, 1981, Journal of Neurophysiology (Bethesda), V46, P339	30	106	108	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0014-4819	1432-1106		EXP BRAIN RES	Exp. Brain Res.	OCT	1995	106	2					248	256					9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	TB527	WOS:A1995TB52700008	8566189				2022-02-06	
J	TAKAHASHI, H; MANAKA, S; SANO, K				TAKAHASHI, H; MANAKA, S; SANO, K			CHANGES IN EXTRACELLULAR POTASSIUM CONCENTRATION IN CORTEX AND BRAIN-STEM DURING THE ACUTE PHASE OF EXPERIMENTAL CLOSED HEAD-INJURY	JOURNAL OF NEUROSURGERY			English	Article											TAKAHASHI, H (corresponding author), UNIV TOKYO HOSP,DEPT NEUROSURG,BUNKYO KU,TOKYO,JAPAN.						AOYAGI N, 1979, CLIN ELECTROENCEPHAL, V21, P482; ASTRUP J, 1980, BRAIN RES, V199, P161, DOI 10.1016/0006-8993(80)90238-3; BOURKE RS, 1979, NEURAL TRAUMA, P95; BURES J, 1958, J COMP PHYSIOL PSYCH, V51, P263, DOI 10.1037/h0048462; BURES J, 1975, EPILEPSIA, V16, P111, DOI 10.1111/j.1528-1157.1975.tb04727.x; BURESOVA O, 1979, PHYSIOL BOHEMOSLOV, V28, P243; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; DUDEL J, 1978, FUNDAMENTALS NEUROPH, P19; Eidelberg E, 1975, Surg Neurol, V3, P317; FOLTZ EL, 1953, J NEUROSURG, V10, P342, DOI 10.3171/jns.1953.10.4.0342; GURDJIAN ES, 1975, IMPACT HEAD INJURY, P139; Hashimoto I, 1979, Neurol Res, V1, P39; HUBSCHMANN OR, 1980, J NEUROSURG, V52, P456, DOI 10.3171/jns.1980.52.4.0456; HUBSCHMANN OR, 1980, J NEUROSURG, V53, P272; KIMELBERG HK, 1979, NEURAL TRAUMA, P137; Konig J. F. R., 1963, RAT BRAIN STEREOTAXI; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359, DOI 10.1152/jn.1944.7.6.359; LUX HD, 1976, ARCH PSYCHIAT NERVEN, V221, P227, DOI 10.1007/BF00418482; MANAKA S, 1977, J JPN ACCIDENT MED A, V28, P202; NILSSON B, 1977, J NEUROSURG, V47, P241, DOI 10.3171/jns.1977.47.2.0241; PORTNOY HD, 1980, J NEUROSURG, V53, P272; SEKINO H, 1980, Neurologia Medico-Chirurgica, V20, P127; SUGAYA E, 1975, J NEUROPHYSIOL, V38, P822, DOI 10.1152/jn.1975.38.4.822; WALKER EA, 1944, J NEUROSURG, V1, P103; WALKER JL, 1971, ANAL CHEM, V43, pA89, DOI 10.1021/ac60298a039	25	106	107	1	7	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.		1981	55	5					708	717		10.3171/jns.1981.55.5.0708			10	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	MN520	WOS:A1981MN52000006	7310492				2022-02-06	
J	Degterev, A; Ofengeim, D; Yuan, JY				Degterev, Alexei; Ofengeim, Dimitry; Yuan, Junying			Targeting RIPK1 for the treatment of human diseases	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						RIPK1; necroptosis; apoptosis; inflammation; neurodegeneration	TNF-INDUCED-NECROPTOSIS; TUMOR-NECROSIS-FACTOR; NEURONAL CELL-DEATH; PROGRAMMED NECROSIS; KINASE-ACTIVITY; INFLAMMATORY CASPASES; ISCHEMIA; ACTIVATION; MICROGLIA; CONTRIBUTES	RIPK1 kinase has emerged as a promising therapeutic target for the treatment of a wide range of human neurodegenerative, autoimmune, and inflammatory diseases. This was supported by extensive studies which demonstrated that RIPK1 is a key mediator of apoptotic and necrotic cell death as well as inflammatory pathways. Furthermore, human genetic evidence has linked the dysregulation of RIPK1 to the pathogenesis of ALS as well as other inflammatory and neurodegenerative diseases. Importantly, unique allosteric small-molecule inhibitors of RIPK1 that offer high selectivity have been developed. These molecules can penetrate the blood-brain barrier, thus offering the possibility to target neuroinflammation and cell death which drive various neurologic conditions including Alzheimer's disease, ALS, and multiple sclerosis as well as acute neurological diseases such as stroke and traumatic brain injuries. We discuss the current understanding of RIPK1 regulatory mechanisms and emerging evidence for the pathological roles of RIPK1 in human diseases, especially in the context of the central nervous systems.	[Degterev, Alexei] Tufts Univ, Sackler Sch Grad Biomed Sci, Dept Dev Mol & Chem Biol, Boston, MA 02445 USA; [Ofengeim, Dimitry] Sanofi US, Rare & Neurol Dis Res Therapeut Area, Framingham, MA 01701 USA; [Yuan, Junying] Harvard Med Sch, Dept Cell Biol, Boston, MA 02115 USA		Yuan, JY (corresponding author), Harvard Med Sch, Dept Cell Biol, Boston, MA 02115 USA.	junying_yuan@hms.harvard.edu		Yuan, Junying/0000-0003-2405-6036	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01AG047231, RF1AG055521, R21AG059073, 1R01CA190542, R21AI124049, 1R56AG058642]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA190542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R21AI124049] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R21AG059073, R01AG047231, R56AG058642] Funding Source: NIH RePORTER	Studies in the authors' laboratories are supported by NIH Grants 1R01AG047231, RF1AG055521, and R21AG059073 (to J.Y.); and 1R01CA190542, R21AI124049, and 1R56AG058642 (to A.D.).	Amin P, 2018, P NATL ACAD SCI USA, V115, pE5944, DOI 10.1073/pnas.1806973115; Annibaldi A, 2018, MOL CELL, V69, P566, DOI 10.1016/j.molcel.2018.01.027; Arnett HA, 2001, NAT NEUROSCI, V4, P1116, DOI 10.1038/nn738; Berger SB, 2014, J IMMUNOL, V192, P5476, DOI 10.4049/jimmunol.1400499; Caccamo A, 2017, NAT NEUROSCI, V20, P1236, DOI 10.1038/nn.4608; Callus BA, 2007, CELL DEATH DIFFER, V14, P73, DOI 10.1038/sj.cdd.4402034; Chandra J, 2000, FREE RADICAL BIO MED, V29, P323, DOI 10.1016/S0891-5849(00)00302-6; Chen YZ, 2018, NEUROSCIENCE, V371, P229, DOI 10.1016/j.neuroscience.2017.12.007; Chiu IM, 2009, P NATL ACAD SCI USA, V106, P20960, DOI 10.1073/pnas.0911405106; Christofferson DE, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.64; Christofferson DE, 2010, CURR OPIN CELL BIOL, V22, P263, DOI 10.1016/j.ceb.2009.12.003; Cirulli ET, 2015, SCIENCE, V347, P1436, DOI 10.1126/science.aaa3650; Collins JS, 2000, AM J MED GENET, V96, P823, DOI 10.1002/1096-8628(20001204)96:6<823::AID-AJMG26>3.0.CO;2-I; Cougnoux A, 2018, MOL GENET METAB, V125, P345, DOI 10.1016/j.ymgme.2018.10.009; Cuchet-Lourenco D, 2018, SCIENCE, V361, P810, DOI 10.1126/science.aar2641; Cullen V, 2011, ANN NEUROL, V69, P940, DOI 10.1002/ana.22400; Daniels BP, 2017, CELL, V169, P301, DOI 10.1016/j.cell.2017.03.011; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107; Degterev A, 2008, NAT CHEM BIOL, V4, P313, DOI 10.1038/nchembio.83; Dillon CP, 2014, CELL, V157, P1189, DOI 10.1016/j.cell.2014.04.018; Dondelinger Y, 2015, MOL CELL, V60, P63, DOI 10.1016/j.molcel.2015.07.032; Dondelinger Y, 2014, CELL REP, V7, P971, DOI 10.1016/j.celrep.2014.04.026; Duprez L, 2011, IMMUNITY, V35, P908, DOI 10.1016/j.immuni.2011.09.020; Dvoriantchikova G, 2014, EXP EYE RES, V123, P1, DOI 10.1016/j.exer.2014.04.009; Elliott PR, 2016, MOL CELL, V63, P990, DOI 10.1016/j.molcel.2016.08.001; Fan H, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024-016-0081-8; Fauster A, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.130; Frank D, 2019, CELL DEATH DIFFER, V26, P99, DOI 10.1038/s41418-018-0212-6; Freischmidt A, 2015, NAT NEUROSCI, V18, P631, DOI 10.1038/nn.4000; Garcia-Carbonell R, 2018, P NATL ACAD SCI USA, V115, pE9192, DOI 10.1073/pnas.1810584115; Geng JF, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00406-w; Gerlach B, 2011, NATURE, V471, P591, DOI 10.1038/nature09816; Gregory AP, 2012, NATURE, V488, P508, DOI 10.1038/nature11307; Harris PA, 2017, J MED CHEM, V60, P1247, DOI 10.1021/acs.jmedchem.6b01751; Hitomi JI, 2008, CELL, V135, P1311, DOI 10.1016/j.cell.2008.10.044; Hong JM, 2016, TOXICOL APPL PHARM, V308, P1, DOI 10.1016/j.taap.2016.08.010; Iannielli A, 2018, CELL REP, V22, P2066, DOI 10.1016/j.celrep.2018.01.089; Ito Y, 2016, SCIENCE, V353, P603, DOI 10.1126/science.aaf6803; Kaiser WJ, 2014, P NATL ACAD SCI USA, V111, P7753, DOI 10.1073/pnas.1401857111; Kaiser WJ, 2013, J BIOL CHEM, V288, P31268, DOI 10.1074/jbc.M113.462341; Kanayama A, 2004, MOL CELL, V15, P535, DOI 10.1016/j.molcel.2004.08.008; Kang SH, 2013, NAT NEUROSCI, V16, P571, DOI 10.1038/nn.3357; Kang TB, 2018, CELL DEATH DIFFER, V25, P1107, DOI 10.1038/s41418-018-0104-9; Kayagaki N, 2015, NATURE, V526, P666, DOI 10.1038/nature15541; Keren-Shaul H, 2017, CELL, V169, P1276, DOI 10.1016/j.cell.2017.05.018; Kim CR, 2017, CURR EYE RES, V42, P771, DOI 10.1080/02713683.2016.1227449; Kim SJ, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.238; Kupka S, 2016, CELL REP, V16, P2271, DOI 10.1016/j.celrep.2016.07.086; Lafont E, 2018, NAT CELL BIOL, V20, P1389, DOI 10.1038/s41556-018-0229-6; Li JX, 2012, CELL, V150, P339, DOI 10.1016/j.cell.2012.06.019; Li Y, 2019, P NATL ACAD SCI USA, V116, P970, DOI 10.1073/pnas.1813582116; Lin J, 2016, NATURE, V540, P124, DOI 10.1038/nature20558; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Liu SZ, 2017, P NATL ACAD SCI USA, V114, pE7450, DOI 10.1073/pnas.1707531114; Liu T, 2016, SCI REP-UK, V6, DOI 10.1038/srep24547; Liu YB, 2017, CELL DEATH DIFFER, V24, P1459, DOI 10.1038/cdd.2017.78; Lukens JR, 2013, NATURE, V498, P224, DOI 10.1038/nature12174; Ma JM, 2011, J NEUROSCI RES, V89, P639, DOI 10.1002/jnr.22567; Man SM, 2017, IMMUNOL REV, V277, P61, DOI 10.1111/imr.12534; Mandrekar-Colucci S, 2010, CNS NEUROL DISORD-DR, V9, P156, DOI 10.2174/187152710791012071; Martens S, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0245-7; McNamara CR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056576; Meng HY, 2018, P NATL ACAD SCI USA, V115, pE2001, DOI 10.1073/pnas.1722013115; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Moquin DM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076841; Najjar M, 2016, IMMUNITY, V45, P46, DOI 10.1016/j.immuni.2016.06.007; Najjar M, 2015, CELL REP, V10, P1850, DOI 10.1016/j.celrep.2015.02.052; Newton K, 2016, CELL DEATH DIFFER, V23, P1565, DOI 10.1038/cdd.2016.46; Newton K, 2016, MOL CELL; Ni Y, 2018, NEUROSCIENCE, V371, P60, DOI 10.1016/j.neuroscience.2017.10.038; Nicotera P, 1999, TRENDS PHARMACOL SCI, V20, P46, DOI 10.1016/S0165-6147(99)01304-8; Nuvolone M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171923; O'Donnell MA, 2011, NAT CELL BIOL, V13, P1437, DOI 10.1038/ncb2362; Oberst A, 2011, NATURE, V471, P363, DOI 10.1038/nature09852; Ofengeim D, 2017, P NATL ACAD SCI USA, V114, pE8788, DOI 10.1073/pnas.1714175114; Ofengeim D, 2015, CELL REP, V10, P1836, DOI 10.1016/j.celrep.2015.02.051; Ofengeim D, 2013, NAT REV MOL CELL BIO, V14, P727, DOI 10.1038/nrm3683; Orning P, 2018, SCIENCE, V362, P1064, DOI 10.1126/science.aau2818; Papassotiropoulos A, 2005, NEURODEGENER DIS, V2, P233, DOI 10.1159/000090362; Pegoretti V, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00925; Peltzer N, 2016, TRENDS CELL BIOL, V26, P445, DOI 10.1016/j.tcb.2016.01.006; Petrie EJ, 2019, TRENDS BIOCHEM SCI, V44, P53, DOI 10.1016/j.tibs.2018.11.002; Platt N, 1998, TRENDS CELL BIOL, V8, P365, DOI 10.1016/S0962-8924(98)01329-4; Polykratis A, 2014, J IMMUNOL, V193, P1539, DOI 10.4049/jimmunol.1400590; Rehker J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185777; Rickard JA, 2014, CELL, V157, P1175, DOI 10.1016/j.cell.2014.04.019; Rosenbaum DM, 2010, J NEUROSCI RES, V88, P1569, DOI 10.1002/jnr.22314; Roskoski R, 2016, PHARMACOL RES, V103, P26, DOI 10.1016/j.phrs.2015.10.021; Safaiyan S, 2016, NAT NEUROSCI, V19, P995, DOI 10.1038/nn.4325; Said-Sadier Najwane, 2012, Biomed J, V35, P437, DOI 10.4103/2319-4170.104408; Saleh D, 2017, J IMMUNOL, V198, P4435, DOI 10.4049/jimmunol.1601717; Sarhan J, 2018, P NATL ACAD SCI USA, V115, pE10888, DOI 10.1073/pnas.1809548115; Sarlus H, 2017, J CLIN INVEST, V127, P3240, DOI 10.1172/JCI90606; SELMAJ KW, 1988, ANN NEUROL, V23, P339, DOI 10.1002/ana.410230405; Shi JJ, 2017, TRENDS BIOCHEM SCI, V42, P245, DOI 10.1016/j.tibs.2016.10.004; Shi JJ, 2015, NATURE, V526, P660, DOI 10.1038/nature15514; Shi ZW, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00721; Shutinoski B, 2016, CELL DEATH DIFFER, V23, P1628, DOI 10.1038/cdd.2016.51; Smith CCT, 2007, CARDIOVASC DRUG THER, V21, P227, DOI 10.1007/s10557-007-6035-1; Streit WJ, 2018, GLIA, V66, P2550, DOI 10.1002/glia.23510; Sun LM, 2012, CELL, V148, P213, DOI 10.1016/j.cell.2011.11.031; Taraborrelli L, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06155-8; Upton JW, 2012, CELL HOST MICROBE, V11, P290, DOI [10.1016/j.chom.2012.01.016, 10.1016/j.chom.2019.09.004]; Vitner EB, 2014, NAT MED, V20, P204, DOI 10.1038/nm.3449; von Massenhausen A, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0394-3; Wallach D, 2016, SCIENCE, V352, DOI 10.1126/science.aaf2154; Walsh DM, 2004, NEURON, V44, P181, DOI 10.1016/j.neuron.2004.09.010; Wang HB, 2017, P NATL ACAD SCI USA, V114, P11944, DOI 10.1073/pnas.1715742114; Wang W, 2018, CANCER CELL, V34, P757, DOI 10.1016/j.ccell.2018.10.006; Weisel K, 2017, PHARMACOL RES PERSPE, V5, DOI 10.1002/prp2.365; Xie T, 2013, STRUCTURE, V21, P493, DOI 10.1016/j.str.2013.01.016; Yoshikawa M, 2018, J MED CHEM, V61, P2384, DOI 10.1021/acs.jmedchem.7b01647; You ZR, 2008, J CEREBR BLOOD F MET, V28, P1564, DOI 10.1038/jcbfm.2008.44; Yuan JY, 2019, NAT REV NEUROSCI, V20, P19, DOI 10.1038/s41583-018-0093-1; Zhang Shehong, 2016, Medicines (Basel), V3, DOI 10.3390/medicines3030016; Zheng TS, 2000, EXP CELL RES, V256, P67, DOI 10.1006/excr.2000.4841; Zhou W, 2014, SEMIN CELL DEV BIOL, V35, P14, DOI 10.1016/j.semcdb.2014.07.013; Zhu KZ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0524-y; 2018, CELL, V174, P1477, DOI DOI 10.1016/J.CELL.2018.07.041; 2018, NAT CELL BIOL, V20, P58, DOI DOI 10.1038/S41556-017-0003-1; 2017, MOL CELL, V66, P698, DOI DOI 10.1016/J.MOLCEL.2017.05.003; 2016, J MED CHEM, V59, P2163, DOI DOI 10.1021/ACS.JMEDCHEM.5B01898	123	105	105	7	22	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	MAY 14	2019	116	20					9714	9722		10.1073/pnas.1901179116			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY0LS	WOS:000467804000010	31048504	Green Published, hybrid			2022-02-06	
J	Ling, HL; Morris, HR; Neal, JW; Lees, AJ; Hardy, J; Holton, JL; Revesz, T; Williams, DDR				Ling, Helen; Morris, Huw R.; Neal, James W.; Lees, Andrew J.; Hardy, John; Holton, Janice L.; Revesz, Tamas; Williams, David D. R.			Mixed pathologies including chronic traumatic encephalopathy account for dementia in retired association football (soccer) players	ACTA NEUROPATHOLOGICA			English	Article						Chronic traumatic encephalopathy; Soccer; Football; Heading; Traumatic brain injury; Concussion; Tauopathy	ALZHEIMERS-DISEASE; NEUROPATHOLOGIC ASSESSMENT; NATIONAL INSTITUTE; BRAIN; CONCUSSION; INJURIES; AGE; CONSORTIUM; GUIDELINES; DEPOSITION	In retired professional association football (soccer) players with a past history of repetitive head impacts, chronic traumatic encephalopathy (CTE) is a potential neurodegenerative cause of dementia and motor impairments. From 1980 to 2010, 14 retired footballers with dementia were followed up regularly until death. Their clinical data, playing career, and concussion history were prospectively collected. Next-of-kin provided consent for six to have post-mortem brain examination. Of the 14 male participants, 13 were professional and 1 was a committed amateur. All were skilled headers of the ball and had played football for an average of 26 years. Concussion rate was limited in six cases to one episode each during their careers. All cases developed progressive cognitive impairment with an average age at onset of 63.6 years and disease duration of 10 years. Neuropathological examination revealed septal abnormalities in all six post-mortem cases, supportive of a history of chronic repetitive head impacts. Four cases had pathologically confirmed CTE; concomitant pathologies included Alzheimer's disease (N = 6), TDP-43 (N = 6), cerebral amyloid angiopathy (N = 5), hippocampal sclerosis (N = 2), corticobasal degeneration (N = 1), dementia with Lewy bodies (N = 1), and vascular pathology (N = 1); and all would have contributed synergistically to the clinical manifestations. The pathological diagnosis of CTE was established in four individuals according to the latest consensus diagnostic criteria. This finding is probably related to their past prolonged exposure to repetitive head impacts from head-to-player collisions and heading the ball thousands of time throughout their careers. Alzheimer's disease and TDP-43 pathologies are common concomitant findings in CTE, both of which are increasingly considered as part of the CTE pathological entity in older individuals. Association football is the most popular sport in the world and the potential link between repetitive head impacts from playing football and CTE as indicated from our findings is of considerable public health interest. Clearly, a definitive link cannot be established in this clinico-pathological series, but our findings support the need for further systematic investigation, including large-scale case-control studies to identify at risk groups of footballers which will justify for the implementation of protective strategies.	[Ling, Helen; Lees, Andrew J.; Hardy, John; Holton, Janice L.; Revesz, Tamas] UCL, UCL Inst Neurol, Queen Sq Brain Bank Neurol Disorders, London, England; [Ling, Helen; Lees, Andrew J.; Hardy, John; Holton, Janice L.; Revesz, Tamas] UCL Inst Neurol, Reta Lila Weston Inst Neurol Studies, 1 Wakefield St, London WC1N 1PJ, England; [Ling, Helen; Hardy, John; Holton, Janice L.; Revesz, Tamas] UCL, UCL Inst Neurol, Dept Mol Neurosci, London, England; [Morris, Huw R.] UCL Inst Neurol, Dept Clin Neurosci, London, England; [Neal, James W.] Cardiff Univ, Dept Cellular Pathol, Cardiff, S Glam, Wales; [Williams, David D. R.] Cefn Coed Hosp, Swansea, W Glam, Wales		Holton, JL; Revesz, T (corresponding author), UCL, UCL Inst Neurol, Queen Sq Brain Bank Neurol Disorders, London, England.; Holton, JL; Revesz, T (corresponding author), UCL Inst Neurol, Reta Lila Weston Inst Neurol Studies, 1 Wakefield St, London WC1N 1PJ, England.; Holton, JL; Revesz, T (corresponding author), UCL, UCL Inst Neurol, Dept Mol Neurosci, London, England.	janice.holton@ucl.ac.uk; t.revesz@ucl.ac.uk	Hardy, John/C-2451-2009; Morris, Huw/B-8527-2008	Hardy, John/0000-0002-3122-0423; Morris, Huw/0000-0002-5473-3774	Drake FoundationSmithsonian InstitutionSmithsonian National Museum of Natural History; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [MR/J004758/1, G0901254, G0701075, MR/K01417X/1, G1001253] Funding Source: UKRI	The Drake Foundation.	Amador-Ortiz C, 2007, ANN NEUROL, V61, P435, DOI 10.1002/ana.21154; Babbs C F, 2001, ScientificWorldJournal, V1, P281; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Bieniek KF, 2015, ACTA NEUROPATHOL, V130, P877, DOI 10.1007/s00401-015-1502-4; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Chio A, 2009, AMYOTROPH LATERAL SC, V10, P205, DOI 10.1080/17482960902721634; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Crary JF, 2014, ACTA NEUROPATHOL, V128, P755, DOI 10.1007/s00401-014-1349-0; Dickson DW, 2002, J NEUROPATH EXP NEUR, V61, P935, DOI 10.1093/jnen/61.11.935; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Grinberg LT, 2016, J ALZHEIMERS DIS, V54, P169, DOI 10.3233/JAD-160312; Hales C, 2014, NEUROLOGY, V83, P2307, DOI 10.1212/WNL.0000000000001081; HOF PR, 1992, ACTA NEUROPATHOL, V85, P23, DOI 10.1007/BF00304630; Hyman BT, 2012, ALZHEIMERS DEMENT, V8, P1, DOI 10.1016/j.jalz.2011.10.007; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Josephs KA, 2016, ACTA NEUROPATHOL, V131, P571, DOI 10.1007/s00401-016-1537-1; Kirkendall DT, 2001, SPORTS MED, V31, P369, DOI 10.2165/00007256-200131050-00006; Koerte IK, 2015, J NEUROTRAUM, V32, P1287, DOI 10.1089/neu.2014.3715; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Kovacs GG, 2008, DEMENT GERIATR COGN, V26, P343, DOI 10.1159/000161560; Kovacs GG, 2016, ACTA NEUROPATHOL, V131, P87, DOI 10.1007/s00401-015-1509-x; Ling HL, 2015, ACTA NEUROPATHOL, V130, P891, DOI 10.1007/s00401-015-1496-y; Ling H, 2015, MOL CELL NEUROSCI, V66, P114, DOI 10.1016/j.mcn.2015.03.012; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Mackenzie IRA, 2011, ACTA NEUROPATHOL, V122, P111, DOI 10.1007/s00401-011-0845-8; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; McCrory P, 2002, BRIT J SPORT MED, V36, P157, DOI 10.1136/bjsm.36.3.157; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKeith IG, 2005, NEUROLOGY, V65, P1863, DOI 10.1212/01.wnl.0000187889.17253.b1; Montine TJ, 2012, ACTA NEUROPATHOL, V123, P1, DOI 10.1007/s00401-011-0910-3; Saito Y, 2004, J NEUROPATH EXP NEUR, V63, P911, DOI 10.1093/jnen/63.9.911; Spiotta AM, 2012, NEUROSURGERY, V70, P1, DOI 10.1227/NEU.0b013e31823021b2; Stamm JM, 2015, NEUROLOGY, V84, P1114, DOI 10.1212/WNL.0000000000001358; Stein TD, 2015, CURR PAIN HEADACHE R, V19, DOI 10.1007/s11916-015-0522-z; Stein TD, 2015, ACTA NEUROPATHOL, V130, P21, DOI 10.1007/s00401-015-1435-y; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Thal DR, 2002, NEUROLOGY, V58, P1791, DOI 10.1212/WNL.58.12.1791; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; Zhang MR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057364	43	105	107	6	41	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	MAR	2017	133	3					337	352		10.1007/s00401-017-1680-3			16	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	EL9ST	WOS:000394961100001	28205009	Green Published, hybrid, Green Submitted			2022-02-06	
J	Wang, W; Nguyen, LTT; Burlak, C; Chegini, F; Guo, F; Chataway, T; Ju, SL; Fisher, OS; Miller, DW; Datta, D; Wu, F; Wu, CX; Landeru, A; Wells, JA; Cookson, MR; Boxer, MB; Thomas, CJ; Gai, WP; Ringe, D; Petsko, GA; Hoang, QQ				Wang, Wei; Nguyen, Linh T. T.; Burlak, Christopher; Chegini, Fariba; Guo, Feng; Chataway, Tim; Ju, Shulin; Fisher, Oriana S.; Miller, David W.; Datta, Debajyoti; Wu, Fang; Wu, Chun-Xiang; Landeru, Anuradha; Wells, James A.; Cookson, Mark R.; Boxer, Matthew B.; Thomas, Craig J.; Gai, Wei Ping; Ringe, Dagmar; Petsko, Gregory A.; Hoang, Quyen Q.			Caspase-1 causes truncation and aggregation of the Parkinson's disease-associated protein alpha-synuclein	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						synuclein; Parkinson's disease; caspase; inflammasome; aggregation	TRAUMATIC BRAIN-INJURY; GROWTH-FACTOR-ALPHA; CEREBROSPINAL-FLUID; MOUSE MODEL; IN-VIVO; NEURODEGENERATION; INTERLEUKIN-1-BETA; NEUROINFLAMMATION; INFLAMMATION; PATHOGENESIS	The aggregation of alpha-synuclein (aSyn) leading to the formation of Lewy bodies is the defining pathological hallmark of Parkinson's disease (PD). Rare familial PD-associated mutations in aSyn render it aggregation-prone; however, PD patients carrying wild type (WT) aSyn also have aggregated aSyn in Lewy bodies. The mechanisms by which WT aSyn aggregates are unclear. Here, we report that inflammation can play a role in causing the aggregation of WT aSyn. We show that activation of the inflammasome with known stimuli results in the aggregation of aSyn in a neuronal cell model of PD. The insoluble aggregates are enriched with truncated aSyn as found in Lewy bodies of the PD brain. Inhibition of the inflammasome enzyme caspase-1 by chemical inhibition or genetic knockdown with shRNA abated aSyn truncation. In vitro characterization confirmed that caspase-1 directly cleaves aSyn, generating a highly aggregation-prone species. The truncation-induced aggregation of aSyn is toxic to neuronal culture, and inhibition of caspase-1 by shRNA or a specific chemical inhibitor improved the survival of a neuronal PD cell model. This study provides a molecular link for the role of inflammation in aSyn aggregation, and perhaps in the pathogenesis of sporadic PD as well.	[Wang, Wei; Nguyen, Linh T. T.; Wu, Chun-Xiang; Landeru, Anuradha; Hoang, Quyen Q.] Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; [Wang, Wei; Nguyen, Linh T. T.; Wu, Chun-Xiang; Landeru, Anuradha; Hoang, Quyen Q.] Indiana Univ Sch Med, Stark Neurosci Res Inst, Indianapolis, IN 46202 USA; [Burlak, Christopher] Univ Minnesota, Dept Surg, Schulze Diabet Inst, Box 242 UMHC, Minneapolis, MN 55455 USA; [Chegini, Fariba; Guo, Feng; Chataway, Tim; Gai, Wei Ping] Flinders Univ S Australia, Dept Human Physiol, Ctr Neurosci, Adelaide, SA 5001, Australia; [Ju, Shulin; Fisher, Oriana S.; Wu, Fang; Ringe, Dagmar; Petsko, Gregory A.] Brandeis Univ, Dept Chem, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02454 USA; [Ju, Shulin; Fisher, Oriana S.; Wu, Fang; Ringe, Dagmar; Petsko, Gregory A.] Brandeis Univ, Dept Biochem, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02454 USA; [Miller, David W.; Cookson, Mark R.] NIH, Neurogenet Lab, Bldg 10, Bethesda, MD 20892 USA; [Datta, Debajyoti; Wells, James A.] Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; [Wells, James A.] Univ Calif San Francisco, Dept Cellular & Mol Physiol, San Francisco, CA 94143 USA; [Boxer, Matthew B.; Thomas, Craig J.] NIH, Natl Ctr Adv Translat Sci, Chem Genom Ctr, Bldg 10, Bethesda, MD 20892 USA; [Ringe, Dagmar; Petsko, Gregory A.] Harvard Med Sch, Dept Neurol, Cambridge, MA 02139 USA; [Ringe, Dagmar; Petsko, Gregory A.] Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02116 USA; [Hoang, Quyen Q.] Indiana Univ Sch Med, Dept Neurol, Indianapolis, IN 46202 USA; [Ju, Shulin] Wright State Univ, Dept Biol Sci, Dayton, OH 45435 USA; [Fisher, Oriana S.] Northwestern Univ, Dept Mol Biosci, Evanston, IL 60208 USA; [Wu, Fang; Petsko, Gregory A.] Univ Calif Berkeley, Dept Mol & Cell Biol, Calif Inst Quantitat Biol, 229 Stanley Hall, Berkeley, CA 94720 USA; [Petsko, Gregory A.; Hoang, Quyen Q.] Weill Cornell Med Coll, Dept Neurol & Neurosci, New York, NY 10065 USA		Hoang, QQ (corresponding author), Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.; Hoang, QQ (corresponding author), Indiana Univ Sch Med, Stark Neurosci Res Inst, Indianapolis, IN 46202 USA.; Petsko, GA (corresponding author), Brandeis Univ, Dept Chem, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02454 USA.; Petsko, GA (corresponding author), Brandeis Univ, Dept Biochem, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02454 USA.; Petsko, GA (corresponding author), Harvard Med Sch, Dept Neurol, Cambridge, MA 02139 USA.; Petsko, GA (corresponding author), Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02116 USA.; Hoang, QQ (corresponding author), Indiana Univ Sch Med, Dept Neurol, Indianapolis, IN 46202 USA.; Petsko, GA (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Calif Inst Quantitat Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.; Petsko, GA; Hoang, QQ (corresponding author), Weill Cornell Med Coll, Dept Neurol & Neurosci, New York, NY 10065 USA.	gpetsko@med.cornell.edu; qqhoang@iu.edu	Petsko, Gregory/AAO-7962-2020; Wells, Jim A/O-9854-2016; Cookson, Mark/AAW-2516-2021	Cookson, Mark/0000-0002-1058-3831; Fisher, Oriana/0000-0003-3215-0831; Chataway, Tim/0000-0003-0254-8099; Thomas, Craig/0000-0001-9386-9001	Community Fast Track grant from Michael J. Fox Foundation; National Institutes of Health GrantsUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R21NS079881-01, 5R01GM111639]; Indiana University School of Medicine Biomedical Research Grant; Indiana University-Purdue University Indianapolis Research Support Funds Grant; Fidelity Biosciences Research Initiative; Ellison Medical FoundationLawrence Ellison Foundation; McKnight Endowment for Neuroscience; Molecular Libraries Initiative of the National Institutes of Health Roadmap for Medical ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Intramural Research Program of the National Human Genome Research Institute, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI); Intramural Research Program of the National Institute on Aging, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM111639, R01GM115844] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS079881] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [ZIAAG000939] Funding Source: NIH RePORTER	We thank S. Lindquist for the yeast expression vectors of aSyn, and Z. Y. Z. Zhang and L. Chen for their generous support and access to the Chemical Genomics Core Facility at Indiana University. Q.Q.H., D.R., and G.A.P. were supported through a Community Fast Track grant from the Michael J. Fox Foundation. Q.Q.H. was also supported by National Institutes of Health Grants 1R21NS079881-01 and 5R01GM111639, an Indiana University School of Medicine Biomedical Research Grant, and an Indiana University-Purdue University Indianapolis Research Support Funds Grant. D.R. and G.A.P. also acknowledge support from the Fidelity Biosciences Research Initiative (with much useful discussion from Dr. S. Weninger) and early support from the Ellison Medical Foundation and the McKnight Endowment for Neuroscience. M.B.B. and C.J.T. acknowledge support from the Molecular Libraries Initiative of the National Institutes of Health Roadmap for Medical Research and the Intramural Research Program of the National Human Genome Research Institute, National Institutes of Health. This research was supported in part by the Intramural Research Program of the National Institute on Aging, National Institutes of Health.	Arai H, 2006, HISTOL HISTOPATHOL, V21, P673, DOI 10.14670/HH-21.673; Bartels AL, 2007, MOVEMENT DISORD, V22, P1852, DOI 10.1002/mds.21552; Bassil F, 2016, P NATL ACAD SCI USA, V113, P9593, DOI 10.1073/pnas.1609291113; Ben-Shlomo Y, 1997, BAILLIERE CLIN NEUR, V6, P55; BlumDegen D, 1995, NEUROSCI LETT, V202, P17, DOI 10.1016/0304-3940(95)12192-7; Boxer MB, 2010, CHEMMEDCHEM, V5, P730, DOI 10.1002/cmdc.200900531; Cullen V, 2011, ANN NEUROL, V69, P940, DOI 10.1002/ana.22400; Dinarello CA, 2006, AM J CLIN NUTR, V83, p447S; Du YS, 2001, P NATL ACAD SCI USA, V98, P14669, DOI 10.1073/pnas.251341998; Furuya T, 2004, J NEUROSCI, V24, P1865, DOI 10.1523/JNEUROSCI.3309-03.2004; Gao HM, 2011, ENVIRON HEALTH PERSP, V119, P807, DOI 10.1289/ehp.1003013; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Harris MA, 2012, MOVEMENT DISORD, V27, P1111, DOI 10.1002/mds.25077; Henry J, 2010, PARKINSONISM RELAT D, V16, P566, DOI 10.1016/j.parkreldis.2010.06.012; Iwata A, 2003, HUM MOL GENET, V12, P2625, DOI 10.1093/hmg/ddg283; Jang HM, 2009, P NATL ACAD SCI USA, V106, P14063, DOI 10.1073/pnas.0900096106; Klevenyi P, 1999, NEUROREPORT, V10, P635, DOI 10.1097/00001756-199902250-00035; Knoblach SM, 2002, J NEUROTRAUM, V19, P1155, DOI 10.1089/08977150260337967; Lang AE, 1998, NEW ENGL J MED, V339, P1130, DOI 10.1056/NEJM199810153391607; Lewis KA, 2010, AM J PATHOL, V177, P3037, DOI 10.2353/ajpath.2010.100552; Lewis KA, 2010, J BIOENERG BIOMEMBR, V42, P85, DOI 10.1007/s10863-009-9258-y; Li WX, 2005, P NATL ACAD SCI USA, V102, P2162, DOI 10.1073/pnas.0406976102; Ling ZD, 2002, MOVEMENT DISORD, V17, P116, DOI 10.1002/mds.10078; Liu B, 2003, ENVIRON HEALTH PERSP, V111, P1065, DOI 10.1289/ehp.6361; Liu CW, 2005, J BIOL CHEM, V280, P22670, DOI 10.1074/jbc.M501508200; MAURIZI CP, 1985, MED HYPOTHESES, V16, P1, DOI 10.1016/0306-9877(85)90034-9; McGeer PL, 2004, PARKINSONISM RELAT D, V10, pS3, DOI 10.1016/j.parkreldis.2004.01.005; MCGEER PL, 1988, ACTA NEUROPATHOL, V76, P550, DOI 10.1007/BF00689592; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Michell AW, 2007, CELL TRANSPLANT, V16, P461, DOI 10.3727/000000007783464911; Mishizen-Eberz AJ, 2003, J NEUROCHEM, V86, P836, DOI 10.1046/j.1471-4159.2003.01878.x; Mogi M, 1996, NEUROSCI LETT, V211, P13, DOI 10.1016/0304-3940(96)12706-3; MOGI M, 1994, NEUROSCI LETT, V180, P147, DOI 10.1016/0304-3940(94)90508-8; MOGI M, 1994, NEUROSCI LETT, V165, P208, DOI 10.1016/0304-3940(94)90746-3; Oh M, 2014, P NATL ACAD SCI USA, V111, P11007, DOI 10.1073/pnas.1320556111; Oueslati A, 2010, PROG BRAIN RES, V183, P115, DOI 10.1016/S0079-6123(10)83007-9; Outeiro TF, 2003, SCIENCE, V302, P1772, DOI 10.1126/science.1090439; Periquet M, 2007, J NEUROSCI, V27, P3338, DOI 10.1523/JNEUROSCI.0285-07.2007; Prasad K, 2012, BRAIN PATHOL, V22, P811, DOI 10.1111/j.1750-3639.2012.00597.x; RAIL D, 1981, J NEUROL NEUROSUR PS, V44, P670, DOI 10.1136/jnnp.44.8.670; Scheer JM, 2005, PROTEIN EXPRES PURIF, V41, P148, DOI 10.1016/j.pep.2005.01.008; Schwartz M, 2006, J NEUROIMMUNE PHARM, V1, P4, DOI 10.1007/s11481-005-9010-2; Sevlever D, 2008, BIOCHEMISTRY-US, V47, P9678, DOI 10.1021/bi800699v; Sung JY, 2005, J BIOL CHEM, V280, P25216, DOI 10.1074/jbc.M503341200; Tanner CM, 2011, ENVIRON HEALTH PERSP, V119, P866, DOI 10.1289/ehp.1002839; Ulusoy A, 2010, EUR J NEUROSCI, V32, P409, DOI 10.1111/j.1460-9568.2010.07284.x; Vanaja SK, 2015, TRENDS CELL BIOL, V25, P308, DOI 10.1016/j.tcb.2014.12.009; Villoslada P, 2008, CLIN IMMUNOL, V128, P294, DOI 10.1016/j.clim.2008.04.003; Wakamatsu M, 2008, NEUROBIOL AGING, V29, P574, DOI 10.1016/j.neurobiolaging.2006.11.017; Wang W, 2011, P NATL ACAD SCI USA, V108, P17797, DOI 10.1073/pnas.1113260108	50	105	111	4	27	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	AUG 23	2016	113	34					9587	9592		10.1073/pnas.1610099113			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DT9ZK	WOS:000381860800060	27482083	Green Published, Bronze, Green Submitted			2022-02-06	
J	Giralt, J; Trigo, J; Nuyts, S; Ozsahin, M; Skladowski, K; Hatoum, G; Daisne, JF; Ancona, ACY; Cmelak, A; Mesia, R; Zhang, A; Oliner, KS; VanderWalde, A				Giralt, Jordi; Trigo, Jose; Nuyts, Sandra; Ozsahin, Mahmut; Skladowski, Krzysztof; Hatoum, Georges; Daisne, Jean-Francois; Yunes Ancona, Alejandro Cesar; Cmelak, Anthony; Mesia, Ricard; Zhang, Alicia; Oliner, Kelly S.; VanderWalde, Ari			Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial	LANCET ONCOLOGY			English	Article							CHEMOTHERAPY; CANCER; RADIATION; CISPLATIN; CETUXIMAB	Background We aimed to compare panitumumab, a fully human monoclonal antibody against EGFR, plus radiotherapy with chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck. Methods In this international, open-label, randomised, controlled, phase 2 trial, we recruited patients with locally advanced squamous-cell carcinoma of the head and neck from 22 sites in eight countries worldwide. Patients aged 18 years and older with stage III, IVa, or IVb, previously untreated, measurable (>= 10 mm for at least one dimension), locally advanced squamous-cell carcinoma of the head and neck (non-nasopharygeal) and an Eastern Cooperative Oncology Group performance status of 0-1 were randomly assigned (2: 3) by an independent vendor to open-label chemoradiotherapy (two cycles of cisplatin 100 mg/m 2 during radiotherapy) or to radiotherapy plus panitumumab (three cycles of panitumumab 9 mg/kg every 3 weeks administered with radiotherapy) using a stratified randomisation with a block size of five. All patients received 70-72 Gy to gross tumour and 54 Gy to areas of subclinical disease with accelerated fractionation radiotherapy. The primary endpoint was local-regional control at 2 years, analysed in all randomly assigned patients who received at least one dose of their assigned protocol-specific treatment (chemotherapy, radiation, or panitumumab). The trial is closed and this is the final analysis. This study is registered with ClinicalTrials.gov, number NCT00547157. Findings Between Nov 30, 2007, and Nov 16, 2009, 152 patients were enrolled, and 151 received treatment (61 in the chemoradiotherapy group and 90 in the radiotherapy plus panitumumab group). Local-regional control at 2 years was 61% (95% CI 47-72) in the chemoradiotherapy group and 51% (40-62) in the radiotherapy plus panitumumab group. The most frequent grade 3-4 adverse events were mucosal inflammation (25 [40%] of 62 patients in the chemoradiotherapy group vs 37 [42%] of 89 patients in the radiotherapy plus panitumumab group), dysphagia (20 [32%] vs 36 [40%]), and radiation skin injury (seven [11%] vs 21 [24%]). Serious adverse events were reported in 25 (40%) of 62 patients in the chemoradiotherapy group and in 30 (34%) of 89 patients in the radiotherapy plus panitumumab group. Interpretation Panitumumab cannot replace cisplatin in the combined treatment with radiotherapy for unresected stage III-IVb squamous-cell carcinoma of the head and neck, and the role of EGFR inhibition in locally advanced squamous-cell carcinoma of the head and neck needs to be reassessed.	[Giralt, Jordi] Hosp Valle De Hebron, Barcelona, Spain; [Giralt, Jordi] Univ Autonoma Barcelona, Bellaterra, Spain; [Trigo, Jose] Hosp Virgen de la Victoria, Malaga, Spain; [Nuyts, Sandra] Univ Hosp Gasthuisberg, Leuven, Belgium; [Ozsahin, Mahmut] CHU Vaudois, CH-1011 Lausanne, Switzerland; [Skladowski, Krzysztof] Inst M Sklodowskiej Curie, Ctr Onkol, Gliwice, Poland; [Hatoum, Georges] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA; [Daisne, Jean-Francois] Clin St Elizabeth, Namur, Belgium; [Yunes Ancona, Alejandro Cesar] Unidad Oncol Serv Salud Estado Puebla, Puebla, Mexico; [Cmelak, Anthony] Vanderbilt Univ, Med Ctr, Nashville, TN USA; [Mesia, Ricard] Inst Catala Oncol ICO Hosp, Barcelona, Spain; [Zhang, Alicia; Oliner, Kelly S.; VanderWalde, Ari] Amgen Inc, Thousand Oaks, CA USA		Giralt, J (corresponding author), Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Dept Radiat Oncol, P Vall dHebron 119-129, Barcelona 08035, Spain.	jgiralt@vhebron.net	de Sagredo, Jordi Giralt Lopez/J-1873-2018; nuyts, sandra/U-8254-2019	de Sagredo, Jordi Giralt Lopez/0000-0002-1840-5159; nuyts, sandra/0000-0002-5540-4796; Daisne, Jean-Francois/0000-0001-8584-4189; Skladowski, Krzysztof/0000-0002-0554-6171	AmgenAmgen	This study was funded by Amgen. We thank the study staff, and the patients and their families, for their contributions to this study. We also thank Jennifer Gansert (Amgen) for her contributions to the study design and protocol development, and to James Ziobro for assistance with the writing of this manuscript (funded by Amgen).	Adelstein DJ, 2003, J CLIN ONCOL, V21, P92, DOI 10.1200/JCO.2003.01.008; Ang KK, 2010, NEW ENGL J MED, V363, P24, DOI 10.1056/NEJMoa0912217; Ang KK, 2011, P AM SOC CLIN ONCO S, V29, P5500; Bonner JA, 2006, NEW ENGL J MED, V354, P567, DOI 10.1056/NEJMoa053422; Bonner JA, 2010, LANCET ONCOL, V11, P21, DOI 10.1016/S1470-2045(09)70311-0; Bourhis J, 2012, LANCET ONCOL, V13, P145, DOI 10.1016/S1470-2045(11)70346-1; BRITTAIN E, 1982, BIOMETRICS, V38, P1003, DOI 10.2307/2529880; Gregoire V, 2010, ANN ONCOL, V21, pv184, DOI 10.1093/annonc/mdq185; Kruser TJ, 2008, INT J RADIAT ONCOL, V72, P534, DOI 10.1016/j.ijrobp.2008.06.1490; Lefebvre JL, 2013, J CLIN ONCOL, V31, P853, DOI 10.1200/JCO.2012.42.3988; Mesia R, 2015, LANCET ONCOL; Pignon JP, 2009, RADIOTHER ONCOL, V92, P4, DOI 10.1016/j.radonc.2009.04.014; Pignon JP, 2000, LANCET, V355, P949, DOI 10.1016/S0140-6736(00)90011-4; Rischin D, 2010, J CLIN ONCOL, V28, P2989, DOI 10.1200/JCO.2009.27.4449; Vermorken JB, 2008, NEW ENGL J MED, V359, P1116, DOI 10.1056/NEJMoa0802656; Vermorken JB, 2013, LANCET ONCOL, V14, P697, DOI 10.1016/S1470-2045(13)70181-5; Yang BB, 2010, CLIN PHARMACOKINET, V49, P729, DOI 10.2165/11535970-000000000-00000	17	105	108	0	13	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1470-2045	1474-5488		LANCET ONCOL	Lancet Oncol.	FEB	2015	16	2					221	232		10.1016/S1470-2045(14)71200-8			12	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	CA3YR	WOS:000348841700038	25596659				2022-02-06	
J	Lingsma, HF; Yue, JK; Maas, AIR; Steyerberg, EW; Manley, GT; Cooper, SR; Dams-O'Connor, K; Gordon, WA; Menon, DK; Mukherjee, P; Okonkwo, DO; Puccio, AM; Schnyer, DM; Valadka, AB; Vassar, MJ; Yuh, EL				Lingsma, Hester F.; Yue, John K.; Maas, Andrew I. R.; Steyerberg, Ewout W.; Manley, Geoffrey T.; Cooper, Shelly R.; Dams-O'Connor, Kristen; Gordon, Wayne A.; Menon, David K.; Mukherjee, Pratik; Okonkwo, David O.; Puccio, Ava M.; Schnyer, David M.; Valadka, Alex B.; Vassar, Mary J.; Yuh, Esther L.		TRACK-TBI Investigators	Outcome Prediction after Mild and Complicated Mild Traumatic Brain Injury: External Validation of Existing Models and Identification of New Predictors Using the TRACK-TBI Pilot Study	JOURNAL OF NEUROTRAUMA			English	Article						TBI; prognostic models; validation; GOS-E	COMMON DATA ELEMENTS; HEAD-INJURY; TRANSFORMING RESEARCH; CLINICAL KNOWLEDGE; PROGNOSTIC MODELS; HEALTH; PERFORMANCE; TOMOGRAPHY; RECOVERY; ALLELE	Although the majority of patients with mild traumatic brain injury (mTBI) recover completely, some still suffer from disabling ailments at 3 or 6 months. We validated existing prognostic models for mTBI and explored predictors of poor outcome after mTBI. We selected patients with mTBI from TRACK-TBI Pilot, an unselected observational cohort of TBI patients from three centers in the United States. We validated two prognostic models for the Glasgow Outcome Scale Extended (GOS-E) at 6 months after injury. One model was based on the CRASH study data and another from Nijmegen, The Netherlands. Possible predictors of 3- and 6-month GOS-E were analyzed with univariate and multi-variable proportional odds regression models. Of the 386 of 485 patients included in the study (median age, 44 years; interquartile range, 27-58), 75% (n=290) presented with a Glasgow Coma Score (GCS) of 15. In this mTBI population, both previously developed models had a poor performance (area under the receiver operating characteristic curve, 0.49-0.56). In multivariable analyses, the strongest predictors of lower 3- and 6-month GOS-E were older age, pre-existing psychiatric conditions, and lower education. Injury caused by assault, extracranial injuries, and lower GCS were also predictive of lower GOS-E. Existing models for mTBI performed unsatisfactorily. Our study shows that, for mTBI, different predictors are relevant as for moderate and severe TBI. These include age, pre-existing psychiatric conditions, and lower education. Development of a valid prediction model for mTBI patients requires further research efforts.	[Lingsma, Hester F.; Steyerberg, Ewout W.] Univ Med Ctr, Erasmus Med Ctr, Rotterdam, Netherlands; [Yue, John K.; Manley, Geoffrey T.; Cooper, Shelly R.; Mukherjee, Pratik; Vassar, Mary J.; Yuh, Esther L.] San Francisco Gen Hosp, Brain & Spinal Injury Ctr, San Francisco, CA 94110 USA; [Yue, John K.; Manley, Geoffrey T.; Cooper, Shelly R.; Vassar, Mary J.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94110 USA; [Maas, Andrew I. R.] Univ Antwerp Hosp, Dept Neurosurg, Edegem, Belgium; [Cooper, Shelly R.; Mukherjee, Pratik; Yuh, Esther L.] Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA; [Dams-O'Connor, Kristen; Gordon, Wayne A.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA; [Okonkwo, David O.; Puccio, Ava M.] Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Pittsburgh, PA USA; [Okonkwo, David O.; Puccio, Ava M.] Univ Pittsburgh, Med Ctr, Neurotrauma Clin Trials Ctr, Pittsburgh, PA USA; [Menon, David K.] Univ Cambridge, Addenbrookes Hosp, Div Anesthesia, Cambridge CB2 2QQ, England; [Schnyer, David M.] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA; [Valadka, Alex B.] Seton Brain & Spine Inst, Austin, TX USA		Manley, GT (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, 1001 Potrero Ave,Bldg 1,Room 101, San Francisco, CA 94110 USA.	manleyg@neurosurg.ucsf.edu	Yue, John K/P-1348-2015; Schnyer, David/ABD-6372-2021	Yue, John K/0000-0001-9694-7722; Schnyer, David/0000-0002-7472-2853; Cooper, Shelly/0000-0003-0026-6688; Mukherjee, Pratik/0000-0001-7473-7409	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RC2 NS0694909, RC2 NS069409-02S1]; Department of DefenseUnited States Department of Defense [USAMRAA W81XWH-13-1-0441]; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10090] Funding Source: researchfish; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RC2NS069409] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health (grant nos. RC2 NS0694909 [to G.T.M.] and RC2 NS069409-02S1 [to G.T.M.]) and the Department of Defense (USAMRAA W81XWH-13-1-0441; to G.T.M.). Registry: ClinicalTrials.gov Identifier NCT01565551.	Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; Faul M, 2010, TRAUMATIC BRAIN INJU; Fleminger S, 2005, BRIT MED J, V331, P1419, DOI 10.1136/bmj.331.7530.1419; Haacke EM, 2010, J MAGN RESON IMAGING, V32, P516, DOI 10.1002/jmri.22259; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Maas AI, 2010, ARCH PHYS MED REHAB, V91, P1641, DOI 10.1016/j.apmr.2010.07.232; Maas AIR, 2011, J NEUROTRAUM, V28, P177, DOI 10.1089/neu.2010.1617; Manley GT, 2013, JAMA-J AM MED ASSOC, V310, P473, DOI 10.1001/jama.2013.169158; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; McAllister TW, 2012, J NEUROTRAUM, V29, P1111, DOI 10.1089/neu.2011.1930; McAllister TW, 2005, AM J PSYCHIAT, V162, P1749, DOI 10.1176/appi.ajp.162.9.1749; McCullagh S, 2003, J NEUROL NEUROSUR PS, V74, P39, DOI 10.1136/jnnp.74.1.39; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; Okonkwo DO, 2013, J NEUROTRAUM, V30, P1490, DOI 10.1089/neu.2013.2883; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Polinder S, 2008, ACCIDENT ANAL PREV, V40, P182, DOI 10.1016/j.aap.2007.05.001; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Roozenbeek B, 2012, CRIT CARE MED, V40, P1609, DOI 10.1097/CCM.0b013e31824519ce; Steyerberg EW, 2010, EPIDEMIOLOGY, V21, P128, DOI 10.1097/EDE.0b013e3181c30fb2; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; Sundstrom A, 2007, INT PSYCHOGERIATR, V19, P159, DOI 10.1017/S1041610206003498; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Thurmond VA, 2010, ARCH PHYS MED REHAB, V91, P1633, DOI 10.1016/j.apmr.2010.06.034; Tosetti P, 2013, J NEUROTRAUM, V30, P1211, DOI 10.1089/neu.2013.2896; van Leeuwen N, 2012, NEUROSURGERY, V70, P811, DOI 10.1227/NEU.0b013e318235d640; von Steinbuechel N, 2012, J NEUROL NEUROSUR PS, V83, P1041, DOI 10.1136/jnnp-2012-302361; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783	39	105	106	0	22	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 15	2015	32	2					83	94		10.1089/neu.2014.3384			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AY6QM	WOS:000347690700002	25025611	Green Published, Green Submitted			2022-02-06	
J	Zanier, ER; Pischiutta, F; Riganti, L; Marchesi, F; Turola, E; Fumagalli, S; Perego, C; Parotto, E; Vinci, P; Veglianese, P; D'Amico, G; Verderio, C; De Simoni, MG				Zanier, Elisa R.; Pischiutta, Francesca; Riganti, Loredana; Marchesi, Federica; Turola, Elena; Fumagalli, Stefano; Perego, Carlo; Parotto, Emanuela; Vinci, Paola; Veglianese, Pietro; D'Amico, Giovanna; Verderio, Claudia; De Simoni, Maria-Grazia			Bone Marrow Mesenchymal Stromal Cells Drive Protective M2 Microglia Polarization After Brain Trauma	NEUROTHERAPEUTICS			English	Article						Traumatic brain injury; Microglia; Macrophages; Mesenchymal stromal cells; Immunomodulation	SPINAL-CORD-INJURY; FOCAL CEREBRAL-ISCHEMIA; TUMOR-NECROSIS-FACTOR; STEM-CELLS; ALTERNATIVE ACTIVATION; MACROPHAGE PLASTICITY; FUNCTIONAL RECOVERY; RESIDENT MICROGLIA; SURFACE EXPRESSION; PHENOTYPE MARKERS	Microglia/macrophages (M) are major contributors to postinjury inflammation, but they may also promote brain repair in response to specific environmental signals that drive classic (M1) or alternative (M2) polarization. We investigated the activation and functional changes of M in mice with traumatic brain injuries and receiving intracerebroventricular human bone marrow mesenchymal stromal cells (MSCs) or saline infusion. MSCs upregulated Ym1 and Arginase-1 mRNA (p < 0.001), two M2 markers of protective M polarization, at 3 and 7 d postinjury, and increased the number of Ym1(+) cells at 7 d postinjury (p < 0.05). MSCs reduced the presence of the lysosomal activity marker CD68 on the membrane surface of CD11b-positive M (p < 0.05), indicating reduced phagocytosis. MSC-mediated induction of the M2 phenotype in M was associated with early and persistent recovery of neurological functions evaluated up to 35 days postinjury (p < 0.01) and reparative changes of the lesioned microenvironment. In vitro, MSCs directly counteracted the proinflammatory response of primary murine microglia stimulated by tumor necrosis factor-alpha + interleukin 17 or by tumor necrosis factor-alpha + interferon-gamma and induced M2 proregenerative traits, as indicated by the downregulation of inducible nitric oxide synthase and upregulation of Ym1 and CD206 mRNA (p < 0.01). In conclusion, we found evidence that MSCs can drive the M transcriptional environment and induce the acquisition of an early, persistent M2-beneficial phenotype both in vivo and in vitro. Increased Ym1 expression together with reduced in vivo phagocytosis suggests M selection by MSCs towards the M2a subpopulation, which is involved in growth stimulation and tissue repair.	[Zanier, Elisa R.; Pischiutta, Francesca; Marchesi, Federica; Fumagalli, Stefano; Perego, Carlo; Parotto, Emanuela; Veglianese, Pietro; De Simoni, Maria-Grazia] Ist Ric Farmacol Mario Negri, IRCCS, Dept Neurosci, I-20156 Milan, Italy; [Riganti, Loredana; Turola, Elena; Verderio, Claudia] CNR, Inst Neurosci, I-20129 Milan, Italy; [Riganti, Loredana; Turola, Elena] Univ Milan, Dept Biotechnol & Translat Med, I-20129 Milan, Italy; [Fumagalli, Stefano] IRCCS Ca Granda Osped Maggiore Policlin, Dept Pathophysiol & Transplantat, I-20122 Milan, Italy; [Parotto, Emanuela] Univ Padua, Inst Anesthesia & Intens Care, I-35128 Padua, Italy; [Vinci, Paola; D'Amico, Giovanna] Clin Pediat Univ Milano Bicocca, Osped San Gerardo, Fdn MBBM, Ctr Ric Tettamanti, I-20900 Monza, Italy; [Verderio, Claudia] Humanitas Clin & Res Ctr, I-20089 Milan, Italy		De Simoni, MG (corresponding author), Ist Ric Farmacol Mario Negri, IRCCS, Dept Neurosci, I-20156 Milan, Italy.	c.verderio@in.cnr.it; desimoni@marionegri.it	D'Amico, Giovanna/AAL-3334-2020; Perego, Carlo/AAA-6513-2020; Zanier, Elisa/AAA-8095-2020; Veglianese, Pietro/AAA-7394-2020; Veglianese, Pietro/R-1871-2019; Vinci, Paola/AAF-4454-2020; Pischiutta, Francesca/AAA-7927-2020; De Simoni, Maria Grazia/I-6021-2012; verderio, claudia/K-4415-2016	D'Amico, Giovanna/0000-0001-7809-7269; Perego, Carlo/0000-0002-0259-0003; Zanier, Elisa/0000-0002-3011-8718; Veglianese, Pietro/0000-0002-0183-9428; Pischiutta, Francesca/0000-0002-7151-0812; De Simoni, Maria Grazia/0000-0001-6695-5297; verderio, claudia/0000-0001-7216-5873; Fumagalli, Stefano/0000-0003-3598-6263; Elena, Turola/0000-0002-1810-8648	Progetto ricerca finalizzataMinistry of Health, ItalyMinistry of Health Italy - Ricerca Finalizzata (MOH-RF) [FR-CCM-2008-1248388, FISM2012/R/17]; association "Esserci con Cate per i Bimbi"	This work was supported by Progetto ricerca finalizzata FR-CCM-2008-1248388 and FISM2012/R/17 to C. V. We thank Professor Maria Pia Abbracchio and Dr. Davide Lecca, 20133 University of Milan, for useful discussions; and Ilaria Prada (IN CNR, Milan) for assistance with some of the experiments. We also thank the association "Esserci con Cate per i Bimbi", which supported this work.	Babcock AA, 2003, J NEUROSCI, V23, P7922; Biswas SK, 2010, NAT IMMUNOL, V11, P889, DOI 10.1038/ni.1937; Bonilla C, 2009, BRAIN INJURY, V23, P760, DOI 10.1080/02699050903133970; Butovsky O, 2007, MOL CELL NEUROSCI, V35, P490, DOI 10.1016/j.mcn.2007.04.009; Capone C, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000373; Chhor V, 2013, BRAIN BEHAV IMMUN, V32, P70, DOI 10.1016/j.bbi.2013.02.005; Cho HH, 2009, CELL PHYSIOL BIOCHEM, V24, P511, DOI 10.1159/000257495; Christie KJ, 2013, FRONT CELL NEUROSCI, V6, DOI 10.3389/fncel.2012.00070; CURTIS R, 1991, EUR J NEUROSCI, V3, P876, DOI 10.1111/j.1460-9568.1991.tb00099.x; Dander E, 2012, LEUKEMIA, V26, P1681, DOI 10.1038/leu.2011.384; David S, 2011, NAT REV NEUROSCI, V12, P388, DOI 10.1038/nrn3053; Denes A, 2007, J CEREBR BLOOD F MET, V27, P1941, DOI 10.1038/sj.jcbfm.9600495; Donnelly DJ, 2009, J NEUROSCI METH, V181, P36, DOI 10.1016/j.jneumeth.2009.04.010; Franquesa M, 2013, TRANSPLANTATION, V96, P234, DOI 10.1097/TP.0b013e318298f9fa; Fumagalli S, 2013, GLIA, V61, P827, DOI 10.1002/glia.22474; Gesuete R, 2009, ANN NEUROL, V66, P332, DOI 10.1002/ana.21740; Giunti D, 2012, STEM CELLS, V30, P2044, DOI 10.1002/stem.1174; HOLNESS CL, 1993, BLOOD, V81, P1607; Hu XM, 2012, STROKE, V43, P3063, DOI 10.1161/STROKEAHA.112.659656; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kim YJ, 2009, GLIA, V57, P13, DOI 10.1002/glia.20731; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Kurushima H, 2000, J LEUKOCYTE BIOL, V67, P104, DOI 10.1002/jlb.67.1.104; Lai AY, 2008, GLIA, V56, P259, DOI 10.1002/glia.20610; Lambertsen KL, 2009, J NEUROSCI, V29, P1319, DOI 10.1523/JNEUROSCI.5505-08.2009; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Longhi L, 2013, J CEREBR BLOOD F MET, V33, P1182, DOI 10.1038/jcbfm.2013.65; Longhi L, 2009, CRIT CARE MED, V37, P659, DOI 10.1097/CCM.0b013e318195998a; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Madinier A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008101; Mahmood A, 2007, NEUROSURGERY, V60, P546, DOI 10.1227/01.NEU.0000255346.25959.99; MICKLEM K, 1989, BRIT J HAEMATOL, V73, P6, DOI 10.1111/j.1365-2141.1989.tb00210.x; Nakajima H, 2012, J NEUROTRAUM, V29, P1614, DOI 10.1089/neu.2011.2109; Neher JJ, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00027; Neher JJ, 2011, J IMMUNOL, V186, P4973, DOI 10.4049/jimmunol.1003600; Ohtaki H, 2008, P NATL ACAD SCI USA, V105, P14638, DOI 10.1073/pnas.0803670105; Ortolano F, 2009, J NEUROPATH EXP NEUR, V68, P964, DOI 10.1097/NEN.0b013e3181b20670; Paxinos G., 2004, MOUSE BRAIN STEREOTA; Perego C, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-174; Pischiutta F, 2014, NEUROPHARMACOLOGY, V79, P119, DOI 10.1016/j.neuropharm.2013.11.001; Qu CS, 2008, BRAIN RES, V1208, P234, DOI 10.1016/j.brainres.2008.02.042; Ramprasad MP, 1996, P NATL ACAD SCI USA, V93, P14833, DOI 10.1073/pnas.93.25.14833; Riglar DT, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2449; Sarnowska A, 2009, EXP NEUROL, V215, P317, DOI 10.1016/j.expneurol.2008.10.023; Sato A, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-65; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Shechter R, 2013, J PATHOL, V229, P332, DOI 10.1002/path.4106; Si Y, 2010, J CLIN INVEST, V120, P1192, DOI 10.1172/JCI40310; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Sierra A, 2010, CELL STEM CELL, V7, P483, DOI 10.1016/j.stem.2010.08.014; Stein VM, 2007, J VET MED A, V54, P314, DOI 10.1111/j.1439-0442.2007.00926.x; Travaglione S, 2002, TOXICOL IN VITRO, V16, P405, DOI 10.1016/S0887-2333(02)00028-0; Verderio C, 2012, ANN NEUROL, V72, P610, DOI 10.1002/ana.23627; Walker PA, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-228; Xiong Y, 2010, DISCOV MED, V10, P434; Xiong Y, 2010, J NEUROSURG, V113, P598, DOI 10.3171/2009.9.JNS09844; Zanier ER, 2013, CNS NEUROSCI THER, V19, P695, DOI 10.1111/cns.12128; Zanier ER, 2011, CRIT CARE MED, V39, P2501, DOI 10.1097/CCM.0b013e31822629ba	60	105	113	0	21	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1933-7213	1878-7479		NEUROTHERAPEUTICS	Neurotherapeutics	JUL	2014	11	3					679	695		10.1007/s13311-014-0277-y			17	Clinical Neurology; Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	AN1VR	WOS:000340372400021	24965140	Green Published			2022-02-06	
J	Kroshus, E; Daneshvar, DH; Baugh, CM; Nowinski, CJ; Cantu, RC				Kroshus, Emily; Daneshvar, Daniel H.; Baugh, Christine M.; Nowinski, Christopher J.; Cantu, Robert C.			NCAA concussion education in ice hockey: an ineffective mandate	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article						Concussion; Ice hockey	CHRONIC TRAUMATIC ENCEPHALOPATHY; SOCIAL-SCIENCES THEORIES; FOOTBALL PLAYERS; INJURY; SPORT; KNOWLEDGE; BRAIN; STATEMENT; CONSENSUS; EFFICACY	Background/aim Despite concussion education being increasingly mandated by states and sports leagues, there has been limited evaluation of what education is in fact effective. The National Collegiate Athletic Association (NCAA) currently mandates that institutions provide concussion education, without specifying content or delivery. The present study evaluated the effectiveness of this general mandate, as enacted for male collegiate ice hockey teams within one conference of competition. Methods In a prospective cohort design, 146 players from 6 male collegiate ice hockey teams in one Division 1 conference completed written surveys before and after receiving their institution-determined concussion education. Knowledge, attitudes, perceived norms and behavioural intention were assessed using validated measures. Education content and delivery was assessed by open-ended responses and consultation with team athletic trainers. Results All teams received concussion education material; however, content and delivery varied. Rates of material recall differed by delivery format. Considering all teams together, there were no significant improvements in knowledge and only a very small decrease in intention to continue playing while experiencing symptoms of a concussion. Pre-education and post-education, there were significant between-team differences in attitudes towards concussion reporting and behavioural intention. Conclusions The NCAA's general education mandate was divergently enacted; it did not significantly change the constructs of interest nor did it mitigate the pre-education team differences in these constructs. Existing educational materials should be evaluated, theory and evidence-driven materials developed, and mandates extended to, at a minimum, recommend materials found to be effective in changing concussion-reporting behaviour.	[Kroshus, Emily] Harvard Univ, Sch Publ Hlth, Dept Social & Behav Sci, Boston, MA 02115 USA; [Daneshvar, Daniel H.; Baugh, Christine M.; Nowinski, Christopher J.] Boston Univ, Sch Med, Ctr Study Traumat Encephalopathy, Boston, MA 02118 USA; [Kroshus, Emily; Nowinski, Christopher J.; Cantu, Robert C.] Sports Legacy Inst, Boston, MA USA; [Baugh, Christine M.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Cantu, Robert C.] Boston Univ, Sch Med, Dept Neurosurg, Boston, MA 02118 USA; [Cantu, Robert C.] Emerson Hosp, Dept Neurosurg, Concord, MA USA		Kroshus, E (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Social & Behav Sci, 677 Huntington Ave,Kresge Bldg 172, Boston, MA 02115 USA.	emk329@mail.harvard.edu	Baugh, Christine/AAG-2324-2020	Baugh, Christine/0000-0002-9340-6338; Daneshvar, Daniel/0000-0003-3691-9513	National Collegiate Athletic Association (NCAA)	National Collegiate Athletic Association (NCAA) 2012-2013 Graduate Student Research Grant.	Ajzen I., 1980, UNDERSTANDING ATTITU; Armitage CJ, 2001, BRIT J SOC PSYCHOL, V40, P471, DOI 10.1348/014466601164939; Bagley AF, 2012, CLIN J SPORT MED, V22, P385, DOI 10.1097/JSM.0b013e3182639bb4; Bandura A, 1986, SOCIAL FDN THOUGHT A; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Bramley H, 2012, CLIN PEDIATR, V51, P332, DOI 10.1177/0009922811425233; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Chrisman SP, 2013, J ADOLESCENT HEALTH, V52, P330, DOI 10.1016/j.jadohealth.2012.10.271; Cohen J., 2013, STAT POWER ANAL BEHA; Cook DJ, 2003, INJURY PREV, V9, P361, DOI 10.1136/ip.9.4.361; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, P683, DOI 10.1016/j.pmr.2011.08.009; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10187; Foundation TNAoN Association NAT, 2010, CONC SPORTS; Gielen AC, 2003, EPIDEMIOL REV, V25, P65, DOI 10.1093/epirev/mxg004; Glasgow RE, 2003, AM J PUBLIC HEALTH, V93, P1261, DOI 10.2105/AJPH.93.8.1261; Guskiewicz KM, 2011, PM&R, V3, P353, DOI 10.1016/j.pmrj.2010.12.006; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Hollis SJ, 2012, BRIT J SPORT MED, V46, P735, DOI 10.1136/bjsm.2011.085332; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McGlashan AJ, 2010, SPORTS MED, V40, P841, DOI 10.2165/11534960-000000000-00000; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meehan WP, 2009, PEDIATRICS, V123, P114, DOI 10.1542/peds.2008-0309; NCAA, 2012, CONC FACT SHEET STUD; NCAA, 2011, 2011 12 NCAA SPORTS; NFL, 2012, LYST LAW OV; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Povlishock JT, 2013, J NEUROTRAUM, V30, P1, DOI 10.1089/neu.2013.9942; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Provvidenza C, 2013, BRIT J SPORT MED, V47, P332, DOI 10.1136/bjsports-2012-092099; Rosenbaum AM, 2010, J CLIN EXP NEUROPSYC, V32, P44, DOI 10.1080/13803390902806535; Saldana J, 2015, CODING MANUAL QUALIT; Seichepine DR, 2013, J NEUROTRAUM, V30, P1299, DOI 10.1089/neu.2012.2690; Signoretti S, 2011, PM&R, V3, pS359, DOI 10.1016/j.pmrj.2011.07.018; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; Talavage TM, 2012, NEUROIMAGE, V62, P641, DOI 10.1016/j.neuroimage.2012.01.006; Trifiletti LB, 2005, HEALTH EDUC RES, V20, P298, DOI 10.1093/her/cyg126; Webb TL, 2006, PSYCHOL BULL, V132, P249, DOI 10.1037/0033-2909.132.2.249; Wetjen NM, 2010, J AM COLL SURGEONS, V211, P553, DOI 10.1016/j.jamcollsurg.2010.05.020; Wiebe DJ, 2011, INJURY PREV, V17, P69, DOI 10.1136/ip.2010.031211; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; Zemek RL, 2013, JAMA PEDIATR, V167, P259, DOI 10.1001/2013.jamapediatrics.216	52	105	106	1	24	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	JAN	2014	48	2					135	U146		10.1136/bjsports-2013-092498			7	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Sport Sciences	276KK	WOS:000328749000016	23956336				2022-02-06	
J	Wright, DW; Kellermann, A; McGuire, LC; Chen, B; Popovic, T				Wright, David W.; Kellermann, Arthur; McGuire, Lisa C.; Chen, Bin; Popovic, Tanja			CDC Grand Rounds: Reducing Severe Traumatic Brain Injury in the United States	MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT			English	Article							HEAD-INJURY; GUIDELINES		[Wright, David W.] Emory Univ, Sch Med, Atlanta, GA USA; [Kellermann, Arthur] RAND Corp, RAND Hlth, Santa Monica, CA USA; [McGuire, Lisa C.] CDC, Off Director, Atlanta, GA 30333 USA			lmcguire@cdc.gov	Wright, David/F-1209-2013	Wright, David/0000-0002-7145-9105			[Anonymous], 2012, TRAFF SAF FACTS 2011; CDC, 2003, REP C MILD TRAUM BRA; CDC, 2010, MMWR-MORBID MORTAL W, V59, P303; CDC, 2012, MMWR, V61; Champion HR, 2009, J TRAUMA, V66, P1468, DOI 10.1097/TA.0b013e3181a27e7f; Community Preventive Services Task Force, 2000, GUID COMM PREV SERV; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Faul M, 2010, TRAUMATIC BRAIN INJU; Faul M, 2007, J TRAUMA, V63, P1271, DOI 10.1097/TA.0b013e3181493080; Finkelstein E., 2006, INCIDENCE EC BURDEN; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Hesdorffer DC, 2007, J TRAUMA, V63, P841, DOI 10.1097/TA.0b013e318123fc21; Koppaka Ram, 2011, Morbidity and Mortality Weekly Report, V60, P619; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; Marr A., 2004, CENTRAL NERVOUS SYST; National Highway Traffic Safety Administration, 2008, EV REINST MOT HELM L; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; Sander AM, 2008, J HEAD TRAUMA REHAB, V23, P271, DOI 10.1097/01.HTR.0000336839.68585.0f; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Stein S. C., 1996, NEUROTRAUMA, P31; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	23	105	106	0	5	CENTERS  DISEASE CONTROL & PREVENTION	ATLANTA	1600 CLIFTON RD, ATLANTA, GA 30333 USA	0149-2195	1545-861X		MMWR-MORBID MORTAL W	MMWR-Morb. Mortal. Wkly. Rep.	JUL 12	2013	62	27					549	552					4	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health	188GU	WOS:000322181500002	23842444				2022-02-06	
J	Howell, D; Osternig, L; Van Donkelaar, P; Mayr, U; Chou, LS				Howell, David; Osternig, Louis; Van Donkelaar, Paul; Mayr, Ulrich; Chou, Li-Shan			Effects of Concussion on Attention and Executive Function in Adolescents	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						SPORT CONCUSSION; EXECUTIVE FUNCTION; ATTENTION; TASK SWITCH	HIGH-SCHOOL; DEFICITS; RECOVERY; EFFICIENCY; COLLEGIATE; SYMPTOMS; TRACKING	Background: Head trauma in adolescents has been linked with deficits in attention and executive function that can compromise the performance of everyday tasks. Although previous research has examined this issue using computerized neuropsychological testing, little work has been done using laboratory-based measurements of attention and executive function in this population. A longitudinal analysis of recovery patterns of these measures among adolescents is central to understanding the effects of concussions across the age spectrum. Purpose: This study prospectively and longitudinally examined laboratory-based measures of attention and executive function in concussed adolescents sequentially during a 2-month period after injury. Methods: Two measures of attention and executive function, the Attentional Network Test and the Task-Switching Test, were administered to 20 concussed adolescents within 72 h postinjury as well as at 1 wk, 2 wk, 1 month, and 2 months postinjury. Twenty healthy, matched control subjects were similarly assessed at the same time intervals. Data were analyzed by two-way, mixed-effects ANOVA to determine the effect of group and time on the dependent variables. Results: Compared with control subjects, the concussed group exhibited a significantly greater switch cost on the Task-Switching Test (P = 0.038, mean difference value = 38 ms) and a significantly greater reaction time for the Attentional Network Test conflict effect component (P = 0.015, mean difference value = 34 ms) for up to 2 months after injury. Conclusions: Concussed adolescents have difficulty recovering executive function after injury and may require extended recuperation time before full recovery is achieved. Evaluations focusing on attention and executive function can be useful additions in the assessment and follow-up after head injury.	[Howell, David; Osternig, Louis; Chou, Li-Shan] Univ Oregon, Dept Human Physiol, Eugene, OR 97403 USA; [Van Donkelaar, Paul] Univ British Columbia, Sch Hlth & Exercise Sci, Kelowna, BC, Canada; [Mayr, Ulrich] Univ Oregon, Dept Psychol, Eugene, OR 97403 USA		Chou, LS (corresponding author), Dept Human Physiol, 122 Esslinger Hall,1240 Univ Oregon, Eugene, OR 97403 USA.	chou@uoregon.edu	Meijer, Anna/K-5118-2016	Howell, David/0000-0002-2955-0191	National Athletic Trainers Association Master's Level Grant; Veterans AdministrationUS Department of Veterans Affairs [A4842C8, A4843C]; Translational Research Award from the University of Oregon; Translational Research Award from the Peace Health Oregon Region; Department of Defense-TATRC Award [W81XWH-11-1-0717]	This work was supported by the National Athletic Trainers Association Master's Level Grant, the Veterans Administration subcontract awards (grant nos. A4842C8 and A4843C), the Translational Research Award from the University of Oregon and Peace Health Oregon Region, and the Department of Defense-TATRC Award (grant no. W81XWH-11-1-0717).	Anderson V, 2008, EXECUTIVE FUNCTIONS, P24; Baillargeon A, 2012, BRAIN INJURY, V26, P211, DOI 10.3109/02699052.2012.654590; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Brooks J, 1999, J TRAUMA, V46, P159, DOI 10.1097/00005373-199901000-00027; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P224; Chan RCK, 2003, BRAIN INJURY, V17, P131, DOI 10.1080/0269905021000010168; Chan RCK, 2002, J CLIN EXP NEUROPSYC, V24, P1081, DOI 10.1076/jcen.24.8.1081.8371; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; Daniel JC, 1999, NEUROPSY NEUROPSY BE, V12, P167; DAVID AS, 1992, BRIT J PSYCHIAT, V161, P244, DOI 10.1192/bjp.161.2.244; Fan J, 2002, J COGNITIVE NEUROSCI, V14, P340, DOI 10.1162/089892902317361886; Fan J, 2005, NEUROIMAGE, V26, P471, DOI 10.1016/j.neuroimage.2005.02.004; Fan J, 2003, NEUROIMAGE, V18, P42, DOI 10.1006/nimg.2002.1319; Fischer K. W., 1996, DEV NEUROIMAGING MAP, P263; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; Hartikainen KM, 2010, J CLIN EXP NEUROPSYC, V32, P767, DOI 10.1080/13803390903521000; Ishigami Y, 2011, FRONT AGING NEUROSCI, V3, DOI 10.3389/fnagi.2011.00017; Ishigami Y, 2010, J NEUROSCI METH, V190, P117, DOI 10.1016/j.jneumeth.2010.04.019; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P196, DOI 10.1097/00001199-200505000-00003; Lezak Muriel D., 2004, NEUROPSYCHOLOGICAL A, VFOURTH, P35; Luna B, 2004, CHILD DEV, V75, P1357, DOI 10.1111/j.1467-8624.2004.00745.x; Luna B, 2010, BRAIN COGNITION, V72, P101, DOI 10.1016/j.bandc.2009.08.005; Luria AR, 1976, WORKING BRAIN INTRO, P249; Mayr U, 2006, PSYCHON B REV, V13, P794, DOI 10.3758/BF03193999; Mayr U, 2006, PSYCHOL SCI, V17, P774, DOI 10.1111/j.1467-9280.2006.01781.x; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrory P., 2009, J ATHL TRAINING, V44, P434, DOI [10.4085/1062-6050-44.4.434, DOI 10.4085/1062-6050-44.4.434]; Minear M, 2008, MEM COGNITION, V36, P1470, DOI 10.3758/MC.336.8.1470; Miyake A, 2012, CURR DIR PSYCHOL SCI, V21, P8, DOI 10.1177/0963721411429458; Norman DA, 1991, COGNITIVE NEUROSCIEN, P376; O'Hare ED, 2008, NEUROIMAGE, V42, P1678, DOI 10.1016/j.neuroimage.2008.05.057; ROGERS RD, 1995, J EXP PSYCHOL GEN, V124, P207, DOI 10.1037/0096-3445.124.2.207; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Spreen O, 1995, DEV NEUROPSYCHOL, P50; Stuss DT, 2002, NEUROPSYCHOLOGY, V16, P500, DOI 10.1037//0894-4105.16.4.500; Stuss DT, 2006, ANN NY ACAD SCI, V769, P191; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677	38	105	108	0	71	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	JUN	2013	45	6					1030	1037		10.1249/MSS.0b013e3182814595			8	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	149MF	WOS:000319323300002	23274602				2022-02-06	
J	Wiggins, A; Austerberry, R; Morrison, D; Ho, KM; Honeybul, S				Wiggins, Anthony; Austerberry, Richard; Morrison, David; Ho, Kwok M.; Honeybul, Stephen			Cranioplasty With Custom-Made Titanium Plates-14 Years Experience	NEUROSURGERY			English	Article						Autologous cranioplasty; Complications; Decompressive craniectomy; Neurotrauma; Titanium cranioplasty	CONTAINING COLLAGEN IMPLANT; SURGICAL SITE INFECTION; MIDDLE CEREBRAL-ARTERY; DECOMPRESSIVE CRANIECTOMY; HYDROXYAPATITE CEMENT; LOCAL APPLICATION; SUBARACHNOID HEMORRHAGE; GRAFT INFECTION; HEAD; COMPLICATIONS	BACKGROUND: There is no consensus on which material is best suited for repair of cranial defects. OBJECTIVE: To investigate the outcomes following custom-made titanium cranioplasty. METHODS: The medical records for all patients who had titanium cranioplasty at 2 major neurosurgical centers in Western Australia were retrieved and analyzed for this retrospective cohort study. RESULTS: Altogether, 127 custom-made titanium cranioplasties on 113 patients were included. Two patients had 3 titanium cranioplasties and 10 patients had 2. Infected bone flap (n = 61, 54%), either from previous craniotomy or autologous cranioplasty, and contaminated bone flap (n = 16, 14%) from the initial injury were the main reasons for requiring titanium cranioplasty. Complications attributed to titanium cranioplasty were common (n = 33, 29%), with infection being the most frequent complication (n = 18 patients, 16%). Complications were, on average, associated with an extra 7 days of hospital stay (interquartile range 2-17). The use of titanium as the material for the initial cranioplasty (P = .58), the presence of skull fracture(s) (P > .99) or scalp laceration(s) (P = .32) at the original surgery, and proven local infection before titanium cranioplasty (P = .78) were not significantly associated with an increased risk of infection. Infection was significantly more common after titanium cranioplasty for large defects (hemicraniectomy [39%] and bifrontal craniectomy [28%]) than after cranioplasty for small defects (P = .04). CONCLUSION: Complications after using titanium plate for primary or secondary cranioplasty were common (29%) and associated with an increased length of hospital stay. Infection was a major complication (16%), and this suggested that more vigorous perioperative infection prophylaxis is needed for titanium plate cranioplasty.	[Wiggins, Anthony; Honeybul, Stephen] Royal Perth Hosp, Dept Neurosurg, Perth, WA, Australia; [Austerberry, Richard; Honeybul, Stephen] Sir Charles Gairdner Hosp, Dept Neurosurg, Perth, WA, Australia; [Morrison, David] Royal Perth Hosp, Dept Med Engn & Phys, Perth, WA, Australia; [Ho, Kwok M.] Royal Perth Hosp, Dept Intens Care, Perth, WA, Australia; [Ho, Kwok M.] Univ Western Australia, Sch Populat Hlth, Perth, WA 6009, Australia		Wiggins, A (corresponding author), Royal Perth Hosp, Dept Neurosurg, Wellington St, Perth Cbd, WA 6000, Australia.	anwiggins77@hotmail.com	Ho, Kwok M./E-3546-2010	Ho, Kwok M./0000-0002-6705-6004; Morrison, David/0000-0003-1305-035X			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Agner C, 2003, MINIM INVAS NEUROSUR, V46, P186; Asano Y, 1993, No To Shinkei, V45, P1145; Bartlett P, 2009, BRIT J ORAL MAX SURG, V47, P238, DOI 10.1016/j.bjoms.2008.08.022; Beauchamp KM, 2010, J TRAUMA, V69, P270, DOI 10.1097/TA.0b013e3181e491c2; Brett-Major DM, 2008, MIL MED, V173, P697, DOI 10.7205/MILMED.173.7.697; Burstein FD, 2006, PLAST RECONSTR SURG, V118, P482, DOI 10.1097/01.prs.0000234811.48147.64; Cabraja M, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS091; CHANDLER CL, 1994, BRIT J NEUROSURG, V8, P409, DOI 10.3109/02688699408995107; Chang V, 2010, J NEUROSURG, V112, P1120, DOI 10.3171/2009.6.JNS09133; Cheng YK, 2008, J CLIN NEUROSCI, V15, P1115, DOI 10.1016/j.jocn.2007.09.022; Chiarini L, 2004, J CRANIO MAXILL SURG, V32, P5, DOI 10.1016/j.jcms.2003.08.005; Chun HJ, 2011, J CRANIOFAC SURG, V22, P203, DOI 10.1097/SCS.0b013e3181f753bd; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Day RE, 2012, BRIT J ORAL MAX SURG, V50, P376, DOI 10.1016/j.bjoms.2011.05.001; DILEK H, 1953, Turk Tip Cemiy Mecm, V19, P281; Dujovny M, 1997, NEUROL RES, V19, P311, DOI 10.1080/01616412.1997.11740818; Eppley BL, 2003, J CRANIOFAC SURG, V14, P209, DOI 10.1097/00001665-200303000-00014; Eufinger H, 1998, PLAST RECONSTR SURG, V102, P300, DOI 10.1097/00006534-199808000-00002; Fathi AR, 2008, J CRANIOFAC SURG, V19, P777, DOI 10.1097/SCS.0b013e31816b1b2a; FISHER CM, 1994, SURG NEUROL, V41, P65, DOI 10.1016/0090-3019(94)90210-0; FODSTAD H, 1984, ACTA NEUROCHIR, V70, P21, DOI 10.1007/BF01406039; Friedman C D, 2000, Arch Facial Plast Surg, V2, P124, DOI 10.1001/archfaci.2.2.124; Gilardino MS, 2009, PLAST RECONSTR SURG, V123, P983, DOI 10.1097/PRS.0b013e318199f6ad; Goh RCW, 2010, J PLAST RECONSTR AES, V63, P1479, DOI 10.1016/j.bjps.2009.08.010; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; Grant FC, 1939, ANN SURG, V110, P488, DOI 10.1097/00000658-193910000-00002; Grant GA, 2004, J NEUROSURG, V100, P163, DOI 10.3171/ped.2004.100.2.0163; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Ho KM, 2011, J TRAUMA, V71, P1637, DOI 10.1097/TA.0b013e31823a08f1; Honeybul S, 2010, J CLIN NEUROSCI, V17, P430, DOI 10.1016/j.jocn.2009.09.007; Honeybul S., 2012, RECONSTRUCTING DEFEC; Honeybul S, 2011, BRIT J NEUROSURG, V25, P343, DOI 10.3109/02688697.2011.568643; Honeybul S, 2011, J NEUROTRAUM, V28, P929, DOI 10.1089/neu.2010.1612; Howard JL, 2008, J TRAUMA, V65, P380, DOI 10.1097/TA.0b013e31817c50d4; Hussain ST, 2012, INT J SURG, V10, pS5, DOI 10.1016/j.ijsu.2012.05.015; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Inoue Akira, 1995, Neurologia Medico-Chirurgica, V35, P804; Iwama T, 2003, NEUROSURGERY, V52, P591, DOI 10.1227/01.NEU.0000047891.86938.46; Joffe J, 1999, BRIT J NEUROSURG, V13, P576, DOI 10.1080/02688699943088; Kakar V, 2009, BRIT J NEUROSURG, V23, P147, DOI 10.1080/02688690902756702; Kamyszek T, 2001, Mund Kiefer Gesichtschir, V5, P233, DOI 10.1007/s100060100317; Kelly AG, 2010, NEUROLOGY, V75, P682, DOI 10.1212/WNL.0b013e3181eee273; Knaepler H, 2012, INT J SURG, V10, pS15, DOI 10.1016/j.ijsu.2012.05.020; Korinek AM, 1997, NEUROSURGERY, V41, P1073, DOI 10.1097/00006123-199711000-00010; Kunze E, 1998, ACT NEUR S, V71, P16; Lee SC, 2009, J CLIN NEUROSCI, V16, P56, DOI 10.1016/j.jocn.2008.04.001; Matic DB, 2004, J CRANIOFAC SURG, V15, P415, DOI 10.1097/00001665-200405000-00012; Matsuno A, 2006, ACTA NEUROCHIR, V148, P535, DOI 10.1007/s00701-006-0740-6; Miller JP, 2009, J NEUROSURG, V110, P247, DOI 10.3171/2008.6.17605; Moreira-Gonzalez A, 2003, J CRANIOFAC SURG, V14, P144, DOI 10.1097/00001665-200303000-00003; Morgalla MH, 2008, J NEUROSURG, V109, P685, DOI 10.3171/JNS/2008/109/10/0685; Mori K, 2004, SURG NEUROL, V62, P420, DOI 10.1016/j.surneu.2003.12.017; Muller A, 2003, J CRANIOFAC SURG, V14, P899; Nagayama K, 2002, NEUROL SURG TOKYO, V30, P165; Pankratiev BE, 1933, ANN SURG, V97, P321, DOI 10.1097/00000658-193303000-00001; Poetker DM, 2004, OTOL NEUROTOL, V25, P604, DOI 10.1097/00129492-200407000-00031; Raja SG, 2012, INT J SURG, V10, pS10, DOI 10.1016/j.ijsu.2012.05.018; Sanan A, 1997, NEUROSURGERY, V40, P588, DOI 10.1097/00006123-199703000-00033; Shoakazemi A, 2009, NEUROSURGERY, V65, P505, DOI 10.1227/01.NEU.0000350870.69891.86; Smith ER, 2002, NEUROSURGERY, V51, P117, DOI 10.1097/00006123-200207000-00018; Staffa G, 2007, ACTA NEUROCHIR, V149, P161, DOI 10.1007/s00701-006-1078-9; Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965; Tokoro K, 1989, Neurol Med Chir (Tokyo), V29, P196, DOI 10.2176/nmc.29.196; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; VANGOOL AV, 1985, J MAXILLOFAC SURG, V13, P2, DOI 10.1016/S0301-0503(85)80005-9; Verret DJ, 2005, OTOLARYNG HEAD NECK, V133, P897, DOI 10.1016/j.otohns.2005.09.001; VITERBO F, 1995, J CRANIOFAC SURG, V6, P80, DOI 10.1097/00001665-199501000-00019; Wen L, 2007, J CRANIOFAC SURG, V18, P526, DOI 10.1097/scs.0b013e3180534348; Winkler PA, 2000, J NEUROSURG, V93, P53, DOI 10.3171/jns.2000.93.1.0053; WOODHALL B, 1945, ANN SURG, V121, P649, DOI 10.1097/00000658-194505000-00009; Wurm G, 2004, SURG NEUROL, V62, P510, DOI 10.1016/j.surneu.2004.01.025; YAMAURA A, 1977, Neurologia Medico-Chirurgica, V17, P43, DOI 10.2176/nmc.17pt1.43; Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9	74	105	114	0	25	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	FEB	2013	72	2					248	256		10.1227/NEU.0b013e31827b98f3			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	073HP	WOS:000313734400041	23149967				2022-02-06	
J	Brenner, M; Stein, D; Hu, P; Kufera, J; Wooford, M; Scalea, T				Brenner, Megan; Stein, Deborah; Hu, Peter; Kufera, Joseph; Wooford, Matthew; Scalea, Thomas			Association Between Early Hyperoxia and Worse Outcomes After Traumatic Brain Injury	ARCHIVES OF SURGERY			English	Article							SEVERE HEAD-INJURY; INTRACRANIAL-PRESSURE; CEREBRAL METABOLISM; OXYGENATION; HYPOXIA	Objective: To investigate the relationship between oxygenation and short-term outcomes in patients with traumatic brain injury (TBI). Design: Logistic regression analysis was used to determine whether average high (>200mmHg) or low (<100 mm Hg) PaO2 levels within the first 24 hours of hospital admission correlated with patient outcomes relative to patients with average PaO2 levels between 100 and 200 mm Hg. Setting: Level 1 trauma center. Patients: We retrospectively reviewed 1547 consecutive patients with severe TBI who survived past 12 hours after hospital admission. Main Outcome Measures: We measured mortality, intensive care unit length of stay, hospital length of stay, and discharge Glasgow Coma Scale (GCS) score. Results: Of the 1547 patients, 77% were male and 89% sustained blunt trauma. Mean (SD) age, admission GCS score, and Injury Severity Score were 41.3(20.6) years, 8.3(4.7), and 31.9(12.5), respectively. Mean (SD) intensive care unit length of stay and hospital length of stay were 8.7(10.5) days and 13.8(13.7) days, respectively. Mean (SD) discharge GCS score was 10.1(4.7). The mortality rate was 28%. After controlling for age, sex, Injury Severity Score, mechanism of injury, and admission GCS score, patients with high PaO2 levels had significantly higher mortality and lower discharge GCS scores than patients with a normal PaO2 (P < .05). Patients with low PaO2 levels also had increased mortality (P < .05). Conclusions: Hyperoxia within the first 24 hours of hospitalization is associated with worse short-term functional outcomes and higher mortality after TBI. Although the mechanism for this has not been completely elucidated, it may involve hyperoxia-induced oxygenfree radical toxicity with or without vasoconstriction. Hyperoxia and hypoxia were found to be equally detrimental to short-term outcomes in patients with TBI. A narrower therapeutic window for oxygenation may improve mortality and functional outcomes.	[Brenner, Megan; Stein, Deborah; Hu, Peter; Kufera, Joseph; Wooford, Matthew; Scalea, Thomas] Univ Maryland, Sch Med, Div Trauma & Surg Crit Care, R Adams Cowley Shock Trauma Ctr, Baltimore, MD 21201 USA		Brenner, M (corresponding author), Univ Maryland, Med Ctr, Div Crit Care Program Trauma, R Adams Cowley Shock Trauma Ctr, 22 S Greene St, Baltimore, MD 21201 USA.	mbrenner@umm.edu		Stein, Deborah/0000-0003-3683-3963	US Department of DefenseUnited States Department of Defense [W81XWH-07-2-0118, FA8650-11-2-6D01]	This research was funded in part by grants W81XWH-07-2-0118 and FA8650-11-2-6D01 from the US Department of Defense.	Ahn Edward S, 2005, Clin Neurosurg, V52, P348; BISSONNETTE B, 1991, CAN J ANAESTH, V38, P654, DOI 10.1007/BF03008204; Bostek C C, 1989, AANA J, V57, P231; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Bratton SL, 2008, J NEUROTRAUM, V25, P276; Chang JJJ, 2009, CRIT CARE MED, V37, P283, DOI 10.1097/CCM.0b013e318192fbd7; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chi JH, 2006, J TRAUMA, V61, P1134, DOI 10.1097/01.ta.0000196644.64653.d8; Davis DP, 2009, J NEUROTRAUM, V26, P2217, DOI 10.1089/neu.2009.0940; Diringer MN, 2007, J NEUROSURG, V106, P526, DOI 10.3171/jns.2007.106.4.526; Doppenberg EMR, 1998, ACT NEUR S, V71, P166; Li J, 2004, FREE RADICAL BIO MED, V36, P1460, DOI 10.1016/j.freeradbiomed.2004.03.005; Menzel M, 1999, J NEUROSURG ANESTH, V11, P240, DOI 10.1097/00008506-199910000-00003; Rangel-Castilla L, 2010, J NEUROTRAUM, V27, P1853, DOI 10.1089/neu.2010.1339; Rockswold SB, 2001, J NEUROSURG, V94, P403, DOI 10.3171/jns.2001.94.3.0403; Rosenthal G, 2008, CRIT CARE MED, V36, P1917, DOI 10.1097/CCM.0b013e3181743d77; Rosenthal G, 2008, J NEUROSURG, V108, P59, DOI 10.3171/JNS/2008/108/01/0059; SAHUQUILLO J, 1993, ACTA NEUROCHIR, V122, P204, DOI 10.1007/BF01405530; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029	21	105	106	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0004-0010	1538-3644		ARCH SURG-CHICAGO	Arch. Surg.	NOV	2012	147	11					1042	1046		10.1001/archsurg.2012.1560			5	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	055EG	WOS:000312397400014	22801994	Bronze			2022-02-06	
J	Shumskaya, E; Andriessen, TMJC; Norris, DG; Vos, PE				Shumskaya, Elena; Andriessen, Teuntje M. J. C.; Norris, David G.; Vos, Pieter E.			Abnormal whole-brain functional networks in homogeneous acute mild traumatic brain injury	NEUROLOGY			English	Article							MINOR HEAD-INJURY; CONNECTIVITY; MEMORY; SCALE; DYSFUNCTION; MECHANISMS; PREDICTION; SYMPTOMS; DEFICITS; REST	Objectives: To evaluate the whole-brain resting-state networks in a homogeneous group of patients with acute mild traumatic brain injury (MTBI) and to identify alterations in functional connectivity induced by MTBI. Methods: Thirty-five patients with acute MTBI and 35 healthy control subjects, matched in age, gender, handedness, and education, underwent resting-state fMRI, susceptibility weighted imaging, neuropsychological, and postconcussive symptom assessments. We ensured the homogeneity of the patient group by limiting the injury mechanism to fronto-occipital impacts. Alterations in functional connectivity were analyzed by using data-driven independent component analysis, which is not biased by a priori region selection. Results: We found a decrease in functional connectivity within the motor-striatal network in the MTBI group. At the same time, patients showed deficits in psychomotor speed as well as in speed of information processing. We propose that although disorders in motor function after MTBI are rarely reported, injury still has an effect on motor functioning, which in its turn may also explain the reduction in speed of information processing. Further, we found a cluster of increased functional connectivity in the right frontoparietal network in the MTBI group. We suggest that this abnormal increased connectivity might reflect increased awareness to external environment and explain excessive cognitive fatigue reported by patients with MTBI. It might also underlie the physical postconcussive symptoms, such as headache and increased sensitivity to noise/light. Conclusions: We proved that whole-brain functional connectivity is altered early (within 4 weeks) after MTBI, suggesting that changes in functional networks underlie the cognitive deficits and postconcussive complaints reported by patients with MTBI. Neurology (R) 2012;79:175-182	[Shumskaya, Elena; Norris, David G.] Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Ctr Cognit Neuroimaging, NL-6525 ED Nijmegen, Netherlands; [Shumskaya, Elena; Andriessen, Teuntje M. J. C.; Vos, Pieter E.] Radboud Univ Nijmegen, Dept Neurol, Med Ctr, NL-6525 ED Nijmegen, Netherlands; [Norris, David G.] Erwin L Hahn Inst Magnet Resonance, Essen, Germany; [Norris, David G.] Univ Twente, MIRA Inst Biomed Technol & Tech Med, NL-7500 AE Enschede, Netherlands		Shumskaya, E (corresponding author), Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Ctr Cognit Neuroimaging, NL-6525 ED Nijmegen, Netherlands.	elena.shumskaya@donders.ru.nl	Norris, David G/A-1937-2010	Norris, David G/0000-0002-3699-6917	Dutch Brain Foundation (Hersenstichting Nederland) [HsN 15F07.34]; Ever Neuro Pharma	Supported by the Dutch Brain Foundation (Hersenstichting Nederland) (HsN 15F07.34).; E. Shumskaya, T. Andriessen, and D. Norris report no disclosures. P. Vos serves on a scientific advisory board and has received funding for travel and speaker honoraria from Ever Neuro Pharma. Go to Neurology.org for full disclosures.	Aaronson NK, 1998, J CLIN EPIDEMIOL, V51, P1055, DOI 10.1016/S0895-4356(98)00097-3; Alberts M, 1997, Ned Tijdschr Geneeskd, V141, P1526; Arnsten AFT, 2010, TRENDS COGN SCI, V14, P365, DOI 10.1016/j.tics.2010.05.003; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Beckmann CF, 2005, PHILOS T R SOC B, V360, P1001, DOI 10.1098/rstb.2005.1634; Cabeza R, 2000, J COGNITIVE NEUROSCI, V12, P1, DOI 10.1162/08989290051137585; Cole DM, 2010, FRONT SYST NEUROSCI, V4, DOI 10.3389/fnsys.2010.00008; Damoiseaux JS, 2006, P NATL ACAD SCI USA, V103, P13848, DOI 10.1073/pnas.0601417103; de la Plata CDM, 2011, ARCH NEUROL-CHICAGO, V68, P74, DOI 10.1001/archneurol.2010.342; Derogatis L.R., 1994, SYMPTOM CHECKLIST 90, V3rd ed.; Filippini N, 2009, P NATL ACAD SCI USA, V106, P7209, DOI 10.1073/pnas.0811879106; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McHugh PR, 2007, J ANXIETY DISORD, V21, P211, DOI 10.1016/j.janxdis.2006.09.003; Park E, 2009, J CEREBR BLOOD F MET, V29, P575, DOI 10.1038/jcbfm.2008.151; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Smith S.M., 2009, NEUROIMAGE, V47, pS148; Smith SM, 2009, P NATL ACAD SCI USA, V106, P13040, DOI 10.1073/pnas.0905267106; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Smits M, 2007, ANN INTERN MED, V146, P397, DOI 10.7326/0003-4819-146-6-200703200-00004; Spikman JM, 2010, J NEUROTRAUM, V27, P1195, DOI 10.1089/neu.2010.1277; Sundin EC, 2002, BRIT J PSYCHIAT, V180, P205, DOI 10.1192/bjp.180.3.205; Tay SY, 2010, J NEUROTRAUM, V27, P77, DOI 10.1089/neu.2009.1074; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Van der Does A.J.W., 2002, MANUAL DUTCH VERSION; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Veer IM, 2010, FRONT SYST NEUROSCI, V4, DOI 10.3389/fnsys.2010.00041; Voller B, 1999, BRAIN INJURY, V13, P821, DOI 10.1080/026990599121214; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Xu YQ, 2010, J CEREBR BLOOD F MET, V30, P883, DOI 10.1038/jcbfm.2009.263; Zuo XN, 2010, NEUROIMAGE, V49, P1432, DOI 10.1016/j.neuroimage.2009.09.037	40	105	108	0	27	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	JUL	2012	79	2					175	182		10.1212/WNL.0b013e31825f04fb			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	971XV	WOS:000306241000017	22744656				2022-02-06	
J	Nishijima, DK; Offerman, SR; Ballard, DW; Vinson, DR; Chettipally, UK; Rauchwerger, AS; Reed, ME; Holmes, JF				Nishijima, Daniel K.; Offerman, Steven R.; Ballard, Dustin W.; Vinson, David R.; Chettipally, Uli K.; Rauchwerger, Adina S.; Reed, Mary E.; Holmes, James F.		CREST Network	Immediate and Delayed Traumatic Intracranial Hemorrhage in Patients With Head Trauma and Preinjury Warfarin or Clopidogrel Use	ANNALS OF EMERGENCY MEDICINE			English	Article							NEW-ORLEANS CRITERIA; BRAIN-INJURY; ANTICOAGULATED PATIENTS; COMATOSE PATIENTS; CT; MORTALITY; HEMATOMA; RISK; RULE; COMPLICATIONS	Study objective: Patients receiving warfarin or clopidogrel are considered at increased risk for traumatic intracranial hemorrhage after blunt head trauma. The prevalence of immediate traumatic intracranial hemorrhage and the cumulative incidence of delayed traumatic intracranial hemorrhage in these patients, however, are unknown. The objective of this study is to address these gaps in knowledge. Methods: A prospective, observational study at 2 trauma centers and 4 community hospitals enrolled emergency department (ED) patients with blunt head trauma and preinjury warfarin or clopidogrel use from April 2009 through January 2011. Patients were followed for 2 weeks. The prevalence of immediate traumatic intracranial hemorrhage and the cumulative incidence of delayed traumatic intracranial hemorrhage were calculated from patients who received initial cranial computed tomography (CT) in the ED. Delayed traumatic intracranial hemorrhage was defined as traumatic intracranial hemorrhage within 2 weeks after an initially normal CT scan result and in the absence of repeated head trauma. Results: A total of 1,064 patients were enrolled (768 warfarin patients [72.2%] and 296 clopidogrel patients [27.8%]). There were 364 patients (34.2%) from Level I or II trauma centers and 700 patients (65.8%) from community hospitals. One thousand patients received a cranial CT scan in the ED. Both warfarin and clopidogrel groups had similar demographic and clinical characteristics, although concomitant aspirin use was more prevalent among patients receiving clopidogrel. The prevalence of immediate traumatic intracranial hemorrhage was higher in patients receiving clopidogrel (33/276, 12.0%; 95% confidence interval [Cl] 8.4% to 16.4%) than patients receiving warfarin (37/724, 5.1%; 95% Cl 3.6% to 7.0%), relative risk 2.31 (95% Cl 1.48 to 3.63). Delayed traumatic intracranial hemorrhage was identified in 4 of 687 (0.6%; 95% Cl 0.2% to 1.5%) patients receiving warfarin and 0 of 243 (0%; 95% Cl 0% to 1.5%) patients receiving clopidogrel. Conclusion: Although there may be unmeasured confounders that limit intergroup comparison, patients receiving clopidogrel have a significantly higher prevalence of immediate traumatic intracranial hemorrhage compared with patients receiving warfarin. Delayed traumatic intracranial hemorrhage is rare and occurred only in patients receiving warfarin. Discharging patients receiving anticoagulant or antiplatelet medications from the ED after a normal cranial CT scan result is reasonable, but appropriate instructions are required because delayed traumatic intracranial hemorrhage may occur. [Ann Emerg Med. 2012;59:460-468.]	[Nishijima, Daniel K.; Holmes, James F.] UC Davis Sch Med, Dept Emergency Med, Sacramento, CA USA; [Offerman, Steven R.] Kaiser Permanente, S Sacramento Med Ctr, Sacramento, CA USA; [Ballard, Dustin W.] Kaiser Permanente, San Rafael Med Ctr & Med Off, San Rafael, CA USA; [Vinson, David R.] Kaiser Permanente, Sacramento Med Ctr & Med Off, Sacramento, CA USA; [Chettipally, Uli K.] Kaiser Permanente, S San Francisco Med Ctr & Med Off, San Francisco, CA USA; [Rauchwerger, Adina S.; Reed, Mary E.] Kaiser Permanente, Div Res, Oakland, CA USA		Nishijima, DK (corresponding author), UC Davis Sch Med, Dept Emergency Med, Sacramento, CA USA.	daniel.nishijima@ucdmc.ucdavis.edu	Vinson, David R/AAK-3227-2020	Vinson, David R/0000-0001-6559-1858; Rauchwerger, Adina/0000-0002-6329-6836	Garfield Memorial Fund (Kaiser Permanente); Mentored Clinical Research Training Program Award [K30, KL2]; National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1 RR024146]; NIH Roadmap for Medical ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024146] Funding Source: NIH RePORTER	By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org). The authors have stated that no such relationships exist. This work was supported by the Garfield Memorial Fund (Kaiser Permanente). Dr. Nishijima was supported through a Mentored Clinical Research Training Program Award (K30 and KL2), grant UL1 RR024146 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. The Garfield Memorial Fund, NCRR, and NIH had no role in the design and conduct of the study, in the analysis or interpretation of the data, or in the preparation of the data.	Quintero-Gonzalez JA, 2010, INVEST CLIN, V51, P269; [Anonymous], HEAD INJ TRIAG ASS I; Ansell J, 2008, CHEST, V133, p160S, DOI 10.1378/chest.08-0670; Brewer ES, 2011, J TRAUMA, V70, pE1, DOI 10.1097/TA.0b013e3181e5e286; Claudia C, 2011, J TRAUMA, V70, P906, DOI 10.1097/TA.0b013e3182031ab7; Cohen DB, 2006, J TRAUMA, V60, P553, DOI 10.1097/01.ta.0000196542.54344.05; Cohen JE, 1996, J TRAUMA, V41, P120, DOI 10.1097/00005373-199607000-00019; Coimbra R, 2005, J TRAUMA, V59, P374, DOI 10.1097/01.ta.000174728.46883.a4; DIAZ FG, 1979, J NEUROSURG, V50, P217, DOI 10.3171/jns.1979.50.2.0217; Franko J, 2006, J TRAUMA, V61, P107, DOI 10.1097/01.ta.0000224220.89528.fc; Garra G, 1999, ACAD EMERG MED, V6, P121, DOI 10.1111/j.1553-2712.1999.tb01048.x; Gittleman AM, 2005, AM J NEURORADIOL, V26, P603; HASELSBERGER K, 1988, ACTA NEUROCHIR, V90, P111, DOI 10.1007/BF01560563; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Hensrud DD, 1999, MAYO CLIN PROC, V74, P443; IMS, TOP 20 GLOB PROD 201; Itshayek E, 2006, NEUROSURGERY, V58, P851, DOI 10.1227/01.NEU.0000209653.B2936.96; Ivascu FA, 2005, J TRAUMA, V59, P1131, DOI 10.1097/01.ta.0000189067.16368.83; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P389, DOI 10.1001/jama.271.5.389; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Jones K, 2006, AM J SURG, V192, P743, DOI 10.1016/j.amjsurg.2006.08.037; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Li J, 2001, LANCET, V357, P771, DOI 10.1016/S0140-6736(00)04163-5; Major J, 2009, EMERG MED J, V26, P871, DOI 10.1136/emj.2008.068643; Mina AA, 2003, J TRAUMA, V54, P842, DOI 10.1097/01.TA.0000063271.05829.15; Mina AA, 2002, J TRAUMA, V53, P668, DOI 10.1097/00005373-200210000-00008; Ohm C, 2005, J TRAUMA, V58, P518, DOI 10.1097/01.TA.0000151671.35280.8B; Ostini R, 2008, PHARMACOEPIDEM DR S, V17, P1077, DOI 10.1002/pds.1638; Pieracci FM, 2007, J TRAUMA, V63, P525, DOI 10.1097/TA.0b013e31812e5216; POON WS, 1992, NEUROSURGERY, V30, P681; Quinn J, 2008, WEST J EMERG MED, V9, P6; Reynolds FD, 2003, J TRAUMA, V54, P492, DOI 10.1097/01.TA.0000051601.60556.FC; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Virjo I, 2010, SCAND J PRIM HEALTH, V28, P237, DOI 10.3109/02813432.2010.514138; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Wong DK, 2008, J TRAUMA, V65, P1303, DOI 10.1097/TA.0b013e318185e234	40	105	105	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644	1097-6760		ANN EMERG MED	Ann. Emerg. Med.	JUN	2012	59	6					460	468		10.1016/j.annemergmed.2012.04.007			9	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	959HA	WOS:000305302300005	22626015	Green Accepted			2022-02-06	
J	Avery, MA; Rooney, TM; Pandya, JD; Wishart, TM; Gillingwater, TH; Geddes, JW; Sullivan, PG; Freeman, MR				Avery, Michelle A.; Rooney, Timothy M.; Pandya, Jignesh D.; Wishart, Thomas M.; Gillingwater, Thomas H.; Geddes, James W.; Sullivan, Patrick G.; Freeman, Marc R.			Wld(S) Prevents Axon Degeneration through Increased Mitochondrial Flux and Enhanced Mitochondrial Ca2+ Buffering	CURRENT BIOLOGY			English	Article							SLOW WALLERIAN DEGENERATION; TRAUMATIC BRAIN-INJURY; C57BL/OLA MICE; MECHANISMS	Wld(S) (slow Wallerian degeneration) is a remarkable protein that can suppress Wallerian degeneration of axons and synapses [1], but how it exerts this effect remains unclear [2]. Here, using Drosophila and mouse models, we identify mitochondria as a key site of action for Wd(S) neuroprotective function. Targeting the NAD(+) biosynthetic enzyme Nmnat to mitochondria was sufficient to fully phenocopy Wld(S), and Wld(S) was specifically localized to mitochondria in synaptic preparations from mouse brain. Axotomy of live wild-type axons induced a dramatic spike in axoplasmic Ca2+ and termination of mitochondrial movement-Wld(S) potently suppressed both of these events. Surprisingly, Wld(S) also promoted increased basal mitochondrial motility in axons before injury, and genetically suppressing mitochondrial motility in vivo dramatically reduced the protective effect of Wld(S). Intriguingly, purified mitochondria from Wld(S) mice exhibited enhanced Ca2+ buffering capacity. We propose that the enhanced Ca2+ buffering capacity of Wld(S+) mitochondria leads to increased mitochondrial motility, suppression of axotomy-induced Ca2+ elevation in axons, and thereby suppression of Wallerian degeneration.	[Avery, Michelle A.; Rooney, Timothy M.; Freeman, Marc R.] Univ Massachusetts, Sch Med, Dept Neurobiol, Worcester, MA 01605 USA; [Avery, Michelle A.; Rooney, Timothy M.; Freeman, Marc R.] Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Worcester, MA 01605 USA; [Wishart, Thomas M.; Gillingwater, Thomas H.] Univ Edinburgh, Euan MacDonald Ctr Motor Neurone Dis Res, Edinburgh EH8 9XD, Midlothian, Scotland; [Wishart, Thomas M.; Gillingwater, Thomas H.] Univ Edinburgh, Ctr Integrat Physiol, Edinburgh EH8 9XD, Midlothian, Scotland; [Pandya, Jignesh D.; Geddes, James W.; Sullivan, Patrick G.] Univ Kentucky, Dept Anat & Neurobiol, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA		Freeman, MR (corresponding author), Univ Massachusetts, Sch Med, Dept Neurobiol, Worcester, MA 01605 USA.	marc.freeman@umassmed.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS062993, NS059991]; Wellcome TrustWellcome TrustEuropean Commission; Department of DefenseUnited States Department of Defense [BC093796]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS059991, R01NS062993] Funding Source: NIH RePORTER; BBSRCUK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC) [BBS/E/D/20251969] Funding Source: UKRI; Biotechnology and Biological Sciences Research CouncilUK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC) [BBS/E/D/20251969] Funding Source: researchfish	All animal procedures were carried out in accordance with National Institutes of Health (NIH) guidelines and the Institutional Animal Care and Use Committee regulations of the University of Kentucky and the University of Edinburgh. This work was supported by NIH grant NS062993 (J.W.G. and P.G.S.), the Wellcome Trust (T.H.G. and M.R.F.), and NIH grant NS059991 (to M.R.F.). M.R.F. is an Early Career Scientist with the Howard Hughes Medical Institute. T.M.R. was supported by a grant from the Department of Defense (BC093796). We thank Vimala Bondada and Dingyuan Lou for preliminary work on the mitochondrial Ca<SUP>2+</SUP> dynamics and all members of the laboratories for helpful discussions.	Avery MA, 2009, J CELL BIOL, V184, P501, DOI 10.1083/jcb.200808042; Barrientos SA, 2011, J NEUROSCI, V31, P966, DOI 10.1523/JNEUROSCI.4065-10.2011; Brown MR, 2004, J NEUROSCI METH, V137, P299, DOI 10.1016/j.jneumeth.2004.02.028; Chang DTW, 2006, NEUROBIOL DIS, V22, P388, DOI 10.1016/j.nbd.2005.12.007; Coleman MP, 2010, ANNU REV NEUROSCI, V33, P245, DOI 10.1146/annurev-neuro-060909-153248; Conforti L, 2000, P NATL ACAD SCI USA, V97, P11377, DOI 10.1073/pnas.97.21.11377; De Vos KJ, 2007, HUM MOL GENET, V16, P2720, DOI 10.1093/hmg/ddm226; Ganitkevich VY, 2003, EXP PHYSIOL, V88, P91, DOI 10.1113/eph8802504; GEORGE EB, 1995, J NEUROSCI, V15, P6445; Gillingwater TH, 2006, BRAIN, V129, P1546, DOI 10.1093/brain/awl101; GLASS JD, 1993, J NEUROCYTOL, V22, P311, DOI 10.1007/BF01195555; Ikegami K, 2003, NEUROSCIENCE, V122, P617, DOI 10.1016/j.neuroscience.2003.08.057; Knoferle J, 2010, P NATL ACAD SCI USA, V107, P6064, DOI 10.1073/pnas.0909794107; LUNN ER, 1989, EUR J NEUROSCI, V1, P27, DOI 10.1111/j.1460-9568.1989.tb00771.x; Mack TGA, 2001, NAT NEUROSCI, V4, P1199, DOI 10.1038/nn770; Naga KK, 2007, J NEUROSCI, V27, P7469, DOI 10.1523/JNEUROSCI.0646-07.2007; Pandya JD, 2007, J NEUROTRAUM, V24, P798, DOI 10.1089/neu.2006.3673; Pandya JD, 2009, EXP NEUROL, V218, P381, DOI 10.1016/j.expneurol.2009.05.023; PERRY VH, 1990, EUR J NEUROSCI, V2, P802, DOI 10.1111/j.1460-9568.1990.tb00472.x; Russo GJ, 2009, J NEUROSCI, V29, P5443, DOI 10.1523/JNEUROSCI.5417-08.2009; Santo-Domingo J, 2010, BBA-BIOENERGETICS, V1797, P907, DOI 10.1016/j.bbabio.2010.01.005; Sasaki Y, 2010, J BIOL CHEM, V285, P41211, DOI 10.1074/jbc.C110.193904; Schon EA, 2011, NEURON, V70, P1033, DOI 10.1016/j.neuron.2011.06.003; Shi P, 2010, BBA-MOL BASIS DIS, V1802, P707, DOI 10.1016/j.bbadis.2010.05.008; Sievers C, 2003, NEUROSCI RES, V46, P161, DOI 10.1016/S0168-0102(03)00039-7; Sunio A, 1997, EXP NEUROL, V146, P46, DOI 10.1006/exnr.1997.6484; Wang XL, 2009, J NEUROCHEM, V109, P153, DOI 10.1111/j.1471-4159.2009.05867.x; Wang XN, 2009, CELL, V136, P163, DOI 10.1016/j.cell.2008.11.046; Yahata N, 2009, J NEUROSCI, V29, P6276, DOI 10.1523/JNEUROSCI.4304-08.2009; Yi MQ, 2004, J CELL BIOL, V167, P661, DOI 10.1083/jcb.200406038	30	105	105	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0960-9822	1879-0445		CURR BIOL	Curr. Biol.	APR 10	2012	22	7					596	600		10.1016/j.cub.2012.02.043			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	926QC	WOS:000302844900021		Green Accepted, Bronze, Green Published			2022-02-06	
J	Blaiss, CA; Yu, TS; Zhang, G; Chen, JA; Dimchev, G; Parada, LF; Powell, CM; Kernie, SG				Blaiss, Cory A.; Yu, Tzong-Shiue; Zhang, Gui; Chen, Jian; Dimchev, Georgi; Parada, Luis F.; Powell, Craig M.; Kernie, Steven G.			Temporally Specified Genetic Ablation of Neurogenesis Impairs Cognitive Recovery after Traumatic Brain Injury	JOURNAL OF NEUROSCIENCE			English	Article							NEURAL STEM-CELLS; ADULT HIPPOCAMPAL NEUROGENESIS; CENTRAL-NERVOUS-SYSTEM; GFP TRANSGENIC MICE; DENTATE GYRUS; SUBVENTRICULAR ZONE; EXPRESSING PROGENITORS; CELLULAR PROLIFERATION; STEM/PROGENITOR CELLS; REACTIVE ASTROCYTES	Significant spontaneous recovery occurs after essentially all forms of serious brain injury, although the mechanisms underlying this recovery are unknown. Given that many forms of brain injury such as traumatic brain injury (TBI) induce hippocampal neurogenesis, we investigated whether these newly generated neurons might play a role in recovery. By modeling TBI in transgenic mice, we determined that injury-induced newly generated neurons persisted over time and elaborated extensive dendritic trees that stably incorporated themselves throughout all neuronal layers of the dentate gyrus. When we selectively ablated dividing stem/progenitors at the time of injury with ganciclovir in a nestin-HSV-TK transgenic model, we eliminated injury-induced neurogenesis and subsequently diminished the progenitor pool. Moreover, using hippocampal-specific behavioral tests, we demonstrated that only injured animals with neurogenesis ablated at the time of injury lost the ability to learn spatial memory tasks. These data demonstrate a functional role for adult neurogenesis after brain injury and offer compelling and testable therapeutic options that might enhance recovery.	[Yu, Tzong-Shiue; Zhang, Gui; Dimchev, Georgi; Kernie, Steven G.] Univ Texas SW Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA; [Yu, Tzong-Shiue; Zhang, Gui; Chen, Jian; Dimchev, Georgi; Parada, Luis F.; Kernie, Steven G.] Univ Texas SW Med Ctr Dallas, Dept Dev Biol, Dallas, TX 75390 USA; [Blaiss, Cory A.; Powell, Craig M.] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA; [Powell, Craig M.] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA		Kernie, SG (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Pediat, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Steven.Kernie@utsouthwestern.edu	Kernie, Steven/AAT-9912-2020; Parada, luis F/B-9400-2014	Powell, Craig/0000-0001-5451-2165; Dimchev, Georgi/0000-0001-8370-6161; Yu, Tzong-Shiue/0000-0003-4277-6213; Kernie, Steven/0000-0003-1371-0549	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS048192]; Seay Endowed Fund for Research on Brain and Spinal Cord Injuries in Children; National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH); National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Hartwell Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD069560] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD065290] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH081164] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048192] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health Grant R01 NS048192 (S.G.K.), the Seay Endowed Fund for Research on Brain and Spinal Cord Injuries in Children (S.G.K.), National Institute of Mental Health (C.M.P.), National Institute of Child Health and Human Development (C.M.P.), and The Hartwell Foundation (C.M.P.).	Aguirre A, 2004, J NEUROSCI, V24, P10530, DOI 10.1523/JNEUROSCI.3572-04.2004; Alvarez-Buylla A, 2001, NAT REV NEUROSCI, V2, P287, DOI 10.1038/35067582; Belachew S, 2003, J CELL BIOL, V161, P169, DOI 10.1083/jcb.200210110; Bessis A, 2007, GLIA, V55, P233, DOI 10.1002/glia.20459; Chen J, 2009, GENESIS, V47, P122, DOI 10.1002/dvg.20465; Chen XH, 2003, J NEUROTRAUM, V20, P623, DOI 10.1089/089771503322144545; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Clelland CD, 2009, SCIENCE, V325, P210, DOI 10.1126/science.1173215; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Deng W, 2010, NAT REV NEUROSCI, V11, P339, DOI 10.1038/nrn2822; Deng W, 2009, J NEUROSCI, V29, P13532, DOI 10.1523/JNEUROSCI.3362-09.2009; Denise A, 2004, NAT NEUROSCI, V7, P1233, DOI 10.1038/nn1340; Doetsch F, 1999, P NATL ACAD SCI USA, V96, P11619, DOI 10.1073/pnas.96.20.11619; Duan X, 2008, CURR OPIN NEUROBIOL, V18, P108, DOI 10.1016/j.conb.2008.04.001; Dupret D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001959; Durieux PF, 2009, NAT NEUROSCI, V12, P393, DOI 10.1038/nn.2286; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Etherton MR, 2009, P NATL ACAD SCI USA, V106, P17998, DOI 10.1073/pnas.0910297106; Ge SY, 2006, NATURE, V439, P589, DOI 10.1038/nature04404; Goosens KA, 2001, LEARN MEMORY, V8, P148, DOI 10.1101/lm.37601; Gould E, 2002, J NEUROSCI, V22, P619, DOI 10.1523/JNEUROSCI.22-03-00619.2002; Hellstraom NAK, 2009, STEM CELLS, V27, P634, DOI 10.1634/stemcells.2008-0732; Imayoshi I, 2008, NAT NEUROSCI, V11, P1153, DOI 10.1038/nn.2185; Kawaguchi A, 2001, MOL CELL NEUROSCI, V17, P259, DOI 10.1006/mcne.2000.0925; Kee N, 2007, NAT NEUROSCI, V10, P355, DOI 10.1038/nn1847; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kernie SG, 2010, NEUROBIOL DIS, V37, P267, DOI 10.1016/j.nbd.2009.11.002; Kokovay E, 2008, NEURON, V60, P420, DOI 10.1016/j.neuron.2008.10.025; Lagace DC, 2007, J NEUROSCI, V27, P12623, DOI 10.1523/JNEUROSCI.3812-07.2007; Lau BWM, 2009, NEUROREPORT, V20, P371, DOI 10.1097/WNR.0b013e328324edcd; Li Y, 2008, NEURON, V59, P399, DOI 10.1016/j.neuron.2008.06.023; Lipp HP, 1998, CURR OPIN NEUROBIOL, V8, P272, DOI 10.1016/S0959-4388(98)80151-7; Luquet S, 2005, SCIENCE, V310, P683, DOI 10.1126/science.1115524; Mattson MP, 2008, ANN NY ACAD SCI, V1144, P97, DOI 10.1196/annals.1418.005; Mignone JL, 2004, J COMP NEUROL, V469, P311, DOI 10.1002/cne.10964; Miles DK, 2008, HIPPOCAMPUS, V18, P793, DOI 10.1002/hipo.20439; Morshead CM, 2003, EUR J NEUROSCI, V18, P76, DOI 10.1046/j.1460-9568.2003.02727.x; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Naylor AS, 2008, P NATL ACAD SCI USA, V105, P14632, DOI 10.1073/pnas.0711128105; Noonan MA, 2010, J NEUROSCI, V30, P304, DOI 10.1523/JNEUROSCI.4256-09.2010; Onishi BKA, 2010, NEUROBIOL LEARN MEM, V93, P165, DOI 10.1016/j.nlm.2009.09.007; Powell CM, 2004, NEURON, V42, P143, DOI 10.1016/S0896-6273(04)00146-1; Pozniak CD, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-3-207; Ramaswamy S, 2005, BRAIN RES, V1053, P38, DOI 10.1016/j.brainres.2005.06.042; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Richmond MA, 1999, BEHAV NEUROSCI, V113, P1189, DOI 10.1037/0735-7044.113.6.1189; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Saxe MD, 2006, P NATL ACAD SCI USA, V103, P17501, DOI 10.1073/pnas.0607207103; Seaberg RM, 2002, J NEUROSCI, V22, P1784, DOI 10.1523/JNEUROSCI.22-05-01784.2002; Shi J, 2007, EUR J NEUROSCI, V25, P3499, DOI 10.1111/j.1460-9568.2007.05624.x; Sofroniew MV, 1999, BRAIN RES, V835, P91, DOI 10.1016/S0006-8993(99)01639-X; Tabuchi K, 2007, SCIENCE, V318, P71, DOI 10.1126/science.1146221; TEMPLE S, 1995, NEURON, V15, P249, DOI 10.1016/0896-6273(95)90030-6; Urrea C, 2007, RESTOR NEUROL NEUROS, V25, P65; Yamaguchi M, 2000, NEUROREPORT, V11, P1991, DOI 10.1097/00001756-200006260-00037; Yokoyama A, 2006, GLIA, V53, P754, DOI 10.1002/glia.20332; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008; Zhang CL, 2008, NATURE, V451, P1004, DOI 10.1038/nature06562	58	105	108	1	13	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	MAR 30	2011	31	13					4906	4916		10.1523/JNEUROSCI.5265-10.2011			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	742JM	WOS:000288938200017	21451029	Green Accepted, Green Published, Bronze			2022-02-06	
J	Unden, J; Romner, B				Unden, Johan; Romner, Bertil			Can Low Serum Levels of S100B Predict Normal CT Findings After Minor Head Injury in Adults?: An Evidence-Based Review and Meta-Analysis	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						evidence; guidelines; head injury; management; meta-analysis; MHI; mild; minor; TBI; S100/S-100/S100B	TRAUMATIC BRAIN-INJURY; NEURON-SPECIFIC ENOLASE; S-100 PROTEIN MEASUREMENTS; CLINICAL DECISION INSTRUMENTS; FIBRILLARY ACIDIC PROTEIN; COMPUTED-TOMOGRAPHY; URINARY S100B; EMERGENCY-DEPARTMENT; MILD; CHILDREN	Objective: To determine whether low levels of S100B in serum can predict normal computed tomography (CT) findings after minor head injury (MHI) in adults. Participants: Not applicable. Design: Systematic evidence-based review of the peer-reviewed literature with meta-analytical interpretation. Primary Measures: Not applicable. Results: We identified 12 eligible articles that specifically studied adult MHI patients with S100B and cranial CT scans in the acute phase after injury, comprising a total of 2466 separate patients. Individual negative predictive values of 90% to 100% were found for the ability of a negative (under cutoff) S100B level to predict a normal CT scan. A total of 6 patients included in the studies had low S100B levels and positive CT scans (0.26%) and only 1 of these patients (0.04%) had a clinically relevant CT finding. The pooled negative predictive value for all studies was more than 99% (95% CI 98%-100%), with an average prevalence for any CT finding at 8%. The studies are consistently classed as level 2 and level 3 grades of evidence, suggesting a grade B recommendation. Conclusion: Low serum S100B levels accurately predict normal CT findings after MHI in adults. S100B sampling should be considered in MHI patients with no focal neurological deficit, an absence of significant extracerebral injury, should be taken within 3 hours of injury, and the cutoff for omitting CT set at less than 0.10 mu g/L. Care givers should also be aware of other clinical factors predictive of intracranial complications after MHI.	[Unden, Johan] Halmstad Reg Hosp, Dept Anaesthesia & Intens Care, S-30185 Halmstad, Sweden; [Romner, Bertil] Rigshosp, Dept Neurosurg, DK-2100 Copenhagen, Denmark		Unden, J (corresponding author), Halmstad Reg Hosp, Dept Anaesthesia & Intens Care, S-30185 Halmstad, Sweden.	johan.unden@Ithalland.se			Vetenskapliga Radet/Landstinget i Halland; Region Skane and Sodra Sjukvardsregionen	JU has received funding from the following noncommercial sources: Vetenskapliga Radet/Landstinget i Halland, Region Skane and Sodra Sjukvardsregionen.	AFGEIJERSTAM JL, BMJ, V333, P465; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Bazarian JJ, 2006, RESTOR NEUROL NEUROS, V24, P163; Bechtel K, 2009, PEDIATRICS, V124, pE697, DOI 10.1542/peds.2008-1493; Berger RP, 2007, J NEUROTRAUM, V24, P1793, DOI 10.1089/neu.2007.0316; Berger RP, 2006, PEDIATRICS, V117, P325, DOI 10.1542/peds.2005-0711; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Berger RP, 2002, J NEUROTRAUM, V19, P1405, DOI 10.1089/089771502320914633; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Biberthaler P, 2002, EUR J MED RES, V7, P164; Biberthaler P, 2001, WORLD J SURG, V25, P93, DOI 10.1007/s002680020370; Biberthaler P, 2001, SHOCK, V16, P97, DOI 10.1097/00024382-200116020-00002; Bouvier D, 2009, ANN BIOL CLIN-PARIS, V67, P425, DOI 10.1684/abc.2009.0347; BRISMAR B, 1983, ACTA CHIR SCAND, V149, P11; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Castellani C, 2009, ACTA PAEDIATR, V98, P1607, DOI 10.1111/j.1651-2227.2009.01423.x; Castellani C, 2008, CLIN CHEM LAB MED, V46, P1296, DOI 10.1515/CCLM.2008.262; Corwin MT, 2009, AM J ROENTGENOL, V192, P1319, DOI 10.2214/AJR.08.1346; de boussard CN, 2004, BRAIN INJURY, V18, P671, DOI 10.1080/02699050310001646215; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; DOEZEMA D, 1991, ANN EMERG MED, V20, P1281, DOI 10.1016/S0196-0644(05)81065-0; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Enochsson L, 2005, EUR J NEUROL, V12, P445, DOI 10.1111/j.1468-1331.2005.00996.x; Gazzolo D, 2004, CRIT CARE MED, V32, P131, DOI 10.1097/01.CCM.0000104116.91462.CD; Gazzolo D, 2003, CLIN CHEM, V49, P967, DOI 10.1373/49.6.967; Goncalves CA, 2008, CLIN BIOCHEM, V41, P755, DOI 10.1016/j.clinbiochem.2008.04.003; Hall EJ, 2008, BRIT J RADIOL, V81, P362, DOI 10.1259/bjr/01948454; HALL EJ, 2008, BRIT J RADIOL, V81, P1148; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Haydel MJ, 2005, JAMA-J AM MED ASSOC, V294, P1551, DOI 10.1001/jama.294.12.1551; Heneghan Carl, 2009, Evid Based Med, V14, P67, DOI 10.1136/ebm.14.3.67; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Ingebrigtsen T, 1996, ACTA NEUROL SCAND, V93, P207; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Jennett B, 1998, ARCH DIS CHILD, V78, P403, DOI 10.1136/adc.78.5.403; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; KANNER AA, 2003, CANCER, V1, P97; Keller T, 2009, NEW ENGL J MED, V361, P868, DOI 10.1056/NEJMoa0903515; Kleindienst A, 2006, J NEUROTRAUM, V23, P1185, DOI 10.1089/neu.2006.23.1185; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Lumpkins KM, 2008, J TRAUMA, V65, P778, DOI 10.1097/TA.0b013e318185db2d; Miller EC, 1996, ANN EMERG MED, V27, P290, DOI 10.1016/S0196-0644(96)70261-5; Morochovic R, 2009, EUR J NEUROL, V16, P1112, DOI 10.1111/j.1468-1331.2009.02653.x; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; Muller K, 2006, CLIN CHEM LAB MED, V44, P1111, DOI 10.1515/CCLM.2006.211; Mussack T, 2002, SHOCK, V18, P395, DOI 10.1097/00024382-200211000-00002; Norlund A, 2006, BMJ-BRIT MED J, V333, P469, DOI 10.1136/bmj.38918.659120.4F; Oh EJ, 2007, J CLIN LAB ANAL, V21, P387, DOI 10.1002/jcla.20201; Berger RP, 2006, PEDIATR CRIT CARE ME, V7, P557, DOI 10.1097/01.PCC.0000244426.37793.23; Parry-Jones BL, 2006, NEUROPSYCHOL REHABIL, V16, P537, DOI 10.1080/09602010500231875; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Pelsers MMAL, 2004, CLIN CHEM, V50, P1568, DOI 10.1373/clinchem.2003.030361; Pickering A, 2008, EMERG MED J, V25, P88, DOI 10.1136/emj.2007.046631; Pineda JA, 2007, J NEUROTRAUM, V24, P354, DOI 10.1089/neu.2006.003789; Poli-de-Figueiredo Luiz F, 2006, Clinics, V61, P41, DOI 10.1590/S1807-59322006000100008; REINUS WR, 1993, ANN EMERG MED, V22, P1148, DOI 10.1016/S0196-0644(05)80981-3; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Ruan S, 2009, J NEUROTRAUM, V26, P1655, DOI 10.1089/neu.2009-0928; Schultke E, 2009, CAN J NEUROL SCI, V36, P612, DOI 10.1017/S031716710000812X; SHARPLES PM, 1990, BRIT MED J, V301, P1193, DOI 10.1136/bmj.301.6762.1193; SLOAN EP, 1989, J TRAUMA, V29, P1647, DOI 10.1097/00005373-198912000-00011; Smits M, 2007, ANN INTERN MED, V146, P397, DOI 10.7326/0003-4819-146-6-200703200-00004; Spinella PC, 2003, CRIT CARE MED, V31, P939, DOI 10.1097/01.CCM.0000053644.16336.52; STEIN SC, 1995, BRAIN INJURY, V9, P437, DOI 10.3109/02699059509008203; Stein SC, 2001, J TRAUMA, V50, P759, DOI 10.1097/00005373-200104000-00032; Stein SC, 2009, ANN EMERG MED, V53, P180, DOI 10.1016/j.annemergmed.2008.01.002; STEINER J, BMC NEUROSCI, V8, P2; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Topal NB, 2008, NEUROL RES, V30, P974, DOI 10.1179/016164108X323799; Townend W, 2006, J NEUROTRAUM, V23, P149, DOI 10.1089/neu.2006.23.149; Unden J, 2005, BRIT J NEUROSURG, V19, P43, DOI 10.1080/02688690500089381; Unden J, 2005, J TRAUMA, V58, P59, DOI 10.1097/01.TA.0000130613.35877.75; Wells PS, 2006, JAMA-J AM MED ASSOC, V295, P199, DOI 10.1001/jama.295.2.199; Whiting Penny F, 1800, BMC Med Res Methodol, V6, P9, DOI 10.1186/1471-2288-6-9; WIESMANN M, 2009, ACTA NEUROL SCAND, V5, P178; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6; Yates DW, 2003, EMERG MED J, V20, P117, DOI 10.1136/emj.20.2.117	83	105	110	2	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2010	25	4					228	240		10.1097/HTR.0b013e3181e57e22			13	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	622FO	WOS:000279646900002	20611042				2022-02-06	
J	Anderson, KJ; Scheff, SW; Miller, KM; Roberts, KN; Gilmer, LK; Yang, C; Shaw, G				Anderson, Kevin J.; Scheff, Stephen W.; Miller, Kelly M.; Roberts, Kelly N.; Gilmer, Lesley K.; Yang, Cui; Shaw, Gerry			The Phosphorylated Axonal Form of the Neurofilament Subunit NF-H (pNF-H) as a Blood Biomarker of Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						cell death; cortical contusion; neurofilaments; serum	CONTROLLED CORTICAL IMPACT; BIOCHEMICAL SERUM MARKERS; CYCLOSPORINE-A; PROTEIN-LEVELS; CLEAVED-TAU; HEAD-INJURY; DAMAGE; PROTEOLYSIS; CALPAIN; RAT	The detection of neuron-specific proteins in blood might allow quantification of the degree of neuropathology in experimental and clinical contexts. We have been studying a novel blood biomarker of axonal injury, the heavily phosphorylated axonal form of the high molecular weight neurofilament subunit NF-H (pNF-H). We hypothesized that this protein would be released from damaged and degenerating neurons following experimental traumatic brain injury (TBI) in amounts large enough to allow its detection in blood and that the levels detected would reflect the degree of injury severity. An enzyme-linked immunosorbent assay (ELISA) capture assay capable of detecting nanogram amounts of pNF-H was used to test blood of rats subjected to experimental TBI using a controlled cortical impact (CCI) device. Animals were subjected to a mild (1.0 mm), moderate (1.5 mm), or severe (2.0 mm) cortical contusion, and blood samples were taken at defined times post-injury. The assay detected the presence of pNF-H as early as 6 h post-injury; levels peaked at 24-48 h, and then slowly decreased to baseline over several days post-injury. No signal above baseline was detectable in control animals. Analysis of variance (ANOVA) showed a significant effect of lesion severity, and post hoc analysis revealed that animals given a moderate and severe contusion showed higher levels of blood pNF-H than controls. In addition, the peak levels of pNF-H detected at both 24 and 48 h post-injury correlated with the degree of injury as determined by volumetric analysis of spared cortical tissue. Relative amounts of pNF-H were also determined in different areas of the central nervous system (CNS) and were found to be highest in regions containing large-diameter axons, including spinal cord and brainstem, and lowest in the cerebral cortex and hippocampus. These findings suggest that the measurement of blood levels of pNF-H is a convenient method for assessing neuropathology following TBI.	[Anderson, Kevin J.] Univ Florida, Dept Physiol Sci, McKnight Brain Inst, Gainesville, FL 32610 USA; [Anderson, Kevin J.; Yang, Cui; Shaw, Gerry] Univ Florida, Dept Neurosci, McKnight Brain Inst, Gainesville, FL 32610 USA; [Anderson, Kevin J.; Scheff, Stephen W.; Miller, Kelly M.; Roberts, Kelly N.; Gilmer, Lesley K.] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; [Shaw, Gerry] EnCor Biotechnol Inc, Gainesville, FL USA		Anderson, KJ (corresponding author), Univ Florida, Dept Physiol Sci, McKnight Brain Inst, POB 100144, Gainesville, FL 32610 USA.	kanders@mbi.ufl.edu	, Gerry/X-2377-2019		Kentucky Spinal Cord and Head Injury Research Trust [5A]; Spinal Cord Research Foundation; Department of Veteran AffairsUS Department of Veterans Affairs; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS39828, AG21981]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG021981] Funding Source: NIH RePORTER	We would like to thank Chris Horrell for his technical assistance. This study was supported by the Kentucky Spinal Cord and Head Injury Research Trust (project no. 5A), the Spinal Cord Research Foundation, the Department of Veteran Affairs, and the NIH (grants NS39828 and AG21981).	Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Baldwin SA, 1996, GLIA, V16, P266; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Bush EC, 2003, BRAIN BEHAV EVOLUT, V61, P1, DOI 10.1159/000068880; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FRAHM HD, 1982, J HIRNFORSCH, V23, P375; Gabbita SP, 2005, J NEUROTRAUM, V22, P83, DOI 10.1089/neu.2005.22.83; GOLDSTEIN ME, 1987, J NEUROIMMUNOL, V14, P149, DOI 10.1016/0165-5728(87)90049-X; GREENWOOD JA, 1993, J NEUROCHEM, V61, P191, DOI 10.1111/j.1471-4159.1993.tb03555.x; Gu YJ, 1996, J NEUROCHEM, V67, P1235; Hashimoto R, 1999, PSYCHIAT CLIN NEUROS, V53, P587, DOI 10.1046/j.1440-1819.1999.00610.x; Hasselblatt M, 2004, NEUROLOGY, V62, P1634, DOI 10.1212/01.WNL.0000123092.97047.B1; Ingebrigtsen T, 2003, RESTOR NEUROL NEUROS, V21, P171; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; JOHNSON GVW, 1991, NEUROCHEM RES, V16, P869, DOI 10.1007/BF00965535; Lewis SB, 2008, J CEREBR BLOOD F MET, V28, P1274, DOI 10.1038/jcbfm.2008.23; Lewis SB, 2008, J CEREBR BLOOD F MET, V28, P1261, DOI 10.1038/jcbfm.2008.12; PANT HC, 1988, BIOCHEM J, V256, P665, DOI 10.1042/bj2560665; Pelinka LE, 2003, BRIT J ANAESTH, V91, P595, DOI 10.1093/bja/aeg225; Petzold A, 2007, NEURODEGENER DIS, V4, P185, DOI 10.1159/000101843; Petzold A, 2007, J IMMUNOL METHODS, V319, P34, DOI 10.1016/j.jim.2006.09.021; Rothoerl RD, 2000, ACTA NEUROCHIR, V142, P199, DOI 10.1007/s007010050024; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; SCHLAEPFER WW, 1985, ANN NY ACAD SCI, V455, P552, DOI 10.1111/j.1749-6632.1985.tb50435.x; Shaw, 1998, NEUROFILAMENTS; Shaw G, 2005, BIOCHEM BIOPH RES CO, V336, P1268, DOI 10.1016/j.bbrc.2005.08.252; Shaw G, 2004, BIOCHEM BIOPH RES CO, V325, P619, DOI 10.1016/j.bbrc.2004.09.223; Shaw GJ, 2002, ANN EMERG MED, V39, P254, DOI 10.1067/mem.2002.121214; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; Strong MJ, 2001, J NEUROCHEM, V76, P1315, DOI 10.1046/j.1471-4159.2001.00094.x; Stroop R, 1998, ACT NEUR S, V71, P303; Stys PK, 2005, J NEUROL SCI, V233, P3, DOI 10.1016/j.jns.2005.03.031; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Togo T, 2002, ACTA NEUROPATHOL, V104, P398, DOI 10.1007/s00401-002-0569-x	40	105	110	0	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2008	25	9					1079	1085		10.1089/neu.2007.0488			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	360JX	WOS:000260054900004	18729720	Green Accepted, Green Published			2022-02-06	
J	Maldonado, MA; Allred, RP; Felthauser, EL; Jones, TA				Maldonado, Monica A.; Allred, Rachel P.; Felthauser, Erik L.; Jones, Theresa A.			Motor skill training, but not voluntary exercise, improves skilled reaching after unilateral ischemic lesions of the sensorimotor cortex in rats	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						exercise; rehabilitation; skilled reaching; experience-dependent plasticity	DENDRITIC STRUCTURAL PLASTICITY; FOCAL CORTICAL ISCHEMIA; TRAUMATIC BRAIN-INJURY; ADULT SQUIRREL-MONKEYS; GROWTH-FACTOR-I; NEUROTROPHIC FACTOR; SYNAPTIC-PLASTICITY; MOVEMENT REPRESENTATIONS; SPINAL-CORD; FUNCTIONAL RECOVERY	Background and Purpose. Exercise and rehabilitative training each have been implicated in the promotion of restorative neural plasticity after cerebral injury. Because motor skill training induces synaptic plasticity and exercise increases plasticity-related proteins, we asked if exercise could improve the efficacy of training on a skilled motor task after focal cortical lesions. Methods. Female young and middle-aged rats were trained on the single-pellet retrieval task and received unilateral ischemic sensorimotor cortex lesions contralateral to the trained limb. Rats then received both, either, or neither voluntary running and/or rehabilitative training for 5 weeks beginning 5 days postlesion. Motor skill training consisted of daily practice of the impaired forelimb in a tray-reaching task. Exercised rats had free access to running wheels for 6 h/day. Reaching function was periodically probed using the single-pellet retrieval task. Results. In young adults, motor skill training significantly enhanced skilled reaching recovery compared to controls. However, exercise did not significantly enhance performance when administered alone or in combination with skill training. There was also no major benefit of exercise in older rats. Additionally, there were no effects of exercise in a measure of coordinated forelimb placement (the foot-fault test) or in immunocytochemical measures of several plasticity-related proteins in the motor cortex. Conclusions. In young and middle-aged animals, exercise did not improve motor skill training efficacy following ischemic lesions. Practicing motor skills more effectively improved recovery of these skills than did exercise. It remains possible that an alternative manner of administering exercise would be more effective.	[Maldonado, Monica A.; Felthauser, Erik L.; Jones, Theresa A.] Univ Texas Austin, Inst Neurosci, Austin, TX 78712 USA; [Allred, Rachel P.; Jones, Theresa A.] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA		Jones, TA (corresponding author), Univ Stn A8000, Austin, TX 78712 USA.	tjones@psy.utexas.edu	Jones, Theresa A/F-1182-2010	Jones, Theresa A/0000-0003-0906-6439; Felthauser, Erik/0000-0001-6688-7458	NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR020700] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH064586, T32MH065728] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F31NS059290, R01NS056839] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [RR020700, P20 RR020700] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH 65728, MH 64586, R01 MH064586, T32 MH065728] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS056839-06, R01 NS056839, R01 NS056839-07, F31 NS059290-01A1] Funding Source: Medline		Adkins DL, 2006, J APPL PHYSIOL, V101, P1776, DOI 10.1152/japplphysiol.00515.2006; Adkins DL, 2005, NEUROSCI LETT, V380, P214, DOI 10.1016/j.neulet.2005.01.036; Adkins DL, 2004, NEUROSCIENCE, V128, P473, DOI 10.1016/j.neuroscience.2004.07.019; Adkins-Muir DL, 2003, NEUROL RES, V25, P780, DOI 10.1179/016164103771953853; Adlard PA, 2004, NEUROSCI LETT, V363, P43, DOI 10.1016/j.neulet.2004.03.058; Allen PB, 1997, P NATL ACAD SCI USA, V94, P9956, DOI 10.1073/pnas.94.18.9956; Allred RP, 2004, EXP NEUROL, V190, P433, DOI 10.1016/j.expneurol.2004.08.005; Barbay S, 2006, EXP BRAIN RES, V169, P106, DOI 10.1007/s00221-005-0129-4; BARTH TM, 1990, BEHAV BRAIN RES, V39, P73, DOI 10.1016/0166-4328(90)90122-U; Biernaskie J, 2004, J NEUROSCI, V24, P1245, DOI 10.1523/JNEUROSCI.3834-03.2004; Biernaskie J, 2001, J NEUROSCI, V21, P5272, DOI 10.1523/JNEUROSCI.21-14-05272.2001; BLACK JE, 1990, P NATL ACAD SCI USA, V87, P5568, DOI 10.1073/pnas.87.14.5568; Bury SD, 2002, J NEUROSCI, V22, P8597; Chen JL, 1999, J NEUROL SCI, V171, P24, DOI 10.1016/S0022-510X(99)00247-6; Conner JM, 2005, NEURON, V46, P173, DOI 10.1016/j.neuron.2005.03.003; Dancause N, 2005, J NEUROSCI, V25, P10167, DOI 10.1523/JNEUROSCI.3256-05.2005; DeBow SB, 2003, STROKE, V34, P1021, DOI 10.1161/01.STR.0000063374.89732.9F; Ding Q, 2006, NEUROSCIENCE, V140, P823, DOI 10.1016/j.neuroscience.2006.02.084; Ding YH, 2004, CURR NEUROVASC RES, V1, P411, DOI 10.2174/1567202043361875; Ding YH, 2006, CURR NEUROVASC RES, V3, P15, DOI 10.2174/156720206775541787; Feng J, 2000, P NATL ACAD SCI USA, V97, P9287, DOI 10.1073/pnas.97.16.9287; Friel KM, 2007, NEUROREHAB NEURAL RE, V21, P51, DOI 10.1177/1545968306291851; Friel KM, 1998, SOMATOSENS MOT RES, V15, P173, DOI 10.1080/08990229870745; Fuxe K, 1997, NEUROREPORT, V8, P2623, DOI 10.1097/00001756-199707280-00040; Gharbawie OA, 2005, BEHAV BRAIN RES, V156, P125, DOI 10.1016/j.bbr.2004.05.015; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; GUNDERSEN HJG, 1988, APMIS, V96, P379, DOI 10.1111/j.1699-0463.1988.tb05320.x; Hsu JE, 2006, EXP NEUROL, V201, P479, DOI 10.1016/j.expneurol.2006.05.003; Humm JL, 1998, BRAIN RES, V783, P286, DOI 10.1016/S0006-8993(97)01356-5; Hutchinson KJ, 2004, BRAIN, V127, P1403, DOI 10.1093/brain/awh160; Johansson BB, 1996, EXP NEUROL, V139, P322, DOI 10.1006/exnr.1996.0106; Jones TA, 1999, J COMP NEUROL, V414, P57; Kleim JA, 2003, NEUROCHEM RES, V28, P1757, DOI 10.1023/A:1026025408742; Kleim JA, 1998, J NEUROPHYSIOL, V80, P3321, DOI 10.1152/jn.1998.80.6.3321; Kleim JA, 2002, BRAIN RES, V934, P1, DOI 10.1016/S0006-8993(02)02239-4; Klintsova AY, 2004, BRAIN RES, V1028, P92, DOI 10.1016/j.brainres.2004.09.003; Kolb B, 1991, CEREB CORTEX, V1, P189, DOI 10.1093/cercor/1.2.189; Komitova M, 2005, EUR J NEUROSCI, V21, P2397, DOI 10.1111/j.1460-9568.2005.04072.x; KOSAR E, 1986, BRAIN RES, V379, P329, DOI 10.1016/0006-8993(86)90787-0; Kozlowski DA, 1996, J NEUROSCI, V16, P4776; Leasure JL, 2004, BEHAV BRAIN RES, V150, P83, DOI 10.1016/S0166-4328(03)00254-7; Li J, 2004, NEUROL RES, V26, P404, DOI 10.1179/016164104225016038; Markham JA, 2004, NEURON GLIA BIOL, V1, P351, DOI 10.1017/S1740925X05000219; Mattson MP, 2005, ANNU REV NUTR, V25, P237, DOI 10.1146/annurev.nutr.25.050304.092526; Mattson MP, 2005, J NUTR BIOCHEM, V16, P129, DOI 10.1016/j.jnutbio.2004.12.007; Molteni R, 2004, P NATL ACAD SCI USA, V101, P8473, DOI 10.1073/pnas.0401443101; Monfils MH, 2005, NEUROSCIENTIST, V11, P471, DOI 10.1177/1073858405278015; Nudo RJ, 1996, J NEUROPHYSIOL, V75, P2144, DOI 10.1152/jn.1996.75.5.2144; Nudo RJ, 1996, J NEUROSCI, V16, P785; Paxinos G, 1986, RAT BRAIN STEREOTAXI; PETERSON GM, 1951, J COMP PHYSIOL PSYCH, V44, P191, DOI 10.1037/h0060555; Ploughman M, 2005, NEUROSCIENCE, V136, P991, DOI 10.1016/j.neuroscience.2005.08.037; Ploughman M, 2007, BRAIN RES, V1150, P207, DOI 10.1016/j.brainres.2007.02.065; Ramanathan D, 2006, P NATL ACAD SCI USA, V103, P11370, DOI 10.1073/pnas.0601065103; Schmanke TD, 1996, J NEUROTRAUM, V13, P293, DOI 10.1089/neu.1996.13.293; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Swain RA, 2003, NEUROSCIENCE, V117, P1037, DOI 10.1016/S0306-4522(02)00664-4; Tropp J, 2001, PHYSIOL BEHAV, V73, P553, DOI 10.1016/S0031-9384(01)00487-5; Vaynman S, 2004, EUR J NEUROSCI, V20, P2580, DOI 10.1111/j.1460-9568.2004.03720.x; Vaynman S, 2003, NEUROSCIENCE, V122, P647, DOI 10.1016/j.neuroscience.2003.08.001; Vaynman S, 2005, NEUROREHAB NEURAL RE, V19, P283, DOI 10.1177/1545968305280753; Wang RY, 2001, BRAIN RES, V922, P140, DOI 10.1016/S0006-8993(01)03154-7; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; WHISHAW IQ, 1986, BRAIN, V109, P805, DOI 10.1093/brain/109.5.805; WHISHAW IQ, 1992, BEHAV BRAIN RES, V52, P45, DOI 10.1016/S0166-4328(05)80323-7; Will B, 2004, PROG NEUROBIOL, V72, P167, DOI 10.1016/j.pneurobio.2004.03.001; Woodlee MT, 2004, RESTOR NEUROL NEUROS, V22, P153; WOOLLEY CS, 1993, J COMP NEUROL, V336, P293, DOI 10.1002/cne.903360210; Ying Z, 2005, EXP NEUROL, V193, P411, DOI 10.1016/j.expneurol.2005.01.015	71	105	107	0	8	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683			NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	MAY-JUN	2008	22	3					250	261		10.1177/1545968307308551			12	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	302IM	WOS:000255962000004	18073324	Green Accepted			2022-02-06	
J	Maikos, JT; Elias, RAI; Shreiber, DI				Maikos, Jason T.; Elias, Ragi A. I.; Shreiber, David I.			Mechanical properties of dura mater from the rat brain and spinal cord	JOURNAL OF NEUROTRAUMA			English	Article						constitutive modeling; injury biomechanics; spinal cord injury; tissue mechanics; traumatic brain injury; viscoelasticity	CEREBROSPINAL-FLUID; IN-VITRO; INJURY; FIBROBLASTS; TENSION; TISSUE; MODEL; DEFORMATION; GLYCEROL; VIVO	The dura mater is the outermost and most substantial meningial layer of central nervous system (CNS) tissue that acts as a protective membrane for the brain and spinal cord. In animal models of traumatic brain injury and spinal cord injury, mechanical insults are often delivered directly to the dura to injure the underlying tissue. As such, including a description of the mechanical properties of dura mater is critical for biomechanical analyses of these models. We have characterized the mechanical response of dura mater from the rat brain and spinal cord in uniaxial tension. Testing was performed at low (0.0014 sec(-1)) and high (19.42 sec(-1)) strain rates. Both rat cranial dura and spinal dura demonstrated non-linear stress-strain responses characteristic of collagenous soft tissues. The non-linear increase in stress lagged in the spinal dura compared to the cranial dura. The slow rate data was fit to a one-term Ogden hyperelastic constitutive law, and significant differences were observed for the stiffness, G, and the parameter, alpha, which nominally introduces non-linearity. High strain rate stress-relaxation tests were performed to 10% strain, which was held for 10 sec. The relaxation was fit to a four-term Prony series exponential decay. Cranial dura and spinal dura demonstrated similar overall relaxation, but significant differences were identified in the distribution of the relaxation over the Prony series parameters, which demonstrated that cranial dura tended to relax faster. Polarized light microscopy revealed that the structural entities of spinal dura were aligned in the axial direction, whereas cranial dura did not demonstrate a preferential alignment. This was confirmed qualitatively with Masson's Tri-chrome and Verhoeff's Van Gieson staining for collagen and elastin, which also indicated greater elastin content for the spinal dura than for the cranial dura.	[Maikos, Jason T.; Elias, Ragi A. I.; Shreiber, David I.] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ 08854 USA		Shreiber, DI (corresponding author), Rutgers State Univ, Dept Biomed Engn, 599 Taylor Rd, Piscataway, NJ 08854 USA.	shreiber@rci.rutgers.edu	Shreiber, David/ABE-8254-2021	Shreiber, David/0000-0001-8248-419X	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49CCR 221744-01] Funding Source: Medline		Berkowitz ED, 1998, REV AM HIST, V26, P620; Bilston LE, 1996, ANN BIOMED ENG, V24, P67; Carpenter PW, 2003, J BIOMECH ENG-T ASME, V125, P857, DOI 10.1115/1.1634281; D'Addario M, 2003, J BIOL CHEM, V278, P53090, DOI 10.1074/jbc.M309027200; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Federspil PA, 2003, LARYNGOSCOPE, V113, P465, DOI 10.1097/00005537-200303000-00014; Fiford RJ, 2005, J BIOMECH, V38, P1509, DOI 10.1016/j.jbiomech.2004.07.009; FRISEN M, 1969, J BIOMECH, V2, P13, DOI 10.1016/0021-9290(69)90037-2; GALFORD JE, 1970, J BIOMECH, V3, P211, DOI 10.1016/0021-9290(70)90007-2; Gefen A, 2003, J NEUROTRAUM, V20, P1163, DOI 10.1089/089771503770802853; Gefen A, 2004, J BIOMECH, V37, P1339, DOI 10.1016/j.jbiomech.2003.12.032; Guertin PA, 2005, SPINAL CORD, V43, P459, DOI 10.1038/sj.sc.3101754; Haimann MCJ, 1998, J ANAT, V192, P99; He YL, 2004, CONNECT TISSUE RES, V45, P28, DOI 10.1080/03008200490278124; Ichihara K, 2001, J NEUROTRAUM, V18, P361, DOI 10.1089/08977150151071053; Jin Xin, 2006, Stapp Car Crash J, V50, P637; Kessler D, 2001, J BIOL CHEM, V276, P36575, DOI 10.1074/jbc.M101602200; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Linninger AA, 2007, IEEE T BIO-MED ENG, V54, P291, DOI 10.1109/TBME.2006.886853; Loth F, 2001, J BIOMECH ENG-T ASME, V123, P71, DOI 10.1115/1.1336144; MCGARVEY KA, 1984, BIOMATERIALS, V5, P109, DOI 10.1016/0142-9612(84)90011-5; MEANEY DF, 1994, J NEUROTRAUM, V11, P599, DOI 10.1089/neu.1994.11.599; Miller K, 2002, J BIOMECH, V35, P483, DOI 10.1016/S0021-9290(01)00234-2; Park J.B., 1984, BIOMATERIALS SCI ENG; PATIN DJ, 1993, ANESTH ANALG, V76, P535; Petroll WM, 2004, INVEST OPHTH VIS SCI, V45, P3466, DOI 10.1167/iovs.04-0361; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Runza M, 1999, ANESTH ANALG, V88, P1317, DOI 10.1097/00000539-199906000-00022; Spicer MA, 2004, NEUROSURGERY, V54, P783, DOI 10.1227/01.NEU.0000114139.16118.F2; Stokes BT, 2002, SPINAL CORD, V40, P101, DOI 10.1038/sj.sc.3101254; STOKES BT, 1992, J NEUROTRAUM, V9, P187, DOI 10.1089/neu.1992.9.187; Taylor Z, 2004, J BIOMECH, V37, P1263, DOI 10.1016/j.jbiomech.2003.11.027; UENO K, 1995, J NEUROTRAUM, V12, P695, DOI 10.1089/neu.1995.12.695; Vandenabeele F, 1996, J ANAT, V189, P417; VANNOORT R, 1981, BIOMATERIALS, V2, P41, DOI 10.1016/0142-9612(81)90086-7; VIIDIK A, 1968, Journal of Biomechanics, V1, P3, DOI 10.1016/0021-9290(68)90032-8; Weed LH, 1938, J ANAT, V72, P181; Young W, 2002, PROG BRAIN RES, V137, P231; Yuan Q, 1998, SPINE, V23, P1677, DOI 10.1097/00007632-199808010-00012	39	105	108	1	36	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2008	25	1					38	51		10.1089/neu.2007.0348			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	258IJ	WOS:000252861300004	18355157				2022-02-06	
J	Singh, IN; Sullivan, PG; Hall, ED				Singh, Indrapal N.; Sullivan, Patrick G.; Hall, Edward D.			Peroxynitrite-mediated oxidative damage to brain mitochondria: Protective effects of peroxynitrite scavengers	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						peroxynitrite; mitochondria; penicillamine; tempol; oxidative damage	MEMBRANE-LIPID-PEROXIDATION; NITRIC-OXIDE; NITROXIDE RADICALS; MOUSE MODEL; INJURY; DYSFUNCTION; SUPEROXIDE; NITRATION; MELATONIN; MECHANISM	Peroxynitrite-mediated oxidative damage has been implicated in brain mitochondrial respiratory dysfunction after traumatic brain injury (TBI), which precedes the onset of neuronal loss. The aim of this study was to investigate the detrimental effects of the peroxynitrite donor SIN-1 (3-morpholinosydnonimine) on isolated brain mitochondria and to screen penicillamine, a stoichiometric (1:1) peroxynitrite-scavenging agent, and tempol, a catalytic scavenger of peroxynitrite-derived radicals, as antioxidant mitochondrial protectants. Exposure of the isolated mitochondria to SIN-1 caused a significant dose-dependent decrease in the respiratory control ratio and was accompanied by a significant increase in state 11 respiration, followed by significant decreases (P < 0.05) in states III and V. These functional alterations occurred together with significant increases in mitochondrial protein carbonyl (PC), lipid peroxidation-related 4-hydroxynonenal (4-HNE), and 3-nitrotyrosine (3-NT) content. Penicillamine hydrochloride (10 mu M) partially but significantly (P < 0.05) protected against SIN-1-induced decreases in states III and V. However, a 2.5 mu M concentration of tempol was able to significantly antagonize a 4-fold molar excess (10 mu M) concentration of SIN-1 as effectively as were higher tempol concentrations, consistent with the likelihood that tempol works by a catalytic mechanism. The protection of mitochondrial respiration by penicillamine and tempol occurred in parallel with attenuation of PC, 4-HNE, and 3-NT. These results indicate that SIN-1 causes mitochondrial oxidative damage and complex I dysfunction and that antioxidant compounds that target either peroxynitrite or its radicals may be effective mitochondrial protectants in the treatment of neural injury. (c) 2007 Wiley-Liss, Inc.	Univ Kentucky, Coll Med, Brain Injury Res Ctr, Lexington, KY 40536 USA		Hall, ED (corresponding author), Univ Kentucky, Coll Med, Brain Injury Res Ctr, B383 BBSRB,741 S Limestone St, Lexington, KY 40536 USA.	edhall@uky.edu	Hall, Edward D/F-8930-2013				Alvarez B, 2003, AMINO ACIDS, V25, P295, DOI 10.1007/s00726-003-0018-8; BECKMAN JS, 1991, J DEV PHYSIOL, V15, P53; BeitYannai E, 1996, BRAIN RES, V717, P22, DOI 10.1016/0006-8993(95)01492-6; Bonini MG, 2002, CHEM RES TOXICOL, V15, P506, DOI 10.1021/tx015571z; BOYER PD, 1977, ANNU REV BIOCHEM, V46, P955, DOI 10.1146/annurev.bi.46.070177.004515; Brown MR, 2004, J NEUROSCI METH, V137, P299, DOI 10.1016/j.jneumeth.2004.02.028; Carroll RT, 2000, CHEM RES TOXICOL, V13, P294, DOI 10.1021/tx990159t; Cassina A, 1996, ARCH BIOCHEM BIOPHYS, V328, P309, DOI 10.1006/abbi.1996.0178; Cirak B, 1999, PEDIATR NEUROSURG, V31, P298, DOI 10.1159/000028879; Denicola A, 1996, ARCH BIOCHEM BIOPHYS, V333, P49, DOI 10.1006/abbi.1996.0363; Frankel EN, 1996, J AGR FOOD CHEM, V44, P131, DOI 10.1021/jf950374p; Fujimura M, 2000, J NEUROSCI, V20, P2817; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Hall ED, 1996, ACT NEUR S, V66, P107; Hall ED, 1999, ANN NY ACAD SCI, V890, P462, DOI 10.1111/j.1749-6632.1999.tb08025.x; Hall ED, 1996, BRAIN RES, V742, P80, DOI 10.1016/S0006-8993(96)00968-7; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hortelano S, 1997, FEBS LETT, V410, P373, DOI 10.1016/S0014-5793(97)00623-6; Lai J C, 1979, Methods Enzymol, V55, P51; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Martin H, 2005, LITHOS, V79, P1, DOI 10.1016/j.lithos.2004.04.048; Mesenge C, 1998, J PINEAL RES, V25, P41, DOI 10.1111/j.1600-079X.1998.tb00384.x; Mesenge C, 1998, EUR J PHARMACOL, V353, P53, DOI 10.1016/S0014-2999(98)00432-4; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; Radi R, 1998, CHEM RES TOXICOL, V11, P720, DOI 10.1021/tx980096z; Radi R, 2002, FREE RADICAL BIO MED, V33, P1451, DOI 10.1016/S0891-5849(02)01111-5; Radi R, 2004, P NATL ACAD SCI USA, V101, P4003, DOI 10.1073/pnas.0307446101; Richards EM, 2006, FREE RADICAL BIO MED, V40, P1960, DOI 10.1016/j.freeradbiomed.2006.01.022; Rohn TT, 1998, BIOCHEM PHARMACOL, V56, P1371, DOI 10.1016/S0006-2952(98)00266-4; Romero N, 1999, ARCH BIOCHEM BIOPHYS, V368, P23, DOI 10.1006/abbi.1999.1272; Sarrafzadeh AS, 2000, ACTA NEUROCHIR, V142, P1293, DOI 10.1007/s007010070028; Sensi SL, 2003, P NATL ACAD SCI USA, V100, P6157, DOI 10.1073/pnas.1031598100; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Sullivan PG, 2004, J BIOENERG BIOMEMBR, V36, P353, DOI 10.1023/B:JOBB.0000041767.30992.19; Sullivan PG, 2000, ANN NEUROL, V48, P723, DOI 10.1002/1531-8249(200011)48:5&lt;723::AID-ANA5&gt;3.0.CO;2-W; Sullivan PG, 2005, EPILEPSY BEHAV, V7, pS12, DOI 10.1016/j.yebeh.2005.08.004; Sullivan PG, 2004, J COMP NEUROL, V474, P524, DOI 10.1002/cne.20130; Sullivan PG, 2003, ANN NEUROL, V53, P711, DOI 10.1002/ana.10543; Yamamoto T, 2002, J NEURAL TRANSM, V109, P1, DOI 10.1007/s702-002-8232-1; Zhang RL, 1998, FREE RADICAL BIO MED, V24, P332, DOI 10.1016/S0891-5849(97)00267-0	41	105	107	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	AUG 1	2007	85	10					2216	2223		10.1002/jnr.21360			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	196XO	WOS:000248516700016	17510982				2022-02-06	
J	Catena, RD; van Donkelaar, P; Chou, LS				Catena, Robert D.; van Donkelaar, Paul; Chou, Li-Shan			Cognitive task effects on gait stability following concussion	EXPERIMENTAL BRAIN RESEARCH			English	Article						concussion; cognition; dual-task; attention; gait	TRAUMATIC BRAIN-INJURY; MILD HEAD-INJURY; CENTER-OF-MASS; DIVIDED ATTENTION; FOOTBALL PLAYERS; RECOVERY; COLLEGIATE; BALANCE; WALKING; DIFFICULTY	The purpose of this study was to determine how two different types of concurrent tasks affect gait stability in patients with concussion and how balance is maintained. Fourteen individuals suffering from a grade II concussion and 14 matched controls performed a single task of level walking and two types of concurrent tasks during level walking: a discrete reaction time task and a continuous sequential question and answer task. Common gait spatial/temporal measurements, whole-body center of mass motion, and the center of pressure trajectory were recorded. Concussed individuals demonstrated differences in gait while performing single-task level walking and while being challenged with a more difficult secondary task compared to normal controls. Concussed individuals adopted a slower, more conservative gait strategy to maintain stability, but still exhibited signs of instability with center of mass deviations in the coronal plane increasing by 13% during the question and answer dual-task and 26% more than control subjects. Trends of attentional deficits were present with the question and answer task, while the reaction time task seemed to help concussed individuals be more alert to their gait and stability. Recommendations for a sensitive testing protocol of deficits following concussion are explained.	1240 Univ Oregon, Mot Anal Lab, Dept Human Physiol, Eugene, OR 97403 USA; Univ Oregon, Eye Hand Lab, Dept Human Physiol, Eugene, OR 97403 USA		Chou, LS (corresponding author), 1240 Univ Oregon, Mot Anal Lab, Dept Human Physiol, Eugene, OR 97403 USA.	chou@uoregon.edu	Catena, Robert/AAT-1510-2021	Catena, Robert/0000-0001-9128-1343	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR021735, CCR023203] Funding Source: Medline		BARDY BG, 1991, PERCEPT MOTOR SKILL, V72, P915, DOI 10.2466/PMS.72.3.915-926; BELL R, 1977, AM FAM PHYSICIAN, V16, P145; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; Bowen A, 2001, AGE AGEING, V30, P319, DOI 10.1093/ageing/30.4.319; Brown LA, 1999, J GERONTOL A-BIOL, V54, pM165, DOI 10.1093/gerona/54.4.M165; BRUKNER P, 2001, CLIN SPORTS MED; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P224; Chou LS, 2004, GAIT POSTURE, V20, P245, DOI 10.1016/j.gaitpost.2003.09.007; Chou LS, 2003, GAIT POSTURE, V18, P125, DOI 10.1016/S0966-6362(02)00067-X; Cock J, 2003, BRAIN INJURY, V17, P561, DOI 10.1080/0269905031000088306; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; DEJONG R, 1995, ACTA PSYCHOL, V90, P287, DOI 10.1016/0001-6918(95)00036-T; EBERSBACH G, 1995, PERCEPT MOTOR SKILL, V81, P107, DOI 10.2466/pms.1995.81.1.107; Gagnon I, 2004, ARCH PHYS MED REHAB, V85, P444, DOI 10.1016/j.apmr.2003.06.014; Godefroy O, 2002, NEUROPSYCHOLOGIA, V40, P2234, DOI 10.1016/S0028-3932(02)00109-4; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; HAALAND KY, 1994, J CLIN EXP NEUROPSYC, V16, P448, DOI 10.1080/01688639408402655; Haggard P, 2000, J NEUROL NEUROSUR PS, V69, P479, DOI 10.1136/jnnp.69.4.479; Hahn ME, 2004, J BIOMECH, V37, P837, DOI 10.1016/j.jbiomech.2003.11.010; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; Kahneman D., 1973, ATTENTION EFFORT; Kaya BK, 1998, J GERONTOL A-BIOL, V53, pM126, DOI 10.1093/gerona/53A.2.M126; Kelly JP, 1997, NEUROLOGY, V48, P581; Krauss JK, 1997, MOVEMENT DISORD, V12, P428, DOI 10.1002/mds.870120326; LAJOIE Y, 1993, EXP BRAIN RES, V97, P139; Maki BE, 1997, J AM GERIATR SOC, V45, P313, DOI 10.1111/j.1532-5415.1997.tb00946.x; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McFadyen BJ, 2003, J HEAD TRAUMA REHAB, V18, P512, DOI 10.1097/00001199-200311000-00005; Mrazik M, 2000, BRAIN INJURY, V14, P921, DOI 10.1080/026990500445736; Parker TM, 2005, CLIN BIOMECH, V20, P389, DOI 10.1016/j.clinbiomech.2004.12.004; PASHLER H, 1990, J EXP PSYCHOL HUMAN, V16, P826, DOI 10.1037/0096-1523.16.4.826; Slobounov S, 2002, CLIN NEUROPHYSIOL, V113, P185, DOI 10.1016/S1388-2457(01)00737-4; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Vallis LA, 2004, EXP BRAIN RES, V157, P94, DOI 10.1007/s00221-003-1824-7; VANDONKELAAR P, 2006, IN PRESS EXERCISE SP, V34; VANDONKELAAR P, 2005, IN PRESS BRAIN INJUR; Weerdesteyn V, 2003, J MOTOR BEHAV, V35, P53, DOI 10.1080/00222890309602121; Winter D.A., 1990, BIOMECHANICS MOTOR C, VVol. 1; WOLTRING HJ, 1986, ADV ENG SOFTW WORKST, V8, P104, DOI 10.1016/0141-1195(86)90098-7	40	105	106	1	13	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0014-4819			EXP BRAIN RES	Exp. Brain Res.	JAN	2007	176	1					23	31		10.1007/s00221-006-0596-2			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	144HQ	WOS:000244787500003	16826411				2022-02-06	
J	Landre, N; Poppe, CJ; Davis, N; Schmaus, B; Hobbs, SE				Landre, Nancy; Poppe, Christopher J.; Davis, Nancy; Schmaus, Brian; Hobbs, Susan E.			Cognitive functioning and postconcussive symptoms in trauma patients with and without mild TBI	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						mild TBI; postconcussive syndrome; cognitive; neuropsychological; trauma; outcome	MINOR HEAD-INJURY; POST-CONCUSSIONAL SYNDROME; BRAIN-INJURY; CHRONIC PAIN; HIGH-SCHOOL; BASE RATES; RECOVERY; SPORTS; PSYCHOGENESIS; PHYSIOGENESIS	Although there is a large body of research on mild traumatic brain injury (MTBI), the portion that pertains to acute patients (those less than 1 month postinjury) is relatively small and yields inconsistent findings. The potential contribution of non-neurological factors, such as pain and emotional distress, to the clinical picture in this population is also lacking. To address these issues, the cognitive performance and symptom complaints of 37 hospitalized MTBI subjects were compared to those of 39 hospitalized trauma subjects, averaging 4.5 days postinjury. MTBI subjects performed significantly worse on all cognitive measures, but did not differ from trauma subjects in their report of postconcussive symptoms. Analyses also revealed that cognitive performance was unrelated to pain severity and emotional distress. Postconcussive symptoms were similarly unrelated to pain severity, but were consistently related to emotional distress. Results are discussed in terms of their etiological and treatment implications. (c) 2006 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	Lutheran Gen Hosp, Neuropsychol Serv, Park Ridge, IL 60068 USA; Ingenium Clin Res, Libertyville, IL USA; Advocate Res & Educ, Park Ridge, IL USA		Landre, N (corresponding author), Lutheran Gen Hosp, Neuropsychol Serv, Parkside Bldg,Suite 690,1775 Dempster St, Park Ridge, IL 60068 USA.	Nancy.Landre@advocatehealth.com					BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; Brooks J, 1999, J TRAUMA, V46, P159, DOI 10.1097/00005373-199901000-00027; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; DIKMEN S, 1987, NEUROBEHAVIORAL RECO; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Ferguson R.J., 1996, SOURCEBOOK PSYCHOL T; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; GFELLER JD, 1994, HEADACHE, V34, P503, DOI 10.1111/j.1526-4610.1994.hed3409503.x; GORDON M, 1982, GORDON DIAGNOSTIC SY; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; GRONWALL D, 1974, LANCET, V2, P605; Hart RP, 2000, NEUROPSYCHOL REV, V10, P131, DOI 10.1023/A:1009020914358; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; JACOBSON RR, 1995, J PSYCHOSOM RES, V39, P675, DOI 10.1016/0022-3999(95)00006-5; KAY T, 1992, PHYSICAL MED REHABIL, V6, P109; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; Lees-Haley PR, 2001, ARCH CLIN NEUROPSYCH, V16, P689, DOI 10.1016/S0887-6177(00)00092-5; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LIDVALL H F, 1974, Acta Neurologica Scandinavica Supplementum, V50, P1; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; MCMILLAN TM, 1987, J NEUROL NEUROSUR PS, V50, P393, DOI 10.1136/jnnp.50.4.393; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; NEWCOMBE F, 1994, J NEUROL NEUROSUR PS, V57, P709, DOI 10.1136/jnnp.57.6.709; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Reitan RM., 1979, TRAIL MAKING TEST MA; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; WARE JE, 1994, SF36 PHYS MENTAL HLT; Wechsler D, 1987, MEMORY SCALE REVISED; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3	56	105	107	0	7	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	MAY	2006	21	4					255	273		10.1016/j.acn.2005.12.007			19	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	067GI	WOS:000239289500002	16716563	Bronze			2022-02-06	
J	Wagner, AK; Sokoloski, JE; Ren, D; Chen, X; Khan, AS; Zafonte, RD; Michael, AC; Dixon, CE				Wagner, AK; Sokoloski, JE; Ren, D; Chen, X; Khan, AS; Zafonte, RD; Michael, AC; Dixon, CE			Controlled cortical impact injury affects dopaminergic transmission in the rat striatum	JOURNAL OF NEUROCHEMISTRY			English	Article						dopamine; dopamine transporter; fast scan cyclic voltammetry; kinetics; rotational behavior; traumatic brain injury	TRAUMATIC BRAIN-INJURY; VESICULAR MONOAMINE TRANSPORTER; CAUDATE-PUTAMEN; METHYLPHENIDATE TREATMENT; TYROSINE-HYDROXYLASE; NUCLEUS-ACCUMBENS; RAPID REGULATION; COCAINE; EXPRESSION; CORTEX	The therapeutic benefits of dopamine (DA) agonists after traumatic brain injury (TBI) imply a role for DA systems in mediating functional deficits post-TBI. We investigated how experimental TBI affects striatal dopamine systems using fast scan cyclic voltammetry (FSCV), western blot, and d-amphetamine-induced rotational behavior. Adult male Sprague-Dawley rats were injured by a controlled cortical impact (CCI) delivered unilaterally to the parietal cortex, or were naive controls. Amphetamine-induced rotational behavior was assessed 10 days post-CCI. Fourteen days post-CCI, animals were anesthetized and underwent FSCV with bilateral striatal carbon fiber microelectrode placement and stimulating electrode placement in the medial forebrain bundle (MFB). Evoked DA overflow was assessed in the striatum as the MFB was electrically stimulated at 60 Hz for 10 s. In 23% of injured animals, but no naive animals, rotation was observed with amphetamine administration. Compared with naives, striatal evoked DA overflow was lower for injured animals in the striatum ipsilateral to injury (p < 0.05). Injured animals exhibited a decrease in V-max (52% of naive, p < 0.05) for DA clearance in the hemisphere ipsilateral to injury compared with naives. Dopamine transporter (DAT) expression was proportionally decreased in the striatum ipsilateral to injury compared with naive animals (60% of naive, p < 0.05), despite no injury-related changes in vesicular monoamine transporter or D-2 receptor expression (DRD2) in this region. Collectively, these data appear to confirm that the clinical efficacy of dopamine agonists in the treatment of TBI may be related to disruptions in the activity of subcortical dopamine systems.	Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Publ Hlth, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Chem, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA 15213 USA		Wagner, AK (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 5th Ave Suite 202, Pittsburgh, PA 15213 USA.	wagnerak@upmc.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD040833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040125] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD40833] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS40125] Funding Source: Medline		BAUR JE, 1988, ANAL CHEM, V60, P1268, DOI 10.1021/ac00164a006; Bergstrom BP, 2001, J NEUROSCI METH, V106, P15, DOI 10.1016/S0165-0270(00)00372-1; Bezard E, 2003, J NEUROSCI, V23, P10999; Cai GP, 2002, J PHARMACOL EXP THER, V302, P1105, DOI 10.1124/jpet.102.036673; Canales JJ, 2002, BRAIN, V125, P2353, DOI 10.1093/brain/awf239; Copland D, 2003, J INT NEUROPSYCH SOC, V9, P1041, DOI 10.1017/S1355617703970081; Crosson B, 2003, J INT NEUROPSYCH SOC, V9, P1027, DOI 10.1017/S1355617703970068; Daws LC, 2002, BIOCHEM BIOPH RES CO, V290, P1545, DOI 10.1006/bbrc.2002.6384; Dixon C. E., 1999, Society for Neuroscience Abstracts, V25, P313; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Donnemiller E, 2000, EUR J NUCL MED, V27, P1410, DOI 10.1007/s002590000308; DunnMeynell AA, 1997, BRAIN RES, V761, P25, DOI 10.1016/S0006-8993(97)00210-2; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1991, J NEUROL REHABIL, V5, P113; Frey K, 1997, EUR J PHARMACOL, V334, P273, DOI 10.1016/S0014-2999(97)01152-7; Garris PA, 1997, BRAIN RES, V753, P225, DOI 10.1016/S0006-8993(97)00003-6; GERFEN CR, 1990, SCIENCE, V250, P1429, DOI 10.1126/science.2147780; Goldstein LB, 2003, BRAIN INJURY, V17, P685, DOI 10.1080/0269905031000107179; Gulley JM, 2003, EUR J PHARMACOL, V479, P139, DOI 10.1016/j.ejphar.2003.08.064; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; HEFTI F, 1980, PHARMACOL BIOCHEM BE, V12, P185, DOI 10.1016/0091-3057(80)90353-6; Hicks RR, 1999, EXP NEUROL, V160, P469, DOI 10.1006/exnr.1999.7216; Hicks RR, 1999, J NEUROTRAUM, V16, P501, DOI 10.1089/neu.1999.16.501; Jones SR, 1998, P NATL ACAD SCI USA, V95, P4029, DOI 10.1073/pnas.95.7.4029; JONES SR, 1995, J NEUROCHEM, V64, P2581; Jones SR, 1996, PSYCHOPHARMACOLOGY, V126, P331, DOI 10.1007/BF02247384; Kaelin DL, 1996, ARCH PHYS MED REHAB, V77, P6, DOI 10.1016/S0003-9993(96)90211-7; Kilbourn MR, 1996, NUCL MED BIOL, V23, P467, DOI 10.1016/0969-8051(96)00023-6; KLINE AE, 1994, PHARMACOL BIOCHEM BE, V48, P773, DOI 10.1016/0091-3057(94)90345-X; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; KLINE AE, 2001, MO CL BI CC, V2, P267; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kochanek PM, 2002, J NEUROTRAUM, V19, P1029, DOI 10.1089/089771502760341947; Kulagina NV, 2001, NEUROSCIENCE, V102, P121, DOI 10.1016/S0306-4522(00)00480-2; Kumer SC, 1996, J NEUROCHEM, V67, P443; MAY LJ, 1989, BRAIN RES, V487, P311, DOI 10.1016/0006-8993(89)90835-4; Michael DJ, 1999, J PHARMACEUT BIOMED, V19, P33, DOI 10.1016/S0731-7085(98)00145-9; MOKRY J, 1995, PHYSIOL RES, V44, P143; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; Rebec GV, 1997, NEUROSCIENCE, V76, P707, DOI 10.1016/S0306-4522(96)00382-X; Runnels PL, 1999, ANAL CHEM, V71, P2782, DOI 10.1021/ac981279t; Sabeti J, 2002, J NEUROSCI METH, V121, P41, DOI 10.1016/S0165-0270(02)00229-7; SACHS C, 1975, BRAIN RES, V99, P277, DOI 10.1016/0006-8993(75)90029-3; VanderBorght T, 1995, EUR J PHARMACOL, V294, P577; Venton BJ, 2003, J NEUROCHEM, V87, P1284, DOI 10.1046/j.1471-4159.2003.02109.x; WAGNER AK, 2005, IN PRESS GENDER ENV; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Whyte J, 2002, J HEAD TRAUMA REHAB, V17, P284, DOI 10.1097/00001199-200208000-00003; WIGHTMAN RM, 1990, BRAIN RES REV, V15, P135, DOI 10.1016/0165-0173(90)90015-G; WIGHTMAN RM, 1988, NEUROSCIENCE, V25, P513, DOI 10.1016/0306-4522(88)90255-2; Wilson JM, 1996, J NEUROSCI, V16, P3507; WILSON JM, 1994, J NEUROSCI, V14, P2966; Wu Q, 2001, J NEUROSCI METH, V112, P119, DOI 10.1016/S0165-0270(01)00459-9; Yan HQ, 2002, NEUROREPORT, V13, P1899, DOI 10.1097/00001756-200210280-00013; Yan HQ, 2001, NEUROREPORT, V12, P2323, DOI 10.1097/00001756-200108080-00009; Yang H, 1998, J NEUROCHEM, V71, P684; Zahniser NR, 2004, NEUROPHARMACOLOGY, V47, P80, DOI 10.1016/j.neuropharm.2004.07.010; Zhou Y, 2001, BRAIN RES, V917, P127, DOI 10.1016/S0006-8993(01)02935-3; Zhuang XX, 2001, P NATL ACAD SCI USA, V98, P1982, DOI 10.1073/pnas.98.4.1982; 2005, J NEUROCHEM, V95, P457	63	105	107	0	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	OCT	2005	95	2					457	465		10.1111/j.1471-4159.2005.03382.x			9	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	968DU	WOS:000232142900016	16190869				2022-02-06	
J	Giacino, J				Giacino, J			The vegetative and minimally conscious states - Current knowledge and remaining questions	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; COMA SCALE; RECOVERY; DISABILITY; PREDICTION; PROGNOSIS; LIFE; NEUROPATHOLOGY; INTERVENTION	In the last 2 decades, the minimally conscious state has been distinguished conceptually from the vegetative state and operational criteria for these diagnoses have been published. Standardized and individualized assessment tools have been developed to assist with the diagnosis of severe disorders of consciousness and the measurement of clinical improvement. The natural course of recovery and the importance of key prognostic predictors have been elucidated. Important advances have also been made in defining the similarities and differences in the pathophysiology of these two states, and functional imaging modalities have begun to explicate the neural substrate underlying the behavioral features of these disorders. Research on the efficacy of treatments for severe disorders of consciousness lags behind, due to the practical and ethical difficulties in executing large rigorously controlled clinical trials. The past and future scientific developments in this area provide an important background for continuing discussions of the ethical controversies surrounding end-of-life decision making and resource allocation.	JFK Johnson Rehabil Inst, Edison, NJ USA; Moss Rehabil Res Inst, Philadelphia, PA USA		Giacino, J (corresponding author), JFK Johnson Rehabil Inst, 65 James St, Edison, NJ USA.	jgiacino@solarishs.org	Giacino, Joseph/AAF-1952-2021	Giacino, Joseph/0000-0002-7916-9698; Whyte, John/0000-0002-4381-1474	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133A031713] Funding Source: Medline		Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; Andrews K, 1996, BRAIN INJURY, V10, P797, DOI 10.1080/026990596123918; ANSELL BJ, 1989, ARCH PHYS MED REHAB, V70, P104; ARNOULD M, 1963, NEUROCHIRURGICA STUT, V6, P1; ARRILLAGE P, 2000, DETROIT NEWS    0312; ARTS WFM, 1985, J NEUROL NEUROSUR PS, V48, P1300, DOI 10.1136/jnnp.48.12.1300; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Ashwal Stephen, 2002, Semin Pediatr Neurol, V9, P19, DOI 10.1053/spen.2002.30334; BECK M, 1996, NEWSWEEK        0226, P56; BERROLL S, 1986, J HEAD TRAUMA REHAB, P1; Boly M, 2004, ARCH NEUROL-CHICAGO, V61, P233, DOI 10.1001/archneur.61.2.233; BORN JD, 1985, NEUROSURGERY, V16, P595, DOI 10.1227/00006123-198505000-00002; Brenner T, 2003, PEDIATR NEUROL, V28, P104, DOI 10.1016/S0887-8994(02)00491-5; *CATH BISH PENNS, 1999, STAT NUTR HYDR REV M; Childs NL, 1996, NEW ENGL J MED, V334, P24, DOI 10.1056/NEJM199601043340105; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; Coleman D, 2002, NEUROLOGY, V58, P506, DOI 10.1212/WNL.58.3.506; DANIS M, 1994, ANN INTERN MED, V120, P567, DOI 10.7326/0003-4819-120-7-199404010-00006; DiPasquale MC, 1996, J HEAD TRAUMA REHAB, V11, P9, DOI 10.1097/00001199-199612000-00004; FLEMING JM, 1994, ARCH PHYS MED REHAB, V75, P156; Garnett MR, 2001, CURR OPIN NEUROL, V14, P753, DOI 10.1097/00019052-200112000-00012; GIACINO J, 2003, 15 ANN JKF MED CTR C; GIACINO J, 2004, INT C LIF SUST TREAT; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P36, DOI 10.1097/00001199-199708000-00005; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P79, DOI 10.1097/00001199-199708000-00008; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2004, J HEAD TRAUMA REHAB, V19, P254, DOI 10.1097/00001199-200405000-00006; GIACINO JT, 1991, ARCH PHYS MED REHAB, V72, P897, DOI 10.1016/0003-9993(91)90008-7; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GIACINO JT, 1995, ARCH PHYS MED REHAB, V76, P205; GIACINO JT, IN PRESS REHABILITAT; Gill-Thwaites H, 2004, BRAIN INJURY, V18, P1255, DOI 10.1080/02699050410001719952; GillThwaites H, 1997, BRAIN INJURY, V11, P723, DOI 10.1080/026990597123098; Gostin LO, 1997, JAMA-J AM MED ASSOC, V278, P1523, DOI 10.1001/jama.278.18.1523; HAIG AJ, 1990, ARCH PHYS MED REHAB, V71, P1081; HANS P, 1989, J NEUROSURG, V71, P54, DOI 10.3171/jns.1989.71.1.0054; HIGASHI K, 1981, J NEUROL NEUROSUR PS, V44, P552, DOI 10.1136/jnnp.44.6.552; HIRSCH J, 2001, SOC NEUR ABSTR, V529, P14; HORN S, 1992, Brain Injury, V6, P321, DOI 10.3109/02699059209034946; JENNETT B, 1972, LANCET, V1, P734; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Jennett B, 2001, NEUROLOGY, V56, P486, DOI 10.1212/WNL.56.4.486; Jennett B, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199708000-00003; JOHNPAUL II, 2004, LIFE SUSTAINING TREA; JUDSON JA, 1990, CRIT CARE MED, V18, P363, DOI 10.1097/00003246-199004000-00003; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; Laureys S, 2004, NEUROLOGY, V63, P916, DOI 10.1212/01.WNL.0000137421.30792.9B; Laureys S, 2002, NEUROIMAGE, V17, P732, DOI 10.1006/nimg.2002.1236; Laureys S, 2000, BRAIN, V123, P1589, DOI 10.1093/brain/123.8.1589; Lew HL, 2003, AM J PHYS MED REHAB, V82, P53, DOI [10.1097/00002060-200301000-00009, 10.1097/01.PHM.0000043771.90606.81]; MACKAY LE, 1992, ARCH PHYS MED REHAB, V73, P635; Majerus S, 2000, NEUROPSYCHOL REHABIL, V10, P167, DOI 10.1080/096020100389237; McMillan TM, 1997, BRAIN INJURY, V11, P483, DOI 10.1080/713802184; McMillan TM, 2000, BRAIN INJURY, V14, P197, DOI 10.1080/026990500120853; Menon DK, 1998, LANCET, V352, P200, DOI 10.1016/S0140-6736(05)77805-3; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; MITCHELL S, 1990, Brain Injury, V4, P273, DOI 10.3109/02699059009026177; Passler MA, 2001, ARCH PHYS MED REHAB, V82, P311, DOI 10.1053/apmr.2001.20831; Patrick PD, 2003, BRAIN INJURY, V17, P497, DOI 10.1080/0269905031000070279; Phipps E, 1999, AM J PHYS MED REHAB, V78, P77, DOI 10.1097/00002060-199901000-00020; PIERCE J P, 1990, Brain Injury, V4, P191, DOI 10.3109/02699059009026165; Plum F., 1982, DIAGNOSIS STUPOR COM, V3rd; Rader M A, 1989, Brain Inj, V3, P141, DOI 10.3109/02699058909004545; RADER MA, 1994, BRAIN INJURY, V8, P309, DOI 10.3109/02699059409150982; RAPPAPORT M, 1992, ARCH PHYS MED REHAB, V73, P628; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Reinhard DL, 1996, ARCH PHYS MED REHAB, V77, P80, DOI 10.1016/S0003-9993(96)90225-7; ROCKSWOLD GL, 1992, J NEUROSURG, V76, P929, DOI 10.3171/jns.1992.76.6.0929; Sackett D., 2000, PRACTICE TEACH EBM, V2nd edn; Schiff ND, 2002, BRAIN, V125, P1210, DOI 10.1093/brain/awf131; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; Shewmon DA, 2002, NEUROLOGY, V58, P506; SHIN DY, 1989, ARCH PHYS MED REHAB, V70, P189; Showalter PEC, 2000, BRAIN INJURY, V14, P997; STANCZAK DE, 1984, J NEUROSURG, V60, P955, DOI 10.3171/jns.1984.60.5.0955; STARMARK JE, 1988, ACTA NEUROCHIR, V91, P12, DOI 10.1007/BF01400521; Strauss DJ, 1999, PEDIATR NEUROL, V21, P626, DOI 10.1016/S0887-8994(99)00051-X; TALBOT LR, 1994, BRAIN INJURY, V8, P689, DOI 10.3109/02699059409151023; TEASDALE G, 1974, LANCET, V2, P81; Tsubokawa T, 1990, Brain Inj, V4, P315; VAPALAHTI M, 1971, BMJ-BRIT MED J, V3, P404, DOI 10.1136/bmj.3.5771.404; Whyte J, 1999, ARCH PHYS MED REHAB, V80, P653, DOI 10.1016/S0003-9993(99)90168-5; Whyte J, 2001, ARCH PHYS MED REHAB, V82, P1355, DOI 10.1053/apmr.2001.26091; WHYTE J, 1995, ARCH PHYS MED REHAB, V76, P804, DOI 10.1016/S0003-9993(95)80543-5; WHYTE J, IN PRESS ARCH PHYS M; Whyte J, 1999, REHABILITATION ADULT, P435; WILSON S L, 1991, Brain Injury, V5, P393, DOI 10.3109/02699059109008112; Wilson SL, 2000, BRAIN INJURY, V14, P319; Yamamoto T, 2002, ACT NEUR S, V79, P79; [No title captured]	93	105	110	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2005	20	1					30	50		10.1097/00001199-200501000-00005			21	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	894AT	WOS:000226762900004	15668569				2022-02-06	
J	Anstey, KJ; Butterworth, P; Jorm, AF; Christensen, H; Rodgers, B; Windsor, TD				Anstey, KJ; Butterworth, P; Jorm, AF; Christensen, H; Rodgers, B; Windsor, TD			A population survey found an association between self-reports of traumatic brain injury and increased psychiatric symptoms	JOURNAL OF CLINICAL EPIDEMIOLOGY			English	Article						traumatic brain injury; depression; anxiety; suicide; epidemiology	ALCOHOL-CONSUMPTION; HEAD-INJURY; COLLEGE-STUDENTS; DEPRESSION; PREVALENCE; DISORDERS; COMMUNITY; ANXIETY; HEALTH; ADULTS	Objective: This study determined whether self-reported Traumatic Brain Injury (TBI), identified in a community sample and occurring up to 60 years previously, is associated with current psychiatric symptoms, suicidality, and psychologic well-being. Study Design and Setting: Three age cohorts (20-24, 40-44, 60-64) were randomly sampled from the cities of Canberra and Queanbeyan, Australia, yielding a total of 7,485 participants. The samples were administered scales measuring anxiety, depression, suicidality, positive and negative affect, personality traits, and physical health status. Results: Of the total sample, 5.7% reported history of TBI involving loss of consciousness for at least 15 min, occurring an average of 22 years previously. History of TBI was associated with increased symptoms of depression, anxiety, negative affect, and suicidal ideation. Conclusion: History of TBI is a risk factor for psychiatric morbidity. The effect is greatest in young adults, and occurs up to several decades subsequent to the occurrence of TBI. (C) 2004 Elsevier Inc. All rights reserved.	Australian Natl Univ, Mental Hlth Res Ctr, Canberra, ACT 0200, Australia		Anstey, KJ (corresponding author), Australian Natl Univ, Mental Hlth Res Ctr, Canberra, ACT 0200, Australia.	kaarin.anstey@anu.edu.au	Rodgers, Bryan/B-2090-2013; Christensen, Helen/F-5053-2012; Anstey, Kaarin/A-3852-2008; Jorm, Anthony F/B-5555-2009	Rodgers, Bryan/0000-0002-2863-3737; Christensen, Helen/0000-0003-0435-2065; Anstey, Kaarin/0000-0002-9706-9316; Jorm, Anthony F/0000-0002-1424-4116; Windsor, Tim/0000-0003-3725-2730; Butterworth, Peter/0000-0002-1531-3881			BROOKS N, 1984, CLOSED HEAD INJURY P, P123; Busch CR, 1998, NEUROPSYCHOL REV, V8, P95, DOI 10.1023/A:1025661200911; BUTTERWORTH P, IN PRESS J CLIN EPID; Cicerone KD, 1997, BRAIN INJURY, V11, P643, DOI 10.1080/026990597123197; Ehlers A, 1998, J ABNORM PSYCHOL, V107, P508, DOI 10.1037/0021-843X.107.3.508; EYSENCK SBG, 1985, PERS INDIV DIFFER, V6, P21, DOI 10.1016/0191-8869(85)90026-1; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Fann JR, 2002, J NEUROL NEUROSUR PS, V72, P615, DOI 10.1136/jnnp.72.5.615; FROOM P, 1992, THEOR MED, V13, P255, DOI 10.1007/BF00489202; GOLDBERG D, 1988, BRIT MED J, V297, P897, DOI 10.1136/bmj.297.6653.897; HOLMES CB, 1991, PERCEPT MOTOR SKILL, V73, P497, DOI 10.2466/PMS.73.5.497-498; JOHANSSON E, 1991, SCAND J REHABIL MED, V23, P179; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Lindelow M, 1997, J EPIDEMIOL COMMUN H, V51, P549, DOI 10.1136/jech.51.5.549; MacCallum H, 2000, J EPIDEMIOL COMMUN H, V54, P77, DOI 10.1136/jech.54.1.77; Mayou R, 2002, PSYCHOL MED, V32, P671, DOI 10.1017/S0033291702005470; McGuire LM, 1998, BRAIN INJURY, V12, P207, DOI 10.1080/026990598122683; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; REDMAN S, 1987, J STUD ALCOHOL, V48, P104, DOI 10.15288/jsa.1987.48.104; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Shakeshaft AP, 1999, ALCOHOL ALCOHOLISM, V34, P636, DOI 10.1093/alcalc/34.4.636; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Simpson G, 2002, PSYCHOL MED, V32, P687, DOI 10.1017/S0033291702005561; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Thomas CS, 2002, BRIT J PSYCHIAT, V180, P392, DOI 10.1192/bjp.180.5.392; Timonen M, 2002, PSYCHIAT RES, V113, P217, DOI 10.1016/S0165-1781(02)00269-X; Triplett G, 1996, PERCEPT MOTOR SKILL, V83, P1344, DOI 10.2466/pms.1996.83.3f.1344; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Watson D., 1994, PANASX MANUAL POSITI; Willer B, 1996, NEUROREHABILITATION, V6, P219, DOI 10.3233/NRE-1996-6308	32	105	105	0	8	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0895-4356			J CLIN EPIDEMIOL	J. Clin. Epidemiol.	NOV	2004	57	11					1202	1209		10.1016/j.jclinepi.2003.11.011			8	Health Care Sciences & Services; Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Health Care Sciences & Services; Public, Environmental & Occupational Health	878UO	WOS:000225672800015	15567638				2022-02-06	
J	Tomaiuolo, F; Carlesimo, GA; Di Paola, M; Petrides, M; Fera, F; Bonanni, R; Formisano, R; Pasqualetti, P; Caltagirone, C				Tomaiuolo, F; Carlesimo, GA; Di Paola, M; Petrides, M; Fera, F; Bonanni, R; Formisano, R; Pasqualetti, P; Caltagirone, C			Gross morphology and morphometric sequelae in the hippocampus, fornix, and corpus callosum of patients with severe non-missile traumatic brain injury without macroscopically detectable lesions: a T1 weighted MRI study	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							CLOSED-HEAD-INJURY; VOLUME MEASUREMENT; AXONAL INJURY; ATROPHY; MEMORY; AMYGDALA; SIZE	Objective: The gross morphology and morphometry of the hippocampus, fornix, and corpus callosum in patients with severe non-missile traumatic brain injury (nmTBI) without obvious neuroradiological lesions was examined and the volumes of these structures were correlated with performance on memory tests. In addition, the predictability of the length of coma from the selected anatomical volumes was examined. Method: High spatial resolution T1 weighted MRI scans of the brain (1 mm(3)) and neuropsychological evaluations with standardised tests were performed at least 3 months after trauma in 19 patients. Results: In comparison with control subjects matched in terms of gender and age, volume reduction in the hippocampus, fornix, and corpus callosum of the nmTBI patients was quantitatively significant. The length of coma correlated with the volume reduction in the corpus callosum. Immediate free recall of word lists correlated with the volume of the fornix and the corpus callosum. Delayed recall of word lists and immediate recall of the Rey figure both correlated with the volume of the fornix. Delayed recall of the Rey figure correlated with the volume of the fornix and the right hippocampus. Conclusion: These findings demonstrate that in severe nmTBI without obvious neuroradiological lesions there is a clear hippocampal, fornix, and callosal volume reduction. The length of coma predicts the callosal volume reduction, which could be considered a marker of the severity of axonal loss. A few memory test scores correlated with the volumes of the selected anatomical structures. This relationship with memory performance may reflect the diffuse nature of the damage, leading to the disruption of neural circuits at multiple levels and the progressive neural degeneration occurring in TBI.	IRCCS Santa Lucia, I-00179 Rome, Italy; Univ Roma Tor Vergata, Neurol Clin, I-00173 Rome, Italy; McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada; CNR, IMSEB, Cosenza, Italy; AFaR Osped Fatebenefratelli, Rome, Italy		Tomaiuolo, F (corresponding author), IRCCS Santa Lucia, Via Ardeatina 309, I-00179 Rome, Italy.	tomaiuolo@hsantalucia.it	Di Paola, Margherita/A-8480-2010; Pasqualetti, Patrizio/D-4496-2013; Tomaiuolo, Francesco/AAC-1534-2019; Caltagirone, Carlo/B-4930-2013	Pasqualetti, Patrizio/0000-0001-5560-1979; Tomaiuolo, Fancesco/0000-0003-1230-2770			Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Adams JH, 1990, HDB CLIN NEUROLOGY, P43; Adams JH, 1994, INTRO NEUROPATHOLOGY; Azouvi P, 2000, CURR OPIN NEUROL, V13, P665, DOI 10.1097/00019052-200012000-00009; Azouvi P., 1993, ANN READAPTATION MED, V36, P1; Bermudez P, 2001, NEUROIMAGE, V13, P1121, DOI 10.1006/nimg.2001.0772; Bigler ED, 1996, NEUROPSYCHOLOGY, V10, P333, DOI 10.1037/0894-4105.10.3.333; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; CAPITANI E, 1987, J NEUROL SCI S, V8, P14; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879, DOI 10.1016/S0733-8619(18)30185-3; Carlesimo G, 2002, NUOVA RIV NEUROLOGIA, V12, P1; Carlesimo GA, 1996, EUR NEUROL, V36, P378, DOI 10.1159/000117297; COLLINS DL, 1994, J COMPUT ASSIST TOMO, V18, P192, DOI 10.1097/00004728-199403000-00005; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GALE SD, 1993, BRAIN RES BULL, V32, P345, DOI 10.1016/0361-9230(93)90198-K; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Henry-Feugeas MC, 2000, BRAIN INJURY, V14, P597; Jancke J, 1999, NEUROREPORT, V10, P2981; Jancke L, 1997, CEREB CORTEX, V7, P48, DOI 10.1093/cercor/7.1.48; Kilpatrick C, 1997, SEIZURE, V6, P213, DOI 10.1016/S1059-1311(97)80008-8; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P1294, DOI 10.1136/jnnp.51.10.1294; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MILNER B, 1968, NEUROPSYCHOLOGIA, V6, P191, DOI 10.1016/0028-3932(68)90019-5; MISHKIN M, 1978, NATURE, V273, P297, DOI 10.1038/273297a0; Paus T, 1996, J COMP NEUROL, V376, P664, DOI 10.1002/(SICI)1096-9861(19961223)376:4<664::AID-CNE12>3.0.CO;2-M; Penhune VB, 1996, CEREB CORTEX, V6, P661, DOI 10.1093/cercor/6.5.661; Pruessner JC, 2000, CEREB CORTEX, V10, P433, DOI 10.1093/cercor/10.4.433; Rey A, 1968, REATTIVO FIGURA COMP; Runnerstam M, 2001, J NEUROTRAUM, V18, P259, DOI 10.1089/08977150151070892; SALAT D, SEX DIFFERENCES CORP; Schmitt JE, 2001, DEV MED CHILD NEUROL, V43, P155, DOI 10.1017/S0012162201000305; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; Spiers HJ, 2001, NEUROCASE, V7, P357, DOI 10.1076/neur.7.5.357.16245; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Tomaiuolo F, 1999, EUR J NEUROSCI, V11, P3033, DOI 10.1046/j.1460-9568.1999.00718.x; Tomaiuolo F, 2002, NEUROREPORT, V13, P2281, DOI 10.1097/00001756-200212030-00022; Wallesch CW, 2001, J NEUROTRAUM, V18, P11, DOI 10.1089/089771501750055730; WATSON C, 1992, NEUROLOGY, V42, P1743, DOI 10.1212/WNL.42.9.1743; Wechsler, 1997, WECHSLER ADULT INTEL; WECHSLER DA, 1981, SCALA INTELLIGENZA A; Wilson JTL, 1990, NEUROPSYCHOLOGY, V4, P261, DOI 10.1037/0894-4105.4.4.261; WILSON JTL, 1995, J NEUROL NEUROSUR PS, V59, P328, DOI 10.1136/jnnp.59.3.328; WITELSON SF, 1989, BRAIN, V112, P799, DOI 10.1093/brain/112.3.799	48	105	108	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	SEP	2004	75	9					1314	1322		10.1136/jnnp.2003.017046			9	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	846QM	WOS:000223330700020	15314123	Bronze, Green Published			2022-02-06	
J	Franulic, A; Carbonell, CG; Pinto, P; Sepulveda, I				Franulic, A; Carbonell, CG; Pinto, P; Sepulveda, I			Psychosocial adjustment and employment outcome 2, 5 and 10 years after TBI	BRAIN INJURY			English	Article							TRAUMATIC BRAIN-INJURY; PSYCHIATRIC-DISORDERS; HEAD-INJURY; DEPRESSION; REHABILITATION; PREDICTORS; RECOVERY; MODERATE; SCALE	Objective: A patient's return to work has been considered a good indicator of his/her overall adaptation after suffering from TBI. A study has been designed at the Hospital del Trabajador to evaluate patients' psycho-pathological and social situations and to describe evolution and return-to-work predictors. Particular attention was paid to subjects' employment situations 2, 5 and 10 years after TBI. Method: TBI patients who had also suffered spinal cord injuries, amputations and other physical impairments were excluded. A total of 202 individuals were evaluated by a psychologist and an occupational therapist during clinical interviews using the Hamilton Anxiety and Depression Rating Scale and the Neurobehavioural Rating Scale (NRS-R). Work situations were evaluated by interviewing the subjects and family members and, whenever possible, a patient's immediate supervisor at his or her place of employment. Results: Unemployed patients presented more severe symptoms of anxiety and depression than those who were working. Significant differences were observed in the NRS-R between employed and unemployed patients. There was no change in the marital status for at least 10 years after TBI. Conclusion: Factors determining a poor prognosis for adaptation and re-insertion into the workplace are age, a low educational level, a lack of job qualifications and greater cognitive impairments. The significant differences found between the NRS-R of employed and unemployed patients suggest that this variable may be used to predict a subject's ability to return to work.	Hosp Trabajador Santiago, Santiago, Chile		Franulic, A (corresponding author), Hosp Trabajador Santiago, Ramon Carnicer 185, Santiago, Chile.	ghtrae@gw.achs.cl		Carbonell, Carmen Gloria/0000-0001-9279-1847			Asikainen I, 1996, BRAIN INJURY, V10, P883, DOI 10.1080/026990596123864; BROWN DSO, 1992, ARCH PHYS MED REHAB, V73, P758; Cespedes JMM, 2000, PSICOTHEMA, V12, P99; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Eames PG, 2001, BRAIN DAM B, P29; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Felmingham KL, 2001, ARCH PHYS MED REHAB, V82, P435, DOI 10.1053/apmr.2001.21985; Fleming J, 1999, BRAIN INJURY, V13, P417; Franulic A, 2000, BRAIN INJURY, V14, P431; FRASER R, 1999, REPORT RECOMMENDATIO, P12; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P991, DOI 10.1016/S0003-9993(99)90049-7; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hoofien D, 2001, BRAIN INJURY, V15, P189; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; Macmillan PJ, 2002, BRAIN INJURY, V16, P41, DOI 10.1080/0269905011008812; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; Novack TA, 2000, BRAIN INJURY, V14, P987; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Satz P, 1998, BRAIN INJURY, V12, P555, DOI 10.1080/026990598122322; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Vanier M, 2000, ARCH PHYS MED REHAB, V81, P796, DOI 10.1016/S0003-9993(00)90114-X; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; Watts R, 1999, BRAIN INJURY, V13, P113, DOI 10.1080/026990599121773; WEST M, 2001, BRAIN INJURY SOURCE, V5, P24	31	105	106	0	18	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	FEB	2004	18	2					119	129		10.1080/0269905031000149515			11	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	751DR	WOS:000187038000002	14660225				2022-02-06	
J	Doppenberg, EMR; Choi, SC; Bullock, R				Doppenberg, EMR; Choi, SC; Bullock, R			Clinical trials in traumatic brain injury: Lessons for the future	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article; Proceedings Paper	Perioperative Neuroprotection Symposium	SEP 13, 2003	ANNAPOLIS, MD	Univ Maryland Sch Med, Univ Maryland Sch Med, Dept Anesthesiol, Program Neurosci Neuroprotect Res Focus Grp, Univ Maryland Sch Med, Off Grad & Continuing Med Educ		neuroprotective; clinical; trials; pitfalls	KALLIKREIN-KININ SYSTEM; ACUTE SUBDURAL-HEMATOMA; CEREBRAL BLOOD-FLOW; THERAPEUTIC HYPOTHERMIA; AXONAL CHANGE; HEAD-INJURY; ISCHEMIA; GLUTAMATE; MEDIATOR; EDEMA	Thus far, none of the neuroprotective drugs that have been tested to reduce or prevent secondary ischemic brain damage have been shown clear benefit. We will attempt to identify factors that may be responsible for some of these failures. We also will give our thoughts on how to prevent these pitfalls in the usefulness and criteria for use of animal models for traumatic brain injury to depict human head injury are discussed. Clearly, mechanism-driven trials, in which individual pathophysiological mechanisms are targeted, are more likely to show benefit in this heterogeneous patient population. Other factors, such as the effect of brain penetration, safety and tolerability of the compound, and the interface between the pharmaceutical industry and academics are a major influence in the success of these trials. Furthermore, the way trials have been analyzes in the past may not always have been be the most appropriate to show benefits. It is clear that a multi-targeted approach is necessary to address the complicated and closely related mechanisms seen after traumatic and or ischemic brain damage.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Neurosurg, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Biostat, Richmond, VA 23298 USA		Bullock, R (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Neurosurg, POB 980631, Richmond, VA 23298 USA.	robulloc@mail2.vcu.edu					ADAMS JH, 1983, ACTA NEUROCHIR, V32, pS15; ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BRANSTON NM, 1974, EXP NEUROL, V45, P195, DOI 10.1016/0014-4886(74)90112-5; BROADDUS WC, 1996, NEUROTRAUMA; Bullock R., 1995, NEUROCHEMICAL MONITO, P64; CHOI SC, 1996, DISCOVERIES HEAD TRA, P67; CLIFTON GL, 1993, NEUROSURGERY, V33, P34; Di X, 1996, RESTOR NEUROL NEUROS, V9, P231, DOI 10.3233/RNN-1996-9406; Drummond M., 1987, METHODS EC EVALUATIO, V4th; GRAHAM DI, 1985, BRIT J ANAESTH, V57, P3, DOI 10.1093/bja/57.1.3; JONES TH, 1981, J NEUROSURG, V54, P773, DOI 10.3171/jns.1981.54.6.0773; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KURODA Y, 1992, NEUROSURGERY, V31, P1062, DOI 10.1227/00006123-199212000-00012; LANDOLT H, 1994, ACTA NEUROCHIR, P475; MAIERHAUFF K, 1984, J NEUROSURG, V61, P97, DOI 10.3171/jns.1984.61.1.0097; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; Marion DW, 1996, CRIT CARE MED, V24, pS81; Marmarou A, 1996, ACT NEUR S, V66, P118; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; SCHRODER ML, 1994, J NEUROSURG, V80, P324, DOI 10.3171/jns.1994.80.2.0324; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; Tsuchida E, 1996, J NEUROSURG, V85, P104, DOI 10.3171/jns.1996.85.1.0104; UNTERBERG A, 1986, J NEUROSURG, V64, P269, DOI 10.3171/jns.1986.64.2.0269; UNTERBERG A, 1984, J NEUROSURG, V61, P87, DOI 10.3171/jns.1984.61.1.0087; WEI EP, 1993, AM J PHYSIOL, V265, pH1439; Whitehead J., 1983, DESIGN ANAL SEQUENTI; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; [No title captured]	31	105	106	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-4921	1537-1921		J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	JAN	2004	16	1					87	94		10.1097/00008506-200401000-00019			8	Anesthesiology; Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Anesthesiology; Neurosciences & Neurology; Surgery	758PR	WOS:000187659800018	14676577				2022-02-06	
J	Coelho, CA				Coelho, CA			Story narratives of adults with closed head injury and non-brain-injured adults: Influence of socioeconomic status, elicitation task, and executive functioning	JOURNAL OF SPEECH LANGUAGE AND HEARING RESEARCH			English	Article						discourse; TBI; pragmatics; stories; adults	DISCOURSE PRODUCTION; COGNITION; DEFICITS; CHILDREN; MILD	Narratives were elicited in two story tasks, retelling and generation, from two groups of adults, 55 with closed head injury (CHI) and 47 non-brain-injured (NBI), recruited from rehabilitation facilities. in three northeastern states. Participants were classified, on the basis of their socioeconomic status (SES), as professional, skilled worker, or unskilled worker. Narratives were analyzed using five discourse measures at the levels of sentence production, intersentential cohesion, and story grammar. Discourse performance was then compared across groups, tasks, and SES levels. Discourse performance of the CHI group was also compared with their scores from the Wisconsin Card Sorting Test, a measure of executive functioning. results indicated that two discourse measures, distinguished the groups. The CHI participants produced significantly fewer words per T-unit and fewer T-units within episode structure than did the NBI group, which was attributed to difficulties with content organization. Performance on all five discourse measures differed for the, story retelling versus the story generation tasks for both CHI and NBI groups. All participants produced longer and more grammatically complex T-units in the story gene ration task than in story retelling. However, cohesive adequacy and story grammar were better in the story retelling task than in the story generation task. It was therefore concluded that story generation was a more challenging task than story retelling for both groups. The only significant difference noted for SES involved the measure of intersentential cohesion. The unskilled workers demonstrated poorer cohesive adequacy. than either the skilled workers or professionals, regardless of group or story task. Finally, modest correlations were noted between the discourse performance of the CHI group and scores from the Wisconsin Card Sorting lest in both story tasks.	Univ Connecticut, Dept Commun Sci, Storrs, CT 06269 USA		Coelho, CA (corresponding author), Univ Connecticut, Dept Commun Sci, U-1085,850 Bolton Rd, Storrs, CT 06269 USA.						Baddeley A.D., 1987, WORKING MEMORY; BODY R, 1999, COMMUNICATION DISORD; CANNIZZARO MS, IN PRESS BRAIN INJUR; COELHO CA, 1995, BRAIN INJURY, V9, P471, DOI 10.3109/02699059509008206; COELHO CA, 1991, ARCH PHYS MED REHAB, V72, P465; COELHO CA, 1995, APHASIOLOGY, V9, P409, DOI 10.1080/02687039508248707; Cohen J, 1977, STAT POWER ANAL BEHA; Connor Lisa Tabor, 2000, Seminars in Speech and Language, V21, P109; Glosser G., 1990, BRAIN LANG, V40, P67; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; HAGEN C, 1980, REHABILITATION HEAD; HART T, 1999, EVALUATION TREATMENT; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; Heaton PDRK., 1993, WISCONSIN CARD SORTI; HOLLINGSHEAD A, 1972, UNPUB 4 FACTOR INDEX; Hughes DL., 1997, GUIDE NARRATIVE LANG; HUNT CEL, 1970, J NUCL MATER, V35, P134, DOI 10.1016/0022-3115(70)90040-1; Kertesz A., 1982, W APHASIA BATTERY; Levin HS, 1996, DEV NEUROPSYCHOL, V12, P17, DOI 10.1080/87565649609540638; LEVIN HS, 1991, DEV NEUROPSYCHOL, V7, P377, DOI 10.1080/87565649109540499; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEZAK MD, 1995, NEUROPSYCHOL ASSESSM; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; LILES BZ, 1985, J SPEECH HEAR RES, V28, P123, DOI 10.1044/jshr.2801.123; Maths S, 1976, GERIATRIC PSYCHIAT; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; MENTIS M, 1987, J SPEECH HEAR RES, V30, P583; Miyake Akira, 2000, Seminars in Speech and Language, V21, P169, DOI 10.1055/s-2000-7563; Murray Laura L., 2000, Seminars in Speech and Language, V21, P153, DOI 10.1055/s-2000-7562; Snow P, 1997, APHASIOLOGY, V11, P947, DOI 10.1080/02687039708249421; SNOW P, 1995, APHASIOLOGY, V9, P365, DOI 10.1080/02687039508248210; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Stein N. L., 1979, NEW DIRECTIONS DISCO, P53; Stout CE, 2000, J MED SPEECH-LANG PA, V8, P15; Tompkins C.A., 1995, RIGHT HEMISPHERE COM; Tucker FM, 1998, BRAIN INJURY, V12, P783, DOI 10.1080/026990598122179; Van Dijk TA., 1983, STRATEGIES DISCOURSE; WINTER P, 1976, BEAR FLY; Ylvisaker M., 2001, LANGUAGE INTERVENTIO, P745; YORKSTON KM, 1993, CLIN APHASIOLOGY, V21, P165	40	105	107	0	10	AMER SPEECH-LANGUAGE-HEARING ASSOC	ROCKVILLE	10801 ROCKVILLE PIKE, ROCKVILLE, MD 20852-3279 USA	1092-4388			J SPEECH LANG HEAR R	J. Speech Lang. Hear. Res.	DEC	2002	45	6					1232	1248		10.1044/1092-4388(2002/099)			17	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	631KM	WOS:000180167000014	12546490				2022-02-06	
J	Shibuya, S; Miyamoto, O; Auer, RN; Itano, T; Mori, S; Norimatsu, H				Shibuya, S; Miyamoto, O; Auer, RN; Itano, T; Mori, S; Norimatsu, H			Embryonic intermediate filament, nestin, expression following traumatic spinal cord injury in adult rats	NEUROSCIENCE			English	Article						glial fibrillary acidic protein; subpial astrocyte; radial glia; pial surface; immunohistochemistry; neural regeneration	CENTRAL-NERVOUS-SYSTEM; NEURAL STEM-CELLS; GROWTH-FACTOR; BRAIN INJURY; WALLERIAN DEGENERATION; SUBEPENDYMAL CELLS; PROGENITOR CELLS; PYRAMIDAL TRACT; MESSENGER-RNA; ASTROCYTES	Precursor cells in the ependyma of the lateral ventricles of adult mammalian brain have been reported in brain, and also in the spinal cord. The present study used antibody to the intermediate filament protein (nestin) as an immunohistochemical marker for neural stem cells and precursor cells in a rat model of spinal cord trauma. Male Sprague-Dawley rats (n = 25) had a laminectomy at Th11-Th12, and spinal cord contusion was created by compression with 30 g of force for 10 min. The rats were killed at 24 h, 1 week and 4 weeks after injury, and four levels of the spinal cord were examined: 5 mm and 10 mm, both rostral and caudal region to the injury center. Time- and region-dependent alterations of nestin immunoreactivity were analyzed. Revealed at 24 h post-injury, 5 min rostral and caudal to the lesions, nestin expression was observed in ependymal cells and around the hemorrhagic and necrotic lesion located in dorsal spinal cord, peaking at 1 week after injury. Moreover, nestin expression was also observed in the white matter of ventral spinal cord, extending into arborizing processes centripetally from the pial surface toward the central canal. At 4 weeks after injury, nestin expression in ependyma decreased 10 min from the injury site. But nestin expression in white matter increased dramatically with a 100-fold increase in nestin originating from the pial surface, and extension now to all the white matter. The latter was accompanied by glial fibrillary acidic protein positivity into very long arborizing processes, morphologically compatible with radial glia. The findings suggest two possible sources of precursor cells in adult mammalian spinal cord; ependyma of the central canal and subpial astrocytes. Subpial astrocytes may be associated with neural repair and regeneration after spinal cord injury. (C) 2002 IBRO. Published by Elsevier Science Ltd. All rights reserved.	Kagawa Med Univ, Dept Biol, Miki, Kagawa 7610793, Japan; Kagawa Med Univ, Dept Orthopaed Surg, Miki, Kagawa 7610793, Japan; Univ Calgary, Fac Med, Neurosci Res Grp, Dept Pathol & Lab Med, Calgary, AB T2N 4N1, Canada		Itano, T (corresponding author), Kagawa Med Univ, Dept Biol, 1750-1 Ikenobe, Miki, Kagawa 7610793, Japan.	toshi@kms.ac.jp	Auer, Roland/F-6661-2017	Auer, Roland/0000-0001-9044-3419			Abe Y, 1999, J NEUROTRAUM, V16, P945, DOI 10.1089/neu.1999.16.945; Ajtai BM, 2000, ANAT EMBRYOL, V202, P313, DOI 10.1007/s004290000117; ANDERSON DK, 1993, ANN EMERG MED, V22, P987, DOI 10.1016/S0196-0644(05)82739-8; Cao QL, 2001, EXP NEUROL, V167, P48, DOI 10.1006/exnr.2000.7536; CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0; Chiasson BJ, 1999, J NEUROSCI, V19, P4462; CHOI BH, 1978, BRAIN RES, V148, P295, DOI 10.1016/0006-8993(78)90721-7; COLLINS GH, 1986, J NEUROPATH EXP NEUR, V45, P742, DOI 10.1097/00005072-198611000-00010; DAHLSTRAND J, 1995, DEV BRAIN RES, V84, P109, DOI 10.1016/0165-3806(94)00162-S; DAHLSTRAND J, 1992, J CELL SCI, V103, P589; DAVIS AA, 1994, NATURE, V372, P263, DOI 10.1038/372263a0; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Duggal N, 1997, BRAIN RES, V768, P1, DOI 10.1016/S0006-8993(97)00588-X; FREDERIKSEN K, 1988, J NEUROSCI, V8, P1144; FRISEN J, 1995, J CELL BIOL, V131, P453, DOI 10.1083/jcb.131.2.453; FUJITA S, 1964, J COMP NEUROL, V122, P311, DOI 10.1002/cne.901220303; FUJITA S, 1962, EXP CELL RES, V28, P52, DOI 10.1016/0014-4827(62)90311-7; FUJITA S, 1963, J COMP NEUROL, V120, P37, DOI 10.1002/cne.901200104; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; Gritti A, 1996, J NEUROSCI, V16, P1091; HOCKFIELD S, 1985, J NEUROSCI, V5, P3310; Holmin S, 1997, EUR J NEUROSCI, V9, P65, DOI 10.1111/j.1460-9568.1997.tb01354.x; Horner PJ, 2000, J NEUROSCI, V20, P2218; Inoue T, 1998, NEUROSCI LETT, V247, P151, DOI 10.1016/S0304-3940(98)00297-3; Isaksson J, 1999, J NEUROTRAUM, V16, P165, DOI 10.1089/neu.1999.16.165; IWASHITA Y, 1994, NATURE, V367, P167, DOI 10.1038/367167a0; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; Kaya SS, 1999, BRAIN RES, V840, P153, DOI 10.1016/S0006-8993(99)01757-6; Krum JM, 1999, EXP NEUROL, V160, P348, DOI 10.1006/exnr.1999.7222; Krum JM, 1998, EXP NEUROL, V154, P57, DOI 10.1006/exnr.1998.6930; Lee YB, 2000, EXP NEUROL, V166, P190, DOI 10.1006/exnr.2000.7494; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; LEVINE JM, 1994, J NEUROSCI, V14, P4716; LEVITT P, 1980, J COMP NEUROL, V193, P815, DOI 10.1002/cne.901930316; Li Y, 1997, SCIENCE, V277, P2000, DOI 10.1126/science.277.5334.2000; Liem RKH, 1993, CURR OPIN CELL BIOL, V5, P12, DOI 10.1016/S0955-0674(05)80003-1; LUDWIN SK, 1990, ACTA NEUROPATHOL, V80, P184, DOI 10.1007/BF00308922; LUDWIN SK, 1984, NATURE, V308, P274, DOI 10.1038/308274a0; Matsuda M, 1996, BRAIN RES, V723, P177, DOI 10.1016/0006-8993(96)00243-0; McDonald JW, 1999, NAT MED, V5, P1410, DOI 10.1038/70986; McTigue DM, 2001, J NEUROSCI, V21, P3392, DOI 10.1523/JNEUROSCI.21-10-03392.2001; MILLER RH, 1984, J NEUROSCI, V4, P585; MITSUHASHI T, 1994, PARAPLEGIA, V32, P524, DOI 10.1038/sc.1994.84; Mokry J, 1999, Gen Physiol Biophys, V18 Suppl 1, P25; NIXON RA, 1992, CELL MOTIL CYTOSKEL, V22, P81, DOI 10.1002/cm.970220202; PIXLEY SKR, 1984, DEV BRAIN RES, V15, P201, DOI 10.1016/0165-3806(84)90097-X; PUCHALA E, 1977, EXP NEUROL, V55, P1, DOI 10.1016/0014-4886(77)90155-8; RAKIC P, 1971, J COMP NEUROL, V141, P283, DOI 10.1002/cne.901410303; RAKIC P, 1972, J COMP NEUROL, V145, P61, DOI 10.1002/cne.901450105; Ramon-Cueto A, 2000, NEURON, V25, P425, DOI 10.1016/S0896-6273(00)80905-8; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Salgado-Ceballos H, 1998, BRAIN RES, V782, P126; SASAKI H, 1989, BRAIN RES, V501, P339, DOI 10.1016/0006-8993(89)90651-3; SCHNITZER J, 1981, J CELL BIOL, V90, P435, DOI 10.1083/jcb.90.2.435; SENTER HJ, 1979, J NEUROSURG, V50, P198, DOI 10.3171/jns.1979.50.2.0198; Shibasaki K, 1981, Nihon Seikeigeka Gakkai Zasshi, V55, P1693; SMITH AJK, 1978, J NEUROSURG, V48, P239, DOI 10.3171/jns.1978.48.2.0239; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; TOHYAMA T, 1992, LAB INVEST, V66, P303; TOLBERT DL, 1987, J COMP NEUROL, V260, P299, DOI 10.1002/cne.902600210; Tropepe V, 1999, DEV BIOL, V208, P166, DOI 10.1006/dbio.1998.9192; Umeoka S, 2001, EPILEPSY RES, V43, P249, DOI 10.1016/S0920-1211(00)00200-X; Vaquero J, 1999, J NEUROSURG, V90, P220, DOI 10.3171/spi.1999.90.2.0220; Weiss S, 1996, J NEUROSCI, V16, P7599; Whittemore SR, 1999, EXP CELL RES, V252, P75, DOI 10.1006/excr.1999.4621	67	105	112	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		2002	114	4					905	916	PII S0306-4522(02)00323-8	10.1016/S0306-4522(02)00323-8			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	613LZ	WOS:000179134900009	12379246				2022-02-06	
J	Van Landeghem, FKH; Stover, JF; Bechmann, I; Bruck, W; Unterberg, A; Buhrer, C; Von Deimling, A				Van Landeghem, FKH; Stover, JF; Bechmann, I; Bruck, W; Unterberg, A; Buhrer, C; Von Deimling, A			Early expression of glutamate transporter proteins in ramified microglia after controlled cortical impact injury in the rat	GLIA			English	Article						astrocytes; controlled cortical impact injury; glutamate; glutamate transporter; glutamate uptake; microglia; traumatic brain injury	TRAUMATIC BRAIN-INJURY; AMINO-ACID TRANSPORTER; RELEASE; LOCALIZATION; GLT-1; EXCITOTOXICITY; INHIBITION; INCREASES; NEURONS; MODEL	Traumatic brain injury is followed by increased extracellular glutamate concentration. Uptake of glutamate is mainly mediated by the glial glutamate transporters GLAST and GLT-1. Extent and distribution of GLAST and GLT-1 were studied in a rat model of controlled cortical impact injury (CCH). Western Blot analysis revealed lowest levels of GLAST and GLT-1 with a decrease by 40%-54% and 42%-49% between 24 and 72 h posttrauma. By 8 h after CCll, CSF glutamate levels were increased (10.5 muM vs. 2.56 VM in controls; P < 0.001), reaching maximum values by 48 h. A significant increase in de novo GLAST and GLT-1 expressing ramified microglia was observed within 4 h, reached a stable level by 48 li, and remained high up to 72 h after CCH. Furthermore, ramified microglia de novo expressed the neuronal glutamate transporter EAAC1 after CCII Following CCII, GLAST/GLT-1 and GFAP coexpressing astrocytes were immediately reduced, reaching minimum levels within 8 h. This reduction of expression could be either due to protein downregulation or loss of astrocytes. At 72 h, a marked population of GLAST- and GLT-1-positive reactive astrocytes appeared. These results support the hypothesis that reduced astrocytic GLAST and GLT-1 protein levels following MI contribute to evolving secondary injury. Microglia are capable of de novo expressing glutamate transporter proteins, indicating that the expression of glial and neuronal glutamate transporters is not restricted to a specific glial or neuronal lineage. Ramified microglia may play an important compensatory role in the early regulation of extracellular glutamate after CCII. (C) 2001 Wiley-Liss, Inc.	Humboldt Univ, Inst Neuropathol, Charite, D-13353 Berlin, Germany; Humboldt Univ, Dept Neurosurg, Charite, D-13353 Berlin, Germany; Humboldt Univ, Inst Anat, Dept Cell & Neurobiol, Charite, D-13353 Berlin, Germany; Humboldt Univ, Dept Neonatol, Charite, D-13353 Berlin, Germany		Van Landeghem, FKH (corresponding author), Humboldt Univ, Inst Neuropathol, Charite, Charite Campus Virchow Klinikum,Augustenburger Pl, D-13353 Berlin, Germany.	frank.van_landeghem@charite.de	von Deimling, Andreas/F-7774-2013	von Deimling, Andreas/0000-0002-5863-540X; van Landeghem, Frank/0000-0002-9404-7031			Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; BALEAR VJ, 1972, J NEUROCHEM, V19, P2657; BLINZING.K, 1968, Z ZELLFORSCH MIK ANA, V85, P145, DOI 10.1007/BF00325030; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; CHAUDHRY FA, 1995, NEURON, V15, P711, DOI 10.1016/0896-6273(95)90158-2; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; DANBOLT NC, 1992, NEUROSCIENCE, V51, P295, DOI 10.1016/0306-4522(92)90316-T; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; Haugeto O, 1996, J BIOL CHEM, V271, P27715, DOI 10.1074/jbc.271.44.27715; Johnston G.A.R., 1981, GLUTAMATE TRANSMITTE, P77; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KIMELBERG HK, 1995, J CEREBR BLOOD F MET, V15, P409, DOI 10.1038/jcbfm.1995.51; Klose J, 1999, METH MOL B, V112, P67; KONDO K, 1995, NEUROSCI LETT, V188, P140, DOI 10.1016/0304-3940(95)11408-O; LEHRE KP, 1995, J NEUROSCI, V15, P1835; LEVY LM, 1993, FEBS LETT, V317, P79, DOI 10.1016/0014-5793(93)81495-L; LEVY LM, 1995, EUR J NEUROSCI, V7, P2036, DOI 10.1111/j.1460-9568.1995.tb00626.x; LI S, 1999, J NEUROSCI, V19, P1; LOGAN WJ, 1972, BRAIN RES, V42, P413, DOI 10.1016/0006-8993(72)90540-9; Lopez-Redondo F, 2000, MOL BRAIN RES, V76, P429, DOI 10.1016/S0169-328X(00)00022-X; Martin LJ, 1997, ANN NEUROL, V42, P335, DOI 10.1002/ana.410420310; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Noda M, 1999, NEUROSCIENCE, V92, P1465, DOI 10.1016/S0306-4522(99)00036-6; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PERRY VH, 1985, NEUROSCIENCE, V15, P313, DOI 10.1016/0306-4522(85)90215-5; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Rao VLR, 2001, J NEUROSCI, V21, P1876, DOI 10.1523/JNEUROSCI.21-06-01876.2001; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; ROTHSTEIN JD, 1993, P NATL ACAD SCI USA, V90, P6591, DOI 10.1073/pnas.90.14.6591; Rutledge EM, 1996, J NEUROSCI, V16, P7803; Rutledge EM, 1998, AM J PHYSIOL-CELL PH, V274, pC1511, DOI 10.1152/ajpcell.1998.274.6.C1511; SCHNEIDER GH, 1992, CAN J PHYSIOL PHARM, V70, pS334, DOI 10.1139/y92-280; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; Stover JF, 2000, BRAIN RES, V875, P51, DOI 10.1016/S0006-8993(00)02597-X; STREIT WJ, 1985, J HISTOCHEM CYTOCHEM, V33, P1042, DOI 10.1177/33.10.4045182; STREIT WJ, 1987, J NEUROCYTOL, V16, P249, DOI 10.1007/BF01795308; STREIT WJ, 1988, J COMP NEUROL, V268, P248, DOI 10.1002/cne.902680209; Swanson RA, 1997, J NEUROSCI, V17, P932; TANAKA H, 1994, ACTA NEUROCHIR, P524; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; Watase K, 1998, EUR J NEUROSCI, V10, P976, DOI 10.1046/j.1460-9568.1998.00108.x	48	105	106	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	SEP	2001	35	3					167	179		10.1002/glia.1082			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	470TB	WOS:000170886300001	11494408				2022-02-06	
J	Beschorner, R; Adjodah, D; Schwab, JM; Mittelbronn, M; Pedal, I; Mattern, R; Schluesener, HJ; Meyermann, R				Beschorner, R; Adjodah, D; Schwab, JM; Mittelbronn, M; Pedal, I; Mattern, R; Schluesener, HJ; Meyermann, R			Long-term expression of heme oxygenase-1 (HO-1, HSP-32) following focal cerebral infarctions and traumatic brain injury in humans	ACTA NEUROPATHOLOGICA			English	Article						heme oxygenase-1; heat shock protein-32; traumatic brain injury; cerebral infarction; immunohistochemistry	TRANSIENT FOREBRAIN ISCHEMIA; RAT-BRAIN; MESSENGER-RNA; OXIDATIVE STRESS; HEAT-SHOCK; PROVIDES PROTECTION; CARBON-MONOXIDE; NITRIC-OXIDE; INDUCTION; PROTEIN	Extracellular heme derived from hemoglobin following hemorrhage or released from dying cells induces the expression of heme oxygenase-1 (HO-1, HSP-32) which metabolizes heme to the gaseous mediator carbon monoxide (CO), iron (Fe) and biliverdin. Biliverdin and its product bilirubin are powerful antioxidants. Thus, expression of HO-1 is considered to be a protective mechanism against oxidative stress and has been described in microglia, astrocytes and neurons following distinct experimental models of pathological alterations to the brain such as subarachnoidal hemorrhage, ischemia and traumatic brain injury (TBI) and in human neurodegenerative diseases. We have now analyzed the expression of HO-1 in human brains following TBI (n = 28; survival times: few minutes up to 6 months) and focal cerebral infarctions (FCI; n = 17; survival time: < 1 day up to months) by immunohistochemistry. Follwing TBI, accumulation of HO-1(+) microglia/macrophages at the hemorrhagic lesion was detected as early as 6 h post trauma and was still pronounced after 6 months. In contrast, after FCI HO-1(+) microglia/macrophages accumulated within focal hemorrhages only and were absent in non-hemorrhagic regions. Further, HO-1 was weakly expressed in astrocytes in the perifocal penumbra. In contrast to experimental data derived from rat focal ischemia, these results indicate a prolonged HO-1 expression in humans after brain injury.	Univ Tubingen, Inst Brain Res, D-72076 Tubingen, Germany; Heidelberg Univ, Inst Legal Med, Heidelberg, Germany		Beschorner, R (corresponding author), Univ Tubingen, Inst Brain Res, Calwer Str 3, D-72076 Tubingen, Germany.	rudi.beschorner@med.uni-tuebingen.de	Beschorner, Rudi/M-6397-2014	Schwab, Jan/0000-0001-6784-4919; Beschorner, Rudi/0000-0003-1109-915X; Mittelbronn, Michel/0000-0002-2998-052X			ABRAHAM NG, 1995, P NATL ACAD SCI USA, V92, P6798, DOI 10.1073/pnas.92.15.6798; AMIT Y, 1993, EXP NEUROL, V121, P248, DOI 10.1006/exnr.1993.1092; BENJAMIN IJ, 1990, P NATL ACAD SCI USA, V87, P6263, DOI 10.1073/pnas.87.16.6263; Bergeron M, 1997, J CEREBR BLOOD F MET, V17, P647; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; CASTELLANI R, 1995, BRAIN RES, V696, P268, DOI 10.1016/0006-8993(95)00535-X; Dwyer BE, 1996, MOL BRAIN RES, V38, P251, DOI 10.1016/0169-328X(95)00341-O; Elbirt KK, 1999, P ASSOC AM PHYSICIAN, V111, P438, DOI 10.1111/paa.1999.111.5.438; Ewing JF, 1997, BRAIN RES PROTOC, V1, P165, DOI 10.1016/S1385-299X(96)00027-X; FORESTI R, 1999, J NEUROSCI RES, V56, P652; Fukuda K, 1996, BRAIN RES, V736, P68, DOI 10.1016/0006-8993(96)00680-4; Geddes JW, 1996, NEUROSCI LETT, V210, P205, DOI 10.1016/0304-3940(96)12703-8; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Hall Edward D., 1993, Journal of Emergency Medicine, V11, P31; Hara E, 1996, BIOCHEM BIOPH RES CO, V224, P153, DOI 10.1006/bbrc.1996.0999; Heye N, 1996, STROKE, V27, P431, DOI 10.1161/01.STR.27.3.431; KADOYA C, 1995, STROKE, V26, P1035, DOI 10.1161/01.STR.26.6.1035; Koistinaho J, 1996, EUR J NEUROSCI, V8, P2265, DOI 10.1111/j.1460-9568.1996.tb01190.x; LAN HY, 1995, J HISTOCHEM CYTOCHEM, V43, P97, DOI 10.1177/43.1.7822770; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; MAINES MD, 1993, J PHARMACOL EXP THER, V264, P457; MARTIN NA, 1995, J NEUROTRAUM, V12, P897, DOI 10.1089/neu.1995.12.897; Massa SM, 1996, CEREBROVAS BRAIN MET, V8, P95; Matz P, 1996, BRAIN RES, V713, P211, DOI 10.1016/0006-8993(95)01511-6; Mautes AEM, 1998, BRAIN RES, V795, P17, DOI 10.1016/S0006-8993(98)00230-3; NAKAGAMI T, 1993, BIOCHIM BIOPHYS ACTA, V1158, P189, DOI 10.1016/0304-4165(93)90013-X; OTTERBEIN L, 1995, AM J RESP CELL MOL, V13, P595, DOI 10.1165/ajrcmb.13.5.7576696; Otterbein LE, 1999, J CLIN INVEST, V103, P1047, DOI 10.1172/JCI5342; Panahian N, 1999, J NEUROCHEM, V72, P1187; Panizzon KL, 1996, NEUROREPORT, V7, P662, DOI 10.1097/00001756-199601310-00067; Postler E, 1997, GLIA, V19, P27, DOI 10.1002/(SICI)1098-1136(199701)19:1<27::AID-GLIA3>3.0.CO;2-7; PREMKUMAR DRD, 1995, J NEUROCHEM, V65, P1399; Schipper HM, 1998, EXP NEUROL, V150, P60, DOI 10.1006/exnr.1997.6752; Schluesener HJ, 1997, GLIA, V20, P365, DOI 10.1002/(SICI)1098-1136(199708)20:4<365::AID-GLIA8>3.0.CO;2-4; SHIBAHARA S, 1987, J BIOL CHEM, V262, P12889; SIESJO BK, 1995, J NEUROSURG ANESTH, V7, P47, DOI 10.1097/00008506-199501000-00009; Snyder SH, 1998, BRAIN RES REV, V26, P167, DOI 10.1016/S0165-0173(97)00032-5; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; Suttner DM, 1999, FASEB J, V13, P1800, DOI 10.1096/fasebj.13.13.1800; Takeda A, 1996, NEUROSCI LETT, V205, P169, DOI 10.1016/0304-3940(96)12405-8; TAKEDA A, 1994, BRAIN RES, V666, P120, DOI 10.1016/0006-8993(94)90292-5; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; TENHUNEN R, 1970, J LAB CLIN MED, V75, P410; Turner CP, 1999, MOL BRAIN RES, V65, P87, DOI 10.1016/S0169-328X(98)00340-4; Turner CP, 1998, J CEREBR BLOOD F MET, V18, P257, DOI 10.1097/00004647-199803000-00004; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; VILE GF, 1994, P NATL ACAD SCI USA, V91, P2607, DOI 10.1073/pnas.91.7.2607; WEBER CM, 1994, J NEUROCHEM, V63, P953; Yachie A, 1999, J CLIN INVEST, V103, P129, DOI 10.1172/JCI4165; Zakhary R, 1996, P NATL ACAD SCI USA, V93, P795, DOI 10.1073/pnas.93.2.795	51	105	107	3	5	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	OCT	2000	100	4					377	384		10.1007/s004010000202			8	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	341KW	WOS:000088590400005	10985695				2022-02-06	
J	Medd, J; Tate, RL				Medd, J; Tate, RL			Evaluation of an anger management therapy programme following acquired brain injury: A preliminary study	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							ABUSE SCREENING-TEST; GENERAL ANGER; RELAXATION; REHABILITATION; DISTURBANCE; REDUCTION; DISORDERS; SKILLS	Problems with anger management after traumatic brain injury are one of the most frequent changes in the long term reported by relatives of injured people. In spite of their impact there have been few reports either describing therapy procedures for this disorder or examining their efficacy. The present study evaluated a cognitive-behavioural intervention for anger management difficulties following acquired brain injury. Participants were screened and randomly allocated to either a Treatment Group (TREAT) or Waiting List Group (WAIT). Each participant in TREAT received approximately six, hourly individual sessions of anger-management therapy while those in WAIT monitored their anger daily. Sixteen participants proceeded through to the final stages of the study. A significant decrease in anger on the State-Trait Anger Expression Inventory (STAXI) was found for TREAT in comparison with WAIT at pout-treatment. Repeated-measures analyses for TREAT showed significant improvements between pre-treatment and post-treatment measures (immediate and 2-month follow-up) on the STAXI. No significant generalisation of treatment effects to self-esteem, anxiety, depression, or degree of self-awareness were found.	Univ Sydney, Dept Psychol, Sydney, NSW 2006, Australia; Univ Sydney, Rehabil Studies Unit, Sydney, NSW 2006, Australia; Royal Rehabil Ctr, Sydney, NSW, Australia								ALDERMAN N, 1995, NEUROPSYCHOL REHABIL, V5, P193, DOI 10.1080/09602019508401467; ALDERMAN N, 1991, NEUROPSYCHOL REHABIL, V1, P65, DOI DOI 10.1080/09602019108401380; ALDERMAN N, 1990, COGNITIVE REHABILITA, P204; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; BEDIAN AG, 1977, PSYCHOL REP, V41, P1041; Burgess P. W., 1990, COGNITIVE REHABILITA, P183; Butler G., 1989, COGNITIVE BEHAV THER, P97; COOPERSMITH S, 1975, SEI SELF ESTEEM INVE; DAWSON H, ANGER MANAGEMENT MAN; DEFFENBACHER JL, 1986, BEHAV RES THER, V24, P481, DOI 10.1016/0005-7967(86)90014-8; DEFFENBACHER JL, 1987, J COUNS PSYCHOL, V34, P171; DEFFENBACHER JL, 1992, J COUNS PSYCHOL, V39, P158, DOI 10.1037/0022-0167.39.2.158; DEFFENBACHER JL, 1990, J COLL STUDENT DEV, V31, P351; DELIS D, 1987, CALIFORNIA VERBAL LE; EAMES P, 1985, J NEUROL NEUROSUR PS, V48, P613, DOI 10.1136/jnnp.48.7.613; GAVIN DR, 1989, BRIT J ADDICT, V84, P301; GOULD RA, 1993, CLIN PSYCHOL REV, V13, P169, DOI 10.1016/0272-7358(93)90039-O; HAZALEUS SL, 1986, J CONSULT CLIN PSYCH, V54, P222, DOI 10.1037/0022-006X.54.2.222; HEATON RK, 1993, WISCONSN CARD SORTIN; HEPPNER PP, 1988, PROBLEM SOLVING INVE; Lezak M.D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI DOI 10.1097/00001199-198703000-00009; LIRA FT, 1983, INT J CLIN NEUROPSYC, V5, P159; LOPEZ FG, 1986, COGNITIVE THER RES, V10, P245, DOI 10.1007/BF01173729; Luria A.R., 1973, WORKING BRAIN; LUSSICK S, 1993, UNPUB ANGER CONTROL; Manchester D, 1997, BRAIN INJURY, V11, P605, DOI 10.1080/026990597123296; MCGLYNN SM, 1990, PSYCHOL BULL, V108, P420, DOI 10.1037/0033-2909.108.3.420; McKinlay WW, 1988, J HEAD TRAUMA REHAB, p[3, 64]; Miller L., 1990, COGN REHABIL, V8, P14; Novaco RW., 1975, ANGER CONTROL DEV EV; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; PRIGATANO GP, 1990, CLIN NEUROPSYCHOL, V4, P163, DOI DOI 10.1080/13854049008401509; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; SHALLICE T, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P125; SKINNER HA, 1982, ADDICT BEHAV, V7, P363, DOI 10.1016/0306-4603(82)90005-3; Spielberger CD., 1988, STATE TRAIT ANGER EX; UOMOTO JM, 1992, ARCH PHYS MED REHAB, V73, P674; Wechsler, 1997, WECHSLER ADULT INTEL; Wood R. L., 1987, BRAIN INJURY REHABIL; Wood RL, 1981, APPL CONDITIONING TH, P81; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; [No title captured], DOI DOI 10.1097/00001199-198812000-00004; [No title captured]	43	105	106	0	14	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	MAR	2000	10	2					185	201		10.1080/096020100389246			17	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	295HK	WOS:000085960500005					2022-02-06	
J	Angeleri, F; Majkowski, J; Cacchio, G; Sobieszek, A; D'Acunto, S; Gesuita, R; Bachleda, A; Polonara, G; Krolicki, L; Signorino, M; Salvolini, I				Angeleri, F; Majkowski, J; Cacchio, G; Sobieszek, A; D'Acunto, S; Gesuita, R; Bachleda, A; Polonara, G; Krolicki, L; Signorino, M; Salvolini, I			Posttraumatic epilepsy risk factors: One-year prospective study after head injury	EPILEPSIA			English	Article						posttraumatic epilepsy; clinical; brain CT; MRI; EEG follow-up; hemosiderin	POST-TRAUMATIC EPILEPSY; SEIZURES; MODEL; POPULATION; VETERANS; EEG; MR	Purpose: Prospective evaluation of risk factors for posttraumatic epilepsy (PTE) by using clinical, EEG, and brain computed tomography (CT) data in four assessments from the head injury (HI) acute phase to 1 year later; and evaluation of the possible epileptogenic role of hemosiderin as shown by brain magnetic resonance imaging (MRI). Methods: Risk factors for PTE were evaluated by using Kaplan-Meier curves, log-rank test, and the Cox model in 137 consecutively enrolled adult inpatients. Percentage differences of patients with brain hyperintense and/or hemosiderin areas shown by MRI 1 year after HI were statistically evaluated by univariate tests considering two subgroups [e.g., patients with (PTE) and without (WLS) late seizures]. Results: The PTE subgroup included 18 patients with at least two seizures between the second and twelfth months. Kaplan-Meier curves demonstrated that Glasgow Coma Scale low score, early seizures, and single brain CT lesions are PTE risk factors, as is the development of an EEG focus 1 month after HI. No significant percentage difference was found between PTE and WLS patients with hemosiderin spots shown by MRI 1 year after HI. Conclusions: the Cox model indicates that, for HI patients with early seizures and brain CT single temporal or frontal lesions in the acute phase, the PTE risk is 8.58 and 3.43 times higher, respectively, than for those without. An EEG focus 1 month after HI is a risk factor 3.49 times higher than for patients without such EEG changes. One year after HI, a higher percentage of PTE than WLS patients had cortical MRI hyperintense areas including hemosiderin.	Univ Ancona, Inst Nervous Dis, Neurol Clin, Ancona, Italy; Univ Ancona, Serv Neuroradiol, Ancona, Italy; Dist Hosp, Dept Neurol & Epileptol, Med Ctr Postgrad Educ, Warsaw, Poland; Dist Hosp, Dept Radiol, Warsaw, Poland; Univ Ancona, Dept Epidemiol Biostat & Med Informat Technol, Ancona, Italy		Angeleri, F (corresponding author), Univ Torrette Ancona, Polo Osped, Inst Nervous Syst Dis, Via Conca 16, I-60020 Ancona, Italy.		Gesuita, Rosaria/AAU-8863-2020	POLONARA, GABRIELE/0000-0002-2866-2749; krolicki, leszek/0000-0002-7117-9621			ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; CHATRIAN GE, 1990, CURRENT PRACTICE CLI, P425; COX DR, 1972, J R STAT SOC B, V34, P187; da Silva A M, 1992, Acta Neurochir Suppl (Wien), V55, P56; DALESSANDRO R, 1983, ARCH NEUROL-CHICAGO, V40, P831, DOI 10.1001/archneur.1983.04050120081022; DALESSANDRO R, 1982, J NEUROL NEUROSUR PS, V45, P1153, DOI 10.1136/jnnp.45.12.1153; DALESSANDRO R, 1988, ARCH NEUROL-CHICAGO, V45, P42, DOI 10.1001/archneur.1988.00520250048019; Dalmady-Israel Christina, 1993, Brain Injury, V7, P263, DOI 10.3109/02699059309029679; De Santis A, 1992, Acta Neurochir Suppl (Wien), V55, P64; FLEISS GL, 1981, STAT METHODS RATES P, P217; Foulkes MA, 1991, J NEUROSURG S, V75, P8, DOI 10.3171/sup.1991.75.1s.00s8; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GODDARD GV, 1983, TRENDS NEUROSCI, V6, P275, DOI 10.1016/0166-2236(83)90118-2; GODDARD GV, 1980, LIMBIC EPILEPSY DYSC, P107; GOMORI JM, 1985, RADIOLOGY, V157, P87, DOI 10.1148/radiology.157.1.4034983; GUTLING E, 1995, NEUROLOGY, V45, P915, DOI 10.1212/WNL.45.5.915; HEIKKINEN ER, 1990, STEREOT FUNCT NEUROS, V54-5, P25, DOI 10.1159/000100186; HESSELINK JR, 1988, AM J ROENTGENOL, V150, P1133; JABBARI B, 1986, ELECTROEN CLIN NEURO, V64, P285, DOI 10.1016/0013-4694(86)90151-3; JENNETT B, 1975, EPILEPSIA, V16, P251, DOI 10.1111/j.1528-1157.1975.tb06055.x; JENNETT B, 1990, REHABILITATION ADULT, P89; JENNETT B, 1975, EPILEPSY NONMISSILE; Jennett BFrankowskiR, 1990, HDB CLIN NEUROLOGY, V13, P1; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAUFMAN L, 1996, PHARM PRACTICE ANAES, P70; KUZNIECKI RI, 1995, MAGNETIC RESONANCE E; LEE TE, 1990, STAT METHODS SURVIVA; MAJKOWSKI J, 1986, ACTA NEUROL SCAND, V74, P97, DOI 10.1111/j.1600-0404.1986.tb04868.x; PAGNI CA, 1990, ACT NEUR S, V50, P38; PAMPIGLIONE G, 1975, OUTCOME SEVERE DAMAG, P263; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; PHILLIPS G, 1954, J NEUROL NEUROSUR PS, V17, P1, DOI 10.1136/jnnp.17.1.1; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; VILBERGER JE, 1987, NEUROSURGERY, V20, P571; WALKER AE, 1989, SURG NEUROL, V32, P235, DOI 10.1016/0090-3019(89)90185-7; WILLMORE LJ, 1992, NEUROL CLIN, V10, P869, DOI 10.1016/S0733-8619(18)30184-1; WILLMORE LJ, 1978, ANN NEUROL, V4, P329, DOI 10.1002/ana.410040408; WILLMORE LJ, 1975, EXP NEUROL, V647, P280	40	105	109	1	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0013-9580			EPILEPSIA	Epilepsia	SEP	1999	40	9					1222	1230		10.1111/j.1528-1157.1999.tb00850.x			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	232JJ	WOS:000082367300006	10487184	Bronze			2022-02-06	
J	Kaya, SS; Mahmood, A; Li, Y; Yavuz, E; Goksel, M; Chopp, M				Kaya, SS; Mahmood, A; Li, Y; Yavuz, E; Goksel, M; Chopp, M			Apoptosis and expression of p53 response proteins and cyclin D1 after cortical impact in rat brain	BRAIN RESEARCH			English	Article						apoptosis; DNA fragmentation; DNA repair; cortical impact; temporal profile; rat; hippocampus	PROGRAMMED CELL-DEATH; CEREBRAL-ARTERY OCCLUSION; SPATIAL MEMORY DEFICITS; FLUID-PERCUSSION MODEL; DNA-DAMAGE; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; ISCHEMIC-INJURY; GRANULE CELLS; FRAGMENTATION	We measured the temporal profile and cellular identification of apoptosis in rat brain after cortical contusion injury. Double staining immunohistochemistry was also used to investigate the relationship between apoptotic cell death and selective protein expression associated with DNA damage and repair (p53, Bar, MDM2, WAF1, Gadd45, PCNA) and cell cycle protein, Cyclin D1, in male Wistar rats 48 h after injury. Cortical contusion was induced in male Wistar rats with a pneumatic impactor device. The animals were sacrificed at different times after trauma (1, 2, and 14 h and 1, 2, 4, 7 and 14 days; n = 4 per time point). Sham-operated rats (a = 4) and normal rats not subjected to any surgical procedure (n = 4) were used as controls for temporal profile determination Additional 11 rats were used for study of protein expression. Coronal brain sections were analyzed using an in situ terminal deoxynucleotdyl transferase-mediated biotinylated deoxyuridine triphosphate nick end labeling (TUNEL), hematoxylin, and immunohistochemical double staining methods. Apoptotic cells were observed as early as 2 h after the impact. Apoptotic cell death peaked at 2 days, gradually tapering off afterward, although scattered apoptotic cells were detected at 2 weeks after the impact. The number of apoptotic cells at 2 days far exceeded their number at other times (p = 0.009). Apoptotic cells were observed primarily in the cortex adjacent to the site of injury. In addition, apoptotic cells in conjunction with few injured cells were present in the ipsilateral hippocampus and localized to the granule layer of dentate gyrus. Our data indicate that DNA fragmentation is present in nearly all neurons subacutely after cortical contusion and persists for at least 2 weeks thereafter. Apoptosis is also present in neurons localized to the hilus of the dentate gyrus at a site remote from the area of injury suggesting a selective role for apoptosis in promoting secondary brain damage and dysfunction after traumatic brain injury. Using double staining, we were able to show that a great majority of apoptotic cells (> 95%) were neurons and the rest were astrocytes and endothelial cells. Proteins associated with DNA damage and repair (p53, Bar, MDM2, WAF1, Gadd 45, PCNA) were expressed in the cytoplasm of normal cells of naive and sham rats. These proteins were translocated to the nuclei of apoptotic and injured cells at 48 h after cortical contusion. Cyclin D1 was not present in apoptotic cells. The differential expression of proteins associated with DNA damage, repair and the cell cycle protein Cyclin D1 in the contused brain suggest a potential role for these proteins in cell survival and apoptosis after cortical contusion. (C) 1999 Published by Elsevier Science B.V. All rights reserved.	Henry Ford Hlth Sci Ctr, Dept Neurosurg, Detroit, MI USA; Henry Ford Hlth Sci Ctr, Dept Neurol, Detroit, MI USA; Oakland Univ, Dept Phys, Rochester, MI USA		Chopp, M (corresponding author), Henry Ford Hosp, Dept Neurol, 2799 W Grand Blvd, Detroit, MI 48202 USA.	chopp@neuro.hfh.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS35504, P01 NS23393] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS023393, R01NS035504] Funding Source: NIH RePORTER		BABB L, 1991, ADV NEUROL, V44, P949; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BREDESEN DE, 1994, APOPTOSIS 2, V1, P397; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CALNE DB, 1994, NEUROLOGY, V44, P5; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; Chopp M, 1996, J CEREBR BLOOD F MET, V16, P578, DOI 10.1097/00004647-199607000-00007; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; CORDONCARDO C, 1995, AM J PATHOL, V147, P545; COWAN WM, 1984, SCIENCE, V225, P1258, DOI 10.1126/science.6474175; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DASH PK, 1995, J NEUROSCI, V15, P2030, DOI 10.1523/JNEUROSCI.15-03-02030.1995; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dixon CE, 1996, NEUROTRAUMA, P1337; Duchen L. W., 1992, GREENFIELDS NEUROPAT, P1; DUVALL E, 1986, IMMUNOL TODAY, V7, P115, DOI 10.1016/0167-5699(86)90152-0; EL DW, 1993, CELL, V75, P817; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FESUS L, 1991, EUR J CELL BIOL, V56, P170; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; GARCIA JH, 1993, AM J PATHOL, V142, P623; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GILLARDON F, 1995, NEUROSCI LETT, V192, P85, DOI 10.1016/0304-3940(95)11619-8; GU Y, 1993, NATURE, V366, P701; GUDAS M, 1994, CELL GROWTH DIFFER, V5, P294; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; HARMON BV, 1990, INT J RADIAT BIOL, V58, P845, DOI 10.1080/09553009014552221; HARPER JW, 1993, CELL, V75, P805; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P557; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KASTAN MB, 1991, CANCER RES, V51, P6304; KENR SE, 1991, SCIENCE, V252, P1608; Li Y, 1997, BRAIN RES, V765, P301, DOI 10.1016/S0006-8993(97)00524-6; LI Y, 1995, J CEREBR BLOOD F MET, V15, P389, DOI 10.1038/jcbfm.1995.49; LI Y, 1995, AM J PATHOL, V146, P1045; Liu XZ, 1997, J NEUROSCI, V17, P5395; Long DA, 1996, BRAIN RES, V717, P109, DOI 10.1016/0006-8993(95)01500-0; LUNA RMD, 1995, NATURE, V378, P203; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; MACMANUS JP, 1993, NEUROSCI LETT, V164, P89, DOI 10.1016/0304-3940(93)90864-H; MARTIN DP, 1991, BIOL BASIS CELL DEAT, V3, P247; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MURNANE JP, 1995, CANCER METAST REV, V14, P17, DOI 10.1007/BF00690208; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NEVANDER G, 1985, ANN NEUROL, V18, P281, DOI 10.1002/ana.410180303; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLNEY JW, 1983, BRAIN RES BULL, V10, P699, DOI 10.1016/0361-9230(83)90038-2; PAXINOS G, 1986, RAT BRAIN STREEOTAXI; PETITO CK, 1987, NEUROLOGY, V37, P1281, DOI 10.1212/WNL.37.8.1281; POSMANTUR R, 1997, NEUROSCIENCE, V77, P765; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; Pravdenkova SV, 1996, BRAIN RES, V729, P151, DOI 10.1016/S0006-8993(96)00222-3; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; RINK A, 1995, AM J PATHOL, V147, P1; ROSE CD, 1993, NEURODEGENERATION, V2, P2878; Sakhi S, 1996, NEUROREPORT, V7, P493, DOI 10.1097/00001756-199601310-00028; SANCHEZ Y, 1995, BIOESSAYS, V17, P545, DOI 10.1002/bies.950170611; SCHREIBER SS, 1994, EXP NEUROL, V130, P368, DOI 10.1006/exnr.1994.1216; SCHWARTZ LM, 1991, BIOESSAYS, V13, P389, DOI 10.1002/bies.950130805; SELVAKUMARAN M, 1994, ONCOGENE, V9, P179; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; TOMINAGA T, 1993, BRAIN RES, V608, P21, DOI 10.1016/0006-8993(93)90768-I; WIJSMAN JH, 1993, J HISTOCHEM CYTOCHEM, V41, P7, DOI 10.1177/41.1.7678025; WOOD KA, 1993, NEURON, V11, P621, DOI 10.1016/0896-6273(93)90074-2; WYLIE AH, 1980, INT REV CYTOL, V68, P251; WYLIE AH, 1980, NATURE, V284, P555	78	105	118	0	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	FEB 6	1999	818	1					23	33		10.1016/S0006-8993(98)01204-9			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	163BC	WOS:000078381500003	9914434				2022-02-06	
J	Cattelani, R; Lombardi, F; Brianti, R; Mazzucchi, A				Cattelani, R; Lombardi, F; Brianti, R; Mazzucchi, A			Traumatic brain injury in childhood: intellectual, behavioural and social outcome into adulthood	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; FOLLOW-UP; YOUNG-ADULTS; CHILDREN; SEQUELAE; REHABILITATION	In order to obtain indicative data regarding intellectual, behavioural and social outcome into adulthood of subjects with a history of childhood head injury (CHI), twenty adults were selected who had been referred to the Neuropsychology Unit at the University of Parma at the: time of a traumatic brain injury (TBI) at an age between 8 and 14 years. The level of intellectual and behavioural impairment was determined and rated by WISC and WAIS IQa and by the frequency of maladjustive behaviour. GOS score and Barthel index were used to detect the level of disability. Social adjustment and community integration were determined by the Social Adjustment Scale (SAS) and the Community Integration Questionnaire (CIQ) respectively. Results indicate that (1) subjects who suffer a severe CHI present a higher pre-injury incidence of character disturbances than the normal population and injury-related difficulties to socialize which persist long-term and add to other problems; (2) even though intellectual and functional sequelae are frequent in these children in adulthood and do not improve in their correlation to age, these do not appear to be the prevailing problems and (3) the prevailing problems seem to be social maladjustment and poor quality of life, which art: still present several years post-injury and seem to be related to behavioural and psychosocial disorders in spite of an increased ADL-functioning. This has already been clearly demonstrated in the case of adulthood trauma.	Univ Parma, Dept Neurol, Neuropsychol Unit, I-43100 Parma, Italy		Cattelani, R (corresponding author), Univ Parma, Ist Neurol, Sez Neuropsicol, Str Quartiere 4, I-43100 Parma, Italy.		Brianti, Rodolfo/H-2152-2013	Brianti, Rodolfo/0000-0001-8069-3502; LOMBARDI, Francesco/0000-0002-7184-6391			Annegers J. F., 1983, PEDIATRIC HEAD TRAUM, P1; BOND MR, 1990, REHABILITATION ADULT, P59; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; BRUZY S, 1996, J HEAD TRAUMA REHAB, V11, P74; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; COSTEFF H, 1990, J NEUROSURG, V73, P684, DOI 10.3171/jns.1990.73.5.0684; DALBY PR, 1991, DEV NEUROPSYCHOL, V7, P35, DOI 10.1080/87565649109540476; DAVIDSON LL, 1988, PEDIATRICS, V82, P644; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; EIBEN CF, 1984, ARCH PHYS MED REHAB, V65, P168; EWINGCOBBS L, 1986, J HEAD TRAUMA REHAB, V1, P57; GOLDSTEIN FC, 1987, J LEARN DISABIL, V20, P518, DOI 10.1177/002221948702000903; GOODMAN R, 1989, CHILDRENS HEAD INJUR, P12; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; JAFFE KM, 1994, ARCH PHYSICAL MED RE, V75, P733; JENNETT B, 1975, LANCET, V1, P480; JORDAN FM, 1994, BRAIN INJURY, V8, P501, DOI 10.3109/02699059409151002; KLONOFF H, 1971, AM J PUBLIC HEALTH N, V61, P2405, DOI 10.2105/AJPH.61.12.2405; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; LANGLEY J, 1983, Journal of Pediatric Psychology, V8, P181, DOI 10.1093/jpepsy/8.2.181; LEZAK MD, 1978, AM J PHYS MED REHAB, V57, P9; LOMBARDI F, 1996, INT C REC ADV NEUR R, P521; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MAHONEY F I, 1965, Md State Med J, V14, P61; MAHONEY WJ, 1983, PEDIATRICS, V71, P756; MANHEIMER DI, 1967, CHILD DEV, V38, P491, DOI 10.1111/j.1467-8624.1967.tb04358.x; MATHENY AP, 1971, J PEDIATR-US, V79, P122, DOI 10.1016/S0022-3476(71)80071-9; MICHAUD LJ, 1993, ARCH PHYS MED REHAB, V74, P368; ODDY M, 1993, NEUROPSYCHOL REHABIL, V3, P301, DOI 10.1080/09602019308401444; PARTINGTON MW, 1960, ARCH DIS CHILD, V35, P215, DOI 10.1136/adc.35.181.215; PRIGATANO GP, 1993, NEUROPSYCHOL REHABIL, V3, P411, DOI 10.1080/09602019308401449; Rimel RW, 1990, REHABILITATION ADULT, P8; SCHALEN W, 1994, BRAIN INJURY, V8, P49, DOI 10.3109/02699059409150958; TATE RL, 1971, J MENTAL NERVOUS DIS, V179, P117; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; WEISSMAN MM, 1975, ARCH GEN PSYCHIAT, V32, P357; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009	39	105	106	0	12	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	APR	1998	12	4					283	296		10.1080/026990598122584			14	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	ZF942	WOS:000072948700004	9562911				2022-02-06	
J	Kelly, DF; Martin, NA; Kordestani, R; Counelis, G; Hovda, DA; Bergsneider, M; McBride, DQ; Shalmon, E; Herman, D; Becker, DP				Kelly, DF; Martin, NA; Kordestani, R; Counelis, G; Hovda, DA; Bergsneider, M; McBride, DQ; Shalmon, E; Herman, D; Becker, DP			Cerebral blood flow as a predictor of outcome following traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; cerebral blood flow; cerebral metabolism cerebral vasoreactivity; hyperemia; intracranial hypertension	SEVERE HEAD-INJURY; FLUID-PERCUSSION INJURY; GLUCOSE-UTILIZATION; SUBDURAL-HEMATOMA; PROTEIN-SYNTHESIS; METABOLISM; CIRCULATION; THRESHOLDS; ISCHEMIA; STATE	As part of a prospective study of the cerebrovascular effects of head injury, 54 moderate and severely injured patients underwent 184 Xe-133-cerebral blood flow (CBF) studies to determine the relationship between the period of maximum blood flow and outcome. The lowest blood flows were observed on the day of injury (Day 0) and the highest CBFs were documented on postinjury Days 1 to 5. Patients were divided into three groups based on CBF values obtained during this period of maximum flow: Group 1 (seven patients), CBF less than 33 ml/100 g/minute on all determinations; Group 2 (13 patients), CBF both less than and greater than or equal to 33 ml/100 g/minute; and Group 3 (34 patients), CBF greater than or equal to 33 ml/100 g/minute on all measurements. For Groups 1, 2, and 3, mean CBF during Days 1 to 5 postinjury was 25.7 +/- 4, 36.5 +/- 4.2, and 49.4 +/- 9.3 ml/100 g/minute, respectively, and PaCO2 at the time of the CBF study was 31.4 +/- 6, 32.7 +/- 2.9, and 33.4 +/- 4.7 mm Hg, respectively. There were significant differences across Groups 1, 2, and 3 regarding mean age, percentage of individuals younger than 35 years of age (42.9%, 23.1%, and 76.5%, respectively), incidence of patients requiring evacuation of intradural hematomas (57.1%, 38.5%, and 17.6%, respectively) and incidence of abnormal pupils (57.1%, 61.5%, and 32.4%, respectively). Favorable neurological outcome at 6 months postinjury in Groups 1, 2, and 3 was 0%, 46.2%, and 58.8%, respectively (p < 0.05). Further analysis of patients in Group 3 revealed that of 14 with poor outcomes, six had one or more episodes of hyperemia-associated intracranial hypertension (simultaneous CBF > 55 ml/100 g/minute and ICP > 20 mm Hg). These six patients were unique in having the highest CBFs for postinjury Days 1 to 5 (mean 59.8 ml/100 g/minute) and the most severe degree of intracranial hypertension and reduced cerebral perfusion pressure (p < 0.0001). These results indicate that a phasic elevation in CBF acutely after head injury is a necessary condition for achieving functional recovery. It is postulated that for the majority of patients, this rise in blood flow results from an increase in metabolic demands in the setting of intact vasoreactivity. In a minority of individuals, however, the constellation of supranormal CBF, severe intracranial hypertension, and poor outcome indicates a state of grossly impaired vasoreactivity with uncoupling between blood flow and metabolism.	UNIV CALIF LOS ANGELES, CEREBRAL BLOOD FLOW LAB, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH PUBL HLTH, DEPT EPIDEMIOL, LOS ANGELES, CA 90024 USA		Kelly, DF (corresponding author), UNIV CALIF LOS ANGELES, DIV NEUROSURG, BRAIN INJURY RES CTR, ROOM 18-218A NPI, BOX 957039, LOS ANGELES, CA 90024 USA.			Martin, Neil/0000-0002-6565-4131	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030308] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 30308] Funding Source: Medline		ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BERTSNEIDER M, 1995, J CEREB BLOOD FLO S1, V15, pS26; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; JENNETT B, 1975, LANCET, V1, P480; JONES TH, 1981, J NEUROSURG, V54, P773, DOI 10.3171/jns.1981.54.6.0773; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Kelly DF, 1996, J NEUROSURG, V85, P762, DOI 10.3171/jns.1996.85.5.0762; KURODA Y, 1992, J NEUROSURG, V76, P471, DOI 10.3171/jns.1992.76.3.0471; LEE SM, 1995, J CEREB BLOOD FLO S1, V15, pS722; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARION DW, 1991, NEUROSURGERY, V29, P869, DOI 10.1227/00006123-199112000-00011; MARMAROU A, 1991, J NEUROSURG, V75, pS21, DOI 10.3171/sup.1991.75.1s.0s21; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; MARTIN NA, 1995, J NEUROTRAUM, V12, P897, DOI 10.1089/neu.1995.12.897; MELAMED E, 1980, STROKE, V11, P31, DOI 10.1161/01.STR.11.1.31; MESSETER K, 1986, J NEUROSURG, V64, P231, DOI 10.3171/jns.1986.64.2.0231; MIES G, 1991, J CEREBR BLOOD F MET, V11, P753, DOI 10.1038/jcbfm.1991.132; Miller J D, 1993, Acta Neurochir Suppl (Wien), V57, P152; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63; NARITOMI H, 1979, ARCH NEUROL-CHICAGO, V36, P410, DOI 10.1001/archneur.1979.00500430040005; NORDSTROM CH, 1988, J NEUROSURG, V68, P424, DOI 10.3171/jns.1988.68.3.0424; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; OBRIST WD, 1993, J CEREB BLOOD FLO S1, V13, pS571; OVERGAARD J, 1981, J NEUROSURG, V55, P63, DOI 10.3171/jns.1981.55.1.0063; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; Ritter A M, 1994, Neurosurg Clin N Am, V5, P633; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SALVANT JB, 1993, NEUROSURGERY, V33, P387; STEWART L, 1994, ACTA NEUROCHIR, P544; THILMANN R, 1986, ACTA NEUROPATHOL, V71, P88, DOI 10.1007/BF00687967; TOUTANT SM, 1984, J NEUROSURG, V61, P691, DOI 10.3171/jns.1984.61.4.0691; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; WANG Q, 1992, J CEREBR BLOOD F MET, V12, P947, DOI 10.1038/jcbfm.1992.131; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	48	105	108	0	12	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	APR	1997	86	4					633	641		10.3171/jns.1997.86.4.0633			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	WP020	WOS:A1997WP02000009	9120627				2022-02-06	
J	BRYAN, RM; CHERIAN, L; ROBERTSON, C				BRYAN, RM; CHERIAN, L; ROBERTSON, C			REGIONAL CEREBRAL BLOOD-FLOW AFTER CONTROLLED CORTICAL IMPACT INJURY IN RATS	ANESTHESIA AND ANALGESIA			English	Article							TRAUMATIC BRAIN INJURY; FLUID-PERCUSSION MODEL; ARTERY OCCLUSION; HEAD-INJURY; ISCHEMIA; CIRCULATION; THRESHOLDS	Regional cerebral blood flow (rCBF) and laser-Doppler perfusion were measured in rats after controlled cortical impact injury (CCII), a model of traumatic brain injury. Male Long-Evans rats were anesthetized with isoflurane and surgically prepared with arterial and venous cannulae. CCII was induced after a craniectomy by deforming the right parietal cortex to a depth of 2 mm with a metal cylinder traveling at a velocity of 5.2 m/s. Laser-Doppler perfusion was monitored from the surface of the left frontal cortex. rCBF, using C-14-isopropyliodoamphetamine, and laser-Doppler perfusion were measured in three groups of rats consisting of a sham group (n = 6), a group 30 min after CCII (n = 6), and a group 4 h after CCII (n = 5). CCII was characterized by cortical ischemia (rCBF < 20 mL.100 g(-1).min(-1)) surrounding the site of impact. The occipital cortex, a cortical region distant from the impact site, was also ischemic in some, but not all, injured rats. In the 30-min group, the ischemic zone showed very sharp boundaries with cortical areas of hyperperfusion surrounding the ischemic zone. In the 4-h group, the ischemic boundaries were not as sharp and the hyperperfusion surrounding the ischemic zone was no longer present. The caudate-putamen, hippocampus, and thalamus showed significant reductions in rCBF ranging from 50% to 30% of control 30 min and 4 h postinjury, respectively. We conclude that complex changes in rCBF occur shortly after CCII and persist for at least 4 h. During this time several brain regions, especially the cortical areas, may suffer damage due to the ischemia.	BAYLOR COLL MED,DEPT NEUROSURG,HOUSTON,TX 77030		BRYAN, RM (corresponding author), BAYLOR COLL MED,DEPT ANESTHESIOL,ROOM 434D,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL041960] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS027616] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [NIHLB-41960] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS27616] Funding Source: Medline		ADAMS H, 1972, SCI F NEUROLOGY, P478; BLAIR RDG, 1970, NEUROLOGY, V20, P802, DOI 10.1212/WNL.20.8.802; BOLANDER HG, 1989, STROKE, V20, P930, DOI 10.1161/01.STR.20.7.930; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; BRYAN RM, 1988, AM J PHYSIOL, V255, pR295, DOI 10.1152/ajpregu.1988.255.2.R295; BRYAN RM, 1986, J NEUROSCI METH, V17, P311, DOI 10.1016/0165-0270(86)90132-9; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; DIXON C E, 1988, Journal of Neurotrauma, V5, P91, DOI 10.1089/neu.1988.5.91; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; GRAHAM DI, 1971, LANCET, V1, P265; HARRIS RJ, 1984, J CEREBR BLOOD F MET, V4, P178, DOI 10.1038/jcbfm.1984.26; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HOEDTRASMUSSEN K, 1967, ARCH NEUROL-CHICAGO, V17, P271, DOI 10.1001/archneur.1967.00470270049007; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MIES G, 1991, J CEREBR BLOOD F MET, V11, P753, DOI 10.1038/jcbfm.1991.132; MUIR JK, 1992, J NEUROTRAUM, V9, P355, DOI 10.1089/neu.1992.9.355; NARITOMI H, 1988, J CEREBR BLOOD F MET, V8, P16, DOI 10.1038/jcbfm.1988.3; NEDERGAARD M, 1986, J CEREBR BLOOD F MET, V6, P414, DOI 10.1038/jcbfm.1986.74; NILSSON B, 1977, J NEUROSURG, V47, P262, DOI 10.3171/jns.1977.47.2.0262; OKIYAMA K, 1994, J NEUROTRAUM, V11, P83, DOI 10.1089/neu.1994.11.83; OVERGAARD J, 1981, J NEUROSURG, V55, P63, DOI 10.3171/jns.1981.55.1.0063; Palkovits M., 1988, MAPS GUIDE MICRODISS; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; SHIGENO T, 1985, SURG NEUROL, V24, P47, DOI 10.1016/0090-3019(85)90063-1; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; TAMURA A, 1981, J CEREBR BLOOD F MET, V1, P61, DOI 10.1038/jcbfm.1981.7; YAMAGUCHI T, 1971, NEUROLOGY, V21, P565, DOI 10.1212/WNL.21.6.565; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	41	105	106	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0003-2999			ANESTH ANALG	Anesth. Analg.	APR	1995	80	4					687	695		10.1097/00000539-199504000-00007			9	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	QP462	WOS:A1995QP46200007	7893019				2022-02-06	
J	KAUFMANN, PM; FLETCHER, JM; LEVIN, HS; MINER, ME; EWINGCOBBS, L				KAUFMANN, PM; FLETCHER, JM; LEVIN, HS; MINER, ME; EWINGCOBBS, L			ATTENTIONAL DISTURBANCE AFTER PEDIATRIC CLOSED-HEAD INJURY	JOURNAL OF CHILD NEUROLOGY			English	Article							CHILDREN; ADOLESCENTS; MEMORY	The influence of severity of closed head injury and age on attentional functioning was prospectively investigated in 36 children (age range, 7 to 16 years) 6 months after injury. Children were placed into mild, moderate, and severe injury groups using established neurologic criteria. Each child received the Wechsler Intelligence Scale for Children-Revised Digit Span subtest and a continuous performance test. Children with severe closed head injury demonstrated significantly poorer continuous performance test scores than mildly or moderately injured children. Injury severity had no effect on Digit Span scores. Younger children exhibited more pronounced impairment on the continuous performance test relative to uninjured age peers. These results extend the persistence of attentional impairments beyond those of previous reports. Closed head injury is not associated with preferential sparing of sustained attention in younger children 6 months after injury. Brain injury earlier in life may result in delayed vulnerability of information processing skills.	UNIV TEXAS,SCH MED,DEPT PEDIAT,HOUSTON,TX 77025; UNIV TEXAS,MED BRANCH,DIV NEUROSURG,GALVESTON,TX 77550; OHIO STATE UNIV HOSP,DIV NEUROSURG,COLUMBUS,OH 43210		KAUFMANN, PM (corresponding author), UNIV ARIZONA,COLL MED,DEPT PEDIAT,PEDIAT NEUROL SECT,1501 N CAMPBELL AVE,TUCSON,AZ 85724, USA.		fletcher, jack/Q-5975-2019; Fletcher, Jack/AAX-2931-2020		NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [NICHD HD-27597] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NINCDS NS-21889] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD027597] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		Annegers J. F., 1983, PEDIATRIC HEAD TRAUM, P1; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; FILLEY CM, 1987, ARCH NEUROL-CHICAGO, V44, P194, DOI 10.1001/archneur.1987.00520140058018; GULBRANDSEN GB, 1984, J CLIN NEUROPSYCHOL, V6, P257, DOI 10.1080/01688638408401217; HANNAY HJ, 1989, J CLIN EXP NEUROPSYC, V11, P444, DOI 10.1080/01688638908400905; Hollingshead AB, 1958, SOCIAL CLASS MENTAL; KAUFMANN PM, 1989, J CLIN EXP NEUROPSYC, V11, P367; KAUFMANN PM, 1989, J CLIN EXP NEUROPSYC, V11, P33; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; MURPHYBERMAN V, 1987, PERCEPT MOTOR SKILL, V64, P1139, DOI 10.2466/pms.1987.64.3c.1139; RICHARDSON F, 1963, DEV MED CHILD NEUROL, V5, P471; ROSVOLD HE, 1956, J CONSULT PSYCHOL, V20, P343, DOI 10.1037/h0043220; SATTLER JM, 1988, ASSESSMENT CHILDRENS; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; TEASDALE G, 1974, LANCET, V2, P81; Wechsler D., 1974, WECHSLER INTELLIGENC; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218	18	105	105	0	1	DECKER PERIODICALS INC	HAMILTON	4 HUGHSON STREET SOUTH PO BOX 620, LCD 1, HAMILTON ON L8N 3K7, CANADA	0883-0738			J CHILD NEUROL	J. Child Neurol.	OCT	1993	8	4					348	353		10.1177/088307389300800410			6	Clinical Neurology; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics	MA260	WOS:A1993MA26000010	8228030				2022-02-06	
J	GRAY, BG; ICHISE, M; CHUNG, DG; KIRSH, JC; FRANKS, W				GRAY, BG; ICHISE, M; CHUNG, DG; KIRSH, JC; FRANKS, W			TECHNETIUM-99M-HMPAO SPECT IN THE EVALUATION OF PATIENTS WITH A REMOTE HISTORY OF TRAUMATIC BRAIN INJURY - A COMPARISON WITH X-RAY COMPUTED-TOMOGRAPHY	JOURNAL OF NUCLEAR MEDICINE			English	Article							CLOSED HEAD-INJURY; MAGNETIC-RESONANCE; TRAUMA; LESIONS; MILD; MR; CT	The functional imaging modality has potential for demonstrating parenchymal abnormalities not detectable by traditional morphological imaging. Fifty-three patients with a remote history of traumatic brain injury (TBI) were studied with SPECT using Tc-99m-hexamethylpropyleneamineoxime (HMPAO) and x-ray computed tomography (CT). Overall, 42 patients (80%) showed regional cerebral blood flow (rCBF) deficits by HMPAO SPECT, whereas 29 patients (55%) showed morphological abnormalities by CT. Out of 20 patients with minor head injury, 12 patients (60%) showed rCBF deficits and 5 patients (25%) showed CT abnormalities. Of 33 patients with major head injury, 30 patients (90%) showed rCBF deficits and 24 patients (72%) showed CT abnormalities. Thus, HMPAO SPECT was more sensitive than CT in detecting abnormalities in patients with a history of TBI, particularly in the minor head injury group. In the major head injury group, three patients showed localized cortical atrophy by CT and normal rCBF by HMPAO SPECT. In the evaluation of TBI patients, HMPAO SPECT is a useful technique to demonstrate regional brain dysfunction in the presence of morphological integrity as assessed by CT.	MT SINAI HOSP, DEPT RADIOL, ROOM 635, 600 UNIV AVE, TORONTO M5G 1X5, ONTARIO, CANADA; UNIV TORONTO, TORONTO M5S 1A1, ONTARIO, CANADA; W PK HOSP, DEPT REHABIL MED, TORONTO, ONTARIO, CANADA								ABDELDAYEM HM, 1987, RADIOLOGY, V165, P221, DOI 10.1148/radiology.165.1.3498184; Alavi A, 1989, J Neuropsychiatry Clin Neurosci, V1, pS45; ALAVI A, 1987, J CEREB BLOOD FLO S1, V7, pS646; ALEXANDER MP, 1982, PSYCHIATRIC ASPECTS, V2, P219; CHANG LT, 1978, IEEE T NUCL SCI, V25, P638, DOI 10.1109/TNS.1978.4329385; FISHER JM, 1985, SEMIN NEUROL, V5, P197, DOI 10.1055/s-2008-1041516; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GEORGE J K, 1989, Journal of Nuclear Medicine, V30, P802; GRAY B, 1990, Journal of Nuclear Medicine, V31, P936; GROSWASSER Z, 1987, SURG NEUROL, V27, P331, DOI 10.1016/0090-3019(87)90007-3; HAN JS, 1984, RADIOLOGY, V150, P71, DOI 10.1148/radiology.150.1.6689790; JENKINS A, 1986, LANCET, V2, P445; JENNETT B, 1979, CENTRAL NERVOUS SYST, P204; JOLLES PR, 1989, J NUCL MED, V30, P1589; JORDAN BD, 1990, JAMA-J AM MED ASSOC, V263, P1670, DOI 10.1001/jama.263.12.1670; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; KRELINA M, 1989, CAN J NEUROL SCI, V2, P279; LANGFITT TW, 1982, J NEUROSURG, V56, P19, DOI 10.3171/jns.1982.56.1.0019; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; LEVIN HS, 1989, NEUROSURGERY, V24, P223, DOI 10.1227/00006123-198902000-00011; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; NEWTON MR, 1989, NUCL MED COMMUN, V10, P254; NIMMON C C, 1989, European Journal of Nuclear Medicine, V15, P507; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; OVERGAARD J, 1976, J NEUROSURG, V45, P292, DOI 10.3171/jns.1976.45.3.0292; PAL J, 1989, J TRAUMA, V29, P746, DOI 10.1097/00005373-198906000-00008; RAO N, 1984, ARCH PHYS MED REHAB, V65, P780; REID RH, 1990, CLIN NUCL MED, V15, P383, DOI 10.1097/00003072-199006000-00003; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUFF RM, 1990, NEUROPSYCHOLOGICAL F, P161; SNOW RB, 1986, NEUROSURGERY, V18, P45, DOI 10.1227/00006123-198601000-00008; SOUDER E, 1990, Journal of Nuclear Medicine, V31, P876; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; ZIMMERMAN RA, 1978, RADIOLOGY, V127, P393, DOI 10.1148/127.2.393; [No title captured]	39	105	107	0	1	SOC NUCLEAR MEDICINE INC	RESTON	1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA	0161-5505	1535-5667		J NUCL MED	J. Nucl. Med.	JAN	1992	33	1					52	58					7	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	GY676	WOS:A1992GY67600017	1730996				2022-02-06	
J	VINK, R; MCINTOSH, TK; WEINER, MW; FADEN, AI				VINK, R; MCINTOSH, TK; WEINER, MW; FADEN, AI			EFFECTS OF TRAUMATIC BRAIN INJURY ON CEREBRAL HIGH-ENERGY PHOSPHATES AND PH - A P-31 MAGNETIC-RESONANCE SPECTROSCOPY STUDY	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article									UNIV CALIF SAN FRANCISCO,CTR NEURAL INJURY,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,MAGNET RESONANCE UNIT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT NEUROL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT RADIOL,SAN FRANCISCO,CA 94143		VINK, R (corresponding author), VET ADM MED CTR,NEUROL SERV 127,4150 CLEMENT ST,SAN FRANCISCO,CA 94121, USA.		Vink, Robert/J-7351-2012; Vink, Robert/S-5616-2019	Vink, Robert/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667			ACKERMAN JJH, 1980, NATURE, V283, P167, DOI 10.1038/283167a0; ACKERMAN JJH, 1984, J MAGN RESON, V56, P318, DOI 10.1016/0022-2364(84)90109-4; ALBIN MS, 1969, J TRAUM, V9, P1000, DOI 10.1097/00005373-196912000-00004; ATKINSON DE, 1968, BIOCHEMISTRY-US, V7, P4030, DOI 10.1021/bi00851a033; BEHAR KL, 1985, J NEUROCHEM, V44, P1045, DOI 10.1111/j.1471-4159.1985.tb08723.x; BOTTOMLEY PA, 1984, RADIOLOGY, V150, P441, DOI 10.1148/radiology.150.2.6691099; BRANSTON NM, 1974, EXP NEUROL, V45, P195, DOI 10.1016/0014-4886(74)90112-5; CADY EB, 1983, LANCET, V1, P1059; CAMPBELL ID, 1973, J MAGN RESON, V11, P172, DOI 10.1016/0022-2364(73)90004-8; CHANCE B, 1978, P NATL ACAD SCI USA, V75, P4925, DOI 10.1073/pnas.75.10.4925; CHANCE B, 1980, P NATL ACAD SCI-BIOL, V77, P7430, DOI 10.1073/pnas.77.12.7430; CHANCE B, 1985, P NATL ACAD SCI USA, V82, P8384, DOI 10.1073/pnas.82.24.8384; COURTEN-MYERS G M, 1985, Stroke, V16, P1016; COX DWG, 1983, BIOCHEM J, V212, P365, DOI 10.1042/bj2120365; CROCKARD A, 1980, STROKE, V11, P494, DOI 10.1161/01.STR.11.5.494; DECORPS M, 1984, FEBS LETT, V168, P1, DOI 10.1016/0014-5793(84)80195-7; DELPY DT, 1982, PEDIATRICS, V70, P310; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DUCKROW RB, 1981, J NEUROSURG, V54, P607, DOI 10.3171/jns.1981.54.5.0607; ERECINSKA M, 1982, J MEMBRANE BIOL, V70, P1, DOI 10.1007/BF01871584; FADEN AI, 1986, ARCH NEUROL-CHICAGO, V43, P501, DOI 10.1001/archneur.1986.00520050073026; GADIAN DG, 1986, ABSTR SOC MAGN RES M, V5, P1109; GONZALEZMENDEZ R, 1985, J CEREBR BLOOD F MET, V5, P512, DOI 10.1038/jcbfm.1985.77; GONZALEZMENDEZ R, 1984, J MAGN RESON, V57, P526, DOI 10.1016/0022-2364(84)90270-1; Gurdjian E. S., 1944, SURG GYNECOL AND OBSTET, V78, P618; GYULAI L, 1985, J BIOL CHEM, V260, P3947; HASELGROVE JC, 1985, BRAIN IMAGING BRAIN, P271; HILBERMAN M, 1984, J CEREBR BLOOD F MET, V4, P334, DOI 10.1038/jcbfm.1984.50; ISHIGE N, 1987, J NEUROSURG, V20, P848; KIM SH, 1985, J CEREBR BLOOD F MET, V5, P432, DOI 10.1038/jcbfm.1985.58; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LITT L, 1985, J CEREBR BLOOD F MET, V5, P537, DOI 10.1038/jcbfm.1985.81; MYERS RE, 1977, ARCH NEUROL-CHICAGO, V34, P65, DOI 10.1001/archneur.1977.00500140019003; NILSSON B, 1977, J NEUROSURG, V47, P252, DOI 10.3171/jns.1977.47.2.0252; NILSSON B, 1977, J NEUROSURG, V47, P262, DOI 10.3171/jns.1977.47.2.0262; PETROFF OAC, 1984, ANN NEUROL, V16, P169, DOI 10.1002/ana.410160203; PETROFF OAC, 1985, NEUROLOGY, V35, P781, DOI 10.1212/WNL.35.6.781; PRICHARD JW, 1986, ANNU REV NEUROSCI, V9, P61; ROSNER MJ, 1984, J NEUROSURG, V60, P961, DOI 10.3171/jns.1984.60.5.0961; SATO M, 1984, J CEREBR BLOOD F MET, V4, P173, DOI 10.1038/jcbfm.1984.25; SAUNDERS ML, 1979, J NEUROSURG, V51, P18, DOI 10.3171/jns.1979.51.1.0018; SHOUBRIDGE EA, 1982, FEBS LETT, V140, P288, DOI 10.1016/0014-5793(82)80916-2; Siesj? BK., 1978, BRAIN ENERGY METABOL; SIESJO BK, 1985, CENTRAL NERVOUS SYST, P513; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; SWANSON PD, 1969, ARCH NEUROL-CHICAGO, V20, P653, DOI 10.1001/archneur.1969.00480120099010; THULBORN KR, 1982, J CEREBR BLOOD F MET, V2, P299, DOI 10.1038/jcbfm.1982.31; VINK R, 1987, IN PRESS ANN NY ACAD; WAGNER KR, 1985, J NEUROSURG, V63, P88, DOI 10.3171/jns.1985.63.1.0088; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617; YOSHIDA S, 1985, J CEREBR BLOOD F MET, V5, P490, DOI 10.1038/jcbfm.1985.75; YOUNKIN DP, 1984, ANN NEUROL, V16, P581, DOI 10.1002/ana.410160509; [No title captured]	54	105	105	1	3	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	OCT	1987	7	5					563	571		10.1038/jcbfm.1987.106			9	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	K4661	WOS:A1987K466100006	3654796	Bronze			2022-02-06	
J	Edlow, BL; Chatelle, C; Spencer, CA; Chu, CJ; Bodien, YG; O'Connor, KL; Hirschberg, RE; Hochberg, LR; Giacino, JT; Rosenthal, ES; Wu, O				Edlow, Brian L.; Chatelle, Camille; Spencer, Camille A.; Chu, Catherine J.; Bodien, Yelena G.; O'Connor, Kathryn L.; Hirschberg, Ronald E.; Hochberg, Leigh R.; Giacino, Joseph T.; Rosenthal, Eric S.; Wu, Ona			Early detection of consciousness in patients with acute severe traumatic brain injury	BRAIN			English	Article						traumatic brain injury; consciousness; functional MRI; EEG; intensive care unit	INTENSIVE-CARE-UNIT; VEGETATIVE STATE; CEREBRAL RESPONSE; FUNCTIONAL OUTCOMES; COVERT COGNITION; OWN NAME; DISORDERS; EEG; SCALE; RECOMMENDATIONS	Patients with acute severe traumatic brain injury may recover consciousness before self-expression. Without behavioural evidence of consciousness at the bedside, clinicians may render an inaccurate prognosis, increasing the likelihood of withholding life-sustaining therapies or denying rehabilitative services. Task-based functional magnetic resonance imaging and electroencephalography techniques have revealed covert consciousness in the chronic setting, but these techniques have not been tested in the intensive care unit. We prospectively enrolled 16 patients admitted to the intensive care unit for acute severe traumatic brain injury to test two hypotheses: (i) in patients who lack behavioural evidence of language expression and comprehension, functional magnetic resonance imaging and electroencephalography detect command-following during a motor imagery task (i. e. cognitive motor dissociation) and association cortex responses during language and music stimuli (i. e. higher-order cortex motor dissociation); and (ii) early responses to these paradigms are associated with better 6-month outcomes on the Glasgow Outcome Scale-Extended. Patients underwent functional magnetic resonance imaging on post-injury Day 9.2 +/- 5.0 and electroencephalography on Day 9.8 +/- 4.6. At the time of imaging, behavioural evaluation with the Coma Recovery Scale-Revised indicated coma (n = 2), vegetative state (n = 3), minimally conscious state without language (n = 3), minimally conscious state with language (n = 4) or post-traumatic confusional state (n = 4). Cognitive motor dissociation was identified in four patients, including three whose behavioural diagnosis suggested a vegetative state. Higher-order cortex motor dissociation was identified in two additional patients. Complete absence of responses to language, music and motor imagery was only observed in coma patients. In patients with behavioural evidence of language function, responses to language and music were more frequently observed than responses to motor imagery (62.5-80% versus 33.3-42.9%). Similarly, in 16 matched healthy subjects, responses to language and music were more frequently observed than responses to motor imagery (87.5-100% versus 68.8-75.0%). Except for one patient who died in the intensive care unit, all patients with cognitive motor dissociation and higher-order cortex motor dissociation recovered beyond a confusional state by 6 months. However, 6-month outcomes were not associated with early functional magnetic resonance imaging and electroencephalography responses for the entire cohort. These observations suggest that functional magnetic resonance imaging and electroencephalography can detect command-following and higher-order cortical function in patients with acute severe traumatic brain injury. Early detection of covert consciousness and cortical responses in the intensive care unit could alter time-sensitive decisions about withholding life-sustaining therapies.	[Edlow, Brian L.; Chatelle, Camille; Bodien, Yelena G.; Hochberg, Leigh R.] Massachusetts Gen Hosp, Ctr Neurotechnol & Neurorecovery, 175 Cambridge St,Suite 300, Boston, MA 02114 USA; [Edlow, Brian L.; Chatelle, Camille; Spencer, Camille A.; Chu, Catherine J.; Bodien, Yelena G.; O'Connor, Kathryn L.; Hochberg, Leigh R.; Rosenthal, Eric S.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, 175 Cambridge St, Boston, MA 02114 USA; [Edlow, Brian L.; Wu, Ona] Harvard Med Sch, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol, 149 13th St, Charlestown, MA 02129 USA; [Chatelle, Camille] Univ Liege, GIGA Consciousness, Coma Sci Grp, Liege, Belgium; [Bodien, Yelena G.; Hirschberg, Ronald E.; Giacino, Joseph T.] Harvard Med Sch, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, 300 First Ave, Charlestown, MA 02129 USA; [Hirschberg, Ronald E.; Giacino, Joseph T.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Phys Med & Rehabil, 55 Fruit St, Boston, MA 02114 USA; [Hochberg, Leigh R.] Brown Univ, Dept Engn, 184 Hope St, Providence, RI 02912 USA		Edlow, BL (corresponding author), Massachusetts Gen Hosp, Ctr Neurotechnol & Neurorecovery, 175 Cambridge St,Suite 300, Boston, MA 02114 USA.	bedlow@mgh.harvard.edu	Giacino, Joseph/AAF-1952-2021; Rosenthal, Eric Scott/A-2085-2017; Hochberg, Leigh/R-6872-2019	Giacino, Joseph/0000-0002-7916-9698; Rosenthal, Eric Scott/0000-0003-3900-356X; Hochberg, Leigh/0000-0003-0261-2273; Chatelle, Camille/0000-0002-7526-2107; Van Pelt, Kathryn/0000-0002-5494-2357; Bodien, Yelena/0000-0003-4858-2903; Wu, Ona/0000-0002-5509-9461	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K23NS094538]; Center for Integration of Medicine & Innovative Technology (Boston, MA, USA); American Academy of Neurology/American Brain Foundation; James S. McDonnell Foundation; Massachusetts General Hospital Department of Neurology; Division of Neurocritical Care and Emergency Neurology; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM007280] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS094538, K23NS092923] Funding Source: NIH RePORTER	This work was supported by grants from the National Institutes of Health (K23NS094538), the Center for Integration of Medicine & Innovative Technology (Boston, MA, USA), the American Academy of Neurology/American Brain Foundation, the James S. McDonnell Foundation, and the Massachusetts General Hospital Department of Neurology and Division of Neurocritical Care and Emergency Neurology.	Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; Bagiella E, 2010, J HEAD TRAUMA REHAB, V25, P375, DOI 10.1097/HTR.0b013e3181d27fe3; Bardin JC, 2012, ARCH NEUROL-CHICAGO, V69, P176, DOI 10.1001/archneurol.2011.892; Bardin JC, 2011, BRAIN, V134, P769, DOI 10.1093/brain/awr005; Beckmann CF, 2003, NEUROIMAGE, V20, P1052, DOI 10.1016/S1053-8119(03)00435-X; Boly M, 2007, NEUROIMAGE, V36, P979, DOI 10.1016/j.neuroimage.2007.02.047; Brattico E, 2011, FRONT PSYCHOL, V2, DOI 10.3389/fpsyg.2011.00308; Bruno M-A., 2012, COMA DISORDERS CONSC, P11, DOI [DOI 10.1007/978-1-4471-2440-5_2, 10.1007/978-1-4471-2440-5_2]; Bruno MA, 2012, J NEUROL, V259, P1087, DOI 10.1007/s00415-011-6303-7; Bruno MA, 2011, J NEUROL, V258, P1373, DOI 10.1007/s00415-011-6114-x; Burges CJC, 1998, DATA MIN KNOWL DISC, V2, P121, DOI 10.1023/A:1009715923555; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; Coleman MR, 2009, BRAIN, V132, P2541, DOI 10.1093/brain/awp183; Cruse D, 2012, NEUROLOGY, V78, P816, DOI 10.1212/WNL.0b013e318249f764; Cruse D, 2011, LANCET, V378, P2088, DOI 10.1016/S0140-6736(11)61224-5; Danielsen A, 2014, NEUROSCIENCE, V275, P469, DOI 10.1016/j.neuroscience.2014.06.029; Davis MH, 2007, P NATL ACAD SCI USA, V104, P16032, DOI 10.1073/pnas.0701309104; Dehaene S, 2006, TRENDS COGN SCI, V10, P204, DOI 10.1016/j.tics.2006.03.007; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; Di HB, 2007, NEUROLOGY, V68, P895, DOI 10.1212/01.wnl.0000258544.79024.d0; Di HB, 2008, CLIN MED, V8, P502, DOI 10.7861/clinmedicine.8-5-502; Edlow BL, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0375-y; Eickhoff SB, 2005, NEUROIMAGE, V25, P1325, DOI 10.1016/j.neuroimage.2004.12.034; Eklund A, 2016, P NATL ACAD SCI USA, V113, P7900, DOI 10.1073/pnas.1602413113; Faugeras F, 2011, NEUROLOGY, V77, P264, DOI 10.1212/WNL.0b013e3182217ee8; Fernandez-Espejo D, 2008, BRAIN INJURY, V22, P882, DOI 10.1080/02699050802403573; Fins JJ, 2015, RIGHTS COME MIND BRA; Fischer C, 2004, NEUROLOGY, V63, P669, DOI 10.1212/01.WNL.0000134670.10384.E2; Fischer DB, 2015, NEUROLOGY, V85, P543, DOI 10.1212/WNL.0000000000001748; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P36, DOI 10.1097/00001199-199708000-00005; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Gill-Thwaites H, 2006, BRAIN INJURY, V20, P1321, DOI 10.1080/02699050601081802; Gosseries O, 2014, BRAIN INJURY, V28, P1141, DOI 10.3109/02699052.2014.920522; Hauger SL, 2017, J HEAD TRAUMA REHAB, V32, P185, DOI 10.1097/HTR.0000000000000267; Hauger SL, 2015, BEHAV NEUROL, V2015, DOI 10.1155/2015/145913; Hirsch LJ, 2013, J CLIN NEUROPHYSIOL, V30, P1, DOI 10.1097/WNP.0b013e3182784729; Katz DI, 2009, PROG BRAIN RES, V177, P73, DOI 10.1016/S0079-6123(09)17707-5; King JR, 2013, NEUROIMAGE, V83, P726, DOI 10.1016/j.neuroimage.2013.07.013; Kovacs S, 2006, INVEST RADIOL, V41, P87, DOI 10.1097/01.rli.0000189637.42344.09; Lepage KQ, 2014, J NEUROSCI METH, V235, P101, DOI 10.1016/j.jneumeth.2014.05.008; Liu XL, 2012, HUM BRAIN MAPP, V33, P2487, DOI 10.1002/hbm.21385; Luaute J, 2010, NEUROLOGY, V75, P246, DOI 10.1212/WNL.0b013e3181e8e8df; Lule D, 2013, CLIN NEUROPHYSIOL, V124, P101, DOI 10.1016/j.clinph.2012.04.030; Maas AI, 2010, ARCH PHYS MED REHAB, V91, P1641, DOI 10.1016/j.apmr.2010.07.232; Majerus S, 2009, PROG BRAIN RES, V177, P49, DOI 10.1016/S0079-6123(09)17705-1; Makris N, 2006, SCHIZOPHR RES, V83, P155, DOI 10.1016/j.schres.2005.11.020; Monti MM, 2010, NEW ENGL J MED, V362, P579, DOI 10.1056/NEJMoa0905370; Noirhomme Q, 2014, NEUROIMAGE-CLIN, V4, P687, DOI 10.1016/j.nicl.2014.04.004; O'Kelly J, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00884; Ojala M, 2010, J MACH LEARN RES, V11, P1833; Okumura Y, 2014, BRAIN INJURY, V28, P944, DOI 10.3109/02699052.2014.888477; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; Piarulli A, 2016, J NEUROL, V263, P1746, DOI 10.1007/s00415-016-8196-y; Portas CM, 2000, NEURON, V28, P991, DOI 10.1016/S0896-6273(00)00169-0; Posner JB, 2007, PLUM POSNERS DIAGNOS; Roberts DJ, 2011, CRIT CARE MED, V39, P2743, DOI 10.1097/CCM.0b013e318228236f; Ropper AH, 2010, NEW ENGL J MED, V362, P648, DOI 10.1056/NEJMe0909667; Schiff N, 1999, J COGNITIVE NEUROSCI, V11, P650, DOI 10.1162/089892999563715; Schiff ND, 2015, JAMA NEUROL, V72, P1413, DOI 10.1001/jamaneurol.2015.2899; Schnakers C, 2015, NEUROLOGY CONSCIOUSN; Schnakers C, 2015, NEUROREHAB NEURAL RE, V29, P308, DOI 10.1177/1545968314547767; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Sherer M, 2005, ARCH PHYS MED REHAB, V86, P896, DOI 10.1016/j.apmr.2004.09.029; Sitt JD, 2014, BRAIN, V137, P2258, DOI 10.1093/brain/awu141; Stender J, 2014, LANCET, V384, P514, DOI 10.1016/S0140-6736(14)60042-8; Stuss DT, 1999, J NEUROSURG, V90, P635, DOI 10.3171/jns.1999.90.4.0635; Tononi Giulio, 2004, BMC Neurosci, V5, P42, DOI 10.1186/1471-2202-5-42; Truog RD, 2008, CRIT CARE MED, V36, P953, DOI 10.1097/CCM.0B013E3181659096; Turgeon AF, 2011, CAN MED ASSOC J, V183, P1581, DOI 10.1503/cmaj.101786; van der Kouwe AJW, 2008, NEUROIMAGE, V40, P559, DOI 10.1016/j.neuroimage.2007.12.025; Wang FY, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0330-7; Whyte J, 2001, ARCH PHYS MED REHAB, V82, P1355, DOI 10.1053/apmr.2001.26091; Whyte J, 2013, ARCH PHYS MED REHAB, V94, P1855, DOI 10.1016/j.apmr.2012.10.041; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Woolrich MW, 2004, NEUROIMAGE, V21, P1732, DOI 10.1016/j.neuroimage.2003.12.023; Wu J, 2013, NEUROSCIENCE, V250, P49, DOI 10.1016/j.neuroscience.2013.06.021; [No title captured]	80	104	109	6	29	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	SEP	2017	140		9				2399	2414		10.1093/brain/awx176			16	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FF0PB	WOS:000408602500021	29050383	Green Published, Bronze			2022-02-06	
J	Sariaslan, A; Sharp, DJ; D'Onofrio, BM; Larsson, H; Fazel, S				Sariaslan, Amir; Sharp, David J.; D'Onofrio, Brian M.; Larsson, Henrik; Fazel, Seena			Long-Term Outcomes Associated with Traumatic Brain Injury in Childhood and Adolescence: A Nationwide Swedish Cohort Study of a Wide Range of Medical and Social Outcomes	PLOS MEDICINE			English	Article							PROFESSIONAL FOOTBALL PLAYERS; SPORT-RELATED CONCUSSION; PSYCHIATRIC-DISORDERS; YOUNG-CHILDREN; HEAD-INJURY; FOLLOW-UP; POPULATION; RISK; PREDICTORS; DISABILITY	Background Traumatic brain injury (TBI) is the leading cause of disability and mortality in children and young adults worldwide. It remains unclear, however, how TBI in childhood and adolescence is associated with adult mortality, psychiatric morbidity, and social outcomes. Methods and Findings In a Swedish birth cohort between 1973 and 1985 of 1,143,470 individuals, we identified all those who had sustained at least one TBI (n = 104,290 or 9.1%) up to age 25 y and their unaffected siblings (n = 68,268) using patient registers. We subsequently assessed these individuals for the following outcomes using multiple national registries: disability pension, specialist diagnoses of psychiatric disorders and psychiatric inpatient hospitalisation, premature mortality (before age 41 y), low educational attainment (not having achieved secondary school qualifications), and receiving means-tested welfare benefits. We used logistic and Cox regression models to quantify the association between TBI and specified adverse outcomes on the individual level. We further estimated population attributable fractions (PAF) for each outcome measure. We also compared differentially exposed siblings to account for unobserved genetic and environmental confounding. In addition to relative risk estimates, we examined absolute risks by calculating prevalence and Kaplan-Meier estimates. In complementary analyses, we tested whether the findings were moderated by injury severity, recurrence, and age at first injury (ages 0-4, 5-9, 6-10, 15-19, and 20-24 y). TBI exposure was associated with elevated risks of impaired adult functioning across all outcome measures. After a median follow-up period of 8 y from age 26 y, we found that TBI contributed to absolute risks of over 10% for specialist diagnoses of psychiatric disorders and low educational attainment, approximately 5% for disability pension, and 2% for premature mortality. The highest relative risks, adjusted for sex, birth year, and birth order, were found for psychiatric inpatient hospitalisation (adjusted relative risk [aRR] = 2.0; 95% CI: 1.9-2.0; 6,632 versus 37,095 events), disability pension (aRR = 1.8; 95% CI: 1.7-1.8; 4,691 versus 29,778 events), and premature mortality (aRR = 1.7; 95% CI: 1.6-1.9; 799 versus 4,695 events). These risks were only marginally attenuated when the comparisons were made with their unaffected siblings, which implies that the effects of TBI were consistent with a causal inference. A dose-response relationship was observed with injury severity. Injury recurrence was also associated with higher risks-in particular, for disability pension we found that recurrent TBI was associated with a 3-fold risk increase (aRR = 2.6; 95% CI: 2.4-2.8) compared to a single-episode TBI. Higher risks for all outcomes were observed for those who had sustained their first injury at an older age (ages 20-24 y) with more than 25% increase in relative risk across all outcomes compared to the youngest age group (ages 0-4 y). On the population level, TBI explained between 2%-6% of the variance in the examined outcomes. Using hospital data underestimates milder forms of TBI, but such misclassification bias suggests that the reported estimates are likely conservative. The sibling-comparison design accounts for unmeasured familial confounders shared by siblings, including half of their genes. Thus, residual genetic confounding remains a possibility but will unlikely alter our main findings, as associations were only marginally attenuated within families. Conclusions Given our findings, which indicate potentially causal effects between TBI exposure in childhood and later impairments across a range of health and social outcomes, age-sensitive clinical guidelines should be considered and preventive strategies should be targeted at children and adolescents.	[Sariaslan, Amir; Fazel, Seena] Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford, England; [Sharp, David J.] Imperial Coll, Computat Cognit & Clin Neuroimaging Lab, London, England; [D'Onofrio, Brian M.] Indiana Univ, Dept Psychol & Brain Sci, Bloomington, IN USA; [Larsson, Henrik] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden; [Larsson, Henrik] Univ Orebro, Sch Med Sci, Orebro, Sweden		Fazel, S (corresponding author), Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford, England.	seena.fazel@psych.ox.ac.uk	Fazel, Seena/B-5307-2008; Sharp, David J/A-2119-2013	Fazel, Seena/0000-0002-5383-5365; Sariaslan, Amir/0000-0002-6151-3278	Wellcome TrustWellcome TrustEuropean Commission [095806]; Swedish Council for Working Life and Social ResearchSwedish Research CouncilSwedish Research Council for Health Working Life & Welfare (Forte); Swedish Research CouncilSwedish Research CouncilEuropean Commission [2010-3184, 2011-2492, 2013-5867]; National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD061817]; National Institute for Health Research (NIHR) ProfessorshipNational Institute for Health Research (NIHR) [NIHR-RP-011-048]; Shire; American Foundation for Suicide Prevention; Indiana Clinical and Translational Sciences Institute; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NIHR-RP-011-048] Funding Source: researchfish	The study was supported by the Wellcome Trust (095806), the Swedish Council for Working Life and Social Research, the Swedish Research Council (2010-3184; 2011-2492; 2013-5867), and the National Institute of Child Health and Human Development (HD061817). DJS is supported by a National Institute for Health Research (NIHR) Professorship (NIHR-RP-011-048). HL has served as a speaker for Eli-Lilly and Shire and has received a research grant from Shire; all outside the submitted work. BMD is receiving funding from the American Foundation for Suicide Prevention and the Indiana Clinical and Translational Sciences Institute, both outside of the submitted work. The funders were not involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, and approval of the manuscript.	Allison PD., 2009, FIXED EFFECTS REGRES; Anderson V, 2012, PEDIATRICS, V129, pE254, DOI 10.1542/peds.2011-0311; Anderson V, 2011, NEUROPSYCHOLOGY, V25, P176, DOI 10.1037/a0021217; Anderson V, 2009, J HEAD TRAUMA REHAB, V24, P303, DOI 10.1097/HTR.0b013e3181ada830; Benson BW, 2013, BRIT J SPORT MED, V47, P321, DOI 10.1136/bjsports-2013-092216; Cancelliere Carol, 2014, Arch Phys Med Rehabil, V95, pS201, DOI 10.1016/j.apmr.2013.10.010; Carlin JB, 2005, INT J EPIDEMIOL, V34, P1089, DOI 10.1093/ije/dyi153; Crowe LM, 2012, PEDIATRICS, V129, pE262, DOI 10.1542/peds.2011-0438; D'Onofrio BM, 2013, AM J PUBLIC HEALTH, V103, P46, DOI 10.2105/AJPH.2013.301252; Dahlqwist E., 2015, MODEL BASED ESTIMATI; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Ewing-Cobbs L, 2013, J INT NEUROPSYCH SOC, V19, P497, DOI 10.1017/S1355617713000210; Faul M, 2010, TRAUMATIC BRAIN INJU, P2; Fazel S, 2006, AM J PSYCHIAT, V163, P1397, DOI 10.1176/appi.ajp.163.8.1397; Fazel S, 2014, JAMA PSYCHIAT, V71, P326, DOI 10.1001/jamapsychiatry.2013.3935; Fazel S, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001150; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Gary KW, 2012, TRAUMATIC BRAIN INJU, P175; Gedeborg R, 2008, EPIDEMIOLOGY, V19, P860, DOI 10.1097/EDE.0b013e318181319e; Griffen J., 2014, HDB NEUROPSYCHOLOGY, P25; Guskiewicz Kevin, 2014, Neurosurgery, V75 Suppl 4, pS113, DOI 10.1227/NEU.0000000000000494; Guskiewicz KM, 2011, PM&R, V3, P353, DOI 10.1016/j.pmrj.2010.12.006; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hallden K., 2008, INT STANDARD CLASSIF; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; Lenroot RK, 2006, NEUROSCI BIOBEHAV R, V30, P718, DOI 10.1016/j.neubiorev.2006.06.001; Llewellyn T, 2014, CLIN J SPORT MED, V24, P76, DOI 10.1097/01.jsm.0000432853.77520.3d; Marshall Stephen W, 2015, Inj Epidemiol, V2, P13; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McKee AC, 2014, ALZHEIMERS DEMENT, V10, pS242, DOI 10.1016/j.jalz.2014.04.003; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; McMillan TM, 2012, J NEUROL NEUROSUR PS, V83, P1086, DOI 10.1136/jnnp-2012-302746; Narusyte J, 2014, EUR J PUBLIC HEALTH, V24, P106, DOI 10.1093/eurpub/ckt039; Narusyte J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023143; National Institute for Health and Care Excellence (NICE), 2014, HEAD INJ TRIAG ASS E; Nilsson AC., 1994, LAKARTIDNINGEN, V91, P603; Nudo RJ, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00887; OECD, 2014, SOC GLANC 2014 OECD; *OECD, 2010, HLTH GLANC 2010; Orlovska S, 2014, AM J PSYCHIAT, V171, P463, DOI 10.1176/appi.ajp.2013.13020190; Paus T, 2008, NAT REV NEUROSCI, V9, P947, DOI 10.1038/nrn2513; Pearce AJ, 2015, J SCI MED SPORT, V18, P500, DOI 10.1016/j.jsams.2014.07.010; Pearce AJ, 2014, J NEUROTRAUM, V31, P1139, DOI 10.1089/neu.2013.3219; Plomin R, 2015, MOL PSYCHIATR, V20, P98, DOI 10.1038/mp.2014.105; Polderman TJC, 2015, NAT GENET, V47, P702, DOI 10.1038/ng.3285; R Core Team, 2018, R LANGUAGE ENV STAT; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rowson S, 2014, J NEUROSURG, V120, P919, DOI 10.3171/2014.1.JNS13916; Ryan NP, 2014, J NEUROTRAUM, V31, P649, DOI 10.1089/neu.2013.3153; Sariaslan A, 2014, BRIT J PSYCHIAT, V205, P286, DOI 10.1192/bjp.bp.113.136200; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Spira JL, 2014, J NEUROTRAUM, V31, P1823, DOI 10.1089/neu.2014.3363; StataCorp, 2015, STAT STAT SOFTW REL; Styrke J, 2007, J NEUROTRAUM, V24, P1425, DOI 10.1089/neu.2007.0266; Thurman DJ, J CHILD NEUROL; von Knorring L, 2006, EUR PSYCHIAT, V21, P349, DOI 10.1016/j.eurpsy.2006.04.005; W.H. Organization, 2006, NEUR DIS PUBL HLTH C; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wittchen HU, 2011, EUR NEUROPSYCHOPHARM, V21, P655, DOI 10.1016/j.euroneuro.2011.07.018	62	104	104	0	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1549-1676			PLOS MED	PLos Med.	AUG	2016	13	8							e1002103	10.1371/journal.pmed.1002103			18	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DW0UD	WOS:000383357400020	27552147	Green Published, Green Submitted, gold			2022-02-06	
J	Kerr, ZY; Marshall, SW; Dompier, TP; Corlette, J; Klossner, DA; Gilchrist, J				Kerr, Zachary Y.; Marshall, Stephen W.; Dompier, Thomas P.; Corlette, Jill; Klossner, David A.; Gilchrist, Julie			College Sports-Related Injuries - United States, 2009-10 Through 2013-14 Academic Years	MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT			English	Article							SURVEILLANCE SYSTEM; DESCRIPTIVE EPIDEMIOLOGY; PREVENTION; CONCUSSION		[Kerr, Zachary Y.; Dompier, Thomas P.] Datalys Ctr Sports Injury Res & Prevent, Indianapolis, IN 46240 USA; [Marshall, Stephen W.] Univ N Carolina, Injury Prevent Res Ctr, Chapel Hill, NC USA; [Corlette, Jill] State Hlth Registry Iowa, Iowa City, IA USA; [Klossner, David A.] Univ Maryland, College Pk, MD 20742 USA; [Gilchrist, Julie] CDC, Natl Ctr Injury Prevent & Control, Div Unintent Injury Prevent, Atlanta, GA 30333 USA		Dompier, TP (corresponding author), Datalys Ctr Sports Injury Res & Prevent, Indianapolis, IN 46240 USA.	tdompier@datalyscenter.org		Kerr, Zachary/0000-0003-1423-1259; Corlette, Jill/0000-0002-9119-487X			Dick R, 2007, J ATHL TRAINING, V42, P278; Gilchrist J, 2008, AM J SPORT MED, V36, P1476, DOI 10.1177/0363546508318188; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Kerr ZY, 2014, J ATHL TRAINING, V49, P552, DOI 10.4085/1062-6050-49.3.58; Kucera KL, 2011, J ATHL TRAINING, V46, P489; Marshall SW, 2007, J ATHL TRAINING, V42, P234; National Collegiate Athletic Association, 2014, SPORTS SPONS PART RA; Parker EM, 2015, J HEAD TRAUMA REHAB, V30, P198, DOI 10.1097/HTR.0000000000000097; Reider B, 2004, AM J SPORT MED, V32, P1383, DOI 10.1177/0363546504268028; Yard EE, 2009, BRAIN INJURY, V23, P888, DOI 10.1080/02699050903283171	10	104	104	0	14	CENTERS  DISEASE CONTROL	ATLANTA	1600 CLIFTON RD, ATLANTA, GA 30333 USA	0149-2195	1545-861X		MMWR-MORBID MORTAL W	MMWR-Morb. Mortal. Wkly. Rep.	DEC 11	2015	64	48					1330	+		10.15585/mmwr.mm6448a2			7	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health	CZ6LJ	WOS:000367212500002	26655724				2022-02-06	
J	Sabirzhanov, B; Zhao, ZR; Stoica, BA; Loane, DJ; Wu, JF; Borroto, C; Dorsey, SG; Faden, AI				Sabirzhanov, Boris; Zhao, Zaorui; Stoica, Bogdan A.; Loane, David J.; Wu, Junfang; Borroto, Carlos; Dorsey, Susan G.; Faden, Alan I.			Downregulation of miR-23a and miR-27a following Experimental Traumatic Brain Injury Induces Neuronal Cell Death through Activation of Proapoptotic Bcl-2 Proteins	JOURNAL OF NEUROSCIENCE			English	Article						apoptosis; Bcl-2 proteins; microRNA; neuroprotection; traumatic brain injury	DNA-DAMAGE; IN-VIVO; POLY(ADP-RIBOSE) POLYMERASE; BH3-ONLY PROTEINS; INDUCED APOPTOSIS; CYTOCHROME-C; PROBE LEVEL; EXPRESSION; P53; MICRORNA	MicroRNAs (miRs) are small noncoding RNAs that negatively regulate gene expression at the post-transcriptional level. To identify miRs that may regulate neuronal cell death after experimental traumatic brain injury (TBI), we profiled miR expression changes during the first several days after controlled cortical impact (CCI) in mice. miR-23a and miR-27a were rapidly downregulated in the injured cortex in the first hour after TBI. These changes coincided with increased expression of the proapoptotic Bcl-2 family members Noxa, Puma, and Bax. In an etoposide-induced in vitro model of apoptosis in primary cortical neurons, miR-23a and miR-27a were markedly downregulated as early as 1 h after exposure, before the upregulation of proapoptotic Bcl-2 family molecules. Administration of miR-23a and miR-27a mimics attenuated etoposide-induced changes in Noxa, Puma, and Bax, reduced downstream markers of caspase-dependent (cytochrome c release and caspase activation) and caspase-independent (apoptosis-inducing factor release) pathways, and limited neuronal cell death. In contrast, miRs hairpin inhibitors enhanced etoposide-induced neuronal apoptosis and caspase activation. Importantly, administration of miR-23a and miR-27a mimics significantly reduced activation of Puma, Noxa, and Bax as well as attenuated markers of caspase-dependent and -independent apoptosis after TBI. Furthermore, miR-23a and miR-27a mimics significantly attenuated cortical lesion volume and neuronal cell loss in the hippocampus after TBI. These findings indicate that post-traumatic decreases in miR-23a and miR-27a contribute to neuronal cell death after TBI by upregulating proapoptotic Bcl-2 family members, thus providing a novel therapeutic target.	[Sabirzhanov, Boris; Zhao, Zaorui; Stoica, Bogdan A.; Loane, David J.; Wu, Junfang; Faden, Alan I.] Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; [Sabirzhanov, Boris; Zhao, Zaorui; Stoica, Bogdan A.; Loane, David J.; Wu, Junfang; Faden, Alan I.] Univ Maryland, Sch Med, Ctr Shock Trauma & Anesthesiol Res, Baltimore, MD 21201 USA; [Borroto, Carlos; Dorsey, Susan G.] Univ Maryland, Sch Nursing, Baltimore, MD 21201 USA; [Dorsey, Susan G.; Faden, Alan I.] Univ Maryland, Program Neurosci, Baltimore, MD 21201 USA		Sabirzhanov, B (corresponding author), Univ Maryland, Sch Med, Shock Trauma & Anesthesiol Res Organized Res Ctr, 655 W Baltimore St,Room 6-010, Baltimore, MD 21201 USA.	bsabirzhanov@anes.umm.edu; bstoica@anes.umm.edu	STOICA, BOGDAN/H-9782-2013; Loane, David/ABD-5177-2021	STOICA, BOGDAN/0000-0002-2501-6434; Loane, David/0000-0003-0393-3503; Faden, Alan I./0000-0003-0128-2348	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS061839-05, R01 NR012686]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS061839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR012686] Funding Source: NIH RePORTER	This work was supported by NIH Grants RO1 NS061839-05 to A.I.F. and R01 NR012686 to S.G.D. We thank Shruti Kabadi, Marie Hanscom, Marta Lipinski, and Chinmoy Sarkar for expert technical assistance.	Chen Q, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.92; Clark RSB, 2001, J NEUROTRAUM, V18, P675, DOI 10.1089/089771501750357627; Cryns VL, 1996, J BIOL CHEM, V271, P31277, DOI 10.1074/jbc.271.49.31277; Culmsee C, 2005, BIOCHEM BIOPH RES CO, V331, P761, DOI 10.1016/j.bbrc.2005.03.149; Di Giovanni S, 2003, ANN NEUROL, V53, P454, DOI 10.1002/ana.10472; Engel T, 2011, J CEREBR BLOOD F MET, V31, P1196, DOI 10.1038/jcbfm.2011.26; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405; Gentleman R., 2005, BIOINFORMATICS COMPU; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; Guo Z, 2013, J DERMATOL SCI, V69, P68, DOI 10.1016/j.jdermsci.2012.10.014; Harraz MM, 2012, P NATL ACAD SCI USA, V109, P18962, DOI 10.1073/pnas.1121288109; Hu ZH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039357; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Jimenez-Mateos EM, 2013, NEUROSCIENCE, V238, P218, DOI 10.1016/j.neuroscience.2013.02.027; Jimenez-Mateos EM, 2011, AM J PATHOL, V179, P2519, DOI 10.1016/j.ajpath.2011.07.036; Kabadi SV, 2012, NEUROTHERAPEUTICS, V9, P405, DOI 10.1007/s13311-011-0095-4; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Kole AJ, 2011, GENE DEV, V25, P125, DOI 10.1101/gad.1975411; Le Rhun Y, 1998, BIOCHEM BIOPH RES CO, V245, P1; Lei P, 2009, BRAIN RES, V1284, P191, DOI 10.1016/j.brainres.2009.05.074; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu DZ, 2010, J CEREBR BLOOD F MET, V30, P92, DOI 10.1038/jcbfm.2009.186; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Lomonosova E, 2008, ONCOGENE, V27, pS2, DOI 10.1038/onc.2009.39; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pietrzak M, 2011, J NEUROCHEM, V117, P1033, DOI 10.1111/j.1471-4159.2011.07279.x; Redell JB, 2011, J NEUROSCI RES, V89, P212, DOI 10.1002/jnr.22539; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Sabirzhanov B, 2012, J NEUROCHEM, V123, P542, DOI 10.1111/j.1471-4159.2012.07927.x; Selvamani A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032662; Shamas-Din A, 2011, BBA-MOL CELL RES, V1813, P508, DOI 10.1016/j.bbamcr.2010.11.024; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siegel C, 2011, P NATL ACAD SCI USA, V108, P11662, DOI 10.1073/pnas.1102635108; Siman R, 2004, NEUROBIOL DIS, V16, P311, DOI 10.1016/j.nbd.2004.03.016; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Stappert L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059011; Steckley D, 2007, J NEUROSCI, V27, P12989, DOI 10.1523/JNEUROSCI.3400-07.2007; Stoica BA, 2005, MOL CELL NEUROSCI, V29, P355, DOI 10.1016/j.mcn.2005.02.009; Stoica BA, 2003, MOL CELL NEUROSCI, V22, P365, DOI 10.1016/S1044-7431(02)00028-3; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Truettner JS, 2013, BRAIN RES, V1533, P122, DOI 10.1016/j.brainres.2013.08.011; Truettner JS, 2011, J CEREBR BLOOD F MET, V31, P1897, DOI 10.1038/jcbfm.2011.33; Vousden KH, 2005, SCIENCE, V309, P1685, DOI 10.1126/science.1118232; Yakovlev AG, 2004, J BIOL CHEM, V279, P28367, DOI 10.1074/jbc.M313526200; Yakovlev AG, 2001, J NEUROSCI, V21, P7439, DOI 10.1523/JNEUROSCI.21-19-07439.2001; Yan HL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055276; Yang XK, 2012, REPRODUCTION, V144, P235, DOI 10.1530/REP-11-0371; Ziu MT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014724	58	104	107	0	4	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JUL 23	2014	34	30					10055	10071		10.1523/JNEUROSCI.1260-14.2014			17	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AO0LV	WOS:000341001600022	25057207	Bronze, Green Published			2022-02-06	
J	Naeser, MA; Zafonte, R; Krengel, MH; Martin, PI; Frazier, J; Hamblin, MR; Knight, JA; Meehan, WP; Baker, EH				Naeser, Margaret A.; Zafonte, Ross; Krengel, Maxine H.; Martin, Paula I.; Frazier, Judith; Hamblin, Michael R.; Knight, Jeffrey A.; Meehan, William P., III; Baker, Errol H.			Significant Improvements in Cognitive Performance Post-Transcranial, Red/Near-Infrared Light-Emitting Diode Treatments in Chronic, Mild Traumatic Brain Injury: Open-Protocol Study	JOURNAL OF NEUROTRAUMA			English	Article						executive function; mTBI; photobiomodulation; treatment for mTBI	LEVEL LASER THERAPY; CYTOCHROME-C-OXIDASE; CEREBRAL-BLOOD-FLOW; CLOSED-HEAD-INJURY; WORKING-MEMORY; NEUROLOGICAL DEFICITS; FUNCTIONAL MRI; FOLLOW-UP; TBI; DYSFUNCTION	This pilot, open-protocol study examined whether scalp application of red and near-infrared (NIR) light-emitting diodes (LED) could improve cognition in patients with chronic, mild traumatic brain injury (mTBI). Application of red/NIR light improves mitochondrial function (especially in hypoxic/compromised cells) promoting increased adenosine triphosphate (ATP) important for cellular metabolism. Nitric oxide is released locally, increasing regional cerebral blood flow. LED therapy is noninvasive, painless, and non-thermal (cleared by the United States Food and Drug Administration [FDA], an insignificant risk device). Eleven chronic, mTBI participants (26-62 years of age, 6 males) with nonpenetrating brain injury and persistent cognitive dysfunction were treated for 18 outpatient sessions (Monday, Wednesday, Friday, for 6 weeks), starting at 10 months to 8 years post-mTBI (motor vehicle accident [MVA] or sports-related; and one participant, improvised explosive device [IED] blast injury). Four had a history of multiple concussions. Each LED cluster head (5.35 cm diameter, 500mW, 22.2 mW/cm(2)) was applied for 10 min to each of 11 scalp placements (13 J/cm(2)). LEDs were placed on the midline from front-to-back hairline; and bilaterally on frontal, parietal, and temporal areas. Neuropsychological testing was performed pre-LED, and at 1 week, and 1 and 2 months after the 18th treatment. A significant linear trend was observed for the effect of LED treatment over time for the Stroop test for Executive Function, Trial 3 inhibition (p = 0.004); Stroop, Trial 4 inhibition switching (p = 0.003); California Verbal Learning Test (CVLT)-II, Total Trials 1-5 (p = 0.003); and CVLT-II, Long Delay Free Recall (p = 0.006). Participants reported improved sleep, and fewer post-traumatic stress disorder (PTSD) symptoms, if present. Participants and family reported better ability to perform social, interpersonal, and occupational functions. These open-protocol data suggest that placebo-controlled studies are warranted.	[Naeser, Margaret A.; Krengel, Maxine H.; Martin, Paula I.; Baker, Errol H.] VA Boston Healthcare Syst, Boston, MA USA; [Naeser, Margaret A.; Krengel, Maxine H.; Martin, Paula I.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Zafonte, Ross; Frazier, Judith] Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Charlestown, MA USA; [Zafonte, Ross] Harvard Univ, Sch Med, Dept Phys Med & Rehabil,Brigham & Womens Hosp, Massachusetts Gen Hosp,Red Sox MGH Home Base Prog, Boston, MA USA; [Hamblin, Michael R.] Harvard Univ, Sch Med, Wellman Ctr Photomed,Massachusetts Gen Hosp, Harvard Mit Div Hlth Sci & Technol,Dept Dermatol, Cambridge, MA 02138 USA; [Knight, Jeffrey A.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA USA; [Meehan, William P., III] Micheli Ctr Sports Injury Prevent, Waltham, MA USA; [Meehan, William P., III] Harvard Univ, Sch Med, Boston Childrens Hosp, Sports Concuss Clin, Boston, MA USA		Naeser, MA (corresponding author), VA Boston Healthcare Syst 12A, 150 So Huntington Ave, Boston, MA 02130 USA.	mnaeser@bu.edu	Hamblin, Michael R/H-2758-2019	Hamblin, Michael R/0000-0001-6431-4605; Krengel, Maxine/0000-0001-7632-590X	Clinical Sciences Research and Development, Department of Veterans Affairs; United States National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01AI050875]; American Medical Society for Sports Medicine (AMSSM) Young Investigator Award; American College of Sports Medicine-American Medical Society for Sports Medicine Foundation Award; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01AI050875] Funding Source: NIH RePORTER	M. Naeser was supported by the Clinical Sciences Research and Development, Department of Veterans Affairs. M. R. Hamblin was supported by United States National Institutes of Health (NIH) grant R01AI050875. W. P. Meehan was supported by an American Medical Society for Sports Medicine (AMSSM) Young Investigator Award and an American College of Sports Medicine-American Medical Society for Sports Medicine Foundation Award. The authors thank Laura Burns for assistance with participant enrollment, Iris Monge for the LED treatments, Anita Saltmarche for assistance with acquisition of the LED units and LED methodology, and Michael D. Ho for assistance with manuscript preparation.	Aimbire F, 2006, PHOTOMED LASER SURG, V24, P33, DOI 10.1089/pho.2006.24.33; Beck A.T., 1993, MANUAL BECK DEPRESSI; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Bogdanova Y, 2012, NEUROPSYCHOL REV, V22, P4, DOI 10.1007/s11065-012-9192-3; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Carter CS, 2007, COGN AFFECT BEHAV NE, V7, P367, DOI 10.3758/CABN.7.4.367; Chew E, 2009, J REHABIL RES DEV, V46, P851, DOI 10.1682/JRRD.2008.09.0120; Curtis CE, 2003, TRENDS COGN SCI, V7, P415, DOI 10.1016/S1364-6613(03)00197-9; Delis D.C., 2000, CALIFORNIA VERBAL LE; Delis DC., 2001, DELIS KAPLAN EXECUTI; DeTaboada L, 2006, LASER SURG MED, V38, P70, DOI 10.1002/lsm.20256; Eells JT, 2004, MITOCHONDRION, V4, P559, DOI 10.1016/j.mito.2004.07.033; Eells JT, 2003, P NATL ACAD SCI USA, V100, P3439, DOI 10.1073/pnas.0534746100; Faul M., 2013, TRAUMATIC BRAIN INJU; Fork M, 2005, BRAIN INJURY, V19, P101, DOI 10.1080/02699050410001726086; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Hamsher K., 1989, MULTILINGUAL APHASIA; Hartikainen KM, 2010, J CLIN EXP NEUROPSYC, V32, P767, DOI 10.1080/13803390903521000; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Karu TI, 2005, LASER SURG MED, V36, P307, DOI 10.1002/lsm.20148; Khuman J, 2012, J NEUROTRAUM, V29, P408, DOI 10.1089/neu.2010.1745; Lane N, 2006, NATURE, V443, P901, DOI 10.1038/443901a; Levin HS, 2013, J NEUROTRAUM, V30, P625, DOI 10.1089/neu.2012.2627; LEVIN HS, 1990, J CLIN EXP NEUROPSYC, V12, P129, DOI 10.1080/01688639008400960; Lew HL, 2008, J REHABIL RES DEV, V45, pXI, DOI 10.1682/JRRD.2008.05.0064; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Maas AIR, 2012, LANCET NEUROL, V11, P12, DOI 10.1016/S1474-4422(11)70267-8; MACLEOD CM, 1991, PSYCHOL BULL, V109, P163, DOI 10.1037/0033-2909.109.2.163; Mayer AR, 2012, BRAIN IMAGING BEHAV, V6, P343, DOI 10.1007/s11682-012-9178-z; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Menon V, 2011, TRENDS COGN SCI, V15, P483, DOI 10.1016/j.tics.2011.08.003; Monson CM, 2008, PSYCHOL ASSESSMENT, V20, P131, DOI 10.1037/1040-3590.20.2.131; Morissette SB, 2011, REHABIL PSYCHOL, V56, P340, DOI 10.1037/a0025462; Naeser MA, 2011, PHOTOMED LASER SURG, V29, P351, DOI 10.1089/pho.2010.2814; Nawashiro H, 2012, PHOTOMED LASER SURG, V30, P231, DOI 10.1089/pho.2011.3044; Oron A, 2007, J NEUROTRAUM, V24, P651, DOI 10.1089/neu.2006.0198; Pain Assessment Visual Analog Scale, 2008, PAIN VIS SCAL; Pastore D, 2000, INT J RADIAT BIOL, V76, P863; Ponsford JL, 2014, J NEUROTRAUM, V31, P64, DOI 10.1089/neu.2013.2997; Reynolds C.R., 2002, COMPREHENSIVE TRAIL; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rojas JC, 2011, EYE BRAIN, V3, P49, DOI 10.2147/EB.S21391; Schiffer F, 2009, BEHAV BRAIN FUNCT, V5, DOI 10.1186/1744-9081-5-46; Siedentopf CM, 2002, NEUROSCI LETT, V327, P53, DOI 10.1016/S0304-3940(02)00383-X; Smith EE, 1998, P NATL ACAD SCI USA, V95, P12061, DOI 10.1073/pnas.95.20.12061; Sompol P, 2006, J MOL NEUROSCI, V29, P279, DOI 10.1385/JMN:29:3:279; Spreen O., 1977, NUEROSENSORY CTR COM; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Uozumi Y, 2010, LASER SURG MED, V42, P566, DOI 10.1002/lsm.20938; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; WAN S, 1981, PHOTOCHEM PHOTOBIOL, V34, P679, DOI 10.1111/j.1751-1097.1981.tb09424.x; Weathers F. W., 1993, USING PTSD CHECKLIST; Wechsler D., 2008, WAIS 4 WESCHLSER ADU; Whitaker HJ, 2006, STAT MED, V25, P1768, DOI 10.1002/sim.2302; Wong-Riley MTT, 2005, J BIOL CHEM, V280, P4761, DOI 10.1074/jbc.M409650200; Wu QH, 2012, LASER SURG MED, V44, P218, DOI 10.1002/lsm.22003; Xuan WJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053454; Zafonte R, 2009, J NEUROTRAUM, V26, P2207, DOI 10.1089/neu.2009.1015; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	72	104	106	2	48	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN 1	2014	31	11					1008	1017		10.1089/neu.2013.3244			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AJ7RS	WOS:000337895300003	24568233	Green Published			2022-02-06	
J	Rohm, M; Schneiders, M; Muller, C; Kreilinger, A; Kaiser, V; Muller-Putz, GR; Rupp, R				Rohm, Martin; Schneiders, Matthias; Mueller, Constantin; Kreilinger, Alex; Kaiser, Vera; Mueller-Putz, Gernot R.; Rupp, Ruediger			Hybrid brain-computer interfaces and hybrid neuroprostheses for restoration of upper limb functions in individuals with high-level spinal cord injury	ARTIFICIAL INTELLIGENCE IN MEDICINE			English	Article						Functional electrical stimulation; Hybrid neuroprosthesis; EEG; Hybrid brain-computer interface (BCI); Motor imagery; BCI training; Spinal cord injury; Tetraplegia	MOTOR IMAGERY; CLINICAL-EVALUATION; HAND GRASP; EEG; SYSTEM; SIGNALS; MODE	Background: The bilateral loss of the grasp function associated with a lesion of the cervical spinal cord severely limits the affected individuals' ability to live independently and return to gainful employment after sustaining a spinal cord injury (SCI). Any improvement in lost or limited grasp function is highly desirable. With current neuroprostheses, relevant improvements can be achieved in end users with preserved shoulder and elbow, but missing hand function. Objective: The aim of this single case study is to show that (1) with the support of hybrid neuroprostheses combining functional electrical stimulation (FES) with orthoses, restoration of hand, finger and elbow function is possible in users with high-level SCI and (2) shared control principles can be effectively used to allow for a brain-computer interface (BCI) control, even if only moderate BCI performance is achieved after extensive training. Patient and methods: The individual in this study is a right-handed 41-year-old man who sustained a traumatic SCI in 2009 and has a complete motor and sensory lesion at the level of C4. He is unable to generate functionally relevant movements of the elbow, hand and fingers on either side. He underwent extensive FES training (30-45 min, 2-3 times per week for 6 months) and motor imagery (MI) BCI training (415 runs in 43 sessions over 12 months). To meet individual needs, the system was designed in a modular fashion including an intelligent control approach encompassing two input modalities, namely an MI-BCI and shoulder movements. Results: After one year of training, the end user's MI-BCI performance ranged from 50% to 93% (average: 70.5%). The performance of the hybrid system was evaluated with different functional assessments. The user was able to transfer objects of the grasp-and-release-test and he succeeded in eating a pretzel stick, signing a document and eating an ice cream cone, which he was unable to do without the system. Conclusion: This proof-of-concept study has demonstrated that with the support of hybrid FES systems consisting of FES and a semiactive orthosis, restoring hand, finger and elbow function is possible in a tetraplegic end-user. Remarkably, even after one year of training and 415 MI-BCI runs, the end user's average BCI performance remained at about 70%. This supports the view that in high-level tetraplegic subjects, an initially moderate BCI performance cannot be improved by extensive training. However, this aspect has to be validated in future studies with a larger population. (C) 2013 Elsevier B.V. All rights reserved.	[Rohm, Martin; Schneiders, Matthias; Mueller, Constantin; Rupp, Ruediger] Univ Heidelberg Hosp, Spinal Cord Injury Ctr, D-69118 Heidelberg, Germany; [Kreilinger, Alex; Kaiser, Vera; Mueller-Putz, Gernot R.] Graz Univ Technol, Inst Knowledge Discovery, Lab Brain Comp Interfaces, A-8010 Graz, Austria		Rupp, R (corresponding author), Univ Heidelberg Hosp, Spinal Cord Injury Ctr Expt Neurorehabil, Schlierbacher Landstr 200A, D-69118 Heidelberg, Germany.	Ruediger.Rupp@med.uni-heidelberg.de		Muller-Putz, Gernot/0000-0002-0087-3720; tete, nilesh/0000-0002-7975-4950	European ICT Programme Project TOBI [FP7-224631]	This study is supported by the European ICT Programme Project TOBI (FP7-224631).	Alkadhi H, 2005, CEREB CORTEX, V15, P131, DOI 10.1093/cercor/bhh116; Alon G, 2003, ARCH PHYS MED REHAB, V84, P119, DOI 10.1053/apmr.2003.50073; Anderson KD, 2004, J NEUROTRAUM, V21, P1371, DOI 10.1089/neu.2004.21.1371; Blankertz B, 2010, NEUROIMAGE, V51, P1303, DOI 10.1016/j.neuroimage.2010.03.022; Cincotti F, 2008, BRAIN RES BULL, V75, P796, DOI 10.1016/j.brainresbull.2008.01.007; Crago P E, 1998, IEEE Trans Rehabil Eng, V6, P1, DOI 10.1109/86.662614; Fazel-Rezai Reza, 2012, Front Neuroeng, V5, P14, DOI 10.3389/fneng.2012.00014; GORDON T, 1994, PHYS THER, V74, P50, DOI 10.1093/ptj/74.1.50; Gourab K, 2010, CLIN NEUROPHYSIOL, V121, P2017, DOI 10.1016/j.clinph.2010.05.012; Graimann B, 2002, CLIN NEUROPHYSIOL, V113, P43, DOI 10.1016/S1388-2457(01)00697-6; Graves, 2003, J SPINAL CORD MED S1, V26, pS50, DOI [10.1080/10790268.2003.11754575, DOI 10.1080/10790268.2003.11754575]; Guidali M, 2011, MED BIOL ENG COMPUT, V49, P1213, DOI 10.1007/s11517-011-0809-0; Halder S, 2011, NEUROIMAGE, V55, P1779, DOI 10.1016/j.neuroimage.2011.01.021; Hentz V R, 2002, SURG REHABILITATION; Kaiser V, 2011, FRONT NEUROSCI-SWITZ, V5, DOI [10.3389/fnins.2011.00086, 10.3389/fninf.2011.00030]; Kaufmann T, 2013, CLIN NEUROPHYSIOL, V124, P893, DOI 10.1016/j.clinph.2012.11.006; Keith MW, 2002, HAND CLIN, V18, P519, DOI 10.1016/S0749-0712(02)00034-3; Kilgore KL, 2008, J HAND SURG-AM, V33A, P539, DOI 10.1016/j.jhsa.2008.01.007; Kubler A., 2011, 5 INT BRAIN COMP INT, P100; Leeb Robert, 2007, Comput Intell Neurosci, P79642, DOI 10.1155/2007/79642; McLachlan G.J., 2004, DISCRIMINANT ANAL ST; Moss CW, 2011, NEUROREHAB NEURAL RE, V25, P847, DOI 10.1177/1545968311410067; Muller-Putz GR, 2006, BIOMED TECH, V51, P57, DOI 10.1515/BMT.2006.011; Mulcahey MJ, 1999, SPINAL CORD, V37, P585, DOI 10.1038/sj.sc.3100889; Muller-Putz GR, 2005, NEUROSCI LETT, V382, P169, DOI 10.1016/j.neulet.2005.03.021; Neuper C, 2005, COGNITIVE BRAIN RES, V25, P668, DOI 10.1016/j.cogbrainres.2005.08.014; NSCISC, 2013, 2006 ANN STAT REP MO; Onose G, 2012, SPINAL CORD, V50, P599, DOI 10.1038/sc.2012.14; Pfurtscheller G, 2000, NEUROSCI LETT, V292, P211, DOI 10.1016/S0304-3940(00)01471-3; Pfurtscheller G, 2003, NEUROSCI LETT, V351, P33, DOI 10.1016/S0304-3940(03)00947-9; Pfurtscheller G, 2001, P IEEE, V89, P1123, DOI 10.1109/5.939829; Pfurtscheller G, 1999, CLIN NEUROPHYSIOL, V110, P1842, DOI 10.1016/S1388-2457(99)00141-8; Pfurtscheller G, 2009, COMPUT INTEL NEUROSC, P104, DOI [10.1155/2009/104180, DOI 10.1155/2009/104180]; Popovic D, 1999, ARCH PHYS MED REHAB, V80, P299, DOI 10.1016/S0003-9993(99)90141-7; Popovic MB, 2003, J REHABIL RES DEV, V40, P443, DOI 10.1682/JRRD.2003.09.0443; Rohm M., 2011, INT J BIOELECTROMAGN, V13, P127; Rupp R., 2012, C P IEEE ENG MED BIO, V183, P5; Schneiders M, 2011, INT J BIOELECTROMAGN, V13, P2; Snoek GJ, 2004, SPINAL CORD, V42, P526, DOI 10.1038/sj.sc.3101638; VANDENHONERT C, 1979, ANN BIOMED ENG, V7, P117, DOI 10.1007/BF02363130; Varoto R, 2008, ARTIF ORGANS, V32, P725, DOI 10.1111/j.1525-1594.2008.00597.x; Williams MR, 2008, IEEE T NEUR SYS REH, V16, P485, DOI 10.1109/TNSRE.2008.2006216; Wolpaw JR, 2002, CLIN NEUROPHYSIOL, V113, P767, DOI 10.1016/S1388-2457(02)00057-3; WUOLLE KS, 1994, J HAND SURG-AM, V19A, P209, DOI 10.1016/0363-5023(94)90008-6; Zhang H, 2011, IEEE INT C REH ROB; Zickler C, 2011, CLIN EEG NEUROSCI, V42, P236, DOI 10.1177/155005941104200409	46	104	113	7	69	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0933-3657	1873-2860		ARTIF INTELL MED	Artif. Intell. Med.	OCT	2013	59	2			SI		133	142		10.1016/j.artmed.2013.07.004			10	Computer Science, Artificial Intelligence; Engineering, Biomedical; Medical Informatics	Science Citation Index Expanded (SCI-EXPANDED)	Computer Science; Engineering; Medical Informatics	256DT	WOS:000327290600009	24064256				2022-02-06	
J	Palacios, EM; Sala-Llonch, R; Junque, C; Roig, T; Tormos, JM; Bargallo, N; Vendrell, P				Palacios, Eva M.; Sala-Llonch, Roser; Junque, Carme; Roig, Teresa; Tormos, Jose M.; Bargallo, Nuria; Vendrell, Pere			Resting-State Functional Magnetic Resonance Imaging Activity and Connectivity and Cognitive Outcome in Traumatic Brain Injury	JAMA NEUROLOGY			English	Article							WHITE-MATTER INTEGRITY; MULTIPLE-SCLEROSIS; WORKING-MEMORY; AXONAL INJURY; NETWORK; IMPAIRMENT; RECOVERY; DEFICITS; HIPPOCAMPAL	IMPORTANCE The study of brain activity and connectivity at rest provides a unique opportunity for the investigation of the brain substrates of cognitive outcome after traumatic axonal injury. This knowledge may contribute to improve clinical management and rehabilitation programs. OBJECTIVE To study functional magnetic resonance imaging abnormalities in signal amplitude and brain connectivity at rest and their relationship to cognitive outcome in patients with chronic and severe traumatic axonal injury. DESIGN Observational study. SETTING University of Barcelona and Hospital Clinic de Barcelona, Barcelona, and Institut Guttmann-Neurorehabilitation Hospital, Badalona, Spain. PARTICIPANTS Twenty patients with traumatic brain injury (TBI) were studied, along with 17 matched healthy volunteers. INTERVENTIONS Resting-state functional magnetic resonance imaging and diffusion tensor imaging data were acquired. After exploring group differences in amplitude of low-frequency fluctuations (ALFF), we studied functional connectivity within the default mode network (DMN) by means of independent component analysis, followed by a dual regression approach and seed-based connectivity analyses. Finally, we performed probabilistic tractography between the frontal and posterior nodes of the DMN. MAIN OUTCOMES AND MEASURES Signal amplitude and functional connectivity during the resting state, tractography related to DMN, and the association between signal amplitudes and cognitive outcome. RESULTS Patients had greater ALFF in frontal regions, which was correlated with cognitive performance. Within the DMN, patients showed increased connectivity in the frontal lobes. Seed-based connectivity analyses revealed augmented connectivity within surrounding areas of the frontal and left parietal nodes of the DMN. Fractional anisotropy of the cingulate tract was correlated with increased connectivity of the frontal node of the DMN in patients with TBI. CONCLUSIONS AND RELEVANCE Increased ALFF is related to better cognitive performance in chronic TBI. The loss of structural connectivity produced by damage to the cingulum tract explained the compensatory increases in functional connectivity within the frontal node of the DMN.	[Palacios, Eva M.; Sala-Llonch, Roser; Junque, Carme; Vendrell, Pere] August Pi & Sunyer Biomed Res Inst, Barcelona, Spain; [Sala-Llonch, Roser; Junque, Carme; Vendrell, Pere] Univ Barcelona, Dept Psychiat & Clin Psychobiol, E-08036 Barcelona, Spain; [Roig, Teresa; Tormos, Jose M.] Neurorehabil Hosp, Inst Guttmann, Badalona, Spain; [Bargallo, Nuria] Hosp Clin Barcelona, Ctr Diagnost Imatge, Barcelona, Spain		Junque, C (corresponding author), Univ Barcelona, Dept Psychiat & Clin Psychobiol, C Casanova 143, E-08036 Barcelona, Spain.	cjunque@ub.edu	Junque, Carme/B-4400-2011; Bargallo, Nuria/G-6854-2016; Vendrell, Pere/B-4392-2011; Sala-Llonch, Roser/L-4135-2015; Lang, Steven/AAE-8102-2021; Sala-Llonch, Roser/E-7882-2012	Junque, Carme/0000-0002-6381-3063; Bargallo, Nuria/0000-0001-6284-5402; Vendrell, Pere/0000-0001-8918-5440; Sala-Llonch, Roser/0000-0003-3576-0475; Lang, Steven/0000-0003-1669-9146; Sala-Llonch, Roser/0000-0003-3576-0475; Tormos Munoz, Jose Maria/0000-0002-8764-2289			Adams JH, 2011, J NEUROTRAUM, V28, P701, DOI 10.1089/neu.2010.1733; Arenivas A, 2014, BRAIN IMAGING BEHAV, V8, P407, DOI 10.1007/s11682-012-9191-2; Beckmann CF, 2005, NEUROIMAGE, V25, P294, DOI 10.1016/j.neuroimage.2004.10.043; Benedictus MR, 2010, ARCH PHYS MED REHAB, V91, P1436, DOI 10.1016/j.apmr.2010.06.019; Biswal BB, 2010, P NATL ACAD SCI USA, V107, P4734, DOI 10.1073/pnas.0911855107; Bonavita S, 2011, MULT SCLER J, V17, P411, DOI 10.1177/1352458510394609; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Castellanos NP, 2010, BRAIN, V133, P2365, DOI 10.1093/brain/awq174; Catani M, 2008, CORTEX, V44, P1105, DOI 10.1016/j.cortex.2008.05.004; Damoiseaux JS, 2006, P NATL ACAD SCI USA, V103, P13848, DOI 10.1073/pnas.0601417103; de la Plata CDM, 2011, ARCH NEUROL-CHICAGO, V68, P74, DOI 10.1001/archneurol.2010.342; Filippini N, 2009, P NATL ACAD SCI USA, V106, P7209, DOI 10.1073/pnas.0811879106; Fox MD, 2007, NAT REV NEUROSCI, V8, P700, DOI 10.1038/nrn2201; Hagmann P, 2008, PLOS BIOL, V6, P1479, DOI 10.1371/journal.pbio.0060159; Hawellek DJ, 2011, P NATL ACAD SCI USA, V108, P19066, DOI 10.1073/pnas.1110024108; Hillary FG, 2011, INT J PSYCHOPHYSIOL, V82, P115, DOI 10.1016/j.ijpsycho.2011.03.011; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Kasahara M, 2011, BRAIN INJURY, V25, P1170, DOI 10.3109/02699052.2011.608210; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; Newcombe V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019214; Palacios EM, 2012, NEUROLOGY, V78, P852, DOI 10.1212/WNL.0b013e31824c465a; Palacios EM, 2013, CORTEX, V49, P646, DOI 10.1016/j.cortex.2012.02.011; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Shumskaya E, 2012, NEUROLOGY, V79, P175, DOI 10.1212/WNL.0b013e31825f04fb; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Smith SM, 2009, P NATL ACAD SCI USA, V106, P13040, DOI 10.1073/pnas.0905267106; van den Heuvel MP, 2010, EUR NEUROPSYCHOPHARM, V20, P519, DOI 10.1016/j.euroneuro.2010.03.008; Wang ZQ, 2011, HUM BRAIN MAPP, V32, P1720, DOI 10.1002/hbm.21140; Zang YF, 2007, BRAIN DEV-JPN, V29, P83, DOI 10.1016/j.braindev.2006.07.002	36	104	108	0	21	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	2168-6149			JAMA NEUROL	JAMA Neurol.	JUL	2013	70	7					845	851		10.1001/jamaneurol.2013.38			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	206YN	WOS:000323563000006	23689958	Bronze			2022-02-06	
J	Huber, BR; Meabon, JS; Martin, TJ; Mourad, PD; Bennett, R; Kraemer, BC; Cernak, I; Petrie, EC; Emery, MJ; Swenson, ER; Mayer, C; Mehic, E; Peskind, ER; Cook, DG				Huber, Bertrand R.; Meabon, James S.; Martin, Tobin J.; Mourad, Pierre D.; Bennett, Raymond; Kraemer, Brian C.; Cernak, Ibolja; Petrie, Eric C.; Emery, Michael J.; Swenson, Erik R.; Mayer, Cynthia; Mehic, Edin; Peskind, Elaine R.; Cook, David G.			Blast Exposure Causes Early and Persistent Aberrant Phospho- and Cleaved-Tau Expression in a Murine Model of Mild Blast-Induced Traumatic Brain Injury	JOURNAL OF ALZHEIMERS DISEASE			English	Article						Blast-induced neurotrauma; brain trauma; cerebellum; mitochondrial oxidative stress; neurodegeneration; tauopathy	HEAD-INJURY; CASPASE ACTIVATION; MOUSE MODEL; ENCEPHALOPATHY; DISEASE; STRESS; HYPERPHOSPHORYLATION; OVERPRESSURE; AFGHANISTAN; INVOLVEMENT	Mild traumatic brain injury (mTBI) is considered the 'signature injury' of combat veterans that have served during the wars in Iraq and Afghanistan. This prevalence of mTBI is due in part to the common exposure to high explosive blasts in combat zones. In addition to the threats of blunt impact trauma caused by flying objects and the head itself being propelled against objects, the primary blast overpressure (BOP) generated by high explosives is capable of injuring the brain. Compared to other means of causing TBI, the pathophysiology of mild-to-moderate BOP is less well understood. To study the consequences of BOP exposure in mice, we employed a well-established approach using a compressed gas-driven shock tube that recapitulates battlefield-relevant open-field BOP. We found that 24 hours post-blast a single mild BOP provoked elevation of multiple phospho- and cleaved-tau species in neurons, as well as elevating manganese superoxide-dismutase (MnSOD or SOD2) levels, a cellular response to oxidative stress. In hippocampus, aberrant tau species persisted for at least 30 days post-exposure, while SOD2 levels returned to sham control levels. These findings suggest that elevated phospho- and cleaved-tau species may be among the initiating pathologic processes induced by mild blast exposure. These findings may have important implications for efforts to prevent blast-induced insults to the brain from progressing into long-term neurodegenerative disease processes.	[Huber, Bertrand R.; Petrie, Eric C.; Mayer, Cynthia; Peskind, Elaine R.] Vet Affairs Puget Sound Hlth Care Syst, Northwest Network Mental Illness Res Educ & Clin, Seattle, WA USA; [Meabon, James S.; Petrie, Eric C.; Peskind, Elaine R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; [Meabon, James S.; Martin, Tobin J.; Kraemer, Brian C.; Cook, David G.] Vet Affairs Puget Sound Hlth Care Syst, GRECC, Seattle, WA USA; [Mourad, Pierre D.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Mourad, Pierre D.] Univ Washington, Appl Phys Lab, Seattle, WA 98105 USA; [Mourad, Pierre D.; Mehic, Edin] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA; [Bennett, Raymond] Baker Engn & Risk Consultants, San Antonio, TX USA; [Kraemer, Brian C.; Cook, David G.] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA USA; [Cernak, Ibolja] Univ Alberta, Fac Rehabil Med, Edmonton, AB T6G 2M7, Canada; [Emery, Michael J.; Swenson, Erik R.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA; [Swenson, Erik R.] Univ Washington, Div Pulm & Crit Care Med, Dept Med, Seattle, WA USA; [Cook, David G.] Univ Washington, Sch Med, Dept Pharmacol, Seattle, WA 98195 USA		Cook, DG (corresponding author), 1660 S Columbian Way, Seattle, WA 98108 USA.	dgcook@u.washington.edu		Petrie, Eric/0000-0003-1188-6321; Ibolja, Cernak/0000-0003-3214-698X	Department of Veterans Affairs Office of Research and Development Medical Research ServiceUS Department of Veterans Affairs; University of Washington Friends of Alzheimer's Research; University of Washington Royalty Research FundUniversity of Washington; Northwest Network Mental Illness Research, Education and Clinical Center; Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment, Department of Veterans Affairs; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 AG000258]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005136, T32AG000258] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01BX002619] Funding Source: NIH RePORTER	This work was supported by the Department of Veterans Affairs Office of Research and Development Medical Research Service (DGC, ERP, BCK), University of Washington Friends of Alzheimer's Research (DGC, ERP), University of Washington Royalty Research Fund (DGC); Northwest Network Mental Illness Research, Education and Clinical Center (ERP), Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment, Department of Veterans Affairs (BRH); NIH T32 AG000258 (JSM); None of the authors have financial or other potential conflicts of interest regarding this report.	Ahlers Stephen Thomas, 2012, Front Neurol, V3, P32, DOI 10.3389/fneur.2012.00032; Alonso AD, 2001, P NATL ACAD SCI USA, V98, P6923, DOI 10.1073/pnas.121119298; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI [10.1089/neu.2008.0898, 10.1089/neu.2009-0898]; Bayir H, 2007, J NEUROCHEM, V101, P168, DOI 10.1111/j.1471-4159.2006.04353.x; Belmont PJ, 2012, J TRAUMA ACUTE CARE, V73, P3, DOI 10.1097/TA.0b013e318250bfb4; Bowen I G, 1967, Fission Prod Inhal Proj, P1; Cernak I, 1999, J TRAUMA, V47, P96, DOI 10.1097/00005373-199907000-00021; Cernak I, 1996, J TRAUMA, V40, pS100, DOI 10.1097/00005373-199603001-00023; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Cernak I, 2000, MAGNESIUM RES, V13, P29; Cernak Ibolja, 2010, Front Neurol, V1, P151, DOI 10.3389/fneur.2010.00151; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; de Calignon A, 2010, NATURE, V464, P1201, DOI 10.1038/nature08890; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Goldstein L.E., 2012, SCI TRANSL MED, V4; Hosek B, 2011, NEW ENGL J MED; Jaffe DH, 2010, ANN SURG, V251, P138, DOI 10.1097/SLA.0b013e3181b5d7ab; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meabon JS, 2012, J HISTOCHEM CYTOCHEM, V60, P139, DOI 10.1369/0022155411430095; Melov S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000536; Moss WC, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.108702; MURTHY JMK, 1979, J NEUROSURG, V50, P260, DOI 10.3171/jns.1979.50.2.0260; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; Omalu BI, 2010, AM J FOREN MED PATH, V31, P130, DOI 10.1097/PAF.0b013e3181ca7f35; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Rostami Elham, 2012, Front Neurol, V3, P115, DOI 10.3389/fneur.2012.00115; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Smith JE, 2011, PHILOS T R SOC B, V366, P291, DOI 10.1098/rstb.2010.0251; Spires-Jones TL, 2008, J NEUROSCI, V28, P862, DOI 10.1523/JNEUROSCI.3072-08.2008; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Wang JZ, 2007, EUR J NEUROSCI, V25, P59, DOI 10.1111/j.1460-9568.2006.05226.x; Wang Y, 2011, J NEUROTRAUM, V28, P2171, DOI 10.1089/neu.2011.1990; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Warden DL, 2009, NEUROIMAGE, V47, pT152, DOI 10.1016/j.neuroimage.2009.01.060; Wood GW, 2013, INJURY PREV, V19, P19, DOI 10.1136/injuryprev-2011-040277; Yelverton JT, 1996, J TRAUMA, V40, pS111, DOI 10.1097/00005373-199603001-00025	47	104	106	2	28	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1387-2877			J ALZHEIMERS DIS	J. Alzheimers Dis.		2013	37	2					309	323		10.3233/JAD-130182			15	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	217EA	WOS:000324338400006	23948882	Green Accepted			2022-02-06	
J	Fazel, S; Lichtenstein, P; Grann, M; Langstrom, N				Fazel, Seena; Lichtenstein, Paul; Grann, Martin; Langstrom, Niklas			Risk of Violent Crime in Individuals with Epilepsy and Traumatic Brain Injury: A 35-Year Swedish Population Study	PLOS MEDICINE			English	Article							NATIONAL INPATIENT REGISTER; ACUTE MYOCARDIAL-INFARCTION; HEAD-INJURY; AGGRESSIVE-BEHAVIOR; SUBSTANCE-ABUSE; SCHIZOPHRENIA; COHORT; PREVALENCE; PRISONERS; REHABILITATION	Background: Epilepsy and traumatic brain injury are common neurological conditions, with general population prevalence estimates around 0.5% and 0.3%, respectively. Although both illnesses are associated with various adverse outcomes, and expert opinion has suggested increased criminality, links with violent behaviour remain uncertain. Methods and Findings: We combined Swedish population registers from 1973 to 2009, and examined associations of epilepsy (n = 22,947) and traumatic brain injury (n = 22,914) with subsequent violent crime (defined as convictions for homicide, assault, robbery, arson, any sexual offense, or illegal threats or intimidation). Each case was age and gender matched with ten general population controls, and analysed using conditional logistic regression with adjustment for socio-demographic factors. In addition, we compared cases with unaffected siblings. Among the traumatic brain injury cases, 2,011 individuals (8.8%) committed violent crime after diagnosis, which, compared with population controls (n = 229,118), corresponded to a substantially increased risk (adjusted odds ratio [aOR] = 3.3, 95% CI: 3.1-3.5); this risk was attenuated when cases were compared with unaffected siblings (aOR = 2.0, 1.8-2.3). Among individuals with epilepsy, 973 (4.2%) committed a violent offense after diagnosis, corresponding to a significantly increased odds of violent crime compared with 224,006 population controls (aOR = 1.5, 1.4-1.7). However, this association disappeared when individuals with epilepsy were compared with their unaffected siblings (aOR = 1.1, 0.9-1.2). We found heterogeneity in violence risk by age of disease onset, severity, comorbidity with substance abuse, and clinical subgroups. Case ascertainment was restricted to patient registers. Conclusions: In this longitudinal population-based study, we found that, after adjustment for familial confounding, epilepsy was not associated with increased risk of violent crime, questioning expert opinion that has suggested a causal relationship. In contrast, although there was some attenuation in risk estimates after adjustment for familial factors and substance abuse in individuals with traumatic brain injury, we found a significantly increased risk of violent crime. The implications of these findings will vary for clinical services, the criminal justice system, and patient charities.	[Fazel, Seena] Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford, England; [Fazel, Seena; Grann, Martin; Langstrom, Niklas] Karolinska Inst, Ctr Violence Prevent, Stockholm, Sweden; [Lichtenstein, Paul; Grann, Martin; Langstrom, Niklas] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden; [Grann, Martin; Langstrom, Niklas] Swedish Prison & Probat Serv, Norrkoping, Sweden		Fazel, S (corresponding author), Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford, England.	seena.fazel@psych.ox.ac.uk	Fazel, Seena/B-5307-2008; Langstrom, Niklas/C-5615-2009	Fazel, Seena/0000-0002-5383-5365; Langstrom, Niklas/0000-0002-2686-6799; lichtenstein, paul/0000-0003-3037-5287	Swedish Research Council - MedicineSwedish Research Council; Swedish Council for Working Life and Social ResearchSwedish Research CouncilSwedish Research Council for Health Working Life & Welfare (Forte); National Prison and Probation Administration RD	Funded by the Swedish Research Council - Medicine, Swedish Council for Working Life and Social Research, and the National Prison and Probation Administration R&D. No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	American Psychiatric Association, 2004, PRACT GUID TREATM PA; Amoroso C, 2006, LANCET, V367, P1143, DOI 10.1016/S0140-6736(06)68503-6; Anderson V, 2009, BRAIN, V132, P45, DOI 10.1093/brain/awn293; Arseneault L, 2000, ARCH GEN PSYCHIAT, V57, P979, DOI 10.1001/archpsyc.57.10.979; Baguley IJ, 2006, J HEAD TRAUMA REHAB, V21, P45, DOI 10.1097/00001199-200601000-00005; BLAKE PY, 1995, NEUROLOGY, V45, P1641, DOI 10.1212/WNL.45.9.1641; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Butler T, 2004, AUST NZ J PUBL HEAL, V28, P344, DOI 10.1111/j.1467-842X.2004.tb00442.x; Christensen J, 2007, LANCET NEUROL, V6, P693, DOI 10.1016/S1474-4422(07)70175-8; Dalman C, 2002, SOC PSYCH PSYCH EPID, V37, P527, DOI 10.1007/s00127-002-0582-3; Damasio AR, 2000, ARCH GEN PSYCHIAT, V57, P128, DOI 10.1001/archpsyc.57.2.128; DAMASIO H, 1994, SCIENCE, V264, P1102, DOI 10.1126/science.8178168; de Boer HM, 2002, EPILEPSIA, V43, P7, DOI 10.1046/j.1528-1157.43.s.6.4.x; Dolmen L, 2001, BROTTSLIGHETEN I OLI; Dyer KFW, 2006, BRAIN INJURY, V20, P1163, DOI 10.1080/02699050601049312; Ekholm B, 2005, NORD J PSYCHIAT, V59, P457, DOI 10.1080/08039480500360906; ELLIOTT FA, 1992, ARCH NEUROL-CHICAGO, V49, P595, DOI 10.1001/archneur.1992.00530300027006; Farrington D. P., 2004, CROSS NATL STUDIES C; Fazel S, 2002, BRIT MED J, V324, P1495, DOI 10.1136/bmj.324.7352.1495; Fazel S, 2006, AM J PSYCHIAT, V163, P1397, DOI 10.1176/appi.ajp.163.8.1397; Fazel S, 2010, ARCH GEN PSYCHIAT, V67, P931, DOI 10.1001/archgenpsychiatry.2010.97; Fazel S, 2009, J NEUROL, V256, P1591, DOI 10.1007/s00415-009-5134-2; Fazel S, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000120; Fazel S, 2009, JAMA-J AM MED ASSOC, V301, P2016, DOI 10.1001/jama.2009.675; Filley CM, 2001, NEUROPSY NEUROPSY BE, V14, P1; Forsgren L, 2005, EUR J NEUROL, V12, P245, DOI 10.1111/j.1468-1331.2004.00992.x; Gedeborg R, 2008, EPIDEMIOLOGY, V19, P860, DOI 10.1097/EDE.0b013e318181319e; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; Graham DP, 2008, ANN NY ACAD SCI, V1141, P148, DOI 10.1196/annals.1441.029; Greve KW, 2001, BRAIN INJURY, V15, P255; GUNN J, 1971, BRIT J PSYCHIAT, V118, P337, DOI 10.1192/bjp.118.544.337; Hammar N, 2001, INT J EPIDEMIOL, V30, pS30, DOI 10.1093/ije/30.suppl_1.S30; Hjern A, 2002, LANCET, V360, P443, DOI 10.1016/S0140-6736(02)09674-5; Huband N, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003499.pub3; JIANG GX, 1995, ACTA NEUROL SCAND, V91, P109; Kale R, 1997, BRIT MED J, V315, P2, DOI 10.1136/bmj.315.7099.2; Klein-Geltink JE, 2007, J CLIN EPIDEMIOL, V60, P766, DOI 10.1016/j.jclinepi.2006.11.008; KREUTZER JS, 1995, BRAIN INJURY, V9, P757, DOI 10.3109/02699059509008232; Lambert M, 2003, NEUROPSYCHIATRY; Leon-Carrion J, 2003, BRAIN INJURY, V17, P207, DOI 10.1080/0269905021000010249; LINDBLAD U, 1993, SCAND J SOC MED, V21, P3, DOI 10.1177/140349489302100102; LIVINGSTON S, 1964, JAMA-J AM MED ASSOC, V188, P172; Ludvigsson JF, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-450; Maudsley Henry, 1870, BODY MIND; National Institute for Health and Clinical Excellence, 2007, HEAD INJ TRAIG ASS I; Qin P, 2005, BMJ-BRIT MED J, V331, P23, DOI 10.1136/bmj.38488.462037.8F; Raine A, 2005, J ABNORM PSYCHOL, V114, P38, DOI 10.1037/0021-843X.114.1.38; RANTAKALLIO P, 1992, ARCH DIS CHILD, V67, P1459, DOI 10.1136/adc.67.12.1459; Reuber M, 2008, EPILEPSIA, V49, P138, DOI 10.1111/j.1528-1167.2007.01269.x; Shih JJ, 2009, NEUROLOGY, V73, P1804, DOI 10.1212/WNL.0b013e3181c2933f; Simpson G, 2000, BRAIN INJURY, V14, P125, DOI 10.1080/026990500120790; Statistics Sweden, 2005, FLERG 2004 BESKR INN; STEIN SC, 1995, PEDIATR SURG INT, V10, P465; Swedish National Board of Health and Welfare, 2011, PAT PAT REG; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tardiff K., 2003, TXB CLIN PSYCHIAT; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; Toone B, 2009, NEW OXFORD TXB PSYCH, P1076; TREIMAN DM, 1986, EPILEPSIA, V27, pS77, DOI 10.1111/j.1528-1157.1986.tb05742.x; Turkstra L, 2003, BRAIN INJURY, V17, P39, DOI 10.1080/0269905021000010122; Wallace C, 1998, BRIT J PSYCHIAT, V172, P477, DOI 10.1192/bjp.172.6.477; WHITMAN S, 1984, NEUROLOGY, V34, P775, DOI 10.1212/WNL.34.6.775; Williams WH, 2010, NEUROPSYCHOL REHABIL, V20, P801, DOI 10.1080/09602011.2010.519613; Williams WH, 2010, BRAIN INJURY, V24, P1184, DOI 10.3109/02699052.2010.495697; Wood RL, 2006, J NEUROPSYCH CLIN N, V18, P333, DOI 10.1176/appi.neuropsych.18.3.333	65	104	106	2	32	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1549-1676			PLOS MED	PLos Med.	DEC	2011	8	12							e1001150	10.1371/journal.pmed.1001150			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	870KM	WOS:000298668100015	22215988	Green Published, gold, Green Submitted			2022-02-06	
J	Wagner, AK; McCullough, EH; Niyonkuru, C; Ozawa, H; Loucks, TL; Dobos, JA; Brett, CA; Santarsieri, M; Dixon, CE; Berga, SL; Fabio, A				Wagner, Amy K.; McCullough, Emily H.; Niyonkuru, Christian; Ozawa, Haishin; Loucks, Tammy L.; Dobos, Julie A.; Brett, Christopher A.; Santarsieri, Martina; Dixon, C. Edward; Berga, Sarah L.; Fabio, Anthony			Acute Serum Hormone Levels: Characterization and Prognosis after Severe Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						global outcome; group based trajectory analysis; sex steroids; structural equations model; traumatic brain injury	ISCHEMIA-REPERFUSION INJURY; TISSUE STROMAL CELLS; CRITICALLY-ILL; ADIPOSE-TISSUE; PITUITARY INSUFFICIENCY; GENDER-DIFFERENCES; AROMATASE-ACTIVITY; ADRENAL-RESPONSE; BINDING GLOBULIN; BLOOD-FLOW	Experimental traumatic brain injury (TBI) studies report the neuroprotective effects of female sex steroids on multiple mechanisms of injury, with the clinical assumption that women have hormonally mediated neuroprotection because of the endogenous presence of these hormones. Other literature indicates that testosterone may exacerbate injury. Further, stress hormone abnormalities that accompany critical illness may both amplify or blunt sex steroid levels. To better understand the role of sex steroid exposure in mediating TBI, we 1) characterized temporal profiles of serum gonadal and stress hormones in a population with severe TBI during the acute phases of their injury; and 2) used a biological systems approach to evaluate these hormones as biomarkers predicting global outcome. The study population was 117 adults (28 women; 89 men) with severe TBI. Serum samples (n = 536) were collected for 7 days post-TBI for cortisol, progesterone, testosterone, estradiol, luteinizing hormone (LH), and follicle-stimulating hormone (FSH). Hormone data were linked with clinical data, including acute care mortality and Glasgow Outcome Scale (GOS) scores at 6 months. Hormone levels after TBI were compared to those in healthy controls (n = 14). Group based trajectory analysis (TRAJ) was used to develop temporal hormone profiles that delineate distinct subpopulations in the cohort. Structural equations models were used to determine inter-relationships between hormones and outcomes within a multivariate model. Compared to controls, acute serum hormone levels were significantly altered after severe TBI. Changes in the post-TBI adrenal response and peripheral aromatization influenced hormone TRAJ profiles and contributed to the abnormalities, including increased estradiol in men and increased testosterone in women. In addition to older age and greater injury severity, increased estradiol and testosterone levels over time were associated with increased mortality and worse global outcome for both men and women. These findings represent a paradigm shift when thinking about the role of sex steroids in neuroprotection clinically after TBI.	[Wagner, Amy K.; McCullough, Emily H.; Niyonkuru, Christian; Ozawa, Haishin; Dobos, Julie A.; Brett, Christopher A.; Santarsieri, Martina; Dixon, C. Edward; Fabio, Anthony] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; [Wagner, Amy K.; Dixon, C. Edward] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Dixon, C. Edward] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15213 USA; [Fabio, Anthony] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15213 USA; [Loucks, Tammy L.; Berga, Sarah L.] Emory Univ, Dept Obstet & Gynecol, Atlanta, GA 30322 USA		Wagner, AK (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 5th Ave,Suite 202, Pittsburgh, PA 15213 USA.	wagnerak@upmc.edu	Loucks, Tammy/N-8223-2019	Loucks, Tammy/0000-0001-7651-7602; Fabio, Anthony/0000-0002-6808-4939	CDCCentre National de la Recherche Scientifique (CNRS)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49/CCR323155]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5P01NS030318-16]; DODUnited States Department of Defense [W81XWH-071-0701, PT073914]; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE323155] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS030318] Funding Source: NIH RePORTER	The authors acknowledge Mary Synnott for figure construction, and the UPMC Trauma Registry team and the Brain Trauma Research Center for their role in data collection. This work was supported by CDC grant # R49/CCR323155 (A. K. W., S. L. B., A. F.), DODW81XWH-071-0701, DOD PT073914 (A. K. W., A. F.), and NIH 5P01NS030318-16 to (C.E.D.).	Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Llompart-Pou JA, 2010, NEUROCRIT CARE, V13, P211, DOI 10.1007/s12028-010-9399-1; Azcoitia I, 2003, ANN NY ACAD SCI, V1007, P298, DOI 10.1196/annals.1286.028; Bavisetty S, 2008, NEUROSURGERY, V62, P1080, DOI 10.1227/01.neu.0000325870.60129.6a; Beale E, 2002, GERONTOLOGY, V48, P84, DOI 10.1159/000048932; Behan LA, 2008, J NEUROL NEUROSUR PS, V79, P753, DOI 10.1136/jnnp.2007.132837; Berger RP, 2007, J NEUROTRAUM, V24, P1793, DOI 10.1089/neu.2007.0316; Berger RP, 2006, J HEAD TRAUMA REHAB, V21, P315, DOI 10.1097/00001199-200607000-00004; Berry C, 2009, J TRAUMA, V67, P950, DOI 10.1097/TA.0b013e3181ba3354; Blair JC, 2010, BRIT J NEUROSURG, V24, P10, DOI 10.3109/02688690903536637; Bullock R., 1996, EUR J EMERG MED, V3, P109, DOI 10.1097/00063110-199606000-00010; Burger HG, 2002, FERTIL STERIL, V77, pS3; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; Constant EL, 2001, J CLIN ENDOCR METAB, V86, P3864, DOI 10.1210/jc.86.8.3864; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Dennis AM, 2009, J NEUROTRAUM, V26, P889, DOI 10.1089/neu.2008.0512; DESAI D, 1989, J TRAUMA, V29, P719, DOI 10.1097/00005373-198906000-00003; Dossett LA, 2008, J TRAUMA, V64, P580, DOI 10.1097/TA.0b013e31816543dd; Dossett LA, 2008, SURG INFECT, V9, P41, DOI 10.1089/sur.2007.037; EFRON B, 1987, J AM STAT ASSOC, V82, P171, DOI 10.2307/2289144; Efron B., 1993, INTRO BOOTSTRAP; Evans MJ, 2001, CLIN BIOCHEM, V34, P107, DOI 10.1016/S0009-9120(01)00196-5; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Farin A, 2004, ACT NEUR S, V89, P101; Faul M, 2010, TRAUMATIC BRAIN INJU; Fisher R.A., 1922, PHILOS T R SOC, V222, P309, DOI [10.1098/rsta.1922.0009, DOI 10.1098/RSTA.1922.0009]; Garcia-Segura LM, 2003, PROG NEUROBIOL, V71, P31, DOI 10.1016/j.pneurobio.2003.09.005; Gasco V., 2010, PITUITARY; Guennoun R, 2008, BRAIN RES REV, V57, P493, DOI 10.1016/j.brainresrev.2007.05.009; Hildreth AN, 2008, J TRAUMA, V65, P573, DOI 10.1097/TA.0b013e31818255e8; HORAN MA, 1994, ANN NY ACAD SCI, V719, P285, DOI 10.1111/j.1749-6632.1994.tb56836.x; Hurn PD, 2000, J CEREBR BLOOD F MET, V20, P631, DOI 10.1097/00004647-200004000-00001; JENNETT B, 1975, LANCET, V1, P480; Jones BL, 2001, SOCIOL METHOD RES, V29, P374, DOI 10.1177/0049124101029003005; Kalantaridou SN, 2004, J REPROD IMMUNOL, V62, P61, DOI 10.1016/j.jri.2003.09.004; Klose M, 2007, CLIN ENDOCRINOL, V67, P598, DOI 10.1111/j.1365-2265.2007.02931.x; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; Little RJA., 1987, STAT ANAL MISSING DA; Llompart-Pou JA, 2007, J ENDOCRINOL INVEST, V30, P393, DOI 10.1007/BF03346316; Llompart-Pou JA, 2008, NEUROCRIT CARE, V9, P230, DOI 10.1007/s12028-008-9115-6; LUEPRASITSAKUL P, 1990, P SOC EXP BIOL MED, V194, P337; LUEPRASITSAKUL P, 1990, STEROIDS, V55, P540, DOI 10.1016/0039-128X(90)90049-H; MacKinnon DP, 2004, MULTIVAR BEHAV RES, V39, P99, DOI 10.1207/s15327906mbr3901_4; Mastorakos G, 2005, HORM METAB RES, V37, P577, DOI 10.1055/s-2005-870426; May AK, 2008, CRIT CARE MED, V36, P62, DOI 10.1097/01.CCM.0000292015.16171.6D; Mendelowitsch A, 2001, BRAIN RES, V901, P230, DOI 10.1016/S0006-8993(01)02359-9; Meric E, 2010, J EMERG MED, V38, P297, DOI 10.1016/j.jemermed.2007.11.032; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; MUTHEN B, 1987, PSYCHOMETRIKA, V52, P431, DOI 10.1007/BF02294365; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; Nagin D.S., 2005, GROUP BASED MODELING; Ottochian M, 2009, AM J SURG, V197, P155, DOI 10.1016/j.amjsurg.2008.09.008; Paul T, 2007, CHRONOBIOL INT, V24, P45, DOI 10.1080/07420520601142569; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Savaridas T, 2004, INTENS CARE MED, V30, P1479, DOI 10.1007/s00134-004-2306-5; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Silverman DHS, 2011, PSYCHONEUROENDOCRINO, V36, P502, DOI 10.1016/j.psyneuen.2010.08.002; SIMPSON ER, 1981, P NATL ACAD SCI-BIOL, V78, P5690, DOI 10.1073/pnas.78.9.5690; SIMPSON ER, 1989, ENDOCR REV, V10, P136, DOI 10.1210/edrv-10-2-136; Singh S., 1997, P 5 EUR C INT TECHN, V3, P1993; Spratt DI, 2008, AM J PHYSIOL-ENDOC M, V295, pE63, DOI 10.1152/ajpendo.00472.2007; Spratt DI, 2006, AM J PHYSIOL-ENDOC M, V291, pE631, DOI 10.1152/ajpendo.00467.2005; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Stein DG, 2008, ANN EMERG MED, V51, P164, DOI 10.1016/j.annemergmed.2007.05.001; Sutton-Tyrrell K, 2005, CIRCULATION, V111, P1242, DOI 10.1161/01.CIR.0000157697.54255.CE; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Torpy DJ, 2007, CLIN ENDOCRINOL, V67, P161, DOI 10.1111/j.1365-2265.2007.02890.x; Van den Berghe G, 2001, J CLIN ENDOCR METAB, V86, P3217, DOI 10.1210/jc.86.7.3217; Wagner AK, 2000, ARCH PHYS MED REHAB, V81, P1267; Wagner J, 2010, J NEUROTRAUM, V27, P1007, DOI 10.1089/neu.2009.1092; WOOLF PD, 1985, J CLIN ENDOCR METAB, V60, P444, DOI 10.1210/jcem-60-3-444; WOOLF PD, 1992, CRIT CARE MED, V20, P216, DOI 10.1097/00003246-199202000-00011; Wothke W, 2000, MODELING LONGITUDINAL AND MULTILEVEL DATA, P219; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Wright DW, 2005, J CLIN PHARMACOL, V45, P640, DOI 10.1177/0091270005276201; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6; Yang SH, 2005, J NEUROBIOL, V62, P341, DOI 10.1002/neu.20103; Yang SH, 2002, J APPL PHYSIOL, V92, P195, DOI 10.1152/jappl.2002.92.1.195; Yildiz BO, 2007, REV ENDOCR METAB DIS, V8, P331, DOI 10.1007/s11154-007-9054-0	81	104	106	1	25	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2011	28	6					871	888		10.1089/neu.2010.1586			18	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	788PT	WOS:000292457600003	21488721	Green Published			2022-02-06	
J	Dang, J; Mitkari, B; Kipp, M; Beyer, C				Dang, Jon; Mitkari, Bhimashankar; Kipp, Markus; Beyer, Cordian			Gonadal steroids prevent cell damage and stimulate behavioral recovery after transient middle cerebral artery occlusion in male and female rats	BRAIN BEHAVIOR AND IMMUNITY			English	Article						Stroke; MCAO; Estrogen; Progesterone; Microglia; Chemokine	TRAUMATIC BRAIN-INJURY; ESTROGEN-MEDIATED NEUROPROTECTION; EXPERIMENTAL STROKE; FOCAL ISCHEMIA; SEX STEROIDS; INFLAMMATORY RESPONSE; FUNCTIONAL RECOVERY; RECEPTOR-ALPHA; ANIMAL-MODELS; TISSUE-INJURY	17 beta-Estradiol (E) and progesterone (P) are neuroprotective factors in the brain preventing neuronal death under different injury paradigms. Our previous work demonstrates that both steroids compensate neuronal damage and activate distinct neuroprotective strategies such as improving local energy metabolism and abating pro-inflammatory responses. The current study explored steroid hormone-mediated protection from brain damage and restoration of behavioral function after 1 h transient middle cerebral artery occlusion (tMCAO). Male and ovariectomized female rats were studied 24 h after stroke. Both steroid hormones reduced the cortical infarct area in males and females to a similar extent. A maximum effect of similar to 60-70% reduction of the infarct size was evident after Panda combined treatment with both hormones. No infarct protection was seen in the basal ganglia. Testing of motor and sensory behavioral revealed an equal high degree of functional recovery in all three hormone groups. Gene expression studies in the delineated penumbra revealed that estrogen receptor (ER) alpha and beta are locally up-regulated. tMCAO-mediated induction of the pro-inflammatory chemokines CCL2, CCL5 and interleukin 6 was attenuated by E and P. whereas the expression of vascular endothelial growth factor (VEGF) was fortified. Local expression of microglia/macrophage/lymphocyte markers, i.e. Iba1, CD68 and CD3, were significantly reduced in the penumbra after hormone treatment suggesting attenuation of microglia and lymphocyte attraction. These results demonstrate the neuroprotective potency of a combined treatment with E and P under ischemic conditions in both sexes and point at the regulation of chemokine-microglia/lymphocyte interactions as a supposable mechanism implicated in cell protection. (C) 2011 Elsevier Inc. All rights reserved.	[Dang, Jon; Mitkari, Bhimashankar; Kipp, Markus; Beyer, Cordian] Rhein Westfal TH Aachen, Inst Neuroanat, Fac Med, D-52074 Aachen, Germany		Beyer, C (corresponding author), Rhein Westfal TH Aachen, Inst Neuroanat, Fac Med, Wendlingweg 2, D-52074 Aachen, Germany.	cbeyer@ukaachen.de	Kipp, Markus/K-2694-2015; tao, li/G-7956-2011		Faculty of Medicine, RWTH Aachen University; B. Braun Melsungen AG (Germany)	The technical support by H. Helten is acknowledged. The work was supported by IZKF BIOMAT (C.B.) and START (M.K.) of the Faculty of Medicine, RWTH Aachen University as well as B. Braun Melsungen AG (Germany).	Acs P, 2009, GLIA, V57, P807, DOI 10.1002/glia.20806; Alkayed NJ, 1998, STROKE, V29, P159, DOI 10.1161/01.STR.29.1.159; Alkayed NJ, 2000, STROKE, V31, P161, DOI 10.1161/01.STR.31.1.161; Ardelt AA, 2005, STROKE, V36, P337, DOI 10.1161/01.STR.0000153795.38388.72; Arevalo M. A., 2009, BIOCHIM BIOPHYS ACTA, V1800, P1106; Arnold S, 2009, J NEUROCHEM, V110, P1, DOI 10.1111/j.1471-4159.2009.06133.x; Babcock AA, 2003, J NEUROSCI, V23, P7922; Benedek A, 2006, BRAIN RES, V1116, P159, DOI 10.1016/j.brainres.2006.07.123; Bona E, 1999, PEDIATR RES, V45, P500, DOI 10.1203/00006450-199904010-00008; Brown CM, 2010, ENDOCRINOLOGY, V151, P4916, DOI 10.1210/en.2010-0371; Cai WY, 2008, NEUROPHARMACOLOGY, V55, P127, DOI 10.1016/j.neuropharm.2008.04.023; Carswell HVO, 2005, J STEROID BIOCHEM, V96, P89, DOI 10.1016/j.jsbmb.2005.02.016; Carwile E, 2009, J NEUROSCI NURS, V41, P18, DOI 10.1097/JNN.0b013e31819345f8; Chen TY, 2010, STROKE, V41, P160, DOI 10.1161/STROKEAHA.109.562850; Chiappetta O, 2007, INT REV NEUROBIOL, V82, P357, DOI 10.1016/S0074-7742(07)82019-8; Conductier G, 2010, J NEUROIMMUNOL, V224, P93, DOI 10.1016/j.jneuroim.2010.05.010; Cross AK, 1999, J NEUROSCI RES, V55, P17, DOI 10.1002/(SICI)1097-4547(19990101)55:1<17::AID-JNR3>3.0.CO;2-J; Denes A, 2010, BRAIN BEHAV IMMUN, V24, P708, DOI 10.1016/j.bbi.2009.09.010; Denes A, 2010, J NEUROSCI, V30, P10086, DOI 10.1523/JNEUROSCI.1227-10.2010; Dhandapani KM, 2007, EXP GERONTOL, V42, P70, DOI 10.1016/j.exger.2006.06.032; Draca S, 2009, MED HYPOTHESES, V73, P1051, DOI 10.1016/j.mehy.2009.04.049; Dubal DB, 2006, ENDOCRINOLOGY, V147, P3076, DOI 10.1210/en.2005-1177; Elzer JG, 2010, J CEREBR BLOOD F MET, V30, P935, DOI 10.1038/jcbfm.2009.258; Gao YJ, 2010, PHARMACOL THERAPEUT, V126, P56, DOI 10.1016/j.pharmthera.2010.01.002; GARCIA JH, 1995, STROKE, V26, P627, DOI 10.1161/01.STR.26.4.627; Gibson CL, 2005, EXP NEUROL, V193, P522, DOI 10.1016/j.expneurol.2005.01.009; Gibson CL, 2004, J CEREBR BLOOD F MET, V24, P805, DOI 10.1097/01.WCB.0000125365.83980.00; Gibson CL, 2009, NEUROSCIENTIST, V15, P324, DOI 10.1177/1073858409333069; Guillemin GJ, 2004, J LEUKOCYTE BIOL, V75, P388, DOI 10.1189/jlb.0303114; Guo JB, 2010, J CEREBR BLOOD F MET, V30, P545, DOI 10.1038/jcbfm.2009.226; Herrmann O, 2005, NAT MED, V11, P1322, DOI 10.1038/nm1323; Herson PS, 2009, SEMIN REPROD MED, V27, P229, DOI 10.1055/s-0029-1216276; Ivanova T, 2003, J NEUROBIOL, V54, P638, DOI 10.1002/neu.10193; Johann S, 2008, J MOL NEUROSCI, V34, P177, DOI 10.1007/s12031-007-9028-4; Kajta M, 2003, ENDOCRINE, V21, P3, DOI 10.1385/ENDO:21:1:3; Kipp M, 2006, FRONT NEUROENDOCRIN, V27, P376, DOI 10.1016/j.yfrne.2006.07.001; Kipp M, 2009, FRONT NEUROENDOCRIN, V30, P188, DOI 10.1016/j.yfrne.2009.04.004; Kramer M, 2010, J NEUROSCI METH, V187, P84, DOI 10.1016/j.jneumeth.2009.12.020; Kriz Jasna, 2006, Critical Reviews in Neurobiology, V18, P145; Lebesgue D, 2009, STEROIDS, V74, P555, DOI 10.1016/j.steroids.2009.01.003; Li XL, 2004, EXP NEUROL, V187, P94, DOI 10.1016/j.expneurol.2004.01.004; LIN TN, 1993, STROKE, V24, P117, DOI 10.1161/01.STR.24.1.117; Liu M, 2010, MINERVA ENDOCRINOL, V35, P127; Liu MY, 2009, RESTOR NEUROL NEUROS, V27, P163, DOI 10.3233/RNN-2009-0467; Liu R, 2010, J PHARMACOL EXP THER, V332, P1006, DOI 10.1124/jpet.109.160937; Lorenz L, 2009, J NEUROENDOCRINOL, V21, P841, DOI 10.1111/j.1365-2826.2009.01903.x; Merchenthaler I, 2003, ANN NY ACAD SCI, V1007, P89, DOI 10.1196/annals.1286.009; Misiak M, 2010, BBA-BIOENERGETICS, V1797, P1178, DOI 10.1016/j.bbabio.2010.04.009; Paxinos G., 2004, RAT NERVOUS SYSTEM; PERTERFALVI A, 2009, CEREBROVASC DIS, V28, P490; Rau SW, 2003, J NEUROSCI, V23, P11420; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Rusa R, 1999, STROKE, V30, P1665, DOI 10.1161/01.STR.30.8.1665; Schilling M, 2009, NEUROSCIENCE, V161, P806, DOI 10.1016/j.neuroscience.2009.04.025; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Sims NR, 2010, BBA-MOL BASIS DIS, V1802, P80, DOI 10.1016/j.bbadis.2009.09.003; Singh M, 2008, FRONT BIOSCI-LANDMRK, V13, P1083, DOI 10.2741/2746; Soderstrom I, 2009, EUR J NEUROSCI, V29, P1215, DOI 10.1111/j.1460-9568.2009.06662.x; Stefini R, 2008, J NEUROSURG, V108, P958, DOI 10.3171/JNS/2008/108/5/0958; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; Strom JO, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-39; Suzuki S, 2009, FRONT NEUROENDOCRIN, V30, P201, DOI 10.1016/j.yfrne.2009.04.007; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Tambuyzer BR, 2009, J LEUKOCYTE BIOL, V85, P352, DOI 10.1189/jlb.0608385; Terao S, 2008, STROKE, V39, P2560, DOI 10.1161/STROKEAHA.107.513150; Toung TJ, 2004, J CEREBR BLOOD F MET, V24, P1160, DOI 10.1097/01.WCB.0000135594.13576.D2; Toung TJK, 1998, STROKE, V29, P1666, DOI 10.1161/01.STR.29.8.1666; Toung TK, 2000, STROKE, V31, P2701, DOI 10.1161/01.STR.31.11.2701; Trotter A, 2006, PEDIATR RES, V60, P60, DOI 10.1203/01.pdr.0000220360.77567.d8; Trotter A, 1999, J CLIN ENDOCR METAB, V84, P4531, DOI 10.1210/jc.84.12.4531; Trotter A, 2009, EARLY HUM DEV, V85, P353, DOI 10.1016/j.earlhumdev.2008.12.013; Vikman P, 2007, EXP BRAIN RES, V183, P499, DOI 10.1007/s00221-007-1062-5; Wang Q, 2007, J NEUROIMMUNOL, V184, P53, DOI 10.1016/j.jneuroim.2006.11.014; WENGER NK, 1993, NEW ENGL J MED, V329, P247, DOI 10.1056/NEJM199307223290406; Yamada Y, 2008, CURR PHARM DESIGN, V14, P3590, DOI 10.2174/138161208786848793; Yao XL, 2005, J NEUROTRAUM, V22, P656, DOI 10.1089/neu.2005.22.656; Zhang B, 2010, J IMMUNOL, V184, P4087, DOI 10.4049/jimmunol.0902339; Zhang QG, 2009, J NEUROSCI, V29, P13823, DOI 10.1523/JNEUROSCI.3574-09.2009; Zhang Z, 2010, NEUROPHARMACOLOGY, V58, P930, DOI 10.1016/j.neuropharm.2010.01.002; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	81	104	105	0	13	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591	1090-2139		BRAIN BEHAV IMMUN	Brain Behav. Immun.	MAY	2011	25	4					715	726		10.1016/j.bbi.2011.01.013			12	Immunology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology; Psychiatry	762GN	WOS:000290463100015	21277368				2022-02-06	
J	Maas, AIR; Harrison-Felix, CL; Menon, D; Adelson, PD; Balkin, T; Bullock, R; Engel, DC; Gordon, W; Langlois-Orman, J; Lew, HL; Robertson, C; Temkin, N; Valadka, A; Verfaellie, M; Wainwright, M; Wright, DW; Schwab, K				Maas, Andrew I. R.; Harrison-Felix, Cynthia L.; Menon, David; Adelson, P. David; Balkin, Tom; Bullock, Ross; Engel, Doortje C.; Gordon, Wayne; Langlois-Orman, Jean; Lew, Henry L.; Robertson, Claudia; Temkin, Nancy; Valadka, Alex; Verfaellie, Mieke; Wainwright, Mark; Wright, David W.; Schwab, Karen			Standardizing Data Collection in Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						clinical studies; common data elements; data coding; data collection; standardization; traumatic brain injury	COMMON DATA ELEMENTS; RECOMMENDATIONS; MODERATE; CLASSIFICATION; RELIABILITY; VALIDITY	Collaboration among investigators, centers, countries, and disciplines is essential to advancing the care for traumatic brain injury (TBI). It is thus important that we "speak the same language.'' Great variability, however, exists in data collection and coding of variables in TBI studies, confounding comparisons between and analysis across different studies. Randomized controlled trials can never address the many uncertainties concerning treatment approaches in TBI. Pooling data from different clinical studies and high-quality observational studies combined with comparative effectiveness research may provide excellent alternatives in a cost-efficient way. Standardization of data collection and coding is essential to this end. Common data elements (CDEs) are presented for demographics and clinical variables applicable across the broad spectrum of TBI. Most recommendations represent a consensus derived from clinical practice. Some recommendations concern novel approaches, for example assessment of the intensity of therapy in severely injured patients. Up to three levels of detail for coding data elements were developed: basic, intermediate, and advanced, with the greatest level of detail attained in the advanced version. More detailed codings can be collapsed into the basic version. Templates were produced to summarize coding formats, explanation of choices, and recommendations for procedures. Endorsement of the recommendations has been obtained from many authoritative organizations. The development of CDEs for TBI should be viewed as a continuing process; as more experience is gained, refinement and amendments will be required. This proposed process of standardization will facilitate comparative effectiveness research and encourage high-quality meta-analysis of individual patient data.	[Maas, Andrew I. R.] Univ Antwerp Hosp, Antwerp, Belgium; [Harrison-Felix, Cynthia L.] Craig Hosp, Englewood, CO USA; [Menon, David] Univ Cambridge, Cambridge, England; [Adelson, P. David] Phoenix Childrens Neurosci Inst, Phoenix, AZ USA; [Balkin, Tom] Walter Reed Army Med Ctr, Walter Reed Army Inst Res, Washington, DC 20307 USA; [Bullock, Ross] Univ Miami, Miller Sch Med, Miami, FL 33136 USA; [Engel, Doortje C.] Univ Heidelberg Hosp, Heidelberg, Germany; [Gordon, Wayne] Mt Sinai Sch Med, New York, NY USA; [Langlois-Orman, Jean] USA, Inst Surg Res, San Antonio, TX USA; [Lew, Henry L.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA USA; [Lew, Henry L.] Virginia Commonwealth Univ, Def & Vet Brain Injury Ctr, Richmond, VA USA; [Robertson, Claudia] Baylor Coll Med, Houston, TX 77030 USA; [Temkin, Nancy] Univ Washington, Seattle, WA 98195 USA; [Valadka, Alex] Seton Brain & Spine Inst, Austin, TX USA; [Verfaellie, Mieke] Boston VA Hlth Care Syst, Boston, MA USA; [Verfaellie, Mieke] Boston Univ, Sch Med, Boston, MA 02118 USA; [Wainwright, Mark] Northwestern Univ, Chicago, IL 60611 USA; [Wright, David W.] Emory Univ, Sch Med, Atlanta, GA USA; [Schwab, Karen] Def & Vet Brain Injury Ctr, Washington, DC USA		Maas, AIR (corresponding author), Univ Antwerp Hosp, Dept Neurosurg, Wilrijkstr 10, B-2650 Edegem, Belgium.	andrew.maas@uza.be	Adelson, David/W-2083-2019; Maas, Andrew IR/C-5584-2013; Wright, David/F-1209-2013	Maas, Andrew IR/0000-0003-1612-1264; Wright, David/0000-0002-7145-9105; Verfaellie, Mieke/0000-0001-5535-4584	National Institutes of Health (NIH)-NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 042691]; National Institute on Disability and Rehabilitation Research; Department of Veterans AffairsUS Department of Veterans Affairs; Defense and Veterans Brain Injury CenterUS Department of Veterans Affairs; Defense Centers of Excellence; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042691] Funding Source: NIH RePORTER	The meetings and activities of the working group "Demographics and Clinical Assessment'' were supported by funding in the context of the interagency initiative towards "an integrated approach to Research in Psychological Health and Traumatic Brain Injury'' (National Institutes of Health (NIH)-NINDS; the National Institute on Disability and Rehabilitation Research; the Department of Veterans Affairs; the Defense and Veterans Brain Injury Center; and the Defense Centers of Excellence). The development of CDEs was further supported by a supplemental grant from NIH-NINDS (NS 042691). The authors greatly acknowledge the input and advice obtained from these international experts: Giuseppe Citerio (Italy), Peter Hutchinson (U.K.), Bertil Romner (Denmark), Juan Sahuquillo (Spain), Franco Servadei (Italy), and Nino Stocchetti (Italy). We are grateful to Nele Kleisz and Anne-Claire van Harderwijk for administrative support in developing the common data elements and templates, and in preparing this manuscript.	*ASS ADV AUT MED, 1990, ABBR INJ SCAL 1990 R, P15; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; FOULKES MA, 1991, J NEUROSURG, V75, pS8, DOI 10.3171/sup.1991.75.1s.00s8; Jorde LB, 2004, NAT GENET, V36, pS28, DOI 10.1038/ng1435; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Kompanje EJO, 2005, ACTA NEUROCHIR, V147, P633, DOI 10.1007/s00701-005-0525-3; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Maas AI, 2010, ARCH PHYS MED REHAB, V91, P1641, DOI 10.1016/j.apmr.2010.07.232; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Manley GT, 2010, ARCH PHYS MED REHAB, V91, P1667, DOI 10.1016/j.apmr.2010.05.018; McMahon CG, 1999, J TRAUMA, V47, P891, DOI 10.1097/00005373-199911000-00013; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; SALAZAR AM, 1995, NEUROSURG CLIN N AM, V6, P715; Schulz KF, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c332; Shore PM, 2006, CRIT CARE MED, V34, P1981, DOI 10.1097/01.CCM.0000220765.22184.ED; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stocchetti N, 2004, INTENS CARE MED, V30, P517, DOI 10.1007/s00134-003-2142-z; Thurmond VA, 2010, ARCH PHYS MED REHAB, V91, P1633, DOI 10.1016/j.apmr.2010.06.034; VANLEEUWEN N, PROGNOSTIC VAL UNPUB; *WHO OMS, 2009, GLOB STAT REP ROAD S; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Wolf SJ, 2009, LANCET, V374, P405, DOI 10.1016/S0140-6736(09)60257-9	32	104	107	1	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2011	28	2					177	187		10.1089/neu.2010.1617			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	719UE	WOS:000287234700002	21162610	Green Published			2022-02-06	
J	Nyein, MK; Jason, AM; Yu, L; Pita, CM; Joannopoulos, JD; Moore, DF; Radovitzky, RA				Nyein, Michelle K.; Jason, Amanda M.; Yu, Li; Pita, Claudio M.; Joannopoulos, John D.; Moore, David F.; Radovitzky, Raul A.			In silico investigation of intracranial blast mitigation with relevance to military traumatic brain injury	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						computational models; personal protection equipment	VIRTUAL TEST FACILITY; SIMULATION; IRAQ; CARE; TBI; WAR	Blast-induced traumatic brain injury is the most prevalent military injury in Iraq and Afghanistan, yet little is known about the mechanical effects of blasts on the human head, and still less is known about how personal protective equipment affects the brain's response to blasts. In this study we investigated the effect of the Advanced Combat Helmet (ACH) and a conceptual face shield on the propagation of stress waves within the brain tissue following blast events. We used a sophisticated computational framework for simulating coupled fluid-solid dynamic interactions and a three-dimensional biofidelic finite element model of the human head and intracranial contents combined with a detailed model of the ACH and a conceptual face shield. Simulations were conducted in which the unhelmeted head, head with helmet, and head with helmet and face shield were exposed to a frontal blast wave with incident overpressure of 10 atm. Direct transmission of stress waves into the intracranial cavity was observed in the unprotected head and head with helmet simulations. Compared to the unhelmeted head, the head with helmet experienced slight mitigation of intracranial stresses. This suggests that the existing ACH does not significantly contribute to mitigating blast effects, but does not worsen them either. By contrast, the helmet and face shield combination impeded direct transmission of stress waves to the face, resulting in a delay in the transmission of stresses to the intracranial cavity and lower intracranial stresses. This suggests a possible strategy for mitigating blast waves often associated with military concussion.	[Joannopoulos, John D.] MIT, Dept Phys, Inst Soldier Nanotechnol, Cambridge, MA 02139 USA; [Nyein, Michelle K.; Jason, Amanda M.; Yu, Li; Pita, Claudio M.; Radovitzky, Raul A.] MIT, Dept Aeronaut & Astronaut, Inst Soldier Nanotechnol, Cambridge, MA 02139 USA; [Moore, David F.] Walter Reed Army Med Ctr, Def & Vet Brain Injury Ctr, Washington, DC 20307 USA		Joannopoulos, JD (corresponding author), MIT, Dept Phys, Inst Soldier Nanotechnol, Cambridge, MA 02139 USA.	joannop@mit.edu; rapa@mit.edu	Radovitzky, Raul A/A-5353-2009; Joannopoulos, John D/E-6401-2013	Radovitzky, Raul A/0000-0001-6339-2708; 	Joint Improvised Explosive Device Defeat Organization through the Army Research Office; MIT Institute for Soldier Nanotechnologies	This work was supported by financial aid from the Joint Improvised Explosive Device Defeat Organization through the Army Research Office. Partial support from the MIT Institute for Soldier Nanotechnologies is also gratefully acknowledged.	ALLEY MD, 2009, BLAST LOADING EXPT D; Bass CR, 2008, J TRAUMA, V65, P604, DOI 10.1097/TA.0b013e3181454ab4; BOWEN IG, 1968, ANN NY ACAD SCI, V152, P122, DOI 10.1111/j.1749-6632.1968.tb11971.x; CERNAK I, 2009, J CEREBR BLOOD F MET, P1; Cummings J, 2002, J SUPERCOMPUT, V23, P39, DOI 10.1023/A:1015733102520; Deiterding R, 2006, ENG COMPUT-GERMANY, V22, P325, DOI 10.1007/s00366-006-0043-9; Dogan A, 1999, J NEUROSURG, V90, P1078, DOI 10.3171/jns.1999.90.6.1078; *DVBIC, 2010, TBI NUMB DEP DEF NUM; Gawande A, 2004, NEW ENGL J MED, V351, P2471, DOI 10.1056/NEJMp048317; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Horgan TJ, 2004, INT J CRASHWORTHINES, V9, P401, DOI 10.1533/ijcr.2004.0299; Jordan P, 2008, LECT NOTES COMPUT SC, V5242, P930, DOI 10.1007/978-3-540-85990-1_112; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Malvern LE, 1969, INTRO MECH CONTINUOU; Marklund N, 2001, ACTA NEUROCHIR, V143, P73, DOI 10.1007/s007010170141; Meyers MA., 1994, DYNAMIC BEHAV MAT, V2nd ed.; Moore DF, 2008, ANN NEUROL, V64, pS30; Moore DF, 2009, NEUROIMAGE, V47, pT10, DOI 10.1016/j.neuroimage.2009.02.019; Moore DF, 2008, FUTUR NEUROL, V3, P243, DOI 10.2217/14796708.3.3.243; Moss W.C., 2009, J ACOUST SOC AM, V125, P2650; Murray CK, 2005, MIL MED, V170, P516, DOI 10.7205/MILMED.170.6.516; NAKAGAWA A, 2009, ACTA NEUROCHIR SUPP, P421; Pervin F, 2009, J BIOMECH, V42, P731, DOI 10.1016/j.jbiomech.2009.01.023; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thompson P.A., 1972, COMPRESSIBLE FLUID D; Wadley HNG, 2010, INT J IMPACT ENG, V37, P317, DOI 10.1016/j.ijimpeng.2009.06.006; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Warden DL, 2005, J NEUROTRAUM, V22, P1178; Willinger R, 2003, INT J CRASHWORTHINES, V8, P605, DOI 10.1533/ijcr.2003.0264; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	33	104	104	0	26	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	NOV 30	2010	107	48					20703	20708		10.1073/pnas.1014786107			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	687ET	WOS:000284762400025	21098257	Bronze, Green Published, Green Submitted			2022-02-06	
J	Kozai, TDY; Marzullo, TC; Hooi, F; Langhals, NB; Majewska, AK; Brown, EB; Kipke, DR				Kozai, T. D. Y.; Marzullo, T. C.; Hooi, F.; Langhals, N. B.; Majewska, A. K.; Brown, E. B.; Kipke, D. R.			Reduction of neurovascular damage resulting from microelectrode insertion into the cerebral cortex using in vivo two-photon mapping	JOURNAL OF NEURAL ENGINEERING			English	Article							TRAUMATIC BRAIN INJURY; MULTIPHOTON MICROSCOPY; BLOOD-FLOW; NEURAL INTERFACES; CALCIUM SIGNALS; TISSUE; MICRODIALYSIS; EDEMA; PROBE; RAT	Penetrating neural probe technologies allow investigators to record electrical signals in the brain. The implantation of probes causes acute tissue damage, partially due to vasculature disruption during probe implantation. This trauma can cause abnormal electrophysiological responses and temporary increases in neurotransmitter levels, and perpetuate chronic immune responses. A significant challenge for investigators is to examine neurovascular features below the surface of the brain in vivo. The objective of this study was to investigate localized bleeding resulting from inserting microscale neural probes into the cortex using two-photon microscopy (TPM) and to explore an approach to minimize blood vessel disruption through insertion methods and probe design. 3D TPM images of cortical neurovasculature were obtained from mice and used to select preferred insertion positions for probe insertion to reduce neurovasculature damage. There was an 82.8 +/- 14.3% reduction in neurovascular damage for probes inserted in regions devoid of major (> 5 mu m) sub-surface vessels. Also, the deviation of surface vessels from the vector normal to the surface as a function of depth and vessel diameter was measured and characterized. 68% of the major vessels were found to deviate less than 49 mu m from their surface origin up to a depth of 500 mu m. Inserting probes more than 49 mu m from major surface vessels can reduce the chances of severing major sub-surface neurovasculature without using TPM.	[Kozai, T. D. Y.; Marzullo, T. C.; Langhals, N. B.; Kipke, D. R.] Univ Michigan, Coll Engn, Dept Biomed Engn, Neural Engn Lab, Ann Arbor, MI 48109 USA; [Hooi, F.] Univ Michigan, Coll Engn, Dept Biomed Engn, Basic Radiol Sci Div, Ann Arbor, MI 48109 USA; [Majewska, A. K.] Univ Rochester, Sch Med & Dent, Dept Neurobiol & Anat, Rochester, NY 14642 USA		Kozai, TDY (corresponding author), Univ Michigan, Coll Engn, Dept Biomed Engn, Neural Engn Lab, Ann Arbor, MI 48109 USA.	tkozai@umich.edu; dkipke@umich.edu	Langhals, Nicholas/C-2123-2008; Kozai, Takashi/I-2214-2012	Langhals, Nicholas/0000-0003-0644-9020; Kozai, Takashi/0000-0002-2507-3295; Majewska, Ania/0000-0002-2167-6849	Center for Neural Communication Technology, National Institute of Biomedical Imaging and Bioengineering (NIBIB)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41 EB002030]; National Institutes of Health (NEI)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [EY019277]; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY019277] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB002030] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS076401] Funding Source: NIH RePORTER	The authors would like to thank Badri Roysam for helpful project discussions, Anna Devor for helpful two-photon vascular imaging discussions and Paras Patel for assistance characterizing neurovasculature. This research is supported by Center for Neural Communication Technology, a P41 Resource Center funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB, P41 EB002030) and supported by the National Institutes of Health (NEI; EY019277), Burroughs Wellcome Fund Career Award in the Biomedical sciences, Fellowship from the Alfred P Sloan Foundation, the Whitehall Foundation, Department of Defense Era of Hope Scholar Award and Pew Scholar in the Biomedical Sciences Award.	Abdul-Karim MA, 2003, MICROVASC RES, V66, P113, DOI 10.1016/S0026-2862(03)00039-6; Azemi E, 2008, ACTA BIOMATER, V4, P1208, DOI 10.1016/j.actbio.2008.02.028; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; BETZ A L, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P133; Biran R, 2005, EXP NEUROL, V195, P115, DOI 10.1016/j.expneurol.2005.04.020; Bjornsson CS, 2006, J NEURAL ENG, V3, P196, DOI 10.1088/1741-2560/3/3/002; Bolan PJ, 2006, NEUROIMAGE, V32, P62, DOI 10.1016/j.neuroimage.2006.03.027; CAMP DM, 1992, J NEUROCHEM, V58, P1706, DOI 10.1111/j.1471-4159.1992.tb10044.x; Chaigneau E, 2003, P NATL ACAD SCI USA, V100, P13081, DOI 10.1073/pnas.2133652100; Chauhan VP, 2009, BIOPHYS J, V97, P330, DOI 10.1016/j.bpj.2009.03.064; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dorr A, 2007, NEUROIMAGE, V35, P1409, DOI 10.1016/j.neuroimage.2006.12.040; Dunn KW, 2008, ILAR J, V49, P66, DOI 10.1093/ilar.49.1.66; DUVERNOY HM, 1981, BRAIN RES BULL, V7, P519, DOI 10.1016/0361-9230(81)90007-1; EDELL DJ, 1992, IEEE T BIO-MED ENG, V39, P635, DOI 10.1109/10.141202; GOLDSMITH JD, 1995, HEARING RES, V83, P80, DOI 10.1016/0378-5955(94)00193-T; Grill WM, 2009, ANNU REV BIOMED ENG, V11, P1, DOI 10.1146/annurev-bioeng-061008-124927; Groothuis DR, 1998, BRAIN RES, V803, P218, DOI 10.1016/S0006-8993(98)00572-1; Helmchen F, 2005, NAT METHODS, V2, P932, DOI 10.1038/NMETH818; Helmchen F, 2008, METHOD ENZYMOL, V444, P231, DOI 10.1016/S0076-6879(08)02810-3; Holson RR, 1998, BRAIN RES, V808, P182, DOI 10.1016/S0006-8993(98)00816-6; House Paul A, 2006, Neurosurg Focus, V20, pE4; Johnson M. D., 2006, C P IEEE ENG MED BIO, V1, P3178; Johnson MD, 2007, J NEUROSCI METH, V160, P276, DOI 10.1016/j.jneumeth.2006.09.023; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; Kipke DR, 2008, J NEUROSCI, V28, P11830, DOI 10.1523/JNEUROSCI.3879-08.2008; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; Kleinfeld D, 1998, P NATL ACAD SCI USA, V95, P15741, DOI 10.1073/pnas.95.26.15741; Kozai TDY, 2009, J NEUROSCI METH, V184, P199, DOI 10.1016/j.jneumeth.2009.08.002; Lauwers F, 2008, NEUROIMAGE, V39, P936, DOI 10.1016/j.neuroimage.2007.09.024; Lee H, 2005, J NEURAL ENG, V2, P81, DOI 10.1088/1741-2560/2/4/003; Levene MJ, 2004, J NEUROPHYSIOL, V91, P1908, DOI 10.1152/jn.01007.2003; Lowery RL, 2009, DEV NEUROBIOL, V69, P674, DOI 10.1002/dneu.20735; Maikos JT, 2008, J NEUROTRAUM, V25, P38, DOI 10.1089/neu.2007.0348; Majewska A, 2000, PFLUG ARCH EUR J PHY, V441, P398, DOI 10.1007/s004240000435; Majewska A, 2000, J NEUROSCI, V20, P1722; McConnell GC, 2009, J NEURAL ENG, V6, DOI 10.1088/1741-2560/6/5/056003; McIntosh TK, 1996, LAB INVEST, V74, P315; NADAL A, 1995, P NATL ACAD SCI USA, V92, P1426, DOI 10.1073/pnas.92.5.1426; Nadal A, 1998, J PHYSIOL-LONDON, V509, P711, DOI 10.1111/j.1469-7793.1998.711bm.x; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Nishimura N, 2007, P NATL ACAD SCI USA, V104, P365, DOI 10.1073/pnas.0609551104; Purcell EK, 2009, J NEURAL ENG, V6, DOI 10.1088/1741-2560/6/2/026005; Rohatgi P, 2009, NEUROSURG FOCUS, V27, DOI 10.3171/2009.4.FOCUS0983; SCHMIDT EM, 1976, EXP NEUROL, V52, P496, DOI 10.1016/0014-4886(76)90220-X; Schwartz AB, 2006, NEURON, V52, P205, DOI 10.1016/j.neuron.2006.09.019; Seymour JP, 2007, BIOMATERIALS, V28, P3594, DOI 10.1016/j.biomaterials.2007.03.024; Shen YF, 2004, ANAL CHEM, V76, P1134, DOI 10.1021/ac034869m; Subbaroyan J, 2005, J NEURAL ENG, V2, P103, DOI 10.1088/1741-2560/2/4/006; Svoboda K, 2006, NEURON, V50, P823, DOI 10.1016/j.neuron.2006.05.019; Szarowski DH, 2003, BRAIN RES, V983, P23, DOI 10.1016/S0006-8993(03)03023-3; Tsai PS, 2009, J NEUROSCI, V29, P14553, DOI 10.1523/JNEUROSCI.3287-09.2009; Turner JN, 1999, EXP NEUROL, V156, P33, DOI 10.1006/exnr.1998.6983; Tyrrell JA, 2005, MICROVASC RES, V70, P165, DOI 10.1016/j.mvr.2005.08.005; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Zhang K, 2000, P NATL ACAD SCI USA, V97, P5621, DOI 10.1073/pnas.090504197; Zhang SX, 2005, J NEUROSCI, V25, P5333, DOI 10.1523/JNEUROSCI.1085-05.2005; Zipfel WR, 2003, NAT BIOTECHNOL, V21, P1368, DOI 10.1038/nbt899	58	104	105	0	15	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	1741-2560	1741-2552		J NEURAL ENG	J. Neural Eng.	AUG	2010	7	4			SI				046011	10.1088/1741-2560/7/4/046011			12	Engineering, Biomedical; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Neurosciences & Neurology	627KP	WOS:000280038600015	20644246	Green Accepted			2022-02-06	
J	Wojcik, BE; Stein, CR; Bagg, K; Humphrey, RJ; Orosco, J				Wojcik, Barbara E.; Stein, Catherine R.; Bagg, Karen; Humphrey, Rebecca J.; Orosco, Jason			Traumatic Brain Injury Hospitalizations of US Army Soldiers Deployed to Afghanistan and Iraq	AMERICAN JOURNAL OF PREVENTIVE MEDICINE			English	Article								Background: Traumatic brain injury (TBI) is a life-altering condition that has affected many of our soldiers returning from war. In the current conflicts, the improvised explosive device (IED) has greatly increased the potential for soldiers to sustain a TBI. This study's objective was to establish benchmark admission rates for U.S. Army soldiers with TBIs identified during deployment to Iraq and Afghanistan. Methods: The study population consisted of U.S. Army soldiers deployed to Iraq and Afghanistan from September 11, 2001, through September 30,2007. Population data were merged with admission data to identify hospitalizations during deployment. Using the international Barell Injury Diagnosis Matrix, TBI-related admissions were categorized into Type 1 (the most severe), Type 2, and Type 3 (the least severe). All analyses were performed in 2008. Results: Of the 2898 identified TBI inpatient episodes of care, 46% were Type 1, 54% were Type 2, and less than 1% were Type 3. Over-65% of Type 1 injuries resulted from explosions, while almost half of all TBIs were non-battle-related. Overall TBI admission rates were 24.6 for Afghanistan and 41.8 for Iraq per 10,000 soldier-years. TBI hospitalization rates rose over time for both campaigns, although U.S. Army soldiers in Iraq experienced 1.7 times higher rates overall and 2.2 times higher Type 1 admission rates than soldiers in Afghanistan. The TBI-related proportion of all injury hospitalizations showed an ascending trend. Conclusions: Future surveillance of TBI hospitalization rates is needed to evaluate the effectiveness of implementation of preventive measures. (Am J Prev Med 2010;38(1S):S108 -S116) Published by Elsevier Inc. on behalf of American journal of Preventive Medicine	[Wojcik, Barbara E.; Stein, Catherine R.; Bagg, Karen; Humphrey, Rebecca J.] USA, Med Dept Ctr & Sch, Ctr Army, Med Dept Strateg Studies, Ft Sam Houston, TX USA; [Orosco, Jason] Lockheed Martin Corp, Bethesda, MD USA		Wojcik, BE (corresponding author), CASS, 1608 Stanley Rd,Suite 47, Ft Sam Houston, TX 78234 USA.	barbara.wojcik@amedd.army.mil					ABBOTT CA, 2009, 09002 RP CTR ARM MED; [Anonymous], 2008, MILD TRAUM BRAIN INJ; Barell V, 2002, INJ PREV, V8, P91, DOI 10.1136/ip.8.2.91; CAJIGAL S, 2007, NEUROLOGY, V7, P21; *CDC, INT COLL EFF ICE INJ; CDC. National Center for Health Statistics, BAR INJ DIAGN MATR C; *CDCP, 2006, FACTS TRAUM BRAIN IN; Galarneau MR, 2008, J NEUROSURG, V108, P950, DOI 10.3171/JNS/2008/108/5/0950; Gaylord KM, 2008, J TRAUMA, V64, pS200, DOI 10.1097/TA.0b013e318160ba42; HARBEN J, 2008, TRAUMATIC BRAIN INJU; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; JAFFEE MS, 2009, COMMUNICATION    WIN, P1; JONES BH, 1999, MIL MED, V164, pS633; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Martin EM, 2008, AM J NURS, V108, P40, DOI 10.1097/01.NAJ.0000315260.92070.3f; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; SUTTON LK, 2009, DCOE ACTION, V2, P2; Tanielian T., 2008, INVISIBLE WOUNDS WAR; *TRAUM BRAIN INJ T, 2007, REP SURG GEN; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; WARDEN DL, 1996, J NEUROTRAUM, V40, P211; 2008, MED SURVEILL MON REP, V15, P2; 2007, MED SURVEILL MON REP, V14, P2	24	104	107	1	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0749-3797	1873-2607		AM J PREV MED	Am. J. Prev. Med.	JAN	2010	38	1		1			S108	S116		10.1016/j.amepre.2009.10.006			9	Public, Environmental & Occupational Health; Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health; General & Internal Medicine	541KM	WOS:000273413900011	20117583				2022-02-06	
J	Allard, CB; Scarpelini, S; Rhind, SG; Baker, AJ; Shek, PN; Tien, H; Fernando, M; Tremblay, L; Morrison, LJ; Pinto, R; Rizoli, SB				Allard, Christopher B.; Scarpelini, Sandro; Rhind, Shawn G.; Baker, Andrew J.; Shek, Pang N.; Tien, Homer; Fernando, Michael; Tremblay, Lorraine; Morrison, Laurie J.; Pinto, Ruxandra; Rizoli, Sandro B.			Abnormal Coagulation Tests Are Associated With Progression of Traumatic Intracranial Hemorrhage	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	67th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma/Meeting of the Association-for-Acute-Medicine	SEP 24-27, 2008	Maui, HI	Amer Assoc Surg Trauma, Assoc Acute Med		Intracerebral hemorrhage; Traumatic brain injury; INR; PTT; Platelet count	PROTHROMBIN COMPLEX CONCENTRATE; ACUTE INTRACEREBRAL HEMORRHAGE; ACTIVATED FACTOR-VII; BRAIN-INJURY; HEAD TRAUMA; ANTICOAGULATION; REVERSAL; COAGULOPATHY; HEMATOMA; THROMBOCYTOPENIA	Background: Intracranial hemorrhage (ICH) is common in traumatic brain injury (TBI) and a major determinant of death and disability. ICH commonly increases in size and coagulopathy has been implicated in such progression. We investigated the association between coagulopathy diagnosed by routine laboratory tests and ICH progression. Methods: Subgroup post hoc analysis from a randomized controlled trial including adult patients with blunt severe TBI (Glasgow Coma Scale score <= 8) and repeat computerized tomography scans in 48 hours. Coagulopathy was defined as international normalized ratio >= 1.3, activated partial thromboplastin time >= 35, or platelet count (PLT) <= 100 x 10(9)/L any time in the first 24 hours. Progression was any size increase or new ICH. TBI-associated coagulopathy was investigated measuring soluble tissue factor (TF) and D-dimer. Results: The ICH progressed in 37 of 72 patients (51%), in 80% if any abnormal laboratory test (coagulopathic patients) versus 36% in noncoagulopathic (p = 0.0004). Abnormal international normalized ratio (odds ratio [OR] 4.09; 95% confidence interval [CI] = 1.29-12.95; p = 0.017), PLT (OR 12.59; 95% CI = 1.52-108.57; p = 0.019), head Abbreviated Injury Scale(AIS)(OR = 1.82; 95% CI = 1.15-2.88; p = 0.011) were significantly associated with progression (univariate analysis). In a multiple logistic regression, only head AIS (OR = 1.81; 95% CI 1.10-2.98; p = 0.0198)and PLT (OR = 11.8; 95% CI = 1.38-101.23; p = 0.024) correlated with progression. All patients with abnormal partial thromboplastin time experienced progression. ICH progression carried a 5-fold higher odds of death; 32% with progression died versus 8.6% without. Age, head AIS, Injury Severity Score, and D-dimer were also associated with mortality. Tissue factor was not associated with progression or mortality. Conclusion: This study demonstrates an association between coagulopathy, diagnosed by routine laboratorial tests in the first 24 hours, with ICH progression; and ICH progression with mortality in patients with severe TBI. The causal relationship between coagulopathy and ICH progression will require further studies.	[Allard, Christopher B.; Scarpelini, Sandro; Tien, Homer; Fernando, Michael; Tremblay, Lorraine; Pinto, Ruxandra; Rizoli, Sandro B.] Sunnybrook Hlth Sci Ctr, Dept Surg, Toronto, ON M4N 3M5, Canada; [Allard, Christopher B.; Scarpelini, Sandro; Tien, Homer; Fernando, Michael; Tremblay, Lorraine; Pinto, Ruxandra; Rizoli, Sandro B.] Sunnybrook Hlth Sci Ctr, Dept Crit Care Med, Toronto, ON M4N 3M5, Canada; [Rhind, Shawn G.; Shek, Pang N.] Def Res & Dev Canada, Toronto, ON, Canada; [Morrison, Laurie J.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Keenan Res Ctr, Prehosp & Transport Med Res Program, Toronto, ON M5B 1W8, Canada		Rizoli, SB (corresponding author), 2075 Bayview Ave,Suite H1-71, Toronto, ON M4N 3M5, Canada.	sandro.rizoli@sunnybrook.ca	morrison, laurie J/A-6325-2012; Scarpelini, Sandro/H-7063-2012	morrison, laurie J/0000-0001-8369-9774; Scarpelini, Sandro/0000-0001-5727-3913; Rhind, Shawn/0000-0003-2300-0620			Boto GR, 2006, J NEUROL NEUROSUR PS, V77, P1054, DOI 10.1136/jnnp.2005.087056; BRODERICK JP, 1993, STROKE, V24, P987, DOI 10.1161/01.STR.24.7.987; Deveras RAE, 2002, ANN INTERN MED, V137, P884, DOI 10.7326/0003-4819-137-11-200212030-00009; Dickneite G, 2007, THROMB RES, V119, P643, DOI 10.1016/j.thromres.2006.05.011; Dzik WH, 2007, TRANSFUSION MED, V17, P367, DOI 10.1111/j.1365-3148.2007.00795.x; Eikelboom JW, 2003, BLOOD COAGUL FIBRIN, V14, P713, DOI 10.1097/00001721-200312000-00004; Engstrom M, 2005, J NEUROTRAUM, V22, P291, DOI 10.1089/neu.2005.22.291; FRANKE CL, 1992, J NEUROL NEUROSUR PS, V55, P653, DOI 10.1136/jnnp.55.8.653; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; GOODNIGHT SH, 1974, NEW ENGL J MED, V290, P1043, DOI 10.1056/NEJM197405092901903; Hulka F, 1996, ARCH SURG-CHICAGO, V131, P923; Jones J, 1999, VOX SANG, V77, P239, DOI 10.1046/j.1423-0410.1999.77402391.x; Levi M, 2007, CRIT CARE MED, V35, P2191, DOI 10.1097/01.CCM.0000281468.94108.4B; MacLeod JBA, 2003, J TRAUMA, V55, P39, DOI 10.1097/01.TA.0000075338.21177.EF; Maegele M, 2007, EUR SURG RES, V39, P372, DOI 10.1159/000107097; MAY AK, 1997, AM SURGEON, V63, P223; Mayer SA, 2008, NEW ENGL J MED, V358, P2127, DOI 10.1056/NEJMoa0707534; Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Pabinger I, 2008, J THROMB HAEMOST, V6, P622, DOI 10.1111/j.1538-7836.2008.02904.x; Riess HB, 2007, THROMB RES, V121, P9, DOI 10.1016/j.thromres.2007.02.009; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; SERVADEI F, 1995, NEUROSURGERY, V37, P906; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; Vanderschueren S, 2000, CRIT CARE MED, V28, P1871, DOI 10.1097/00003246-200006000-00031; Vaslef SN, 2002, J TRAUMA, V53, P291, DOI 10.1097/00005373-200208000-00017; Wada R, 2007, STROKE, V38, P1257, DOI 10.1161/01.STR.0000259633.59404.f3; YAMAKI T, 1990, ACTA NEUROCHIR, V103, P112, DOI 10.1007/BF01407516	30	104	121	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	NOV	2009	67	5					959	967		10.1097/TA.0b013e3181ad5d37			9	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	518XO	WOS:000271729500011	19901655				2022-02-06	
J	Grossetete, M; Phelps, J; Arko, L; Yonas, H; Rosenberg, GA				Grossetete, Mark; Phelps, Jeremy; Arko, Leopold; Yonas, Howard; Rosenberg, Gary A.			ELEVATION OF MATRIX METALLOPROTEINASES 3 AND 9 IN CEREBROSPINAL FLUID AND BLOOD IN PATIENTS WITH SEVERE TRAUMATIC BRAIN INJURY	NEUROSURGERY			English	Article						Cerebrospinal fluid; Matrix metalloproteinases; Traumatic brain injury; Ventriculostomy	SPONTANEOUS INTRACEREBRAL HEMORRHAGE; GENE KNOCK-OUT; MULTIPLE-SCLEROSIS; BACTERIAL-MENINGITIS; BARRIER DISRUPTION; MATRIX-METALLOPROTEINASE-9; EXPRESSION; NEUROINFLAMMATION; ACTIVATION; INHIBITORS	OBJECTIVE: Traumatic brain injury (TBI) causes an increase in matrix metalloproteinases (MMPs), which are associated with neuroinflammation, blood-brain barrier disruption, hemorrhage, and cell death. We hypothesized that patients with TBI have an increase in MMPs in ventricular cerebrospinal fluid (CSF) and plasma. METHODS: patients with TBI and a ventricular catheter were entered into the study. Samples of CSF and plasma were collected at the time of catheter placement and at 24 and 72 hours after admission. Seven TBI patients were entered into the study, with 6 having complete data for analysis. Only patients who had a known time of insult that fell within a 6-hour window from initial insult to ventriculostomy were accepted into the study. Control CSF came from ventricular fluid in patients undergoing shunt placement for normal pressure hydrocephalus. Both MMP-2 and MMP-9 were measured with gelatin zymography and MMP-3 with Western immunoblot. RESULTS: We found a significant elevation in the levels of the latent form of MMP-9 (92-kD) in the CSF obtained at the time of arrival (P < 0.05). Elevated levels of MMP-2 were detected in plasma at 72 hours, but not in the CSF. Using albumin from both CSF and blood, we calculated the MMP-9 index, which was significantly increased in the CSF, indicating endogenous MMP production. Western immunoblot showed elevated levels of MMP-3 in CSF at all times measured, whereas MMP-3 was not detected in the CSF of normal pressure hydrocephalus. CONCLUSION: We show that MMPs are increased in the CSF of TBI patients. Although the number of patients was small, the results were robust and clearly demonstrated increases in MMP-3 and MMP-9 in ventricular CSF in TBI patients compared with controls. Although these preliminary results will need to be replicated, we propose that MMPs may be important in blood-brain barrier opening and hemorrhage secondary to brain injury in patients.	[Grossetete, Mark; Arko, Leopold; Rosenberg, Gary A.] Univ New Mexico, Hlth Sci Ctr, Dept Neurol, Albuquerque, NM 87131 USA; [Rosenberg, Gary A.] Univ New Mexico, Hlth Sci Ctr, Dept Cell Biol & Physiol, Albuquerque, NM 87131 USA; [Phelps, Jeremy; Yonas, Howard] Univ New Mexico, Hlth Sci Ctr, Dept Neurosurg, Albuquerque, NM 87131 USA		Rosenberg, GA (corresponding author), Univ New Mexico, Hlth Sci Ctr, Dept Neurol, MSC 10 5620, Albuquerque, NM 87131 USA.	grosenberg@salud.unm.edu		Arko, Leopold/0000-0003-1052-5671	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS045847, RO1 NS052305]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000997] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052305, R01NS045847] Funding Source: NIH RePORTER	This study was supported by grants from University of New Mexico Health Sciences Center Clinical Translational Science Center Research Core Pilot Project Award in Clinical and Translational Research and Department of Health and Human Services/Public Health Service/Public Health Service/National Institutes of Health/National Center for Research Resources/General Clinical Research Center grant MO1RR00997 and National Institutes of Health grant to Gary A. Rosenberg, M.D. (RO1 NS045847 and RO1 NS052305). The authors have no personal financial or institutional interest in any of the drugs, materials, or devices described in this article.	Abilleira S, 2003, J NEUROSURG, V99, P65, DOI 10.3171/jns.2003.99.1.0065; Adair JC, 2004, STROKE, V35, pE159, DOI 10.1161/01.STR.0000127420.10990.76; Alvarez-Sabin J, 2004, STROKE, V35, P1316, DOI 10.1161/01.STR.0000126827.69286.90; Asahi M, 2001, J NEUROSCI, V21, P7724, DOI 10.1523/JNEUROSCI.21-19-07724.2001; Buss A, 2007, BMC NEUROL, V7, DOI 10.1186/1471-2377-7-17; Candelario-Jalil E, 2007, J PHARMACOL EXP THER, V323, P488, DOI 10.1124/jpet.107.127035; Chakraborti S, 2003, MOL CELL BIOCHEM, V253, P269, DOI 10.1023/A:1026028303196; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Gottschall PE, 1996, NEUROIMMUNOMODULAT, V3, P69, DOI 10.1159/000097229; Gu ZZ, 2002, SCIENCE, V297, P1186, DOI 10.1126/science.1073634; Gurney KJ, 2006, NEUROBIOL DIS, V23, P87, DOI 10.1016/j.nbd.2006.02.006; Kim HJ, 2005, EXP NEUROL, V192, P60, DOI 10.1016/j.expneurol.2004.10.014; Langlois J. A., 2006, TRAUMATIC BRAIN INJU, P1; Leppert D, 2000, CLIN INFECT DIS, V31, P80, DOI 10.1086/313922; Leppert D, 2001, BRAIN RES REV, V36, P249, DOI 10.1016/S0165-0173(01)00101-1; Liuzzi GM, 2002, MULT SCLER, V8, P222, DOI 10.1191/1352458502ms800oa; Lo EH, 2002, J NEUROSCI RES, V69, P1, DOI 10.1002/jnr.10270; Morita-Fujimura Y, 2000, J CEREBR BLOOD F MET, V20, P130, DOI 10.1097/00004647-200001000-00017; Mun-Bryce S, 2002, BRAIN RES, V933, P42, DOI 10.1016/S0006-8993(02)02303-X; Rosell A, 2006, STROKE, V37, P1399, DOI 10.1161/01.STR.0000223001.06264.af; ROSENBERG GA, 1995, J NEUROTRAUM, V12, P833, DOI 10.1089/neu.1995.12.833; Rosenberg GA, 2002, NEUROSCIENTIST, V8, P586, DOI 10.1177/1073858402238517; Rozanov DV, 2003, J BIOL CHEM, V278, P8257, DOI 10.1074/jbc.M213246200; Shigemori Y, 2006, ACTA NEUROCHIR SUPPL, V96, P130; Silva Y, 2005, STROKE, V36, P86, DOI 10.1161/01.STR.0000149615.51204.0b; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Suehiro E, 2004, J NEUROTRAUM, V21, P1706, DOI 10.1089/0897715042664957; Van Baalen B, 2003, DISABIL REHABIL, V25, P9, DOI 10.1080/713813430; Vilalta A, 2008, INTENS CARE MED, V34, P1384, DOI 10.1007/s00134-008-1056-1; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Yong VW, 2005, NAT REV NEUROSCI, V6, P931, DOI 10.1038/nrn1807; Yong VW, 2001, NAT REV NEUROSCI, V2, P502, DOI 10.1038/35081571	34	104	109	1	10	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	OCT	2009	65	4					702	708		10.1227/01.NEU.0000351768.11363.48			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	502WY	WOS:000270492300015	19834375	Green Accepted			2022-02-06	
J	Motherway, JA; Verschueren, P; Van der Perre, G; Sloten, JV; Gilchrist, MD				Motherway, Julie A.; Verschueren, Peter; Van der Perre, Georges; Sloten, Jos Vander; Gilchrist, Michael D.			The mechanical properties of cranial bone: The effect of loading rate and cranial sampling position	JOURNAL OF BIOMECHANICS			English	Article						Skull fracture; Mechanical properties; Dynamic loading; Head impact; Adult human	HUMAN PARIETAL BONE; INFANT SKULL; BRAIN-INJURY; BIOMECHANICS; SUTURE; SHEAR	Linear and depressed skull fractures are frequent mechanisms of head injury and are often associated with traumatic brain injury. Accurate knowledge of the fracture of cranial bone can provide insight into the prevention of skull fracture injuries and help aid the design of energy absorbing head protection systems and safety helmets. Cranial bone is a complex material comprising of a three-layered structure: external layers consist of compact, high-density cortical bone and the central layer consists of a low-density, irregularly porous bone structure. In this study, cranial bone specimens were extracted from 8 fresh-frozen cadavers (F = 4, M = 4; 81 +/- 11 years old). 63 specimens were obtained from the parietal and frontal cranial bones. Prior to testing, all specimens were scanned using a mu CT scanner at a resolution of 56.9 mu m. The specimens were tested in a three-point bend set-up at different dynamic speeds (0.5, 1 and 2.5 m/s). The associated mechanical properties that were calculated for each specimen include the 2nd moment of inertia, the sectional elastic modulus, the maximum force at failure, the energy absorbed until failure and the maximum bending stress. Additionally, the morphological parameters of each specimen and their correlation with the resulting mechanical parameters were examined. It was found that testing speed, strain rate, cranial sampling position and intercranial variation all have a significant effect on some or all of the computed mechanical parameters. A modest correlation was also found between percent bone volume and both the elastic modulus and the maximum bending stress. (C) 2009 Elsevier Ltd. All rights reserved.	[Motherway, Julie A.; Gilchrist, Michael D.] Univ Coll Dublin, Sch Elect Elect & Mech Engn, Dublin 4, Ireland; [Verschueren, Peter; Van der Perre, Georges; Sloten, Jos Vander] Katholieke Univ Leuven, Div Biomech & Engn Design, B-3001 Heverlee, Belgium		Gilchrist, MD (corresponding author), Univ Coll Dublin, Sch Elect Elect & Mech Engn, Dublin 4, Ireland.	Michael.Gilchrist@ucd.ie	Gilchrist, Michael D/B-6100-2017	Gilchrist, Michael D/0000-0003-1765-429X			Caprino G, 2009, COMPOS STRUCT, V88, P360, DOI 10.1016/j.compstruct.2008.04.014; Coats B, 2006, J NEUROTRAUM, V23, P1222, DOI 10.1089/neu.2006.23.1222; Delille C., 2003, MEC IND, V4, P119, DOI DOI 10.1016/S1296-2139(03)00029-0; Delille R, 2007, INT J CRASHWORTHINES, V12, P101, DOI 10.1080/13588260701433081; Doorly M. C., 2006, Computer Methods in Biomechanics and Biomedical Engineering, V9, P371, DOI 10.1080/10255840601003551; EVANS FG, 1957, J APPL PHYSIOL, V10, P493, DOI 10.1152/jappl.1957.10.3.493; Gefen A, 2004, J BIOMECH, V37, P1339, DOI 10.1016/j.jbiomech.2003.12.032; HARDY WN, 2001, STAPP CAR CRASH J, V45, P368; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; HUBBARD RP, 1971, J BIOMECH, V4, P251, DOI 10.1016/0021-9290(71)90031-5; JANS G, 2003, THESIS KATHOLIEKE U; Margulies SS, 2000, J BIOMECH ENG-T ASME, V122, P364, DOI 10.1115/1.1287160; MCELHANEY JH, 1970, J BIOMECH, V3, P495, DOI 10.1016/0021-9290(70)90059-X; MCPHERSON GK, 1980, J BIOMECH, V13, P9, DOI 10.1016/0021-9290(80)90003-2; Miller K, 1997, J BIOMECH, V30, P1115, DOI 10.1016/S0021-9290(97)00092-4; Motherway J, 2009, Leg Med (Tokyo), V11 Suppl 1, pS220, DOI 10.1016/j.legalmed.2009.01.072; Peterson J, 2003, ANAT REC PART A, V274A, P785, DOI 10.1002/ar.a.10096; Peterson J, 2002, ANAT REC, V268, P7, DOI 10.1002/ar.10131; PRANGE MT, 2002, J BIOMECHANICAL ENG, V124, P224; Roark R.J., 1986, FORMULAS STRESS STRA; *SKYSCAN, 2008, MORPH PAR CT AN; Timoshenko S., 1970, THEORY ELASTICITY; WOOD JL, 1971, J BIOMECH, V4, P1, DOI 10.1016/0021-9290(71)90010-8; [No title captured], DOI DOI 10.1088/0022-3727/8/16/003; [No title captured]	25	104	108	1	40	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290	1873-2380		J BIOMECH	J. Biomech.	SEP 18	2009	42	13					2129	2135		10.1016/j.jbiomech.2009.05.030			7	Biophysics; Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Engineering	502RO	WOS:000270478000018	19640538	Green Submitted			2022-02-06	
J	Randolph, C; Millis, S; Barr, WB; McCrea, M; Guskiewicz, KM; Hammeke, TA; Kelly, JP				Randolph, Christopher; Millis, Scott; Barr, William B.; McCrea, Michael; Guskiewicz, Kevin M.; Hammeke, Thomas A.; Kelly, James P.			Concussion Symptom Inventory: An Empirically Derived Scale for Monitoring Resolution of Symptoms Following Sport-Related Concussion	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Brain injury; Post-concussion; Scale	COLLEGIATE FOOTBALL PLAYERS; NEUROPSYCHOLOGICAL TEST PROTOCOL; TRAUMATIC BRAIN-INJURY; 2ND IMPACT SYNDROME; HIGH-SCHOOL; POSTURAL STABILITY; NCAA CONCUSSION; HEAD-INJURY; RELIABILITY; PREVENTION	Self-report post-concussion symptom scales have been a key method for monitoring recovery from sport-related concussion, to assist in medical management, and return-to-play decision-making. To date, however, item selection and scaling metrics for these instruments have been based solely upon clinical judgment, and no one scale has been identified as the "gold standard". We analyzed a large set of data from existing scales obtained from three separate case-control studies in order to derive a sensitive and efficient scale for this application by eliminating items that were found to be insensitive to concussion. Baseline data from symptom checklists including a total of 27 symptom variables were collected from a total of 16,350 high school and college athletes. Follow-up data were obtained from 641 athletes who subsequently incurred a concussion. Symptom checklists were administered at baseline (preseason), immediately post-concussion, post-game, and at 1, 3, and 5 days post-injury. Effect-size analyses resulted in the retention of only 12 of the 27 variables. Receiver-operating characteristic analyses were used to confirm that the reduction in items did not reduce sensitivity or specificity. The newly derived Concussion Symptom Inventory is presented and recommended as a research and clinical tool for monitoring recovery from sport-related concussion.	[Randolph, Christopher] Loyola Univ, Med Ctr, Dept Neurol, Maywood, IL 60153 USA; [Millis, Scott] Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Detroit, MI USA; [Barr, William B.] NYU, Sch Med, Dept Neurol, New York, NY USA; [Barr, William B.] NYU, Sch Med, Dept Psychiat, New York, NY USA; [McCrea, Michael] Waukesha Mem Hosp, Ctr Neurosci, Waukesha, WI USA; [McCrea, Michael; Hammeke, Thomas A.] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; [Guskiewicz, Kevin M.] Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC USA; [Guskiewicz, Kevin M.] Univ N Carolina, Dept Orthoped, Chapel Hill, NC USA; [Kelly, James P.] Univ Colorado, Sch Med, Dept Neurosurg, Denver, CO USA; [Kelly, James P.] Univ Colorado, Sch Med, Dept Phys Med & Rehabil, Denver, CO USA		Randolph, C (corresponding author), 1 E Erie,Suite 355, Chicago, IL 60611 USA.	crandol@lumc.edu		Guskiewicz, Kevin/0000-0002-8682-2130; Barr, William/0000-0001-7711-7758	NCAA; National Operating Committee on Standards for Athletic Equipment (NOCSAE); Center for Disease Control's National Center for Injury Prevention and Control (NPIPC); National Academy of Neuropsychology; Waukesha Memorial Hospital Foundation; National Federation of State High School Associations; NFL Charities; Green Bay Packer Foundation; Milwaukee Bucks; Herbert H. Kohl Charities; Waukesha Service Club; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [M01-RR00058]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000058] Funding Source: NIH RePORTER	This project was supported in part by funding from the NCAA, the National Operating Committee on Standards for Athletic Equipment (NOCSAE), Center for Disease Control's National Center for Injury Prevention and Control (NPIPC), National Academy of Neuropsychology, Waukesha Memorial Hospital Foundation, National Federation of State High School Associations, NFL Charities, Green Bay Packer Foundation, Milwaukee Bucks, Herbert H. Kohl Charities, Waukesha Service Club, and the Medical College of Wisconsin General Clinical Research Center (M01-RR00058 from the National Institutes of Health).	Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barr WB, 2001, J ATHL TRAINING, V36, P297; Barth JT, 1989, MILD HEAD INJURY, P257; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Hinton-Bayre AD, 2002, NEUROLOGY, V59, P1068, DOI 10.1212/WNL.59.7.1068; HSIAO JK, 1989, ARCH GEN PSYCHIAT, V46, P664; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; LeBlanc K E, 1998, J La State Med Soc, V150, P312; Linacre JM, 2004, INTRO RASCH MEASUREM, P258, DOI DOI 10.1891/JNUM.10.3.189.52562; Love J. A., 2003, HDB METATHESIS, V2, P296; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Maroon JC, 2000, NEUROSURGERY, V47, P669; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; Mori T, 2006, ACTA NEUROCHIR SUPPL, V96, P40; Mrazik M, 2000, BRAIN INJURY, V14, P921, DOI 10.1080/026990500445736; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Piland SG, 2003, J ATHL TRAINING, V38, P104; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Randolph C, 2005, J ATHL TRAINING, V40, P139; Randolph C, 2001, J ATHL TRAINING, V36, P288; Rasch G., 1960, PROBABILISTIC MODELS; Zhou XH., 2002, STAT METHODS DIAGNOS	47	104	104	1	10	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	MAY	2009	24	3					219	229		10.1093/arclin/acp025			11	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	483WJ	WOS:000269001900003	19549721	Green Published, Bronze			2022-02-06	
J	Barr, RG; Barr, M; Fujiwara, T; Conway, J; Catherine, N; Brant, R				Barr, Ronald G.; Barr, Marilyn; Fujiwara, Takeo; Conway, Jocelyn; Catherine, Nicole; Brant, Rollin			Do educational materials change knowledge and behaviour about crying and shaken baby syndrome? A randomized controlled trial	CANADIAN MEDICAL ASSOCIATION JOURNAL			English	Article							TRAUMATIC BRAIN-INJURY; AGE-RELATED INCIDENCE; SLEEP POSITION; PERPETRATOR; INFANTS; TRIGGER; CURVE; POWER	Background: Shaken baby syndrome often occurs after shaking in response to crying bouts. We questioned whether the use of the educational materials from the Period of PURPLE Crying program would change maternal knowledge and behaviour related to shaking. Methods: We performed a randomized controlled trial in which 1279 mothers received materials from the Period of PURPLE Crying program or control materials during a home visit by a nurse by 2 weeks after the birth of their child. At 5 weeks, the mothers completed a diary to record their behaviour and their infants' behaviour. Two months after giving birth, the mothers completed a telephone survey to assess their knowledge and behaviour. Results: The mean score (range 0-100 points) for knowledge about infant crying was greater among mothers who received the PURPLE materials (63.8 points) than among mothers who received the control materials (58.4 points) (difference 5.4 points, 95% confidence interval [CI] 4.1 to 6.5 points). The mean scores were similar for both groups for shaking knowledge and reported maternal responses to crying, inconsolable crying and self-talk responses. Compared with mothers who received control materials, mothers who received the PURPLE materials reported sharing information about walking away if frustrated more often (51.5% v. 38.5%, difference 13.0%, 95% CI 6.9% to 19.2%), the dangers of shaking (49.3% v. 36.4%, difference 12.9%, 95% CI 6.8% to 19.0%), and infant crying (67.6% v. 60.0%, difference 7.6%, 95% CI 1.7% to 13.5%). Walking away during inconsolable crying was significantly higher among mothers who received the PURPLE materials than among those who received control materials (0.067 v. 0.039 events per day, rate ratio 1.7, 95% CI 1.1 to 2.6). Interpretation: The receipt of the Period of PURPLE Crying materials led to higher maternal scores for knowledge about infant crying and for some behaviours considered to be important for the prevention of shaking. (Clinical-Trials. gov trial register no. NCT00175422.)	[Barr, Ronald G.; Fujiwara, Takeo; Catherine, Nicole] Univ British Columbia, Child & Family Res Inst, Ctr Community Child Hlth Res, Vancouver, BC V6H 3V4, Canada; [Barr, Ronald G.; Fujiwara, Takeo] Univ British Columbia, Dept Pediat, Vancouver, BC V5Z 1M9, Canada; [Brant, Rollin] Univ British Columbia, Dept Stat, Vancouver, BC V5Z 1M9, Canada; [Barr, Marilyn; Conway, Jocelyn] BC Childrens Hosp, Prevent Shaken Baby Syndrome BC, Vancouver, BC, Canada; [Barr, Marilyn] Natl Ctr Shaken Baby Syndrome, Ogden, UT USA		Barr, RG (corresponding author), Univ British Columbia, Child & Family Res Inst, Ctr Community Child Hlth Res, 4480 Oak St,L408, Vancouver, BC V6H 3V4, Canada.	rbarr@cw.bc.ca		Brant, Rollin/0000-0002-8026-2451	British Columbia Ministry of Children and Family Development; British Columbia Children's Hospital; Human Early Learning Partnership; Child and Family Research Institute es	This study was supported by the British Columbia Ministry of Children and Family Development, the British Columbia Children's Hospital, the Human Early Learning Partnership, and a Child and Family Research Institute establishment grant to Ronald Barr. None of the funding agencies had any role in the design and conduct of the study; the collection, management, analysis and interpretation of the data; or the preparation, review or approval of the manuscript.	[Anonymous], 2001, Paediatr Child Health, V6, P663; Barlow KM, 2000, LANCET, V356, P1571, DOI 10.1016/S0140-6736(00)03130-5; Barr R. G., 1997, RONNICLOG BABYS DAY; Barr R. G., 2006, ENCY EARLY CHILDHOOD, P1; Barr R. G., 1985, BABYS DAY DIARY; Barr R.G, 2004, PERIOD PURPLE CRYING; Barr RG, 2006, CHILD ABUSE NEGLECT, V30, P7, DOI 10.1016/j.chiabu.2005.06.009; Barr RG, 2005, J DEV BEHAV PEDIATR, V26, P14; BARR RG, 1989, PEDIATRICS, V84, P514; BARR RG, 1988, ARCH DIS CHILD, V63, P380, DOI 10.1136/adc.63.4.380; BARR RG, 1990, DEV MED CHILD NEUROL, V32, P356; BARR RG, PEDIATRICS IN PRESS; Barr RG, 2000, HDB DEV PSYCHOPATHOL, P327; Brewster AL, 1998, CHILD ABUSE NEGLECT, V22, P91, DOI 10.1016/S0145-2134(97)00132-4; Brookes ST, 2004, J CLIN EPIDEMIOL, V57, P229, DOI 10.1016/j.jclinepi.2003.08.009; CALINOIU N, 1998, DIARY INDICES PACIFI; *CAN PED SOC, 2002, SAF TIPS PAR; Catherine NLA, 2008, J DEV BEHAV PEDIATR, V29, P508, DOI 10.1097/DBP.0b013e31818d0c0c; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Cummings P, 2001, INJURY CONTROL, P64; Dias MS, 2005, PEDIATRICS, V115, DOI 10.1542/peds.2004-1896; DIAS MS, 2003, AAP NEWS         JUL, P16; *FORCE4 PROD LTD, 1992, CHILD SAF LEARN KEEP; Glynn RJ, 1996, BMJ-BRIT MED J, V312, P364; *HLTH CAN CAN PED, 1999, BACK SLEEP; HUNZIKER UA, 1986, PEDIATRICS, V77, P641; Kairys SW, 2001, PEDIATRICS, V108, P206; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; Kramer MS, 2001, JAMA-J AM MED ASSOC, V286, P322, DOI 10.1001/jama.286.3.322; KRAMER MS, 1981, CLIN PHARMACOL THER, V29, P111, DOI 10.1038/clpt.1981.18; Layzer, 2001, NATL EVALUATION FAMI; Lazoritz S, 1997, CHILD ABUSE NEGLECT, V21, P1009, DOI 10.1016/S0145-2134(97)00061-6; Lee C, 2007, J DEV BEHAV PEDIATR, V28, P288, DOI 10.1097/DBP.0b013e3180327b55; LEHTONEN L, 1998, PACIFIER USE INFANTS; Little R. J., 2019, STAT ANAL MISSING DA, V793; Majnemer A, 2006, J PEDIATR-US, V149, P623, DOI 10.1016/j.jpeds.2006.05.009; *NAT I CHILD HLTH, 1999, BACK SLEEP SUDD INF; Nicholson, 2003, INFLICTED CHILDHOOD, P269; Royston P, 2005, STATA J, V5, P527, DOI 10.1177/1536867X0500500404; Soltis J, 2004, BEHAV BRAIN SCI, V27, P443, DOI 10.1017/S0140525X0400010X; St James-Roberts I, 2006, PEDIATRICS, V117, pE1146, DOI 10.1542/peds.2005-2387; Starling SP, 2004, ARCH PEDIAT ADOL MED, V158, P454, DOI 10.1001/archpedi.158.5.454; STARLING SP, 1995, PEDIATRICS, V95, P259; STJAMESROBERTS I, 1993, ARCH DIS CHILD, V68, P82, DOI 10.1136/adc.68.1.82; Talvik I, 2008, ACTA PAEDIATR, V97, P782, DOI 10.1111/j.1651-2227.2008.00778.x; WILLINGER M, 1994, PEDIATRICS, V93, P814	46	104	105	0	15	CMA-CANADIAN MEDICAL ASSOC	OTTAWA	1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 5W8, CANADA	0820-3946	1488-2329		CAN MED ASSOC J	Can. Med. Assoc. J.	MAR 31	2009	180	7					727	733		10.1503/cmaj.081419			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	421MC	WOS:000264362000010	19255065	gold, Green Published			2022-02-06	
J	Bilotta, F; Caramia, R; Paoloni, FP; Delfini, R; Rosa, G				Bilotta, Federico; Caramia, Remo; Paoloni, Francesca P.; Delfini, Roberto; Rosa, Giovanni			Safety and Efficacy of Intensive Insulin Therapy in Critical Neurosurgical Patients	ANESTHESIOLOGY			English	Article; Proceedings Paper	Joint Annual Meeting of the European-Society-of-Anaesthesiology/Annual Meeting of the EAA	JUN 03-06, 2006	Madrid, SPAIN	European Soc Anaesthesiol, EAA			PLASMA-GLUCOSE CONCENTRATIONS; TRAUMATIC BRAIN-INJURY; STROKE TRIAL GIST; ILL PATIENTS; ISCHEMIC BRAIN; BLOOD-GLUCOSE; CARE-UNIT; DIABETES-MELLITUS; GLYCEMIC CONTROL; MEDICAL ICU	Background: Intensive insulin therapy to maintain blood glucose at or below 6.11 mM reduces morbidity and mortality after cardiac surgery and morbidity in medical intensive care unit (ICU) patients. The authors investigated the clinical safety and outcome effects of intensive insulin therapy compared to conventional insulin therapy in patients receiving postoperative intensive care after neurosurgical procedures. Methods: In this prospective randomized controlled trial, 483 patients undergoing elective or emergency brain surgery were prospectively and randomly assigned either to intensive insulin therapy (241 patients), receiving insulin titrated to maintain blood glucose levels within the range of 4.44-6.11 mM, or to conventional insulin therapy (242 patients), receiving insulin to maintain blood glucose levels below 11.94 mM. Primary end-point was incidence of hypoglycemia (defined as blood glucose < 2.78 mM). Efficacy measures included the length of ICU stay, infection rate, and 6 months follow-tip Glasgow outcome scale score and overall survival. Results: Hypoglycemia episodes were more frequent in patients receiving intensive insulin therapy, median (min-max): 8 (0-23) versus 3 (0-4); P < 0.0001. The length of stay in the ICU was shorter (6 vs. 8 days; P = 0.0001), and the infection rate was lower (25.7% vs. 39.3%; P = 0.0018). Glasgow outcome scale score and overall survival at 6 months were similar in the two groups. Conclusions: Intensive insulin therapy in patients admitted to a postoperative neurosurgical ICU after brain surgery is associated with iatrogenic hypoglycemia, but it can also reduce the infection rate and shorten the ICU stay.	[Bilotta, Federico] Univ Roma La Sapienza, Policlin Umberto 1, Dept Anesthesiol Crit Care & Pain Med, I-00199 Rome, Italy		Bilotta, F (corresponding author), Univ Roma La Sapienza, Policlin Umberto 1, Dept Anesthesiol Crit Care & Pain Med, Viale Somalia 81, I-00199 Rome, Italy.	bilotta@tiscali.it		Paoloni, Francesca/0000-0001-5527-981X			Bhalla A, 2003, EUR J NEUROL, V10, P25, DOI 10.1046/j.1468-1331.2003.00504.x; Bilotta F, 2008, NEUROCRIT CARE, V9, P159, DOI 10.1007/s12028-008-9084-9; Bilotta Federico, 2007, J Neurosurg Anesthesiol, V19, P156, DOI 10.1097/ANA.0b013e3180338e69; BOYLE PJ, 1988, NEW ENGL J MED, V318, P1487, DOI 10.1056/NEJM198806093182302; Brunkhorst FM, 2008, NEW ENGL J MED, V358, P125, DOI 10.1056/NEJMoa070716; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Donnan GA, 2007, LANCET NEUROL, V6, P380, DOI 10.1016/S1474-4422(07)70086-8; Egi M, 2006, ANESTHESIOLOGY, V105, P244, DOI 10.1097/00000542-200608000-00006; Gandhi GY, 2007, ANN INTERN MED, V146, P233, DOI 10.7326/0003-4819-146-4-200702200-00002; Gerstein HC, 2008, NEW ENGL J MED, V358, P2545, DOI 10.1056/NEJMoa0802743; Gray CS, 2007, LANCET NEUROL, V6, P397, DOI 10.1016/S1474-4422(07)70080-7; Horan TC., 2004, SURVEILLANCE NOSOCOM, V3rd, P1659; Kimura K, 2007, J NEUROL SCI, V255, P90, DOI 10.1016/j.jns.2007.02.005; Krinsley JS, 2007, CRIT CARE MED, V35, P2262, DOI 10.1097/01.CCM.0000282073.98414.4B; Krinsley JS, 2004, MAYO CLIN PROC, V79, P992, DOI 10.4065/79.8.992; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; LI PA, 1994, NEUROSCI LETT, V177, P63, DOI 10.1016/0304-3940(94)90045-0; Lukins MB, 2005, ANESTH ANALG, V100, P1129, DOI 10.1213/01.ANE.0000146943.45445.55; McCowen KC, 2001, CRIT CARE CLIN, V17, P107, DOI 10.1016/S0749-0704(05)70154-8; Mechanick JI, 2007, CURR OPIN CLIN NUTR, V10, P193, DOI 10.1097/MCO.0b013e32802b7016; Pasternak JJ, 2004, J NEUROSURG ANESTH, V16, P122, DOI 10.1097/00008506-200404000-00003; Pittas AG, 2004, ARCH INTERN MED, V164, P2005, DOI 10.1001/archinte.164.18.2005; Preiser JC, 2007, CRIT CARE MED, V35, pS503, DOI 10.1097/01.CCM.0000278046.24345.C7; PULSINELLI WA, 1983, AM J MED, V74, P540, DOI 10.1016/0002-9343(83)91007-0; Scott JF, 1999, STROKE, V30, P793, DOI 10.1161/01.STR.30.4.793; Souba WW, 1997, NEW ENGL J MED, V336, P41, DOI 10.1056/NEJM199701023360107; Thomas G, 2007, NEPHROL DIAL TRANSPL, V22, P2849, DOI 10.1093/ndt/gfm401; Todd MM, 2005, NEW ENGL J MED, V352, P135, DOI 10.1056/NEJMoa040975; Turina M, 2006, CRIT CARE MED, V34, pS291, DOI 10.1097/01.ccm.0000231887.84751.04; *U MI MED CTR, 2006, APSF NEWSL; Van den Berghe G, 2005, NEUROLOGY, V64, P1348, DOI 10.1212/01.WNL.0000158442.08857.FC; Van den Berghe G, 2006, NEW ENGL J MED, V354, P449, DOI 10.1056/NEJMoa052521; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Van den Berghe G, 2006, DIABETES, V55, P3151, DOI 10.2337/db06-0855; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Vriesendorp TM, 2006, CRIT CARE MED, V34, P2714, DOI 10.1097/01.CCM.0000241155.36689.91; Vriesendorp TM, 2006, CRIT CARE MED, V34, P96, DOI 10.1097/01.CCM.0000194536.89694.06; Walia S, 2002, INJURY, V33, P339, DOI 10.1016/S0020-1383(02)00053-0; Wass CT, 1996, MAYO CLIN PROC, V71, P801; Weinstein MP, 1997, CLIN INFECT DIS, V24, P584, DOI 10.1093/clind/24.4.584; Weinstein MP, 1998, J CLIN MICROBIOL, V36, P2089, DOI 10.1128/JCM.36.7.2089-2092.1998; WIDOM B, 1990, ANN INTERN MED, V112, P904, DOI 10.7326/0003-4819-112-12-904; Wilson JTL, 2002, J NEUROTRAUM, V19, P999, DOI 10.1089/089771502760341910; Yamada K, 2007, CRIT CARE, V11, DOI 10.1186/cc5953	44	104	112	1	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022			ANESTHESIOLOGY	Anesthesiology	MAR	2009	110	3					611	619		10.1097/ALN.0b013e318198004b			9	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Anesthesiology	412OU	WOS:000263734900024	19237874	Bronze			2022-02-06	
J	Tsenter, J; Beni-Adani, L; Assaf, Y; Alexandrovich, AG; Trembovler, V; Shohami, E				Tsenter, Jeanna; Beni-Adani, Liana; Assaf, Yaniv; Alexandrovich, Alexander G.; Trembovler, Victoria; Shohami, Esther			Dynamic changes in the recovery after traumatic brain injury in mice: Effect of injury severity on T2-weighted MRI abnormalities, and motor and cognitive functions	JOURNAL OF NEUROTRAUMA			English	Article						closed head injury; memory; object recognition; outcome measures	CLOSED-HEAD INJURY; OBJECT RECOGNITION MEMORY; LONG-TERM POTENTIATION; CONTROLLED CORTICAL IMPACT; ONE-TRIAL TEST; PERIRHINAL CORTEX; DOPAMINE-D4 RECEPTORS; FORNIX TRANSECTION; NEUROTOXIC LESIONS; WORKING-MEMORY	Memory and neurobehavioral dysfunctions are among the sequelae of traumatic brain injury (TBI). The Neurological Severity Score (NSS) includes 10 tasks and was previously designed to assess the functional status of mice after TBI. The object recognition task (ORT) measures specific episodic memory and is expressed by the percent time spent by an animal at a novel, unfamiliar object (Discrimination Index [DI]). It is an ideal tool for evaluating cognitive function after TBI. The present study sought to validate the use of the NSS and ORT in severe and mild focal TBI in mice, and to confirm that the spontaneous recovery and the radiological abnormalities, shown by T2-weighted magnetic resonance imaging (MRI), are dependent upon injury severity. Mice were subjected to severe and mild closed head injury (NSS at 1 h 7.52 +/- 0.34 and 4.62 +/- 0.14, respectively). NSS was evaluated for 25 days and showed a decrease by 3.86 +/- 0.26 and 2.54 +/- 0.35 units in the severely and mildly injured mice, respectively. ORT revealed DI in severely injured group of 51.7 +/- 6.15%, (vs similar to 75-80% in uninjured animal) on day 3 and 66.2 +/- 6.81% on day 21. In contrast, the mildly injured mice did not show cognitive impairment throughout the same period. The damage seen by MRI at 24 h after injury, strongly correlated with NSS(1h) (R = 0.87, p < 0.001). We conclude that NSS is a reliable tool for evaluation of neurological damage in head-injured mice, NSS(1h) predicts the motor dysfunction, cognitive damage, and brain-damage characteristics as depicted by T2-weighted MRI. The combined assessment of neurobehavioral and cognitive function along with MRI is most useful in evaluating recovery from injury, especially when testing effectiveness of novel treatments or genetic manipulations.	[Tsenter, Jeanna; Alexandrovich, Alexander G.; Trembovler, Victoria; Shohami, Esther] Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel; [Tsenter, Jeanna] Hebrew Univ Jerusalem, Hadassah Med Ctr, Dept Rehabil, Jerusalem, Israel; [Beni-Adani, Liana] Dana Childrens Hosp, Dept Neurosurg & Pediat Neurosurg, Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel; [Assaf, Yaniv] Tel Aviv Univ, Dept Neurobiochem, IL-69978 Tel Aviv, Israel		Shohami, E (corresponding author), Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel.	esty@cc.huji.ac.il		assaf, yaniv/0000-0001-6828-7595			Albensi BC, 2000, J NEUROSCI RES, V62, P177, DOI 10.1002/1097-4547(20001015)62:2&lt;177::AID-JNR3&gt;3.0.CO;2-D; Ariano MA, 1997, BRAIN RES, V752, P26, DOI 10.1016/S0006-8993(96)01422-9; Ashwal S, 2006, DEV NEUROSCI-BASEL, V28, P309, DOI 10.1159/000094157; Assaf Y, 1997, MAGN RESON IMAGING, V15, P77, DOI 10.1016/S0730-725X(96)00246-9; Baker KB, 2002, LEARN MEMORY, V9, P58, DOI 10.1101/lm.46102; Barker GRI, 2007, J NEUROSCI, V27, P2948, DOI 10.1523/JNEUROSCI.5289-06.2007; Beni SM, 2004, FASEB J, V18, P149, DOI 10.1096/fj.03-0323fje; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Bigler ED, 2006, AM J PHYS MED REHAB, V85, P793, DOI 10.1097/01.phm.0000237873.26250.e1; BONTKE CF, 1996, NEUROTRAUMA, P841; Chen GQ, 2000, NATURE, V408, P975, DOI 10.1038/35050103; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Demetriades D, 2004, J AM COLL SURGEONS, V199, P216, DOI 10.1016/j.jamcollsurg.2004.02.030; Eichenbaum H, 1999, BEHAV BRAIN RES, V103, P123, DOI 10.1016/S0166-4328(99)00044-3; Ennaceur A, 2005, BEHAV BRAIN RES, V159, P247, DOI 10.1016/j.bbr.2004.11.006; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; ENNACEUR A, 1992, BEHAV BRAIN RES, V51, P83, DOI 10.1016/S0166-4328(05)80315-8; Ennaceur A, 1996, BEHAV BRAIN RES, V80, P9, DOI 10.1016/0166-4328(96)00006-X; Ennaceur A, 1997, BEHAV BRAIN RES, V88, P181, DOI 10.1016/S0166-4328(97)02297-3; Gobbel GT, 2007, CHILD NERV SYST, V23, P1171, DOI 10.1007/s00381-007-0345-2; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hammond RS, 2004, NEUROBIOL LEARN MEM, V82, P26, DOI 10.1016/j.nlm.2004.03.005; Kornecook TJ, 1999, BEHAV BRAIN RES, V98, P67; Lee Bruce, 2005, NeuroRx, V2, P372; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Marciano D, 2007, J NEUROTRAUM, V24, P1378, DOI 10.1089/neu.2007.0318; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; McIntosh TK, 1996, LAB INVEST, V74, P315; Messier C, 1997, NEUROBIOL LEARN MEM, V67, P172, DOI 10.1006/nlme.1996.3755; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Mrzljak L, 1996, NATURE, V381, P245, DOI 10.1038/381245a0; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Paschen W, 2004, J NEUROCHEM, V88, P983, DOI 10.1046/j.1471-4159.2003.02218.x; Pittenger C, 2002, NEURON, V34, P447, DOI 10.1016/S0896-6273(02)00684-0; Postle BR, 2006, NEUROSCIENCE, V139, P23, DOI 10.1016/j.neuroscience.2005.06.005; Rancan M, 2003, J CEREBR BLOOD F MET, V23, P1070, DOI 10.1097/01.WCB.0000084250.20114.2C; Roach JT, 2004, BRAIN RES, V1015, P161, DOI 10.1016/j.brainres.2004.05.004; Salmond CH, 2005, CURR OPIN CRIT CARE, V11, P111, DOI 10.1097/01.ccx.0000155358.31983.37; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Steckler T, 1998, PROG NEUROBIOL, V54, P313, DOI 10.1016/S0301-0082(97)00061-0; Ullman Shimon, 1996, HIGH LEVEL VISION OB; Vaucher E, 2002, EXP NEUROL, V175, P398, DOI 10.1006/exnr.2002.7915; Wedzony K, 2000, J PHYSIOL PHARMACOL, V51, P205; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Yaka R, 2007, FASEB J, V21, P2033, DOI 10.1096/fj.06-7856com; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; YOUNG B, 1996, NEUROTRAUMA, P352	51	104	108	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2008	25	4					324	333		10.1089/neu.2007.0452			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	282PL	WOS:000254579600005	18373482				2022-02-06	
J	Bettger, JAP; Stineman, MG				Bettger, Janet A. Prvu; Stineman, Margaret G.			Effectiveness of multidisciplinary rehabilitation services in postacute care: State-of-the-science. A review	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	State of the Science Symposium on Post-Acute Rehabilitation	FEB 12-13, 2007	Arlington, VA			evidence-based medicine; rehabilitation; review [publication type]	HIP FRACTURE PATIENTS; STROKE REHABILITATION; INPATIENT REHABILITATION; PARKINSONS-DISEASE; SYSTEMATIC REVIEWS; CLINICAL-TRIALS; OUTCOMES; QUALITY; METAANALYSIS; POPULATION	Objectives: To summarize the efficacy of postacute rehabilitation and to outline future research strategies for increasing knowledge of its effectiveness. Data Sources: English-language systematic reviews that examined multidisciplinary therapy-based rehabilitation services for adults, published in the last 25 years and available through Cochrane, Medline, or CINAHL databases. We excluded multidisciplinary biopsychosocial rehabilitation prograins and mental health services. Study Selection: Using the search term rehabilitation, 167 records were identified in the Cochrane database. 1163 meta-analyses and reviews were identified in Medline, and 226 in CINAHL. The Medline and CINAHL search was further refined with 3 additional search terms: therapy, multidisciplinary v, and interdisciplinary. In summary, we used 12 reviews to summarize the efficacy of multidisciplinary, therapy-based postacute rehabilitation; the 12 covered only 5 populations. Data Extraction: Two reviewers extracted information about study populations, sample sizes, study designs, the settings and timing of rehabilitation, interventions, and findings. Data Synthesis: Based on systematic reviews, the evidence for efficacy of postacute rehabilitation services across the continuum was strongest for stroke. There was also strong evidence supporting multidisciplinary inpatient rehabilitation for patients with rheumatoid arthritis, moderate to severe acquired brain injury, including traumatic etiologies, and for older adults. Heterogeneity limited our ability to conclude a benefit or a lack of a benefit for rehabilitation in other postacute settings for the other conditions in which systematic reviews had been completed. The efficacy of multidisciplinary rehabilitation services has not been systematically reviewed for many of the diagnostic conditions treated in rehabilitation. We did not complete a summary of findings from individual studies. Conclusions: Given the limitations and paucity of systematic reviews, information from carefully designed nonrandomn ized studies could be used to complement randomized controlled trials in the study of the effectiveness of postacute rehabilitation. Consequently, a stronger evidence base would become available with which to inform policy decisions, guide the use of services, and improve patient access and outcomes.	Univ Penn, Dept Phys Med & Rehabil, Sch Med, Philadelphia, PA 19104 USA		Stineman, MG (corresponding author), Univ Penn, Dept Phys Med & Rehabil, Sch Med, 3615 Chestnut St,101 Ralston Penn Ctr, Philadelphia, PA 19104 USA.	mstinema@mail.med.upenn.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD042588] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD007425] Funding Source: NIH RePORTER		Adunsky A, 2003, J GERONTOL A-BIOL, V58, P542; *AG HEALTHC RES QU, 2006, NEXT STEPS YOUR DIAG; Anderson C, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000443.pub2; Asplund K, 1997, BMJ-BRIT MED J, V314, P1151; AZIZ NA, 2006, COCHRANE DB SYST REV; Beaupre LA, 2005, J GEN INTERN MED, V20, P1019, DOI 10.1111/j.1525-1497.2005.00219.x; CAMERON ID, 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000106; COOK RJ, 1995, PLANT PHYSIOL, V108, P4; COUNSELL C, 1995, STROKE, V26, P498, DOI 10.1161/01.STR.26.3.498; Coyte PC, 2000, J HEALTH ECON, V19, P907, DOI 10.1016/S0167-6296(00)00041-2; DeJong G, 2005, ARCH PHYS MED REHAB, V86, pS1, DOI 10.1016/j.apmr.2005.09.003; Dekker R, 1998, SCAND J REHABIL MED, V30, P87; Des Jarlais DC, 2004, AM J PUBLIC HEALTH, V94, P361, DOI 10.2105/AJPH.94.3.361; Di Fabio RP, 1998, ARCH PHYS MED REHAB, V79, P141, DOI 10.1016/S0003-9993(98)90290-8; Esselman PC, 2004, JAMA-J AM MED ASSOC, V292, P1746, DOI 10.1001/jama.292.14.1746; EVANS RL, 1995, SOC SCI MED, V40, P1699, DOI 10.1016/0277-9536(94)00286-3; Evans RL, 1998, DISABIL REHABIL, V20, P298, DOI 10.3109/09638289809166085; Freeman JA, 1997, ANN NEUROL, V42, P236, DOI 10.1002/ana.410420216; Freeman JA, 1999, NEUROLOGY, V52, P50, DOI 10.1212/WNL.52.1.50; GREEN SB, 1984, STAT MED, V3, P361, DOI 10.1002/sim.4780030413; Greener J, 2002, CLIN REHABIL, V16, P69, DOI 10.1191/0269215502cr469oa; GROTZINGER KM, 1994, MED CARE, V32, P989, DOI 10.1097/00005650-199410000-00002; Huusko TM, 2002, ACTA ORTHOP SCAND, V73, P425, DOI 10.1080/00016470216324; Inman C, 1999, CLIN REHABIL, V13, P25, DOI 10.1191/026921599674943310; KANE RL, 1990, MEASURING EFFECTIVEN, P429; Khan F, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006036.pub2; KHAN F, 2005, COCHRANE DB SYST REV; Klienbaum DG, 1982, EPIDEMIOLOGIC RES PR; Ko CK, 1999, CLIN REHABIL, V13, P33, DOI 10.1191/026921599669648143; Kramer AM, 1997, JAMA-J AM MED ASSOC, V277, P396, DOI 10.1001/jama.277.5.396; LABBE KA, 1987, ANN INTERN MED, V107, P224, DOI 10.7326/0003-4819-107-2-224; Langhorne P, 2001, STROKE, V32, P268, DOI 10.1161/01.STR.32.1.268; Lytle BW, 1999, J THORAC CARDIOV SUR, V117, P855, DOI 10.1016/S0022-5223(99)70365-X; Mechanic D, 2001, MILBANK Q, V79, P459, DOI 10.1111/1468-0009.00215; Moher D, 2005, EXPLORE-NY, V1, P40, DOI 10.1016/j.explore.2004.11.001; *MOR CO, 2006, UT TRENDS INP REH; Nagi SZ., 1991, DISABILITY AM NATL A, P309; OTTENBACHER KJ, 1993, ARCH NEUROL-CHICAGO, V50, P37, DOI 10.1001/archneur.1993.00540010033014; Outpatient Service Trialists, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002925; Ozdemir F, 2001, ARCH PHYS MED REHAB, V82, P1375, DOI 10.1053/apmr.2001.25973; PATTON MQ, 1997, EVAL PRACT, V18, P147; Pezzin LE, 2000, ARCH PHYS MED REHAB, V81, P292, DOI 10.1053/apmr.2000.0810292; Plint AC, 2006, MED J AUSTRALIA, V185, P263, DOI 10.5694/j.1326-5377.2006.tb00557.x; Rice-Oxley M, 1999, CLIN REHABIL, V13, P7, DOI 10.1191/026921599668051623; Robinson JC, 2001, MILBANK Q, V79, P149, DOI 10.1111/1468-0009.00202; ROSENBAUM P, 2002, OVERT BIAS OBSERVATI, pCH3; ROSENBAUM PR, 1984, J AM STAT ASSOC, V79, P516, DOI 10.2307/2288398; Ryan T, 2006, CLIN REHABIL, V20, P123, DOI 10.1191/0269215506cr933oa; Shyu YIL, 2005, J AM GERIATR SOC, V53, P811, DOI 10.1111/j.1532-5415.2005.53253.x; Stineman MG, 2007, DISABIL REHABIL, V29, P1165, DOI 10.1080/09638280600976145; Stineman MG, 2001, AM J PHYS MED REHAB, V80, P147, DOI 10.1097/00002060-200102000-00016; STINEMAN MG, 2000, DISABIL STUD Q, V20, P11; STUCK AE, 1993, LANCET, V342, P1032, DOI 10.1016/0140-6736(93)92884-V; THACKER SB, 1988, JAMA-J AM MED ASSOC, V259, P1685, DOI 10.1001/jama.259.11.1685; Thompson AJ, 2000, J REHABIL RES DEV, V37, P455; Trend P, 2002, CLIN REHABIL, V16, P717, DOI 10.1191/0269215502cr545oa; Turner-Stokes L, 1999, CLIN REHABIL, V13, P83; Turner-Stokes L, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004170.pub2; Vlieland TPMV, 1997, SEMIN ARTHRITIS RHEU, V27, P110, DOI 10.1016/S0049-0172(97)80011-X; Vogel WB, 2002, J REHABIL RES DEV, V39, P367; Wade DT, 2003, J NEUROL NEUROSUR PS, V74, P158, DOI 10.1136/jnnp.74.2.158; WARD D, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003164; Whyte J, 2003, AM J PHYS MED REHAB, V82, pS16, DOI 10.1097/01.PHM.0000086992.95121.C2; World Health Organization, 2001, INT CLASS FUNCT DIS	64	104	108	0	15	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	2007	88	11					1526	1534		10.1016/j.apmr.2007.06.768			9	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	Rehabilitation; Sport Sciences	229AT	WOS:000250774400026	17964900	Green Accepted			2022-02-06	
J	Pieracci, FM; Eachempati, SR; Shou, J; Hydo, LJ; Barie, PS				Pieracci, Fredric M.; Eachempati, Soumitra R.; Shou, Jian; Hydo, Lynn J.; Barie, Philip S.			Degree of anticoagulation, but not warfarin use itself, predicts adverse outcomes after traumatic brain injury in elderly trauma patients	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	20th Annual Meeting of the Eastern-Association-for-the-Surgery-of-Trauma	JAN 16-20, 2007	Ft Myers, FL	Eastern Assoc Surg Trauma		warfarin; intracranial hemorrhage; traumatic brain injury; geriatrics; anticoagulation	PREINJURY WARFARIN; ATRIAL-FIBRILLATION; INTRACRANIAL HEMORRHAGE; ANTITHROMBOTIC THERAPY; METAANALYSIS; MORTALITY; REVERSAL; STROKE; IMPACT; RISK	Background: The relationship between preinjury warfarin use and outcomes after traumatic brain injury in elderly trauma patients remains controversial. We hypothesized that, among elderly warfarin users, the degree of anticoagulation, rather than warfarin therapy itself, would predict the severity of traumatic brain injury. Methods: Retrospective study (20042006) of all elderly trauma patients (age a:65 years) who were evaluated by the trauma service at a Level I trauma center and underwent computed tomography of the head for suspicion of an intracranial injury was performed. Three cohorts were grouped: (1) warfarin users with an admission International Normalized Ratio >= 2 (therapeutic group), (2) warfarin users with an admission International Normalized Ratio < 2 (nontherapeutic group), and (3) warfarin nonusers. Main outcome variables were presenting with a Glasgow Coma Scale (GCS) score :513 points, intracranial hemorrhage (ICH), overall mortality, and mortality after ICH. Results: A total of 225 trauma patients were studied, including 40 warfarin users (17.3%), of whom 22 (55.0%) were in the therapeutic group. Age, gender, and mechanism of injury were similar among groups. Likelihood of Glasgow Coma Scale score <= 13 (odds ratio [OR] = 5.13, 95% confidence interval [CI] 1.97-13.39, p = 0.001), ICH (OR = 2.59, 95% CI 0.92-7.32, p = 0.07), overall mortality (OR = 4.48, 95% CI 1.60-12.50, p = 0.004), and mortality after ICH (OR = 3.42, 95% CI 1.09-10.76, p = 0.03) was increased in the therapeutic as compared with the nonuser group. There was no difference in any measured outcome between the nonuser and nontherapeutic groups. Conclusions: Therapeutic anticoagulation with warfarin, rather than warfarin use itself, is associated with adverse outcomes after traumatic brain injury in elderly patients.	Cornell Univ, Weill Med Coll, Dept Surg, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Publ Hlth, New York, NY 10021 USA		Pieracci, FM (corresponding author), Cornell Univ, Weill Med Coll, Dept Surg, 411 E 69th St,KB-220, New York, NY 10021 USA.	frp9005@med.cornell.edu	Barie, Philip/AAN-8811-2020				Cohen DB, 2006, J TRAUMA, V60, P553, DOI 10.1097/01.ta.0000196542.54344.05; Coimbra R, 2005, J TRAUMA, V59, P374, DOI 10.1097/01.ta.000174728.46883.a4; Franko J, 2006, J TRAUMA, V61, P107, DOI 10.1097/01.ta.0000224220.89528.fc; Gage BF, 2005, AM J MED, V118, P612, DOI 10.1016/j.amjmed.2005.02.022; Hart RG, 1999, ANN INTERN MED, V131, P492, DOI 10.7326/0003-4819-131-7-199910050-00003; Ivascu FA, 2005, J TRAUMA, V59, P1131, DOI 10.1097/01.ta.0000189067.16368.83; Karni A, 2001, AM SURGEON, V67, P1098; Kennedy DM, 2000, J TRAUMA, V48, P451, DOI 10.1097/00005373-200003000-00012; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; Lavoie A, 2004, J TRAUMA, V56, P802, DOI 10.1097/01.TA.0000066183.02177.AF; Mina AA, 2003, J TRAUMA, V54, P842, DOI 10.1097/01.TA.0000063271.05829.15; SCHWAB CW, 2000, TRAUMA, P1099; van Walraven C, 2002, JAMA-J AM MED ASSOC, V288, P2441, DOI 10.1001/jama.288.19.2441; Wojcik R, 2001, J TRAUMA, V51, P1147, DOI 10.1097/00005373-200112000-00021	14	104	106	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	2007	63	3					525	530		10.1097/TA.0b013e31812e5216			6	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	211DA	WOS:000249503300008	18073596				2022-02-06	
J	Chen, XR; Besson, VC; Palmier, B; Garcia, Y; Plotkine, M; Marchand-Leroux, C				Chen, Xiao Ru; Besson, Valerie C.; Palmier, Bruno; Garcia, Yannick; Plotkine, Michel; Marchand-Leroux, Catherine			Neurological recovery-promoting, anti-inflammatory, and anti-oxidative effects afforded by fenofibrate, a PPAR alpha agonist, in traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						fenofibrate; neuroinflammation; oxidative stress; peroxisome proliferator-activated receptor alpha; traumatic brain injury	ACTIVATED-RECEPTOR-ALPHA; NITRIC-OXIDE SYNTHASE; OXIDATIVE STRESS; INFLAMMATORY RESPONSES; SELECTIVE-INHIBITION; MOUSE MODEL; GLUTATHIONE; MATRIX-METALLOPROTEINASE-9; NEUROPROTECTION; PEROXYNITRITE	We previously demonstrated that fenofibrate, a peroxisome proliferator-activated receptor alpha (PPAR alpha) agonist, reduced the neurological deficit, the edema and the cerebral lesion induced by traumatic brain injury (TBI). In order to elucidate these beneficial effects, in the present study, we investigated, in the same TBI model, fenofibrate's effects on the inflammation and oxidative stress. Male Sprague Dawley rats were randomized in four groups: non-operated, sham-operated, TBI + vehicle, TBI + fenofibrate. TBI was induced by lateral fluid percussion of the temporoparietal cortex. Rats were given fenofibrate (50 mg/kg) or its vehicle (water containing 0.2% methylcellulose), p.o. 1 and 6 h after brain injury. A neurological assessment was done 24 h after TBI, then rats were killed and the brain COX2, MMP9 expression, GSx, GSSG levels were determined. The same schedule of treatment was used to evaluate the effect of fenofibrate on immunohistochemistry of 3NT, 4HNE and iNOS at 24 h post-injury. Our results showed that fenofibrate promotes neurological recovery by exerting anti-inflammatory effect evidenced by a decrease in iNOS, COX2 and MMP9 expression. In addition, fenofibrate showed anti-oxidant effect demonstrated by a reduction of markers of oxidative stress: loss of glutathione, glutathione oxidation ratio, 3NT and 4HNE staining. Our data suggest that PPAR alpha activation could mediate pleiotropic effects and strengthen that it could be a promising therapeutic strategy for TBI.	Univ Paris 05, Pharmacol Lab, UPRES EA 2510, Fac Pharm,Lab Pharmacol Circulat Cerebrale, F-75006 Paris, France		Besson, VC (corresponding author), Univ Paris 05, Pharmacol Lab, UPRES EA 2510, Fac Pharm,Lab Pharmacol Circulat Cerebrale, 4 Ave Observ, F-75006 Paris, France.	valerie.besson@univ-paris5.fr	BESSON, VALERIE/AAZ-9989-2020; besson, valerie C/L-7388-2017; MARCHAND-LEROUX, Catherine/L-7453-2017	BESSON, VALERIE/0000-0002-1491-2380; besson, valerie C/0000-0002-1491-2380; MARCHAND-LEROUX, Catherine/0000-0003-0113-5348			Arnaiz SL, 1995, BBA-MOL BASIS DIS, V1272, P175; Bains JS, 1997, BRAIN RES REV, V25, P335, DOI 10.1016/S0165-0173(97)00045-3; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Besson VC, 2005, NEUROSCI LETT, V388, P7, DOI 10.1016/j.neulet.2005.06.019; Besson VC, 2003, BRAIN RES, V989, P58, DOI 10.1016/S0006-8993(03)03362-6; Bordet R, 2006, BIOCHEM SOC T, V34, P1341, DOI 10.1042/BST0341341; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chew LJ, 2006, MENT RETARD DEV D R, V12, P105, DOI 10.1002/mrdd.20102; Collino M, 2006, FREE RADICAL BIO MED, V41, P1619, DOI 10.1016/j.freeradbiomed.2006.09.013; Cuzzocrea S, 2004, LAB INVEST, V84, P1643, DOI 10.1038/labinvest.3700185; Delayre-Orthez C, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-91; Deplanque D, 2003, J NEUROSCI, V23, P6264; Duval C, 2004, ARCH MAL COEUR VAISS, V97, P665; Fruchart JC, 1999, CURR OPIN LIPIDOL, V10, P245, DOI 10.1097/00041433-199906000-00007; Gahm C, 2006, J NEUROTRAUM, V23, P1343, DOI 10.1089/neu.2006.23.1343; Genovese T, 2005, EXP NEUROL, V194, P267, DOI 10.1016/j.expneurol.2005.03.003; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hooper DC, 2000, FASEB J, V14, P691, DOI 10.1096/fasebj.14.5.691; Hurley SD, 2002, J NEUROTRAUM, V19, P1, DOI 10.1089/089771502753460196; Inoue H, 2003, NEUROSCI LETT, V352, P203, DOI 10.1016/j.neulet.2003.09.001; Inoue I, 2001, METABOLISM, V50, P3, DOI 10.1053/meta.2001.19415; Jafarian-Tehrani M, 2005, NITRIC OXIDE-BIOL CH, V12, P61, DOI 10.1016/j.niox.2004.12.001; Lee JH, 2005, NEUROREPORT, V16, P829; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Lo Verme J, 2005, MOL PHARMACOL, V67, P15, DOI 10.1124/mol.104.006353; Louin G, 2006, NEUROPHARMACOLOGY, V50, P182, DOI 10.1016/j.neuropharm.2005.08.020; Louin G, 2004, J NEUROSCI METH, V138, P73, DOI 10.1016/j.jneumeth.2004.03.010; Mandard S, 2004, CELL MOL LIFE SCI, V61, P393, DOI 10.1007/s00018-003-3216-3; Ogata T, 2004, J AM COLL CARDIOL, V43, P1481, DOI 10.1016/j.jacc.2003.11.043; OUK T, 2005, J CEREB BLOOD FLO S1, V26, pS59; Pahan K, 2002, J BIOL CHEM, V277, P45984, DOI 10.1074/jbc.M200250200; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Rival Y, 2004, DNA CELL BIOL, V23, P283, DOI 10.1089/104454904323090912; Rosenberg GA, 2002, GLIA, V39, P279, DOI 10.1002/glia.10108; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Schulz JB, 2000, EUR J BIOCHEM, V267, P4904, DOI 10.1046/j.1432-1327.2000.01595.x; Shu H, 2000, BIOCHEM BIOPH RES CO, V267, P345, DOI 10.1006/bbrc.1999.1968; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; Strauss KI, 2000, J NEUROTRAUM, V17, P695, DOI 10.1089/089771500415436; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; Toyama T, 2004, BIOCHEM BIOPH RES CO, V324, P697, DOI 10.1016/j.bbrc.2004.09.110; von Gertten C, 2003, J NEUROSCI RES, V73, P803, DOI 10.1002/jnr.10729; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Xu JH, 2005, J NEUROSCI RES, V81, P403, DOI 10.1002/jnr.20518; Zhang JW, 1997, J NEUROSCI METH, V76, P15, DOI 10.1016/S0165-0270(97)00065-4	46	104	109	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2007	24	7					1119	1131		10.1089/neu.2006.0216			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	186DV	WOS:000247760200004	17610352				2022-02-06	
J	Jagannathan, J; Okonkwo, DO; Dumont, AS; Ahmed, H; Bahari, A; Prevedello, DM; Jane, JA; Jane, JA				Jagannathan, Jay; Okonkwo, David O.; Dumont, Aaron S.; Ahmed, Hazem; Bahari, Abbas; Prevedello, Daniel M.; Jane, John A., Sr.; Jane, John A., Jr.			Outcome following decompressive craniectomy in children with severe traumatic brain injury: a 10-year single-center experience with long-term follow up	JOURNAL OF NEUROSURGERY			English	Article						trauma; brain injury; craniectomy; outcome; pediatric neurosurgery	SEVERE HEAD-INJURY; CEREBRAL BLOOD-FLOW; INTRACRANIAL HYPERTENSION; EDEMA; PRESSURE; ADOLESCENTS; CRANIOTOMY; THERAPY; ADULTS; TRIAL	Object. The authors examine the indications for and outcomes following decompressive craniectomy in a single-center pediatric patient population with traumatic brain injury (TBI). Methods. A retrospective review of data was performed using a prospectively acquired database of patients who underwent decompressive craniectomy at the authors' institution between January 1995 and April 2006. The patients' neuroimages were examined to evaluate the extent of intracranial injury, and the patients' records were reviewed to determine the admission Glasgow Coma Scale (GCS) score, the extent of systemic injuries, the time to craniectomy, and the indications for craniectomy. Long-term functional outcome and independence levels were evaluated using the Glasgow Outcome Scale (GOS) and a Likert patient quality-of-life rating scale. Twenty-three craniectomies were performed in children during the study period. The mean patient age at craniectomy was 11.9 years (range 2-19 years). In all patients, the computed tomography scans obtained at presentation revealed pathological findings, with diffuse axonal injury and traumatic contusions being the most common abnormalities. The median presenting GCS score was 4.6 (range 3-9). Nineteen patients (83%) suffered from other systemic injuries. One patient (4%) died intraoperatively and six patients (26%) died postoperatively. Postoperative intracranial pressure (ICP) control was obtained in 19 patients (83%); an ICP greater than 20 mm Hg was found to have the strongest correlation with subsequent brain death (p = 0.001). The mean follow-up duration was 63 months (range 11-126 months, median 49 months). The mean GOS score at the 2-year follow-up examination was 4.2 (median 5). At the most recent follow-up examination, 13 (81%) of 16 survivors had returned to school and only three survivors (18%) were dependent on caregivers. Conclusions. Although the mortality rate for children with severe TBI remains high, decompressive craniectomy is effective in reducing ICP and is associated with good outcomes in surviving patients.	Univ Virginia Hlth Syst, Dept Neurol Surg, Charlottesville, VA 22908 USA		Jagannathan, J (corresponding author), Univ Virginia Hlth Syst, Dept Neurol Surg, POB 800212, Charlottesville, VA 22908 USA.	jj5a@virginia.edu	Jane, John/AAY-3201-2021				Adelson P David, 2003, Pediatr Crit Care Med, V4, pS72; ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BARIE PS, 1993, J TRAUMA, V35, P88, DOI 10.1097/00005373-199307000-00015; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; Berger S, 2002, J TRAUMA, V53, P558, DOI 10.1097/00005373-200209000-00027; Biagas KV, 1996, J NEUROTRAUM, V13, P189, DOI 10.1089/neu.1996.13.189; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; CALEY DW, 1970, J COMP NEUROL, V138, P31, DOI 10.1002/cne.901380104; Chambers IR, 2005, ACT NEUR S, V95, P21; COOPER PR, 1979, NEUROSURGERY, V4, P296, DOI 10.1227/00006123-197904000-00004; Cushing H, 1908, ANN SURG, V47, P641, DOI 10.1097/00000658-190805000-00001; DIETRICH AM, 1993, ANN EMERG MED, V22, P1535, DOI 10.1016/S0196-0644(05)81254-5; EVANS CAN, 1974, J PHYSIOL-LONDON, V238, P371, DOI 10.1113/jphysiol.1974.sp010530; Figaji AA, 2003, CHILD NERV SYST, V19, P666, DOI 10.1007/s00381-003-0804-3; Hieu PD, 1996, CHILD NERV SYST, V12, P270; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; Jorge RE, 2005, CURR OPIN PSYCHIATR, V18, P289, DOI 10.1097/01.yco.0000165600.90928.92; Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337; Kelly DF, 1997, J NEUROSURG, V86, P633, DOI 10.3171/jns.1997.86.4.0633; Kirkness CJ, 2005, ACTA NEUROCHIR SUPPL, V95, P13; KITA H, 1994, ACTA NEUROCHIR, P452; KJELLBERG RN, 1971, J NEUROSURG, V34, P488, DOI 10.3171/jns.1971.34.4.0488; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; LANG DA, 1994, J NEUROSURG, V80, P675, DOI 10.3171/jns.1994.80.4.0675; Murgio A, 1999, CHILD NERV SYST, V15, P318, DOI 10.1007/s003810050401; Paolin A, 1998, J TRAUMA, V44, P495, DOI 10.1097/00005373-199803000-00012; PFENNINGER J, 1983, INTENS CARE MED, V9, P13, DOI 10.1007/BF01693699; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Prabhakaran P, 2004, J NEUROSURG, V100, P454, DOI 10.3171/ped.2004.100.5.0454; Ruf B, 2003, CRIT CARE, V7, pR133, DOI 10.1186/cc2361; Rutigliano D, 2006, J PEDIATR SURG, V41, P83, DOI 10.1016/j.jpedsurg.2005.10.010; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Timofeev I, 2006, ACTA NEUROCHIR SUPPL, V96, P11; YOSHINO E, 1985, J NEUROSURG, V63, P830, DOI 10.3171/jns.1985.63.6.0830	36	104	110	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	APR	2007	106	4		S			268	275		10.3171/ped.2007.106.4.268			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	172UO	WOS:000246830200003	17465359				2022-02-06	
J	Leddy, JJ; Kozlowski, K; Fung, M; Pendergast, DR; Willer, B				Leddy, John J.; Kozlowski, Karl; Fung, Michael; Pendergast, David R.; Willer, Barry			Regulatory and autoregulatory physiological dysfunction as a primary characteristic of post concussion syndrome: Implications for treatment	NEUROREHABILITATION			English	Article							TRAUMATIC BRAIN-INJURY; HEART-RATE-VARIABILITY; CEREBRAL-BLOOD-FLOW; PROFESSIONAL FOOTBALL PLAYERS; SPORTS-RELATED CONCUSSION; COGNITIVE IMPAIRMENT; RECURRENT CONCUSSION; PHYSICAL-ACTIVITY; POSTCONCUSSIVE SYMPTOMS; EXERCISE WITHDRAWAL	Although most patients with concussion recover within days to weeks, a small but significant minority develop persistent signs and symptoms of post-concussion syndrome (PCS). The standard treatments of PCS, rest and cognitive adaptation, have limited effectiveness. PCS patients are advised not to exercise because of the concern for symptom exacerbation. Prolonged rest, however, leads to deconditioning (especially in athletes) and may cause secondary effects including depressive symptoms. Concussion is associated with metabolic and physiological changes in the brain and in other organ systems (for example, autonomic function of the heart and altered cerebral autoregulation, sleep, and circadian rhythms). We propose that PCS results from ongoing central and systemic physiologic regulatory dysfunction after traumatic brain injury (TBI) and we further propose that this physiologic dysfunction may be reduced or alleviated by individualized controlled sub-symptom threshold aerobic exercise rehabilitation.	SUNY Buffalo, Sch Med & Biomed Sci, Buffalo, NY 14214 USA; SUNY Buffalo, Sch Publ Hlth & Hlth Prof, Buffalo, NY 14260 USA		Leddy, JJ (corresponding author), SUNY Buffalo, Sch Med & Biomed Sci, 160 Farber Hall,3435 Main St, Buffalo, NY 14214 USA.	leddy@buffalo.edu	Kozlowski, Karl/H-5253-2019				Almli CR, 2000, EXP NEUROL, V166, P99, DOI 10.1006/exnr.2000.7492; Ayalon L, 2007, NEUROLOGY, V68, P1136, DOI 10.1212/01.wnl.0000258672.52836.30; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; Barnes DE, 2003, J AM GERIATR SOC, V51, P459, DOI 10.1046/j.1532-5415.2003.51153.x; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Berlin AA, 2006, PSYCHOSOM MED, V68, P224, DOI 10.1097/01.psy.0000204628.73273.23; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Brys M, 2003, AM J PHYSIOL-HEART C, V285, pH1048, DOI 10.1152/ajpheart.00062.2003; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Carter JB, 2003, SPORTS MED, V33, P33, DOI 10.2165/00007256-200333010-00003; Cayen B, 2002, BRAIN INJURY, V16, P397, DOI 10.1080/02699050110103931; Cicerone KD, 2002, BRAIN INJURY, V16, P185, DOI 10.1080/02699050110103959; Cline K, 1996, ANNU REV CELL DEV BI, V12, P1, DOI 10.1146/annurev.cellbio.12.1.1; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; Dewitt DS, 2003, J NEUROTRAUM, V20, P795, DOI 10.1089/089771503322385755; Doering TJ, 1998, AM J PHYS MED REHAB, V77, P490, DOI 10.1097/00002060-199811000-00006; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; Ferris LT, 2007, MED SCI SPORT EXER, V39, P728, DOI 10.1249/mss.0b013e31802f04c7; Ford ES, 2002, EPIDEMIOLOGY, V13, P561, DOI 10.1097/00001648-200209000-00012; FORDYCE DE, 1993, BRAIN RES, V619, P111, DOI 10.1016/0006-8993(93)91602-O; Gall B, 2004, BRIT J SPORT MED, V38, P773, DOI 10.1136/bjsm.2003.009530; Gall B, 2004, MED SCI SPORT EXER, V36, P1269, DOI 10.1249/01.MSS.0000135787.73757.4D; Giza CC, 2001, J ATHL TRAINING, V36, P228; Golding EM, 1999, AM J PHYSIOL-HEART C, V277, pH1457, DOI 10.1152/ajpheart.1999.277.4.H1457; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; GOLDING EM, 1998, AM J PHYSIOL, V275, pR1287; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; GROSS PM, 1980, J APPL PHYSIOL, V48, P213, DOI 10.1152/jappl.1980.48.2.213; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hamilton MT, 2004, EXERC SPORT SCI REV, V32, P161; Hanna-Pladdy B, 2001, CLIN NEUROPSYCHOL, V15, P289, DOI 10.1076/clin.15.3.289.10272; Hartlage LC, 2001, ARCH CLIN NEUROPSYCH, V16, P561, DOI 10.1016/S0887-6177(00)00067-6; Ho MR, 1997, ARCH CLIN NEUROPSYCH, V12, P1; Humm JL, 1999, EXP NEUROL, V157, P349, DOI 10.1006/exnr.1999.7061; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2004, BRAIN INJURY, V18, P1; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; Kalsotra A, 2003, J NEUROTRAUM, V20, P1339, DOI 10.1089/089771503322686139; Kelly JP, 1998, J HEAD TRAUMA REHAB, V13, P53, DOI 10.1097/00001199-199804000-00008; King ML, 1997, BRAIN INJURY, V11, P445; Koch A, 2005, CLIN AUTON RES, V15, P83, DOI 10.1007/s10286-005-0249-8; Korn A, 2005, J CLIN NEUROPHYSIOL, V22, P1, DOI 10.1097/01.WNP.0000150973.24324.A7; Kraus Jess F., 1994, P3; Laurin D, 2001, ARCH NEUROL-CHICAGO, V58, P498, DOI 10.1001/archneur.58.3.498; Lee SM, 1999, ANN NY ACAD SCI, V893, P337, DOI 10.1111/j.1749-6632.1999.tb07849.x; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Lyketsos CG, 2002, JAMA-J AM MED ASSOC, V288, P1475, DOI 10.1001/jama.288.12.1475; McAllister TW, 2002, NEUROREHABILITATION, V17, P265; MCARDLE WD, 1996, EXERCISE PHYSL ENERG, P393; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory Paul, 2005, Clin J Sport Med, V15, P48; Molteni R, 2002, EUR J NEUROSCI, V16, P1107, DOI 10.1046/j.1460-9568.2002.02158.x; North T C, 1990, Exerc Sport Sci Rev, V18, P379; Ogoh S, 2005, AM J PHYSIOL-HEART C, V288, pH1461, DOI 10.1152/ajpheart.00948.2004; POMERANZ B, 1985, AM J PHYSIOL, V248, pH151, DOI 10.1152/ajpheart.1985.248.1.H151; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Scully D, 1998, BRIT J SPORT MED, V32, P111, DOI 10.1136/bjsm.32.2.111; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Solomon GS, 2007, J NEUROPSYCH CLIN N, V19, P195, DOI 10.1176/appi.neuropsych.19.2.195; Strebel S, 1997, SURG NEUROL, V47, P128, DOI 10.1016/S0090-3019(96)00459-4; STUMMER W, 1994, STROKE, V25, P1862, DOI 10.1161/01.STR.25.9.1862; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; van Praag H, 1999, NAT NEUROSCI, V2, P266, DOI 10.1038/6368; Vanravenswaaijarts CMA, 1993, ANN INTERN MED, V118, P436, DOI 10.7326/0003-4819-118-6-199303150-00008; Vissing J, 1996, J CEREBR BLOOD F MET, V16, P729, DOI 10.1097/00004647-199607000-00025; Weinstein AA, 2007, MED SCI SPORT EXER, V39, P735, DOI 10.1249/mss.0b013e31802f590c; Willer Barry, 2006, Curr Treat Options Neurol, V8, P415, DOI 10.1007/s11940-006-0031-9; Youngstedt SD, 2005, CLIN SPORT MED, V24, P355, DOI 10.1016/j.csm.2004.12.003; Zasler N., 1993, J HEAD TRAUMA REHAB, V8, P13, DOI 10.1097/00001199-199309000-00004	79	104	105	0	19	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2007	22	3					199	205					7	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	216NM	WOS:000249884800006	17917170				2022-02-06	
J	Stalnacke, BM				Stalnacke, B.-M.			Community integration, social support and life satisfaction in relation to symptoms 3 years after mild traumatic brain injury	BRAIN INJURY			English	Article						traumatic brain injury; brain concussion; community integration; life satisfaction; post-concussion symptoms; depression; post-traumatic stress disorder	QUALITY-OF-LIFE; POST-CONCUSSION SYMPTOMS; MINOR HEAD-INJURY; POSTTRAUMATIC-STRESS-DISORDER; NEURON-SPECIFIC ENOLASE; FOLLOW-UP; EVENT SCALE; HOROWITZS IMPACT; SERUM-LEVELS; ACUTE-PHASE	Primary objective: To investigate the relation between psychosocial functioning ( community integration, life satisfaction and social support) and symptoms ( post-concussion, post-traumatic stress and depression) in persons with mild traumatic brain injury ( MTBI) 3 years after the trauma. Methods: Population-based follow-up study of 163 patients. At follow-up, an assessment of community integration, social support, life satisfaction and symptoms was made. Results: Total score of Community Integration Questionnaire ( CIQ) was negatively correlated to total score of the Rivermead Post-Concussion Symptoms Questionnaire ( RPQ, r=- 0.270, p < 0.001) and to total score of the Beck Depression Inventory ( BDI, r=- 0.332, p < 0.001). Life satisfaction ( LiSat- 11) was negatively correlated to the RPQ ( r=- 0.459, p < 0.001), to total score of the Impact of Event Scale ( IES, r=- 0.365, p < 0.001) and to the BDI ( r=- 0.642, p < 0.001). Low levels of life satisfaction were common at follow-up. Conclusions: A large proportion of the individuals with MTBI experienced both psychosocial difficulties, with low levels of life satisfaction in particular and symptoms ( post- concussion, post- traumatic stress and depression) 3 years after trauma. Since the possibility of pre-injury factors contributing to the condition at follow-up cannot be ruled out, the study indicates that all these factors should be taken into consideration in the management of persons with MTBI.	Umea Univ, Umea Univ Hosp, Dept Community Med & Rehabil Rehabil Med, SE-90185 Umea, Sweden		Stalnacke, BM (corresponding author), Umea Univ, Umea Univ Hosp, Dept Community Med & Rehabil Rehabil Med, Bldg 9A, SE-90185 Umea, Sweden.	stalnacke@rehabmed.umu.se					Anke AGW, 2003, CLIN REHABIL, V17, P431, DOI 10.1191/0269215503cr629oa; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Beck A.T., 1996, BDI BECK DEPRESSION; BECK AT, 1984, J CLIN PSYCHOL, V40, P1365, DOI 10.1002/1097-4679(198411)40:6<1365::AID-JCLP2270400615>3.0.CO;2-D; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BOHNEN N, 1992, INT J NEUROSCI, V64, P97, DOI 10.3109/00207459209000536; Bryant RA, 2001, J CLIN EXP NEUROPSYC, V23, P718, DOI 10.1076/jcen.23.6.718.1024; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; Dijkers M, 1997, J HEAD TRAUMA REHAB, V12, P74, DOI 10.1097/00001199-199712000-00007; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; Evans CC, 2005, J HEAD TRAUMA REHAB, V20, P488, DOI 10.1097/00001199-200511000-00002; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; Fleming J, 1999, BRAIN INJURY, V13, P417; Fugl-Meye KS., 1991, CLIN REHABIL, V5, P25, DOI [10.1177/026921559100500105, DOI 10.1177/026921559100500105]; Fugl-Meyer AR, 2002, J REHABIL MED, V34, P239, DOI 10.1080/165019702760279242; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; Goranson TE, 2003, BRAIN INJURY, V17, P759, DOI 10.1080/0269905031000088513; Greenspan AI, 2006, BRAIN INJURY, V20, P733, DOI 10.1080/02699050600773276; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; High WM, 2006, ARCH PHYS MED REHAB, V87, P334, DOI 10.1016/j.apmr.2005.11.028; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; HOUSE JS, 1988, SCIENCE, V241, P540, DOI 10.1037/0003-066X.59.8.676; Johansson U, 2003, BRAIN INJURY, V17, P991, DOI 10.1080/0269905031000110508; Joseph S, 2000, J TRAUMA STRESS, V13, P101, DOI 10.1023/A:1007777032063; Kalpakjian CZ, 2004, AM J PHYS MED REHAB, V83, P255, DOI 10.1097/01.PHM.0000118033.07952.8C; KARLSSON J, 1995, J CLIN EPIDEMIOL, V48, P817, DOI 10.1016/0895-4356(94)00196-W; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1999, BRIT J CLIN PSYCHOL, V38, P15, DOI 10.1348/014466599162638; Kinsella G, 1989, Int Disabil Stud, V11, P9; KRAUS JF, 1989, MILD MODERATE HEAD I, P9; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; Paniak C, 1999, J HEAD TRAUMA REHAB, V14, P211, DOI 10.1097/00001199-199906000-00002; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Reistetter Timothy A, 2005, Occup Ther Int, V12, P196; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rothweiler B, 1998, ARCH PHYS MED REHAB, V79, P881, DOI 10.1016/S0003-9993(98)90082-X; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Saeki S, 2006, J REHABIL MED, V38, P333, DOI 10.1080/16501970600780245; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; Sojka P, 2006, BRAIN INJURY, V20, P613, DOI 10.1080/02699050600676982; Stalnacke BM, 2005, J REHABIL MED, V37, P300, DOI 10.1080/16501970510032910; Sundin EC, 2003, PSYCHOSOM MED, V65, P870, DOI 10.1097/01.PSY.0000084835.46074.F0; Sundin EC, 2002, BRIT J PSYCHIAT, V180, P205, DOI 10.1192/bjp.180.3.205; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TEASDALE G, 1974, LANCET, V2, P81; Teasdale TW, 2005, BRAIN INJURY, V19, P1041, DOI 10.1080/02699050500110397; Tepper S, 1996, BRAIN INJURY, V10, P575, DOI 10.1080/026990596124142; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Tomberg T, 2005, BRAIN INJURY, V19, P1181, DOI 10.1080/02699050500150153; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009; Winkler D, 2006, J HEAD TRAUMA REHAB, V21, P8, DOI 10.1097/00001199-200601000-00002; Zhang L, 2002, J HEAD TRAUMA REHAB, V17, P497, DOI 10.1097/00001199-200212000-00002	64	104	104	0	16	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2007	21	9					933	942		10.1080/02699050701553189			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	202ZA	WOS:000248942600005	17729046				2022-02-06	
J	Heitger, MH; Jones, RD; Dalrymple-Alford, JC; Frampton, CM; Ardagh, MW; Anderson, TJ				Heitger, Marcus H.; Jones, Richard D.; Dalrymple-Alford, John C.; Frampton, Chris M.; Ardagh, Michael W.; Anderson, Tim J.			Motor deficits and recovery during the first year following mild closed head injury	BRAIN INJURY			English	Article						closed head injury; recovery; saccades; oculomotor smooth pursuit; upper-limb	TRAUMATIC BRAIN-INJURY; POST-CONCUSSION SYMPTOMS; POSITRON-EMISSION-TOMOGRAPHY; CORTICAL CONTROL; TECHNETIUM-99M-HMPAO SPECT; NEUROIMAGING FINDINGS; COMPUTED-TOMOGRAPHY; WORKING-MEMORY; EYE-MOVEMENT; DAMAGE	Objective: This study examined motor impairments over 1 year following mild closed head injury (CHI). It is the first study to serially assess long-term oculomotor and upper-limb visuomotor function following mild head trauma. Methods: Thirty-seven patients with mild CHI and 37 matched controls were compared at 1 week, 3 months and 6 months and 31 available pairs at 12 months post-injury on measures of saccades, oculomotor smooth pursuit, upper-limb visuomotor function and neuropsychological performance. Symptomatic recovery was sampled using the Rivermead Postconcussion Symptoms Questionnaire. Results: At 1 week, the group with CHI reported high levels of post-concussional symptoms and exhibited prolonged saccade latencies, increased directional errors, decreased saccade accuracy and impaired fast sinusoidal smooth pursuit concomitant with increased arm movement reaction time, decreased arm movement speed and decreased motor accuracy on upper-limb visuomotor tracking tasks. Neuropsychological testing identified deficits only in verbal learning and speed of processing while attention, short-term/working memory and general cognitive performance were preserved. At 3 and 6 months, the group with CHI continued to show deficits on several oculomotor and upper-limb visuomotor measures in combination with some deficits on verbal learning and improved, yet abnormal, levels of post-concussional symptoms. At 12 months, the group with CHI had no cognitive impairment but residual deficits in eye and arm motor function and continued to show elevated levels of post-concussional symptoms. Conclusions: The findings indicate that multiple motor systems are measurably impaired up to 12 months following mild CHI and that instrumented motor assessment may provide sensitive and objective markers of cerebral dysfunction during recovery from mild head trauma independent of neuropsychological assessment and patient self-report.	Van Veer Inst Parkinsons & Brain Res, Christchurch, New Zealand; Christchurch Sch Med & Hlth Sci, Dept Med, Christchurch, New Zealand; Christchurch Hosp, Dept Med Phys & Bioengn, Christchurch, New Zealand; Univ Canterbury, Dept Psychol, Christchurch 1, New Zealand; Christchurch Hosp, Dept Emergency, Christchurch, New Zealand; Christchurch Hosp, Dept Neurol, Christchurch, New Zealand		Heitger, MH (corresponding author), Van Veer Inst Parkinsons & Brain Res, 16 St Asaph St, Christchurch, New Zealand.	marcus.heitger@chmeds.ac.nz		Jones, Richard/0000-0003-2287-3358			Abu-Judeh HH, 1999, NUCL MED COMMUN, V20, P505, DOI 10.1097/00006231-199906000-00003; Anderson CV, 1995, J CLIN EXP NEUROPSYC, V17, P900, DOI 10.1080/01688639508402438; ANDERSON TJ, 1994, BRAIN, V117, P1073, DOI 10.1093/brain/117.5.1073; Arbuthnott K, 2000, J CLIN EXP NEUROPSYC, V22, P518, DOI 10.1076/1380-3395(200008)22:4;1-0;FT518; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; *CDCP NAT CTR INJ, 1999, TRAUM BRAIN INJ US R; Chen SHA, 2003, J NEUROL NEUROSUR PS, V74, P326, DOI 10.1136/jnnp.74.3.326; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; Delis DC, 1987, CALIFORNIA VERBAL LE; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; DISTEFANO G, 1995, ACTA NEUROL SCAND, V91, P346; Ellermann JM, 1998, J MAGN RESON, V131, P272, DOI 10.1006/jmre.1998.1379; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GRAY BG, 1992, J NUCL MED, V33, P52; Graziano MSA, 2002, NEURON, V36, P349, DOI 10.1016/S0896-6273(02)01003-6; Gronwall D, 1989, MILD HEAD INJURY, P153; GRONWALL DMA, 1977, PACED AUDITORY SERIA; HAALAND KY, 1994, J CLIN EXP NEUROPSYC, V16, P448, DOI 10.1080/01688639408402655; HAGGARD P, 1995, J NEUROL NEUROSUR PS, V58, P433, DOI 10.1136/jnnp.58.4.433; Hamzei F, 2002, EXP BRAIN RES, V146, P273, DOI 10.1007/s00221-002-1139-0; Heitger MH, 2005, BRAIN INJURY, V19, P109, DOI 10.1080/02699050410001720095; Heitger MH, 2004, BRAIN, V127, P575, DOI 10.1093/brain/awh066; Heitger MH, 2002, PROG BRAIN RES, V140, P433; Hills EC, 1998, BRAIN INJURY, V12, P69, DOI 10.1080/026990598122872; Hofman PAM, 2002, J NEUROPSYCH CLIN N, V14, P176, DOI 10.1176/appi.neuropsych.14.2.176; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Jacobs A, 1996, J NUCL MED, V37, P1605; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Jones R D, 1981, Int Rehabil Med, V3, P71; JONES RD, 2000, BIOMEDICAL ENG HDB, P1; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; KRAUS JF, 1989, MILD HEAD INJURY, P8; Kuhtz-Buschbeck JP, 2003, ARCH PHYS MED REHAB, V84, P424, DOI 10.1053/apmr.2003.50017; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Mallinson AI, 1998, AM J OTOL, V19, P809; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McGregor K, 1997, SOC SCI MED, V45, P295, DOI 10.1016/S0277-9536(96)00345-0; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; Muir S. R., 2003, Australasian Physical & Engineering Sciences in Medicine, V26, P18; OMMAYA AK, 1995, J NEUROTRAUM, V12, P527, DOI 10.1089/neu.1995.12.527; Perbal S, 2003, NEUROPSYCHOLOGIA, V41, P1599, DOI 10.1016/S0028-3932(03)00110-6; Pierrot-Deseilligny C, 2003, PROG BRAIN RES, V142, P3; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Prigatano GP, 1999, REHABIL PSYCHOL, V44, P145, DOI 10.1037/0090-5550.44.2.145; Psychological Corporation, 1999, WECHSL ABBR SCAL INT; Radanov BP, 1999, J NEUROL NEUROSUR PS, V66, P485, DOI 10.1136/jnnp.66.4.485; Reitan RM, 2003, ARCH CLIN NEUROPSYCH, V18, P11, DOI 10.1016/S0887-6177(01)00177-9; REULEN JPH, 1988, MED BIOL ENG COMPUT, V26, P20, DOI 10.1007/BF02441823; Richardson JTE., 2000, CLIN NEUROPSYCHOLOGI; Ruffolo LF, 2000, CLIN NEUROPSYCHOL, V14, P223, DOI 10.1076/1385-4046(200005)14:2;1-Z;FT223; Savola O, 2003, EUR J NEUROL, V10, P175, DOI 10.1046/j.1468-1331.2003.00552.x; Sherman EMS, 1997, CLIN NEUROPSYCHOL, V11, P34, DOI 10.1080/13854049708407027; SIETSEMA JM, 1993, AM J OCCUP THER, V47, P19, DOI 10.5014/ajot.47.1.19; Smith, 1973, SYMBOL DIGIT MODALIT; Spreen O, 1991, COMPENDIUM NEUROPSYC; SWAINE BR, 1992, ARCH PHYS MED REHAB, V73, P55; Sweeney JA, 1996, J NEUROPHYSIOL, V75, P454, DOI 10.1152/jn.1996.75.1.454; Umile EM, 1998, BRAIN INJURY, V12, P577; Wiegner S, 1999, J CLIN EXP NEUROPSYC, V21, P159, DOI 10.1076/jcen.21.2.159.925; Williams IM, 1997, J CLIN NEUROSCI, V4, P186, DOI 10.1016/S0967-5868(97)90072-2; Wrightson P, 1998, NEW ZEAL MED J, V111, P99	71	104	104	1	28	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	2006	20	8					807	824		10.1080/02699050600676354			18	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	081ZO	WOS:000240356300004	17060148	Green Accepted			2022-02-06	
J	Ziino, C; Ponsford, J				Ziino, Carlo; Ponsford, Jennie			Selective attention deficits and subjective fatigue following traumatic brain injury	NEUROPSYCHOLOGY			English	Article						brain injury; fatigue; attention	CLOSED-HEAD-INJURY; DUAL-TASK PERFORMANCE; REACTION-TIME; SCALE; VALIDITY; ANXIETY	The present study aimed to investigate the relationship between subjective fatigue and selective attention deficits following traumatic brain injury (TBI). Forty-six participants with mild-severe TBI and 46 healthy controls completed fatigue scales (Visual Analogue Scale - Fatigue, Fatigue Severity Scale [FSS] and Causes of Fatigue Questionnaire [COF]), and attentional measures including subtests from the Test of Everyday Attention, and the Complex Selective Attention Task (C-SAT). TBI participants reported greater fatigue on the FSS and COF, performed more slowly on attentional measures, and made more errors on the C-SAT. After controlling for anxiety and depression, fatigue was significantly correlated with performance only on the C-SAT. Findings suggest a relationship between subjective fatigue and impairment on tasks requiring higher order attentional processes.	Monash Univ, Dept Psychol, Clayton, Vic 3800, Australia		Ziino, C (corresponding author), Monash Univ, Dept Psychol, Clayton Campus,POB 17, Clayton, Vic 3800, Australia.	Carlo.Ziino@med.monash.edu.au					Annett J, 2002, ERGONOMICS, V45, P966, DOI 10.1080/00140130210166951; AVIES DR, 1984, VARIEITES ATTENTION, P395; Azouvi P, 1996, J CLIN EXP NEUROPSYC, V18, P317, DOI 10.1080/01688639608408990; Bate AJ, 2001, CLIN NEUROPSYCHOL, V15, P405, DOI 10.1076/clin.15.3.405.10279; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; BROUWER WH, 1989, CORTEX, V25, P219, DOI 10.1016/S0010-9452(89)80038-3; Caci H, 2003, PSYCHIAT RES, V118, P89, DOI 10.1016/S0165-1781(03)00044-1; Chan RCK, 2000, BRAIN INJURY, V14, P227, DOI 10.1080/026990500120709; Ferraccioli G, 1996, J RHEUMATOL, V23, P1539; Harter M, 2001, DISABIL REHABIL, V23, P737; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; Leclercq M, 2000, J CLIN EXP NEUROPSYC, V22, P339, DOI 10.1076/1380-3395(200006)22:3;1-V;FT339; LEE KA, 1991, PSYCHIAT RES, V36, P291, DOI 10.1016/0165-1781(91)90027-M; LEWIS G, 1992, J EPIDEMIOL COMMUN H, V46, P92, DOI 10.1136/jech.46.2.92; MCKINLAY WW, 1983, J NEUROL NEUROSUR PS, V46, P1084, DOI 10.1136/jnnp.46.12.1084; Meek PM, 2000, NURS RES, V49, P181, DOI 10.1097/00006199-200007000-00001; NELSON HE, 1994, NATL ADULT READING T; NORMAN A, 1986, CONSCIOUSNESS SELF R, V4; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Park NW, 1999, NEUROPSYCHOLOGIA, V37, P1119, DOI 10.1016/S0028-3932(99)00034-2; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; PONSFORD J, 1991, NEUROPSYCHOL REHABIL, P241; POSNER MI, 1971, PSYCHOL REV, V78, P391, DOI 10.1037/h0031333; Ream E, 1996, INT J NURS STUD, V33, P519, DOI 10.1016/0020-7489(96)00004-1; ROA V, 2002, CURRENT TREATMENT OP, V4, P77; Robertson I., 1994, TEST EVERYDAY ATTENT; Robertson I H, 1996, J Int Neuropsychol Soc, V2, P525; Segalowitz S J, 1997, J Int Neuropsychol Soc, V3, P95; SHIFFRIN RM, 1977, PSYCHOL REV, V84, P127, DOI 10.1037/0033-295X.84.2.127; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; SMETS EMA, 1993, BRIT J CANCER, V68, P220, DOI 10.1038/bjc.1993.319; Smith, 1973, SYMBOL DIGIT MODALIT; Snaith R., 1994, HOSP ANXIETY DEPRESS; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Spikman JM, 2000, J CLIN EXP NEUROPSYC, V22, P325, DOI 10.1076/1380-3395(200006)22:3;1-V;FT325; Sturm W, 2001, NEUROIMAGE, V14, pS76, DOI 10.1006/nimg.2001.0839; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; SUSS DT, 1986, FRONTAL LOBES; Thaxton L, 2002, J HEAD TRAUMA REHAB, V17, P335, DOI 10.1097/00001199-200208000-00007; TROMP E, 1991, J CLIN EXP NEUROPSYC, V13, P821, DOI 10.1080/01688639108405100; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; VANZOMEREN AH, 1984, CLOSED HEAD INJURY P; VANZOMEREN AH, 1987, NEUROBEHAVIOURAL REC; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357; Winstead-Fry P, 1998, J Nurs Meas, V6, P111; Zahn TP, 1999, J CLIN EXP NEUROPSYC, V21, P352, DOI 10.1076/jcen.21.3.352.924; Ziino C, 2005, J INT NEUROPSYCH SOC, V11, P416, DOI 10.1017/S1355617705050472	50	104	105	0	13	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	MAY	2006	20	3					383	390		10.1037/0894-4105.20.3.383			8	Psychology, Clinical; Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	047UN	WOS:000237904300013	16719631				2022-02-06	
J	Solaroglu, I; Cahill, J; Jadhav, V; Zhang, JH				Solaroglu, I; Cahill, J; Jadhav, V; Zhang, JH			A novel neuroprotectant granulocyte-colony stimulating factor	STROKE			English	Article						granulocyte-colony stimulating factor; growth factor; neuroprotection; stem cell; stroke	FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; TUMOR-NECROSIS-FACTOR; FACTOR G-CSF; PROGENITOR CELLS; FACTOR-RECEPTOR; STEM-CELLS; BCL-2 EXPRESSION; STROKE; ACTIVATION	Background and Purpose - Granulocyte-colony stimulating factor (G-CSF) is a growth factor that orchestrates the proliferation, differentiation, and survival of hematopoietic progenitor cells. It has been used for many years in clinical practice to accelerate the recovery of patients from neutropenia after cytotoxic therapy. However, there is a growing body of evidence from experimental studies suggesting that G-CSF also has important nonhematopoietic functions in the central nervous system. Summary of Review - The presence of the G-CSF/G-CSF-receptor system in the brain and its role in neuroprotection and neural tissue repair has been investigated in many recent studies. The neuroprotective actions of G-CSF have mainly been attributed to its anti-inflammatory and antiapoptotic effects. Furthermore, it induces neurogenesis and angiogenesis and improves functional recovery. In this review, we summarize the role of G-CSF and the corresponding signal transduction pathways regulated by G-CSF in neuroprotection. Conclusions - Much additional work is needed to better understand the precise mechanisms of G-CSF - induced neuroprotection. However, there is emerging data suggesting that G-CSF is a potential new agent for neuroprotection.	Loma Linda Univ, Med Ctr, Div Neurosurg, Sch Med, Loma Linda, CA 92354 USA; Loma Linda Univ, Sch Med, Dept Physiol & Pharmacol, Loma Linda, CA 92354 USA; Loma Linda Univ, Sch Med, Dept Anesthesiol, Loma Linda, CA 92354 USA		Zhang, JH (corresponding author), Loma Linda Univ, Med Ctr, Div Neurosurg, Sch Med, 11234 Anderson St,Room 2562B, Loma Linda, CA 92354 USA.	johnzhang3910@yahoo.com	Solaroglu, Ihsan/ABE-8816-2020; Cahill, Julian/M-1916-2019; Solaroglu, Ihsan/ABF-7606-2020	Solaroglu, Ihsan/0000-0002-9472-1735; Cahill, Julian/0000-0003-0296-4412; Zhang, John H./0000-0002-4319-4285	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD043120] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045694, R01NS043338] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD43120] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS43338, NS45694] Funding Source: Medline		ALOISI F, 1992, J IMMUNOL, V149, P2358; Barone FC, 1999, J CEREBR BLOOD F MET, V19, P819, DOI 10.1097/00004647-199908000-00001; BENSINGER WI, 1995, BLOOD, V85, P1655, DOI 10.1182/blood.V85.6.1655.bloodjournal8561655; Boneberg EM, 2000, BLOOD, V95, P270, DOI 10.1182/blood.V95.1.270; BUDEL LM, 1989, BLOOD, V74, P2668; BUSSOLINO F, 1989, NATURE, V337, P471, DOI 10.1038/337471a0; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Carlsson G, 2004, BRIT J HAEMATOL, V126, P127, DOI 10.1111/j.1365-2141.2004.05008.x; DEL PL, 1997, SCIENCE, V278, P687; DEMETRI GD, 1991, BLOOD, V78, P2791; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Dong F, 2000, BLOOD, V95, P1656, DOI 10.1182/blood.V95.5.1656.005k29_1656_1662; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Fujio Y, 1999, MOL CELL BIOL, V19, P5073; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; Gibson CL, 2005, J CEREBR BLOOD F MET, V25, P431, DOI 10.1038/sj.jcbfm.9600033; Gibson CL, 2005, J NEUROPATH EXP NEUR, V64, P763, DOI 10.1097/01.jnen.0000179196.10032.dd; GRIGG AP, 1995, BLOOD, V86, P4437, DOI 10.1182/blood.V86.12.4437.bloodjournal86124437; HANAZONO Y, 1990, EXP HEMATOL, V18, P1097; Hunter MG, 1998, J IMMUNOL, V160, P4979; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Kaptanoglu E, 2004, NEUROSURG REV, V27, P113, DOI 10.1007/s10143-003-0300-y; Katakowski M, 2003, J NEUROSCI RES, V74, P494, DOI 10.1002/jnr.10775; Khan M, 2005, J CEREBR BLOOD F MET, V25, P177, DOI 10.1038/sj.jcbfm.9600012; Kim S, 2001, J BIOL CHEM, V276, P12864, DOI 10.1074/jbc.M001492200; Kleinschnitz C, 2004, MOL BRAIN RES, V131, P73, DOI 10.1016/j.molbrainres.2004.08.011; Kocherlakota P, 1997, PEDIATRICS, V100, part. no., DOI 10.1542/peds.100.1.e6; KOMINEKOBAYASHI M, 2005, J CEREB BLOOD F 0727; KONISHI Y, 1993, BRAIN RES, V609, P29, DOI 10.1016/0006-8993(93)90850-M; Lee H, 2003, FASEB J, V17, P1943, DOI 10.1096/fj.03-0057fje; Lee ST, 2005, BRAIN RES, V1058, P120, DOI 10.1016/j.brainres.2005.07.076; Levesque JP, 2003, J CLIN INVEST, V111, P187, DOI 10.1172/JCI200315994; Liu LD, 2003, P NATL ACAD SCI USA, V100, P8532, DOI 10.1073/pnas.1332804100; MALIPIERO UV, 1990, J IMMUNOL, V144, P3816; Morikawa K, 2002, BRIT J HAEMATOL, V118, P296, DOI 10.1046/j.1365-2141.2002.03574.x; Park HK, 2005, BRAIN RES, V1041, P125, DOI 10.1016/j.brainres.2004.11.067; Peng H, 2004, J NEUROSCI RES, V76, P35, DOI 10.1002/jnr.20045; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; QUAGLIARELLO VJ, 1991, J CLIN INVEST, V87, P1360, DOI 10.1172/JCI115140; Robin AM, 2006, J CEREBR BLOOD F MET, V26, P125, DOI 10.1038/sj.jcbfm.9600172; ROSENMAN SJ, 1995, J IMMUNOL, V154, P1888; Schabitz WR, 2003, STROKE, V34, P745, DOI 10.1161/01.STR.0000057814.70180.17; Schabitz WR, 2000, STROKE, V31, P2212, DOI 10.1161/01.STR.31.9.2212; Schneider A, 2005, J CLIN INVEST, V115, P2083, DOI 10.1172/JCI23559; Sheibani N, 2004, CRIT CARE MED, V32, P2274, DOI 10.1097/01.CCM.0000145998.11686.ED; SHIMODA K, 1993, J CLIN INVEST, V91, P1310, DOI 10.1172/JCI116330; Shimoda K, 1997, BLOOD, V90, P597, DOI 10.1182/blood.V90.2.597.597_597_604; Shyu WC, 2004, CIRCULATION, V110, P1847, DOI 10.1161/01.CIR.0000142616.07367.66; Six I, 2003, EUR J PHARMACOL, V458, P327, DOI 10.1016/S0014-2999(02)02785-1; Solaroglu I, 2003, CHILD NERV SYST, V19, P19, DOI 10.1007/s00381-002-0680-2; Stumm RK, 2002, J NEUROSCI, V22, P5865; Tehranchi R, 2003, BLOOD, V101, P1080, DOI 10.1182/blood-2002-06-1774; TIAN SS, 1994, BLOOD, V84, P1760; Wang L, 2005, J CEREBR BLOOD F MET, V25, P1150, DOI 10.1038/sj.jcbfm.9600112; Ward AC, 2000, LEUKEMIA, V14, P973, DOI 10.1038/sj.leu.2401808; Watson FL, 2001, NAT NEUROSCI, V4, P981, DOI 10.1038/nn720; Wells JA, 1996, ANNU REV BIOCHEM, V65, P609, DOI 10.1146/annurev.bi.65.070196.003141; Welte K, 1996, BLOOD, V88, P1907, DOI 10.1182/blood.V88.6.1907.bloodjournal8861907; Whalen MJ, 2000, CRIT CARE MED, V28, P3710, DOI 10.1097/00003246-200011000-00029; Zavala F, 2002, J IMMUNOL, V168, P2011, DOI 10.4049/jimmunol.168.4.2011	61	104	109	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	APR	2006	37	4					1123	1128		10.1161/01.STR.0000208205.26253.96			6	Clinical Neurology; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Cardiovascular System & Cardiology	025UJ	WOS:000236292100044	16514095	Green Published, Bronze			2022-02-06	
J	Parcell, DL; Ponsford, JL; Rajaratnam, SM; Redman, JR				Parcell, DL; Ponsford, JL; Rajaratnam, SM; Redman, JR			Self-reported changes to nighttime sleep after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						anxiety; brain injuries; depression; rehabilitation; sleep	EXCESSIVE DAYTIME SLEEPINESS; LATENCY TEST MSLT; DEPRESSION SCALE; HOSPITAL ANXIETY; INSOMNIA; VALIDATION; DISORDERS; APNEA; POPULATIONS; RELIABILITY	Objectives: To explore subjective sleep reports from people in the chronic stages of traumatic brain injury (TBI) and to examine the extent and nature of sleep complaints in this population. Design: Survey. Setting: All participants were community based at the time of data collection. Participants: Sixty-three subjects with TBI consecutively recruited after discharge from rehabilitation and 63 age- and sex-matched controls from the general community. Interventions: Not applicable. Main Outcome Measures: A 7-day self-reported sleep-wake diary assessing sleep and wake times, sleep onset latency, frequency, and duration of nocturnal awakenings and daytime naps; a general sleep questionnaire used to evaluate sleep changes and quality; and the Epworth Sleepiness Scale to measure daytime sleepiness. Results: Group-wise comparisons showed a significantly higher frequency of reported sleep changes after TBI (80%) relative to the control group (23%), supporting previous findings. The TBI group reported more nighttime awakenings and longer sleep onset latency; these changes were more frequently reported by participants with TBI with milder injuries. Increased levels of anxiety and depression were associated with increased reporting of sleep changes. Conclusions: These findings confirm the experience of changes to sleep after TBI and may at least in part account for the reported increased daytime sleepiness in this population. Sleep disturbance should be addressed during rehabilitation. Treatments need to focus on correcting the underlying cause of the sleep problem and to address patients' subjective experiences of their sleep, possibly through education and mood stabilization.	Monash Univ, Sch Psychol Psychiat & Psychol Med, Melbourne, Vic 3800, Australia; Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia		Ponsford, JL (corresponding author), Monash Univ, Sch Psychol Psychiat & Psychol Med, POB 17, Melbourne, Vic 3800, Australia.	jennie.ponsford@med.monash.edu.au	Rajaratnam, Shantha/D-8144-2012; Sanguansri, Luz/B-6630-2011	Sanguansri, Luz/0000-0003-1908-7604; Rajaratnam, Shantha/0000-0001-7527-8558			American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Anch A. M., 1988, SLEEP SCI PERSPECTIV; Armitage R, 2001, SLEEP MED REV, V5, P237, DOI 10.1053/smrv.2000.0144; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; Benca R. M., 2000, PRINCIPLES PRACTICE, P1140; BLIWISE DL, 2000, PRINCIPLES PRACTICE, P26; Boivin DB, 2003, NEUROLOGY, V60, P1841, DOI 10.1212/01.WNL.0000061482.24750.7C; Braekeland F, 1971, ARCH GEN PSYCHIAT, V24, P548; Briones B, 1996, SLEEP, V19, P583, DOI 10.1093/sleep/19.7.583; CARSKADON MA, 1986, SLEEP, V9, P519, DOI 10.1093/sleep/9.4.519; Castriotta RJ, 2001, ARCH PHYS MED REHAB, V82, P1403, DOI 10.1053/apmr.2001.26081; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; COHEN M, 1992, J NEUROL NEUROSUR PS, V55, P313, DOI 10.1136/jnnp.55.4.313; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; Evans BM, 2002, J ROY SOC MED, V95, P591, DOI 10.1258/jrsm.95.12.591; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Fichtenberg NL, 2000, BRAIN INJURY, V14, P659; Fichtenberg NL, 2002, BRAIN INJURY, V16, P197, DOI 10.1080/02699050110103940; Flashman LA, 2002, NEUROREHABILITATION, V17, P285; GUILLEMINAULT C, 1983, NEUROLOGY, V33, P1584, DOI 10.1212/WNL.33.12.1584; Hauri P., 1977, CURRENT CONCEPTS SLE; Herrmann C, 1997, J PSYCHOSOM RES, V42, P17, DOI 10.1016/S0022-3999(96)00216-4; JOHNS MW, 1992, SLEEP, V15, P376, DOI 10.1093/sleep/15.4.376; JOHNS MW, 1993, CHEST, V103, P30, DOI 10.1378/chest.103.1.30; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Johns MW, 2000, J SLEEP RES, V9, P5, DOI 10.1046/j.1365-2869.2000.00177.x; Johnston M, 2000, J PSYCHOSOM RES, V48, P579, DOI 10.1016/S0022-3999(00)00102-1; Jorge R, 2002, NEUROREHABILITATION, V17, P311; Khan F, 2003, MED J AUSTRALIA, V178, P290, DOI 10.5694/j.1326-5377.2003.tb05199.x; Lockley SW, 2004, NEW ENGL J MED, V351, P1829, DOI 10.1056/NEJMoa041404; Lockley SW, 1999, J SLEEP RES, V8, P175, DOI 10.1046/j.1365-2869.1999.00155.x; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; MCCALL WV, 1995, SLEEP, V18, P646, DOI 10.1093/sleep/18.8.646; Means MK, 2003, SLEEP MED, V4, P285, DOI 10.1016/S1389-9457(03)00057-1; Monk TH, 2000, CHRONOBIOL INT, V17, P49, DOI 10.1081/CBI-100101031; MONROE LJ, 1967, J ABNORM PSYCHOL, V72, P255, DOI 10.1037/h0024563; Ouellet MC, 2004, NEUROREHAB NEURAL RE, V18, P187, DOI 10.1177/1545968304271405; Parkes JD, 1998, J SLEEP RES, V7, P41, DOI 10.1046/j.1365-2869.1998.00093.x; PARSONS LC, 1982, NURS RES, V31, P260; Phipps-Nelson J, 2003, SLEEP, V26, P695, DOI 10.1093/sleep/26.6.695; PONSFORD J, 1995, TRAUMATIC BRAIN INJU, P1; Prigatano G.P., 1991, J HEAD TRAUMA REHAB, V6, P1, DOI [10.1097/00001199-199112000-00004, DOI 10.1097/00001199-199112000-00004]; Quinto C, 2000, NEUROLOGY, V54, P250, DOI 10.1212/WNL.54.1.250; Rao Vani, 2002, Curr Treat Options Neurol, V4, P77, DOI 10.1007/s11940-002-0006-4; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; Riemann D, 2001, BIOL PSYCHOL, V57, P67, DOI 10.1016/S0301-0511(01)00090-4; ROGERS AE, 1993, NURS RES, V42, P368; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; SALINPASCUAL RJ, 1992, AM J PSYCHIAT, V149, P904; Sherer M, 2003, ARCH PHYS MED REHAB, V84, P168, DOI 10.1053/apmr.2003.50045; Shiffman S., 2001, APPL CLIN TRIALS, V10, P46; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Steele DL, 2005, CHRONOBIOL INT, V22, P89, DOI 10.1081/CBI-200042428; Stone AA, 2002, BMJ-BRIT MED J, V324, P1193, DOI 10.1136/bmj.324.7347.1193; Thaxton L, 2002, J HEAD TRAUMA REHAB, V17, P335, DOI 10.1097/00001199-200208000-00007; UHDE TW, 2000, PRINCIPLES PRACTICE, P1123; Vanable PA, 2000, SLEEP, V23, P71; Voderholzer U, 2003, DEPRESS ANXIETY, V17, P162, DOI 10.1002/da.10101; WIGGINS CL, 1990, SLEEP, V13, P245, DOI 10.1093/sleep/13.3.245; Wilson KG, 1998, PAIN, V75, P75, DOI 10.1016/S0304-3959(97)00207-8; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	63	104	105	0	9	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	2006	87	2					278	285		10.1016/j.apmr.2005.10.024			8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	013CJ	WOS:000235386900021	16442985				2022-02-06	
J	Howe, JA; Inness, EL; Venturini, A; Williams, JI; Verrier, MC				Howe, J. A.; Inness, E. L.; Venturini, A.; Williams, J. I.; Verrier, M. C.			The Community Balance and Mobility Scale - a balance measure for individuals with traumatic brain injury	CLINICAL REHABILITATION			English	Article							HEAD-INJURY; SWAY; WALKING; GAIT	Objective: To provide evidence for the validity and reliability of a new outcome measure of balance, the Community Balance and Mobility Scale, developed for the ambulatory individual with traumatic brain injury. Design: A validity and reliability study. Setting: Acute care, in- and outpatient rehabilitation and day hospital settings. Subjects: Two convenience samples (n = 36, 32) of ambulatory patients with traumatic brain injury. Main measures: The content and construct validity, test-retest, inter- and intra-rater reliability and internal consistency of the Community Balance and Mobility Scale. Results: Content validity was demonstrated by the involvement of patients with traumatic brain injury (n = 7) and clinicians (n = 17) in the process of item generation and by physical therapists' ratings of item relevance. Further support is the correlation of the Community Balance and Mobility Scale scores with physical therapists' global balance ratings of the patient (r = 0.62). Construct validity was supported by the ability of the measure to differentiate between patients along the continuum of care and also by comparisons with maximal walking velocity (r= 0.64). Patients who scored greater than or less than 50 on the balance measure demonstrated significantly different Community Integration Questionnaire scores (P = 0.004). The Community Balance and Mobility Scale demonstrated intraclass correlation coefficients (ICCs) of 0.977, 0.977, 0.975 and Cronbach's alpha of 0.96 for intra-, inter-, test-retest reliability and internal consistency, respectively. Conclusion: The Community Balance and Mobility Scale is a valid and reliable outcome measure for the ambulatory individual with traumatic brain injury.	Toronto Rehabil Inst, Toronto, ON M5G 2A2, Canada; Univ Toronto, Fac Med, Dept Phys Therapy, Toronto, ON, Canada; Univ Toronto, Fac Med, Grad Dept Rehabil Sci, Toronto, ON, Canada		Howe, JA (corresponding author), Toronto Rehabil Inst, 550 Univ Ave, Toronto, ON M5G 2A2, Canada.	howe.jo-anne@torontorehab.on.ca		Inness, Elizabeth L./0000-0002-9217-4619			Altman D.G., 1990, PRACTICAL STAT MED R; Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; BERG K, 1989, Physiotherapy Canada, V41, P304; Colton T, 1974, STAT MED; Dean S, 2000, PSYCHOL REP, V86, P653, DOI 10.2466/pr0.2000.86.2.653; FLEISS JL, 1978, PSYCHOMETRIKA, V43, P259, DOI 10.1007/BF02293867; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Hillier SL, 1997, BRAIN INJURY, V11, P661; LEHMANN JF, 1990, ARCH PHYS MED REHAB, V71, P955; McFadyen BJ, 2003, J HEAD TRAUMA REHAB, V18, P512, DOI 10.1097/00001199-200311000-00005; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; NIECHWIEJSZWEDO E, 2006, IN PRESS GAIT POSTUR; Nunnally JC., 1978, PSYCHOMETRIC THEORY, V2; OBERG T, 1993, J REHABIL RES DEV, V30, P210; PERRY J, 1995, STROKE, V26, P982, DOI 10.1161/01.STR.26.6.982; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Swaine BR, 1996, BRAIN INJURY, V10, P347, DOI 10.1080/026990596124368; Wade LD, 1997, ARCH PHYS MED REHAB, V78, P1107, DOI 10.1016/S0003-9993(97)90136-2; Willems D, 1996, PHYSIOTHER CAN, V48, P179; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009; WOBER C, 1993, ARCH PHYS MED REHAB, V74, P1151; WONG P, 1999, BRAIN INJURY, V7, P283	23	104	105	0	3	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2155			CLIN REHABIL	Clin. Rehabil.		2006	20	10					885	895		10.1177/0269215506072183			11	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	098YG	WOS:000241559100005	17008340				2022-02-06	
J	Pellman, EJ; Lovell, MR; Viano, DC; Casson, IR; Tucker, AM				Pellman, EJ; Lovell, MR; Viano, DC; Casson, IR; Tucker, AM			Concussion in professional football: Neuropsychological testing - Part 6	NEUROSURGERY			English	Article						concussion; neuropsychological testing; sport injury; traumatic brain injury	HIGH-SCHOOL; HEAD-INJURY; SPORTS; RECOVERY; PERFORMANCE; PLAYERS; IMPACTS	OBJECTIVE: The National Football League (NFL) neuropsychological testing program is reviewed, and neuropsychological test data are presented on various samples of NFL athletes who sustained concussion (mild traumatic brain injury, MTBI). METHODS: This study evaluated post-MTBI neuropsychological testing of NFL players from 1996 to 2001. All athletes completed a standardized battery of neuropsychological tests and underwent postinjury neuropsychological testing within a few days after concussion. Test scores were compared with baselines using analysis of variance for athletes having on-field memory dysfunction, three or more concussions, or 7+ days out from practice and play. RESULTS: The MTBI group did not display significant neuropsychological dysfunction relative to baseline scores within a few days of injury. However, a subsample of the injured athletes who displayed on-field memory dysfunction performed significantly more poorly on two of the memory tests. The neuropsychological test results of a group of athletes with a history of three or more MTBIs did not differ significantly compared with a group who had fewer than three concussions or compared with league-wide normative data. The neuropsychological performance of athletes who were out from full participation 7+ days was not significantly different from the group who returned to play within 7 days or the norms. CONCLUSION: Neuropsychological testing is used within the overall medical evaluation and care of NFL athletes. Players who experience MTBI generally demonstrate rapid recovery of neuropsychological performance, although poorer neuropsychological test results were related to on-field memory dysfunction. NFL players did not demonstrate evidence of neurocognitive decline after multiple (three or more) MTBIs or in those players out 7+ days. The data show that MTBI in this population is characterized by a rapid return of neuropsychological function in the days after injury.	ProBiomech LLC, Bloomfield Hills, MI 48304 USA; Natl Football League, Mild Traumat Brain Injury Comm, New York, NY USA; ProHEALTH Care Associates LLP, Lake Success, NY USA; Univ Pittsburgh, Med Ctr, Dept Orthopaed & Sports Med, Pittsburgh, PA USA; Long Isl Jewish Med Ctr, Dept Neurol, New Hyde Pk, NY 11042 USA; NYU, Med Ctr, Dept Neurol, New York, NY 10016 USA; Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10467 USA; Univ Maryland, Sch Med, Lutherville Timonium, MD USA		Viano, DC (corresponding author), ProBiomech LLC, 265 Warrington Rd, Bloomfield Hills, MI 48304 USA.	dviano@comcast.net					ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barr WB, 2003, ARCH CLIN NEUROPSYCH, V18, P91, DOI 10.1016/S0887-6177(01)00185-8; Barth JT, 1989, MILD HEAD INJURY; Benedict R., 1997, BRIEF VISUOSPATIAL M; Benton A., 1978, MULTILINGUAL APHASIA; Brandt J, 1991, CLIN NEUROPSYCHOL, V5, P125, DOI [10.1080/13854049108403297, DOI 10.1080/13854049108403297]; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; CASSON IR, 1984, JAMA-J AM MED ASSOC, V251, P2663, DOI 10.1001/jama.251.20.2663; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; Hovda DA, 1999, SPORTS-RELATED CONCUSSION, P12; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; LANG DA, 1994, J NEUROSURG, V80, P675, DOI 10.3171/jns.1994.80.4.0675; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Lovell MR, 1999, SPORTS-RELATED CONCUSSION, P200; LOVELL MR, 2000, NEUROLOGIC ATHLETIC, P109; LOVELL MR, 1996, 1 ANN SPORTS REL MIL; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; OLVEY S, 2002, NEW DEV SPORTS REL C; Pellman E, 2004, NEUROSURGERY, V55, P860, DOI 10.1227/01.NEU.0000137657.00146.7D; Pellman EJ, 2004, NEUROSURGERY, V55, P1100, DOI 10.1227/01.NEU.0000147063.12873.F5; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P797, DOI 10.1093/neurosurgery/53.3.797; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; ROSS RJ, 1983, JAMA-J AM MED ASSOC, V249, P211, DOI 10.1001/jama.249.2.211; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Smith A., 1982, SYMBOL DIGIT MODALIT; *STATS INC, 2001, STAT; SYMONDS C, 1962, LANCET, V1, P1; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; YARNELL PR, 1970, LANCET, V1, P863	45	104	104	0	25	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	DEC	2004	55	6					1290	1305		10.1227/01.NEU.0000149244.97560.91			16	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	878CB	WOS:000225623000008	15574211				2022-02-06	
J	Stone, JR; Okonkwo, DO; Dialo, AO; Rubin, DG; Mutlu, LK; Povlishock, JT; Helm, GA				Stone, JR; Okonkwo, DO; Dialo, AO; Rubin, DG; Mutlu, LK; Povlishock, JT; Helm, GA			Impaired axonal transport and altered axolemmal permeability occur in distinct populations of damaged axons following traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						traumatic axonal injury; diffuse axonal injury; traumatic brain injury; axolemmal permeability; impaired axonal transport; impact acceleration; dextran; rat	AMYLOID PRECURSOR PROTEIN; NEUROFILAMENT COMPACTION; RETROGRADE CONVERSION; CYCLOSPORINE-A; PROTEOLYSIS; MARKER; APP	Traumatic axonal injury (TAI) evolves within minutes to hours following traumatic brain injury (TBI). Previous studies have identified axolemmal disruption and impaired axonal transport (AxT) as key mechanisms in the evolution of TAL While initially hypothesized that axolemmal disruption culminates in impaired AxT, previous studies employed single-label methodologies that did not allow for a full determination of the spatial-temporal relationships of these two events. To explore directly the relationship between impaired AxT and altered axolemmal permeability, the current investigation employed 40, 10, and 3 kDa fluorescently conjugated dextrans as markers of axolemmal integrity, with antibodies targeting the anterogradely transported amyloid precursor protein (APP) utilized as a marker of impaired AxT. Rats underwent impact acceleration TBI and were intrathecally administered 40 kDa, 40 + 10 kDa or 40 + 3 kDa fluorescently tagged dextrans, with brains subsequently prepared for APP immunofluorescence. Brainstem corticospinal tracts (CSpT), medial lemnisci (ML), and medial longitudinal fasciculi were examined for evidence of TAL APP and all dextrans consistently localized to distinct classes of TAL Dextrans were noted as early as 5 min following injury within axonal segments demonstrating an irregular/tortuous appearance, and were seen within thin and elongate/vacuolated axons by 30 min-6 h following injury. APP, first noted within swollen axons at 30 min following injury, was found within progressively swollen axons that showed no dextran colocalization within 3 h of injury. However, by 6 h, dextrans colocalized in disconnected axonal bulbs. At this time-point, dextrans also persisted within single-labeled, highly vacuolated/thin, and elongate axons. These studies confirm that axolemmal disruption and impaired AxT occur as distinct non-related events early in the pathogenesis of TAL Further, these studies provide evidence that the process of impaired axonal transport and subsequent axonal disconnection leads to delayed axolemmal instability, rather than proceeding as a consequence of initial axolemmal failure. This finding underscores the need of multiple approaches to fully assess the axonal response to TBI. (C) 2004 Elsevier Inc. All rights reserved.	Univ Virginia, Dept Neurosurg, Charlottesville, VA 22908 USA; Virginia Commonwealth Univ, Dept Anat, Richmond, VA 23298 USA		Stone, JR (corresponding author), Univ Virginia Hlth Syst, Dept Neurosurg, POB 800212, Charlottesville, VA 22908 USA.	jrs7r@virginia.edu					Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Buki A, 2000, J NEUROSCI, V20, P2825; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; MARTZ D, 1989, BRAIN RES, V476, P199, DOI 10.1016/0006-8993(89)91559-X; MAX W, 1990, INQUIRY-J HEALTH CAR, V27, P332; Maxwell WL, 1999, J NEUROTRAUM, V16, P273, DOI 10.1089/neu.1999.16.273; Okonkwo DO, 1998, BRAIN RES, V784, P1, DOI 10.1016/S0006-8993(97)01075-5; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; Povlishock JT, 1996, ACT NEUR S, V66, P81; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; SAHENK Z, 1988, BRAIN RES, V460, P199, DOI 10.1016/0006-8993(88)91224-3; SHERRIFF FE, 1994, NEUROREPORT, V5, P1085, DOI 10.1097/00001756-199405000-00016; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Stone JR, 2002, J NEUROTRAUM, V19, P601, DOI 10.1089/089771502753754073; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001	28	104	106	0	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	NOV	2004	190	1					59	69		10.1016/j.expneurol.2004.05.022			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	867DJ	WOS:000224822100005	15473980				2022-02-06	
J	Anderson, RCE; Kan, P; Klimo, P; Brockmeyer, DL; Walker, ML; Kestle, JRW				Anderson, RCE; Kan, P; Klimo, P; Brockmeyer, DL; Walker, ML; Kestle, JRW			Complications of intracranial pressure monitoring in children with head trauma	JOURNAL OF NEUROSURGERY			English	Article						ventriculostomy; external ventricular drain; head trauma; intracranial pressure monitoring; fiberoptic monitor; children	INTRA-CRANICAL PRESSURE; VENTRICULOSTOMY-RELATED INFECTIONS; BRAIN-TISSUE PRESSURE; FIBEROPTIC DEVICE; CLINICAL-PRACTICE; AGGRESSIVE TREATMENT; RISK-FACTORS; INJURY; EXPERIENCE; MANAGEMENT	Object. Intracranial pressure (ICP) monitoring has become routine in the management of patients with traumatic brain injury (TBI). Many surgeons prefer to use external ventricular drains (EVDs) over fiberoptic monitors to measure ICP because of the added benefit of cerebrospinal fluid drainage. The purpose of this study was to examine a consecutive series of children with TBI and compare the incidence of complications after placement of an EVD, a fiberoptic intraparencyhmal monitor, or both. Methods. A retrospective chart review was conducted to identify children with TBI who met the criteria for insertion of an ICP monitor. All patients underwent head CT scanning on admission and after placement of an ICP monitor. During a 5-year period 80 children met the criteria for inclusion in the study. Eighteen children (22.5%) underwent EVD placement only, 18 (22.5%) underwent placement of a fiberoptic device only, and 44 (55%) received both. A total of 62 fiberoptic devices (48%) were inserted, and 68 EVDs (52%) were placed. Overall, there was a fourfold increased risk of complications in children who received an EVD compared with those in whom a fiberoptic monitor was placed (p = 0.004). Hemorrhagic complications were detected in 12 (17.6%) of 62 patients who received an EVD compared with four (6.5%) of 62 patients who received a fiberoptic monitor (p = 0.025). Six (8.8%) of 68 EVDs were malpositioned and required replacement; in three (50%) of these cases a hemorrhagic complication occurred. Only one infection was noted in a patient with an EVD (1.5%). Conclusions. In this retrospective cohort of pediatric patients with TBI, complication rates were significantly higher in those receiving EVDs than in those in whom fiberoptic monitors were placed. Although the majority of these complications did not entail clinical sequelae, surgeons should be aware of the different complication rates when choosing the most appropriate device for each patient.	Univ Utah, Primary Childrens Med Ctr, Dept Neurosurg, Salt Lake City, UT USA		Anderson, RCE (corresponding author), Neurol Inst, 4th Floor,710 W 168th St, New York, NY 10032 USA.	rceanderson@yahoo.com					AUCOIN PJ, 1986, AM J MED, V80, P369, DOI 10.1016/0002-9343(86)90708-4; BADER MK, 1995, HEART LUNG, V24, P166, DOI 10.1016/S0147-9563(05)80012-3; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Bekar A, 1998, NEUROSURG REV, V21, P254, DOI 10.1007/BF01105781; Blaha M, 2003, PEDIATR NEUROSURG, V39, P27, DOI 10.1159/000070877; Bochicchio M, 1996, INTENS CARE MED, V22, P1070, DOI 10.1007/BF01699230; CRUTCHFIELD JS, 1990, J NEUROSURG, V72, P482, DOI 10.3171/jns.1990.72.3.0482; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; DEAN JM, 1981, NEUROSURGERY, V9, P627; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; FELDMAN Z, 1993, HEAD INJURY, P247; GAMBARDELLA G, 1992, NEUROSURGERY, V31, P918, DOI 10.1227/00006123-199211000-00014; Guyot LL, 1998, ACT NEUR S, V71, P47; Hader WJ, 2000, NEUROSURGERY, V46, P1149, DOI 10.1097/00006123-200005000-00025; Hammer GB, 1997, PEDIAT NEUROSURGICAL, P13; Jensen RL, 1997, SURG NEUROL, V47, P16, DOI 10.1016/S0090-3019(96)00276-5; Khan SH, 1998, ACT NEUR S, V71, P50; Lozier AP, 2002, NEUROSURGERY, V51, P170, DOI 10.1097/00006123-200207000-00024; LUERSSEN TG, 1997, PEDIAT NEUROSURGICAL, P37; Lyke KE, 2001, CLIN INFECT DIS, V33, P2028, DOI 10.1086/324492; Maitinez-Manas RM, 2000, J NEUROL NEUROSUR PS, V69, P82, DOI 10.1136/jnnp.69.1.82; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; Munch E, 1998, ACTA NEUROCHIR, V140, P1113, DOI 10.1007/s007010050224; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; NORTH B, 1986, NEUROSURGERY, V18, P730, DOI 10.1227/00006123-198606000-00009; OSTRUP RC, 1987, J NEUROSURG, V67, P206, DOI 10.3171/jns.1987.67.2.0206; PARAMORE CG, 1994, ACTA NEUROCHIR, V127, P79, DOI 10.1007/BF01808552; Piek J, 1994, Zentralbl Neurochir, V55, P48; Poca MA, 2002, J NEUROTRAUM, V19, P439, DOI 10.1089/08977150252932398; POPLE IK, 1995, PEDIATR NEUROSURG, V23, P64, DOI 10.1159/000120938; Rossi S, 1998, ACT NEUR S, V71, P91; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; SCHICKNER DJ, 1992, SURG NEUROL, V37, P251, DOI 10.1016/0090-3019(92)90147-F; Schurer L, 1997, ACT NEUR S, V70, P296; Shapiro S, 1996, SURG NEUROL, V45, P278, DOI 10.1016/0090-3019(95)00359-2; STENAGER E, 1986, ACTA NEUROCHIR, V83, P20, DOI 10.1007/BF01420503; SUNDBARG G, 1987, J NEUROSURG, V67, P841, DOI 10.3171/jns.1987.67.6.0841; Wiesmann M, 2001, J CLIN NEUROSCI, V8, P126, DOI 10.1054/jocn.2000.0749; WINN HR, 1977, SURG NEUROL, V8, P41; YABLON JS, 1993, J CLIN MONITOR, V9, P171, DOI 10.1007/BF01617024	43	104	106	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	AUG	2004	101	1		S			53	58		10.3171/ped.2004.101.2.0053			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	843QS	WOS:000223100100009	16206972				2022-02-06	
J	Wagner, AK; Willard, LA; Kline, AE; Wenger, MK; Bolinger, BD; Ren, DX; Zafonte, RD; Dixon, CE				Wagner, AK; Willard, LA; Kline, AE; Wenger, MK; Bolinger, BD; Ren, DX; Zafonte, RD; Dixon, CE			Evaluation of estrous cycle stage after experimental and gender on behavioral outcome traumatic brain injury	BRAIN RESEARCH			English	Article						gender; estrogen; progesterone; traumatic brain injury; spatial memory; motor function	CONTROLLED CORTICAL IMPACT; COGNITIVE RECOVERY; RECEPTOR-ALPHA; WORKING-MEMORY; CEREBRAL EDEMA; MESSENGER-RNA; PROGESTERONE; PERFORMANCE; ESTRADIOL; MODEL	Female sex hormones are acutely neuroprotective in experimental models of traumatic brain injury (TBI). Because hormonal profiles are known to vary with estrous cycle stage, the purpose of this study was to evaluate how pre-injury estrous stage affects motor and cognitive performance after experimental TBI. We also sought to compare post-injury behavioral performance in males vs. females. Under anesthesia, male (n = 18) and female (n = 35) Sprague-Dawley rats underwent either controlled cortical impact (CCI) injury (2.7 mm; 4 m/s) or sham operations. Females were grouped according to estrous stage (proestrous or non-proestrous) at the time of surgery. Motor function was assessed pre-injury and for the first 5 days after surgery using beam balance and walking tasks. Spatial memory was assessed beginning 14 days post-injury utilizing the Morris water maze (MWM) task. No significant differences were found on any task between injured females regardless of estrous cycle stage. Females performed significantly better than males on both motor tasks, but gender did not influence MWM performance. Mixed effects multivariate analysis corroborated these results by showing that pre-injury serum hormone levels had little affect on behavioral performance. The results suggest that the presence of endogenous circulating hormones, rather than hormonal status at time of injury, may confer early neuroprotection in females after TBI. The impact of early neuroprotection on later behavioral outcome and the anatomic structural specificity of hormonal neuroprotection require further study. (C) 2003 Elsevier B.V. All rights reserved.	Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Publ Hlth, Pittsburgh, PA 15260 USA		Wagner, AK (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 5th Ave,Suite 201, Pittsburgh, PA 15213 USA.	wagnerak@msx.upmc.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD040833, R03HD041399] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R03HD41399, K08HD40833] Funding Source: Medline; ODCDC CDC HHS [CCR310285-07] Funding Source: Medline		Behl C, 2002, NAT REV NEUROSCI, V3, P433, DOI 10.1038/nrn846; BEHL C, 1995, BIOCHEM BIOPH RES CO, V216, P473, DOI 10.1006/bbrc.1995.2647; Berry B, 1997, BEHAV NEUROSCI, V111, P267, DOI 10.1037/0735-7044.111.2.267; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; BRYAN JM, 2001, J NEUROTRAUM, V18, P1129; BUTCHER RL, 1974, ENDOCRINOLOGY, V94, P1704, DOI 10.1210/endo-94-6-1704; Candelario-Jalil E, 2001, NEUROSCI RES, V41, P233, DOI 10.1016/S0168-0102(01)00282-6; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879, DOI 10.1016/S0733-8619(18)30185-3; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dubal DB, 2001, P NATL ACAD SCI USA, V98, P1952, DOI 10.1073/pnas.98.4.1952; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Fugger HN, 1998, HORM BEHAV, V34, P163, DOI 10.1006/hbeh.1998.1475; Galani R, 2001, RESTOR NEUROL NEUROS, V18, P161; Garcia-Segura LM, 1998, NEUROREPORT, V9, P593, DOI 10.1097/00001756-199803090-00006; Grossman KJ, 2000, BEHAV BRAIN RES, V116, P141, DOI 10.1016/S0166-4328(00)00275-8; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Harukuni I, 2001, BRAIN RES, V900, P137, DOI 10.1016/S0006-8993(01)02278-8; Healy SD, 1999, P ROY SOC B-BIOL SCI, V266, P2303, DOI 10.1098/rspb.1999.0923; Hurn PD, 2000, J CEREBR BLOOD F MET, V20, P631, DOI 10.1097/00004647-200004000-00001; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kline AE, 2001, HEAD TRAUMA, P65; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kolb B, 1996, BEHAV NEUROSCI, V110, P1271, DOI 10.1037/0735-7044.110.6.1271; Mendelowitsch A, 2001, BRAIN RES, V901, P230, DOI 10.1016/S0006-8993(01)02359-9; Mize AL, 2003, ENDOCRINOLOGY, V144, P306, DOI 10.1210/en.2002-220698; Pelligrino DA, 1998, NEUROREPORT, V9, P3285, DOI 10.1097/00001756-199810050-00026; Rissman EF, 2002, P NATL ACAD SCI USA, V99, P3996, DOI 10.1073/pnas.012032699; ROOF RL, 1993, BEHAV BRAIN RES, V57, P47, DOI 10.1016/0166-4328(93)90060-4; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Shi J, 1998, BRAIN RES, V810, P87, DOI 10.1016/S0006-8993(98)00888-9; Shughrue PJ, 2003, NEUROSCIENCE, V116, P851, DOI 10.1016/S0306-4522(02)00790-X; Shughrue PJ, 1997, J COMP NEUROL, V388, P507, DOI 10.1002/(SICI)1096-9861(19971201)388:4<507::AID-CNE1>3.0.CO;2-6; SMITH SS, 1994, PROG NEUROBIOL, V44, P55, DOI 10.1016/0301-0082(94)90057-4; Suckow MA, 1998, LAB RAT; Sudo S, 1997, NEUROSCI RES, V29, P345, DOI 10.1016/S0168-0102(97)00106-5; Wagner AK, 2002, NEUROSCI LETT, V334, P165, DOI 10.1016/S0304-3940(02)01103-5; Wagner AK, 2000, J TRAUMA, V49, P411, DOI 10.1097/00005373-200009000-00005; Warren SG, 1997, BEHAV NEUROSCI, V111, P259, DOI 10.1037/0735-7044.111.2.259; Williams NI, 2001, ENDOCRINOLOGY, V142, P2381, DOI 10.1210/en.142.6.2381; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820	47	104	107	0	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	FEB 13	2004	998	1					113	121		10.1016/j.brainres.2003.11.027			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	771QA	WOS:000188796500013	14725974				2022-02-06	
J	Brown, AW; Leibson, CL; Malec, JF; Perkins, PK; Diehl, NN; Larson, DR				Brown, AW; Leibson, CL; Malec, JF; Perkins, PK; Diehl, NN; Larson, DR			Long-term survival after traumatic brain injury: A population-based analysis	NEUROREHABILITATION			English	Article						brain injuries; head trauma; longevity; mortality	LIFE EXPECTANCY; HEAD-INJURY; EPIDEMIOLOGY; CHILDREN; TRENDS; SEIZURES; DEATH	This population-based retrospective cohort study identified all Olmsted County, MN residents with any diagnosis indicative of potential traumatic brain injury (TBI) during the years 1985 to 2000. The complete community-based medical records of a random sample (n = 7,175) were reviewed to confirm and characterize the event, and to determine vital status through 2002. The review identified 1,448 confirmed incident cases; 164 (11%) were moderate to severe; 1,284 were mild. The estimated 30-day case fatality rate was 29% for moderate to severe cases and 0.2% for mild cases. Comparison of observed mortality over the full period of follow-up with that expected revealed a risk ratio (95% CI) of 5.29 (4.11-6.71) for moderate to severe cases and 1.33 (1.05-1.65) for mild cases. Proportional hazards modeling showed the adjusted hazard of all-cause mortality for moderate to severe cases relative to mild cases was 5.18 (3.65-7.3) within six months of the event and 1.04 (0.57-1.88) for the remaining follow-up period. This analysis indicates that persons who experience mild TBI exhibit a small but statistically significant reduction in long-term survival compared to the general population. The case fatality rate for persons with moderate to severe TBI is very high, but among six-month survivors, long-term survival is similar to that for persons with mild TBI.	Mayo Clin, Dept Phys Med & Rehabil, Rochester, MN 55905 USA; Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA; Mayo Clin, Dept Psychiat & Psychol, Rochester, MN USA		Brown, AW (corresponding author), Mayo Clin, Dept Phys Med & Rehabil, Rochester, MN 55905 USA.	brown.allen@mayo.edu		Brown, Allen W./0000-0001-7228-3351			ADEKOYA N, 2002, SURVEILLANCE SUMMARI, V51, P1; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Annegers JF, 2000, SEIZURE-EUR J EPILEP, V9, P453, DOI 10.1053/seiz.2000.0458; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Baguley I, 2000, BRAIN INJURY, V14, P505; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; LCGARRY LJ, 2002, J TRAUMA INJURY INFE, V53, P1152; Masson F, 1997, J CLIN EPIDEMIOL, V50, P595, DOI 10.1016/S0895-4356(97)00012-7; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; Melton LJ, 1996, MAYO CLIN PROC, V71, P266, DOI 10.4065/71.3.266; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; RISH BL, 1983, J NEUROSURG, V59, P775, DOI 10.3171/jns.1983.59.5.0775; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; Sosin DM, 1996, BRAIN INJURY, V10, P47; Strauss DJ, 2000, PEDIATR NEUROL, V23, P312, DOI 10.1016/S0887-8994(00)00194-6; Strauss DJ, 1998, PEDIATR NEUROL, V18, P143, DOI 10.1016/S0887-8994(97)00172-0; Strauss DJ, 1998, ARCH PHYS MED REHAB, V79, P1095, DOI 10.1016/S0003-9993(98)90177-0; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman D, 1999, TRAUMATIC BRAIN INJU, DOI http://www.cdc.gov/ncipc/tbi/tbi_congress/TBI_in_the_US.PDF; VAZQUEZBARQUERO A, 1992, EUR J EPIDEMIOL, V8, P832, DOI 10.1007/BF00145328; WALKER AE, 1971, ARCH NEUROL-CHICAGO, V24, P95, DOI 10.1001/archneur.1971.00480320023001; WEISS GH, 1982, ARCH NEUROL-CHICAGO, V39, P741, DOI 10.1001/archneur.1982.00510240003001	24	104	107	0	2	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2004	19	1					37	43					7	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	777KA	WOS:000189176500005	14988586				2022-02-06	
J	Millar, K; Nicoll, JAR; Thornhill, S; Murray, GD; Teasdale, GM				Millar, K; Nicoll, JAR; Thornhill, S; Murray, GD; Teasdale, GM			Long term neuropsychological outcome after head injury: relation to APOE genotype	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							TRAUMATIC BRAIN INJURY; ALZHEIMERS-DISEASE; APOLIPOPROTEIN-E; PRACTICAL SCALE; RISK-FACTORS; EPSILON-4; ASSOCIATION; REANALYSIS; ADULTHOOD; ALLELE	Background: Existing evidence suggests that some patients who sustain a head injury suffer cognitive decline many years later, and that head injury and possession of the APOE epsilon4 allele are each risk factors for Alzheimer's disease. Objective: To determine whether late cognitive decline after head injury is more prevalent among carriers of APOE epsilon4. Methods: A database of head injured patients was used. Initial assessment was at the time of their injury, between 1968 and 1985, and outcome data at six months were available. Their ages at the time of injury ranged between 2 and 70 years. A cohort of 396 subjects was reassessed at a mean of 18 years later, with determination of APOE genotype and detailed neuropyschological testing. Results: Judging by the Glasgow outcome scale, twice as many patients had deteriorated as improved between six months after injury and the late assessment; 22.2% of APOE epsilon4 carriers had a good late outcome compared with 30.5% of non-carriers (95% confidence interval for the difference, -0.7% to 17.2%; p = 0.084). There were no clear differences between e 4 carriers and non-carriers in detailed neuropsychological assessments. Conclusions: Although this study provides additional evidence that a late decline may occur after head injury, there was no clear relation to APOE genotype. Despite the follow up interval of 15 to 25 years, the cohort is still too young ( mean age 42.1 years) to assess the risk of Alzheimer's disease.	Univ Glasgow, Div Behav Med, Dept Psychol Med, Gartnavel Royal Hosp, Glasgow, Lanark, Scotland; Univ Southampton, Southampton Gen Hosp, Div Clin Neurosci, Southampton, Hants, England; Univ Glasgow, Dept Neurosurg, So Gen Hosp, Glasgow, Lanark, Scotland; Univ Edinburgh, Sch Med, Dept Community Hlth Sci, Edinburgh, Midlothian, Scotland		Nicoll, JAR (corresponding author), Southampton Gen Hosp, Mailpoint 813,Level E, Southampton SO16 6YD, Hants, England.		; Nicoll, James/I-9253-2017	Murray, Gordon/0000-0001-9866-4734; Nicoll, James/0000-0002-9444-7246			CORKIN S, 1989, J NEUROSCI, V9, P3876; CORSELLIS JAN, 1989, BRIT MED J, V298, P105, DOI 10.1136/bmj.298.6666.105; Fox NC, 1998, BRAIN, V121, P1631, DOI 10.1093/brain/121.9.1631; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Graham DI, 1999, ACT NEUR S, V73, P89; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Horsburgh K, 2000, NEUROBIOL AGING, V21, P245, DOI 10.1016/S0197-4580(00)00097-X; JENNETT B, 1975, LANCET, V1, P480; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Lichtman SW, 2000, NEUROLOGY, V55, P1536, DOI 10.1212/WNL.55.10.1536; Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MAYEUX R, 1993, ANN NEUROL, V33, P494, DOI 10.1002/ana.410330513; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; Millar K, 2001, BRIT J ANAESTH, V86, P63, DOI 10.1093/bja/86.1.63; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Newcombe F, 1996, J CLIN EXP NEUROPSYC, V18, P1, DOI 10.1080/01688639608408258; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; VANDUIJN CM, 1994, GENET EPIDEMIOL, V11, P539, DOI 10.1002/gepi.1370110609; WALKER AE, 1989, ARCH NEUROL-CHICAGO, V46, P23, DOI 10.1001/archneur.1989.00520370025013; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	30	104	109	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	AUG	2003	74	8					1047	1052		10.1136/jnnp.74.8.1047			6	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	703MJ	WOS:000184283100011	12876232	Green Accepted, Green Published, Bronze			2022-02-06	
J	Zhang, L; Abreu, BC; Seale, GS; Masel, B; Christiansen, CH; Ottenbacher, KJ				Zhang, L; Abreu, BC; Seale, GS; Masel, B; Christiansen, CH; Ottenbacher, KJ			A virtual reality environment for evaluation of a daily living skill in brain injury rehabilitation: Reliability and validity	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	78th Annual Meeting of the American-Congress-of-Rehabilitation-Medicine	OCT 25-26, 2001	TUCSON, AZ			brain injuries; outcomes assessment (health care); rehabilitation; virtual systems	HEAD-INJURY; COGNITIVE REHABILITATION; FUTURE; ADULTS	Objective: To establish the stability and validity of information collected in a virtual reality environment from persons with traumatic brain injury (TBI). Design: Prospective correlation design to, examine 3-week test-retest results for equivalence reliability between computer- simulated and natural environments. Setting: A residential rehabilitation center for brain injury, Participants: fifty-four consecutive patients with TBI who received comprehensive rehabilitation services and who were at different stages of recovery Intervention: An immersive virtual kitchen was developed in which a meal preparation task involving multiple steps was performed. The subjects completed meal preparation both in a virtual reality kitchen and an actual kitchen twice over a 3-week period. Main Outcome Measures: Time and errors on task completion using virtual reality assessment, actual kitchen performance (analogous to the virtual reality environment), occupational therapy (OT) evaluation, and neuropsychologic tests. Results: The stability of performance using the simulated virtual environment was estimated with-intraclass correlation coefficients (ICCs). The ICC value for total performance, based on all steps involved in the meal preparation task, was .76 (P<.01). The construct validity of the simulated environment was examined by correlatin. 9 performance in the virtual environment with that in the actual kitchen (r=.63, P<.01), the OT evaluation (r=.30, P=.05 for meal preparation; r=.40, P=.01 for cognitive subskills), and neuropsychologic tests (r=.56, P<.01 for the full-scale intelligence quotient [IQ]; r=.40, P<.01 for the verbal IQ; r=.56, P<.01 for the performance IQ). Finally, a multiple regression analysis revealed that the virtual reality environment test was a good predictor for the actual assessment kitchen (beta=35, P=.01). Conclusion; The virtual reality system showed adequate reliability and validity as a method of assessment in persons with brain injury. (C) 2603 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Univ Texas, Med Branch, Div Rehabil Sci, Sch Allied Hlth Sci, Galveston, TX 77555 USA; Transit Learning Ctr, Galveston, TX USA		Ottenbacher, KJ (corresponding author), Univ Texas, Med Branch, Div Rehabil Sci, Sch Allied Hlth Sci, 301 Univ Blvd, Galveston, TX 77555 USA.	kottenba@utmb.edu	, Charles/V-6218-2019	Ottenbacher, Kenneth/0000-0001-5990-3982; Christiansen, Charles/0000-0003-0542-1042	NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG017638] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [3R01AG17638] Funding Source: Medline		Abreu BC, 2001, ARCH PHYS MED REHAB, V82, P49, DOI 10.1053/apmr.2001.9167; Andreae MH, 1996, BMJ-BRIT MED J, V312, P4, DOI 10.1136/bmj.312.7022.4; BOND MR, 1991, PSYCHIAT CLOSED HEAD, P148; *BRAIN INJ ASS INC, WHO WE AR VIS STAT; BRICKENKAMP R, 1981, CONCENTRATION ENDURA; Brown D., 1995, ABILITY, V15, P24; CHAMBERLIN M, 1995, TRAUMATIC BRAIN INJU; Christiansen C, 1998, ARCH PHYS MED REHAB, V79, P888, DOI 10.1016/S0003-9993(98)90083-1; Christiansen C, 1996, J MED VIRTUAL REALIT, V1, P6; DAWSON DR, 1995, BRAIN INJURY, V9, P339, DOI 10.3109/02699059509005774; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; INMAN DP, 1995, P VIRT REAL PERS DIS, P57; Jack D, 2001, IEEE T NEUR SYS REH, V9, P308, DOI 10.1109/7333.948460; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Jennett B, 1981, MANAGEMENT HEAD INJU; KENYON RV, 1995, ANN BIOMED ENG, V23, P445, DOI 10.1007/BF02584444; KOZAK JJ, 1993, ERGONOMICS, V36, P777, DOI 10.1080/00140139308967941; LOFTIN RB, 1995, IEEE COMPUT GRAPH, V15, P31, DOI 10.1109/38.403825; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; NEISTADT ME, 1994, AM J OCCUP THER, V48, P431, DOI 10.5014/ajot.48.5.431; Ottenbacher KJ, 1996, ARCH PHYS MED REHAB, V77, P1226, DOI 10.1016/S0003-9993(96)90184-7; Passig D, 2001, CYBERPSYCHOL BEHAV, V4, P681, DOI 10.1089/109493101753376623; Portney LG, 1993, FDN CLIN RES APPL PR, V3rd; REGAN EC, 1994, AVIAT SPACE ENVIR MD, V65, P527; Rizzo AA, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199712000-00002; Rose FD, 2000, ERGONOMICS, V43, P494, DOI 10.1080/001401300184378; ROTHBAUM BO, 1995, AM J PSYCHIAT, V152, P626; SATAVA RM, 1992, MINIM INVASIV THER, V1, P357; Sohlberg M.M., 1989, INTRO COGNITIVE REHA; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; WANN JP, 1993, BAILLIERE CLIN NEUR, V2, P15; Wechsler D., 1939, MEASUREMENT ADULT IN; Whyte J, 1993, REHABILITATION MED P, P825; Witmer BG, 1996, INT J HUM-COMPUT ST, V45, P413, DOI 10.1006/ijhc.1996.0060; Zhang L, 2001, AM J PHYS MED REHAB, V80, P597, DOI 10.1097/00002060-200108000-00010	35	104	111	1	23	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2003	84	8					1118	1124		10.1016/S0003-9993(03)00203-X			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	Rehabilitation; Sport Sciences	709LQ	WOS:000184627000004	12917848				2022-02-06	
J	Hartings, JA; Williams, AJ; Tortella, FC				Hartings, JA; Williams, AJ; Tortella, FC			Occurrence of nonconvulsive seizures, periodic epileptiform discharges, and intermittent rhythmic delta activity in rat focal ischemia	EXPERIMENTAL NEUROLOGY			English	Article						ischemia; electroencephalography; epilepsy; nonconvulsive seizure; PLED; IRDA; MCAo; in vivo; paroxysm; rat	INTENSIVE-CARE UNIT; CONVULSIVE STATUS EPILEPTICUS; SUSTAINED POTENTIAL SHIFTS; TRAUMATIC BRAIN INJURY; CONTINUOUS EEG; ELECTROGRAPHIC SEIZURES; PAROXYSMAL DISCHARGES; SPECTRAL-ANALYSIS; MODEL; HIPPOCAMPUS	A significant proportion of neurologic patients suffer electroencephalographic (EEG) seizures in the acute phase following traumatic or ischemic brain injury, including many without overt behavioral manifestations. Although such nonconvulsive seizures may exacerbate neuropathological processes, they have received limited attention clinically and experimentally. Here we characterize seizure episodes following focal cerebral ischemia in the rat as a model for brain injury-induced seizures. Cortical EEG activity was recorded continuously from both hemispheres up to 72 h following middle cerebral artery occlusion (MCAo). Seizure discharges appeared in EEG recordings within 1 h of MCAo in 13/16 (81%) animals and consisted predominantly of generalized 1-3 Hz rhythmic spiking. During seizures animals engaged in quiet awake or normal motor behaviors, but exhibited no motor convulsant activity. Animals had a mean of 10.6 seizure episodes within 2 h, with a mean duration of 60 s per episode. On average, seizures ceased at 1 h 59 min post-MCAo in permanently occluded animals and did not occur following reperfusion at 2 h in transiently occluded animals. In addition to seizures, periodic lateralized epileptiform discharges (PLEDs) appeared over penumbral regions in the injured hemisphere while intermittent rhythmic delta activity (IRDA) recurred in the contralateral hemisphere with frontoparietal dominance. PLEDs and IRDA persisted up to 72 It in permanent MCAo animals, and early onset of the former was predictive of prolonged seizure activity. The presentation of these EEG waveforms, each with characteristic features replicating those in clinical neurologic populations, validates rat MCAo for study of acutely induced brain seizures and other neurophysiological aspects of brain injury. Published by Elsevier Science (USA).	Walter Reed Army Inst Res, Div Neurosci, Silver Spring, MD 20910 USA		Hartings, JA (corresponding author), Walter Reed Army Inst Res, Div Neurosci, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.			Hartings, Jed/0000-0001-8583-3471			Azouz R, 1996, J PHYSIOL-LONDON, V492, P211, DOI 10.1113/jphysiol.1996.sp021302; Bergui M, 1997, J NEUROSURG, V87, P803; Borck C, 1999, J NEUROPHYSIOL, V82, P2130, DOI 10.1152/jn.1999.82.5.2130; CHATRIAN GE, 1964, ELECTROEN CLIN NEURO, V17, P177, DOI 10.1016/0013-4694(64)90149-X; FARIELLO RG, 1982, ELECTROEN CLIN NEURO, V54, P194, DOI 10.1016/0013-4694(82)90161-4; Garzon E, 2001, NEUROLOGY, V57, P1175, DOI 10.1212/WNL.57.7.1175; GLOOR P, 1977, NEUROLOGY, V27, P326, DOI 10.1212/WNL.27.4.326; GRANDMAISON F, 1991, ELECTROEN CLIN NEURO, V79, P264, DOI 10.1016/0013-4694(91)90121-J; Gross DW, 1999, CLIN NEUROPHYSIOL, V110, P1516, DOI 10.1016/S1388-2457(99)00119-4; HANDFORTH A, 1994, EPILEPSIA, V35, P876, DOI 10.1111/j.1528-1157.1994.tb02526.x; JENSEN MS, 1988, ANN NEUROL, V24, P591, DOI 10.1002/ana.410240502; JORDAN K G, 1992, Neurology, V42, P194; Jordan KG, 1999, J CLIN NEUROPHYSIOL, V16, P14, DOI 10.1097/00004691-199901000-00002; JORDAN KG, 1995, NEUROL CLIN, V13, P579, DOI 10.1016/S0733-8619(18)30035-5; JORDAN KG, 1993, J CLIN NEUROPHYSIOL, V10, P445, DOI 10.1097/00004691-199310000-00006; Krsek P, 2001, EPILEPSIA, V42, P171, DOI 10.1046/j.1528-1157.2001.35799.x; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; Lu XCM, 2001, NEUROPATH APPL NEURO, V27, P481, DOI 10.1046/j.1365-2990.2001.00357.x; MARKAND ON, 1971, NEUROLOGY, V21, P975, DOI 10.1212/WNL.21.10.975; McIntosh TK, 1996, LAB INVEST, V74, P315; Meltzer CC, 2000, EPILEPSIA, V41, P193, DOI 10.1111/j.1528-1157.2000.tb00139.x; MIES G, 1993, NEUROREPORT, V4, P709, DOI 10.1097/00001756-199306000-00027; NEDERGAARD M, 1993, J CEREBR BLOOD F MET, V13, P568, DOI 10.1038/jcbfm.1993.74; Neufeld MY, 1999, J NEUROL SCI, V164, P56, DOI 10.1016/S0022-510X(99)00018-0; PohlmannEden B, 1996, J CLIN NEUROPHYSIOL, V13, P519, DOI 10.1097/00004691-199611000-00007; RAROQUE H G JR, 1991, Epilepsia, V32, P77; REIHER J, 1991, ELECTROEN CLIN NEURO, V78, P12, DOI 10.1016/0013-4694(91)90013-T; SCHAUL N, 1981, ARCH NEUROL-CHICAGO, V38, P690, DOI 10.1001/archneur.1981.00510110050006; SCHRAEDER PL, 1980, EPILEPSIA, V21, P647, DOI 10.1111/j.1528-1157.1980.tb04318.x; SCHWARTZ MS, 1973, BRAIN, V96, P613, DOI 10.1093/brain/96.3.613; Silbert PL, 1996, ELECTROEN CLIN NEURO, V98, P223, DOI 10.1016/0013-4694(95)00268-5; SNODGRASS SM, 1989, J CLIN NEUROPHYSIOL, V6, P159, DOI 10.1097/00004691-198904000-00003; SOMJEN GG, 1985, J NEUROPHYSIOL, V53, P1079, DOI 10.1152/jn.1985.53.4.1079; Striano S, 1986, Acta Neurol (Napoli), V8, P1; Sun DA, 2001, STROKE, V32, P2344, DOI 10.1161/hs1001.097242; Tortella FC, 1997, J PHARMACOL EXP THER, V282, P286; TRAYNELIS SF, 1988, J NEUROPHYSIOL, V59, P259, DOI 10.1152/jn.1988.59.1.259; TREIMAN DM, 1990, EPILEPSY RES, V5, P49, DOI 10.1016/0920-1211(90)90065-4; Treiman DM, 1998, NEW ENGL J MED, V339, P792, DOI 10.1056/NEJM199809173391202; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 1999, J CLIN NEUROPHYSIOL, V16, P1, DOI 10.1097/00004691-199901000-00001; VESPA PM, 1997, CRIT CARE MED S, V25, pA120; WADMAN WJ, 1992, BRAIN RES, V570, P85, DOI 10.1016/0006-8993(92)90567-S; WALSH JM, 1987, EPILEPSIA, V28, P533, DOI 10.1111/j.1528-1157.1987.tb03684.x; Williams AJ, 2002, BRAIN RES, V932, P45, DOI 10.1016/S0006-8993(02)02275-8; WILLIAMS AL, 2001, SOC NEUR ABSTR, V27; WOODS L, 2001, SOC NEUR ABSTR, V27; Young G, 1988, AM J EEG TECHNOL, V28, P1; Young GB, 1996, NEUROLOGY, V47, P83	49	104	109	0	8	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	FEB	2003	179	2					139	149	PII S0014-4886(02)00013-4	10.1016/S0014-4886(02)00013-4			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	653JM	WOS:000181432100002	12618120				2022-02-06	
J	Liberman, JN; Stewart, WF; Wesnes, K; Troncoso, J				Liberman, JN; Stewart, WF; Wesnes, K; Troncoso, J			Apolipoprotein E epsilon 4 and short-term recovery from predominantly mild brain injury	NEUROLOGY			English	Article							SEVERE HEAD-INJURY; PROTEIN; CONCUSSION; EXPRESSION; PREDICTION; DEPOSITION; MODERATE; ALLELE; APOE; RAT	Objective: To determine whether APOE genotype explained variability in short-term recovery from predominantly mild traumatic brain injury (TBI). Methods: A total of 87 adult patients presenting with mild or moderate TBI to a shock trauma center were enrolled prospectively. A battery of 13 neuropsychological tests was administered twice, at approximately 3 and 6 weeks after injury. Eighty of 87 patients were successfully genotyped for APOE using a buccal swab technique. Results: Ninety percent of study patients had mild TBI (Glasgow Coma Scale score of 13 to 15); 18 (22.5%) had one APOE epsilon4 and none had two epsilon4 alleles. After adjusting for potential confounders, patients positive for the APOE epsilon4 allele had lower mean scores on 12 of 13 neuropsychological outcomes at visit I compared with APOE epsilon4-negative patients. Two of the differences were significant (grooved pegboard test, p = 0.005; paced auditory serial addition task 2.8-second trial, p = 0.004). At visit 2, APOE epsilon4-positive patients had lower adjusted mean scores on 11 of the 13 neuropsychological outcomes. None of the differences was significant. Conclusions: APOE genotype may influence the severity of the acute injury. However, with no consistent pattern to the recovery curves, it is not clear if APOE genotype influences the rate of recovery.	Johns Hopkins Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; Johns Hopkins Sch Med, Dept Pathol, Baltimore, MD USA; Johns Hopkins Sch Med, Dept Neurol, Baltimore, MD USA; Cognit Drug Res Ltd, Reading, Berks, England		Liberman, JN (corresponding author), IMR Inc, 11350 McCormack Rd,Execut Pl 2,Suite1000, Hunt Valley, MD 21031 USA.	jliberman@imrinc.com	Wesnes, Keith A/D-7148-2018	Wesnes, Keith/0000-0002-4498-8511			Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; GRONWALL D, 1975, LANCET, V2, P995; Gronwall D, 1974, PSYCHOL EFFECTS CONC; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HAYNEY MS, 1995, MAYO CLIN PROC, V70, P951, DOI 10.4065/70.10.951; HIXSON JE, 1990, J LIPID RES, V31, P545; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; KALARIA RN, 1993, NEUROREPORT, V4, P211, DOI 10.1097/00001756-199302000-00025; KAWARABAYASHI T, 1991, BRAIN RES, V563, P334, DOI 10.1016/0006-8993(91)91558-I; Keith MS, 1998, BRAIN INJURY, V12, P1037, DOI 10.1080/026990598121945; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; KlOve H, 1963, MED CLIN N AM; Lannoo E, 1998, ACTA NEUROCHIR, V140, P245, DOI 10.1007/s007010050091; Lezak MD., 1983, NEUROPSYCHOLOGICAL A, V2nd ed.; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Marques M, 1997, ALZHEIMER RES, V3, P1; Matthews CG., 1964, INSTRUCTION MANUAL A; McCarron MO, 1998, STROKE, V29, P1882, DOI 10.1161/01.STR.29.9.1882; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Ommaya A. K., 1967, P 11 STAPP CAR CRASH; OMMAYA AK, 1964, J NEUROSURG, V21, P249, DOI 10.3171/jns.1964.21.4.0249; Pierce JES, 1996, J NEUROSCI, V16, P1083; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; Rothweiler B, 1998, ARCH PHYS MED REHAB, V79, P881, DOI 10.1016/S0003-9993(98)90082-X; Satz P, 1998, BRAIN INJURY, V12, P555, DOI 10.1080/026990598122322; Slooter AJC, 1997, JAMA-J AM MED ASSOC, V277, P818, DOI 10.1001/jama.277.10.818; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Sun YL, 1998, J NEUROSCI, V18, P3261; TSUBOKAWA T, 1975, Neurologia Medico-Chirurgica, V15, P57, DOI 10.2176/nmc.15pt1.57; Wesnes KA, 1999, DIAGNOSIS MANAGEMENT, P124; [No title captured]; [No title captured]	38	104	110	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	APR 9	2002	58	7					1038	1044		10.1212/WNL.58.7.1038			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	539JC	WOS:000174865900010	11940689				2022-02-06	
J	Donders, J; Tulsky, DS; Zhu, JJ				Donders, J; Tulsky, DS; Zhu, JJ			Criterion validity of new WAIS-III subtest scores after traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article; Proceedings Paper	Annual Meeting of the American-Psychological-Association	AUG 24-28, 2001	San Francisco, CA	Amer Psychol Assoc		WAIS-III; traumatic brain injury; criterion validity	MEMORY MALINGERING TOMM; VERBAL-LEARNING TEST; TEST-PERFORMANCE; HEAD-INJURY; EDUCATION; REITAN; NORMS; AGE	The criterion validity of the new subtests from the Wechsler Adult Intelligence Scale-Third Edition (WAIS-III Wechsler, 1997) was evaluated in a sample of 100 patients with traumatic brain injury (TBI). Letter-Number Sequencing and Symbol Search, but not Matrix Reasoning, yielded statistically significant differences, in performance between patients with moderate-severe TBI, patient with mild TBI, and demographically matched controls. Level of education accounted for a statistically significant amount of variance in the performance of patients with TBI, in addition to that explained by injury severity variable. It is concluded that Letter-Number Sequencing and Symbol Search have e satisfactory, criterion validity. but that they need to he supplemented with other measure in the context of neuropsychological evaluations. Matrix Reasoning, on the other hand, is not sensitive to the sequelae of TBI and more studies are needed to determine ho it can he used for neuropsychological assessment purposes.	Mary Free Bed Hosp & Rehabil Ctr, Psychol Serv, Grand Rapids, MI USA; Kessler Med Rehabil Res & Educ Corp, W Orange, NJ USA; Psychol Corp, San Antonio, TX USA		Donders, J (corresponding author), Mary Free Bed Hosp & Rehabil Ctr, Psychol Serv, 235 Wealthy,SE, Grand Rapids, MI USA.	jdonders@mfbrc.com		Tulsky, David/0000-0002-4335-4509			Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; CHARTER RA, 1994, J CLIN EXP NEUROPSYC, V16, P744, DOI 10.1080/01688639408402687; Crosson B., 1990, CLIN NEUROPSYCHOL, V4, P253, DOI 10.1080/13854049008401908; Diehr MC, 1998, ASSESSMENT, V5, P375, DOI 10.1177/107319119800500407; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Dugbartey AT, 1999, CLIN NEUROPSYCHOL, V13, P396, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT396; Hawkins KA, 1998, CLIN NEUROPSYCHOL, V12, P535, DOI 10.1076/clin.12.4.535.7236; Heaton PDRK., 1993, WISCONSIN CARD SORTI; Heaton RK, 1996, NEUROPSYCHOLOGICAL A, P141; HEATON RK, 2000, C NAT AC NEUR ORL FL; IVERSON G, 2000, C AM PSYCH ASS WASH; Jones R. D., 1996, P395; KAUFMAN AS, 1999, ESSENTIALS WAIS 3 AS; MANLY J, 2000, C AM PSYCH ASS WASH; Manly JJ, 1998, NEUROLOGY, V50, P1238, DOI 10.1212/WNL.50.5.1238; Martin TA, 2000, REHABIL PSYCHOL, V45, P402, DOI 10.1037/0090-5550.45.4.402; MILLIS SR, 1997, M INT NEUR SOC BERG; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; Moses JA, 1999, ARCH CLIN NEUROPSYCH, V14, P445, DOI 10.1016/S0887-6177(98)00030-4; Naglieri J. A., 1997, GEN ABILITY MEASURE; Nixon S.J., 1996, NEUROPSYCHOLOGY CLIN, P9, DOI [DOI 10.1037/10198-001, https://doi.org/10.1037/10198-001]; Norman MA, 2000, J CLIN EXP NEUROPSYC, V22, P80, DOI 10.1076/1380-3395(200002)22:1;1-8;FT080; Rees LM, 1998, PSYCHOL ASSESSMENT, V10, P10, DOI 10.1037/1040-3590.10.1.10; Reinecke MA, 1999, J AM ACAD CHILD PSY, V38, P322, DOI 10.1097/00004583-199903000-00020; Reitan R M, 1997, Appl Neuropsychol, V4, P16, DOI 10.1207/s15324826an0401_3; REITAN RM, 1995, CLIN NEUROPSYCHOL, V9, P151, DOI 10.1080/13854049508401597; Reynolds CR, 1997, ARCH CLIN NEUROPSYCH, V12, P29, DOI 10.1016/S0887-6177(96)00015-7; SATTLER JM, 1999, ASSESSMENT CHILDREN; Sherrill-Pattison S, 2000, CLIN NEUROPSYCHOL, V14, P496, DOI 10.1076/clin.14.4.496.7196; TEASDALE G, 1974, LANCET, V2, P81; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Vanderploeg RD, 1997, CLIN NEUROPSYCHOL, V11, P210, DOI 10.1080/13854049708407054; Warrington E, 1984, RECOGNITION MEMORY T, V1; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D, 1991, WECHSLER INTELLIGENC, VTHIRD; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Wechsler D., 1997, WAIS 3 WMS 3 TECHNIC; Wiegner S, 1999, J CLIN EXP NEUROPSYC, V21, P159, DOI 10.1076/jcen.21.2.159.925; Wiegner S, 1999, ASSESSMENT, V6, P179, DOI 10.1177/107319119900600205	40	104	104	0	23	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	NOV	2001	7	7					892	898		10.1017/S1355617701777132			7	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology; Psychiatry; Psychology	496YV	WOS:000172426700013	11771633				2022-02-06	
J	Strauss, KI; Barbe, MF; Marshall, RM; Raghupathi, R; Mehta, S; Narayan, RK				Strauss, KI; Barbe, MF; Marshall, RM; Raghupathi, R; Mehta, S; Narayan, RK			Prolonged cyclooxygenase-2 induction in neurons and glia following traumatic brain injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						neural gene expression; quantitative mRNA measurements; hippocampus; parietal cortex; perirhinal cortex; piriform cortex	CEREBRAL BLOOD-FLOW; LONG-TERM POTENTIATION; HEAD-INJURY; MESSENGER-RNA; INDUCIBLE CYCLOOXYGENASE; HIPPOCAMPAL-FORMATION; ENDOTHELIAL-CELLS; FEBRILE RESPONSE; ARACHIDONIC-ACID; GENE-EXPRESSION	Cyclooxygenase-2 (COX2) is a primary inflammatory mediator that converts arachidonic acid into precursors of vasoactive prostaglandins, producing reactive oxygen species in the process. Under normal conditions COX2 is not detectable, except at low abundance in the brain. This study demonstrates a distinctive pattern of COX2 increases in the brain over time following traumatic brain injury (TBI). Quantitative lysate ribonuclease protection assays indicate acute and sustained increases in COX2 mRNA in two rat models of TBI. In the lateral fluid percussion model, COX2 mRNA is significantly elevated (>twofold, p < 0.05, Dunnett) at 1 day postinjury in the injured cortex and bilaterally in the hippocampus, compared to sham-injured controls. In the lateral cortical impact model (LCI), COX2 mRNA peaks around 6 h postinjury in the ipsilateral cerebral cortex (fivefold induction, p < 0.05, Dunnett) and in the ipsilateral and contralateral hippocampus (two- and sixfold induction, respectively, p < 0.05, Dunnett). Increases are sustained out to 3 days postinjury in the injured cortex in both models. Further analyses use the LCI model to evaluate COX2 induction. Immunoblot analyses confirm increased levels of COX2 protein in the cortex and hippocampus. Profound increases in COX2 protein are observed in the cortex at 1-3 days, that return to sham levels by 7 days postinjury (p < 0.05, Dunnett). The cellular pattern of COX2 induction following TBI has been characterized using immunohistochemistry. COX2-immunoreactivity (-ir) rises acutely (cell numbers and intensity) and remains elevated for several days following TBI. Increases in COX2-ir colocalize with neurons (MAP2-ir) and glia (GFAP-ir). Increases in COX2-ir are observed in cerebral cortex and hippocampus, ipsilateral and contralateral to injury as early as 2 h postinjury. Neurons in the ipsilateral parietal, perirhinal and piriform cortex become intensely COX2-ir from 2 h to at least 3 days postinjury. In agreement with the mRNA and immunoblot results, COX2-ir appears greatest in the contralateral hippocampus. Hippocampal COX2-ir progresses from the pyramidal cell layer of the CA1 and CA2 region at 2 h, to the CA3 pyramidal cells and dentate polymorphic and granule cell layers by 24 h postinjury. These increases are distinct from those observed following inflammatory challenge, and correspond to brain areas previously identified with the neurological and cognitive deficits associated with TBI. While COX2 induction following TBI may result in selective beneficial responses, chronic COX2 production may contribute to free radical mediated cellular damage, vascular dysfunction, and alterations in cellular metabolism. These may cause secondary injuries to the brain that promote neuropathology and worsen behavioral outcome.	Temple Univ, Sch Med, Dept Neurosurg, Philadelphia, PA 19122 USA; Temple Univ, Dept Phys Therapy, Philadelphia, PA 19122 USA; Temple Univ, Dept Anat & Cell Biol, Philadelphia, PA 19122 USA; Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA USA		Strauss, KI (corresponding author), Temple Neurotrauma Res Lab, 3420 N Broad St,MRB 711, Philadelphia, PA 19140 USA.	kstrauss@thunder.temple.edu	Raghupathi, Ramesh/AAX-5538-2021		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038654] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS038654, R01 NS38654] Funding Source: Medline		Adams J, 1996, J NEUROCHEM, V66, P6; AMARAL DG, 1984, J COMP NEUROL, V224, P307, DOI 10.1002/cne.902240302; BABB TL, 1988, J COMP NEUROL, V278, P121, DOI 10.1002/cne.902780108; BENEDEK G, 1987, CAN J NEUROL SCI, V14, P145; BIESTRO AA, 1995, J NEUROSURG, V83, P627, DOI 10.3171/jns.1995.83.4.0627; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; BREDER CD, 1995, J COMP NEUROL, V355, P296, DOI 10.1002/cne.903550208; BREDER CD, 1992, J COMP NEUROL, V322, P409, DOI 10.1002/cne.903220309; Busija David W., 1996, Microcirculation (Philadelphia), V3, P379, DOI 10.3109/10739689609148310; Caggiano AO, 1996, J COMP NEUROL, V376, P447, DOI 10.1002/(SICI)1096-9861(19961216)376:3<447::AID-CNE7>3.0.CO;2-2; CAJAL SRY, 1995, HISTOLOGY NERVOUS SY, P638; Cao CY, 1997, ANN NY ACAD SCI, V813, P307, DOI 10.1111/j.1749-6632.1997.tb51710.x; CAO CY, 1995, BRAIN RES, V697, P187, DOI 10.1016/0006-8993(95)00839-I; Cao CY, 1999, J NEUROSCI, V19, P716; CHEN J, 1995, NEUROREPORT, V6, P245; CollacoMoraes Y, 1996, J CEREBR BLOOD F MET, V16, P1366, DOI 10.1097/00004647-199611000-00035; Conti AC, 1998, J NEUROSCI, V18, P5663; Dahl B, 1996, ACTA NEUROCHIR, V138, P265, DOI 10.1007/BF01411736; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; DeWitt DS, 1988, J NEUROTRAUM, V5, P303, DOI 10.1089/neu.1988.5.303; DHILLON HS, 1994, J NEUROTRAUM, V11, P405, DOI 10.1089/neu.1994.11.405; Dixon CE, 1997, J NEUROTRAUM, V14, P161, DOI 10.1089/neu.1997.14.161; Dixon CE, 1996, PHARMACOL BIOCHEM BE, V53, P679, DOI 10.1016/0091-3057(95)02069-1; DUBOIS RN, 1994, AM J PHYSIOL, V266, pG822; ELLIS E F, 1989, Journal of Neurotrauma, V6, P31, DOI 10.1089/neu.1989.6.31; ELLIS EF, 1988, AM J PHYSIOL, V255, pH397, DOI 10.1152/ajpheart.1988.255.2.H397; ELLIS EF, 1979, AM J PHYSIOL, V237, pH381, DOI 10.1152/ajpheart.1979.237.3.H381; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FENG L, 1993, ARCH BIOCHEM BIOPHYS, V307, P361, DOI 10.1006/abbi.1993.1601; FU JY, 1990, J BIOL CHEM, V265, P16737; GRAHAM SH, 1996, J NEUROTRAUM, V13, pA620; GRAHAM SH, 1996, NEUROLOGY S, V46, pA406; Ho L, 1998, J NEUROIMMUNOL, V89, P142, DOI 10.1016/S0165-5728(98)00132-5; Ino T, 1998, NEUROSCI RES, V32, P241, DOI 10.1016/S0168-0102(98)00093-5; ISAACS KR, 1995, CELL TISSUE RES, V280, P639, DOI 10.1007/s004410050391; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kaufmann WE, 1996, P NATL ACAD SCI USA, V93, P2317, DOI 10.1073/pnas.93.6.2317; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; KEMPSKI O, 1987, STROKE, V18, P111, DOI 10.1161/01.STR.18.1.111; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kong D. L., 1997, Society for Neuroscience Abstracts, V23, P2181; Kontos H A, 1980, Adv Exp Med Biol, V131, P243; KONTOS HA, 1980, SCIENCE, V209, P1242, DOI 10.1126/science.7403881; Lacroix S, 1998, J NEUROCHEM, V70, P452, DOI 10.1046/j.1471-4159.1998.70020452.x; LERANTH C, 1987, J COMP NEUROL, V261, P33, DOI 10.1002/cne.902610104; LEWEN A, 1996, J NEUROTRAUM, V13, pA600; LI DY, 1993, J PHARMACOL EXP THER, V267, P1292; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Lukiw WJ, 1997, J NEUROSCI RES, V50, P937, DOI 10.1002/(SICI)1097-4547(19971215)50:6<937::AID-JNR4>3.0.CO;2-E; Luukinen H, 1999, NEUROLOGY, V52, P557, DOI 10.1212/WNL.52.3.557; Marcheselli VL, 1996, J BIOL CHEM, V271, P24794, DOI 10.1074/jbc.271.40.24794; MARKLUND N, 1996, J NEUROTRAUM, V13, pA600; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Moore S. A., 1997, Society for Neuroscience Abstracts, V23, P1166; MUIR JK, 1992, J NEUROTRAUM, V9, P355, DOI 10.1089/neu.1992.9.355; Nakayama M., 1996, Society for Neuroscience Abstracts, V22, P1670; Nakayama M, 1998, P NATL ACAD SCI USA, V95, P10954, DOI 10.1073/pnas.95.18.10954; NISHIHARA I, 1995, NEUROSCI LETT, V196, P57, DOI 10.1016/0304-3940(95)11839-O; Nishizaki T, 1999, BIOCHEM BIOPH RES CO, V254, P446, DOI 10.1006/bbrc.1998.9961; Nogawa S, 1997, J NEUROSCI, V17, P2746; O'Banion MK, 1999, CRIT REV NEUROBIOL, V13, P45, DOI 10.1615/CritRevNeurobiol.v13.i1.30; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; PALKOVITS M, 1973, BRAIN RES, V59, P449, DOI 10.1016/0006-8993(73)90290-4; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Pasinetti GM, 1998, NEUROSCIENCE, V87, P319, DOI 10.1016/S0306-4522(98)00218-8; Povlishock J T, 1985, Cent Nerv Syst Trauma, V2, P285; PRASAD MR, 1994, J NEUROCHEM, V63, P773; RAZ A, 1988, J BIOL CHEM, V263, P3022; Resnick DK, 1998, J NEUROTRAUM, V15, P1005, DOI 10.1089/neu.1998.15.1005; Sairanen T, 1998, ANN NEUROL, V43, P738, DOI 10.1002/ana.410430608; Sanz O, 1997, NEUROSCIENCE, V80, P221, DOI 10.1016/S0306-4522(97)00089-4; SAPER CB, 1992, PROG BRAIN RES, V93, P419; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; SEVANIAN A, 1985, Journal of Free Radicals in Biology and Medicine, V1, P263, DOI 10.1016/0748-5514(85)90130-8; SHOHAMI E, 1987, J CEREBR BLOOD F MET, V7, P58, DOI 10.1038/jcbfm.1987.8; SHOHAMI E, 1989, J NEUROCHEM, V53, P1541, DOI 10.1111/j.1471-4159.1989.tb08550.x; STRAUSS KI, 1993, MOL BRAIN RES, V20, P229, DOI 10.1016/0169-328X(93)90045-Q; STRAUSS KI, 1997, J NEUROTRAUM, V14, pA794; STRAUSS KI, 1998, J NEUROTRAUM, V15, pA898; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; TSUBOKURA S, 1991, BRAIN RES, V543, P15, DOI 10.1016/0006-8993(91)91043-Z; VanDam AM, 1996, FASEB J, V10, P351, DOI 10.1096/fasebj.10.2.8641570; VANGROEN T, 1990, J COMP NEUROL, V302, P515, DOI 10.1002/cne.903020308; vanHaeften T, 1997, J NEUROSCI, V17, P862; VANSTUCK SL, 1996, J NEUROTRAUM, V13, pA618; Wallace CS, 1998, J NEUROSCI, V18, P26; Walton M, 1997, MOL BRAIN RES, V50, P165, DOI 10.1016/S0169-328X(97)00181-2; WEI EP, 1980, AM J PHYSIOL, V238, pH226, DOI 10.1152/ajpheart.1980.238.2.H226; WEST JR, 1979, BRAIN RES, V160, P203, DOI 10.1016/0006-8993(79)90419-0; Wolf MJ, 1995, FEBS LETT, V377, P358, DOI 10.1016/0014-5793(95)01371-7; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YOUNG B, 1996, NEUROTRAUMA, P345	95	104	114	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2000	17	8					695	711		10.1089/089771500415436			17	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	347WF	WOS:000088951600006	10972245	Green Accepted, Green Submitted			2022-02-06	
J	Fontaine, A; Azouvi, P; Remy, P; Bussel, B; Samson, Y				Fontaine, A; Azouvi, P; Remy, P; Bussel, B; Samson, Y			Functional anatomy of neuropsychological deficits after severe traumatic brain injury	NEUROLOGY			English	Article; Proceedings Paper	5th Conference of the International-Association-for-the-Study-of-Traumatic-Brain-Injury	NOV 15-18, 1996	MELBOURNE, AUSTRALIA	Int Assoc Study Traumat Brain Injury		traumatic brain injury; PET; neuropsychological deficits	CLOSED-HEAD-INJURY; POSITRON EMISSION TOMOGRAPHY; ANTERIOR CINGULATE CORTEX; GLUCOSE METABOLIC-RATE; VERBAL MEMORY; HUMANS; SPECT; PET; ATTENTION; BEHAVIOR	Background: Neurobehavioral disorders after Severe traumatic brain injury (TBI) are poorly correlated with focal lesions detected by structural neuroimaging techniques such as CT scan or MRI. Objective: To explore the relationships between regional cerebral glucose metabolism at rest, as measured by PET, and neurobehavioral status after severe TBI at the subacute stage. Methods: Thirteen patients without focal structural lesion on MRI were studied. Neuropsychological assessment included tests of memory, attention and speed of information processing, and executive functions, and a global neurobehavioral assessment. Regional cerebral glucose metabolism at rest was measured with (F-18)-fluorodeoxyglucose and PET. Results: A close link was found between cognitive and behavioral disorders and decreased cortical metabolism in prefrontal and cingulate cortex. Tests of memory and executive functions significantly correlated with regional metabolism in the mesial and lateral prefrontal cortex and the cingulate gyrus. Behavioral disorders correlated significantly with mesial prefrontal and cingulate metabolisms. Conclusion: These results suggest a predominant role of prefrontal and cingulate dysfunction in cognitive and behavioral disorders of patients with severe traumatic brain injury, even in the absence of focal structural lesion of the brain. Further cognitive functional activation research using PET or functional MRI might help clarify the relative contributions of both areas to dysfunction.	Univ Paris 05, Hosp Raymond Poincare AP HP, Serv Reeduc Neurol, Format Rech Claude Bernard,UFR Paris Ouest, Garches, France; Hop Orsay, CEA, Dept Biol, Serv Hosp Frederic Joliot, Orsay, France		Azouvi, P (corresponding author), Reymond Poincare Hosp, Dept Neurol Rehabil, F-92380 Garches, France.		samson, yves/C-5647-2013	Remy, Philippe/0000-0003-2150-2563; samson, yves/0000-0002-8080-1427			ADAMS JH, 1984, GREENFIELDS NEUROPAT, P85; Azouvi P., 1993, Annales de Readaptation et de Medecine Physique, V36, P157; BENES FM, 1993, SCHIZOPHRENIA BULL, V19, P537, DOI 10.1093/schbul/19.3.537; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; CORBETTA M, 1991, J NEUROSCI, V11, P2383; DEVINSKY O, 1995, BRAIN, V118, P279, DOI 10.1093/brain/118.1.279; FLETCHER PC, 1995, BRAIN, V118, P401, DOI 10.1093/brain/118.2.401; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GOLDENBERG G, 1992, J NEUROL NEUROSUR PS, V55, P362, DOI 10.1136/jnnp.55.5.362; GROBER E, 1987, DEV NEUROPSYCHOL, V3, P13, DOI 10.1080/87565648709540361; JENNETT B, 1975, LANCET, V1, P480; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; LAPLANE D, 1981, J NEUROL SCI, V51, P289, DOI 10.1016/0022-510X(81)90107-6; LEVIN H S, 1990, Annales de Readaptation et de Medecine Physique, V33, P35; LEVIN HS, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P318; LEVIN HS, 1986, J CLIN EXP NEUROPSYC, V8, P643, DOI 10.1080/01688638608405185; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LOCKWOOD AH, 1993, HEPATOLOGY, V18, P1061; MANGIN JF, 1994, J CEREBR BLOOD F MET, V14, P749, DOI 10.1038/jcbfm.1994.96; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; ODER W, 1992, J NEUROL NEUROSUR PS, V55, P475, DOI 10.1136/jnnp.55.6.475; PARDO JV, 1990, P NATL ACAD SCI USA, V87, P256, DOI 10.1073/pnas.87.1.256; PENNIELLO MJ, 1995, BRAIN, V118, P697, DOI 10.1093/brain/118.3.697; PERANI D, 1993, BRAIN, V116, P903, DOI 10.1093/brain/116.4.903; PHELPS ME, 1979, ANN NEUROL, V6, P371, DOI 10.1002/ana.410060502; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; RAO N, 1984, ARCH PHYS MED REHAB, V65, P780; REIVICH M, 1985, J CEREBR BLOOD F MET, V5, P179, DOI 10.1038/jcbfm.1985.24; Sarazin M, 1998, NEUROLOGY, V51, P142, DOI 10.1212/WNL.51.1.142; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; SHIMAMURA AP, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P173; SIGNORET JL, 1991, BATTERIE EVALUATION, V144; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; Stuss D. T, 1987, NEUROBEHAVIORAL RECO, V166; Talairach J., 1988, COPLANAR STEREOTAXIC; TULVING E, 1994, P NATL ACAD SCI USA, V91, P2016, DOI 10.1073/pnas.91.6.2016; VILKKI J, 1992, NEUROPSYCHOLOGIA, V30, P807, DOI 10.1016/0028-3932(92)90084-Y	41	104	107	2	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	DEC 10	1999	53	9					1963	1968		10.1212/WNL.53.9.1963			6	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology	265QR	WOS:000084255300012	10599766				2022-02-06	
J	D'Ambrosio, R; Maris, DO; Grady, MS; Winn, HR; Janigro, D				D'Ambrosio, R; Maris, DO; Grady, MS; Winn, HR; Janigro, D			Selective loss of hippocampal long-term potentiation, but not depression, following fluid percussion injury	BRAIN RESEARCH			English	Article						brain injury; glia/neuronal interaction; swelling; synaptic plasticity; sprouting	TRAUMATIC BRAIN INJURY; NITRIC-OXIDE SYNTHASE; DENTATE GYRUS; SYNAPTIC TRANSMISSION; RAT-BRAIN; NEURONS; POTASSIUM; LTP; DYSFUNCTION; GLUTAMATE	We investigated the early effects of in vivo fluid percussion injury (FPI) on hippocampal synaptic potentials and excitability. In vitro field potential recordings and immunocytochemistry were performed in the CA1 region in slices from naive, post-FPI, or sham-operated rats. The following electrophysiological and morphological parameters were affected following FPI: (1) threshold for population spike generation was increased suggesting that post-FPI neurons were hypoexcitable; (2) long-term potentiation (LTP) could not be induced in injured hippocampi; (3) GFAP and inducible NO synthase (iNOS) immunoreactivity were enhanced post-FPI; and (4) following injury, synaptophysin immunoreactivity was enhanced in CAI stratum radiatum. The effects of FPI on synaptic plasticity were LTP-specific, since long-term depression (LTD) could be equally induced and maintained in post-FPI, sham-operated and control slices. Sham-operated slices were characterized by synaptic excitability indistinguishable from naive controls, but displayed decreased ability for LTP production and expressed high levels of iNOS. We conclude that FPI causes a selective loss of LTP, possibly due to a previous potentiation induced by trauma as reflected by the increased expression of synaptic proteins. Sham surgical procedures were, however, not without effects on long-term potentiation itself; the latter effects appear to be mediated by an increased production of NO. Our study demonstrates for the first time that hippocampal slices can be used to investigate the correlates of in vivo FPI. Furthermore, we describe LTP-specific deficits in post-traumatic brain injury, suggesting that FPI can selectively erase one of the two main NMDA-dependent forms of synaptic plasticity in the hippocampus. (C) 1998 Elsevier Science B.V.	Univ Washington, Harborview Med Ctr, Dept Neurol Surg, Sch Med, Seattle, WA 98104 USA; Univ Washington, Sch Med, Dept Environm Hlth, Seattle, WA 98104 USA		Janigro, D (corresponding author), Univ Washington, Harborview Med Ctr, Dept Neurol Surg, Sch Med, 325 9Th Ave,Box 359914, Seattle, WA 98104 USA.	ciao@u.washington.edu		Janigro, Damir/0000-0003-2165-5826	NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R29HL051614, R01HL051614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021076] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [NHLB 51614] Funding Source: Medline; NIEHS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [ES 07033] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 21076] Funding Source: Medline		ARTOLA A, 1993, TRENDS NEUROSCI, V16, P480, DOI 10.1016/0166-2236(93)90081-V; Barth A, 1997, BRAIN RES, V762, P79, DOI 10.1016/S0006-8993(97)00348-X; Bear Mark F., 1994, Current Opinion in Neurobiology, V4, P389, DOI 10.1016/0959-4388(94)90101-5; BENARI Y, 1990, NEUROSCIENCE, V37, P55, DOI 10.1016/0306-4522(90)90191-6; CASULLO J, 1987, CAN J PHYSIOL PHARM, V65, P847, DOI 10.1139/y87-136; CONTZEN R, 1994, BRAIN RES, V340, P340; CREPEL V, 1993, J NEUROPHYSIOL, V69, P494, DOI 10.1152/jn.1993.69.2.494; Dawson VL, 1996, J NEUROSCI, V16, P2479; FLECK MW, 1992, BRAIN RES, V580, P100, DOI 10.1016/0006-8993(92)90931-X; GALLUCI E, 1997, IN PRESS J NEUROTRAU; HARRISON CM, 1993, BRAIN RES, V602, P175, DOI 10.1016/0006-8993(93)90261-K; HATTEN ME, 1991, GLIA, V4, P233, DOI 10.1002/glia.440040215; Holscher C, 1997, TRENDS NEUROSCI, V20, P298, DOI 10.1016/S0166-2236(97)01065-5; Hoque AM, 1996, SHOCK, V6, P365, DOI 10.1097/00024382-199611000-00011; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; JANIGRO D, 1988, BRAIN RES, V453, P265, DOI 10.1016/0006-8993(88)90166-7; Janigro D, 1997, J NEUROSCI, V17, P2813; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kimelberg H K, 1987, Cent Nerv Syst Trauma, V4, P3; KOMBIAN SB, 1994, NATURE, V368, P242, DOI 10.1038/368242a0; LANDIS DMD, 1994, ANNU REV NEUROSCI, V17, P133, DOI 10.1146/annurev.ne.17.030194.001025; Largo C, 1996, NEUROL RES, V18, P445; Largo C, 1996, J NEUROSCI, V16, P1219; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; Linden DJ, 1997, NEURON, V18, P983, DOI 10.1016/S0896-6273(00)80337-2; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYNCH MA, 1994, NEUROSCIENCE, V60, P1, DOI 10.1016/0306-4522(94)90197-X; MACCAFERRI G, 1994, NEUROREPORT, V5, P1813, DOI 10.1097/00001756-199409080-00032; MASLIAH E, 1991, EXP NEUROL, V113, P131, DOI 10.1016/0014-4886(91)90169-D; MEFFERT MK, 1994, NEURON, V13, P1225, DOI 10.1016/0896-6273(94)90060-4; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; Nakanishi H, 1996, BRAIN RES, V732, P232, DOI 10.1016/0006-8993(96)00689-0; NELSON MT, 1995, AM J PHYSIOL-CELL PH, V268, pC799, DOI 10.1152/ajpcell.1995.268.4.C799; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Sastry B R, 1990, Adv Exp Med Biol, V268, P377; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; WENZEL J, 1991, BRAIN RES, V560, P122, DOI 10.1016/0006-8993(91)91222-M; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	40	104	105	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAR 9	1998	786	1-2					64	79		10.1016/S0006-8993(97)01412-1			16	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	ZJ738	WOS:000073248000008	9554957				2022-02-06	
J	Jaicks, RR; Cohn, SM; Moller, BA				Jaicks, RR; Cohn, SM; Moller, BA			Early fracture fixation may be deleterious after head injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						head trauma; secondary brain injury; fracture fixation	MULTIPLE TRAUMA PATIENTS; LONG-BONE FRACTURES; FEMUR FRACTURES; PULMONARY; OSTEOSYNTHESIS; MANAGEMENT; STATE	Objective: To determine the neurologic risks associated with early fracture fixation (FF) in multitrauma patients with head injuries. Methods: We reviewed 33 blunt trauma patients with significant closed head injuries (Abbreviated Injury Scale (AIS) score greater than or equal to 2) requiring operative FF. Nineteen patients underwent early FF defined as less than or equal to 24 hours after injury, and 14 patients underwent late FF defined as >24 hours after injury, The two groups were well matched in regards to age, 40.3 years (range, 8-88 years) versus 36.4 Sears (range, 8-75 Sears), admission Glasgow Coma Scale score (12 +/- 4 vs. 11 +/- 5), and Injury Severity Score (25 +/- 10 vs. 27 +/- 12). Additionally, the groups had similar neurologic and orthopedic injury scores (AIS-CNS score = 3.3 +/- 0.9 vs. 3.1 +/- 0.9, AIS-Ortho score = 3.0 +/- 0.9 vs. 2.9 +/- 0.7), Data were collected concerning the volume of fluid resuscitation, neurologic complications, and clinical outcomes. Results: The early FF group received significantly more fluids in the first 48 hours (14.0 +/- 10.2 vs. 8.7 +/- 3.5 liters, p < 0.05). The early group trended towards a higher rate of intraoperative hypotension (systolic blood pressure < 90 mm Hg, 16% vs. 7%) and intraoperative hypoxia (O-2-Saturation less than or equal to 90, 11% vs. 7%), The neurologic complication rate was similar in the two groups (early FF = 16% vs. late FF = 21%), but the average discharge Glasgow Coma Scale score was lower in the early group (13.5 +/- 3.7) when compared with the late FF patient group (15.0 +/- 0.0). Conclusions: Early FF leads to greater fluid administration in patients with head injuries, Hypoxemia and hypotension, risk factors for secondary brain injury, may contribute to a poor neurologic outcome after early fixation, Prospective studies evaluating the impact of the timing of FF on head injury are indicated.	YALE UNIV,SCH MED,DEPT SURG,SECT TRAUMA & SURG CRIT CARE,NEW HAVEN,CT 06520								BECKMAN SB, 1989, AM SURGEON, V56, P356; BEHRMAN SW, 1990, J TRAUMA, V30, P792, DOI 10.1097/00005373-199007000-00005; BONE LB, 1989, J BONE JOINT SURG AM, V71A, P336, DOI 10.2106/00004623-198971030-00004; BONE LB, 1994, J TRAUMA, V37, P262, DOI 10.1097/00005373-199408000-00019; CHARASH WE, 1994, J TRAUMA, V37, P667, DOI 10.1097/00005373-199410000-00023; Chesnut R M, 1995, New Horiz, V3, P366; FAKHRY SM, 1994, J TRAUMA, V37, P255, DOI 10.1097/00005373-199408000-00018; GORIS RJA, 1982, J TRAUMA, V22, P895, DOI 10.1097/00005373-198211000-00002; HOFMAN PAM, 1991, J TRAUMA, V31, P261, DOI 10.1097/00005373-199131020-00020; JOHNSON KD, 1985, J TRAUMA, V25, P375, DOI 10.1097/00005373-198505000-00001; KOTWICA Z, 1990, ACTA NEUROCHIR, V102, P19, DOI 10.1007/BF01402180; LOZMAN J, 1986, ARCH SURG-CHICAGO, V121, P992; PAPE HC, 1993, J TRAUMA, V34, P540, DOI 10.1097/00005373-199304000-00010; PELIAS ME, 1992, SURGERY, V111, P576; POOLE GV, 1992, J TRAUMA, V32, P654, DOI 10.1097/00005373-199205000-00019; REYNOLDS MA, 1995, ANN SURG, V222, P470; RISKA EB, 1977, J TRAUMA, V17, P111, DOI 10.1097/00005373-197702000-00005; ROGERS FB, 1994, J TRAUMA, V36, P774, DOI 10.1097/00005373-199406000-00004; SEIBEL R, 1985, ANN SURG, V202, P283, DOI 10.1097/00000658-198509000-00003; VANOS JP, 1994, J TRAUMA, V37, P262	20	104	107	0	2	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JAN	1997	42	1					1	5		10.1097/00005373-199701000-00001			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	WD269	WOS:A1997WD26900001	9003250				2022-02-06	
J	Fukuda, K; Richmon, JD; Sato, M; Sharp, FR; Panter, SS; Noble, LJ				Fukuda, K; Richmon, JD; Sato, M; Sharp, FR; Panter, SS; Noble, LJ			Induction of heme oxygenase-1 (HO-1) in glia after traumatic brain injury	BRAIN RESEARCH			English	Article						heme oxygenase; astrocyte; microglia; macrophage; Bergmann glia; heat shock protein	HEAT-SHOCK PROTEIN; MESSENGER-RNA; RAT-BRAIN; LIPID-PEROXIDATION; RAPID INDUCTION; EXPRESSION; ANTIOXIDANT; MECHANISMS; HYPERTHERMIA; MICROGLIA	In this study we examined the induction of heme oxygenase-1 (HO-1) in glia in the traumatized rat brain. HO-1 was immunolocalized in fixed sections of brain 3 h to 5 days after injury. Induction of this enzyme in astrocytes, microglia/macrophages, and oligodendrocytes was evaluated using immunofluorescent double labeling with monoclonal antibodies to glial fibrillary acidic protein, complement C3bi receptor, and myelin basic protein. Induction of HO-1 was apparent in the injured hemisphere and cerebellum as early as 24 h postinjury. The protein was likewise noted in similar regions of the brain at 72 h postinjury but appeared to be more widespread in its distribution. At 5 days postinjury, there was a notable decline in the degree of immunostaining for HO-1. HO-1 was typically induced in astrocytes in the cerebral cortex at the site of impact, in the deep cortical layers adjacent to the hemorrhagic lesions, and in the hippocampus. HO-1 was induced in Bergmann glia in the vermis of cerebellum. In addition, HO-1 was also induced in microglia/macrophages scattered throughout the ipsilateral cerebral cortex, cerebellum and subarachnoid space. These findings demonstrate prolonged glial induction of HO-1 in the traumatized brain. Such a response may reflect a protective role of these cells against secondary insults including oxidative stress.	SAN FRANCISCO GEN HOSP,DEPT NEUROSURG,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,DEPT NEUROSURG,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT NEUROL,SAN FRANCISCO,CA 94143; VET AFFAIRS MED CTR,SAN FRANCISCO,CA 94121				Richmon, Jeremy/ABI-4295-2020	Richmon, Jeremy/0000-0002-6588-6549	NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL053040] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS014543, P50NS014543, R01NS028167] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL53040] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS28167, NS14543] Funding Source: Medline		APPLEGATE LA, 1991, CANCER RES, V51, P974; BRAUGHLER JM, 1986, J BIOL CHEM, V261, P282; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; DWYER BE, 1992, GLIA, V5, P300, DOI 10.1002/glia.440050407; DWYER BE, 1995, MOL BRAIN RES, V30, P37, DOI 10.1016/0169-328X(94)00273-H; EWING JF, 1992, J NEUROCHEM, V58, P1140, DOI 10.1111/j.1471-4159.1992.tb09373.x; EWING JF, 1991, P NATL ACAD SCI USA, V88, P5364, DOI 10.1073/pnas.88.12.5364; EWING JF, 1993, J NEUROCHEM, V60, P1512, DOI 10.1111/j.1471-4159.1993.tb03315.x; EWING JF, 1992, MOL CELL NEUROSCI, V3, P559, DOI 10.1016/1044-7431(92)90068-D; Fukuda K, 1996, J NEUROTRAUM, V13, P255, DOI 10.1089/neu.1996.13.255; FUKUDA K, 1995, NEUROSCI LETT, V199, P127, DOI 10.1016/0304-3940(95)12042-3; Hall Edward D., 1993, Journal of Emergency Medicine, V11, P31; KUTTY RK, 1995, P NATL ACAD SCI USA, V92, P1177, DOI 10.1073/pnas.92.4.1177; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; MATZ P, 1996, MOL BRAIN RES, V713, P211; NAKAJIMA K, 1993, NEUROSCI RES, V17, P187, DOI 10.1016/0168-0102(93)90047-T; PASCHEN W, 1994, NEUROSCI LETT, V180, P5, DOI 10.1016/0304-3940(94)90900-8; PREMKUMAR DRD, 1995, J NEUROCHEM, V65, P1399; SCHIPPER HM, 1995, ANN NEUROL, V37, P758, DOI 10.1002/ana.410370609; SHIBAHARA S, 1987, J BIOL CHEM, V262, P12889; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; STOCKER R, 1987, P NATL ACAD SCI USA, V84, P5918, DOI 10.1073/pnas.84.16.5918; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; TAKEDA A, 1994, BRAIN RES, V666, P120, DOI 10.1016/0006-8993(94)90292-5; TANNO H, 1993, J CEREBR BLOOD F MET, V13, P116, DOI 10.1038/jcbfm.1993.14; THOMAS WE, 1992, BRAIN RES REV, V17, P61; TRAKSHEL GM, 1986, J BIOL CHEM, V261, P1131; TURNER CP, 1995, SOC NEUR ABSTR, V25, P496; WHITE BC, 1993, ANN EMERG MED, V22, P970, DOI 10.1016/S0196-0644(05)82737-4	29	104	106	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	OCT 14	1996	736	1-2					68	75		10.1016/0006-8993(96)00680-4			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	VR613	WOS:A1996VR61300009	8930310				2022-02-06	
J	Levin, HS; Fletcher, JM; Kufera, JA; Harward, H; Lilly, MA; Mendelsohn, D; Bruce, D; Eisenberg, HM				Levin, HS; Fletcher, JM; Kufera, JA; Harward, H; Lilly, MA; Mendelsohn, D; Bruce, D; Eisenberg, HM			Dimensions of cognition measured by the Tower of London and other cognitive tasks in head-injured children and adolescents	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							LESIONS	To determine the factor structure of executive functioning in head-injured (n = 81) and normal children (n = 102), we administered tests of concept formation and problem solving, plus planning, verbal fluency, design fluency, memory (to evaluate semantic organization), and response modulation using a Go/No-Go task. The children who sustained closed head injury (CHI) were divided into subgroups who sustained severe (n = 39) and mild/moderate (n = 42) injury. The CHI groups and normal controls were also grouped according to age at the time of testing (6-8, 9-12, and 13-16). The principal components analysis disclosed a five-factor solution that accounted for 79% of the variance: Conceptual-Productivity (Factor 1), Planning (Factor 2), Schema (Factor 3), Cluster (Factor 4), and Inhibition (Factor 5). Age had a significant effect on Factors 1, 2, and 5, whereas severity of CHI affected Factors 1, 2, 4, and 5. Using hierarchial regression in which the Glasgow Coma Scale score, age, and their interaction were entered first, the volume of frontal lobe lesion contributed significantly to predicting Factors 1 (Conceptual-Productivity) and 2 (Planning), whereas the volume of left frontal lesions also predicted Factor 3 (Schema). The volume of extrafrontal lesions augmented the prediction of Factor 3, supporting the general relation of left hemisphere abnormality to the cognitive variables loading on this factor. Pending replication in a different sample of head-injured children, caution is advised in interpreting the findings due to potential instability of the factor structure.	UNIV TEXAS, SCH MED, DEPT PEDIAT, AUSTIN, TX USA; UNIV MARYLAND MED SYST, DIV NEUROSURG, COLLEGE PK, MD 20742 USA; UNIV TEXAS, MED BRANCH, DIV NEUROSURG, GALVESTON, TX 77550 USA; UNIV TEXAS, SW MED SCH, DEPT RADIOL, DALLAS, TX USA; UNIV TEXAS, SW MED SCH, DEPT NEUROSURG, DALLAS, TX USA		Levin, HS (corresponding author), BAYLOR COLL MED, COGNIT NEUROSCI LAB, A-205, 1333 MOURSUND, HOUSTON, TX 77030 USA.		Fletcher, Jack/AAX-2931-2020; fletcher, jack/Q-5975-2019				BENTON AL, 1968, NEUROPSYCHOLOGIA, V6, P53, DOI 10.1016/0028-3932(68)90038-9; DENNEY DR, 1973, DEV PSYCHOL, V9, P275, DOI 10.1037/h0035092; DREWE E A, 1975, Cortex, V11, P8; FLETCHER JM, 1995, TRAUMATIC HEAD INJUR, P3; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Heaton PDRK., 1993, WISCONSIN CARD SORTI; JONESGOTMAN M, 1977, NEUROPSYCHOLOGIA, V15, P653, DOI 10.1016/0028-3932(77)90070-7; Levin H. S., 1994, NEUROPSYCHOLOGY, V87, P171, DOI DOI 10.1037/0894-4105.8.2.171; LEVIN HS, 1991, DEV NEUROPSYCHOL, V7, P377, DOI 10.1080/87565649109540499; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; OWEN AM, 1990, NEUROPSYCHOLOGIA, V28, P1021, DOI 10.1016/0028-3932(90)90137-D; Passler MA, 1985, DEV NEUROPSYCHOL, V1, P349, DOI 10.1080/87565648509540320; PEENNINGTON BF, 1994, FUTURE ORIENTED PROC, P243; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; TEASDALE G, 1974, LANCET, V2, P81; [No title captured]	16	104	104	0	13	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.		1996	12	1					17	34		10.1080/87565649609540638			18	Psychology, Developmental; Psychology; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	UM970	WOS:A1996UM97000003					2022-02-06	
J	SERVADEI, F; NANNI, A; NASI, MT; ZAPPI, D; VERGONI, G; GIULIANI, G; ARISTA, A				SERVADEI, F; NANNI, A; NASI, MT; ZAPPI, D; VERGONI, G; GIULIANI, G; ARISTA, A			EVOLVING BRAIN-LESIONS IN THE FIRST 12 HOURS AFTER HEAD-INJURY - ANALYSIS OF 37 COMATOSE PATIENTS	NEUROSURGERY			English	Article						COMATOSE PATIENTS; EVOLVING INTRACRANIAL LESIONS; SUBDURAL, EXTRADURAL, AND INTRACEREBRAL HEMATOMAS; SURGICAL INDICATIONS; TIMING OF COMPUTED TOMOGRAPHIC SCAN	ACUTE SUBDURAL-HEMATOMA; ACUTE EXTRADURAL HEMATOMA; EPIDURAL HEMATOMAS; MANAGEMENT; TRAUMA; RESOLUTION; TOMOGRAPHY; MORTALITY	FROM JANUARY 1, 1990, to April 30, 1994, 412 patients were admitted to our intensive care unit in coma after head injuries. Our study group consisted of 37 patients who were retrospectively identified as harboring lesions or developing new lesions within a 12-hour period from the time of admission. We defined the evolution of a lesion as an increase or decrease in the size of an already present hematoma or as the appearance of a totally new lesion. There were 25 male and 12 female patients (mean age, 34.9 yr), and the cause of trauma was road traffic accidents in 32 patients. Nine patients presented with shock, and six had evidence of abnormal coagulation at admission, Patients were divided into two different groups. In Group 1, 15 patients harbored lesions that evolved toward reabsorption. In Group 2, 22 patients harbored hematomas that evolved toward lesions requiring surgical removal. Fifteen of these patients had initial diagnoses of diffuse injury that evolved in this manner, whereas the remaining seven patients had already been operated upon and had developed second, noncontiguous, surgical lesions. Patients with lesions that required surgical evacuation had their computed tomographic (CT) scans obtained earlier and had a higher incidence of clinical deterioration. There was a significant difference in the evolution of the different lesions (P < 0.001), with subdural hematomas being more prone to reabsorption and intracerebral and extradural hematomas being more likely to increase in size or to appear as new lesions. Second CT scans were obtained because of clinical deterioration in 10 patients and because of increase in intracranial pressure in 5 patients. Scheduled CT scans were obtained in 13 patients, whereas in the remaining 9 patients, the diagnosis emerged from a combination of scheduled CT scans and intracranial pressure monitoring. There was a trend toward a poorer result among the patients with clinical deterioration, which, however, was not significant. A significant proportion of post-traumatic patients, particularly those who are unconscious, harbor early evolving intracranial lesions. When the first CT scan is performed within 3 hours after injury, a CT scan should be repeated within 12 hours.	OSPED GEN PROVINCIALE M BUFALINI, INTENS CARE UNIT, I-47023 CESENA, ITALY; OSPED GEN PROVINCIALE M BUFALINI, SERV NEURORADIOL, I-47023 CESENA, ITALY		SERVADEI, F (corresponding author), OSPED GEN PROVINCIALE M BUFALINI, DIV NEUROSURG, I-47023 CESENA, ITALY.			Servadei, Franco/0000-0002-3595-3464			AOKI N, 1986, J NEUROSURG, V65, P555, DOI 10.3171/jns.1986.65.4.0555; BUCCI MN, 1986, NEUROSURGERY, V19, P65, DOI 10.1227/00006123-198607000-00009; BULLOCK R, 1990, HDB CLIN NEUROLOGY H, V13, P249; COOPER PR, 1979, NEUROSURGERY, V5, P566, DOI 10.1227/00006123-197911000-00004; COOPER PR, 1993, HEAD INJURY, P275; CROCE MA, 1994, J TRAUMA, V36, P820, DOI 10.1097/00005373-199406000-00012; GALBRAITH S, 1981, J NEUROSURG, V55, P75, DOI 10.3171/jns.1981.55.1.0075; JENNETT B, 1975, LANCET, V1, P480; KATAYAMA Y, 1993, INTRACRANIAL PRESSUR, V8, P678; KNUCKEY NW, 1989, J NEUROSURG, V70, P392, DOI 10.3171/jns.1989.70.3.0392; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MATHEW P, 1993, ACTA NEUROCHIR, V121, P100, DOI 10.1007/BF01809258; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MILLER JD, 1987, ACTA NEUROCHIR, V85, P80, DOI 10.1007/BF01456102; NAGAO T, 1986, NEUROSURGERY, V19, P465, DOI 10.1227/00006123-198609000-00024; OLSON JD, 1989, NEUROSURGERY, V24, P825, DOI 10.1227/00006123-198906000-00007; POLMAN CH, 1986, NEUROSURGERY, V19, P446, DOI 10.1227/00006123-198609000-00019; POON WS, 1992, NEUROSURGERY, V30, P681; REALE F, 1985, SURG NEUROL, V24, P260, DOI 10.1016/0090-3019(85)90034-5; ROBERSON FC, 1979, SURG NEUROL, V12, P161; SAKAI H, 1988, J NEUROSURG, V68, P566, DOI 10.3171/jns.1988.68.4.0566; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; SERVADEI F, 1989, J TRAUMA, V29, P880, DOI 10.1097/00005373-198906000-00030; SMITH HK, 1991, NEUROSURGERY, V29, P258, DOI 10.1227/00006123-199108000-00016; SOLONIUK D, 1986, J TRAUMA, V26, P787, DOI 10.1097/00005373-198609000-00003; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212; YAMAKI T, 1990, ACTA NEUROCHIR, V103, P112, DOI 10.1007/BF01407516; ZIMMERMAN RA, 1978, RADIOLOGY, V127, P393, DOI 10.1148/127.2.393; ZIMMERMAN RA, 1982, RADIOLOGY, V144, P809, DOI 10.1148/radiology.144.4.7111729	31	104	109	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	NOV	1995	37	5					899	906		10.1227/00006123-199511000-00008			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	TC381	WOS:A1995TC38100023	8559338				2022-02-06	
J	IP, RY; DORNAN, J; SCHENTAG, C				IP, RY; DORNAN, J; SCHENTAG, C			TRAUMATIC BRAIN INJURY - FACTORS PREDICTING RETURN TO WORK OR SCHOOL	BRAIN INJURY			English	Article							HEAD-INJURY; REHABILITATION	Prediction of outcome for brain-injured individuals will facilitate effective rehabilitation programme planning which will ultimately improve the patient's quality of life. A sample of traumatic brain-injured subjects who had completed their rehabilitation were contacted post-discharge to identify predictive factors for return to work/school. Subjects were given a telephone interview and their charts were examined retrospectively along five subsets of variables in the predictive matrix: sociodemographics, chronicity, indices of severity, physical impairment, and cognitive functioning. Forty-five subjects were used as the study sample to investigate their vocational and educational outcome, and to generate the best predictive model for return to work/school. Twenty subjects made up the test sample used to evaluate the generalizability of the predictive model. Performance IQ score of the Wechsler Adult Intelligence Scale-Revised emerged as the most significant predictor of return to work/school. Implications of these findings for treatment and rehabilitation are discussed.			IP, RY (corresponding author), QUEEN ELIZABETH HOSP,ACQUIRED BRAIN INJURY PROGRAM,550 UNIV AVE,TORONTO,ON M5G 2A2,CANADA.						BLISHEN BR, 1976, CAN REV SOC ANTHROP, V13, P71, DOI 10.1111/j.1755-618X.1976.tb00759.x; BRENNAN MA, 1981, IRISH MED J, V74, P5; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; DIKMEN S, 1988, REHABILITATION COUNS, V31, P276; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; JENNETT B, 1975, LANCET, V1, P480; JOHNSON R, 1987, INT DISABILITY STUDI, V9, P45; LEVATI A, 1982, J NEUROSURG, V57, P779, DOI 10.3171/jns.1982.57.6.0779; Malec James F., 1993, Brain Injury, V7, P15, DOI 10.3109/02699059309008153; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; MEIER MJ, 1974, APA CONVENTION NEW O; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; RAO N, 1990, Brain Injury, V4, P49, DOI 10.3109/02699059009026148; RAO N, 1992, ARCH PHYS MED REHAB, V73, P911; REITAN RM, 1978, REITAN NEUROLOGICAL; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; STAMBROOK M, BRAIN INJURY, V4, P183; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D, 1987, MEMORY SCALE REVISED; WEHMAN PH, 1990, ARCH PHYS MED REHAB, V71, P1047; Wong Pauline P., 1993, Brain Injury, V7, P283, DOI 10.3109/02699059309034955; 1991, CANADIAN YB MINISTRY	24	104	106	0	5	TAYLOR & FRANCIS LTD LONDON	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	JUL	1995	9	5					517	532		10.3109/02699059509008211			16	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	RJ331	WOS:A1995RJ33100010	7550223				2022-02-06	
J	DEWITT, DS; PROUGH, DS; TAYLOR, CL; WHITLEY, JM				DEWITT, DS; PROUGH, DS; TAYLOR, CL; WHITLEY, JM			REDUCED CEREBRAL BLOOD-FLOW, OXYGEN DELIVERY, AND ELECTROENCEPHALOGRAPHIC ACTIVITY AFTER TRAUMATIC BRAIN INJURY AND MILD HEMORRHAGE IN CATS	JOURNAL OF NEUROSURGERY			English	Article						CEREBRAL BLOOD FLOW; HEAD INJURY; SHOCK; HEMORRHAGE; CAT	FLUID-PERCUSSION INJURY; HEAD-INJURY; ISOVOLEMIC HEMODILUTION; HYPERTONIC SALINE; RESUSCITATION; SHOCK; HYPOTENSION; METABOLISM; HEMODYNAMICS; ISCHEMIA	The authors investigated the effects of transient, mild hemorrhagic hypotension after fluid-percussion traumatic brain injury on intracranial pressure, cerebral blood flow (CBF), cerebral oxygen delivery (CBF x arterial O2 content), and electroencephalographic (EEG) activity. Adult mongrel cats were anesthetized with 1.6% isoflurane in N2O:O2 (70:30) and prepared for trauma and for radioactive microsphere CBF measurement. Isoflurane concentration was decreased to 0.8%, and the cats were randomly assigned to one of four control groups or to an experimental group. Animals in the four control groups underwent either mild hemorrhage (18 ml . kg-1) immediately followed by resuscitation with equal volumes of 10% Hetastarch (eight cats), mild hemorrhage followed by replacement of shed blood (six cats), isovolemic hemodilution with 18 ml . kg-1 of Hetastarch (six cats), or moderate (2.2 atm) trauma alone (eight cats). The experimental group received a combination of trauma and mild hemorrhage followed by resuscitation with Hetastarch (eight cats). Mild hemorrhage produced no significant changes in CBF, renal blood flow, or cardiac output. Following resuscitation from mild hemorrhage, mean arterial blood pressure, cardiac output, renal blood flow, and CBF were not significantly different from baseline; cardiac output and renal blood flow did not differ significantly from baseline 2 hours after Hetastarch resuscitation. Neither hemorrhage nor trauma alone produced significant decreases in CBF or in EEG activity, but trauma followed by hemorrhage and resuscitation produced significant (p < 0.01) decreases in CBF, cerebral oxygen delivery, and EEG score. These data demonstrate that, following traumatic brain injury, even mild hemorrhagic hypotension is associated with significant deficits in cerebral oxygen availability and neurological function.	WAKE FOREST UNIV,MED CTR,DEPT ANAT,WINSTON SALEM,NC 27109; WAKE FOREST UNIV,MED CTR,DEPT NEUROL,WINSTON SALEM,NC 27109; WAKE FOREST UNIV,MED CTR,DEPT PUBL HLTH SCI,WINSTON SALEM,NC 27109		DEWITT, DS (corresponding author), WAKE FOREST UNIV,MED CTR,DEPT ANESTHESIA,WINSTON SALEM,NC 27157, USA.		Prough, Donald S/G-5793-2013	Prough, Donald S/0000-0001-7994-532X	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [19355] Funding Source: Medline		ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ANDERSEN BJ, 1988, J NEUROSURG, V68, P601, DOI 10.3171/jns.1988.68.4.0601; CHEN RYZ, 1984, STROKE, V15, P343, DOI 10.1161/01.STR.15.2.343; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; COKER LH, 1989, ANESTHESIOLOGY, V71, P108; COLE JWL, 1966, BIOMETRICS, V22, P810, DOI 10.2307/2528076; CONOVER WJ, 1981, AM STAT, V35, P124, DOI 10.2307/2683975; DeWitt DS, 1988, J NEUROTRAUM, V5, P303, DOI 10.1089/neu.1988.5.303; ELLIS EF, 1981, J NEUROCHEM, V37, P892, DOI 10.1111/j.1471-4159.1981.tb04476.x; EMERSON TE, 1981, CEREBRAL MICROCIRCUL, P379; FIESCHI C, 1972, EUR NEUROL, V8, P192, DOI 10.1159/000114577; Fleiss JL, 1981, STAT METHODS RATES P, V2, P22; GREENBERG RP, 1981, J NEUROSURG, V55, P227, DOI 10.3171/jns.1981.55.2.0227; GREENBERG RP, 1981, SURG FORUM, V32, P492; GREGORY PC, 1979, STROKE, V10, P719, DOI 10.1161/01.STR.10.6.719; HAYES RL, 1984, SCIENCE, V223, P301, DOI 10.1126/science.6701514; HOFFBRAND BI, 1969, CARDIOVASC RES, V3, P426, DOI 10.1093/cvr/3.4.426; HOLM S, 1979, SCAND J STAT, V6, P65; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; Jenkins LW, 1988, J NEUROTRAUM, V5, P275, DOI 10.1089/neu.1988.5.275; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; KONG DL, 1991, CRIT CARE MED, V19, P532, DOI 10.1097/00003246-199104000-00013; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; LINDGREN S, 1966, BIOPHYSIK, V3, P174, DOI 10.1007/BF01191611; LINDGREN STEN, 1965, BIOPHYSIK, V2, P320; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565, DOI 10.1152/ajpendo.1987.253.5.E565; MCNAMARA JJ, 1983, J TRAUMA, V23, P552, DOI 10.1097/00005373-198307000-00002; MICHENFELDER JD, 1969, ANESTHESIOLOGY, V31, P449, DOI 10.1097/00000542-196911000-00017; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; NEES JE, 1978, SURGERY, V83, P639; POOLE GV, 1987, J TRAUMA, V27, P18, DOI 10.1097/00005373-198701000-00004; POOLE GV, 1986, CRIT CARE MED, V14, P629, DOI 10.1097/00003246-198607000-00009; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; PRIOR PF, 1978, BRIT J ANAESTH, V50, P993, DOI 10.1093/bja/50.10.993; PROUGH DS, 1986, J NEUROSURG, V64, P627, DOI 10.3171/jns.1986.64.4.0627; ROSENBLUM WI, 1981, NEUROSURGERY, V9, P613, DOI 10.1227/00006123-198112000-00001; ROSNER MJ, 1984, J NEUROSURG, V61, P76, DOI 10.3171/jns.1984.61.1.0076; RUDOLPH AM, 1967, CIRC RES, V21, P163, DOI 10.1161/01.RES.21.2.163; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; TEASDALE G, 1974, LANCET, V2, P81; TODD MM, 1985, J NEUROSURG, V63, P944, DOI 10.3171/jns.1985.63.6.0944; TOMMASINO C, 1988, CRIT CARE MED, V16, P862, DOI 10.1097/00003246-198809000-00009; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37	46	104	104	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	MAY	1992	76	5					812	821		10.3171/jns.1992.76.5.0812			10	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	HQ269	WOS:A1992HQ26900013	1564544				2022-02-06	
J	LIEHLAI, MW; THEODOROU, AA; SARNAIK, AP; MEERT, KL; MOYLAN, PM; CANADY, AI				LIEHLAI, MW; THEODOROU, AA; SARNAIK, AP; MEERT, KL; MOYLAN, PM; CANADY, AI			LIMITATIONS OF THE GLASGOW COMA SCALE IN PREDICTING OUTCOME IN CHILDREN WITH TRAUMATIC BRAIN INJURY	JOURNAL OF PEDIATRICS			English	Article							CLOSED-HEAD-INJURY; MANAGEMENT	Objective: To study the hypothesis that, in the absence of an ischemic-hypoxic state, children with severe traumatic brain injury and with unfavorable Glasgow Coma Scale scores may have good recovery. Design: Retrospective, observational, cross-sectional study with factorial design. Setting: Inpatient population in a university hospital. Patients: Seventy-nine children with traumatic brain injury admitted to the intensive care unit. Interventions: All patients received close monitoring and strict control of intracranial pressure (< 20 mm Hg) and cerebral perfusion pressure (> 60 mm Hg). Measurements and results: Admission Glasgow Coma Scale score, survival, need for cardiopulmonary resuscitation, presence of shock, peak intracranial pressure, duration of coma, Glasgow Outcome Scale score, and the results of neuropsychologic tests were analyzed. Of 79 children, 70 (89%) survived. Although the mortality rate was higher among patients with Glasgow Coma Scale scores of 3 to 5,14 (64%) of 22 of these children survived. Nonsurvivors had a significantly higher incidence of shock and need for cardiopulmonary resuscitation. Except for two patients who had prolonged hypoxemia, all children, including those with Glasgow Coma Scale scores of 3 to 5, had a satisfactory outcome (Glasgow Outcome Scale scores of 4 or 5). Neuropsychologic outcome was not significantly different in the survivors with Glasgow Coma Scale scores of 3 to 5 and those with Glasgow Coma Scale scores of 6 or more. Conclusions: A low Glasgow Coma Scale score does not always accurately predict the outcome of severe traumatic brain injury; in the absence of hypoxic-ischemic injury, children with traumatic brain injury and Glasgow Coma Scale scores of 3 to 5 can recover independent function.	WAYNE STATE UNIV, CHILDRENS HOSP MICHIGAN, SCH MED, DIV PEDIAT NEUROSURG, DETROIT, MI 48201 USA		LIEHLAI, MW (corresponding author), WAYNE STATE UNIV, CHILDRENS HOSP MICHIGAN, SCH MED, DIV CRIT CARE MED, DETROIT, MI 48201 USA.						BAXT WG, 1987, J TRAUMA, V27, P602, DOI 10.1097/00005373-198706000-00003; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BIJUR PE, 1990, PEDIATRICS, V86, P337; BRINK JD, 1980, J PEDIATR-US, V97, P721, DOI 10.1016/S0022-3476(80)80253-8; BRUCE DA, 1979, CHILD BRAIN, V5, P174; FILLEY CM, 1987, ARCH NEUROL-CHICAGO, V44, P194, DOI 10.1001/archneur.1987.00520140058018; Gerring J P, 1986, Pediatr Rev, V8, P115, DOI 10.1542/pir.8-4-115; GIBSON RM, 1989, LANCET, V2, P369; GOLDSTEIN FC, 1987, J LEARN DISABIL, V20, P518, DOI 10.1177/002221948702000903; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1976, LANCET, V1, P1031; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; KRIEL RL, 1988, ARCH PHYS MED REHAB, V69, P678; LEVATI A, 1982, J NEUROSURG, V57, P779, DOI 10.3171/jns.1982.57.6.0779; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MAYER T, 1981, CHILD BRAIN, V8, P189; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; SARNAIK AP, 1989, J TRAUMA, V29, P1434, DOI 10.1097/00005373-198910000-00023	19	104	105	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3476	1097-6833		J PEDIATR-US	J. Pediatr.	FEB	1992	120	2	1				195	199		10.1016/S0022-3476(05)80426-3			5	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	HC901	WOS:A1992HC90100005	1735814				2022-02-06	
J	Deistung, A; Schweser, F; Reichenbach, JR				Deistung, Andreas; Schweser, Ferdinand; Reichenbach, Juergen R.			Overview of quantitative susceptibility mapping	NMR IN BIOMEDICINE			English	Article; Proceedings Paper	4th International Workshop on MRI Phase Contrast and Quantitative Susceptibility Mapping (QSM)	SEP 26-28, 2016	Univ Graz, Graz, AUSTRIA		Univ Graz	magnetic susceptibility; quantitative susceptibility mapping; susceptibility tensor imaging; functional MRI; multiple sclerosis	MULTIPLE-SCLEROSIS LESIONS; BACKGROUND FIELD REMOVAL; TRAUMATIC BRAIN-INJURY; GRADIENT-ECHO MRI; PHASE UNWRAPPING ALGORITHM; SUBCORTICAL GRAY-MATTER; DIFFUSE AXONAL INJURY; NON-HAEMIN IRON; MAGNETIC-SUSCEPTIBILITY; IN-VIVO	Magnetic susceptibility describes the magnetizability of a material to an applied magnetic field and represents an important parameter in the field of MRI. With the recently introduced method of quantitative susceptibility mapping (QSM) and its conceptual extension to susceptibility tensor imaging (STI), the non-invasive assessment of this important physical quantity has become possible with MRI. Both methods solve the ill-posed inverse problem to determine the magnetic susceptibility from local magnetic fields. Whilst QSM allows the extraction of the spatial distribution of the bulk magnetic susceptibility from a single measurement, STI enables the quantification of magnetic susceptibility anisotropy, but requires multiple measurements with different orientations of the object relative to the main static magnetic field. In this review, we briefly recapitulate the fundamental theoretical foundation of QSM and STI, as well as computational strategies for the characterization of magnetic susceptibility with MRI phase data. In the second part, we provide an overview of current methodological and clinical applications of QSM with a focus on brain imaging. Copyright (C) 2016 John Wiley & Sons, Ltd.	[Deistung, Andreas; Reichenbach, Juergen R.] Friedrich Schiller Univ Jena, Jena Univ Hosp, Med Phys Grp, Inst Diagnost & Intervent Radiol, Philosophenweg 3, D-07743 Jena, Germany; [Schweser, Ferdinand] SUNY Buffalo, Jacobs Sch Med & Biomed Sci, Buffalo Neuroimaging Anal Ctr, Dept Neurol, Buffalo, NY USA; [Schweser, Ferdinand] SUNY Buffalo, Jacobs Sch Med & Biomed Sci, MRI Clin & Translat Res Ctr, Buffalo, NY USA; [Reichenbach, Juergen R.] Friedrich Schiller Univ Jena, Michael Stifel Ctr Data Driven & Simulat Sci Jena, Jena, Germany		Deistung, A; Reichenbach, JR (corresponding author), Friedrich Schiller Univ Jena, Jena Univ Hosp, Med Phys Grp, Inst Diagnost & Intervent Radiol, Philosophenweg 3, D-07743 Jena, Germany.	andreas.deistung@med.uni-jena.de; juergen.reichenbach@med.uni-jena.de	Schweser, Ferdinand/Q-6932-2019; Deistung, Andreas/AAN-9412-2021; Reichenbach, Jurgen R./B-4333-2011	Schweser, Ferdinand/0000-0003-0399-9211; Reichenbach, Jurgen R./0000-0002-2640-0630; Deistung, Andreas/0000-0002-2427-1302	German Research Foundation (DFG)German Research Foundation (DFG) [RE1123/9-2, DE2516/1-1]; International Society for Magnetic Resonance in Medicine (ISMRM); Friedrich Schiller University Jena; Interdisciplinary Center for Clinical Research (IZKF) in Jena, Germany; German Academic Exchange Service (DAAD)Deutscher Akademischer Austausch Dienst (DAAD) [57131995]	We are deeply grateful for support from Berengar W. Lehr, Li Huang, Karsten Sommer, Xiang Feng, Barthelemy Serres, Martin Stenzel, Hans-Joachim Mentzel, Matthias Schwab, Andreas Schafer, Robert Turner, Dagmar Timmann, Jan Klohs, Till Schneider and Alexander Radbruch. We acknowledge funding from the German Research Foundation (DFG, RE1123/9-2, DE2516/1-1), seed grants awarded to F.S. by the International Society for Magnetic Resonance in Medicine (ISMRM) and the Friedrich Schiller University Jena, and a seed grant awarded to A.D. by the Interdisciplinary Center for Clinical Research (IZKF) in Jena, Germany. Support is also acknowledged from the bilateral PPP - USA 2015/2016 program (project 57131995 - Quantitative MRI for Neurological Studies) of the German Academic Exchange Service (DAAD) awarded to JRR.	Abdul-Rahman HS, 2007, APPL OPTICS, V46, P6623, DOI 10.1364/AO.46.006623; Abduljalil AM, 2003, J MAGN RESON IMAGING, V18, P284, DOI 10.1002/jmri.10362; Acosta-Cabronero J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081093; Anderson LJ, 2001, EUR HEART J, V22, P2171, DOI 10.1053/euhj.2001.2822; ANDREWS BT, 1989, NEUROSURGERY, V24, P514, DOI 10.1227/00006123-198904000-00005; [Anonymous], QUANT SUSC MAPP TOOL; Ashkan K, 2007, BRIT J NEUROSURG, V21, P197, DOI 10.1080/02688690701272240; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; Bahr O, 2011, NEURO-ONCOLOGY, V13, P1020, DOI 10.1093/neuonc/nor099; Bagnato F, 2011, BRAIN, V134, P3599, DOI 10.1093/brain/awr278; Bai Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053237; Balla DZ, 2014, NEUROIMAGE, V100, P112, DOI 10.1016/j.neuroimage.2014.06.011; BEARD JL, 1993, NUTR REV, V51, P157, DOI 10.1111/j.1753-4887.1993.tb03096.x; Berg D, 2002, ARCH NEUROL-CHICAGO, V59, P999, DOI 10.1001/archneur.59.6.999; Berg D, 2008, LANCET NEUROL, V7, P1044, DOI 10.1016/S1474-4422(08)70239-4; BERNSTEIN MA, 1994, MAGN RESON MED, V32, P330, DOI 10.1002/mrm.1910320308; Bianciardi M, 2014, HUM BRAIN MAPP, V35, P2191, DOI 10.1002/hbm.22320; Bilgic B, 2016, QUANTITATIVE SUSCEPT; Bilgic B, 2016, NEUROIMAGE, V125, P1131, DOI 10.1016/j.neuroimage.2015.08.015; Bilgic B, 2015, MAGN RESON MED, V73, P2152, DOI 10.1002/mrm.25347; Bilgic B, 2014, J MAGN RESON IMAGING, V40, P181, DOI 10.1002/jmri.24365; Bilgic B, 2012, NEUROIMAGE, V59, P2625, DOI 10.1016/j.neuroimage.2011.08.077; Bioucas-Dias JM, 2007, IEEE T IMAGE PROCESS, V16, P698, DOI 10.1109/TIP.2006.888351; Blazejewska AI, 2015, J MAGN RESON IMAGING, V41, P1065, DOI 10.1002/jmri.24644; Blazejewska AI, 2013, NEUROLOGY, V81, P534, DOI 10.1212/WNL.0b013e31829e6fd2; Boddaert N, 2007, BLOOD, V110, P401, DOI 10.1182/blood-2006-12-065433; Boesch C, 1997, MAGN RESON MED, V37, P484, DOI 10.1002/mrm.1910370403; Bonekamp D, 2015, MAGN RESON MED, V73, P544, DOI 10.1002/mrm.25144; da Silva CB, 2014, EUR J NEUROL, V21, P1131, DOI 10.1111/ene.12448; Bowen CV, 2002, MAGNET RESON MED, V48, P52, DOI 10.1002/mrm.10192; Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; BRITTENHAM GM, 1982, NEW ENGL J MED, V307, P1671, DOI 10.1056/NEJM198212303072703; Buch S, 2015, MAGN RESON MED, V73, P2185, DOI 10.1002/mrm.25350; CERVOSNAVARRO J, 1991, J NEUROL SCI, V103, pS3; Chandran AS, 2016, J NEUROSURG, V124, P96, DOI 10.3171/2015.1.JNS142066; Chen WW, 2014, RADIOLOGY, V271, P183, DOI 10.1148/radiol.13130353; Chen WW, 2014, RADIOLOGY, V270, P496, DOI 10.1148/radiol.13122640; Chen ZK, 2015, J NEUROSCI METH, V241, P85, DOI 10.1016/j.jneumeth.2014.12.014; Chen ZK, 2013, J NEUROSCI METH, V216, P33, DOI 10.1016/j.jneumeth.2013.03.003; Cheng ZT, 2015, OPT EXPRESS, V23, P32337, DOI 10.1364/OE.23.032337; Cobzas D, 2015, J MAGN RESON IMAGING, V42, P1601, DOI 10.1002/jmri.24951; Compston A, 2008, LANCET, V372, P1502, DOI 10.1016/S0140-6736(08)61620-7; Cook DM, 1975, PROPERTIES MATTER, P289; COX IJ, 1986, J MAGN RESON, V70, P163, DOI 10.1016/0022-2364(86)90373-2; Damier P, 1999, BRAIN, V122, P1437, DOI 10.1093/brain/122.8.1437; de Rochefort L, 2008, MAGN RESON MED, V60, P1003, DOI 10.1002/mrm.21710; de Rochefort L, 2010, MAGN RESON MED, V63, P194, DOI 10.1002/mrm.22187; de Zwart JA, 2002, MAGN RESON MED, V48, P1011, DOI 10.1002/mrm.10303; Deh K, 2015, J MAGN RESON IMAGING, V42, P1592, DOI 10.1002/jmri.24943; Deistung A, 2015, P 23 ANN M ISMRM TOR, P284; Deistung A, 2008, MAGN RESON MED, V60, P1155, DOI 10.1002/mrm.21754; Deistung A, 2006, Z MED PHYS, V16, P261, DOI 10.1078/0939-3889-00324; Deistung A, 2016, CEREBELLUM, V15, P21, DOI 10.1007/s12311-015-0738-9; Deistung A, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00710; Deistung A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057924; Deistung A, 2013, NEUROIMAGE, V65, P299, DOI 10.1016/j.neuroimage.2012.09.055; Deistung A, 2009, J MAGN RESON IMAGING, V29, P1478, DOI 10.1002/jmri.21673; DEXTER DT, 1991, BRAIN, V114, P1953, DOI 10.1093/brain/114.4.1953; Di Corato R, 2013, ACS NANO, V7, P7500, DOI 10.1021/nn401095p; Dibb R, 2015, J CARDIOVASC MAGN R, V17, DOI 10.1186/s12968-015-0159-4; Diedrichsen J, 2011, NEUROIMAGE, V54, P1786, DOI 10.1016/j.neuroimage.2010.10.035; Donato Stefano Di, 2012, Handb Clin Neurol, V103, P399, DOI 10.1016/B978-0-444-51892-7.00025-5; Dong JW, 2015, IEEE T MED IMAGING, V34, P531, DOI 10.1109/TMI.2014.2361764; Duerst Y, 2016, MAGN RESON MED, V76, P430, DOI 10.1002/mrm.25838; Durrant CJ, 2003, CONCEPTS MAGN RESO A, V18A, P72, DOI 10.1002/cmr.a.10067; Duyn J, 2013, J MAGN RESON, V229, P198, DOI 10.1016/j.jmr.2012.11.013; Duyn JH, 2007, P NATL ACAD SCI USA, V104, P11796, DOI 10.1073/pnas.0610821104; Eskildsen SF, 2012, NEUROIMAGE, V59, P2362, DOI 10.1016/j.neuroimage.2011.09.012; Fan AP, 2015, NEUROIMAGE, V104, P146, DOI 10.1016/j.neuroimage.2014.09.068; Fan AP, 2014, MAGN RESON MED, V72, P149, DOI 10.1002/mrm.24918; FAUL D, 1984, Radiology, V153, P303; Feng X, 2015, P 23 ANN M ISMRM TOR, P3497; Fernandez-Seara MA, 2000, MAGNET RESON MED, V44, P358, DOI 10.1002/1522-2594(200009)44:3<358::AID-MRM3>3.0.CO;2-I; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Fukunaga M, 2010, P NATL ACAD SCI USA, V107, P3834, DOI 10.1073/pnas.0911177107; Gallichan D, 2016, MAGN RESON MED, V75, P1030, DOI 10.1002/mrm.25670; Ghiglia DC, 1996, J OPT SOC AM A, V13, P1999, DOI 10.1364/JOSAA.13.001999; Gierga K, 2009, NEUROPATH APPL NEURO, V35, P515, DOI 10.1111/j.1365-2990.2009.01015.x; GOOD PF, 1992, ANN NEUROL, V31, P286, DOI 10.1002/ana.410310310; Haacke EM, 2010, J MAGN RESON IMAGING, V32, P663, DOI 10.1002/jmri.22276; Haacke E.M., 2011, SUSCEPTIBILITY WEIGH; Haacke EM, 2015, MAGN RESON IMAGING, V33, P1, DOI 10.1016/j.mri.2014.09.004; Haacke EM, 2005, MAGN RESON IMAGING, V23, P1, DOI 10.1016/j.mri.2004.10.001; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; Haacke EM, 1997, HUM BRAIN MAPP, V5, P341, DOI 10.1002/(SICI)1097-0193(1997)5:5<341::AID-HBM2>3.0.CO;2-3; HAACKE EM, 1999, MAGNETIC RESONANCE I, P741; Hadzhieva M, 2014, NEUROPATH APPL NEURO, V40, P240, DOI 10.1111/nan.12096; HALLGREN B, 1960, J NEUROCHEM, V5, P307, DOI 10.1111/j.1471-4159.1960.tb13369.x; HALLGREN B, 1958, J NEUROCHEM, V3, P41, DOI 10.1111/j.1471-4159.1958.tb12607.x; Hametner S, 2013, ANN NEUROL, V74, P848, DOI 10.1002/ana.23974; Hammond KE, 2008, NEUROIMAGE, V39, P1682, DOI 10.1016/j.neuroimage.2007.10.037; Hammond KE, 2008, ANN NEUROL, V64, P707, DOI 10.1002/ana.21582; Hankins JS, 2009, BLOOD, V113, P4853, DOI 10.1182/blood-2008-12-191643; He NY, 2015, HUM BRAIN MAPP, V36, P4407, DOI 10.1002/hbm.22928; He Q, 2015, P 23 ANN M ISMRM TOR, P1725; He X, 2009, P NATL ACAD SCI USA, V106, P13558, DOI 10.1073/pnas.0904899106; Hebbrecht G, 1999, NUCL INSTRUM METH B, V150, P208, DOI 10.1016/S0168-583X(98)00938-0; Herrmann KH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150371; Hinoda T, 2015, INVEST RADIOL, V50, P522, DOI 10.1097/RLI.0000000000000159; HOLT RW, 1994, JMRI-J MAGN RESON IM, V4, P809, DOI 10.1002/jmri.1880040612; Hopkins JA, 1997, MAGNET RESON MED, V37, P494, DOI 10.1002/mrm.1910370404; Huang YL, 2015, NEUROLOGY, V84, P580, DOI 10.1212/WNL.0000000000001237; HWANG SN, 1995, J MAGN RESON SER B, V109, P126, DOI 10.1006/jmrb.1995.0002; Jain M, 2007, DIAMAGNETIC SUSCEPTI; Jain V, 2013, MAGN RESON MED, V70, P785, DOI 10.1002/mrm.24519; Jain V, 2012, MAGN RESON MED, V68, P863, DOI 10.1002/mrm.23282; Jezzard P, 1999, HUM BRAIN MAPP, V8, P80, DOI 10.1002/(SICI)1097-0193(1999)8:2/3<80::AID-HBM2>3.0.CO;2-C; KAWAMURA Y, 1981, MOL CRYST LIQ CRYST, V67, P733; Khabipova D, 2015, P 23 ANN M ISMRM TOR, P929; Khabipova D, 2015, NEUROIMAGE, V107, P163, DOI 10.1016/j.neuroimage.2014.11.038; Kidd D, 1999, BRAIN, V122, P17, DOI 10.1093/brain/122.1.17; Kiselev VG, 2001, MAGN RESON MED, V46, P1113, DOI 10.1002/mrm.1307; Klassen L, 2005, P INT SOC MAGN RESON, V13, P496; Klockgether T, 2011, CURR OPIN NEUROL, V24, P339, DOI 10.1097/WCO.0b013e32834875ba; Klohs J, 2016, J CEREBR BLOOD F MET, V36, P1614, DOI 10.1177/0271678X15621500; Koeppen AH, 2007, ACTA NEUROPATHOL, V114, P163, DOI 10.1007/s00401-007-0220-y; Koeppen AH, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-26; Koeppen AH, 2012, CEREBELLUM, V11, P845, DOI 10.1007/s12311-012-0383-5; Koopmans PJ, 2008, MAGN RESON MATER PHY, V21, P149, DOI 10.1007/s10334-007-0101-3; Kornienko V. N., 2009, DIAGNOSTIC NEURORADI; Kressler B, 2010, IEEE T MED IMAGING, V29, P273, DOI 10.1109/TMI.2009.2023787; Langkammer C, 2015, NEUROIMAGE, V111, P622, DOI 10.1016/j.neuroimage.2015.02.041; Langkammer C, 2013, RADIOLOGY, V267, P551, DOI 10.1148/radiol.12120707; Langkammer C, 2012, NEUROIMAGE, V62, P1593, DOI 10.1016/j.neuroimage.2012.05.049; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; Lee J, 2011, NEUROIMAGE, V54, P2779, DOI 10.1016/j.neuroimage.2010.10.071; Lee J, 2010, P NATL ACAD SCI USA, V107, P5130, DOI 10.1073/pnas.0910222107; Leskovjan AC, 2011, NEUROIMAGE, V55, P32, DOI 10.1016/j.neuroimage.2010.11.073; Leutritz T, 2013, MAGN RESON MED, V69, P263, DOI 10.1002/mrm.24223; LeVine SM, 1997, BRAIN RES, V760, P298, DOI 10.1016/S0006-8993(97)00470-8; Li L, 2004, MAGN RESON MED, V51, P1077, DOI 10.1002/mrm.20054; Li L, 2001, J MAGN RESON, V148, P442, DOI 10.1006/jmre.2000.2267; Li Wei, 2013, J Neurosci Neuroeng, V2, P431; Li W, 2015, NEUROIMAGE, V108, P111, DOI 10.1016/j.neuroimage.2014.12.043; Li W, 2014, HUM BRAIN MAPP, V35, P2698, DOI 10.1002/hbm.22360; Li W, 2014, NMR BIOMED, V27, P219, DOI 10.1002/nbm.3056; Li W, 2012, NEUROIMAGE, V59, P2088, DOI 10.1016/j.neuroimage.2011.10.038; Li X, 2016, J MAGN RESON IMAGING, V43, P463, DOI 10.1002/jmri.24976; Li X, 2014, MAGN RESON MED, V72, P610, DOI 10.1002/mrm.25322; Li X, 2012, NEUROIMAGE, V62, P314, DOI 10.1016/j.neuroimage.2012.04.042; Lim IAL, 2014, NEUROIMAGE, V86, P265, DOI 10.1016/j.neuroimage.2013.09.072; Lin PY, 2015, AM J NEURORADIOL, V36, P467, DOI 10.3174/ajnr.A4137; Liu C, 2016, STI SUITE; Liu CL, 2015, TOMOGRAPHY, V1, P3, DOI 10.18383/j.tom.2015.00136; Liu CL, 2015, J MAGN RESON IMAGING, V42, P23, DOI [10.3969/j.issn.1001-2400.2015.01.004, 10.1002/jmri.24768]; Liu CL, 2013, FRONT INTEGR NEUROSC, V7, DOI 10.3389/fnint.2013.00011; Liu CL, 2013, NEUROIMAGE, V67, P193, DOI 10.1016/j.neuroimage.2012.10.050; Liu CL, 2011, NEUROIMAGE, V56, P930, DOI 10.1016/j.neuroimage.2011.02.024; Liu CL, 2010, MAGN RESON MED, V63, P1471, DOI 10.1002/mrm.22482; Liu J, 2012, NEUROIMAGE, V59, P2560, DOI 10.1016/j.neuroimage.2011.08.082; Liu J, 2016, J NEUROTRAUM, V33, P10, DOI 10.1089/neu.2014.3856; Liu JM, 2015, MAGN RESON MED, V73, P1654, DOI 10.1002/mrm.25247; Liu S, 2015, P 23 ANN M ISMRM TOR, P3309; Liu T, 2013, RADIOLOGY, V269, P216, DOI 10.1148/radiol.13121991; Liu T, 2013, MAGN RESON MED, V69, P467, DOI 10.1002/mrm.24272; Liu T, 2011, NMR BIOMED, V24, P1129, DOI 10.1002/nbm.1670; Liu T, 2009, MAGN RESON MED, V61, P196, DOI 10.1002/mrm.21828; Liu W, 2016, RADIOLOGY, V278, P536, DOI 10.1148/radiol.2015150160; Lobel U, 2010, NEURORADIOLOGY, V52, P1167, DOI 10.1007/s00234-010-0771-9; Loktyushin A, 2013, MAGN RESON MED, V70, P1608, DOI 10.1002/mrm.24615; Lonsdale K, 1939, PROC R SOC LON SER-A, V171, P0541, DOI 10.1098/rspa.1939.0083; Lorentz H., 1916, THEORY ELECT ITS APP; Lotfipour AK, 2012, J MAGN RESON IMAGING, V35, P48, DOI 10.1002/jmri.22752; Louis DN, 2007, WHO CLASSIFICATION T, V4th; Luo J, 2014, MAGN RESON MED, V71, P1251, DOI 10.1002/mrm.24762; Ma YJ, 2015, MED PHYS, V42, P637, DOI 10.1118/1.4905163; Maderwald S, 2012, NEUROIMAGE, V63, P1421, DOI 10.1016/j.neuroimage.2012.07.063; Mahlknecht P, 2013, NEURODEGENER DIS, V12, P212, DOI 10.1159/000348595; Marques JP, 2005, CONCEPT MAGN RESON B, V25B, P65, DOI 10.1002/cmr.b.20034; Mittal S, 2009, AM J NEURORADIOL, V30, P232, DOI 10.3174/ajnr.A1461; Moon Y, 2016, J ALZHEIMERS DIS, V51, P737, DOI 10.3233/JAD-151037; MORRIS CM, 1992, ACTA ANAT, V144, P235; Moser E, 2012, NMR BIOMED, V25, P695, DOI 10.1002/nbm.1794; Murakami Y, 2015, AM J NEURORADIOL, V36, P1102, DOI 10.3174/ajnr.A4260; Nakada T, 2008, J NEUROIMAGING, V18, P125, DOI 10.1111/j.1552-6569.2007.00179.x; Navarro MA, 2012, OPT EXPRESS, V20, P2556, DOI 10.1364/OE.20.002556; Neelavalli J, 2011, MRI SUSCEPTIBILITY W, P17; Neelavalli J, 2009, J MAGN RESON IMAGING, V29, P937, DOI 10.1002/jmri.21693; Nordsmark M, 2005, RADIOTHER ONCOL, V77, P18, DOI 10.1016/j.radonc.2005.06.038; Ogawa S, 1998, ANNU REV BIOPH BIOM, V27, P447, DOI 10.1146/annurev.biophys.27.1.447; Barbosa JHO, 2015, MAGN RESON IMAGING, V33, P559, DOI 10.1016/j.mri.2015.02.021; Patel NK, 2008, STEREOT FUNCT NEUROS, V86, P153, DOI 10.1159/000120427; Patenaude B, 2011, NEUROIMAGE, V56, P907, DOI 10.1016/j.neuroimage.2011.02.046; Perlmutter JS, 2006, ANNU REV NEUROSCI, V29, P229, DOI 10.1146/annurev.neuro.29.051605.112824; Persson N, 2015, NEUROIMAGE, V122, P385, DOI 10.1016/j.neuroimage.2015.07.050; Pruessmann KP, 1999, MAGNET RESON MED, V42, P952, DOI 10.1002/(SICI)1522-2594(199911)42:5<952::AID-MRM16>3.3.CO;2-J; Qin L, 2009, MAGN RESON MED, V62, P924, DOI 10.1002/mrm.22076; Ramos P, 2014, J TRACE ELEM MED BIO, V28, P13, DOI 10.1016/j.jtemb.2013.08.001; Reichenbach JR, 2015, CLIN NEURORADIOL, V25, P225, DOI 10.1007/s00062-015-0432-9; Reichenbach JR, 1997, JMRI-J MAGN RESON IM, V7, P266, DOI 10.1002/jmri.1880070203; Reichenbach JR, 1997, RADIOLOGY, V204, P272, DOI 10.1148/radiology.204.1.9205259; Robinson S, 2014, MAGN RESON MED, V72, P80, DOI 10.1002/mrm.24897; Robinson S, 2011, MAGN RESON MED, V65, P1638, DOI 10.1002/mrm.22753; Robitaille PML, 1998, NMR BIOMED, V11, P263, DOI 10.1002/(SICI)1099-1492(199810)11:6<263::AID-NBM549>3.0.CO;2-0; Rodgers ZB, 2015, NEUROIMAGE, V106, P441, DOI 10.1016/j.neuroimage.2014.10.061; ROEMER PB, 1990, MAGNET RESON MED, V16, P192, DOI 10.1002/mrm.1910160203; Ros C, 2008, 4th European Conference of the International Federation for Medical and Biological Engineering - ECIFMBE 2008, P803; Rudko DA, 2014, RADIOLOGY, V272, P851, DOI 10.1148/radiol.14132475; Salomir R, 2003, CONCEPT MAGN RESON B, V19B, P26, DOI 10.1002/cmr.b.10083; Schafer A, 2012, HUM BRAIN MAPP, V33, P2831, DOI 10.1002/hbm.21404; Schafer A, 2009, NEUROIMAGE, V48, P126, DOI 10.1016/j.neuroimage.2009.05.093; Schafer A, 2014, P 22 M INT SOC MAGN, P3267; Schenck JF, 2005, PROG BIOPHYS MOL BIO, V87, P185, DOI 10.1016/j.pbiomolbio.2004.08.009; Schenck JF, 2003, J NEUROL SCI, V207, P99, DOI 10.1016/S0022-510X(02)00431-8; Schenck JF, 1996, MED PHYS, V23, P815, DOI 10.1118/1.597854; Schneider TM, 2016, OPER NEUROSURG, V12, P330, DOI 10.1227/NEU.0000000000001256; Schofield MA, 2003, OPT LETT, V28, P1194, DOI 10.1364/OL.28.001194; SCHUBERT D, 1995, BIOCHEM BIOPH RES CO, V216, P702, DOI 10.1006/bbrc.1995.2678; Schweser F, 2014, P 22 ANN M ISMRM MIL, P632; Schweser F, 2011, P 19 ANN M ISMRM MON, P2667; Schweser F, 2011, P 19 ANN M ISMRM MON, P1014; Schweser F., 2011, P INT SOC MAG RESON, P120; Schweser F, 2016, Z MED PHYS, V26, P6, DOI 10.1016/j.zemedi.2015.10.002; Schweser F, 2013, MAGN RESON MED, V69, P1581, DOI 10.1002/mrm.24405; Schweser F, 2012, NEUROIMAGE, V62, P2083, DOI 10.1016/j.neuroimage.2012.05.067; Schweser F, 2011, NEUROIMAGE, V54, P2789, DOI 10.1016/j.neuroimage.2010.10.070; Schweser F, 2010, MED PHYS, V37, P5165, DOI 10.1118/1.3481505; Schweser Ferdinand, 2012, P INT SOC MAGN RESON, V20, P409; Sehgal V, 2006, J MAGN RESON IMAGING, V24, P41, DOI 10.1002/jmri.20598; SEPULVEDA NG, 1994, IEEE T MAGN, V30, P5062, DOI 10.1109/20.334296; Serres B, 2015, P 23 ANN M ISMRM TOR, P290; Sharma SD, 2015, MAGN RESON MED, V74, P673, DOI 10.1002/mrm.25448; Shi HL, 2007, FRONT BIOSCI-LANDMRK, V12, P1318, DOI 10.2741/2150; Shmueli K, 2011, MAGN RESON MED, V65, P35, DOI 10.1002/mrm.22604; Shmueli K, 2009, MAGN RESON MED, V62, P1510, DOI 10.1002/mrm.22135; Shoamanesh A, 2011, CEREBROVASC DIS, V32, P528, DOI 10.1159/000331466; Silbernagl S, 2001, TASCHENATLAS PHYSL, P88; Smith MA, 2010, J ALZHEIMERS DIS, V19, P363, DOI 10.3233/JAD-2010-1239; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Solbach K, 2014, NEUROIMAGE-CLIN, V6, P93, DOI 10.1016/j.nicl.2014.08.018; Spees WM, 2001, MAGN RESON MED, V45, P533, DOI 10.1002/mrm.1072; St Pierre TG, 2004, NMR BIOMED, V17, P446, DOI 10.1002/nbm.905; Stefanescu MR, 2015, BRAIN, V138, P1182, DOI 10.1093/brain/awv064; Stoffel W., 2012, CELLULAR METABOLISM, P55; Straub S, 2015, 32 ANN SCI M ESMRMB, P178; Straub S, 2016, MAGN RESON MED, V75, P2526, DOI 10.1002/mrm.25812; Stuber C, 2014, NEUROIMAGE, V93, P95, DOI 10.1016/j.neuroimage.2014.02.026; Sun H, 2016, MATLAB SCRIPTS QSM; Sun HF, 2016, MAGN RESON MED, V76, P781, DOI 10.1002/mrm.25919; Sun HF, 2015, MAGN RESON MED, V73, P1932, DOI 10.1002/mrm.25316; Sun HF, 2015, NEUROIMAGE, V105, P486, DOI 10.1016/j.neuroimage.2014.11.010; Sun HF, 2014, MAGN RESON MED, V71, P1151, DOI 10.1002/mrm.24765; Tan H, 2013, 2 WORKSH MRI PHAS CO, P110; Tang J, 2013, MAGN RESON MED, V69, P1396, DOI 10.1002/mrm.24384; Terreno E, 2006, MAGN RESON MED, V55, P491, DOI 10.1002/mrm.20793; THULBORN KR, 1982, BIOCHIM BIOPHYS ACTA, V714, P265, DOI 10.1016/0304-4165(82)90333-6; Thunberg P, 2005, MAGN RESON IMAGING, V23, P795, DOI 10.1016/j.mri.2005.06.002; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Topfer R, 2015, MAGN RESON MED, V73, P851, DOI 10.1002/mrm.25148; Ulrich R, 2003, J MAGN RESON, V164, P115, DOI 10.1016/S1090-7807(03)00208-8; van Gelderen P, 2015, MAGN RESON MED, V74, P1388, DOI 10.1002/mrm.25524; Vannesjo SJ, 2015, MAGN RESON MED, V73, P1833, DOI 10.1002/mrm.25303; Versluis MJ, 2010, NEUROIMAGE, V51, P1082, DOI 10.1016/j.neuroimage.2010.03.048; Waldvogel D, 1999, ANN NEUROL, V46, P123, DOI 10.1002/1531-8249(199907)46:1<123::AID-ANA19>3.0.CO;2-H; Walsh DO, 2000, MAGNET RESON MED, V43, P682, DOI 10.1002/(SICI)1522-2594(200005)43:5<682::AID-MRM10>3.0.CO;2-G; Wang Y, 2015, MAGN RESON MED, V73, P82, DOI 10.1002/mrm.25358; Ward R, 2014, LANCET NEUROL, V13, P1045, DOI 10.1016/S1474-4422(14)70117-6; Wei H, 2015, P 23 ANN M ISMRM TOR; Wei HJ, 2017, NMR BIOMED, V30, DOI 10.1002/nbm.3501; Wei HJ, 2015, NMR BIOMED, V28, P1294, DOI 10.1002/nbm.3383; Weisberg LA, 1996, ESSENTIALS CLIN NEUR, P356; WEISSKOFF RM, 1992, MAGNET RESON MED, V24, P375, DOI 10.1002/mrm.1910240219; Wen J, 2015, MAGN RESON MED, V73, P195, DOI 10.1002/mrm.25114; Wen Y, 2016, MAGN RESON MED, V75, P823, DOI 10.1002/mrm.25652; Wen Y, 2014, MAGN RESON MED, V72, P1065, DOI 10.1002/mrm.24998; Wengenack TM, 2011, NEUROIMAGE, V54, P113, DOI 10.1016/j.neuroimage.2010.08.033; Wharton S, 2010, NEUROIMAGE, V53, P515, DOI 10.1016/j.neuroimage.2010.06.070; Wharton S, 2010, MAGN RESON MED, V63, P1292, DOI 10.1002/mrm.22334; Wharton S, 2015, MAGN RESON MED, V73, P1258, DOI 10.1002/mrm.25189; Wisnieff C, 2015, MAGN RESON MED, V74, P564, DOI 10.1002/mrm.25420; Wisnieff C, 2013, NEUROIMAGE, V70, P363, DOI 10.1016/j.neuroimage.2012.12.050; Witoszynskyj S, 2009, MED IMAGE ANAL, V13, P257, DOI 10.1016/j.media.2008.10.004; Wolber J, 2000, MAGNET RESON MED, V43, P491, DOI 10.1002/(SICI)1522-2594(200004)43:4<491::AID-MRM1>3.0.CO;2-6; Wong R, 2012, ANN BIOMED ENG, V40, P1328, DOI 10.1007/s10439-011-0482-3; Wood JC, 2005, BLOOD, V106, P1460, DOI 10.1182/blood-2004-10-3982; Wu B, 2012, MAGN RESON MED, V67, P137, DOI 10.1002/mrm.23000; Wu B, 2012, NEUROIMAGE, V59, P297, DOI 10.1016/j.neuroimage.2011.07.019; Wu DM, 2016, MAGN RESON MED, V76, P478, DOI 10.1002/mrm.25878; XIANG QS, 1995, JMRI-J MAGN RESON IM, V5, P529, DOI 10.1002/jmri.1880050509; Xie LK, 2015, MAGN RESON MED, V73, P1270, DOI 10.1002/mrm.25219; Xu B, 2015, MAGN RESON MED, V73, P1540, DOI 10.1002/mrm.25257; Xu B, 2014, MAGN RESON MED, V72, P438, DOI 10.1002/mrm.24937; Yablonskiy DA, 2015, MAGN RESON MED, V73, P757, DOI 10.1002/mrm.25538; Yablonskiy DA, 2012, P NATL ACAD SCI USA, V109, P14212, DOI 10.1073/pnas.1206037109; YAMADA N, 1992, MAGN RESON IMAGING, V10, P559, DOI 10.1016/0730-725X(92)90007-M; Yamada N, 1996, RADIOLOGY, V198, P171, DOI 10.1148/radiology.198.1.8539373; YE FQ, 1995, MAGNET RESON MED, V34, P713, DOI 10.1002/mrm.1910340510; YOUNG IR, 1989, J COMPUT ASSIST TOMO, V13, P490, DOI 10.1097/00004728-198905000-00023; YOUNG IR, 1987, J COMPUT ASSIST TOMO, V11, P2, DOI 10.1097/00004728-198701000-00002; Zaitsev M, 2006, NEUROIMAGE, V31, P1038, DOI 10.1016/j.neuroimage.2006.01.039; Zhang JW, 2015, MAGN RESON MED, V74, P945, DOI 10.1002/mrm.25463; Zheng WL, 2013, NEUROIMAGE, V78, P68, DOI 10.1016/j.neuroimage.2013.04.022; Zhong K, 2008, NEUROIMAGE, V40, P1561, DOI 10.1016/j.neuroimage.2008.01.061; Zhou D, 2014, NMR BIOMED, V27, P312, DOI 10.1002/nbm.3064	295	103	103	4	39	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0952-3480	1099-1492		NMR BIOMED	NMR Biomed.	APR	2017	30	4			SI				e3569	10.1002/nbm.3569			27	Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy	EQ5CY	WOS:000398100400004	27434134				2022-02-06	
J	Hernandez, F; Wu, LC; Yip, MC; Laksari, K; Hoffman, AR; Lopez, JR; Grant, GA; Kleiven, S; Camarillo, DB				Hernandez, Fidel; Wu, Lyndia C.; Yip, Michael C.; Laksari, Kaveh; Hoffman, Andrew R.; Lopez, Jaime R.; Grant, Gerald A.; Kleiven, Svein; Camarillo, David B.			Six Degree-of-Freedom Measurements of Human Mild Traumatic Brain Injury	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Concussion; Mild traumatic brain injury (mTBI); Instrumented mouthguard; Six degree-of-freedom (6DOF) kinematics; Finite element model; Brain strain	DIFFUSE AXONAL INJURY; HEAD IMPACT; CEREBRAL CONCUSSION; FOOTBALL; ACCELERATION; SYSTEM; KINEMATICS; CLASSIFICATION; VALIDATION; PREDICTORS	This preliminary study investigated whether direct measurement of head rotation improves prediction of mild traumatic brain injury (mTBI). Although many studies have implicated rotation as a primary cause of mTBI, regulatory safety standards use 3 degree-of-freedom (3DOF) translation-only kinematic criteria to predict injury. Direct 6DOF measurements of human head rotation (3DOF) and translation (3DOF) have not been previously available to examine whether additional DOFs improve injury prediction. We measured head impacts in American football, boxing, and mixed martial arts using 6DOF instrumented mouthguards, and predicted clinician-diagnosed injury using 12 existing kinematic criteria and 6 existing brain finite element (FE) criteria. Among 513 measured impacts were the first two 6DOF measurements of clinically diagnosed mTBI. For this dataset, 6DOF criteria were the most predictive of injury, more than 3DOF translation-only and 3DOF rotation-only criteria. Peak principal strain in the corpus callosum, a 6DOF FE criteria, was the strongest predictor, followed by two criteria that included rotation measurements, peak rotational acceleration magnitude and Head Impact Power (HIP). These results suggest head rotation measurements may improve injury prediction. However, more 6DOF data is needed to confirm this evaluation of existing injury criteria, and to develop new criteria that considers directional sensitivity to injury.	[Hernandez, Fidel; Camarillo, David B.] Stanford Univ, Dept Mech Engn, Stanford, CA 94305 USA; [Wu, Lyndia C.; Yip, Michael C.; Laksari, Kaveh; Camarillo, David B.] Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA; [Hoffman, Andrew R.] Stanford Univ, Dept Med, Stanford, CA 94305 USA; [Lopez, Jaime R.] Stanford Univ, Dept Neurol, Stanford, CA 94305 USA; [Grant, Gerald A.] Stanford Univ, Dept Neurosurg, Stanford, CA 94305 USA; [Kleiven, Svein] KTH Royal Inst Technol, Dept Neuron Engn, Stockholm, Sweden		Camarillo, DB (corresponding author), Stanford Univ, Dept Mech Engn, Stanford, CA 94305 USA.	dcamarillo@stanford.edu	Wu, Lyndia/AAQ-1106-2020	Wu, Lyndia/0000-0002-8236-032X; Hernandez, Fidel/0000-0002-6078-0518	National Institutes of Health (NIH) National Institute of Biomedical Imaging and Bioengineering (NIBIB)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [3R21EB01761101S1]; David and Lucile Packard FoundationThe David & Lucile Packard Foundation [38454]; Child Health Research Institute of Stanford University; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [UL1 TR000093]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000093, UL1TR001085] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R21EB017611] Funding Source: NIH RePORTER	We thank the Stanford Department of Athletics (Palo Alto, CA) for enabling this research, notably Scott Anderson, Director of Athletic Training, and Mike Gleeson, Video Director. We thank Kevin Bui and Bradley Hammoor for work in processing the event video, Joseph Schooler for coordinating human subject protocols, and Maria Malone for device manufacturing and deployment. We thank X2 Biosystems (Seattle, WA) for early device prototypes and continual support. We thank Roy Englebrecht Promotions (Newport Beach, CA) and B Street Boxing (San Mateo, CA) for help with subject recruitment. The study was supported by the National Institutes of Health (NIH) National Institute of Biomedical Imaging and Bioengineering (NIBIB) 3R21EB01761101S1, David and Lucile Packard Foundation 38454, Child Health Research Institute of Stanford University, and NIH UL1 TR000093 for biostatistics consultation.	Abrahams S, 2014, BRIT J SPORT MED, V48, P91, DOI 10.1136/bjsports-2013-092734; Allison MA, 2014, MED SCI SPORT EXER, V46, P115, DOI 10.1249/MSS.0b013e3182a32d0d; Arbogast KB, 1998, J BIOMECH, V31, P801, DOI 10.1016/S0021-9290(98)00068-2; Arenth PM, 2014, J HEAD TRAUMA REHAB, V29, pE1, DOI 10.1097/HTR.0b013e318289ede5; Bartsch A., 2013, ENV MONITORING, V1, P2; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Beckwith JG, 2007, J APPL BIOMECH, V23, P238, DOI 10.1123/jab.23.3.238; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P747, DOI 10.1249/MSS.0b013e3182793067; Beckwith JG, 2012, ANN BIOMED ENG, V40, P237, DOI 10.1007/s10439-011-0422-2; Beusenberg MC., 2000, P INT RES C BIOM IMP; Bianchi A, 2015, IEEE T BIO-MED ENG, V62, P145, DOI 10.1109/TBME.2014.2342653; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Caccese V, 2016, EXP TECHNIQUES, V40, P413, DOI [10.1111/ext.12079, 10.1007/s40799-016-0046-4]; Camarillo DB, 2013, ANN BIOMED ENG, V41, P1939, DOI 10.1007/s10439-013-0801-y; Cao C, 2008, IEEE T NEUR SYS REH, V16, P327, DOI 10.1109/TNSRE.2008.918422; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Coats B, 2012, INT J DEV NEUROSCI, V30, P191, DOI 10.1016/j.ijdevneu.2011.12.009; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Eucker SA, 2011, EXP NEUROL, V227, P79, DOI 10.1016/j.expneurol.2010.09.015; Federal Motor Vehicle Safety Standards (FMVSS), 2014, 202A FMVSS 571, P531; Feng Y, 2013, J MECH BEHAV BIOMED, V23, P117, DOI 10.1016/j.jmbbm.2013.04.007; Gadd C. W, 1966, SAE TECHNICAL PAPER, DOI 10.4271/660793; GAZZANIGA MS, 1998, COGNITIVE NEUROSCIEN; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli TA, 1992, J EMERGENCY MED, V11, P5; Giordano C, 2014, J R SOC INTERFACE, V11, DOI 10.1098/rsif.2013.0914; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; GURDJIAN ES, 1953, NEUROLOGY, V3, P417, DOI 10.1212/WNL.3.6.417; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Higgins M, 2007, J ATHL TRAINING, V42, P5; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holbourn AHS, 1943, LANCET, V2, P438; Jadischke R, 2013, J BIOMECH, V46, P2310, DOI 10.1016/j.jbiomech.2013.05.030; Ji SB, 2014, ANN BIOMED ENG, V42, P11, DOI 10.1007/s10439-013-0907-2; Kang YS, 2011, J BIOMECH ENG-T ASME, V133, DOI 10.1115/1.4005427; Kimpara, 2011, INT J AUTOMOT ENG, V2, P13, DOI [10.20485/jsaeijae.2.2_13, DOI 10.20485/JSAEIJAE.2.2_13]; Kimpara H, 2012, ANN BIOMED ENG, V40, P114, DOI 10.1007/s10439-011-0414-2; King A. I., 2003, IRCOBI C LISB PORT; Kleinberger M., 1998, NHTSA DOCKET, V4405, P12; Kleiven S, 2006, INT J CRASHWORTHINES, V11, P65, DOI 10.1533/ijcr.2005.0384; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; Marjoux D, 2008, ACCIDENT ANAL PREV, V40, P1135, DOI 10.1016/j.aap.2007.12.006; Moon D W, 1971, Med Sci Sports, V3, P44; National Operating Committee on Standards for Athletic Equipment (NOCSAE), 2012, ND00111M12 NOCSAE; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Naunheim RS, 2003, MED SCI SPORT EXER, V35, P1406, DOI 10.1249/01.MSS.0000078933.84527.AE; Newman J., 1986, INT IRCOBI C BIOM IM, V14, P121; Newman J A, 2000, Stapp Car Crash J, V44, P215; Newman JA, 2005, J BIOMECH, V38, P1469, DOI 10.1016/j.jbiomech.2004.06.025; NEWMAN JA, 2000, STAPP CAR CRASH J, V44, P362; OMMAYA AK, 1968, J AMER MED ASSOC, V204, P285, DOI 10.1001/jama.204.4.285; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; OMMAYA AK, 1966, SCIENCE, V153, P211, DOI 10.1126/science.153.3732.211; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Pincemaille Y, 1989, P 33 STAPP CAR CRASH, P177; Prasad P, 2008, STAPP CAR C, V52, P187; Prichep LS, 2012, IEEE T NEUR SYS REH, V20, P806, DOI 10.1109/TNSRE.2012.2206609; Qian H., 2008, P 10 IEEE C CONTR AU, P17; Reid S E, 1974, J Sports Med, V2, P86; Roth TL, 2014, NATURE, V505, P223, DOI 10.1038/nature12808; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Rowson S, 2011, ANN BIOMED ENG, V39, P2130, DOI 10.1007/s10439-011-0322-5; Rowson S, 2011, J APPL BIOMECH, V27, P8, DOI 10.1123/jab.27.1.8; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Sturdivant RX, 2013, APPL LOGISTIC REGRES, V3rd; TAKHOUNTS E, 2013, STAPP CAR CRASH J, V57, P1; Takhounts EG, 2008, STAPP CAR C, V52, P1; Ungerleider LG., 1982, ANAL VISUAL BEHAV; Versace J, 1971, SAE TECHNICAL PAPER, DOI [10.4271/710881, DOI 10.4271/710881]; Ward C., 1980, STAPP CAR CRASH J, P163; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	80	103	103	1	36	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	AUG	2015	43	8					1918	1934		10.1007/s10439-014-1212-4			17	Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Engineering	CN2KM	WOS:000358249800018	25533767	Green Accepted			2022-02-06	
J	Rochfort, KD; Cummins, PM				Rochfort, Keith D.; Cummins, Philip M.			The blood-brain barrier endothelium: a target for pro-inflammatory cytokines	BIOCHEMICAL SOCIETY TRANSACTIONS			English	Article						blood-brain barrier; endothelial; interleukin-6 (IL-6); NADPH oxidase; neuroinflammation; tumour necrosis factor-alpha (TNF-alpha)	NECROSIS-FACTOR-ALPHA; TIGHT JUNCTION PROTEINS; IN-VITRO MODEL; TNF-ALPHA; OXIDATIVE STRESS; NADPH OXIDASE; NOX ENZYMES; KAPPA-B; CELLS; DYSFUNCTION	An intact functioning blood-brain barrier (BBB) is fundamental to proper homoeostatic maintenance and perfusion of the central nervous system (CNS). Inflammatory damage to the unique microvascular endothelial cell monolayer that constitutes the luminal BBB surface, leading to elevated capillary permeability, has been linked to various neurological disorders ranging from ischaemic stroke and traumatic brain injury, to neurodegenerative disease and CNS infections. Moreover, the neuroinflammatory cascade that typically accompanies BBB failure in these circumstances has been strongly linked to elevated levels of proinflammatory cytokines such as tumour necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6). This mini review will examine our current knowledge of how cytokines may dysregulate the interendothelial paracellular pathway leading to elevated BBB permeability. The mechanistic role of nicotinamide adenine dinucleotide phosphate oxidase (NADPH oxidase)-induced oxidative stress in these events will also be addressed.	[Rochfort, Keith D.; Cummins, Philip M.] Dublin City Univ, Sch Biotechnol, Dublin 9, Ireland; [Cummins, Philip M.] Dublin City Univ, Ctr Prevent Med, Dublin 9, Ireland		Cummins, PM (corresponding author), Dublin City Univ, Sch Biotechnol, Dublin 9, Ireland.	phil.cummins@dcu.ie	Rochfort, Keith/R-7009-2019	Rochfort, Keith/0000-0003-1198-5952	Irish National Development Plan/Higher Education Authority Programme for Research in Third Level Institutes (NDP/HEA-PRTLI Cycle 4: T3 Targeted Therapeutics Theranostics)	This work was supported by the Irish National Development Plan/Higher Education Authority Programme for Research in Third Level Institutes (NDP/HEA-PRTLI Cycle 4: T3 Targeted Therapeutics & Theranostics).	Abdullah Z, 2014, MOL CELL NEUROSCI, V61, P72, DOI 10.1016/j.mcn.2014.06.002; Lopez-Ramirez MA, 2012, J IMMUNOL, V189, P3130, DOI 10.4049/jimmunol.1103460; Altenhofer S., 2014, ANTIOXID RE IN PRESS; Alves JL, 2014, J NEUROSCI RES, V92, P141, DOI 10.1002/jnr.23300; Aslam M, 2012, CYTOKINE, V57, P269, DOI 10.1016/j.cyto.2011.10.016; Aveleira CA, 2010, DIABETES, V59, P2872, DOI 10.2337/db09-1606; Balda MS, 1998, J CELL SCI, V111, P541; Basuroy S, 2006, AM J PHYSIOL-CELL PH, V291, pC897, DOI 10.1152/ajpcell.00032.2006; Bazzoni G, 2004, PHYSIOL REV, V84, P869, DOI 10.1152/physrev.00035.2003; Bennett J, 2010, J NEUROIMMUNOL, V229, P180, DOI 10.1016/j.jneuroim.2010.08.011; Borlongan CV, 2012, CURR PHARM DESIGN, V18, P3615; Chaudhuri A, 2008, BLOOD, V111, P2062, DOI 10.1182/blood-2007-05-091207; Chen JY, 2014, J PINEAL RES, V57, P340, DOI 10.1111/jpi.12173; Clark IA, 2010, PHARMACOL THERAPEUT, V128, P519, DOI 10.1016/j.pharmthera.2010.08.007; Cohen SS, 2013, NEUROIMMUNOMODULAT, V20, P264, DOI 10.1159/000350470; Desai TR, 2002, J SURG RES, V104, P118, DOI 10.1006/jsre.2002.6415; Ferrarese C, 1999, J CEREBR BLOOD F MET, V19, P1004, DOI 10.1097/00004647-199909000-00008; Fiala M, 1997, MOL MED, V3, P553, DOI 10.1007/BF03401701; Figiel I, 2008, ACTA NEUROBIOL EXP, V68, P526; Forster C, 2008, J PHYSIOL-LONDON, V586, P1937, DOI 10.1113/jphysiol.2007.146852; Frey RS, 2009, ANTIOXID REDOX SIGN, V11, P791, DOI 10.1089/ARS.2008.2220; Frey RS, 2002, CIRC RES, V90, P1012, DOI 10.1161/01.RES.0000017631.28815.8E; Gertzberg N, 2004, AM J PHYSIOL-LUNG C, V286, pL37, DOI 10.1152/ajplung.00116.2003; Griffin W Sue T, 2010, US Neurol, V6, P19; Hawkins BT, 2005, PHARMACOL REV, V57, P173, DOI 10.1124/pr.57.2.4; Hou TY, 2008, CURR CARDIOL REV, V4, P179, DOI 10.2174/157340308785160570; Labus J, 2014, J NEUROSCI METH, V228, P35, DOI 10.1016/j.jneumeth.2014.03.002; Lambeth JD, 2008, SEMIN IMMUNOPATHOL, V30, P339, DOI 10.1007/s00281-008-0123-6; Lutgendorf MA, 2014, REPROD SCI, V21, P483, DOI 10.1177/1933719113503410; Lv S, 2010, LIVER INT, V30, P1198, DOI 10.1111/j.1478-3231.2010.02211.x; Macleod MR, 2008, STROKE, V39, P2824, DOI 10.1161/STROKEAHA.108.515957; Manea A, 2010, ARTERIOSCL THROM VAS, V30, P105, DOI 10.1161/ATVBAHA.109.193896; Marcos-Ramiro B, 2014, THROMB HAEMOSTASIS, V112, P1088, DOI 10.1160/TH14-04-0299; Mark KS, 1999, LIFE SCI, V64, P1941, DOI 10.1016/S0024-3205(99)00139-3; MARUO N, 1992, ENDOCRINOLOGY, V131, P710, DOI 10.1210/en.131.2.710; Mckenzie JAG, 2007, J CELL PHYSIOL, V213, P221, DOI 10.1002/jcp.21114; Naik P, 2014, BMC NEUROSCI, V15, DOI 10.1186/1471-2202-15-51; Nishioku T, 2010, J PHARMACOL SCI, V112, P251, DOI 10.1254/jphs.09292SC; Persidsky Y, 2006, J NEUROIMMUNE PHARM, V1, P223, DOI 10.1007/s11481-006-9025-3; Rochfort KD, 2015, J CEREBR BLOOD F MET, V35, P1648, DOI 10.1038/jcbfm.2015.102; Rochfort KD, 2015, MICROVASC RES, V100, P48, DOI 10.1016/j.mvr.2015.04.010; Rochfort KD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101815; Schroeder K, 2009, ARTERIOSCL THROM VAS, V29, P239, DOI 10.1161/ATVBAHA.108.174219; SHARIEF MK, 1992, J NEUROIMMUNOL, V38, P27, DOI 10.1016/0165-5728(92)90087-2; Sorce S, 2009, ANTIOXID REDOX SIGN, V11, P2481, DOI [10.1089/ars.2009.2578, 10.1089/ARS.2009.2578]; Strazza M, 2011, BRAIN RES, V1399, P96, DOI 10.1016/j.brainres.2011.05.015; Taddei A, 2008, NAT CELL BIOL, V10, P923, DOI 10.1038/ncb1752; Tuttolomondo A, 2008, CURR PHARM DESIGN, V14, P3574, DOI 10.2174/138161208786848739; Voigt A, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00042; Walsh TG, 2011, J CELL PHYSIOL, V226, P3053, DOI 10.1002/jcp.22655; Wassmann S, 2004, CIRC RES, V94, P534, DOI 10.1161/01.RES.0000115557.25127.8D; Wilson CM, 2009, INT J RADIAT ONCOL, V74, P934, DOI 10.1016/j.ijrobp.2009.02.035	52	103	108	2	29	PORTLAND PRESS LTD	LONDON	CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND	0300-5127	1470-8752		BIOCHEM SOC T	Biochem. Soc. Trans.	AUG	2015	43		4				702	706		10.1042/BST20140319			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	CO2QJ	WOS:000359001400028	26551716				2022-02-06	
J	Ferguson, AR; Nielson, JL; Cragin, MH; Bandrowski, AE; Martone, ME				Ferguson, Adam R.; Nielson, Jessica L.; Cragin, Melissa H.; Bandrowski, Anita E.; Martone, Maryann E.			Big data from small data: data-sharing in the 'long tail' of neuroscience	NATURE NEUROSCIENCE			English	Article							TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; NEURONAL MORPHOLOGY; KNOWLEDGE; SCIENCE; PROJECT; REPLICATION; INFORMATION; FRAMEWORK; IMPACT	The launch of the US BRAIN and European Human Brain Projects coincides with growing international efforts toward transparency and increased access to publicly funded research in the neurosciences. The need for data-sharing standards and neuroinformatics infrastructure is more pressing than ever. However, 'big science' efforts are not the only drivers of data-sharing needs, as neuroscientists across the full spectrum of research grapple with the overwhelming volume of data being generated daily and a scientific environment that is increasingly focused on collaboration. In this commentary, we consider the issue of sharing of the richly diverse and heterogeneous small data sets produced by individual neuroscientists, so-called long-tail data. We consider the utility of these data, the diversity of repositories and options available for sharing such data, and emerging best practices. We provide use cases in which aggregating and mining diverse long-tail data convert numerous small data sources into big data for improved knowledge about neuroscience-related disorders.	[Ferguson, Adam R.; Nielson, Jessica L.] Univ Calif San Francisco, Dept Neurol Surg, Brain & Spinal Injury Ctr, San Francisco, CA 94143 USA; [Cragin, Melissa H.] Natl Sci Fdn, Directorate Biol Sci, Arlington, VA 22230 USA; [Bandrowski, Anita E.; Martone, Maryann E.] Univ Calif San Diego, Ctr Res Biol Struct, San Diego, CA 92103 USA; [Martone, Maryann E.] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA		Martone, ME (corresponding author), Univ Calif San Diego, Ctr Res Biol Struct, San Diego, CA 92103 USA.	mmartone@ucsd.edu		Ferguson, Adam/0000-0001-7102-1608; Martone, Maryann/0000-0002-8406-3871; Nielson, Jessica/0000-0002-3677-3959; Bandrowski, Anita/0000-0002-5497-0243	NIH Neuroscience Blueprint via the National Institute on Drug Abuse [HHSN271200800035C]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS067092, NS079030]; Craig H. Neilsen foundation; Wings for Life foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F32NS079030, R01NS067092] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [U24DA039832] Funding Source: NIH RePORTER	We thank the NIF staff, especially B. Ozyurt for his text mining expertise and tools that contributed substantially to Supplementary Table 1. The Neuroscience Information Framework is supported by a contract from the NIH Neuroscience Blueprint HHSN271200800035C via the National Institute on Drug Abuse. VISION-SCI is supported by NIH grants NS067092 (A.R.F.) and NS079030 (J.L.N.), and the Craig H. Neilsen foundation (A.R.F) and Wings for Life foundation (A.R.F). This material is based on (M.H.C.) work supported while serving at the National Science Foundation. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the author(s) and do not reflect the views of the National Science Foundation.	Agarwal G, 2014, SCIENCE, V344, P626, DOI 10.1126/science.1250444; Ascoli GA, 2007, J NEUROSCI, V27, P9247, DOI 10.1523/JNEUROSCI.2055-07.2007; Bohannon J, 2014, SCIENCE, V344, P788, DOI 10.1126/science.344.6186.788; Boline J, 2008, FRONT NEUROSCI-SWITZ, V2, P100, DOI 10.3389/neuro.01.012.2008; Boulton G, 2011, LANCET, V377, P1633, DOI 10.1016/S0140-6736(11)60647-8; Chan AW, 2014, LANCET, V383, P257, DOI 10.1016/S0140-6736(13)62296-5; Costa Luciano Da Fontoura, 2010, Front Comput Neurosci, V4, P150, DOI 10.3389/fncom.2010.00150; Cragin MH, 2010, PHILOS T R SOC A, V368, P4023, DOI 10.1098/rsta.2010.0165; Fawcett JW, 2007, SPINAL CORD, V45, P190, DOI 10.1038/sj.sc.3102007; Ferguson AR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059712; Fernandez JJ, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-178; Fisher M, 2009, STROKE, V40, P2244, DOI 10.1161/STROKEAHA.108.541128; Gardner D, 2003, NEUROINFORMATICS, V1, P289, DOI 10.1385/NI:1:3:289; Gardner D, 2008, NEUROINFORMATICS, V6, P149, DOI 10.1007/s12021-008-9024-z; Goodman A, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003542; Gorgolewski KJ, 2013, GIGASCIENCE, V2, DOI 10.1186/2047-217X-2-6; Gorgolewski KJ, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00009; Halavi M, 2012, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00049; Hansen MB, 2013, FRONT INTEGR NEUROSC, V7, DOI 10.3389/fnint.2013.00031; Heidorn PB, 2008, LIBR TRENDS, V57, P280; HUERTA MF, 1993, TRENDS NEUROSCI, V16, P436, DOI 10.1016/0166-2236(93)90069-X; Kennedy DN, 2014, NEUROINFORMATICS, V12, P361, DOI 10.1007/s12021-014-9239-0; Kwon BK, 2010, J NEUROTRAUM, V27, P21, DOI 10.1089/neu.2009.1048; Langborg T, 2013, DATA SCI J, V12, P1; Lemmon VP, 2014, J NEUROTRAUM, V31, P1354, DOI 10.1089/neu.2014.3400; Maas AIR, 2013, LANCET NEUROL, V12, P1200, DOI 10.1016/S1474-4422(13)70234-5; Maas AIR, 2011, J NEUROTRAUM, V28, P177, DOI 10.1089/neu.2010.1617; Manley GT, 2013, JAMA-J AM MED ASSOC, V310, P473, DOI 10.1001/jama.2013.169158; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; Martone ME, 2004, NAT NEUROSCI, V7, P467, DOI 10.1038/nn1229; Martone ME, 2002, J STRUCT BIOL, V138, P145, DOI 10.1016/S1047-8477(02)00006-0; Mennes M, 2013, NEUROIMAGE, V82, P683, DOI 10.1016/j.neuroimage.2012.10.064; Mueck L, 2013, NAT NANOTECHNOL, V8, P693, DOI 10.1038/nnano.2013.204; Nielson JL, 2014, J NEUROTRAUM, V31, P1789, DOI 10.1089/neu.2014.3399; Perrino T, 2013, PERSPECT PSYCHOL SCI, V8, P433, DOI 10.1177/1745691613491579; Poldrack RA, 2013, FRONT NEUROINFORM, V7, DOI 10.3389/fninf.2013.00012; Poline JB, 2012, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00096; Research Data Alliance, 2014, RES DAT SHAR BARR; Roche DG, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001779; Roysam B, 2009, NEUROINFORMATICS, V7, P1, DOI 10.1007/s12021-008-9043-9; Sena ES, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000344; Shepherd GM, 1998, TRENDS NEUROSCI, V21, P460, DOI 10.1016/S0166-2236(98)01300-9; Steward O, 2012, EXP NEUROL, V233, P597, DOI 10.1016/j.expneurol.2011.06.017; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Tenopir C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021101; Turner CF, 2011, DATABASE-OXFORD, DOI 10.1093/database/bar043; Turner Jessica A, 2010, Front Neuroinform, V4, DOI 10.3389/fninf.2010.00010; Van Essen DC, 2013, NEUROIMAGE, V80, P62, DOI 10.1016/j.neuroimage.2013.05.041; Van Horn JD, 2013, NEUROIMAGE, V82, P677, DOI 10.1016/j.neuroimage.2012.11.010; Wallis JC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067332; WEINBERG AM, 1961, SCIENCE, V134, P161, DOI 10.1126/science.134.3473.161; Wicherts JM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026828; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783	54	103	107	2	80	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1097-6256	1546-1726		NAT NEUROSCI	Nat. Neurosci.	NOV	2014	17	11					1442	1447		10.1038/nn.3838			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AS0LT	WOS:000343969300008	25349910	Green Published, Green Accepted			2022-02-06	
J	Papa, L; Silvestri, S; Brophy, GM; Giordano, P; Falk, JL; Braga, CF; Tan, CN; Ameli, NJ; Demery, JA; Dixit, NK; Mendes, ME; Hayes, RL; Wang, KKW; Robertson, CS				Papa, Linda; Silvestri, Salvatore; Brophy, Gretchen M.; Giordano, Philip; Falk, Jay L.; Braga, Carolina F.; Tan, Ciara N.; Ameli, Neema J.; Demery, Jason A.; Dixit, Neha K.; Mendes, Matthew E.; Hayes, Ronald L.; Wang, Kevin K. W.; Robertson, Claudia S.			GFAP Out-Performs S100 beta in Detecting Traumatic Intracranial Lesions on Computed Tomography in Trauma Patients with Mild Traumatic Brain Injury and Those with Extracranial Lesions	JOURNAL OF NEUROTRAUMA			English	Article						computed tomography (CT); fractures; glial fibrillary acidic protein (GFAP); mild traumatic brain injury/concussion; S100 beta	FIBRILLARY ACIDIC PROTEIN; MINOR HEAD-INJURY; SERUM S100B LEVELS; DECISION-MAKING; BIOMARKERS; DAMAGE; MULTICENTER; S-100B; BLOOD; INDEX	Both glial fibrillary acidic protein (GFAP) and S100 beta are found in glial cells and are released into serum following a traumatic brain injury (TBI), however, the clinical utility of S100 beta as a biomarker has been questioned because of its release from bone. This study examined the ability of GFAP and S100 beta to detect intracranial lesions on computed tomography (CT) in trauma patients and also assessed biomarker performance in patients with fractures and extracranial injuries on head CT. This prospective cohort study enrolled a convenience sample of adult trauma patients at a Level I trauma center with and without mild or moderate traumatic brain injury (MMTBI). Serum samples were obtained within 4 h of injury. The primary outcome was the presence of traumatic intracranial lesions on CT scan. There were 397 general trauma patients enrolled: 209 (53%) had a MMTBI and 188 (47%) had trauma without MMTBI. Of the 262 patients with a head CT, 20 (8%) had intracranial lesions. There were 137 (35%) trauma patients who sustained extracranial fractures below the head to the torso and extremities. Levels of S100 beta were significantly higher in patients with fractures, compared with those without fractures (p < 0.001) whether MMTBI was present or not. However, GFAP levels were not significantly affected by the presence of fractures (p > 0.05). The area under the receiver operating characteristics curve (AUC) for predicting intracranial lesions on CT for GFAP was 0.84 (0.73-0.95) and for S100 beta was 0.78 (0.67-0.89). However, in the presence of extracranial fractures, the AUC for GFAP increased to 0.93 (0.86-1.00) and for S100 beta decreased to 0.75 (0.61-0.88). In a general trauma population, GFAP out-performed S100 beta in detecting intracranial CT lesions, particularly in the setting of extracranial fractures.	[Papa, Linda; Silvestri, Salvatore; Giordano, Philip; Falk, Jay L.; Braga, Carolina F.; Tan, Ciara N.; Ameli, Neema J.] Orlando Reg Med Ctr Inc, Dept Emergency Med, Orlando, FL 32806 USA; [Brophy, Gretchen M.] Virginia Commonwealth Univ, Dept Pharmacotherapy & Outcomes Sci, Richmond, VA USA; [Brophy, Gretchen M.] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA USA; [Demery, Jason A.; Dixit, Neha K.] North Floridas Vet Hlth Syst, Dept Psychol, Gainesville, FL USA; [Mendes, Matthew E.] Univ Cent Florida, Orlando, FL 32816 USA; [Hayes, Ronald L.] Banyan Biomarkers Inc, Ctr Innovat Res, Alachua, FL USA; [Wang, Kevin K. W.] Univ Florida, Dept Psychiat, Gainesville, FL 32611 USA; [Robertson, Claudia S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA		Papa, L (corresponding author), Orlando Reg Med Ctr Inc, Dept Emergency Med, 86 W Underwood S-200, Orlando, FL 32806 USA.	lpstat@aol.com		Wang, Kevin/0000-0002-9343-6473; Brophy, Gretchen/0000-0002-4749-2693	National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS057676]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS057676] Funding Source: NIH RePORTER	This study was supported in part by Award Number R01NS057676 from the National Institute of Neurological Disorders and Stroke. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Neurological Disorders and Stroke or the National Institutes of Health.	Bechtel K, 2009, PEDIATRICS, V124, pE697, DOI 10.1542/peds.2008-1493; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Bohmer AE, 2011, NEUROSURGERY, V68, P1624, DOI 10.1227/NEU.0b013e318214a81f; ENG LF, 1971, BRAIN RES, V28, P351, DOI 10.1016/0006-8993(71)90668-8; Herrmann M, 2001, NEUROSURGERY, V49, P1272, DOI 10.1097/00006123-200111000-00058; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; Metting Z, 2012, NEUROLOGY, V78, P1428, DOI 10.1212/WNL.0b013e318253d5c7; Missler U, 1999, CLIN CHEM, V45, P138; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Olsson B, 2011, PROG NEUROBIOL, V95, P520, DOI 10.1016/j.pneurobio.2011.04.006; Papa L, 2012, POTEOMICS HUMAN DIS; Papa L, 2013, J NEUROTRAUM, V30, P324, DOI 10.1089/neu.2012.2545; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; PHILLIPS JP, 1980, BRIT MED J, V281, P777, DOI 10.1136/bmj.281.6243.777; Piazza O, 2007, PEDIATR NEUROSURG, V43, P258, DOI 10.1159/000103304; Rothoerl RD, 1998, J TRAUMA, V45, P765, DOI 10.1097/00005373-199810000-00025; Rothoerl RD, 2001, NEUROSURGERY, V49, P1490, DOI 10.1097/00006123-200112000-00054; Unden J, 2005, J TRAUMA, V58, P59, DOI 10.1097/01.TA.0000130613.35877.75; Vajtr D., 2013, SOUD LEK, V57, P7; van Geel WJA, 2002, CLIN CHIM ACTA, V326, P151, DOI 10.1016/S0009-8981(02)00330-3; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Xiong H, 2000, Sheng Li Ke Xue Jin Zhan, V31, P217; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2; Zurek J, 2012, ACTA NEUROCHIR, V154, P93, DOI 10.1007/s00701-011-1175-2	31	103	108	2	15	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV 1	2014	31	22					1815	U11		10.1089/neu.2013.3245			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CB4ZO	WOS:000349637400001	24903744	Green Published			2022-02-06	
J	Rashid, B; Destrade, M; Gilchrist, MD				Rashid, Badar; Destrade, Michel; Gilchrist, Michael D.			Mechanical characterization of brain tissue in simple shear at dynamic strain rates	JOURNAL OF THE MECHANICAL BEHAVIOR OF BIOMEDICAL MATERIALS			English	Article						Diffuse axonal injury (DAI); Ogden; Mooney-Rivlin; Traumatic brain injury (TBI); Homogeneous; Viscoelastic; Relaxation	VISCOELASTIC PROPERTIES; CONSTITUTIVE MODEL; IN-VIVO; BEHAVIOR; INJURY; DEFORMATION; STRETCH; IMPLEMENTATION; COMPRESSION; ELASTICITY	During severe impact conditions, brain tissue experiences a rapid and complex deformation, which can be seen as a mixture of compression, tension and shear. Diffuse axonal injury (DAI) occurs in animals and humans when both the strains and strain rates exceed 10% and 10/s, respectively. Knowing the mechanical properties of brain tissue in shear at these strains and strain rates is thus of particular importance, as they can be used in finite element simulations to predict the occurrence of brain injuries under different impact conditions. However, very few studies in the literature provide this information. In this research, an experimental setup was developed to perform simple shear tests on porcine brain tissue at strain rates <= 120/s. The maximum measured shear stress at strain rates of 30, 60, 90 and 120/s was 1.15+/-0.25 kPa, 1.34+/-0.19 kPa, 2.19+/-0.225 kPa and 2.52+/-0.27 kPa, (mean +/- SD), respectively at the maximum amount of shear, K=1. Good agreement of experimental, theoretical (Ogden and Mooney-Rivlin models) and numerical shear stresses was achieved (p=0.7866-0.9935). Specimen thickness effects (2.0-10.0 mm thick specimens) were also analyzed numerically and we found that there is no significant difference (p=0.9954) in the shear stress magnitudes, indicating a homogeneous deformation of the specimens during simple shear tests. Stress relaxation tests in simple shear were also conducted at different strain magnitudes (10-60% strain) with the average rise time of 14 ms. This allowed us to estimate elastic and viscoelastic parameters (initial shear modulus, mu=4942.0 Pa, and Prony parameters: g(1)=0.520, g(2)=0.3057, tau(1)=0.0264 s, and tau(2)=0.011 s) that can be used in FE software to analyze the non-linear viscoelastic behavior of brain tissue. This study provides new insight into the behavior in finite shear of brain tissue under dynamic impact conditions, which will assist in developing effective brain injury criteria and adopting efficient countermeasures against traumatic brain injury. (C) 2013 Elsevier Ltd. All rights reserved.	[Rashid, Badar; Destrade, Michel; Gilchrist, Michael D.] Univ Coll Dublin, Sch Mech & Mat Engn, Dublin 4, Ireland; [Destrade, Michel] Natl Univ Ireland Galway, Sch Math Stat & Appl Math, Galway, Ireland		Gilchrist, MD (corresponding author), Univ Coll Dublin, Sch Mech & Mat Engn, Dublin 4, Ireland.	badar.rashid@ucdconnect.ie; michel.destrade@nuigalway.ie; michael.gilchrist@ucd.ie	Destrade, Michel/O-5825-2019	Destrade, Michel/0000-0002-6266-1221	Irish Research Council for Science, Engineering and Technology (IRCSET), IrelandIrish Research Council for Science, Engineering and Technology; Irish Research Council (IRC)Irish Research Council for Science, Engineering and Technology	The authors thank Dr. John D. Finan of Columbia University for his valuable input regarding implementation of the non-linear viscoelastic model. This work was supported for the first author by a Postgraduate Research Scholarship awarded in 2009 by the Irish Research Council for Science, Engineering and Technology (IRCSET), Ireland, and for the second author, by a New Foundations award from the Irish Research Council (IRC).	ANDERSON R, 2000, THESIS U ADELAIDE S; Arbogast K., 1995, 952716 SAE; Arbogast KB, 1998, J BIOMECH, V31, P801, DOI 10.1016/S0021-9290(98)00068-2; Arbogast KB, 1997, J BIOMECH, V30, P757, DOI 10.1016/S0021-9290(97)00023-7; Atay SM, 2008, J BIOMECH ENG-T ASME, V130, DOI 10.1115/1.2899575; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bayly PV, 2006, J BIOMECH, V39, P1086, DOI 10.1016/j.jbiomech.2005.02.014; Bilston LE, 1997, BIORHEOLOGY, V34, P377, DOI 10.1016/S0006-355X(98)00022-5; Bilston LE, 2001, BIORHEOLOGY, V38, P335; Brands D.W.A., 2000, P WAM2000 ASME S CRA; BRANDS D. W. A., 2000, P STAPP CAR CRASH C, V44, P249; Brands D.W.A., 1999, P 43 STAPP CAR CRASH, P313; Brands DWA, 2004, J BIOMECH, V37, P127, DOI 10.1016/S0021-9290(03)00243-4; Cheng S, 2007, J BIOMECH, V40, P117, DOI 10.1016/j.jbiomech.2005.11.004; Claessens M., 1997, THESIS EINDHOVEN U T; Coats B, 2006, J BIOMECH, V39, P2521, DOI 10.1016/j.jbiomech.2005.07.020; Darvish KK, 2001, MED ENG PHYS, V23, P633, DOI 10.1016/S1350-4533(01)00101-1; Destrade M, 2012, INT J NONLIN MECH, V47, P210, DOI 10.1016/j.ijnonlinmec.2011.05.008; Destrade M, 2008, J BIOMECH ENG-T ASME, V130, DOI 10.1115/1.2979869; Donnelly BR, 1997, J BIOMECH ENG-T ASME, V119, P423, DOI 10.1115/1.2798289; Elkin BS, 2011, J BIOMECH ENG-T ASME, V133, DOI 10.1115/1.4004494; ESTES MS, 1970, 70BHF13 ASME; FALLENSTEIN GT, 1969, J BIOMECH, V2, P217, DOI 10.1016/0021-9290(69)90079-7; Finan JD, 2012, ANN BIOMED ENG, V40, P70, DOI 10.1007/s10439-011-0394-2; Franceschini G, 2006, J MECH PHYS SOLIDS, V54, P2592, DOI 10.1016/j.jmps.2006.05.004; Fung Y. C., 1993, BIOMECHANICS MECH PR; FUNG YC, 1979, AM J PHYSIOL, V237, pH620, DOI 10.1152/ajpheart.1979.237.5.H620; FUNG YCB, 1967, AM J PHYSIOL, V213, P1532, DOI 10.1152/ajplegacy.1967.213.6.1532; Funk JR, 2000, J BIOMECH ENG-T ASME, V122, P15, DOI 10.1115/1.429623; Garo A, 2007, BIORHEOLOGY, V44, P51; Gefen A, 2004, J BIOMECH, V37, P1339, DOI 10.1016/j.jbiomech.2003.12.032; Gennarelli TA, 1972, STAPP CAR CRASH J, V16, P296; Gent AN, 1996, RUBBER CHEM TECHNOL, V69, P59, DOI 10.5254/1.3538357; Hirakawa K, 1981, No To Shinkei, V33, P1057; Ho J, 2009, J BIOMECH, V42, P2074, DOI 10.1016/j.jbiomech.2009.06.051; Holzapfel GA., 2008, NONLINEAR SOLID MECH; HORGAN CO, 1995, SIAM REV, V37, P53, DOI 10.1137/1037003; Horgan CO, 2001, P ROY SOC A-MATH PHY, V457, P1999, DOI 10.1098/rspa.2001.0798; Horgan CO, 2011, P ROY SOC A-MATH PHY, V467, P760, DOI 10.1098/rspa.2010.0288; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; Hrapko M, 2006, BIORHEOLOGY, V43, P623; Hrapko M, 2008, J BIOMECH ENG-T ASME, V130, DOI 10.1115/1.2907746; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Laksari K, 2012, J BIOMECH, V45, P642, DOI 10.1016/j.jbiomech.2011.12.023; LaPlaca MC, 2005, J BIOMECH, V38, P1093, DOI 10.1016/j.jbiomech.2004.05.032; Lin DC, 2009, BIOMECH MODEL MECHAN, V8, P345, DOI 10.1007/s10237-008-0139-9; Lippert SA, 2004, BIORHEOLOGY, V41, P681; MARGULIES S S, 1989, Journal of Biomechanical Engineering, V111, P241; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; Meaney D.F., 1990, P INT C BIOM IMP IRC; Merodio J, 2005, INT J NONLIN MECH, V40, P213, DOI 10.1016/j.ijnontinmec.2004.05.003; Miller K, 1997, J BIOMECH, V30, P1115, DOI 10.1016/S0021-9290(97)00092-4; Miller K, 2002, J BIOMECH, V35, P483, DOI 10.1016/S0021-9290(01)00234-2; MOONEY M, 1964, J APPL PHYS, V35, P23, DOI 10.1063/1.1713076; Morrison B, 2006, J NEUROSCI METH, V150, P192, DOI 10.1016/j.jneumeth.2005.06.014; Morrison B, 2000, J BIOMECH ENG-T ASME, V122, P224, DOI 10.1115/1.429650; Morrison Barclay 3rd, 2003, Stapp Car Crash J, V47, P93; Nicolle S, 2005, BIORHEOLOGY, V42, P209; Nicolle Stephane, 2004, Stapp Car Crash J, V48, P239; Ogden R.W., 1997, NONLINEAR ELASTIC DE; Ogden RW, 2004, COMPUT MECH, V34, P484, DOI 10.1007/s00466-004-0593-y; OGDEN RW, 1972, PROC R SOC LON SER-A, V326, P565, DOI 10.1098/rspa.1972.0026; Ommaya AK, 1966, P 10 STAPP CAR CRASH, V10, P314; Pervin F, 2009, J BIOMECH, V42, P731, DOI 10.1016/j.jbiomech.2009.01.023; Pfister BJ, 2003, ANN BIOMED ENG, V31, P589, DOI 10.1114/1.1566445; Prange M T, 2000, Stapp Car Crash J, V44, P205; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Rashid B, 2012, P I MECH ENG P-J SPO, V226, P170, DOI 10.1177/1754337112436900; Rashid B, 2012, J MECH BEHAV BIOMED, V10, P23, DOI 10.1016/j.jmbbm.2012.01.022; RUAN JS, 1994, J BIOMECH ENG-T ASME, V116, P44, DOI 10.1115/1.2895703; Shen F, 2006, J BIOMECH ENG-T ASME, V128, P797, DOI 10.1115/1.2264393; SHUCK LZ, 1972, J BASIC ENG-T ASME, V94, P905, DOI 10.1115/1.3425588; Takhounts Erik G, 2003, Stapp Car Crash J, V47, P107; Tamura A, 2007, J BIOMECH SCI ENG, V2, P115, DOI [10.1299/jbse.2.115, DOI 10.1299/JBSE.2.115]; Tamura A, 2008, J BIOMECH SCI ENG, V3, P263, DOI DOI 10.1299/JBSE.3.263; Thibault KL, 1998, J BIOMECH, V31, P1119, DOI 10.1016/S0021-9290(98)00122-5; Trexler MM, 2011, J MECH BEHAV BIOMED, V4, P1920, DOI 10.1016/j.jmbbm.2011.06.008; Velardi F, 2006, BIOMECH MODEL MECHAN, V5, P53, DOI 10.1007/s10237-005-0007-9; Wismans, 1997, P 41 STAPP CAR CRASH, V41, P315, DOI DOI 10.4271/973338; Zhang L, 2001, Stapp Car Crash J, V45, P369	81	103	106	2	50	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	1751-6161	1878-0180		J MECH BEHAV BIOMED	J. Mech. Behav. Biomed. Mater.	DEC	2013	28				SI		71	85		10.1016/j.jmbbm.2013.07.017			15	Engineering, Biomedical; Materials Science, Biomaterials	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Materials Science	269IH	WOS:000328234500008	23973615	Green Submitted			2022-02-06	
J	Strain, J; Didehbani, N; Cullum, CM; Mansinghani, S; Conover, H; Kraut, MA; Hart, J; Womack, KB				Strain, Jeremy; Didehbani, Nyaz; Cullum, C. Munro; Mansinghani, Sethesh; Conover, Heather; Kraut, Michael A.; Hart, John, Jr.; Womack, Kyle B.			Depressive symptoms and white matter dysfunction in retired NFL players with concussion history	NEUROLOGY			English	Article							CHRONIC TRAUMATIC ENCEPHALOPATHY; FUNCTIONAL CONNECTIVITY; PSYCHOMETRIC EVALUATION; BRAIN-INJURY; INTEGRITY; INVENTORY; FREQUENCY; DEATH	Objective: To determine whether correlates of white matter integrity can provide general as well as specific insight into the chronic effects of head injury coupled with depression symptom expression in professional football players. Method: We studied 26 retired National Football League (NFL) athletes who underwent diffusion tensor imaging (DTI) scanning. Depressive symptom severity was measured using the Beck Depression Inventory II (BDI-II) including affective, cognitive, and somatic subfactor scores (Buckley 3-factor model). Fractional anisotropy (FA) maps were processed using tract-based spatial statistics from FSL. Correlations between FA and BDI-II scores were assessed using both voxel-wise and region of interest (ROI) techniques, with ROIs that corresponded to white matter tracts. Tracts demonstrating significant correlations were further evaluated using a receiver operating characteristic curve that utilized the mean FA to distinguish depressed from nondepressed subjects. Results: Voxel-wise analysis identified widely distributed voxels that negatively correlated with total BDI-II and cognitive and somatic subfactors, with voxels correlating with the affective component (p < 0.05 corrected) localized to frontal regions. Four tract ROIs negatively correlated (p < 0.01) with total BDI-II: forceps minor, right frontal aslant tract, right uncinate fasciculus, and left superior longitudinal fasciculus. FA of the forceps minor differentiated depressed from nondepressed athletes with 100% sensitivity and 95% specificity. Conclusion: Depressive symptoms in retired NFL athletes correlate negatively with FA using either an unbiased voxel-wise or an ROI-based, tract-wise approach. DTI is a promising biomarker for depression in this population.	[Strain, Jeremy; Didehbani, Nyaz; Mansinghani, Sethesh; Conover, Heather; Kraut, Michael A.; Hart, John, Jr.] Ctr Brain Hlth, Berman Lab Learning & Memory, Dallas, TX 75235 USA; [Cullum, C. Munro; Womack, Kyle B.] Univ Texas Dallas, Dept Psychiat, Sch Behav & Brain Sci, Dallas, TX 75230 USA; [Cullum, C. Munro; Hart, John, Jr.; Womack, Kyle B.] Univ Texas SW Med Ctr Dallas, Dept Neurol & Neurotherapeut, Dallas, TX 75390 USA; [Kraut, Michael A.] Johns Hopkins Sch Med, Dept Radiol, Baltimore, MD USA		Hart, J (corresponding author), Ctr Brain Hlth, Berman Lab Learning & Memory, Dallas, TX 75235 USA.	jhart@utdallas.edu	Womack, Kyle/O-5422-2018; Cullum, C. Munro/AAC-2496-2019	Womack, Kyle/0000-0002-6060-9075; Cullum, C. Munro/0000-0001-9706-5465; Mansinghani, Sethesh/0000-0001-5861-3764; Didehbani, Nyaz/0000-0001-6121-5759	BrainHealth Institute for Athletes at the Center for BrainHealth, a research center at the University of Texas at Dallas; National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA); NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K23AG030006] Funding Source: NIH RePORTER	Supported by the BrainHealth Institute for Athletes at the Center for BrainHealth, a research center at the University of Texas at Dallas, and by a National Institute on Aging grant.	American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Bae JN, 2006, BIOL PSYCHIAT, V60, P1356, DOI 10.1016/j.biopsych.2006.03.052; Bajwa S, 2008, J NERV MENT DIS, V196, P671, DOI 10.1097/NMD.0b013e318183f86f; Beck AT, 1996, J PERS ASSESS, V67, P588, DOI 10.1207/s15327752jpa6703_13; Buckley TC, 2001, J SUBST ABUSE TREAT, V20, P197, DOI 10.1016/S0740-5472(00)00169-0; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; de la Plata CDM, 2011, ARCH NEUROL-CHICAGO, V68, P74, DOI 10.1001/archneurol.2010.342; de la Plata CM, 2007, J NEUROTRAUM, V24, P591, DOI 10.1089/neu.2006.0214; Dotson VM, 2013, INT J GERIATR PSYCH, V28, P66, DOI 10.1002/gps.3791; Douaud G, 2007, BRAIN, V130, P2375, DOI 10.1093/brain/awm184; Dozois DJA, 1998, PSYCHOL ASSESSMENT, V10, P83, DOI 10.1037/1040-3590.10.2.83; Gavett BE, 2011, CURR OPIN NEUROL, V24, P525, DOI 10.1097/WCO.0b013e32834cd477; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Guo WB, 2012, PROG NEURO-PSYCHOPH, V38, P201, DOI 10.1016/j.pnpbp.2012.03.012; Hart Jr J, 2013, JAMA NEUROL, V1, P1; Huang H, 2012, NEUROBIOL AGING, V33, P2029, DOI 10.1016/j.neurobiolaging.2011.06.027; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Peng HJ, 2012, J AFFECT DISORDERS, V136, P249, DOI 10.1016/j.jad.2011.12.006; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; Tang CY, 2012, TRANSL NEUROSCI, V3, P9, DOI 10.2478/s13380-012-0003-3; Taylor Warren D, 2007, Neuropsychiatr Dis Treat, V3, P669; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; Xu K., 2012, J PSYCHIATR NEUROSCI, V37; Yuan YG, 2007, NEUROREPORT, V18, P1845, DOI 10.1097/WNR.0b013e3282f1939f	34	103	103	0	44	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	JUL 2	2013	81	1					25	32		10.1212/WNL.0b013e318299ccf8			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	304JC	WOS:000330741900009	23709590	Green Published			2022-02-06	
J	Claassen, J; Perotte, A; Albers, D; Kleinberg, S; Schmidt, JM; Tu, B; Badjatia, N; Lantigua, H; Hirsch, LJ; Mayer, SA; Connolly, ES; Hripcsak, G				Claassen, Jan; Perotte, Adler; Albers, David; Kleinberg, Samantha; Schmidt, J. Michael; Tu, Bin; Badjatia, Neeraj; Lantigua, Hector; Hirsch, Lawrence J.; Mayer, Stephan A.; Connolly, E. Sander; Hripcsak, George			Nonconvulsive Seizures after Subarachnoid Hemorrhage: Multimodal Detection and Outcomes	ANNALS OF NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; CRITICALLY-ILL; ELECTROGRAPHIC SEIZURES; STATUS EPILEPTICUS; TISSUE HYPOXIA; SPREADING DEPOLARIZATION; EEG PATTERNS; CARE; PRESSURE; BLOOD	ObjectiveSeizures have been implicated as a cause of secondary brain injury, but the systemic and cerebral physiologic effects of seizures after acute brain injury are poorly understood. MethodsWe analyzed intracortical electroencephalographic (EEG) and multimodality physiological recordings in 48 comatose subarachnoid hemorrhage patients to better characterize the physiological response to seizures after acute brain injury. ResultsIntracortical seizures were seen in 38% of patients, and 8% had surface seizures. Intracortical seizures were accompanied by elevated heart rate (p = 0.001), blood pressure (p < 0.001), and respiratory rate (p < 0.001). There were trends for rising cerebral perfusion pressure (p = 0.03) and intracranial pressure (p = 0.06) seen after seizure onset. Intracortical seizure-associated increases in global brain metabolism, partial brain tissue oxygenation, and regional cerebral blood flow (rCBF) did not reach significance, but a trend for a pronounced delayed rCBF rise was seen for surface seizures (p = 0.08). Functional outcome was very poor for patients with severe background attenuation without seizures and best for those without severe attenuation or seizures (77% vs 0% dead or severely disabled, respectively). Outcome was intermediate for those with seizures independent of the background EEG and worse for those with intracortical only seizures when compared to those with intracortical and scalp seizures (50% and 25% death or severe disability, respectively). InterpretationWe replicated in humans complex physiologic processes associated with seizures after acute brain injury previously described in laboratory experiments and illustrated differences such as the delayed increase in rCBF. These real world physiologic observations may permit more successful translation of laboratory research to the bedside. Ann Neurol 2013;74:53-64	[Claassen, Jan; Schmidt, J. Michael; Badjatia, Neeraj; Lantigua, Hector; Mayer, Stephan A.] Columbia Univ, Div Crit Care Neurol, Dept Neurol, New York, NY 10032 USA; [Claassen, Jan; Tu, Bin; Hirsch, Lawrence J.] Columbia Univ, Comprehens Epilepsy Ctr, Dept Neurol, New York, NY 10032 USA; [Claassen, Jan; Badjatia, Neeraj; Mayer, Stephan A.; Connolly, E. Sander] Columbia Univ, Dept Neurosurg, New York, NY 10032 USA; [Perotte, Adler; Albers, David; Kleinberg, Samantha; Hripcsak, George] Columbia Univ, Dept Biomed Informat, Coll Phys & Surg, New York, NY 10032 USA		Claassen, J (corresponding author), Columbia Univ, Div Crit Care Neurol, 177 Ft Washington Ave,MHB 8 Ctr,Room 300, New York, NY 10032 USA.	jc1439@columbia.edu	Badjatia, Neeraj/AAS-4855-2021; Claassen, Jan/AAA-5451-2020	Perotte, Adler/0000-0002-6695-0282; Hirsch, Lawrence/0000-0002-6333-832X; Badjatia, Neeraj/0000-0003-1509-9034; Schmidt, J. Michael/0000-0001-8141-2944	National Center for Research Resources (NCRR)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1 RR024156]; National Library of MedicineUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM) [R01 LM006910]; Training in Biomedical Informatics at Columbia University [T15 LM007079]; Charles A. Dana Foundation; National Science Foundation for the Computing Research Association [1019343]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024156] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM) [T15LM007079, R01LM006910] Funding Source: NIH RePORTER	This publication was made possible by a Grant entitled "Impact of Electrographic Seizures and Periodic Epileptiform Patterns on Neuronal Function and Outcome in Brain Injured Patients" (UL1 RR024156; J.C.) from the National Center for Research Resources (NCRR), a component of the NIH, and NIH Roadmap for Medical Research. Information on the NCRR is available at the NCRR website. Information on re-engineering the clinical research enterprise can be obtained from the NIH Roadmap website. Additional support for this work included grants from the National Library of Medicine, ("Discovering and applying knowledge in clinical databases" [R01 LM006910; G.H., D.A.] and "Training in Biomedical Informatics at Columbia University" [T15 LM007079; G.H., A.P.]), the Charles A. Dana Foundation (S.A.M.), and the National Science Foundation for the Computing Research Association CIFellows project (#1019343; S.K.). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NCRR, NIH, National Science Foundation, or Dana Foundation.	Bahar S, 2006, NEUROREPORT, V17, P499, DOI 10.1097/01.wnr.0000209010.78599.f5; Baumgartner C, 2001, EPILEPTIC DISORD, V3, P103; Bederson JB, 2009, STROKE, V40, P994, DOI 10.1161/STROKEAHA.108.191395; Carrera E, 2010, J NEUROL NEUROSUR PS, V81, P793, DOI 10.1136/jnnp.2009.174425; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Chong DJ, 2005, J CLIN NEUROPHYSIOL, V22, P79, DOI 10.1097/01.WNP.0000158699.78529.AF; Claassen J, 2007, NEUROLOGY, V69, P1356, DOI 10.1212/01.wnl.0000281664.02615.6c; Claassen J, 2006, NEUROCRIT CARE, V4, P103, DOI 10.1385/NCC:4:2:103; Claassen J, 2001, STROKE, V32, P2012, DOI 10.1161/hs0901.095677; Claassen J, 2001, NEUROLOGY, V57, P1036, DOI 10.1212/WNL.57.6.1036; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Czosnyka M, 2003, ACT NEUR S, V86, P581; Dreier JP, 2012, BRAIN, V135, P259, DOI 10.1093/brain/awr303; Dreier JP, 2011, NAT MED, V17, P439, DOI 10.1038/nm.2333; Drislane FW, 1999, J CLIN NEUROPHYSIOL, V16, P323, DOI 10.1097/00004691-199907000-00004; Fried R, 2000, LECT NOTES COMPUT SC, V1933, P67; Frykholm P, 2004, ACTA NEUROL SCAND, V109, P25, DOI 10.1034/j.1600-0404.2003.00174.x; Geneslaw AS, 2011, J CEREBR BLOOD F MET, V31, P1394, DOI 10.1038/jcbfm.2011.16; Gornbein J A, 1992, Stat Methods Med Res, V1, P275; Helbok R, 2011, STROKE, V42, P1534, DOI 10.1161/STROKEAHA.110.604488; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Hirsch LJ, 2005, J CLIN NEUROPHYSIOL, V22, P128, DOI 10.1097/01.WNP.0000158701.89576.4C; Hopwood SE, 2005, J CEREBR BLOOD F MET, V25, P391, DOI 10.1038/sj.jcbfm.9600050; Hripcsak G, 2011, J AM MED INFORM ASSN, V18, pI109, DOI 10.1136/amiajnl-2011-000463; Iadecola C, 2011, NAT NEUROSCI, V14, P1363, DOI 10.1038/nn.2953; Imhoff M, 1998, INTENS CARE MED, V24, P1305, DOI 10.1007/s001340050767; Iyer VN, 2009, CRIT CARE MED, V37, P3024, DOI 10.1097/CCM.0b013e3181b08ac7; Jones PA, 2003, PHYSIOL MEAS, V24, P201, DOI 10.1088/0967-3334/24/1/315; Kaplan PW, 2005, NEUROLOGIST, V11, P348, DOI 10.1097/01.nrl.0000162954.76053.d2; Kirkman MA, 2011, J CEREBR BLOOD F MET, V31, P2135, DOI 10.1038/jcbfm.2011.124; Ko SB, 2011, ARCH NEUROL-CHICAGO, V68, P1323, DOI 10.1001/archneurol.2011.240; Komotar RJ, 2009, NEUROSURGERY, V64, P397, DOI 10.1227/01.NEU.0000338946.42939.C7; la Fougere C, 2009, EPILEPSY BEHAV, V15, P50, DOI 10.1016/j.yebeh.2009.02.025; LANDIS JR, 1977, BIOMETRICS, V33, P363, DOI 10.2307/2529786; Litt B, 1998, EPILEPSIA, V39, P1194, DOI 10.1111/j.1528-1157.1998.tb01311.x; Losiniecki A, 2010, CURR TREAT OPTION NE, V12, P142, DOI 10.1007/s11940-010-0063-z; Manley GT, 2010, ARCH PHYS MED REHAB, V91, P1667, DOI 10.1016/j.apmr.2010.05.018; McIntosh N, 2002, CLIN MED, V2, P349, DOI 10.7861/clinmedicine.2-4-349; O'Collins VE, 2006, ANN NEUROL, V59, P467, DOI 10.1002/ana.20741; Rossetti AO, 2010, ANN NEUROL, V67, P301, DOI 10.1002/ana.21984; Shuaib A, 2007, NEW ENGL J MED, V357, P562, DOI 10.1056/NEJMoa070240; Sorani MD, 2007, NEUROCRIT CARE, V7, P45, DOI 10.1007/s12028-007-0043-7; Steiner LA, 2003, STROKE, V34, P2404, DOI 10.1161/01.STR.0000089014.59668.04; Stuart RM, 2010, NEUROCRIT CARE, V12, P188, DOI 10.1007/s12028-010-9330-9; Su IC, 2009, ACTA NEUROCHIR, V151, P1631, DOI 10.1007/s00701-009-0517-9; Suh M, 2005, J NEUROSCI, V25, P68, DOI 10.1523/JNEUROSCI.2823-04.2005; Suh M, 2006, MOL NEUROBIOL, V33, P181, DOI 10.1385/MN:33:3:181; Topolnik L, 2003, CEREB CORTEX, V13, P883, DOI 10.1093/cercor/13.8.883; Vajkoczy P, 2000, J NEUROSURG, V93, P265, DOI 10.3171/jns.2000.93.2.0265; van der Bilt IAC, 2009, NEUROLOGY, V72, P635, DOI 10.1212/01.wnl.0000342471.07290.07; van der Worp HB, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000245; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Vespa PM, 2010, NEUROLOGY, V75, P792, DOI 10.1212/WNL.0b013e3181f07334; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Waziri A, 2009, ANN NEUROL, V66, P366, DOI 10.1002/ana.21721; Zerbet A, 2003, COMMUN STAT-THEOR M, V32, P573, DOI 10.1081/STA-120018552; Zhang SH, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006778.pub2; Zhao MR, 2011, J NEUROSCI, V31, P13292, DOI 10.1523/JNEUROSCI.2597-11.2011	59	103	104	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	JUL	2013	74	1					53	64		10.1002/ana.23859			12	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	282UH	WOS:000329198600008	23813945	Green Accepted			2022-02-06	
J	Leddy, JJ; Cox, JL; Baker, JG; Wack, DS; Pendergast, DR; Zivadinov, R; Willer, B				Leddy, John J.; Cox, Jennifer L.; Baker, John G.; Wack, David S.; Pendergast, David R.; Zivadinov, Robert; Willer, Barry			Exercise Treatment for Postconcussion Syndrome: A Pilot Study of Changes in Functional Magnetic Resonance Imaging Activation, Physiology, and Symptoms	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						exercise; fMRI; physiology; postconcussion syndrome	TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; VOLUNTARY EXERCISE; UP-REGULATION; HEAD-INJURY; RECOVERY; RELIABILITY; MRI; ABNORMALITIES; VALIDATION	Purpose: To compare functional magnetic resonance imaging (fMRI) activation patterns during a cognitive task, exercise capacity, and symptoms in postconcussion syndrome (PCS) patients who received exercise treatment (n = 4) with a PCS placebo stretching group (n = 4) and a healthy control group (n = 4). Methods: Subjects completed a math processing task during fMRI and an exercise treadmill test before (time 1) and after approximately 12 weeks (time 2). Exercise subjects performed aerobic exercise at 80% of the heart rate (HR) attained on the treadmill test, 20 minutes per day with an HR monitor at home, 6 days per week. The program was modified as the HR for symptom exacerbation increased. Results: At time 1, there was no difference in fMRI activation between the 2 PCS groups but healthy controls had significantly greater activation in the posterior cingulate gyrus, lingual gyrus, and cerebellum versus all PCS subjects (P < .05, corrected for multiple comparisons). At time 2, exercise PCS did not differ from healthy controls whereas placebo stretching PCS had significantly less activity in the cerebellum (P < .05 corrected) and in the anterior cingulate gyrus and thalamus (P < .001, uncorrected) versus healthy controls. At time 2, exercise PCS achieved a significantly greater exercise HR (P < .001) and had fewer symptoms (P < .0004) than placebo stretching PCS. Cognitive performance did not differ by group or time. Conclusions: Controlled aerobic exercise rehabilitation may help restore normal cerebral blood flow regulation, as indicated by fMRI activation, in PCS patients. The PCS symptoms may be related to abnormal cerebral blood flow regulation.	[Leddy, John J.; Baker, John G.] SUNY Buffalo, Dept Orthopaed, Buffalo, NY 14260 USA; [Leddy, John J.; Baker, John G.] SUNY Buffalo, Univ Sports Med, Buffalo, NY 14260 USA; [Cox, Jennifer L.; Zivadinov, Robert] SUNY Buffalo, Buffalo Neuroimaging Anal Ctr, Dept Neurol, Buffalo, NY 14260 USA; [Baker, John G.; Wack, David S.] SUNY Buffalo, Dept Nucl Med, Buffalo, NY 14260 USA; [Pendergast, David R.] SUNY Buffalo, Dept Physiol & Biophys, Buffalo, NY 14260 USA; [Willer, Barry] SUNY Buffalo, Dept Psychiat, Buffalo, NY 14260 USA		Leddy, JJ (corresponding author), Univ Sports Med, 160 Farber Hall SUNY, Buffalo, NY 14214 USA.	leddy@buffalo.edu	Zivadinov, Robert/Q-2054-2019	Zivadinov, Robert/0000-0002-7799-1485	University at Buffalo; Robert Rich Family Foundation; Buffalo Sabres Foundation	The authors acknowledge the assistance of the Buffalo Neuroimaging Analysis Center (BNAC), located in the Jacobs Neurological Institute (JNI) at the Buffalo General Hospital, for performing the fMRI studies for this project. Dr Leddy received funding from the University at Buffalo Interdisciplinary Research Development Fund. Drs Willer and Leddy received funding from the Robert Rich Family Foundation and the Buffalo Sabres Foundation.	ACSM's Guidelines for Exercise Testing and Prescription, 2006, ACSMS GUID EX TEST P; Baillieux H, 2008, CLIN NEUROL NEUROSUR, V110, P763, DOI 10.1016/j.clineuro.2008.05.013; Bonte FJ, 2004, J NUCL MED, V45, P771; Brys M, 2003, AM J PHYSIOL-HEART C, V285, pH1048, DOI 10.1152/ajpheart.00062.2003; Carter JB, 2003, SPORTS MED, V33, P33, DOI 10.2165/00007256-200333010-00003; Chein JM, 2011, NEUROIMAGE, V54, P550, DOI 10.1016/j.neuroimage.2010.07.067; Chen JK, 2008, CLIN J SPORT MED, V18, P241, DOI 10.1097/JSM.0b013e318170b59d; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Doering TJ, 1998, AM J PHYS MED REHAB, V77, P490, DOI 10.1097/00002060-199811000-00006; Giza CC, 2001, J ATHL TRAINING, V36, P228; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Hanna-Pladdy B, 2001, CLIN NEUROPSYCHOL, V15, P289, DOI 10.1076/clin.15.3.289.10272; Kozlowski KF, 2007, NEUROREHABILITATION, V22, P191; Leddy JJ, 2007, NEUROREHABILITATION, V22, P199; Leddy JJ, 2011, CLIN J SPORT MED, V21, P89, DOI 10.1097/JSM.0b013e3181fdc721; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Matsuda H, 2007, AM J NEURORADIOL, V28, P731; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Saalmann YB, 2009, CURR OPIN NEUROBIOL, V19, P408, DOI 10.1016/j.conb.2009.05.007; Segalowitz SJ, 2007, NEUROREHABILITATION, V22, P243; Short P, 2007, ARCH CLIN NEUROPSYCH, V22, pS63, DOI 10.1016/j.acn.2006.10.012; Stoodley CJ, 2009, NEUROIMAGE, V44, P489, DOI 10.1016/j.neuroimage.2008.08.039	29	103	105	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2013	28	4					241	249		10.1097/HTR.0b013e31826da964			9	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	298ZO	WOS:000330363900001	23249769				2022-02-06	
J	Menge, T; Zhao, YH; Zhao, J; Wataha, K; Gerber, M; Zhang, JH; Letourneau, P; Redell, J; Shen, L; Wang, J; Peng, ZL; Xue, H; Kozar, R; Cox, CS; Khakoo, AY; Holcomb, JB; Dash, PK; Pati, S				Menge, Tyler; Zhao, Yuhai; Zhao, Jing; Wataha, Kathryn; Gerber, Michael; Zhang, Jianhu; Letourneau, Phillip; Redell, John; Shen, Li; Wang, Jing; Peng, Zhalong; Xue, Hasen; Kozar, Rosemary; Cox, Charles S., Jr.; Khakoo, Aarif Y.; Holcomb, John B.; Dash, Pramod K.; Pati, Shibani			Mesenchymal Stem Cells Regulate Blood-Brain Barrier Integrity Through TIMP3 Release After Traumatic Brain Injury	SCIENCE TRANSLATIONAL MEDICINE			English	Article							TISSUE INHIBITOR; VASCULAR-PERMEABILITY; MODEL; EXPRESSION; SECRETION; APOPTOSIS; LUNG	Mesenchymal stem cells (MSCs) may be useful for treating a variety of disease states associated with vascular instability including traumatic brain injury (TBI). A soluble factor, tissue inhibitor of matrix metalloproteinase-3 (TIMP3), produced by MSCs is shown to recapitulate the beneficial effects of MSCs on endothelial function and to ameliorate the effects of a compromised blood-brain barrier (BBB) due to TBI. Intravenous administration of recombinant TIMP3 inhibited BBB permeability caused by TBI, whereas attenuation of TIMP3 expression in intravenously administered MSCs blocked the beneficial effects of the MSCs on BBB permeability and stability. MSCs increased circulating concentrations of soluble TIMP3, which blocked vascular endothelial growth factor-A-induced breakdown of endothelial cell adherens junctions in vitro and in vivo. These findings elucidate a potential molecular mechanism for the beneficial effects of MSCs on the BBB after TBI and demonstrate a role for TIMP3 in the regulation of BBB integrity.	[Menge, Tyler; Wataha, Kathryn; Pati, Shibani] Blood Syst Res Inst, San Francisco, CA 94118 USA; [Zhao, Yuhai; Gerber, Michael; Letourneau, Phillip; Peng, Zhalong; Kozar, Rosemary; Holcomb, John B.] Univ Texas Houston, Hlth Sci Ctr, Dept Surg, Houston, TX 77030 USA; [Zhao, Yuhai; Gerber, Michael; Letourneau, Phillip; Peng, Zhalong; Kozar, Rosemary; Holcomb, John B.] Univ Texas Houston, Hlth Sci Ctr, Ctr Translat Injury Res, Houston, TX 77030 USA; [Zhao, Jing; Redell, John; Dash, Pramod K.] Univ Texas Houston, Hlth Sci Ctr, Dept Neurobiol & Anat, Houston, TX 77030 USA; [Zhang, Jianhu; Shen, Li; Wang, Jing] Univ Texas Houston, MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA; [Xue, Hasen; Cox, Charles S., Jr.] Univ Texas Houston, Hlth Sci Ctr, Dept Pediat Surg, Houston, TX 77030 USA; [Xue, Hasen; Cox, Charles S., Jr.] Univ Texas Houston, Hlth Sci Ctr, Inst Mol Med, Houston, TX 77030 USA; [Khakoo, Aarif Y.] Amgen Inc, San Francisco, CA 94080 USA; [Pati, Shibani] Univ Calif San Francisco, San Francisco, CA 94118 USA		Pati, S (corresponding author), Blood Syst Res Inst, San Francisco, CA 94118 USA.	spati@bloodsystems.org		Dash, Pramod/0000-0001-6746-1002; holcomb, john/0000-0001-8312-9157	Mission Connect; Texas Institute for Rehabilitation and Research; Bentsen Foundation, Houston, TX; National Heart, Lung, and Blood Institute K18 award [K18HL102256-01]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA016672] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [K18HL102256] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008792] Funding Source: NIH RePORTER	This work is funded in part by Mission Connect; the Texas Institute for Rehabilitation and Research; the Bentsen Foundation, Houston, TX; and National Heart, Lung, and Blood Institute K18 award (K18HL102256-01).	Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; Black RA, 2004, NAT GENET, V36, P934, DOI 10.1038/ng0904-934; Block GJ, 2009, STEM CELLS, V27, P670, DOI [10.1634/stemcells.stemcells.2008-0742, 10.1002/stem.20080742]; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Fang XH, 2010, J BIOL CHEM, V285, P26211, DOI 10.1074/jbc.M110.119917; Fischer UM, 2009, STEM CELLS DEV, V18, P683, DOI 10.1089/scd.2008.0253; Garofalo M, 2009, CANCER CELL, V16, P498, DOI 10.1016/j.ccr.2009.10.014; Gill SE, 2010, AM J PATHOL, V176, P64, DOI 10.2353/ajpath.2010.090158; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Jacobson SG, 2002, ARCH OPHTHALMOL-CHIC, V120, P376; Kaur I, 2010, P NATL ACAD SCI USA, V107, pE112, DOI 10.1073/pnas.1007476107; Khakoo AY, 2006, J EXP MED, V203, P1235, DOI 10.1084/jem.20051921; KISHNANI NS, 1995, MATRIX BIOL, V14, P479, DOI 10.1016/0945-053X(95)90005-5; Koyama Junji, 2007, Kobe J Med Sci, V53, P199; Kwak HI, 2009, MATRIX BIOL, V28, P470, DOI 10.1016/j.matbio.2009.07.007; Lee JK, 2008, NEUROBIOL DIS, V30, P174, DOI 10.1016/j.nbd.2008.01.004; Lee RH, 2009, CELL STEM CELL, V5, P54, DOI 10.1016/j.stem.2009.05.003; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; Matthay MA, 2010, CRIT CARE MED, V38, pS569, DOI 10.1097/CCM.0b013e3181f1ff1d; Pati S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025171; Pati S, 2011, STEM CELLS DEV, V20, P89, DOI 10.1089/scd.2010.0013; Picinich SC, 2007, EXPERT OPIN BIOL TH, V7, P965, DOI 10.1517/14712598.7.7.965; Pounds S, 2003, BIOINFORMATICS, V19, P1236, DOI 10.1093/bioinformatics/btg148; Qi JH, 2003, NAT MED, V9, P407, DOI 10.1038/nm846; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; Weis SM, 2005, NATURE, V437, P497, DOI 10.1038/nature03987; Zhao J, 2012, J NEUROTRAUM, V29, P1209, DOI 10.1089/neu.2011.1858	27	103	105	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	1946-6234	1946-6242		SCI TRANSL MED	Sci. Transl. Med.	NOV 21	2012	4	161							161ra150	10.1126/scitranslmed.3004660			11	Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Research & Experimental Medicine	041UO	WOS:000311426900003	23175708	Green Accepted			2022-02-06	
J	[Anonymous]				[Anonymous]			Effect of tranexamic acid in traumatic brain injury: a nested randomised, placebo controlled trial (CRASH-2 Intracranial Bleeding Study)	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEMORRHAGE; CT	Objective To assess the effect of tranexamic acid (which reduces bleeding in surgical patients and reduces mortality due to bleeding in trauma patients) on intracranial haemorrhage in patients with traumatic brain injury. Methods A nested, randomised, placebo controlled trial. All investigators were masked to treatment allocation. All analyses were by intention to treat. Patients 270 adult trauma patients with, or at risk of, significant extracranial bleeding within 8 hours of injury, who also had traumatic brain injury. Interventions Patients randomly allocated to tranexamic acid (loading dose 1 g over 10 minutes, then infusion of 1 g over 8 hours) or matching placebo. Main outcome measures Intracranial haemorrhage growth (measured by computed tomography) between hospital admission and then 24-48 hours later, with adjustment for Glasgow coma score, age, time from injury to the scans, and initial haemorrhage volume. Results Of the 133 patients allocated to tranexamic acid and 137 allocated to placebo, 123 (92%) and 126 (92%) respectively provided information on the primary outcome. All patients provided information on clinical outcomes. The mean total haemorrhage growth was 5.9 ml (SD 26.8) and 8.1 mL (SD 29.2) in the tranexamic acid and placebo groups respectively (adjusted difference -3.8 mL (95% confidence interval -11.5 to 3.9)). New focal cerebral ischaemic lesions occurred in 6 (5%) patients in the tranexamic acid group versus 12 (9%) in the placebo group (adjusted odds ratio 0.51 (95% confidence interval 0.18 to 1.44)). There were 14 (11%) deaths in the tranexamic acid group and 24 (18%) in the placebo group (adjusted odds ratio 0.47 (0.21 to 1.04)). Conclusions This trial shows that neither moderate benefits nor moderate harmful effects of tranexamic acid in patients with traumatic brain injury can be excluded. However, the analysis provides grounds for further clinical trials evaluating the effect of tranexamic acid in this population.					IBIS, NEUROCRITICOS/C-1805-2016	Prieto-Merino, David/0000-0001-5001-0061; Al-Shahi Salman, Rustam/0000-0002-2108-9222	UK NIHRNational Institute for Health Research (NIHR); PfizerPfizer; BUPA Foundation; J P Moulton Charitable Foundation; UK Health Technology Assessment programmeNational Institute for Health Research (NIHR) [06/303/20]; UK MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC); Scottish Funding Council through the SINAPSE Collaboration (Scottish Imaging Network, A Platform for Scientific Excellence); Scottish Funding Council; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G108/613, G1002605] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [09/102/01] Funding Source: researchfish; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G108/613, G1002605] Funding Source: UKRI	The CRASH-2 study was funded by the UK NIHR Health Technology Assessment programme, Pfizer, BUPA Foundation, and J P Moulton Charitable Foundation. This sub-study was funded by the UK Health Technology Assessment programme (06/303/20). Rustam Al-Shahi Salman was funded by a UK MRC clinician scientist fellowship. Joanna Wardlaw was funded by the Scottish Funding Council through the SINAPSE Collaboration (Scottish Imaging Network, A Platform for Scientific Excellence).; All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: the submitted work was funded by the UK Health Technology Assessment programme (06/303/20), Rustam Al-Shahi Salman was funded by a UK MRC clinician scientist fellowship, Joanna Wardlaw was funded by the Scottish Funding Council; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.	Baigent C, 2010, OXFORD TXB MED, DOI DOI 10.1093/MED/9780199204854.003.020303_UPDATE_002; Bayir A, 2006, NEUROL INDIA, V54, P363, DOI 10.4103/0028-3886.28106; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Cohan MJ, 2007, J TRAUMA, V63, P1254, DOI 10.1097/TA.0b013e318156ee4c; Cordoba G, 2010, BMJ-BRIT MED J, V341, pc3920; Edwards P, 2005, LANCET, V365, P1957; Gebel JM, 1998, STROKE, V29, P1799, DOI 10.1161/01.STR.29.9.1799; GREENE KA, 1995, J NEUROSURG, V83, P445, DOI 10.3171/jns.1995.83.3.0445; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Henry DA, 2007, COCHRANE DB SYST REV, V17; Lustenberger T, 2010, J TRAUMA, V69, P1410, DOI 10.1097/TA.0b013e3181cdae81; Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Perel P, 2009, BMC EMERG MED, V9, DOI 10.1186/1471-227X-9-15; Perel P, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007877.pub2; Perel P, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-72; PETERSEN OF, 1984, NEURORADIOLOGY, V26, P363, DOI 10.1007/BF00327488; Roos YB, 2003, COCHRANE DB SYST REV, V2, DOI [DOI 10.1002/14651858.CD001245, 10.1002/14651858.CD001245]; Shakur H, 2010, LANCET, V376, P23, DOI 10.1016/S0140-6736(10)60835-5; Stein SC, 2007, INDIAN J MED RES, V125, P186; Wardlaw JM, 2002, J NEUROL NEUROSUR PS, V72, P188, DOI 10.1136/jnnp.72.2.188; WARDLAW JM, 1994, AM J NEURORADIOL, V15, P1933	22	103	104	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 1	2011	343								d3795	10.1136/bmj.d3795			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	788QD	WOS:000292458600002	21724564	Green Published, hybrid, Green Accepted			2022-02-06	
J	Bailes, JE; Mills, JD				Bailes, Julian E.; Mills, James D.			Docosahexaenoic Acid Reduces Traumatic Axonal Injury in a Rodent Head Injury Model	JOURNAL OF NEUROTRAUMA			English	Article						amyloid precursor protein; docosahexaenoic acid; omega-3 fatty acids; traumatic axonal injury	POLYUNSATURATED FATTY-ACIDS; SPINAL-CORD-INJURY; BRAIN-INJURY; CELL-DEATH; OMEGA-3-FATTY-ACIDS; APOPTOSIS; SUPPLEMENTATION; INFLAMMATION; MECHANISMS; PLASMA	Traumatic brain injury (TBI) remains the most common cause of death in persons under age 45 in the Western world. Recent evidence from animal studies suggests that supplementation with omega-3 fatty acids (O3FA) improves functional outcomes following focal neural injury. The purpose of this study is to determine the benefits of DHA supplementation following diffuse axonal injury in rats. Four groups of 10 adult male Sprague-Dawley rats were subjected to an impact acceleration injury and then received 30 days of supplementation with either 10 mg/kg/d or 40 mg/kg/d of docosahexaenoic acid (DHA). Serum fatty acid levels were determined from the isolated plasma phospholipids prior to injury and at the end of the 30 days of DHA supplementation. Following sacrifice, brainstem white matter tracts underwent fluorescent immunohistochemical processing for labeling of beta-amyloid precursor protein (APP), a marker of axonal injury. Dietary supplementation with either 10 mg/kg/d or 40 mg/kg/d of DHA for 30 days results in significantly (p < 0.05) increased DHA serum levels of 123% and 175% over baseline, respectively. Immunohistochemical analysis reveals significantly (p < 0.05) decreased numbers of APP-positive axons in animals receiving dietary supplementation with DHA, 26.1 (SD 5.3) for 10 mg/kg/d, and 19.6 (SD 4.7) for 40 mg/kg/d axons per mm(2), versus 147.7 (SD 7.1) axons in unsupplemented animals. Sham-injured animals had 6.4 (SD 13.9) APP positive axons per mm(2). Dietary supplementation with DHA increases serum levels in a dose-dependent manner. DHA supplementation significantly reduces the number of APP-positive axons at 30 days post-injury, to levels similar to seen those in uninjured animals. DHA is safe, affordable, and readily available worldwide to potentially reduce the burden of TBI.	[Bailes, Julian E.; Mills, James D.] W Virginia Univ, Dept Neurosurg, Sch Med, Morgantown, WV 26506 USA		Bailes, JE (corresponding author), W Virginia Univ, Dept Neurosurg, Sch Med, POB 9183, Morgantown, WV 26506 USA.	jbailes@hsc.wvu.edu			Martek, Inc.; Martek Biosciences, Inc.	This work was supported by a grant from Martek, Inc. The authors would like to recognize Rebecca Kessler for assistance with manuscript preparation.; This work was financially supported by Martek Biosciences, Inc., for which Dr. Bailes serves as a consultant.	Aoyama N, 2008, BRAIN RES, V1230, P310, DOI 10.1016/j.brainres.2008.07.006; Bazan NG, 2005, BRAIN PATHOL, V15, P159; Belayev L, 2009, STROKE, V40, P3121, DOI 10.1161/STROKEAHA.109.555979; Blondeau N, 2002, NEUROSCIENCE, V109, P231, DOI 10.1016/S0306-4522(01)00473-0; Brossard N, 1996, AM J CLIN NUTR, V64, P577, DOI 10.1093/ajcn/64.4.577; Buki A, 2000, J NEUROSCI, V20, P2825; Calder PC, 2003, BRAZ J MED BIOL RES, V36, P433, DOI 10.1590/S0100-879X2003000400004; Calderon F, 2004, J NEUROCHEM, V90, P979, DOI 10.1111/j.1471-4159.2004.02520.x; Cao DH, 2004, PHARMACOL BIOCHEM BE, V79, P651, DOI 10.1016/j.pbb.2004.09.016; Carver JD, 2001, BRAIN RES BULL, V56, P79, DOI 10.1016/S0361-9230(01)00551-2; Danthi SJ, 2005, BIOCHEM BIOPH RES CO, V327, P485, DOI 10.1016/j.bbrc.2004.12.033; Doppenberg EMR, 1997, ANN NY ACAD SCI, V825, P305, DOI 10.1111/j.1749-6632.1997.tb48441.x; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; Emsley R, 2003, CNS DRUGS, V17, P1081, DOI 10.2165/00023210-200317150-00003; Hogyes E, 2003, NEUROSCIENCE, V119, P999, DOI 10.1016/S0306-4522(03)00198-2; HOLUB BJ, 1987, METHOD ENZYMOL, V141, P234; Hovda DA, 2007, CRIT CARE MED, V35, P663, DOI 10.1097/01.CCM.0000254442.66789.52; Jump DB, 2002, CURR OPIN LIPIDOL, V13, P155, DOI 10.1097/00041433-200204000-00007; Lang-Lazdunski L, 2003, J VASC SURG, V38, P564, DOI 10.1016/S0741-5214(03)00473-7; Lauritzen I, 2000, EMBO J, V19, P1784, DOI 10.1093/emboj/19.8.1784; Lonergan PE, 2004, J NEUROCHEM, V91, P20, DOI 10.1111/j.1471-4159.2004.02689.x; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MARTINEZ M, 1994, WORLD REV NUTR DIET, V75, P70; MARTINEZ M, 1992, J PEDIATR-US, V120, pS129, DOI 10.1016/S0022-3476(05)81247-8; Mills JD, 2003, J BIOMED OPT, V8, P347, DOI 10.1117/1.1584443; Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101; MURPHY EJ, 1994, MOL CHEM NEUROPATHOL, V23, P13, DOI 10.1007/BF02858504; NEEDLEMAN P, 1979, P NATL ACAD SCI USA, V76, P944, DOI 10.1073/pnas.76.2.944; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Salem N, 2001, LIPIDS, V36, P945, DOI 10.1007/s11745-001-0805-6; Sarsimaz M, 2003, NEUROSCI RES COMMUN, V33, P114, DOI 10.1002/nrc.10087; Schlanger S, 2002, EPILEPSIA, V43, P103, DOI 10.1046/j.1528-1157.2002.13601.x; Schwab JM, 2007, NATURE, V447, P869, DOI 10.1038/nature05877; Songur A, 2004, PROG NEURO-PSYCHOPH, V28, P693, DOI 10.1016/j.pnpbp.2004.05.006; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Vidgren HM, 1997, LIPIDS, V32, P697, DOI 10.1007/s11745-997-0089-x; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wang X, 2003, NEUROREPORT, V14, P2457, DOI 10.1097/00001756-200312190-00033; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457; Wu AG, 2007, J NEUROTRAUM, V24, P1587, DOI 10.1089/neu.2007.0313; Xu GY, 2004, EXP NEUROL, V187, P329, DOI 10.1016/j.expneurol.2004.01.029	47	103	104	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2010	27	9					1617	1624		10.1089/neu.2009.1239			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	649TJ	WOS:000281796500008	20597639				2022-02-06	
J	Covassin, T; Elbin, RJ; Stiller-Ostrowski, JL; Kontos, AP				Covassin, Tracey; Elbin, Robert J., III; Stiller-Ostrowski, Jennifer L.; Kontos, Anthony P.			Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) Practices of Sports Medicine Professionals	JOURNAL OF ATHLETIC TRAINING			English	Article						concussions; baseline testing; computerized neurocognitive testing	TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL; AGREEMENT STATEMENT; SOCCER PLAYERS; EPIDEMIOLOGY; MANAGEMENT; RECOVERY	Context: Computerized neurocognitive testing is becoming popular among clinicians evaluating sport-related concussions across all levels of sport. Baseline neurocognitive testing has been recommended to provide more accurate representation of the preconcussion cognitive status of individual athletes. However, little is known about the use of baseline neurocognitive testing in concussion assessment and management. Objective: To examine implementation and practice trends of sports medicine professionals using baseline neurocognitive testing at the high school and collegiate levels. Design: Quantitative survey research. Setting: Online survey. Patients or Other Participants: Certified athletic trainers (ATs) from approximately 1209 US institutions listed on the ImPACT Web site were recruited. A total of 399 ATs completed the survey, for a response return rate of 32.7%. Main Outcome Measure(s): Survey questions addressed educational level, years of certification, employment setting, percentage of athletes baseline tested, and accuracy of baseline tests. Other items addressed postconcussive neurocognitive testing protocols and scenarios for return-to-play decisions based on neurocognitive testing. Results: Nearly all ATs (94.7%) administered baseline computerized neurocognitive testing to their athletes. However, only 51.9% examined these baseline tests for validity. The majority of ATs indicated that they administer baseline neurocognitive tests most frequently to football players (88.4%), followed by women's soccer players (78.8%) and men's soccer players (71.2%). Nearly all respondents (95.5%) stated that they would not return a symptomatic athlete to play if the athlete's neurocognitive scores were back to baseline. However, when asked if they would return an athlete who is symptom free but who scores below his or her baseline, 86.5% responded no, 9.8% responded yes, and 3.8% indicated that it depended on the importance of the competition. Conclusions: The use of baseline testing, baseline testing readministration, and postconcussion protocols among ATs is increasing. However, the ATs in this study reported that they relied more on symptoms than on neurocognitive test scores when making return-to-play decisions.	[Covassin, Tracey; Elbin, Robert J., III; Stiller-Ostrowski, Jennifer L.] Michigan State Univ, E Lansing, MI 48823 USA; [Kontos, Anthony P.] Humboldt State Univ, Arcata, CA 95521 USA		Covassin, T (corresponding author), Michigan State Univ, 105 IM Sports Circle, E Lansing, MI 48823 USA.	covassin@msu.edu		Kontos, Anthony/0000-0002-3749-4310			[Anonymous], 2006, MED SCI SPORTS EXERC, V38, P395; [Anonymous], 2006, IMM POSTC ASS COGN T; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Barth JT, 1989, MILD HEAD INJURY, P257; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; Ferrara Michael S., 2001, J Athl Train, V36, P145; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lovell M., CLIN INTERPRETATION; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677	26	103	104	1	23	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050			J ATHL TRAINING	J. Athl. Train.	NOV-DEC	2009	44	6					639	644		10.4085/1062-6050-44.6.639			6	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	522OU	WOS:000272008400011	19911091	Green Published			2022-02-06	
J	Rivera, PA; Elliott, TR; Berry, JW; Grant, JS				Rivera, Patricia A.; Elliott, Timothy R.; Berry, Jack W.; Grant, Joan S.			Problem-solving training for family caregivers of persons with traumatic brain injuries: A randomized controlled trial	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; caregivers; problem-solving; randomized controlled trials; rehabilitation	STROKE SURVIVORS; PHYSICAL HEALTH; INITIAL YEAR; INTERVENTION; THERAPY; STRESS; MODEL; PREDICTORS; ADJUSTMENT; DEPRESSION	Objective: To test the hypothesis that a problem-solving training program Would lower depression, health complaints. and burden, and increase well-being reported by community-residing family caregivers of persons with traumatic brain injuries (TBIs). Design: Randomized controlled trial. Setting: General community. Participants: Of the 180 people who expressed interest in the Study, 113 did not meet eligibility criteria. A consenting sample of family caregivers were randomized into a problem-solving training group (4 men, 29 women; average age, 5 1.3y) or an education-only control group (34 women, average age, 50.8y). Care recipients included 26 men and 7 women in the intervention group (average age, 36.5y) and 24 men and 10 women in the control group (average age, 37.2y). Intervention: Problem-solving training based oil the 9 D'Zurilla and Nezu social problem-solving model was provided to caregivers in the intervention group in 4 in-home sessions and 8 telephone follow-up calls over the course of their year-long participation. Control group participants received written educational materials and telephone calls at set intervals throughout their 12 months of participation. Main Outcome Measures: Caregiver depression, health complaints, well-being, and social problem-solving abilities. Results: Hierarchical linear models revealed caregivers receiving problem-solving training reported significant decreases in depression, health complaints, and in dysfunctional problem-solving styles over time. No effects were observed oil caregiver well-being, burden, or Constructive problem-solving styles. Conclusions: Problem-solving training provided in file home appears to be effective in alleviating distress and in decreasing dysfunctional problem-solving styles among family caregivers of persons with TBI. Methodologic limitations and the implications for interventions and future research are discussed.	[Rivera, Patricia A.] Birmingham VAMC, Birmingham, AL 35233 USA; [Elliott, Timothy R.] Texas A&M Univ, Dept Educ Psychol, College Stn, TX 77843 USA; [Berry, Jack W.] Univ Alabama Birmingham, Injury Control Res Ctr, Birmingham, AL USA; [Grant, Joan S.] Univ Alabama Birmingham, Sch Nursing, Birmingham, AL USA		Rivera, PA (corresponding author), Birmingham VAMC, 700 19th St S, Birmingham, AL 35233 USA.	patricia.rivera@va.gov	Janson, Patrick/AAC-7581-2022; Elliott, Timothy R./I-5301-2012	Elliott, Timothy R./0000-0002-6608-7714; Grant, Joan/0000-0001-6000-4060	National Institute for Disability and Rehabilitation Research [H133A02050]; U.S. Department of health and Human Services, Centers for Disease Control and Prevention - National Center for Injury Prevention [R49/CE000191]; National Institute oil Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32 HD07420]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD007420, R01HD037661] Funding Source: NIH RePORTER; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE000191] Funding Source: NIH RePORTER	Supported by the National Institute for Disability and Rehabilitation Research (grant no. H133A02050) by the U.S. Department of health and Human Services, Centers for Disease Control and Prevention - National Center for Injury Prevention (grant no. R49/CE000191). and by the National Institute oil Child Health and Human Development (grant no. T32 HD07420).	Boake C, 1996, ARCH PHYS MED REHAB, V77, P765, DOI 10.1016/S0003-9993(96)90254-3; Boschen K, 2007, NEUROREHABILITATION, V22, P19; Bucher JA, 1999, J PSYCHOSOC ONCOL, V16, P73, DOI 10.1300/J077v16n03_05; Chronister J, 2006, REHABIL PSYCHOL, V51, P190, DOI 10.1037/0090-5550.51.3.190; Chwalisz K, 1996, REHABIL PSYCHOL, V41, P91, DOI 10.1037/0090-5550.41.2.91; D'Zurilla T.J., 2002, SOCIAL PROBLEM SOLVI; D'Zurilla TJ., 2004, SOCIAL PROBLEM SOLVI, P11, DOI [10.1037/10805-001, DOI 10.1037/10805-001]; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; DODDS TA, 1993, ARCH PHYS MED REHAB, V74, P531, DOI 10.1016/0003-9993(93)90119-U; Dreer LE, 2007, REHABIL PSYCHOL, V52, P351, DOI 10.1037/0090-5550.52.3.351; ELLIOTT T, 2008, BIENNIAL REV COUNSEL, V1; Elliott TR, 2001, J COUNS PSYCHOL, V48, P223, DOI 10.1037//0022-0167.48.2.223; Elliott TR, 2000, COGNITIVE BEHAV INTE, P309; Ellis C, 2007, EJC SUPPL, V5, P8, DOI 10.1016/S1359-6349(07)71715-9; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GRANGER CV, 1993, ARCH PHYS MED REHAB, V74, P133; Grant JS, 2006, ARCH PHYS MED REHAB, V87, P343, DOI 10.1016/j.apmr.2005.09.019; Grant JS, 2004, REHABIL PSYCHOL, V49, P172, DOI 10.1037/0090-5550.49.2.172; Grant JS, 2002, STROKE, V33, P2060, DOI 10.1161/01.STR.0000020711.38824.E3; Hayes AM, 2007, CLIN PSYCHOL REV, V27, P715, DOI 10.1016/j.cpr.2007.01.008; Hedeker D, 1999, J EDUC BEHAV STAT, V24, P70, DOI 10.3102/10769986024001070; Houts PS, 1996, PATIENT EDUC COUNS, V27, P63, DOI 10.1016/0738-3991(95)00790-3; Johnson MO, 2006, HEALTH PSYCHOL, V25, P355, DOI 10.1037/0278-6133.25.3.355; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; Laurenceau JP, 2007, CLIN PSYCHOL REV, V27, P682, DOI 10.1016/j.cpr.2007.01.007; Lipsey M. W., 2001, APPL SOCIAL RES METH, V49; LITTLE RJA, 1988, J AM STAT ASSOC, V83, P1198, DOI 10.2307/2290157; Lui MHL, 2005, STROKE, V36, P2514, DOI 10.1161/01.STR.0000185743.41231.85; Malouff JM, 2007, CLIN PSYCHOL REV, V27, P46, DOI 10.1016/j.cpr.2005.12.005; Miller EA, 2007, HEALTH POLICY, V82, P133, DOI 10.1016/j.healthpol.2006.09.011; MYNORSWALLIS LM, 1995, BMJ-BRIT MED J, V310, P441, DOI 10.1136/bmj.310.6977.441; Nezu AM, 2004, BEHAV THER, V35, P1, DOI 10.1016/S0005-7894(04)80002-9; Nezu AM, 2003, J CONSULT CLIN PSYCH, V71, P1036, DOI 10.1037/0022-006X.71.6.1036; OBERST MT, 1989, CANCER NURS, V12, P209; Pennebaker JW., 1982, PSYCHOL PHYS SYMPTOM; Perlesz A, 1999, REHABIL PSYCHOL, V44, P6, DOI 10.1037/0090-5550.44.1.6; Perri MG, 2001, J CONSULT CLIN PSYCH, V69, P722, DOI 10.1037/0022-006X.69.4.722; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rath JF, 2003, REHABIL PSYCHOL, V48, P137, DOI 10.1037/0090-5550.48.3.137; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; RIVERA PA, 2003, TOP SPINAL CORD INJ, V9, P53, DOI DOI 10.1310/G82F-BR2R-T69L-3QX8; Rivera P, 2007, NEUROREHABILITATION, V22, P3; Rivera PA, 2006, J CLIN PSYCHOL MED S, V13, P431, DOI 10.1007/s10880-006-9043-6; Sahler OJZ, 2005, J CONSULT CLIN PSYCH, V73, P272, DOI 10.1037/0022-006X.73.2.272; *STAT U NEW YORK B, 1996, GUID US UN DAT SET M; Tucker JA, 2006, ADDICTION, V101, P918, DOI 10.1111/j.1360-0443.2006.01396.x; UITENBROEK DG, SISA FISHER 2 5 2000; Vitaliano PP, 2003, PSYCHOL BULL, V129, P946, DOI 10.1037/0033-2909.129.6.946; Wade SL, 2006, J CONSULT CLIN PSYCH, V74, P445, DOI 10.1037/0022-006X.74.3.445; Wade SL, 2006, REHABIL PSYCHOL, V51, P179, DOI 10.1037/0090-5550.51.3.179; Wade SL, 2001, J CONSULT CLIN PSYCH, V69, P406, DOI 10.1037//0022-006X.69.3.406; Wisniewski SR, 2003, PSYCHOL AGING, V18, P375, DOI 10.1037/0882-7974.18.3.375	52	103	104	1	33	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2008	89	5					931	941		10.1016/j.apmr.2007.12.032			11	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	341ST	WOS:000258735900020	18452743	Green Accepted			2022-02-06	
J	Wu, X; Hu, J; Zhuo, LF; Fu, CW; Hui, GZ; Wang, YH; Yang, WZ; Teng, LZ; Lu, ST; Xu, GS				Wu, Xing; Hu, Jin; Zhuo, Liangfu; Fu, Chaowei; Hui, Guozhen; Wang, Yehan; Yang, Weizhong; Teng, Liangzhu; Lu, Sitin; Xu, Gengsheng			Epidemiology of traumatic brain injury in eastern China, 2004: A prospective large case study	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						traumatic brain injury; epidemiology; eastern China	HEAD-INJURY; UNITED-STATES; HELMET USE; NATIONAL EVALUATION; COUNTY; CARE; AGE; IMPLEMENTATION; MORTALITY; PATTERNS	Background: Traumatic brain injury (TBI) is the leading cause of death for traumatic injury, which is the fifth highest killer in China and the highest killer in adults under 40 years of age. But, there is a lack of epidemiologic data of TBI in China during the past decade. This study aimed to investigate the epidemiologic data of TBI in eastern China, based on a prospective multicenter trial. Methods: Data were collected from the 77 hospitals by standardized structured questionnaires in this region during the 1-year period (2004). Results: A total of 14,948 of cases of traumatic brain injury were identified from 77 hospitals in eastern China. There were 11,446 men (76.6%) and 3,502 women (25.4%). Male adolescents and young adults were affected more often by brain injury. Traffic accidents (60.9%), knock on head (13.4%), and falls (13.1%) were the leading causes of patients with TBI. Approximately one-thirds of the traffic-related TBI were motorcyclists, 31% were pedestrians, and 21.9% were cyclists, whereas motor vehicle occupants only counted for 14% of the cases. The distribution of head injury severity, on the basis of Glasgow Coma Scale scores, was mild in 62%, moderate in 18.1%, and severe in 20% for all cases. The traffic accidents caused the most of severe injuries, which accounted for about 70.4%. Based on Glasgow Outcome Scale assessment, 10.8% of the patients died, 2.6% were in vegetation status, 2.2 % had severe disability, 7.2% had moderate disability, and 77.3% had good recovery. And, the outcome depended on age, injury mechanism and initial Glasgow Coma Scale score. Conclusions: The prospective cohort study shows an alteration of TBI during the past decade in eastern China. It is essential to establish a standardized surveillance system of TBI incidence, risk factors, causes, and outcomes for development of new, more effective, targeted strategies to prevent TBI.	[Wu, Xing; Zhuo, Liangfu] Fudan Univ, Dept Neurosurg, Shanghai Med Sch, Huashan Hosp, Shanghai 200040, Peoples R China; [Hu, Jin] Shanghai Jiao Tong Univ, Ctr Trauma, Shanghai Peoples Hosp 6, Shanghai 200030, Peoples R China; [Fu, Chaowei] Fudan Univ, Shanghai Med Coll, Dept Publ Hlth, Shanghai 200040, Peoples R China; [Hui, Guozhen] Suzhou Univ, Dept Neurosurg, First Hosp, Suzhou, Jiangsu, Peoples R China; [Wang, Yehan] Anhui Med Univ, Anhui Prov Hosp, Dept Neurosurg, Hefei, Anhui, Peoples R China; [Teng, Liangzhu] Sandong Univ, Sandong Prov Hosp, Dept Neurosurg, Sandong, Peoples R China; [Lu, Sitin] Zhejiang Univ, Second Hosp, Dept Neurosurg, Hangzhou, Zhejiang, Peoples R China		Zhuo, LF (corresponding author), Fudan Univ, Dept Neurosurg, Shanghai Med Sch, Huashan Hosp, 12 Wulumuqizhong Rd, Shanghai 200040, Peoples R China.	Lfzhou.neuro@yahoo.com.cn	Fu, Chaowei/H-7811-2013	Fu, Chaowei/0000-0003-0966-8552			Attewell RG, 2001, ACCIDENT ANAL PREV, V33, P345, DOI 10.1016/S0001-4575(00)00048-8; Auman KM, 2002, AM J PUBLIC HEALTH, V92, P1352, DOI 10.2105/AJPH.92.8.1352; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; CALES RH, 1985, ANN EMERG MED, V14, P853, DOI 10.1016/S0196-0644(85)80633-8; *CRTAS, 2004, CHIN ROAD TRAFF ACC; *CRTAS, 2003, CHIN ROAD TRAFF ACC; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; GABELLA B, 1995, ACCIDENT ANAL PREV, V27, P363, DOI 10.1016/0001-4575(94)00079-2; [高进东 Gao Jindong], 2002, [中华创伤杂志, Chinese Journal of Traumatology], V18, P743; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Harden CL, 2003, NEUROLOGY, V61, P451, DOI 10.1212/01.WNL.0000081228.48016.44; He J, 2005, NEW ENGL J MED, V353, P1124, DOI 10.1056/NEJMsa050467; Hotz GA, 2002, J TRAUMA, V52, P469, DOI 10.1097/00005373-200203000-00009; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Javouhey E, 2006, ACCIDENT ANAL PREV, V38, P225, DOI 10.1016/j.aap.2005.08.001; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Liberman M, 2004, J TRAUMA, V56, P1330, DOI 10.1097/01.TA.0000071297.76727.8B; [刘娜 Liu Na], 2005, [中华流行病学杂志, Chinese Journal of Epidemiology], V26, P746; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Nathens AB, 2000, J TRAUMA, V48, P25, DOI 10.1097/00005373-200001000-00005; Schieber RA, 2001, PUBLIC HEALTH REP, V116, P113, DOI 10.1016/S0033-3549(04)50003-1; Schwab W, 2000, J TRAUMA, V48, P30; Sethi D, 2002, J TRAUMA, V53, P508, DOI 10.1097/00005373-200209000-00019; Siegel JH, 2001, J TRAUMA, V51, P975, DOI 10.1097/00005373-200111000-00024; SMITH GS, 1991, AM J EPIDEMIOL, V134, P1146, DOI 10.1093/oxfordjournals.aje.a116018; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; Sosin DM, 1996, PEDIATRICS, V98, P868; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TEASDALE G, 1974, LANCET, V2, P81; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; TIRET L, 1986, INT J EPIDEMIOL, V19, P133; Valent F, 2002, J TRAUMA, V52, P745, DOI 10.1097/00005373-200204000-00023; WANG CC, 1986, ARCH NEUROL-CHICAGO, V43, P570, DOI 10.1001/archneur.1986.00520060034013; Wang ZG, 1996, CHINESE MED J-PEKING, V109, P24; WINKLER J V, 1984, Journal of Emergency Medicine, V2, P1, DOI 10.1016/0736-4679(84)90038-6; WU D, 2006, BEIJING AUTOMOTIVE E, P5; YANG J, 1996, CHIN J TRAUMA, V12, P1996; Yang YC, 1987, CHINESE J NEUROSURGE, V3, P23; Zhang Y.Q., 1999, CHIN J TRAUMA, V15, P51; ZHU GL, 1989, CHIN J NEUROSURG S, P44; [朱佩芳 Zhu Peifang], 2002, [中华创伤杂志, Chinese Journal of Traumatology], V18, P329; 赵小纲, 2003, [中华创伤杂志, Chinese Journal of Traumatology], V19, P680; 李培, 2004, [中华创伤杂志, Chinese Journal of Traumatology], V20, P619	47	103	122	0	20	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAY	2008	64	5					1313	1319		10.1097/TA.0b013e318165c803			7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	301SH	WOS:000255915400029	18469656				2022-02-06	
J	Nagamoto-Combs, K; Mcneal, DW; Morecraft, RJ; Combs, CK				Nagamoto-Combs, Kumi; Mcneal, David W.; Morecraft, Robert J.; Combs, Colin K.			Prolonged microgliosis in the rhesus monkey central nervous system after traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						microglia; motor cortex; motor recovery; spinal cord; stroke	TRKB NEUROTROPHIN RECEPTORS; OUTGROWTH IN-VITRO; RAT SPINAL-CORD; TRUNCATED TRKB; KAINIC ACID; ARM REPRESENTATION; MULTIPLE-SCLEROSIS; NONHUMAN-PRIMATES; MOTOR CORTEX; RECOVERY	Impaired fine motor functions after traumatic brain injury (TBI) in humans and non-human primates often continue to improve months after injury. To initiate a series of studies in the primate model designed to investigate possible involvement of microglia/macrophage in the long-term recovery processes, changes in these cells were studied in the rhesus monkey central nervous system at 1, 6, and 12 months after a combined unilateral lesion of the arm area of the primary motor cortex and arm area of the lateral premotor cortex. Immunohistological studies showed profound CD68 immunoreactivity in the lesion area and the contralateral lateral corticospinal tract in the spinal cord at all time points, demonstrating that microglia/macrophage remain reactive at the sites of injury and axonal degeneration/survival for at least 12 months. We also observed marked increases in brain-derived neurotrophic factor (BDNF) and its receptor subtypes, TrkB[gp145] and TrkB[TK-], around the cortical lesion site after 6-month survival. Similar increases were also observed in the spinal cord, although it was less apparent for TrkB[gp145]. Double-labeling revealed that a sub-population of CD68-immunoreacitve microglia/macrophage co-expressed BDNF in the cortex and spinal cord, and also TrkB[gp145] or TrkB[TK-] in the spinal cord. In contrast, cytokine expression of tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1 beta), and interleukin-6 (IL-6) at these time intervals was less prominent, suggesting that immediate inflammatory responses had subsided. These results demonstrate that microglia/macrophage undergo prolonged activation after TBI in the non-human primate brain and express BDNF and its receptors, suggesting their tropic/trophic roles in the long-term recovery processes.	Univ N Dakota, Sch Med & Hlth Sci, Dept Pharmacol Physiol & Therapeut, Grand Forks, ND 58202 USA; Univ S Dakota, Sch Med, Div Basic Biomed Sci, Vermillion, SD USA		Nagamoto-Combs, K (corresponding author), Univ N Dakota, Sch Med & Hlth Sci, Dept Pharmacol Physiol & Therapeut, 504 Hamline St, Neurosci Bldg, Grand Forks, ND 58202 USA.	ccombs@medicine.nodak.edu	Nagamoto-Combs, Kumi/AAN-6697-2021		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R56NS046367, R01NS046367] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 046367] Funding Source: Medline		Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Asami T, 2006, BIOCHEM BIOPH RES CO, V344, P941, DOI 10.1016/j.bbrc.2006.03.228; Batchelor PE, 2002, MOL CELL NEUROSCI, V21, P436, DOI 10.1006/mcne.2002.1185; Batchelor PE, 2002, EUR J NEUROSCI, V15, P826, DOI 10.1046/j.1460-9568.2002.01914.x; Beck H, 2003, J CEREBR BLOOD F MET, V23, P709, DOI 10.1097/01.WCB.0000065940.18332.8D; BECK KD, 1993, J NEUROSCI, V13, P4001; Butefisch CM, 2006, NEUROL SCI, V27, pS18, DOI 10.1007/s10072-006-0540-z; Cagnin A, 2001, BRAIN, V124, P2014, DOI 10.1093/brain/124.10.2014; Carmichael ST, 2003, NEUROSCIENTIST, V9, P64, DOI 10.1177/1073858402239592; Coull JAM, 2005, NATURE, V438, P1017, DOI 10.1038/nature04223; Dancause N, 2005, J NEUROSCI, V25, P10167, DOI 10.1523/JNEUROSCI.3256-05.2005; Darling WG, 2006, J NEUROSCI METH, V154, P38, DOI 10.1016/j.jneumeth.2005.11.013; Eide FF, 1996, J NEUROSCI, V16, P3123; Elkabes S, 1996, J NEUROSCI, V16, P2508; Fleming JC, 2006, BRAIN, V129, P3249, DOI 10.1093/brain/awl296; Frost SB, 2003, J NEUROPHYSIOL, V89, P3205, DOI 10.1152/jn.01143.2002; Fryer RH, 1997, EXP NEUROL, V148, P616, DOI 10.1006/exnr.1997.6699; Gerhard A, 2005, NEUROIMAGE, V24, P591, DOI 10.1016/j.neuroimage.2004.09.034; Goutan E, 1998, MOL BRAIN RES, V59, P154, DOI 10.1016/S0169-328X(98)00156-9; Haapasalo A, 2001, BIOCHEM BIOPH RES CO, V280, P1352, DOI 10.1006/bbrc.2001.4296; JORGENSEN MB, 1993, EXP NEUROL, V120, P70, DOI 10.1006/exnr.1993.1041; Kasahara K, 2006, SPINE, V31, P2059, DOI 10.1097/01.brs.0000231893.21964.f2; Katz DI, 2004, ARCH PHYS MED REHAB, V85, P865, DOI 10.1016/j.apmr.2003.11.020; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Kerschensteiner M, 1999, J EXP MED, V189, P865, DOI 10.1084/jem.189.5.865; King VR, 2000, EXP NEUROL, V165, P327, DOI 10.1006/exnr.2000.7480; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; Kopp B, 1999, NEUROREPORT, V10, P807, DOI 10.1097/00001756-199903170-00026; Kuhtz-Buschbeck JP, 2003, DEV MED CHILD NEUROL, V45, P821, DOI 10.1017/S001216220300152X; Ladeby R, 2005, BRAIN RES REV, V48, P196, DOI 10.1016/j.brainresrev.2004.12.009; Livingston DH, 2005, J TRAUMA, V59, P1298, DOI 10.1097/01.ta.0000196002.03681.18; Mack CL, 2003, J NEUROIMMUNOL, V144, P68, DOI 10.1016/j.jneuroim.2003.08.032; Malcangio M, 2003, TRENDS PHARMACOL SCI, V24, P116, DOI 10.1016/S0165-6147(03)00025-7; Morecraft RJ, 2004, J COMP NEUROL, V469, P37, DOI 10.1002/cne.10980; Morecraft RJ, 2002, BRAIN, V125, P176, DOI 10.1093/brain/awf011; MORECRAFT RJ, 1992, J COMP NEUROL, V323, P341, DOI 10.1002/cne.903230304; Morecraft RJ, 2007, J COMP NEUROL, V504, P149, DOI 10.1002/cne.21438; Morecraft RJ, 2007, J COMP NEUROL, V500, P134, DOI 10.1002/cne.21165; Nakamura M, 2001, EXP NEUROL, V169, P407, DOI 10.1006/exnr.2001.7670; Niemeier JP, 2007, NEUROPSYCHOL REHABIL, V17, P293, DOI 10.1080/09602010600814729; Novikova LN, 2000, EUR J NEUROSCI, V12, P776, DOI 10.1046/j.1460-9568.2000.00978.x; Nudo Randolph J, 2006, NeuroRx, V3, P420; NUDO RJ, 1992, J NEUROSCI, V12, P2918, DOI 10.1523/JNEUROSCI.12-08-02918.1992; Nudo RJ, 1999, CURR OPIN NEUROBIOL, V9, P740, DOI 10.1016/S0959-4388(99)00027-6; Panagis L, 2005, EUR J NEUROSCI, V21, P2305, DOI 10.1111/j.1460-9568.2005.04046.x; Pizzimenti MA, 2007, J NEUROPHYSIOL, V98, P1015, DOI 10.1152/jn.00354.2007; Rose CR, 2003, NATURE, V426, P74, DOI 10.1038/nature01983; Salie R, 2005, INT J DEV NEUROSCI, V23, P587, DOI 10.1016/j.ijdevneu.2005.07.003; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; Shelton FDAP, 2001, STROKE, V32, P107, DOI 10.1161/01.STR.32.1.107; Smith ME, 2001, MICROSC RES TECHNIQ, V54, P81, DOI 10.1002/jemt.1123; Streit WJ, 2000, TOXICOL PATHOL, V28, P28, DOI 10.1177/019262330002800104; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; Sun W, 2003, MOL CELL NEUROSCI, V24, P875, DOI 10.1016/S1044-7431(03)00219-7; Suzuki H, 2001, NEUROSCI LETT, V312, P95, DOI 10.1016/S0304-3940(01)02198-X; Tanaka R, 2003, NEUROSCIENCE, V117, P531, DOI 10.1016/S0306-4522(02)00954-5; Taub Edward, 2003, Phys Med Rehabil Clin N Am, V14, pS77, DOI 10.1016/S1047-9651(02)00052-9; WADE DT, 1985, J NEUROL NEUROSUR PS, V48, P7, DOI 10.1136/jnnp.48.1.7; Weidner N, 2001, P NATL ACAD SCI USA, V98, P3513, DOI 10.1073/pnas.051626798; Wenzelburger R, 2005, BRAIN, V128, P64, DOI 10.1093/brain/awh317; Widenfalk J, 2001, J NEUROSCI, V21, P3457, DOI 10.1523/JNEUROSCI.21-10-03457.2001; Wilson S, 2004, J NEUROTRAUM, V21, P239, DOI 10.1089/089771504322972031; Wong JYF, 1997, EXP NEUROL, V148, P83, DOI 10.1006/exnr.1997.6670; Zhang JM, 2003, EXP NEUROL, V183, P469, DOI 10.1016/S0014-4886(03)00222-X	64	103	106	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2007	24	11					1719	1742		10.1089/neu.2007.0377			24	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	234MZ	WOS:000251169500005	18001202				2022-02-06	
J	Cernich, A; Reeves, D; Sun, WY; Bleiberg, J				Cernich, Alison; Reeves, Dennis; Sun, Wenyu; Bleiberg, Joseph			Automated Neuropsychological Assessment Metrics sports medicine battery	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						brain concussion; athletic injuries; neuropsychology; psychometric	MINOR HEAD-INJURY; STANDARDIZED ASSESSMENT; BRAIN-INJURY; CONCUSSION; RECOVERY; PERFORMANCE; GUIDELINES; RETURN; TESTS; COLLEGIATE	This paper describes the development and ongoing validation of the ANAM-sports medicine battery (ASMB) for use in concussion surveillance and management. A review of previous research utilizing the ASMB highlights current issues in concussion surveillance including: tracking cognitive recovery, effect of previous concussion history on acute concussion presentation, and clinical decision making using computerized measures. ASMB interpretation using reliable change indices or impairment indices is highlighted. Future development of the ASMB is discussed as it relates to interpretation of ASMB, development of appropriate norms, and defining adequate baseline assessment. This includes the definition of practice effects, the effects of maturation on test performance and definition of adequate baseline assessment that clearly defines a subject's normal cognitive performance level. ASMB is ready for cautious introduction into clinical practice for use by neuropsychologists with experience in both sports concussion and computerized testing. (c) 2006 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	Baltimore Vet Affairs Med Ctr, Baltimore, MD 21201 USA; Natl Rehabil Hosp, Clinvest Inc, Springfield, MO USA		Cernich, A (corresponding author), Baltimore Vet Affairs Med Ctr, BT 116 MH, Baltimore, MD 21201 USA.	Alison.cernich@va.gov					Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barr WB, 2003, ARCH CLIN NEUROPSYCH, V18, P91, DOI 10.1016/S0887-6177(01)00185-8; Barth JT, 1989, MILD HEAD INJURY, P257; Benton A., 1978, MULTILINGUAL APHASIA; Bleiberg J, 1998, J HEAD TRAUMA REHAB, V13, P36, DOI 10.1097/00001199-199804000-00006; Bleiberg J, 1997, NEUROPSY NEUROPSY BE, V10, P247; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Bleiberg J, 2000, CLIN NEUROPSYCHOL, V14, P287, DOI 10.1076/1385-4046(200008)14:3;1-P;FT287; BLEIBERG J, 2002, COMPUTERIZED NEUROPS; BOHNEN NI, 1995, BRAIN INJURY, V9, P27, DOI 10.3109/02699059509004568; Brandt J, 1991, CLIN NEUROPSYCHOL, V5, P125, DOI [10.1080/13854049108403297, DOI 10.1080/13854049108403297]; Cameron KL, 1999, J ATHL TRAINING, V34, P34; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; CANTU RC, 1992, SPORTS MED, V14, P64, DOI 10.2165/00007256-199214010-00005; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; CDC: Center for Disease Control, 2006, TRAUM BRAIN INJ US E; Chelune G.J., 1993, NEUROPSYCHOLOGY, V7, P41, DOI [10.1037/0894-4105.7.1.41, DOI 10.1037/0894-4105.7.1.41]; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Daniel JC, 1999, NEUROPSY NEUROPSY BE, V12, P167; DELIS C, 1987, CALIFORNIA VERBAL LE; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P232; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GOLDEN C, 1978, STROOP COLOR WORLD T; GRONWALL D, 1974, LANCET, V2, P1452; GRONWALL D, 1975, LANCET, V2, P995; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Halstead WC, 1947, BRAIN INTELLIGENCE Q; Hinton-Bayre AD, 2002, NEUROLOGY, V59, P1068, DOI 10.1212/WNL.59.7.1068; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; JASTAK S, 1984, WIDE RANGE ACHEIVEME; KANE R, 1996, 8 HOUR CE WORKSH AM; KANE R, 1997, 8 HOUR CE WORKSH AM; KANE R, 1995, 8 HOUR CE WORKSH AM; KANE RL, 1992, NEUROPSYCHOL REV, V3, P1, DOI 10.1007/BF01108787; Kelly J, 1997, JAMA-J AM MED ASSOC, V277, P1190; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P581; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LOVE MR, 2002, IMPACT CONCUSSION MA; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; MEYERS JL, 2003, RES DESIGN STAT ANAL; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; *NAT SAF KIDS CAMP, 2003, INJ FACTS RECR INJ; PETERSON LR, 1959, J EXP PSYCHOL, V10, P12; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Reeves DL, 2007, ARCH CLIN NEUROPSYCH, V22, pS15, DOI 10.1016/j.acn.2006.10.013; REITAN R, 1985, HALSTEAD REITAN NEUR, P1; ROEBUCKSPENCER TM, IN PRESS ARCH CLIN N; Schretlen D., 1997, BRIEF TEST ATTENTION; WARDEN D, 2003, 55 ANN M AM AC NEUR; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524; Wechsler, 1997, WECHSLER ADULT INTEL; Woodard J., 2002, J INT NEUROPSYCHOLOG, V8, P175	68	103	103	0	23	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	FEB	2007	22	1		S			S101	S114		10.1016/j.acn.2006.10.008			14	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	161DZ	WOS:000245995900010	17118625	Bronze			2022-02-06	
J	Hester, RL; Murphy, K; Foxe, JJ; Foxe, DM; Javitt, DC; Garavan, H				Hester, RL; Murphy, K; Foxe, JJ; Foxe, DM; Javitt, DC; Garavan, H			Predicting success: Patterns of cortical activation and deactivation prior to response inhibition	JOURNAL OF COGNITIVE NEUROSCIENCE			English	Article							TRAUMATIC BRAIN-INJURY; ANTERIOR CINGULATE CORTEX; EVENT-RELATED FMRI; SUSTAINED ATTENTION; PREFRONTAL CORTEX; WORKING-MEMORY; BEHAVIORAL-INHIBITION; EXECUTIVE FUNCTIONS; DEFAULT MODE; BLOOD-FLOW	The present study investigated the relationships between attention and other preparatory processes prior to a response inhibition task and the processes involved in the inhibition itself. To achieve this, a mixed fMRI design was employed to identify the functional areas activated during both inhibition decision events and the block of trials following a visual cue introduced 2 to 7 sec prior (cue period). Preparing for successful performance produced increases in activation for both the cue period and the inhibition itself in the frontoparietal cortical network. Furthermore, preparation produced activation decreases in midline areas (insula and medial prefrontal) argued to be responsible for monitoring internal emotional states, and these cue period deactivations alone predicted subsequent success or failure. The results suggest that when cues are provided to signify the imminent requirement for behavioral control, successful performance results from a coordinated pattern of preparatory activation in task-relevant areas and deactivation of task-irrelevant ones.	Univ Dublin Trinity Coll, Dept Psychol, Dublin 2, Ireland; Nathan S Kline Inst Psychiat Res, Orangeburg, NY 10962 USA		Garavan, H (corresponding author), Univ Dublin Trinity Coll, Dept Psychol, Dublin 2, Ireland.	Hugh.Garavan@tcd.ie	Hester, Robert/F-2097-2011; Murphy, Kevin/A-1581-2010; Javitt, Daniel/U-6015-2019	Hester, Robert/0000-0003-0982-8026; Murphy, Kevin/0000-0002-6516-313X; Foxe, John/0000-0002-4300-3098	NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR00058] Funding Source: Medline; NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA14100] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH63434, MH65350] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000058] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH065350, R03MH063434] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA014100] Funding Source: NIH RePORTER		Barkley RA, 1997, PSYCHOL BULL, V121, P65, DOI 10.1037/0033-2909.121.1.65; Bate AJ, 2001, J CLIN EXP NEUROPSYC, V23, P386, DOI 10.1076/jcen.23.3.386.1190; Bate AJ, 2001, CLIN NEUROPSYCHOL, V15, P405, DOI 10.1076/clin.15.3.405.10279; Brass M, 2002, CEREB CORTEX, V12, P908, DOI 10.1093/cercor/12.9.908; Bush G, 2000, TRENDS COGN SCI, V4, P215, DOI 10.1016/S1364-6613(00)01483-2; Bush G, 1999, BIOL PSYCHIAT, V45, P1542, DOI 10.1016/S0006-3223(99)00083-9; Cabeza R, 2000, J COGNITIVE NEUROSCI, V12, P1, DOI 10.1162/08989290051137585; Chan RCK, 2001, BRAIN INJURY, V15, P819, DOI 10.1080/02699050110034325; Cohen MS, 1997, NEUROIMAGE, V6, P93, DOI 10.1006/nimg.1997.0278; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Cummings JL, 2001, AGING-CLIN EXP RES, V13, P240, DOI 10.1007/BF03351482; Damasio AR, 2000, NAT NEUROSCI, V3, P1049, DOI 10.1038/79871; Drevets WC, 1998, COGNITION EMOTION, V12, P353, DOI 10.1080/026999398379646; Fiez JA, 2001, J CLIN EXP NEUROPSYC, V23, P19, DOI 10.1076/jcen.23.1.19.1221; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Garavan H, 2002, NEUROIMAGE, V17, P1820, DOI 10.1006/nimg.2002.1326; Garavan H, 1999, P NATL ACAD SCI USA, V96, P8301, DOI 10.1073/pnas.96.14.8301; Gray JR, 2002, P NATL ACAD SCI USA, V99, P4115, DOI 10.1073/pnas.062381899; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; Gusnard DA, 2001, P NATL ACAD SCI USA, V98, P4259, DOI 10.1073/pnas.071043098; Gusnard DA, 2001, NAT REV NEUROSCI, V2, P685, DOI 10.1038/35094500; Keppel G., 1991, DESIGN ANAL RES HDB; Konishi S, 1998, EUR J NEUROSCI, V10, P1209, DOI 10.1046/j.1460-9568.1998.00167.x; Konrad KN, 2000, BRAIN INJURY, V14, P859; Lawrence NS, 2003, J COGNITIVE NEUROSCI, V15, P1028, DOI 10.1162/089892903770007416; Liddle PF, 2001, HUM BRAIN MAPP, V12, P100, DOI 10.1002/1097-0193(200102)12:2<100::AID-HBM1007>3.0.CO;2-6; Luks TL, 2002, NEUROIMAGE, V17, P792, DOI 10.1006/nimg.2002.1210; MacDonald AW, 2000, SCIENCE, V288, P1835, DOI 10.1126/science.288.5472.1835; Matochik JA, 1996, BRAIN RES, V723, P23, DOI 10.1016/0006-8993(96)00177-1; Mayberg HS, 1999, AM J PSYCHIAT, V156, P675; Perlstein WM, 2001, AM J PSYCHIAT, V158, P1105, DOI 10.1176/appi.ajp.158.7.1105; Phan KL, 2002, NEUROIMAGE, V16, P331, DOI 10.1006/nimg.2002.1087; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Rapport LJ, 2001, CLIN NEUROPSYCHOL, V15, P479, DOI 10.1076/clin.15.4.479.1878; Reiman EM, 1997, AM J PSYCHIAT, V154, P918; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; ROGERS RD, 1995, J EXP PSYCHOL GEN, V124, P207, DOI 10.1037/0096-3445.124.2.207; Sakai K, 2003, NAT NEUROSCI, V6, P75, DOI 10.1038/nn987; Shulman GL, 1997, J COGNITIVE NEUROSCI, V9, P648, DOI 10.1162/jocn.1997.9.5.648; Simpson JR, 2000, J COGNITIVE NEUROSCI, V12, P157, DOI 10.1162/089892900564019; Stevens J, 2002, DEV NEUROPSYCHOL, V21, P117, DOI 10.1207/S15326942DN2102_1; Talairach J., 1988, COPLANAR STEREOTAXIC; Tekin S, 2002, J PSYCHOSOM RES, V53, P647, DOI 10.1016/S0022-3999(02)00428-2; van Veen V, 2001, NEUROIMAGE, V14, P1302, DOI 10.1006/nimg.2001.0923; van Veen V, 2002, PHYSIOL BEHAV, V77, P477, DOI 10.1016/S0031-9384(02)00930-7; Watanabe J, 2002, NEUROIMAGE, V17, P1207, DOI 10.1006/nimg.2002.1198; Whyte J, 1997, NEUROPSYCHOLOGIA, V35, P313, DOI 10.1016/S0028-3932(96)00092-9; WHYTE J, 1995, NEUROPSYCHOLOGIA, V33, P797, DOI 10.1016/0028-3932(95)00029-3; Yount R, 2002, J NEUROPSYCH CLIN N, V14, P416, DOI 10.1176/appi.neuropsych.14.4.416	49	103	103	0	4	MIT PRESS	CAMBRIDGE	ONE ROGERS ST, CAMBRIDGE, MA 02142-1209 USA	0898-929X	1530-8898		J COGNITIVE NEUROSCI	J. Cogn. Neurosci.	JUN	2004	16	5					776	785		10.1162/089892904970726			10	Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	829FK	WOS:000222031700006	15200705	Green Submitted, Green Accepted			2022-02-06	
J	Kaups, KL; Davis, JW; Parks, SN				Kaups, KL; Davis, JW; Parks, SN			Routinely repeated computed tomography after blunt head trauma: Does it benefit patients?	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	62nd Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 11-13, 2003	MINNEAPOLIS, MN	Amer Assoc Surg Trauma		computed tomography of the head; closed head injury; brain injury	BRAIN-INJURY; FOLLOW-UP; NONOPERATIVE MANAGEMENT; CT SCANS; HYPOTENSION; HEMORRHAGE; MODERATE; UTILITY; HEMATOMAS; CHILDREN	Background. Computed tomography of the head (HCT) is an integral part of the diagnosis and management of the patient with head injury, but the utility of repeated HCT performed solely for routine follow-up in the patient with blunt head trauma has not been defined. In the absence of clinical indications, routinely repeated HCT, even in patients with significant brain injury, does not contribute to patient care. Methods. Trauma registry records at a Level I trauma center from July 1, 1997, to June 30, 2002, were reviewed. Patients with severe blunt head injury (Abbreviated Injury Scale score greater than or equal to 3) admitted to the intensive care unit and who had a repeat HCT scan obtained for scheduled follow-up were included. Those patients with initial craniotomy, repeat HCT more than 72 hours after the initial HCT, or repeat HCT ordered for clinical indications were excluded. Data included were age, mechanism of injury, time to initial (HCT1) and repeat HCT (HCT2), indications for HCT2, and HCT findings. Additional data included Glasgow Coma Scale (GCS) score (admission and at HCT2); Injury Severity Score; occurrence of hypotension, coagulopathy, or elevated intracranial pressure (ICP); interventions made; and patient outcome. Results. Entry criteria were met in 462 patients. Most were injured in motor vehicle crashes; the average age was 36 years and the mean initial GCS score was 9. The mean time to HCT1 was 1.3 hours and the mean time to HCT2 was 22.6 hours. HCT2 showed worsening in 85 patients (18.4%), and 16 patients had interventions in response to HCT2 (repeat HCT in 8, ICP monitoring or drainage in 6, and craniotomy in 2). No patient undergoing routine repeat HCT without other clinical findings required intervention. All patients with worsening HCT findings requiring intervention had coagulopathy, hypotension, ICP elevation, or marked decrease in GCS score. Conclusion: In the absence of clinical indicators or risk factors, repeat HCT after blunt head injury does not alter patient management and is unnecessary.	Calif State Univ Fresno, Med Ctr, Dept Surg, Fresno, CA 93702 USA		Kaups, KL (corresponding author), Calif State Univ Fresno, Med Ctr, Dept Surg, 4th Floor,445 S Cedar Ave, Fresno, CA 93702 USA.	kaups@ucsfresno.edu					Allins A, 1996, AM SURGEON, V62, P883; ASHKENAZI E, 1990, J TRAUMA, V30, P613, DOI 10.1097/00005373-199005000-00015; *BRAIN TRAUM FDN, 1996, GUID MAN SEV HEAD IN; BUCCI MN, 1986, NEUROSURGERY, V19, P65, DOI 10.1227/00006123-198607000-00009; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Chao A, 2001, J TRAUMA, V51, P870, DOI 10.1097/00005373-200111000-00008; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; COOPER PR, 1979, NEUROSURGERY, V5, P566, DOI 10.1227/00006123-197911000-00004; Davis KA, 1996, ARCH SURG-CHICAGO, V131, P255; Falimirski ME, 2003, J TRAUMA, V55, P1, DOI 10.1097/01.TA.0000071295.67263.A2; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Givner A, 2002, J PEDIATR SURG, V37, P381, DOI 10.1053/jpsu.2002.30825; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; HURST JM, 1992, J TRAUMA, V33, P582, DOI 10.1097/00005373-199210000-00015; Lee TT, 1997, ACTA NEUROCHIR, V139, P1042, DOI 10.1007/BF01411558; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; Nagy KK, 1999, J TRAUMA, V46, P268, DOI 10.1097/00005373-199902000-00012; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Patel NY, 2000, J TRAUMA, V48, P367, DOI 10.1097/00005373-200003000-00001; PIETROPAOLI JA, 1992, J TRAUMA, V33, P403, DOI 10.1097/00005373-199209000-00011; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; Servadei E, 2000, BRIT J NEUROSURG, V14, P110; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; Servadei F, 2002, ACT NEUR S, V81, P81; Servadei F, 2000, NEUROSURGERY, V46, P70, DOI 10.1093/neurosurgery/46.1.70; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; SMITH HK, 1991, NEUROSURGERY, V29, P258, DOI 10.1227/00006123-199108000-00016; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Sullivan TP, 1999, AM J NEURORADIOL, V20, P107; Tabori U, 2000, CRIT CARE MED, V28, P840, DOI 10.1097/00003246-200003000-00038; Thaemert BC, 1997, J TRAUMA, V43, P748, DOI 10.1097/00005373-199711000-00003; Winchell RJ, 1996, ARCH SURG-CHICAGO, V131, P533	36	103	107	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAR	2004	56	3					475	480		10.1097/01.TA.0000114304.56006.D4			6	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	808CM	WOS:000220547200003	15128116				2022-02-06	
J	Nimmo, AJ; Cernak, I; Heath, DL; Hu, X; Bennett, CJ; Vink, R				Nimmo, AJ; Cernak, I; Heath, DL; Hu, X; Bennett, CJ; Vink, R			Neurogenic inflammation is associated with development of edema and functional deficits following traumatic brain injury in rats	NEUROPEPTIDES			English	Article						neurotrauma; capsaicin; diffuse brain injury; edema; magnesium; neuropeptides	PRIMARY SENSORY NEURONS; SUBSTANCE-P; CAPSAICIN TREATMENT; BINDING-SITES; RECEPTOR NK1; SPINAL-CORD; HEAD-INJURY; TIME-COURSE; ADULT-RAT; NEUROPEPTIDES	The present study has used capsaicin-induced neuropeptide depletion to examine the role of neurogenic inflammation in the development of edema and functional deficits following traumatic brain injury (TBI). Adult, male rats were treated with capsaicin (neuropeptide-depleted) or equal volume vehicle (controls) 14 days prior to induction of moderate/severe diffuse TBI. Injury in vehicle treated control animals resulted in acute (4-5 h) edema formation, which was confirmed as being vasogenic in origin by diffusion weighted magnetic resonance imaging and the presence of increased permeability of the blood-brain barrier (BBB) to Evans blue dye. There was also a significant decline in brain magnesium concentration, as assessed by phosphorus magnetic resonance spectroscopy, and the development of profound motor and cognitive deficits. In contrast, capsaicin pre-treatment resulted in a significant reduction in post-traumatic edema formation (p < 0.001), BBB permeability (p < 0.001), free magnesium decline (p < 0.01) and both motor and cognitive deficits (p < 0.001). We conclude that neurogenic inflammation may play an integral role in the development of edema and functional deficits following TBI, and that neuropeptides may be a novel target for development of interventional pharmacological strategies. (C) 2004 Elsevier Ltd. All rights reserved.	Georgetown Univ, Dept Neurosci, Washington, DC 20007 USA; James Cook Univ N Queensland, Sch Pharm & Mol Sci, Townsville, Qld 4811, Australia; Univ Adelaide, Dept Pathol, Adelaide, SA 5005, Australia		Vink, R (corresponding author), Georgetown Univ, Dept Neurosci, Washington, DC 20007 USA.	robert.vink@adelaide.edu.au	Vink, Robert/S-5616-2019; Cernak, Ibolja/A-6399-2008; Vink, Robert/J-7351-2012	Vink, Robert/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667; Ibolja, Cernak/0000-0003-3214-698X; Nimmo, Alan/0000-0002-0718-7934			Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; Bareyre F, 1997, J NEUROTRAUM, V14, P839, DOI 10.1089/neu.1997.14.839; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; BOCK JL, 1987, BIOCHIM BIOPHYS ACTA, V928, P8, DOI 10.1016/0167-4889(87)90079-6; Bracci-Laudiero L, 1999, NEUROSCI LETT, V275, P57, DOI 10.1016/S0304-3940(99)00737-5; CADIEUX A, 1986, NEUROSCIENCE, V19, P605, DOI 10.1016/0306-4522(86)90285-X; CERNAK I, 2001, J NEUROTRAUM, V19, P1397; CUELLO AC, 1981, N-S ARCH PHARMACOL, V315, P185, DOI 10.1007/BF00499834; DRAY A, 1992, BIOCHEM PHARMACOL, V44, P611, DOI 10.1016/0006-2952(92)90393-W; FADEN AI, 1986, ARCH NEUROL-CHICAGO, V43, P501, DOI 10.1001/archneur.1986.00520050073026; Feickert HJ, 1999, J TRAUMA, V47, P33, DOI 10.1097/00005373-199907000-00008; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Fox GB, 1998, J NEUROTRAUM, V15, P1037, DOI 10.1089/neu.1998.15.1037; GAUMANN DM, 1990, NEUROSCIENCE, V39, P761, DOI 10.1016/0306-4522(90)90259-7; Geraghty DP, 2003, BRAIN RES, V979, P230, DOI 10.1016/S0006-8993(03)02871-3; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; Heath DL, 1999, J PHARMACOL EXP THER, V288, P1311; Heath DL, 1995, J NEUROTRAUM, V12, P1027, DOI 10.1089/neu.1995.12.1027; HUSTON JP, 1995, BEHAV BRAIN RES, V66, P117, DOI 10.1016/0166-4328(94)00132-Y; Kashiba H, 1997, NEUROSCIENCE, V76, P299; KITA H, 1994, ACTA NEUROCHIR, P452; Leroy V, 2000, EXPERT OPIN INV DRUG, V9, P735, DOI 10.1517/13543784.9.4.735; LEVASSEUR JE, 1993, J NEUROSURG, V78, P610, DOI 10.3171/jns.1993.78.4.0610; Lin RCS, 1995, NEUROREPORT, V7, P310, DOI 10.1097/00001756-199512290-00074; Malcangio M, 2000, EUR J NEUROSCI, V12, P397, DOI 10.1046/j.1460-9568.2000.00946.x; MANTYH PW, 1989, P NATL ACAD SCI USA, V86, P5193, DOI 10.1073/pnas.86.13.5193; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; NEWBOLD P, 1995, BRIT J PHARMACOL, V114, P570, DOI 10.1111/j.1476-5381.1995.tb17177.x; O'Connor CA, 2003, J NEUROTRAUM, V20, P533, DOI 10.1089/089771503767168465; Parsadaniantz SM, 2000, J NEUROENDOCRINOL, V12, P766, DOI 10.1046/j.1365-2826.2000.00517.x; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; Rupniak NMJ, 1999, TRENDS PHARMACOL SCI, V20, P485, DOI 10.1016/S0165-6147(99)01396-6; SHARMA HS, 1990, NEUROSCIENCE, V38, P205, DOI 10.1016/0306-4522(90)90386-I; Stumm RK, 2001, J NEUROSCI, V21, P798, DOI 10.1523/JNEUROSCI.21-03-00798.2001; Tjen-A-Looi S, 1998, REGUL PEPTIDES, V74, P1, DOI 10.1016/S0167-0115(98)00007-X; Vink R, 2000, FRONT BIOSCI, V5, pD656, DOI 10.2741/Vink; VINK R, 2002, ABSTR BRAIN EDEMA S, P57; WOIE K, 1993, CIRC RES, V73, P839, DOI 10.1161/01.RES.73.5.839	41	103	110	0	11	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0143-4179	1532-2785		NEUROPEPTIDES	Neuropeptides	FEB	2004	38	1					40	47		10.1016/j.npep.2003.12.003			8	Endocrinology & Metabolism; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Neurosciences & Neurology	806WK	WOS:000220463800006	15003715				2022-02-06	
J	Wagner, AK; Bayir, H; Ren, DX; Puccio, A; Zafonte, RD; Kochanek, PM				Wagner, AK; Bayir, H; Ren, DX; Puccio, A; Zafonte, RD; Kochanek, PM			Relationships between cerebrospinal fluid markers of excitotoxicity, ischemia, and oxidative damage after severe TBI: The impact of gender, age, and hypothermia	JOURNAL OF NEUROTRAUMA			English	Article						excitotoxicity; gender; hypothermia; ischemia; lipid peroxidation; oxidative damage; traumatic brain injury	TRAUMATIC BRAIN-INJURY; FACTOR MESSENGER-RNA; SEVERE HEAD-INJURY; CEREBRAL-ISCHEMIA; MODERATE HYPOTHERMIA; LIPID-PEROXIDATION; GLOBAL-ISCHEMIA; BLOOD-FLOW; RAT-BRAIN; GLUTAMATE	Excitotoxicity and ischemia can result in oxidative stress after TBI. Female sex hormones are hypothesized to be neuroprotective after TBI by affecting multiple mechanisms of secondary injury, including oxidative damage, excitotoxicity and ischemia. Ca2+ mediated oxidative stress increases with age, and hypothermia is known to attenuate secondary injury. The purpose of this study was to determine if the relationship between cerebral spinal fluid (CSF) markers of excitotoxicity, ischemia, and oxidative damage are gender and age specific and the role of hypothermia in affecting these relationships. F-2-isoprostane, glutamate, and lactate/pyruvate, were assessed in CSF from adults (n = 68) with severe TBI (Glasgow coma scale [GCS] score less than or equal to 8) using ventricular CSF samples (n = 207) collected on days 1, 2, and 3 post-injury. F-2-isoprostane/glutamate and F2-isoprostane/lactate/pyruvate ratios were determined for patients at each time point. Six-month Glasgow Outcome Scores (GOS) were also obtained. Repeated measures multivariate analysis showed a significant gender effect (p < 0.002) and gender*time interaction (p = 0.012) on F-2-isoprostane/glutamate ratios. A significant gender effect (p = 0.050) and gender*time interaction (p = 0.049) was also seen with F2-isoprostane/lactate/pyruvate. Hypothermia (p = 0.001) and age (p = 0.026) significantly increased F2-isoprostane/glutamate ratios. Females had a significant inverse relationship between day 1 F2-isoprostane/glutamate ratios and GOS scores (r = -0.43; p = 0.05) as well as day 1 F-2-isoprostane/lactate/pyruvate ratio (r = -0.46; p = 0.04) and GOS scores. These results indicate that females have smaller oxidative damage loads than males for a given excitotoxic or ischemic insult and female gonadal hormones may play a role in mediating this neuroprotective effect. These results also suggest that susceptibility to glutamate mediated oxidative damage increases with age and that hypothermia differentially attenuates CSF glutamate versus F-2-isoprostane production. Gender and age differences in TBI pathophysiology should be considered when conducting clinical trials in TBI.	Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA USA; Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; Univ Pittsburgh, Sch Publ Hlth, Pittsburgh, PA USA		Wagner, AK (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15260 USA.	wagnerak@msx.upmc.edu	Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD040833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD40833] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS30318] Funding Source: Medline		AMES BN, 1995, BBA-MOL BASIS DIS, V1271, P165, DOI 10.1016/0925-4439(95)00024-X; BAKAY RAE, 1986, NEUROSURGERY, V18, P234, DOI 10.1227/00006123-198602000-00023; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Behl C, 2002, NAT REV NEUROSCI, V3, P433, DOI 10.1038/nrn846; Berchtold NC, 2001, EUR J NEUROSCI, V14, P1992, DOI 10.1046/j.0953-816x.2001.01825.x; Bergeron R, 1996, J NEUROSCI, V16, P1193; Boris-Moller F, 1998, EXP BRAIN RES, V121, P277, DOI 10.1007/s002210050461; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Butterfield DA, 2001, CURR MED CHEM, V8, P815, DOI 10.2174/0929867013373048; Chatzipanteli K, 1999, J NEUROCHEM, V72, P2047, DOI 10.1046/j.1471-4159.1999.0722047.x; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; ELOVIC E, 1996, MED REHABILITATION T, P1; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Floyd RA, 2002, NEUROBIOL AGING, V23, P795, DOI 10.1016/S0197-4580(02)00019-2; FOLBERGROVA J, 1992, J CEREBR BLOOD F MET, V12, P25, DOI 10.1038/jcbfm.1992.4; Glass TF, 2002, NEUROSCI LETT, V328, P133, DOI 10.1016/S0304-3940(02)00510-4; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GRANHOLM L, 1969, SCAND J CLIN LAB INV, V23, P361, DOI 10.3109/00365516909081702; Greco A, 1999, NEUROLOGY, V53, P1876, DOI 10.1212/WNL.53.8.1876; HALLSTROM A, 1989, J PHARMACOL METHOD, V22, P113; Hof PR, 2002, BRAIN RES, V928, P175, DOI 10.1016/S0006-8993(01)03345-5; Huang FP, 1998, NEUROCHEM RES, V23, P991, DOI 10.1023/A:1021088523137; ILLIEVICH UM, 1994, ANESTHESIOLOGY, V80, P177, DOI 10.1097/00000542-199401000-00025; Inder T, 2002, PEDIATR RES, V52, DOI 10.1203/01.PDR.0000020088.11295.13; JENNETT B, 1975, LANCET, V1, P480; Kassell NF, 1996, J NEUROSURG, V84, P221, DOI 10.3171/jns.1996.84.2.0221; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; KumeKick J, 1996, BRAIN RES, V738, P8, DOI 10.1016/0006-8993(96)00744-5; LIN BW, 1992, J NEUROCHEM, V59, P2213; Love S, 1999, BRAIN PATHOL, V9, P119; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Marks JD, 2000, DEV BRAIN RES, V124, P101, DOI 10.1016/S0165-3806(00)00096-1; Marks JD, 1996, DEV BRAIN RES, V97, P194, DOI 10.1016/S0165-3806(96)00149-6; MARSHALL LF, 1992, J NEUROTRAUMA, V9, P287; MAZZUCCHI A, 1992, J NEUROL, V239, P256; Mendelowitsch A, 2001, BRAIN RES, V901, P230, DOI 10.1016/S0006-8993(01)02359-9; Metz C, 1996, J NEUROSURG, V85, P533, DOI 10.3171/jns.1996.85.4.0533; Montine TJ, 1999, NEUROLOGY, V52, P562, DOI 10.1212/WNL.52.3.562; Nilsen J, 2002, BRAIN RES, V930, P216, DOI 10.1016/S0006-8993(02)02254-0; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; Pellerin L, 1998, DEV NEUROSCI-BASEL, V20, P291, DOI 10.1159/000017324; Pellerin L, 1996, DEV NEUROSCI-BASEL, V18, P336, DOI 10.1159/000111426; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; Reinert M, 2000, ACTA NEUROCHIR SUPPL, V76, P439; ROOF RL, 1992, RESTOR NEUROL NEUROS, V4, P425, DOI 10.3233/RNN-1992-4608; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; SCHRODER ML, 1994, J NEUROSURG, V80, P324, DOI 10.3171/jns.1994.80.2.0324; Schroder ML, 1996, J NEUROTRAUM, V13, P17, DOI 10.1089/neu.1996.13.17; Schroder ML, 1998, ACT NEUR S, V71, P127; Siesj? BK., 1978, BRAIN ENERGY METABOL; Sinz EH, 1998, J CEREBR BLOOD F MET, V18, P610, DOI 10.1097/00004647-199806000-00002; SMITH SS, 1994, PROG NEUROBIOL, V44, P55, DOI 10.1016/0301-0082(94)90057-4; Solum DT, 2002, J NEUROSCI, V22, P2650, DOI 10.1523/JNEUROSCI.22-07-02650.2002; Sonnewald U, 1997, GLIA, V21, P56, DOI 10.1002/(SICI)1098-1136(199709)21:1<56::AID-GLIA6>3.0.CO;2-#; URQUHART N, 1975, J NEUROCHEM, V24, P1071, DOI 10.1111/j.1471-4159.1975.tb03679.x; von Oettingen G, 2002, NEUROSURGERY, V50, P781, DOI 10.1097/00006123-200204000-00019; Wagner AK, 2000, J TRAUMA, V49, P411, DOI 10.1097/00005373-200009000-00005; Weaver CE, 1997, BRAIN RES, V761, P338, DOI 10.1016/S0006-8993(97)00449-6; Zhang YQ, 1998, BRAIN RES, V784, P321, DOI 10.1016/S0006-8993(97)00502-7	65	103	107	0	5	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	FEB	2004	21	2					125	136		10.1089/089771504322778596			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	774WB	WOS:000189008200001	15000754				2022-02-06	
J	Yogev-Falach, M; Amit, T; Bar-Am, O; Youdim, MBH				Yogev-Falach, M; Amit, T; Bar-Am, O; Youdim, MBH			The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives for MAPK-dependent amyloid precursor protein processing	FASEB JOURNAL			English	Article						mitogen-activated protein kinase; Alzheimer's disease	CLOSED-HEAD INJURY; MAO-B INHIBITOR; ENDOGENOUS NEUROTOXIN; BETA-PROTEIN; ALZHEIMERS-DISEASE; CHOLINESTERASE; APOPTOSIS; N-METHYL(R)SALSOLINOL; RIVASTIGMINE; PEPTIDE	Rasagiline [N-propargyl-(1R)-aminoindan] a highly potent selective irreversible monoamine oxidase (MAO)-B inhibitor exerts neuroprotective and antiapoptotic effects against a variety of insults in cell cultures and in vivo and has finished its phase III clinical trials for Parkinson's disease. In the present study, we show that rasagiline (1 and 10 muM) significantly protected rat PC12 cells against beta-amyloid (Abeta(1-42)) toxicity. In addition, rasagiline significantly increased (approximately threefold) the secretion of the nonamyloidogenic soluble form of the amyloid precursor protein (sAPPalpha) from SH-SY5Y neuroblastoma and PC12 cells. The increase of sAPPa. was dose-dependent and was blocked by the hydroxamic acid-based metalloprotease inhibitor Ro31-9790 (100 muM), suggesting that the effect is mediated via alpha-secretase activity. Rasagiline-induced sAPPa. release was significantly reduced by the inhibitors of protein kinase C (PKC), GF109203X, and ERK mitogen-activated protein kinase (MAPK) PD98059. Moreover, rasagiline dose dependently (0.1-10 muM) increased the phosphorylation of p44 and p42 MAPK, which was abolished by PD98059 (30 muM) and GF109203X (2.5 muM). By comparing the actions of rasagiline with those of its S-isomer TVP1022, which is not an MAO inhibitor, we have been able to demonstrate that MAO-B inhibition is not a prerequisite for either sAPPalpha-induced release or ERK phosphorylation. In addition, structure-activity relationship among rasagiline-related compounds suggests the crucial role of the propargyl moiety in these molecules, because propargylamine itself significantly induced the secretion of sAPPa. and increased MAPK phosphorylation with similar potency to that of rasagiline and its derivatives.	Technion Israel Inst Technol, Fac Med, Dept Pharmacol, Eve Topf Ctr Neurodegenerat Dis, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Fac Med, Dept Pharmacol, NPF Ctr Neurodegenerat Dis, IL-31096 Haifa, Israel		Youdim, MBH (corresponding author), Technion Israel Inst Technol, Fac Med, Dept Pharmacol, Eve Topf Ctr Neurodegenerat Dis, POB 9697, IL-31096 Haifa, Israel.	Youdim@tx.technion.ac.il					Akao Y, 2002, J NEUROCHEM, V82, P913, DOI 10.1046/j.1471-4159.2002.01047.x; Akao Y, 2002, NEUROSCI LETT, V326, P105, DOI 10.1016/S0304-3940(02)00332-4; Akao Y, 1999, NEUROSCI LETT, V267, P153, DOI 10.1016/S0304-3940(99)00361-4; Bejar C, 1999, EUR J PHARMACOL, V383, P231, DOI 10.1016/S0014-2999(99)00643-3; Cardoso SM, 2002, BRAIN RES, V931, P117, DOI 10.1016/S0006-8993(02)02256-4; CHECLER F, 1995, J NEUROCHEM, V65, P1431; Chen Y, 1998, J NEUROTRAUM, V15, P231, DOI 10.1089/neu.1998.15.231; Desai A, 2001, Expert Opin Pharmacother, V2, P653, DOI 10.1517/14656566.2.4.653; Finberg J P, 1999, Adv Neurol, V80, P495; Grant SM, 1999, NEUROREPORT, V10, P41, DOI 10.1097/00001756-199901180-00008; Huang W, 1999, EUR J PHARMACOL, V366, P127, DOI 10.1016/S0014-2999(98)00929-7; HUNG AY, 1993, J BIOL CHEM, V268, P22959; Jang JH, 2003, FREE RADICAL BIO MED, V34, P1100, DOI 10.1016/S0891-5849(03)00062-5; KIEBURTZ K, 2001, PARK RELAT DISORD S, V60; Kim KS., 1988, NEUROSCI RES COMMUN, V2, P121; Lamb HM, 2001, PHARMACOECONOMICS, V19, P303, DOI 10.2165/00019053-200119030-00008; Lu DC, 2000, NAT MED, V6, P397, DOI 10.1038/74656; Maruyama W, 2002, J NEURAL TRANSM, V109, P467, DOI 10.1007/s007020200038; Maruyama W, 2001, ANN NY ACAD SCI, V939, P320; Maruyama W, 2000, ADV RES NEURODEGENER, V8, P171; Maruyama W, 2001, J NEURAL TRANSM, V108, P11, DOI 10.1007/s007020170093; Maruyama W, 2001, J NEUROCHEM, V78, P727, DOI 10.1046/j.1471-4159.2001.00448.x; MARUYAMA W, 2000, ANN NY ACAD SCI, V939, P320; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; Mills J, 1999, J NEUROCHEM, V72, P443, DOI 10.1046/j.1471-4159.1999.0720443.x; Moreira PI, 2002, J NEUROSCI RES, V69, P257, DOI 10.1002/jnr.10282; Nunan J, 2000, FEBS LETT, V483, P6, DOI 10.1016/S0014-5793(00)02076-7; Pereira C, 1998, NEUROREPORT, V9, P1749, DOI 10.1097/00001756-199806010-00015; Rabey JM, 2000, CLIN NEUROPHARMACOL, V23, P324, DOI 10.1097/00002826-200011000-00005; Savage MJ, 1998, J NEUROSCI, V18, P1743; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Speiser Z, 1999, J NEURAL TRANSM, V106, P593, DOI 10.1007/s007020050182; Tatton WG, 2002, J PHARMACOL EXP THER, V301, P753, DOI 10.1124/jpet.301.2.753; Weinstock M, 1999, CNS DRUGS, V12, P307, DOI 10.2165/00023210-199912040-00005; Weinstock M, 2000, DRUG DEVELOP RES, V50, P216, DOI 10.1002/1098-2299(200007/08)50:3/4<216::AID-DDR4>3.3.CO;2-Q; WEINSTOCK M, 2000, J NEURAL TRANSM-SUPP, V60, pS157; Xu X, 1999, P NATL ACAD SCI USA, V96, P7547, DOI 10.1073/pnas.96.13.7547; Yogev-Falach M, 2002, FASEB J, V16, P1674, DOI 10.1096/fj.02-0198fje; Youdim M B, 1991, J Neural Transm Suppl, V34, P61; Youdim MBH, 2002, MECH AGEING DEV, V123, P1081, DOI 10.1016/S0047-6374(01)00391-8; Youdim MBH, 2001, CELL MOL NEUROBIOL, V21, P555, DOI 10.1023/A:1015131516649; Youdim MBH, 2001, BRIT J PHARMACOL, V132, P500, DOI 10.1038/sj.bjp.0703826; Youdim MBH, 2001, ANN NY ACAD SCI, V939, P450; YOUDIM MBH, 2003, IN PRESS BIOCH PHARM	44	103	105	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					2325	+		10.1096/fj.03-0078fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	WOS:000186343300004	14525944				2022-02-06	
J	Sun, MC; Honey, CR; Berk, C; Wong, NLM; Tsui, JKC				Sun, MC; Honey, CR; Berk, C; Wong, NLM; Tsui, JKC			Regulation of aquaporin-4 in a traumatic brain injury model in rats	JOURNAL OF NEUROSURGERY			English	Article						aquaporin; brain edema; brain injury; trauma	INSENSITIVE WATER CHANNEL; MESSENGER-RNA EXPRESSION; FOCAL CEREBRAL-ISCHEMIA; GLIAL-CELLS; EDEMA; ASTROCYTES; PROTEIN; IMMUNOLOCALIZATION; LOCALIZATION; TISSUES	Object. Aquaporin-4 (AQP4) plays a significant role in the regulation of brain water homeostasis. In this study the authors investigated the regulation of AQP4 following a focal cortical contusion injury in rats. Methods. Thirty-three adult male Wistar rats received a focal cortical contusion of the parietal cortex. An additional nine rats underwent a craniectomy, but no trauma was inflicted (sham injury). Animals were killed 1, 4, and 24 hours later. The rat brains were examined for water content by comparing the wet and dry weights of each hemisphere. Aquaporin-4 messenger (m)RNA was measured by reverse transcription-polymerase chain reaction. A ratio of AQP4 mRNA expression in the lesioned hemisphere compared with that in the contralateral control hemisphere was calculated for each animal at the injury site (parietal cortex) and at sites adjacent to (occipital cortex) and distant from the injury (frontal pole cortex). Brain edema was significantly increased at the injury site. The expression of AQP4 mRNA was significantly increased at the injury site, significantly decreased adjacent to the injury site, and not significantly different at a site distant from the injury. The magnitude of AQP4 mRNA upregulation at the injured parietal cortex correlated with the degree of downregulation in the adjacent occipital cortex. Conclusions. Data from this study demonstrate that an upregulation of AQP4 occurs at the site of traumatic brain injury and that a downregulation of this molecule occurs adjacent to the site of injury. Understanding the physiology of AQP4 and its regulation following brain injury may allow for the development of novel treatments for cerebral edema that accompanies head injury.	Univ British Columbia, Div Neurosurg, Dept Med, Vancouver, BC V5Z 4E5, Canada; Univ British Columbia, Ctr Neurodegenerat Disorders, Vancouver, BC V5Z 4E5, Canada; Cardinal Tien Hosp, Taipei, Taiwan; Fu Jen Catholic Univ, Taipei, Taiwan		Honey, CR (corresponding author), Univ British Columbia, Div Neurosurg, Dept Med, Suite 325,700 W 10th Ave, Vancouver, BC V5Z 4E5, Canada.	chris.honey@telus.net					Allen AR., 1911, JAMA-J AM MED ASSOC, V57, P878, DOI DOI 10.1001/JAMA.1911.04260090100008; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Baskaya MK, 2000, J NEUROTRAUM, V17, P93, DOI 10.1089/neu.2000.17.93; Baskaya MK, 1997, NEUROSURGERY, V40, P364; Baumgart E, 1997, HISTOCHEM CELL BIOL, V108, P185, DOI 10.1007/s004180050160; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DUCKER TB, 1976, HDB CLIN NEUROLOGY, V25, P9; Elkjaer ML, 2000, BIOCHEM BIOPH RES CO, V276, P1118, DOI 10.1006/bbrc.2000.3505; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FRIGERI A, 1995, P NATL ACAD SCI USA, V92, P4328, DOI 10.1073/pnas.92.10.4328; FRIGERI A, 1995, J CELL SCI, V108, P2993; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; HASEGAWA H, 1994, J BIOL CHEM, V269, P5497; Jackson PS, 1997, PEDIATR NEUROSURG, V27, P286, DOI 10.1159/000121272; JUNG JS, 1994, P NATL ACAD SCI USA, V91, P13052, DOI 10.1073/pnas.91.26.13052; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Nagelhus EA, 1998, J NEUROSCI, V18, P2506; Nakahama K, 1999, GLIA, V25, P240, DOI 10.1002/(SICI)1098-1136(19990201)25:3<240::AID-GLIA4>3.0.CO;2-C; Neely JD, 1999, BIOCHEMISTRY-US, V38, P11156, DOI 10.1021/bi990941s; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P7275, DOI 10.1073/pnas.90.15.7275; Nielsen S, 1997, J NEUROSCI, V17, P171; NIELSEN S, 1993, J CELL BIOL, V120, P371, DOI 10.1083/jcb.120.2.371; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; Stewart-Wallace AM, 1939, BRAIN, V62, P426, DOI 10.1093/brain/62.4.426; Taniguchi M, 2000, MOL BRAIN RES, V78, P131, DOI 10.1016/S0169-328X(00)00084-X; Vajda Z, 2000, BIOCHEM BIOPH RES CO, V270, P495, DOI 10.1006/bbrc.2000.2472; Venero JL, 1999, NEUROSCIENCE, V94, P239, DOI 10.1016/S0306-4522(99)00182-7; Vizuete ML, 1999, NEUROBIOL DIS, V6, P245, DOI 10.1006/nbdi.1999.0246	30	103	129	1	7	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAR	2003	98	3					565	569		10.3171/jns.2003.98.3.0565			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	653WW	WOS:000181460900017	12650429				2022-02-06	
J	Sander, AM; Caroselli, JS; High, WM; Becker, C; Neese, L; Scheibel, R				Sander, AM; Caroselli, JS; High, WM; Becker, C; Neese, L; Scheibel, R			Relationship of family functioning to progress in a post-acute rehabilitation programme following traumatic brain injury	BRAIN INJURY			English	Article; Proceedings Paper	28th Annual Meeting of the International-Neuropsychological-Society	FEB, 2000	DENVER, COLORADO	Int Neuropsychol Soc			DISABILITY RATING-SCALE; CLOSED-HEAD-INJURY; ASSESSMENT DEVICE; RELATIVES; CAREGIVERS; RECOVERY; RELIABILITY; PREDICTORS; COMMUNITY; VALIDITY	Primary objective: To investigate the relationship of family functioning to patients' progress in a post-acute TBI rehabilitation programme. Research design: Cohort study investigating predictors of change from admission to follow-up. Methods and procedures: Caregivers of 37 persons with severe TBI consecutively admitted to a residential post-acute rehabilitation facility completed the Family Assessment Device (FAD) within a few weeks of admission. The Disability Rating Scale (DRS) was completed upon admission and similar to1 month after discharge. FAD scores were used to predict DRS change scores after controlling for injury severity, admit FAD scores, and time from admission to follow-up. Main outcomes and results: Persons with unhealthy family functioning showed less improvement on DRS total, level of functioning (LOF), and employability (EMP) scores. Conclusions: The results emphasize that family functioning is an important variable to include in future models predicting rehabilitation outcome, and the importance of family intervention as part of the rehabilitation process.	Brain Injury Res Ctr, Inst Rehabil & Res, Houston, TX 77030 USA; Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Transit Learning Ctr Galveston, Galveston, TX USA		Sander, AM (corresponding author), Brain Injury Res Ctr, Inst Rehabil & Res, 2455 S Braeswood, Houston, TX 77030 USA.						Ben-Yishay Y., 1987, J HEAD TRAUMA REHAB, V2, P35, DOI [10.1097/00001199-198703000-00007, DOI 10.1097/00001199-198703000-00007]; Boake C, 1996, AM J PHYS MED REHAB, V75, P105, DOI 10.1097/00002060-199603000-00005; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Kozloff R., 1987, J HEAD TRAUMA REHAB, V2, P14, DOI [DOI 10.1097/00001199-198709000-00004, 10.1097/00001199-198709000-00004]; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; Malec James F., 1993, Brain Injury, V7, P15, DOI 10.3109/02699059309008153; McCauley SR, 2001, J INT NEUROPSYCH SOC, V7, P457, DOI 10.1017/S1355617701744025; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; PRIGATANO GP, 1994, J HEAD TRAUMA REHAB, V9, P91, DOI DOI 10.1097/00001199-199403000-00011; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Sander AM, 1997, BRAIN INJURY, V11, P235, DOI 10.1080/026990597123548; Uysal S, 1998, J HEAD TRAUMA REHAB, V13, P57, DOI 10.1097/00001199-199812000-00007; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WHITENECK GG, 1987, ASSESSING MED REHABI, P91; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009; Witol AD, 1996, NEUROREHABILITATION, V7, P175, DOI 10.3233/NRE-1996-7303; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; ZARSKI J, 1988, J HEAD TRAUMA REHAB, V3, P31; [No title captured]	36	103	104	0	6	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	AUG	2002	16	8					649	657		10.1080/02699050210128889			9	Neurosciences; Rehabilitation	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	583GP	WOS:000177399100001	12182162				2022-02-06	
J	Alessandri, B; Rice, AC; Levasseur, J; DeFord, M; Hamm, RJ; Bullock, MR				Alessandri, B; Rice, AC; Levasseur, J; DeFord, M; Hamm, RJ; Bullock, MR			Cyclosporin A improves brain tissue oxygen consumption and learning/memory performance after lateral fluid percussion injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						behavior; cyclosporin A; fluid percussion injury; rat	MITOCHONDRIAL PERMEABILITY TRANSITION; MUSCARINIC ACETYLCHOLINE-RECEPTORS; TRANSIENT FOREBRAIN ISCHEMIA; GERBIL HIPPOCAMPUS; MEMORY FORMATION; AXONAL DAMAGE; CELL-DEATH; CALCIUM; METABOLISM; ACTIVATION	Traumatic brain injury (TBI) triggers a complex pathophysiological cascade, leading to cell death. A major factor in the pathogenesis of TBI is neuronal overloading with calcium, causing the opening of mitochondrial permeability transition pores (MPTP), which consequently inhibit normal mitochondrial function. The immunosuppressant Cyclosporin A (CsA) has been shown to block MPTPs, and to be neuroprotective in ischemia and TBI. However, the translation of these effects on mitochondrial function, into behavioral endpoints has not been investigated thoroughly. Therefore, we tested the effect of a low, clinically evaluated, CsA dose of 0.125 mg/kg (infused for 3 h) and a higher "known" neuroprotective dose of 18.75 mg/kg on brain tissue O-2 consumption, and on motor and cognitive performance following lateral fluid percussion injury (FPI) in rats. CsA at both concentrations abolished the 25% decrease in O-2 consumption (VO2), seen in saline-treated animals at 5 h post-FPI. Furthermore, the lower dose of CsA also ameliorated acute motor deficits (days 1-5 post-FPI) and learning and memory impairments in a Morris water maze test on days 11-15 post-FPI. Although, the higher dose of CsA improved cognitive performance, it worsened acute motor functional recovery. These results suggest, that the CsA-induced preservation of mitochondrial function, as assessed by tissue O-2 consumption, directly translated into improvements in motor and cognitive behavior.	Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Div Med, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Psychol, Richmond, VA 23298 USA		Bullock, MR (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, POB 980631,1200 E Broad St, Richmond, VA 23298 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 12587] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587, P01NS012587] Funding Source: NIH RePORTER		Albensi BC, 2000, EXP NEUROL, V162, P385, DOI 10.1006/exnr.1999.7338; ALESSANDRI B, 1998, PROGR BRAIN RES, P311; ANDERSEN BJ, 1988, J NEUROSURG, V68, P601, DOI 10.3171/jns.1988.68.4.0601; Andreyev AY, 1998, FEBS LETT, V439, P373, DOI 10.1016/S0014-5793(98)01394-5; Bennett PC, 1998, FEBS LETT, V431, P386, DOI 10.1016/S0014-5793(98)00795-9; Bennett PC, 1996, BRAIN RES, V730, P107; Berman SB, 2000, EXP NEUROL, V164, P415, DOI 10.1006/exnr.2000.7438; Borlongan CV, 1998, NEUROSCI RES, V32, P195, DOI 10.1016/S0168-0102(98)00088-1; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Chen T, 2000, J NEUROTRAUM, V17, P135, DOI 10.1089/neu.2000.17.135; Di X, 1996, J NEUROTRAUM, V13, P497, DOI 10.1089/neu.1996.13.497; Di X, 2000, ACT NEUR S, V76, P379; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Dubinsky JM, 1998, J NEUROSCI RES, V53, P728, DOI 10.1002/(SICI)1097-4547(19980915)53:6<728::AID-JNR10>3.0.CO;2-U; FAYNOR SM, 1984, MAYO CLIN PROC, V59, P571, DOI 10.1016/S0025-6196(12)61496-7; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Folbergrova J, 1997, EXP BRAIN RES, V114, P44, DOI 10.1007/PL00005622; Friberg H, 1999, J NEUROCHEM, V72, P2488, DOI 10.1046/j.1471-4159.1999.0722488.x; Friberg H, 1998, J NEUROSCI, V18, P5151, DOI 10.1523/JNEUROSCI.18-14-05151.1998; FUKUDA K, 1995, J NEUROTRAUM, V12, P315, DOI 10.1089/neu.1995.12.315; Gijtenbeek JMM, 1999, J NEUROL, V246, P339, DOI 10.1007/s004150050360; Hamm RJ, 1994, NEUROBIOLOGY CENTRAL, P86; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Kondo Y, 1999, NEUROCHEM RES, V24, P9, DOI 10.1023/A:1020915727119; KONDO Y, 1995, NEUROSCI RES, V22, P123, DOI 10.1016/0168-0102(95)00878-W; Kristian T, 2000, J NEUROCHEM, V74, P1999, DOI 10.1046/j.1471-4159.2000.0741999.x; Kuroda S, 1999, BRAIN RES, V835, P148, DOI 10.1016/S0006-8993(99)01535-8; Lemasters JJ, 1998, BIOFACTORS, V8, P283, DOI 10.1002/biof.5520080316; Levasseur JE, 2000, J NEUROTRAUM, V17, P101, DOI 10.1089/neu.2000.17.101; Li PA, 1997, BRAIN RES, V753, P133, DOI 10.1016/S0006-8993(97)00005-X; Matsumoto S, 1999, J CEREBR BLOOD F MET, V19, P736, DOI 10.1097/00004647-199907000-00002; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Morioka M, 1999, PROG NEUROBIOL, V58, P1, DOI 10.1016/S0301-0082(98)00073-2; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Petersen A, 2000, BRAIN RES, V857, P20, DOI 10.1016/S0006-8993(99)02320-3; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; RINK A, 1995, AM J PATHOL, V147, P1575; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; Rzigalinski BA, 1998, J NEUROCHEM, V70, P2377; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; SHIGA Y, 1992, BRAIN RES, V595, P145, DOI 10.1016/0006-8993(92)91465-Q; Siesjo BK, 1999, ACTA NEUROCHIR SUPPL, V73, P7; SIGNORETTI S, 2000, RESTOR NEUROL NEUROS, V16, P218; STEINER R, 1996, EARTH ISL J, V11, P2; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; SZABO I, 1991, J BIOL CHEM, V266, P3376; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767, DOI 10.1152/jn.1995.74.6.2767; Uchino H, 1995, ACTA PHYSIOL SCAND, V155, P469, DOI 10.1111/j.1748-1716.1995.tb09999.x; Uchino H, 1998, BRAIN RES, V812, P216, DOI 10.1016/S0006-8993(98)00902-0; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; VINK R, 1994, J NEUROTRAUM, V11, P265, DOI 10.1089/neu.1994.11.265; VINK R, 1988, MAGNET RESON MED, V6, P37, DOI 10.1002/mrm.1910060105; WORLEY G, 1995, DEV MED CHILD NEUROL, V37, P213; Yoshimoto T, 1999, BRAIN RES, V839, P283, DOI 10.1016/S0006-8993(99)01733-3; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A; [No title captured]	65	103	105	0	6	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	2002	19	7					829	841		10.1089/08977150260190429			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	577JL	WOS:000177057700003	12184853				2022-02-06	
J	Chiaretti, A; Piastra, M; Pulitano, S; Pietrini, D; De Rosa, G; Barbaro, R; Di Rocco, C				Chiaretti, A; Piastra, M; Pulitano, S; Pietrini, D; De Rosa, G; Barbaro, R; Di Rocco, C			Prognostic factors and outcome of children with severe head injury: an 8-year experience	CHILDS NERVOUS SYSTEM			English	Article						severe head injury; childhood; Glasgow outcome score; prognostic factors; therapeutic algorithms	TRAUMATIC BRAIN INJURY; DISSEMINATED INTRAVASCULAR COAGULATION; GLASGOW COMA SCALE; EARLY POSTTRAUMATIC SEIZURES; MANAGEMENT; GUIDELINES; HYPERGLYCEMIA; HYPOTENSION; PREDICTION; HYPOXIA	Objectives: Our aim was to analyze prognostic factors and their association with outcome among children with severe head injury. Methods: We conducted a retrospective study among children with severe head injury admitted to our Pediatric Intensive Care Unit (PICU) from November 1992 to December 2000. The patients were immediately evaluated for the severity of head injury (Glasgow Coma Score, GCS), clinical presentation, cerebral axial tomography, early complications (hypoxia and hypotension), metabolic and hematological alterations and early post-traumatic seizures. Six months after injury we applied the Glasgow Outcome Score (GOS). Correlations with GOS were evaluated using univariate and multivariate logistic models. Results: In all, 122 children with severe head injury were identified. The patients presented the following scores: 18 (14.7.0%) children had a GOS of 1; 2 had a GOS of 2 (1.6%); 27 (22.2%) a GOS of 3 and 75 (61.5%) a GOS of 4 or 5. A low GOS was significantly and independently associated with low GCS, multiple trauma, the presence of hypoxia and hypotension, disseminated intravascular coagulation (DIC), hyperglycemia and early post-traumatic seizures. Hematological alterations (white blood cells) were also associated with a low GOS, though not significantly. Conclusion: In addition to GCS, types of trauma and brain lesion, hypoxia and hypotension, hemocoagulative disorders (DIC), hyperglycemia and early post-traumatic seizures are predictors of GOS. A knowledge of these prognostic factors and the correct management of children with severe head injury helps clinicians to improve outcome and to reduce morbidity and mortality.	Gemelli Hosp, Pediat Intens Care Unit, I-00168 Rome, Italy; Gemelli Hosp, Dept Anesthesiol, I-00168 Rome, Italy		Chiaretti, A (corresponding author), Gemelli Hosp, Pediat Intens Care Unit, I-00168 Rome, Italy.	chiarant@katamail.com		Pulitano, Silvia Maria/0000-0001-6815-6421			Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; BRUCE DA, 1999, PEDIAT NEUROSURGERY, P355; Bullock MR, 1996, J NEUROTRAUM, V13, P643; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Chiaretti A, 2000, CHILD NERV SYST, V16, P862, DOI 10.1007/s003810000368; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; GANDO S, 1992, CRIT CARE MED, V20, P594, DOI 10.1097/00003246-199205000-00009; GHAJAR J, 1992, PEDIATR CLIN N AM, V39, P1093; Glasgow JF, 1997, CURR PEDIAT, V7, P187; Gordini G, 1992, Minerva Anestesiol, V58, P217; GREWAL M, 1991, J PEDIATR SURG, V26, P1161, DOI 10.1016/0022-3468(91)90323-L; Hymel KP, 1997, PEDIATRICS, V99, P371, DOI 10.1542/peds.99.3.371; JENNETT B, 1975, LANCET, V1, P480; KALFF R, 1989, CHILD NERV SYST, V5, P156, DOI 10.1007/BF00272118; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; KUMURA E, 1987, ACTA NEUROCHIR, V85, P23, DOI 10.1007/BF01402365; KUSHNER M, 1990, ANN NEUROL, V28, P129, DOI 10.1002/ana.410280204; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; Lee ST, 1997, CAN J NEUROL SCI, V24, P40, DOI 10.1017/S0317167100021077; Levi M, 1999, NEW ENGL J MED, V341, P586, DOI 10.1056/NEJM199908193410807; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LEWIS RJ, 1993, ANN EMERG MED, V22, P1114, DOI 10.1016/S0196-0644(05)80974-6; LIEHLAI MW, 1992, J PEDIATR-US, V120, P195, DOI 10.1016/S0022-3476(05)80426-3; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Mansfield RT, 1997, CRIT CARE CLIN, V13, P611, DOI 10.1016/S0749-0704(05)70331-6; Meyer P, 1999, CHILD NERV SYST, V15, P732, DOI 10.1007/s003810050462; MICHAUD LJ, 1991, J TRAUMA, V31, P1356, DOI 10.1097/00005373-199110000-00007; MINER ME, 1982, J PEDIATR-US, V100, P687, DOI 10.1016/S0022-3476(82)80565-9; MORONT ML, 1994, PEDIATR CLIN N AM, V41, P1201; OLSON JD, 1989, NEUROSURGERY, V24, P825, DOI 10.1227/00006123-198906000-00007; Ong LC, 1996, PEDIATR NEUROSURG, V24, P285, DOI 10.1159/000121057; Ong LC, 1996, J PAEDIATR CHILD H, V32, P173, DOI 10.1111/j.1440-1754.1996.tb00917.x; Palmer S, 2001, J TRAUMA, V50, P657, DOI 10.1097/00005373-200104000-00010; Paret Gideon, 1999, Harefuah, V136, P677; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; Pillai S, 2001, PEDIATR NEUROSURG, V34, P98, DOI 10.1159/000056002; Pondaag W, 1979, Acta Neurochir Suppl (Wien), V28, P98; PRESTON FE, 1974, J NEUROL NEUROSUR PS, V37, P241, DOI 10.1136/jnnp.37.3.241; Rivara FP, 1999, PEDIATRICS, V103, P883; SHARPLES PM, 1990, BRIT MED J, V300, P87, DOI 10.1136/bmj.300.6717.87; Tikk A, 1979, Acta Neurochir Suppl (Wien), V28, P96; Tilford JM, 2001, CRIT CARE MED, V29, P1056, DOI 10.1097/00003246-200105000-00037; UHL MW, 1994, J NEUROTRAUM, V11, P303, DOI 10.1089/neu.1994.11.303; Wright M M, 1999, AACN Clin Issues, V10, P32, DOI 10.1097/00044067-199902000-00004; ZHUANG J, 1993, J TRAUMA, V35, P415, DOI 10.1097/00005373-199309000-00014	49	103	107	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0256-7040	1433-0350		CHILD NERV SYST	Childs Nerv. Syst.	APR	2002	18	3-4					129	136		10.1007/s00381-002-0558-3			8	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	555LU	WOS:000175796200006	11981619				2022-02-06	
J	Ginis, I; Jaiswal, R; Klimanis, D; Liu, H; Greenspon, J; Hallenbeck, JM				Ginis, I; Jaiswal, R; Klimanis, D; Liu, H; Greenspon, J; Hallenbeck, JM			TNF-alpha-induced tolerance to ischemic injury involves differential control of NF-kappa B transactivation: The role of NF-kappa B association with p300 adaptor	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						astrocytes; stress adaptation; tolerance; tumor necrosis factor; NF-kappa B; p300 adapter protein; protein kinase A	TUMOR-NECROSIS-FACTOR; SUPEROXIDE-DISMUTASE GENE; ACTIVATED PROTEIN-KINASE; INTERCELLULAR-ADHESION MOLECULE-1; SIGNAL-REGULATED KINASE; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN INJURY; BETA-PEPTIDE TOXICITY; CREB-BINDING PROTEIN; C-ZETA	Preconditioning with sublethal ischemia results in natural tolerance to ischemic stress, where multiple mediators of ischemic damage are simultaneously counteracted. Tumor necrosis factor alpha (TNF-alpha) has been implicated in development of ischemic tolerance. Using cellular models of ischemic tolerance, we have demonstrated that an effector of TNF-alpha-induced preconditioning is ceramide, a sphingolipid messenger in TNF-alpha signaling. TNF-alpha/ceramide-induced preconditioning protected cultured neurons against ischemic death and cultured astrocytes against proinflammatory effects of TNF-alpha. TNF-alpha activates a transcription factor NF-kappaB that binds promoters of multiple genes, thus ensuring pleiotropic effects of TNF-alpha. We describe here a mechanism that allows selective suppression of TNF-alpha/NF-kappaB-induced harmful genes in preconditioned cells while preserving cytoprotective responses. We demonstrate that in astrocytes activation of an adhesion molecule ICAM-1 by TNF-alpha is regulated through association of the phosphorylated p65 subunit of NF-kappaB with an adapter protein, p300, and that in preconditioned cells p65 remains unphosphorylated and ICAM-1 transcription is inhibited. However, TNF-alpha-activated transcription of a protective enzyme, MnSOD, does not depend on p300 and does not become inhibited in preconditioned cells. This new understanding of TNF-alpha-induced adaptation to ischemic stress and inflammation could suggest novel avenues for clinical intervention during ischemic and inflammatory diseases.	NINCDS, Mol Biol Lab, Stroke Branch, NIH, Bethesda, MD 20892 USA		Ginis, I (corresponding author), NINCDS, Mol Biol Lab, Stroke Branch, NIH, 36 Convent Dr,MSC 4092,Bldg 36,Room 3C12, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [ZIANS002924, Z01NS002924] Funding Source: NIH RePORTER		Andjelkovic AV, 2000, J LEUKOCYTE BIOL, V68, P545; Anrather J, 1999, J BIOL CHEM, V274, P13594, DOI 10.1074/jbc.274.19.13594; Arvin B, 1995, ANN NY ACAD SCI, V765, P62, DOI 10.1111/j.1749-6632.1995.tb16561.x; Baeuerle PA, 1998, CELL, V95, P729, DOI 10.1016/S0092-8674(00)81694-3; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; BARGER SW, 1995, P NATL ACAD SCI USA, V92, P9328, DOI 10.1073/pnas.92.20.9328; Barone FC, 1999, J CEREBR BLOOD F MET, V19, P819, DOI 10.1097/00004647-199908000-00001; Bird TA, 1997, J BIOL CHEM, V272, P32606, DOI 10.1074/jbc.272.51.32606; Borrello S, 1997, ARCH BIOCHEM BIOPHYS, V348, P289, DOI 10.1006/abbi.1997.0355; Botchkina GI, 1999, MOL MED, V5, P372, DOI 10.1007/BF03402126; Chen J, 1997, NEUROLOGY, V48, P306, DOI 10.1212/WNL.48.2.306; Chen Y, 2001, J CEREBR BLOOD F MET, V21, P34, DOI 10.1097/00004647-200101000-00005; Das KC, 1998, J BIOL CHEM, V273, P34639, DOI 10.1074/jbc.273.51.34639; Dawson DA, 1996, NEUROSCI LETT, V218, P41, DOI 10.1016/S0304-3940(96)13116-5; del Zoppo G, 2000, BRAIN PATHOL, V10, P95; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; Furuya K, 2001, J CEREBR BLOOD F MET, V21, P226, DOI 10.1097/00004647-200103000-00006; GalveRoperh I, 1997, FEBS LETT, V415, P271, DOI 10.1016/S0014-5793(97)00985-X; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Ginis I, 1999, AM J PHYSIOL-CELL PH, V276, pC1171, DOI 10.1152/ajpcell.1999.276.5.C1171; Ginis I, 2000, MOL MED, V6, P1028, DOI 10.1007/BF03402054; GINIS I, 1997, AM J PHYSIOL, V41, pC295; Gonzalez-Zulueta M, 2000, P NATL ACAD SCI USA, V97, P436, DOI 10.1073/pnas.97.1.436; Goodman Y, 1996, J NEUROCHEM, V66, P869, DOI 10.1046/j.1471-4159.1996.66020869.x; Hanna AN, 1999, J BIOL CHEM, V274, P12722, DOI 10.1074/jbc.274.18.12722; HERY C, 1995, J NEUROIMMUNOL, V57, P101, DOI 10.1016/0165-5728(94)00168-N; HURT J, 1992, NUCLEIC ACIDS RES, V20, P2985, DOI 10.1093/nar/20.12.2985; Jones PL, 1997, MOL CELL BIOL, V17, P6970, DOI 10.1128/MCB.17.12.6970; Keller JN, 1998, J NEUROSCI, V18, P687; Kim HP, 1999, J BIOL CHEM, V274, P37455, DOI 10.1074/jbc.274.52.37455; Kyrkanides S, 1999, J NEUROIMMUNOL, V95, P95, DOI 10.1016/S0165-5728(98)00270-7; Lee SJ, 2000, J IMMUNOL, V165, P4658, DOI 10.4049/jimmunol.165.8.4658; Lee SJ, 1998, J NEUROIMMUNOL, V92, P196, DOI 10.1016/S0165-5728(98)00209-4; LIU J, 1994, J BIOL CHEM, V269, P3047; Liu J, 2000, AM J PHYSIOL-CELL PH, V278, pC144, DOI 10.1152/ajpcell.2000.278.1.C144; LOZANO J, 1994, J BIOL CHEM, V269, P19200; Mattson MP, 2000, CELL TISSUE RES, V301, P173, DOI 10.1007/s004419900154; Mattson MP, 2000, J NEUROCHEM, V74, P443, DOI 10.1046/j.1471-4159.2000.740443.x; Merrill AH, 1997, TOXICOL APPL PHARM, V142, P208, DOI 10.1006/taap.1996.8029; Muller G, 1998, EMBO J, V17, P732, DOI 10.1093/emboj/17.3.732; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; Nawashiro H, 1997, J CEREBR BLOOD F MET, V17, P483, DOI 10.1097/00004647-199705000-00001; O'Connor TM, 2000, QJM-INT J MED, V93, P323, DOI 10.1093/qjmed/93.6.323; Pahan K, 1999, J NEUROCHEM, V73, P513, DOI 10.1046/j.1471-4159.1999.0730513.x; Perkins ND, 2000, TRENDS BIOCHEM SCI, V25, P434, DOI 10.1016/S0968-0004(00)01617-0; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; SCHMITZ ML, 1994, J BIOL CHEM, V269, P25613; Schneider A, 1999, NAT MED, V5, P554, DOI 10.1038/8432; Sheppard KA, 1998, J BIOL CHEM, V273, P29291, DOI 10.1074/jbc.273.45.29291; Shibayama M, 1996, J NEUROTRAUM, V13, P801, DOI 10.1089/neu.1996.13.801; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Taglialatela G, 1998, NEUROREPORT, V9, P489, DOI 10.1097/00001756-199802160-00024; Tasaki K, 1997, BRAIN RES, V748, P267, DOI 10.1016/S0006-8993(96)01383-2; True AL, 2000, AM J PHYSIOL-LUNG C, V279, pL302, DOI 10.1152/ajplung.2000.279.2.L302; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Vanden Berghe W, 1999, J BIOL CHEM, V274, P32091, DOI 10.1074/jbc.274.45.32091; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Wang YM, 1999, J NEUROSCI RES, V55, P293, DOI 10.1002/(SICI)1097-4547(19990201)55:3<293::AID-JNR4>3.0.CO;2-9; WOLFF RA, 1994, J BIOL CHEM, V269, P19605; YANG KY, 1995, NEUROSCI LETT, V197, P101, DOI 10.1016/0304-3940(95)11919-N; Yoza BK, 1996, J BIOL CHEM, V271, P18306, DOI 10.1074/jbc.271.31.18306; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zimmermann C, 2001, BRAIN RES, V895, P59, DOI 10.1016/S0006-8993(01)02028-5	67	103	117	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	FEB	2002	22	2					142	152		10.1097/00004647-200202000-00002			11	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	517KB	WOS:000173608700002	11823712	Bronze			2022-02-06	
J	Marsh, NV; Kersel, DA; Havill, JH; Sleigh, JW				Marsh, NV; Kersel, DA; Havill, JH; Sleigh, JW			Caregiver burden during the year following severe traumatic brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							HEAD-INJURY; SOCIAL-ADJUSTMENT; FAMILY; RELATIVES; STRESS; MEMBERS	Fifty-two primary caregivers of people with a severe traumatic brain injury (TBI) were assessed at 6-months and 1-year postinjury. Caregiver appraisal of the person with TBI's physical, cognitive, emotional, behavioural, and social functioning was assessed. Caregiver psychosocial functioning and levels of subjective and objective burden were also assessed. Some aspects of the difficulties reported for the people with TBI remained stable, while others increased in frequency, over time. At 6-months postinjury, approximately one third of caregivers reported clinically significant symptoms of anxiety and depression, and poor social adjustment. By 1-year postinjury, the prevalence of anxiety and depression remained the same, although only one-quarter continued to report poor social adjustment. There was some evidence of adaptation by caregivers, as the frequency with which various types of objective burden were reported remained stable, while the distress caused by these decreased in the first year postinjury. It appears that the impact on caregivers of physical impairment is comparatively short-lived and that caregivers learn some practical ways to manage the behavioural problems of the people with TBI. Despite this, over time the person with TBI's behavioural and cognitive problems begins to play a larger role in the level of distress experienced by the caregiver. However, it is the person with TBI's social isolation that has a stable and consistent role in the experience of subjective burden for primary caregivers in the first year postinjury.	Univ Waikato, Dept Psychol, Hamilton, New Zealand; Univ Glasgow, Dept Psychol Med, Glasgow, Lanark, Scotland; Waikato Hosp, Intens Care Unit, Hamilton, New Zealand		Marsh, NV (corresponding author), Univ Teesside, Sch Hlth & Social Care, Middlesbrough TS1 3BA, Cleveland, England.		Marsh, Nigel V./F-5433-2019; Marsh, Nigel/ABA-3609-2021	Marsh, Nigel V./0000-0002-4060-6432; Marsh, Nigel/0000-0002-4060-6432			Acorn S., 1993, CANADIAN J REHABILIT, V7, P149; BECK AT, 1972, POSTGRAD MED, V52, P81, DOI 10.1080/00325481.1972.11713319; Brooks D N, 1979, Int Rehabil Med, V1, P160; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; CHWALISZ K, 1992, REHABIL PSYCHOL, V37, P189, DOI 10.1037/h0079103; Florian V, 1989, Brain Inj, V3, P219, DOI 10.3109/02699058909029637; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Holland D, 1998, BRAIN INJURY, V12, P993, DOI 10.1080/026990598121918; JENNETT B, 1975, LANCET, V1, P480; Kersel DA, 2001, BRAIN INJURY, V15, P283, DOI 10.1080/02699050010005887; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; KNIGHT RG, 1984, J CLIN PSYCHOL, V40, P751, DOI 10.1002/1097-4679(198405)40:3<751::AID-JCLP2270400320>3.0.CO;2-Y; Kosciulek JF, 1999, BRAIN INJURY, V13, P245, DOI 10.1080/026990599121610; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; Livingston MG., 1990, REHABILITATION ADULT, P225; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; MARSH NV, 1999, BRAIN DAM B, P175; MOORE A, 1993, BRAIN INJURY, V7, P247, DOI 10.3109/02699059309029677; NOVACK TA, 1991, J HEAD TRAUMA REHAB, V6, P69, DOI DOI 10.1097/00001199-199112000-00014; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Panting A, 1972, REHABILITATION, V38, P33; Perlesz A, 1998, INT J REHABIL RES, V21, P339, DOI 10.1097/00004356-199812000-00001; Perlesz A, 1999, REHABIL PSYCHOL, V44, P6, DOI 10.1037/0090-5550.44.1.6; RAPE RN, 1992, REHABIL PSYCHOL, V37, P3, DOI 10.1037/h0079094; Smith LM, 1995, FAMILY SUPPORT PROGR; Spielberger CD, 1989, MANUAL STATE TRAIT A, V2nd; STEVENSON C, 1999, BRAIN IMPAIRMENT REH, P133; Tabachnick B. G., 2013, USING MULTIVARIATE S, V6th; TEASDALE G, 1974, LANCET, V2, P81; Walker A E, 1972, Scand J Rehabil Med, V4, P5; Wallace CA, 1998, BRAIN INJURY, V12, P483, DOI 10.1080/02699052.1998.11910751; Watanabe Y, 2000, CLIN REHABIL, V14, P172, DOI 10.1191/026921500666833742; WEISSMAN MM, 1978, J NERV MENT DIS, V166, P317, DOI 10.1097/00005053-197805000-00002; WEISSMAN MM, 1976, ARCH GEN PSYCHIAT, V33, P1111	35	103	106	0	15	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2002	24	4					434	447		10.1076/jcen.24.4.434.1030			14	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	568ZJ	WOS:000176574600003	12187457				2022-02-06	
J	Moser, RS; Schatz, P				Moser, RS; Schatz, P			Enduring effects of concussion in youth athletes	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article; Proceedings Paper	Annual Conference on Sports Related Concussion and Nervous System Injuries	1999	ORLANDO, FL			concussion; youth sports; neuropsychological testing; baseline screening; mild head injury	TRAUMATIC BRAIN-INJURY	The purpose of this study was to explore the mild, enduring effects of concussion in otherwise healthy youth athletes. Reported history of concussion and cognitive functioning was examined in an initial sample of 35 youth athletes, 21 of whom were considered healthy volunteers (No Recent Concussion within the past 6 months) with no identified medical or neuropsychological difficulties related to concussion. The remaining 14 volunteers had each sustained a concussion within I week of testing (Recent Concussion). Significant differences in performances on a general cognitive measure, and specifically in the area of attention, were found as a function of number of concussions reported by the No Recent Concussion athletes. Furthermore, on some of the measures, No Recent Concussion athletes with a history of two or more concussions appeared to resemble Recent Concussion athletes more so than No Recent Concussion athletes with a history of one or no concussion. The importance of assessment of youth concussion and the use of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) for this purpose are discussed. (C) 2001 National Academy of Neuropsychology. Published by Elsevier Science Ltd.	RSM Psychol Ctr LLC, Lawrenceville, NJ 08648 USA; St Josephs Univ, Philadelphia, PA 19131 USA		Moser, RS (corresponding author), RSM Psychol Ctr LLC, 3131 Princeton Pike,Bldg 5, Lawrenceville, NJ 08648 USA.	r.moser@rcn.com		Schatz, Philip/0000-0002-6222-6545			Barth JT, 1989, MILD HEAD INJURY, P257; BARTH JT, 1998, RECOVERY, V9, P30; CANTU R, 1998, CLIN SPORTS MED, P27; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; ECHEMENDIA R, 1999, ANN SPORTS REL CONC; GENUARDI FJ, 1995, PEDIATRICS, V95, P216; GRADY D, 1998, NY TIMES        0501, pA18; GRONWALL D, 1976, NZ PSYCHOL, V5, P72; Hovda DA, 1999, SPORTS-RELATED CONCUSSION, P12; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; KUTNER K, 1998, NAN B, V13, P19; LAPOINTE J, 1998, NY TIMES        0322, pL3; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Macciocchi SN, 1998, CLIN SPORT MED, V17, P27, DOI 10.1016/S0278-5919(05)70058-2; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; *QUAL STAND SUBC, 1997, NEUROLOGY, V48, P481; Randolph C., 1998, REPEATABLE BATTERY A; ROOS R, 1996, PHYSICIAN SPORTSMED, V24, P1	21	103	105	1	22	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JAN	2002	17	1					91	100		10.1016/S0887-6177(01)00108-1			10	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH); Conference Proceedings Citation Index - Science (CPCI-S)	Psychology	504XD	WOS:000172880700008	14589756	Bronze			2022-02-06	
J	Masel, BE; Scheibel, RS; Kimbark, T; Kuna, ST				Masel, BE; Scheibel, RS; Kimbark, T; Kuna, ST			Excessive daytime sleepiness in adults with brain injuries	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	50th Annual Meeting of the American-Academy-of-Neurology	APR 25-MAY 02, 1998	MINNEAPOLIS, MINNESOTA	Amer Acad Neurol		Xbrain injuries; disorders of excessive somnolence; rehabilitation; sleep apnea syndromes; sleep disorders	CLOSED-HEAD-INJURY; LATENCY TEST; SCALE; POPULATION; PREVALENCE	Objectives: To determine the prevalence, demographics, and causes of excessive daytime sleepiness in adults with brain injuries after the acute phase of their injury and to investigate the relations between self-report and objective measures of hypersomnolence. Design: A case series of patients enrolled consecutively into a residential rehabilitation program. Setting: University sleep laboratory, live-in rehabilitation center. Patients: Adults with brain injuries (n = 71); mean time +/- standard deviation from injury to study, 38 +/- 60 months. Interventions: A polysomnogram and Multiple Sleep Latency Test (MSLT) were performed in each subject. Each subject also completed the Epworth Sleepiness Scale (ESS) and Pittsburgh Sleep Quality Index (PSQI) questionnaires. Main Outcome Measures: Sleep patterns, by polysomnogram. Daytime hypersomnolence, diagnosed by mean sleep latency on the MSLT less than or equal to 10 minutes. Sleep apnea-hypopnea syndrome, diagnosed by Apnea-Hypopnea Index greater than 10 events/hr. Periodic limb movement disorder, diagnosed by a Periodic Leg Movement Index greater than 10 events/hr. Results: Mean sleep latency was : 10 minutes in 47% of the cohort and less than or equal to 5 minutes in 18.3%. Subjects were classified into 3 groups: nonhypersomnolent (n = 38, 53%), hypersomnolent with abnormal indices (n = 12, 17%), or hypersomnolent with normal indices (n = 21, 30%). Among the 3 groups, no significant differences were present in Glasgow Coma Scale score, length of coma, or time since brain injury. No differences across groups were found in nature of the injury, gender, or medications. No significant correlation existed between the ESS or PSQI results and mean sleep latency on the MSLT. Conclusions: Hypersomnia is common in adults with brain injuries, with a relatively high prevalence of sleep apnea-hypopnea syndrome, periodic limb movement disorder, and posttraurnatic hypersomnia. Subjects with objectively measured sleepiness were not identified on self-reporting questionnaires, suggesting their inability to perceive their hypersomnolence. (C) 2001 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Transit Learning Ctr Galveston, Galveston, TX 77550 USA; Univ Texas, Med Branch, Galveston, TX 77550 USA; Univ Penn, Vet Affairs Med Ctr, Philadelphia, PA 19104 USA		Masel, BE (corresponding author), Transit Learning Ctr Galveston, 1528 PO, Galveston, TX 77550 USA.				NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [RR-73] Funding Source: Medline		*AM SLEEP DIS ASS, 1997, INT CLASS SLEEP DIS; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; ANCOLIISRAEL S, 1991, SLEEP, V14, P496, DOI 10.1093/sleep/14.6.496; Benbadis SR, 1999, NEUROLOGY, V52, P209, DOI 10.1212/WNL.52.1.209; Benbadis SR, 1999, ANN INTERN MED, V130, P289, DOI 10.7326/0003-4819-130-4-199902160-00014; Benton A., 1994, CONTRIBUTIONS NEUROP; BIXLER EO, 1982, RES COMMUN CHEM PATH, V36, P129; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; CARSKADON MA, 1986, SLEEP, V9, P519, DOI 10.1093/sleep/9.4.519; Chervin RD, 1999, NEUROLOGY, V52, P125, DOI 10.1212/WNL.52.1.125; COHEN M, 1992, J NEUROL NEUROSUR PS, V55, P313, DOI 10.1136/jnnp.55.4.313; DALESSANDRO R, 1995, SLEEP, V18, P389; Dorsey CM, 1996, NEUROPSYCHOPHARMACOL, V14, P437, DOI 10.1016/0893-133X(95)00148-7; Flemons WW, 1999, SLEEP, V22, P667, DOI 10.1093/sleep/22.5.667; GUILLEMINAULT C, 1976, ACTA NEUROL SCAND, V54, P71, DOI 10.1111/j.1600-0404.1976.tb07621.x; GUILLEMINAULT C, 1983, NEUROLOGY, V33, P1584, DOI 10.1212/WNL.33.12.1584; Guilleminault C, 2000, NEUROLOGY, V54, P653, DOI 10.1212/WNL.54.3.653; Harada M, 1976, Kumamoto Med J, V29, P110; Heaton R.K., 1981, WISCONSIN CARD SORTI; JOHNS MW, 1994, SLEEP, V17, P703, DOI 10.1093/sleep/17.8.703; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; LANKFORD DA, 1994, SLEEP, V17, pS25, DOI 10.1093/sleep/17.suppl_8.S25; MANN MR, 1997, ARCH PHYS MED REHAB, V78, P1086; MANN NR, 1997, ARCH PHYS MED REHAB, V78, P1055; MILLON T, 1987, MANUAL MCMI II; PRIGATANO GP, 1982, J NEUROL NEUROSUR PS, V45, P78, DOI 10.1136/jnnp.45.1.78; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; SCHEIBEL RS, 1997, J NEUROPSYCHOL CLIN, V9, P673; Wechsler D, 1987, MEMORY SCALE REVISED; Wechsler D., 1981, WAIS R MANUAL; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704	31	103	104	0	3	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	2001	82	11					1526	1532		10.1053/apmr.2001.26093			7	Rehabilitation; Sport Sciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	488WK	WOS:000171959600004	11689971				2022-02-06	
J	Cherry, SR				Cherry, SR			Fundamentals of positron emission tomography and applications in preclinical drug development	JOURNAL OF CLINICAL PHARMACOLOGY			English	Article							TRAUMATIC BRAIN INJURY; RESOLUTION PET SCANNER; IMAGING SMALL ANIMALS; IN-VIVO; PHARMACOKINETIC ANALYSIS; PERFORMANCE EVALUATION; LIVING ANIMALS; REPORTER GENE; MICROPET; ONCOLOGY	Positron emission tomography (PET) is a nuclear imaging technique that can dynamically image trace amounts of positron-labeled radiopharmaceuticals in vivo. Tracer concentrations can be determined quantitatively, and by application of appropriate tracer kinetic models, the rates of a wide range of different biological processes can be measured noninvasively in humans. PET has been used as a research tool for more than 25 years and has also found clinical applications, particularly in oncology, neurological disorders, and cardiovascular disease. Recently, there has been tremendous interest in applying PET technology to in vivo small-animal imaging. Significant improvements in the imaging technology now permit a wide range of PET studies in mice and rats, using compact, relatively low-cost, dedicated small-animal PET scanners. This article reviews the fundamental basis of PET imaging and discusses the development of small-animal PET scanners and their possible application in preclinical drug development. (C) 2001 the American College of Clinical Pharmacology.	Univ Calif Los Angeles, Sch Med, Crump Inst Mol Imaging, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA		Cherry, SR (corresponding author), Univ Calif Los Angeles, Sch Med, Crump Inst Mol Imaging, Box 951770, Los Angeles, CA 90095 USA.		Cherry, Simon/AAH-1000-2019	Cherry, Simon/0000-0002-0155-5644	NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA069370, R01CA074036] Funding Source: NIH RePORTER; NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [CA 74036, CA 69370] Funding Source: Medline		Adam LE, 1997, IEEE T NUCL SCI, V44, P1172, DOI 10.1109/23.596983; Beanlands R, 1996, CAN J CARDIOL, V12, P875; Bergmann SR, 1998, SEMIN NUCL MED, V28, P320, DOI 10.1016/S0001-2998(98)80036-6; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Beyer T, 2000, J NUCL MED, V41, P1369; BLOOMFIELD PM, 1995, PHYS MED BIOL, V40, P1105, DOI 10.1088/0031-9155/40/6/010; Brooks DJ, 1997, BAILLIERE CLIN NEUR, V6, P69; Budinger TF, 1998, SEMIN NUCL MED, V28, P247, DOI 10.1016/S0001-2998(98)80030-5; Burns HD, 1999, CURR OPIN CHEM BIOL, V3, P388, DOI 10.1016/S1367-5931(99)80059-3; Chatziioannou AF, 1999, J NUCL MED, V40, P1164; CHERRY SR, 1995, IEEE T NUCL SCI, V42, P1064, DOI 10.1109/23.467748; Cherry SR, 1997, IEEE T NUCL SCI, V44, P1161, DOI 10.1109/23.596981; Chugani H T, 1999, Adv Neurol, V79, P883; Correia JA, 1999, IEEE T NUCL SCI, V46, P631, DOI 10.1109/23.775590; ENGEL J, 1995, ADV NEUROL, V66, P223; Fischman AJ, 1997, DRUG METAB REV, V29, P923, DOI 10.3109/03602539709002238; Gambaccini M, 1998, NUCL INSTRUM METH A, V409, P508, DOI 10.1016/S0168-9002(97)01304-1; Gambhir SS, 2000, NEOPLASIA, V2, P118, DOI 10.1038/sj.neo.7900083; Gambhir SS, 1999, P NATL ACAD SCI USA, V96, P2333, DOI 10.1073/pnas.96.5.2333; GUERRERO TM, 1990, IEEE T NUCL SCI, V37, P676, DOI 10.1109/23.106697; Hoffman J M, 1995, J Med Assoc Ga, V84, P125; Hoh CK, 1997, SEMIN NUCL MED, V27, P94, DOI 10.1016/S0001-2998(97)80042-6; HUANG S-C, 1986, P287; HUME SP, 1995, SYNAPSE, V21, P45, DOI 10.1002/syn.890210107; Hume SP, 1996, J NEUROSCI METH, V67, P103; Hume SP, 1998, EUR J NUCL MED, V25, P173, DOI 10.1007/s002590050211; Jeavons AP, 1999, IEEE T NUCL SCI, V46, P468, DOI 10.1109/23.775564; Kornblum HI, 2000, NAT BIOTECHNOL, V18, P655, DOI 10.1038/76509; KUDO T, 1999, J NUCL MED, V40; Lammertsma AA, 1996, NEUROIMAGE, V4, P153, DOI 10.1006/nimg.1996.0066; Lecomte R, 1996, IEEE T NUCL SCI, V43, P1952, DOI 10.1109/23.507252; Lewellen TK, 1996, IEEE T NUCL SCI, V43, P2199, DOI 10.1109/23.531882; MacLaren DC, 1999, GENE THER, V6, P785, DOI 10.1038/sj.gt.3300877; MARRIOTT CJ, 1994, J NUCL MED, V35, P1390; McCarthy TJ, 1998, SEMIN NUCL MED, V28, P235, DOI 10.1016/S0001-2998(98)80029-9; Mielke R, 1998, J NEURAL TRANSM-SUPP, P237; Moore AH, 2000, J CEREBR BLOOD F MET, V20, P1492, DOI 10.1097/00004647-200010000-00011; Offord SJ, 1999, J CLIN PHARMACOL, V39, p17S, DOI 10.1002/j.1552-4604.1999.tb05933.x; OLLINGER J, 1997, IEEE SIGNAL PROC MAG, P43; Pichler B, 1998, IEEE T NUCL SCI, V45, P1298, DOI 10.1109/23.682020; Qi JY, 1998, PHYS MED BIOL, V43, P1001, DOI 10.1088/0031-9155/43/4/027; Rubins DJ, 1999, J NUCL MED, V40, p261P; Schelbert H R, 1998, Curr Probl Cardiol, V23, P69, DOI 10.1016/S0146-2806(98)80011-X; Schiepers C, 1998, EUR RADIOL, V8, P1481, DOI 10.1007/s003300050579; Shao Y, 1997, IEEE T NUCL SCI, V44, P1167, DOI 10.1109/23.596982; Slates R, 1999, IEEE T NUCL SCI, V46, P565, DOI 10.1109/23.775580; Tewson TJ, 1998, SEMIN NUCL MED, V28, P221, DOI 10.1016/S0001-2998(98)80028-7; TILSLEY DWO, 1993, CANCER SURV, V17, P425; Tornai MP, 1999, J NUCL MED, V40, P1176; TORRES EM, 1995, NEUROREPORT, V6, P2017, DOI 10.1097/00001756-199510010-00016; WAGNER HN, 1983, SCIENCE, V221, P1264, DOI 10.1126/science.6604315; Weber S, 1999, IEEE T NUCL SCI, V46, P1177, DOI 10.1109/23.790853; Weber WA, 1999, STRAHLENTHER ONKOL, V175, P356, DOI 10.1007/s000660050022; Welch MJ, 2000, J NUCL MED, V41, P315; WU AM, 1999, J NUCL MED, V40; [No title captured]	56	103	106	1	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0091-2700	1552-4604		J CLIN PHARMACOL	J. Clin. Pharmacol.	MAY	2001	41	5					482	491		10.1177/00912700122010357			10	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	427UW	WOS:000168424700002	11361044				2022-02-06	
J	Dikmen, S; Machamer, J; Temkin, N				Dikmen, S; Machamer, J; Temkin, N			Mild head injury: Facts and artifacts	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							RECOVERY; CONCUSSION; DEFICITS	While most would agree that mild traumatic brain injury (TBI) is associated with early neuropsychological problems, disagreement exists regarding their persistence and whether they are the cause of the disabilities experienced by some people. The aim of this study was to examine how the criteria used to define mild TBI and how the pre-injury characteristics of people affect their neuropsychological outcome. A total of 157 unselected hospitalized cases with Glasgow Coma Scale scores of 13-15 and 109 trauma controls were prospectively recruited and administered a number of cognitive measures at 1 month and 12 months after injury. The results indicated early impairments that decreased with time and the stringency of the definition of 'mild' TBI. The contribution of demographics was usually significant and often stronger than the mild TBI effect. Subtle variation of the demographics of the brain injured or the comparison subjects can be sufficient to mimic or mask mild brain injury effects.	Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA		Dikmen, S (corresponding author), Univ Washington, Dept Rehabil Med, Box 356490, Seattle, WA 98195 USA.	dikmen@u.washington.edu			AGENCY FOR HEALTHCARE RESEARCH AND QUALITYUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [R01HS005304] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD033677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019643] Funding Source: NIH RePORTER; AHRQ HHSUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [HS05304] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD33677] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS19643] Funding Source: Medline		Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Bohnen N, 1992, Clin Neuropsychol, V6, P178, DOI 10.1080/13854049208401854; BOHNEN NI, 1995, BRAIN INJURY, V9, P27, DOI 10.3109/02699059509004568; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN S, 1987, NEUROBEHAVIORAL RECO, P73; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; GRONWALL D, 1974, LANCET, V2, P605; Heaton RK, 1996, NEUROPSYCHOLOGICAL A, P141; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Stuss DT, 1989, CLIN NEUROPSYCHOL, V3, P145, DOI [DOI 10.1080/13854048908403287, 10.1080/ 13854048908403287]; TEASDALE G, 1974, LANCET, V2, P81; Wechsler D., 1955, MANUAL WECHSLER ADUL; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wolfson, 1993, HALSTEAD REITAN NEUR; [No title captured], DOI DOI 10.1037/0894-4105.7.3.296	28	103	103	0	8	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2001	23	6					729	738		10.1076/jcen.23.6.729.1019			10	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	535QL	WOS:000174655200003	11910540				2022-02-06	
J	McAllister, TW; Sparling, MB; Flashman, LA; Saykin, AJ				McAllister, TW; Sparling, MB; Flashman, LA; Saykin, AJ			Neuroimaging findings in mild traumatic brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD-INJURY; MAGNETIC-RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; DIFFUSE AXONAL INJURY; COMPUTED-TOMOGRAPHY; TECHNETIUM-99M-HMPAO SPECT; INTRACRANIAL INJURY; CEREBRAL PERFUSION; IMAGING FINDINGS; MRI	The role of neuroimaging in the diagnosis and management of mild traumatic brain injury (TBI) is evolving. In general, the structural imaging techniques play a role in acute diagnosis and management, while the functional imaging techniques show promise for clarification of pathophysiology, symptom genesis, and mechanisms of recovery. A wide array of neuropathological processes are involved in mild TBI including changes in bone (e.g., a skull fracture), tissue density and water content (edema), blood flow, white matter integrity and pathway connectivity (diffuse axonal injury), and subtle changes in the neuronal and extracellular biochemical milieu. No single imaging technique is capable of addressing all these processes. It is, therefore, important to be aware of the advantages and limitations of the various available imaging modalities. This paper selectively reviews the pertinent literature on the structural and functional imaging in mild TBI.	Dartmouth Coll Sch Med, Sect Neuropsychiat, Lebanon, NH USA; Dartmouth Coll Sch Med, Brain Imaging Lab, Lebanon, NH USA; New Hampshire Hosp, Concord, NH USA; Def & Vet Head Injury Program, Washington, DC USA		McAllister, TW (corresponding author), Dartmouth Hitchcock Med Ctr, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	Thomas.W.McAllister@Dartmouth.edu	Saykin, Andrew/A-1318-2007	Saykin, Andrew/0000-0002-1376-8532	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040472] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS40472-01] Funding Source: Medline		Abdel-Dayem HM, 1998, CLIN NUCL MED, V23, P309, DOI 10.1097/00003072-199805000-00009; ABDELDAYEM HM, 1987, RADIOLOGY, V165, P221, DOI 10.1148/radiology.165.1.3498184; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS RD, 1985, PRINCIPLES NEUROLOGY; Alavi A, 1989, J Neuropsychiatry Clin Neurosci, V1, pS45; Alavi A, 1996, J NUCL MED, V37, P1170; Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Alsop DC, 1996, J NEUROTRAUM, V13, P515, DOI 10.1089/neu.1996.13.515; ANDERSON CV, 1995, J NEUROPSYCH CLIN N, V7, P42; Anderson CV, 1996, J NEUROTRAUM, V13, P59, DOI 10.1089/neu.1996.13.59; AUERBACH SH, 1989, PHYSICAL MED REHABIL, V3, P1; Bagley LJ, 2000, J MAGN RESON IMAGING, V11, P1, DOI 10.1002/(SICI)1522-2586(200001)11:1<1::AID-JMRI1>3.0.CO;2-H; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BORCZUK P, 1995, ANN EMERG MED, V25, P731, DOI 10.1016/S0196-0644(95)70199-0; Campbell B G, 1998, Top Magn Reson Imaging, V9, P208; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; CHOE BY, 1995, INVEST RADIOL, V30, P502, DOI 10.1097/00004424-199508000-00008; CHOKSEY MS, 1991, J NEUROL NEUROSUR PS, V54, P6, DOI 10.1136/jnnp.54.1.6; CLARK JM, 1974, J NEUROL NEUROSUR PS, V37, P463, DOI 10.1136/jnnp.37.4.463; Eisenberg H.M., 1989, MILD HEAD INJURY, P133; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Gennarelli, 1998, Semin Clin Neuropsychiatry, V3, P160; Gennarelli T. A., 1987, HEAD INJURY, P108; GEORGE J K, 1989, Journal of Nuclear Medicine, V30, P802; GODERSKY JC, 1990, ACT NEUR S, V51, P311; GOLDENBERG G, 1992, J NEUROL NEUROSUR PS, V55, P362, DOI 10.1136/jnnp.55.5.362; GRAHAM DI, 1987, NEUROPATH APPL NEURO, V13, P209, DOI 10.1111/j.1365-2990.1987.tb00184.x; GRAY BG, 1992, J NUCL MED, V33, P52; Greenspan S L, 1998, Magn Reson Imaging Clin N Am, V6, P53; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; HARAD FT, 1992, J TRAUMA, V32, P359, DOI 10.1097/00005373-199203000-00014; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; HUMAYUN MS, 1989, NUCL MED COMMUN, V10, P335, DOI 10.1097/00006231-198905000-00004; ICHISE M, 1994, J NUCL MED, V37, P463; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; JACOBS A, 1994, J NUCL MED, V35, P942; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; JENKINS A, 1986, LANCET, V2, P445; Kawamoto H, 1997, ACTA NEUROCHIR, V139, P566, DOI 10.1007/BF02751001; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; LEVIN H, 1997, ARCH NEUROL-CHICAGO, V53, P88; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Lewine JD, 1999, AM J NEURORADIOL, V20, P857; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; McAllister T., 2001, J NEUROPSYCHIATRY CL, V13, P141; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; MCALLISTER TW, IN PRESS NEURO IMAGE; McGowan JC, 2000, AM J NEURORADIOL, V21, P875; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Miller Erik C., 1997, Journal of Emergency Medicine, V15, P453, DOI 10.1016/S0736-4679(97)00071-1; NAGAMACHI S, 1995, NUCL MED COMMUN, V16, P17, DOI 10.1097/00006231-199501000-00006; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; PELLICANO G, 1997, NEURORADIOLOGY, V39, pS82; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; REID RH, 1990, CLIN NUCL MED, V15, P383, DOI 10.1097/00003072-199006000-00003; Ricci B, 1997, NEURORADIOLOGY, V39, P313, DOI 10.1007/s002340050415; ROBERTS MA, 1995, BRAIN INJURY, V9, P427, DOI 10.3109/02699059509008202; ROPER SN, 1991, J NUCL MED, V32, P1684; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Rubin Y, 1997, J NEUROTRAUM, V14, P441, DOI 10.1089/neu.1997.14.441; Ruff R. M., 1989, NEUROPSY NEUROPSY BE, V2, P103; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; Saykin AJ, 1999, BRAIN, V122, P1963, DOI 10.1093/brain/122.10.1963; SCHYNOLL W, 1993, AM J EMERG MED, V11, P321, DOI 10.1016/0735-6757(93)90160-D; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; SILVERMAN IE, 1993, J NUCL MED, V34, P1447; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; Tsurushima H, 1996, NEUROL SURG TOKYO, V24, P891; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; Werring DJ, 1998, J NEUROL NEUROSUR PS, V65, P863, DOI 10.1136/jnnp.65.6.863; Wiedmann KD, 1989, NEUROPSYCHOLOGY, V3, P267, DOI 10.1037//0894-4105.3.4.267; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; WOOD DMG, 1995, BRAIN RES BULL, V38, P545, DOI 10.1016/0361-9230(95)02026-0; [No title captured]	85	103	103	0	8	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2001	23	6					775	791		10.1076/jcen.23.6.775.1026			17	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	535QL	WOS:000174655200007	11910544				2022-02-06	
J	Movsesyan, VA; O'Leary, DM; Fan, L; Bao, WL; Mullins, PGM; Knoblach, SM; Faden, AI				Movsesyan, VA; O'Leary, DM; Fan, L; Bao, WL; Mullins, PGM; Knoblach, SM; Faden, AI			mGluR5 antagonists 2-methyl-6-(phenylethynyl)-pyridine and (E)-2-methyl-6-(2-phenylethenyl)-pyridine reduce traumatic neuronal injury in vitro and in vivo by antagonizing N-methyl-D-aspartate receptors	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; BRAIN INJURY; NMDA-RECEPTORS; AMINO-ACIDS; CELL-DEATH; IN-VITRO; RAT; NEUROTOXICITY; ACTIVATION; MK801	The effect of selective group I metabotropic glutamate receptor subtype 5 (mGluR5) antagonists 2-methyl-6-(phenylethynyl) pyridine (MPEP) and (E)-2-methyl-6-(2-phenylethenyl)-pyridine (SIB-1893) on neuronal cell survival and post-traumatic recovery was examined using rat in vitro and in vivo trauma models. Treatment with MPEP and SIB-1893 showed significant neuroprotective effects in rat cortical neuronal cultures subjected to mechanical injury. Application of the antagonists also attenuated glutamate- and N-methyl-D-aspartate (NMDA)-induced neuronal cell death in vitro. Intracerebroventricular administration of MPEP to rats markedly improved motor recovery and reduced deficits of spatial learning after lateral fluid percussion-induced traumatic brain injury. Lesion volumes as assessed by magnetic resonance imaging were also substantially reduced by MPEP treatment. Although we show that MPEP acts as a potent mGluR5 antagonist in our culture system, where it completely blocks agonist-induced phosphoinositide hydrolysis, electrophysiological and pharmacological studies indicate that MPEP and SIB-1893 also inhibit NMDA receptor activity at higher concentrations that are neuroprotective. Taken together, these data suggest that MPEP and SIB-1893 may have therapeutic potential in brain injury, although the mechanisms of neuroprotective action for these drugs may reflect their ability to modulate NMDA receptor activity.	Georgetown Univ, Med Ctr, Dept Neurosci, Georgetown Inst Cognit & Computat Sci, Washington, DC 20007 USA		Faden, AI (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, Georgetown Inst Cognit & Computat Sci, 3900 Reservoir Rd NW,Res Bldg,Rm EP12, Washington, DC 20007 USA.			Mullins, Paul/0000-0002-1339-6361	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037313] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS37313] Funding Source: Medline		Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; BAGETTA G, 1990, BRIT J PHARMACOL, V101, P776, DOI 10.1111/j.1476-5381.1990.tb14156.x; BERRIDGE MJ, 1982, BIOCHEM J, V206, P587, DOI 10.1042/bj2060587; DOBERTY AJ, 1997, NEUROPHARMACOLOGY, V36, P265; FADEN AI, 1993, J NEUROTRAUM, V10, P91, DOI 10.1089/neu.1993.10.91; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Gasparini F, 1999, NEUROPHARMACOLOGY, V38, P1493, DOI 10.1016/S0028-3908(99)00082-9; Haghighi SS, 1996, NEUROL RES, V18, P509; HOCKINGS PD, 1995, JMRI-J MAGN RESON IM, V5, P437, DOI 10.1002/jmri.1880050412; Holscher C, 1999, NEUROSCI BIOBEHAV R, V23, P399, DOI 10.1016/S0149-7634(98)00045-1; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; KNOEPFEL T, 1995, J MED CHEM, V38, P1417, DOI 10.1021/jm00009a001; Kornhuber J, 1997, BIOL PSYCHIAT, V41, P135, DOI 10.1016/S0006-3223(96)00047-9; Loubinoux I, 1997, STROKE, V28, P419, DOI 10.1161/01.STR.28.2.419; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Mukhin A, 1996, J NEUROSCI, V16, P6012; Mukhin AG, 1997, J NEUROTRAUM, V14, P651, DOI 10.1089/neu.1997.14.651; Mukhin AG, 1997, NEUROREPORT, V8, P2561, DOI 10.1097/00001756-199707280-00028; Mukhin AG, 1998, J NEUROSCI RES, V51, P748, DOI 10.1002/(SICI)1097-4547(19980315)51:6<748::AID-JNR8>3.0.CO;2-B; MURASE K, 1989, NEUROSCI LETT, V103, P56, DOI 10.1016/0304-3940(89)90485-0; Nakanishi S, 1998, BRAIN RES REV, V26, P230, DOI 10.1016/S0165-0173(97)00033-7; Nicoletti F, 1999, NEUROPHARMACOLOGY, V38, P1477, DOI 10.1016/S0028-3908(99)00102-1; OLEARY DM, 2001, IN PRESS BR J PHARM; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; Pellegrini-Giampietro DE, 1999, NEUROPHARMACOLOGY, V38, P1607, DOI 10.1016/S0028-3908(99)00097-0; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; RINK A, 1995, AM J PATHOL, V147, P1575; Schoepp DD, 1999, NEUROPHARMACOLOGY, V38, P1431, DOI 10.1016/S0028-3908(99)00092-1; SINENSKY MC, 1995, TOXICOL LETT, V75, P101; Strasser U, 1998, EUR J NEUROSCI, V10, P2848, DOI 10.1046/j.1460-9568.1998.00291.x; SUN FY, 1995, BRAIN RES, V673, P133, DOI 10.1016/0006-8993(94)01413-C; UEDA Y, 1995, NEUROSCI LETT, V185, P107, DOI 10.1016/0304-3940(94)11236-C; Varney MA, 1999, J PHARMACOL EXP THER, V290, P170; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	36	103	105	0	2	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0022-3565			J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	JAN	2001	296	1					41	47					7	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	384NM	WOS:000165951800006	11123360				2022-02-06	
J	Wagner, KR; Hua, Y; De Courten-Myers, GM; Broderick, JP; Nishimura, RN; Lu, SY; Dwyer, BE				Wagner, KR; Hua, Y; De Courten-Myers, GM; Broderick, JP; Nishimura, RN; Lu, SY; Dwyer, BE			Tin-mesoporphyrin, a potent heme oxygenase inhibitor, for treatment of intracerebral hemorrhage: In vivo and in vitro studies	CELLULAR AND MOLECULAR BIOLOGY			English	Article						edema; while matter; pigs; iron	LONG-TERM POTENTIATION; NITRIC-OXIDE SYNTHASE; RAT ASTROGLIAL CELLS; LIPID-PEROXIDATION; HEAT-SHOCK; BILIRUBIN PRODUCTION; HYDROGEN-PEROXIDE; SN-MESOPORPHYRIN; BRAIN; IRON	Spontaneous intracerebral hemorrhage (ICH) is the stroke subtype with highest mortality and morbidity. ICH can also occur following traumatic brain injury and thrombolysis for ischemic stroke and myocardial infarction. Development of ICH-induced hemispheric edema can elevate intracranial pressure and cause death. In survivors, edema-related white matter injury can lead to life-long neurological deficits. At present, there are no scientifically proven treatments for ICH. Heme oxygenase products, particularly iron and bilirubin, can be toxic to cells. In cerebral ischemia models, metalloporphyrins that are potent heme oxygenase inhibitors, reduce edema and infarct size. Tin-mesoporphyrin (SnMP) is a neuroprotectant that has also been used clinically to treat hyperbilirubinemia. Presently, we tested the hypothesis that SnMP treatment would reduce edema development following experimental ICH. We produced hematomas in pentobarbital-anesthetized pigs (9-11 kg) by infusing autologous blood into the frontal white matter. To maximize tissue concentrations, SnMP (87.5 mu M in DMSO) or DMSO (vehicle controls) was included in the infused blood. Pig brains were frozen in situ at 24 hrs. following ICH and hematoma acid edema volumes were determined on coronal sections by computer-assisted image analysis. We also examined the effects of SnMP in vitro on ferritin iron release, the formation of iron-induced thiobarbituric acid reactive substances (TBARS) and initial clot formation and hemolysis. SnMP treatment significantly reduced intracerebral mass following ICH. This was due to significant decreases in hematoma (0.68 +/- 0.08 vs. 1.39 +/- 0.30 cc, vehicle controls p<0.025) and edema volumes (edema = 1.16 +/- 0.33 vs. 1.77 +/- 0.31 cc, p<0.05). In vitro, SnMP did not stabilize ferritin iron against reductive release nor did it decrease iron-induced TBARS formation in brain homogenates. SnMP or DMSO added to pig blood did not alter clot weights. In conclusion, SnMP reduced intracerebral mass in an ICH model by decreasing both hematoma and edema volumes SnMP's mechanism of action is presently unknown but may involve its potent inhibition of heme oxygenase activity. SnMP's effect appears unrelated to ferritin iron release, antioxidant activity or initial clot formation. Since SnMP treatment could be brain protective following ICH, further investigations into neurological and neuropathological outcomes and as well as into its mechanism of action are warranted.	Univ Cincinnati, Coll Med, Dept Neurol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Pathol & Lab Med, Cincinnati, OH 45267 USA; Vet Affairs Med Ctr, Med Res Serv, Cincinnati, OH 45220 USA; Vet Affairs Med Ctr, Dept Neurol 111N1, Sepulveda, CA USA; Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90024 USA; Vet Affairs Med Ctr, Res Serv 151, White River Jct, VT USA; Dartmouth Med Sch, Dept Med Neurol, Hanover, NH USA		Wagner, KR (corresponding author), Univ Cincinnati, Coll Med, Dept Neurol, Cincinnati, OH 45267 USA.	wagnerkr@email.uc.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-30652] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS030652] Funding Source: NIH RePORTER		ABRAHAM NG, 1995, P NATL ACAD SCI USA, V92, P6798, DOI 10.1073/pnas.92.15.6798; Abraham NG, 1996, CELL PHYSIOL BIOCHEM, V6, P129, DOI 10.1159/000154819; Appleton SD, 1999, DRUG METAB DISPOS, V27, P1214; BABBS CF, 1990, METHOD ENZYMOL, V186, P464; BRAUGHLER JM, 1987, J BIOL CHEM, V262, P10438; BRODERICK JP, 1993, STROKE, V24, P987, DOI 10.1161/01.STR.24.7.987; BUETTNER GR, 1990, METHOD ENZYMOL, V186, P125; Chan PH, 1996, STROKE, V27, P1124, DOI 10.1161/01.STR.27.6.1124; Crow JP, 1999, ARCH BIOCHEM BIOPHYS, V371, P41, DOI 10.1006/abbi.1999.1414; daSilva JL, 1996, J LAB CLIN MED, V128, P290, DOI 10.1016/S0022-2143(96)90030-X; Day BJ, 1999, FREE RADICAL BIO MED, V26, P730, DOI 10.1016/S0891-5849(98)00261-5; Day BJ, 1997, ARCH BIOCHEM BIOPHYS, V347, P256, DOI 10.1006/abbi.1997.0341; Dore S, 1999, MOL MED, V5, P656, DOI 10.1007/BF03401984; DRUMMOND GS, 1987, ARCH BIOCHEM BIOPHYS, V255, P64, DOI 10.1016/0003-9861(87)90294-3; Dul K, 1994, INTRACEREBRAL HEMORR, P73; Dwyer BE, 1996, MOL BRAIN RES, V38, P251, DOI 10.1016/0169-328X(95)00341-O; DWYER BE, 1992, GLIA, V5, P300, DOI 10.1002/glia.440050407; Dwyer BE, 1998, J NEUROCHEM, V71, P2497; ESTERBAUER H, 1990, METHOD ENZYMOL, V186, P407; FOULKES MA, 1988, STROKE, V19, P547, DOI 10.1161/01.STR.19.5.547; Gebel JM, 1998, STROKE, V29, P563, DOI 10.1161/01.STR.29.3.563; Giandomenico AR, 1997, FREE RADICAL BIO MED, V23, P426, DOI 10.1016/S0891-5849(97)00113-5; GREEN D, 1990, J LAB CLIN MED, V115, P144; Hall N, 1999, J NEUROCHEM, V72, pS33; Hall N, 1998, STROKE, V29, P273; KADOYA C, 1995, STROKE, V26, P1035, DOI 10.1161/01.STR.26.6.1035; KASE CCL, 1994, INTRACEREBRAL HEMORR; Lamb NJ, 1999, BIOCHEM J, V344, P153, DOI 10.1042/0264-6021:3440153; Lin T. N., 1999, Society for Neuroscience Abstracts, V25, P1587; LISK DR, 1994, NEUROLOGY, V44, P133, DOI 10.1212/WNL.44.1.133; LO YK, 1994, ACTA NEUROL SCAND, V90, P83; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; Martinez JC, 1999, PEDIATRICS, V103, P1, DOI 10.1542/peds.103.1.1; Matsuoka Y, 1999, J CEREBR BLOOD F MET, V19, P1247, DOI 10.1097/00004647-199911000-00009; Mautes AEM, 1998, BRAIN RES, V795, P17, DOI 10.1016/S0006-8993(98)00230-3; MAYER SA, 1994, NEUROLOGY, V44, P1379, DOI 10.1212/WNL.44.8.1379; McCord JM, 1998, SEMIN HEMATOL, V35, P5; McCoubrey WK, 1997, EUR J BIOCHEM, V247, P725, DOI 10.1111/j.1432-1033.1997.00725.x; MEFFERT MK, 1994, NEURON, V13, P1225, DOI 10.1016/0896-6273(94)90060-4; NATH KA, 1992, J CLIN INVEST, V90, P267, DOI 10.1172/JCI115847; Packard B. A., 1999, Society for Neuroscience Abstracts, V25, P1849; Panahian N, 1999, J NEUROCHEM, V72, P1187; Panizzon KL, 1996, NEUROREPORT, V7, P662, DOI 10.1097/00001756-199601310-00067; Patel M, 1999, TRENDS PHARMACOL SCI, V20, P359, DOI 10.1016/S0165-6147(99)01336-X; Peeling J, 1998, BRAIN RES, V795, P63, DOI 10.1016/S0006-8993(98)00253-4; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10919, DOI 10.1073/pnas.94.20.10919; POSS KD, 1995, NEURON, V15, P867, DOI 10.1016/0896-6273(95)90177-9; Raju VS, 1997, BBA-GENE STRUCT EXPR, V1351, P89, DOI 10.1016/S0167-4781(96)00183-2; REIF DW, 1990, ARCH BIOCHEM BIOPHYS, V283, P537, DOI 10.1016/0003-9861(90)90680-W; RIBAS GC, 1992, J NEUROTRAUM, V9, pS265; Richmon JD, 1998, BRAIN RES, V780, P108, DOI 10.1016/S0006-8993(97)01314-0; SCHIPPER HM, 1991, J NEUROSCI, V11, P2170; SCHIPPER HM, 1993, J NEUROPATH EXP NEUR, V52, P399, DOI 10.1097/00005072-199307000-00007; Schipper HM, 1999, J NEUROCHEM, V72, P1802, DOI 10.1046/j.1471-4159.1999.0721802.x; Schmidt J, 1999, MOL BRAIN RES, V73, P50, DOI 10.1016/S0169-328X(99)00231-4; SHIBAHARA S, 1987, J BIOL CHEM, V262, P12889; Suttner DM, 1999, FASEB J, V13, P1800, DOI 10.1096/fasebj.13.13.1800; Turner CP, 1999, MOL BRAIN RES, V65, P87, DOI 10.1016/S0169-328X(98)00340-4; VALAES T, 1994, PEDIATRICS, V93, P1; Wagner K, 1998, STROKE, V29, P332; Wagner K. R., 1998, Society for Neuroscience Abstracts, V24, P1230; WAGNER KR, 1985, EXP NEUROL, V89, P146, DOI 10.1016/0014-4886(85)90272-9; Wagner KR, 1997, STROKE, V28, P170; Wagner KR, 1998, J NEUROSURG, V88, P1058, DOI 10.3171/jns.1998.88.6.1058; Wagner KR, 1996, STROKE, V27, P490, DOI 10.1161/01.STR.27.3.490; Wagner KR, 1999, J NEUROSURG, V90, P491, DOI 10.3171/jns.1999.90.3.0491; WAGNER KR, 1995, J CEREB BLOOD FLO S1, V15, pS28; WEBER CM, 1994, J NEUROCHEM, V63, P953; Welch GN, 1998, NEW ENGL J MED, V338, P1042, DOI 10.1056/NEJM199804093381507; Yachie A, 1999, J CLIN INVEST, V103, P129, DOI 10.1172/JCI4165; YAGI K, 1984, METHOD ENZYMOL, V105, P328; Yoo JH, 1998, STROKE, V29, P2478, DOI 10.1161/01.STR.29.12.2478	73	103	110	0	0	C M B  ASSOC	POITIERS	34 BOULEVARD SOLFERINO, 86000 POITIERS, FRANCE	0145-5680	1165-158X		CELL MOL BIOL	Cell. Mol. Biol.	MAY	2000	46	3					597	608					12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	324QV	WOS:000087633600011	10872746				2022-02-06	
J	Kaya, SS; Mahmood, A; Li, Y; Yavuz, E; Chopp, M				Kaya, SS; Mahmood, A; Li, Y; Yavuz, E; Chopp, M			Expression of nestin after traumatic brain injury in rat brain	BRAIN RESEARCH			English	Article						nestin; traumatic brain injury; astrocyte; microglia; plasticity	NERVE GROWTH-FACTOR; RADIAL GLIA; ASTROCYTES; CELLS; CNS; CORTEX	We tested the hypothesis that traumatic brain injury upregulates expression of nestin, an embryonic cell intermediate filament protein. Brain from rats (n = 24) subjected to controlled cortical impact injury and sham operated (n = 3) and normal(n = 3) rats were processed for dual label immunohistochemical study to identify cellular expression of nestin. Our results show that in normal noninjured animals, nestin is expressed slightly and localized only in a few endothelial and subventricular cells. In contrast, at 1-4 weeks postinjury nestin is strongly expressed in astrocytes and microglia. The expression of nestin in astrocytes and microglia after traumatic brain injury support the hypothesis that injured cerebral tissue expresses developmental proteins, and that these proteins may promote recovery after injury. (C) 1999 Elsevier Science B.V. All rights reserved.	Henry Ford Hlth Sci Ctr, Dept Neurosurg, Detroit, MI 48202 USA; Henry Ford Hlth Sci Ctr, Dept Neurol, Detroit, MI USA; Oakland Univ, Dept Phys, Rochester, MI USA		Mahmood, A (corresponding author), Henry Ford Hlth Sci Ctr, Dept Neurosurg, 2799 W Grand Blvd, Detroit, MI 48202 USA.	nsaam@neuro.hfh.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS023393, R01NS035504] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS35504, P01 NS23393] Funding Source: Medline		BARRES BA, 1991, J NEUROSCI, V11, P3685; BIGNAMI A, 1974, NATURE, V252, P55, DOI 10.1038/252055a0; CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0; CLARKE SR, 1994, NEUROREPORT, V5, P1885, DOI 10.1097/00001756-199410000-00011; Crino PB, 1996, P NATL ACAD SCI USA, V93, P14152, DOI 10.1073/pnas.93.24.14152; CULICAN SM, 1990, J NEUROSCI, V10, P684; DAHLSTRAND J, 1995, DEV BRAIN RES, V84, P109, DOI 10.1016/0165-3806(94)00162-S; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Duggal N, 1997, BRAIN RES, V768, P1, DOI 10.1016/S0006-8993(97)00588-X; FREDERIKSEN K, 1988, NEURON, V1, P439, DOI 10.1016/0896-6273(88)90175-4; FRISEN J, 1995, J CELL BIOL, V131, P453, DOI 10.1083/jcb.131.2.453; GALLO V, 1995, J NEUROSCI, V15, P394; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; HATTEN ME, 1991, GLIA, V4, P233, DOI 10.1002/glia.440040215; Holmin S, 1997, EUR J NEUROSCI, V9, P65, DOI 10.1111/j.1460-9568.1997.tb01354.x; ISHIKAWA R, 1991, NEUROSCI LETT, V127, P70, DOI 10.1016/0304-3940(91)90897-3; KIMELBERG HK, 1989, SCI AM, V260, P66, DOI 10.1038/scientificamerican0489-66; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Schmitt A, 1997, J NEUROSCI, V17, P1, DOI 10.1523/jneurosci.17-01-00001.1997; STREIT WJ, 1990, J HISTOCHEM CYTOCHEM, V38, P1683, DOI 10.1177/38.11.2212623	20	103	108	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	SEP 4	1999	840	1-2					153	157		10.1016/S0006-8993(99)01757-6			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	234GY	WOS:000082477300017	10517963				2022-02-06	
J	Hoffmann, GF; Zschocke, J				Hoffmann, GF; Zschocke, J			Glutaric aciduria type I: From clinical, biochemical and molecular diversity to successful therapy	JOURNAL OF INHERITED METABOLIC DISEASE			English	Article; Proceedings Paper	36th Annual Symposium of the SSIEM	1998	YORK, ENGLAND	Soc Study Inborn Errors Metabolism			COA-DEHYDROGENASE-DEFICIENCY; ACIDEMIA TYPE-I; DIAGNOSIS; MUTATIONS; GENE; ENCEPHALOPATHY; EXPRESSION; KINDREDS; DISORDER; COENZYME	The biochemical hallmark of glutaric aciduria type I (GA I) due to glutaryl-CoA dehydrogenase deficiency is the accumulation of glutaric acid, and to a lesser degree of 3-hydroxyglutaric and glutaconic acids. Abnormal metabolites vary from gross organic aciduria to only slightly or intermittently elevated or even normal excretion of glutaric acid, making the diagnosis sometimes difficult. Close to 100 pathogenic mutations have been identified in the gene encoding glutaryl-CoA dehydrogenase. Specific mutations correlate with low or no excretion of glutaric acid, but there appears to be no correlation between genotype and clinical phenotype. GA I causes unique age- and location-specific neuropathological sequelae. Starting in the second half of gestation, maturation of the frontal and temporal cortex is hindered, leading to the characteristic appearance of frontotemporal atrophy. Between 6 and 18 months of age, relatively mild neurological symptoms may become exacerbated by fever or a catabolic state in the course of common infections or routine immunizations, by fasts required for surgery, or by minor head injuries. Putamen and caudate are destroyed, resulting in a permanent movement disorder that is similar to cerebral palsy and ranges from extreme hypotonia to choreoathetosis to rigidity with spasticity. Recently, the underlying pathophysiology could be delineated to an environmentally triggered age- and location-specific overstimulation of the NMDA 2B receptor subtype. Current therapy prevents brain degeneration in more than 90% of affected infants who are treated prospectively. Without treatment, more than 90% of affected children will develop severe neurological disabilities. Recognition of this disorder before the brain has been injured is essential to treatment. GA I may be recognized in routine neonatal screening performed with tandem mass spectrometry by an elevation of glutarylcarnitine. Where this is not done, timely diagnosis depends on the recognition of relatively nonspecific physical findings such as hypotonia, irritability, macrocephaly, on the detection of suggestive abnormalities in neuroimaging and on quantitative urinary organic acid analysis by gas chromatography - mass spectrometry.	Univ Marburg, Dept Neuropaediat & Metab Dis, Marburg, Germany		Hoffmann, GF (corresponding author), Univ Childrens Hosp, Dept Neuropaediat & Metab Dis, Deutschhausstr 12, D-35033 Marburg, Germany.		Zschocke, Johannes/C-5885-2013	Zschocke, Johannes/0000-0002-0046-8274			AMIR N, 1989, J PEDIATR-US, V114, P983, DOI 10.1016/S0022-3476(89)80442-1; Baric I, 1998, J INHERIT METAB DIS, V21, P326, DOI 10.1023/A:1005390105171; Baric I., 1997, Journal of Inherited Metabolic Disease, V20, P34; BARIC I, 1997, 7 INT C INB ERR MET; BENNETT MJ, 1991, J INHERIT METAB DIS, V14, P165, DOI 10.1007/BF01800589; BERGMAN I, 1989, PEDIATRICS, V83, P228; Biery BJ, 1996, AM J HUM GENET, V59, P1006; CAMPISTOL J, 1992, J PEDIATR-US, V121, P83, DOI 10.1016/S0022-3476(05)82548-X; CHRISTENSEN E, 1993, CLIN CHIM ACTA, V220, P71, DOI 10.1016/0009-8981(93)90007-Q; Christensen E, 1997, J INHERIT METAB DIS, V20, P383, DOI 10.1023/A:1005390214391; FLORET D, 1979, ARCH FR PEDIATR, V36, P462; FlottRahmel B, 1997, J INHERIT METAB DIS, V20, P387, DOI 10.1023/A:1005342331229; GOODMAN SI, 1975, BIOCHEM MED METAB B, V12, P12, DOI 10.1016/0006-2944(75)90091-5; GOODMAN SI, 1995, HUM MOL GENET, V4, P1493; Goodman SI, 1998, HUM MUTAT, V12, P141, DOI 10.1002/(SICI)1098-1004(1998)12:3<141::AID-HUMU1>3.0.CO;2-K; GOODMAN SI, 1977, J PEDIATR-US, V90, P746, DOI 10.1016/S0022-3476(77)81240-7; GOODMAN SI, 1995, METABOLIC MOL BASES, P1451; Greene JG, 1998, NEUROSCIENCE, V84, P503, DOI 10.1016/S0306-4522(97)00389-8; HAWORTH JC, 1991, J PEDIATR-US, V118, P52, DOI 10.1016/S0022-3476(05)81843-8; Hoffmann GF, 1996, NEUROPEDIATRICS, V27, P115, DOI 10.1055/s-2007-973761; HOFFMANN GF, 1991, PEDIATRICS, V88, P1194; Kolker S, 1999, J INHERIT METAB DIS, V22, P259; Liesert M, 1999, J INHERIT METAB DIS, V22, P256, DOI 10.1023/A:1005525903207; McDonald JW, 1997, BRAIN RES, V759, P228, DOI 10.1016/S0006-8993(97)00248-5; MERINERO B, 1995, NEUROPEDIATRICS, V26, P238, DOI 10.1055/s-2007-979763; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MORTON DH, 1991, AM J MED GENET, V41, P89, DOI 10.1002/ajmg.1320410122; Muntau AC, 1997, MONATSSCHR KINDERH, V145, P646, DOI 10.1007/s001120050166; Schwartz M, 1998, HUM GENET, V102, P452, DOI 10.1007/s004390050720; ZIADEH R, 1994, 6 INT C INB ERR MET	30	103	112	0	10	KLUWER ACADEMIC PUBL	DORDRECHT	SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS	0141-8955			J INHERIT METAB DIS	J. Inherit. Metab. Dis.	JUN	1999	22	4					381	391		10.1023/A:1005543904484			11	Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental Medicine	204CG	WOS:000080744900006	10407775				2022-02-06	
J	LaPlaca, MC; Lee, VMY; Thibault, LE				LaPlaca, MC; Lee, VMY; Thibault, LE			An in vitro model of traumatic neuronal injury: Loading rate-dependent changes in acute cytosolic calcium and lactate dehydrogenase release	JOURNAL OF NEUROTRAUMA			English	Article						cellular injury; intracellular free calcium; lactate dehydrogenase; mechanical injury; NT2-N cells; traumatic brain injury models	EXPERIMENTAL BRAIN INJURY; NTERA-2 CELLS; INVITRO; CULTURE; ANTAGONISTS; RESPONSES; CONTUSION; PROTEINS; PRIMATE; DAMAGE	We developed a new in vitro model of neuronal injury using NT2-N cells to examine the effects of hydrodynamic loading rate on intraneuronal calcium dynamics and lactate dehydrogenase (LDH) release, Our apparatus consisted of a parallel disk viscometer which induced fluid shear stress with well-defined magnitudes and loading rates to cultured cells, We found that the deformation response of the cells was dependent on the severity of the insult, with increased cellular strains generated for higher shear stresses at a constant loading rate, Peak intracellular free calcium concentration correlated with strain, suggesting that mechanical deformation may regulate calcium response, Slowly applied fluid shear stress elicited no response, whereas high loading rates resulted in peak calcium increases 2.9 to 3.6 times baseline values as injury severity was increased, LDH release measured within 5 min after the insult correlated with loading rate, Zn addition, LDH release continued to increase out to 24 h following high loading rate conditions, demonstrating that the application of fluid shear stress led to prolonged cell damage, The acute response in NT2-N cells subjected to an insult with the CSID is dependent on the loading rate, and these results suggest that initial membrane deformation may trigger subsequent events.	UNIV PENN, DEPT PATHOL & LAB MED, PHILADELPHIA, PA 19104 USA; ALLEGHENY UNIV HLTH SCI, DEPT NEUROSURG, DIV BIOENGN, PHILADELPHIA, PA 19102 USA		LaPlaca, MC (corresponding author), UNIV PENN, DIV NEUROSURG, DEPT BIOENGN, 102B HAYDEN HALL, 3320 SMITH WALK, PHILADELPHIA, PA 19104 USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R491CCR304684] Funding Source: Medline		BALENTINE JD, 1988, LAB INVEST, V58, P93; Cargill RS, 1996, J NEUROTRAUM, V13, P395, DOI 10.1089/neu.1996.13.395; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; CHOI DW, 1990, FID RES FDN, V4, P235; *DEP HLTH HUM SERV, 1989, INT HEAD INJ TASK FO; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENNARELLI TA, 1984, CENTRAL NERVOUS SYST; GENNARELLI TA, 1972, 16 STAPP CAR CRASH C; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; GOLDSTEIN DM, 1994, J NEUROTRAUM, V11, P110; Graham D I, 1993, Acta Neurochir Suppl (Wien), V57, P41; GROSS GW, 1983, J NEUROSCI, V3, P1979; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; LaPlaca MC, 1997, ANN BIOMED ENG, V25, P665, DOI 10.1007/BF02684844; LEE VMY, 1986, J NEUROSCI, V6, P514; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; LUCAS J H, 1990, Journal of Neurotrauma, V7, P169, DOI 10.1089/neu.1990.7.169; LUCAS JH, 1991, BRAIN RES, V543, P181, DOI 10.1016/0006-8993(91)90027-S; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; MCINTOSH TK, 1989, NEUROSCI; MURPHY EJ, 1993, J NEUROTRAUM, V10, P431, DOI 10.1089/neu.1993.10.431; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; ORRENIUS S, 1989, TRENDS PHARMACOL SCI, V10, P281, DOI 10.1016/0165-6147(89)90029-1; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; PLEASURE SJ, 1993, J NEUROSCI RES, V35, P585, DOI 10.1002/jnr.490350603; REGAN RF, 1994, BRAIN RES, V633, P236, DOI 10.1016/0006-8993(94)91544-X; ROE MW, 1990, CELL CALCIUM, V11, P63, DOI 10.1016/0143-4160(90)90060-8; RZIGALINSKI BA, 1996, J NEUROTRAUM, V13, P609; SAATMAN KE, 1994, J NEUROTRAUMA, V11, P125; SCHANNE FAX, 1979, SCIENCE, V206, P700, DOI 10.1126/science.386513; SHEPARD SR, 1991, J SURG RES, V51, P417, DOI 10.1016/0022-4804(91)90144-B; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; SIMON SI, 1990, BIOPHYS J, V58, P319, DOI 10.1016/S0006-3495(90)82379-1; SMITH DH, 1993, J NEUROSCI, V13, P5383, DOI 10.1523/JNEUROSCI.13-12-05383.1993; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; SOMERSON SK, 1987, EXP NEUROL, V96, P82, DOI 10.1016/0014-4886(87)90170-1; TECOMA ES, 1989, NEURON, V2, P1541, DOI 10.1016/0896-6273(89)90042-1; THIBAULT LE, 1993, ACCIDENTAL INJURY BI, P512; THIBAULT LE, 1985, BIOMECHANICS DIFFUSE; TRUMP B F, 1992, Current Opinion in Cell Biology, V4, P227; TYMNAISKI M, 1993, NEURON, V11, P221; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; YOUNG W, 1982, BRAIN RES, V253, P105, DOI 10.1016/0006-8993(82)90677-1	50	103	108	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	1997	14	6					355	368		10.1089/neu.1997.14.355			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	XJ836	WOS:A1997XJ83600001	9219851				2022-02-06	
J	Lahz, S; Bryant, RA				Lahz, S; Bryant, RA			Incidence of chronic pain following traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							HEAD-INJURY; SEVERITY	Objective: To index the frequency of reported chronic pain in patients with traumatic brain injury (TBI). Design: A case series study was conducted on consecutive patients with TBI. Setting: TBI patients were recruited from an adult tertiary care center brain injury clinic. Patients: A consecutive sample of 132 patients who attended a brain injury rehabilitation center after TBI. The sample included 53 mild and 79 moderate/severe TBI patients. Outcome Measures: Patients were administered a protocol that indexed pain site, frequency, severity, and duration. Results: Chronic pain was reported by 58% of mild TBI and 52% of moderate/severe TBI patients. Headaches were the most commonly reported pain problem. Chronic headaches were reported by 47% of mild TBI patients and 34% of moderate/severe TBI patients. Neck/shoulder, back, upper limb, and lower limb pain were reported similarly by mild and moderate/severe TBI patients. Conclusions: Findings indicate that chronic pain is a significant problem in mild and moderate/severe TBI patients. More effective diagnosis of TBI patients with chronic pain may facilitate rehabilitation of these patients. (C) 1996 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation	UNIV NEW S WALES,SCH PSYCHOL,SYDNEY,NSW 2052,AUSTRALIA; WESTMEAD HOSP,BRAIN INJURY REHABIL UNIT,WESTMEAD,NSW 2145,AUSTRALIA				Bryant, Richard/AAA-6479-2019	Bryant, Richard/0000-0002-9607-819X			ANDERSON JM, 1990, ARCH PHYS MED REHAB, V71, P703; Bohnen N., 1992, J NERV MENT DIS, V180, P183; BRYANT RA, 1993, PAIN, V52, P379; GELLMAN H, 1992, PAIN, V51, P307, DOI 10.1016/0304-3959(92)90214-V; GROSWASSER Z, 1990, Brain Injury, V4, P161, DOI 10.3109/02699059009026161; HORN IJ, 1990, REHABILITATION ADULT, P107; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; MOORE A D, 1992, Brain Injury, V6, P89, DOI 10.3109/02699059209008129; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; TEASDALE G, 1974, LANCET, V2, P81; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; UOMOTO JM, 1990, KRUSENS HDB PHYSICAL, P1252; YAMAGUCHI M, 1992, HEADACHE, V32, P427, DOI 10.1111/j.1526-4610.1992.hed3209427.x	14	103	103	0	0	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	1996	77	9					889	891		10.1016/S0003-9993(96)90275-0			3	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	VG419	WOS:A1996VG41900008	8822679				2022-02-06	
J	KACZOROWSKI, SL; SCHIDING, JK; TOTH, CA; KOCHANEK, PM				KACZOROWSKI, SL; SCHIDING, JK; TOTH, CA; KOCHANEK, PM			EFFECT OF SOLUBLE COMPLEMENT RECEPTOR-1 ON NEUTROPHIL ACCUMULATION AFTER TRAUMATIC BRAIN INJURY IN RATS	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						BRAIN; COMPLEMENT; NEUTROPHIL; RAT; TRAUMA	INFLAMMATION; TISSUE; TYPE-1; REPERFUSION; LEUKOCYTES; SYSTEM; ASSAY	As part of the acute inflammatory response, neutrophils accumulate in the central nervous system after injury. Recently, a soluble human recombinant complement receptor (sCR1; BRL 55730; T Cell Sciences, Inc., Cambridge, MA, U.S.A.) has been developed that inhibits the activation of both the classical and the alternative pathways of complement. sCR1 attenuates the effects of the acute inflammatory response in several models of injury outside the central nervous system. The role of complement in traumatic brain injury, however, remains undefined. We hypothesized that treatment with sCR1 would attenuate neutrophil accumulation in the brain after cerebral trauma. Using a randomized, blinded protocol, 18 anesthetized Sprague-Dawley rats were pretreated with sCR1 or saline (control) at both 2 h and 2 min before trauma (weight drop) to the exposed right parietal cortex. A third dose of sCR1 (or saline) was given 6 h after trauma. Coronal brain sections centered on the site of trauma were obtained at 24 h after trauma and analyzed for myeloperoxidase (MPO) activity as a marker of neutrophil accumulation. Complete blood counts with differential were obtained before treatment with sCR1 and at 24 h after trauma. At 24 h after trauma, brain MPO activity was reduced by 41% in sCR1-treated rats compared with control rats [0.1599 +/- 0.102 versus 0.2712 +/- 0.178 U/g (mean +/- SD); p = 0.02]. The neutrophil count in peripheral blood increased approximately twofold in both groups. Neutrophil accumulation occurring in the brain after trauma is inhibited by sCR1 treatment. This suggests that complement activation is involved in the local inflammatory response to traumatic brain injury and plays an important role in neutrophil accumulation in the injured brain.	UNIV PITTSBURGH,SCH MED,DEPT ANESTHESIOL & CRIT CARE MED,PITTSBURGH,PA 15261; UNIV PITTSBURGH,SCH MED,DEPT PEDIAT,PITTSBURGH,PA 15261; T CELL SCI INC,CAMBRIDGE,MA				Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X			BARONE FC, 1991, J NEUROSCI RES, V29, P336, DOI 10.1002/jnr.490290309; BECKER P, 1987, ANAESTHESIST, V36, P301; BIAGAS KV, 1992, J NEUROTRAUM, V9, P363, DOI 10.1089/neu.1992.9.363; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; CHOPP M, 1993, STROKE, V25, P869; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; DAVIES CL, 1984, J TRAUMA, V24, P99, DOI 10.1097/00005373-198402000-00002; DELZOPPO GJ, 1991, STROKE, V22, P1276, DOI 10.1161/01.STR.22.10.1276; FEARON D T, 1991, Clinical and Experimental Immunology, V86, P43; FRIEDL HP, 1989, AM J PATHOL, V135, P203; GALLINARO R, 1992, SURG GYNECOL OBSTET, V174, P435; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; HILL J, 1992, J IMMUNOL, V149, P1723; HORNER HC, 1992, SOC NEUR ABSTR, V8, P173; KATORI M, 1989, JPN J PHARMACOL, V50, P234, DOI 10.1254/jjp.50.234; MULLIGAN MS, 1992, J IMMUNOL, V148, P1479; NILSSON UR, 1967, J EXP MED, V125, P1, DOI 10.1084/jem.125.1.1; PASNINETTI GM, 1992, EXP NEUROL, V188, P117; REBHUN J, 1991, ANN ALLERGY, V66, P335; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; TUOMANEN E, 1986, MICROB PATHOGENESIS, V1, P15, DOI 10.1016/0882-4010(86)90028-8; UHL MW, 1994, J NEUROTRAUM, V11, P303, DOI 10.1089/neu.1994.11.303; WEISMAN HF, 1990, SCIENCE, V249, P146, DOI 10.1126/science.2371562; WILLIAMS CA, 1984, J NEUROIMMUNOL, V9, P29; YEH CG, 1991, J IMMUNOL, V146, P250	25	103	104	0	1	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	SEP	1995	15	5					860	864		10.1038/jcbfm.1995.107			5	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	RQ020	WOS:A1995RQ02000016	7673379	Bronze			2022-02-06	
J	DAWSON, DR; CHIPMAN, M				DAWSON, DR; CHIPMAN, M			THE DISABLEMENT EXPERIENCED BY TRAUMATICALLY BRAIN-INJURED ADULTS LIVING IN THE COMMUNITY	BRAIN INJURY			English	Article							CLOSED HEAD-INJURY; FOLLOW-UP; IMPAIRMENT; RECOVERY; DISABILITY; CONCUSSION; SKILLS; LONG	The disablement that occurs following traumatic brain injury (TBI) can be extensive and severe and consequently has been difficult to report on in a comprehensive and thorough manner. We were able to address this difficulty by analysing a sub group of data from the Canadian Health and Activity Limitation Survey (HALS) using the theoretical framework of disablement developed by the World Health Organization, the International Classification of Impairment, Disability and Handicap (ICIDH). There were 454 survey respondents (representing 12290 in the Canadian population) with disability resulting from a TBI and a mean time post-injury of 13 years. Three handicaps identified in the ICIDH were the focus of the study: physical independence, work, social integration. The prevalence of long term handicap was very high with 66% of the sample reporting the need for ongoing assistance with some activities of daily living, 75% not working, and 90% reporting some limitations or dissatisfaction with their social integration. Multivariate regression analysis was used to investigate the determinants of the handicaps. The determinants included: age, gender, level of education, living alone, physical environment, and specific disabilities. The implications of these findings are discussed in relation to rehabilitation issues, the usefulness of the ICIDH as a model to investigate outcomes, and directions for future research.	SUNNYBROOK HLTH SCI CTR,TORONTO,ON M4N 3M5,CANADA; UNIV TORONTO,DEPT PREVENT MED & BIOSTAT,TORONTO,ON,CANADA		DAWSON, DR (corresponding author), UNIV TORONTO,DEPT OCCUPAT THERAPY,256 MCCAUL ST,TORONTO,ON M5T 1W5,CANADA.		Dawson, Deirdre R/I-8882-2014	Dawson, Deirdre R/0000-0001-7517-6121			[Anonymous], 1980, INT CLASSIFICATION I; Asberg K H, 1988, Scand J Caring Sci, V2, P171; Badley E M, 1987, Int Disabil Stud, V9, P122; Badley E M, 1990, Int Disabil Stud, V12, P47; BERROL S, 1989, TRAUMATIC BRAIN INJU, V2, P31; Bryden J, 1989, MODELS BRAIN INJURY, P17; DAWSON DR, 1993, THESIS U TORONTO; DEATON A, 1993, BRAIN INJURY, V2, P99; DOLSON D, 1987, SUURVEY METHODOLOGY, V13, P93; FURRIE A, 1989, HLTH ACTIVITY LIMITA; Granger C V, 1985, Int Rehabil Med, V7, P45; GRONWALL D, 1975, LANCET, V2, P995; GRONWALL D, 1974, LANCET, V2, P605; HAFFEY W, 1989, MODELS BRAIN INJURY, P205; HAHN H, 1985, SOC SCI J, V22, P87; Hamilton BB, 1987, REHABILITATION OUTCO, P137; HERBERT R, 1988, AGE AGEING, V17, P293; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; JOHNSON R, 1987, INJURY, V18, P7, DOI 10.1016/0020-1383(87)90374-3; JOHNSTON MV, 1991, AM J PHYS MED REHAB, V70, pS114; KAY T, 1986, MINOR HEAD INJURY IN; KLEIN RM, 1982, ARCH PHYS MED REHAB, V63, P335; KORN EL, 1991, AM J PUBLIC HEALTH, V81, P1166, DOI 10.2105/AJPH.81.9.1166; LAVIGNE M, 1991, 82615 MIN SUPPL SERV, V4; LEZAK MD, 1990, TRAUMATIC BRAIN INJU, P365; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; MAHONEY F I, 1965, Md State Med J, V14, P61; MAURETTE P, 1992, J TRAUMA, V33, P728, DOI 10.1097/00005373-199211000-00023; MCDOWELL I, 1988, HLTH ADTIVITY LIMITA; Mckinnon A. L, 1992, CANADIAN J OCCUPATIO, V59, P102, DOI [10.1177/000841749205900206, DOI 10.1177/000841749205900206]; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; MILLS V M, 1992, Brain Injury, V6, P219, DOI 10.3109/02699059209029663; Naugle RI, 1990, TRAUMATIC BRAIN INJU, P69; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; PANIKOFF LB, 1983, AM J OCCUP THER, V37, P735, DOI 10.5014/ajot.37.11.735; PARKINSON D, 1985, CAN J SURG, V28, P79; POPE AM, 1991, DISABILITY AM, P309; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; RAO N, 1990, Brain Injury, V4, P49, DOI 10.3109/02699059009026148; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; SPECTOR WD, 1987, J CHRON DIS, V40, P481, DOI 10.1016/0021-9681(87)90004-X; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; STRUGAR J, 1993, J TRAUMA, V34, P555, DOI 10.1097/00005373-199304000-00012; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Vogenthaler D R, 1989, Brain Inj, V3, P355, DOI 10.3109/02699058909004560; Vogenthaler D R, 1989, Brain Inj, V3, P369, DOI 10.3109/02699058909004561; WILLER B, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P18; 1989, UNPUB INTERAGENCY HE; 1991, SERVICES PROGRAMS AL; 1988, HLTH ACTIVITY LIMITA	52	103	103	0	8	TAYLOR & FRANCIS LTD LONDON	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	MAY-JUN	1995	9	4					339	353		10.3109/02699059509005774			15	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	QY080	WOS:A1995QY08000002	7640680				2022-02-06	
J	DEKOSKY, ST; GOSS, JR; MILLER, PD; STYREN, SD; KOCHANEK, PM; MARION, D				DEKOSKY, ST; GOSS, JR; MILLER, PD; STYREN, SD; KOCHANEK, PM; MARION, D			UP-REGULATION OF NERVE GROWTH-FACTOR FOLLOWING CORTICAL TRAUMA	EXPERIMENTAL NEUROLOGY			English	Article							ADULT-RAT BRAIN; MESSENGER-RNA; HEAD-INJURY; CHOLINERGIC NEURONS; NEUROTROPHIC FACTOR; ASTROCYTE CULTURES; ASTROGLIAL CELLS; SYSTEM TRAUMA; INTERLEUKIN-1; EXPRESSION	As part of the inflammatory response to brain injury, CSF and tissue levels of interleukin-1 beta (IL-1 beta) are elevated after trauma. This elevation in IL-1 beta initiates a cascade of events among which may be an upregulation in nerve growth factor (NGF) in brain tissue. We infused IL-1 beta into the ventricle of adult rats and found a two- to fourfold increase in NGF in the cerebral cortex, hippocampus, and cerebellum, suggesting that IL-1 beta induced in vivo may also increase NGF in the brain. To test this hypothesis we utilized two models of traumatic brain injury (TBI) in the rat and examined NGF protein and RNA in the cortex over a period of several days. Both weight drop and controlled cortical contusion models of CNS trauma demonstrated large and significant increases in NGF protein in the cortex. NGF RNA was assessed in the controlled cortical contusion model and increased approximately fivefold by 1 day post-trauma. The remarkable elevation of NGF observed following TBI suggests that its role in response to injury may be other than as a target derived growth substance. We hypothesize that the elevation of NGF in trauma induces upregulation of enzymes which suppress free-radical formation after injury. (C) 1994 Academic Press, Inc.	UNIV PITTSBURGH,SCH MED,DEPT NEUROL,PITTSBURGH,PA 15261; UNIV PITTSBURGH,SCH MED,DEPT NEUROBIOL,PITTSBURGH,PA 15261; UNIV PITTSBURGH,SCH MED,DEPT NEUROL SURG,PITTSBURGH,PA 15261; UNIV PITTSBURGH,SCH MED,DEPT ANESTHESIOL,PITTSBURGH,PA 15261; WESTERN PSYCHIAT INST & CLIN,PITTSBURGH,PA		DEKOSKY, ST (corresponding author), UNIV PITTSBURGH,SCH MED,DEPT PSYCHIAT,PITTSBURGH,PA, USA.		Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; DeKosky, Steven/0000-0003-3743-2758	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318, P20NS030318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005133] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG05133] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30318] Funding Source: Medline		BAKHIT C, 1991, BRAIN RES, V560, P76, DOI 10.1016/0006-8993(91)91217-O; BALLARIN M, 1991, EXP NEUROL, V114, P35, DOI 10.1016/0014-4886(91)90082-N; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DACUNHA A, 1993, J NEUROIMMUNOL, V42, P71, DOI 10.1016/0165-5728(93)90214-J; DEKOSKY ST, 1994, J NEUROTRAUMA, V11, P106; DREYFUS CF, 1989, TRENDS PHARMACOL SCI, V10, P145, DOI 10.1016/0165-6147(89)90166-1; FAN L, 1993, SOC NEUR ABSTR, V19; FARRAR WL, 1987, J IMMUNOL, V139, P459; FRIEDMAN WJ, 1990, J NEUROSCI RES, V27, P374, DOI 10.1002/jnr.490270316; FURUKAWA S, 1986, BIOCHEM BIOPH RES CO, V136, P57, DOI 10.1016/0006-291X(86)90876-4; GIULIAN D, 1988, J NEUROSCI, V8, P709; HAGG T, 1988, EXP NEUROL, V101, P303, DOI 10.1016/0014-4886(88)90013-1; Hall E D, 1991, J Neurotrauma, V8 Suppl 1, pS31; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; HALL ED, 1987, J PHARMACOL EXP THER, V242, P137; HEFTI F, 1986, J NEUROSCI, V6, P2155; JOHNSON EM, 1988, TRENDS NEUROSCI, V11, P299, DOI 10.1016/0166-2236(88)90090-2; Kochanek P, 1991, J NEUROTRAUM, V8, P19, DOI 10.1089/neu.1991.8.19; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KROMER LF, 1987, SCIENCE, V235, P214, DOI 10.1126/science.3798108; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; LINDHOLM D, 1988, J BIOL CHEM, V263, P16348; Lindholm D, 1990, Neuroreport, V1, P9; LINDSAY RM, 1982, BRAIN RES, V243, P329, DOI 10.1016/0006-8993(82)90257-8; LIU T, 1993, STROKE, V24, P1746, DOI 10.1161/01.STR.24.11.1746; LOREZ H, 1989, NEUROSCI LETT, V98, P339, DOI 10.1016/0304-3940(89)90425-4; LOREZ HP, 1988, BRAIN RES, V454, P355, DOI 10.1016/0006-8993(88)90837-2; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; NIETOSAMPEDRO M, 1987, J NEUROSCI RES, V17, P214, DOI 10.1002/jnr.490170303; PAN ZH, 1993, J NEUROCHEM, V61, P1713, DOI 10.1111/j.1471-4159.1993.tb09808.x; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; ROCAMORA N, 1992, MOL BRAIN RES, V13, P27, DOI 10.1016/0169-328X(92)90041-9; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; SPINA MB, 1992, J NEUROCHEM, V59, P99, DOI 10.1111/j.1471-4159.1992.tb08880.x; SPRANGER M, 1990, EUR J NEUROSCI, V2, P69, DOI 10.1111/j.1460-9568.1990.tb00382.x; TAKAO T, 1990, NEUR ABSTR, V16, P1213; TIMMUSK T, 1992, SOC NEUR ABSTR, V18; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; WETMORE C, 1992, SOC NEUR ABSTR, V18; WHITTEMORE SR, 1987, BRAIN RES REV, V12, P439, DOI 10.1016/0165-0173(87)90008-7; WHITTEMORE SR, 1988, J NEUROSCI RES, V20, P403, DOI 10.1002/jnr.490200402; YOUNG AB, 1988, J NEUROSURG, V69, P375, DOI 10.3171/jns.1988.69.3.0375	45	103	107	0	1	ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS	SAN DIEGO	525B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495	0014-4886			EXP NEUROL	Exp. Neurol.	DEC	1994	130	2					173	177		10.1006/exnr.1994.1196			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	QJ162	WOS:A1994QJ16200001	7867748				2022-02-06	
J	PANTER, SS; FADEN, AI				PANTER, SS; FADEN, AI			PRETREATMENT WITH NMDA ANTAGONISTS LIMITS RELEASE OF EXCITATORY AMINO-ACIDS FOLLOWING TRAUMATIC BRAIN INJURY	NEUROSCIENCE LETTERS			English	Article						CGS-19755; DEXTRORPHAN; EXTRACELLULAR EXCITATORY AMINO ACID; HIPPOCAMPUS; MICRODIALYSIS; N-METHYL-D-ASPARTATE ANTAGONIST; TRAUMATIC BRAIN INJURY	SPINAL-CORD INJURY; CEREBRAL-ISCHEMIA; INTRACEREBRAL MICRODIALYSIS; RECEPTOR ANTAGONIST; ASPARTATE; GLUTAMATE; RAT; CGS-19755	After central nervous system (CNS) trauma, there are marked elevations in the extracellular levels of excitatory amino acids (EAA), which are believed to contribute to delayed tissue damage. Administration of N-methyl-D-aspartate (NMDA) receptor antagonists reduces injury severity after brain or spinal cord trauma, presumably by blocking the postsynaptic NMDA receptor. In the present studies, levels of extracellular amino acids were monitored by microdialysis during, and after, a moderately severe fluid-percussion brain injury to rats. Pretreatment (15 min prior to injury) with the non-competitive NMDA antagonist dextrorphan or the competitive NMDA antagonist CGS 19755 significantly attenuated the post-traumatic increase in extracellular glutamate. Pretreatment with dextrorphan attenuated the post-traumatic increase in extracellular levels of aspartate; although these differences did not reach significance when examined as absolute values, they were significant when analyzed as percent increase over pre-trauma baseline levels. These results are consistent with recent experiments and suggest that NMDA antagonists may limit the release of glutamate and aspartate after trauma through a presynaptic mechanism.	LETTERMAN ARMY INST RES,DIV BLOOD RES,SAN FRANCISCO,CA 94129; GEORGETOWN UNIV,SCH MED,DEPT NEUROL & PHARMACOL,WASHINGTON,DC 20007						NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027849] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [SR01NS27849-02] Funding Source: Medline		ALBERS GW, 1989, ANN NEUROL, V25, P398, DOI 10.1002/ana.410250412; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; CRAWFORD D, 1989, SOC NEUR ABSTR, V15, P358; FADEN AI, 1990, EUR J PHARMACOL, V175, P165, DOI 10.1016/0014-2999(90)90227-W; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GLOBUS MYT, 1988, J NEUROCHEM, V51, P1455, DOI 10.1111/j.1471-4159.1988.tb01111.x; GOMEZPINILLA F, 1989, EXP NEUROL, V104, P118, DOI 10.1016/S0014-4886(89)80004-4; GRAHAM SH, 1990, NEUROSCI LETT, V110, P124, DOI 10.1016/0304-3940(90)90799-F; GROTTA JC, 1990, ANN NEUROL, V27, P612, DOI 10.1002/ana.410270605; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; LEHMANN J, 1988, J PHARMACOL EXP THER, V246, P65; LOBNER D, 1989, Society for Neuroscience Abstracts, V15, P358; MCBEAN GJ, 1981, NATURE, V291, P593, DOI 10.1038/291593a0; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MORIMOTO BH, 1990, P NATL ACAD SCI USA, V87, P3518, DOI 10.1073/pnas.87.9.3518; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; PANTER SS, 1990, ANN NEUROL, V28, P594, DOI 10.1002/ana.410280431; PANTER SS, 1990, ANN NEUROL, V27, P96, DOI 10.1002/ana.410270115; SIMON R, 1990, ANN NEUROL, V27, P606, DOI 10.1002/ana.410270604; SNEDECOR GW, 1980, STATISTICAL METHODS, P333; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16	24	103	104	0	1	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	MAR 2	1992	136	2					165	168		10.1016/0304-3940(92)90040-E			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HG894	WOS:A1992HG89400008	1353624				2022-02-06	
J	Chen, X; Park, YJ; Kang, M; Kang, SK; Koo, J; Shinde, SM; Shin, J; Jeon, S; Park, G; Yan, Y; MacEwan, MR; Ray, WZ; Lee, KM; Rogers, JA; Ahn, JH				Chen, Xiang; Park, Yong Ju; Kang, Minpyo; Kang, Seung-Kyun; Koo, Jahyun; Shinde, Sachin M.; Shin, Jiho; Jeon, Seunghyun; Park, Gayoung; Yan, Ying; MacEwan, Matthew R.; Ray, Wilson Z.; Lee, Kyung-Mi; Rogers, John A.; Ahn, Jong-Hyun			CVD-grown monolayer MoS2 in bioabsorbable electronics and biosensors	NATURE COMMUNICATIONS			English	Article							CHEMICAL-VAPOR-DEPOSITION; TRANSITION-METAL DICHALCOGENIDES; THIN-FILM TRANSISTORS; MOLYBDENUM-DISULFIDE; LAYER MOS2; TRANSIENT ELECTRONICS; GRAIN-BOUNDARIES; GRAPHENE; WS2; INTERCALATION	Transient electronics represents an emerging technology whose defining feature is an ability to dissolve, disintegrate or otherwise physically disappear in a controlled manner. Envisioned applications include resorbable/degradable biomedical implants, hardware-secure memory devices, and zero-impact environmental sensors. 2D materials may have essential roles in these systems due to their unique mechanical, thermal, electrical, and optical properties. Here, we study the bioabsorption of CVD-grown monolayer MoS2, including long-term cytotoxicity and immunological biocompatibility evaluations in biofluids and tissues of live animal models. The results show that MoS2 undergoes hydrolysis slowly in aqueous solutions without adverse biological effects. We also present a class of MoS2-based bioabsorbable and multi-functional sensor for intracranial monitoring of pressure, temperature, strain, and motion in animal models. Such technology offers specific, clinically relevant roles in diagnostic/therapeutic functions during recovery from traumatic brain injury. Our findings support the broader use of 2D materials in transient electronics and qualitatively expand the design options in other areas.	[Chen, Xiang; Park, Yong Ju; Kang, Minpyo; Shinde, Sachin M.; Ahn, Jong-Hyun] Yonsei Univ, Sch Elect & Elect Engn, 50 Yonsei Ro, Seoul 03722, South Korea; [Kang, Seung-Kyun] Korea Adv Inst Sci & Technol, KI Hlth Sci & Technol KIHST, Dept Bio & Brain Engn, Daejeon 34141, South Korea; [Koo, Jahyun; Rogers, John A.] Northwestern Univ, Dept Mat Sci & Engn, Evanston, IL 60208 USA; [Shin, Jiho; Rogers, John A.] Univ Illinois, Frederick Seitz Mat Res Lab, Urbana, IL 61801 USA; [Jeon, Seunghyun; Park, Gayoung; Lee, Kyung-Mi] Korea Univ, Coll Med, Dept Biochem & Mol Biol, Seoul 02841, South Korea; [Yan, Ying; MacEwan, Matthew R.; Ray, Wilson Z.] Washington Univ, Sch Med, Dept Neurol Surg, St Louis, MO 63110 USA; [Rogers, John A.] Northwestern Univ, Simpson Querrey Inst Nano Biotechnol, Ctr Bio Integrated Elect, Dept Biomed Engn, Evanston, IL 60208 USA; [Rogers, John A.] Northwestern Univ, Simpson Querrey Inst Nano Biotechnol, Ctr Bio Integrated Elect, Dept Chem, Evanston, IL 60208 USA; [Rogers, John A.] Northwestern Univ, Simpson Querrey Inst Nano Biotechnol, Ctr Bio Integrated Elect, Dept Mech Engn, Evanston, IL 60208 USA; [Rogers, John A.] Northwestern Univ, Simpson Querrey Inst Nano Biotechnol, Ctr Bio Integrated Elect, Dept Elect Engn, Evanston, IL 60208 USA; [Rogers, John A.] Northwestern Univ, Simpson Querrey Inst Nano Biotechnol, Ctr Bio Integrated Elect, Dept Comp Sci, Evanston, IL 60208 USA		Ahn, JH (corresponding author), Yonsei Univ, Sch Elect & Elect Engn, 50 Yonsei Ro, Seoul 03722, South Korea.; Rogers, JA (corresponding author), Northwestern Univ, Dept Mat Sci & Engn, Evanston, IL 60208 USA.; Rogers, JA (corresponding author), Univ Illinois, Frederick Seitz Mat Res Lab, Urbana, IL 61801 USA.; Lee, KM (corresponding author), Korea Univ, Coll Med, Dept Biochem & Mol Biol, Seoul 02841, South Korea.; Rogers, JA (corresponding author), Northwestern Univ, Simpson Querrey Inst Nano Biotechnol, Ctr Bio Integrated Elect, Dept Biomed Engn, Evanston, IL 60208 USA.; Rogers, JA (corresponding author), Northwestern Univ, Simpson Querrey Inst Nano Biotechnol, Ctr Bio Integrated Elect, Dept Chem, Evanston, IL 60208 USA.; Rogers, JA (corresponding author), Northwestern Univ, Simpson Querrey Inst Nano Biotechnol, Ctr Bio Integrated Elect, Dept Mech Engn, Evanston, IL 60208 USA.; Rogers, JA (corresponding author), Northwestern Univ, Simpson Querrey Inst Nano Biotechnol, Ctr Bio Integrated Elect, Dept Elect Engn, Evanston, IL 60208 USA.; Rogers, JA (corresponding author), Northwestern Univ, Simpson Querrey Inst Nano Biotechnol, Ctr Bio Integrated Elect, Dept Comp Sci, Evanston, IL 60208 USA.	kyunglee@korea.ac.kr; jrogers@northwestern.edu; ahnj@yonsei.ac.kr	Ahn, Jong-Hyun/L-9825-2016; Kang, Seung-Kyun/L-3053-2017; Chen, Xiang/AAO-6631-2020; Rogers, John/L-2798-2016; huang, yonggang/O-6236-2019	Ahn, Jong-Hyun/0000-0002-8135-7719; Chen, Xiang/0000-0001-5100-1482; Jeon, Seunghyun/0000-0002-4320-2644; Lee, Kyung-Mi/0000-0002-5378-9258; Koo, Jahyun/0000-0003-1503-0731; WANG, KE/0000-0003-2004-2745	National Research Foundation of Korea (NRF) - Korean government (MSIT) [NRF-2015R1A3A2066337, NRF-2016M3A9B6948342]	This work was supported by the National Research Foundation of Korea (NRF) funded by the Korean government (MSIT) (NRF-2015R1A3A2066337, NRF-2016M3A9B6948342).	Appel JH, 2016, ACS BIOMATER SCI ENG, V2, P361, DOI 10.1021/acsbiomaterials.5b00467; Bettinger CJ, 2010, ADV MATER, V22, P651, DOI 10.1002/adma.200902322; Camposeo A, 2014, ACS NANO, V8, P10893, DOI 10.1021/nn504720b; Chen CR, 2016, ACS NANO, V10, P10389, DOI 10.1021/acsnano.6b06256; Chen X, 2016, NANOSCALE, V8, P15181, DOI 10.1039/c6nr03318k; Dungey KE, 1998, J CATAL, V175, P129, DOI 10.1006/jcat.1998.1963; Fu KK, 2016, CHEM MATER, V28, P3527, DOI 10.1021/acs.chemmater.5b04931; Gan XR, 2017, BIOSENS BIOELECTRON, V89, P56, DOI 10.1016/j.bios.2016.03.042; Ganatra R, 2014, ACS NANO, V8, P4074, DOI 10.1021/nn405938z; Gao J, 2016, ACS NANO, V10, P2628, DOI 10.1021/acsnano.5b07677; Hao JL, 2017, ADV SCI, V4, DOI 10.1002/advs.201600160; Hwang SW, 2014, ADV MATER, V26, P3905, DOI 10.1002/adma.201306050; Hwang SW, 2013, ADV FUNCT MATER, V23, P4087, DOI 10.1002/adfm.201300127; Irimia-Vladu M, 2010, ADV FUNCT MATER, V20, P4069, DOI 10.1002/adfm.201001031; Jia XT, 2016, ADV FUNCT MATER, V26, P1454, DOI 10.1002/adfm.201503498; Kalantar-zadeh K, 2015, ADV FUNCT MATER, V25, P5086, DOI 10.1002/adfm.201500891; Kang K, 2015, NATURE, V520, P656, DOI 10.1038/nature14417; Kang SK, 2014, ADV FUNCT MATER, V24, P4427, DOI 10.1002/adfm.201304293; Kurapati R, 2017, ADV FUNCT MATER, V27, DOI 10.1002/adfm.201605176; Lee G, 2017, ADV ENERGY MATER, V7, DOI 10.1002/aenm.201700157; Lee W, 2015, SMALL, V11, P6272, DOI 10.1002/smll.201502338; Lee YH, 2012, ADV MATER, V24, P2320, DOI 10.1002/adma.201104798; Lin Z, 2016, 2D MATER, V3, DOI 10.1088/2053-1583/3/4/042001; Ling X, 2014, NANO LETT, V14, P464, DOI 10.1021/nl4033704; Mittal R, 2005, INJURY, V36, P333, DOI 10.1016/j.injury.2004.09.015; Park G, 2014, ADV HEALTHC MATER, V3, P515, DOI 10.1002/adhm.201300220; Park J, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad8568; Park K, 2010, ADV FUNCT MATER, V20, P3577, DOI 10.1002/adfm.201001107; Park M, 2016, ADV MATER, V28, P2556, DOI 10.1002/adma.201505124; Park W, 2014, ACS NANO, V8, P4961, DOI 10.1021/nn501019g; Radisavljevic B, 2011, NAT NANOTECHNOL, V6, P147, DOI [10.1038/nnano.2010.279, 10.1038/NNANO.2010.279]; Rong YM, 2015, ACS NANO, V9, P3695, DOI 10.1021/acsnano.5b00852; ROSS S, 1955, J PHYS CHEM-US, V59, P889, DOI 10.1021/j150531a020; Santosh KC, 2015, J APPL PHYS, V117, DOI 10.1063/1.4916536; Tan CL, 2017, CHEM REV, V117, P6225, DOI 10.1021/acs.chemrev.6b00558; Tan MJ, 2016, J MATER CHEM C, V4, P5531, DOI 10.1039/c6tc00678g; Teo WZ, 2014, CHEM-EUR J, V20, P9627, DOI 10.1002/chem.201402680; van der Zande AM, 2013, NAT MATER, V12, P554, DOI [10.1038/nmat3633, 10.1038/NMAT3633]; Wang LF, 2014, J AM CHEM SOC, V136, P6693, DOI 10.1021/ja501686w; Wang XF, 2014, ACS NANO, V8, P11394, DOI 10.1021/nn505501v; Wang ZY, 2016, ENVIRON SCI TECHNOL, V50, P7208, DOI 10.1021/acs.est.6b01881; Wu HH, 2011, ACS NANO, V5, P1276, DOI 10.1021/nn102941b; Wu LB, 2004, BIOMATERIALS, V25, P5821, DOI 10.1016/j.biomaterials.2004.01.038; Yamamoto M, 2013, J PHYS CHEM C, V117, P25643, DOI 10.1021/jp410893e; Yang LM, 2014, NANO LETT, V14, P6275, DOI 10.1021/nl502603d; Yin L, 2015, ADV MATER, V27, P1857, DOI 10.1002/adma.201404579; Yin L, 2014, ADV FUNCT MATER, V24, P645, DOI 10.1002/adfm.201301847; Yin XB, 2014, SCIENCE, V344, P488, DOI 10.1126/science.1250564; Yu KJ, 2016, NAT MATER, V15, P782, DOI [10.1038/NMAT4624, 10.1038/nmat4624]; Zhang J, 2014, ACS NANO, V8, P6024, DOI 10.1021/nn5020819; Zhang LQ, 2016, RSC ADV, V6, P96035, DOI 10.1039/c6ra18188k; Zheng Q, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1501478; Zhou W, 2013, NANO LETT, V13, P2615, DOI 10.1021/nl4007479	53	102	104	23	140	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2041-1723			NAT COMMUN	Nat. Commun.	APR 27	2018	9								1690	10.1038/s41467-018-03956-9			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE1WV	WOS:000431008400006	29703901	gold, Green Published			2022-02-06	
J	Alosco, ML; Kasimis, AB; Stamm, JM; Chua, AS; Baugh, CM; Daneshvar, DH; Robbins, CA; Mariani, M; Hayden, J; Conneely, S; Au, R; Torres, A; McClean, MD; McKee, AC; Cantu, RC; Mez, J; Nowinski, CJ; Martin, BM; Chaisson, CE; Tripodis, Y; Stern, RA				Alosco, M. L.; Kasimis, A. B.; Stamm, J. M.; Chua, A. S.; Baugh, C. M.; Daneshvar, D. H.; Robbins, C. A.; Mariani, M.; Hayden, J.; Conneely, S.; Au, R.; Torres, A.; McClean, M. D.; McKee, A. C.; Cantu, R. C.; Mez, J.; Nowinski, C. J.; Martin, B. M.; Chaisson, C. E.; Tripodis, Y.; Stern, R. A.			Age of first exposure to American football and long-term neuropsychiatric and cognitive outcomes	TRANSLATIONAL PSYCHIATRY			English	Article							CHRONIC TRAUMATIC ENCEPHALOPATHY; HEAD IMPACT EXPOSURE; SPORTS-RELATED CONCUSSION; HIGH-SCHOOL FOOTBALL; RETIRED NFL PLAYERS; LEAGUE PLAYERS; ADULT COGNITION; YOUTH FOOTBALL; BRAIN-INJURY; RECURRENT CONCUSSION	Previous research suggests that age of first exposure (AFE) to football before age 12 may have long-term clinical implications; however, this relationship has only been examined in small samples of former professional football players. We examined the association between AFE to football and behavior, mood and cognition in a large cohort of former amateur and professional football players. The sample included 214 former football players without other contact sport history. Participants completed the Brief Test of Adult Cognition by Telephone (BTACT), and self-reported measures of executive function and behavioral regulation (Behavior Rating Inventory of Executive Function-Adult Version Metacognition Index (MI), Behavioral Regulation Index (BRI)), depression (Center for Epidemiologic Studies Depression Scale (CES-D)) and apathy (Apathy Evaluation Scale (AES)). Outcomes were continuous and dichotomized as clinically impaired. AFE was dichotomized into <12 and >= 12, and examined continuously. Multivariate mixed-effect regressions controlling for age, education and duration of play showed AFE to football before age 12 corresponded with >2 x increased odds for clinically impaired scores on all measures but BTACT: (odds ratio (OR), 95% confidence interval (CI): BRI, 2.16,1.19-3.91; MI, 2.10,1.17-3.76; CES-D, 3.08,1.65-5.76; AES, 2.39,1.32-4.32). Younger AFE predicted increased odds for clinical impairment on the AES (OR, 95% CI: 0.86, 0.76-0.97) and CES-D (OR, 95% CI: 0.85,0.74-0.97). There was no interaction between AFE and highest level of play. Younger AFE to football, before age 12 in particular, was associated with increased odds for impairment in self-reported neuropsychiatric and executive function in 214 former American football players. Longitudinal studies will inform youth football policy and safety decisions.	[Alosco, M. L.; Kasimis, A. B.; Stamm, J. M.; Baugh, C. M.; Daneshvar, D. H.; Robbins, C. A.; Mariani, M.; Hayden, J.; Conneely, S.; McKee, A. C.; Cantu, R. C.; Mez, J.; Nowinski, C. J.; Martin, B. M.; Chaisson, C. E.; Tripodis, Y.; Stern, R. A.] Boston Univ, Alzheimers Dis & CTE Ctr, Sch Med, 72 East Concord St,B7800, Boston, MA 02118 USA; [Alosco, M. L.; Baugh, C. M.; Au, R.; McKee, A. C.; Cantu, R. C.; Mez, J.; Stern, R. A.] Boston Univ, Dept Neurol, Sch Med, Boston, MA USA; [Stamm, J. M.] Univ Wisconsin Madison, Dept Kinesiol, Madison, WI USA; [Chua, A. S.; Tripodis, Y.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA; [Baugh, C. M.] Harvard Univ, Interfac Initiat Hlth Policy, Boston, MA USA; [Robbins, C. A.; Cantu, R. C.; Nowinski, C. J.] Concuss Legacy Fdn, Boston, MA USA; [Au, R.] Boston Univ, Sch Med, Boston, MA USA; [Au, R.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA; [Au, R.; Stern, R. A.] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA USA; [Torres, A.] Boston Univ, Sch Med, Pediat Neurol, Boston, MA USA; [Torres, A.] Boston Med Ctr, Pediat Neurol, Boston, MA USA; [McClean, M. D.] Boston Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA; [McKee, A. C.] US Dept Vet Affairs, VA Boston Healthcare Syst, Boston, MA USA; [McKee, A. C.] Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA USA; [McKee, A. C.] Dept Vet Affairs Med Ctr, Bedford, MA USA; [Cantu, R. C.; Stern, R. A.] Boston Univ, Sch Med, Dept Neurosurg, Boston, MA USA; [Cantu, R. C.] Emerson Hosp, Dept Neurosurg, Concord, MA USA; [Martin, B. M.; Chaisson, C. E.] Boston Univ, Sch Publ Hlth, Data Coordinating Ctr, Boston, MA USA		Stern, RA (corresponding author), Boston Univ, Alzheimers Dis & CTE Ctr, Sch Med, 72 East Concord St,B7800, Boston, MA 02118 USA.	bobstern@bu.edu	, Bob/ABA-8507-2020; Baugh, Christine/AAG-2324-2020; Chua, Alicia/AAA-3628-2019	Baugh, Christine/0000-0002-9340-6338; Tripodis, Yorghos/0000-0003-2190-7608; Daneshvar, Daniel/0000-0003-3691-9513; Chua, Alicia/0000-0001-6908-8539	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS 078337, R56 9500304025, U01 NS093334, U01NS086659-01, K23AG046377]; National Center for Advancing Translational Sciences, NIH, through BU-CTSI [1UL1TR001430]; Concussion Legacy Foundation; Pilot Grant from the Boston University Alzheimer's Disease Center [AG013846]; NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F32NS096803]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001430] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F32NS096803, U01NS086659, R01NS078337, U01NS093334] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG013846, K23AG046377] Funding Source: NIH RePORTER	This work was supported by grants from the National Institutes of Health (NIH; R01 NS 078337; R56 9500304025; U01 NS093334; U01NS086659-01; and K23AG046377). This publication was also supported by the National Center for Advancing Translational Sciences, NIH, through BU-CTSI Grant Number 1UL1TR001430, as well as the Concussion Legacy Foundation. Michael L Alosco and research reported in this publication are supported by a Pilot Grant from the Boston University Alzheimer's Disease Center (AG013846), and NIH/NINDS under grant number F32NS096803. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. There is no sponsor.	Abbas K, 2015, DEV NEUROPSYCHOL, V40, P51, DOI 10.1080/87565641.2014.990455; Adler CM, 2016, CLIN J SPORT MED; Alosco ML, 2017, BRAIN INJURY, V31, P1116, DOI 10.1080/02699052.2017.1294709; Alosco ML, 2017, J NEUROTRAUM, V34, P772, DOI 10.1089/neu.2016.4536; Alosco ML, 2016, J NEUROPSYCHIATRY CL, V29, P6; Amen DG, 2016, J ALZHEIMERS DIS, V53, P237, DOI 10.3233/JAD-160207; Anderson V, 2011, BRAIN, V134, P2197, DOI 10.1093/brain/awr103; Bahrami N, 2016, RADIOLOGY, V281, P919, DOI 10.1148/radiol.2016160564; Bazarian JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094734; Bieniek KF, 2015, ACTA NEUROPATHOL, V130, P877, DOI 10.1007/s00401-015-1502-4; Borna Merchant-, 2017, BRAIN IMAGING BEHAV; Bryan CJ, 2013, JAMA PSYCHIAT, V70, P686, DOI 10.1001/jamapsychiatry.2013.1093; Casson IR, 2014, SPORTS HEALTH, V6, P384, DOI 10.1177/1941738114540270; Caviness VS, 1996, CEREB CORTEX, V6, P726, DOI 10.1093/cercor/6.5.726; CHUGANI HT, 1987, ANN NEUROL, V22, P487, DOI 10.1002/ana.410220408; Cobb BR, 2013, ANN BIOMED ENG, V41, P2463, DOI 10.1007/s10439-013-0867-6; Coughlin JM, 2017, JAMA NEUROL, V74, P67, DOI 10.1001/jamaneurol.2016.3764; Courchesne E, 2000, RADIOLOGY, V216, P672, DOI 10.1148/radiology.216.3.r00au37672; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Didehbani N, 2013, ARCH CLIN NEUROPSYCH, V28, P418, DOI 10.1093/arclin/act028; Ducharme S, 2014, CEREB CORTEX, V24, P2941, DOI 10.1093/cercor/bht151; Epstein HT, 1999, BRAIN DEV-JPN, V21, P535, DOI 10.1016/S0387-7604(99)00066-2; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Ford JH, 2013, J NEUROTRAUM, V30, P1683, DOI 10.1089/neu.2012.2535; Gallagher M, 1996, CURR OPIN NEUROBIOL, V6, P221, DOI 10.1016/S0959-4388(96)80076-6; Gardner Raquel C, 2015, Neurol Clin Pract, V5, P285; Gardner RC, 2016, J NEUROTRAUM, V33, P157, DOI 10.1089/neu.2014.3805; Gavett BE, 2013, NEUROREHABILITATION, V32, P253, DOI 10.3233/NRE-130842; Giedd JN, 2008, J ADOLESCENT HEALTH, V42, P335, DOI 10.1016/j.jadohealth.2008.01.007; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Gioia GA, 2009, BRIT J SPORT MED, V43, pI13, DOI 10.1136/bjsm.2009.058255; Gioia GA, 2000, CHILD NEUROPSYCHOL, V6, P235, DOI 10.1076/chin.6.3.235.3152; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; Gurnani AS, 2015, ARCH CLIN NEUROPSYCH, V30, P280, DOI 10.1093/arclin/acv005; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2011, PM&R, V3, P353, DOI 10.1016/j.pmrj.2010.12.006; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hampshire A, 2013, SCI REP-UK, V3, DOI 10.1038/srep02972; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Kant R, 1998, BRAIN INJURY, V12, P87, DOI 10.1080/026990598122908; Kerr ZY, 2015, AM J SPORT MED, V43, P606, DOI 10.1177/0363546514562180; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; Kerr ZY, 2012, MED SCI SPORT EXER, V44, P377, DOI 10.1249/MSS.0b013e31823240f2; Koerte IK, 2016, J NEUROTRAUM, V33, P346, DOI 10.1089/neu.2015.3880; Lebel C, 2008, NEUROIMAGE, V40, P1044, DOI 10.1016/j.neuroimage.2007.12.053; Lewinsohn PM, 1997, PSYCHOL AGING, V12, P277, DOI 10.1037/0882-7974.12.2.277; Lin AP, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0094-5; Ling HL, 2017, ACTA NEUROPATHOL, V133, P337, DOI 10.1007/s00401-017-1680-3; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; MARIN RS, 1991, PSYCHIAT RES, V38, P143, DOI 10.1016/0165-1781(91)90040-V; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mez J, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0148-8; Montenigro PH, 2017, J NEUROTRAUM, V34, P328, DOI 10.1089/neu.2016.4413; Montenigro PH, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0068-z; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Munce TA, 2015, MED SCI SPORT EXER, V47, P1567, DOI 10.1249/MSS.0000000000000591; Phelps EA, 2004, CURR OPIN NEUROBIOL, V14, P198, DOI 10.1016/j.conb.2004.03.015; Poole VN, 2015, DEV NEUROPSYCHOL, V40, P12, DOI 10.1080/87565641.2014.984810; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Randolph C, 2013, J INT NEUROPSYCH SOC, V19, P873, DOI 10.1017/S1355617713000805; Rasia-Filho AA, 2000, J PSYCHIATR NEUROSCI, V25, P14; Robbins CA, 2014, OPEN ACCESS J SPORTS, V5, P99, DOI 10.2147/OAJSM.S58005; Roth RM, 2005, BRIEF A BEHAV RATING; Seichepine DR, 2013, J NEUROTRAUM, V30, P1299, DOI 10.1089/neu.2012.2690; Shaw P, 2006, NATURE, V440, P676, DOI 10.1038/nature04513; Shaw P, 2008, J NEUROSCI, V28, P3586, DOI 10.1523/JNEUROSCI.5309-07.2008; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; Singh R, 2014, JAMA-J AM MED ASSOC, V311, P1883, DOI 10.1001/jama.2014.3313; Snook L, 2005, NEUROIMAGE, V26, P1164, DOI 10.1016/j.neuroimage.2005.03.016; Solomon GS, 2016, AM J SPORT MED, V44, P1106, DOI 10.1177/0363546515626164; Stamm JM, 2015, J NEUROTRAUM, V32, P1768, DOI 10.1089/neu.2014.3822; Stamm JM, 2015, NEUROLOGY, V84, P1114, DOI 10.1212/WNL.0000000000001358; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Strain JF, 2017, J NEUROTRAUM, V34, P372, DOI 10.1089/neu.2016.4446; Strain JF, 2015, JAMA NEUROL, V72, P773, DOI 10.1001/jamaneurol.2015.0206; THATCHER RW, 1991, DEV NEUROPSYCHOL, V7, P397, DOI 10.1080/87565649109540500; Tun PA, 2006, AGE AGEING, V35, P629, DOI 10.1093/ageing/afl095; Uematsu A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046970; Wilson RS, 2005, NEUROEPIDEMIOLOGY, V25, P19, DOI 10.1159/000085309; Wright MJ, 2016, J CLIN EXP NEUROPSYC, V38, P561, DOI 10.1080/13803395.2016.1139057; Zuckerman Scott L, 2012, Surg Neurol Int, V3, P130, DOI 10.4103/2152-7806.102945	82	102	101	6	58	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	2158-3188			TRANSL PSYCHIAT	Transl. Psychiatr.	SEP 19	2017	7								e1236	10.1038/tp.2017.197			8	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	FH9KJ	WOS:000411529100004	28926003	gold, Green Published			2022-02-06	
J	O'Connor, KL; Baker, MM; Dalton, SL; Dompier, TP; Broglio, SP; Kerr, ZY				O'Connor, Kathryn L.; Baker, Melissa M.; Dalton, Sara L.; Dompier, Thomas P.; Broglio, Steven P.; Kerr, Zachary Y.			Epidemiology of Sport-Related Concussions in High School Athletes: National Athletic Treatment, Injury and Outcomes Network (NATION), 2011-2012 Through 2013-2014	JOURNAL OF ATHLETIC TRAINING			English	Article						injury surveillance; traumatic brain injuries; return to play	COLLEGIATE FOOTBALL PLAYERS; STATES HIGH-SCHOOL; RECURRENT CONCUSSION; RISK-FACTORS; ASSOCIATION; RATES; YOUTH; PERCEPTIONS; MANAGEMENT; CHILDREN	Context: Sports participation is one of the leading causes of concussions among nearly 8 million US high school student-athletes. Objective: To describe the epidemiology of sport-related concussion (SRC) in 27 high school sports during the 20112012 through 2013-2014 academic years. Design: Descriptive epidemiology study. Setting: Aggregate injury and exposure data from 27 sports in 147 high schools in the National Athletic Treatment, Injury and Outcomes Network (NATION). Patients or Other Participants: Boy and girl high school athletes during the 2011-2012 through 2013-2014 academic years. Main Outcome Measure(s): Sport-related concussion counts, percentages, rates per 10 000 athlete-exposures (AEs), rate ratios (RRs), and injury proportion ratios (IPRs) were reported with 95% confidence intervals (CIs). Rate ratios and IPRs with 95% CIs not containing 1.0 were considered significant. Results: Overall, 2004 SRCs were reported among 27 high school sports, for a rate of 3.89 per 10 000 AEs. Football had the highest SRC rate (9.21/10 000 AEs), followed by boys' lacrosse 6.65/10 000 AEs) and girls' soccer (6.11/10 000 AEs). The SRC rate was higher in competition than in practice (RR = 3.30; 95% CI = 3.02, 3.60). Among sex-comparable sports, the SRC rate was higher in girls than in boys (RR = 1.56; 95% CI = 1.34, 1.81); however, the proportion of SRCs due to player-to-player contact was higher in boys than in girls (IPR = 1.48; 95% CI = 1.27, 1.73). Common symptoms reported among all athletes with SRCs were headache (94.7%), dizziness (74.8%), and difficulty concentrating (61.0%). Only 0.8% of players with SRCs returned to play within 24 hours. The majority of athletes with SRCs (65.8%) returned to play between 7 and 28 days. More players had symptoms resolve after 7 days (48.8%) than less than a week (40.7%). Conclusions: Our findings provide updated high school SRC incidence estimates and further evidence of sex differences in reported SRCs. Few athletes with SRCs returned to play within 24 hours or a week. Most injured players returned after 7 days, despite a smaller proportion having symptoms resolve within a week.	[O'Connor, Kathryn L.; Broglio, Steven P.] Univ Michigan, NeuroTrauma Res Lab, Ann Arbor, MI 48109 USA; [Baker, Melissa M.; Dalton, Sara L.; Dompier, Thomas P.] Datalys Ctr Sports Injury Res & Prevent Inc, Indianapolis, IN USA; [Kerr, Zachary Y.] Univ North Carolina Chapel Hill, Dept Exercise & Sport Sci, 313 Woollen Gym,CB 8700, Chapel Hill, NC 27599 USA		Kerr, ZY (corresponding author), Univ North Carolina Chapel Hill, Dept Exercise & Sport Sci, 313 Woollen Gym,CB 8700, Chapel Hill, NC 27599 USA.	zkerr@email.unc.edu		Van Pelt, Kathryn/0000-0002-5494-2357	National Athletic Trainers' Association Research and Education Foundation; Central Indiana Corporate Partnership Foundation; BioCrossroads	This study would not have been possible without the assistance of the many high school ATs who participated in the program. This project was funded by the National Athletic Trainers' Association Research and Education Foundation and the Central Indiana Corporate Partnership Foundation in cooperation with BioCrossroads. The content of this report is solely the responsibility of the authors and does not necessarily reflect the views of the National Athletic Trainers' Association Research and Education Foundation, Central Indiana Corporate Partnership Foundation, or BioCrossroads.	[Anonymous], 2013, RUL CHANG SAF GAM; Bailey R, 2006, J SCHOOL HEALTH, V76, P397, DOI 10.1111/j.1746-1561.2006.00132.x; Baker JG, 2016, CLIN PEDIATR, V55, P771, DOI 10.1177/0009922815606417; Bloodgood B, 2013, J ADOLESCENT HEALTH, V53, P34, DOI 10.1016/j.jadohealth.2013.01.022; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Collins CL, 2014, J PRIM PREV, V35, P309, DOI 10.1007/s10935-014-0355-2; Comstock RD, 2015, JAMA PEDIATR, V169, P830, DOI 10.1001/jamapediatrics.2015.1062; Currie DW, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-2447; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Dompier TP, 2015, J ATHL TRAINING, V50, P862, DOI 10.4085/1062-6050-50.5.04; Dompier TP, 2015, JAMA PEDIATR, V169, P659, DOI 10.1001/jamapediatrics.2015.0210; Emery C, 2011, CAN MED ASSOC J, V183, P1249, DOI 10.1503/cmaj.101540; Emery CA, 2006, AM J SPORT MED, V34, P1960, DOI 10.1177/0363546506290061; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Funk JR, 2012, ANN BIOMED ENG, V40, P79, DOI 10.1007/s10439-011-0400-8; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gibson TB, 2015, JAMA PEDIATR, V169, P163, DOI 10.1001/jamapediatrics.2014.2320; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hinton RY, 2005, AM J SPORT MED, V33, P1305, DOI 10.1177/0363546504274148; Institute of Medicine, 2013, SOD CONT POP ASS EV, P1; Kerr ZY, 2015, ORTHOP J SPORTS MED, V3, DOI 10.1177/2325967115610545; Kerr ZY, 2016, AM J SPORT MED, V44, P220, DOI 10.1177/0363546515612082; Kerr ZY, 2014, J ATHL TRAINING, V49, P552, DOI 10.4085/1062-6050-49.3.58; Kerr ZY, 2015, ORTHOP J SPORTS MED, V3; King H, 2015, J PHYS ACT HEALTH, V12, P1162, DOI 10.1123/jpah.2014-0356; Knowles SB, 2006, J ATHL TRAINING, V41, P207; Kroshus E, 2015, HEALTH EDUC RES, V30, P1004, DOI 10.1093/her/cyv047; LaRoche AA, 2016, CLIN J SPORT MED, V26, P33, DOI 10.1097/JSM.0000000000000192; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Llewellyn T, 2014, CLIN J SPORT MED, V24, P76, DOI 10.1097/01.jsm.0000432853.77520.3d; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Marshall SW, 2001, J ATHL TRAINING, V36, P334; Martini DN, 2011, ARCH PHYS MED REHAB, V92, P585, DOI 10.1016/j.apmr.2010.11.029; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; McGuine TA, 2014, AM J SPORT MED, V42, P2470, DOI 10.1177/0363546514541926; Meehan WP, 2011, AM J SPORT MED, V39, P2304, DOI 10.1177/0363546511423503; Membership statistics, 2015, MEMB STAT; Miyashita TL, 2014, ORTHOP J SPORTS MED, V2, DOI 10.1177/2325967114554549; National Collegiate Athletic Association, NCAA FOOTB REC MAD R; National Federation of State High School Associations, 2015, NFHS HDB 2015 16; Pfister T, 2016, BRIT J SPORT MED, V50, P292, DOI 10.1136/bjsports-2015-094978; Pryor RR, 2015, J ATHL TRAINING, V50, P156, DOI 10.4085/1062-6050-50.2.03; Rosenthal JA, 2014, AM J SPORT MED, V42, P1710, DOI 10.1177/0363546514530091; Rowhani-Rahbar A, 2016, J NEUROTRAUM, V33, P784, DOI 10.1089/neu.2015.4100; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Shields BJ, 2009, J ATHL TRAINING, V44, P586, DOI 10.4085/1062-6050-44.6.586; Soshnick S, 2014, FOOTBALL PARTICIPATI; Strauss B., 2015, NEW YORK TIMES; Wasserman EB, 2016, AM J SPORT MED, V44, P226, DOI 10.1177/0363546515610537; Zuckerman SL, 2015, AM J SPORT MED, V43, P2654, DOI 10.1177/0363546515599634	57	102	101	0	12	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	MAR	2017	52	3					175	185		10.4085/1062-6050-52.1.15			11	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Sport Sciences	ES0NE	WOS:000399222500004	28387555	Green Published, Green Submitted, Bronze			2022-02-06	
J	Pearce, KL; Sufrinko, A; Lau, BC; Henry, L; Collins, MW; Kontos, AP				Pearce, Kelly L.; Sufrinko, Alicia; Lau, Brian C.; Henry, Luke; Collins, Michael W.; Kontos, Anthony P.			Near Point of Convergence After a Sport-Related Concussion: Measurement Reliability and Relationship to Neurocognitive Impairment and Symptoms	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						concussion; eye injuries; convergence insufficiency; neurocognitive impairment	EYE-MOVEMENT; INSUFFICIENCY; AREA; CLASSIFICATION; SPECIFICITY; SENSITIVITY; NEARPOINT; DEFICITS; NEURONS; IMPACT	Background: Convergence insufficiency (CI) is a common binocular vision deficit after a sport-related concussion (SRC). CI may result in visual discomfort and vision-mediated functional difficulties such as slowed reading and compromised attention, leading to impaired academic, work, and sport performance. Purpose: To test the reliability of repeated near point of convergence (NPC) measurements in a sample of athletes after an SRC; compare the symptoms and cognitive impairment of athletes with normal NPC to those with CI after an SRC; and explore the relationship among age, sex, learning disability, migraine history, and CI. Study Design: Cross-sectional study; Level of evidence, 3. Methods: A total of 78 athletes (mean age, 14.31 2.77 years) who were seen a mean 5.79 5.63 days after an SRC were administered 3 trials of an NPC assessment, along with neurocognitive (Immediate Post-Concussion Assessment and Cognitive Testing [ImPACT]) and symptom assessments. Patients were divided into normal NPC (NPC 5 cm; n = 45) and CI (NPC >5 cm; n = 33) groups. Intraclass correlation coefficients (ICCs) and repeated-measures analyses of variance (ANOVAs) assessed the consistency of NPC across the 3 trials. The ANOVAs were employed to examine differences on neurocognitive composites and symptoms between the normal NPC and CI groups. Stepwise regressions (controlling for age and symptom scores on the Post-Concussion Symptom Scale [PCSS]) were conducted to evaluate the predictive utility of the NPC distance for neurocognitive impairment. Results: Groups did not differ on demographic or injury characteristics. NPC differed between trial 1 and trials 2 (P = .02) and 3 (P = .01) for the CI group but not the normal NPC group. Internal consistency was high across NPC measurements (ICC range, 0.95-0.98). Patients with CI performed worse on verbal memory (P = .02), visual motor speed (P = .02), and reaction time (P = .001, (2) = .13) and had greater total symptom scores (P = .02) after the injury. Results of hierarchical regression revealed that the NPC distance contributed significantly to the model for reaction time (P < .001). Conclusion: CI was common (similar to 42%) in athletes evaluated within 1 month after an SRC. Athletes with CI had worse neurocognitive impairment and higher symptom scores than did those with normal NPC. Clinicians should consider routinely screening for NPC as part of a comprehensive concussion evaluation to help inform treatment recommendations, academic accommodations, and referrals for vision therapy.	[Pearce, Kelly L.; Sufrinko, Alicia; Lau, Brian C.; Henry, Luke; Collins, Michael W.; Kontos, Anthony P.] Univ Pittsburgh, Pittsburgh, PA USA		Kontos, AP (corresponding author), UPMC, Ctr Sports Med, 3200 South Water St, Pittsburgh, PA 15203 USA.	akontos@pitt.edu		Kontos, Anthony/0000-0002-3749-4310	National Institute on Deafness and Other Communication Disorders, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [1K01DC012332-01A1]; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [K01DC012332] Funding Source: NIH RePORTER	One or more of the authors has declared the following potential conflict of interest or source of funding: This research was supported in part by a grant to the University of Pittsburgh from the National Institute on Deafness and Other Communication Disorders, National Institutes of Health (1K01DC012332-01A1). M.W.C. is a cofounder and 10% shareholder of ImPACT Applications Inc.	Alvarez TL, 2012, OPTOMETRY VISION SCI, V89, P1740, DOI 10.1097/OPX.0b013e3182772dce; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Borsting Eric, 2005, Optometry, V76, P588, DOI 10.1016/j.optm.2005.07.007; Brahm KD, 2009, OPTOMETRY VISION SCI, V86, P817, DOI 10.1097/OPX.0b013e3181adff2d; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Capo-Aponte JE, 2012, MIL MED, V177, P804, DOI 10.7205/MILMED-D-12-00061; Ciuffreda Kenneth J, 2007, Optometry, V78, P155, DOI 10.1016/j.optm.2006.11.011; Cohen M, 1989, Brain Inj, V3, P187, DOI 10.3109/02699058909004551; Collins MW, 2014, KNEE SURG SPORT TR A, V22, P235, DOI 10.1007/s00167-013-2791-6; COOPER J, 1978, J AM OPTOM ASSOC, V49, P673; Cooper J, 2012, OPTOMETRY, V83, P20; Corwin DJ, 2015, J PEDIATR-US, V166, P1221, DOI 10.1016/j.jpeds.2015.01.039; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; DAVIES CE, 1946, CAN MED ASSOC J, V55, P47; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; Ellis MJ, 2015, BRAIN INJURY, V29, P238, DOI 10.3109/02699052.2014.965207; Gamlin PD, 2000, NATURE, V407, P1003, DOI 10.1038/35039506; GNADT JW, 1995, J NEUROPHYSIOL, V73, P280, DOI 10.1152/jn.1995.73.1.280; GRISHAM JD, 1988, AM J OPTOM PHYS OPT, V65, P448; Halstead ME, 2013, PEDIATRICS, V132, P948, DOI 10.1542/peds.2013-2867; Hayes GJ, 1998, OPTOMETRY VISION SCI, V75, P506, DOI 10.1097/00006324-199807000-00019; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Maples WC, 2007, OPTOMETRY VISION SCI, V84, P224, DOI 10.1097/OPX.0b013e3180339f44; MAYS LE, 1984, J NEUROPHYSIOL, V51, P1091, DOI 10.1152/jn.1984.51.5.1091; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McGregor ML, 2014, PEDIATR CLIN N AM, V61, P621, DOI 10.1016/j.pcl.2014.03.010; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; Pierrot-Deseilligny C, 2004, CURR OPIN NEUROL, V17, P17, DOI 10.1097/00019052-200402000-00005; Prince SJD, 2000, J NEUROSCI, V20, P3387, DOI 10.1523/JNEUROSCI.20-09-03387.2000; Rambold H, 2004, NEUROLOGY, V62, P1850, DOI 10.1212/01.WNL.0000125331.95849.62; Rouse MW, 2002, OPTOMETRY VISION SCI, V79, P254, DOI 10.1097/00006324-200204000-00012; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Scheiman M, 2003, OPTOMETRY VISION SCI, V80, P214, DOI 10.1097/00006324-200303000-00011; Schneider KJ, 2013, BRIT J SPORT MED, V47, P304, DOI 10.1136/bjsports-2013-092190; Singman Eric L, 2014, Am Orthopt J, V64, P112, DOI 10.3368/aoj.64.1.112; Thiagarajan P, 2013, J REHABIL RES DEV, V50, P1223, DOI 10.1682/JRRD.2012.12.0235; Zuckerman SL, 2012, NEUROSURGERY, V71, pE558, DOI 10.1227/01.neu.0000417735.94052.d6	39	102	102	0	36	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	DEC	2015	43	12					3055	3061		10.1177/0363546515606430			7	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	CX5RU	WOS:000365761000025	26453625	Green Accepted			2022-02-06	
J	Blanchette, M; Daneman, R				Blanchette, Marie; Daneman, Richard			Formation and maintenance of the BBB	MECHANISMS OF DEVELOPMENT			English	Article						Angiogenesis; Blood-brain barrier; Central nervous system; Embryogenesis; Endothelial cells; Neurovascular unit		The central nervous system (CNS) is vascularized by a dense capillary network that is critical to deliver oxygen and nutrients, and remove carbon dioxide and waste products, from the neural tissue. These blood vessels contain a series of properties, termed the blood-brain barrier (BBB), which distinguishes them from vasculature in other tissues, enabling CNS vessels to stringently regulate the transfer of ions, molecules and cells between the blood and the tissue. This barrier is critical to maintain brain homeostasis which allows for proper neuronal function and also to protect the tissue from injury and disease and many neurological diseases are associated with BBB dysfunction, including traumatic brain injuries, Alzheimer's disease, stroke, epilepsy, and multiple sclerosis. Therefore, a better understanding of the mechanisms controlling the development of the BBB may lead to improved comprehension of the pathophysiology of these diseases, and further aid in the identification of targets to modulate the barrier to treat different neurological diseases. Many of the properties of the BBB are possessed by the endothelial cells that form the walls of the blood vessels but are acquired through a series of complex cellular interactions with the microenvironment throughout its development. We will review what is known about the induction and regulation of BBB properties during development. (C) 2015 Elsevier Ireland Ltd. All rights reserved.	Univ Calif San Diego, Dept Neurosci, San Diego, CA 92093 USA; [Daneman, Richard] Univ Calif San Diego, Dept Pharmacol, San Diego, CA 92093 USA		Daneman, R (corresponding author), Univ Calif San Diego, Dept Pharmacol, 9500 Gilman Dr, San Diego, CA 92093 USA.	rdaneman@ucsd.edu		Blanchette, Marie/0000-0003-1187-8700			Abbott NJ, 2010, NEUROBIOL DIS, V37, P13, DOI 10.1016/j.nbd.2009.07.030; Altaba ARI, 2002, NAT REV NEUROSCI, V3, P24; Alvarez JI, 2011, SCIENCE, V334, P1727, DOI 10.1126/science.1206936; Anderson KD, 2011, P NATL ACAD SCI USA, V108, P2807, DOI 10.1073/pnas.1019761108; Andrae J, 2008, GENE DEV, V22, P1276, DOI 10.1101/gad.1653708; Armulik A, 2010, NATURE, V468, P557, DOI 10.1038/nature09522; Bell R. D., 2012, APOLIPOPROTEIN E, P512; Bell RD, 2010, NEURON, V68, P409, DOI 10.1016/j.neuron.2010.09.043; Ben-Zvi A, 2014, NATURE, V509, P507, DOI 10.1038/nature13324; BERTLER A, 1966, PHARMACOL REV, V18, P369; Bjarnegard M, 2004, DEVELOPMENT, V131, P1847, DOI 10.1242/dev.01080; Bolz S, 1996, CELL TISSUE RES, V284, P355, DOI 10.1007/s004410050596; Braniste V, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009759; BRIGHTMA.MW, 1969, J CELL BIOL, V40, P648, DOI 10.1083/jcb.40.3.648; BUTT AM, 1990, J PHYSIOL-LONDON, V429, P47, DOI 10.1113/jphysiol.1990.sp018243; Correale J, 2009, NEUROCHEM RES, V34, P2067, DOI 10.1007/s11064-009-0081-y; Cucullo L, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471-2202-12-40; Cullen M, 2011, P NATL ACAD SCI USA, V108, P5759, DOI 10.1073/pnas.1017192108; Daneman R, 2010, NATURE, V468, P562, DOI 10.1038/nature09513; Daneman R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013741; Daneman R, 2009, P NATL ACAD SCI USA, V106, P641, DOI 10.1073/pnas.0805165106; Deli MA, 2005, CELL MOL NEUROBIOL, V25, P59, DOI 10.1007/s10571-004-1377-8; Diaz-Flores L, 2009, HISTOL HISTOPATHOL, V24, P909, DOI 10.14670/HH-24.909; Dohgu S, 2005, BRAIN RES, V1038, P208, DOI 10.1016/j.brainres.2005.01.027; Ek CJ, 2010, TOXICOL LETT, V197, P51, DOI 10.1016/j.toxlet.2010.04.025; Ek CJ, 2006, J COMP NEUROL, V496, P13, DOI 10.1002/cne.20885; El-Bacha RS, 1999, CELL MOL BIOL, V45, P15; Enge M, 2002, EMBO J, V21, P4307, DOI 10.1093/emboj/cdf418; Etchevers HC, 2001, DEVELOPMENT, V128, P1059; Gaillard PJ, 2000, PHARMACEUT RES, V17, P1198, DOI 10.1023/A:1026406528530; Hayashi Y, 1997, GLIA, V19, P13, DOI 10.1002/(SICI)1098-1136(199701)19:1<13::AID-GLIA2>3.0.CO;2-B; Hellstrom M, 1999, DEVELOPMENT, V126, P3047; Helms HC, 2012, GLIA, V60, P882, DOI 10.1002/glia.22321; Huber JD, 2001, TRENDS NEUROSCI, V24, P719, DOI 10.1016/S0166-2236(00)02004-X; JANZER RC, 1987, NATURE, V325, P253, DOI 10.1038/325253a0; Junge HJ, 2009, CELL, V139, P299, DOI 10.1016/j.cell.2009.07.048; Keller A, 2013, NAT GENET, V45, P1077, DOI 10.1038/ng.2723; Kim MO, 2003, NEUROSCI LETT, V336, P93, DOI 10.1016/S0304-3940(02)01260-0; Korn J, 2002, J COMP NEUROL, V442, P78, DOI 10.1002/cne.1423; Kuhnert F, 2010, SCIENCE, V330, P985, DOI 10.1126/science.1196554; Kurz H, 2009, CELL ADHES MIGR, V3, P205, DOI 10.4161/cam.3.2.7855; Lee SW, 2003, NAT MED, V9, P900, DOI 10.1038/nm889; Liebner S, 2008, J CELL BIOL, V183, P409, DOI 10.1083/jcb.200806024; Maretto S, 2003, P NATL ACAD SCI USA, V100, P3299, DOI 10.1073/pnas.0434590100; Mathiisen TM, 2010, GLIA, V58, P1094, DOI 10.1002/glia.20990; Menezes MJ, 2014, J NEUROSCI, V34, P15260, DOI 10.1523/JNEUROSCI.3678-13.2014; Moon Randall T, 2005, Sci STKE, V2005, pcm1; Neuwelt E, 2008, LANCET NEUROL, V7, P84, DOI 10.1016/S1474-4422(07)70326-5; Neuwelt EA, 2011, NAT REV NEUROSCI, V12, P169, DOI 10.1038/nrn2995; Nishitsuji K, 2011, J BIOL CHEM, V286, P17536, DOI 10.1074/jbc.M111.225532; Ohlmann A, 2012, PROG RETIN EYE RES, V31, P243, DOI 10.1016/j.preteyeres.2012.02.002; OLDENDORF WH, 1977, ANN NEUROL, V1, P409, DOI 10.1002/ana.410010502; Osada T, 2011, J CEREBR BLOOD F MET, V31, P1972, DOI 10.1038/jcbfm.2011.99; Paes KT, 2011, INVEST OPHTH VIS SCI, V52, P6452, DOI 10.1167/iovs.10-7146; Ransohoff RM, 2009, NATURE, V462, P41, DOI 10.1038/462041a; REESE TS, 1967, J CELL BIOL, V34, P207, DOI 10.1083/jcb.34.1.207; Reis M, 2012, J EXP MED, V209, P1611, DOI 10.1084/jem.20111580; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Rubin LL, 1999, ANNU REV NEUROSCI, V22, P11, DOI 10.1146/annurev.neuro.22.1.11; RUBIN LL, 1991, J CELL BIOL, V115, P1725, DOI 10.1083/jcb.115.6.1725; Sauvageot CM, 2002, CURR OPIN NEUROBIOL, V12, P244, DOI 10.1016/S0959-4388(02)00322-7; SHEPRO D, 1993, FASEB J, V7, P1031, DOI 10.1096/fasebj.7.11.8370472; Siegenthaler JA, 2013, BIOL OPEN, V2, P647, DOI 10.1242/bio.20135009; SIMS DE, 1986, TISSUE CELL, V18, P153, DOI 10.1016/0040-8166(86)90026-1; Smallwood PM, 2007, J BIOL CHEM, V282, P4057, DOI 10.1074/jbc.M609618200; Sobue K, 1999, NEUROSCI RES, V35, P155, DOI 10.1016/S0168-0102(99)00079-6; Sohet F, 2015, J CELL BIOL, V208, P703, DOI 10.1083/jcb.201410131; Stenman JM, 2008, SCIENCE, V322, P1247, DOI 10.1126/science.1164594; STEWART PA, 1981, DEV BIOL, V84, P183, DOI 10.1016/0012-1606(81)90382-1; Taddei A, 2008, NAT CELL BIOL, V10, P923, DOI 10.1038/ncb1752; Tam SJ, 2012, DEV CELL, V22, P403, DOI 10.1016/j.devcel.2011.11.018; Tien AC, 2012, DEVELOPMENT, V139, P2477, DOI 10.1242/dev.077214; Varjosalo M, 2008, GENE DEV, V22, P2454, DOI 10.1101/gad.1693608; Wang YS, 2012, CELL, V151, P1332, DOI 10.1016/j.cell.2012.10.042; Winkler EA, 2011, NAT NEUROSCI, V14, P1398, DOI 10.1038/nn.2946; Wolburg H, 2002, VASC PHARMACOL, V38, P323, DOI 10.1016/S1537-1891(02)00200-8; Wosik K, 2007, J NEUROSCI, V27, P9032, DOI 10.1523/JNEUROSCI.2088-07.2007; Yang YJ, 2013, J NEURODEV DISORD, V5, DOI 10.1186/1866-1955-5-22; Yao Y, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4413; Ye X, 2009, CELL, V139, P285, DOI 10.1016/j.cell.2009.07.047; YOSHIDA Y, 1988, DEV BRAIN RES, V44, P211, DOI 10.1016/0165-3806(88)90219-2; Zhou YL, 2014, DEV CELL, V31, P248, DOI 10.1016/j.devcel.2014.08.018; Zhou YL, 2014, J CLIN INVEST, V124, P3825, DOI 10.1172/JCI76431	83	102	105	3	17	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0925-4773	1872-6356		MECH DEVELOP	Mech. Dev.	NOV	2015	138		1				8	16		10.1016/j.mod.2015.07.007			9	Developmental Biology	Science Citation Index Expanded (SCI-EXPANDED)	Developmental Biology	CW9MZ	WOS:000365324200003	26215350	Bronze			2022-02-06	
J	Mietto, BS; Mostacada, K; Martinez, AMB				Mietto, Bruno Siqueira; Mostacada, Klauss; Blanco Martinez, Ana Maria			Neurotrauma and Inflammation: CNS and PNS Responses	MEDIATORS OF INFLAMMATION			English	Article							SPINAL-CORD-INJURY; PERIPHERAL NERVOUS-SYSTEM; RESIDENT ENDONEURIAL MACROPHAGES; LEUKEMIA INHIBITORY FACTOR; NECROSIS-FACTOR-ALPHA; WALLERIAN DEGENERATION; AXON REGENERATION; SCHWANN-CELLS; NEUTROPHIL RECRUITMENT; FUNCTIONAL RECOVERY	Traumatic injury to the central nervous system (CNS) or the peripheral nervous system (PNS) triggers a cascade of events which culminate in a robust inflammatory reaction. The role played by inflammation in the course of degeneration and regeneration is not completely elucidated. While, in peripheral nerves, the inflammatory response is assumed to be essential for normal progression of Wallerian degeneration and regeneration, CNS trauma inflammation is often associated with poor recovery. In this review, we discuss key mechanisms that trigger the inflammatory reaction after nervous system trauma, emphasizing how inflammations in both CNS and PNS differ from each other, in terms of magnitude, cell types involved, and effector molecules. Knowledge of the precise mechanisms that elicit and maintain inflammation after CNS and PNS tissue trauma and their effect on axon degeneration and regeneration is crucial for the identification of possible pharmacological drugs that can positively affect the tissue regenerative capacity.	[Mietto, Bruno Siqueira; Mostacada, Klauss; Blanco Martinez, Ana Maria] Univ Fed Rio de Janeiro, Hosp Univ Clementino Fraga Filho, Lab Neurodegeneracao & Reparo, Dept Patol,Fac Med, BR-21941550 Rio De Janeiro, RJ, Brazil		Martinez, AMB (corresponding author), Univ Fed Rio de Janeiro, Hosp Univ Clementino Fraga Filho, Lab Neurodegeneracao & Reparo, Dept Patol,Fac Med, BR-21941550 Rio De Janeiro, RJ, Brazil.	martinez@histo.ufrj.br	Mietto, Bruno/J-1261-2016; MARTINEZ, Ana/AAE-8358-2019	Mietto, Bruno/0000-0002-4172-2670; Reis, AlessanRSS/0000-0001-8486-7469			Ankeny DP, 2009, J CLIN INVEST, V119, P2990, DOI 10.1172/JCI39780; [Anonymous], 2014, NEUROSCIENCE; Arthur-Farraj PJ, 2012, NEURON, V75, P633, DOI 10.1016/j.neuron.2012.06.021; Baetas-da-Cruz W, 2009, J PERIPHER NERV SYST, V14, P84, DOI 10.1111/j.1529-8027.2009.00217.x; Bareyre FM, 2003, TRENDS NEUROSCI, V26, P555, DOI 10.1016/j.tins.2003.08.004; Barrette B, 2008, J NEUROSCI, V28, P9363, DOI 10.1523/JNEUROSCI.1447-08.2008; Bastien D, 2014, EXP NEUROL, V258, P62, DOI 10.1016/j.expneurol.2014.04.006; Be'eri M, 1998, EUR J NEUROSCI, V10, P2707; Beck KD, 2010, BRAIN, V133, P433, DOI 10.1093/brain/awp322; Benowitz LI, 2011, CURR OPIN NEUROL, V24, P577, DOI 10.1097/WCO.0b013e32834c208d; BISBY MA, 1990, BRAIN RES, V530, P117, DOI 10.1016/0006-8993(90)90666-Y; Boivin A, 2007, J NEUROSCI, V27, P12565, DOI 10.1523/JNEUROSCI.3027-07.2007; Bomze HM, 2001, NAT NEUROSCI, V4, P38, DOI 10.1038/82881; Boven LA, 2006, BRAIN, V129, P517, DOI 10.1093/brain/awh707; BROWN MC, 1992, J NEUROBIOL, V23, P521, DOI 10.1002/neu.480230507; Cafferty WBJ, 2001, J NEUROSCI, V21, P7161, DOI 10.1523/JNEUROSCI.21-18-07161.2001; Cardona AE, 2006, NAT NEUROSCI, V9, P917, DOI 10.1038/nn1715; Caroleo MC, 2001, J NEUROIMMUNOL, V113, P193, DOI 10.1016/S0165-5728(00)00441-0; CHEN S, 1993, J COMP NEUROL, V333, P449, DOI 10.1002/cne.903330310; Chen ZL, 2003, J CELL BIOL, V163, P889, DOI 10.1083/jcb.200307068; Chen ZL, 2007, ANNU REV NEUROSCI, V30, P209, DOI 10.1146/annurev.neuro.30.051606.094337; Coleman MP, 2010, ANNU REV NEUROSCI, V33, P245, DOI 10.1146/annurev-neuro-060909-153248; Coleman MP, 2002, TRENDS NEUROSCI, V25, P532, DOI 10.1016/S0166-2236(02)02255-5; David S, 2002, NEUROSCIENTIST, V8, P33, DOI 10.1177/107385840200800108; DAVID S, 1995, J NEUROSCI RES, V42, P594, DOI 10.1002/jnr.490420417; David S, 2011, NAT REV NEUROSCI, V12, P388, DOI 10.1038/nrn3053; de Lima S, 2012, P NATL ACAD SCI USA, V109, P9149, DOI 10.1073/pnas.1119449109; Deumens R, 2010, PROG NEUROBIOL, V92, P245, DOI 10.1016/j.pneurobio.2010.10.002; Donnelly DJ, 2011, J NEUROSCI, V31, P9910, DOI 10.1523/JNEUROSCI.2114-11.2011; Dubovy P, 2011, ANN ANAT, V193, P267, DOI 10.1016/j.aanat.2011.02.011; Dumic J, 2006, BBA-GEN SUBJECTS, V1760, P616, DOI 10.1016/j.bbagen.2005.12.020; Elkabes S, 1996, J NEUROSCI, V16, P2508; Ferguson AR, 2008, J NEUROSCI, V28, P11391, DOI 10.1523/JNEUROSCI.3708-08.2008; FERNANDEZVALLE C, 1995, J NEUROCYTOL, V24, P667, DOI 10.1007/BF01179817; Ferraz LC, 2008, EUR J IMMUNOL, V38, P2762, DOI 10.1002/eji.200737986; Filbin MT, 2003, NAT REV NEUROSCI, V4, P703, DOI 10.1038/nrn1195; Filer A, 2009, ARTHRITIS RHEUM, V60, P1604, DOI 10.1002/art.24574; Fry EJ, 2007, NEURON, V53, P649, DOI 10.1016/j.neuron.2007.02.009; Gaudet AD, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-110; Giger RJ, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001867; Gilley J, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000300; Girolami EI, 2010, EXP NEUROL, V223, P173, DOI 10.1016/j.expneurol.2009.06.018; Goethals S, 2010, GLIA, V58, P1701, DOI 10.1002/glia.21041; Gosselin RD, 2008, CURR MED CHEM, V15, P2866, DOI 10.2174/092986708786242822; Griffin JW, 2010, EXP NEUROL, V223, P60, DOI 10.1016/j.expneurol.2009.12.033; Guertin AD, 2005, J NEUROSCI, V25, P3478, DOI 10.1523/JNEUROSCI.3766-04.2005; Gustavsson P, 2007, NEUROREPORT, V18, P669, DOI 10.1097/WNR.0b013e3280bef97b; Harkey H Louis 3rd, 2003, Anat Rec B New Anat, V271, P41, DOI 10.1002/ar.b.10012; Hausmann O, 2003, SPINAL CORD, V41, P369, DOI 10.1038/sj.sc.3101483; Inohara H, 1998, EXP CELL RES, V245, P294, DOI 10.1006/excr.1998.4253; Jeon SB, 2010, J IMMUNOL, V185, P7037, DOI 10.4049/jimmunol.1000154; Jessen KR, 2008, GLIA, V56, P1552, DOI 10.1002/glia.20761; Jin R, 2010, J LEUKOCYTE BIOL, V87, P779, DOI 10.1189/jlb.1109766; Jung J, 2011, J NEUROSCI, V31, P2009, DOI 10.1523/JNEUROSCI.4537-10.2011; Juranek JK, 2013, DIABETES, V62, P931, DOI 10.2337/db12-0632; Kawai T, 2006, CELL DEATH DIFFER, V13, P816, DOI 10.1038/sj.cdd.4401850; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Kigerl KA, 2014, EXP NEUROL, V258, P5, DOI 10.1016/j.expneurol.2014.01.001; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kim D, 2009, CURR TOP MICROBIOL, V336, P169, DOI 10.1007/978-3-642-00549-7_10; Kolaczkowska E, 2013, NAT REV IMMUNOL, V13, P159, DOI 10.1038/nri3399; Komori T, 2011, NEUROREPORT, V22, P911, DOI 10.1097/WNR.0b013e32834cd76a; Kroner A, 2014, NEURON, V83, P1098, DOI 10.1016/j.neuron.2014.07.027; Kurimoto T, 2013, J NEUROSCI, V33, P14816, DOI 10.1523/JNEUROSCI.5511-12.2013; Lee H, 2006, BIOCHEM BIOPH RES CO, V350, P742, DOI 10.1016/j.bbrc.2006.09.108; Leon S, 2000, J NEUROSCI, V20, P4615, DOI 10.1523/JNEUROSCI.20-12-04615.2000; Leonhard C, 2002, EUR J NEUROSCI, V16, P1654, DOI 10.1046/j.1460-9568.2002.02236.x; Levy D, 2001, J NEUROPATH EXP NEUR, V60, P411, DOI 10.1093/jnen/60.5.411; Lopez-Vales R, 2008, BRAIN, V131, P2620, DOI 10.1093/brain/awn188; LUBINSKA L, 1977, BRAIN RES, V130, P47, DOI 10.1016/0006-8993(77)90841-1; Lutz AB, 2014, DEV CELL, V28, P7, DOI 10.1016/j.devcel.2013.12.002; Makwana M, 2005, FEBS J, V272, P2628, DOI 10.1111/j.1742-4658.2005.04699.x; MALBOUISSON AMB, 1985, J NEUROL SCI, V67, P307, DOI 10.1016/0022-510X(85)90155-8; Martinez AMB, 2000, BRAZ J MED BIOL RES, V33, P1477, DOI 10.1590/S0100-879X2000001200012; Martinez AMB, 1998, J SUBMICR CYTOL PATH, V30, P451; Martini R, 2008, GLIA, V56, P1566, DOI 10.1002/glia.20766; Maurer M, 2002, NEUROMUSCULAR DISORD, V12, P405, DOI 10.1016/S0960-8966(01)00302-9; Mautes AEM, 2000, PHYS THER, V80, P673, DOI 10.1093/ptj/80.7.673; Mietto B. S., 2011, ADV UNDERSTANDING NE; Mietto BS, 2013, EUR J NEUROSCI, V37, P1682, DOI 10.1111/ejn.12161; Mueller M, 2003, LAB INVEST, V83, P175, DOI 10.1097/01.LAB.0000056993.28149.BF; Mueller M, 2001, AM J PATHOL, V159, P2187, DOI 10.1016/S0002-9440(10)63070-2; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Nadeau S, 2011, J NEUROSCI, V31, P12533, DOI 10.1523/JNEUROSCI.2840-11.2011; Narciso MS, 2009, EXP NEUROL, V217, P7, DOI 10.1016/j.expneurol.2009.01.008; Noble LJ, 2002, J NEUROSCI, V22, P7526; Norenberg MD, 2004, J NEUROTRAUM, V21, P429, DOI 10.1089/089771504323004575; Parr AM, 2007, BONE MARROW TRANSPL, V40, P609, DOI 10.1038/sj.bmt.1705757; Perrin FE, 2005, BRAIN, V128, P854, DOI 10.1093/brain/awh407; PERRY VH, 1995, EUR J NEUROSCI, V7, P271, DOI 10.1111/j.1460-9568.1995.tb01063.x; Pineau I, 2009, GLIA, V57, P351, DOI 10.1002/glia.20763; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; Popovich PG, 2003, TRENDS PHARMACOL SCI, V24, P13, DOI 10.1016/S0165-6147(02)00006-8; Popovich PG, 2012, EXP NEUROL, V233, P615, DOI 10.1016/j.expneurol.2010.11.016; Raff MC, 2002, SCIENCE, V296, P868, DOI 10.1126/science.1068613; Raivich G, 2004, NEURON, V43, P57, DOI 10.1016/j.neuron.2004.06.005; REICHERT F, 1994, J NEUROSCI, V14, P3231; Ren Y, 2013, NEURAL PLAST, V2013, DOI 10.1155/2013/945034; Rock RB, 2004, CLIN MICROBIOL REV, V17, P942, DOI 10.1128/CMR.17.4.942-964.2004; Rolls A, 2009, NAT REV NEUROSCI, V10, P235, DOI 10.1038/nrn2591; ROTSHENKER S, 1992, J NEUROIMMUNOL, V39, P75, DOI 10.1016/0165-5728(92)90176-L; Rotshenker S, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-109; Rotshenker S, 2009, J MOL NEUROSCI, V39, P99, DOI 10.1007/s12031-009-9186-7; Ruff RL, 2008, ANN NY ACAD SCI, V1142, P1, DOI 10.1196/annals.1444.004; Seijffers R, 2006, MOL CELL NEUROSCI, V32, P143, DOI 10.1016/j.mcn.2006.03.005; Shamash S, 2002, J NEUROSCI, V22, P3052, DOI 10.1523/JNEUROSCI.22-08-03052.2002; Shi C, 2011, NAT REV IMMUNOL, V11, P762, DOI 10.1038/nri3070; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Simard JM, 2007, J CLIN INVEST, V117, P2105, DOI 10.1172/JCI32041; Stirling DP, 2009, J NEUROSCI, V29, P753, DOI 10.1523/JNEUROSCI.4918-08.2009; Stoll G, 2002, J PERIPHER NERV SYST, V7, P13, DOI 10.1046/j.1529-8027.2002.02002.x; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Taoka Y, 1997, NEUROSCIENCE, V79, P1177, DOI 10.1016/S0306-4522(97)00011-0; Thompson SWN, 1997, EUR J NEUROSCI, V9, P1244, DOI 10.1111/j.1460-9568.1997.tb01479.x; Trigueros SDA, 2003, MOL CELL NEUROSCI, V24, P753, DOI 10.1016/S1044-7431(03)00241-0; TRUPP M, 1995, J CELL BIOL, V130, P137, DOI 10.1083/jcb.130.1.137; Vargas ME, 2007, ANNU REV NEUROSCI, V30, P153, DOI 10.1146/annurev.neuro.30.051606.094354; Vargas ME, 2010, P NATL ACAD SCI USA, V107, P11993, DOI 10.1073/pnas.1001948107; Wagner R, 1996, NEUROSCIENCE, V73, P625, DOI 10.1016/0306-4522(96)00127-3; Waller, 1850, PHILOS T R SOC LOND, VI, P423, DOI [10.1098/rspl.1843.0224, DOI 10.1098/RSTL.1850.0021]; Wang JT, 2012, J CELL BIOL, V196, P7, DOI 10.1083/jcb.201108111; WEKERLE H, 1986, EUR J IMMUNOL, V16, P1551, DOI 10.1002/eji.1830161214; Williams MR, 2011, TRENDS IMMUNOL, V32, P461, DOI 10.1016/j.it.2011.06.009; Winzeler AM, 2011, J NEUROSCI, V31, P6481, DOI 10.1523/JNEUROSCI.3004-10.2011; Ydens E, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-176; Yin YQ, 2006, NAT NEUROSCI, V9, P843, DOI 10.1038/nn1701; Yin YQ, 2009, P NATL ACAD SCI USA, V106, P19587, DOI 10.1073/pnas.0907085106; Yiu G, 2006, NAT REV NEUROSCI, V7, P617, DOI 10.1038/nrn1956; Yong VW, 2005, NAT REV NEUROSCI, V6, P931, DOI 10.1038/nrn1807; You SJ, 1997, GLIA, V20, P87, DOI 10.1002/(SICI)1098-1136(199706)20:2<87::AID-GLIA1>3.0.CO;2-1; Zedler S, 2006, CURR OPIN CRIT CARE, V12, P595, DOI 10.1097/MCC.0b013e3280106806; Zhai QW, 2003, NEURON, V39, P217, DOI 10.1016/S0896-6273(03)00429-X; Zhou H, 2009, J IMMUNOL, V183, P5244, DOI 10.4049/jimmunol.0901309	133	102	104	2	19	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	0962-9351	1466-1861		MEDIAT INFLAMM	Mediat. Inflamm.		2015	2015								251204	10.1155/2015/251204			14	Cell Biology; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Immunology	CF9HC	WOS:000352874000001	25918475	Green Submitted, gold, Green Published			2022-02-06	
J	Easter, JS; Bakes, K; Dhaliwal, J; Miller, M; Caruso, E; Haukoos, JS				Easter, Joshua S.; Bakes, Katherine; Dhaliwal, Jasmeet; Miller, Michael; Caruso, Emily; Haukoos, Jason S.			Comparison of PECARN, CATCH, and CHALICE Rules for Children With Minor Head Injury: A Prospective Cohort Study	ANNALS OF EMERGENCY MEDICINE			English	Article							CLINICAL DECISION RULES; COMPUTED-TOMOGRAPHY; RADIATION-EXPOSURE; 3 COUNTRIES; EMERGENCY; PREDICTION; MANAGEMENT; ASTHMA; RISK	Study objective: We evaluate the diagnostic accuracy of clinical decision rules and physician judgment for identifying clinically important traumatic brain injuries in children with minor head injuries presenting to the emergency department. Methods: We prospectively enrolled children younger than 18 years and with minor head injury (Glasgow Coma Scale score 13 to 15), presenting within 24 hours of their injuries. We assessed the ability of 3 clinical decision rules (Canadian Assessment of Tomography for Childhood Head Injury [CATCH], Children's Head Injury Algorithm for the Prediction of Important Clinical Events [CHALICE], and Pediatric Emergency Care Applied Research Network [PECARN]) and 2 measures of physician judgment (estimated of <1% risk of traumatic brain injury and actual computed tomography ordering practice) to predict clinically important traumatic brain injury, as defined by death from traumatic brain injury, need for neurosurgery, intubation greater than 24 hours for traumatic brain injury, or hospital admission greater than 2 nights for traumatic brain injury. Results: Among the 1,009 children, 21 (2%; 95% confidence interval [CI] 1% to 3%) had clinically important traumatic brain injuries. Only physician practice and PECARN identified all clinically important traumatic brain injuries, with ranked sensitivities as follows: physician practice and PECARN each 100% (95% CI 84% to 100%), physician estimates 95% (95% CI 76% to 100%), CATCH 91% (95% CI 70% to 99%), and CHALICE 84% (95% CI 60% to 97%). Ranked specificities were as follows: CHALICE 85% (95% CI 82% to 87%), physician estimates 68% (95% CI 65% to 71%), PECARN 62% (95% CI 59% to 66%), physician practice 50% (95% CI 47% to 53%), and CATCH 44% (95% CI 41% to 47%). Conclusion: Of the 5 modalities studied, only physician practice and PECARN identified all clinically important traumatic brain injuries, with PECARN being slightly more specific. CHALICE was incompletely sensitive but the most specific of all rules. CATCH was incompletely sensitive and had the poorest specificity of all modalities.	[Easter, Joshua S.; Bakes, Katherine; Caruso, Emily; Haukoos, Jason S.] Denver Hlth, Dept Emergency Med, Denver Emergency Ctr Children, Denver, CO 80204 USA; [Easter, Joshua S.; Bakes, Katherine; Caruso, Emily; Haukoos, Jason S.] Univ Colorado, Sch Med, Dept Emergency Med, Aurora, CO USA; [Easter, Joshua S.] Bon Secours St Marys Hosp, Dept Emergency Med, Richmond, VA USA; [Easter, Joshua S.] Univ Virginia, Dept Emergency Med, Charlottesville, VA USA; [Dhaliwal, Jasmeet; Miller, Michael] Denver Hlth Emergency Med Residency, Denver, CO USA; [Haukoos, Jason S.] Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO USA		Easter, JS (corresponding author), Denver Hlth, Dept Emergency Med, Denver Emergency Ctr Children, Denver, CO 80204 USA.	joshua_easter@bshsi.org			Agency for Healthcare Research and QualityUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [K12HS019464, K02HS017526]; National Institutes of Health (NIH)/NCATS Colorado Clinical and Translational Science Institute [UL1 TR001082]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITYUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [K12HS019464, K02HS017526] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001082] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01AI106057] Funding Source: NIH RePORTER	By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org). Dr. Easter (K12HS019464) and Dr. Haukoos (K02HS017526) had financial support from the Agency for Healthcare Research and Quality for the submitted work. Dr. Easter was also supported by National Institutes of Health (NIH)/NCATS Colorado Clinical and Translational Science Institute grant UL1 TR001082. No authors had financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years.	Bleeker SE, 2003, J CLIN EPIDEMIOL, V56, P826, DOI 10.1016/S0895-4356(03)00207-5; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; CENTOR RM, 1984, NEW ENGL J MED, V310, P577, DOI 10.1056/NEJM198403013100907; Dunning J, 2006, ARCH DIS CHILD, V91, P885, DOI 10.1136/adc.2005.083980; Hamilton M, 2010, PEDIATRICS, V126, pE33, DOI 10.1542/peds.2009-0692; Hennelly KE, 2013, J PEDIATR-US, V162, P392, DOI 10.1016/j.jpeds.2012.07.018; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Lyttle MD, 2013, EMERG MED J, V30, P790, DOI 10.1136/emermed-2012-201887; Lyttle MD, 2012, EMERG MED J, V29, P785, DOI 10.1136/emermed-2011-200225; Mannix R, 2012, J PEDIATR-US, V160, P136, DOI 10.1016/j.jpeds.2011.06.024; Martin TP, 1997, ANN EMERG MED, V29, P459, DOI 10.1016/S0196-0644(97)70217-8; McGinn TG, 2000, JAMA-J AM MED ASSOC, V284, P79, DOI 10.1001/jama.284.1.79; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0; Perry JJ, 2012, CAN J EMERG MED, V14, P83, DOI 10.2310/8000.2012.110552; Perry JJ, 2011, CAN J EMERG MED, V13, P19, DOI 10.2310/8000.2011.100269; Perry JJ, 2009, CAN J EMERG MED, V11, P516; ROSE CC, 1984, NEW ENGL J MED, V310, P573, DOI 10.1056/NEJM198403013100906	18	102	105	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	AUG	2014	64	2					145	152		10.1016/j.annemergmed.2014.01.030			8	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	AM9PV	WOS:000340214400009	24635987	Green Accepted			2022-02-06	
J	Higgins, DM; Kerns, RD; Brandt, CA; Haskell, SG; Bathulapalli, H; Gilliam, W; Goulet, JL				Higgins, Diana M.; Kerns, Robert D.; Brandt, Cynthia A.; Haskell, Sally G.; Bathulapalli, Harini; Gilliam, Wesley; Goulet, Joseph L.			Persistent Pain and Comorbidity Among Operation Enduring Freedom/Operation Iraqi Freedom/Operation New Dawn Veterans	PAIN MEDICINE			English	Article						Anxiety; Depression; Obesity; Pain Management; Persistent Pain; Post-traumatic Stress Syndrome; Substance Abuse	TRAUMATIC BRAIN-INJURY; CHRONIC BACK-PAIN; OLDER-ADULTS; CARE; PREVALENCE; POLYTRAUMA; DEPRESSION; DISORDERS; AFGHANISTAN; MANAGEMENT	ObjectiveChronic pain is a significant concern for the Veterans Health Administration (VHA), with chronic pain conditions among those most frequently reported by Operation Enduring Freedom (OEF)/Operation Iraqi Freedom (OIF)/Operation New Dawn (OND) veterans. The current study examined VHA electronic medical record data to examine variation in demographics and high prevalence and high impact medical and mental health conditions in order to characterize the differences between patients with persistent pain and no pain. DesignA conservative operational definition of chronic or persistent pain based on multiple indicators of pain (i.e., pain intensity ratings, prescription opioids, pain clinic visits, International Classification of Diseases, Ninth Revision codes) was employed. Analyses included the entire roster of longitudinal clinical data on OEF/OIF/OND veterans who used VHA care to compare those with persistent pain with those with no clinical evidence of pain. ResultsResults of logistic regression models suggest that sex, race, education, military variables, body mass index (BMI), traumatic brain injury (TBI), and mental health conditions, but not age, reliably discriminate the two groups. Those with persistent pain were more likely to be Black, female, on active duty, enlisted, Army service members, have a high school education or less, and have diagnoses of mood disorders, post-traumatic stress disorder, substance use disorders, anxiety disorders, TBI, and have a BMI consistent with overweight and obesity. ConclusionsThe operational definition of chronic pain used in this study may have research implications for examining predictors of incident and chronic pain. These data have important clinical implications in that addressing comorbid conditions of persistent pain may improve adaptive coping and functioning in these patients.	[Higgins, Diana M.] VA Boston Healthcare Syst, Boston, MA 02130 USA; [Higgins, Diana M.] Boston Univ, Sch Med, Boston, MA 02118 USA; [Kerns, Robert D.; Brandt, Cynthia A.; Haskell, Sally G.; Goulet, Joseph L.] VA Connecticut Healthcare Syst, West Haven, CT USA; [Kerns, Robert D.; Brandt, Cynthia A.; Haskell, Sally G.; Bathulapalli, Harini; Goulet, Joseph L.] Yale Univ, Sch Med, New Haven, CT USA		Higgins, DM (corresponding author), VA Boston Healthcare Syst, Res Serv Psychol Serv 116B-2,150 South Huntington, Boston, MA 02130 USA.	diana.higgins2@va.gov	Bathulapalli, Harini/B-7451-2015	Bathulapalli, Harini/0000-0002-2531-0238; Goulet, Joseph/0000-0002-0842-804X	VA Health Services Research and Development award [DHI07-065]; Veterans AffairsUS Department of Veterans Affairs [I01HX000915] Funding Source: NIH RePORTER	This research was supported by a VA Health Services Research and Development award (PI: SH & CB), #DHI07-065.	Agency for Healthcare Research and Quality (AHRQ), 2009, CLIN CLASS SOFTW CCS; Bair MJ, 2008, PSYCHOSOM MED, V70, P890, DOI 10.1097/PSY.0b013e318185c510; Buckwalter JA, 2000, CLIN ORTHOP RELAT R, P159; Burgess DJ, 2013, CLIN J PAIN, V29, P118, DOI 10.1097/AJP.0b013e31826a86ae; Carroll LJ, 2004, PAIN, V107, P134, DOI 10.1016/j.pain.2003.10.009; Clark ME, 2007, J REHABIL RES DEV, V44, P179, DOI 10.1682/JRRD.2006.05.0057; Cleeland CS, 2003, CLIN J PAIN, V19, P298, DOI 10.1097/00002508-200309000-00003; Currie SR, 2004, PAIN, V107, P54, DOI 10.1016/j.pain.2003.09.015; Department of Veterans Affairs, 1999, VET HLTH ADM MEM PAI; Edlund MJ, 2007, PAIN, V129, P355, DOI 10.1016/j.pain.2007.02.014; Frayne S, 2010, J GEN INTERN MED, V25, P333; GATCHEL RJ, 1995, HEALTH PSYCHOL, V14, P415, DOI 10.1037/0278-6133.14.5.415; Gironda RJ, 2009, REHABIL PSYCHOL, V54, P247, DOI 10.1037/a0016906; Goulet JL, 2007, CLIN INFECT DIS, V45, P1593, DOI 10.1086/523577; Green CR, 2003, J PAIN, V4, P82, DOI 10.1054/jpai.2003.8; Hagen EM, 2006, SPINE, V31, P1491, DOI 10.1097/01.brs.0000219947.71168.08; Hankin CS, 1999, AM J PSYCHIAT, V156, P1924; Haskell SG, 2011, WOMEN HEALTH ISS, V21, P92, DOI 10.1016/j.whi.2010.08.001; Haskell SG, 2009, PAIN MED, V10, P1167, DOI 10.1111/j.1526-4637.2009.00714.x; Hestbaek L, 2003, J MANIP PHYSIOL THER, V26, P243, DOI 10.1016/S0161-4754(03)00003-4; Institute of Medicine of the National Academies, 2011, REL PAIN AM BLU TRAN; Janke EA, 2007, J REHABIL RES DEV, V44, P245, DOI 10.1682/JRRD.2006.06.0060; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; LURIE N, 1992, HOSP COMMUNITY PSYCH, V43, P69; National Heart Lung and Blood Institute, 1998, CLIN GUID ID EV TREA; Quintana JM, 2008, AGING CLIN EXP RES, V20, P329; Sayer NA, 2009, PM&R, V1, P23, DOI 10.1016/j.pmrj.2008.10.003; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Shipherd JC, 2007, J REHABIL RES DEV, V44, P153, DOI 10.1682/JRRD.2006.06.0065; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; VHA Office of Public Health and Environmental Hazards, 2009, VHA OFF PUBL HLTH EN; Walkup JT, 2004, MED CARE, V42, P756, DOI 10.1097/01.mlr.0000132749.20897.46; Wijnhoven HAH, 2006, CLIN J PAIN, V22, P717, DOI 10.1097/01.ajp.0000210912.95664.53	33	102	103	1	23	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1526-2375	1526-4637		PAIN MED	Pain Med.	MAY	2014	15	5					782	790		10.1111/pme.12388			9	Anesthesiology; Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology; General & Internal Medicine	AH9JS	WOS:000336458900011	24548466	Bronze			2022-02-06	
J	Tan, KT; Huang, HH; Sun, CT				Tan, K. T.; Huang, H. H.; Sun, C. T.			Blast-wave impact mitigation using negative effective mass density concept of elastic metamaterials	INTERNATIONAL JOURNAL OF IMPACT ENGINEERING			English	Article						Blast-wave; Negative effective mass density; Elastic metamaterials; Wave propagation; Wave attenuation	TRAUMATIC BRAIN-INJURY; SIMULATION; MODULUS	This paper presents the use of elastic metamaterials for impact attenuation and blast-wave mitigation. Metamaterials represent a novel and emerging research area where materials exhibit exceptional properties not commonly found in natural materials. These unique properties are enacted by specifically designed microstructures. In this study, a single-resonator model and a dual-resonator microstructural design are proposed to exhibit negative effective mass density. The effect of negative effective mass density is explicitly confirmed by analysis of wave propagation using numerical simulations. Results evidently show that impact stress wave attenuation occurs over a wider frequency spectrum for the dual-resonator model as compared to the narrow band gap of a single-resonator design. Parametric studies of blast-wave simulation reveal that the mass and number of internal resonators have significant influence over the frequency range of blast-wave attenuation. The effectiveness and performance of the single-resonator and dual-resonator models on blast-wave mitigation are examined and discussed. Finally, practical ways to design and manufacture elastic metamaterials with negative effective mass density are presented and explored. (C) 2013 Elsevier Ltd. All rights reserved.	[Tan, K. T.; Sun, C. T.] Purdue Univ, Sch Aeronaut & Astronaut, W Lafayette, IN 47907 USA; [Huang, H. H.] Natl Taiwan Univ, Dept Engn Sci & Ocean Engn, Taipei 10617, Taiwan		Tan, KT (corresponding author), Purdue Univ, Sch Aeronaut & Astronaut, W Lafayette, IN 47907 USA.	kttan@purdue.edu		Tan, K.T./0000-0003-1266-6582	Agency for Science, Technology and Research (A*STAR, Singapore)Agency for Science Technology & Research (ASTAR); National Science Council, TaiwanMinistry of Science and Technology, Taiwan [NSC-101-2218-E-002-013-MY3]; AFOSRUnited States Department of DefenseAir Force Office of Scientific Research (AFOSR) [FA9550-10-1-0061]	K.T. Tan gratefully appreciates the financial support provided by Agency for Science, Technology and Research (A*STAR, Singapore). H.H. Huang acknowledges the financial support from the National Science Council, Taiwan, grant NSC-101-2218-E-002-013-MY3. C.T. Sun would like to acknowledge the support by an AFOSR grant #FA9550-10-1-0061.	Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; Chen JS, 2011, COMPOS STRUCT, V93, P2120, DOI 10.1016/j.compstruct.2011.02.007; Christou GA, 2012, INT J IMPACT ENG, V47, P48, DOI 10.1016/j.ijimpeng.2012.03.003; Dawson MA, 2009, INT J IMPACT ENG, V36, P1288, DOI 10.1016/j.ijimpeng.2009.03.008; Fang N, 2006, NAT MATER, V5, P452, DOI 10.1038/nmat1644; Grujicic M, 2013, MATER DESIGN, V51, P113, DOI 10.1016/j.matdes.2013.04.004; Grujicic M, 2010, MATER DESIGN, V31, P4050, DOI 10.1016/j.matdes.2010.05.002; Huang HH, 2011, J MECH PHYS SOLIDS, V59, P2070, DOI 10.1016/j.jmps.2011.07.002; Huang HH, 2009, INT J ENG SCI, V47, P610, DOI 10.1016/j.ijengsci.2008.12.007; Huang HH, 2009, NEW J PHYS, V11, DOI 10.1088/1367-2630/11/1/013003; Lai Y, 2011, NAT MATER, V10, P620, DOI [10.1038/nmat3043, 10.1038/NMAT3043]; Li J, 2004, PHYS REV E, V70, DOI 10.1103/PhysRevE.70.055602; Liu ZY, 2000, SCIENCE, V289, P1734, DOI 10.1126/science.289.5485.1734; Milton GW, 2007, P ROY SOC A-MATH PHY, V463, P855, DOI 10.1098/rspa.2006.1795; Nesterenko VF, GRANULAR MAT BASED T, V759; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Pendry JB, 2000, PHYS REV LETT, V85, P3966, DOI 10.1103/PhysRevLett.85.3966; Su ZB, 2008, INT J IMPACT ENG, V35, P336, DOI 10.1016/j.ijimpeng.2007.04.001; Sun CT, 2013, DEV NEGATIVE E UNPUB, P1; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Tan KT, 2012, APPL PHYS LETT, V101, DOI 10.1063/1.4770370; Valentine J, 2008, NATURE, V455, P376, DOI 10.1038/nature07247; Wadley HNG, 2010, INT J IMPACT ENG, V37, P317, DOI 10.1016/j.ijimpeng.2009.06.006; Yao SS, 2008, NEW J PHYS, V10, DOI 10.1088/1367-2630/10/4/043020	24	102	105	4	61	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0734-743X	1879-3509		INT J IMPACT ENG	Int. J. Impact Eng.	FEB	2014	64						20	29		10.1016/j.ijimpeng.2013.09.003			10	Engineering, Mechanical; Mechanics	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Mechanics	278TK	WOS:000328912500002					2022-02-06	
J	Dams-O'Connor, K; Gibbons, LE; Bowen, JD; McCurry, SM; Larson, EB; Crane, PK				Dams-O'Connor, Kristen; Gibbons, Laura E.; Bowen, James D.; McCurry, Susan M.; Larson, Eric B.; Crane, Paul K.			Risk for late-life re-injury, dementia and death among individuals with traumatic brain injury: a population-based study	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							ALZHEIMERS-DISEASE; HEAD-INJURY; APOLIPOPROTEIN-E; REHABILITATION; AGE	Objectives To determine the association of self-reported traumatic brain injury (TBI) with loss of consciousness (LOC) with late-life re-injury, dementia diagnosis and mortality. Design Ongoing longitudinal population-based prospective cohort study. Setting Seattle-area integrated health system. Participants 4225 dementia-free individuals age 65 and older were randomly selected and enrolled between 1994 and 2010. Participants were seen every 2 years, with mean (range) follow-up of 7.4 (0-16) years. 606 (14%) participants reported a lifetime history of TBI with LOC at enrolment. 3466 participants provided information regarding lifetime history of TBI and completed at least one follow-up visit. Main outcome measures Self-reported TBI with LOC after study entry, incident all-cause dementia and Alzheimer's disease (AD), and all-cause mortality. Results There were 25 567 person-years of follow-up. History of TBI with LOC reported at study enrolment was associated with increased risk for TBI with LOC during follow-up, with adjusted HRs ranging from 2.54 (95% CI 1.42 to 4.52) for those reporting first injury before age 25 to 3.79 (95% CI 1.89 to 7.61) for those with first injury after age 55. History of TBI with LOC was not associated with elevated risk for developing dementia or AD. There was no association between baseline history of TBI with LOC and mortality, though TBI with LOC since the previous study visit ('recent TBI') was associated with increased mortality (HR 2.12, 95% CI 1.62 to 2.78). Conclusions Individuals aged 65 or older who reported a history of TBI with LOC at any time in their lives were at elevated risk of subsequent re-injury. Recent TBI with LOC sustained in older adulthood was associated with increased risk for mortality. Findings support the need for close clinical monitoring of older adults who sustain a TBI with LOC.	[Dams-O'Connor, Kristen] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA; [Gibbons, Laura E.; Larson, Eric B.; Crane, Paul K.] Univ Washington, Dept Med, Seattle, WA USA; [Bowen, James D.] Swedish Neurosci Inst, Seattle, WA USA; [McCurry, Susan M.] Univ Washington, Sch Nursing, Dept Psychosocial & Community Hlth, Seattle, WA 98195 USA; [Larson, Eric B.] Grp Hlth Res Inst, Seattle, WA USA		Dams-O'Connor, K (corresponding author), Mt Sinai Sch Med, Dept Rehabil Med, 1 Gustave Levy Pl,Box 1240, New York, NY 10029 USA.	kristen.dams-o'connor@mountsinai.org	McCurry, Susan M/E-4731-2015	McCurry, Susan M/0000-0001-8624-3772; Crane, Paul/0000-0003-4278-7465	National Institute on Aging (NIA) of the National Institutes of Health (NIH) [U01 AG006781]; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R24 HD065702]; NIH/NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K01HD074651, R24HD065702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [U01AG006781] Funding Source: NIH RePORTER	This project was supported by Grant Number #U01 AG006781 from the National Institute on Aging (NIA) of the National Institutes of Health (NIH) and Grant Number #R24 HD065702 from the National Institutes of Health (NIH). The NIH did not play any role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication. The authors submit this manuscript independent from the funding source.; EBL and PKC received support from NIH/NIA for the submitted work. EBL is employed by Group Health Research Institute where the Adult Changes in Thought Study is run, and receives royalties from book chapters.	American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; de la Plata CAM, 2008, ARCH PHYS MED REHAB, V89, P896, DOI 10.1016/j.apmr.2007.12.030; Faul M, 2010, TRAUMATIC BRAIN INJU; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Giza CC, 2001, J ATHL TRAINING, V36, P228; Harrison-Felix C, 2006, J HEAD TRAUMA REHAB, V21, P22, DOI 10.1097/00001199-200601000-00003; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; Hill G, 2003, J CLIN EPIDEMIOL, V56, P293, DOI 10.1016/S0895-4356(02)00571-1; Institute of Medicine Committee on Gulf War Health, 2009, GULF WAR HLTH, V7, P197; KATZMAN R, 1989, ANN NEUROL, V25, P317, DOI 10.1002/ana.410250402; Kukull WA, 2002, ARCH NEUROL-CHICAGO, V59, P1737, DOI 10.1001/archneur.59.11.1737; Larson EB, 2006, ANN INTERN MED, V144, P73, DOI 10.7326/0003-4819-144-2-200601170-00004; Launer LJ, 1999, NEUROLOGY, V52, P78, DOI 10.1212/WNL.52.1.78; Luukinen H, 2005, EUR J NEUROL, V12, P86, DOI 10.1111/j.1468-1331.2004.00953.x; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Ponsford J, 2011, J NEUROTRAUM, V28, P1683, DOI 10.1089/neu.2010.1623; SALCIDO R, 1992, Brain Injury, V6, P293, DOI 10.3109/02699059209029671; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; StataCorp, 2011, STAT STAT SOFTW REL; Teng E L, 1994, Int Psychogeriatr, V6, P45, DOI 10.1017/S1041610294001602; Thompson HJ, 2012, J NEUROTRAUM, V29, P1864, DOI 10.1089/neu.2011.2284; Ventura T, 2010, ARCH PHYS MED REHAB, V91, P20, DOI 10.1016/j.apmr.2009.08.151; WILLIAMS DB, 1991, NEUROLOGY, V41, P1554, DOI 10.1212/WNL.41.10.1554	32	102	102	1	26	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	FEB	2013	84	2					177	182		10.1136/jnnp-2012-303938			6	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Surgery	070ZP	WOS:000313554700012	23172868	Green Accepted			2022-02-06	
J	Ropper, AH				Ropper, Allan H.			Hyperosmolar Therapy for Raised Intracranial Pressure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; CEREBROSPINAL-FLUID PRESSURE; SEVERE HEAD-INJURY; HYPERTONIC SALINE; MANNITOL; HYPERTENSION; CHILDREN; DEATH; CARE	A 49-year-old female passenger was thrown against the doorframe during an automobile accident. After being pulled from the car, she opened her eyes intermittently, moaned, and had flexion withdrawal of her limbs (Glasgow Coma Scale score, 8). Her pupils were 5 mm in diameter and reactive to light. Her blood pressure was 165/85 mm Hg, her heart rate 112 beats per minute, and her breathing regular. After her spine was stabilized, she was conveyed to an intensive care unit (ICU). In the ICU, she no longer opened her eyes, had flexion posturing of her arms, and made no verbal responses (Glasgow Coma Scale score, 5). There was a contusion on her right frontal scalp but no sign of other organ injury. Computed tomography showed large regions of frontal brain contusion with surrounding edema (Fig. 1). The patient was intubated, and an external ventricular drain was placed in order to measure intracranial pressure, which was 29 mm Hg with periodic elevations to 36 mm Hg. After drainage of cerebrospinal fluid, the intracranial pressure transiently decreased to 26 mm Hg. The serum sodium concentration was 139 mmol per liter. The neurointensivist recommended an intravenous bolus infusion of 23% saline to reduce intracranial pressure and attain a serum sodium concentration of 150 mmol per liter. The patient's weight was 55 kg.	Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA		Ropper, AH (corresponding author), Brigham & Womens Hosp, Dept Neurol, 75 Francis St, Boston, MA 02115 USA.	aropper@partners.org					Adrogue HJ, 2000, NEW ENGL J MED, V342, P1493, DOI 10.1056/NEJM200005183422006; Baker A, 2006, CAN J ANAESTH, V53, P722, DOI 10.1007/BF03021632; Better OS, 1997, KIDNEY INT, V52, P886, DOI 10.1038/ki.1997.409; Bullock MR, 2007, J NEUROTRAUMA S1, V24, pS14; Bullock MR, 2007, J NEUROTRAUM, V24, pvii; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Diringer MN, 2004, NEUROCRIT CARE, V1, P219, DOI 10.1385/NCC:1:2:219; FISHER B, 1992, J NEUROSURG ANESTH, V4, P4, DOI 10.1097/00008506-199201000-00002; Francony G, 2008, CRIT CARE MED, V36, P795, DOI 10.1097/CCM.0B013E3181643B41; Horn P, 1999, NEUROL RES, V21, P758, DOI 10.1080/01616412.1999.11741010; JAMES HE, 1977, ACTA NEUROCHIR, V36, P189, DOI 10.1007/BF01405391; JAVID M, 1956, JAMA-J AM MED ASSOC, V160, P943, DOI 10.1001/jama.1956.02960460021006; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kellie George, 1824, Trans Med Chir Soc Edinb, V1, P84; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Koenig MA, 2008, NEUROLOGY, V70, P1023, DOI 10.1212/01.wnl.0000304042.05557.60; Langlois JA, 2006, TRAUMATIC BRAIN INJU; MCDOWELL ME, 1955, AM J PHYSIOL, V180, P545, DOI 10.1152/ajplegacy.1955.180.3.545; Monro A., 1835, OBSERVATIONS STRUCTU, V1835, P5; MUIZELAAR JP, 1983, J NEUROSURG, V59, P822, DOI 10.3171/jns.1983.59.5.0822; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; Paczynski RP, 1997, CRIT CARE CLIN, V13, P105, DOI 10.1016/S0749-0704(05)70298-0; Palo J, 1999, LANCET, V354, P1909, DOI 10.1016/S0140-6736(05)76879-3; Simma B, 1998, CRIT CARE MED, V26, P1265, DOI 10.1097/00003246-199807000-00032; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Treggiari MM, 2007, NEUROCRIT CARE, V6, P104, DOI 10.1007/s12028-007-0012-1; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; Videen TO, 2001, NEUROLOGY, V57, P2120, DOI 10.1212/WNL.57.11.2120; Weed LH, 1919, AM J PHYSIOL, V48, P512, DOI 10.1152/ajplegacy.1919.48.4.512; WISE BL, 1962, J NEUROSURG, V19, P1038, DOI 10.3171/jns.1962.19.12.1038	30	102	110	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 23	2012	367	8					746	752		10.1056/NEJMct1206321			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	992CX	WOS:000307754200009	22913684				2022-02-06	
J	Liu, AL; Margaill, I; Zhang, SD; Labombarda, F; Coqueran, B; Delespierre, B; Liere, P; Marchand-Leroux, C; O'Malley, BW; Lydon, JP; De Nicola, AF; Sitruk-Ware, R; Mattern, C; Plotkine, M; Schumacher, M; Guennoun, R				Liu, Ailing; Margaill, Isabelle; Zhang, Shaodong; Labombarda, Florencia; Coqueran, Berard; Delespierre, Brigitte; Liere, Philippe; Marchand-Leroux, Catherine; O'Malley, Bert W.; Lydon, John P.; De Nicola, Alejandro F.; Sitruk-Ware, Regine; Mattern, Claudia; Plotkine, Michel; Schumacher, Michael; Guennoun, Rachida			Progesterone Receptors: A Key for Neuroprotection in Experimental Stroke	ENDOCRINOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; MIDDLE CEREBRAL-ARTERY; NEUROACTIVE STEROIDS; INFARCT VOLUME; SPINAL-CORD; MICE; NEUROSTEROIDS; OCCLUSION; ISCHEMIA; QUANTIFICATION	Progesterone receptors (PR) are expressed throughout the brain. However, their functional significance remains understudied. Here we report a novel role of PR as crucial mediators of neuroprotection using a model of transient middle cerebral artery occlusion and PR knockout mice. Six hours after ischemia, we observed a rapid increase in progesterone and 5 alpha-dihydroprogesterone, the endogenous PR ligands, a process that may be a part of the natural neuroprotective mechanisms. PR deficiency, and even haploinsufficiency, increases the susceptibility of the brain to stroke damage. Within a time window of 24 h, PR-dependent signaling of endogenous brain progesterone limits the extent of tissue damage and the impairment of motor functions. Longer-term improvement requires additional treatment with exogenous progesterone and is also PR dependent. The potent and selective PR agonist Nestorone is also effective. In contrast to progesterone, levels of the neurosteroid allopregnanolone, which modulates gamma-aminobutyric acid type A receptors, did not increase after stroke, but its administration protected both wild-type and PR-deficient mice against ischemic damage. These results show that 1) PR are linked to signaling pathways that influence susceptibility to stroke, and 2) PR are direct key targets for both endogenous neuroprotection and for therapeutic strategies after stroke, and they suggest a novel indication for synthetic progestins already validated for contraception. Although allopregnanolone may not be an endogenous neuroprotective agent, its administration protects the brain against ischemic damage by signaling mechanisms not involving PR. Collectively, our data clarify the relative roles of PR and allopregnanolone in neuroprotection after stroke. (Endocrinology 153: 3747-3757, 2012)	[Liu, Ailing; Zhang, Shaodong; Delespierre, Brigitte; Liere, Philippe; Schumacher, Michael; Guennoun, Rachida] Inst Natl Sante & Rech Med, Unite Mixte Rech 788, F-94276 Le Kremlin Bicetre, France; [Liu, Ailing; Zhang, Shaodong; Delespierre, Brigitte; Liere, Philippe; Schumacher, Michael; Guennoun, Rachida] Univ Paris 11, F-94276 Le Kremlin Bicetre, France; [Margaill, Isabelle; Coqueran, Berard; Marchand-Leroux, Catherine; Plotkine, Michel] Univ Paris 05, Pharmacol Circulat Cerebrale EA4475, F-75006 Paris, France; [Labombarda, Florencia; De Nicola, Alejandro F.] Univ Buenos Aires, Inst Biol & Med Expt, RA-1428 Buenos Aires, DF, Argentina; [Labombarda, Florencia; De Nicola, Alejandro F.] Univ Buenos Aires, Dept Human Biochem, RA-1428 Buenos Aires, DF, Argentina; [O'Malley, Bert W.; Lydon, John P.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Sitruk-Ware, Regine] Rockefeller Univ, Populat Council, Ctr Biomed Res, New York, NY 10065 USA; [Mattern, Claudia] M&P Pharma AG, CH-6370 Stans, Switzerland		Guennoun, R (corresponding author), Inst Natl Sante & Rech Med, Unite Mixte Rech 788, 80 Rue Gen Leclerc, F-94276 Le Kremlin Bicetre, France.	rachida.guennoun@inserm.fr	Guennoun, Rachida/F-2420-2011; Margaill, Isabelle/ABA-4362-2020; Schumacher, Michael/G-3581-2013; MARCHAND-LEROUX, Catherine/L-7453-2017	Guennoun, Rachida/0000-0002-9219-7300; Margaill, Isabelle/0000-0002-7941-6644; Schumacher, Michael/0000-0001-6117-5371; MARCHAND-LEROUX, Catherine/0000-0003-0113-5348	Institut National de la Sante et de la Recherche Medicale (INSERM), University Paris-Sud; Barrus Foundation; University Paris-Sud; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD007857, R01HD008188] Funding Source: NIH RePORTER	This work was supported by Institut National de la Sante et de la Recherche Medicale (INSERM), University Paris-Sud, a cooperative program between the Governments of France and Argentina (INSERM/CONICET), and by the Barrus Foundation. A. L. was beneficiary of a postdoctoral fellowship from University Paris-Sud. M. S. is the beneficiary of an Interface Program of INSERM and the Assistance Publique-Hopitaux de Paris.	Attardi BJ, 2010, MOL CELL ENDOCRINOL, V328, P16, DOI 10.1016/j.mce.2010.06.010; Baulieu EE, 2001, INT REV NEUROBIOL, V46, P1; BEDERSON JB, 1986, STROKE, V17, P1304, DOI 10.1161/01.STR.17.6.1304; Belelli D, 2005, NAT REV NEUROSCI, V6, P565, DOI 10.1038/nrn1703; Blaustein JD, 2008, ENDOCRINOLOGY, V149, P2737, DOI 10.1210/en.2008-0395; Conneely OM, 2002, RECENT PROG HORM RES, V57, P339, DOI 10.1210/rp.57.1.339; Connolly ES, 1996, NEUROSURGERY, V38, P523, DOI 10.1097/00006123-199603000-00021; Dobkin BH, 2008, NAT CLIN PRACT NEURO, V4, P76, DOI 10.1038/ncpneuro0709; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; Gibson CL, 2004, J CEREBR BLOOD F MET, V24, P805, DOI 10.1097/01.WCB.0000125365.83980.00; Gibson CL, 2008, BRAIN, V131, P318, DOI 10.1093/brain/awm183; Gibson CL, 2011, BRAIN, V134, P2125, DOI 10.1093/brain/awr132; Gofflot F, 2007, CELL, V131, P405, DOI 10.1016/j.cell.2007.09.012; GOLANOV EV, 1995, J CEREBR BLOOD F MET, V15, P172, DOI 10.1038/jcbfm.1995.19; Hosie AM, 2006, NATURE, V444, P486, DOI 10.1038/nature05324; Hussain R, 2011, ENDOCRINOLOGY, V152, P3820, DOI 10.1210/en.2011-1219; Krebs CJ, 2000, P NATL ACAD SCI USA, V97, P12816, DOI 10.1073/pnas.97.23.12816; Kumar N, 2000, STEROIDS, V65, P629, DOI 10.1016/S0039-128X(00)00119-7; Labombarda F, 2006, ENDOCRINOLOGY, V147, P1847, DOI 10.1210/en.2005-0955; Labombarda F, 2010, NEUROSCIENCE, V166, P94, DOI 10.1016/j.neuroscience.2009.12.012; Langmade SJ, 2006, P NATL ACAD SCI USA, V103, P13807, DOI 10.1073/pnas.0606218103; Liere P, 2004, J LIPID RES, V45, P2287, DOI 10.1194/jlr.M400244-JLR200; Liere P, 2009, J LIPID RES, V50, P2430, DOI 10.1194/jlr.M900162-JLR200; Liu L, ENDOCRINOLOGY, V151, P5782; Liu MY, 2009, RESTOR NEUROL NEUROS, V27, P163, DOI 10.3233/RNN-2009-0467; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; LOPEZ AD, 2006, MEASURING GLOBAL BUR; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; Mani SK, 1997, HORM BEHAV, V31, P244, DOI 10.1006/hbeh.1997.1393; Meffre D, 2007, ENDOCRINOLOGY, V148, P2505, DOI 10.1210/en.2006-1678; PARSONS B, 1982, J NEUROSCI, V2, P1446; Peinnequin Andre, 2004, BMC Immunology, V5, P1, DOI 10.1186/1471-2172-5-3; PFAFF DW, 1983, SCIENCE, V219, P808, DOI 10.1126/science.6297008; Reddy DS, 2005, NEUROPHARMACOLOGY, V48, P14, DOI 10.1016/j.neuropharm.2004.09.002; Rupprecht R, 1996, EUR J PHARMACOL, V303, P227, DOI 10.1016/0014-2999(96)00036-2; RUPPRECHT R, 1993, NEURON, V11, P523, DOI 10.1016/0896-6273(93)90156-L; Sayeed I, 2006, ANN EMERG MED, V47, P381, DOI 10.1016/j.annemergmed.2005.12.011; Sayeed I, 2009, BRAIN RES, V1263, P165, DOI 10.1016/j.brainres.2009.01.045; Sayeed L, 2007, RESTOR NEUROL NEUROS, V25, P151; Schifilliti D, 2010, CNS DRUGS, V24, P893, DOI 10.2165/11584760-000000000-00000; Schumacher M, 2007, ENDOCR REV, V28, P387, DOI 10.1210/er.2006-0050; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; Stein DG, 2008, ANN EMERG MED, V51, P164, DOI 10.1016/j.annemergmed.2007.05.001; Thomas P, 2008, FRONT NEUROENDOCRIN, V29, P292, DOI 10.1016/j.yfrne.2008.01.001; Tureyen K, 2004, J NEUROSCI METH, V139, P203, DOI 10.1016/j.jneumeth.2004.04.029; van der Worp HB, 2007, BRAIN, V130, P3063, DOI 10.1093/brain/awm083; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887	48	102	104	0	19	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0013-7227	1945-7170		ENDOCRINOLOGY	Endocrinology	AUG	2012	153	8					3747	3757		10.1210/en.2012-1138			11	Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism	977JD	WOS:000306652400022	22635678	Green Published, Bronze			2022-02-06	
J	Lipton, ML; Kim, N; Park, YK; Hulkower, MB; Gardin, TM; Shifteh, K; Kim, M; Zimmerman, ME; Lipton, RB; Branch, CA				Lipton, Michael L.; Kim, Namhee; Park, Young K.; Hulkower, Miriam B.; Gardin, Tova M.; Shifteh, Keivan; Kim, Mimi; Zimmerman, Molly E.; Lipton, Richard B.; Branch, Craig A.			Robust detection of traumatic axonal injury in individual mild traumatic brain injury patients: Intersubject variation, change over time and bidirectional changes in anisotropy	BRAIN IMAGING AND BEHAVIOR			English	Article						Mild traumatic brain injury (mTBI); MRI; Diffusion tensor imaging (DTI); Traumatic axonal injury (TAI); Image processing and analysis	TENSOR IMAGING DETECTS; WHITE-MATTER INTEGRITY; MOUSE MODEL; EXECUTIVE DYSFUNCTION; REGISTRATION; MODERATE; DAMAGE; ABNORMALITIES; PATHOGENESIS; IMPAIRMENT	To identify and characterize otherwise occult inter-individual spatial variation of white matter abnormalities across mild traumatic brain injury (mTBI) patients. After informed consent and in compliance with Health Insurance Portability and Accountability Act (HIPAA), Diffusion tensor imaging (DTI) was performed on a 3.0 T MR scanner in 34 mTBI patients (19 women; 19-64 years old) and 30 healthy control subjects. The patients were imaged within 2 weeks of injury, 3 months after injury, and 6 months after injury. Fractional anisotropy (FA) images were analyzed in each patient. To examine white matter diffusion abnormalities across the entire brain of individual patients, we applied Enhanced Z-score Microstructural Assessment for Pathology (EZ-MAP), a voxelwise analysis optimized for the assessment of individual subjects. Our analysis revealed areas of abnormally low or high FA (voxel-wise P-value < 0.05, cluster-wise P-value < 0.01(corrected for multiple comparisons)). The spatial pattern of white matter FA abnormalities varied among patients. Areas of low FA were consistent with known patterns of traumatic axonal injury. Areas of high FA were most frequently detected in the deep and subcortical white matter of the frontal, parietal, and temporal lobes, and in the anterior portions of the corpus callosum. The number of both abnormally low and high FA voxels changed during follow up. Individual subject assessments reveal unique spatial patterns of white matter abnormalities in each patient, attributable to inter-individual differences in anatomy, vulnerability to injury and mechanism of injury. Implications of high FA remain unclear, but may evidence a compensatory mechanism or plasticity in response to injury, rather than a direct manifestation of brain injury.	[Lipton, Michael L.; Kim, Namhee; Park, Young K.; Hulkower, Miriam B.; Gardin, Tova M.; Branch, Craig A.] Yeshiva Univ, Gruss Magnet Resonance Res Ctr, Albert Einstein Coll Med, Bronx, NY 10461 USA; [Lipton, Michael L.; Kim, Namhee; Branch, Craig A.] Yeshiva Univ, Dept Radiol, Albert Einstein Coll Med, Bronx, NY 10461 USA; [Lipton, Michael L.] Yeshiva Univ, Dept Psychiat & Behav Sci, Albert Einstein Coll Med, Bronx, NY 10461 USA; [Lipton, Michael L.] Yeshiva Univ, Dominick P Purpura Dept Neurosci, Albert Einstein Coll Med, Bronx, NY 10461 USA; [Kim, Mimi; Lipton, Richard B.] Yeshiva Univ, Dept Epidemiol & Populat Hlth, Albert Einstein Coll Med, Bronx, NY 10461 USA; [Zimmerman, Molly E.; Lipton, Richard B.] Yeshiva Univ, Saul R Korey Dept Neurol, Albert Einstein Coll Med, Bronx, NY 10461 USA; [Branch, Craig A.] Yeshiva Univ, Dept Physiol & Biophys, Albert Einstein Coll Med, Bronx, NY 10461 USA; [Lipton, Michael L.; Gardin, Tova M.; Shifteh, Keivan] Montefiore Med Ctr, Dept Radiol, Bronx, NY 10467 USA		Lipton, ML (corresponding author), Yeshiva Univ, Gruss Magnet Resonance Res Ctr, Albert Einstein Coll Med, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	michael.lipton@einstein.yu.edu	Lipton, Richard Bruce/AAY-2818-2021; Lipton, Richard B/B-5060-2011				Ardekani BA, 2005, J NEUROSCI METH, V142, P67, DOI 10.1016/j.jneumeth.2004.07.014; ARDEKANI BA, 1995, J COMPUT ASSIST TOMO, V19, P615, DOI 10.1097/00004728-199507000-00022; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bennett RE, 2012, NEUROSCI LETT, V513, P160, DOI 10.1016/j.neulet.2012.02.024; Bigler E. D, 2012, BRAIN IMAGING BEHAV; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; CROOKS DA, 1991, J PATHOL, V165, P5, DOI 10.1002/path.1711650103; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; Friston K J, 1994, Hum Brain Mapp, V1, P210, DOI 10.1002/hbm.460010306; Geary EK, 2010, J INT NEUROPSYCH SOC, V16, P506, DOI 10.1017/S135561771000010X; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; Hammoud DA, 2002, NEUROIMAG CLIN N AM, V12, P205, DOI 10.1016/S1052-5149(02)00011-4; Hartikainen KM, 2010, J CLIN EXP NEUROPSYC, V32, P767, DOI 10.1080/13803390903521000; Holmes CJ, 1998, J COMPUT ASSIST TOMO, V22, P324, DOI 10.1097/00004728-199803000-00032; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Kim N., 2011, ISMRM 19 ANN M EXH M; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Lim KO, 2006, AM J PSYCHIAT, V163, P2008, DOI 10.1176/appi.ajp.163.11.2008; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McArthur DL, 2004, BRAIN PATHOL, V14, P185, DOI 10.1111/j.1750-3639.2004.tb00052.x; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Muller HP, 2009, MAGN RESON IMAGING, V27, P324, DOI 10.1016/j.mri.2008.07.003; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Oishi K., 2010, JHU MNI SS ATLAS; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Poupon C, 2000, NEUROIMAGE, V12, P184, DOI 10.1006/nimg.2000.0607; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; POVLISHOCK JT, 1986, ACTA NEUROPATHOL, V70, P53, DOI 10.1007/BF00689514; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Rosenbaum S. B., 2012, BRAIN IMAGING BEHAV; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Scholz J, 2009, NAT NEUROSCI, V12, P1370, DOI 10.1038/nn.2412; Sharp DJ, 2011, CURR OPIN NEUROL, V24, P558, DOI 10.1097/WCO.0b013e32834cd523; Shenton M. E., 2012, BRAIN IMAGING BEHAV; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2007, NAT PROTOC, V2, P499, DOI 10.1038/nprot.2007.45; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Spain A, 2010, J NEUROTRAUM, V27, P1429, DOI 10.1089/neu.2010.1288; Wang SL, 2009, CANCER RES, V69, P1190, DOI 10.1158/0008-5472.CAN-08-2661	50	102	106	0	13	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557			BRAIN IMAGING BEHAV	Brain Imaging Behav.	JUN	2012	6	2			SI		329	342		10.1007/s11682-012-9175-2			14	Neuroimaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	967LI	WOS:000305908900012	22684769				2022-02-06	
J	Vos, PE; Alekseenko, Y; Battistin, L; Ehler, E; Gerstenbrand, F; Muresanu, DF; Potapov, A; Stepan, CA; Traubner, P; Vecsei, L; von Wild, K				Vos, P. E.; Alekseenko, Y.; Battistin, L.; Ehler, E.; Gerstenbrand, F.; Muresanu, D. F.; Potapov, A.; Stepan, C. A.; Traubner, P.; Vecsei, L.; von Wild, K.			Mild traumatic brain injury	EUROPEAN JOURNAL OF NEUROLOGY			English	Article						guideline; mild traumatic brain injury	MINOR HEAD-INJURY; COMPUTED-TOMOGRAPHY; VALIDATION; GUIDELINES; RECOMMENDATIONS; RULE; CT; RELIABILITY; PREDICTION; MANAGEMENT	Traumatic Brain Injury (TBI) is among the most frequent neurological disorders. Of all TBIs 90% are considered mild with an annual incidence of 100-300/100.000. Intracranial complications of Mild Traumatic Brain Injury (MTBI) are infrequent (10%), requiring neurosurgical intervention in a minority of cases (1%), but potentially life-threatening (case fatality rate 0,1%). Hence, a true health management problem exists because of the need to exclude the small chance of a life threatening complication in large numbers of individual patients. The 2002 EFNS guidelines used a best evidence approach based on the literature until 2001 to guide initial management with respect to indications for CT, hospital admission, observation and follow up of MTBI patients. This updated EFNS guideline version for initial management in MTBI proposes a more selectively strategy for CT when major(dangerous mechanism, GCS<15, 2 points deterioration on the GCS, clinical signs of (basal) skull fracture, vomiting, anticoagulation therapy, post traumatic seizure) or minor(age, loss of consciousness, persistent anterograde amnesia, focal deficit, skull contusion, deterioration on the GCS) risk factors are present based on published decision rules with a high level of evidence. In addition clinical decision rules for CT now exist for children as well. Since 2001 recommendations, although with a lower level of evidence, have been published for clinical in hospital observation to prevent and treat other potential threads to the patient including behavioral disturbances (amnesia, confusion and agitation) and infection.	[Vos, P. E.] Radboud Univ Nijmegen, Med Ctr, Dept Neurol, NL-6500 HB Nijmegen, Netherlands; [Alekseenko, Y.] Vitebsk Med Univ, Vitebsk, BELARUS; [Battistin, L.] Clin Neurol I, Padua, Italy; [Ehler, E.] Neurol Clin, Pradubice, Czech Republic; [Gerstenbrand, F.] Ludwig Boltzmann Inst Restorat Neurol & Neuromodu, Vienna, Austria; [Muresanu, D. F.] Univ Med & Pharm Iuliu Hatieganu, Univ CFR Hosp, Cluj Napoca, Romania; [Potapov, A.] Russian Acad Med Sci, Inst Neurosurg, Moscow 109801, Russia; [Stepan, C. A.] Neurol Hosp Rosenh Gel, Vienna, Austria; [Traubner, P.] Comenius Univ, Sch Med, Bratislava, Slovakia; [Vecsei, L.] Szent Gyorgyi Univ Hosp, Szeged, Hungary; [von Wild, K.] Westphalien Univ Munster, Fac Med, Hannover, Germany; [von Wild, K.] Inst INI, Hannover, Germany		Vos, PE (corresponding author), Radboud Univ Nijmegen, Med Ctr, Dept Neurol, Hp 935,Reinier Postlaan 4,POB 9101, NL-6500 HB Nijmegen, Netherlands.	p.vos@neuro.umcn.nl	Inglese, Matilde/AAH-3189-2020; Muresanu, Fior-Dafin/AAI-8120-2021; Vos, Pieter/A-6043-2012; Alekseenko, Yuri/G-9497-2016; Vecsei, Laszlo/ABA-6137-2021; Vecsei, Laszlo/B-2066-2010	Inglese, Matilde/0000-0002-9610-0297; Ehler, Edvard/0000-0002-0595-7712; Vecsei, Laszlo/0000-0001-8037-3672; Alekseenko, Urii Vladimirovic/0000-0002-1356-9496; Ehler, Edvard/0000-0001-6212-6301			af Geijerstam JL, 2006, BMJ-BRIT MED J, V333, P465, DOI 10.1136/bmj.38918.669317.4F; af Geijerstam JL, 2005, EMERG MED J, V22, P103, DOI 10.1136/emj.2004.015396; Alex BV, 1996, NEUROTRAUMA, P119; American College of Surgeons, 1997, ADV TRAUM LIF SUPP D, V6th ed; [Anonymous], 2007, NAT I CLIN EXC HEAD; ARTIOLAIFORTUNY L, 1980, J NEUROL NEUROSUR PS, V43, P377, DOI 10.1136/jnnp.43.5.377; Bartlett J, 1998, BRIT J NEUROSURG, V12, P349, DOI 10.1080/02688699844871; Bergman DA, 1999, PEDIATRICS, V104, P1407; Brainin M, 2004, EUR J NEUROL, V11, P577, DOI 10.1111/j.1468-1331.2004.00867.x; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; Dunning J, 2006, ARCH DIS CHILD, V91, P885, DOI 10.1136/adc.2005.083980; FROWEIN R A, 1989, Neurosurgical Review, V12, P184, DOI 10.1007/BF01790644; Geijerstam JLA, 2003, ACTA NEUROCHIR, V145, P843, DOI 10.1007/s00701-003-0115-1; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Haydel MJ, 2003, ANN EMERG MED, V42, P507, DOI 10.1067/S0196-0644(03)00512-2; Hirtz D, 2007, NEUROLOGY, V68, P326, DOI 10.1212/01.wnl.0000252807.38124.a3; Ibanez J, 2004, J NEUROSURG, V100, P825, DOI 10.3171/jns.2004.100.5.0825; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MASTERS SJ, 1987, NEW ENGL J MED, V316, P84, DOI 10.1056/NEJM198701083160205; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; SERVADEI F, 1995, ACTA NEUROCHIR, V133, P50, DOI 10.1007/BF01404947; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; SMITH HK, 1991, NEUROSURGERY, V29, P258, DOI 10.1227/00006123-199108000-00016; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; Smits M, 2007, RADIOLOGY, V245, P831, DOI 10.1148/radiol.2452061509; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Tate RL, 2000, J NEUROL NEUROSUR PS, V68, P178, DOI 10.1136/jnnp.68.2.178; TEASDALE GM, 1990, BRIT MED J, V300, P363, DOI 10.1136/bmj.300.6721.363; [The American Association of Neurological Surgeons The Brain Trauma Foundation], 2000, J NEUROTRAUM, V17, P463; Twijnstra A, 2001, COMMISSIE KWALITEITS, V1, P1; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177	34	102	105	2	33	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1351-5101	1468-1331		EUR J NEUROL	Eur. J. Neurol.	FEB	2012	19	2					191	198		10.1111/j.1468-1331.2011.03581.x			8	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	878KH	WOS:000299255300006	22260187	Bronze			2022-02-06	
J	Meehan, WP; d'Hemecourt, P; Collins, CL; Comstock, RD				Meehan, William P., III; d'Hemecourt, Pierre; Collins, Christy L.; Comstock, R. Dawn			Assessment and Management of Sport-Related Concussions in United States High Schools	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						athletic injuries; athletic trainer; medical personnel; computed tomography; neuropsychological testing	CHRONIC TRAUMATIC ENCEPHALOPATHY; SEX-DIFFERENCES; CONTACT-SPORTS; BRAIN-INJURY; SYMPTOMS; EPIDEMIOLOGY; RISK	Background: Little existing data describe which medical professionals and which medical studies are used to assess sport-related concussions in high school athletes. Purpose: To describe the medical providers and medical studies used when assessing sport-related concussions. To determine the effects of medical provider type on timing of return to play, frequency of imaging, and frequency of neuropsychological testing. Study Design: Descriptive epidemiology study. Methods: All concussions recorded by the High School Reporting Information Online (HS RIO) injury surveillance system during the 2009 to 2010 academic year were included. chi 2 analyses were conducted for categorical variables. Fisher exact test was used for nonparametric data. Logistic regression analyses were used when adjusting for potential confounders. Statistical significance was considered for P < .05. Results: The HS RIO recorded 1056 sport-related concussions, representing 14.6% of all injuries. Most (94.4%) concussions were assessed by athletic trainers (ATs), 58.8% by a primary care physician. Few concussions were managed by specialists. The assessment of 21.2% included computed tomography. Computerized neuropsychological testing was used for 41.2%. For 50.1%, a physician decided when to return the athlete to play; for 46.2%, the decision was made by an AT. After adjusting for potential confounders, no associations between timing of return to play and the type of provider (physician vs AT) deciding to return the athlete to play were found. Conclusion: Concussions account for nearly 15% of all sport-related injuries in high school athletes. The timing of return to play after a sport-related concussion is similar regardless of whether the decision to return the athlete to play is made by a physician or an AT. When a medical doctor is involved, most concussions are assessed by primary care physicians as opposed to subspecialists. Computed tomography is obtained during the assessment of 1 of every 5 concussions occurring in high school athletes.	[Meehan, William P., III; d'Hemecourt, Pierre; Collins, Christy L.; Comstock, R. Dawn] Childrens Hosp, Sports Concuss Clin, Div Sports Med, Boston, MA 02115 USA		Meehan, WP (corresponding author), Childrens Hosp, Sports Concuss Clin, Div Sports Med, 319 Longwood Ave, Boston, MA 02115 USA.	william.meehan@childrens.harvard.edu			Centers for Disease Control and Prevention (CDC)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49/CE000674-01, R49/CE001172-01]; National Federation of State High School Associations (NFHS); National Operating Committee on Standards for Athletic Equipment (NOCSAE); EyeBlack; DonJoy Orthotics; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 HD040128-06A1]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040128] Funding Source: NIH RePORTER; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE000674, R49CE001172] Funding Source: NIH RePORTER	The Research Institute at Nationwide Children's Hospital, Columbus, Ohio. One or more of the authors has declared the following potential conflict of interest or source of funding: The content of this work was funded in part by the Centers for Disease Control and Prevention (CDC) grants #R49/CE000674-01 and #R49/CE001172-01. The content of this work is solely the responsibility of the authors and does not necessarily represent the official views of the CDC. The authors also acknowledge the generous research funding contributions of the National Federation of State High School Associations (NFHS), the National Operating Committee on Standards for Athletic Equipment (NOCSAE), EyeBlack, and DonJoy Orthotics. This study was supported by the National Institutes of Health (NIH) T32 Award to Dr Meehan (T32 HD040128-06A1).	Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Brody AS, 2007, PEDIATRICS, V120, P677, DOI 10.1542/peds.2007-1910; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Cantu RC, 2007, NEUROSURGERY, V61, P223, DOI 10.1227/01.NEU.0000255514.73967.90; Comstock R. D., 2006, Morbidity and Mortality Weekly Report, V55, P1037; Covassin T, 2003, J ATHL TRAINING, V38, P238; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Farace E, 2000, Neurosurg Focus, V8, pe6; Ferrara Michael S., 2001, J Athl Train, V36, P145; Foreman Megan, 2010, State Legis, V36, P28; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; Mannix R, 2010, ACAD EMERG MED, V17, P694, DOI 10.1111/j.1553-2712.2010.00797.x; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, J SCI MED SPORT, V12, P340, DOI 10.1016/j.jsams.2009.02.004; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Meehan WP, 2010, J PEDIATR-US, V157, P889, DOI 10.1016/j.jpeds.2010.06.040; Mendez CV, 2005, J NEUROPSYCH CLIN N, V17, P297, DOI 10.1176/appi.neuropsych.17.3.297; Pleacher MD, 2006, BRIT J SPORT MED, V40, DOI 10.1136/bjsm.2005.019067; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Prabhu SP, 2011, CLIN SPORT MED, V30, P103, DOI 10.1016/j.csm.2010.09.003; PRESS A, 2010, NFL NEWS        1213; Rechel JA, 2008, J ATHL TRAINING, V43, P197, DOI 10.4085/1062-6050-43.2.197; RICKERSON J, 2010, CONCUSSION LAWS; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; SCHWARZ A, 2009, NY TIMES        1220; Shankar PR, 2007, AM J SPORT MED, V35, P1295, DOI 10.1177/0363546507299745; Tommasone BA, 2006, J ATHL TRAINING, V41, P470; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; WAXENBERG R, 2009, ATHLETIC TRAINERS FI	36	102	102	0	17	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	NOV	2011	39	11					2304	2310		10.1177/0363546511423503			7	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	838KG	WOS:000296287900003	21969181	Green Accepted			2022-02-06	
J	Moubarik, C; Guillet, B; Youssef, B; Codaccioni, JL; Piercecchi, MD; Sabatier, F; Lionel, P; Dou, L; Foucault-Bertaud, A; Velly, L; Dignat-George, F; Pisano, P				Moubarik, Chahrazad; Guillet, Benjamin; Youssef, Bennis; Codaccioni, Jean-Laurent; Piercecchi, Marie-Dominique; Sabatier, Florence; Lionel, Pellegrini; Dou, Laetitia; Foucault-Bertaud, Alexandrine; Velly, Lionel; Dignat-George, Francoise; Pisano, Pascale			Transplanted Late Outgrowth Endothelial Progenitor Cells as Cell Therapy Product for Stroke	STEM CELL REVIEWS AND REPORTS			English	Article						Stroke; Late endothelial progenitors; Angiogenesis; Apoptosis	FOCAL CEREBRAL-ISCHEMIA; MARROW STROMAL CELLS; UMBILICAL-CORD BLOOD; TRAUMATIC BRAIN-INJURY; REDUCES INFARCT VOLUME; BONE-MARROW; BEHAVIORAL DEFICITS; VASCULAR INJURY; GROWTH-FACTOR; RAT MODEL	Endothelial progenitor cells (EPCs) seem to be a promising option to treat patients with ischemic diseases. Here, we investigated the effects of late outgrowth EPCs, or endothelial colony-forming cells (ECFCs), a recently defined homogeneous subtype of EPCs, in a rat model of transient middle cerebral artery occlusion (MCAO). Either vehicle or 4.10(6) ECFCs, isolated from human cord blood, were intravenously injected 24 h after 1 h MCAO in rats assigned to control and transplanted groups respectively. In-111-oxine-labeled ECFCs specifically homed to ischemic hemisphere and CM-Dil prelabeled ECFCs preferentially settled in the inner boundary of the core area of transplanted animals. Although incorporation of cells into neovessels was hardly detectable, ECFCs transplantation was associated with a reduction in apoptotic cell number, an increase in capillary density and a stimulation of neurogenesis at the site of injury. These effects were associated with an increase in growth factors expression in homogenates from ischemic area and may be related to the secretion by ECFCs of soluble factors that could affect apoptosis, vascular growth and neurogenesis. Microscopic examination of the ischemic hemisphere showed that ECFCs transplantation was also associated with a reduction in reactive astrogliosis. In conclusion, we demonstrated that ECFCs injected 24 h after MCAO settled in the injured area and improved functional recovery. The neurological benefits may be linked to a reduction in ischemia-induced apoptosis and a stimulation of ischemia-induced angiogenesis and neurogenesis. These findings raise perspectives for the use of ECFCs as a well-characterized cell therapy product for optimal therapeutic outcome after stroke.	[Guillet, Benjamin] Fac Pharm Marseille, INSERM, UMR 608, Lab Pharmacodynam, F-13005 Marseille, France; [Moubarik, Chahrazad; Guillet, Benjamin; Youssef, Bennis; Piercecchi, Marie-Dominique; Sabatier, Florence; Dou, Laetitia; Foucault-Bertaud, Alexandrine; Dignat-George, Francoise; Pisano, Pascale] Univ Mediterranee, INSERM, UMR 608, Fac Pharm, Marseille, France; [Codaccioni, Jean-Laurent; Lionel, Pellegrini; Velly, Lionel] CHU Timone, Dept Anesthesie Reanimat, Marseille, France; [Dignat-George, Francoise] CHU Concept, Dept Hematol, Marseille, France; [Sabatier, Florence] CHU Concept, INSERM CIC BT 510, Lab Culture & Therapie Cellulaire, Marseille, France		Guillet, B (corresponding author), Fac Pharm Marseille, INSERM, UMR 608, Lab Pharmacodynam, 27 Blvd Jean Moulin, F-13005 Marseille, France.	benjamin.guillet@pharmacie.univ-mrs.fr	Bennis, Youssef/ABC-8816-2020; pascale, pisano/C-1733-2013; Dou, Laetitia/Q-4963-2017; DIGNAT-GEORGE, Francoise/R-1129-2016; guillet, benjamin A/G-2848-2013	Bennis, Youssef/0000-0002-0186-4797; Dou, Laetitia/0000-0002-4594-4676; DIGNAT-GEORGE, Francoise/0000-0001-7006-4462; 			Aicher A, 2003, CIRCULATION, V107, P2134, DOI 10.1161/01.CIR.0000062649.63838.C9; Bang OY, 2005, ANN NEUROL, V57, P874, DOI 10.1002/ana.20501; Bechara C, 2007, MED SCI MONITOR, V13, pRA87; Bin Deng Y, 2010, NEUROL RES, V32, P148, DOI 10.1179/174313209X414434; Candelario-Jalil E, 2009, NEUROSCIENCE, V158, P983, DOI 10.1016/j.neuroscience.2008.06.025; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chen JL, 2003, J NEUROSCI RES, V73, P778, DOI 10.1002/jnr.10691; Chen JL, 2003, CIRC RES, V92, P692, DOI 10.1161/01.RES.0000063425.51108.8D; Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3; Chopp M, 2009, STROKE, V40, pS143, DOI 10.1161/STROKEAHA.108.533141; Codaccioni JL, 2009, ANESTHESIOLOGY, V110, P1271, DOI 10.1097/ALN.0b013e3181a1fe68; Corselli M, 2008, EXP HEMATOL, V36, P340, DOI 10.1016/j.exphem.2007.10.008; Delorme B, 2005, THROMB HAEMOSTASIS, V94, P1270, DOI 10.1160/TH05-07-0499; Di Stefano R, 2009, THROMB RES, V123, P925, DOI 10.1016/j.thromres.2008.10.013; Dinkel K, 2004, P NATL ACAD SCI USA, V101, P331, DOI 10.1073/pnas.0303510101; DUBOWITZ V, 1985, MUSCLE BIOPSY PRACTI, P504; Fedoroff S, 1997, NEUROSCI BIOBEHAV R, V21, P187, DOI 10.1016/S0149-7634(96)00009-7; Hau S, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-30; He TR, 2005, AM J PHYSIOL-HEART C, V289, pH968, DOI 10.1152/ajpheart.01166.2004; Hur J, 2004, ARTERIOSCL THROM VAS, V24, P288, DOI 10.1161/01.ATV.0000114236.77009.06; Iihoshi S, 2004, BRAIN RES, V1007, P1, DOI 10.1016/j.brainres.2003.09.084; Ingram DA, 2004, BLOOD, V104, P2752, DOI 10.1182/blood-2004-04-1396; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Jourde-Chiche N, 2009, J THROMB HAEMOST, V7, P1576, DOI 10.1111/j.1538-7836.2009.03540.x; Kooijman R, 2009, STROKE, V40, pE83, DOI 10.1161/STROKEAHA.108.528356; Krupinski J, 1997, STROKE, V28, P564, DOI 10.1161/01.STR.28.3.564; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Li Y, 2001, NEUROLOGY, V56, P1666, DOI 10.1212/WNL.56.12.1666; LIN TN, 1993, STROKE, V24, P117, DOI 10.1161/01.STR.24.1.117; Liu XS, 2007, J NEUROSCI RES, V85, P2120, DOI 10.1002/jnr.21359; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Mahmood A, 2006, J NEUROSURG, V104, P272, DOI 10.3171/jns.2006.104.2.272; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Mokudai T, 2000, STROKE, V31, P1679, DOI 10.1161/01.STR.31.7.1679; Mouw G, 2002, METAB BRAIN DIS, V17, P143, DOI 10.1023/A:1019921904378; Newcomb JD, 2006, CELL TRANSPLANT, V15, P213, DOI 10.3727/000000006783982043; Rouhl RPW, 2008, STROKE, V39, P2158, DOI 10.1161/STROKEAHA.107.507251; Scholler K, 2004, BRAIN RES, V1023, P272, DOI 10.1016/j.brainres.2004.01.094; Sobrino T, 2007, STROKE, V38, P2759, DOI 10.1161/STROKEAHA.107.484386; Sun D, 2010, J NEUROTRAUM, V27, P923, DOI 10.1089/neu.2009.1209; Vendrame M, 2004, STROKE, V35, P2390, DOI 10.1161/01.STR.0000141681.06735.9b; Wang CH, 2008, ARTERIOSCL THROM VAS, V28, P54, DOI 10.1161/ATVBAHA.107.147256; Wechsler L, 2009, STROKE, V40, P510, DOI 10.1161/STROKEAHA.108.526863; Yi L, 2005, GLIA, V49, P407, DOI 10.1002/glia.20126; Yoder MC, 2007, BLOOD, V109, P1801, DOI 10.1182/blood-2006-08-043471; Zampetaki A, 2008, CARDIOVASC RES, V78, P413, DOI 10.1093/cvr/cvn081; Zhang L, 2006, EUR J HAEMATOL, V76, P1, DOI 10.1111/j.1600-0609.2005.00579.x; Zhang ZG, 2009, LANCET NEUROL, V8, P491, DOI 10.1016/S1474-4422(09)70061-4	49	102	117	1	14	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1550-8943	1558-6804		STEM CELL REV REP	Stem Cell Rev. Rep.	MAR	2011	7	1					208	220		10.1007/s12015-010-9157-y			13	Cell & Tissue Engineering; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Research & Experimental Medicine	709TV	WOS:000286465200018	20526754				2022-02-06	
J	Matthews, SC; Strigo, IA; Simmons, AN; O'Connell, RM; Reinhardt, LE; Moseley, SA				Matthews, Scott C.; Strigo, Irina A.; Simmons, Alan N.; O'Connell, Ryan M.; Reinhardt, Lindsay E.; Moseley, Suzanne A.			A multimodal imaging study in US veterans of Operations Iraqi and Enduring Freedom with and without major depression after blast-related concussion	NEUROIMAGE			English	Article						Depression; Concussion; Traumatic brain injury; Combat; Emotion processing; Amygdala; fMRI; Diffusion tensor imaging; Fractional anisotropy	TRAUMATIC BRAIN-INJURY; LATE-LIFE DEPRESSION; EVENT-RELATED FMRI; WHITE-MATTER; HUMAN AMYGDALA; MICROSTRUCTURAL ABNORMALITIES; DISORDER; INDIVIDUALS; ASSOCIATION; AFGHANISTAN	Although the exact number of affected individuals is unknown, it has been estimated that approximately 20% of U. S. veterans of Operations Enduring Freedom (OEF) and Iraqi Freedom (OIF) have experienced mild traumatic brain injury (mTBI) (i.e., concussion), which is defined as a brief loss or alteration of consciousness from a blow or jolt to the head. Blast exposure is among the most common causes of concussion in OEF-OIF warriors. Although the mechanism is unknown, major depressive disorder (MDD) after head injury is common. The purpose of this study was to use diffusion tensor imaging (DTI) and functional magnetic resonance imaging (fMRI) to examine the structural and functional neural correlates of MDD in OEF-OIF combat veterans with a self-reported history of blast-related concussion. We hypothesized that subjects in the MDD group (i.e., individuals with a history of blast-related concussion who were experiencing current MDD) relative to individuals in the non-MDD group (i.e., individuals with a history of blast-related concussion but no current or lifetime history of MDD) would show amygdala hyperactivity and disruption of white matter tracts connecting prefrontal and limbic brain regions. To test these hypotheses, 11 MDD and 11 non-MDD individuals underwent DTI and performed a validated emotional face matching task during fMRI. MDD relative to non-MDD individuals showed greater activity during fear matching trials in the amygdala and other emotion processing structures, lower activity during fear matching trials in emotional control structures such as the dorsolateral prefrontal cortex and lower fractional anisotropy (FA) in several white matter tracts including the superior longitudinal fasciculus (SLF). Greater depressive symptom severity correlated negatively with FA in the SLF. These results suggest a biological basis of MDD in OEF-OIF veterans who have experienced blast-related concussion, and may contribute to the development of treatments aimed at improving the clinical care of this unique population of wounded warriors. Published by Elsevier Inc.	[Matthews, Scott C.; O'Connell, Ryan M.; Reinhardt, Lindsay E.; Moseley, Suzanne A.] Vet Affairs San Diego Healthcare Syst, San Diego, CA USA; [Matthews, Scott C.; Strigo, Irina A.; Simmons, Alan N.; O'Connell, Ryan M.; Reinhardt, Lindsay E.; Moseley, Suzanne A.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA		Matthews, SC (corresponding author), 3350 La Jolla Village Dr,116-A, San Diego, CA 92161 USA.	scmatthews@ucsd.edu	Simmons, Alan N/A-9815-2008; strigo, irina A/L-9882-2016	Simmons, Alan N/0000-0003-3963-2112; strigo, irina A/0000-0002-8799-716X	Veterans AdministrationUS Department of Veterans Affairs; Congressionally Directed Medical Research ProgramUnited States Department of Defense	The authors are grateful to Martin Paulus, M. D., Dean Delis, Ph.D. and Larry Frank, Ph.D. for their contributions to this research, which was supported by grants from the Veterans Administration and the Congressionally Directed Medical Research Program.	Adolphs R, 1998, NATURE, V393, P470, DOI 10.1038/30982; Alexopoulos GS, 2002, AM J PSYCHIAT, V159, P1929, DOI 10.1176/appi.ajp.159.11.1929; Baldwin RC, 2000, INT J GERIATR PSYCH, V15, P1097, DOI 10.1002/1099-1166(200012)15:12<1097::AID-GPS251>3.0.CO;2-N; Beck A., 1996, BECK DEPRESSION INVE, V78, P490; BECK AT, 1963, ARCH GEN PSYCHIAT, V9, P324; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Buchel C, 1998, NEURON, V20, P947, DOI 10.1016/S0896-6273(00)80476-6; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; CASTRO CA, 2006, M P RTO MP HFM 134 N; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; DeWitt DS, 2009, J NEUROTRAUM, V26, P877, DOI 10.1089/neu.2007.0439; Drevets WC, 1997, NATURE, V386, P824, DOI 10.1038/386824a0; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; First M., 1997, STRUCTURED CLIN INTE; Hariri AR, 2002, NEUROIMAGE, V17, P317, DOI 10.1006/nimg.2002.1179; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; JOHNSON S, 2009, INT STAT OF THE SCI; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kroenke K, 2002, PSYCHOSOM MED, V64, P258, DOI 10.1097/00006842-200203000-00008; LaBar KS, 1998, NEURON, V20, P937, DOI 10.1016/S0896-6273(00)80475-4; Lacerda ALT, 2005, J PSYCHIATR RES, V39, P347, DOI 10.1016/j.jpsychires.2004.10.004; Lancaster JL, 2000, HUM BRAIN MAPP, V10, P120, DOI 10.1002/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8; LeDoux J, 1996, PROG BRAIN RES, V107, P437; LeDoux J.E., 1996, EMOTIONAL BRAIN; LeDoux JE, 2000, ANNU REV NEUROSCI, V23, P155, DOI 10.1146/annurev.neuro.23.1.155; Liberzon I, 2003, NEUROPSYCHOPHARMACOL, V28, P726, DOI 10.1038/sj.npp.1300113; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Matthews SC, 2008, J AFFECT DISORDERS, V111, P13, DOI 10.1016/j.jad.2008.05.022; Mayberg HS, 1997, J NEUROPSYCH CLIN N, V9, P471; Mesulam MM, 1998, BRAIN, V121, P1013, DOI 10.1093/brain/121.6.1013; Mollica RF, 2009, ARCH GEN PSYCHIAT, V66, P1221, DOI 10.1001/archgenpsychiatry.2009.127; Moore DF, 2009, NEUROIMAGE, V47, pT10, DOI 10.1016/j.neuroimage.2009.02.019; Mora C.A., 1989, PSYCHOL ASSESSMENT J, V1, P53, DOI [10.1037/1040-3590.1.1.53, DOI 10.1037/1040-3590.1.1.53]; Nobuhara K, 2006, J NEUROL NEUROSUR PS, V77, P120, DOI 10.1136/jnnp.2004.055129; Ochsner KN, 2005, TRENDS COGN SCI, V9, P242, DOI 10.1016/j.tics.2005.03.010; OGAWA S, 1990, P NATL ACAD SCI USA, V87, P9868, DOI 10.1073/pnas.87.24.9868; Peloso PM, 2004, J REHABIL MED, V36, P106, DOI 10.1080/16501960410023868; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Schmahmann JD, 2007, BRAIN, V130, P630, DOI 10.1093/brain/awl359; Schwab KA, 2006, NEUROLOGY, V66, pA235; Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007; Siegle GJ, 2002, BIOL PSYCHIAT, V51, P693, DOI 10.1016/S0006-3223(02)01314-8; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Strigo IA, 2008, ARCH GEN PSYCHIAT, V65, P1275, DOI 10.1001/archpsyc.65.11.1275; TALAIRACH J, 1998, COPLANAR STEREOTAXI; Taylor WD, 2004, AM J PSYCHIAT, V161, P1293, DOI 10.1176/appi.ajp.161.7.1293; TEASDALE G, 1974, LANCET, V2, P81; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Yang Q, 2007, INT PSYCHOGERIATR, V19, P757, DOI 10.1017/S1041610207004875; Zald DH, 2003, BRAIN RES REV, V41, P88, DOI 10.1016/S0165-0173(02)00248-5; Zou K, 2008, J PSYCHIATR NEUROSCI, V33, P525	56	102	103	0	21	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	JAN	2011	54			1			S69	S75		10.1016/j.neuroimage.2010.04.269			7	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	813ZF	WOS:000294408600010	20451622				2022-02-06	
J	Martinez, JA; Zhang, ZQ; Svetlov, SI; Hayes, RL; Wang, KK; Larner, SF				Martinez, Juan A.; Zhang, Zhiqun; Svetlov, Stanislav I.; Hayes, Ronald L.; Wang, Kevin K.; Larner, Stephen F.			Calpain and caspase processing of caspase-12 contribute to the ER stress-induced cell death pathway in differentiated PC12 cells	APOPTOSIS			English	Article						ER stress; Thapsigargin; Unfolded protein response; Calpain; Caspase; PC12 cells	ENDOPLASMIC-RETICULUM STRESS; MITOCHONDRIAL PERMEABILITY TRANSITION; UNFOLDED PROTEIN RESPONSE; INTRINSIC PATHWAY; APOPTOTIC CELLS; NEURONAL APOPTOSIS; II-SPECTRIN; CROSS-TALK; ACTIVATION; THAPSIGARGIN	Neuronal cell death after traumatic brain injury, Alzheimer's disease and ischemic stroke may in part be mediated through endoplasmic reticulum (ER) stress and unfolded protein response (UPR). UPR results in induction of molecular chaperone GRP78 and the ER-resident caspase-12, whose activation has been proposed to be mediated by calpain and caspase processing, although their relative contribution remains unclear. In this study we induced ER stress with thapsigargin (TG), and determined the activation profile of calpain-2, caspase-3, caspase-7, and caspase-12 by analyses of protein levels, corresponding substrates and breakdown products (BDP). Specific calpain and caspase activity was assessed by analysis of alpha II-spectrin BDP of 145 kDa (SBDP145), BDP of 150 kDa (SBDP150) and BDP of 120 kDa (SBDP120). Decrease in pro-calpain-2 protein and increased SBDP145 levels by 3 h after TG treatment indicated early calpain activity. Active caspase-7 (p20) increase occurred after 8 h, followed by concomitant up-regulation of active caspase-3 and SBDP120 after 24 h. In vitro digestion experiments supported that SBDP120 was exclusively generated by active caspase-3 and validated that kinectin and co-chaperone p23 were calpain and caspase-7 substrates, respectively. Pro-caspase-12 protein processing by the specific action of calpain and caspase-3/7 was observed in a time-dependent manner. N-terminal pro-domain processing of pro-caspase-12 by calpain generated a 38 kDa fragment, while caspase-3/7 generated a 35 kDa fragment. Antibody developed specifically against the caspase-3/7 C-terminal cleavage site D(341) detected the presence of large subunit (p20) containing 23 kDa fragment that increased after 24 h of TG treatment. Significant caspase-12 enzyme activity was only detected after 24 h of TG treatment and was completely inhibited by caspase 3/7 inhibitor DEVD-fmk and partially by calpain inhibitor SNJ-1945. ER-stress-induced cell death pathway in TG-treated PC12 cells was characterized by up-regulation of GRP-78 and processing and activation of caspase-12 by the orchestrated proteolytic activity of calpain-2 and caspase-3/7.	[Martinez, Juan A.; Zhang, Zhiqun; Svetlov, Stanislav I.; Hayes, Ronald L.; Wang, Kevin K.; Larner, Stephen F.] Banyan Biomarkers Inc, Ctr Innovat Res, Alachua, FL 32615 USA		Martinez, JA (corresponding author), Banyan Biomarkers Inc, Ctr Innovat Res, 12085 Res Dr, Alachua, FL 32615 USA.	jmartinez@banyanbio.com; sflarner@banyanbio.com		Wang, Kevin/0000-0002-9343-6473	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS051431]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS051431] Funding Source: NIH RePORTER	This work was supported by NIH Grant R01NS051431 to R. L. H. Dr. K. K. W. Wang and Dr. R. L. Hayes hold equity in Banyan Biomarkers, Inc. (Alachua, FL), a company commercializing the brain injury biomarker technology.	Baumgartner HK, 2009, J BIOL CHEM, V284, P20796, DOI 10.1074/jbc.M109.025353; Chan SL, 1999, J NEUROSCI RES, V58, P167, DOI 10.1002/(SICI)1097-4547(19991001)58:1<167::AID-JNR16>3.0.CO;2-K; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Freeze HH, 2007, CURR MOL MED, V7, P389, DOI 10.2174/156652407780831548; Fujita E, 2002, CELL DEATH DIFFER, V9, P1108, DOI 10.1038/sj.cdd.4401080; Harriman JF, 2002, CELL DEATH DIFFER, V9, P734, DOI 10.1038/sj.cdd.4401029; Harwood SM, 2005, ANN CLIN BIOCHEM, V42, P415, DOI 10.1258/000456305774538238; Hiroi T, 2005, PHARMACOGENOMICS J, V5, P102, DOI 10.1038/sj.tpj.6500296; Hoppe V, 2004, FEBS LETT, V576, P277, DOI 10.1016/j.febslet.2004.09.012; Jang M, 2007, BIOCHEM BIOPH RES CO, V363, P388, DOI 10.1016/j.bbrc.2007.08.183; Kim I, 2008, NAT REV DRUG DISCOV, V7, P1013, DOI 10.1038/nrd2755; Korfali N, 2004, J BIOL CHEM, V279, P1030, DOI 10.1074/jbc.M306277200; Korge P, 1999, EUR J BIOCHEM, V265, P273, DOI 10.1046/j.1432-1327.1999.00724.x; Larner SF, 2006, J NEUROTRAUM, V23, P807, DOI 10.1089/neu.2006.23.807; Lee W, 2005, APOPTOSIS, V10, P407, DOI 10.1007/s10495-005-0814-6; Lindholm D, 2006, CELL DEATH DIFFER, V13, P385, DOI 10.1038/sj.cdd.4401778; Machleidt T, 1998, FEBS LETT, V436, P51, DOI 10.1016/S0014-5793(98)01095-3; Mao WK, 2006, AM J PHYSIOL-CELL PH, V290, pC1373, DOI 10.1152/ajpcell.00369.2005; Masud A, 2007, J BIOL CHEM, V282, P14132, DOI 10.1074/jbc.M700077200; Momoi T, 2004, J CHEM NEUROANAT, V28, P101, DOI 10.1016/j.jchemneu.2004.05.008; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Muruganandan S, 2006, TOXICOL SCI, V94, P118, DOI 10.1093/toxsci/kfl084; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Nath R, 2000, NEUROCHEM INT, V37, P351, DOI 10.1016/S0197-0186(00)00040-1; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; Newcomb-Fernandez JK, 2001, J CEREBR BLOOD F MET, V21, P1281, DOI 10.1097/00004647-200111000-00004; Rao RV, 2002, J BIOL CHEM, V277, P21836, DOI 10.1074/jbc.M202726200; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; Saleh M, 2004, NATURE, V429, P75, DOI 10.1038/nature02451; Sanges D, 2006, APOPTOSIS, V11, P1629, DOI 10.1007/s10495-006-9006-2; Shimoke K, 2005, NEUROSCI LETT, V389, P124, DOI 10.1016/j.neulet.2005.07.030; Shirasaki Y, 2005, BIOORGAN MED CHEM, V13, P4473, DOI 10.1016/j.bmc.2005.04.059; Stegh AH, 2008, P NATL ACAD SCI USA, V105, P10703, DOI 10.1073/pnas.0712034105; Tan YF, 2006, J BIOL CHEM, V281, P16016, DOI 10.1074/jbc.M601299200; Tran H, 2002, J CELL SCI, V115, P2031; Truettner JS, 2007, J NEUROTRAUM, V24, P599, DOI 10.1089/neu.2006.0186; Truettner JS, 2009, BRAIN RES, V1249, P9, DOI 10.1016/j.brainres.2008.10.032; Van de Craen M, 1997, FEBS LETT, V403, P61, DOI 10.1016/S0014-5793(97)00026-4; Voccoli V, 2007, BRAIN RES, V1147, P1, DOI 10.1016/j.brainres.2007.01.145; Walsh JG, 2008, P NATL ACAD SCI USA, V105, P12815, DOI 10.1073/pnas.0707715105; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Yoshida H, 2007, FEBS J, V274, P630, DOI 10.1111/j.1742-4658.2007.05639.x; Zhang KZ, 2006, NEUROLOGY, V66, pS102, DOI 10.1212/01.wnl.0000192306.98198.ec; Zhang ZQ, 2009, APOPTOSIS, V14, P1289, DOI 10.1007/s10495-009-0405-z; Zhao LH, 2006, CURR OPIN CELL BIOL, V18, P444, DOI 10.1016/j.ceb.2006.06.005	49	102	110	0	10	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	1360-8185			APOPTOSIS	Apoptosis	DEC	2010	15	12					1480	1493		10.1007/s10495-010-0526-4			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	688HL	WOS:000284840300008	20640600				2022-02-06	
J	Warner, MA; Youn, TS; Davis, T; Chandra, A; de la Plata, CM; Moore, C; Harper, C; Madden, CJ; Spence, J; McColl, R; Devous, M; King, RD; Diaz-Arrastia, R				Warner, Matthew A.; Youn, Teddy S.; Davis, Tommy; Chandra, Alvin; de la Plata, Carlos Marquez; Moore, Carol; Harper, Caryn; Madden, Christopher J.; Spence, Jeffrey; McColl, Roderick; Devous, Michael; King, Richard D.; Diaz-Arrastia, Ramon			Regionally Selective Atrophy After Traumatic Axonal Injury	ARCHIVES OF NEUROLOGY			English	Article							MAGNETIC-RESONANCE IMAGES; CORPUS-CALLOSUM ATROPHY; VOXEL-BASED MORPHOMETRY; SURFACE-BASED ANALYSIS; BRAIN-INJURY; ALZHEIMERS-DISEASE; FRONTOTEMPORAL DEMENTIA; LONGITUDINAL CHANGES; DIFFUSION-TENSOR; CEREBRAL ATROPHY	Objectives: To determine the spatial distribution of cortical and subcortical volume loss in patients with diffuse traumatic axonal injury and to assess the relationship between regional atrophy and functional outcome. Design: Prospective imaging study. Longitudinal changes in global and regional brain volumes were assessed using high-resolution magnetic resonance imaging-based morphometric analysis. Setting: Inpatient traumatic brain injury unit. Patients or Other Participants: Twenty-five patients with diffuse traumatic axonal injury and 22 age- and sex-matched controls. Main Outcome Measure: Changes in global and regional brain volumes between initial and follow-up magnetic resonance imaging were used to assess the spatial distribution of posttraumatic volume loss. The Glasgow Outcome Scale-Extended score was the primary measure of functional outcome. Results: Patients underwent substantial global atrophy with mean whole-brain parenchymal volume loss of 4.5% (95% confidence interval, 2.7%-6.3%). Decreases in volume (at a false discovery rate of 0.05) were seen in several brain regions including the amygdala, hippocampus, thalamus, corpus callosum, putamen, precuneus, postcentral gyrus, paracentral lobule, and parietal and frontal cortices, while other regions such as the caudate and inferior temporal cortex were relatively resistant to atrophy. Loss of whole-brain parenchymal volume was predictive of long-term disability, as was atrophy of particular brain regions including the inferior parietal cortex, pars orbitalis, pericalcarine cortex, and supramarginal gyrus. Conclusion: Traumatic axonal injury leads to substantial posttraumatic atrophy that is regionally selective rather than diffuse, and volume loss in certain regions may have prognostic value for functional recovery.	[Warner, Matthew A.; Davis, Tommy; Chandra, Alvin; Moore, Carol; Harper, Caryn; Diaz-Arrastia, Ramon] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA; [Madden, Christopher J.] Univ Texas SW Med Ctr Dallas, Dept Neurol Surg, Dallas, TX 75390 USA; [Spence, Jeffrey] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA; [McColl, Roderick; Devous, Michael] Univ Texas SW Med Ctr Dallas, Dept Radiol, Dallas, TX 75390 USA; [de la Plata, Carlos Marquez] Univ Dallas, Ctr Brain Hlth, Dallas, TX USA; [Youn, Teddy S.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA; [King, Richard D.] Univ Utah, Dept Neurol, Salt Lake City, UT USA		Diaz-Arrastia, R (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Neurol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	ramon.diaz-arrastia@utsouthwestern.edu	Youn, Teddy/AAM-7705-2020; Youn, Teddy Si/ABH-9887-2020; Youn, Teddy Si/N-1535-2017	Youn, Teddy Si/0000-0002-7325-1148; Diaz-Arrastia, Ramon/0000-0001-6051-3594; McColl, Roderick/0000-0001-7022-100X	Doris Duke Charitable FoundationDoris Duke Charitable Foundation (DDCF); National Institutes of Health National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD48179, U01 HD42652]; US Department of EducationUS Department of Education [H133 A020526]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01HD042652] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048179] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS060827] Funding Source: NIH RePORTER	This study was supported by a Clinical Research Fellowship through the Doris Duke Charitable Foundation (Mr Warner and Dr Youn), grants R01 HD48179 and U01 HD42652 from the National Institutes of Health National Institute of Child Health and Human Development (Dr Diaz-Arrastia), and grant H133 A020526 from the US Department of Education (Dr Diaz-Arrastia).	Agosta F, 2009, P NATL ACAD SCI USA, V106, P2018, DOI 10.1073/pnas.0812697106; Ariza M, 2006, NEUROPSYCHOLOGIA, V44, P1956, DOI 10.1016/j.neuropsychologia.2005.11.007; Basso M, 2006, PSYCHIAT RES-NEUROIM, V146, P251, DOI 10.1016/j.pscychresns.2006.01.007; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bigler ED, 2006, AM J PHYS MED REHAB, V85, P793, DOI 10.1097/01.phm.0000237873.26250.e1; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Buckner RL, 2005, J NEUROSCI, V25, P7709, DOI 10.1523/JNEUROSCI.2177-05.2005; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; Ding K, 2008, J NEUROTRAUM, V25, P1433, DOI 10.1089/neu.2008.0683; Fischl B, 1999, NEUROIMAGE, V9, P195, DOI 10.1006/nimg.1998.0396; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Fischl B, 2000, P NATL ACAD SCI USA, V97, P11050, DOI 10.1073/pnas.200033797; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Holland D, 2009, P NATL ACAD SCI USA, V106, P20954, DOI 10.1073/pnas.0906053106; Kim J, 2008, NEUROIMAGE, V39, P1014, DOI 10.1016/j.neuroimage.2007.10.005; Langlois JA, 2006, TRAUMATIC BRAIN INJU; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Maxwell WL, 2010, BRAIN, V133, P139, DOI 10.1093/brain/awp264; McDonald CR, 2008, EPILEPSY RES, V79, P130, DOI 10.1016/j.eplepsyres.2008.01.006; Merkley TL, 2008, J NEUROTRAUM, V25, P1343, DOI 10.1089/neu.2008.0615; Pengas G, 2009, J NEUROIMAGING, V19, P37, DOI 10.1111/j.1552-6569.2008.00246.x; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Salmond CH, 2005, BRAIN, V128, P189, DOI 10.1093/brain/awh352; Scahill RI, 2002, P NATL ACAD SCI USA, V99, P4703, DOI 10.1073/pnas.052587399; Shiino A, 2008, DEMENT GERIATR COGN, V26, P175, DOI 10.1159/000151241; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Tae WS, 2008, NEURORADIOLOGY, V50, P569, DOI 10.1007/s00234-008-0383-9; Teipel SJ, 2006, J NEUROL, V253, P794, DOI 10.1007/s00415-006-0120-4; Teipel SJ, 2003, NEUROBIOL AGING, V24, P85, DOI 10.1016/S0197-4580(02)00044-1; Teipel SJ, 2002, ARCH NEUROL-CHICAGO, V59, P243, DOI 10.1001/archneur.59.2.243; Tomaiuolo F, 2005, J NEUROTRAUM, V22, P76, DOI 10.1089/neu.2005.22.76; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Trivedi MA, 2007, J NEUROTRAUM, V24, P766, DOI 10.1089/neu.2006.0205; van der Kouwe AJW, 2008, NEUROIMAGE, V40, P559, DOI 10.1016/j.neuroimage.2007.12.025; Wang PJ, 2006, NEUROBIOL AGING, V27, P1613, DOI 10.1016/j.neurobiolaging.2005.09.035; Xu YQ, 2010, J CEREBR BLOOD F MET, V30, P883, DOI 10.1038/jcbfm.2009.263; Yamauchi H, 2000, J NEUROL NEUROSUR PS, V69, P623, DOI 10.1136/jnnp.69.5.623	39	102	103	1	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0003-9942	1538-3687		ARCH NEUROL-CHICAGO	Arch. Neurol.	NOV	2010	67	11					1336	1344		10.1001/archneurol.2010.149			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	676RQ	WOS:000283935300011	20625067	Bronze, Green Accepted			2022-02-06	
J	Zweifel, C; Castellani, G; Czosnyka, M; Helmy, A; Manktelow, A; Carrera, E; Brady, KM; Hutchinson, PJA; Menon, DK; Pickard, JD; Smielewski, P				Zweifel, Christian; Castellani, Gianluca; Czosnyka, Marek; Helmy, Adel; Manktelow, Anne; Carrera, Emmanuel; Brady, Kenneth M.; Hutchinson, Peter J. A.; Menon, David K.; Pickard, John D.; Smielewski, Peter			Noninvasive Monitoring of Cerebrovascular Reactivity with Near Infrared Spectroscopy in Head-Injured Patients	JOURNAL OF NEUROTRAUMA			English	Article						cerebrovascular pressure reactivity; near infrared spectroscopy; optimal arterial blood pressure; optimal cerebral perfusion pressure; cerebrovascular pressure reactivity; total hemoglobin reactivity	CEREBRAL PERFUSION-PRESSURE; TRAUMATIC BRAIN-INJURY; COMPUTERIZED-TOMOGRAPHY; INTRACRANIAL-PRESSURE; BLOOD-PRESSURE; AUTOREGULATION	Monitoring of cerebrovascular pressure reactivity (PRx) has diagnostic and prognostic value in head-injured patients, but requires invasive monitoring of intracranial pressure (ICP). Near infrared spectroscopy (NIRS) is a noninvasive method that is suitable for continuous detection of cerebral blood volume changes. We compared a NIRS-based index of cerebrovascular reactivity, called total hemoglobin reactivity (THx), against standard measurements of PRx in a prospective observational study. Forty patients with closed-head injury were monitored daily with arterial blood pressure (ABP), ICP, and a NIRS-based total hemoglobin index. PRx and THx were calculated as the moving correlation coefficients using 5-min time windows between 10-sec averaged values of ICP and ABP, and total hemoglobin index and ABP, respectively. A total of 120 recordings were performed between the median first (IQR 0.75-2) and fourth (IQR 2-6) day after head injury, giving a total duration of 1760 hours. PRx and THx demonstrated a significant association across averaged individual recordings (r=0.49, p<0.0001), and across patients (r=0.56, p=0.0002). Assessment of optimal cerebral perfusion pressure (CPP) and ABP using THx was possible in about 50% of recordings, and showed a significant agreement with the optimal CPP and ABP assessed with PRx. THx may be of diagnostic value to optimize therapy oriented toward restoration and continuity of cerebrovascular reactivity, especially in patients for whom direct ICP monitoring is not feasible.	[Zweifel, Christian; Castellani, Gianluca; Czosnyka, Marek; Helmy, Adel; Carrera, Emmanuel; Hutchinson, Peter J. A.; Pickard, John D.; Smielewski, Peter] Univ Cambridge, Sch Clin, Acad Neurosurg Unit, Cambridge, England; [Manktelow, Anne; Menon, David K.] Univ Cambridge, Sch Clin, Dept Anaesthet, Cambridge, England; [Zweifel, Christian] Univ Basel Hosp, Dept Neurosurg, CH-4031 Basel, Switzerland; [Castellani, Gianluca] Fdn Policlin San Matteo, Dept Anaesthesia & Crit Care, Pavia, Italy; [Brady, Kenneth M.] Johns Hopkins Univ Hosp, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21287 USA		Zweifel, C (corresponding author), Addenbrookes Hosp, Acad Neurosurg Unit, Dept Clin Neurosci, Level 4,A Block, Cambridge CB2 2QQ, England.	zweifelch@gmx.ch	Helmy, Adel/AAS-3084-2020	Helmy, Adel/0000-0002-0531-0556; Carrera, Emmanuel/0000-0003-0045-5382; Smielewski, Peter/0000-0001-5096-3938	National Institute of Health Research, Biomedical Research CentreNational Institute for Health Research (NIHR); Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986, G9439390]; NIHRNational Institute for Health Research (NIHR); Swiss National Science Foundation, Bern, SwitzerlandSwiss National Science Foundation (SNSF) [PBBSP3-125550, PASSMP3-124262]; Academy of Medical Science Health Foundation; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G9439390, G0600986, G0001237, G0601025, G0802251] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001237, G0601025, G0802251] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [ACF-2006-14-004, NF-SI-0508-10327] Funding Source: researchfish	This work was supported by the National Institute of Health Research, Biomedical Research Centre (Neuroscience Theme), the Medical Research Council (grants G0600986 and G9439390), and NIHR Senior Investigator Awards (to J.D.P. and D.K.M.); and also by the Swiss National Science Foundation (PBBSP3-125550 to C.Z. and PASSMP3-124262 to E.C.), Bern, Switzerland. E.C. was additionally supported by the SICPA Foundation, Lausanne, Switzerland. P.J.A.H. is supported by an Academy of Medical Science Health Foundation Senior Surgical Scientific Fellowship.	Al-Rawi PG, 2001, STROKE, V32, P2492, DOI 10.1161/hs1101.098356; Balestreri M, 2005, ACT NEUR S, V95, P25; BARZO P, 1993, NEUROSURGERY, V32, P611; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Diedler J, 2009, STROKE, V40, P815, DOI 10.1161/STROKEAHA.108.531020; HARRIS DN, 1993, LANCET, V342, P586, DOI 10.1016/0140-6736(93)91412-F; Hiler M, 2006, J NEUROSURG, V104, P731, DOI 10.3171/jns.2006.104.5.731; Jaeger M, 2010, CRIT CARE MED, V38, P1343, DOI 10.1097/CCM.0b013e3181d45530; Lee JS, 2009, STROKE, V40, pE131; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Menon DK, 2004, ANAESTHESIA, V59, P785, DOI 10.1111/j.1365-2044.2004.03800.x; Ragauskas A, 2005, ACTA NEUROCHIR SUPPL, V95, P367; Schmidt B, 1997, STROKE, V28, P2465, DOI 10.1161/01.STR.28.12.2465; Smielewski P, 2005, ACT NEUR S, V95, P43; Soul JS, 2007, PEDIATR RES, V61, P467, DOI 10.1203/pdr.0b013e31803237f6; Steiner LA, 2003, J CEREBR BLOOD F MET, V23, P1371, DOI 10.1097/01.WCB.0000090861.67713.10; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Steiner LA, 2009, NEUROCRIT CARE, V10, P122, DOI 10.1007/s12028-008-9140-5; Tofteng F, 2004, METAB BRAIN DIS, V19, P207, DOI 10.1023/B:MEBR.0000043970.34533.04; Wang EC, 2006, BRIT J NEUROSURG, V20, P24, DOI 10.1080/02688690600598257; Yoshitani K, 2007, ANESTHESIOLOGY, V106, P458, DOI 10.1097/00000542-200703000-00009; Zweifel C, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E2	23	102	103	1	11	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	NOV	2010	27	11					1951	1958		10.1089/neu.2010.1388			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	682BZ	WOS:000284375500002	20812789				2022-02-06	
J	Anderson, V; Brown, S; Newitt, H; Holle, H				Anderson, Vicki; Brown, Sandra; Newitt, Held; Holle, Hannah			Educational, Vocational, Psychosocial, and Quality-of-Life Outcomes for Adult Survivors of Childhood Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						child; education; long-term outcomes; qualify of life; traumatic brain injury; vocation	HEAD-INJURY; BEHAVIOR PROBLEMS; FOLLOW-UP; MILD; CHILDREN; REHABILITATION; TBI; AGE	Objective: To examine long-term outcomes from child traumatic brain injury (TBI) and relevance of injury severity. Design: A retrospective cross-sectional design. Participants: One hundred and twenty-four young adult survivors of childhood TBI (81 men), aged 18 to 30 years at evaluation (mean = 23.5, SD = 2.9), with injury on average 13.7 years prior to evaluation divided according to injury severity: mild (n = 60), moderate (n = 27), and severe (n = 37). Main Measures: Questionnaires assessed educational and employment status, psychosocial function, and quality-of-life issues. Results: Functional difficulties persisted into adulthood. Injury severity was a particularly strong predictor of long-term outcomes, with environmental factors playing a less consistent role. Survivors of severe TBI were particularly vulnerable, demonstrating global impairment: poorer school performance, employment difficulties, poor quality of life, and increased risk of mental health problems. Mild and moderate TBI were more benign, although lower educational attainment and employment status were identified, and moderate TBI was associated with late developing mental health issues. Conclusions: Traumatic brain injury is a lifelong problem, compromising the individual's capacity to meet developmental expectations across a wide range of functional domains.	[Anderson, Vicki] Royal Childrens Hosp, Dept Psychol, Melbourne, Vic 3052, Australia; [Anderson, Vicki; Brown, Sandra] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Anderson, Vicki; Newitt, Held; Holle, Hannah] Univ Melbourne, Melbourne, Vic, Australia		Anderson, V (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Melbourne, Vic 3052, Australia.						Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson VA, 2005, J NEUROL NEUROSUR PS, V76, P401, DOI 10.1136/jnnp.2003.019174; Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; Asikainen I, 1996, BRAIN INJURY, V10, P883, DOI 10.1080/026990596123864; *AUSTR BUR STAT, DIS LONG TERM HLTH C; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; Daniel A., 1983, POWER PRIVILEGE PRES; Engberg AW, 2004, BRAIN INJURY, V18, P533, DOI 10.1080/02699050310001645829; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; FLETCHER EJ, 1995, RECEPTOR CHANNEL, V3, P21; Hawley CA, 2004, BRAIN INJURY, V18, P645, DOI 10.1080/02699050310001646189; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; Hoofien D, 2001, BRAIN INJURY, V15, P189; Hoofien D, 2002, BRAIN INJURY, V16, P9, DOI 10.1080/02699050110088227; Jonsson CA, 2004, BRAIN INJURY, V18, P921, DOI 10.1080/02699050410001671900; Kieslich M, 2001, DISABIL REHABIL, V23, P665; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; MAX J, 1997, J AM ACAD CHILD ADOL, V36, P83; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; Nybo T, 1999, BRAIN INJURY, V13, P759; Pepping M, 1991, NEUROPSYCHOLOGY EVER, P215; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; PRIGATANO GP, 1993, NEUROPSYCHOL REHABIL, V3, P411, DOI 10.1080/09602019308401449; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; VIGNOLO G, 1980, ITAL J NEUROL, V2, P65; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64	32	102	102	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2009	24	5					303	312		10.1097/HTR.0b013e3181ada830			10	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	509WG	WOS:000271049300001	19858964				2022-02-06	
J	Broglio, SP; Pontifex, MB; O'Connor, P; Hillman, CH				Broglio, Steven P.; Pontifex, Mathew B.; O'Connor, Philip; Hillman, Charles H.			The Persistent Effects of Concussion on Neuroelectric Indices of Attention	JOURNAL OF NEUROTRAUMA			English	Article						electroencephalogram (EEG); event-related potentials (ERP); mild traumatic brain injury; N2; novelty oddball; P3	CHRONIC TRAUMATIC ENCEPHALOPATHY; COLLEGE FOOTBALL PLAYERS; HIGH-SCHOOL; NEUROCOGNITIVE PERFORMANCE; PROFESSIONAL FOOTBALL; MENTAL CHRONOMETRY; AUDITORY-STIMULI; P300 COMPONENT; LEAGUE PLAYER; BRAIN-INJURY	Mild traumatic brain injuries (mTBIs) that result from participation in sports are a major public health issue affecting 1.6-3.8 million individuals annually. The injury has been postulated as transient and void of long-term consequences when rapidly diagnosed and properly managed. Emerging evidence, however, has suggested an increased risk for late life cognitive dysfunction in those with previous injuries. The purpose of this investigation was to evaluate young adults with and without a history of concussion using a standard clinical assessment and highly sensitive electrophysiological measures for persistent changes in cognitive functioning. Ninety participants (19.7 +/- 1.3 years; 44 without mTBI and 46 with previous mTBI) were evaluated using the ImPACT and event-related brain potentials (ERPs) that were recorded during a three-stimulus oddball task. Those with a history of concussion reported an average of 3.4 years post-injury. No significant differences were found between groups on the ImPACT. Significant decrements in the N2 and P3b amplitudes of the stimulus-locked ERP were noted for those with a history relative to those without a history of concussion. Although the previously concussed participants performed equal to those without injury on the clinical cognitive assessment, these findings support the notion that sport mTBI can no longer be thought of as a transient injury resulting in short-lived neurological impairment. It is not clear if these persistent deficits will manifest into clinical pathologies later in life.	[Broglio, Steven P.; Pontifex, Mathew B.; O'Connor, Philip; Hillman, Charles H.] Univ Illinois, Dept Kinesiol & Community Hlth, Urbana, IL 61801 USA		Broglio, SP (corresponding author), 906 S Goodwin Ave, Urbana, IL 61801 USA.	broglio@illinois.edu	Pontifex, Matthew B/A-4474-2009; Hillman, Charles/A-4479-2009; Hillman, Charles/AAD-4828-2019	Pontifex, Matthew B/0000-0001-9819-9625; Hillman, Charles/0000-0002-3722-5612	Mary Jane Neer Fund for Disability Research; University of Illinois	This project was funded by grants from the Mary Jane Neer Fund for Disability Research and the Research Board at the University of Illinois.	Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Broglio SP, 2006, BRIT J SPORT MED, V40, P802, DOI 10.1136/bjsm.2006.028019; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Collie A, 2006, BRIT J SPORT MED, V40, P550, DOI 10.1136/bjsm.2005.019802; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; DONCHIN E, 1981, PSYCHOPHYSIOLOGY, V18, P493, DOI 10.1111/j.1469-8986.1981.tb01815.x; DONCHIN E, 1988, BEHAV BRAIN SCI, V11, P357, DOI 10.1017/S0140525X00058027; Donchin E., 1986, PSYCHOPHYSIOLOGY SYS, P309; DUNCANJOHNSON CC, 1981, PSYCHOPHYSIOLOGY, V18, P207; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Ellemberg D, 2007, CLIN J SPORT MED, V17, P369, DOI 10.1097/JSM.0b013e31814c3e3e; Folstein JR, 2008, PSYCHOPHYSIOLOGY, V45, P152, DOI 10.1111/j.1469-8986.2007.00602.x; Fratiglioni L, 2007, J ALZHEIMERS DIS, V12, P11; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; Hillman CH, 2005, MED SCI SPORT EXER, V37, P1967, DOI 10.1249/01.mss.0000176680.79702.ce; Ilan AB, 1999, CLIN NEUROPHYSIOL, V110, P367; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; JOHNSON R, 1993, PSYCHOPHYSIOLOGY, V30, P90; KATZMAN R, 1988, ANN NEUROL, V23, P138, DOI 10.1002/ana.410230206; Kaufman A.S., 1990, KAUFMAN BRIEF INTELL; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; Knight RT, 1997, J COGNITIVE NEUROSCI, V9, P75, DOI 10.1162/jocn.1997.9.1.75; KNIGHT RT, 1984, ELECTROENCEPHALOGR C, V52, P9; Kok A, 2001, PSYCHOPHYSIOLOGY, V38, P557, DOI 10.1017/S0048577201990559; KUTAS M, 1977, SCIENCE, V197, P792, DOI 10.1126/science.887923; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; MAGLIERO A, 1984, PSYCHOPHYSIOLOGY, V21, P171, DOI 10.1111/j.1469-8986.1984.tb00201.x; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; Mayers L, 2008, ARCH NEUROL-CHICAGO, V65, P1158, DOI 10.1001/archneur.65.9.1158; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Ohman A., 2000, HDB PSYCHOPHYSIOLOGY, V2nd, P533; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Peters A, 2002, NEUROSCI BIOBEHAV R, V26, P733, DOI 10.1016/S0149-7634(02)00060-X; Polich J, 1997, EVOKED POTENTIAL, V104, P244, DOI 10.1016/S0168-5597(97)96139-6; Polich J, 1996, PSYCHOPHYSIOLOGY, V33, P747, DOI 10.1111/j.1469-8986.1996.tb02371.x; Polich J, 1996, PSYCHOPHYSIOLOGY, V33, P334, DOI 10.1111/j.1469-8986.1996.tb01058.x; POLICH J, 1987, ELECTROEN CLIN NEURO, V68, P311, DOI 10.1016/0168-5597(87)90052-9; Polich J, 2007, CLIN NEUROPHYSIOL, V118, P2128, DOI 10.1016/j.clinph.2007.04.019; Ridderinkhof KR, 2000, BIOL PSYCHOL, V54, P55, DOI 10.1016/S0301-0511(00)00053-3; SQUIRES NK, 1975, ELECTROEN CLIN NEURO, V38, P387, DOI 10.1016/0013-4694(75)90263-1; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; Verleger R, 1997, PSYCHOPHYSIOLOGY, V34, P131, DOI 10.1111/j.1469-8986.1997.tb02125.x; 2009, OFFLINE ANAL ACQUIRE	56	102	103	0	34	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2009	26	9					1463	1470		10.1089/neu.2008.0766			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	489NG	WOS:000269426200003	19331519				2022-02-06	
J	Rao, V; Rosenberg, P; Bertrand, M; Salehinia, S; Spiro, J; Vaishnavi, S; Rastogi, P; Noll, K; Schretlen, DJ; Brandt, J; Cornwell, E; Makley, M; Miles, QS				Rao, Vani; Rosenberg, Paul; Bertrand, Melaine; Salehinia, Saeed; Spiro, Jennifer; Vaishnavi, Sandeep; Rastogi, Pramit; Noll, Kathy; Schretlen, David J.; Brandt, Jason; Cornwell, Edward; Makley, Michael; Miles, Quincy Samus			Aggression After Traumatic Brain Injury: Prevalence and Correlates	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							OVERT AGGRESSION; HEAD-INJURY; POPULATION; AGITATION; BEHAVIOR; SCALE; ONSET	Aggression after traumatic brain injury (TBI) is common but not well defined. Sixty-seven participants with first-time TBI were evaluated for aggression within 3 months of injury. The prevalence of aggression was found to be 28.4%, predominantly verbal aggression. Post-TBI aggression was associated with new-onset major depression (p=0.02), poorer social functioning (p=0.04), and increased dependency in activities of daily living (p=0.03), but not with a history Of substance abuse or adult/childhood behavioral problems. Implications of the study include early screening for aggression, evaluation for depression, and consideration of psychosocial support in aggressive patients. (The journal of Neuropsychiatry and Clinical Neurosciences 2009; 21:420-429)	[Rao, Vani] Johns Hopkins Univ, Div Neuropsychiat & Geriatr Psychiat, Dept Psychiat, Johns Hopkins Sch Med, Baltimore, MD 21224 USA; [Vaishnavi, Sandeep] Alexian Bros Behav Hlth Hosp, Div Neuropsychiat, Alexian Neurosci Inst, Chicago, IL USA; [Noll, Kathy] Johns Hopkins Sch Med, Dept Surg, Baltimore, MD USA; [Schretlen, David J.; Brandt, Jason] Johns Hopkins Sch Med, Div Med Psychol, Dept Psychiat, Baltimore, MD USA; [Cornwell, Edward] Howard Univ, Coll Med, Dept Surg, Washington, DC USA; [Makley, Michael] Univ Maryland, Kernan Hosp, Baltimore, MD 21201 USA		Rao, V (corresponding author), Johns Hopkins Univ, Div Neuropsychiat & Geriatr Psychiat, Dept Psychiat, Johns Hopkins Sch Med, 5300 Alpha Commons Dr,4th Floor 444, Baltimore, MD 21224 USA.	vrao@jhmi.edu		Brandt, Jason/0000-0001-7381-6244	NIMHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23 MH 066894]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23MH066894, K01MH085142] Funding Source: NIH RePORTER	This study was supported by grant K23 MH 066894 from the NIMH. The abstract was presented at the 2008 annual neuropsychiatry conference in Savannah, Georgia.	Baguley IJ, 2006, J HEAD TRAUMA REHAB, V21, P45, DOI 10.1097/00001199-200601000-00005; Benedict, 2001, HOPKINS VERBAL LEARN; Benedict R., 1997, BRIEF VISUOSPATIAL M; BOWMAN M, 1997, BRAIN IMPAIRMENT IMP, P116; BROOKE MM, 1992, ARCH PHYS MED REHAB, V73, P320, DOI 10.1016/0003-9993(92)90003-F; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Diaz F G, 1995, Med Law, V14, P131; Dunlop T W, 1991, J Neuropsychiatry Clin Neurosci, V3, P150; Dyer KFW, 2006, BRAIN INJURY, V20, P1163, DOI 10.1080/02699050601049312; Eaton WW, 2008, ARCH GEN PSYCHIAT, V65, P513, DOI 10.1001/archpsyc.65.5.513; First M., 1997, STRUCTURED CLIN INTE; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Garno JL, 2008, BIPOLAR DISORD, V10, P285, DOI 10.1111/j.1399-5618.2007.00489.x; Golden J. C., 1978, STROOP COLOR WORD TE; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Greve KW, 2001, BRAIN INJURY, V15, P255; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Hellings JA, 2005, J NEUROPSYCH CLIN N, V17, P29, DOI 10.1176/appi.neuropsych.17.1.29; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kafantaris V, 1996, J NEUROPSYCH CLIN N, V8, P186; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Klonoff PS, 1998, ARCH PHYS MED REHAB, V79, P684, DOI 10.1016/S0003-9993(98)90045-4; KREUTZER JS, 1995, BRAIN INJURY, V9, P757, DOI 10.3109/02699059509008232; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; LEWIS DO, 1986, AM J PSYCHIAT, V143, P838; Lyketsos CG, 1999, J AM GERIATR SOC, V47, P487, DOI 10.1111/j.1532-5415.1999.tb07245.x; MCNIEL DE, 1991, AM J PSYCHIAT, V148, P1317; Nelson H.E., 1982, NATL ADULT READING T; Rapoport M, 2002, NEUROPSY NEUROPSY BE, V15, P123, DOI 10.1097/01.WNN.0000016801.80266.36; Reitan RM, 1985, HALSTEADREITAN NEURO; ROBINSON RG, 1985, AM J PSYCHIAT, V142, P1424; ROSENBAUM A, 1994, J CONSULT CLIN PSYCH, V62, P1187, DOI 10.1037/0022-006X.62.6.1187; Schretlen D., 1996, BRIEF TEST ATTENTION; Silver J M, 1991, J Neuropsychiatry Clin Neurosci, V3, pS22; Slaughter B, 2003, BRAIN INJURY, V17, P731, DOI 10.1080/0269905031000088649; Sloane PD, 2004, J AM GERIATR SOC, V52, P1795, DOI 10.1111/j.1532-5415.2004.52501.x; Spreen O., 1977, NEUROSENSORY CTR COM, VRev; Spreen O., 1969, NEUROSENSORY CTR COM; Starkstein SE, 1997, J NERV MENT DIS, V185, P108, DOI 10.1097/00005053-199702000-00007; STARR LB, 1983, EXP AGING RES, V9, P101, DOI 10.1080/03610738308258434; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; TEASDALE G, 1974, LANCET, V2, P81; Weissman MM, 2000, ARCH GEN PSYCHIAT, V57, P675, DOI 10.1001/archpsyc.57.7.675; YUDOFSKY SC, 1986, AM J PSYCHIAT, V143, P35	46	102	103	1	18	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	FAL	2009	21	4					420	429					10	Clinical Neurology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry	526RR	WOS:000272311300009	19996251	Green Accepted			2022-02-06	
J	Yu, SJ; Kaneko, Y; Bae, E; Stahl, CE; Wang, Y; van Loveren, H; Sanberg, PR; Borlongan, CV				Yu, Seongjin; Kaneko, Yuji; Bae, Eunkyung; Stahl, Christine E.; Wang, Yun; van Loveren, Harry; Sanberg, Paul R.; Borlongan, Cesar V.			Severity of controlled cortical impact traumatic brain injury in rats and mice dictates degree of behavioral deficits	BRAIN RESEARCH			English	Article						Head injury; Cortical damage; Locomotor and cognitive behaviors; Animal model	THERAPEUTIC STRATEGY; UNITED-STATES; CELL THERAPY; TRANSPLANTATION; STROKE; VOLUME; DEATH	The clinical presentation of traumatic brain injury (TBI) involves either mild, moderate, or severe injury to the head resulting in long-term and even permanent disability. The recapitulation of this clinical scenario in animal models should allow examination of the pathophysiology of the trauma and its treatment. To date, only a few studies have demonstrated TBI animal models encompassing the three levels of trauma severity. Thus, in the present study we characterized in mice and rats both brain histopathologic and behavioral alterations across a range of injury magnitudes arising from mild, moderate, and severe TBI produced by controlled cortical impact injury technique. Here, we replicated the previously observed TBI severity-dependent brain damage as revealed by 2,3,5-triphenyltetrazolium chloride staining (severe > moderate > mild) in rats, but also extended this pattern of histopathologic changes in mice. Moreover, we showed severity-dependent abnormalities in locomotor and cognitive behaviors in TBI-exposed rats and mice. Taken together, these results support the use of rodent models of TBI as a sensitive platform for investigations of the injury-induced neurostructural and behavioral deficits, which should serve as key outcome parameters for testing experimental therapeutics. (C) 2009 Elsevier B.V. All rights reserved.	[van Loveren, Harry; Sanberg, Paul R.; Borlongan, Cesar V.] Univ S Florida, Dept Neurosurg, Tampa, FL 33612 USA; [Yu, Seongjin; Kaneko, Yuji; Bae, Eunkyung; Borlongan, Cesar V.] Med Coll Georgia, Dept Neurol, Augusta, GA 30912 USA; [Stahl, Christine E.] Dwight D Eisenhower Army Med Ctr, Dept Internal Med, Augusta, GA 30905 USA; [Wang, Yun] NIDA, Neural Protect & Regenerat Sect, NIH, Baltimore, MD 21224 USA		Borlongan, CV (corresponding author), Univ S Florida, Dept Neurosurg, Tampa, FL 33612 USA.	cborlong@health.usf.edu	Kaneko, Yuji/J-6447-2012	Borlongan, Cesar/0000-0002-2966-9782	NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [ZIADA000429, ZIADA000461] Funding Source: NIH RePORTER		Baskaya MK, 2000, J NEUROTRAUM, V17, P93, DOI 10.1089/neu.2000.17.93; Boockvar JA, 2005, NEUROSURGERY, V56, P163, DOI 10.1227/01.NEU.0000145866.25433.FF; Borlongan CV, 2008, REGEN MED, V3, P249, DOI 10.2217/17460751.3.3.249; Borlongan CV, 2009, STROKE, V40, pS146, DOI 10.1161/STROKEAHA.108.533091; Chuck Y, 2008, MILD TRAUMATIC BRAIN; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; Dikranian K, 2008, EXP NEUROL, V211, P551, DOI 10.1016/j.expneurol.2008.03.012; Gao JL, 2006, EXP NEUROL, V201, P281, DOI 10.1016/j.expneurol.2006.04.039; Gerlai R, 2000, BEHAV BRAIN RES, V108, P63, DOI 10.1016/S0166-4328(99)00130-8; Hellmich HL, 2005, BRAIN RES, V1044, P144, DOI 10.1016/j.brainres.2005.02.054; Igarashi T, 2007, EXP NEUROL, V203, P258, DOI 10.1016/j.expneurol.2006.08.030; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; LaPlaca MC, 2007, PROG BRAIN RES, V161, P13, DOI 10.1016/S0079-6123(06)61002-9; Longhi L, 2005, TRANSPL IMMUNOL, V15, P143, DOI 10.1016/j.trim.2005.09.003; Mahmood A, 2008, J NEUROTRAUM, V25, P1441, DOI 10.1089/neu.2007.0495; Mammis A, 2009, SURG NEUROL, V71, P527, DOI 10.1016/j.surneu.2008.02.040; Perri BR, 1997, J NEUROTRAUM, V14, P15, DOI 10.1089/neu.1997.14.15; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Sandhir R, 2008, EXP NEUROL, V213, P372, DOI 10.1016/j.expneurol.2008.06.013; Schouten JW, 2004, J NEUROTRAUM, V21, P1501, DOI 10.1089/neu.2004.21.1501; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; Suh M, 2006, NEUROSCI LETT, V401, P108, DOI 10.1016/j.neulet.2006.02.074; Tehranian R, 2008, J NEUROTRAUM, V25, P755, DOI 10.1089/neu.2007.0441; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Wang Y, 2001, STROKE, V32, P775, DOI 10.1161/01.STR.32.3.775; Xia CF, 2006, HYPERTENSION, V47, P752, DOI 10.1161/01.HYP.0000214867.35632.0e; Yasuhara T, 2008, REJUV RES, V11, P201, DOI 10.1089/rej.2007.0608; You ZR, 2008, J CEREBR BLOOD F MET, V28, P1564, DOI 10.1038/jcbfm.2008.44; Yu GL, 2004, BRAIN RES, V1015, P50, DOI 10.1016/j.brainres.2004.04.055	31	102	103	0	13	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	SEP 1	2009	1287						157	163		10.1016/j.brainres.2009.06.067			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	489XR	WOS:000269460100016	19573519				2022-02-06	
J	Aukema, EJ; Caan, MWA; Oudhuis, N; Majoie, CBLM; Vos, FM; Reneman, L; Last, BF; Grootenhuis, MA; Schouten-van Meeteren, AYN				Aukema, Eline J.; Caan, Matthan W. A.; Oudhuis, Nienke; Majoie, Charles B. L. M.; Vos, Frans M.; Reneman, Liesbeth; Last, Bob F.; Grootenhuis, Martha A.; Schouten-van Meeteren, Antoinette Y. N.			WHITE MATTER FRACTIONAL ANISOTROPY CORRELATES WITH SPEED OF PROCESSING AND MOTOR SPEED IN YOUNG CHILDHOOD CANCER SURVIVORS	INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS			English	Article; Proceedings Paper	40th Congress Meeting of the International-Society-of-Paediatric-Oncology (SIOP)	OCT 02-06, 2008	Berlin, GERMANY	Int Soc Paediat Oncol		DTI; Children; Cancer; Neuropsychology; MTX	TRAUMATIC BRAIN-INJURY; ACUTE LYMPHOBLASTIC-LEUKEMIA; DIFFUSION-TENSOR; NEUROCOGNITIVE DEFICITS; COGNITIVE FUNCTIONS; CHILDREN; MEDULLOBLASTOMA; CHEMOTHERAPY; ADOLESCENCE; ASSOCIATION	Purpose: To determine whether childhood medulloblastoma and acute lymphoblastic leukemia (ALL) survivors have decreased white matter fractional anisotropy (WMFA) and whether WMFA is related to the speed of processing and motor speed. Methods and Materials: For this study, 17 patients (6 medulloblastoma, 5 ALL treated with high-dose methotrexate (MTX) (4 x 5 g/m(2)) and 6 with low-dose MTX (3 x 2 g/m(2))) and 17 age-matched controls participated. On a 3.0-T magnetic resonance imaging (MRI) scanner, diffusion tensor imaging (DTI) was performed, and WMFA values were calculated, including specific regions of interest (ROIs), and correlated with the speed of processing and motor speed. Results: Mean WMFA in the patient group, mean age 14 years (range 8.9 - 16.9), was decreased compared with the control group (p = 0.01), as well as WMFA in the right inferior fronto-occipital fasciliculus (IFO) (p = 0.03) and in the genu of the corpus callosum (gCC) (p = 0.01). Based on neurocognitive results, significant positive correlations were present between processing speed and WMFA in the splenium (sCC) (r = 0.53, p = 0.03) and the body of the corpus callosum (bCC) (r = 0.52, p = 0.03), whereas the right IFO WMFA was related to motor speed (r = 0.49, p < 0.05). Conclusions: White matter tracts, using a 3.0-T MRI scanner, show impairment in childhood cancer survivors, medulloblastoma survivors, and also those treated with high doses of MTX. In particular, white matter tracts in the sCC, bCC and right IFO are positively correlated with speed of processing and motor speed. (C) 2009 Elsevier Inc.	[Aukema, Eline J.; Oudhuis, Nienke; Last, Bob F.; Grootenhuis, Martha A.] Univ Amsterdam, Acad Med Ctr, Pediat Psychosocial Dept, Emma Childrens Hosp, NL-1105 AZ Amsterdam, Netherlands; [Schouten-van Meeteren, Antoinette Y. N.] Univ Amsterdam, Acad Med Ctr, Dept Pediat Oncol, Emma Childrens Hosp, NL-1105 AZ Amsterdam, Netherlands; [Caan, Matthan W. A.; Majoie, Charles B. L. M.; Vos, Frans M.; Reneman, Liesbeth] Univ Amsterdam, Acad Med Ctr, Dept Radiol, NL-1105 AZ Amsterdam, Netherlands; [Caan, Matthan W. A.; Vos, Frans M.] Delft Univ Technol, Delft, Netherlands; [Last, Bob F.] Free Univ Amsterdam, Dept Dev Psychol, Amsterdam, Netherlands		Aukema, EJ (corresponding author), Univ Amsterdam, Acad Med Ctr, Pediat Psychosocial Dept, Emma Childrens Hosp, Meibergdreef 9,G8-224, NL-1105 AZ Amsterdam, Netherlands.	e.j.aukema@amc.uva.nl		Caan, Matthan W.A./0000-0002-5162-8880; Reneman, Liesbeth/0000-0002-5912-9971			Barnea-Goraly N, 2005, CEREB CORTEX, V15, P1848, DOI 10.1093/cercor/bhi062; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Ben Bashat D, 2005, J MAGN RESON IMAGING, V21, P503, DOI 10.1002/jmri.20281; Buizer AI, 2005, PEDIATR BLOOD CANCER, V45, P281, DOI 10.1002/pbc.20397; Buizer AI, 2005, J INT NEUROPSYCH SOC, V11, P554, DOI 10.1017/S135561770505666; Butler RW, 2006, MENT RETARD DEV D R, V12, P184, DOI 10.1002/mrdd.20110; Butler RW, 2005, J PEDIATR PSYCHOL, V30, P65, DOI 10.1093/jpepsy/jsi017; Caan M, 2008, LECT NOTES COMPUT SC, V5241, P535, DOI 10.1007/978-3-540-85988-8_64; Campbell LK, 2007, PEDIATR BLOOD CANCER, V49, P65, DOI 10.1002/pbc.20860; Cohen J., 2013, STAT POWER ANAL BEHA; GARDNER RA, 1979, J CLIN CHILD PSYCHOL, V8, P156, DOI 10.1080/15374417909532912; Giedd JN, 1999, PROG NEURO-PSYCHOPH, V23, P571; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Iuvone L, 2002, CANCER-AM CANCER SOC, V95, P2562, DOI 10.1002/cncr.10999; Khong PL, 2006, J CLIN ONCOL, V24, P884, DOI 10.1200/JCO.2005.02.4505; Khong PL, 2005, RADIOLOGY, V236, P647, DOI 10.1148/radiol.2362041066; Khong PL, 2003, AM J NEURORADIOL, V24, P734; Kort W, 2005, HANDLEIDING VERANTWO; Mabbott DJ, 2006, NEUROIMAGE, V33, P936, DOI 10.1016/j.neuroimage.2006.07.024; Mangin J.F, 2001, LNCS, V2208, P186; Moleski M, 2000, ARCH CLIN NEUROPSYCH, V15, P603, DOI 10.1016/S0887-6177(99)00050-5; Moore BD, 2005, J PEDIATR PSYCHOL, V30, P51, DOI 10.1093/jpepsy/jsi016; Mulhern RK, 2001, J CLIN ONCOL, V19, P472, DOI 10.1200/JCO.2001.19.2.472; Mulrooney DA, 2008, CURR TREAT OPTION ON, V9, P51, DOI 10.1007/s11864-008-0054-4; Nagy Z, 2004, J COGNITIVE NEUROSCI, V16, P1227, DOI 10.1162/0898929041920441; Nathan PC, 2007, ARCH PEDIAT ADOL MED, V161, P798, DOI 10.1001/archpedi.161.8.798; QUI D, 2007, J RAD ONCOL BIOL PHY, V69, P846; Reddick WE, 2006, CANCER-AM CANCER SOC, V106, P941, DOI 10.1002/cncr.21679; Reddick WE, 2005, NEURO-ONCOLOGY, V7, P12, DOI 10.1215/S1152851704000079; Reddick WE, 2003, CANCER-AM CANCER SOC, V97, P2512, DOI 10.1002/cncr.11355; Ronning C, 2005, PEDIATR NEUROSURG, V41, P15, DOI 10.1159/000084860; Schmithorst VJ, 2005, HUM BRAIN MAPP, V26, P139, DOI 10.1002/hbm.20149; Villarreal G, 2004, PSYCHIAT RES-NEUROIM, V131, P227, DOI 10.1016/j.pscychresns.2004.05.002; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Yuan W, 2007, AM J NEURORADIOL, V28, P1919, DOI 10.3174/ajnr.A0698	35	102	104	1	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0360-3016	1879-355X		INT J RADIAT ONCOL	Int. J. Radiat. Oncol. Biol. Phys.	JUL 1	2009	74	3					837	843		10.1016/j.ijrobp.2008.08.060			7	Oncology; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	Oncology; Radiology, Nuclear Medicine & Medical Imaging	455JJ	WOS:000266754800027	19117694				2022-02-06	
J	Courtney, AC; Courtney, MW				Courtney, A. C.; Courtney, M. W.			A thoracic mechanism of mild traumatic brain injury due to blast pressure waves	MEDICAL HYPOTHESES			English	Article							ARMOR BLUNT TRAUMA; TYMPANIC-MEMBRANE PERFORATION; MISSILE EXTREMITY IMPACT; CENTRAL-NERVOUS-SYSTEM; SMALL-BOWEL INJURY; INDUCED NEUROTRAUMA; IMPULSE NOISE; SHELL SHOCK; TRANSIENT; DAMAGE	The mechanisms by which blast pressure waves cause mild-to-moderate traumatic brain injury (mTBI) are an open question. Possibilities include acceleration of the head, direct passage of the blast wave via the cranium, and propagation of the blast wave to the brain via a thoracic mechanism. The hypothesis that the blast pressure wave reaches the brain via a thoracic mechanism is considered in light of ballistic and blast pressure wave research. Ballistic pressure waves, caused by penetrating ballistic projectiles or ballistic impacts to body armor, can only reach the brain via an internal mechanism and have been shown to cause cerebral effects. Similar effects have been documented when a blast pressure wave has been applied to the whole body or focused on the thorax in animal models. While vagotomy reduces apnea and bradycardia due to ballistic or blast pressure waves, it does not eliminate neural damage in the brain, suggesting that the pressure wave directly affects the brain cells via a thoracic mechanism. An experiment is proposed which isolates the thoracic mechanism from cranial mechanisms of mTBI due to blast wave exposure. Results have implications for evaluating risk of mTBI due to blast exposure and for developing effective protection. Published by Elsevier Ltd.	[Courtney, A. C.] US Mil Acad, Dept Phys, West Point, NY 10996 USA; [Courtney, M. W.] Ballist Testing Grp, West Point, NY 10996 USA		Courtney, AC (corresponding author), US Mil Acad, Dept Phys, POB 24, West Point, NY 10996 USA.	amy_courtney@post.harvard.edu; michael_courtney@alum.mit.edu		Courtney, Amy/0000-0002-1925-8736			BELLAMY RF, 1990, TXB MILITARY MED; Bhatoe HS, 2003, NEUROL INDIA, V51, P507; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; Cannon L, 2001, J R Army Med Corps, V147, P87; CARROLL AW, 1978, ANN SURG, V188, P753, DOI 10.1097/00000658-197812000-00007; Cernak I, 1999, J TRAUMA, V47, P96, DOI 10.1097/00005373-199907000-00021; Cernak I, 1996, J TRAUMA, V40, pS100, DOI 10.1097/00005373-199603001-00023; Cernak I, 1999, WORLD J SURG, V23, P44, DOI 10.1007/s002689900563; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Cernak I, 1996, J TRAUMA, V40, pS148, DOI 10.1097/00005373-199603001-00032; CERNAK I, 2005, RESTORATIVE NEUROLOG, V23, P139; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; Cooper GJ, 1996, J TRAUMA, V40, pS105, DOI 10.1097/00005373-199603001-00024; Courtney A, 2007, BRAIN INJURY, V21, P657, DOI 10.1080/02699050701481571; COURTNEY M, EXPT OBSERVATIONS IN; COURTNEY M, 2007, METHOD TESTING HANDG; DARAIO C, 2006, PHYS REV LETT, V96, P580; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; DONEY R, 2006, PHYS REV LETT, V97, P1555; Drobin D, 2007, J TRAUMA, V63, P405, DOI 10.1097/01.ta.0000236015.68105.48; Finkel MF, 2006, J NEUROL SCI, V249, P63, DOI 10.1016/j.jns.2006.06.005; GORANSSON AM, 1988, J TRAUMA, V28, pS204; Gryth D, 2008, J TRAUMA, V64, P1420, DOI 10.1097/TA.0b013e318054e247; Gryth D, 2007, MIL MED, V172, P1110, DOI 10.7205/MILMED.172.10.1110; Gutierrez de Ceballos J Peral, 2005, Crit Care Med, V33, pS107, DOI 10.1097/01.CCM.0000151072.17826.72; HARVEY EN, 1947, J EXP MED, V85, P321, DOI 10.1084/jem.85.3.321; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Irwin RJ, 1999, J TRAUMA, V47, P105, DOI 10.1097/00005373-199907000-00023; JOHANSSON L, 1982, ACTA CHIR SCAND, V148, P15; Jones E, 2007, AM J PSYCHIAT, V164, P1641, DOI 10.1176/appi.ajp.2007.07071180; KARMYJONES R, 1994, MIL MED, V159, P536, DOI 10.1093/milmed/159.7.536; Knudsen SK, 2003, NEUROSCI RES, V46, P377, DOI 10.1016/S0168-0102(03)00101-9; Krave U, 2005, EUR J NEUROSCI, V21, P2876, DOI 10.1111/j.1460-9568.2005.04115.x; Lai XN, 1996, J TRAUMA, V40, pS60, DOI 10.1097/00005373-199603001-00013; Lee M, 1997, J FLUID STRUCT, V11, P819, DOI 10.1006/jfls.1997.0103; Li Chao-jun, 2006, Chin J Traumatol, V9, P242; LIDEN E, 1988, J TRAUMA, V28, pS145, DOI 10.1097/00005373-198801001-00029; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LUDWIG GD, 1950, J ACOUST SOC AM, V22, P862, DOI 10.1121/1.1906706; Merkle AC, 2008, J TRAUMA, V64, P1555, DOI 10.1097/TA.0b013e318160ff3a; METKER LW, 1978, TR78034 ARCSL; Metting Z, 2007, LANCET NEUROL, V6, P699, DOI 10.1016/S1474-4422(07)70191-6; Mines M, 2000, OPHTHALMOLOGY, V107, P837, DOI 10.1016/S0161-6420(00)00030-0; Moore DF, 2008, FUTUR NEUROL, V3, P243, DOI 10.2217/14796708.3.3.243; Peters CE., 1990, J TRAUMA CHINA, V6, P308; Petras JM, 1997, TOXICOLOGY, V121, P41, DOI 10.1016/S0300-483X(97)03654-8; PHILLIPS YY, 1990, TXB MILITARY MED; Pompei A, 2007, J SOUND VIB, V302, P925, DOI 10.1016/j.jsv.2006.12.018; Ritenour AE, 2008, J TRAUMA, V64, pS174, DOI 10.1097/TA.0b013e318160773e; Roberts JC, 2007, J TRAUMA, V62, P1127, DOI 10.1097/01.ta.0000231779.99416.ee; Roberts JC, 2005, J TRAUMA, V58, P1241, DOI 10.1097/01.TA.0000169805.81214.DC; Saljo A, 2003, J NEUROTRAUM, V20, P787, DOI 10.1089/089771503767870014; SASAKI LS, 1995, J TRAUMA, V39, P602; Sharp D, 2006, LANCET, V368, P975, DOI 10.1016/S0140-6736(06)69395-1; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Singerm E, 2008, TECHNOL REV, V111, P52; STUHMILLER JH, 2008, QUANTITATIVE PHYSL P; Sturtevant B, 1998, SADHANA-ACAD P ENG S, V23, P579, DOI 10.1007/BF02744581; SUNESON A, 1988, J TRAUMA, V28, pS197, DOI 10.1097/00005373-198801001-00041; SUNESON A, 1987, J TRAUMA, V27, P782, DOI 10.1097/00005373-198707000-00016; SUNESON A, 1990, J TRAUMA, V30, P295, DOI 10.1097/00005373-199003000-00007; SUNESON A, 1990, J TRAUMA, V30, P281, DOI 10.1097/00005373-199003000-00006; Suneson A, 2000, MIL MED, V165, P119, DOI 10.1093/milmed/165.2.119; SUNESON A, 1989, J TRAUMA, V29, P10, DOI 10.1097/00005373-198901000-00003; Sylvia FR, 2001, MIL MED, V166, P918, DOI 10.1093/milmed/166.10.918; Tatic V, 1996, J TRAUMA, V40, pS94, DOI 10.1097/00005373-199603001-00022; Thach AB, 2008, OPHTHALMOLOGY, V115, P377, DOI 10.1016/j.ophtha.2007.04.032; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Tien HC, 2007, J TRAUMA, V62, P762, DOI 10.1097/01.ta.0000231555.81174.9e; Toth Z, 1997, J NEUROSCI, V17, P8106; Treib J, 1996, MIL MED, V161, P61, DOI 10.1093/milmed/161.1.61; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; Velitchkov NG, 2000, J TRAUMA, V48, P169, DOI 10.1097/00005373-200001000-00035; Wang Q, 2004, J TRAUMA, V56, P604, DOI 10.1097/01.TA.0000058122.57737.0E; Xydakis MS, 2007, NEW ENGL J MED, V357, P830, DOI 10.1056/NEJMc076071; Yang ZH, 1996, J TRAUMA, V40, pS81, DOI 10.1097/00005373-199603001-00019; Yelverton J. T., 1973, 3114T DNA; YLIKOSKI ME, 1995, SCAND AUDIOL, V24, P3, DOI 10.3109/01050399509042203; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	81	102	107	0	12	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0306-9877	1532-2777		MED HYPOTHESES	Med. Hypotheses	JAN	2009	72	1					76	83		10.1016/j.mehy.2008.08.015			8	Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine	385YZ	WOS:000261850800023	18829180	Green Submitted			2022-02-06	
S	Thaut, MH; Gardiner, JC; Holmberg, D; Horwitz, J; Kent, L; Andrews, G; Donelan, B; McIntosh, GR		DallaBella, S; Kraus, N; Overy, K; Pantev, C; Snyder, JS; Tervaniemi, M; Tillmann, B; Schlaug, G		Thaut, Michael H.; Gardiner, James C.; Holmberg, Dawn; Horwitz, Javan; Kent, Luanne; Andrews, Garrett; Donelan, Beth; McIntosh, Gerald R.			Neurologic Music Therapy Improves Executive Function and Emotional Adjustment in Traumatic Brain Injury Rehabilitation	NEUROSCIENCES AND MUSIC III: DISORDERS AND PLASTICITY	Annals of the New York Academy of Sciences		English	Article; Proceedings Paper	Conference on the Neurosciences and Music III	JUN 25-28, 2008	McGill Univ, Montreal, CANADA		McGill Univ	brain injury; neurologic music therapy; cognitive rehabilitation; attention; memory; executive function; emotional adjustment	MEMORY; ATTENTION; STIMULATION; MNEMONICS; RESPONSES; CORRELATE; RECALL	This study examined the immediate effects of neurologic music therapy (NMT) on cognitive functioning and emotional adjustment with brain-injured persons. Four treatment sessions were held, during which participants were given a pre-test, participated in 30 min of NMT that focused on one aspect of rehabilitation (attention, memory, executive function, or emotional adjustment), which was followed by post-testing. Control participants engaged in a pre-test, 30 min of rest, and then a post-test. Treatment participants showed improvement in executive function and overall emotional adjustment, and lessening of depression, sensation seeking, and anxiety. Control participants improved in emotional adjustment and lessening of hostility, but showed decreases in measures of memory, positive affect, and sensation seeking.	[Thaut, Michael H.; Holmberg, Dawn; McIntosh, Gerald R.] Colorado State Univ, Ctr Biomed Res Mus, Ft Collins, CO 80523 USA; [Gardiner, James C.; Horwitz, Javan; Kent, Luanne; Andrews, Garrett; Donelan, Beth] Vet Affairs Black Hills Hlth Care Syst, Mental Hlth Serv, Ft Meade, SD USA		Thaut, MH (corresponding author), Colorado State Univ, Ctr Biomed Res Mus, Ft Collins, CO 80523 USA.	michael.thaut@colostate.edu					Baur B, 2000, NEUROCASE, V6, P415, DOI 10.1080/13554790008402712; Ben-Yishay Y., 1987, NEUROPSYCHOLOGICAL R, P165; BENNETT T, 1998, J COGN REHABIL, V16, P8; BICKMAN L, 1991, VANDERBILT MENTAL HL; Blood AJ, 1999, NAT NEUROSCI, V2, P382, DOI 10.1038/7299; Blood AJ, 2001, P NATL ACAD SCI USA, V98, P11818, DOI 10.1073/pnas.191355898; Campbell DT., 1963, EXPT QUASI EXPT DESI; Carruth EK, 1997, J MUSIC THER, V34, P165, DOI 10.1093/jmt/34.3.165; Chan AS, 1998, NATURE, V396, P128, DOI 10.1038/24075; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; CLAUSSEN DW, 1997, CAN J MUSIC THER, V5, P55; Cowles A, 2003, NEUROCASE, V9, P493, DOI 10.1076/neur.9.6.493.29378; Derogatis L.R., 2000, BRIEF SYMPTOM INVENT; Deutsch D., 1982, MUSIC MIND BRAIN, P119; Foster NA, 2001, EXP AGING RES, V27, P215, DOI 10.1080/036107301300208664; GEFFEN GM, 1994, ARCH CLIN NEUROPSYCH, V9, P303, DOI 10.1016/0887-6177(94)90018-3; GFELLER KE, 1983, J MUSIC THER, V20, P179, DOI 10.1093/jmt/20.4.179; GIANUTSOS R, 1979, Journal of Clinical Neuropsychology, V1, P117, DOI 10.1080/01688637908414446; Gold C, 2004, MUSIC THERAPY PERSPE, V22, P91, DOI DOI 10.1093/MTP/22.2.91; Goldberg E., 2001, EXECUTIVE BRAIN FRON; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; GORDON WA, 1992, NEUROPSYCHOLOGY, V6, P361; Gregory D, 2002, J MUSIC THER, V39, P244, DOI 10.1093/jmt/39.4.244; HANSER SB, 1994, J GERONTOL, V49, pP265, DOI 10.1093/geronj/49.6.P265; Haslam C, 2002, NEUROCASE, V8, P453, DOI 10.1093/neucas/8.3.169; Ho YC, 2003, NEUROPSYCHOLOGY, V17, P439, DOI 10.1037/0894-4105.17.3.439; Homberg V, 2005, ACTA NEUROCHIR SUPPL, V93, P3; Hummelsheim H, 1999, CURR OPIN NEUROL, V12, P697, DOI 10.1097/00019052-199912000-00007; Iwaki T, 1997, PERCEPT MOTOR SKILL, V84, P515, DOI 10.2466/pms.1997.84.2.515; Jones M.R., 1992, COGNITIVE BASES MUSI; Klein JM, 1996, PERCEPT PSYCHOPHYS, V58, P34, DOI 10.3758/BF03205473; Kleinstauber M., 2006, J COGN REHAB, V24, P4; Knox R, 1996, CAN J REHABIL, V9, P169; Knox R, 2003, MUSIC THER PERSPECT, V21, P99, DOI [10.1093/mtp/21.2.99, DOI 10.1093/mtp/21.2.99, DOI 10.1093/MTP/21.2.99]; Levitin DJ, 2006, THIS IS YOUR BRAIN M; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Lubin, 1965, MANUAL MULTIPLE AFFE; Manly T, 2002, NEUROPSYCHOLOGIA, V40, P271, DOI 10.1016/S0028-3932(01)00094-X; MCCAFFREY RJ, 1993, ARCH CLIN NEUROPSYCH, V8, P519; MCCAFFREY RJ, 1992, CLIN NEUROPSYCHOL, V0006, P00032, DOI [DOI 10.1080/138540492084041_15, DOI 10.1080/13854049208404115]; MORTON LL, 1990, J MUSIC THER, V26, P58; Nayak S, 2000, REHABIL PSYCHOL, V45, P274, DOI 10.1037/0090-5550.45.3.274; O'Connor C, 2004, BRAIN COGNITION, V54, P133, DOI 10.1016/S0278-2626(03)00268-9; PARENTE R., 1996, RETRAINING COGNITION; Peretz I, 2005, ANNU REV PSYCHOL, V56, P89, DOI 10.1146/annurev.psych.56.091103.070225; PURDIE H, 1997, CRIT REV PHYS REHABI, V9, P205; Rey A., 1964, EXAMEN CLIN PSYCHOL; Rimmele C T, 1987, Arch Clin Neuropsychol, V2, P353; SLOBODA J., 1985, MUSICAL MIND COGNITI; Sohlberg M. M., 1989, ATTENTION PROCESS TR; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Sturm W, 2002, APPLIED NEUROPSYCHOLOGY OF ATTENTION: THEORY DIAGNOSIS AND REHABILITATION, P365; STUSS DT, 1987, J CLIN EXP NEUROPSYC, V9, P131, DOI 10.1080/01688638708405353; Thaut MH, 2005, ANN NY ACAD SCI, V1060, P243, DOI 10.1196/annals.1360.017; Thaut MH, 1999, IEEE ENG MED BIOL, V18, P101, DOI 10.1109/51.752991; Thaut MH., 2005, RHYTHM MUSIC BRAIN S; Thaut MH, 1999, TRAINING MANUAL NEUR; THAUT MH, 2005, MUSICAL COMMUNICATIO, P171; UNKEFER RF, 2002, MUSIC THERAPY TREATM; WALLACE WT, 1994, J EXP PSYCHOL LEARN, V20, P1471, DOI 10.1037/0278-7393.20.6.1471; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Wilkinson L, 1999, AM PSYCHOL, V54, P594, DOI 10.1037/0003-066X.54.8.594; Zakzanis KK, 2001, ARCH CLIN NEUROPSYCH, V16, P653, DOI 10.1016/S0887-6177(00)00076-7; Zatorre RJ, 2001, ANN NY ACAD SCI, V930, P193, DOI 10.1111/j.1749-6632.2001.tb05734.x; Zatorre RJ, 2003, ANN NY ACAD SCI, V999, P4, DOI 10.1196/annals.1284.001	65	102	110	7	77	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN STREET, MALDEN 02148, MA USA	0077-8923		978-1-57331-739-9	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2009	1169						406	416		10.1111/j.1749-6632.2009.04585.x			11	Psychology, Developmental; Multidisciplinary Sciences; Neurosciences; Psychology; Psychology, Experimental	Conference Proceedings Citation Index - Science (CPCI-S); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH); Science Citation Index Expanded (SCI-EXPANDED)	Psychology; Science & Technology - Other Topics; Neurosciences & Neurology	BKY88	WOS:000269652300061	19673815				2022-02-06	
J	Hwang, SW; Colantonio, A; Chiu, S; Tolomiczenko, G; Kiss, A; Cowan, L; Redelmeier, DA; Levinson, W				Hwang, Stephen W.; Colantonio, Angela; Chiu, Shirley; Tolomiczenko, George; Kiss, Alex; Cowan, Laura; Redelmeier, Donald A.; Levinson, Wendy			The effect of traumatic brain injury on the health of homeless people	CANADIAN MEDICAL ASSOCIATION JOURNAL			English	Article							ADDICTION SEVERITY INDEX; PSYCHIATRIC-DISORDERS; RISK-FACTORS; RELIABILITY; VALIDITY; PREVALENCE; SAMPLE; MEN	Background: We sought to determine the lifetime prevalence of traumatic brain injury and its association with current health conditions in a representative sample of homeless people in Toronto, Ontario. Methods: We surveyed 601 men and 303 women at homeless shelters and meal programs in 2004-2005 (response rate 76%). We defined traumatic brain injury as any self-reported head injury that left the person dazed, confused, disoriented or unconscious. Injuries resulting in unconsciousness lasting 30 minutes or longer were defined as moderate or severe. We assessed mental health, alcohol and drug problems in the past 30 days using the Addiction Severity Index. Physical and mental health status was assessed using the SF-12 health survey. We examined associations between traumatic brain injury and health conditions. Results: The lifetime prevalence among homeless participants was 53% for any traumatic brain injury and 12% for moderate or severe traumatic brain injury. For 70% of respondents, their first traumatic brain injury occurred before the onset of homelessness. After adjustment for demographic characteristics and lifetime duration of homelessness, a history of moderate or severe traumatic brain injury was associated with significantly increased likelihood of seizures (odds ratio [OR] 3.2, 95% confidence interval [CI] 1.8 to 5.6), mental health problems (OR 2.5, 95% CI 1.5 to 4.1), drug problems (OR 1.6, 95% CI 1.1 to 2.5), poorer physical health status (-8.3 points, 95% CI -11.1 to -5.5) and poorer mental health status (-6.0 points, 95% CI -8.3 to -3.7). Interpretation: Prior traumatic brain injury is very common among homeless people and is associated with poorer health.	[Hwang, Stephen W.; Chiu, Shirley] St Michaels Hosp, Ctr Res Inner City Hlth, Keenan Res Ctr Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada; [Hwang, Stephen W.; Redelmeier, Donald A.] Univ Toronto, Div Gen Internal Med, Dept Med, Toronto, ON M5S 1A1, Canada; [Tolomiczenko, George] Univ Toronto, Dept Psychiat, Toronto, ON M5S 1A1, Canada; [Colantonio, Angela] Univ Toronto, Toronto Rehabil Inst, Dept Occupat Sci & Occupat Therapy, Toronto, ON M5S 1A1, Canada; [Kiss, Alex] Sunnybrook Hlth Sci Ctr, Dept Res Design & Biostat, Toronto, ON, Canada; [Redelmeier, Donald A.] Sunnybrook Hlth Sci Ctr, Inst Clin Evaluat Sci, Toronto, ON, Canada; [Tolomiczenko, George] Crohns & Colitis Fdn Canada, Toronto, ON, Canada; [Cowan, Laura] St Hlth Community Nursing Fdn, Toronto, ON, Canada		Hwang, SW (corresponding author), St Michaels Hosp, Ctr Res Inner City Hlth, Keenan Res Ctr Li Ka Shing Knowledge Inst, 30 Bond St, Toronto, ON M5B 1W8, Canada.	hwangs@smh.toronto.on.ca	Hwang, Stephen W./D-2297-2011	Hwang, Stephen W./0000-0002-1276-1101; Colantonio, Angela/0000-0003-2094-4765	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Canada Research Chair in Medical Decision SciencesCanada Research Chairs; AGENCY FOR HEALTHCARE RESEARCH AND QUALITYUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [R01HS014129] Funding Source: NIH RePORTER	Stephen Hwang is the recipient of a New Investigator Award from the Canadian Institutes of Health Research. Donald Redelmeier is supported by the Canada Research Chair in Medical Decision Sciences.; We thank Marko Katic, Department of Research Design and Biostatistics, Sunnybrook Health Sciences Centre, for expert programming and analyses. We are grateful for collaboration with the Institute for Clinical Evaluative Sciences. The views expressed in this publication are the views of the authors and do not necessarily reflect the views of the Ontario Ministry of Health and Long-Term Care or any of the other above-named organizations.	Bremner AJ, 1996, BRIT J PSYCHIAT, V169, P434, DOI 10.1192/bjp.169.4.434; BROWN P, 2006, STREET NEEDS ASSESSM; Burt M.R., 1999, HOMELESSNESS PROGRAM; Burt M.R, 2001, HELPING AM HOMELESS; *CIT TO, 2003, TOR REP CARD HOUS HO; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Diamond PM, 2007, J HEAD TRAUMA REHAB, V22, P330, DOI 10.1097/01.HTR.0000300228.05867.5c; DRAKE RE, 1995, J STUD ALCOHOL, V56, P161, DOI 10.15288/jsa.1995.56.161; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Herman DB, 1997, AM J PUBLIC HEALTH, V87, P249, DOI 10.2105/AJPH.87.2.249; Housing Family and Social Statistics Division, 2002, ETHN DIV SURV QUEST; Hwang SW, 2005, J URBAN HLTH S2, V82, pii46; Joyner LM, 1996, SUBST USE MISUSE, V31, P729, DOI 10.3109/10826089609045836; Kass F, 1990, J Neuropsychiatry Clin Neurosci, V2, P15; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kelly G, 2007, BRAIN IMPAIR, V8, P262, DOI DOI 10.1375/BRIM.8.3.262; Kosinski M., 1995, SF 12 SCORE SF 12 PH; Kushel MB, 2003, ARCH INTERN MED, V163, P2492, DOI 10.1001/archinte.163.20.2492; Larson CO, 2002, HEALTH SERV RES, V37, P733, DOI 10.1111/1475-6773.00046; McGahan P.L., 1986, ADDICTION SEVERITY I; MCLELLAN AT, 1992, J SUBST ABUSE TREAT, V9, P199, DOI 10.1016/0740-5472(92)90062-S; Morrell R.F., 1998, J OFFENDER REHABIL, V27, P1, DOI [DOI 10.1300/J076V27N03_01, https://doi.org/10.1300/J076v27n03_01]; National Center for Injury Prevention and Control, 2008, WHAT IS TRAUM BRAIN; Parry-Jones BL, 2006, NEUROPSYCHOL REHABIL, V16, P537, DOI 10.1080/09602010500231875; Robertson MJ, 1996, ANNU REV PUBL HEALTH, V17, P311; Schofield PW, 2006, BRAIN INJURY, V20, P499, DOI 10.1080/02699050600664749; Shinn M, 1998, AM J PUBLIC HEALTH, V88, P1651, DOI 10.2105/AJPH.88.11.1651; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Slaughter B, 2003, BRAIN INJURY, V17, P731, DOI 10.1080/0269905031000088649; Solliday-McRoy C, 2004, J NERV MENT DIS, V192, P471, DOI 10.1097/01.nmd.0000131962.30547.26; Spence S, 2004, J ROY SOC MED, V97, P375, DOI 10.1258/jrsm.97.8.375; SUSSER E, 1993, EPIDEMIOL REV, V15, P546, DOI 10.1093/oxfordjournals.epirev.a036133; Waldmann CA, 2004, HLTH HOMELESS PERSON, P237; Zakrison TL, 2004, J URBAN HEALTH, V81, P596, DOI 10.1093/jurban/jth143; ZANIS DA, 1994, J SUBST ABUSE TREAT, V11, P541, DOI 10.1016/0740-5472(94)90005-1	35	102	102	0	5	CMA-CANADIAN MEDICAL ASSOC	OTTAWA	1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 3Y6, CANADA	0820-3946			CAN MED ASSOC J	Can. Med. Assoc. J.	OCT 7	2008	179	8					779	784		10.1503/cmaj.080341			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	353CL	WOS:000259543600015	18838453	gold, Green Published			2022-02-06	
J	RangeL-Castilla, L; Gasco, J; Nauta, HJW; Okonkwo, DO; Robertson, CS				RangeL-Castilla, Leonardo; Gasco, Jaime; Nauta, Haring J. W.; Okonkwo, David O.; Robertson, Claudia S.			Cerebral pressure autoregulation in traumatic brain injury	NEUROSURGICAL FOCUS			English	Article						cerebral autoregulation; cerebral vasculature; intracranial hypertension; pressure autoregulation; traumatic brain injury	SEVERE HEAD-INJURY; OXIDE SYNTHASE EXPRESSION; TISSUE OXYGEN-TENSION; BLOOD-FLOW; NITRIC-OXIDE; ERYTHROPOIETIN PROTECTS; PERFUSION-PRESSURE; REACTIVITY; HYPEROXIA; HYPERVENTILATION	An understanding of normal cerebral autoregulation and its response to pathological derangements is helpful in the diagnosis, monitoring, management, and prognosis of severe traumatic brain injury (TBI). Pressure autoregulation is the most common approach in testing the effects of mean arterial blood pressure on cerebral blood flow. A gold standard for measuring cerebral pressure autoregulation is not available, and the literature shows considerable disparity in methods. This fact is not surprising given that cerebral autoregulation is more a concept than a physically measurable entity. Alterations in cerebral autoregulation can vary from patient to patient and over time and are critical during the first 4-5 days after injury. An assessment of cerebral autoregulation as part of bedside neuromonitoring in the neurointensive care unit can allow the individualized treatment of secondary injury in a patient with severe TBI. The assessment of cerebral autoregulation is best achieved with dynamic autoregulation methods. Hyperventilation, hyperoxia, nitric oxide and its derivates, and erythropoietin are some of the therapies that can be helpful in managing cerebral autoregulation. In this review the authors summarize the most important points related to cerebral pressure autoregulation in TBI as applied in clinical practice, based on the literature as well as their own experience.	[RangeL-Castilla, Leonardo; Gasco, Jaime; Nauta, Haring J. W.] Univ Texas Med Branch, Div Neurosurg, Galveston, TX 77555 USA; [Okonkwo, David O.] Univ Pittsburgh, Med Ctr, Dept Neurosurg, Pittsburgh, PA USA; [Robertson, Claudia S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA		RangeL-Castilla, L (corresponding author), Univ Texas Med Branch, Div Neurosurg, 301 Univ Blvd,Suite 9-121 ZC, Galveston, TX 77555 USA.	lerangel@utmb.edu					AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS14, DOI 10.1089/neu.2007.9994; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Bratton SL, 2007, J NEUROTRAUMA S1, V24, P555, DOI DOI 10.1089/NEU.2007.9988; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Cherian L, 1999, CRIT CARE MED, V27, P2512, DOI 10.1097/00003246-199911000-00031; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; Czosnyka M, 1996, ACTA NEUROCHIR, V138, P531, DOI 10.1007/BF01411173; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; Czosnyka M, 2007, NEUROL RES, V29, P672, DOI 10.1179/016164107X240053; DEWEY RC, 1974, J NEUROSURG, V41, P597, DOI 10.3171/jns.1974.41.5.0597; Floyd TF, 2003, J APPL PHYSIOL, V95, P2453, DOI 10.1152/japplphysiol.00303.2003; GROSS PM, 1979, CIRC RES, V44, P288, DOI 10.1161/01.RES.44.2.288; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; Heistad D D, 1980, Physiologist, V23, P44; Hlatky R, 2005, NEUROSURGERY, V57, P917, DOI 10.1227/01.NEU.0000180025.43747.fc; Hlatky R, 2008, J NEUROSURG, V108, P53, DOI 10.3171/JNS/2008/108/01/0053; Howells T, 2005, J NEUROSURG, V102, P311, DOI 10.3171/jns.2005.102.2.0311; Jafarian-Tehrani M, 2005, NITRIC OXIDE-BIOL CH, V12, P61, DOI 10.1016/j.niox.2004.12.001; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; Kajita Y, 1998, NEUROSURGERY, V42, P834, DOI 10.1097/00006123-199804000-00087; Kirkness C J, 2001, Biol Res Nurs, V2, P175, DOI 10.1177/109980040100200303; LASSEN NA, 1959, PHYSIOL REV, V39, P183, DOI 10.1152/physrev.1959.39.2.183; Lee J, 2003, P NATL ACAD SCI USA, V100, P6646, DOI 10.1073/pnas.0631696100; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; Longhi L, 2002, ACT NEUR S, V81, P315; Louin G, 2006, NEUROPHARMACOLOGY, V50, P182, DOI 10.1016/j.neuropharm.2005.08.020; Lu J, 2003, NEUROPHARMACOLOGY, V44, P253, DOI 10.1016/S0028-3908(02)00380-5; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; Matta BF, 1996, BRIT J ANAESTH, V76, P790, DOI 10.1093/bja/76.6.790; MEIXENSBERGER J, 1993, ACTA NEUROCHIR, P58; MELAMED E, 1980, STROKE, V11, P31, DOI 10.1161/01.STR.11.1.31; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Newell DW, 1996, NEUROSURGERY, V39, P35, DOI 10.1097/00006123-199607000-00008; OSOL G, 1985, AM J PHYSIOL, V249, pH914, DOI 10.1152/ajpheart.1985.249.5.H914; Panerai RB, 1998, PHYSIOL MEAS, V19, P305, DOI 10.1088/0967-3334/19/3/001; PANNIER JL, 1971, EUR NEUROL, V6, P123, DOI 10.1159/000114479; Puppo C, 2008, NEUROCRIT CARE, V8, P344, DOI 10.1007/s12028-008-9069-8; ROBERTSON CS, 1989, J NEUROSURG, V70, P222, DOI 10.3171/jns.1989.70.2.0222; Sahuquillo J, 1999, J NEUROSURG, V90, P16, DOI 10.3171/jns.1999.90.1.0016; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Sarrafzadeh AS, 1998, ACT NEUR S, V71, P186; Schmidt EA, 2003, J NEUROIMAGING, V13, P248, DOI 10.1177/1051228403013003008; Schmidt EA, 2003, J NEUROSURG, V99, P991, DOI 10.3171/jns.2003.99.6.0991; SIMARD JM, 1989, AM J CARDIOL, V63, pC32, DOI 10.1016/0002-9149(89)90403-7; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Steiner LA, 2003, J NEUROL NEUROSUR PS, V74, P765, DOI 10.1136/jnnp.74.6.765; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; TIECKS FP, 1995, STROKE, V26, P1014, DOI 10.1161/01.STR.26.6.1014; Verdonck O, 2007, J CEREBR BLOOD F MET, V27, P1369, DOI 10.1038/sj.jcbfm.9600443	54	102	103	2	10	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	OCT	2008	25	4							E7	10.3171/FOC.2008.25.10.E7			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	355HX	WOS:000259701100007	18828705	Bronze			2022-02-06	
J	Deng-Bryant, Y; Singh, IN; Carrico, KM; Hall, ED				Deng-Bryant, Ying; Singh, Indrapal N.; Carrico, Kimberly M.; Hall, Edward D.			Neuroprotective effects of tempol, a catalytic scavenger of peroxynitrite-derived free radicals, in a mouse traumatic brain injury model	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						calpain; controlled cortical impact; neurodegeneration; oxidative damage; peroxynitrite; tempol	INDUCED AXONAL INJURY; CLOSED-HEAD INJURY; OXIDATIVE DAMAGE; MITOCHONDRIAL-MEMBRANE; LIPID-PEROXIDATION; NITROXIDE RADICALS; CALPAIN; NEURODEGENERATION; DEGRADATION; MICE	We examined the ability of tempol, a catalytic scavenger of peroxynitrite (PN)-derived free radicals, to reduce cortical oxidative damage, mitochondrial dysfunction, calpain-mediated cytoskeletal (alpha-spectrin) degradation, and neurodegeneration, and to improve behavioral recovery after a severe (depth 1.0mm), unilateral controlled cortical impact traumatic brain injury (CCI-TBI) in male CF-1 mice. Administration of a single 300 mg/kg intraperitoneal dose of tempol 15 mins after TBI produced a complete suppression of PN-mediated oxidative damage (3-nitrotyrosine, 3NT) in injured cortical tissue at 1 h after injury. Identical tempol dosing maintained respiratory function and attenuated 3NT in isolated cortical mitochondria at 12 h after injury, the peak of mitochondrial dysfunction. Multiple dosing with tempol (300 mg/kg intraperitoneally at 15 mins, 3, 6, 9, and 12 h) also suppressed alpha-spectrin degradation by 45% at its 24 h post-injury peak. The same dosing regimen improved 48 h motor function and produced a significant, but limited (17.4%, P < 0.05), decrease in hemispheric neurodegeneration at 7 days. These results are consistent with a mechanistic link between PN-mediated oxidative damage to brain mitochondria, calpain-mediated proteolytic damage, and neurodegeneration. However, the modest neuroprotective effect of tempol suggests that multitarget combination strategies may be needed to interfere with posttraumatic secondary injury to a degree worthy of clinical translation.	[Hall, Edward D.] Univ Kentucky, Spinal Cord & Brain Injuiry Res Ctr, Chandler Med Ctr, Lexington, KY 40536 USA; Univ Kentucky, Dept Anat & Neurobiol, Chandler Med Ctr, Lexington, KY 40536 USA		Hall, ED (corresponding author), Univ Kentucky, Spinal Cord & Brain Injuiry Res Ctr, Chandler Med Ctr, B483 Biomed & Biol Sci Bldg,741 S Limestone St, Lexington, KY 40536 USA.	edhall@uky.edu	Hall, Edward D/F-8930-2013		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS051220, R01NS046566] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1P30 NS051220, 1R01 NS046566] Funding Source: Medline		Bartus RT, 1997, NEUROSCIENTIST, V3, P314, DOI 10.1177/107385849700300513; Behringer W, 2002, J CEREBR BLOOD F MET, V22, P105, DOI 10.1097/00004647-200201000-00013; BeitYannai E, 1996, BRAIN RES, V717, P22, DOI 10.1016/0006-8993(95)01492-6; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Carroll RT, 2000, CHEM RES TOXICOL, V13, P294, DOI 10.1021/tx990159t; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; DEOLMOS JS, 1994, NEUROTOXICOL TERATOL, V16, P545, DOI 10.1016/0892-0362(94)90033-7; Echtay KS, 2003, EMBO J, V22, P4103, DOI 10.1093/emboj/cdg412; Faddis BT, 1997, J NEUROSCI, V17, P951; Gadelha FR, 1997, ARCH BIOCHEM BIOPHYS, V345, P243, DOI 10.1006/abbi.1997.0259; Giulivi C, 2003, FREE RADICAL BIO MED, V34, P397, DOI 10.1016/S0891-5849(02)01298-4; Grune T, 1997, FASEB J, V11, P526, DOI 10.1096/fasebj.11.7.9212076; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; Kamatari M, 2002, FREE RADICAL RES, V36, P1115, DOI 10.1080/1071576021000028352; KOWALTOWSKI AJ, 1995, AM J PHYSIOL-CELL PH, V269, pC141, DOI 10.1152/ajpcell.1995.269.1.C141; Krishna MC, 1996, J BIOL CHEM, V271, P26026, DOI 10.1074/jbc.271.42.26026; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; Liu YB, 2002, J NEUROCHEM, V80, P780, DOI 10.1046/j.0022-3042.2002.00744.x; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; Pandya JD, 2007, J NEUROTRAUM, V24, P798, DOI 10.1089/neu.2006.3673; Povlishock JT, 1999, ACT NEUR S, V73, P15; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; Ringger NC, 2004, J NEUROTRAUM, V21, P1443, DOI 10.1089/neu.2004.21.1443; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; Singh IN, 2007, J NEUROSCI RES, V85, P2216, DOI 10.1002/jnr.21360; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Switzer RC, 2000, TOXICOL PATHOL, V28, P70, DOI 10.1177/019262330002800109; Wada K, 1999, NEUROSURGERY, V45, P601, DOI 10.1097/00006123-199909000-00031; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Zhang RL, 1998, FREE RADICAL BIO MED, V24, P332, DOI 10.1016/S0891-5849(97)00267-0	33	102	103	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JUN	2008	28	6					1114	1126		10.1038/jcbfm.2008.10			13	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	304NR	WOS:000256116700005	18319733	Bronze			2022-02-06	
J	Kim, J; Avants, B; Patel, S; Whyte, J; Coslett, BH; Pluta, J; Detre, JA; Gee, JC				Kim, Junghoon; Avants, Brian; Patel, Sunil; Whyte, John; Coslett, Branch H.; Pluta, John; Detre, John A.; Gee, James C.			Structural consequences of diffuse traumatic brain injury: A large deformation tensor-based morphometry study	NEUROIMAGE			English	Article						traumatic brain injury; atrophy; tensor-based morphometry; diffeomorphic; magnetic resonance imaging	VOXEL-BASED MORPHOMETRY; REGIONAL SPATIAL NORMALIZATION; BLUNT HEAD-INJURY; VEGETATIVE STATE; CORPUS-CALLOSUM; COMPUTATIONAL ANATOMY; UNITED-STATES; 3D PATTERN; NEUROPATHOLOGY; MATTER	Traumatic brain injury (TBI) is one of the most common causes of long-term disability. Despite the importance of identifying neuropathology in individuals with chronic TBI, methodological challenges posed at the stage of inter-subject image registration have hampered previous voxel-based MRI studies from providing a clear pattern of structural atrophy after TBI. We used a novel symmetric diffeomorphie image normalization method to conduct a tensor-based morphometry (TBM) study of TBI. The key advantage of this method is that it simultaneously estimates an optimal template brain and topology preserving deformations between this template and individual subject brains. Detailed patterns of atrophies are then revealed by statistically contrasting control and subject deformations to the template space. Participants were 29 survivors of TBI and 20 control subjects who were matched in terms of age, gender, education, and ethnicity. Localized volume losses were found most prominently in white matter regions and the subcortical nuclei including the thalamus, the midbrain, the corpus callosum, the mid- and posterior cingulate cortices, and the caudate. Significant voxel-wise volume loss clusters were also detected in the cerebellum and the frontal/temporal neocortices. Volume enlargements were identified largely in ventricular regions. A similar pattern of results was observed in a subgroup analysis where we restricted our analysis to the 17 TBI participants who had no macroscopic focal lesions (total lesion volume >1.5 cm(3)). The current study confirms, extends, and partly challenges previous structural MRI studies in chronic TBI. By demonstrating that a large deformation image registration technique can be successfully combined with TBM to identify TBI-induced diffuse structural changes with greater precision, our approach is expected to increase the sensitivity of future studies examining brain-behavior relationships in the TBI population. (c) 2007 Elsevier Inc. All rights reserved.	[Kim, Junghoon; Patel, Sunil; Whyte, John] Albert Einstein Healthcare Network, Moss Rehabil Res Inst, Philadelphia, PA 19141 USA; [Avants, Brian; Detre, John A.; Gee, James C.] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA; [Coslett, Branch H.; Detre, John A.] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA; [Pluta, John; Detre, John A.] Univ Penn, Ctr Funct Imaging, Philadelphia, PA 19104 USA; [Whyte, John] Thomas Jefferson Univ, Dept Rehabil Med, Philadelphia, PA 19107 USA		Kim, J (corresponding author), Albert Einstein Healthcare Network, Moss Rehabil Res Inst, 1200 W Tabor Rd, Philadelphia, PA 19141 USA.	kimj@einstein.edu	Kim, Junghoon John/I-6702-2019; Kim, Junghoon/A-6669-2012	Kim, Junghoon John/0000-0001-5729-8993; Whyte, John/0000-0002-4381-1474; avants, brian/0000-0002-4212-3362	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD39621, R24 HD039621-01, R24 HD039621] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS045839, P30 NS045839-01, P30 NS045839] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD039621] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS045839] Funding Source: NIH RePORTER		ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Ashburner J, 1998, HUM BRAIN MAPP, V6, P348, DOI 10.1002/(SICI)1097-0193(1998)6:5/6<348::AID-HBM4>3.0.CO;2-P; Avants B, 2005, ALZ DIS ASSOC DIS, V19, pS25, DOI 10.1097/01.wad.0000183083.14939.82; Avants B, 2004, NEUROIMAGE, V23, pS139, DOI 10.1016/j.neuroimage.2004.07.010; AVANTS BB, IN PRESS MED IMAGE A; Avants BB, 2006, MED IMAGE ANAL, V10, P397, DOI 10.1016/j.media.2005.03.005; Bermudez P, 2001, NEUROIMAGE, V13, P1121, DOI 10.1006/nimg.2001.0772; Bigler E.D., 2005, TXB TRAUMATIC BRAIN, P79, DOI DOI 10.1007/S00417-005-0003-X; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bookstein FL, 2001, NEUROIMAGE, V14, P1454, DOI 10.1006/nimg.2001.0770; Brambati SM, 2007, NEUROIMAGE, V35, P998, DOI 10.1016/j.neuroimage.2007.01.028; Cardenas VA, 2007, NEUROIMAGE, V34, P879, DOI 10.1016/j.neuroimage.2006.10.015; Chau W, 2005, NEUROIMAGE, V25, P408, DOI 10.1016/j.neuroimage.2004.12.007; Chiang MC, 2007, NEUROIMAGE, V34, P44, DOI 10.1016/j.neuroimage.2006.08.030; Chung MK, 2001, NEUROIMAGE, V14, P595, DOI 10.1006/nimg.2001.0862; Davatzikos C, 2004, NEUROIMAGE, V23, P17, DOI 10.1016/j.neuroimage.2004.05.010; Davatzikos C, 2001, NEUROIMAGE, V14, P1361, DOI 10.1006/nimg.2001.0937; Davatzikos C, 1996, J COMPUT ASSIST TOMO, V20, P88, DOI 10.1097/00004728-199601000-00017; Dubb A, 2005, ACAD RADIOL, V12, P3, DOI 10.1016/j.acra.2004.06.009; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Gaser C, 1999, NEUROIMAGE, V10, P107, DOI 10.1006/nimg.1999.0458; Gaser C, 2001, NEUROIMAGE, V13, P1140, DOI 10.1006/nimg.2001.0771; Genovese CR, 2002, NEUROIMAGE, V15, P870, DOI 10.1006/nimg.2001.1037; GOLDMANRAKIC PS, 1985, J COMP NEUROL, V242, P535, DOI 10.1002/cne.902420406; Good CD, 2001, NEUROIMAGE, V14, P21, DOI 10.1006/nimg.2001.0786; Graham DI, 2005, PROG BRAIN RES, V150, P445, DOI 10.1016/S0079-6123(05)50031-1; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; KINNEY HC, 1994, J NEUROPATH EXP NEUR, V53, P548, DOI 10.1097/00005072-199411000-00002; Kochunov P, 2001, J COMPUT ASSIST TOMO, V25, P805, DOI 10.1097/00004728-200109000-00023; Kochunov P, 2005, HUM BRAIN MAPP, V24, P325, DOI 10.1002/hbm.20090; Lancaster JL, 2000, HUM BRAIN MAPP, V10, P120, DOI 10.1002/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8; Lee AD, 2007, NEUROIMAGE, V34, P924, DOI 10.1016/j.neuroimage.2006.09.043; Leow AD, 2006, NEUROIMAGE, V31, P627, DOI 10.1016/j.neuroimage.2005.12.013; Levine B., 2002, PRINCIPLES FRONTAL L, P448; Levine B, 2006, J NEUROTRAUM, V23, P1396, DOI 10.1089/neu.2006.23.1396; Mai JK, 2004, ATLAS HUMAN BRAIN; MAX W, 1990, INQUIRY-J HEALTH CAR, V27, P332; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; Mendez CV, 2005, J NEUROPSYCH CLIN N, V17, P297, DOI 10.1176/appi.neuropsych.17.3.297; Miller MI, 2002, ANNU REV BIOMED ENG, V4, P375, DOI 10.1146/annurev.bioeng.4.092101.125733; Miller MI, 2004, NEUROIMAGE, V23, pS19, DOI 10.1016/j.neuroimage.2004.07.021; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Romanski LM, 1997, J COMP NEUROL, V379, P313; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Salmond CH, 2005, BRAIN, V128, P189, DOI 10.1093/brain/awh352; Senjem ML, 2005, NEUROIMAGE, V26, P600, DOI 10.1016/j.neuroimage.2005.02.005; Studholme C, 2004, NEUROIMAGE, V21, P1387, DOI 10.1016/j.neuroimage.2003.12.009; Talairach J., 1988, COPLANAR STEREOTAXIC; Thirion J P, 1998, Med Image Anal, V2, P243, DOI 10.1016/S1361-8415(98)80022-4; Thompson PM, 2000, NATURE, V404, P190, DOI 10.1038/35004593; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tisserand DJ, 2002, NEUROIMAGE, V17, P657, DOI 10.1006/nimg.2002.1173; Tomaiuolo F, 2005, J NEUROTRAUM, V22, P76, DOI 10.1089/neu.2005.22.76; Van Essen DC, 2001, VISION RES, V41, P1359, DOI 10.1016/S0042-6989(01)00045-1; Woods RP, 2003, NEUROIMAGE, V18, P769, DOI 10.1016/S1053-8119(03)00019-3; YOO T, 2003, INSIGHT IMAGES PRINC; Yudofsky S.C., 2005, TXB TRAUMATIC BRAIN, P27; Yushkevich PA, 2006, NEUROIMAGE, V31, P1116, DOI 10.1016/j.neuroimage.2006.01.015; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	64	102	104	0	15	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	FEB 1	2008	39	3					1014	1026		10.1016/j.neuroimage.2007.10.005			13	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	255XN	WOS:000252691800011	17999940	Green Accepted			2022-02-06	
J	El Sayed, T; Mota, A; Fraternali, F; Ortiz, M				El Sayed, Tamer; Mota, Alejandro; Fraternali, Fernando; Ortiz, Michael			Biomechanics of traumatic brain injury	COMPUTER METHODS IN APPLIED MECHANICS AND ENGINEERING			English	Article						Brain tissue damage; Finite deformation; Plasticity; Finite viscoelasticity; Diffuse axonal injury; Cavitation injury; Traumatic brain injury	VARIATIONAL CONSTITUTIVE MODEL; HEAD-INJURY; MECHANICAL-PROPERTIES; LARGE-DEFORMATION; TISSUE; IMPACT; FORMULATION; IMPLEMENTATION; CONCUSSION; ELASTOMERS	A biomechanical model for traumatic brain injury and soft tissue damage is presented. A variational constitutive model for soft biological tissues is utilized to reproduce axonal damage and cavitation injury through inelastic deformation. The material response is split into elastoplastic and viscoelastic components, including rate effects, shear and porous plasticity, and finite viscoelasticity. Mechanical damage of brain tissue is classified as volumetric (compression/tension) and shear-type. Finite element simulations of brain injuries are presented, examining frontal and oblique head impacts with external objects. Localization, extension, intensity and reversibility/irreversibility of tissue damage are predicted. Future directions of this work, relating mechanical damage and physiological brain dysfunction, and application to relevant medical and engineering problems are discussed. (c) 2008 Elsevier B.V. All rights reserved.	[El Sayed, Tamer; Mota, Alejandro; Ortiz, Michael] CALTECH, Div Engn & Appl Sci, Pasadena, CA 91125 USA; [Fraternali, Fernando] Univ Salerno, Dept Civil Engn, I-84084 Fisciano, SA, Italy		Ortiz, M (corresponding author), CALTECH, Div Engn & Appl Sci, Pasadena, CA 91125 USA.	ortiz@aero.caltech.edu	Fraternali, Fernando/A-4237-2018	Fraternali, Fernando/0000-0002-7549-6405	Regione Campania, ItalyRegione Campania	The support of the Regione Campania, Italy, through the program "Modeling Shape, Structure and Mechanical Behavior of the Skull-Encephalon Complex" is greatly acknowledged. The authors also want to sincerely thank Davide Zuppa, graduate student at the Department of Civil Engineering of the University of Salerno, for his relevant and precious collaboration with the present work.	ADAMS JH, 1984, RECENT ADV HISTOPATH; Bergstrom JS, 2001, MECH MATER, V33, P523, DOI 10.1016/S0167-6636(01)00070-9; Brands Dave W A, 2002, Stapp Car Crash J, V46, P103; Brands DWA, 2004, J BIOMECH, V37, P127, DOI 10.1016/S0021-9290(03)00243-4; BRENNEN CE, 2003, 5 INT S CAV OS JAP; CARDAMONE L, 2005, ANAL NUMERICA TRAUMA; El Sayed T, 2008, J BIOMECH, V41, P1458, DOI 10.1016/j.jbiomech.2008.02.023; ELSAYED T, 2007, THESIS CALTECH; Franceschini G, 2006, J MECH PHYS SOLIDS, V54, P2592, DOI 10.1016/j.jmps.2006.05.004; FUJIWARA S, 1989, FORENSIC SCI INT, V43, P159, DOI 10.1016/0379-0738(89)90132-1; Gasser TC, 2002, COMPUT MECH, V29, P340, DOI 10.1007/s00466-002-0347-6; GROSS AG, 1958, J NEUROSURG, V15, P548, DOI 10.3171/jns.1958.15.5.0548; HARDY WN, 1994, INT J IMPACT ENG, V15, P561, DOI 10.1016/0734-743X(94)80034-7; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; JOHNSON EAC, 2006, C2006 DIG HUM MOD DE; Kleiven S, 2002, J BIOMECH, V35, P153, DOI 10.1016/S0021-9290(01)00202-0; KLEIVEN S, 2002, THESIS ROYAL I TECHN; Leestma J, 1987, FORENSIC NEUROPATHOL; LINDGREN S, 1966, BIOPHYSIK, V3, P174, DOI 10.1007/BF01191611; LUBOCK P, 1980, J BIOMECH, V13, P1041, DOI 10.1016/0021-9290(80)90048-2; Meaney DF, 2003, BIOMECH MODEL MECHAN, V1, P279, DOI 10.1007/s10237-002-0020-1; MENDIS KK, 1995, J BIOMECH ENG-T ASME, V117, P279, DOI 10.1115/1.2794182; Miller K, 2005, J BIOMECH, V38, P153, DOI 10.1016/j.jbiomech.2004.03.004; Miller K, 1997, J BIOMECH, V30, P1115, DOI 10.1016/S0021-9290(97)00092-4; Miller K, 2002, J BIOMECH, V35, P483, DOI 10.1016/S0021-9290(01)00234-2; Miller K, 2000, J BIOMECH, V33, P1369, DOI 10.1016/S0021-9290(00)00120-2; MILLER K, 2006, RES REPORT INTELLIGE; Nahum AM, 1977, P 21 STAPP CAR CRASH; NUSHOLTZ GS, 1996, P NATO AGARD HEAD IM; Ogden, 1984, NONLINEAR ELASTIC DE; ORTIZ M, 1992, J APPL MECH-T ASME, V59, P48, DOI 10.1115/1.2899463; Ortiz M, 1999, COMPUT METHOD APPL M, V171, P419, DOI 10.1016/S0045-7825(98)00219-9; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; RODRIGES SR, 2003, BIOMECH 2003; RUAN JS, 1994, J BIOMECH ENG-T ASME, V116, P44, DOI 10.1115/1.2895703; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Thoutireddy P, 2002, INT J NUMER METH ENG, V53, P1337, DOI 10.1002/nme.337; Velardi F, 2006, BIOMECH MODEL MECHAN, V5, P53, DOI 10.1007/s10237-005-0007-9; Weinberg K, 2005, COMP MATER SCI, V32, P588, DOI 10.1016/j.commatsci.2004.09.005; Weinberg K, 2006, COMPUT MECH, V37, P142, DOI 10.1007/s00466-005-0685-2; Yang Q, 2006, J MECH PHYS SOLIDS, V54, P401, DOI 10.1016/j.jmps.2005.08.010; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749; ZHOU C, 1995, SAE N 952714, P121; Zhou C, 1995, P 39 STAPP CAR CRASH	46	102	103	1	35	ELSEVIER SCIENCE SA	LAUSANNE	PO BOX 564, 1001 LAUSANNE, SWITZERLAND	0045-7825	1879-2138		COMPUT METHOD APPL M	Comput. Meth. Appl. Mech. Eng.		2008	197	51-52					4692	4701		10.1016/j.cma.2008.06.006			10	Engineering, Multidisciplinary; Mathematics, Interdisciplinary Applications; Mechanics	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Mathematics; Mechanics	374BG	WOS:000261016600015					2022-02-06	
J	Buttram, SDW; Wisniewski, SR; Jackson, EK; Adelson, PD; Feldman, K; Bayir, H; Berger, RP; Clark, RSB; Kochanek, PM				Buttram, Sandra D. W.; Wisniewski, Stephen R.; Jackson, Edwin K.; Adelson, P. David; Feldman, Keri; Bayir, Hulya; Berger, Rachel P.; Clark, Robert S. B.; Kochanek, Patrick M.			Multiplex assessment of cytokine and chemokine levels in cerebrospinal fluid following severe pediatric traumatic brain injury: Effects of moderate hypothermia	JOURNAL OF NEUROTRAUMA			English	Article						children; head trauma; inflicted childhood neurotrauma; interleukin; Luminex	GROWTH-FACTOR PRODUCTION; RAT-BRAIN; CRYPTOCOCCUS-NEOFORMANS; INFLAMMATORY RESPONSE; BARRIER FUNCTION; HEAD TRAUMA; EXPRESSION; INTERLEUKIN-10; CHILDREN; SERUM	This study performed a comprehensive analysis of cerebrospinal fluid (CSF) cytokine levels after severe traumatic brain injury (TBI) in children using a multiplex bead array assay and to evaluate the effects of moderate hypothermia on cytokine levels. To this end, samples were collected during two prospective randomized controlled trials of therapeutic moderate hypothermia in pediatric TBI. Thirty-six children with severe TBI ( Glasgow Coma Scale [GCS] score of <= 8) and 10 children with negative diagnostic lumbar punctures. All children with TBI had continuous monitoring of intracranial pressure and CSF drainage via an intraventricular catheter. Moderate hypothermia (32-33 degrees C) was maintained for 48 h in 17 patients, and they were slowly re-warmed at 48-72 h. A multiplex bead array assay was used to analyze serial CSF samples (< 18 h, 24 +/- 6 h, 48 +/- 6 h, and 72 +/- 6 h) for 21 pro-and anti-inflammatory cytokines and chemokines. Interleukin (IL)-8 and transforming growth factor beta were measured by enzyme-linked immunosorbant assay (ELISA). There was a strong correlation ( Spearman correlation coefficient = 0.92, p < 0.001) between multiplex assay and ELISA for IL-8. Pro-inflammatory IL-1 beta, -6 and -12p70, anti-inflammatory IL-10 and chemokines IL-8 and MIP-1 alpha were increased after TBI compared to controls, p < 0.05; however, there was no association between cytokines and age, gender, initial GCS, or outcome. Hypothermia did not attenuate the increases in CSF cytokine levels after TBI versus normothermia. This investigation confirmed that the multiplex bead array assay is a useful method to measure CSF cytokine levels. Severe TBI in infants and children induces increases in pro- and anti-inflammatory cytokines and chemokines. It is the first clinical report of increased levels of MIP-1 alpha after TBI in any patient population and the most comprehensive assessment of cytokines after TBI to date. Moderate therapeutic hypothermia did not attenuate the increase in CSF cytokine levels in children after TBI.	Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Epidemiol & Publ Hlth, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Neurol Surg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15260 USA; Childrens Hosp Pittsburgh, Pittsburgh, PA USA		Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Crit Care Med, Pittsburgh, PA 15260 USA.	kochanekpm@ccm.upmc.edu	Adelson, David/W-2083-2019; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Wisniewski, Stephen/0000-0002-3877-9860; Jackson, Edwin/0000-0002-8101-6009	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318, P20NS030318, P01NS030318] Funding Source: NIH RePORTER; NCATS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1 TR000005] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS-34884, NS 30318] Funding Source: Medline		Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Aibiki M, 1999, J NEUROTRAUM, V16, P225, DOI 10.1089/neu.1999.16.225; Amick Jonathan E., 2001, Pediatr Crit Care Med, V2, P260, DOI 10.1097/00130478-200107000-00013; BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Berger RP, 2006, PEDIATRICS, V117, P325, DOI 10.1542/peds.2005-0711; Berger RP, 2004, J NEUROTRAUM, V21, P1123; Bernard S, 2003, RESUSCITATION, V56, P9, DOI 10.1016/S0300-9572(02)00276-9; Bethea JR, 1999, J NEUROTRAUM, V16, P851, DOI 10.1089/neu.1999.16.851; Biswas AK, 2002, CRIT CARE MED, V30, P2742, DOI 10.1097/00003246-200212000-00020; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; CHEN B, 2004, JHEP, V12, P57; Chiaretti A, 2005, CHILD NERV SYST, V21, P185, DOI 10.1007/s00381-004-1032-1; Clausen BH, 2005, NEUROSCIENCE, V132, P879, DOI 10.1016/j.neuroscience.2005.01.031; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; de Jager W, 2003, CLIN DIAGN LAB IMMUN, V10, P133, DOI 10.1128/CDLI.10.1.133-139.2003; Decken K, 1998, INFECT IMMUN, V66, P4994, DOI 10.1128/IAI.66.10.4994-5000.1998; Du WY, 2003, INFECT IMMUN, V71, P3947, DOI 10.1128/IAI.71.7.3947-3953.2003; Galasso JM, 2000, NEUROSCIENCE, V101, P737, DOI 10.1016/S0306-4522(00)00399-7; Hans VHJ, 1999, NEUROREPORT, V10, P409; HART BA, 2005, J IMMUNOL, V175, P4761, DOI DOI 10.4049/JIMMUN0L.175.7.4761; Hausmann EHS, 1998, BRAIN RES, V788, P49, DOI 10.1016/S0006-8993(97)01160-8; Holmin S, 2004, NEUROSCI LETT, V369, P108, DOI 10.1016/j.neulet.2004.07.044; Hulse RE, 2004, J NEUROSCI METH, V136, P87, DOI 10.1016/j.jneumeth.2003.12.023; Jones NC, 2005, EUR J NEUROSCI, V22, P72, DOI 10.1111/j.1460-9568.2005.04221.x; Juric DM, 2001, INT J DEV NEUROSCI, V19, P675, DOI 10.1016/S0736-5748(01)00044-2; Kamm K, 2006, J TRAUMA, V60, P152, DOI 10.1097/01.ta.0000196345.81169.a1; Khan SS, 2004, CYTOM PART B-CLIN CY, V61B, P35, DOI 10.1002/cyto.b.20021; KIKUCHI T, 1995, NEUROL RES, V17, P106, DOI 10.1080/01616412.1995.11740296; Kim KY, 2003, INVERSE PROBL ENG, V11, P1, DOI 10.1080/1068276021000014705; Kleinschek MA, 2006, J IMMUNOL, V176, P1098, DOI 10.4049/jimmunol.176.2.1098; Kline AE, 2002, BRAIN RES, V937, P22, DOI 10.1016/S0006-8993(02)02458-7; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; LINDHOLM D, 1992, J CELL BIOL, V117, P395, DOI 10.1083/jcb.117.2.395; LOGAN A, 1992, BRAIN RES, V587, P216, DOI 10.1016/0006-8993(92)91000-5; Lu KT, 2005, J NEUROTRAUM, V22, P885, DOI 10.1089/neu.2005.22.885; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Martins TB, 2002, AM J CLIN PATHOL, V118, P346; Morganti-Kossmann MC, 1999, J NEUROTRAUM, V16, P617, DOI 10.1089/neu.1999.16.617; Nozari A, 2006, CIRCULATION, V113, P2690, DOI 10.1161/CIRCULATIONAHA.106.613349; Otto VI, 2001, NEUROREPORT, V12, P2059, DOI 10.1097/00001756-200107030-00053; Berger RP, 2006, PEDIATR CRIT CARE ME, V7, P557, DOI 10.1097/01.PCC.0000244426.37793.23; Prabhakar U, 2002, J IMMUNOL METHODS, V260, P207, DOI 10.1016/S0022-1759(01)00543-9; Rosler A, 1998, J NEUROL SCI, V157, P82, DOI 10.1016/S0022-510X(98)00061-6; Sato M, 2003, PEDIATRICS, V112, P1103, DOI 10.1542/peds.112.5.1103; Shiozaki T, 1999, J NEUROSURG, V91, P185, DOI 10.3171/jns.1999.91.2.0185; SHORE PM, 2003, PEDIAT CRIT CARE SA, V4, P413; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; Stahel PF, 1998, NEUROSCI LETT, V249, P123, DOI 10.1016/S0304-3940(98)00410-8; Truettner JS, 2005, MOL BRAIN RES, V138, P124, DOI 10.1016/j.molbrainres.2005.04.006; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561; WINDHAGEN A, 1995, J EXP MED, V182, P1985, DOI 10.1084/jem.182.6.1985	55	102	105	2	17	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	NOV	2007	24	11					1707	1717		10.1089/neu.2007.0349			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	234MZ	WOS:000251169500004	18001201				2022-02-06	
J	Wu, AG; Ying, Z; Gomez-Pinilla, F				Wu, Aiguo; Ying, Zhe; Gomez-Pinilla, Fernando			Omega-3 fatty acids supplementation restores mechanisms that maintain brain Homeostasis in traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						hippocampus; omega-3 fatty acids; oxidative stress; Sir2 alpha	TRANSCRIPTION FACTOR FOXO3A; LIFE-SPAN EXTENSION; CALORIE RESTRICTION; SACCHAROMYCES-CEREVISIAE; SIRT1 DEACETYLASE; OXIDATIVE STRESS; NAD; SIR2-ALPHA; NEURONS; PATHWAY	Traumatic brain injury TBI) produces a state of vulnerability that reduces the brain capacity to cope with secondary insults. The silent information regulator 2 (Sir2) has been implicated with maintaining genomic stability and cellular homeostasis under challenging situation. Here we explore the possibility that the action of Sir2 alpha (mammalian Sir2) in the brain can extend to serve neuronal plasticity. We provide novel evidence showing that mild TBI reduces the expression of Sir2a in the hippocampus, in proportion to increased levels of protein oxidation. In addition, we show that dietary supplementation of omega-3 fatty acids that ameliorates protein oxidation was effective to reverse the reduction of Sir2a level in injured rats. Given that oxidative stress is a subproduct of dysfunctional energy homeostasis, we measured AMP-activated protein kinase (AMPK) and phosphorylated-AMPK (p-AMPK) to have an indication of the energy status of cells. Hippocampal levels of total and phosphorylated AMPK were reduced after TBI and levels were normalized by omega-3 fatty acts supplements. Further, we found that TBI reduced ubiquitous mitochondrial creatine kinase (uMtCK), an enzyme implicated in the energetic regulation of Ca2+-pumps and in the maintenance of Ca2+ -homeostasis. Omega-3 fatty acids supplements normalized the levels of uMtCK after lesion. Furthermore, we found that the correlation between Sir2a and AMPK or p-AMPK was disrupted by TBI, but restored by omega-3 fatty acids supplements. Our results suggest that TBI may compromise neuronal protective mechanisms by involving the action of Sir2a. In addition, results show the capacity of omega-3 fatty acids to counteract some of the effects of TBI by normalizing levels of molecular systems associated with energy homeostasis.	Univ Calif Los Angeles, Dept Physiol Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Brain Injury Res Ctr, Div Neurosurg, Los Angeles, CA USA		Gomez-Pinilla, F (corresponding author), Univ Calif Los Angeles, Dept Physiol Sci, 621 Charles E Young Dr, Los Angeles, CA 90095 USA.	fgomezpi@ucla.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 48804] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [50465] Funding Source: Medline		Anderson RM, 2003, NATURE, V423, P181, DOI 10.1038/nature01578; Araki T, 2004, SCIENCE, V305, P1010, DOI 10.1126/science.1098014; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Cheng HL, 2003, P NATL ACAD SCI USA, V100, P10794, DOI 10.1073/pnas.1934713100; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Daitoku H, 2004, P NATL ACAD SCI USA, V101, P10042, DOI 10.1073/pnas.0400593101; Guarente L, 2000, GENE DEV, V14, P1021; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; Parker JA, 2005, NAT GENET, V37, P349, DOI 10.1038/ng1534; Sakamoto J, 2004, FEBS LETT, V556, P281, DOI 10.1016/S0014-5793(03)01444-3; Sinclair D, 2005, NAT GENET, V37, P339, DOI 10.1038/ng0405-339; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457; Wu A, 2003, NEUROSCIENCE, V119, P365, DOI 10.1016/S0306-4522(03)00154-4; Wu AG, 2006, EUR J NEUROSCI, V23, P2573, DOI 10.1111/j.1460-9568.2006.04807.x	17	102	104	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2007	24	10					1587	1595		10.1089/neu.2007.0313			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	227HZ	WOS:000250649100005	17970622				2022-02-06	
J	Meffre, D; Pianos, A; Liere, P; Eychenne, B; Cambourg, A; Schumacher, M; Stein, DG; Guennoun, R				Meffre, D.; Pianos, A.; Liere, P.; Eychenne, B.; Cambourg, A.; Schumacher, M.; Stein, D. G.; Guennoun, R.			Steroid profiling in brain and plasma of male and pseudopregnant female rats after traumatic brain injury: Analysis by gas chromatography/mass spectrometry	ENDOCRINOLOGY			English	Article							PERIPHERAL BENZODIAZEPINE-RECEPTOR; MEMBRANE PROGESTIN RECEPTOR; SPINAL-CORD-INJURY; MASS-SPECTROMETRY; NEUROACTIVE STEROIDS; GABA(A) RECEPTOR; NERVOUS-SYSTEM; DEVELOPMENTAL REGULATION; IMMOBILIZATION STRESS; NADPH-P450 REDUCTASE	Steroids in brain arise from the peripheral endocrine glands and local synthesis. In traumatic brain injury ( TBI), the endogenous circulating hormones at the time of injury are important for neuroprotection. In particular, pseudopregnant females recover better than males from TBI. We investigated the effect of pseudopregnancy and TBI on steroid levels in plasma and in three brain regions ( within, adjacent, and distal to the lesion site), 6 and 24 h after prefrontal cortex injury. The following steroids were analyzed by gas chromatography/ mass spectrometry: pregnenolone, progesterone, 5 alpha-dihydroprogesterone, 3 alpha, 5 alpha-tetrahydroprogesterone, 3 beta, 5 alpha-tetrahydroprogesterone, dehydroepiandrosterone, Delta(4)-androstenedione, testosterone, 5 alpha-dihydrotestosterone, 3 alpha, 5 alpha-tetrahydrotestosterone, 3 beta, 5 alpha-tetrahydrotestosterone, and 17 beta-estradiol. Corticosterone was assayed in plasma to account for stress in the rats. We found different steroid profiles in brain and plasma of male and pseudopregnant female rats and specific profile changes after TBI. In sham-operated pseudopregnant females, much higher levels of progesterone, 5 alpha-dihydroprogesterone, 3 alpha, 5 alpha-tetrahydroprogesterone, and 3 beta, 5 alpha-tetrahydroprogesterone were measured in both brain and plasma, compared with sham-operated males. Plasma levels of corticosterone were high in all groups, indicating that the surgeries induced acute stress. Six hours after TBI, the levels of pregnenolone, progesterone, and 5 alpha-dihydroprogesterone increased, and those of testosterone decreased in male brain, whereas levels of 5 alpha-dihydroprogesterone and 3 beta, 5 alpha-tetrahydroprogesterone increased in brain of pseudopregnant female rats. Plasma levels of 5 alpha-dihydroprogesterone did not change after TBI, suggesting a local activation of the 5 alpha-reduction pathway of progesterone in both male and pseudopregnant female brain. The significant increase in neurosteroid levels in the male brain after TBI is consistent with their role in neuroprotection. In pseudopregnant females, high levels of circulating progestagens may provide protection against TBI.	INSERM, UMR788, F-94276 Le Kremlin Bicetre, France; Univ Paris 11, F-94276 Le Kremlin Bicetre, France; Emory Univ, Brain Res Lab, Atlanta, GA 30322 USA; Emory Univ, Dept Emergency Med, Atlanta, GA 30322 USA		Guennoun, R (corresponding author), INSERM, UMR788, 80 Rue Gen Leclerc, F-94276 Le Kremlin Bicetre, France.	guennoun@kb.inserm.fr	Stein, Donald/AAJ-5139-2020; Guennoun, Rachida/F-2420-2011; Schumacher, Michael/G-3581-2013	Guennoun, Rachida/0000-0002-9219-7300; Schumacher, Michael/0000-0001-6117-5371; MEFFRE, Delphine/0000-0002-9204-2245	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [1R01N540825, 1R01N538664] Funding Source: Medline		ATTELLA MJ, 1987, BEHAV NEURAL BIOL, V48, P352, DOI 10.1016/S0163-1047(87)90918-6; Auchus RJ, 2003, ARCH BIOCHEM BIOPHYS, V409, P134, DOI 10.1016/S0003-9861(02)00491-5; Backstrom T, 2005, EUR J PHARMACOL, V512, P15, DOI 10.1016/j.ejphar.2005.01.049; Barbaccia ML, 1996, NEUROENDOCRINOLOGY, V63, P166, DOI 10.1159/000126953; Barbaccia ML, 2001, INT REV NEUROBIOL, V46, P243; BARNEA A, 1990, ENDOCRINOLOGY, V127, P500, DOI 10.1210/endo-127-1-500; Baulieu EE, 1997, RECENT PROG HORM RES, V52, P1; Belelli D, 2005, NAT REV NEUROSCI, V6, P565, DOI 10.1038/nrn1703; Belelli D, 2002, NEUROPHARMACOLOGY, V43, P651, DOI 10.1016/S0028-3908(02)00172-7; BILLIAR RB, 1975, BRAIN RES, V94, P99, DOI 10.1016/0006-8993(75)90880-X; Bixo M, 1997, BRAIN RES, V764, P173, DOI 10.1016/S0006-8993(97)00455-1; CHENEY DL, 1995, J NEUROSCI, V15, P4641; Ciriza I, 2004, J NEUROENDOCRINOL, V16, P58, DOI 10.1111/j.1365-2826.2004.01121.x; CLARK JDA, 1988, CLIN ENDOCRINOL, V29, P153, DOI 10.1111/j.1365-2265.1988.tb00257.x; Coirini H, 2002, NEUROSCIENCE, V113, P883, DOI 10.1016/S0306-4522(02)00224-5; CORPECHOT C, 1993, ENDOCRINOLOGY, V133, P1003, DOI 10.1210/en.133.3.1003; De Nicola AF, 2006, J MOL NEUROSCI, V28, P3, DOI 10.1385/JMN:28:1:3; di Michele F, 2000, NEUROSCI LETT, V284, P65, DOI 10.1016/S0304-3940(00)00965-4; Dong E, 2001, P NATL ACAD SCI USA, V98, P2849, DOI 10.1073/pnas.051628598; Ebner MJ, 2006, ENDOCRINOLOGY, V147, P179, DOI 10.1210/en.2005-1065; FINK G, 1991, J STEROID BIOCHEM, V40, P123, DOI 10.1016/0960-0760(91)90175-5; Gago N, 2004, J NEUROSCI RES, V78, P770, DOI 10.1002/jnr.20348; Garcia-Ovejero D, 2005, BRAIN RES REV, V48, P273, DOI 10.1016/j.brainresrev.2004.12.018; Garcia-Segura LM, 2001, PROG NEUROBIOL, V63, P29, DOI 10.1016/S0301-0082(00)00025-3; GARLAND HO, 1987, J ENDOCRINOL, V113, P435, DOI 10.1677/joe.0.1130435; Griffin LD, 2004, NAT MED, V10, P704, DOI 10.1038/nm1073; Guennoun R, 2003, CONTRO ISSU CLIM MED, P57; He J, 2004, RESTOR NEUROL NEUROS, V22, P19; Higashi T, 2005, STEROIDS, V70, P1, DOI 10.1016/j.steroids.2004.08.001; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; Huang C, 2000, ALZHEIMERS REP, V3, P275; JAMBART S, 1980, ACTA ENDOCRINOL-COP, V93, P264, DOI 10.1530/acta.0.0930264; KARAVOLAS HJ, 1990, CIBA F SYMP, V153, P22; Kostic T, 1998, J STEROID BIOCHEM, V66, P51, DOI 10.1016/S0960-0760(98)00003-X; Labombarda F, 2006, ENDOCRINOLOGY, V147, P1847, DOI 10.1210/en.2005-0955; Lacor P, 1999, BRAIN RES, V815, P70, DOI 10.1016/S0006-8993(98)01105-6; Lacor P, 1996, NEUROSCI LETT, V220, P61, DOI 10.1016/S0304-3940(96)13187-6; Lambert JJ, 1996, CELL MOL NEUROBIOL, V16, P155, DOI 10.1007/BF02088174; LEE SC, 1994, BRAIN INJURY, V8, P571; Liere P, 2000, J CHROMATOGR B, V739, P301, DOI 10.1016/S0378-4347(99)00563-0; Liere P, 2004, J LIPID RES, V45, P2287, DOI 10.1194/jlr.M400244-JLR200; Maric D, 1996, J STEROID BIOCHEM, V58, P351, DOI 10.1016/0960-0760(96)00044-1; MARTINI L, 1993, J STEROID BIOCHEM, V47, P195, DOI 10.1016/0960-0760(93)90075-8; Marwah A, 2001, J CHROMATOGR B, V757, P333, DOI 10.1016/S0378-4347(01)00171-2; MCEWEN BS, 1981, SCIENCE, V211, P1303, DOI 10.1126/science.6259728; MCEWEN BS, 1994, HORM BEHAV, V28, P396, DOI 10.1006/hbeh.1994.1036; Meffre D, 2005, J NEUROCHEM, V93, P1314, DOI 10.1111/j.1471-4159.2005.03127.x; Micevych PE, 2007, ENDOCRINOLOGY, V148, P782, DOI 10.1210/en.2006-0774; Mills CD, 2005, MOL CELL NEUROSCI, V30, P228, DOI 10.1016/j.mcn.2005.07.010; NAFTOLIN F, 1994, J REPROD MED, V39, P257; NORMINGTON K, 1992, J BIOL CHEM, V267, P19548; ORR TE, 1994, J ANDROL, V15, P302; Rao VLR, 2000, EXP NEUROL, V161, P102, DOI 10.1006/exnr.1999.7269; Richard I., 2001, Annales de Readaptation et de Medecine Physique, V44, P19, DOI 10.1016/S0168-6054(00)00059-3; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; RUPPRECHT R, 1993, NEURON, V11, P523, DOI 10.1016/0896-6273(93)90156-L; Rupprecht R, 1996, J STEROID BIOCHEM, V56, P163, DOI 10.1016/0960-0760(95)00233-2; Safarinejad MR, 2001, UROLOGY, V58, P671, DOI 10.1016/S0090-4295(01)01353-X; Schumacher M, 2004, GROWTH HORM IGF RES, V14, pS18, DOI 10.1016/j.ghir.2004.03.007; Schumacher M, 2001, BRAIN RES REV, V37, P343, DOI 10.1016/S0165-0173(01)00139-4; Selmin O, 1996, CARCINOGENESIS, V17, P2609, DOI 10.1093/carcin/17.12.2609; SHET MS, 1994, ARCH BIOCHEM BIOPHYS, V311, P402, DOI 10.1006/abbi.1994.1255; Shu PY, 2003, J CHROMATOGR B, V783, P93, DOI 10.1016/S1570-0232(02)00520-2; Sierra A, 2003, EUR J NEUROSCI, V18, P1458, DOI 10.1046/j.1460-9568.2003.02872.x; Sinchak K, 2003, DEV NEUROSCI-BASEL, V25, P343, DOI 10.1159/000073511; SMITH MS, 1975, ENDOCRINOLOGY, V96, P219, DOI 10.1210/endo-96-1-219; Soma KK, 2005, ENDOCRINOLOGY, V146, P4386, DOI 10.1210/en.2005-0569; Stein DG, 2005, ANN NY ACAD SCI, V1052, P152, DOI 10.1196/annals.1347.011; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Toran-Allerand CD, 2005, ENDOCRINOLOGY, V146, P3843, DOI 10.1210/en.2004-1616; Vallee M, 2000, ANAL BIOCHEM, V287, P153, DOI 10.1006/abio.2000.4841; van Hees P.A.W., 2003, WATER AIR SOIL POLL, V3, P5, DOI [10.1023/A:1024115111377, DOI 10.1023/A:1024115111377]; Verleye M, 2005, PHARMACOL BIOCHEM BE, V82, P712, DOI 10.1016/j.pbb.2005.11.013; Wang JM, 2005, J NEUROSCI, V25, P4706, DOI 10.1523/JNEUROSCI.4520-04.2005; Wang MD, 2002, J NEUROSCI, V22, P3366; WELSCHEN R, 1975, J ENDOCRINOL, V64, P37, DOI 10.1677/joe.0.0640037; WRIGHT DW, IN PRESS ANN EMERG M; Zhu Y, 2003, P NATL ACAD SCI USA, V100, P2231, DOI 10.1073/pnas.0336132100; Zhu Y, 2003, P NATL ACAD SCI USA, V100, P2237, DOI 10.1073/pnas.0436133100	79	102	104	0	11	ENDOCRINE SOC	WASHINGTON	2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA	0013-7227	1945-7170		ENDOCRINOLOGY	Endocrinology	MAY	2007	148	5					2505	2517		10.1210/en.2006-1678			13	Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism	158RG	WOS:000245810600062	17303653	Bronze			2022-02-06	
J	Catroppa, C; Anderson, VA; Morse, SA; Haritou, F; Rosenfeld, JV				Catroppa, Cathy; Anderson, Vicki A.; Morse, Sue A.; Haritou, Flora; Rosenfeld, Jeffrey V.			Children's attentional skills 5 years Post-TBI	JOURNAL OF PEDIATRIC PSYCHOLOGY			English	Article						attention; children; traumatic brain injury	TRAUMATIC BRAIN-INJURY; CLOSED-HEAD-INJURY; ACADEMIC-PERFORMANCE; EARLY-CHILDHOOD; RECOVERY; PREDICTORS; ADOLESCENTS; SEVERITY; SEQUELAE; MEMORY	Objective While a small number of research papers have reported findings on attentional deficits following pediatric traumatic brain injury (TBI), no study to date has reported findings in this area at 5 years post-TBI in very young children. This study examined attentional skills in a group of children who had sustained a mild, moderate, or severe TBI between the ages of 2 and 7 years. Methods The sample comprised 70 children, 54 of these had sustained a TBI and 16 the non-injured control group. Children were assessed 5 years post-TBI, with focus on tests of attentional ability. Results Attentional and processing speed (PS) deficits do occur and persist up to 5 years post-TBI, particularly following severe TBI in early childhood. Predictors of attentional outcomes varied depending on the component of attention investigated. Conclusions Those skills developing or emerging at time of injury (e.g., sustained attention, shifting attention, divided attention, PS) are more compromised and may not develop at a normal rate of post-injury.	Royal Childrens Hosp, Dept Psychol, Parkville, Vic 3052, Australia; Murdoch Univ, Childrens Res Inst, Australian Ctr Child Neuropsychol Studies, Murdoch, WA 6150, Australia; Univ Melbourne, Melbourne, Vic, Australia; Alfred Hosp, Melbourne, Vic, Australia; Monash Univ, Melbourne, Vic 3004, Australia		Catroppa, C (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.	cathy.catroppa@mcri.edu.au	Rosenfeld, Jeffrey V/B-7249-2011; Catroppa, Cathy/AAX-9458-2021	Catroppa, Cathy/0000-0002-9750-0436			Anderson P, 2002, CHILD NEUROPSYCHOL, V8, P71, DOI 10.1076/chin.8.2.71.8724; Anderson V, 1998, NEUROPSYCHOL REHABIL, V8, P283; Anderson V, 2005, BRAIN INJURY, V19, P699, DOI 10.1080/02699050400025281; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Anderson VA, 2001, DEV NEUROPSYCHOL, V20, P385, DOI 10.1207/S15326942DN2001_5; BETTS J, IN PRESS CHILD NEURO; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Catroppa C, 1999, J INT NEUROPSYCH SOC, V5, P48, DOI 10.1017/S1355617799511077; Catroppa C, 2005, J INT NEUROPSYCH SOC, V11, P84, DOI 10.1017/S1355617705050101; Catroppa C, 2003, NEUROPSYCHOL REHABIL, V13, P517, DOI 10.1080/09602010343000084; Catroppa C, 2003, DEV NEUROPSYCHOL, V23, P359, DOI 10.1207/S15326942DN2303_3; Catroppa C, 1999, CHILD NEUROPSYCHOL, V5, P251, DOI 10.1076/0929-7049(199912)05:04;1-R;FT251; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHADWICK O, 1981, J CHILD PSYCHOL PSYC, V22, P117, DOI 10.1111/j.1469-7610.1981.tb00538.x; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; Ciccetti D., 1984, VINELAND ADAPTIVE BE; COOLEY EL, 1990, DEV NEUROPSYCHOL, V6, P239, DOI 10.1080/87565649009540465; Daniel A., 1983, POWER PRIVILEGE PRES; Dennis M, 1995, TRAUMATIC HEAD INJUR; Dennis M., 1989, CLIN NEUROPSYCHOLOGY; Donders J, 1997, CHILD NEUROPSYCHOL, V3, P71, DOI 10.1080/09297049708401369; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; Fidell L.S., 2000, USING MULTIVARIATE S; Goldstein FC, 1992, COGNITIVE DISORDERS; Gronwall D, 1997, J Int Neuropsychol Soc, V3, P592; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; HAAS JF, 1987, J NEUROL NEUROSUR PS, V50, P52, DOI 10.1136/jnnp.50.1.52; HALPERIN JM, 1991, INT J NEUROSCI, V58, P171, DOI 10.3109/00207459108985433; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; KAIL R, 1986, CHILD DEV, V57, P969, DOI 10.1111/j.1467-8624.1986.tb00259.x; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P1294, DOI 10.1136/jnnp.51.10.1294; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; Manly T., 1999, TEST EVERYDAY ATTENT; Max JE, 1998, J AM ACAD CHILD PSY, V37, P83, DOI 10.1097/00004583-199801000-00021; MCKAY KE, 1994, DEV NEUROPSYCHOL, V10, P121, DOI 10.1080/87565649409540572; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; Rebok GW, 1997, CHILD NEUROPSYCHOL, V3, P28, DOI 10.1080/09297049708401366; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; RUIJS MBM, 1993, EUR J PEDIATR, V152, P844, DOI 10.1007/BF02073384; RUIJS MBM, 1994, NEUROPEDIATRICS, V25, P73, DOI 10.1055/s-2008-1071589; Stein SC, 1995, PEDIATR NEUROSURG, V23, P299, DOI 10.1159/000120975; Stuss DT, 1995, ANN NY ACAD SCI, V769, P191, DOI 10.1111/j.1749-6632.1995.tb38140.x; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TEASDALE G, 1974, LANCET, V2, P81; Timmermans SR, 1991, COGNITIVE REHABILITA, V9, P26; VANZOMORON AH, 1994, CLIN NEUROPSYCHOLOGY; Wechsler D., 1991, MANUAL WECHSLER INTE, V3rd; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514	59	102	102	2	7	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-8693			J PEDIATR PSYCHOL	J. Pediatr. Psychol.	APR	2007	32	3					354	369		10.1093/jpepsy/jsl019			16	Psychology, Developmental	Social Science Citation Index (SSCI)	Psychology	145BL	WOS:000244840200013	16840790	Green Published, Bronze			2022-02-06	
J	Hessen, E; Nestvold, K; Anderson, V				Hessen, Erik; Nestvold, Knut; Anderson, Vicki			Neuropsychological function 23 years after mild traumatic brain injury: A comparison of outcome after paediatric and adult head injuries	BRAIN INJURY			English	Article						mild head injury; TBI; cognitive deficits; neuropsychological impairment	WORKING-MEMORY; CHILDREN; CHILDHOOD; MODERATE; CLASSIFICATION; CONSEQUENCES; EPIDEMIOLOGY; ADOLESCENTS; TOMOGRAPHY; IMPAIRMENT	Primary objective: To the authors' knowledge no study comparing very long-term neuropsychological outcome after mild paediatric and adult traumatic brain injury ( TBI) has been published. The primary objective of this study was to compare neuropsychological outcome 23 years after mainly mild paediatric and adult TBI. Research design: The study was a neuropsychological follow-up 23 years after a prospective head injury study conducted at a Norwegian public hospital. Methods and procedures: One hundred and nineteen patients were assessed with a comprehensive neuropsychological test battery. Of these, 45 were paediatric TBI and 74 were adult TBI. Main outcomes and results: Both the paediatric and adult groups obtained scores in the normal range. In the paediatric group significant relationships were found between head injury severity and current neuropsychological function. The most important predictors of poor outcome were length of post-traumatic amnesia ( PTA) and a combination of PTA and EEG pathology within 24 hours of injury. No influence of pre- and post-injury risk factors on current neuropsychological function was evident. Conclusions: The findings indicate that children sustaining complicated mild TBI may be more vulnerable to development of chronic mild neuropsychological dysfunction than adults sustaining similar head injuries.	Akershus Univ Hosp, Dept Neurol, N-1478 Lorenskog, Norway; Univ Melbourne, Melbourne, Vic, Australia		Hessen, E (corresponding author), Akershus Univ Hosp, Dept Neurol, N-1478 Lorenskog, Norway.	erik.hessen@nevropsykologi.no					*AET NORW, 2006, SUBJ DIS BEN NORW; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2001, J CLIN EXP NEUROPSYC, V23, P705, DOI 10.1076/jcen.23.6.705.1015; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Anderson VA, 2000, BRAIN INJURY, V14, P679; Andersson EH, 2003, ACTA NEUROL SCAND, V107, P256, DOI 10.1034/j.1600-0404.2003.00112.x; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BLAND JM, 1995, BRIT MED J, V310, P170, DOI 10.1136/bmj.310.6973.170; Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; DIKMEN SS, 1989, MILD HEAD INJURY, P229; DOLAN RJ, 1994, PSYCHOL MED, V24, P849, DOI 10.1017/S0033291700028944; Duus B R, 1991, Ugeskr Laeger, V153, P2111; Egeland J., 2005, J NORWEGIAN PSYCHOL, V42, P99; Egeland J, 2006, CLIN NEUROPSYCHOL, V20, P716, DOI 10.1080/13854040500351008; ENGVIK H, 1978, WECHSLER ADULT INTEL; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; GIMSE R, 1995, WECHSLER MEMORY SCAL; Hartlage LC, 2001, ARCH CLIN NEUROPSYCH, V16, P561, DOI 10.1016/S0887-6177(00)00067-6; HAYES RL, 1994, SEMIN NEUROL, V14, P25, DOI 10.1055/s-2008-1041055; Heaton RK, 1991, COMPREHENSIVE NORMS; Hessen E, 2006, EPILEPSIA, V47, P1870, DOI 10.1111/j.1528-1167.2006.00830.x; Hessen E, 2006, SCAND J PSYCHOL, V47, P245, DOI 10.1111/j.1467-9450.2006.00514.x; Hux K, 2000, J COMMUN HEALTH, V25, P47, DOI 10.1023/A:1005140918066; JENNETT B, 1975, LANCET, V1, P480; Johnson David A, 2003, Pediatr Rehabil, V6, P103, DOI 10.1080/1363849031000166730; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Levin HS, 2004, NEUROPSYCHOLOGY, V18, P240, DOI 10.1037/0894-4105.18.2.240; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Lund C, 2005, ANN THORAC SURG, V80, P2126, DOI 10.1016/j.athoracsur.2005.06.012; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; MILLER JD, 1990, NEUROSURGERY, V27, P669, DOI 10.1227/00006123-199011000-00001; Miller L, 1996, J COGNITIVE REHABILI, V14, P8; Nell V, 2000, ARCH PHYS MED REHAB, V81, P614, DOI 10.1053/mr.2000.3877; NESTVOLD K, 1988, NEUROEPIDEMIOLOGY, V7, P134, DOI 10.1159/000110147; Rees PM, 2003, ARCH PHYS MED REHAB, V84, P1885, DOI 10.1016/j.apmr.2003.03.001; Reitan R, 1985, HALSTEAD REITAN NEUR; Roncadin C, 2004, DEV NEUROPSYCHOL, V25, P21; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; *STAT NORW, 2001, LEV ED PERS 16 YEARS; Statistics Norway, 2004, LEV ED PERS 16 YEARS; Tellier A, 1999, BRAIN INJURY, V13, P463; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Wechsler D, 1987, MEMORY SCALE REVISED; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th Edn; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WRIGHTSON P, 1999, MILD HEAD INJURY; ZAKZANIS KK, 1999, MILD TRAUMATIC BRAIN, P163	65	102	102	0	13	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2007	21	9					963	979		10.1080/02699050701528454			17	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	202ZA	WOS:000248942600008	17729049				2022-02-06	
J	Thornton, M; Marshall, S; McComas, J; Finestone, H; McCormick, A; Sveistrup, H				Thornton, M; Marshall, S; McComas, J; Finestone, H; McCormick, A; Sveistrup, H			Benefits of activity and virtual reality based balance exercise programmes for adults with traumatic brain injury: Perceptions of participants and their caregivers	BRAIN INJURY			English	Article						virtual reality; self-efficacy; self-concept; physiotherapy; balance confidence; community integration	CONFIDENCE ABC SCALE; PHYSICAL-ACTIVITY; PEOPLE; REHABILITATION; METAANALYSIS; AWARENESS; RECOVERY; OUTCOMES; FALLS; LIFE	Objective: To explore multi-dimensional benefits of exercise participation perceived by adults with traumatic brain injury (TBI) and their caregivers. Methods: Adults (n = 27, aged 18 - 66) with moderate or severe TBI 6 months or more earlier participated in focus groups following 6 weeks of an activity-based (ABE) or a virtual reality (VR) delivered balance exercise programme. Family members and care providers participated in separate focus groups. Perceptions related to programme participation as well as balance confidence and lower extremity function were extracted from focus group verbatim and quantitative scales, respectively. Outcomes: Benefits in three domains, psychosocial, physical and programme, were identified from transcription and analyses of focus group verbatim. Improvements were noted in balance confidence and function in both groups. Substantially greater enthusiasm and knowledge was expressed by participants in the VR group and their caregivers. Conclusions: Both exercise programmes offered benefits in addition to improved balance. The VR participants had greater improvements on quantitative measures and provided more comments expressing enjoyment and improved confidence. Applications in terms of community reintegration and quality of life are discussed.	Univ Ottawa, Fac Hlth Sci, Sch Rehabil Sci, Ottawa, ON K1H 8M5, Canada; Univ Ottawa, Sch Human Kinet, Ottawa, ON K1N 6N5, Canada; Sisters Char Ottawa Hlth Serv, Ottawa, ON, Canada; Childrens Hosp Eastern Ontario, Toronto, ON, Canada		Sveistrup, H (corresponding author), Univ Ottawa, Fac Hlth Sci, Sch Rehabil Sci, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.	hsveist@uottawa.ca					Allison L., 1999, NEUROLOGY REPORT, V23, P13, DOI DOI 10.1097/01253086-199923010-00010; Binkley JM, 1999, PHYS THER, V79, P371; Blair SN, 1996, J AM GERIATR SOC, V44, P599, DOI 10.1111/j.1532-5415.1996.tb01450.x; Carter ND, 2001, SPORTS MED, V31, P427, DOI 10.2165/00007256-200131060-00003; Cattaneo D, 2001, CYBERPSYCHOL BEHAV, V4, P687, DOI 10.1089/109493101753376632; *CDC, 2003, TRAUM BRAIN INJ US R; *CDC, 2003, WHAT IS BRAIN INJ; CONDELUCI A, 1990, BRAIN INJURY, V6, P543; Dunn AL, 2001, MED SCI SPORT EXER, V33, pS587, DOI 10.1097/00005768-200106001-00027; Durgin CJ, 2000, J HEAD TRAUMA REHAB, V15, P1195, DOI 10.1097/00001199-200012000-00002; EMERSON EB, 1985, AM J MENT DEF, V90, P277; Etnier JL, 1997, J SPORT EXERCISE PSY, V19, P249, DOI 10.1123/jsep.19.3.249; Finch E, 2002, PHYS REHABILITATION; FOUGEYROLLAS P, 1995, DISABIL REHABIL, V17, P145, DOI 10.3109/09638289509166709; Fougeyrollas P, 1998, QUEBEC CLASSIFICATIO; Gettman L R, 1983, Phys Sportsmed, V11, P56, DOI 10.1080/00913847.1983.11708657; Grealy MA, 1999, ARCH PHYS MED REHAB, V80, P661, DOI 10.1016/S0003-9993(99)90169-7; Hillier SL, 1997, BRAIN INJURY, V11, P661; JANKOWSKI LW, 1990, ARCH PHYS MED REHAB, V71, P500; Kennedy MRT, 2001, BRAIN INJURY, V15, P469, DOI 10.1080/02699050010007380; KIZONY R, 2003, USING VIDEO PROJECTE, P82; Lord S, 1994, Aust J Physiother, V40, P83, DOI 10.1016/S0004-9514(14)60454-2; Man DWK, 2003, BRAIN INJURY, V17, P775, DOI 10.1080/0269905031000088577; MAZZEO RS, 2004, PHYS SPORTSMEDICINE, V27, P115; Miller WC, 2002, PHYS THER, V82, P856, DOI 10.1093/ptj/82.9.856; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Myers AM, 1998, J GERONTOL A-BIOL, V53, pM287, DOI 10.1093/gerona/53A.4.M287; Myers AM, 1996, J GERONTOL A-BIOL, V51, pM37, DOI 10.1093/gerona/51A.1.M37; *NAT CTR CHRON DIS, 2003, MORBIDITY MORTALITY, V49, P420; NORAEU L, 2000, DISABILITY REHABILIT, V22, P170; PATLA AE, 1992, CAN J PUBLIC HEALTH, V83, pS29; Port A, 2002, BRAIN INJURY, V16, P277, DOI 10.1080/02699050110103274; Powell JM, 2001, ARCH PHYS MED REHAB, V82, P1025, DOI 10.1053/apmr.2001.25082; POWELL LE, 1995, J GERONTOL A-BIOL, V50, pM28, DOI 10.1093/gerona/50A.1.M28; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; PROVINCE MA, 1995, JAMA-J AM MED ASSOC, V273, P1341, DOI 10.1001/jama.273.17.1341; Reid D, 2002, CYBERPSYCHOL BEHAV, V5, P559, DOI 10.1089/109493102321018204; Rose DJ, 2002, J AGING PHYS ACTIV, V10, P207, DOI 10.1123/japa.10.2.207; Shumway-Cook A, 1990, J HEAD TRAUMA REHAB, V5, P51, DOI DOI 10.1097/00001199-199012000-00007; Skelton DA, 2001, AGE AGEING, V30, P33, DOI 10.1093/ageing/30.suppl_4.33; Skelton Dawn A., 1999, Physiotherapy Theory and Practice, V15, P105, DOI 10.1080/095939899307801; STRATFORD PW, 2000, PHYSIOTHER CAN, V52, P97; SULLIVAN S J, 1990, Brain Injury, V4, P407, DOI 10.3109/02699059009026194; Tennsledt S, 1998, J GERONTOL B-PSYCHOL, V53, pP384, DOI 10.1093/geronb/53B.6.P384; THORNTON M, 2004, P CAN PHYS ASS NAT C; Tillerson JL, 2002, NEUROSCIENTIST, V8, P574, DOI 10.1177/1073858402238516; van Gool CH, 2003, AGE AGEING, V32, P81, DOI 10.1093/ageing/32.1.81; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; Weiss PL, 2003, CYBERPSYCHOL BEHAV, V6, P335, DOI 10.1089/109493103322011650; WILLER B, 2004, BRAIN INJURY REHABIL, P355	50	102	106	1	34	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	NOV	2005	19	12					989	1000		10.1080/02699050500109944			12	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	983ZA	WOS:000233269700005	16263641				2022-02-06	
J	Anderson, V; Catroppa, C; Morse, S; Haritou, F; Rosenfeld, J				Anderson, V; Catroppa, C; Morse, S; Haritou, F; Rosenfeld, J			Attentional and processing skills following traumatic brain injury in early childhood	BRAIN INJURY			English	Article						brain injury; child; sustained attention	CLOSED-HEAD-INJURY; SELECTIVE ATTENTION; PERFORMANCE; CHILDREN; PERSPECTIVE; MATURATION; TIME	Primary objective: Attentional deficits are common following TBI in adults. This study examined whether these skills are also vulnerable following early childhood injury, when such skills are rapidly developing. Research design: This study investigated attention 30 months post-TBI in pre-schoolers (n = 56) and age-matched controls (n = 26). TBI children were divided into mild, moderate and severe injury groups. Methods and procedure: Pre-injury data were collected at time of injury. Assessment of attention included the Continuous Performance Test, Wechsler Intelligence Scale and Personality Inventory for Children. Main outcomes and results: Severe TBI was associated with reduced accuracy and slowed processing, particularly on complex motor responses. Sustained attention was more intact. Parental reports indicate internalized behavioural problems and somatic complaints. Conclusions: Young children with severe TBI are at risk for severe, persisting attentional impairments. Children with mild and moderate TBI show better outcome, with pre-injury behaviour and age also predictive of attentional skills at 30 months post-injury.	Royal Childrens Hosp, Murdoch Childrens Res Inst, Melbourne, Vic, Australia; Univ Melbourne, Parkville, Vic 3052, Australia; Monash Univ, Clayton, Vic 3168, Australia		Anderson, V (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.	vicki.anderson@rch.org.au	Catroppa, Cathy/AAX-9458-2021	Catroppa, Cathy/0000-0002-9750-0436			Anderson V, 1998, BRAIN INJURY, V12, P937, DOI 10.1080/026990598121990; Anderson V, 1998, NEUROPSYCHOL REHABIL, V8, P283; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; ANDERSON V, 2001, PEDIAT NEUROPSYCHOLO; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; Anderson VA, 2000, BRAIN INJURY, V14, P679; BAKKER K, 2000, PEDIAT REHABIL, V3, P149; Casey BJ, 2000, BIOL PSYCHOL, V54, P241, DOI 10.1016/S0301-0511(00)00058-2; Catroppa C, 1999, J INT NEUROPSYCH SOC, V5, P48, DOI 10.1017/S1355617799511077; Catroppa C, 2003, DEV NEUROPSYCHOL, V23, P359, DOI 10.1207/S15326942DN2303_3; Catroppa C, 1999, CHILD NEUROPSYCHOL, V5, P251, DOI 10.1076/0929-7049(199912)05:04;1-R;FT251; Ciccetti D., 1984, VINELAND ADAPTIVE BE; COOLEY EL, 1990, DEV NEUROPSYCHOL, V6, P239, DOI 10.1080/87565649009540465; Daniel A., 1983, POWER PRIVILEGE PRES; Dennis M, 1995, TRAUMATIC HEAD INJUR; Dennis M, 1989, CLIN NEUROPSYCHOLOGY, P89; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Ewing-Cobbs L, 1998, CHILD NEUROPSYCHOL, V4, P35, DOI 10.1076/chin.4.1.35.3194; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; Goldstein FC, 1985, DEV NEUROPSYCHOL, V1, P195, DOI 10.1080/87565648509540310; Gronwall D, 1997, J Int Neuropsychol Soc, V3, P592; HALPERIN JM, 1991, INT J NEUROSCI, V58, P171, DOI 10.3109/00207459108985433; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; KINSBOURNE M, 1996, COGNITIVE NEUROSCIEN, P1321; Kraus JF., 1995, TRAUMATIC HEAD INJUR, P117; Lachar D., 1992, PERSONALITY INVENTOR; LANE DM, 1982, MERRILL PALMER QUART, V28, P317; LANE DM, 1979, J EXP CHILD PSYCHOL, V28, P16, DOI 10.1016/0022-0965(79)90099-7; Lenneberg E.H., 1967, BIOL FDN LANGUAGE; Manly T, 2001, J CHILD PSYCHOL PSYC, V42, P1065, DOI 10.1111/1469-7610.00806; Manly T., 1999, TEACH TEST EVERYDAY; MCKAY KE, 1994, DEV NEUROPSYCHOL, V10, P121, DOI 10.1080/87565649409540572; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; Mirsky A.F., 1996, ATTENTION MEMORY EXE, P71; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; Rebok GW, 1997, CHILD NEUROPSYCHOL, V3, P28, DOI 10.1080/09297049708401366; ROSVOLD HE, 1956, J CONSULT PSYCHOL, V20, P343, DOI 10.1037/h0043220; Ruff H. A., 1996, ATTENTION EARLY DEV; SHEPP BE, 1987, J EXP CHILD PSYCHOL, V43, P159, DOI 10.1016/0022-0965(87)90057-9; SHUM DHK, 1990, J CLIN EXP NEUROPSYC, V12, P247, DOI 10.1080/01688639008400971; Sowell ER, 2001, J INT NEUROPSYCH SOC, V7, P312, DOI 10.1017/S135561770173305X; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; TEASDALE G, 1974, LANCET, V2, P81; THATCHER RW, 1991, DEV NEUROPSYCHOL, V7, P397, DOI 10.1080/87565649109540500; Timmermans SR, 1991, COGNITIVE REHABILITA, V9, P26; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; VANDERMEERE J, 1988, J ABNORM CHILD PSYCH, V16, P641, DOI 10.1007/BF00913475; Vriezen ER, 2000, BRAIN COGNITION, V44, P67; Walsh K. W., 1978, NEUROPSYCHOLOGY CLIN; Warschausky S, 1996, ARCH CLIN NEUROPSYCH, V11, P147, DOI 10.1016/0887-6177(95)00004-6; Wechsler D., 1987, MANUAL PRESCHOOL PRI; Wechsler D., 1991, MANUAL WECHSLER INTE, V3rd; Willmott C, 2000, DEV NEUROPSYCHOL, V17, P361, DOI 10.1207/S15326942DN1703_5	56	102	102	0	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	AUG	2005	19	9					699	710		10.1080/02699050400025281			12	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	945EH	WOS:000230484600008	16195184				2022-02-06	
J	Ehrenreich, H; Aust, C; Krampe, H; Jahn, H; Jacob, S; Herrmann, M; Siren, AL				Ehrenreich, H; Aust, C; Krampe, H; Jahn, H; Jacob, S; Herrmann, M; Siren, AL			Erythropoietin: Novel approaches to neuroprotection in human brain disease	METABOLIC BRAIN DISEASE			English	Article; Proceedings Paper	3rd International Hannover Conference on Hepatic Encephalopathy	MAY 31-AUG 21, 2003	Bremen, GERMANY	Solvay Pharmacut GmbH		EPO; stroke; schizophrenia; treatment; regeneration	PERMANENT CEREBRAL-ISCHEMIA; IN-VITRO; SCHIZOPHRENIA; RECEPTOR; DISORDER; PROTECTS; HYPOXIA; NEUROGENESIS; EXPRESSION; NEURONS	With the increased life expectancy in western industrialized countries, the incidence and prevalence of brain diseases dramatically increased. Stroke and a wide spectrum of neuropsychiatric illnesses such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, traumatic head injury, and schizophrenia all lead to severe disability. However, targeted effective therapies for treatment of these diseases are lacking. Even more frustrating is the fact that we do not yet clearly understand the basic mechanisms underlying the disease processes in these conditions. We propose a hypothesis of loss of neuronal function via a final common deleterious pathway in this clinically very heterogeneous disease group. This review presents a novel neuroprotective concept for treatment of brain disease: Erythropoietin (EPO). EPO is a natural body-own-protein hormone that has been used for treatment of anemia for more than a decade. The neuroprotective approach using EPO in brain disease represents a totally new frontier. The "Gottingen EPO-stroke trial" represents the first effective use in man of a neuroprotective therapy in an acute brain disease while the experimental EPO therapy to combat cognitive decline in patients with schizophrenia will be introduced as an example of a neuroprotective strategy for a chronic brain disease.	Max Planck Inst Expt Med, Clin Neurosci Lab, D-37075 Gottingen, Germany; Univ Bremen, Dept Neuropsychol & Behav Neurobiol, D-2800 Bremen 33, Germany		Ehrenreich, H (corresponding author), Max Planck Inst Expt Med, Clin Neurosci Lab, Hermann Rein Str 3, D-37075 Gottingen, Germany.	ehrenreich@em.mpg.de	Siren, Anna-Leena/AAE-1374-2019; Herrmann, Manfred/H-3931-2011	Siren, Anna-Leena/0000-0002-2217-0081; Herrmann, Manfred/0000-0003-1872-8406; Ehrenreich, Hannelore/0000-0001-8371-5711			Agnello D, 2002, BRAIN RES, V952, P128, DOI 10.1016/S0006-8993(02)03239-0; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Aydin A, 2003, BRAIN DEV-JPN, V25, P494, DOI 10.1016/S0387-7604(03)00039-1; Bernaudin M, 2002, J CEREBR BLOOD F MET, V22, P393, DOI 10.1097/00004647-200204000-00003; Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007; Bohlius Julia F., 2002, Blood, V100, P3430; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Cai ZQ, 2003, CIRCULATION, V108, P79, DOI 10.1161/01.CIR.0000078635.89229.8A; Calvillo L, 2003, P NATL ACAD SCI USA, V100, P4802, DOI 10.1073/pnas.0630444100; Campana WM, 2001, FASEB J, V15, P1804, DOI 10.1096/fj.00-0857fje; CARLSSON A, 1988, NEUROPSYCHOPHARMACOL, V1, P179, DOI 10.1016/0893-133X(88)90012-7; Celik M, 2002, P NATL ACAD SCI USA, V99, P2258, DOI 10.1073/pnas.042693799; Chattopadhyay A, 2000, BIOCHEM PHARMACOL, V59, P419, DOI 10.1016/S0006-2952(99)00277-4; Chong ZZ, 2003, J NEUROSCI RES, V71, P659, DOI 10.1002/jnr.10528; De Keyser J, 1999, TRENDS NEUROSCI, V22, P535, DOI 10.1016/S0166-2236(99)01463-0; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Ehrenreich H, 2004, MOL PSYCHIATR, V9, P42, DOI 10.1038/sj.mp.4001442; Ehrenreich H, 2001, EUR ARCH PSY CLIN N, V251, P149, DOI 10.1007/s004060170034; Erbayraktar S, 2003, P NATL ACAD SCI USA, V100, P6741, DOI 10.1073/pnas.1031753100; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Genc S, 2002, NEUROSCI LETT, V321, P73, DOI 10.1016/S0304-3940(02)00041-1; Genc S, 2001, NEUROSCI LETT, V298, P139, DOI 10.1016/S0304-3940(00)01716-X; Grimm C, 2002, NAT MED, V8, P718, DOI 10.1038/nm723; Hacke W, 1998, LANCET, V352, P1245, DOI 10.1016/S0140-6736(98)08020-9; Hafner H, 2000, EUR ARCH PSY CLIN N, V250, P271, DOI 10.1007/s004060070001; Herrmann M, 2003, RESTOR NEUROL NEUROS, V21, P177; Jelkmann W., 2000, Current Pharmaceutical Biotechnology, V1, P11, DOI 10.2174/1389201003379068; Junk AK, 2002, P NATL ACAD SCI USA, V99, P10659, DOI 10.1073/pnas.152321399; Kawakami M, 2001, J BIOL CHEM, V276, P39469, DOI 10.1074/jbc.M105832200; Kilts CD, 2001, BIOL PSYCHIAT, V50, P845, DOI 10.1016/S0006-3223(01)01286-0; Knabe W, 2004, ANAT EMBRYOL, V207, P503, DOI 10.1007/s00429-003-0365-y; Koshimura K, 1999, J NEUROCHEM, V72, P2565, DOI 10.1046/j.1471-4159.1999.0722565.x; Kraepelin E., 1919, DEMENTIA PRAECOX PAR; Kremen WS, 2001, BIOL PSYCHIAT, V50, P453, DOI 10.1016/S0006-3223(01)01099-X; Kuhn HG, 2001, EUR ARCH PSY CLIN N, V251, P152, DOI 10.1007/s004060170035; Lewczuk P, 2000, NEUROREPORT, V11, P3485, DOI 10.1097/00001756-200011090-00017; Lewis DA, 2002, ANNU REV NEUROSCI, V25, P409, DOI 10.1146/annurev.neuro.25.112701.142754; Lieberman JA, 1999, BIOL PSYCHIAT, V46, P729, DOI 10.1016/S0006-3223(99)00147-X; Lipska BK, 2000, NEUROPSYCHOPHARMACOL, V23, P223, DOI 10.1016/S0893-133X(00)00137-8; Magavi SS, 2000, NATURE, V405, P951, DOI 10.1038/35016083; Malaspina D, 2001, AM J PSYCHIAT, V158, P440, DOI 10.1176/appi.ajp.158.3.440; Marenco S, 2000, DEV PSYCHOPATHOL, V12, P501, DOI 10.1017/S0954579400003138; Marti HH, 1996, EUR J NEUROSCI, V8, P666, DOI 10.1111/j.1460-9568.1996.tb01252.x; MASUDA S, 1993, J BIOL CHEM, V268, P11208; McGlashan TH, 2000, ARCH GEN PSYCHIAT, V57, P637, DOI 10.1001/archpsyc.57.7.637; Mielke R, 1998, ALZ DIS ASSOC DIS, V12, pS29; Morishita E, 1997, NEUROSCIENCE, V76, P105, DOI 10.1016/s0306-4522(96)00306-5; Nakano T, 1996, SCIENCE, V272, P722, DOI 10.1126/science.272.5262.722; Parsa CJ, 2003, J CLIN INVEST, V112, P999, DOI 10.1172/JCI200318200; Prass K, 2003, STROKE, V34, P1981, DOI 10.1161/01.STR.0000080381.76409.B2; Ruscher K, 2002, J NEUROSCI, V22, P10291, DOI 10.1523/jneurosci.22-23-10291.2002; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Sasaki R, 2001, NEWS PHYSIOL SCI, V16, P110; Shingo T, 2001, J NEUROSCI, V21, P9733, DOI 10.1523/JNEUROSCI.21-24-09733.2001; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Siren AL, 2001, EUR ARCH PSY CLIN N, V251, P179, DOI 10.1007/s004060170038; Siren AL, 2001, ACTA NEUROPATHOL, V101, P271, DOI 10.1007/s004010000297; Stuckmann I, 2003, DEV BIOL, V255, P334, DOI 10.1016/S0012-1606(02)00078-7; Thompson PM, 2001, P NATL ACAD SCI USA, V98, P11650, DOI 10.1073/pnas.201243998; Tramontano AF, 2003, BIOCHEM BIOPH RES CO, V308, P990, DOI 10.1016/S0006-291X(03)01503-1; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Villa P, 2003, J EXP MED, V198, P971, DOI 10.1084/jem.20021067; Wu H, 1999, DEVELOPMENT, V126, P3597; Yu XB, 2002, DEVELOPMENT, V129, P505	65	102	110	0	4	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0885-7490	1573-7365		METAB BRAIN DIS	Metab. Brain Dis.	DEC	2004	19	3-4					195	206		10.1023/B:MEBR.0000043969.96895.3c			12	Endocrinology & Metabolism; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Endocrinology & Metabolism; Neurosciences & Neurology	860EO	WOS:000224325500005	15554415				2022-02-06	
J	Yune, TY; Kim, SJ; Lee, SM; Lee, YK; Oh, YJ; Kim, YC; Markelonis, GJ; Oh, TH				Yune, TY; Kim, SJ; Lee, SM; Lee, YK; Oh, YJ; Kim, YC; Markelonis, GJ; Oh, TH			Systemic administration of 17 beta-estradiol reduces apoptotic cell death and improves functional recovery following traumatic spinal cord injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						apoptosis; BB score; bcl-2; bcl-x; caspase-3; DNA laddering; estrogen; functional recovery; lesion area; neuroprotection; spinal cord injury; TUNEL	ESTROGEN REPLACEMENT THERAPY; BETA-ESTRADIOL PROTECTS; INDUCED NEURONAL DEATH; NECROSIS-FACTOR-ALPHA; CEREBRAL-ISCHEMIA; BCL-2 EXPRESSION; GLOBAL-ISCHEMIA; MOUSE MODEL; OXIDATIVE STRESS; GLIAL APOPTOSIS	Recent evidence indicates that estrogen exerts neuroprotective effects in both brain injury and neurodegenerative diseases. We examined the protective effect of estrogen on functional recovery after spinal cord injury (SCI) in rats. 17beta-estradiol (3, 100, or 300 mug/kg) was administered intravenously 1-2 h prior to injury (pre-treatment), and animals were then subjected to a mild, weight-drop spinal cord contusion injury. Estradiol treatment significantly improved hind limb motor function as determined by the Basso-Beattie-Bresnahan (BBB) locomotor open field behavioral rating test. Fifteen to 30 days after SCI, BBB scores were significantly higher in estradiol-treated (100 mug/kg) rats when compared to vehicle-treated rats. Morphological analysis showed that lesion sizes increased progressively in either vehicle-treated or 17beta-estradiol-treated spinal cords. However, in response to treatment with 17beta-estradiol, the lesion size was significantly reduced 18-28 days after SCI when compared to vehicle-treated controls. Terminal deoxynucleotidyl transferase-mediated UTP nick-end labeling (TUNEL) staining and DNA gel electrophoresis revealed that apoptotic cell death peaked 24-48 h after injury. Also, SCI induced a marked increase in activated caspase-3 in the spinal cord, evident by 4 h after injury. However, administration of 17beta-estradiol significantly reduced the SCI-induced increase in apoptotic cell death and caspase-3 activity after SCI. Furthermore, 17beta-estradiol significantly increased expression of the anti-apoptotic genes, bcl-2 and bcl-x, after SCI while expression of the pro-apoptotic genes, bad and bax, was not affected by drug treatment. Finally, intravenous administration of 17beta-estradiol (100 mug/kg) immediately after injury (post-treatment) also significantly improved hind limb motor function 19-30 days after SCI compared to vehicle-treated controls. These data suggest that after SCI, 17beta-estradiol treatment improved functional recovery in the injured rat, in part, by reducing apoptotic cell death.	Univ Maryland, Sch Med, Dept Anat & Neurobiol, Baltimore, MD 21201 USA; Korea Inst Sci & Technol, Ctr Biomed Res, Seoul 130650, South Korea; Yonsei Univ, Dept Biol, Seoul 120749, South Korea; Seoul Natl Univ, Coll Pharm, Seoul, South Korea		Oh, TH (corresponding author), Univ Maryland, Sch Med, Dept Anat & Neurobiol, 685 W Baltimore St, Baltimore, MD 21201 USA.	toh@umaryland.edu					Alkayed NJ, 2001, J NEUROSCI, V21, P7543, DOI 10.1523/JNEUROSCI.21-19-07543.2001; Alkayed NJ, 1998, STROKE, V29, P159, DOI 10.1161/01.STR.29.1.159; Antonawich FJ, 1999, EXP NEUROL, V156, P130, DOI 10.1006/exnr.1998.7004; Azcoitia I, 1998, NEUROREPORT, V9, P3075, DOI 10.1097/00001756-199809140-00029; BALENTINE JD, 1978, LAB INVEST, V39, P236; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Basso DM, 1996, J NEUROTRAUM, V13, P343, DOI 10.1089/neu.1996.13.343; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; Beattie MS, 1997, EXP NEUROL, V148, P453, DOI 10.1006/exnr.1997.6695; Behl C, 1997, MOL PHARMACOL, V51, P535, DOI 10.1124/mol.51.4.535; Callier S, 2000, SYNAPSE, V37, P245, DOI 10.1002/1098-2396(20000915)37:4<245::AID-SYN1>3.0.CO;2-5; Casha S, 2001, NEUROSCIENCE, V103, P203, DOI 10.1016/S0306-4522(00)00538-8; Chen J, 2000, J CEREBR BLOOD F MET, V20, P1033, DOI 10.1097/00004647-200007000-00002; CHEN J, 1995, NEUROREPORT, V6, P394, DOI 10.1097/00001756-199501000-00040; Chen J, 1997, J CEREBR BLOOD F MET, V17, P2, DOI 10.1097/00004647-199701000-00002; CHEN J, 1998, J CEREB BLOOD FLOW M, V18, P931; Citron BA, 2000, EXP NEUROL, V166, P213, DOI 10.1006/exnr.2000.7523; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Culmsee C, 1999, J CEREBR BLOOD F MET, V19, P1263, DOI 10.1097/00004647-199911000-00011; Dare E, 2000, J NEUROSCI RES, V62, P557, DOI 10.1002/1097-4547(20001115)62:4<557::AID-JNR10>3.0.CO;2-9; Disshon KA, 1997, BRAIN RES, V764, P9, DOI 10.1016/S0006-8993(97)00418-6; Dluzen DE, 2000, J NEUROCYTOL, V29, P387, DOI 10.1023/A:1007117424491; Du S, 1999, EXP NEUROL, V157, P96, DOI 10.1006/exnr.1999.7041; Dubal DB, 1999, J NEUROSCI, V19, P6385; Dubal DB, 1998, J CEREBR BLOOD F MET, V18, P1253, DOI 10.1097/00004647-199811000-00012; Dubal DB, 2001, ENDOCRINOLOGY, V142, P43, DOI 10.1210/en.142.1.43; Emery E, 1998, J NEUROSURG, V89, P911, DOI 10.3171/jns.1998.89.6.0911; Friedlander RM, 1998, CELL DEATH DIFFER, V5, P823, DOI 10.1038/sj.cdd.4400433; Gail MH, 1999, J NATL CANCER I, V91, P1829, DOI 10.1093/jnci/91.21.1829; Garcia-Segura LM, 2001, PROG NEUROBIOL, V63, P29, DOI 10.1016/S0301-0082(00)00025-3; Garcia-Segura LM, 1998, NEUROREPORT, V9, P593, DOI 10.1097/00001756-199803090-00006; Goodman SB, 1998, BIOL REPROD, V59, P820, DOI 10.1095/biolreprod59.4.820; Goodman YD, 1996, J NEUROCHEM, V66, P1836; Greene K, 1997, WOMEN POLIT, V17, P17, DOI 10.1300/J014v17n03_02; GREENLUND LJS, 1995, NEURON, V15, P649, DOI 10.1016/0896-6273(95)90153-1; Gridley KE, 1998, MOL PHARMACOL, V54, P874, DOI 10.1124/mol.54.5.874; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; HALL ED, 1991, J CEREBR BLOOD F MET, V11, P292, DOI 10.1038/jcbfm.1991.61; Hata R, 1999, METAB BRAIN DIS, V14, P117, DOI 10.1023/A:1020709814456; He Z, 2002, J NEUROL SCI, V193, P79, DOI 10.1016/S0022-510X(01)00648-7; Henderson VW, 1996, PSYCHONEUROENDOCRINO, V21, P421, DOI 10.1016/0306-4530(95)00060-7; Honda K, 2000, J NEUROSCI RES, V60, P321, DOI 10.1002/(SICI)1097-4547(20000501)60:3<321::AID-JNR6>3.3.CO;2-K; Honkaniemi J, 1996, MOL BRAIN RES, V42, P79, DOI 10.1016/S0169-328X(96)00121-0; Jover T, 2002, J NEUROSCI, V22, P2115, DOI 10.1523/JNEUROSCI.22-06-02115.2002; Kawas C, 1997, NEUROLOGY, V48, P1517, DOI 10.1212/WNL.48.6.1517; Kitagawa K, 1998, STROKE, V29, P2616, DOI 10.1161/01.STR.29.12.2616; LEE SM, 2004, IN PRESS J NEUROTRAU; Lee YB, 2000, EXP NEUROL, V166, P190, DOI 10.1006/exnr.2000.7494; Li GL, 1996, J NEUROPATH EXP NEUR, V55, P280, DOI 10.1097/00005072-199603000-00003; Li M, 2000, NEUROSCIENCE, V99, P333, DOI 10.1016/S0306-4522(00)00173-1; Li YQ, 2000, RADIAT RES, V154, P268, DOI 10.1667/0033-7587(2000)154[0268:RIAITN]2.0.CO;2; LINNIK MD, 1995, STROKE, V26, P1670, DOI 10.1161/01.STR.26.9.1670; Liu XZ, 1997, J NEUROSCI, V17, P5395; Lu AG, 2002, J CEREBR BLOOD F MET, V22, P183, DOI 10.1097/00004647-200202000-00006; MacManus JP, 1997, J CEREBR BLOOD F MET, V17, P815, DOI 10.1038/aj.jcbfm.9590266; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; Matsushita K, 2000, J NEUROSCI, V20, P6879, DOI 10.1523/JNEUROSCI.20-18-06879.2000; Merry DE, 1997, ANNU REV NEUROSCI, V20, P245, DOI 10.1146/annurev.neuro.20.1.245; Nesic O, 2001, J NEUROTRAUM, V18, P947, DOI 10.1089/089771501750451857; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; Ona VO, 1999, NATURE, V399, P263, DOI 10.1038/20446; PAGANINIHILL A, 1995, PROG CARDIOVASC DIS, V38, P223, DOI 10.1016/S0033-0620(95)80014-X; Pelligrino DA, 1998, NEUROREPORT, V9, P3285, DOI 10.1097/00001756-199810050-00026; Pike CJ, 1999, J NEUROCHEM, V72, P1552, DOI 10.1046/j.1471-4159.1999.721552.x; Regan RF, 1997, BRAIN RES, V764, P133, DOI 10.1016/S0006-8993(97)00437-X; Rusa R, 1999, STROKE, V30, P1665, DOI 10.1161/01.STR.30.8.1665; SABOURIN JC, 1994, INT J CANCER, V59, P1, DOI 10.1002/ijc.2910590102; Sawada H, 2000, FASEB J, V14, P1202, DOI 10.1096/fasebj.14.9.1202; Sawada H, 1998, J NEUROSCI RES, V54, P707, DOI 10.1002/(SICI)1097-4547(19981201)54:5<707::AID-JNR16>3.0.CO;2-T; Schielke GP, 1998, J CEREBR BLOOD F MET, V18, P180, DOI 10.1097/00004647-199802000-00009; Schmidt R, 1996, J AM GERIATR SOC, V44, P1307, DOI 10.1111/j.1532-5415.1996.tb01400.x; SELINA CC, 1989, BRAIN RES, V482, P271; Shi J, 1998, BRAIN RES, V810, P87, DOI 10.1016/S0006-8993(98)00888-9; SHIMAZAKI K, 1994, NEUROSCI RES, V20, P95, DOI 10.1016/0168-0102(94)90026-4; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.0.CO;2-Y; Simpkins JW, 1997, J NEUROSURG, V87, P724, DOI 10.3171/jns.1997.87.5.0724; Singer CA, 1999, J NEUROSCI, V19, P2455; Singer CA, 1998, NEUROREPORT, V9, P2565, DOI 10.1097/00001756-199808030-00025; Singer CA, 1996, NEUROSCI LETT, V212, P13, DOI 10.1016/0304-3940(96)12760-9; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; Springer JE, 2000, J NEUROSCI, V20, P7246; Sudo S, 1997, NEUROSCI RES, V29, P345, DOI 10.1016/S0168-0102(97)00106-5; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; Thompson KE, 2002, ENDOCRINOLOGY, V143, P1058, DOI 10.1210/en.143.3.1058; Toung TJK, 1998, STROKE, V29, P1666, DOI 10.1161/01.STR.29.8.1666; Vedder H, 1999, J NEUROCHEM, V72, P2531, DOI 10.1046/j.1471-4159.1999.0722531.x; Weaver CE, 1997, BRAIN RES, V761, P338, DOI 10.1016/S0006-8993(97)00449-6; Yakovlev AG, 2001, MOL NEUROBIOL, V24, P131; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yang SH, 2000, STROKE, V31, P745, DOI 10.1161/01.STR.31.3.745; Yong C, 1998, J NEUROTRAUM, V15, P459, DOI 10.1089/neu.1998.15.459; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Yune TY, 2003, J NEUROTRAUM, V20, P207, DOI 10.1089/08977150360547116; Zaulyanov LL, 1999, CELL MOL NEUROBIOL, V19, P705, DOI 10.1023/A:1006948921855; Zhang YQ, 1998, BRAIN RES, V784, P321, DOI 10.1016/S0006-8993(97)00502-7	96	102	117	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2004	21	3					293	306		10.1089/089771504322972086			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	806CI	WOS:000220411600007	15115604				2022-02-06	
J	Villarreal, PM; Monje, F; Junquera, LM; Mateo, J; Morillo, AJ; Gonzalez, C				Villarreal, PM; Monje, F; Junquera, LM; Mateo, J; Morillo, AJ; Gonzalez, C			Mandibular condyle fractures: Determinants of treatment and outcome	JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY			English	Article							OPEN REDUCTION; FOLLOW-UP; CHILDREN	Purpose: The objective of this study was to analyze the principal variables that determine the choice of the method of treatment and the outcome in condylar fractures. Materials and Methods: We conducted a retrospective analysis of 104 mandibular condyle fractures to analyze and determine the relation between the principal clinical variables and the postoperative results. All patients underwent a clinic-radiologic investigation focusing on fracture remodeling, evolution, dental occlusion, and symmetry of the mandible. We analyzed the influence of the preoperative clinical variables (level of fracture, treatment, postoperative physical therapy, displacement and dislocation, comminution, loss of ramus height, patient age, gender, etiology, occlusion, status of dentition, and presence of facial and mandibular fractures) over the postoperative results and outcome. Results: The principal factors that determined the treatment decision were the level of the fracture and the degree of displacement. The level of the fracture influenced the degree of preoperative coronal and sagittal displacement (neck fractures had greater medial and anterior displacement than head and subcondylar fractures) and the treatment applied. The functional improvement obtained by open methods was greater than that obtained by closed treatment. Open treatment increased the incidence of postoperative condylar deformities and mandibular asymmetry. Conclusion: The variables that influenced the method of treatment and predicted the prognosis are the level of fracture, degree and direction of displacement of the fractured segments, age, medical status of the patient, concomitant injuries, and status of dentition. (C) 2004 American Association of Oral and Maxillofacial Surgeons.	Hosp Cabuenes, Dept Oral & Maxillofacial Surg, Gijon, Spain; Hosp Infanta Cristina, Dept Oral & Maxillofacial Surg, Badajoz, Spain; Hosp Cent Asturias, Dept Oral & Maxillofacial Surg, Oviedo, Spain		Villarreal, PM (corresponding author), C Monte Auseva 12 4 B, Oviedo 33012, Spain.	pedrovillarreal@eresmas.com					Bos RRM, 1999, BRIT J ORAL MAX SURG, V37, P87; BUCHBINDER D, 1993, J ORAL MAXIL SURG, V51, P1174, DOI 10.1016/S0278-2391(10)80285-X; Choi BH, 1997, INT J ORAL MAX SURG, V26, P344, DOI 10.1016/S0901-5027(97)80794-1; Choi BH, 2001, J ORAL MAXIL SURG, V59, P734, DOI 10.1053/joms.2001.24283; DAHLSTROM L, 1989, INT J ORAL MAX SURG, V18, P18, DOI 10.1016/S0901-5027(89)80009-8; Ellis E, 1999, J ORAL MAXIL SURG, V57, P1307, DOI 10.1016/S0278-2391(99)90867-4; Ellis E, 2000, J ORAL MAXIL SURG, V58, P27, DOI 10.1016/S0278-2391(00)80010-5; HAYWARD JR, 1993, J ORAL MAXIL SURG, V51, P57, DOI 10.1016/S0278-2391(10)80391-X; HOOPES JE, 1970, PLAST RECONSTR SURG, V46, P357, DOI 10.1097/00006534-197010000-00005; OLSON RA, 1982, J ORAL MAXIL SURG, V40, P23, DOI 10.1016/S0278-2391(82)80011-6; RAVEH J, 1989, J ORAL MAXIL SURG, V47, P120, DOI 10.1016/S0278-2391(89)80100-4; SOREL B, 1998, ORAL MAXILLOFAC SURG, V10, P541; SPIESSL B, 1972, RECONSTRUCTION SURGERY AND TRAUMATOLOGY, V13, P124; TAKENOSHITA Y, 1990, J ORAL MAXIL SURG, V48, P1191, DOI 10.1016/0278-2391(90)90535-A; Thoren H, 2001, J ORAL MAXIL SURG, V59, P768, DOI 10.1053/joms.2001.23369; XIEN Z, 1991, J ORAL MAXIL SURG, V49, P1181, DOI 10.1016/0278-2391(91)90414-H; YAMAOKA M, 1994, BRIT J ORAL MAX SURG, V32, P77, DOI 10.1016/0266-4356(94)90131-7; ZIDE MF, 1983, J ORAL MAXIL SURG, V41, P89, DOI 10.1016/0278-2391(83)90214-8	18	102	109	1	11	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-2391	1531-5053		J ORAL MAXIL SURG	J. Oral Maxillofac. Surg.	FEB	2004	62	2					155	163		10.1016/j.joms.2003.08.010			9	Dentistry, Oral Surgery & Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Dentistry, Oral Surgery & Medicine	768MT	WOS:000188547300006	14762747				2022-02-06	
J	Bedard, M; Felteau, M; Mazmanian, D; Fedyk, K; Klein, R; Richardson, J; Parkinson, W; Minthorn-Biggs, MB				Bedard, M; Felteau, M; Mazmanian, D; Fedyk, K; Klein, R; Richardson, J; Parkinson, W; Minthorn-Biggs, MB			Pilot evaluation of a mindfulness-based intervention to improve quality of life among individuals who sustained traumatic brain injuries	DISABILITY AND REHABILITATION			English	Article							STRESS REDUCTION INTERVENTION; BECK DEPRESSION INVENTORY; CLOSED-HEAD-INJURY; PEER SUPPORT; CHRONIC PAIN; COMMUNITY INTEGRATION; ANXIETY DISORDERS; FAMILY MEMBERS; FOLLOW-UP; REHABILITATION	Primary objective: To examine the potential efficacy of a mindfulness-based stress reduction approach to improve quality of life in individuals who have suffered traumatic brain injuries. Research design: Pre-post design with drop-outs as controls. Methods and procedures: We recruited individuals with mild to moderate brain injuries, at least 1 year post-injury. We measured their quality of life, psychological status, and function. Results of 10 participants who completed the programme were compared to three drop-outs with complete data. Experimental intervention: The intervention was delivered in 12-weekly group sessions. The intervention relied on insight meditation, breathing exercises, guided visualization, and group discussion. We aimed to encourage a new way of thinking about disability and life to bring a sense of acceptance, allowing participants to move beyond limiting beliefs. Main outcomes and results: The treatment group mean quality of life (SF-36) improved by 15.40 (SD = 9.08) compared to - 1.67 (SD = 16.65; p = 0.036) for controls. Improvements on the cognitive-affective domain of the Beck Depression Inventory II (BDI-II) were reported (p = 0.029), while changes in the overall BDI-II (p = 0.059) and the Positive Symptom Distress Inventory of the SCL-90R (p = 0.054) approached statistical significance. Conclusions: The intervention was simple, and improved quality of life after other treatment avenues for these participants were exhausted.	Lakehead Univ, Dept Psychol, Thunder Bay, ON P7B 5E1, Canada; Lakehead Psychiat Hosp, Thunder Bay, ON, Canada; Lakehead Univ, Canadian Parapleg Assoc, Thunder Bay, ON P7B 5E1, Canada; McMaster Univ, Hamilton, ON L8S 4L8, Canada		Bedard, M (corresponding author), Lakehead Univ, Dept Psychol, 955 Oliver Rd, Thunder Bay, ON P7B 5E1, Canada.			Richardson, Julie Anne/0000-0001-6356-0492			Astin JA, 1997, PSYCHOTHER PSYCHOSOM, V66, P97, DOI 10.1159/000289116; Beck A., 1996, BECK DEPRESSION INVE; BECK AT, 1988, BECK SCALE SUICIDAL; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; BENYISHAY Y, 1993, ARCH PHYS MED REHAB, V74, P204; Brazil K, 1992, Int J Rehabil Res, V15, P93, DOI 10.1097/00004356-199206000-00001; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; CONZEN M, 1992, Brain Injury, V6, P45, DOI 10.3109/02699059209008121; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Davidson L, 1999, CLIN PSYCHOL-SCI PR, V6, P165, DOI 10.1093/clipsy/6.2.165; Delmonico RL, 1998, J HEAD TRAUMA REHAB, V13, P10, DOI 10.1097/00001199-199812000-00004; Derogatis L. R., 1994, SCL 90 R ADM SCORING, VThird; Dombovy ML, 1997, BRAIN INJURY, V11, P305, DOI 10.1080/026990597123467; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; Dunn J, 1999, J COMMUNITY APPL SOC, V9, P13, DOI 10.1002/(SICI)1099-1298(199901/02)9:1<13::AID-CASP488>3.0.CO;2-F; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; Frosch S, 1997, BRAIN INJURY, V11, P891; Gillen R, 1998, J HEAD TRAUMA REHAB, V13, P31, DOI 10.1097/00001199-199806000-00004; GODFREY HPD, 1993, NEW ZEAL MED J, V106, P301; Gosling J, 1999, BRAIN INJURY, V13, P785; Green A, 2001, BRAIN INJURY, V15, P1021, DOI 10.1080/02699050110074187; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; Harris JKJ, 2001, BRAIN INJURY, V15, P223; Hopman WM, 2000, CAN MED ASSOC J, V163, P265; Kabat-Zinn J, 1998, PSYCHOSOM MED, V60, P625, DOI 10.1097/00006842-199809000-00020; KABATZINN J, 1982, GEN HOSP PSYCHIAT, V4, P33, DOI 10.1016/0163-8343(82)90026-3; KABATZINN J, 1985, J BEHAV MED, V8, P163, DOI 10.1007/BF00845519; KABATZINN J, 1992, AM J PSYCHIAT, V149, P936; Kolb D. A., 1984, EXPT LEARNING EXPERI; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; Lahz S, 1996, ARCH PHYS MED REHAB, V77, P889, DOI 10.1016/S0003-9993(96)90275-0; Leon-Carrion J, 1998, INT J NEUROSCI, V94, P75, DOI 10.3109/00207459808986440; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LINN RT, 1994, BRAIN INJURY, V8, P135, DOI 10.3109/02699059409150965; MASSION AO, 1995, MED HYPOTHESES, V44, P39, DOI 10.1016/0306-9877(95)90299-6; Mazaux JM, 1998, DISABIL REHABIL, V20, P435, DOI 10.3109/09638289809166108; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; McCleary C, 1998, J CLIN EXP NEUROPSYC, V20, P270, DOI 10.1076/jcen.20.2.270.1172; McColl MA, 1998, BRAIN INJURY, V12, P15, DOI 10.1080/026990598122827; McGuire LM, 1998, BRAIN INJURY, V12, P207, DOI 10.1080/026990598122683; MILLER JJ, 1995, GEN HOSP PSYCHIAT, V17, P192, DOI 10.1016/0163-8343(95)00025-M; MOORE AD, 1995, BRAIN INJURY, V9, P109, DOI 10.3109/02699059509008185; Nochi M, 1998, SOC SCI MED, V46, P869, DOI 10.1016/S0277-9536(97)00211-6; Ommaya AK, 1996, J TRAUMA, V41, P972, DOI 10.1097/00005373-199612000-00005; PESSAR LF, 1993, BRAIN INJURY, V7, P231, DOI 10.3109/02699059309029675; PONSFORD J, 1995, TRAUMATIC BRAIN INJU; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; Prigatano GP, 1999, ARCH PHYS MED REHAB, V80, P77, DOI 10.1016/S0003-9993(99)90311-8; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Sander AM, 2001, J HEAD TRAUMA REHAB, V16, P356, DOI 10.1097/00001199-200108000-00006; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; Semlyen JK, 1998, ARCH PHYS MED REHAB, V79, P678, DOI 10.1016/S0003-9993(98)90044-2; Sinnakaruppan I, 2001, BRAIN INJURY, V15, P653; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; Thurman DJ, 1996, WESTERN J MED, V165, P192; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; vanBalen HGG, 1996, DISABIL REHABIL, V18, P181, DOI 10.3109/09638289609166298; Vogenthaler D R, 1989, Brain Inj, V3, P355, DOI 10.3109/02699058909004560; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; WALLSTON KA, 1978, HEALTH EDUC QUART, V6, P160, DOI 10.1177/109019817800600107; Ware JE, 2001, SF 36 PHYSICAL MENTA; Watanabe Y, 2001, DISABIL REHABIL, V23, P370; Whisman MA, 2000, J CLIN PSYCHOL, V56, P545, DOI 10.1002/(SICI)1097-4679(200004)56:4<545::AID-JCLP7>3.0.CO;2-U; Wilson BA, 1998, CURR OPIN NEUROBIOL, V8, P281, DOI 10.1016/S0959-4388(98)80152-9; Wilson ME, 1999, PSYCHIATR REHABIL J, V22, P239, DOI 10.1037/h0095238; Woischneck D, 1997, NEUROL RES, V19, P305, DOI 10.1080/01616412.1997.11740817	73	102	102	0	42	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1464-5165			DISABIL REHABIL	Disabil. Rehabil.	JUL 8	2003	25	13					722	731		10.1080/0963828031000090489			10	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	695YH	WOS:000183857600004	12791557				2022-02-06	
J	Brehaut, JC; Miller, A; Raina, P; McGrail, KM				Brehaut, JC; Miller, A; Raina, P; McGrail, KM			Childhood behavior disorders and injuries among children and youth: A population-based study	PEDIATRICS			English	Article						methylphenidate; attention-deficit/hyperactivity disorder; behavior disorders; injury; children; database analysis	DEFICIT-HYPERACTIVITY DISORDER; ATTENTION-DEFICIT/HYPERACTIVITY-DISORDER; SCHOOL-AGE-CHILDREN; YOUNG-ADULTS; FOLLOW-UP; METHYLPHENIDATE; PRESCRIPTION; ADOLESCENTS; MEDICATION; DATABASE	Context. While an association between pediatric behavioral disorders and injuries is generally acknowledged, no studies have measured the risk for injury in the context of a large, population-based study that is free of cohort biases. Objectives. To examine the association between childhood behavior disorders ([CBDs] as indicated by prescription for methylphenidate [MPH]) and a variety of injury outcomes, and to evaluate the risk for injury among these children after controlling for known demographic correlates. Design. Population-based database analysis of all children in British Columbia (BC) under the age of 19 as of December 31, 1996; comparison of those who had been prescribed MPH and therefore placed in the CBD group (n = 16 806) and those who were not (n = 1 010 067). Demographic information collected was as follows: age, sex, measures of socioeconomic status, and region of residence. Outcome Measures. Common types of childhood injury in BC: International Classification of Diseases, Ninth Revision N-codes (fractures, open wounds, poisoning/ toxic effect, concussion, intracranial, burns) and E-codes (falls, postoperative complications, motor vehicle accidents, struck by object, adverse effects of drugs, suffocation, drowning). Data Source. BC Linked Health Data Set and the BC Triplicate Prescription Program. Results. After controlling for known demographic correlates, odds for injury was greater among those treated with MPH and presumed to have a behavioral disorder, when injury was characterized either by type (1.67; 99% confidence interval: 1.54-1.81) or cause (1.52; 99% confidence interval: 1.40-1.66) of injury. This increased risk extended to unexpected categories of injury such as postoperative complications and adverse effects of drugs. Conclusions. Children with CBDs have >1.5 times the odds of sustaining injuries of a variety of types from a variety of causes, even after controlling for known demographic correlates, than those without behavioral disorders. The risks for these children extend beyond those that might be directly associated with impulsivity and overactivity. Injury prevention strategies aimed at this group of children and youth would be beneficial. Policy-makers should account for increased risk of a wide variety of injuries in this group of children and youth.	Ottawa Hosp, Clin Epidemiol Unit, Ottawa Hlth Res Inst, Ottawa, ON K1Y 4E9, Canada; Childrens & Womens Hlth Ctr British Columbia, Ctr Community Hlth & Hlth Evaluat Res, Vancouver, BC, Canada; Univ British Columbia, Dept Pediat, Vancouver, BC V6T 1W5, Canada; Univ British Columbia, Dept Hlth Care & Epidemiol, Vancouver, BC V6T 1W5, Canada; British Columbia Injury Res & Prevent Unit, Vancouver, BC, Canada; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; Univ British Columbia, Ctr Hlth Serv & Policy Res, Vancouver, BC V5Z 1M9, Canada		Brehaut, JC (corresponding author), Ottawa Hosp, Clin Epidemiol Unit, Ottawa Hlth Res Inst, Civ Campus,F6-1053 Carling Ave, Ottawa, ON K1Y 4E9, Canada.		Miller, Anton/U-5719-2018	Miller, Anton/0000-0002-6509-2589			American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; BARKLEY RA, 1993, PEDIATRICS, V92, P212; BARKLEY RA, 1990, J AM ACAD CHILD PSY, V29, P546, DOI 10.1097/00004583-199007000-00007; Barkley RA, 1996, PEDIATRICS, V98, P1089; Barkley RA, 2001, EC NEUROSCI, V3, P64; BIJUR P, 1988, AM J DIS CHILD, V142, P1307, DOI 10.1001/archpedi.1988.02150120061041; Brownell MD, 2001, CAN J PSYCHIAT, V46, P264, DOI 10.1177/070674370104600307; Bussing R, 1996, ARCH PEDIAT ADOL MED, V150, P50, DOI 10.1001/archpedi.1996.02170260054009; Chamberlayne R, 1998, CAN J PUBLIC HEALTH, V89, P270, DOI 10.1007/BF03403934; Christoffel KK, 1996, PEDIATRICS, V97, P33; Cox DJ, 2000, J NERV MENT DIS, V188, P230, DOI 10.1097/00005053-200004000-00006; DAVIDSON LL, 1987, J DEV BEHAV PEDIATR, V8, P335; DiScala C, 1998, PEDIATRICS, V102, P1415, DOI 10.1542/peds.102.6.1415; Dulcan M, 1997, J AM ACAD CHILD PSY, V36, pS85, DOI 10.1097/00004583-199710001-00007; FARMER JE, 1995, HEALTH PSYCHOL, V14, P325, DOI 10.1037/0278-6133.14.4.325; HALPERIN JM, 1995, J CHILD PSYCHOL PSYC, V36, P1199, DOI 10.1111/j.1469-7610.1995.tb01365.x; *HLTH CAN, 1999, SURV ATT DEF HYP DIS; Hoagwood K, 2000, J AM ACAD CHILD PSY, V39, P198, DOI 10.1097/00004583-200002000-00020; HUSBAND P, 1972, ARCH DIS CHILD, V47, P396, DOI 10.1136/adc.47.253.396; Jolly B T, 1998, Ann Emerg Med, V32, P267; Kohen D E, 2000, Inj Prev, V6, P223, DOI 10.1136/ip.6.3.223; Kozyrskyj AL, 1998, ANN PHARMACOTHER, V32, P1152, DOI 10.1345/aph.18117; KRALL V, 1953, J ABNORM SOC PSYCH, V48, P99, DOI 10.1037/h0054392; KWASMAN A, 1995, ARCH PEDIAT ADOL MED, V149, P1211, DOI 10.1001/archpedi.1995.02170240029004; LeFever GB, 1999, AM J PUBLIC HEALTH, V89, P1359, DOI 10.2105/AJPH.89.9.1359; Leibson CL, 2001, JAMA-J AM MED ASSOC, V285, P60, DOI 10.1001/jama.285.1.60; MANHEIMER DI, 1967, CHILD DEV, V38, P491, DOI 10.1111/j.1467-8624.1967.tb04358.x; MEYER RJ, 1963, J PEDIATR, V71, P95; Miller AR, 2001, CAN MED ASSOC J, V165, P1489; Ng E, 1993, Health Rep, V5, P179; RAPPLEY MD, 1995, ARCH PEDIAT ADOL MED, V149, P675, DOI 10.1001/archpedi.1995.02170190085015; Robison LM, 1999, CLIN PEDIATR, V38, P209, DOI 10.1177/000992289903800402; RUEL JM, 1992, CAN J PSYCHIAT, V37, P570, DOI 10.1177/070674379203700809; Safer D J, 2000, Ann Clin Psychiatry, V12, P55, DOI 10.3109/10401230009147088; SAFER DJ, 1988, JAMA-J AM MED ASSOC, V260, P2256, DOI 10.1001/jama.260.15.2256; SHAPIRO ED, 1989, INFECT CONT HOSP EP, V10, P167, DOI 10.2307/30144323; SOUBHI H, 1999, UNINTENTIONAL INJURI; SZATMARI P, 1989, J CHILD PSYCHOL PSYC, V30, P205, DOI 10.1111/j.1469-7610.1989.tb00235.x; TAMBLYN R, 1995, J CLIN EPIDEMIOL, V48, P999, DOI 10.1016/0895-4356(94)00234-H; TSUANG MT, 1985, AM J PSYCHIAT, V142, P538; WEISS G, 1979, ARCH GEN PSYCHIAT, V36, P675; *WHO, 1985, INT CLASS DIS 9 REV; Zito JM, 1999, ARCH PEDIAT ADOL MED, V153, P1257, DOI 10.1001/archpedi.153.12.1257	43	102	104	0	9	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	FEB	2003	111	2					262	269		10.1542/peds.111.2.262			8	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Pediatrics	640VR	WOS:000180709100022	12563049				2022-02-06	
J	Stocchetti, N; Rossi, S; Zanier, ER; Colombo, A; Beretta, L; Citerio, G				Stocchetti, N; Rossi, S; Zanier, ER; Colombo, A; Beretta, L; Citerio, G			Pyrexia in head-injured patients admitted to intensive care	INTENSIVE CARE MEDICINE			English	Article						antipyretic therapy; brain injury; cerebral perfusion pressure; Pyrexia; intracranial pressure	TRAUMATIC BRAIN INJURY; ACUTE CEREBRAL-DAMAGE; INTRACRANIAL HYPERTENSION; MODERATE HYPOTHERMIA; CORE TEMPERATURE; BODY-TEMPERATURE; MILD HYPOTHERMIA; HYPERTHERMIA; FEVER; ISCHEMIA	Objectives: (a) To quantify the occurrence of pyrexia during the first week after head injury; (b) to elucidate the relationships between pyrexia and neurological severity, length of stay in the ICU, intracranial hypertension, and cerebral perfusion pressure (CPP); and (c) to describe the effects of antipyretic. therapy on temperature, intracranial pressure (ICP) and CPP. Design and setting: Multicenter retrospective observational study in three ICUs in the Milan area. Patients: 110 patients with traumatic brain injury. Measurements and results: Eighty patients suffered pyrexia, defined as an external temperature higher than 38degreesC or internal temperature higher than 38.4degreesC. Occurrence and duration of pyrexia were associated with the degree of neurological impairment and with prolonged ICU stay. In patients with normal perimesencephalic cisterns the episodes of in-creased ICP were more frequent in febrile cases. Various antipyretic therapies were used in 66 patients. Pharmacological treatment was slightly effective (mean temperature reduction 0.58 +/- 0.7degreesC) but caused a significant drop in CPP (6.5 +/- 12.5 mmHg). Conclusions: Pyrexia is extremely frequent in the acute phase after head injury. Its incidence is higher in more severe cases and is correlated with a longer ICU stay. It may affect ICP, but its contribution is difficult to assess when other major causes of increased intracranial volume are present. Antipyretic therapy is poorly effective for controlling body temperature and may be deleterious for CPP.	Osped Maggiore, Policlin IRCCS, I-3520122 Milan, Italy; Neurorianimaz Osped S Raffaele, Milan, Italy; Terapia Intens Osped S Gerardo, Monza, Italy		Stocchetti, N (corresponding author), Osped Maggiore, Policlin IRCCS, Via S Sforza, I-3520122 Milan, Italy.		Zanier, Elisa/AAA-8095-2020; Stocchetti, Nino/O-7444-2017; Citerio, Giuseppe/B-1839-2015	Zanier, Elisa/0000-0002-3011-8718; Stocchetti, Nino/0000-0003-3250-6834; Citerio, Giuseppe/0000-0002-5374-3161; Rossi, Sandra/0000-0002-9963-8121			Albrecht RF, 1998, MAYO CLIN PROC, V73, P629; BUSTO R, 1989, STROKE, V20, P1113, DOI 10.1161/01.STR.20.8.1113; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; Castillo J, 1998, STROKE, V29, P2455, DOI 10.1161/01.STR.29.12.2455; Circiumaru B, 1999, INTENS CARE MED, V25, P668, DOI 10.1007/s001340050928; CLASEN RA, 1974, J NEUROSURG, V41, P576, DOI 10.3171/jns.1974.41.5.0576; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Cormio M, 2000, INTENS CARE MED, V26, P552, DOI 10.1007/s001340051203; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; Fallis WM, 2002, AM J CRIT CARE, V11, P38, DOI 10.4037/ajcc2002.11.1.38; Fulbrook P, 1993, Intensive Crit Care Nurs, V9, P217, DOI 10.1016/S0964-3397(05)80002-3; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1250; Henker RA, 1998, NEUROSURGERY, V42, P1071, DOI 10.1097/00006123-199805000-00071; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Kilpatrick MM, 2000, NEUROSURGERY, V47, P850, DOI 10.1097/00006123-200010000-00011; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Marik PE, 2000, CHEST, V117, P855, DOI 10.1378/chest.117.3.855; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; MELLERGARD P, 1994, ACTA NEUROCHIR, P485; MINAMISAWA H, 1990, ANN NEUROL, V28, P26, DOI 10.1002/ana.410280107; Morimoto T, 1997, BRAIN RES, V746, P43, DOI 10.1016/S0006-8993(96)01154-7; NIERMAN DM, 1991, CRIT CARE MED, V19, P818, DOI 10.1097/00003246-199106000-00015; Ozveri ES, 1999, INTENS CARE MED, V25, P1155, DOI 10.1007/s001340051028; PICKARD JD, 1993, J NEUROL NEUROSUR PS, V56, P845, DOI 10.1136/jnnp.56.8.845; Reglodi D, 2000, EXP NEUROL, V163, P399, DOI 10.1006/exnr.2000.7367; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; Robinson J, 1998, CAN J ANAESTH, V45, P317, DOI 10.1007/BF03012021; Rossi S, 2001, J NEUROL NEUROSUR PS, V71, P448, DOI 10.1136/jnnp.71.4.448; Rumana CS, 1998, CRIT CARE MED, V26, P562, DOI 10.1097/00003246-199803000-00032; Schwarz S, 2000, NEUROLOGY, V54, P354, DOI 10.1212/WNL.54.2.354; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Stocchetti N, 1999, INTENS CARE MED, V25, P371, DOI 10.1007/s001340050860; TAKAGI K, 1994, AM J PHYSIOL-HEART C, V267, pH1770, DOI 10.1152/ajpheart.1994.267.5.H1770; Tateishi A, 1998, NEUROSURGERY, V42, P1065, DOI 10.1097/00006123-199805000-00066; TOUTANT SM, 1984, J NEUROSURG, V61, P691, DOI 10.3171/jns.1984.61.4.0691; Wang Y, 2000, STROKE, V31, P404, DOI 10.1161/01.STR.31.2.404; WASS CT, 1995, ANESTHESIOLOGY, V83, P325, DOI 10.1097/00000542-199508000-00013; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	41	102	108	0	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	NOV	2002	28	11					1555	1562		10.1007/s00134-002-1513-1			8	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	641HL	WOS:000180739300006	12415441				2022-02-06	
J	Radelet, MA; Lephart, SM; Rubinstein, EN; Myers, JB				Radelet, MA; Lephart, SM; Rubinstein, EN; Myers, JB			Survey of the injury rate for children in community sports	PEDIATRICS			English	Article						first aid training; injury risk; injury prevention; gender differences	PREVENTION	Objective. To determine the baseline injury rate for children ages 7 to 13 participating in community organized baseball, softball, soccer, and football. Methods. In this observational cohort study, 1659 children were observed during 2 seasons of sports participation in an urban area. Data were collected by coaches using an injury survey tool designed for the study. A reportable injury was defined as one requiring on-field evaluation by coaching staff, or causing a player to stop participation for any period of time, or requiring first aid during an event. Logistic regression analyses were done within and across sports for injury rates, game versus practice injury frequencies, and gender differences where appropriate. Results. The injury rates, calculated per 100 athlete exposures during total events (games plus practices), were: baseball, 1.7; softball, 1.0; soccer, 2.1; and football, 1.5. The injury rates for baseball and football were not significantly different. Across sports, contusions were the most frequent type of injury. Contact with equipment was the most frequent method of injury, except in football where contact with another player was the most frequent method. In baseball, 3% of all injuries reported were considered serious (fracture, dislocation, concussion); in soccer, 1% were considered serious; and in football, 14% were considered serious. The frequency of injury per team per season (FITS), an estimation of injury risk, was 3 for baseball and soccer, 2 for softball, and 14 for football for total events. For all sports, there were more game than practice injuries; this difference was significant except for softball. There were no significant gender differences in soccer for injury rates during total events. Conclusions. Given the classification of football as a collision sport, the high number of exposures per player, the FITS score, and the percentage of injuries considered serious, youth football should be a priority for injury studies. Health professionals should establish uniform medical coverage policies for football even at this age level. Recommendations for Modifications. Injury surveillance for youth sports is gaining momentum as an important step toward formulating injury prevention methods. However, establishing patterns of injuries, taking preventive measures, and evaluating equipment and coaching modifications may take years. In addition to the objective findings of this study, our direct observations of community sports through 2 seasons showed areas where immediate modifications could reduce injury risk. The first recommendation is that youth sports leagues provide and require first aid training for coaches. Training could be done by sports medicine professionals and include recognition and immediate response to head, neck, and spine injuries, as well as heat-related illnesses. The second recommendation is that youth sports leagues have clear, enforceable return to play guidelines for concussions, neck and back injuries, fractures, and dislocations. The third recommendation is that baseball and softball leagues consider the injury prevention potential of face guards on batting helmets.	Univ Pittsburgh, Neuromuscular Res Lab, Pittsburgh, PA 15203 USA; Univ Pittsburgh, Off Measurements & Evaluat Teaching, Pittsburgh, PA 15203 USA		Lephart, SM (corresponding author), Univ Pittsburgh, Neuromuscular Res Lab, 3200 S Water St, Pittsburgh, PA 15203 USA.	neurolab@pitt.edu					AARON DJ, 1977, EXERCISE SPORT SCI R, V25, P391; Andersen JC, 2002, J ATHL TRAINING, V37, P99; Anderson SJ, 2000, PEDIATRICS, V105, P659, DOI 10.1542/peds.105.3.640; ARNHEIM D, 1999, ESSENTIALS ATHLETIC; Beachy G, 1997, AM J SPORT MED, V25, P675, DOI 10.1177/036354659702500515; BIJUR PE, 1995, ARCH PEDIAT ADOL MED, V149, P1009, DOI 10.1001/archpedi.1995.02170220075010; Buckley Steven L., 1994, Current Opinion in Pediatrics, V6, P80, DOI 10.1097/00008480-199402000-00014; CANTU RC, 1995, CLIN SPORT MED, V14, P517; deLoes M, 1997, SPORTS MED, V24, P172, DOI 10.2165/00007256-199724030-00005; Finch CF, 1997, SPORTS MED, V24, P157, DOI 10.2165/00007256-199724030-00002; GALLAGHER SS, 1984, AM J PUBLIC HEALTH, V74, P1340, DOI 10.2105/AJPH.74.12.1340; GOLDBERG B, 1984, PHYSICIAN SPORTSMED, V128, P122; GROLLMAN LF, 1995, J ATHLETIC TRAININ S, pS39; Hergenroeder AC, 1998, PEDIATRICS, V101, P1057, DOI 10.1542/peds.101.6.1057; *INT FED SPORTS ME, 1998, SID; Janda DH, 1997, SPORTS MED, V24, P169, DOI 10.2165/00007256-199724030-00004; Koester MC, 2000, J ATHL TRAINING, V35, P466; LEVY MI, 1988, AM J SPORT MED, V16, pS132; Lindenfeld T N, 1988, Am J Sports Med, V16 Suppl 1, pS69; MAFFULLI N, 1995, SPORTS MED, V19, P137, DOI 10.2165/00007256-199519020-00005; Marchi AG, 1999, ARCH DIS CHILD, V81, P324, DOI 10.1136/adc.81.4.324; Meeuwisse WH, 1997, SPORTS MED, V24, P184, DOI 10.2165/00007256-199724030-00008; MICHELI LJ, 1995, CLIN SPORT MED, V14, P727; Mills D, 1998, AM J NURS, V98, P58; Mueller FO, 2001, PHYSICIAN SPORTSMED, V29, P41, DOI 10.3810/psm.2001.07.874; OUTERBRIDGE AR, 1995, CLIN SPORT MED, V14, P503; Patel DR, 2000, MED CLIN N AM, V84, P983, DOI 10.1016/S0025-7125(05)70270-4; PERRIELLO VA, 2000, CONT PEDIAT, V2, P132; Powell J W, 1988, Am J Sports Med, V16 Suppl 1, pS134; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; ROEMMICH JN, 1995, CLIN SPORT MED, V14, P483; Stanitski CL, 1997, CLIN SPORT MED, V16, P613, DOI 10.1016/S0278-5919(05)70045-4; Twellaar M, 1996, AM J SPORT MED, V24, P528, DOI 10.1177/036354659602400419; vanMechelen W, 1997, SPORTS MED, V24, P176, DOI 10.2165/00007256-199724030-00006; vanMechelen W, 1997, SPORTS MED, V24, P164, DOI 10.2165/00007256-199724030-00003; Wallace R B, 1988, Am J Sports Med, V16 Suppl 1, pS22; Washington RL, 2001, PEDIATRICS, V107, P782, DOI 10.1542/peds.107.4.782; Weaver NL, 1999, MED SCI SPORT EXER, V31, P176, DOI 10.1097/00005768-199901000-00027; Wells Michael J., 1995, Journal of Athletic Training, V30, P249; Zito M, 1983, J Orthop Sports Phys Ther, V5, P20	40	102	102	1	22	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	SEP	2002	110	3							e28	10.1542/peds.110.3.e28			11	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	589MN	WOS:000177762900001	12205278	Green Published			2022-02-06	
J	Rees, LM; Tombaugh, TN; Boulay, L				Rees, LM; Tombaugh, TN; Boulay, L			Depression and the Test of Memory Malingering	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						depression; TOMM; affective state; memory impairment; neurological impairment; memory dysfunction	TRAUMATIC BRAIN INJURY; MINI-MENTAL STATE; NORMATIVE DATA; TOMM	Research on the Test of Memory Malingering (TOMM) [Tombaugh, T. N., 1996. The Test of Memory Malingering. Toronto, Canada: Multi-Health Systems], has consistently shown that it is sensitive to exaggerated or deliberate faking of memory impairment, but it is relatively unaffected by a wide variety of neurological impairments causing genuine memory dysfunction. However, there is little research on the effects that affective disorders have on the TOMM. The current study examined how inpatients diagnosed with major depression performed on the TOMM. Results show that the TOMM is unaffected by affective state. These results, combined with those from previous research, provide converging evidence that performance on the TOMM below a cutoff score of 45 cannot be attributable to depression, neurological impairment, age or education. (C) 2001 National Academy of Neuropsychology. Published by Elsevier Science Ltd.	Carleton Univ, Ottawa Concuss Clin, Ottawa, ON K1S 5B6, Canada; Royal Ottawa Hosp, Ottawa, ON K1Z 7K4, Canada		Rees, LM (corresponding author), Carleton Univ, Ottawa Concuss Clin, Room B550,Loeb Bldg, Ottawa, ON K1S 5B6, Canada.						*AM PSYCH ASS APA, 1994, DIAGN STAT MAN MENT; Busch CR, 1998, NEUROPSYCHOL REV, V8, P95, DOI 10.1023/A:1025661200911; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Kaplan H., 1991, SYNOPSIS PSYCHIAT; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; NIES KJ, 1994, ARCH CLIN NEUROPSYCH, V9, P501, DOI 10.1016/0887-6177(94)90041-8; OUELLETTEHUGHES N, 1991, THESIS CARLETON U OT; Rees LM, 1998, PSYCHOL ASSESSMENT, V10, P10, DOI 10.1037/1040-3590.10.1.10; REES LM, 1996, THESIS CARLETON U OT; Rosenstein LD, 1998, NEUROPSYCHOL REV, V8, P109, DOI 10.1023/A:1025628925796; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Tombaugh TN, 1996, PSYCHOL ASSESSMENT, V8, P48, DOI 10.1037/1040-3590.8.1.48; Weingartner H., 1986, HDB CLIN MEMORY ASSE, P218, DOI [10.1037/10057-018, DOI 10.1037/10057-018]	15	102	102	1	8	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JUL	2001	16	5					501	506		10.1016/S0887-6177(00)00064-0			6	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	443HK	WOS:000169335600006	14590163	Bronze			2022-02-06	
J	Silver, CH				Silver, CH			Ecological validity of neuropsychological assessment in childhood traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						assessment; brain injury; child; validity	EXECUTIVE FUNCTIONS SCALE; CLOSED-HEAD-INJURY; ACADEMIC PLACEMENT; CHILDREN; SEVERITY; RECOVERY; MEMORY	Empirical investigation of the degree to which testing predicts children's real-world functioning following traumatic brain injury (TBI) is sparse. This article reviews the research in neuropsychology, which offers only moderate correlations between test scores and everyday functioning. This line of research is hindered by several methodological issues: difficulty translating performance on standardized testing into real-world capacities, measurement of real-world functioning, developmental factors, and the influence of intervening variables in the natural environment. Ecologically valid assessment may require multiple data sources. More research is needed to respond effectively to questions about children's everyday functioning after traumatic brain injury.	Univ Texas, SW Med Ctr, Dallas, TX USA		Silver, CH (corresponding author), Univ Texas, SW Med Ctr, 5323 Harry Hines Blvd, Dallas, TX USA.						Achenbach TM, 1991, MANUAL CHILD BEHAV C; Acker MB, 1990, NEUROPSYCHOLOGY EVER, P19; *AHCPR, 2000, AHCPR PUBL; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; BRUININKS RH, 1985, WOODCOCKJOHNSON PSYC; CHAPMAN SB, 1995, J HEAD TRAUMA REHAB, V10, P36, DOI 10.1097/00001199-199510000-00006; Chelune G. J, 1986, NEUROPSYCHOLOGY HDB, P489; Ciccetti D., 1984, VINELAND ADAPTIVE BE; Clark E, 1999, SCHOOL PSYCHOL REV, V28, P242; Cohen J., 2013, STAT POWER ANAL BEHA; Cripe L., 1996, ECOLOGICAL VALIDITY, P171; DONDERS J, 1994, J SCHOOL PSYCHOL, V32, P53, DOI 10.1016/0022-4405(94)90028-0; Ewing-Cobbs L, 1998, J CLIN EXP NEUROPSYC, V20, P769, DOI 10.1076/jcen.20.6.769.1109; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; FARMER JE, 1995, SCHOOL PSYCHOL REV, V24, P230; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; Fletcher JM, 1996, J CHILD NEUROL, V11, P283, DOI 10.1177/088307389601100404; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Franzen M.D., 1996, ECOLOGICAL VALIDITY, P91; Goldstein, 1996, ECOLOGICAL VALIDITY, P75; Goulden LG, 1997, ARCH CLIN NEUROPSYCH, V12, P326, DOI 10.1093/arclin/12.4.326; HART T, 1986, CLIN NEUROPSYCHOLOGY, P21; HARTLAGE LC, 1996, ECOLOGICAL VALIDITY, P301; Isquith PK, 1999, CLIN NEUROPSYCHOL, V13, P222; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; KINSELLA G, 1995, J PEDIATR PSYCHOL, V20, P753, DOI 10.1093/jpepsy/20.6.753; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; KLESGES RC, 1983, CLIN NEUROPSYCHOLOGY, V1, P28; KOLB B, 1995, BRAIN PLASTICITY BEH, P67; Long, 1996, ECOLOGICAL VALIDITY, P15; MCDONALD CM, 1994, ARCH PHYS MED REHAB, V75, P328, DOI 10.1016/0003-9993(94)90038-8; Molho CE, 1997, ARCH CLIN NEUROPSYCH, V12, P370, DOI 10.1093/arclin/12.4.370a; PAPERO PH, 1993, NEUROPSYCHOL REHABIL, V3, P321, DOI 10.1080/09602019308401445; Papero PH, 1997, J HEAD TRAUMA REHAB, V12, P51, DOI 10.1097/00001199-199706000-00006; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; RIZZO AA, 1999, J INT NEUROPSYCH SOC, V5, P125; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; TEASDALE G, 1974, LANCET, V2, P81; Williams JM, 1996, ECOLOGICAL VALIDITY, P129; Wilson, 1993, APPL PREV PSYCHOL, V2, P209, DOI DOI 10.1016/S0962-1849(05)80091-5; WILSON BA, 1993, J CLIN EXP NEUROPSYC, V15, P474, DOI 10.1080/01688639308402572; Woodward H, 1999, J HEAD TRAUMA REHAB, V14, P351, DOI 10.1097/00001199-199908000-00004; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Ylvisaker M., 1998, TRAUMATIC BRAIN INJU, P159; Yorkston KM, 1997, ARCH PHYS MED REHAB, V78, P1096, DOI 10.1016/S0003-9993(97)90134-9	46	102	103	0	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	AUG	2000	15	4					973	988		10.1097/00001199-200008000-00002			16	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	340DK	WOS:000088517700002	10876170				2022-02-06	
J	Ewing-Cobbs, L; Fletcher, JM; Levin, HS; Iovino, I; Miner, ME				Ewing-Cobbs, L; Fletcher, JM; Levin, HS; Iovino, I; Miner, ME			Academic achievement and academic placement following traumatic brain injury in children and adolescents: A two-year longitudinal study	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD-INJURY; READING-DISABILITY; PERFORMANCE; SEVERITY; SEQUELAE; RECOVERY; COHORT; PREVALENCE; COGNITION; MEMORY	Prospective, longitudinal follow-up of academic status following pediatric traumatic brain injury (TBI) identified that patients with severe TBI (n = 33) obtained significantly lower reading recognition, spelling, and arithmetic scores than those with mild to moderate TBI (n = 28). Independent of injury severity, adolescents scored lower than children on computational arithmetic and reading comprehension subtests. Although all achievement scores increased significantly from the baseline evaluation to 6 months after the injury, no further change was noted from 6 months to 2 years. Despite average achievement test scores by 2 years after TBI, 79% of the severely injured patients had either failed a grade or received special educational assistance. Traditional achievement tests may be insensitive to posttraumatic academic deficits.	Univ Texas, Hlth Sci Ctr, Dept Pediat, Houston, TX 77030 USA; Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA; Dept Clin Serv Neurobehav Resources, Houston, TX USA; Ohio State Univ, Sch Med, Dept Neurol Surg, Columbus, OH 43210 USA		Ewing-Cobbs, L (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pediat, 7000 Fannin,2400 Univ Ctr Tower, Houston, TX 77030 USA.	lewing@pedl.med.uth.tmc.edu	Fletcher, Jack/AAX-2931-2020; fletcher, jack/Q-5975-2019		PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [21889, 29462, 27597] Funding Source: Medline		BARNES MA, IN PRESS DEV NEUROPS; BAWDEN HN, 1985, J CLIN EXP NEUROPSYC, V7, P39, DOI 10.1080/01688638508401241; BERGERGROSS P, 1985, PERCEPT MOTOR SKILL, V61, P254, DOI 10.2466/pms.1985.61.1.254; BIJUR PE, 1990, PEDIATRICS, V86, P337; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; DONDERS J, 1994, J SCHOOL PSYCHOL, V32, P53, DOI 10.1016/0022-4405(94)90028-0; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Ewing-Cobbs L, 1998, CHILD NEUROPSYCHOL, V4, P35, DOI 10.1076/chin.4.1.35.3194; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; EWINGCOBBS L, 1998, TRAUMATIC BRAIN INJU, P11; EWINGCOBBS L, 1996, J INT NEUROPSYCH SOC, V2, P39; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; Fletcher JM, 1996, J CHILD NEUROL, V11, P283, DOI 10.1177/088307389601100404; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V57, P1; Fletcher JM, 1987, NEUROBEHAVIORAL RECO, P279; HAAS JF, 1987, J NEUROL NEUROSUR PS, V50, P52, DOI 10.1136/jnnp.50.1.52; HARNADEK MCS, 1994, J LEARN DISABIL, V27, P144, DOI 10.1177/002221949402700303; HEBB D. O., 1942, PROC AMER PHIL SOC, V85, P275; HEISKANEN O, 1974, DEV MED CHILD NEUROL, V16, P11; Hollingshead AB, 1958, 2 FACTOR INDEX SOCIA; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; Jastak S., 1978, WIDE RANGE ACHIEVEME; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; KINSELLA G, 1995, J PEDIATR PSYCHOL, V20, P753, DOI 10.1093/jpepsy/20.6.753; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Levin HS, 1996, DEV NEUROPSYCHOL, V12, P17, DOI 10.1080/87565649609540638; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; LEVIN HS, 1985, 2 EUR S DEV NEUR; Markwardt F., 1970, PEABODY INDIVIDUAL A; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; SHAFFER D, 1980, J AM ACAD CHILD PSY, V19, P592, DOI 10.1016/S0002-7138(09)60964-X; SHAYWITZ SE, 1990, JAMA-J AM MED ASSOC, V264, P998, DOI 10.1001/jama.264.8.998; Shurtleff H. A., 1988, J PSYCHOEDUCATIONAL, V6, P298, DOI 10.1177/073428298800600313; TEASDALE G, 1974, LANCET, V2, P81; THOMPSON NM, 1994, NEUROPSYCHOLOGY, V8, P333, DOI DOI 10.1037/0894-4105.8.3.333; Wilkinson, 1984, WIDE RANGE ACHIEVEME; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218; WRIGHTSON P, 1995, J NEUROL NEUROSUR PS, V59, P375, DOI 10.1136/jnnp.59.4.375; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78	48	102	102	0	11	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	DEC	1998	20	6					769	781		10.1076/jcen.20.6.769.1109			13	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	204RQ	WOS:000080778300001	10484689				2022-02-06	
J	Paniak, C; Toller-Lobe, G; Durand, A; Nagy, J				Paniak, C; Toller-Lobe, G; Durand, A; Nagy, J			A randomized trial of two treatments for mild traumatic brain injury	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; NEUROPSYCHOLOGICAL REHABILITATION; POSTCONCUSSIVE SYMPTOMS; CONCUSSION	The purpose of this study was to compare an education-oriented single session treatment (SS) for mild traumatic brain injury (MTBI) to a more extensive assessment, education, and treatment-as-needed intervention (TAN). Participants were 111 adults with MTBI who were recruited from consecutive admissions to two hospital emergency wards. They were randomly assigned to either the SS or TAN modality. The groups did not differ on any demographic, injury-related, or questionnaire variable when first seen within 3 weeks of injury. The groups generally improved a similar amount and did not differ from each other on any symptom-related, functional, or vocational variables 3-4 months alter their baseline session. Patient satisfaction ratings with services provided were also similar for the two groups. Brief educational intervention given soon after MTBI appears to be adequate for most MTBI survivors.	Glenrose Rehabil Hosp, Edmonton, AB T5G 0B7, Canada; Univ Alberta, Edmonton, AB, Canada		Paniak, C (corresponding author), Glenrose Rehabil Hosp, 10230-111 Ave, Edmonton, AB T5G 0B7, Canada.						ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL; Bennett T L, 1997, Appl Neuropsychol, V4, P55, DOI 10.1207/s15324826an0401_7; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BLISHEN BR, 1987, CAN REV SOC ANTHROP, V24, P465; BOLLA KI, 1991, ARCH NEUROL-CHICAGO, V48, P61, DOI 10.1001/archneur.1991.00530130069022; Cicerone KD, 1996, BRAIN INJURY, V10, P277, DOI 10.1080/026990596124458; DACEY R, 1991, J TRAUMA, V31, P217, DOI 10.1097/00005373-199131020-00011; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; FOX DD, 1995, NEUROPSYCHOLOGY, V9, P606, DOI 10.1037/0894-4105.9.4.606; GRONWALL D, 1986, J HEAD TRAUMA REHAB, V1, P53, DOI DOI 10.1097/00001199-198606000-00009; GUALTIERI CT, 1995, NEUROPSY NEUROPSY BE, V8, P127; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; HALL KM, 1994, ARCH PHYS MED REHAB, V75, pSC10; Ho MR, 1997, ARCH CLIN NEUROPSYCH, V12, P1; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; KAY T, 1995, J HEAD TRAUMA REHAB, V10, P12, DOI 10.1097/00001199-199504000-00004; KAY T, 1986, UNSEEN INJURY MINOR; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P74, DOI [DOI 10.1097/00001199-199309000-00009, 10.1097/00001199-199309000-00009]; King NS, 1997, CLIN REHABIL, V11, P13, DOI 10.1177/026921559701100104; Kraus Jess F., 1994, P3; KRAUS JF, 1989, MILD HEAD INJURY, P8; MATEER CA, 1992, REHABILITATION POSTC, P143; MAX W, 1991, J HEAD TRAUMA REHAB, V6, P79; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; MITTENBERG W, 1994, BRAIN INJURY, V8, P429, DOI 10.3109/02699059409150994; NOVACEK MJ, 1988, PHYLOGENY CLASSIFICA, V2, P31; PANIAK C, 1992, DISS ABSTR INT, V52, P6093; PANIAK CE, 1992, ARCH CLIN NEUROPSYCH, V7, P529, DOI 10.1016/0887-6177(92)90143-B; RELANDER M, 1972, BMJ-BRIT MED J, V4, P777, DOI 10.1136/bmj.4.5843.777; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; TRAHAN DE, 1998, J INT NEUROPSYCH SOC, V4, P8; Veiel HOF, 1997, J CLIN EXP NEUROPSYC, V19, P587, DOI 10.1080/01688639708403745; WARE JE, 1988, MED CARE, V26, P393, DOI 10.1097/00005650-198804000-00008; WARE JE, 1992, SF 36 HLTH SURVEY MA; Willer B., 1993, BRAIN INJURY REHABIL, P355	41	102	103	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	1998	12	12					1011	1023		10.1080/026990598121927			13	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	150BW	WOS:000077643400002	9876861				2022-02-06	
J	Clinchot, DM; Bogner, J; Mysiw, WJ; Fugate, L; Corrigan, J				Clinchot, DM; Bogner, J; Mysiw, WJ; Fugate, L; Corrigan, J			Defining sleep disturbance after brain injury	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						traumatic brain injury; sleep; fatigue	HEAD-INJURY; NARCOLEPSY	Sleep disorders are a relatively common occurrence after brain injury. Sleep disturbances often result in a poor daytime performance and a poor individual sense of well-being. Unfortunately, there has been minimal attention paid to this common and often disabling sequela of brain injury. This study attempts to define and to correlate the incidence and type of sleep disturbances that occur after brain injury. Consecutive admissions to a rehabilitation unit were used to create a longitudinal database designed to predict long-term outcomes for individuals who suffered a brain injury. Fifty percent of subjects had difficulty sleeping. Sixty-four percent described waking up too early, 25% described sleeping more than usual, and 45% described problems falling asleep. Eighty percent of subjects reporting sleep problems also reported problems with fatigue. Logistic regression analysis revealed the following: the more severe the brain injury the less likely the subject would be to have a sleep disturbance; subjects who had sleep disturbances were more likely to have problems with fatigue; females were more likely to have trouble with sleep. This study demonstrates the substantial prevalence of sleep disturbances after brain injury. It underscores the relationship between sleep disorders and perception of fatigue. It also underscores the need for clinicians to strive for interventional studies to look at the treatment of sleep and fatigue problems after brain injury.	Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA		Clinchot, DM (corresponding author), Ohio State Univ, Dept Phys Med & Rehabil, Dodd Hall,480 W 9th Ave, Columbus, OH 43210 USA.		Mysiw, Walter/E-3724-2011; Sanguansri, Luz/B-6630-2011; Corrigan, John D./E-2921-2011	Sanguansri, Luz/0000-0003-1908-7604; Clinchot, Daniel/0000-0002-2810-7227			ANSELL BJ, 1989, W NEURO SENSORY STIM; ASERINSKY E, 1953, SCIENCE, V118, P273, DOI 10.1126/science.118.3062.273; BILLIARD M, 1986, SLEEP, V9, P149, DOI 10.1093/sleep/9.1.149; CLINCHOT DM, 1993, HEARSAY J OHIO SPEEC, V8, P4; COHEN M, 1992, J NEUROL NEUROSUR PS, V55, P313, DOI 10.1136/jnnp.55.4.313; CORRIGAN JD, 1985, ARCH PHYS MED REHAB, V66, P626; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; CORRIGAN JD, 1989, J CLIN EXP NEUROPSYC, V11, P261, DOI 10.1080/01688638908400888; DRAKE ME, 1986, NEUROLOGY, V36, P867, DOI 10.1212/WNL.36.6.867; GEORGE B, 1981, NEUROCHIRURGIE, V27, P35; GERBER DJ, 1995, J HEAD TRAUMA REHAB, V10, P28, DOI 10.1097/00001199-199508000-00004; GOOD JL, 1989, J NEUROSURG, V71, P765, DOI 10.3171/jns.1989.71.5.0765; Granger C. V., 1986, TOP GERIATR REHABIL, V1, P59, DOI DOI 10.1097/00013614-198604000-00007; GUILLEMINAULT C, 1983, NEUROLOGY, V33, P1584, DOI 10.1212/WNL.33.12.1584; HARDA M, 1976, KUMAMOTO MED J, V29, P110; HARTMANN E, 1973, PSYCHOSOMATICS, V14, P95; JONES HS, 1968, ELECTROEN CLIN NEURO, V24, P378, DOI 10.1016/0013-4694(68)90199-5; JOUVET M, 1969, SCIENCE, V163, P32, DOI 10.1126/science.163.3862.32; JOUVET M, 1967, PHYSIOL REV, V47, P117, DOI 10.1152/physrev.1967.47.2.117; Landau-Ferey J, 1981, Rev Electroencephalogr Neurophysiol Clin, V11, P116, DOI 10.1016/S0370-4475(81)80042-1; LOOMIS ALFRED L., 1935, SCIENCE, V81, P597, DOI 10.1126/science.81.2111.597; MARKAND ON, 1976, NEUROLOGY, V26, P769, DOI 10.1212/WNL.26.8.769; MCCUBBIN H, 1987, FAMILY ASSESSMENT IN, P203; MEDDIS R, 1973, ELECTROEN CLIN NEURO, V35, P213, DOI 10.1016/0013-4694(73)90180-6; PATTEN SB, 1992, J AM ACAD CHILD PSY, V31, P100, DOI 10.1097/00004583-199201000-00015; PRIGATANO GP, 1982, J NEUROL NEUROSUR PS, V45, P78, DOI 10.1136/jnnp.45.1.78; Reitan R, 1985, HALSTEAD REITAN NEUR; RON S, 1980, ELECTROEN CLIN NEURO, V48, P432, DOI 10.1016/0013-4694(80)90135-2; Willer B., 1993, BRAIN INJURY REHABIL, P355; [No title captured]	30	102	105	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	JUL-AUG	1998	77	4					291	295		10.1097/00002060-199807000-00006			5	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	109VQ	WOS:000075344900005	9715917				2022-02-06	
J	Li, GH; Keyl, PM; Smith, GS; Baker, SP				Li, GH; Keyl, PM; Smith, GS; Baker, SP			Alcohol and injury severity: Reappraisal of the continuing controversy	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	56th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 19-21, 1996	HOUSTON, TX	Amer Assoc Surg Trauma		alcohol; epidemiology; injury; potentiating effect; trauma	TRAUMATIC BRAIN INJURY; HOSPITAL COURSE; ETHANOL; INTOXICATION; PERFORMANCE; DEPENDENCE; IMPACT; ABUSE; SCORE; ORDER	It is well recognized that alcohol increases the risk of injury, It is controversial, however, whether alcohol also has an effect on the degree and outcome of injury after controlling for the severity of impact, This review examines the evidence from experimental studies in animals regarding the potentiating effects of alcohol on trauma, and the methodologic issues that may have contributed to the contradictory findings of clinical and epidemiologic studies, Most experimental studies indicate that alcohol can adversely affect the degree and outcome of injury, In controlled laboratory conditions, alcohol is found to reduce cardiac output, to increase the susceptibility to hemorrhagic shock, and to increase the pulmonary vascular resistance after standardized experimental injuries, However, it is difficult to extrapolate these findings to humans, partly because the interactive effects of chronic and acute alcohol use on trauma are rarely considered in experimental studies, The conflicting results in studies involving trauma patients are due in part to the differences in study design, particularly selection of study populations, and in measuring and controlling for kinetic forces on the body, Studies indicating that alcohol is associated with an increased risk of serious or fatal injury are usually based on data from emergency departments or police departments, The alcohol-injury severity relationship reported in these studies is attributable to a great extent to the effects of correlates of alcohol, such as speeding and not wearing seat belts, rather than the biological effects of alcohol, Studies indicating that alcohol is not associated with the degree and outcomes of injury are mostly those involving patients who were admitted to hospitals or trauma centers, Methodologic issues concerning the alcohol-injury severity controversy, including conceptual models and future research needs, are discussed.	JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, CTR INJURY RES & POLICY, BALTIMORE, MD USA		Li, GH (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT EMERGENCY MED, 600 N WOLFE ST, MARBURG B194A, BALTIMORE, MD 21287 USA.			Smith, Gordon/0000-0002-2911-3071	NIAAA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R29AA09963, R01AA07700] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR302486] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R29AA009963, R01AA007700] Funding Source: NIH RePORTER		ALTURA BM, 1995, ALCOHOL, V12, P433, DOI 10.1016/0741-8329(95)00026-N; ANDERSEN JA, 1990, J TRAUMA, V30, P415, DOI 10.1097/00005373-199030040-00007; Anderson T E, 1986, Cent Nerv Syst Trauma, V3, P183; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BALLIN JC, 1986, JAMA-J AM MED ASSOC, V255, P522; BLOMBERG RD, 1979, P AM ASS AUT MED, V26, P1; BLOMQVIST S, 1987, J TRAUMA, V27, P40, DOI 10.1097/00005373-198701000-00007; BRADBURY A, 1991, INJURY, V22, P132, DOI 10.1016/0020-1383(91)90074-O; BRICKLEY MR, 1995, INJURY, V26, P311, DOI 10.1016/0020-1383(95)00034-7; BRODNER RA, 1981, J TRAUMA, V21, P124, DOI 10.1097/00005373-198102000-00005; Cherpitel CJ, 1996, ALCOHOL CLIN EXP RES, V20, P338, DOI 10.1111/j.1530-0277.1996.tb01649.x; CHERPITEL CJ, 1994, ALCOHOL ALCOHOLISM, V29, P211; CHIN JH, 1981, MOL PHARMACOL, V19, P425; DESIDERIO MA, 1986, J TRAUMA, V26, P467, DOI 10.1097/00005373-198605000-00011; DICKERSIN K, 1993, ANN NY ACAD SCI, V703, P135, DOI 10.1111/j.1749-6632.1993.tb26343.x; DISCHINGER PC, 1988, P AM ASS AUTOMOTIVE, V32, P299; ELMER O, 1985, ACTA CHIR SCAND, V151, P305; EVANS L, 1993, J STUD ALCOHOL, V54, P441, DOI 10.15288/jsa.1993.54.441; FLAMM ES, 1977, J NEUROSURG, V46, P328, DOI 10.3171/jns.1977.46.3.0328; FULLER MG, 1995, J ADDICT DIS, V14, P47, DOI 10.1300/J069v14n01_05; GARRISON HG, 1984, ANN EMERG MED, V13, P26, DOI 10.1016/S0196-0644(84)80379-0; GENTILELLO LM, 1993, J TRAUMA, V34, P669, DOI 10.1097/00005373-199305000-00009; GRANT BF, 1994, ALCOHOL HEALTH RES W, V18, P243; GRUBER J E, 1992, Journal of Emergency Medicine, V10, P545, DOI 10.1016/0736-4679(92)90134-F; GURNEY JG, 1992, J TRAUMA, V33, P709, DOI 10.1097/00005373-199211000-00020; HADDON W, 1961, J CHRON DIS, V14, P655, DOI 10.1016/0021-9681(61)90122-9; HOEK JB, 1990, ALCOHOL ALCOHOLISM, V25, P143, DOI 10.1093/oxfordjournals.alcalc.a044989; HONKANEN R, 1991, INJURY, V22, P225, DOI 10.1016/0020-1383(91)90047-I; HONKANEN R, 1983, J STUD ALCOHOL, V44, P231, DOI 10.15288/jsa.1983.44.231; House EG, 1982, P AM ASS AUTOMOTIVE, V26, P349; HUTH JF, 1983, J TRAUMA, V23, P494, DOI 10.1097/00005373-198306000-00009; JAGGER J, 1984, NEUROSURGERY, V15, P303, DOI 10.1227/00006123-198409000-00002; JURKOVICH GJ, 1992, ANN EMERG MED, V21, P704, DOI 10.1016/S0196-0644(05)82783-0; JURKOVICH GJ, 1993, JAMA-J AM MED ASSOC, V270, P51, DOI 10.1001/jama.270.1.51; KIM K, 1995, ACCIDENT ANAL PREV, V27, P469, DOI 10.1016/0001-4575(95)00001-G; KNOTT DH, 1963, NEW ENGL J MED, V269, P292, DOI 10.1056/NEJM196308082690604; KNOTT DH, 1967, JAMA-J AM MED ASSOC, V84, P179; KOELEGA HS, 1995, PSYCHOPHARMACOLOGY, V118, P233, DOI 10.1007/BF02245951; Last J. M., 1995, DICT EPIDEMIOLOGY, P134; LIEDTKE AJ, 1975, AM J CARDIOL, V35, P243, DOI 10.1016/0002-9149(75)90008-9; LUNA GK, 1984, J TRAUMA, V24, P695, DOI 10.1097/00005373-198408000-00001; MCCALL D, 1989, BIOCHEM PHARMACOL, V38, P2593, DOI 10.1016/0006-2952(89)90543-1; MCCARROLL JR, 1962, J CHRON DIS, V15, P811, DOI 10.1016/0021-9681(62)90051-6; MENGERT P, 1992, US COAST GUARD PUBLI; MIDANIK LT, 1994, AM J PUBLIC HEALTH, V84, P1218, DOI 10.2105/AJPH.84.8.1218; MOSS LK, 1959, SURG FORUM, V10, P390; National Institute on Alcohol Abuse and Alcoholism, 1994, NIH PUBL, P233; NEWSOME HH, 1988, J TRAUMA, V28, P1, DOI 10.1097/00005373-198801000-00001; NICHOLAS GG, 1980, J TRAUMA, V20, P58, DOI 10.1097/00005373-198020010-00009; NIE Y, 1989, ARCH BIOCHEM BIOPHYS, V268, P349, DOI 10.1016/0003-9861(89)90596-1; NILSSEN O, 1994, J TRAUMA, V36, P784, DOI 10.1097/00005373-199406000-00006; OLKKONEN S, 1990, ACCIDENT ANAL PREV, V22, P89, DOI 10.1016/0001-4575(90)90010-I; PORIES SE, 1992, J TRAUMA, V32, P60, DOI 10.1097/00005373-199201000-00013; PORTANS I, 1989, PSYCHOPHARMACOLOGY, V97, P365, DOI 10.1007/BF00439452; RAPPAPORT WD, 1990, J TRAUMA, V30, P1518, DOI 10.1097/00005373-199012000-00014; Ridella S A, 1986, Cent Nerv Syst Trauma, V3, P195; RUNYAN CW, 1992, NEW ENGL J MED, V327, P859, DOI 10.1056/NEJM199209173271207; SCHUCKIT MA, 1991, NEUROPSYCHOPHARMACOL, V4, P157; SODERSTROM CA, 1992, JAMA-J AM MED ASSOC, V267, P2756, DOI 10.1001/jama.267.20.2756; SPAITE DW, 1995, J TRAUMA, V38, P287, DOI 10.1097/00005373-199502000-00028; STEWART JR, 1989, ACCIDENT ANAL PREV, V21, P575, DOI 10.1016/0001-4575(89)90071-7; THAL ER, 1985, ARCH SURG-CHICAGO, V120, P708; TIKELLIS JI, 1986, AM SURGEON, V52, P53; TULLOH BR, 1994, INJURY, V25, P539, DOI 10.1016/0020-1383(94)90097-3; Vinson D C, 1995, Arch Fam Med, V4, P505, DOI 10.1001/archfami.4.6.505; WALLER JA, 1988, J TRAUMA, V28, P1632, DOI 10.1097/00005373-198812000-00003; WALLER PF, 1986, JAMA-J AM MED ASSOC, V256, P1461, DOI 10.1001/jama.256.11.1461; WALLER PF, 1989, P AM ASS AUTOMOTIVE, V33, P1; WARD RE, 1982, AM J SURG, V144, P153, DOI 10.1016/0002-9610(82)90617-1; Warren RA, 1981, P AM ASS AUTOMOTIVE, V28, P133; WECHSLER H, 1969, PUBLIC HEALTH REP, V84, P1043, DOI 10.2307/4593753; WINEK CL, 1984, FORENSIC SCI INT, V25, P159, DOI 10.1016/0379-0738(84)90189-0; ZINK BJ, 1995, J NEUROSURG, V82, P822, DOI 10.3171/jns.1995.82.5.0822; ZINK BJ, 1993, J NEUROTRAUM, V10, P275, DOI 10.1089/neu.1993.10.275	74	102	103	1	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAR	1997	42	3					562	569		10.1097/00005373-199703000-00032			8	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	WR152	WOS:A1997WR15200052	9095132				2022-02-06	
J	Cicerone, KD; Tanenbaum, LN				Cicerone, KD; Tanenbaum, LN			Disturbance of social cognition after traumatic orbitofrontal brain injury	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article							FRONTAL-LOBE DAMAGE; PREFRONTAL CORTEX; BEHAVIOR; IMPAIRMENTS; DEFICITS	A patient with traumatic orbitomedial frontal lobe damage demonstrated good neurocognitive recovery but a lasting, profound disturbance of emotional regulation and social cognition. initial neuropsychological findings included a complete anosmia, mildly reduced fluency and disturbed motor regulation. The impairments of fluency and motor regulation resolved, and formal measures of ''frontal lobe'' functioning were generally intact. However, she remained impaired on tasks requiring the interpretation of social situations, which mirrored her impairment in real life functioning. This disturbance in social cognition appeared related to difficulty appreciating and integrating the relatively subtle social and emotional cues required for the appropriate interpretation of events. The patient's presentation represents an intermediate position between patients with profound neurobehavioral deficits and patients with impaired real-life social cognition despite intact neuropsychological performance following orbitofrontal damage. Variations in the orbitofrontal behavioral syndrome may be related to extent of lesion, time post injury and the course of recovery in different patients. (C) 1997 National Academy of Neuropsychology.	JFK MED CTR,NEW JERSEY NEUROSCI INST,EDISON,NJ		Cicerone, KD (corresponding author), JFK JOHNSON REHABIL INST,2048 OAK TREE RD,EDISON,NJ 08820, USA.						BARBAS H, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P35; BAYLESS JD, 1989, J CLIN EXP NEUROPSYC, V11, P913, DOI 10.1080/01688638908400944; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Bigler E D, 1988, Arch Clin Neuropsychol, V3, P279, DOI 10.1016/0887-6177(88)90020-0; BRAZZELLI M, 1994, CORTEX, V30, P27, DOI 10.1016/S0010-9452(13)80323-1; Bryant B. R., 1991, SCHOLASTIC ABILITIES; BUTTER C M, 1972, Acta Neurobiologiae Experimentalis (Warsaw), V32, P525; CANCELLIERE AEB, 1990, BRAIN COGNITION, V13, P133, DOI 10.1016/0278-2626(90)90046-Q; CURRIE J, 1991, ARCH NEUROL-CHICAGO, V48, P644, DOI 10.1001/archneur.1991.00530180102024; DAMASIO AR, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P217; DAMASIO AR, 1990, BEHAV BRAIN RES, V41, P81, DOI 10.1016/0166-4328(90)90144-4; Damasio H., 1989, LESION ANAL NEUROPSY; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; HEBB DO, 1945, ARCH NEURO PSYCHIATR, V54, P10, DOI 10.1001/archneurpsyc.1945.02300070020002; KLING A, 1976, BRAIN BEHAV EVOLUT, V13, P216, DOI 10.1159/000123811; KRIKORIAN R, 1994, J CLIN EXP NEUROPSYC, V16, P840, DOI 10.1080/01688639408402697; LEZAK MD, 1994, NEUROPSYCHOLOGICAL A; LHERMITTE F, 1986, ANN NEUROL, V19, P335, DOI 10.1002/ana.410190405; Luria A.R., 1980, HIGHER CORTICAL FUNC, V2d; MALLOY P, 1993, ARCH CLIN NEUROPSYCH, V8, P185, DOI 10.1016/0887-6177(93)90035-Y; MESULAM MM, 1986, ANN NEUROL, V19, P320, DOI 10.1002/ana.410190403; O'Sullivan M., 1976, 4 FACTOR TESTS SOCIA; Orrison Jr. WW, 1995, ATLAS BRAIN FUNCTION; Robinson L J, 1991, Arch Clin Neuropsychol, V6, P27, DOI 10.1016/0887-6177(91)90019-6; ROLLS ET, 1994, J NEUROL NEUROSUR PS, V57, P1518, DOI 10.1136/jnnp.57.12.1518; Ruff RM, 1988, RUFF FIGURAL FLUENCY; SAVER JL, 1991, NEUROPSYCHOLOGIA, V29, P1241, DOI 10.1016/0028-3932(91)90037-9; SERGENT J, 1994, LOCALIZATION NEUROIM, P473; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHALLICE T, 1989, BRAIN, V112, P1587, DOI 10.1093/brain/112.6.1587; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; SIRIGU A, 1995, CORTEX, V31, P301, DOI 10.1016/S0010-9452(13)80364-4; Spivack, 1975, MANUAL MEANS ENDS PR; Varney NR., 1993, J HEAD TRAUMA REHAB, V8, P32, DOI [10.1097/00001199-199303000-00005, DOI 10.1097/00001199-199303000-00005]; VONCRAMON DY, 1994, NEUROPSYCHOL REHABIL, V4, P399, DOI 10.1080/09602019408401608; [No title captured]	36	102	103	0	9	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.		1997	12	2					173	188		10.1016/S0887-6177(96)00022-4			16	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	WV548	WOS:A1997WV54800009	14588429	Bronze			2022-02-06	
J	Hill, SJ; Barbarese, E; McIntosh, TK				Hill, SJ; Barbarese, E; McIntosh, TK			Regional heterogeneity in the response of astrocytes following traumatic brain injury in the adult rat	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						blood-brain barrier; Cajal's gold sublimate; fluid percussion; glial fibrillary acidic protein; S100 protein; vimentin	FIBRILLARY ACIDIC PROTEIN; REACTIVE ASTROCYTES; S-100 PROTEIN; VIMENTIN; FLUID; CELLS; IMMUNOFLUORESCENCE; PHOSPHORYLATION; PROLIFERATION; INTERLEUKIN-1	The regional distribution and temporal appearance of astrocytes expressing glial fibrillary acidic protein (GFAP), S100 protein, and vimentin were determined in a nonpenetrating lateral fluid percussion (LFP) brain injury model. Following injury, reactive astrocytes were observed in the subcortical white matter tracts as early as 1 day, in the hippocampus and injured cortex by 3 days, and in the thalamus by 1 week. Reactive astrocytes in the injured cortex, subcortical white matter tracts, and CA3 region of the hippocampus were all vimentin positive at 1 month post-injury. These astrocytes had a distinct morphology characterized by an enlarged cell body and long intertwined processes. In contrast, reactive astrocytes in the thalamic nuclei never expressed vimentin, and displayed an enlarged cell body with thick shortened processes. An increase in S100 protein was detected in all reactive astrocytes following LFP brain injury. Quantitative assessment of GFAP, S100, and vimentin polypeptides confirmed the immunohistochemical evaluation. Our data indicate that although astrogliosis mirrors the spatial pattern of post-traumatic neuronal cell loss, the expression of vimentin and the cellular morphology of the cells were regionally distinct, suggesting that astrogliosis may be modulated by factors present in the post-traumatic brain.	UNIV PENN,DEPT NEUROSURG,PHILADELPHIA,PA 19104; UNIV CONNECTICUT,CTR HLTH,DEPT NEUROL,FARMINGTON,CT 06030						NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS19943, NSPO1088003, NSRO126818] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019943] Funding Source: NIH RePORTER		BARGER SW, 1992, J BIOL CHEM, V267, P9689; BAUDIER J, 1988, J BIOL CHEM, V263, P5876; BIANCHI R, 1993, J BIOL CHEM, V268, P12669; BIGNAMI A, 1972, BRAIN RES, V43, P429, DOI 10.1016/0006-8993(72)90398-8; BIGNAMI A, 1974, J COMP NEUROL, V153, P27, DOI 10.1002/cne.901530104; CALVO JL, 1990, BRAIN RES, V532, P355, DOI 10.1016/0006-8993(90)91784-E; CALVO JL, 1991, BRAIN RES, V566, P333, DOI 10.1016/0006-8993(91)91720-L; CIESIELSKITRESKA J, 1988, J NEUROCYTOL, V17, P79, DOI 10.1007/BF01735380; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; ENG LF, 1985, J NEUROIMMUNOL, V8, P203, DOI 10.1016/S0165-5728(85)80063-1; Fan Lei, 1995, Molecular Brain Research, V30, P125, DOI 10.1016/0169-328X(94)00287-O; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; GUILIAN D, 1989, Journal of Neuroscience, V9, P4416; GUILIAN D, 1988, J NEUROSCI, V8, P2485; GUILIAN D, 1985, SCIENCE, V228, P497; HATTEN ME, 1985, J CELL BIOL, V100, P384, DOI 10.1083/jcb.100.2.384; HICKS RR, IN PRESS BRAIN RES; KIMELBERG HK, 1994, NEUROBIOLOGY CENTRAL, P193; KLIGMAN D, 1986, J NEUROCHEM, V47, P298; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MATHEWSON AJ, 1985, BRAIN RES, V327, P61, DOI 10.1016/0006-8993(85)91499-4; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; PIXLEY SKR, 1984, DEV BRAIN RES, V15, P201, DOI 10.1016/0165-3806(84)90097-X; POLVISHOCK JT, 1994, J NEUROTRAUM, V11, P723; SCHIFFER D, 1986, BRAIN RES, V374, P110, DOI 10.1016/0006-8993(86)90399-9; SCHNITZER J, 1981, J CELL BIOL, V90, P435, DOI 10.1083/jcb.90.2.435; SHASHOUA VE, 1984, J NEUROCHEM, V42, P1536, DOI 10.1111/j.1471-4159.1984.tb12739.x; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; SOARES HD, 1996, IN PRESS J NEUROSCI; TAKAMIYA Y, 1988, DEV BRAIN RES, V38, P201, DOI 10.1016/0165-3806(88)90045-4; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; THOMPSON SW, 1966, SELECTED HISTOCHEMIC, P814; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANELDIK LJ, 1987, BRAIN RES, V436, P367, DOI 10.1016/0006-8993(87)91681-7; VAUGHN JE, 1969, J COMP NEUROL, V131, P143; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S	40	102	106	1	5	AMER ASSN NEUROPATHOLOGISTS INC	LAWRENCE	1041 NEW HAMPSHIRE ST, LAWRENCE, KS 66044	0022-3069			J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	DEC	1996	55	12					1221	1229		10.1097/00005072-199612000-00005			9	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	VW890	WOS:A1996VW89000006	8957445	Bronze			2022-02-06	
J	Maddocks, D; Saling, M				Maddocks, D; Saling, M			Neuropsychological deficits following concussion	BRAIN INJURY			English	Article							MINOR HEAD-INJURY; MILD CONCUSSION	The term 'concussion' has been applied to head injuries of varying severity. Most studies have examined subjects suffering concussion of a severity requiring hospital observation, usually as a consequence of motor vehicle accidents. Milder concussive injuries such as those resulting from contact sport are often not reported in hospital-based studies. In this study, subjects with mild concussive injuries were studied with the aim of determining ifneuropsychological sequelae are detectable. The subjects received their injuries while playing Australian Rules Football. Baseline (pre-injury) measures on the Paced Auditory Serial Addition Test (PASAT), Digit Symbol Substitution Test (DSST) and Four-Choice Reaction time, involving measures of decision time (DT) and movement time (MT), were obtained in a sample of 130 players. Ten players subsequently concussed were re-tested at 5 days post-injury. A control group of age-matched umpires were assessed on two corresponding occasions. Analyses of covariance showed poorer performances following concussion on the DSST and DT measures. The results suggested that neuropsychological deficits are detectable after resolution of neurological symptoms in the early stages following mild concussive injury.	TRANSPORT ACCID COMMISS,REHABIL CTR,GLEN WAVERLEY,VIC,AUSTRALIA		Maddocks, D (corresponding author), UNIV MELBOURNE,DEPT PSYCHOL,SCH BEHAV SCI,PARKVILLE,VIC 3052,AUSTRALIA.						Barth JT, 1989, MILD HEAD INJURY, P257; Dicker G, 1986, Aust Fam Physician, V15, P455; EWING R, 1980, Journal of Clinical Neuropsychology, V2, P147, DOI 10.1080/01688638008403789; GRONWALL D, 1975, LANCET, V2, P995; GRONWALL D, 1974, LANCET, V2, P605; Gronwall D, 1974, PSYCHOL EFFECTS CONC; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; MADDOCKS D, 1988, ATHLETE MAXIMISING P, P235; MERRITT HH, 1959, TXB NEUROLOGY; ROWLAND L, 1984, MERRITTS TXB NEUROLO, P281; Van Zomeren A. H., 1981, REACTION TIME ATTENT; Wechsler, 1997, WECHSLER ADULT INTEL; 1966, CLIN NEUROSURG, V12, P386	15	102	102	0	10	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	FEB	1996	10	2					99	103		10.1080/026990596124584			5	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	UB726	WOS:A1996UB72600003	8696320				2022-02-06	
J	Anderson, CV; Bigler, ED; Blatter, DD				Anderson, CV; Bigler, ED; Blatter, DD			Frontal lobe lesions, diffuse damage, and neuropsychological functioning in traumatic brain-injured patients	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							CARD SORTING TEST; AXONAL INJURY; ATROPHY	This study quantified lesion volume in relation to damage location and executive functioning in traumatic brain-injured (TBI) patients. Magnetic resonance (MR) scans of 68 TBI patients were analyzed by taking volumetric measures of lesion sites. Patients were grouped according the presence/absence of frontal lobe lesions. Measures of frontal lesion volume were studied as predictors for outcome on designated tests of executive functioning (Halstead Category Test and Wisconsin Card Sorting Test). Results showed no significant differences in level of deficit between groups. In addition, no significant differences were found between groups on other tests of neuropsychological functioning (Trail Making Test, Parts A and B, and Wechsler Adult Intelligence Scale-Revised). These results suggest that tests that are traditionally used to detect ''frontal lobe'' damage may not be adequate for distinguishing specific frontal lobe dysfunction, and do not add anything unique about frontal lobe integrity and neuropsychological functioning in TBI patients.	BRIGHAM YOUNG UNIV,DEPT PSYCHOL,PROVO,UT 84602; LATTER DAY ST HOSP,SALT LAKE CITY,UT 84143								ANDERSON CV, 1995, J NEUROPSYCH CLIN N, V7, P42; ANDERSON SW, 1991, J CLIN EXP NEUROPSYC, V13, P909, DOI 10.1080/01688639108405107; ARNETT PA, 1994, NEUROLOGY, V44, P420, DOI 10.1212/WNL.44.3_Part_1.420; BARKLEY RA, 1994, CLIN NEUROPSYCHOL, V8, P121, DOI 10.1080/13854049408401552; Berg EA, 1948, J GEN PSYCHOL, V39, P15, DOI 10.1080/00221309.1948.9918159; Bigler E, 1990, TRAUMATIC BRAIN INJU, P13; Bigler E D, 1988, Arch Clin Neuropsychol, V3, P279, DOI 10.1016/0887-6177(88)90020-0; BIGLER ED, 1988, DIAGNOSTIC CLIN NEUR; BIGLER ED, 1994, FUNCTIONAL NEUROIMAG, P121; Bigler Erin D., 1993, Brain Injury, V7, P125, DOI 10.3109/02699059309008166; BLATTER DD, 1995, AM J NEURORADIOL, V16, P241; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; CULLUM CM, 1986, J CLIN EXP NEUROPSYC, V8, P437, DOI 10.1080/01688638608401333; CULLUM CM, 1990, TRAUMATIC BRAIN INJU, P129; Damasio H., 1989, LESION ANAL NEUROPSY; DeFilippis NA, 1979, BOOKLET CATEGORY TES; DUFFY JD, 1994, J NEUROPSYCH CLIN N, V6, P379; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GOLDBERG E, 1994, J NEUROPSYCH CLIN N, V6, P371; GOLDBERG E, 1995, J CLIN EXT NEUROPSYC, V17, P192; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; GRATTAN LM, 1994, NEUROPSY NEUROPSY BE, V7, P251; Gronwall D., 1990, HEAD INJURY FACTS; Gurdjian ES, 1975, IMPACT HEAD INJURY; Halstead W.C., 1947, BRAIN INTELLIGENCE; Heaton R.K., 1981, WISCONSIN CARD SORTI; Heaton RK, 1991, COMPREHENSIVE NORMS; HECK ET, 1986, J CLIN EXP NEUROPSYC, V8, P313, DOI 10.1080/01688638608401321; Hellman S. G., 1992, INT J METH PSYCH RES, V2, P151; HOM J, 1990, J CLIN EXP NEUROPSYC, V12, P644, DOI 10.1080/01688639008401008; Johnson SC, 1994, NEUROPSYCHOLOGY, V8, P307, DOI DOI 10.1037/0894-4105.8.3.301; Katz D, 1992, J HEAD TRAUMA REHAB, V72, P1, DOI [10.1097/00001199-200501000-00008, DOI 10.1097/00001199-200501000-00008]; KURTH SM, 1994, BRAIN INJURY, V8, P489, DOI 10.3109/02699059409151001; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; LEVIN HS, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P318; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LOONG J, 1990, COMPUTERIZED CATEGOR; Loong J.W.K., 1990, WISCONSIN CARD SORTI; MALLOY PF, 1994, J NEUROPSYCH CLIN N, V6, P399; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; RASBAND W, 1993, IMAGE 1 52 COMPUTER; Reitan R., 1985, NEUROANATOMY NEUROPA; Reitan R, 1985, HALSTEAD REITAN NEUR; REITAN RM, 1995, CLIN NEUROPSYCHOL, V9, P50, DOI 10.1080/13854049508402057; ROBB RA, 1995, 3 DIMENSIONAL BIOMED; ROSENTHAL M, 1993, TRAUMATIC BRAIN INJU; SALAZAR AM, 1992, CHALLENGES NEUROLOGY, P55; *SOC NEUR, 1990, BRAIN FACTS PRIM BRA; Spreen O, 1991, COMPENDIUM NEUROPSYC; Stuss D.T., 1994, NEUROPSYCHOLOGY, V8, P355, DOI [https://doi.org/10.1037/0894-4105.8.3.355, DOI 10.1037/0894-4105.8.3.355]; SULLIVAN EV, 1993, PSYCHIAT RES, V46, P175, DOI 10.1016/0165-1781(93)90019-D; VANDENBROEK MD, 1993, BRIT J CLIN PSYCHOL, V32, P333; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th Edn; WILSON JTL, 1992, J HEAD TRAUMA REHAB, V7, P29; [No title captured]	58	102	104	0	15	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	DEC	1995	17	6					900	908		10.1080/01688639508402438			9	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	TM776	WOS:A1995TM77600009	8847395				2022-02-06	
J	BORZOTTA, AP; PENNINGS, J; PAPASADERO, B; PAXTON, J; MARDESIC, S; BORZOTTA, R; PARROTT, A; BLEDSOE, F				BORZOTTA, AP; PENNINGS, J; PAPASADERO, B; PAXTON, J; MARDESIC, S; BORZOTTA, R; PARROTT, A; BLEDSOE, F			ENTERAL VERSUS PARENTERAL-NUTRITION AFTER SEVERE CLOSED-HEAD INJURY	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	24th Annual Meeting of the Western-Trauma-Association	FEB 27-MAR 04, 1994	CRESTED BUTTE, CO	W TRAUMA ASSOC			BRAIN INJURY; METABOLIC RESPONSE; PATIENT; BENEFITS; TRAUMA	We measured energy expenditure (MREE) and nitrogen excretion (UUN) in patients with severe head injury randomized to early parenteral (TPN, n = 21) or jejunal (ENT, n = 27) feeding with identical formulations. The MREE rose to 2400 +/- 531 kcal/day in both groups and remained at 135% +/- 26% to 146% +/- 42% of predicted energy expenditure over 4 weeks. Nitrogen excretion peaked the second week at 33.4 +/- 10 (TPN) and 31.2 +/- 7.5 (ENT) g N/day. Both routes were equally effective at meeting nutritional goals (1.2 x MREE, 2.5 g protein/kg/day intake, stabilized albumin and transferrin levels). Infections were equally frequent: 1.86 episodes/TPN patient versus 1.89 episodes/ENT patient. While patient charges were much greater for TPN, the hospital costs were similar for TPN and ENT support regimens. These findings show that patients with head injuries are hypermetabolic for weeks, that only 27% are capable of spontaneously eating nutritional requirements by discharge, and that either TPN or ENT support is equally effective when prescribed according to individual measurements of MREE and nitrogen excretion.			BORZOTTA, AP (corresponding author), LEGACY EMANUEL HOSP & HLTH CTR,TRAUMA SERV,2801 N GANTENBEIN AVE,PORTLAND,OR 97227, USA.						ADAMS S, 1986, J TRAUMA, V26, P882, DOI 10.1097/00005373-198610000-00004; BOUZARTH NF, 1972, SURG GYNECOL OBSTET, V126, P995; BRANSON R D, 1990, Respiratory Care, V35, P640; CERRA F, 1987, ANN SURG, V205, P282, DOI 10.1097/00000658-198703000-00011; CLIFTON GL, 1986, J NEUROSURG, V64, P895, DOI 10.3171/jns.1986.64.6.0895; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; CLIFTON GL, 1984, J NEUROSURG, V60, P687, DOI 10.3171/jns.1984.60.4.0687; DEUTSCHMAN CS, 1986, J NEUROSURG, V64, P89, DOI 10.3171/jns.1986.64.1.0089; FELL D, 1984, CRIT CARE MED, V12, P649, DOI 10.1097/00003246-198408000-00009; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; GRAHM TW, 1989, NEUROSURGERY, V25, P729, DOI 10.1227/00006123-198911000-00007; HAIDER W, 1975, EUR J INTEN CARE MED, V1, P19, DOI 10.1007/BF00735865; KIRBY DF, 1991, JPEN-PARENTER ENTER, V15, P298, DOI 10.1177/0148607191015003298; MOORE EE, 1986, J TRAUMA, V26, P874, DOI 10.1097/00005373-198610000-00003; NORTON JA, 1987, J NEUROSURG, V67, P846; OTT L, 1987, JPEN-PARENTER ENTER, V11, P488, DOI 10.1177/0148607187011005488; OTT L, 1989, NUTRITION, V5, P75; PHILLIPS R, 1988, J NEUROSURG, V68, P62; RAPP RP, 1983, J NEUROSURG, V58, P906, DOI 10.3171/jns.1983.58.6.0906; ROBERTSON CS, 1984, NEUROSURGERY, V15, P307, DOI 10.1227/00006123-198409000-00003; ROBERTSON CS, 1985, J NEUROSURG, V63, P714, DOI 10.3171/jns.1985.63.5.0714; SUNDERLAND PM, 1992, NEUROSURGERY, V31, P246, DOI 10.1227/00006123-199208000-00009; TWYMAN D, 1985, JPEN-PARENTER ENTER, V9, P679, DOI 10.1177/0148607185009006679; VANE DW, 1982, J PEDIATR SURG, V17, P960, DOI 10.1016/S0022-3468(82)80475-2; YOUNG B, 1985, NEUROSURGERY, V17, P784, DOI 10.1227/00006123-198511000-00010	25	102	101	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	1994	37	3					459	468		10.1097/00005373-199409000-00022			10	Critical Care Medicine; Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	PG534	WOS:A1994PG53400023	8083910				2022-02-06	
J	JORGE, RE; ROBINSON, RG; ARNDT, SV; FORRESTER, AW; GEISLER, F; STARKSTEIN, SE				JORGE, RE; ROBINSON, RG; ARNDT, SV; FORRESTER, AW; GEISLER, F; STARKSTEIN, SE			COMPARISON BETWEEN ACUTE-ONSET AND DELAYED-ONSET DEPRESSION FOLLOWING TRAUMATIC BRAIN INJURY	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							SEVERE HEAD-INJURY; RELATIVES	Sixty-six patients admitted for the treatment of acute closed head injury were assessed for the presence of mood disorders during the in-hospital period and at 3-, 6-, and 12-month follow-ups. Diagnosis was made using a structured psychiatric interview and DSM-III criteria. A total of 28 patients had major depression at some time during the study: 17 had acute-onset depression and 11 had delayed-onset depression. Acute-onset depressions are related to lesion location and may have their etiology in biological responses of the injured brain, whereas delayed depressions may be mediated by psychosocial factors, suggesting psychological reaction as a possible mechanism.	UNIV IOWA,COLL MED,DEPT PSYCHIAT,IOWA CITY,IA 52242; JOHNS HOPKINS UNIV,SCH MED,DEPT PSYCHIAT,BALTIMORE,MD 21205; UNIV MARYLAND,DIV NEUROSURG,DEPT SURG,MARYLAND INST EMERGENCY MED SERV SYST,CTR SHOCK TRAUMA,BALTIMORE,MD 21201; INST NEUROL INVEST DR RAUL CARREA,DEPT BEHAV NEUROL,BUENOS AIRES,ARGENTINA				Arndt, Stephan/A-6976-2013; Robinson, Robert/AAF-6191-2021	Arndt, Stephan/0000-0003-0783-8204; 	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH040355] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH00163, MH40355] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS151178] Funding Source: Medline		CONOVER WJ, 1981, AM STAT, V35, P124, DOI 10.2307/2683975; DERENZI E, 1962, BRAIN, V85, P665, DOI 10.1093/brain/85.4.665; Eisenberg, 1987, NEUROBEHAVIORAL RECO, P215; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Hollingshead AB, 1958, SOCIAL CLASS MENTAL; JORGE R, IN PRESS J AFFECTIVE; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; LEVINE DN, 1984, NEUROLOGY, V34, P577, DOI 10.1212/WNL.34.5.577; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; ROBINSON RG, 1981, ANN NEUROL, V9, P447, DOI 10.1002/ana.410090506; RUTHERFORD WH, 1977, LANCET, V1, P1; Silver J. M., 1991, NEUROPSY NEUROPSY BE, V4, P12; STARR LB, 1983, EXP AGING RES, V9, P101, DOI 10.1080/03610738308258434; TEASDALE G, 1974, LANCET, V2, P81; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; VANZOMEREN AH, 1990, HDB CLIN NEUROLOGY, V13, P397; Wing J. K., 1974, MEASUREMENT CLASSIFI	22	102	104	0	4	AMER PSYCHIATRIC ASSOCIATION	WASHINGTON	1400 K ST NW, WASHINGTON, DC 20005	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	WIN	1993	5	1					43	49					7	Clinical Neurology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry	KK041	WOS:A1993KK04100007	8428134				2022-02-06	
J	NEWTON, MR; GREENWOOD, RJ; BRITTON, KE; CHARLESWORTH, M; NIMMON, CC; CARROLL, MJ; DOLKE, G				NEWTON, MR; GREENWOOD, RJ; BRITTON, KE; CHARLESWORTH, M; NIMMON, CC; CARROLL, MJ; DOLKE, G			A STUDY COMPARING SPECT WITH CT AND MRI AFTER CLOSED HEAD-INJURY	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							CEREBRAL BLOOD-FLOW; TRAUMA	After closed head injury nineteen patients had single photon emission tomography (SPECT) using the lipophilic tracer 99m-Technetium hexamethyl-propylene-amineoxime (HMPAO) to compare the defects shown by CT and MRI. SPECT showed more focal cerebral lesions than either CT or MRI alone or in combination. Most lesions shown by SPECT were not shown by CT or MRI in the corresponding anatomical regions. The most severely disabled patients showed the highest number of SPECT lesions (average four per patient) and the lowest (mean, SE) cerebral blood flow (718, 69 ml/min) compared with the less disabled patients (two per patient and 1058, 51 ml/min, p < 0.05). There was a correlation between the Glasgow Outcome Scale grade and the global cerebral blood flow (r 0.74, p < 0.05). The perfusion defects may correlate with clinical signs that were not explained by CT or MRI findings. SPECT may complement the clinical evaluation in the assessment of outcome after head injury.	HOMERTON HOSP,REG NEUROL REHABIL UNIT,HOMERTON ROW,LONDON E9 6SR,ENGLAND; ST BARTHOLOMEWS HOSP,DEPT NUCL MED,LONDON EC1A 7BE,ENGLAND; ST BARTHOLOMEWS HOSP,DEPT NEURORADIOL,LONDON EC1A 7BE,ENGLAND								ABDELDAYEM HM, 1987, RADIOLOGY, V165, P221, DOI 10.1148/radiology.165.1.3498184; BRITTON KE, 1985, NUCL MED COMMUN, V6, P251, DOI 10.1097/00006231-198505000-00002; COSTA D C, 1987, Nuclear Medicine Communications, V8, P573; COSTA DC, 1986, NUCL MED COMMUN, V7, P647; ELL PJ, 1985, LANCET, V2, P50; GANDY SE, 1984, ANN NEUROL, V16, P254, DOI 10.1002/ana.410160217; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; GROSWASSER Z, 1987, SURG NEUROL, V27, P331, DOI 10.1016/0090-3019(87)90007-3; JENKINS A, 1986, LANCET, V2, P445; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; LEVIN HS, 1985, ARCH NEUROL-CHICAGO, V42, P963, DOI 10.1001/archneur.1985.04060090045012; NIMMON CC, 1985, 1983 P INT S MEAS CE, P214; NIMMON CC, 1986, NEUROLOGIJA, V35, P161; PODREKA I, 1987, Nuclear Medicine Communications, V8, P559	14	102	102	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	FEB	1992	55	2					92	94		10.1136/jnnp.55.2.92			3	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	HD380	WOS:A1992HD38000002	1538233	Bronze, Green Published			2022-02-06	
J	Bogoslovsky, T; Wilson, D; Chen, Y; Hanlon, D; Gill, J; Jeromin, A; Song, LN; Moore, C; Gong, YH; Kenney, K; Diaz-Arrastia, R				Bogoslovsky, Tanya; Wilson, David; Chen, Yao; Hanlon, David; Gill, Jessica; Jeromin, Andreas; Song, Linan; Moore, Carol; Gong, Yunhua; Kenney, Kimbra; Diaz-Arrastia, Ramon			Increases of Plasma Levels of Glial Fibrillary Acidic Protein, Tau, and Amyloid beta up to 90 Days after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						diagnostic and prognostic biomarkers; GFAP; highly sensitive immunoassays; TBI; total tau	C-TERMINAL HYDROLASE-L1; GLASGOW COMA SCALE; CEREBROSPINAL-FLUID; ELEVATED LEVELS; CLEAVED-TAU; SERUM; BIOMARKERS; CSF; MILD; PREDICTORS	Glial fibrillary acidic protein (GFAP), microtubule-associated protein tau, and amyloid beta peptide (A beta 42) have been proposed as diagnostic and prognostic biomarkers in traumatic brain injury (TBI). Single molecule array (Simoa) is a novel technology that employs highly sensitive immunoassays for accurate measurements of candidate biomarkers found at low concentration in biological fluids. Our objective was to trace the trajectory of tau, GFAP, and A beta 42 levels in plasma from the acute through subacute stages after TBI, compared with controls. Samples from 34 TBI subjects enrolled in the Citicoline Brain Injury Treatment Trial (COBRIT) were studied. Injury severity was assessed by Glasgow Coma Scale (GCS) and admission CT. Glasgow Outcome Scale Extended (GOSE) was assessed 6 months after injury. Plasma was collected within 24 h (Day 0), and 30 and 90 days after the TBI. Plasma collected from 69 healthy volunteers was used for comparison. At every time point, increases were noted in plasma GFAP (p < 0.0001 for all comparisons), tau (p < 0.0001, p < 0.0001, and p = 0.0044, at Days 0, 30, and 90, respectively), and A beta 42 (p < 0.001, p < 0.0001, and p = 0.0203, respectively) in TBI cases compared with controls. The levels were maximal at Day 0 for GFAP and tau and at Day 30 for A beta 42. Area under curve (AUC) analyses for Day 0 GFAP and tau were excellent for discrimination of complicated mild TBI (cmTBI) from controls (0.936 and 0.901, correspondingly). Discriminant component analysis (DCA) for all three biomarkers at Days 0 and 30 differentiated controls from cmTBI (91.1% and 89.7% correctly classified, at each time point). Duration of post-traumatic amnesia (PTA) correlated weakly with tau levels at 30 days (Spearman's r = 0.40; 95% CI 0.0003-0.60, p = 0.044). The Marshall CT Grade on admission correlated weakly with Day 30 tau levels (Spearman's r = 0.41; 95% CI 0.04-0.68, p = 0.027). Day 30A beta 42 correlated with GOSE (standardized beta-0.486, p = 0.042). GFAP, tau and A beta 42 were increased up to 90 days after TBI compared with controls. Total tau levels correlated with clinical and radiological variables of TBI severity. Plasma A beta 42 correlated with clinical outcome. Combination of all three biomarkers at Days 0 and 30 can be used to differentiate controls from cmTBI populations, and may be useful as biomarkers of TBI in both acute and subacute phases.	[Bogoslovsky, Tanya; Gill, Jessica; Moore, Carol; Gong, Yunhua; Kenney, Kimbra; Diaz-Arrastia, Ramon] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, 12725 Twinbrook Pkwy, Rockville, MD 20852 USA; [Wilson, David; Chen, Yao; Hanlon, David; Jeromin, Andreas; Song, Linan] Quanterix Inc, Lexington, MA USA; [Gill, Jessica] NINR, NIH, Bethesda, MD 20892 USA		Bogoslovsky, T (corresponding author), Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, 12725 Twinbrook Pkwy, Rockville, MD 20852 USA.	tanya.bogoslovsky.ctr@usuhs.edu	Gill, Gill M/Q-2020-2017	Diaz-Arrastia, Ramon/0000-0001-6051-3594	Center for Neuroscience and Regenerative Medicine (CNRM), GE/NFL TBI Award [U01 HD 42652]; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [ZIANR000033] Funding Source: NIH RePORTER	This work was supported by the Center for Neuroscience and Regenerative Medicine (CNRM), GE/NFL TBI Award, U01 HD 42652.	Anderson JM, 2008, BRAIN, V131, P1736, DOI 10.1093/brain/awn119; Bazarian JJ, 2006, BRAIN INJURY, V20, P759, DOI 10.1080/02699050500488207; Berger RP, 2012, J NEUROTRAUM, V29, P162, DOI 10.1089/neu.2011.1989; Bledsoe BE, 2015, PREHOSP DISASTER MED, V30, P46, DOI 10.1017/S1049023X14001289; Blennow K, 2006, LANCET, V368, P387, DOI 10.1016/S0140-6736(06)69113-7; Bohmer AE, 2011, NEUROSURGERY, V68, P1624, DOI 10.1227/NEU.0b013e318214a81f; Buonora JE, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00068; Corso P, 2006, INJURY PREV, V12, P212, DOI 10.1136/ip.2005.010983; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Emmerling MR, 2000, ANN NY ACAD SCI, V903, P118, DOI 10.1111/j.1749-6632.2000.tb06357.x; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; Gabbita SP, 2005, J NEUROTRAUM, V22, P83, DOI 10.1089/neu.2005.22.83; Gatson JW, 2014, J NEUROSURG, V121, P1232, DOI 10.3171/2014.7.JNS132474; Gentleman SM, 1997, NEUROREPORT, V8, P1519, DOI 10.1097/00001756-199704140-00039; Hong YT, 2014, JAMA NEUROL, V71, P23, DOI 10.1001/jamaneurol.2013.4847; Irizarry Michael C, 2004, NeuroRx, V1, P226; Izumi K, 2014, J CANCER RES CLIN, V140, P1413, DOI 10.1007/s00432-014-1681-8; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnson VE, 2009, J NEUROTRAUM, V26, P1197, DOI [10.1089/neu.2008.0843, 10.1089/neu.2008-0843]; Kavalci C, 2007, AM J EMERG MED, V25, P391, DOI 10.1016/j.ajem.2006.10.008; Lawrence DW, 2015, BRAIN INJURY, V29, P1018, DOI 10.3109/02699052.2015.1005131; Lesko LJ, 2001, ANNU REV PHARMACOL, V41, P347, DOI 10.1146/annurev.pharmtox.41.1.347; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Mehta PD, 2001, NEUROSCI LETT, V304, P102, DOI 10.1016/S0304-3940(01)01754-2; Mondello S, 2014, SCI REP-UK, V4, DOI 10.1038/srep06446; Neselius S, 2013, BRAIN INJURY, V27, P425, DOI 10.3109/02699052.2012.750752; Olivera A, 2015, JAMA NEUROL, V72, P1109, DOI 10.1001/jamaneurol.2015.1383; Olsson A, 2004, J NEUROL, V251, P870, DOI 10.1007/s00415-004-0451-y; Ost M, 2006, NEUROLOGY, V67, P1600, DOI 10.1212/01.wnl.0000242732.06714.0f; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Quiroz YT, 2015, JAMA NEUROL, V72, P912, DOI 10.1001/jamaneurol.2015.1099; Randall J, 2013, RESUSCITATION, V84, P351, DOI 10.1016/j.resuscitation.2012.07.027; Rissin DM, 2010, NAT BIOTECHNOL, V28, P595, DOI 10.1038/nbt.1641; ROSENGREN LE, 1994, J NEUROSCI METH, V51, P197, DOI 10.1016/0165-0270(94)90011-6; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Sherer M, 2008, J NEUROL NEUROSUR PS, V79, P678, DOI 10.1136/jnnp.2006.111187; Strathmann FG, 2014, CLIN BIOCHEM, V47, P876, DOI 10.1016/j.clinbiochem.2014.01.028; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Wang TJ, 2006, NEW ENGL J MED, V355, P2631, DOI 10.1056/NEJMoa055373; Washington PM, 2014, J NEUROTRAUM, V31, P125, DOI 10.1089/neu.2013.3017; Wilson D.H., 2015, J LAB AUTOM; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Zafonte RD, 2012, JAMA-J AM MED ASSOC, V308, P1993, DOI 10.1001/jama.2012.13256; Zetterberg H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028263	45	101	102	2	24	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 1	2017	34	1					66	73		10.1089/neu.2015.4333			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	EF6DE	WOS:000390420100009	27312416	Green Published			2022-02-06	
J	Mierzwa, AJ; Marion, CM; Sullivan, GM; McDaniel, DP; Armstrong, RC				Mierzwa, Amanda J.; Marion, Christina M.; Sullivan, Genevieve M.; McDaniel, Dennis P.; Armstrong, Regina C.			Components of Myelin Damage and Repair in the Progression of White Matter Pathology After Mild Traumatic Brain Injury	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Axon damage; Demyelination; Neuroinflammation; Oligodendrocyte; Redundant myelin; Remyelination; Traumatic axonal injury	CORPUS-CALLOSUM; AXONAL INJURY; EXPERIMENTAL DEMYELINATION; OLIGODENDROCYTE LINEAGE; WALLERIAN DEGENERATION; POSTERIOR FUNICULUS; UNMYELINATED AXONS; DORSAL RHIZOTOMY; ADULT CAT; REMYELINATION	White matter tracts are highly vulnerable to damage from impact-acceleration forces of traumatic brain injury (TBI). Mild TBI is characterized by a low density of traumatic axonal injury, whereas associated myelin pathology is relatively unexplored. We examined the progression of white matter pathology in mice after mild TBI with traumatic axonal injury localized in the corpus callosum. Adult mice received a closed-skull impact and were analyzed from 3 days to 6 weeks post-TBI/sham surgery. At all times post-TBI, electron microscopy revealed degenerating axons distributed among intact fibers in the corpus callosum. Intact axons exhibited significant demyelination at 3 days followed by evidence of remyelination at 1 week. Accordingly, bromodeoxyuridine pulse-chase labeling demonstrated the generation of new oligodendrocytes, identified by myelin proteolipid protein messenger RNA expression, at 3 days post-TBI. Overall oligodendrocyte populations, identified by immunohistochemical staining for CC1 and/or glutathione S-transferase pi, were similar between TBI and sham mice by 2 weeks. Excessively long myelin figures, similar to redundant myelin sheaths, were a significant feature at all post-TBI time points. At 6 weeks post-TBI, microglial activation and astrogliosis were localized to areas of axon and myelin pathology. These studies show that demyelination, remyelination, and excessive myelin are components of white matter degeneration and recovery in mild TBI with traumatic axonal injury.	[Mierzwa, Amanda J.; Sullivan, Genevieve M.; Armstrong, Regina C.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; [Mierzwa, Amanda J.; Sullivan, Genevieve M.; Armstrong, Regina C.] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Marion, Christina M.; Armstrong, Regina C.] Uniformed Serv Univ Hlth Sci, Program Neurosci, Bethesda, MD 20814 USA; [McDaniel, Dennis P.] Uniformed Serv Univ Hlth Sci, Biomed Instrumentat Ctr, Bethesda, MD 20814 USA		Armstrong, RC (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	regina.armstrong@usuhs.edu	Sullivan, Genevieve/AAK-7415-2021; Marion, Christina M/B-8120-2015	Sullivan, Genevieve/0000-0002-3561-223X; Marion, Christina M/0000-0003-0381-4109	US Department of Defense in the Center for Neuroscience and Regenerative MedicineUnited States Department of Defense	This work was supported by the US Department of Defense in the Center for Neuroscience and Regenerative Medicine.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Armstrong RC, 2002, J NEUROSCI, V22, P8574; Armstrong RC, 2006, J NEUROPATH EXP NEUR, V65, P245, DOI 10.1097/01.jnen.0000205142.08716.7e; Baki SGA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012490; Bennett RE, 2014, J NEUROTRAUM, V31, P1647, DOI 10.1089/neu.2013.3320; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Bigler ED, 2011, NEUROREHABILITATION, V28, P63, DOI 10.3233/NRE-2011-0633; Bruce CC, 2010, HORM BEHAV, V57, P56, DOI 10.1016/j.yhbeh.2009.06.004; BUNGE MB, 1961, J BIOPHYS BIOCHEM CY, V10, P67, DOI 10.1083/jcb.10.1.67; Clarner T, 2012, GLIA, V60, P1468, DOI 10.1002/glia.22367; Conforti L, 2014, NAT REV NEUROSCI, V15, P394, DOI 10.1038/nrn3680; Conti AC, 1998, J NEUROSCI, V18, P5663; Dams-O'Connor K, 2013, J NEUROTRAUM, V30, P2014, DOI 10.1089/neu.2013.3049; DiLeonardi AM, 2009, BRAIN RES, V1263, P174, DOI 10.1016/j.brainres.2009.01.021; Donders J, 2015, ASSESSMENT, V22, P17, DOI 10.1177/1073191114530776; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Flygt J, 2013, EUR J NEUROSCI, V38, P2153, DOI 10.1111/ejn.12179; FRANSON P, 1989, ANAT EMBRYOL, V180, P273, DOI 10.1007/BF00315885; FRANSON P, 1984, J COMP NEUROL, V223, P138, DOI 10.1002/cne.902230111; Gallo V, 2014, NEURON, V83, P283, DOI 10.1016/j.neuron.2014.06.010; Gallyas F, 2006, ACTA NEUROPATHOL, V111, P229, DOI 10.1007/s00401-006-0034-3; Gibson EM, 2014, SCIENCE, V344, P487, DOI 10.1126/science.1252304; Hibbits N, 2012, ASN NEURO, V4, DOI 10.1042/AN20120062; Irvine KA, 2008, BRAIN, V131, P1464, DOI 10.1093/brain/awn080; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kim JJ, 2011, NEUROTHERAPEUTICS, V8, P39, DOI 10.1007/s13311-010-0003-3; Liu J, 2012, NAT NEUROSCI, V15, P1621, DOI 10.1038/nn.3263; Lotocki G, 2011, NEUROSCI LETT, V499, P143, DOI 10.1016/j.neulet.2011.05.056; LUDWIN SK, 1984, J NEUROL SCI, V64, P193, DOI 10.1016/0022-510X(84)90037-6; Maxwell WL, 2015, J NEUROTRAUM, V32, P780, DOI 10.1089/neu.2014.3369; Maxwell WL, 2013, BRAIN SCI, V3, P1374, DOI 10.3390/brainsci3031374; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Mierzwa AJ, 2014, ASN NEURO, V6, DOI 10.1177/1759091414551782; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Murtie JC, 2005, NEUROBIOL DIS, V19, P171, DOI 10.1016/j.nbd.2004.12.006; Nayak D, 2014, ANNU REV IMMUNOL, V32, P367, DOI 10.1146/annurev-immunol-032713-120240; Neumann H, 2009, BRAIN, V132, P288, DOI 10.1093/brain/awn109; Peters A, 2002, J NEUROCYTOL, V31, P581, DOI 10.1023/A:1025731309829; Reeves TM, 2012, J NEUROPATH EXP NEUR, V71, P198, DOI 10.1097/NEN.0b013e3182482590; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Reichard RR, 2005, NEUROPATH APPL NEURO, V31, P304, DOI 10.1111/j.1365-2990.2005.00645.x; REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; ROSENBLUTH J, 1966, J CELL BIOL, V28, P73, DOI 10.1083/jcb.28.1.73; RUSHTON WAH, 1951, J PHYSIOL-LONDON, V115, P101, DOI 10.1113/jphysiol.1951.sp004655; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Smith DH, 2013, J NEUROTRAUM, V30, P307, DOI 10.1089/neu.2012.2825; Snaidero N, 2014, CELL, V156, P277, DOI 10.1016/j.cell.2013.11.044; Song SK, 2005, NEUROIMAGE, V26, P132, DOI 10.1016/j.neuroimage.2005.01.028; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; STURROCK RR, 1980, NEUROPATH APPL NEURO, V6, P415, DOI 10.1111/j.1365-2990.1980.tb00219.x; Sullivan GM, 2013, J NEUROPATH EXP NEUR, V72, P1106, DOI 10.1097/NEN.0000000000000009; Tobin JE, 2011, J NEUROPATH EXP NEUR, V70, P157, DOI 10.1097/NEN.0b013e31820937e4; Tomassy GS, 2014, SCIENCE, V344, P319, DOI 10.1126/science.1249766; Vargas ME, 2007, ANNU REV NEUROSCI, V30, P153, DOI 10.1146/annurev.neuro.30.051606.094354; Villegas R, 2014, J NEUROSCI, V34, P7179, DOI 10.1523/JNEUROSCI.4784-13.2014; Xie MQ, 2010, J NEUROPATH EXP NEUR, V69, P704, DOI 10.1097/NEN.0b013e3181e3de90; Yeh PH, 2014, HUM BRAIN MAPP, V35, P2652, DOI 10.1002/hbm.22358; Yuh EL, 2014, J NEUROTRAUM, V31, P1457, DOI 10.1089/neu.2013.3171; Zhou YX, 2012, NEUROBIOL DIS, V45, P196, DOI 10.1016/j.nbd.2011.08.004	62	101	103	0	10	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	MAR	2015	74	3					218	232		10.1097/NEN.0000000000000165			15	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	CB7AG	WOS:000349777700004	25668562	hybrid, Green Published			2022-02-06	
J	Wachter, D; Reineke, K; Behm, T; Rohde, V				Wachter, Dorothee; Reineke, Kim; Behm, Timo; Rohde, Veit			Cranioplasty after decompressive hemicraniectomy: Underestimated surgery-associated complications?	CLINICAL NEUROLOGY AND NEUROSURGERY			English	Article						Decompressive hemicraniectomy; Bone flap reimplantation; Surgery-associated complications; Bone flap resorption	TRAUMATIC BRAIN-INJURY; MIDDLE CEREBRAL-ARTERY; LARGE CRANIAL DEFECTS; BONE-GRAFT INFECTION; SEVERE HEAD-INJURY; SUBARACHNOID HEMORRHAGE; SURGICAL DECOMPRESSION; DELAYED CRANIOPLASTY; MALIGNANT INFARCTION; CASE SERIES	Objective: Decompressive hemicraniectomy (DC) and duroplasty after malignant brain infarction or traumatic brain injury is a common surgical procedure. Usually, preserved bone flaps are being reimplanted after resolution of brain swelling. Alloplast cranioplasties are seldom directly implanted due to the risk of wound healing disorders. While numerous studies deal with DC, little is known about the encountered problems of bone flap reimplantation. Thus, aim of the study was to identify surgery-associated complications after bone flap reimplantation. Methods: We performed a retrospective chart analysis of patients that underwent DC and subsequent bone flap reimplantation between 2001 and 2011 at our institution. We registered demographic data, initial clinical diagnosis and surgery-associated complications. Results: We identified 136 patients that underwent DC and subsequent reimplantation. Forty-one patients (30.1%) had early or late surgery-associated complications after bone flap reimplantation. Most often, bone flap resorption and postoperative wound infections were the underlying causes (73%, n = 30/41). Multivariate analysis identified age (p = 0.045; OR = 16.30), GOS prior to cranioplasty (p = 0.03; OR = 2.38) and nicotine abuse as a prognostic factor for surgery-associated complications (p = 0.043; OR = 4.02). Furthermore, patients with early cranioplasty had a better functional outcome than patients with late cranioplasty (p < 0.05). Conclusions: Almost one-third of the patients that are operated on for bone flap reimplantation after DC suffer from surgery-associated complications. Most often, wound healing disorders as well as bone flap resorption lead to a second or even third operation with the need for artificial bone implantation. These results might raise the question, if subsequent operations can be avoided, if an artificial bone is initially chosen for cranioplasty. (C) 2012 Published by Elsevier B.V.	[Wachter, Dorothee; Reineke, Kim; Behm, Timo; Rohde, Veit] Univ Gottingen, Dept Neurosurg, D-37075 Gottingen, Germany		Wachter, D (corresponding author), Univ Gottingen, Dept Neurosurg, Robert Koch Str 40, D-37075 Gottingen, Germany.	dorothee.wachter@med.uni-goettingen.de	Mielke, Dorothee/AAU-6776-2021				Adamo MA, 2008, J NEUROSURG, V108, P174, DOI 10.3171/JNS/2008/108/01/0174; Ahmadi SA, 2010, BRAIN INJURY, V24, P1539, DOI 10.3109/02699052.2010.523049; Al-Tamimi YZ, 2012, BRIT J NEUROSURG, V26, P510, DOI 10.3109/02688697.2011.633640; Archavlis E, 2012, ACTA NEUROCHIR, V154, P1055, DOI 10.1007/s00701-012-1333-1; Beauchamp KM, 2010, J TRAUMA, V69, P270, DOI 10.1097/TA.0b013e3181e491c2; Bentley JN, 2009, NEUROSURG FOCUS, V27, DOI 10.3171/2009.8.FOCUS09166; Chang V, 2010, J NEUROSURG, V112, P1120, DOI 10.3171/2009.6.JNS09133; Cheng YK, 2008, J CLIN NEUROSCI, V15, P1115, DOI 10.1016/j.jocn.2007.09.022; Chibbaro S, 2011, WORLD NEUROSURG, V75, P558, DOI 10.1016/j.wneu.2010.10.020; Coutinho JM, 2009, STROKE, V40, P2233, DOI 10.1161/STROKEAHA.108.543421; De Bonis P, 2012, J NEUROTRAUM, V29, P1071, DOI 10.1089/neu.2011.2116; De Bonis P, 2011, J NEUROTRAUM, V28, P2043, DOI 10.1089/neu.2011.1889; De Bonis P, 2010, J NEUROSURG, V112, P1150, DOI 10.3171/2009.7.JNS09505; Diedler Jennifer, 2009, J Intensive Care Med, V24, P168, DOI 10.1177/0885066609332808; Dorfer C, 2010, WORLD NEUROSURG, V74, P465, DOI 10.1016/j.wneu.2010.08.001; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; Guresir E, 2009, J NEUROL NEUROSUR PS, V80, P799, DOI 10.1136/jnnp.2008.155630; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Hill CS, 2012, BRIT J NEUROSURGERY; Hofmeijer J, 2009, LANCET NEUROL, V8, P326, DOI 10.1016/S1474-4422(09)70047-X; Honeybul S, 2012, PLAST RECONSTR SURG, V130, P1110, DOI 10.1097/PRS.0b013e318267d4de; Honeybul S, 2011, J NEUROTRAUM, V28, P2199, DOI 10.1089/neu.2011.1907; Huang YH, 2011, INJURY; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Iwama T, 2003, NEUROSURGERY, V52, P591, DOI 10.1227/01.NEU.0000047891.86938.46; Juttler E, 2007, STROKE, V38, P2518, DOI 10.1161/STROKEAHA.107.485649; Lee CH, 2012, J TRAUMA ACUTE CARE, V73, P255, DOI 10.1097/TA.0b013e318256a150; Lu Y, 2012, BRIT J NEUROSURG, V26, P216, DOI 10.3109/02688697.2011.629699; Matsuno A, 2006, ACTA NEUROCHIR, V148, P535, DOI 10.1007/s00701-006-0740-6; Meier U, 2008, ACTA NEUROCHIR SUPPL, V102, P29, DOI 10.1007/978-3-211-85578-2_6; Morina Arsim, 2011, Surg Neurol Int, V2, P72, DOI 10.4103/2152-7806.81735; Murthy JMK, 2005, NEUROCRIT CARE, V2, P258, DOI 10.1385/NCC:2:3:258; Piedra MP, 2012, J NEUROSURG-PEDIATR, V10, P268, DOI 10.3171/2012.6.PEDS1268; Schuss P, 2012, J NEUROTRAUM, V29, P1090, DOI 10.1089/neu.2011.2176; Sobani Zain A, 2011, Surg Neurol Int, V2, P123, DOI 10.4103/2152-7806.85055; Sturiale CL, 2012, J NEUROTRAUMA; Thavarajah D, 2012, BRIT J NEUROSURG, V26, P78, DOI 10.3109/02688697.2011.603850; Vahedi K, 2007, STROKE, V38, P2506, DOI 10.1161/STROKEAHA.107.485235; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; Wen L, 2007, J CRANIOFAC SURG, V18, P526, DOI 10.1097/scs.0b013e3180534348; Werndle MC, 2012, CLIN NEUROL NEUROSUR, V114, P962, DOI 10.1016/j.clineuro.2012.02.019; Yadla S, 2011, NEUROSURGERY, V68, P1124, DOI 10.1227/NEU.0b013e31820a5470	42	101	105	0	10	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0303-8467	1872-6968		CLIN NEUROL NEUROSUR	Clin. Neurol. Neurosurg.	AUG	2013	115	8					1293	1297		10.1016/j.clineuro.2012.12.002			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	198NJ	WOS:000322929300017	23273384				2022-02-06	
J	Lee, JY; Kim, HS; Choi, HY; Oh, TH; Yune, TY				Lee, Jee Y.; Kim, Hwang S.; Choi, Hye Y.; Oh, Tae H.; Yune, Tae Y.			Fluoxetine inhibits matrix metalloprotease activation and prevents disruption of blood-spinal cord barrier after spinal cord injury	BRAIN			English	Article						blood-brain barrier; fluoxetine; matrix metalloprotease; spinal cord injury; tight junction	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; FUNCTIONAL RECOVERY; CONTUSION INJURY; INTRACEREBRAL HEMORRHAGE; INFLAMMATORY RESPONSE; ENDOTHELIAL-CELLS; BASEMENT-MEMBRANE; OXIDATIVE STRESS	After spinal cord injury, the disruption of blood-spinal cord barrier by activation of matrix metalloprotease is a critical event leading to infiltration of blood cells, inflammatory responses and neuronal cell death, contributing to permanent neurological disability. Recent evidence indicates that fluoxetine, an anti-depressant drug, is shown to have neuroprotective effects in ischaemic brain injury, but the precise mechanism underlying its protective effects is largely unknown. Here, we show that fluoxetine prevented blood-spinal cord barrier disruption via inhibition of matrix metalloprotease activation after spinal cord injury. After a moderate contusion injury at the T9 level of spinal cord with an infinite horizon impactor in the mouse, fluoxetine (10 mg/kg) was injected intraperitoneally and further administered once a day for indicated time points. Fluoxetine treatment significantly inhibited messenger RNA expression of matrix metalloprotease 2, 9 and 12 after spinal cord injury. By zymography and fluorimetric enzyme activity assay, fluoxetine also significantly reduced matrix metalloprotease 2 and matrix metalloprotease 9 activities after injury. In addition, fluoxetine inhibited nuclear factor kappa B-dependent matrix metalloprotease 9 expression in bEnd.3, a brain endothelial cell line, after oxygen-glucose deprivation/reoxygenation. Fluoxetine also attenuated the loss of tight junction molecules such as zona occludens 1 and occludin after injury in vivo as well as in bEnd.3 cultures. By immunofluorescence staining, fluoxetine prevented the breakdown of the tight junction integrity in endothelial cells of blood vessel after injury. Furthermore, fluoxetine inhibited the messenger RNA expression of chemokines such as Gro alpha, MIP1 alpha and 1 beta, and prevented the infiltration of neutrophils and macrophages, and reduced the expression of inflammatory mediators after injury. Finally, fluoxetine attenuated apoptotic cell death and improved locomotor function after injury. Thus, our results indicate that fluoxetine improved functional recovery in part by inhibiting matrix metalloprotease activation and preventing blood-spinal cord barrier disruption after spinal cord injury. Furthermore, our study suggests that fluoxetine may represent a potential therapeutic agent for preserving blood-brain barrier integrity following ischaemic brain injury and spinal cord injury in humans.	[Yune, Tae Y.] Kyung Hee Univ, Sch Med, Dept Biochem & Mol Biol, Seoul 130701, South Korea; [Lee, Jee Y.; Kim, Hwang S.; Choi, Hye Y.; Oh, Tae H.; Yune, Tae Y.] Kyung Hee Univ, Sch Med, Age Related & Brain Dis Res Ctr, Seoul 130701, South Korea; [Lee, Jee Y.; Yune, Tae Y.] Kyung Hee Univ, Sch Med, Neurodegenerat Control Res Ctr, Seoul 130701, South Korea; [Kim, Hwang S.; Yune, Tae Y.] Kyung Hee Univ, Sch Med, Grad Programme Neurosci, Seoul 130701, South Korea		Yune, TY (corresponding author), Kyung Hee Univ, Sch Med, Dept Biochem & Mol Biol, Med Bldg,10th Floor,Hoegi Dong 1, Seoul 130701, South Korea.	tyune@khu.ac.kr			Brain Research Center of 21st Century Frontier Research Program [2011K000282, 2011K000291]; Pioneer Research Center Program through National Research Foundation of KoreaNational Research Foundation of Korea [20110001692]; Basic Science Research Program through National Research Foundation of Korea [20110000932]; Ministry of Education, Science and Technology (MEST), Republic of KoreaMinistry of Education, Science and Technology, Republic of Korea	This study was supported by Brain Research Center of the 21st Century Frontier Research Program (No. 2011K000282, 2011K000291), the Pioneer Research Center Program through the National Research Foundation of Korea (No. 20110001692), and Basic Science Research Program through the National Research Foundation of Korea grant (No. 20110000932) funded by the Ministry of Education, Science and Technology (MEST), the Republic of Korea.	Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Agrawal S, 2006, J EXP MED, V203, P1007, DOI 10.1084/jem.20051342; Anjaneyulu M, 2006, EUR J PHARMACOL, V538, P80, DOI 10.1016/j.ejphar.2006.03.067; Asahi M, 2001, J NEUROSCI, V21, P7724, DOI 10.1523/JNEUROSCI.21-19-07724.2001; Asensio VC, 1999, TRENDS NEUROSCI, V22, P504, DOI 10.1016/S0166-2236(99)01453-8; Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; Bauer AT, 2010, J CEREBR BLOOD F MET, V30, P837, DOI 10.1038/jcbfm.2009.248; Beattie MS, 2000, J NEUROTRAUM, V17, P915, DOI 10.1089/neu.2000.17.915; Begovic Amra, 2004, Bosn J Basic Med Sci, V4, P79; Benton RL, 2008, J COMP NEUROL, V507, P1031, DOI 10.1002/cne.21570; BIANCHI M, 1995, INFLAMM RES, V44, P466, DOI 10.1007/BF01837911; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Chang DI, 2003, J CEREBR BLOOD F MET, V23, P1408, DOI 10.1097/01.WCB.0000091765.61714.30; Chen XS, 2008, J NEUROCHEM, V107, P1147, DOI 10.1111/j.1471-4159.2008.05697.x; Choi DC, 2010, NEUROBIOL DIS, V39, P272, DOI 10.1016/j.nbd.2010.04.003; Chung ES, 2010, BRAIN RES, V1363, P143, DOI 10.1016/j.brainres.2010.09.049; Chung YC, 2011, NEUROPHARMACOLOGY, V60, P963, DOI 10.1016/j.neuropharm.2011.01.043; Dam M, 1996, STROKE, V27, P1211, DOI 10.1161/01.STR.27.7.1211; Diamond M, 2006, EUR NEUROPSYCHOPHARM, V16, P481, DOI 10.1016/j.euroneuro.2005.11.011; Fazzino F, 2009, INT IMMUNOPHARMACOL, V9, P463, DOI 10.1016/j.intimp.2009.01.011; Feng SR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020599; Fulcher YG, 2011, BIOCHEMISTRY-US, V50, P9488, DOI 10.1021/bi2009807; Gainotti G, 2010, CURR ALZHEIMER RES, V7, P271, DOI 10.2174/156720510791050858; Gerzanich V, 2009, NAT MED, V15, P185, DOI 10.1038/nm.1899; Ghirnikar RS, 2001, J NEUROSCI RES, V64, P582, DOI 10.1002/jnr.1110; Hamada Y, 1996, J NEUROCHEM, V66, P1525; Hartung HP, 2000, J NEUROIMMUNOL, V107, P140, DOI 10.1016/S0165-5728(00)00225-3; Hawkins BT, 2005, PHARMACOL REV, V57, P173, DOI 10.1124/pr.57.2.4; Heo JH, 1999, J CEREBR BLOOD F MET, V19, P624, DOI 10.1097/00004647-199906000-00005; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; Horsfield SA, 2002, INT J PSYCHIAT MED, V32, P337, DOI 10.2190/KQ48-XT0L-2H14-5UMV; Hosokawa T, 2011, J NEUROIMMUNOL, V236, P81, DOI 10.1016/j.jneuroim.2011.04.009; Hsu JYC, 2006, J NEUROSCI, V26, P9841, DOI 10.1523/JNEUROSCI.1993-06.2006; Jin YJ, 2011, CELL SIGNAL, V23, P125, DOI 10.1016/j.cellsig.2010.08.012; Karpus WJ, 1998, J IMMUNOL, V161, P2667; Lee JY, 2010, ENDOCRINOLOGY, V151, P3815, DOI 10.1210/en.2009-1416; Li XQ, 2011, ACTA PHARMACOL SIN, V32, P217, DOI 10.1038/aps.2010.187; Lim CM, 2009, J NEUROSCI RES, V87, P1037, DOI 10.1002/jnr.21899; Liu WL, 2009, J NEUROCHEM, V108, P811, DOI 10.1111/j.1471-4159.2008.05821.x; Mabon PJ, 2000, EXP NEUROL, V166, P52, DOI 10.1006/exnr.2000.7488; McTigue DM, 1998, J NEUROSCI RES, V53, P368, DOI 10.1002/(SICI)1097-4547(19980801)53:3<368::AID-JNR11>3.0.CO;2-1; Miyazaki K, 2011, J NEUROSCI RES, V89, P718, DOI 10.1002/jnr.22594; Mun-Bryce S, 1998, J CEREBR BLOOD F MET, V18, P1163, DOI 10.1097/00004647-199811000-00001; Mun-Bryce S, 1998, AM J PHYSIOL-REG I, V274, pR1203, DOI 10.1152/ajpregu.1998.274.5.R1203; NOBLE LJ, 1989, BRAIN RES, V482, P57, DOI 10.1016/0006-8993(89)90542-8; Noble LJ, 2002, J NEUROSCI, V22, P7526; Okada S, 2004, J NEUROSCI RES, V76, P265, DOI 10.1002/jnr.20044; Ousman SS, 2001, J NEUROSCI, V21, P4649, DOI 10.1523/JNEUROSCI.21-13-04649.2001; Pariente J, 2001, ANN NEUROL, V50, P718, DOI 10.1002/ana.1257; Pellegrino TC, 2002, BRAIN BEHAV IMMUN, V16, P87, DOI 10.1006/brbi.2001.0625; Popovich PG, 2003, EXP NEUROL, V182, P275, DOI 10.1016/S0014-4886(03)00120-1; Rosenberg GA, 2002, GLIA, V39, P279, DOI 10.1002/glia.10108; Rosenberg GA, 1997, NEUROLOGY, V48, P921, DOI 10.1212/WNL.48.4.921; ROSENBERG GA, 1994, LAB INVEST, V71, P417; Rosenberg GA, 1995, BRAIN RES, V703, P151, DOI 10.1016/0006-8993(95)01089-0; Rosenberg GA, 1998, STROKE, V29, P2189, DOI 10.1161/01.STR.29.10.2189; Roumestan C, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-35; Saiwai H, 2010, AM J PATHOL, V176, P2352, DOI 10.2353/ajpath.2010.090839; Salam OMEA, 2004, PHARMACOL RES, V50, P309, DOI 10.1016/j.phrs.2004.01.010; Simard JM, 2007, J CLIN INVEST, V117, P2105, DOI 10.1172/JCI32041; Simard JM, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000522; Sixt M, 2001, J CELL BIOL, V153, P933, DOI 10.1083/jcb.153.5.933; Sounvoravong S, 2007, ACTA BIOL HUNG, V58, P369, DOI 10.1556/ABiol.58.2007.4.4; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; Stirling DP, 2008, J NEUROSCI RES, V86, P1944, DOI 10.1002/jnr.21659; Tahanian E, 2011, DRUG DES DEV THER, V5, P299, DOI 10.2147/DDDT.S19931; Taoka Y, 1997, NEUROSCIENCE, V79, P1177, DOI 10.1016/S0306-4522(97)00011-0; Tian DS, 2009, J NEUROCHEM, V109, P1658, DOI 10.1111/j.1471-4159.2009.06077.x; Toft-Hansen H, 2006, J IMMUNOL, V177, P7242, DOI 10.4049/jimmunol.177.10.7242; Utepbergenov DI, 1998, FEBS LETT, V424, P197, DOI 10.1016/S0014-5793(98)00173-2; Wasserman JK, 2007, EXP NEUROL, V207, P227, DOI 10.1016/j.expneurol.2007.06.025; Wells JEA, 2003, J NEUROSCI, V23, P10107, DOI 10.1523/jneurosci.23-31-10107.2003; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Wiart L, 2000, STROKE, V31, P1829, DOI 10.1161/01.STR.31.8.1829; Wu C, 2009, NAT MED, V15, P519, DOI 10.1038/nm.1957; Xu J, 2001, J NEUROSCI, V21, P92, DOI 10.1523/JNEUROSCI.21-01-00092.2001; Yang Y, 2007, J CEREBR BLOOD F MET, V27, P697, DOI 10.1038/sj.jcbfm.9600375; Yong C, 1998, J NEUROTRAUM, V15, P459, DOI 10.1089/neu.1998.15.459; Yu F, 2008, J NEUROTRAUM, V25, P184, DOI 10.1089/neu.2007.0438; Yune TY, 2007, J NEUROSCI, V27, P7751, DOI 10.1523/JNEUROSCI.1661-07.2007; Yune TY, 2009, J NEUROCHEM, V110, P1276, DOI 10.1111/j.1471-4159.2009.06214.x; Yune TY, 2004, J NEUROTRAUM, V21, P1778, DOI 10.1089/neu.2004.21.1778; Zhang HQ, 2011, J NEUROSCI, V31, P15894, DOI 10.1523/JNEUROSCI.3943-11.2011; Zlokovic BV, 2008, NEURON, V57, P178, DOI 10.1016/j.neuron.2008.01.003	85	101	104	0	20	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950			BRAIN	Brain	AUG	2012	135		8				2375	2389		10.1093/brain/aws171			15	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	984DQ	WOS:000307170300017	22798270	Bronze			2022-02-06	
J	Stocchetti, N; Paterno, R; Citerio, G; Beretta, L; Colombo, A				Stocchetti, Nino; Paterno, Rosalia; Citerio, Giuseppe; Beretta, Luigi; Colombo, Angelo			Traumatic Brain Injury in an Aging Population	JOURNAL OF NEUROTRAUMA			English	Article						adult brain injury; age; geriatric brain injury; outcome measures	HEAD-INJURY; AGE; MORTALITY; OUTCOMES; IMPACT; COMA; CLASSIFICATION; PROGNOSIS; ADULTS; SCALE	The epidemiology of traumatic brain injury (TBI) is changing in several Western countries, with an increasing proportion of elderly TBI patients admitted to the intensive care unit (ICU). We describe a series of 1366 adult patients admitted to three neuro-ICUs in which 44% of cases were 50 years of age or older. The health status before trauma (rated using the APACHE score) was worse in older patients. In all 604 patients had emergency removal of intracranial masses, with extradural hematomas more frequent in young cases and subdural hematomas more frequent in older patients. Outcomes were classified according to the Glasgow Outcome Scale (GOS) 6 months post-trauma, as favorable (GOS score 4-5), or unfavorable (GOS score 1-3). Favorable outcomes were achieved by 50% of patients, but the proportions of unfavorable outcomes rose with age. Mortality was the main cause of unfavorable outcomes 6 months after injury in older patients. Logistic regression analysis indicates that several parameters independently contributed to outcome, including the motor component of the Glasgow Coma Scale (GCS), pupils, CT findings, and early hypotension. Additionally, the odds ratios were very high for age and health status before TBI. Patients admitted to the ICU are increasingly older, have co-morbidities, and have specific types of intracranial lesions. Early rescue, surgical treatment, and intensive care of these patients may produce excellent results up to the age of 59 years, with favorable outcomes still possible for 39% of cases aged 60-69 years, without an excessive burden of severely disabled patients.	[Stocchetti, Nino; Paterno, Rosalia; Colombo, Angelo] Univ Milan, Milan, Italy; [Stocchetti, Nino; Paterno, Rosalia; Colombo, Angelo] Fdn IRCCS Ca Granda Osped Maggiore Policlin, NeuroIntens Care Unit, Milan, Italy; [Citerio, Giuseppe] Osped San Gerardo, NeuroIntens Care Unit, Monza, Italy; [Beretta, Luigi] Osped San Raffaele, NeuroIntens Care Unit, Monza, Italy		Stocchetti, N (corresponding author), Fond IRCCS Ca Granda Osped Maggiore Policlin, Neurointens Care Unit, Via Francesco Sforza 35, I-2122 Milan, Italy.	stocchet@policinico.mi.it	Viani, Rafael/V-1196-2018; Stocchetti, Nino/O-7444-2017; Citerio, Giuseppe/B-1839-2015	Stocchetti, Nino/0000-0003-3250-6834; Citerio, Giuseppe/0000-0002-5374-3161			Beretta L, 2007, ACTA NEUROCHIR, V149, P903, DOI 10.1007/s00701-007-1257-3; Beretta L., 2003, MINERVA ANESTESIOL, V69, P223; Bouras T, 2007, J NEUROTRAUM, V24, P1355, DOI 10.1089/neu.2005.370; Brazinova A, 2010, J NEUROTRAUM, V27, P1549, DOI 10.1089/neu.2010.1315; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; Glorioso C, 2011, PROG NEUROBIOL, V93, P165, DOI 10.1016/j.pneurobio.2010.11.006; Heiden J.S., 1979, NEURAL TRAUMA, P181; HOWARD MA, 1989, J NEUROSURG, V71, P858, DOI 10.3171/jns.1989.71.6.0858; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; KNAUS WA, 1981, CRIT CARE MED, V9, P591, DOI 10.1097/00003246-198108000-00008; Kovacs EJ, 2005, EXP GERONTOL, V40, P549, DOI 10.1016/j.exger.2005.04.009; Lu J, 2005, ACT NEUR S, V95, P281; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; McGwin G, 2001, ARCH SURG-CHICAGO, V136, P197, DOI 10.1001/archsurg.136.2.197; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Stein SC, 2010, J NEUROTRAUM, V27, P1343, DOI 10.1089/neu.2009.1206; Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131; Stocchetti N, 2008, INTENS CARE MED, V34, P461, DOI 10.1007/s00134-007-0948-9; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Tokutomi T, 2008, J NEUROTRAUM, V25, P1407, DOI 10.1089/neu.2008.0577; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Woolcott JC, 2009, ARCH INTERN MED, V169, P1952, DOI 10.1001/archinternmed.2009.357; World Health Organization, 2010, GLOB STAT REP ROAD S	27	101	104	1	18	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	APR	2012	29	6					1119	1125		10.1089/neu.2011.1995			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	927ZL	WOS:000302949100012	22220762	Green Submitted			2022-02-06	
J	Zongo, D; Ribereau-Gayon, R; Masson, F; Laborey, M; Contrand, B; Salmi, LR; Montaudon, D; Beaudeux, JL; Meurin, A; Dousset, V; Loiseau, H; Lagarde, E				Zongo, Drissa; Ribereau-Gayon, Regis; Masson, Francoise; Laborey, Magali; Contrand, Benjamin; Salmi, Louis Rachid; Montaudon, Daniele; Beaudeux, Jean Louis; Meurin, Antoine; Dousset, Vincent; Loiseau, Hugues; Lagarde, Emmanuel			S100-B Protein as a Screening Tool for the Early Assessment of Minor Head Injury	ANNALS OF EMERGENCY MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; BIOCHEMICAL SERUM MARKERS; COMPUTED-TOMOGRAPHY; EMERGENCY-DEPARTMENT; PROGNOSTIC-FACTORS; DECISION-MAKING; CLINICAL POLICY; S-100B PROTEIN; MANAGEMENT; ELIMINATION	Study objective: A computed tomography (CT) scan has high sensitivity in detecting intracranial injury in patients with minor head injury but is costly, exposes patients to high radiation doses, and reveals clinically relevant lesions in less than 10% of cases. We evaluate S100-B protein measurement as a screening tool in a large population of patients with minor head injury. Methods: We conducted a prospective observational study in the emergency department of a teaching hospital (Bordeaux, France). Patients with minor head injury (2,128) were consecutively included from December 2007 to February 2009. CT scans and plasma S100-B levels were compared for 1,560 patients. The main outcome was to evaluate the diagnostic value of the S100-B test, focusing on the negative predictive value and the negative likelihood ratio. Results: CT scan revealed intracranial lesions in 111 (7%) participants, and their median S100-B protein plasma level was 0.46 mu g/L (interquartile range [IQR] 0.27 to 0.72) versus 0.22 mu g/L (IQR 0.14 to 0.36) in the other 1,449 patients. With a cutoff of 0.12 mu g/L, traumatic brain injuries on CT were identified with a sensitivity of 99.1% (95% confidence interval [CI] 95.0% to 100%), a specificity of 19.7% (95% CI 17.7% to 21.9%), a negative predictive value of 99.7% (95% CI 98.1% to 100%), a positive likelihood ratio of 1.24 (95% CI 1.20 to 1.28), and a negative likelihood ratio of 0.04 (95% CI 0.006 to 0.32). Conclusion: Measurement of plasma S100-B on admission of patients with minor head injury is a promising screening tool that may be of help to support the clinician's decision not to perform CT imaging in certain cases of low-risk head injury. [Ann Emerg Med. 2012;59:209-218.]	[Zongo, Drissa; Ribereau-Gayon, Regis] Hop Pellegrin, Serv Urgences Adultes, F-33076 Bordeaux, France; [Masson, Francoise] Hop Pellegrin, Serv Anesthesie Reanimat, F-33076 Bordeaux, France; [Montaudon, Daniele] Hop Pellegrin, Serv Neuroradiol Diagnost & Therapeut, Biochim Lab, F-33076 Bordeaux, France; [Meurin, Antoine; Dousset, Vincent] Hop Pellegrin, Serv Neuroimagerie, F-33076 Bordeaux, France; [Loiseau, Hugues] Hop Pellegrin, Serv Neurochirurg, F-33076 Bordeaux, France; [Salmi, Louis Rachid] Ctr Hosp Univ Bordeaux, Serv Informat Med, Bordeaux, France; [Zongo, Drissa; Laborey, Magali; Contrand, Benjamin; Salmi, Louis Rachid; Lagarde, Emmanuel] Univ Bordeaux Segalan, Inst Sante Publ Epidemiol & Dev, Bordeaux, France; [Zongo, Drissa; Ribereau-Gayon, Regis; Masson, Francoise; Laborey, Magali; Contrand, Benjamin; Salmi, Louis Rachid; Lagarde, Emmanuel] INSERM, Equipe Prevent & Prise Charge Traumatismes, Unite 897, Bordeaux, France; [Beaudeux, Jean Louis] Hop Charles Foix, APHP, Biochim Lab, Paris, France		Zongo, D (corresponding author), Hop Pellegrin, Serv Urgences Adultes, F-33076 Bordeaux, France.	drissa.zongo@isped.u-bordeaux2.fr	Regis, RIBEREAU-GAYON/U-5423-2019; Salmi, Louis-Rachid/T-1982-2019; Lagarde, Emmanuel/F-7132-2013; contrand, benjamin/T-1994-2019	DOUSSET, VINCENT/0000-0003-0427-3236	INSERMInstitut National de la Sante et de la Recherche Medicale (Inserm)European Commission; Reunica Group; teaching hospital of Bordeaux (PHRC)	By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org). This study was funded by INSERM, the Reunica Group, and the teaching hospital of Bordeaux (PHRC 2007).	af Geijerstam JL, 2006, BMJ-BRIT MED J, V333, P465, DOI 10.1136/bmj.38918.669317.4F; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Beaudeux J-L, 2009, Ann Pharm Fr, V67, P187, DOI 10.1016/j.pharma.2009.03.002; Ben Abdesselam O, 2003, CLIN CHEM, V49, P836, DOI 10.1373/49.5.836; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Biberthaler P, 2001, WORLD J SURG, V25, P93, DOI 10.1007/s002680020370; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Cushman JG, 2001, J TRAUMA, V51, P1016, DOI 10.1097/00005373-200111000-00034; Fabbri A, 2004, J NEUROL NEUROSUR PS, V75, P410, DOI 10.1136/jnnp.2003.016113; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Ikeda Yasuhiko, 2005, Rinsho Byori, V53, P395; Ingebrigtsen T, 2003, RESTOR NEUROL NEUROS, V21, P171; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Jagoda AS, 2002, ANN EMERG MED, V40, P231, DOI [10.1067/mem.2002.125782, 10.1016/j.jen.2008.12.010]; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Rothoerl RD, 1998, J TRAUMA, V45, P765, DOI 10.1097/00005373-199810000-00025; Ruan S, 2009, J NEUROTRAUM, V26, P1655, DOI 10.1089/neu.2009-0928; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Sedaghat F, 2008, HIPPOKRATIA, V12, P198; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Smith-Bindman R, 2010, NEW ENGL J MED, V363, P1, DOI 10.1056/NEJMp1002530; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; Springborg Jtiaocnob Bertram, 2009, Ugeskr Laeger, V171, P978; STEIN SC, 1990, NEUROSURGERY, V26, P638, DOI 10.1227/00006123-199004000-00012; Stiell IG, 2001, ANN EMERG MED, V38, P160, DOI 10.1067/mem.2001.116796; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tort ABL, 2003, CLIN BIOCHEM, V36, P629, DOI 10.1016/S0009-9120(03)00107-3; Townend W, 2006, J NEUROTRAUM, V23, P149, DOI 10.1089/neu.2006.23.149; Unden J, 2005, J TRAUMA, V58, P59, DOI 10.1097/01.TA.0000130613.35877.75; Unden J, 2009, SCAND J CLIN LAB INV, V69, P13, DOI 10.1080/00365510802651833; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; Woertgen C, 2002, BRAIN INJURY, V16, P807, DOI 10.1080/02699050210128933; Yates PJ, 2006, J NEUROL NEUROSUR PS, V77, P699, DOI 10.1136/jnnp.2005.081901	40	101	107	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644	1097-6760		ANN EMERG MED	Ann. Emerg. Med.	MAR	2012	59	3					209	218		10.1016/j.annemergmed.2011.07.027			10	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	905MM	WOS:000301276300010	21944878				2022-02-06	
J	Sharma, SK; Kharkwal, GB; Sajo, M; Huang, YY; De Taboada, L; McCarthy, T; Hamblin, MR				Sharma, Sulbha K.; Kharkwal, Gitika B.; Sajo, Mari; Huang, Ying-Ying; De Taboada, Luis; McCarthy, Thomas; Hamblin, Michael R.			Dose Response Effects of 810 nm Laser Light on Mouse Primary Cortical Neurons	LASERS IN SURGERY AND MEDICINE			English	Article						low level laser therapy; LLLT; photobiomodulation; cultured cortical neurons; near-infra red laser; reactive oxygen species; nitric oxide; mitochondrial membrane potential; intracellular calcium; ATP; biphasic dose response	HELIUM-NEON LASER; TERM NEUROLOGICAL DEFICITS; TRAUMATIC BRAIN-INJURY; HUMAN SKIN FIBROBLASTS; NITRIC-OXIDE; PROMOTES REGENERATION; FUNCTIONAL RECOVERY; ISCHEMIC-STROKE; INFRARED LIGHT; ATP SYNTHESIS	Background and Objectives: In the past four decades numerous studies have reported the efficacy of low level light (laser) therapy (LLLT) as a treatment for diverse diseases and injuries. Recent studies have shown that LLLT can biomodulate processes in the central nervous system and has been extensively studied as a stroke treatment. However there is still a lack of knowledge on the effects of LLLT at the cellular level in neurons. The present study aimed to study the effect of 810 nm laser on several cellular processes in primary cortical neurons cultured from embryonic mouse brains. Study Design/Materials and Methods: Neurons were irradiated with fluences of 0.03, 0.3, 3, 10, or 30 J/cm(2) of 810-nm laser delivered over varying times at 25 mW/cm(2) and intracellular levels of reactive oxygen species (ROS), nitric oxide and calcium were measured using fluorescent probes within 5 minutes of the end of irradiation. The changes in mitochondrial function in response to light were studied in terms of adenosine triphosphate (ATP) and mitochondrial membrane potential (MMP). Results: Light induced a significant increase in calcium, ATP and MMP at lower fluences and a decrease at higher fluences. ROS was significantly induced at low fluences, followed by a decrease and a second larger increase at 30 J/cm(2). Nitric oxide levels showed a similar pattern of a double peak but values were less significant compared to ROS. Conclusions: The results suggest that LLLT at lower fluences is capable of inducing mediators of cell signaling processes which in turn may be responsible for the beneficial stimulatory effects of the low level laser. At higher fluences beneficial mediators are reduced and high levels of Janus-type mediators such as ROS and NO (beneficial at low concentrations and harmful at high concentrations) may be responsible for the damaging effects of high-fluence light and the overall biphasic dose response. Lasers Surg. Med. 43:851-859, 2011. (C) 2011 Wiley-Liss, Inc.	[Sharma, Sulbha K.; Kharkwal, Gitika B.; Sajo, Mari; Huang, Ying-Ying; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA; [Sharma, Sulbha K.; Kharkwal, Gitika B.; Huang, Ying-Ying; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA; [Sajo, Mari] Univ Tokyo, Grad Sch Pharmaceut, Tokyo, Japan; [Huang, Ying-Ying] Guangxi Med Univ, Aesthet & Plast Ctr, Nanning, Peoples R China; [De Taboada, Luis; McCarthy, Thomas] Photothera Inc, Carlsbad, CA USA; [Hamblin, Michael R.] Harvard Univ, MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA		Hamblin, MR (corresponding author), Massachusetts Gen Hosp, Wellman Ctr Photomed, 40 Blossom St, Boston, MA 02114 USA.	hamblin@helix.mgh.harvard.edu	Huang, yingying/J-7329-2012; Hamblin, Michael R/H-2758-2019; Huang, Ying-ying/G-3153-2011	Huang, yingying/0000-0002-4038-0277; Hamblin, Michael R/0000-0001-6431-4605; Huang, Ying-ying/0000-0003-3066-6981; De Taboada, Luis/0000-0002-0153-6419	Photothera, Inc.; Photothera; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01AI050875]; Center for Integration of Medicine and Innovative Technology [DAMD17-02-2-0006]; CDMRP Program in TBI [W81XWH-09-1-0514]; Air Force Office of Scientific ResearchUnited States Department of DefenseAir Force Office of Scientific Research (AFOSR) [FA9950-04-1-0079]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01AI050875] Funding Source: NIH RePORTER	This study was partly supported by a sponsored research agreement from Photothera, Inc. Luis De Taboada and Thomas McCarthy are employees and stockholders in Photothera, Inc. Michael R Hamblin has received research support, loan of equipment and consulting fees from Photothera.; Contract grant sponsor: NIH; Contract grant number: R01AI050875; Contract grant sponsor: Center for Integration of Medicine and Innovative Technology; Contract grant number: DAMD17-02-2-0006; Contract grant sponsor: CDMRP Program in TBI; Contract grant number: W81XWH-09-1-0514; Contract grant sponsor: Air Force Office of Scientific Research; Contract grant number: FA9950-04-1-0079.	Anders JJ, 2004, NEUROL RES, V26, P233, DOI 10.1179/016164104225013914; Ball KA, 2011, J PHOTOCH PHOTOBIO B, V102, P182, DOI 10.1016/j.jphotobiol.2010.12.002; Borutaite V, 2000, BBA-BIOENERGETICS, V1459, P405, DOI 10.1016/S0005-2728(00)00178-X; BREWER GJ, 1995, J NEUROSCI RES, V42, P674, DOI 10.1002/jnr.490420510; Brookes PS, 2005, FREE RADICAL BIO MED, V38, P12, DOI 10.1016/j.freeradbiomed.2004.10.016; Brookes PS, 2004, AM J PHYSIOL-CELL PH, V287, pC817, DOI 10.1152/ajpcell.00139.2004; Byrnes KR, 2005, LASER SURG MED, V36, P171, DOI 10.1002/lsm.20143; Calabrese V, 2007, NAT REV NEUROSCI, V8, P766, DOI 10.1038/nrn2214; Chen AC-H, 2009, ROLE REACTIVE OXYGEN; Chen AC-H, 2009, LOW LEVEL LASER THER, V7165, p0B; Chow R, 2006, PHOTOMED LASER SURG, V24, P69, DOI 10.1089/pho.2006.24.69; De Taboada L, 2011, J ALZHEIMERS DIS, V23, P521, DOI 10.3233/JAD-2010-100894; DeTaboada L, 2006, LASER SURG MED, V38, P70, DOI 10.1002/lsm.20256; Fulop AM, 2010, CLIN J PAIN, V26, P729, DOI 10.1097/AJP.0b013e3181f09713; Gahm C, 2006, J NEUROTRAUM, V23, P1343, DOI 10.1089/neu.2006.23.1343; Hamblin MR, 2008, PROC SPIE, V6846, DOI 10.1117/12.764918; Hashmi JT, 2010, PM&R, V2, pS292, DOI 10.1016/j.pmrj.2010.10.013; Hawkins D, 2006, PHOTOMED LASER SURG, V24, P705, DOI 10.1089/pho.2006.24.705; Hawkins DH, 2006, LASER SURG MED, V38, P74, DOI 10.1002/lsm.20271; Hu WP, 2007, J INVEST DERMATOL, V127, P2048, DOI 10.1038/sj.jid.5700826; Huang L., 2010, J CELL PHYSL; Huang YY, 2009, DOSE-RESPONSE, V7, P358, DOI 10.2203/dose-response.09-027.Hamblin; Karu T, 1999, J PHOTOCH PHOTOBIO B, V49, P1, DOI 10.1016/S1011-1344(98)00219-X; Karu TI, 2005, LASER SURG MED, V36, P307, DOI 10.1002/lsm.20148; Konstantinovic LM, 2010, PAIN MED, V11, P1169, DOI 10.1111/j.1526-4637.2010.00907.x; Lampl Y, 2007, STROKE, V38, P1843, DOI 10.1161/STROKEAHA.106.478230; Lane N, 2006, NATURE, V443, P901, DOI 10.1038/443901a; Lapchak PA, 2010, ANN MED, V42, P576, DOI 10.3109/07853890.2010.532811; Lapchak PA, 2010, BRAIN RES, V1306, P100, DOI 10.1016/j.brainres.2009.10.022; Lohr NL, 2009, J MOL CELL CARDIOL, V47, P256, DOI 10.1016/j.yjmcc.2009.03.009; Lu DY, 2003, J NEUROSURG, V99, P351, DOI 10.3171/jns.2003.99.2.0351; LUBART R, 1992, J PHOTOCH PHOTOBIO B, V15, P337, DOI 10.1016/1011-1344(92)85139-L; Lubart R, 2006, PHOTOMED LASER SURG, V24, P179, DOI 10.1089/pho.2006.24.179; Lucas C, 2002, LASER MED SCI, V17, P110, DOI 10.1007/s101030200018; Michalikova S, 2008, NEUROBIOL LEARN MEM, V89, P480, DOI 10.1016/j.nlm.2007.07.014; MILLER RJ, 1987, SCIENCE, V235, P46, DOI 10.1126/science.2432656; Morales-Medina JC, 2007, SYNAPSE, V61, P785, DOI 10.1002/syn.20406; Naeser MA, 2011, PHOTOMED LASER SURG, V29, P351, DOI 10.1089/pho.2010.2814; Oron A, 2007, J NEUROTRAUM, V24, P651, DOI 10.1089/neu.2006.0198; Oron A, 2006, STROKE, V37, P2620, DOI 10.1161/01.STR.0000242775.14642.b8; Oron U, 2007, PHOTOMED LASER SURG, V25, P180, DOI 10.1089/pho.2007.2064; PASSARELLA S, 1984, FEBS LETT, V175, P95, DOI 10.1016/0014-5793(84)80577-3; Pastore D, 1996, BIOCHEM MOL BIOL INT, V39, P149; Patel NJ, 2010, EUR J PHARMACOL, V633, P1, DOI 10.1016/j.ejphar.2010.01.012; Peplow PV, 2010, PHOTOMED LASER SURG, V28, P291, DOI 10.1089/pho.2008.2446; Peres MFP, 2010, CEPHALALGIA, V30, P1408, DOI 10.1177/0333102410362121; Poyton RO, 2011, DISCOV MED, V11, P154; REERS M, 1991, BIOCHEMISTRY-US, V30, P4480, DOI 10.1021/bi00232a015; Sommer AP, 2001, J CLIN LASER MED SUR, V19, P29, DOI 10.1089/104454701750066910; Sun XG, 2010, FEBS J, V277, P4789, DOI 10.1111/j.1742-4658.2010.07884.x; Tafur J, 2008, PHOTOMED LASER SURG, V26, P323, DOI 10.1089/pho.2007.2184; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; Vincent SR, 2010, PROG NEUROBIOL, V90, P246, DOI 10.1016/j.pneurobio.2009.10.007; Wang F, 2005, LASER SURG MED, V36, P2, DOI 10.1002/lsm.20130; Wu SN, 2009, J CELL PHYSIOL, V218, P603, DOI 10.1002/jcp.21636; Wu XJ, 2009, LASER SURG MED, V41, P36, DOI 10.1002/lsm.20729; Xavier M, 2010, LASER SURG MED, V42, P553, DOI 10.1002/lsm.20896; Yang WZ, 2007, PHOTOCHEM PHOTOBIOL, V83, P979, DOI 10.1111/j.1751-1097.2007.00116.x; Yasukawa A, 2007, J VET MED SCI, V69, P799, DOI 10.1292/jvms.69.799; Yoshihara Y, 2009, CURR OPIN NEUROBIOL, V19, P146, DOI 10.1016/j.conb.2009.05.013; YOUNG S R, 1990, Laser Therapy, V2, P53; Zhang LL, 2010, J CELL PHYSIOL, V224, P218, DOI 10.1002/jcp.22123; Zhang R, 2009, J MOL CELL CARDIOL, V46, P4, DOI 10.1016/j.yjmcc.2008.09.707	63	101	103	0	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0196-8092	1096-9101		LASER SURG MED	Lasers Surg. Med.	SEP	2011	43	8					851	859		10.1002/lsm.21100			9	Dermatology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Dermatology; Surgery	824WG	WOS:000295232300010	21956634	Green Accepted			2022-02-06	
J	Prevost, TP; Balakrishnan, A; Suresh, S; Socrate, S				Prevost, Thibault P.; Balakrishnan, Asha; Suresh, Subra; Socrate, Simona			Biomechanics of brain tissue	ACTA BIOMATERIALIA			English	Article						Brain tissue mechanics; Nonlinear dynamic behavior; Visco-hyperelastic; Bulk response; High rate	ELASTIC-PLASTIC DEFORMATION; FINITE-ELEMENT-ANALYSIS; CENTRAL-NERVOUS-SYSTEM; MECHANICAL-PROPERTIES; CONSTITUTIVE MODEL; PORCINE LIVER; IN-VIVO; STRAIN; BEHAVIOR; SHEAR	The dynamic behavior of porcine brain tissue, obtained from a series of in vitro observations and experiments, is analyzed and described here with the aid of a large strain, nonlinear, viscoelastic constitutive model. Mixed gray and white matter samples excised from the superior cortex were tested in unconfined uniaxial compression within 15 h post mortem. The test sequence consisted of three successive load-unload segments at strain rates of 1, 0.1 and 0.01 s(-1), followed by stress relaxation (n = 25). The volumetric compliance of the tissue was assessed for a subset of specimens (n = 7) using video extensometry techniques. The tissue response exhibited moderate compressibility, substantial nonlinearity, hysteresis, conditioning and rate dependence. A large strain kinematics nonlinear viscoelastic model was developed to account for the essential features of the tissue response over the entire deformation history. The corresponding material parameters were obtained by fitting the model to the measured conditioned response (axial and volumetric) via a numerical optimization scheme. The model successfully captures the observed complexities of the material response in loading, unloading and relaxation over the entire range of strain rates. The accuracy of the model was further verified by comparing model predictions with the tissue response in unconfined compression at higher strain rate (10 s(-1)) and with literature data in uniaxial tension. The proposed constitutive framework was also found to be adequate to model the loading response of brain tissue in uniaxial compression over a wider range of strain rates (0.01-3000 s(-1)), thereby providing a valuable tool for simulations of dynamic transients (impact, blast/shock wave propagation) leading to traumatic brain injury. (c) 2010 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.	[Suresh, Subra; Socrate, Simona] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA; [Prevost, Thibault P.; Suresh, Subra] MIT, Dept Mat Sci & Engn, Cambridge, MA 02139 USA; [Balakrishnan, Asha; Suresh, Subra] MIT, Dept Mech Engn, Cambridge, MA 02139 USA		Socrate, S (corresponding author), MIT, Harvard Mit Div Hlth Sci & Technol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	ssocrate@mit.edu	Suresh, Subra/B-8289-2008	Suresh, Subra/0000-0002-6223-6831	US Army Research Office, through the MIT Institute for Soldier Nanotechnologies [W911NF-07-D-0004]; Joint Improvised Explosive Devices Defeat Organization [W911NF-07-1-0035]; Ecole Nationale des Ponts et Chaussees (Universite Paris-Est, France); Singapore-MIT Alliance for Research and Technology CentreSingapore-MIT Alliance for Research & Technology Centre (SMART)	The authors acknowledge the support of the US Army Research Office, through the MIT Institute for Soldier Nanotechnologies (W911NF-07-D-0004) and the Joint Improvised Explosive Devices Defeat Organization (W911NF-07-1-0035), and that of Ecole Nationale des Ponts et Chaussees (Universite Paris-Est, France). Partial support for this work was also obtained from the Computational Systems Biology Programme of the Singapore-MIT Alliance and from the Interdisciplinary Research Group on Infectious Diseases, funded by the Singapore-MIT Alliance for Research and Technology Centre. The authors are grateful to Professor Wayne Chen from Purdue University for providing the high rate tissue data. There is no conflict of interest to be reported.	ANAND L, 1979, J APPL MECH-T ASME, V46, P78, DOI 10.1115/1.3424532; Arbogast KB, 1998, J BIOMECH, V31, P801, DOI 10.1016/S0021-9290(98)00068-2; ARRUDA EM, 1993, J MECH PHYS SOLIDS, V41, P389, DOI 10.1016/0022-5096(93)90013-6; Atay SM, 2008, J BIOMECH ENG-T ASME, V130, DOI 10.1115/1.2899575; Balakrishnan A, 2008, EXP MECH, V48, P549, DOI 10.1007/s11340-007-9087-z; BALAKRISHNAN A, 2007, THESIS MIT CAMBRIDGE; BASSER PJ, 1992, MICROVASC RES, V44, P143, DOI 10.1016/0026-2862(92)90077-3; Bergstrom JS, 2001, MECH MATER, V33, P523, DOI 10.1016/S0167-6636(01)00070-9; BERNICK K, 2009, P ASME 2009 SUMM BIO; Bilston LE, 1997, BIORHEOLOGY, V34, P377, DOI 10.1016/S0006-355X(98)00022-5; Bilston LE, 2001, BIORHEOLOGY, V38, P335; Biot MA, 1941, J APPL PHYS, V12, P155, DOI 10.1063/1.1712886; BOYCE MC, 1989, J MECH PHYS SOLIDS, V37, P647, DOI 10.1016/0022-5096(89)90033-1; Brands Dave W A, 2002, Stapp Car Crash J, V46, P103; Brands DWA, 2004, J BIOMECH, V37, P127, DOI 10.1016/S0021-9290(03)00243-4; Cheng S, 2007, J BIOMECH, V40, P117, DOI 10.1016/j.jbiomech.2005.11.004; Chui C, 2007, MED BIOL ENG COMPUT, V45, P99, DOI 10.1007/s11517-006-0137-y; Coats B, 2006, J BIOMECH, V39, P2521, DOI 10.1016/j.jbiomech.2005.07.020; Criscione JC, 2002, COMPUT STRUCT, V80, P1895, DOI 10.1016/S0045-7949(02)00208-0; Darvish KK, 2001, MED ENG PHYS, V23, P633, DOI 10.1016/S1350-4533(01)00101-1; DICKERSON JW, 1967, PROC R SOC SER B-BIO, V166, P384, DOI 10.1098/rspb.1967.0002; Donnelly BR, 1997, J BIOMECH ENG-T ASME, V119, P423, DOI 10.1115/1.2798289; Duhaime AC, 2000, J NEUROSURG, V93, P455, DOI 10.3171/jns.2000.93.3.0455; El Sayed T, 2008, COMPUT METHOD APPL M, V197, P4692, DOI 10.1016/j.cma.2008.06.006; El Sayed T, 2008, J BIOMECH, V41, P1458, DOI 10.1016/j.jbiomech.2008.02.023; ESTES MS, 1970, MECH ENG, V92, P58; FALLENSTEIN GT, 1969, J BIOMECH, V2, P217, DOI 10.1016/0021-9290(69)90079-7; Fang MR, 2005, NEUROSIGNALS, V14, P102, DOI 10.1159/000086292; FLYNN TJ, 1984, NEUROCHEM RES, V9, P935, DOI 10.1007/BF00964525; Franceschini G, 2006, J MECH PHYS SOLIDS, V54, P2592, DOI 10.1016/j.jmps.2006.05.004; GALFORD JE, 1970, J BIOMECH, V3, P211, DOI 10.1016/0021-9290(70)90007-2; Gardel ML, 2006, P NATL ACAD SCI USA, V103, P1762, DOI 10.1073/pnas.0504777103; Gefen A, 2003, J NEUROTRAUM, V20, P1163, DOI 10.1089/089771503770802853; Gefen A, 2004, J BIOMECH, V37, P1339, DOI 10.1016/j.jbiomech.2003.12.032; Guillaume A, 1997, J BIOMECH, V30, P383, DOI 10.1016/S0021-9290(96)00153-4; Holzapfel GA., 2000, NONLINEAR SOLID MECH; Hrapko M, 2006, BIORHEOLOGY, V43, P623; Jordan P, 2009, J MECH BEHAV BIOMED, V2, P192, DOI 10.1016/j.jmbbm.2008.08.006; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; Kohandel M, 2006, MED ENG PHYS, V28, P449, DOI 10.1016/j.medengphy.2005.01.005; Lagarias JC, 1998, SIAM J OPTIMIZ, V9, P112, DOI 10.1137/S1052623496303470; LEE EH, 1969, J APPL MECH, V36, P1, DOI 10.1115/1.3564580; Lodish H., 2007, MOL CELL BIOL, Vsixth; McElhaney JH, 1973, PERSPECTIVES BIOMEDI, P215, DOI DOI 10.1007/978-1-349-01604-4_34; MENDIS KK, 1995, J BIOMECH ENG-T ASME, V117, P279, DOI 10.1115/1.2794182; METZ H, 1970, J BIOMECH, V3, P453, DOI 10.1016/0021-9290(70)90017-5; Miller K, 1999, J BIOMECH, V32, P531, DOI 10.1016/S0021-9290(99)00010-X; Miller K, 1997, J BIOMECH, V30, P1115, DOI 10.1016/S0021-9290(97)00092-4; Miller K, 2002, J BIOMECH, V35, P483, DOI 10.1016/S0021-9290(01)00234-2; Miller K, 2000, J BIOMECH, V33, P1369, DOI 10.1016/S0021-9290(00)00120-2; Moore DF, 2009, NEUROIMAGE, V47, pT10, DOI 10.1016/j.neuroimage.2009.02.019; Mulliken AD, 2006, INT J SOLIDS STRUCT, V43, P1331, DOI 10.1016/j.ijsolstr.2005.04.016; Nicholson C, 2001, REP PROG PHYS, V64, P815, DOI 10.1088/0034-4885/64/7/202; Nicolle S, 2005, BIORHEOLOGY, V42, P209; Nicolle Stephane, 2004, Stapp Car Crash J, V48, P239; PAMIDI MR, 1978, J BIOMECH ENG-T ASME, V100, P44, DOI 10.1115/1.3426188; PAMPIGLIONE G, 1971, P ROY SOC MED, V64, P429, DOI 10.1177/003591577106400441; Pervin F, 2009, J BIOMECH, V42, P731, DOI 10.1016/j.jbiomech.2009.01.023; Peters GWM, 1997, BIORHEOLOGY, V34, P127, DOI 10.1016/S0006-355X(97)00009-7; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; RUAN JS, 1994, J BIOMECH ENG-T ASME, V116, P44, DOI 10.1115/1.2895703; Saraf H, 2007, J BIOMECH, V40, P1960, DOI 10.1016/j.jbiomech.2006.09.021; Shreiber DI, 2009, BIOMECH MODEL MECHAN, V8, P311, DOI 10.1007/s10237-008-0137-y; SHUCK LZ, 1972, J BASIC ENG-T ASME, V94, P905, DOI 10.1115/1.3425588; Takhounts Erik G, 2003, Stapp Car Crash J, V47, P79; Tamura A, 2007, J BIOMECH SCI ENG, V2, P115, DOI [10.1299/jbse.2.115, DOI 10.1299/JBSE.2.115]; Thibault KL, 1998, J BIOMECH, V31, P1119, DOI 10.1016/S0021-9290(98)00122-5; Velardi F, 2006, BIOMECH MODEL MECHAN, V5, P53, DOI 10.1007/s10237-005-0007-9; WALSH EK, 1977, AM J PHYSIOL, V232, pR27, DOI 10.1152/ajpregu.1977.232.1.R27; Zhang Liying, 2002, Stapp Car Crash J, V46, P145; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749	72	101	103	3	71	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1742-7061	1878-7568		ACTA BIOMATER	Acta Biomater.	JAN	2011	7	1					83	95		10.1016/j.actbio.2010.06.035			13	Engineering, Biomedical; Materials Science, Biomaterials	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Materials Science	687RJ	WOS:000284795300007	20603231				2022-02-06	
J	Muller, F; Simion, A; Reviriego, E; Galera, C; Mazaux, JM; Barat, M; Joseph, PA				Muller, Francois; Simion, Audrey; Reviriego, Elsa; Galera, Cedric; Mazaux, Jean-Michel; Barat, Michel; Joseph, Pierre-Alain			Exploring theory of mind after severe traumatic brain injury	CORTEX			English	Article						Theory of mind; Empathy; Head injury; Social cognition	VENTROMEDIAL PREFRONTAL CORTEX; HIGH-FUNCTIONING AUTISM; EMOTION RECOGNITION; ASPERGER-SYNDROME; SOCIAL COMMUNICATION; NONVERBAL TASK; EMPATHY; ATTRIBUTION; INTENTIONS; COGNITION	Previous studies have reported a dissociation between social behavioral impairments after severe traumatic brain injury (TBI) and relatively preserved performances in traditional tasks that investigate cognitive abilities. Theory of mind (ToM) refers to the ability to make inferences about other's mental states and use them to understand and predict others' behavior. We tested a group of 15 patients with severe TBI and 15 matched controls on a series of four verbal and non-verbal ToM tasks: the faux pas test, the first-order and second-order false belief task, the character intention task and the Reading the Mind in the Eyes Test. Participants with severe TBI were also compared to controls on non-ToM inference tasks of indirect speech act from the Montreal Evaluation of Communication (M.E.C.) Protocol and empathy (Davis Interpersonal Reactivity Index - I.R.I.) and tests for executive functions. Subjects with TBI performed worse than control subjects on all ToM tasks, except the first-order false belief task. The findings converge with previous evidence for ToM deficit in TBI and dissociation between ToM and executive functions. We show that ToM deficit is probably distinct from other aspects of social cognition like empathy and pragmatic communication skills. (C) 2009 Elsevier Srl. All rights reserved.	[Muller, Francois; Simion, Audrey; Reviriego, Elsa; Mazaux, Jean-Michel; Barat, Michel; Joseph, Pierre-Alain] CHU Pellegrin, Serv Med Phys & Readaptat, F-33076 Bordeaux, France; [Galera, Cedric] Ctr Hosp Charles Perrens, Serv Univ Psychiat Enfant & Adolescent, Bordeaux, France		Muller, F (corresponding author), CHU Pellegrin, Serv Med Phys & Readaptat, F-33076 Bordeaux, France.	fmuller.gassies@ugecamaq.fr	Galera, Cedric/T-4896-2019	GALERA, CEDRIC/0000-0003-0549-9608			Allerdings MD, 2006, BRAIN COGNITION, V60, P193, DOI 10.1016/j.bandc.2004.09.018; Azouvi P, 2000, CURR OPIN NEUROL, V13, P665, DOI 10.1097/00019052-200012000-00009; BACH L, 1998, COGNITIVE NEUROPSYCH, V3, P139; Baron-Cohen S, 2001, J CHILD PSYCHOL PSYC, V42, P241, DOI 10.1017/S0021963001006643; Baron-Cohen S, 1999, J AUTISM DEV DISORD, V29, P407, DOI 10.1023/A:1023035012436; BaronCohen S, 1997, J CHILD PSYCHOL PSYC, V38, P813, DOI 10.1111/j.1469-7610.1997.tb01599.x; Bibby H, 2005, NEUROPSYCHOLOGIA, V43, P99, DOI 10.1016/j.neuropsychologia.2004.04.027; Brunet E, 2000, NEUROIMAGE, V11, P157, DOI 10.1006/nimg.1999.0525; BRUYER R., 1995, ARCH PSYCHOL, V63, P257; CARDEBAT D, 1990, ACTA NEUROL BELG, V90, P207; Channon S, 2005, BRAIN LANG, V93, P123, DOI 10.1016/j.bandl.2004.09.002; Channon S, 2000, NEUROPSYCHOLOGIA, V38, P1006, DOI 10.1016/S0028-3932(99)00154-2; Croker V, 2005, BRAIN INJURY, V19, P787, DOI 10.1080/02699050500110033; Dahlberg C, 2006, BRAIN INJURY, V20, P425, DOI 10.1080/02699050600664574; DAVIS MH, 1983, J PERS SOC PSYCHOL, V44, P113, DOI 10.1037/0022-3514.44.1.113; DELIS DC, 1988, J CONSULT CLIN PSYCH, V56, P123, DOI 10.1037/0022-006X.56.1.123; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; Eslinger PJ, 1998, EUR NEUROL, V39, P193, DOI 10.1159/000007933; Frith CD, 1996, PSYCHOL MED, V26, P521, DOI 10.1017/S0033291700035601; Gallagher HL, 2000, NEUROPSYCHOLOGIA, V38, P11, DOI 10.1016/S0028-3932(99)00053-6; Havet-Thomassin V, 2006, BRAIN INJURY, V20, P83, DOI 10.1080/02699050500340655; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P1623, DOI 10.1016/j.neuropsychologia.2006.03.020; Joanette Y, 2004, PROTOCOLE MONTREAL E; Koenigs M, 2007, NATURE, V446, P908, DOI 10.1038/nature05631; Levin H S, 1991, Neurosurg Clin N Am, V2, P457; Martin I, 2005, APHASIOLOGY, V19, P712, DOI 10.1080/02687030500172203; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Milders M, 2008, J INT NEUROPSYCH SOC, V14, P318, DOI 10.1017/S1355617708080351; PERNER J, 1985, J EXP CHILD PSYCHOL, V39, P437, DOI 10.1016/0022-0965(85)90051-7; Perner J, 1999, TRENDS COGN SCI, V3, P337, DOI 10.1016/S1364-6613(99)01362-5; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Powell J., 2000, COGNITIVE NEUROPSYCH, V5, P175, DOI [DOI 10.1080/13546800050083520, 10.1080/13546800050083520]; PREMACK D, 1978, BEHAV BRAIN SCI, V1, P515, DOI 10.1017/S0140525X00076512; Rowe AD, 2001, BRAIN, V124, P600, DOI 10.1093/brain/124.3.600; Russell J, 1999, J CHILD PSYCHOL PSYC, V40, P859, DOI 10.1017/S0021963099004229; Sarfati Y, 1997, SCHIZOPHR RES, V25, P199, DOI 10.1016/S0920-9964(97)00025-X; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Shallice T, 2001, BRAIN, V124, P247, DOI 10.1093/brain/124.2.247; Shamay-Tsoory SG, 2003, J COGNITIVE NEUROSCI, V15, P324, DOI 10.1162/089892903321593063; Shamay-Tsoory SG, 2007, NEUROPSYCHOLOGIA, V45, P3054, DOI 10.1016/j.neuropsychologia.2007.05.021; Siegal M, 2002, NAT REV NEUROSCI, V3, P463, DOI 10.1038/nrn844; Spinella M, 2005, BIOL PSYCHOL, V70, P175, DOI 10.1016/j.biopsycho.2004.01.005; STEMMER B, 1994, BRAIN LANG, V47, P1, DOI 10.1006/brln.1994.1040; Stone VE, 1998, J COGNITIVE NEUROSCI, V10, P640, DOI 10.1162/089892998562942; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Stuss DT, 2001, BRAIN, V124, P279, DOI 10.1093/brain/124.2.279; Tranel D, 2005, BRAIN, V128, P2872, DOI 10.1093/brain/awh643; Turkstra LS, 2008, BRAIN INJURY, V22, P397, DOI 10.1080/02699050802027059; Vollm BA, 2006, NEUROIMAGE, V29, P90, DOI 10.1016/j.neuroimage.2005.07.022; WECHSLER DA, 1987, STANDARDIZED MEMORY; WIMMER H, 1983, COGNITION, V13, P103, DOI 10.1016/0010-0277(83)90004-5; Wolfson, 1993, HALSTEAD REITAN NEUR	53	101	102	1	55	ELSEVIER MASSON	MILANO	VIA PALEOCAPA 7, 20121 MILANO, ITALY	0010-9452			CORTEX	Cortex	OCT	2010	46	9					1088	1099		10.1016/j.cortex.2009.08.014			12	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	659JA	WOS:000282561600004	19828142				2022-02-06	
J	Maruta, J; Suh, M; Niogi, SN; Mukherjee, P; Ghajar, J				Maruta, Jun; Suh, Minah; Niogi, Sumit N.; Mukherjee, Pratik; Ghajar, Jamshid			Visual Tracking Synchronization as a Metric for Concussion Screening	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						Attention Network Test (ANT); California Verbal Learning Test; 2nd edition (CVLT-II); diffuse axonal injury (DAI); hemispheric specialization; head injury; neuroimaging; neuropsychology; prefrontal cortex; smooth pursuit; traumatic axonal injury	TRAUMATIC BRAIN-INJURY; DIFFUSE AXONAL INJURY; PURSUIT EYE-MOVEMENTS; WHITE-MATTER INJURY; HEAD-INJURY; SMOOTH-PURSUIT; PREFRONTAL CORTEX; WORKING-MEMORY; COGNITIVE CONTROL; REACTION-TIME	Our goal was to determine whether performance variability during predictive visual tracking can provide a screening measure for mild traumatic brain injury (mTBI). Seventeen subjects with chronic postconcussive syndrome and 9 healthy control subjects were included in this study. Eye movements were recorded with video-oculography as the subject visually tracked a target that moved through a circular trajectory. We compared the variability of gaze positional errors relative to the target with the microstructural integrity of white matter tracts as measured by the fractional anisotropy (FA) parameter of diffusion tensor imaging. Gaze error variability was significantly correlated with the mean FA values of the right anterior corona radiata (ACR) and the left superior cerebellar peduncle, tracts that support spatial processing and sustenance of attention, and the genu of the corpus callosum. Because the ACR and the genu are among the most frequently damaged white matter tracts in mTBI, the correlations imply that gaze error variability during visual tracking may provide a useful screening tool for mTBI. Gaze error variability was also significantly correlated with attention and working memory measures in neurocognitive testing; thus, measurement of visual tracking performance is promising as a fast and practical screening tool for mTBI.	[Maruta, Jun; Ghajar, Jamshid] Brain Trauma Fdn, New York, NY 10007 USA; [Suh, Minah] Sungkyunkwan Univ, Dept Biol Sci, Suwon, South Korea; [Mukherjee, Pratik] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA; [Niogi, Sumit N.] Weill Cornell Med Coll, Dept Radiol, New York, NY USA; [Ghajar, Jamshid] Weill Cornell Med Coll, Dept Neurol Surg, New York, NY USA		Ghajar, J (corresponding author), Brain Trauma Fdn, 7 World Trade Ctr,34th Floor,250 Greenwich St, New York, NY 10007 USA.	ghajar@braintrauma.org	Maruta, Jun/I-3790-2019; Mukherjee, Pratik/A-5446-2008	Maruta, Jun/0000-0002-5054-6605; Mukherjee, Pratik/0000-0001-7473-7409	Department of DefenseUnited States Department of Defense [W81XWH-08-10646, W81XWH-08-2-0177]; James S. McDonnell Foundation	This study was supported by Department of Defense grants W81XWH-08-10646 and W81XWH-08-2-0177 and James S. McDonnell Foundation grant for the Cognitive Neurobiological Research Consortium in Traumatic Brain Injury. The authors thank Rachel Kolster and Ranjeeta Sarkar for technical assistance with eye movement and cognitive testing, and Drs. Carl Johnson and Robert Zimmerman for the clinicalMRI analyses.	ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Allen G, 1997, SCIENCE, V275, P1940, DOI 10.1126/science.275.5308.1940; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Assaf Y, 2008, J MOL NEUROSCI, V34, P51, DOI 10.1007/s12031-007-0029-0; BARBAS H, 1984, EXP BRAIN RES, V55, P187; Barnes GR, 2008, BRAIN COGNITION, V68, P309, DOI 10.1016/j.bandc.2008.08.020; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Chan JHM, 2003, NEURORADIOLOGY, V45, P34, DOI 10.1007/s00234-002-0891-y; Chen Y, 2002, PROG BRAIN RES, V140, P255; Chua TC, 2008, CURR OPIN NEUROL, V21, P83, DOI 10.1097/WCO.0b013e3282f4594b; Corbetta M, 2002, NAT REV NEUROSCI, V3, P201, DOI 10.1038/nrn755; de Xivry JJO, 2007, J PHYSIOL-LONDON, V584, P11, DOI 10.1113/jphysiol.2007.139881; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Fan J, 2002, J COGNITIVE NEUROSCI, V14, P340, DOI 10.1162/089892902317361886; Fork M, 2005, BRAIN INJURY, V19, P101, DOI 10.1080/02699050410001726086; Fox MD, 2006, P NATL ACAD SCI USA, V103, P10046, DOI 10.1073/pnas.0604187103; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Ghajar J, 2009, NEUROSCIENTIST, V15, P232, DOI 10.1177/1073858408326429; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Holbourn AHS, 1943, LANCET, V2, P438; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; IACONO WG, 1979, PSYCHOPHYSIOLOGY, V16, P94, DOI 10.1111/j.1469-8986.1979.tb01451.x; Jacobs ML, 2007, ARCH CLIN NEUROPSYCH, V22, P143, DOI 10.1016/j.acn.2006.12.002; Jiang HY, 2006, COMPUT METH PROG BIO, V81, P106, DOI 10.1016/j.cmpb.2005.08.004; Jones DK, 1999, STROKE, V30, P393, DOI 10.1161/01.STR.30.2.393; JONIDES J, 1993, NATURE, V363, P623, DOI 10.1038/363623a0; Kelly RM, 2003, J NEUROSCI, V23, P8432; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Krauzlis RJ, 2005, NEUROSCIENTIST, V11, P124, DOI 10.1177/1073858404271196; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; Le TH, 2009, MT SINAI J MED, V76, P145, DOI 10.1002/msj.20102; Lim KO, 1999, ARCH GEN PSYCHIAT, V56, P367, DOI 10.1001/archpsyc.56.4.367; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; LISBERGER SG, 1987, ANNU REV NEUROSCI, V10, P97, DOI 10.1146/annurev.ne.10.030187.000525; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; Mesulam MM, 1999, PHILOS T R SOC B, V354, P1325, DOI 10.1098/rstb.1999.0482; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; NEVIN NC, 1967, J NEUROPATH EXP NEUR, V26, P77, DOI 10.1097/00005072-196701000-00006; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; PARDO JV, 1991, NATURE, V349, P61, DOI 10.1038/349061a0; Petrides M, 1999, EUR J NEUROSCI, V11, P1011, DOI 10.1046/j.1460-9568.1999.00518.x; Pfefferbaum A, 2000, MAGNET RESON MED, V44, P259, DOI 10.1002/1522-2594(200008)44:2<259::AID-MRM13>3.0.CO;2-6; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; Ptak T, 2003, AM J ROENTGENOL, V181, P1401, DOI 10.2214/ajr.181.5.1811401; Ptito A, 2007, NEUROREHABILITATION, V22, P217; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Ropper AH, 2007, NEW ENGL J MED, V356, P166, DOI 10.1056/NEJMcp064645; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Salo R, 2009, BIOL PSYCHIAT, V65, P122, DOI 10.1016/j.biopsych.2008.08.004; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Schrader Harald, 2009, BMC Med Imaging, V9, P11, DOI 10.1186/1471-2342-9-11; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Stoodley CJ, 2009, NEUROIMAGE, V44, P489, DOI 10.1016/j.neuroimage.2008.08.039; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; TUSA RJ, 1988, ANN NEUROL, V23, P174, DOI 10.1002/ana.410230211; Ullen F, 2008, J NEUROSCI, V28, P4238, DOI 10.1523/JNEUROSCI.0825-08.2008; UMEDA Y, 1975, ORL J OTO-RHINO-LARY, V37, P290, DOI 10.1159/000275237; Unsworth N, 2007, PSYCHOL REV, V114, P104, DOI 10.1037/0033-295X.114.1.104; VANDERSTEEN J, 1983, VISION RES, V23, P1655, DOI 10.1016/0042-6989(83)90180-3; VANGELDER P, 1990, COMPR PSYCHIAT, V31, P253, DOI 10.1016/0010-440X(90)90009-H; Weber B, 2005, J COGNITIVE NEUROSCI, V17, P113, DOI 10.1162/0898929052880002; White Tonya, 2008, Top Magn Reson Imaging, V19, P97, DOI 10.1097/RMR.0b013e3181809f1e	74	101	102	0	34	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2010	25	4					293	305		10.1097/HTR.0b013e3181e67936			13	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	622FO	WOS:000279646900007	20611047				2022-02-06	
J	Hergenroeder, GW; Moore, AN; McCoy, JP; Samsel, L; Ward, NH; Clifton, GL; Dash, PK				Hergenroeder, Georgene W.; Moore, Anthony N.; McCoy, J. Philip, Jr.; Samsel, Leigh; Ward, Norman H., III; Clifton, Guy L.; Dash, Pramod K.			Serum IL-6: a candidate biomarker for intracranial pressure elevation following isolated traumatic brain injury	JOURNAL OF NEUROINFLAMMATION			English	Article							C-REACTIVE PROTEIN; CEREBROSPINAL-FLUID; INTERLEUKIN-6 LEVELS; TNF-ALPHA; CYTOKINE; DAMAGE; ASSOCIATION; INDUCTION; CHILDREN; RECEPTOR	Background: Increased intracranial pressure (ICP) is a serious, life-threatening, secondary event following traumatic brain injury (TBI). In many cases, ICP rises in a delayed fashion, reaching a maximal level 48-96 hours after the initial insult. While pressure catheters can be implanted to monitor ICP, there is no clinically proven method for determining a patient's risk for developing this pathology. Methods: In the present study, we employed antibody array and Luminex-based screening methods to interrogate the levels of inflammatory cytokines in the serum of healthy volunteers and in severe TBI patients (GCS <= 8) with or without incidence of elevated intracranial pressure (ICP). De-identified samples and ELISAs were used to confirm the sensitivity and specificity of IL-6 as a prognostic marker of elevated ICP in both isolated TBI patients, and polytrauma patients with TBI. Results: Consistent with previous reports, we observed sustained increases in IL-6 levels in TBI patients irrespective of their ICP status. However, the group of patients who subsequently experienced ICP >= 25 mm Hg had significantly higher IL-6 levels within the first 17 hours of injury as compared to the patients whose ICP remained <= 20 mm Hg. When blinded samples (n = 22) were assessed, a serum IL-6 cut-off of <5 pg/ml correctly identified 100% of all the healthy volunteers, a cut-off of >128 pg/ml correctly identified 85% of isolated TBI patients who subsequently developed elevated ICP, and values between these cut-off values correctly identified 75% of all patients whose ICP remained <= 20 mm Hg throughout the study period. In contrast, the marker had no prognostic value in predicting elevated ICP in polytrauma patients with TBI. When the levels of serum IL-6 were assessed in patients with orthopedic injury (n = 7) in the absence of TBI, a significant increase was found in these patients compared to healthy volunteers, albeit lower than that observed in TBI patients. Conclusions: Our results suggest that serum IL-6 can be used for the differential diagnosis of elevated ICP in isolated TBI.	[Moore, Anthony N.; Dash, Pramod K.] Univ Texas Houston, Sch Med, Dept Neurobiol & Anat, Houston, TX 77225 USA; [Hergenroeder, Georgene W.; Ward, Norman H., III; Clifton, Guy L.] Univ Texas Houston, Sch Med, Dept Neurosurg, Houston, TX 77225 USA; [Hergenroeder, Georgene W.] Univ Texas Houston, Sch Med, Vivian L Smith Ctr Neurol Res, Houston, TX 77225 USA; [McCoy, J. Philip, Jr.; Samsel, Leigh] NHLBI, NIH, Bethesda, MD 20892 USA		Dash, PK (corresponding author), Univ Texas Houston, Sch Med, Dept Neurobiol & Anat, Houston, TX 77225 USA.	p.dash@uth.tmc.edu	mccoy, john philip/ABD-9348-2021	Dash, Pramod/0000-0001-6746-1002; Hergenroeder, Georgene/0000-0002-6170-2191	Mission Connect/TIRR Foundation; NHLBIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI); NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [ZICHL005905] Funding Source: NIH RePORTER	The authors thank Dr. Shibani Pati and Dr. Aarif Khakoo for their assistance in facilitating this project. We would like to thank the Memorial Hermann Hospital Neurotrauma ICU, and Trauma and EMS coders; and Elizabeth Jones, MD, Molly S. Bray, PhD, Brian McFarlin, PhD, Ian Turpin, and Madelene Ottosen, MSN RN for assistance with recruiting orthopedic patients and healthy volunteers for the study. This work was supported in part by a grant from Mission Connect/TIRR Foundation and by the Intramural Research Program of NHLBI. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ali C, 2000, J CEREBR BLOOD F MET, V20, P956, DOI 10.1097/00004647-200006000-00008; [Anonymous], 2008, ABBR INJ SCAL AIS 20; Arand M, 2001, LANGENBECK ARCH SURG, V386, P241, DOI 10.1007/s004230100204; Basu A, 2002, J NEUROSCI, V22, P6071; BEAGLEY KW, 1992, GASTROENTEROL CLIN N, V21, P347; Bell MJ, 1997, ACT NEUR S, V70, P96; Berger RP, 2009, PEDIATR RES, V65, P97, DOI 10.1203/PDR.0b013e31818c7e27; Carlson NG, 1999, J IMMUNOL, V163, P3963; CAVAILLON JM, 1994, BIOMED PHARMACOTHER, V48, P445, DOI 10.1016/0753-3322(94)90005-1; Chiaretti A, 2005, CHILD NERV SYST, V21, P185, DOI 10.1007/s00381-004-1032-1; Chiaretti A, 2008, J NEUROTRAUM, V25, P225, DOI 10.1089/neu.2007.0405; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Cui X, 2003, BBA-GEN SUBJECTS, V1619, P325, DOI 10.1016/S0304-4165(02)00491-9; DASH PK, J NEUROSCI RES; Dash PK, 2010, NEUROTHERAPEUTICS, V7, P100, DOI 10.1016/j.nurt.2009.10.019; Dearden NM, 1998, CLIN NEUROPATHOL, V17, P221; Fernandez-Real JM, 2001, J CLIN ENDOCR METAB, V86, P1154, DOI 10.1210/jc.86.3.1154; Goodman JC, 2008, ACTA NEUROCHIR SUPPL, V102, P437, DOI 10.1007/978-3-211-85578-2_85; Hans VHJ, 1999, NEUROREPORT, V10, P409; Harris TB, 1999, AM J MED, V106, P506, DOI 10.1016/S0002-9343(99)00066-2; Hensler T, 2002, J TRAUMA, V52, P962, DOI 10.1097/00005373-200205000-00023; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Jantzen JPAH, 2007, BEST PRACT RES-CLIN, V21, P517, DOI 10.1016/j.bpa.2007.09.001; John GR, 2005, GLIA, V49, P161, DOI 10.1002/glia.20109; Kadhim Hazim J, 2008, J Intensive Care Med, V23, P236, DOI 10.1177/0885066608318458; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Libby P, 2002, NATURE, V420, P868, DOI [10.1038/nature01323, 10.1161/ATVBAHA.108.179705]; LOPPNOW H, 1989, LYMPHOKINE RES, V8, P293; Minambres E, 2003, CRIT CARE MED, V31, P933, DOI 10.1097/01.CCM.0000055370.66389.59; MURPHY PG, 1995, J NEUROSCI, V15, P5130; Oto J, 2008, J ANESTH, V22, P207, DOI 10.1007/s00540-008-0639-x; PATEL RT, 1994, BRIT J SURG, V81, P1306, DOI 10.1002/bjs.1800810914; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Penkowa M, 2000, GLIA, V32, P271, DOI 10.1002/1098-1136(200012)32:3<271::AID-GLIA70>3.0.CO;2-5; Ringheim GE, 1995, J NEUROIMMUNOL, V63, P113, DOI 10.1016/0165-5728(95)00134-4; Shore PM, 2004, J NEUROTRAUM, V21, P1113; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; Stangl M, 2001, TRANSPL P, V33, P1284, DOI 10.1016/S0041-1345(00)02479-9; Stocchetti N, 2007, J NEUROTRAUM, V24, P1339, DOI 10.1089/neu.2007.0300; Sullivan NJ, 2009, ONCOGENE, V28, P2940, DOI 10.1038/onc.2009.180; TEASDALE G, 1974, LANCET, V2, P81; Wetmore JB, 2008, NEPHROLOGY, V13, P593, DOI 10.1111/j.1440-1797.2008.01021.x; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; Yamagami H, 2004, STROKE, V35, P677, DOI 10.1161/01.STR.0000116876.96334.82; YOSHIZAKI K, 1990, Cytokine, V2, P381, DOI 10.1016/1043-4666(90)90069-6; Zemlan FP, 2002, BRAIN RES, V947, P131, DOI 10.1016/S0006-8993(02)02920-7; ZHANG YH, 1988, J BIOL CHEM, V263, P6177; ZWEIG MH, 1993, CLIN CHEM, V39, P561	49	101	104	0	6	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	MAR 11	2010	7								19	10.1186/1742-2094-7-19			13	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	586BV	WOS:000276877000001	20222971	Green Published, gold			2022-02-06	
J	Chapman, LA; Wade, SL; Walz, NC; Taylor, HG; Stancin, T; Yeates, KO				Chapman, Leah A.; Wade, Shari L.; Walz, Nicolay C.; Taylor, H. Gerry; Stancin, Terry; Yeates, Keith O.			Clinically Significant Behavior Problems During the Initial 18 Months Following Early Childhood Traumatic Brain Injury	REHABILITATION PSYCHOLOGY			English	Article						traumatic brain injury; early childhood; behavior problems	ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; FAMILY ASSESSMENT DEVICE; LONG-TERM OUTCOMES; YOUNG-CHILDREN; HEAD-INJURY; SOCIAL COMPETENCE; PREDICTORS; RECOVERY; SKILLS; RELIABILITY	Objective: This study looked at the emergence of clinically significant problems in behavior, executive function skills, and social competence during the initial 18 months following traumatic brain injury (TBI) in young, children relative to a cohort of children with orthopedic injuries (OI) and the environmental factors that predict difficulties postinjury, Participants: Children. ages 3-7 years, hospitalized for severe TBI, moderate TBI. or OI were seen shortly after their injury (M = 40 days) and again 6 months, 12 months, and 18 months postinjury. Design: Behavioral parent self-reports, demographic data. family functioning reports, and home environment reports were collected at injury baseline and each time point postinjury. Results: Results suggest that. compared with the 01 group. the severe TBI group developed significantly more externalizing behavior problems and executive function problems following injury that persisted through the 18-month follow-up. Minimal social competence difficulties appeared at the 18-month follow-up, suggesting a possible pattern of emerging deficits rather than a recovery over time. Conclusions: Predictors of the emergence of clinically significant problems included permissive parenting, family dysfunction. and low socioeconomic status. The findings are similar to those found in school-age children.	[Walz, Nicolay C.] Cincinnati Childrens Hosp, Med Ctr, Dept Pediat, Div Behav Med & Clin Psychol, Cincinnati, OH 45229 USA; [Chapman, Leah A.] Univ Cincinnati, Dept Psychol, Cincinnati, OH 45221 USA; [Taylor, H. Gerry] Case Western Reserve Univ, Div Dev & Behav Pediat & Pediat Psychol, Dept Pediat, Cleveland, OH 44106 USA; [Taylor, H. Gerry] Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA; [Stancin, Terry] Metrohlth Med Ctr, Dept Pediat, Div Pediat Psychol, Cleveland, OH USA; [Yeates, Keith O.] Ohio State Univ, Dept Pediat, Div Psychol, Columbus, OH 43210 USA; [Yeates, Keith O.] Nationwide Childrens Hosp, Res Inst, Ctr Biobehav Hlth, Columbus, OH USA		Chapman, LA (corresponding author), Cincinnati Childrens Hosp, Med Ctr, Dept Pediat, Div Behav Med & Clin Psychol, 333 Burnet Ave, Cincinnati, OH 45229 USA.	chapmala@email.uc.edu	Stancin, Terry/L-7993-2019; Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892	NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1 RR026314, UL1 RR026314-01] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD042729-01, R01 HD042729] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD042729] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR026314] Funding Source: NIH RePORTER		Achenbach T.M., 2000, MANUAL ASEBA PRESCHO; Achenbach T. M., 2001, MANUAL ASEBA SCH AGE; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; Arroyos-Jurado E, 2000, J SCHOOL PSYCHOL, V38, P571, DOI 10.1016/S0022-4405(00)00053-4; Bayer JK, 2006, J APPL DEV PSYCHOL, V27, P542, DOI 10.1016/j.appdev.2006.08.002; BRADLEY RH, 1984, DEV PSYCHOL, V20, P315, DOI 10.1037/0012-1649.20.2.315; Burnham KP, 2004, SOCIOL METHOD RES, V33, P261, DOI 10.1177/0049124104268644; Burnham KP., 2002, MODEL SELECTION MULT; BYLES J, 1988, FAM PROCESS, V27, P97, DOI 10.1111/j.1545-5300.1988.00097.x; Caldwell B., 1984, HOME OBSERVATION MEA; Catroppa C, 2007, J PEDIATR PSYCHOL, V32, P354, DOI 10.1093/jpepsy/jsl019; DeaterDeckard K, 1997, PSYCHOL INQ, V8, P161, DOI 10.1207/s15327965pli0803_1; DONDERS J, 1992, J ABNORM CHILD PSYCH, V20, P233, DOI 10.1007/BF00916690; Fay TB, 2009, NEUROPSYCHOLOGY, V23, P271, DOI 10.1037/a0014936; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Ganesalingam K, 2006, J INT NEUROPSYCH SOC, V12, P609, DOI 10.1017/S1355617706060796; GELMAN A, 2004, TEXTS STAT SCI BAYES; Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P249, DOI 10.1076/chin.8.4.249.13513; Gioia GA IP, 2000, BEHAV RATING INVENTO; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Landry SH, 2004, DEV NEUROPSYCHOL, V26, P707, DOI 10.1207/s15326942dn2603_4; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1032, DOI 10.1097/01.chi.0000173293.05817.b1; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1041, DOI 10.1097/01.chi.0000173292.05817.f8; Merrell K. W., 2002, PRESCHOOL KINDERGART; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Moos RH, 1994, LIFE STRESSORS SOCIA; Nadebaum C, 2007, DEV NEUROPSYCHOL, V32, P703, DOI 10.1080/87565640701376086; Querido JG, 2002, J CLIN CHILD ADOLESC, V31, P272, DOI 10.1207/S15374424JCCP3102_12; Robinson C. C., 1996, BIENN C INT SOC STUD; ROBINSON CC, 1995, PSYCHOL REP, V77, P819, DOI 10.2466/pr0.1995.77.3.819; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Sesma HW, 2008, PEDIATRICS, V121, pE1686, DOI 10.1542/peds.2007-2461; Stancin T, 2008, J DEV BEHAV PEDIATR, V29, P253, DOI 10.1097/DBP.0b013e31816b6b0f; Taylor H. G., J HEAD TRAU IN PRESS; Taylor HG, 2008, J INT NEUROPSYCH SOC, V14, P734, DOI 10.1017/S1355617708081150; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; Wade SL, 2006, J CONSULT CLIN PSYCH, V74, P445, DOI 10.1037/0022-006X.74.3.445; Wade SL, 1996, J LEARN DISABIL, V29, P652, DOI 10.1177/002221949602900609; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64	43	101	101	1	132	EDUCATIONAL PUBLISHING FOUNDATION	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	FEB	2010	55	1					48	57		10.1037/a0018418			10	Psychology, Clinical; Rehabilitation	Social Science Citation Index (SSCI)	Psychology; Rehabilitation	563NJ	WOS:000275139000006	20175634	Green Accepted			2022-02-06	
J	Mainwaring, LM; Bisschop, SM; Comper, P; Richards, DW; Hutchison, M				Mainwaring, Lynda M.; Bisschop, Sean M.; Comper, Paul; Richards, Doug W.; Hutchison, Michael			Emotional response to sport concussion compared to ACL injury	BRAIN INJURY			English	Article						Sport concussion; emotional disturbance; profile of mood states; recovery; ACL injury	COLLEGIATE FOOTBALL PLAYERS; COGNITIVE IMPAIRMENT; BETA-ENDORPHIN; HEAD-INJURY; PROFESSIONAL FOOTBALL; RECURRENT CONCUSSION; MILD; DEPRESSION; SYMPTOMS; RECOVERY	Research design: Pre-injury, post-injury and longitudinal emotional functioning of athletes with concussion (n = 16), athletes with ACL injuries (n = 7) and uninjured athletes (n = 28) were compared in a prospective repeated-measures design. Methods and procedures: Participants completed the short version of the Profile of Mood States (POMS). ANOVAs and trend analysis were used to examine between and within group differences across time on two sub-scales, Total Mood Disturbance and Depression. Main outcomes and results: Athletes with ACL injury reported higher levels of depression for a longer duration than athletes with concussion. Relative to un-injured controls, athletes with concussion reported significant changes in Total Mood Disturbance and Depression post-injury, whereas athletes with ACL injuries reported significant changes in Depression scores only. Different patterns of post-injury emotional disturbance for the injured groups were observed by trend analyses. Conclusions: Concussed athletes do not report as much emotional disturbance as athletes with ACL injuries. Differential patterns of emotional disturbance were detected between injured groups. The authors recommended that clinical protocols and educational programmes address emotional sequelae associated with sport concussion and ACL injury.	[Mainwaring, Lynda M.; Richards, Doug W.; Hutchison, Michael] Univ Toronto, Fac Phys Educ & Hlth, Toronto, ON M5S 2W6, Canada; [Bisschop, Sean M.; Comper, Paul] Toronto Rehabil Inst, Toronto, ON, Canada		Mainwaring, LM (corresponding author), Univ Toronto, Fac Phys Educ & Hlth, 55 Harbord St, Toronto, ON M5S 2W6, Canada.	lynda.mainwaring@utoronto.ca		Bisschop, Sean/0000-0002-3307-292X			Bechara A, 1999, J NEUROSCI, V19, P5473; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; BORNSTEIN RA, 1989, J NEUROSURG, V70, P509, DOI 10.3171/jns.1989.70.4.0509; BREWER BW, 1995, CLIN J SPORT MED, V5, P241, DOI 10.1097/00042752-199510000-00006; Brewer BW, 2000, REHABIL PSYCHOL, V45, P20, DOI 10.1037/0090-5550.45.1.20; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; CHAN CS, 1988, PERCEPT MOTOR SKILL, V66, P875, DOI 10.2466/pms.1988.66.3.875; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; CHUTE N, 1997, THESIS QUEENS U KING; CRONBACH LJ, 1955, PSYCHOL BULL, V52, P281, DOI 10.1037/h0040957; DALY JM, 1995, J SPORT REHABIL, V0004, P00023; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Driver S, 2009, BRAIN INJURY, V23, P203, DOI 10.1080/02699050802695574; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; Giza CC, 2001, J ATHL TRAINING, V36, P228; GROVE JR, 1992, INT J SPORT PSYCHOL, V23, P93; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; Hoffman P., 1997, PHYS ACTIVITY MENTAL, P163; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; Hovda DA, 1999, SPORTS-RELATED CONCUSSION, P12; Hutchison M, 2009, CLIN J SPORT MED, V19, P13, DOI 10.1097/JSM.0b013e318190ba06; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Jorge R, 2002, NEUROREHABILITATION, V17, P311; KRAEMER WJ, 1993, J APPL PHYSIOL, V74, P450; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Kristman VL, 2008, CLIN J SPORT MED, V18, P322, DOI 10.1097/JSM.0b013e31817e6f3e; LEDDY MH, 1994, RES Q EXERCISE SPORT, V65, P347, DOI 10.1080/02701367.1994.10607639; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Liotti M, 2000, BIOL PSYCHIAT, V48, P30, DOI 10.1016/S0006-3223(00)00874-X; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Lyketsos CG, 2002, JAMA-J AM MED ASSOC, V288, P1475, DOI 10.1001/jama.288.12.1475; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Mainwaring L, 1999, CAN J REHABIL, V12, P145; Mainwaring LM, 2004, J SPORT EXERCISE PSY, V26, P119, DOI 10.1123/jsep.26.1.119; MALIA K, 1995, BRAIN INJURY, V9, P697, DOI 10.3109/02699059509008226; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McDonald SA, 1990, SPORT PSYCHOL, V4, P261; MILLER WN, 1998, J APPL SPORT PSYCH S, V10, pS127; Morrey MA, 1999, CLIN J SPORT MED, V9, P63, DOI 10.1097/00042752-199904000-00004; Nixon H. L. II, 1992, Journal of Sport and Social Issues, V16, P127, DOI 10.1177/019372359201600208; NUNNELY J, 1978, PSYCHOMETRIC THEORY; Paniak C, 2002, J CLIN EXP NEUROPSYC, V24, P187, DOI 10.1076/jcen.24.2.187.999; Pearson L, 1992, PHYSIOTHERAPY, V78, P762, DOI DOI 10.1016/S0031-9406(10)61642-2; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; PELLMAN EJ, 2004, NEUROSURGERY, V55, P1303; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Reeves DL, 2007, ARCH CLIN NEUROPSYCH, V22, pS15, DOI 10.1016/j.acn.2006.10.013; ROH J, 1998, J APPL SPORT PSYCH S, V10, pS54; SCHWARZ L, 1990, EUR J APPL PHYSIOL O, V61, P165, DOI 10.1007/BF00357593; SCHWARZ L, 1992, SPORTS MED, V13, P25, DOI 10.2165/00007256-199213010-00003; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; SMITH AM, 1993, MAYO CLIN PROC, V68, P939, DOI 10.1016/S0025-6196(12)62265-4; SMITH AM, 1990, MAYO CLIN PROC, V65, P38, DOI 10.1016/S0025-6196(12)62108-9	62	101	101	2	32	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2010	24	4					589	597		10.3109/02699051003610508			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	570ML	WOS:000275682300003	20235761				2022-02-06	
J	Siman, R; Toraskar, N; Dang, A; McNeil, E; McGarvey, M; Plaum, J; Maloney, E; Grady, MS				Siman, Robert; Toraskar, Nikhil; Dang, Antony; McNeil, Elizabeth; McGarvey, Micheal; Plaum, Justin; Maloney, Eileen; Grady, M. Sean			A Panel of Neuron-Enriched Proteins as Markers for Traumatic Brain Injury in Humans	JOURNAL OF NEUROTRAUMA			English	Article						14-3-3; biomarker panel; calpain; necrosis; neurofilament; traumatic brain injury; UCH-L1	TISSUE-PLASMINOGEN ACTIVATOR; SPECTRIN BREAKDOWN PRODUCTS; CEREBROSPINAL-FLUID; CALPAIN-I; AXONAL DAMAGE; NEUROBIOCHEMICAL MARKERS; MONOCLONAL-ANTIBODIES; BIOCHEMICAL MARKERS; SURROGATE MARKERS; TEMPORAL PROFILE	Surrogate markers have enormous potential for contributing to the diagnosis, prognosis, and therapeutic evaluation of acute brain damage, but extensive prior study of individual candidates has not yielded a biomarker in widespread clinical practice. We hypothesize that a panel of neuron-enriched proteins measurable in cerebrospinal fluid (CSF) and blood should vastly improve clinical evaluation and therapeutic management of acute brain injuries. Previously, we developed such a panel based initially on the study of protein release from degenerating cultured neurons, and subsequently on rodent models of traumatic brain injury (TBI) and ischemia, consisting of 14-3-3 beta, 14-3-3 zeta, three distinct phosphoforms of neurofilament H, ubiquitin hydrolase L1, neuron-specific enolase, alpha-spectrin, and three calpain- and caspase-derived fragments of alpha-spectrin. In the present study, this panel of 11 proteins was evaluated as CSF and serum biomarkers for severe TBI in humans. By quantitative Western blotting and sandwich immunoassays, the CSF protein levels were near or below the limit of detection in pre-surgical and most normal pressure hydrocephalus (NPH) controls, but following TBI nine of the 11 were routinely elevated in CSF. Whereas different markers peaked coordinately, the time to peak varied across TBI cases from 24-96 h post-injury. In serum, TBI increased all four members of the marker panel for which sandwich immunoassays are currently available: a calpain-derived NH2-terminal alpha-spectrin fragment and the three neurofilament H phosphoforms. Our results identify neuron-enriched proteins that may serve as a panel of CSF and blood surrogate markers for the minimally invasive detection, management, mechanistic, and therapeutic evaluation of human TBI.	[Siman, Robert; Toraskar, Nikhil; Dang, Antony; McNeil, Elizabeth; Plaum, Justin; Maloney, Eileen; Grady, M. Sean] Univ Penn, Sch Med, Dept Neurosurg, Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA; [McGarvey, Micheal] Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA		Siman, R (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, Ctr Brain Injury & Repair, 105 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.	siman@mail.med.upenn.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS048234]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048234] Funding Source: NIH RePORTER	This research was supported by the National Institutes of Health (grant NS048234 to R. S.).	Agren-Wilsson A, 2007, ACTA NEUROL SCAND, V116, P333, DOI 10.1111/j.1600-0404.2007.00890.x; AITKEN A, 1995, BIOCHEM SOC T, V23, P605, DOI 10.1042/bst0230605; Anderson KJ, 2008, J NEUROTRAUM, V25, P1079, DOI 10.1089/neu.2007.0488; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Begaz T, 2006, J NEUROTRAUM, V23, P1201, DOI 10.1089/neu.2006.23.1201; Chen XH, 1999, J NEUROPATH EXP NEUR, V58, P588, DOI 10.1097/00005072-199906000-00003; DAY INM, 1992, BIOCHEM SOC T, V20, P637, DOI 10.1042/bst0200637; Fassbender K, 1997, J NEUROL SCI, V148, P101, DOI 10.1016/S0022-510X(96)05351-8; Foussas SG, 2007, HEART, V93, P952, DOI 10.1136/hrt.2005.084954; Gloeckner SF, 2008, J ALZHEIMERS DIS, V14, P17; GOODMAN SR, 1987, BRAIN RES BULL, V18, P787, DOI 10.1016/0361-9230(87)90217-6; Grubb NR, 2007, HEART, V93, P1268, DOI 10.1136/hrt.2006.091314; Harwood SM, 2005, ANN CLIN BIOCHEM, V42, P415, DOI 10.1258/000456305774538238; Hasselblatt M, 2004, NEUROLOGY, V62, P1634, DOI 10.1212/01.WNL.0000123092.97047.B1; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Jauch EC, 2006, STROKE, V37, P2508, DOI 10.1161/01.STR.0000242290.01174.9e; Kleine TO, 2003, BRAIN RES BULL, V61, P265, DOI 10.1016/S0361-9230(03)00090-X; Konstantinopoulos PA, 2008, NAT CLIN PRACT ONCOL, V5, P577, DOI 10.1038/ncponc1178; Lawrence EJ, 2005, RESUSCITATION, V64, P383, DOI 10.1016/j.resuscitation.2004.07.016; McKeating EG, 1998, ACT NEUR S, V71, P117; Morrow David A, 2007, Circulation, V115, pe356; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; Nylen K, 2008, ACTA NEUROCHIR, V150, P221, DOI 10.1007/s00701-007-1489-2; Petzold A, 2006, J NEUROL NEUROSUR PS, V77, P753, DOI 10.1136/jnnp.2005.085175; Petzold A, 2005, J NEUROL NEUROSUR PS, V76, P206, DOI 10.1136/jnnp.2004.043315; Petzold A, 2003, J IMMUNOL METHODS, V278, P179, DOI 10.1016/S0022-1759(03)00189-3; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Pineda JA, 2007, J NEUROTRAUM, V24, P354, DOI 10.1089/neu.2006.003789; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; ROBERTSLEWIS JM, 1993, ANN NY ACAD SCI, V679, P78; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Rosen H, 2004, J NEUROL SCI, V221, P19, DOI 10.1016/j.jns.2004.03.003; Ross JS, 2008, ONCOLOGIST, V13, P477, DOI 10.1634/theoncologist.2007-0248; Routsi C, 2006, SHOCK, V26, P20, DOI 10.1097/01.shk.0000209546.06801.d7; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Shaw G, 2005, BIOCHEM BIOPH RES CO, V336, P1268, DOI 10.1016/j.bbrc.2005.08.252; Siman R, 2005, J CEREBR BLOOD F MET, V25, P1433, DOI 10.1038/sj.jcbfm.9600138; SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1; Siman R, 2004, NEUROBIOL DIS, V16, P311, DOI 10.1016/j.nbd.2004.03.016; SIMAN R, 1989, J NEUROSCI, V9, P1579; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; Siman R, 2001, J BIOL CHEM, V276, P44736, DOI 10.1074/jbc.M104092200; Siman R, 2008, BRAIN RES, V1213, P1, DOI 10.1016/j.brainres.2008.03.034; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; Tanaka Y, 2007, BRAIN RES, V1154, P194, DOI 10.1016/j.brainres.2007.03.085; TEEPKER M, 2008, HEADACHE IN PRESS; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; WILKINSON KD, 1989, SCIENCE, V246, P670, DOI 10.1126/science.2530630; Williams R.C. Jr, 1983, Cell and Muscle Motility, V3, P41; Wunderlich MT, 1999, STROKE, V30, P1190, DOI 10.1161/01.STR.30.6.1190; Xu JL, 2001, BRAIN RES, V898, P171, DOI 10.1016/S0006-8993(01)02156-4; Zemlan FP, 1999, J NEUROCHEM, V72, P741, DOI 10.1046/j.1471-4159.1999.0720741.x; Zemlan FP, 2002, BRAIN RES, V947, P131, DOI 10.1016/S0006-8993(02)02920-7; Zhang C, 2002, NEUROBIOL DIS, V10, P289, DOI 10.1006/nbdi.2002.0526	55	101	104	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2009	26	11					1867	1877		10.1089/neu.2009.0882			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	523CO	WOS:000272049600002	19811094	Green Published			2022-02-06	
J	Szmydynger-Chodobska, J; Strazielle, N; Zink, BJ; Ghersi-Egea, JF; Chodobski, A				Szmydynger-Chodobska, Joanna; Strazielle, Nathalie; Zink, Brian J.; Ghersi-Egea, Jean-Francois; Chodobski, Adam			The role of the choroid plexus in neutrophil invasion after traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						blood-cerebrospinal fluid barrier; choroid plexus; CXC chemokines; neutrophils; traumatic brain injury	TUMOR-NECROSIS-FACTOR; CENTRAL-NERVOUS-SYSTEM; MESSENGER-RNA; RAT-BRAIN; SALMONELLA-TYPHIMURIUM; INTESTINAL EPITHELIA; ADHESION MOLECULES; REPERFUSION INJURY; GROWTH-FACTOR; KAPPA-B	Traumatic brain injury (TBI) frequently results in neuroinflammation, which includes the invasion of neutrophils. After TBI, neutrophils infiltrate the choroid plexus (CP), a site of the blood-cerebrospinal fluid (CSF) barrier (BCSFB), and accumulate in the CSF space near the injury, from where these inflammatory cells may migrate to brain parenchyma. We have hypothesized that the CP functions as an entry point for neutrophils to invade the injured brain. Using the controlled cortical impact model of TBI in rats and an in vitro model of the BCSFB, we show that the CP produces CXC chemokines, such as cytokine-induced neutrophil chemoattractant (CINC)-1 or CXCL1, CINC-2 alpha or CXCL3, and CINC-3 or CXCL2. These chemokines are secreted both apically and basolaterally from the choroidal epithelium, a prerequisite for neutrophil migration across epithelial barriers. Consistent with these findings, we also provide electron microscopic evidence that neutrophils infiltrate the choroidal stroma and subsequently reach the intercellular space between choroidal epithelial cells. This is the first detailed analysis of the BCSFB function related to neutrophil trafficking. Our observations support the role of this barrier in posttraumatic neutrophil invasion. Journal of Cerebral Blood Flow & Metabolism (2009) 29, 1503-1516; doi:10.1038/jcbfm.2009.71; published online 27 May 2009	[Szmydynger-Chodobska, Joanna; Zink, Brian J.; Chodobski, Adam] Brown Univ, Dept Emergency Med, Warren Alpert Med Sch, Providence, RI 02903 USA; [Strazielle, Nathalie] Brain I, Lyon, France; [Ghersi-Egea, Jean-Francois] Univ Lyon 1, Fac Med Laennec, INSERM, U842, F-69365 Lyon, France		Szmydynger-Chodobska, J (corresponding author), Brown Univ, Dept Emergency Med, Warren Alpert Med Sch, George Bldg,Room 314,593 Eddy St, Providence, RI 02903 USA.	joanna_szmydynger-chodobska@brown.edu		Ghersi-Egea, Jean-Francois/0000-0002-0181-4909	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS49479, R07057CS]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049479] Funding Source: NIH RePORTER	This work was supported by Grant NS49479 from the NIH (to AC) and by ANR R07057CS (to JFGE).	ANDERSSON PB, 1992, J EXP MED, V176, P255, DOI 10.1084/jem.176.1.255; Beech JS, 2001, J CEREBR BLOOD F MET, V21, P683, DOI 10.1097/00004647-200106000-00006; BLOOM GS, 1989, J BIOL CHEM, V264, P16083; Buttram SDW, 2007, J NEUROTRAUM, V24, P1707, DOI 10.1089/neu.2007.0349; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; Chodobski A, 2003, NEUROSCIENCE, V122, P853, DOI 10.1016/j.neuroscience.2003.08.055; ERICSSON A, 1995, J COMP NEUROL, V361, P681, DOI 10.1002/cne.903610410; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Fan Lei, 1995, Molecular Brain Research, V30, P125, DOI 10.1016/0169-328X(94)00287-O; FAYEIN NA, 1992, BIOL CELL, V76, P1, DOI 10.1016/0248-4900(92)90189-8; Handa O, 2004, J PHARMACOL EXP THER, V309, P670, DOI 10.1124/jpet.103.062216; HUANG S, 1992, AM J PATHOL, V141, P981; HUANG SL, 1992, BIOCHEM BIOPH RES CO, V184, P922, DOI 10.1016/0006-291X(92)90679-F; Kamada Kyousuke, 1995, Neurologia Medico-Chirurgica, V35, P1, DOI 10.2176/nmc.35.1; Kivisakk P, 2003, P NATL ACAD SCI USA, V100, P8389, DOI 10.1073/pnas.1433000100; Kobayashi Y, 2008, FRONT BIOSCI-LANDMRK, V13, P2400, DOI 10.2741/2853; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; Kuschert GSV, 1999, BIOCHEMISTRY-US, V38, P12959, DOI 10.1021/bi990711d; Ling EA, 1998, MICROSC RES TECHNIQ, V41, P43, DOI 10.1002/(SICI)1097-0029(19980401)41:1<43::AID-JEMT5>3.0.CO;2-V; Magnoni S, 2003, J NEUROTRAUM, V20, P251, DOI 10.1089/089771503321532833; Matsumoto T, 1997, LAB INVEST, V77, P119; MCCORMICK BA, 1995, J CELL BIOL, V131, P1599, DOI 10.1083/jcb.131.6.1599; McCormick BA, 1998, J IMMUNOL, V160, P455; Nadeau S, 1999, NEUROSCIENCE, V93, P1449, DOI 10.1016/S0306-4522(99)00225-0; Nagra RM, 1997, J NEUROIMMUNOL, V78, P97, DOI 10.1016/S0165-5728(97)00089-1; NAKAGAWA H, 1994, BIOCHEM J, V301, P545, DOI 10.1042/bj3010545; Praetorius J, 2006, AM J PHYSIOL-CELL PH, V291, pC59, DOI 10.1152/ajpcell.00433.2005; Quan N, 1999, J NEUROIMMUNOL, V93, P72, DOI 10.1016/S0165-5728(98)00193-3; Redzic ZB, 2005, CURR TOP DEV BIOL, V71, P1, DOI 10.1016/S0070-2153(05)71001-2; Scapini P, 2000, IMMUNOL REV, V177, P195, DOI 10.1034/j.1600-065X.2000.17706.x; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; SNOW AD, 1994, AM J PATHOL, V144, P337; Strazielle N, 1999, J NEUROSCI, V19, P6275; Strazielle N, 2000, J NEUROPATH EXP NEUR, V59, P561, DOI 10.1093/jnen/59.7.561; Strazielle N, 2003, J NEUROPATH EXP NEUR, V62, P1254, DOI 10.1093/jnen/62.12.1254; Strazielle Nathalie, 2003, Methods Mol Med, V89, P291; Takaishi K, 2000, J BIOCHEM-TOKYO, V127, P511, DOI 10.1093/oxfordjournals.jbchem.a022634; Wong D, 2007, J NEUROIMMUNOL, V184, P136, DOI 10.1016/j.jneuroim.2006.12.003; Yamasaki Y, 1997, BRAIN RES, V759, P103, DOI 10.1016/S0006-8993(97)00251-5	40	101	102	2	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	SEP	2009	29	9					1503	1516		10.1038/jcbfm.2009.71			14	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	489UF	WOS:000269447600002	19471279	Green Accepted, Bronze			2022-02-06	
J	Alla, S; Sullivan, SJ; Hale, L; McCrory, P				Alla, S.; Sullivan, S. J.; Hale, L.; McCrory, P.			Self-report scales/checklists for the measurement of concussion symptoms: a systematic review	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article; Proceedings Paper	3rd International Conference on Concussion in Sport	NOV, 2008	Zurich, SWITZERLAND				SPORT-RELATED CONCUSSION; COLLEGIATE FOOTBALL PLAYERS; MILD HEAD-INJURY; RETURN-TO-PLAY; HIGH-SCHOOL; PROFESSIONAL FOOTBALL; SEX-DIFFERENCES; NEUROPSYCHOLOGICAL PERFORMANCE; NEUROCOGNITIVE PERFORMANCE; CEREBRAL CONCUSSION	Objective: To identify self-reported sport concussion symptom scales and to describe the psychometric properties of these identified scales. Design: Systematic review. Intervention: PubMed, Medline, CINAHL, Scopus, Web of Science, Sport Discus, PsycINFO and AMED were searched from their establishment until December 2008. The medical subject heading terms "brain concussion'', "signs or symptoms'' and "athletic injuries''. The search was limited to articles published in English. An additional search of the reference lists of the retrieved articles was conducted. Only full-text articles were considered for this study and these were retrieved to determine whether they met the inclusion criteria. Results: The initial search resulted in 421 articles, which were reduced to 290 articles after removing duplicates. The hand search resulted in 17 articles, thus giving a total of 307 articles. Full text was available for 295 articles of which 60 met the criteria for inclusion. The excluded 235 articles were case reports, reviews and guidelines on concussion management or studies that had not used a symptom scale or checklist. Conclusions: Six core scales were identified with a broad range of symptom items but with limited information on their psychometric properties. There were numerous derivative scales reported, most of which have not been methodically developed or subjected to scientific scrutiny. Despite this, they do make a contribution to the detection, assessment and return to play decisions but there is a need for the clinical user to be aware that many of these scales have "evolved'' rather than being scientifically developed.	[Alla, S.; Sullivan, S. J.; Hale, L.] Univ Otago, Ctr Physiotherapy Res, Dunedin, New Zealand; [McCrory, P.] Univ Melbourne, Ctr Hlth Exercise & Sports Med, Melbourne, Vic, Australia		McCrory, P (corresponding author), POB 93 Shoreham, Melbourne, Vic 3916, Australia.	paulmccr@bigpond.net.au	McCrory, Paul/Q-8688-2019	McCrory, Paul/0000-0003-4850-0568			Asplund CA, 2004, CLIN J SPORT MED, V14, P339, DOI 10.1097/00042752-200411000-00003; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Barth JT, 1989, MILD HEAD INJURY, P257; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; Broglio SP, 2006, BRIT J SPORT MED, V40, P802, DOI 10.1136/bjsm.2006.028019; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Bruce JM, 2004, NEUROLOGY, V63, P1516; Cameron KL, 1999, J ATHL TRAINING, V34, P34; Cavanaugh JT, 2006, J ATHL TRAINING, V41, P305; Cobb Sarah, 2004, J Sch Nurs, V20, P262; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2008, J ATHL TRAINING, V43, P119, DOI 10.4085/1062-6050-43.2.119; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Delaney JS, 2001, CLIN J SPORT MED, V11, P234, DOI 10.1097/00042752-200110000-00005; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; DENNYBROWN D, 1945, JAMA-J AM MED ASSOC, V127, P429, DOI 10.1001/jama.1945.02860080001001; Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Ferguson RJ, 1999, NEUROPSYCHOLOGY, V13, P582, DOI 10.1037/0894-4105.13.4.582; Ferrara Michael S., 2001, J Athl Train, V36, P145; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Hynes LM, 2006, BRAIN INJURY, V20, P179, DOI 10.1080/02699050500443707; Irving DB, 2006, J SCI MED SPORT, V9, P11, DOI 10.1016/j.jsams.2006.02.004; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Iverson G, 2007, CLIN J SPORT MED, V17, P31; JANUSZ J, 2004, BRIT J SPORT MED, V36, P659; Johnson PD, 2002, CLIN J SPORT MED, V12, P12, DOI 10.1097/00042752-200201000-00006; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Langburt W, 2001, J CHILD NEUROL, V16, P83, DOI 10.1177/088307380101600203; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; Leclerc S, 2001, SPORTS MED, V31, P629, DOI 10.2165/00007256-200131080-00007; LECLERC S, 2004, ASSESSMENT CONCUSSIO; Lovell M, 2000, IMPACT IMMEDIATE POS; Lovell M. R., 2004, TRAUMATIC BRAIN INJU; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Lovell MR, 1999, SPORTS-RELATED CONCUSSION, P200; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Maroon JC, 2000, NEUROSURGERY, V47, P69; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140, DOI 10.1097/JSM.0b013e31803212ae; MCMILLAN TM, 1987, J NEUROL NEUROSUR PS, V50, P393, DOI 10.1136/jnnp.50.4.393; Meyer A, 1904, AM J INSANITY, V60, P373, DOI 10.1176/ajp.60.3.373; Mihalik JP, 2007, DENT TRAUMATOL, V23, P14, DOI 10.1111/j.1600-9657.2006.00488.x; Mihalik JP, 2005, J NEUROSURG, V102, P850, DOI 10.3171/jns.2005.102.5.0850; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; Patel AV, 2007, J ATHL TRAINING, V42, P66; Pellman E, 2004, NEUROSURGERY, V55, P860, DOI 10.1227/01.NEU.0000137657.00146.7D; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Pellman EJ, 2004, NEUROSURGERY, V55, P1100, DOI 10.1227/01.NEU.0000147063.12873.F5; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Pellman EJ, 2003, NEUROSURGERY, V53, P797, DOI 10.1093/neurosurgery/53.3.797; PELLMAN EJ, 2004, NEUROSURGERY, V55, P1303; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Piland SG, 2006, MED SCI SPORT EXER, V38, P27, DOI 10.1249/01.mss.0000183186.98212.d5; Piland SG, 2003, J ATHL TRAINING, V38, P104; RANDOLPH C, 2006, CONCUSSION SYMPTOM I; RECKASE MD, 2000, HDB PSYCHOL ASSESSME, P43; Register-Mihalik J, 2007, CLIN J SPORT MED, V17, P282, DOI 10.1097/JSM.0b013e31804ca68a; RICHARDSON JTE, 2000, CLIN NEUROPSYCHOL AS; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2003, APPL NEUROPSYCHOL, V10, P42, DOI 10.1207/S15324826AN1001_6; Thompson B., 2004, EXPLORATORY CONFIRMA; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677	102	101	101	0	19	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	MAY	2009	43			1			I3	I12		10.1136/bjsm.2009.058339			10	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	Sport Sciences	450YO	WOS:000266438100002	19433422				2022-02-06	
J	Cockerham, GC; Goodrich, GL; Weichel, LTCED; Orcutt, JC; Rizzo, JF; Bower, COLKS; Schuchard, RA				Cockerham, Glenn C.; Goodrich, Gregory L.; Weichel, L. T. C. Eric D.; Orcutt, James C.; Rizzo, Joseph F.; Bower, C. O. L. Kraig S.; Schuchard, Ronald A.			Eye and visual function in traumatic brain injury	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						blast injury; blindness; eye trauma; oculomotor; quality of life; rehabilitation; traumatic brain injury; vision; visual disturbance; visual field	COMBAT OCULAR TRAUMA; OPTIC NEUROPATHY; BLAST INJURY; IRAQ; WAR; REHABILITATION; DYSFUNCTION; MILITARY; PROGRAM; NEGLECT	Combat blast is an important cause of traumatic brain injury (TBI) in the Department of Veterans Affairs polytrauma population, whereas common causes of TBI in the civilian sector include motor vehicle accidents and falls. Known visual consequences of civilian TBI include compromised visual acuity, visual fields, and oculomotor function. The visual consequences of TBI related to blast remain largely unknown. Blast injury may include open globe (eye) injury, which is usually detected and managed early in the rehabilitation journey. The incidence, locations, and types of ocular damage in eyes without open globe injury after exposure to powerful blast have not been systematically studied. Initial reports and preliminary data suggest that binocular function, visual fields, and other aspects of visual function may be impaired after blast-related TBI, despite relatively normal visual acuity. Damage to the ocular tissues may occur from blunt trauma without rupture or penetration (closed globe injury). Possible areas for research are development of common taxonomy and assessment tools across services, surgical management, and outcomes for blast-related eye injury; the incidence, locations, and natural history of closed globe injury; binocular and visual function impairment; quality of life in affected service-members; pharmacological and visual therapies; and practice patterns for screening, management, and rehabilitation.	[Cockerham, Glenn C.] Dept Vet Affairs VA Palo Alto Hlth Care Syst, Ophthalmol Sect, Palo Alto, CA 94304 USA; [Cockerham, Glenn C.] Stanford Univ, Dept Ophthalmol, Stanford, CA 94305 USA; [Goodrich, Gregory L.] VA Palo Alto Hlth Care Syst, Psychol Serv, Palo Alto, CA USA; [Weichel, L. T. C. Eric D.; Bower, C. O. L. Kraig S.] Walter Reed Army Med Ctr, Ophthalmol Serv, Washington, DC 20307 USA; [Orcutt, James C.] VA Puget Sound Hlth Care Syst, Ophthalmol Sect, Seattle, WA USA; [Orcutt, James C.] Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA; [Rizzo, Joseph F.] VA Jama Plain, Ctr Innovat Visual Restorat, Boston, MA USA; [Rizzo, Joseph F.] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02114 USA; [Bower, C. O. L. Kraig S.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; [Schuchard, Ronald A.] Atlanta VA Med Ctr, Res & Dev Ctr Excellence, Atlanta, GA USA; [Schuchard, Ronald A.] Emory Univ, Dept Neurol, Atlanta, GA 30322 USA		Cockerham, GC (corresponding author), Dept Vet Affairs Palo Alto Hlth Care Syst, Ophthalmol Sect 112 B1, 3801 Miranda Ave, Palo Alto, CA 94304 USA.	glenn.cockerham@va.gov	Goodrich, Gregory L./AAF-7184-2019		VAUS Department of Veterans Affairs [C5018R]; Quality Enhancement Research Initiative [RRP 07-339]	This material was based in part on work supported by the VA through Merit Review Award C5018R and Quality Enhancement Research Initiative grant RRP 07-339.	Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; Bochicchio GV, 2008, AM SURGEON, V74, P267; Cernak I, 1999, J TRAUMA, V47, P96, DOI 10.1097/00005373-199907000-00021; Ciuffreda K. J., 1996, J BEHAV OPTOM, V7, P31; Ciuffreda Kenneth J, 2007, Optometry, V78, P155, DOI 10.1016/j.optm.2006.11.011; Ciuffreda Kenneth J, 2008, Optometry, V79, P18, DOI 10.1016/j.optm.2007.10.004; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; Goodrich GL, 2007, J REHABIL RES DEV, V44, P929, DOI 10.1682/JRRD.2007.01.0003; GROSWASSER Z, 1990, Brain Injury, V4, P161, DOI 10.3109/02699059009026161; HEIER JS, 1993, ARCH OPHTHALMOL-CHIC, V111, P795, DOI 10.1001/archopht.1993.01090060083028; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holmes JM, 2005, OPHTHALMOLOGY, V112, P2035, DOI 10.1016/j.ophtha.2005.06.013; Kasten E, 2007, J CLIN EXP NEUROPSYC, V29, P569, DOI 10.1080/13803390600878919; Klavora P, 1998, PERCEPT MOTOR SKILL, V86, P23, DOI 10.2466/pms.1998.86.1.23; Klavora P, 2000, ARCH PHYS MED REHAB, V81, P701, DOI 10.1016/S0003-9993(00)90096-0; Levin LA, 1999, OPHTHALMOLOGY, V106, P1268, DOI 10.1016/S0161-6420(99)00707-1; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; Lew HL, 2005, BRAIN INJURY, V19, P177, DOI 10.1080/02699050400017171; Lumpkins K, 2008, J TRAUMA, V64, P358, DOI 10.1097/TA.0b013e318160df9b; Mader TH, 2006, OPHTHALMOLOGY, V113, P97, DOI 10.1016/j.ophtha.2005.07.018; Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050; McInnes JK., 2000, VIS IMPAIR RES, V2, P129, DOI DOI 10.1076/VIMR.2.3.129.4422; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Padula WV, 1996, NEUROREHABILITATION, V6, P165, DOI 10.3233/NRE-1996-6302; PELI E, 2000, VISION REHABILITATIO, P104; PHILLIPS YY, 1991, CONVENTIONAL WARFARE, P221; Pizzamiglio L, 2006, RESTOR NEUROL NEUROS, V24, P337; Raphael BA, 2006, AM J OPHTHALMOL, V142, P1026, DOI 10.1016/j.ajo.2006.06.060; SCHLAGETER K, 1993, BRAIN INJURY, V7, P439, DOI 10.3109/02699059309029687; Schoth F, 2006, NEUROSCI LETT, V398, P178, DOI 10.1016/j.neulet.2005.12.088; STAPCZYNSKI JS, 1982, ANN EMERG MED, V11, P687, DOI 10.1016/S0196-0644(82)80268-0; STARCK T, 2000, LIGHTHOUSE HDB VISIO, P143; Steinsapir KD, 2006, J NEURO-OPHTHALMOL, V26, P65, DOI 10.1097/01.wno.0000204646.94991.68; STONE SP, 1993, AGE AGEING, V22, P46, DOI 10.1093/ageing/22.1.46; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Thach AB, 2008, OPHTHALMOLOGY, V115, P377, DOI 10.1016/j.ophtha.2007.04.032; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; Ueki S, 2006, AM J OPHTHALMOL, V142, P591, DOI 10.1016/j.ajo.2006.05.042; *US GAO, 2008, GAO08276; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; WARREN M, 1993, AM J OCCUP THER, V47, P42, DOI 10.5014/ajot.47.1.42; Weichel EA, 2009, J HEAD TRAUMA REHAB, V24, P41, DOI 10.1097/HTR.0b013e3181956ffd; Weichel ED, 2008, OPHTHALMOLOGY, V115, P2235, DOI 10.1016/j.ophtha.2008.08.033; 2007, LANCET, V370, P1879, DOI DOI 10.1016/S0140-6736(07)61785-1	44	101	101	1	35	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711			J REHABIL RES DEV	J. Rehabil. Res. Dev.		2009	46	6					811	818		10.1682/JRRD.2008.08.0109			8	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	531BQ	WOS:000272638100012	20104404	Bronze			2022-02-06	
J	Zhang, B; West, EJ; Van, KC; Gurkoff, GG; Zhou, J; Zhang, XM; Kozikowski, AP; Lyeth, BG				Zhang, Bin; West, Eric J.; Van, Ken C.; Gurkoff, Gene G.; Zhou, Jia; Zhang, Xiu-Mei; Kozikowski, Alan P.; Lyeth, Bruce G.			HDAC inhibitor increases histone H3 acetylation and reduces microglia inflammatory response following traumatic brain injury in rats	BRAIN RESEARCH			English	Article						traumatic brain injury; microglia; inflammation; histone deacetylase; fluid percussion	LATERAL FLUID-PERCUSSION; ACUTE NEURONAL DEGENERATION; TRANSGENIC MOUSE MODEL; DEACETYLASE INHIBITORS; VALPROIC ACID; NEURODEGENERATIVE DISEASES; BEHAVIORAL DEFICITS; HUNTINGTONS-DISEASE; ALZHEIMERS-DISEASE; SODIUM-BUTYRATE	Traumatic brain injury (TBI) produces a rapid and robust inflammatory response in the brain characterized in part by activation of microglia. A novel histone deacetylase (HDAC) inhibitor, 4-dimethylamino-N-[5-(2-mercaptoacetylamino)pentyl]benzamide (DMA-PB), was administered (0, 0.25, 2.5, 25 mg/kg) systemically immediately after lateral fluid percussion TBI in rats. Hippocampal CA2/3 tissue was processed for acetyl-histone H3 immunolocalization, OX-42 immunolocalization (for microglia), and Fluoro-Jade B histofluorescence (for degenerating neurons) at 24 h after injury. Vehicle-treated TBI rats exhibited a significant reduction in acetyl-histone H3 immunostaining in the ipsilateral CA2/3 hippocampus compared to the sham TBI group (p<0.05). The reduction in acetyl-histone H3 immunostaining was attenuated by each of the DMA-PB dosage treatment groups. Vehicle-treated TBI rats exhibited a high density of phagocytic microglia in the ipsilateral CA2/3 hippocampus compared to sham TBI in which none were observed. All doses of DMA-PB significantly reduced the density of phagocytic microglia (P<0.05). There was a trend for DMA-PB to reduce the number of degenerating neurons in the ipsilateral CA2/3 hippocampus (p = 0.076). We conclude that the HDAC inhibitor DMA-PB is a potential novel therapeutic for inhibiting neuroinflammation associated with TBI. (C) 2008 Elsevier B.V. All rights reserved.	[Zhang, Bin; West, Eric J.; Van, Ken C.; Gurkoff, Gene G.; Lyeth, Bruce G.] Univ Calif Davis, Dept Neurol Surg, Davis, CA 95616 USA; [Zhang, Bin; Zhang, Xiu-Mei] Shandong Univ, Sch Med, Dept Pharmacol, Jinan 250012, Shandong, Peoples R China; [Kozikowski, Alan P.] Univ Illinois, Drug Discovery Program, Dept Med Chem & Pharmacognosy, Chicago, IL 60612 USA; [Zhou, Jia] PsychoGen Inc, Tarrytown, NY 10591 USA		Lyeth, BG (corresponding author), Univ Calif Davis, Dept Neurol Surg, 1515 Newton Court,1 Shields Ave, Davis, CA 95616 USA.	bglyeth@ucdavis.edu		Lyeth, Bruce/0000-0003-4811-1474	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS29995, NS45136]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045136, R01NS029995] Funding Source: NIH RePORTER	This research was supported by NIH NS29995, NS45136 to BGL.	Adcock IM, 2007, BRIT J PHARMACOL, V150, P829, DOI 10.1038/sj.bjp.0707166; AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; Atkins CM, 2007, EXP NEUROL, V208, P145, DOI 10.1016/j.expneurol.2007.08.011; Butler KV, 2008, CURR PHARM DESIGN, V14, P505; Camelo S, 2005, J NEUROIMMUNOL, V164, P10, DOI 10.1016/j.jneuroim.2005.02.022; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; Chen B, 2005, BIOORG MED CHEM LETT, V15, P1389, DOI 10.1016/j.bmcl.2005.01.006; Chen PS, 2007, NEUROSCIENCE, V149, P203, DOI 10.1016/j.neuroscience.2007.06.053; Chung YL, 2003, MOL THER, V8, P707, DOI 10.1016/S1525-0016(03)00235-1; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Dietrich WD, 2004, ACTA NEUROCHIR SUPPL, V89, P69; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dompierre JP, 2007, J NEUROSCI, V27, P3571, DOI 10.1523/JNEUROSCI.0037-07.2007; Faraco G, 2006, MOL PHARMACOL, V70, P1876, DOI 10.1124/mol.106.027912; Ferrante RJ, 2003, J NEUROSCI, V23, P9418; Gao WM, 2006, BRAIN RES, V1070, P31, DOI 10.1016/j.brainres.2005.11.038; Garden GA, 2006, J NEUROIMMUNE PHARM, V1, P127, DOI 10.1007/s11481-006-9015-5; Gardian G, 2005, J BIOL CHEM, V280, P556, DOI 10.1074/jbc.M410210200; Gehrmann Jochen, 1995, P883; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; Glauben R, 2006, J IMMUNOL, V176, P5015, DOI 10.4049/jimmunol.176.8.5015; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; HUITINGA I, 1990, J EXP MED, V172, P1025, DOI 10.1084/jem.172.4.1025; Huuskonen J, 2004, BRIT J PHARMACOL, V141, P874, DOI 10.1038/sj.bjp.0705682; Jellinger KA, 2001, EUR J NEUROL, V8, P707, DOI 10.1046/j.1468-1331.2001.00322.x; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; Kawaguchi Y, 2003, CELL, V115, P727, DOI 10.1016/S0092-8674(03)00939-5; Kim HJ, 2007, J PHARMACOL EXP THER, V321, P892, DOI 10.1124/jpet.107.120188; KOZIKOWSKI AP, 2007, J MED CHEM; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lin HS, 2007, BRIT J PHARMACOL, V150, P862, DOI 10.1038/sj.bjp.0707165; Liu B, 2003, J PHARMACOL EXP THER, V304, P1, DOI 10.1124/jpet.102.035048; Lyeth BG, 2001, EXP NEUROL, V169, P191, DOI 10.1006/exnr.2001.7643; McGeer PL, 1998, ALZ DIS ASSOC DIS, V12, pS1; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Nishida K, 2004, ARTHRITIS RHEUM-US, V50, P3365, DOI 10.1002/art.20709; Pandey UB, 2007, AUTOPHAGY, V3, P643, DOI 10.4161/auto.5050; Petri S, 2006, NEUROBIOL DIS, V22, P40, DOI 10.1016/j.nbd.2005.09.013; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; Popovich PG, 2002, J NEUROPATH EXP NEUR, V61, P623, DOI 10.1093/jnen/61.7.623; Ren M, 2004, J NEUROCHEM, V89, P1358, DOI 10.1111/j.1471-4159.2004.02406.x; Saha RN, 2006, CELL DEATH DIFFER, V13, P539, DOI 10.1038/sj.cdd.4401769; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, TOXICOL PATHOL, V28, P91, DOI 10.1177/019262330002800111; Sinn DI, 2007, NEUROBIOL DIS, V26, P464, DOI 10.1016/j.nbd.2007.02.006; Streit WJ, 2002, GLIA, V40, P133, DOI 10.1002/glia.10154; Teasdale GM, 1998, NEUROSURGERY, V43, P723, DOI 10.1097/00006123-199810000-00001; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Van Den Heuvel C, 2007, PROG BRAIN RES, V161, P303, DOI 10.1016/S0079-6123(06)61021-2; Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031; Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283; Zhong CL, 2005, J NEUROTRAUM, V22, P266, DOI 10.1089/neu.2005.22.266; Zhou Y, 2005, MOL CELL PROTEOMICS, V4, P1471, DOI 10.1074/mcp.M500114-MCP200	58	101	104	1	16	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	AUG 21	2008	1226						181	191		10.1016/j.brainres.2008.05.085			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	351MG	WOS:000259427800021	18582446	Green Accepted			2022-02-06	
J	Liu, CL; Chen, S; Dietrich, D; Hu, BR				Liu, Cindy L.; Chen, Shaoyi; Dietrich, Dalton; Hu, Bingren R.			Changes in autophagy after traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						ATG12-ATG5; autophagy; LC3-ATG8-APG8; lysosome; traumatic brain injury; ubiquitin	TRANSIENT CEREBRAL-ISCHEMIA; NEURODEGENERATIVE DISEASE; PROTEIN AGGREGATION; HYPOXIA-ISCHEMIA; CELL-DEATH; MECHANISMS; SYSTEM; LC3; MITOCHONDRIA; STORAGE	Autophagy is the chief machinery for bulk degradation of superfluous or aberrant cytoplasmic components. This study used the rat moderate fluid percussion injury model to investigate whether the autophagy pathway plays a key role after traumatic brain injury (TBI). Induction of autophagy is manifested by accumulation of autophagosomes (APs), observable under transmission electron microscopy (EM). Two hallmarks of autophagy, i. e., the microtubule-associated protein light chain 3 (LC3)-II and the autophagy-related gene (ATG) 12-ATG5 conjugates, were explored by biochemical and confocal microscopic analyses of brain tissues. Under EM, both APs and autolysosomes were markedly accumulated in neurons from 4 h onward after TBI. Western blot analysis showed that ATG12-ATG5 conjugate was markedly redistributed during 5 to 15 days in brain tissues after TBI. LC3-II conjugate was initially unchanged but was drastically upregulated from 24 h onward in the pre-AP-containing fraction after TBI. LC-3 immunostaining was mainly located in living neurons under confocal microscopy. These results clearly show that the autophagy pathway is persistently activated after TBI. Because the autophagy pathway is the chief machinery for bulk elimination of aberrant cell components, we propose that activation of this pathway serves as a protective mechanism for maintaining cellular homeostasis after TBI.	[Liu, Cindy L.; Chen, Shaoyi; Hu, Bingren R.] Univ Miami, Sch Med, Dept Neurol, Neurochem Lab Brain Injury, Miami, FL 33136 USA; [Dietrich, Dalton] Univ Miami, Sch Med, Dept Neurosurg, Miami, FL 33136 USA; [Dietrich, Dalton] Univ Miami, Sch Med, Miami Project Cure Paralysis, Miami, FL 33136 USA		Hu, BR (corresponding author), Univ Miami, Sch Med, Dept Neurol, Neurochem Lab Brain Injury, POB 16960, Miami, FL 33136 USA.	cliu@med.Miami.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS036810, R01 NS040407-08, R29 NS036810, NS36810, NS040407, R56 NS036810, R01 NS040407, P50 NS030291, NS030291] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291, R01NS036810, R56NS036810, R01NS040407, R29NS036810] Funding Source: NIH RePORTER		Adhami F, 2007, AUTOPHAGY, V3, P42, DOI 10.4161/auto.3412; Adhami F, 2006, AM J PATHOL, V169, P566, DOI 10.2353/ajpath.2006.051066; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Brunk UT, 2002, EUR J BIOCHEM, V269, P1996, DOI 10.1046/j.1432-1033.2002.02869.x; Chu CT, 2006, J NEUROPATH EXP NEUR, V65, P423, DOI 10.1097/01.jnen.0000229233.75253.be; Ciechanover A, 2006, NEUROLOGY, V66, pS7, DOI 10.1212/01.wnl.0000192261.02023.b8; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; Eskelinen Eeva-Liisa, 2006, Molecular Aspects of Medicine, V27, P495, DOI 10.1016/j.mam.2006.08.005; Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724; Hu BR, 1998, J NEUROSCI, V18, P625; Hu BR, 2000, J NEUROSCI, V20, P3191, DOI 10.1523/JNEUROSCI.20-09-03191.2000; HU BR, 2006, IN PRESS HDB NEUROCH, V23; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131; Kiselyov K, 2007, AUTOPHAGY, V3, P259, DOI 10.4161/auto.3906; Klionsky DJ, 2006, NATURE, V441, P819, DOI 10.1038/441819a; Klionsky DJ, 2005, CURR BIOL, V15, pR282, DOI 10.1016/j.cub.2005.04.013; Koike M, 2005, AM J PATHOL, V167, P1713, DOI 10.1016/S0002-9440(10)61253-9; Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723; LAI Y, 2007, J CEREB BLOOD F 0905; Liu CL, 2005, NEUROSCIENCE, V134, P1273, DOI 10.1016/j.neuroscience.2005.05.015; Martinez A, 1999, PLANT J, V19, P97, DOI 10.1046/j.1365-313X.1999.00504.x; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Moore MN, 2006, MAR ENVIRON RES, V62, pS420, DOI 10.1016/j.marenvres.2006.04.055; Nishino Ichizo, 2006, Semin Pediatr Neurol, V13, P90, DOI 10.1016/j.spen.2006.06.004; Nixon RA, 2006, TRENDS NEUROSCI, V29, P528, DOI 10.1016/j.tins.2006.07.003; PONTEN U, 1973, J NEUROCHEM, V21, P1121, DOI 10.1111/j.1471-4159.1973.tb07566.x; SIESJO BK, 1995, J NEUROSURG ANESTH, V7, P47, DOI 10.1097/00008506-199501000-00009; Swanson MS, 2006, J IMMUNOL, V177, P4945, DOI 10.4049/jimmunol.177.8.4945; Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009; Yorimitsu T, 2005, CELL DEATH DIFFER, V12, P1542, DOI 10.1038/sj.cdd.4401765; Zhu C, 2005, CELL DEATH DIFFER, V12, P162, DOI 10.1038/sj.cdd.4401545; Zhu CL, 2006, J NEUROCHEM, V96, P1016, DOI 10.1111/j.1471-4159.2005.03639.x	33	101	104	0	9	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	APR	2008	28	4					674	683		10.1038/sj.jcbfm.9600587			10	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	280GS	WOS:000254414500002	18059433	Green Accepted, Bronze			2022-02-06	
J	Le Gall, F; Carling, C; Reilly, T				Le Gall, Franck; Carling, Christopher; Reilly, Thomas			Injuries in young elite female soccer players	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						training; trauma; overuse; women	LOWER-EXTREMITY KINEMATICS; MEDICAL-RESEARCH PROGRAM; RISK-FACTORS; EUROPEAN FOOTBALL; DATA-COLLECTION; HEAD-INJURIES; ANKLE SPRAINS; PREVENTION; CONCUSSION; AUDIT	Background: Epidemiologic data on injuries in young female soccer players at elite levels are scarce. Purpose: The aim of the present study is to investigate the incidence of soccer-related injuries in young elite female French players. Study Design: Cohort study; Level of evidence, 2. Methods: Injuries sustained by players between 15 and 19 years of age, during 8 seasons, were diagnosed and documented by a sports physician according to type, location, severity, the date the injury occurred, and playing position. Results: Altogether 619 injuries were documented for 110 players (92.4%). Of these injuries, 64.6% (4.6/1000 training hours; 95% confidence interval [Cl], 4.2-5.0) and 35.4% (22.4/1000 match hours; 95% Cl, 19.4-25.4) were sustained during training and matches, respectively. The risk of injury was greater in the youngest (under age 15) group compared with the oldest (under 19) group (relative risk 1.7; 95% Cl, 1.3-2.3). Traumatic injuries amounted to 536 (86.4%) and 83 (13.4%) were overuse injuries. There were 51.9% minor injuries, 35.7% moderate injuries, and 12.4% major injuries. Most injuries were located at the lower extremities (83.4%), with the majority affecting the ankle (n = 157). The most commonly diagnosed injury was ankle sprain (16.8%). Twelve anterior cruciate ligament ruptures were sustained, with the majority occurring during matches (n = 10; 1.0/1000 match hours; 95% Cl, 0.4-1.6). Reinjuries accounted for 4.4% of total injuries, and September was the predominant month for injury (14.2%). Conclusions: The results, when compared with those of other investigations on female soccer players, revealed high rates of both traumatic injury and match injury, whereas recurrence of injury was low. Injuries, notably sprains, to the ankle were common, suggesting a need for the implementation of specific injury prevention strategies for this joint.	LOSC Lille Metropole Football Club, Ctr Format, F-59650 Villeneuve Dascq, France; [Le Gall, Franck] Inst Natl Football, Ctr Tech Natl Fernand Sastre, Clairefontaine En Yvelin, France; [Reilly, Thomas] Liverpool John Moores Univ, Res Inst Sport & Exercise Sci, Liverpool L3 5UX, Merseyside, England		Carling, C (corresponding author), LOSC Lille Metropole Football Club, Ctr Format, Stadium Lille Metropole 30 Av Chatellenie, F-59650 Villeneuve Dascq, France.	chris.carling@free.fr					Al-Kashmiri A, 2006, TRAUMA, V8, P189, DOI 10.1177/1460408606071144; Andersen TE, 2004, BRIT J SPORT MED, V38, P690, DOI 10.1136/bjsm.2003.009357; Arnason A, 2004, AM J SPORT MED, V32, p5S, DOI 10.1177/0363546503258912; BACKOUS DD, 1988, AM J DIS CHILD, V142, P839, DOI 10.1001/archpedi.1988.02150080045019; Bennett P, 2006, TRAUMA, V8, P69, DOI 10.1177/1460408606072682; Bjordal JM, 1997, AM J SPORT MED, V25, P341, DOI 10.1177/036354659702500312; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Delaney JS, 1999, CLIN J SPORT MED, V9, P121; Dvorak J, 2000, AM J SPORT MED, V28, pS3; Elias SR, 2001, MED SCI SPORT EXER, V33, P359, DOI 10.1097/00005768-200103000-00004; Emery CA, 2005, AM J SPORT MED, V33, P1882, DOI 10.1177/0363546505279576; ENGSTROM B, 1991, AM J SPORT MED, V19, P372, DOI 10.1177/036354659101900408; Faude O, 2006, BRIT J SPORT MED, V40, P785, DOI 10.1136/bjsm.2006.027540; Faude O, 2005, AM J SPORT MED, V33, P1694, DOI 10.1177/0363546505275011; Fuller CW, 2006, BRIT J SPORT MED, V40, P193, DOI 10.1136/bjsm.2005.025270; Gioftsidou A, 2006, PERCEPT MOTOR SKILL, V103, P151, DOI 10.2466/PMS.103.1.151-159; Giza E, 2005, BRIT J SPORT MED, V39, P212, DOI 10.1136/bjsm.2004.011973; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Hagglund M, 2005, BRIT J SPORT MED, V39, P340, DOI 10.1136/bjsm.2005.018267; Hagglund M, 2005, SCAND J MED SCI SPOR, V15, P21, DOI 10.1111/j.1600-0838.2004.00395.x; Hawkins RD, 1999, BRIT J SPORT MED, V33, P196, DOI 10.1136/bjsm.33.3.196; Hawkins RD, 2001, BRIT J SPORT MED, V35, P43, DOI 10.1136/bjsm.35.1.43; Heidt RS, 2000, AM J SPORT MED, V28, P659, DOI 10.1177/03635465000280050601; Hewett TE, 1996, AM J SPORT MED, V24, P765, DOI 10.1177/036354659602400611; INKLAAR H, 1994, SPORTS MED, V18, P81, DOI 10.2165/00007256-199418020-00002; Jacobson I, 2007, SCAND J MED SCI SPOR, V17, P84, DOI 10.1111/j.1600-0838.2006.00524.x; Jacobson I, 2006, EUR J PHYSIOTHER, V8, P66, DOI 10.1080/14038190600621706; Junge A, 2000, AM J SPORT MED, V28, pS40; Knobloch K, 2005, SPORTVERLETZ SPORTSC, V19, P123, DOI 10.1055/s-2005-858345; Le Gall F, 2006, AM J SPORT MED, V34, P928, DOI 10.1177/0363546505283271; LEGALL F, 2005, TRAUMATISMES FOOTBAL; MAEHLUM S, 1986, PHYSICIAN SPORTSMED, V14, P73, DOI 10.1080/00913847.1986.11709124; McGuine TA, 2006, AM J SPORT MED, V34, P1103, DOI 10.1177/0363546505284191; MURIER A, 2006, MAGAZINE MINISTERE J, V106, P11; Ostenberg A, 2000, SCAND J MED SCI SPOR, V10, P279, DOI 10.1034/j.1600-0838.2000.010005279.x; Peterson L, 2000, AM J SPORT MED, V28, pS51; Pickett W, 2005, BRIT J SPORT MED, V39, P226, DOI 10.1136/bjsm.2004.013169; Pollard CD, 2006, CLIN J SPORT MED, V16, P223, DOI 10.1097/00042752-200605000-00006; Price RJ, 2004, BRIT J SPORT MED, V38, P466, DOI 10.1136/bjsm.2003.005165; Soderman K, 2001, SCAND J MED SCI SPOR, V11, P299, DOI 10.1034/j.1600-0838.2001.110508.x; SURVE I, 1994, AM J SPORT MED, V22, P601, DOI 10.1177/036354659402200506; Tol JL, 2002, AM J SPORT MED, V30, P45, DOI 10.1177/03635465020300012101; TROPP H, 1985, AM J SPORT MED, V13, P259, DOI 10.1177/036354658501300408; Yu B, 2005, AM J SPORT MED, V33, P1356, DOI 10.1177/0363546504273049	44	101	104	2	17	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	FEB	2008	36	2					276	284		10.1177/0363546507307866			9	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	255NE	WOS:000252663900007	17932408				2022-02-06	
J	Bushnik, T; Englander, J; Wright, J				Bushnik, Tamara; Englander, Jefftey; Wright, Jerry			The experience of fatigue in the first 2 years after moderate-to-severe traumatic brain injury: A preliminary report	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						depression; fatigue; pain; sleep; traumatic brain injury	GROWTH-HORMONE DEFICIENCY; DISABILITY RATING-SCALE; MINOR HEAD-INJURY; INVENTORY; REHABILITATION; RELIABILITY; INSTRUMENT; DEPRESSION; RECOVERY; INSOMNIA	Fatigue is a well-recognized issue for individuals with traumatic brain injury (TBI). This prospective study examined the rate and types of fatigue that are experienced by a cohort of individuals with TBI within the first 2 years, using a multidimensional fatigue scale. The impact of factors such as demographics, Injury severity indices, and concomitant psychosocial variables was also examined. Using 2 measures of overall fatigue, 16%-32% at Year 1 and 21%-34% at Year 2 reported significant levels of fatigue. Fatigue did not appear to change between 1 and 2 years post-TBI. Sleep quality was the most prevalent concomitant disturbance followed by depression and pain.	[Bushnik, Tamara; Englander, Jefftey; Wright, Jerry] Santa Clara Valley Med Ctr, Rehabil Res Ctr, No California TBI Model Syst Care, Co PI, San Jose, CA 95128 USA		Bushnik, T (corresponding author), Santa Clara Valley Med Ctr, Rehabil Res Ctr, No California TBI Model Syst Care, Co PI, 751 S Bascom Ave, San Jose, CA 95128 USA.	tamara@thi-sci.org		Bushnik, Tamara/0000-0003-3328-257X			Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Barroso Julie, 2002, J Assoc Nurses AIDS Care, V13, P66, DOI 10.1016/S1055-3290(06)60242-2; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; BELZA BL, 1995, J RHEUMATOL, V22, P639; Borgaro SR, 2005, J HEAD TRAUMA REHAB, V20, P416, DOI 10.1097/00001199-200509000-00003; Bormann J, 2001, J Assoc Nurses AIDS Care, V12, P75, DOI 10.1016/S1055-3290(06)60146-5; BUSHNIK T, 2006, 2 FED INT C TBI MARC; Bushnik T, 2007, BRAIN INJURY, V21, P559, DOI 10.1080/02699050701426915; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Carroll PV, 1998, J CLIN ENDOCR METAB, V83, P382, DOI 10.1210/jc.83.2.382; Castriotta RJ, 2001, ARCH PHYS MED REHAB, V82, P1403, DOI 10.1053/apmr.2001.26081; Centers for Disease Control and Prevention, 1998, BEH RISK FACT SURV S; Chistyakov AV, 1998, ACTA NEUROCHIR, V140, P467, DOI 10.1007/s007010050126; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; DAVID A, 1990, BMJ-BRIT MED J, V301, P1199, DOI 10.1136/bmj.301.6762.1199; de Rijk AE, 1999, J PSYCHOSOM RES, V47, P509, DOI 10.1016/S0022-3999(99)00049-5; Dittner AJ, 2004, J PSYCHOSOM RES, V56, P157, DOI 10.1016/S0022-3999(03)00371-4; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; Fichtenberg NL, 2002, BRAIN INJURY, V16, P197, DOI 10.1080/02699050110103940; FINKELMAN JM, 1994, HUM FACTORS, V36, P232, DOI 10.1177/001872089403600205; FOA EB, 1993, J TRAUMA STRESS, V6, P459, DOI 10.1002/jts.2490060405; FRYER LJ, 1987, J HEAD TRAUMA REHAB, V2, P51, DOI DOI 10.1097/00001199-198709000-00007; Furberg H, 2005, J PSYCHOSOM RES, V59, P283, DOI 10.1016/j.jpsychores.2005.05.008; Glader EL, 2002, STROKE, V33, P1327, DOI 10.1161/01.STR.0000014248.28711.D6; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; Grady C, 1998, NURS RES, V47, P227, DOI 10.1097/00006199-199807000-00008; Hillier SL, 1997, BRAIN INJURY, V11, P661; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; Lieberman SA, 1996, J PEDIATR-US, V128, pS58, DOI 10.1016/S0022-3476(96)70013-6; Lou JS, 2001, MOVEMENT DISORD, V16, P190, DOI 10.1002/mds.1042; Mazaux JM, 1998, DISABIL REHABIL, V20, P435, DOI 10.3109/09638289809166108; MELLICK D, 1999, J REHABIL OUTCOMES, V3, P12; Michael Kathleen, 2002, Rehabil Nurs, V27, P89; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; *NAT HOUS SURV DRU, SUBST AB MENT HLTH S; Novack T, 2000, ORIENTATION LOG; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; PAWLIKOWSKA T, 1994, BRIT MED J, V308, P763, DOI 10.1136/bmj.308.6931.763; Powell JM, 2001, ARCH PHYS MED REHAB, V82, P1025, DOI 10.1053/apmr.2001.25082; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Resnick HE, 2006, J CLIN SLEEP MED, V2, P163; Schwartz CE, 1996, ARCH PHYS MED REHAB, V77, P165, DOI 10.1016/S0003-9993(96)90162-8; SHARAR E, 1990, J FAM PRACTICE, V31, P257; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Taylor RR, 2002, PSYCHOSOM MED, V64, P319, DOI 10.1097/00006842-200203000-00016; WALKER GC, 1991, ARCH PHYS MED REHAB, V72, P469; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; Winstead-Fry P, 1998, J Nurs Meas, V6, P111; Ziino C, 2005, J INT NEUROPSYCH SOC, V11, P416, DOI 10.1017/S1355617705050472	55	101	101	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2008	23	1					17	24		10.1097/01.HTR.0000308717.80590.22			8	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	256HS	WOS:000252719800005	18219231				2022-02-06	
J	Kharatishvili, I; Immonen, R; Grohn, O; Pitkanen, A				Kharatishvili, Irina; Immonen, Riikka; Grohn, Olli; Pitkanen, Asla			Quantitative diffusion MRI of hippocampus as a surrogate marker for post-traumatic epileptogenesis	BRAIN			English	Article						traumatic brain injury; magnetic resonance imaging; surrogate marker; post-traumatic epilepsy; video-EEG monitoring	TRAUMATIC BRAIN-INJURY; TEMPORAL-LOBE EPILEPSY; FIBER SYNAPTIC REORGANIZATION; CLOSED-HEAD INJURY; WEIGHTED MR; STATUS EPILEPTICUS; WATER-DIFFUSION; DENTATE GYRUS; TIME-COURSE; SPONTANEOUS SEIZURES	The need to use animal models to develop imaging markers that could be linked to electrophysiological abnormalities in epilepsy and able to predict epileptogenicity in human studies is widely acknowledged. This study aimed to investigate the value of early magnetic resonance imaging (MRI) in predicting the long-term increased seizure susceptibility in the clinically relevant model of post-traumatic epilepsy (PTE). Moderate traumatic brain injury (TBI) was induced by lateral fluid-percussion in two groups of adult rats (34 injured, 16 controls). In Experiment 1, MRI follow-up was performed using a 4.7 T magnet at 3 h, 3 days, 9 days, 23 days, 2 months, 3 months and 6 months after TBI. T2 and 1/3 of the trace of the diffusion tensor (D-av) were quantified from a single slice using a fast spin-echo sequence. In Experiment 2, MRI was performed at 7 and 11 months post-injury. In both groups, seizure susceptibility was tested by injecting a single dose of pentylenetetrazol at 12 months post-injury. Electrographic and behavioural responses were monitored for 1 h. Total number of spikes, total number of epileptiform discharges (EDs) and latency to first spike were measured. Finally, the severity of mossy fibre sprouting was evaluated. In both experiments, EEG parameters such as total number of spikes or EDs proved to be reliable indicators of increased seizure susceptibility in injured animals when compared to controls (P < 0.05). In the hippocampus ipsilateral to TBI, D-av correlated with these EEG parameters at both early (3 h), and chronic (23 days, 2, 3, 6, 7 and 11 months) time points after TBI, as well as with the density of mossy fibre sprouting. These results for the first time demonstrate that quantitative diffusion MRI can serve as a tool to facilitate prediction of increased seizure susceptibility in a clinically relevant model of human PTE.	Univ Kuopio, Inst Mol Sci, FI-70211 Kuopio, Finland; Univ Kuopio, Epilepsy Res Grp, FI-70211 Kuopio, Finland; Univ Kuopio, Biomed NMR Res Grp, FI-70211 Kuopio, Finland; Univ Kuopio, AI Virtanen Inst Mol Sci, Dept Neurobiol, FI-70211 Kuopio, Finland; Univ Kuopio, Dept Neurosci, FI-70211 Kuopio, Finland		Pitkanen, A (corresponding author), Univ Kuopio, Inst Mol Sci, PO Box 1627, FI-70211 Kuopio, Finland.	asla.pitkanen@uku.fi					Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Alsop DC, 1996, J NEUROTRAUM, V13, P515, DOI 10.1089/neu.1996.13.515; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Annegers JF., 1996, TREATMENT EPILEPSY P, P165; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Assaf BA, 2003, AM J NEURORADIOL, V24, P1857; Assaf Y, 1997, MAGN RESON IMAGING, V15, P77, DOI 10.1016/S0730-725X(96)00246-9; Bragin A, 1999, EPILEPSIA, V40, P1210, DOI 10.1111/j.1528-1157.1999.tb00849.x; Buckmaster PS, 1997, J COMP NEUROL, V385, P385; CAVAZOS JE, 1991, J NEUROSCI, V11, P2795; Coulter DA, 1996, EPILEPSY RES, V26, P81, DOI 10.1016/S0920-1211(96)00044-7; Diaz-Arrastia R, 2000, ARCH NEUROL-CHICAGO, V57, P1611, DOI 10.1001/archneur.57.11.1611; Diehl B, 2005, EPILEPSY RES, V65, P137, DOI 10.1016/j.eplepsyres.2005.05.007; Diehl B, 2001, EPILEPSIA, V42, P21, DOI 10.1046/j.1528-1157.2001.19500.x; Diehl B, 1999, EPILEPSIA, V40, P1667, DOI 10.1111/j.1528-1157.1999.tb02056.x; Dubreuil CI, 2006, EXP NEUROL, V198, P361, DOI 10.1016/j.expneurol.2005.12.002; Duncan JS, 2002, EPILEPSY RES, V50, P131, DOI 10.1016/S0920-1211(02)00075-X; Duncan JS, 1997, BRAIN, V120, P339, DOI 10.1093/brain/120.2.339; Ebisu T, 1996, MAGNET RESON MED, V36, P821, DOI 10.1002/mrm.1910360604; Elmer E, 1997, NEUROREPORT, V8, P1193, DOI 10.1097/00001756-199703240-00027; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; GOLARAI G, 1992, BRAIN RES, V593, P257, DOI 10.1016/0006-8993(92)91316-7; Golarai G, 2001, J NEUROSCI, V21, P8523, DOI 10.1523/JNEUROSCI.21-21-08523.2001; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Gupta RK, 2005, EPILEPSIA, V46, P1465, DOI 10.1111/j.1528-1167.2005.01205.x; Haltiner AM, 1999, J NEUROSURG, V91, P588, DOI 10.3171/jns.1999.91.4.0588; HAUSER WA, 1991, EPILEPSIA, V32, P429, DOI 10.1111/j.1528-1157.1991.tb04675.x; Herman ST, 2002, NEUROLOGY, V59, pS21, DOI 10.1212/WNL.59.9_suppl_5.S21; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HOUSER CR, 1990, J NEUROSCI, V10, P267; Hufnagel A, 2003, EPILEPSIA, V44, P54, DOI 10.1046/j.1528-1157.2003.07802.x; Hugg JW, 1999, NEUROLOGY, V53, P173, DOI 10.1212/WNL.53.1.173; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Kantarci K, 2002, NEUROLOGY, V58, P1745, DOI 10.1212/WNL.58.12.1745; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kim JA, 2001, AM J NEURORADIOL, V22, P1149; KOTAPKA MJ, 1993, NEUROPATH APPL NEURO, V19, P128, DOI 10.1111/j.1365-2990.1993.tb00417.x; KOTAPKA MJ, 1994, J NEUROTRAUM, V11, P317, DOI 10.1089/neu.1994.11.317; Lee JH, 2004, ACTA NEUROL SCAND, V110, P53, DOI 10.1111/j.1600-0404.2004.00261.x; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; Longo BM, 1998, EPILEPSY RES, V32, P172, DOI 10.1016/S0920-1211(98)00049-7; LOSCHER W, 1991, EPILEPSY RES, V8, P171, DOI 10.1016/0920-1211(91)90062-K; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Marks MP, 1996, RADIOLOGY, V199, P403, DOI 10.1148/radiology.199.2.8668785; MASON CR, 1972, EPILEPSIA, V13, P663, DOI 10.1111/j.1528-1157.1972.tb04401.x; Mathern GW, 1998, J NEUROSCI RES, V54, P734, DOI 10.1002/(SICI)1097-4547(19981215)54:6<734::AID-JNR2>3.0.CO;2-P; MATHERN GW, 1995, J NEUROSURG, V82, P211, DOI 10.3171/jns.1995.82.2.0211; Mathern GW, 1996, EPILEPSY RES, V26, P151, DOI 10.1016/S0920-1211(96)00052-6; MATHERN GW, 1995, J NEUROSURG, V82, P220, DOI 10.3171/jns.1995.82.2.0220; MATHERN GW, 1994, EPILEPSY RES, V19, P129, DOI 10.1016/0920-1211(94)90023-X; McCarthy MM, 2003, EXP NEUROL, V184, P40, DOI 10.1016/j.expneurol.2003.08.020; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MELLO LEAM, 1993, EPILEPSIA, V34, P985, DOI 10.1111/j.1528-1157.1993.tb02123.x; NAKASU Y, 1995, AM J NEURORADIOL, V16, P1185; Nissinen J, 2000, EPILEPSY RES, V38, P177, DOI 10.1016/S0920-1211(99)00088-1; Nissinen J, 2001, HIPPOCAMPUS, V11, P299, DOI 10.1002/hipo.1044; Pitkanen A, 2007, EPILEPSIA, V48, P13, DOI 10.1111/j.1528-1167.2007.01063.x; REPRESA A, 1993, HIPPOCAMPUS, V3, P257, DOI 10.1002/hipo.450030303; Rugg-Gunn FJ, 2002, LANCET, V359, P1748, DOI 10.1016/S0140-6736(02)08615-4; Rugg-Gunn FJ, 2001, BRAIN, V124, P627, DOI 10.1093/brain/124.3.627; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; Schierhout G, 1998, J NEUROL NEUROSUR PS, V64, P108, DOI 10.1136/jnnp.64.1.108; Semah F, 1998, NEUROLOGY, V51, P1256, DOI 10.1212/WNL.51.5.1256; Sloviter RS, 2006, J COMP NEUROL, V494, P944, DOI 10.1002/cne.20850; SLOVITER RS, 1982, BRAIN RES BULL, V8, P771, DOI 10.1016/0361-9230(82)90104-6; Sloviter RS, 1999, EPILEPSIA, V40, pS34, DOI 10.1111/j.1528-1157.1999.tb00876.x; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH DH, 1995, J NEUROTRAUM, V12, P573, DOI 10.1089/neu.1995.12.573; Sundgren PC, 2004, NEURORADIOLOGY, V46, P339, DOI 10.1007/s00234-003-1114-x; SUTULA T, 1988, SCIENCE, V239, P1147, DOI 10.1126/science.2449733; SUTULA T, 1989, ANN NEUROL, V26, P321, DOI 10.1002/ana.410260303; Swartz BE, 2006, EPILEPSIA, V47, P1373, DOI 10.1111/j.1528-1167.2006.00602.x; Swinyard E. A., 1989, ANTIEPILEPTIC DRUGS, P85; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; Thivard L, 2005, NEUROIMAGE, V28, P682, DOI 10.1016/j.neuroimage.2005.06.045; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Toth Z, 1997, J NEUROSCI, V17, P8106; Velisek L, 2006, MODELS OF SEIZURES AND EPILEPSY, P127, DOI 10.1016/B978-012088554-1/50013-X; Wang Y, 1996, EPILEPSIA, V37, P1000, DOI 10.1111/j.1528-1157.1996.tb00539.x; Wieshmann UC, 1999, MAGN RESON IMAGING, V17, P29, DOI 10.1016/S0730-725X(98)00153-2; Wieshmann UC, 1999, LANCET, V353, P1242, DOI 10.1016/S0140-6736(99)00248-2; Wilde EA, 2007, DEV MED CHILD NEUROL, V49, P294, DOI 10.1111/j.1469-8749.2007.00294.x; Yoo SY, 2002, AM J NEURORADIOL, V23, P809; ZHONG J, 1993, MAGN RESON MED, V30, P241, DOI 10.1002/mrm.1910300214; Zhong JH, 1997, MAGN RESON MED, V37, P1, DOI 10.1002/mrm.1910370102	93	101	101	0	13	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	DEC	2007	130		12				3155	3168		10.1093/brain/awm268			14	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	236WX	WOS:000251335200012	18055492	Bronze			2022-02-06	
J	Dias, CP; De Lima, MNM; Presti-Torres, J; Dornelles, A; Garcia, VA; Scalco, FS; Guimaraes, MR; Constantino, L; Budni, P; Dal-Pizzol, F; Schroder, N				Dias, C. Pieta; De Lima, M. N. Martins; Presti-Torres, J.; Dornelles, A.; Garcia, V. A.; Scalco, F. Siciliani; Guimaraes, M. Rewsaat; Constantino, L.; Budni, P.; Dal-Pizzol, Felipe; Schroder, N.			Memantine reduces oxidative damage and enhances long-term recognition memory in aged rats	NEUROSCIENCE			English	Article						aging; neuroprotection; oxidative stress; protein carbonyl; hippocampus; cortex	NMDA RECEPTOR ANTAGONISTS; SEVERE ALZHEIMERS-DISEASE; TRAUMATIC BRAIN-INJURY; COGNITIVE DYSFUNCTION; SYNAPTIC PLASTICITY; RECEIVING DONEPEZIL; PARKINSONS-DISEASE; PROTEIN OXIDATION; CONTROLLED-TRIAL; SPATIAL MEMORY	Many neurodegenerative diseases, including Alzheimer's (AD), Parkinson's (PD) and Huntington's diseases (HD), are caused by different mechanisms but may share a common pathway to neuronal injury as a result of the overstimulation of glutamate receptors. It has been suggested that this pathway can be involved in generation of cognitive deficits associated with normal aging. Previous studies performed in our laboratory have demonstrated that aged rats presented recognition memory deficits. The aim of the present study was to evaluate the effect of memantine, a low-affinity N-methyl-D-aspartate (NMDA) receptor antagonist, on age-induced recognition memory deficits. Additionally, parameters of oxidative damage in cerebral regions related to memory formation were evaluated. In order to do that, male Wistar rats (24 months old) received daily injections of saline solution or memantine (20 mg/kg i.p.) during 21 days. The animals were submitted to a novel object recognition task I week after the last injection. Memantine-treated rats showed normal recognition memory while the saline group showed long-term recognition memory deficits. The results show that memantine is able to reverse age-induced recognition memory deficits. We also demonstrated that memantine reduced the oxidative damage to proteins in cortex and hippocampus, two important brain regions involved in memory formation. Thus, the present findings suggest that, at least in part, age-induced cognitive deficits are related to oxidative damage promoted by NMDA receptor overactivation. (C) 2007 IBRO. Published by Elsevier Ltd. All rights reserved.	Pontifical Catholic Univ, Fac Biosci, Neurobiol & Dev Biol Lab, BR-90619900 Porto Alegre, RS, Brazil; Pontifical Catholic Univ, Sao Lucas Hosp, Inst Geriatr & Gerontol, Grad Program Biomed Gerontol, BR-90619900 Porto Alegre, RS, Brazil; Pontifical Catholic Univ, Fac Biosci, Grad Program Cellular & Mol Biol, BR-90619900 Porto Alegre, RS, Brazil; Univ So Santa Catarina, Dept Med, Phytopathol Lab, BR-88806000 Circiuma, SC, Brazil		Schroder, N (corresponding author), Pontificial Catholic Univ, Fac Biosci, Dept Physiol Sci, Av Ipiranga,6681 Predio 12C,Sala 266, BR-90619900 Porto Alegre, RS, Brazil.	nadja_s@terra.com.br	Presti-Torres, Juliana/L-8475-2013; Schroder, Nadja/AAE-9376-2019; de Lima, Maria/A-8745-2010; Dal-Pizzol, Felipe/F-2756-2015; Dias, Caroline Pietta/AAW-5848-2021	Presti-Torres, Juliana/0000-0002-3560-0052; Dal-Pizzol, Felipe/0000-0003-3003-8977; Dias, Caroline Pietta/0000-0002-3883-4938; Schroder, Nadja/0000-0002-4227-5702; Constantino, Larissa/0000-0002-5400-6331			Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; Balu M, 2005, INT J DEV NEUROSCI, V23, P501, DOI 10.1016/j.ijdevneu.2005.06.001; Beal MF, 1998, ANN NEUROL, V44, pS110; Bertaina-Anglade V., 2006, Journal of Pharmacological and Toxicological Methods, V54, P99, DOI 10.1016/j.vascn.2006.04.001; Canzoniero LMT, 2005, J ALZHEIMERS DIS, V8, P147; Castellani Rudy J, 2006, Am J Alzheimers Dis Other Demen, V21, P126, DOI 10.1177/153331750602100213; Castellano C, 2001, CURR DRUG TARGETS, V2, P273, DOI 10.2174/1389450013348515; Chen HSV, 2006, J NEUROCHEM, V97, P1611, DOI 10.1111/j.1471-4159.2006.03991.x; CINI M, 1995, NEUROBIOL AGING, V16, P53, DOI 10.1016/0197-4580(95)80007-E; Clark RE, 2005, CURR OPIN NEUROBIOL, V15, P593, DOI 10.1016/j.conb.2005.08.014; Cowan CM, 2006, CURR TOP DEV BIOL, V75, P25, DOI 10.1016/S0070-2153(06)75002-5; Creeley C, 2006, J NEUROSCI, V26, P3923, DOI 10.1523/JNEUROSCI.4883-05.2006; Cummings JL, 2006, NEUROLOGY, V67, P57, DOI 10.1212/01.wnl.0000223333.42368.f1; Dantoine T, 2006, INT J CLIN PRACT, V60, P110, DOI 10.1111/j.1368-5031.2005.00769.x; Dautzenberg PLJ, 2006, INT PSYCHOGERIATR, V18, P179, DOI 10.1017/S104161020625347x; de Lima MN, 2005, EXP GERONTOL, V40, P506, DOI 10.1016/j.exger.2005.03.004; de Lima MNM, 2005, EXP NEUROL, V196, P177, DOI 10.1016/j.expneurol.2005.07.017; de Lima MNM, 2005, EUR J NEUROSCI, V21, P2521, DOI 10.1111/j.1460-9568.2005.04083.x; de Lima MNM, 2005, BEHAV BRAIN RES, V156, P139, DOI 10.1016/j.bbr.2004.05.016; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Dix SL, 1999, BEHAV BRAIN RES, V99, P191, DOI 10.1016/S0166-4328(98)00079-5; El Mohsen MMA, 2005, BIOCHEM BIOPH RES CO, V336, P386, DOI 10.1016/j.bbrc.2005.07.201; FERRIS S, 2006, IN PRESS INT J GERIA; Foster TC, 1997, HIPPOCAMPUS, V7, P602, DOI 10.1002/(SICI)1098-1063(1997)7:6<602::AID-HIPO3>3.0.CO;2-G; Friguet B, 2006, FEBS LETT, V580, P2910, DOI 10.1016/j.febslet.2006.03.028; Gupta RC, 2007, TOXICOL APPL PHARM, V219, P97, DOI 10.1016/j.taap.2006.10.028; Hartmann S, 2003, INT CLIN PSYCHOPHARM, V18, P81, DOI 10.1097/00004850-200303000-00003; HOYER S, 1995, DRUG AGING, V6, P210, DOI 10.2165/00002512-199506030-00004; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Kadar T, 1998, J NEURAL TRANSM, V105, P987, DOI 10.1007/s007020050107; Kaul M, 2006, CURR HIV RES, V4, P307, DOI 10.2174/157016206777709384; Kayali R, 2006, CELL BIOCHEM FUNCT, V24, P79, DOI 10.1002/cbf.1190; Kelly KM, 2006, EPILEPSY RES, V68, pS5, DOI 10.1016/j.eplepsyres.2005.07.015; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Liu RL, 2003, P NATL ACAD SCI USA, V100, P8526, DOI 10.1073/pnas.1332809100; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mancuso C, 2007, FRONT BIOSCI-LANDMRK, V12, P1107, DOI 10.2741/2130; Martin I, 2006, MECH AGEING DEV, V127, P411, DOI 10.1016/j.mad.2006.01.008; Martinez M, 2000, BRAIN RES, V855, P100, DOI 10.1016/S0006-8993(99)02349-5; Marvanova M, 2004, NEUROPSYCHOPHARMACOL, V29, P1070, DOI 10.1038/sj.npp.1300398; Minkeviciene R, 2004, J PHARMACOL EXP THER, V311, P677, DOI 10.1124/jpet.104.071027; Miyamoto E, 2006, J PHARMACOL SCI, V100, P433, DOI 10.1254/jphs.CPJ06007X; Mumby DG, 2001, BEHAV BRAIN RES, V127, P159, DOI 10.1016/S0166-4328(01)00367-9; Nabeshi H, 2006, FREE RADICAL RES, V40, P1173, DOI 10.1080/10715760600847580; Nakamura S, 2006, EUR J PHARMACOL, V548, P115, DOI 10.1016/j.ejphar.2006.07.049; Nicolle MM, 2001, NEUROSCIENCE, V107, P415, DOI 10.1016/S0306-4522(01)00374-8; Peskind ER, 2006, AM J GERIAT PSYCHIAT, V14, P704, DOI 10.1097/01.JGP.0000224350.82719.83; Rammsayer TH, 2001, LEARN MEMORY, V8, P20, DOI 10.1101/lm.33701; Rampon C, 2000, NAT NEUROSCI, V3, P238, DOI 10.1038/72945; Rao VLR, 2001, BRAIN RES, V911, P96; Reisberg B, 2003, NEW ENGL J MED, V348, P1333, DOI 10.1056/NEJMoa013128; Riederer P, 2006, J NEURAL TRANSM, V113, P1671, DOI 10.1007/s00702-006-0591-6; Rosi S, 2006, NEUROSCIENCE, V142, P1303, DOI 10.1016/j.neuroscience.2006.08.017; Schroder N, 2003, SYNAPSE, V49, P89, DOI 10.1002/syn.10210; Scott GS, 2007, BIOCHEM PHARMACOL, V73, P228, DOI 10.1016/j.bcp.2006.09.021; Smith-Swintosky V L, 1994, J Neural Transm Suppl, V44, P29; Tariot PN, 2004, JAMA-J AM MED ASSOC, V291, P317, DOI 10.1001/jama.291.3.317; Toescu EC, 2004, J CELL MOL MED, V8, P181, DOI 10.1111/j.1582-4934.2004.tb00273.x; Topic B, 2002, NEUROBIOL AGING, V23, P135, DOI 10.1016/S0197-4580(01)00241-X; van Damme P, 2005, NEURODEGENER DIS, V2, P147, DOI 10.1159/000089620; Vernon AC, 2005, EUR J NEUROSCI, V22, P1799, DOI 10.1111/j.1460-9568.2005.04362.x; WENK GL, 1994, BRAIN RES, V655, P7, DOI 10.1016/0006-8993(94)91590-3; Wenk GL, 1997, BEHAV BRAIN RES, V83, P129, DOI 10.1016/S0166-4328(97)86056-1; Winblad B, 1999, INT J GERIATR PSYCH, V14, P135, DOI 10.1002/(SICI)1099-1166(199902)14:2<135::AID-GPS906>3.0.CO;2-0; Yamada K, 2005, BEHAV BRAIN RES, V162, P191, DOI 10.1016/j.bbr.2005.02.036; Zajaczkowski W, 1996, EUR J PHARMACOL, V296, P239, DOI 10.1016/0014-2999(95)00716-4; Zoladz PR, 2006, PHARMACOL BIOCHEM BE, V85, P298, DOI 10.1016/j.pbb.2006.08.011	68	101	103	0	9	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	JUN 8	2007	146	4					1719	1725		10.1016/j.neuroscience.2007.03.018			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	176RB	WOS:000247101500027	17445991				2022-02-06	
J	Staffa, G; Nataloni, A; Compagnone, C; Servadei, F				Staffa, G.; Nataloni, A.; Compagnone, C.; Servadei, F.			Custom made cranioplasty prostheses in porous hydroxy-apatite using 3D design techniques: 7 years experience in 25 patients	ACTA NEUROCHIRURGICA			English	Article						skull defect; ceramic; porous hydroxy-apatite; cranioplasty	POSTTRAUMATIC INTRACRANIAL HYPERTENSION; TRAUMATIC BRAIN-INJURY; QUICK-SETTING MATERIAL; CRANIAL BONE DEFECTS; DECOMPRESSIVE CRANIECTOMY; CEMENT CRANIOPLASTY; CERAMIC IMPLANTS; CRANIOFACIAL SKELETON; TECHNICAL NOTE; SKULL DEFECTS	Background. None of the materials currently used to reconstruct skull defects is fully satisfactory. Their biological and physical properties are very different to those of natural bone. Solid state, high porosity hydroxyapatite (HA) seems to be a good support for bone regeneration within the prostheses, enabling integration of the heterologous material with low post-implant infective risk. Materials and methods. A model of the cranium of each patient was made in epoxy resin by stereolithography. The prosthesis was built on this model using a ceramic sintering process. In each case, an exact copy of the missing bone flap was obtained (curvature, dimensions, margins, irregularities and thickness). The porosity obtained is the same as that of the spongy bone of the skull with interconnected macropores (> 150 mu m) to promote osteoblast migration into the prosthetic core. In The Neurosurgery Division of Cesena, 26 cranioplasty prostheses have been implanted with this technique in 7 years (from 1998 to 2004). No particular criteria were pre-established, but the main indications for use of ceramic prostheses were complex and/or extended (surface > 25 cm(2)) post-surgery craniolacuna and/or previous unsuccessful procedures due to rejection, infection or bone flap reabsorption. Results. Twenty-five patients were included in this study. A clinical check-up and 3D CT (mean follow-up 30 months, range 12-79) always showed an excellent aesthetic result. No cases of infection, rejection or spontaneous prosthesis fragmentation were found. The surgical procedure was simpler and shorter than for other described procedures. Conclusions. Bioceramic porous hydroxy-apatite prosthesis have been demonstrated as a valid alternative to traditional cranioplasty techniques both aesthetically and in terms of absence of infections/rejections. Principal limitations for the use of HA prostheses are the need for stereolithography process, the poor malleability of the material and the high cost.	Presidio Osped, Div Neurotraumatol, I-47023 Cesena, Italy; Ceram Faenza, Div Biomed, Faenza, Italy; Intens Care Unit, Presidio Osped Bufalini, Cesena, Italy		Staffa, G (corresponding author), Presidio Osped, Div Neurotraumatol, Via Ghirotti 286, I-47023 Cesena, Italy.	gstaffa@ausl-cesena.emr.it		Compagnone, Christian/0000-0001-9951-5503; Servadei, Franco/0000-0002-3595-3464			Agner C, 2003, MINIM INVAS NEUROSUR, V46, P186; Arriaga MA, 2002, OTOLARYNG HEAD NECK, V126, P512, DOI 10.1067/mhn.2002.124436; Artico M, 2003, SURG NEUROL, V60, P71, DOI 10.1016/S0090-3019(03)00031-4; Boyde A, 1999, BONE, V24, P579, DOI 10.1016/S8756-3282(99)00083-6; Bruce JN, 2003, J NEUROSURG, V98, P1203, DOI 10.3171/jns.2003.98.6.1203; Bryant KJ, 2003, J AM VET MED ASSOC, V223, P67, DOI 10.2460/javma.2003.223.67; Chen TM, 2002, ANN PLAS SURG, V49, P272, DOI 10.1097/00000637-200209000-00006; Choi SH, 1998, PEDIATR NEUROSURG, V29, P324, DOI 10.1159/000028747; COCCHI R, 1999, BIOCERAMICS, P57; Coplin WM, 2001, J TRAUMA, V50, P1050, DOI 10.1097/00005373-200106000-00013; Costantino PD, 2000, OTOLARYNG HEAD NECK, V123, P409, DOI 10.1067/mhn.2000.107679; COSTANTINO PD, 1992, PLAST RECONSTR SURG, V90, P174, DOI 10.1097/00006534-199290020-00003; DAVOLIO F, 2001, ATT CONV NAZ RIC CRA, P69; De Luca GP, 2000, ACTA NEUROCHIR SUPPL, V76, P401; Denissen H, 2000, J PERIODONTOL, V71, P272, DOI 10.1902/jop.2000.71.2.272; Ducic J, 2002, J ORAL MAXIL SURG, V60, P272, DOI 10.1053/joms.2002.30575; Durham SR, 2003, NEUROSURGERY, V52, P842, DOI 10.1227/01.NEU.0000054220.01290.8E; Eppley BL, 2003, J CRANIOFAC SURG, V14, P209, DOI 10.1097/00001665-200303000-00014; Eppley BL, 2003, J CRANIOFAC SURG, V14, P85, DOI 10.1097/00001665-200301000-00015; FABBRI M, 1995, BIOMATERIALS, V16, P225, DOI 10.1016/0142-9612(95)92121-L; FABBRI M, 1995, 4 EUR CER, V8, P109; GLADSTONE HB, 1995, OTOLARYNG CLIN N AM, V28, P381; Gosain AK, 1997, J CRANIOFAC SURG, V8, P506, DOI 10.1097/00001665-199711000-00017; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Hobar PC, 2003, PLAST RECONSTR SURG, V111, P1667, DOI 10.1097/01.PRS.0000054752.72999.DB; Iwama T, 2003, NEUROSURGERY, V52, P591, DOI 10.1227/01.NEU.0000047891.86938.46; JOFFE JM, 1992, BRIT J NEUROSURG, V6, P343, DOI 10.3109/02688699209023793; Johnson PJ, 2000, OTOLARYNG HEAD NECK, V123, P515, DOI 10.1067/mhn.2000.105182; Kawaguchi T, 2003, NEUROL MED-CHIR, V43, P320, DOI 10.2176/nmc.43.320; Komolafe E O, 2003, West Afr J Med, V22, P35; Kubo S, 2002, NEUROSURGERY, V51, P1094, DOI 10.1097/00006123-200210000-00046; Liao CC, 2002, J CLIN NEUROSCI, V9, P553, DOI 10.1054/jocn.2002.1116; Marcacci M, 1999, CALCIFIED TISSUE INT, V64, P83, DOI 10.1007/s002239900583; Mastrogiacomo M, 2005, Orthod Craniofac Res, V8, P277, DOI 10.1111/j.1601-6343.2005.00350.x; MENABUE L, 1992, BIOMATERIALI, P107; Miyake H, 2000, NEUROSURGERY, V46, P414, DOI 10.1097/00006123-200002000-00028; Moreira-Gonzalez A, 2003, J CRANIOFAC SURG, V14, P144, DOI 10.1097/00001665-200303000-00003; Munch E, 2000, NEUROSURGERY, V47, P315, DOI 10.1097/00006123-200008000-00009; Nakagawa S, 2003, NEUROL MED-CHIR, V43, P120, DOI 10.2176/nmc.43.120; Narayan D, 2002, NEUROSURG CLIN N AM, V13, P505, DOI 10.1016/S1042-3680(02)00022-0; NATALONI A, 2000, ATT 13 INT S CER MED, P881; NATALONI A, 2000, ATT 6 M SEM CER CELL, P198; NATALONI A, 2001, CERAMICA ACTA, V13, P102; Ono I, 1999, PLAST RECONSTR SURG, V104, P339, DOI 10.1097/00006534-199908000-00003; ONO I, 1993, PLAST RECONSTR SURG, V92, P819, DOI 10.1097/00006534-199392050-00007; OSBORN JF, 1989, Z MATERIAL, P2; Ozerdem OR, 2002, ANN PLAS SURG, V49, P127; Park HK, 2002, BIOMED SCI INSTRUM, V38, P429; Pompili A, 1998, J NEUROSURG, V89, P236, DOI 10.3171/jns.1998.89.2.0236; Saringer W, 2002, ACTA NEUROCHIR, V144, P1193, DOI 10.1007/s00701-002-0995-5; Verheggen R, 2001, ACTA NEUROCHIR, V143, P919, DOI 10.1007/s007010170022; Vories A, 2001, Ear Nose Throat J, V80, P29; Wang Jing, 2002, Hunan Yi Ke Da Xue Xue Bao, V27, P187; Whitfield PC, 2001, BRIT J NEUROSURG, V15, P500, DOI 10.1080/02688690120105110; Wurm G, 2004, SURG NEUROL, V62, P510, DOI 10.1016/j.surneu.2004.01.025; Yap C, 2002, BRIT J NEUROSURG, V16, P523, DOI 10.1080/0268869021000030951	56	101	102	1	18	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	FEB	2007	149	2					161	170		10.1007/s00701-006-1078-9			10	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	132UV	WOS:000243968800012	17242849				2022-02-06	
J	Setnik, L; Bazarian, JJ				Setnik, Lon; Bazarian, Jeffrey J.			The characteristics of patients who do not seek medical treatment for traumatic brain injury	BRAIN INJURY			English	Article						traumatic brain injury; survey; internet	COMPUTED-TOMOGRAPHY; UNITED-STATES; HEAD-INJURY; MILD; INTERNET; PREDICTORS	Primary objective: To identify factors associated with not seeking medical care for traumatic brain injury (TBI). Research Design: Internet survey. Methods and procedures: The survey consisted of 17 questions related to demographics, TBI case ascertainment, location and mechanism of injury, type of treatment sought, and post-concussive (PC) symptoms. Logistic regression was used to identify factors associated with not seeking medical care. Main outcome and results: Of the 1381 survey respondents with TBI, 584 (42%) did not seek medical care. TBI respondents were less likely to seek care if they were older (OR 0.98, 95% CI 0.97-0.99), suffered a mild TBI grade 2/3 (OR 0.42, 95% CI 0.31-0.58), or were injured in the home (OR 0.53, 95% CI 0.36-0.78). Conclusions: Several factors associated with not seeking medical care after TBI were identified. Raising public awareness of the signs and symptoms of TBI, and the benefits of medical care, could help increase the number of TBI patients who seek medical care.	Univ Rochester, Sch Med, Dept Emergency Med, Rochester, NY USA; Elliot Hosp, Manchester, NH USA		Bazarian, JJ (corresponding author), Univ Rochester, Sch Med, Dept Emergency Med, Box 655, Rochester, NY USA.	Jeff_Bazarian@urmc.rochester.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1K23NS41952-05] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS041952] Funding Source: NIH RePORTER		ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bazarian JJ, 2006, ACAD EMERG MED, V13, P199, DOI 10.1197/j.aem.2005.07.031; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; BOREZUK P, 1997, EMERGENCY MED CLIN N, V15, P563; BOREZUK P, 1995, ANN EMERG MED, V25, P1; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Diaz JA, 2002, J GEN INTERN MED, V17, P180, DOI 10.1046/j.1525-1497.2002.10603.x; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Houston TK, 2002, J MED INTERNET RES, V4, DOI 10.2196/jmir.4.2.e7; Houston TK, 2001, PSYCHIATR SERV, V52, P362, DOI 10.1176/appi.ps.52.3.362; *INT WORLD STAT, US POP STAT; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Miller EC, 1996, ANN EMERG MED, V27, P290, DOI 10.1016/S0196-0644(96)70261-5; Nathanson AT, 1999, WILD ENVIRON MED, V10, P218, DOI 10.1580/1080-6032(1999)010[0218:WIROAP]2.3.CO;2; Palchak MJ, 2003, ANN EMERG MED, V42, P492, DOI 10.1067/S0196-0644(03)00425-6; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; Sosin DM, 1996, BRAIN INJURY, V10, P47; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Thurman DJ., 1995, GUIDELINES SURVEILLA; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; J HOPKINS SKIING SNO; ONLINE REPORTING SYS; NIH POLICY REPORTING; 2000, SOCIAL SCI Q, V81, P868	34	101	101	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2007	21	1					1	9		10.1080/02699050601111419			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	141FQ	WOS:000244564600001	17364514				2022-02-06	
J	Ji, ZS; Mullendorff, K; Cheng, IH; Miranda, RD; Huang, YD; Mahley, RW				Ji, ZS; Mullendorff, K; Cheng, IH; Miranda, RD; Huang, YD; Mahley, RW			Reactivity of apolipoprotein E4 and amyloid beta peptide - Lysosomal stability and neurodegeneration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; RECEPTOR-RELATED PROTEIN; ONSET ALZHEIMER-DISEASE; TRANSGENIC MOUSE MODEL; TRAUMATIC BRAIN-INJURY; PRECURSOR PROTEIN; CELL-DEATH; E GENOTYPE; ENDOCYTIC PATHWAY; TRANSPORT PROTEIN	We previously demonstrated that apolipoprotein E4 (apoE4) potentiates lysosomal leakage and apoptosis induced by amyloid beta (A beta) peptide in cultured Neuro-2a cells and hypothesized that the low pH of lysosomes accentuates the conversion of apoE4 to a molten globule, inducing reactive intermediates capable of destabilizing cellular membranes. Here we report that neutralizing lysosomal pH with bafilomycin or NH4Cl abolished the apoE4 potentiation of A beta-induced lysosomal leakage and apoptosis in Neuro-2a cells. Consistent with these results, apoE4 at acidic pH bound more avidly to phospholipid vesicles and disrupted them to a greater extent than at pH 7.4. Comparison of "Arctic" mutant A beta, which forms multimers, and GM6 mutant A beta, which remains primarily monomeric, showed that aggregation is essential for apoE4 to potentiate A beta-induced lysosomal leakage and apoptosis. Both apoE4 and A beta 1-42 had to be internalized to exert these effects. Blocking the low density lipoprotein receptor-related protein with small interfering RNA abolished the enhanced effects of apoE4 and A beta on lysosomes and apoptosis. In cultured Neuro-2a cells, A beta 1-42 increased lysosome formation to a greater extent in apoE3- or apoE4-transfected cells than in Neo-transfected cells, as shown by immunostaining for lysosome-associated membrane protein 1. Similarly, in transgenic mice expressing apoE and amyloid precursor protein, hippocampal neurons displayed increased numbers of lysosomes. Thus, apoE4 and A beta 1-42 may work in concert in neurons to increase lysosome formation while increasing the susceptibility of lysosomal membranes to disruption, release of lysosomal enzymes into the cytosol, and neuronal degeneration.	Univ Calif San Francisco, Gladstone Inst Neurol Dis, San Francisco, CA 94158 USA; Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94158 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94158 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94158 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94158 USA		Mahley, RW (corresponding author), Univ Calif San Francisco, Gladstone Inst Neurol Dis, 1650 Owens St, San Francisco, CA 94158 USA.	rmahley@gladstone.ucsf.edu			NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [C06RR018928] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS046465] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG022074] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [C06 RR18928] Funding Source: Medline; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01 AG022074] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21 NS046465] Funding Source: Medline		Arelin K, 2002, MOL BRAIN RES, V104, P38, DOI 10.1016/S0169-328X(02)00203-6; ARISPE N, 1993, P NATL ACAD SCI USA, V90, P10573, DOI 10.1073/pnas.90.22.10573; Buttini M, 2000, NEUROSCIENCE, V97, P207, DOI 10.1016/S0306-4522(00)00069-5; Buttini M, 1999, J NEUROSCI, V19, P4867; Cataldo AM, 2000, AM J PATHOL, V157, P277, DOI 10.1016/S0002-9440(10)64538-5; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Cheng IH, 2004, NAT MED, V10, P1190, DOI 10.1038/nm1123; Chromy BA, 2003, BIOCHEMISTRY-US, V42, P12749, DOI 10.1021/bi030029q; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Dahlgren KN, 2002, J BIOL CHEM, V277, P32046, DOI 10.1074/jbc.M201750200; Deane R, 2004, NEURON, V43, P333, DOI 10.1016/j.neuron.2004.07.017; Deary IJ, 2002, NATURE, V418, P932, DOI 10.1038/418932a; Demattos RB, 2004, J MOL NEUROSCI, V23, P255, DOI 10.1385/JMN:23:3:255; Ditaranto K, 2001, NEUROBIOL DIS, V8, P19, DOI 10.1006/nbdi.2000.0364; Dobson CM, 2001, PHILOS T R SOC B, V356, P133, DOI 10.1098/rstb.2000.0758; Drory VE, 2001, J NEUROL SCI, V190, P17, DOI 10.1016/S0022-510X(01)00569-X; Fagan AM, 2002, NEUROBIOL DIS, V9, P305, DOI 10.1006/nbdi.2002.0483; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; Gouras GK, 2000, AM J PATHOL, V156, P15, DOI 10.1016/S0002-9440(10)64700-1; Guicciardi ME, 2004, ONCOGENE, V23, P2881, DOI 10.1038/sj.onc.1207512; Harhangi BS, 2000, NEUROLOGY, V54, P1272, DOI 10.1212/WNL.54.6.1272; Holtzman DM, 2004, J MOL NEUROSCI, V23, P247, DOI 10.1385/JMN:23:3:247; Horsburgh K, 1999, J NEUROPATH EXP NEUR, V58, P227, DOI 10.1097/00005072-199903000-00002; Huang YD, 1998, J BIOL CHEM, V273, P26388, DOI 10.1074/jbc.273.41.26388; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Irizarry MC, 2004, J NEUROCHEM, V90, P1132, DOI 10.1111/j.1471-4159.2004.02581.x; Ji Y, 2003, NEUROSCIENCE, V122, P305, DOI 10.1016/j.neuroscience.2003.08.007; JI ZS, 1993, J BIOL CHEM, V268, P10160; Ji ZS, 2002, J BIOL CHEM, V277, P21821, DOI 10.1074/jbc.M112109200; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Jordan J, 1998, J NEUROSCI, V18, P195; Kaback M M, 1977, Prog Clin Biol Res, V18, P267; Kane MD, 1999, J NEUROCHEM, V72, P1939, DOI 10.1046/j.1471-4159.1999.0721939.x; Kang DE, 2000, J CLIN INVEST, V106, P1159, DOI 10.1172/JCI11013; Karageorgos LE, 1997, EXP CELL RES, V234, P85, DOI 10.1006/excr.1997.3581; Klug GMJA, 2003, EUR J BIOCHEM, V270, P4282, DOI 10.1046/j.1432-1033.2003.03815.x; KNAUER MF, 1992, P NATL ACAD SCI USA, V89, P7437, DOI 10.1073/pnas.89.16.7437; KOO EH, 1994, J BIOL CHEM, V269, P17386; Lacomblez L, 2002, NEUROLOGY, V58, P1112, DOI 10.1212/WNL.58.7.1112; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Li YJ, 2002, AM J HUM GENET, V70, P985, DOI 10.1086/339815; Lin HJ, 2001, ANAL BIOCHEM, V294, P118, DOI 10.1006/abio.2001.5155; Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507; Mahley RW, 1999, J LIPID RES, V40, P1; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 2001, METABOLIC MOL BASES, V2, P2835; Morrow JA, 2002, J BIOL CHEM, V277, P50380, DOI 10.1074/jbc.M204898200; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; Nacmias B, 2004, NEUROSCI LETT, V367, P379, DOI 10.1016/j.neulet.2004.06.039; Narita M, 1997, J NEUROCHEM, V69, P1904; Nilsberth C, 2001, NAT NEUROSCI, V4, P887, DOI 10.1038/nn0901-887; Nilsson LNG, 2004, NEUROBIOL AGING, V25, P1153, DOI 10.1016/j.neurobiolaging.2003.12.011; Nixon RA, 2000, NEUROCHEM RES, V25, P1161, DOI 10.1023/A:1007675508413; Nixon RA, 2001, J ALZHEIMERS DIS, V3, P97, DOI 10.3233/JAD-2001-3114; Panas M, 1999, J NEUROL, V246, P574, DOI 10.1007/s004150050406; Perez RG, 1999, J BIOL CHEM, V274, P18851, DOI 10.1074/jbc.274.27.18851; Permanne B, 1997, BIOCHEM BIOPH RES CO, V240, P715, DOI 10.1006/bbrc.1997.7727; Raber J, 1998, P NATL ACAD SCI USA, V95, P10914, DOI 10.1073/pnas.95.18.10914; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; SchraderFischer G, 1996, BRAIN RES, V716, P91, DOI 10.1016/0006-8993(96)00002-9; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Slooter AJC, 1997, JAMA-J AM MED ASSOC, V277, P818, DOI 10.1001/jama.277.10.818; Srinivasan R, 2003, J MOL BIOL, V333, P1003, DOI 10.1016/j.jmb.2003.09.001; Stenh C, 2002, NEUROREPORT, V13, P1857, DOI 10.1097/00001756-200210280-00005; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; Su Y, 2001, BRAIN RES, V893, P287, DOI 10.1016/S0006-8993(00)03322-9; Terzi E, 1997, BIOCHEMISTRY-US, V36, P14845, DOI 10.1021/bi971843e; Tsuang DW, 2002, ARCH NEUROL-CHICAGO, V59, P1622, DOI 10.1001/archneur.59.10.1622; Van Everbroeck B, 2001, NEUROSCI LETT, V313, P69, DOI 10.1016/S0304-3940(01)02264-9; Walsh DM, 2000, BIOCHEMISTRY-US, V39, P10831, DOI 10.1021/bi001048s; White F, 2001, NEUROBIOL DIS, V8, P611, DOI 10.1006/nbdi.2001.0401; Wurth C, 2002, J MOL BIOL, V319, P1279, DOI 10.1016/S0022-2836(02)00399-6; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4; Ye CP, 2003, NEUROBIOL DIS, V13, P177, DOI 10.1016/S0969-9961(03)00068-8; Yu ZQ, 2003, FREE RADICAL BIO MED, V34, P1243, DOI 10.1016/S0891-5849(03)00109-6	77	101	102	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2683	2692		10.1074/jbc.M506646200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	WOS:000234931800034	16298992	hybrid			2022-02-06	
J	Sanchez, B; Waxman, K; Jones, T; Conner, S; Chung, R; Becerra, S				Sanchez, B; Waxman, K; Jones, T; Conner, S; Chung, R; Becerra, S			Cervical spine clearance in blunt trauma: Evaluation of a computed tomography-based protocol	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	75th Annual Meeting of the Pacific-Coast-Surgical-Associaton	FEB 15-16, 2004	Maui, HI	Pacific Coast Surg Assoc		cervical spine; cervical spine clearance; blunt trauma; spiral computed tomographic scan	RADIOGRAPHY; CT; FRACTURES; INJURIES	Background. Prompt identification of cervical spine injuries has been a critical issue in trauma management. In 1998, the authors developed a new protocol to evaluate cervical spines in blunt trauma. This protocol relies on clinical clearance for appropriate patients and helical computed tomography instead of plain radiographs for patients who cannot be clinically cleared. The authors then prospectively collected data on all cervical spine evaluations to assess the sensitivity and specificity of their approach. Methods Any patient without clinical evidence of neurologic injury, alcohol or drug intoxication, or distracting injury underwent cervical spine evaluation by clinical examination. Patients who did not meet these criteria underwent helical computed tomographic scanning of the entire cervical spine. For patients who had neurologic deficits, a magnetic resonance image was obtained. If the patient was not evaluable secondary to coma, the computed tomographic scan was without abnormality, and the patient was moving all four extremities at arrival in the emergency department, the cervical spine was cleared, and spinal precautions were removed. Data were collected for all patients admitted to Santa Barbara Cottage Hospital trauma service between 1999 and 2002. The authors selected for analysis patients with blunt trauma and further identified those with closed head injuries (Glasgow Coma Scale score < 15 and loss of consciousness). In addition, all blunt cervical spine injuries were reviewed. Results. During the period of study, 2,854 trauma patients were admitted, of whom 2,603 (91%) had blunt trauma. Of these, 1,462 (56%) had closed head injuries. One hundred patients (7% of patients admitted for blunt trauma) had cervical spine or spinal cord injuries, of which 99 were identified by the authors' protocol. Only one injury was not appreciated in a patient with syringomyelia. Fifteen percent of patients with spinal cord injury had no radiographic abnormality; all of these patients presented with neurologic deficits. The sensitivity for detecting cervical spine injury was thus 99%, and the specificity was 100%. The risk of missing a cervical spine injury in these blunt trauma patients was 0.04%. The authors missed no spine injuries in patients with head injuries. Conclusions. The use of the authors' protocol resulted in excellent sensitivity and specificity in detecting cervical spine injuries. In addition, it allowed early removal of spinal precautions.	Santa Barbara Cottage Hosp, Dept Surg, Santa Barbara, CA 93102 USA; Santa Barbara Cottage Hosp, Dept Neurosurg, Santa Barbara, CA 93102 USA		Waxman, K (corresponding author), Santa Barbara Cottage Hosp, Dept Surg, POB 689, Santa Barbara, CA 93102 USA.	kwaxman@sbch.org					Amar AP, 1999, J AM COLL SURGEONS, V188, P550, DOI 10.1016/S1072-7515(99)00013-7; Barba CA, 2001, J TRAUMA, V51, P652, DOI 10.1097/00005373-200110000-00005; Berne JD, 1999, J TRAUMA, V47, P896, DOI 10.1097/00005373-199911000-00014; Besman A, 2003, AM SURGEON, V69, P1010; Blackmore CC, 1999, RADIOLOGY, V212, P117, DOI 10.1148/radiology.212.1.r99jl08117; BOROCK EC, 1991, J TRAUMA, V31, P1001, DOI 10.1097/00005373-199107000-00021; Crim JR, 2001, SEMIN ULTRASOUND CT, V22, P283, DOI 10.1016/S0887-2171(01)90023-X; Diaz JJ, 2003, J TRAUMA, V55, P658, DOI 10.1097/01.TA.0000088120.99247.4A; Hanson JA, 2002, AM J ROENTGENOL, V178, P1261, DOI 10.2214/ajr.178.5.1781261; Hoffman JR, 1998, ANN EMERG MED, V32, P461, DOI 10.1016/S0196-0644(98)70176-3; Hoffman JR, 2000, NEW ENGL J MED, V343, P94, DOI 10.1056/NEJM200007133430203; MARION D, PRACTICE PARAMETERS; Novelline RA, 1999, RADIOLOGY, V213, P321, DOI 10.1148/radiology.213.2.r99nv01321; Pasquale M, 1998, J TRAUMA, V44, P941, DOI 10.1097/00005373-199806000-00001; RAVICHANDRAN G, 1982, BRIT MED J, V284, P953, DOI 10.1136/bmj.284.6320.953; ROBERGE RJ, 1988, J TRAUMA, V28, P784, DOI 10.1097/00005373-198806000-00010; Sheridan R, 2003, J TRAUMA, V55, P665, DOI 10.1097/01.TA.0000048094.38625.B5; Weisskopf M, 2001, EUR SPINE J, V10, P250, DOI 10.1007/s005860000208; WOODRING JH, 1993, J TRAUMA, V34, P32, DOI 10.1097/00005373-199301000-00006	19	101	105	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUL	2005	59	1					179	183		10.1097/01.TA.0000171449.94650.81			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	956ZN	WOS:000231339000039	16096560				2022-02-06	
J	Jellinger, KA				Jellinger, KA			Head injury and dementia	CURRENT OPINION IN NEUROLOGY			English	Article						Alzheimer's disease; amyloid deposition; dementia; experimental models; genetic factors; traumatic brain injury; tau pathology	TRAUMATIC BRAIN-INJURY; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN-E POLYMORPHISM; LONG-TERM ACCUMULATION; ALZHEIMERS-DISEASE; RISK-FACTOR; PSYCHIATRIC-DISORDERS; CEREBROSPINAL-FLUID; EARLY ADULTHOOD; BETA-SECRETASE	Purpose of review The link between head injury and dementia/Alzheimer's disease is controversial. This review discusses some recent epidemiological, human autopsy and experimental studies on the relationship between traumatic head injury and dementia. Recent findings Recent epidemiological studies have shown that head injury is a risk factor for the development of dementia/Alzheimer's disease, whereas others have not. After experimental brain trauma the long-term accumulation of amyloid P peptide suggests that neurodegeneration is influenced by apolipoprotein E epsilon4, and after human brain injury both amyloid beta peptide deposition and tau pathology are seen, even in younger patients. Amyloid beta peptide levels in the cerebrospinal fluid and the overproduction of beta amyloid precursor protein in humans and animals after traumatic brain injury are increased. Repeated mild head trauma in both animals and humans accelerates amyloid beta peptide accumulation and cognitive impairment. Retrospective autopsy data support clinical studies suggesting that severe traumatic brain injury with long-lasting morphological residuals are a risk factor for the development of dementia/ Alzheimer's disease. The influence of the apolipoprotein E genotype on the prognosis of traumatic brain injury is under discussion. Summary Although epidemiological studies and retrospective autopsy data provide evidence that a later cognitive decline may occur after severe traumatic brain injury, the relationship between dementia after head/brain trauma and apolipoprotein E status is still ambiguous. Both human postmortem and experimental studies showing apolipoprotein beta deposition and tau pathology after head injury support the link between traumatic brain injury and dementia, and further studies are warranted to clarify this relationship.	Inst Clin Neurobiol, A-1070 Vienna, Austria		Jellinger, KA (corresponding author), Inst Clin Neurobiol, Kenyongasse 18, A-1070 Vienna, Austria.	kurt.jellinger@univie.ac.at					Albensi BC, 2003, BRAIN INJURY, V17, P653, DOI 10.1080/0269905031000107142; ALSARRAJ ST, 2004, J NEUROL NEUROSUR PS, V63, P234; ATTEMS J, 2004, 7 VIENN INT C GER VI; Barnett C, 2003, INT J GERIATR PSYCH, V18, P88, DOI 10.1002/gps.728; Blasko I, 2004, J NEURAL TRANSM, V111, P523, DOI 10.1007/s00702-003-0095-6; Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183; Bramlett HM, 2003, EXP NEUROL, V184, P27, DOI 10.1016/S0014-4886(03)00401-1; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Chiang MF, 2003, ACTA NEUROCHIR, V145, P649, DOI 10.1007/s00701-003-0069-3; Emmerling MR, 2000, ANN NY ACAD SCI, V903, P118, DOI 10.1111/j.1749-6632.2000.tb06357.x; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Genis L, 2000, J NEUROSCI RES, V60, P559, DOI 10.1002/(SICI)1097-4547(20000515)60:4<559::AID-JNR15>3.0.CO;2-K; Golden Z, 2003, INT J NEUROSCI, V113, P869, DOI 10.1080/00207450390200927; Gottlieb S, 2000, BRIT MED J, V321, P1100; Hartman RE, 2002, J NEUROSCI, V22, P10083; Hinkebein JH, 2003, BRAIN INJURY, V17, P1035, DOI 10.1080/0269905031000110490; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Horner Arlene, 2002, AACN Clin Issues, V13, P73, DOI 10.1097/00044067-200202000-00008; Hy LX, 2000, NEUROLOGY, V55, P198, DOI 10.1212/WNL.55.2.198; Iwata A, 2002, J NEUROPATH EXP NEUR, V61, P1056, DOI 10.1093/jnen/61.12.1056; Jellinger KA, 2004, J NEUROL NEUROSUR PS, V75, P511; Jellinger KA, 2001, EUR J NEUROL, V8, P707, DOI 10.1046/j.1468-1331.2001.00322.x; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Koponen S, 2004, NEUROLOGY, V63, P749, DOI 10.1212/01.WNL.0000134603.57107.2F; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Leon-Carrion J, 2002, NEUROREHABILITATION, V17, P115; Luukinen H, 1999, NEUROLOGY, V52, P557, DOI 10.1212/WNL.52.3.557; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Mazzini L, 2003, EPILEPSIA, V44, P569, DOI 10.1046/j.1528-1157.2003.34902.x; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; Nakagawa Y, 2000, EXP NEUROL, V163, P244, DOI 10.1006/exnr.2000.7375; Nandoe RDS, 2002, J ALZHEIMERS DIS, V4, P303, DOI 10.3233/JAD-2002-4405; Nathoo N, 2003, J NEUROSURG, V98, P302, DOI 10.3171/jns.2003.98.2.0302; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Ohashi Masahiro, 2004, Nihon Rinsho, V62 Suppl, P285; Olsson A, 2004, J NEUROL, V251, P870, DOI 10.1007/s00415-004-0451-y; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Rapoport MJ, 2000, BRAIN INJURY, V14, P749; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; Roche NL, 2002, BRAIN INJURY, V16, P931, DOI 10.1080/02699050210138581; Rutherford A, 2003, NEUROPSYCHOL REV, V13, P153, DOI 10.1023/A:1025525613477; Sabo T, 2000, NEUROSCIENCE, V101, P879, DOI 10.1016/S0306-4522(00)00438-3; Sanz O, 2002, J NEUROSCI RES, V67, P772, DOI 10.1002/jnr.10140; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Smith C, 2003, NEUROPATH APPL NEURO, V29, P496, DOI 10.1046/j.1365-2990.2003.00488.x; Stone JR, 2002, J NEUROTRAUM, V19, P601, DOI 10.1089/089771502753754073; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Ubis JIQ, 2003, ACTAS ESP PSIQUIATRI, V31, P353; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Uryu K, 2004, NEUROBIOL AGING S1, V25, pP2; Wilson JTL, 2003, J NEUROL NEUROSUR PS, V74, P841, DOI 10.1136/jnnp.74.7.841; Zhang Qingchen, 2003, Curr Psychiatry Rep, V5, P197, DOI 10.1007/s11920-003-0042-0	56	101	106	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1350-7540	1473-6551		CURR OPIN NEUROL	Curr. Opin. Neurol.	DEC	2004	17	6					719	723		10.1097/00019052-200412000-00012			5	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	878XY	WOS:000225682000011	15542981				2022-02-06	
J	Varelas, PN; Conti, MM; Spanaki, MV; Potts, E; Bradford, D; Sunstrom, C; Fedder, W; Bey, LH; Jaradeh, S; Gennarelli, TA				Varelas, PN; Conti, MM; Spanaki, MV; Potts, E; Bradford, D; Sunstrom, C; Fedder, W; Bey, LH; Jaradeh, S; Gennarelli, TA			The impact of a neurointensivist-led team on a semiclosed neurosciences intensive care unit	CRITICAL CARE MEDICINE			English	Article						neurointensivist; intensive care unit; neurological; neurosurgical; closed; documentation	SEVERE HEAD-INJURY; RESOURCE UTILIZATION; THERAPEUTIC EFFICACY; PATIENT OUTCOMES; COHORT; DOCUMENTATION; HEMORRHAGE; GUIDELINES; EFFICIENCY; MODELS	Objective: To evaluate the impact of a newly appointed neurointensivist on neurosciences intensive care unit (NICU) patient outcomes and quality of care variables. Design: Observational cohort with historical controls. Setting: Ten-bed neurointensive care unit in tertiary university hospital. Patients: Mortality, length of stay (LOS), and discharge disposition of all patients admitted to the NICU were compared between two 19-month periods, before and after the appointment of a neurointensivist. Data regarding these patients were collected using the hospital database and the University Hospitals Consortium database. Individual patient medical records were reviewed for major complications and important prognostic variable documentation. Interventions: Appointment of a neurointensivist. Measurements and Main Results: We analyzed 1,087 patients before and 1,279 after the neurointensivist's appointment. The unadjusted in-hospital mortality decreased from 10.1% in the before to 9.1% in the after period (95% confidence interval, -1.3 to 3%, relative mortality reduction of 9.9%), but this decrease was significantly different than the expected increase of 1.4% in University Hospitals Consortium mortality during the same period (p = .048). The unadjusted mortality in the NICU decreased from 8% to 6.3% (95% confidence interval, -0.5 to 4, relative mortality reduction 21%) and mean NICU LOS from 3.5 to 2.9 days (95% confidence interval, 0.2 to 0.9, relative NICU LOS reduction 17%). A significant 42% reduction of the risk of death during the first 3 days of NICU admission (p = .003) and a 12% greater risk for NICU discharge (p = .02) were found in the after period in multivariate proportional hazard models. Discharge home increased from 51.7% in the before to 59.7% in the after period (95% confidence interval, 4 to 12, relative increase of 15%) and discharge to a nursing home decreased from 8.1% to 6.8% (95% confidence interval, -1 to 4, relative decrease of 16%). Although a higher total number of complications occurred in the after period, fewer of them occurred in the NICU (odds ratio, 0.2; 95% confidence interval, 0.08 to 0.54, p = .001); this may possibly be due to the better documentation by the NICU team in the after period. Conclusions. The institution of a neurointensivist-led team model was associated with an independent positive impact on patient outcomes, including a lower intensive care unit mortality, LOS, and discharge to a skilled nursing facility and a higher discharge home.	Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Radiol, Milwaukee, WI 53226 USA; Froedtert Hosp, Milwaukee, WI USA		Varelas, PN (corresponding author), Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA.		Varelas, Panayiotis/V-1702-2019				Arabi Y, 2004, INT J QUAL HEALTH C, V16, P149, DOI 10.1093/intqhc/mzh025; Baggs JG, 1999, CRIT CARE MED, V27, P1991, DOI 10.1097/00003246-199909000-00045; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Carlson RW, 1996, CRIT CARE CLIN, V12, P525, DOI 10.1016/S0749-0704(05)70260-8; Carson SS, 1996, JAMA-J AM MED ASSOC, V276, P322, DOI 10.1001/jama.276.4.322; CHARLSON ME, 1987, J CHRON DIS, V40, P31, DOI 10.1016/0021-9681(87)90094-4; Cook D, 2003, NEW ENGL J MED, V349, P1123, DOI 10.1056/NEJMoa030083; COX DR, 1972, J R STAT SOC B, V34, P187; Diringer MN, 2001, CRIT CARE MED, V29, P635, DOI 10.1097/00003246-200103000-00031; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; Goodlin SJ, 1999, JAMA-J AM MED ASSOC, V282, P2333, DOI 10.1001/jama.282.24.2333; GROEGER JS, 1992, CRIT CARE MED, V20, P846, DOI 10.1097/00003246-199206000-00024; Hanson CW, 1999, CRIT CARE MED, V27, P270, DOI 10.1097/00003246-199902000-00030; HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LEMESHOW S, 1993, JAMA-J AM MED ASSOC, V270, P2478, DOI 10.1001/jama.270.20.2478; Mirski MA, 2001, J NEUROSURG ANESTH, V13, P83, DOI 10.1097/00008506-200104000-00004; Multz AS, 1998, AM J RESP CRIT CARE, V157, P1468, DOI 10.1164/ajrccm.157.5.9708039; POLLACK MM, 1988, CRIT CARE MED, V16, P11, DOI 10.1097/00003246-198801000-00003; Pronovost PJ, 1999, JAMA-J AM MED ASSOC, V281, P1310, DOI 10.1001/jama.281.14.1310; Pronovost PJ, 2002, JAMA-J AM MED ASSOC, V288, P2151, DOI 10.1001/jama.288.17.2151; Rapoport J, 1996, AM J RESP CRIT CARE, V153, P185, DOI 10.1164/ajrccm.153.1.8542114; RON A, 1989, ARCH INTERN MED, V149, P338, DOI 10.1001/archinte.149.2.338; Soto CM, 2002, BMC HEALTH SERV RES, V2, DOI 10.1186/1472-6963-2-22; Suarez Jose I., 2003, Neurology, V60, pA360; *U HEALTH SYST CON, 1998, UHC CLIN INF MAN RIS; Vincent JL, 2003, INTENS CARE MED, V29, pS74; WARME PE, 1991, ACTA NEUROCHIR, V110, P57, DOI 10.1007/BF01402049; Wood DL, 2001, AM J MED, V110, P332, DOI 10.1016/S0002-9343(00)00748-8; YEH TS, 1984, PEDIATR RES, V18, P445, DOI 10.1203/00006450-198405000-00011; Young M P, 2000, Eff Clin Pract, V3, P284	34	101	103	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	NOV	2004	32	11					2191	2198		10.1097/01.CCM.0000146131.03578.21			8	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	872MN	WOS:000225211400003	15640630				2022-02-06	
J	Olsson, A; Csajbok, L; Ost, M; Hoglund, K; Nylen, K; Rosengren, L; Nellgard, B; Blennow, K				Olsson, A; Csajbok, L; Ost, M; Hoglund, K; Nylen, K; Rosengren, L; Nellgard, B; Blennow, K			Marked increase of beta-amyloid((1-42)) and amyloid precursor protein in ventricular cerebrospinal fluid after severe traumatic brain injury	JOURNAL OF NEUROLOGY			English	Article						Alzheimer's disease; amyloid precursor protein; beta-amyloid; cerebrospinal fluid; traumatic brain injury	ALZHEIMERS-DISEASE; HEAD-INJURY; AXONAL INJURY; BETA-PROTEIN; ALPHA-SECRETASE; DOWNS-SYNDROME; PEPTIDE 1-42; PLASMA; APP; ACCUMULATION	Severe traumatic brain injury (TBI) may result in widespread damage to axons, termed diffuse axonal injury. Alzheimer's disease (AD) is characterised by synaptic and axonal degeneration together with senile plaques (SP). SP are mainly composed of aggregated beta-amyloid (Abeta), which are peptides derived from the amyloid precursor protein (APP). Apart from TBI in itself being considered a risk factor for AD, severe head injury seems to initiate a cascade of molecular events that are also associated with AD. We have therefore analysed the 42 amino acid forms of Abeta (Abeta((1-42))) and two soluble forms of APP (alpha-sAPP and sssAPP) in ventricular cerebrospinal fluid (VCSF) and Abeta((1-42)) in plasma from 28 patients in a serial samples 0-11 days after TBI. The levels of alpha-sAPP, ss-sAPP and Abeta((1-42)) were determined using ELISA assays. After TBI, there was a significant stepwise increase in VCSF-Abeta((1-42)) up to 1173 % from day 0-1 to day 5-6 and in VCSF-beta-sAPP up to 2033 % increase from day 0-1 to day 7-11. There was also a slight but significant increase of VCSF-beta-sAPP from day 0-1 to day 5-6 and day 7-11. By contrast, the plasma- Abeta((1-42)) level is unchanged after injury. The marked increase in VCSFAbeta(( 1-42)) implies that increased Abeta expression may occur as a secondary phenomenon after TBI with axonal damage. The unchanged level of plasma-Abeta((1-42)) in contrast to the marked increase in VCSF-Abeta((1-42)) after severe TBI, supports the suggestion that plasma Abeta((1-42)) does not reflect Abeta metabolism in the central nervous system (CNS).	Sahlgrens Univ Hosp, Inst Clin Neurosci Sect, SE-43180 Molndal, Sweden; Sahlgrens Univ Hosp, Dept Anaesthesia & Intens Care Med, SE-41345 Gothenburg, Sweden; Sahlgrens Univ Hosp, Inst Clin Neurosci, SE-41345 Gothenburg, Sweden		Olsson, A (corresponding author), Sahlgrens Univ Hosp, Inst Clin Neurosci Sect, SE-43180 Molndal, Sweden.	Annika.Olsson@neuro.gu.se	Hoglund, Kina/I-8451-2012; Ost, Martin/AAY-5827-2020	Rosengren, Lars/0000-0003-0505-8896; Hoglund, Kina/0000-0002-1213-9953			Blennow K, 2000, J NEURAL TRANSM, V107, P1065, DOI 10.1007/s007020070052; De Strooper B, 2000, J CELL SCI, V113, P1857; Emmerling MR, 2000, ANN NY ACAD SCI, V903, P118, DOI 10.1111/j.1749-6632.2000.tb06357.x; Furukawa K, 1996, J NEUROCHEM, V67, P1882, DOI 10.1046/j.1471-4159.1996.67051882.x; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; Graham DI, 1996, ACT NEUR S, V66, P96; Grande PO, 2002, ACTA ANAESTH SCAND, V46, P929, DOI 10.1034/j.1399-6576.2002.460802.x; Hamberger A, 2003, J NEUROTRAUM, V20, P169, DOI 10.1089/08977150360547080; Hesse Camilla, 2000, Journal of Alzheimer's Disease, V2, P199; Horsburgh K, 2000, NEUROPATH APPL NEURO, V26, P124, DOI 10.1046/j.1365-2990.2000.026002124.x; ICHIHARA N, 1995, BRAIN RES, V695, P173, DOI 10.1016/0006-8993(95)00729-A; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; KAWARABAYASHI T, 1991, BRAIN RES, V563, P334, DOI 10.1016/0006-8993(91)91558-I; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; LeBlanc AC, 1996, J NEUROCHEM, V66, P2300; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Matsubara E, 1999, ANN NEUROL, V45, P537, DOI 10.1002/1531-8249(199904)45:4<537::AID-ANA20>3.3.CO;2-U; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Mayeux R, 1999, ANN NEUROL, V46, P412, DOI 10.1002/1531-8249(199909)46:3<412::AID-ANA19>3.0.CO;2-A; MCKENZIE JE, 1994, NEUROREPORT, V6, P161, DOI 10.1097/00001756-199412300-00041; Mehta PD, 2000, ARCH NEUROL-CHICAGO, V57, P100, DOI 10.1001/archneur.57.1.100; OHGAMI T, 1992, NEUROSCI LETT, V136, P75, DOI 10.1016/0304-3940(92)90651-M; Olsson A, 2003, EXP NEUROL, V183, P74, DOI 10.1016/S0014-4886(03)00027-X; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; OTSUKA N, 1991, BRAIN RES, V568, P335, DOI 10.1016/0006-8993(91)91422-W; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Raby CA, 1998, J NEUROCHEM, V71, P2505; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SIMAN R, 1989, NEURON, V3, P275, DOI 10.1016/0896-6273(89)90252-3; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; Tamaoka A, 1996, J NEUROL SCI, V141, P65, DOI 10.1016/0022-510X(96)00143-8; TAMAOKA A, 1994, BIOCHEM BIOPH RES CO, V205, P834, DOI 10.1006/bbrc.1994.2740; Teller JK, 1996, NAT MED, V2, P93, DOI 10.1038/nm0196-93; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P280, DOI 10.1007/BF00308813; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Vanderstichele H, 2000, AMYLOID, V7, P245, DOI 10.3109/13506120009146438; VANDUIJN CM, 1992, AM J EPIDEMIOL, V135, P775, DOI 10.1093/oxfordjournals.aje.a116364	43	101	107	0	4	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0340-5354	1432-1459		J NEUROL	J. Neurol.	JUL	2004	251	7					870	876		10.1007/s00415-004-0451-y			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	838CU	WOS:000222691600014	15258792				2022-02-06	
J	Raghupathi, R; Mehr, MF; Helfaer, MA; Margulies, SS				Raghupathi, R; Mehr, MF; Helfaer, MA; Margulies, SS			Traumatic axonal injury is exacerbated, following repetitive closed head injury in the neonatal pig	JOURNAL OF NEUROTRAUMA			English	Article						children; mild head injury; neurofilament; white matter	SHAKEN-BABY SYNDROME; PERCUSSION BRAIN-INJURY; FLUID-PERCUSSION; COGNITIVE IMPAIRMENT; IMMATURE RAT; MODEL; NEUROPATHOLOGY; INFANTS; VULNERABILITY; BEHAVIOR	Inflicted brain injury is associated with widespread traumatic axonal injury (TAI) and subdural hematoma and is the leading cause of death in infants and children. Anesthetized 3-5-day-old piglets were subjected to either a single (n = 5) or double (n = 6, 15 min apart) rapid (< 15 msec), non-impact, axial rotations of the head. Peak rotational velocities (averaging 172 rad/sec for single and 138 rad/sec for double loads) were lower than those utilized to induce severe injuries (240-260 rad/sec; Raghupathi and Margulies, 2002). At 6 h post-injury, brains were evaluated for the presence TAI using immunohistochemistry for the 200-kDa neurofilament protein (NF200). Accumulation of NF200 was observed in both contiguous (swellings) and in disconnected axons (axon bulbs) predominantly in central deep and peripheral subcortical white matter regions in the frontal, temporal, and parietal lobes of all injured piglets. Although the density of injured axons did not significantly increase after two rotational loads, the distribution of injured axons shifted from a few foci (2.2 +/- 2.3 per animal) with 1-2 swellings/bulbs following a single rotation to significantly more foci (14.7 +/- 11.9), and additional foci (2.5 +/- 1.9) containing 3 or more axon swellings/bulbs following two rotational loads. The density and distribution of injured axons following a single mild rotation were significantly reduced compared with those obtained previously following a single more severe rotational load. Collectively, these data are indicative of the graded response of the immature brain to rotational load magnitude, and importantly, the vulnerability to repeated, mild, non-impact loading conditions.	Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Anesthesia & Crit Care, Philadelphia, PA 19104 USA		Margulies, SS (corresponding author), Univ Penn, Dept Bioengn, 105D Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.	margulies@seas.upenn.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039679, R01NS041561] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS39679, R01-NS41561] Funding Source: Medline; ODCDC CDC HHS [R49-CCR312712] Funding Source: Medline		Adelson PD, 1996, J NEUROSURG, V85, P877, DOI 10.3171/jns.1996.85.5.0877; Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; Allen GV, 2000, NEUROSCIENCE, V99, P93, DOI 10.1016/S0306-4522(00)00185-8; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; Bonnier C, 2002, BRAIN PATHOL, V12, P320; Brodhun M, 2001, ACTA NEUROPATHOL, V101, P424; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; DeRoss AL, 2002, J TRAUMA, V52, P708, DOI 10.1097/00005373-200204000-00017; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; Durham SR, 2000, PEDIATR NEUROSURG, V33, P76, DOI 10.1159/000028980; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; Gleckman AM, 1999, ARCH PATHOL LAB MED, V123, P146; Ikonomidou C, 1996, PEDIATR RES, V39, P1020, DOI 10.1203/00006450-199606000-00015; Kanayama G, 1996, METHOD FIND EXP CLIN, V18, P105; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; LUERSSEN TG, 1991, CONC PED N, V11, P87; Macciocchi SN, 1998, CLIN SPORT MED, V17, P27, DOI 10.1016/S0278-5919(05)70058-2; Marin-Padilla M, 2002, ACTA NEUROPATHOL, V103, P321, DOI 10.1007/s00401-001-0470-z; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/S0165-3806(96)00098-3; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Raghupathi R, 2002, J NEUROTRAUM, V19, P843, DOI 10.1089/08977150260190438; SALCIDO R, 1992, Brain Injury, V6, P293, DOI 10.3109/02699059209029671; Shannon P, 1998, ACTA NEUROPATHOL, V95, P625, DOI 10.1007/s004010050849; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Smith SL, 1998, J NEUROTRAUM, V15, P693, DOI 10.1089/neu.1998.15.693; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; VOWLES GH, 1987, J CLIN PATHOL, V40, P185, DOI 10.1136/jcp.40.2.185; Winston, 1998, CHILD MALTREATMENT, V3, P116, DOI [DOI 10.1177/1077559598003002006, 10.1177/1077559598003002006]; YOSHIKAWA T, 1968, ATLAS BRAINS DOMESTI, P1	31	101	102	2	14	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2004	21	3					307	316		10.1089/089771504322972095			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	806CI	WOS:000220411600008	15115605				2022-02-06	
J	Hawley, CA; Ward, AB; Long, J; Owen, DW; Magnay, AR				Hawley, CA; Ward, AB; Long, J; Owen, DW; Magnay, AR			Prevalence of traumatic brain injury amongst children hospital in one health district: a population-based admitted to study	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article							HEAD-INJURY; ADOLESCENTS; INFANTS	There is a dearth of information regarding the prevalence of brain injury, serious enough to require hospital admission, amongst children in UK. In North Staffordshire, a register of all children admitted with traumatic brain injury (TBI) has been maintained since 1992 presenting an opportunity to investigate the incidence of TBI within the region in terms of age, cause of injury, injury severity and social deprivation. The register contains details of 1553 children with TBI, two-thirds of whom are male. This population-based study shows that TBI is most prevalent amongst children from families living in more deprived areas, however, social deprivation was not related to the cause of injury. Each year, 280 per 100,000 children are admitted for greater than or equal to24 h with a TBI, of these 232 will have a mild brain injury, 25 moderate, 17 severe, and 2 will die. The incidence of moderate and severe injuries is higher than previous estimates. Children under 2 years of age account for 18.5% of all TBIs, usually due to falls, being dropped or non-accidental injuries (NAIs). Falls account for 60% of TBIs in the under 5 years. In the 10-15 age group road traffic accidents (RTAs) were the most common cause (185, 36.7%). These findings will help to plan health services and target accident prevention initiatives more accurately. (C) 2003 Elsevier Science Ltd. All rights reserved.	Univ Warwick, Ctr Hlth Serv Studies, Coventry CV4 7AL, W Midlands, England; N Staffordshire Rehabil Ctr, Stoke On Trent ST6 7AG, Staffs, England; Univ Warwick, Ctr Res Ethn Relat, Coventry CV4 7AL, W Midlands, England; City Gen Hosp, Paediat Intens Care Unit, Stoke On Trent ST4 6QG, Staffs, England		Hawley, CA (corresponding author), Univ Warwick, Ctr Hlth Serv Studies, Coventry CV4 7AL, W Midlands, England.		Hawley, Carol/AAG-3830-2019				*BRIT SOC REH MED, 1998, REH TRAUM BRAIN INJ; Cicerone KD, 1996, BRAIN INJURY, V10, P277, DOI 10.1080/026990596124458; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; EWINGCOBBS L, 1994, NEUROSURGERY, V35, P225, DOI 10.1227/00006123-199408000-00007; *HOUS COMM SEL COM, 2001, 3 HOUS COMM SEL COMM; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; MILLER JD, 1990, REHABILITATION ADULT; *N STAFF HLTH AUTH, 1994, HLTH N STAFF ANN REP; Parmelee D X, 1989, Psychiatr Med, V7, P11; ROBERTS MA, 1995, BRAIN INJURY, V9, P427, DOI 10.3109/02699059509008202; SHARPLES PM, 1990, BRIT MED J, V300, P87, DOI 10.1136/bmj.300.6717.87; TEASDALE G, 1974, LANCET, V2, P81; Townsend P, 1986, INEQUALITIES HLTH NO	14	101	103	0	13	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383			INJURY	Injury-Int. J. Care Inj.	MAY	2003	34	4					256	260	PII S0020-1383(02)00193-6	10.1016/S0020-1383(02)00193-6			5	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	668KR	WOS:000182290300003	12667776				2022-02-06	
J	Bryant, RA; Moulds, ML; Nixon, RVD				Bryant, RA; Moulds, ML; Nixon, RVD			Cognitive behaviour therapy of acute stress disorder: a four-year follow-up	BEHAVIOUR RESEARCH AND THERAPY			English	Article						acute stress disorder; PTSD; cognitive behaviour therapy	2-YEAR PROSPECTIVE EVALUATION; TRAUMATIC BRAIN INJURY; INTERVIEW; SCALE	The aim of this study was to index the long-term benefits of early provision of cognitive behavior therapy to trauma survivors with acute stress disorder. Civilian trauma survivors (n = 80) with acute stress disorder were randomly allocated to either cognitive behavior therapy (CBT) or supportive counseling (SC) - 69 completed treatment, and 41 were assessed four years post-treatment for post-traumatic stress disorder (PTSD) with the Clinician Administered PTSD Scale. Two CBT patients (8%) and four SC patients (25%) met PTSD criteria at four-year follow-up. Patients who received CBT reported less intense PTSD symptoms, and particularly less frequent and less avoidance symptoms, than patients who received SC. These findings suggest that early provision of CBT in the initial month after trauma has long-term benefits for people who are at risk of developing PTSD. (C) 2003 Elsevier Science Ltd. All rights reserved.	Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia		Bryant, RA (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.		Bryant, Richard/AAA-6479-2019; Nixon, Reginald/A-6095-2015; Moulds, Michelle/B-2928-2010	Bryant, Richard/0000-0002-9607-819X; Nixon, Reginald/0000-0003-1507-8428; Moulds, Michelle/0000-0001-7064-4248			BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Blanchard E. B., 1997, CRASH ASSESSMENT TRE; Bryant RA, 1999, AM J PSYCHIAT, V156, P1780; Bryant RA, 1998, J CONSULT CLIN PSYCH, V66, P862, DOI 10.1037/0022-006X.66.5.862; Bryant RA, 1998, PSYCHOL ASSESSMENT, V10, P215, DOI 10.1037/1040-3590.10.3.215; Bryant RA, 1997, CLIN PSYCHOL REV, V17, P757, DOI 10.1016/S0272-7358(97)00052-4; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Ehlers A, 1995, Behav Cogn Psychother, V23, P217, DOI 10.1017/S135246580001585X; Foa EB, 2000, J CLIN PSYCHIAT, V61, P43; Harvey AG, 1999, J CONSULT CLIN PSYCH, V67, P985, DOI 10.1037/0022-006X.67.6.985; Harvey AG, 1998, J CONSULT CLIN PSYCH, V66, P507, DOI 10.1037/0022-006X.66.3.507; Harvey AG, 2000, AM J PSYCHIAT, V157, P626, DOI 10.1176/appi.ajp.157.4.626; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; Peters L, 1996, INT J METHOD PSYCH, V6, P167, DOI 10.1002/(SICI)1234-988X(199610)6:3<167::AID-MPR159>3.3.CO;2-Z; SPEILBERGER CD, 1983, MANUAL STATE TRAIT A	16	101	105	0	11	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0005-7967			BEHAV RES THER	Behav. Res. Ther.	APR	2003	41	4					489	494		10.1016/S0005-7967(02)00179-1			6	Psychology, Clinical	Social Science Citation Index (SSCI)	Psychology	662LT	WOS:000181948800008	12643970				2022-02-06	
J	Barr, WB				Barr, WB			Neuropsychological testing of high school athletes - Preliminary norms and test-retest indices	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						sports injury; concussion; test reliability; traumatic brain injury; sex differences; adolescents	TRAUMATIC BRAIN INJURY; MILD HEAD-INJURY; FOOTBALL PLAYERS; SEX-DIFFERENCES; CONCUSSION; SPORTS; RELIABILITY; PERFORMANCE; COLLEGIATE; MATURATION	This study provides preliminary norms and test-retest indices on a brief battery of neuropsychological tests administered to a sample of 60 male and 40 female high school athletes. Forty-eight subjects completed retesting 8 weeks later. Analyses of baseline scores indicate that girls outperform boys on selected measures of processing speed and executive functions [Wechsler Adult Intelligence Scale-III (WAIS-III) Digit Symbol, Trails B, and Controlled Oral Word Association Test (COWAT)]. Test-retest reliability was low and varied widely among the tests. There were no gender differences in test-retest reliability. Reliable Change Indices (RCIs) were computed on the test-retest data for use in clinical interpretation. These preliminary results indicate that caution should be used in interpreting neuropsychological test data from high school athletes. The current findings indicate that separate norms for boys and girls are warranted. Caution should be used in interpreting discrepancies from baseline scores as a result of what may turn out to be poor test-retest reliability in this population. (C) 2002 National Academy of Neuropsychology. Published by Elsevier Science Ltd. All rights reserved.	NYU, Sch Med, Comprehens Epilepsy Ctr, New York, NY 10016 USA		Barr, WB (corresponding author), NYU, Sch Med, Comprehens Epilepsy Ctr, Rivergate 4th Floor,560 1st Ave, New York, NY 10016 USA.	william.barr@med.nyu.edu		Barr, William/0000-0001-7711-7758			Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Barth JT, 1989, MILD HEAD INJURY, P257; Benedict RHB, 1998, CLIN NEUROPSYCHOL, V12, P43, DOI 10.1076/clin.12.1.43.1726; Benton A., 1978, MULTILINGUAL APHASIA; Brandt J, 1991, CLIN NEUROPSYCHOL, V5, P125, DOI [10.1080/13854049108403297, DOI 10.1080/13854049108403297]; Chelune G.J., 1993, NEUROPSYCHOLOGY, V7, P41, DOI [10.1037/0894-4105.7.1.41, DOI 10.1037/0894-4105.7.1.41]; COHEN J, 1994, AM PSYCHOL, V49, P997, DOI 10.1037/0003-066X.49.12.997; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Dikmen SS, 1999, J INT NEUROPSYCH SOC, V5, P346, DOI 10.1017/S1355617799544056; Franzen MD, 1999, SPORTS-RELATED CONCUSSION, P171; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Halpern DF, 1997, AM PSYCHOL, V52, P1091, DOI 10.1037/0003-066X.52.10.1091; Hermann BP, 1996, EPILEPSIA, V37, P942, DOI 10.1111/j.1528-1157.1996.tb00531.x; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; JENSEN AR, 1983, PERS INDIV DIFFER, V4, P223, DOI 10.1016/0191-8869(83)90029-6; Kaufman AlanS., 1990, ASSESSING ADOLESCENT; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; MACCIOCCHI SN, 1990, J CLIN PSYCHOL, V46, P628, DOI 10.1002/1097-4679(199009)46:5<628::AID-JCLP2270460514>3.0.CO;2-V; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Powell JW, 1999, SPORTS-RELATED CONCUSSION, P75; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; SANDERS B, 1986, DEV PSYCHOL, V22, P199, DOI 10.1037/0012-1649.22.2.199; Sawrie S M, 1996, J Int Neuropsychol Soc, V2, P556; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Temkin NR, 1999, J INT NEUROPSYCH SOC, V5, P357, DOI 10.1017/S1355617799544068; Vanderploeg RD, 2000, CLIN NEUROPSYCHOL, V14, P318, DOI 10.1076/1385-4046(200008)14:3;1-P;FT318; WABER DP, 1976, SCIENCE, V192, P572, DOI 10.1126/science.1257795; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Wojtys EM, 1999, AM J SPORT MED, V27, P676, DOI 10.1177/03635465990270052401	39	101	101	0	17	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JAN	2003	18	1					91	101	PII S0887-6177(01)00185-8	10.1016/S0887-6177(01)00185-8			11	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	645RJ	WOS:000180992000009	14591481				2022-02-06	
J	Hawley, CA				Hawley, CA			Reported problems and their resolution following mild, moderate and severe traumatic brain injury amongst children and adolescents in the UK	BRAIN INJURY			English	Article							HEAD-INJURIES; CHILDHOOD; SEQUELAE; OUTCOMES; SCALE	Primary objectives : To examine the problems reported by families of children who have suffered traumatic brain injury (TBI), and how these differ from problems reported by control families. To identify those problems most likely to resolve over time, and to examine information and follow-up requirements. Design, methods and procedures : The families of 97 children with mild (49), moderate (19) and severe (29) TBI, aged 5-15 at injury, were interviewed and assessed at a mean of 2.29 years post-injury and compared with 31 healthy controls. A structured questionnaire was used to collect information on problems pre- and post-TBI. Initially, respondents reported problems spontaneously, and were subsequently prompted using a checklist of problem categories. Problems of behaviour and emotion were measured using the Vineland Adaptive Behaviour Scales (VABS) and the Hospital Anxiety and Depression Scale (HADS). Main outcomes and results : Following the TBI, 83 children (85.6%) received no therapeutic input, 74 families (76.3%) had unmet information needs, particularly regarding long-term consequences. At first interview, 1097 problems were reported by the TBI group. Behavioural and school problems were frequently reported by all TBI groups, significantly more than controls (pless than or equal to0.001). On the VABS, approximately two thirds of children with TBI exhibited significant maladaptive behaviours, significantly more than controls (p=0.002). Children in the mild and moderate/severe groups were significantly more anxious than controls on the HADS (p=0.04). At 12 month follow-up, there were no significant differences in problem resolution between the TBI groups: 498 (53.9%) problems remained unchanged and 75 (8.1%) had worsened. Physical problems were most likely to resolve. Conclusions : Parents should be given information and support following their child's TBI, children should be routinely followed-up by health professionals and their needs assessed. It was found that children with TBI may be at risk of anxiety, yet few parents reported this as a particular concern. Future research should examine the relationship between anxiety and TBI.	Univ Warwick, Ctr Hlth Serv Studies, Coventry CV4 7AL, W Midlands, England		Hawley, CA (corresponding author), Univ Warwick, Ctr Hlth Serv Studies, Coventry CV4 7AL, W Midlands, England.	c.a.hawley@warwick.ac.uk	Hawley, Carol/AAG-3830-2019				ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; Barry CT, 1996, CHILD NEUROPSYCHOL, V2, P213, DOI 10.1080/09297049608402254; Bowen A, 2001, BRAIN INJURY, V15, P29, DOI 10.1080/02699050150209101; *BRIT SOC REH MED, 1998, REH TRAUM BRAIN INJ; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; Ciccetti D., 1984, VINELAND ADAPTIVE BE; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; Fletcher J M, 1991, Brain Inj, V5, P337, DOI 10.3109/02699059109008106; GUYER B, 1990, AM J DIS CHILD, V144, P649, DOI 10.1001/archpedi.1990.02150300047016; HAWLEY CA, IN PRESS BRAIN INJUR; *HOUS COMM SEL COM, 2001, 3 REP HEAD INJ REH; KLONOFF H, 1971, AM J PUBLIC HEALTH N, V61, P2405, DOI 10.2105/AJPH.61.12.2405; Klonoff H, 1995, TRAUMATIC HEAD INJUR, P219; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Light R, 1998, J CONSULT CLIN PSYCH, V66, P1023; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; ODDY M, 1993, NEUROPSYCHOL REHABIL, V3, P301, DOI 10.1080/09602019308401444; Parmelee D X, 1989, Psychiatr Med, V7, P11; SNOW JH, 1994, PEDIAT TRAUMATIC BRA; STILWELL J, 1998, REPORT NATL TRAUMATI; Stilwell P, 1999, NEUROPSYCHOL REHABIL, V9, P277, DOI 10.1080/096020199389374; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; TEASDALE G, 1974, LANCET, V2, P81; Townsend P, 1986, INEQUALITIES HLTH NO; Vasa RA, 2002, J AM ACAD CHILD PSY, V41, P148, DOI 10.1097/00004583-200202000-00008; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	30	101	103	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2003	17	2					105	129		10.1080/0269905021000010131			25	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	633LL	WOS:000180284700002	12519639				2022-02-06	
J	Faden, AI				Faden, AI			Neuroprotection and traumatic brain injury: theoretical option or realistic proposition	CURRENT OPINION IN NEUROLOGY			English	Article						traumatic brain injury; neuroprotection; apoptosis; necrosis; trial design	APOPTOTIC CELL-DEATH; IN-VITRO; NEURONAL APOPTOSIS; HEAD-INJURY; FEMALE RATS; ACTIVATION; EXPRESSION; SUSCEPTIBILITY; VULNERABILITY; CONTRIBUTES	Purpose of review Preclinical studies have shown that treatment to limit secondary cell damage can significantly improve outcome after traumatic brain injury. In contrast, neuroprotection trials in human traumatic brain injury have failed to convincingly demonstrate therapeutic benefit. Recent literature has begun to address this discrepancy between preclinical and clinical trials. Recent findings Perhaps the most important recent observations relate to the potential role of apoptosis in secondary brain injury. Because apoptosis peaks more than 24 h after injury, concepts about the therapeutic window for traumatic brain injury treatment have changed. Apoptosis and necrosis are in delicate balance and inhibition of one cell death pathway may enhance the other. This raises questions about the ultimate effectiveness of treatment strategies directed toward a single injury mechanism. In contrast to clinical head injury, which reflects a complex multifactorial disorder, animal models are generally designed to address only a single injury component and are performed in genetically inbred animals of a single sex. Moreover, animal studies usually employ pretreatment or early posttreatment administration, examine moderate rather than severe injury, fail to examine brain drug levels or treatment optimization, and do not use an intent-to-treat methodology. Summary Recognition of these methodological differences between animal and human studies has led to new trial design proposals. For clinical studies, there should be better stratification of patients, a focus on moderate injury and earlier treatment, and larger sample sizes. Animal experiments should better parallel clinical studies and address therapeutic window and treatment optimization. Recognition of multiple cell death pathways should lead to new treatment strategies - including both combination drug treatment and drugs that affect multiple components of the secondary injury cascade.	Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20057 USA		Faden, AI (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, 3970 Reservoir Rd NW,Room EP-12, Washington, DC 20057 USA.	fadena@georgetown.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS036537, R01NS041119] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS 36537-04, R01 NS 41119-02] Funding Source: Medline		Allen JW, 1999, FASEB J, V13, P1875, DOI 10.1096/fasebj.13.13.1875; BRAAKMAN R, 1994, J NEUROSURG, V80, P797; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Cerami A, 2002, NEPHROL DIAL TRANSPL, V17, P8, DOI 10.1093/ndt/17.suppl_1.8; Clausen T, 2001, CURR PHARM DESIGN, V7, P1517, DOI 10.2174/1381612013397267; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Dickinson K, 2000, BMJ-BRIT MED J, V320, P1308, DOI 10.1136/bmj.320.7245.1308; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; ESHHAR N, 1995, EUR J PHARMACOL, V283, P19, DOI 10.1016/0014-2999(95)00271-L; Faden AI, 1999, AM J PHYSIOL-REG I, V277, pR1196, DOI 10.1152/ajpregu.1999.277.4.R1196; Faden AI, 2001, ARCH NEUROL-CHICAGO, V58, P1553, DOI 10.1001/archneur.58.10.1553; FADEN AI, 1996, NEUROTRAUMA, P1479; Fink K, 1998, J CEREBR BLOOD F MET, V18, P1071, DOI 10.1097/00004647-199810000-00003; Frantseva MV, 2002, J NEUROSCI, V22, P644, DOI 10.1523/JNEUROSCI.22-03-00644.2002; Glazner GW, 2000, J NEUROSCI, V20, P3641, DOI 10.1523/JNEUROSCI.20-10-03641.2000; Golarai G, 2001, J NEUROSCI, V21, P8523, DOI 10.1523/JNEUROSCI.21-21-08523.2001; Grotta J, 2002, STROKE, V33, P306, DOI 10.1161/str.33.1.306; Gupta AK, 2002, BRIT J ANAESTH, V88, P188, DOI 10.1093/bja/88.2.188; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; Harter L, 2001, J NEUROIMMUNOL, V121, P76, DOI 10.1016/S0165-5728(01)00409-X; Igarashi T, 2001, EXP NEUROL, V172, P332, DOI 10.1006/exnr.2001.7820; Kim BT, 2001, J NEUROSURG, V95, P674, DOI 10.3171/jns.2001.95.4.0674; Kline AE, 2001, NEUROSCIENCE, V106, P547, DOI 10.1016/S0306-4522(01)00300-1; KNOBLACH S, 2000, SOC NEUROSCIENCE, V26, P2300; Kumar A, 2002, J NEUROSCI RES, V67, P781, DOI 10.1002/jnr.10181; Lees KR, 2002, STROKE, V33, P308, DOI 10.1161/str.33.1.308; Lenzlinger PM, 2002, J NEUROIMMUNOL, V122, P167, DOI 10.1016/S0165-5728(01)00466-0; Lynch JR, 2002, ANN NEUROL, V51, P113, DOI 10.1002/ana.10098; Maas AIR, 2001, EXPERT OPIN INV DRUG, V10, P753, DOI 10.1517/13543784.10.4.753; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; Mukhin A, 1996, J NEUROSCI, V16, P6012; Peterson DA, 2002, CURR OPIN PHARMACOL, V2, P34, DOI 10.1016/S1471-4892(01)00118-7; Philips MF, 2001, J NEUROSURG, V94, P765, DOI 10.3171/jns.2001.94.5.0765; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; Povlishock JT., 1996, NEUROTRAUMA, P1325; Qiu JH, 2002, J NEUROSCI, V22, P3504; RINK A, 1995, AM J PATHOL, V147, P1575; Sanz O, 2002, J NEUROSCI RES, V67, P772, DOI 10.1002/jnr.10140; Suehiro E, 2001, EXP NEUROL, V172, P199, DOI 10.1006/exnr.2001.7765; SUN FY, 1995, BRAIN RES, V693, P163, DOI 10.1016/0006-8993(95)00731-5; TEASDALE G, 1990, ACT NEUR S, V51, P315; Temple MD, 2001, HEAD TRAUMA, P87; Yakovlev AG, 2001, J NEUROSCI, V21, P7439, DOI 10.1523/JNEUROSCI.21-19-07439.2001; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Zwienenberg M, 2001, NEUROSURGERY, V48, P1119, DOI 10.1097/00006123-200105000-00031	49	101	107	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1350-7540	1473-6551		CURR OPIN NEUROL	Curr. Opin. Neurol.	DEC	2002	15	6					707	712		10.1097/00019052-200212000-00008			6	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	627VD	WOS:000179956100008	12447109				2022-02-06	
J	Scheff, SW; Saucier, DA; Cain, ME				Scheff, SW; Saucier, DA; Cain, ME			A statistical method for analyzing rating scale data: The BBB locomotor score	JOURNAL OF NEUROTRAUMA			English	Article						behavioral recovery; data analysis; neurotrauma; spinal cord injury	RATS	The Basso, Beattie and Bresnahan (BBB) locomotor rating scale is widely used to test behavioral consequences of spinal cord injury (SCI) to. the rat. Sensitivity of this rating scale can differentiate hind limb locomotor skills over a wide range of injury severities. While the 21-point BBB scale is ordinal in nature, the present discussion recommends the use of parametric statistics to evaluate the locomotor results. Specifically, it defines appropriate statistical analysis of these data in order to facilitate interpretation of results between laboratories and to provide a common methodology for the correct interpretation of SCI behavioral data.	Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; Univ Kentucky, Dept Psychol, Lexington, KY 40536 USA		Scheff, SW (corresponding author), Univ Kentucky, Sanders Brown Ctr Aging 233, Lexington, KY 40536 USA.			Cain, Mary/0000-0002-2165-990X			Aron A., 1999, STAT PSYCHOL; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Basso DM, 1996, J NEUROTRAUM, V13, P343, DOI 10.1089/neu.1996.13.343; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Cohen J., 2013, STAT POWER ANAL BEHA; Erdfelder E, 1996, BEHAV RES METH INS C, V28, P1, DOI 10.3758/BF03203630; Howell D. C., 1999, FUNDAMENTAL STAT BEH, V4th; Howell DC., 2002, STAT METHODS PSYCHOL, V5; Lankhorst AJ, 1999, J NEUROTRAUM, V16, P323, DOI 10.1089/neu.1999.16.323; Rosenthal R, 1991, ESSENTIALS BEHAV RES, V2nd; Wilkinson L, 1999, AM PSYCHOL, V54, P594, DOI 10.1037/0003-066X.54.8.594	11	101	113	0	6	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	2002	19	10					1251	1260		10.1089/08977150260338038			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	605MJ	WOS:000178681400012	12427332				2022-02-06	
J	Raghupathi, R; Margulies, SS				Raghupathi, R; Margulies, SS			Traumatic axonal injury after closed head injury in the neonatal pig	JOURNAL OF NEUROTRAUMA			English	Article						axonal injury; head injury; infants; subarachnoid hematoma; white matter	PERCUSSION BRAIN INJURY; FLUID-PERCUSSION; CORTICAL IMPACT; DEVELOPING RAT; IMMATURE RAT; DAMAGE; MODEL; NEUROPATHOLOGY; CHILDREN; AGE	Closed head injury is the leading cause of morbidity and mortality in infants and children, and results in pathologies such as diffuse axonal injury (DAI) and subarachnoid hematoma (SAH). To better understand the mechanical environment associated with closed head injury in the pediatric population, animal models that include salient features of human infant brain must be utilized. Based on detailed information regarding the parallels between brain development in the pig and the human, the 3-5-day-old piglet was used to represent the infant at less than 3 months of age. Anesthetized piglets (n = 7) were subjected to rapid, inertial (nonimpact) rotation of the head about its axial plane and sacrificed at 6 h postinjury. Immediately following injury, five of seven piglets were apneic, with an absence of pupillary and pain reflexes. All piglets exhibited severe coma immediately postinjury, but recovered by sacrifice time. Blood was present on the surface of the frontal lobes, cerebellum, and brainstem, and subarachnoid hemorrhage was evident in the frontal cortex. In six of seven brain-injured piglets, accumulation of the 68-kDa neurofilament protein was evident in contiguous axons (swollen) and occasionally in disconnected axons (axonal bulbs), suggestive of traumatic axonal injury (TAI). Mapping of the regional pattern of TAI revealed injured axons predominantly in central and peripheral white matter tracts in the frontal and temporal lobes and in the midbrain. The number of injured axons was equivalent in both hemispheres, and did not correlate to the load applied to the head. Together, these data demonstrate that rapid rotation of the piglet head without impact results in SAH and TAI, similar to that observed in children following severe brain trauma.	Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA		Margulies, SS (corresponding author), Univ Penn, Dept Bioengn, 105D Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS41561, R01-NS39679] Funding Source: Medline; ODCDC CDC HHS [R49-CCR312712] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041561, R01NS039679] Funding Source: NIH RePORTER		ADAMS JH, 1982, RECENT ADV NEUROPATH, P165; Adelson PD, 1996, J NEUROSURG, V85, P877, DOI 10.3171/jns.1996.85.5.0877; Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; Armstead WM, 1999, J NEUROTRAUM, V16, P391, DOI 10.1089/neu.1999.16.391; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Brodhun M, 2001, ACTA NEUROPATHOL, V101, P424; Conti AC, 1998, J NEUROSCI, V18, P5663; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Duhaime AC, 2000, J NEUROSURG, V93, P455, DOI 10.3171/jns.2000.93.3.0455; Durham SR, 2000, PEDIATR NEUROSURG, V33, P76, DOI 10.1159/000028980; Fisher M D, 1997, Crit Care Nurs Q, V20, P36; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HOEHNER PJ, 1994, STROKE, V25, P2060, DOI 10.1161/01.STR.25.10.2060; Ikonomidou C, 1996, PEDIATR RES, V39, P1020, DOI 10.1203/00006450-199606000-00015; Kolb B, 2000, DEV NEUROPSYCHOL, V18, P423, DOI 10.1207/S1532694208Kolb; LOWENHIELM P, 1975, J BIOMECH, V8, P351, DOI 10.1016/0021-9290(75)90069-X; LUERSSEN TG, 1991, CONC PED N, V11, P87; MADSEN FF, 1990, ACTA NEUROCHIR, V105, P150, DOI 10.1007/BF01670000; MADSEN FF, 1987, ACTA NEUROCHIR WIEN, V102, P65; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; MEANEY DF, 1994, J NEUROTRAUM, V11, P599, DOI 10.1089/neu.1994.11.599; Ommaya AK, 1967, 11 STAPP CAR CRASH C, P73; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/S0165-3806(96)00098-3; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Shannon P, 1998, ACTA NEUROPATHOL, V95, P625, DOI 10.1007/s004010050849; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; Villablanca JR, 2000, NEUROSCIENCE, V95, P625; YOSHIKAWA T, 1968, ATLAS BRAINS DOMESTI, V5, P1	42	101	103	0	4	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	2002	19	7					843	853		10.1089/08977150260190438			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	577JL	WOS:000177057700004	12184854				2022-02-06	
J	McCrea, M				McCrea, M			Standardized mental status assessment of sports concussion	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						brain injuries; brain concussion; athletic injuries; neuropsychologic tests	MILD HEAD-INJURY; FOOTBALL PLAYERS; MANAGEMENT; RECOVERY	Neurocognitive status is often considered the domain of neurologic functioning most sensitive to change following concussion, but the effects are often subtle and difficult to detect on routine clinical examination. Recent efforts have focused on the development of brief, standardized methods of mental status assessment for use by sports medicine clinicians to quantify the acute neurocognitive effects of concussion and objectively track postinjury recovery. Research has demonstrated the reliability, validity, and sensitivity of these measures in detecting concussion in athletes and providing empirical data for consideration in the context of other examination findings, neuropsychologic test data, and neuroimaging results. Standardized measures of mental status and other postconcussive symptoms are valuable tools to assist clinicians in the assessment and management of concussion, but should nut be used as a replacement for medical evaluation or viewed as a stand-alone means for determining readiness to return to competition after injury.	Waukesha Mem Hosp, Neuropsychol Serv, Waukesha, WI 53188 USA; Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA		McCrea, M (corresponding author), Waukesha Mem Hosp, Neuropsychol Serv, 721 Amer Ave,Suite 501, Waukesha, WI 53188 USA.						Alexander, 1997, Semin Clin Neuropsychiatry, V2, P177; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; BARR W, IN PRESS J INT NEURO; Barth JT, 1989, MILD HEAD INJURY, P257; *C NEUR SURG, 1966, CLIN NEUROSURG, V12, P386; Cantu RC, 1996, BRIT J SPORT MED, V30, P289, DOI 10.1136/bjsm.30.4.289; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879, DOI 10.1016/S0733-8619(18)30185-3; CLIFTON GL, 1992, NEUROSURGERY, V31, P975, DOI 10.1227/00006123-199211000-00028; *COL MED SOC, 1991, REP SPORTS MED COMM; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; COLLINS MW, 1999, JAMA-J AM MED ASSOC, P2282; FARRARA M, IN PRESS J ATHLETIC; Ferguson RJ, 1999, NEUROPSYCHOLOGY, V13, P582, DOI 10.1037/0894-4105.13.4.582; FISHER CM, 1966, NEUROLOGY, V16, P826, DOI 10.1212/WNL.16.8.826; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gordon WR, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199812000-00006; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; GUSKIEWICZ KM, 1997, MED SCI SPORTS EXERC, V29, P213; Harmon KG, 1999, AM FAM PHYSICIAN, V60, P887; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; KUTNER KC, 1998, NATL ACAD NEUROPSYCH, V5, P19; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 1996, STANDARDIZED ASSESSM; McCrea M., 2000, STANDARDIZED ASSESSM; *NAT ATHL TRAIN AS, 1994, P MILD BRAIN INJ SUM; ONATE JA, 2000, J ATHL TRAINING, V35, pS54; Pottinger LS, 1999, ARCH CLIN NEUROPSYCH, V14, P39, DOI 10.1093/arclin/14.1.39a; Riemann BL, 2000, J ATHL TRAINING, V35, P19; RIEMANN BL, 1999, J SPORT REHABIL, V8, P1; ROBERTS WO, 1992, PHYSICIAN SPORTSMED, V20, P66, DOI 10.1080/00913847.1992.11710295; STEIN SC, 1993, BRAIN INJURY, V7, P425, DOI 10.3109/02699059309029685; STEIN SC, 1996, NEUROTRAUMA, P23; TEASDALE G, 1974, LANCET, V2, P81; TEIN SC, 1996, NEUROTRAUMA, P31; Wechsler D., 1997, WECHSLER MEMORY SCAL; YARNELL PR, 1973, NEUROLOGY, V23, P196, DOI 10.1212/WNL.23.2.196; YARNELL PR, 1970, LANCET, V1, P863	46	101	102	0	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1050-642X			CLIN J SPORT MED	Clin. J. Sport Med.	JUL	2001	11	3					176	181		10.1097/00042752-200107000-00008			6	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Orthopedics; Physiology; Sport Sciences	454YG	WOS:000169998900007	11495322				2022-02-06	
J	Buki, A; Koizumi, H; Povlishock, JT				Buki, A; Koizumi, H; Povlishock, JT			Moderate posttraumatic hypothermia decreases early calpain-mediated proteolysis and concomitant cytoskeletal compromise in traumatic axonal injury	EXPERIMENTAL NEUROLOGY			English	Article; Proceedings Paper	2nd Conference of Cellular and Molecular Treatments of Neurological Diseases (CMT)	OCT, 1998	CAMBRIDGE, MASSACHUSETTS			traumatic brain injury; axonal injury; hypothermia; calpain; spectrin; calcium; cytoskeleton	SPINAL-CORD INJURY; SEVERE HEAD-INJURY; MICROTUBULE-ASSOCIATED PROTEIN-2; EXPERIMENTAL BRAIN INJURY; ISCHEMIC NEURONAL INJURY; TRANSIENT FOCAL ISCHEMIA; MILD HYPOTHERMIA; FOREBRAIN ISCHEMIA; AMINO-ACIDS; AXOLEMMAL PERMEABILITY	Traumatic brain injury (TBI) in animals and man generates widespread axonal injury characterized by focal axolemmal permeability changes, induction of calpain-mediated proteolysis, and neurofilament sidearm modification associated with neurofilament compaction (NFC) evolving to axonal disconnection. Recent observations have suggested that moderate hypothermia is neuroprotective in several models of TBI. Nevertheless, the pathway by which hypothermia prevents traumatic axonal injury (TAI) is still a matter of debate. The present study was conducted to evaluate the effects of moderate, early posttraumatic hypothermia on calpain-mediated spectrin proteolysis (CMSP), implicated in the pathogenesis of TAT. Using moderate (32 degrees C) hypothermia of 90 min duration without rewarming, the density of CMSP immunoreactive/damaged axons was quantified via LM analysis in vulnerable brain stem fiber tracts of hypothermic and normothermic rats subjected to impact acceleration TBI (90 min postinjury survival). To assess the influence of posthypothermic rewarming, a second group of animals was subjected to 90 min of hypothermia followed by 90 min of rewarming to normothermic levels when CMSP was analyzed to detect if any purported CMSP prevention persisted (180 min postinjury survival). Additionally, to determine if this protection translated into comparable cytoskeletal protection in the same foci showing decreased CMSP, antibodies targeting altered/compacted NF subunits were also employed. Moderate hypothermia applied in the acute postinjury period drastically reduced the number of damaged axons displaying CMSP at both time points and significantly reduced NFC immunoreactivity at 180 min postinjury. These results suggest that the neuroprotective effects of hypothermia in TBI are associated with the inhibition of axonal/cytoskeletal damage. (C) 1999 Academic Press.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, Richmond, VA 23298 USA; Univ Pecs, Sch Med, Dept Neurosurg, H-7624 Pecs, Hungary; Yamaguchi Univ, Sch Med, Dept Neurosurg, Ube, Yamaguchi 755, Japan		Buki, A (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, Richmond, VA 23298 USA.		Buki, Andras/B-1960-2010		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020193] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 20193] Funding Source: Medline		Banik NL, 1998, ANN NY ACAD SCI, V844, P131, DOI 10.1111/j.1749-6632.1998.tb08228.x; Banik NL, 1997, BRAIN RES, V752, P301, DOI 10.1016/S0006-8993(96)01488-6; Bartus RT, 1998, BRAIN RES, V790, P1, DOI 10.1016/S0006-8993(97)01414-5; Bartus RT, 1997, NEUROSCIENTIST, V3, P314, DOI 10.1177/107385849700300513; BARTUS RT, 1995, J CEREBR BLOOD F MET, V15, P969, DOI 10.1038/jcbfm.1995.123; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; BUSTO R, 1989, NEUROSCI LETT, V101, P299, DOI 10.1016/0304-3940(89)90549-1; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; DIETRICH WD, 1990, STROKE, V21, P1318, DOI 10.1161/01.STR.21.9.1318; Farooque M, 1997, J NEUROTRAUM, V14, P63, DOI 10.1089/neu.1997.14.63; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GOODMAN SR, 1995, BRAIN RES BULL, V36, P593, DOI 10.1016/0361-9230(94)00264-2; HARRIS AS, 1989, J BIOL CHEM, V264, P17401; Henker RA, 1998, NEUROSURGERY, V42, P1071, DOI 10.1097/00006123-199805000-00071; HONG SC, 1994, BRAIN RES, V661, P43, DOI 10.1016/0006-8993(94)91178-9; Kaibara T, 1999, J NEUROSURG, V90, P339, DOI 10.3171/jns.1999.90.2.0339; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kataoka K, 1996, MOL CHEM NEUROPATHOL, V28, P191, DOI 10.1007/BF02815222; KNOXDUBOIS CY, 1999, J NEUROTRAUM, V15, P877; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; Koizumi H, 1997, BRAIN RES, V747, P304, DOI 10.1016/S0006-8993(96)01240-1; KOIZUMI H, 1999, IN PRESS BRAIN RES; LEE VMY, 1987, J NEUROSCI, V7, P3474; LI ZH, 1995, NEUROCHEM INT, V27, P425, DOI 10.1016/0197-0186(95)00024-3; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; Mariame B, 1996, BIOTECHNIQUES, V21, P18; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Metz C, 1996, J NEUROSURG, V85, P533, DOI 10.3171/jns.1996.85.4.0533; MINAMISAWA H, 1990, ANN NEUROL, V28, P26, DOI 10.1002/ana.410280107; MITANI A, 1991, BRAIN RES, V562, P159, DOI 10.1016/0006-8993(91)91201-B; MITANI A, 1991, NEUROSCIENCE, V42, P661, DOI 10.1016/0306-4522(91)90035-M; MIYAZAWA T, 1993, ACTA NEUROPATHOL, V85, P526; Morimoto T, 1997, BRAIN RES, V746, P43, DOI 10.1016/S0006-8993(96)01154-7; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; Okonkwo DO, 1998, BRAIN RES, V784, P1, DOI 10.1016/S0006-8993(97)01075-5; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Povlishock JT, 1996, ACT NEUR S, V66, P81; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; Sakamoto KI, 1997, J NEUROTRAUM, V14, P349, DOI 10.1089/neu.1997.14.349; Schwab S, 1998, STROKE, V29, P2461, DOI 10.1161/01.STR.29.12.2461; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1; SIMAN R, 1989, J NEUROSCI, V9, P1579; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; Takata T, 1997, NEUROSCI LETT, V227, P41, DOI 10.1016/S0304-3940(97)00296-6; TAKIGI K, 1994, AM J PHYSIOL, V267, pH1770; Tuzgen S, 1998, SPINAL CORD, V36, P654, DOI 10.1038/sj.sc.3100660; Tymianski M, 1996, NEUROSURGERY, V38, P1176; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Yanamoto H, 1996, BRAIN RES, V718, P207, DOI 10.1016/0006-8993(96)00122-9; ZAGON IS, 1986, J NEUROSCI, V6, P2977; Zhao XR, 1998, J CEREBR BLOOD F MET, V18, P161, DOI 10.1097/00004647-199802000-00006	73	101	102	0	2	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	SEP	1999	159	1					319	328		10.1006/exnr.1999.7139			10	Neurosciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	237FM	WOS:000082644700031	10486200				2022-02-06	
J	Knight, RG; Devereux, R; Godfrey, HPD				Knight, RG; Devereux, R; Godfrey, HPD			Caring for a family member with a traumatic brain injury	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; SOCIAL SUPPORT; CAREGIVER BURDEN; RELATIVES; STRESS; APPRAISAL	The responses to a questionnaire on subjective burden are reported for 52 primary caregivers of a group of persons with traumatic brain injuries sustained an average of 6 years previously. The aim of the study was to examine satisfaction with social support, perception of coping skills, and appraisal of symptoms as predictors of strain in the carer;. A range of responses, both positive and negative, to the work of caring for a relative with a head injury was reported. A high prevalence rate of emotional and behavioural changes in the persons with head injuries was found and the amount of distress caused by these symptoms was found to be predictive of burden. The other factor important in predicting burden was the carers' ratings of their satisfaction with their ability to cope with the work of caregiving. Social support, injury severity, and the demographic characteristics of the persons with head injury and their carer; were not significant predictor;. Depression in the carers was also investigated and the variable most predictive of elevated depression scores was coping satisfaction. These findings reinforce the importance of strengthening carers coping resources in rehabilitation work with head injured persons and their families.	Univ Otago, Dept Psychol, Dunedin, New Zealand		Knight, RG (corresponding author), Univ Otago, Dept Psychol, Box 56, Dunedin, New Zealand.						ALLEN K, 1994, REHABIL PSYCHOL, V39, P29, DOI 10.1037/0090-5550.39.1.29; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; BROOKS WP, 1986, LETT APPL MICROBIOL, V2, P1, DOI 10.1111/j.1472-765X.1986.tb01502.x; CHWALISZ K, 1992, REHABIL PSYCHOL, V37, P189, DOI 10.1037/h0079103; COCKERILL R, 1990, J REHABIL, V56, P41; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; FOLKMAN S, 1994, J CONSULT CLIN PSYCH, V62, P746, DOI 10.1037/0022-006X.62.4.746; Folkman S., 1984, STRESS; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; Godfrey HPD, 1996, J HEAD TRAUMA REHAB, V11, P29, DOI 10.1097/00001199-199612000-00006; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; HALEY WE, 1987, PSYCHOL AGING, V2, P323, DOI 10.1037/0882-7974.2.4.323; Haley WE, 1996, J CONSULT CLIN PSYCH, V64, P121, DOI 10.1037/0022-006X.64.1.121; Knight RG, 1997, J CLIN EXP NEUROPSYC, V19, P7, DOI 10.1080/01688639708403832; Knight RG, 1997, BEHAV RES THER, V35, P373, DOI 10.1016/S0005-7967(96)00107-6; KOSCIULEK JF, 1994, REHABIL PSYCHOL, V39, P215, DOI 10.1037/h0080325; Lezak M.D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI DOI 10.1097/00001199-198703000-00009; Liss M, 1990, Int J Rehabil Res, V13, P309, DOI 10.1097/00004356-199012000-00004; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; Moore A. D., 1991, J HEAD TRAUMA REHAB, V6, P83; MOORE AD, 1995, BRAIN INJURY, V9, P109, DOI 10.3109/02699059509008185; NOVACK TA, 1991, J HEAD TRAUMA REHAB, V6, P69, DOI DOI 10.1097/00001199-199112000-00014; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; PEARLIN LI, 1990, GERONTOLOGIST, V30, P583, DOI 10.1093/geront/30.5.583; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; SARASON IG, 1983, J PERS SOC PSYCHOL, V44, P127, DOI 10.1037/0022-3514.44.1.127; Smith LM, 1995, FAMILY SUPPORT PROGR; TOSELAND RW, 1992, GERONTOLOGIST, V32, P382, DOI 10.1093/geront/32.3.382; Zarit SH., 1985, HIDDEN VICTIMS ALZHE; [No title captured], DOI DOI 10.1097/00001199-198812000-00004	34	101	106	0	9	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUN	1998	12	6					467	481		10.1080/026990598122430			15	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	ZU400	WOS:000074193300003	28925744				2022-02-06	
J	Spain, DA; Richardson, JD; Polk, HC; Bergamini, TM; Wilson, MA; Miller, FB				Spain, DA; Richardson, JD; Polk, HC; Bergamini, TM; Wilson, MA; Miller, FB			Venous thromboembolism in the high-risk trauma patient: Do risks justify aggressive screening and prophylaxis?	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	56th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 19-21, 1996	HOUSTON, TX	Amer Assoc Surg Trauma			CAVA FILTER INSERTION; PULMONARY-EMBOLISM; SUBCUTANEOUS HEPARIN; MULTIPLE TRAUMA; THROMBOSIS; EFFICACY; PREVENTION; INJURY	Objective: Deep venous thrombosis (DVT) and pulmonary embolism (PE) are considered to be a major source of morbidity and mortality among trauma patients, Several reports have identified high-risk patients with recommendations for management ranging from frequent duplex scanning to placement of prophylactic inferior vena cava (IVC) filters, We reviewed our experience with a large trauma population to determine whether such approaches are justified. Methods: We analyzed 2,868 consecutive trauma admissions over 22 months and identified 280 patients (10%) in high-risk groups who survived greater than or equal to 48 hours: (1) severe closed head injury with mechanical ventilation greater than or equal to 72 hours, (2) closed head injury with lower extremity fractures, (3) spinal column/cord injury, (4) combined pelvic and lower extremity fractures, and (5) major infrarenal venous injuries, The remaining nonthermal injury patients constituted the low-risk group. Results: There were 280 high-risk patients, 213 of whom (76%) received prophylaxis with compression therapy, There were 12 cases of DVT (5%) with four nonfatal PE (1.4%), Six patients (2%) had therapeutic IVC filters inserted and only one patient had prophylactic placement. There were 38 deaths in this group, attributable primarily to severe closed head injury or spine injuries, and none were caused by PE, In the 2,249 low-risk patients, there were three cases of DVT (0.1%,p < 0.05 vs, high risk) and no PE (p < 0.05 vs, high risk). Conclusions: Although these patients were at increased risk for thromboembolic events, the overall incidence of DVT was still extremely low with no apparent PE deaths, In our patient population, aggressive screening and prophylactic IVC filters would not have benefited 95% of ''high-risk'' patients without DVT and would not have prevented any deaths, We could not identify any population, except perhaps venous injuries, where such expensive and potentially harmful maneuvers seemed justified. Our experience with DVT and PE does not support either aggressive screening or prophylactic IVC filters as the standards of care.	VET ADM MED CTR, LOUISVILLE, KY USA		Spain, DA (corresponding author), UNIV LOUISVILLE, DEPT SURG, LOUISVILLE, KY 40292 USA.						ALEXANDER JJ, 1994, AM J SURG, V168, P102, DOI 10.1016/S0002-9610(94)80045-6; BERNSTEIN MJ, 1986, JAMA-J AM MED ASSOC, V256, P744; Britt LD, 1996, AM J SURG, V172, P13, DOI 10.1016/S0002-9610(96)00079-7; BURNS GA, 1993, J TRAUMA, V35, P405, DOI 10.1097/00005373-199309000-00012; COLLINS R, 1988, NEW ENGL J MED, V318, P1162, DOI 10.1056/NEJM198805053181805; DENNIS JW, 1993, J TRAUMA, V35, P132, DOI 10.1097/00005373-199307000-00021; FAUNO P, 1994, J BONE JOINT SURG AM, V76A, P1814, DOI 10.2106/00004623-199412000-00007; FERRIS EJ, 1993, RADIOLOGY, V188, P851, DOI 10.1148/radiology.188.3.8351361; GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401; GERSIN K, 1994, J TRAUMA, V37, P205, DOI 10.1097/00005373-199408000-00009; HARRIS EJ, 1995, J VASC SURG, V22, P606, DOI 10.1016/S0741-5214(95)70047-1; HEPARIN RD, 1994, J BONE JOINT SURG AM, V76, P1174; KNUDSON MM, 1994, J TRAUMA, V37, P480, DOI 10.1097/00005373-199409000-00025; KNUDSON MM, 1992, J TRAUMA, V32, P2, DOI 10.1097/00005373-199201000-00002; KUDSK KA, 1989, AM J SURG, V158, P515, DOI 10.1016/0002-9610(89)90182-7; LEACH TA, 1994, AM SURGEON, V60, P292; NAPOLITANO LM, 1995, J TRAUMA, V39, P651, DOI 10.1097/00005373-199510000-00006; Owings John T., 1995, Journal of Trauma, V39, P159; Patton JH, 1996, J TRAUMA, V41, P231, DOI 10.1097/00005373-199608000-00006; Piotrowski JJ, 1996, AM J SURG, V172, P210, DOI 10.1016/S0002-9610(96)00154-7; Rodriguez JL, 1996, J TRAUMA, V40, P797, DOI 10.1097/00005373-199605000-00020; ROGERS FB, 1993, J TRAUMA, V35, P637, DOI 10.1097/00005373-199310000-00021; ROGERS FB, 1995, J AM COLL SURGEONS, V180, P641; Rosenthal D, 1994, Cardiovasc Surg, V2, P52; SCHMIDT U, 1992, J TRAUMA, V33, P312, DOI 10.1097/00005373-199208000-00023; UPCHURCH GR, 1995, AM SURGEON, V61, P749; WILSON JT, 1994, NEUROSURGERY, V35, P234, DOI 10.1227/00006123-199408000-00008; WINCHELL RJ, 1994, J TRAUMA, V37, P600, DOI 10.1097/00005373-199410000-00013	28	101	103	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAR	1997	42	3					463	467		10.1097/00005373-199703000-00014			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	WR152	WOS:A1997WR15200025	9095114				2022-02-06	
J	Nilsson, P; Laursen, H; Hillered, L; Hansen, AJ				Nilsson, P; Laursen, H; Hillered, L; Hansen, AJ			Calcium movements in traumatic brain injury: The role of glutamate receptor-operated ion channels	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						calcium ion-selective microelectrode; 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[F]quinoxaline; glutamate; MK-801; rat; traumatic brain injury	SPREADING DEPRESSION; RAT-BRAIN; AMINO-ACIDS; ISCHEMIA; ACCUMULATION; POTASSIUM; CONTUSION; BREAKDOWN; BARRIER	Ion-selective microelectrodes were used to study acute effects of N-methyl-D-aspartate (NMDA) and alpha-amino-3-hydroxy-5-methyl-4-isoxazole (AMPA) receptor blockade on posttraumatic calcium disturbances. An autoradiographic technique with Ca-45(2+) was used to study calcium disturbances at 8, 24, and 72 h. Compression contusion trauma of the cerebral cortex was produced by a 21-g weight dropped from a height of 35 cm onto a piston that compressed the brain 2 mm. Pre- and posttrauma interstitial [Ca2+] ([Ca2+](e)) concentrations were measured in the perimeter, i.e., the shear stress zone (SSZ) and in the central region (CR) of the trauma site. For the [Ca2+](e) studies the animals were divided into controls and groups pretreated with dizocilipine maleate (MK-801) or with 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[F]quinoxaline (NBQX). In all groups, [Ca2+](e) decreased from pretrauma values of approximately 1 mM to posttraumatic values of 0.1 mM in both the CR and the SSZ. This was followed by a slow restitution toward pretraumatic levels during the 2-h observation period. There was no significant difference in recovery pattern between controls and pretreated animals. Accumulation of Ca-45(2+) and serum proteins was seen in the entire SSZ, while neuronal necrosis was confined to a narrow band within the SSZ. The CR was unaffected apart from occasional eosinophilic neurons and showed no accumulation of Ca-45(2+). Posttraumatic treatment with MK-801 or NBQX had no obvious effect on neuronal injury in the SSZ. We conclude that (a) acute [Ca2+](e) disturbances in compression contusion brain trauma are not affected by blockade of NMDA or AMPA receptors, (b) C-45(2+) accumulation in the SSZ reflects mainly protein accumulation due to blood-brain barrier breakdown rather than cell death, and (c) acute cellular Ca2+ overload per se does not seem to be a major determinant of cell death after cerebral trauma in our model.	UNIV UPPSALA HOSP,DEPT CLIN CHEM,S-75185 UPPSALA,SWEDEN; UNIV UPPSALA HOSP,DEPT NEUROSURG,S-75185 UPPSALA,SWEDEN; UNIV COPENHAGEN,INST NEUROPATHOL,COPENHAGEN,DENMARK; NOVO NORDISK AS,DIV PHARMACEUT,MALOV,DENMARK								CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DIENEL GA, 1984, J NEUROCHEM, V43, P913, DOI 10.1111/j.1471-4159.1984.tb12825.x; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; GILL R, 1992, J CEREBR BLOOD F MET, V12, P371, DOI 10.1038/jcbfm.1992.54; HANSEN AJ, 1988, NEUROCHEM PATHOL, V9, P195; HANSEN AJ, 1981, ACTA PHYSIOL SCAND, V113, P437, DOI 10.1111/j.1748-1716.1981.tb06920.x; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359, DOI 10.1152/jn.1944.7.6.359; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; NELLGARD B, 1992, ACTA PHYSIOL SCAND, V146, P497, DOI 10.1111/j.1748-1716.1992.tb09451.x; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; SACHS F, 1991, MOL CELL BIOCHEM, V104, P57; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; TANNO H, 1992, J NEUROTRAUM, V9, P335, DOI 10.1089/neu.1992.9.335; YOUNG W, 1982, BRAIN RES, V253, P105, DOI 10.1016/0006-8993(82)90677-1; YOUNG W, 1986, BRAIN RES, V365, P42, DOI 10.1016/0006-8993(86)90720-1; YOUNG W, 1992, J NERUOTRAUMA, V9, pS1	25	101	101	0	1	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAR	1996	16	2					262	270		10.1097/00004647-199603000-00011			9	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	TW393	WOS:A1996TW39300011	8594058	Bronze			2022-02-06	
J	RIVARA, JB; JAFFE, KM; FAY, GC; POLISSAR, NL; MARTIN, KM; SHURTLEFF, HA; LIAO, SQ				RIVARA, JB; JAFFE, KM; FAY, GC; POLISSAR, NL; MARTIN, KM; SHURTLEFF, HA; LIAO, SQ			FAMILY FUNCTIONING AND INJURY SEVERITY AS PREDICTORS OF CHILD FUNCTIONING ONE-YEAR FOLLOWING TRAUMATIC BRAIN INJURY	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							CLOSED HEAD-INJURY; ENVIRONMENT; ADOLESCENTS; ADAPTATION; ADJUSTMENT; ILLNESS; MODEL		UNIV WASHINGTON,DEPT REHABIL MED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PEDIAT,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PSYCHIAT & BEHAV SCI,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT NEUROL SURG,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT NEUROSURG,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOSTAT,SEATTLE,WA 98195; UNIV WASHINGTON,STAT & EPIDEMIOL RES CORP,SEATTLE,WA 98195; UNIV WASHINGTON,SCH SOCIAL WORK,SEATTLE,WA 98195; UNIV WASHINGTON,CTR QUANTITAT SCI,SEATTLE,WA 98195; UNIV WASHINGTON,CHILDRENS HOSP & MED CTR,SEATTLE,WA 98195					Shurtleff, Hillary/0000-0003-0959-2842	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR002299] Funding Source: Medline		ACHENBACH TM, 1983, MANUAL CHILD BEHAVIO; ASARNOW RF, 1991, J PED PSYCHOL, V16, P545; BILLINGS AG, 1987, HEALTH PSYCHOL, V6, P343, DOI 10.1037/0278-6133.6.4.343; BLACK P, 1969, LATE EFFECTS HEAD IN; BORROW ES, 1985, DIABETES CARE, V2, P146; BRESLAU N, 1985, J ABNORM CHILD PSYCH, V13, P199, DOI 10.1007/BF00910642; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Edelbrock C., 1986, MANUAL TEACHERS REPO; EWINGCOBBS L, 1986, J HEAD TRAUMA REHAB, V1, P57; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; GOLDSTEIN FC, 1987, J LEARN DISABIL, V20, P518, DOI 10.1177/002221948702000903; HAUSER ST, 1985, FAM RELAT, V34, P99, DOI 10.2307/583762; Hollingshead AB., 1975, 4 FACTOR INDEX SOCIA; JACOBSON MS, 1986, PEDIATRICS, V77, P236; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; JOHNSON SB, 1988, J CHILD PSYCHOL PSYC, V29, P729; KUPST M J, 1982, Journal of Pediatric Psychology, V7, P157; MCCLEAN WE, 1992, J PEDIATR PSYCHOL, V2, P159; McCubbin HI, 1980, FAMILY ASSESSMENT RE; Miller R. G., 1981, SIMULTANEOUS STAT IN; Moos RH, 1974, SOCIAL CLIMATE SCALE; MRAZEK D, 1985, 32ND P ANN M AM AC C; MURCH RL, 1989, J PEDIATR PSYCHOL, V14, P193, DOI 10.1093/jpepsy/14.2.193; PERROTT SB, 1991, DEV NEUROPSYCHOL, V1, P69; PLESS IB, 1972, INT J EPIDEMIOL, V1, P271, DOI 10.1093/ije/1.3.271; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; TEASDALE G, 1974, LANCET, V2, P81; THOMPSON RJ, 1990, J PEDIATR PSYCHOL, V1, P3; UNGERER JA, 1988, PEDIATRICS, V81, P195; VARNI JW, 1989, PEDIATRICS, V84, P323; VARNI JW, 1988, HEALTH PSYCHOL, V7, P421, DOI 10.1037/0278-6133.7.5.421; WERTLIEB D, 1986, J PEDIATR PSYCHOL, V4, P463	32	101	101	0	2	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	1993	74	10					1047	1055		10.1016/0003-9993(93)90060-N			9	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	MB216	WOS:A1993MB21600007	8215855				2022-02-06	
J	Lippa, SM; Fonda, JR; Fortier, CB; Amick, MA; Kenna, A; Milberg, WP; McGlinchey, RE				Lippa, Sara M.; Fonda, Jennifer R.; Fortier, Catherine B.; Amick, Melissa A.; Kenna, Alexandra; Milberg, William P.; McGlinchey, Regina E.			Deployment-Related Psychiatric and Behavioral Conditions and Their Association with Functional Disability in OEF/OIF/OND Veterans	JOURNAL OF TRAUMATIC STRESS			English	Article							TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; PERSISTENT POSTCONCUSSIVE SYMPTOMS; STRUCTURED CLINICAL INTERVIEW; MENTAL-HEALTH PROBLEMS; PAIN; AFGHANISTAN; COMBAT; IRAQ; VALIDITY	Understanding the factors that influence veterans' functional outcome after deployment is critical to provide appropriately targeted care. Mild traumatic brain injury (mTBI) and posttraumatic stress disorder (PTSD) have been related to disability, but other psychiatric and behavioral conditions are not as well examined. We investigated the impact of deployment-related psychiatric and behavioral conditions on disability among 255 OEF/OIF/OND service members and veterans. Structured clinical interviews assessed TBI and the psychiatric conditions of depression, PTSD, anxiety, and substance use. Self-report questionnaires assessed disability and the behavioral conditions of sleep disturbance and pain. Over 90% of participants had a psychiatric and/or behavioral condition, with approximately half presenting with 3 conditions. Exploratory factor analysis revealed 4 clinically relevant psychiatric and behavioral factors which accounted for 76.9% of the variance: (a) depression, PTSD, and military mTBI (deployment trauma factor); (b) pain and sleep (somatic factor); (c) anxiety disorders, other than PTSD (anxiety factor); and (d) substance abuse or dependence (substance use factor). Individuals with the conditions comprising the deployment trauma factor were more likely to be substantially disabled than individuals with depression and PTSD, but no military mTBI, OR = 3.52; 95% CI [1.09, 11.37]. Depression, PTSD, and a history of military mTBI may comprise an especially harmful combination associated with high risk for substantial disability.	[Lippa, Sara M.; Fonda, Jennifer R.; Fortier, Catherine B.; Amick, Melissa A.; Kenna, Alexandra; Milberg, William P.; McGlinchey, Regina E.] VA Boston Healthcare Syst, Translat Res Ctr TBI & Stress Disorders TRACTS, Boston, MA 02130 USA; [Lippa, Sara M.; Fonda, Jennifer R.; Fortier, Catherine B.; Amick, Melissa A.; Kenna, Alexandra; Milberg, William P.; McGlinchey, Regina E.] VA Boston Healthcare Syst, GRECC, Boston, MA 02130 USA; [Lippa, Sara M.] Walter Reed Natl Mil Med Ctr, Def & Vet Brain Injury Ctr, Bethesda, MD USA; [Fonda, Jennifer R.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA; [Fortier, Catherine B.; Milberg, William P.; McGlinchey, Regina E.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA; [Amick, Melissa A.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA		McGlinchey, RE (corresponding author), VA Boston Healthcare Syst, TRACTS GRECC JP 182, 150 South Huntington Ave, Boston, MA 02130 USA.	regina_mcglinchey@hms.harvard.edu	McGlinchey, Regina E/R-1971-2016; Fortier, Catherine/AAS-2163-2021; Fonda, Jennifer R./ABG-2890-2021	Fortier, Catherine/0000-0002-8953-9904; Fonda, Jennifer R./0000-0001-9482-2918	Translational Research Center for TBI and Stress Disorders (TRACTS), a VA Rehabilitation Research and Development (RR&D) Traumatic Brain Injury Center of Excellence [B6796-C]; VA CSR&D Merit Review Award; NIH NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K01AG024898]; National Center for Complementary & Integrative HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21AT009430] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K01AG024898, K23AG034258] Funding Source: NIH RePORTER	This research was supported by the Translational Research Center for TBI and Stress Disorders (TRACTS), a VA Rehabilitation Research and Development (RR&D) Traumatic Brain Injury Center of Excellence (B6796-C) and VA CSR&D Merit Review Award to Regina McGlinchey, and NIH NIA K01AG024898 to Catherine Fortier. We would like to thank Wally Musto for his championing of our work among military personnel and his tireless recruitment efforts on our behalf, as well as the entire TRACTS team for their assistance with data collection and management. We would also like to thank Drs. Patricia Dorn and Stuart Hoffman of VA RR&D for their support of our TBI CoE. Lastly, we would like to thank the anonymous reviewers of this manuscript for their thoughtful comments, which substantially strengthened the manuscript.	American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU, V5, DOI [10.1176/appi.books.9780890425596.dsm02, 10.1176/appi.books.9780890425596]; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; [Anonymous], 2012, AN VA HLTH CAR UT OP; Bay E, 2011, J HEAD TRAUMA REHAB, V26, P355, DOI 10.1097/HTR.0b013e3181f20146; Beder J, 2011, SOC WORK HEALTH CARE, V50, P515, DOI 10.1080/00981389.2011.554279; Blake D. D., 1990, BEHAV THER, V13, P187, DOI DOI 10.1007/BF02105408; Bryant Richard, 2011, Dialogues Clin Neurosci, V13, P251; Carpenter JS, 1998, J PSYCHOSOM RES, V45, P5, DOI 10.1016/S0022-3999(97)00298-5; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cifu DX, 2013, J REHABIL RES DEV, V50, P1169, DOI 10.1682/JRRD.2013.01.0006; Erbes CR, 2011, J REHABIL RES DEV, V48, P1159, DOI 10.1682/JRRD.2010.11.0212; Fichtenberg NL, 2002, BRAIN INJURY, V16, P197, DOI 10.1080/02699050110103940; Fichtenberg NL, 2001, AM J PHYS MED REHAB, V80, P339, DOI 10.1097/00002060-200105000-00003; First M.B., 1996, STRUCTURED CLIN INTE; Fortier CB, 2014, J HEAD TRAUMA REHAB, V29, P89, DOI 10.1097/HTR.0b013e3182865859; Grafton KV, 2005, CLIN J PAIN, V21, P73, DOI 10.1097/00002508-200501000-00009; Guyker WM, 2013, MIL MED, V178, P377, DOI 10.7205/MILMED-D-12-00223; Higgins DM, 2014, PAIN MED, V15, P782, DOI 10.1111/pme.12388; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; King LA, 2006, MIL PSYCHOL, V18, P89, DOI 10.1207/s15327876mp1802_1; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Lippa SM, 2014, ARCH CLIN NEUROPSYCH, V29, P236, DOI 10.1093/arclin/acu002; Lobbestael J, 2011, CLIN PSYCHOL PSYCHOT, V18, P75, DOI 10.1002/cpp.693; MELZACK R, 1987, PAIN, V30, P191, DOI 10.1016/0304-3959(87)91074-8; Pietrzak RH, 2009, DEPRESS ANXIETY, V26, P739, DOI 10.1002/da.20574; Pittman JOE, 2012, QUAL LIFE RES, V21, P99, DOI 10.1007/s11136-011-9918-3; Sayer NA, 2010, PSYCHIAT SERV, V61, P589, DOI 10.1176/ps.2010.61.6.589; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schnurr PP, 2009, CLIN PSYCHOL REV, V29, P727, DOI 10.1016/j.cpr.2009.08.006; Seal KH, 2009, AM J PUBLIC HEALTH, V99, P1651, DOI 10.2105/AJPH.2008.150284; Soberg HL, 2012, ARCH PHYS MED REHAB, V93, P765, DOI 10.1016/j.apmr.2011.08.050; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thomas JL, 2010, ARCH GEN PSYCHIAT, V67, P614, DOI 10.1001/archgenpsychiatry.2010.54; U. S. Department of Defense, 2012, DEM PROF MIL COMM; UCLA Statistical Counseling Group, 2014, US PROC MLTTEST PER; United States Department of Veterans Affairs & Department of Defense, 2009, VA DOD CLIN PRACT GU; Vanderploeg RD, 2014, J HEAD TRAUMA REHAB, V29, P1, DOI 10.1097/HTR.0b013e318281966e; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Von Korff M, 2005, PSYCHOSOM MED, V67, P233, DOI 10.1097/01.psy.0000155662.82621.50; Walker WC, 2013, J HEAD TRAUMA REHAB, V28, P68, DOI 10.1097/HTR.0b013e318255dfd0; Weathers FW, 1999, PSYCHOL ASSESSMENT, V11, P124, DOI 10.1037/1040-3590.11.2.124; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; WILLIAMS JBW, 1992, ARCH GEN PSYCHIAT, V49, P630; World Health Organization, 2004, NEWSL NONC DIS MENT; World Health Organization, 2010, MEAS HLTH DIS MAN WH	49	100	100	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-9867	1573-6598		J TRAUMA STRESS	J. Trauma Stress	FEB	2015	28	1					25	33		10.1002/jts.21979			9	Psychology, Clinical; Psychiatry	Social Science Citation Index (SSCI)	Psychology; Psychiatry	CB9XF	WOS:000349986900004	25703936	Green Accepted			2022-02-06	
J	Wang, XQ; Campos, CR; Peart, JC; Smith, LK; Boni, JL; Cannon, RE; Miller, DS				Wang, Xueqian; Campos, Christopher R.; Peart, John C.; Smith, Lindsay K.; Boni, Jessica L.; Cannon, Ronald E.; Miller, David S.			Nrf2 Upregulates ATP Binding Cassette Transporter Expression and Activity at the Blood-Brain and Blood-Spinal Cord Barriers	JOURNAL OF NEUROSCIENCE			English	Article						ABC transporters; blood-brain barrier; drug delivery; NF-kappa B; P-glycoprotein; p53	P-GLYCOPROTEIN EXPRESSION; XENOBIOTIC EFFLUX TRANSPORTERS; PLACEBO-CONTROLLED PHASE-3; MULTIPLE-SCLEROSIS; ENDOTHELIAL-CELLS; DEFENSE PATHWAY; ORAL BG-12; INJURY; ACTIVATION; MICE	Activation of nuclear factor E2-related factor-2 (Nrf2), a sensor of oxidative stress, is neuroprotective in animal models of cerebral ischemia, traumatic brain injury, subarachnoid hemorrhage, and spinal cord injury. We show here that Nrf2 activation with sulforaphane (SFN) in vivo or in vitro increases expression and transport activity of three ATP-driven drug efflux pumps at the blood-brain barrier [P-glycoprotein, ATP binding cassette b1 (Abcb1); multidrug resistance-associated protein-2 (Mrp2), Abcc2; and breast cancer resistance protein (Bcrp), Abcg2]. Dosing rats with SFN increased protein expression of all three transporters in brain capillaries and decreased by 50% brain accumulation of the P-glycoprotein substrate verapamil. Exposing rat or mouse brain capillaries to SFN increased P-glycoprotein, Bcrp, and Mrp2 transport activity and protein expression; SFN increased P-glycoprotein activity in mouse spinal cord capillaries. Inhibiting transcription or translation abolished upregulation of P-glycoprotein activity. No such effects were seen in brain capillaries from Nrf2-null mice, indicating Nrf2 dependence. Nrf2 signaled indirectly to increase transporter activity/expression. The p53 inhibitor pifithrin abolished the SFN-induced increase in transporter activity/expression, and the p53-activator nutlin-3 increased P-glycoprotein activity. SFN did not alter P-glycoprotein transport activity in brain and spinal cord capillaries from p53-null mice. Inhibitors of p38 MAPK and nuclear factor kappa B (NF-kappa B) blocked the effects of SFN and nutlin-3 on P-glycoprotein activity. These results implicate Nrf2, p53, and NF-kappa B in the upregulation of P-glycoprotein, Bcrp, and Mrp2 at blood-CNS barriers. They imply that the barriers are tightened selectively (efflux transporter upregulation) by oxidative stress, providing increased neuroprotection, but also reduced penetration of many therapeutic drugs.	[Wang, Xueqian; Campos, Christopher R.; Peart, John C.; Smith, Lindsay K.; Boni, Jessica L.; Cannon, Ronald E.; Miller, David S.] NIEHS, Lab Toxicol & Pharmacol, NIH, Res Triangle Pk, NC 27709 USA		Miller, DS (corresponding author), NIEHS, Lab Toxicol & Pharmacol, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	miller@niehs.nih.gov		Strickler, Jessica/0000-0003-1219-3682	Intramural Research Program of the National Institute of Environmental Health Sciences, National Institutes of Health; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [ZIAES080048, ZIAES080060] Funding Source: NIH RePORTER	This work was supported by the Intramural Research Program of the National Institute of Environmental Health Sciences, National Institutes of Health.	Agarwal S, 2011, CURR PHARM DESIGN, V17, P2793, DOI 10.2174/138161211797440186; Aleksunes LM, 2007, TOXICOL PATHOL, V35, P459, DOI 10.1080/01926230701311344; Aleksunes LM, 2012, DRUG METAB DISPOS, V40, P1366, DOI 10.1124/dmd.112.045112; Alfieri A, 2011, J PHYSIOL-LONDON, V589, P4125, DOI 10.1113/jphysiol.2011.210294; Bauer B, 2004, MOL PHARMACOL, V66, P413; Bauer B, 2008, J CEREBR BLOOD F MET, V28, P1222, DOI 10.1038/jcbfm.2008.16; Bauer B, 2008, MOL PHARMACOL, V73, P1444, DOI 10.1124/mol.107.041210; Bauer B, 2006, MOL PHARMACOL, V70, P1212, DOI 10.1124/mol.106.023796; Campos CR, 2012, J CEREBR BLOOD F MET, V32, P1559, DOI 10.1038/jcbfm.2012.47; Cannon RE, 2012, P NATL ACAD SCI USA, V109, P15930, DOI 10.1073/pnas.1203534109; Chen G, 2011, J NEUROSCI RES, V89, P515, DOI 10.1002/jnr.22577; Chen WM, 2012, ANTIOXID REDOX SIGN, V17, P1670, DOI 10.1089/ars.2012.4674; Cho HY, 2007, FREE RADICAL BIO MED, V42, P433, DOI 10.1016/j.freeradbiomed.2006.11.021; Copple IM, 2012, ADV PHARMACOL, V63, P43, DOI 10.1016/B978-0-12-398339-8.00002-1; Copple Ian M, 2010, Handb Exp Pharmacol, P233, DOI 10.1007/978-3-642-00663-0_9; Dash PK, 2009, NEUROSCI LETT, V460, P103, DOI 10.1016/j.neulet.2009.04.028; Felix RA, 2002, J NEUROCHEM, V80, P64, DOI 10.1046/j.0022-3042.2001.00660.x; Fox RJ, 2012, NEW ENGL J MED, V367, P1087, DOI 10.1056/NEJMoa1206328; Gold R, 2012, NEW ENGL J MED, V367, P1098, DOI 10.1056/NEJMoa1114287; Hartz AMS, 2004, MOL PHARMACOL, V66, P387, DOI 10.1124/mol.104.001503; Hawkins BT, 2010, J NEUROSCI, V30, P1417, DOI 10.1523/JNEUROSCI.5103-09.2010; Klaassen CD, 2005, CURR DRUG METAB, V6, P309, DOI 10.2174/1389200054633826; Li B, 2012, EXP DIABETES RES, DOI 10.1155/2012/216512; Linker RA, 2011, BRAIN, V134, P678, DOI 10.1093/brain/awq386; Maher JM, 2005, DRUG METAB DISPOS, V33, P956, DOI 10.1124/dmd.105.003798; Mao L, 2012, J TRAUMA ACUTE CARE, V72, P189, DOI 10.1097/TA.0b013e31821bf541; Miller DS, 2010, TRENDS PHARMACOL SCI, V31, P246, DOI 10.1016/j.tips.2010.03.003; Miller DS, 2000, MOL PHARMACOL, V58, P1357, DOI 10.1124/mol.58.6.1357; Nwaozuzu OM, 2003, J NEUROCHEM, V87, P1043, DOI 10.1046/j.1471-4159.2003.02061.x; Paine A, 2010, BIOCHEM PHARMACOL, V80, P1895, DOI 10.1016/j.bcp.2010.07.014; Rotblat B, 2012, ONCOTARGET, V3, P1272; Schneider G, 2011, BBA-REV CANCER, V1815, P90, DOI 10.1016/j.bbcan.2010.10.003; SCHRAMM U, 1995, AM J PHYSIOL-RENAL, V268, pF46, DOI 10.1152/ajprenal.1995.268.1.F46; Vurusaner B, 2012, FREE RADICAL BIO MED, V52, P7, DOI 10.1016/j.freeradbiomed.2011.09.035; Wakabayashi N, 2010, ANTIOXID REDOX SIGN, V13, P1649, DOI 10.1089/ars.2010.3216; Wang XL, 2012, J NEUROTRAUM, V29, P936, DOI 10.1089/neu.2011.1922; Wang XQ, 2013, FASEB J, V27, P1167, DOI 10.1096/fj.12-218495; Wang XQ, 2011, FASEB J, V25, P644, DOI 10.1096/fj.10-169227; Wang XQ, 2010, MOL PHARMACOL, V78, P376, DOI 10.1124/mol.110.063685; Wang Z, 2012, J PINEAL RES, V53, P129, DOI 10.1111/j.1600-079X.2012.00978.x; Yan W, 2008, NEUROSCI LETT, V431, P150, DOI 10.1016/j.neulet.2007.11.060; Zhao B, 2006, J BIOCHEM MOL TOXIC, V20, P103, DOI 10.1002/jbt.20126; Zhao J, 2006, NEUROSCI LETT, V393, P108, DOI 10.1016/j.neulet.2005.09.065	43	100	103	1	17	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JUN 18	2014	34	25					8585	8593		10.1523/JNEUROSCI.2935-13.2014			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AK5FD	WOS:000338449200019	24948812	Green Published, Bronze			2022-02-06	
J	Helmy, A; Guilfoyle, MR; Carpenter, KLH; Pickard, JD; Menon, DK; Hutchinson, PJ				Helmy, Adel; Guilfoyle, Mathew R.; Carpenter, Keri L. H.; Pickard, John D.; Menon, David K.; Hutchinson, Peter J.			Recombinant human interleukin-1 receptor antagonist in severe traumatic brain injury: a phase II randomized control trial	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						chemokines; IL1ra; microdialysis; neuroinflammation; randomized control trial; traumatic brain injury	NEUROPROTECTION; OVEREXPRESSION; NEUTRALIZATION; MICRODIALYSIS; CYTOKINES; ANAKINRA; SYSTEM; DAMAGE; EDEMA; MICE	Traumatic brain injury (TBI) is the commonest cause of death and disability in those aged under 40 years. Interleukin-1 receptor antagonist (Lira) is an endogenous competitive antagonist at the interleukin-1 type-1 receptor (IL-1R). Antagonism at the IL-1R confers neuroprotection in several rodent models of neuronal injury (i.e., trauma, stroke and excitotoxicity). We describe a single center, phase II, open label, randomized-control study of recombinant human IL1ra (rhIL1ra, anakinra) in severe TBI, at a dose of 100 mg subcutaneously once a day for 5 days in 20 patients randomized 1:1. We provide safety data (primary outcome) in this pathology, utilize cerebral microdialysis to directly determine brain extracellular concentrations of ILI ra and 41 cytokines and chemokines, and use principal component analysis (PCA) to explore the resultant cerebral cytokine profile. Interleukin-1 receptor antagonist was safe, penetrated into plasma and the brain extracellular fluid. The PCA showed a separation in cytokine profiles after IL1ra administration. A candidate cytokine from this analysis, macrophage-derived chemoattractant, was significantly lower in the rhIL1ra-treated group. Our results provide promising data for rhIL1ra as a therapeutic candidate by showing safety, brain penetration and a modification of the neuroinflammatory response to TBI by a putative neuroprotective agent in humans for the first time.	[Helmy, Adel; Guilfoyle, Mathew R.; Carpenter, Keri L. H.; Pickard, John D.; Hutchinson, Peter J.] Univ Cambridge, Div Neurosurg, Dept Clin Neurosci, Cambridge CB2 0QQ, England; [Carpenter, Keri L. H.; Pickard, John D.; Menon, David K.; Hutchinson, Peter J.] Univ Cambridge, Dept Clin Neurosci, Wolfson Brain Imaging Ctr, Cambridge, England; [Menon, David K.] Univ Cambridge, Dept Med, Div Anaesthesia, Cambridge CB2 2QQ, England		Helmy, A (corresponding author), Univ Cambridge, Div Neurosurg, Dept Clin Neurosci, Box 167,Cambridge Biomed Campus, Cambridge CB2 0QQ, England.	adelhelmy@cantab.net	Helmy, Adel/AAS-3084-2020	Helmy, Adel/0000-0002-0531-0556; Carpenter, Keri/0000-0001-8236-7727	Medical Research Council/Royal College of Surgeons of England Clinical Research Training FellowshipUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0802251]; Raymond Fellowship; Royal College of Surgeons of England Research Fellowship; National Institute for Health Research Biomedical Research Centre, CambridgeNational Institute for Health Research (NIHR); National Institute for Health Research Senior Investigator Awards; National Institute for Health Research Professorship; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986 ID 79068]; Beverly Sackler Fellowship; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0802251, G1000183B, G9439390, G0001354, G0001354B, G0600986, G1002277] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NIHR-RP-R3-12-013, NF-SI-0508-10327, NF-SI-0512-10090, ACF-2006-14-004] Funding Source: researchfish; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0600986, G1002277, G0802251, G9439390] Funding Source: UKRI	AH is supported by a joint Medical Research Council/Royal College of Surgeons of England Clinical Research Training Fellowship (G0802251). AN and MRG are supported by Raymond and Beverly Sackler Fellowships. MRG is supported by the Royal College of Surgeons of England Research Fellowship. KLHC is supported by the National Institute for Health Research Biomedical Research Centre, Cambridge (Neuroscience Theme; Brain Injury and Repair Theme). DKM and JDP are supported by National Institute for Health Research Senior Investigator Awards. PJAH is supported a National Institute for Health Research Professorship. Study support was provided by the Medical Research Council (Grant number G0600986 ID 79068) and the National Institute for Health Research Biomedical Research Centre, Cambridge. PJAH and JDP are directors of Technicam. AH and MRG have received specialist training in multivariate projection methods from CAMO Software AS (Oslo, Norway). PJAH and JDP are directors of Technicam.	BETZ AL, 1995, J CEREBR BLOOD F MET, V15, P547, DOI 10.1038/jcbfm.1995.68; British Medical Association and Royal Pharmaceutical Society of Great Britain, 2012, BRIT NATL FORMULARY, V63; Burdi DF, 2007, BIOORG MED CHEM LETT, V17, P3141, DOI 10.1016/j.bmcl.2007.03.030; Cadosch D, 2010, INJURY, V41, pE4, DOI 10.1016/j.injury.2009.09.001; Cahn A, 2013, BMC PHARMACOL TOXICO, V14, DOI 10.1186/2050-6511-14-14; Clark SR, 2008, J CEREBR BLOOD F MET, V28, P387, DOI 10.1038/sj.jcbfm.9600537; Clausen F, 2007, J NEUROTRAUM, V24, P1295, DOI 10.1089/neu.2006.0258; Clausen F, 2011, EUR J NEUROSCI, V34, P110, DOI 10.1111/j.1460-9568.2011.07723.x; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Cox AL, 2006, J NEUROIMMUNOL, V174, P180, DOI 10.1016/j.jneuroim.2006.01.007; Emsley HCA, 2005, J NEUROL NEUROSUR PS, V76, P1366, DOI 10.1136/jnnp.2004.054882; Fassbender K, 2000, NEUROSCI LETT, V284, P135, DOI 10.1016/S0304-3940(00)00977-0; Fearnside M, 2005, HEAD INJURY PATHOPHY; Galea J, 2011, J CEREBR BLOOD F MET, V31, P439, DOI 10.1038/jcbfm.2010.103; Gong HW, 2012, MOLECULES, V17, P9961, DOI 10.3390/molecules17089961; Helmy A, 2007, BRIT J ANAESTH, V99, P32, DOI 10.1093/bja/aem139; Helmy A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039677; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Helmy A, 2009, J NEUROTRAUM, V26, P549, DOI 10.1089/neu.2008.0719; Hendrix S, 2007, J NEUROIMMUNOL, V184, P100, DOI 10.1016/j.jneuroim.2006.11.019; Janowitz T, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000330; Lawrence CB, 1998, EUR J NEUROSCI, V10, P1188, DOI 10.1046/j.1460-9568.1998.00136.x; Lazovic J, 2005, STROKE, V36, P2226, DOI 10.1161/01.STR.0000182255.08162.6a; Mantovani A, 2000, J LEUKOCYTE BIOL, V68, P400; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Moher D, 2010, BMJ-BRIT MED J, V340, DOI [10.1136/bmj.c869, 10.1016/j.ijsu.2011.10.001, 10.1016/j.jclinepi.2010.03.004]; Opal SM, 1997, CRIT CARE MED, V25, P1115, DOI 10.1097/00003246-199707000-00010; Osborn O, 2011, CYTOKINE, V53, P311, DOI 10.1016/j.cyto.2010.11.017; POWER CA, 1995, J BIOL CHEM, V270, P19495, DOI 10.1074/jbc.270.33.19495; RELTON JK, 1992, BRAIN RES BULL, V29, P243, DOI 10.1016/0361-9230(92)90033-T; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Schwartz M, 2009, NEUROSCIENCE, V158, P1133, DOI 10.1016/j.neuroscience.2008.12.013; Shannon RJ, 2013, J PHARMACOKINET PHAR, V40, P343, DOI 10.1007/s10928-013-9306-4; Shore PM, 2004, J NEUROTRAUM, V21, P1113; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; Weiclenbusch M, 2012, J INNATE IMMUN, V4, P463, DOI 10.1159/000336717; Yang BB, 2003, CLIN PHARMACOL THER, V74, P85, DOI 10.1016/S0009-9236(03)00094-8	38	100	103	0	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAY	2014	34	5					845	851		10.1038/jcbfm.2014.23			7	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	AG5AE	WOS:000335430700015	24569690	Green Published, Bronze			2022-02-06	
J	Bouzat, P; Sala, N; Suys, T; Zerlauth, JB; Marques-Vidal, P; Feihl, F; Bloch, J; Messerer, M; Levivier, M; Meuli, R; Magistretti, PJ; Oddo, M				Bouzat, Pierre; Sala, Nathalie; Suys, Tamarah; Zerlauth, Jean-Baptiste; Marques-Vidal, Pedro; Feihl, Francois; Bloch, Jocelyne; Messerer, Mahmoud; Levivier, Marc; Meuli, Reto; Magistretti, Pierre J.; Oddo, Mauro			Cerebral metabolic effects of exogenous lactate supplementation on the injured human brain	INTENSIVE CARE MEDICINE			English	Article						Brain metabolism; Lactate; Cerebral microdialysis; Traumatic brain injury; Hypertonic	INTRACRANIAL HYPERTENSIVE EPISODES; GLUCOSE-METABOLISM; COMBINED MICRODIALYSIS; AEROBIC GLYCOLYSIS; ENERGY-METABOLISM; SODIUM LACTATE; HEAD-INJURY; FDG-PET; GLUTAMATE; INCREASE	Experimental evidence suggests that lactate is neuroprotective after acute brain injury; however, data in humans are lacking. We examined whether exogenous lactate supplementation improves cerebral energy metabolism in humans with traumatic brain injury (TBI). We prospectively studied 15 consecutive patients with severe TBI monitored with cerebral microdialysis (CMD), brain tissue PO2 (PbtO(2)), and intracranial pressure (ICP). Intervention consisted of a 3-h intravenous infusion of hypertonic sodium lactate (aiming to increase systemic lactate to ca. 5 mmol/L), administered in the early phase following TBI. We examined the effect of sodium lactate on neurochemistry (CMD lactate, pyruvate, glucose, and glutamate), PbtO(2), and ICP. Treatment was started on average 33 +/- A 16 h after TBI. A mixed-effects multilevel regression model revealed that sodium lactate therapy was associated with a significant increase in CMD concentrations of lactate [coefficient 0.47 mmol/L, 95 % confidence interval (CI) 0.31-0.63 mmol/L], pyruvate [13.1 (8.78-17.4) mu mol/L], and glucose [0.1 (0.04-0.16) mmol/L; all p < 0.01]. A concomitant reduction of CMD glutamate [-0.95 (-1.94 to 0.06) mmol/L, p = 0.06] and ICP [-0.86 (-1.47 to -0.24) mmHg, p < 0.01] was also observed. Exogenous supplemental lactate can be utilized aerobically as a preferential energy substrate by the injured human brain, with sparing of cerebral glucose. Increased availability of cerebral extracellular pyruvate and glucose, coupled with a reduction of brain glutamate and ICP, suggests that hypertonic lactate therapy has beneficial cerebral metabolic and hemodynamic effects after TBI.	[Bouzat, Pierre; Sala, Nathalie; Suys, Tamarah; Oddo, Mauro] Univ Lausanne Hosp, Fac Biol & Med, Dept Intens Care Med, Neurosci Crit Care Res Grp, CH-1011 Lausanne, Switzerland; [Bouzat, Pierre] Univ Grenoble 1, Grenoble, France; [Zerlauth, Jean-Baptiste; Meuli, Reto] Univ Lausanne Hosp, Fac Biol & Med, Dept Radiol, CH-1011 Lausanne, Switzerland; [Marques-Vidal, Pedro] Univ Lausanne Hosp, Fac Biol & Med, Inst Social & Prevent Med, CH-1011 Lausanne, Switzerland; [Feihl, Francois] Univ Lausanne Hosp, Fac Biol & Med, Dept Internal Med, Div Clin Pathophysiol, CH-1011 Lausanne, Switzerland; [Bloch, Jocelyne; Messerer, Mahmoud; Levivier, Marc] Univ Lausanne Hosp, Fac Biol & Med, Dept Clin Neurosci, Div Neurosurg, CH-1011 Lausanne, Switzerland; [Magistretti, Pierre J.] Univ Lausanne Hosp, Fac Biol & Med, Ctr Neurosci Psychiat,Lab Neuroenerget & Cellular, Ecole Polytech Fed Lausanne,Brain Mind Inst, CH-1011 Lausanne, Switzerland		Oddo, M (corresponding author), Univ Lausanne Hosp, Fac Biol & Med, Dept Intens Care Med, Neurosci Crit Care Res Grp, Rue Bugnon 46, CH-1011 Lausanne, Switzerland.	PBouzat@chu-grenoble.fr; mauro.oddo@chuv.ch	Marques-Vidal, Pedro M/C-9449-2009; Bloch, Jocelyne/A-9668-2017; Bouzat, Pierre/AAC-4105-2019; Bouzat, Pierre/L-6881-2014; Oddo, Mauro/R-3370-2016; Messerer, Mahmoud/AAZ-3527-2020	Marques-Vidal, Pedro M/0000-0002-4548-8500; Bloch, Jocelyne/0000-0002-6405-1590; Bouzat, Pierre/0000-0003-4667-6738; Oddo, Mauro/0000-0002-6155-2525; Magistretti, Pierre Julius/0000-0002-6678-320X; Levivier, Marc/0000-0002-6273-2595	Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission [320030_138191]; European Critical Care Research Network; European Society of Intensive Care Medicine; Gueules Cassees Foundation	The authors thank Beatrice Pellet, from the Division of Pharmacy, for the preparation of sodium lactate, as well as all neurosurgical fellows, ICU physicians, and ICU nurses for their help and support. This work was supported by grants from the Swiss National Science Foundation (Grant Nr. 320030_138191, to M.O.), the European Critical Care Research Network, European Society of Intensive Care Medicine (to M.O.), and the Gueules Cassees Foundation (to P.B.). This work received the best abstract award at the European Society of Intensive Care Medicine congress in Paris, 2013.	Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bergsneider M, 2001, J HEAD TRAUMA REHAB, V16, P135, DOI 10.1097/00001199-200104000-00004; Boumezbeur F, 2010, J NEUROSCI, V30, P13983, DOI 10.1523/JNEUROSCI.2040-10.2010; Bouzier-Sore AK, 2003, J CEREBR BLOOD F MET, V23, P1298, DOI 10.1097/01.WCB.0000091761.61714.25; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS55; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Chen T, 2000, BRAIN RES, V861, P281, DOI 10.1016/S0006-8993(00)01992-2; Dienel GA, 2012, J CEREBR BLOOD F MET, V32, P1107, DOI 10.1038/jcbfm.2011.175; Gallagher CN, 2009, BRAIN, V132, P2839, DOI 10.1093/brain/awp202; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; Gordon GRJ, 2008, NATURE, V456, P745, DOI 10.1038/nature07525; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hutchinson P, 2009, ACTA NEUROCHIR, V151, P51, DOI 10.1007/s00701-008-0169-1; Ichai C, 2013, INTENS CARE MED, V39, P1413, DOI 10.1007/s00134-013-2978-9; Ichai C, 2009, INTENS CARE MED, V35, P471, DOI 10.1007/s00134-008-1283-5; Jalloh I, 2013, J NEUROTRAUM, V30, P2031, DOI 10.1089/neu.2013.2947; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; MAGISTRETTI PJ, 2008, FUNDAMENTAL NEUROSCI, P271; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; McKenna MC, 2007, J NEUROSCI RES, V85, P3347, DOI 10.1002/jnr.21444; Oddo M, 2012, STROKE, V43, P1418, DOI 10.1161/STROKEAHA.111.648568; Oddo M, 2008, CRIT CARE MED, V36, P3233, DOI 10.1097/CCM.0b013e31818f4026; Pellerin L, 1998, DEV NEUROSCI-BASEL, V20, P291, DOI 10.1159/000017324; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; Pellerin L, 2012, J CEREBR BLOOD F MET, V32, P1152, DOI 10.1038/jcbfm.2011.149; Revelly JP, 2005, CRIT CARE MED, V33, P2235, DOI 10.1097/01.CCM.0000181525.99295.8F; Rice AC, 2002, BRAIN RES, V928, P156, DOI 10.1016/S0006-8993(01)03299-1; Roquilly A, 2013, CRIT CARE, V17, DOI 10.1186/cc12686; Sala N, 2013, J CEREBR BLOOD F MET, V33, P1815, DOI 10.1038/jcbfm.2013.142; Schurr A, 2007, NEUROSCIENCE, V147, P613, DOI 10.1016/j.neuroscience.2007.05.002; Schurr A, 1999, J NEUROSCI, V19, P34, DOI 10.1523/JNEUROSCI.19-01-00034.1999; SCHURR A, 1988, SCIENCE, V240, P1326, DOI 10.1126/science.3375817; Simpson IA, 2007, J CEREBR BLOOD F MET, V27, P1766, DOI 10.1038/sj.jcbfm.9600521; Smith D, 2003, J CEREBR BLOOD F MET, V23, P658, DOI 10.1097/01.WCB.0000063991.19746.11; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF	36	100	102	0	12	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	MAR	2014	40	3					412	421		10.1007/s00134-013-3203-6			10	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AC3YL	WOS:000332457400012	24477453	Green Submitted			2022-02-06	
J	Hong, YT; Veenith, T; Dewar, D; Outtrim, JG; Mani, V; Williams, C; Pimlott, S; Hutchinson, PJA; Tavares, A; Canales, R; Mathis, CA; Klunk, WE; Aigbirhio, FI; Coles, JP; Baron, JC; Pickard, JD; Fryer, TD; Stewart, W; Menon, DK				Hong, Young T.; Veenith, Tonny; Dewar, Deborah; Outtrim, Joanne G.; Mani, Vaithianadan; Williams, Claire; Pimlott, Sally; Hutchinson, Peter J. A.; Tavares, Adriana; Canales, Roberto; Mathis, Chester A.; Klunk, William E.; Aigbirhio, Franklin I.; Coles, Jonathan P.; Baron, Jean-Claude; Pickard, John D.; Fryer, Tim D.; Stewart, William; Menon, David K.			Amyloid Imaging With Carbon 11-Labeled Pittsburgh Compound B for Traumatic Brain Injury	JAMA NEUROLOGY			English	Article							HEAD-INJURY; PROTEIN DEPOSITION; ALZHEIMERS-DISEASE; TERM SURVIVORS; BETA; ACCUMULATION; PATHOLOGY; PLAQUES; AXONS; PRESENILIN-1	OBJECTIVES To image amyloid deposition in patients with traumatic brain injury (TBI) using carbon 11-labeled Pittsburgh Compound B ([C-11] PiB) positron emission tomography (PET) and to validate these findings using tritium-labeled PiB ([H-3] PiB) autoradiography and immunocytochemistry in autopsy-acquired tissue. DESIGN, SETTING, AND PARTICIPANTS In vivo PET at tertiary neuroscience referral center and ex vivo immunocytochemistry of autopsy-acquired brain tissue from a neuropathology archive. [C-11] PiB PET was used to image amyloid deposition in 11 controls (median [range] age, 35 [24-60] years) and in 15 patients (median [range] age, 33 [21-50] years) between 1 and 361 days after a TBI. [H-3] PiB autoradiography and immunocytochemistry for beta-amyloid (A beta) and beta-amyloid precursor protein in brain tissue were obtained from separate cohorts of 16 patients (median [range] age, 46 [21-70] years) who died between 3 hours and 56 days after a TBI and 7 controls (median [range] age, 61 [29-71] years) who died of other causes. MAIN OUTCOMES AND MEASURES We quantified the [C-11] PiB distribution volume ratio and standardized uptake value ratio in PET images. The distribution volume ratio and the standardized uptake value ratio were measured in cortical gray matter, white matter, and multiple cortical and white matter regions of interest, as well as in striatal and thalamic regions of interest. We examined [H-3] PiB binding and A beta and beta-amyloid precursor protein immunocytochemistry in autopsy-acquired brain tissue. RESULTS Compared with the controls, the patients with TBI showed significantly increased [C-11] PiB distribution volume ratios in cortical gray matter and the striatum (corrected P <.05 for both), but not in the thalamus or white matter. Increases in [C-11] PiB distribution volume ratios in patients with TBI were seen across most cortical subregions, were replicated using comparisons of standardized uptake value ratios, and could not be accounted for by methodological confounders. Autoradiography revealed [H-3] PiB binding in neocortical gray matter, in regions where amyloid deposition was demonstrated by immunocytochemistry; white matter showed A beta and beta-amyloid precursor protein by immunocytochemistry, but no [H-3] PiB binding. No plaque-associated amyloid immunoreactivity or [H-3] PiB binding was seen in cerebellar gray matter in autopsy-acquired tissue from either controls or patients with TBI, although 1 sample of cerebellar tissue from a patient with TBI showed amyloid angiopathy in meningeal vessels. CONCLUSIONS AND RELEVANCE [C-11] PiB shows increased binding following TBI. The specificity of this binding is supported by neocortical [H-3] PiB binding in regions of amyloid deposition in the postmortem tissue of patients with TBI. [C-11] PiB PET could be valuable in imaging amyloid deposition following TBI.	[Hong, Young T.; Canales, Roberto; Aigbirhio, Franklin I.; Baron, Jean-Claude; Pickard, John D.; Fryer, Tim D.; Menon, David K.] Univ Cambridge, Wolfson Brain Imaging Ctr, Cambridge CB2 2QQ, England; [Veenith, Tonny; Outtrim, Joanne G.; Mani, Vaithianadan; Williams, Claire; Coles, Jonathan P.; Menon, David K.] Univ Cambridge, Div Anaesthesia, Addenbrookes Hosp, Cambridge CB2 2QQ, England; [Dewar, Deborah; Tavares, Adriana] Univ Glasgow, Inst Neurosci & Psychol, Glasgow G12 8QQ, Lanark, Scotland; [Pimlott, Sally; Stewart, William] Univ Glasgow, Glasgow, Lanark, Scotland; [Pimlott, Sally; Stewart, William] So Gen Hosp, Glasgow G51 4TF, Lanark, Scotland; [Hong, Young T.; Hutchinson, Peter J. A.; Canales, Roberto; Aigbirhio, Franklin I.; Baron, Jean-Claude; Pickard, John D.; Fryer, Tim D.] Univ Cambridge, Dept Clin Neurosci, Cambridge, England; [Mathis, Chester A.] Univ Pittsburgh, Dept Radiol, Pittsburgh, PA 15260 USA; [Mathis, Chester A.] Univ Pittsburgh, Dept Pharmaceut Sci, Pittsburgh, PA USA; [Klunk, William E.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA; [Klunk, William E.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA; [Baron, Jean-Claude] Univ Paris 05, INSERM, U894, Sorbonne Paris Cite, Paris, France		Menon, DK (corresponding author), Univ Cambridge, Div Anaesthesia, Addenbrookes Hosp, Box 93, Cambridge CB2 2QQ, England.	dkm13@wbic.cam.ac.uk	Veenith, Tonny/AAI-3067-2020; Pimlott, Sally L/F-8098-2010; Veenith, Tonny V/A-9948-2010	Veenith, Tonny/0000-0002-4125-8804; Pimlott, Sally L/0000-0002-8396-3392; Veenith, Tonny V/0000-0002-4125-8804; Coles, Jonathan/0000-0003-4013-679X; Tavares, Adriana/0000-0001-7505-9144; baron, jean-claude/0000-0002-5264-2588; Stewart, William/0000-0003-2199-2582; Outtrim, Joanne/0000-0001-8118-6430; Klunk, William/0000-0001-5512-0251	National Institute for Health Research Cambridge Biomedical Research CentreNational Institute for Health Research (NIHR); Medical Research Council (United Kingdom)UK Research & Innovation (UKRI)Medical Research Council UK (MRC) [RG46503]; Academy of Medical SciencesAcademy of Medical Sciences (AMS);  [P50 AG005133];  [R37 AG025516];  [P01 AG025204]; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0900903, G0600986, G9439390, G1002277] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986, G0900903, G1002277, G0001354B, G1000183B, G0001354, G9439390] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10090, NF-SI-0508-10327, NIHR-RP-R3-12-013] Funding Source: researchfish; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG025204, P50AG005133, RF1AG025516, R37AG025516] Funding Source: NIH RePORTER	This study was supported by the Neuroscience Theme of the National Institute for Health Research Cambridge Biomedical Research Centre. Drs Menon and Pickard are supported by National Institute for Health Research Senior Investigator awards. Dr Hutchinson is supported by funding from the Academy of Medical Sciences. Radiochemistry development of [<SUP>11</SUP>C] PiB was supported by grant RG46503 from the Medical Research Council (United Kingdom). Data collection in controls was undertaken by funding awarded to Dr Baron by the National Institute for Health Research Cambridge Biomedical Research Centre. Dr Klunk is supported by the following grants: P50 AG005133, R37 AG025516, P01 AG025204.	Cairns NJ, 2009, ARCH NEUROL-CHICAGO, V66, P1557, DOI 10.1001/archneurol.2009.279; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; DeKosky ST, 2007, ARCH NEUROL-CHICAGO, V64, P541, DOI 10.1001/archneur.64.4.541; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Devanand DP, 2010, J GERIATR PSYCH NEUR, V23, P185, DOI 10.1177/0891988710363715; Dewar D, 1996, J NEUROTRAUM, V13, P181, DOI 10.1089/neu.1996.13.181; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Fodero-Tavoletti MT, 2009, J NUCL MED, V50, P198, DOI 10.2967/jnumed.108.057984; Gentleman SM, 1997, NEUROREPORT, V8, P1519, DOI 10.1097/00001756-199704140-00039; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; Herholz K, 2011, LANCET NEUROL, V10, P667, DOI 10.1016/S1474-4422(11)70123-5; Horsburgh K, 2000, NEUROPATH APPL NEURO, V26, P124, DOI 10.1046/j.1365-2990.2000.026002124.x; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Ikonomovic MD, 2012, ACTA NEUROPATHOL, V123, P433, DOI 10.1007/s00401-012-0943-2; Innis RB, 2007, J CEREBR BLOOD F MET, V27, P1533, DOI 10.1038/sj.jcbfm.9600493; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Klunk WE, 2004, ANN NEUROL, V55, P306, DOI 10.1002/ana.20009; Klunk WE, 2007, J NEUROSCI, V27, P6174, DOI 10.1523/JNEUROSCI.0730-07.2007; Landt J, 2011, ARCH NEUROL-CHICAGO, V68, P890, DOI 10.1001/archneurol.2011.36; Logan J, 1996, J CEREBR BLOOD F MET, V16, P834, DOI 10.1097/00004647-199609000-00008; LUCY LB, 1974, ASTRON J, V79, P745, DOI 10.1086/111605; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Mintun MA, 2006, NEUROLOGY, V67, P446, DOI 10.1212/01.wnl.0000228230.26044.a4; Morris JC, 2010, ANN NEUROL, V67, P122, DOI 10.1002/ana.21843; RICHARDSON WH, 1972, J OPT SOC AM, V62, P55, DOI 10.1364/JOSA.62.000055; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Rosen RF, 2010, ACTA NEUROPATHOL, V119, P221, DOI 10.1007/s00401-009-0583-3; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; Stankoff B, 2011, ANN NEUROL, V69, P673, DOI 10.1002/ana.22320; Villemagne VL, 2009, ARCH NEUROL-CHICAGO, V66, P1537, DOI 10.1001/archneurol.2009.285; Whitaker Chastity, 2003, J Alzheimers Dis, V5, P491; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Younkin S G, 1997, Rinsho Shinkeigaku, V37, P1099; Zhou WD, 2008, J NEUROTRAUM, V25, P279, DOI 10.1089/neu.2007.0489	37	100	102	0	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6149	2168-6157		JAMA NEUROL	JAMA Neurol.	JAN	2014	71	1					23	31		10.1001/jamaneurol.2013.4847			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	301YH	WOS:000330567700005	24217171	Green Submitted, Bronze, Green Accepted			2022-02-06	
J	Guan, J; Zhu, ZH; Zhao, RC; Xiao, ZF; Wu, CX; Han, Q; Chen, L; Tong, WM; Zhang, J; Han, QQ; Gao, J; Feng, M; Bao, XJ; Dai, JW; Wang, RZ				Guan, Jian; Zhu, Zhaohui; Zhao, Robert Chunhua; Xiao, Zhifeng; Wu, Chenxi; Han, Qin; Chen, Lei; Tong, Weimin; Zhang, Jin; Han, Qianqian; Gao, Jun; Feng, Ming; Bao, Xinjie; Dai, Jianwu; Wang, Renzhi			Transplantation of human mesenchymal stem cells loaded on collagen scaffolds for the treatment of traumatic brain injury in rats	BIOMATERIALS			English	Article						Brain trauma; Nuclear imaging; Stem cells; Biomaterials; Differentiation	MARROW STROMAL CELLS; CEREBRAL-ISCHEMIA; PRIMATE MODEL; DIFFERENTIATION; RECOVERY; DISEASE; BIODISTRIBUTION; PHARMACOLOGY; STRATEGIES; APOPTOSIS	Studies have suggested that mesenchymal stem cells (MSCs) have therapeutic effects following traumatic brain injury (TBI). However, cell distribution and survival rate are two major barriers to their success as therapeutic treatment. The improvement of cell therapy using collagen delivery matrices had been reported. However, we know very little about the mechanisms. We labeled human bone marrow-derived mesenchymal stem cells (hMSCs) with a positron emission tomography (PET) tracer, 18F-fluoro-2-deoxy-n-glucose (FDG). hMSCs were transplanted with or without collagen scaffolds into rats with experimental TBI and the whole-body nuclear images were compared. Collagen scaffolds increased the retention of hBMSC in the lesion site and limited its distribution at the transplanted region. Significantly more hMSCs were detected in the brain when transplanted with collagen scaffolds. The results showed collagen scaffolds also efficiently improved cell survival and neurite outgrowth in vivo, resulting in better neural functional recovery. In addition, brain metabolism also improved in the collagen scaffold implanted group, as evaluated by PET. We speculated that collagen scaffolds would improve early engraftment and support the survival of grafted cells post-transplantation. (C) 2013 Elsevier Ltd. All rights reserved.	[Guan, Jian; Gao, Jun; Feng, Ming; Bao, Xinjie; Wang, Renzhi] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Neurosurg, Beijing 100730, Peoples R China; [Guan, Jian; Zhu, Zhaohui; Zhao, Robert Chunhua; Wu, Chenxi; Han, Qin; Tong, Weimin; Gao, Jun; Feng, Ming; Bao, Xinjie; Wang, Renzhi] Peking Union Med Coll, Beijing 100730, Peoples R China; [Xiao, Zhifeng; Chen, Lei; Dai, Jianwu] Chinese Acad Sci, Inst Genet & Dev Biol, Key Lab Mol Dev Biol, Beijing 100080, Peoples R China; [Zhu, Zhaohui; Wu, Chenxi] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Nucl Med, Beijing 100730, Peoples R China; [Zhao, Robert Chunhua; Han, Qin] Chinese Acad Med Sci, Inst Basic Med Sci, Ctr Excellence Tissue Engn, Beijing 100730, Peoples R China; [Zhang, Jin] Dalian Med Univ Hosp, Dept Neurosurg, Dalian 116044, Peoples R China; [Han, Qianqian] Natl Inst Food & Drug Control, Dept Med Devices Testing, Beijing 100050, Peoples R China; [Tong, Weimin] Chinese Acad Med Sci, Dept Pathol, Inst Basic Med Sci, Beijing 100730, Peoples R China; [Tong, Weimin] Chinese Acad Med Sci, Ctr Expt Anim Res, Inst Basic Med Sci, Beijing 100730, Peoples R China		Wang, RZ (corresponding author), Beijing Union Med Coll Hosp, Dept Neurosurg, Beijing 100005, Peoples R China.	jwdai@genetics.ac.cn; wangrz@126.com			National High Technology Research and Development Program ("863" Program) of ChinaNational High Technology Research and Development Program of China [2012AA020501, 2011AA020112]; Ministry of Science and Technology of ChinaMinistry of Science and Technology, China [2011CB965001]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30930032, 81200916, 81171370, 81100869]	This work was supported by National High Technology Research and Development Program ("863" Program) of China (2012AA020501 and 2011AA020112), the Ministry of Science and Technology of China (2011CB965001) and National Natural Science Foundation of China (30930032, 81200916, 81171370 and 81100869).	Bao XJ, 2011, EUR J NEUROSCI, V34, P87, DOI 10.1111/j.1460-9568.2011.07733.x; Bao XJ, 2011, BRAIN RES, V1367, P103, DOI 10.1016/j.brainres.2010.10.063; Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3; Chen RY, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-13; Chen XG, 2002, NEUROPATHOLOGY, V22, P275, DOI 10.1046/j.1440-1789.2002.00450.x; Day LB, 1996, BEHAV NEUROSCI, V110, P998; Detante O, 2009, CELL TRANSPLANT, V18, P1369, DOI 10.3727/096368909X474230; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Doi D, 2012, STEM CELLS, V30, P935, DOI 10.1002/stem.1060; Elhami E, 2011, EUR J NUCL MED MOL I, V38, P1323, DOI 10.1007/s00259-011-1753-9; Feng M, 2011, J NUCL MED, V52, P90, DOI 10.2967/jnumed.110.080325; Galindo LT, 2011, NEUROL RES INT, V2011, DOI 10.1155/2011/564089; Guan J, 2012, BIOMATERIALS, V33, P1386, DOI 10.1016/j.biomaterials.2011.10.073; Han Q, 2007, LEUKEMIA RES, V31, P1469, DOI 10.1016/j.leukres.2006.12.016; Henriksson HB, 2009, SPINE, V34, P141, DOI 10.1097/BRS.0b013e31818f8c20; Jiang Q, 2011, NMR BIOMED, V24, P1119, DOI 10.1002/nbm.1667; Kim HJ, 2010, J NEUROTRAUM, V27, P131, DOI [10.1089/neu.2008.0818, 10.1089/neu.2008-0818]; Kolacna L, 2007, PHYSIOL RES, V56, pS51, DOI 10.33549/physiolres.931302; Maegele M, 2008, MINIM INVASIV THER, V17, P119, DOI 10.1080/13645700801970087; Mahmood A, 2006, J NEUROSURG, V104, P272, DOI 10.3171/jns.2006.104.2.272; McConeghy KW, 2012, CNS DRUGS, V26, P613, DOI 10.2165/11634020-000000000-00000; Otto WR, 2011, FIBROGENESIS TISSUE, V4, DOI 10.1186/1755-1536-4-20; Pendharkar AV, 2010, STROKE, V41, P2064, DOI 10.1161/STROKEAHA.109.575993; Qu CS, 2011, BRAIN RES, V1371, P129, DOI 10.1016/j.brainres.2010.10.088; Royo NC, 2003, CURR OPIN PHARMACOL, V3, P27, DOI 10.1016/S1471-4892(02)00006-1; Savani BN, 2005, BIOL BLOOD MARROW TR, V11, P223, DOI 10.1016/j.bbmt.2004.12.328; Shen LH, 2007, STROKE, V38, P2150, DOI 10.1161/STROKEAHA.106.481218; Shi CY, 2011, BIOMATERIALS, V32, P2508, DOI 10.1016/j.biomaterials.2010.12.026; Soler R, 2012, J UROLOGY, V187, P1491, DOI 10.1016/j.juro.2011.11.079; Suuronen EJ, 2006, CIRCULATION, V114, pI138, DOI 10.1161/CIRCULATIONAHA.105.001081; Uemura M, 2010, J NEUROSCI RES, V88, P542, DOI 10.1002/jnr.22223; Wang B, 2007, NEUROSCI LETT, V421, P191, DOI 10.1016/j.neulet.2007.04.081; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; Xiong Y, 2009, BRAIN RES, V1263, P183, DOI 10.1016/j.brainres.2009.01.032; Zhang J, 2005, EXP NEUROL, V195, P16, DOI 10.1016/j.expneurol.2005.03.018; Zhang Y, 2008, CIRC-CARDIOVASC IMAG, V1, P197, DOI 10.1161/CIRCIMAGING.108.781120; Zhao YN, 2009, TISSUE ENG PT A, V15, P13, DOI 10.1089/ten.tea.2008.0039; Zhou H, 2010, BIOL BLOOD MARROW TR, V16, P403, DOI 10.1016/j.bbmt.2009.11.006	38	100	109	6	70	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0142-9612			BIOMATERIALS	Biomaterials	AUG	2013	34	24					5937	5946		10.1016/j.biomaterials.2013.04.047			10	Engineering, Biomedical; Materials Science, Biomaterials	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Materials Science	164SS	WOS:000320430400007	23664090				2022-02-06	
J	Feng, JF; Liu, J; Zhang, XZ; Zhang, L; Jiang, JY; Nolta, J; Zhao, M				Feng, Jun-Feng; Liu, Jing; Zhang, Xiu-Zhen; Zhang, Lei; Jiang, Ji-Yao; Nolta, Jan; Zhao, Min			Guided Migration of Neural Stem Cells Derived from Human Embryonic Stem Cells by an Electric Field	STEM CELLS			English	Article						Human neural stem cells; Directional cell migration; Electric field; Electrotaxis; Rho-kinase; C-X-C chemokine receptor type 4	FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; IN-VITRO; PROGENITOR CELLS; HIPPOCAMPAL-NEURONS; DIRECTED MIGRATION; PRECURSOR CELLS; SPINAL-CORD; RAT MODEL; TRANSPLANTATION	Small direct current (DC) electric fields (EFs) guide neurite growth and migration of rodent neural stem cells (NSCs). However, this could be species dependent. Therefore, it is critical to investigate how human NSCs (hNSCs) respond to EF before any possible clinical attempt. Aiming to characterize the EF-stimulated and guided migration of hNSCs, we derived hNSCs from a well-established human embryonic stem cell line H9. Small applied DC EFs, as low as 16 mV/mm, induced significant directional migration toward the cathode. Reversal of the field polarity reversed migration of hNSCs. The galvanotactic/electrotactic response was both time and voltage dependent. The migration directedness and distance to the cathode increased with the increase of field strength. (Rho-kinase) inhibitor Y27632 is used to enhance viability of stem cells and has previously been reported to inhibit EF-guided directional migration in induced pluripotent stem cells and neurons. However, its presence did not significantly affect the directionality of hNSC migration in an EF. Cytokine receptor [C-X-C chemokine receptor type 4 (CXCR4)] is important for chemotaxis of NSCs in the brain. The blockage of CXCR4 did not affect the electrotaxis of hNSCs. We conclude that hNSCs respond to a small EF by directional migration. Applied EFs could potentially be further exploited to guide hNSCs to injured sites in the central nervous system to improve the outcome of various diseases. STEM CELLS 2012; 30:349355.	[Feng, Jun-Feng; Liu, Jing; Zhang, Xiu-Zhen; Zhang, Lei; Nolta, Jan; Zhao, Min] Univ Calif Davis, Inst Regenerat Cures, Sch Med, Sacramento, CA 95817 USA; [Feng, Jun-Feng; Zhang, Xiu-Zhen; Zhang, Lei; Zhao, Min] Univ Calif Davis, Sch Med, Dept Dermatol, Sacramento, CA 95817 USA; [Liu, Jing; Nolta, Jan] Univ Calif Davis, Sch Med, Dept Internal Med, Stem Cells Program, Sacramento, CA 95817 USA; [Zhao, Min] Univ Calif Davis, Sch Med, Dept Ophthalmol, Sacramento, CA 95817 USA; [Feng, Jun-Feng; Jiang, Ji-Yao] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Neurosurg, Shanghai 200030, Peoples R China		Zhao, M (corresponding author), Univ Calif Davis, Inst Regenerat Cures, Sch Med, 2921 Stockton Blvd, Sacramento, CA 95817 USA.	minzhao@ucdavis.edu		Nolta, Jan/0000-0003-4576-8542	California Institute of Regenerative MedicineCalifornia Institute for Regenerative Medicine [RB1-01417, TR1-01257]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01EY019101, 5P30AG010129, 5RC1AG036022-02, 2P51RR000169-49]; NSFNational Science Foundation (NSF) [MCB-0951199]; UC Davis; Research to Prevent Blindness, Inc.Research to Prevent Blindness (RPB); NSFCNational Natural Science Foundation of China (NSFC) [30901543]; Shriners of Northern California; CIRMCalifornia Institute for Regenerative Medicine; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P51RR000169] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY019101] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG010129, RC1AG036022] Funding Source: NIH RePORTER	We thank Dr. Lin Cao and other members from the Zhao and Nolta laboratories for assistance. This work was supported by grants from the California Institute of Regenerative Medicine RB1-01417 (to M.Z.) and TR1-01257 (to J.N.). M.Z. is also supported by NIH 1R01EY019101, NSF MCB-0951199, and UC Davis Dermatology Developmental Fund, and in part by the Research to Prevent Blindness, Inc. J.N. is also supported by the NIH (5P30AG010129, 5RC1AG036022-02, and 2P51RR000169-49). J.F.F. is supported by NSFC (30901543). J.L. is supported by a fellowship from the Shriners of Northern California.; M.Z. has research funding/contracted research with CIRM.	Aguirre A, 2005, J NEUROSCI, V25, P11092, DOI 10.1523/JNEUROSCI.2981-05.2005; Arocena M, 2010, J NEUROSCI RES, V88, P3267, DOI 10.1002/jnr.22502; CASSEL JC, 1993, NEUROSCI LETT, V150, P89, DOI 10.1016/0304-3940(93)90115-2; Chang TC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009187; Cheng ZK, 2008, MOL THER, V16, P571, DOI 10.1038/sj.mt.6300374; CORK RJ, 1994, J NEUROBIOL, V25, P1509, DOI 10.1002/neu.480251204; Cormie P, 2007, NEUROSCI LETT, V411, P128, DOI 10.1016/j.neulet.2006.10.030; Cummings BJ, 2006, NEUROL RES, V28, P474, DOI 10.1179/016164106X115116; Darsalia V, 2011, J CEREBR BLOOD F MET, V31, P235, DOI 10.1038/jcbfm.2010.81; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; Gao JL, 2006, EXP NEUROL, V201, P281, DOI 10.1016/j.expneurol.2006.04.039; Hartman NW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015856; Hatami M, 2009, CYTOTHERAPY, V11, P618, DOI 10.1080/14653240903005802; Heng BC, 2009, TISSUE CELL, V41, P376, DOI 10.1016/j.tice.2009.01.004; HINKLE L, 1981, J PHYSIOL-LONDON, V314, P121, DOI 10.1113/jphysiol.1981.sp013695; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Jin KL, 2010, AGING CELL, V9, P1076, DOI 10.1111/j.1474-9726.2010.00638.x; Jin KL, 2010, J CEREBR BLOOD F MET, V30, P534, DOI 10.1038/jcbfm.2009.219; Joo KM, 2009, MOL THER, V17, P570, DOI 10.1038/mt.2008.290; Karp JM, 2009, CELL STEM CELL, V4, P206, DOI 10.1016/j.stem.2009.02.001; Kelly S, 2004, P NATL ACAD SCI USA, V101, P11839, DOI 10.1073/pnas.0404474101; Khaidoyanidi S, 2008, CELL STEM CELL, V2, P198, DOI 10.1016/j.stem.2008.02.012; Kim SK, 2006, CLIN CANCER RES, V12, P5550, DOI 10.1158/1078-0432.CCR-05-2508; Koyanagi M, 2008, J NEUROSCI RES, V86, P270, DOI 10.1002/jnr.21502; Lee SH, 2009, NEUROL RES, V31, P996, DOI 10.1179/174313209X385626; Li L, 2008, STEM CELLS, V26, P2193, DOI 10.1634/stemcells.2007-1022; Li QA, 2011, J SURG RES, V166, P162, DOI 10.1016/j.jss.2009.08.031; Li XY, 2008, STEM CELLS DEV, V17, P1079, DOI 10.1089/scd.2007.0247; Lindvall O, 2004, NAT MED, V10, pS42, DOI 10.1038/nm1064; McCaig CD, 2005, PHYSIOL REV, V85, P943, DOI 10.1152/physrev.00020.2004; Meng XT, 2011, EXP NEUROL, V227, P210, DOI 10.1016/j.expneurol.2010.11.002; Miller RJ, 2008, J NEUROIMMUNOL, V198, P31, DOI 10.1016/j.jneuroim.2008.04.008; Parent JM, 2002, ANN NEUROL, V52, P802, DOI 10.1002/ana.10393; PATEL N, 1982, J NEUROSCI, V2, P483; Rajasekharan S, 2010, J NEUROCHEM, V113, P1589, DOI 10.1111/j.1471-4159.2010.06717.x; RAJNICEK AM, 1992, EXP PHYSIOL, V77, P229, DOI 10.1113/expphysiol.1992.sp003580; Rajnicek AM, 2006, J CELL SCI, V119, P1723, DOI 10.1242/jcs.02896; Redmond DE, 2007, P NATL ACAD SCI USA, V104, P12175, DOI 10.1073/pnas.0704091104; Robin AM, 2006, J CEREBR BLOOD F MET, V26, P125, DOI 10.1038/sj.jcbfm.9600172; Robinson KR, 2008, DEV NEUROBIOL, V68, P274, DOI 10.1002/dneu.20570; Salazar DL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012272; Shih CC, 2007, STEM CELLS DEV, V16, P893, DOI 10.1089/scd.2007.0070; Song B, 2007, NAT PROTOC, V2, P1479, DOI 10.1038/nprot.2007.205; Srivastava AS, 2006, STEM CELLS, V24, P1689, DOI 10.1634/stemcells.2005-0531; Suzuki T, 2006, STEM CELLS, V24, P2406, DOI 10.1634/stemcells.2005-0587; Tai GP, 2009, METHODS MOL BIOL, V571, P77, DOI 10.1007/978-1-60761-198-1_5; van der Meulen AAE, 2009, NEUROPATH APPL NEURO, V35, P579, DOI 10.1111/j.1365-2990.2009.01036.x; Wennersten A, 2004, J NEUROSURG, V100, P88, DOI 10.3171/jns.2004.100.1.0088; Yao L, 2008, J CELL PHYSIOL, V216, P527, DOI 10.1002/jcp.21431; Yao L, 2009, HIPPOCAMPUS, V19, P855, DOI 10.1002/hipo.20569; Yasuhara T, 2006, J NEUROSCI, V26, P12497, DOI 10.1523/JNEUROSCI.3719-06.2006; Zhang J., 2011, STEM CELL REV; Zhang RL, 2001, NEUROSCIENCE, V105, P33, DOI 10.1016/S0306-4522(01)00117-8; Zhang SC, 2001, NAT BIOTECHNOL, V19, P1129, DOI 10.1038/nbt1201-1129; Zhao M, 1996, J CELL SCI, V109, P1405; Zhao M, 2009, SEMIN CELL DEV BIOL, V20, P674, DOI 10.1016/j.semcdb.2008.12.009	56	100	107	4	58	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1066-5099	1549-4918		STEM CELLS	Stem Cells	FEB	2012	30	2					349	355		10.1002/stem.779			7	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology	877UW	WOS:000299209200026	22076946	Bronze, Green Accepted			2022-02-06	
J	Harch, PG; Andrews, SR; Fogarty, EF; Amen, D; Pezzullo, JC; Lucarini, J; Aubrey, C; Taylor, DV; Staab, PK; Van Meter, KW				Harch, Paul G.; Andrews, Susan R.; Fogarty, Edward F.; Amen, Daniel; Pezzullo, John C.; Lucarini, Juliette; Aubrey, Claire; Taylor, Derek V.; Staab, Paul K.; Van Meter, Keith W.			A Phase I Study of Low-Pressure Hyperbaric Oxygen Therapy for Blast-Induced Post-Concussion Syndrome and Post-Traumatic Stress Disorder	JOURNAL OF NEUROTRAUMA			English	Article						hyperbaric oxygen therapy; post-concussion syndrome; post-traumatic stress disorder; single photon emission computed tomography; traumatic brain injury	TRAUMATIC BRAIN-INJURY; WECHSLER ABBREVIATED SCALE; CLOSED-HEAD INJURY; CONTROLLED-TRIALS; MILD; HIPPOCAMPAL; VALIDITY; INTELLIGENCE; RECOVERY; NEURONS	This is a preliminary report on the safety and efficacy of 1.5 ATA hyperbaric oxygen therapy (HBOT) in military subjects with chronic blast-induced mild to moderate traumatic brain injury (TBI)/post-concussion syndrome (PCS) and post-traumatic stress disorder (PTSD). Sixteen military subjects received 40 1.5 ATA/60 min HBOT sessions in 30 days. Symptoms, physical and neurological exams, SPECT brain imaging, and neuropsychological and psychological testing were completed before and within 1 week after treatment. Subjects experienced reversible middle ear barotrauma (5), transient deterioration in symptoms (4), and reversible bronchospasm (1); one subject withdrew. Post-treatment testing demonstrated significant improvement in: symptoms, neurological exam, full-scale IQ (+14.8 points; p < 0.001), WMS IV Delayed Memory (p = 0.026), WMS-IV Working Memory (p = 0.003), Stroop Test (p < 0.001), TOVA Impulsivity (p = 0.041), TOVA Variability (p = 0.045), Grooved Pegboard (p = 0.028), PCS symptoms (Rivermead PCSQ: p = 0.0002), PTSD symptoms (PCL-M: p < 0.001), depression (PHQ-9: p < 0.001), anxiety (GAD-7: p = 0.007), quality of life (MPQoL: p = 0.003), and self-report of percent of normal (p < 0.001), SPECT coefficient of variation in all white matter and some gray matter ROIs after the first HBOT, and in half of white matter ROIs after 40 HBOT sessions, and SPECT statistical parametric mapping analysis (diffuse improvements in regional cerebral blood flow after 1 and 40 HBOT sessions). Forty 1.5 ATA HBOT sessions in 1 month was safe in a military cohort with chronic blast-induced PCS and PTSD. Significant improvements occurred in symptoms, abnormal physical exam findings, cognitive testing, and quality-of-life measurements, with concomitant significant improvements in SPECT.	[Harch, Paul G.; Staab, Paul K.; Van Meter, Keith W.] Louisiana State Univ, Hlth Sci Ctr, Dept Med, Hyperbar Med Dept,Sect Emergency & Hyperbar Med, New Orleans, LA 70112 USA; [Andrews, Susan R.] Louisiana State Univ, Hlth Sci Ctr, Sch Med, Dept Med & Psychiat, New Orleans, LA 70112 USA; [Fogarty, Edward F.] Univ N Dakota, Dept Radiol, Sch Med & Hlth Sci, Bismarck, ND USA; [Amen, Daniel; Taylor, Derek V.] Univ Calif Irvine, Sch Med, Amen Clin Inc, Newport Beach, CA USA; [Pezzullo, John C.] Georgetown Univ, Med Ctr, Dept Med, Washington, DC 20007 USA; [Lucarini, Juliette; Aubrey, Claire] Adm Off, New Orleans, LA USA		Harch, PG (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Med, Hyperbar Med Dept,Sect Emergency & Hyperbar Med, 1542 Tulane Ave,Room 452,Box T4M2, New Orleans, LA 70112 USA.	paulharchmd@gmail.com					Andrykowski MA, 1998, J CONSULT CLIN PSYCH, V66, P586, DOI 10.1037/0022-006X.66.3.586; [Anonymous], 2008, US NAV DIV MAN REV 6, V1; [Anonymous], 2009, MAST REVISED; Ashburner J, 1999, HUM BRAIN MAPP, V7, P254, DOI 10.1002/(SICI)1097-0193(1999)7:4<254::AID-HBM4>3.0.CO;2-G; Axelrod BN, 2002, ASSESSMENT, V9, P17, DOI 10.1177/1073191102009001003; Bartels C, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-118; Basso MR, 2002, CLIN NEUROPSYCHOL, V16, P57, DOI 10.1076/clin.16.1.57.8329; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI [10.1089/neu.2008.0898, 10.1089/neu.2009-0898]; Beauregard M, 2009, NORD J PSYCHIAT, V63, P5, DOI 10.1080/08039480802421182; Benson K, 2000, NEW ENGL J MED, V342, P1878, DOI 10.1056/NEJM200006223422506; Bremner JD, 2007, NEUROIMAG CLIN N AM, V17, P523, DOI 10.1016/j.nic.2007.07.003; Calabrese C, 2008, J ALTERN COMPLEM MED, V14, P707, DOI 10.1089/acm.2008.0018; Carlson C. F., 2010, J HEAD TRAUMA R 0713; Centers for Medicare and Medicaid Services, 2006, CTR MED MED SERV P 1; Clark J, 2009, HYPERBARIC OXYGEN TH, P217; CLARK JM, 1993, PHYSL MED DIVING, P121; Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507; Cyceron, PLAT IM BIOM; Doraiswamy PM, 2007, PSYCHOPHARMACOL BULL, V40, P54; Dougherty G, 1996, MED ENG PHYS, V18, P557, DOI 10.1016/1350-4533(96)00011-2; Falleti MG, 2006, J CLIN EXP NEUROPSYC, V28, P1095, DOI 10.1080/13803390500205718; Franzen M D, 1987, Arch Clin Neuropsychol, V2, P265, DOI 10.1016/0887-6177(87)90014-X; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Garcia AJ, 2010, J APPL PHYSIOL, V109, P804, DOI 10.1152/japplphysiol.91429.2008; GAVIN DR, 1989, BRIT J ADDICT, V84, P301; Gesell L. B, 2009, HYPERBARIC OXYGEN TH; Godman CA, 2010, CELL STRESS CHAPERON, V15, P431, DOI 10.1007/s12192-009-0159-0; Golden Z, 2006, DISABIL REHABIL, V28, P1379, DOI 10.1080/09638280600638364; Golden ZL, 2002, INT J NEUROSCI, V112, P119, DOI 10.1080/00207450212027; Greenberg LM., 1996, TEST VARIABLES ATTEN; Hampson NB, 1996, UNDERSEA HYPERBAR M, V23, P215; Harch P. G., 2004, TXB HYPERBARIC MED, P471; Harch PG, 2007, BRAIN RES, V1174, P120, DOI 10.1016/j.brainres.2007.06.105; Harch Paul G, 2009, Cases J, V2, P6538, DOI 10.4076/1757-1626-2-6538; Harch PG, 1996, TXB HYPERBARIC MED, P480; Harch PG, 2009, TXB HYPERBARIC MED, P505; Harch PG, 1996, UNDERSEA HYPERB ME S, V23, P48; Harch PG, 2004, TXB HYPERBARIC MED, P223; Harch PG, 2009, TXB HYPERBARIC MED, P235; HARCH PG, 1994, UNDERSEA HYPERB ME S, V21, P30; Harch PG, 2002, P 2 INT S HYP OX CER, P31; HARCH PG, 1999, TXB HYPERBARIC MED, P319; Hardy P, 2007, J NEUROL SCI, V253, P94, DOI 10.1016/j.jns.2006.12.005; Hays JR, 2002, PSYCHOL REP, V90, P355, DOI 10.2466/PR0.90.2.355-359; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; HOSSMANN KA, 1993, PROG BRAIN RES, V96, P161; Jarcho JM, 2009, CLIN PHARMACOL THER, V86, P352, DOI 10.1038/clpt.2009.126; Jorge RE, 2010, ARCH GEN PSYCHIAT, V67, P187, DOI 10.1001/archgenpsychiatry.2009.185; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lesak M., 2004, NEUROPSYCHOLOGICAL A, V776, P365; LIDVALL HF, 1975, LANCET, V1, P100; Lin JW, 2008, ACTA NEUROCHIR SUPPL, V101, P145; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; MARX RE, 1990, AM J SURG, V160, P519, DOI 10.1016/S0002-9610(05)81019-0; Mezey E, 2003, P NATL ACAD SCI USA, V100, P1364, DOI 10.1073/pnas.0336479100; Mora C.A., 1989, PSYCHOL ASSESSMENT J, V1, P53, DOI [10.1037/1040-3590.1.1.53, DOI 10.1037/1040-3590.1.1.53]; NEUBAUER RA, 1990, LANCET, V335, P542, DOI 10.1016/0140-6736(90)90777-3; NEUBAUER RA, 1994, SOUTHERN MED J, V87, P933, DOI 10.1097/00007611-199409000-00015; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; PATRICK DL, 1988, J GEN INTERN MED, V3, P218, DOI 10.1007/BF02596335; Powell JM, 2001, ARCH PHYS MED REHAB, V82, P1025, DOI 10.1053/apmr.2001.25082; PTSD Checklist-Military, 2009, PTSD CHECKLIST MILIT; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rossignol DA, 2007, MED HYPOTHESES, V68, P1208, DOI 10.1016/j.mehy.2006.09.064; Ryan JJ, 2003, APPL NEUROPSYCHOL, V10, P252, DOI 10.1207/s15324826an1004_8; Siddiqui A, 1997, PLAST RECONSTR SURG, V99, P148, DOI 10.1097/00006534-199701000-00023; Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; SYMONDS C, 1962, LANCET, V1, P1; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Thom SR, 2006, AM J PHYSIOL-HEART C, V290, pH1378, DOI 10.1152/ajpheart.00888.2005; Tulsky D., 1997, WAIS 3 WMS 3 TECHNIC; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; Vorstrup S, 1988, Acta Neurol Scand Suppl, V114, P1; WAIS-IV, 2009, WAIS 4; Wang Z, 2010, ARCH GEN PSYCHIAT, V67, P296, DOI 10.1001/archgenpsychiatry.2009.205; WASI, 2009, WASI; WechslerD, 2001, WECHSLER TEST ADULT; Wilson B.A., 1985, RIVERMEAD BEHAV MEMO; WMS-IV, 2009, WMS 4; Wolfson, 1993, HALSTEAD REITAN NEUR; Woon FL, 2008, HIPPOCAMPUS, V18, P729, DOI 10.1002/hipo.20437; Wright JK, 2009, UNDERSEA HYPERBAR M, V36, P391; Zhang T, 2010, BRAIN INJURY, V24, P1350, DOI 10.3109/02699052.2010.504525	87	100	104	2	14	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2012	29	1					168	185		10.1089/neu.2011.1895			18	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	879GI	WOS:000299317300020	22026588	Bronze			2022-02-06	
J	Meterko, M; Baker, E; Stolzmann, KL; Hendricks, AM; Cicerone, KD; Lew, HL				Meterko, Mark; Baker, Errol; Stolzmann, Kelly L.; Hendricks, Ann M.; Cicerone, Keith D.; Lew, Henry L.			Psychometric Assessment of the Neurobehavioral Symptom Inventory-22: The Structure of Persistent Postconcussive Symptoms Following Deployment-Related Mild Traumatic Brain Injury Among Veterans	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							POST-CONCUSSION SYNDROME; CONSTRUCT-VALIDITY		[Meterko, Mark; Baker, Errol; Stolzmann, Kelly L.; Hendricks, Ann M.] VA Boston Healthcare Syst, Boston, MA 02130 USA; [Meterko, Mark; Baker, Errol; Stolzmann, Kelly L.] VA Ctr Org Leadership & Management Res, Boston, MA USA; [Meterko, Mark; Hendricks, Ann M.] Boston Univ, Sch Publ Hlth, Boston, MA USA; [Cicerone, Keith D.] JFK Johnson Rehabil Inst, Edison, NJ USA; [Lew, Henry L.] Univ Hawaii Manoa, Def & Vet Brain Injury Ctr, Honolulu, HI 96822 USA; [Lew, Henry L.] Univ Hawaii Manoa, John A Burns Sch Med, Honolulu, HI 96822 USA		Meterko, M (corresponding author), VA Boston Healthcare Syst, Mail Stop 152M,150 S Huntington Ave, Boston, MA 02130 USA.	mark.meterko@va.gov			VHA HSRD [SDR 08-405]	This research was supported by VHA HSR&D grant SDR 08-405. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs.	Ayr LK, 2009, J INT NEUROPSYCH SOC, V15, P19, DOI 10.1017/S1355617708090188; Benge JF, 2009, REHABIL PSYCHOL, V54, P270, DOI 10.1037/a0016736; Brown TA., 2015, CONFIRMATORY FACTOR, V2; Caplan LJ, 2010, J HEAD TRAUMA REHAB, V25, P447, DOI 10.1097/HTR.0b013e3181d5bdbd; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cohen J, 1977, STAT POWER ANAL BEHA; Department of Veterans Affairs, 2000, PAIN 5 VIT SIGN TOOL; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; O'Connor BP, 2000, BEHAV RES METH INS C, V32, P396, DOI 10.3758/BF03200807; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Pett MA., 2003, MAKING SENSE FACTOR; Piland SG, 2003, J ATHL TRAINING, V38, P104; Sawchyn JM, 2000, ARCH CLIN NEUROPSYCH, V15, P1, DOI 10.1016/S0887-6177(98)00041-9; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Tabachnick B.G., 2001, USING MULTIVARIATE S; Weathers F.W., 1993, 9 ANN C ISTSS; [No title captured]; [No title captured]	21	100	100	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2012	27	1					55	62		10.1097/HTR.0b013e318230fb17			8	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	879JV	WOS:000299326400006	22190009				2022-02-06	
J	Rivara, FP; Koepsell, TD; Wang, J; Temkin, N; Dorsch, A; Vavilala, MS; Durbin, D; Jaffe, KM				Rivara, Frederick P.; Koepsell, Thomas D.; Wang, Jin; Temkin, Nancy; Dorsch, Andrea; Vavilala, Monica S.; Durbin, Dennis; Jaffe, Kenneth M.			Disability 3, 12, and 24 Months After Traumatic Brain Injury Among Children and Adolescents	PEDIATRICS			English	Article						traumatic brain injury; disability; functional outcome	QUALITY-OF-LIFE; GENERIC CORE SCALES; POSTCONCUSSIVE SYMPTOMS; AFTER-DISCHARGE; RELIABILITY; OUTCOMES; HEAD; SEVERITY; VALIDITY; TERM	OBJECTIVE: To examine disability in children and adolescents after traumatic brain injury (TBI) across the spectrum of injury severity. METHODS: This was a prospective cohort study of children younger than 18 years treated for a TBI (n = 729) or an arm injury (n = 197) between March 1, 2007, and September 30, 2008. The main outcome measures were disability in health-related quality of life, adaptive skills, and participation in social and community activities 3, 12, and 24 months after injury compared with preinjury functioning. RESULTS: The health-related quality of life for children with moderate or severe TBI was lower at all follow-up times compared with baseline, but there was some improvement during the first 2 years after injury. Three months after injury, there was a substantial decrease in the level of activities in which children with moderate and severe TBI were able to participate; these activities improved at 12 and 24 months but were still significantly impaired. Communication and self-care abilities in children with moderate and severe TBI were lower at 3 months than at baseline and did not improve by 24 months. Children who met the definition of mild TBI but had an intracranial hemorrhage had lower quality-of-life scores at 3 months. CONCLUSIONS: Children with moderate or severe TBI and children with mild TBI who had intracranial hemorrhage had substantial long-term reduction in their quality of life, participation in activities with others, and ability to communicate and care for themselves. Pediatrics 2011; 128: e1129-e1138	[Rivara, Frederick P.; Koepsell, Thomas D.; Wang, Jin; Vavilala, Monica S.; Jaffe, Kenneth M.] Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA; [Rivara, Frederick P.; Wang, Jin; Vavilala, Monica S.] Univ Washington, Dept Pediat, Seattle, WA 98104 USA; [Rivara, Frederick P.; Koepsell, Thomas D.] Univ Washington, Dept Epidemiol, Seattle, WA 98104 USA; [Temkin, Nancy] Univ Washington, Dept Biostat, Seattle, WA 98104 USA; [Temkin, Nancy] Univ Washington, Dept Neurol Surg, Seattle, WA 98104 USA; [Dorsch, Andrea] Univ Washington, Dept Rehabil Med, Seattle, WA 98104 USA; [Vavilala, Monica S.] Univ Washington, Dept Anesthesiol, Seattle, WA 98104 USA; [Durbin, Dennis] Childrens Hosp Philadelphia, Dept Emergency Med, Philadelphia, PA 19104 USA; [Durbin, Dennis] Univ Penn, Philadelphia, PA 19104 USA		Rivara, FP (corresponding author), Univ Washington, Harborview Injury Prevent & Res Ctr, Box 359960,325 9th Ave, Seattle, WA 98104 USA.	fpr@uw.edu	Durbin, Dennis/AAD-7829-2022		National Center for Injury Prevention and Control, CDCUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49 CE 001021]; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE001021] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025014] Funding Source: NIH RePORTER	This project was supported by the National Center for Injury Prevention and Control, CDC grant R49 CE 001021. The CDC had no role in the design or conduct of the study; collection, management, analysis, or interpretation of the data; or preparation, review, or approval of the manuscript.	Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2010, J NEUROTRAUM, V27, P863, DOI 10.1089/neu.2009.1169; Anderson V, 2009, PEDIATRICS, V124, pE1064, DOI 10.1542/peds.2009-0365; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Bedell G., 2006, BRAIN INJ PROF, V3, P14; Bedell GM, 2004, NEUROREHABILITATION, V19, P191; Bordignon KC, 2002, ARQ NEURO-PSIQUIAT, V60, P204, DOI 10.1590/S0004-282X2002000200004; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Catroppa C, 2009, NEUROPSYCHOL REHABIL, V19, P716, DOI 10.1080/09602010902732868; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Ewing-Cobbs Linda, 2002, Semin Pediatr Neurol, V9, P209, DOI 10.1053/spen.2002.35502; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; Fay TB, 2010, J INT NEUROPSYCH SOC, V16, P94, DOI 10.1017/S1355617709991007; Fay TB, 2009, NEUROPSYCHOLOGY, V23, P271, DOI 10.1037/a0014936; Fletcher JM, 1996, J CHILD NEUROL, V11, P283, DOI 10.1177/088307389601100404; Gennarelli TA., 2008, ABBREVIATED INJURY S; Guice KS, 2007, J TRAUMA, V63, pS68, DOI 10.1097/TA.0b013e31815acbb6; Harrison P. L., 2003, ADAPTIVE BEHAV ASSES, V2nd; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; Iverson GL, 2006, BRAIN INJURY, V20, P1335, DOI 10.1080/02699050601082156; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; Kirkwood MW, 2009, ACTA PAEDIATR, V98, P1409, DOI 10.1111/j.1651-2227.2009.01448.x; Kirkwood MW, 2010, PEDIAT TRAUMATIC BRA; Koepsell TD, 2011, INCIDENCE D IN PRESS; Lange RT, 2009, BRAIN INJURY, V23, P83, DOI 10.1080/02699050802635281; Langlois J. A., 2000, TRAUMATIC BRAIN INJU; Levin HS, 2008, J NEUROSURG-PEDIATR, V1, P461, DOI 10.3171/PED/2008/1/6/461; Marr A., 2004, CENTRAL NERVOUS SYST; McCarthy ML, 2007, J TRAUMA, V63, pS122, DOI 10.1097/TA.0b013e31815accdf; McCarthy ML, 2006, ARCH PEDIAT ADOL MED, V160, P252, DOI 10.1001/archpedi.160.3.252; McCarthy ML, 2005, ARCH PHYS MED REHAB, V86, P1901, DOI 10.1016/j.apmr.2005.03.026; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Meeske K, 2004, CANCER, V101, P2116, DOI 10.1002/cncr.20609; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Mueller BA, 2008, EPIDEMIOLOGY, V19, P270, DOI 10.1097/EDE.0b013e318163567c; Muscara F, 2008, DEV NEUROPSYCHOL, V33, P623, DOI 10.1080/87565640802171162; Muscara F, 2009, NEUROPSYCHOL REHABIL, V19, P541, DOI 10.1080/09602010802365223; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Odetola FO, 2010, ARCH PEDIAT ADOL MED, V164, P277, DOI 10.1001/archpediatrics.2009.285; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; Sadowski-Cron C, 2006, BRAIN INJURY, V20, P1131, DOI 10.1080/02699050600832569; Shi JX, 2009, BRAIN INJURY, V23, P602, DOI 10.1080/02699050903014907; Sills MR, 2005, ARCH PEDIAT ADOL MED, V159, P665, DOI 10.1001/archpedi.159.7.665; Thompson DC, 1996, JAMA-J AM MED ASSOC, V276, P1968, DOI 10.1001/jama.276.24.1968; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; Tilford JM, 2005, CRIT CARE MED, V33, P2074, DOI 10.1097/01.CCM.0000171839.65687.F5; Varni JW, 2007, HEALTH QUAL LIFE OUT, V5, DOI 10.1186/1477-7525-5-2; Varni JW, 2009, PEDIATR CLIN N AM, V56, P843, DOI 10.1016/j.pcl.2009.05.016; Varni JW, 2001, MED CARE, V39, P800, DOI 10.1097/00005650-200108000-00006; Varni JW, 2002, CANCER-AM CANCER SOC, V94, P2090, DOI 10.1002/cncr.10428; Ventura T, 2010, ARCH PHYS MED REHAB, V91, P20, DOI 10.1016/j.apmr.2009.08.151; Wetherington CE, 2010, J PEDIATR PSYCHOL, V35, P662, DOI 10.1093/jpepsy/jsp081; World Health Organization, 2007, INT CLASS FUNCT DIS; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093	57	100	101	0	14	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	NOV	2011	128	5					E1129	E1138		10.1542/peds.2011-0840			10	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Pediatrics	843YO	WOS:000296714000011	22025592				2022-02-06	
J	Ando, T; Xuan, WJ; Xu, T; Dai, TH; Sharma, SK; Kharkwal, GB; Huang, YY; Wu, QH; Whalen, MJ; Sato, S; Obara, M; Hamblin, MR				Ando, Takahiro; Xuan, Weijun; Xu, Tao; Dai, Tianhong; Sharma, Sulbha K.; Kharkwal, Gitika B.; Huang, Ying-Ying; Wu, Qiuhe; Whalen, Michael J.; Sato, Shunichi; Obara, Minoru; Hamblin, Michael R.			Comparison of Therapeutic Effects between Pulsed and Continuous Wave 810-nm Wavelength Laser Irradiation for Traumatic Brain Injury in Mice	PLOS ONE			English	Article							CONTROLLED CORTICAL IMPACT; HELIUM-NEON LASER; TERM NEUROLOGICAL DEFICITS; LEVEL LIGHT THERAPY; CLOSED-HEAD INJURY; SPINAL-CORD-INJURY; PROMOTES REGENERATION; FUNCTIONAL RECOVERY; MEMORY PERFORMANCE; ISCHEMIC-STROKE	Background and Objective: Transcranial low-level laser therapy (LLLT) using near-infrared light can efficiently penetrate through the scalp and skull and could allow non-invasive treatment for traumatic brain injury (TBI). In the present study, we compared the therapeutic effect using 810-nm wavelength laser light in continuous and pulsed wave modes in a mouse model of TBI. Study Design/Materials and Methods: TBI was induced by a controlled cortical-impact device and 4-hours post-TBI 1-group received a sham treatment and 3-groups received a single exposure to transcranial LLLT, either continuous wave or pulsed at 10-Hz or 100-Hz with a 50% duty cycle. An 810-nm Ga-Al-As diode laser delivered a spot with diameter of 1-cm onto the injured head with a power density of 50-mW/cm(2) for 12-minutes giving a fluence of 36-J/cm(2). Neurological severity score (NSS) and body weight were measured up to 4 weeks. Mice were sacrificed at 2, 15 and 28 days post-TBI and the lesion size was histologically analyzed. The quantity of ATP production in the brain tissue was determined immediately after laser irradiation. We examined the role of LLLT on the psychological state of the mice at 1 day and 4 weeks after TBI using tail suspension test and forced swim test. Results: The 810-nm laser pulsed at 10-Hz was the most effective judged by improvement in NSS and body weight although the other laser regimens were also effective. The brain lesion volume of mice treated with 10-Hz pulsed-laser irradiation was significantly lower than control group at 15-days and 4-weeks post-TBI. Moreover, we found an antidepressant effect of LLLT at 4-weeks as shown by forced swim and tail suspension tests. Conclusion: The therapeutic effect of LLLT for TBI with an 810-nm laser was more effective at 10-Hz pulse frequency than at CW and 100-Hz. This finding may provide a new insight into biological mechanisms of LLLT.	[Ando, Takahiro; Xuan, Weijun; Xu, Tao; Dai, Tianhong; Sharma, Sulbha K.; Kharkwal, Gitika B.; Huang, Ying-Ying; Wu, Qiuhe; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA; [Ando, Takahiro; Obara, Minoru] Keio Univ, Dept Elect & Elect Engn, Yokohama, Kanagawa 223, Japan; [Xuan, Weijun; Xu, Tao; Dai, Tianhong; Kharkwal, Gitika B.; Huang, Ying-Ying; Wu, Qiuhe; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA; [Xuan, Weijun] Tradit Chinese Med Univ Guangxi, Dept Otolaryngol, Nanning, Peoples R China; [Xu, Tao] Shanghai Jiao Tong Univ, Lab Anesthesiol, Shanghai 200030, Peoples R China; [Huang, Ying-Ying] Guangxi Med Univ, Aesthet & Plast Ctr, Nanning, Peoples R China; [Wu, Qiuhe] Shandong Univ, Jinan Cent Hosp, Dept Burns & Plast Surg, Jinan 250100, Peoples R China; [Whalen, Michael J.] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA; [Sato, Shunichi] Natl Def Med Coll, Res Inst, Div Biomed Informat Sci, Tokorozawa, Saitama 359, Japan; [Hamblin, Michael R.] Harvard Univ, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02138 USA		Ando, T (corresponding author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.	hamblin@helix.mgh.harvard.edu	Huang, Ying-ying/G-3153-2011; Ando, Takahiro/R-8374-2019; Ando, Takahiro/H-5209-2019; Dai, Tianhong/P-5961-2018; Huang, yingying/J-7329-2012; Hamblin, Michael R/H-2758-2019	Huang, Ying-ying/0000-0003-3066-6981; Dai, Tianhong/0000-0001-8960-8896; Huang, yingying/0000-0002-4038-0277; Hamblin, Michael R/0000-0001-6431-4605; Xu, Tao/0000-0001-5868-4079	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01AI050875]; Center for Integration of Medicine and Innovative Technology [DAMD17-02-2-0006]; Congressionally Directed Medical Research Program in Traumatic Brain Injury [W81XWH-09-1-0514]; Air Force Office of Scientific ResearchUnited States Department of DefenseAir Force Office of Scientific Research (AFOSR) [FA9950-04-1-0079]; Ministry of Education, Culture, Sport, Science and Technology, JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT); Japan Society for the Promotion of Science (JSPS)Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [10J04881] Funding Source: KAKEN; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01AI050875] Funding Source: NIH RePORTER	This research was supported by National Institutes of Health (NIH) grant R01AI050875 (to Dr. Hamblin), Center for Integration of Medicine and Innovative Technology (DAMD17-02-2-0006), Congressionally Directed Medical Research Program in Traumatic Brain Injury (W81XWH-09-1-0514) and Air Force Office of Scientific Research Military Photomedicine Program (FA9950-04-1-0079). Dr. Ando was supported in part by a Grant-in-Aid for the Global Center of Excellence for High-Level Global Cooperation for Leading-Edge Platform on Access Spaces from the Ministry of Education, Culture, Sport, Science and Technology, Japan, and a Grant-in-Aid for Research Fellows of the Japan Society for the Promotion of Science (JSPS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALEY KO, 1989, N-S ARCH PHARMACOL, V339, P306; ANDERS JJ, 1993, LASER SURG MED, V13, P72, DOI 10.1002/lsm.1900130113; Anders JJ, 2004, NEUROL RES, V26, P233, DOI 10.1179/016164104225013914; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Brondon P, 2009, LASER SURG MED, V41, P222, DOI 10.1002/lsm.20740; Byrnes KR, 2005, LASER SURG MED, V36, P171, DOI 10.1002/lsm.20143; Castro-e-Silva O, 2003, LASER SURG MED, V32, P50, DOI 10.1002/lsm.10141; Davis PJ, 2007, METHODS NUMERICAL IN, Vxii, P612; DeTaboada L, 2006, LASER SURG MED, V38, P70, DOI 10.1002/lsm.20256; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Faul M, 2007, J TRAUMA, V63, P1271, DOI 10.1097/TA.0b013e3181493080; Finkelstein E., 2006, INCIDENCE EC BURDEN; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; GREEN JD, 1954, J NEUROPHYSIOL, V17, P533, DOI 10.1152/jn.1954.17.6.533; Hackett ML, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003437.pub3; Hashmi JT, 2010, LASER SURG MED, V42, P450, DOI 10.1002/lsm.20950; Hu WP, 2007, J INVEST DERMATOL, V127, P2048, DOI 10.1038/sj.jid.5700826; Huang L, 2011, J CELL PHYSIOL, V226, P588, DOI 10.1002/jcp.22367; Huang YY, 2009, DOSE-RESPONSE, V7, P358, DOI 10.2203/dose-response.09-027.Hamblin; Ilic S, 2006, PHOTOMED LASER SURG, V24, P458, DOI 10.1089/pho.2006.24.458; Karu T, 1999, J PHOTOCH PHOTOBIO B, V49, P1, DOI 10.1016/S1011-1344(98)00219-X; Karu T, 1998, SCI LOW OWER LASER T; Karu TI, 2005, LASER SURG MED, V36, P307, DOI 10.1002/lsm.20148; Kharkwal GB, 2011, P SPIE; Kymplova J, 2003, J CLIN LASER MED SUR, V21, P35, DOI 10.1089/10445470360516725; Lampl Y, 2007, STROKE, V38, P1843, DOI 10.1161/STROKEAHA.106.478230; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Lapchak PA, 2007, NEUROSCIENCE, V148, P907, DOI 10.1016/j.neuroscience.2007.07.002; Lapchak PA, 2004, STROKE, V35, P1985, DOI 10.1161/01.STR.0000131808.69640.b7; Lapchak PA, 2008, STROKE, V39, P3073, DOI 10.1161/STROKEAHA.108.516393; Lapchak PA, 2010, ANN MED, V42, P576, DOI 10.3109/07853890.2010.532811; Lapchak PA, 2010, BRAIN RES, V1306, P100, DOI 10.1016/j.brainres.2009.10.022; Lin F, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-16; Lucki I, 2001, PSYCHOPHARMACOLOGY, V155, P315, DOI 10.1007/s002130100694; Marion DW, 1998, NEUROL CLIN, V16, P485, DOI 10.1016/S0733-8619(05)70073-6; Mayorga AJ, 2001, J PHARMACOL EXP THER, V298, P1101; McMarthy T, 2011, P SPIE; Michalikova S, 2008, NEUROBIOL LEARN MEM, V89, P480, DOI 10.1016/j.nlm.2007.07.014; Mochizuki-Oda N, 2002, NEUROSCI LETT, V323, P207, DOI 10.1016/S0304-3940(02)00159-3; Oron A, 2007, J NEUROTRAUM, V24, P651, DOI 10.1089/neu.2006.0198; Oron A, 2006, STROKE, V37, P2620, DOI 10.1161/01.STR.0000242775.14642.b8; PASSARELLA S, 1984, FEBS LETT, V175, P95, DOI 10.1016/0014-5793(84)80577-3; Pastore D, 1996, BIOCHEM MOL BIOL INT, V39, P149; Porsolt RD, 2000, REV NEUROSCIENCE, V11, P53; PORSOLT RD, 1977, NATURE, V266, P730, DOI 10.1038/266730a0; PRIESTLEY T, 1994, MOL PHARMACOL, V46, P1191; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Sauerbeck A, 2011, EXP NEUROL, V227, P128, DOI 10.1016/j.expneurol.2010.10.003; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; STERU L, 1985, PSYCHOPHARMACOLOGY, V85, P367, DOI 10.1007/BF00428203; Sushko B S, 2007, Fiziol Zh, V53, P51; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Ueda Y, 2003, J CLIN LASER MED SUR, V21, P271, DOI 10.1089/104454703322564479; VANDERWOLF CH, 1969, ELECTROEN CLIN NEURO, V26, P407, DOI 10.1016/0013-4694(69)90092-3; Walker PA, 2009, DIS MODEL MECH, V2, P23, DOI 10.1242/dmm.001198; WINSON J, 1972, BEHAV BIOL, V7, P479, DOI 10.1016/S0091-6773(72)80210-4; Wong-Riley MTT, 2005, J BIOL CHEM, V280, P4761, DOI 10.1074/jbc.M409650200; Wu Q, 2010, P SPIE; Wu SN, 2009, J CELL PHYSIOL, V218, P603, DOI 10.1002/jcp.21636; Wu XJ, 2009, LASER SURG MED, V41, P36, DOI 10.1002/lsm.20729; Zhang Q, 2000, J BIOMED OPT, V5, P206, DOI 10.1117/1.429988	67	100	101	1	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 18	2011	6	10							e26212	10.1371/journal.pone.0026212			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	837ID	WOS:000296186900034	22028832	Green Published, Green Submitted, gold			2022-02-06	
J	Henry, LC; Tremblay, S; Leclerc, S; Khiat, A; Boulanger, Y; Ellemberg, D; Lassonde, M				Henry, Luke C.; Tremblay, Sebastien; Leclerc, Suzanne; Khiat, Abdesselam; Boulanger, Yvan; Ellemberg, Dave; Lassonde, Maryse			Metabolic changes in concussed American football players during the acute and chronic post-injury phases	BMC NEUROLOGY			English	Article						MRI spectroscopy; sports concussion; recovery; metabolism	TRAUMATIC BRAIN-INJURY; MAGNETIC-RESONANCE-SPECTROSCOPY; PROTON MR SPECTROSCOPY; NEUROCOGNITIVE PERFORMANCE; INTERNATIONAL-CONFERENCE; COMPUTED-TOMOGRAPHY; N-ACETYLASPARTATE; SPORTS CONCUSSION; CELL-VOLUME; RAT-BRAIN	Background: Despite negative neuroimaging findings many athletes display neurophysiological alterations and post-concussion symptoms that may be attributable to neurometabolic alterations. Methods: The present study investigated the effects of sports concussion on brain metabolism using H-1-MR Spectroscopy by comparing a group of 10 non-concussed athletes with a group of 10 concussed athletes of the same age (mean: 22.5 years) and education (mean: 16 years) within both the acute and chronic post-injury phases. All athletes were scanned 1-6 days post-concussion and again 6-months later in a 3T Siemens MRI. Results: Concussed athletes demonstrated neurometabolic impairment in prefrontal and motor (M1) cortices in the acute phase where NAA:Cr levels remained depressed relative to controls. There was some recovery observed in the chronic phase where Glu:Cr levels returned to those of control athletes; however, there was a pathological increase of m-I:Cr levels in M1 that was only present in the chronic phase. Conclusions: These results confirm cortical neurometabolic changes in the acute post-concussion phase as well as recovery and continued metabolic abnormalities in the chronic phase. The results indicate that complex pathophysiological processes differ depending on the post-injury phase and the neurometabolite in question.	[Henry, Luke C.; Tremblay, Sebastien; Ellemberg, Dave; Lassonde, Maryse] Univ Montreal, Dept Psychol, Ctr Rech Neuropsychol & Cognit, Montreal, PQ H3C 3J7, Canada; [Leclerc, Suzanne; Ellemberg, Dave] Univ Montreal, Dept Kinesiol, Ctr Rech Neuropsychol & Cognit, Montreal, PQ, Canada; [Khiat, Abdesselam; Boulanger, Yvan] Univ Montreal, Dept Radiol, Montreal, PQ, Canada; [Khiat, Abdesselam; Boulanger, Yvan] Hop St Luc, Montreal, PQ H2X 1P1, Canada		Henry, LC (corresponding author), Univ Montreal, Dept Psychol, Ctr Rech Neuropsychol & Cognit, CP 6128, Montreal, PQ H3C 3J7, Canada.	luke.henry@umontreal.ca		Tremblay, Sebastien/0000-0001-6251-9797	CIHRCanadian Institutes of Health Research (CIHR); FRSQFonds de la Recherche en Sante du Quebec	This study was funded by CIHR grants to LCH, DE, and ML and an FRSQ award to ST.	Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Angelie E, 2001, AM J NEURORADIOL, V22, P119; Arciniegas David B., 2002, Curr Treat Options Neurol, V4, P43, DOI 10.1007/s11940-002-0004-6; Ariza M, 2004, ARCH NEUROL-CHICAGO, V61, P541, DOI 10.1001/archneur.61.4.541; Ashwal S, 2004, J NEUROTRAUM, V21, P1539, DOI 10.1089/0897715042441756; Asplund CA, 2004, CLIN J SPORT MED, V14, P339, DOI 10.1097/00042752-200411000-00003; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; BABIKIAN T, 2006, J MAGN RESON IMAGING; Barr M., 2005, HUMAN NERVOUS SYSTEM; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Bergsneider M, 2001, J HEAD TRAUMA REHAB, V16, P135, DOI 10.1097/00001199-200104000-00004; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Brooks WM, 2001, J HEAD TRAUMA REHAB, V16, P149, DOI 10.1097/00001199-200104000-00005; CANTU RC, 1992, SPORTS MED, V14, P64, DOI 10.2165/00007256-199214010-00005; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Chen SHA, 2003, J NEUROL NEUROSUR PS, V74, P326, DOI 10.1136/jnnp.74.3.326; Cimatti M, 2006, J Neurosurg Sci, V50, P83; Cohen BA, 2007, AM J NEURORADIOL, V28, P907; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Denny-Brown D, 1940, J PHYSIOL-LONDON, V99, P153, DOI 10.1113/jphysiol.1940.sp003887; DENNYBROWN D, 1961, ARCH NEUROL-CHICAGO, V5, P1; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Ellemberg D, 2009, J NEUROTRAUM, V26, P2365, DOI 10.1089/neu.2009.0906; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Fisher SK, 2002, J NEUROCHEM, V82, P736, DOI 10.1046/j.1471-4159.2002.01041.x; Fleminger S, 2008, EUR J ANAESTH, V25, P123, DOI 10.1017/S0265021507003250; Gaetz M, 2000, BRAIN INJURY, V14, P815; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; Giza CC, 2001, J ATHL TRAINING, V36, P228; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Govindaraju V, 2004, AM J NEURORADIOL, V25, P730; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; GULLANS SR, 1993, ANNU REV MED, V44, P289, DOI 10.1146/annurev.med.44.1.289; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; HOLBOURN AHS, 1945, BRIT MED BULL, V3, P147, DOI 10.1093/oxfordjournals.bmb.a071895; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Holshouser BA, 2006, J MAGN RESON IMAGING, V24, P33, DOI 10.1002/jmri.20607; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Jenkins BG, 1999, CURR OPIN NEUROL, V12, P753, DOI 10.1097/00019052-199912000-00016; Johnston KM, 2001, CLIN J SPORT MED, V11, P166, DOI 10.1097/00042752-200107000-00007; JORDAN BD, 1990, JAMA-J AM MED ASSOC, V263, P1670, DOI 10.1001/jama.263.12.1670; JORDAN BD, 1992, RADIOLOGY, V185, P509, DOI 10.1148/radiology.185.2.1410364; JORDAN BD, 1988, ARCH NEUROL-CHICAGO, V45, P1207, DOI 10.1001/archneur.1988.00520350045014; Kandel E. R., 2000, PRINCIPLES NEUROSCIE; Kirov I, 2007, BRAIN INJURY, V21, P1147, DOI 10.1080/02699050701630383; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; LEVIN H, 2010, J NEUROTRAUMA; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; LOHR JW, 1988, LIFE SCI, V43, P271, DOI 10.1016/0024-3205(88)90317-7; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Macleod AD, 2010, MED HYPOTHESES, V74, P1033, DOI 10.1016/j.mehy.2010.01.002; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Marino S, 2007, J NEUROL NEUROSUR PS, V78, P501, DOI 10.1136/jnnp.2006.099796; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M., 2008, MILD TRAUMATIC BRAIN; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 1999, BRIT J SPORT MED, V33, P136, DOI 10.1136/bjsm.33.2.136; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Miller JR, 2007, AM J SPORT MED, V35, P1284, DOI 10.1177/0363546507300261; Moffett JR, 2007, PROG NEUROBIOL, V81, P89, DOI 10.1016/j.pneurobio.2006.12.003; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; Payen JF, 2005, ANN FR ANESTH, V24, P522, DOI 10.1016/j.annfar.2005.03.005; Petroff OAC, 2003, NEUROLOGY, V60, P1646, DOI 10.1212/01.WNL.0000068020.85450.8B; Ruff R, 2009, J HEAD TRAUMA REHAB, V24, P131, DOI 10.1097/01.HTR.0000348755.42649.e9; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Sabet AA, 2008, J BIOMECH, V41, P307, DOI 10.1016/j.jbiomech.2007.09.016; Shutter L, 2006, J HEAD TRAUMA REHAB, V21, P334, DOI 10.1097/00001199-200607000-00005; SNOW RB, 1986, NEUROSURGERY, V18, P45, DOI 10.1227/00006123-198601000-00008; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; STRANGE K, 1992, J AM SOC NEPHROL, V3, P12; TAYLOR DL, 1994, J NEUROCHEM, V62, P2349; Theriault M, 2009, BRAIN INJURY, V23, P899, DOI 10.1080/02699050903283189; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524; Willer Barry, 2006, Curr Treat Options Neurol, V8, P415, DOI 10.1007/s11940-006-0031-9; WU TC, 2010, J NEUROTRAUMA; Yoon SJ, 2005, CLIN REHABIL, V19, P209, DOI 10.1191/0269215505cr813oa; CONCUSSION	101	100	102	0	0	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1471-2377		BMC NEUROL	BMC Neurol.	AUG 23	2011	11								105	10.1186/1471-2377-11-105			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	821UM	WOS:000294999900001	21861906	gold, Green Published			2022-02-06	
J	Huizinga, M; Smidts, DP				Huizinga, Mariette; Smidts, Diana P.			Age-Related Changes in Executive Function: A Normative Study with the Dutch Version of the Behavior Rating Inventory of Executive Function (BRIEF)	CHILD NEUROPSYCHOLOGY			English	Article						Executive function; Development; Children; Behavior regulation; Metacognition	ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; AUTISM SPECTRUM DISORDERS; TRAUMATIC BRAIN-INJURY; INTEGRATIVE THEORY; PREFRONTAL CORTEX; FUNCTION DEFICITS; WORKING-MEMORY; CHILDREN; COGNITION; DIMENSIONS	This study examined age-related change in executive function by using a Dutch translation of the Behavior Rating Inventory of Executive Function (BRIEF; Gioia et al., 2000) that was applied to a normative sample (age range 5-18 years). In addition, we examined the reliability and factorial structures of the Dutch BRIEF. Results with respect to age revealed a decrease in reported executive function problems with increasing age. On the Behavior Regulation Index (BRI), 5- to 8-year-olds showed significantly more executive function problems than 9- to 11-year-olds, as did the 12- to 14-year-olds compared to 15- to 18-year-olds (except on the Shift subscale). On the Metacognition Index, we found that 9- to 11-year-olds differed significantly from 5- to 8-year-olds on the Working Memory subscale. In addition, the current study showed that the internal consistency of the Dutch BRIEF is very high, and that this version of the BRIEF has a high test-retest stability. Item factor analysis confirmed the expected eight common factor model, and factor analysis of the eight test scores confirmed the two-factor model, as proposed by Gioia et al., in the Dutch data.	[Huizinga, Mariette] Univ Amsterdam, Dept Psychol, Dev Psychol Sect, NL-1018 WB Amsterdam, Netherlands		Huizinga, M (corresponding author), Univ Amsterdam, Dept Psychol, Dev Psychol Sect, Roetersstr 15, NL-1018 WB Amsterdam, Netherlands.	m.huizinga@uva.nl		Huizinga, M./0000-0001-7007-8952			Achenbach T. M., 2001, MANUAL ASEBA SCH AGE; Achenbach TM, 1991, MANUAL CHILD BEHAV C; Amso D, 2006, CURR DIR PSYCHOL SCI, V15, P24, DOI 10.1111/j.0963-7214.2006.00400.x; Anderson PJ, 2004, AUST J PSYCHOL, V56, P156; Anderson V, 2005, BRAIN INJURY, V19, P459, DOI 10.1080/02699050400004823; Anderson VA, 2002, CHILD NEUROPSYCHOL, V8, P231, DOI 10.1076/chin.8.4.231.13509; Baddeley A.D., 1986, WORKING MEMORY; Best JR, 2009, DEV REV, V29, P180, DOI 10.1016/j.dr.2009.05.002; Bodnar LE, 2007, CHILD NEUROPSYCHOL, V13, P345, DOI 10.1080/09297040600899867; Brocki KC, 2004, DEV NEUROPSYCHOL, V26, P571, DOI 10.1207/s15326942dn2602_3; Bull R, 2008, COGNITION, V107, P663, DOI 10.1016/j.cognition.2007.07.015; Casey BJ, 2005, TRENDS COGN SCI, V9, P104, DOI 10.1016/j.tics.2005.01.011; Castellanos FX, 2006, TRENDS COGN SCI, V10, P117, DOI 10.1016/j.tics.2006.01.011; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; COHEN JD, 1992, PSYCHOL REV, V99, P45, DOI 10.1037/0033-295X.99.1.45; Cronbach LJ, 2004, EDUC PSYCHOL MEAS, V64, P391, DOI 10.1177/0013164404266386; Diamond A., 2002, PRINCIPLES FRONTAL L, P466, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0029; Emslie H., 2003, BEHAV ASSESSMENT DYS; Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P249, DOI 10.1076/chin.8.4.249.13513; Gioia GA IP, 2000, BEHAV RATING INVENTO; Happe F, 2006, BRAIN COGNITION, V61, P25, DOI 10.1016/j.bandc.2006.03.004; Heaton PDRK., 1993, WISCONSIN CARD SORTI; Huizinga M, 2006, NEUROPSYCHOLOGIA, V44, P2017, DOI 10.1016/j.neuropsychologia.2006.01.010; Joreskog K. G., 1999, LISREL 8 NEW STAT FE, P8; Joreskog K. G., 1993, TESTING STRUCTURAL E, P294, DOI DOI 10.1093/SF/73.3.1161; Kenworthy L, 2008, NEUROPSYCHOL REV, V18, P320, DOI 10.1007/s11065-008-9077-7; Kimberg DY, 1997, CURR DIR PSYCHOL SCI, V6, P185, DOI 10.1111/1467-8721.ep10772959; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Lehto JE, 2003, BRIT J DEV PSYCHOL, V21, P59, DOI 10.1348/026151003321164627; Lehto JH, 1996, Q J EXP PSYCHOL-A, V49, P29, DOI 10.1080/027249896392793; Levin HS, 1996, DEV NEUROPSYCHOL, V12, P17, DOI 10.1080/87565649609540638; Little TD, 1997, MULTIVAR BEHAV RES, V32, P53, DOI 10.1207/s15327906mbr3201_3; Mahone EM, 2002, ARCH CLIN NEUROPSYCH, V17, P643, DOI 10.1016/S0887-6177(01)00168-8; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; Marlow N, 2007, PEDIATRICS, V120, P793, DOI 10.1542/peds.2007-0440; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Muthen L. K., 2018, MPLUS USERS GUIDE; Nadebaum C, 2007, DEV NEUROPSYCHOL, V32, P703, DOI 10.1080/87565640701376086; Nigg JT, 2005, DEV PSYCHOPATHOL, V17, P785, DOI 10.1017/S0954579405050376; Norman DA., 1986, CONSCIOUSNESS SELF R, P1, DOI [10.1007/978-1-4757-0629-1_1, DOI 10.1007/978-1-4757-0629-1_1]; Nunally J.C., 1994, PSYCHOMETRIC THEORY, V3rd ed.; Rabbitt P, 2001, EUR J COGN PSYCHOL, V13, P5, DOI 10.1080/09541440042000197; Reich W, 1997, DIAGNOSTIC INTERVIEW; Rothbart MK, 2001, CHILD DEV, V72, P1394, DOI 10.1111/1467-8624.00355; Schermelleh-Engel K., 2003, METHODS PSYCHOL RES, V8, P23; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; SIMON HA, 1975, COGNITIVE PSYCHOL, V7, P268, DOI 10.1016/0010-0285(75)90012-2; Smidts D, 2009, BRIEF EXECUTIEVE FUN; STUSS DT, 1995, STRUCTURE FUNCTIONS; Tabacknick B.G., 2001, USING MULTIVARIATE S; Thorell LB, 2008, DEV NEUROPSYCHOL, V33, P536, DOI 10.1080/87565640802101516; Toplak ME, 2009, CHILD NEUROPSYCHOL, V15, P53, DOI 10.1080/09297040802070929; WELSH MC, 1991, DEV NEUROPSYCHOL, V7, P131, DOI 10.1080/87565649109540483; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Zelazo PD, 2003, MONOGR SOC RES CHILD, V68, P1, DOI 10.1111/j.0037-976X.2003.00261.x	56	100	102	5	63	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0929-7049	1744-4136		CHILD NEUROPSYCHOL	Child Neuropsychol.		2011	17	1					51	66	PII 931899940	10.1080/09297049.2010.509715			16	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	716BK	WOS:000286939700004	21218296	Green Published			2022-02-06	
J	Kishk, NA; Gabr, H; Hamdy, S; Afifi, L; Abokresha, N; Mahmoud, H; Wafaie, A; Bilal, D				Kishk, Nirmeen A.; Gabr, Hala; Hamdy, Sherif; Afifi, Lamia; Abokresha, Noha; Mahmoud, Hayam; Wafaie, Ahmed; Bilal, Dalia			Case Control Series of Intrathecal Autologous Bone Marrow Mesenchymal Stem Cell Therapy for Chronic Spinal Cord Injury	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						mesenchymal stem cell; spinal cord injury; SSEP	STROMAL CELLS; TRANSPLANTATION; REHABILITATION; BRAIN	Background: Autologous bone marrow mesenchymal cells that include stem cells (MSCs) are a clinically attractive cellular therapy option to try to treat severe spinal cord injury (SCI). Objective: To study the possible value of MSCs injected intrathecally to enhance rehabilitation. Methods: This case control, convenience sample included 64 patients, at a mean of 3.6 years after SCI. Forty-four subjects received monthly intrathecal autologous MSCs for 6 months and 20 subjects, who would not agree to the procedures, served as controls. All subjects received rehabilitation therapies 3 times weekly. Subjects were evaluated at entry and at 12 months after completing the 6-months intervention. By the ASIA Impairment Scale, ASIA grading of completeness of injury, Ashworth Spasticity Scale, Functional Ambulation Classification, and bladder and bowel control questionnaire. Results: No differences were found in baseline measures and descriptors between the MSC group and control group. Although a higher percentage of the MSC group increased motor scores by 1-2 points and changed from ASIA A to B, no significant between-group improvements were found in clinical measures. Adverse effects of cells included spasticity and, in 24 out of the 43 patients developed neuropathic pain. One subject with a history of post-infectious myelitis developed encephalomyelitis after her third injection. Conclusion: Autologus MSCs may have side effects and may be contraindicated in patients with a history of myelitis. Their utility in treating chronic traumatic SCI needs further study in pre-clinical models and in randomized controlled trials before they should be offered to patients.	[Kishk, Nirmeen A.; Hamdy, Sherif; Abokresha, Noha] Cairo Univ, Dept Neurol, Cairo, Egypt; [Gabr, Hala] Cairo Univ, Dept Clin Pathol, Cairo, Egypt; [Afifi, Lamia] Cairo Univ, Clin Neurophysiol Unit, Cairo, Egypt; [Wafaie, Ahmed] Cairo Univ, Dept Radiol, Cairo, Egypt; [Bilal, Dalia] Cairo Univ, Natl Canc Inst, Dept Biostat & Epidemiol, Cairo, Egypt		Abokresha, N (corresponding author), Cairo Univ, Kaser Al Aini Hosp, Cairo, Egypt.	nhtaha@yahoo.com	Mahmoud, Hayam/C-1452-2019; Abokrysha, Noha/AAG-1693-2020	Mahmoud, Hayam/0000-0002-9352-4916; Abokrysha, Noha/0000-0002-3857-8698; Gabr, Hala/0000-0003-0262-8558; kishk, nirmeen/0000-0003-4410-7814; Wafaie, Ahmed/0000-0003-3089-9240			Abrams MB, 2009, RESTOR NEUROL NEUROS, V27, P307, DOI 10.3233/RNN-2009-0480; Akiyama Y, 2002, J NEUROSCI, V22, P6623; American Spinal Injury Association, 1984, STAND NEUR CLASS SPI; Bakshi A, 2006, J NEUROTRAUM, V23, P55, DOI 10.1089/neu.2006.23.55; Blesch A, 2002, BRAIN RES BULL, V57, P833, DOI 10.1016/S0361-9230(01)00774-2; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Callera F, 2007, STEM CELLS DEV, V16, P461, DOI 10.1089/scd.2007.0083; CHAE WP, 2009, INT J STEM CELLS, V2, P59; Dobkin BH, 2007, STROKE, V38, P832, DOI 10.1161/01.STR.0000248408.49398.9c; Dobkin BH, 2010, NEUROREHAB NEURAL RE, V24, P7, DOI 10.1177/1545968309354457; Fawcett JW, 2007, SPINAL CORD, V45, P190, DOI 10.1038/sj.sc.3102007; Geffner LF, 2008, CELL TRANSPLANT, V17, P1277, DOI 10.3727/096368908787648074; HOLDEN MK, 1986, PHYS THER, V66, P1530, DOI 10.1093/ptj/66.10.1530; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Kabos P, 2002, EXP NEUROL, V178, P288, DOI 10.1006/exnr.2002.8039; Kadoya K, 2009, NEURON, V64, P165, DOI 10.1016/j.neuron.2009.09.016; Levit K., 1997, AM OCC THER ASS ANN; Lima C, 2010, NEUROREHAB NEURAL RE, V24, P10, DOI 10.1177/1545968309347685; MAHONEY FI, 1994, PHYS REHABILITATION, P198; Mazurier F, 2003, NAT MED, V9, P959, DOI 10.1038/nm886; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Park HC, 2005, TISSUE ENG, V11, P913, DOI 10.1089/ten.2005.11.913; SCOTT J, 1976, PAIN, V2, P175, DOI 10.1016/0304-3959(76)90113-5; Sykova E, 2006, CELL TRANSPLANT, V15, P675, DOI 10.3727/000000006783464381; Zhang J, 2008, J NEUROSCI RES, V86, P1501, DOI 10.1002/jnr.21617	26	100	106	1	15	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683	1552-6844		NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	OCT	2010	24	8					702	708		10.1177/1545968310369801			7	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	657RH	WOS:000282429500003	20660620				2022-02-06	
J	Wu, TC; Wilde, EA; Bigler, ED; Yallampalli, R; McCauley, SR; Troyanskaya, M; Chu, ZL; Li, XQ; Hanten, G; Hunter, JV; Levin, HS				Wu, Trevor C.; Wilde, Elisabeth A.; Bigler, Erin D.; Yallampalli, Ragini; McCauley, Stephen R.; Troyanskaya, Maya; Chu, Zili; Li, Xiaoqi; Hanten, Gerri; Hunter, Jill V.; Levin, Harvey S.			Evaluating the Relationship between Memory Functioning and Cingulum Bundles in Acute Mild Traumatic Brain Injury Using Diffusion Tensor Imaging	JOURNAL OF NEUROTRAUMA			English	Article						diffusion tensor imaging; learning and memory; magnetic resonance imaging; pediatric brain injury; traumatic brain injury	AXONAL INJURY; ABNORMALITIES; DEPRESSION	Compromised memory functioning is one of the commonly reported cognitive sequelae seen following mild traumatic brain injury (mTBI). Diffusion tensor imaging (DTI) has been shown to be sufficiently sensitive at detecting early microstructural pathological alterations after mTBI. Given its location and shape, the cingulate, which is comprised of the cingulate gyrus (gray matter) and cingulum bundles (white matter), is selectively vulnerable to mTBI. In this study we examined the integrity of cingulum bundles using DTI, and the relationship between cingulum bundles and memory functioning. Twelve adolescents with mTBI and 11 demographically-matched healthy controls were studied. All participants with mTBI had a Glasgow Coma Scale score of 15, and were without intracranial findings on CT scan. Brain scans were performed on average 2.92 days post-injury, and all participants were administered the Verbal Selective Reminding Test (VSRT), an episodic verbal learning and memory task. Participants with mTBI had a significantly lower apparent diffusion coefficient (ADC) bilaterally than controls (p<0.001). Despite the marginal significance of the group difference in fractional anisotropy (FA), the effect size between groups was moderate (d=0.66). Cognitively, healthy controls performed better than the TBI group on immediate and delayed recall; however, the difference did not reach statistical significance. In the mTBI group, FA of the left cingulum bundle was significantly correlated with 30-min delayed recall (r = -0.56, p = 0.05). A marginally significant correlation was found between ADC of the left cingulum bundle and the total words of immediate recall (r = 0.59, p = 0.07). No significant correlation was found between DTI metrics and memory functioning for the control group. These preliminary findings indicate that cingulate injury likely contributes to the cognitive sequelae seen during the early phase post-mTBI.	[Wu, Trevor C.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.] Brigham Young Univ, Ctr Neurosci, Provo, UT 84602 USA; [Wilde, Elisabeth A.; Yallampalli, Ragini; McCauley, Stephen R.; Troyanskaya, Maya; Li, Xiaoqi; Hanten, Gerri; Levin, Harvey S.] Univ Texas Houston, Sch Med, Houston, TX USA; [Wilde, Elisabeth A.; Yallampalli, Ragini; McCauley, Stephen R.; Troyanskaya, Maya; Li, Xiaoqi; Hanten, Gerri; Levin, Harvey S.] Phys Med & Rehabil Alliance Baylor Coll Med, Houston, TX USA; [Wilde, Elisabeth A.] Baylor Coll Med, Dept Radiol & Neurol, Houston, TX 77030 USA; [McCauley, Stephen R.] Baylor Coll Med, Dept Pediat, Hematol Oncol Sect, Houston, TX 77030 USA; [Chu, Zili; Hunter, Jill V.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Levin, Harvey S.] Baylor Coll Med, Dept Neurol Neurosurg & Pediat, Houston, TX 77030 USA; [Bigler, Erin D.] Univ Utah, Dept Psychiat, Salt Lake City, UT USA; [Bigler, Erin D.] Univ Utah, Utah Brain Inst, Salt Lake City, UT USA; [Chu, Zili; Hunter, Jill V.] Texas Childrens Hosp, EB Singleton Dept Diagnost Imaging, Houston, TX 77030 USA		Wilde, EA (corresponding author), Baylor Coll Med, Dept Phys Med & Rehabil, 1709 Dryden Rd,Suite 725, Houston, TX 77030 USA.	ewilde@bcm.edu			National Institutes of Health/National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS056202]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS056202] Funding Source: NIH RePORTER	This research was supported by National Institutes of Health/National Institute of Neurological Disorders and Stroke grant no. P01 NS056202. We would also like to acknowledge the generous support by Mission Connect of the TIRR Foundation (The Institute for Rehabilitation and Research).	Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Behrens TEJ, 2009, SCIENCE, V324, P1160, DOI 10.1126/science.1169694; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bigler ED, 2007, NEUROPSYCHOLOGY, V21, P515, DOI 10.1037/0894-4105.21.5.515; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Christensen TA, 2008, NEUROREPORT, V19, P1101, DOI 10.1097/WNR.0b013e3283060a9d; CHU Z, 2009, AM J NEURORADIO 1203; Dikranian K, 2008, EXP NEUROL, V211, P551, DOI 10.1016/j.expneurol.2008.03.012; Ebert D, 1996, BIOL PSYCHIAT, V39, P1044, DOI 10.1016/0006-3223(95)00320-7; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Gean AD, 1994, IMAGING HEAD TRAUMA; Jones DK, 1999, MAGNET RESON MED, V42, P515, DOI 10.1002/(SICI)1522-2594(199909)42:3<515::AID-MRM14>3.0.CO;2-Q; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kurca E, 2006, NEURORADIOLOGY, V48, P661, DOI 10.1007/s00234-006-0109-9; Larrabee GJ, 2000, CLIN NEUROPSYCHOL, V14, P110, DOI 10.1076/1385-4046(200002)14:1;1-8;FT110; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; Malojcic B, 2008, J NEUROTRAUM, V25, P30, DOI 10.1089/neu.2007.0384; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; NETSCH T, 2001, INT C COMP VIS; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Rushworth MFS, 2008, NAT NEUROSCI, V11, P389, DOI 10.1038/nn2066; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Sargin D, 2009, GLIA, V57, P693, DOI 10.1002/glia.20797; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Topal NB, 2008, NEUROL RES, V30, P974, DOI 10.1179/016164108X323799; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; Yount R, 2002, J NEUROPSYCH CLIN N, V14, P416, DOI 10.1176/appi.neuropsych.14.4.416; Zago L, 2008, NEUROPSYCHOLOGIA, V46, P2403, DOI 10.1016/j.neuropsychologia.2008.03.001	36	100	100	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2010	27	2					303	307		10.1089/neu.2009.1110			5	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	557JG	WOS:000274664800002	19877826	Green Published			2022-02-06	
J	Simard, JM; Kilbourne, M; Tsymbalyuk, O; Tosun, C; Caridi, J; Ivanova, S; Keledjian, K; Bochicchio, G; Gerzanich, V				Simard, J. Marc; Kilbourne, Michael; Tsymbalyuk, Orest; Tosun, Cigdem; Caridi, John; Ivanova, Svetlana; Keledjian, Kaspar; Bochicchio, Grant; Gerzanich, Volodymyr			Key Role of Sulfonylurea Receptor 1 in Progressive Secondary Hemorrhage after Brain Contusion	JOURNAL OF NEUROTRAUMA			English	Article						contusion; glibenclamide; hemorrhage; sulfonylurea receptor 1; traumatic brain injury	SPINAL-CORD-INJURY; NONSELECTIVE CATION CHANNEL; LATERAL FLUID PERCUSSION; ADULT-RAT BRAIN; ISCHEMIC-STROKE; VASCULAR DISRUPTION; REACTIVE ASTROCYTES; HEAD TRAUMA; GLIBENCLAMIDE; CELLS	An important but poorly understood feature of traumatic brain injury (TBI) is the clinically serious problem of spatiotemporal progression ("blossoming'') of a hemorrhagic contusion, a phenomenon we term progressive secondary hemorrhage (PSH). Molecular mechanisms of PSH are unknown and efforts to reduce it by promoting coagulation have met with equivocal results. We hypothesized that PSH might be due to upregulation and activation of sulfonylurea receptor 1 (SUR1)-regulated NCCa-ATP channels in capillary endothelial cells, predisposing to oncotic death of endothelial cells and catastrophic failure of capillary integrity. Anesthetized adult male rats underwent left parietal craniectomy for induction of a focal cortical contusion. The regulatory subunit of the channel, SUR1, was prominently upregulated in capillaries of penumbral tissues surrounding the contusion. In untreated rats, PSH was characterized by progressive enlargement of the contusion deep into the site of cortical impact, including corpus callosum, hippocampus, and thalamus, by progressive accumulation of extravasated blood, with a doubling of the volume during the first 12 h after injury, and by capillary fragmentation in penumbral tissues. Block of SUR1 using low-dose (non-hypoglycemogenic) glibenclamide largely eliminated PSH and capillary fragmentation, and was associated with a significant reduction in the size of the necrotic lesion and in preservation of neurobehavioral function. Antisense oligodeoxynucleotide against SUR1, administered after injury, reduced both SUR1 expression and PSH, consistent with a requirement for transcriptional upregulation of SUR1. Our findings provide novel insights into molecular mechanisms responsible for PSH associated with hemorrhagic contusions, and point to SUR1 as a potential therapeutic target in TBI.	[Simard, J. Marc; Tsymbalyuk, Orest; Tosun, Cigdem; Caridi, John; Ivanova, Svetlana; Keledjian, Kaspar; Gerzanich, Volodymyr] Univ Maryland, Sch Med, Dept Neurosurg, Baltimore, MD 21201 USA; [Simard, J. Marc] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; [Simard, J. Marc] Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; [Bochicchio, Grant] Univ Maryland, Sch Med, Dept Surg, Baltimore, MD 21201 USA; [Kilbourne, Michael] Walter Reed Army Med Ctr, Dept Surg, Washington, DC 20307 USA; [Bochicchio, Grant] R Adams Cowley Shock Trauma Ctr, Baltimore, MD USA		Simard, JM (corresponding author), Univ Maryland, Sch Med, Dept Neurosurg, Baltimore, MD 21201 USA.	msimard@smail.umaryland.edu	Tosun, Cigdem/AAG-4026-2020		Department of Veterans Affairs (Baltimore, MD)US Department of Veterans Affairs; National Heart, Lung and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL082517]; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS061808, NS060801, NS061934]; Christopher and Dana Reeve Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL082517] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS061808, R01NS061934] Funding Source: NIH RePORTER	This work was supported by grants to J.M.S. from the Department of Veterans Affairs (Baltimore, MD), the National Heart, Lung and Blood Institute (HL082517), the National Institute of Neurological Disorders and Stroke (NS061808 and NS060801), and the Christopher and Dana Reeve Foundation, and to V. G. from the National Institute of Neurological Disorders and Stroke (NS061934).	Atkins CM, 2007, EXP NEUROL, V208, P145, DOI 10.1016/j.expneurol.2007.08.011; Belayev L, 2001, J NEUROTRAUM, V18, P1031, DOI 10.1089/08977150152693728; Belayev L, 2002, J NEUROSURG, V96, P1077, DOI 10.3171/jns.2002.96.6.1077; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Chang EF, 2006, NEUROSURGERY, V58, P647, DOI 10.1227/01.NEU.0000197101.68538.E6; Chen MK, 2003, J NEUROSCI, V23, P8568; Chen MK, 2001, J NEUROSCI, V21, P6512, DOI 10.1523/JNEUROSCI.21-17-06512.2001; Cooper P R, 1992, Neurosurg Clin N Am, V3, P659; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Engel DC, 2008, J NEUROTRAUM, V25, P739, DOI 10.1089/neu.2007.0480; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Frey LC, 2009, J NEUROSCI METH, V177, P267, DOI 10.1016/j.jneumeth.2008.10.022; Fromm L, 2004, J AM COLL NUTR, V23, p529S, DOI 10.1080/07315724.2004.10719396; Frontczak-Baniewicz M, 2007, J PHYSIOL PHARMACOL, V58, P193; Gerzanich V, 2009, NAT MED, V15, P185, DOI 10.1038/nm.1899; Golstein PE, 1999, PFLUG ARCH EUR J PHY, V437, P652, DOI 10.1007/s004240050829; GUDEMAN SK, 1979, NEUROSURGERY, V5, P309, DOI 10.1227/00006123-197909000-00002; Haseloff RF, 2006, PROTEOMICS, V6, P1803, DOI 10.1002/pmic.200500182; Hicks RR, 1997, MOL CHEM NEUROPATHOL, V32, P1, DOI 10.1007/BF02815164; Kawamata T, 2007, PROG BRAIN RES, V161, P235, DOI 10.1016/S0079-6123(06)61016-9; Kunte H, 2007, STROKE, V38, P2526, DOI 10.1161/STROKEAHA.107.482216; Lin B, 2001, J NEUROTRAUM, V18, P389, DOI 10.1089/089771501750170958; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; MERTOL T, 1991, British Journal of Neurosurgery, V5, P491, DOI 10.3109/02688699108998478; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Narayan RK, 2008, NEUROSURGERY, V62, P776, DOI 10.1227/01.NEU.0000297095.04013.C4; Nikulina E, 2004, P NATL ACAD SCI USA, V101, P8786, DOI 10.1073/pnas.0402595101; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Park E, 2009, J CEREBR BLOOD F MET, V29, P575, DOI 10.1038/jcbfm.2008.151; Payen L, 2001, BRIT J PHARMACOL, V132, P778, DOI 10.1038/sj.bjp.0703863; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; Regan RF, 1998, J NEUROTRAUM, V15, P645, DOI 10.1089/neu.1998.15.645; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; Simard JM, 2008, CURR OPIN PHARMACOL, V8, P42, DOI 10.1016/j.coph.2007.10.004; Simard JM, 2007, J CLIN INVEST, V117, P2105, DOI 10.1172/JCI32041; Simard JM, 2007, LANCET NEUROL, V6, P258, DOI 10.1016/S1474-4422(07)70055-8; Simard JM, 2009, J CEREBR BLOOD F MET, V29, P317, DOI 10.1038/jcbfm.2008.120; Simard JM, 2009, STROKE, V40, P604, DOI 10.1161/STROKEAHA.108.522409; Simard JM, 2006, NAT MED, V12, P433, DOI 10.1038/nm1390; Smith JS, 2007, J TRAUMA, V63, P75, DOI 10.1097/01.ta.0000245991.42871.87; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Tseng Sheng-Hong, 1992, Journal of the Formosan Medical Association, V91, P585; Utagawa A, 2008, BRAIN RES, V1207, P155, DOI 10.1016/j.brainres.2008.02.057; Vink R, 2003, NEUROSCI LETT, V336, P41, DOI 10.1016/S0304-3940(02)01244-2; Wang XY, 2002, STROKE, V33, P1882, DOI 10.1161/01.STR.0000020121.41527.5D; Yadav YR, 2006, NEUROL INDIA, V54, P377, DOI 10.4103/0028-3886.28109; Yokoshiki H, 1999, PFLUG ARCH EUR J PHY, V437, P400, DOI 10.1007/s004240050794; YOUNG HA, 1984, NEUROSURGERY, V14, P22, DOI 10.1227/00006123-198401000-00006	54	100	104	0	8	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	2009	26	12					2257	2267		10.1089/neu.2009.1021			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	536AI	WOS:000273013200013	19604096	Green Published, Bronze			2022-02-06	
J	Gironda, RJ; Clark, ME; Ruff, RL; Chait, S; Craine, M; Walker, R; Scholten, J				Gironda, Ronald J.; Clark, Michael E.; Ruff, Robert L.; Chait, Sari; Craine, Michael; Walker, Robyn; Scholten, Joel			Traumatic Brain Injury, Polytrauma, and Pain: Challenges and Treatment Strategies for the Polytrauma Rehabilitation	REHABILITATION PSYCHOLOGY			English	Article						pain; headache; polytrauma; traumatic brain injury; postconcussive syndrome; posttraumatic stress disorder	OPERATIONS ENDURING FREEDOM; TENSION-TYPE HEADACHE; SPINAL MANIPULATION; IRAQI-FREEDOM; OLDER-ADULTS; MIGRAINE; VETERANS; SLEEP; NIGHTMARES; EXPERIENCE	Problem: Chronic pain conditions are common sequelae of traumatic brain injury (TBI). Unfortunately, the incidence of TBI among personnel deployed for Operations Enduring Freedom and Iraqi Freedom (OEF/OIF) is significant, and there is growing evidence that ongoing pain, particularly headaches, will be a primary concern for these individuals. Objective: This article synthesizes empirical data from civilian and veteran populations and clinical experience with OEF/OIF personnel with polytrauma to provide recommendations for the assessment and treatment of chronic pain among those with TBI. Conclusions: ne available data signal the need for the incorporation of early and aggressive pain management strategies into existing treatment models. Challenges to providing effective pain management for OEF/OIF veterans are numerous and include comorbid cognitive, medical, and emotional impairments that complicate readjustment to civilian life. It is likely that the problem of polytrauma pain and associated comorbid conditions such as posttraumatic stress disorder and postconcussive syndrome will require the development of integrated approaches to clinical care which bridge traditional subspecialty divisions. A proposed model of treatment is presented.	[Gironda, Ronald J.; Clark, Michael E.; Walker, Robyn] James A Haley Vet Hosp, Mental Hlth & Behav Sci Serv, Tampa, FL 33612 USA; [Clark, Michael E.] Univ S Florida, Coll Med, Dept Neurol, Tampa, FL 33620 USA; [Ruff, Robert L.] Case Western Reserve Univ, Neurol Serv, Cleveland, OH 44106 USA; [Ruff, Robert L.] Case Western Reserve Univ, Cleveland Funct Elect Stimulat Ctr, Louis Stokes VA Med Ctr, Cleveland, OH 44106 USA; [Ruff, Robert L.] Case Western Reserve Univ, Dept Neurol, Cleveland, OH 44106 USA; [Ruff, Robert L.] Case Western Reserve Univ, Dept Neurosci, Cleveland, OH 44106 USA; [Chait, Sari] James A Haley Vet Hosp, Res & Dev Serv, Tampa, FL USA; [Chait, Sari] Univ S Florida, Dept Psychol, Tampa, FL 33620 USA; [Craine, Michael] Univ Colorado, Sch Med, Hlth Psychol Sect, VA Eastern Colorado Hlth Care Syst, Boulder, CO 80309 USA; [Craine, Michael] Univ Colorado, Sch Med, Dept Phys Med & Rehabil, Boulder, CO 80309 USA; [Scholten, Joel] James A Haley Vet Hosp, Phys Med & Rehabil Serv, Tampa, FL USA; [Scholten, Joel] Univ S Florida, Coll Med, Div Phys Med & Rehabil, Tampa, FL 33620 USA		Gironda, RJ (corresponding author), James A Haley Vet Hosp, Mental Hlth & Behav Sci Serv 116A, 13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.	Ronald.Gironda@va.gov					ANDREWS EE, 2009, J PAIN S1, V10, P74; Ashina M, 2004, CEPHALALGIA, V24, P161, DOI 10.1111/j.1468-2982.2003.00644.x; Asmundson GJG, 2002, CAN J PSYCHIAT, V47, P930, DOI 10.1177/070674370204701004; Aurora SK, 2007, CEPHALALGIA, V27, P1442, DOI 10.1111/j.1468-2982.2007.01502.x; Baker A, 1996, Perspectives, V20, P4; Bendtsen L, 2000, CEPHALALGIA, V20, P486, DOI 10.1046/j.1468-2982.2000.00070.x; Bigal ME, 2008, HEADACHE, V48, P1157, DOI 10.1111/j.1526-4610.2008.01217.x; Bigal ME, 2009, PAIN, V142, P179, DOI 10.1016/j.pain.2009.01.013; Black JA, 2004, PAIN, V108, P237, DOI 10.1016/j.pain.2003.12.035; Bolay H, 2002, NAT MED, V8, P136, DOI 10.1038/nm0202-136; BOLINE PD, 1995, J MANIP PHYSIOL THER, V18, P148; Bove G, 1998, JAMA-J AM MED ASSOC, V280, P1576, DOI 10.1001/jama.280.18.1576; Breslau N, 2003, NEUROLOGY, V60, P1308, DOI 10.1212/01.WNL.0000058907.41080.54; Carey ME, 1996, J TRAUMA, V40, pS165, DOI 10.1097/00005373-199603001-00036; Chibnall JT, 2001, PAIN, V92, P173, DOI 10.1016/S0304-3959(00)00485-1; Clark ME, 2004, PAIN MED, V5, P333, DOI 10.1111/j.1526-4637.2004.04059.x; CLARK ME, 2009, NAT VA PAIN MAN C E; Clark ME, 2007, J REHABIL RES DEV, V44, P179, DOI 10.1682/JRRD.2006.05.0057; Clark ME, 2009, PAIN MED, V10, P456, DOI 10.1111/j.1526-4637.2009.00589.x; Clark ME, 2009, PAIN MED, V10, P447, DOI 10.1111/j.1526-4637.2009.00590.x; Coppola G, 2007, Cephalalgia, V27, P1427, DOI 10.1111/j.1468-2982.2007.01500.x; Couch JR, 2001, HEADACHE, V41, P559, DOI 10.1046/j.1526-4610.2001.041006559.x; Daly CM, 2005, MIL MED, V170, P513, DOI 10.7205/MILMED.170.6.513; De Benedittis G, 1983, J Neurosurg Sci, V27, P177; Dierks MR, 2007, ANN PHARMACOTHER, V41, P1013, DOI 10.1345/aph.1H588; Edna T H, 1987, J Oslo City Hosp, V37, P41; Evans RW, 2004, NEUROL CLIN, V22, P237, DOI 10.1016/S0733-8619(03)00097-5; Feldt K S, 2000, Pain Manag Nurs, V1, P13, DOI 10.1053/jpmn.2000.5831; Ferrell B, 2002, J AM GERIATR SOC, V50, pS205, DOI 10.1046/j.1532-5415.50.6s.1.x; Ferrell BA, 2000, CLIN GERIATR MED, V16, P853, DOI 10.1016/S0749-0690(05)70048-3; Ferrell BA, 1995, J PAIN SYMPTOM MANAG, V10, P591, DOI 10.1016/0885-3924(95)00121-2; Foa EB, 1997, ANNU REV PSYCHOL, V48, P449, DOI 10.1146/annurev.psych.48.1.449; Follett PL, 2004, J NEUROSCI, V24, P4412, DOI 10.1523/JNEUROSCI.0477-04.2004; Frank MG, 2001, NEURON, V30, P275, DOI 10.1016/S0896-6273(01)00279-3; Gallagher R, 2006, J AM MED DIR ASSOC, V7, P432, DOI 10.1016/j.jamda.2006.04.010; Garcia-Monco JC, 2007, CEPHALALGIA, V27, P920, DOI 10.1111/j.1468-2982.2007.01367.x; Gironda RJ, 2006, PAIN MED, V7, P339, DOI 10.1111/j.1526-4637.2006.00146.x; Hadjistavropoulos T, 2000, CLIN J PAIN, V16, P54, DOI 10.1097/00002508-200003000-00009; Hains BC, 2006, J NEUROSCI, V26, P4308, DOI 10.1523/JNEUROSCI.0003-06.2006; Hains BC, 2005, BRAIN, V128, P2359, DOI 10.1093/brain/awh623; Hargreaves RJ, 1999, CAN J NEUROL SCI, V26, pS12, DOI 10.1017/S0317167100000147; Herr K, 2006, J PAIN SYMPTOM MANAG, V31, P170, DOI 10.1016/j.jpainsymman.2005.07.001; Herr KA, 2001, CLIN GERIATR MED, V17, P457, DOI 10.1016/S0749-0690(05)70080-X; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; HOLROYD KA, 1990, PAIN, V42, P1, DOI 10.1016/0304-3959(90)91085-W; Huffman Jeff C, 2007, Dialogues Clin Neurosci, V9, P29; Ivanhoe CB, 2004, J HEAD TRAUMA REHAB, V19, P29, DOI 10.1097/00001199-200401000-00004; Jha SK, 2005, J NEUROSCI, V25, P9266, DOI 10.1523/JNEUROSCI.2722-05.2005; Kalra M, 2003, J VASC SURG, V38, P215, DOI 10.1016/S0741-5214(03)00331-8; Kaniecki R, 2003, JAMA-J AM MED ASSOC, V289, P1430, DOI 10.1001/jama.289.11.1430; Kaniecki R, 2004, STANDARDS CARE HEADA, P40; Kato K, 2007, J NEUROSURG, V106, P667, DOI 10.3171/jns.2007.106.4.667; Keidel M, 1997, NERVENARZT, V68, P769, DOI 10.1007/s001150050193; Koltyn KF, 1998, BRIT J SPORT MED, V32, P20, DOI 10.1136/bjsm.32.1.20; Kovach CR, 1999, J PAIN SYMPTOM MANAG, V18, P412, DOI 10.1016/S0885-3924(99)00094-9; Lahz S, 1996, ARCH PHYS MED REHAB, V77, P889, DOI 10.1016/S0003-9993(96)90275-0; LANDY S, 2004, STANDARDS CARE HEADA, P27; LEEDHAM CS, 1993, MIL MED, V158, P508, DOI 10.1093/milmed/158.8.508; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; LEW HL, J REHABILIT IN PRESS; MATHEW N, 2004, STANDARDS CARE HEADA, P73; *MIL TBI TASK FORC, 2007, REP MIL TBI TASK FOR; Miller L J, 1998, Appl Neuropsychol, V5, P172, DOI 10.1207/s15324826an0504_2; Montagna P, 2000, CEPHALALGIA, V20, P3, DOI 10.1046/j.1468-2982.2000.00003.x; Morello R, 2007, PAIN, V133, P87, DOI 10.1016/j.pain.2007.03.007; Mulleners WM, 2001, HEADACHE, V41, P565, DOI 10.1046/j.1526-4610.2001.041006565.x; Nicholson K, 2004, J HEAD TRAUMA REHAB, V19, P2, DOI 10.1097/00001199-200401000-00002; Ofek H, 2007, PAIN, V131, P330, DOI 10.1016/j.pain.2007.06.015; Otis JD, 2003, J REHABIL RES DEV, V40, P397, DOI 10.1682/JRRD.2003.09.0397; Penzien DB, 2002, APPL PSYCHOPHYS BIOF, V27, P163, DOI 10.1023/A:1016247811416; Ramadan NM, 2007, HEADACHE, V47, pS52, DOI 10.1111/j.1526-4610.2007.00677.x; Raskind MA, 2007, BIOL PSYCHIAT, V61, P928, DOI 10.1016/j.biopsych.2006.06.032; *ROYAL COLL PHYS B, 2007, CONC GUID GOOD PRACT, V8; Ruff RL, 2008, J REHABIL RES DEV, V45, P941, DOI 10.1682/JRRD.2008.02.0028; RUOFF G, 2004, STANDARDS CARE HEADA, P53; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Sandor PS, 2007, CEPHALALGIA, V27, P1440, DOI 10.1111/j.1468-2982.2007.01501.x; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Sherer M, 2007, BRAIN INJURY, V21, P663, DOI 10.1080/02699050701481589; Sherman Kristen Brewer, 2006, Phys Med Rehabil Clin N Am, V17, P473, DOI 10.1016/j.pmr.2005.11.007; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; Stankewitz A, 2007, CEPHALALGIA, V27, P1454, DOI 10.1111/j.1468-2982.2007.01503.x; Stolee P, 2005, J AM GERIATR SOC, V53, P319, DOI 10.1111/j.1532-5415.2005.53121.x; Stoudemire A, 1984, Psychiatr Med, V2, P211; Tononi G, 2003, BRAIN RES BULL, V62, P143, DOI 10.1016/j.brainresbull.2003.09.004; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; Veterans Health Administration, 2006, VHA HDB 2A, P1; WALKER RL, 2009, POSTDEPLOYMENT UNPUB; Walker RL, 2008, NAT M VA HLTH SERV R; Warden DL, 2005, J NEUROTRAUM, V22, P1178; Waxman SG, 2006, TRENDS NEUROSCI, V29, P207, DOI 10.1016/j.tins.2006.02.003; Weiner D, 1996, PAIN, V67, P461, DOI 10.1016/0304-3959(96)03150-8; Weiner DK, 2002, PERSISTENT PAIN IN OLDER ADULTS: INTERDISCIPLINARY GUIDE FOR TREATMENT, P18; Young James A, 2007, Phys Med Rehabil Clin N Am, V18, P145, DOI 10.1016/j.pmr.2006.11.008; Zhao P, 2007, J NEUROSCI, V27, P2357, DOI 10.1523/JNEUROSCI.0138-07.2007; ZOROYA G, 2006, CTR WAR RELATED BRAI	97	100	100	0	14	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	AUG	2009	54	3					247	258		10.1037/a0016906			12	Psychology, Clinical; Rehabilitation	Social Science Citation Index (SSCI)	Psychology; Rehabilitation	488SW	WOS:000269371100002	19702423				2022-02-06	
J	Laufer, J; Zhang, E; Raivich, G; Beard, P				Laufer, Jan; Zhang, Edward; Raivich, Gennadij; Beard, Paul			Three-dimensional noninvasive imaging of the vasculature in the mouse brain using a high resolution photoacoustic scanner	APPLIED OPTICS			English	Article; Proceedings Paper	Biomedical Topical Meeting	MAR 16-20, 2008	St Petersburg, FL	Opt Soc Amer			IN-VIVO; TOMOGRAPHY	The application of a novel photoacoustic imaging instrument based on a Fabry-Perot polymer film sensing interferometer to imaging the small animal brain is described. This approach provides a convenient backward mode sensing configuration that offers the prospect of overcoming the limitations of existing piezoelectric based detection schemes for small animal brain imaging. Noninvasive images of the vasculature in the mouse brain were obtained at different wavelengths between 590 and 889 nm, showing that the cerebral vascular anatomy can be visualized with high contrast and spatial resolution to depths up to 3.7 mm. It is considered that the instrument has a role to play in characterizing small animal models of human disease and injury processes such as stroke, epilepsy, and traumatic brain injury. (C) 2009 Optical Society of America	[Laufer, Jan; Zhang, Edward; Raivich, Gennadij; Beard, Paul] UCL, Dept Med Phys & Bioengn, London WC1E 6BT, England; [Raivich, Gennadij] UCL, Ctr Perinatal Brain Res, London WC1E 6BT, England		Beard, P (corresponding author), UCL, Dept Med Phys & Bioengn, Gower St, London WC1E 6BT, England.	pbeard@medphys.ucl.ac.uk	Raivich, Gennadij/AAL-7229-2021; Raivich, Gennadij/A-6770-2011	Laufer, Jan/0000-0002-9688-8993			Allen TJ, 2006, OPT LETT, V31, P3462, DOI 10.1364/OL.31.003462; [Anonymous], 1994, 608251 BS EN, P1; Balaban R S, 2001, ILAR J, V42, P248; BEARD PC, 2001, Patent No. 03039364; Cherry SR, 2004, PHYS MED BIOL, V49, pR13, DOI 10.1088/0031-9155/49/3/R01; Cope M, 1991, THESIS U COLL LONDON; De La Zerda A, 2008, NAT NANOTECHNOL, V3, P557, DOI 10.1038/nnano.2008.231; Fang H, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.184501; Gamelin J, 2008, J BIOMED OPT, V13, DOI 10.1117/1.2907157; Gibson AP, 2005, PHYS MED BIOL, V50, pR1, DOI 10.1088/0031-9155/50/4/R01; Hillman EMC, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2789693; Kostli KP, 2001, PHYS MED BIOL, V46, P1863, DOI 10.1088/0031-9155/46/7/309; Kruger Robert A, 2003, Mol Imaging, V2, P113, DOI 10.1162/153535003322331993; Lamont M, 2006, ELECTRON LETT, V42, P187, DOI 10.1049/el:20064135; Laufer J, 2007, PHYS MED BIOL, V52, P141, DOI 10.1088/0031-9155/52/1/010; Li ML, 2008, P IEEE, V96, P481, DOI 10.1109/JPROC.2007.913515; Lythgoe MF, 2003, BRIT MED BULL, V65, P235, DOI 10.1093/bmb/65.1.235; MASLOV K, 2007, P SPIE, V6437; Song KH, 2006, OPT LETT, V31, P2453, DOI 10.1364/OL.31.002453; STEIN EW, 2008, P SPIE, V6856; Wang L.V., 2007, BIOMEDICAL OPTICS PR; Wang LV, 2008, IEEE J SEL TOP QUANT, V14, P171, DOI 10.1109/JSTQE.2007.913398; Wang XD, 2004, OPT LETT, V29, P730, DOI 10.1364/OL.29.000730; Wang XD, 2003, OPT LETT, V28, P1739, DOI 10.1364/OL.28.001739; Wang XD, 2003, NAT BIOTECHNOL, V21, P803, DOI 10.1038/nbt839; Yang S, 2007, MED PHYS, V34, P3294, DOI 10.1118/1.2757088; Zhang E, 2008, APPL OPTICS, V47, P561, DOI 10.1364/AO.47.000561; ZHANG EZ, 2007, P SPIE, V6437; Zhang QZ, 2008, PHYS MED BIOL, V53, P1921, DOI 10.1088/0031-9155/53/7/008	29	100	103	1	19	OPTICAL SOC AMER	WASHINGTON	2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA	1559-128X	2155-3165		APPL OPTICS	Appl. Optics	APR 1	2009	48	10					D299	D306		10.1364/AO.48.00D299			8	Optics	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Optics	436VH	WOS:000265443700034	19340121				2022-02-06	
J	Betker, AL; Desai, A; Nett, C; Kapadia, N; Szturm, T				Betker, Aimee L.; Desai, Ankur; Nett, Cristabel; Kapadia, Naaz; Szturm, Tony			Game-based exercises for dynamic short-sitting balance rehabilitation of people with chronic spinal cord and traumatic brain injuries	PHYSICAL THERAPY			English	Article							VIRTUAL-REALITY; STROKE; TECHNOLOGY; MOBILITY; THERAPY; TASK; AGE	Background and Purpose Goal-oriented, task-specific training has been shown to improve function; however, it can be difficult to maintain patient interest. This report describes a rehabilitation protocol for the maintenance of balance in a short-sitting position following spinal cord and head injuries by use of a center-of-pressure-controlled video game-based tool. The scientific justification for the selected treatment is discussed. Case Descriptions Three adults were treated: 1 young adult with spina bifida (T10 and L1-L2), 1 middle-aged adult with complete paraplegia (complete. lesion at T11-L1), and 1 middle-aged adult with traumatic brain injury. All patients used wheelchairs full-time. Outcomes The patients showed increased motivation to perform the game-based exercises and increased dynamic short-sitting balance. Discussion The patients exhibited increases in practice volume and attention span during training with the game-based tool. In addition, they demonstrated substantial improvements in dynamic balance control. These observations indicate that a video game-based exercise approach can have a substantial positive effect by improving dynamic short-sitting balance.	Univ Manitoba, Div Phys Therapy, Sch Med Rehabil, Winnipeg, MB R3E 0T6, Canada; Univ Manitoba, Dept Elect & Comp Engn, Winnipeg, MB R3T 2N2, Canada		Szturm, T (corresponding author), Univ Manitoba, Div Phys Therapy, Sch Med Rehabil, R106-771 McDermot Ave, Winnipeg, MB R3E 0T6, Canada.	ptsturm@cc.umanitoba.ca		Kapadia, Naaz/0000-0001-7999-7488			Allum JHJ, 2002, GAIT POSTURE, V16, P264, DOI 10.1016/S0966-6362(02)00011-5; Baratto L, 2002, MOTOR CONTROL, V6, P246, DOI 10.1123/mcj.6.3.246; Betker AL, 2005, P ANN INT IEEE EMBS, P2341, DOI 10.1109/IEMBS.2005.1616935; Betker AL, 2006, ARCH PHYS MED REHAB, V87, P1141, DOI 10.1016/j.apmr.2006.04.010; Betker AL, 2005, IEEE T BIO-MED ENG, V52, P345, DOI 10.1109/TBME.2004.840466; Bourbonnais D, 2002, AM J PHYS MED REHAB, V81, P890, DOI 10.1097/00002060-200212000-00002; Bryanton C, 2006, CYBERPSYCHOL BEHAV, V9, P123, DOI 10.1089/cpb.2006.9.123; Cogan A., 1977, 4 ANN C SYST DEV DIS, P187; COLLINS JJ, 1995, EXP BRAIN RES, V104, P480, DOI 10.1007/BF00231982; Cunningham D, 1999, ST HEAL T, V62, P90; Douglas J, 2005, DIABETES SELF MANAG, V22, P55; Douglas J, 2005, DIABETES SELF MANAG, V22, P51; Douglas Jean, 2005, Diabetes Self Manag, V22, P47; Dozza Marco, 2005, J Neuroeng Rehabil, V2, P13, DOI 10.1186/1743-0003-2-13; Edgerton VR, 2006, J NEUROTRAUM, V23, P560, DOI 10.1089/neu.2006.23.560; Fung J, 2006, CYBERPSYCHOL BEHAV, V9, P157, DOI 10.1089/cpb.2006.9.157; GARR JH, 1998, NEUROLOGICAL REHABIL; Geiger RA, 2001, PHYS THER, V81, P995, DOI 10.1093/ptj/81.4.995; Glanz M, 1997, J ROY SOC MED, V90, P33, DOI 10.1177/014107689709000110; Harkema SJ, 2001, NEUROSCIENTIST, V7, P455, DOI 10.1177/107385840100700514; Huxham FE, 2001, AUST J PHYSIOTHER, V47, P89, DOI 10.1016/S0004-9514(14)60300-7; Jack D, 2001, IEEE T NEUR SYS REH, V9, P308, DOI 10.1109/7333.948460; Kwakkel G, 2006, DISABIL REHABIL, V28, P823, DOI 10.1080/09638280500534861; Malone T.W, 1982, CHI 82 P 1982 C HUMA, P63; Nelson DL, 1996, AM J OCCUP THER, V50, P639, DOI 10.5014/ajot.50.8.639; Norris JA, 2005, J BIOMECH, V38, P1263, DOI 10.1016/j.jbiomech.2004.06.014; O'Connor TJ, 2000, NEUROREHAB NEURAL RE, V14, P21, DOI 10.1177/154596830001400103; Remple MS, 2001, BEHAV BRAIN RES, V123, P133, DOI 10.1016/S0166-4328(01)00199-1; Richards CL, 2004, NEUROREHAB NEURAL RE, V18, P199, DOI 10.1177/1545968304269397; Schultheis MT, 2001, REHABIL PSYCHOL, V46, P296, DOI 10.1037/0090-5550.46.3.296; SHUMWAYCOOK A, 1986, PHYS THER, V66, P1548, DOI 10.1093/ptj/66.10.1548; Szturm T, 1998, J VESTIBUL RES-EQUIL, V8, P381; Todorov E, 1997, J MOTOR BEHAV, V29, P147, DOI 10.1080/00222899709600829; Tsang WWN, 2004, MED SCI SPORT EXER, V36, P658, DOI 10.1249/01.MSS.0000122077.87090.2E; Webster JS, 2001, ARCH PHYS MED REHAB, V82, P769, DOI 10.1053/apmr.2001.23201; Yoo EY, 2006, CLIN REHABIL, V20, P388, DOI 10.1191/0269215506cr962oa; You SH, 2005, STROKE, V36, P1166, DOI 10.1161/01.STR.0000162715.43417.91	37	100	102	1	20	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0031-9023	1538-6724		PHYS THER	Phys. Ther.	OCT	2007	87	10					1389	1398		10.2522/ptj.20060229			10	Orthopedics; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Rehabilitation	217WA	WOS:000249976800014	17712036	Bronze			2022-02-06	
J	Styrke, J; Stalnacke, BM; Sojka, P; Bjornstig, U				Styrke, Johan; Stalnacke, Britt-Marie; Sojka, Peter; Bjornstig, Ulf			Traumatic brain injuries in a well-defined population: Epidemiological aspects and severity	JOURNAL OF NEUROTRAUMA			English	Article						epidemiology; head trauma; traumatic brain injury	CT-SCAN; HEAD; MILD	The aim was to describe epidemiological and medical aspects of 449 cases of traumatic brain injury (TBI) from a well-defined geographical area with a population of 137,000 inhabitants. An episode of disturbed consciousness was a prerequisite for inclusion in the study. The incidence of TBI was 354/100,000 inhabitants. Median age was 23 years, range 0-91 years; 55% were men and 45% were women; 33% children 0-14 years, 50% adults 15-64 years, and 17% elderly persons 65-91 years old. Severity classification was based on Glasgow Coma Scale (GCS) on arrival; mild TBI 97% (GCS 13-15), moderate 1% (GCS 9-12), and severe 2% ( GCS 3-8). The most common injury events were falls (55%) and vehicle-related events (30%). The percentage of falls was high among children and elderly persons but among adults vehicle-related injury events were also prominent. At least 17% of all patients were under the influence of alcohol, especially adult male bicyclists. CT was performed on 163 cases (36%) revealing 34 cases with intracranial hemorrhage (ICH) which is 21% of the examined or 8% of all the injured. The rate of ICH increased with increasing age (from 3% among children to 17% among the elderly persons) and also increased with decreasing GCS from 6% in the group of mild TBI to 60% among those with severe TBI. Attention should be directed to acute management of mild TBI in order to detect potentially dangerous ICH as well as to preventive actions against falls and vehicle related accidents.	Umea Univ, Dept Surg & Perioperat Sci, Div Surg, Umea, Sweden; Umea Univ, Dept Community Med & Rehabil, Umea, Sweden		Styrke, J (corresponding author), Umea Univ, Dept Surg & Perioperat Sci, Div Surg, Umea, Sweden.	jonste00@student.umu.se	Styrke, Johan/AAE-1193-2021				Andersson EH, 2003, ACTA NEUROL SCAND, V107, P256, DOI 10.1034/j.1600-0404.2003.00112.x; BJORNSTIG K, 2006, VEHICLE RELATED INJU; BJORNSTIG U, 1992, J TRAUMA, V33, P887; Bordignon KC, 2002, ARQ NEURO-PSIQUIAT, V60, P204, DOI 10.1590/S0004-282X2002000200004; BORG BM, 2000, 153 SWEED COUNC TECH; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; BYLUND PO, 2001, P ASS ADV AUT MED C, V45, P1; BYLUND PO, 1996, J TRAFFIC MED, V24, P27; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; *COMM TRAUM, 2004, ADV TRAUM LIF SUPP D; de boussard CN, 2004, BRAIN INJURY, V18, P671, DOI 10.1080/02699050310001646215; EVANS L, 2000, CRASH PREV INJ CONTR, V2, P111; EWANUELSON I, 2003, ACTA NEUROL SCAND, V108, P332; Geijerstam JLA, 2003, ACTA NEUROCHIR, V145, P843, DOI 10.1007/s00701-003-0115-1; Grande PO, 2002, ACTA ANAESTH SCAND, V46, P929, DOI 10.1034/j.1399-6576.2002.460802.x; HONKANEN R, 1977, SCAND J SOC MED, V5, P91, DOI 10.1177/140349487700500207; Ingebrigtsen T, 1996, ACTA NEUROL SCAND, V93, P207; JOHANSSON E, 1991, SCAND J REHABIL MED, V23, P179; Kay A, 2001, WORLD J SURG, V25, P1210, DOI 10.1007/s00268-001-0084-6; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kleiven Svein, 2003, Inj Control Saf Promot, V10, P173, DOI 10.1076/icsp.10.3.173.14552; Krafft Maria, 2006, Traffic Inj Prev, V7, P125, DOI 10.1080/15389580500509278; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; *NAT BOARD HLTH WE, 1997, INT STAT CLASS DIS R; *NAT CTR INJ CONTR, 2003, REP C MILD TRAUM BRA; Nordstrom C H, 2005, Acta Neurochir Suppl, V95, P475; Paden M., 2002, INJURY LEADING CAUSE; Peloso PM, 2004, J REHABIL MED, V36, P22, DOI 10.1080/16501960410023714; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Stalnacke BM, 2005, J REHABIL MED, V37, P300, DOI 10.1080/16501970510032910; STEIN SC, 1991, ANN EMERG MED, V20, P1286, DOI 10.1016/S0196-0644(05)81066-2; TEASDALE G, 1974, LANCET, V2, P81; TEASDALE GM, 1990, BRIT MED J, V300, P363, DOI 10.1136/bmj.300.6721.363; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; von Wild KRH, 2005, ACTA NEUROCHIR SUPPL, V93, P15; Wahlberg T, 1995, Lakartidningen, V92, P658; WAHLBERG T, 1994, HJARNSKAKINGETIOLOGI; Yates PJ, 2006, J NEUROL NEUROSUR PS, V77, P699, DOI 10.1136/jnnp.2005.081901	39	100	101	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2007	24	9					1425	1436		10.1089/neu.2007.0266			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	214ZT	WOS:000249777600002	17892405	Green Submitted			2022-02-06	
J	Deng, Y; Thompson, BM; Gao, X; Hall, ED				Deng, Ying; Thompson, Brian M.; Gao, Xiang; Hall, Edward D.			Temporal relationship of peroxymtrite-induced oxidative damage, calpain-mediated cytoskeletal degradation and neurodegeneration after traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						peroxynitrite; oxidative damage; calpain; cytoskeletal degradation; neurodegeneration; controlled cortical impact (CCI); TBI	NITRIC-OXIDE SYNTHASE; EXPERIMENTAL HEAD-INJURY; CONTROLLED CORTICAL IMPACT; LIPID-PEROXIDATION; MITOCHONDRIAL DYSFUNCTION; PEROXYNITRITE REACTIONS; NEURONAL DEGENERATION; TYROSINE NITRATION; NERVOUS-SYSTEM; MOUSE MODEL	We assessed the temporal and spatial characteristics of PN-induced oxidative damage and its relationship to calpain-mediated cytoskeletal degradation and neurodegeneration in a severe unilateral controlled cortical impact (CCI) traumatic brain injury (TBI) model. Quantitative temporal time course studies were performed to measure two oxidative damage markers: 3-nitrotyrosine (3NT) and 4-hydroxynonenal (4HNE) at 30 min, 1, 3, 6, 12, 24, 48, 72 h and 7 days after injury in ipsilateral cortex of young adult male CF- I mice. Secondly, the time course of Ca++-activated, calpain-mediated proteolysis was also analyzed using quantitative western-blot measurement of breakdown products of the cytoskeletal protein alpha-spectrin. Finally, the time course of neurodegeneration was examined using de Olmos silver staining. Both oxidative damage markers increased in cortical tissue immediately after injury (30 min) and elevated for the first 3-6 h before returning to baseline. In the immunostaining study, the PN-selective marker, 3NT, and the lipid peroxidation marker, 4HNE, were intense and overlapping in the injured cortical tissue. alpha-Spectrin breakdown products, which were used as biomarker for calpain-mediated cytoskeletal degradation, were also increased after injury, but the time course lagged behind the peak of oxidative damage and did not reach its maximum until 24 h post-injury. In turn, cytoskeletal degradation preceded the peak of neurodegeneration which occurred at 48 h post-injury. These studies have led us to the hypothesis that PN-mediated oxidative damage is an early event that contributes to a compromise of Ca++ homeostatic mechanisms which causes a massive Ca++ overload and calpain activation which is a final common pathway that results in post-traumatic neurodegeneration. (C) 2007 Elsevier Inc. All rights reserved.	Univ Kentucky, Albert B Chandler Med Ctr, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA		Hall, ED (corresponding author), Univ Kentucky, Albert B Chandler Med Ctr, Spinal Cord & Brain Injury Res Ctr, 741 S Limestone St,B383 Biomed & Biol Sci Res Bld, Lexington, KY 40536 USA.	edhall@uky.edu	Hall, Edward D/F-8930-2013		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS046566-04, R01 NS046566-02, P30 NS051220-019005, P30 NS051220-01, P30 NS051220-02, P30 NS051220, R01 NS046566-01A1, R01 NS046566-03, P30 NS051220-029005, R01 NS046566] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS051220, R01NS046566] Funding Source: NIH RePORTER		ARRIGONI E, 1991, NEUROCHEM RES, V16, P483; Awasthi D, 1997, SURG NEUROL, V47, P575, DOI 10.1016/S0090-3019(96)00461-2; BARTUS RT, 1995, NEUROL RES, V17, P249, DOI 10.1080/01616412.1995.11740322; BATES TE, 1995, BIOCHEM BIOPH RES CO, V213, P896, DOI 10.1006/bbrc.1995.2213; Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445; BeitYannai E, 1996, BRAIN RES, V717, P22, DOI 10.1016/0006-8993(95)01492-6; BENUCK M, 1992, BRAIN RES, V596, P296, DOI 10.1016/0006-8993(92)91560-2; Bicker G, 2001, ARCH INSECT BIOCHEM, V48, P100, DOI 10.1002/arch.1062; Bringold U, 2000, FREE RADICAL BIO MED, V29, P343, DOI 10.1016/S0891-5849(00)00318-X; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; Carroll RT, 2000, CHEM RES TOXICOL, V13, P294, DOI 10.1021/tx990159t; Chakraborti T, 1999, CELL SIGNAL, V11, P77, DOI 10.1016/S0898-6568(98)00025-4; Chiueh CC, 1999, ANN NY ACAD SCI, V890, P301, DOI 10.1111/j.1749-6632.1999.tb08007.x; Cobbs CS, 1997, BRAIN RES, V751, P336, DOI 10.1016/S0006-8993(96)01429-1; Dawson VL, 1996, P SOC EXP BIOL MED, V211, P33; DEOLMOS JS, 1994, NEUROTOXICOL TERATOL, V16, P545, DOI 10.1016/0892-0362(94)90033-7; DeRidder MN, 2006, NEUROBIOL DIS, V22, P165, DOI 10.1016/j.nbd.2005.10.011; Elfering SL, 2002, J BIOL CHEM, V277, P38079, DOI 10.1074/jbc.M205256200; Gahm C, 2000, NEUROSURGERY, V46, P169, DOI 10.1093/neurosurgery/46.1.169; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; Ghafourifar P, 1999, J BIOL CHEM, V274, P31185, DOI 10.1074/jbc.274.44.31185; Ghafourifar P, 1997, FEBS LETT, V418, P291, DOI 10.1016/S0014-5793(97)01397-5; Giulivi C, 2003, FREE RADICAL BIO MED, V34, P397, DOI 10.1016/S0891-5849(02)01298-4; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Guttmann RP, 1998, J BIOL CHEM, V273, P13331, DOI 10.1074/jbc.273.21.13331; Guttmann RP, 1997, J BIOL CHEM, V272, P2005, DOI 10.1074/jbc.272.3.2005; HALL ED, 1994, ANN NY ACAD SCI, V738, P15; Hall ED, 1999, ANN NY ACAD SCI, V890, P462, DOI 10.1111/j.1749-6632.1999.tb08025.x; Hall ED, 1997, J NEUROSCI METH, V76, P115, DOI 10.1016/S0165-0270(97)00089-7; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; Hall ED, 2005, J NEUROTRAUM, V22, P669, DOI 10.1089/neu.2005.22.669; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; HALLIWELL B, 1999, OXFORD SCI PUBLICATI; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; Lacza Z, 2001, FREE RADICAL BIO MED, V31, P1609, DOI 10.1016/S0891-5849(01)00754-7; Lau A, 2006, J NEUROSCI, V26, P11540, DOI 10.1523/JNEUROSCI.3507-06.2006; Lopez-Figueroa MO, 2000, BIOCHEM BIOPH RES CO, V272, P129, DOI 10.1006/bbrc.2000.2748; Marklund N, 2001, J CEREBR BLOOD F MET, V21, P1259, DOI 10.1097/00004647-200111000-00002; Mesenge C, 1998, EUR J PHARMACOL, V353, P53, DOI 10.1016/S0014-2999(98)00432-4; Mesenge C, 1996, J NEUROTRAUM, V13, P209, DOI 10.1089/neu.1996.13.209; Mohanakumar KP, 1998, J CHEM NEUROANAT, V14, P195, DOI 10.1016/S0891-0618(98)00032-5; Mori T, 1998, ACT NEUR S, V71, P120; Murphy MP, 1998, GEN PHARMACOL, V31, P179, DOI 10.1016/S0306-3623(97)00418-7; Neely MD, 1999, J NEUROCHEM, V72, P2323, DOI 10.1046/j.1471-4159.1999.0722323.x; Neumar RW, 2001, EXP NEUROL, V170, P27, DOI 10.1006/exnr.2001.7708; Okabe E, 2000, ANTIOXID REDOX SIGN, V2, P47, DOI 10.1089/ars.2000.2.1-47; Orihara Y, 2001, FORENSIC SCI INT, V123, P142, DOI 10.1016/S0379-0738(01)00537-0; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; Radi R, 1998, CHEM RES TOXICOL, V11, P720, DOI 10.1021/tx980096z; Radi R, 2002, FREE RADICAL BIO MED, V33, P1451, DOI 10.1016/S0891-5849(02)01111-5; RADI R, 1994, ARCH BIOCHEM BIOPHYS, V308, P89, DOI 10.1006/abbi.1994.1013; ROVERI A, 1992, ARCH BIOCHEM BIOPHYS, V297, P265, DOI 10.1016/0003-9861(92)90671-I; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; SARAN M, 1990, FREE RADICAL RES COM, V10, P221, DOI 10.3109/10715769009149890; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Singh LN, 2006, J NEUROTRAUM, V23, P991; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Switzer RC, 2000, TOXICOL PATHOL, V28, P70, DOI 10.1177/019262330002800109; Thompson SN, 2006, EXP NEUROL, V201, P253, DOI 10.1016/j.expneurol.2006.04.013; Vicente S, 2006, J NEUROSCI RES, V84, P78, DOI 10.1002/jnr.20853; Volbracht C, 2005, J NEUROCHEM, V93, P1280, DOI 10.1111/j.1471-4159.2005.03122.x; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Whiteman M, 2004, FASEB J, V18, P1395, DOI 10.1096/fj.03-1096fje; Xiong YQ, 2007, J NEUROCHEM, V100, P639, DOI 10.1111/j.1471-4159.2006.04312.x; Zhou F, 2001, J CLIN NEUROSCI, V8, P561, DOI 10.1054/jocn.2001.0980	72	100	106	0	6	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	MAY	2007	205	1					154	165		10.1016/j.expneurol.2007.01.023			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	166TO	WOS:000246403400018	17349624	Green Accepted			2022-02-06	
J	Popa-Wagner, A; Badan, I; Walker, L; Groppa, S; Patrana, N; Kessler, C				Popa-Wagner, Aurel; Badan, Irina; Walker, Lary; Groppa, Sergiu; Patrana, Nicoleta; Kessler, Christof			Accelerated infarct development, cytogenesis and apoptosis following transient cerebral ischemia in aged rats	ACTA NEUROPATHOLOGICA			English	Article						stroke; aging; recovery; ischemia; rat; BrdU; GFAP; oligodendrocytes; microglia; CD8+lymphocytes; cytogenesis; vascular tree	AMYLOID PRECURSOR PROTEIN; TRAUMATIC BRAIN-INJURY; MESSENGER-RNA; ARTERY OCCLUSION; GENE-EXPRESSION; DENTATE GYRUS; ADULT RATS; STRUCTURAL PLASTICITY; CELL-PROLIFERATION; OXIDATIVE STRESS	Old age is associated with a deficient recovery from stroke, but the cellular mechanisms underlying such phenomena are poorly understood. To address this issue, focal cerebral ischemia was produced by reversible occlusion of the right middle cerebral artery in 3- and 20-month-old male Sprague-Dawley rats. Aged rats showed a delayed and suboptimal functional recovery in the post-stroke period. Using BrdU-labeling, quantitative immunohistochemistry and 3-D reconstruction of confocal images, we found that aged rats are predisposed to rapidly develop an infarct within the first few days after ischemia. The emergence of the necrotic zone is associated with a high rate of cellular degeneration, premature accumulation of proliferating BrdU-positive cells that appear to emanate from capillaries in the infarcted area, and a large number of apoptotic cells. With double labeling techniques, we were able to identify, for the first time, over 60% of BrdU-positive cells either as reactive microglia (45%), oligodendrocyte progenitors (17%), astrocytes (23%), CD8+ lymphocytes (4%), or apoptotic cells (< 1%). Paradoxically, despite a robust reactive phenotype of microglia and astrocytes in aged rats, at 1-week post-stroke, the number of proliferating microglia and astrocytes was lower in aged rats than in young rats. Our data indicate that aging is associated with rapid infarct development and a poor prognosis for full recovery from stroke that is correlated with premature cellular proliferation and increased cellular degeneration and apoptosis in the infarcted area.	Ernst Moritz Arndt Univ Greifswald, Dept Neurol, D-17487 Greifswald, Germany; Emory Univ, Yerkes Natl Primate Res Ctr, Atlanta, GA USA; Emory Univ, Dept Neurol, Atlanta, GA USA; Univ Med & Pharm, Craiova, Romania; Univ Klinikum Schleswig Holstein, Klin Neuropadiatrie, Kiel, Germany		Popa-Wagner, A (corresponding author), Ernst Moritz Arndt Univ Greifswald, Dept Neurol, Ellernholzstr 1-2, D-17487 Greifswald, Germany.	wagnerap@uni-greifswald.de	Walker, L C/J-6541-2015; Popa-Wagner, Aurel/I-2581-2019; Groppa, Sergiu/A-5711-2019; Popa-Wagner, Aurel/E-2541-2013; Groppa, Sergiu/G-4606-2014	Walker, L C/0000-0001-9166-3261; Groppa, Sergiu/0000-0002-2551-5655; 	NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [RR00165] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P51RR000165] Funding Source: NIH RePORTER		Adams MM, 2001, EXP NEUROL, V172, P244, DOI 10.1006/exnr.2001.7794; Adams MM, 2001, P NATL ACAD SCI USA, V98, P8071, DOI 10.1073/pnas.141215898; Aliev G, 2002, BRAIN PATHOL, V12, P21; Ardel-Rahman A, 2004, GLIA, V47, P299, DOI 10.1002/glia.20047; Asher RA, 2000, J NEUROSCI, V20, P2427; Badan I, 2004, EUR J NEUROSCI, V19, P2270, DOI 10.1111/j.0953-816X.2004.03323.x; Badan I, 2003, J CEREBR BLOOD F MET, V23, P845, DOI 10.1097/01.WCB.0000071883.63724.A7; Barnett HJM, 2002, CLIN EXP HYPERTENS, V24, P563, DOI 10.1081/CEH-120015333; Bondolfi L, 2002, J NEUROSCI, V22, P515, DOI 10.1523/JNEUROSCI.22-02-00515.2002; Brown AW, 2003, NEUROBIOL AGING, V24, P607, DOI 10.1016/S0197-4580(02)00129-X; Bury SD, 2002, J NEUROSCI, V22, P8597; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; Chen ZJ, 2002, MOL CELL NEUROSCI, V20, P125, DOI 10.1006/mcne.2002.1102; DAVIS M, 1995, STROKE, V26, P1072, DOI 10.1161/01.STR.26.6.1072; Dewar D, 2003, J CEREBR BLOOD F MET, V23, P263, DOI 10.1097/01.WCB.0000053472.41007.F9; Floyd RA, 2002, NEUROBIOL AGING, V23, P795, DOI 10.1016/S0197-4580(02)00019-2; Floyd RA, 2000, ANN NY ACAD SCI, V899, P222; Frost SB, 2003, J NEUROPHYSIOL, V89, P3205, DOI 10.1152/jn.01143.2002; GARCIA JH, 1995, STROKE, V26, P627, DOI 10.1161/01.STR.26.4.627; Gozal D, 2003, J NEUROCHEM, V86, P1545, DOI 10.1046/j.1471-4159.2003.01973.x; HAJDU MA, 1990, CIRC RES, V66, P1747, DOI 10.1161/01.RES.66.6.1747; Hess DC, 2004, ARCH NEUROL-CHICAGO, V61, P483, DOI 10.1001/archneur.61.4.483; Hiona A, 2004, ANN NY ACAD SCI, V1019, P96, DOI 10.1196/annals.1297.018; Hoane MR, 2004, BEHAV BRAIN RES, V153, P189, DOI 10.1016/j.bbr.2003.11.012; Hoehn BD, 2005, STROKE, V36, P2718, DOI 10.1161/01.STR.0000190020.30282.cc; HOFF SF, 1982, J COMP NEUROL, V205, P246, DOI 10.1002/cne.902050304; Howard C.V., 1998, UNBIASED STEREOLOGY, V1; HSU JE, 2006, EXP NEUROL      0621; Jones TA, 1999, J NEUROSCI, V19, P10153; Justicia C, 2006, J CEREBR BLOOD F MET, V26, P421, DOI 10.1038/sj.jcbfm.9600198; Kempermann G, 2003, DEVELOPMENT, V130, P391, DOI 10.1242/dev.00203; Kuan CY, 2004, J NEUROSCI, V24, P10763, DOI 10.1523/JNEUROSCI.3883-04.2004; Li Y, 2002, J NEUROL SCI, V193, P137, DOI 10.1016/S0022-510X(01)00657-8; Li Y, 2001, CELL TRANSPLANT, V10, P31; Lindner MD, 2003, J NEUROSCI, V23, P10913; Mabuchi T, 2000, STROKE, V31, P1735, DOI 10.1161/01.STR.31.7.1735; Markus TM, 2005, ANN NEUROL, V58, P950, DOI 10.1002/ana.20676; Morgenstern DA, 2002, PROG BRAIN RES, V137, P313; NICHOLS NR, 1995, NEUROBIOL AGING, V16, P105, DOI 10.1016/0197-4580(95)80013-H; Ohta K, 2003, NEUROSCI LETT, V335, P159, DOI 10.1016/S0304-3940(02)01177-1; Packard D S Jr, 1973, Differentiation, V1, P397, DOI 10.1111/j.1432-0436.1973.tb00137.x; PARHAD IM, 1995, J NEUROSCI RES, V41, P355, DOI 10.1002/jnr.490410308; Petullo D, 1999, LIFE SCI, V64, P1099, DOI 10.1016/S0024-3205(99)00038-7; Popa-Wagner A, 1998, STROKE, V29, P2196, DOI 10.1161/01.STR.29.10.2196; Popa-Wagner A, 1999, J CEREBR BLOOD F MET, V19, P425, DOI 10.1097/00004647-199904000-00008; Popa-Wagner A, 1999, NEUROSCIENCE, V94, P395, DOI 10.1016/S0306-4522(99)00204-3; Popa-Wagner A, 2000, J GERONTOL A-BIOL, V55, pB242, DOI 10.1093/gerona/55.5.B242; Priller J, 2001, J CELL BIOL, V155, P733, DOI 10.1083/jcb.200105103; Rakic P, 2002, J NEUROSCI, V22, P614, DOI 10.1523/JNEUROSCI.22-03-00614.2002; Retchkiman I, 1996, NEUROBIOL AGING, V17, P41, DOI 10.1016/0197-4580(95)02022-5; Riddle DR, 2003, AGEING RES REV, V2, P149, DOI 10.1016/S1568-1637(02)00064-8; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; Roberts EL, 1997, ADV EXP MED BIOL, V411, P83; SCHAUWECKER PE, 1995, J NEUROSCI, V15, P2462, DOI 10.1523/JNEUROSCI.15-03-02462.1995; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Shetty AK, 2004, J NEUROSCI RES, V78, P520, DOI 10.1002/jnr.20302; Shimamura M, 2004, MOL BRAIN RES, V122, P47, DOI 10.1016/j.molbrainres.2003.11.015; Stoll G, 1998, PROG NEUROBIOL, V56, P149, DOI 10.1016/S0301-0082(98)00034-3; Stone DJ, 2000, EXP NEUROL, V165, P46, DOI 10.1006/exnr.2000.7455; Sutherland GR, 1996, STROKE, V27, P1663, DOI 10.1161/01.STR.27.9.1663; Tomimoto H, 2003, ACTA NEUROPATHOL, V106, P527, DOI 10.1007/s00401-003-0749-3; Vallieres L, 2003, J NEUROSCI, V23, P5197; Vogelgesang S, 2002, CLIN NEUROPATHOL, V21, P99; WANG LJC, 1995, STROKE, V26, P2087, DOI 10.1161/01.STR.26.11.2087; Wilhelmsson U, 2004, J NEUROSCI, V24, P5016, DOI 10.1523/JNEUROSCI.0820-04.2004; Woods AG, 1998, NEUROSCIENCE, V83, P663; Yu WH, 2002, NEUROBIOL AGING, V23, P105, DOI 10.1016/S0197-4580(01)00258-5	67	100	105	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	MAR	2007	113	3					277	293		10.1007/s00401-006-0164-7			17	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	134EF	WOS:000244065100006	17131130				2022-02-06	
J	Dahlberg, C; Hawley, L; Morey, C; Newman, J; Cusick, CP; Harrison-Felix, C				Dahlberg, C; Hawley, L; Morey, C; Newman, J; Cusick, CP; Harrison-Felix, C			Social communication skills in persons with post-acute traumatic brain injury: Three perspectives	BRAIN INJURY			English	Article						traumatic brain injury; social communication skills; participation	QUALITY-OF-LIFE; HEAD-INJURY; FOLLOW-UP; COMPETENCE; DISCOURSE; OUTCOMES; SATISFACTION; INDIVIDUALS; DYSFUNCTION; INTEGRATION	Objective: To describe social communication skills problems identified by individuals with traumatic brain injury (TBI) compared to significant other (SO) and clinician ratings; and associations between these skills and participation outcome measures. Design: Cohort study. Methods: Sixty individuals with TBI >= 1 year post-injury were administered measures of social communication, societal participation, social integration and life satisfaction. Clinicians and SOs rated the social communication skills of the subjects. Results: Subjects were able to identify social communication skills problems, associated with lower ratings of community integration and satisfaction with life. Males reported higher scores in social communication and social integration than females. SOs and clinicians identified more social skills problems than subjects. Conclusions: Persons with TBI experience social communication skills deficits, associated with decreased societal participation and life satisfaction. Further research is needed to determine efficacy of social communication skills treatment and association with improved participation and satisfaction with life.	Craig Hosp, CCC, SLP, Englewood, CO USA		Dahlberg, C (corresponding author), Craig Hosp, CCC, SLP, 3425 S Clarkson St, Englewood, CO USA.	cdahlberg@craighospital.org					Barsky AJ, 2001, J GEN INTERN MED, V16, P266, DOI 10.1046/j.1525-1497.2001.016004266.x; Bond F, 1997, BRAIN INJURY, V11, P319, DOI 10.1080/026990597123476; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; COEHLO CA, 1991, J HEAD TRAUMA REHAB, V6, P92; COELHO CA, 1995, BRAIN INJURY, V9, P471, DOI 10.3109/02699059509008206; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dijkers M., 1991, J AM PARAPLEGIA SOC, V14, P85; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; GROHER M, 1999, REHABILITATION ADULT, P87; HAGEN C, 1974, RANCHO AMIGOS SCALES; Hillier SL, 1997, BRAIN INJURY, V11, P525, DOI 10.1080/713802189; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Linscott RJ, 1996, BRAIN INJURY, V10, P397, DOI 10.1080/026990596124269; LoBello SC, 2003, J REHABIL RES DEV, V40, P293, DOI 10.1682/JRRD.2003.07.0293; Long K, 1998, J AM GERIATR SOC, V46, P1103, DOI 10.1111/j.1532-5415.1998.tb06648.x; MARSH NV, 1991, J CLIN EXP NEUROPSYC, V13, P729, DOI 10.1080/01688639108401086; McDonald S, 1998, BRAIN LANG, V61, P88, DOI 10.1006/brln.1997.1846; McGann W, 1997, BRAIN INJURY, V11, P621, DOI 10.1080/026990597123179; MILTON SB, 1984, CLIN APHASIOLOGY C P, P114; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Pavot W., 1993, PSYCHOL ASSESSMENT, V52, P164, DOI DOI 10.1037/1040-3590.5.2.164; Prigatano G. P., 1987, COMMUNITY REENTRY HE, P1; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; Ragnarsson KT, 1993, J HEAD TRAUMA REHAB, V8, P1, DOI DOI 10.1097/00001199-199308020-00003; SNOW P, 1995, APHASIOLOGY, V9, P365, DOI 10.1080/02687039508248210; Snow P, 1997, BRAIN INJURY, V11, P409; SOHLBERG MM, 1989, INTRO COGNITIVEF REH, P214; Sokol K, 1999, 127 ANN M AM PUBL HL; *STAT U NEW YORK B, 1996, GUID UN DAT SET MED; TEASDALE G, 1974, LANCET, V2, P81; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Turkstra LS, 2001, J HEAD TRAUMA REHAB, V16, P469, DOI 10.1097/00001199-200110000-00006; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009; Ylvisaker M., 1987, COMMUNITY REENTRY HE, P137; Ylvsaker M, 2001, BRAIN INJ SOURCE, V5	38	100	100	0	9	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	APR	2006	20	4					425	435		10.1080/02699050600664574			11	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	045GN	WOS:000237730700007	16716988				2022-02-06	
J	Yasukawa, A; Patel, P; Sisung, C				Yasukawa, A; Patel, P; Sisung, C			Pilot study: Investigating the effects of Kinesio Taping (R) in an acute pediatric rehabilitation setting	AMERICAN JOURNAL OF OCCUPATIONAL THERAPY			English	Article							UPPER-LIMB FUNCTION; JOINT PROPRIOCEPTION; ATHLETIC TAPE; IMPINGEMENT; MOVEMENT	OBJECTIVES. The purpose of this pilot study is to describe the use of the Kinesio Taping (R) method for the upper extremity in enhancing functional motor skills in children admitted into an acute rehabilitation program. METHOD. Fifteen children (10 females and 5 males; 4 to 16 years of age), who were receiving rehabilitation services at the Rehabilitation Institute of Chicago participated in this study. For 13 of the inpatients, this was the initial rehabilitation following an acquired disability, which included encephalitis, brain tumor, cerebral vascular accident, traumatic brain injury, and spinal cord injury. The Melbourne Assessment of Unilateral Upper Limb Function (Melbourne Assessment) was used to measure upper-limb functional change prior to use of Kinesio Tape (R), immediately after application of the tape, and 3 days after wearing tape. Children's upper-limb function was compared over the three assessments using analysis of variance. RESULTS. The improvement from pre- to posttaping was statistically significant, F(1, 14) = 18.9; p < .02. CONCLUSION. These results suggest that Kinesio Tape may be associated with improvement in upper-extremity control and function in the acute pediatric rehabilitation setting. The use of Kinesio Tape as an adjunct to treatment may assist with the goal-focused occupational therapy treatment during the child's inpatient stay. Further study is recommended to test the effectiveness of this method and to determine the lasting effects on motor skills and functional performance once the tape is removed.	LaRabida Childrens Hosp, Chicago, IL 60649 USA; Rehabil Inst Chicago, Chicago, IL 60611 USA		Yasukawa, A (corresponding author), LaRabida Childrens Hosp, E 65th St, Chicago, IL 60649 USA.	ayasukawa@larabida.org					BACH TM, 1994, DEV MED CHILD NEUROL, V36, P974; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; Bourke-Taylor H, 2003, DEV MED CHILD NEUROL, V45, P92, DOI 10.1017/S0012162203000185; Bragg RW, 2002, MED SCI SPORT EXER, V34, P403, DOI 10.1097/00005768-200203000-00004; Cabri J, 2002, SPORT VERLETZUNG SPO, V16, P595; Callaghan MJ, 2002, J ATHL TRAINING, V37, P19; GRELSAMER RP, 1998, PATELLA TEAM APPROAC; HAMILTON BB, 1987, FUNCTIONAL INDEPENDE; Hertling D., 1996, MANAGEMENT COMMON MU; HOST HH, 1995, PHYS THER, V75, P803, DOI 10.1093/ptj/75.9.803; JOHNSON LM, 1994, DEV MED CHILD NEUROL, V36, P965; Kase K., 2000, ILLUSTRATED KINESIO; Kase K, 2003, CLIN THERAPEUTIC APP, VSecond; KASE K, 1997, UNPUB CHANGES VOLUME; MACDONALD R, 1994, TAPING TECHNIQUES PR; Murray H, 2001, J ORTHOP SPORT PHYS, V31, pA, DOI DOI 10.2519/JOSPT.2001.31.1.A1; Randall M, 1999, MELBOURNE ASSESSMENT; REDDIHOUGH DS, 1990, DEV MED CHILD NEUROL, V33, P902; Schmitt L, 1999, J ORTHOP SPORT PHYS, V29, P31, DOI 10.2519/jospt.1999.29.1.31; SHEPHERD J, 2001, OCCUPATIONAL THERAPY; Shoger M, 2000, J ATHL TRAINING, V35, pS44; Simoneau GG, 1997, J ATHL TRAINING, V32, P141; *STAT U NEW YORK B, 1993, GUID UN DAT SET MED	23	100	117	3	22	AMER OCCUPATIONAL THERAPY ASSOC, INC	BETHESDA	4720 MONTGOMERY LANE, BETHESDA, MD 20814-3425 USA	0272-9490			AM J OCCUP THER	Am. J. Occup. Ther.	JAN-FEB	2006	60	1					104	110		10.5014/ajot.60.1.104			7	Rehabilitation	Social Science Citation Index (SSCI)	Rehabilitation	003GJ	WOS:000234669500012	16541989				2022-02-06	
J	Parker, TM; Osternig, LR; Lee, HJ; van Donkelaar, P; Chou, LS				Parker, TM; Osternig, LR; Lee, HJ; van Donkelaar, P; Chou, LS			The effect of divided attention on gait stability following concussion	CLINICAL BIOMECHANICS			English	Article						traumatic brain injury; center of mass; gait; balance	TRAUMATIC BRAIN-INJURY; CENTER-OF-MASS; POSTURAL STABILITY; DYNAMIC INSTABILITY; HEAD-INJURY; MILD HEAD; BALANCE; SWAY; PERFORMANCE; MOTION	Background. The need to identify functional impairment following a brain injury is critical to prevent re-injury during the period of recovery. While many neuropsychological tests have been developed to assess cognitive performance, relatively little information on gait and dynamic stability is available on motor task performance for young adults following concussion. This study was performed to investigate the effect of divided attention following concussion on various gait variables. It was hypothesized that, when compared to uninjured controls, concussed subjects would demonstrate deficits in maintenance of dynamic stability. Methods. Ten subjects with Grade 2 concussion completed testing within 48 h of injury as well as 10 age-, height-, weight-, and activity-snatched controls. The gait protocol consisted of level walking under two conditions: (1) undivided attention (single-task) and (2) while simultaneously completing simple mental tasks (dual-task). Whole-body motion data were collected using a six-camera motion analysis system. A 13-segment biomechanical model was used to compute whole body center of mass motion and velocity. Findings. Walking with a concurrent cognitive task resulted in significant changes in gait and center of mass measurements for both groups. Concussed subjects were found to be able to conservatively adjust their whole body center of mass motion to maintain dynamic stability while walking without divided attention. However, while walking with divided attention, subjects with concussion demonstrated a significantly greater medio-lateral center of mass sway. Interpretation. These data suggest that the ability to control and maintain stability in the frontal plane during walking is diminished under divided attention in individuals following a concussion. (c) 2004 Elsevier Ltd. All rights reserved.	Univ Oregon, Dept Human Physiol, Mot Anal Lab, Eugene, OR 97403 USA		Chou, LS (corresponding author), Univ Oregon, Dept Human Physiol, Mot Anal Lab, Eugene, OR 97403 USA.	chou@uoregon.edu		Lee, Heng-Ju/0000-0001-6506-4062	ODCDC CDC HHS [R49/CCR021735, CCR023203] Funding Source: Medline		Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; *AM AC NEUR, NEUROLOGY, V48, P581; Bailes JE, 2001, J ATHL TRAINING, V36, P236; Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; BELL R, 1977, AM FAM PHYSICIAN, V16, P145; Cantu RC, 1997, CLIN SPORT MED, V16, P531, DOI 10.1016/S0278-5919(05)70038-7; *CDCP, 1999, EP TRAUM BRAIN INJ U; Chou LS, 2004, GAIT POSTURE, V20, P245, DOI 10.1016/j.gaitpost.2003.09.007; Chou LS, 2003, GAIT POSTURE, V18, P125, DOI 10.1016/S0966-6362(02)00067-X; EBERSBACH G, 1995, PERCEPT MOTOR SKILL, V81, P107, DOI 10.2466/pms.1995.81.1.107; Geurts ACH, 1999, ARCH PHYS MED REHAB, V80, P144, DOI 10.1016/S0003-9993(99)90111-9; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Hahn ME, 2003, CLIN BIOMECH, V18, P737, DOI 10.1016/S0268-0033(03)00139-6; INGERSOLL CD, 1992, MED SCI SPORT EXER, V24, P739; Lahat E, 1996, PEDIATR NEUROL, V15, P299, DOI 10.1016/S0887-8994(96)00221-4; LAJOIE Y, 1993, EXP BRAIN RES, V97, P139; LEHMANN JF, 1990, ARCH PHYS MED REHAB, V71, P955; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; McFadyen BJ, 2003, J HEAD TRAUMA REHAB, V18, P512, DOI 10.1097/00001199-200311000-00005; Pai YC, 1997, J BIOMECH, V30, P347, DOI 10.1016/S0021-9290(96)00165-0; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; RUBIN AM, 1995, AM J OTOL, V16, P216; Wade LD, 1997, ARCH PHYS MED REHAB, V78, P1107, DOI 10.1016/S0003-9993(97)90136-2; Weerdesteyn V, 2003, J MOTOR BEHAV, V35, P53, DOI 10.1080/00222890309602121; WINTER DA, 1990, BIOMECHANICS MOTOR C, P56; WOBER C, 1993, ARCH PHYS MED REHAB, V74, P1151; Wojtys EM, 1999, AM J SPORT MED, V27, P676, DOI 10.1177/03635465990270052401; WOLTRING HJ, 1986, ADV ENG SOFTW WORKST, V8, P104, DOI 10.1016/0141-1195(86)90098-7	32	100	100	0	19	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0268-0033	1879-1271		CLIN BIOMECH	Clin. Biomech.	MAY	2005	20	4					389	395		10.1016/j.clinbiomech.2004.12.004			7	Engineering, Biomedical; Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Orthopedics; Sport Sciences	908JM	WOS:000227783300006	15737446				2022-02-06	
J	Engstrom, M; Polito, A; Reinstrup, P; Romner, B; Ryding, E; Ungerstedt, U; Nordstrom, CH				Engstrom, M; Polito, A; Reinstrup, P; Romner, B; Ryding, E; Ungerstedt, U; Nordstrom, CH			Intracerebral microdialysis in severe brain trauma: the importance of catheter location	JOURNAL OF NEUROSURGERY			English	Article						microdialysis; brain trauma; penumbra zone	CEREBRAL PERFUSION-PRESSURE; SEVERE HEAD-INJURY; BLOOD-FLOW; INTERSTITIAL GLYCEROL; ENERGY-METABOLISM; VOLUME REGULATION; ISCHEMIA; GLUTAMATE; THERAPY; PRINCIPLES	Object. Intracerebral microdialysis has attracted increasing interest as a monitoring technique during neurological/neurosurgical intensive care. The purpose of this study was to compare cerebral energy metabolism, an indicator of secondary excitotoxic injury and cell membrane degradation close to focal traumatic lesions ("penumbra zones") and in remote and apparently intact brain regions of the ipsilateral and contralateral hemispheres. Methods. The study included 22 consecutive patients with a mean age 44 17 years and an estimated postresuscitation Glasgow Coma Scale motor score less than 5. Altogether 40 microdialysis catheters with radiopaque.tips were inserted. Two catheters could not be localized on postoperative computerized tomography (CT) scans and were excluded from the analysis. The perfusates were analyzed at the patient's bedside for levels of glucose, pyruyate, lactate, glutamate, and glycerol with the aid of a CMA 600 Analyzer. The positions of eight (22%) of the 36 catheters were reclassified after a review of findings on CT scans. Except for pyruvate the values of all biochemical variables and the lactate/pyruvate (L/P) ratio were significantly different in the penumbra zone when compared with mean values found in "normal" tissue ipsilateral to the parenchymal damage and in contralateral normal tissue (p < 0.001). In the penumbra zone a slow normalization of the UP ratio and levels of glutamate and glycerol were observed. In normal tissue these parameters remained within normal limits. Conclusions. Data obtained from intracerebral microdialysis can be correctly interpreted only if the locations of the catheters as they relate to focal brain lesions are visualized. A "biochemical penumbra zone" surrounds focal traumatic brain lesions. It remains to be proven whether therapeutic interventions can protect the penumbra zone from permanent damage.	Univ Lund Hosp, Dept Neurosurg, S-22185 Lund, Sweden; Univ Lund Hosp, Dept Anesthesia & Intens Care, S-22185 Lund, Sweden; Univ Lund Hosp, Dept Neurophysiol, S-22185 Lund, Sweden; Karolinska Inst, Dept Physiol & Pharmacol, Stockholm, Sweden		Nordstrom, CH (corresponding author), Univ Lund Hosp, Dept Neurosurg, S-22185 Lund, Sweden.	carl-henrik.nordstrom@neurokir.lu.se					ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chesnut RM, 1998, J TRAUMA, V44, P958, DOI 10.1097/00005373-199806000-00003; Ederoth P, 2004, BRIT J CLIN PHARMACO, V57, P427, DOI 10.1046/j.1365-2125.2003.02032.x; Eker C, 1998, CRIT CARE MED, V26, P1881, DOI 10.1097/00003246-199811000-00033; Frykholm P, 2001, J NEUROL NEUROSUR PS, V71, P455, DOI 10.1136/jnnp.71.4.455; Furuya Y, 2003, NEUROSURGERY, V52, P340, DOI 10.1227/01.NEU.0000043931.83041.AA; Grande PO, 2002, ACTA ANAESTH SCAND, V46, P929, DOI 10.1034/j.1399-6576.2002.460802.x; Hillered L, 1998, J NEUROL NEUROSUR PS, V64, P486, DOI 10.1136/jnnp.64.4.486; Hutchinson PJA, 2002, ACT NEUR S, V81, P359; JORGENSEN MB, 1982, ACTA NEUROL SCAND, V66, P536; Marion DW, 2002, CRIT CARE MED, V30, P2619, DOI 10.1097/00003246-200212000-00001; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; Nordstrom Carl-Henrik, 2003, Neurosurg Focus, V15, pE5; Nordstrom CH, 2003, ANESTHESIOLOGY, V98, P809, DOI 10.1097/00000542-200304000-00004; NORDSTROM CH, 1978, J NEUROCHEM, V30, P479, DOI 10.1111/j.1471-4159.1978.tb06553.x; NORDSTROM CH, 1996, BRAIN PROTECTION SEV, P117; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Robinson BH, 2000, PEDIATR RES, V48, P581, DOI 10.1203/00006450-200011000-00004; ROTHMAN SM, 1983, SCIENCE, V220, P536, DOI 10.1126/science.6836300; Siesj? BK., 1978, BRAIN ENERGY METABOL; Stahl N, 2003, ACTA NEUROL SCAND, V108, P211, DOI 10.1034/j.1600-0404.2003.00095.x; Stahl N, 2001, INTENS CARE MED, V27, P1215, DOI 10.1007/s001340101004; Stahl N, 2001, ACTA ANAESTH SCAND, V45, P977, DOI 10.1034/j.1399-6576.2001.450810.x; Ungerstedt U, 1997, PHYSIOLOGY, STRESS, AND MALNUTRITION, P361; Valadka AB, 1998, J NEUROTRAUM, V15, P509, DOI 10.1089/neu.1998.15.509; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; von Oettingen G, 2002, NEUROSURGERY, V50, P781, DOI 10.1097/00006123-200204000-00019; Zauner A, 2002, J NEUROSURG, V97, P643, DOI 10.3171/jns.2002.97.3.0643	33	100	102	0	5	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAR	2005	102	3					460	469		10.3171/jns.2005.102.3.0460			10	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	911PR	WOS:000228017200010	15796380				2022-02-06	
J	Lynch, JR; Wang, H; Mace, B; Leinenweber, S; Warner, DS; Bennett, ER; Vitek, MP; McKenna, S; Laskowitz, DT				Lynch, JR; Wang, H; Mace, B; Leinenweber, S; Warner, DS; Bennett, ER; Vitek, MP; McKenna, S; Laskowitz, DT			A novel therapeutic derived from apolipoprotein E reduces brain inflammation and improves outcome after closed head injury	EXPERIMENTAL NEUROLOGY			English	Article						apolipoprotein E; brain inflammation; closed head injury	MICROGLIAL ACTIVATION; MIMETIC PEPTIDES; GENOTYPE; MODEL; APOE; RAT; EXCITOTOXICITY; DEFICITS; MOTOR	Although apolipoprotein E4 (APOE4) was initially identified as a susceptibility gene for the development of Alzheimer's disease, the presence of the APOE4 allele is also associated with poor outcome after acute brain injury. One mechanism by which apoE may influence neurological outcome is by downregulating the neuroinflammatory response. Because it does not readily cross the blood-brain barrier, the apoE holoprotein has limited therapeutic potential. We demonstrate that a single intravenous injection of a small peptide derived from the apoE receptor binding region crosses the blood-brain barrier and significantly improves histological and functional outcomes after traumatic brain injury (TBI). The development of an apoE-based intervention represents a novel therapeutic strategy in the management of acute brain injury. (C) 2004 Elsevier Inc. All rights reserved.	Duke Univ, Med Ctr, Dept Med, Div Neurol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Multidisciplinary Neurpprotect Labs, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA; Univ N Carolina, Dept Anesthesiol Pediat Crit Care, Chapel Hill, NC 27516 USA; Cognosci Inc, Res Triangle Pk, NC 27709 USA		Lynch, JR (corresponding author), Duke Univ, Med Ctr, Dept Med, Div Neurol, 227E Bryan Res Bldg,Box 2900, Durham, NC 27710 USA.	lynch004@duke.edu		Vitek, Michael/0000-0001-8140-8048; Mace, Brian/0000-0002-5478-6227	NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K08AG022230] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [1K08AG022230-01] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1 R21NS4487-01, 1R01NS368087] Funding Source: Medline		Aono M, 2003, NEUROSCIENCE, V116, P437, DOI 10.1016/S0306-4522(02)00709-1; Aono M, 2002, NEUROBIOL DIS, V11, P214, DOI 10.1006/nbdi.2002.0541; Barger SW, 1997, NATURE, V388, P878, DOI 10.1038/42257; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; Colton CA, 2002, NEUROBIOL AGING, V23, P777, DOI 10.1016/S0197-4580(02)00016-7; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Laskowitz DT, 1997, J NEUROIMMUNOL, V76, P70, DOI 10.1016/S0165-5728(97)00021-0; Laskowitz DT, 2001, EXP NEUROL, V167, P74, DOI 10.1006/exnr.2001.7541; Leung CHS, 2002, STROKE, V33, P548, DOI 10.1161/hs0202.102326; LINTON MF, 1991, J CLIN INVEST, V88, P270, DOI 10.1172/JCI115288; Lynch JR, 2003, J BIOL CHEM, V278, P48529, DOI 10.1074/jbc.M306923200; Lynch JR, 2002, ANN NEUROL, V51, P113, DOI 10.1002/ana.10098; Lynch JR, 2001, J NEUROIMMUNOL, V114, P107, DOI 10.1016/S0165-5728(00)00459-8; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Misra UK, 2001, J LEUKOCYTE BIOL, V70, P677; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Schauwecker PE, 1998, EXP NEUROL, V149, P87, DOI 10.1006/exnr.1997.6679; Schiefermeier M, 2000, STROKE, V31, P2068, DOI 10.1161/01.STR.31.9.2068; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249	25	100	110	0	8	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	MAR	2005	192	1					109	116		10.1016/j.expneurol.2004.11.014			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	899LZ	WOS:000227147200012	15698624				2022-02-06	
J	Herbertsson, P; Josefsson, PO; Hasserius, R; Besjakov, J; Nyqvist, F; Karlsson, MK				Herbertsson, P; Josefsson, PO; Hasserius, R; Besjakov, J; Nyqvist, F; Karlsson, MK			Fractures of the radial head and neck treated with radial head excision	JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME			English	Article							TERM-FOLLOW-UP; MASON TYPE-II; INTERNAL-FIXATION; CLOSED FRACTURE; ELBOW; DISLOCATIONS; RESECTION	Background: The reported long-term outcomes of the treatment of radial head and neck fractures with excision of the radial head have been mixed. The purpose of the present study was to evaluate the long-term outcomes of primary or delayed radial head excision for the treatment of these fractures. Methods: Sixty-one individuals (mean age, forty-four years) with thirty-nine Mason type-II, ten Mason type-III, and twelve Mason type-IV fractures were evaluated subjectively, objectively, and radiographically at a mean of eighteen years (range, eleven to thirty-three years) after treatment. Forty-three fractures were treated with primary radial head excision, and the remaining eighteen were treated with delayed radial head excision at a median of five months (range, one to 238 months) after the injury. Results: At the time Of follow-up, twenty-eight individuals had no symptoms, twenty-seven had occasional elbow pain, and six had daily pain. Four individuals with daily pain had had a Mason type-IV fracture. The range of motion of the formerly injured upper extremities was slightly less than that of the uninjured upper extremities in terms of flexion (139degrees +/- 11degrees compared with 142degrees +/- 8degrees), extension (-7degrees +/- 12degrees compared with -1degrees +/- 6degrees), and supination (77degrees +/- 20degrees compared with 85degrees +/- 10degrees) (all p < 0.01). A higher percentage of formerly injured elbows than uninjured elbows had cysts, sclerosis, and osteophytes (73% compared with 7%; p < 0.001), but none had a reduced joint space. No differences were found between the outcomes for individuals treated with a primary radial head excision and those for individuals treated with a delayed excision. Conclusions: Following a displaced radial head or neck fracture, excision of the radial head often leads to a good or fair result. We found no differences in outcome between primary and delayed radial head excisions following a Mason type-II, III, or IV fracture. The outcomes are associated with the type of fracture, with Mason type-IV fractures having the worst results, rather than with the timing of the radial head excision (primary or delayed). Level of Evidence: Therapeutic study, Level III-2 (retrospective cohort study). See Instructions to Authors for a complete description of levels of evidence.	Malmo Univ Hosp, Dept Orthopaed, SE-20502 Malmo, Sweden; Malmo Univ Hosp, Dept Radiol, SE-20502 Malmo, Sweden		Herbertsson, P (corresponding author), Malmo Univ Hosp, Dept Orthopaed, SE-20502 Malmo, Sweden.	par.herbertsson@skane.se; peo.josefsson@skane.se; ralph.hasserius@skane.se; jack.besjakov@skane.se; caroline.karlsson@skane.se; magnus.karlsson@orto.mas.lu.se					ARNER O, 1957, Acta Chir Scand, V112, P115; BAKALIM G, 1970, ACTA ORTHOP SCAND, V41, P320, DOI 10.3109/17453677008991518; BROBERG MA, 1986, J BONE JOINT SURG AM, V68A, P669, DOI 10.2106/00004623-198668050-00005; BROBERG MA, 1987, CLIN ORTHOP RELAT R, P109; COLEMAN DA, 1987, J BONE JOINT SURG AM, V69A, P385; Conn J, 1961, J TRAUMA ACUTE CARE, V1, P248, DOI DOI 10.1097/00005373-196105000-00004; ESSER RD, 1995, J ORTHOP TRAUMA, V9, P318, DOI 10.1097/00005131-199509040-00008; GOLDBERG I, 1986, J BONE JOINT SURG AM, V68A, P675, DOI 10.2106/00004623-198668050-00006; HELFERICH H, 1899, FRACTURES DISLOCATIO, P96; Herbertsson P, 2004, J BONE JOINT SURG AM, V86A, P569, DOI 10.2106/00004623-200403000-00016; HERBERTSSON P, 2003, ANN M SWED SOC ORTH; Ikeda M, 2000, ACTA ORTHOP SCAND, V71, P191, DOI 10.1080/000164700317413184; JOHNSTON G W, 1962, Ulster Med J, V31, P51; JOSEFSSON PO, 1984, J BONE JOINT SURG AM, V66A, P927, DOI 10.2106/00004623-198466060-00014; KNIGHT DJ, 1993, J BONE JOINT SURG BR, V75, P572, DOI 10.1302/0301-620X.75B4.8331111; Malmvik J, 2003, J PEDIATR ORTHOP B, V12, P63, DOI 10.1097/00009957-200301000-00012; MASON ML, 1954, BRIT J SURG, V42, P123, DOI 10.1002/bjs.18004217203; MIKIC ZD, 1983, CLIN ORTHOP RELAT R, P220; MORREY BF, 1981, J BONE JOINT SURG AM, V63, P872, DOI 10.2106/00004623-198163060-00002; MORREY BF, 1979, J BONE JOINT SURG AM, V61, P63, DOI 10.2106/00004623-197961010-00012; Murray RC, 1940, BRIT J SURG, V28, P106, DOI 10.1002/bjs.18002810911; Odelberg-Johnson G, 1924, ACTA RADIOL, V3, P45, DOI 10.3109/00016922409133476; POULSEN JO, 1974, ACTA ORTHOP SCAND, V45, P66, DOI 10.3109/17453677408989123; RADIN EL, 1966, J BONE JOINT SURG AM, VA 48, P1055, DOI 10.2106/00004623-196648060-00003; Ring D, 2002, J BONE JOINT SURG AM, V84A, P1811, DOI 10.2106/00004623-200210000-00011; STEINBERG EL, 1988, J PEDIATR ORTHOPED, V8, P35, DOI 10.1097/01241398-198801000-00009; STEPHEN IBM, 1981, ACTA ORTHOP SCAND, V52, P409, DOI 10.3109/17453678109050121; Watson-Jones R., 1941, FRACTURES OTHER BONE, P336; Wilson PD, 1933, SURG GYNECOL OBSTET, V56, P335	29	100	104	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0021-9355	1535-1386		J BONE JOINT SURG AM	J. Bone Joint Surg.-Am. Vol.	SEP	2004	86A	9					1925	1930		10.2106/00004623-200409000-00010			6	Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Surgery	852ZJ	WOS:000223795200010	15342754				2022-02-06	
J	Mickeviciene, D; Schrader, H; Obelieniene, D; Surkiene, D; Kunickas, R; Stovner, LJ; Sand, T				Mickeviciene, D; Schrader, H; Obelieniene, D; Surkiene, D; Kunickas, R; Stovner, LJ; Sand, T			A controlled prospective inception cohort study on the post-concussion syndrome outside the medicolegal context	EUROPEAN JOURNAL OF NEUROLOGY			English	Article						concussion; post-concussion syndrome; post-traumatic headache	TRAUMATIC BRAIN-INJURY; MILD HEAD-INJURY; SYMPTOMS; EXPECTATION	In an earlier historical cohort study on the post-concussion syndrome (PCS) in Lithuania, a country in which there are few confounding factors, the validity of this condition as a disease entity could not be confirmed. In order to register the post-traumatic symptoms, the influence of sociodemographic factors, and the effect of expectation on these symptoms more reliably, we performed a controlled prospective study. Three hundred subjects with concussion were followed up with repeated questionnaires for 1 year. For each study subject, a sex- and age-matched control person with minor non-head injury was identified. These controls received similar questionnaires. Headache both after 3 months and after 1 year did not differ significantly between the head-injured participants and the non-head-injured controls. Several other symptoms attributed to PCS did not differ significantly between the groups after 3 months. After 1 year the vast majority of symptoms did not differ significantly. Exceptions were slightly significant differences concerning memory problems, concentration problems, dizziness and tiredness. These differences were insignificant when analysing symptoms in unmarried and/or people with lower education, separately. No relationship between cognitive dysfunction and the severity of concussion was found. Although the possibility of a mild organic brain injury cannot be completely ruled out, our results cast doubt on the validity of PCS as a useful clinical entity, at least for head injuries with loss of consciousness for <15 min. Sociodemographic factors and expectation seem to influence reporting of symptoms after concussion.	Univ Trondheim Hosp, Dept Neurol & Clin Neurophysiol, N-7006 Trondheim, Norway; Red Cross Hosp, Dept Neurol, Kaunas, Lithuania; Med Univ Clin, Dept Neurol, Kaunas, Lithuania; Red Cross Hosp, Emergency Ward, Dept Traumatol, Kaunas, Lithuania		Schrader, H (corresponding author), Univ Trondheim Hosp, Dept Neurol & Clin Neurophysiol, N-7006 Trondheim, Norway.	harald.schrader@medisin.ntnu.no		Schrader, Harald/0000-0001-9975-1960; Obelieniene, Diana/0000-0002-7356-7150			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; BINDER LM, 1990, J CLIN EXP NEUROPSYC, V12, P45; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; Ferrari R, 2001, CLIN NEUROL NEUROSUR, V103, P184, DOI 10.1016/S0303-8467(01)00143-3; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Martelli MF, 1999, J HEAD TRAUMA REHAB, V14, P49, DOI 10.1097/00001199-199902000-00007; McCullagh S, 2003, J NEUROL NEUROSUR PS, V74, P39, DOI 10.1136/jnnp.74.1.39; Mickeviciene D, 2002, EUR J NEUROL, V9, P581, DOI 10.1046/j.1468-1331.2002.00497.x; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; World Health Organization, 1978, ICD 9 CLASS MENT BEH	14	100	100	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1351-5101	1468-1331		EUR J NEUROL	Eur. J. Neurol.	JUN	2004	11	6					411	419		10.1111/j.1468-1331.2004.00816.x			9	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	824NS	WOS:000221693900008	15171738				2022-02-06	
J	Slaughter, B; Fann, JR; Ehde, D				Slaughter, B; Fann, JR; Ehde, D			Traumatic brain injury in a county jail population: prevalence, neuropsychological functioning and psychiatric disorders	BRAIN INJURY			English	Article							SUBSTANCE-ABUSE; HEAD-INJURY; REHABILITATION; OFFENDERS; ATTENTION; BEHAVIOR; SYSTEM; TRIAL	Primary objective : To determine the prevalence of traumatic brain injury (TBI) among inmates in a county jail population. Research design : Cross-sectional, observational study. Methods and procedures : A standardized interview was used to determine prevalence of TBI in 69 randomly selected inmates. To examine cognitive and emotional differences between subjects with and without recent TBI, neuropsychological tests and structured psychiatric diagnostic interviews were conducted with 50 subjects (the first 25 with TBI and the first 25 without TBI in the prior year). Results : Sixty (87.0%) reported TBI over their lifetime; 25 (36.2%) reported TBI in the prior year. The latter group had significantly worse anger and aggression scores and had a trend towards poorer cognitive test results and a higher prevalence of psychiatric disorders than the group without TBI in the prior year. Conclusion : This study suggests the need for increased attention to TBI and its cognitive, behavioural and psychiatric sequelae in jail populations.	Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA		Fann, JR (corresponding author), Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Box 356560, Seattle, WA 98195 USA.		Ehde, Dawn/K-1883-2016	Ehde, Dawn/0000-0002-9555-2347			Barnfield TV, 1998, BRAIN INJURY, V12, P455, DOI 10.1080/026990598122421; Basso MR, 2000, CLIN NEUROPSYCHOL, V14, P325, DOI 10.1076/1385-4046(200008)14:3;1-P;FT325; BECK AJ, 2000, US DEP JUSTICE BUREA; Benton AL, 1994, MULTILINGUAL APHASIA; Braverman SE, 1999, BRAIN INJURY, V13, P405; Ditton P., 1999, MENTAL HLTH TREATMEN; EAMES P, 1985, J NEUROL NEUROSUR PS, V48, P613, DOI 10.1136/jnnp.48.7.613; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; HATZITASKOS P, 1994, JUVENILE FAM COURT J, V45, P29; IVERSON GL, 1993, CRIM JUSTICE BEHAV, V20, P347, DOI 10.1177/0093854893020004003; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KRAKOWSKI MI, 1989, J PSYCHIAT RES, V23, P57, DOI 10.1016/0022-3956(89)90017-4; KREUTZER JS, 1995, BRAIN INJURY, V9, P757, DOI 10.3109/02699059509008232; Lamb HR, 1998, PSYCHIATR SERV, V49, P483, DOI 10.1176/ps.49.4.483; Lamb HR, 1999, PSYCHIATR SERV, V50, P907, DOI 10.1176/ps.50.7.907; LEWIS DO, 1986, AM J PSYCHIAT, V143, P838; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; MARTELL DA, 1992, J FORENSIC SCI, V37, P878; Mateer CA, 1996, J HEAD TRAUMA REHAB, V11, P1; Metzner JL, 1998, TREATMENT OF OFFENDERS WITH MENTAL DISORDERS, P211; Metzner JL, 1993, CRIM BEHAV MENT HEAL, V3, P252, DOI DOI 10.1002/CMB.1993.3.4.252; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; *PIERC COUNT DET C, 1999, AUG 1999 JAIL CENS R; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Sarapatta M, 1998, BRAIN INJURY, V12, P821, DOI 10.1080/026990598122061; SILVER JM, 1985, INT DRUG THERAPY NEW, V20, P9; SPITZER RL, 1994, JAMA-J AM MED ASSOC, V272, P1749, DOI 10.1001/jama.272.22.1749; TEMPLER DI, 1992, PERCEPT MOTOR SKILL, V75, P195, DOI 10.2466/PMS.75.4.195-202; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; Wechsler D, 1987, MEMORY SCALE REVISED; [No title captured], DOI DOI 10.1177/088626087002002003	34	100	100	1	26	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	SEP	2003	17	9					731	741		10.1080/0269905031000088649			11	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	691ML	WOS:000183610000001	12850940				2022-02-06	
J	Kiening, KL; van Landeghem, FKH; Schreiber, S; Thomale, UW; von Deimling, A; Unterberg, AW; Stover, JF				Kiening, KL; van Landeghem, FKH; Schreiber, S; Thomale, UW; von Deimling, A; Unterberg, AW; Stover, JF			Decreased hemispheric Aquaporin-4 is linked to evolving brain edema following controlled cortical impact injury in rats	NEUROSCIENCE LETTERS			English	Article						Astrocytes; traumatic brain injury; water channel; cortical perfusion	WATER; EXPRESSION; GLUTAMATE; HYPOXANTHINE	The cerebral Aquaporin-4 (AQP4) water channel is suggested to be involved in brain edema formation aggravated by reduced cerebral blood flow early after traumatic brain injury (TBI). Therefore, the temporal profile of brain edema formation, AQP4 expression, and cortical perfusion were investigated following focal TBI in rats. Brain edema was maximal by 24 h. Concurrently, AQP4 protein expression was decreased in both hemispheres, being more pronounced in the traumatized hemisphere (-50%) 48 h after trauma. Cortical perfusion was only decreased in the ipsilateral cortex (-40%) between 4 and 8 h after trauma, reaching baseline values at 24 h. Globally reduced AQP4 expression following induction of a focal contusion coincides with edema development and seems to be independent of changes in cortical perfusion. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.	Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Humboldt Univ, Virchow Med Ctr, Charite, Inst Neuropathol, D-13353 Berlin, Germany; Humboldt Univ, Virchow Med Ctr, Charite, Dept Neurosurg, D-13353 Berlin, Germany		Stover, JF (corresponding author), Univ Penn, Dept Neurosurg, 105 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.	stover@mail.med.upenn.edu	von Deimling, Andreas/F-7774-2013	von Deimling, Andreas/0000-0002-5863-540X			CUEVAS P, 1985, ANAT EMBRYOL, V172, P171, DOI 10.1007/BF00319599; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Ke CS, 2001, NEUROSCI LETT, V301, P21, DOI 10.1016/S0304-3940(01)01589-0; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; Kobayashi H, 2001, NEUROSCI LETT, V297, P163, DOI 10.1016/S0304-3940(00)01705-5; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kroppenstedt SN, 2000, CRIT CARE MED, V28, P3792, DOI 10.1097/00003246-200012000-00004; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Nielsen S, 1997, J NEUROSCI, V17, P171; Niermann H, 2001, J NEUROSCI, V21, P3045, DOI 10.1523/JNEUROSCI.21-09-03045.2001; Sato S, 2000, ACTA NEUROCHIR SUPPL, V76, P239; Stover JF, 2001, J NEUROSURG, V94, P782, DOI 10.3171/jns.2001.94.5.0782; Stroop R, 1998, ACT NEUR S, V71, P303; Taniguchi M, 2000, MOL BRAIN RES, V78, P131, DOI 10.1016/S0169-328X(00)00084-X; Van Landeghem FKH, 2001, GLIA, V35, P167, DOI 10.1002/glia.1082; Yamamoto N, 2001, MOL BRAIN RES, V90, P26, DOI 10.1016/S0169-328X(01)00064-X; Yang BX, 1997, J BIOL CHEM, V272, P16140, DOI 10.1074/jbc.272.26.16140	17	100	132	0	6	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	MAY 17	2002	324	2					105	108	PII S0304-3940(02)00180-5	10.1016/S0304-3940(02)00180-5			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	555KK	WOS:000175793100005	11988338				2022-02-06	
J	McPherson, K; Headrick, L; Moss, F				McPherson, K; Headrick, L; Moss, F			Working and learning together: good quality care depends on it, but how can we achieve it?	QUALITY IN HEALTH CARE			English	Article						interprofessional education; multiprofessional learning; teamwork	TRAUMATIC BRAIN-INJURY; INTERPROFESSIONAL EDUCATION; STROKE CARE; REHABILITATION; IMPROVE; INTERVENTION; TEAMWORK; EFFICACY; VIEW; PAIN	Educating healthcare professionals is a key issue in the provision of quality healthcare services, and interprofessional education (IPE) has been proposed as a means of meeting this challenge. Evidence that collaborative working can be essential for good clinical outcomes underpins the real need to find out how best to develop a work force that can work together effectively. We identify barriers to mounting successful IPE programmes, report on recent educational initiatives that have aimed to develop collaborative working, and discuss the lessons learned. To develop education strategies that really prepare learners to collaborate we must: agree on the goals of IPE, identify effective methods of delivery, establish what should be learned when, attend to the needs of educators and clinicians regarding their own competence in interprofessional work, and advance our knowledge by robust evaluation using both qualitative and quantitative approaches. We must ensure that our education strategies allow students to recognise, value, and engage with the difference arising from the practice of a range of health professionals. This means tackling some long held assumptions about education and identifying where it fosters norms and attitudes that interfere with collaboration or fails to engender interprofessional knowledge and skill. We need to work together to establish education strategies that enhance collaborative working along with profession specific skills to produce a highly skilled, proactive, and respectful work force focused on providing safe and effective health for patients and communities.	Univ Southampton, Sch Hlth Profess & Rehabil Sci, Southampton SO17 1BJ, Hants, England; Case Western Reserve Univ, Cleveland, OH 44106 USA; Univ London, Univ Coll London Hosp, London, England		McPherson, K (corresponding author), Univ Southampton, Sch Hlth Profess & Rehabil Sci, Southampton SO17 1BJ, Hants, England.	kmcpherson@wnmeds.ac.nz		McPherson, Kathryn/0000-0003-1240-8882; McPherson, Kath/0000-0003-0487-8497			ANNENDALE SJ, 2000, J INTERPROFESSIONAL, V14, P161; Asplund K, 1997, STROKE, V28, P2139, DOI 10.1161/01.STR.28.11.2139; Baker G R, 1998, Qual Manag Health Care, V6, P1; BALDWIN DC, 1998, MISSION MANAGEMENT N; Balestreire J J, 1998, Qual Manag Health Care, V6, P31; BARR H, 2000, INTERPROFESSIONAL ED, P1; Barrett H., 2000, EVALUATION INTERPROF, P1; BEHRINGER BA, 1994, CATALYSTS INTERDISCI, P43; Boaden N, 2000, MED EDUC, V34, P921, DOI 10.1046/j.1365-2923.2000.00794.x; Brennan A, 1997, Br J Nurs, V6, P697; Campbell JK, 1999, BRIT MED J, V318, P1272; Campbell NC, 1996, J PUBLIC HEALTH MED, V18, P478, DOI 10.1093/oxfordjournals.pubmed.a024548; Centre for the Advancement of Interprofessional Education (CAIPE), 1997, CAIPE B, V13, P19; Chesnut RM, 1999, J HEAD TRAUMA REHAB, V14, P176, DOI 10.1097/00001199-199904000-00007; CLEGHORN GD, 2000, J INTERPROF CARE, V14, P147; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; *COUNC GRAD MED ED, 2000, COLL ED ENS PAT SAF, P9; Curley C, 1998, MED CARE, V36, pAS4, DOI 10.1097/00005650-199808001-00002; Dafoe W, 1997, CAN MED ASSOC J, V156, P527; Department of Health, 2000, NHS PLAN PLAN INV PL; Department of Health, 2000, HLTH SERV ALL TAL DE; DIFABIO RP, 1995, PHYS THER, V75, P865, DOI 10.1093/ptj/75.10.865; Finch J, 2000, BRIT MED J, V321, P1138, DOI 10.1136/bmj.321.7269.1138; Firth-Cozens J, 2001, QUAL HEALTH CARE, V10, P65, DOI 10.1136/qhc.10.2.65; FULGINITI VA, 1994, CATALYSTS INTERDISCI, P7; GUILLILAND K, 2001, INTERDISCIPLINARY UN; Hackman J. R., 1990, GROUPS WORK THOSE DO; Hammick M, 2000, MED TEACH, V22, P461, DOI 10.1080/01421590050110713; Headrick LA, 1998, BRIT MED J, V316, P771, DOI 10.1136/bmj.316.7133.771; Headrick LA, 1996, JOINT COMM J QUAL IM, V22, P149, DOI 10.1016/S1070-3241(16)30217-6; HEADRICK LA, 2000, LEARNING IMPROVE COM, P77; HEALTH CARE FIN. ADMIN, 2000, MAT SERV REF DOC, P9; Institute of Medicine Committee on Quality of Health Care in America, 2001, CROSS QUAL CHASM NEW; *INT PROF ED COLL, 1999, GUID ACC TEACH LEARN; *JA HARTF FDN, 2000, JA HARTF FDN ANN REP; Kalra L, 2000, LANCET, V356, P894, DOI 10.1016/S0140-6736(00)02679-9; Katz Warren A., 1998, American Journal of Medicine, V105, p2S, DOI 10.1016/S0002-9343(98)00068-0; KNAPP ML, 2000, J INTERPROF CARE, V14, P119, DOI DOI 10.1080/713678558; KOHN LT, 2000, ERR HUMAN BUILDING S; KOPPEL I, 2001, ISSUES INTERDISCIPLI, V3, P41; Langhorne P, 2001, STROKE, V32, P268, DOI 10.1161/01.STR.32.1.268; Maugeri FS, 1998, EUR HEART J, V19, P466; McGregor K, 1997, SOC SCI MED, V45, P295, DOI 10.1016/S0277-9536(96)00345-0; Munin MC, 1998, JAMA-J AM MED ASSOC, V279, P847, DOI 10.1001/jama.279.11.847; OConnor GT, 1996, JAMA-J AM MED ASSOC, V275, P841, DOI 10.1001/jama.275.11.841; Opie A, 1998, QUAL HEALTH RES, V8, P188, DOI 10.1177/104973239800800204; OPIE A, 1999, HLTH SOC AOTEAROA NZ, P181; Papps E., 1997, DOCTORING CHILDBIRTH; PARKER DL, 1997, ACAD MED, P451; Pierce-Bulger M, 2001, Qual Manag Health Care, V9, P40; Roberts C, 2000, MED TEACH, V22, P386; RUBENSTEIN LZ, 1991, J AM GERIATR SOC S, V0039, P00008; Semlyen JK, 1998, ARCH PHYS MED REHAB, V79, P678, DOI 10.1016/S0003-9993(98)90044-2; Smith BH, 1999, FAM PRACT, V16, P475, DOI 10.1093/fampra/16.5.475; STEIN LI, 1967, ARCH GEN PSYCHIAT, V16, P699; Wilcock M, 2000, J INTERPROF CARE, V14, P111; WILLIAMS PC, 1999, CATALYSTS INTERDISCI, P79; ZWARENSTEIN M, 2000, COCHRANE LIBR; [No title captured]	59	100	100	0	23	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0963-8172			QUAL HEALTH CARE	Qual. Health Care	DEC	2001	10			2			46	53					8	Health Care Sciences & Services; Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Health Care Sciences & Services; Public, Environmental & Occupational Health	506KF	WOS:000172969100009					2022-02-06	
J	Platt, SR; Radaelli, ST; McDonnell, JJ				Platt, SR; Radaelli, ST; McDonnell, JJ			The prognostic value of the modified Glasgow Coma Scale in head trauma in dogs	JOURNAL OF VETERINARY INTERNAL MEDICINE			English	Article; Proceedings Paper	14th Annual European-Society-of-Veterinary-Neurology Symposium	SEP 20-23, 2000	LONDON, ENGLAND	European Soc Vet Neurol		oculocephalic reflex; skull fracture; traumatic brain injury	BRAIN INJURY; MANAGEMENT	A clinical coma scale modified from the Glasgow Coma Scale used for humans has been suggested as a useful predictor of outcome in the head trauma patient. The objective of this study was to correlate the modified Glasgow Coma Scale (MGCS) score of dogs with head trauma with their probability of survival. Thirty-eight dogs with head trauma were selected and retrospectively evaluated. The information retrieved from the medical record of each dog included signalment, body weight, cause of head trauma, MGCS, presence of concurrent neck pain, and outcome (dead or alive) after 48 hours. Logistic regression was used to model survival in the Ist 48 hours as a function of MGCS, gender, weight, and calvarial fractures. The MGCS ranged from 5 to 18. Seven dogs died within 48 hours of the head trauma. The MGCS could predict the probability of survival in the 1st 48 hrs after head trauma with 50% probability in a patient with a score of 8. Gender, weight, and presence of skull fractures did not predict survival. In conclusion, the MGCS is a useful index for prediction of outcome in dogs with head trauma.	Ctr Small Anim Studies, Anim Hlth Trust, Newmarket CB8 7UU, Suffolk, England; Leibniz Univ Hannover, Klin Kleine Haustiere, D-30173 Hannover, Germany; Tufts Univ, Coll Vet Med, North Grafton, MA USA		Platt, SR (corresponding author), Ctr Small Anim Studies, Anim Hlth Trust, Newmarket CB8 7UU, Suffolk, England.	simon.platt@aht.org.uk		Platt, Simon/0000-0002-7818-1011			Agresti A., 1990, CATEGORICAL DATA ANA; *BRAIN TRAUM TASK, 2000, J NEUROTRAUM, V17, P557; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHOI SC, 1983, J NEUROSURG, V59, P294, DOI 10.3171/jns.1983.59.2.0294; Dewey CW, 2000, VET CLIN N AM-SMALL, V30, P207, DOI 10.1016/S0195-5616(00)50010-2; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; FENNER WR, 1995, TXB VET INTERNAL MED, P578; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; Gruen P, 1998, EMERG MED CLIN N AM, V16, P63, DOI 10.1016/S0733-8627(05)70349-7; Hopkins AL, 1996, VET CLIN N AM-SMALL, V26, P875, DOI 10.1016/S0195-5616(96)50110-5; JOHNSON JA, 2000, KIRKS CURRENT VET TH, V13, P178; KAUFMAN HH, 1993, MED CLIN N AM, V77, P43, DOI 10.1016/S0025-7125(16)30271-1; KOLATA RJ, 1974, J AM VET MED ASSOC, V164, P499; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; PIETROPAOLI JA, 1992, J TRAUMA, V33, P403, DOI 10.1097/00005373-199209000-00011; Shores A., 1983, CURRENT VET THERAPY, P847; Zink Brian J., 1996, Emergency Medicine Clinics of North America, V14, P115	20	100	101	0	33	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1939-1676			J VET INTERN MED	J. Vet. Intern. Med.	NOV-DEC	2001	15	6					581	584		10.1892/0891-6640(2001)015<0581:TPVOTM>2.3.CO;2			4	Veterinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Veterinary Sciences	492NF	WOS:000172173900011	11817064	Bronze			2022-02-06	
J	Nochi, M				Nochi, M			Reconstructing self-narratives in coping with traumatic brain injury	SOCIAL SCIENCE & MEDICINE			English	Article						traumatic brain injury; rehabilitation counseling; adjustment; self-image	TIME PERSPECTIVE; DISABILITY; DISEASE; PEOPLE	This study examined qualitative data from ten individuals with traumatic brain injuries (TBI) who fell at ease with their current situations. An analysis based on the grounded theory method revealed that one's experience of coping or adjustment to the disability was represented as narratives about him or herself. Each one with TBI reconstructed certain self-narratives in coping with their changed self-images and daily lives. The common narratives were classified into five categories: "the self better than others," "the grown self," "the recovering self" ''the self living hen and now," and "the protesting self." These self-narratives reflected renewed ways to view the selves, which were conceptualized to be intact "in spite of TBI" or to be worthwhile "because of TBI." The informants achieved this conceptualization by managing their perspectives on time or on space. This classification will serve as a framework for rehabilitation practice and for future research. (C) 2000 Elsevier Science Ltd. All rights reserved.	Teikyo Univ, Dept Psychol, Hachioji, Tokyo 1920395, Japan		Nochi, M (corresponding author), Teikyo Univ, Dept Psychol, 359 Otsuka, Hachioji, Tokyo 1920395, Japan.						ANDERSSON SI, 1992, SCAND J PSYCHOL, V33, P289, DOI 10.1111/j.1467-9450.1992.tb00918.x; BOGDAN R, 1994, SOCIAL MEANING MENT; Bogdan R.C., 1998, QUALITATIVE RES ED I, V3rd; BRUNER J, 1986, ACTUAL MIND POSSIBLE; Caplan G., 1964, PRINCIPLES PREVENTIV; Capps Lisa., 1995, CONSTRUCTING PANIC D; Charmaz, 1991, GOOD DAYS BAD DAYS S; CORBIN J, 1990, Z SOZIOL, V19, P418, DOI 10.1007/BF00988593; Crisp R., 1994, J APPL REHABILITATIO, V25, P16; David Karp, 1996, SPEAKING SADNESS DEP; DEJONG G, 1979, ARCH PHYS MED REHAB, V60, P435; ELLIOTT TR, 1991, J PERS SOC PSYCHOL, V61, P608, DOI 10.1037/0022-3514.61.4.608; Epston, 1990, NARRATIVE MEANS THER; Gergen Kenneth, 1994, REALITIES RELATIONSH; GERGEN KJ, 1991, THERAPY SOCIAL CONST; Glaser B., 1967, DISCOVERY GROUNDED T; HERMANS HJM, 1992, AM PSYCHOL, V47, P23, DOI 10.1037/0003-066X.47.1.23; Herrmann M, 1997, DISABIL REHABIL, V19, P6, DOI 10.3109/09638289709166439; HOLMES TH, 1967, J PSYCHOSOM RES, V11, P213, DOI 10.1016/0022-3999(67)90010-4; Hoskins M, 1996, J COUNS DEV, V74, P243, DOI 10.1002/j.1556-6676.1996.tb01860.x; JOHNSON CN, 1990, CHILD DEV, V61, P962, DOI 10.2307/1130868; Kelley P, 1996, SOCIAL WORK TREATMEN, P461; LENNINGS CJ, 1992, J CLIN PSYCHOL, V48, P510, DOI 10.1002/1097-4679(199207)48:4<510::AID-JCLP2270480412>3.0.CO;2-M; Lewin K., 1951, FIELD THEORY SOCIAL; MAHON NE, 1994, PERCEPT MOTOR SKILL, V79, P395, DOI 10.2466/pms.1994.79.1.395; MILLER L, 1993, PSYCHOTHERAPY BRAIN; Nochi M, 1997, DISABIL SOC, V12, P533, DOI 10.1080/09687599727119; Nochi M, 1998, QUAL HEALTH RES, V8, P665, DOI 10.1177/104973239800800507; Nochi M, 1998, SOC SCI MED, V46, P869, DOI 10.1016/S0277-9536(97)00211-6; NOSEK MA, 1998, REHABILITATION COUNS, P107; PONSFORD J, 1995, TRAUMATIC BRAIN INJU; Richardson L., 1990, WRITING STRATEGIES R; RUSSELL RA, 1981, REHABIL LIT, V42, P330; Sarbin T. E., 1986, NARRATIVE PSYCHOL ST; Wasley D, 1998, PERCEPT MOTOR SKILL, V86, P1402, DOI 10.2466/pms.1998.86.3c.1402; *WHO, 1986, A29INFDOC1 WHO; Wright, 1975, REHABIL PSYCHOL, V22, P1, DOI [10.1037/h0090832, DOI 10.1037/H0090832]; [No title captured]	38	100	101	0	14	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0277-9536			SOC SCI MED	Soc. Sci. Med.	DEC	2000	51	12					1795	1804		10.1016/S0277-9536(00)00111-8			10	Public, Environmental & Occupational Health; Social Sciences, Biomedical	Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health; Biomedical Social Sciences	379DF	WOS:000165625100007	11128267				2022-02-06	
J	Heyen, JRR; Ye, SM; Finck, BN; Johnson, RW				Heyen, JRR; Ye, SM; Finck, BN; Johnson, RW			Interleukin (IL)-10 inhibits IL-6 production in microglia by preventing activation of NF-kappa B	MOLECULAR BRAIN RESEARCH			English	Article						microglia; lipopolysaccharide; NF-kappa B; interleukin-6; interleukin-10	TUMOR-NECROSIS-FACTOR; TRAUMATIC BRAIN INJURY; CENTRAL-NERVOUS-SYSTEM; CEREBROSPINAL-FLUID; TRANSCRIPTION FACTOR; GENE-EXPRESSION; FACTOR-ALPHA; PARKINSONS-DISEASE; TRANSGENIC MICE; LPS FEVER	The purpose of this study was to determine if interleukin (IL)-10 inhibits lipopolysaccharide (LPS)-induced IL-6 production in microglia by inhibiting activation of nuclear factor-kappa B (NF-kappa B). N13 microglia (a murine microglial cell line) and primary microglia from neonatal mice were cultured in the presence or absence of LPS and increasing amounts of murine IL-10 for 24 h. As predicted, LPS treatment increased supernatant IL-6 concentration in both N13 and primary microglia cultures. Pretreatment with IL-10, however, decreased LPS-induced IL-6 secretion in a dose-dependent manner in both culture systems. Likewise, ribonuclease protection assays showed that LPS increased steady-state IL-6 mRNA levels, but that pretreatment with IL-10 blocked the LPS-induced increase in IL-6 mRNA. Because NF-kappa B is the predominant transcription factor responsible for IL-6 transcription in response to inflammatory stimuli, it was hypothesized that IL-10 inhibited IL-6 production by preventing nuclear translocation of NF-kappa B. Consistent with this idea, LPS increased nuclear translocation of NF-kappa B as assessed by gel mobility shift assay. Supershift assays and immunocytochemical staining showed that both the p50 and p65 subunits of NF-kappa B translocated from the cytoplasm to the nucleus upon LPS stimulation. Pretreatment with IL-10, however, inhibited LPS-induced activation of NF-kappa B. Furthermore, inhibition of NF-kappa B activity with tosyl-Phe-chloro-methlyketone (a serine protease inhibitor that prevents degradation of the NF-kappa B-I kappa B complex), completely blocked LPS-induced IL-6 production. These data suggest that IL-10 inhibited IL-6 production in microglia by decreasing the activity of NF-kappa B and, therefore, extend what little is known of the intricate relationship between anti-inflammatory and inflammatory cytokines in the central nervous system. (C) 2000 Elsevier Science B.V. All rights reserved.	Univ Illinois, Dept Anim Sci, Lab Integrat Biol, Urbana, IL 61808 USA		Johnson, RW (corresponding author), Univ Illinois, Dept Anim Sci, Lab Integrat Biol, Urbana, IL 61808 USA.	rwjohn@ux6.cso.uiuc.edu		Johnson, Rodney/0000-0002-2376-1852	NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [DK51576] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R29DK051576] Funding Source: NIH RePORTER		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; BlumDegen D, 1995, NEUROSCI LETT, V202, P17, DOI 10.1016/0304-3940(95)12192-7; Bluthe RM, 1999, PSYCHONEUROENDOCRINO, V24, P301, DOI 10.1016/S0306-4530(98)00077-8; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; CASSATELLA MA, 1994, J EXP MED, V179, P1695, DOI 10.1084/jem.179.5.1695; Chai Z, 1996, J EXP MED, V183, P311, DOI 10.1084/jem.183.1.311; DE WMR, 1991, J EXP MED, V174, P1209; DENDORFER U, 1994, MOL CELL BIOL, V14, P4443, DOI 10.1128/MCB.14.7.4443; Dickensheets HL, 1997, BLOOD, V90, P4162, DOI 10.1182/blood.V90.10.4162; FATTORI E, 1994, J EXP MED, V180, P1243, DOI 10.1084/jem.180.4.1243; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; Gruol DL, 1997, MOL NEUROBIOL, V15, P307, DOI 10.1007/BF02740665; Hans VHJ, 1999, NEUROREPORT, V10, P409; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Heyser CJ, 1997, P NATL ACAD SCI USA, V94, P1500, DOI 10.1073/pnas.94.4.1500; KIM HK, 1995, J IMMUNOL, V154, P4741; KLIR JJ, 1993, AM J PHYSIOL, V265, pR512, DOI 10.1152/ajpregu.1993.265.3.R512; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; Kozak W, 1997, AM J PHYSIOL-REG I, V272, pR621, DOI 10.1152/ajpregu.1997.272.2.R621; LAYE S, 1994, MOL BRAIN RES, V27, P157, DOI 10.1016/0169-328X(94)90197-X; Lenczowski MJP, 1999, AM J PHYSIOL-REG I, V276, pR652, DOI 10.1152/ajpregu.1999.276.3.R652; Leon LR, 1999, AM J PHYSIOL-REG I, V276, pR81, DOI 10.1152/ajpregu.1999.276.1.R81; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; Mogi M, 1996, NEUROSCI LETT, V211, P13, DOI 10.1016/0304-3940(96)12706-3; Nava F, 1997, INT J IMMUNOPHARMACO, V19, P31, DOI 10.1016/S0192-0561(97)00006-4; OKA T, 1995, BRAIN RES, V692, P123, DOI 10.1016/0006-8993(95)00691-I; PERLSTEIN RS, 1993, ENDOCRINOLOGY, V132, P946, DOI 10.1210/en.132.3.946; PlataSalaman R, 1996, NEUROREPORT, V7, P841, DOI 10.1097/00001756-199602290-00038; RAY A, 1990, MOL CELL BIOL, V10, P5736, DOI 10.1128/MCB.10.11.5736; RIGHI M, 1989, EUR J IMMUNOL, V19, P1443, DOI 10.1002/eji.1830190815; Rothwell N, 1997, J CLIN INVEST, V100, P2648, DOI 10.1172/JCI119808; Sambrook J., 1989, MOL CLONING LAB MANU; *SAS, 1990, SAS STAT US GUID VER; Sawada M, 1999, J NEUROCHEM, V72, P1466, DOI 10.1046/j.1471-4159.1999.721466.x; SHENG WS, 1995, CLIN DIAGN LAB IMMUN, V2, P604, DOI 10.1128/CDLI.2.5.604-608.1995; SHIMIZU H, 1990, MOL CELL BIOL, V10, P561, DOI 10.1128/MCB.10.2.561; Spera PA, 1998, NEUROSCI LETT, V251, P189, DOI 10.1016/S0304-3940(98)00537-0; Takeshita S, 1996, J IMMUNOL, V156, P2591; TANABE O, 1988, J IMMUNOL, V141, P3875; Tilg H, 1997, IMMUNOL TODAY, V18, P428, DOI 10.1016/S0167-5699(97)01103-1; ToliverKinsky T, 1997, J NEUROSCI RES, V48, P580, DOI 10.1002/(SICI)1097-4547(19970615)48:6<580::AID-JNR11>3.0.CO;2-Z; WANG P, 1994, J IMMUNOL, V153, P811; WONG ML, 1994, P NATL ACAD SCI USA, V90, P227; Yao JH, 1997, MOL BRAIN RES, V51, P170, DOI 10.1016/S0169-328X(97)00235-0; Ye SM, 1999, J NEUROIMMUNOL, V93, P139, DOI 10.1016/S0165-5728(98)00217-3; ZHANG Y, 1990, MOL CELL BIOL, V10, P3818, DOI 10.1128/MCB.10.7.3818	50	100	106	1	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0169-328X			MOL BRAIN RES	Mol. Brain Res.	APR 14	2000	77	1					138	147		10.1016/S0169-328X(00)00042-5			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	317WX	WOS:000087250900015	10814840				2022-02-06	
J	Chatzipanteli, K; Yanagawa, Y; Marcillo, AE; Kraydieh, S; Yezierski, RP; Dietrich, WD				Chatzipanteli, K; Yanagawa, Y; Marcillo, AE; Kraydieh, S; Yezierski, RP; Dietrich, WD			Posttraumatic hypothermia reduces polymorphonuclear leukocyte accumulation following spinal cord injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						hypothermia; inflammation; MPO; rat; spinal cord injury	TRAUMATIC BRAIN INJURY; MODERATE HYPOTHERMIA; LIPID-PEROXIDATION; REPERFUSION INJURY; AMINO-ACIDS; ISCHEMIA; NEUTROPHIL; PROTECTION; DAMAGE; INFILTRATION	The present study addresses the effects of moderate posttraumatic hypothermia (32 degrees C) on the temporal and regional profile of polymorphonuclear leukocyte (PMNL) accumulation after traumatic spinal cord injury (SCI). We hypothesized that posttraumatic hypothermia would reduce the degree of inflammation by reducing PMNL infiltration. Rats underwent moderate spinal cord injury at T10 using the NYU impactor device. In the first study, the temporal profile of myeloperoxidase (MPO) activity (a marker of neutrophil accumulation) under normothermic (37 degrees C) conditions was determined. The animals were allowed to survive for 3 or 24 h, or 3 or 7 days after SCI. Spinal cords were dissected into five segments rostral and caudal to the injury site. Additional animals were studied for the immunocytochemical visualization of MPO. In the second study, rats were sacrificed at 24 h after a monitoring period of normothermia (36.5 degrees C/3 h) or hypothermia (32.4 degrees C/3 h) with their controls. In the time course studies, MPO enzymatic activity was significantly increased at 3 and 24 h within the traumatized T10 segment compared to controls. MPO activity was also increased at 3 h within the rostral T8 and T9 segments and caudal T11 and T12 segments compared to controls. At 24 h after trauma, MPO activity remained elevated within both the rostral and caudal segments compared to control. By 3 days, the levels of MPO activity were reduced compared to the 24-h values but remained significantly different from control. Neutrophils that exhibited MPO immunoreactivity were seen at 6 and 24 h, with a higher number at 3 days. PMNLs were located within the white and gray matter of the lesion and both rostral and caudal to the injury site. Post-traumatic hypothermia reduced MPO activity at 24 h in the injured spinal cord segment, compared to normothermic values. The results of this study indicate that a potential mechanism by which hypothermia improves outcome following SCI is by attenuating posttraumatic inflammation.	Univ Miami, Sch Med, Dept Neurol Surg, Miami, FL 33136 USA; Univ Miami, Sch Med, Dept Neurol, Miami, FL 33136 USA; Univ Miami, Sch Med, Miami Project Cure Paralysis, Miami, FL 33136 USA		Dietrich, WD (corresponding author), Univ Miami, Sch Med, Dept Neurol Surg, 1600 NW 10th Ave R-48, Miami, FL 33136 USA.	ddietrich@miami.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 30291] Funding Source: Medline		AKRIOTIS V, 1985, J LEUKOCYTE BIOL, V37, P51, DOI 10.1002/jlb.37.1.51; ALLEN BT, 1994, J VASC SURG, V19, P332, DOI 10.1016/S0741-5214(94)70108-3; ANDERSON DK, 1993, ANN EMERG MED, V22, P987, DOI 10.1016/S0196-0644(05)82739-8; BARONE FC, 1991, J NEUROSCI RES, V29, P336, DOI 10.1002/jnr.490290309; Bethea JR, 1999, J NEUROTRAUM, V16, P851, DOI 10.1089/neu.1999.16.851; Bethea JR, 1998, J NEUROSCI, V18, P3251; BIAGAS KV, 1992, J NEUROTRAUM, V9, P363, DOI 10.1089/neu.1992.9.363; BIGGAR WD, 1984, INFECT IMMUN, V46, P857, DOI 10.1128/IAI.46.3.857-859.1984; BLIGHT AR, 1992, J NEUROTRAUM, V9, pS83; BLIGHT AR, 1992, J NEUROTRAUM, V9, P147, DOI 10.1089/neu.1992.9.147; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Chatzipanteli K, 1999, J NEUROCHEM, V72, P2047, DOI 10.1046/j.1471-4159.1999.0722047.x; CHOPP M, 1994, STROKE, V25, P869, DOI 10.1161/01.STR.25.4.869; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; DEMOPOULOS HB, 1980, ACTA PHYSIOL SCAND, P91; Dietrich WD, 1996, NEUROTRAUMA, P1491; DOBRINA A, 1994, EUR J NEUROSCI, V6, P712; Farooque M, 1999, NEUROREPORT, V10, P131, DOI 10.1097/00001756-199901180-00024; Forster C, 1999, ACTA NEUROPATHOL, V97, P215, DOI 10.1007/s004010050977; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; GOSS JR, 1996, J NEUROTRAUM, V13, P809; GRANERT C, 1994, J CLIN INVEST, V93, P929, DOI 10.1172/JCI117098; Green B A, 1973, Surg Forum, V24, P436; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; Hamada Y, 1996, J NEUROCHEM, V66, P1525; HARLAN JM, 1987, SEMIN THROMB HEMOST, V13, P434, DOI 10.1055/s-2007-1003520; HERNANDEZ LA, 1987, AM J PHYSIOL, V253, pH699, DOI 10.1152/ajpheart.1987.253.3.H699; HEROLD JA, 1994, J THORAC CARDIOV SUR, V107, P536, DOI 10.1016/S0022-5223(12)70100-9; Isaksson J, 1999, J NEUROTRAUM, V16, P165, DOI 10.1089/neu.1999.16.165; Ishikawa T, 1999, CELL MOL NEUROBIOL, V19, P199, DOI 10.1023/A:1005401926320; IWASA K, 1989, FREE RADICAL BIO MED, V6, P599, DOI 10.1016/0891-5849(89)90067-1; Kakinohana M, 1999, ANESTHESIOLOGY, V90, P789, DOI 10.1097/00000542-199903000-00022; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Marsala M, 1997, J NEUROSCI METH, V74, P97, DOI 10.1016/S0165-0270(97)02270-X; MARSALA M, 1994, STROKE, V25, P2038, DOI 10.1161/01.STR.25.10.2038; MARTINEZARIZALA A, 1992, J NEUROTRAUM, V9, pS497; Matsumoto M, 1997, ANESTHESIOLOGY, V86, P1120, DOI 10.1097/00000542-199705000-00016; MATSUO Y, 1994, STROKE, V25, P1469, DOI 10.1161/01.STR.25.7.1469; MEANS ED, 1983, J NEUROPATH EXP NEUR, V42, P707, DOI 10.1097/00005072-198311000-00009; NAKAKIMURA K, 1997, ANESTHESIOLOGY, V86, P1120; NAUSEEF WM, 1983, J CLIN INVEST, V71, P1297, DOI 10.1172/JCI110880; NYSTROM B, 1988, ACTA NEUROL SCAND, V78, P467, DOI 10.1111/j.1600-0404.1988.tb03689.x; PERSSON L, 1976, VIRCHOWS ARCH B, V22, P21; PUCHALA E, 1977, EXP NEUROL, V55, P1, DOI 10.1016/0014-4886(77)90155-8; ROBERTSON CS, 1986, J NEUROSURG, V64, P633, DOI 10.3171/jns.1986.64.4.0633; ROKKAS CK, 1995, J THORAC CARDIOV SUR, V110, P27, DOI 10.1016/S0022-5223(05)80006-6; ROSOMOFF HL, 1985, ARCH NEUROL-CHICAGO, V13, P337; SAGANOVA K, 1994, EXP NEUROL, V130, P337, DOI 10.1006/exnr.1994.1212; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; SCHURER L, 1990, ACT NEUR S, V51, P49; SHIGA Y, 1991, NEUROSCI LETT, V125, P110, DOI 10.1016/0304-3940(91)90003-C; SIEMIONOW M, 1993, J HAND SURG-AM, V18A, P963, DOI 10.1016/0363-5023(93)90384-F; Soriano SG, 1996, ANN NEUROL, V39, P618, DOI 10.1002/ana.410390511; Svensson LG, 1999, ANN THORAC SURG, V67, P1935, DOI 10.1016/S0003-4975(99)00395-1; TABAYASHI K, 1993, ANN THORAC SURG, V56, P494, DOI 10.1016/0003-4975(93)90885-L; Taoka Y, 1997, NEUROSCIENCE, V79, P1177, DOI 10.1016/S0306-4522(97)00011-0; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Toyoda T, 1996, NEUROSURGERY, V39, P1200, DOI 10.1097/00006123-199612000-00024; TUOMANEN EI, 1989, J EXP MED, V170, P959, DOI 10.1084/jem.170.3.959; Tuzgen S, 1998, SPINAL CORD, V36, P654, DOI 10.1038/sj.sc.3100660; UHL MW, 1994, J NEUROTRAUM, V11, P303, DOI 10.1089/neu.1994.11.303; VACANTI FX, 1984, STROKE, V15, P695, DOI 10.1161/01.STR.15.4.695; VANICKY I, 1993, J NEUROSURG, V79, P736, DOI 10.3171/jns.1993.79.5.0736; Whalen MJ, 1999, J NEUROTRAUM, V16, P299, DOI 10.1089/neu.1999.16.299; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561; WISSELINK W, 1994, J VASC SURG, V19, P788, DOI 10.1016/S0741-5214(94)70003-6; XU J, 1990, J NEUROCHEM, V55, P907, DOI 10.1111/j.1471-4159.1990.tb04577.x; ZHANG XD, 1994, IEEE PARALL DISTRIB, V2, P3	70	100	101	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2000	17	4					321	332		10.1089/neu.2000.17.321			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	302LA	WOS:000086365500005	10776915				2022-02-06	
J	Ewing-Cobbs, L; Prasad, M; Kramer, L; Louis, PT; Baumgartner, J; Fletcher, JM; Alpert, B				Ewing-Cobbs, L; Prasad, M; Kramer, L; Louis, PT; Baumgartner, J; Fletcher, JM; Alpert, B			Acute neuroradiologic findings in young children with inflicted or noninflicted traumatic brain injury	CHILDS NERVOUS SYSTEM			English	Article						child abuse; shaken baby syndrome; brain injury; infants; children; neuroimaging	SHAKEN BABY SYNDROME; HEAD-INJURY; COMPUTED-TOMOGRAPHY; IMPACT SYNDROME; ABUSED-CHILD; INFANTS; COMA; SCALE; MECHANISMS; AGE	Acute CT/MRI findings were examined in a prospective, longitudinal study of 60 children 0-6 years of age hospitalized for moderate to severe traumatic brain injury (TBI). TBI was categorized as either inflicted (n=31) or noninflicted (n=29). Glasgow Coma Scale scores and perinatal history were comparable in both groups. Acute CT/MRI studies were visually inspected by a radiologist blind to group membership. Compared with the noninflicted TBI group, the inflicted TBI group had significantly elevated rates of subdural interhemispheric and convexity hemorrhages as well as signs of pre-existing brain abnormality, including cerebral atrophy, subdural hygroma, and ex vacuo ventriculomegaly. Intraparenchymal hemorrhage, shear injury, and skull fractures were more frequent after noninflicted TBI. Subarachnoid hemorrhage and infarct/edema occurred with comparable frequency in both groups. Characteristic acute neuroimaging findings of inflicted TBI included multiple extraaxial hemorrhages in addition to the mild atrophy, subdural hygromas, and ventriculomegaly that suggest prior brain abnormality.	Univ Texas, Hlth Sci Ctr, Dept Pediat, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Dept Radiol, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Dept Surg, Houston, TX 77030 USA		Ewing-Cobbs, L (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pediat, 7000 Fannin,Suite 2431, Houston, TX 77030 USA.	lewing@pedl.med.uth.tmc.edu	fletcher, jack/Q-5975-2019; Fletcher, Jack/AAX-2931-2020		NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR002558] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01-RR-02558] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [29462] Funding Source: Medline		Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; ALEXANDER R, 1990, AM J DIS CHILD, V144, P58, DOI 10.1001/archpedi.1990.02150250068033; BILLMIRE ME, 1985, PEDIATRICS, V75, P340; BRODY BA, 1987, J NEUROPATH EXP NEUR, V46, P283, DOI 10.1097/00005072-198705000-00005; BRUCE DA, 1989, PEDIATR ANN, V18, P482, DOI 10.3928/0090-4481-19890801-07; CAFFEY J, 1972, AM J DIS CHILD, V124, P161, DOI 10.1001/archpedi.1972.02110140011001; CALDER IM, 1984, J CLIN PATHOL, V37, P1095, DOI 10.1136/jcp.37.10.1095; COHEN RA, 1986, AM J ROENTGENOL, V146, P97, DOI 10.2214/ajr.146.1.97; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Duhaime AC, 1996, PEDIATR NEUROSURG, V24, P292, DOI 10.1159/000121058; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; FISCHER H, 1994, CLIN PEDIATR, V33, P696, DOI 10.1177/000992289403301113; GENNARELLI TA, 1985, NEUROSURGERY; GOLDSTEIN B, 1993, CRIT CARE MED, V21, P1328, DOI 10.1097/00003246-199309000-00016; GROSSMAN RI, 1994, NEURORADIOLOGY REQUI, P149; HAHN YS, 1983, CHILD BRAIN, V10, P229; HAHN YS, 1988, CHILD NERV SYST, V4, P34; HOBBS CJ, 1984, ARCH DIS CHILD, V59, P246, DOI 10.1136/adc.59.3.246; Hymel KP, 1997, PEDIATR RADIOL, V27, P743, DOI 10.1007/s002470050215; JASPAN T, 1992, PEDIATR RADIOL, V22, P237, DOI 10.1007/BF02019848; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; KRUGMAN RD, 1993, PEDIATRICS, V92, P872; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LINDENBERG R, 1969, ARCH PATHOL, V87, P298; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; MCCLELLAND CQ, 1980, CHILD BRAIN, V7, P225; MERTEN DF, 1984, PEDIATR RADIOL, V14, P272, DOI 10.1007/BF01601874; MESERVY CJ, 1987, AM J ROENTGENOL, V149, P173, DOI 10.2214/ajr.149.1.173; RAIMONDI AJ, 1984, CHILD BRAIN, V11, P12; RODRIGUEZ JG, 1990, AM J DIS CHILD, V144, P627; SATO Y, 1989, RADIOLOGY, V173, P653, DOI 10.1148/radiology.173.3.2813768; Shugerman RP, 1996, PEDIATRICS, V97, P664; SINAL SH, 1987, SOUTHERN MED J, V80, P1505, DOI 10.1097/00007611-198712000-00006; TEASDALE G, 1974, LANCET, V2, P81; VOWLES GH, 1987, J CLIN PATHOL, V40, P185, DOI 10.1136/jcp.40.2.185; ZIMMERMAN RA, 1979, RADIOLOGY, V130, P687, DOI 10.1148/130.3.687	38	100	101	0	10	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0256-7040	1433-0350		CHILD NERV SYST	Childs Nerv. Syst.	JAN	2000	16	1					25	33		10.1007/s003810050006			9	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	275VH	WOS:000084840500006	10672426				2022-02-06	
J	Newell, KL; Boyer, P; Gomez-Tortosa, E; Hobbs, W; Hedley-Whyte, ET; Vonsattel, JP; Hyman, BT				Newell, KL; Boyer, P; Gomez-Tortosa, E; Hobbs, W; Hedley-Whyte, ET; Vonsattel, JP; Hyman, BT			alpha-synuclein immunoreactivity is present in axonal swellings in neuroaxonal dystrophy and acute traumatic brain injury	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						alpha-synuclein; axonal spheroids; axonal swellings; diffuse axonal injury; Hallervorden-Spatz syndrome; Lewy body; neuroaxonal dystrophy	AMYLOID PRECURSOR PROTEIN; MULTIPLE SYSTEM ATROPHY; HALLERVORDEN-SPATZ SYNDROME; LEWY BODY DISEASE; GLIAL CYTOPLASMIC INCLUSIONS; PARKINSONS-DISEASE; NEURODEGENERATIVE DISORDERS; ALZHEIMERS-DISEASE; BODIES; DEMENTIA	The primary neuroaxonal dystrophies (NAD), which include infantile NAD and Hallervorden-Spatz syndrome (HSS), an characterized by dystrophic terminal axons and axonal swellings. Lewy bodies have been found in some cases. In Parkinson disease (PD) and dementia with Lewy bodies (DLB), Lewy bodies and neurites display prominent alpha-synuclein immunoreactivity. We examined 2 cases of HSS and 4 cases of infantile NAD with alpha-synuclein immunohistochemistry to test the hypothesis that these disorders with similar morphological findings might share a biochemical phenotype. Furthermore, we compared them to 8 cases of secondary or physiologic NAD of various causes and 2 cases of recent traumatic head injury. alpha-Synuclein positive neuronal cytoplasmic inclusions, including Lewy bodies, and neurites were numerous in 1 HSS and 1 infantile NAD case. In addition, axonal spheroids were immunostained in all 6 cases of primary NAD, 5 cases of secondary NAD, and 2 cases of recent head injury. Axonal spheroids were faintly stained in the 3 physiologic NAD cases. alpha-Synuclein positive axonal swellings may suggest a mechanism, such as axonal injury, leading to the neuronal cytoplasmic accumulation of alpha-synuclein in NAD and other disorders.	Harvard Univ, Massachusetts Gen Hosp, CS Kubik Lab Neuropathol, Boston, MA USA; Harvard Univ, Massachusetts Gen Hosp, Dept Pathol, Boston, MA USA; Harvard Univ, Massachusetts Gen Hosp, Dept Neurol, Boston, MA USA		Newell, KL (corresponding author), Massachusetts Gen Hosp E, Alzheimers Dis Res Unit, 149 13th St,Room 6604B, Charlestown, MA 02129 USA.		Hedley-Whyte, E Tessa/AAJ-9975-2021	Hedley-Whyte, E Tessa/0000-0002-1687-8905	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG05134] Funding Source: Medline		ALBERCA R, 1987, J NEUROL NEUROSUR PS, V50, P1665, DOI 10.1136/jnnp.50.12.1665; ANTOINE JC, 1985, REV NEUROL-FRANCE, V141, P806; Arawaka S, 1998, NEUROLOGY, V51, P887, DOI 10.1212/WNL.51.3.887; Baba M, 1998, AM J PATHOL, V152, P879; COCHRAN E, 1991, AM J PATHOL, V139, P485; DEFENDINI R, 1973, J NEUROL SCI, V20, P7, DOI 10.1016/0022-510X(73)90114-7; DOOLING EC, 1974, ARCH NEUROL-CHICAGO, V30, P70, DOI 10.1001/archneur.1974.00490310072012; EIDELBERG D, 1987, BRAIN, V110, P993, DOI 10.1093/brain/110.4.993; Ellison D, 1998, NEUROPATHOLOGY; GAYTANGARCIA S, 1990, CLIN NEUROPATHOL, V9, P136; GOMEZTORTOSA E, IN PRESS NEUROLOGY; GULTEKIN SH, 1994, ARCH PATHOL LAB MED, V118, P168; HEDLEYWHYTE ET, 1968, NEUROLOGY, V18, P891, DOI 10.1212/WNL.18.9.891; Irizarry MC, 1998, J NEUROPATH EXP NEUR, V57, P334, DOI 10.1097/00005072-199804000-00005; Lippa CF, 1998, AM J PATHOL, V153, P1365, DOI 10.1016/S0002-9440(10)65722-7; LOWE J, 1997, GREENFIELDS NEUROPAT, V2, P336; McKeith IG, 1996, NEUROLOGY, V47, P1113, DOI 10.1212/WNL.47.5.1113; Mezey E, 1998, NAT MED, V4, P755, DOI 10.1038/nm0798-755; OHGAMI T, 1992, NEUROSCI LETT, V136, P75, DOI 10.1016/0304-3940(92)90651-M; PARK BE, 1975, NEUROLOGY, V25, P1172, DOI 10.1212/WNL.25.12.1172; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; ROZDILSKY B, 1971, ACTA NEUROPATHOL, V17, P331, DOI 10.1007/BF00685019; SEITELBERGER F, 1986, HDB CLIN NEUROLOGY, V5, P391; Seitelberger F., 1971, ACTA NEUROPATH BER S, V5, P17; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Spillantini MG, 1998, NEUROSCI LETT, V251, P205, DOI 10.1016/s0304-3940(98)00504-7; SUGIYAMA H, 1993, CLIN NEUROPATHOL, V12, P147; Takeda A, 1998, AM J PATHOL, V152, P367; Taylor TD, 1996, NAT GENET, V14, P479, DOI 10.1038/ng1296-479; Tu PH, 1998, ANN NEUROL, V44, P415, DOI 10.1002/ana.410440324; Wakabayashi K, 1998, ACTA NEUROPATHOL, V96, P445, DOI 10.1007/s004010050918; Wakabayashi K, 1998, NEUROSCI LETT, V249, P180, DOI 10.1016/S0304-3940(98)00407-8; WILLIAMSON K, 1982, ANN NEUROL, V11, P335, DOI 10.1002/ana.410110403	35	100	100	0	2	AMER ASSN NEUROPATHOLOGISTS INC	LAWRENCE	1041 NEW HAMPSHIRE ST, LAWRENCE, KS 66044 USA	0022-3069			J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	DEC	1999	58	12					1263	1268		10.1097/00005072-199912000-00007			6	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	267JU	WOS:000084355500007	10604751	Bronze			2022-02-06	
J	Schwartz, MF; Buxbaum, LJ; Montgomery, MW; Fitzpatrick-DeSalme, E; Hart, T; Ferraro, M; Lee, SS; Coslett, HB				Schwartz, MF; Buxbaum, LJ; Montgomery, MW; Fitzpatrick-DeSalme, E; Hart, T; Ferraro, M; Lee, SS; Coslett, HB			Naturalistic action production following right hemisphere stroke	NEUROPSYCHOLOGIA			English	Article						right hemisphere stroke; naturalistic action; supervisory attention; neglect; resource capacity	SUSTAINED ATTENTION; CEREBRAL ACTIVATION; VISUAL NEGLECT; BRAIN-DAMAGE; LATERALITY; DOMINANCE; BEHAVIOR; SYSTEM	An unselected group of right hemisphere, semi-acute stroke patients (n = 30) was run on a laboratory test of naturalistic action production and was found to commit errors of action at a higher rate than what was previously reported for recovering head injury patients [Schwartz et al., Naturalistic action impairment in closed head injury. Neuropsychology, 1997, 8, 59-72]. There were strong similarities in how these two patient groups responded to variations in task demands and in the pattern of errors they produced. Hemispatial biases were evident in the errors of right hemisphere patients with neglect but not those without neglect; and neglect patients also many errors that were unrelated to the spatial layout. We argue that a non-specific resource limitation - which might translate as reduced arousal or effort - is central to the breakdown of naturalistic action production after brain damage, and right hemisphere patients are especially vulnerable to this resource limitation and its behavioral consequences. (C) 1998 Elsevier Science Ltd. All rights reserved.	Moss Rehabil Res Inst, Philadelphia, PA 19141 USA; Temple Univ, Philadelphia, PA 19122 USA; American Univ, Washington, DC 20016 USA		Schwartz, MF (corresponding author), Moss Rehabil Res Inst, 1200 W Tabor Rd, Philadelphia, PA 19141 USA.	mschwar@vm.temple.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS031824] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS31824] Funding Source: Medline		Alderman N., 1996, BADS BEHAV ASSESSMEN; ALLPORT A, 1993, ATTENTION PERFORMANC, V14; BAARS BJ, 1992, EXPT SLIPS HUMAN ERR; BOYD TM, 1993, APPL COGNITIVE PSYCH, V7, P171, DOI 10.1002/acp.2350070208; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; Buxbaum LJ, 1997, COGNITIVE NEUROPSYCH, V14, P219, DOI 10.1080/026432997381565; Buxbaum LJ, 1995, NEUROCASE, V1, P3, DOI 10.1093/neucas/1.1.3; BUXBAUM LJ, IN PRESS COGNITIVE N; Cooper R, 1997, PROCEEDINGS OF THE NINETEENTH ANNUAL CONFERENCE OF THE COGNITIVE SCIENCE SOCIETY, P131; COSLETT HB, 1987, NEUROLOGY, V37, P957, DOI 10.1212/WNL.37.6.957; GAINOTTI G, 1990, J NEUROL NEUROSUR PS, V53, P422, DOI 10.1136/jnnp.53.5.422; GLISKY EL, 1986, J CLIN EXPT NEUROPSY, V8, P293; HALLIGAN PW, 1992, J NEUROL NEUROSUR PS, V55, P1060, DOI 10.1136/jnnp.55.11.1060; HEILMAN KM, 1979, NEUROPSYCHOLOGIA, V17, P315, DOI 10.1016/0028-3932(79)90077-0; HEILMAN KM, 1972, NEUROLOGY, V22, P660, DOI 10.1212/WNL.22.6.660; HEILMAN KM, 1978, NEUROLOGY, V28, P229, DOI 10.1212/WNL.28.3.229; HEILMAN KM, 1977, ADV NEUROL, V15, P93; Kahneman D., 1973, ATTENTION EFFORT; Kleinbaum D.G., 1978, APPL REGRESSION ANAL; NAVON D, 1984, PSYCHOL REV, V91, P216, DOI 10.1037/0033-295X.91.2.216; NORMAN DA, 1981, PSYCHOL REV, V88, P1, DOI 10.1037/0033-295X.88.1.1; PARDO JV, 1991, NATURE, V349, P61, DOI 10.1038/349061a0; Pocock, 1983, CLIN TRIALS PRACTICA; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; POSNER MI, 1987, PSYCHOBIOLOGY, V15, P107; Reason J., 1982, ABSENT MINDED PSYCHO; ROBERTSON I, 1992, INT J NEUROSCI, V62, P45; ROBERTSON I, 1989, NEUROPSYCHOLOGIA, V27, P157, DOI 10.1016/0028-3932(89)90168-1; Robertson I., 1994, TEST EVERYDAY ATTENT; ROBERTSON IH, 1994, CORTEX, V30, P199, DOI 10.1016/S0010-9452(13)80193-1; ROBERTSON IH, 1995, J CLIN EXP NEUROPSYC, V17, P416, DOI 10.1080/01688639508405133; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Robertson MM, 1997, CRIT REV NEUROBIOL, V11, P1; Schwartz M. F., 1997, APRAXIA NEUROPSYCHOL, P269; Schwartz M. F., 1993, J HEAD TRAUMA REHAB, V8, P59, DOI [10.1097/00001199-199303000-00007, DOI 10.1097/00001199-199303000-00007]; SCHWARTZ MF, 1991, COGN NEUROPSYCHOL, V8, P381, DOI 10.1080/02643299108253379; Schwartz MF, 1995, COGNITIVE NEUROPSYCH, V12, P863, DOI 10.1080/02643299508251406; Schwartz MF, 1998, NEUROPSYCHOLOGY, V12, P13, DOI 10.1037/0894-4105.12.1.13; Schwartz MF, 1995, ANN NY ACAD SCI, V769, P321, DOI 10.1111/j.1749-6632.1995.tb38148.x; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Shallice T, 1996, PHILOS T R SOC B, V351, P1405, DOI 10.1098/rstb.1996.0124; SHALLICE T, 1989, BRAIN, V112, P1587, DOI 10.1093/brain/112.6.1587; Shallice T., 1988, NEUROPSYCHOLOGY MENT; *STAT U NEW YORK B, 1993, GUID US UN DAT SET M; Stuss DT, 1995, ANN NY ACAD SCI, V769, P191, DOI 10.1111/j.1749-6632.1995.tb38140.x; WEINTRAUB S, 1987, ARCH NEUROL-CHICAGO, V44, P621, DOI 10.1001/archneur.1987.00520180043014; WICKENS C. D., 1984, VARIETIES ATTENTION, P63; WILKINS AJ, 1987, NEUROPSYCHOLOGIA, V25, P359, DOI 10.1016/0028-3932(87)90024-8; Wilson B.A., 1985, RIVERMEAD BEHAV MEMO	49	100	100	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia	JAN	1999	37	1					51	66					16	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	148TL	WOS:000077548900007	9920471				2022-02-06	
